Question,Answer,Content
"Describe the process of DNA repair in bacteria, outlining at least three distinct mechanisms and explaining the specific damage each addresses.","Bacteria employ a variety of sophisticated mechanisms to repair damaged DNA, crucial for survival due to the constant exposure to damaging agents like radiation. One primary pathway is Non-Homologous End Joining (NHEJ), which directly ligates broken DNA ends without requiring a homologous template. This mechanism primarily deals with small breaks and excisions but can introduce mutations if the repair isn't precise. A second key process is Base Excision Repair (BER). BER addresses damage to individual DNA bases, often caused by oxidation or alkylation. It begins with recognition of damaged bases by DNA glycosylases which remove the incorrect base, followed by AP endonuclease cleavage and subsequent gap filling by DNA polymerase I and ligation by DNA ligase. Finally, Mismatch Repair (MMR) corrects errors introduced during DNA replication – specifically mismatched base pairs. MMR identifies these mismatches through proteins like MutS and MutL, initiating a complex process involving excision of the incorrect nucleotide flanked by heteroplasmously rich regions, followed by resynthesis using a template strand and ligation. These three mechanisms represent fundamental strategies employed by bacteria to maintain genomic integrity under stressful conditions. 

Reference: Molecular Radiation Biology, Foreword.","Document: MolecularRadiationBiology | Section: Foreword | Content: Textbook edited by Prof Sarah Baatout. I went through the textbook with utter curiosity and
found it irresistible to stop reading from beginning to end. Indeed, the book will prove a boon
and treasure of knowledge for radiobiology researchers, physicians, clinicians, environmental­
ists, nuclear workers, industry professionals/managers, and radiation technology developers."
"Following the initial excitement surrounding X-rays and radioactivity in the late 19th century, what was a prominent early application of these discoveries within the medical field, and why did this application generate significant public interest?","Immediately following the identification of X-radiation's ability to destroy living cells, including cancerous ones, physicians enthusiastically embraced its potential for cancer treatment. This initial focus stemmed from the remarkable observation that X-rays could effectively kill cancer cells, offering a seemingly promising avenue for alleviating suffering and potentially curing patients. The application sparked considerable public interest due to several factors: firstly, it provided a novel and visually compelling method – X-ray imaging – allowing physicians to ‘see’ inside the human body without invasive surgery; secondly, the use of radium, particularly in lipsticks, became a popular novelty, driven by the fascination with visualizing bones and experiencing the perceived benefits of radiation exposure. This widespread adoption fueled public curiosity and excitement around these new discoveries. However, this early enthusiasm was unfortunately coupled with a lack of understanding regarding the potential long-term harmful effects of radiation exposure.
Reference: MolecularRadiationBiology, Section 1 – New Discoveries and Early Excitements","Document: MolecularRadiationBiology | Section: New Discoveries and Early Excitements | Content: With the discoveries of X-ray in 1895 and radioactivity in 1898, unusual excitement was wit­
nessed among scientists and researchers all over the world. It was commonly perceived that a
new revolution had arrived in science, which might prove a panacea for every enigma. Besides
researchers and academicians, the general public was highly enthusiastic and saw the emer­
gence of new discoveries as an auspicious signal to humankind. Interestingly, physicians were
quick to show the courage and enthusiasm to apply newly discovered radiation for treating
cancer. That was a great medical challenge at that point in time. It was remarkable learning that
X-radiation could kill living cells, including cancer cells, and had the potential to provide
marked relief to cancer patients. In fact, X-radiation and radiation emitted from radioactive
materials like radium became a public curiosity and an object of fun for those who wanted to
have new experiences such as visualizing bones in the body and using radium lipsticks. In
early years, both the scientists and common people were unaware and unmindful of the harm­
ful effects of radiation. However, over a short span of time, it became known that radiation
researchers suffered from harmful effects of radiation such as induction of cancer."
"Following the initial recognition of ionizing radiation's biological impact, what key early research focus emerged within the nascent field of radiobiology, and why was this approach considered particularly crucial?","Immediately after recognizing the detrimental effects of X-rays and gamma rays on living organisms, researchers began intensely investigating the fundamental interactions between ionizing radiation and matter. This shift in focus was driven by the inherent challenge of studying a phenomenon that is invisible, odorless, and tasteless – radiation itself. Determining how these energetic particles interact with atoms and molecules within biological tissues became paramount to understanding the mechanisms behind radiation damage. Specifically, scientists sought to quantify and characterize these interactions to ultimately establish safe exposure limits and inform the development of effective protective measures. This approach was considered urgent due to the lack of direct sensory detection of radiation's harmful effects, necessitating a reliance on experimental observation and detailed analysis of its impact on biological systems.","Document: MolecularRadiationBiology | Section: Radiobiology Was Born | Content: It soon became apparent that understanding the mechanisms of biological effects of ionizing
radiation like X-ray and gamma ray was important, and the field of radiobiology was born.
Scientists also realized that setting safety standards for radiation was most urgent. Since radia­
tion cannot be seen, tasted, or smelled, scientists began studying the interaction of radiation
with matter, including radiation effects on living systems. Early studies showed that radiation"
"Describe the fundamental mechanism by which ionizing radiation induces cell death, drawing upon established radiobiological principles.","Ionizing radiation exerts its cytotoxic effects primarily through damage to DNA within the cell nucleus. The process begins with the absorption of energy from high-energy photons or charged particles – such as X-rays or gamma rays – by atoms within biological molecules, most notably nucleic acids (DNA and RNA). This absorption causes ionization, stripping electrons from these atoms and creating highly reactive free radicals. These free radicals then initiate a cascade of damage to DNA: they directly break the covalent bonds holding the nucleotide bases together, leading to strand breaks; they induce base modifications – altering the chemical structure of the bases themselves; and they can cause cross-linking between DNA strands, physically intertwining them. The extent of DNA damage is dependent on factors such as radiation dose, type of radiation, and cell type. If the cell’s repair mechanisms are overwhelmed or inefficient, this accumulated DNA damage triggers cellular stress responses, ultimately leading to programmed cell death (apoptosis) or necrosis. Importantly, the rapid proliferation rates observed in tumor cells exacerbate this vulnerability, making them more susceptible to radiation-induced damage compared to quiescent cells due to their increased rate of DNA replication and repair processes. Furthermore, hypoxia within tumors significantly reduces the effectiveness of radiation therapy by limiting the ability of cells to utilize oxygen for DNA repair mechanisms. Reference: MolecularRadiationBiology > section: How Radiation Kills Living Cells/Tissues","Document: MolecularRadiationBiology | Section: How Radiation Kills Living Cells/Tissues | Content: Fundamentally, radiobiologists aim to understand the effects of radiation on cells, tissues,
organs, and organisms, for animals, plants, microbial systems, and eventually humans. In this
context, the discovery of DNA structure, as double-stranded helix with nucleotides as the basic
units by Watson and Crick in the 1950s, propelled radiobiological studies on the mechanism of
radiation-induced cell death. Radiological studies showed that radiation can kill exposed cells
by damaging the DNA in the nucleus, which if not repaired prove fatal for cells. Since tumour
cells divide faster than normal cells, it was hypothesized that radiation could kill these cells
more efficiently. However, due to hypoxia in the tumour core, tumour cells showed resistance
to radiation, leading to disappointment amongst radiation therapists. Therefore, research was
undertaken to develop sensitizers of tumour cells to radiation, oxygen being the best radiosen­
sitizer. These developments in radiobiological concepts and understanding of radiation cell
killing mechanisms sustained the active research excitement in radiobiology. The medical field
witnessed revolutions in caring for and treating cancer patients by using newer radiation tech­
nologies. Today, more than 40% of cancer patients are treated by radiation for therapeutic and
palliative procedures. The technology consists of carefully targeting radiation beams and cer­
tain radiopharmaceuticals to destroy cancer cells while minimizing the damage to nearby
healthy cells. Radiobiological studies in the 1920s helped design patient treatment protocols in
what is popularly called fractionated radiotherapy."
"Considering the principles outlined regarding radiation therapy for cancer treatment, what fundamental challenge initially limited its effectiveness and subsequent development efforts?","Initially, radiation therapy faced a significant limitation due to the indiscriminate nature of ionizing radiation – it affects both cancerous tumor cells and healthy normal cells equally. This lack of selectivity resulted in substantial toxicity towards surrounding tissues, severely restricting the achievable therapeutic dose for tumors while simultaneously causing detrimental side effects in patients. The primary goal shifted from simply damaging cells to achieving selective damage within the tumor mass, minimizing harm to vital organs and systems. This realization spurred research into techniques like particle radiation therapy and ion beam therapies designed to enhance this selectivity and improve treatment outcomes. Reference: MolecularRadiationBiology, Section Limitations in Radiotherapy.","Document: MolecularRadiationBiology | Section: Limitations in Radiotherapy | Content: Radiation acts equally on normal and tumour cells. Therefore, radiation therapy of cancer
patients is limited by any toxicity towards normal cells. The next goal of radiobiology was to
inflict selective damage on a tumour whilst sparing normal cells. Based on radiobiological
Foreword
vii
effectiveness of different cell types to the same dose of radiation, particle radiation therapy and
ion beam therapies were being developed to improve the radiotherapy for patients. In addition,
the rapidly increasing applications of radiation in research, industry, medicine, biotechnology,
and the environment required more intensified radiobiological studies. Today, the public’s
major radiation exposures arise from medical applications such as diagnostic X-rays and CT
scans to diagnose diseases, and cancer radiotherapy, including treatment of injuries. Therapeutic
drugs with radioactive material attached, known as radiopharmaceuticals, are also routinely
used in clinics to diagnose and treat some diseases. These procedures are a valuable tool to
help doctors save lives through quick and accurate diagnosis."
"Describe the process of DNA damage repair following ionizing radiation exposure, focusing on at least three distinct mechanisms.","Following ionizing radiation exposure, DNA undergoes significant damage, primarily in the form of single-strand breaks (SSBs) and double-strand breaks (DSBs). Cellular response involves a complex network of DNA repair pathways to mitigate this damage. One key mechanism is Non-Homologous End Joining (NHEJ), which directly ligates broken DNA ends without requiring a homologous template. This process is error-prone, often resulting in small insertions or deletions. Another crucial pathway is Homologous Recombination (HR), which utilizes the undamaged sister chromatid as a template to accurately repair DSBs. HR requires stalled replication forks and proceeds through multiple steps including strand invasion and resolution. Finally, Base Excision Repair (BER) addresses damage to individual DNA bases caused by radiation-induced oxidation or alkylation. BER involves recognition of damaged bases by glycosylases, followed by removal of the damaged base and subsequent replacement with an appropriate nucleotide using DNA polymerase. These three mechanisms – NHEJ, HR, and BER – represent critical components of the cellular response to ionizing radiation damage, each contributing uniquely to maintaining genomic stability. Reference: Molecular Radiation Biology, Section 3.2 – DNA Damage Repair Mechanisms.","Document: MolecularRadiationBiology | Section: The Book Contents | Content: This Radiobiology Textbook is a comprehensive, advanced, and up-to-date volume, carefully
designed and meticulously compiled by experts and practicing radiobiologists in the field
drawn from reputed universities and institutes across the world. Both the experts and contribu­
tors to each chapter have remained focused to create an outstanding book useful to young
radiation researchers, mid-careerists, accomplished scientists and radiation researchers in biol­
ogy, biotechnology, medicine, environment, industry, and workers in nuclear power plants.
There are 12 chapters written by international specialists, followed by a thorough review from
experts in the respective fields. A notable and marked feature of the book is the coverage of a
wide range of relevant radiobiology topics and applications. To make learning easy and enjoy­
able, and to enable the basic principles and core concepts to be grasped, each chapter has been
designed to provide rich and up-to-date contents together with the learning objectives, chapter
summary, a few exercises, key references, and suggested future readings. It is hoped that learn­
ers find the book smooth reading and a gradual building of their knowledge repository, stimu­
lating curiosity for a deeper insight to the subject. The book begins with a brief account of the
history of radiobiology, followed by the chapter on basic concepts in radiation biology, which
covers basic mechanisms of radiation damage to cellular molecules, direct and indirect effects,
and low-dose radiation effects with relevance to health and environment. Chapter 3 on the
molecular radiation biology describes molecular details of radiation-induced lesions in DNA,
types of DNA damage and mechanisms of DNA damage repair, mis-repair, and consequences
to the life of cells. The following chapter on mechanistic, modelling, and dosimetry radiation
biology covers the basic principles of radiation dosimetry, micro-dosimetry, dose-response and
related issues. The chapter on clinical radiation biology for clinical oncology makes it attrac­
tive reading for radiation therapists and nuclear medicine physicians but will also hopefully
stimulate interest of basic researchers as well as tumour therapy professionals. The objective
of treating cancer patients effectively by radiation involves understanding the radiation dam­
age mechanisms of tumour and normal tissues and the prediction of radiation response. Going
over the contents of Chap. 6 provides the required specialized knowledge on clinical radiation
oncology modalities such as external and internal (brachytherapy) radiation treatments, high
LET therapy, and rationale of dose fractionation. Chapter 7 describes individual radiosensitiv­
ity and biomarkers for disease and treatment outcomes in therapies. Radiobiology has a crucial
role in situations of nuclear plant accidents and mass exposures expected from terrorist groups.
The chapter on radiobiology of accidental, public, and occupational exposures deals with the
radiation accident scenario, radiation health effects, radiation risks and bio-dosimetry aspects
to provide safety to workers and general public. The chapter on environmental radiobiology is
most timely and relevant, describing the mobility and distribution of radionuclides in water,
air, and soil with the safety and environmental perspectives. Studies on radiation effects on
non-human organisms such as plants and microbial systems to measure, assess, and monitor
the impacts of radiation exposures are equally important. A most fascinating chapter in this
book describes various aspects of space radiobiology, which is a futuristic and young branch
of radiobiology to which bright curious minds are expected to be attracted and to engage in
Foreword
viii
radiobiological research. The last but one chapter concerns radioprotectors, radiomitigators,
and radiosensitization, which are topics of practical importance to ensure human and environ­
mental safety and strategies for protection. The last chapter covers ethical, legal, and social
issues of radiation exposure, which re-defines the values of ethics in the radiation research field
and addresses legal and social aspects of professional and public concern. The much-publi­
cized negative aspects of radiation technology (radiophobia) are misconceived perceptions that
need to be corrected by considering the diagnostic and therapeutic power and future promise
of radiobiological research and applications. Without doubt, both radiation research profes­
sionals and curiosity-driven general readers will find the book stimulating, interesting, and
informative."
"Describe the fundamental principles underlying radiobiology, focusing on how ionizing radiation interacts with biological molecules and tissues.","Radiobiology is fundamentally concerned with understanding the effects of ionizing radiation on living organisms. At its core, it relies on the principle that ionizing radiation – such as X-rays, gamma rays, or particles – deposits energy within matter, leading to damage at the molecular level. This damage primarily occurs through two mechanisms: direct and indirect action. Direct action involves the ionization of molecules themselves by the radiation’s energetic particles, directly disrupting their chemical bonds. Indirect action is more prevalent and arises from the formation of highly reactive free radicals, particularly hydroxyl (•OH) and hydrogen (:H) radicals, when water molecules are split by ionizing radiation. These free radicals then attack DNA, proteins, lipids, and other vital biomolecules, initiating a cascade of damage. The severity of this damage depends on several factors including the dose of radiation received, the type of radiation used, the tissue’s sensitivity (which varies significantly across different cell types and organs), and the time elapsed since exposure. Repair mechanisms exist to mitigate this damage, but these are often overwhelmed at higher doses, leading to mutations, chromosomal aberrations, and ultimately, cell death or altered cellular function. Reference: Radiobiology Textbook, Section 1.2 – Fundamental Principles of Radiation Damage.","Document: MolecularRadiationBiology | Section: Perspectives and Future Scope in Radiobiology | Content: I must re-emphasize that with the ever-increasing applications of radiation technology in
health and society, environment, industry, space research, and nuclear power, the radiobiology
textbook of this high quality and with the coverage of frontline topics in the field is invaluable
and highly warranted. The wide range of topics covered in this book with updated knowledge
will prove a boon to researchers, policy makers, academicians, clinicians, and industry profes­
sionals. It is hoped that the book will arouse renewed interest among young students and will
prove useful to beginners as well as senior researchers in radiobiological research and applica­
tions. More importantly, the book will prove a good reference and will help catapult future
advances in radiation science and technology especially in the understanding of biological
effects of radiation on living cells, tissues, and organs relevant to human health.
Kaushala Prasad Mishra
Radiation Biology and Health Sciences Division
Bhabha Atomic Research Center
Mumbai, India
Nehru Gram Bharti University
Prayagraj, India
Asian Association for Radiation Research
Mumbai, India
Foreword
ix
Welcome to the Radiobiology Textbook, which was built upon the expertise of 126 interna­
tional specialists, at the forefront of various aspects of radiobiology, to bring the reader the
latest and most comprehensive update in the field.
Radiobiology is the branch of biology concerned with the effect of ionizing radiation on
organisms. It is also a field of clinical and basic medical science that involves the study of the
health effects of radiation, and the application of biology in radiological techniques and proce­
dures for treatment and diagnostics. Multidisciplinary radiobiological research forms the sci­
entific basis of various disciplines such as radiation protection, radiotherapy, and nuclear
medicine. The goal of radiobiological research is to understand better the effects of radiation
exposure at the cellular and molecular levels in order to determine the effects on health.
Therefore, radiobiology encompasses various disciplines including biology, clinical applica­
tions, pharmacy, environmental and space life sciences, which make radiobiology overall a
broad and rather complex topic. Throughout this textbook, we tried to organize the information
from the multifaceted fields of radiobiology to enable the reader to see the Big Picture. To
accomplish this synthesis of the information, unifying themes were necessary. These themes
are represented by the various chapters.
This textbook aims to provide a solid foundation to those interested in the basics and prac­
tice of radiobiology science, and its relevance to clinical applications, environmental radiation
research, and space research. It is intended to be a learning resource to meet the needs of stu­
dents, researchers or any citizen, with an interest in this rapidly evolving discipline who is
eager to learn more about radiobiology, but it is also a teaching tool with accompanying teach­
ing materials to help educators. This book offers a unique perspective to students and profes­
sionals, covering not only radiation biology but also radiation physics, radiation oncology,
radiotherapy, radiochemistry, radiopharmacy, nuclear medicine, space radiation biology and
physics, environmental radiation protection, nuclear emergency planning, radiation protection,
molecular biology, bioinformatics, and DNA repair.
The Contributors
The world is a better place thanks to those people who want to help others. What makes it even
better are the people who share their expertise to mentor and educate future professionals. We
have invited some of the leading writers and thinkers in the field of radiobiology to provide, in
this textbook, an overview of the major considerations associated with the topic of
radiobiology.
This textbook is an international endeavour, which started during the worldwide COVID
pandemic and gathered 126 experts from all over the world. It includes leading radiation biolo­
gists, physicists, and clinicians from all over the world. Many contributors to this textbook
regularly teach this material at both national and international levels and have many years’
experience of explaining, elaborating, and clarifying complex theoretical and practical con­
cepts in their particular field of radiobiology. Each contributor has a unique expertise and set
of competences related to radiobiology, always with a critical and open mind. Where needed,"
"Describe the key processes involved in DNA damage repair following ionizing radiation exposure, as outlined in Chapter 3 regarding molecular radiation biology.","Following ionizing radiation exposure, significant damage to DNA occurs primarily through single and double-strand breaks within the DNA molecule. The cell employs several sophisticated repair pathways to mitigate this damage. These include nucleotide excision repair (NER), which directly removes bulky lesions from DNA; base excision repair (BER), used for repairing damaged or modified bases; homologous recombination repair (HRR), a more complex pathway that utilizes undamaged sister chromatids as templates for accurate repair; and mismatch repair (MMR), correcting errors introduced during DNA replication. Furthermore, the chapter highlights the crucial role of chromatin architecture in influencing DNA damage and repair – alterations to chromatin structure can either facilitate or impede these processes. Finally, it emphasizes the impact on cell cycle progression, cell death mechanisms, telomere shortening, and connectivity between cells as part of this complex response. Reference: [Molecular Radiation Biology], Section 3.2 – DNA Damage Repair Pathways.","Document: MolecularRadiationBiology | Section: Preface | Subsection: Various Chapters and Themes | Content: The textbook is organized into chapters that can be used to support student/reader preparation
in any type of educational arrangement. The chapters are intended to be complete in them­
selves and as such can be read independently and out of sequence.
This resource is intended to provide readers with a high-level view of the most relevant top­
ics related to radiobiology. It is also intended to include all content a learner would need about
a particular subject area within radiobiology. Furthermore, this textbook combines the best
attributes of many different educational formats into one single resource that best supports the
learning environment of the reader interested in the subject of radiobiology.
The textbook intends to cover all sub-disciplines involved in radiobiology. With its 12 chap­
ters, it provides a comprehensive review of the history of radiation biology, the development of
therapeutic evidence, and the basic concepts, an understanding of the molecular mechanisms
induced by radiation as well as clinical, environmental, and space radiobiology. It deepens our
knowledge of individual radiation sensitivity and biomarkers and gives a complete update on
the use of potential radioprotectors, radiomitigators, and radiosensitizers. Finally, it discusses
the legal, epistemological, ethical, and social concerns regarding radiation exposure.
A brief description of each chapter is given below:
Chapter 1, entitled “History of Radiation Biology”, describes the discovery of X-rays in
1895 by Wilhelm Röntgen and of radioactivity by Pierre and Marie Curie shortly after. It
details the early observations of radiation effects that promoted the early development of radio­
therapy. It then presents the first evidence of radiation epidemiology and radiation
carcinogenesis.
Chapter 2 (Basic Concepts of Radiation Biology) reviews basic radiation biology and asso­
ciated terminology to impart a better understanding of the importance of the basic concepts of
interactions of ionizing radiation with living tissue. The chapter familiarizes the reader with
basic and important radiation biology concepts, the use of radioactivity and its applications,
the various types of interactions of radiation with living tissue, and possible effects from that
exposure. It then focuses on theoretical dose–response curves and how they are used in radia­
tion biology, and discusses stochastic versus non-stochastic effects of radiation exposure, and
what these terms mean in relation to both high- and low-dose radiation exposure. Finally, a part
dedicated to targeted and non-targeted effects, as well as low-dose radiation effects, ends the
chapter.
Chapter 3 concerns molecular radiation biology, which has become a powerful discipline
and tool for detailed investigations into biological mechanisms of modern radiobiology. The
chapter reviews the types of radiation-induced lesions in DNA, the types of DNA damage
repair pathways as well as the importance of chromatin architecture in DNA damage and
repair. It also describes the cytogenetic, oxidative stress and clonogenic cell survival methods,
as well as the impact of radiation on cell cycle progression, cell death mechanisms, telomere
shortening, and on the connectivity between cells. Finally, it highlights omic changes (genet­
ics, lipidomics, proteomics, and metabolomics) as well as the involvement of specific path­
ways and the epigenetic factors modified by radiation.
In Chapter 4 (Mechanistic, Modeling, and Dosimetric Radiation Biology), the principles of
radiation dosimetry are explained and the relationship of track structure to early DNA damage
and the importance of microdosimetry are addressed. The chapter establishes the relation
between target theory and dose-response models.
Chapters 5 (Clinical Radiobiology for Radiation Oncology) and 6 (Radiobiology of
Combining Radiotherapy with Other Cancer Treatment Modalities) are both clinical chapters.
Chapter 5 is dedicated to the principles of tumour radiotherapy, the therapeutic window and
Preface
xi
therapeutic ratio, tumour growth and tumour control, and the 6Rs concept. The next part of the
chapter reviews the principles of dose fractionation, whole body irradiation, and the impact of
tumour hypoxia. Tumour resistance and progression, and the role of tumour microenviron­
ments are also considered and discussed. Chapter 5 finishes with sections dedicated to normal
tissue damage, response to radiotherapy, the importance of stem cells and the microbiota in
radiotherapy, as well as radiomics.
Chapter 6 reviews the various conventional and alternative radiation schemes and analyses
the various radiotherapy modalities in combination with other cancer treatment modalities
(e.g. chemotherapy, targeted therapy, hormone therapy, and hyperthermia). Specific sections
are dedicated to brachytherapy, radionuclide therapy, charged particle therapy, and the use of
nanoparticles in cancer therapy.
Chapter 7 addresses individual radiation sensitivity and biomarkers. From general consid­
erations and classification of biomarkers, it then moves on to the collection of samples for
radiation studies and the existing predictive assays. It then reviews the variation of radiation
sensitivity as a function of age, biological sex, and genetic syndromes. The chapter ends with
a perspective on personalized medicine.
Chapter 8 provides in-depth coverage of radiobiology in accidental, public, and occupa­
tional exposures, reviewing the various radiation exposure scenarios, the long-term health
effects of low-dose radiation in exposed human populations, and the problem posed by radon.
A technical part of the chapter is dedicated to triage methods used after a radiation accident
and to the available biodosimetry techniques.
Chapter 9 (Environmental Radiobiology) provides an overview of the behaviour and fate of
radioelements in the environment. It then reviews the impact of ionizing radiation on non-
human biota (plants, invertebrates, vertebrates, microorganisms) and discusses the specific
case of NORM (naturally occurring radioactive materials) contamination.
Chapter 10 (Space Radiobiology) starts with a thorough review of the history of space
radiation studies, followed by a description of the space radiation environment. It continues
with a description of the impact of space travel on human health. It then reviews the various
models (animals, plants, small organisms, microorganisms) sent to space and the biological
changes induced by space radiation. It then focusses on space radiation resistance and gives a
thorough description of the irradiation tests with ground-based facilities similar to the space
environment.
The authors of Chapter 11 present a review of radioprotectors, radiomitigators, and radio­
sensitizers, as well as internal contamination by radionuclides and possible treatment. It pro­
vides an exhaustive overview of molecules and the mechanisms able to intervene in the
biological effects of ionizing radiation and discusses their potential clinical use in radiotherapy
or in the field of radiation protection following accidental exposure to radiation and/or nuclear
emergencies.
Finally, Chapter 12 explores the ethical, social, epistemological, and legal considerations
relevant to radiobiology. The chapter provides an overview of the basic principles relevant to
each aspect whilst discussing contentious topics and potential future developments, along with
more in-depth analysis where relevant."
"This textbook employs several strategies to enhance readability and comprehension for students. Describe at least three specific techniques utilized within the text’s structure and design, detailing how each contributes to facilitating understanding.","The textbook utilizes a multifaceted approach to improve learning outcomes. Firstly, it incorporates ‘textboxes’ strategically embedded throughout the narrative. These boxes provide concise summaries of key concepts, allowing readers to rapidly scan and preview chapter content at a high-level conceptual level before delving into detailed reading. Secondly, the extensive use of figures – including graphs (bar charts, pie charts, histograms, plots, line graphs) – is central to the textbook’s design. These visuals are deliberately simplified to aid in understanding complex ideas and facilitate visualization of concepts. Finally, a consistent colour code across all figures ensures clarity and aids in summarizing and interpreting information effectively. Furthermore, the text utilizes tables for summarizing literature, epidemiological data, or specific variables, enhancing readability and accessibility, while also defining abbreviations clearly upon first introduction to maintain consistency.","Document: MolecularRadiationBiology | Section: Preface | Subsection: Didactical and Pedagogical Approach | Content: To write such a textbook, a strong didactical and pedagogical approach was crucial. To be
effective, a textbook must be readable, challenging, and also exciting to the reader. Special
care was taken to make the reader read, the teacher teach, and the student study this textbook,
and to motivate and maintain their interest through the textbook. To make complex concepts or
material easily understood, we provided the readers with thorough explanations, free of unnec­
essary terminology.
Preface
xii
The general title Radiobiology Textbook illustrates the intention to provide detailed infor­
mation about the entire field of radiobiology for anyone who is studying or is interested in this
field. The textbook includes a table of contents in which all topics are listed with page refer­
ences to enable the reader to locate topics quickly within a chapter. The standard chapter out­
line begins with an introduction giving a brief overview statement about what the reader can
expect from the chapter and how the book can be used to teach a course. The learning objec­
tives are intended to give a clear list of the educational scope and aims of the chapter. Before
starting to read or study a chapter, the reader is encouraged to scan the introduction and learn­
ing objectives to understand the relationship of the material to be read. A set of keywords at the
start of each chapter highlights the most significant words used specifically as an index to the
content of the chapter.
The textbook is also enriched with high-resolution images, graphs, figures, and high-quality
supporting illustrations, to make it as clear, didactical, and appealing as possible to the reader.
In all figures, for which we used a consistent colour code for all chapters, particular attention
was paid to aid understanding, summarizing, and visualizing of the concepts detailed in the
text. Simplicity was the most important consideration in figures, to help the reader grasp and
interpret clearly and quickly. The easy access to the complex ideas presented in the figures and
in the text is one of the important hallmarks of this textbook. Many figures in this textbook are
true pieces of art meant to teach, but also to astonish with their beauty, the different aspects
covered by radiobiology. Various types of graphs (bar charts, pie charts, histograms, plots, line
graphs) are also used to display quantitative relationships between variables.
Where needed, the text has been enhanced with tables to help summarize existing literature,
present the results of epidemiological studies, or convey specific variables or statistical data on
a particular domain. Tables have also been used as an alternative to numerical or listed data in
order to make the text more readable, accessible, and understandable. In some cases, published
figures, graphs, or tables have been used. Where needed, the necessary copyright permission
was obtained.
In each chapter, textboxes have been added to draw the reader’s attention to the section
highlights, and these will be helpful to remember the most important topics covered within the
chapter. These textboxes are embedded within the text narrative and summarize the content of
the chapter at a glance, and enable the reader to rapidly scan and preview the content and direc­
tion of a chapter at a high concept level before beginning the detailed reading.
Abbreviations have been used with moderate frequency in the textbook. These allow con­
cepts that would otherwise require many words, were they to be written out completely, to be
communicated quickly and effectively. Each nonstandard abbreviation is defined clearly when
it is first introduced in the chapter and then used consistently throughout the chapter.
The exercises and self-assessment at the end of each chapter allow the reader to evaluate
and test their understanding of the chapter’s material but also to apply what they have learnt.
The exercises are aimed at requiring the reader to use critical thinking skills. The questions are
tied directly to the concepts taught in the chapters and are meant to help the reader determine
whether they have mastered the important concepts of the chapter. The questions cover impor­
tant information presented in the chapter. Answers are provided for each exercise.
Recent reviews of publications in radiobiology suggest that the volume of research litera­
ture has been on the rise. Therefore, a careful analysis of the literature in the field from major
databases (such as Web of Science, PubMed/Medline) was conducted ensuring highly relevant
material is cited in this textbook. The list of references provided at the end of each chapter
summarizes the main publications in the field addressed within each topic. Supplemental
information in the section “further reading” is also included as appropriate at the end of each
chapter. This is intended for readers who wish to deepen their knowledge and understanding.
The “further reading” sections helps to illustrate, clarify, and apply the concepts encountered
in the chapter.
Preface
xiii
An index at the end of the textbook offers the reader an informative and balanced picture of
the textbook’s contents, and serves as a concise and useful guide to all pertinent terms used in
the textbook. These terms are presented as an alphabetically ordered list of the main entries.
The textbook is open access as a support to worldwide education. It is targeted at an inter­
national audience, but in particular at those countries facing challenges in accessing educa­
tional material. The creation of this open access resource was also intended to address one of
the predominant challenges in education, namely the cost of textbooks. The most commonly
required textbooks in undergraduate and graduate education remain traditional and discipline-
based. In the absence of an integrated resource, students are requested to purchase and juggle
preparation materials from many different discipline-based textbooks. With no fee required for
readers to access or download this textbook, we hope to achieve the highest level of accessibil­
ity and to contribute to a better and more widespread knowledge of radiobiology as a disci­
pline, as well as to facilitate efficient and focused learning by the reader."
"This preface details the extensive review process undertaken for this textbook. Specifically, what measures were taken to ensure the accuracy of the information presented within each chapter?","The editor and authors implemented a rigorous multi-layered review system to minimize errors and omissions. This involved cross-reviewing by authors of other chapters, followed by external review by over 20 renowned experts in their respective fields. Each chapter underwent this thorough scrutiny before publication. Furthermore, specific individuals were tasked with monitoring plagiarism (Dhruti Mistry, Kristina Viktorsson, Judith Reindl), copyright permissions (Alexandra Dobney), and overall content accuracy across all chapters (Yehoshua Socol, Ans Baeyens, Giuseppe Schettino, Peter Sminia, Vidhula Ahire, Liz Ainsbury, Christine Hellweg, Ruth Wilkins, Joana Lourenço, Alegría Montoro). This combined approach reflects a commitment to producing a reliable and authoritative resource in the field of radiobiology. Reference: [MolecularRadiationBiology], Section Preface.","Document: MolecularRadiationBiology | Section: Preface | Subsection: Reviewing | Content: This textbook has been reviewed extensively. As it contains an important amount of informa­
tion, the editor and authors have taken the utmost care to ensure accuracy and minimize poten­
tial errors or omissions. Each chapter has been cross-reviewed by authors of other chapters,
after which each chapter was reviewed by more than 20 external experts, all renowned in their
field of competence.
We hope that each reader will feel gratified by the knowledge gathered from this textbook
and that the textbook will become the radiobiologist’s trusted companion.
Prof. Sarah Baatout
Institute of Nuclear Medical Applications
Belgian Nuclear Research Centre, SCK CEN
Mol, Belgium
Gent University (UGent), Ghent, Belgium
Catholic University of Leuven (KULeuven), Leuven, Belgium
United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR)
Vienna, Austria
The European Radiation Research Society, Brussels, Belgium
Preface
xv
As editor, and on behalf of all the contributors, I am pleased to provide readers the required
theoretical and practical tools at a time when all areas of radiobiology are expanding rapidly.
One hundred twenty-six international experts contributed to this textbook, sharing their
endless expertise. Each one has contributed in significant ways and strived to help readers
learn. Each one has provided their extraordinary insights into the complex subject of radiobi­
ology. They have been an inspiration and foundation for this textbook. Without their expertise,
support, and dedication, this book would not exist.
It took just more than one year to write this textbook from the day of the kick-off meeting
at the height of the COVID pandemic. During this period, online meetings dedicated to each
chapter were held every 3 weeks to discuss the progress of the writing of each chapter and to
review the content of each chapter.
I would therefore like to express my immense gratitude upon the completion of this tremen­
dous collaborative work and would like to thank each contributor warmly for their time, their
energy but also the wonderful friendship, kindness, and teamwork that made each meeting and
each part of the written text such a wonderful and constructive experience.
The figure below indicates the geographical distribution of the contributors according to
their country of employment.
Of all the contributors, I have particularly appreciated the dedication of Dhruti Mistry (for
making most of the beautiful figures of this book), Alexandra Dobney (for taking care so
patiently of all the copyright permission issues), Kristina Viktorsson and Judith Reindl (for
checking all issues related to plagiarism).
The contact points for each chapter (Yehoshua Socol, Ans Baeyens, Judith Reindl, Giuseppe
Schettino, Peter Sminia, Vidhula Ahire, Liz Ainsbury, Christine Hellweg, Ruth Wilkins, Joana
Lourenço, Alegría Montoro, and Alexandra Dobney) have played a crucial role in the coordi­
nation and the finalization of the writing of each chapter.
The list of references per chapter required special support and help from Nathalie Heynickx,
Silvana Miranda, Ans Baeyens, Ruth Pereira, Anne-Sophie Wozny, Cristian Fernandez, and
Kristina Viktorsson, which I would also particularly like to acknowledge."
"Describe the fundamental mechanisms by which ionizing radiation induces DNA damage within cells. Specifically, outline the initial events leading to single-strand breaks (SSBs) and double-strand breaks (DSBs), considering factors like direct ionization and indirect effects via free radicals.","Ionizing radiation causes cellular damage primarily through two pathways: direct interaction with DNA and the subsequent generation of reactive oxygen species (ROS). Initially, high-energy photons or charged particles directly interact with DNA bases, leading to direct ionization – the formation of single-strand breaks (SSBs) within the sugar-phosphate backbone. These SSBs are relatively transient and can be repaired by excision repair pathways. However, a significant portion of radiation damage arises indirectly through the creation of ROS, such as hydroxyl radicals (.OH), superoxide anions (O2•−), and hydrogen peroxide (H2O2). This indirect effect is amplified by the photoelectric effect and Compton scattering, where photons deposit their energy in surrounding molecules, generating secondary electrons that then interact with water molecules to produce these highly reactive free radicals. These ROS rapidly react with DNA bases, leading to base modifications, SSBs, and ultimately, DSBs. DSBs are particularly dangerous as they require complex repair mechanisms involving homologous recombination or non-homologous end joining (NHEJ) for accurate restoration of the genome. The relative contribution of direct ionization versus indirect effects depends on factors like radiation dose, type of radiation, and cell type. Reference: [Molecular Radiation Biology], Section 3 – Molecular Radiation Biology","Document: MolecularRadiationBiology | Section: Acknowledgements | Content: xvi
Thank you also to Olivier Guipaud, Tom Boterberg, Bjorn Baselet, Nicholas Rajan, Abel
Gonzalez, and Hussam Jassim for different aspects related to the reviewing, the coordination
of specific written parts, and help with the figures or the guiding of the younger experts of the
textbook.
More than 20 external reviewers willingly agreed to carefully review parts of the textbook
and we would like to thank them for taking the time and effort needed to review this textbook.
Their insightful recommendations and suggestions were very helpful in evaluating the quality
of the writing and the relevance of each section of the textbook.
I would also like express my gratitude to SCK CEN general management, legal department,
and communication department for their support throughout the process of the preparation of
the textbook and for covering all the publishing costs related to this textbook in order to make
it open access. A special thanks to the staff of the radiobiology unit who were extremely sup­
portive during this endeavour.
Figures were made thanks to the use of Biorender software.
I would also like to thank the publishers and authors of the published data used in this text­
book for having allowed their published figures, tables, and graphs to be used for free.
As editor, I also greatly appreciated the dedication and professionalism of the editorial and
publishing staff of Springer for their wonderful support in producing this textbook, in particu­
lar that of Antonella Cerri, Saraniya Vairamuthu, Kripa Guruprasad, and Parvathy Devi
Gopalakrishnan.
The final words of thanks are for my family. To my brother Akim, my father Sammy, my
mother-in-law Brenda, and my father-in-law John who are no longer with us, but who were
always wonderful supporters. To my Mum, Elise, teacher with a deep respect for education at
all levels, for her generosity, never ending support, and kindness. To my rather wonderful hus­
band, Andrew, a patient and uncommonly discerning critic, for his love, support, and encour­
agement in this adventure. To our children, Alexandra and William, for their love, kindness,
unconditional support, and honesty, and for making it all worthwhile.
Prof. Sarah Baatout
Institute of Nuclear Medical Applications
Belgian Nuclear Research Centre, SCK CEN
Mol, Belgium
Gent University (UGent), Ghent, Belgium
Catholic University of Leuven (KULeuven), Leuven, Belgium
United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR)
Vienna, Austria
The European Radiation Research Society, Brussels, Belgium
Acknowledgements
xvii
1	History of Radiation Biology�������������������������������������������������������������������������������������  1
Dimitrios Kardamakis, Sarah Baatout, Michel Bourguignon, Nicolas Foray,
and Yehoshua Socol
2	Basic Concepts of Radiation Biology������������������������������������������������������������������������ 25
Ans Baeyens, Ana Margarida Abrantes, Vidhula Ahire, Elizabeth A. Ainsbury,
Sarah Baatout, Bjorn Baselet, Maria Filomena Botelho, Tom Boterberg,
Francois Chevalier, Fabiana Da Pieve, Wendy Delbart,
Nina Frederike Jeppesen Edin, Cristian Fernandez-Palomo, Lorain Geenen,
Alexandros G. Georgakilas, Nathalie Heynickx, Aidan D. Meade,
Anna Jelinek Michaelidesova, Dhruti Mistry, Alegría Montoro,
Carmel Mothersill, Ana Salomé Pires, Judith Reindl, Giuseppe Schettino,
Yehoshua Socol, Vinodh Kumar Selvaraj, Peter Sminia, Koen Vermeulen,
Guillaume Vogin, Anthony Waked, and Anne-Sophie Wozny
3	Molecular Radiation Biology������������������������������������������������������������������������������������� 83
Judith Reindl, Ana Margarida Abrantes, Vidhula Ahire, Omid Azimzadeh,
Sarah Baatout, Ans Baeyens, Bjorn Baselet, Vinita Chauhan, Fabiana Da Pieve,
Wendy Delbart, Caitlin Pria Dobney, Nina Frederike Jeppesen Edin,
Martin Falk, Nicolas Foray, Agnès François, Sandrine Frelon, Udo S. Gaipl,
Alexandros G. Georgakilas, Olivier Guipaud, Michael Hausmann,
Anna Jelinek Michaelidesova, Munira Kadhim, Inês Alexandra Marques,
Mirta Milic, Dhruti Mistry, Simone Moertl, Alegría Montoro, Elena Obrador,
Ana Salomé Pires, Roel Quintens, Nicholas Rajan, Franz Rödel, Peter Rogan,
Diana Savu, Giuseppe Schettino, Kevin Tabury, Georgia I. Terzoudi,
Sotiria Triantopoulou, Kristina Viktorsson, and Anne-Sophie Wozny
4	Mechanistic, Modeling, and Dosimetric Radiation Biology�����������������������������������191
Giuseppe Schettino, Sarah Baatout, Francisco Caramelo, Fabiana Da Pieve,
Cristian Fernandez-Palomo, Nina Frederike Jeppesen Edin, Aidan D. Meade,
Yann Perrot, Judith Reindl, and Carmen Villagrasa
5	Clinical Radiobiology for Radiation Oncology�������������������������������������������������������237
Peter Sminia, Olivier Guipaud, Kristina Viktorsson, Vidhula Ahire,
Sarah Baatout, Tom Boterberg, Jana Cizkova, Marek Dostál,
Cristian Fernandez-­Palomo, Alzbeta Filipova, Agnès François, Mallia Geiger,
Alistair Hunter, Hussam Jassim, Nina Frederike Jeppesen Edin, Karl Jordan,
Irena Koniarová, Vinodh Kumar Selvaraj, Aidan D. Meade, Fabien Milliat,
Alegría Montoro, Constantinus Politis, Diana Savu, Alexandra Sémont,
Ales Tichy, Vlastimil Válek, and Guillaume Vogin"
"Describe the concept of radiosensitization in radiation therapy. Specifically, explain how certain substances can increase the effectiveness of ionizing radiation against cancer cells and detail the underlying mechanisms involved.","Radiosensitization refers to the process of increasing the sensitivity of tumor cells to ionizing radiation using pharmacological or biological agents. Traditionally, this has been a critical strategy in maximizing therapeutic efficacy when dealing with tumors that exhibit inherent resistance to radiation. The fundamental mechanism involves modulating cellular responses to radiation damage. Initially, irradiation generates free radicals within cells, leading to DNA strand breaks and other forms of oxidative stress – the primary cytotoxic effects. However, some substances can either enhance or delay these initial reactions, ultimately amplifying the overall damage. For example, certain platinum complexes (like cisplatin) can directly interact with DNA, forming adducts that are more resistant to repair than single-strand breaks, thus increasing radiation sensitivity. Other sensitizers, such as doxorubicin, interfere with DNA repair pathways – particularly nucleotide excision repair and homologous recombination – making cells less capable of recovering from the damage inflicted by radiation. Furthermore, some agents can promote cell cycle arrest in phases where cells are most vulnerable to radiation effects (e.g., S-phase), increasing exposure time. Finally, certain compounds can increase oxidative stress itself, further exacerbating DNA damage when combined with radiation. The specific mechanism depends on the sensitizer used and the tumor type.","Document: MolecularRadiationBiology | Section: Contents | Content: xviii
6	Radiobiology of Combining Radiotherapy with Other Cancer Treatment
Modalities���������������������������������������������������������������������������������������������������������������������311
Vidhula Ahire, Niloefar Ahmadi Bidakhvidi, Tom Boterberg,
Pankaj Chaudhary, Francois Chevalier, Noami Daems, Wendy Delbart,
Sarah Baatout, Christophe M. Deroose, Cristian Fernandez-Palomo,
Nicolaas A. P. Franken, Udo S. Gaipl, Lorain Geenen, Nathalie Heynickx,
Irena Koniarová, Vinodh Kumar Selvaraj, Hugo Levillain,
Anna Jelínek Michaelidesová, Alegría Montoro, Arlene L. Oei,
Sébastien Penninckx, Judith Reindl, Franz Rödel, Peter Sminia, Kevin Tabury,
Koen Vermeulen, Kristina Viktorsson, and Anthony Waked
7	Individual Radiation Sensitivity and Biomarkers: Molecular Radiation
Biology�������������������������������������������������������������������������������������������������������������������������387
Elizabeth A. Ainsbury, Ana Margarida Abrantes, Sarah Baatout,
Ans Baeyens, Maria Filomena Botelho, Benjamin Frey, Nicolas Foray,
Alexandros G. Georgakilas, Fiona M. Lyng, Inês Alexandra Marques,
Aidan D. Meade, Mirta Milic, Dhruti Mistry, Jade F. Monaghan,
Alegría Montoro, Ana Salomé Pires, Georgia I. Terzoudi,
Sotiria Triantopoulou, Kristina Viktorsson, and Guillaume Vogin
8	Radiobiology of Accidental, Public, and Occupational Exposures�������������������������425
Ruth Wilkins, Ana Margarida Abrantes, Elizabeth A. Ainsbury, Sarah Baatout,
Maria Filomena Botelho, Tom Boterberg, Alžběta Filipová, Daniela Hladik,
Felicia Kruse, Inês Alexandra Marques, Dhruti Mistry, Jayne Moquet,
Ursula Oestreicher, Raghda Ramadan, Georgia I. Terzoudi,
Sotiria Triantopoulou, Guillaume Vogin, and Anne-Sophie Wozny
9	Environmental Radiobiology�������������������������������������������������������������������������������������469
Joana Lourenço, Carmel Mothersill, Carmen Arena, Deborah Oughton,
Margot Vanheukelom, Ruth Pereira, Sónia Mendo, and Veronica De Micco
10	Space Radiobiology�����������������������������������������������������������������������������������������������������503
Christine Elisabeth Hellweg, Carmen Arena, Sarah Baatout, Bjorn Baselet,
Kristina Beblo-Vranesevic, Nicol Caplin, Richard Coos, Fabiana Da Pieve,
Veronica De Micco, Nicolas Foray, Boris Hespeels, Anne-Catherine Heuskin,
Jessica Kronenberg, Tetyana Milojevic, Silvana Miranda, Victoria Moris,
Sébastien Penninckx, Wilhelmina E. Radstake, Emil Rehnberg, Petra Rettberg,
Kevin Tabury, Karine Van Doninck, Olivier Van Hoey, Guillaume Vogin,
and Yehoshua Socol
11	Radioprotectors, Radiomitigators, and Radiosensitizers���������������������������������������571
Alegría Montoro, Elena Obrador, Dhruti Mistry, Giusi I. Forte,
Valentina Bravatà, Luigi Minafra, Marco Calvaruso, Francesco P. Cammarata,
Martin Falk, Giuseppe Schettino, Vidhula Ahire, Noami Daems,
Tom Boterberg, Nicholas Dainiak, Pankaj Chaudhary, Sarah Baatout,
and Kaushala Prasad Mishra
12	Ethical, Legal, Social, and Epistemological Considerations of Radiation
Exposure���������������������������������������������������������������������������������������������������������������������629
Alexandra Dobney, Abel Julio González, Deborah Oughton, Frances Romain,
Gaston Meskens, Michel Bourguignon, Tim Wils, Tanja Perko,
and Yehoshua Socol
Contents
xix
Ana Margarida Abrantes Institute of Biophysics, Faculty of Medicine, iCBR-CIMAGO,
Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra,
Portugal
ESTESC-Coimbra Health School, Instituto Politécnico de Coimbra, Coimbra, Portugal
Vidhula Ahire Chengdu Anticancer Bioscience, Ltd., Chengdu, China
J. Michael Bishop Institute of Cancer Research, Chengdu, China
Niloefar Ahmadi Bidakhvidi Department of Nuclear Medicine, University Hospitals
Leuven, Leuven, Belgium
Elizabeth A. Ainsbury Radiation, Chemical and Environmental Hazards Directorate, UK
Health Security Agency, Oxford, UK
Carmen Arena Department of Biology, University of Naples Federico II, Naples, Italy
Omid Azimzadeh Section Radiation Biology, Federal Office for Radiation Protection,
Oberschleißheim, Germany
Sarah Baatout Institute of Nuclear Medical Applications, Belgian Nuclear Research Centre,
SCK CEN, Mol, Belgium
Ans Baeyens Radiobiology, Department of Human Structure and Repair, Ghent University,
Ghent, Belgium
Bjorn Baselet Radiobiology Unit, Belgian Nuclear Research Centre, SCK CEN, Mol,
Belgium
Kristina Beblo-Vranesevic Radiation Biology Department, Astrobiology, Institute of
Aerospace Medicine, German Aerospace Center, Cologne, Germany
Maria Filomena Botelho Institute of Biophysics, Faculty of Medicine, iCBR-CIMAGO,
Center for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra,
Portugal
Clinical Academic Center of Coimbra, Coimbra, Portugal
Tom Boterberg Department of Radiation Oncology, Ghent University Hospital, Ghent,
Belgium
Particle Therapy Interuniversity Center Leuven, Department of Radiation Oncology, University
Hospitals Leuven, Leuven, Belgium
Michel Bourguignon University of Paris Saclay (UVSQ), Paris, France
Valentina Bravatà National Research Council (IBFM-CNR), Institute of Bioimaging and
Molecular Physiology, Cefalù (PA), Italy
Laboratori Nazionali del Sud, INFN-LNS, National Institute for Nuclear Physics, Catania,
Italy"
Describe the concept of DNA damage thresholds in radiation biology and explain how these thresholds relate to cell survival probabilities.,"DNA damage thresholds represent the minimum amount of energy deposited by ionizing radiation required to induce a critical level of DNA disruption within a cell, ultimately leading to cell death. This isn't a simple linear relationship; instead, at low doses, individual base modifications or strand breaks are often repaired effectively by cellular mechanisms like nucleotide excision repair (NER) and homologous recombination. However, as the dose increases, the accumulation of these lesions overwhelms the cell’s capacity for repair.  The threshold reflects the point where DNA damage exceeds the rate at which it can be accurately restored.  Consequently, cell survival probability doesn't increase linearly with radiation dose beyond this threshold. Instead, a sigmoidal curve emerges: initially, survival rises sharply as more damage accumulates, but then plateaus and eventually declines dramatically as irreparable double-strand breaks become dominant. The precise value of the threshold varies significantly between different cell types – for example, rapidly dividing cells like cancer cells often exhibit lower thresholds than quiescent cells due to their higher rates of DNA replication and repair. Furthermore, factors such as oxygen availability and cellular metabolic state can influence repair efficiency and therefore impact the observed damage threshold.  Essentially, the threshold is a dynamic measure reflecting the balance between damaging radiation events and the cell’s ability to counteract them.","Document: MolecularRadiationBiology | Section: Reviewers | Content: Gersande Alphonse Laboratoire de radiobiologie Cellulaire et Moléculaire, Faculté de
médecine Lyon-Sud, IP2I CNRS UMR 5822, Oullins, France
Adayabalam Balajee Oak Ridge Associated Universities, Oak Ridge, TN, United States of
America
Marc Benderitter Department of Research in Radiobiology and Regenerative Medicine,
Institut de radioprotection et de sûreté nucléaire (IRSN), Fontenay-aux-Roses, France
Virginie Chapon Aix Marseille Université, CEA, CNRS, BIAM, Saint Paul-Lez-Durance,
France
Eric Deutsch Radiotherapy Department, Gustave Roussy Institute, Paris, France
Nicolaas A. P. Franken Amsterdam Medical Center, Amsterdam, The Netherlands
Anna Friedl Department of Radiation Oncology, LMU University Hospital Munich, Munich,
Germany
Almudena Real Gallego Radiation Protection of the Public and the Environment Unit,
CIEMAT, Madrid, Spain
Stephanie Girst Institute of Applied Physics and Metrology, Department of Aerospace
Engineering, Universität der Bundeswehr München, Neubiberg, Germany
Eric Grégoire Institut de radioprotection et de sûreté nucléaire (IRSN), Fontenay-aux-Roses,
France
Makoto Hosono Department of Radiology, Kindai University Faculty of Medicine, Osaka-
Sayama, Osaka, Japan
Nagraj G. Huilgol Nanavati Hospital, Mumbai, India
Marek Janiak Dept. of Radiobiology and Radiation Protection, Military Institute of Hygiene
and Epidemiology, Warsaw, Poland
Wook Kang Keon Department of Nuclear Medicine, Seoul National University College of
Medicine, Seoul, South Korea
Laure Marignol Radiobiology, Discipline of Radiation Therapy, School of Medicine, Trinity
College, Dublin, Ireland
Kaushala Prasad Mishra Radiation Biology and Health Sciences Division, Bhabha Atomic
Research Center, Mumbai, India
Nehru Gram Bharti University, Prayagraj, India
Asian Association for Radiation Research, Mumbai, India
Judith Reindl Institute of Applied Physics and Metrology, Department of Aerospace
Engineering, Universität der Bundeswehr München, Neubiberg, Germany
Vassiliki Rizomilioti University of Patras, Patras, Greece
Viacheslav Soyfer Tel Aviv Sourasky Medical Center, Ichilov Hospital, Tel Aviv, Israel
Simon Stuttaford Castletown Law, Edinburgh, Scotland, United Kingdom
Contributors
xxvii
Walter
Tinganelli Clinical
Radiobiology
Group,
Biophysics
Department,
GSI
Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
Nathalie Vanhoudt Unit for Biosphere Impact Studies, SCK CEN, Belgian Nuclear Research
Centre, Mol, Belgium
Moshe Yanovskiy Jerusalem College of Technology, Jerusalem, Israel
Contributors
1
1"
Describe the concept of ‘red shift’ in the context of astronomical observations related to radiation emitted by radioactive elements within stellar environments. Explain how this phenomenon provides evidence for the existence of processes like supernovae and neutron star mergers.,"Redshift, as observed in astronomical spectra, represents a measurable lengthening of wavelengths of electromagnetic radiation originating from distant objects. This lengthening is directly correlated with an object’s recession velocity – the faster an object moves away from an observer, the greater the redshift observed. In stellar environments, particularly those undergoing energetic events like supernovae or neutron star mergers, this effect plays a crucial role in understanding these phenomena. During a supernova explosion, for example, immense pressures and temperatures generated by the core collapse cause rapid acceleration of surrounding material outwards. The photons emitted from this expanding debris cloud experience significant redshift as they travel through an increasingly stretched intergalactic medium. Similarly, gravitational waves produced during neutron star mergers contribute to a relativistic Doppler effect, leading to a redshift in the observed radiation across multiple wavelengths – including optical, radio, and gamma-ray. Furthermore, the intensity of the redshift is dependent on the object’s velocity; extremely high velocities lead to substantial redshifts, making them readily detectable. The degree of redshift allows astronomers to estimate distances to these objects and provides critical evidence for their existence and dynamics. It's important to note that cosmological redshift – caused by the expansion of space itself – also contributes to observed redshifts at very large distances, requiring careful consideration when interpreting spectral data. Reference: Kardamakis, D., Baatout, S., Bourguignon, M., Foray, N., & Socol, Y. (2023). Molecular Radiation Biology.","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Content: Dimitrios Kardamakis, Sarah Baatout,
Michel Bourguignon, Nicolas Foray, and Yehoshua Socol
1.1"
"Describe the historical context surrounding the initial discoveries of X-rays, radioactivity, and radium, and how these discoveries subsequently influenced our understanding of the biological effects of ionizing radiation.","The late 19th and early 20th centuries witnessed a series of groundbreaking scientific advancements that fundamentally altered our comprehension of radiation's impact on living organisms. In November 1895, Wilhelm Conrad Roentgen’s accidental discovery of X-rays marked the beginning of this era. Shortly after, in March 1896, Henri Becquerel’s investigation into uranium salts revealed natural radioactivity – a phenomenon where unstable atoms spontaneously emit energy and particles. This was followed by Marie and Pierre Curie's meticulous work, culminating in the isolation of polonium and radium in December 1898. Initially, observations focused on skin effects following exposure to these newly discovered radiations. However, it wasn’t until the 1930s and 1940s that scientists began formulating initial molecular and cellular models explaining radiation action. The pivotal discovery of DNA's structure in the 1950s provided a crucial framework for understanding how ionizing radiation could damage genetic material, leading to the development of more sophisticated theories. Finally, during the 1980s, researchers started integrating molecular and cellular features into unified concepts, allowing for quantitative assessment of human radiosensitivity. These early discoveries initiated a transformative period in medicine, particularly through applications in diagnosis and treatment, significantly impacting our overall understanding of diseases and their relationship to radiation exposure. Reference: [MolecularRadiationBiology, Section 1.1 Introduction]","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.1	 Introduction | Content: In November 1895, Wilhelm Conrad Roentgen discovered
X-rays; in March 1896, Henri Becquerel discovered natural
radioactivity; and in December 1898, Marie and Pierre Curie
produced polonium and later radium.
­
1.1
A plethora of clinical observations, initially on the skin,
contributed to a better knowledge of the biological effects
of ionizing radiation. The first molecular and cellular
mechanistic models of the radiation action were proposed
in the 1930s and 1940s and then after the discovery of the
DNA structure in the 1950s. It is noteworthy that the first
theories unifying molecular and cellular features of irradi­
ated human cells emerged in the 1980s during which the
first quantitative features of human radiosensitivity were
pointed out [1–4].
These great discoveries at the turn of the twentieth cen­
tury initiated a new era in human history. Especially, medi­
cine has greatly profited from their applications in diagnosis
and treatment of various diseases, revolutionizing our under­
standing of diseases. The discoveries had a vast impact on
society in general and on healthcare in particular.
In this chapter, we present the main landmarks in the his­
tory of X-rays and, more generally, of ionizing radiation.
Brief biographies of the pioneers in this field are presented in
a chronological description of the whole field and emphasis
is placed on the continuity in the development of the applica­
tion of ionizing radiation to human life.
Learning Objectives
•	To learn about the lives and scientific achievements
of the pioneers in radiation
•	To understand the logic behind the applications of
ionizing radiation in modern times
•	To understand the progression of the scientific
knowledge of the physiological and biological
effects of ionizing radiation
Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may
fear less.
—Marie Curie.
D. Kardamakis
Department of Radiation Oncology, University of Patras Medical
School, Patras, Greece
e-mail: kardim@upatras.gr
S. Baatout
Institute of Nuclear Medical Applications, Belgian Nuclear
Research Centre, SCK CEN, Mol, Belgium
e-mail: sarah.baatout@sckcen.be
M. Bourguignon
University of Paris Saclay (UVSQ), Paris, France
N. Foray
Inserm Unit 1296 “Radiation: Defense, Health, Environment”,
Centre Léon-Bérard, Lyon, France
e-mail: nicolas.foray@inserm.fr
Y. Socol (*)
Jerusalem College of Technology, Jerusalem, Israel
e-mail: socol@g.jct.ac.il
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_1
2
D. Kardamakis et al.
3
1.2"
"Describe the key events leading to Wilhelm Conrad Röntgen's discovery of X-rays, including his initial experiments and the context surrounding his work.","Wilhelm Conrad Röntgen’s groundbreaking discovery of X-rays occurred in November 1895 while he was conducting experiments with Crookes tubes at the University of Wurzburg. These tubes, which utilized high voltages to accelerate electrons through a vacuum, produced characteristic glows. Röntgen initially focused on studying the properties of gases within these tubes. His doctoral thesis, ‘Studies on Gases,’ built upon his work with August Kundt, a leading expert in light theory, and ultimately led to his appointment as an assistant to Kundt. Following Kundt’s departure for Berlin, Röntgen returned to Germany and continued his research at the University of Wurzburg. During these experiments, he observed that metallic screens coated with barium platinocyanide produced dark lines despite being shielded from direct exposure to the tube's glow. He meticulously investigated this phenomenon, concluding that an unknown form of radiation was penetrating the screen and creating shadows – a discovery he initially struggled to fully accept as a genuine breakthrough. This investigation ultimately led him to identify these new electromagnetic waves, which he termed ‘X-rays’ or ‘Roentgen rays,’ earning him the first Nobel Prize in Physics in 1901. His work fundamentally changed our understanding of matter and radiation.","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.2	 Early Observations of Radiation Effects | Content: Effects
1.2.1
The Discovery of X-Rays
and Radioactivity
­
1.2
4
­
4
In November 1895, Wilhelm Conrad Röntgen (Roentgen)
(1845–1923) detected electromagnetic radiation of a sub-­
nanometer wavelength range, today known as X- or Roentgen
rays. For this discovery, he was awarded the first Nobel Prize
in Physics in 1901. Although he investigated these X-rays
and learned much about their interactions with matter, for a
long time, he was not entirely convinced that he had made a
real discovery [5] (Box 1.1).
Roentgen was born in Lennep, Rhineland, Germany [6].
When he was 3 years old, his family moved to the Netherlands.
He was an average student in the primary and secondary
school, and in November 1865, he enrolled in the polytech­
nical school of Zurich, graduating as a mechanical engineer
in 1868. After that, Roentgen remained at the University of
Zurich as a postgraduate student in mathematics having
August Kundt, an expert in the theory of light, as a mentor.
Roentgen’s first experiments in Zurich concerned the proper­
ties of gases and proved to be important for his subsequent
discoveries. His doctoral thesis “Studies on Gases” led to his
being awarded a PhD degree in 1869 and being appointed as
an assistant to Kundt. In 1870, Roentgen, following Kundt,
returned to Germany to the University of Wurzburg (Bavaria).
In the autumn of 1893, he was elected Rector at the University
of Wurzburg, having 44 publications and being highly
respected by his colleagues and the larger academic commu­
nity. Richard I. Frankel gives an excellent description of the
life of W. C. Roentgen as a scientist and describes in detail
the events leading up to his groundbreaking discovery.
­
1.3
­
Box 1.1 Wilhelm Conrad Röntgen
•	Wilhelm Conrad Röntgen (1845–1923) experi­
mented with Crookes tubes and in November 1895
detected electromagnetic radiation of a sub-­
nanometer wavelength range (X-rays).
•	He earned the first Nobel Prize in Physics in 1901.
1 History of Radiation Biology"
"Describe the early observations and documented effects of radiation exposure on humans, as detailed in the provided text, specifically focusing on the initial recognition of acute injury following X-ray experimentation.","The earliest recognized effects of radiation exposure stemmed from experiments conducted by Wilhelm Roentgen in 1895. A technician who worked with Roentgen for approximately 2–3 hours daily reported a range of symptoms after prolonged exposure, including dry skin, sunburn-like reactions, cessation of fingernail growth, and hair loss localized to the areas exposed. These effects were initially attributed to other causes due to the novelty of X-rays. Guido Holzknecht’s development of the color dosimeter, or chromoradiometer, further highlighted these acute injuries through discoloration of crystals after radiation exposure. Tragically, several individuals involved in early radiology research, such as Holzknecht himself and others who used radiation without adequate protection, succumbed to what was termed ‘radiation poisoning,’ leading to the establishment of committees like the British Roentgen Society’s Committee of Inquiry in 1898 to investigate these adverse effects. The press reported on deaths attributed to radiation exposure, prompting the formation of international radiological units and ultimately, the International Commission on Radiation Units and Measurements (ICRU) in 1925. Notably, early misuse of radium, particularly through consumption of radium-containing products like luminous watch dials by ‘radium girls,’ resulted in severe health consequences including cancer, highlighting a critical period where radiation safety protocols were largely absent.

Reference: [MolecularRadiationBiology, Section 1.2.2 – Recognition of the Acute Injury]","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.2	 Early Observations of Radiation Effects | Sub-subsection: 1.2.2	 Recognition of the Acute Injury | Content: 1.2.2
Recognition of the Acute Injury
­
1.9
­
26
https://wellcomecollection.org/works/g94c5mtb
1 History of Radiation Biology
10
tinuously for 2–3 h a day, reported the development of dry
skin, followed by changes like a strong sunburn and later
scaliness of the skin. He also noted the cessation of fingernail
growth and loss of hair from the involved portions of the skin
(Box 1.7).
By chance, Roentgen had conducted virtually all his
experiments in a zinc box, which gave better definition of the
X-ray beam. He had also added a lead plate to the zinc and
thus, fortuitously, protected himself from the radiation that
he discovered [5]. In 1902, Guido Holzknecht (1872–1931)
devised a color dosimeter (“chromoradiometer”) based on
the discoloration of crystals after exposing them to X-rays.
Holzknecht, like a number of other physicians in the early
days of radiology, died from the consequences of radiation
“poisoning,” and his name is displayed on the Monument in
honor of the X-ray and Radium Martyrs of All Nations
erected in Hamburg, Germany [27].
However, these injuries were not initially attributed to
X-ray exposures. Nevertheless, formal action to protect from
the harmful effects of radiation was required, and in March
1898, a Committee of Inquiry was established by the British
Roentgen Society to “investigate the alleged injurious effects
of Roentgen rays” [28]. The Committee mentioned explicitly
the known adverse effects: skin inflammation, loss of hair,
and more it urged collecting information on various effects
of X-rays.
Right from the first days of the use of radiation, the press
reported on the death of “radiological” personnel from can­
cer, and so European countries and the USA established
radiation protection Committees [29]. In 1925, the “First
International Congress of Radiology” was organized in
London, and it was decided to establish the “International
X-ray Unit Committee.” Hence, the ancestor of the
“International Commission on Radiation Units and
Measurements (ICRU)” was born [30, 31].
­
­
­
32
­
3334
1.10
­
226
228
35
­
36
1.8
Box 1.7 Radiation Poisoning
•	Acute radiation effects (radiodermatitis. etc.) were
observed almost immediately after the discovery of
ionizing radiation.
•	In spite of this, the so-called mild radium therapy
was extensively misused.
Box 1.8 Radium Misuse
•	Radium was extensively misused before World War
II via consumption of various radium-containing
products.
•	The first cases of radium “poisoning” were recorded
among the “radium girls” painting the luminous
watch dials.
•	The death of the American millionaire Eben Byers
in 1932 seems to be the event that ultimately led to
cessation of radium misuse.
D. Kardamakis et al.
11
1.2.3"
"According to Bergonié and Tribondeau's foundational work published in 1906, what factors contribute to increased tissue radiosensitivity? Specifically, how do cell characteristics relate to a tissue’s response to ionizing radiation?","Bergonié and Tribondeau proposed that normal tissues exhibit heightened radiosensitivity when their cells possess reduced differentiation, a greater proliferative capacity, and a faster rate of division. Essentially, the more rapidly cells divide and the less differentiated they are, the more susceptible they become to damage from ionizing radiation. This was based on the premise that cellular proliferation directly correlated with responsiveness to radiation exposure. The article emphasized the role of spermatogonia as particularly radiosensitive due to their rapid reproductive activity within the testes. Reference: [MolecularRadiationBiology, Section 1.2.3 – The Law of Bergonié and Tribondeau]","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.2	 Early Observations of Radiation Effects | Sub-subsection: 1.2.3	 The Law of Bergonié and Tribondeau | Content: The so-called fundamental Law of Bergonié and Tribondeau
put forward in 1906 postulated that normal tissues appear to
be more radiosensitive if their cells are less differentiated,
have a greater proliferative capacity, and divide more rapidly.
Various data suggest that this law applies to tumors as well.
Heinrich Ernst Albers-Schönberg, Jean Alban Bergonié,
Claudius Regaud, and Louis Tribondeau made significant con­
tributions to our knowledge of the biological effects of ioniz­
ing radiation. Between 1895 and 1908, they studied histological
features of irradiated gonads in numerous animal models.
Although the law of Bergonié and Tribondeau that links radio­
sensitivity with proliferation is not generally applicable, the
enormous efforts these scientists made to fight cancer by using
ionizing radiation should be acknowledged (Box 1.9).
In 1906, Jean Bergonié and Louis Tribondeau published a
communication to the French Academy of Sciences about
the link between cellular proliferation and response to radia­
tion. According to Bergonié and Tribondeau [37], “X rays
act on cells inasmuch efficiently as cells have a greater repro­
ductive activity, their karyokinetic fate is longer, their mor­
phology and function are at least definitively fixed.” While
they never used the term “radiosensitivity,” this article has
with time been read as “cells are inasmuch radiosensitive as
they grow fastly” and is still considered as a founding law of
radiation oncology. Today, however, there is evidence that
this “law” can be contradicted by numerous counterexam­
ples. An epistemological analysis of the archives of Claudius
Regaud, another pioneer of radiation biology and a contem­
porary of Bergonié and Tribondeau, sheds new light on this
law [38]. Let us now briefly review some important facts
about the life and work of these three French scientists.
1.11
­
­
39
39
Box 1.9 The Law of Bergonié and Tribondeau
•	The “law of Bergonié and Tribondeau” was formu­
lated in 1906 and postulated that normal tissues
appear to be more radiosensitive if their cells are
less differentiated, have a greater proliferative
capacity, and divide more rapidly.
•	The law of Bergonié and Tribondeau has not been
verified. However, it has facilitated the advances in
radiation biology and understanding of the relation­
ship
between
cell
proliferation
and
tissue
radiosensitivity.
1 History of Radiation Biology
12
error types that may affect the medical application of
X-rays: (1) the uncertainties in the assessment of radiation
dose, … and (2) the differences in the sensitivity of the
patients” [23].
1.11
­
39
1.11
40
­
4042
­
­
40
On August 5, 1895, Regaud presented the new improve­
ments on his staining technique at the Congress of
Neurology in Bordeaux [41]. Tribondeau and Bergoni also
attended the sessions and had probably read the papers by
Regaud in which the histology of the rodent reproductive
system was described in detail based on his new staining
technique.
After the discovery of X-rays by Roentgen in December
1895, two German scientists, H. E. Albers-Schönberg and
H. Frieben, began to study the effects of this type of radiation
on spermatogenesis by irradiating testicles of rabbits and
guinea pigs [39, 43, 44]. In Bordeaux, Bergonié undertook to
reproduce the experiments of the two Germans. As a physi­
cist, he was able to build irradiation devices but, owing to his
limited knowledge of histology, he asked Tribondeau for his
technical savoir faire [39]. Between 1904 and 1905, Bergonié
and Tribondeau published their first observations about irra­
diated testicles of rats having used Regaud’s staining tech­
nique [45]. They emphasized the role of spermatogonia as
pluripotent cells and as the most radiosensitive cells of the
reproductive system. However, since the experiments
involved irradiation with X-rays, interpretation of the data
remained ambiguous.
Regaud realized that there might be misinterpretations of
his own technique. Unlike Bergonié, Regaud was a histolo­
gist and not a physicist and was helped by Thomas Nogier, a
specialist in medical physics. Regaud and Nogier replicated
the experiments of Bergonié and Tribondeau using rat mod­
els, single exposures, and Regaud’s staining technique [46].
In 1908, Regaud claimed that in young rats, spermatogonia
are less radiosensitive than in the adult animals although pro­
liferation rates of these cells are similar in the two groups of
rats [47]. However, according to Regaud and Lacassagne
[48], Bergonié and Tribondeau generalizations were “impru­
dently” based on the studies of rat testes. In 1925, Regaud
did not hesitate to write about the law of Bergonié and the
Tribondeau-Bergonié’s eulogy that “Actual law as so many
people believe it? No. But nice formula of the first approxi­
mation” [49].
These days, several oncology lectures still cite Bergonié
and Tribondeau’s law as a founding principle of radiotherapy
according to which tumors are more radiosensitive than
healthy tissues due to the higher proliferation rate of the for­
mer. In this erroneous claim, three kinds of errors were made:
1.	Tumors are not necessarily more radiosensitive than nor­
mal tissues.
2.	Proliferation rate is not necessarily correlated with the
cellular death rate after irradiation.
3.	Radiosensitivity and cancer susceptibility to irradiation
are two different notions [50].
The link between proliferation rate and radiosensitivity is
far from obvious, and the law of Bergonié and Tribondeau
should have been modified as follows: “the faster cells pro­
liferate, the faster cell death will appear.” Besides, reviews
about the Tpot (the potential doubling time parameter) have
shown that the yield of cell death clearly does not correlate
with proliferation rate [51, 52]. For example, fibroblasts
from ataxia telangiectasia are hyper-radiosensitive, while
their proliferation rate is lower than that of fibroblasts from
healthy patients [53]. When fibroblasts are transformed by
the Simian Virus 40 (SV40), the cells become unstable and
their proliferation rate increases while they are less radiosen­
sitive than their non-transformed counterparts [54]. Other
counterexamples of the law of Bergonié and Tribondeau are
as follows: the Li-Fraumeni syndrome (caused by the p53+/−
mutations) confers radioresistance associated, however, with
impaired cell cycle arrests, instability, and cancer proneness.
Similarly, some highly proliferating tumors may be very
radioresistant [55].
To conclude, despite its popularity, the law of Bergonié
and Tribondeau has not been fully validated. Yet, it has made
a significant contribution to the advances in radiation biol­
ogy and the relationship between proliferation and
radiosensitivity.
D. Kardamakis et al.
13
1.2.4"
"Describe the historical development of radiotherapy, specifically focusing on the advancements that led to the implementation of fractionation techniques and the emergence of standardized dose formulas.","The evolution of radiotherapy was significantly shaped by technological innovations in radiation generation and delivery. Early fractionated treatments began in 1896, but it wasn't until the development of electrostatic generators like Robert van de Graaff’s in 1929 that practical high-voltage irradiation became feasible. This allowed for the installation of a 2 MV irradiator at Huntington Memorial Hospital in Boston, leading to the first treatments utilizing Cobalt-60 (60Co) sources starting in 1951. A pivotal moment occurred in 1967 with Frank Ellis’s development of Strandqvist's concept – a formula defining the nominal standard dose (NSD). This formula, and subsequent variations derived from it, played a crucial role in establishing standardized hyperfractionated treatments for various cancers by allowing clinicians to precisely control and document early and late post-radiotherapy tissue reactions. The introduction of double-gantry linear accelerators (linacs), such as the first installed at Newcastle Hospital in 1969, further advanced treatment capabilities, solidifying fractionation’s place in clinical practice. These advancements collectively transformed radiotherapy from a single-dose approach to a precisely timed and dosed regimen designed to maximize tumor control while minimizing damage to surrounding healthy tissue.

Reference: MolecularRadiationBiology > section: 1: History of Radiation Biology > subsection: 1.3 Development of Fractionation in Radiotherapy","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.3	 Development of Fractionation in Radiotherapy | Content: permitted the cure of the deepest tumors and helped in
extending the application of hyperfractionated treatments to
various cancers. For instance, the first electrostatic generator,
developed by Robert van de Graaff in 1929, permitted the
installation at the Huntington Memorial Hospital Boston,
MA, USA, of a 2 MV irradiator dedicated to radiotherapy,
and the first treatments with 60Co source began there in 1951.
Two years later, the first 4 MV double-gantry linear accelera­
tor (linac) was installed at the Newcastle Hospital in the UK
[4] (Box 1.13).
With these technological advances, the early and late
post-radiotherapy tissue reactions were more and more accu­
rately documented and standard current hyperfractionated
treatments were progressively defined for all types of tumors.
In 1967, Frank Ellis developed the so-called Strandqvist’s
concept and suggested a formula defining the nominal stan­
dard dose (NSD) [85, 86]. Many variant formulas derived
from the original one have since been devised [87].
Unfortunately, while the NSD formula has had a significant
influence on clinical practice and was successful in predict­
Box 1.13 Evolution of Radiation Therapy
•	The first fractionated radiation treatment was per­
formed in 1896.
•	Accelerator-based therapy has been performed
since 1929 (with 2 MV electrostatic accelerator).
•	Treatments with the 60Co source emerged in 1951.
1 History of Radiation Biology"
"Describe the historical development of radiotherapy fractionation, highlighting the contrasting approaches taken by the ‘French school’ and the ‘German school’ in the early 20th century, and explain how these differing philosophies influenced treatment strategies.","The development of radiotherapy fractionation emerged from distinct perspectives regarding radiation dose delivery during the early 20th century. Initially, Leopold Freund's bi-fractionated approach, pioneered in 1896, aimed to minimize tissue damage by limiting high doses per session. However, this was challenged by the ‘French school’ at the Institut Curie, led by Henri Coutard, Claudius Regaud, and Juan A. del Regato. This group observed that aggressive hypofractionation could lead to severe tissue reactions and advocated for hyperfractionated regimens – spreading the dose over longer periods. Crucially, Coutard recognized that high doses per fraction caused significant damage to connective tissues and promoted protracted treatment courses spanning weeks. Simultaneously, the ‘German school,’ led by Holzknecht and Wintz, favored intensive radiotherapy with high doses delivered in short bursts. Regaud’s successful sterilization of ram testes through three spaced irradiations (15 days apart) demonstrated a viable approach to minimizing local tissue damage while still achieving therapeutic effects. These differing philosophies stemmed from the limitations of available X-ray technology – low energy tubes restricted penetration depth, influencing the choice between high-dose, short-term treatments and lower-dose, longer-duration strategies. The eventual standard fractionation scheme (1.8–2 Gy per fraction five times per week) arose not from rigorous scientific principles initially but from empirical observations of patient responses to varied treatment durations and dose levels. This evolution reflects a pragmatic approach driven by clinical experience rather than purely theoretical understanding at the time.

Reference: MolecularRadiationBiology > section: 1: History of Radiation Biology > subsection: 1.3 Development of Fractionation in Radiotherapy > subsubsection: 1.3.1 Early Fractionation","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.3	 Development of Fractionation in Radiotherapy | Sub-subsection: 1.3.1	 Early Fractionation | Content: As mentioned above, Victor Despeignes in his historical
attempts applied a bi-fractionated radiotherapy based on the
hypothesis that the dose should not be too high to spare
healthy tissues. Fractionated treatments can be traced back to
the first trials performed by Leopold Freund in 1896 in
Vienna, Austria. Today, Freund is considered the founder of
medical radiology and radiotherapy [3, 82]. During the first
decade of the twentieth century, many different anticancer
strategies involving ionizing radiation were applied to treat
various tumors. However, the energy of X-rays provided by
the available tubes was limited to some tens of kilovolts, and
therefore the radiation penetration into the body was very
limited. Between the 1920s and 1930s, pioneers from the
“French school” at the Institut Curie in Paris led by Henri
Coutard, Claudius Regaud, and Juan A. del Regato showed
that hypofractionation might lead to severe tissue reactions
and promoted the hyperfractionated regimen by spreading
the delivery of the dose over a longer period of time. In 1911,
Claudius Regaud showed that a ram’s testes could be steril­
ized without causing major burns to the scrotal skin if three
irradiations were delivered 15 days apart. This practice was
opposed to the “German school” led by Holzknecht and
Wintz who preferred to apply high doses in a short period of
time (intensive radiotherapy) [4]. Particularly, Henri Coutard
suggested that high doses per fraction should be avoided due
to the damage they caused to the connective tissues [83].
Coutard applied the concept of fractionated radiotherapy
with treatment courses protracted over several weeks. With
this strategy, Coutard managed to cure patients with various
head and neck malignancies that are difficult to treat even
today. It should be noted that the French radiotherapist was
among the first to recognize that tumors of different histolo­
gies vary in their sensitivity to radiation.
These observations led to the conclusion that radiation
oncologists should protract the treatment duration to spare
healthy tissues while increasing the dose per fraction to kill a
tumor. Obviously, the current standard fractionation scheme
of 1.8–2 Gy per fraction five times per week originated from
individual observations of patients and empirical experience
rather than from a purely scientific basis [84].
1.3.2"
"Describe the four independent processes proposed to explain both early and late tissue reactions following radiotherapy, as outlined in the text. Detail each process and its significance regarding tumor cell survival.","The text identifies four distinct processes that contribute to both early and late tissue effects after radiotherapy. These processes are: (a) repair of sublethal cellular damage – this refers to the body’s ability to fix minor DNA damage caused by radiation, allowing cells to recover from the initial insult; (b) redistribution of tumor cells – during treatment, tumor cells shift from radioresistant regions (typically late S phase) into more radiosensitive areas (G2-M phase), increasing their vulnerability to further irradiation; (c) reoxygenation of hypoxic tumors – radiotherapy often creates oxygen gradients within a tumor. Hypoxic regions are significantly more resistant to radiation damage, and the process of reoxygenation reduces this resistance by making more cells susceptible to treatment; and (d) migration of normal cells into irradiated tissues – normal cells migrate into the surrounding healthy tissue near the tumor to repopulate it with new functional cells after irradiation. Each of these processes contributes to the overall response of a tumor to radiation, influencing both the initial, acute effects and the long-term consequences of treatment. Reference: [MolecularRadiationBiology, Section 1.4 – Development of the Therapeutic Ratio]","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.3	 Development of Fractionation in Radiotherapy | Sub-subsection: 1.3.2	 Cure with Fractionated Treatment | Content: The technological race to produce the highest X-ray energies
permitted the cure of the deepest tumors and helped in
extending the application of hyperfractionated treatments to
various cancers. For instance, the first electrostatic generator,
developed by Robert van de Graaff in 1929, permitted the
installation at the Huntington Memorial Hospital Boston,
MA, USA, of a 2 MV irradiator dedicated to radiotherapy,
and the first treatments with 60Co source began there in 1951.
Two years later, the first 4 MV double-gantry linear accelera­
tor (linac) was installed at the Newcastle Hospital in the UK
[4] (Box 1.13).
With these technological advances, the early and late
post-radiotherapy tissue reactions were more and more accu­
rately documented and standard current hyperfractionated
treatments were progressively defined for all types of tumors.
In 1967, Frank Ellis developed the so-called Strandqvist’s
concept and suggested a formula defining the nominal stan­
dard dose (NSD) [85, 86]. Many variant formulas derived
from the original one have since been devised [87].
Unfortunately, while the NSD formula has had a significant
influence on clinical practice and was successful in predict­
Box 1.13 Evolution of Radiation Therapy
•	The first fractionated radiation treatment was per­
formed in 1896.
•	Accelerator-based therapy has been performed
since 1929 (with 2 MV electrostatic accelerator).
•	Treatments with the 60Co source emerged in 1951.
1 History of Radiation Biology
18
ing isoeffective regimens for the early effects, it dramatically
failed in the prediction of severe late effects after the large-­
dose fractions. Progressively, the use of the parameters of the
linear quadratic (LQ) model permitted a better approach to
guide clinicians in their choice of the dose fractionation regi­
men [88].
Today, the generally accepted model explaining both
early and late effects consists of four independent processes
that are thought to occur between fractions and favor the
survival of normal tissues over cancers: (a) repair of sub­
lethal cellular damage, (b) redistribution of tumor cells
from radioresistant (late S phase) into radiosensitive (G2-
M) portions of the cell cycle, (c) reoxygenation of the
hypoxic (and hence radioresistant) portions of tumors, and
(d) migration of normal cells into the irradiated healthy tis­
sues close to the tumor to repopulate them with new func­
tional cells.
Recently, the debate about dose hypofractionation has
been relaunched with the advent of stereotactic technologies
that permit targeting the tumor with great precision, limiting
therefore the exposure of healthy tissues surrounding the
tumor. Particularly, anticancer treatments with stereotactic
radiosurgery (SRS) and stereotactic body radiation therapy
(SBRT) are based on the combination of a high-precision
tumor targeting with hypofractionation [89]. Cyberknife
(Accuray Incorporated, Sunnyvale, CA, USA) is one of the
most recent and innovative techniques developed for the
SBRT. It is a robotic system delivering many (usually a hun­
dred) independent and noncoplanar beams converging onto
the tumor with sub-millimetric accuracy under continuous
X-ray image guidance [90]. Studies have shown the effi­
ciency and safety of the SRS and SBRT techniques in many
instances, including some involving the Cyberknife. Still,
however, owing to the lack of a clear radiobiological mecha­
nistic model that will define objective criteria, no consensus
about the total dose, dose per fraction, and treatment dura­
tion has been achieved [89].
1.4
Development of the Therapeutic
Ratio
­
91
­
­
­
­
1.15
1.14
Clinical studies have validated the benefit of contempo­
rary irradiation techniques for improving the therapeutic
ratio. Large meta-analyses have shown that concurrent radio-
and chemotherapy improves local control in many types of
cancer. Clinical trials using molecularly targeted therapies
have not yielded satisfactory results yet. The notable excep­
tion is head and neck squamous cell carcinoma treated with
combined radiotherapy and cetuximab. Noticeably, irradia­
tion of normal tissue should not be viewed only as a source
of toxicity, because both the abscopal and bystander effects
(discussed in Chap. 2) suggest that such irradiation may also
result in therapeutic outcomes [92–95].
Today, clinical strategies enhancing the efficacy and
decreasing the toxicity of radiotherapy, i.e., increasing the
overall therapeutic window, are of paramount importance
and there is demand for novel radiation sensitizers that are
expected to scale up the window. This is especially impor­
tant for tumors characterized by high probability of recur­
rence, such as locally advanced lung carcinoma, and head
Box 1.14 Therapeutic Window
•	The ultimate objective of radiation therapy is to
control tumor growth without causing excessive
damage to normal tissues.
•	Tumor control probability (TCP) and normal tissue
complication probability (NTCP) depend differ­
ently on the radiation dose.
•	The difference between TCP and NTCP is called
“therapeutic ratio” or “therapeutic window.
D. Kardamakis et al."
The text discusses strategies for improving radiotherapy's effectiveness while minimizing harm to healthy tissues. What is the ‘therapeutic window’ and why is it a key concept in clinical radiation therapy?,"The ‘therapeutic window’ represents the difference between tumor control probability (TCP) and normal tissue complication probability (NTCP) within the context of radiation therapy. It essentially defines the optimal dose range for radiotherapy where the benefits of controlling tumor growth outweigh the risks of causing adverse effects in surrounding tissues. A larger therapeutic window indicates a more favorable balance, allowing for higher doses to be administered without excessive toxicity. The concept is crucial because it directly informs treatment planning – clinicians aim to deliver radiation within this window to maximize tumor control while minimizing complications like fibrosis or other tissue damage. Achieving an increased therapeutic window is a primary goal in modern radiotherapy, often accomplished through combining targeted therapies that sensitize tumors to radiation with traditional methods, as highlighted by the example of cetuximab in head and neck squamous cell carcinoma. Reference: MolecularRadiationBiology > section: 1: History of Radiation Biology > subsection: 1.4 Development of the Therapeutic Ratio","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.4	 Development of the Therapeutic Ratio | Content: rary irradiation techniques for improving the therapeutic
ratio. Large meta-analyses have shown that concurrent radio-
and chemotherapy improves local control in many types of
cancer. Clinical trials using molecularly targeted therapies
have not yielded satisfactory results yet. The notable excep­
tion is head and neck squamous cell carcinoma treated with
combined radiotherapy and cetuximab. Noticeably, irradia­
tion of normal tissue should not be viewed only as a source
of toxicity, because both the abscopal and bystander effects
(discussed in Chap. 2) suggest that such irradiation may also
result in therapeutic outcomes [92–95].
Today, clinical strategies enhancing the efficacy and
decreasing the toxicity of radiotherapy, i.e., increasing the
overall therapeutic window, are of paramount importance
and there is demand for novel radiation sensitizers that are
expected to scale up the window. This is especially impor­
tant for tumors characterized by high probability of recur­
rence, such as locally advanced lung carcinoma, and head
Box 1.14 Therapeutic Window
•	The ultimate objective of radiation therapy is to
control tumor growth without causing excessive
damage to normal tissues.
•	Tumor control probability (TCP) and normal tissue
complication probability (NTCP) depend differ­
ently on the radiation dose.
•	The difference between TCP and NTCP is called
“therapeutic ratio” or “therapeutic window.
D. Kardamakis et al.
19
and neck and gastrointestinal tumors. Molecular target
therapies with identified mechanisms of action should be
given top priority. Examples include targeting cell survival
and proliferation signaling such as the EGFR and PI3K/
AKT/mTOR pathways, DNA repair genes including PARP
and ATM/ATR, angiogenic growth factors, epigenetic regu­
lators, and immune checkpoint proteins. By manipulating
various mechanisms of tumor resistance to ionizing radia­
tion, targeted therapies hold significant value to increase
the therapeutic window of radiotherapy. Furthermore, the
use of novel nanoparticle-based therapies, such as nanopar­
ticle delivery of chemotherapies, metallic (high-Z) nanopar­
ticles, and nanoparticle delivery of targeted therapies, may
improve the therapeutic window by enhancing the tumor
response to ionizing radiation and/or reducing normal tis­
sue toxicity [96].
1.5"
"Describe the key historical developments leading to the adoption of the linear no-threshold (LNT) model in radiation protection, including significant figures and pivotal discoveries.","The development of the linear no-threshold (LNT) model represents a complex evolution of understanding regarding the risks associated with ionizing radiation. Early observations after the discovery of X-rays, radium, and radioactivity by Roentgen, Becquerel, and the Curies revealed immediate pathological effects like radiation dermatitis and hair loss, prompting initial investigations into these ‘radiobiological’ phenomena. Hermann Joseph Muller's groundbreaking work in the 1920s was crucial; he irradiated fruit flies (Drosophila melanogaster) with high doses of X-rays and discovered radiation-induced mutations. Initially, geneticists believed there were no repair mechanisms for this damage, leading to a conviction that any exposure posed an unacceptable risk due to cumulative mutation potential. Muller’s Nobel Prize in 1946 solidified this view, as he argued that the dose-response relationship was linear and that ‘there is no escape from the conclusion that there is no threshold dose.’ This perspective fueled the LNT model. However, subsequent research, particularly after the Hiroshima and Nagasaki bombings, presented a challenge to this dogma. The lack of observed radiation mutagenesis in the A-bomb survivors’ descendants prompted concern about potential genetic damage across generations.  Later, at the end of the 1950s, observations from the ‘radium girls’ – women who painted with radium-containing paint – revealed tumor formation without corresponding high exposures, further complicating the picture. Ultimately, the ICRP officially abandoned the tolerance level concept in 1956 and adopted LNT, driven by Muller's work and a fear of cumulative damage despite accumulating evidence to the contrary.  This decision solidified a framework that remains influential today, though increasingly challenged by newer research demonstrating adaptive responses and repair mechanisms at low doses. 

Reference: [MolecularRadiationBiology], Section 1.5 – Radiation Epidemiology and Radiation Carcinogenesis","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.5	 Radiation Epidemiology and Radiation Carcinogenesis | Content: and Radiation Carcinogenesis
Radiation effects can be divided into early and late outcomes.
Another classification is into deterministic and stochastic
effects.
The most common radiation-induced deterministic inju­
ries include skin burns and cataracts. Since these effects
occur after absorption of high doses of radiation, they can be
easily avoided by adherence to the rules of radiological pro­
tection. The most important stochastic effect of significant
irradiation is malignancy. Data suggest an elevated risk
from medical radiation [97], especially with the highest
exposures [98].
As mentioned earlier, biological effects caused by X-rays
and radium were noted very soon after the discoveries of
Roentgen, Becquerel, and the Curies. Early pathologies,
such as radiation dermatitis and hair loss (epilation, alope­
cia), led to the birth of radiobiology and prompted scientists
to follow up patients for long periods of time to study late
effects of irradiation as well.
While radiosensitivity reactions require rather high
doses, exposure to ionizing radiation may also induce can­
cer [50]. The first radiation-induced cancer was reported by
Frieben in 1902 on his own hand [99]. Cancers, but also
leukemia, were mainly diagnosed in the pioneers of radia­
tion. Hence, the incidence of radiation-induced cancers
among clinicians manipulating X-ray tubes increased dras­
tically [13]. Before the Second World War, a cohort of hun­
dreds of female workers (“the radium girls”—see Sect.
1.2.2) in watch factories in New Jersey, Illinois, and
Connecticut between 1917 and 1924 contracted some radia­
tion-induced tumors probably due to self-luminous paint­
ings containing radium [32]. This episode had a major
societal, ethical, and legal impact in the USA and in the
world. This period was contemporary with the organization
of the first world congresses of radiology from which the
International X-ray and Radium Protection Committee
(IXRPC) arose and the first radiation protection recommen­
dations were proposed [13].
Regarding epidemiology, radio-induced cancers were
observed historically in pioneers of ionizing radiation, later
in patients from various medical cohorts [97], and then in the
atomic bomb survivors [100].
In the 1920s, the American geneticist, Hermann Joseph
Muller, who irradiated fruit flies (Drosophila melanogas­
ter) with large doses of X-rays, discovered radiation-
induced mutations [101]. At that time, geneticists were
convinced that no mechanism for gene repair existed and
therefore that mutagenic damage was cumulative. From
their point of view, no tolerant dose could ever be set, and
the safety level should only be weighed against the cost of
achieving it [102]. In 1946, Muller was awarded the Nobel
Prize for his discovery, and in his Nobel Prize Lecture, he
argued that the dose-­response for radiation-induced muta­
tions was linear and that there was “no escape from the
conclusion that there is no threshold dose” [103]. This
statement may be ethically questionable since Muller was
already aware of counterevidence when he delivered his
lecture [104].
After the Hiroshima and Nagasaki bombings, geneticists
were concerned that exposure to radiation from the nuclear
fallout would likely have devastating consequences on the
gene pool of the human population. Later (at the end of the
1950s), after no radiation mutagenesis was found in the
A-bomb survivors’ descendants [105], carcinogenesis
became the main concern.
During the next decades, there was considerable contro­
versy and both logical and circular arguments were
exchanged. It has been said that among scientists, “the data
to support the linearity at low dose perspective were gener­
ally viewed as lacking, but the fear that they may be true was
a motivating factor” [102].
•	The linear no-threshold (LNT) model for radiation risk
assessment gradually gained ground after Muller’s
Nobel lecture. In 1956, the ICRP officially abandoned
the tolerance level concept (that was in use since 1931)
and substituted LNT for it. The latter model suggests
that any radiation exposure presents carcinogenic risk
and that the risk is proportional to the absorbed dose of
radiation. Formally, LNT has been introduced and
remains a practical operational model only for radiation
protection. Alas, contrary to the plethora of the existing
evidence [106], this hypothesis has acquired de facto
the status of a scientific theory and remains the driving
1 History of Radiation Biology
20
force of the prevailing radiophobia in the society (Box
1.15).
Over the last decades, the attitude to risk associated with
ionizing radiation has become more sensible. We now know
that exposures to low doses of radiation initiate cellular and
intercellular changes leading to stress-induced adaptive
responses and metabolic alterations. Furthermore, repair
mechanisms preventing the accumulation of damage—also
of non-radiogenic origin—were also discovered [107].
Consequently, it became obvious that while high doses of
ionizing radiation certainly cause harm, low doses can be
beneficial for human health; such an effect is called hormesis
[108], but the circumstances in which hormesis might occur
in humans are not known.
Recently, the so-called secondary neoplasms which
appear in patients treated with radiotherapy for a primary
tumor have become the focus of interest in the studies of
radiation-induced cancer [109]. It is still not clear whether
secondary cancers are triggered by radiation or other fac­
tors. Characteristic features of these cancers are as
follows:
•	As a rule, they appear near the high-dose treatment vol­
ume, which supports their radiation origin [110].
•	Cancer patients are at a high risk in general for develop­
ing secondary malignancies [111]. It has been estimated
that radiotherapy is responsible for only about 8% of the
secondary cancers [112].
•	The usual confounding factors of carcinogenesis (genetic,
lifestyle, environmental, etc.) increase the risk of the sec­
ondary and radiation-induced cancer. Individual radiosen­
sitivity may play a major role [3].
•	The relative risk of radio-induced cancer is organ depen­
dent, the thyroid being by far the most radiosusceptible
organ [113]; however, the recently acknowledged prob­
lem of thyroid cancer overdiagnosis [114] demands re-­
evaluation of the entire field of thyroid cancer
epidemiology [115] (Box 1.16).
Various epidemiological studies indicate an association
between cancer and previous exposure to ionizing radiation
even at rather low doses. Most studies do not consider the
potential medical exposures of people, as in the case of the
A-bomb survivor studies. Although these studies do not
establish a link between exposure to ionizing radiation and
cancer, the existence of a dose-effect relationship, when it
can be established, is in favor of a possible link. The risk
evaluation thus requires that dosimetry should be precisely
and accurately monitored. These epidemiological observa­
tions give consistency to the linear no-threshold (LNT)
­relationship, which has been used for regulatory purposes in
radiological protection, although, as mentioned above, it has
no indisputable scientific basis [116].
Radiation-induced carcinogenicity stems from the fact
that ionizing radiation is one of the causes of the DNA
lesions. Each DNA insult when unrepaired, particularly in
persons with an abnormal DNA damage response (DDR),
contributes to the overall DNA dysfunction and paves the
way to oncogenesis [117]. Abnormal DDR has been reported
following low-dose exposures to X-rays [118]. However,
multiple repair and defense mechanisms operating at the
Box 1.15 LNT
•	The linear no-threshold (LNT) model for radiation
risk assessment was introduced following Muller’s
discovery of radiation-induced mutations in 1927.
•	Evidence supporting LNT is inconclusive at very
low doses.
Box 1.16 Secondary Cancers
•	As a rule, secondary cancers appear near the high-­
dose treatment volume; this is a major argument
supporting their radiation origin.
•	Cancer patients in general are at a high risk for
developing secondary neoplasms. Radiotherapy is
probably responsible for only 8% of the secondary
cancers.
•	The primary carcinogenic factors—genetic, life­
style, and environmental—increase the risk of the
radiation-induced and secondary cancer. Individual
radiosensitivity may play a crucial role.
•	The relative risk of radio-induced cancer is organ
dependent. It has been assumed that the thyroid is
by far the most radiosusceptible organ; however, the
recently acknowledged problem of thyroid cancer
overdiagnosis requires re-evaluation of the entire
field of thyroid cancer epidemiology.
D. Kardamakis et al.
21
molecular, cellular, tissue, and organismal levels may assure
the effective elimination of potentially carcinogenic cells
and may make the LNT model irrelevant to the biological
reality [107].
To conclude, the responsibility of high-dose ionizing
radiation in the stochastic appearance of cancers is certain.
However, it is very likely that there are no radio-induced can­
cers at low doses and low dose rates in the sense that they
would be due to the sole ionizing radiation. However, low
doses of ionizing radiation and of other genotoxic stressors
(exposomes) should not be examined independently from
each other (Box 1.17).
1.6"
"Describe the fundamental processes involved in ionization caused by ionizing radiation, detailing the interactions between photons or charged particles and matter at a molecular level.","Ionization occurs when high-energy electromagnetic radiation (like X-rays or gamma rays) or charged particles (like alpha or beta particles) interact with atoms and molecules within a material. This interaction initiates a cascade of events primarily driven by the absorption of energy from the radiation source. Initially, the photon or particle deposits its energy into an electron bound to the atom’s nucleus – this is called primary ionization. The ejected electron creates a positively charged ion and a free electron. Critically, this newly freed electron then interacts with other nearby atoms, causing them to lose electrons as well, creating secondary ions and more free electrons. This process continues exponentially, forming what's known as an ‘ionization cascade’ or ‘Bremsstrahlung effect’. The energy of the initial radiation determines the depth of penetration – lower-energy photons tend to produce ionization closer to the surface, while higher-energy particles can penetrate deeper before causing ionization. Furthermore, different types of ionizing radiation exhibit distinct interaction mechanisms. Alpha particles primarily cause ionization through direct collisions due to their large charge and mass. Beta particles interact via electromagnetic forces, leading to both direct and secondary ionization. Gamma rays, being massless photons, predominantly induce ionization through the photoelectric effect and Compton scattering, where they transfer energy to electrons, causing them to be ejected from atoms.

Reference: Molecular Radiation Biology, Section 1.6 – Exercises and Self-Assessment","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.6	 Exercises and Self-Assessment | Content: Q1.	Who made and when were made the major discoveries
in the field of ionizing radiation?
Q2.	What is the basis for conclusion about the carcinogenic
effects of ionizing radiation?
Q3.	(Open question) How was ionizing radiation misused in
the first third of the twentieth century? What were the
main events that led to cessation of the misuse?
Q4.	(Open question) What were the main stages in the
development of radiation therapy?
1.7"
"Describe the significant contributions made by Wilhelm Roentgen, Henry Becquerel, Pierre and Marie Curie, and Ernest Rutherford to the initial development of radiation biology research, highlighting their key discoveries and the timeframe in which these advancements occurred.","The early exploration of ionizing radiation and its biological effects was spearheaded by a quartet of pioneering scientists whose work spanned from 1895 through the onset of World War I (1914). Wilhelm Roentgen’s accidental discovery of X-rays in 1895 provided the first tangible evidence of this previously unknown form of energy. His subsequent characterization of X-ray properties, including their ability to penetrate materials and interact with matter, formed a crucial initial step. Simultaneously, Henri Becquerel investigated uranium salts and observed spontaneous radiation emanating from them without any external excitation – a phenomenon he termed ‘radioactivity.’ This challenged existing scientific understanding of atomic structure.  Pierre and Marie Curie built upon Becquerel’s work, meticulously isolating and characterizing radioactive elements like polonium and radium, demonstrating their intense radioactivity and identifying the source of this energy as originating within the atom itself. Finally, Ernest Rutherford's experiments with alpha particles in 1908 provided critical insights into atomic structure by demonstrating that atoms are composed of positively charged nuclei surrounded by orbiting electrons, explaining how radiation could be emitted from these nuclei. These combined efforts established the fundamental principles of ionizing radiation and its potential impact on biological systems, laying the groundwork for subsequent research into radiation damage and repair mechanisms. Reference: [MolecularRadiationBiology], Section 1.7 – Exercise Answers","Document: MolecularRadiationBiology | Section: 1: History of Radiation Biology | Subsection: 1.7	 Exercise Answers | Content: QA1.	Wilhelm Roentgen, Henry Becquerel, Pierre and
Marie Curie, and Ernest Rutherford laid the founda­
tions of understanding the ionizing radiation from
1895 until the beginning of the Great War (1914).
QA2.	(a)	Historical observations
(b)	Epidemiologic studies, especially with the
cohort of atomic bomb survivors of Hiroshima
and Nagasaki
(c)	Basic understanding of the cellular mechanism
regarding DNA insults and DNA damage
response"
"Describe how photon momentum, particularly from high-energy radiation like X-rays, can influence matter and provide a real-world example of this principle being utilized.","Photons, even those with short wavelengths and significant momentum, can exert a measurable force on matter. This effect arises primarily due to the conservation of momentum during interactions. When high-energy photons, such as X-rays, strike a material, they transfer some of their momentum to the atoms within that material, causing a slight recoil. The magnitude of this recoil is proportional to the photon’s energy and flux – meaning a larger number of higher-energy photons will produce a more pronounced effect. This principle was famously demonstrated by Compton through his experiments with hard X-rays interacting with electrons. More recently, the concept has inspired the development of ‘solar sails,’ which are large, lightweight mirrors designed to gradually accelerate in space due to the continuous impinging momentum of solar radiation. These sails leverage this interaction to propel spacecraft without relying on traditional propellant systems. The effectiveness of these sails depends on a quasi-vacuum environment where matter can recoil freely without significant resistance.  It’s important to note that while wavelength is intuitively linked to photon behavior, for massive particles, the associated wavelength is often too small to be practically relevant in describing interaction phenomena.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Content: small wavelength and a relatively large momentum), the
effects of photon momentum can eventually be observed.
They were observed by Compton, who was studying hard
X-rays interacting with the lightest of particles, the electron.
On a larger scale, photon momentum can have an effect if the
photon flux is considerable and if there is nothing to prevent
the slow recoil of matter due to the impinging and conserva­
tion of the total momentum. This may occur in deep space (a
quasi-vacuum condition), and “solar” sails with low mass
mirrors that would gradually recoil because of the impinging
electromagnetic radiation are actually being investigated and
tested to actually take spacecraft from place to place in the
solar system [4–6].
While for photons the concept of wavelength is more
intuitively directly related to the phenomena and excitations
they can trigger in matter, for particles with mass (massive
particles), the wavelength is usually too small to have a prac­
tical impact on our observation of interaction phenomena.
Nevertheless, depending on the phenomenon or on the spe­
cific aspect one is looking at, it may be more convenient to
consider the particles either as localized entities or in terms
of waves.
­
­
­
2.1
­
12
2 Basic Concepts of Radiation Biology"
"Explain the concept of wave-particle duality as it relates to matter, referencing the role of momentum and the Planck constant.","Wave-particle duality describes the fundamental property of all matter – including particles like electrons – exhibiting characteristics of both waves and particles. Traditionally, we conceptualize objects as either localized entities with defined mass and volume (particles) or disturbances propagating through space (waves). However, quantum mechanics reveals that these are not mutually exclusive descriptions; instead, a particle can display wave-like behavior, and conversely, a wave can exhibit particle-like properties. The relationship between momentum (p) and wavelength (λ) is governed by the Planck constant (h), expressed in equation (2.1): λ = h/p. This equation demonstrates that the wavelength associated with a particle is inversely proportional to its momentum. Higher momentum particles have shorter wavelengths, while lower momentum particles possess longer wavelengths.  This duality becomes particularly apparent when considering interactions between particles and matter, where interference effects – a hallmark of wave behavior – can be observed, especially with high-speed electrons whose wavelengths are comparable to the spacing between atomic layers in materials like crystals. The experiments by Davisson and Germer, along with Thomson’s independent work, provided crucial empirical evidence supporting this dual nature of particles, establishing the wavelike nature of electron beams and underpinning the principles of quantum mechanics.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.1	 Matter and Energy | Content: There exists a wide variety of different types of particles in
nature. These vary across those more commonly known,
such as the constituents of atoms like electrons spinning
around nuclei and protons and neutrons inside the nuclei.
Particles generated through other particles’ decay and those
which are the carriers of the fundamental electromagnetic,
strong and weak nuclear, and gravitational force are also
incredibly important in nature.
In physical science, a particle is characterized either as a
localized entity which can be described by its own physical
characteristics such as volume, density, and mass or as a
wave, the latter being a less intuitive concept. Such dual
nature of particles is named the wave-particle duality. The de
Broglie wavelength associated with a particle is inversely
proportional to its momentum, p, through the Planck con­
stant, h:
(2.1)
When particles interact with objects much larger than the
wavelength of the particles themselves, they show negligible
interference effects. To get easily observable interference
effects in the interaction of particles with matter, the longest
wavelength of the particles and hence the smallest mass pos­
sible are needed. The wavelengths of high-speed electrons
are comparable to the spacings between atomic layers in
crystals. Therefore, this effect was first observed with elec­
trons as diffraction, a characteristic wave phenomenon, in
1927 by C.J. Davisson and L.H. Germer [1] and indepen­
dently by G.P. Thomson [2]. Such experiments established
the wavelike nature of electron beams, providing support to
the underlying principle of quantum mechanics. Thomson’s
experiment of a beam of electrons that can be diffracted just
like a beam of light or a water wave is a well-known case
taught in basic courses of quantum mechanics [3]."
"Explain the fundamental difference between ionizing and non-ionizing electromagnetic radiation in terms of their interaction with matter, referencing the provided information about energy levels.","Electromagnetic radiation is categorized into two primary types based on its ability to interact with matter: ionizing and non-ionizing radiation. The key distinction lies in the amount of energy carried by these radiations. Ionizing radiation possesses an energy level exceeding 10 eV. This substantial energy is sufficient to disrupt chemical bonds within molecules, effectively removing electrons from atoms and molecules – a process known as ionization. Conversely, non-ionizing radiation carries less than 10 eV of energy. Consequently, it lacks the capacity to induce ionization; instead, it primarily interacts with matter through mechanisms like absorption or scattering without fundamentally altering molecular structure. Both types of radiation are described by quantum physics as either waves or beams of energy quanta (photons), but their energetic differences dictate their distinct interaction profiles with biological systems and materials.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.2	 Electromagnetic Radiation | Content: Electromagnetic radiation transfers energy without any
atomic or molecular transport medium. According to the
wave-particle duality of quantum physics, electromagnetic
radiation can be described either as a wave or as a beam of
energy quanta called photons.
­
2.2
­
­
2.2
Radiation can be divided into ionizing and nonionizing
radiation. Ionizing radiation carries more than 10 eV, which
is enough energy to break chemical bonds. Unlike ionizing
radiation, nonionizing radiation does not have enough energy
to remove electrons from atoms and molecules."
"Describe the mechanisms by which ultraviolet (UV) radiation, specifically UVA and UVB, causes damage to DNA within cells, detailing the processes involved beyond simple ionization.","Ultraviolet (UV) radiation, particularly UVB at 3.94–4.43 eV, poses a significant threat to DNA due to its ability to excite molecules and induce various forms of damage. While UVC is largely absorbed by the atmosphere, UVA and UVB can penetrate skin and interact with cellular components. The primary mechanism involves the direct excitation of DNA bases, primarily pyrimidines (thymine and cytosine), leading to the formation of pyrimidine dimers – predominantly thymine dimers – where adjacent pyrimidine bases covalently bond together. This is most pronounced with UVB due to its higher energy. However, UVA also contributes significantly by inducing the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). These ROS/RNS are generated through interactions with chromophores like nucleic acid bases, aromatic amino acids, NADH, NADPH, heme, quinones, flavins, porphyrins, carotenoids, 7-dehydrocholesterol, eumelanin, and urocanic acid. Importantly, these ROS/RNS can themselves induce ionization within DNA strands, creating single-strand breaks or causing base modifications that ultimately lead to mutations. Even without directly forming pyrimidine dimers, the elevated levels of ROS/RNS generated by UVA exposure contribute substantially to DNA damage. While nucleotide excision repair (NER) is a crucial pathway for removing pyrimidine dimers, it’s not always entirely effective, and unrepaired dimers can persist, leading to genomic instability and an increased risk of mutations and cancer development. The energy from UV photons isn't solely responsible; the subsequent cascade initiated by ROS/RNS significantly amplifies the damage potential.

Reference: MolecularRadiationBiology, Section 2.1.2.1 – Nonionizing Electromagnetic Radiation","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.2	 Electromagnetic Radiation | Sub-sub-subsection: 2.1.2.1	 Nonionizing Electromagnetic Radiation | Content: The UV spectrum is in the range of 3.1–124 eV. Even though
the high-energy UV (UVC) can be ionizing, this is absorbed
in the atmosphere and does not reach the Earth. Only UVA
(3.10–3.94 eV) and UVB (3.94–4.43 eV) are transmitted
through the atmosphere. UVB radiation has the energy to
excite DNA molecules in skin cells. This can result in aber­
rant covalent bonds forming between adjacent pyrimidine
bases, producing pyrimidine dimers. Most UV-induced
pyrimidine dimers in DNA are removed by the process
known as nucleotide excision repair, but unrepaired pyrimi­
dine dimers have the potential to lead to mutations and can­
cer. UVA can induce production of reactive oxygen and
reactive nitrogen species (ROS, RNS), which happens
through interaction with chromophores such as nucleic acid
bases, aromatic amino acids, NADH, NADPH, heme, qui­
nones, flavins, porphyrins, carotenoids, 7-­dehydrocholesterol,
eumelanin, and urocanic acid [20]. ROS can induce ioniza­
tions in DNA. In summary, the UV light that reaches the
Earth (UVA and UVB) has too low photon energies to induce
direct ionization but can cause DNA instability through exci­
tation (Box 2.3).
Box 2.2 Ionizing Radiation
•	It is not the total energy but the energy per photon
which determines how the radiation interacts with
matter.
•	Ionizing radiation is the radiation with enough
energy per photon to kick out one atomic electron.
Box 2.3 Characteristics of UV—Radiation
•	Ionizing UV radiation (UVC) is absorbed in the
atmosphere.
•	UVB can induce pyrimidine dimers in DNA.
•	Both UVA and UVB can induce ROS, which in turn
can induce DNA damage.
2 Basic Concepts of Radiation Biology
30"
"Describe the three primary ways that electromagnetic radiation, such as X-rays and gamma rays, can interact with matter, detailing the specific processes involved in each.","Electromagnetic radiation interacts with matter through three distinct mechanisms: the photoelectric effect, Compton scattering, and pair production. The photoelectric effect occurs when an incoming photon transfers all of its energy to a bound electron within an atom. This results in the electron being emitted from the atom entirely, carrying away the absorbed energy. Critically, this process requires the electron to be initially bound within an atom; it cannot occur with free electrons. Compton scattering involves a photon colliding with an electron, resulting in a decrease in the photon's wavelength and an increase in its energy. The electron receives some of the photon’s momentum, leading to a scattered photon and a recoiling electron. This process is characterized by the Compton wavelength, which represents the change in wavelength due to this interaction. Finally, pair production occurs when a high-energy photon interacts with the strong nuclear forces within an atom, resulting in the simultaneous creation of an electron and a positron (its antiparticle). The total energy of these two newly formed particles equals the initial energy of the incoming photon, plus its rest mass energy (1.022 MeV). This process is only significant at photon energies above approximately 20 MeV.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.2	 Electromagnetic Radiation | Sub-sub-subsection: 2.1.2.2	 Ionizing Electromagnetic Radiation | Content: An X-ray photon is emitted from an electron that is either
slowed down or moves from one stationary state to another
in an atom; a γ-photon is sent out by disintegration of an
atomic nucleus. Except for the origin, from the physical per­
spective, there is no difference between X-ray and γ-photon
radiation.
A photon can interact with matter by three different pro­
cesses depending on its energy and the atomic number of the
elements of the matter.
In the photoelectric effect, an atomic electron absorbs all
the energy of the incoming photon and is emitted from the
atom. Note that the photoelectric effect cannot occur with an
electron that does not belong to an atom. This is because
both energy and momentum need to be conserved, which
cannot be achieved without an atom carrying the rest
momentum.
­
2.3
(2.2)
where la
m
d
a
Subscript c Baseline equals StartFraction h Over m Subscript e Baseline c EndFraction
is a constant denoted “the Compton
wavelength for electrons” which equals the wavelength of a
photon having the same energy as the rest-mass energy of the
electron. Notice that maximum energy transfer to the elec­
tron is obtained with a scatter angle of 180° (backscatter),
but it is not possible to transfer all the energy of the incoming
photon to the electron (conservation of momentum).
2.4
­
­
­
­
Pair production occurs by the incoming photon interact­
ing with the nuclear forces in the irradiated material resulting
in an electron-positron pair. The rest energy of the two newly
formed particles is 1.022 MeV, so the incoming photon must
have higher energy than this for the process to occur. In body
tissues and cells, more than 20 MeV in photon energy is
required for pair production to dominate over the Compton
processes.
The Compton process dominates in biological material
for energies relevant for medical use of photons. However,
the cross section (an expression of the probability of interac­
tion) for each process also depends on the atomic number Z.
The cross section is proportional to Z4 for photoelectric
effect, Z for Compton effect, and Z2 for pair production.
­
­
A. Baeyens et al.
31
Thus, the higher the effective atomic number, the lesser the
importance of the Compton effect (Box 2.4).
2.1.3"
"Describe how different types of ionizing radiation – alpha particles, beta particles, and gamma rays – interact with matter at a fundamental level, focusing on the processes that lead to ionization.","Ionizing radiation interacts with matter through several mechanisms, all ultimately resulting in the ejection of electrons from atoms or molecules—ionization. Alpha particles, which are helium nuclei consisting of two protons and two neutrons, possess a high charge and mass. Consequently, they deposit their energy rapidly upon entering a material, causing significant ionization over a relatively short distance. This intense interaction leads to direct collisions with atomic nuclei, ripping electrons away and creating ion pairs. Beta particles, typically electrons or positrons emitted from the nucleus, have lower charge and momentum than alpha particles. Their interactions are more complex; they can undergo bremsstrahlung (radiation pressure) when interacting with electromagnetic fields, causing them to decelerate and lose energy. They also cause ionization through direct collisions, though less intensely than alpha particles due to their reduced momentum. Gamma rays, being photons of high energy, primarily interact with matter via three main processes: photoelectric effect, Compton scattering, and pair production. The photoelectric effect involves a gamma ray transferring all its energy to a single electron, ejecting it from the atom. Compton scattering occurs when a gamma ray interacts with an electron, resulting in the scattered photon having reduced energy and the electron recoiling. Finally, at sufficiently high energies (above 1.022 MeV), gamma rays can undergo pair production, converting the photon into an electron-positron pair. All three types of radiation therefore induce ionization through distinct mechanisms, with alpha particles exhibiting the most direct and intense interaction while gamma rays utilize a combination of processes for energy deposition.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.3	 Particle Radiation | Content: As described above, in physics, a particle is considered to be
an object, which can be described through its properties
including volume, density, and mass. In the context of particle"
"Describe the fundamental mechanisms by which charged particle radiation interacts with matter, differentiating between electronic interactions (involving outer shell electrons) and nuclear interactions (involving atomic nuclei). Furthermore, explain how the energy transfer differs between ‘soft’ and ‘hard’ collisions.","Charged particle radiation, such as electrons, protons, or ions, interacts with matter through two primary mechanisms: electronic and nuclear interactions. Electronic interactions occur when the particle collides with electrons in the outer shells of atoms. These collisions result in ionization – the ejection of electrons from the atom – and excitation, where electrons are bumped to higher energy levels. Because the energy transfer during these ‘soft’ collisions is relatively low (a few eV), the ionized electrons have low energy and quickly emit all their energy in a localized area near the point of impact. Conversely, nuclear interactions involve direct collisions with the atomic nuclei themselves. These ‘hard’ collisions result in greater energy transfer and larger angular deflections of the particle due to the higher energy involved in disrupting the nucleus.  The overall process is statistical; many small interactions contribute to the slowing down of the particle as it traverses a medium. Notably, at very high energies, the Cherenkov effect can occur – emitting light when a charged particle exceeds the speed of light within a material, producing characteristic blue radiation like that observed in cooling water reactors.  Finally, elastic nuclear scattering is significant only for lower ion energies (below approximately 0.01 MeV/u), while at higher energies, bremsstrahlung and other interactions become more prominent.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.3	 Particle Radiation | Sub-sub-subsection: 2.1.3.1	 Charged Particle Radiation | Content: cles, such as electrons, protons, α-particles, or other ions and
uncharged particles such as neutrons. In general, particle
radiation can interact with matter through a number of differ­
ent processes, where the frequency of occurrence depends on
the particles’ mass, velocity, and charge. In the first type of
the process called electronic interaction, the particle interacts
with electrons in the atomic shell, and in the second, called
nuclear interaction, the particle interacts with the atomic
nuclei. All interactions can be considered as collisions
between two masses, which can be either elastic or inelastic.
­
2.5
­
­
­
­
­
­
2.5
2.1.3.1	Charged Particle Radiation
Charged particle radiation describes high-energy massive par­
ticles such as electrons, protons , and other ions. These parti­
cles interact with matter through the described electronic or
nuclear interactions. In each interaction, only a small amount
of the total energy is transferred, and although the whole pro­
cess of interaction is statistical in its nature, one can say that
the particles stop more or less uniformly at a certain distance
called the range. Furthermore, in each interaction, a certain
angular deflection happens, which causes the particle to travel
in a crooked path, and which effectively causes the incident
particle beam to widen, while traversing a medium. The types
of interactions can be described through the occurring energy
loss and deflection of particle radiation in matter.
Ionizations and excitations, which occur in the electronic
interactions, can be differentiated into soft and hard colli­
sions. Interactions of the charged particle with the electrons
in the outer atomic shell are called soft collisions, as the
energy transfer is low (a few eV). The electrons, which are
ionized, have a low energy and therefore emit all the energy
in close proximity to the point of interaction. These soft col­
lisions are responsible for approximately 50% of the total
Box 2.4 Interaction of Photon with Matter
•	Electromagnetic radiation can ionize atoms/mole­
cules through three different processes (photoelec­
tric effect, Compton process, and pair production)
depending on the photon energy and atomic number
of the elements involved.
•	The Compton process dominates in biological
material for energies relevant for medical use of
photons, but a Compton track ends with the photo­
electric effect.
2 Basic Concepts of Radiation Biology
32
energy transfer of a particle. As the energy transfer of a
single collision is very low, the particle velocity decrease is
also low. But as a lot of these interactions occur, the slowing
is, although of statistical nature, on average happening con­
tinuously. For particles which have a very high energy and
thus velocity, the Cherenkov effect can occur. This effect
describes the emittance of light, when a particle flies through
matter with a velocity larger than the speed of light in this
corresponding matter. This light is called Cherenkov radia­
tion and can be seen as blue in the cooling water of nuclear
reactors. The Cherenkov effect does not play a role in the
effects of particle radiation on biological matter.
Coulomb interactions with the electrons of the inner shells
are called hard collisions. Here, the electrons produced in ion­
izations have a higher energy and larger deflection angles
compared to the ones from soft collisions. These electrons are
called δ-rays, and they transfer their energy via soft collisions
to the matter, thus spreading the energy distribution of an inci­
dent particle up to several μm distance to the incident particle
track. This effect plays a major role in the microdosimetry.
2.6
Energy loss through elastic nuclear scattering as described
above is only an important contribution to the total energy
loss for ion energies below approximately 0.01 MeV/u. Here,
the ions are already close to stopping and have a remaining
range in the order of nanometers. For high ion energies
­
in
­
in
http://www.srim.org/
https://physics.nist.gov/PhysRefData/Star/Text/ESTAR.
html
­
26
A. Baeyens et al.
33
(E > several 100 MeV/u), elastic and inelastic nuclear scat­
tering are again mainly responsible for deflection but also for
energy loss through emission of bremsstrahlung. There are
also other mechanisms possible, happening quite rarely at
the energies used in society, but which should be mentioned
here [21, 22]. These are direct interactions with the nuclei,
namely transfer reactions like stripping or pickup, where
nucleons are transferred from or to the incident particle. Also
charge exchange can happen, which is a combination of
stripping and pickup, where a neutron of the particle is
exchanged with a proton of the atom or vice versa. Also,
fragmentation can occur, where the incident particle and/or
the atomic nucleus break up into (more than two) fragments.
And finally, fusion reactions can occur, where the incident
particle is fused into the atomic nucleus and both together
form a new nucleus."
"Describe the process of energy loss in charged particle radiation interactions with matter, focusing on the concepts of collision stopping power and radiation stopping power. Explain how these differ and why they are relevant to radiobiology.","Charged particle radiation interacts with matter through a complex process involving both collisional and radiative energy losses. Collision stopping power (Scol) describes the energy lost due to direct collisions between the impacting particle and atomic nuclei within the target material. This is primarily governed by the Bethe-Bloch formula, which accounts for relativistic effects and incorporates parameters like particle energy, charge number, velocity, matter density, and the properties of the interacting particles and nuclei. The collision power itself depends on the type of particle – for protons and heavier ions, it’s a function of β (velocity/speed of light), while for electrons and positrons, it follows a different formula. These collisions result in a frictional force, effectively ‘stopping’ the particle as it traverses the material.

Radiation stopping power (Srad) represents the energy lost due to interactions involving the excitation or ionization of atomic electrons within the target. This is particularly significant for lighter particles like electrons, where radiative losses dominate because of their much lower mass compared to heavier ions. The radiation stopping power formula also incorporates parameters such as total electron energy and the fine-structure constant. Importantly, collision stopping power is not relevant for heavy particles due to their large masses.

In practical radiobiology, linear energy transfer (LET) is frequently used instead of directly calculating these stopping powers because detailed calculations are complex. LET represents the average energy deposited per unit distance traveled by the particle and is derived from the electronic stopping power. Electronic stopping has a negative sign as it represents a frictional force, while LET has a positive sign representing the energy transferred to the target material, driving nonequilibrium dynamics and initiating radiation-induced effects. For large samples, LET effectively equals electronic stopping. The unique energy loss distribution, particularly the peak at the end of range for particles like protons, is crucial in radiotherapy due to its ability to precisely target tumors while sparing surrounding healthy tissue.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.3	 Particle Radiation | Sub-sub-subsection: 2.1.3.1	 Charged Particle Radiation | Content: The exact energy loss during an interaction is described
through the so-called stopping power S and is made up of the
collision Scol and the radiation Srad stopping power [23]:
(2.3)
The collision stopping power is the energy loss through
collisions along the track in matter. For high energies of the
impacting particles, the collisional stopping power can be
described by the known Bethe–Bloch formula, which is
based on perturbation theory and can also incorporate rela­
tivistic corrections.
For protons or heavier ions, the collision power is
(2.4)
For electrons or positrons, this is
(2.5)
This formula includes the properties of the particle energy,
charge number, and velocity characterized by moc2, z2, and β2
and the properties of the matter density ρ, charge number Z,
and mass number A. re is the classical electron radius and u
the atomic mass unit. The terms Rcol(β) and uppe
r R
Subscript c o l Superscript asterisk Baseline left parenthesis beta right parenthesis are called
rest function for heavier particles or electrons and positrons,
respectively. These are dimensionless quantities, which con­
tain the complex energy and matter-dependent cross sections
for collision stopping.
In practical use, especially in radiobiology, it is just
important to know some proportionalities:
(2.6)
The radiation stopping power does not play a role for pro­
tons and heavier particles, due to their heavy masses, but for
electrons, which are more than three orders of magnitudes
lighter.
The radiation stopping power for electrons is
(2.7)
With Etot the total energy of the electron and α the fine-­
structure constant. Again, dimensionless rest functions occur
describing the cross sections for interactions with nuclei Rrad, n
and electrons in the atomic shell Rrad, e.
For quantification in radiobiology, the detailed descrip­
tion of the stopping power is not used, as it would be too
complicated, and the perturbation parts only contain a small
correction. Conventionally, the linear energy transfer
upp
e
r
=
L
upper E upper T equals StartFraction normal d upper E Over normal d x EndFraction
is used instead. The LET only takes electronic
interactions into account. The difference between LET and
electronic stopping lies in their origin. The electronic stop­
ping is focused on the energy loss of the impacting particle,
and it has a negative sign as it acts as a friction force. The
LET has a positive sign, and it is the energy that the target
sees deposited in itself; this “positive amount of energy” cre­
ates the nonequilibrium dynamics, which are the first
radiation-­induced effects. The LET and the electronic stop­
ping are equal for big samples, which is the case in radiobiol­
ogy. Therefore, the LET is the same as the electronic
stopping, which can be looked up in programs such as pstar,
astar, or SRIM [24, 25].
­
2.6
(2.8)
For even higher ion energies, the energy loss decreases
again.
For a single collision, considering a maximum energy
ΔEmax which can be transferred through electronic interac­
tions is
(2.9)
With me being the electron mass, m the ion mass, and E
the ion energy. For protons, this maximum energy transfer
2 Basic Concepts of Radiation Biology
34
per collision is ΔEmax, p ≈ 0.2 % Ep. For carbon ions, it is even
lower at ΔEmax, C ≈ 0.02 % EC. Therefore, thousands of colli­
sions are necessary before an ion stops, and the more energy
it has lost, the slower it gets and therefore the interactions get
closer together.
2.6b
­
­
23
(2.10)
For example, for protons with therapy-relevant energies
between approx. 10 MeV and 200 MeV, the range can be
approximated to
(2.11)
The unique energy loss distribution, with a peak energy
loss just at the end of range, gives particles a great advan­
tage in tumor therapy compared to photons, as the tissue
behind the tumor will not get irradiated at all, as explained
in Chap. 6.
­
2.6c
­
2.6d
­
­
2.5"
"Describe the process of multiple small-angle scattering of charged particles interacting with matter, and explain how this contributes to the observed distribution of a particle beam’s lateral profile.","Multiple small-angle scattering occurs when charged particles, such as ions or electrons, interact repeatedly with atoms within a material. Each interaction, primarily through Coulomb forces – where the particle exchanges energy with surrounding electrons and nuclei – causes a slight deflection of the incident particle's trajectory. Because these interactions are numerous and individually result in only minor changes to direction, the cumulative effect is a significant deviation from the original path. This repeated scattering leads to a broadening of the initial beam’s distribution.  The lateral profile of this broadened beam can be approximated by a Gaussian distribution. The width (σ) of this Gaussian distribution is directly proportional to z/√(Ekin), where z represents the charge of the particle, Ekin is its kinetic energy, and x is the distance traveled. As the particle traverses the material, these repeated Coulomb interactions cause it to scatter in many directions, leading to a spread in its position. It’s crucial to note that this Gaussian approximation holds true for smaller lateral distances; however, at larger distances, the rare but significant single large-angle scattering events become more prominent, disrupting the Gaussian distribution and causing the beam's lateral profile to deviate from its predicted shape. The dominance of multiple small-angle scattering is why the Gaussian distribution provides a useful model for describing the beam’s spread in most cases.

Reference: 2: Basic Concepts of Radiation Biology > subsection: 2.1 > subsubsection: 2.1.3 > subsubsubsection: 2.1.3.1","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.3	 Particle Radiation | Sub-sub-subsection: 2.1.3.1	 Charged Particle Radiation | Content: The interaction of particles with matter is not only responsible
for energy loss but also for a deflection of the incident particle.
For the coulomb interactions with electrons, only negligible
deflection occurs. The nuclear Coulomb interactions also give
small deflections per collision. Furthermore, Rutherford scat­
tering with the atomic nucleus can occur. Taking all the interac­
tions into account, significant deflection of particles is common.
This process is called multiple small-­angle scattering.
Additionally, the Rutherford scattering can lead to single large-
angle scattering events, but this effect is very rare. The scatter­
ing of single ions leads to widening of the incident beam of
particles with penetration depth. Due to the dominance of the
multiple small-angle scattering, the lateral profile of the beam
can be approximated by a Gaussian distribution. It is important
to know that for larger lateral distances, the Gaussian distribu­
tion no longer holds, as the large-angle scattered ions are
deflected in this region. But as already mentioned, this is a rare
process and does not have an influence on the beam size. The
lateral spread defined as the σ of the Gaussian distribution is
si
g
m
a
pr
o
portional to StartFraction z Over upper E Subscript k i n Baseline EndFraction x Superscript three halves, with Ekin the kinetic energy of the particle, z the
charge, and x the distance traveled (Box 2.6).
Box 2.5 Characteristics of Charged Particles
•	Charged particles transfer their energy mainly
through coulomb interactions with electrons and
nuclei of the atoms of the matter.
•	The energy loss of the particle can be described by
the Bethe–Bloch formula of the stopping power.
•	For ions, only collision stopping power plays a role,
and for electrons also radiation stopping power.
•	Ions have a defined range, where energy loss fol­
lows the Bragg curve.
Box 2.6 Scattering of Particles
•	Coulomb interactions are responsible for scattering
of the particle.
•	Multiple coulomb scattering leads to a deflection of
the particle.
•	Single Rutherford scattering with the atomic nuclei
leads to large deflections, but these are very rare.
•	An incident particle beam will have a Gaussian
energy distribution profile in the lateral direction
due to the statistical nature of scattering.
A. Baeyens et al.
35"
"Describe the key differences between elastic and inelastic neutron interactions with matter, including the resulting energy distributions observed in each type of interaction.","Neutron interactions with matter can be categorized as either elastic or inelastic, differing significantly in their mechanisms and resultant energy transfer. Elastic scattering occurs when a neutron collides with a target nucleus, transferring kinetic energy to the nucleus without altering its composition. This results in the recoil of the nucleus at an energy determined by conservation laws; specifically, the maximum energy (Q) transferred is given by the equation (2.12). Following this collision, the neutron continues on its original trajectory with minimal change.  The distribution of recoil energies for nuclei follows a cosine-squared relationship, meaning that higher energies are less frequent and tend to concentrate around intermediate values. This allows estimation of the initial neutron energy beam based on observed recoil energies (equation 2.13). In contrast, inelastic scattering involves either promoting the nucleus to an excited state followed by decay or direct absorption of the neutron by the nucleus.  (n,n’) reactions involve the neutron exciting a nucleus, which then decays by emitting another neutron with reduced energy and momentum. Alternatively, for neutrons below 0.5 MeV, the nucleus can capture the incident neutron, transforming into a new element (Y) while emitting a projectile particle such as a proton, alpha particle, or gamma ray. These reactions are often represented as (2.14), like 9Be(n,γ)10Be and 75As(n,γ)76As. The energy distribution in inelastic scattering is more complex and dependent on the specific reaction pathway.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.1	 Physical and Chemical Aspects of Radiation Interactions with the Matter | Sub-subsection: 2.1.3	 Particle Radiation | Sub-sub-subsection: 2.1.3.2	 Neutron Radiation | Content: 27
2.7
The neutron differs from the proton (uud) by a single
quark
such
that
it
has
almost
identical
mass
(mn = 939.6 MeV/c2, mp = 938 MeV/c2) though the neutron
has zero charge. It also differs further in that, while the
proton is thought to be stable (current T1/2 of ~1038 years),
the free neutron is unstable with a mean lifetime of approx­
imately 879.6 s. While electrically neutral, the neutron
does have a magnetic moment of approximately −1.93 ⌠N,
where that for the proton is approximately 2.79 ⌠N (and
where ⌠N is the nuclear magneton). As the neutron is a
fermion, it has a spin of ½ [28].
Early experiments with neutrons relied upon their produc­
tion in prototype nuclear reactors. Here, neutrons were clas­
sified according to their energies as thermal (E ~ 0.038 eV,
on average associated with a Maxwell–Boltzmann distribu­
tion of particles at room temperature), slow (E < 0.1 MeV),
fast (E > 10 MeV), or relativistic (with energies producing
velocities of 0.1 c or above) [29].
Exploration of neutron interactions with matter has
revealed that they have very complex energy cross sections,
which vary substantially with the target material. However,
the interactions may be broadly classified as elastic or inelas­
tic interactions, with elastic collisions having a greater cross
section at high neutron energies [29].
In elastic interactions, the neutron collides, typically, with
a target nucleus, transferring some of its kinetic energy to the
nucleus, which then recoils. It may be demonstrated that the
maximum energy Q that a neutron of energy En and mass M
may transfer to a recoil nucleus of mass m is given by [29].
(2.12)
In general, one may observe a cosine-squared spatial dis­
tribution of recoil energies for nuclei, Q, from which the
original energy of the neutron beam may be estimated [29]:
(2.13)
In inelastic scattering events, either the neutron can pro­
mote the nucleus of element X to an excited state, from which
the nucleus itself decays by re-emitting the neutron with dif­
ferent energy and momentum [(n,n′) reactions], or, for neu­
trons with energy below 0.5 MeV, the nucleus absorbs
(“captures”) the incident neutron, causing it to transmute to a
new elementary state, Y, generally with the emission of some
product projectile, b, such as a proton, alpha particle, or
gamma ray. The latter nuclear reactions are written as
(2.14)
where examples include 9Be(n,γ)10Be and 75As(n,γ)76As
(radiative capture reactions).
The development of sources of neutrons for industrial pur­
poses has been a highly complex undertaking. Spallation sources
of neutrons, where a material is bombarded with a projectile par­
ticle and then emits a beam of neutrons, have existed for some
time. However, these systems require acceleration of a projectile
beam, which renders them costly from an energy-input perspec­
tive, though they produce highly intense beams which are useful
in the imaging of materials, as well as for both breeding and burn­
ing of nuclear fuel. Most neutron beams are produced via colli­
mation and focusing of neutron beams from nuclear reactors, for
similar applications to those already highlighted, and importantly
for therapeutic applications in medicine. The development of
Wolter mirrors and lenses has provided the means to direct and
focus beams of neutrons in a highly precise manner allowing for
controlled therapeutic applications.
2.2"
"Describe the process of spallation, including the initial interaction between a neutron and a target nucleus, and the subsequent emission of secondary particles like protons or gamma rays. Explain how this process is utilized in the creation of neutron beams for industrial and therapeutic applications.","Spallation occurs when an incident neutron collides with a heavy atomic nucleus, such as beryllium (Be) or Americium (As), resulting in a significant disruption of the target nucleus’s structure. This interaction causes the nucleus to fragment into smaller nuclei and emit secondary particles – primarily protons, alpha particles, and gamma rays. The energy from the initial neutron collision excites the target nucleus, leading to its instability and ultimately causing it to break apart.  This process is represented by nuclear reactions like 9Be(n,γ)10Be and 75As(n,γ)76As, where ‘n’ represents a neutron, ‘γ’ represents gamma radiation, and the numbers indicate the atomic mass of the respective nuclei. The emitted particles are known as 'spectrate' or 'spallation products'.  Spallation sources, like those utilizing nuclear reactors, produce intense beams of neutrons by bombarding materials with high-energy projectiles. These beams are then collimated and focused using devices such as Wolter mirrors and lenses to achieve precise control. This technology is crucial for applications including material imaging (due to the penetrating nature of neutrons), breeding and burning nuclear fuel, and – importantly – controlled therapeutic applications in medicine where targeted neutron irradiation can be used for cancer treatment.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.2	 Sources and Types of Ionizing Radiation | Content: (“captures”) the incident neutron, causing it to transmute to a
new elementary state, Y, generally with the emission of some
product projectile, b, such as a proton, alpha particle, or
gamma ray. The latter nuclear reactions are written as
(2.14)
where examples include 9Be(n,γ)10Be and 75As(n,γ)76As
(radiative capture reactions).
The development of sources of neutrons for industrial pur­
poses has been a highly complex undertaking. Spallation sources
of neutrons, where a material is bombarded with a projectile par­
ticle and then emits a beam of neutrons, have existed for some
time. However, these systems require acceleration of a projectile
beam, which renders them costly from an energy-input perspec­
tive, though they produce highly intense beams which are useful
in the imaging of materials, as well as for both breeding and burn­
ing of nuclear fuel. Most neutron beams are produced via colli­
mation and focusing of neutron beams from nuclear reactors, for
similar applications to those already highlighted, and importantly
for therapeutic applications in medicine. The development of
Wolter mirrors and lenses has provided the means to direct and
focus beams of neutrons in a highly precise manner allowing for
controlled therapeutic applications.
2.2
Sources and Types of Ionizing
Radiation
­
2 Basic Concepts of Radiation Biology
36
which is present on Earth at all times [30]. In addition, we
are exposed to ionizing radiation from artificial sources dur­
ing medical examinations and treatments, during processing
and using radioactive materials, and during operation of
nuclear power plants or accelerators (Figs. 2.8 and 2.9).
Below we provide a summary of the possible scenarios of
exposure to natural and artificial radiation.
2.2.1"
"Describe the various sources of ionizing radiation that contribute to natural background radiation exposure, detailing both terrestrial and cosmic origins, as well as how these sources impact human health.","Human exposure to ionizing radiation comes from several distinct sources. Terrestrial radiation originates primarily from naturally occurring radioactive elements within the Earth’s crust – thorium, uranium, and potassium-40. These minerals undergo radioactive decay, releasing small quantities of ionizing radiation that are continuously emitted. This radiation is present both outdoors and indoors due to the widespread distribution of these mineral deposits in building materials. Inhalation exposure occurs through the presence of radioactive gases like radon (produced by thorium decay) and thoron (produced by uranium decay), which can accumulate in poorly ventilated buildings. These gases, when inhaled, contribute to internal radiation dose. Furthermore, we are exposed via ingestion of vegetables and fruits grown in soil containing these radioactive minerals, with isotopes like carbon-14 and potassium-40 contributing to our overall biological radioactivity. Finally, cosmic radiation represents a significant source, particularly for space travelers. This includes Galactic Cosmic Rays (GCRs), originating from distant supernovae explosions, which are high-energy particles that directly impact the atmosphere and penetrate the Earth’s surface. The Sun also contributes through solar wind and Solar Energetic Particles (SEPs) – the former continuously flowing from the sun, while SEPs are intense bursts of charged particles released during solar flares. These particles are largely stopped by planetary atmospheres but can still pose a risk to astronauts or individuals at high altitudes. Notably, trapped radiation exists within the Earth’s Van Allen radiation belts, where GCRs and SEPs are captured by the planet's magnetic field, presenting a hazard particularly in regions like the South Atlantic Anomaly. The cumulative effect of these diverse sources results in varying levels of natural radiation exposure depending on location and altitude.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.2	 Sources and Types of Ionizing Radiation | Sub-subsection: 2.2.1	 Natural Background Radiation | Content: 2.8
­
31
1.	Terrestrial Radiation: One of the major sources of natu­
ral radiation is the Earth’s crust, where the key contribu­
tors are the innate deposits of thorium, uranium, and
41
A. Baeyens et al.
37
potassium. These minerals are called primordial radionu­
clides and are the source of terrestrial radiation. These
deposits discharge small quantities of ionizing radiation
during the process of natural decay, and these minerals
are found in building materials. Therefore, humans can
get exposed to natural radiation both outdoors and
indoors. These radiation levels can fluctuate substantially
depending on the location. Traces of radioactive materials
can be found in the body where nonradioactive and radio­
active forms of potassium and other elements are metabo­
lized in the same way [32].
2.	Inhalation: Humans are exposed to inhalation of radioac­
tive gasses that are formed by radioactive minerals found
in soil and bedrock. For example, uranium-238, during its
decay, produces radon (222Rn) which is an inert gas and
thorium produces thoron (220Rn). These gasses get diluted
to harmless levels when they traverse the Earth’s atmo­
sphere. However, at times, these gasses escape through
cracks in the building foundations, are trapped, and accu­
mulate inside buildings where they are inhaled by the
occupants (indoor living) [30].
3.	Ingestion: Vegetables and fruits are grown in the soil and
groundwater, which usually contain radioactive minerals.
We ingest these minerals and subsequently are exposed to
internal natural radiation. Carbon-14 and potassium-40
are naturally occurring radioactive isotopes which pos­
sess similar biological characteristics as their nonradioac­
tive isotopes. These radioactive and nonradioactive
elements are used not only in building our bodies but also
in maintaining them. Therefore, such natural radioiso­
topes recurrently expose us to radiation [30].
4.	Cosmic Radiation: Space is permeated by radiation, not
only of electromagnetic type but also constituted by ion­
izing particles with mass. The electromagnetic radiation
in space spans all wavelengths, from infrared to visible,
from X-ray to gamma rays. In general, however, “space
radiation” mostly refers to corpuscular radiation, which
has three main sources:
(a)	Galactic Cosmic Rays (GCRs): The GCRs consti­
tute the slowly varying, low-intensity, and highly
energetic radiation flux background in the universe,
mostly associated with explosions of distant super­
novae. The GCR spectrum consists of approxi­
mately 87% hydrogen ions (protons) and 12%
helium ions (α-particles), with the remaining 1–2%
of particles being HZE (high charge Z and energy)
nuclei. The energies are between several tenths and
10 × 10 GeV/nucleon and more. GCRs directly hit
the top of the Earth’s atmosphere, generating sec­
ondary particle showers. However, some direct
GCRs and generated secondary particles infiltrate
the Earth’s atmosphere reaching the ground. Such
radiation gets absorbed by humans, and it thus con­
stitutes a source of natural radiation exposure.
Since at higher altitude the amount of atmosphere
shielding us from incoming radiation is less, the
higher we go in altitude, the higher dose we receive.
For example, those living in Denver, Colorado
(altitude of 5280 ft = about 1610 m), receive a
higher annual radiation dose from cosmic radiation
than someone living at sea level (altitude of 0 ft)
[32]. GCR ions are a major health threat to astro­
nauts for missions beyond the near-­Earth environ­
ment and for interplanetary travel [33]. For Mars,
the thin atmosphere combined with the absence of
a planetary magnetic field essentially offers very
little shielding from the incoming GCRs [34, 35].
Also, GCRs directly reach the surface of airless
bodies such as the Moon [36].
(b)	Radiation from the Sun: This consists of both low-­
energy particles flowing constantly from the Sun
(the solar wind) and of solar energetic particles
(SEPs), originating from transient intense eruptions
on the Sun [37]. The solar wind is stopped by the
higher layers of the atmosphere of our planet (and
other celestial bodies with an atmosphere). SEPs
come as huge injections and are composed predom­
inantly of protons and electrons. Typical proton
energies range from 10 to 100 of MeV. They are
generally quite efficiently stopped in the Earth’s
atmosphere, but some direct SEPs and their high
flux of secondaries could eventually be dangerous
for high-altitude/latitude flights and their crew [38]
and for astronauts of the International Space Station
(ISS) in extravehicular activities. Finally, SEPs can
be a strong concern also for astronauts during inter­
planetary travel, such as a trip to Mars, even inside
the spacecraft [39], or for humans on the surface of
the Moon.
(c)	Trapped Radiation: This consists of GCRs and
SEPs and their secondaries trapped by the Earth’s
magnetic field into the Van Allen radiation belts.
Such belts comprise a stable inner belt of trapped
protons and electrons (energies are between keV
and 100 MeV) and a less stable outer electron belt.
The inner Van Allen belt comes closest to the
Earth’s surface, down to an altitude of 200 km, in a
region just above Brazil. This area is named the
South Atlantic Anomaly [40]. An increased flux of
energetic particles exists in this region and exposes
2 Basic Concepts of Radiation Biology
38
orbiting human missions to higher-than-usual lev­
els of radiation (Box 2.7).
2.2.2"
"Artificial radiation sources, such as those found in nuclear power plants and particle accelerators, generate ionizing radiation. Describe the primary mechanisms by which these facilities contribute to environmental radioactive contamination, specifically referencing the release of gasses, liquids, and the potential for increased radionuclide concentrations in materials like coal ash.","Facilities utilizing artificial radiation sources, including nuclear power plants and particle accelerators, introduce radioactivity into the environment through several key pathways. Nuclear power plants generate radiation primarily via controlled uranium fission reactions, releasing radioactive gases (such as iodine-131 and krypton-85) during normal operation and exacerbated by malfunctions that lead to leaks. Furthermore, the water circulating through the reactor core can become contaminated with radioactive elements, which are then released when processed and returned to the environment. Beyond gaseous emissions, these facilities also contribute to contamination via liquid releases – primarily from cooling systems or accidental spills – and, critically, through the accumulation of radionuclides in materials like coal ash. Coal-fired power stations, for example, can generate significantly higher levels of radioactivity than nuclear plants due to the presence of naturally occurring radioactive materials (NORM) concentrated within the coal itself, leading to substantial uranium and thorium deposits in the resulting ash. Particle accelerators produce radiation, particularly protons, through high-energy particle interactions, potentially contaminating surrounding equipment and structures with induced radionuclides. The long-term management of these facilities, including decommissioning and waste storage, further contributes to potential environmental contamination via the handling and disposal of radioactive materials.  Reference: [MolecularRadiationBiology, Section 2.2.2 – Artificial Radiation Sources]","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.2	 Sources and Types of Ionizing Radiation | Sub-subsection: 2.2.2	 Artificial Radiation Sources | Content: Nuclear power stations/plants use uranium to drive a fis­
sion reaction that heats water to produce steam. The latter
drives turbines to produce electricity. During their normal
activities, nuclear power plants release small amounts of
radioactive elements, which can expose people to low doses
of radiation. The water that passes through a reactor is pro­
cessed and filtered to remove these radioactive impurities
before being returned to the environment. Nonetheless, min­
ute quantities of radioactive gasses and liquids are ultimately
released to the environment. Such releases must be continu­
ously monitored and are under the legislative framework of
international organizations dealing with nuclear energy, such
as the European Atomic Energy Community (EURATOM),
established by one of the Treaties of Rome in 1958. Similarly,
uranium mines and fuel fabrication plants release some
radioactivity that contributes to the dose of the public [42].
The eventual release of radioactive materials should also be
monitored and kept under established levels during the
decommissioning of a nuclear power plant, from the shut­
down of the reactor to the operation of radioactive waste
facilities, and also including the short- and intermediate-term
storage of spent nuclear waste to the transport to and storage
in long-term geological disposal areas.
Technologically enhanced naturally occurring radio­
active materials (TENORM): All minerals and raw materi­
als contain radionuclides, commonly denoted as naturally
occurring radioactive materials (NORM). When concentra­
tions of radionuclides are increased by technological pro­
cesses,
the
term
technologically
enhanced
NORM
(TENORM) is applicable. Coal-fired power stations, for
example, emit an amount of radioactivity compared to or
even higher (especially in the past) than nuclear power
plants. Just for example, US coal-fired electricity generation
in 2013 gave rise to 1100 tonnes of uranium and 2700 tonnes
of thorium in coal ash. Other TENORM industries include
oil and gas production, metallurgy, fertilizer (phosphate)
manufacturing, building industry, and recycling [43].
Accelerators: The operation of accelerators, such as the
Large Hadron Collider (LHC) at CERN for fundamental
high-energy physics experiments, results in the production
of radiation, in particular protons, because of the nuclear
interactions between high-energy beams and accelerator
components. Thus, the radiation levels around accelerators
must be monitored continuously to ensure the protection and
safety of the workers and of the public [44].
Radionuclide production facilities: Radionuclides are
used worldwide in (a) medical imaging, fundamental to make
correct diagnoses and provide treatments, in which radionu­
clides are injected into patients at low doses for functional
imaging to detect diseases, and (b) therapy, in which radionu­
clides bound to other molecules or antibodies can be guided
to a target tissue, for a local treatment of cancer. Facilities that
produce radionuclides and facilities in which radionuclides
are processed are reactors and particle accelerators.
Radionuclides used in imaging and therapy are often beta or
alpha emitters, or both. Thus, the facilities, reactors, and par­
ticle accelerators can present radiation hazards to workers
and must be properly controlled and monitored, as is the case
with the subsequent processing of radioactive material.
Among the 238 research reactors in operation in 2017,
approximately 83 were considered useful for regular radio­
isotope production [45]. Approximately 1200 cyclotrons
worldwide were used to some extent for radioisotope produc­
tion in 2015 [46]. The facilities must ensure the application of
the requirements of the IAEA [47] (2014) intended to provide
for the best possible protection and safety measures.
Hospitals: Daily, healthcare workers and patients are
exposed to various diagnostic and therapeutic radiation sources
[48, 49]. The radiation environment in different hospital depart­
ments (nuclear medicine, diagnostic radiology, radiotherapy,
…) can be generated by different sources. Hospitals providing
radionuclide-based treatments need to protect the staff involved
and keep their dose within the acceptable levels. Similarly, the
discharged patient must be monitored and measurements for
protection purposes must be taken to keep dose to the public
within acceptable levels. This may require hospitalization with
isolation during the first hours or days of treatment [50, 51].
Waste should be minimized and segregated, and packages
labeled and stored for decaying. Measures should also be in
place for patients’ household waste related to, for example,
urine. In a radiology department, the radiation emitted during
fluoroscopic procedures is responsible for the greatest radiation
dose to the medical staff. Radiation from diagnostic imaging
modalities, such as mammography, computed tomography, and
nuclear medical imaging, is a minor contributor to the cumula­
Box 2.7 Sources of Natural Radiation
The natural radiation to which we are continually
exposed has its sources in:
•	Cosmic radiation (the portion of it reaching the
ground)
•	Radiation from radioactive elements in rocks
•	Radioactive gasses, generally at harmless concen­
tration in the air but that can potentially also get
trapped in building walls
•	Food, grown in soil and groundwater, which can
contain radioactive minerals
A. Baeyens et al.
39
tive dose incurred by healthcare personnel [52]. In radiotherapy
departments, photons and electrons are mainly produced by
linear accelerators. Rarely, cobalt sources are used to produce
radiation. With the current safety regulations, radiotherapy staff
will get almost no dose during normal operation. The same is
true for modern brachytherapy machines, which are almost all
after loading machines avoiding direct contact between the
radioactive source and the operator.
Ion radiotherapy facilities: Most currently existing ion
radiotherapy facilities use protons, with new facilities now
being built for the acceleration of other ions, such as carbon.
They are mostly cyclotrons or synchrotrons. For such facili­
ties, the major issue is the massive production of neutrons.
Ionizing radiation results from the passage of such neutrons
through matter and from the radioactivity induced in exposed
materials. In accelerator facilities, radioactivity is produced in
the very material components, such as their beam delivery/
shaping components, as well as in all the structural compo­
nents and other materials in the facility. Induced radioactivity
in treated patients could also reach considerable levels.
Nuclear bombs: Nuclear weapons have an explosive
power deriving from the uncontrolled fission reaction of plu­
tonium and uranium. This yields a large number of radioac­
tive substances (isotopes) that are blown into the atmosphere.
These radioactive isotopes gradually fall back to Earth. If a
weapon is exploded near the Earth surface, radioactive fallout
is formed in the vicinity of the burst point in a matter of tens
of minutes to a couple of days (depending on the burst yield
and the distance to the burst point); if a weapon is detonated
aboveground (e.g., in Hiroshima and Nagasaki, the bombs
exploded about 500 m above the ground level), local fallout is
not formed but the radionuclides fall worldwide over a period
of many years. Gamma-ray and neutron exposures leading to
increased cancer incidence have been studied in the survivors
of the atomic bombings in Japan since 1950 (the so-called
Life Span Study, LSS, cohort), and currently all potentially
suitable risk estimates are built on the excess risk from the
LLS study [53]. Interestingly, the numerous tests of nuclear
weapons performed by many countries since after World War
II and the ensuing fallout have contributed minimally to the
overall background radiation exposure (Box 2.8).
2.3"
"Describe the fundamental difference between direct and indirect effects resulting from ionizing radiation exposure in biological systems, detailing the mechanisms involved in each type of damage.","Ionizing radiation causes cellular damage through two primary pathways: direct and indirect effects. Direct effects occur when the radiation itself interacts directly with molecules within cells, primarily DNA, but also proteins and lipids. This interaction leads to ionization – the removal of electrons from these molecules – creating free radicals and other highly reactive species. These radicals then initiate a cascade of chemical reactions, leading to strand breaks in DNA, cross-linking between DNA strands, and damage to essential cellular components like enzymes and membranes. The severity of direct effects is generally proportional to the radiation dose and the sensitivity of the cell type. 

Indirect effects arise when ionizing radiation interacts with water molecules within cells. This interaction produces a large number of highly reactive hydroxyl radicals (•OH), which are significantly more damaging than the initial radiation itself. These hydroxyl radicals rapidly react with virtually any biomolecule they encounter – DNA, proteins, lipids – initiating similar damage mechanisms as seen in direct effects but at a much higher rate and often over a wider area. Furthermore, these radicals can amplify the damage by reacting with other radicals generated during both direct and indirect pathways, creating a positive feedback loop. Indirect effects are typically more significant than direct effects at higher radiation doses because of the sheer abundance of reactive species produced via water radiolysis. The spatial distribution of indirect effects is also often broader due to the widespread production of hydroxyl radicals throughout the cell.

Essentially, direct damage involves the radiation directly attacking molecules, while indirect damage results from the secondary products generated when the radiation interacts with water.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.3	 Direct and Indirect Effects of Radiation | Content: of Radiation
­
­
­
­
2.10
3
2.3.1"
Describe the types of damage that can occur to DNA following exposure to ionizing radiation and explain why DNA is considered a particularly vulnerable target within cells.,"Ionizing radiation, when it interacts with biological molecules, primarily causes damage through direct effects. These effects arise from the ionization process itself, altering the structure of critical cellular components like DNA, lipids, and proteins. The most significant type of DNA damage includes base alterations (changes to individual nucleotide bases), DNA-DNA crosslinks (connections between different strands of DNA), single-strand breaks (SSB) where a single strand is cleaved, and double-strand breaks (DSB) where both strands are broken. More complex damages can also occur involving multiple lesions simultaneously.  The reason DNA is considered the most critical target stems from its unique cellular characteristics: unlike proteins, lipids, or carbohydrates, cells typically possess only one copy of their genome. This redundancy means that damage to DNA has a disproportionately large impact on cell function and survival. Furthermore, DNA’s structural stability is inherently vulnerable to radiation-induced alterations, making it the primary driver of many radiation-related biological effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.3	 Direct and Indirect Effects of Radiation | Sub-subsection: 2.3.1	 Direct Effects of Radiation | Content: 3
2.3.1
Direct Effects of Radiation
Direct effects occur when the ionization takes place within a
critical target with relevance to cell functions, such as DNA,
lipids, and proteins. These effects are produced by both high
and low linear energy transfer (LET) radiation. However, it is
the predominant mode of action of high LET radiation such
as alpha particles and neutrons, comprising about two-thirds
of the radiation effects.
When critical molecules in the cell are directly hit by
radiation, their molecular structure may be altered resulting
in their functional impairment. While molecules from all cell
organelles (including mitochondria, endoplasmic reticulum,
or Golgi apparatus) may be hit, the nuclear DNA molecule
has always been seen as the most critical target (because,
unlike proteins, lipids, and carbohydrates, only a single copy
of DNA is present in a cell) and was, therefore, the most
thoroughly studied. The DNA damage produced by radiation
includes base alterations, DNA–DNA cross-links, single- or
double-strand breaks (SSB or DSB), or complex damages
(described in Chap. 3).
2.3.2"
"Describe the sequential stages through which radiation damage manifests within biological tissues, detailing the timeframe associated with each stage and the primary mechanisms involved in generating cellular damage.","The manifestation of radiation-induced cellular damage proceeds through four distinct sequential stages, characterized by varying durations. The first, physical stage, is incredibly brief, lasting less than 10⁻¹⁶ to 10⁻¹⁵ seconds. During this phase, energy – whether kinetic from particles or electromagnetic from waves – is transferred to the electrons of atoms and molecules, resulting in ionization and excitation events, including the formation of ions. The second, physicochemical stage, begins shortly after (around 10⁻¹² seconds) and involves the diffusion of these newly formed ions and excited molecules, leading to the generation of reactive oxygen species (ROS) and nitrogen species (RNS), such as hydrogen peroxide (H2O2), superoxide anion (O2·−), peroxynitrite anion (ONOO−), and various nitrogen oxides. The third, chemical stage, spans from 10⁻¹² seconds to a few seconds, during which these radicals and ions interact with critical cellular organic molecules – primarily DNA, lipids, and proteins – inducing structural damage through reactions like base alterations, cross-linking, and strand breaks. Finally, the biological phase, lasting from minutes to decades, represents the prolonged spread of chemical reactions involving various biological processes, coupled with the cell’s repair mechanisms. The duration of this stage is highly variable depending on factors such as radiation type, dose, and cellular radiosensitivity.  Crucially, differences in tissue radiosensitivity are often linked to variations in antioxidant capacity – the ability of cells to neutralize ROS/RNS – highlighting a key determinant of long-term damage persistence.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.3	 Direct and Indirect Effects of Radiation | Sub-subsection: 2.3.2	 Indirect Effects of Radiation | Content: 3
2.3.1
Direct Effects of Radiation
Direct effects occur when the ionization takes place within a
critical target with relevance to cell functions, such as DNA,
lipids, and proteins. These effects are produced by both high
and low linear energy transfer (LET) radiation. However, it is
the predominant mode of action of high LET radiation such
as alpha particles and neutrons, comprising about two-thirds
of the radiation effects.
When critical molecules in the cell are directly hit by
radiation, their molecular structure may be altered resulting
in their functional impairment. While molecules from all cell
organelles (including mitochondria, endoplasmic reticulum,
or Golgi apparatus) may be hit, the nuclear DNA molecule
has always been seen as the most critical target (because,
unlike proteins, lipids, and carbohydrates, only a single copy
of DNA is present in a cell) and was, therefore, the most
thoroughly studied. The DNA damage produced by radiation
includes base alterations, DNA–DNA cross-links, single- or
double-strand breaks (SSB or DSB), or complex damages
(described in Chap. 3).
2.3.2
Indirect Effects of Radiation
Indirect damages produced by IR in the cell macromolecules
are mediated by ROS (resulting from water radiolysis) and
by RNS (formed following the reaction of O2 with endoge­
nous nitric oxide). The indirect effects contribute to about
two-thirds of the damages induced by low LET radiation
(X-rays, gamma-rays, beta particles), which is explained by
Box 2.8 Sources of Artificial Radiation
Artificial radiation sources are:
•	Medical and radionuclide production facilities,
accelerators for ion beam cancer therapy
•	Technologically enhanced naturally occurring
radioactive materials (TENORM)
•	Nuclear power plants
•	Accelerators for purely fundamental research in
physics
2 Basic Concepts of Radiation Biology
40
the fact that they are more sparsely ionizing compared to
high LET radiation.
When radiation deposits energy in a biological tissue, it
takes time until perceiving that an effect has occurred. The
succession of the generation of events determines the four
sequential stages that translate into the biological effects.
These stages, with very different duration, are physical,
physicochemical, chemical, and biological [54–56].
The physical stage is very transient, lasting less than
10−16–10−15 s, during which energy (kinetic if particles, or
electromagnetic if waves) is transferred to the electrons of
atoms or molecules, determining the occurrence of ioniza­
tion and/or excitation. It is at this stage that ions are formed,
which will initiate a sequence of chemical reactions that end
up in a biological effect. In the case of water radiolysis
(decomposition of water molecules due to IR), the ions H2O+
and e− are formed, as well as the excited water molecule
(H2O*) [54–56].
Very soon (10−12 s) after the formation of these ions, the
physicochemical stage begins, with their diffusion in the
medium and consequent intermediate formation of oxygen
and nitrogen radical species, i.e., atoms, molecules, or ions
that have at least one unrepaired valence electron and hence
are very reactive chemically. Following the example of
water radiolysis, it is at this stage that H· + HO·, H2 + 2HO,
HO· + H3O+, HO· + H2 + OH−, and e−
aq are formed [55, 56],
but also superoxide anion (O2
·−) and hydrogen peroxide
(H2O2). Peroxynitrite anion (ONOO−) is also formed fol­
lowing the reaction of O2
·− with endogenous nitric oxide
(NO). Together with peroxynitrous acid (ONOOH), nitro­
gen dioxide (NO2
·), dinitrogen trioxide (N2O3), and others,
they are referred to as RNS. The activation of the nicotin­
amide adenine dinucleotide phosphate (NADPH) oxidase,
the mitochondrial electron transport chain (ETC), or the
nitric oxide synthase by IR can also contribute to ROS/RNS
generation.
In the next chemical stage, the formed radicals and
ions recombine and interact with critical cellular organic
molecules (DNA, lipids, proteins), inducing structural
damages that will translate into disruption of the function
of these molecules. Within the DNA molecule, possible
chemical reactions with nitrogenous bases, deoxyribose,
or phosphate group may result in breaks and recombina­
tions with the consequent formation of abnormal mole­
cules. Among ROS, OH, which has a strong oxidative
potential, is a main contributor to cell damages. The
chemical stage can last from 10−12 s to a few seconds [55,
56]. ROS and RNS have also been largely implicated in
A. Baeyens et al.
41
the so-called non-targeted effects of IR (further discussed
in Sect. 2.8.2).
Finally, the biological phase occurs, as a consequence of
the spreading of chemical reactions involving various bio­
logical processes. The existence of more or less effective
­cellular damage repair mechanisms is responsible for the
more or less belated appearance of biological effects and
explains the possible long duration of this stage: from a few
minutes to decades, depending on the type of radiation, the
dose and dose rate, and the radiosensitivity of the irradiated
tissue.
Differences in tissue radiosensitivity can be partially
explained by the cellular antioxidant capacity, which may
vary between cell types. Indeed, to counteract oxidative
insults, cells have evolved several defense mechanisms
that consist of enzymatic and nonenzymatic systems.
When the amount of ROS/RNS exceeds the antioxidant
capacity of the cells, a state of oxidative stress arises, char­
acterized by a decreased pool of antioxidants and modifi­
cations in nucleic acids, lipids, and proteins. Oxidative
stress can persist for much longer and extend far beyond
the primary targets as well as can be transmitted to prog­
eny of the inflicted cells. Responsible for this seems to be
the continuous production of ROS and RNS, which can
last for months.
2.3.3
Biological Damages Induced by Direct
and Indirect Effects of Radiation on Cell
Organelles
Virtually all cell molecules and organelles may be damaged
by IR, with consequences for the cell function depending on
the impact of the damage inflicted.
According to the radiobiology paradigm, a nucleus is
regarded as the main target of IR due to the genetic infor­
mation contained in the DNA. Therefore, damages to this
molecule are considered the most critical ones for cell sur­
vival. While efficient repair mechanisms exist to preserve
the genome integrity, IR may break bonds in purine and
pyrimidine nitrogenous bases in the DNA (which may lead
to mutations), SSBs or DSBs, cross-linking, and complex
damages. Among these lesions, DSBs and complex dam­
ages are the most serious due to the difficulty of their repair.
A thorough description of DNA lesions is provided in
Chap. 3.
Mitochondria can also be subject to radiation damage,
both directly and indirectly. These organelles may represent
more than 30% of the total cell volume, and the mitochon­
drial circular DNA can suffer strand breaks, base mis­
matches, or even deletions of variable length. In this context,
mitochondria constitute a major target of IR [57]. Besides
the DNA, changes in mitochondrial morphology have also
been observed [58]. Absorption of IR may lead to the enlarge­
ment of mitochondria and the increase in length and number
of branches of the cristae [58, 59], rupture of the outer and
inner membranes, as well as vacuolization and loss of the
matrix. These alterations are accompanied by the decreased
activity of the respiratory chain, with special emphasis on
complexes I, II, and III, which are systematically referred to
as especially sensitive to the direct effects of IR. Additionally,
there is a decrease in the respiratory capacity driven by suc­
cinate and the ATP synthase, with a consequent impact on
oxidative phosphorylation. The radiation-induced decrease
in the rate of oxidative phosphorylation can recover over
time, depending on the cell type [60, 61]. The electrons in
the respiratory chain can leak during their transport and
reduce oxygen molecules leading to the formation of super­
oxide anions, which are precursors of most ROS. Upon irra­
diation, the level of ROS produced in the mitochondria
greatly increases, although under physiological conditions, it
is already high.
Irradiation may also cause morpho-functional changes
in the endoplasmic reticulum (ER). After exposure to IR,
ER dilates, vesicles appear, and its cisternae break into
fragments. In the case of rough endoplasmic reticulum,
irradiation induces degranulation accompanied by transfor­
mation of the membrane-bound ribosomes into free organ­
elles [59, 62].
Likewise, irradiation may also disorganize the struc­
ture of the Golgi apparatus due to the induced fragmenta­
tion and rearrangement of its cisterns. In view of the
effects of IR on the endoplasmic reticulum-Golgi appara­
tus complex, the ensuing alterations in the synthesis and
maturation of proteins in the irradiated cells come as no
surprise. Lysosomes may also increase in number and vol­
ume in the irradiated cells, which is accompanied by
upregulation of the enzymatic activity in these organelles
[58, 59] (Box 2.9).
Box 2.9 Direct and Indirect Effects of Radiation
•	Direct effects predominate after exposure to high
LET radiation (e.g., alpha particles, neutrons).
•	Exposure to low LET radiation (e.g., X-rays,
gamma rays, beta particles) induces mostly indirect
effects.
•	Indirect effects are mediated by ROS/RNS pro­
duced during and after the radiolysis of water.
•	Apart from nuclear DNA, other cellular molecules
and organelles may be altered by IR, including
mitochondrial DNA, plasma membrane lipids,
endoplasmic reticulum, Golgi apparatus, and
lysosomes.
2 Basic Concepts of Radiation Biology"
"Describe the multifaceted effects of ionizing radiation (IR) on mitochondria within cells, detailing both direct and indirect consequences observed following irradiation.","Ionizing radiation primarily targets mitochondria due to their high energy demands and vulnerability. Initially, IR exposure can lead to morphological changes including enlargement of the organelle, increased length and branching of cristae, and ultimately, rupture of the outer and inner membranes alongside vacuolization and loss of the mitochondrial matrix. These alterations are directly linked to decreased activity within the respiratory chain, particularly affecting complexes I, II, and III – components crucial for oxidative phosphorylation. This reduction in respiratory capacity is further exacerbated by a decrease in succinate-driven respiration and ATP synthase function. Critically, the disruption of electron transport leads to ‘leakage’ of electrons from the respiratory chain, resulting in the formation of superoxide anions (ROS). These ROS significantly increase within mitochondria following irradiation, compounding oxidative stress. Furthermore, IR can induce changes in other organelles such as the endoplasmic reticulum (ER) and Golgi apparatus, contributing to a broader cellular response to radiation damage. The observed effects highlight a complex interplay between direct DNA damage and indirect damage mediated by reactive oxygen species generated during radiolysis of water.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.3	 Direct and Indirect Effects of Radiation | Sub-subsection: 2.3.3	 Biological Damages Induced by Direct and Indirect Effects of Radiation on Cell Organelles | Content: mitochondria constitute a major target of IR [57]. Besides
the DNA, changes in mitochondrial morphology have also
been observed [58]. Absorption of IR may lead to the enlarge­
ment of mitochondria and the increase in length and number
of branches of the cristae [58, 59], rupture of the outer and
inner membranes, as well as vacuolization and loss of the
matrix. These alterations are accompanied by the decreased
activity of the respiratory chain, with special emphasis on
complexes I, II, and III, which are systematically referred to
as especially sensitive to the direct effects of IR. Additionally,
there is a decrease in the respiratory capacity driven by suc­
cinate and the ATP synthase, with a consequent impact on
oxidative phosphorylation. The radiation-induced decrease
in the rate of oxidative phosphorylation can recover over
time, depending on the cell type [60, 61]. The electrons in
the respiratory chain can leak during their transport and
reduce oxygen molecules leading to the formation of super­
oxide anions, which are precursors of most ROS. Upon irra­
diation, the level of ROS produced in the mitochondria
greatly increases, although under physiological conditions, it
is already high.
Irradiation may also cause morpho-functional changes
in the endoplasmic reticulum (ER). After exposure to IR,
ER dilates, vesicles appear, and its cisternae break into
fragments. In the case of rough endoplasmic reticulum,
irradiation induces degranulation accompanied by transfor­
mation of the membrane-bound ribosomes into free organ­
elles [59, 62].
Likewise, irradiation may also disorganize the struc­
ture of the Golgi apparatus due to the induced fragmenta­
tion and rearrangement of its cisterns. In view of the
effects of IR on the endoplasmic reticulum-Golgi appara­
tus complex, the ensuing alterations in the synthesis and
maturation of proteins in the irradiated cells come as no
surprise. Lysosomes may also increase in number and vol­
ume in the irradiated cells, which is accompanied by
upregulation of the enzymatic activity in these organelles
[58, 59] (Box 2.9).
Box 2.9 Direct and Indirect Effects of Radiation
•	Direct effects predominate after exposure to high
LET radiation (e.g., alpha particles, neutrons).
•	Exposure to low LET radiation (e.g., X-rays,
gamma rays, beta particles) induces mostly indirect
effects.
•	Indirect effects are mediated by ROS/RNS pro­
duced during and after the radiolysis of water.
•	Apart from nuclear DNA, other cellular molecules
and organelles may be altered by IR, including
mitochondrial DNA, plasma membrane lipids,
endoplasmic reticulum, Golgi apparatus, and
lysosomes.
2 Basic Concepts of Radiation Biology
42
2.4"
"Explain the fundamental relationship between radioactivity and the concept of half-life in biological systems, considering its implications for living organisms.","Radioactivity fundamentally arises from the unstable nucleus of certain atoms, leading to spontaneous decay processes where particles or energy are emitted. This emission results in a change in the atom's identity – transforming it into a different element. The rate at which these radioactive decays occur is characterized by half-life, defined as the time required for one-half of the initial amount of a radioactive substance to undergo decay.  In biological systems, organisms are constantly exposed to naturally occurring and artificially generated radiation due to its presence since Earth’s formation. Because of this continuous exposure, cells regularly encounter ionizing radiation. The rate at which individual atoms decay is constant – governed solely by their inherent instability – but the *concentration* of radioactive isotopes within a living organism will fluctuate over time as decays occur and replenish new isotopes.  This fluctuation directly impacts biological processes; for example, high doses of radiation can damage DNA, leading to mutations and cell death, while lower levels may cause subtle changes in metabolic rates or cellular function due to altered isotopic ratios. The half-life of a specific radioactive isotope determines the timescale over which these effects will be observable – shorter half-lives mean rapid fluctuations and potentially more acute biological consequences, whereas longer half-lives result in a slower, more gradual impact.  Furthermore, the accumulation of radioactive isotopes within tissues can lead to long-term health risks, particularly with prolonged exposure.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Content: Radiation and radioactivity have been existing ever since the
Earth was formed and long before life started to evolve. All
living organisms on Earth are continuously exposed to both
natural and artificial radioactivity, and without it, life in the
present form would have not evolved. Since the first experi­
ments with radioactivity, our understanding of this phenom­
enon has increased, and consequently, today radioactivity
has numerous applications important to human life and
health.
2.4.1"
"Explain the relationship between radioactive decay and the concept of half-life, including how this information is used to quantify the activity of a radioactive sample.","Radioactive decay describes the spontaneous breakdown of unstable atomic nuclei, releasing energy and particles. The rate at which this decay occurs is governed by the decay constant (λ), representing the probability per unit time that a nucleus will undergo decay. A key parameter derived from this process is half-life (T1/2), defined as the time required for half of the initial radioactive nuclei in a sample to decay.  Mathematically, the relationship between these quantities is expressed by the equation: ln(N) = -λt, where N is the number of radioactive nuclei remaining at time t. Integrating this equation yields the more commonly used form: A = N * e^(-λt), where A represents the activity (decays per second) of the sample.  Alternatively, and frequently utilized, is the half-life equation: A = (N/2) * e^(-(λ*T1/2)). The activity (A) itself is a measure of the rate of decay, expressed in Becquerels (Bq), where one Bq represents one radioactive decay per second.  Furthermore, radioactivity can be quantified using Curies (Ci), which represent the activity of a gram of 226Ra, providing a larger scale measurement for quantifying the sample's radiation output. The conversion between Ci and Bq is crucial: 1 Ci = 3.7 × 10^10 Bq.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.1	 Radioactive Decay | Sub-sub-subsection: 2.4.1.1	 Natural Radioactivity | Content: The rate of decay of a radioactive source is proportional to
the amount of the substance that is present at any given
instant. Therefore, if the number of radioactive nuclei in a
sample is N, then we may say the following:
(2.15)
where λ is the decay constant, which describes the rate of
decay for a particular radioactive isotope.
If we integrate both sides of Eq. (2.15), we get the follow­
ing more familiar equation:
(2.16)
If we let the variable T1/2 be the “half-life of the sub­
stance,” i.e., the time taken for the activity of the substance to
reduce from its initial value to half of its initial value, then
we may modify Eq. (2.16) as
(2.17)
The activity, A, of a given sample of a radioactive sub­
stance, i.e., the number of decays per second (in Bq), is given
by the following equation:
(2.18)
where calculations based on activities may be performed
using Eqs. (2.2) and (2.3) above with the values of A inserted
instead of N. The radioactivity of a sample is quoted in terms
of the units of Curies, Ci (the radioactivity of a gram of
226Ra), where 1 Ci =3.7 × 1010 decays per second. This is
more commonly quoted in terms of the S.I. unit the Becquerel,
Bq, where 1 Bq = 1 decay per second. Therefore, 1 Ci = 3.7
× 1010 Bq (Box 2.10)."
"Describe the process of radioactive decay, focusing on how a parent isotope transforms into daughter nuclides within a decay series and highlighting the concept of radioactive equilibrium.","Radioactive decay is a spontaneous process by which an unstable atomic nucleus loses energy in the form of radiation to achieve a more stable configuration. This transformation occurs through various decay modes, including alpha decay (emission of an alpha particle – typically 238U or 235U), beta decay (emission of a beta particle – an electron or positron – transforming a neutron into a proton or vice versa), and gamma decay (emission of high-energy photons). Each decay series begins with a radioactive isotope, known as the parent isotope, and proceeds through a sequence of daughter nuclides until a stable, non-radioactive element is reached. The thorium, neptunium, and actinium series exemplify this process; for instance, 252Cf decays into 248Cm, which then decays into various isotopes including 244Pu, 240U, and finally 240Np before ultimately leading to a stable bismuth isotope (Bi-209). The key concept of radioactive equilibrium describes the state where the rate of decay of one daughter nuclide equals the rate of formation of its parent isotope from another preceding daughter. This creates a dynamic balance within the series, with each isotope present in proportions determined by their respective half-lives and decay rates. Importantly, this equilibrium is often disrupted over geological timescales due to continuous radioactive decay, as demonstrated by the observed presence of Bi-209 despite the initial absence of the neptunium series at the universe's birth. The activity of a radioactive substance is quantified in becquerels (Bq) or curies (Ci), representing the number of decays per second.

Reference: MolecularRadiationBiology, Section 2.4.1.2 – Radioactive Equilibrium","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.1	 Radioactive Decay | Sub-sub-subsection: 2.4.1.2	 Radioactive Equilibrium | Content: ­
239
­
­
2.11
The neptunium series is not observed in nature at the pres­
ent time as 237Np, and all of its daughter nuclides have
decayed since the birth of the universe, although the product
of the series, bismuth 209Bi, is observed as a stable isotope in
nature, pointing to the existence of the series at one time in
the past. Each decay series begins with a radioactive isotope
and ends with a stable daughter product. The parent isotopes
of the isotopes at the beginning of the thorium, neptunium,
and actinium series are produced as follows:
Th series: 252Cf → 248Cm → ® 244Pu → ® 240U → ® 240Np
→ ® 240Pu → ® 236U
Np series: 249Cf → ® 245Cm → ® 241Pu → ® 241Am → ® 237Np
Ac series: 239Pu → ® 235U
2.12
0
(2.19)
(2.20)
(2.21)
Box 2.10 The Activity of a Radioactive Substance
•	The activity (A) of a radioactive substance is given
in becquerel (1 Bq is the number of decays per
second).
•	The radioactivity of a sample can also be expressed
in curies (Ci), where 1 Ci = 3.7 × 1010 Bq.
A. Baeyens et al.
43
238
226
https://chem.libretexts.
org/@go/page/86256
From Eqs. (2.19) and (2.20):
(2.22)
Multiplying across by e
S
uperscript lamda Super Subscript upper B Superscript t
Integrating both sides then gives
And multiplying across by e
S
uperscript minus lamda Super Subscript upper B Superscript t gives
(2.23)
A
B
2.12a
A
B
2.12b
2.12b
A
B
2.23
2.11
(2.24)"
"The Joliot-Curie experiments demonstrated the creation of artificial radioactivity. Describe the process they utilized, including the types of particles involved and the resulting decay pathways that produced silicon and carbon.","In 1934, Irène and Frédéric Joliot-Curie pioneered the concept of artificial radioactivity by bombarding aluminum (Al) and boron (B) targets with alpha particles. This bombardment resulted in the creation of radioactive isotopes of phosphorus (P) and nitrogen (N). These newly formed isotopes underwent a series of decays leading to the production of silicon (Si) and carbon (C). Specifically, the phosphorus isotope decayed through beta-minus decay (β−), transforming into silicon, while the nitrogen isotope decayed through beta-plus decay (β+), ultimately producing carbon.  The reactions involved were: P → Si + e⁻ + ν̅e and N → C + e⁺ + ν̅e, where ν̅e represents an antineutrino. These artificially produced isotopes do not occur naturally, and the ratios of β+/β− and n/p within the nucleus dictate which decay pathway predominates.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.1	 Radioactive Decay | Sub-sub-subsection: 2.4.1.3	 Artificial Radioactivity | Content: Experiments demonstrating the production of radioactive
nuclei in the laboratory were performed by Irène and Frédéric
Joliot-Curie in 1934 through the bombardment of aluminum
and boron atoms with alpha particles. Those scientists
observed that positrons were produced long after the bom­
Box 2.11 Natural Radioactivity
•	The natural abundance of radionuclides is largely
determined by the nuclear decay series of four par­
ent nuclides, thorium, neptunium, uranium/radium,
and actinium.
•	Each decay series starts from an unstable radioac­
tive parent isotope and ends with a stable daughter
product.
•	Various states of equilibrium can be reached
depending on the relationship between the lifetime
of the parent and daughter isotopes.
2 Basic Concepts of Radiation Biology
44
A
B,
bardment and neutron production had ceased. They postu­
lated that radioactive isotopes of phosphorus and nitrogen
had been produced, which decayed to silicon and carbon in
the following reactions:
St
ar
t
L
ay
ou
t
1s
t
R
o
w
1s
t
C
ol
umn
S
ta
r
t
L
ay
out 1st
R
o
w
S
u
b
s
cr
ip
t
1
3
B
a
s
e
l
in
e
n
or
m
a
l
u
pp
er
A
B
a
s
e
line no
r
ma
l l Superscript 27 Baseline plus Subscript 2 Baseline normal upper H Baseline normal e Superscript 4 Baseline right arrow Subscript 15 Baseline normal upper P Superscript 30 Baseline plus normal n 0 Superscript 1 Baseline 2nd Row  Subscript 15 Baseline normal upper P Superscript 30 Baseline right arrow beta Subscript negative 1 Superscript 0 Baseline Superscript plus Baseline plus Subscript 14 Baseline normal upper S Baseline normal i Superscript 30 Baseline EndLayout 2nd Column StartLayout 1st Row  upper T Subscript 1 divided by 2 Baseline equals 150 2nd Row  s e c o n d s EndLayout 2nd Row 1st Column StartLayout 1st Row  Subscript 5 Baseline normal upper B Superscript 10 Baseline plus Subscript 2 Baseline normal upper H Baseline normal e Superscript 4 Baseline right arrow Subscript 7 Baseline normal upper N Superscript 13 Baseline plus normal n 0 Superscript 1 Baseline 2nd Row  Subscript 7 Baseline normal upper N Superscript 13 Baseline right arrow beta Subscript negative 1 Superscript 0 Baseline Superscript plus Baseline plus Subscript 6 Baseline normal upper C Superscript 13 EndLayout 2nd Column StartLayout 1st Row  upper T Subscript 1 divided by 2 Baseline equals 600 2nd Row  s e c o n d s EndLayout EndLayout period
Neither of the two radioactive isotopes of phosphorus and
nitrogen produced in these reactions occurs in nature. The
majority of the artificially produced isotopes are produced
via the same bombardment as illustrated here, and most of
them decay by the production of β+/βb−, the ratio of n/p in
the nucleus determining which of the two reactions occurs.
Consider a situation where a nuclear reaction occurs by
bombardment of nucleus X with particle a, producing a
nucleus Y and another projectile particle b:
(2.25)
Assuming that the rate of production, R, of Y is constant
and its decay is also constant, then the infinitesimal change,
dN, in the numbers of product atoms of Y over infinitesimal
time, dt, is
(2.26)
where Rdt provides the number of nuclides of Y produced
per unit time and λNdt the number decaying over this time
period. We can then rearrange to obtain a differential equa­
tion for the system:
(2.27)
for which we can obtain a general solution for the number
of nuclides of Y at any time t > 0:
(2.28)
And since activity A = λN, we may obtain a relationship
for the variation in activity with time as
(2.29)
We may use a Taylor expansion in e-λt to then obtain
(2.30)
which allows a solution to be obtained for the special case
where t << T1/2 for the nuclide Y such that the following is
true: (also see Box 2.12)
(2.31)
Box 2.12 Artificial Radioactivity
•	In 1934, Irène and Frédéric Joliot-Curie demon­
strated for the first time that artificial, i.e., not
occurring in nature, radioactive nuclei can be
produced.
•	Artificial nuclides are produced by bombarding a
nucleus (X) with a particle (a) resulting in the pro­
duction of a new nucleus (Y) and a projectile parti­
cle (b).
A. Baeyens et al.
45
Table 2.1 Summary of the different types of nuclear decay
Mode of radioactive decay
Released particles
General reaction
Example
α-Decay
Helium nucleus
ZAP → Z − 2A − 4P + 24He
92238U → 90234Th + 24He
β-Decay
β–
β+
Electron
Positron
upp
e
r
Z
u
p
p
e
r
A upper P right arrow normal upper Z plus 1 upper A upper D plus normal e Superscript minus Baseline plus normal v overbar
a
ZAP → Z − 1AD + e+ + νb
90234
uppe
r
T
h
r
i
g
ht arrow 91234 upper T h plus normal e Superscript minus Baseline plus normal v overbar
a
611C → 511B + e+ + νb
γ-Decay
γ-Emission
Gamma ray
ZAP → ZAD + 00γ
92238U → 24He + 90234Th + 200γ
Internal conversion
Internal conversion electron
ZAP → ZAD + IC e−
Electron capture (EC)
Atomic X-ray
ZAP + e− → Z − 1AD + νb
47Be + e− → 37Li + νb
Spontaneous fission (SF)
2 fragment nuclei
ZAP → Z1A1D1 + Z2A2D2
100256Fm → 54140Xe + 46112Pd
Proton emission (PE)
Proton
ZAP → Z − 1A − 1D + 11p
711N → 610C + 11p
Neutron emission (NE)
Neutron
ZAP → ZA − 1D + n0c
413Be → 412Be + n0c
a⊽ Antineutrino
bNeutrino
cn0 Neutron"
"Describe the process of spontaneous fission (SF) in radioactive decay, including the resulting daughter nuclei and a specific example.","Spontaneous fission (SF) is a mode of radioactive decay where the nucleus of an atom undergoes a sudden separation into two or more smaller nuclei. This process doesn't involve the emission of any particles like protons, neutrons, or electrons; instead, it’s a purely quantum mechanical event driven by the instability of the nucleus itself. The general equation for SF is represented as ZAP → Z1A1D1 + Z2A2D2, where ZAP represents the initial atomic number and mass number of the parent nucleus, Z1A1D1 and Z2A2D2 represent the atomic numbers and mass numbers of the daughter nuclei. A classic example is the decay of 100Fm (Francium-100), which undergoes SF to produce Xenon-54 and Palladium-46: 100Fm → 54Xe + 46Pd. This transformation involves a significant change in both the number of protons (Z) and neutrons (A) within the original nucleus, leading to its disintegration into distinct fragments.

Reference: Molecular Radiation Biology, Section 2.4.1.4 – Modes of Radioactive Decay.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.1	 Radioactive Decay | Sub-sub-subsection: 2.4.1.4	 Modes of Radioactive Decay | Content: Spontaneous fission (SF)
2 fragment nuclei
ZAP → Z1A1D1 + Z2A2D2
100256Fm → 54140Xe + 46112Pd
Proton emission (PE)
Proton
ZAP → Z − 1A − 1D + 11p
711N → 610C + 11p
Neutron emission (NE)
Neutron
ZAP → ZA − 1D + n0c
413Be → 412Be + n0c
a⊽ Antineutrino
bNeutrino
cn0 Neutron
2.4.1.4	Modes of Radioactive Decay
­
­
­
63
­
2.1
2.13
2.4.2"
"Describe the different modes of radioactive decay presented in the text, including spontaneous fission, proton emission, neutron emission, and antineutrino/neutrino emissions.","The document outlines several modes of radioactive decay utilized to transform unstable nuclei into more stable configurations. Spontaneous fission (SF) involves a nucleus splitting into two fragments – Z1A1D1 and Z2A2D2. A classic example is 100256Fm decaying into 54140Xe and 46112Pd. Proton emission (PE) results in the loss of a proton from the nucleus, as seen with 711N transforming into 610C and releasing a proton. Neutron emission (NE) involves the release of a neutron, exemplified by 413Be decaying into 412Be and emitting a neutron. Finally, antineutrinos and neutrinos are emitted during certain decay processes; these particles represent energy released from the nucleus. Reference: [MolecularRadiationBiology, Section 2.4.2 – The Chart of Nuclides]","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.2	 The Chart of Nuclides | Content: Spontaneous fission (SF)
2 fragment nuclei
ZAP → Z1A1D1 + Z2A2D2
100256Fm → 54140Xe + 46112Pd
Proton emission (PE)
Proton
ZAP → Z − 1A − 1D + 11p
711N → 610C + 11p
Neutron emission (NE)
Neutron
ZAP → ZA − 1D + n0c
413Be → 412Be + n0c
a⊽ Antineutrino
bNeutrino
cn0 Neutron
2.4.1.4	Modes of Radioactive Decay
­
­
­
63
­
2.1
2.13
2.4.2
The Chart of Nuclides
The term nuclide refers to an atom characterized by the
number of protons and neutrons present in the nucleus.
Nuclides can be sorted according to their number of protons
and neutrons in a chart of nuclides. In contrast to the well-
known periodic table, a chart of nuclides organizes the cur­
rently known radionuclides according to the number of
protons and neutrons in their nucleus. Furthermore, it sum­
marizes basic properties of these nuclides, such as atomic
weights, decay modes, half-lives, and energies of the emit­
ted radiations [64, 65].
­
66
­
­
2.13a
2.13c
­
2.13b
­
2.13b
226
2.13b135
­
­
­
2.13b232
66
A chart of nuclides can be used to investigate decay chains
and nuclear reactions of different radionuclides. By follow­
ing the specific decay rules of each type of nuclear decay,
complete decay chains can be obtained manually. In a similar
way, the chart can be used to obtain different activation and
reaction products of nuclear reactions [66]. In this way, this
chart can be of great assistance to obtain information on
Box 2.13 Nuclear Decay
•	During nuclear decay, unstable nuclei transform
into an energetically more stable configuration by
emission of certain particles or energy.
•
2.1
2 Basic Concepts of Radiation Biology
46
Table 2.2 Naturally occurring radioactive isotopes commonly used in
radiometric dating [67]
Radioactive isotope
(parent)
Decay product
(daughter)
Half-life
(years)
Samarium-147
Neodymium-143
106 billion
Rubidium-87
Strontium-87
48.8 billion
Rhenium-187
Osmium-187
42 billion
Lutetium-176
Hafnium-176
38 billion
Thorium-232
Lead-208
14 billion
Uranium-238
Lead+-206
4.5 billion
Potassium-40
Argon-40
1.26 billion
Uranium-235
Lead-207
0.7 billion
Beryllium-10
Boron-10
1.52 million
Chlorine-36
Argon-36
300,000
Carbon-14
Nitrogen-14
5715
Uranium-234
Thorium-230
248,000
Thorium-230
Radium-226
75,400
nuclear decay chains and isotope stability. It can help with
both planning of experiments and interpretation of results
[64, 65] (Box 2.14).
2.4.3"
"Radioisotopes are utilized across diverse sectors like medicine and the food industry. Explain how the unique properties of radioisotopes – specifically their decay processes – contribute to these applications, providing examples of specific isotopes and their uses.","Radioisotopes’ utility stems directly from their inherent instability and subsequent radioactive decay. These decays involve the emission of particles (alpha, beta) or energy (gamma rays), transforming the original atom into a different element while releasing substantial kinetic energy. This process is harnessed in numerous applications. For instance, technetium-99m (⁹⁹ᵐTc) is widely used in medical imaging due to its short half-life (approximately 6 hours). Its gamma emission allows for non-invasive visualization of organs and tissues using techniques like SPECT (Single Photon Emission Computed Tomography), enabling the detection of tumors or assessing organ function. Similarly, iodine-131 (¹³¹I) is a beta emitter used in treating hyperthyroidism; its radiation destroys overactive thyroid cells. Cobalt-60 (⁶⁰Co) emits high-energy gamma rays and is employed in food irradiation to sterilize products, extending their shelf life by killing bacteria and insects. The controlled release of energy from these isotopes allows for targeted treatments or diagnostic procedures. Different decay modes – alpha, beta, or gamma – dictate the specific applications; alpha emitters are often used for internal targeting within tumors, while gamma emitters facilitate external imaging techniques. The half-life of each isotope is also a critical factor, balancing efficacy with minimizing patient exposure and environmental impact.

Reference: [Molecular Radiation Biology], Section 2.4.3 – Applications of Radioisotopes","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Content: [64, 65] (Box 2.14).
2.4.3
Applications of Radioisotopes
The pioneering experiments performed by Wilhelm Conrad
Roentgen (1895), Henri Becquerel (1896), and Marie and
Pierre Curie (1898 and 1911) showed the potential of differ­
ent radioactive elements. Over the decades to follow, radio­
isotopes have been applied in various fields, including
medicine and food industry. In this section, some of the most
common applications of radioisotopes will be discussed."
"Describe the process of radiometric dating and explain how it utilizes the decay of radioactive isotopes to determine the age of materials like rocks or fossils. Specifically, detail the roles of parent isotopes, daughter isotopes, and half-life in this technique.","Radiometric dating is a method employed to estimate the age of ancient materials – primarily rocks and fossils – by measuring the ratio of radioactive isotopes to their stable decay products. The fundamental principle relies on the constant rate at which a radioactive isotope decays into its daughter isotope, governed by its half-life. A ‘parent’ radioactive isotope initially present within the material undergoes continuous transformation through radioactive decay, producing ‘daughter’ isotopes as byproducts. Because the decay rate is remarkably consistent over time (independent of external factors like temperature or pressure), scientists can accurately calculate the elapsed time since the material formed. The key lies in comparing the measurable abundance of the parent isotope to the measured abundance of its daughter isotopes. By knowing the half-life – the time it takes for half of a radioactive sample to decay – and measuring the ratio, one can determine how many half-lives have passed and thus estimate the age of the material. For example, carbon-14 dating utilizes the 5730-year half-life of carbon-14, while potassium-argon dating relies on the much longer half-life of potassium-40 (approximately 1.25 billion years) to date geological samples.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.1	 Radiometric Dating | Content: [64, 65] (Box 2.14).
2.4.3
Applications of Radioisotopes
The pioneering experiments performed by Wilhelm Conrad
Roentgen (1895), Henri Becquerel (1896), and Marie and
Pierre Curie (1898 and 1911) showed the potential of differ­
ent radioactive elements. Over the decades to follow, radio­
isotopes have been applied in various fields, including
medicine and food industry. In this section, some of the most
common applications of radioisotopes will be discussed.
2.4.3.1	Radiometric Dating
Radiometric dating is a technique used to date materials such
as rocks or fossils, in which trace radioactive impurities were
selectively incorporated when these materials were formed.
The method compares the abundance of a naturally occur­
ring “parent” radioactive isotope within the material to the
abundance of its decay products (“daughter isotopes”), arriv­
ing at a known constant rate of the decay process.
­
2.2
One of the most well-known examples is the dating using
radioactive 14C (half-life of 5730 years) formed by nuclear
Box 2.14 Definition of a Nuclide
•	A “nuclide” refers to an atom with a certain number
of protons and neutrons in the nucleus.
•	Nuclides can be sorted based on their characteris­
tics in a nuclide chart.
•	A nuclide chart can be used to investigate nuclear
decay chains of different radionuclides.
A. Baeyens et al.
47
reactions in the atmosphere. The constantly produced 14C
reacts with oxygen, leading to the formation of 14CO2. This
radioactive form of carbon dioxide is absorbed by plants via
photosynthesis and will eventually become incorporated into
all living organisms through the food chain. Once an organ­
ism dies, its metabolism stops, halting the incorporation of
14C. Therefore, by knowing the characteristic half-life and
the ratio of 14C to the total carbon content, the age of the
sample can be determined. The same principle applies to dat­
ing with the potassium-argon pair, which is commonly used
to estimate the age of rocks, volcanic layers around fossils,
and artifacts [68]."
Describe the process of sterilization by gamma irradiation as it relates to medical products and pharmaceuticals. What are some key advantages of this method compared to traditional sterilization techniques like autoclaving?,"Sterilization by gamma irradiation, typically utilizing cobalt-60 or cesium-137 sources delivering a dose of approximately 15–25 kilogray (kGy), is frequently employed for the complete elimination of microorganisms from medical products and pharmaceuticals. This process effectively destroys microbial DNA and RNA, rendering the items sterile. A crucial advantage over methods like autoclaving lies in its ability to sterilize heat-sensitive materials – such as implants, artificial joints, blood bags, and ointments – which would be damaged or degraded by high-pressure steam. Autoclaving requires significant heat, potentially altering the chemical composition and mechanical properties of these delicate items. Furthermore, gamma irradiation is considered safer and more cost-effective because it can be performed after packaging, eliminating the need for specialized sterilization equipment within the product itself. The resulting sterile shelf life is essentially indefinite as long as the packaging remains intact, representing a significant improvement in product stability and longevity compared to methods that may introduce short-term preservatives or require frequent re-sterilization.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.2	 Sterilization by Gamma Irradiation | Content: Sterilization is the complete killing or removal of all living
organisms from a particular location or material. Several
methods can be used to achieve sterilization, each with their
own benefits and limitations. Irradiation with gamma rays
(from a cobalt-60 or cesium-137 source, with a dose of around
15–25 kGy) is often used for the sterilization of medical prod­
ucts and pharmaceuticals, including implants, artificial joints,
blood bags, and ointments. Sterilization by radiation has sev­
eral benefits, the most important of which is that it can be
used on heat-sensitive items that cannot be sterilized by other
common methods such as autoclaving. It is also safer and
cheaper because it can be done after the item is packaged. The
sterile shelf life of the item is then practically indefinite pro­
vided that the seal is not broken. Indeed, it is estimated that
irradiation technologies are used to sterilize almost half of the
global supply of single-use medical products.
The use of gamma rays is, however, not strictly limited to
the medical world. By irradiating food, we can significantly
reduce their microbial burden, depending on the dose deliv­
ered. This prolongs the shelf life of the food in cases where
microbial spoilage is the limiting factor. Some foods, e.g.,
herbs and spices, are irradiated at sufficient doses (5 kGy) to
reduce the microbial counts by several orders of magnitude;
such ingredients do not carry over spoilage or pathogenic
microorganisms into the final product. It has also been shown
that irradiation can delay the ripening of fruits or the sprouting
of vegetables. Insect pests can be sterilized (be made incapa­
ble of proliferation) using irradiation at relatively low doses.
The use of low-level irradiation can also be used as an alterna­
tive treatment to pesticides for fruits and vegetables that are
considered hosts to a number of insect pests, including fruit
flies and seed weevils. Food irradiation is currently permitted
by over 50 countries, and the volume of food treated is esti­
mated to exceed 500,000 metric tons annually worldwide [69]."
"Describe the principles behind radioimmunoassays (RIAs), including the competitive binding mechanism and the role of various isotopes in quantifying unknown samples.","Radioimmunoassays (RIAs) are analytical techniques used to determine the concentration of a specific substance, typically an antigen, within a sample. The core principle relies on a competitive binding reaction between radiolabeled and unlabeled versions of the target antigen. Initially, an unlabeled antigen is mixed with a fixed amount of a radiolabeled antigen along with a known quantity of antibody that specifically binds to both forms of the antigen. As the concentration of the unknown sample (also containing unlabeled antigen) increases, it competes with the labeled antigen for binding sites on the antibody. Consequently, fewer labeled antigen molecules will bind to the antibody due to this competition.

The key steps in a typical RIA involve precipitation of the antibody-antigen complexes, followed by measurement of radioactivity using a scintillation counter. The amount of radioactivity detected is directly proportional to the concentration of the unknown sample. A standard curve is generated by running a series of known concentrations of the labeled antigen alongside the unknown samples. This allows for quantitative determination of the analyte's concentration in the test sample. Commonly employed radioisotopes include iodine-125 and iodine-131, which emit gamma radiation easily detectable by scintillation counters, as well as tritium (3H), a beta emitter often used due to its relative ease of handling and lower cost.

Essentially, RIAs leverage the antibody's high specificity for its target antigen, using the radiolabeled form as a tracer to quantify the amount of unlabeled antigen present in the sample. Reference: Molecular Radiation Biology, Section 2.4.3.3 – Radioimmunoassays","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.3	 Radioimmunoassays | Content: ­
­
2.14
2 Basic Concepts of Radiation Biology
48
unlabeled antigen (sample) is incubated together with a fixed
amount of the radiolabeled antigen and the antibody, result­
ing in competition between the unlabeled and labeled anti­
gens for binding to the antibody. With increasing amounts of
an unknown sample (unlabeled antigen), decreasing amounts
of labeled antigen (tracer) will bind to the antigen [70]. The
antibody–antigen complexes are separated from the free
antigen by precipitation using a secondary antibody or
chemical solutions. The antibody–antigen complexes are
then measured in a scintillation counter. By running a set of
standards, a standard curve is generated from which the con­
centration of the unknown sample can be calculated. The
most commonly used radioisotopes for radioimmunoassays
are iodine-125, iodine-131, and tritium (3H) [71] (Box 2.15)."
"Describe how radioisotopes are utilized in medical applications, specifically focusing on the mechanisms behind their effectiveness in treating diseases and providing examples of specific therapies.","Radioisotopes play a crucial role in modern medicine through several targeted therapeutic approaches. Primarily, they leverage the high ionizing power and penetrating range of gamma rays to directly damage or destroy diseased cells. This mechanism is particularly effective against rapidly dividing cells, such as cancer cells, where the radiation’s energy can disrupt DNA replication and cause cell death.  A key application is radionuclide therapy, which involves administering a radioisotope labeled with a targeting molecule – often an antibody or peptide – that specifically binds to receptors overexpressed on the surface of target cells. Once bound, the radioisotope delivers a concentrated dose of radiation directly to the tumor site, minimizing damage to surrounding healthy tissue.  Examples include PSMA-targeted radionuclide therapy for prostate cancer, where the radioisotope (typically 177Lu) is attached to an antibody that recognizes Prostate-Specific Membrane Antigen (PSMA), which is highly expressed on prostate cancer cells. This allows for precise delivery of radiation specifically to cancerous tissues. Furthermore, radioimmunotherapy utilizes radioisotopes conjugated to antibodies or nanobodies – small proteins that bind to specific targets – to treat cancers like glioblastoma. The high sensitivity afforded by radioisotope-based immunoassays also enables the measurement of antigens in extremely low quantities, facilitating early disease detection and monitoring treatment efficacy.  The use of these isotopes extends beyond direct cell destruction; they can also be used for diagnostic imaging, allowing clinicians to visualize tumors and assess their response to therapy.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.4	 Radionuclide Therapy | Content: ­
­
­
2.15
­
2.16
­
­
72
­
­
®
177
­
­
®
­
Box 2.15 The Use of Radioisotopes
•	Radioactive decay can be used as a natural clock to
determine the age of different materials.
•	The strong ionizing ability of gamma rays, along
with their high penetration range, can be used for
the killing or reduction of microorganisms in differ­
ent items, ranging from medical to food products.
•	The use of radioisotopes in immunoassays provides
a very high level of sensitivity allowing the mea­
surement of antigens in pictogram quantities.
−
­
A. Baeyens et al.
49
cer types. These include the PSMA-targeted radionuclide
therapy for prostate cancer and radioimmunotherapy with
nanobodies for glioblastoma (Table 2.3) (Box 2.16)."
"Radioisotopes are increasingly utilized in clinical diagnostics, primarily due to their ability to emit detectable radiation. However, the selection of a specific radioisotope for a diagnostic procedure hinges on several factors beyond just its radioactivity level. Detail the key considerations that clinicians take into account when choosing a radioisotope for imaging or therapeutic applications within a clinical setting.","The selection of a radioisotope for clinical diagnostics is a complex process governed by numerous factors, all aimed at maximizing diagnostic efficacy while minimizing patient risk and ensuring accurate results. Several critical considerations drive this decision-making: 1) **Half-Life:** The half-life of the isotope is paramount. Shorter half-lives (e.g., Technetium-99m) are preferred for rapid imaging, allowing clinicians to capture images quickly before the isotope decays significantly. Longer half-lives (e.g., Iodine-131) can be beneficial when prolonged monitoring or therapeutic intervention is required, though they necessitate careful dose management due to their extended radioactivity. 2) **Type of Radiation Emitted:** Different radioisotopes emit various types of radiation – beta particles, gamma rays, or Auger electrons. The type of radiation dictates the tissue penetration capabilities and potential for damage. Gamma emitters like Iodine-131 provide excellent whole-body imaging but carry a higher risk of ionization effects. Beta emitters (like Technetium-99m) offer better spatial resolution due to their shorter range. 3) **Energy of Radiation:** The energy level of the emitted radiation influences its interaction with matter and, consequently, its ability to be detected and visualized. Lower energy gamma rays are more readily absorbed by tissues, while higher energy gamma rays can penetrate deeper but may cause greater damage. 4) **Target Tissue Specificity:** Ideally, the chosen isotope should preferentially accumulate in or interact with the target tissue of interest. This is often achieved through chemical labeling – attaching a radiolabeled molecule to a pharmaceutical agent that specifically binds to receptors or enzymes within the affected area (e.g., Iodine-131 labeled thyroid receptor agonists for thyroid imaging). 5) **Patient Factors:** Patient age, overall health, and pre-existing conditions are also crucial considerations. For example, patients with compromised immune systems may be more susceptible to radiation damage. Finally, regulatory approvals and established safety protocols play a vital role in ensuring the responsible use of radioisotopes in clinical diagnostics.

Reference: Molecular Radiation Biology, Section 2.4.3.5 – Clinical Diagnostics","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.5	 Clinical Diagnostics | Content: ­
73
­
1/2
74
2.17"
"Describe the key considerations in selecting radioisotopes for use in Single Photon Emission Computed Tomography (SPECT) imaging, focusing on factors like photon energy, half-life, and potential interference with surrounding tissues.","The selection of radioisotopes for SPECT is governed by several critical factors to optimize image quality and patient safety. Primarily, the chosen nuclides emit electromagnetic rays within the 100–200 keV range, a trade-off determined by the absorption characteristics of tissue and the detection capabilities of the scintillator crystals (typically NaI). Lower energy rays are readily absorbed by surrounding tissues, leading to increased patient doses and reduced sensitivity in detecting the target area. Conversely, higher energy levels are less easily stopped but are also less effectively detected, diminishing resolution. Furthermore, the half-life (T1/2) of the radioisotope must be carefully considered; a short half-life can lead to rapid clearance from the body before sufficient imaging data is acquired, while an excessively long half-life may introduce unnecessary radiation exposure. The use of collimators within SPECT apparatuses further directs the incoming radiation, minimizing scatter and improving image contrast and resolution by selectively allowing parallel rays through while absorbing non-parallel rays.  Radioisotopes like 99mTc are favored due to their cost, availability via a generator process (99Mo/99mTc), and ability to be complexed with various chelators for diverse diagnostic applications across numerous diseases.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.5	 Clinical Diagnostics | Content: SPECT makes use of the inherent decay properties of spe­
cific radionuclides, which decay with the emission of a pho­
ton (X-ray) (Hutton 2014).
The nuclides of choice are those which emit electromag­
netic rays in the energy range of 100–200 keV. This is deter­
mined based on the absorption of the electromagnetic rays
by the subject and the designated detector and is a trade-off
between sensitivity and resolution. Low-energy rays are
more easily absorbed by surrounding tissue (tissue not under
investigation), leading to higher patient doses and less effi­
cient detection. However, higher energy levels are not opti­
Table 2.3 Examples of radionuclides used for therapy (World Nuclear
Association)
Radioisotope
Half-­
life
Therapeutic applications
Actinium-225
10 days
Targeted alpha therapy (TAT)
Prostate cancer
Bismuth-213
46 min
TAT
Leukemia, cystic glioma, and melanoma
Erbium-169
9.4
days
Arthritis pain relief in synovial joints
Holmium-166
26 h
Diagnosis and treatment of liver tumors
Iodine-131
8 days
Thyroid cancer treatment
Nonmalignant thyroid disorders
Iridium-192
74 days
High-dose-rate brachytherapy
Prostate, head, and breast cancer
Lead-212
10.6 h
TAT, alpha radioimmunotherapy, or PRRT
Melanoma, breast, pancreatic, and ovarian
cancer
Lutetium-177
6.7
days
Imaging and therapy of multiple tumor
types (e.g., endocrine, prostate)
Phosphorus-3214 days
Polycythemia vera treatment (excess red
blood cells)
Radium-223
11.4
days
TAT brachytherapy in the bone
Samarium-15347 h
Pain relief of bone metastases from, e.g.,
prostate and breast cancer
75
Box 2.16 Radionuclide Therapy
•	In radionuclide therapy (RNT), radioisotopes are
used to treat cancer or other medical conditions by
administration of radiation sources to patients.
•	Three types of radioisotopes can be used for RNT,
namely alpha and beta particles and Auger electrons.
•	The most important applications to date of RNT are
iodine-131 for thyroid cancer, Lutathera® for neuro­
endocrine tumors, and PSMA-targeted RNT for
prostate cancer.
2 Basic Concepts of Radiation Biology
50
mally detected (stopped) by the scintillation NaI crystals.
Additionally, the half-life (T1/2) of the radionuclide should be
tailored to the conducted experiment.
A SPECT apparatus typically contains two cameras
which rotate around the body of the patient and are focused
on an area under investigation. The cameras contain a lead
collimator to directionalize the incoming radiation. As such,
only rays parallel to the holes of the collimator will reach the
detector, and radiation coming from scatter or other tissues
not under investigation will be absorbed less by the scintilla­
tion detector, leading to less interference in image recon­
struction and in turn increase in the contrast and hence the
resolution but decrease in the sensitivity significantly.
Compared to planar (2D) X-ray imaging, where the elec­
tromagnetic rays are projected on an imaging detector lead­
ing to reduced contrast of the tissue under investigation
compared to the background, SPECT imaging provides a
noninvasive 3D method to determine the accumulation of
administered diagnostic radiopharmaceuticals [73]. The
term tomography indicates the use of a combination of indi­
vidual “slices” to generate a 3D image.
The most widely used SPECT radioisotope, 99mTc, is
metastable and decays via isomeric transition with emission
of γ-rays of approximately 140 keV with a T1/2 = 6 h. Further,
99mTc is a radiometal that can be complexed by various chela­
tors and can be incorporated into different ligands used in
different investigations of a plethora of diseases (bone, heart,
cancer, brain, liver). Another benefit of 99mTc is the cost and
the ease of acquirement via a 99Mo/99mTc generator.
2.4"
Describe the key mechanisms by which positron emission tomography (PET) utilizes radioactive isotopes for clinical diagnostics and explain why low atomic mass radioisotopes with short half-lives are typically favored in PET probes.,"Positron Emission Tomography (PET) leverages the unique properties of radioactive decay to provide highly sensitive imaging of biological processes. The fundamental principle relies on injecting a radiolabeled pharmaceutical vector molecule containing a radionuclide, such as fluorine-18 ([18F]) or carbon-11 ([11C]), into a patient. These isotopes undergo positron emission – they transform into an electron with a corresponding antiparticle, the positron.  Positrons have a very short half-life (typically minutes to hours), meaning that only a small amount of tracer is needed for administration, significantly minimizing potential pharmaceutical or toxicological effects. The emitted positrons quickly collide with electrons in the surrounding tissue, resulting in annihilation – the complete destruction of both particles and the creation of two high-energy gamma photons traveling in opposite directions (180 degrees).  Detectors surrounding the patient capture these coincident gamma rays. The detectors’ ability to precisely measure the origin of these photons allows for a three-dimensional reconstruction of the distribution of the radiotracer within the body, effectively visualizing metabolic activity or other processes linked to the tracer's uptake. This is particularly valuable in detecting early molecular changes and tracking disease progression as PET can detect subtle differences in tracer accumulation that might not be visible with conventional imaging techniques [74, 78, 79, 80, 81, 82, 83].

The preference for low atomic mass radioisotopes (carbon, nitrogen, oxygen, fluorine) with short half-lives is crucial for several reasons. Firstly, the shorter half-life minimizes radiation exposure to the patient during both the production and administration of the tracer. Secondly, lower atomic mass isotopes result in gamma photons with lower energy, which are more easily detected by PET scanners. Finally, these isotopes frequently occur naturally within biomolecules (like glucose), allowing for seamless incorporation into pharmaceutical vectors without significantly altering their chemical structure or biological activity [77].","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.4	 Radioactivity and Its Applications | Sub-subsection: 2.4.3	 Applications of Radioisotopes | Sub-sub-subsection: 2.4.3.5	 Clinical Diagnostics | Content: PET probes generally consist of a pharmaceutical vector
molecule, which carries a coupled radionuclide to the target.
Because of the radioactive decay, only a low mass amount of
the tracer needs to be administered to the subject. As such,
pharmaceutical or toxicological effects are avoided. The
radioactive decay further enables highly sensitive detection
of emitted γ-rays by a dedicated ring of detectors. PET
allows to detect early molecular changes and follow-up of
disease progression [74]. Typically, low atomic mass radio­
isotopes (C, N, O, F), with a rather short T1/2 of minutes to
hours, are coupled to the pharmaceutical vector. Additionally,
these radioisotopes are commonly found in different small
molecules and biomolecules, so they can be incorporated
without changing the chemical structure of the compounds.
Advances in radiolabeling techniques are continuously
increasing the radiochemical and -pharmaceutical space,
which allows for a more robust and quicker radiolabeling
[77]. PET is increasingly used in the drug development
stream, as it enables examination of pharmacodynamics,
drug-target interaction, and dose occupancy [78].
+
­
+
18
11
­
­
­
Table 2.4 SPECT radionuclides [73, 76]
RadionuclideT1/2
Nuclear reaction
Mode of
decay
Energy
(keV)
67Ga
3.26
days
67Zn(p,n)67Ga
68Zn(p, 2n)67Ga
EC (100%)93
67Cu
3 days
68Zn(γ,p)67Cu
β− (100%)
γ (52%)
185
299mTc
6.06 h
99Mo/99mTc-­
generator
IT (89%)
140
111In
2.83
days
111Cd(p,n)111In
112Cd(p,2n)111In
EC (100%)245
123I
13.2 h
123Xe/123I
generator
124Xe(p,pn)123I
EC (100%)159
201Ti
73 h
203Ti (p,3n) 201Ti
EC (100%)69–80 (Hg
X-rays)
135 (9%)
167 (27%)
EC electron capture, IT internal transition, thermal neutron
bombardment
A. Baeyens et al.
51
18
Table 2.5 PET radionuclides (Vermeulen et al. 2019)
Radionuclide
T1/2
Nuclear
reaction
Mode of
decay
Energy
(MeV)
11C
20.4 min
14N(p,α)11C
β+ (100%)
0.960 (β+
Emax)
13N
10.0 min
16O(p,α)13N
β+ (100%)
1.199 (β+
Emax)
15O
2.0 min
14N(d,n)15O
β+ (100%)
1.732 (β+
Emax)
18F
109.7 min
18O(p,n)18F
20Ne(d,α)18F
β+ (97%)
EC (3%)
0.634 (β+
Emax)
64Cu
12.7 h
64Ni(p,n)64Cu
β+ (18%)
EC (24%)
β− (37%)
0.653 (β+
Emax)
0.3293–1.675
0.5794
68Ga
67.6 min
68Ge/68Ga-­
generator
β+ (89%)
EC (11%)
1.899 (β+
Emax)
0.227–2.821
76Br
16.0 h
76Se(p,n)76Br
β+ (55%)
EC (45%)
3.382 (β+
Emax)
0.599
82Rb
1.3 min
82Sr/82Rb-­
generator
β+ (100%)
3.378 (β+
Emax)
86Y
14.7
86Sr(p,n)86Y
β+ (32%)
IT (68%)
1.221, 1.545,
1.988 (β+
1,2,3
Emax)
0.433–1.920
89Zr
78.4 h
89Y(p,n)89Zr
β+ (23%)
EC (77%)
0.902 (β+
Emax)
0.909
124I
4.2 days
124Te(p,n)124I
β+ (26%)
EC (74%)
2.138, 1.535
(β+
1,2 Emax)
602
EC electron capture, IT isomeric transition
Box 2.17 SPECT and PET
•	SPECT and PET are noninvasive imaging tech­
niques that allow to functionally diagnose different
pathologies, including cancer, neurodegenerative
diseases, and cardiovascular aberrations.
•	SPECT and PET make use of radiolabeled drugs to
specifically target aberrantly expressed receptors,
enzymes, etc.
increased sensitivity (up to 40-fold) compared to normal
PET scanners [79]. The worldwide workhorse of PET imag­
ing is a radiolabeled glucose derivative, 2-[18F]fluoro-2-­
deoxy-­d-glucose ([18F]FDG), which visualizes the glucose
metabolism and is hence taken up and trapped in organs with
extensive glucose metabolism such as brain and heart and
aberrant growth. Because of this, [18F]FDG can be applied in
the diagnostic imaging of cancer, inflammation, cardiology,
and neurology [80]. [18F]FDG differs from glucose by the
replacement of the hydroxyl moiety by 18F at C-2. This has
consequences for the metabolization process of [18F]FDG
and is depicted in Fig. 2.18. Both glucose and [18F]FDG are
taken up by glucose transporters (Glut) and processed by
glycolysis. Hexokinase will phosphorylate the C-6
OH-moiety of both molecules. As this brings a negative
charge to the molecules, they will remain trapped inside the
cell. Glucose is then further processed to fructose-6-­
phosphate by glucose-6-phosphate isomerase on the C-2
OH-moiety, and further metabolization will yield pyruvate.
As [18F]FDG lacks the C-2 OH-moiety, further metaboliza­
tion will not take place and the molecule will remain trapped
in the cell until decay (T1/2 = 109.7 min) of 18F to 18O, after
which metabolization can resume.
PET radiopharmaceutical development has been favored
over investigation into SPECT tracers over the last years.
PET omits the use of mechanical collimation, replacing it
with electronic collimation, increasing detector efficiency
100-fold compared to SPECT. The spatial resolution of PET
is also higher with less influence of scattered photons.
Attenuation correction is more efficient, and the imaging
contrast is also better compared to SPECT [81]. A disadvan­
tage of PET is the cost and the availability of PET radioiso­
topes, which need to be generated in a cyclotron (except for
68Ga, which is generator based). Furthermore, the short T1/2
of routinely used PET isotopes (carbon-11, fluorine-18,
nitrogen-13, oxygen-15) requires production by an in-house
cyclotron [82, 83].
2.5
2.17
2 Basic Concepts of Radiation Biology
52
2.5
Doses, Dose Rates, and Units
in Radiation Protection
2.5.1
Dose and Absorbed Dose
Dose or absorbed dose is the mean energy imparted by ion­
izing radiation to a material.
Absorbed dose = dE/dm
where dE is the mean energy imparted by ionizing radia­
tion and dm is the mass of the material.
The SI unit of dose is gray (Gy) and is defined as absorbed
energy per unit of mass of tissue, given by one joule per kg.
The old unit is rad, and the conversion is defined as
1 Gy = 100 rad [84].
2.5.2
Dose Rate
Dose rate is defined as the dose of ionizing radiation absorbed
or delivered per unit time. It is measured in gray per hour.
The biological effect of a certain dose is dependent on its
dose rate, known as the dose rate effect. The biologic effect
of a given dose is reduced if the exposure time is extended,
and so if the dose rate is lowered. This is due to repair of
sublethal damage that occurs during long radiation exposure.
It is also due to redistribution of cells in cell cycle and cell
proliferation (see Chap. 5 for details).
On the contrary, inverse dose rate effect is observed when
increased biologic effects of a given dose at lowering the
dose rate occur. This only happens at a limited range of dose
rates. This is attributed to progression of cells through the
cell cycle and accumulation in the G2 cell cycle phase, which
is a radiosensitive phase. Further lowering of the dose rate
below this critical level leads to lowering of biologic effects
as cells cross the G2 block and divide, leading to cell
proliferation.
Importantly, dose rate reduction has a differential effect
between most tumors or early-responding normal tissues and
late-responding normal tissues. Late-responding normal tis­
sues are more sensitive to dose rate changes, like changes in
fraction size in external beam radiotherapy [85].
The dose rate of environmental exposure is low (around
0.1 μGy/min). Clinically, the concept of dose rate is utilized
in brachytherapy. Accordingly, there are different categories
such as
1.	Ultralow dose rate (ULDR)—less than 0.4 Gy/h
2.	Low dose rate (LDR)—0.4–2Gy/h
3.	Medium dose rate (MDR)—2–12 Gy/h
4.	High dose rate (HDR)—more than 12 Gy/h
Low-dose-rate irradiation can be considered as an extreme
form of fractionation.
There is another entity called pulsed dose rate (PDR),
which is used in brachytherapy. Dose and treatment time are
prescribed for LDR, but radiation is delivered in a pulsed
manner every 1–4 h in many small fractions. Contrastingly,
in FLASH radiotherapy, an ultrahigh dose rate of more than
1,44,000 Gy/h is administered [86].
The biological effect will be explained in Chaps. 5 and 6
(Box 2.18).
2.5.3
Units of Radiation Protection
2.5.3.1	Equivalent Dose
The interaction of radiation with matter or tissue is also
influenced by the type of radiation. Some types of radiation
produce different effects than others for the same amount of
energy. This is because the pattern of dose distribution and
the density of ionization events will be different. To account
for these variations when describing human biological harm
from radiation exposure, the “equivalent dose” is used. For
example, for equal absorbed doses, neutrons may be 20 times
as damaging as X-rays. The equivalent dose is the product of
the absorbed dose averaged over the tissue or organ and the
radiation weighting factor WR particular for the type and
energy of radiation involved. It is based on the absorbed dose
to an organ, adjusted to account for the effectiveness of the
type of radiation [85, 87]:
Box 2.18 Definition of Dose and Dose Rate
•	Dose or absorbed dose is the mean energy imparted
by ionizing radiation to a material. The SI unit of
dose is gray (Gy).
•	Dose rate is defined as a dose of ionizing radiation
absorbed or delivered per unit time. The SI unit of
dose rate is gray/hour.
•	SPECT makes use of the inherent γ- or X-ray decay
of the used radioisotope, whereas the PET principle
is based on the coincidental detection of the emis­
sion of 511 keV γ-rays, resulting from the annihila­
tion of a β+ and an electron.
•	The most frequently used SPECT radioisotope is
99mTc, which can be incorporated in a plethora of
vector molecules.
•	The most widely used PET radiotracer is [18F]FDG,
a radioactive glucose analogue.
A. Baeyens et al."
Describe pulsed dose rate (PDR) radiotherapy and contrast it with FLASH radiotherapy in terms of their delivery methods and associated dose rates.,"Pulsed Dose Rate (PDR) radiotherapy utilizes a technique where radiation is delivered in small fractions, typically administered every 1-4 hours. This involves prescribing both the total dose and treatment time, but unlike traditional Linear Energy Transfer (LET) based approaches, the radiation is not delivered continuously. Instead, it’s pulsed repeatedly over this timeframe. Conversely, FLASH radiotherapy employs an ultrahigh dose rate – exceeding 1,44,000 Gy/hour. This represents a significantly more intense and rapid delivery of radiation compared to PDR. The key difference lies in the magnitude and frequency of the delivered dose; PDR utilizes lower, repeated doses over time while FLASH delivers extremely high doses at an exceptionally fast rate.

Reference: [Document Name], Section 2.5 – Doses, Dose Rates, and Units in Radiation Protection.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Content: There is another entity called pulsed dose rate (PDR),
which is used in brachytherapy. Dose and treatment time are
prescribed for LDR, but radiation is delivered in a pulsed
manner every 1–4 h in many small fractions. Contrastingly,
in FLASH radiotherapy, an ultrahigh dose rate of more than
1,44,000 Gy/h is administered [86].
The biological effect will be explained in Chaps. 5 and 6
(Box 2.18).
2.5.3
Units of Radiation Protection
2.5.3.1	Equivalent Dose
The interaction of radiation with matter or tissue is also
influenced by the type of radiation. Some types of radiation
produce different effects than others for the same amount of
energy. This is because the pattern of dose distribution and
the density of ionization events will be different. To account
for these variations when describing human biological harm
from radiation exposure, the “equivalent dose” is used. For"
"Explain the concepts of dose and absorbed dose in radiation biology, including their definitions and associated units.","In radiation biology, ‘dose’ and ‘absorbed dose’ represent distinct but related measures of radiation exposure. Absorbed dose quantifies the amount of energy deposited by ionizing radiation within a material. It's defined mathematically as dE/dm, where dE represents the *mean* energy imparted by the ionizing radiation and dm signifies the mass of the absorbing material. Essentially, it’s a measure of how much energy is being taken up by the tissue or substance exposed to the radiation. The standard SI unit for absorbed dose is the gray (Gy), which is defined as one joule of energy per kilogram (1 J/kg). Historically, the ‘rad’ was used as a unit of equivalent exposure; one rad equals 0.01 Gy. Therefore, converting between these units involves a factor of 100 (1 Gy = 100 rad).

It's crucial to differentiate absorbed dose from ‘dose,’ which is a more general term often used in radiation protection and refers to the total energy deposited by ionizing radiation. Absorbed dose provides a precise measurement of energy transfer, while ‘dose’ can encompass other factors like tissue response or biological effects.
","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.1	 Dose and Absorbed Dose | Content: Dose or absorbed dose is the mean energy imparted by ion­
izing radiation to a material.
Absorbed dose = dE/dm
where dE is the mean energy imparted by ionizing radia­
tion and dm is the mass of the material.
The SI unit of dose is gray (Gy) and is defined as absorbed
energy per unit of mass of tissue, given by one joule per kg.
The old unit is rad, and the conversion is defined as
1 Gy = 100 rad [84].
2.5.2"
"Explain the relationship between dose rate, biological effects of radiation, and the cell cycle, including why a lower dose rate can sometimes lead to increased biological damage.","Dose rate refers to the amount of ionizing radiation absorbed per unit of time. The biological effect of a given dose is significantly influenced by its dose rate – this phenomenon is known as the dose rate effect. Generally, at lower dose rates, cells have more opportunity for DNA repair mechanisms to function effectively. When radiation damages DNA, cells initiate repair processes to correct the damage before replication can occur. A slower dose rate allows these repair pathways to operate more fully and efficiently, reducing the overall biological impact of the exposure. However, when the dose rate is increased, cells are subjected to a higher flux of ionizing events, overwhelming their ability to repair all the DNA damage promptly. This leads to an accumulation of unrepaired lesions, ultimately resulting in greater genomic instability and potentially cell death or mutation.

Furthermore, as described in the text, a critical dose rate exists within the G2 phase of the cell cycle. At this rate, cells become trapped in the G2 phase due to accumulated DNA damage, leading to an accumulation of cells in this radiosensitive stage. Lowering the dose rate below this critical level causes these stalled cells to eventually cross the G2 block and proceed through cell division, effectively diluting the impact of the radiation across a larger population of cells. Conversely, increasing the dose rate above this point can exacerbate damage because it overwhelms repair mechanisms and accelerates progression through the cell cycle, leading to increased mutation rates.

Finally, it’s important to note that different tissues exhibit varying sensitivities to dose rate changes. Late-responding normal tissues are particularly vulnerable, often showing heightened sensitivity at lower dose rates due to their slower response times in repairing radiation damage and their greater reliance on mechanisms like cell cycle arrest.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.2	 Dose Rate | Content: in Radiation Protection
2.5.1
Dose and Absorbed Dose
Dose or absorbed dose is the mean energy imparted by ion­
izing radiation to a material.
Absorbed dose = dE/dm
where dE is the mean energy imparted by ionizing radia­
tion and dm is the mass of the material.
The SI unit of dose is gray (Gy) and is defined as absorbed
energy per unit of mass of tissue, given by one joule per kg.
The old unit is rad, and the conversion is defined as
1 Gy = 100 rad [84].
2.5.2
Dose Rate
Dose rate is defined as the dose of ionizing radiation absorbed
or delivered per unit time. It is measured in gray per hour.
The biological effect of a certain dose is dependent on its
dose rate, known as the dose rate effect. The biologic effect
of a given dose is reduced if the exposure time is extended,
and so if the dose rate is lowered. This is due to repair of
sublethal damage that occurs during long radiation exposure.
It is also due to redistribution of cells in cell cycle and cell
proliferation (see Chap. 5 for details).
On the contrary, inverse dose rate effect is observed when
increased biologic effects of a given dose at lowering the
dose rate occur. This only happens at a limited range of dose
rates. This is attributed to progression of cells through the
cell cycle and accumulation in the G2 cell cycle phase, which
is a radiosensitive phase. Further lowering of the dose rate
below this critical level leads to lowering of biologic effects
as cells cross the G2 block and divide, leading to cell
proliferation.
Importantly, dose rate reduction has a differential effect
between most tumors or early-responding normal tissues and
late-responding normal tissues. Late-responding normal tis­
sues are more sensitive to dose rate changes, like changes in
fraction size in external beam radiotherapy [85].
The dose rate of environmental exposure is low (around
0.1 μGy/min). Clinically, the concept of dose rate is utilized
in brachytherapy. Accordingly, there are different categories
such as
1.	Ultralow dose rate (ULDR)—less than 0.4 Gy/h
2.	Low dose rate (LDR)—0.4–2Gy/h
3.	Medium dose rate (MDR)—2–12 Gy/h
4.	High dose rate (HDR)—more than 12 Gy/h
Low-dose-rate irradiation can be considered as an extreme
form of fractionation.
There is another entity called pulsed dose rate (PDR),
which is used in brachytherapy. Dose and treatment time are
prescribed for LDR, but radiation is delivered in a pulsed
manner every 1–4 h in many small fractions. Contrastingly,
in FLASH radiotherapy, an ultrahigh dose rate of more than
1,44,000 Gy/h is administered [86].
The biological effect will be explained in Chaps. 5 and 6
(Box 2.18).
2.5.3"
"Describe the concept of pulsed dose rate (PDR) radiation therapy, including its application in brachytherapy and how it differs from traditional linear-rapidity (LDR) treatment.","Pulsed Dose Rate (PDR) is a specialized radiation delivery technique primarily utilized within brachytherapy. In this approach, radiation is administered in short, high-dose pulses – typically occurring every 1 to 4 hours – delivered as small fractions over an extended period. Unlike Linear-Rapidity (LDR) treatment, where a continuous dose is prescribed for a specific duration, PDR disrupts the cellular repair mechanisms that normally occur between these doses. This interruption forces cells to undergo more frequent DNA damage checkpoints and repair cycles. The key difference lies in the timing of radiation exposure; LDR allows for significant repair processes, while PDR deliberately minimizes or prevents these repairs. This heightened level of DNA damage is intended to selectively target tumor cells while minimizing harm to surrounding healthy tissues. It’s important to note that the biological effects associated with PDR are detailed further in Chapters 5 and 6. Furthermore, FLASH radiotherapy represents an extreme form of PDR, employing ultrahigh dose rates exceeding 1,44,000 Gy/h.

Reference: [Document Name], Section 2.5.3 – Units of Radiation Protection","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Content: There is another entity called pulsed dose rate (PDR),
which is used in brachytherapy. Dose and treatment time are
prescribed for LDR, but radiation is delivered in a pulsed
manner every 1–4 h in many small fractions. Contrastingly,
in FLASH radiotherapy, an ultrahigh dose rate of more than
1,44,000 Gy/h is administered [86].
The biological effect will be explained in Chaps. 5 and 6
(Box 2.18).
2.5.3
Units of Radiation Protection"
Explain the concept of pulsed dose rate (PDR) in radiation therapy and contrast it with FLASH radiotherapy regarding dose delivery.,"Pulsed Dose Rate (PDR) is a technique utilized primarily in brachytherapy, where radiation is delivered in small fractions – typically administered every 1-4 hours – over an extended period. This contrasts sharply with FLASH radiotherapy, which employs an ultrahigh dose rate exceeding 1,440,000 Gy/hour. The key difference lies in the magnitude and frequency of radiation delivery. PDR involves a more gradual accumulation of radiation damage, while FLASH radiotherapy aims to induce significant cellular damage within a very short timeframe due to the extremely high dose rates involved. This rapid exposure is hypothesized to bypass typical DNA repair mechanisms, leading to potentially enhanced therapeutic effects.

It’s important to note that the biological consequences of these different approaches are detailed in Chapters 5 and 6 (Box 2.18). The varying dose rates fundamentally alter the interaction between radiation and tissue, impacting cellular response and ultimately influencing treatment outcomes.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.1	 Equivalent Dose | Content: There is another entity called pulsed dose rate (PDR),
which is used in brachytherapy. Dose and treatment time are
prescribed for LDR, but radiation is delivered in a pulsed
manner every 1–4 h in many small fractions. Contrastingly,
in FLASH radiotherapy, an ultrahigh dose rate of more than
1,44,000 Gy/h is administered [86].
The biological effect will be explained in Chaps. 5 and 6
(Box 2.18).
2.5.3
Units of Radiation Protection
2.5.3.1	Equivalent Dose
The interaction of radiation with matter or tissue is also
influenced by the type of radiation. Some types of radiation
produce different effects than others for the same amount of
energy. This is because the pattern of dose distribution and
the density of ionization events will be different. To account
for these variations when describing human biological harm
from radiation exposure, the “equivalent dose” is used. For
example, for equal absorbed doses, neutrons may be 20 times
as damaging as X-rays. The equivalent dose is the product of
the absorbed dose averaged over the tissue or organ and the
radiation weighting factor WR particular for the type and
energy of radiation involved. It is based on the absorbed dose
to an organ, adjusted to account for the effectiveness of the
type of radiation [85, 87]:
Box 2.18 Definition of Dose and Dose Rate
•	Dose or absorbed dose is the mean energy imparted
by ionizing radiation to a material. The SI unit of
dose is gray (Gy).
•	Dose rate is defined as a dose of ionizing radiation
absorbed or delivered per unit time. The SI unit of
dose rate is gray/hour.
•	SPECT makes use of the inherent γ- or X-ray decay
of the used radioisotope, whereas the PET principle
is based on the coincidental detection of the emis­
sion of 511 keV γ-rays, resulting from the annihila­
tion of a β+ and an electron.
•	The most frequently used SPECT radioisotope is
99mTc, which can be incorporated in a plethora of
vector molecules.
•	The most widely used PET radiotracer is [18F]FDG,
a radioactive glucose analogue.
A. Baeyens et al.
53
(2.32)
The SI unit of equivalent dose is sievert (Sv). The unit
“rem” (roentgen equivalent in man) is also still used. One
rem is equivalent to 0.01 Sv.
2.6
If a mixture of radiation types is used, the equivalent dose
is the sum of the individual doses of the various types of radia­
tion, each multiplied by the corresponding weighting factor:
(2.33)"
"What is the effective dose, and what unit is used to measure it?","The effective dose represents a calculated quantity designed to quantify the overall risk associated with ionizing radiation exposure to humans. It accounts for both the equivalent dose – which reflects the biological damage caused by radiation based on its type and energy – and tissue weighting factors. These factors represent the relative sensitivity of different tissues (such as bone, muscle, or skin) to radiation-induced effects, acknowledging that organs like the thyroid gland are generally more susceptible than others. The SI unit for expressing effective dose is the sievert (Sv). It’s important to note that effective dose isn't a directly measurable physical quantity but rather a calculated value used for comparing and assessing risks across different exposure scenarios and radiation types. According to ICRP Publication 103, it’s primarily utilized in radiological protection for planning, optimization, and regulatory compliance.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.2	 Effective Dose | Content: ­
­
­
T
858788
2.7
The effective dose is the product of the equivalent dose
and the tissue weighting factor:
(2.34)
The SI unit of effective dose is sievert (Sv).
Despite differences in the sensitivity of tissue due to age
and sex of the person, for the purpose of radiation protection,
the values for tissue weighting factors are taken as constants
and are applicable to the average population. The effective
dose is a calculated quantity and not a physical, measurable
quantity.
The effective dose is used to compare radiation exposure
and risks between different radiation types and exposure
modes and a total body exposure. According to the ICRP
Publication 103, effective dose is to be used for “prospective
dose assessment for planning and optimization in radiologi­
cal protection, and retrospective demonstration of compli­
ance for regulatory purposes.”
Annual dose limits for occupational and public exposure
are given in terms of the annual effective dose."
The concept of 'committed equivalent dose' is central to understanding radiation damage. Explain what it represents and why calculating this value is crucial when dealing with internal irradiation from radioactive materials.,"The committed equivalent dose (CEd) represents the total radiation exposure a person receives over their entire lifetime, as if that exposure were delivered uniformly across all 50 years following the initial uptake of a radioactive substance. It’s not simply about the instantaneous absorbed dose at the time of ingestion or external irradiation; rather, it accounts for the *time-dependent* distribution of the radiation within the body. This is particularly important with internal emitters because radionuclides have varying half-lives. A short-lived radionuclide will deliver its dose rapidly initially and then decline over time, while a long-lived one distributes its dose more gradually across the 50-year period. Calculating CEd allows for a realistic assessment of potential health risks by considering how the radiation’s impact evolves over an individual's lifespan, taking into account tissue uptake and subsequent decay rates. This integrated approach provides a far more accurate representation of overall risk than simply looking at peak doses or short-term exposures. The integral calculation ensures that all contributions to dose from every tissue over the 50-year period are accounted for.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.3	 Committed Equivalent Dose | Content: In case of external irradiation, the absorbed dose is delivered
at the time of exposure. In the case of internal irradiation,
when radionuclides are taken into the body, the total absorbed
dose is distributed over time as well as to different tissues in
the body. The dose rate falls depending on the half-lives of
the radionuclides. The committed equivalent dose considers
the varying time distributions of dose delivery. The commit­
ted equivalent dose is calculated as the integral over 50 years
of the equivalent dose in each tissue after intake of a radionu­
clide [85, 87]."
"Explain the concept of the 'committed effective dose' in radiation protection, detailing its components and significance.","The ‘committed effective dose’ is a critical metric used in radiation protection to estimate the long-term health risks associated with exposure to ionizing radiation. It represents the total biological effect resulting from an irradiation event, considering both the magnitude of the absorbed dose and the potential for that dose to reach sensitive tissues or organs over time. Specifically, it's calculated as the sum of the committed equivalent doses to individual tissues or organs multiplied by their respective weighting factors (WT). The ‘WT’ value reflects the relative sensitivity of each tissue or organ to radiation damage; organs with higher WT values are considered more vulnerable and therefore contribute disproportionately to the overall risk assessment. This approach acknowledges that even if a dose is delivered over an extended period, the tissues most susceptible to radiation damage will still experience significant biological effects. Consequently, the committed effective dose provides a comprehensive measure of long-term health hazard rather than simply focusing on instantaneous dose levels. Reference: Radiation Protection and Shielding, Section 2.5 – Doses, Dose Rates, and Units in Radiation Protection.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.4	 Committed Effective Dose | Content: This is the sum of the committed equivalent dose to the
individual tissues or organs multiplied by their respec­
tive WT."
"Explain the concept of ‘collective equivalent dose’ within radiation protection, detailing its calculation and significance.","The collective equivalent dose represents the total biological effect of a radiation exposure to a group or population. It's calculated by multiplying the average equivalent dose received per individual within that group by the number of people exposed. This provides a measure of the overall risk associated with a radiation event, considering not just the immediate effects on individuals but also the potential for cumulative damage across an entire population. The unit of measurement is the man-sievert (man-Sv), where 1 man-Sv equals the equivalent dose received by one person over one year.  Crucially, this metric acknowledges that multiple people can be exposed to radiation simultaneously and allows for a comprehensive assessment of public health risks following incidents involving widespread radiation release or exposure. It’s particularly important in scenarios like nuclear accidents or industrial contamination where large numbers of individuals may be affected.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.5	 Collective Equivalent Dose | Content: tive WT.
2.5.3.5	Collective Equivalent Dose
The radiation doses discussed above relate to exposures of
individuals. The collective equivalent dose is used to mea­
sure the total impact of a radiation exposure to a group or
population. The collective equivalent dose is the product of
the average equivalent dose to a population and the number
of persons exposed. It is measured in man-sievert (man-Sv)."
"Explain the concept of collective equivalent dose and collective effective dose in radiation protection, including the units used for their measurement and how they relate to population-level risk assessment.","The concepts of collective equivalent dose and collective effective dose are utilized within radiation protection to quantify the overall impact of a radiation exposure on a group or population. Collective equivalent dose represents the total biological effect resulting from an exposure, calculated by multiplying the average equivalent dose received by each individual in the exposed population by the number of individuals exposed. This is expressed in man-sieverts (man-Sv). Essentially, it’s a measure of the ‘total damage’ inflicted across a group.

The collective effective dose builds upon this concept by incorporating tissue weighting factors. These factors reflect the relative sensitivity of different tissues and organs to radiation damage. The average effective dose is calculated for the population, taking into account these tissue weighting factors – meaning that exposure to radiation causing significant damage in highly sensitive tissues (like bone marrow or the thyroid) will contribute more significantly to the collective effective dose than similar exposures affecting less sensitive tissues.

Therefore, the collective effective dose provides a rough estimation of potential health risks to a population after radiation exposure. It’s crucial to note that these doses are *population-level* metrics and do not directly translate to individual risk; further analysis would be needed to determine specific health outcomes for individuals within the exposed group. The use of tissue weighting factors allows for a more nuanced assessment of potential harm compared to simply summing equivalent doses without considering tissue sensitivity.

Reference: MolecularRadiationBiology, Section 2.5.3.6 – Units of Radiation Protection.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.6	 Collective Effective Dose | Content: tive WT.
2.5.3.5	Collective Equivalent Dose
The radiation doses discussed above relate to exposures of
individuals. The collective equivalent dose is used to mea­
sure the total impact of a radiation exposure to a group or
population. The collective equivalent dose is the product of
the average equivalent dose to a population and the number
of persons exposed. It is measured in man-sievert (man-Sv).
2.5.3.6	Collective Effective Dose
The collective effective dose allows a rough estimation of the
potential health risks to a population after exposure to radia­
tion. It is the product of the average effective dose to a popu­
lation and the number of persons exposed. It is measured in
man-sievert (man-Sv).
Table 2.6 Radiation weighting factors (ICRP 103)
WR
X-γ-rays
1
β+–β−
1
Protons and charged particles
2
Neutrons
5–20
α-Particles
20
Table 2.7 Tissue weighting factors (ICRP 103)
Tissue/organ
2007 WT
Bone marrow
0.12
Breast
0.12
Colon
0.12
Lung
0.12
Stomach
0.12
Bladder
0.04
Esophagus
0.04
Gonads
0.08
Liver
0.04
Thyroid
0.04
Bone surface
0.01
Brain
0.01
Salivary glands
0.01
Skin
0.01
Remainder tissues
0.12
2 Basic Concepts of Radiation Biology
54"
"Explain the concept of linear energy transfer (LET) in radiation biology, including distinctions between unrestricted LET (LET∞), restricted LET, and how it relates to different types of radiation like electrons and X-rays/gamma rays.","Linear energy transfer (LET) is a critical parameter in radiobiology that quantifies the amount of energy deposited by ionizing radiation per unit length as charged particles traverse matter. It’s essentially a measure of how densely the radiation's energy is concentrated along its path, accounting for both excitations and ionizations. Unrestricted LET (LET∞) considers all possible energy transfers occurring within a particle’s range – including those involving particles that exit the volume of interest. This value is numerically equivalent to electronic stopping power. Conversely, restricted LET focuses solely on the locally transferred energy per unit length *within* the considered site, excluding the kinetic energy of particles leaving that area. This concept is particularly important for electrons due to their significant ranges and potential for substantial lateral spread. Electrons with energies above approximately 100 eV are often referred to as ‘δ electrons’ or ‘δ rays’ because they can deposit a large amount of energy over a relatively wide distance. X-rays and gamma rays are generally considered low LET radiation (typically around 10 keV/μm) due to their sparse ionization, while high-energy protons, neutrons, and heavier ions are classified as high LET radiation – although the distinction has been debated recently with the emergence of new paradigms in radiation biology considering proton LET at higher energies. The definition of LET is typically expressed in keV/μm.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.5	 Doses, Dose Rates, and Units in Radiation Protection | Sub-subsection: 2.5.3	 Units of Radiation Protection | Sub-sub-subsection: 2.5.3.7	 Collective Committed Effective Dose | Content: If a population is exposed to internal exposure by radionu­
clides, the integral of the effective dose over 50 years is
called the collective committed effective dose. It is measured
in man-sievert (man-Sv) (Box 2.19).
2.6
Linear Energy Transfer and Relative
Biological Effectiveness
2.6.1
Linear Energy Transfer
Ionizing radiation causes significant physical and chemical
modifications, which eventually lead to biological effects in
the exposed tissue. The amount of energy absorbed by the
tissue (absorbed dose) and the rate at which such energy is
deposited (dose rate and fractionation for clinical applica­
tions) play a critical role in determining the type and extent
of the effects. However, other physical parameters can also
affect the biological response. It is therefore necessary to
introduce a radiation quality term to discriminate between
different radiation types. Radiobiological data and models
clearly point to the spatial distribution of energy deposition
as a key radiation quality parameter. However, the stochastic
nature of the interaction of radiation with matter prevents a
comprehensive and unique description and measurements of
the ionization patterns produced by the pathway of charged
particles in matter. The alternative is, therefore, to define a
suitable but inevitably incomplete characterization of radia­
tion quality that will enable radiobiological predictions with
sufficient accuracy.
The concept of linear energy transfer (LET), the amount
of energy transferred per unit length, was introduced by
Zirkle et al. [89] to account for the density of energy transfer
occurring along the track of charged particles, including
excitations and ionizations, until the particles reach the end
of their range. LET values are generally reported in keV/μm.
The symbol LET∞ (unrestricted LET) is used when all pos­
sible energy transfers are included, and also the energy depo­
sition by particles that in principle exit the volume of interest.
The LET∞ is numerically equivalent to electronic stopping
power, i.e., the energy loss by the incoming particle (which
may be a primary or a secondary particle) without any
restrictions in energy and range. The formula for the elec­
tronic stopping power contains a negative sign as it is seen as
the slowing force acting on charged particles, due to interac­
tion with matter, resulting in loss of particle energy:
(2.35)
where S(E) is the stopping power, dl is the distance tra­
versed by the particle, and dE is the mean energy loss due to
collisions with energy transfers.
There is however a conceptual difference: the stopping
power deals with the energy loss of the particle, while the
LET∞ focuses on the energy deposition in the medium, and
thus, the LET generally has an opposite sign. For large vol­
umes, the electronic stopping and the LET∞ coincide (same
absolute value), as for large volumes all the energy loss by the
impacting particles is well likely deposited in the sample.
In radiobiology, the concept of “restricted LET” is mostly
used. This is the locally transferred energy per unit length,
with “locally” restricting to only the energy fraction, which
leads to ionizations and/or excitations within the considered
site. The remaining kinetic energy of particles leaving the
site is excluded. This is particularly relevant for electrons
since they may possess considerably long ranges. For exam­
ple, for ions with E > 1000 MeV/μ, these electrons can have
energies higher than 1 MeV. The lateral spread of the track is
usually 100 s of nm, but for higher energies of the ions such
as 1000 MeV/μ, this lateral spread can even be 1 cm.
According to the ICRU 1970, the linear energy transfer of
charged particles in a medium is the quotient of dE by dl.
Here, dE is less than some specified value Δ. The definition
includes an energy cutoff rather than a range cutoff as this is
of more practical use:
(2.36)
It has become customary to specify a limit of energy
deposition below which the deposition is considered to be
local (energy restriction); 100 eV has been widely accepted,
which corresponds to an electron range of about 5 nm.
Electrons of longer ranges are called “δ electrons” or “δ
rays.”
X-rays and gamma rays are considered low LET (sparsely
ionizing) radiation types, while high-energetic protons, neu­
trons, and heavy charged particles are considered as high
LET (densely ionizing) radiation. A proton can have high or
low LET, depending on its energy. Although commonly
high-energy protons have been considered low LET radia­
tion, recently this has been questioned, starting a new “para­
digm in radiation biology” [90]. For indirectly ionizing
neutrons, LET refers to that of the secondary charged parti­
cles they produce. The value which is generally considered
to mark the distinction between low and high LET is about
10 keV/μm.
Box 2.19 Definition of Units in Radiation Protection
•	The effective dose is the product of the equivalent
dose and the tissue weighting factor. The SI unit of
effective dose is sievert (Sv).
•	The equivalent dose is the product of the absorbed
dose averaged over the tissue or organ and the radi­
ation weighting factor WR. The SI unit of equivalent
dose is sievert (Sv).
A. Baeyens et al."
Explain the concept of ‘restricted LET’ in radiobiology and why it is particularly relevant for electron radiation.,"In radiobiology, ‘restricted LET’ refers to the locally transferred energy per unit length within a specific volume of tissue. Critically, this definition excludes the kinetic energy of particles that have passed beyond that localized site. This concept is primarily used when considering ionizing radiation, particularly electrons, which can exhibit significant range effects due to their ability to penetrate deeply into materials. Electrons with high energies (e.g., >1000 MeV/μm) can deposit a substantial amount of energy within a volume and then continue traveling through the tissue, carrying away a considerable portion of their initial kinetic energy. The lateral spread of an electron track – typically around 100 nm at lower energies – becomes less relevant when dealing with electrons possessing energies exceeding 1 MeV/μm, where this spread can extend up to 1 cm or more. Consequently, the ‘restricted LET’ calculation focuses solely on the energy deposition within the immediate vicinity of the initial ionization event, providing a more accurate representation of the radiation dose delivered to the tissue at that specific location and reflecting the primary mechanism of damage – direct ionization and excitation. This approach is essential because it accounts for the fact that electrons don't simply ‘stop’ after depositing their initial energy; they continue their trajectory, potentially causing further damage elsewhere in the tissue.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Content: There is however a conceptual difference: the stopping
power deals with the energy loss of the particle, while the
LET∞ focuses on the energy deposition in the medium, and
thus, the LET generally has an opposite sign. For large vol­
umes, the electronic stopping and the LET∞ coincide (same
absolute value), as for large volumes all the energy loss by the
impacting particles is well likely deposited in the sample.
In radiobiology, the concept of “restricted LET” is mostly
used. This is the locally transferred energy per unit length,
with “locally” restricting to only the energy fraction, which
leads to ionizations and/or excitations within the considered
site. The remaining kinetic energy of particles leaving the
site is excluded. This is particularly relevant for electrons
since they may possess considerably long ranges. For exam­
ple, for ions with E > 1000 MeV/μ, these electrons can have
energies higher than 1 MeV. The lateral spread of the track is
usually 100 s of nm, but for higher energies of the ions such
as 1000 MeV/μ, this lateral spread can even be 1 cm."
"What is linear energy transfer (LET), and how does it relate to the type of radiation considered ‘high LET’ versus ‘low LET’? Explain the significance of the 100 eV cutoff in defining these categories.","Linear energy transfer (LET) represents the amount of energy deposited by a charged particle per unit length as it traverses matter. It's typically expressed in keV/μm and is crucial for understanding radiation damage because it directly correlates with the density of ionization or excitation events occurring along the particle’s track. Radiation types are categorized as ‘high LET’ or ‘low LET’ based on their LET values. Generally, high-LET radiation possesses a higher LET (typically above 10 keV/μm), meaning it deposits energy more densely and creates a greater number of ionization and excitation events per unit length. Conversely, low-LET radiation has a lower LET (below approximately 10 keV/μm) and distributes its energy less intensely. The 100 eV cutoff is significant because it defines the range of electrons that can be considered ‘δ electrons’ or ‘δ rays’. Electrons with energies exceeding 100 eV have ranges long enough to cause lateral spread beyond this distance (approximately 5 nm), leading to a more diffuse ionization pattern and thus classifying them as high-LET radiation. Particles with energies below 100 eV are considered low LET due to their short range and localized energy deposition.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.1	 Linear Energy Transfer | Content: Biological Effectiveness
2.6.1
Linear Energy Transfer
Ionizing radiation causes significant physical and chemical
modifications, which eventually lead to biological effects in
the exposed tissue. The amount of energy absorbed by the
tissue (absorbed dose) and the rate at which such energy is
deposited (dose rate and fractionation for clinical applica­
tions) play a critical role in determining the type and extent
of the effects. However, other physical parameters can also
affect the biological response. It is therefore necessary to
introduce a radiation quality term to discriminate between
different radiation types. Radiobiological data and models
clearly point to the spatial distribution of energy deposition
as a key radiation quality parameter. However, the stochastic
nature of the interaction of radiation with matter prevents a
comprehensive and unique description and measurements of
the ionization patterns produced by the pathway of charged
particles in matter. The alternative is, therefore, to define a
suitable but inevitably incomplete characterization of radia­
tion quality that will enable radiobiological predictions with
sufficient accuracy.
The concept of linear energy transfer (LET), the amount
of energy transferred per unit length, was introduced by
Zirkle et al. [89] to account for the density of energy transfer
occurring along the track of charged particles, including
excitations and ionizations, until the particles reach the end
of their range. LET values are generally reported in keV/μm.
The symbol LET∞ (unrestricted LET) is used when all pos­
sible energy transfers are included, and also the energy depo­
sition by particles that in principle exit the volume of interest.
The LET∞ is numerically equivalent to electronic stopping
power, i.e., the energy loss by the incoming particle (which
may be a primary or a secondary particle) without any
restrictions in energy and range. The formula for the elec­
tronic stopping power contains a negative sign as it is seen as
the slowing force acting on charged particles, due to interac­
tion with matter, resulting in loss of particle energy:
(2.35)
where S(E) is the stopping power, dl is the distance tra­
versed by the particle, and dE is the mean energy loss due to
collisions with energy transfers.
There is however a conceptual difference: the stopping
power deals with the energy loss of the particle, while the
LET∞ focuses on the energy deposition in the medium, and
thus, the LET generally has an opposite sign. For large vol­
umes, the electronic stopping and the LET∞ coincide (same
absolute value), as for large volumes all the energy loss by the
impacting particles is well likely deposited in the sample.
In radiobiology, the concept of “restricted LET” is mostly
used. This is the locally transferred energy per unit length,
with “locally” restricting to only the energy fraction, which
leads to ionizations and/or excitations within the considered
site. The remaining kinetic energy of particles leaving the
site is excluded. This is particularly relevant for electrons
since they may possess considerably long ranges. For exam­
ple, for ions with E > 1000 MeV/μ, these electrons can have
energies higher than 1 MeV. The lateral spread of the track is
usually 100 s of nm, but for higher energies of the ions such
as 1000 MeV/μ, this lateral spread can even be 1 cm.
According to the ICRU 1970, the linear energy transfer of
charged particles in a medium is the quotient of dE by dl.
Here, dE is less than some specified value Δ. The definition
includes an energy cutoff rather than a range cutoff as this is
of more practical use:
(2.36)
It has become customary to specify a limit of energy
deposition below which the deposition is considered to be
local (energy restriction); 100 eV has been widely accepted,
which corresponds to an electron range of about 5 nm.
Electrons of longer ranges are called “δ electrons” or “δ
rays.”
X-rays and gamma rays are considered low LET (sparsely
ionizing) radiation types, while high-energetic protons, neu­
trons, and heavy charged particles are considered as high
LET (densely ionizing) radiation. A proton can have high or
low LET, depending on its energy. Although commonly
high-energy protons have been considered low LET radia­
tion, recently this has been questioned, starting a new “para­
digm in radiation biology” [90]. For indirectly ionizing
neutrons, LET refers to that of the secondary charged parti­
cles they produce. The value which is generally considered
to mark the distinction between low and high LET is about
10 keV/μm.
Box 2.19 Definition of Units in Radiation Protection
•	The effective dose is the product of the equivalent
dose and the tissue weighting factor. The SI unit of
effective dose is sievert (Sv).
•	The equivalent dose is the product of the absorbed
dose averaged over the tissue or organ and the radi­
ation weighting factor WR. The SI unit of equivalent
dose is sievert (Sv).
A. Baeyens et al.
55
As ionizing particles decelerate along their track, the LET
decreases, leading to a LET distribution, and consequently
two different LET average concepts can be defined. The
“track average LET” is calculated by performing a weighted
average considering the proportion of the total track length
that is within specified LET intervals and assigning equal
statistical weight to each unit of the track length. On the
other hand, the “dose average LET” is a weighted average of
the LET values taking into account the proportion of the
energy that is deposited for each LET interval so equal statis­
tical weight is assigned to each unit of the energy deposition.
In the first approximation, the dose-averaged LET is more
suitable as the radiation quality factors are based on such
quantity.
Apart from ionizations and excitations, among which ion­
izations bring the highest contribution to electronic stopping
over a wide range of energies [91], other mechanisms cause
energy loss of the impinging particle and thus induce depos­
ited energy. At energies below some few keV/μm of the trav­
eling ion, also nuclear collisions can occur. Such elastic
nuclear collisions (described by the concept of nuclear stop­
ping), which cause displacement of atoms, can induce altera­
tion and breaking of bonds, and thus also contribute to
biological damage. For particles with high energy, inelastic
nuclear collisions, where the impacting particle causes frag­
mentation of the nuclei generating daughter nuclei with
emission of several secondary particles, can also occur.
These loss mechanisms are not described by the concept of
stopping. A significant loss of primary beam fluence is
caused by such nuclear reactions. The inelastic nuclear cross
section determines the number of particles left at a certain
depth. For instance, for protons hitting a water target with an
energy of 160 MeV, at the Bragg peak position, approxi­
mately 20% of the incident protons will be lost [92].
2.19
25
Sparse energy deposition events along the track of a par­
ticle per unit of energy deposited appear to be less biologi­
cally damaging than “dense” deposition. The value of the
LET that seems “optimal” for cell killing is in the range of
100 keV/μm. This is linked to the fact that the average sepa­
ration of ionization events at this LET is about the same as
the diameter (2 nm) of the DNA double helix, implying a
higher probability of DSB, from the passage of a single par­
ticle. Clusters of lesions in the DNA molecule play a key role
in biological damage [93] (Box 2.20).
2.6.2
From Microdosimetry
to Nanodosimetry: Spatial Pattern
of Ionization Events
There is an intrinsic relationship between the quantities in
dosimetry, e.g., absorbed dose (see Sect. 2.5), linked to the
electronic stopping power, and quantities at the microscale
and down to the nanoscale.
Box 2.20 Definition of LET
•	LET is a parameter that quantifies the amount of
transferred energy per unit length.
•	LET is reported in units of keV/μm.
•	LET increases with the ion mass and with decreas­
ing ion energy.
2 Basic Concepts of Radiation Biology"
"Explain the concept of Linear Energy Transfer (LET) and its significance in radiation biology, referencing the provided text’s definition and related quantities.","Linear Energy Transfer (LET) is a fundamental parameter in radiation biology that quantifies the amount of energy deposited by ionizing radiation per unit length traveled through matter. It's defined as keV/μm – meaning kiloelectronvolts per micrometer – representing the energy transferred to the target material for each micron of distance traversed by the radiation particle. The key aspect highlighted is that LET increases with both ion mass and decreasing ion energy; heavier ions, when moving at lower energies, transfer more energy over a given distance due to their greater interaction cross-sections. This concept is central to microdosimetry, which studies the spatial pattern of ionization events at the micrometer scale. Microdosimetry examines fluctuations in energy deposition within microscopic volumes, considering factors like LET distribution, track length distribution (accounting for statistical energy loss along particle tracks), and energy transport by δ-rays. Specifically, the text introduces two key quantities derived from the linear energy transfer concept: yS (the ‘frequency mean lineal energy’) and yD (the ‘dose mean lineal energy’).  yS represents the first moment of the probability distribution of LET, while yD is the first moment of the dose distribution, both providing insights into the overall energy deposition characteristics. These quantities are stochastic and expressed in terms of interaction probabilities, reflecting the random nature of radiation interactions within matter. Understanding LET is crucial for assessing biological damage because it directly relates to the amount of ionization occurring at a specific location, which ultimately determines the severity of cellular effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.2	 From Microdosimetry to Nanodosimetry: Spatial Pattern of Ionization Events | Content: of Ionization Events
There is an intrinsic relationship between the quantities in
dosimetry, e.g., absorbed dose (see Sect. 2.5), linked to the
electronic stopping power, and quantities at the microscale
and down to the nanoscale.
Box 2.20 Definition of LET
•	LET is a parameter that quantifies the amount of
transferred energy per unit length.
•	LET is reported in units of keV/μm.
•	LET increases with the ion mass and with decreas­
ing ion energy.
2 Basic Concepts of Radiation Biology
56
The study of the pattern of energy deposition at microm­
eter length scale is called microdosimetry [94]. In particu­
lar, microdosimetry studies the fluctuations and pattern of
energy deposition in a micrometer-sized target, providing a
comprehensive view of the energy deposition more detailed
than the one given just by the LET alone. The measured
spectra are distributions of energy depositions in the micro­
scopic volume, which are a combination of several stochas­
tic processes including the LET distribution, the track
length distribution, the energy loss straggling (statistical
fluctuation of energy loss along the particle track) of the
primary particles, and the transport of energy by δ-rays
[95]. Microdosimetric quantities are stochastic and there­
fore given in terms of particle interaction probabilities [95,
96]. The relevant quantities in microdosimetry are as
follows:
•	y: the lineal energy, which is defined as the energy
imparted to matter in the microscopic volume by a single
event divided by the mean chord length in that volume
and the mean length of randomly oriented chords in a
given convex volume
•	f (y): the probability distribution of linear energy
•	y
S
u
b
sc
ri
p
t
upper F Baseline underbar equals integral Subscript 0 Superscript infinity Baseline y f left parenthesis y right parenthesis normal d y: the first moment of f (y), also called the
frequency mean lineal energy
•	dy = yf (y)/y Subscript upper F Baseline underbar: the dose distribution, which is important
for obtaining the dose components of the microdosimetric
spectrum
•	• y
S
u
bs
cr
i
p
t
upper D Baseline underbar equals integral Subscript 0 Superscript infinity Baseline y normal d left parenthesis y right parenthesis normal d y: the first moment of d (y), also called the
dose mean lineal energy
2.6.3"
"Explain the concept of Relative Biological Effectiveness (RBE) and how it relates to linear energy transfer (LET). Furthermore, describe the factors that influence RBE values as outlined in the text.","Relative Biological Effectiveness (RBE) is a crucial metric used in radiation biology to compare the biological damage caused by different types of radiation. It represents the ratio between the absorbed dose required for a specific effect (an isoeffect) using one type of radiation and the absorbed dose needed to produce the same effect with a reference radiation, which is typically low-LET radiation like X-rays. Essentially, RBE quantifies how effectively a particular radiation type causes biological damage relative to a standard. The text highlights that RBE is a dimensionless quantity, meaning it doesn't have units and simply represents this comparative ratio. Several factors influence the RBE value, including LET (linear energy transfer), which describes the amount of energy deposited by a particle per unit distance; radiation dose – the total absorbed energy; fractionation (the way in which doses are delivered over time); dose rate; the biological system being exposed to (e.g., cell type, tissue); the endpoint measured (e.g., mutation rate, chromosome damage); and even the radiation quality itself. Critically, the spatial distribution of energy deposition at the subcellular scale – particularly clustered lesions within DNA – plays a significant role in determining RBE, as more complex lesions are less efficiently repaired and prone to error during repair processes. The text specifically mentions efforts to develop models for radiation quality factors and RBE based on nanodosimetry, recognizing that these models must account for variations in energy deposition clustering.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.3	 Induced Biological Effects Depend on LET | Sub-sub-subsection: 2.6.3.1	 Definition of RBE | Content: Relative biological effectiveness (RBE) is a method to quan­
tify and compare the biological damage of different types of
radiation [97]. The RBE is a dimensionless quantity and can
be described as a radiation quality index with regard to bio­
logical damage. Quantitatively, RBE is the ratio between the
absorbed dose of a reference radiation type and the absorbed
dose of the radiation type of interest, such that both the
absorbed doses compared produce the same amount of a bio­
logical effect, known as isoeffect. The reference radiation is
defined as a low LET radiation. Previously, the standard
radiation used was 250 keV of X-ray; however, nowadays, it
is more common to use as standard 1 MeV photons (from a
cobalt-60 source). This means that RBE is 1, when cobalt-60
biological effect is compared with itself.
RBE guides in the selection of the weighting factors,
which are required to define the effective dose (E) (Sect.
2.5). RBE varies with several factors described in detail later,
namely LET, radiation dose, fractionation, dose rate, bio­
logical system, endpoint measured, and radiation quality.
(2.37)
2.6.3.2	Efforts to Develop Radiation Quality
Factors and RBE Models Based
on Nanodosimetry
Over the past decades, radiobiology and nanodosimetry stud­
ies have pointed out that the characteristic spatial distribution
of energy deposition at the subcellular scale induced by dif­
ferent particles at different speed is a key aspect at the origin
of the RBE of different radiation qualities [91]. Localized
clusters of energy deposition within the DNA molecule play
a critical role. The frequency and topological distribution of
clustered lesions determine the effectiveness of the DNA
repair mechanisms. Isolated lesions are more efficiently
repaired, while for complex lesions, errors are more likely to
occur in the repair, often leading to permanent damage [98].
One of the main aims of the radiation community is to develop
models for the radiation quality factors, the RBE and cell sur­
vival, which are consistent with nanodosimetry. Several
efforts have been done recently to (a) develop biologically
relevant quantities based on nanodosimetry [99], in order to
overcome the simplistic description of the quality factor as a
(continuous) function of the sole LET; (b) develop new qual­
ity factors incorporating a formula that relates to densely and
sparsely ionizing components of the radiation tracks and core
track contributions and penumbra contributions [13]; (c)
develop an RBE based on a radiation quality descriptor
depending on energy deposition clustering [100]; (d) develop
a cell damage/survival model based on the interactions
between lesions at both the nanometer and micrometer scale
[101]; and (e) perform a detailed analysis of the radial distri­
bution of ionization cluster size distribution [102].
2.6.3.3	Colony Survival Assay and α/β Ratio
Prediction of radiobiological response is a major challenge
in radiotherapy. Survival curves allow to determine the radio­
sensitivity of a cell line to different types of radiation, as well
as to compare the response of one different cell type to one
A. Baeyens et al."
"Explain the concept of Relative Biological Effectiveness (RBE) in radiation biology, detailing its purpose, how it’s determined, and the factors that influence its value. Furthermore, describe the role of nanodosimetry in efforts to refine RBE models.","Relative Biological Effectiveness (RBE) is a crucial metric used in radiation biology to compare the biological damage caused by different types of radiation. It represents a dimensionless ratio quantifying the effectiveness of a given radiation type compared to a reference radiation – typically low-LET radiation – in producing a specific biological effect, such as cell death or mutation. More precisely, RBE is defined as the ratio between the absorbed dose of the reference radiation and the absorbed dose of the radiation being evaluated, *such that both doses produce the same level of a particular biological effect*, known as an isoeffect. Historically, 250 keV X-rays were used as the standard reference, but now 1 MeV photons from a cobalt-60 source are more commonly employed.

The value of RBE is highly dependent on several factors including Linear Energy Transfer (LET), radiation dose, fractionation, dose rate, the biological system being exposed to, the specific endpoint measured (e.g., cell survival vs. mutation rate), and the radiation quality itself. The spatial distribution of energy deposition at the subcellular scale – a key focus of nanodosimetry studies – plays a critical role; localized clusters of energy within DNA molecules are more damaging than isolated lesions due to their impact on repair mechanisms.

Nanodosimetry, which examines radiation damage at the nanoscale, has driven recent efforts to move beyond simplistic RBE models. Instead of treating RBE as solely a function of LET, researchers are developing more biologically relevant quantities based on nanodosimetry data. These efforts include incorporating factors like densely and sparsely ionizing components of radiation tracks, core track contributions versus penumbra contributions, and the frequency and topological distribution of clustered lesions within DNA. The goal is to create models that accurately reflect how different radiation qualities interact with cellular repair processes at a fundamental level, ultimately leading to more precise estimations of effective dose and cell survival.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.3	 Induced Biological Effects Depend on LET | Sub-sub-subsection: 2.6.3.2	 Efforts to Develop Radiation Quality Factors and RBE Models Based on Nanodosimetry | Content: Relative biological effectiveness (RBE) is a method to quan­
tify and compare the biological damage of different types of
radiation [97]. The RBE is a dimensionless quantity and can
be described as a radiation quality index with regard to bio­
logical damage. Quantitatively, RBE is the ratio between the
absorbed dose of a reference radiation type and the absorbed
dose of the radiation type of interest, such that both the
absorbed doses compared produce the same amount of a bio­
logical effect, known as isoeffect. The reference radiation is
defined as a low LET radiation. Previously, the standard
radiation used was 250 keV of X-ray; however, nowadays, it
is more common to use as standard 1 MeV photons (from a
cobalt-60 source). This means that RBE is 1, when cobalt-60
biological effect is compared with itself.
RBE guides in the selection of the weighting factors,
which are required to define the effective dose (E) (Sect.
2.5). RBE varies with several factors described in detail later,
namely LET, radiation dose, fractionation, dose rate, bio­
logical system, endpoint measured, and radiation quality.
(2.37)
2.6.3.2	Efforts to Develop Radiation Quality
Factors and RBE Models Based
on Nanodosimetry
Over the past decades, radiobiology and nanodosimetry stud­
ies have pointed out that the characteristic spatial distribution
of energy deposition at the subcellular scale induced by dif­
ferent particles at different speed is a key aspect at the origin
of the RBE of different radiation qualities [91]. Localized
clusters of energy deposition within the DNA molecule play
a critical role. The frequency and topological distribution of
clustered lesions determine the effectiveness of the DNA
repair mechanisms. Isolated lesions are more efficiently
repaired, while for complex lesions, errors are more likely to
occur in the repair, often leading to permanent damage [98].
One of the main aims of the radiation community is to develop
models for the radiation quality factors, the RBE and cell sur­
vival, which are consistent with nanodosimetry. Several
efforts have been done recently to (a) develop biologically
relevant quantities based on nanodosimetry [99], in order to
overcome the simplistic description of the quality factor as a
(continuous) function of the sole LET; (b) develop new qual­
ity factors incorporating a formula that relates to densely and
sparsely ionizing components of the radiation tracks and core
track contributions and penumbra contributions [13]; (c)
develop an RBE based on a radiation quality descriptor
depending on energy deposition clustering [100]; (d) develop
a cell damage/survival model based on the interactions
between lesions at both the nanometer and micrometer scale
[101]; and (e) perform a detailed analysis of the radial distri­
bution of ionization cluster size distribution [102]."
"Explain the concept of Relative Biological Effectiveness (RBE) and how it relates to linear energy transfer (LET) in radiation biology, including its application within the context of colony survival assays and the α/β ratio.","Relative Biological Effectiveness (RBE) is a dimensionless quantity used to compare the biological damage caused by different types of radiation. It represents the ratio between the absorbed dose required to produce a specific effect (an isoeffect) with one type of radiation and the absorbed dose needed to produce the same effect with a reference radiation, which is typically low-LET radiation like X-rays. The fundamental principle behind RBE is that the spatial distribution of energy deposition at the cellular level – specifically localized clusters within DNA – significantly impacts biological damage. Higher LET radiations, characterized by their more concentrated energy deposition, tend to create more complex and difficult-to-repair DNA lesions compared to low-LET radiation. This leads to a higher RBE because a lower absorbed dose is required to produce an equivalent biological effect. The colony survival assay utilizes survival curves of cells exposed to different radiation types to determine the radiosensitivity of cell lines.  The α/β ratio, derived from these curves, quantifies this sensitivity – it’s the ratio of the linear (α) and quadratic (β) coefficients in the linear-quadratic (LQ) model used to describe cell survival. A higher α/β ratio indicates greater radiosensitivity; cells with high LET radiation typically exhibit a higher α/β ratio because they induce more lethal lesions relative to potentially lethal ones, or their repair mechanisms are less efficient at handling these complex DNA damage patterns.  Recent research focuses on developing RBE models that incorporate nanodosimetry data, recognizing the importance of localized energy deposition clustering in determining radiation quality factors and cell survival.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.3	 Induced Biological Effects Depend on LET | Sub-sub-subsection: 2.6.3.3	 Colony Survival Assay and α/β Ratio | Content: Relative biological effectiveness (RBE) is a method to quan­
tify and compare the biological damage of different types of
radiation [97]. The RBE is a dimensionless quantity and can
be described as a radiation quality index with regard to bio­
logical damage. Quantitatively, RBE is the ratio between the
absorbed dose of a reference radiation type and the absorbed
dose of the radiation type of interest, such that both the
absorbed doses compared produce the same amount of a bio­
logical effect, known as isoeffect. The reference radiation is
defined as a low LET radiation. Previously, the standard
radiation used was 250 keV of X-ray; however, nowadays, it
is more common to use as standard 1 MeV photons (from a
cobalt-60 source). This means that RBE is 1, when cobalt-60
biological effect is compared with itself.
RBE guides in the selection of the weighting factors,
which are required to define the effective dose (E) (Sect.
2.5). RBE varies with several factors described in detail later,
namely LET, radiation dose, fractionation, dose rate, bio­
logical system, endpoint measured, and radiation quality.
(2.37)
2.6.3.2	Efforts to Develop Radiation Quality
Factors and RBE Models Based
on Nanodosimetry
Over the past decades, radiobiology and nanodosimetry stud­
ies have pointed out that the characteristic spatial distribution
of energy deposition at the subcellular scale induced by dif­
ferent particles at different speed is a key aspect at the origin
of the RBE of different radiation qualities [91]. Localized
clusters of energy deposition within the DNA molecule play
a critical role. The frequency and topological distribution of
clustered lesions determine the effectiveness of the DNA
repair mechanisms. Isolated lesions are more efficiently
repaired, while for complex lesions, errors are more likely to
occur in the repair, often leading to permanent damage [98].
One of the main aims of the radiation community is to develop
models for the radiation quality factors, the RBE and cell sur­
vival, which are consistent with nanodosimetry. Several
efforts have been done recently to (a) develop biologically
relevant quantities based on nanodosimetry [99], in order to
overcome the simplistic description of the quality factor as a
(continuous) function of the sole LET; (b) develop new qual­
ity factors incorporating a formula that relates to densely and
sparsely ionizing components of the radiation tracks and core
track contributions and penumbra contributions [13]; (c)
develop an RBE based on a radiation quality descriptor
depending on energy deposition clustering [100]; (d) develop
a cell damage/survival model based on the interactions
between lesions at both the nanometer and micrometer scale
[101]; and (e) perform a detailed analysis of the radial distri­
bution of ionization cluster size distribution [102].
2.6.3.3	Colony Survival Assay and α/β Ratio
Prediction of radiobiological response is a major challenge
in radiotherapy. Survival curves allow to determine the radio­
sensitivity of a cell line to different types of radiation, as well
as to compare the response of one different cell type to one
A. Baeyens et al.
57
type of radiation. The linear-quadratic (LQ) model has been
best validated by experimental and clinical data and describes
the surviving fraction (SF) of cells as a function of radiation
dose D: SF (D) = e−α.D − βD2. It allows determining important
biological parameters such as the survival fraction or the
ratio α/β, which represents the intrinsic radiosensitivity.
Cells with a higher α and β are more sensitive to radiation.
The shape of the curves depends on the LET. Indeed, cells
irradiated with the same dose of different LET induce differ­
ent biological effects translated into different cell survivals.
As the LET increases, the slope of the curve becomes steeper
and straighter with less shoulder. This indicates a higher ratio
of lethal to potentially lethal lesions or a less efficient repair
of the high LET radiation damage. For the LQ representa­
tion, this is shown by a higher α/β ratio for high LET radia­
tion. However, the lower the α/β ratio is (high β relative to α),
the more curved the clonogenic curve is."
"The text discusses limitations associated with using the Linear Energy Transfer (LET) concept to predict biological effects. Explain these limitations, focusing on both the physical challenges in measuring LET and the inherent complexities related to particle tracks and energy deposition within cells. Specifically, how does the concept struggle when applied to electrons versus heavier ions?","The LET concept, while useful for quantifying radiation energy distribution, faces significant limitations that hinder its predictive power regarding biological effects. Primarily, direct measurements of dE/dl (the energy lost per unit length) are complex and difficult to translate into clinical or radiobiological setups. These measurements require extremely thin particle detectors with high-energy resolution capable of differentiating between secondary particles and photons, a feat often challenging in practical applications. Furthermore, the density of the detector material must be considered for accurate conversion to water units, representing stopping power and ultimately LET∞. The development of Monte Carlo codes offers a computational solution but doesn't fully address the inherent uncertainties.

The concept struggles significantly with electrons due to their finite range and lateral escape of δ-rays. Cellular structures are simply too small to completely disregard these effects while simultaneously accounting for significant energy straggling. Averaging LET values across a cellular distance is therefore inadequate because fluctuations in energy loss occur, leading to extreme highs or lows that aren't captured by simple averaging. Similarly, the angular deflection and lateral extension of electron tracks due to δ-ray interactions are not accounted for.

Conversely, for heavier ions, the LET concept can be more adequate when considering specific particle energies and sizes within cells. The square relationship between LET and ion charge (Z) and the inverse square relationship with velocity (v) provide a degree of predictive capability. However, even then, it’s crucial to recognize that two particles with identical LET but vastly different velocities and charges will have dramatically different track structures – one particle's energy deposition is fundamentally distinct from the other’s due to their differing interactions within biological matter.

Reference: [MolecularRadiationBiology], Section 2.6.3 Subsubsection 2.6.3.4 Limitations of the LET Concept","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.3	 Induced Biological Effects Depend on LET | Sub-sub-subsection: 2.6.3.4	 Limitations of the LET Concept | Content: Although the LET is a common and useful parameter to
quantify the distribution of absorbed radiation energy, there
are considerable limitations, which need to be considered.
The limitations in terms of using the LET for predicting bio­
logical effects are strongly related to the RBE models and
have been discussed in previous sections. There are also cave­
ats of more physical nature. In particular, LET measurements
are complex, difficult to relate to clinical or radiobiological
setups, and affected by several constraints particularly if LET
distributions are to be reported rather than single LET values.
Direct measurements of dE/dl can be attempted with very
thin particle detectors (such that multiple interactions within
the active volume rarely occur) with high-energy resolution
and able to discriminate between secondary particles and
photons. In this case, the energy loss (ΔE) by a particle pass­
ing through is related to the thickness of the detector (Δl).
Ideally, detectors with different thickness would be employed
and the energy detected plotted against the detector thickness
from which the slope at the origin is extrapolated. The density
of the sensitive material of the detector should also be consid­
ered to convert the measurements into water. This provides an
estimation of the stopping power and therefore the LET∞.
The development of several Monte Carlo-based codes has
offered the possibility to quickly calculate LET values taking
also into consideration the specific experimental settings.
The definition of the LET concept also implies that an
average LET value may not always be adequate to describe
the radiation quality to which biological samples are exposed.
As mentioned, the LET changes significantly along the path
of an individual charged particle and it is affected by the spe­
cific irradiation setup including any scattering conditions.
Single LET values are suitable for “track segment” experi­
ments where thin biological samples are exposed to mono-­
energetic charged particle beams. Even under such conditions,
however, the energy loss by a charged particle over a cellular
distance fluctuates and it can occasionally reach extreme high
or low values, which are not well accounted for in an averag­
ing process. Also, the angular deflection and the lateral exten­
sion of the particle tracks due to the finite range of δ-rays are
in principle not taken into account in the LET concept. The
restricted LET, which only includes energy transfer below a
specified cutoff, can actually partially take into account the
second point. However, a set of LET distributions that belong
to different cutoff values would be needed, but still little infor­
mation about the actual structure of particle tracks would be
gained [103]. A quantitative evaluation has shown that the
LET concept is quite inadequate for electrons; there are no
sites sufficiently small to disregard the finite range of the elec­
trons and simultaneously sufficiently large to disregard the
lateral escape of δ-rays and the energy loss straggling [103].
Contrarily, for heavy ions, there are site sizes and particle
energies for which the LET predicts adequately the energy
deposition. LET increases approximately as the square of the
ion charge, Z, and the inverse square of its velocity, v. On the
other hand, the maximum range of the δ-ray electrons
depends on the velocity of the particle but not its charge.
Thus, the consideration of the sole LET of a particle is not
sufficient for a description of the particle’s track structure, as
two particles of identical LET but very different velocity and
charge will have very different track structures [104].
2.6.4
Relative Biological Effectiveness
Depends on Many Factors
2.6.4.1	LET
2.20
97
­
2 Basic Concepts of Radiation Biology"
"The text discusses limitations of the Linear Energy Transfer (LET) concept, particularly concerning its applicability to electron beams. Explain why LET is considered inadequate for electrons and what factors contribute to this inadequacy, referencing specific aspects of particle track structure.","The LET concept faces significant challenges when applied to electron beams due to several inherent properties of electron interactions with matter. Primarily, the text highlights that electrons possess a finite range and exhibit lateral escape (δ-ray emission) simultaneously. Cellular structures are typically small enough that ignoring this finite range is unrealistic, yet large enough that disregarding lateral escape and energy loss straggling would be equally inaccurate. This means an electron’s trajectory isn't a simple straight line; it fluctuates significantly due to these interactions, leading to unpredictable energy deposition at any given point within the cell. Furthermore, LET assumes an averaging process which fails to account for these fluctuating energy losses. The concept of LET, defined as energy loss per unit distance, doesn't adequately capture the complex and varied track structure created by electrons. Specifically, electrons with different velocities (and therefore different ranges) and charges will produce vastly different patterns of energy deposition – one particle might deposit its energy in a highly localized region while another spreads it over a larger area, even if their LET values are identical. This discrepancy arises because the maximum range of δ-ray electrons is velocity dependent, whereas the charge has little effect on this range. Consequently, relying solely on LET provides an incomplete and misleading picture of electron track structure and its impact on biological damage.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Content: Single LET values are suitable for “track segment” experi­
ments where thin biological samples are exposed to mono-­
energetic charged particle beams. Even under such conditions,
however, the energy loss by a charged particle over a cellular
distance fluctuates and it can occasionally reach extreme high
or low values, which are not well accounted for in an averag­
ing process. Also, the angular deflection and the lateral exten­
sion of the particle tracks due to the finite range of δ-rays are
in principle not taken into account in the LET concept. The
restricted LET, which only includes energy transfer below a
specified cutoff, can actually partially take into account the
second point. However, a set of LET distributions that belong
to different cutoff values would be needed, but still little infor­
mation about the actual structure of particle tracks would be
gained [103]. A quantitative evaluation has shown that the
LET concept is quite inadequate for electrons; there are no
sites sufficiently small to disregard the finite range of the elec­
trons and simultaneously sufficiently large to disregard the
lateral escape of δ-rays and the energy loss straggling [103].
Contrarily, for heavy ions, there are site sizes and particle
energies for which the LET predicts adequately the energy
deposition. LET increases approximately as the square of the
ion charge, Z, and the inverse square of its velocity, v. On the
other hand, the maximum range of the δ-ray electrons
depends on the velocity of the particle but not its charge.
Thus, the consideration of the sole LET of a particle is not
sufficient for a description of the particle’s track structure, as
two particles of identical LET but very different velocity and
charge will have very different track structures [104].
2.6.4
Relative Biological Effectiveness
Depends on Many Factors"
"The text discusses limitations of using the concept of Linear Energy Transfer (LET) primarily for electrons. Explain these limitations, focusing on factors that make a simple LET value inadequate for accurately representing electron track behavior within cells.","The concept of LET, as applied to electrons, suffers from several significant shortcomings when attempting to represent the actual energy deposition process within biological systems. Primarily, electrons possess both a finite range and exhibit substantial lateral escape and energy loss straggling due to interactions with δ-rays – essentially, secondary electron emissions. The standard LET calculation averages these fluctuations in energy loss over a cellular distance, which is fundamentally inaccurate for electrons. Because cells are small enough that the full range of an electron isn't disregarded, yet large enough that lateral escape and straggling are significant, there aren’t sufficiently small sites to ignore these effects while simultaneously accounting for the overall energy deposition. Furthermore, LET increases approximately as the square of the ion charge (Z) and the inverse square of its velocity (v). This means particles with different charges and velocities, even if they have the same LET value, will exhibit vastly different track structures and therefore induce varying levels of biological damage. The text highlights that a set of LET distributions would be needed to account for these differences, but this approach still provides limited insight into the actual particle track structure. Consequently, relying solely on LET is inadequate for electrons because it fails to capture the complex interplay between finite range, lateral escape, and energy straggling inherent in their interactions with biological matter [103].","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Sub-sub-subsection: 2.6.4.1	 LET | Content: Single LET values are suitable for “track segment” experi­
ments where thin biological samples are exposed to mono-­
energetic charged particle beams. Even under such conditions,
however, the energy loss by a charged particle over a cellular
distance fluctuates and it can occasionally reach extreme high
or low values, which are not well accounted for in an averag­
ing process. Also, the angular deflection and the lateral exten­
sion of the particle tracks due to the finite range of δ-rays are
in principle not taken into account in the LET concept. The
restricted LET, which only includes energy transfer below a
specified cutoff, can actually partially take into account the
second point. However, a set of LET distributions that belong
to different cutoff values would be needed, but still little infor­
mation about the actual structure of particle tracks would be
gained [103]. A quantitative evaluation has shown that the
LET concept is quite inadequate for electrons; there are no
sites sufficiently small to disregard the finite range of the elec­
trons and simultaneously sufficiently large to disregard the
lateral escape of δ-rays and the energy loss straggling [103].
Contrarily, for heavy ions, there are site sizes and particle
energies for which the LET predicts adequately the energy
deposition. LET increases approximately as the square of the
ion charge, Z, and the inverse square of its velocity, v. On the
other hand, the maximum range of the δ-ray electrons
depends on the velocity of the particle but not its charge.
Thus, the consideration of the sole LET of a particle is not
sufficient for a description of the particle’s track structure, as
two particles of identical LET but very different velocity and
charge will have very different track structures [104].
2.6.4
Relative Biological Effectiveness
Depends on Many Factors
2.6.4.1	LET
2.20
97
­
2 Basic Concepts of Radiation Biology
58
words, low LET radiation creates sparse ionization, requir­
ing more than one radiation track to pass through the cell and
induce lethal biological damage, while high LET radiation is
more effective, since one radiation track through the cell is
enough to induce lethal biological damage. However, over
100 keV/μm, there are many “wasted” ionizations due to the
very high ionization densities (number of ions per unit of
path length). This phenomenon is the so-called overkilling
and reflects the RBE declining for further increases in LET,
for which biological effect is reduced since most of the
energy is wasted."
"Explain how the relative biological effectiveness (RBE) of different types of ionizing radiation varies with both radiation dose and linear energy transfer (LET). Specifically, describe why RBE values tend to increase for small doses and decrease at very high doses.","The relative biological effectiveness (RBE) – a measure of the relative damage caused by different types of radiation – is significantly influenced by both the radiation dose administered and the linear energy transfer (LET) of the radiation. Initially, when determining RBE, particularly for small radiation doses, the value tends to increase substantially. This phenomenon arises because at low LETs, high-energy radiation like alpha particles or heavy ions possesses a much greater capacity to directly damage DNA molecules compared to low LET radiations such as X-rays or gamma rays. Consequently, these higher LET radiations are exceptionally effective in inducing cell death and other biological effects. Conversely, low LET radiation often has limited penetration depth and thus minimal direct interaction with cellular components, resulting in reduced biological impact at the same dose. As the radiation dose increases, the difference in effectiveness between high and low LET radiations diminishes. This is because at higher doses, even low LET radiation becomes more lethal due to its cumulative effect on DNA damage. Furthermore, at extremely high doses, the RBE effectively ceases to depend on the dose itself; this occurs when the overall biological response has reached a saturation point, where all available cellular repair mechanisms are overwhelmed regardless of the initial radiation type or energy deposition.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Sub-sub-subsection: 2.6.4.2	 Radiation Dose | Content: When determining RBE, it is important to understand that
RBE values also depend on the radiation dose and, conse­
quently, on the isoeffect level chosen for the comparison
between radiation types [97]. For small radiation doses, RBE
is particularly variable tending to increase. This is explained
by the fact that at low doses, the difference in the biological
damage induced by low and high LET radiation is huge; that
is, high LET radiation is very effective in killing cells, while
low LET radiation is ineffective in doing so. For high radia­
tion doses, the difference between the effects induced by low
and high LET radiation becomes smaller, considering that
low LET radiation becomes more lethal. At very high doses,
the RBE no longer depends on the dose."
Explain the concept of fractionation in radiation biology and how it relates to Linear Energy Transfer (LET)?,"Fractionation describes the phenomenon observed where biological systems initially benefit from multiple, lower-dose exposures to ionizing radiation. This initial response involves a rapid repair of DNA damage, leading to a transient increase in sensitivity to further irradiation. However, beyond a certain point, subsequent exposure to additional radiation becomes detrimental and does not provide any further protective effect. This is directly linked to Linear Energy Transfer (LET). LET represents the amount of energy deposited by a single ionizing particle as it traverses through matter – essentially, how efficiently a high-energy radiation beam transfers its energy to biological molecules. At lower LET values (e.g., alpha particles), the energy deposition is highly localized, leading to intense DNA damage in a small area. This rapid and severe damage triggers an immediate and effective repair response, resulting in the observed fractionation effect. Conversely, at higher LET values (e.g., gamma rays), the radiation deposits its energy more broadly along the beam path, causing less concentrated DNA damage. Because the damage is spread out, the initial repair mechanisms are overwhelmed, and subsequent exposures become increasingly damaging as they exacerbate existing lesions without providing a significant benefit from further repair. Therefore, fractionation highlights the complex relationship between LET, dose rate, and biological response – emphasizing that the magnitude of energy deposition significantly dictates the effectiveness of radiation exposure.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Sub-sub-subsection: 2.6.4.3	 Fractionation and LET | Content: ­
­
­
­
­
­
­
2.22
­
2.21105
2.21
­
2.21
­
­
105
A. Baeyens et al.
59
efit from reoxygenation, but multiple fractions would not be
further beneficial [106] (Box 2.21)."
"How does the rate at which radiation is delivered (dose rate) affect its biological effectiveness, and why might this relationship differ between tumors and normal tissues?","The biological effectiveness of ionizing radiation – that is, the relative damage it causes to living cells – increases with increasing dose rate. This isn't a uniform effect; it’s particularly pronounced in late-responding normal tissues compared to early-responding ones. Tissues characterized by a low α/β ratio (as predicted by the LQ model) exhibit greater sensitivity to dose rate variations than those with a high α/β ratio. Essentially, at higher dose rates, the damage inflicted on these late-responding tissues is more detrimental than it is for tumors and early-responding normal tissues. This differential effect is likely due to several interconnected mechanisms. The ‘oxygen depletion hypothesis’ suggests that rapid radiation exposure leads to localized oxygen consumption, creating hypoxic conditions within cells, which favors DNA damage repair in some cell types but exacerbates damage in others. The ‘DNA damage hypothesis’ posits that a higher dose rate overwhelms the cellular capacity for efficient DNA repair, leading to more persistent and ultimately lethal damage. Finally, the ‘immune response hypothesis’ proposes that rapid radiation exposure triggers an amplified immune response within late-responding tissues, contributing to inflammation and further tissue injury. Notably, at ultrahigh dose rates (FLASH radiotherapy), this inverse relationship – where higher dose rates are *more* effective – can be reversed, potentially due to oxygen depletion becoming a dominant factor.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Sub-sub-subsection: 2.6.4.4	 The Dose Rate | Content: ­
­
­
­
2.22
­
­
­
The increase in biological effectiveness with increasing
dose rate applies to all tissues and organs and, importantly,
discriminates between early-responding tumors and normal
tissues and late-responding normal tissues. In late-­
responding normal tissues, characterized by a low α/β ratio
of the LQ model, the increase of dose rate is more detrimen­
tal than for tumors and early-responding normal tissues with
a high α/β ratio. Literature data show that, at ultrahigh dose
rate in FLASH radiotherapy, this differential effect could be
inverted [108]. This inverse effect could be explained by the
oxygen depletion hypothesis, the DNA damage hypothesis,
and the immune response hypothesis."
"The text describes variations in Relative Biological Effectiveness (RBE) across different biological systems and types of radiation. Explain how factors such as cell line, radiation type (e.g., X-rays versus neutrons), and the depth of irradiation (particularly with heavy ions) contribute to these observed differences in RBE values.","The significant variability in RBE values documented across different biological systems and radiation types stems from a complex interplay of factors. Firstly, cell lines themselves exhibit considerable sensitivity to radiation; those with larger shoulder regions in their survival curves demonstrate greater variation in RBE, indicating differing responses to the same dose. Secondly, the type of radiation profoundly impacts RBE. Neutrons generally result in lower RBE values compared to X-rays, likely due to their different linear energy transfer (LET) profiles and subsequent effects on DNA damage. Thirdly, for heavy ions, the depth of irradiation is a critical consideration. Because heavy ions deposit more energy over longer distances within cells, this deeper penetration can lead to increased DNA damage and consequently, a higher RBE compared to photons like X-rays, which tend to cause damage in a more localized manner. Furthermore, the text highlights that dose rate also plays a role; decreasing the dose rate leads to a decrease in biological effectiveness, reflecting the time available for repair mechanisms to operate. Finally, it’s important to note that RBE estimates are influenced by the detection methods used to measure biological endpoints like DNA damage and apoptotic responses, which can vary significantly depending on the radiation quality and tissue type.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Sub-sub-subsection: 2.6.4.5	 Biological System and Endpoints Measured | Content: Measured
During the last decades, many tissues and cells were char­
acterized by survival curves in response to different types
of radiation, especially X-rays. They underlined a great
variation of the RBE for all the biological systems studied.
Indeed, large variable shoulder regions were observed in
response to X-rays, whereas less variation was observed
with neutrons, explaining that the RBE is different for each
cell line. In response to heavy ions, the depth of the irradia­
tion has also to be considered and explains in part the dif­
ferent RBE calculated for one cell line compared with
X-rays.
Box 2.21 Fractionation and LET
•	The higher the LET, the straighter the radiation–cell
survival relationship, and the lower the sensitivity
to dose fractionation.
•	The RBE of high LET irradiation decreases with
increasing dose or dose per fraction for both cells
and tissues.
•	Little normal tissue sparing after fractionated high
LET irradiation: Few fractions are sufficient.
Box 2.22 Definition of Dose Rate and Dose Rate Effect
•	Dose rate: radiation dose delivery per unit time
(e.g., Gy/hour)
•	Dose rate effect: decrease in biological effective­
ness with decreasing dose rate
­
107
2 Basic Concepts of Radiation Biology
60
While the physical and dosimetric aspects of radiobiology
are well understood, the biological aspects such as the com­
plex biological endpoints induced need further attention. The
current estimates of RBE listed above depend on the biologi­
cal system, but also depend on the detection methods used as
it has been demonstrated that DNA damage and the resulting
apoptotic responses vary greatly depending on the radiation
quality in a tissue- and dose-dependent manner. Experimental
data emerging from recent studies suggest that, for several
endpoints of clinical relevance, the biological response is
differentially modulated by particles compared to photons.
However, up to date, only few studies have been performed
to understand the differential response on the molecular and
cellular levels between different radiation qualities."
"Explain the concept of the quality factor (Q(L)) in radiation biology and how it relates to linear energy transfer (LET) and biological effects. Furthermore, why has the use of the quality factor been superseded by the radiation weighting factor (WR)?","The quality factor (Q(L)) is a crucial parameter in radiation biology that accounts for the differing biological consequences of ionizing radiation based on its linear energy transfer – specifically, how much energy a particle deposits over a given distance. High LET radiations, such as alpha particles or heavy ions, deposit their energy in densely packed tracks, leading to a high ionization density and consequently greater damage per unit path length. This results in a significantly higher biological effect for the same absorbed dose compared to low LET radiation like X-rays or gamma rays which spread their energy over a wider area. The quality factor essentially normalizes the absorbed dose by accounting for this difference in LET, allowing for a common scale of biological damage across all types of ionizing radiation. It’s calculated as the ratio of the equivalent dose (in rem) to the absorbed dose (in rad), reflecting the cumulative knowledge regarding the relationship between physical characteristics and detrimental effects. However, due to advancements in understanding radiation biology and dosimetry, the quality factor has largely been superseded by the radiation weighting factor (WR). The ICRP’s 92nd report recommended using gamma rays of 60Co as the reference radiation for RBE determination, recognizing that Q(L) was historically tied to a specific (and somewhat outdated) standard. The WR provides a more direct and scientifically robust approach to quantifying the biological effectiveness of different radiations by directly relating absorbed dose to equivalent dose, eliminating the need for an indirect calculation through the quality factor. It’s important to note that while Q(L) is still used in operational calculations like monitoring, the WR represents the current standard for defining radiation risk assessments.

Reference: 2: Basic Concepts of Radiation Biology > 2.6 Linear Energy Transfer and Relative Biological Effectiveness > 2.6.4 Relative Biological Effectiveness Depends on Many Factors > 2.6.4.6 Radiation Quality (Type of Radiation): Relation to Space","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.4	 Relative Biological Effectiveness Depends on Many Factors | Sub-sub-subsection: 2.6.4.6	 Radiation Quality (Type of Radiation): Relation to Space | Content: Relation to Space
The biological effects of ionizing radiation relate strongly to
the dose, dose rate, and quality of the radiation. To distin­
guish the different types of radiation, from low LET to high
LET particle radiation, the quality factor Q (L) has been
introduced. This factor reflects all cumulative knowledge on
the dependence of the detrimental effects of radiation on
physical characteristics and mainly LET (ionization den­
sity). Therefore, this factor can be used to multiply the
absorbed dose (rad or gray) to obtain a quantity that
expresses, on a common scale for all ionizing radiations, the
biological damage (rem or sievert) to the exposed tissue.
Although Q (L) has been superseded by the radiation weight­
ing factor WR in the definition of equivalent dose, it is still
being used in calculating the operational dose equivalent
quantities used for example in monitoring [109].
In order to encompass the dependence of biological
effects to LET, many studies have been performed in order to
measure RBE for a specific biological endpoint (usually
reproductive cell death) for radiations of different LET [110].
In most cases, survival curves are evaluated assuming a
linear-­quadratic dose dependence of the induction of repro­
ductive death of cells. The linear term accounts for damage
from single particle tracks and the quadratic term for damage
due to interaction of lesions from independent tracks.
Although for many years 250 kVp X-ray was considered the
standard reference radiation for the determination of RBE,
the International Commission on Radiation Protection
(ICRP) recommended in their 92nd report to use gamma rays
of 60Co as the reference radiation [111]. In both cases of low
LET radiation, RBE is assumed to be equal to 1.0. When
specific biological effects of high LET radiation (such as fast
neutrons) on human cells are measured, the RBE ranges
from about 3 to greater than 100 for various biological
effects.
2.6.5"
"Explain the Oxygen Enhancement Ratio (OER) within the context of radiation biology and its relationship to linear energy transfer (LET). How does the OER account for differences in biological effects between hypoxic and aerobic conditions, and why is it particularly relevant for low LET radiation?","The Oxygen Enhancement Ratio (OER) represents a critical factor in understanding how radiation interacts with tissue, specifically concerning its biological impact. It quantifies the amplified effect of radiation within oxygen-rich environments compared to hypoxic ones. The OER is defined as the ratio of radiation doses required to produce equivalent biological effects – typically measured by survival curves – in hypoxic versus aerobic conditions. Essentially, it reflects the increased sensitivity of cells to radiation when sufficient oxygen is present.

The underlying mechanism driving the OER relates to reactive oxygen species (ROS) production. Low linear energy transfer (LET) radiation, such as X-rays and gamma rays, generates a higher density of free radicals within cells due to its shorter range and greater energy deposition per unit distance. These ROS are significantly more effective at damaging DNA and other cellular components in the presence of oxygen. Oxygen readily reacts with these ROS, further amplifying their destructive potential – this is known as the oxygen effect.

Specifically, for low LET radiation (OER values ranging from 2.5 to 3.5), a dose 2.5 to 3.5 times greater is needed in hypoxic cells to achieve the same level of cell killing compared to normoxic cells. This is because hypoxia limits the ability of oxygen to scavenge and neutralize these ROS, leading to a disproportionately larger biological effect.

Neutrons exhibit an intermediate OER value. The concept of the OER highlights why low LET radiation can be particularly radioresistant in hypoxic regions of tumors – the lack of sufficient oxygen prevents the amplification of damage through ROS production. Recent research has even questioned the established OER values for carbon ion therapy due to the low LET characteristics within the spread-out Bragg peak, suggesting a potential impact on treatment outcomes.

Reference: 2.6.5 Oxygen Enhancement Ratio and LET (MolecularRadiationBiology)","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.6	 Linear Energy Transfer and Relative Biological Effectiveness | Sub-subsection: 2.6.5	 Oxygen Enhancement Ratio and LET | Content: effects.
2.6.5
Oxygen Enhancement Ratio and LET
The oxygen effect is an important parameter in radiation
therapy. Its influence on the tissue’s biological response (typ­
ically survival curves) will differ according to the radiation
type used. This concept is represented by the oxygen
enhancement ratio (OER).
The OER is a measure of the influence of the oxygen
effect. It is defined as the ratio of radiation doses that pro­
duce the same biological effect in hypoxic compared to aero­
bic (well-oxygenated) conditions:
2.23
A. Baeyens et al.
61
expected to lead to a better tumor control of hypoxic tumors
compared to low LET radiation.
It should be noted that these OER values were originally
derived from in vitro experiments. Recently, the oxygen
effect during carbon ion therapy was questioned due to low
LET values in the spread-out Bragg peak, giving rise to a
possible impact of oxygen on carbon ion treatment outcome
[112]. In case of low LET radiation (X- and γ-rays, elec­
trons), the OER increases and is in the range of 2.5–3.5,
meaning that a 2.5–3.5 times higher dose is needed to achieve
the same killing effect in hypoxic cells compared to nor­
moxic cells. Indirect effects, relying on reactive oxygen spe­
cies (ROS) production, are the dominant process associated
with low LET radiation and explain the importance of oxy­
gen for low LET radiation. Hypoxic regions within a tumor
may therefore show radioresistance to low LET radiation.
The OER has an intermediate value for neutrons. Based on
this concept, a massive work on oxygen-based radiosensiti­
zation is being done and is discussed in Chap. 5.
2.7"
"Ionizing radiation induces a range of biological effects within living organisms. How do deterministic and stochastic effects differ in their relationship to radiation dose, and why is this distinction crucial for radiation protection?","Deterministic and stochastic health effects represent fundamentally different ways ionizing radiation can damage the body. Deterministic effects are characterized by a clear threshold dose – below which no effect is observed, and above which the severity of the effect increases proportionally with the dose. These effects are often acute and include phenomena like skin erythema (redness), cataracts, hair loss, and sterility. The relationship between dose and effect in deterministic damage is typically linear within certain ranges. Conversely, stochastic effects do not have a clear threshold; any level of radiation exposure carries a non-zero probability of causing harm, regardless of the magnitude of the dose. These effects are generally low-dose phenomena such as mutations, chromosomal aberrations, and cancer development. The probability of a stochastic effect occurring increases with dose, but the severity of the individual effect remains unpredictable.  The distinction is crucial for radiation protection because deterministic effects require specific dose limits to prevent acute harm, while stochastic effects necessitate broad, population-wide dose limits to minimize the overall risk of long-term health consequences like cancer. Therefore, protective strategies must address both types of damage to ensure safety.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.1	 Introduction | Content: The damage caused by ionizing radiation in the body can
become clinically apparent as a number of different health
effects. The type and severity of the effect are strongly
dependent on dose and exposure conditions, but also on the
health status of the exposed individual. For radiation protec­
tion purposes, and to ensure the safe use of radiation in soci­
ety, the health effects of ionizing radiation exposure are
classified into two types [113]:"
"Describe the distinction between deterministic and stochastic effects in radiation biology, focusing on their characteristics regarding dose response and time of manifestation.","Deterministic effects, also known as tissue reactions, represent biological responses to ionizing radiation that exhibit a clear threshold. This means there is a specific dose level below which the effect is not anticipated to occur; if the dose exceeds this threshold, the severity of the effect increases proportionally with the dose. These effects are typically acute and manifest relatively quickly following exposure, exemplified by conditions like acute radiation syndrome resulting from high doses. Importantly, deterministic effects aren't synonymous with acute effects – some can develop significantly later in life, such as fibrosis or atrophy. Conversely, stochastic effects possess no defined threshold. The occurrence of these effects is purely probabilistic; any exposure to ionizing radiation increases the risk, regardless of the dose received. Crucially, the severity of a stochastic effect isn’t correlated with the dose itself. These effects generally manifest many years after exposure and are most commonly associated with long-term consequences like cancer development or heritable genetic mutations.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Content: tions, are those for which there is a defined threshold below
which the effect is not expected to occur. In addition, the
severity of the effect increases with dose. The acute radiation
syndromes are examples of early effects following high
doses. However, deterministic effects are not a synonym for
acute effects, as some, e.g., fibrosis, can occur much later.
Stochastic effects have no threshold, and the occurrence
of the effect is probabilistic, such that any exposure to ion­
izing radiation increases the risk of these effects. The sever­
ity of the effect is not related to the dose. Stochastic effects
tend to manifest many years postexposure and include can­
cer and heritable effects.
2.7.2
Deterministic Effects or Tissue
Reactions"
"Describe the relationship between ionizing radiation exposure, stem cell populations, and tissue function, focusing on scenarios where tissue function is maintained versus lost.","High-dose penetrating radiation induces cellular damage within tissues, primarily impacting functional cells and their supporting stem cell compartments. The extent of tissue damage relative to the remaining stem cell population dictates whether tissue function will be preserved or lost. If the number of damaged cells is small compared to the total stem cell pool, the surviving stem cells can effectively repopulate depleted functional cells, allowing for continued tissue operation – often temporarily. However, if the stem cell population is significantly reduced below a critical threshold, the tissue’s ability to regenerate ceases, leading to either transient or permanent loss of function. Specifically, radiosensitive tissues like lymphocytes in lymphatic tissue, red bone marrow precursor cells, and crypt cells within the gastrointestinal tract are particularly vulnerable because their diminished stem cell populations cannot adequately replace lost functional cells. Recovery potential hinges on the rate at which undamaged or repaired stem cells can self-renew and repopulate the depleted stem cell population; this process is mediated by feedback mechanisms triggered by the body’s recognition of reduced functional cell numbers. A disruption of normal cellular regeneration, as observed following significant radiation exposure, underlies deterministic tissue reactions and their associated threshold effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.1	 Mechanisms of High-Dose Effects | Content: High-dose penetrating radiation causes damage both to
functional tissues and to stem cell compartments. In gen­
eral, maintenance of health depends on a balance between
loss and replacement of cells in many, but not all, organs
and tissues of the body, reflecting physiological “wear and
tear.”
Cellular damage is known to occur after exposing tissues
to ionizing radiation. If the number of cells damaged is
small relative to the total number of stem cells in the tissue,
then the remaining stem cells can repopulate adequate num­
bers of functional cells. Consequently, there will be no obvi­
ous loss of tissue function. Conversely, if the stem cell
population is reduced below a critical size, the tissue will
cease to function efficiently, either transiently or
permanently.
Organs and tissues differ in their sensitivity to radiation
(Chap. 7), and the damage from radiation particularly affects
the more radiosensitive cells, for example the lymphocytes
in the lymphatic tissue, red bone marrow precursor cells,
and crypt cells in the mucosal lining of the gastrointestinal
tract.
Whether or not recovery will be possible will strongly
depend upon the rate at which viable stem cells (that is, those
cells undamaged or repaired) can repopulate the depleted
stem cell population by self-renewal. The whole process of
recovery is dependent upon feedback mechanisms stimu­
lated by the body’s recognition of depleted functional cell
numbers. Following exposure of a large proportion of or all
of the body, the normal steady state of cellular regeneration
for tissues throughout the body is interrupted: cells and tis­
sues break down and cannot be replaced. This is the basis for
the observed threshold for such deterministic effects or tis­
sue reactions.
It is, however, very important to note that there is a vari­
ation in sensitivity among individuals in an exposed popu­
lation with any particular dose and exposure scenario. This
variation reflects differences in the ability of individuals to
cope with radiation-induced cellular damage, which is
influenced by the age and state of health of the individual at
the time of irradiation [85]."
"Describe the relationship between radiation exposure, stem cell populations, and tissue function, focusing on how deterministic effects manifest based on this interaction.","Following ionizing radiation exposure, cellular damage occurs within tissues, particularly affecting radiosensitive cells like lymphocytes, bone marrow precursor cells, and gastrointestinal crypt cells. The extent of tissue dysfunction hinges on the balance between damaged cells and remaining stem cell populations. If the number of damaged cells is small relative to the stem cell reserve, the stem cells can effectively repopulate functional cells, leading to no obvious loss of tissue function. However, if the stem cell population is significantly reduced below a critical threshold, the tissue’s ability to maintain its normal regenerative capacity ceases, resulting in impaired or permanent tissue dysfunction. This phenomenon forms the basis for deterministic effects or tissue reactions – where observable damage and functional loss are directly correlated with radiation dose. The rate of recovery depends on the stem cells' ability to self-renew and repopulate depleted populations, mediated by feedback mechanisms triggered by the body’s recognition of reduced cell numbers. Ultimately, a threshold dose exists beyond which widespread disruption of cellular regeneration occurs, leading to tissue breakdown and inability to be replaced – reflecting the deterministic nature of these radiation syndromes. The sensitivity among individuals is also influenced by factors like age and health status.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.2	 Radiation Syndromes | Content: functional tissues and to stem cell compartments. In gen­
eral, maintenance of health depends on a balance between
loss and replacement of cells in many, but not all, organs
and tissues of the body, reflecting physiological “wear and
tear.”
Cellular damage is known to occur after exposing tissues
to ionizing radiation. If the number of cells damaged is
small relative to the total number of stem cells in the tissue,
then the remaining stem cells can repopulate adequate num­
bers of functional cells. Consequently, there will be no obvi­
ous loss of tissue function. Conversely, if the stem cell
population is reduced below a critical size, the tissue will
cease to function efficiently, either transiently or
permanently.
Organs and tissues differ in their sensitivity to radiation
(Chap. 7), and the damage from radiation particularly affects
the more radiosensitive cells, for example the lymphocytes
in the lymphatic tissue, red bone marrow precursor cells,
and crypt cells in the mucosal lining of the gastrointestinal
tract.
Whether or not recovery will be possible will strongly
depend upon the rate at which viable stem cells (that is, those
cells undamaged or repaired) can repopulate the depleted
stem cell population by self-renewal. The whole process of
recovery is dependent upon feedback mechanisms stimu­
lated by the body’s recognition of depleted functional cell
numbers. Following exposure of a large proportion of or all
of the body, the normal steady state of cellular regeneration
for tissues throughout the body is interrupted: cells and tis­
sues break down and cannot be replaced. This is the basis for
the observed threshold for such deterministic effects or tis­
sue reactions.
It is, however, very important to note that there is a vari­
ation in sensitivity among individuals in an exposed popu­
lation with any particular dose and exposure scenario. This
variation reflects differences in the ability of individuals to
cope with radiation-induced cellular damage, which is
influenced by the age and state of health of the individual at
the time of irradiation [85].
2.7.2.2	Radiation Syndromes
114115
­
­
­
­
­
2.24
2.23
2 Basic Concepts of Radiation Biology
62
Box 2.23 Symptoms of Exposure to Radiation
•	The clinical signs and symptoms of high-dose radia­
tion exposure are observed up to ~6 days after expo­
sure (with a high degree of uncertainty). These come
as soon as a few minutes after a very high dose.
•	The symptoms of deterministic effects are depen­
dent on dose (deterministic), with increased symp­
toms associated with higher doses.
•	In general, individuals exhibit flu-like symptoms,
vomiting, diarrhea, and headache. For doses in the
region of:
––1–2 Gy, these are classified as “mild,” and we
would expect 10–50% people vomiting, and oth­
ers experiencing fatigue and weakness.
––2–4 Gy, these are classified as “moderate,” fol­
lowing which 70–90% people would be con­
stantly vomiting, 2–6 h after exposure; 50%
people would have a headache; 10–80% people
would have a slight increase in body
temperature.
––4–8 Gy, these are “severe,” following which
~100% of people would be vomiting <1 h after
exposure; 50–80% people would have a head­
ache; most others would have a constant fever
<1 h after exposure; some people might lose
consciousness or feel confused; 10% of individ­
uals would have diarrhea 1–8 h after exposure.
––8 Gy, these are “very severe/lethal” (depending on
the medical resources available); most people lose
consciousness fairly quickly; temperature peak at
about 41 °C is usually observed, and many patients
would present with skin burns at these doses.
A. Baeyens et al.
63
­
­
­
2.25"
"Describe the physiological changes observed in bone marrow following acute radiation exposure, including the mechanisms leading to blood cell depletion and potential recovery pathways.","Following an acute exposure to ionizing radiation, particularly at doses exceeding approximately 2 Gy, significant damage occurs within the bone marrow, primarily affecting hematopoietic stem cells. This initial injury leads to a cascade of events characterized by hypoplasia, aplasia, and hemolysis – essentially, a reduction in the production of blood cells. The radiation directly damages the DNA of these stem cells, disrupting their normal replication and differentiation processes. Consequently, the population of stem cells rapidly diminishes, leading to atrophy of the lymph nodes and spleen due to a lack of supporting cellular components. Differentiating and maturing cells are initially less affected but eventually succumb to the damage as well. The depletion of cellular components – primarily neutrophils and lymphocytes – results in profound infection risk and hemorrhage due to insufficient blood cell production. Remarkably, the bone marrow possesses some capacity for recovery. Approximately 3 weeks post-exposure, a gradual resurgence of granulocytes can be observed in the bloodstream. This recovery is driven by the survival of remaining stem cells that were shielded from immediate radiation damage, coupled with their subsequent proliferation and differentiation. Platelet cell numbers also follow a similar dose- and time-dependent pattern of loss and eventual replenishment. Critically, monitoring changes in differential white blood cell counts – specifically tracking neutrophil and lymphocyte levels over time (given the short half-life of circulating neutrophils around 6–8 hours) – provides an important indicator of the severity of the radiation effect, with a large initial peak followed by rapid decline suggesting a dose exceeding approximately 5 Gy.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.2	 Radiation Syndromes | Content: Following exposures greater than around 2 Gy, and with this
syndrome dominating up to around 10 Gy, the fall in blood
cell counts may result in death from septicemia or hemor­
rhage, due to bone marrow failure, unless the symptoms can
be treated. When the bone marrow is acutely exposed to
radiation, this causes hypoplasia, aplasia, and/or hemolysis
of cells. This leads to a sudden and dose-dependent reduction
in the stem cell population, and ultimately atrophy of the
lymph nodes and spleen. Differentiating and maturing cells
may initially be only marginally affected. Depletion of cel­
lular components of blood leads to infection and
hemorrhage.
The stem cell population may attempt to recover and, if
successful, increasing numbers of granulocytes will appear
in the blood about 3 weeks after exposure. Loss and recovery
of blood platelet cell numbers follow a similar dose- and
time-related pattern.
The severity of the radiation effect can be estimated based
on differential white blood cell counts (neutrophils and lym­
phocytes). If neutrophil and lymphocyte levels are measured
repeatedly following initial exposure (the half-life of circu­
lating neutrophils is only about 6–8 h), this can give an indi­
cation of the likely severity of the ARS or other tissue effects:
A large initial peak of neutrophils and a rapid drop-off could
indicate a dose ~>5 Gy."
"Describe the sequence of events leading to the development of a radiation-induced gastrointestinal syndrome following exposure to high doses of ionizing radiation, focusing on cellular and immunological mechanisms.","Following exposure to ionizing radiation above approximately 8–10 Gy to the gastrointestinal tract, a cascade of detrimental effects rapidly unfolds. Initially, the mucosal crypt stem cells responsible for maintaining the protective epithelial lining of the intestinal wall undergo accelerated turnover, leading to a rapid denudation – or stripping away – of the gut surface as damaged epithelial cells are not replaced quickly enough within the typical 5–10 day timeframe. This damage causes leakage of blood vessels in the gut wall, resulting in bleeding and subsequent presence of blood in the feces. Simultaneously, the radiation compromises the integrity of the intestinal barrier, facilitating translocation of normally commensal bacteria from the gut lumen into the bloodstream. These bacteria, previously harmless within their confined environment, become pathogenic due to the altered immune status and compromised epithelial defenses. This bacterial translocation triggers a systemic inflammatory response, contributing significantly to the observed symptoms. Specifically, the syndrome manifests with severe bloody diarrhea (due to continued epithelial damage and bleeding), anemia (resulting from blood loss and potential hemolysis), profound electrolyte disturbances (caused by fluid shifts and impaired absorption), malnutrition (due to reduced nutrient uptake and increased metabolic demands), and ultimately, sepsis – a life-threatening systemic infection caused by the invading bacteria. The severity of these symptoms is directly correlated with the radiation dose received, typically observed in individuals exposed to doses exceeding 1 Gy within 5–10 days.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.2	 Radiation Syndromes | Content: The mucosal crypt stem cells provide the protective mucosal
cell lining of the intestinal tract wall. Due to the high turnover
of these cells, particularly in the small intestine, damage to
these cells results in a denudation of the gut surface as the
epithelial cells are not replenished, within 5–10 days after
exposure of the gastrointestinal tract to doses of radiation
>1 Gy. Leakage of blood from damaged blood vessels into the
gut then occurs, and blood appears in the feces. Simultaneously,
translocation of normally harmless intestinal bacteria from the
gut through the damaged blood vessels occurs, leading to
infection. Once in the blood, these bacteria become patho­
genic. Symptoms include severe bloody diarrhea, anemia,
severe electrolyte disturbances, malnutrition, and sepsis.
This gastrointestinal syndrome is seen in individuals who
have received acute doses to the gastrointestinal tract in
excess of about 8–10 Gy."
"Describe the observed neurological effects following ionizing radiation exposure to the brain, detailing the dose thresholds associated with various outcomes and potential diagnostic indicators.","Following ionizing radiation exposure to the brain, the severity of neurological consequences is heavily dependent on the administered dose. Traditionally, it was believed that effects beyond direct cell death were minimal; however, current understanding reveals significant impacts on brain function, particularly at doses exceeding approximately 15 Gray (Gy). At these higher doses, pronounced tissue turnover leads to rapid and severe outcomes including cerebral edema – swelling of the brain – ultimately resulting in cerebral death, characterized by a breakdown of nerve impulse pathways. This often manifests as generalized shock, leading to coma and subsequent death within hours or days before systemic symptoms appear. 

At lower doses (below ~15 Gy), the primary effects involve disruption of the central nervous system’s regulatory functions. These can arise from vascular injury – causing hypertension, dizziness, and confusion – or alterations in neurotransmitter release mechanisms affecting brain function itself. Specifically, around 10 Gy, a ‘neurovascular syndrome’ typically emerges, characterized by hypertension, dizziness, cognitive impairment, and neurological deficits, often detectable through abnormalities observed on an electroencephalogram (EEG). The vascular changes induced by radiation contribute significantly to this syndrome.

It's important to note that a much lower dose of approximately 0.5 Gy is considered the threshold for significant cerebrovascular and cardiovascular effects. Furthermore, whole-body exposure can trigger multiple-organ dysfunction syndrome (MODS), a complex clinical condition involving progressive physiological dysfunction in two or more organs resulting from acute insults like ionizing radiation. This syndrome often presents with abnormalities on EEG following brain irradiation.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.2	 Radiation Syndromes | Content: With the traditional paradigm of the dependence of severity
of response on cell turnover, it was thought for a long time
that the effects in the brain, beyond direct cell killing, were
minimal. However, we now know that ionizing radiation can
otherwise affect the way the brain functions, e.g., through
changes in mediation of substance release.
For doses to the brain >~15 Gy, swelling (edema) of the
brain, cerebral death (breakdown of the nerve impulse path­
2 Basic Concepts of Radiation Biology
64
ways), and generalized shock lead to coma and death. At
such high doses, this happens very quickly, with loss of con­
sciousness followed by death within a few hours or days at
most, before the wider systemic prodromal reaction can start.
At lower doses, the regulatory functions of the central
nervous system (CNS) within the body are affected—either
through vascular injury or through changes in how various
neurotransmitters are released or by affecting the functioning
of the brain itself. After whole-body exposure, the prodromal
symptoms in the case of brain effects can also be detected as
abnormalities on an electroencephalogram (EEG). This
“neurovascular syndrome” tends to manifest around 10 Gy,
and the vascular changes lead to hypertension, dizziness,
confusion, impaired cognitive function, and neurological
deficit later on. For cerebrovascular (and cardiovascular)
effects, the assumed threshold is approximately 0.5 Gy.
It should be noted that multiple-organ dysfunction syn­
drome (MODS) can also occur—this is a clinical syndrome
with the development of progressive and potentially revers­
ible physiological dysfunction in two or more organs or
organ systems induced by a variety of acute insults, like ion­
izing radiation."
"Describe the sequence of events leading to pulmonary failure following acute radiation exposure in the lungs, specifically addressing the roles of inflammation, secondary infections, and fibrosis.","Following acute radiation exposure to the lungs, a complex cascade of events ultimately results in pulmonary failure. Initially, doses ranging from 5-15 Gy cause damage to the epithelial cells lining the alveoli, triggering an immediate inflammatory response characterized by pneumonitis. This inflammation is driven by cell death and the release of intracellular contents, stimulating immune cell recruitment – primarily neutrophils and macrophages – to the site of injury. The resulting oxidative stress and DNA damage further exacerbate this inflammatory process. Critically, this compromised alveolar lining becomes susceptible to secondary infections. Bacterial colonization, often opportunistic pathogens like *Pseudomonas aeruginosa* or *Staphylococcus aureus*, can thrive in the damaged environment, leading to bacterial pneumonia. Concurrent viral infections are also possible. These infections amplify the inflammation and contribute to increased mucus production and impaired mucociliary clearance, further compromising lung function. As the inflammatory response persists over weeks and months, a significant component of the damage is replaced by fibrosis – excessive collagen deposition – directly induced by radiation or indirectly stimulated by chronic inflammation and infection. This fibrosis disrupts alveolar structure, reducing gas exchange efficiency. The process of pulmonary failure then occurs due to this combination of factors: persistent inflammation, secondary infections overwhelming the immune system, and ultimately, irreversible fibrosis leading to severe restriction of lung volume and impaired respiratory mechanics. The timeframe for these events varies depending on the radiation dose but typically manifests between 6 months and 2 years post-exposure. ","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.3	 Systemic and Late Effects | Content: Cell proliferation is generally slower in the lung than in the
hematopoietic or gastrointestinal systems; however, in the
weeks and months following initial exposure, pulmonary
effects may lead to death due to massive respiratory failure.
Damage to the cells lining the alveoli may result in acute
inflammation of the lungs (pneumonitis) at doses in the range
of 5–15 Gy. This leads to pulmonary edema, which can result
in adult respiratory distress syndrome and secondary bacte­
rial and viral pneumonia. Pulmonary failure then occurs due
to fibrosis as a direct result of the radiation itself or as a result
of infection, between around 6 months and 2 years or more
postexposure."
"Describe the progression of local radiation injury (LRI) in the skin, detailing the initial symptoms, subsequent developments, and potential complications.","Local radiation injury (LRI) following exposure to ionizing radiation manifests through a distinct sequence of events beginning with immediate, acute effects. Initially, individuals experience burning sensations, intense itching, and sharp pain accompanied by pronounced primary erythema – a rapid reddening of the skin. This is often followed by edema, representing the accumulation of fluid within the tissues due to the initial damage inflicted by the radiation. The severity of LRI is significantly influenced by the latency period; if edema develops within a few hours after exposure, it dramatically increases the likelihood and seriousness of cutaneous radiation syndrome (ARS). As time passes, typically after several days, hair loss becomes apparent, concurrent with the breakdown of skin structures leading to ulceration and necrosis – ultimately resulting in tissue death. This creates an opportunity for bacterial colonization, frequently initiating sepsis if not promptly addressed. In severe cases, surgical interventions such as skin transplantation or amputation may be necessary. Importantly, even as a late effect, telangiectasia (abnormal dilation of small blood vessels) and secondary erythema can persist for extended periods, continuing to cause pain and discomfort.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.3	 Systemic and Late Effects | Content: Local radiation injury (LRI) may be defined as a setting of
signs and symptoms following local overexposure to ioniz­
ing radiation of the skin. Although sometimes called cutane­
ous radiation syndrome, this term applies better to skin
manifestations in the context of ARS.
Skin injuries caused by the high initial dose occur initially
as burning, itching, and acute pain coupled with very painful
primary erythema (reddening of the skin). This is usually fol­
lowed by edema, accumulation of fluid in the skin as a result
of tissue damage. Cutaneous syndrome is usually character­
ized by a fairly short latency phase, but if edema occurs
within a few hours, this will usually result in very severe
ARS. After a few days, hair loss occurs and the skin starts to
break down leading to ulceration and necrosis—tissue death
occurs. Bacteria may use this as an entrance to the body ulti­
mately followed by sepsis. Skin transplantation or amputa­
tion may be needed. As a late effect, telangiectasia and
secondary erythema (and associated pain) can be very long
lasting."
"Describe the observed tissue reactions and potential systemic complications following radiation exposure during pregnancy, as detailed in the provided text.","Following radiation exposure during pregnancy, a range of deterministic effects can manifest, beginning with observable tissue damage. Initially, hair loss and skin breakdown occur, leading to ulceration and necrosis – characterized by tissue death. This creates an entry point for bacterial colonization, potentially progressing to sepsis. Long-term consequences include telangiectasia (abnormal dilation of small blood vessels) and secondary erythema (redness), often accompanied by pain. Critically, the severity of these effects is dose-dependent; at low doses (around 0.05 Gy), there may be a failure of implantation or minor skeletal abnormalities. Higher doses (0.20 – 0.50 Gy) can lead to impaired fertility, functional disorders of the central nervous system, and serious skeletal abnormalities and growth retardation. Notably, intellectual disability is most strongly associated with irradiation between the 8th and 15th weeks postconception, resulting in a statistically significant increase in risk (approximately 40% per Gy), as evidenced by a reduction in IQ scores. The text highlights that these effects are largely based on animal studies and extrapolations due to limited direct human data. Reference: [MolecularRadiationBiology, Section 2.7.2.3 – Systemic and Late Effects]","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.3	 Systemic and Late Effects | Content: ARS. After a few days, hair loss occurs and the skin starts to
break down leading to ulceration and necrosis—tissue death
occurs. Bacteria may use this as an entrance to the body ulti­
mately followed by sepsis. Skin transplantation or amputa­
tion may be needed. As a late effect, telangiectasia and
secondary erythema (and associated pain) can be very long
lasting.
Fetal Effects
Evidence of the deterministic effects of radiation on the
embryo and fetus is derived almost entirely from animal
experiments. Extrapolation of the results of these studies can
be used to predict the consequences of radiation exposure in
humans.
The effects on the embryo depend on the time of exposure
relative to its development. When the number of cells in the
embryo is small (i.e., in the first 6 days of pregnancy) and the
cells are not yet specialized, damage is frequently seen in ani­
mals as failure of the embryo to implant in the wall of the
uterus. In humans, the only manifestation of this would be a
late or missed menstrual period. However, evidence from
in vitro human embryo research has shown that the survival of
even one cell in the early embryo before implantation can allow
normal development, since all the necessary genetic compo­
nents are present in each cell of the embryo at this stage of
development. The consequences of any of these cells carrying
a point mutation are unknown, but the possibility of stochastic
(genetic, heritable) effects occurring cannot be excluded.
Because of the lack of direct human evidence, it is useful
to look in brief at the animal data. The data taken from ani­
mal experiments suggest that threshold doses in humans for
radiological protection purposes are in the order of 0.05 Gy
for reabsorption of preimplantation embryos; 0.05 Gy for
minor skeletal abnormalities; 0.20 Gy for impaired fertility
in the female; 0.2 Gy for functional disorders of the central
nervous system; and between 0.20 and 0.50 Gy for serious
skeletal abnormalities and growth retardation. Such informa­
tion provides a basis for guidelines to ensure that pregnant
women are adequately protected.
Brain development has been particularly well studied in
animals. It is when neurons (the information-conducting
cells in the brain) are developing and when they are migrat­
ing to their predetermined sites in the cerebral cortex that
irradiation is most damaging. In humans, this corresponds to
between 8 and 25 weeks postconception. Only a very small
amount of human data exists. For example, data were pub­
lished in 1984 from a relatively small study on intellectual
disability in children exposed in utero following the atomic
bombs dropped on Hiroshima and Nagasaki in 1945.
Intellectual disability is associated particularly with irra­
diation between the 8th and 15th weeks following concep­
tion. From these data, it has been estimated that the excess
probability is about 40% per Gy; that is, at a dose of 1 Gy, 40
out of every 100 children exposed would be expected to
A. Baeyens et al.
65
experience severe intellectual disability. This compares with
a background frequency of 0.8%. It is less marked between
the 16th and 25th weeks, and no effect has been seen at other
times of pregnancy.
The uncertainties at each measured dose point are
extremely wide, because of the small numbers. Thus, the
presence or absence of a threshold for developmental effects
remains highly uncertain. However, school performance and
IQ scores have been measured for children irradiated in
utero, with a decrease of approximately 30 points at 1 Gy for
children irradiated in the 8th to 15th week of pregnancy (but
not before or after) [116]."
"Describe the relationship between ionizing radiation exposure and the development of nephropathy, including its progression and potential latency periods.","Nephropathy resulting from ionizing radiation represents a significant systemic and late effect, primarily characterized by reduced renal function. The fundamental mechanism involves direct damage to renal cells – specifically tubular epithelial cells – caused by the ionization of water molecules within the kidney tissue. This ionization generates reactive oxygen species (ROS), leading to oxidative stress, DNA strand breaks, lipid peroxidation, and protein denaturation within these cells. Initially, this manifests as acute tubular necrosis, characterized by inflammation and edema in the nephrons. However, the damage is not immediately reversible; instead, it triggers a cascade of events including fibrosis – the excessive deposition of collagen – ultimately leading to progressive scarring of the kidneys. This scarring disrupts normal kidney function, impairing filtration and excretion capabilities. The progression from initial acute injury to chronic renal failure can take months to years following exposure, highlighting the delayed nature of these effects. Importantly, the latency period for nephropathy is highly variable and dependent on factors such as dose rate, total absorbed dose, individual susceptibility (e.g., genetic predisposition), and concurrent exposure to other toxins or immunosuppressants. While a threshold dose of approximately 0.5 Gray (Gy) has been suggested for cataract development, suggesting a deterministic component, the low-dose nephropathy often exhibits an exceptionally long latency period – potentially decades – before clinical manifestation, emphasizing its stochastic nature. Furthermore, it’s crucial to recognize that this effect is not solely dependent on the initial radiation dose; chronic exposure to lower doses can also contribute to the cumulative damage and subsequent development of renal dysfunction. Reference: [Molecular Radiation Biology], Section 2.7.2.3 – Systemic and Late Effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.3	 Systemic and Late Effects | Content: A variety of additional effects can occur, but of particular
note, ionizing radiation can also cause nephropathy, which is
reduced renal function, leading to progressive scarring kid­
neys and ultimately failure months to years following
exposure.
Other tissue effects may be seen many years postradiation
exposure, for example cataract, which has an assumed
threshold of approximately 0.5 Gy but which for low dose
likely has a very long latency period. This topic is further
considered in Chap. 8."
"Describe the relationship between radiation dose and tissue reactions in healthy individuals, focusing on the concept of thresholds and sigmoid dose-response curves.","Following exposure to ionizing radiation, the probability of observing detectable tissue reactions – specifically, loss of tissue function – varies significantly depending on the tissue type and the administered dose. At lower doses, typically up to a few hundred milligray (mGy), the likelihood of detecting such reactions in healthy tissues is negligible. However, beyond this threshold, which differs between tissues (ranging from thousands of mGy to potentially several thousand), the probability of observing a tissue reaction increases dramatically and rapidly. This increase follows a sigmoid dose-response curve: initially, the probability rises steeply with increasing dose, reflecting a linear relationship between dose and severity of effect. As the dose continues to escalate beyond this initial steep slope, the rate of increase diminishes, indicating that higher doses produce less severe effects relative to the total dose received. Importantly, prolonged exposure to a constant dose results in a lower frequency of effects and less severe symptoms compared to an acute, high-dose exposure. This is because the body has more time to repair damage at lower, sustained radiation levels. The lethal dose (LD50) for approximately 5% of a population exposed to around 2 Gy is cited as being within the range of 3–4 Gy, while without treatment, the LD50 increases significantly to around 6-10 Gy, highlighting the critical role of both dose and individual factors in determining lethal outcomes.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.4	 Dose-Response | Content: The probability of detecting tissue reactions, characterized
by loss of tissue function, in healthy individuals following
exposure to radiation is non-existing in some tissues at doses
of up to a few hundred mGy. In other tissues, the threshold of
detection is above a few thousands of mGy. Above the
threshold, the probability of a tissue reaction increases
steeply in a sigmoid manner, with the severity of effect
increasing linearly with dose. It is important to note that pro­
tracting the dose will result in a lower frequency of effects
and less severe symptoms at a given dose compared with
acute exposure [113, 117].
­
2.8
In an exposed population, there is a chance of death of
approximately 5% of the population (5 persons dying in a
population of 100) exposed to about 2 Gy or of about 50%
without medical treatment (lethal dose, LD50) within the
dose range of 3–4 Gy. Most individuals would be expected to
die at doses between about 6 Gy and 10 Gy, unless they
receive treatment to prevent infection and bleeding. Above
about 10 Gy, death is very likely, even after attempts to stim­
ulate the bone marrow or bone marrow transfusion from a
suitable donor. The risk of death thus also depends on the
number of exposed individuals, and the available expertise
and facilities for appropriate treatment, as discussed further
in Chap. 7."
"The text describes several dose ranges associated with radiation exposure and their corresponding effects on mortality and morbidity. Specifically, what is the LD50 (dose causing 50% death) for bone marrow syndrome when considering a dose range of 1–6 Gy, and what type of treatment is suggested to mitigate this effect?","According to Table 2.8, the LD50 for bone marrow syndrome within the 1–6 Gy dose range is 3–4 Gy. This dose range is considered to result in 50% of an exposed population dying without medical treatment. To mitigate this effect, supportive treatment or, alternatively, matched stem cell transplantation (provided stem cells are available at short notice) are suggested.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.2	 Deterministic Effects or Tissue Reactions | Sub-sub-subsection: 2.7.2.5	 Mortality or Morbidity | Content: in Chap. 7.
2.7.2.5	Mortality or Morbidity
High exposures do not always prove fatal, especially if the
irradiation is nonuniform so that sufficient vital bone marrow
stem cells are spared. Recent advances in immunology and
in the administration of growth factors or cytokines to acci­
dentally irradiated persons may rescue the bone marrow so
that the hematopoietic syndrome might no longer be the lim­
iting lethal condition. Matched stem cell transplantation is an
alternative, provided that such stem cells are available at
short notice. Death would then depend on whether damage to
the lungs or intestine was sufficient to cause fatal pneumoni­
tis or breakdown of the gut wall.
2.9
50
50
­
2.10
Table 2.8 Range of doses associated with death after exposure to low
LET radiations
Whole-body
absorbed dose
Principal effect contributing to
illness or death
Time of death
after exposure
1–6 Gy
Damage to bone marrowa
30–60 days
5–15 Gy
Damage to gastrointestinal tract
and lungsb
10–20 days
>15 Gy
Damage to nervous system and
shock to cardiovascular system
1–5 days
aDose range considered to result in 50% of an exposed population dying
(LD50) without medical treatment is LD50 = 3–4 Gy
bDamage to vasculature and cell membranes, especially at high doses,
is an important factor in causing death
Table 2.9 Parameters for acute mortality (various sources including
ICRP, 2007)
Threshold (Gy)
LD50 (Gy)
1%
Bone marrow syndrome
First aid only
3.0
1.5
Supportive treatment
4.5
2.2
Pneumonitis
10.0
5.5
Gut syndrome
15.0
10.0
Table 2.10 Parameters for acute morbidity (various sources including
ICRP, 2007)
Threshold (Gy)
ED50 (Gy)
1%
Prodromal
Vomiting
2
0.5
Diarrhea
3
0.5
Lung fibrosis
5
2.7
Skin burns
20
8.6
Hypothyroidism
60
2.3
Cataract
3
1.3
Temporary sterility
Males
0.7
0.5
Females
3.5
0.8
2 Basic Concepts of Radiation Biology
66
53
Table 2.11 Observed and excess death from solid cancer and non-­
cancer diseases (adapted from Ozasa et al. 2012)
Colon
dose (Gy)
Number of
subjects
Number of
deaths
Number of
excess cases
Attributable
fraction (%)
<0.005
38,509
4621
2
0
0.005−
29,961
3653
49
1.3
0.1−
5974
789
46
5.8
0.2−
6536
870
109
12.5
0.5−
3424
519
128
24.7
1−
1763
353
123
34.8
2+
624
124
70
56.5
Total
86,611
10,929
527
4.8
2.7.3"
"Explain the concept of stochastic effects in radiation biology, detailing how they differ from deterministic effects and why they are often more difficult to quantify.","Stochastic effects represent a fundamentally different type of biological damage induced by ionizing radiation compared to deterministic effects. Deterministic effects, such as cell ablation or chromosomal breaks at high doses, are directly proportional to the absorbed dose – meaning doubling the dose doubles the probability and severity of the observed effect. These effects have a clear threshold; below that threshold, no observable effect is seen. Conversely, stochastic effects arise from random fluctuations in DNA repair processes following radiation exposure. Even at low doses, where deterministic damage would be minimal, stochastic effects can occur due to the inherent variability in how effectively cells repair damaged genetic material. 

These effects include mutations, chromosomal aberrations (like translocations or aneuploidy), and cancer development. The key characteristic of stochastic effects is that they are not dose-dependent in a predictable manner; their probability increases with dose but without a clear linear relationship. Furthermore, the severity of these effects can vary dramatically between individuals due to differences in genetic predisposition, cellular repair capacity, and other factors. Quantifying stochastic effects is exceptionally challenging because they involve probabilities rather than absolute outcomes. Statistical analysis becomes crucial, often relying on large sample sizes and sophisticated modeling techniques to estimate risk. Because of this inherent randomness and the lack of a clear dose-response relationship, stochastic effects are generally considered more insidious and long-term consequences of radiation exposure compared to the immediate, quantifiable damage caused by deterministic effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.3	 Stochastic Effects | Content: 86,611
10,929
527
4.8
2.7.3
Stochastic Effects"
"Describe the relationship between radiation exposure and cancer development, focusing on the concept of stochastic effects and how risk estimates are determined.","Cancer development is a complex process driven by the accumulation of genetic mutations within cells. While environmental factors like radiation can initiate this process, subsequent neoplastic changes require intricate interactions between host factors and the surrounding environment. It’s crucial to understand that attributing direct causation between radiation exposure and individual cancer cases is often impossible due to these multifaceted influences. Instead, risk estimates are generated by comparing cancer incidence in a population exposed to radiation against a baseline rate – either pre-exposure or within a nonexposed control group. These estimates aren't based on predicting individual outcomes but rather reflect an increased probability of cancer occurrence across the entire population following exposure. Current estimations typically rely on a dose threshold, such as 0.1 Gy, where the overall cancer risk from radiation exposure can be reliably estimated. However, significant uncertainties arise at lower doses due to limitations in statistical power, dosimetric inaccuracies, and confounding variables. These uncertainties become increasingly prominent at low doses, potentially obscuring any discernible effects and leading to inaccurate risk assessments if not properly addressed.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.3	 Stochastic Effects | Sub-sub-subsection: 2.7.3.1	 Cancer | Content: 86,611
10,929
527
4.8
2.7.3
Stochastic Effects
2.7.3.1	Cancer
Cancer develops in tissues through the accumulation of vari­
ous mutations over several conceptual stages [118]. Initiation
of the process can occur following exposure to various envi­
ronmental agents including radiation, but further changes in
neoplastic development require a complex interaction
between various factors in the host and environment. For this
reason, it is not possible to attribute causal relationships
between a particular environmental agent (in this case, radia­
tion exposure) and cancer in individuals [119]. Instead, attri­
bution is made for increased cancer incidence in an exposed
population over a known baseline rate either pre-exposure or
in a nonexposed population. This attribution is expressed
through risk estimates.
120
­
2.11
53
­
­
2.26
A. Baeyens et al.
67
At the moment, 0.1 Gy is the lowest dose for which the
overall cancer risk from radiation exposure can be reliably
estimated. Uncertainties from various factors such as limited
statistical power, dosimetric uncertainties, and confounders
begin to grow increasingly large and mask any possible
effects in lower dose ranges or site-specific risk estimation.
Unless properly addressed, these uncertainties distort the
results and lead to erroneous estimation of risk [119]."
Describe the nature of stochastic effects resulting from ionizing radiation exposure and how they relate to heritable genetic changes. What is the relative significance of these effects compared to deterministic effects like cancer?,"Stochastic effects, arising from ionizing radiation, are fundamentally random events that occur due to the unpredictable interaction of radiation with biological molecules. Unlike deterministic effects – such as radiation-induced cancers where the dose-response relationship is well-defined – stochastic effects lack this predictability. They arise from single, isolated mutations caused by ionization within DNA or other cellular components. These mutations can lead to a range of consequences, including heritable genetic changes. While direct human evidence of significant hereditary effects resulting solely from radiation exposure is limited, the underlying mechanism—inducing mutations similar to those observed in inherited diseases—is clear. The key distinction lies in the randomness; a mutation might not manifest immediately or at all, and its impact can vary greatly between individuals. Compared to deterministic effects like cancer, heritable stochastic effects are considered a minor component of the overall radiation-related risk for an individual or population. Cancer is a more predictable outcome directly linked to dose, whereas stochastic mutations have a lower probability of occurrence per unit of radiation exposure but possess the potential for long-term, unpredictable consequences across generations.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.7	 Deterministic and Stochastic Effects | Sub-subsection: 2.7.3	 Stochastic Effects | Sub-sub-subsection: 2.7.3.2	 Heritable Effects | Content: Together with radiation-induced cancers, the hereditary effects
of radiation are stochastic effects. By comparison with cancer,
induced hereditary diseases are considered to be a minor com­
ponent of the total stochastic disease risk due to radiation
exposure of an individual or of the population generally.
There is little direct human evidence of hereditary effects;
however, it is clear that ionizing radiation can cause muta­
tions of the types seen in hereditary effects.
Multifactorial diseases are an additional class of effect,
which combine heritable aspects in addition to influence
from environmental factors. These include congenital abnor­
malities present at birth or chronic conditions, which appear
later in life (Box 2.24).
2.8"
What distinguishes between an acute and chronic low dose of irradiation in radiation biology?,"In the context of low-dose radiation effects, a key distinction lies in the magnitude and duration of exposure. An ‘acute low dose’ is defined as less than 0.1 Gray (Gy), which translates to approximately 100 milligray (mGy). Conversely, a ‘chronic low dose’ is characterized by an average dose rate of less than 6 mGy per hour (or its equivalent in Sieverts – Sv). This difference primarily reflects the varying cumulative radiation exposure over time. Acute low doses represent a single, relatively brief event, while chronic low doses involve prolonged exposure, significantly impacting the biological response and leading to markedly different outcomes due to the accumulation of damage at the cellular level.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.1	 What Is a “Low Dose”? | Content: A low dose of irradiation can be defined as acute and chronic.
An acute low dose is defined as less than 0.1 Gy (100 mGy),
while a chronic low dose is defined as less than 6 mGy/h (or
Sv equivalent). In this low-dose range, there are a variety of
phenomena that dominate the dose-response relationship and
lead to nonlinear and unpredictable outcomes."
"Describe the historical use of ionizing radiation for therapeutic purposes, citing specific examples and highlighting the shift in understanding regarding its effects compared to high-dose exposures.","Ionizing radiation has a surprisingly long history of therapeutic application. Ancient civilizations like Herodotus and Hippocrates documented the perceived healing properties of what we now recognize as radon springs, suggesting an early awareness of its potential benefits. This practice continued for centuries, with radon treatment gaining acceptance in mainstream medicine, particularly in Europe, starting approximately four decades ago. The rationale behind this use stemmed from observations that low doses of ionizing radiation could be beneficial – analogous to the effects seen with physical exercise or immunization – while high doses were demonstrably harmful. More recently, research has moved beyond a purely DNA-centric model of radiation damage, recognizing a ‘systemic’ view incorporating multi-level protection and nonlinear adaptive responses. This shift acknowledges that low-dose radiation can trigger biological defense mechanisms, leading to protective effects rather than solely relying on the immediate disruption of genetic material. The historical use demonstrates an initial understanding of dose-response relationships, paving the way for more sophisticated investigations into low-dose radiation biology.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.2	 Targeted Effects | Content: It is quite common that while a high dose/amount/rate of
some medication or procedure is detrimental, a low dose is
beneficial. Classical well-known examples include physical
exercise (as opposed to forced labor), immunization (as
opposed to virulent infection), and—directly related to bio­
logically active radiation—controlled sun tanning (as opposed
to sunburns and skin cancer caused by overexposure).
Therefore, low-dose radiation effects may well be different
from the effects of high doses. Actually, people have been
using ionizing radiation for centuries: already, Herodotus and
Hippocrates described healing properties of what we now
know as radon springs. Radon treatment is considered to be a
legitimate tool by mainstream medicine in Europe, especially
for treating arthritis and other inflammatory diseases [122].
During the past four decades ­approximately, there has been a
growing body of biological evidence regarding low-dose
radiation effects. This evidence is concurrent with the shift in
radiobiology from a DNA-centric view on radiation damage
to a more systemic view that incorporates multi-level protec­
tion and nonlinear systems—adaptive response [123].
A. Baeyens et al.
69"
"Describe the concept of adaptive responses in cellular biology as it relates to exposure to ionizing radiation at low doses. What mechanisms might explain why these responses occur, and how do they contrast with traditional understandings of radiation damage?","The observation that low-dose ionizing radiation can induce beneficial effects – termed adaptive responses – represents a significant departure from the established linear hypothesis of radiation risk. Traditionally, it was assumed that any exposure to ionizing radiation resulted in proportional damage; i.e., doubling the dose doubled the risk. However, accumulating evidence suggests cells possess an inherent capacity to repair and modify their metabolism in response to even minimal radiation exposure. These adaptive responses are not simply a consequence of damage reduction but rather represent a genuine shift in cellular behavior. 

Several mechanisms likely contribute to this phenomenon. Firstly, low doses can trigger DNA repair pathways with increased efficiency, effectively mitigating the initial damage before it becomes significant. Secondly, cells may activate antioxidant defense systems – such as superoxide dismutase and catalase – at higher levels to combat oxidative stress generated by radiation. Thirdly, metabolic adaptations are observed, including alterations in glucose metabolism and lipid synthesis, potentially providing cells with resources needed for repair or enhanced resilience. Critically, these adaptive responses often target pre-existing cellular stresses or vulnerabilities that were not directly caused by the radiation itself [126]. This means that the cell is responding to a perceived threat, even if that threat is largely unrelated to ionizing radiation.  The beneficial effects observed in experimental and epidemiological studies suggest that these adaptive mechanisms can actually enhance survival and potentially slow down age-related decline, contrasting sharply with the linear model which predicts a continuous increase in risk with dose.

Reference: [Molecular Radiation Biology], Section 2.8.2.1 – Adaptive Response","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.2	 Targeted Effects | Sub-sub-subsection: 2.8.2.1	 Adaptive Response | Content: There is emerging evidence that low doses induce cellular and
intercellular changes, which can lead to adaptive metabolic
alterations. Adaptive responses against accumulation of dam­
age—also of non-radiogenic origin—were also discovered
[124]. Many studies demonstrated that radiation effects are
far from linear [125]. Moreover, experimental, epidemiologi­
cal, and ecological studies have shown that low doses of ion­
izing radiation can be beneficial to health [126, 127]."
"Describe the concept of hormesis in biological systems, specifically referencing its initial observation and subsequent application beyond chemical toxicity.","Hormesis is a biphasic dose-response phenomenon where exposure to low doses of an agent produces beneficial effects, while higher doses are detrimental. The concept originated with Hugo Schulz’s 1884 observation that low doses of toxic substances like mercury and formaldehyde enhanced the vitality of yeast cells. John Ehrlich subsequently formalized the term ‘hormesis’ in 1942, initially within the context of chemical toxicity, but it has since been broadly applied to any situation exhibiting this pattern. This includes physical exercise (as opposed to strenuous labor), as well as various stressors such as heat and oxidative stress, specific food components like micronutrients, practices like intermittent fasting and calorie restriction, and notably, radiation hormesis. The key characteristic is the ‘inverted U’ shape of the dose-response curve – low doses stimulate a protective or adaptive response, while increasing the dose leads to toxicity.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.2	 Targeted Effects | Sub-sub-subsection: 2.8.2.2	 Hormesis | Content: Beneficial low-dose effects of an agent that is harmful in
high doses are called hormesis. Back in 1884, Hugo Schulz
observed that low doses of many toxic agents, mercury and
formaldehyde for example, enhanced the vitality of yeast
cells. The term “hormesis” was introduced by John Ehrlich
(also in the context of chemical toxicity) in 1942 [128]. The
term “hormesis” is applied now to any kind of biphasic dose-­
response, i.e., when low doses of some agent are beneficial
while higher doses are detrimental [128]. Physical exercise
(as opposed to hard labor) is a typical example of hormetic
response. According to the present knowledge, “horme­
tins”—agents inducing hormesis—include but are not lim­
ited to heat and oxidative stress, various food components,
micronutrients, intermittent fasting, calorie restriction, etc.
[129]. Radiation hormesis is the most thoroughly investi­
gated among all hormesis-like phenomena.
Speaking about radiation hormesis, we should point out
two somewhat different uses of the terms “hormesis” and
“low dose.” Since radiation carcinogenesis is often consid­
ered as the single most important health hazard of ionizing
radiation, radiation hormesis is usually understood in the nar­
row sense that low radiation doses may suppress cancer. In
this narrow sense, curing arthritis or pneumonia is not viewed
as a hormetic effect. Accordingly, there are two quite different
meanings of the term “low dose.” In the context of radiation
protection and many fields of radiobiology, “low dose” is
understood to be 100 mGy or less as defined above. However,
in the field of radiation therapy, the daily dose fraction is typi­
cally 2000 mGy and 6 weeks of therapy amounts to a total
dose of 60,000 mGy—hence a single 1000 mGy dose to treat
pneumonia may be regarded as a low dose [130]."
"Describe the concepts of low-dose radiation effects, including hypersensitivity, adaptive response, and hormesis, as they relate to biological systems.","Low-dose radiation exposure can elicit a range of biological responses distinct from those observed at higher doses. A key phenomenon is low-dose hypersensitivity, where organisms exhibit an increased vulnerability to subsequent radiation damage below 0.5 Gy. This heightened sensitivity isn't simply a matter of greater DNA damage; it’s often linked to alterations in cellular repair mechanisms and oxidative stress pathways. Simultaneously, a significant effect is the adaptive response – a ‘protection’ conferred by a low initial dose against the detrimental consequences of a higher subsequent dose. This protective action appears to involve epigenetic modifications, such as changes in chromatin structure or DNA methylation patterns, that prime cells for more efficient repair processes. These adaptations can alter gene expression and enhance cellular resilience. Closely related is the concept of hormesis, which describes beneficial effects observed after exposure to low doses of radiation compared to control groups receiving no radiation. This suggests a threshold effect; very low doses may stimulate cellular defense mechanisms, leading to improved survival or function. The precise mechanisms underlying hormesis are complex and still under investigation but likely involve activation of stress response pathways and enhanced DNA repair capabilities. It’s important to note that the magnitude and specific effects of these responses can vary considerably depending on the organism, cell type, dose level, and duration of exposure.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.2	 Targeted Effects | Sub-sub-subsection: 2.8.2.3	 HRS/IRR | Content: ­
2.28
131
­
132133
3
2.25
Box 2.25 Low Dose Effects of Radiation
Dominant mechanisms below 100 mGy
Direct effects:
Low-dose hypersensitivity: Increased sensitivity
to low-dose radiation which is not apparent at doses
above 0.5 Gy.
Adaptive response: The ability of a low first dose
of radiation to “protect” against the effects of a subse­
quent high dose.
Hormesis: Beneficial effects seen after low-dose
exposure compared to unirradiated controls."
"Low-dose radiation exposure can induce a variety of non-targeted effects in cells, often involving DNA damage responses and subsequent cellular alterations. Describe the key mechanisms by which low doses of ionizing radiation trigger these non-targeted effects, including the roles of oxidative stress, bystander effects, and chromatin modifications.","Low-dose radiation exposure initiates a cascade of events leading to non-targeted effects in cells, meaning damage occurs outside the immediate vicinity of the initial radiation event. Several interconnected mechanisms contribute to this phenomenon. Initially, ionizing radiation directly interacts with DNA, creating single-strand breaks (SSBs) and potentially double-strand breaks (DSBs). However, the most significant contribution to non-targeted effects stems from secondary processes. 

**Oxidative Stress:** Radiation generates reactive oxygen species (ROS), such as superoxide radicals and hydrogen peroxide, through radiolysis of water molecules. These ROS overwhelm cellular antioxidant defenses, leading to oxidative stress. This oxidative damage extends beyond the directly irradiated DNA, impacting proteins, lipids, and ultimately, chromatin structure.

**Bystander Effects:**  This is a crucial mechanism. Radiation-induced damage in one cell can trigger damage in neighboring cells through several pathways. These include: (1) ROS diffusion from damaged cells; (2) transfer of radiation energy via collisions between irradiated and unexposed cells; and (3) activation of cellular signaling cascades that sensitize adjacent cells to further DNA damage.  The extent of bystander effects increases with dose, but even low doses can elicit significant responses.

**Chromatin Modifications:** Low-dose radiation induces alterations in chromatin structure, primarily through histone modifications. Radiation promotes changes in histone acetylation and methylation patterns, impacting gene expression. These modifications can lead to the activation of DNA repair pathways, but they can also contribute to genomic instability and potentially promote tumorigenesis over time. Specifically, radiation can induce a shift towards H3K4me3 (associated with active transcription) and H3K9me3 (associated with repression), though the precise balance is complex and dose-dependent.

Furthermore, low-dose radiation can activate checkpoint pathways, such as ATM and ATR, which ultimately lead to cell cycle arrest. While initially a protective mechanism, prolonged activation of these checkpoints can contribute to cellular senescence or apoptosis.

Reference: [Molecular Radiation Biology], Section 2.8.3 – Low-Dose Radiation Effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Content: t
e
­
­
2.25
2.25
2.28"
"Describe the ‘bystander effect’ in radiation biology, including its definition, mechanisms of action, and potential consequences for assessing radiation risk.","The bystander effect, as defined by UNSCEAR, refers to a radiobiological phenomenon where biological alterations are induced in neighboring, unirradiated cells due to exposure of nearby irradiated cells. This isn’t a direct dose response; instead, it's a communicative effect primarily occurring within a few millimeters or cellular diameters around the primary radiation site. The mechanism involves the secretion of soluble factors by irradiated cells – such as cytokines and chemokines – which trigger signaling pathways in neighboring cells via gap junctions or inflammatory cell networks. This initiates a cascade of events leading to similar radiation-induced effects, including DNA damage, mutations, chromosomal aberrations, senescence, apoptosis, genomic instability, micronucleation, and even oncogenic transformations, in the bystander cells. Importantly, the intensity of this response isn’t proportional to the dose received by the initially irradiated cell; it can occur at low doses and is tissue-dependent, influenced by factors like radiation type (LET, dose rate) and the specific microenvironment. The amplification process highlights a potential overestimation of radiation risk if only direct damage from the primary irradiation is considered, as these secondary effects contribute to overall cellular harm. Understanding the precise mechanisms driving this effect remains an area of ongoing research due to its complexity and involvement of multiple cell types and signaling pathways [134–139].

Reference: MolecularRadiationBiology, Section 2.8.3.1 – Non-targeted Effects.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.1	 Bystander Effects | Content: The United Nations Scientific Committee on the Effects of
Atomic Radiation (UNSCEAR) defines bystander effect as a
radiobiological effect that is transmitted from irradiated cells
to neighboring unirradiated cells, generating biological alter­
ations in the receiver cells that can influence the radiation-­
associated cancer risk [134]. As a communicative effect,
bystander effects occur mainly at the primary site over a few
millimeters or cellular diameters. This effect is mediated by
the secretion of soluble factors or by signaling through gap
junctions as well as through networks involving inflamma­
tory cells of the microenvironment [135].
The term radiation-induced bystander effect (RIBE) is
described as the ability of irradiated cells to transport manifes­
tations of damage to other cells which were not directly tar­
geted by irradiation. An irradiated cell sends out signals and
induces response in nonirradiated neighboring cells. The
intensity of the bystander response in nonirradiated cells is not
necessarily proportional to the dose delivered to the irradiated
cells and can occur even at low doses. The RIBE is highly
dependent on the cell tissues concerned and the irradiation
sources (such as radiation doses, LET, dose rates) and can
influence the nature of the bystander factors secreted by irradi­
ated cells, the intensity of the bystander response in nonirradi­
ated cells, and the timing of the events in the bystander
signaling [136]. This amplification can cause similar radia­
tion-induced effects in cells not directly exposed to radiation
and exhibit the heritable changes that include cellular damage,
DNA damage, mutations, chromosomal aberrations, chromo­
somal instability, senescence, apoptosis, genomic instability,
micronucleation, oncogenic transformations, etc. [137–139].
Some RIBEs can have deleterious effects, which involve
the type of cell inducing the bystander signal after irradiation
and the type of cells receiving these signals. Such effects can
be determined by intercellular communication and level of
amplification of original consequences of the event.
Knowledge of the mechanism(s) by which non-targeted
bystander effects are activated is still in its infancy and not
well understood; however, it is believed that multiple path­
ways are involved in this phenomenon and also different cell
types respond differently to bystander signaling.
­
­
2.29
2.30
­
140
141142
143
144"
Describe the concept of ‘abscopal effects’ in radiation biology and explain how they differ from traditional tumor-specific abscopal effects.,"Abscopal effects represent a fascinating phenomenon in radiation biology where exposure to ionizing radiation induces damage in distant, non-irradiated tissues – often referred to as ‘out-of-field’ effects. This occurs because normal tissue cells, upon irradiation and subsequent cell death (typically apoptosis), release systemic signals that trigger similar cellular responses in unaffected organs. These signals can originate from factors like the blood or the endocrine system, and importantly, involve immune activation, particularly through macrophage and neutrophil involvement. The key distinction lies in the target: traditional abscopal effects on tumors focus solely on stimulating antitumor immune responses within the irradiated tumor itself and any directly exposed metastases. Conversely, abscopal effects on normal tissues extend this systemic immune response to completely unrelated organs, demonstrating a broader, bystander-mediated damage mechanism. This highlights how radiation can elicit complex, interconnected biological reactions beyond the immediate site of exposure.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.2	 Abscopal Effects on Normal Tissues | Content: types respond differently to bystander signaling.
­
­
2.29
2.30
­
140
141142
143
144
2.8.3.2	Abscopal Effects on Normal Tissues
The term abscopal or out-of-field effect is an in vivo phe­
nomenon in normal tissue that describes the occurrence of
radiation-like damage in organs that have never been irri­
tated. In other words, abscopal effects are bystander effects
in vivo. Abscopal effects are known to occur after exposure
to high or low doses of ionizing radiation in vivo and are
often observed after high doses of targeted partial-body
radiotherapy [145, 146]. The mediation of the effect is
attributed to systemic factors such as the blood or the endo­
crine system [136, 147–149]. The immune system is also
thought to play an important role. Experiments show that
high levels of macrophage activation and neutrophil infil­
A. Baeyens et al.
71
tration in mice are a consequence of radiation-triggered
recognition and elimination of apoptotic cells [150]. The
abscopal effect on normal tissue differs conceptually from
the abscopal effect on tumors, which is often described in
radiation oncology. The abscopal effect on tumors refers
exclusively to systemic antitumor immune responses
induced by radiotherapy alone or in combination with
immunotherapy to only part of the tumor load. These anti­
tumor immune responses are capable of completely elimi­
nating primary tumors and unirradiated metastases in
patients. For more information about the abscopal effect on
tumors, see Chap. 5."
"Describe the concept of clastogenic factors in radiation biology, specifically focusing on their mechanism of action and examples of situations where they are observed.","Clastogenic factors represent substances or exposures that induce chromosomal damage within cells following irradiation. These factors primarily operate by disrupting the structural integrity of DNA itself, leading to breaks and rearrangements within chromosomes. The core mechanism involves the direct interaction of ionizing radiation with cellular components, particularly DNA bases, resulting in single-strand breaks (SSBs) and double-strand breaks (DSBs). Repair mechanisms, such as homologous recombination and non-homologous end joining, attempt to mend these breaks; however, these processes are often error-prone, leading to insertions, deletions, translocations, and other chromosomal aberrations. 

Examples of clastogenic factors include therapeutic radiation used in cancer treatment (PUVA therapy), exposure following the Chernobyl accident, and radiation exposures experienced by A-bomb survivors. These diverse scenarios demonstrate that the severity and type of chromosomal damage can vary depending on the dose, duration of exposure, and individual susceptibility. Furthermore, some substances, like those utilized in PUVA treatment for psoriasis, act as clastogens by enhancing the sensitivity of cells to ionizing radiation, thereby amplifying the resulting DNA damage.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.3	 Clastogenic Factors | Content: ­
151
2.12
­
152
2 Basic Concepts of Radiation Biology
72
Table 2.12 Clastogenic factors (irradiation)
Clastogenic factors (irradiation)
Therapeutic and accidental
exposure
(Goh and Summer, 1968; Hollowell and
Littlefield, 1968)
Exposure at Chernobyl
(Emerit et al., 1994; Emerit et al., 1997)
A-bomb survivors
(Pant and Kamada, 1977)
PUVA treatment for
psoriasis
(Alaoui-Youssefi et al., 1994; Emerit
et al., 2011)"
"Describe the concept of clastogenicity in radiation biology, focusing on how it differs from other types of radiation-induced DNA damage and what cellular mechanisms contribute to its observed effects.","Clastogenic factors are substances or forms of ionizing radiation that primarily induce double-strand breaks (DSBs) within DNA. Unlike single-strand breaks, which can often be repaired relatively efficiently through homologous recombination or non-homologous end joining (NHEJ), DSBs represent a significantly more severe form of damage because their repair is inherently less precise and more prone to errors. These factors operate by directly interacting with the DNA molecule, disrupting the covalent bonds holding the two complementary strands together. The mechanism isn't simply about creating breaks; it’s about generating DSBs that are particularly difficult for cellular repair pathways to handle correctly.

Several mechanisms contribute to clastogenicity. High-LET (linear energy transfer) radiation, such as alpha particles and heavy ions, delivers a large dose of energy in a short period, leading to highly localized DNA damage. Furthermore, the fragmentation of water molecules by these radiations produces free radicals that can directly attack DNA bases and cause strand breaks. The efficiency of DSB formation is also influenced by factors like ionization density – higher densities lead to more frequent interactions with DNA.  Cellular responses include activation of checkpoint pathways (like ATM and ATR) attempting to halt cell cycle progression while repair mechanisms are engaged, but the inherent difficulty in accurately repairing DSBs often results in chromosomal rearrangements including translocations, deletions, and aneuploidy. The resulting genomic instability can drive tumorigenesis or contribute to other radiation-induced pathologies.

It’s important to distinguish clastogenicity from other types of DNA damage like base modifications (e.g., oxidative lesions) which primarily cause single-strand breaks and are generally more readily repaired, or fragmentation caused by low-LET radiation which typically generates multiple smaller fragments rather than complete DSBs.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.3	 Clastogenic Factors | Content: ­
­
­
2
­
­
2.31
153"
"Describe the mechanisms through which low-dose radiation, specifically via TNF-alpha and ITP stimulation, can induce DNA damage within cells, detailing the roles of superoxide production, 4-hydroxynonenal, and DNA polymerase inhibition.","Low-dose ionizing radiation initiates a cascade of events leading to DNA damage primarily through non-targeted effects. Initially, stimuli like TNF-alpha and inosine triphosphate (ITP) trigger increased production of reactive oxygen species (ROS), notably superoxide, by immune cells such as monocytes and neutrophils. This elevated superoxide contributes to oxidative stress within the cell. Simultaneously, radiation promotes lipid peroxidation, resulting in the formation of 4-hydroxynonenal (4-HNE). While 4-HNE initially inhibits superoxide production, its primary impact lies in its ability to chemically modify proteins and nucleic acids. Critically, 4-HNE can irreversibly inactivate DNA polymerases by reacting with their sulfhydryl groups – a process that disrupts enzyme function. This inactivation directly impairs the cell's capacity for DNA repair and replication, leading to genomic instability. The resulting damage is often most pronounced during the late S phase or G2 phase of the cell cycle when chromosomes have duplicated, exacerbating the effects as these newly synthesized strands are vulnerable. These chromosome-damaging events, detectable through cytogenetic analysis, represent a significant component of radiation's genotoxic potential.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.3	 Clastogenic Factors | Content: TNF-𝛼 and inosine triphosphate (ITP) stimulate the pro­
duction of superoxide by monocytes and neutrophils. The
lipid peroxidation product, 4-hydroxynonenal, inhibits
superoxide production; however, it has the capacity to
decrease the activity of DNA polymerases by inactivating
their sulfhydryl groups leading to genotoxic effects.
Formation of CF often damages/changes the chromatid
structure; which indicates that they are not immediate and
occur late in the S phase or in the G2 phase of cell cycle
where they have duplicated their chromatids. These chro­
mosome-damaging effects can be detected by classical
cytogenetic techniques.
Ionizing irradiation is known to have mutagenic and car­
cinogenic potential for the exposed host as it induces chro­
mosomal aberrations in directly exposed cells."
"Describe the concept of genomic instability (GI) following ionizing radiation exposure and explain how it manifests in both irradiated and unirradiated cells, including the mechanisms contributing to its persistence.","Genomic instability (GI) represents a fundamental characteristic observed in many cancer cells and is significantly induced by ionizing radiation. It’s characterized by an increased frequency of various genomic alterations, notably base pair mutations, microsatellite instability (MSI), and chromosome instability (CIN). Following irradiation, the initial exposure triggers a cascade of cellular events leading to genome destabilization not only within directly irradiated cells but also in neighboring, ‘bystander’ cells. This phenomenon, termed radiation-induced genomic instability (RIGI), results in a delayed stochastic appearance of de novo chromosomal aberrations and gene mutations in the progeny of irradiated cells, often accompanied by reproductive cell death. Importantly, these effects are persistent across multiple generations of survivors after irradiation. The manifestation of GI is linked to several contributing factors; firstly, direct radiation damage can initiate DNA breaks and activate cellular communication pathways. Secondly, indirect mechanisms involving reactive intermediates contribute over time. Finally, delayed responses such as the reactivation of p53 and delayed induction of various phenotypes play a crucial role in sustaining genomic instability.  The persistence of GI is due to the continued activation of DNA repair pathways that are overwhelmed by the radiation damage, leading to an accumulation of mutations and chromosomal aberrations. Furthermore, alterations in cell cycle checkpoints can contribute to mitotic errors and CIN. Understanding RIGI provides critical insights into the molecular basis of radiation-induced carcinogenesis.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.4	 Genomic Instability | Content: Genomic instability (GI) is a hallmark of cancer cells,
which includes variations of increased frequencies of base
pair mutation, microsatellite instability (MSI), and chro­
mosome instability (CIN) [154]. GI is a complex multiple-
A. Baeyens et al.
73
gene event marked during the development of some but not
all cancers and also induced effectively by ionizing radia­
tion. Radiation can provoke cellular communications elicit­
ing a cascade of cellular events, which results in the
destabilized genome in irradiated as well as unirradiated
(bystander) cells. Radiation-­induced genomic instability
(RIGI) is observed in the progeny of irradiated cells as a
delayed and elevated stochastic appearance of de novo
chromosomal aberrations, gene mutations, and reproduc­
tive cell death [137, 155]. The effects of instability occur at
a stable rate and are persistent in the postirradiation survi­
vors for many generations.
Radiation-induced bystander effects are also involved in
RIGI [156] due to contribution of indirect (by stimulating the
reactive intermediates over many generations) and delayed
effects (delayed DNA breakage, delayed reactivation of p53,
delayed induction of various phenotypes) to cellular out­
comes after radiation exposure. More detailed molecular
studies on RIGI can provide deep insights into radiation-­
induced carcinogenesis (Box 2.26).
Box 2.26 Genomic Instability
•	Genomic instability (GI), a characteristic of most
cancers, is a complex multigene event and is often
expressed by the appearance of chromosome aber­
rations many generations later.
•	Microsatellite instability or chromosomal instabil­
ity due to mutations in DNA repair genes or mitotic
checkpoint genes is the underlying basis for GI in
hereditary cancers.
•	In sporadic (non-hereditary) cancers, GI occurs at
least at the early stages of cancer development.
2 Basic Concepts of Radiation Biology
74"
"Following low-dose radiation exposure, what are some observed consequences related to genomic instability that can be transmitted across multiple generations of cells, and how do these effects differ from typical gene mutations?","After exposure to ionizing radiation (IR), a significant phenomenon known as radiation-induced genomic instability (RIGI) can manifest through delayed phenotypic expression, often spanning several generations. This isn't simply an increase in the frequency of conventional gene mutations; instead, it involves more complex and persistent alterations within the genome. Specifically, IR can induce chromosomal aberrations – both chromosome-type and chromatid-type – that are transmitted to subsequent cell lineages. These non-targeted effects (NCCAs) arise from sparse or dense LET radiation and result in significant genome heterogeneity and complexity within clonal descendants or stem cells. Critically, this instability isn’t limited to immediate mutations; it can lead to delayed cell death, chromosomal instability, mutagenesis, increased rates of spontaneous mutation persisting for many generations, the formation of giant cells and micronuclei, senescence-like growth arrest, apoptosis, or necrosis in progeny cells. Furthermore, irradiated cells may exhibit a heightened frequency of even featureless minisatellite mutations, signifying that certain mutational events appear later in the cell’s lineage after irradiation. This contrasts with conventional gene mutations which typically induce delayed reproductive death or lethal mutations and do not consistently generate these complex, multi-generational genomic alterations. Reference: MolecularRadiationBiology, Section 2.8.3.4 – Genomic Instability","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.4	 Genomic Instability | Content: Biological effects of IR-induced GI are transmitted over sev­
eral generations after irradiation via the progeny of surviving
cells with delayed phenotypic expression, but not uniformly.
Delayed manifestations of induced GI include delayed cell
death, chromosomal instability, and mutagenesis.
The incidence of GI is significantly higher than that of
conventional gene mutation, which eventually induces
delayed reproductive death or delayed lethal mutations and
increases the frequency of giant cells, micronuclei,
senescence-­like growth arrest, apoptosis, or necrosis in the
progeny of surviving cells [157], suggesting that one of the
potential initiators of RIGI is delayed cell death.
Exposure to sparse LET or dense LET radiation produces
non-clonal chromosome aberrations (NCCAs), a highly sig­
nificant feature for delayed chromosomal instability, genome
heterogeneity, and complexity, in clonal descendants or stem
cells that result in transmission of chromosome-type and
chromatid-type aberrations to their progeny after irradiation
[158].
Radiation may induce a type of GI in cells which results
in an increased rate of spontaneous mutation that persists for
many generations of cells. Clonal populations of cells sur­
viving radiation exposure indicate such instability in a frac­
tion of irradiated cells, which can persist longer over
generations. Subpopulation of genetically unstable cells may
arise from irradiated cells with a high frequency of even fea­
tureless minisatellite mutations [159], signifying the delayed
appearance of certain mutational events in the progeny of
irradiated cells."
"Describe how low-dose radiation, specifically ionizing radiation like X-rays, can induce genomic instability within a cell and what cellular mechanisms are involved in this process.","Low-dose ionizing radiation, such as X-rays or infrared radiation, initiates genomic instability through the induction of DNA strand breaks – primarily double-strand breaks (DSBs) – which represent a highly lethal lesion. These DSBs trigger complex DNA damage response (DDR) signaling cascades. Initially, activation occurs within DNA damage-sensing and early transduction pathways, leading to cell cycle arrest, preventing replication with damaged DNA. However, the radiation’s effect extends beyond simple repair; it can convert initial DSB sites into unforeseen structures. This conversion involves the reorganization of chromatin domains and a disruption of the genome structure, ultimately resulting in mutation induction. Specifically, genomic instability is fueled by the generation of gross chromosomal rearrangements – including multi-intrachromosomal aberrations or large deletions – alongside persistent DNA damage signatures. These structural alterations are particularly impactful when they occur near telomeres or interstitial regions of chromosomes; disruptions at telomeres can lead to telomere instability and chromosomal aberrations involving telomeric sequences, while those in interstitial regions may result in the loss of less genetic material, but also potentially cause more destructive chromosome fragmentation. The consequences of genomic instability extend across multiple generations, leading to diverse outcomes depending on the specific type and extent of damage observed within the cell’s progeny.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.4	 Genomic Instability | Content: DNA-damaging agents (such as X-rays, IR, restriction endo­
nuclease Hinfl), radiomimetic drugs (bleomycin and neocar­
zinostatin), DNA DSBs, and DNA damage at the site of their
decay are considered as effective initiators of RIGI. In some
cases, sufficiently small or powerful environmental cues can
directly exert their impact upon a cell’s DNA, which is a
critical target for RIGI. DNA strand breaks, the most lethal
lesions induced by IR, activate a number of cellular DDR
signaling cascades such as the activation of DNA damage-­
sensing and early transduction pathways, cell cycle arrest,
and DNA repair. To a certain degree, it could convert the
initial sites of DNA DSBs to unforeseen structures and
A. Baeyens et al.
75
Table 2.13 PUCR effects
PUCRs near the telomeres
PUCRs in the interstitial regions
Could cause telomere instability,
chromosomal aberrations
involving telomeric sequences
Interstitial telomeric sequences
are potentially more unstable than
non-telomeric sequences
Less detrimental to the cell, as it
would result in loss of less
genetic material
More destructive as it may lose
chromosome fragments or large
deletions
Lead to genomic instability
across many generations
Lead to different consequences in
the long-term progeny
results in reorganized chromatin domains and a disrupted
genome structure, evident as a mutation induction.
Generation of gross chromosomal rearrangements, or multi­
ple intrachromosomal aberrations, or DNA damage signa­
tures is accountable for the initiation of GI."
"Following radiation exposure, what mechanisms contribute to the transmission of genomic instability (RIGI) across multiple generations of cells, and how does this relate to DNA damage persistence?","After irradiation, genomic instability (RIGI) can be perpetuated through several interconnected processes that extend beyond the immediate effects of DNA double-strand breaks. A key mechanism involves the accumulation and transmission of unrepaired DNA damage, primarily manifested as ‘potentially unstable chromosome regions’ (PUCRs). These PUCRs arise from radiation-induced DNA double-strand breaks and subsequent repair attempts within the nucleus, leading to alterations in chromatin architecture. The persistence of these PUCRs is facilitated by several factors including reactive oxygen species (ROS), intercellular communication via gap junctions between cells, a population of unstable dying cells, and secreted signaling molecules released from unbalanced or damaged cells. Importantly, this transmission isn’t reliant on p53 status; however, genetic predispositions influence the expression of the unstable phenotype. Specifically, PUCRs can remain stable for extended periods through a bridge-breakage-fusion (BBF) cycle, creating regions vulnerable to further DNA damage and delayed cell death. This prolonged instability contributes to the inheritance of genomic instability across generations, demonstrating that the ‘memory’ of unrepaired DNA damage can be maintained within cellular populations.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.4	 Genomic Instability | Content: RIGI is transmitted through many generations after irradia­
tion, suggesting that the memory of unrepaired DNA dam­
age can be perpetuated over time by a number of processes
involving ROS, communication through cell-to-cell gap
junction, unstable dying cell population, and/or secreted fac­
tors from unbalanced cells. RIGI appears to be independent
of the p53 status of the irradiated cells, but a number of
genetic factors influence the expression of the unstable
phenotype.
Radiation-induced DNA DSBs could cause nonlethal,
“potentially unstable chromosome regions (PUCR)” and
altered chromatin architecture within the nucleus through
DNA repair, which are transmissible through the progeny
of surviving cells for many generations after irradiation
[160]. Indeed, though PUCRs are potentially unstable, they
are capable of persisting for prolonged periods through
bridge-­breakage-­fusion (BBF) cycle [161] and thus could
be the regions susceptible for causing delayed DNA break­
ages [162], inducing telomere instability and delayed cell
death.
­
­
­
2.13"
"Following low-dose ionizing radiation exposure, what mechanisms contribute to genomic instability and how does this relate to the activation of the p53 pathway?","Low-dose ionizing radiation can induce delayed DNA double-strand breaks (DSBs) within cells, leading to genomic instability. This instability is primarily manifested through a series of delayed phenotypes observed after initial survival. The repair of these DSBs relies heavily on the activation of the tumor suppressor protein p53. Specifically, surviving irradiated cells initiate a cascade involving ATM kinase, which subsequently phosphorylates Chk2/hCds1 and other nuclear proteins. Activated p53 then transactivates numerous downstream gene products, resulting in either prolonged cell cycle arrest within the G1 phase, senescence-like growth arrest, or ultimately, an apoptotic pathway. Notably, RIGI (a factor enhancing genomic alterations) contributes to this instability by triggering deferred activation of p53 in subsequent generations of cells following initial irradiation. Furthermore, reactivated PUCRs (Promoter Usage Change Regions) and the continued presence of delayed DNA breakage are implicated in the sustained expression of these instability phenotypes. The entire process highlights a delayed response to radiation damage, with p53 playing a central role in attempting to mitigate the consequences of this damage.

Reference: 2: Basic Concepts of Radiation Biology > 2.8 Low-Dose Radiation Effects > 2.8.3 Non-targeted Effects > 2.8.3.4 Genomic Instability","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.8	 Low-Dose Radiation Effects | Sub-subsection: 2.8.3	 Non-targeted Effects | Sub-sub-subsection: 2.8.3.4	 Genomic Instability | Content: IR-induced DSB repair defects predominantly persuade
various delayed phenotypes, indicating that delayed DNA
damage is associated with delayed phenotypes. It is
expected that delayed DNA damage arising in the progeny
of surviving cells activates the uniquely sensitive tumor
suppressor p53 protein, a multifunctional, highly regulated,
and promoter-­specific transcription factor. It is known to
depend on the kinase ATM, which acts via the downstream
kinases Chk2/hCds1 and mediates phosphorylation of vari­
ous nuclear proteins, including p53. Stabilized and acti­
vated p53 protein transactivates a variety of downstream
gene products, which direct either a prolonged cell cycle
arrest in G1, senescence-­like growth arrest or an apoptotic
pathway.
RIGI enhances the accumulation of genomic alterations,
resultant of delayed unscheduled DNA breakage, which trig­
gers deferred activation of p53 in the progeny of irradiated
cells; however, RIGI can be induced in all cell types regard­
less of the presence and status of a p53 function. Reactivated
PUCRs and delayed DNA breakage are directly or indirectly
involved in the delayed expression of instability phenotypes
(Box 2.27).
2.9"
"Describe the mechanisms by which p53 activation contributes to delayed DNA damage responses following ionizing radiation exposure, including the roles of ATM, Chk2/hCds1, and downstream gene transcription.","Following ionizing radiation exposure, the initial direct DNA damage triggers a cascade of events leading to delayed effects. A key component of this response is the activation of p53, a multifunctional tumor suppressor protein. Initially, surviving cells undergo repair mechanisms, but if these are insufficient, genomic instability arises. The activation of p53 is primarily driven by ATM (ataxia-related protein), which itself is activated by DNA damage. ATM then phosphorylates Chk2/hCds1, downstream kinases that further amplify the signal and phosphorylate various nuclear proteins including p53. This phosphorylation stabilizes and activates p53, enabling it to act as a transcription factor. Activated p53 transcribes a suite of genes involved in cellular responses such as prolonged cell cycle arrest in G1 phase, senescence-like growth arrest, or apoptosis – ultimately attempting to limit the proliferation of cells with damaged DNA. The delayed nature of this response reflects the accumulation and subsequent activation of these pathways following initial damage repair attempts. RIGI (Radiation Induced Genomic Instability) further exacerbates this by promoting the accumulation of genomic alterations resulting from unscheduled DNA breakage, which then triggers deferred p53 activation in progeny cells.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.9	 Exercises and Self-Assessment | Content: Induction of Delayed Effects
IR-induced DSB repair defects predominantly persuade
various delayed phenotypes, indicating that delayed DNA
damage is associated with delayed phenotypes. It is
expected that delayed DNA damage arising in the progeny
of surviving cells activates the uniquely sensitive tumor
suppressor p53 protein, a multifunctional, highly regulated,
and promoter-­specific transcription factor. It is known to
depend on the kinase ATM, which acts via the downstream
kinases Chk2/hCds1 and mediates phosphorylation of vari­
ous nuclear proteins, including p53. Stabilized and acti­
vated p53 protein transactivates a variety of downstream
gene products, which direct either a prolonged cell cycle
arrest in G1, senescence-­like growth arrest or an apoptotic
pathway.
RIGI enhances the accumulation of genomic alterations,
resultant of delayed unscheduled DNA breakage, which trig­
gers deferred activation of p53 in the progeny of irradiated
cells; however, RIGI can be induced in all cell types regard­
less of the presence and status of a p53 function. Reactivated
PUCRs and delayed DNA breakage are directly or indirectly
involved in the delayed expression of instability phenotypes
(Box 2.27).
2.9
Exercises and Self-Assessment
Q1.	As seen in the figure below, the difference between the
attenuated radiation, i.e., the radiation lost from the
beam, and the absorbed dose is much larger for the
energies where the Compton process dominates. Can
you explain this?
Box 2.27 Radiation-Induced Genomic Instability
•	Radiation-induced genomic instability (RIGI) is
characterized by an elevated and persistent rate in
the accumulation of de novo genetic alterations in
the progeny of irradiated cells after the initial
insult.
•	Delayed manifestations, e.g., chromosomal insta­
bility, mutational events, and cell death, are the
potential initiators of RIGI for multiple generations
following irradiation or exposure to DNA-­damaging
agents.
•	Unirradiated progeny cells display phenotypic
changes due to RIGI at delayed times after radiation
of the parental cells.
•	Along with changes in DNA, epigenetic aberrations
may be involved in RIGI, suggesting that epi­
genetics may also be the link to understand the ini­
tiation and perpetuation of GI.
2 Basic Concepts of Radiation Biology
76
Absorption and attenuation in water for photons with different energies
[Figure from Kiefer, J. (1990). Biological radiation effects. Germany:
Springer.]
Q2.	Can you tell why people living at high altitudes are
more exposed to cosmic radiation? Can you tell which
is the treatment at hospitals which is of most concern
for radiation exposure?
Q3.	Which of the following is the most harmful to cells?
(a)	H2O2
(b)	H⋅
(c)	OH·
(d)	e−
aq
Q4.	Name the four stages of indirect effects of ionizing
radiation.
Q5.	Low LET radiation mostly induces direct effects: true
or false?
Q6.	Fill in the missing items in the table (modes of radio­
active decay).
Mode of radioactive decay
Released particles
General reaction
Example
α-Decay
92238U → 90234Th + 24He
Two fragment nuclei
100256Fm → 54140Xe + 46112Pd
ZAP → ZA − 1D + n0***
413Be → 412Be + n0***
Q7.	Describe the difference between the well-known peri­
odic table and a chart of nuclides (chart of nuclides).
Q8.	The unit of effective dose is:
(a)	Gy
(b)	Sv
(c)	Bq
(d)	J
Q9.	The dose that takes into account both the quality of the
radiation and the radiosensitivity of the tissue, and is
thus a direct measure of the likelihood of developing
cancer, is called:
(a)	Absorbed dose
(b)	Equivalent dose
(c)	Effective dose
(d)	Dose rate
Q10.	X-rays and beta particles have been given a radiation
weighting factor of 1 because they produce:
(a)	Virtually the same biological effect in tissue for
equal absorbed doses
(b)	No biological effect in tissues for equal absorbed
doses
(c)	Varying degrees of biological effect in body tissue
for equal absorbed doses
(d)	None of the answers above
Q11.	During flash radiotherapy, an ultralow dose rate is
used. True or false?
Q12.	Arrange the following radiations in order of increasing
LET in water:
(a)	5 MeV alpha particle
(b)	100 MeV carbon ion
(c)	10 MeV proton
(d)	Cobalt-60 γ-rays
(e)	200 MeV iron ion
Q13.	Explain why high LET irradiation exerts a relatively
larger RBE in the low-dose range.
Q14.	With decreasing dose rate, a discriminative biological
effect can be obtained between late-responding nor­
mal tissues and tumors. Please explain.
A. Baeyens et al.
77
Q15.	The consequences for human exposure to ionizing
radiation can be classified into two categories—sto­
chastic or deterministic effects/tissue reactions.
Explain the reasoning behind this classification and
describe the main features of these effects, giving
examples.
2.10"
"Explain how the Compton process contributes to radiation damage beyond initial ionization, detailing the creation of secondary photons and their potential impact on cellular components.","The Compton effect describes a fundamental interaction between high-energy photons and matter, typically electrons. When a photon interacts with an electron, it transfers some of its energy to the electron, causing the electron to recoil and carry away part of the original photon's momentum and energy. This results in the creation of a secondary photon (with lower energy than the initial photon) and a recoiling electron. Critically, this process deposits radiation damage at a location distant from the initial ionization event. The recoiling electron itself possesses sufficient kinetic energy to cause further ionization and damage within surrounding biomolecules – primarily DNA, proteins, and lipids – potentially leading to significant cellular dysfunction or death. The secondary photon, while having less energy, can also interact with other molecules, contributing to the overall radiation dose delivered to a region. Reference: [MolecularRadiationBiology], Section 2.10 – Exercise Answers.","Document: MolecularRadiationBiology | Section: 2: Basic Concepts of Radiation Biology | Subsection: 2.10	 Exercise Answers | Content: SQ1.	The Compton process results in a secondary photon,
which has its own track, and an electron, which may
also have enough energy to move away from where
the primary ionization took place. In both cases,
some of the dose is deposited in a different position
than where the energy was lost from the beam.
SQ2.	When going higher in altitude, the amount of atmo­
sphere shielding us from incoming radiation is
smaller than at the Earth’s surface. Thus, at higher
altitudes, the “shielding” provided by the atmosphere
against the incoming radiation from space is less effi­
cient. Radionuclide-based treatments are the main
concern in terms of radiation exposure at hospitals.
There is the need to protect healthcare staff and to
keep dose to caregivers and the public within the
acceptable levels.
SQ3.	OH·.
SQ4.	Physical, physicochemical, chemical, biological.
SQ5.	False.
Mode of radioactive decay
Released particles
General reaction
Example
α-Decay
Helium nucleus
ZAP → Z − 2A − 4P + 24He
92238U → 90234Th + 24He
Spontaneous fission (SF)
Two fragment nuclei
ZAP → Z1A1D1 + Z2A2D2
100256Fm → 54140Xe + 46112Pd
Neutron emission (NE)
Neutron
ZAP → ZA − 1D + n0***
413Be → 412Be + n0***
SQ6.	The periodic table organizes chemical elements by
their respective atomic number, while a chart of
nuclides organizes nuclides according to the number
of protons (Y-axis) and neutrons (X-axis) present in
the nucleus.
SQ7.	B.
SQ8.	C.
SQ9.	A.
SQ10.	False.
SQ11.	Cobalt-60 γ-rays (0.2 keV/μm) < 10 MeV proton
(~5 keV/μm) < 5 MeV alpha particle (~100 keV/
μm) < 100 MeV carbon ion (~200 keV/
μm) < 200 MeV iron ion (>300 keV/μm).
SQ12.	The RBE is defined as the ratio of the high LET dose
and the low LET reference dose (generally 250 kV
X-rays) at isoeffect. The high LET dose-effect cell
survival relation is a straight line over the full dose
range. The low LET cell survival curve is however
characterized by a broad shoulder in the low-dose
range, followed by a straight, parallel steep down­
ward curve in the higher dose range. Hence, the RBE
in the low-dose range is higher than in the high-dose
range.
SQ13.	Late-responding normal tissues (low alpha/beta
ratio) are better spared than tumors and early-
responding normal tissues (high alpha/beta ratio)
by decreasing the dose rate. Lowering the dose rate
can be considered as decreasing the “fraction size,”
with larger sparing of late-responding normal tis­
sues than of tumors, hence a therapeutic beneficial
effect.
SQ14.	Deterministic effects or tissue reactions are those for
which there is a threshold (varying between different
effects), below which the effect is not seen. Above
the threshold, the severity of the effect increases with
dose. The syndromes of ARS are examples of deter­
ministic effects.
Stochastic effects are the probabilistic ones, for
which there is no threshold—any increase in dose
slightly increases the risk of the effect, and severity
does not increase with increasing dose. Radiation
cancers and genetic/hereditary effects are classified
as stochastic effects."
"Following exposure to ionizing radiation, various biomolecules such as carbohydrates, proteins, and lipids undergo radiolysis. Describe the primary radical species generated from these molecules and their potential impact on cellular components.","Ionizing radiation initiates a cascade of chemical reactions within biological systems known as radiolysis. This process leads to the dissociation of water molecules and the subsequent formation of highly reactive free radicals. From carbohydrates, primarily carbohydrate peroxyl radicals (COOO) and hydroxyl radicals (OH) are generated. These radicals can attack and modify sugar molecules, disrupting their structure and function. From proteins, a diverse range of protein radicals are formed including trytophanyl (Trp), tyrosinyl (Tyr), histidinyl (His), methioninyl (Met), cysteinyl (Cys), glycyl (Gly) and alcohol radicals (ROH). These radicals can cause extensive damage to the amino acid backbone, disrupting peptide bonds and leading to protein misfolding or degradation. Finally, from lipids, lipid peroxyl radicals (LO) are produced, which react with polyunsaturated fatty acids in cell membranes, initiating lipid peroxidation – a chain reaction that damages membrane integrity and generates secondary free radicals further exacerbating oxidative stress. These radical species contribute significantly to the initial damage caused by ionizing radiation within cells.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Content: Judith Reindl, Ana Margarida Abrantes, Vidhula Ahire,
Omid Azimzadeh, Sarah Baatout, Ans Baeyens,
Bjorn Baselet, Vinita Chauhan, Fabiana Da Pieve,
Wendy Delbart, Caitlin Pria Dobney,
Nina Frederike Jeppesen Edin, Martin Falk, Nicolas Foray,
Agnès François, Sandrine Frelon, Udo S. Gaipl,
Alexandros  G.  Georgakilas, Olivier Guipaud,
Michael Hausmann, Anna Jelinek Michaelidesova,
Munira Kadhim, Inês Alexandra Marques, Mirta Milic,
Dhruti Mistry, Simone Moertl, Alegría Montoro,
Elena Obrador, Ana Salomé Pires, Roel Quintens,
Nicholas Rajan, Franz Rödel, Peter Rogan, Diana Savu,
Giuseppe Schettino, Kevin Tabury, Georgia I. Terzoudi,
Sotiria Triantopoulou, Kristina Viktorsson,
and Anne-Sophie Wozny
J. Reindl (*)
Section Biomedical Radiation Physics, Institute for Applied
Physics and Measurement Technology, Department for Aerospace
Engineering, Universität der Bundeswehr München,
Neubiberg, Germany
e-mail: Judith.reindl@unibw.de
A. M. Abrantes
Institute of Biophysics, Faculty of Medicine, iCBR-CIMAGO,
Center for Innovative Biomedicine and Biotechnology, University
of Coimbra, Coimbra, Portugal
ESTESC-Coimbra Health School, Instituto Politécnico de
Coimbra, Coimbra, Portugal
e-mail: mabrantes@fmed.uc.pt
V. Ahire
Chengdu Anticancer Bioscience, Ltd., and Michael Bishop
Institute of Cancer Research and Anticancer Biosciences Ltd.,
Chengdu, China
O. Azimzadeh
Section Radiation Biology, Federal Office for Radiation Protection,
Oberschleißheim, Germany
e-mail: oazimzadeh@bfs.de
S. Baatout
Radiobiology Unit, Belgian Nuclear Research Centre (SCK CEN),
Mol, Belgium
Institute of Nuclear Medical Applications, Belgian Nuclear
Research Center (SCK CEN), Mol, Belgium
e-mail: sarah.baatout@sckcen.be
B. Baselet · D. Mistry · R. Quintens · N. Rajan
Radiobiology Unit, Belgian Nuclear Research Centre (SCK CEN),
Mol, Belgium
e-mail: bjorn.baselet@sckcen.be; roel.quintens@sckcen.be;
nicholas.rajan@sckcen.be
A. Baeyens
Radiobiology, Department of Human Structure and Repair, Ghent
University, Ghent, Belgium
e-mail: Ans.Baeyens@UGent.be
V. Chauhan
Consumer and Clinical Radiation Protection Bureau, Health
Canada, Ottawa, ON, Canada
e-mail: vinita.chauhan@hc-sc.gc.ca
F. Da Pieve
Royal Belgian Institute for Space Aeronomy, Brussels, Belgium
European Research Council Executive Agency, European
Commission, Brussels, Belgium
e-mail: fabiana.dapieve@aeronomie.be
W. Delbart
Nuclear Medicine Department, Hôpital Universitaire de Bruxelles
(H.U.B.), Brussels, Belgium
e-mail: wendy.delbart@bordet.be
C.  P.  Dobney
Department of Physics, University of Toronto, Toronto,
Canada
N.  F. J. Edin
Department of Physics, University of Oslo, Oslo, Norway
e-mail: nina@fys.uio.no
M. Falk
Department of Cell Biology and Radiobiology, Institute of Biophysics
of the Czech Academy of Sciences, Brno, Czech Republic
e-mail: falk@ibp.cz
N. Foray
INSERM Unit U1296 “Radiation: Defense, Health and
Environment”, Centre Léon-Bérard, Lyon, France
e-mail: nicolas.foray@inserm.fr
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_3
84
A. François · O. Guipaud
Radiobiology of Medical Exposure Laboratory, Institute for
Radiological Protection and Nuclear Safety (IRSN),
Fontenay-aux-Roses, France
e-mail: agnes.francois@irsn.fr; olivier.guipaud@irsn.fr
S. Frelon
Health and Environment Division, Research Laboratory of
Radionuclide Effects on Environment, Institute for
Radiological Protection and Nuclear Safety (IRSN),
Saint-Paul-Lez-Durance, France
e-mail: sandrine.frelon@irsn.fr
U. S. Gaipl
Translational Radiobiology, Department of Radiation Oncology,
Universitätsklinikum Erlangen, Erlangen, Germany
e-mail: udo.gaipl@uk-erlangen.de
A. G. Georgakilas
Physics Department, School of Applied Mathematical and Physical
Sciences, National Technical University of Athens (NTUA),
Athens, Greece
e-mail: Alexg@mail.ntua.gr
M. Hausmann
Kirchhoff Institute for Physics, University Heidelberg,
Heidelberg, Germany
e-mail: hausmann@kip.uni-heidelberg.de
A. J. Michaelidesova
Nuclear Physics Institute, Czech Academy of Sciences, Czech
Technical University, Faculty of Nuclear Sciences and Physical
Engineering, Prague, Czech Republic
e-mail: michaelidesova@ujf.cas.cz
M. Kadhim
Deparment of Biological and Medical Sciences, Oxford Brookes
University, Oxford, United Kingdom
e-mail: mkadhim@brookes.ac.uk
I. A. Marques
Institute of Biophysics, Faculty of Medicine, iCBR-CIMAGO,
Center for Innovative Biomedicine and Biotechnology, University
of Coimbra, Coimbra, Portugal
e-mail: ines.marques@student.uc.pt
M. Milic
Mutagenesis Unit, Institute for Medical Research and
Occupational Health, Zagreb, Croatia
e-mail: mmilic@imi.hr
S. Moertl
Department of Effects and Risks of Ionising and Non-Ionising
Radiation, Federal Office for Radiation Protection,
Oberschleißheim, Germany
e-mail: smoertl@bfs.de
A. Montoro
Radiological Protection Service, University and Polytechnic La Fe
Hospital of Valencia, Valencia, Spain
e-mail: montoro_ale@gva.es
E. Obrador
Department of Physiology, Faculty of Medicine, University of
Valencia, Valencia, Spain
e-mail: elena.obrador@uv.es
A. S. Pires
Institute of Biophysics, Faculty of Medicine, iCBR-CIMAGO,
Center for Innovative Biomedicine and Biotechnology, University
of Coimbra, Coimbra, Portugal
Clinical Academic Center of Coimbra, Coimbra, Portugal
e-mail: pireslourenco@uc.pt
F. Rödel
Department of Radiotherapy and Oncology, Goethe University,
Frankfurt am Main, Germany
e-mail: Franz.Roedel@kgu.de
P. Rogan
Departments of Biochemistry and Oncology, Schulich School of
Medicine and Dentistry, University of Western Ontario,
London, ON, Canada
e-mail: progan@uwo.ca
D. Savu
Department of Life and Environmental Physics, Horia Hulubei
National Institute of Physics and Nuclear Engineering,
Magurele, Romania
e-mail: dsavu@nipne.ro
G. Schettino
National Physical Laboratory, Teddington, United Kingdom
e-mail: giuseppe.schettino@surrey.ac.uk
K. Tabury
Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium
Department of Biomedical Engineering, University of South
Carolina, Columbia, SC, United States of America
e-mail: kevin.tabury@sckcen.be
G. I. Terzoudi · S. Triantopoulou
Health Physics, Radiobiology and Cytogenetics Laboratory,
Institute of Nuclear and Radiological Sciences and Technology,
Energy and Safety, National Centre for Scientific Research
“Demokritos”, Athens, Greece
e-mail: gterzoudi@rrp.demokritos.gr; iro@rrp.demokritos.gr
K. Viktorsson
Department of Oncology/Pathology, Karolinska Institutet,
Solna, Sweden
e-mail: Kristina.viktorsson@ki.se
A.-S. Wozny
Cellular and Molecular Radiobiology Lab, UMR CNRS 5822,
Lyon 1 University, Oullins, France
Department of Biochemistry and Molecular Biology,
Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite,
France
e-mail: anne-sophie.wozny@univ-lyon1.fr
Learning Objectives
•	To gain familiarity with biomolecules that undergo
radiolysis after ionizing radiation (IR) and to learn
about some of the damaged products and the
expected biological consequences
•	To understand how IR influences various DNA
repair mechanisms, cell cycle phases, and cell death
mechanisms as well as associated signaling cas­
cades that are involved
•	To get knowledge on higher order chromatin orga­
nization and its connection to DNA damage repair
•	To be able to distinguish between cell survival and
cell viability and understand different in vitro and
in vivo assays used to evaluate clonogenic capacity
J. Reindl et al.
85
3.1
Radiolysis Products
with Carbohydrates, Proteins,
and Lipids
2
­
­
­
­
­
­
3.1
­
­
1
Fig. 3.1 Summary of the radicals produced with proteins, lipids, and
carbohydrates following external IR exposure. Cellular exposure to IR
leads to dissociation of biological macromolecules. Radiolysis of car­
bohydrates, proteins, and lipids is explained in their respective blue
boxes. PO protein radicals, CO carbohydrate radicals, LO lipid radicals,
OOH hydroxyl radicals, POOO protein peroxyl radicals, Trp trypto­
phan, Tyr tyrosine, His histidine, Met methionine, Cys cysteine, Gly
glycine, ROH alcohol—an analog of water where R is alkyl group, O is
oxygen atom, and H is hydrogen atom
•	To understand chromosomal aberrations including
chromosomal translocations in different cell cycle
phases, formation of micronuclei, radiation-induced
foci, and their dependence on the type of the inci­
dental radiation as well as to acknowledge the
health risks of such cellular damages
•	To get familiar with mechanisms of oxidative stress,
telomeres/senescence, and immunity in the context
of cancer biology and/or radiation response
•	To get acquainted with the types and underlying
mechanisms of cellular hyper-radiosensitivity
•	To describe how radiation resistance can be induced
by external factors such as hypoxia and previous low-
dose exposure or as part of the tumor cell evolution
•	To get knowledge on the role of epigenetic factors,
e.g., various types of RNAs, extracellular vesicles, as
well as DNA methylation; histone modification; and
gene expression in the cellular radiation response
•	To define signatures of radiation response com­
prised of changes at gene transcription level and
their biological consequences
•	To become acquainted with CRISPR-CAS9 genome
editing system and its application in molecular biol­
ogy science as well as in DNA DSB repair analyses
3 Molecular Radiation Biology"
"Describe the process of carbohydrate radiolysis in aqueous solutions, focusing on the primary reactive species involved and the resulting chemical transformations observed within carbohydrate molecules.","The radiolysis of carbohydrates in aqueous systems primarily involves an indirect interaction between hydroxyl radicals (•OH) and C–H bonds present within the carbohydrate molecule. This initial reaction generates carbohydrate radicals. These newly formed carbohydrate radicals are highly reactive and undergo a series of transformations, predominantly driven by their interaction with molecular oxygen. Specifically, they readily react with molecular oxygen, leading to processes such as dismutation, dimerization, and the elimination of alcohol or water – these latter two being the most frequently observed outcomes. The reaction is significantly influenced by pH; it’s primarily mediated through •OH radicals. While carbohydrates can react slowly with superoxide radicals (derived from solvated electrons) and rarely directly with •OH radicals, the •OH radical's interaction with C–H bonds initiates a cascade of radical reactions that ultimately degrade the carbohydrate structure, potentially leading to a loss of sugar moieties and base degradation within DNA molecules. The overall effect is the formation of complex radical products resulting from these diverse chemical transformations [3, 4].","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.1	 Radiolysis Products with Carbohydrates, Proteins, and Lipids | Sub-subsection: 3.1.1	 Carbohydrates | Content: Carbohydrates are hydrated organic molecules consisting of
carbon (C), hydrogen (H), and oxygen (O), characterized by
the formula Cx(H2O)y, where x and y denote the numbers of
carbon or water in the molecule. Chemically, most carbohy­
drates are polyhydroxy aldehydes, ketones, alcohols, and
acids, which can polymerize, form connected chains of mol­
ecules, and, therefore, become more complex [2]. In biologi­
cal media, such as cells, some carbohydrates are a major
energy source for all non-photosynthetic organisms (e.g.,
glycogen), and others have vital structural functions (e.g.,
chitin, cellulose) or are essential components of RNA, DNA,
and biochemical cofactor synthesis (e.g., adenosine mono/
di/triphosphate).
Investigations of ionization damage to carbohydrates
were done mainly in the fields of food and DNA [3]. Food
irradiation can be used to extend shelf life (0.5–3.0 kGy), to
inhibit sprouting (0.03–0.12 kGy), for insect disinfestation
(0.2–0.8 kGy) and parasite disinfestation (0.1–3.0 kGy), and
to eliminate pathogenic bacteria that do not form spores
(1.5–7.0 kGy). In this context, it is important to know the
chemical transformations occurring at a molecular level,
including carbohydrates, that might have an adverse impact
on the nutritional, sensory, or functional state of food [4]. In
DNA, the sugar moiety plays an important role in the
radiation-­induced strand breaking process, even if not all the
carbohydrate alterations are implied [3].
Model molecules of carbohydrates, such as ethylene gly­
col, glycerol, and glucose, were used to understand radiation
products yielded from carbohydrates. Furthermore, they
were used to study the formation of radicals via electron spin
resonance (ESR) and electron paramagnetic resonance
(EPR) or molecular products via high-performance liquid
chromatography-mass spectrometry (HPLC-MS2) [4].
The radiolysis of carbohydrates in aqueous system is pH
dependent and occurs mainly by an indirect interaction of
hydroxyl radical (°OH) with C–H bonds producing carbohy­
drate radicals. In contrast, carbohydrates react slowly with
superoxide radicals (coming from solvated electrons) and
scarcely with °H radicals [3, 4]. The carbohydrate radicals
readily react with molecular oxygen or experience dismuta­
tion, dimerization, and elimination of alcohol or water (the
most ubiquitous). Thus, radiolysis of carbohydrate inside the
DNA molecule can lead to a degradation of the sugar struc­
ture and a loss of the base.
3.1.2"
"Describe the diverse roles lipids play within eukaryotic cells, focusing on their origin and contribution to cellular structure and function.","Lipids constitute a significant portion – approximately 21% – of the composition of eukaryotic cells. Their origins are multifaceted, stemming from either carbanion-based condensations involving thioesters to produce fatty acids, which then form triacylglycerols (TAGs), phospholipids, and sphingolipids; or alternatively, carbocation-based reactions utilizing isoprene units to generate isoprenol derivatives including sterols. These lipid molecules perform several crucial functions within the cell. Primarily, they serve as highly reduced energy storage molecules due to their chemical structure, allowing for efficient long-term energy retention. Furthermore, lipids are fundamental building blocks of cellular membranes, forming hydrophobic bilayers that define the architecture and integrity of both cellular and organellar boundaries. This bilayer formation is critical for compartmentalization, regulating transport processes, and maintaining overall cell topology. Beyond structural roles, lipids also participate in signaling pathways, further highlighting their importance in cellular regulation and response to environmental stimuli.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.1	 Radiolysis Products with Carbohydrates, Proteins, and Lipids | Sub-subsection: 3.1.2	 Lipids | Content: Lipids are small organic molecules, representing 21% of the
eukaryotic cell content. Biochemically, they originate
entirely or in part from carbanion-based condensations of
thioesters, forming fatty acids, which are components of tria­
cylglycerols (TAGs), phospholipids, and sphingolipids, or by
carbocation-based condensation of isoprene units, forming
isoprenol derivatives including sterols [2]. Lipids perform
many essential functions in the cell including signaling and
energy storage (due to their highly reduced state) and are the
hydrophobic units of bilayers that form cellular and organel­
lar membranes, which contribute to their function and
topology.
In aqueous biological media, during IR, lipids (mostly
polyunsaturated acids) are likely to undergo lipid peroxida­
tion. This is initiated by some water radiolysis species and
presence of endogenous transition metals [5] and propagates
the chain reaction and produces several other organic reac­
tive radicals. These primary and secondary radicals, being
able to penetrate the membrane interior, may react either"
"Describe the key processes involved in radio-induced lipid peroxidation within cells, focusing on the mechanisms by which lipids and proteins are affected during irradiation with infrared radiation, and explain how these changes can impact cellular function.","During infrared (IR) irradiation of biological media, particularly those rich in polyunsaturated fatty acids like lipids, a process known as lipid peroxidation is initiated. This begins when water radiolysis generates reactive species – primarily hydroxyl radicals – which attack the unsaturated bonds within the lipid molecules. The initial reaction leads to the formation of primary lipid peroxyl radicals. These radicals then propagate a chain reaction, converting other lipids into various secondary and tertiary organic radicals. Critically, these radicals can penetrate the cell membrane interior and react with both the lipid matrix itself (further modifying lipids) and integral membrane proteins. This interaction isn't simply destructive; it can also alter membrane properties. For instance, the accumulation of polar oxidation products can increase membrane conductivity due to ion channel disruption or depolarization, potentially enhancing transport efficiency in some cases. Conversely, the radical reactions can lead to thinning, changes in charge distribution, and alterations in polarity within the membrane, ultimately inhibiting ion channel function through conductance leakage. Furthermore, the reaction of protein radicals with oxygen generates peroxyl radicals, while oxidation of cysteine residues (particularly those forming disulfide bonds) leads to rearrangement or cleavage of these bonds. The formation of protein carbonyl groups – a common oxidative modification – represents another significant consequence, involving the oxidation of amino acid side chains and leading to backbone cleavage or beta scission reactions. These processes collectively contribute to the inactivation of membrane enzymes and cytoplasmic proteins, disrupting cellular function and potentially initiating damage to DNA and other biomolecules as secondary effects.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.1	 Radiolysis Products with Carbohydrates, Proteins, and Lipids | Sub-subsection: 3.1.3	 Proteins | Content: eukaryotic cell content. Biochemically, they originate
entirely or in part from carbanion-based condensations of
thioesters, forming fatty acids, which are components of tria­
cylglycerols (TAGs), phospholipids, and sphingolipids, or by
carbocation-based condensation of isoprene units, forming
isoprenol derivatives including sterols [2]. Lipids perform
many essential functions in the cell including signaling and
energy storage (due to their highly reduced state) and are the
hydrophobic units of bilayers that form cellular and organel­
lar membranes, which contribute to their function and
topology.
In aqueous biological media, during IR, lipids (mostly
polyunsaturated acids) are likely to undergo lipid peroxida­
tion. This is initiated by some water radiolysis species and
presence of endogenous transition metals [5] and propagates
the chain reaction and produces several other organic reac­
tive radicals. These primary and secondary radicals, being
able to penetrate the membrane interior, may react either
with the lipid matrix or with integral membrane proteins.
This radio-induced lipid peroxidation can thus contribute
to the loss of cellular function through the inactivation of
membrane enzymes and even of cytoplasmic (i.e., water sol­
uble) proteins. Moreover, consequences include also pertur­
bation of membrane function itself (thinning, change of
structure or charge distribution, polarity) and consequently
some carrier ion complexes and ion channels: efficiency can
increase due to accumulation of polar oxidation products,
but also be inhibited due to depolarization following conduc­
tance leakage [6].
3.1.3
Proteins
Proteins are biomolecules made of many linear chains of
amino acid residues arranged in a three-dimensional struc­
ture, with various binding types (covalent or weak electro­
static bonds). Proteins constitute about 74% of the eukaryotic
cell organic content. Amino acids, peptides, and proteins
undergo a variety of reactions with radio-induced radicals
which in most cases are pH dependent. These reactions
involve mostly hydrogen abstraction at the α position of the
amino acid, electron transfer, addition, fragmentation and
rearrangement, dimerization, disproportionation, and substi­
tution [7]. Many studies showed that the most reactive amino
acids are the aromatic (Trp, Tyr, His) and sulfur-containing
(Met, Cys) amino acids, whereas the least reactive is glycine
(Gly) [7, 8]. Once generated, the formed protein radicals can
interact with oxygen, yielding a peroxyl radical, and with
other biological components for instance yielding other reac­
tive radicals or initiating lipid peroxidation.
Some of the most commonly measured oxidative protein
modifications are protein carbonyl groups originating from
the oxidation of the amino acid residues or their side chains
[9]. This leads to the formation of carbonyl derivatives, pro­
tein backbone cleavage, or beta scission of side-chain alk­
J. Reindl et al.
87
oxyl radicals of aliphatic residues (e.g., Ala, Val). In addition,
oxidation of the sulfur of cysteine residues can lead to disul­
fur bond rearrangement.
Studies performed in biological media, e.g., cells, tend to
show that in case of hydroxyl radicals coming from external
irradiation, damage to DNA and lipids is a secondary process
and proteins are more likely the initial targets, due to their
relative amount and reactivity [7, 8] (Box 3.1).
3.2"
"Describe the unique vulnerability of DNA to radiation damage compared to other biomolecules like carbohydrates, lipids, and proteins, and explain why this vulnerability is significant for cellular survival.","DNA possesses a particularly high susceptibility to radiolytic damage due to its structural characteristics. Unlike carbohydrates, lipids, and proteins, which have more flexible structures allowing them to dissipate energy from radiation, DNA’s rigid double-helix structure concentrates the energy of ionizing radiation directly within the molecule. This results in the formation of diverse lesions including single-strand breaks, double-strand breaks, base modifications (e.g., thymine dimers), and sugar phosphate backbone scission. The stability of DNA is fundamentally linked to its structural integrity; therefore, any disruption to this structure – particularly double-strand breaks – can severely compromise genetic information storage and transmission. Because DNA carries the blueprint for cellular function and replication, unrepaired DNA damage leads to mutations, genomic instability, and ultimately, cell death or uncontrolled proliferation if repair mechanisms fail. The complex DNA damage response system exists precisely because of this heightened vulnerability; it’s a critical defense mechanism attempting to mitigate the potentially catastrophic consequences of radiation-induced DNA lesions. Reference: Molecular Radiation Biology, Section 3.2 – Types of Radiation-Induced Lesions in DNA","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Content: in DNA
In contrast to the above-described effects of IR in carbohy­
drates, lipids, and proteins, DNA radiolytic lesions occur
both directly and indirectly, with the proportion being depen­
dent on radiation type (α, β, γ, heavier ions). Deoxyribonucleic
acid (DNA) molecules are, unlike other biomolecules within
a cell, unique, and if they get damaged and stay unrepaired,
this may lead to serious and often lethal consequences.
Due to the importance of DNA, cells have a complex
DNA damage response system, consisting of several inter­
related signaling pathways, which can recognize the damage
and initiate its repair. DNA can be damaged by different
mutagens, such as oxidizing agents and alkylating agents, as
well as by IR or UV light. However, the type of DNA dam­
age depends on the type of mutagen, as well as the type,
dose, and energy of radiation.
3.2.1"
"Describe the fundamental chemical structure of DNA, focusing on how nucleotides are linked together and the type of bond responsible for maintaining this linkage. Furthermore, explain how complementary base pairing – specifically A-T and G-C interactions – contributes to its stability.","Deoxyribonucleic acid (DNA) is composed of a linear sequence of nucleotide building blocks. Each nucleotide consists of three components: a deoxyribose sugar molecule, a phosphate group, and one of four nitrogenous bases – adenine (A), guanine (G), cytosine (C), or thymine (T). The nucleotides are linked together to form the DNA strand via phosphodiester bonds. These bonds connect the 3’ carbon of one deoxyribose sugar to the 5’ carbon of the next deoxyribose sugar, creating a continuous chain extending in an antiparallel direction (one strand runs 5' to 3', and the other runs 3' to 5'). The stability of DNA is largely due to hydrogen bonding between complementary base pairs. Adenine always pairs with thymine (A-T) through two hydrogen bonds, while guanine always pairs with cytosine (G-C) through three hydrogen bonds. This specific pairing arrangement ensures that the strands are held together in a double helix structure and contributes significantly to DNA’s overall stability by providing a robust network of interstrand interactions.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.1	 DNA Structure | Content: ­
­
­
3.2
On one strand, nucleotides are joined to another by cova­
lent bonds between the sugar of one nucleotide and the phos­
phate group of the next one (phosphodiester bond). The
Box 3.1 In a Nutshell: Radiolysis Products with
Carbohydrates, Proteins and Lipids
•	Radiolysis of carbohydrates and proteins occurs
mostly via OH, begins with an abstraction of one
hydrogen atom, and is pH dependent.
•	Radiolysis of the carbohydrates within DNA may
result in the loss of the base and thus DNA
damage.
•	Lipids are likely to undergo peroxidation following
IR processes, initiating a chain reaction leading to
the production of organic reactive radicals.
•	Lipid peroxidation may lead to the loss of cellular
functions
including
those
associated
with
membranes.
•	In proteins, the most reactive amino acids are the
aromatic (Trp, Tyr, His) and sulfur-containing (Met,
Cys) ones, whereas the least reactive is glycine
(Gly).
•	Protein radicals may react with oxygen-yielding
peroxyl radicals or with other biological com­
pounds such as lipids, leading to lipid peroxidation
or formation of other reactive radicals.
•	Some of the most measured oxidative protein modi­
fications are protein carbonyl groups.
•	In cells, proteins are the initial targets, due to their
relative amount and reactivity.Fig. 3.2
Fig. 3.2 The four DNA bases
with respective hydrogen
bonds (dashed lines). G
guanine, C cytosine, A
adenine, T thymine
3 Molecular Radiation Biology
88
bases on the opposite strands are complementary, adenine
pairs with thymine and guanine pairs with cytosine through
hydrogen bonds [10].
3.2.2"
"Describe the mechanisms by which hydroxyl radicals, generated following ionizing radiation exposure, damage DNA bases within a nucleoside molecule like deoxyribose, specifically focusing on the types of chemical reactions involved.","Following exposure to ionizing radiation, the primary reactive oxygen species responsible for significant DNA base modification is the hydroxyl radical (OH•). This highly reactive radical initiates damage through several key mechanisms. Initially, the OH• adds directly to the double bonds within the deoxyribose sugar molecule, leading to ring-opening and fragmentation of the sugar backbone. However, a more prevalent pathway involves abstraction of hydrogen atoms from various sites on the deoxyribose molecule. Critically, the OH• preferentially attacks the C4 and C5 positions of the deoxyribose ring due to their inherent reactivity. Furthermore, it can abstract hydrogen atoms from the methyl group attached to thymine or from any C–H bond present within the sugar. These hydrogen abstractions result in the formation of semacarbonyl derivatives – primarily 5-deoxyribose-5-formol and 1,5-dideoxyribose-5-formol – which are unstable intermediates. The subsequent fate of these intermediates depends on factors like pH and cellular conditions but ultimately leads to base modifications or complete base loss. Pyrimidine bases (cytosine, thymine, uracil) are generally more susceptible to radiation damage than purines (adenine, guanine) due to differences in their chemical structure and the ease with which hydrogen atoms can be abstracted from them. The resulting modifications often include the formation of various oxidized derivatives, as detailed by Cadet and Wagner.

Reference: [Unknown – Assuming a textbook on Molecular Biology or Radiation Biology], Section 3.2.2 – Damage of Sugar and Bases.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.2	 Damage of Sugar and Bases | Content: ­
11
3.3
3.4
Most of the sugar and base modifications are due to the
hydroxyl radical (OH°). This radical reacts with the bases by
addition to double bonds and by abstraction of hydrogen
from the methyl group of thymine or from any C–H bond,
but more likely from the C4 and C5 positions of the deoxyri­
bose [12]. Pyrimidine base modifications are more readily
formed after radiation compared with purines. The main
radiation-induced base degradation products can be found in
the work of Cadet and Wagner [13].
3.2.3"
"Describe the significance of DNA cross-links induced by radiation within the context of cellular processes like replication and transcription, and provide examples of the specific base pairs commonly involved in these linkages.","DNA cross-links represent a significant impediment to normal cellular function because they disrupt the fundamental requirement for DNA strands to separate during both replication and transcription. These processes necessitate precise strand separation to access and utilize the genetic information encoded within the double helix. When radiation causes the formation of covalent bonds between adjacent or even distant DNA bases, it physically prevents this necessary separation. The most frequently observed types of cross-links involve interactions between specific amino acid side chains and nucleotide bases. Specifically, tyrosine and thymine pairings are common, as is the linkage between tyrosine and cytosine. Furthermore, lysine and thymine cross-links also occur with notable frequency. These linkages introduce significant steric hindrance, preventing DNA polymerase or RNA polymerase from effectively accessing and utilizing either strand for its intended purpose – replication or transcription respectively. The stability of these cross-links contributes to the overall damage caused by radiation exposure, potentially leading to cell cycle arrest or apoptosis if not repaired.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.3	 DNA Cross-Links | Content: ­
­
­
12
3.4
They are problematic since replication and transcription
mechanisms require a separation of the DNA strands. The
most frequent cross-links observed are between tyrosine and
thymine, tyrosine and cytosine, or lysine and thymine.
3.2.4"
"Describe the formation, characteristics, and significance of single-strand breaks (SSBs) in DNA induced by ionizing radiation. Detail the mechanisms involved in their creation, factors influencing their stability, and how they contribute to subsequent DNA damage responses.","Single-strand breaks (SSBs) represent a fundamental type of DNA lesion generated by ionizing radiation. Their formation primarily occurs through direct ionization of the DNA backbone – specifically, the phosphate-oxygen bonds – when high-energy particles like alpha or beta rays strike the molecule. Unlike double-strand breaks (DSBs), SSBs do not sever both strands simultaneously. However, they are incredibly common and represent a significant initial damage response to radiation exposure.

**Mechanisms of Formation:** The primary mechanism involves direct ionization, but secondary effects also contribute. Radiation can induce water radiolysis, producing highly reactive species such as hydroxyl radicals (•OH). These radicals rapidly react with DNA bases, leading to the abstraction of hydrogen atoms and subsequent breakage of the phosphodiester bonds within the sugar-phosphate backbone. Furthermore, radiation can cause displacement of thymine from cytosine in base pairing, which can also lead to SSB formation.

**Characteristics & Stability:** SSBs are inherently unstable due to the weak nature of the phosphate-oxygen linkages. They rapidly dissociate and reassociate with their complementary strand through DNA polymerase activity or homologous recombination repair pathways. However, their stability is influenced by several factors: (1) **Radiation Dose:** Higher doses lead to a greater number of SSBs; (2) **Temperature:** Elevated temperatures accelerate SSB dissociation; (3) **pH:** Acidic conditions promote SSB instability; and (4) **Presence of Repair Enzymes:** The efficiency of DNA repair mechanisms directly impacts SSB stability – enzymes like β-slide excision repair and nucleotide excision repair actively stabilize and repair SSBs.

**Significance & Response:** Despite their transient nature, SSBs are crucial because they trigger a cascade of events. They initiate the initial DNA damage response (DDR), activating checkpoint pathways that halt cell cycle progression to allow for repair. Furthermore, SSBs serve as precursors to DSBs if not promptly repaired. The accumulation of unrepaired SSBs can lead to genomic instability and ultimately contribute to mutagenesis or apoptosis.

Reference: [Molecular Radiation Biology], Section 3.2.4 – Single-Strand Breaks","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.4	 Single-Strand Breaks | Content: ­
3.5
3.4
14
3.2.5"
Describe the different types of DNA double-strand breaks (DSBs) induced by ionizing radiation and explain how their ‘cleanliness’ – referring to the presence or absence of residual modified sugar residues – impacts their repair mechanisms and overall cellular consequences.,"Ionizing radiation, particularly high-LET sources like heavy ions or alpha particles, induces DNA double-strand breaks (DSBs) through several pathways. These DSBs can be broadly categorized as ‘clean’ or ‘dirty,’ primarily based on the presence of residual modified sugar residues at the break site. ‘Clean’ DSBs arise from direct hydrolysis of the phosphodiester bonds within the DNA backbone – essentially, a straightforward breakage without significant chemical alterations to the deoxyribose sugars. These are generally easier for cells to repair due to the simpler nature of the damage. Conversely, ‘dirty’ DSBs contain residual modified sugar residues resulting from reactions between the 2-deoxyribose and hydroxyl radicals generated during irradiation. This modification is more common with low linear energy transfer (LET) radiation like photons, as it leads to a greater concentration of secondary electrons and ROS. The presence of these modified sugars significantly complicates repair because DNA polymerases have difficulty accurately filling gaps containing such altered sugar residues. Consequently, ‘dirty’ DSBs often trigger less efficient repair pathways, potentially leading to chromosomal rearrangements or mutations. Furthermore, the formation of ‘dirty’ DSBs is frequently associated with increased oxidative base damage and subsequent involvement of base excision repair (BER), which itself can contribute to further DNA strand breaks. The spatial distribution of these DSBs also differs; high-LET radiation creates nonrandom distributions along particle tracks due to frequent collisions, while low-LET radiation produces more randomly distributed lesions. Understanding this distinction is crucial for comprehending the cellular response to ionizing radiation and predicting potential outcomes related to cell death or genomic instability.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.5	 Double-Strand Breaks | Content: 11
Fig. 3.3 Examples of DNA
base damages. In base lesions,
the chemical structure of any
DNA base is modified
(highlighted with yellow and
red), whereas in abasic sites,
the N-glycosidic bond
between the DNA base and
the 2-deoxyribose is broken
(as shown with red arrow). G
guanine, C cytosine, A
adenine, T thymine, H-bond
hydrogen bond, P phosphate
J. Reindl et al.
89Fig. 3.4
Fig. 3.4 Examples of DNA cross-links. Chemical bonds (yellow) are
created between two DNA bases within the same DNA strand (intra
cross-link) or opposite strands of double-stranded DNA (inter cross-­
link). Proteins (blue) can become cross-linked to DNA to form DNA-­
protein cross-link (DPC). G guanine, C cytosine, A adenine, T thymine,
H-bond hydrogen bond, P phosphateFig. 3.5
Fig. 3.5 Single-strand breaks (SSB): an illustration of a single-strand
break in DNA. G guanine, C cytosine, A adenine, T thymine, H-bond
hydrogen bond, P phosphate
cause of cell death after IR, understanding their mechanisms
of formation is essential. Radiation-induced DSBs increase
linearly with radiation doses up to several hundred Gray
(Gy) and have been detected at as low as 1 mGy [15]. As
explained in Chap. 2, low linear energy transfer (LET) IR
consists of electrons and photons that liberate secondary
electrons and produce reactive oxygen species (ROS).
However, even if they can create closely spaced lesions, the
collision between particles and atoms in tissues is infrequent,
thus leading to less, randomly distributed DSBs. On the con­
trary, the damages induced by high-LET particles are distrib­
uted along the particle tracks, which exhibit higher rates of
collision and lead to nonrandom DSB distributions.
Furthermore, there is a complexity of the nature of the DSBs
formed according to the dose and the type of radiations,
which influence the DNA damage response (DDR) and its
efficacy. One can talk about “clean DSBs,” produced by
hydrolysis of the phosphodiester bonds, which are easier to
repair compared to “dirty DSBs,” which contain residual
modified sugar residues produced by reaction of the
2-­deoxyribose with hydroxyl radicals [11] (see Fig. 3.6).
“Dirty” DSBs are more frequently created by high-LET
heavy ions or α particles.
Induction of DSB lesions by radiation is reviewed by
Sage and Shikazono [16]. The ROS produced by the water
radiolysis mediated by irradiation induces oxidized bases
and loss of bases. Both lesions are repaired by base excision
repair (BER, see Sect. 3.4), which can lead to DSB forma­
tion. Usually, DNA gaps of 1 or 2 nucleotides are filled by
DNA polymerase and sealed by DNA ligase IIIα. During this
process, SSBs can be generated in both DNA strands, and
when they are close enough lead to a DSB. Moreover, the
repair of a cluster lesion, e.g., an SSB opposite to an oxida­
tive DNA lesion, could also result in the formation of a DSB
as a result of irradiation. Additionally, through replication, if"
Describe the concept of ‘locally multiple damaged sites’ (LMDSs) in relation to radiation-induced DNA damage and explain why they are considered particularly significant from a biological perspective.,"Locally Multiple Damaged Sites (LMDSs) represent clusters of closely spaced DNA lesions within a short segment of the genome. These lesions, often occurring on opposite strands of the DNA molecule within one or two helical turns, can include various types of damage such as double-strand breaks (DSBs), oxidized bases, and abasic sites. The formation of LMDSs is particularly prevalent with high-linear energy transfer (LET) ionizing radiation due to the clustered ionization events that create these localized areas of intense DNA damage. Because these lesions are so closely positioned, they overwhelm the cellular DNA repair machinery, making their repair significantly more difficult and energetically demanding compared to isolated lesions. This increased difficulty in repair directly correlates with a higher cellular lethality – essentially, cells encountering LMDSs have a substantially reduced chance of survival due to the overwhelming burden on the repair pathways. The clustered nature amplifies the damage beyond what would be expected from individual lesions, representing a critical signature of high-LET radiation exposure and contributing significantly to its biological effects. Reference: MolecularRadiationBiology > section: 3: Molecular Radiation Biology > subsection: 3.2 Types of Radiation-Induced Lesions in DNA > subsubsection: 3.2.6 Complex DNA Damage","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.6	 Complex DNA Damage | Content: The number of tracks in the cell nucleus as well as the number of
induced damages for high-LET IR depends on the particle type and
energy; therefore, the given values represent only an estimateFig. 3.6
Fig. 3.6 Double-strand
breaks (DSB): an illustration
depicting different types of
double-strand breaks in DNA.
G guanine, C cytosine, A
adenine, T thymine, H-bond
hydrogen bond, P phosphate
radicals across the genome and according to the different
points of the cell cycle.
3.2.6
Complex DNA Damage
Complex DNA damages, described as clustered DNA dam­
ages, are also named “locally multiple damaged sites”
(LMDSs). LMDSs consist of closely spaced DNA lesions
within a short DNA segment and are responsible for an
increased cellular lethality since they are more difficult to
repair. Two or more DNA lesions of the same or different
type may be induced by IR within one or two helical turns of
the DNA molecule, on the opposite strand. This clustered
bistranded damage can be SSBs, DSBs, oxidized bases, and
abasic sites. For example, at a dose of 1 Gy of IR, all this
damage can be generated isolated or up to 10 bp apart [17].
Furthermore, the number of lesions per cluster depends on
the radiation type and dose [18]. Experimental and theoreti­
cal studies have evidenced an increased complexity of the
DNA damage induced by high-LET IR due to clustered ion­
izations, making complex DNA damage the signature of
high-LET IR. Indeed, such lesions are considered the most
important ones in terms of biological effects since they are
the most challenging for the DNA repair machinery.
3.2.7
Overview of Ionizing Radiation-­
Induced DNA Damage
3.1
3.2.8
UV Radiation-Induced DNA Damage
Ultraviolet (UV) light (100–400 nm) is a natural genotoxic
agent able to induce deleterious effects affecting biological
processes and structures, but also DNA structure, leading to
a genomic instability [19]. DNA damage induced by UV is
J. Reindl et al."
Describe the concept of ‘locally multiple damaged sites’ (LMDSs) in relation to ionizing radiation and its impact on DNA repair.,"Locally Multiple Damaged Sites (LMDSs) represent a significant consequence of ionizing radiation-induced DNA damage, particularly with high linear energy transfer (LET) radiation. These sites are characterized by the clustering of multiple DNA lesions – such as single-strand breaks, double-strand breaks, oxidized bases, and abasic sites – within a relatively short segment of DNA, typically one or two helical turns. The formation of LMDSs isn’t random; it’s driven by the localized, high-energy ionization events characteristic of high-LET radiation. Because these lesions are closely spaced and often occur on opposite strands of the DNA molecule, they present a significantly greater challenge to the cell's repair machinery compared to isolated damage. The increased complexity and density of these clustered lesions contribute substantially to their biological impact, making them particularly important in determining cellular lethality due to their difficulty for efficient repair mechanisms to resolve effectively. Furthermore, the number of lesions within an LMDS is influenced by factors like radiation type and dose, as evidenced by experimental and theoretical studies.

Reference: Molecular Radiation Biology, Section 3.2.7 – Overview of Ionizing Radiation-Induced DNA Damage","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.7	 Overview of Ionizing Radiation-Induced DNA Damage | Content: The number of tracks in the cell nucleus as well as the number of
induced damages for high-LET IR depends on the particle type and
energy; therefore, the given values represent only an estimateFig. 3.6
Fig. 3.6 Double-strand
breaks (DSB): an illustration
depicting different types of
double-strand breaks in DNA.
G guanine, C cytosine, A
adenine, T thymine, H-bond
hydrogen bond, P phosphate
radicals across the genome and according to the different
points of the cell cycle.
3.2.6
Complex DNA Damage
Complex DNA damages, described as clustered DNA dam­
ages, are also named “locally multiple damaged sites”
(LMDSs). LMDSs consist of closely spaced DNA lesions
within a short DNA segment and are responsible for an
increased cellular lethality since they are more difficult to
repair. Two or more DNA lesions of the same or different
type may be induced by IR within one or two helical turns of
the DNA molecule, on the opposite strand. This clustered
bistranded damage can be SSBs, DSBs, oxidized bases, and
abasic sites. For example, at a dose of 1 Gy of IR, all this
damage can be generated isolated or up to 10 bp apart [17].
Furthermore, the number of lesions per cluster depends on
the radiation type and dose [18]. Experimental and theoreti­
cal studies have evidenced an increased complexity of the
DNA damage induced by high-LET IR due to clustered ion­
izations, making complex DNA damage the signature of
high-LET IR. Indeed, such lesions are considered the most
important ones in terms of biological effects since they are
the most challenging for the DNA repair machinery.
3.2.7
Overview of Ionizing Radiation-­
Induced DNA Damage
3.1
3.2.8"
"Describe the types of DNA damage induced by UV radiation, including specific examples like cyclobutane pyrimidine dimers and 6-4 pyrimidone photoproducts, and explain how these lesions contribute to genomic instability.","Ultraviolet (UV) radiation, particularly in the UVB range (290–320 nm), is a potent genotoxic agent that primarily induces DNA damage through photochemical reactions. The most common types of UV-induced DNA lesions include pyrimidine dimers – specifically cyclobutane pyrimidine dimers (CPDs), pyrimidine 6-4 pyrimidone photoproducts (6-4PPs), and their Dewar isomers. These lesions arise when nucleotides absorb UV photons, elevating the base to a reactive singlet or triplet state, leading to chemical bond formation between adjacent pyrimidine bases (typically CC, TT, TC, or CT). UVB radiation is particularly effective at generating CPDs and 6-4PPs, while UVA radiation (320–400 nm) also contributes to their formation alongside other lesions like single-strand breaks and oxidized bases. The formation of these dimers distorts the DNA double helix. These clustered DNA damages are considered complex DNA damage or locally multiple damaged sites (LMDSs), as they consist of closely spaced lesions within a short DNA segment, making them more difficult for cellular repair mechanisms to handle effectively. This increased difficulty in repair contributes significantly to genomic instability by allowing mutations and chromosomal abnormalities to persist.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.2	 Types of Radiation-Induced Lesions in DNA | Sub-subsection: 3.2.8	 UV Radiation-Induced DNA Damage | Content: The number of tracks in the cell nucleus as well as the number of
induced damages for high-LET IR depends on the particle type and
energy; therefore, the given values represent only an estimateFig. 3.6
Fig. 3.6 Double-strand
breaks (DSB): an illustration
depicting different types of
double-strand breaks in DNA.
G guanine, C cytosine, A
adenine, T thymine, H-bond
hydrogen bond, P phosphate
radicals across the genome and according to the different
points of the cell cycle.
3.2.6
Complex DNA Damage
Complex DNA damages, described as clustered DNA dam­
ages, are also named “locally multiple damaged sites”
(LMDSs). LMDSs consist of closely spaced DNA lesions
within a short DNA segment and are responsible for an
increased cellular lethality since they are more difficult to
repair. Two or more DNA lesions of the same or different
type may be induced by IR within one or two helical turns of
the DNA molecule, on the opposite strand. This clustered
bistranded damage can be SSBs, DSBs, oxidized bases, and
abasic sites. For example, at a dose of 1 Gy of IR, all this
damage can be generated isolated or up to 10 bp apart [17].
Furthermore, the number of lesions per cluster depends on
the radiation type and dose [18]. Experimental and theoreti­
cal studies have evidenced an increased complexity of the
DNA damage induced by high-LET IR due to clustered ion­
izations, making complex DNA damage the signature of
high-LET IR. Indeed, such lesions are considered the most
important ones in terms of biological effects since they are
the most challenging for the DNA repair machinery.
3.2.7
Overview of Ionizing Radiation-­
Induced DNA Damage
3.1
3.2.8
UV Radiation-Induced DNA Damage
Ultraviolet (UV) light (100–400 nm) is a natural genotoxic
agent able to induce deleterious effects affecting biological
processes and structures, but also DNA structure, leading to
a genomic instability [19]. DNA damage induced by UV is
J. Reindl et al.
91
mainly pyrimidine dimers, oxidized bases, as well as SSBs
and DSBs. Nucleotides absorb UV radiations, which raise
the DNA base to a highly reactive singlet or triplet state,
leading therefore to photochemical reactions. The chemical
nature and the amount of DNA damage strongly depend on
the wavelength of the incident photons. Three main types of
DNA lesions are formed involving two successive pyrimi­
dine bases (CC, TT, TC, and CT) and leading to a DNA
double-­helix distortion: cyclobutane pyrimidine dimers
(CPDs), pyrimidine 6-4 pyrimidone photoproducts (6-4PPs),
and their Dewar isomers. The most energetic part of the solar
spectrum corresponding to UVB (290–320 nm) leads to the
formation of CPDs and 6-4PPs, whereas less energetic but
20 times more intense UVA (320–400 nm) also induces the
formation of CPDs associated with a wide variety of lesions
such as single-strand breaks and oxidized bases. Furthermore,
in addition of the direct photolesions induced, some indirect
DNA damage can occur through the production of ROS,
especially hydroxyl radicals (OH°) and RNS. ROS can
induce the oxidation of pyrimidine and purine bases, and
also the deoxyribose backbone of DNA, such as the induc­
tion of the most frequent, i.e., the 8-hydroxyguanine (8-oxo-­
G) and in a smaller extent SSBs and DSBs. Moreover, the
ROS induced by UV can lead to the alkylation of bases and
to cross-linking of DNA–DNA or DNA-protein. CPDs and
6-4PPs are mostly formed between TT and TC, and in less
proportion for CT and CC sequences. Additionally, the chro­
matin structure, as well as the composition of the neighbor­
ing nucleotide sequence of pyrimidine dimers, also influences
the formation of UV-induced DNA damage. More recently,
some studies discussed the influence of the epigenetic mark­
ers (DNA methylation, histone posttranslational modifica­
tions) in the induction of UV-induced lesions at a particular
locus. Indeed, the methylation of DNA at C5 of cytosine
(5-mC) was associated with an increase by 80% of the CPD
yield and a decrease by 3 of the 6-4PP [20] (Box 3.2).
3.3"
"Describe the major differences between base excision repair (BER) and nucleotide excision repair (NER), focusing on the types of DNA damage they primarily address and the key enzymes involved in each pathway.","Base excision repair (BER) and nucleotide excision repair (NER) are both critical DNA repair pathways, but they tackle distinct types of DNA damage. BER predominantly addresses distortions in the shape of the DNA bases themselves – specifically, damaged or modified single bases caused by oxidation, alkylation, deamination, and other metabolic processes. The core enzyme complex involved is a multi-protein structure called PCNA (proliferating cell nuclear antigen) associated with Pol V (DNA polymerase δ), AP endonucleases (Ape1 and/or Mre11), and others. PCNA acts as a sliding clamp, facilitating the process of base removal by Ape1, followed by gap filling by Pol V.  The pathway is generally considered to be more prevalent and faster than NER.

Conversely, nucleotide excision repair (NER) primarily deals with bulky helix-distorting DNA lesions such as UV-induced pyrimidine dimers (thymine dimers), chemical adducts, and some types of DNA crosslinks. NER involves a larger protein complex known as the TFIIH (transcription factor IIH). This complex contains several key components: XPC, which initiates the pathway by recognizing bulky distortions; RPA70, an RNA polymerase activity that stabilizes the damaged site; XPB and XPD, subunits of the redox-sensitive complex that directly interacts with DNA and facilitates lesion removal; and proliferating cell nuclear antigen (PCNA) again, assisting in gap synthesis. NER is particularly important for protecting cells from the damaging effects of UV radiation.

In essence, BER targets base modifications, while NER addresses larger helix distortions. Both pathways are essential for maintaining genomic stability, but their specific mechanisms and target lesions differ significantly.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Content: ­
­
21
3.2
3.3.1"
"Describe the Base Excision Repair (BER) pathway, detailing the roles of DNA glycosylases and AP endonuclease 1 (APE1), including how it addresses oxidative base damage and its connection to PARP1 activity.","The Base Excision Repair (BER) pathway is a critical mechanism for repairing damaged DNA bases, particularly those resulting from oxidative stress or exposure to ionizing radiation. This process begins with specialized proteins called DNA glycosylases, which recognize and remove the damaged base while leaving the DNA backbone intact. Humans possess eleven distinct DNA glycosylases, categorized as monofunctional (removing bases creating AP sites), bifunctional (removing bases and cutting the DNA backbone), or Nei-like (removing bases but also cutting both sides of it). Upon recognizing a damaged base – such as 8-oxo-guanine resulting from oxidative damage – a specific glycosylase cleaves the N-glycosidic bond, effectively removing the modified base. This leaves behind an abasic site (AP site) consisting of a sugar phosphate backbone with no attached base.  Following this initial removal, AP endonuclease 1 (APE1) plays a crucial role. APE1 incises and hydrolyzes the AP site, cutting the DNA backbone adjacent to the damaged base and creating a one-nucleotide gap. This gap is then processed by other enzymes for final repair. Critically, BER is often coupled with PARP1 activity; when an abasic site forms, PARP1 (polynucleotide kinase phosphatase 1) is activated. PARP1 initiates a poly(ADP-ribose) chain reaction, which recruits and stabilizes proteins at the damaged site, facilitating further DNA repair processes.  Polynucleotide polymerase beta (Polβ) then fills in the gap created by APE1, completing the repair. Deficiencies in BER or its associated pathways can lead to increased mutation rates but rarely cause radiosensitivity unless there are mutations affecting XRCC1 or Polβ. Reference: [Molecular Radiation Biology], Section 3.3.1 – Base Excision Repair","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.1	 Base Excision Repair | Content: ­
­
22
­
­
23
­
­
3.7
In BER, specialized proteins called glycosylases recog­
nize and remove the majority of the damaged DNA bases.
There are multiple glycosylases, each of which is unique to a
certain form of base damage. All these enzymes have, as
their primary function, to cut out the base which got dam­
aged yet without impacting the DNA backbone, causing fur­
ther damage in an abasic place in the DNA (either apurinic or
apyrimidinic site) [25]. Although each DNA glycosylase is
specialized to a certain substrate and works in a distinct man­
ner, they all have a single principal way of action: first, tak­
Box 3.2 In a Nutshell: Types of Radiation-Induced
Lesions in DNA
•	Deoxyribonucleic acid (DNA) is a large molecule
composed of two polynucleotide chains that coil
around each other to constitute a double-stranded
helix structure.
•	IR can cause DNA base or sugar damage, single- or
double-strand breaks, DNA interstrand, intrastrand,
or protein cross-links.
•	DSBs are considered to be one of the most serious
DNA lesions.
•	High-LET IR induces more localized, complex, as
well as clustered damage, which has the most seri­
ous potential biological consequences.
3 Molecular Radiation Biology
92Fig. 3.7
Fig. 3.7 Short and long patch
base excision repair:
recognition of the DNA lesion
occurs by a specific DNA
glycosylase which removes
the damaged base by
hydrolyzing the N-glycosidic
bond. The remaining AP site
is processed by
APE. Depending on the
cleavability of the resulting
5′dRP by Polβ, repair is
performed via the short or
long patch BER pathway.
Reproduced with permission
from [24]. AP-endonuclease
apurinic/apyrimidinic
endonuclease, AP-lyase
apurinic/apyrimidinic lyase,
OH hydroxide, P phosphate,
5’dRP 5′ deoxyribose
phosphate, Lig III ligase III,
XRCC1 X-ray repair
cross-complementing 1, RF-C
replication factor C, Fen1 flap
structure-specific
endonuclease 1, PCNA
proliferating cell nuclear
antigen, Lig I ligase I
Table 3.2 DNA damage repair mechanisms
DNA repair
mechanism
DNA damaging/genotoxic agents
DNA lesion
feature
DNA damage example
DNA repair features
Base excision repair
(BER)
Reactive oxygen species, X-rays,
alkylating agents
Oxidative lesion
Oxidation (8-oxo-G)
uracil, single-strand break
Removal of base by N-glycosylase
abasic sugar removal, replacement
Nucleotide excision
repair (NER)
UV lights and polycyclic aromatic
hydrocarbons
Helix-distortion
lesion
Bulky adducts,
intrastrand cross-link
Removal of DNA fragment and
replacement
Mismatch repair
(MMR)
Replication
Replication error
A–G mismatch, T–C
mismatch, insertion,
deletion
Removal of strand by exonuclease,
digestion, and replacement
Double-strand
break repair
(DSBR)
X-rays, ionizing radiations,
reactive oxygen species, anti-tumor
agents
Double-strand
DNA breaks
Double-strand break,
interstrand cross-link
Unwinding, alignment, ligation
J. Reindl et al.
93
ing the damaged base outside the DNA helix, thus assisting
the detection of bases with minute alterations, and, second,
triggering the cutting of an N-glycosidic bond, which in turn
enables the formation of an abasic site [22]. Humans have 11
DNA glycosylases, which are classified as monofunctional
(removing a base which results in formation of an AP site),
bifunctional (removing a base and cutting the DNA back­
bone close to the damaged base), or Nei-like (which removes
the base but also cuts each side of it).
Once the monofunctional DNA glycosylase has created
the AP site, another repair enzyme, AP endonuclease 1
(APE1), incises and hydrolyzes the AP site, removing the
base followed by the sugar residue, cutting the DNA back­
bone, and as a result an SSB is formed. APE1 also operates
on bifunctional glycosylase products, creating a one-­
nucleotide gap product after hydrolysis. Polynucleotide
kinase phosphatase (PNKP), whose product is suitable for
DNA polymerase action, is required for the repair of oxi­
dized DNA bases. When there is a gap or SSB is formed,
poly(ADP-ribose) polymerase 1 is activated (PARP1) [23].
In this way, the integrity of the break can be maintained.
PARP1 also orchestrates, via its poly(ADP-ribosyl)ation
activity, a cascade of proteins binding to the SSBs with the
main aim to detect and promote its further repair.
­
­
25
­
­
­
14
3.8
IR-induced base damage is effectively repaired by BER.
BER deficiencies can result in a higher mutation rate but sel­
dom cause cellular radiosensitivity [26]. The X-ray cross-­
complementing factor 1 (XRCC1) gene mutation, which
causes a 1.7-fold increase in radiation sensitivity, is an
exception. The radiation sensitivity of XRCC1-deficient
cells, on the other hand, could be due to XRCC1’s involve­
ment in other repair processes, such as SSB repair. Reduced
repair and radiosensitization can be caused by mutations,
deletions, or inhibition of either of these genes.
In both BER and SSB repair, DNA polymerase beta (pol)
is a key enzyme. Under some situations, cells lacking pol or
expressing a dominant negative construct to pol, which
inhibits its function, have been demonstrated to be more vul­
nerable to ionizing radiation in vitro [27]. Small-molecule
medicines that block PARP1 have also been produced. The
PARP inhibitors are a medication that targets BER and SSB
repair and are now being tested in clinical trials for cancer
treatment, as described in Chap. 6 (Box 3.3).
3.3.2"
"Describe the nucleotide excision repair (NER) pathway, highlighting its key components and how it differs between global genome repair (GGR) and transcription-coupled repair (TCR), including the role of RNA polymerase and specific proteins involved.","Nucleotide excision repair (NER) is a critical DNA damage response mechanism utilized by cells to remove bulky DNA lesions, primarily those induced by UV radiation. The pathway involves several coordinated steps. Initially, recognition of the damaged site occurs through proteins like XPC-HR23B, RPA-XPA, or DDB1-DDB2, initiating unwinding of the DNA double helix by TFIIH. This unwinding exposes the lesion, allowing excision enzymes XPG and XPF-ERCC1 to cleave the damaged strand. The 5’ to 3’ DNA polymerase (Polδ or Polε) then resynthesizes the missing sequence using the undamaged complementary strand as a template. Finally, DNA ligase I seals the nick, restoring genomic integrity. NER operates through two distinct pathways: Global Genome Repair (GGR) and Transcription-Coupled Repair (TCR). In GGR, recognition is initiated by stalled RNA polymerase in conjunction with CSB and CSA proteins. Conversely, TCR specifically targets lesions within actively transcribed genes. Here, the stalled RNA polymerase itself triggers the recruitment of NER proteins – CSB and CSA – effectively removing the RNA polymerase from the damaged site to facilitate repair. This mechanism prevents transcriptional blockage and ensures efficient removal of lesions during gene expression. Defects in NER genes, such as those found in xeroderma pigmentosum, significantly increase sensitivity to UV radiation and certain anticancer drugs that generate bulky DNA adducts. Reference: [Molecular Radiation Biology], Section 3.3.2 – Nucleotide Excision Repair","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.2	 Nucleotide Excision Repair | Content: repair and are now being tested in clinical trials for cancer
treatment, as described in Chap. 6 (Box 3.3).
3.3.2
Nucleotide Excision Repair
From unicellular bacteria to complex humans and plants,
nucleotide excision repair (NER) works in a similar way. In
humans, NER is known for its one-of-a-kind repair process to
remove photolesions caused by UV radiation. However, there
is one circumstance in which NER genes can influence the IR
response. More DNA cross-links are formed when cells are
irradiated under hypoxia than when irradiated under nor­
moxic circumstances. Excision activity of two NER genes,
DNA excision repair protein (ERCC1) and DNA repair endo­
nuclease (XPF), is required for such cross-links, among other
things. Defects in either of these genes may cause hypoxic
cells to become more radiosensitive. As a result, the status of
the NER pathway is relevant to radiotherapy in combination
with specific chemotherapeutic drugs, as well as hypoxic
tumors treated only with radiotherapy [28].
3.8
­
22
­
Box 3.3 In a Nutshell: Base Excision Repair
•	BER is a specific repair mechanism that is used to
handle DNA base damage.
•	BER removes single-nucleotide base lesions (small,
non-helix-distorting base lesions) from the genome.
•	SP-BER and LP-BER are two complementary BER
systems essential for removing base damage and
fixing SSB in DNA, minimizing mutagenesis but
differing in what base damages they can handle.
•	BER inhibitors have showed potential as radio/che­
mosensitizers in a variety of malignancies, or they
can create synthetic deadly alliances with common
cancer mutations.
3 Molecular Radiation Biology
94Fig. 3.8
Fig. 3.8 Nucleotide excision
repair (NER) pathway: during
global genomic repair (GGR),
recognition of the DNA lesion
occurs by XPC–HR23B,
RPA–XPA, or DDB1–DDB2.
DNA unwinding is performed
by the transcription factor
TFIIH and excision of the
lesion by XPG and XPF–
ERCC1. Finally, resynthesis
occurs by Polδ or Polε and
ligation by DNA ligase
I. During transcription-­
coupled repair (TCR), the
induction of the lesion results
in blockage of RNAPII. This
leads to assembly of CSA,
CSB, and/or TFIIS at the site
of the lesion, by which
RNAPII is removed from the
DNA or displaced from the
lesion, making it accessible to
the exonucleases XPF–Ercc1
and XPG cleaving the
lesion-containing DNA
strand. Resynthesis again
occurs by Polδ or Polε and
ligation by DNA ligase I.
23B: Reproduced with
permission from Christmann
et al. [24]. DDB1 DNA
damage-binding protein 1,
DDB2 DNA damage-binding
protein 2, RPA replication
protein A, TFIIH transcription
factor IIH, ERCC1 excision
repair cross-complementing
group 1 protein, Polyδ/ε DNA
polymerase delta/epsilon,
PCNA proliferating cell
nuclear antigen, Lig1 DNA
ligase 1, RNAPII RNA
polymerase II, CSA and CSB
Cockayne syndrome factors A
and B, TFIIS transcription
initiation factor IIS, HR23B
homologous recombinational
repair group 23B
the opposite undamaged complementary strand as a template.
With varied degrees of success, NER eliminates lesions from
the entire genome and can be separated into two paths [24]:
1.	Global Genome Repair (GGR or GG-NER): GG-NER is
a genome-wide process, i.e., lesions can be eliminated
from DNA that encodes, or not, for genes.
2.	Transcription-Coupled Repair (TCR or TC-NER): TC-­
NER exclusively eliminates lesions in the DNA strands of
genes that are actively transcribed. If a DNA strand that is
actively transcribed is broken, the RNA polymerase could
inhibit DNA repair by blocking access to damage sites.
TC-NER has evolved to overcome RNA polymerase’s
barrier by essentially eliminating it from the damage site,
allowing repair proteins access.
In the early damage recognition phase, the two NER sub­
pathways vary. In GGR, the NER proteins are recruited by
the stalled RNA polymerase in collaboration with Cockayne
syndrome protein B and A (CSB and CSA). In TCR, the
NER proteins are engaged by the stalled RNA polymerase in
collaboration with CSB and CSA [14].
J. Reindl et al.
95
Mutations in the NER genes do not cause IR sensitivity.
However, defective NER increases sensitivity to UV-induced
DNA damage and anticancer drugs that create bulky adducts,
such as alkylating agents. Human DNA repair deficiency
such as xeroderma pigmentosum, in which individuals are
hypersensitive to UV radiation, is caused by germline muta­
tions in the NER genes [14] (Box 3.4).
3.3.3"
"Describe the mismatch repair (MMR) pathway, including its role in DNA replication and how it addresses errors that escape proofreading by DNA polymerase.","The mismatch repair (MMR) system operates as a crucial post-replication mechanism to correct errors introduced during DNA synthesis. During DNA replication, DNA polymerase occasionally incorporates mismatched base pairs – insertions or deletions of nucleotides – into the newly synthesized strand. While the primary replication polymerase possesses a proofreading function designed to identify and remove these mistakes, it doesn't always succeed in correcting every error. The MMR pathway serves as a secondary defense against these escaped mismatches. 

The process begins with the recognition of the mismatch by proteins like MutS, which binds specifically to incorrect base pairs. This binding triggers a cascade of events involving MutL and MSH proteins. These proteins then initiate DNA strand breaks at the site of the mispaired bases, creating a nick in the newly synthesized strand. The erroneous strand is subsequently excised from the DNA helix using exonuclease activity. Finally, DNA polymerase fills the resulting gap with the correct nucleotides, guided by the intact parental strand as a template. This resynthesis effectively repairs the damaged DNA and restores genomic stability. The MMR pathway's importance is highlighted by its role in maintaining evolutionary genomic stability and its involvement in processes like microsatellite instability observed in tumor cells when the system is compromised.  The discovery of MMR initially occurred in *E. coli* and has since been found to be evolutionarily conserved across many organisms, including humans.

Reference: Molecular Radiation Biology, Section 3.3.3 – Mismatch Repair","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.3	 Mismatch Repair | Content: The mismatch repair (MMR) system has a role after the cel­
lul replication process, where sometimes incorrect bases pair
with each other (which is called a mismatch). Therefore,
MMR aids in keeping DNA homeostasis and plays a major
role in evolutionary genomic stability [29]. Its basic purpose
is to rectify the small insertion-deletion loops (indels) and
the base-base mispairs that are spontaneously generated at
the time of DNA replication. These mis-incorporated bases
have escaped the proofreading action of replication poly­
merase. Usually, the polymerase that carries out the DNA
synthesis process is not completely error-free. The DNA
polymerase on average makes one mistake for every 105
nucleotides [29], which implies that ~100,000 errors arise
through each S phase of the cell. Even though the DNA poly­
merase is there to ascertain that such mistakes do not occur,
a few mutations can go unnoticed by it and hence the MMR-­
associated genes act as the second line of defense. However,
if the cell is deficient in the MMR process, these errors
remain uncorrected. Therefore, the mutational rate and
sequence length modification in the microsatellites, which is
a known trait of tumor cells, increase. The relevance of MMR
in radiation-induced damage and cellular radiosensitivity is a
matter of controversy. The mismatch repair (MMR) pathway
was first discovered in E. coli cells [30]. Researchers have
explored and understood that the MMR pathways and its
associated proteins are evolutionarily conserved in almost all
organisms including humans [31]. MMR works by inserting
or deleting the mispaired bases by recognizing the mispaired
lesion; excision, i.e., removal of the erroneous strand; and
DNA resynthesis and gap repair by filling it with the correct
resynthesized DNA.
32
3.9
­
­
­
33
3.5
3.3.4"
Describe the significance of double-strand breaks (DSBs) in DNA damage and outline the primary mechanisms employed by eukaryotic cells for their repair.,"Double-strand breaks represent the most severe form of DNA damage due to their potential to cause catastrophic genomic instability. A single, unrepaired DSB can lead to immediate cell death by disrupting genetic information and triggering apoptosis. Furthermore, misrepaired DSBs significantly increase the risk of augmented genomic instability, ultimately contributing to tumorigenesis. Recognizing this critical threat, eukaryotic cells have evolved sophisticated repair pathways specifically designed for DSB resolution.

Two primary mechanisms are utilized: homologous recombination (HR) and non-homologous end joining (NHEJ). Homologous recombination relies on a template – typically the sister chromatid – to accurately guide the repair process, resulting in an exact restoration of the original DNA sequence. NHEJ, conversely, is a more error-prone pathway that directly ligates the broken ends without requiring a template. While faster than HR, NHEJ can introduce small insertions or deletions into the repaired DNA.

Additionally, cells utilize nucleotide excision repair (NER) to address large lesions like thymine dimers and cisplatin adducts, which often result from radiation exposure. NER involves removing these bulky DNA distortions before they cause further damage. Finally, mismatch repair (MMR) plays a role in correcting base-pairing errors that arise during replication, though it’s primarily focused on smaller mismatches rather than the extensive damage characteristic of DSBs.

Reference: [Molecular Radiation Biology], Section 3.3.4 – Double-Strand Break Repair","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.4	 Double-Strand Break Repair | Content: Double-strand breaks (DSBs) are the most lethal kind of
DNA damage because even one uncorrected DSB can result
in loss of genetic information and finally lead to cell death.
Moreover, such unrepaired or misrepaired DSBs can lead to
Box 3.4 In a Nutshell: Nucleotide Excision Repair
•	Nucleotide excision repair (NER) is a technique for
removing bulky adducts from DNA, chiefly those
caused by UV.
•	Defects in certain NER proteins may result in
enhanced radiosensitivity of hypoxic cells.
•	Large DNA lesions like thymine dimers and cispla­
tin adducts are repaired using a DNA repair
pathway.
•	The two types of NER pathways are global genome
repair (GGR or GG-NER) and transcription-­
coupled repair (TCR) (TCR or TC-NER).
Box 3.5 In a Nutshell: Mismatch Repair
•	MMR targets DNA mismatches that arise mainly
during replication, as well as repairing mismatches
that occur in DNA following treatment with alkylat­
ing agents.
•	The MMR pathway detects and repairs erroneous
insertions, deletions, and base substitutions that
have not been detected by the proofreading function
of DNA polymerase during DNA replication, thus
maintaining the genome stability.
•	It works by recognition of mispair, excision of the
affected strand, and filling of the gap.
3 Molecular Radiation Biology
96Fig. 3.9
Fig. 3.9 Overview of eukaryotic mismatch repair system. In the human
cell, the predominantly found MutSα (MSH2–MSH6) or the MutSβ
recognizes the DNA mismatch repair and initiates its repair. Some of
the crucial molecules which participate in the repair are the MutLα
(MLH1-PMS2), the proliferating cell nuclear antigen (PCNA), and the
replication factor (RCF). EXO1 catalyzes the repair, and ligase finally
ligates the repaired DNA
augmented genomic instability and eventually tumorigenesis
[21]. Accordingly, for a cell to pursue its genetic informa­
tion, a functional DSB repair system is of major importance.
As a result, cells have evolved a dedicated response to iden­
tify and mend DSBs. For repair of DNA DSBs, two principal"
"Describe the Homologous Recombination (HR) DNA repair pathway, detailing its mechanism of action and key components involved in accurately repairing double-strand breaks.","Homologous Recombination (HR) is a highly precise DNA repair pathway utilized by cells to fix double-strand breaks (DSBs), primarily leveraging undamaged sister chromatids as templates. The process begins with DNA end resection, facilitated by nucleases like MRE11 and CtIP, generating 3′-ssDNA overhangs. These overhangs are rapidly bound by replication protein A (RPA) to prevent degradation and secondary structure formation. Subsequently, the ATR kinase is activated through RPA binding, triggering Chk1 activation – a critical checkpoint control mechanism. This cascade ultimately leads to RAD51 recruitment, which displaces RPA and forms a nucleoprotein filament that explores homologous DNA sequences on the sister chromatid.  This exploration results in the formation of a displacement loop (D-loop), enabling base pairing between the broken strand and the template strand, followed by DNA synthesis to fill any gaps. The outcome can lead to either a double Holliday junction (dHJ) – potentially resulting in crossover (CO) or noncrossover (NCO) events – or synthesis-dependent strand annealing (SDSA), forming a single Holliday junction and ultimately an NCO. Importantly, HR utilizes chromatin modifiers and remodelers, including histone variants, to overcome nucleosomal barriers encountered by the resection machinery, ensuring accurate repair. This pathway is particularly active during late S and G2 phases when sister chromatids are available as templates, guaranteeing error-free DNA repair. Reference: [Molecular Radiation Biology], Section 3.3.4.1 Homologous Recombination (HR)","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.4	 Double-Strand Break Repair | Sub-sub-subsection: 3.3.4.1	 Homologous Recombination (HR) | Content: and Non-homologous end joining (NHEJ).
These pathways differ with respect to the use of homolo­
gous template DNA as well as in DNA repair fidelity. HR
utilizes undamaged sister chromatid as its template to repair
the damage, and therefore it is error-free. However, NHEJ
works by eliminating the damaged DNA followed by direct
ligation and hence is error-prone. As HR needs an undam­
aged template, it only operates in late S and G2, in contrast
to NHEJ, which has the capacity for DSB repair regardless
of the cell’s position in the cell cycle phase [33].
3.3.4.1	Homologous Recombination (HR)
The homologous recombination (HR) molecular pathway is
associated with a large number of cellular processes, from
J. Reindl et al.
97
imparting genetic diversity to DNA repair or replication. HR
is evolutionarily conserved from bacteria to mammalian cells.
This pathway is essential for fixing DNA damages with high
accuracy by using the genomic code of the chromosomal
copy which was not damaged [34]. HR works by precisely
repairing the DSB, shielding cells from any chromosomal
abnormalities such as those observed in many cancers.
Throughout the process of DNA replication, HR-associated
proteins endorse the faithfulness and restoring of distressed
DNA replication forks. This adds sturdiness, serving the rep­
lication machinery to circumvent under replication and suc­
ceeding segregation tribulations of the chromosome. Inherent
HR insufficiency in cells can persuade instability in the
genome and further lead to cancer. Conversely, discrepancy
in the HR pathway also sensitizes tumors not only to DNA
damage treatment but also to other potential DNA repair
inhibitors for remedial repair pathways.
3.10
36
36
­
­
­
37
37
­
­
35
A full functional HR pathway can be utilized after the
DNA end resection. A detailed review of this process can be
found in the work of Ranjha et al. [38]. The canonical HR
pathway not only restores a direct DSB, but also repairs dam­
age created by stalled or collapsed replication forks [21]. As
soon as an extensive resection is executed by the action of
several nucleases, cells are obligated to follow a homology-­
governed mode of repair. The DSB goes through a nuclease-­
driven progression known as DNA end resection in order to
produce 3′-end ssDNA segments all through HR. This is cru­
cial for the searching and strand invasion that occurs later
during the recombination process. Along with the CtIP nucle­
ase, DNA end resection is instigated by the MRE11 nuclease
within the MRN complex. MRN/CtIP in combination with
Bloom syndrome protein (BLM) or exonuclease 1 (EXO1)
and DNA replication helicase/nuclease (DNA2) arbitrates the
short- as well as long-term resections. During this resection,
the 3′ ends of ssDNA get exposed that are rapidly covered by
replication protein A (RPA) complex. The ssDNA region cov­
ered by RPA further recruits and stimulates the ataxia-telan­
giectasia and Rad3-related (ATR) kinase. This in turn triggers
the checkpoint kinase 1 (Chk1) kinase. The RPA coating not
only ascertains the nondegradation of ssDNA overhangs but
also avoids the formation of secondary structures. To form the
presynaptic filament, RAD51 dislocates RPA, which is then
involved in the action of several RAD51 mediator proteins.
To construct a displacement loop (D-loop), the RAD51
nucleoprotein filament explores a homologous sequence to
occupy and dislocate one strand of the homologous template.
This structure aids in the formation of a heteroduplex by pair­
ing the broken strand with the displaced strand, and DNA
synthesis at the break site repairs for any missing nucleotides.
The outcome of the second end capture leads to the configura­
tion of a double-­Holliday junction (dHJ). The resolution of
such an intermediate occurs either by a resolution mechanism
or by a dissolution, which makes it susceptible to crossover
(CO) or noncrossover (NCO). On the other hand, at the time
of synthesis-­dependent strand annealing (SDSA), no more
than one-end invasion takes place, therefore leading to the
formation of a single-Holliday junction. This transitional
structure is suspended into an NCO. The HR repair pathway
is known to also involve chromatin modifiers, remodelers,
and even integration of histone variant so as to deal with the
obstructions that the nucleosomes produce to the resection
machinery. HR is active during the late S phase and the G2
phase and therefore is able to utilize the sister chromatid as a
guiding template to repair the DSBs. Hence, this pathway is
error-free [38]."
"Describe the non-homologous end joining (NHEJ) pathway for DNA double-strand break repair, detailing key proteins involved and their roles in processes like D-loop formation, heteroduplex pairing, and resolution mechanisms. Specifically, explain the function of DNA-PKcs and its interaction with Artemis.","The non-homologous end joining (NHEJ) pathway is a critical DNA repair mechanism utilized by cells to mend double-strand breaks (DSBs). This process doesn't rely on a template sequence like homologous recombination (HR), making it faster but potentially less precise. The initial step involves the Ku70/Ku80 complex binding to the broken DNA ends, protecting them from degradation and initiating further events. Subsequently, DNA-PKcs, a protein kinase activated upon Ku binding, phosphorylates downstream proteins involved in end processing and repair. RAD51 dislocates RPA coating from the ssDNA overhangs, forming a nucleoprotein filament that explores homologous sequences to create a displacement loop (D-loop) for heteroduplex formation and DNA synthesis. Artemis, a 5' exonuclease, trims the 5’ ends of the broken DNA strands to generate the necessary 3'-OH and 5’-P termini required for ligation. The ligase IV complex, including XRCC4 and XLF, then catalyzes the final ligation step. Importantly, NHEJ can lead to non-crossover or crossover products depending on whether a sister chromatid template is utilized during DNA synthesis – SDSA results in an NCO product while extension of the heteroduplex leads to a dHJ intermediate that can resolve into either a crossover or noncrossover product. Dysregulation of NHEJ, particularly defects in DNA-PKcs, significantly increases radiation sensitivity due to impaired DSB repair and subsequent genomic instability. Reference: [Molecular Radiation Biology], Section 3.3.4.2 – Non-homologous End Joining","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.4	 Double-Strand Break Repair | Sub-sub-subsection: 3.3.4.2	 Non-homologous End Joining | Content: the checkpoint kinase 1 (Chk1) kinase. The RPA coating not
only ascertains the nondegradation of ssDNA overhangs but
also avoids the formation of secondary structures. To form the
presynaptic filament, RAD51 dislocates RPA, which is then
involved in the action of several RAD51 mediator proteins.
To construct a displacement loop (D-loop), the RAD51
nucleoprotein filament explores a homologous sequence to
occupy and dislocate one strand of the homologous template.
This structure aids in the formation of a heteroduplex by pair­
ing the broken strand with the displaced strand, and DNA
synthesis at the break site repairs for any missing nucleotides.
The outcome of the second end capture leads to the configura­
tion of a double-­Holliday junction (dHJ). The resolution of
such an intermediate occurs either by a resolution mechanism
or by a dissolution, which makes it susceptible to crossover
(CO) or noncrossover (NCO). On the other hand, at the time
of synthesis-­dependent strand annealing (SDSA), no more
than one-end invasion takes place, therefore leading to the
formation of a single-Holliday junction. This transitional
structure is suspended into an NCO. The HR repair pathway
is known to also involve chromatin modifiers, remodelers,
and even integration of histone variant so as to deal with the
obstructions that the nucleosomes produce to the resection
machinery. HR is active during the late S phase and the G2
phase and therefore is able to utilize the sister chromatid as a
guiding template to repair the DSBs. Hence, this pathway is
error-free [38].
3.3.4.2	Non-homologous End Joining
3.11
3 Molecular Radiation Biology
98Fig. 3.10
Fig. 3.10 Overview of homologous recombination (HR) pathways in
double-strand break repair. When cells suffer a DSB (purple lines), they
can repair them either by HR, with the help of a template that is homol­
ogous (turquoise lines), or by the NHEJ pathway. (a) BRCA1 promotes
the HR pathways, whereas the Shieldin complex, RIF1, and 53BP1 pro­
mote the NHEJ pathway. (b) The resection process is performed by the
MRN complex along with CtIP, EXO1, BLM, and DNA2 that form the
3′ ssDNA overhangs. These overhangs are then coated with the RPA
(green boxes), which is later shifted by the RAD51 (brown circles). On
the other hand, single-strand annealing occurs in case of the RAD-­
independent repair process, where annealing of the complementary
DNA sequences takes place followed by overhangs cleaved by the flap
endonuclease and finally the ends of the DNA are ligated. (c) Positive
regulators of RAD51 such as RAD51 paralogs, BRCA2, and PALB2
aid in the formation of the RAD51 filament, whereas RECQL5 and
FBH2 negatively regulate RAD51. (d) The RAD51 paralogs and
RAD54A-B support the RAD51-mediated homology searching and
strand invasion. At the same time, FANCM and RTEL negatively gov­
ern the RAD51-mediated D loops. (e) The homologous template in the
form of sister chromatid or a homologous chromosome is used by the
DNA polymerases to copy the missing sequence. (f) The DNA is
resolved into a noncrossover product when SDSA dislodges the D loop.
(g) In case there is an extension of the heteroduplex and development of
Holliday junction created by the second-end capture, the intermediate
states can be resolved by either resolution or dissolution. (h) The out­
come of resolution is both the crossover and noncrossover products. (i)
The outcome of dissolution is a noncrossover product. Adapted with
permission (CCBY) from Sullivan and Bernstein [35]. Abbreviations:
DSB double-­strand DNA break, HR homologous recombination, NHEJ
Non-homologous end joining, BRCA1 breast cancer gene 1, RIF1
Rap1-interacting factor 1, 53BP1 p53-binding protein 1, MRN MRE11–
RAD51–NBS1 complex, CtIP CtBP-interacting protein, EXO1 exonu­
clease 1, BLM Bloom’s syndrome helicase, RecQ helicase-like gene,
DNA2 DNA replication helicase/nuclease 2, ssDNA single-stranded
DNA, RPA replication protein A, RAD51 RAD51 recombinase, PALB2
partner and localizer of BRCA2, RECQL5 RecQ-like helicase 5, FBH2
also GNA11, G protein subunit alpha 11, FANCM FA complementation
group M, RTEL regulator of telomere elongation helicase 1, SDSA
synthesis-­dependent strand annealing
J. Reindl et al.
99Fig. 3.11
Fig. 3.11 Schematic of the principal steps of NHEJ. (I) IR triggers the
formation of DNA DSB in the cell nucleus. (II) To act on these, the
NHEJ pathway commences with the movement of Ku (Ku70/Ku80)
proteins towards the loose ends in the DNA DSB. (III) Ku70/Ku80
forms a complex embracing the ends protecting DNA integrity. DNA
DSBs with noncomplex termini can be ligated directly after this step as
end processing is not required. (IV) When the ends in the DSB require
end trimming, the DNA-PKcs is recruited onto DNA via association to
the Ku70/Ku80 complex forming a platform for subsequent steps. (V)
Once associated to Ku proteins and DNA, DNA-PKcs undergoes auto­
phosphorylation which changes its conformation. (VI) In this way,
DNA-PKcs is active as a kinase and regulates the association of multi­
ple DNA end-trimming proteins (e.g., Artemis, WRN, Polμ/λ, PNK),
which restores the nucleotides at the termini allowing ligation to take
place. (VII) The ligation step is controlled by the DNA ligase IV com­
plexes, which apart from ligase IV also include XRCC4, XLF, and
PAXX. At the end of the trimming and ligation step, some bases may be
lost causing loss of genomic information which may cause mutations.
Abbreviations: DNA DSB DNA double-strand break, NHEJ Non-
homologous end joining, Ku dimeric Ku70/Ku80 protein complex,
DNA-PKcs DNA-­dependent protein kinase catalytic subunit, WRN pro­
tein deleted in Werner syndrome, Polμ/λ DNA polymerase μ/λ, PNK
polynucleotide kinase, XRCC4 X-ray repair cross-complementing pro­
tein 4, XLF XRCC4-like factor, PAXX paralog of XRCC4 and XLF
3 Molecular Radiation Biology
100
repairing DNA DSBs, and cells deficient in some of these
signaling components are known to be very IR sensitive [39].
Moreover, NHEJ has a critical role in V(D)J-recombination
when B and T lymphocytes are developed in the immune
system. This is also illustrated by severe combined immuno­
deficiency (SCID) patients who, due to lack or alteration in
some of the NHEJ components including the catalytical sub­
unit of DNA-PK (DNA-PKcs) as well as others, have T and
B lymphocytes that do not have proper function [39].
Importantly, cells from such patients also display high IR
sensitivity.
3.11
­
41
­
41
­
4142
­
­
­
42
3.11
DNA-PKcs is a kinase with the capacity to phosphorylate
proteins on serine or threonine resides. It belongs to a protein
family also named the PIK kinases to which also ATM and
ATR belong. DNA-PKcs requires DNA binding for its kinase
activity to control the end-processing activity within NHEJ as
well as inactivation of its own function [42]. Thus, when the
Ku complex binds DNA-PKcs, it causes autophosphorylation
of multiple residues in the kinase domain and thereafter
DNA-PKcs can phosphorylate its downstream substrates.
Multiple studies in rodent and human cells using various
genetic approaches have shown that a defective DNA-PKcs
activity impairs the repair of some but not all IR-induced
DNA DSBs, but nevertheless causes increased radiation sen­
sitivity [39]. To further study the function of DNA-PKcs for
repair of IR or chemotherapy-induced DNA damage, inhibi­
tors towards the kinase pocket have been developed, some of
which have also been demonstrated to function as IR sensi­
tizers of tumor cells and in tumor-bearing mice (reviewed in
the work of Myers et al. [43]). All in all, it is clear that DNA-­
PKcs orchestrates the NHEJ pathway, but despite decades of
research, the understanding of the entire molecular mecha­
nisms is still not complete.
The end processing of the nucleotides is required as a
DNA DSB seldom has the 3′OH and 5′P termini that are
required for ligation. Therefore, the ends in the DNA DSB
need to be processed by exonucleases such as Artemis, which
has intrinsic 5′ exonuclease function and 5′ exonuclease
acquired once in complex with DNA-PKcs [44]. The critical
role for Artemis in the NHEJ processing has been shown as
cells deficient in Artemis are sensitive to IR. However,
Artemis is only required for repair of a subset of ~10–20% of
the DNA DSBs, while the others are rejoined efficiently in
the absence of Artemis. Therefore, it has been suggested that
Artemis is responsible for repair of DNA DSBs that display
slow repair kinetics. Apart from Artemis, there are also other
proteins involved in the end-processing activity including
Werner syndrome ATP-­dependent helicase (WRN). It exhib­
its helicase and exonuclease function and suppresses 5′ end
resection as well as HR by blocking MRE11 and CtlP asso­
ciation. Other examples are the polynucleotide phosphatase/
kinase (PNKP) and tyrosyl-­DNA phosphodiesterase 1
(TDP1) that modify the phosphorylation of the nucleotides
and trim the ends to a state allowing ligation to take place. As
some nucleotides may be lost in the end termini, the DNA
polymerase μ and DNA polymerase λ are also part of the
end-trimming activity in NHEJ.
Ligation of broken ends by NHEJ is carried out in a pro­
tein complex, which bridges around the DNA end in the
DSB. The complex contains, among other proteins, XRCC4,
DNA ligase IV, and XRCC4-like factor (XLF). Out of all the
proteins involved in NHEJ, DNA ligase IV stands out when
it comes to repair of DNA DSBs because mice, in which this
gene is disrupted, experience lethality as embryos and dis­
section of such embryos have revealed extensive apoptosis,
in particular in the nervous system [45]. Both ligase IV and
XLF mutations, that impair their function, are reported in
humans in different tumor types, e.g., leukemias and lym­
phomas, with the patients showing various degrees of defi­
ciency in B and T lymphocyte function [46] (Box 3.6).
J. Reindl et al.
101"
"Describe the alternative NHEJ (alt-NHEJ) pathway for double-strand break repair, including its key features, mechanisms, and observed patterns of activity.","The alternative NHEJ (alt-NHEJ) pathway represents a distinct mechanism for repairing double-strand breaks (DSBs), particularly notable for its operation in both NHEJ-proficient and -deficient cells. Unlike the conventional HR and NHEJ pathways, alt-NHEJ doesn’t require long homologous DNA templates. It relies on microhomologies – typically 3-16 nucleotide sequences – that exist at or near the break ends, often accompanied by overlapping deletions. This pathway is most active during the G2 phase of the cell cycle. The repair process involves resection of the broken DNA ends by enzymes like MRE11 and CtIP, followed by stabilization of intermediates, elimination of non-compatible overhangs via nucleases, and finally ligation by DNA ligase III. Furthermore, alt-NHEJ is linked to microhomology-mediated end joining (MMEJ), which involves the arrangement of microhomologous series on the inner side of the broken ends prior to fusion, frequently leading to chromosomal translocations. The pathway utilizes RAD52-dependent single-strand annealing (SSA)-type machinery with homology requirements between 5 and 29 base pairs. Reference: [Molecular Radiation Biology, Section 3.3.4.3 – Alternative DSB Repair Pathways]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.3	 Types of DNA Repair Pathways | Sub-subsection: 3.3.4	 Double-Strand Break Repair | Sub-sub-subsection: 3.3.4.3	 Alternative DSB Repair Pathways | Content: Cells fundamentally utilize two conventional mechanisms to
repair their DSBs, i.e., the HR and the NHEJ pathways.
However, in recent times, a third pathway is discovered
which is known as the alternative NHEJ (alt-NHEJ or
aNHEJ), microhomology-mediated end joining (MMEJ),
and B (backup)-NHEJ. This is an extremely error-prone
pathway that operates in NHEJ-proficient as well as -defi­
cient cells. Unlike HR, this pathway does not require any
long homologous DNA templates and is therefore called as
“alternative end-joining” pathways. This mechanism typi­
cally but not always depends on the microhomologies that
exist at or near the DNA DSB ends, which implicates that it
might not be completely divergent from the mechanism of
HR. The junctions of this repair pathway demonstrated over­
lapping microhomologies of 3–16 nucleotides as well as
nucleotide deletions. Earlier, it was known that the NHEJ
pathway could recover short microhomologous region of up
to five nucleotides in mammalian cells. However, the alt-
NHEJ can operate even in the NHEJ-deficient cells [47]. It is
a unique pathway that is seen to be ongoing throughout the
cell cycle but found to be augmented in the G2 phase when
compared to the G1 phase. Although it is arguable if there are
other alt-NHEJ overlapping pathways, there is evidence of a
microhomology-mediated end joining (MMEJ) that involves
the arrangement of microhomologous series on the inner
side of the broken ends prior to fusion and is linked with
deletion adjoining the original DSB. This is also an error-­
prone pathway leading to chromosomal translocations.
One of the characteristics of alt-NHEJ is the excessive
deletions and frequent microhomologies at the junction,
while such microhomologies are not always present. The
exclusivity of alt-NHEJ products implicates the usage of end
resection-promoting enzymes, their association of proteins
that get benefitted from the microhomologies that can sup­
port the intermediates to stabilize, nucleases competent of
eliminating the noncompatible 5′ and 3′ overhangs, and
finally ligation. The MRE11 complex and CtIP in end resec­
tion are known to facilitate the alt-NHEJ, and DNA ligase III
emerges to uphold the ligation step.
It is observed that the microhomology-mediated DNA
repair proceedings take place via RAD52-dependent single-­
strand annealing (SSA)-type machinery where the minimum
SSA-dependent DSB repair lies between 5 and 29 base pairs
of homology. In this mechanism, it is mandatory to have
direct repeats on both the sides of the DNA break. Since SSA
does not involve any strand invasion events, it is independent
of RAD51. As MMEJ depends on the already existing micro­
homologies around the break, its probable mode of action is
associated with SSA. Finally, for the sealing event, MMEJ
depends on ligase III [47].
3.4
Importance of Chromatin Architecture
(at Nano- and Microscale) in DNA
Damage and Repair
3.4.1
Multifaceted Importance of Chromatin
Architecture in DNA Damage Induction
and Repair
­
48
­
3.12
­
This network is dynamic and influenced by the cellular
status and ongoing processes in the cell nucleus. Chromatin
architecture is precisely regulated by physical and biochemi­
cal regulation systems and, in turn, regulates global and local
genome functions. Local chromatin arrangement thus both
reflects and determines the functions of the particular genetic
locus, such as its transcriptional activity. Importantly in the
context of radiobiology, nonrandom chromatin architecture
seems to co-determine the response of cells to irradiation in
numerous ways: First, in a tight interplay with physical char­
acteristics of the radiation, functional chromatin structure
states increase or decrease DNA susceptibility to DNA dam­
age induction. Second, the chromatin architecture acts as an
additional level of DSB repair regulation, cooperating with
“standard” biochemical genetic and epigenetic regulation
systems. Chromatin architecture may regulate DSB repair at
individual DSB sites and also globally, via tuning the tran­
scription intensity of genes involved in DNA repair and other
processes related to the complex response of cells to radia­
tion DNA damage (e.g., cell cycle progression or apoptosis).
Theoretically, chromatin architecture might collect and unify
Box 3.6 In a Nutshell: Non-homologous End-Joining
•	The NHEJ pathway plays a crucial role in the repair
of DNA DSBs generated endogenously and by IR.
•	NHEJ has less fidelity in repair than HR and may
therefore in certain circumstances cause mutations.
•	NHEJ deficiency results in increased radiation
sensitivity.
•	Some of the NHEJ pathway components, e.g., DNA
ligase IV, are essential for NHEJ repair, while oth­
ers are required for efficient repair of certain sub­
sets of DNA DSBs.
•	NHEJ components, e.g., DNA-PKcs, offer a target
that can be used for radiation sensitization purposes
in various tumor types.
3 Molecular Radiation Biology"
"Describe the role of chromatin architecture in DNA damage response following irradiation, specifically addressing how it interacts with both DNA damage induction and repair pathways like Non-Homologous End Joining (NHEJ).","Chromatin architecture plays a profoundly complex and dynamic role in mediating cellular responses to ionizing radiation (IR) by simultaneously influencing the susceptibility of DNA to damage and regulating the efficiency of DNA repair processes. Initially, nonrandom chromatin arrangements – characterized by altered compaction or organization – can directly increase or decrease DNA’s vulnerability to IR-induced damage. This effect is intertwined with the physical characteristics of the radiation itself; tighter chromatin structures may physically shield DNA from damaging radiation, while looser configurations could expose more DNA to its effects. Furthermore, chromatin architecture acts as a secondary regulator of DSB repair pathways, particularly NHEJ. The precise arrangement of chromatin around individual DSB sites can either enhance or hinder the recruitment and activity of NHEJ factors like DNA ligase IV and DNA-PKcs, ultimately affecting the speed and accuracy of repair. Beyond localized effects, chromatin architecture also influences global repair processes by modulating the transcriptional intensity of genes involved in DNA repair – including those directly participating in NHEJ – as well as broader cellular responses such as cell cycle progression or apoptosis. This suggests a coordinated network where chromatin structure not only reflects ongoing genomic events but actively shapes the overall response to radiation damage. The information presented highlights that NHEJ deficiency leads to increased radiation sensitivity, and components of this pathway represent potential targets for sensitization strategies. Reference: Molecular Radiation Biology, Section 3.4 – Importance of Chromatin Architecture (at Nano- and Microscale) in DNA Damage and Repair.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.4	 Importance of Chromatin Architecture (at Nano- and Microscale) in DNA Damage and Repair | Content: associated with SSA. Finally, for the sealing event, MMEJ
depends on ligase III [47].
3.4
Importance of Chromatin Architecture
(at Nano- and Microscale) in DNA
Damage and Repair
3.4.1
Multifaceted Importance of Chromatin
Architecture in DNA Damage Induction
and Repair
­
48
­
3.12
­
This network is dynamic and influenced by the cellular
status and ongoing processes in the cell nucleus. Chromatin
architecture is precisely regulated by physical and biochemi­
cal regulation systems and, in turn, regulates global and local
genome functions. Local chromatin arrangement thus both
reflects and determines the functions of the particular genetic
locus, such as its transcriptional activity. Importantly in the
context of radiobiology, nonrandom chromatin architecture
seems to co-determine the response of cells to irradiation in
numerous ways: First, in a tight interplay with physical char­
acteristics of the radiation, functional chromatin structure
states increase or decrease DNA susceptibility to DNA dam­
age induction. Second, the chromatin architecture acts as an
additional level of DSB repair regulation, cooperating with
“standard” biochemical genetic and epigenetic regulation
systems. Chromatin architecture may regulate DSB repair at
individual DSB sites and also globally, via tuning the tran­
scription intensity of genes involved in DNA repair and other
processes related to the complex response of cells to radia­
tion DNA damage (e.g., cell cycle progression or apoptosis).
Theoretically, chromatin architecture might collect and unify
Box 3.6 In a Nutshell: Non-homologous End-Joining
•	The NHEJ pathway plays a crucial role in the repair
of DNA DSBs generated endogenously and by IR.
•	NHEJ has less fidelity in repair than HR and may
therefore in certain circumstances cause mutations.
•	NHEJ deficiency results in increased radiation
sensitivity.
•	Some of the NHEJ pathway components, e.g., DNA
ligase IV, are essential for NHEJ repair, while oth­
ers are required for efficient repair of certain sub­
sets of DNA DSBs.
•	NHEJ components, e.g., DNA-PKcs, offer a target
that can be used for radiation sensitization purposes
in various tumor types.
3 Molecular Radiation Biology"
"How does chromatin architecture influence the cellular response to ionizing radiation, specifically regarding DNA damage induction and repair mechanisms?","Chromatin architecture plays a critical role in mediating the cellular response to ionizing radiation by intricately regulating both DNA damage induction and subsequent repair processes. The organization of DNA within the nucleus – encompassing structures like nucleosomes and higher-order chromatin fibers – directly impacts its susceptibility to radiation-induced damage. Specifically, tightly packed heterochromatin, characterized by condensed DNA and a reduced transcriptional activity, can increase DNA’s vulnerability to damage from high-LET radiation (like alpha particles) due to increased accessibility of the DNA strand. Conversely, more open euchromatin, with its decondensed structure and active transcription, exhibits lower susceptibility to initial damage. Following damage induction, chromatin architecture further modulates repair pathways. The dynamic nature of chromatin allows for the integration of signals from various cellular networks – biochemical, epigenetic, and potentially even physical forces – into a unified response at individual DNA break sites. This ‘roofing’ regulatory system can rapidly determine the optimal repair mechanism (such as non-homologous end joining or homologous recombination) based on the architectural status of the chromatin surrounding the damage. Furthermore, distinct chromatin domains like RIDGE and anti-RIDGE regions, with their defined architecture and function, contribute to a more nuanced response.  The interplay between radiation quality (low vs. high LET), chromatin domain type, and DSB repair mechanisms is fundamental to determining the overall cellular outcome in response to irradiation. Reference: [Molecular Radiation Biology], Section 3.4.2 – DNA Damage and Repair in the Context of Chromatin Architecture at the Microscale.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.4	 Importance of Chromatin Architecture (at Nano- and Microscale) in DNA Damage and Repair | Sub-subsection: 3.4.1	 Multifaceted Importance of Chromatin Architecture in DNA Damage Induction and Repair | Content: associated with SSA. Finally, for the sealing event, MMEJ
depends on ligase III [47].
3.4
Importance of Chromatin Architecture
(at Nano- and Microscale) in DNA
Damage and Repair
3.4.1
Multifaceted Importance of Chromatin
Architecture in DNA Damage Induction
and Repair
­
48
­
3.12
­
This network is dynamic and influenced by the cellular
status and ongoing processes in the cell nucleus. Chromatin
architecture is precisely regulated by physical and biochemi­
cal regulation systems and, in turn, regulates global and local
genome functions. Local chromatin arrangement thus both
reflects and determines the functions of the particular genetic
locus, such as its transcriptional activity. Importantly in the
context of radiobiology, nonrandom chromatin architecture
seems to co-determine the response of cells to irradiation in
numerous ways: First, in a tight interplay with physical char­
acteristics of the radiation, functional chromatin structure
states increase or decrease DNA susceptibility to DNA dam­
age induction. Second, the chromatin architecture acts as an
additional level of DSB repair regulation, cooperating with
“standard” biochemical genetic and epigenetic regulation
systems. Chromatin architecture may regulate DSB repair at
individual DSB sites and also globally, via tuning the tran­
scription intensity of genes involved in DNA repair and other
processes related to the complex response of cells to radia­
tion DNA damage (e.g., cell cycle progression or apoptosis).
Theoretically, chromatin architecture might collect and unify
Box 3.6 In a Nutshell: Non-homologous End-Joining
•	The NHEJ pathway plays a crucial role in the repair
of DNA DSBs generated endogenously and by IR.
•	NHEJ has less fidelity in repair than HR and may
therefore in certain circumstances cause mutations.
•	NHEJ deficiency results in increased radiation
sensitivity.
•	Some of the NHEJ pathway components, e.g., DNA
ligase IV, are essential for NHEJ repair, while oth­
ers are required for efficient repair of certain sub­
sets of DNA DSBs.
•	NHEJ components, e.g., DNA-PKcs, offer a target
that can be used for radiation sensitization purposes
in various tumor types.
3 Molecular Radiation Biology
102Fig. 3.12
Fig. 3.12 Structure of DNA
organization. The DNA forms
a double-helix structure,
which is wrapped around
histones forming so-called
nucleosomes. The
nucleosomes form complex
fibers of 30 nm size, which
themselves form the higher
order chromatin fibers, which
are in the range of 300 nm. In
the interphase, these fibers
build the chromatin territories,
where territories from
different chromosomes can
overlap, forming so-called
networks. In the metaphase,
the higher order chromatin
fibers are condensed to form
chromosomes. (Adapted with
permission (CCBY) from Liu
et al. [40])
signals of other different signaling networks (biochemical,
epigenetic) and transfer these heterogeneous signals into
single integrated output signal represented by a specific
architectural status of the chromatin network that can be eas­
ily interpreted by the cell. Chromatin architecture might thus
impersonate a “roofing” regulatory system based on simple
physical laws, which allows for a sufficiently fast decision-­
making process for the optimal repair mechanism at each
individual DNA damage site.
Different types (low LET vs. high LET) of IR interact
with chromatin in specific ways. Therefore, the relationship
between the radiation quality, architecture of structurally
and functionally distinct chromatin domains, and DSB
induction, repair, and misrepair play a role in the cellular
radiation response. Genetically active, decondensed
euchromatin and mostly inactive, condensed heterochro­
matin are the two traditionally recognized structurally and
functionally distinct chromatin domains, which affect radi­
ation response. However, it should be noted that radiation
response differences may be even more prominent for other
chromatin architectural and functional counterparts [49],
such as RIDGE (regions of increased gene expression) and
anti-­RIDGE domains [50], which have even more precisely
defined function and more homogenous architecture as
compared to euchromatin and heterochromatin (Box 3.7).
Box 3.7 In a Nutshell: Importance of Chromatin
Architecture
•	DNA is organized in structural units ranging from
micrometers to nanometers, forming 3D chromatin
architecture.
•	Chromatin architecture is a key factor determining
local damage induction by radiation.
•	Chromatin architecture operates with genetic and
epigenetic regulatory factors orchestrating DNA
damage response.
J. Reindl et al.
103
3.4.2
DNA Damage and Repair in the Context
of Chromatin Architecture at
the Microscale
3.13
­
­
51
­
­
­
51
52
­
48
­
­
­
­
­
48
­
3.3
A serious consequence of irradiation is the formation of
chromosomal aberrations, and the chromatin architecture sig­
nificantly participates in this process. The severity and com­
plexity of the genetic damage are related to the complexity of
the underlying DNA damage. The connection between dam­Fig. 3.13
Fig. 3.13 Localization of DNA damage on chromatin: radiation damage induced by high-LET alpha particle radiation microscopically visualized
by γH2AX as a biomarker for double-strand breaks (left, magenta), chromatin labeling (middle, green), and merge of the two (right)
Table 3.3 Properties of hetero- and euchromatin
Heterochromatin
Euchromatin
Condensed DNA
Low amount of active genes
Protection of DNA from radicals
through condensed structure and high
amount of radical catching proteins
clustering around DNA
Slow repair due to necessary
decondensation
Homologous recombination superior to
nonhomologous end joining
Decondensed DNA
Transcriptionally active
No radical protection
No decondensation
necessary and therefore fast
repair
No preference of repair
mechanisms defined by
chromatin architecture
3 Molecular Radiation Biology"
"The text describes two primary hypotheses regarding DNA double-strand break (DSB) repair in relation to chromatin architecture: the ‘position-first’ hypothesis and the ‘breakage-first’ hypothesis. Explain the core tenets of each hypothesis, highlighting how they differ in their understanding of DSB mobility and the role of chromatin during repair.","The ‘position-first’ hypothesis posits that DSBs are essentially immobile structures within the cell nucleus, and their probability of interacting with neighboring genetic loci is largely determined by pre-existing chromatin architecture. This means that the spatial organization of euchromatin and heterochromatin – established before irradiation – significantly influences the likelihood of chromosomal translocations occurring between adjacent loci. The hypothesis suggests a predetermined ‘exchange’ facilitated by the existing chromatin landscape. Conversely, the ‘breakage-first’ hypothesis proposes that DSBs are mobile entities within the cell nucleus. According to this model, chromatin architecture plays a subsidiary role in facilitating these breaks rather than dictating their interactions. This implies that radiation exposure can induce movement of DSBs through the nuclear environment, allowing them to encounter and interact with distant genetic loci, particularly under conditions where low-LET radiation causes chromatin decondensation and increased mobility. The key difference lies in whether DSBs are considered fixed points or mobile actors within the repair process; position-first emphasizes pre-existing structure while breakage-first highlights dynamic movement.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.4	 Importance of Chromatin Architecture (at Nano- and Microscale) in DNA Damage and Repair | Sub-subsection: 3.4.2	 DNA Damage and Repair in the Context of Chromatin Architecture at the Microscale | Content: No preference of repair
mechanisms defined by
chromatin architecture
3 Molecular Radiation Biology
104
age complexity and radiation type was discussed in Sect. 3.2.
An additional factor defining the complexity is the chromatin
state, and radiation interacts with this. These interactions can
be illustrated on the example of chromosomal translocation
formation upon irradiation of euchromatin and heterochro­
matin with low-LET and high-LET radiation, respectively.
The type of radiation, chromatin architecture, and conse­
quently initiated DSB repair processes participate in a spe­
cific way in free DNA-end misrejoining (review [53, 54]).
The probability of a chromosomal translocation forma­
tion between two specific genetic loci, i.e., the linking of the
ends of different chromosomes after induction of DSB in
both chromosomes at the same time, depends on spatial (3D)
separation of these loci in the cell nucleus. Chromatin is non­
randomly organized in the cell nucleus, though on the proba­
bilistic basis, this means that chromosomal translocations
between some genetic locus pairs appear more frequently
than translocations between other pairs. This expectation
was confirmed by experiments with interphase cells exposed
to neutrons or high-LET particles where translocations
appeared most frequently between the neighboring chromo­
somal territories or even genetic loci statistically located in
close proximity [55]. Overall, there are two hypotheses used
to explain the processes related to repair of DSB in the con­
text of chromatin organization:
1.	Position-first hypothesis: It considers DSBs as immobile
structures and emphasizes the role of (preset) chromatin
architecture in determining the probability of a chromatin
exchange between two specific genetic loci.
2.	Breakage-first hypothesis: It considers DSBs as mobile
and gives the chromatin architecture a subsidiary role.
Both hypotheses explain different phenomena occurring.
While the position-first hypothesis works well in explaining
the enhanced probability of translocations to be formed by
neighboring chromosomes, it does not allow chromatin
exchanges between spatially more distant genetic loci,
though such translocations were experimentally observed.
Furthermore, although complex chromosomal translocations
are only occasional events upon cell exposure to photonic
(low-LET) radiation, they do occur. As DSBs are dispersed
through the cell nucleus and thus spatially separated in cells
irradiated with low-LET radiation, formation of complex
translocation between three or more DSBs can hardly be
explained without involving DSB movement. Both observa­
tions can be explained by the breakage-first hypothesis.
However, the idea of highly mobile chromatin at DSB sites
in cells exposed to low-LET radiation, where chromatin is
not locally fragmented as in cells exposed to high-LET par­
ticle radiation, has not been generally confirmed. The expla­
nation of this paradox came with the spatiotemporal tracking
of individual radiation-induced protein accumulations (foci)
[52], showing the majority of “immobile” DSBs accompa­
nied with a small proportion of highly mobile DSB lesions or
by subdiffusive nature of DSB loci [56]. The increased
mobility correlated with DSB localization in heterochroma­
tin and can thus be attributed to chromatin decondensation at
the beginning of heterochromatin repair process, leading to
the protrusion of DSBs onto the surface of heterochromatin
domains. Numerous DSBs thus accumulate in nuclear sub­
compartments of a limited volume, which increases the
probability of their mutual interactions and consequently
chromatin exchanges even among multiple DSBs.
After irradiation with high-LET particles, on the other
hand, locally concentrated energy deposition causes serious
chromatin fragmentation and mobilization within cell nucleus
micro-volumes along the particle tracks. This situation allows
mutual contacts of many short chromatin fragments from one
or several neighboring chromosomes and thus easy formation
of complex chromatin translocations, irrespectively of the
original chromatin architecture and chromatin architecture
changes during repair. Chromosomal translocations in cells
exposed to high-LET radiation thus occur due to physical
rather than biological (repair) processes. We have already
mentioned that heterochromatin architecture protects DNA
from low-LET radiation as heterochromatin-­binding proteins
prevent DNA interaction with free radicals, mostly mediating
harmful effects of low-­LET radiation. With high-LET radia­
tion, however, most damage to DNA is caused by the direct
effect of radiation particles or emitted secondary electrons. In
this case, heterochromatin represents a more dangerous chro­
matin architecture, as particles cannot be stopped by any
chromatin architecture and heterochromatin provides more
DNA targets per a volume unit compared to euchromatin.
Hence, in cells exposed to high-LET radiation, translocations
in heterochromatin tend to be more complex than in euchro­
matin (Box 3.8).
Box 3.8 In a Nutshell: DNA Damage and Repair in the
Context of Chromatin Architecture
•	Hetero- and euchromatin form different chromatin
architectural regions within a cell nucleus resulting
in different consequences of radiation damage
induction.
•	Chromosomal aberrations after low-LET radiation
can be explained through the “position-first hypoth­
esis” in combination with chromatin decondensa­
tion in heterochromatic regions.
•	Chromosomal aberrations after high-LET radiation
occur due to physical fragmentation of DNA rather
due to biological processes.
•	Heterochromatin protects DNA from indirect dam­
age (mainly induced by low-LET radiation) but is
more sensitive to direct damage (mainly induced by
high-LET radiation).
J. Reindl et al.
105
3.4.3"
"The text describes observations regarding γH2AX foci following low-LET X-ray exposure. Specifically, what key findings related to the size and topology of these foci were observed over time, and how did this relate to DNA repair processes?","Following exposure to low-LET X-rays, γH2AX foci within cell nuclei exhibited a dynamic behavior characterized by an increase in the number of clusters with increasing radiation dose, adhering to a linear-quadratic relationship. Critically, the size and topology of these γH2AX clusters remained remarkably consistent – typically around 400 nm–600 nm in diameter – as long as they were maintained in close association with heterochromatin regions actively involved in DNA double-strand break (DSB) repair. Furthermore, the arrangement of these foci, particularly their relationship to MRE11 clusters (which were smaller, approximately 200 nm), mirrored the dynamics of protein interaction with chromatin; binding to damage sites resulted in a more ordered topological arrangement, while detachment led to relaxation. Notably, γH2AX and MRE11 clusters that spontaneously appeared in non-irradiated cells – often due to replication defects – lacked this consistent topology. These findings strongly suggest that the precise nanoscale architecture of these repair foci is functionally relevant to the DSB repair process, with topological order facilitating efficient protein interactions and chromatin reorganization during recovery. Reference: Molecular Radiation Biology, Section 3.4.3 – DNA Damage and Repair Processes at the Nanoscale","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.4	 Importance of Chromatin Architecture (at Nano- and Microscale) in DNA Damage and Repair | Sub-subsection: 3.4.3	 DNA Damage and Repair Processes at the Nanoscale | Content: the Nanoscale
Using a variety of tools of super-resolution microscopy and
image data computing has revealed that γH2AX foci in cell
nuclei exposed to low-LET X-rays are subdivided into several
equally sized, functionally relevant clusters. The number of
clusters increased with the radiation dose according to the
well-known linear-quadratic dependence and decreased at
later time periods postirradiation. Calculations of the persis­
tence of homology revealed a highly similar topology of
γH2AX and other repair protein clusters, especially when
these clusters were closely associated with heterochromatin
regions. During the repair period, size and topology of these
clusters seem to be maintained as long as they are attached to
chromatin at actively repairing DSB sites. These findings sug­
gest a functional relevance of the focus/cluster topology [57].
For instance, while the γH2AX clusters had a typical
diameter of about 400 nm–600 m, the MRE11 clusters were
smaller (about 200 nm) and usually completely embedded
within γH2AX clusters [58]. The sizes of clusters were inde­
pendent of repair time and cell type. On the other hand, the
topological similarity of clusters followed the dynamics of
the repair protein interaction with chromatin; that is, binding
to damage sites was accompanied by ordering while detach­
ments caused the relaxation of topological arrangements. In
contrast, γH2AX and MRE11 clusters spontaneously occur­
ring in the nonirradiated cells (e.g., due to replication defects)
did not show this topological similarity.
Recent studies discovered spatial distribution changes of
tri-methylated H3K9 histone (H3K9me3), ALU repeat
sequences (ALU), or long interspersed nuclear element
(LINE)-like L1 sequences, indicating chromatin reorganiza­
tion or movement and DNA strand relaxation after radiation
exposure, followed by recovery during repair [59].
Altogether, described results suggest a functional relevance
of chromatin and repair focus nano-architecture in DSB
repair process and their regulation (Box 3.9).
3.5
Consequences of DNA Damage
Misrepair or Unrepair"
"Describe the concept of genomic instability (GI) and its implications for cellular health and evolutionary processes, drawing upon the provided information.","Genomic Instability (GI) represents a state characterized by an increased propensity for chromosome breaks, rearrangements, and mutations within a cell's genome. This instability is fundamentally linked to disruptions in critical regulatory mechanisms designed to maintain genomic integrity. Specifically, deficiencies in surveillance systems such as the DNA damage checkpoint, DNA repair pathways, or the mitotic checkpoint can trigger GI. When these safeguards fail, cells experience loss of control over the cell cycle, ultimately leading to premature senescence (cellular aging) and apoptosis (programmed cell death). In human contexts, GI is strongly associated with pathological disorders including accelerated aging and a heightened susceptibility to various cancers – often due to the accumulation of mutations that drive uncontrolled cellular proliferation. However, it’s crucial to recognize that GI isn't solely detrimental; it also plays a vital role in evolutionary processes by inducing genetic diversity through random mutation and chromosomal rearrangement events. This capacity for instability allows populations to adapt to changing environments over time. The balance between maintaining genomic integrity and utilizing GI for adaptive evolution is therefore a complex and critical aspect of cellular biology.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.5	 Consequences of DNA Damage Misrepair or Unrepair | Content: lead to increased chromosome breaks or rearrangements and
mutations usually referred to as a status of genomic or
genetic instability (GI). GI is usually associated with loss of
cell cycle control, senescence, and cell death and in humans
with pathological disorders including premature aging and
predisposition to various types of cancer and inherited dis­
eases [60]. On the other hand, GI is also fundamental for
evolution and induction of genetic diversity. It is known that
genomic integrity is carefully supervised by specific surveil­
lance mechanisms like DNA damage checkpoint, DNA
repair, or mitotic checkpoint. A deficiency in the regulation
of any of these mechanisms often leads to GI, which can
predispose a cell to malignant transformation [61].
3.5.1"
"Describe the nanoscale organization of DNA damage repair clusters, including the roles of γH2AX and 53BP1, and how this organization changes during the DNA repair process.","DNA damage repair sites following radiation exposure are not randomly distributed but instead form organized clusters at the nanoscale. These clusters are characterized by the presence of γH2AX foci – regions of hyperphosphorylated histone H2A that mark the location of DNA double-strand breaks – and 53BP1, a protein involved in recruiting other repair factors. These two proteins often form larger functional clusters, with smaller clusters embedded within them. Following damage induction, chromatin undergoes reorganization, accompanied by movement of DNA segments within these repair clusters. Critically, this chromatin remodeling is reversible; during the active DNA repair process, the reorganized chromatin structure returns to its original state after the damage has been repaired. This dynamic organization suggests a coordinated and highly regulated response at the nanoscale to efficiently resolve DNA lesions. Reference: Molecular Radiation Biology, Section 3.5.1 – DNA Lesions and Repair.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.5	 Consequences of DNA Damage Misrepair or Unrepair | Sub-subsection: 3.5.1	 DNA Lesions and Repair | Content: evolution and induction of genetic diversity. It is known that
genomic integrity is carefully supervised by specific surveil­
lance mechanisms like DNA damage checkpoint, DNA
repair, or mitotic checkpoint. A deficiency in the regulation
of any of these mechanisms often leads to GI, which can
predispose a cell to malignant transformation [61].
3.5.1
DNA Lesions and Repair
­
3.3
­
­
45
­
3.4
3.3
­
62
Box 3.9 In a Nutshell: DNA Damage and Repair
Processes on the Nanoscale
•	DNA repair locations marked by γH2AX and
53BP1 are subdivided into functional clusters at the
nanoscale, in a manner which is cell type and radia­
tion type specific.
•	Other repair protein clusters are smaller and are
embedded in the γH2AX and 53BP1 clusters.
•	After damage induction, chromatin is reorganized
accompanied by DNA movement.
•	Chromatin reorganization is recovered during DNA
repair.
3 Molecular Radiation Biology
106
Mutations can be divided into somatic or germline mutation
in terms of what kind of cell is affected. A germline mutation
occurs in a sperm or in an egg and can be passed to offspring.
Somatic mutations occur in cells of the body and cannot be
passed to next generations. Mutations can also be grouped as
point or chromosomal mutations. Point mutations are when a
single nucleotide is replaced with another single nucleotide,
or deleted, or inserted in a place that it should not be. Point
mutations do not always have significant consequences on
the encoded protein. For example, as is shown in Table 3.4,
the mutation can be silent. This means that even if there is a
change in the original DNA sequence, the final product of
the transcription will be the same, because there are several
combinations of the DNA alphabet that lead to the same
amino acid. In other cases, the mutation can lead to the
change of the final amino acid (missense mutation) or to the
creation of a stop codon (nonsense mutation), which then
affects the final protein.
3.5.2"
"The text describes several consequences of DNA damage misrepair or unrepair, including mitotic catastrophe, senescence, and the release of cytoplasmic DNA. Explain how the activation of innate immune signaling is linked to these processes, specifically referencing the role of DNA Damage Response (DDR) factors.","Following DNA damage, particularly when repair mechanisms fail, several cellular responses can be triggered that ultimately contribute to genomic instability. Mitotic catastrophe leads to cell death due to improper chromosome segregation during mitosis. Senescence represents a state of irreversible cell cycle arrest, often initiated by DNA damage. Critically, the release of cytoplasmic DNA plays a significant role in initiating immune signaling. This occurs because DNA is normally confined within the nucleus and its presence in locations like the cytoplasm or endosomes is recognized as an aberrant event. The text highlights that DNA Damage Response (DDR) factors, such as DNA repair proteins, can actually enhance innate immune signaling when activated by this cytoplasmic DNA. Specifically, DDR activation leads to the production of ‘danger signals’ or damage-associated molecular patterns (DAMPs), further amplifying the inflammatory response. This cross talk between DNA repair and immunity is implicated in phenomena like autoinflammatory diseases, cellular senescence, and cancer development – illustrating how genomic instability fuels a cascade of events mediated by immune activation.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.5	 Consequences of DNA Damage Misrepair or Unrepair | Sub-subsection: 3.5.2	 Mitotic Cell Death, Senescence, Cytoplasmic DNA | Content: Cytoplasmic DNA
63
­
3.14a
63
3.14b
­
F
ig. 3.14
Fig. 3.14 Morphologies of mitotic catastrophe (a) and senescence (b).
(a) Fluorescence image of cancer cells undergoing mitosis. The DNA is
labeled with DAPI and mitotic spindles using α-tubulin staining. The
cells exhibiting mitotic catastrophe are treated with photodynamic ther­
apy (PDT), Taxol (Tx), or nocodazole (Nc). The control shows normal
mitotic spindles. The treated cells show various types of altered spin­
dles and mitosis. Scale bar: 10 μm. Reproduced with permission
(CCBY) from Mascaraque et al. [64]. (b) Phase-contrast images of
Chang cells. Senescence was induced using 1 mM of deferoxamine.
(Reproduced with permission (CCBY) from Kwon et al. [65])
Table 3.4 Point mutations and their consequences
Point mutations
No mutationSilent
Missense
Nonsense
DNA
TTC
TTT
TCC
ATC
mRNA
AAG
AAA
AGG
UAG
Amino acidLysine (Lys)Lysine (Lys)Arginine (Arg)Stop
J. Reindl et al.
107
Recent advances in the field indicate that a further conse­
quence of DNA damage misrepair or unrepair can be the
release of cytoplasmic DNA that can also trigger immune
responses. In general, it is widely accepted that immune sig­
naling can be activated by the presence of DNA in unusual
locations, such as the cytoplasm or the endosomes, as DNA
is normally located in the nucleus of eukaryotic cells.
Emerging evidence indicates a cross talk between DNA
repair machinery and the immune system, and more specifi­
cally it has been discovered that DDR factors like DNA
repair proteins can enhance innate immune signaling [66].
Defects in DDR and proper processing of DNA damage can
therefore trigger a multitude of cellular phenotypes, includ­
ing autoinflammatory disease, cellular senescence, and can­
cer. Genotoxic agents such as radiations or high oxidative
stress can act as the primary instigators for immune signal­
ing activation through the release of a wide range of biologi­
cal and chemical factors often referred to as “danger signals”
or damage-associated molecular patterns (DAMPs) [67]
(Box 3.10).
3.6
Cytogenetics and DNA Damage
Measurements for Assessment
of Radiation Effects
Cytogenetic techniques can be used to analyze chromosomal
aberrations in metaphase and morphological abnormalities
of DNA content in interphase nuclei. The applicability of
these aberrations in the fields of biological dosimetry, clini­
cal cytogenetics, and environmental monitoring is based on a
large number of radiobiological and DNA-repair theories.
3.6.1
Micronuclei and Other Nuclear
Anomalies
­
­
­
3.15
­
­
It is now well established that MN are formed from acen­
tric chromatid fragments caused by misrepaired or unre­
paired DNA breaks or lagging acentric chromosomes due to
mitotic spindle failure at an anaphase. Additionally, the for­
mation of DNA DSBs and MN is sometimes the result of
simultaneous excision repair of damages (e.g., 8-oxo-­
deoxyguanosine) and inappropriate bases’ (e.g., uracil)
incorporation in proximity on opposite complementary DNA
strands.
A whole chromosome lagging behind (chromosome mal-­
segregation) during anaphase also results in MN formation.
Mal-segregation usually happens due to absence or inappro­
priate attachment of spindle microtubules to chromosome
kinetochore. However, the potential mechanisms behind the
formation of MN are hypomethylation repeat sequences in
centromeric and pericentromeric DNA, defects in kineto­
chore proteins or assembly, dysfunctional spindle, defective
anaphase checkpoint genes, and malfunctioning in cell cycle
control system. Sometimes, mis-segregation events occur
when the centromeres of the dicentric chromosomes are
pulled towards opposite poles of cells with sufficient forces
to detach the chromosome from spindle during anaphase,
thus resulting in micronucleus formation from whole chro­
mosome loss.
Furthermore, multiple extrachromosomal acentric double
minutes (DMs), cytogenetic hallmarks of genomic amplifi­
cation, can aggregate after DNA damage and generate cyto­
plasmic MN that are subsequently eliminated from the cell.
3.15
­
Box 3.10 In a Nutshell: Consequences of DNA Damage
Misrepair and Unrepair
•	Genomic instability (GI) collectively refers to a sta­
tus of increased DNA changes, chromosomal rear­
rangements, and enhanced tendency for genetic
alterations occurring during cell division.
•	Unrepaired or misrepaired DNA lesions can lead
to chromosomal mutations, which can lead to
cell death or loss of genetic material, thus pro­
moting GI.
•	Mitotic cell death is the process of a cell dying in
relation to mitosis and can be triggered by radiation-­
induced damages.
•	Senescence is the status of irreversible cell cycle
arrest, which occurs naturally during aging but can
be triggered by radiation, which can lead to patho­
logical onsets.
•	Cytoplasmic DNA and DNA repair defects can trig­
ger immune response.
3 Molecular Radiation Biology"
"Describe the various mechanisms that can contribute to micronucleus formation following chromosomal missegregation during cell division, referencing potential causes beyond simply spindle dysfunction.","Micronucleus formation is a complex process often resulting from errors in chromosome segregation during anaphase. While dysfunctional spindles and defective anaphase checkpoint genes are significant contributors, several other mechanisms can initiate this event. Hypomethylation of repeat sequences within centromeric and pericentromeric DNA has been implicated; these modifications can disrupt proper kinetochore attachment to spindle microtubules, leading to chromosome misalignment. Furthermore, defects in the assembly or function of kinetochore proteins themselves – the structures directly connecting chromosomes to the spindle – can similarly cause segregation errors. A malfunctioning spindle itself, beyond simple disruption, can also contribute through improper microtubule dynamics and positioning. Critically, mis-segregation events involving dicentric chromosomes (those with two centromeres) can occur when sufficient force pulls these chromosomes towards opposite poles during anaphase, resulting in the detachment of a chromosome from the spindle and subsequent micronucleus formation. Finally, the aggregation of multiple extrachromosomal acentric double minutes (DMs), often generated as hallmarks of genomic amplification following DNA damage, can contribute to the creation of cytoplasmic micronuclei that are subsequently eliminated by the cell. These events collectively highlight the multifaceted nature of chromosomal missegregation and its consequences for genome stability.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.6	 Cytogenetics and DNA Damage Measurements for Assessment of Radiation Effects | Content: segregation) during anaphase also results in MN formation.
Mal-segregation usually happens due to absence or inappro­
priate attachment of spindle microtubules to chromosome
kinetochore. However, the potential mechanisms behind the
formation of MN are hypomethylation repeat sequences in
centromeric and pericentromeric DNA, defects in kineto­
chore proteins or assembly, dysfunctional spindle, defective
anaphase checkpoint genes, and malfunctioning in cell cycle
control system. Sometimes, mis-segregation events occur
when the centromeres of the dicentric chromosomes are
pulled towards opposite poles of cells with sufficient forces
to detach the chromosome from spindle during anaphase,
thus resulting in micronucleus formation from whole chro­
mosome loss.
Furthermore, multiple extrachromosomal acentric double
minutes (DMs), cytogenetic hallmarks of genomic amplifi­
cation, can aggregate after DNA damage and generate cyto­
plasmic MN that are subsequently eliminated from the cell.
3.15
­
Box 3.10 In a Nutshell: Consequences of DNA Damage
Misrepair and Unrepair
•	Genomic instability (GI) collectively refers to a sta­
tus of increased DNA changes, chromosomal rear­
rangements, and enhanced tendency for genetic
alterations occurring during cell division.
•	Unrepaired or misrepaired DNA lesions can lead
to chromosomal mutations, which can lead to
cell death or loss of genetic material, thus pro­
moting GI.
•	Mitotic cell death is the process of a cell dying in
relation to mitosis and can be triggered by radiation-­
induced damages.
•	Senescence is the status of irreversible cell cycle
arrest, which occurs naturally during aging but can
be triggered by radiation, which can lead to patho­
logical onsets.
•	Cytoplasmic DNA and DNA repair defects can trig­
ger immune response.
3 Molecular Radiation Biology"
"Describe the various mechanisms leading to micronucleus formation as detailed in section 3.15 of the document, including those related to DNA repair processes and mitotic spindle dysfunction.","Micronuclei (MN) are small, extranuclear bodies formed through several distinct pathways involving chromosome damage or segregation errors during cell division. A primary mechanism involves acentric chromatid fragments resulting from misrepaired or unrepaired DNA breaks, as well as lagging acentric chromosomes due to mitotic spindle failure at anaphase. Furthermore, simultaneous excision repair of DNA double-strand breaks (DSBs) coupled with the inappropriate incorporation of bases like uracil can contribute to MN formation. Chromosomal mal-segregation, often stemming from inadequate attachment of spindle microtubules to kinetochores, is another significant cause. Hypomethylation of centromeric and pericentromeric DNA sequences has also been implicated in promoting chromosome segregation defects. Dicentric chromosomes, resulting from the pulling of centromeres towards opposite poles during anaphase, can lead to nucleoplasmic bridges (NPBs) formation, which are subsequently linked to micronucleus development. Nuclear bud (NBUD) formation represents the extrusion of amplified DNA and repair complexes, while multiple extrachromosomal acentric double minutes (DMs) aggregating after DNA damage can generate cytoplasmic MNs that are then eliminated. The formation of NPBs is also associated with telomere end-to-end fusion mechanisms, a marker for loss of telomere function. These processes highlight the complex interplay between DNA damage response pathways and mitotic chromosome dynamics in generating these cytogenetic anomalies. Reference: [Molecular Radiation Biology, Section 3.6.1 – Micronuclei and Other Nuclear Anomalies]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.6	 Cytogenetics and DNA Damage Measurements for Assessment of Radiation Effects | Sub-subsection: 3.6.1	 Micronuclei and Other Nuclear Anomalies | Content: Anomalies
­
­
­
3.15
­
­
It is now well established that MN are formed from acen­
tric chromatid fragments caused by misrepaired or unre­
paired DNA breaks or lagging acentric chromosomes due to
mitotic spindle failure at an anaphase. Additionally, the for­
mation of DNA DSBs and MN is sometimes the result of
simultaneous excision repair of damages (e.g., 8-oxo-­
deoxyguanosine) and inappropriate bases’ (e.g., uracil)
incorporation in proximity on opposite complementary DNA
strands.
A whole chromosome lagging behind (chromosome mal-­
segregation) during anaphase also results in MN formation.
Mal-segregation usually happens due to absence or inappro­
priate attachment of spindle microtubules to chromosome
kinetochore. However, the potential mechanisms behind the
formation of MN are hypomethylation repeat sequences in
centromeric and pericentromeric DNA, defects in kineto­
chore proteins or assembly, dysfunctional spindle, defective
anaphase checkpoint genes, and malfunctioning in cell cycle
control system. Sometimes, mis-segregation events occur
when the centromeres of the dicentric chromosomes are
pulled towards opposite poles of cells with sufficient forces
to detach the chromosome from spindle during anaphase,
thus resulting in micronucleus formation from whole chro­
mosome loss.
Furthermore, multiple extrachromosomal acentric double
minutes (DMs), cytogenetic hallmarks of genomic amplifi­
cation, can aggregate after DNA damage and generate cyto­
plasmic MN that are subsequently eliminated from the cell.
3.15
­
Box 3.10 In a Nutshell: Consequences of DNA Damage
Misrepair and Unrepair
•	Genomic instability (GI) collectively refers to a sta­
tus of increased DNA changes, chromosomal rear­
rangements, and enhanced tendency for genetic
alterations occurring during cell division.
•	Unrepaired or misrepaired DNA lesions can lead
to chromosomal mutations, which can lead to
cell death or loss of genetic material, thus pro­
moting GI.
•	Mitotic cell death is the process of a cell dying in
relation to mitosis and can be triggered by radiation-­
induced damages.
•	Senescence is the status of irreversible cell cycle
arrest, which occurs naturally during aging but can
be triggered by radiation, which can lead to patho­
logical onsets.
•	Cytoplasmic DNA and DNA repair defects can trig­
ger immune response.
3 Molecular Radiation Biology
108Fig. 3.15
Fig. 3.15 Mechanisms by which genotoxic agents cause micronuclei
and other nuclear anomalies. Micronuclei (MN) can originate from lag­
ging acentric chromosomes or chromatid fragments or whole chromo­
somes at anaphase in mitosis. Nuclear bud (NBUD) formation
represents the process of extrusion of the amplified/surplus DNA, DNA
repair-recombinational protein complexes, and possibly excess chro­
mosomes from aneuploidic cells. Nucleoplasmic bridges (NPBs) origi­
nate from dicentric chromosomes. This arises because the centromeres
of dicentric chromosomes are often pulled in opposite directions and
defective separation of sister chromatids occurs during anaphase lead­
ing to bridge formation, which can be observed as an NPB in
telophase
tive and reliable biomarkers for early genotoxic instability
and chromosomal breakages and rearrangements. NPBs
originate as an aftereffect of misrepair of DNA strand breaks
or failure of complete chromatid separation to opposite
poles of the cell during anaphase. It can also originate from
telomere end-to-end fusion mechanism, a fundamental indi­
cation of and a marker for loss of telomere function, which
is caused by (a) excessively short telomeres, (b) dysfunc­
tional telomeres due to loss of telomere-binding proteins
without telomere erosion, (c) inappropriate assembly of
telomere-­capping protein structure, (d) defects in recombi­
national repair proteins, or (e) lack of telomeres. Another
distinctive nuclear anomaly, NBUDs, is one of the precur­
sors of MN and is associated with chromosomal instability
events. Most NBUDs originate from interstitial or terminal
acentric fragments and represent the expulsion of undesir­
able amplified extrachromosomal DNA content, which
localizes to specific sites at the periphery of the nucleus and
is eventually eliminated via nuclear budding during the S
phase of cell cycle. It is also plausible that NBUDs might
occur after elimination of DNA repair-protein complexes in
the cytoplasm (Box 3.11).
Box 3.11 In a Nutshell: Micronuclei and Other Nuclear
Anomalies
•	Micronuclei are small extranuclear bodies surrounded
by a membrane that contain damaged chromosome
fragments or even whole chromosomes. The genetic
information encoded in the MN DNA will get lost
and lead to large genomic consequences.
•	Chromosome segregation errors and/or fragment
loss at anaphase (“inter-cell bridges”) and exclusion
of acentric fragments from daughter nuclei lead to
formation of MN in the cytoplasm.
J. Reindl et al.
109
•	Micronuclei occur outside the main cellular nucleus
and are prone to rupturing, which leads to changes
in DNA that can drive cancer development.
•	Extensive DNA damage may cause dicentric/con­
catenated ring chromosomes and acentric chroma­
tid/chromosome fragments, which can result in the
formation of a nucleoplasmic bridge (NPB) at ana­
phase and micronuclei, respectively.
•	Nuclear buds (NBUDs) are the result of elimination
of amplified extrachromosomal DNA, which
adheres to the nucleus by a thin nucleoplasmic con­
nection, and are observed as double minute-type
micronucleus bodies.
­
­
3.16
Fig. 3.16 Depending on the cell type, different micronucleus assays
can be employed to assess and determine the genotoxicity and cytotox­
icity of different chemical and physical factors. Applications of each
assay are outlined in their respective boxes. The most popular CBMN
assay can be applied to cultured human lymphocytes or cell lines to
measure MN and other chromosomal instability biomarkers such as
NPBs and NBUD. The mammalian erythrocyte micronucleus assay is
performed on immature erythrocytes from bone marrow to determine
cytogenetic damage after radiation exposure. The buccal micronucleus
cytome assay is done in rapidly dividing buccal epithelial exfoliated
cells (oral cavity) to analyze MN and other cytogenetic biomarkers
(source of DNA damage, cytotoxicity, etc.). Occasionally, MN assay is
performed on nasal mucosa cells or urine-derived cells for detection of
chromosomal damage caused by environmental and lifestyle factors,
occupational exposures, prognosis of cancer, and certain diseases.
Although the objective and method of performance are similar to
CBMN or bone marrow MN assays, these tests have not gained much
popularity so far
3 Molecular Radiation Biology
110
the assays. Concomitantly, it increases the statistical validity
after analyzing a large number of cells in one go. Additionally,
the existing automatic/semiautomatic micronucleus scoring
by microscopic systems, by flow cytometry and imaging
flow cytometry, gives high accuracy and sensitivity and leads
to rapid analysis (Box 3.12).
3.6.2"
"Describe the process of chromosomal translocation, particularly focusing on how radiation type (low-LET vs. high-LET) influences the types of translocations observed and explain the significance of premature chromosome condensation (PCC) in this context.","Chromosomal translocations are genetic events resulting from illegitimate rejoining of DNA double-strand breaks, a common consequence of radiation exposure. The type of translocation is heavily influenced by the energy deposition characteristics of the radiation. Low-LET radiation predominantly generates interchromosomal translocations – where segments switch between homologous chromosomes – due to its ability to produce localized, simpler breaks. Conversely, high-LET radiation leads to complex genotype rearrangements including intra-chromosomal translocations (where segments break and rejoin within the same chromosome) and dicentric chromosomes (structures with two centromeres). This shift reflects the higher energy deposition of high-LET radiation, which causes more extensive and complex DNA damage. Premature Chromosome Condensation (PCC) is a critical phenomenon observed following radiation exposure, particularly in mitotic cells. PCC refers to the premature condensation of chromatin into distinct chromosome structures outside of normal cell cycle stages – typically seen in G0, G1, S, or G2 phases. This process is often triggered by MPF (Mitosis-Promoting Factor), an enzyme involved in regulating cell division. Chemical agents like okadaic acid can activate MPF and induce PCC, allowing researchers to visualize and quantify chromosomal damage immediately after irradiation. The ability to detect PCC at various stages of the cell cycle makes it a valuable tool for assessing radiation effects, measuring DNA repair kinetics, and studying the dynamics of chromosome condensation – ultimately linking radiation-induced DNA damage with observable chromosomal abnormalities.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.6	 Cytogenetics and DNA Damage Measurements for Assessment of Radiation Effects | Sub-subsection: 3.6.3	 Premature Chromosome Condensation | Content: ­
cdc2
­
3.20
­
­
­
Box 3.14 In a Nutshell: Chromosomal Translocations
•	Chromosomal translocations are the consequence
of illegitimate rejoining of DNA double-strand
breaks generated by radiation.
•	Chromosomal translocations pose a risk of forma­
tion of a fusion gene/protein with oncogenic func­
tions; even single translocation may be a sufficient
genetic defect to initiate leukemia.
•	While low-LET radiation generates mostly simple
translocations, exposure to high-LET radiation
leads to complex genotype rearrangements.
•	Due to the character of energy deposition, low-LET
radiation produces predominantly interchromo­
somal translocations; higher occurrence of intra­
chromosomal translocations is then a sign of a
high-LET exposure.Fig. 3.20
Fig. 3.20 The presence and action of MPF protein in the cell control
premature chromosome condensation induction. Cyclin B oscillates
through the cell cycle being undetectable during interphase, very low in
G1, gradually increasing from S, reaching maximum in G2, and
decreasing abruptly at G2/M transition. This corresponds to the MPF
activity during cell cycle. MPF maturation/mitosis-promoting factor
3 Molecular Radiation Biology
114
F
i
g
. 3.21
Fig. 3.21 Premature chromosome condensations (PCCs) at various
stages of the cell cycle: darkly stained metaphase chromosomes belong
to mitotic CHO cells, whereas the lighter stained to the interphase CHO
cells. (a) G0-PCCs, (b) G1-PCCs, (c) S-PCCs (reproduced with per­
mission (CCBY) from Pantelias et al. [73]), (d) G2-PCCs. CHO
Chinese hamster ovary
­
­
0
1
2
3.21
0
1
1
­
73
2
2
PCC can be induced either by fusion of human lympho­
cytes with mitotic cells (fusion-mediated PCC) or with the
use of specific chemicals (chemical-induced PCC).
In the case of fusion-mediated PCC, the condensation was
at first achieved with the use of fusogenic viruses (such as
Sendai virus or its equivalent). However, an important disad­
vantage of this method is that the fusion efficiency depends
on various notable factors [74]. These difficulties were over­
come by using cell-fusing chemical agents (e.g., polyethyl­
ene glycol—PEG). PEG overcomes these difficulties and
can be widely used for radiation cytogenetic studies.
J. Reindl et al.
115
Chemical-induced PCC exploits specific inhibitors for
serine/threonine protein phosphatase, which can activate
endogenous intracellular MPF, which is much simpler and
easier than fusion-induced PCC. Chemicals that can be used
for the achievement of drug-induced PCC are okadaic acid,
calyculin A, 2-aminopurine, staurosporine, wortmannin, and
sodium vanadate. A limitation of this method is that no PCC
can be induced in G0 resting-phase cells (Box 3.15).
Because of its unique properties, PCC is used for visual­
izing and scoring chromosomal damage induced by radiation
or other clastogenic agents, measuring the induction yield
and repair kinetics of chromosome damage in cells at various
cell cycle stages immediately after irradiation. It can also be
used for the study of condensation dynamics and conforma­
tional changes that occur during the cell cycle. The data
obtained using the PCC assay can correlate radiation-induced
DNA damage and CAs observable at metaphase [75].
Mitotic cell fusion-induced PCC in human lymphocytes
(G0-PCC) allows early detection of cytogenetic damage in
interphase, the stage of human lymphocytes in peripheral
blood, and is the most suitable technique especially for bio­
dosimetry applications in radiation emergency accidents as
well as for triage biodosimetry [76]. A later ring PCC (rPCC)
assay is an alternative biodosimetry method to the “gold
standard” cytogenetic approach (dicentric analysis in meta­
phase) for high-dose exposure to radiation and can be applied
in a simulated mass casualty accident either after chemical
induction of PCC [77] or by means of cell fusion providing a
much faster assessment of dose [78].
3.6.4"
"Describe the proposed mechanisms leading to chromothripsis, specifically focusing on those triggered by radiation exposure, and explain how these mechanisms contribute to genomic instability.","Chromothripsis, characterized by localized shattering of one or a few chromosomes resulting in extensive genomic rearrangements, is believed to arise from several interacting events. A key mechanism involves DNA damage, particularly double-strand breaks (DSBs) and chromosomal aberrations induced by high-LET radiation like alpha particles. These lesions disrupt the normal progression of mitosis, leading to aberrant chromosome behavior. Specifically, when a micronucleus – a small, unstable nucleus formed during cell division – enters mitosis while DNA replication is still ongoing within it, this asynchronous state creates conditions ripe for chromosome shattering. Furthermore, PCC (premature chromosome condensation), often triggered by the mechanical stress induced by micronuclei or chemically facilitated through agents like cdc25 inhibition, accelerates chromosome condensation and fragmentation. This can result in the pulverization of both single and sister chromatids. Random genomic rearrangements within these micro-nuclei can then be integrated into the cell’s genome, leading to amplification of oncogenes and ultimately increasing the risk of cancer development. Recent research has demonstrated that high-LET irradiation directly induces chromothripsis-like aberrations through clustered DNA lesions and chromatin decompaction along particle tracks. The ability of radiation to trigger this localized shattering is a critical factor in its potential to cause chromothripsis, with implications for both radiation oncology and space radiation protection due to the increased hazard of secondary induced cancers. Reference: [3.22]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.6	 Cytogenetics and DNA Damage Measurements for Assessment of Radiation Effects | Sub-subsection: 3.6.4	 Chromothripsis-Like Alterations | Content: 79
80
­
­
­
3.22
The mechanisms responsible for chromothripsis are still
under debate. However, studies have shown several situa­
tions that could be catastrophic for the cell and result in chro­
mothripsis. One possible mechanism proposed is that DNA
damage such as DSBs and chromosomal aberrations may
cause aberrant mitosis and formation of MN including one or
more chromosomes that may undergo localized shattering
and chromothripsis. Chromosome shuttering and chro­
mothripsis may emerge in MN when the main nucleus enters
mitosis while DNA is still being replicated within micronu­
clei. Additionally, PCC induces a mechanical stress in the
asynchronous micronucleated cells leading to chromosome
shattering [73]. Random genomic rearrangements in micro­
nuclei can then be integrated into the cell’s genome, trigger­
ing amplification of oncogenes and cancer development
[81]. Other additional mechanisms have also been proposed,
such as dicentric chromosome formation, telomere erosion,
and abortive apoptosis [82].
Regarding radiation-induced chromothripsis-like chro­
mosomal alterations, it was tested recently whether clustered
DNA lesions and chromatin decompaction induced by high-­
LET irradiation can subsequently evolve in localized chro­
mosome shattering in chromosome domains along the
particle tracks. This is a critical risk for chromothripsis to
occur, and the results obtained provided experimental evi­
dence that high-LET particle radiation is effective in induc­
ing chromothripsis-like aberrations, which can be used as a
fingerprint of high-LET exposure [83]. These discoveries are
valuable in the fields of radiation oncology and space radia­
tion protection, since chromothripsis-like aberrations can be
responsible for adverse effects and increase the hazard for
secondary induced cancer.
Box 3.15 In a Nutshell: Premature Chromosome
Condensation
•	The appearance of a prematurely condensed inter­
phase chromosome depends on the stage of cell
cycle.
•	PCC can be done in two main ways either by the
fusion of human lymphocytes with mitotic cells
(fusion-mediated PCC) or by the use of chemicals
(chemical-induced PCC).
•	G1-PCC displays very long single chromatids; PCC
in an early, middle, and late S-phase cell shows
crushed and pulverized appearance of both single
and sister chromatids; G2-PCC demonstrates still
long separated sister chromatids with no clearly vis­
ible centromere.
•	The dephosphorylated active form of MPF, a
p34cdc2/cyclin B complex, promotes chromosome
condensation in meiotic and mitotic cells.
•	Upon inhibition of protein phosphatase enzymes,
cdc25 and cyclin B/cdc2 complex is activated
which promotes condensation of chromosomes
prematurely.
3 Molecular Radiation Biology
116Fig. 3.22
Fig. 3.22 Schematic
illustration of chromothripsis.
It is a phenomenon where one
single catastrophic event leads
to a massive and localized
shattering of one or few
chromosomes. Shattered
chromosome fragments are
not properly rejoined resulting
in a new genome
configuration and a large
number of complicated
chromosomal aberrationsFig. 3.23
Fig. 3.23 Radiation-induced DNA damage foci. 53BP1 (left, cyan)
and γΗ2ΑΧ (middle, magenta) foci in HeLa cells irradiated with 1.2 Gy
alpha particles and spatially fixed at 60 min postirradiation.
Colocalization of γΗ2ΑΧ and 53BP1 foci is shown (right). Yellow line
indicates the cell nucleus
3.6.5"
"Describe the formation and characteristics of ionizing radiation-induced foci (IRIFs), including their relationship to γH2AX, and how they contribute to understanding DNA damage repair mechanisms.","Ionizing radiation-induced foci (IRIFs) are microscopic structures formed at sites of double-strand breaks (DSBs) in DNA following irradiation. These foci represent the accumulation of proteins involved in DNA repair processes. The formation of IRIFs is intimately linked to γH2AX, a histone modification that marks DSB sites. Immediately after radiation exposure, histone H2AX undergoes phosphorylation at serine 139 – catalyzed by kinases like ATM, ATR, and DNA-PK – leading to the rapid appearance of compact γH2AX foci around the break. These γH2AX foci then serve as a scaffold for the recruitment of various repair proteins, including 53BP1, NBS1, MRE11, Ku70/80, RAD51, and Brca1/2. The size and topology of IRIFs can vary depending on the type of radiation (e.g., high-LET vs. low-LET), the cell cycle stage at the time of irradiation, and the specific repair pathway activated. Importantly, IRIF formation is transient; initially, a dense accumulation of proteins occurs within minutes after exposure, but as DNA repair proceeds, these foci eventually disassemble.  Interestingly, recent research has revealed that spontaneously forming foci differ from radiation-induced ones in size and topology, often correlating with replication stress or apoptosis. Furthermore, the spatial distribution of γH2AX IRIF can be distinguished from non-irradiation induced IRIF based on staining patterns, offering a valuable tool for triage during biodosimetry assessments.  The composition and characteristics of these foci – including protein colocalization – provide insights into the specific DNA repair mechanisms engaged following radiation exposure.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.6	 Cytogenetics and DNA Damage Measurements for Assessment of Radiation Effects | Sub-subsection: 3.6.5	 Ionizing Radiation-Induced Foci (IRIF) | Content: ­
3.23
­
­
84
3.4
­
84
85
­
86
Furthermore, DNA damage induction and repair pro­
cesses can be studied in individual cells using the IRIF assay.
In practice, this is important in situations where individual
J. Reindl et al.
117
cells can be differentially affected by irradiation, such as in
the cases of a partial-body exposure. The ability to study
individual cells is critically important also for radiobiologi­
cal research as individual cells, even if irradiated homoge­
neously, appear in different phases of the cell cycle, belong
to specific (cancer) cell clones, may be to a various extent
affected by the bystander effect, etc.
On the other hand, the biochemical nature of IRIF means
that their formation potentially depends on various factors,
which may introduce some variability to DSB quantification.
It remains a subject of discussion whether all DSBs neces­
sarily require IRIF formation for successful repair.
Additionally, some foci may persist at DSB sites even after
the break rejoining. A real obstacle could follow from the
fact that IRIF occur, to some extent, in nonirradiated cells.
However, recent results have proved that the spontaneously
forming foci differ in size and topology from the radiation-­
induced ones. So, staining patterns corresponding, for
instance, to replication-stressed or apoptotic cells can be dis­
tinguished from IRIF related to DNA repair [87]. Importantly,
this phenomenon is more prominent only in cancer cells,
which are not relevant for biodosimetry. In any case, “the
second γH2AX assay intercomparison exercise” carried out
in the framework of the European biodosimetry network
(RENEB) confirmed a high fidelity of irradiated victims’ tri­
age (dose categorization, rather than dosimetry) based on
IRIF detection of the postradiation modification of histone
variant H2AX, called γH2AX [84].
γH2AX is formed by the phosphorylation of histone
H2AX at ser139 [57]. This process is mediated by ATM,
ATR, and DNA-PK kinases, appears in minutes after DNA
breakage, and spreads over ~2 Mbps of DSB-surrounding
chromatin. Due to this extent of chromatin modification,
γH2AX can be microscopically visualized as compact IRIF
at DSB sites of 400–600 nm size as described in Sect. 3.5.
­
3.24
49
49
­
3.24
­
F
i
g. 3
.24
Fig. 3.24 DNA repair kinetics. (a) Formation and disassembly of
γH2AX foci in human cancer cells irradiated with 1 Gy or 2 Gy X-rays.
(b) Representative microscopic images for γH2AX foci 1 h and 2 h
after X-ray irradiation. (Reproduced with permission (CCBY) from
Mariotti et al. [88])
3 Molecular Radiation Biology
118
cells exposed to high-LET radiation or high doses of low-LET
radiation. From the perspective of biodosimetry, this means
that the highest precision of the absorbed dose estimation can
be achieved in a few-hour window immediately after irradia­
tion. This requirement can be fulfilled during planned medical
care, where, in addition, the monitoring of γH2AX foci forma­
tion and disassembly (DSB repair kinetics) may be used to
identify patients hypersensitive to radiotherapy or radioresis­
tant tumors. However, in the case of unpredicted accidents
with mass screening, IRIF-based biodosimetry must rely on
the persistent foci due to the necessary reaction time. This
requires suitable mathematical models for the absorbed dose
estimation and restricts the method applicability to the acute
photon dose range of ~0.5 to ~8.5 Gy and days after exposure
(i.e., 1 day after 1 Gy and 14 days after 8.5 Gy) [89]. For mili­
tary countermeasures, it should also be kept in mind that some
chemical warfare agents, such as mustard gas, also generate
γH2AX foci. Furthermore, background levels may vary due to
non-irradiation-induced IRIF, which are also counted and vary
individually, so this assay is best suited for triage rather for
accurate dosimetry.
In addition to the analysis of γH2AX IRIF numbers, the
spatial distribution of γH2AX foci can be determined by
microscopy. This is an important advantage of microscopy
over flow cytometry as low-LET and high-LET exposures
can be distinguished according to nuclear topology of
γH2AX foci [90] as described in Sect. 3.5. On the other
hand, flow cytometry offers more room for automation than
microscopy and can analyze much higher cell numbers,
making it the more suitable method for routine biodosimetry
in most circumstances (Box 3.16).
γH2AX attracts numerous proteins with specific signaling
and/or repair functions to DSB sites. These proteins, in turn,
form IRIF with protein-specific time occurrence and extent
of colocalization with γH2AX. Hence, IRIF formed by
numerous repair proteins can be used to quantify DSBs and
estimate the absorbed dose in the same way as it was
described above for γH2AX. Alternatively, repair protein
and γH2AX foci can be detected simultaneously to enhance
the fidelity of DSB evaluation. Furthermore, the protein
composition and structure of IRIF protein complexes (e.g.,
their specific persistent homology at the nanoscale), and dif­
ferences of these parameters in specific chromatin domains
and after exposure to different types of ionizing radiation,
help to understand the mechanisms of DNA repair.
91
3.25
­
52
­
­
57
­
57
­
­
3.23
­
­
­
4857
It should be noted that not all γH2AX foci necessarily
colocalize with 53BP1 (or other repair proteins) at early time
periods postirradiation. This includes also the period of
30 min postirradiation when the maximum γH2AX focus
Box 3.16 In a Nutshell: γH2AX as Radiation Damage
Marker
•	γH2AX IRIF form as the histone H2AX is phos­
phorylated after DSB induction.
•	γH2AX IRIF formation starts a few minutes after
irradiation and peaks at 30 min–1 h postirradiation.
•	Especially after high-dose irradiation or irradiation
with high-LET particles, persistent γH2AX IRIF
are left after repair.
•	γH2AX IRIF can be used for triage-level biodosim­
etry by counting foci either in the first hours or per­
sistent foci in microscopic images.
J. Reindl et al.
119Fig. 3.25
Fig. 3.25 DNA repair
protein markers forming small
foci. 2BN hTert (XLF-­
deficient) human fibroblasts
were analyzed 2 h post-IR
with 1 Gy. Cells were stained
against DAPI, pATM, and
RAD51, or DAPI, γH2AX,
and RAD51. RAD51 is
present in a subset of pATM
and γH2AX foci. Reproduced
with permission (CCBY)
from Geuting et al. [92].
DAPI 4′,6-diamidino-2-­
phenylindole used for staining
nuclei, XLF XRCC4-like
factor
Table 3.7 DNA repair proteins and occurrence
Protein/IRIF
Occurrence
γH2AX
53BP1
NBS1
MRE11
Ku70/80
RAD51
Brca1
Brca2
All DSB
All DSB
Part of MRN complex
Part of MRN complex
All DSB
Predominantly HR
Transition between NHEJ and HR
Predominantly HR
numbers are detected. On the other hand, at late time periods
after irradiation, 53BP1 foci may persist in cells without
being accompanied by γH2AX. These non-colocalizing
53BP1 foci probably label and protect incompletely repaired
chromatin [93].
94
­
16
3.7
3.17
3.7
Oxidative Stress: Redox Control
and Mitochondrial DNA Damage
3.7.1
Oxidative Stress and Consequences
for Cell Macromolecules
­
­
2
3.2
3.26
­
­
3.8
­
­
Oxidants are produced from exogenous, such as air pollut­
ants, xenobiotics, and IR, and endogenous sources as normal
cellular metabolism by-products. Examples are the mitochon­
drial electron transport chain (ETC), nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, xanthine oxidase,
and peroxidases. Low to moderate ROS levels are crucial in
physiological function of cell to avoid oxidative stress involved
in aging and several neurodegenerative diseases, diabetes,
cancer, atherosclerosis, etc. ROS are also signaling molecules
involved in the IR non-targeted effects (see Chap. 2).
Box 3.17 In a Nutshell: Ionizing Radiation Induced Foci
•	Repair protein IRIF, depending on the protein’s role
throughout repair, can also be used for biodosimetry.
•	Repair protein IRIF can be used to understand
repair mechanisms and pathways of individual DSB
sites.
•	IRIF can be used to understand the effect of radia­
tion of different LET.
3 Molecular Radiation Biology"
"Describe the role of the mitochondrial electron transport chain (ETC) in generating oxidative stress, and explain why low to moderate levels are sometimes considered beneficial for cellular function.","The mitochondrial electron transport chain (ETC) is a crucial component of cellular respiration responsible for generating ATP. However, as electrons pass through the ETC complexes – specifically Complexes I, III, and IV – a significant portion of the released energy is dissipated as heat. More importantly, this process generates reactive oxygen species (ROS), primarily superoxide radicals (O2•−). The ETC’s function involves transferring electrons from NADH and FADH2 to molecular oxygen, ultimately forming water. This transfer isn't perfectly efficient; some electrons ‘leak’ prematurely, leading to the formation of superoxide. Complex III is particularly implicated in ROS production due to its role in facilitating electron transfer between ubiquinone and cytochrome c. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase also contributes significantly to ROS generation by catalyzing the reduction of oxygen to superoxide. Xanthine oxidase produces superoxide as a byproduct of purine metabolism, and peroxidases can generate ROS through various enzymatic reactions. Low to moderate levels of ROS generated by the ETC are considered beneficial because they act as signaling molecules involved in cellular processes like DNA repair, immune responses, and regulation of apoptosis (programmed cell death). These controlled bursts of oxidative stress trigger adaptive mechanisms that enhance cellular resilience and protect against damage from other stressors. However, excessive ROS accumulation – oxidative stress – is detrimental, contributing to aging, neurodegenerative diseases, diabetes, cancer, and atherosclerosis by damaging lipids, proteins, and DNA.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Content: 3.7.1
Oxidative Stress and Consequences
for Cell Macromolecules
­
­
2
3.2
3.26
­
­
3.8
­
­
Oxidants are produced from exogenous, such as air pollut­
ants, xenobiotics, and IR, and endogenous sources as normal
cellular metabolism by-products. Examples are the mitochon­
drial electron transport chain (ETC), nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, xanthine oxidase,
and peroxidases. Low to moderate ROS levels are crucial in
physiological function of cell to avoid oxidative stress involved
in aging and several neurodegenerative diseases, diabetes,
cancer, atherosclerosis, etc. ROS are also signaling molecules
involved in the IR non-targeted effects (see Chap. 2).
Box 3.17 In a Nutshell: Ionizing Radiation Induced Foci
•	Repair protein IRIF, depending on the protein’s role
throughout repair, can also be used for biodosimetry.
•	Repair protein IRIF can be used to understand
repair mechanisms and pathways of individual DSB
sites.
•	IRIF can be used to understand the effect of radia­
tion of different LET.
3 Molecular Radiation Biology"
"Describe the mechanisms by which ionizing radiation generates reactive oxygen species (ROS) and explain how these ROS contribute to cellular damage, referencing specific examples of macromolecule targets.","Ionizing radiation induces oxidative stress primarily through the disruption of the mitochondrial electron transport chain (ETC). When radiation interacts with biological molecules, particularly within mitochondria, it excites electrons within the ETC. These excited electrons cascade down the chain, ultimately leading to a decrease in the efficiency of electron transfer and an increased production of reactive oxygen species (ROS), including superoxide radical (O2•−), hydrogen peroxide (H2O2), and hydroxyl radicals (°OH). Furthermore, radiation can activate NADPH oxidase, another enzyme involved in ROS generation. Xanthine oxidase, often upregulated following IR exposure, also contributes to ROS formation via the oxidation of hypoxanthine. These generated ROS then initiate a chain of oxidative damage. Specifically, lipid peroxidation is a major consequence; ROS react with polyunsaturated fatty acids (PUFAs) within cell membranes, initiating free radical chain reactions that produce toxic products like malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE), and isoprostanes (IsoPs). These lipids alter membrane permeability and disrupt ion gradients. Protein damage occurs through oxidation of vulnerable amino acid residues such as cysteine, methionine, and tyrosine, leading to conformational changes and loss of function. DNA itself is also a target, with radiation directly causing strand breaks and indirectly contributing to oxidative base damage. The resulting inflammation further exacerbates the problem by increasing ROS production via RNS formation.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.1	 Oxidative Stress and Consequences for Cell Macromolecules | Content: 3.7.1
Oxidative Stress and Consequences
for Cell Macromolecules
­
­
2
3.2
3.26
­
­
3.8
­
­
Oxidants are produced from exogenous, such as air pollut­
ants, xenobiotics, and IR, and endogenous sources as normal
cellular metabolism by-products. Examples are the mitochon­
drial electron transport chain (ETC), nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase, xanthine oxidase,
and peroxidases. Low to moderate ROS levels are crucial in
physiological function of cell to avoid oxidative stress involved
in aging and several neurodegenerative diseases, diabetes,
cancer, atherosclerosis, etc. ROS are also signaling molecules
involved in the IR non-targeted effects (see Chap. 2).
Box 3.17 In a Nutshell: Ionizing Radiation Induced Foci
•	Repair protein IRIF, depending on the protein’s role
throughout repair, can also be used for biodosimetry.
•	Repair protein IRIF can be used to understand
repair mechanisms and pathways of individual DSB
sites.
•	IRIF can be used to understand the effect of radia­
tion of different LET.
3 Molecular Radiation Biology
120Fig. 3.26
Fig. 3.26 Possible ROS-­
mediated oxidative stress.
Upon exposure to IR,
oxidative stress can induce
collateral damage, such as
lipid peroxidation, protein
denaturation, nuclear and
DNA damage, mitochondrial
damage, and apoptotic death
by releasing cytochrome c.
Oxidative stress owing to
excess ROS generation
induces overexpression of
antioxidant enzymes in an
attempt to control ROS levels.
At high levels of oxidative
stress, antioxidant defenses
are overwhelmed, which leads
to inflammatory and cytotoxic
responses. (Reproduced with
permission from Sanvicens
and Marco [95]). NP
nanoparticles, ROS reactive
oxygen species
Table 3.8 List of free radicals and non-radicals
Free radicals
Non-radicals
Reactive oxygen species (ROS)
Superoxide °O2
−
Hydrogen peroxide H2O2
Hydroxyl °OH
Singlet oxygen 1O2
Peroxyl °ROO
Ozone O3
Lipid peroxyl LO°O
Hypochlorous acid HOCl
Lipid peroxide LOOH
Reactive nitrogen species (RNS)
Nitric oxide °NO
Nitrous acid HNO2
Nitrogen dioxide °NO2
Peroxynitrite ONOO−
Dinitrogen trioxide N2O3
OS occurs in pathologic conditions, when the cellular
antioxidant defenses are overwhelmed by free radicals and
oxidants. Their great oxidative ability leads to oxidative
damages to cellular biomolecules (DNA, proteins, and lip­
ids) resulting in multiple damage affecting cell membrane,
cellular signaling, and genome integrity. The accepted radia­
tion biology paradigm considered DNA for a long time as the
critical IR target and the primary cause for the harmful
effects of IR, due to its content of genetic information, with
nucleic acid damage being extensively characterized, ­without
consideration that damaged lipids and proteins may also
have detrimental effects on cellular function.
Further targets of radiation-generated ROS are lipids,
major constituents of the cell membrane, because of their
molecular structure containing abundant reactive double
bonds [96]. Upon ROS reaction with polyunsaturated fatty
acids (PUFA), chain reactions occur, leading to lipid peroxi­
dation (LP) and generation of toxic decomposition products
such as malondialdehyde (MDA), 4-hydroxy-2-nonenal
(4-HNE), and isoprostanes (IsoPs), which are quantifiable
markers of LP reactions. Biological LP consequences include
changes in the permeability and fluidity of the membrane
lipid bilayer, ion gradient disruption across membrane, and
alterations in membrane-associated protein activity [96].
Potential oxidative damage to proteins is multiple, cyste­
ine, methionine, and tyrosine residues. Chemical modifica­
tions include oxidation, carbonylation, and nitration and lead
to posttranslational modifications inducing conformational
changes affecting protein structure and function, i.e., loss of
enzyme activity.
While the physical and chemical reactions initiated by
radiation occur in less than a millisecond, the resulting bio­
logical effects may take hours, days, months, or years to be
expressed and may differ among individuals due to varying
intrinsic radiosensitivity. In particular, since the oxidative
damage extent depends on the antioxidant availability,
increased expression of antioxidant defense systems has
been linked to decreased radiosensitivity [97].
OS also has a central role within the inflammatory pro­
cess. ROS such as superoxide can rapidly combine with
NO to form other RNS, such as peroxynitrite, and is 3–4
times faster than the dismutation of superoxide by the
SOD. The RNS, in turn, induces nitrosative stress, which
J. Reindl et al.
121
adds to the pro-inflammatory burden of ROS. Injured cells
release chemoattractant molecules, and NO increases vas­
cular permeability and vasodilation that trigger local
inflammation. Neutrophils are the first inflammatory cells
to arrive at the site of injury, and the increased expression
of intercellular adhesion molecule 1 (ICAM-1) and platelet
endothelial cell adhesion molecule 1 (PECAM-1) on dis­
rupted endothelial surfaces contributes to neutrophil extrav­
asation. When leukocytes come into contact with collagen
fragments and ­fibronectin, they release pro-inflammatory
cytokines like tumor necrosis factor alpha (TNF-α), IL-1,
and IL-6 that increase ROS production and lead to even
greater local inflammation that can perpetuate inducing
chronic radiation injury, which in some cases develop into
fibrosis [98] (Box 3.18).
3.7.2"
"Describe the mechanisms by which mitochondria contribute to oxidative stress following radiation exposure, focusing on the role of NRF2 and antioxidant defense pathways.","Following radiation exposure, mitochondria play a central role in generating oxidative stress through the production of reactive oxygen species (ROS). Radiation can disrupt mitochondrial function, particularly within the electron transport chain, leading to an overproduction of ROS such as superoxide radical (O₂•⁻), hydrogen peroxide (H₂O₂), and ultimately, damaging levels of free radicals. This excess ROS directly damages mitochondrial DNA (mtDNA) and proteins, further exacerbating oxidative stress. To mitigate this damage, cells activate a complex defense system primarily mediated by the NRF2 pathway. Specifically, radiation-induced oxidative stress modifies KEAP1, releasing NRF2 from its cytoplasmic repression. Once free, NRF2 translocates to the nucleus and initiates a cascade of gene expression, upregulating antioxidant enzymes like superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione S-transferase (GST). These enzymes catalyze the detoxification of ROS, converting them into less harmful products. Simultaneously, NRF2 promotes the synthesis and recycling of glutathione (GSH) through upregulation of glutamate–cysteine ligase (GCLC and GCLM) subunits, GR, and GPx, providing a crucial antioxidant shield. Furthermore, NRF2 stimulates mitochondrial biogenesis via nuclear respiratory factor 1 (NRF1), enhancing mitochondrial function and reducing ROS production.  The activation of heme oxygenase-1 (HO-1) by NRF2 also contributes to the defense by producing carbon monoxide (CO), which inhibits NF-κB signaling – a key regulator of inflammation – further dampening the inflammatory response triggered by oxidative stress. Ultimately, this coordinated action protects cells from radiation-induced apoptosis and damage.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.2	 Redox Control: Antioxidant Defenses | Content: 3.27
­
­
­
­
­
2
2
2
­
­
2
2
­
­
­
­
­
3.27
­
99
2
2
­
­
3.27
­
­
3.28
Box 3.18 In a Nutshell: Oxidative Stress
•	Oxidative stress is characterized by an imbalance
between prooxidant molecules and antioxidants.
•	Oxidative stress participates in the oxidative dam­
age of cellular components.
•	Antioxidants play a key role in stopping the oxida­
tive chain reactions by scavenging the free radical
intermediates.
•	Excessive generation of ROS, that provokes mito­
chondrial DNA mutations, impairs the mitochon­
drial respiratory chain and modifies membrane
permeability and mitochondria-associated defense
systems.
•	Several biomarkers of oxidative stress exist and
comprise direct ROS measurement, indirect mea­
sure of oxidative stress by quantifying oxidation
products, and measure of antioxidant defenses.
3 Molecular Radiation Biology
122Fig. 3.27
Fig. 3.27 Antioxidant
defense mechanismsFig. 3.28
Fig. 3.28 NRF2 protection against oxidative stress and excessive
inflammatory responses involved in IR injury. NRF2 induces antioxi­
dant response genes, like SOD, CAT, GPX, and GST that enhance ROS
elimination. In addition, expression of enzymes such as GR and GS
increases GSH cellular content and antioxidant capacity of the cell.
Reduction in ROS levels decreases the expression of NFKβ, the main
contributor to the inflammatory response. Moreover, NRF2 enhances
the expression of HO-1 and its activity in the production of CO that
reduces NFKβ activity, pro-inflammatory cytokine secretion (IL-6,
TNFα, and IL-1β), and pro-inflammatory enzyme activity (COX-2 and
iNOS). ARE antioxidant-responsive element, NRF2 NF-E2-related
factor 2, SOD superoxide dismutase, CAT catalase, GPx glutathione
peroxidase, GST glutathione S-transferase, GS glutathione synthetase,
GR glutathione reductase, GSH glutathione, ROS reactive oxygen spe­
cies, NFKβ nuclear factor kappa β, IL-6 and 10 interleukin 6 and 10,
IL-1β interleukin 1 beta, TNFα tumor necrosis factor alpha, COX-2
cyclooxygenase 2, iNOS inducible nitric oxide synthase, HO-1 heme
oxygenase 1
genes that are crucial to metabolize electrophilic attack and
protect against OS and inflammatory damage. Kelch-like
ECH-associated protein 1 (KEAP1) is a key cytoplasmic
repressor of NRF2. KEAP1 interaction with NRF2 leads to
NRF2 proteasomal degradation. In the presence of OS or
inducers, key “sensor” cysteine thiol groups on KEAP1 are
modified, disrupting the degradation process and allowing
NRF2 to directly translocate into the nucleus. NRF2 then
upregulates the expression of enzymes involved in the
­synthesis and recycling of GSH, such as the catalytic and
modulator subunits of glutamate–cysteine ligase (GCLC and
GCLM), GR, GPx, SOD, and several GST. Moreover, sev­
eral proteins within the redoxin family, such as Trx, TrxRs,
Prxs, and sulfiredoxins, are also upregulated by NRF2 [100]
J. Reindl et al.
123Fig. 3.29
Fig. 3.29 Mitochondria as the key player in radiation-induced oxida­
tive stress-mediated apoptosis. Various stimuli like radiation or
improper functioning of the oxidative phosphorylation induce oxidative
stress via ROS production. This causes the mitochondria to dysfunction
and subsequently leads to cell death by apoptosis. NAD+ nicotinamide
adenine dinucleotide, NADH nicotinamide adenine dinucleotide hydro­
gen, H+ hydrogen, FAD flavin adenine dinucleotide, FADH2 flavin
adenine dinucleotide hydrogen, ATP adenosine triphosphate, ADP ade­
nosine diphosphate, Mn-SOD manganese superoxide dismutase, GPx
glutathione peroxidase, H2O2 hydrogen peroxide, CuZn-SOD copper
zinc superoxide dismutase, ROS reactive oxygen species, Bcl-2 B-cell
lymphoma 2, Bax Bcl2-associated X, APAF1 apoptotic protease-­
activating factor 1
as shown in Fig. 3.29. NRF2 stimulates the mitochondrial
biogenesis program through activation of nuclear respiratory
factor 1 and indirectly prevents/attenuates inflammation,
because NRF2 activation results in the expression of previ­
ously mentioned antioxidant enzymes, which detoxify ROS,
and in turn this reduces the expression of NLRP3 inflamma­
some and NFKβ (the main regulator of pro-inflammatory
response). Moreover, NRF2 upregulates heme oxygenase
activity (HO-1) and increases CO production, which in turn
reduces NFKβ activity. In response to this, pro-inflammatory
cytokine (IL6 and TNFa) production is reduced, and at the
same time the production of anti-inflammatory cytokines
(such as IL10) increases. As a consequence of these changes,
NRF2 facilitates cells to survive oxidative stress and the
inflammatory response that aggravates their cytotoxic effects
(Fig. 3.29).
3.7.3"
"Describe the relationship between mitochondrial DNA (mtDNA) vulnerability to ionizing radiation (IR), its repair mechanisms, and subsequent cellular consequences.","Mitochondria (Mts) play a crucial role in energy production and are particularly vulnerable to damage from ionizing radiation (IR). Human mtDNA, a circular DNA molecule containing 37 genes essential for mitochondrial function, exhibits a significantly higher mutation rate compared to nuclear DNA (nDNA) due to several factors. Primarily, mtDNA is less efficiently repaired; it lacks the protective histones found in nDNA and utilizes repair mechanisms like base excision repair (BER), mismatch repair (MMR), and homologous recombination (HR) – but not nucleotide excision repair (NER) or classical NHEJ – which are more effective for nDNA. Furthermore, oxidative stress generated during energy production creates a high concentration of reactive oxygen species (ROS) specifically targeting mtDNA. This ROS accumulation leads to direct DNA damage, including point mutations and deletions, such as the well-known 4977 base pair deletion affecting ATPase, NADH dehydrogenase complex I, and cytochrome c oxidase genes. Following IR exposure or oxidative stress, mitochondrial dysfunction can manifest through various mechanisms: loss of mitochondrial membrane potential leading to fission or fusion events, autophagy (mitophagy) for removal of damaged mitochondria, apoptosis, alterations in mtDNA copy number per cell (mtDNAcn), and global DNA hypomethylation due to decreased methyltransferase activity. These processes ultimately contribute to a persistent state of oxidative stress, further impairing respiratory chain function, increasing ROS production, and accelerating cellular damage. Reference: [Molecular Radiation Biology, Section 3.7.3 – The Role of Mitochondria in Oxidative Stress]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.3	 The Role of Mitochondria in Oxidative Stress | Content: Stress
Mts are double-membrane multifunctional organelles associ­
ated with biosynthesis, metabolism, cell survival, signaling
of ROS, etc. In the late 1960s, it was found that radiation
could significantly modify the structural form of mts and
also the mitochondrial DNA. Human mtDNA is a 16,569
base pair (bp) double-strand circular DNA molecule contain­
ing 37 genes, encoding 13 polypeptides for the mt electron
transport chain, 2 ribosomal RNA, and 22 transfer RNA for
mt protein synthesis. Somatic cells have an average of 100–
500 mts with 1–15 mtDNA molecules per mitochondrion.
Although nuclear DNA (nDNA) is the main IR target, mts
are constantly removing excess ROS created during energy
production and mtDNA is much more vulnerable to IR
effects than nDNA. mtDNA is generally repaired less effi­
ciently than nDNA [101], although it uses the same repair
mechanisms such as BER, MMR, and HR but not NER and
classical NHEJ. Furthermore, the histones for better expo­
sure protection are lacking. Together, this leads to a mutation
rate which is 10–1000 times higher than nDNA [102]. Both
direct IR exposure and irradiated cell-conditioned medium
induce mtDNA damage and alter directed protein synthesis.
As a consequence, IR exposure can cause the loss of mt
membrane potential, leading to mt undergoing either fission,
division of one mitochondrion, or fusion, combination of
several mitochondria, autophagy (mitophagy), apoptosis,
3 Molecular Radiation Biology
124
modification in the mtDNA copy number per cell (mtD­
NAcn), and cause DNA damage and mutations, like point
mutations or deletions. A common deletion mutation of 4977
base pair deletion in mtDNA genes coding for subunits of the
mitochondrial ATPase, NADH dehydrogenase complex I,
and cytochrome c oxidase is known as a marker for oxidative
damage [101].
Changes in mtDNAcn or mutations in mtDNA both caused
by high intra-mtROS control mt-dependent methylation
potential of nDNA by decreasing methyltransferase activity
and thus causing global DNA hypomethylation or changes in
the expression of specific genes [103]. Global DNA methyla­
tion levels depend on human mtDNA variants and are also
tissue specific and, therefore, may be connected with the dif­
ferences in susceptibility to the pathogenic processes result­
ing from IR exposure and OS in different tissues [103].
OS also appears to target the mitochondrial DNA
polymerase-γ activity required for replication and repair of
mtDNA, thereby reducing the overall repair capacity.
Therefore, subsequent to radiation exposure, mtDNA might
be damaged, with an ensuing decrease in respiratory chain
activity and decrease of mitochondrial function, giving rise
to an increased ROS production. Moreover, mutations in
mtDNA could lead to an increase in accessibility of reduced
components of the ETCs to O2, which may result in an
increase in prooxidant formation. The functional disable­
ment can be weighed by the limitations of the complexes I
and III of the mitochondria, reduction of succinate-induced
respiratory competence, augmented ROS levels, and
increased mitochondrial protein oxidation. The net conse­
quence is persistent metabolic OS that continues to cause de
novo oxidative damage to critical biological structures. Such
mitochondrial dysfunction can lead to stress signals, which
lead to reduced electron transport chain (ETC), and oxidative
phosphorylation can cause imbalance in the mitochondrial
ROS production, decrease in the mitochondrial membrane
potential, and lesser cellular ATP or energy. Although mts
are the main producer of ROS, mts themselves can be sus­
ceptible to the pathological outcomes once targeted by
ROS. By triggering the mitochondrial stress and downstream
signaling, the increased levels of free radicals linked to the
mtDNA oxidative damage lead to apoptosis.
­
­
­
104
3.28
­
­
3.29
3.7.4"
"Describe how oxidative stress biomarkers are utilized in assessing cellular damage, specifically addressing the limitations associated with their direct measurement.","Oxidative stress biomarkers represent molecules whose state changes as a result of interactions with reactive oxygen species (ROS) or alterations within the antioxidant defense system. These modifications occur when cells experience elevated levels of oxidative stress. Measurement of these biomarkers can provide insight into cellular damage, but their utility is complicated by the transient nature of ROS themselves. While fluorescent probes and commercial kits exist to detect intracellular ROS such as hydrogen peroxide (H2O2), nitric oxide (NO), or superoxide radicals (•O2−), direct monitoring of ROS levels is generally impractical for biomonitoring applications. This limitation stems primarily from the extremely short half-life of ROS – they are rapidly neutralized by antioxidants – and the lack of specificity. A measurement taken at a single point in time would reflect only a fleeting moment within the dynamic redox environment, potentially masking underlying damage or failing to accurately correlate with radiation exposure due to the rapid turnover of these reactive species. Therefore, while ROS detection methods offer valuable mechanistic information, they are rarely used for assessing overall cellular damage in biomonitoring contexts.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.4	 Oxidative Stress Biomarkers | Content: 3.29
3.7.4
Oxidative Stress Biomarkers
Biomarkers of OS can be classified as molecules that are
modified by interactions with ROS or molecules of the anti­
oxidant system that change in response to increased OS. ROS
levels can also be monitored using fluorescent probes of
commercial kits, which specifically detect intracellular ROS
such as H2O2, NO, or °O2
−. However, assays that monitor
ROS levels are unlikely to be useful for biomonitoring pur­
poses due to the short half-life of ROS and the fact that the
response is not specific to radiation exposure."
Describe the role of glutathione (GSH) and its redox state (GSH/GSSG ratio) as a biomarker for oxidative stress following radiation exposure. Explain how changes in this ratio are detected and what implications they have regarding cellular damage.,"Glutathione (GSH) plays a crucial role in mitigating oxidative stress induced by reactive oxygen species (ROS), particularly after radiation exposure. GSH is a tripeptide antioxidant that directly scavenges ROS like superoxide radicals (O2−•) and hydrogen peroxide (H2O2). However, the antioxidant activity of GSH isn't static; it undergoes redox cycling itself. During antioxidant reactions, GSH is oxidized to glutathione disulfide (GSSG). This oxidation-reduction process is fundamental to its function – GSH effectively ‘uses up’ ROS, preventing them from damaging cellular components like DNA, lipids, and proteins. The ratio of GSH to GSSG, therefore, serves as a key biomarker for oxidative stress.

Following radiation exposure, the initial surge in ROS overwhelms the antioxidant defenses, leading to a significant decrease in intracellular GSH/GSSG ratio. This reduction primarily reflects an increase in the concentration of GSSG due to the rapid oxidation of GSH. Because GSSG is highly reactive and unstable, it’s preferentially secreted out of the cell via various mechanisms. Consequently, monitoring blood levels of both GSH and GSSG provides a sensitive indication of glutathione depletion within the irradiated tissue. The timing of this change – typically observed within 6 hours after a single dose of irradiation (e.g., 5 Gy) – is critical; it signifies that oxidative damage has already occurred and that the cell’s initial antioxidant capacity has been overwhelmed.  This decrease in GSH/GSSG is not just a measure of ROS levels, but also reflects the overall cellular response to radiation-induced injury.

Reference: [Molecular Radiation Biology], Section 3.7.4.1 – Antioxidant Defenses.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.4	 Oxidative Stress Biomarkers | Sub-sub-subsection: 3.7.4.1	 Antioxidant Defenses | Content: 3.29
3.7.4
Oxidative Stress Biomarkers
Biomarkers of OS can be classified as molecules that are
modified by interactions with ROS or molecules of the anti­
oxidant system that change in response to increased OS. ROS
levels can also be monitored using fluorescent probes of
commercial kits, which specifically detect intracellular ROS
such as H2O2, NO, or °O2
−. However, assays that monitor
ROS levels are unlikely to be useful for biomonitoring pur­
poses due to the short half-life of ROS and the fact that the
response is not specific to radiation exposure.
3.7.4.1	Antioxidant Defenses
3.30
­
­
105
J. Reindl et al.
125Fig. 3.30
Fig. 3.30 Main oxidative
products of DNA, lipids, and
proteins. Oxidative products
(listed in gray boxes) are
formed depending on the free
radicals (RNS/ROS) and the
biomolecule target (amino
acids, proteins, phospholipids,
nucleic acids). These products
can be used as oxidative stress
biomarkers. RNS reactive
nitrogen species, ROS reactive
oxygen species
The participation of GSH in antioxidant reactions, either
chemically or enzymatically via GPx, results in its own
oxidation to GSSG. Decrease in intracellular GSH/GSSG
ratio is one of the most used biomarkers of OS. In these
conditions, GSSG is preferentially secreted out of the cell,
and therefore, blood levels of GSH and GSSG may reflect
changes in glutathione status in other less accessible tis­
sues. 6 h after a single dose of irradiation (equivalent to
5 Gy), GSH/GSSG ratio decreases in blood. The decrease
in GSH/GSSG is mainly due to an increase in the concen­
tration of GSSG, because GSH levels do not change signifi­
cantly [106]."
"Explain the concept of Total Antioxidant Capacity (TAC) in biological samples, detailing its measurement and significance within the context of assessing oxidative stress.","Total Antioxidant Capacity (TAC) represents a comprehensive assessment of an organism's or tissue’s ability to neutralize free radicals. It is determined by measuring the total amount of free radical scavengers present in a sample – including both endogenous antioxidants like enzymes (such as superoxide dismutase - SOD, catalase - CAT, and glutathione peroxidase - GPxs) and dietary antioxidants (like vitamins C and E). The TAC system operates through a colorimetric assay where the test solution is exposed to a known concentration of a free radical generator. The extent to which this oxidant is neutralized by the sample’s antioxidant components dictates the measured TAC value. This measurement typically utilizes commercially available colorimetric kits, quantifying the reduction in absorbance due to the oxidation of the radical generator. Importantly, TAC provides an integrated parameter reflecting the cumulative effect of all antioxidants within a biological sample – it's not focused on identifying specific antioxidant molecules. However, significant variability exists between different methodologies used for TAC assessment, leading to potential comparability issues. Due to this complexity and the in-vivo nature of measuring TAC, experts like Dr. Sies emphasize that direct measurement of individual oxidative stress parameters (like glutathione levels - GSH, urate, ascorbate, tocopherol, etc.) and antioxidant enzyme activities are more reliable for understanding an organism’s overall exposure to oxidative stress. These focused measurements provide a more nuanced picture than simply assessing the total capacity of antioxidants within a sample removed from its biological context.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.4	 Oxidative Stress Biomarkers | Sub-sub-subsection: 3.7.4.2	 Total Antioxidant Capacity (TAC) and Other Antioxidant Biomarkers | Content: and Other Antioxidant Biomarkers
Antioxidants protect the body from the harmful effects of
free radical damage. Thus, measurement of antioxidant lev­
els in target tissues or biofluids has been widely used to
assess the extent of oxidant exposure and, in turn, OS. TAC
is the measure of the free radical amount scavenged by a test
solution, being used to evaluate the antioxidant capacity of
biological samples (tissues or biofluids). The TAC system
involves enzymes (SOD, CAT, GPxs, and other enzymes),
endogenous antioxidants, and dietary antioxidants (men­
tioned before), which are generally decreased when OS
increases. TAC can be easily measured in cells, tissue lysates,
and biological fluids by commercial colorimetric kits and
represents a global approach (integrated parameter consid­
ered as the cumulative effect of all antioxidants of the bio­
logical sample) if no specific antioxidant molecule is to be
investigated. One of the critical points is that the results
obtained with different methods are not always comparable,
depending on the different technologies used for their assess­
ment. Moreover, as mentioned by Dr. Sies (who coined the
concept of oxidative stress): “neither the term ‘total’ nor the
term ‘capacity’ are applicable to the in vivo assays using an
arbitrarily selected oxidant generator assaying a sample
removed from its biological context, which is characterized
by enzymatic maintenance of steady state” [107]. For that
reason, we agree with him “that investigators should mea­
sure individually parameters associated with oxidative stress
(GSH, urate, ascorbate, tocopherol, etc.) and antioxidant
enzymes activities (in tissues samples and lymphocytes (in
the case of blood samples) if their want to have an idea of the
exposure of the entire organism to oxidative stress” [108]."
"Describe the significance of measuring oxidative stress biomarkers like protein carbonyls and GSH, particularly in relation to assessing an organism's exposure to oxidative stress.","The measurement of oxidative stress biomarkers is crucial for determining an organism’s level of exposure to damaging reactive oxygen species (ROS). Researchers typically assess this by quantifying parameters such as glutathione (GSH), urate, ascorbate, tocopherol, and protein carbonyls. GSH serves as a primary antioxidant within cells, actively neutralizing ROS through redox reactions. Elevated levels of GSH can indicate increased oxidative stress due to the cell’s attempt to maintain its redox balance. Conversely, decreased GSH levels may signify an overwhelming oxidative burden. Protein carbonyls are particularly important biomarkers because they represent irreversible protein modifications resulting from oxidation – specifically, the addition of a carbonyl group to proteins. This modification fundamentally alters protein structure and function, contributing directly to cellular dysfunction and tissue damage. Unlike many other ROS-derived products that are rapidly cleared, protein carbonyls are relatively stable and accumulate over time with continued oxidative stress exposure. Their quantification provides a reliable indicator of sustained oxidative burden. Furthermore, the fact that proteins scavenge a majority (50–75%) of generated reactive species highlights their central role in mitigating oxidative damage. The stability, detectable concentration accumulation, and correlation of these biomarkers with oxidative stress exposure are key criteria for them to function effectively as biological indicators.  The ability to measure OGG1, an enzyme involved in DNA repair, also provides insight into the organism’s response to oxidative damage at a molecular level. Reference: [Molecular Radiation Biology], Section 3.7.4.3 – Oxidation Products of DNA, Lipids, and Proteins","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.7	 Oxidative Stress: Redox Control and Mitochondrial DNA Damage | Sub-subsection: 3.7.4	 Oxidative Stress Biomarkers | Sub-sub-subsection: 3.7.4.3	 Oxidation Products of DNA, Lipids, and Proteins | Content: removed from its biological context, which is characterized
by enzymatic maintenance of steady state” [107]. For that
reason, we agree with him “that investigators should mea­
sure individually parameters associated with oxidative stress
(GSH, urate, ascorbate, tocopherol, etc.) and antioxidant
enzymes activities (in tissues samples and lymphocytes (in
the case of blood samples) if their want to have an idea of the
exposure of the entire organism to oxidative stress” [108].
3.7.4.3	Oxidation Products of DNA, Lipids,
and Proteins
­
7
­
­
3.30
­
­
­
­
­
109
­
­
3 Molecular Radiation Biology
126
through lesion repair or cell death depending on the magni­
tude of guanine oxidation. OGG1 may also be measured as an
OS marker.
3.30The
­
­
­
­
prosta­
glandin
DNA bases
­
96
It has been estimated that proteins scavenge a majority
(50–75%) of generated reactive species. To function as bio­
markers, protein oxidation products must be stable, accumu­
late in detectable concentrations, and correlate with OS
exposition. Protein carbonylation is an irreversible protein
modification, associated with alterations in functional and
structural integrity of proteins, contributing to cellular dys­
function and tissue damages. Due to relatively early formation
during OS, higher stability in comparison to other oxidation
products, and simple analysis methods, protein carbonyls are
one of the most OS biomarkers. Protein carbonyls can be eas­
ily quantified in plasma, serum, tissue samples, and also saliva
by enzyme-linked immunosorbent assay (ELISA) [110].
2
−
2
−
­
­
­
­
110
­
­
­
­
3.30
3.8"
"Describe the key phases of the eukaryotic cell cycle and explain the significance of each phase, including the specific events that occur within them.","The eukaryotic cell cycle is a tightly regulated process comprising distinct phases essential for accurate DNA replication and subsequent cellular division. It’s broadly divided into two major phases: interphase and mitosis. Interphase itself is further subdivided into three stages: G1, S, and G2. The G1 phase represents the initial growth stage of the cell; during this time, the cell increases in size, synthesizes proteins and organelles, and monitors its environment for signals that might trigger division. Crucially, it’s a period of significant metabolic activity and preparation. Following G1 is the S phase, which is characterized by DNA replication – the duplication of the entire genome to ensure each daughter cell receives a complete set of genetic information. This process involves complex enzymatic reactions and precise alignment of chromosomes. Finally, the G2 phase prepares the cell for mitosis; it continues to synthesize proteins necessary for chromosome segregation and organizes the mitotic machinery. Mitosis itself is then divided into several stages: prophase, prometaphase, metaphase, anaphase, and telophase. Prophase involves chromosome condensation and the breakdown of the nuclear envelope. Prometaphase sees chromosomes attach to spindle fibers. Metaphase aligns chromosomes at the cell’s equator. Anaphase is marked by sister chromatid separation and movement toward opposite poles of the cell. Telophase reverses many prophasal events, with reformation of the nuclear envelope and chromosome decondensation. Cytokinesis, the final step, physically divides the cytoplasm to form two distinct daughter cells. The entire cycle is meticulously controlled by checkpoints that monitor DNA integrity and ensure accurate progression through each phase. Reference: [Textbook Title - Placeholder], Section [Cell Cycle Regulation].","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.8	 Cell Cycle Effects | Content: The cell cycle is a fundamental process through which the
cell grows and accurately duplicates the genetic material
before it divides to give rise to two daughter cells. The cell
cycle is divided into two phases: interphase in which the
cell spends most of its time, followed by mitosis during
which the cell divides into two daughter cells. The inter­
phase has three distinct phases. The first phase is the G1
phase in which the cell grows and prepares itself for DNA
synthesis. Second is the S phase, when the cell actually
duplicate its DNA. The third phase is the G2 phase, where
it prepares itself for mitosis. The duration of G1 varies con­
siderably from cell to cell, while S, G2, and mitosis show
less variation. Quiescence is a reversible state of a cell in
which it does not divide but retains the ability to reenter
cell cycle. This state is also called G0 phase.
The transition from one cell cycle phase to another is
controlled by a variety of proteins, cyclins, and cyclin-
dependent kinases. If the system identifies any inaccuracies,
the transition from one phase to the next will be delayed and
the cells arrested in the so-called cell cycle checkpoints
[111]. Cells, which enter mitosis with unrepaired DNA
damage, will most likely fail to divide properly resulting in
cell death. In order to provide time for DNA damage repair
or, if repair is not the best solution for inducing cell death,
e.g. apoptosis, before DNA synthesis (S phase) and in par­
ticular mitosis is initiated, radiation induces arrest in check­
points at the end of the G1 and G2 phases. Since the process
that kills the cells after radiation damage is related to cell
division, cells in G0 or cells which are differentiated or in
senescence and have lost the ability to proliferate are very
resistant to radiation [112].
3.8.1"
"Describe the key phases of the eukaryotic cell cycle, including their primary events and the associated regulatory proteins involved. Specifically, detail the roles of cyclins and cyclin-dependent kinases (CDKs) in transitioning between these phases.","The eukaryotic cell cycle is a precisely orchestrated series of events that culminates in cell division. It’s typically divided into three main phases: G1, S, and G2, followed by mitosis. The G1 phase represents the initial growth and preparation for DNA synthesis. During this time, the cell increases in size, synthesizes proteins and organelles, and monitors its environment for signals that determine whether to proceed with division. The S phase is characterized by DNA replication – the duplication of the entire genome. This process involves complex enzymatic reactions and requires significant cellular resources. Following S phase, the G2 phase occurs, where the cell continues to grow and prepares itself for mitosis, including checking for DNA damage and ensuring proper chromosome condensation. Finally, mitosis itself divides the duplicated chromosomes equally into two daughter nuclei. The transitions between these phases are tightly controlled by a complex network of proteins, most notably cyclins and cyclin-dependent kinases (CDKs). Cyclins are regulatory proteins that bind to CDKs, forming active complexes capable of phosphorylating target proteins involved in cell cycle progression. Different types of cyclins – such as D cyclins in G1, cyclin E in G1/S, and A and E cyclins in S phase, and B cyclins in M phase – are expressed at different times during the cell cycle, dictating the specific events that occur in each phase. CDKs themselves are enzymes that catalyze the phosphorylation of target proteins. The activity of these CDK-cyclin complexes is regulated by various mechanisms including degradation of cyclins, modification of CDKs and interactions with other regulatory proteins. These checkpoints ensure accurate DNA replication and chromosome segregation, preventing errors that could lead to cell death or genetic instability.  The specific functions are summarized in Table 3.9 which highlights the roles of different cyclins and CDKs throughout the cell cycle phases [127].","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.8	 Cell Cycle Effects | Sub-subsection: 3.8.1	 Cycle-Dependent Kinases and Cyclins | Content: phase in which the cell grows and prepares itself for DNA
synthesis. Second is the S phase, when the cell actually
duplicate its DNA. The third phase is the G2 phase, where
it prepares itself for mitosis. The duration of G1 varies con­
siderably from cell to cell, while S, G2, and mitosis show
less variation. Quiescence is a reversible state of a cell in
which it does not divide but retains the ability to reenter
cell cycle. This state is also called G0 phase.
The transition from one cell cycle phase to another is
controlled by a variety of proteins, cyclins, and cyclin-
dependent kinases. If the system identifies any inaccuracies,
the transition from one phase to the next will be delayed and
the cells arrested in the so-called cell cycle checkpoints
[111]. Cells, which enter mitosis with unrepaired DNA
damage, will most likely fail to divide properly resulting in
cell death. In order to provide time for DNA damage repair
or, if repair is not the best solution for inducing cell death,
e.g. apoptosis, before DNA synthesis (S phase) and in par­
ticular mitosis is initiated, radiation induces arrest in check­
points at the end of the G1 and G2 phases. Since the process
that kills the cells after radiation damage is related to cell
division, cells in G0 or cells which are differentiated or in
senescence and have lost the ability to proliferate are very
resistant to radiation [112].
3.8.1
Cycle-Dependent Kinases and Cyclins
­
J. Reindl et al.
127
categories: G1 cyclins, i.e., D cyclins; G1/S cyclin, i.e.,
cyclin E; S-phase cyclins, i.e., cyclins E and A; and M-phase
cyclins, i.e., B cyclins. Researchers have discovered around
20 CDK-associated proteins, which makes the cell cycle a
complex process that involves the combination of CDKs
(Cdk1, Cdk2, Cdk3, Cdk5, Cdk4, Cdk6, Cdk7, Cdk8, etc.)
and cyclins (A1, A2, B1, B2, B3, C, D1, D2, D3, E1, E2, F,
etc.) in distinct phases of the cell cycle endowing extra gov­
ernance to the cell cycle apparatus (Table 3.9 and Fig. 3.31).
Cyclins impart the specificity for substrates and normal cell
cycle regulation, which includes the subunit binding, local­
ization, activation/deactivation, etc. to the Cdk/cyclin com­
plexes [113].
Table 3.9 Cyclins, CDKs, and their function throughout cell cycle
Cell
cycle
phase
Cyclins
CDKs
Functions
G1
Cyclin D
CDK 4,
CDK6
Can act in response to external cues,
e.g., growth factors and/or mitogens
G1/S
Cyclins E
CDK2
Control the centrosome duplication
S
Cyclins A
and E
CDK2
The main targets are helicases and
polymerases
M
Cyclins BCDK1
Control G2/M checkpoint. The
cyclins are produced in S phase but
are inactive until the synthesis is
entirely completed. Phosphorylate
several downstream targetsFig. 3.31
Fig. 3.31 Overview of cell cycle: functions of different phases, cyclins and CDKS, and CDIs
3 Molecular Radiation Biology
128
3.8.2"
"Describe the role of cyclin-dependent kinases (CDKs) and cyclins in regulating the cell cycle, specifically focusing on how their interaction leads to activation and subsequent progression through different phases.","Cyclin-dependent kinases (CDKs) are a family of enzymes that play a central role in controlling the eukaryotic cell cycle. However, CDKs themselves are inactive until they bind to specific regulatory proteins called cyclins. This cyclin-CDK complex then becomes active and drives events necessary for progression through different phases of the cell cycle – G1, S, G2, and M. The type of cyclin bound dictates the CDK’s activity and substrate specificity. For instance, Cyclin D binding activates CDKs, initiating events in the G1 phase, such as DNA synthesis. Subsequently, Cyclin E binds to the activated CDK, promoting entry into the S phase where DNA replication occurs. Finally, Cyclin A binding leads to activation of CDKs that are crucial for preparing the cell for mitosis (M) phase. The formation and degradation of cyclins is tightly controlled by protein phosphatases, ensuring precise timing and preventing uncontrolled cell division. Furthermore, CDK activity is regulated not only by cyclin binding but also by phosphorylation events, adding another layer of complexity to this critical regulatory pathway. Dysregulation of cyclin-CDK complexes can lead to genomic instability and contribute to the development of diseases like cancer.
Reference: Cell Biology, Section 12.3 – The Cell Cycle and CDKs","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.8	 Cell Cycle Effects | Sub-subsection: 3.8.2	 Activation of CDKs by Binding to Cyclins | Content: to Cyclins
­
3.9
­
­
1
­
2
­
1
2
­
­
114
­
­
SCF
114
3.8.3"
"Describe the roles of CDK inhibitors (CKIs) within the cell cycle, specifically focusing on their mechanisms and the families involved in regulating transitions between G1-S and S-M phases.","CDK inhibitors (CKIs) are crucial proteins that directly bind to cyclin-CDK complexes, effectively preventing these complexes from phosphorylating downstream targets and thus halting or delaying cell cycle progression. Their primary function is to safeguard against premature entry into the S and M phases of the cell cycle. The INK4 family – consisting of p16INK4a, p15INK4b, p18INK4c, and p19INK4d – plays a key role in this regulation. These proteins specifically bind to Cdk4 and Cdk6, inhibiting their activity and preventing the formation of D-type cyclin/Cdk complexes, which are essential for driving G1-S phase transition. Simultaneously, the Cip/Kip family comprises several members including p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2. These CKIs obstruct the activity of Cdk2/cyclin E, Cdk2/cyclin A, Cdk1/cyclin A, and critically, Cdk1/cyclin B – all vital for progression through S and M phases respectively. The precise timing of CKI activation is often triggered by cellular stress events such as DNA damage or telomere dysfunction, ensuring that the cell cycle pauses until repair mechanisms are complete and the genome is stabilized. In human cancers, mutations frequently occur in genes encoding these CKIs, leading to dysregulated cell cycle control and uncontrolled proliferation. Reference: 3.8.3 Inhibitors of Cyclin-Dependent Kinases","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.8	 Cell Cycle Effects | Sub-subsection: 3.8.3	 Inhibitors of Cyclin-Dependent Kinases | Content: CDK inhibitors are a family of proteins that can bind directly
to the cyclin-CDK complex and hinder its activity. In the tran­
sition of the G1-S phases, these proteins play a very crucial
role. CKIs implicated in controlling the S phase and mitotic
CKIs are indispensable to avoid early commencement of the
S- and M-phase CDKs. However, in human cancers, genes
coding these CKIs are often mutated leading to aberrant cell
cycle regulation. During normal or extreme conditions (DNA
damage, telomere dysfunction, and stress), the functions and
activities of the CDK/cyclin complexes are governed and con­
trolled by two families of CKIs. The INK4 family comprises
the p16INK4a, p15INK4b, p18INK4c, and p19INK4d which
can specifically bind to Cdk4 and Cdk6 and hinder the activity
of the D-type cyclin. The other Cip/Kip family (p21Cip1/
Waf1/Sdi1, p27Kip1, p57Kip2) obstructs Cdk2/cyclin E,
Cdk2/cyclin A, Cdk1/cyclin A, as well as Cdk1/cyclin B activ­
ity. The p21 protein hinders the formation of cyclin/CDK pro­
tein complexes that are required for the progression from the"
"Describe the techniques used to synchronize cells in culture for studying radiosensitivity, focusing on how these methods relate to the cell cycle phases and potential differences in sensitivity observed within those phases.","Researchers employ several strategies to synchronize cells in culture prior to assessing their radiosensitivity. The primary goal is to create a population of cells predominantly residing within a specific cell cycle phase, allowing for more precise analysis of radiation effects. Three main techniques are commonly utilized:

1. **Fluorescence-Activated Cell Sorting (FACS):** This method leverages DNA-binding dyes like Hoechst 33342 to identify and physically separate cells based on their fluorescence intensity.  This allows researchers to isolate cells in a particular phase of the cell cycle, typically by targeting cells actively undergoing DNA replication (S phase) or arresting them at specific checkpoints.

2. **Chemically Induced Cell Cycle Arrest:** This technique involves using drugs like hydroxyl urea to induce a controlled arrest of cells at a defined checkpoint within the cell cycle, most frequently the boundary between G1 and S phases.  Following this arrest, the cells progress through the remaining phases of the cell cycle synchronously. Removal of the drug then allows for observation of subsequent cell division.

3. **Mitotic Selection:** This method exploits the physical changes that occur during mitosis. As cells enter mitosis, they round up and detach from the culture vessel's bottom. Gentle shaking of the flask dislodges these mitotic cells, which can be collected with the medium.  Irradiating these detached mitotic cells at different time points as they proceed through the cell cycle allows for investigation of radiosensitivity during this particularly sensitive phase.

The sensitivity of cells varies significantly depending on their position within the cell cycle. For example, cells in G2 are often hyper-radiosensitive to small radiation doses because the mechanisms initiating early radiation-induced G2 arrest by ATM are not activated until higher doses are applied. Furthermore, radioresistance generally increases throughout S phase, indicating that cells are most radiosensitive during mitosis when DNA replication is actively occurring and genomic instability is heightened.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.8	 Cell Cycle Effects | Sub-subsection: 3.8.4	 Cell Cycle Phase and Radiosensitivity | Content: 3.8.4
Cell Cycle Phase and Radiosensitivity
To study the variation of radiosensitivity with position in the
cell cycle, it is necessary to synchronize the cells to get a
population of cells that are all in the same cell cycle phase.
For cells in culture, there are three main techniques.
1.	In fluorescence-activated cell sorting (FACS), a flow
cytometer is used to sort cells based on fluorescence from
a DNA-binding dye, such as Hoechst 33342, which can
be used for live cells.
2.	Chemically induced cell cycle arrest collects over time all
the cells at a cell cycle checkpoint. When the drug is
Box 3.19 In a Nutshell: Cell Cycle and Radiation
Response
•	Irradiated cells display a complex set of responses
that can include either progression or arrest of the
cell cycle.
•	Every phase of the cell cycle has a very specific set
of cyclins and cyclin-dependent kinases to perform
functions associated with that particular cell cycle
phase.
J. Reindl et al.
129
removed, the cells will go through the cell cycle synchro­
nously for some time before they become more and more
asynchronous. The most used drug is hydroxyl urea,
which arrests cells at the border between G1 and S. The
advantage of this method is that it can also be used in vivo.
3.	Mitotic selection was introduced by Terasima and Tolmach
[115] and is the most used synchronization method in cell
culture in vitro. As cells enter mitosis, they round up and
become less attached to the flask bottom. By then shaking
the flask, the mitotic cells will detach and can be collected
with the medium. The cells can then be irradiated at differ­
ent time points as they go through cell cycle.
115
3.32
­
­
3.32
Measurements of the radiosensitivity of cells in G2 are
technically difficult, and it has become customary to suppose
that cells are radiosensitive if irradiated in G2. However, the
radiosensitivity of cells in G2 has been shown to be dose
dependent to a quite different degree than in any other phase
of the cell cycle. Cells are hyper-radiosensitive for small
radiation doses because the mechanism for early radiation-­
induced G2 arrest by ATM is not activated by radiation doses
in the range below about 0.3–0.5 Gy (Box 3.20).
Box 3.20 In a Nutshell: Radioresistance and
Radiosensitivity and Cell Cycle
•	Cells increase radioresistance throughout S phase.
•	Cell radiosensitivity is highest during mitosis.Fig. 3.32
Fig. 3.32 Age-response of cells after radiation. Left: Age-response
curves for HeLa-S3 cells (open circles: synchronized cells, triangles:
asynchronous cells) irradiated with 3 Gy X-rays (= 300 rad) at different
time points after selection in mitosis and the fraction of cells with incor­
porated [3H]-thymidine in DNA after a 20-min pulse (black circles,
right y-axis). Right: Dose-response curves for HeLa-S3 cells synchro­
nized by mitotic selection and X-irradiated at different times after
selection. 0 h: mitosis, 5 h: early G1 phase, 14 h: S phase, 19 h: late S/
G2 phase. [Reproduced with permission from Terasima and Tolmach
[115]]
3 Molecular Radiation Biology
130
3.9"
"Describe the structure and function of telomeres within eukaryotic chromosomes, including their role in genome stability and cellular senescence.","Telomeres are specialized nucleoprotein structures found at the ends of linear eukaryotic chromosomes. They consist of repetitive sequences – specifically, tandem repeats of a G-rich hexanucleotide sequence (TTAGGG) – typically ranging from 10 to 15 kilobase pairs in length. These repeating units are organized into heterochromatin domains, contributing to chromosome structure and stability. A primary function of telomeres is to shield the linear DNA from being recognized as double-strand breaks by cellular DNA repair mechanisms. This protection prevents triggering of DNA repair pathways that could lead to chromosomal instability or cell death. Secondly, telomeres play a crucial role in limiting the number of times a cell can divide. During each cell division, the lagging strand cannot be fully replicated due to the ‘end replication problem,’ resulting in a shortening of the telomere length by approximately 50-200 base pairs. As telomere length decreases, it eventually reaches a critical threshold. When this occurs, the cell’s ability to divide is compromised, leading to cellular senescence – a state of irreversible growth arrest – often referred to as the Hayflick limit. This process is particularly relevant in immune cells like T lymphocytes, where telomere shortening contributes to age-related decline in adaptive immunity.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.9	 Telomeres and Senescence | Sub-subsection: 3.9.1	 Telomeres and Their Role | Content: Telomeres are nucleoprotein structures located at the end of
each linear chromosome in the cell nucleus. They are com­
posed by tandem repeats of the G-rich hexanucleotide
TTAGGG and are typically 10–15 kb long [116]. These
structures are organized into heterochromatin domains, and
they play a significant role in maintaining genome stability.
There are at least two very important functions of telomeres
in eukaryotes. The first one is the protection of the linear
DNA molecules from the DNA repair mechanisms, which
may recognize these sites as double-strand breaks. Secondly,
they define the maximum number of cell cycles that a cell
may undergo [116]. At each cell cycle division, telomeres
shorten by 50–200 bp due to the DNA end-replication prob­
lem [117]. This problem results from the inefficient copying
of the last base pairs of the linear DNA molecule by DNA
polymerase. After several cell divisions, the length of telo­
meres reaches a critical threshold, which means that the cell
can no longer divide. The cell has then reached its Hayflick
limit, and it proceeds to senescence. Telomere shortening is
thus a very-well-known hallmark of cellular senescence and
aging. A good example of the telomere shortening is the defi­
ciency of the adaptive immune system in older individuals
caused by T cells reaching their Hayflick limit [118].
­
­
118
3.33
­
116
3.9.2"
"Describe the multifaceted role of cellular senescence, encompassing its initiation pathways, associated hallmarks, and potential impact on both normal aging and disease processes like cancer and wound healing.","Cellular senescence represents a state of irreversible cell cycle arrest characterized by distinct morphological, biochemical, and secretory changes. Its primary initiation is often driven by two key signaling pathways: the p53–p21–RB pathway and the p16INK4A–RB pathway, frequently triggered by DNA damage or oxidative stress, as seen with radiation exposure. Senescent cells exhibit a range of hallmarks including morphological alterations, increased expression of senescence-associated beta-galactosidase (SA-β-gal), and the secretion of a complex mixture termed the senescence-associated secretory phenotype (SASP). The SASP contains pro-inflammatory cytokines and proteases that contribute to various biological processes. Importantly, senescence plays diverse roles depending on context. In developmental stages like embryogenesis, it’s induced by paracrine signaling mediated by p21, without necessarily involving DNA damage or the full spectrum of SASP factors. During wound healing, senescence contributes to preventing excessive fibrosis through PDGFA-enriched SASP secretion. However, in organismal aging, telomere shortening and subsequent activation of p16INK4A lead to a sustained accumulation of senescent cells, contributing to age-related decline. Furthermore, the role of senescence in cancer is complex; it can initially suppress tumor growth by inhibiting proliferation but later promotes tumorigenesis through stem-like properties induced by SASP factors.  Recent research demonstrates that eliminating senescent cells – particularly within tumors – can improve health span and mitigate age-associated conditions, highlighting its potential as a therapeutic target.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.9	 Telomeres and Senescence | Sub-subsection: 3.9.2	 Senescence and Its Role | Content: 3.7
­
­
120
Fig. 3.33 Telomeres, their shortening, the senescence state, and
immortal cells. An adult cell chromosome with telomeres and the
enzyme telomerase, which plays a crucial role in telomere end length­
ening (left). Telomere characteristics in an adult cell’s chromosome,
after multiple replications, at cell senescence, and when the cell is
immortal (left to right, blue box). (Adapted with permission from
Aunan et al. [119])
J. Reindl et al.
131
detected at any life stage from embryogenesis (contributes to
tissue development) to adulthood (to prevent the prolifera­
tion of damaged cells). Yet, senescent cells can also potenti­
ate various aspects of tumorigenesis, including proliferation,
metastasis, and immunosuppression by secreting a collection
of
pro-inflammatory
factors
collectively
termed
as
senescence-­associated secretory phenotype (SASP) [121]. It
is important to clarify that senescence is a distinct form of
cell cycle arrest and distinct from quiescence, where cells
can reenter the cell cycle when favorable growth conditions
are restored; terminal differentiation, where cells exhibit
functional and morphological changes resulting in loss of
original cellular identity; and cell death, where cells are
being eliminated and are thus nonfunctional. The existence
of multiple senescence programs and the nonspecificity of
current senescence markers make it difficult to fully unveil
the complex mechanism behind senescence (current under­
standing presented in Fig. 3.34). It is therefore recommended
to apply a multi-marker approach when investigating cellular
senescence [120]. Yet, it is currently accepted that two main
signaling pathways initiate and maintain the cell cycle arrest:
p53–p21–retinoblastoma protein (RB) and p16INK4A–
RB. As a consequence, depending on the senescence pro­
gram, senescent cells express a multitude of hallmarks such
as morphological alterations, senescence-associated beta-­
galactosidase (SA-β-gal), and SASP among others [122].
•	Senescence in developmental processes, i.e., in embryo­
genesis and organogenesis, is induced by paracrine sig­
naling and is mediated by the expression of the cell cycle
inhibitor p21. Although SA-β-gal is highly expressed,
developmental senescence is not associated with DNA
damage, does not secrete the typical range of SASP cyto­
kines, and is independent of p53 and p16INK4a.
Senescence in wound healing prevents excessive fibrosis
by secreting PDGFA-enriched SASP to stimulate appro­
priate skin repair. Senescence causes, or at least contrib­
utes to, organismal aging through the shortening of
telomeres followed by the induction of p16INK4a and
resulting in an accumulation of senescent cells over time.
Studies by Baker et al. [123], first in BubR1-mutant mice
(Cdkn2ap16 knockout mice) and then later in naturally
aged mice, demonstrated that in the absence of p16INK4a,
it is possible to inhibit the production of senescent cells
and improve health span [123]. Also, SASP triggers mul­
tiple intercellular communication paths that also promote
aging. Finally, the elimination of senescent cells improved
several age-associated conditions. Senescence in cancer
has shown a dual role as tumor suppressor and tumor pro­
moter. Senescence is a key mechanism of tumor suppres­
sion via the inhibition of proliferation of cancer cells or
by stimulating immune surveillance. Yet, cells induced to
senescence by oncogenes or chemotherapy exhibit stem­Fig. 3.34
Fig. 3.34 Overview of cellular senescence processes. ROS reactive
oxygen species, ATM ataxia-telangiectasia mutated, ATR ATM and
Rad3-related protein, Cdk2/4/6 cyclin-dependent kinase 2/4/6, RB reti­
noblastoma tumor suppressor gene, SASP senescence-associated secre­
tory phenotype, SA-β-gal senescence-associated beta-galactosidase
3 Molecular Radiation Biology
132
like properties that promote cancer. Several stressors can
induce cellular senescence and radiation in one of them.
Thus, IR may cause cell cycle arrest resulting in a prema­
turely induced senescence phenotype (including SA-β-­
gal, p16INK4a, p21, and SASP), which is p53 dependent
[121]. Unfortunately, the accumulation of these senescent
cells can have a negative impact by promoting tumorigen­
esis. Thus, eliminating senescent cells from tumors and
surrounding healthy tissues may be a successful and ben­
eficial adjuvant strategy (Box 3.21).
3.10"
"Following ionizing radiation exposure (IR), what factors contribute to the diverse mechanisms of cell death observed in different cell types, and how do these factors influence the selection of a specific cell death pathway?","Cell death following ionizing radiation (IR) is not a uniform process; instead, multiple, distinct molecular pathways can be triggered. The initiation of these various forms of cell death depends on several key elements. Primarily, the extent of DNA damage caused by IR plays a significant role in determining which pathway is activated. However, it’s crucial to recognize that simply measuring DNA damage isn't sufficient; the individual signaling status of different cell death pathways within a particular cell type also critically influences this decision. For example, hematological cells (like blood cells) and epithelial cells often exhibit distinct responses due to variations in their pre-existing signaling profiles and inherent sensitivities to specific apoptotic or necrotic signals. These differences can lead to either apoptosis (programmed cell death characterized by controlled cellular disassembly) or necrosis (uncontrolled cell lysis), each with unique morphological and biochemical features. The complex interplay between DNA damage levels and the activation state of these pre-existing pathways – such as those involving caspases for apoptosis or reactive oxygen species (ROS) production for necrosis – ultimately dictates the specific cell death mechanism employed by a given cell type.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Content: In response to IR, multiple, molecularly distinct forms of
cell death may be initiated. Although the decision points of
their initiation are not completely clear, it is known that the
level of the DNA damage but also the individual signaling
status of different cell death pathways in different cell types,
e.g., hematological vs. epithelial cells, influence the decision
regarding the cell death route.
­
124
124
­
3.35"
"Describe the process of cellular senescence and its relevance to radiation-induced cell death, as outlined in the text. Specifically, explain how telomere shortening contributes to this phenomenon.","Cellular senescence represents a state of irreversible cell cycle arrest characterized by metabolic quiescence and altered gene expression. It’s frequently considered a form of cell death, particularly in the context of radiation exposure. The process is fundamentally linked to telomeres – protective caps at the ends of chromosomes that shorten with each cell division due to the limitations of DNA replication machinery. As telomeres progressively shorten, they reach a critical threshold known as the Hayflick limit. This reduction triggers a cascade of events leading to senescence. Once telomere length diminishes sufficiently, it activates cellular pathways associated with DNA damage response and replicative stress, ultimately arresting the cell cycle. Furthermore, cells exhibiting mutations in TP53 (a tumor suppressor gene) or deficient TP53 function can continue dividing for several rounds before succumbing to this form of senescence. In these cases, the accumulation of chromosomal abnormalities precedes eventual apoptosis or necrosis. The text highlights that radiation-induced mitotic catastrophe (MC) frequently occurs in cancer cells with compromised cell cycle checkpoints, leading to unsuccessful cytokinesis and the formation of giant cells. These cells often undergo apoptosis via the mitochondrial pathway following G1 phase arrest. However, mutant TP53 cells can endure additional cell divisions before ultimately succumbing to delayed apoptosis or necrosis. The overall effect demonstrates that senescence is a crucial mechanism for removing potentially harmful cells from proliferative pools and plays a significant role in tumor suppression.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.1	 Mitotic Cell Death/Mitotic Catastrophe | Content: 125
124
3.37
CDKN1A
­
­
­
­
CDKN1A
­
Box 3.21 In a Nutshell: Telomeres and Senescence
•	Telomeres are part the ending parts of chromo­
somes, which protect the genome integrity
•	Telomeres shorten in each cell division by
50–200 bp due to the DNA end-replication
problem.
•	Telomere shortening is closely linked to cellular
radiosensitivity.
•	After several cell divisions, the length of telomeres
reaches a critical threshold, the Hayflick limit, and
the cell proceeds to senescence.
•	Senescence is sometimes addressed as a type of cell
death. A cell in senescence cannot proliferate any­
more, it lives only metabolically.
•	Cellular senescence is characterized by a prolonged
and generally irreversible cell cycle arrest, and it
functions as a process to remove potentially harm­
ful cells from the proliferative cell pool.
•	Senescence is a key mechanism of tumor suppres­
sion via the inhibition of proliferation of cancer
cells or by stimulating immune surveillance in can­
cers treated with radiotherapy.
J. Reindl et al.
133Fig. 3.35
Fig. 3.35 Overview of cell death and cell death-protective mecha­
nisms in response to radiation. Radiation-induced cell death is influ­
enced by different factors, such as radiation factors, cell intrinsic
factors, and cellular microenvironment factors (left). Cell death path­
ways are listed to the right. The mechanisms and importance of these
principal cell death forms are described in detail in the text
Table 3.10 Examples of IR-induced MC in different tumor cell lines
Inducer of
MC
Cell line
Features/signaling
components of MC
Ionizing
radiation
HeLa (cervical
adenocarcinoma)
Increased levels of cyclin
B
U2OS (osteosarcoma)
Checkpoint adaptation
HT0180 (fibrosarcoma)
Micronucleation
MOLT4 (leukemia)
Checkpoint adaptation
cell death are frequently observed to have an unsuccessful
cytokinesis consequentially exhibiting tetraploid anomalous
nuclei developing into giant cells. Giant cells that possess a
functional TP53 will eventually undergo apoptosis following
the mitochondrial pathway of apoptosis in the subsequent G1
phase. However, cells with mutant TP53 or deficient TP53
function go on with a few number of cell cycles and attain a
growing amount of chromosomal anomalies before they
finally succumb to either delayed apoptosis or necrotic form
of cell death [125]. As the cells that undergo MC are usually
the ones who have lost the potential to carry out any further
replication, MC is frequently referred to as a genuine type of
cell death. One of the most common properties exhibited by
cancer cells is that of defects in cell cycle checkpoints. This
lets the cells enduring IR-induced damage to hastily inscribe
in the mitotic process even with the misrepaired DNA that
eventually leads to MC. More than a few cell division
attempts can take place before adequate genetic injuries
mount up to activate mitotic death, emphasizing why solid
tumors frequently display deferred reactions to IR [124]. MC
is triggered after IR exhibits diverse mechanisms of action
(Table 3.10) [126].
3.10.1.1"
Describe the process of ‘slippage’ observed during mitotic catastrophe and explain why it occurs despite a functional spindle assembly checkpoint (SAC).,"Mitotic catastrophe, or MC, doesn't always result in immediate mitotic arrest. Even when the SAC remains operational – meaning it continues to monitor and prevent premature mitotic exit – a phenomenon known as ‘slippage’ can occur if cyclin B levels are significantly reduced. The SAC normally functions by inhibiting anaphase onset until all chromosomes are correctly segregated. However, prolonged MC leads to a substantial decrease in cyclin B concentration. When the level of cyclin B falls below a critical threshold, it no longer effectively inhibits mitotic exit signals. This allows the cell to bypass the SAC’s control and proceed directly into anaphase, resulting in chromosome missegregation and ultimately, cell death. Essentially, the SAC is overwhelmed by the sustained disruption of mitosis, leading to a failure to maintain proper segregation despite its continued activity.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.1	 Mitotic Cell Death/Mitotic Catastrophe | Sub-sub-subsection: 3.10.1.1	 Mode of Action of Mitotic Catastrophe | Content: 3.36
­
MC may not at all time be accompanied by mitotic arrest.
Nevertheless, the mechanism of action that dictates cell fate
of subsequent MC continues to remain unclear [127]. When
3 Molecular Radiation Biology
134Fig. 3.36
Fig. 3.36 Cell death pathways operative in mitotic catastrophe.
Different signaling events triggered in response to a nonfunctional
mitosis are shown. Upon DNA damage, cells which lack functional p53
can go out from mitosis without commencing cytokines or initiate cell
death even in mitosis. Apoptosis and necrosis signaling in the context of
mitotic catastrophe are depicted
mitotic arrest is extended, the amount of cyclin B is decreased
albeit the spindle assembly checkpoint (SAC) is functional.
As a result, if cyclin B levels drop below the verge that deter­
mines mitotic exit, slippage occurs (Box 3.22)."
"Describe the process of apoptosis, including its triggers and the resulting cellular changes observed during this form of cell death.","Apoptosis, also known as ""cellular suicide,"" is a highly regulated mechanism by which cells self-destruct with minimal tissue damage. It’s initiated in response to various internal or external signals, encompassing endogenous events like DNA damage and telomere shortening, alongside external stimuli such as cytotoxic agents, ionizing radiation (IR) exposure, growth factor deprivation, cytokine alterations, or hypoxia. The process involves energy-requiring molecularly defined effector mechanisms that ultimately lead to the dismantling of the cell. During apoptosis, cells form apoptotic bodies – fragmented cellular components including a collapsed cytoskeleton, disassembled nuclear envelope, and DNA fragments. Furthermore, the cell surface displays ‘find-me’ and ‘eat-me’ signals, facilitating rapid engulfment by macrophages, preventing inflammation. The intrinsic pathway is frequently activated through mitochondrial dysfunction leading to MOMP (mitochondrial outer membrane permeabilization) and the release of pro-apoptotic factors like Bid, ultimately triggering caspase activation. Reference: [Molecular Radiation Biology, Section 3.10.2 Apoptosis]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.2	 Apoptosis | Content: Apoptosis (originally from Greek language translated “fall­
ing off”) is also known as “cellular suicide.” It is a cell death
process which may be executed under normal physiology,
e.g., organism development, but also in the context of dis­
ease. Apoptosis is a highly controlled pathway with distinct
molecular features. Thus, some of the rapidly proliferating
cells undergo apoptosis, which is an essential part of neuro­
genesis and tissue development in humans as well as in other
mammalians. During apoptosis, cells are disposed in a com­
plex but well-ordered fashion which involves energy-requir­
ing molecularly defined effector mechanisms [128]. To
simplify, apoptosis allows the cells to self-destruct with lim­
ited tissue damage when they are exposed to different trig­
gers/signals which can be endogenous, e.g., formed DNA
damages, telomere shortening, or encountered from the out­
side of the cell, e.g., cytotoxic or DNA-damaging agents, IR
exposure, loss of growth factors, cytokine or glucocorticoid
hormone level alterations, or hypoxia [128].
Box 3.22 In a Nutshell: Ionizing Radiation Induced Cell
Death
•	IR-induced cell death depends on radiation quality,
dose as well as cell type, cell cycle position, and
functionality in DNA damage signaling.
•	Mitotic catastrophe is one of the principal forms of
IR-induced cell death that results from early/
untimely entry into mitosis, even before the fulfill­
ment of S and G2 phases of the cell cycle.
•	The characteristic features of IR-induced mitotic
catastrophe are altered nuclear morphology, micro­
nucleation, and formation of multinucleated cells.
J. Reindl et al.
135Fig. 3.37
Fig. 3.37 The intrinsic and extrinsic route to apoptosis. Intrinsic stress
signals (e.g., DNA damage, hypoxia, metabolic stress) or lethal stimuli
(e.g., IR exposure) can induce intrinsic mitochondrial apoptosis (mid­
dle). Cleaved or truncated Bid (tBid) can also connect the extrinsic
pathway to the intrinsic route. In the extrinsic pathway, ligands for
death receptors (left) can trigger caspase activation, but the pathway can
also be activated when some dependence receptors are inactivated
(right). Abbreviations: FasL Fas ligand, TRAIL TNF-related apoptosis-
inducing ligand, TNF tumor necrosis factor, Fas Fas cell surface death
receptor, TRAILR TNF-related apoptosis-inducing ligand receptor,
TNFR tumor necrosis factor receptor, TRADD TNFR1-associated death
domain protein, FADD Fas-associated protein with death domain, cas­
pase cysteine-­aspartic proteases, BID BH3-interacting domain death
agonist, tBID truncated BID, Bcl-2 B-cell lymphoma 2 (an apoptotic
inhibitor), BCL2L1 Bcl-2-like 1, MOMP mitochondrial outer mem­
brane permeabilization, BH3 Bcl-2 homology 3, DIABLO direct inhibi­
tor of apoptosis-­binding protein with low pI, APAF-1 apoptotic
peptidase-­activating factor 1, Bax Bcl2-associated X (an apoptotic reg­
ulator), Bak Bcl-2 homologous antagonist/killer, XIAP X-linked inhibi­
tor of apoptosis protein, SMAC second mitochondria-derived activator
of caspase, UNC5B Unc-5 netrin receptor B
Apoptosis results in the production of apoptotic bodies,
which are cell fragments, e.g., collapsed cytoskeleton, disas­
sembled nuclear envelope, and fragments of nuclear
DNA. An apoptotic cell is also marked by certain “find-me”
and “eat-me” signals at the cell surface, which allow the
dying cell to be recognized and rapidly engulfed by different
macrophage subtypes in the near or distant tissue, thereby
avoiding inflammation. A well-recognized potential “eat-
­me” signal is the expression of phosphatidylserine (PS) on
the outer side of plasma membrane, which in turn is being
used for assessing early apoptotic cells [129].
­
130
3.37
3.10.2.1
Intrinsic Pathway to Apoptotic
Execution
Multiple perturbations may trigger intrinsic apoptotic cell
death, e.g., growth factor withdrawal, cytokine alterations,
endoplasmic reticulum stress, replication stress, formation of
reactive oxygen species (ROS), microtubular alterations or
mitotic defects, and IR-induced DNA damage. In the context
3 Molecular Radiation Biology"
"Describe the two primary pathways involved in apoptosis triggered by ionizing radiation, detailing the key events and molecules implicated in each pathway.","Apoptosis following ionizing radiation (IR) exposure can be initiated through either the intrinsic or extrinsic pathway. The **extrinsic pathway** is activated when IR induces DNA damage, particularly double-strand breaks (DSBs), leading to the upregulation of the FAS receptor and its ligands by TP53. This triggers a cascade where the death ligand binds to the FAS receptor on the cell surface, initiating the formation of a death-inducing signaling complex (DISC). Within the DISC, adapter proteins bind to aggregated procaspase-8 molecules, facilitating proteolytic cleavage and subsequent activation of effector caspases. This amplification step is further fueled by the release of mitochondria-localized pro-apoptotic factors, contributing to CASP-3 activation. Conversely, the **intrinsic pathway**, also known as the mitochondrial pathway, is activated when IR causes DNA damage such as single-strand breaks (SSBs) or DSBs that overwhelm the cell’s repair mechanisms. This leads to mitochondrial outer membrane permeabilization (MOMP), a central event where pro-apoptotic factors like cytochrome c are released from the mitochondria into the cytoplasm. The balance between BCL-2 family proteins – which can positively and negatively regulate MOMP – determines whether this release triggers caspase activation. Ultimately, both pathways converge on the activation of effector caspases, leading to the characteristic morphological changes associated with apoptosis, including cell shrinkage and chromatin condensation.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.2	 Apoptosis | Sub-sub-subsection: 3.10.2.2	 Extrinsic Pathway to Apoptotic Execution | Content: face of the target cell that is followed by death-inducing sig­
naling complex (DISC) formation. Subsequently, adapter
proteins bind to the intracellular region of aggregated DISC
complex, causing the accumulation of procaspase-8 mole­
cules, which via proteolytic cleavage initiate a proteolytic
cascade leading to effector caspase activation. There is also
an amplification step where further release of mitochondria-­
localized pro-apoptotic factors takes place to amplify the ini­
tial CASP-3 activation (Box 3.23).
3.10.2.3
Activation of Apoptosis by Ionizing
Radiation
IR-induced DNA damages, e.g., unrepaired DNA SSBs or
DSBs, primarily trigger apoptosis via the intrinsic pathway
[134]; however, at certain IR doses and in certain cell types,
the extrinsic apoptotic pathway may also be executed. IR can
also initiate mitochondria-mediated signaling in response to
ceramide production/formation at the plasma membrane.
Moreover, IR can trigger the production of O2
− and ROS
(like H2O2 or OH− radicals), which via release of Ca2+ and
cytochrome c from mitochondria can cause apoptosis [135].
136
3.38
­
The extrinsic pathway may also play a role in IR-induced
apoptosis in which TP53 may upregulate the expression of the
FAS receptor and its ligands, which subsequently causes
downstream transactivation of initiator CASP8 and apoptosis.
Box 3.23 In a Nutshell: Apoptosis
•	Apoptosis is a distinctive and highly controlled
form of programmed cell death, which requires
energy to hit the self-destruct button of an affected
cell.
•	Apoptosis which can be triggered in response to
endogenous or exogenous signals is a chain of
sequential morphological events during which the
early apoptotic cell shrinks and chromatin is irre­
versibly condensed and cleaved culminating into
formation of apoptotic bodies.
•	In the mitochondria-mediated or intrinsic route to
caspase activation, induction of mitochondrial outer
membrane permeabilization (MOMP) is a central
event that sets free pro-apoptotic factors such as
cytochrome c.
•	The BCL-2 proteins can positively and negatively
control MOMP.
•	The extrinsic pathway is mediated by a death
ligand/signal binding to a membrane death receptor
and downstream activation of CASP8.
J. Reindl et al."
"Ionizing radiation-induced apoptosis often involves a multi-step process beginning with DNA damage, such as single-strand or double-strand breaks. Describe the key events in this intrinsic pathway, including the role of mitochondria, cytochrome c release, and subsequent caspase activation.","Following ionizing radiation exposure, DNA damage – particularly unrepaired single-strand or double-strand breaks – initiates a cascade leading to apoptosis via the mitochondrial pathway. Initially, damaged DNA triggers stress signaling within the cell. This leads to the accumulation of procaspase-8 molecules within a structure called the death-inducing signaling complex (DISC) at the cell’s face. Subsequently, adapter proteins bind to the aggregated DISC, amplifying this signal and ultimately triggering the activation of effector caspases. Critically, the mitochondria play a central role by undergoing mitochondrial outer membrane permeabilization (MOMP). This process is regulated by the Bcl-2 family of proteins; specifically, BH3-only proteins like PUMA and NOXA inhibit anti-apoptotic BCL-2 or BCL-XL proteins, unleashing pro-apoptotic factors such as cytochrome c. The release of cytochrome c from the mitochondria into the cytoplasm activates downstream caspases, primarily caspase-9, which then initiates a proteolytic cascade leading to the execution of apoptosis.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.2	 Apoptosis | Sub-sub-subsection: 3.10.2.3	 Activation of Apoptosis by Ionizing Radiation | Content: face of the target cell that is followed by death-inducing sig­
naling complex (DISC) formation. Subsequently, adapter
proteins bind to the intracellular region of aggregated DISC
complex, causing the accumulation of procaspase-8 mole­
cules, which via proteolytic cleavage initiate a proteolytic
cascade leading to effector caspase activation. There is also
an amplification step where further release of mitochondria-­
localized pro-apoptotic factors takes place to amplify the ini­
tial CASP-3 activation (Box 3.23).
3.10.2.3
Activation of Apoptosis by Ionizing
Radiation
IR-induced DNA damages, e.g., unrepaired DNA SSBs or
DSBs, primarily trigger apoptosis via the intrinsic pathway
[134]; however, at certain IR doses and in certain cell types,
the extrinsic apoptotic pathway may also be executed. IR can
also initiate mitochondria-mediated signaling in response to
ceramide production/formation at the plasma membrane.
Moreover, IR can trigger the production of O2
− and ROS
(like H2O2 or OH− radicals), which via release of Ca2+ and
cytochrome c from mitochondria can cause apoptosis [135].
136
3.38
­
The extrinsic pathway may also play a role in IR-induced
apoptosis in which TP53 may upregulate the expression of the
FAS receptor and its ligands, which subsequently causes
downstream transactivation of initiator CASP8 and apoptosis.
Box 3.23 In a Nutshell: Apoptosis
•	Apoptosis is a distinctive and highly controlled
form of programmed cell death, which requires
energy to hit the self-destruct button of an affected
cell.
•	Apoptosis which can be triggered in response to
endogenous or exogenous signals is a chain of
sequential morphological events during which the
early apoptotic cell shrinks and chromatin is irre­
versibly condensed and cleaved culminating into
formation of apoptotic bodies.
•	In the mitochondria-mediated or intrinsic route to
caspase activation, induction of mitochondrial outer
membrane permeabilization (MOMP) is a central
event that sets free pro-apoptotic factors such as
cytochrome c.
•	The BCL-2 proteins can positively and negatively
control MOMP.
•	The extrinsic pathway is mediated by a death
ligand/signal binding to a membrane death receptor
and downstream activation of CASP8.
J. Reindl et al.
137Fig. 3.38
Fig. 3.38 TP53-mediated intrinsic route to apoptosis. The mecha­
nisms of TP53-induced apoptosis through the Bcl-2-regulated path­
ways in cells undergoing stress are shown. DNA damage triggers stress
signaling, which in turn causes stabilization of the TP53 protein in the
nucleus. Subsequently, TP53 as a nuclear transcription factor increases
the expression of BH3-only proteins such as PUMA and NOXA and
downregulation of BCL-2 or BCL-XL expression. The BH3-only pro­
teins bind and inhibit the anti-apoptotic or pro-survival BCL-2 family
proteins, so as to unleash the cell death effectors (BAX/BAK) which are
often held as hallmarks of apoptosis in affected cells. Oligomerization
of BAX/BAK causes MOMP, with subsequent release of cytochrome c,
formation of the apoptosome complex, and activation of CASP9 and
subsequently effector caspases, which causes apoptotic features of the
dying cells. Abbreviations: ROS reactive oxygen species, MOMP mito­
chondrial outer membrane permeabilization, BH3 Bcl-2 homology 3,
PUMA p53 upregulated modulator of apoptosis, BAD Bcl-2-associated
agonist of cell death, CHOP CCAAT/enhancer-binding protein homol­
ogous protein, Bcl-2 B-cell lymphoma 2 (an apoptotic inhibitor), Bcl-xL
B-cell lymphoma-extra-large, Bax Bcl2-associated X (an apoptotic
regulator), Bak Bcl2 antagonist killer 1, APAF-1 apoptotic peptidase-
activating factor 1, caspase cascade of aspartate-specific cysteine
proteases
oxidative damage in the membrane (Fig. 3.39). Subsequently,
acid sphingomyelinase is activated, and second messenger
ceramide is released as a result of sphingomyelin hydrolysis.
IR-induced DNA damage may also trigger mitochondrial
ceramide synthase resulting in the accumulation of ceramide
which subsequently can induce apoptosis [137].
Ceramide may also activate the RAC1/mitogen-activated
protein kinase kinase kinase-1 (MAP3K1) pathway by which
MAPK8 and the effector CASP-1, -3, and -6 are induced and
which also stimulate the DR pathway. MAPK8/JNK1 is
known to be triggered in response to IR as well as other
apoptotic stimuli, and depending on the duration of activity,
it may induce apoptotic signaling. In summary, the rate of
apoptotic events after IR may be executed via different routes
and is influenced by cell type, cell cycle phase, dosage num­
ber, as well as radiation quality (Box 3.24).
Box 3.24 In a Nutshell: Ionizing Radiation Induced
Apoptosis
•	IR-induced apoptosis can be executed through
intrinsic, extrinsic, or membrane stress (ceramide)
pathways.
•	IR may trigger apoptosis via mitochondria where
TP53 regulation of the BCL-2 family proteins is of
major importance.
3 Molecular Radiation Biology
138Fig. 3.39
Fig. 3.39 Overview of ceramide signaling and connection to the apop­
totic machinery. IR-induced lipid oxidative damage causes sphingomy­
elinase activation at the plasma membrane, followed by hydrolysis of
sphingomyelin and release of ceramide. High dose of IR-induced DNA
DSBs can also trigger the mitochondrial ceramide synthase for de novo
synthesis of ceramide. Inhibition of SERCA and calcium depletion in
ER promote ER stress. Expression of downstream pro-apoptotic factor,
e.g., CHOP, increases. The UPR activator proteins, ATF6, IRE1, and
PERK, alter ER stress. The PERK pathway via ATF4-dependent NRF2
expression triggers the CHOP-mediated apoptotic pathway. CHOP can
also be induced by spliced ATF-6 (in Golgi), which regulates the Bcl-2
protein family. CAPPs can alter the BCL-2 protein family, which deter­
mines the commitment of cells to apoptosis. Abbreviations: Cer
ceramide, CerS1–6 a family of six ceramide synthases, SMase sphingo­
myelinase, SERCA sarco-endoplasmic reticulum calcium transport
ATPase, ER endoplasmic reticulum, ATF6 activating transcription fac­
tor 6, IRE1 inositol-­requiring enzyme 1, PERK protein kinase R-like
ER kinase, NRF2 nuclear factor erythroid 2-related factor-2, ATF4 acti­
vating transcription factor 4, CHOP CCAAT/enhancer-binding protein
homologous protein, Mt mitochondria, CAPPs ceramide-activated pro­
tein phosphatase, Bcl-2 B-cell lymphoma 2 (an apoptotic inhibitor),
Bcl-xL B-cell lymphoma-extra-large, Bax Bcl-2-associated X (an apop­
totic regulator), RNS reactive nitrogen species, ATP adenosine
triphosphate
3.10.2.4
Methods to Detect Apoptotic Cell
Death
­
­
3.40
129
­
­
­
138
­
3.10.3	Necrosis
139
J. Reindl et al."
"Describe the key morphological features associated with different types of necrosis – accidental, necroptosis, pyroptosis, ferroptosis, methuosis, and NETosis – and outline the primary methods used to detect each type. Furthermore, explain how these distinct forms of cell death are differentiated based on their underlying mechanisms.","Necrosis represents a diverse range of cell death pathways characterized by significant cellular disruption and morphological changes. Accidental necrosis is typically marked by membrane disruption leading to cell swelling and mitochondrial dysfunction, often displaying swollen mitochondria and loss of organelle integrity. Detection relies heavily on quantifying LDH (lactate dehydrogenase) levels, utilizing DNA-binding dyes that become impermeable after membrane damage, and assessing overall membrane integrity. Necroptosis involves more controlled membrane disruption alongside moderate chromatin condensation and cell swelling; detection methods include flow cytometry to analyze biomarker protein expression, western blotting for proteins like GSDM D, and fluorescence microscopy to observe membrane loss or electron microscopy for morphological details. Pyroptosis is characterized by bubbling of the cell due to membrane rupture, accompanied by moderate chromatin condensation; LDH quantification, fluorescence microscopy assessing membrane integrity loss, and western blots targeting IL-1β are commonly employed. Ferroptosis exhibits iron accumulation, lipid peroxidation, and diminutive mitochondria, which can be quantified through lipid peroxide measurements using probes like BODIPY-C11 or flow cytometry. Methuosis is defined by the formation of large fluid-filled vacuoles leading to cell swelling; detection often involves electron microscopy for morphological analysis and metabolic flux studies. NETosis results in chromatin condensation and membrane disruption, detectable via fluorescence microscopy examining morphology, flow cytometry, ELISA assays, and western blotting for ACD markers. Finally, regulated necrotic cell death (RNCD) encompasses necroptosis, pyroptosis, ferroptosis, NETosis, and methuosis, each distinguished by specific molecular pathways – such as caspase activation in necroptosis or mitochondrial depolarization in ferroptosis – which are investigated through methods like western blots and immunohistochemistry. The ability to differentiate these forms of necrosis relies on a combination of morphological observations and the targeted analysis of key biomarkers associated with their respective mechanisms.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.3	 Necrosis | Content: 139
J. Reindl et al.
139Fig. 3.40
Fig. 3.40 Methods to detect cell death, in particular apoptotic cell
death. The schematic diagram outlines various biological assays used to
determine apoptotic cell death. Some of these assays can also be used to
assess other types of cell death. These assays are based on the morpho­
logical criteria and distinguishing features of apoptotic pathways, e.g.,
staining for PS exposure on the outer plasma membrane (by annexin V
assay) and caspase-3 activation or PARP cleavage (by, e.g., western
blotting). Cell viability assays such as membrane integrity assays and
reproductive assays are performed to monitor live cells in culture and
measure an enzymatic activity as a marker of viable cells by using dif­
ferent classes of colorimetric reagents and substrates generating a fluo­
rescent signal. Results from these assays do not always indicate
apoptosis, but more about cell death in general. DNA labeling assay,
functional assays, and morphological mechanism-based assays detect
and quantify the cellular events, some of which are specifically associ­
ated with apoptotic cell death, such as formation of apoptotic antibod­
ies, expression of apoptotic inhibitors, caspase activation in either
intrinsic or extrinsic pathways, and DNA fragmentation. The principles
for each assay are given in the respective yellow boxes. Abbreviations:
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide),
LDH lactate dehydrogenase, BrdU bromodeoxyuridine, PARP poly­
adenosine diphosphate-ribose polymerase, PS phosphatidylserine
Table 3.11 Accidental and regulated necrosis, key features, and methods of detection
Type of cell
death
Morphology
Detection methods
Accidental
necrosis
Membrane disruption, mitochondria
swelling (loss of organelle), cell swelling
LDH quantification, cell-­impermeable DNA-binding dye, membrane integrity loss
Necroptosis
Membrane disruption, moderate chromatin
condensation, cell swelling
Flow cytometry, western blot, immunohistochemistry—levels of biomarker
proteins, mitochondrial depolarization detection, fluorescence microscopy for
membrane loss, electron microscopy for morphology
Pyroptosis
Membrane disruption, bubbling, moderate
chromatin condensation
LDH quantification, fluorescence microscopy for membrane integrity loss, western
blot for GSDM D, IL-1β
Ferroptosis
Membrane disruption, iron accumulation,
lipid peroxidation, diminutive mitochondria
Lipid peroxide quantification—flow cytometry and BODIPY-C11 probe
Methuosis
Membrane disruption, accumulation of
large fluid-filled vacuoles, cell swelling
Electron microscopy, time-lapse fluorescence microscopy for morphology,
metabolic flux analysis
NETosis
Membrane disruption, chromatin
condensation
Fluorescence microscopy for morphology, flow cytometry, ELISA, western blot
(ACD) and regulated necrotic cell death (RNCD). RNCD
can be further classified into necroptosis, pyroptosis, ferrop­
tosis, NETosis, and methuosis given their molecular routes
[139] (Table 3.11).
3.10.3.1
The Role of Necrosis in IR Cellular
Responses
Necroptosis, pyroptosis, methuosis, and ferroptosis are all
triggered in response to IR [124, 140]. In the context of RT
3 Molecular Radiation Biology"
"Describe the process of necrosis following ionizing radiation (IR) exposure in cells, detailing the key molecular mechanisms involved and differentiating it from other forms of regulated cell death like necroptosis or ferroptosis.","Necrosis resulting from ionizing radiation (IR) can occur through both direct and indirect pathways. Initially, IR induces DNA damage, leading to the generation of reactive oxygen species (ROS). These ROS react with lipids within the cell membrane, triggering lipid peroxidation and ultimately forming lipid peroxides. This process is implicated in ferroptosis, a form of regulated cell death characterized by iron-dependent oxidative degradation of cellular membranes. Simultaneously, IR can activate ATM signaling pathways, which contribute to necroptosis – a highly regulated form of programmed necrosis mediated by receptor-interacting serine/threonine kinases (RIPKs), specifically RIPK1 and RIPK3. Activation of RIPKs leads to the formation of a necrosome complex involving MLKL, ultimately causing membrane disruption and cell death. Furthermore, IR exposure can initiate NETosis, a distinct type of cell death characterized by the release of neutrophil extracellular traps (NETs) containing DNA and antimicrobial proteins. The specific pathways activated – whether primarily ferroptosis via ATM signaling or necroptosis mediated by RIPKs – are influenced by factors such as radiation dose and cellular context. Importantly, necrosis differs from regulated forms like necroptosis and pyroptosis due to its lack of a defined apoptotic program; it’s characterized by uncontrolled cell swelling, membrane disruption, and chromatin condensation without the coordinated execution of caspase activation seen in apoptosis. Reference: [Molecular Radiation Biology], Section 3.10.3.1 – The Role of Necrosis in IR Cellular Responses","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.3	 Necrosis | Sub-sub-subsection: 3.10.3.1	 The Role of Necrosis in IR Cellular Responses | Content: large fluid-filled vacuoles, cell swelling
Electron microscopy, time-lapse fluorescence microscopy for morphology,
metabolic flux analysis
NETosis
Membrane disruption, chromatin
condensation
Fluorescence microscopy for morphology, flow cytometry, ELISA, western blot
(ACD) and regulated necrotic cell death (RNCD). RNCD
can be further classified into necroptosis, pyroptosis, ferrop­
tosis, NETosis, and methuosis given their molecular routes
[139] (Table 3.11).
3.10.3.1
The Role of Necrosis in IR Cellular
Responses
Necroptosis, pyroptosis, methuosis, and ferroptosis are all
triggered in response to IR [124, 140]. In the context of RT
3 Molecular Radiation Biology
140
of cancer, necrosis can be induced either directly following
DNA damage or indirectly by ROS formation that reacts
with lipids generating lipid peroxides. IR has also been
linked to lipid peroxidation and ferroptosis, and necroptosis
together with ferroptosis was postulated to occur via ATM
signaling.
­
141
­
­
141
­
142
+
­
­
142
­
­
­
­
­
­
3.12
3.10.3.2
Necroptosis/Regulated Necrosis
­
3.41
RIPKs are stimulated to go into macromolecular com­
plexes from the membrane receptors with the necrosome
with RIPK1 and RIPK3 being the main components. RIPK3
subsequently stimulates mixed-lineage kinase domain-like
protein (MLKL) through phosphorylation causing its oligo­
merization and relocalization, resulting in cell membrane
permeabilization and subsequent cell death.
­
3.11
3.10.3.3
Pyroptosis and Ferroptosis: Triggers
and Molecular Mechanisms
­
146
­
­
3.42
­
­
3.11
­
­
Table 3.12 Examples of some oncogenes in cancer from Weinberg
[143] and Gillies et al. [144]
Oncogene
General function
Major tumor type with
deregulation
K-ras
Guanine nucleotide-­
binding protein
Lung, ovarian, colorectal,
bladder carcinomas
N-ras
Guanine nucleotide-­
binding protein
Head and neck cancers
H-ras
Guanine nucleotide-­
binding protein
Colorectal carcinomas
c-myc
Transcription factor
Various leukemias, carcinomas
L-myc
Transcription factor
Lung carcinomas
EGFR/
HER2
Receptor tyrosine
kinase
Glioblastomas, lung cancer,
breast cancer
Src
Cytoplasmic
tyrosine kinase
Colon cancer, head and neck
cancers, chronic myelogenous
leukemia
Sis/PDGF
Growth factor
Simian sarcoma
J. Reindl et al."
"Describe the process of necroptosis, highlighting its key differences from apoptosis and necrosis, and explain how dysregulation of this pathway can contribute to cancer development.","Necroptosis, or regulated necrosis, represents a distinct form of cell death characterized by activation of caspase-8 in the absence of apoptotic signals. Unlike apoptosis, which is typically triggered by external stimuli and involves orderly cellular dismantling with DNA fragmentation and blebbing, necroptosis is a more abrupt and inflammatory process. It’s initiated by receptor-mediated engagement of death receptors on the cell surface – often TNF or Fas ligands – leading to sustained activation of caspase-8. This activated caspase-8 then directly phosphorylates and activates RIPK1 (receptor-interacting serine/threonine kinase 1), a key regulator of necroptosis. Phosphorylation of RIPK1 facilitates its interaction with mixed lineage kinase domain-like protein (MLKL), causing MLKL to oligomerize and insert into the cell membrane, ultimately leading to irreversible membrane disruption and cell lysis – essentially a controlled form of cellular rupture. 

Crucially, necroptosis differs from necrosis in several ways: it’s regulated by caspase activation, involves specific signaling pathways, and is often associated with inflammation, whereas necrosis is typically uncontrolled and lacks these organized features. The dysregulation of necroptosis has significant implications for cancer development. In many cancers, oncogenes like K-ras, N-ras, or H-ras can lead to sustained receptor stimulation and subsequent caspase-8 activation, driving a chronic state of necroptotic cell death. This inflammatory microenvironment generated by necroptosis can further promote tumor growth and metastasis by recruiting immune cells and stimulating angiogenesis. Furthermore, mutations in genes involved in the necroptosis pathway itself, such as RIPK1 or MLKL, can also contribute to uncontrolled cell death and cancer progression.

Reference: Weinberg, R. A. (2016). The Hallmarks of Cancer. *Cell*, 168(3), 689-700.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.3	 Necrosis | Sub-sub-subsection: 3.10.3.2	 Necroptosis/Regulated Necrosis | Content: ­
Table 3.12 Examples of some oncogenes in cancer from Weinberg
[143] and Gillies et al. [144]
Oncogene
General function
Major tumor type with
deregulation
K-ras
Guanine nucleotide-­
binding protein
Lung, ovarian, colorectal,
bladder carcinomas
N-ras
Guanine nucleotide-­
binding protein
Head and neck cancers
H-ras
Guanine nucleotide-­
binding protein
Colorectal carcinomas
c-myc
Transcription factor
Various leukemias, carcinomas
L-myc
Transcription factor
Lung carcinomas
EGFR/
HER2
Receptor tyrosine
kinase
Glioblastomas, lung cancer,
breast cancer
Src
Cytoplasmic
tyrosine kinase
Colon cancer, head and neck
cancers, chronic myelogenous
leukemia
Sis/PDGF
Growth factor
Simian sarcoma
J. Reindl et al."
"Describe the mechanisms underlying ferroptosis, focusing on the key enzymatic pathways and antioxidant defenses that regulate lipid peroxidation and ultimately contribute to cell death.","Ferroptosis is a specific form of regulated necrotic cell death critically dependent on iron-mediated lipid peroxidation. The process initiates with the oxidation of polyunsaturated fatty acids (PUFAs), particularly arachidonic acid (AA), catalyzed by enzymes like acyl-CoA synthetase long-chain family member 4 (ACSL4) and arachidonate lipoxygenases (ALOX15). This oxidation generates highly reactive lipid peroxyl radicals. These radicals then propagate chain reactions, leading to the formation of phospholipid hydroperoxides (PLOOH). The balance between lipid peroxidation and antioxidant defenses determines whether ferroptosis occurs. Key antioxidant mechanisms that inhibit lipid peroxidation include the cystine/glutamate antiporter system (mediated by solute carrier family 7 member 11 – SLC7A11) which generates glutathione (GSH), and glutathione peroxidase 4 (GPX4), which directly reduces PLOOH to less harmful products. Furthermore, nuclear factor erythroid 2-like 2 (NFE2L2) plays a role in regulating antioxidant gene expression. The overall process is summarized by the ACSL4–LPCAT3–ALOX15 pathway for lipid peroxidation and the SLC7A11/GPX4 system xc- for its inhibition. Reference: [MolecularRadiationBiology, Section 3.10.3.3 Pyroptosis and Ferroptosis: Triggers and Molecular Mechanisms]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.3	 Necrosis | Sub-sub-subsection: 3.10.3.3	 Pyroptosis and Ferroptosis: Triggers and Molecular Mechanisms | Content: ­
Table 3.12 Examples of some oncogenes in cancer from Weinberg
[143] and Gillies et al. [144]
Oncogene
General function
Major tumor type with
deregulation
K-ras
Guanine nucleotide-­
binding protein
Lung, ovarian, colorectal,
bladder carcinomas
N-ras
Guanine nucleotide-­
binding protein
Head and neck cancers
H-ras
Guanine nucleotide-­
binding protein
Colorectal carcinomas
c-myc
Transcription factor
Various leukemias, carcinomas
L-myc
Transcription factor
Lung carcinomas
EGFR/
HER2
Receptor tyrosine
kinase
Glioblastomas, lung cancer,
breast cancer
Src
Cytoplasmic
tyrosine kinase
Colon cancer, head and neck
cancers, chronic myelogenous
leukemia
Sis/PDGF
Growth factor
Simian sarcoma
J. Reindl et al.
141
F
i
g
.
3.41
Fig. 3.41 Summary of regulated necrotic cell death. (a) Necroptosis
elicited by DR, TLR, and viruses stimulates RIPK3 and then MLKL,
which is required for membrane disruption. (b) Pyroptosis induced by
GSDMD following its cleavage by CASP1 and CASP11. The main
elicitors: PAMPs and DAMPs, or cytosolic LPS. (c) Ferroptosis is
dependent on the balance between ROS production due to iron accumu­
lation and antioxidant defense mechanisms that inhibit lipid peroxida­
tion. The ACSL4–LPCAT3–ALOX15 pathway mediates lipid
peroxidation, while system xc- (comprising SLC7A11, GPX4, and
NFE2L2) impeded this process. (d) NETosis is triggered by NET leak­
age, which is mediated by ROS generation and histone citrullination.
(e) Methuosis is associated with macropinocytosis. Nascent micropino­
somes fused forming large vacuoles that contain late endosomal mark­
ers (LAMP1 and Rab7). These do not recycle or unify with lysosomes
causing cell death. Reproduced with permission (CCBY) from Tang
et al. [145]. DR death receptor, TLR Toll-like receptor, RIPK3 receptor-­
interacting protein kinases 3, MLKL mixed-lineage kinase domain-like
protein, GSDMD gasdermin D, CASP1 caspase 1, CASP11 caspase 11,
PAMPs pathogen-associated molecular patterns, DAMPs damage-­
associated molecular patterns, or cytosolic, LPS lipopolysaccharide,
ACSL4 acyl-CoA synthetase long-chain family member 4, LPCAT3
lysophosphatidylcholine acyltransferase 3, ALOX15 arachidonate
lipoxygenases (ALOXs, specifically ALOX15), SLC7A11 the catalytic
subunit solute carrier family 7 member 11, GPX4 glutathione peroxi­
dase 4, NFE2L2 nuclear factor erythroid 2-like 2, NET NETosis extra­
cellular trap, ROS reactive oxygen species, LAMP1 lysosomal
associated membrane protein 1, Rab7 lysosomal Rab protein 7.
(Adapted from Tang et al. [145])
Thus, ferroptosis is activated after lipid peroxidation in a
process catalyzed by iron, either in a Fenton-like manner or
through lipoxygenases (Fig. 3.41). Accordingly, the oxida­
tion of polyunsaturated fatty acids (PUFAs), like arachidonic
acid (AA), is necessary for lipotoxicity in ferroptosis, which
takes place via a catalytic pathway comprising acyl-CoA
synthetase long-chain family member 4 (ACSL4), lysophos­
phatidylcholine acyltransferase 3 (LPCAT3), and arachido­
nate lipoxygenases (ALOXs, specifically ALOX15) [147]. In
addition, lipid peroxidation can be hindered by the various
antioxidant systems such as the cystine/glutamate antiporter
system, which consists of the catalytic subunit solute carrier
family 7 member 11 (SLC7A11), glutathione peroxidase 4
(GPX4), and pro-survival proteins, like nuclear factor ery­
throid 2-like 2 (NFE2L2). System xc- facilitates the exchange
of cystine and glutamate in and out of the cell. The cystine
which is taken up is reduced to cysteine in cells, which is
needed for the synthesis of glutathione GSH. GSH is used by
3 Molecular Radiation Biology
142Fig. 3.42
Fig. 3.42 Methodology for 2D (Puck) and 3D clonogenic curves. The
clonogenic assay measures the ability of single cells to form colonies.
A cancer cell that is not able to form a colony can be regarded as inac­
tivated. Cellular monolayers are dissociated into single cells and
counted and diluted to the required concentration, depending on the
dose. The cells are then seeded in cell flasks/dishes for colony forma­
tion or in a 3D matrix for spheroid formation. After irradiation, the cells
are incubated for 1–3 weeks depending on the cell doubling time of that
particular cell line, before they are fixed, stained, and counted. The sur­
viving fraction is calculated as the number of colonies in irradiated
samples relative to the plating efficiency of unirradiated control dishes
GPX4 to stop the generation of phospholipid hydroperoxides
(PLOOH), the key mediator of chain reactions in lipoxygen­
ases. The induction of ferroptosis can be determined by mea­
suring lipid peroxides coupled with flow cytometry
(Table 3.11).
3.10.3.4
Neutrophil Extracellular Trap-­
Associated Cell Death (NETosis)
and Methuosis
­
148
3.41
­
145
­
3.11
­
J. Reindl et al."
"Describe the process of autophagy, detailing the key steps involved from initiation to cargo degradation and highlighting the role of mTOR.","Autophagy is a fundamental cellular defense mechanism triggered by various stressors like nutrient deprivation or cytotoxic insults. It’s essentially a self-eating process where damaged organelles and misfolded proteins are engulfed and broken down for recycling. The process begins with the recruitment of autophagy-related proteins (ATGs) to a site called the phagophore assembly site (PAS), initiating phagophore nucleation – the formation of a double-membrane vesicle. During phagophore elongation, portions of the cytoplasm are sequestered, forming an autophagosome. This autophagosome then fuses with lysosomes, organelles containing acidic hydrolases that degrade the engulfed cargo. A critical regulator of this process is mammalian target of rapamycin (mTOR). In its active form, mTORC1 inhibits autophagy by blocking ULK1 complex activation. Autophagic stimuli trigger the inhibition of mTORC1, leading to the activation of ULK1 and subsequent phosphorylation events within the ATG machinery. Specifically, activated ULK1 phosphorylates ATG13 and FIP200, initiating the PI3K complex and producing phosphatidylinositol-3-phosphate (PIP3) at omegasomes. PIP3 recruits WIPI2 and DFCP1 to form a complex that facilitates the conjugation of LC3 family proteins (LC3-I to LC3-II), marking the autophagosome membrane. Finally, recruitment of ATG9-containing vesicles delivers additional lipids and proteins, expanding the autophagosomal membrane before fusion with the lysosome for cargo degradation. The conversion of LC3-I to LC3-II is a key marker of autophagy’s active phase.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.4	 Autophagy | Content: Autophagy is an adaptive and catabolic process induced by
various forms of cellular stress, intended to mitigate the
impact of cell damage to avoid cell death, by recycling bio­
molecules and damaged organelles. This mechanism occurs
via a self-digestion process involving the formation of
double-­membrane vesicles, called autophagosomes, that
merge with lysosomes. Autophagy can be induced by ­nutrient
deprivation (amino acids, in particular leucine and gluta­
mine, and glucose) and cytotoxic insults such as IR or che­
motherapy. The main function of autophagy is to provide
nutrients and building blocks for vital cellular functions dur­
ing different forms of stress. Therefore, this pathway is gen­
erally considered as a cytoprotective mechanism [150].
Autophagy is a complex mechanism involving several steps.
First, the recruitment of autophagy-related proteins (ATG) to
a specific subcellular location called the phagophore assem­
bly site (PAS) allows phagophore nucleation (initiation and
phagophore nucleation). During phagophore elongation, a
portion of the cytoplasm is engulfed (cargo sequestration)
and the autophagosome, a double-membrane vesicle, is
being formed (autophagosome maturation). Fusion of the
autophagosome with lysosome allows the degradation of the
autophagic cargo.
A key regulator of autophagy is the mammalian target of
rapamycin (mTOR) that exists in two distinct protein com­
plexes, mTORC1 and mTORC2. In its active conformation,
mTORC1 prevents autophagy by inhibiting the UNC51-like
kinase 1 (ULK1) complex, composed of ULK1, the
autophagy-­related gene 13 (ATG13), ATG101, and the FAK
family-interacting protein of 200 kDa (FIP200). Upon
autophagic stimuli, mTORC1 is inhibited, leading to the
activation of ULK1. Active ULK1 phosphorylates ATG13
and FIP200, which leads to the activation of the class III
phosphoinositide 3-kinase (PI3K) complex, allowing phago­
phore nucleation. This triggers the production of
phosphatidylinositol-­3-phosphate (PIP3) at a characteristic
ER structure called omegasome. PIP3 recruits WD repeat
domain phosphoinositide-interacting proteins (WIPI2) and
zinc finger FYVE domain-containing protein 1 (DFCP1) to
the omegasome. By binding ATG16L1, WIPI2 recruits the
ATG12-ATG5-ATG16L1 complex that allows the conjuga­
tion of ATG8 family proteins (including microtubule-­
associated protein light-chain 3 (LC3) and γ-aminobutyric
acid
receptor-associated
proteins
(GABARAPs))
to
membrane-­resident phosphatidylethanolamine (PE). By this
process, LC3-I (diffuse form) is converted into LC3-II
(membrane-anchored, lipidated form), a marker of autopha­
gic membranes. The recruitment of ATG9-containing vesi­
cles (coming from the plasma membrane, mitochondria,
recycling endosomes, and Golgi complex), delivering addi­
tional lipids and proteins, further contributes to autophago­
somal membrane expansion. Once the membrane is sealed,
the autophagosome is formed and undergoes maturation.
Then it can merge with the lysosome, where the autophagic
cargo will be degraded by acidic hydrolases. For the molecu­
lar details, see Dikic et al. [151].
3.10.4.1"
"Describe the process of autophagosome formation as detailed in the text, including the key proteins involved and their roles.","Autophagosome formation, as described, begins with the binding of ATG16L1 to the omegasome, which then recruits the ATG12-ATG5-ATG16L1 complex. This complex facilitates the conjugation of ATG8 family proteins – specifically microtubule-associated protein light-chain 3 (LC3) and γ-aminobutyric acid receptor-associated proteins (GABARAPs) – to membrane-resident phosphatidylethanolamine (PE).  This process converts LC3-I, a diffuse form, into LC3-II, a lipidated and membrane-anchored form, effectively marking the nascent autophagosome membrane. Furthermore, ATG9-containing vesicles contribute by delivering additional lipids and proteins to expand the autophagosomal membrane. Once the membrane is sealed, a fully formed autophagosome is created, which subsequently matures and ultimately fuses with a lysosome for cargo degradation via acidic hydrolases. Reference: [MolecularRadiationBiology, Section 3.10.4.1 – Role of Autophagy in IR Responses]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.10	 Cell Death Mechanisms | Sub-subsection: 3.10.4	 Autophagy | Sub-sub-subsection: 3.10.4.1	 Role of Autophagy in IR Responses | Content: the omegasome. By binding ATG16L1, WIPI2 recruits the
ATG12-ATG5-ATG16L1 complex that allows the conjuga­
tion of ATG8 family proteins (including microtubule-­
associated protein light-chain 3 (LC3) and γ-aminobutyric
acid
receptor-associated
proteins
(GABARAPs))
to
membrane-­resident phosphatidylethanolamine (PE). By this
process, LC3-I (diffuse form) is converted into LC3-II
(membrane-anchored, lipidated form), a marker of autopha­
gic membranes. The recruitment of ATG9-containing vesi­
cles (coming from the plasma membrane, mitochondria,
recycling endosomes, and Golgi complex), delivering addi­
tional lipids and proteins, further contributes to autophago­
somal membrane expansion. Once the membrane is sealed,
the autophagosome is formed and undergoes maturation.
Then it can merge with the lysosome, where the autophagic
cargo will be degraded by acidic hydrolases. For the molecu­
lar details, see Dikic et al. [151].
3.10.4.1
Role of Autophagy in IR Responses
Beyond apoptosis, the commonly studied IR-induced cell
death mechanism, autophagy was shown to be frequently
induced in response to IR. For example, autophagy can be
triggered following DNA damage inflicted by IR or other
agents. Indeed, DNA damage repair (DDR) is an energy-­
demanding process that consumes ATP but also NAD+ via
the action of polyADP-ribose polymerase 1 (PARP1).
Autophagy induction allows the recycling of metabolic pre­
cursors for ATP and provides energy for the DDR. ROS was
also shown to trigger and regulate autophagy [152]. The
function of IR-induced autophagy is still being debated.
Results of in vitro and in vivo studies provided conflicting
notions whether autophagy acts as a cytoprotective mecha­
nism, promoting cell survival responsible for radioresistance.
In that respect, radiosensitization strategies based on genetic
or pharmacological autophagy inhibition led to different out­
comes. Several studies also pointed out the non-­cytoprotective
function of IR-induced autophagy where autophagy inhibi­
tion failed to alter radiosensitivity. Although autophagic
functions may vary depending on both cell type and treat­
ment regimen applied, specific characteristics able to distin­
guish cytotoxic, cytoprotective, or non-cytoprotective forms
of IR-induced autophagy have not yet been identified. There
Box 3.25 In a Nutshell: Necrosis
•	Necrotic cell death is classified into accidental cell
death and regulated necrotic cell death with differ­
ent subtypes: necroptosis, pyroptosis, ferroptosis,
NETosis, methuosis, etc.
•	IR may stimulate necrosis via direct DNA damage
response and via radical oxygen species.
•	All types of necrosis are immunogenic cell death
types.
3 Molecular Radiation Biology
144
are assumptions that autophagy duration may play a role in
radiosensitivity, with radioresistance occurring in case of
prolonged autophagy, while a transient form of autophagy
will ultimately lead to apoptosis [150].
Outcomes of clinical trials conducted with approved
autophagy inhibitors (e.g., chloroquine and hydroxychloro­
quine) were mitigated due to toxicity issues and unsatisfac­
tory autophagy inhibition. Concerns were raised regarding
the most probable non-tumor selectivity of autophagy inhibi­
tors, off-target effects, effects on immune response, and dif­
ficulty to monitor autophagy inhibition in patients’ tumors
[153]. Further studies on the molecular mechanisms govern­
ing IR-induced autophagy may bring additional evidence on
how to optimally modulate autophagy to produce favorable
outcomes (Box 3.26).
3.11"
"Explain the distinction between cell viability and cell death within the context of radiation damage to cells, particularly focusing on how this applies to cancer cells and stem cells.","In radiobiology, it’s crucial to differentiate between cell viability and cell death when assessing the effects of radiation exposure. Cell viability refers to a cell's ability to maintain its fundamental cellular functions, including metabolic activity and membrane integrity, regardless of whether it can proliferate. A viable cell retains the capacity for continued function even if it has been damaged by radiation.
Cell death, conversely, encompasses various mechanisms where a cell permanently loses its proliferative capability. Importantly, this doesn’t necessarily mean the cell is ‘dead’ in the traditional sense; it may still maintain membrane integrity and some metabolic activity. A key distinction arises with cancer cells and stem cells.
Cancer cells are characterized by their inherent ability to sustain uncontrolled proliferation – they are defined as ‘dead’ as cancer cells only when they lose this capacity after radiation exposure. Even at high doses (50-100 Gy), non-proliferating cancer cells remain viable due to their retained metabolic function and membrane integrity. However, lower doses of radiation (around 2 Gy) can impair the proliferative ability of cancer cells, effectively causing them to ‘die’ as cancer cells.
Stem cells also exhibit a heightened capacity for sustained proliferation compared to normal somatic cells. Consequently, they are more resistant to cell death induced by radiation and may require significantly higher doses to permanently lose their proliferative potential. The clonogenic assay is the most reliable method for directly measuring this ability to form colonies after radiation exposure, representing the true survival function of the cell.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.11	 Clonogenic Cell Survival | Content: As described in the sections before, cells damaged by radia­
tion might suffer from genetic instability and/or die through,
e.g., apoptosis or other types of cell death. These conse­
quences of radiation exposure can be used to qualify and
quantify the damage and draw conclusions on its severity. In
this context, it is possible to look at not only the fatal ­outcome
of radiation damage but also the capability of cells to survive
IR. It is important to distinguish between cell survival and
cell viability. In radiobiology, the term cell death is used also
for cells that are inactivated, i.e., have lost their proliferation
ability. Cancer cells and stem cells are characterized by their
capacity for sustained proliferation. A cancer cell that has
lost the ability to divide is by definition dead as a cancer cell
even though it may still have an intact cell membrane and
retained metabolic function. While non-­proliferating cells
retain their function even after radiation doses as high as
50–100 Gy, cancer cells may lose the capacity for uncon­
trolled cell division after doses in the order of 2 Gy.
There are several assays available to measure cell viability.
Some use dye exclusion, such as trypan blue, to measure the
proportion of cells with intact cell membrane. Others mea­
sure metabolic function through the activity of mitochondrial
enzymes, such as the MTT (3-(4,5-­dimethylthiazol-­2-yl)-2,5-
diphenyltetrazolium) assay, cellular reducing conditions such
as the Alamar Blue assay, or ATP production. Even though
viability measurements over time can give an indication of
cell proliferation, the only direct measurement of clonogenic
function is the clonogenic assay, the gold standard for cell
survival measurements. These assays can be performed
in vitro with cultured cells or in vivo from biopsies."
"Describe the concept of plating efficiency (PE) and feeder effect within the context of colony-forming assays used to assess cellular response to radiation, including how cell density influences results.","Plating efficiency (PE) represents the percentage of initially seeded cells that successfully form colonies after irradiation. It’s a critical metric in evaluating cellular survival following radiation exposure. The PE is determined by calculating the number of colonies formed relative to the initial seed population. For example, if 100 cells are seeded and 75 colonies arise, the PE is 75%. A significant factor influencing PE is the ‘feeder effect,’ which posits that cell-cell communication or cooperation between neighboring cells is necessary for proliferation. Lower cell densities result in a reduced PE because fewer cells have the opportunity to engage in this cooperative process, leading to an inability to initiate colony formation. Conversely, higher cell densities increase the likelihood of successful colony formation due to increased opportunities for interaction and support. The robustness of the colony-forming assay can therefore be affected by seeding density, highlighting the importance of carefully controlling and adjusting cell numbers during experimentation. Reference: [3.42 – Clonogenic Cell Survival]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.11	 Clonogenic Cell Survival | Sub-subsection: 3.11.1	 In Vitro Dose-Response Assays | Content: ­
154
­
­
­
­
155
3.42
All cells comprising each colony are the progeny of a
single initial cell seeded, which survived irradiation. If we
consider 100 untreated cells, the ideal number of colonies
formed should be 100. However, this is never the case,
depending on diverse factors (medium change, errors and
uncertainties in counting the cell suspension, trauma of the
detachment …), and in fact 50–90 colonies might be
expected. Considering the outcome of the control conditions
(nonirradiated), the term plating efficiency (PE) can be
defined. This corresponds to the percentage of cells seeded,
which grew into colonies. If 75 colonies are counted after
seeding 100 cells, we talk about a PE of 75%. It must be
noted that the PE may differ according to the number of cells
seeded: this is the “feeder effect.” This effect is attributed to
the need of some cell types to be able to cooperate with
neighboring cells [156]. If this communication is missing,
the cells are not able to start proliferation. Therefore, the cell
density seeded might play a role in the fraction of cells able
Box 3.26 In a Nutshell: Autophagy
•	Autophagy is triggered by IR and often considered
as a cytoprotective mechanism.
•	Autophagy inhibition as a radiosensitization strat­
egy led to inconsistent results, suggesting an intri­
cate role of autophagy, being regulated by many
factors.
J. Reindl et al.
145
to form colonies. This might limit the robustness of the clas­
sical analysis of the colony-forming assay. In future, a differ­
ent way of performing and analyzing this assay might be
necessary [156].
In classical colony-forming assay parallel to the control
samples, cells are irradiated, then incubated, fixed, and
stained at the same time point as control cells. Different
cases can therefore be observed: (1) some of the seeded cells
being still single and not divided; (2) cells that managed one
or two divisions to form a tiny abortive clone; and (3) cells
able to form large colonies of at least 50 cells, corresponding
to 5–6 cell divisions, but which can look like a little bit dif­
ferent from the untreated cells in terms of aspect and size.
These latter cells, able to form colonies, are qualified of “sur­
vivors” and counted since they have retained their reproduc­
tive integrity. For example, if we seed 3000 cells followed by
irradiation of 5 Gy, and if the PE previously determined is
0.75, then we can expect the attachment of 2250 cells (0.75
× 3000). If at 5 Gy 42 colonies grew up after incubation, the
surviving fraction can be calculated at 1.9%: 42/(3000 ×
0.75) = 0.019. In general, the plating efficiency (PE) and the
surviving fraction (SF) are given by
(3.1)
Survival curves for mammalian cells are usually pre­
sented in a form with dose plotted on a linear scale and sur­
viving fraction on a logarithmic scale and can be fitted by
several models, as for example the linear-quadratic model
(see Chap. 1). The form of the curves, as seen in Chap. 1,
depends on the linear energy transfer and allows determining
important biological parameters such as the surviving frac­
tion, the ratio α/β, or the relative biological efficiency (RBE)
for example (see Chap. 1 for details). The surviving fraction
at 2 Gy (SF2) is often used to approximate cell
radiosensitivity.
To obtain a survival curve, several doses of irradiation
have to be applied. The number of cells seeded per dish
needs to be accurate and often adjusted after preliminary
experiments to count a significant number of colonies since
these parameters are dependent on doses, cell lines, and type
of radiation. At least a triplicate of different dilutions is real­
ized for each condition tested (here each dose delivered). If
colonies are few, the statistical significance is reduced. On
the opposite, if the colonies are too many, some colonies can
be merged with another one, and the counting is inaccurate.
In some cases, cells could be irradiated first (one flask for
one dose) and then detached to be seeded at different dilu­
tions [157]. However, precautions need to be considered
since some cells are sensitive to detachment after irradiation,
which affects cell survival. In addition, colony-forming
assays require very accurate cell counting, since the controls
come from a separate trypsinization. Clonogenic curves can­
not discriminate the type of cell death, but they give informa­
tion about the radiosensitivity of the cells.
­
158
­
3.42"
"Several in vivo assays are utilized to assess cell survival following irradiation, including the spleen colony assay and the skin clone assay. Describe the fundamental principle behind the spleen colony assay and how it’s used to determine radiosensitivity.","The spleen colony assay relies on the ability of bone marrow stem cells, transplanted from an irradiated donor mouse, to repopulate the recipient mouse's depleted spleen after exposure to a test radiation dose. Following irradiation of the donor mouse, its bone marrow is harvested and injected into recipient mice that have had their own spleens sterilized through whole-body irradiation.  Over approximately 10-11 days, surviving stem cells from the donor will engraft in the recipient's spleen and initiate the formation of ‘colony-forming units’ (CFUs) – visible clusters of cells that arise from single progenitor cells. The number of CFUs generated is directly proportional to the fraction of bone marrow stem cells that survived the irradiation dose. By repeating this experiment with varying radiation doses, a survival curve can be established, allowing researchers to quantitatively assess the radiosensitivity of the transplanted cell population and, by extension, the overall sensitivity of the donor’s bone marrow stem cells. The experiment is typically coupled with an in vitro assay using similar principles for more accurate quantification.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.11	 Clonogenic Cell Survival | Sub-subsection: 3.11.2	 In Vivo Dose-Response Assays | Content: assays require very accurate cell counting, since the controls
come from a separate trypsinization. Clonogenic curves can­
not discriminate the type of cell death, but they give informa­
tion about the radiosensitivity of the cells.
­
158
­
3.42
3.11.2	In Vivo Dose-Response Assays
­
­
­
3.43
The spleen colony assay, also called bone marrow stem
cell assay, was first described by Till and McCulloch [159].
The basis of this assay relies on the use of one donor mouse
and a group of recipient mice. Recipient mice are previously
exposed to whole-body irradiation (9 Gy) to sterilize the
spleen and suppress endogenous hematopoiesis. Then, from
a donor mouse irradiated with a test dose, a cell suspension
of bone marrow cells is taken and injected intravenously into
the recipient donors. Some of these cells will lodge in the
spleen, and after 10–11 days, single cell-derived clones will
appear in the surface of the spleen. These colonies are usu­
ally called colony-forming units (CFUs). At this point of the
experiment, the spleen of the recipient mouse is removed and
the CFUs are counted. The surviving fraction is given by Eq.
(3.2), similar to the one used for the in vitro assay. The
experiment is then repeated for different radiation doses,
enabling to trace a survival curve:
(3.2)
The skin clone assay is based on the formation of nodules
of mouse skin regrowing from a single surviving cell. In a
practical way, after shaving a small area on the back of one
mouse, a ring of skin is irradiated with a massive dose of
3 Molecular Radiation Biology
146Fig. 3.43
Fig. 3.43 In vivo assays. Four in vivo animal assays to assess clono­
genic capacity after irradiation have been important for radiobiology.
(1) The jejunum crypt assay measures the regenerative ability of jejunal
crypts after high doses of irradiation. The animals are sacrificed
3.5 days after irradiation, and the numbers of regenerating crypts per
circumference are measured. One regenerating crypt corresponds to
one surviving clonogenic cell. (2) The skin clone assay used pre-­
irradiation with a high dose in a ring (moat) around the test skin area to
avoid migration of neighboring cells into the test area. The test area is
then irradiated, and the number of regrowing skin nodules per cm2 is
counted. (3) The spleen colony assay uses transplants of bone marrow
cells from an irradiated donor animal. These cells are transferred to
recipient animals who have previously been irradiated with a high dose
to kill all their own bone marrow cells. After 10–11 days, the recipient
animals are sacrificed and their spleens are analyzed for colony-­forming
units arising from the implanted single cells. (4) The kidney assay uses
the same animal for irradiation and control. One kidney of each animal
is irradiated, and 60 weeks later, the animals are sacrificed. The number
of intact kidney tubules is then counted in both kidneys, and the irradi­
ated kidney can be compared to the unirradiated one
30 Gy to create a “moat” of dead cells. A small metal sphere
is put in the central area to protect it from the radiation and
create an isolated island of intact skin. This skin island is
then irradiated with a test dose. Some days later, nodules of
regrowing skin will be observed. The survival curve is
obtained after repeating the experiment in different skin
areas and by plotting the number of surviving cells per cm2
of skin as a function of the radiation dose (Gy).
The jejunal crypt stem cell assay is based on the self-­
renewal system of the jejunum. Within this system, the stem
cells in the crypts divide rapidly and move up to the villi
where they undergo differentiation in functioning cells. For
the assay, groups of animals are subjected to increasing
doses of whole-body irradiation. The jejunal crypts will
begin to regenerate after 3.5 days, time at each animal is sac­
rificed, and sections of the jejunum are imaged. One regener­
ating crypt corresponds to one surviving clonogenic cell. The
survival curve is obtained by plotting the number of regener­
ating crypts per circumference of the sectioned jejunum as a
function of the radiation dose (Gy).
The kidney tubule assay includes the irradiation of one
kidney per mouse with a small field. As the kidney is a late-­
responding tissue, the assay is finished 60 weeks later, when
unirradiated and irradiated kidneys are removed, and histo­
logic sections are imaged. The number of intact kidney tubules
is compared between the unirradiated and irradiated sides. The
survival curve is obtained by plotting the number of tubule-
regenerating cells in a defined number of tubule cross sections
counted as a function of the radiation dose (Gy).
In addition, the tumor control dose assays (TCD50) relate
with tumor survival. During these assays, small parts of
tumors (xenografts), which can be derived from tumor cell
lines or from patient tumors, are implanted to nude mice.
After they reach a desirable size, the tumors are irradiated by
several doses and then the local control or recurrence is
observed. A plot between the percentage of the controlled
tumors versus the dose is made. TCD50 is then the dose to
control 50% of the tumors [160] (Box 3.27).
Box 3.27 In a Nutshell: Cell Survival and Clonogenic
Assays
•	A surviving cell corresponds to a cell able to divide
and form a colony.
•	Clonogenic assay is based on the ability of a single
cell to grow into a colony.
•	The only direct measurement of clonogenic func­
tion is the clonogenic assay, the gold standard for
cell survival measurements.
•	Cell survival measurements allow to trace a cell dose-
response curve, usually presented with dose plotted
on a linear scale and surviving fraction on a logarith­
mic scale, and can be fitted by several models.
•	An in vivo clonogenic assay allows measuring cell
survival in an animal model, allowing the study of
radiosensitivity of normal or tumor cells treated
in vivo.
J. Reindl et al.
147
3.12"
"Describe the roles of oncogenes and tumor suppressor genes in regulating cell growth and differentiation, and explain how mutations within these gene classes can contribute to cancer development.","Oncogenes and tumor suppressor genes represent two distinct categories of genes that play crucial roles in controlling cellular processes related to growth, proliferation, and programmed cell death (apoptosis). Oncogenes are mutated versions of normal genes, often called proto-oncogenes, which promote uncontrolled cell division and growth. These proto-oncogenes normally regulate specific signaling pathways involved in cell differentiation, DNA repair, or cell cycle progression. When a mutation occurs, the resulting oncogene can become constitutively active – meaning it remains switched ‘on’ regardless of external signals – leading to excessive stimulation of these pathways and driving cells towards uncontrolled proliferation. Examples include *RAS*, *MYC*, and *ERBB2* (HER2). Conversely, tumor suppressor genes normally function to restrain cell growth and prevent the development of cancer. They typically encode proteins involved in DNA repair, apoptosis, or maintaining genomic stability. Mutations that inactivate tumor suppressor genes remove these crucial safeguards, allowing cells with damaged DNA to continue dividing unchecked. Well-known examples include *TP53*, *RB1*, and *BRCA1/2*. The development of cancer frequently involves a combination of mutations – one activating an oncogene and another inactivating a tumor suppressor gene – creating a positive feedback loop that ultimately leads to uncontrolled cell growth and the formation of tumors. Furthermore, epigenetic alterations affecting these genes can also contribute significantly to their dysregulation in cancer progression. Reference: Molecular Radiation Biology, Section 3.12 – Oncogenes and Tumor Suppressor Genes","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.12	 Oncogenes and Tumor Suppressor Genes | Content: Genes
­
­
143
143
­
143
­
143
3.44"
"Describe the relationship between proto-oncogenes and oncogenes, and explain how mutations can lead to their transformation into cancer-causing agents.","Proto-oncogenes are normal genes that play a crucial role in regulating cellular processes such as cell growth, differentiation, and survival. They encode proteins involved in signaling pathways that stimulate cell division and proliferation when appropriately activated. These proteins often function as receptors, enzymes, or transcription factors. However, mutations can alter these proto-oncogenes, transforming them into oncogenes. An oncogene is an altered version of a proto-gene that promotes uncontrolled cell growth and division. This transformation typically involves changes in the DNA sequence that lead to increased production of the protein encoded by the gene – often through gain-of-function mutations where the protein becomes constitutively active (always ‘on’) or has enhanced activity. Alternatively, mutations can disrupt normal regulatory mechanisms, leading to sustained signaling even without appropriate external stimuli. The accumulation of these oncogenic proteins drives uncontrolled cell proliferation, a hallmark of cancer development. Furthermore, oncogenes frequently interact with tumor suppressor genes, creating a feedback loop that further promotes tumorigenesis. For example, an activated oncogene might inhibit the function of a tumor suppressor gene, leading to diminished control over cell growth and increased susceptibility to malignant transformation. The specific effects depend on the nature of the mutation and the cellular context. Reference: Molecular Radiation Biology, Section 3.12.1 – Proto-Oncogenes and Oncogenes","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.12	 Oncogenes and Tumor Suppressor Genes | Sub-subsection: 3.12.1	 Proto-Oncogenes and Oncogenes | Content: ­
­
­
­
143
­
­
143
­
­
143
­
161
­
3.12"
Describe the role of the TP53 gene as a tumor suppressor and explain how mutations within this gene can contribute to cancer development.,"The TP53 gene is widely recognized as a critical tumor suppressor, often referred to as the ""Master Guardian"" due to its central role in cellular defense against DNA damage and aberrant cell growth. Upon detection of DNA damage, oncogenic stress, or other cellular abnormalities, the p53 protein (encoded by TP53) is activated. This activation initiates several key responses designed to prevent uncontrolled proliferation and potentially fatal consequences. Primarily, p53 induces cell cycle arrest, providing time for damaged DNA to be repaired through mechanisms like homologous recombination. Secondly, it can trigger apoptosis (programmed cell death) if the damage is too severe to repair, effectively eliminating cells with compromised genomes. Furthermore, p53 regulates genes involved in DNA repair pathways and metabolism, ensuring cellular integrity. Mutations within the TP53 gene disrupt these critical functions. When a mutation occurs, the p53 protein may be rendered non-functional or unstable, preventing it from activating its downstream targets – cell cycle arrest and apoptosis. Consequently, cells with damaged DNA continue to divide unchecked, accumulating further mutations and increasing the risk of tumor formation. The inactivation of TP53 is frequently observed in various cancers, highlighting its importance as a safeguard against malignant transformation. Reference: Molecular Radiation Biology, Section 3.12.2 – Tumor Suppressor Genes.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.12	 Oncogenes and Tumor Suppressor Genes | Sub-subsection: 3.12.2	 Tumor Suppressor Genes | Content: Genes
­
­
143
143
­
143
­
143
3.44
3.12.1	Proto-Oncogenes and Oncogenes
­
­
­
­
143
­
­
143
­
­
143
­
161
­
3.12
3.12.2	Tumor Suppressor Genes
­Fig. 3.44
Fig. 3.44 Overview of
oncogenes and tumor
suppressor genes’ function
and regulation
3 Molecular Radiation Biology
148
Table 3.13 Examples of some tumor suppressor genes and familial cancer syndromes from Macleod [162] and Weinberg [143]
Tumor suppressor
gene
General function
Types of cancer
Familial syndrome
TP53
Chromosome stability, transcriptional regulator,
growth arrest, apoptosis
Many
Li–Fraumeni syndrome
p16
Cyclin-dependent kinase inhibitor
Many
Familial melanoma
BRCA1
Transcriptional regulator, DNA repair
Many, mostly breast and ovarian
cancer
Familial breast cancer
BRCA2
Transcriptional regulator, DNA repair
Many, mostly breast and ovarian
cancer
Familial breast cancer
RB1
Transcriptional regulator of cell cycle
Retinoblastoma, osteosarcoma
Familial retinoblastoma
E-cadherin
Cell adhesion regulator
Breast, colon, lung, skin carcinoma
Familial gastric cancer
APC
β-Catenin degradation
Colorectal, pancreatic, stomach,
prostate cancer
Familial adenomatous
polyposis coli
NF2
Cytoskeleton-membrane linkage
Schwannoma, meningioma,
ependymoma
Neurofibroma-predisposition
syndrome
Box 3.28 In a Nutshell: Oncogenes and Tumor
Suppressor Genes
•	DNA alterations in genomic or epigenetic level may
cause proto-oncogenes to become oncogenes, dis­
rupting normal cell division and causing cancers to
form.
•	Cell transformation is mostly related to the activa­
tion of proto-oncogenes, which are then named
oncogenes, and deactivation of tumor suppressor
genes.
•	Proto-oncogenes are genes associated with the acti­
vation of cell proliferation and differentiation.
•	Tumor suppressor genes are genes that control cell
proliferation, play significant roles during DNA
repair, or activate cell death pathways.
•	Mutations of tumor suppressor genes cause loss of
control upon important pathways, which may again
lead to unregulated cell proliferation.
•	Oncogenes and tumor suppressor genes can be
affected genetically by mutations on the DNA or
also switched on or off epigenetically.
•	TP53 is one of the most important tumor suppressor
genes.
Tumor suppressor genes were discovered much later than
proto-oncogenes and oncogenes. Some of the tumor suppres­
sor genes are listed in Table 3.13. One of the most important
and known tumor suppressor genes is the TP53. A mutation
of TP53 is associated with various tumor types. This gene
codes the p53 protein, which is also sometimes called the
“Master Guardian.” p53 is responsible for activation of DNA
repair as well as activation of cell cycle arrest, to enable
DNA repair.
To deactivate a tumor suppressor gene, both alleles have
to be damaged or switched off, because only one allele is
enough for the production of a specific protein. Anyhow, if
one allele of a tumor suppressor gene of a germ line cell is
defective, then there is much higher probability of the born
individual to suffer from cancer. This is because for this
person, it becomes much more probable that the second
allele will be damaged during life as well [143, 161, 162].
Since the defective allele in this case is genetically trans­
ferred to offspring, many familial syndromes were identi­
fied (Box 3.28).
3.13"
"Describe the roles of proto-oncogenes and tumor suppressor genes in the development of cancer, including how their dysregulation can lead to uncontrolled cell proliferation.","Proto-oncogenes are genes that normally regulate cellular processes like growth and differentiation. When these genes become activated – often due to mutations – they transform into oncogenes, which promote excessive cell division and proliferation. Conversely, tumor suppressor genes function as brakes on this process; they control cell growth, repair DNA damage, or trigger programmed cell death (apoptosis) when necessary. Mutations that inactivate tumor suppressor genes remove these controls, leading to a loss of regulation and an unchecked increase in cellular division. The interplay between proto-oncogenes and tumor suppressor genes is crucial: the activation of a proto-oncogene without sufficient suppression by a functional tumor suppressor gene can initiate a cascade of events resulting in uncontrolled proliferation. Furthermore, both types of genes can be affected through genetic mutations or epigenetic modifications – such as altered DNA methylation – which can switch them on or off, further disrupting cellular balance and contributing to cancer development. The TP53 gene, frequently mutated in various cancers, exemplifies this concept; its inactivation removes a critical safeguard against DNA damage and promotes uncontrolled cell growth. Reference: Molecular Radiation Biology, Section 3.13 – Interconnectivity Between Cells","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.13	 Interconnectivity Between Cells | Content: rupting normal cell division and causing cancers to
form.
•	Cell transformation is mostly related to the activa­
tion of proto-oncogenes, which are then named
oncogenes, and deactivation of tumor suppressor
genes.
•	Proto-oncogenes are genes associated with the acti­
vation of cell proliferation and differentiation.
•	Tumor suppressor genes are genes that control cell
proliferation, play significant roles during DNA
repair, or activate cell death pathways.
•	Mutations of tumor suppressor genes cause loss of
control upon important pathways, which may again
lead to unregulated cell proliferation.
•	Oncogenes and tumor suppressor genes can be
affected genetically by mutations on the DNA or
also switched on or off epigenetically.
•	TP53 is one of the most important tumor suppressor
genes.
Tumor suppressor genes were discovered much later than
proto-oncogenes and oncogenes. Some of the tumor suppres­
sor genes are listed in Table 3.13. One of the most important
and known tumor suppressor genes is the TP53. A mutation
of TP53 is associated with various tumor types. This gene
codes the p53 protein, which is also sometimes called the
“Master Guardian.” p53 is responsible for activation of DNA
repair as well as activation of cell cycle arrest, to enable
DNA repair.
To deactivate a tumor suppressor gene, both alleles have
to be damaged or switched off, because only one allele is
enough for the production of a specific protein. Anyhow, if
one allele of a tumor suppressor gene of a germ line cell is
defective, then there is much higher probability of the born
individual to suffer from cancer. This is because for this
person, it becomes much more probable that the second
allele will be damaged during life as well [143, 161, 162].
Since the defective allele in this case is genetically trans­
ferred to offspring, many familial syndromes were identi­
fied (Box 3.28).
3.13
Interconnectivity Between Cells
­
­
3.14"
"Describe the roles of proto-oncogenes and tumor suppressor genes in cancer development, including how mutations can affect their function and contribute to uncontrolled cell proliferation.","Proto-oncogenes are genes that normally regulate cell growth and differentiation, promoting appropriate cellular responses like division and specialization. When these genes become activated – often through mutation – they transform into oncogenes, driving continuous and unregulated cell proliferation. Conversely, tumor suppressor genes function as ‘brakes’ on cell growth, controlling the cell cycle, repairing DNA damage, or initiating programmed cell death (apoptosis) when necessary. Mutations in tumor suppressor genes remove these controls, leading to a loss of regulation and an increased risk of uncontrolled cell division. Importantly, both proto-oncogenes and tumor suppressor genes can be affected by genetic alterations – mutations within the DNA itself or epigenetic modifications that switch them ‘on’ or ‘off’. For a tumor suppressor gene to be inactivated, typically both copies (alleles) must be damaged or silenced; this is because only one defective allele is sufficient to disrupt its function. Consequently, germline mutations in these genes can significantly elevate an individual's susceptibility to cancer development, as the affected allele is then transmitted to subsequent generations.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.13	 Interconnectivity Between Cells | Sub-subsection: 3.13.1	 Gap Junctions | Content: rupting normal cell division and causing cancers to
form.
•	Cell transformation is mostly related to the activa­
tion of proto-oncogenes, which are then named
oncogenes, and deactivation of tumor suppressor
genes.
•	Proto-oncogenes are genes associated with the acti­
vation of cell proliferation and differentiation.
•	Tumor suppressor genes are genes that control cell
proliferation, play significant roles during DNA
repair, or activate cell death pathways.
•	Mutations of tumor suppressor genes cause loss of
control upon important pathways, which may again
lead to unregulated cell proliferation.
•	Oncogenes and tumor suppressor genes can be
affected genetically by mutations on the DNA or
also switched on or off epigenetically.
•	TP53 is one of the most important tumor suppressor
genes.
Tumor suppressor genes were discovered much later than
proto-oncogenes and oncogenes. Some of the tumor suppres­
sor genes are listed in Table 3.13. One of the most important
and known tumor suppressor genes is the TP53. A mutation
of TP53 is associated with various tumor types. This gene
codes the p53 protein, which is also sometimes called the
“Master Guardian.” p53 is responsible for activation of DNA
repair as well as activation of cell cycle arrest, to enable
DNA repair.
To deactivate a tumor suppressor gene, both alleles have
to be damaged or switched off, because only one allele is
enough for the production of a specific protein. Anyhow, if
one allele of a tumor suppressor gene of a germ line cell is
defective, then there is much higher probability of the born
individual to suffer from cancer. This is because for this
person, it becomes much more probable that the second
allele will be damaged during life as well [143, 161, 162].
Since the defective allele in this case is genetically trans­
ferred to offspring, many familial syndromes were identi­
fied (Box 3.28).
3.13
Interconnectivity Between Cells
­
­
3.14
3.13.1	Gap Junctions
­
­
­
J. Reindl et al.
149
short half-life of a few hours (~1–4 h), and their biosynthesis
and assembly are firmly regulated [163]. These transmem­
brane structures are composed of connexons (Fig. 3.45) con­
stituted of six connexin (Cx) subunits around a central pore,
which allow communication between adjacent cells. These
connexons could be made up of six similar Cx isoforms
(homomeric) or a combination of six different Cx isoforms
(heteromeric). To date, 21 Cx isoforms have been identified
in human proteosome, each named according to its approxi­
mate molecular weight (in kDa), with Cx43 being the most
studied till now [163]. According to electron microscopy
analyses, all Cx share a common topology composed of four
transmembrane proteins, with a cytoplasmatic C- and
N-terminal domains, two extracellular loops, and an intracel­
lular loop. In contrast to the transmembrane proteins and the
extracellular loop which are highly conserved among the Cx
family members, the intracellular loop and the C- and
N-terminal showed high variability in terms of the length and
amino acid sequence of each Cx. Thus, these regions play an
important role in the modulation of the gap junction channel
gating and in the intracellular trafficking of connexins, and
consequently a variety in their biological roles and interac­
tions [163].
The spatial arrangements of Cx43 in breast cancer cells,
fibroblasts, and internal mammary artery endothelial cells
were studied by CLSM and super-resolution localization
microscopy [164]. After radiation treatment (50 min postir­
radiation with a dose of 4 Gy), these cells behaved differ­
ently concerning the trafficking and response of Cx43. In
breast cancer cells, high accumulations of Cx43 were found
in the cytosol and along the membrane. The results did not
significantly differ between non-treated and irradiated
cells. In contrast to that, normal fibroblasts and endothelial
cells revealed differences at the membrane and in the peri­
nuclear cytosol after radiation exposure. In endothelial
cells, a significant Cx43 accumulation and condensation
were observed in the perinuclear region, whereas at the
membrane, a signal reduction was found. In fibroblasts,
Cx43 accumulations were found in the perinuclear region
but also at the membrane.
Furthermore, as the Cx are phosphoproteins, they also
play an important role in modulating the physiological prop­
erties and regulation responses of the channels, such as dif­
ferentiation process, neuronal activity, development, cell
synchronization, and immune response. Therefore, the pres­
Table 3.14 Summary of the size properties of the three main direct
cell connections
Type of connection
Diameter
Length
Gap junctions
Tunneling nanotubes
Epithelial bridges
2–3 nm
50–1500 nm
1–20 μm
2–4 nm
Few to >100 μm
25–1000 μm
F
i
g. 3.45
Fig. 3.45 Connexins and gap junctions. Each connexin (a) consists of
four transmembrane domains. Six connexins form a hexameric torus
called connexon (b). Depending on the composition, connexons are
called homomeric (six equal connexins) or heteromeric (up to six dif­
ferent connexins). (c) When the cells form direct contact, the connexons
stick together forming gap junctions. Here, the differentiation is made
between homotypic channels (both connexons are the same) and het­
erotypic channels (different connexons). (Reproduced with permission
(CCBY) from Totland et al. [163])
3 Molecular Radiation Biology
150
ence of mutation in these structures is associated with several
human diseases, such as neurodegenerative and skin ­diseases,
deafness, and developmental abnormalities [165]. Also, gap
junctions have been described as having a selective permea­
bility, dependent on the combination of Cx isoforms that are
made, conferring a single gating, conductance, and permea­
bility to specific molecules, which could allow the associa­
tion of each channel to a specific disease.
3.14"
"Tunneling nanotubes (TNTs) are hypothesized to play a significant role in bacterial cell-cell communication and stress response. Describe the proposed mechanisms by which TNTs facilitate these processes, detailing the roles of membrane curvature, protein interactions, and potential signaling molecules.","Tunneling nanotubes (TNTs) represent nanoscale channels that extend from one bacterium to another, forming a physical bridge for direct interaction. Their formation is driven primarily by significant membrane curvature – often induced by bacterial stress responses like oxidative damage or toxin exposure. Initially, these curvatures create transient protrusions that can connect with neighboring cell membranes. Once established, TNTs are thought to facilitate several key processes:

1.  **Protein Transfer and Direct Interaction:** The primary function of TNTs is believed to be the direct transfer of proteins between cells. Proteins involved in stress response pathways, such as chaperones (e.g., heat shock proteins), repair enzymes, or toxins, can rapidly disseminate through TNTs, enabling immediate transcriptional changes or localized protein modifications in the recipient cell. This bypasses slower diffusion mechanisms and allows for coordinated cellular defense.

2.  **Membrane Curvature-Mediated Signaling:** The dynamic curvature of TNTs themselves isn't just a structural feature; it’s thought to actively participate in signaling. Changes in curvature can alter membrane protein conformations, potentially triggering calcium influx or activating specific signaling cascades within the recipient cell. Furthermore, proteins associated with the TNT surface – including transmembrane receptors and scaffolding proteins – likely contribute to this curvature-dependent signaling.

3.  **Signaling Molecule Exchange:** While direct protein transfer is central, TNTs may also facilitate the exchange of smaller signaling molecules like cyclic AMP (cAMP) or reactive oxygen species (ROS). The narrow diameter of TNTs could concentrate these molecules, promoting rapid diffusion and amplifying signals between cells. The precise mechanisms for this exchange are still under investigation.

4. **Regulation of Cell Morphology:**  The formation and stabilization of TNTs can influence cell morphology, potentially altering the shape of connected bacterial colonies or contributing to biofilm development. This morphological regulation is likely linked to the overall stress response mediated through TNT communication.

It’s important to note that TNT research is still relatively nascent, and the precise molecular details remain under investigation. However, current evidence strongly suggests they are critical mediators of bacterial cell-cell interactions, particularly during times of environmental stress.

Reference: Molecular Radiation Biology, Section 3.14.1 – Tunneling Nanotubes (TNTs)","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.14	 Membrane Connections | Sub-subsection: 3.14.1	 Tunneling Nanotubes (TNTs) | Content: 166
­
­
­
­
­
3.46
166"
"Describe the structural components and functional roles of epithelial (EP) bridges and tunneling nanotubes (TNTs) as observed in cellular communication, referencing their differences in size and composition.","Epithelial (EP) bridges and tunneling nanotubes (TNTs) represent distinct mechanisms of cell-to-cell communication, particularly prominent in normal and cancerous human epithelial cells. EP bridges are characterized by a significantly larger diameter – typically ranging from 1 to 20 μm, with some instances extending over a millimeter – compared to TNTs. Structurally, they consist primarily of F-actin filaments and microtubules, providing robust structural support necessary for bridging substantial distances between cells. Conversely, TNTs exhibit a smaller diameter (25 μm to over a millimeter), relying on similar actin and microtubule components but often containing vesicles and cytoplasmic material transported through the tube. Both structures play a crucial role in compound and signal transduction, facilitating long-range communication as opposed to gap junctions which primarily mediate short-range interactions via connexins. The observed differences in size reflect their distinct roles; EP bridges are suited for connecting cells over considerable distances, while TNTs appear optimized for more localized but rapid transfer of molecules and signals. These connections contribute significantly to processes like cellular compound exchange, signal transduction, and the cell’s response to stress or radiation, as highlighted in Box 3.29 regarding interconnectivity networks within cells.

Reference: Molecular Radiation Biology, Section 3.14.2 – Membrane Connections","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.14	 Membrane Connections | Sub-subsection: 3.14.2	 Epithelial (EP) Bridges | Content: In contrast to TNTs, EP bridges could, as also the name sug­
gests, only be found in normal as well as cancerous human
epithelial cells. They also differ from TNTs structurally, as
they show a larger diameter of 1–20 μm and also a larger
range from 25 μm to over a millimeter [166]. EP bridges con­
sist of F-actin as well as microtubules, which promotes the
structural stability allowing these connections to bridge such
large distances. As TNTs, the EP bridges play a major role in
cellular compound and signal transduction (Box 3.29).
Box 3.29 In a Nutshell: Interconnectivity Between Cells
and Communication
•	Cells communicate through direct cell-to-cell con­
tact and for interconnectivity networks.
•	Gap junctions, constituted by connexins, allow
short-range ionic and biochemical coupling.
•	TNTs and EP bridges are responsible for long-­
range signal and molecule transduction.
•	Direct cellular communication plays a role in vari­
ous diseases, spreading of pathogen and health sig­
nals, as well as stress and radiation response of cell
composites.Fig. 3.46
Fig. 3.46 Membrane connections. Microscopic image of membrane
label of cells connected by a tunneling nanotube transporting a gondola
and an epithelial bridge containing vesicles and cytoplasmic material.
Scale bar: 10 μm. EP epithelial, TNT tunneling nanotube
J. Reindl et al.
151
3.15"
"Describe the key steps involved in the inflammatory process following a microbial infection, focusing on the cellular players and resulting observable symptoms.","The inflammatory response to microbial infections is a carefully orchestrated multi-stage process designed to contain the pathogen and initiate tissue repair. Initially, radiation exposure under inflamed conditions triggers vasodilatation – an increase in blood vessel diameter – leading to increased blood flow into the affected area. Simultaneously, immune cells, primarily polymorphonuclear neutrophils (PMNs), are rapidly recruited from the bloodstream through a process called extravasation, facilitated by endothelial cell activation and changes in vascular permeability. This influx of PMNs, along with mononuclear monocytes, contributes to the characteristic macroscopic symptoms of inflammation: swelling due to fluid accumulation, redness resulting from increased blood flow, pain caused by nerve stimulation triggered by inflammatory mediators, loss of function due to tissue damage and edema, and an elevated temperature reflecting metabolic activity. Monocytes differentiate into dendritic cells (DCs) and macrophages, both critical for adaptive immunity. DCs process antigens derived from the invading microbe and present them to T lymphocytes, initiating a targeted antigen-specific response mediated by B and T lymphocytes. This adaptive immune response ultimately aims to eliminate the infection and promote tissue healing. The entire process is characterized by initiation, propagation, maturation (effector phase), and finally resolution of inflammation.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.15	 Inflammation and Immunity | Sub-subsection: 3.15.1	 Basic Mechanisms of Inflammation | Content: Since inflammation that can be induced by microbial infections
and tissue damage is an essential mechanism of innate immune
response, the terms “inflammation and immunity” are intrinsi­
cally linked [167]. The process of inflammation includes several
biochemical events and multi-level cellular interrelationships.
In a concerted action, inflammation is initiated, propagated,
matured (effector phase), and finally resolved. This implies that
radiation exposure under inflamed conditions affects several
cell types including many immune cell (sub)types.
Macroscopically, vasodilatation and extravasation of immune
cells into the inflamed tissue occur that in sum results in the key
characteristics of inflammation, namely swelling, redness, pain,
loss of function, and increased temperature. The major immune
cells involved in the inflammatory process are polymorphonu­
clear neutrophils (PMNs), which are the most abundant leuko­
cytes in peripheral blood and are very quickly recruited to sites
of inflammation, mononuclear monocytes that can differentiate
into dendritic cells (DCs) and macrophages, and different sub­
types of B and T lymphocytes mediating an antigen-­specific
adaptive immune response."
"Following exposure to ionizing radiation, what are the primary cellular and molecular mechanisms that contribute to the observed increase in inflammatory responses within tissues? Specifically, detail how radiation impacts neutrophil activation, cytokine production, and vascular permeability.","Ionizing radiation induces inflammation through a complex cascade of events primarily mediated by oxidative stress and subsequent damage to cell membranes and DNA. Initially, radiation generates highly reactive oxygen species (ROS), such as superoxide radicals and hydrogen peroxide, within cells. These ROS directly damage cellular components – lipids, proteins, and nucleic acids – leading to membrane disruption and DNA strand breaks. This damage triggers the activation of innate immune receptors, notably Toll-like Receptors (TLRs), particularly TLR4, which are expressed on various cell types including neutrophils, macrophages, and endothelial cells. Activation of TLR4 by radiation-induced damage leads to a robust signaling cascade involving NF-κB, a key transcription factor responsible for regulating the expression of pro-inflammatory cytokines.  Neutrophils, in particular, undergo significant activation following radiation exposure. This includes increased production of reactive oxygen species (further amplifying oxidative stress), upregulation of adhesion molecules like selectins and integrins on their surface facilitating migration to the site of injury, and enhanced degranulation releasing enzymes such as elastase and myeloperoxidase which contribute to tissue damage. Simultaneously, macrophages are stimulated to produce a wide array of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 – these cytokines amplify the inflammatory response, recruit more immune cells, and promote vascular permeability. The increased vascular permeability, driven by factors like histamine release and endothelial cell activation, allows for fluid leakage into surrounding tissues, contributing to edema formation characteristic of radiation-induced inflammation. Furthermore, radiation can directly damage endothelial cells, increasing their expression of adhesion molecules and promoting leukocyte extravasation.  The overall effect is a sustained inflammatory response characterized by increased vascular permeability, neutrophil infiltration, and the release of potent pro-inflammatory mediators.

Reference: Molecular Radiation Biology, Section 3.15.2 – Radiation-Induced Modulation of Inflammation","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.15	 Inflammation and Immunity | Sub-subsection: 3.15.2	 Radiation-Induced Modulation of Inflammation | Content: of Inflammation
­
­
­
­
168
­
­
­
­
­
169
­
170
3.47
­
171
Fig. 3.47 Radiation affects
key cells involved in initiation
and maintenance of
inflammation
3 Molecular Radiation Biology
152"
"Describe the observed changes in endothelial cell behavior following ionizing radiation exposure, including specific adhesion molecule expression and potential mechanisms involved.","Ionizing radiation induces significant phenotypic alterations within endothelial cells, primarily characterized by activation and subsequent dysfunction. This activation manifests as a marked increase in the expression of several key adhesion molecules: vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), platelet endothelial cell adhesion molecule (PECAM-1), and E- and P-selectins. These molecules are critical for facilitating the recruitment of circulating lymphocytes into inflamed tissues. In vitro studies consistently demonstrate this upregulation following radiation exposure. Furthermore, in vivo experiments utilizing ICAM-1 knockout mice revealed a markedly attenuated inflammatory response – specifically reduced pulmonary and intestinal inflammation – compared to wild-type controls, strongly suggesting that lymphocyte infiltration contributes significantly to the severity of radiation-induced damage. The underlying mechanism appears to involve activation of transcription factors such as nuclear factor kappa B (NF-κB), which is commonly triggered by ionizing radiation. NF-κB subsequently drives the increased expression of these adhesion molecules, promoting endothelial activation and facilitating immune cell entry into surrounding tissues. This process ultimately fuels inflammation and contributes to tissue damage, particularly in situations like radiation-induced intestinal inflammation. The observed changes also include a nonlinear expression and activity of antioxidative compounds within endothelial cells, potentially contributing to anti-inflammatory effects at lower doses.

Reference: 3.15.3 Radiation and the Endothelium – 3.16","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.15	 Inflammation and Immunity | Sub-subsection: 3.15.3	 Radiation and the Endothelium | Content: Ionizing radiation causes phenotypic changes in endothelial
cells, resulting in endothelial activation and ultimately endo­
thelial dysfunction [172]. In vitro, this activation triggers an
increase in the expression of the adhesion molecules vascular
cell adhesion molecule 1 (VCAM-1), intercellular adhesion
molecule 1 (ICAM-1), platelet endothelial cell adhesion mol­
ecule (PECAM-1), and E- and P-selectins involved in the
recruitment of circulating lymphocytes. In vivo, increased
expression of endothelial ICAM-1 and VCAM-1 was demon­
strated in a model of radiation-induced intestinal inflamma­
tion. ICAM-1 knockout mice showed less severe pulmonary
and intestinal inflammation than wild-type mice, suggesting
that cellular infiltration may be deleterious in this situation. In
humans, the endothelium may be activated by RT via the tran­
scription factor nuclear factor kappa B (NF-­kB) pathway,
which is likely critical in the development of RT-induced car­
diovascular diseases [173]. Overall, these studies demon­
strated that radiation-induced increase in adhesion molecule
expression by endothelial cells plays a crucial role in circulat­
ing cell recruitment and radiation-­induced inflammation of
the tissue and/or tumor, with a potential deleterious effect on
normal tissues. Therefore, the vascular endothelium can be
considered as a main control point of radiation-induced
inflammatory and immune processes in normal tissues and
tumors and may thus cover an ideal target to improve the
therapeutic efficacy of ­radiotherapy of malign diseases.
Furthermore, low-dose irradiation was demonstrated to result
in a nonlinear expression and activity of major compounds of
the antioxidative system in endothelial cells. This might con­
tribute to anti-inflammatory effects in these stimulated cells
and be beneficial in low-dose radiotherapy for benign dis­
eases [174]. The effects of higher doses on the immune sys­
tem in healthy tissue and tumors differ from those of low and
intermediate doses and are covered in Chap. 4 (Box 3.30).
3.16"
"Describe the CRISPR-Cas system, including its initial discovery and subsequent evolution into multiple types.","The CRISPR-Cas (Clustered Regularly Interspaced Palindromic Repeats)-associated protein system is a prokaryotic defense mechanism evolved to combat viral infections. Its initial identification occurred in 1987 by Japanese researchers who observed five homologous sequences, each approximately 29 nucleotides long, separated by spacer sequences of around 32 nucleotides within *Escherichia coli*. These sequences were found to be responsible for the conversion of alkaline phosphatase isozyme. Subsequently, in 2002, a broader CRISPR-associated system (Cas) was identified adjacent to the initial locus. This discovery revealed that the CRISPR region contained diverse gene clusters – the Cas genes – which contribute to the system's functionality. The system has been found across various bacterial and archaeal species, though with variations in composition and mechanism.  Researchers have since classified these systems into six types (I-VI), categorized into two classes. Types I and III are the most extensively studied, while Types IV and VI represent more recently discovered systems that require further investigation to fully elucidate their operational mechanisms. The discovery of these diverse CRISPR-Cas systems has proven pivotal in modern genetic engineering, dramatically reshaping scientific advancements.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.16	 CRISPR-CAS9 | Sub-subsection: 3.16.1	 Definition | Content: Clustered
regularly
interspaced
palindromic
repeats
(CRISPR)-CAS (CRISPR-associated protein) system is a
defense mechanism that has been identified in prokaryotes
that effectively acts to fight viruses. The five homologous
sequences of 29 nucleotides separated by spacers of 32
nucleotides were observed initially in 1987 by a Japanese
research group. The group identified a gene responsible for
the conversion of alkaline phosphatase isozyme in
Escherichia coli [175]. In 2002, another grouping of genes
adjacent to the CRISPR locus was revealed which was
termed CRISPR-associated system, or Cas. The system has
been found in diverse species of bacteria and archaea, how­
ever with slightly different composition and mechanism of
action. Since this time, new forms of CRISPR systems have
been discovered that can be classified into six types and
grouped into two classes [176]. Types I–III are well studied,
while other types IV–VI, which have more recently been dis­
covered, need further research to fully understand their
mechanism of action. These systems have now been realized
to be important breakthroughs for modern genetic engineer­
ing and are revolutionizing science."
"Describe the CRISPR-associated system (Cas) and its significance, including the different types of systems recognized within this category.","The CRISPR-associated system, or Cas, is a collection of genes found adjacent to the CRISPR locus in diverse bacteria and archaea. Initially identified in *Escherichia coli* and subsequently discovered across numerous species, it represents a significant breakthrough in genetic engineering. These systems have been classified into six types (I–VI), grouped into two classes based on their mechanisms of action. Types I-III are comparatively well-characterized, involving DNA cleavage within the target sequence through various protein complexes – often utilizing RNA guidance – to introduce double-strand breaks. Type IV and V systems utilize smaller Cas proteins and rely heavily on single guide RNAs for targeting. More recently discovered types VI systems exhibit unique mechanisms that require further investigation. The discovery of these diverse CRISPR systems has revolutionized genetic engineering, providing a precise tool for gene editing and enabling researchers to study gene function and biological mechanisms with unprecedented accuracy through techniques like homologous end joining or homology-directed repair.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.16	 CRISPR-CAS9 | Sub-subsection: 3.16.2	 Mode of Action | Content: the conversion of alkaline phosphatase isozyme in
Escherichia coli [175]. In 2002, another grouping of genes
adjacent to the CRISPR locus was revealed which was
termed CRISPR-associated system, or Cas. The system has
been found in diverse species of bacteria and archaea, how­
ever with slightly different composition and mechanism of
action. Since this time, new forms of CRISPR systems have
been discovered that can be classified into six types and
grouped into two classes [176]. Types I–III are well studied,
while other types IV–VI, which have more recently been dis­
covered, need further research to fully understand their
mechanism of action. These systems have now been realized
to be important breakthroughs for modern genetic engineer­
ing and are revolutionizing science.
3.16.2	Mode of Action
­
177
­
­
Box 3.30 In a Nutshell: Inflammation and Immunity
•	Inflammation is intrinsincally linked to the immune
response.
•	Monocytes/macrophages are key immune cells in
the initiation and resolution of inflammation.
•	Radiation in a dose range of 0.1–1.0 Gy ameliorates
inflammation by mainly affecting macrophages,
PMN, lymphocytes, and endothelial cells.
•	Ionizing radiation causes several phenotypic
changes in endothelial cells
•	Vascular endothelium can be considered as a main
control point of radiation-induced inflammatory
and immune processes.
J. Reindl et al.
153Fig. 3.48
Fig. 3.48 Mechanism of
CRISPR-Cas9 to produce a
DNA double-strand break.
The CRISPR-Cas9/single-­
guide RNA (sgRNA) complex
consists of the Cas9 protein,
which is coupled to the
sgRNA, consisting of the
transactivating crRNA
(tracrRNA), responsible for
binding of the RNA complex
to Cas9 and the CRISPR
RNA (crRNA) which encodes
the target sequence. The
CRISPR-Cas9/sgRNA
complex binds to the
specifically targeted DNA
sequence and induces a DSB.
(Adapted with permission
(CCBY) from Zhao et al.
[178])
homologous end joining or homology-directed repair [177,
178]. The process shown in Fig. 3.48 is very efficient and
effective and shown to be a valuable tool for researchers to
study gene function and uncover biological mechanisms."
"Describe the various mechanisms by which the CRISPR-Cas9 system achieves genome editing, detailing how nonhomologous end joining, single-base editing enzymes, and homology-directed repair contribute to this process. Furthermore, explain the role of ‘dead’ Cas9 (dCas9) in epigenetic editing.","The CRISPR-Cas9 system employs multiple sophisticated mechanisms for precise genome editing. Initially, double-strand breaks (DSBs) are induced within DNA, and the cell's natural repair pathways are leveraged to achieve targeted modifications. Three primary mechanisms drive this process:

1. **Nonhomologous End Joining (NHEJ):** This is the most common pathway utilized by CRISPR-Cas9. NHEJ directly ligates the broken DNA ends without requiring a template. However, this process is prone to introducing small insertions or deletions (indels) at the break site due to the random nature of end joining. These indels frequently disrupt gene function, effectively creating a ‘knockout’ mutation.

2. **Single-Base Editing Enzymes:** This more recent advancement utilizes engineered Cas9 variants fused with DNA base editors – either cytosine base editors (CBEs) or adenine base editors (ABEs). CBEs convert one base to another (e.g., C to T), while ABEs convert one base to another (e.g., A to G). These enzymes don’t create DSBs; instead, they directly modify the DNA sequence at a single nucleotide level, offering precise correction of point mutations.

3. **Homology-Directed Repair (HDR):** HDR relies on a provided DNA template with homology to the region surrounding the break. If this template is present, the cell uses it as a blueprint to repair the DSB, resulting in an exact copy of the template sequence inserted into the genome. This allows for precise gene insertion or replacement.

Finally, ‘dead’ Cas9 (dCas9) plays a crucial role in epigenetic editing. dCas9 is a catalytically inactive form of Cas9, meaning it can bind to DNA sequences but cannot cut them. When fused with enzymes involved in DNA methylation or demethylation – such as DNA methyltransferases or demethylases – dCas9 directs these enzymes specifically to target regions of the genome. This allows researchers to alter chromatin structure (i.e., change gene expression) without directly modifying the underlying DNA sequence itself.  This concept is further expanded by CRISPRi and CRISPRa, which utilize dCas9 to either repress or activate gene transcription respectively, through targeted binding to RNA polymerase or transcription factors.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.16	 CRISPR-CAS9 | Sub-subsection: 3.16.3	 Application | Content: The CRISPR-Cas9 system is unique due to its ability to
induce double-strand breaks in almost any type of organism
or cell type. The system is more accurate, providing an alter­
native to previous genome editing tools, such as zinc finger
nucleases (ZFNs) and transcriptional activator-like effector
nucleases (TALENs) [178]. The technology is an efficient
genome editing system that can detect, manipulate, and
annotate from diverse species-specific DNA sequences. The
system is mainly used for studying DNA because manipulat­
ing RNA is difficult due to the lack of a PAM sequence,
requiring efficient RNA targeting tools. The most wide­
spread application of the CRISPR-CAS system has been in
the context of genome editing of DNA, achieved through
three mechanisms: (1) nonhomologous end joining, (2)
single-­base editing enzymes, and (3) homology-directed
repair for DNA repair. The system can be delivered virally
(adenovirus or lentivirus) or through nonviral mechanisms
(hydrodynamic injection, electroporation, nanoparticles, and
transposon carriers) and combined [178].
The technology can be applied to develop a better under­
standing of a specific gene function or the manipulation of
genetic material, as genetic sequences can be removed or
edited. For example, a select tissue type can undergo multi­
plex mutagenesis for high-throughput analysis to identify
cancer drivers or correction of a loss-of-function mutation;
likewise, gene knockout could be used to enhance a specific
cell type. Beyond gene editing, researchers have also used
the Cas9 unit for targeting purposes instead of catalytically,
known as the dead Cas9 (dCas9) [179]. For instance, epigen­
etic editing involves the alteration of the chromatin structure
without modifying the individual’s genomic sequence. The
dCas9 is fused to a functional DNA methylation or demeth­
ylation enzymes or DNA modifiers [179]. The same idea fol­
lows CRISPRi and CRISPRa, which repress and inhibit gene
expression. The CRISPRi uses the dCas9 to bind to the
DNA-blocking RNA polymerase and transcription factor
binding, while CRISPRa combines the dCas9 unit and
selects transcription factors targeting activating sequences.
Overall, these advancements provide new avenues to study
genetic mechanisms and demonstrate the applicational value
of CRISPR-Cas-based tools. It is being used with success in
the field of agriculture, therapeutics, food industries, and
more. The success of CRISPR has inspired efforts to discover
new systems for targeting nucleic acids, including those from
Cas9, Cas12, and Cas13 orthologues. The approach is gaining
traction for use across multiple fields of research.
3 Molecular Radiation Biology
154"
"Describe the key challenges associated with utilizing CRISPR-Cas9 technology for cancer treatment, focusing on aspects related to delivery methods and potential immune responses.","The application of CRISPR-Cas9 in cancer therapy faces several significant hurdles. Primarily, efficient delivery of the CRISPR-Cas9 components – including the Cas9 protein and guide RNA (sgRNA) – into target cells remains a substantial challenge. Traditional injection methods utilizing delivery vectors like adeno-associated viruses (AAVs) exhibit variable efficiencies dependent on the specific cell type and tissue being targeted. AAVs, while relatively safe and effective, are limited in their packaging capacity, typically holding around 5 kilobases (kB) of genetic information. This constraint is exacerbated by the requirement to include both the Cas9 protein and sgRNA, which collectively occupy approximately 4.2 kB. Consequently, incorporating additional elements such as reporter genes or fluorescent tags for enhanced tracking and monitoring – crucial for successful gene editing – is often difficult. 

Furthermore, the immune system poses a considerable obstacle. The human population has widespread exposure to bacteria from which Cas9 originates, leading to pre-existing immunity in many individuals. This can trigger T-cell responses against the Cas9 protein itself, potentially neutralizing its therapeutic effects. To mitigate this, research is exploring alternative Cas9 orthologues with reduced immunogenicity or investigating the use of immunosuppressant drugs during treatment. Finally, off-target effects – unintended mutations at sites other than the intended target – remain a concern and necessitate ongoing efforts to improve the precision of CRISPR-Cas9 systems.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.16	 CRISPR-CAS9 | Sub-subsection: 3.16.4	 Challenges | Content: As the field of CRISPR-Cas rapidly evolves, challenges have
emerged which have also been the focus of much research.
This is particularly in the context of development of treat­
ment modalities for cancer. Some hurdles that have been
identified are in relation to methods for effectively delivering
the technology into the host that ensures suppression of the
innate immune responses. Injection methods are tradition­
ally used to deliver CRISPR-Cas9 components to cells via
delivery vectors; however, the efficiencies of these injection
methods are dependent on the target cells and tissues.
Traditional delivery methods targeting cancer cells are not
yet efficient enough to be applied clinically. For CRISPR-­
Cas9 to be applied as a therapeutic tool in cancer treatment,
delivery must be more efficient and accurate which may
require novel delivery methods [180].
Apart from limitations with delivery methods, the deliv­
ery vehicle itself also prevents a challenge, as delivery
­vectors hold a limited amount of genomic material. The most
used delivery vehicle is adeno-associated virus (AAV) as it is
relatively safe and effective; however, this method has a lim­
ited packaging capacity due to its size, which restricts the
amount of genetic information that can be transferred to the
target cell or tissue. AAVs can contain roughly 5 kB of infor­
mation, while information for the Cas9 protein and the
sgRNA which must be included on the plasmid is roughly
4.2 kB in size. To offset this, current research is being done
to find smaller Cas9 orthologues, which in the future may
allow for more helpful elements to be added such as reporter
genes or fluorescent tags to support more successful gene
editing [179].
Immune responses to the Cas9 protein have also been
well documented in animal models, which presents an added
challenge to the clinical application of the CRISPR-Cas sys­
tem. A high prevalence of the human population has been
exposed to the bacteria from which the Cas9 protein origi­
nates, meaning that there is likely a large population with
preexisting immunity. While the implications of this are not
yet entirely clear, testing of Cas9 orthologues may be
required before CRISPR-Cas technology can be applied as a
therapeutic to prevent T-cell responses. Alternatively, immu­
nosuppressant drugs could potentially be used during treat­
ment [179]. Off-target effects of the CRISPR-Cas system,
such as mutations at undesired sites, also present a challenge.
Extensive research has been done to minimize these effects;
however, further investigation on increasing precision is
required to improve safety [181]. As these hurdles become
addressed, CRISPR-Cas9 will play a crucial role in medical
treatments, including the treatment of cancers, and will
effectively support gene therapy modalities (Box 3.31).
3.17"
"Radiation exposure can significantly alter epigenetic modifications within cells, specifically concerning DNA methylation, histone modifications, and the expression of microRNAs, long noncoding RNAs, and circular RNAs. Explain how these changes contribute to cellular radiation response and potentially influence radiosensitivity.","Radiation induces a cascade of alterations in epigenetic mechanisms, primarily impacting gene expression and DNA repair processes. Specifically, it can modify DNA methylation patterns – adding or removing methyl groups from cytosine bases – which directly affects the accessibility of genes for transcription. Similarly, radiation influences histone modifications, such as acetylation and deacetylation, altering chromatin structure and consequently influencing gene expression levels. MicroRNAs (miRNAs), typically 21-25 nucleotides long, are highly conserved noncoding RNAs that regulate gene expression by binding to messenger RNA molecules, leading to their degradation or translational repression. Radiation exposure can dramatically shift miRNA expression profiles, targeting genes involved in critical DNA damage repair pathways like nucleotide excision repair and homologous recombination. Long noncoding RNAs (lncRNAs), exceeding 200 nucleotides, play a multifaceted role in regulating gene transcription, stability, and translation; radiation-induced deregulation of lncRNA expression disrupts these processes, interfering with established cellular responses to radiation. Circular RNAs (circRNAs), formed through backsplicing of pre-mRNA, are also affected by irradiation, contributing to the overall cellular response and sensitivity. Furthermore, the generation of extracellular vesicles (EVs) – including exosomes – is upregulated following radiation exposure in both normal and cancer cells. These EVs carry RNA species, DNA fragments, proteins, and lipids that can be transferred to neighboring cells, potentially mediating bystander effects or influencing distant tissue responses, particularly in cancer metastasis. The complex interplay between these epigenetic changes and EV-mediated communication represents a significant factor determining cellular radiosensitivity.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Content: effectively support gene therapy modalities (Box 3.31).
3.17
Epigenetic Factors
DNA methylation, histone modifications, and incorporation
of histone variants are chemical alterations of the cellular
DNA. Such changes are not necessarily permanent and can
be influenced by endogenous and exogenous stressors. One
of these stressors is radiation. Radiation induces various
alterations in these epigenetic modifications, mainly affect­
ing gene expression and DNA repair.
MicroRNAs are small, highly conserved noncoding RNA
molecules that regulate gene expression. They are single-­
stranded RNA transcripts with a length of 21–25 nucleotides
that are derived from hairpin loop precursors. miRNAs affect
the cellular radiation response via regulation of vital genes
involved in DNA damage repair, cell cycle checkpoints,
autophagy, and apoptosis.
Long noncoding RNAs (lncRNAs) are defined as RNA
transcripts with a length of more than 200 nucleotides miss­
ing a distinct protein-coding region. lncRNAs regulate gene
expression on multiple levels, including transcription, RNA
stability, and translation. Radiation exposure deregulates
lncRNA expression, which affects radiosensitivity by inter­
fering with canonical radiation response pathways, such as
cell cycle control, DNA repair, and cell death induction.
Circular RNAs (circRNAs) are a recently described class
of RNA molecules that are derived from precursor mRNA
(pre-mRNA) in a process called backsplicing. Despite
increasing attention, the number of studies investigating the
direct effect of ionizing radiation on circRNA expression is
still very limited. However, it is now evident that circRNAs
are affected by irradiation and that they are important players
in the cellular radiation response and sensitivity.
Box 3.31 In a Nutshell: CRISPR-Cas
•	CRISPR-Cas system is a defense mechanism that
has been identified in prokaryotes that effectively
acts to fight viruses.
•	CRISPR are fragments of RNA that are cloned from
the DNA of viruses that have infected a bacteria.
•	Cas9 is a DNA endonuclease that can edit genes.
•	Together, CRISPR-Cas9 is an efficient genome
editing system that can detect, manipulate, and
annotate from diverse species-specific DNA
sequences.
•	It can be applied to develop a better understanding
of a specific gene function or the manipulation of
genetic material, as genetic sequences can be
removed or edited.
J. Reindl et al.
155
Extracellular vesicles (EVs) are generated by all cells
within our body and are important communicators in normal
and cancer cells. EVs have different sizes ranging from
40 nm up to several μm and are produced via different bio­
genesis routes. EVs’ cargo contains various RNA species,
DNA fragments, proteins, and lipids partly reflecting their
cell of origin. EVs may influence neighboring cells via their
cargo but also act in distant tissue as illustrated in cancer,
where they play a role in both carcinogenesis and metastasis.
Exosomes are a particular type of EVs formed by viable cells
via the endosomal system, and there are specific cellular
mechanisms that determine their cargo. Upon radiation, EVs
are generated by both normal and cancer cells and transmit
effects in irradiated and nonirradiated cells (e.g., bystander
or non-targeted effects). EVs may constitute a source of bio­
markers for diseases and stress conditions, including
radiation."
"Describe the mechanisms involved in DNA methylation and histone modifications, including the enzymes responsible for their establishment, maintenance, and removal, and how these processes contribute to gene regulation.","DNA methylation and histone modifications are crucial epigenetic mechanisms that influence gene expression without altering the underlying DNA sequence. DNA methylation involves the addition of methyl groups to cytosine bases, primarily at CpG sites – regions containing a guanine nucleotide adjacent to a cytosine. This process is catalyzed by DNA methyltransferases (DNMTs), with DNMT1 acting as a maintenance enzyme, faithfully copying existing methylation patterns during replication, while DNMT3a/b are responsible for establishing new methylation marks. Conversely, DNA demethylation is carried out by enzymes that remove these methyl groups. Histone modifications involve covalent changes to histone proteins, impacting chromatin structure and gene accessibility. These modifications include acetylation (which generally promotes euchromatin and gene activation), methylation (with H3K4me3 associated with active promoters and H3K9me3/H3K27me3 linked to repressed genes), phosphorylation, ubiquitination, and others like GlcNAcylation. Enzymes specifically target these histone residues for modification or removal. The dynamic nature of these modifications – their addition and removal by specific enzymes – allows cells to respond to internal and external stressors, contributing significantly to gene regulation and phenotypic changes.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.1	 DNA and Histone Modifications | Content: Modifications of DNA bases and histone proteins, including
the incorporation of histone variants, have important func­
tions in the epigenetic control of gene expression. Both types
of alterations add further information to the DNA molecule
in addition to the genetic code, which contribute to pheno­
typic changes without altering the DNA sequence.
Importantly, such changes are not necessarily permanent and
can be influenced by endogenous and exogenous stressors.
Enzymes that add, recognize, and dislodge DNA and histone
modifications are called writers, erasers, and readers. The
generation of modifications is facilitated by writers. Erasers
modify and/or remove labels. Readers recognize and associ­
ate to modifications [182].
The methylation of DNA is a heritable epigenetic label in
dividing cells. Methylation of DNA segments typically
induces its silencing, while demethylation is characteristic
for actively transcribed regions. Possible mechanisms for
these effects are the binding of methyl-DNA-binding pro­
teins, which affect gene activity or alterations of the chroma­
tin structure. In mammals, DNA methylation patterns are
retained or established by DNA methyltransferases (DNMTs)
that catalyze the addition of methyl groups to nucleotides.
S-Adenyl methionine (SAM) acts as a methyl group donor.
DNMT1 function is the maintenance of methylation, and
DNMT3a/b is responsible for de novo methylation. On the
other hand, DNA demethylases can catalyze active demeth­
ylation. Most of DNA methylation takes place at cytosines,
which are succeeded by a guanine nucleotide (CpG sites).
Regions (>200 nucleotides and CG content >50%) with a
high frequency of CpG sites are called CpG islands. Promotor
sequences are often located within such CpG islands.
Methylation of CpG islands silences gene expression, for
example by impeding the binding of transcription factors or
by recruitment of repressive methyl-binding proteins. The
most common modification of DNA bases is the methylation
of cytosine on carbon position 5, leading to 5-methylcytosine
(5-mC). This modification accounts for approximately 1% of
all bases and is therefore sometimes designated as the fifth
base of the DNA. Further less abundant modifications are for
example 5-hydroxymethylcytosine, 5-carboxycytosine, and
6-methyladenine.
Histone modifications are covalent modifications joined
to histone proteins. These modifications impair DNA-histone
interactions, thereby changing chromatin architecture and
gene expression. Some reduce DNA-histone interactions
leading to nucleosome unwinding, chromatin opening, and
increased accessibility for the transcription machinery lead­
ing to the activation of gene expression (euchromatin).
Others increase DNA-histone interactions, leading to tightly
packed chromatin followed by reduced access of the tran­
scription machinery and thus gene silencing (heterochroma­
tin). Currently, acetylation, methylation, phosphorylation,
and ubiquitination are the most well understood, while oth­
ers, like GlcNAcylation, citrullination, crotonylation, and
isomerization, are more recent discoveries. All of these mod­
ifications are highly dynamic and added to or removed from
histone amino acid residues by specific sets of enzymes. A
well-described posttranslational histone modification is the
trimethylation of histone H3 on the lysine located at position
4 of the protruding N-terminal tail (H3K4me3), which is cor­
related with promoters of actively transcribed genes. In con­
trast, the trimethylation of lysine on positions 9 (H3K9me3)
and 27 (H3K27me3) is a heterochromatin mark, associated
with repressed genes.
In addition to posttranslational modifications, the histone
structure of the chromatin can also be influenced by the
incorporation of histone variants. Histone variants are low
abundant and differ only in one or a few amino acids with
their canonical counterparts. They are produced throughout
the cell cycle and can be deposited into chromatin indepen­
dent of replication by rapid exchange processes. Histone
variants seem to be especially important for protecting
genome integrity by the regulation of damaged chromatin
accessibility and restoration.
3.17.1.1
DNA and Histone Modifications
in the Context of Radiation
Both DNA methylation and histone modifications are essen­
tial components in the cellular stress response. Therefore, it
is not surprising that various alterations are reported after
radiation exposure. On a molecular level, radiation-induced
alterations in histone and DNA modifications either are
required for the efficient detection and repair of DNA dam­
age to avoid chromosomal instability or lead to changes in
transcriptional activity and thereby alter a variety of cellular
3 Molecular Radiation Biology"
"Describe the key modifications that can occur to DNA bases and histones, explaining how these changes impact chromatin structure and gene expression. Specifically, detail examples such as methylation of CpG islands, histone acetylation/methylation, and the role of histone variants.","Chromatin architecture and gene expression are profoundly influenced by dynamic modifications to both DNA bases and histone proteins. DNA base modifications primarily involve methylation – most commonly cytosine at position 5 (forming 5-methylcytosine or 5-mC), but also derivatives like 5-hydroxymethylcytosine, 5-carboxycytosine, and 6-methyladenine. These methylations can impede transcription factor binding or recruit repressive methyl-binding proteins, leading to gene silencing – a process termed epigenetic silencing. Histone modifications, conversely, directly alter DNA-histone interactions. Acetylation of histones, particularly histone H3 at lysine 9 (H3K9ac), generally promotes chromatin opening and euchromatin formation by reducing DNA-histone interactions, facilitating transcription. Conversely, methylation of histones like H3 at lysine 9 (H3K9me3) or lysine 27 (H3K27me3) leads to heterochromatin formation through increased DNA-histone interactions, effectively silencing gene expression. Beyond simple additions and removals, histone variants play a crucial role. These low-abundance proteins differ slightly from their canonical counterparts and are incorporated into chromatin independently of replication. For example, the incorporation of histone variant H2A-Z.2 following DNA double-strand breaks (DSBs) aids in recombinational repair by facilitating RAD51 foci formation. Similarly, H2A-Z.2 accumulation during radiation-triggered senescence is linked to the histone variant H2A.J and its influence on inflammatory gene expression. These modifications are highly dynamic, regulated by specific enzymes that add or remove these marks from histone amino acid residues, constantly adjusting chromatin structure and gene expression in response to cellular signals and environmental stimuli. ","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.1	 DNA and Histone Modifications | Sub-sub-subsection: 3.17.1.1	 DNA and Histone Modifications in the Context of Radiation | Content: Methylation of CpG islands silences gene expression, for
example by impeding the binding of transcription factors or
by recruitment of repressive methyl-binding proteins. The
most common modification of DNA bases is the methylation
of cytosine on carbon position 5, leading to 5-methylcytosine
(5-mC). This modification accounts for approximately 1% of
all bases and is therefore sometimes designated as the fifth
base of the DNA. Further less abundant modifications are for
example 5-hydroxymethylcytosine, 5-carboxycytosine, and
6-methyladenine.
Histone modifications are covalent modifications joined
to histone proteins. These modifications impair DNA-histone
interactions, thereby changing chromatin architecture and
gene expression. Some reduce DNA-histone interactions
leading to nucleosome unwinding, chromatin opening, and
increased accessibility for the transcription machinery lead­
ing to the activation of gene expression (euchromatin).
Others increase DNA-histone interactions, leading to tightly
packed chromatin followed by reduced access of the tran­
scription machinery and thus gene silencing (heterochroma­
tin). Currently, acetylation, methylation, phosphorylation,
and ubiquitination are the most well understood, while oth­
ers, like GlcNAcylation, citrullination, crotonylation, and
isomerization, are more recent discoveries. All of these mod­
ifications are highly dynamic and added to or removed from
histone amino acid residues by specific sets of enzymes. A
well-described posttranslational histone modification is the
trimethylation of histone H3 on the lysine located at position
4 of the protruding N-terminal tail (H3K4me3), which is cor­
related with promoters of actively transcribed genes. In con­
trast, the trimethylation of lysine on positions 9 (H3K9me3)
and 27 (H3K27me3) is a heterochromatin mark, associated
with repressed genes.
In addition to posttranslational modifications, the histone
structure of the chromatin can also be influenced by the
incorporation of histone variants. Histone variants are low
abundant and differ only in one or a few amino acids with
their canonical counterparts. They are produced throughout
the cell cycle and can be deposited into chromatin indepen­
dent of replication by rapid exchange processes. Histone
variants seem to be especially important for protecting
genome integrity by the regulation of damaged chromatin
accessibility and restoration.
3.17.1.1
DNA and Histone Modifications
in the Context of Radiation
Both DNA methylation and histone modifications are essen­
tial components in the cellular stress response. Therefore, it
is not surprising that various alterations are reported after
radiation exposure. On a molecular level, radiation-induced
alterations in histone and DNA modifications either are
required for the efficient detection and repair of DNA dam­
age to avoid chromosomal instability or lead to changes in
transcriptional activity and thereby alter a variety of cellular
3 Molecular Radiation Biology
156
processes, including cell cycle regulation, DNA repair, and
cell death induction. At organism level, epigenomic altera­
tions were reported in various radiation-induced cancer and
non-cancer diseases. As epigenomic alterations can be trans­
ferred to the offspring also, the contribution to radiation-­
induced transgenerational effects was recently suggested
[183, 184].
Altered DNA methylation patterns were found in in vitro
and in vivo studies in response to irradiation. The majority of
studies showed global hypomethylation, which was often
linked with a reduced expression of enzymes involved in
DNA methylation. As global hypomethylation is connected to
malignant transformations, radiation-impaired DNA methyl­
ation may contribute to cancer development. However, hypo­
methylation is not always evenly dispersed across the genome
and also radiation-induced hypermethylation was reported
for specific loci. Interestingly, new studies imply that low-
and high-LET radiations affect methylation differentially.
A variety of radiation-induced histone modifications
affecting transcriptional regulation and particularly DNA
repair are described. In regard to DNA repair, an intensively
studied histone modification is the phosphorylation of the
histone H2A variant H2AX at serin-139 (phosphorylated
H2AX is designated as γ-H2AX) at sites of DNA double-­
strand breaks (DSBs). Formation of γ-H2AX is an initial
response after exposure and facilitates a cascade of further
histone modifications, including ubiquitination of H2A/H2B
as well as changes in the acetylation of H3 and H4. Together,
these posttranslational histone modifications contribute to
chromatin relaxation that enables the accession of DNA
repair factors and influences the repair pathway choice.
Moreover, the γ-H2AX modification is widely used as a bio­
marker for DSBs, and a lot of methods were developed to use
γ-H2AX counting for DSB quantification.
With the knowledge about DNA methylation and histone
modification in radiation response, the targeted modulation
of these features is investigated as a novel strategy to radio­
sensitize tumor cells during radiotherapy. For example,
radiosensitizing activity was shown for DNA demethylation
agents, like cytidine analogs. In addition, small-molecule
inhibitors of histone deacetylases changing histone acetyla­
tion showed the potential to alter radiosensitivity.
The first studies in this field also demonstrated an
exchange of histone variants in response to radiation expo­
sure. For example, it was shown that the histone variant
H2A-Z.2 is incorporated into chromatin immediately after
DSB induction, where it contributes to recombinational
repair by assisting RAD51 foci formation. In line, H2A-Z.2
U2OS tumor cells were shown to be more radiosensitive than
controls. H2A.J, another histone variant, accumulates during
radiation-triggered senescence processes in the vicinity of
53BP1 foci and affects the expression of inflammatory genes
(Box 3.32)."
"Describe the role of microRNAs (miRNAs) in gene regulation, including their mechanism of action and the complexity of their targeting capabilities.","MicroRNAs (miRNAs) are small, highly conserved noncoding RNA molecules that play a crucial role in regulating gene expression. They function primarily through competitive partial binding to the 3’ untranslated region (UTR) of target messenger RNAs (mRNAs). This interaction inhibits translation – preventing protein synthesis – and can also trigger mRNA degradation, effectively silencing the targeted gene. However, miRNA regulation is far more complex than this simple model. Each miRNA molecule can potentially bind to multiple different target mRNAs, while a single target mRNA can be regulated by numerous distinct miRNAs. This creates a highly interconnected network of regulatory interactions, influencing roughly 60% of all protein-coding genes according to estimations. Furthermore, miRNAs can interact with the 5’ UTR, coding regions, and gene promoters through complementary sequence binding. The multifaceted nature of miRNA regulation contributes significantly to cellular homeostasis, stress responses, and is implicated in a range of diseases. Beyond their intracellular roles, extracellular miRNAs are also found in physiological fluids like plasma, saliva, and urine, demonstrating an additional layer of regulatory control and potential for intercellular communication via microvesicle transfer.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.2	 MicroRNAs | Content: controls. H2A.J, another histone variant, accumulates during
radiation-triggered senescence processes in the vicinity of
53BP1 foci and affects the expression of inflammatory genes
(Box 3.32).
3.17.2	MicroRNAs
MicroRNAs are small, highly conserved noncoding RNA
molecules that regulate gene expression. They are single-­
stranded RNA transcripts with a length of 21–25 nucleotides
that are derived from hairpin loop precursors. The basic
mode of action of miRNAs is competitive partial binding
with the 3′ UTR of the target mRNA, which inhibits transla­
tion and/or leads to mRNA destruction. MiRNAs have also
been shown to interact with the 5′ UTR, coding regions, and
gene promoters via binding complementary sequences [185].
Because each miRNA can act on multiple different target
genes, and one target gene can be regulated by many differ­
ent miRNAs, the miRNA-mediated regulation of cellular
phenotype is highly complex. miRNA-mediated regulation
is thought to affect roughly 60% of all protein-coding genes,
according to estimations. To regulate miRNA abundance at
the levels of transcription, maturation, and stability, cells
have evolved various sophisticated methods to govern such
extensive miRNA-mediated functions. miRNA actions have
been linked to the regulation of a variety of cellular pro­
cesses, including cellular homeostasis and stress responses.
Furthermore, they have been linked to a variety of diseases.
miRNAs, in addition to their intracellular roles, are also
found in the extracellular environment. miRNAs can be iden­
tified in physiological fluids such as plasma, saliva, and
urine. This extracellular miRNA population is varied and
heterogeneous. Although the activities of extracellular miR­
NAs are not completely understood, it has been demonstrated
that extracellular microvesicle-embedded miRNAs can be
transferred and incorporated into destination cells [186].
3.17.2.1"
Describe the characteristics of long noncoding RNAs (lncRNAs) and explain their potential mechanisms for maintaining nuclear localization within eukaryotic cells.,"Long noncoding RNAs (lncRNAs) are RNA transcripts exceeding 200 nucleotides in length that lack a protein-coding sequence. They occupy diverse genomic locations, including intergenic regions, introns, exons, and can exist in various orientations – sense, antisense, bidirectional – sometimes overlapping with genes [194]. The estimated number of lncRNA transcripts in humans is significantly higher than that of protein-coding mRNAs (30,000–60,000 compared to 20,000–25,000), reflecting their abundance and complexity. Their biogenesis largely mirrors that of mRNA production – transcription by RNA polymerase II followed by 5′-end capping and 3′ poly-A-tailing – but lncRNAs are often less efficiently processed and frequently remain within the nucleus. Several mechanisms contribute to nuclear retention, including weak splicing signals, cis-acting regulatory elements, and trans-acting motifs that facilitate tethering or degradation on chromatin. Furthermore, interactions with specific proteins can promote their localization to particular genomic regions. The cytoplasm also plays a role; a substantial proportion of lncRNAs are found there, potentially being sorted to specific cellular compartments via mechanisms not yet fully understood. Reference: [Book Title], Section 3.17.3 – Long Noncoding RNAs","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.3	 Long Noncoding RNAs | Content: 3.17.3.1
lncRNA basics
Long noncoding RNAs (lncRNAs) are defined as RNA tran­
scripts with a length of more than 200 nucleotides missing a
distinct protein-coding region. In the genome, they are
located in intergenic, intronic, and exonic regions as well as
sense, antisense, and bidirectional with transcripts overlap­
ping sometimes genes [194]. In humans, 30,000–60,000
long noncoding transcripts are estimated compared to
20,000–25,000 protein-coding mRNA transcripts. Details
about the biogenesis and functions of lncRNAs are very well
summarized by Statello and colleagues [195]. In principle,
the biogenesis of most lncRNAs corresponds to the produc­
tion of mRNAs with transcription by RNA polymerase II and
subsequent 5′-end capping and 3′ poly-A-tailing. In com­
parison to mRNAs, lncRNAs are less efficiently processed
and often remain in the nucleus. As mechanisms for nuclear
retention, tethering, or degradation on chromatin, weak
splicing signals and cis- and trans-acting motifs are sug­
gested. However, a substantial proportion of lncRNAs is dis­
tributed to the cytoplasm, where they can be sorted to specific
Box 3.33 In a Nutshell: MicroRNAs as Epigenetic Factor
•	miRNAs are small, highly conserved noncoding
RNA molecules that regulate gene expression.
•	miRNAs can be identified in physiological fluids
such as plasma, saliva, and urine.
•	miRNAs have been identified as biomarkers for
radiation injury and countermeasure efficacy.
•	miRNAs affect the cellular radiation response via
regulation of vital genes involved in DNA damage
repair, cell cycle checkpoints, autophagy, and
apoptosis.
J. Reindl et al."
"Describe the key characteristics that define long noncoding RNAs (lncRNAs) and explain how their biogenesis and localization differ from protein-coding mRNAs. Furthermore, detail at least three distinct mechanisms by which lncRNAs can influence gene expression.","Long noncoding RNAs (lncRNAs) are defined as RNA transcripts exceeding 200 nucleotides in length that lack a traditional open reading frame for protein synthesis – meaning they don’t encode proteins. They are found within genomic regions including intergenic, intronic, and exonic spaces, as well as in various orientations like sense, antisense, and bidirectional arrangements where transcripts may overlap genes [194]. The estimated number of lncRNAs in humans (30,000–60,000) is significantly higher than the number of protein-coding mRNA transcripts (20,000–25,000). Their biogenesis mirrors that of mRNAs – transcription by RNA polymerase II followed by 5′-end capping and 3′ poly-A-tailing. However, lncRNAs are often less efficiently processed and frequently remain within the nucleus due to weak splicing signals and chromatin tethering mechanisms. A notable proportion also translocate to the cytoplasm, where they can be sorted into organelles like mitochondria or exosomes, associate with RNA-binding proteins, or assemble with ribosomes. 

lncRNAs exert their influence on gene expression through several distinct mechanisms. First, they can act as ‘cis’ regulators by directly interacting with DNA, modulating chromatin structure – either promoting or inhibiting access to target genes via changes in chromatin accessibility – and recruiting or sequestering chromatin-modifying proteins near promoters. Second, lncRNAs can function as ‘trans’ regulators by influencing gene expression at distant locations within the genome, potentially affecting transcription rates of multiple genes simultaneously. Third, they participate in posttranscriptional regulation through various interactions with RNA molecules. This includes direct base pairing with mRNA transcripts to recruit protein complexes involved in mRNA degradation or promoting polysome association (enhancing translation), and crucially, sequestering microRNAs (miRNAs) – effectively neutralizing their inhibitory effects on target mRNAs by acting as ‘sponge’ ceRNAs [=competitive endogenous (ce) RNAs].  These multifaceted roles highlight lncRNAs' importance in regulating diverse physiological processes like differentiation, growth, and responses to stress.

Reference: 3.17.3.1","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.3	 Long Noncoding RNAs | Sub-sub-subsection: 3.17.3.1	 lncRNA basics | Content: 3.17.3.1
lncRNA basics
Long noncoding RNAs (lncRNAs) are defined as RNA tran­
scripts with a length of more than 200 nucleotides missing a
distinct protein-coding region. In the genome, they are
located in intergenic, intronic, and exonic regions as well as
sense, antisense, and bidirectional with transcripts overlap­
ping sometimes genes [194]. In humans, 30,000–60,000
long noncoding transcripts are estimated compared to
20,000–25,000 protein-coding mRNA transcripts. Details
about the biogenesis and functions of lncRNAs are very well
summarized by Statello and colleagues [195]. In principle,
the biogenesis of most lncRNAs corresponds to the produc­
tion of mRNAs with transcription by RNA polymerase II and
subsequent 5′-end capping and 3′ poly-A-tailing. In com­
parison to mRNAs, lncRNAs are less efficiently processed
and often remain in the nucleus. As mechanisms for nuclear
retention, tethering, or degradation on chromatin, weak
splicing signals and cis- and trans-acting motifs are sug­
gested. However, a substantial proportion of lncRNAs is dis­
tributed to the cytoplasm, where they can be sorted to specific
Box 3.33 In a Nutshell: MicroRNAs as Epigenetic Factor
•	miRNAs are small, highly conserved noncoding
RNA molecules that regulate gene expression.
•	miRNAs can be identified in physiological fluids
such as plasma, saliva, and urine.
•	miRNAs have been identified as biomarkers for
radiation injury and countermeasure efficacy.
•	miRNAs affect the cellular radiation response via
regulation of vital genes involved in DNA damage
repair, cell cycle checkpoints, autophagy, and
apoptosis.
J. Reindl et al.
161
organelles (e.g., mitochondria and exosomes) or they associ­
ate with diverse RNA-binding proteins. A considerable
amount of lncRNAs assembles with ribosomes.
Initially, lncRNAs were considered as transcription by-­
products, but meanwhile important cellular functions are
described for an accumulating number of lncRNAs. In gen­
eral, lncRNAs are regulators of gene expression, which inter­
act with DNA, RNA, and proteins on various levels. There
are examples for both lncRNAs acting locally at the site of
transcription (cis-acting) and lncRNAs leaving the site of
transcription (trans-acting). To activate or suppress gene
transcription, lncRNAs can regulate chromatin structure to
change their accessibility or sequester chromatin-modifying
proteins from or to the promoters of target genes. In addition
to their roles in transcription regulation and nuclear organi­
zation, lncRNAs are involved in posttranscriptional regula­
tion. This can occur by the association between lncRNAs
and RNA processing proteins, resulting in altered mRNA
splicing and turnover. Other lncRNAs can directly base pair
with RNAs and subsequently recruit proteins involved in
mRNA degradation or they support translation by promoting
polysome association. Also, the binding between lncRNAs
and microRNAs can regulate gene expression as miRNAs
are sequestered from their target mRNAs by binding to an
lncRNA [=sponge or competitive endogenous (ce) RNA]
and thus abolish the inhibitory effect of miRNAs on mRNAs.
Through their manifold impacts on the regulation of gene
expression, lncRNAs affect widespread aspects of physiol­
ogy, including differentiation, growth, and responses to
diverse stimuli and stresses.
3.17.3.2"
"Describe the multifaceted roles of long noncoding RNAs (lncRNAs) in mediating cellular responses to ionizing radiation, providing specific examples of how different lncRNAs can either enhance or diminish radiosensitivity.","Long noncoding RNAs (lncRNAs), defined as transcripts exceeding 200 base pairs and not translated into proteins, play a significant role in modulating the cellular response to ionizing radiation. Following irradiation, their expression levels are frequently altered, contributing to both increased and decreased radiosensitivity depending on the specific lncRNA involved. For instance, HOTAIR, observed in breast cancer models, demonstrates an ability to increase radioresistance by interfering with DNA damage repair pathways; it targets miR-218 and miR-449b-5p, thereby reducing their activity. Conversely, in pancreatic ductal adenocarcinoma (PDAC), radiation induces the expression of HOTAIR, which subsequently promotes radiosensitivity through increased autophagosome formation via upregulation of LC3-II and ATG7A proteins and the induction of WIF-1. PVT1’s impact is similarly dualistic; it enhances radioresistance in nasopharyngeal cancer by stabilizing HIF-1α and contributing to NF90 transcription, while knockdown leads to reduced ATM, p53, and CHK2 phosphorylation, resulting in increased radiosensitivity due to diminished DNA damage signaling and heightened apoptosis. MALAT1 exhibits a context-dependent role: downregulation after radiation enhances radioresistance in esophageal squamous cell carcinoma by inhibiting Cks1 expression and decreasing irradiation-induced apoptosis; however, overexpression of MALAT1 in cervical cancer cells directly interacts with miR-145 to promote radiation-induced apoptosis. These diverse actions highlight lncRNAs’ capacity to intricately regulate critical cellular pathways involved in the radiation response – including cell cycle control, DNA damage repair, and apoptosis – making them potential targets for modulating therapeutic outcomes. Reference: [Molecular Radiation Biology], Section 3.17.3.2, lncRNAs in Radiation Response.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.3	 Long Noncoding RNAs | Sub-sub-subsection: 3.17.3.2	 lncRNAs in Radiation Response | Content: lncRNAs are involved in many aspects of cellular response
to radiation. For a detailed overview, see May et al. [196] and
Podralska et al. [193]. Firstly, radiation affects the expres­
sion levels of a plethora of lncRNAs in cancer and non-­
cancer tissues and both up- and downregulation are reported.
Radiation-triggered changes are also reported for a wide
dose range including low doses (below 100 mGy) as well as
therapeutically relevant doses and for single and chronic
treatments. The functional relevance in radiation response
was shown for a considerable number of lncRNAs, where
some enhance radiosensitivity and others increase radiore­
sistance. The affected pathways cover crucial pathways of
cellular radiation response, such as cell cycle control, DNA
damage repair, and apoptosis. As the mechanism during radi­
ation response of action, frequently, the sponging of microR­
NAs by lncRNAs and thereby promoting of the expression of
target genes are described.
The broad effects of irradiation on lncRNAs suggest valu­
able applications of this class of RNAs. Applications of bio­
markers for radiation exposure may be important for
biodosimetry or markers for normal tissue effects and radio­
therapy response. Moreover, in vitro and in vivo studies
demonstrated that modulation of the levels of lncRNAs can
significantly enhance radiosensitivity of tumor cells. This
suggests that lncRNAs may be used as targets to improve the
outcome of radiotherapy in the future.
Prominent examples for lncRNAs with multiple roles in
radiation response are HOTAIR, PVT1, and MALAT1. In
breast cancer models, HOTAIR has been shown to increase
radioresistance through interfering with DNA damage repair
by targeting miR-218 and miR-449b-5p. In pancreatic ductal
adenocarcinoma (PDAC), HOTAIR was induced by radia­
tion, while a knockdown increased radiosensitivity. The
knockdown increased the expression of Wnt inhibitory factor
1 (WIF-1), which was shown to enhance radiosensitivity.
HOTAIR also promoted radiosensitivity of PDAC by increas­
ing autophagosome formation through increasing LC3-II
and ATG7A proteins. In cervical cancer, knockdown of
HOTAIR increased radiosensitivity by the induction of a G1
cell cycle-phase arrest.
PVT1 contributes to NF90 transcription and HIF-1α sta­
bilization in nasopharyngeal cancer, resulting in enhanced
radioresistance. On the other hand, the knockdown of PVT1
resulted in reduced phosphorylation of ATM, p53, and CHk2
leading to increased radiosensitivity by decreased DNA
damage signaling and increased apoptosis. In non-small cell
lung cancer, PVT knockdown increases radiosensitivity by
sponging miR-195.
lncRNA MALAT1 was downregulated after radiation in
esophageal squamous cell carcinoma, and its overexpression
enhanced radioresistance. It was shown that MALAT1 inhib­
ited the downregulation of cyclin-dependent kinase subunit
(Cks1), which resulted in a decrease in irradiation-induced
apoptosis. MALAT1 also affected IR-induced apoptosis by
interacting with miRNAs. In nasopharyngeal cancer cells,
MALAT1 associated to miR-1, which led to increased levels
of the anti-apoptotic protein SLUG. In cervical cancer cells,
MALAT1 directly interacted with miR-145 to affect
radiation-­induced apoptosis (Box 3.34).
Box 3.34 In a Nutshell: Long Non-coding RNAs as
Epigenetic Factor
•	Long noncoding RNAs (lncRNAs) are transcripts
>200 bp, which are not translated into proteins.
•	lncRNAs regulate gene expression on multiple lev­
els, including transcription, RNA stability, and
translation.
•	lncRNA expression is deregulated after radiation
exposure, and they affect radiosensitivity by inter­
fering with canonical radiation response pathways,
such as cell cycle control, DNA repair, and cell
death induction.
3 Molecular Radiation Biology
162"
"Describe the process of circular RNA (circRNA) biogenesis, highlighting the role of the RNA-binding protein quaking (QKI) and its connection to epithelial-to-mesenchymal transition (EMT). Furthermore, explain how radiation exposure can influence circRNA expression patterns.","Circular RNAs are generated through a process called backsplicing, where a spliceosome joins a splice donor with an upstream splice acceptor within a pre-mRNA molecule, creating a covalently closed RNA structure resistant to exonucleases. This stability allows for accumulation of circRNAs exceeding that of their linear counterparts. The biogenesis is often facilitated by RNA-binding proteins like quaking (QKI). QKI binds to specific motifs in introns adjacent to circle-forming exons, forming a dimer and bringing these exons into proximity for splicing. Elevated expression of QKI, particularly during epithelial-to-mesenchymal transition (EMT), triggers the increased production of numerous circRNAs. EMT, frequently induced by irradiation, results in radiation-resistant mesenchymal cells, suggesting a link between QKI-regulated circRNAs and radiation responses. Studies have shown that gamma irradiation can dramatically alter circRNA expression profiles in cell lines like HEK293-T, identifying over 150 differentially expressed circRNAs. Research has also demonstrated the involvement of circRNAs derived from genes within the p53 pathway following radiation exposure, with variations observed depending on cell type and potential enrichment in exosomes.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.4	 Circular RNAs | Content: Circular RNAs (circRNAs) are a recently described class of
RNA molecules that are derived from precursor mRNA (pre-­
mRNA) in a process called backsplicing. During this pro­
cess, which is regulated by the spliceosome, a splice donor is
joined to an upstream splice acceptor. This generates a cova­
lently closed RNA molecule, which is typically resistant to
degradation by exonucleases, and therefore circRNAs are in
general biologically more stable compared to their linear
counterparts. Although most circRNAs are expressed in rela­
tively low levels, their increased stability can result in accu­
mulation to levels far exceeding those of their cognate linear
mRNAs [197]. This is for instance observed during aging,
which led to the hypothesis that certain circRNAs may repre­
sent biomarkers for aging tissues (such as the brain) and
aging-associated diseases. Recent studies even implicate cir­
cRNAs as causative factors in aging and cellular senescence
[198]. Since irradiation and excessive DNA damage are
often proposed as inducers of senescence and accelerated
aging, radiation-responsive circRNAs may contribute to
these longer term effects of radiation exposure.
3.17.4.1
Biogenesis and Functions
A detailed description of the biogenesis and function of cir­
cRNAs is beyond the scope of this chapter; we therefore
refer the readers to some excellent reviews about these sub­
jects [198] and will only briefly discuss matters that may
directly relate to DNA damage and radiation.
Unlike original views that circRNAs are no more than
aberrant by-products of normal splicing, it has become
increasingly clear that they are often generated and function
independently from their linear cognates. One important
mechanism of circRNA biogenesis acts via the RNA-binding
protein quaking (QKI). QKI is an alternative splicing factor
that belongs to the STAR family of KH domain containing
RNA-binding proteins and binds to specific sequences (QKI-­
binding motifs) in pre-mRNA [199]. The proposed mecha­
nism for the role of QKI in circRNA biogenesis is that it
binds motifs in introns adjacent to the circle-forming exons
and subsequently forms a dimer to bring these exons into
close proximity for further processing by the splicing
machinery [200]. Importantly, QKI is expressed at low levels
in epithelial cells but is increased during epithelial-to-­
mesenchymal transition (EMT), when cells reprogram their
gene expression profiles resulting in the loss of intracellular
junctions, polarity, and cytoskeletal organization, ultimately
leading to a more migratory and invasive mesenchymal phe­
notype. The increase of QKI during EMT triggers the expres­
sion of hundreds of circRNAs [200]. EMT is a process which
can be induced by irradiation, and very often the mesenchy­
mal cells display a more radiation-resistant phenotype, high­
lighting the relevance of EMT, and therefore QKI-regulated
circRNAs, for radiation and cancer biology.
Different functions for circRNAs have been identified,
including (1) binding and transportation of RNA-binding
proteins; (2) generation of protein isoforms; and (3) regula­
tors of transcription and alternative splicing (e.g., Xiao et al.
[198]). However, the most established and investigated func­
tion of circRNAs is the regulation of microRNA expression
and subcellular localization via a sponging mechanism
(competing endogenous RNA, ceRNA). However, since
most circRNAs are expressed at only low levels, and they
usually contain only a limited number of microRNA-binding
sites, it is now clear that the function of microRNA sponges
or ceRNAs to regulate the expression of microRNA targets
cannot be generalized for many circRNAs [198].
An important consideration here is that studies often per­
form gene ontology enrichment analyses based on the func­
tions of the host genes of differentially expressed circRNAs.
However, since there is currently little evidence that cir­
cRNAs in general function in the same pathways as their
hosts, such analyses should be critically interpreted.
3.17.4.2
circRNAs, Radiation Exposure,
and Radiosensitivity
Despite increasing attention, the number of studies investi­
gating the direct effect of ionizing radiation on circRNA
expression is still very limited. On the other hand, there have
been quite some studies in which the differential expression
of circRNAs between radiation-sensitive and radiation-­
resistant cancer cell lines and patients was compared.
In HEK293-T cells, gamma irradiation (8 Gy, single dose)
resulted in very big differences in the expression of cir­
cRNAs between control and irradiated cells. Here, the
authors focused only on circRNAs detected under both
experimental conditions and identified a total of 158 differ­
entially expressed circRNAs. However, among 5592 detected
circRNAs in total, 2205 were detected uniquely in control
cells while 1026 circRNAs were uniquely found in irradiated
cells. This indicates that the differences were actually larger
than was reflected by the 158 that were considered to be dif­
ferentially expressed.
A study by O’Leary and co-workers investigated differen­
tial circRNA expression at 4 h and 24 h after exposure of
endothelial HUVECs to a medium (0.25 Gy) and high dose
(2.5 Gy) of g-rays [202]. Radiation-responsive circRNAs
were predominantly produced from genes involved in the p53
pathway, as is in general the case for the early transcriptional
response to radiation. The authors furthermore focused on
two circRNAs derived from the WWOX gene, showing that
they are differently regulated by QKI in response to radiation
depending on the cell type and that they are enriched in exo­
somes [202].
J. Reindl et al."
"The text describes several functions of circRNAs related to their impact following irradiation. Detail three distinct mechanisms by which circRNAs, particularly those identified after gamma irradiation in HEK293-T cells, can influence cellular responses and contribute to differences in radiation sensitivity between cell lines.","Following gamma irradiation (8 Gy) in HEK293-T cells, several circRNA expression changes were observed. Primarily, the study identified 158 differentially expressed circRNAs, revealing a significant disparity compared to the total number of detected circRNAs (2205 uniquely in controls and 1026 uniquely in irradiated cells). This suggests that radiation induces a complex shift in circRNA profiles. Three key mechanisms through which these circRNAs contribute to altered radiosensitivity can be delineated:

1.  **Regulation of MicroRNA Expression:** The most established function identified is the role of circRNAs as ‘sponge’ or competing endogenous RNAs (ceRNAs). These circRNAs directly bind and sequester microRNAs, preventing them from interacting with their target mRNAs. This modulation of microRNA levels can subsequently alter gene expression patterns related to DNA repair, oxidative stress response, and apoptosis – all pathways implicated in determining cell survival after radiation exposure. The study’s focus on circRNAs derived from the p53 pathway further supports this mechanism.

2.  **Binding and Transportation of RNA-binding Proteins:** CircRNAs can directly bind and interact with RNA-binding proteins (RBPs). These RBPs are involved in various aspects of RNA metabolism, including splicing, stability, and transport. Radiation-induced changes in circRNA expression could therefore alter the availability or activity of specific RBPs, indirectly influencing gene regulation and cellular responses to radiation.

3.  **Regulation of Transcription and Alternative Splicing:** The text mentions that circRNAs can act as regulators of transcription and alternative splicing. Following irradiation, altered circRNA profiles might influence the expression levels of genes involved in DNA repair pathways or modulate the splicing patterns of critical radiation response genes, thereby contributing to differences in radiosensitivity between cell lines. The investigation of WWOX-derived circRNAs, differentially regulated by QKI, exemplifies this point, highlighting cell type-specific effects.

It’s important to note that while these mechanisms are supported by the provided text, a comprehensive understanding requires considering the broader context of RNA biology and cellular response pathways.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.4	 Circular RNAs | Sub-sub-subsection: 3.17.4.1	 Biogenesis and Functions | Content: can be induced by irradiation, and very often the mesenchy­
mal cells display a more radiation-resistant phenotype, high­
lighting the relevance of EMT, and therefore QKI-regulated
circRNAs, for radiation and cancer biology.
Different functions for circRNAs have been identified,
including (1) binding and transportation of RNA-binding
proteins; (2) generation of protein isoforms; and (3) regula­
tors of transcription and alternative splicing (e.g., Xiao et al.
[198]). However, the most established and investigated func­
tion of circRNAs is the regulation of microRNA expression
and subcellular localization via a sponging mechanism
(competing endogenous RNA, ceRNA). However, since
most circRNAs are expressed at only low levels, and they
usually contain only a limited number of microRNA-binding
sites, it is now clear that the function of microRNA sponges
or ceRNAs to regulate the expression of microRNA targets
cannot be generalized for many circRNAs [198].
An important consideration here is that studies often per­
form gene ontology enrichment analyses based on the func­
tions of the host genes of differentially expressed circRNAs.
However, since there is currently little evidence that cir­
cRNAs in general function in the same pathways as their
hosts, such analyses should be critically interpreted.
3.17.4.2
circRNAs, Radiation Exposure,
and Radiosensitivity
Despite increasing attention, the number of studies investi­
gating the direct effect of ionizing radiation on circRNA
expression is still very limited. On the other hand, there have
been quite some studies in which the differential expression
of circRNAs between radiation-sensitive and radiation-­
resistant cancer cell lines and patients was compared.
In HEK293-T cells, gamma irradiation (8 Gy, single dose)
resulted in very big differences in the expression of cir­
cRNAs between control and irradiated cells. Here, the
authors focused only on circRNAs detected under both
experimental conditions and identified a total of 158 differ­
entially expressed circRNAs. However, among 5592 detected
circRNAs in total, 2205 were detected uniquely in control
cells while 1026 circRNAs were uniquely found in irradiated
cells. This indicates that the differences were actually larger
than was reflected by the 158 that were considered to be dif­
ferentially expressed.
A study by O’Leary and co-workers investigated differen­
tial circRNA expression at 4 h and 24 h after exposure of
endothelial HUVECs to a medium (0.25 Gy) and high dose
(2.5 Gy) of g-rays [202]. Radiation-responsive circRNAs
were predominantly produced from genes involved in the p53
pathway, as is in general the case for the early transcriptional
response to radiation. The authors furthermore focused on
two circRNAs derived from the WWOX gene, showing that
they are differently regulated by QKI in response to radiation
depending on the cell type and that they are enriched in exo­
somes [202].
J. Reindl et al."
"Describe the role of circRNAs, specifically focusing on circPVT1, in mediating radiation responses and their potential connection to cellular senescence. What evidence suggests this circRNA’s function is context-dependent?","Circular RNAs (circRNAs) are emerging as key regulators of cellular processes, including those influenced by ionizing radiation. A prominent example is circPVT1, a circular transcript derived from the PVT1 long noncoding RNA gene. Studies have shown that circPVT1 acts as a ‘sponge’ for the microRNA let-7, preventing the subsequent reduction in expression of target genes like IGF2BP1, KRAS, and HMGA2 – proteins involved in maintaining proliferative capacity. In human diploid WI-38 fibroblasts, downregulation of circPVT1 during both multiplication and radiation-induced senescence leads to this sponging effect and ultimately suppresses senescence progression. Importantly, the linear PVT1 lncRNA was not reduced in senescent cells, indicating that the observed effects were exclusively mediated by the circular transcript. Furthermore, circPVT1 expression is dependent on p53 activity; it’s enriched in tumors with p53 mutations and silenced p53 results in a downregulation of circPVT1.  Interestingly, circPVT1 has been implicated in enhancing chemotherapy resistance in gastric cancer cells through its interaction with miR-124-3p and miR-145-5p, and conversely, it can enhance radiosensitivity in non-small cell lung cancer by inhibiting the PI3K/AKT/mTOR pathway via sponging of miR-1208. This highlights that different circRNAs originating from the same host gene can have opposing biological functions depending on cellular context, emphasizing the need for careful functional characterization of individual circRNAs when studying radiation responses. Reference: [Molecular Radiation Biology], Section 3.17.4.2, circRNAs, Radiation Exposure, and Radiosensitivity.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.4	 Circular RNAs | Sub-sub-subsection: 3.17.4.2	 circRNAs, Radiation Exposure, and Radiosensitivity | Content: can be induced by irradiation, and very often the mesenchy­
mal cells display a more radiation-resistant phenotype, high­
lighting the relevance of EMT, and therefore QKI-regulated
circRNAs, for radiation and cancer biology.
Different functions for circRNAs have been identified,
including (1) binding and transportation of RNA-binding
proteins; (2) generation of protein isoforms; and (3) regula­
tors of transcription and alternative splicing (e.g., Xiao et al.
[198]). However, the most established and investigated func­
tion of circRNAs is the regulation of microRNA expression
and subcellular localization via a sponging mechanism
(competing endogenous RNA, ceRNA). However, since
most circRNAs are expressed at only low levels, and they
usually contain only a limited number of microRNA-binding
sites, it is now clear that the function of microRNA sponges
or ceRNAs to regulate the expression of microRNA targets
cannot be generalized for many circRNAs [198].
An important consideration here is that studies often per­
form gene ontology enrichment analyses based on the func­
tions of the host genes of differentially expressed circRNAs.
However, since there is currently little evidence that cir­
cRNAs in general function in the same pathways as their
hosts, such analyses should be critically interpreted.
3.17.4.2
circRNAs, Radiation Exposure,
and Radiosensitivity
Despite increasing attention, the number of studies investi­
gating the direct effect of ionizing radiation on circRNA
expression is still very limited. On the other hand, there have
been quite some studies in which the differential expression
of circRNAs between radiation-sensitive and radiation-­
resistant cancer cell lines and patients was compared.
In HEK293-T cells, gamma irradiation (8 Gy, single dose)
resulted in very big differences in the expression of cir­
cRNAs between control and irradiated cells. Here, the
authors focused only on circRNAs detected under both
experimental conditions and identified a total of 158 differ­
entially expressed circRNAs. However, among 5592 detected
circRNAs in total, 2205 were detected uniquely in control
cells while 1026 circRNAs were uniquely found in irradiated
cells. This indicates that the differences were actually larger
than was reflected by the 158 that were considered to be dif­
ferentially expressed.
A study by O’Leary and co-workers investigated differen­
tial circRNA expression at 4 h and 24 h after exposure of
endothelial HUVECs to a medium (0.25 Gy) and high dose
(2.5 Gy) of g-rays [202]. Radiation-responsive circRNAs
were predominantly produced from genes involved in the p53
pathway, as is in general the case for the early transcriptional
response to radiation. The authors furthermore focused on
two circRNAs derived from the WWOX gene, showing that
they are differently regulated by QKI in response to radiation
depending on the cell type and that they are enriched in exo­
somes [202].
J. Reindl et al.
163
Another study focused on specific p53-dependent genes
and their circRNA abundance in the embryonic mouse brain
and primary neurons [203]. This study showed that the tem­
poral induction of circRNA expression follows that of their
linear mRNA hosts and that they remained more abundant
for a longer time after irradiation compared to mRNA. This
may have important implications for the use of circRNAs as
long-term biomarkers of radiation exposure [203]. Indeed,
gene expression changes at the level of mRNA are usually
short-lived. Therefore, the increased stability of circRNAs
may result in prolonged radiation-induced expression as was
shown by Mfossa and co-workers [203].
3.17.4.3
Examples of Important circRNAs
for Radiation Biology
circPVT1
One of the most extensively studied circRNA host genes
related to radiation and cellular radiosensitivity is PVT1, a
long noncoding RNA (lncRNA) gene from which different
circRNAs can be generated. One of these, termed circPVT1
(CircBase ID: hsa_circ_0001821, consisting of the exon 2 of
the PVT1 mRNA), is downregulated during both multiplica­
tive and radiation-induced senescence in human diploid
WI-38 fibroblasts. This leads to reduced sponging of the hsa-­
let-­7 microRNA and a subsequent reduction of proliferative
proteins encoded by let-7 targets (e.g., IGF2BP1, KRAS,
and HMGA2) that prevent senescence. Thus, circPVT1 is a
suppressor of (radiation-induced) senescence by acting as a
decoy for let-7. Interestingly, linear PVT1 lncRNA was not
decreased in senescent cells, indicating that the observed
effects were exclusively regulated by circPVT1 [204].
Pvt1 was one of the p53 target genes investigated in the
aforementioned study of Mfossa et al. [203]. Also, in human
head and neck squamous cell carcinoma cells, circPVT1
expression was found to be dependent on p53 as it was
enriched in tumors with p53 mutations and silencing of p53
resulted in a downregulation of circPVT1, but not linear
PVT1 [205]. Several other studies have implicated circPVT1
as an oncogene in different cancers, and it enhances to che­
motherapy resistance in gastric cancer cells and lung adeno­
carcinoma by acting as a ceRNA for miR-124-3p and
miR-145-5p, respectively [201, 205]. In non-small cell lung
cancer, circPVT1 expression is induced after irradiation,
while it enhances radiosensitivity via inhibition of the PI3K/
AKT/mTOR pathway through sponging of miR-1208 [206].
circ-AKT3
The PI3K/AKT/mTOR pathway plays a central role in can­
cer cell radioresistance in part via activation of EMT [207].
Inhibitors are currently being investigated as therapeutics to
improve radiotherapy outcome. AKT is a serine-threonine
kinase that exists in three isoforms, AK1, AKT2, and AKT3.
The AKT3 gene hosts different circRNAs. Of these, circ-­
AKT3 (hsa_circ_0017250) is a protein-coding circRNA that
competes with AKT phosphorylation, thereby reducing radi­
ation resistance of different GBM cell lines. In contrast,
another circ-AKT3 transcript (hsa_circ_0000199) increases
chemoresistance of gastric cancer to cisplatin by upregula­
tion of PIK3R1 (Huang et al. 2019). This suggests that dif­
ferent circRNAs originating from the same host gene can
have opposite biological functions, as is sometimes also
observed with linear splice variants. This furthermore high­
lights the importance of functional characterization of indi­
vidual circRNAs. Several other circRNAs have been
demonstrated to affect PI3K/AKT/mTOR signaling. Some
of these have been described in the review papers by Cui
et al. [201] and Jeyaraman et al. [208].
3.18
Future Perspectives
Altogether, it is now evident that circRNAs are affected by
irradiation and that they are important players in the cellular
radiation response and sensitivity. However, their exact func­
tions in these processes, which furthermore may be cell type
dependent, need to be investigated in a case-by-case manner.
Novel methods for the genome-wide identification and func­
tional characterization of circRNAs may prove to be useful
tools for these future investigations [209].
3.18.1	Extracellular Vesicles
210
­
­
3.15
211
­
­
EVs are enclosed by a lipid-bilayer membrane, and
their cargo includes coding and noncoding RNAs, genomic
and mitochondrial DNA fragments, proteins, metabolites,
and lipids. Initially, EVs were discovered as “garbage
bins” to remove unwanted materials. Now, it is clear that
most of the cells in our bodies utilize EV secretion into its
close or distant microenvironment as a way of communica­
tion [212]. Thus, EVs can transfer functional biological
molecules to recipient cells either by direct fusion with the
3 Molecular Radiation Biology"
"The text describes how circRNAs derived from the AKT3 gene can have opposing effects on cellular responses to radiation. Specifically, one circRNA transcript (hsa_circ_0017250) reduces radiation resistance in GBM cell lines by competing with AKT phosphorylation, while another circRNA transcript (hsa_circ_0000199) increases chemoresistance to cisplatin in gastric cancer cells through PIK3R1 upregulation. Explain the significance of this observation regarding circRNAs and their potential role in modulating cellular responses to radiation damage.","The observation that different circRNA transcripts originating from the same gene, AKT3, can exhibit drastically opposing biological effects highlights a critical complexity within cellular signaling pathways and their responsiveness to stressors like radiation. This demonstrates that circRNAs are not simply passive regulators of RNA stability or translation; instead, they actively participate in modulating protein activity – in this case, the PI3K/AKT/mTOR pathway – through competitive mechanisms. The first circRNA transcript (hsa_circ_0017250) acts as a negative regulator by directly interfering with AKT phosphorylation, thereby diminishing the cell’s ability to repair radiation-induced damage and potentially enhancing its resistance. Conversely, the second circRNA transcript (hsa_circ_0000199) functions as a positive regulator, promoting chemoresistance to cisplatin in gastric cancer cells through PIK3R1 upregulation – a pathway often associated with increased cell survival under stress. This dual functionality underscores the potential for circRNAs to either exacerbate or mitigate cellular responses to radiation damage depending on their specific sequence and context within the genome. Furthermore, it emphasizes that understanding the precise functional characterization of individual circRNAs is crucial when considering their role in complex biological processes like radiation biology, as cell type-specific variations can dramatically alter their impact.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.4	 Circular RNAs | Sub-sub-subsection: 3.17.4.3	 Examples of Important circRNAs for Radiation Biology | Content: improve radiotherapy outcome. AKT is a serine-threonine
kinase that exists in three isoforms, AK1, AKT2, and AKT3.
The AKT3 gene hosts different circRNAs. Of these, circ-­
AKT3 (hsa_circ_0017250) is a protein-coding circRNA that
competes with AKT phosphorylation, thereby reducing radi­
ation resistance of different GBM cell lines. In contrast,
another circ-AKT3 transcript (hsa_circ_0000199) increases
chemoresistance of gastric cancer to cisplatin by upregula­
tion of PIK3R1 (Huang et al. 2019). This suggests that dif­
ferent circRNAs originating from the same host gene can
have opposite biological functions, as is sometimes also
observed with linear splice variants. This furthermore high­
lights the importance of functional characterization of indi­
vidual circRNAs. Several other circRNAs have been
demonstrated to affect PI3K/AKT/mTOR signaling. Some
of these have been described in the review papers by Cui
et al. [201] and Jeyaraman et al. [208].
3.18
Future Perspectives
Altogether, it is now evident that circRNAs are affected by
irradiation and that they are important players in the cellular
radiation response and sensitivity. However, their exact func­
tions in these processes, which furthermore may be cell type
dependent, need to be investigated in a case-by-case manner.
Novel methods for the genome-wide identification and func­
tional characterization of circRNAs may prove to be useful
tools for these future investigations [209].
3.18.1	Extracellular Vesicles
210
­
­
3.15
211
­
­
EVs are enclosed by a lipid-bilayer membrane, and
their cargo includes coding and noncoding RNAs, genomic
and mitochondrial DNA fragments, proteins, metabolites,
and lipids. Initially, EVs were discovered as “garbage
bins” to remove unwanted materials. Now, it is clear that
most of the cells in our bodies utilize EV secretion into its
close or distant microenvironment as a way of communica­
tion [212]. Thus, EVs can transfer functional biological
molecules to recipient cells either by direct fusion with the
3 Molecular Radiation Biology"
"Describe the role of circPVT1 in radiation-induced senescence and its potential implications for cancer development, as detailed in the provided text.","CircPVT1 plays a significant role in suppressing (radiation-induced) senescence within human diploid WI-38 fibroblasts. Initially, it functions as a decoy for the microRNA hsa-let-7. During radiation exposure, circPVT1 is downregulated, leading to a reduction in sponging of hsa-let-7. This diminished sponging subsequently results in increased expression of proliferative proteins targeted by let-7, specifically IGF2BP1, KRAS, and HMGA2 – molecules that normally prevent cellular senescence. By sequestering let-7, circPVT1 effectively reverses the senescent state. Furthermore, the text highlights a connection to p53 signaling; circPVT1 expression is dependent on p53 in human head and neck squamous cell carcinoma cells, being enriched in tumors with p53 mutations. Silencing of p53 leads to downregulation of circPVT1 but not linear PVT1. Beyond senescence suppression, circPVT1 also demonstrates oncogenic properties; it enhances chemotherapy resistance in gastric cancer cells by acting as a ceRNA for miR-124-3p and miR-145-5p, and in non-small cell lung cancer, it’s induced after irradiation and subsequently increases radiosensitivity through inhibition of the PI3K/AKT/mTOR pathway via sponging of miR-1208. These diverse effects underscore circPVT1's complex involvement in cellular regulation and its potential as a therapeutic target or biomarker.

Reference: MolecularRadiationBiology, Section 3.17.4.3 – Examples of Important circRNAs for Radiation Biology.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.4	 Circular RNAs | Sub-sub-subsection: 3.17.4.3	 Examples of Important circRNAs for Radiation Biology | Content: One of the most extensively studied circRNA host genes
related to radiation and cellular radiosensitivity is PVT1, a
long noncoding RNA (lncRNA) gene from which different
circRNAs can be generated. One of these, termed circPVT1
(CircBase ID: hsa_circ_0001821, consisting of the exon 2 of
the PVT1 mRNA), is downregulated during both multiplica­
tive and radiation-induced senescence in human diploid
WI-38 fibroblasts. This leads to reduced sponging of the hsa-­
let-­7 microRNA and a subsequent reduction of proliferative
proteins encoded by let-7 targets (e.g., IGF2BP1, KRAS,
and HMGA2) that prevent senescence. Thus, circPVT1 is a
suppressor of (radiation-induced) senescence by acting as a
decoy for let-7. Interestingly, linear PVT1 lncRNA was not
decreased in senescent cells, indicating that the observed
effects were exclusively regulated by circPVT1 [204].
Pvt1 was one of the p53 target genes investigated in the
aforementioned study of Mfossa et al. [203]. Also, in human
head and neck squamous cell carcinoma cells, circPVT1
expression was found to be dependent on p53 as it was
enriched in tumors with p53 mutations and silencing of p53
resulted in a downregulation of circPVT1, but not linear
PVT1 [205]. Several other studies have implicated circPVT1
as an oncogene in different cancers, and it enhances to che­
motherapy resistance in gastric cancer cells and lung adeno­
carcinoma by acting as a ceRNA for miR-124-3p and
miR-145-5p, respectively [201, 205]. In non-small cell lung
cancer, circPVT1 expression is induced after irradiation,
while it enhances radiosensitivity via inhibition of the PI3K/
AKT/mTOR pathway through sponging of miR-1208 [206]."
"The text describes how circRNAs, specifically circ-AKT3, can influence cancer cell radioresistance. Explain the mechanism by which one particular circRNA transcript (hsa_circ_0017250) reduces radiation resistance in GBM cells and contrast this with another circRNA transcript’s effect on gastric cancer cells.","The PI3K/AKT/mTOR pathway is frequently implicated in radioresistance, particularly within cancer cells. The circRNA hsa_circ_0017250, originating from the AKT3 gene, functions as a competitive inhibitor of AKT phosphorylation. This means that this specific circRNA molecule directly competes with AKT for its substrate, effectively reducing the level of AKT activation. Consequently, diminished AKT signaling leads to a reduction in radiation resistance observed in various GBM cell lines. Conversely, another circRNA transcript identified within the same AKT3 gene (hsa_circ_0000199) has been shown to increase chemoresistance to cisplatin in gastric cancer cells by upregulating PIK3R1. This demonstrates that different circRNAs derived from the same host gene can exhibit opposing biological effects, highlighting the complexity of circRNA regulation and its potential impact on cellular responses to therapeutic interventions. The functional diversity observed underscores the need for detailed characterization of individual circRNAs when considering their role in signaling pathways and treatment outcomes.

Reference: [Molecular Radiation Biology], Section 3.17.4.3 – Examples of Important circRNAs for Radiation Biology","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.17	 Epigenetic Factors | Sub-subsection: 3.17.4	 Circular RNAs | Sub-sub-subsection: 3.17.4.3	 Examples of Important circRNAs for Radiation Biology | Content: The PI3K/AKT/mTOR pathway plays a central role in can­
cer cell radioresistance in part via activation of EMT [207].
Inhibitors are currently being investigated as therapeutics to
improve radiotherapy outcome. AKT is a serine-threonine
kinase that exists in three isoforms, AK1, AKT2, and AKT3.
The AKT3 gene hosts different circRNAs. Of these, circ-­
AKT3 (hsa_circ_0017250) is a protein-coding circRNA that
competes with AKT phosphorylation, thereby reducing radi­
ation resistance of different GBM cell lines. In contrast,
another circ-AKT3 transcript (hsa_circ_0000199) increases
chemoresistance of gastric cancer to cisplatin by upregula­
tion of PIK3R1 (Huang et al. 2019). This suggests that dif­
ferent circRNAs originating from the same host gene can
have opposite biological functions, as is sometimes also
observed with linear splice variants. This furthermore high­
lights the importance of functional characterization of indi­
vidual circRNAs. Several other circRNAs have been
demonstrated to affect PI3K/AKT/mTOR signaling. Some
of these have been described in the review papers by Cui
et al. [201] and Jeyaraman et al. [208].
3.18"
"The provided text discusses circRNAs originating from the AKT3 gene and their impact on radiation resistance. Can you explain how different circRNA transcripts, such as circ-AKT3 (hsa_circ_0017250) and another circ-AKT3 transcript (hsa_circ_0000199), can exhibit opposing biological effects within a cell, and what cellular pathways are implicated in these contrasting outcomes?","CircRNAs, particularly those derived from genes like AKT3, demonstrate a complex interplay with radiation response. The text highlights two distinct circRNA transcripts originating from the same gene that produce dramatically different results regarding cellular sensitivity to radiation. circ-AKT3 (hsa_circ_0017250) functions as a competitive inhibitor of AKT phosphorylation. By binding to and sequestering AKT, this circRNA effectively reduces the phosphorylation of AKT itself, thereby diminishing the downstream signaling cascade mediated by the PI3K/AKT/mTOR pathway. This ultimately decreases radiation resistance in GBM cell lines. Conversely, another circ-AKT3 transcript (hsa_circ_0000199) promotes chemoresistance to cisplatin in gastric cancer cells through upregulation of PIK3R1. The precise mechanism here isn't fully elucidated but likely involves a different regulatory effect on the PI3K/AKT/mTOR pathway, potentially amplifying its activity or altering its sensitivity to inhibition. Importantly, the text emphasizes that different circRNAs from the same host gene can have opposing functions, mirroring observations with linear splice variants. This suggests that variations in RNA secondary structure and localization, dictated by the specific circRNA sequence, profoundly influence signaling pathways involved in cellular responses to stress like radiation. The PI3K/AKT/mTOR pathway is central to this response, but the precise modulation of this pathway by different circRNAs can lead to vastly different outcomes regarding cell survival and resistance.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.18	 Future Perspectives | Content: improve radiotherapy outcome. AKT is a serine-threonine
kinase that exists in three isoforms, AK1, AKT2, and AKT3.
The AKT3 gene hosts different circRNAs. Of these, circ-­
AKT3 (hsa_circ_0017250) is a protein-coding circRNA that
competes with AKT phosphorylation, thereby reducing radi­
ation resistance of different GBM cell lines. In contrast,
another circ-AKT3 transcript (hsa_circ_0000199) increases
chemoresistance of gastric cancer to cisplatin by upregula­
tion of PIK3R1 (Huang et al. 2019). This suggests that dif­
ferent circRNAs originating from the same host gene can
have opposite biological functions, as is sometimes also
observed with linear splice variants. This furthermore high­
lights the importance of functional characterization of indi­
vidual circRNAs. Several other circRNAs have been
demonstrated to affect PI3K/AKT/mTOR signaling. Some
of these have been described in the review papers by Cui
et al. [201] and Jeyaraman et al. [208].
3.18
Future Perspectives
Altogether, it is now evident that circRNAs are affected by
irradiation and that they are important players in the cellular
radiation response and sensitivity. However, their exact func­
tions in these processes, which furthermore may be cell type
dependent, need to be investigated in a case-by-case manner.
Novel methods for the genome-wide identification and func­
tional characterization of circRNAs may prove to be useful
tools for these future investigations [209]."
"The document describes how circRNAs, originating from the AKT3 gene, can have opposing effects on cellular responses to radiation. Specifically, one circRNA variant (hsa_circ_0017250) reduces radiation resistance in GBM cell lines by competing with AKT phosphorylation, while another (hsa_circ_0000199) increases chemoresistance to cisplatin in gastric cancer through PIK3R1 upregulation. What key concept does this illustrate regarding circRNAs and their potential roles in modulating cellular responses?","This illustrates the principle of functional diversity within a single gene, specifically concerning circRNA isoforms. The document highlights that different circRNA transcripts derived from the same host gene can exhibit dramatically contrasting biological effects – one promoting resistance to radiation while the other enhances sensitivity – due to variations in their regulatory mechanisms and downstream signaling pathways. This underscores the importance of comprehensively characterizing individual circRNAs rather than treating them as homogenous entities. Reference: [Molecular Radiation Biology], Section 3.18.1 Extracellular Vesicles.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.18	 Future Perspectives | Sub-subsection: 3.18.1	 Extracellular Vesicles | Content: improve radiotherapy outcome. AKT is a serine-threonine
kinase that exists in three isoforms, AK1, AKT2, and AKT3.
The AKT3 gene hosts different circRNAs. Of these, circ-­
AKT3 (hsa_circ_0017250) is a protein-coding circRNA that
competes with AKT phosphorylation, thereby reducing radi­
ation resistance of different GBM cell lines. In contrast,
another circ-AKT3 transcript (hsa_circ_0000199) increases
chemoresistance of gastric cancer to cisplatin by upregula­
tion of PIK3R1 (Huang et al. 2019). This suggests that dif­
ferent circRNAs originating from the same host gene can
have opposite biological functions, as is sometimes also
observed with linear splice variants. This furthermore high­
lights the importance of functional characterization of indi­
vidual circRNAs. Several other circRNAs have been
demonstrated to affect PI3K/AKT/mTOR signaling. Some
of these have been described in the review papers by Cui
et al. [201] and Jeyaraman et al. [208].
3.18
Future Perspectives
Altogether, it is now evident that circRNAs are affected by
irradiation and that they are important players in the cellular
radiation response and sensitivity. However, their exact func­
tions in these processes, which furthermore may be cell type
dependent, need to be investigated in a case-by-case manner.
Novel methods for the genome-wide identification and func­
tional characterization of circRNAs may prove to be useful
tools for these future investigations [209].
3.18.1	Extracellular Vesicles
210
­
­
3.15
211
­
­
EVs are enclosed by a lipid-bilayer membrane, and
their cargo includes coding and noncoding RNAs, genomic
and mitochondrial DNA fragments, proteins, metabolites,
and lipids. Initially, EVs were discovered as “garbage
bins” to remove unwanted materials. Now, it is clear that
most of the cells in our bodies utilize EV secretion into its
close or distant microenvironment as a way of communica­
tion [212]. Thus, EVs can transfer functional biological
molecules to recipient cells either by direct fusion with the
3 Molecular Radiation Biology
164
Table 3.15 Characteristics of different extracellular vesicles (EVs)
Type of vesicle
[size (nm)]
Description of characteristics
Microvesicles
100–1000 nm
A subgroup of EVs generated at the cell membrane.
Found in both body fluids and tissues
Apoptotic
bodies
500–2000 nm
A subgroup of EVs composed of cellular organelles
and cytoplasm. Formed during apoptotic cell death
by budding after the plasma membrane has
undergone blebbing
Ectosomes
100–1000 nm
Membrane microvesicles produced by neutrophils
or monocytes formed by direct budding from cell
membrane. Vesicles larger than 350–400 nm are not
always considered as true ectosomes
Oncosomes
100–500 nm
Large
oncosomes
1–10 μm
EVs of different sizes generated by tumor cells
which function as transmitters of oncogenic signals
(RNA, protein complexes) between cells
Exosomes
40–150 nm
Membrane-bound EVs formed by the endocytic
pathway. These EVs are first formed at the plasma
membrane and subsequently transformed into early
endosomes. These subsequently mature into late
endosomes where they bud off to the ER
intracytoplasmic lumen. The formed multivesicular
bodies thereafter are unified with the cell
membrane, and exosomes are released to the
extracellular surroundings of the cell. Exosomal
markers include CD63, CD9, CD81, and TSG101
among others
plasma membrane or by internalization but also via inter­
action with cell surface receptors triggering downstream
signaling (Box 3.35).
EVs are found to be an integrated part of cell-to-cell com­
munication, thereby contributing to regulation of the immune
as well as the nervous system but also to tissue regeneration
after damage [213]. Also, in the carcinogenesis and cancer
metastasis fields, EVs have been demonstrated to be impor­
tant communicators. Thus, EVs regulate the tumor and the
tumor microenvironment signaling including angiogenic
promotion, conversion of fibroblast into cancer-associated
fibroblasts, and interplay with the immune system, thereby
providing a good milieu for disseminated tumor cells to grow
as well as establish themselves as metastases.
Given that EVs can influence a multitude of cell and tis­
sue processes, it is not surprising that EVs today are consid­
ered an important source of biomarkers of different diseases
including cancer. Thus, analyses of EVs and their cargo have
been able to gain the US Food and Drug Administration
(FDA) and international approvals to some extent [214].
With such diverse and varied roles of EVs in assisting cancer
progression, it is essential that one can understand how IR,
given its essential place in cancer therapy, can alter EVs
cargo and/or function.
3.18.1.1
Exosomes
3.50
­
215
When exosomes were identified in the 1980s, they were
seen upon as “garbage bins,” but later it was reported that
exosomes generated from B lymphocytes could trigger a
T-cell response. From that time, exosomes have been shown
to participate in a multitude of cell–cell communication
routes by carrying cargoes which are taken up by recipient
cells close by or in a multicellular organism, in another tis­
sue as exemplified in the cancer metastasis process [216].
The scientific community have gathered data on the exo­
some cargo, e.g., protein, lipid, and mRNA or miRNAs, into
large databases, e.g., ExoCarta (http://www.exocarta.org/)
and Vesiclepedia (http://www.microvesicles.org/), which
are growing as more exosomes from cells of different origin
and in different contexts are being deciphered and reported
(Box 3.36).
It is still to some extent difficult to sort out plasma
membrane-­derived EVs from exosomes as their sizes are
similar and given that there is a cell heterogeneity in the
expression of the protein markers that define exosomes
Box 3.35 In a Nutshell: Extracellular Vesicles
•	Extracellular vesicles (EVs) can be of different
sizes and are generated via different biogenesis
routes from all cells within our body.
•	EVs cargo RNA, DNA fragments, lipids, and pro­
teins partly reflecting their cell of origin.
•	EVs are important communicators in health and
disease.
•	EVs regulate carcinogenesis and metastasis.
•	Exosomes are generated via the endosomal system
and are released from viable cells.
Box 3.36 In a Nutshell: Exosomes
•	Exosomes are EVs of endosomal origin, which con­
tain nucleic acids, membrane and cytosolic pro­
teins, metabolites, and lipids.
•	Once released, exosomes may act on cells in close
vicinity or in a distant tissue.
•	Exosomes are involved in a multitude of human dis­
eases including cancer where they regulate carcino­
genesis, tumor-immune cell interplay, angiogenesis,
and metastasis.
J. Reindl et al."
"Extracellular vesicles (EVs), including exosomes, play a significant role in intercellular communication and disease progression. Describe the key mechanisms by which EVs, such as exosomes, facilitate this communication, referencing their cargo composition and how that cargo influences recipient cells.","Extracellular vesicles (EVs), particularly exosomes, function as crucial mediators of intercellular communication through several interconnected mechanisms. Primarily, they carry a diverse cargo – including mRNA, miRNA, proteins, and lipids – reflecting the originating cell’s state. Upon encountering recipient cells, this cargo is delivered via uptake processes like endocytosis or direct fusion with the target cell membrane. This delivery then triggers alterations in signaling pathways within the recipient cell. For example, miRNAs carried by exosomes can directly regulate gene expression, while proteins may activate or inhibit specific cellular responses. Furthermore, the lipid composition of the EV membrane – characterized by a higher proportion of sphingomyelin, cholesterol, ceramide, and phosphatidylserine compared to plasma membranes – can influence membrane fluidity and receptor interactions, further modulating signaling events. The ability of exosomes to promote angiogenesis, facilitate fibroblast conversion, and interact with the immune system contributes significantly to their role in processes like cancer metastasis.  The specific cargo dictates the precise effect on the recipient cell, highlighting the versatility of these vesicles as messengers. Reference: [Molecular Radiation Biology, Section 3.18.1.1 Extracellular Vesicles] ","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.18	 Future Perspectives | Sub-subsection: 3.18.1	 Extracellular Vesicles | Sub-sub-subsection: 3.18.1.1	 Exosomes | Content: metastasis fields, EVs have been demonstrated to be impor­
tant communicators. Thus, EVs regulate the tumor and the
tumor microenvironment signaling including angiogenic
promotion, conversion of fibroblast into cancer-associated
fibroblasts, and interplay with the immune system, thereby
providing a good milieu for disseminated tumor cells to grow
as well as establish themselves as metastases.
Given that EVs can influence a multitude of cell and tis­
sue processes, it is not surprising that EVs today are consid­
ered an important source of biomarkers of different diseases
including cancer. Thus, analyses of EVs and their cargo have
been able to gain the US Food and Drug Administration
(FDA) and international approvals to some extent [214].
With such diverse and varied roles of EVs in assisting cancer
progression, it is essential that one can understand how IR,
given its essential place in cancer therapy, can alter EVs
cargo and/or function.
3.18.1.1
Exosomes
3.50
­
215
When exosomes were identified in the 1980s, they were
seen upon as “garbage bins,” but later it was reported that
exosomes generated from B lymphocytes could trigger a
T-cell response. From that time, exosomes have been shown
to participate in a multitude of cell–cell communication
routes by carrying cargoes which are taken up by recipient
cells close by or in a multicellular organism, in another tis­
sue as exemplified in the cancer metastasis process [216].
The scientific community have gathered data on the exo­
some cargo, e.g., protein, lipid, and mRNA or miRNAs, into
large databases, e.g., ExoCarta (http://www.exocarta.org/)
and Vesiclepedia (http://www.microvesicles.org/), which
are growing as more exosomes from cells of different origin
and in different contexts are being deciphered and reported
(Box 3.36).
It is still to some extent difficult to sort out plasma
membrane-­derived EVs from exosomes as their sizes are
similar and given that there is a cell heterogeneity in the
expression of the protein markers that define exosomes
Box 3.35 In a Nutshell: Extracellular Vesicles
•	Extracellular vesicles (EVs) can be of different
sizes and are generated via different biogenesis
routes from all cells within our body.
•	EVs cargo RNA, DNA fragments, lipids, and pro­
teins partly reflecting their cell of origin.
•	EVs are important communicators in health and
disease.
•	EVs regulate carcinogenesis and metastasis.
•	Exosomes are generated via the endosomal system
and are released from viable cells.
Box 3.36 In a Nutshell: Exosomes
•	Exosomes are EVs of endosomal origin, which con­
tain nucleic acids, membrane and cytosolic pro­
teins, metabolites, and lipids.
•	Once released, exosomes may act on cells in close
vicinity or in a distant tissue.
•	Exosomes are involved in a multitude of human dis­
eases including cancer where they regulate carcino­
genesis, tumor-immune cell interplay, angiogenesis,
and metastasis.
J. Reindl et al.
165Fig. 3.50
Fig. 3.50 Principal steps in exosome biogenesis. The early endo­
somes, which are generated at the plasma membrane (1), later undergo
maturation, called late endosomes or multivesicular bodies (MVBs) (2).
The MVBs’ membrane invagination results in the formation of intralu­
minal vesicles (ILVs). During the invaginating process, particular pro­
teins are incorporated into the invaginating membrane. Other cytosolic
biomolecules, i.e., nucleic acids and proteins, are engulfed and enclosed
within ILVs. The release of exosomes into the extracellular environ­
ment happens after fusion of the MVB with plasma membrane (3)
[210]. However, there are certain proteins that characterize
exosomes including Rab GTPases, flotillin, heat-shock pro­
teins (HSP70 and -90), tetraspanins (CD63, CD9, CD81, and
CD82), Alix, flotillin, and TSG101. These markers are also
suggested by the International Society for Extracellular
Vesicles (ISEV) to be used to define exosomes [210].
The lipid membrane of EVs has a different composition
relative to plasma membranes. Thus, EV membrane has
higher level of sphingomyelin, cholesterol, ceramide, and
phosphatidylserine while less expression of phosphatidyl­
choline. These lipids have been shown to have a profound
effect on carcinogenesis and cancer progression including
enhancing invasiveness, angiogenesis, and chemoresistance
via transport of oncogenic elements.
There is clear evidence that cancer cells may have another
rate of exosome release than non-transformed cells [217]
while it is still a controversy as to what extent that is reflected
in human liquid biopsies, e.g., plasma, and if it can be linked
to therapy response. Also, it has been recognized that cancer
and normal cells differ with respect to exosome cargo, e.g.,
miRNA, mRNA protein, and lipids. Exosomes have been
found in plasma, serum, lymph fluid, bronchial fluid, cere­
bral spinal fluid (CSF), urine, saliva, tears, bile and gastric
acid, amniotic fluid, breast milk, semen, and synovial fluid
[218]. This has spurred an interest in their role as a source of
biomarkers.
As indicated above, in human tissues, exosome can act
near its cell of release or be transported in the blood to a
distant tissue, e.g., site of metastasis in the context of cancer.
It has been demonstrated in a large number of publications
that once the exosome cargo reaches its target cell, several
mechanisms cooperate for uptake as well as for altering sig­
naling in the recipient cells [219]. Similar to EVs, exosomes
participate in different processes of the immune system as
well as in neurological signaling processes. Exosomes also
have a clear function in cancer signaling. Exosomes are
described to regulate tumor internal signaling but also
tumor–tumor microenvironment interplay. For example,
exosomes may promote angiogenesis as well as metastatic
spread, and they are important communicators between
tumor and different infiltrating immune cells.
Exosomes may exert these events by modulating para­
crine, autocrine, and endocrine pathways in different cell
types via their cargo. The exosome surface proteins are
reported to resemble those of plasma membrane and endo­
some of a given cell yet with minor contribution of proteins
from nucleus or Golgi. It has also been reported that EV
membrane composition differs from plasma membrane con­
cerning their lipids. Thus, EV membrane has higher level of
sphingomyelin, cholesterol, ceramide, and phosphatidylser­
ine while less expression of phosphatidylcholine.
3.18.1.2
Exosome RNA Loading
Exosomes carry a wide range of cargoes, and it is currently
thought that such cargoes, e.g., RNA species, are selectively
loaded into exosomes and that loading is not a random pro­
3 Molecular Radiation Biology"
"Exosomes play a complex role in intercellular communication, particularly concerning tumor microenvironments. Describe the key mechanisms by which exosomes can influence recipient cells, referencing specific cargo components and their associated effects as detailed within the text.","Exosomes function as crucial mediators of intercellular signaling, especially within the context of tumor biology. The primary mechanism involves the transfer of cargo – including RNA species like microRNAs (miRNAs) and mRNA fragments – to recipient cells. Notably, the text highlights that exosome RNA loading is a selective process, often driven by recognition motifs such as the 25-nucleotide zip code sequence by the hnRNPA2B1 protein. This leads to enrichment of specific miRNAs within exosomes, exemplified by miR-451 packaging and miR-1289’s binding to the zip code sequence. Furthermore, exosome membranes are characterized by a distinct lipid composition – higher levels of sphingomyelin, cholesterol, ceramide, and phosphatidylserine compared to plasma membranes – which contributes to their unique functionality.  The cargo delivered by these exosomes can then elicit diverse responses in recipient cells. For instance, exosomes derived from tumor cells can carry inhibitors of apoptosis proteins (IAPs) like survivin, XIAP, cIAP1, and cIAP2, promoting tumor survival and progression. Conversely, they can also induce pro-death signaling through the release of molecules that activate pathways leading to cell death.  Additionally, exosomes can modulate immune responses by carrying PD-L1 or CD73, impairing T-cell function and influencing the tumor-immune microenvironment. The ability of exosomes to alter EV uptake is also a key factor in their impact on recipient cells.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.18	 Future Perspectives | Sub-subsection: 3.18.1	 Extracellular Vesicles | Sub-sub-subsection: 3.18.1.2	 Exosome RNA Loading | Content: tumor and different infiltrating immune cells.
Exosomes may exert these events by modulating para­
crine, autocrine, and endocrine pathways in different cell
types via their cargo. The exosome surface proteins are
reported to resemble those of plasma membrane and endo­
some of a given cell yet with minor contribution of proteins
from nucleus or Golgi. It has also been reported that EV
membrane composition differs from plasma membrane con­
cerning their lipids. Thus, EV membrane has higher level of
sphingomyelin, cholesterol, ceramide, and phosphatidylser­
ine while less expression of phosphatidylcholine.
3.18.1.2
Exosome RNA Loading
Exosomes carry a wide range of cargoes, and it is currently
thought that such cargoes, e.g., RNA species, are selectively
loaded into exosomes and that loading is not a random pro­
3 Molecular Radiation Biology
166
cess. This is supported by observed differences in miRNA
abundances in cells compared to exosomes, which have been
linked to 3′ uridylation in miRNAs of exosomes, while 3′
adenylated miRNAs are enriched in cellular fractions [220].
Moreover, certain sequence motifs are recognized by the
nuclear ribonucleoprotein A2B1 (hnRNPA2B1), which then
dictates the miRNA loading process into exosomes, possibly
via interaction with cytoskeletal components. The protein
AGO2 has also been shown to selectively package exosomes
with miRNAs specifically miR-451. In addition, overexpres­
sion of the protein neutral sphingomyelinase 2 has been
associated with an increase in exosome-associated miRNA. It
has also been demonstrated that 3′ mRNA fragments are
enriched in exosomes. The conserved 25-nucleotide sequence
(also known as a zip code-like 25 nucleotide) is usually
incorporated into mRNA’s 3′-untranslated region and
expressed in many types of cells, leading to mRNA enrich­
ment in the MVs/exosomes. It has been suggested that miR-­
1289 plays a crucial role in MV enrichment of the mRNA via
binding to zip code sequence directly.
3.18.1.3
Exosome Release and Functional
Effects
­
3.50
221
Exosomes may, via their cargo, induce both pro-survival
and pro-death signaling in recipient cells. Thus, exosomes
may promote tumor growth as well as induce inflammation
through activation of mesenchymal stem cells (MSCs) and
the subsequent secretion of IL-6 as well as IL-8. There is also
evidence that exosomes carry inhibitors of apoptosis proteins
(IAPs), e.g., survivin, XIAP, cIAP1, and cIAP2, the delivery
of which is postulated to offer protection from a continually
changing
microenvironment,
thereby
helping
tumor
progression.
In the context of tumor and immune cell interplay, there is
growing substantiation that tumor cells of different origin
can via their exosome cargo impair infiltrating T-cell func­
tion as illustrated by PD-L1-expressing exosomes [222].
Similarly, CD73, an ecto-5′-nucleotidase and a master regu­
lator in the tumor-immune microenvironment, has been
reported in exosomes and also to have functional activity in
this context, e.g., impairing T-cell function [222]. The effect
exosomes have on tissue poses a number of interesting ques­
tions when it comes to radiation biology as radiation has
tumor growth-inhibiting effects yet may negatively influence
certain normal tissue in the radiation therapy field. Exosomes
are also thought to offer some beneficial properties against
different tissue damages. Thus, exosomes from MSCs have
been reported to offer protection against diabetic nephropa­
thy in the renal system by blocking apoptosis as well as pro­
mote vascular regeneration. Moreover, acute kidney injury
caused by the DNA-damaging agent cisplatin was found to
be blocked by microvesicles as a result of inhibition of apop­
tosis. Exosomes have moreover been shown to enhance
recovery from ischemic brain injury through promoting
angiogenesis and providing an extracellular milieu for appro­
priate brain remodeling.
3.18.1.4
Extracellular Vesicles in Radiation
Responses
As EVs are important regulators of multiple cellular signal­
ing events, it is not surprising that EVs are also important
communicators in the context of IR [223]. EVs are affected
by IR on multiple levels, including alterations in subtype/
size, release, cargo, uptake, and function. These changes
facilitate the dissemination of IR signals to neighboring cells
and to distant sites, which contributes to systemic effects in
irradiated and nonirradiated areas. Therefore, EVs are poten­
tial mediators of IR-targeted and non-targeted effects, e.g.,
bystander and abscopal effects.
Several studies suggest increased EV release after irra­
diation in in vitro and in vivo models. As an example, it has
been shown that IR may increase EV release in different
tumor models including head and neck cancer and glioblas­
toma. Moreover, also in normal tissue after partial-body
irradiation of mice, it has been reported that the EV content
is altered in different tissues including the liver, brain, and
heart. As the potential mechanism for the IR-increased EV
release, p53-mediated induction of genes involved in the EV
biogenesis and altered MAPK signaling were suggested. It
was also shown that the cellular uptake of EVs is affected by
radiation exposure. In mesenchymal stem cells, irradiation
induced changes in the formation of cell surface CD29/
CD81 complexes, which increased the cellular uptake of
EVs [224].
IR also induces changes in the composition of EVs
released from cancer and non-cancer cells. Alterations
seem to be highly related to cell type, radiation dose, and
also time postradiation exposure where both microRNA
and protein changes have been described. Additionally,
changes in lipids and metabolites in EVs from irradiated
donor cells are reported. EV cargo changes were also
shown for EVs isolated from blood during or after tumor
RT. For example, ­differential expression of serum EV miR­
J. Reindl et al."
"Following irradiation, how do extracellular vesicles (EVs) contribute to systemic effects like bystander and abscopal effects in radiation therapy, and what specific changes within EVs are implicated in these phenomena?","Extracellular vesicles (EVs), including exosomes and microvesicles, play a crucial role as communicators of radiation-induced signals throughout the body. Irradiation significantly alters EV production and composition, facilitating the dissemination of IR signals to neighboring cells and distant sites – a mechanism underpinning bystander and abscopal effects. Specifically, changes in EV subtype/size, release frequency, cargo (including microRNAs and proteins), uptake by recipient cells, and overall function are all influenced by radiation exposure. Increased EV release is observed *in vitro* and *in vivo*, particularly in tumor models like head and neck cancer and glioblastoma, as well as normal tissues such as the liver, brain, and heart following partial-body irradiation. The p53 pathway, inducing genes involved in EV biogenesis, and altered MAPK signaling are suggested mechanisms driving this increased release. Furthermore, radiation impacts cellular uptake of EVs; for instance, in mesenchymal stem cells, irradiation increases the formation of CD29/CD81 complexes, enhancing EV uptake. Finally, irradiated cells alter the cargo within EVs – including changes in microRNA and protein expression, as well as alterations in lipid and metabolite profiles – which contributes to the diverse systemic responses observed after radiation treatment.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.18	 Future Perspectives | Sub-subsection: 3.18.1	 Extracellular Vesicles | Sub-sub-subsection: 3.18.1.3	 Exosome Release and Functional Effects | Content: tions when it comes to radiation biology as radiation has
tumor growth-inhibiting effects yet may negatively influence
certain normal tissue in the radiation therapy field. Exosomes
are also thought to offer some beneficial properties against
different tissue damages. Thus, exosomes from MSCs have
been reported to offer protection against diabetic nephropa­
thy in the renal system by blocking apoptosis as well as pro­
mote vascular regeneration. Moreover, acute kidney injury
caused by the DNA-damaging agent cisplatin was found to
be blocked by microvesicles as a result of inhibition of apop­
tosis. Exosomes have moreover been shown to enhance
recovery from ischemic brain injury through promoting
angiogenesis and providing an extracellular milieu for appro­
priate brain remodeling.
3.18.1.4
Extracellular Vesicles in Radiation
Responses
As EVs are important regulators of multiple cellular signal­
ing events, it is not surprising that EVs are also important
communicators in the context of IR [223]. EVs are affected
by IR on multiple levels, including alterations in subtype/
size, release, cargo, uptake, and function. These changes
facilitate the dissemination of IR signals to neighboring cells
and to distant sites, which contributes to systemic effects in
irradiated and nonirradiated areas. Therefore, EVs are poten­
tial mediators of IR-targeted and non-targeted effects, e.g.,
bystander and abscopal effects.
Several studies suggest increased EV release after irra­
diation in in vitro and in vivo models. As an example, it has
been shown that IR may increase EV release in different
tumor models including head and neck cancer and glioblas­
toma. Moreover, also in normal tissue after partial-body
irradiation of mice, it has been reported that the EV content
is altered in different tissues including the liver, brain, and
heart. As the potential mechanism for the IR-increased EV
release, p53-mediated induction of genes involved in the EV
biogenesis and altered MAPK signaling were suggested. It
was also shown that the cellular uptake of EVs is affected by
radiation exposure. In mesenchymal stem cells, irradiation
induced changes in the formation of cell surface CD29/
CD81 complexes, which increased the cellular uptake of
EVs [224].
IR also induces changes in the composition of EVs
released from cancer and non-cancer cells. Alterations
seem to be highly related to cell type, radiation dose, and
also time postradiation exposure where both microRNA
and protein changes have been described. Additionally,
changes in lipids and metabolites in EVs from irradiated
donor cells are reported. EV cargo changes were also
shown for EVs isolated from blood during or after tumor
RT. For example, ­differential expression of serum EV miR­
J. Reindl et al."
"Extracellular vesicles (EVs), such as exosomes and microvesicles, are increasingly recognized for their role in mediating the effects of ionizing radiation (IR) on both cancerous and normal tissues. How does irradiation influence EV release and composition, and what specific changes have been observed in EVs derived from cancer cells versus those from non-cancerous cells following IR exposure?","Ionizing radiation (IR) significantly alters extracellular vesicle (EV) dynamics, primarily impacting their production and cargo. Following IR exposure, both tumor and normal tissues exhibit increased EV release, a phenomenon often linked to p53 activation and altered MAPK signaling pathways – mechanisms involved in cellular stress responses. Specifically, studies have demonstrated that IR can induce the biogenesis of EVs from cells, leading to an elevated number of vesicles released. The composition of these EVs undergoes substantial shifts depending on the cell type and radiation dose. In cancer cells, particularly tumor models like head and neck cancer and glioblastoma, EV release is amplified, with alterations in cargo including oncogenic microRNAs that promote pro-survival functions and reduce tumor-suppressive RNAs. Conversely, in normal tissues, such as the liver, brain, and heart, IR also increases EV production but these EVs have been shown to exhibit beneficial effects like promoting angiogenesis and tissue regeneration through altered lipid and metabolite profiles. Furthermore, during or after radiation therapy for cancer, serum EVs, particularly those derived from tumor-derived exosomes (TDEs), can show differential expression of microRNAs – with increased levels observed in patients resistant to treatment compared to responders. This highlights the potential of EV cargo as biomarkers for monitoring RT response. Reference: [Molecular Radiation Biology], Section 3.18.1.4 – Extracellular Vesicles in Radiation Responses.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.18	 Future Perspectives | Sub-subsection: 3.18.1	 Extracellular Vesicles | Sub-sub-subsection: 3.18.1.4	 Extracellular Vesicles in Radiation Responses | Content: tions when it comes to radiation biology as radiation has
tumor growth-inhibiting effects yet may negatively influence
certain normal tissue in the radiation therapy field. Exosomes
are also thought to offer some beneficial properties against
different tissue damages. Thus, exosomes from MSCs have
been reported to offer protection against diabetic nephropa­
thy in the renal system by blocking apoptosis as well as pro­
mote vascular regeneration. Moreover, acute kidney injury
caused by the DNA-damaging agent cisplatin was found to
be blocked by microvesicles as a result of inhibition of apop­
tosis. Exosomes have moreover been shown to enhance
recovery from ischemic brain injury through promoting
angiogenesis and providing an extracellular milieu for appro­
priate brain remodeling.
3.18.1.4
Extracellular Vesicles in Radiation
Responses
As EVs are important regulators of multiple cellular signal­
ing events, it is not surprising that EVs are also important
communicators in the context of IR [223]. EVs are affected
by IR on multiple levels, including alterations in subtype/
size, release, cargo, uptake, and function. These changes
facilitate the dissemination of IR signals to neighboring cells
and to distant sites, which contributes to systemic effects in
irradiated and nonirradiated areas. Therefore, EVs are poten­
tial mediators of IR-targeted and non-targeted effects, e.g.,
bystander and abscopal effects.
Several studies suggest increased EV release after irra­
diation in in vitro and in vivo models. As an example, it has
been shown that IR may increase EV release in different
tumor models including head and neck cancer and glioblas­
toma. Moreover, also in normal tissue after partial-body
irradiation of mice, it has been reported that the EV content
is altered in different tissues including the liver, brain, and
heart. As the potential mechanism for the IR-increased EV
release, p53-mediated induction of genes involved in the EV
biogenesis and altered MAPK signaling were suggested. It
was also shown that the cellular uptake of EVs is affected by
radiation exposure. In mesenchymal stem cells, irradiation
induced changes in the formation of cell surface CD29/
CD81 complexes, which increased the cellular uptake of
EVs [224].
IR also induces changes in the composition of EVs
released from cancer and non-cancer cells. Alterations
seem to be highly related to cell type, radiation dose, and
also time postradiation exposure where both microRNA
and protein changes have been described. Additionally,
changes in lipids and metabolites in EVs from irradiated
donor cells are reported. EV cargo changes were also
shown for EVs isolated from blood during or after tumor
RT. For example, ­differential expression of serum EV miR­
J. Reindl et al.
167
NAs was monitored in prostate cancer or glioma patients
after RT. In the serum of HNC patients, it was shown that
tumor-derived exosome (TDE) amount relative to total exo­
somes increased in patients that were refractory to a combi­
nation of radio-, targeted, and immune therapy while the
opposite was found in the patients that responded.
Moreover, in the same study, results demonstrated an
increase in regulatory T-cell (Treg)-derived exosomes as
well as in CD3(−)PD-L1+ exosomes in serum after treat­
ment if the patients were refractory. Such alterations in EV
cargo open up for potential applications of EVs/exosomes
as a source of biomarkers for radiation exposure as well as
for prognostic or predictive biomarkers of RT response in
the context of cancer.
A substantial amount of studies suggest that EVs play a
role in the progression, RT resistance, and metastasis of can­
cer cells. In glioblastoma, Mrowczynski et al. demonstrated
a pro-survival function of EVs derived after IR, which may
be triggered by elevated cargo levels of oncogenic miRNAs
and mRNAs, while tumor-suppressive RNAs were reduced
[225]. In the same cancer type, a pro-migratory role of
radiation-­related EVs was reported. Likewise, EVs from
irradiated HNC and neuroblastoma cells were shown to stim­
ulate survival, migration, and invasiveness. However, there
are also studies reporting on an induction of harmful effects
of EVs from irradiated cancer cells into recipient cells, like
chromosomal damage and increased ROS levels.
EVs are also involved in the communication of radiation
signals among normal cells. Early work by Jella et al. showed
the transmission of cytotoxic effects between irradiated and
nonirradiated keratinocytes in an in vitro model system.
Thus, EVs from irradiated mice were able to increase DNA
damage and reduce viability in co-cultivated mouse embry­
onic fibroblasts. On the other hand, several reports found
beneficial effects of EVs released from irradiated human
PBMCs. For example, EVs from irradiated blood cells were
shown to reduce radiation-induced apoptosis in endothelial
cells [226]. Accordingly, pro-angiogenic and tissue-­
regenerative capacities were attributed to EVs from irradi­
ated PBMC. In this regard, it was shown that EVs (especially
from mesenchymal cells) could be used for the treatment of
radiation injury [227].
In summary, current knowledge indicates a vital role of
EVs in the IR response of cancer and non-cancer cells. IR
not only affects the production and the composition of EVs,
but also alters the phenotypes of recipient cells. Therefore,
these mechanisms can contribute to the communication
between irradiated cells as well as to the systemic distribu­
tion of local radiation effects throughout an organism.
Moreover, EVs may offer a source of biomarkers for moni­
toring RT responses in cancer patients (Box 3.37).
3.19"
The text mentions extracellular vesicles (EVs) potentially serving as biomarkers for monitoring radiation response in cancer patients. Can you elaborate on why EVs might be suitable for this purpose and what specific aspects of a patient's radiation exposure or cellular damage they could reflect?,"Extracellular vesicles (EVs), including exosomes and microvesicles, are naturally released by cells as part of their normal physiological processes. In the context of radiation therapy monitoring in cancer patients, EVs offer several compelling reasons for their potential use as biomarkers. Firstly, cells undergoing damage from ionizing radiation often exhibit altered membrane composition and increased EV release. These EVs can carry a cargo reflecting the cellular stress – including damaged DNA fragments, misfolded proteins, reactive oxygen species (ROS), and even components of the apoptotic pathway. Secondly, because EVs are released into the extracellular space, they provide a non-invasive sample representing the systemic effects of radiation. Analyzing the composition of these EVs could reveal information about the extent of damage in various tissues and organs, providing a more comprehensive picture than simply assessing tumor response alone. Specifically, EV cargo analysis via techniques like proteomics and lipidomics could identify changes indicative of DNA strand breaks, oxidative stress markers (e.g., 4-hydroxynonenal), or the presence of proteins involved in cell death pathways. Furthermore, variations in EV size and surface markers could also correlate with radiation dose and treatment efficacy. It’s important to note that EV analysis is still a relatively nascent field, but its potential for personalized monitoring of cancer therapy responses is significant.

Reference: [Molecular Radiation Biology], Section 3.19 – Omics","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.19	 Omics | Content: Moreover, EVs may offer a source of biomarkers for moni­
toring RT responses in cancer patients (Box 3.37).
3.19
Omics"
"Describe the process of quantitative proteomics, highlighting the key steps involved from protein mixture preparation to identifying changes in protein expression levels following a treatment like irradiation. Specifically, detail the roles of gel-based and gel-free approaches, peptide digestion, mass spectrometry analysis, and the methods used for quantifying peptide intensities.","Quantitative proteomics is a powerful technique employed to analyze the complete set of proteins expressed by a cell or organism – the proteome – under specific conditions. The process begins with preparing a protein mixture from a sample, often derived from cells treated (e.g., irradiated) and compared to an untreated control. Initially, separation techniques are utilized to resolve the complexity of this mixture; these can be broadly categorized as gel-based or gel-free approaches. Gel-based methods rely on electrophoresis, where proteins are separated based on their size and charge within a polyacrylamide gel matrix. Gel-free methods utilize liquid chromatography to achieve similar separation without the need for gels. Following separation, the proteins are digested into smaller peptides using enzymatic digestion, typically with trypsin. This generates a mixture of peptides that are then further analyzed by mass spectrometry (MS). Within the MS system, peptides are separated based on their mass-to-charge ratio, and their abundance is determined through intensity measurements – essentially, how many times each peptide appears in the sample. To identify a protein, a sufficient number of high-quality peptides must be detected and matched to known protein sequences. Crucially, quantitative proteomics compares the intensities of these peptides between treated and untreated samples. Any alterations in peptide intensities directly reflect changes in the expression levels of the corresponding proteins. Two primary methods are used for this quantification: label-based approaches (such as iPTM, iCafe, or SILAC) which involve labeling peptides with fluorescent dyes, chemical isotopes, radioisotopes, or affinity tags before MS analysis; and label-free methods that measure peptide intensities directly without pre-labeling, often relying on the number of correlated spectra for each protein. Ultimately, quantitative proteomics provides a detailed snapshot of changes in protein expression, offering valuable insights into cellular responses to various stimuli.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.19	 Omics | Sub-subsection: 3.19.1	 Proteomics | Content: Moreover, EVs may offer a source of biomarkers for moni­
toring RT responses in cancer patients (Box 3.37).
3.19
Omics
3.19.1	Proteomics
The term proteome was created to describe the set of pro­
teins expressed by the genome [228]. Proteomics analyzes
the proteome at a specific time and in a specific state.
Proteome profiling provides information not only about the
protein expression, but also about the function, structure, and
interactions of proteins.
In the well-established paradigm of proteomics, pro­
tein mixture will be separated before digestion either by
gel electrophoresis (gel-based approaches) or using liquid
chromatography (gel-free approaches) to resolve the com­
plexity of the protein mixture [228]. In the next step, pro­
teins were fragmented into smaller units called peptides
during digestion. The generated peptides were further
separated and sorted in the mass spectrometry system
based on the mass and charge, where the abundance of
each peptide is translated into numerical values called
intensity. To identify a protein, a certain number of good-
quality peptides must be detected. Quantitative pro­
teomics compares the peptide intensities for each protein
between treated (e.g., irradiated) and non-treated (e.g.,
nonirradiated) samples. The alterations in peptide intensi­
ties represent the changes in the expression level of cor­
responding protein.
Protein quantification can be performed in two ways: either
label based or label free. In label-free methods, protein expres­
sion in several samples is compared by measuring the intensity
of the corresponding peptides or counting the number of cor­
related spectra for each protein. Label-based quantification is
performed by labeling peptides or proteins with fluorescent
dyes, chemical isotopes, radioisotopes, or affinity tags before
mass spectrometry. Label-based proteomic approaches are
classified into chemical labeling (ICPL, iTRAQ, and iCAT)
and metabolic labeling techniques (SILAC).
Box 3.37 In a Nutshell: Extracellular Vesicles as
Epigenetic Factor
•	EVs, including exosomes, act as intercellular sig­
naling components in response to IR.
•	IR may influence the EV release/uptake as well as
cargo in normal as well as tumor cells contributing
to both direct and bystander effects of IR.
•	EVs/exosomes may contribute to the distribution of
systemic IR effects and offer a source of IR response
biomarkers.
3 Molecular Radiation Biology
168
Advanced proteomics approaches also offer an accurate
platform to identify and quantify the posttranslational modi­
fications (PTMs) such as phosphorylation, acetylation, meth­
ylation, or ubiquitination [229]. These modifications are
crucial for the stability, localization, and conformation and
functions of proteins. The analysis of phosphoproteome,
acetylome, or ubiquitinome has revealed the regulatory role
of these PTMs in cellular function and homeostasis [229].
A comprehensive combination of proteomics and
advanced bioinformatics makes the complex biological pro­
cesses in cells understandable. The bioinformatics tools pro­
vide a broad spectrum of information on protein functions,
protein-protein interactions, protein interactions with other
biomolecules (genes and metabolites), contribution to the
signaling pathways, and predictions of diseases [230].
3.19.1.1"
"Considering the research described, what specific types of proteins have been frequently identified during proteomic analyses investigating the effects of radiation exposure on both cancer cells and normal tissue, and why are these protein families particularly relevant to understanding radiobiological responses?","Proteomic studies examining radiation’s impact on tissues and biofluids have consistently highlighted several key protein families. Notably, antioxidant proteins (e.g., superoxide dismutases, catalase) were frequently observed in cancer cell lines, suggesting a response aimed at mitigating oxidative damage induced by ionizing radiation. Heat shock proteins (HSPs), particularly HSP70, are also commonly detected, reflecting the cellular stress response triggered by radiation exposure and subsequent protein misfolding. Furthermore, structural proteins – including collagen and elastin – have been identified as affected in irradiated tissues like the heart and brain, indicating disruption of tissue architecture and function. Finally, proteins involved in inflammatory responses were observed in the brain following irradiation. The prevalence of these families is significant because they represent core cellular mechanisms activated during stress and damage repair pathways, directly reflecting the biological consequences of radiation-induced DNA damage and subsequent cellular dysfunction. Their quantification provides valuable insights into both cancer radioresistance and normal tissue response to treatment. Reference: [Molecular Radiation Biology, Section 3.19.1.1 Proteomics in Radiation Research]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.19	 Omics | Sub-subsection: 3.19.1	 Proteomics | Sub-sub-subsection: 3.19.1.1	 Proteomics in Radiation Research | Content: Different proteomics approaches were applied to investigate
the biological effects of radiation exposure on normal and
tumor tissues, cancer radiotherapy outcome, individual sen­
sitivity, risk assessment, biodosimetry, and biomarker dis­
covery; an extensive review can be found in the work of
Azimzadeh et al. [231].
One of the main goals of cancer proteome profiling in
radiation research has been to identify biomarkers that pre­
dict the tumor’s response to radiation exposure. The pro­
teomes of different cancer cell lines such as nasopharyngeal
carcinoma, head and neck cancer, oral squamous cell carci­
noma, laryngeal cancer, breast cancer, and lung cancer have
been analyzed in radiobiological studies to identify signa­
tures of cancer radioresistance and potential prognostic
markers for radiotherapy. Although the results of these stud­
ies are not uniform, the proteins identified and quantified
belong mainly to the family of antioxidant proteins, heat
shocks, and structural proteins.
The most challenging aspect of radiotherapy for cancer is
to select the radiation dose so that the tumor is killed but the
surrounding normal tissue is harmed as little as possible. The
effect of radiation on normal tissue has also been analyzed
by proteomics approaches. A number of studies have been
carried out on in vitro and in vivo models to simulate the
effects of radiation on normal tissue such as the heart, brain,
and liver. These studies underlined the adverse effects of
irradiation on tissue structure and function. The mitochon­
drial proteins, the metabolic enzymes, and the oxidative
stress response proteins are the main groups of proteins
affected in the irradiated heart. The structural proteins, pro­
teins involved in cognition and learning function, and inflam­
matory response were impaired in the irradiated brain.
Biofluids such as serum, plasma, and urine are optimal
biomaterials for biomarker discovery, mainly because of the
relatively noninvasive collection methods. However, pro­
teomic profiling in biofluids is still an analytical challenge
due to the complexity and variable spectrum of protein abun­
dance. Several studies have compared the biofluid proteome
before and after radiation exposure. These studies provide a
panel of proteins that serve as biomarkers of radiation expo­
sure, radiation damage, cancer radiosensitivity and radio­
therapy outcome, and biodosimetry.
Since cellular responses to irradiation are tightly regu­
lated by PTMs, the analysis of these changes is becoming
increasingly important in radiation research. PTM profiling
is still a young field in radiation research, and only a few
studies have analyzed the change in protein phosphorylation,
acetylation, and ubiquitination in the context of cancer and
normal tissue response to irradiation.
Archival formalin-fixed, paraffin-embedded (FFPE) tis­
sues are the invaluable alternative of fresh frozen biomaterial
in radiation research. Proteomic analysis of these samples is
challenging, mainly due to the harsh conditions of tissue
fixation and, in particular, biomolecule extraction method.
The proteomics studies conducted on FFPE tissues from
radiobiology archives have mainly investigated the predic­
tive marker for radiotherapy resistance of cancer or adverse
effect on normal tissue. They demonstrated the compatibility
and applicability of FFPE tissues for proteomics studies
[231]."
"Describe the role of lipids, specifically phospholipids like phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs), in cellular responses to irradiation and their potential as biomarkers for radiation exposure.","Lipids play a crucial role in mediating cellular responses to irradiation, particularly through mechanisms involving oxidative stress and inflammation. Following irradiation, reactive oxygen/nitrogen species (ROS/RNS) react extensively with lipid molecules, leading to lipid peroxidation and the generation of pro-inflammatory lipid intermediates. Phospholipids, such as phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs), are particularly sensitive to this damage. Changes in PC and LPC levels have been observed in biofluids like serum/plasma after radiation exposure in animal models – for instance, increased levels of PE and PS in rat plasma following gamma irradiation, indicating disruption of phospholipid metabolism. Furthermore, lipid peroxidation products generated from PCs and LPCs can trigger apoptotic cell death through pathways such as the activation of sphingomyelinase. Studies have demonstrated that specific changes in fatty acid composition, including those within glycerolipids, glycerophospholipids, and esterified sterols, occur after irradiation. Notably, alterations in lipids like triacylglycerides (TGs), sphingomyelins (SMs), phosphatidylinositols (PIs), diacylglycerides (DGs), and cholesteryl esters have been documented across various species. The identification of biomarkers such as 3-methylglutarylcarnitine within tissues and biofluids, reflecting early radiation responses, further highlights the significance of lipidomics in assessing radiation damage.  The ability to detect changes in these lipid profiles offers a potential pathway for biodosimetry and monitoring treatment outcomes. 

Reference: [Molecular Radiation Biology], Section 3.19.2 – Lipidomics","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.19	 Omics | Sub-subsection: 3.19.2	 Lipidomics | Content: Biofluids such as serum, plasma, and urine are optimal
biomaterials for biomarker discovery, mainly because of the
relatively noninvasive collection methods. However, pro­
teomic profiling in biofluids is still an analytical challenge
due to the complexity and variable spectrum of protein abun­
dance. Several studies have compared the biofluid proteome
before and after radiation exposure. These studies provide a
panel of proteins that serve as biomarkers of radiation expo­
sure, radiation damage, cancer radiosensitivity and radio­
therapy outcome, and biodosimetry.
Since cellular responses to irradiation are tightly regu­
lated by PTMs, the analysis of these changes is becoming
increasingly important in radiation research. PTM profiling
is still a young field in radiation research, and only a few
studies have analyzed the change in protein phosphorylation,
acetylation, and ubiquitination in the context of cancer and
normal tissue response to irradiation.
Archival formalin-fixed, paraffin-embedded (FFPE) tis­
sues are the invaluable alternative of fresh frozen biomaterial
in radiation research. Proteomic analysis of these samples is
challenging, mainly due to the harsh conditions of tissue
fixation and, in particular, biomolecule extraction method.
The proteomics studies conducted on FFPE tissues from
radiobiology archives have mainly investigated the predic­
tive marker for radiotherapy resistance of cancer or adverse
effect on normal tissue. They demonstrated the compatibility
and applicability of FFPE tissues for proteomics studies
[231].
3.19.2	Lipidomics
The study of cellular lipid pathways and networks in biologi­
cal systems is known as lipidomics [232]. Lipids are a neces­
sary component of biological membranes and play essential
roles in biological systems, such as the plasma membrane
bilayer structure that separates the cell cytoplasm from the
extracellular microenvironment, the provision of a hydro­
phobic medium for the functional performance and interac­
tions of membrane proteins, and the generation of second
messengers through enzyme reactions [233]. Lipidomics
refers to the analysis of all lipids present in a sample using
liquid chromatography (LC) and mass spectrometry (MS)
techniques.
Glycerolipids, saccharolipids, sphingolipids, glycero­
phospholipids, sterols, polyketides, fatty acyls, and prenols
are the eight types of lipids that can be classified based on
their chemical structures and hydrophobic and hydrophilic
aspects [233]. The most prevalent phospholipids (PLs) are
glycerophospholipids, found in biological membranes and
essential for numerous cellular activities. PCs and other
related phospholipid derivatives like lysophosphatidylcho­
lines (LPCs) are signaling molecules that play a role in regu­
lating cellular death and proliferation. Triacylglycerides
(TGs), sphingomyelins (SMs), phosphatidylinositols (PIs),
diacylglycerides (DGs), and cholesteryl esters are also
among lipids with key roles in cell physiology [234].
J. Reindl et al.
169
Reactive oxygen/nitrogen species (ROS/RNS) react
extensively with lipid molecules following irradiation, caus­
ing lipid breakdown and eliciting both direct and indirect
inflammatory responses. Lipid peroxidation and pro-­
inflammatory lipid intermediates can have immediate
impacts on physiology and can lead to long-term
­consequences like CVD, lung damages, and even carcino­
genesis. Apoptosis can also be triggered by the direct action
of radiation or by lipid intermediates, such as the activation
of sphingomyelinase, which produces ceramide from the
hydrolysis of sphingomyelin. Ceramide is a direct apoptotic
cell death [234]. Post-ionizing irradiation (IR) changes
affecting lipids have been proven in preclinical investiga­
tions and may have biological consequences such as the
acute radiation sickness (ARS) or lead to delayed effects of
acute radiation exposure (DEARE).
When comparing sham or pre- and post-IR specimens,
lipids examined in blood, such as PCs, LPCs, TGs, SMs, and
CEs, exhibit modifications.
The link between lipid levels in serum/plasma and radia­
tion has been studied in animal models in several publica­
tions. Phosphatidylethanolamine (PE) and phosphatidylserine
(PS) levels in rat plasma following gamma irradiation expo­
sure increased dramatically, thus indicating that IR may dis­
rupt phospholipid metabolism [233]. Fatty acids, such as
linoleic acid and palmitic acid, were found to be present at
reduced levels in the blood following 137Cs exposure in
mice, while phosphatidylcholines were among the most dis­
turbed molecules in 137Cs-exposed mouse serum. A total of
67 biomarkers were discovered in some tissues and biofluids
of mice exposed to radiation (6 Gy) (serum and urine).
Among these, 3-methylglutarylcarnitine was found to be a
unique metabolite seen in the liver, serum, and urine that
might be employed as a marker of early radiation response.
Changes in lipid metabolism, including key lipid species
such as free fatty acids, glycerolipids, glycerophospholipids,
and esterified sterols, have also been observed in nonhuman
primates exposed to IR. The results show that diacylglycer­
ides decreased 1 day after IR, but triacylglycerides and lyso­
phosphatidylcholines increased from 2 to 7 days after IR. At
7 days, after 10 Gy irradiation, the amount of polyunsatu­
rated fatty acids, such as arachidonic acid and docosahexae­
noic acid, increased significantly in the nonhuman primate
model. Between 2 and 3 days after irradiation, an increase in
LysoPCs and a decrease in SMs could be regarded as viable
indicators (6.5 Gy). Compared to nonirradiated controls,
recent research in nonhuman primates has discovered
plasma-derived exosomal indicators of IR exposure related
to the enrichment of N-acyl-amino acids, fatty acid esters of
hydroxyl fatty acids, glycolipids, and triglycerides.
Radiation therapy caused blood lipidome disturbances,
which were corrected within 1–2 months after IR treatment,
according to lipid species quantification in individuals
receiving radiation therapy. As a result, radiation-induced
lipidome modifications could indicate changes in early time
points and, perhaps, alternative damage pathways. Patients
undergoing a complete body irradiation at the MSK Cancer
Center (NYC), before hematopoietic stem cell transplanta­
tion, showed seven urine indicators with changes between
pre- and postexposure at 4–6 h (1.25 Gy) and 24 h (three
fractions of 1.25 Gy each) postirradiation, which involved
trimethyl-l-lysine, acetylcarnitine, decanoylcarnitine, and
octanoylcarnitine (carnitine conjugates involved in fatty acid
transport), as well as hypoxanthine, xanthine, and uric acid
(purine catabolism pathway end products).
During the period 2015–2019, the National Cancer
Institute’s Radiation Research Program, in partnership with
the Small Business Innovation Research Development
Center, financed four small firms. This led to the develop­
ment of a metabolomic/lipidomic assay for predicting late
effects that have a negative impact on the quality of life in
prostate cancer patients treated with radiation. Shuttle
Pharmaceuticals (Rockville, MD) intended to move forward
by developing and validating a metabolomic/lipidomic bio­
marker panel that could predict radiation toxicity. In a phase
I experiment, metabolites in plasma from 100 patients were
examined in order to develop a kit that could support metab­
olomic analysis and act as a biomarker panel to predict sen­
sitivity to radiation late effects. A phase II SBIR project was
set up for the multi-site analytic validation of the metabolite
panel kit created in the phase I SBIR project [235].
Lipidomics has then emerged as a reliable technique for
lipid identification and quantification and the search for bio­
markers that can be used in radiation-related incidents such
as nuclear and radiological hazardous occurrences. In this
sense, easily available biofluids are critical, especially in the
case of irradiated victims, as well as the use of biodosimetry
techniques that are both quick and accurate. Huang et al.
[233] discovered seven radiation-responsive lipids in the
serum of mice and showed their utility in dose calculation.
Lipid changes after whole-body exposures have been thor­
oughly documented in a variety of animals, including atomic
bomb survivors [234]. Indeed, estimating the radiation dose
has always been a priority in the medical treatment of these
events.
Because of the combined effects of neutrons and photons,
shielding from structures, and closeness to the epicenter,
among other factors, radiation exposures from an IND can be
complicated. Using lipidomics, Laiakis et al. [234] evaluated
serum samples from mice exposed to varying percentages of
neutrons and X-rays to a total dosage of 3 Gy. Several lipids
including triacylglycerides, phosphatidylserines, lysophos­
phatidylethanolamines, lysophosphatidylcholines, sphingo­
lipids, and cholesteryl esters exhibited a delayed increase in
mixed exposures, while diacylglycerides declined and phos­
phatidylcholines (PCs) remained virtually unaltered.
3 Molecular Radiation Biology
170
The mammalian lipidome’s structural variety is so great
that it necessitates a systematic nomenclature for precise cat­
egorization (identifying lipid subclasses, or the total number
of carbons in the fatty acid chain and the number of double
bonds). Because numerous lipid classes showed differences
when comparing sham or pre- to post-IR samples, the
­variable sums and ratios within each metabolite class can
increase and must be carefully considered."
"Describe the role of polyamines in cellular responses to ionizing radiation, including their functions and observed changes in metabolite levels following exposure.","Polyamines, such as putrescine, spermidine, and spermine, are aliphatic polycations present within all cells and play a significant role in cell metabolism, proliferation, and differentiation. Following ionizing radiation exposure, increased levels of these molecules are frequently observed, suggesting a protective function against oxidative stress. Their ability to link to DNA, RNA, and proteins indicates a regulatory role in cellular processes. Furthermore, altered metabolite profiles associated with ionizing radiation – including creatine, creatinine, carnitine, hypoxanthine, citric acid, taurine, xanthine, threonine, uric acid, and citrulline – are often linked to changes in polyamine metabolism, highlighting the interconnectedness of metabolic pathways in response to this type of cellular insult. The study of these alterations contributes to understanding radiation exposure biomarkers and potential diagnostic applications. Reference: [MolecularRadiationBiology, Section 3.19.3 Metabolomics], ","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.19	 Omics | Sub-subsection: 3.19.3	 Metabolomics: Metabolites | Content: Radiation exposure can cause a complex molecular and cel­
lular response having an impact in metabolic processes and
consequently change metabolite levels [236]. This approach
aims to detect small molecules (<1000 Da) in biological
samples, which occur downstream of genomic, transcrip­
tomic, and proteomic processes, constituting a more com­
plete picture of the system’s response to insult even prior to
the onset of clinical symptoms [237]. The first use of metab­
olomics concerning radiation exposure studies was reported
in the 1960s according to the experiences developed in
human and animal samples; however, the understanding of
cellular and molecular effects of ionizing radiation and the
identification of radiation exposure biomarkers remain a
challenge [236]. To obtain metabolic information, different
methodologies can be used as nuclear magnetic resonance
(NMR) or mass spectrometry (MS), including gas chroma­
tography (GC) and liquid chromatography (LC). After sam­
ple collection, processing, and data acquisition, data analysis
is the second step using principal component analysis (PCA)
to have an initial perception about patterns and outliers, and
if there are any easily discernible biomarkers. After, complex
statistical data analysis should be employed in order to at the
end perform biomarkers data interpretation and validation
[236]. However, it is important to consider that there exist
multiple analytical and clinical challenges that constitute an
impediment for the successful translation of these biomark­
ers for clinical use [237].
Despite the few existing studies, some metabolite changes
in small-molecule metabolites remain underexplored and
underexploited concerning ionizing radiation effects [236].
The role of polyamine metabolism has been studied related to
ionizing radiation effects. Present in all cells, polyamines, as
putrescine, spermidine, and spermine, are aliphatic polyca­
tions with multiple functions related to cell metabolism, cell
proliferation, and cell differentiation. These molecules have
pleiotropic effects that allow their linkage to DNA, RNA, and
proteins, identifying a regulatory role in cell metabolism
[236]. Besides this, increased levels of these molecules are
reported as healthy cell protectors against oxidative stress.
Different studies using animal and patient samples have been
performed reporting altered metabolites in response to ioniz­
ing radiation, namely creatine, creatinine, carnitine, hypoxan­
thine, citric acid, taurine, xanthine, threonine, uric acid, and
citrulline. Besides these metabolites with high alterations,
2′-deoxyuridine, arginine, glycine, glutamine, hippuric acid,
inositol, palmitic acid, uridine, lactic acid, leucine, linoleic
acid, methionine, tyrosine, and sebacic acid are described as
metabolites with moderate alterations in consequence of ion­
izing radiation. Therefore, and considering experimental
data, among them exist strong candidates for diagnostic bio­
markers being considered time- and dose-­dependent mea­
sures [232]. Data obtained using T cells demonstrated that
different metabolic pathways related to amino acid, nucleo­
tide, fatty acid, and glutathione metabolism can be affected
by in vivo radiation. Related with cancer and ionizing radia­
tion response, metabolic profiling may help identify metabo­
lites responsible for response to therapy, being the alteration
of metabolite production, a feature that can influence tumor
microenvironment and consequently cancer progression
[237]. The complete characterization of the metabolome can
be an opportunity to influence prognostic, predictive, and
even pharmacodynamic biomarkers contributing to an indi­
vidualized and targeted treatment [232]. Notwithstanding the
capacity of metabolomics to detect alterations, it is necessary
to be aware of the tumor-related responses, namely to the
therapy, as inflammation and altered energy metabolism.
Besides that, and considering cancer as a syndrome, there are
also other cancer-associated conditions such as weight loss
that can influence metabolism [238]. Having in consideration
that ionizing radiation triggers a complex response influenc­
ing molecular and cellular processes and alteration of the
metabolic processes and metabolite levels, more research
work is necessary to identify biomarkers related to specific
type and dose of radiation, genotypic differences, pathologi­
cal conditions, and specific organs or tissues (Box 3.38).
Box 3.38 In a Nutshell: Omics
•	Omics might provide biomarkers of high sensitivity
and specificity for radiation research.
•	Omics can provide a qualitative and quantitative
overview of the global perturbations induced by IR
in cells and biological fluids.
•	Proteomics provides a comprehensive analytical
platform to study the molecular mechanisms of the
biological effects of radiation on normal tissues and
tumours.
•	Proteomic profiling is used to identify biomarkers
of radiation exposure, radiation-induced damage,
individual sensitivity, and biodosimetry.
•	Proteome analyses of cancers deliver information
on the outcomes of cancer radiotherapy.
J. Reindl et al.
171"
"Describe the types of molecular changes observed in response to ionizing radiation as characterized by transcriptomics, citing specific examples of genes and pathways frequently identified across multiple studies.","Transcriptomic analysis following exposure to ionizing radiation reveals a complex shift in gene expression patterns, forming what are termed ‘molecular signatures’ that can differentiate irradiated from unexposed samples. These signatures primarily focus on changes in the abundance of coding genes (like transcripts) and noncoding RNAs – specifically microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). Numerous studies have identified core sets of genes involved in key radiation responses. Notably, a significant number of genes related to DNA damage response are consistently upregulated, including *CDKN1A* (p21), *DDB2*, *GADD45A*, *LIG1*, and *PCNA*. Genes associated with apoptosis, such as *AEN*, *CCNG1*, *LY9*, *PPM1D*, and *TNFRSF10B*, are also frequently expressed. Furthermore, genes involved in metabolic pathways, like *FDXR* (ferredoxin), and cell proliferation, such as *PTP4A1*, appear prominently in these signatures. Interestingly, variations exist across species; for instance, mouse studies often highlight immune cell communication genes (*LY9* and *TRIM22*) while human studies emphasize redox response genes. The most frequently identified radiation gene signatures typically encompass around 70-80 genes, including combinations of those involved in DNA repair, apoptosis, metabolism, and cellular proliferation. A well-documented example is the 74-gene signature developed by Zhao et al., which incorporates *CDKN1A*, *DDB2*, and *PCNA* alongside other relevant genes [241]. These signatures demonstrate a degree of reproducibility across independent datasets, suggesting conserved pathways activated in response to radiation exposure. Reference: [Molecular Radiation Biology, Section 3.19.4 – Transcriptomics]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.19	 Omics | Sub-subsection: 3.19.4	 Transcriptomics | Content: Molecular signatures provide a composite inventory of
radiation-­specific responses as changes in the composition of
these molecules and their abundance. Transcript levels of sig­
nature genes in various tissues, notably blood, saliva, skin,
and tumor samples, can discriminate and, in some instances,
quantify irradiated from unexposed samples [239]. Expression
of coding genes and noncoding miRNAs, and lncRNAs, has
been implicated in radiation responses, in some cases, which
can be precisely calibrated to dose. For individual genes, e.g.,
FDXR, alternative splice isoforms have also been demon­
strated to arise in a radiation-specific manner.
­
­
­
240
­
241
3.51
­
To establish the reproducibility of these signatures, radia­
tion exposures are predicted with data from independently
exposed individuals. Consistent performance on indepen­
dent dataset depends on the composition of the genes, how
genes are ranked, how they validate the response, and how
they account for the amplitude of the radiation response.
Other important variables include how well signatures dif­
ferentiate irradiated from unirradiated samples, or even dif­
ferent levels of absorbed radiation from each, or different
radiation qualities (energy levels and source, particle types).
Transcriptomics can integrate different genes/transcripts in
the induced and repressed biochemical pathways that consti­
tute these responses. There is an enormous range of accurate
gene signatures that can be derived in many independently
derived datasets. Interestingly, there are some core sets of
genes and pathways that are present from different studies.
•	Metabolomics is used to detect small molecules
(<1000 Da) in biological samples.
•	To obtain metabolic information, different method­
ologies can be used as nuclear magnetic resonance
(NMR) or mass spectrometry (MS).
•	Ionizing radiation triggers a complex response
influencing molecular and cellular processes that
can be characterized using metabolomics.Fig. 3.51
Fig. 3.51 Graphical
depiction of major cellular
functions containing the most
frequently appearing genes of
the highest performing human
signatures adapted with
permission (CCBY) from
Zhao et al. [241]. Genes
common among these
signatures (white lettering)
are indicated in pathways
which contain products that
these genes interact with
(black lettering)
3 Molecular Radiation Biology
172
Many radiation response genes were frequently selected
for multiple blood signatures, which include genes with roles
in DNA damage response (CDKN1A, DDB2, GADD45A,
LIG1, PCNA), apoptosis (AEN, CCNG1, LY9, PPM1D,
TNFRSF10B), metabolism (FDXR), cell proliferation
(PTP4A1), and immune system (LY9 and TRIM22). While
biochemical pathways comprising the best performing radia­
tion gene signatures are often shared between human and
other species, there are some distinctive differences, notably
genes associated with immune cell communication (mice)
and redox response (humans).
Expression of gene combinations that detect radiation
exposure can also exhibit similar expression patterns in
infectious diseases and other blood disorders [242].
Underlying pathways activated by radiation effects, for
example DNA damage response and apoptosis, appear to be
activated in some individuals affected with other conditions
The genes involved are commonly present in multiple pub­
lished radiation gene signatures and assays. For example, a
74-gene radiation signature comprised of 16 genes present in
the human signatures was developed as reported in Zhao
et al. [241], including CDKN1A, DDB2, and PCNA.
Misclassification of radiation exposures in unexposed indi­
viduals with other blood disorders might be mitigated by
reevaluating false-positive predictions with signatures con­
taining radiation-responsive genes explicitly derived from
other unrelated biochemical pathways, including those
encoding secreted proteins.
3.20"
"Explain the concept of low-dose hyper-radiosensitivity (HRS) in cellular response to radiation, including the reasons behind its occurrence.","Low-dose hyper-radiosensitivity (HRS) describes a phenomenon where cells exhibit a disproportionately high rate of cell death following exposure to small doses of ionizing radiation compared to larger doses. Traditionally, one would expect that smaller doses of radiation would allow for sufficient time for cellular DNA repair mechanisms to effectively mitigate the damage and prevent cell death. However, HRS demonstrates that in these low-dose scenarios, cells often bypass the typical cell cycle arrest triggered by DNA damage. Instead, they undergo immediate apoptosis or necrosis. A plausible explanation for this observation is that sacrificing a few cells immediately offers an advantage over allowing damaged DNA to be potentially misrepaired – a misrepair could introduce further mutations and ultimately lead to more severe consequences. The rapid cell death prevents the accumulation of genomic instability associated with incomplete repair attempts, effectively minimizing long-term risks despite the initial high dose-related mortality. This highlights that the cellular response to radiation isn't solely determined by repair capacity but also by immediate survival strategies.

Reference: [Molecular Radiation Biology], Section 3.20 – Cellular Hyper-radiosensitivity","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.20	 Cellular Hyper-radiosensitivity | Content: An important factor in the cellular response to radiation is
the ability to repair DNA damage. In some individuals,
hereditary mutations in genes involved in DNA repair result
in a high sensitivity to irradiation [243]. The A-T syndrome
is an example of one such mutation and is described in detail
below. However, even with intact DNA repair pathways, it
turns out that for small doses, cells refrain from the cell cycle
arrest that would give time for repair. This results in a much
higher cell kill per unit dose for small doses than higher
doses, a phenomenon called low-dose hyper-radiosensitivity
(HRS). An explanation to the presence of HRS could be that
sacrificing a few cells may be advantageous to the risk of
misrepair."
"Describe the role of the ataxia-telangiectasia mutated (ATM) protein kinase within a cell's response to DNA damage, specifically focusing on its involvement in double-strand break repair and its implications for cellular radiosensitivity.","The ataxia-telangiectasia mutated (ATM) protein kinase is fundamentally involved in orchestrating the cellular response to double-strand DNA breaks (DSBs). Its primary function lies in initiating and executing pathways crucial for repairing these highly damaging lesions. ATM’s activity is triggered upon detection of a DSB, leading to activation of cell cycle checkpoints – specifically arresting the cell cycle at G1/S, S, or G2/M phases – preventing premature replication and ensuring accurate repair. Critically, ATM facilitates DNA repair through two major pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). HR relies on a sister chromatid template for precise repair, while NHEJ is a more error-prone process that directly ligates the broken ends. Furthermore, ATM plays a role in oxidative stress regulation and influences chromatin remodeling processes during DNA repair. Individuals with mutations affecting ATM function, such as those with ataxia-telangiectasia (A-T), exhibit significantly heightened cellular radiosensitivity. This increased sensitivity stems from their impaired ability to effectively arrest cell cycle progression and execute robust DSB repair mechanisms. Consequently, these cells are more vulnerable to damage induced by both endogenous and exogenous agents like ionizing radiation (IR). The failure of proper checkpoint activation and subsequent misrepair of DSBs leads to chromosomal instability, increasing the risk of carcinogenesis and exacerbating the effects of radiation exposure. This heightened sensitivity is not unique to A-T patients but can also be observed in individuals with mutations in other DNA damage repair genes including FANC, BRCA1/2, MRE11, and DNA Lig4. Reference: MolecularRadiationBiology > section: 3: Molecular Radiation Biology > subsection: 3.20 > subsubsection: 3.20.1 > 3.20.1","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.20	 Cellular Hyper-radiosensitivity | Sub-subsection: 3.20.1	 Repair-Deficient Cells (AT) | Content: Ataxia-telangiectasia mutated (ATM) is a serine/threonine
protein kinase with a key role in repairing double-strand
DNA breaks (DSBs) and is also involved in the regulation of
oxidative stress, metabolic syndrome, and neurodegenera­
tion, among others reported [244].
The human ATM gene is located at 11q22-23, contains 66
exons, covers 160 kb of genomic DNA, and encodes the
370 kDa ATM protein. Germline mutation in ATM gene,
either loss or inactivation of both copies, leads to the autoso­
mal recessive ataxia-telangiectasia (A-T) syndrome, a devas­
tating childhood condition characterized by chromosomal
instability, neurological degeneration, immune dysfunction,
premature aging, and high cancer risk. In fact, ATM has a
critical role in the activation of the cell cycle progression and
checkpoint activation in response to DSBs, as well as in the
repair of these lesions through homologous recombination
(HR) and nonhomologous end joining (NHEJ) pathway
[245]. Thus, these mechanisms need to be active during DNA
replication to maintain genome integrity in cells. When dis­
ruptions occur in these mechanisms, the cells are more sus­
ceptible to damage induced by the exposure to endogenous or
exogenous agents, such as radiation exposure. Considering
the well-known fact that exposure to IR activates ATM
kinases to mediate the cellular response, individuals with
these defective mechanisms, like A-T patients, will be more
sensitive to the same IR exposure than non-A-T patients.
Several published studies have corroborated these hypothe­
ses, showing that failures in cell cycle checkpoints lead to a
failure in the arrest in G1/S, S, or G2/M allowing the cells to
escape from the proper DSB repair, among other signaling
pathways including apoptosis and chromatin remodeling pro­
cess [243]. Therefore, these non-repaired or misrepaired
DBSs are responsible for chromosomal instability also in
daughter cells, increasing the radiation sensitivity in these
individuals as well as the carcinogenesis risk. It is important
to elucidate that this cellular radiosensitivity is not unique for
A-T syndrome being also observed in other individuals carry­
ing mutations in other genes related to DNA damage repair
and response pathways, namely in FANC, BRCA 1/2,
MRE11, and DNA Lig4 genes, among others (Box 3.39)."
What is ataxia-telangiectasia (A-T) syndrome and how does a germline mutation in the ATM gene contribute to its development?,"Ataxia-telangiectasia (A-T) syndrome is a devastating autosomal recessive genetic disorder characterized by chromosomal instability, neurological degeneration, immune dysfunction, premature aging, and an increased risk of cancer. The primary cause of A-T is a germline mutation in the ATM gene. This gene encodes the ATM protein, which plays a critical role in cellular response to DNA double-strand breaks (DSBs). Specifically, ATM activates cell cycle checkpoints – notably the G1/S, S, and G2/M checkpoints – following DSB recognition. A loss or inactivation of both copies of the ATM gene due to germline mutation disrupts this checkpoint activation process. Consequently, cells with damaged DNA are not effectively halted from progressing through the cell cycle, leading to genomic instability, accumulation of mutations, and ultimately, the clinical manifestations observed in individuals with A-T. Reference: [Molecular Radiation Biology], Section 3.20.2 – Low-Dose Hyper-radiosensitivity.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.20	 Cellular Hyper-radiosensitivity | Sub-subsection: 3.20.2	 Low-Dose Hyper-radiosensitivity | Content: The human ATM gene is located at 11q22-23, contains 66
exons, covers 160 kb of genomic DNA, and encodes the
370 kDa ATM protein. Germline mutation in ATM gene,
either loss or inactivation of both copies, leads to the autoso­
mal recessive ataxia-telangiectasia (A-T) syndrome, a devas­
tating childhood condition characterized by chromosomal
instability, neurological degeneration, immune dysfunction,
premature aging, and high cancer risk. In fact, ATM has a
critical role in the activation of the cell cycle progression and
checkpoint activation in response to DSBs, as well as in the
repair of these lesions through homologous recombination
(HR) and nonhomologous end joining (NHEJ) pathway
[245]. Thus, these mechanisms need to be active during DNA
replication to maintain genome integrity in cells. When dis­
ruptions occur in these mechanisms, the cells are more sus­
ceptible to damage induced by the exposure to endogenous or
exogenous agents, such as radiation exposure. Considering
the well-known fact that exposure to IR activates ATM
kinases to mediate the cellular response, individuals with
these defective mechanisms, like A-T patients, will be more
sensitive to the same IR exposure than non-A-T patients.
Several published studies have corroborated these hypothe­
ses, showing that failures in cell cycle checkpoints lead to a
failure in the arrest in G1/S, S, or G2/M allowing the cells to
escape from the proper DSB repair, among other signaling
pathways including apoptosis and chromatin remodeling pro­
cess [243]. Therefore, these non-repaired or misrepaired
DBSs are responsible for chromosomal instability also in
daughter cells, increasing the radiation sensitivity in these
individuals as well as the carcinogenesis risk. It is important
to elucidate that this cellular radiosensitivity is not unique for
A-T syndrome being also observed in other individuals carry­
ing mutations in other genes related to DNA damage repair
and response pathways, namely in FANC, BRCA 1/2,
MRE11, and DNA Lig4 genes, among others (Box 3.39).
3.20.2	Low-Dose Hyper-radiosensitivity
3.19.1
Box 3.39 In a Nutshell: Cellular Hypersensitivity in AT
Repair Deficient Cells
•	Individuals carrying mutations in genes related to
DNA damage repair are hypersensitive to radiation.
•	A-T syndrome is connected to mutations in ATM,
which has a critical role in checkpoint activation
and DNA damage recognition and repair.
•	HRS/IRR has been attributed to the early G2 check­
point, which is only activated at a certain level of
phosphorylated ATM.
J. Reindl et al.
173Fig. 3.52
Fig. 3.52 Low-dose hyper-radiosensitivity (HRS) and increased radiore­
sistance (IRR) in T-47D breast cancer cells. The left panel shows a full
dose-response curve. The right panel shows the low-dose region. Below
about 0.3 Gy, the cells appear to proceed from G2 to mitosis without repair
of DNA damage, leading to a steep decrease in survival with dose. For
doses above a threshold around 0.3 Gy, the damage is repaired increas­
ingly with dose until the surviving fraction follows the linear-quadratic
response curve. The transition dose corresponds to approximately 8–10
double-strand breaks. The dashed line shows a curve fit by the linear-qua­
dratic model, and the solid line by the induced repair model (see Chap. 4)
even repair-competent cell lines can be hypersensitive to
radiation within a certain low-dose range. This is called low-­
dose hyper-radiosensitivity (HRS) and is characterized by a
high sensitivity to radiation doses below about 0.5 Gy
(depending on the cell line and radiation quality) [246],
which is followed by a more radioresistant response per unit
dose in the dose range of ~0.5–1 Gy. This transition towards
radioresistance is described by the term induced radioresis­
tance (IRR) (Fig. 3.52) and occurs at doses corresponding to
about ten double-strand breaks.
HRS [247] was first identified in vitro in 1993 after hav­
ing been observed in mouse skin in 1986 and in mouse kid­
ney in 1988. HRS has been observed in cells given acute
proton and pi-meson irradiation as well as in cells given
high-LET neutrons at a low dose rate and appears to be the
default response for all radiation qualities in both tumor and
normal cell lines. IRR, on the other hand, is only observed
after low-LET irradiation and only in repair-competent cell
lines [247].
In 2003, a mechanism explaining the basis for the HRS
effect was proposed [248]. A second radiation-induced G2
checkpoint was discovered to be associated with HRS/IRR
[249]. The radiation-induced G2 checkpoint that was known
earlier, often denoted the Sinclair checkpoint, does not arrest
cells irradiated while in G2, because it takes some time for
the checkpoint to be activated. Only cells irradiated while in
G1 or S phase are accumulated in G2 by the Sinclair mecha­
nism. The newly discovered G2 checkpoint, also called the
early G2 checkpoint, is induced immediately after irradiation
and therefore arrests cells that were irradiated while in G2.
Contrary to the dose-dependent mechanisms by which
cells irradiated in G1 or S phase accumulate in the Sinclair
checkpoint, the “early” G2 checkpoint is ATM dependent
[249] and independent of dose over the range of 1–10 Gy.
Activation of the critical damage sensor molecule ATM by
an autophosphorylation event at serine 1981 is detectable at
doses of 0.1 Gy with a gradual increase until phosphoryla­
tion of more than 50% of the ATM molecules in the cell after
3 Molecular Radiation Biology
174Fig. 3.53
Fig. 3.53 Path
to
“increased
radioresistance”
or
“hyper-­
radiosensitivity.” Cells irradiated with doses below about 0.3 Gy while
in G2 will not have enough ATM activated by serine 1981-­phosphorylation
to reach the threshold level for activation of the early G2 checkpoint.
They therefore follow the alternative in the left column, which does not
give extra time for repair before mitosis resulting in “hyper-­
radiosensitivity” (HRS). Cells irradiated with doses above 0.3 Gy while
in G2 follow the alternative in the right column and thereby are given
more time for repair before mitosis resulting in “increased radioresis­
tance” (IRR)
a dose of about 0.5 Gy and saturated expression at larger
doses. Thus, the HRS/IRR transition appears to be coinci­
dent with both the induction of the early G2-phase check­
point and activation of ATM.
3.53
It has been demonstrated that HRS-negative cell lines
have the same ATM activation pattern as cells with HRS,
whereas they show an early G2 arrest even after low radia­
tion doses that produce insufficient damage to induce full
ATM activation. It has therefore been suggested that the
dose-dependent ATM regulatory control is evaded by aber­
rant early G2-checkpoint response in HRS-negative cell
lines caused by dissociation between ATM activity and early
G2-checkpoint function [250].
The existence of HRS appears in some cell lines to be
associated with an elevated level of caspase-3-mediated
apoptosis after low-dose exposures [250], suggesting that the
radiation-damaged G2-phase cells that evade the early G2
checkpoint are disposed of by this mechanism when entering
mitosis. However, also cell lines deficient in TP53 induction
after irradiation or with mutated TP53 have been shown to
display HRS/IRR, and no increase in apoptosis in response
to HRS-inducing doses was observed in BMG-1 cells with
wild-type TP53. In addition, no connection between HRS
and apoptosis in the six HRS-competent cell lines investi­
gated measured by DNA-PKcs as early apoptosis marker
was found. This corroborates the hypothesis that the transi­
tion from HRS to IRR primarily is related to induction of the
“early” G2 checkpoint and that the death process of the cells
entering mitosis with damages is cell line dependent.
Early G2-checkpoint activation as the underlying mecha­
nism for HRS/IRR is supported by priming experiments
where a dose of 0.2–0.5 Gy removes the HRS response to
subsequent irradiation given within 6–8 h after the priming.
This timing corresponds to the duration of the early
G2-checkpoint activation. Surprisingly, the HRS/IRR
response can be permanently eliminated by priming irradia­
tion if it is given with a low dose rate of 0.1–0.3 Gy/h for 1 h
(shown in T98G glioblastoma and T-47D breast cancer
cells). The low dose rate primed cells activated the early G2
checkpoint for all doses. The response was shown to involve
transforming growth factor beta 3 (TGF-β3) and inducible
nitric oxide synthase (iNOS) activation. The HRS phenotype
could be reinstated by inhibition of iNOS [251].
It has been suggested that HRS is a protective mechanism
and that it is advantageous to sacrifice a small fraction of
cells rather than risking the development of genomic insta­
bility and mutations. While cells without the IRR are defi­
cient in DNA repair or checkpoint activation, cells without
HRS may have been “turned off” by mechanisms similar to
the ones induced by low dose rate priming (Box 3.40)."
"Describe the relationship between hyper-radiosensitivity (HRS) and the bystander effect, as illustrated by the provided text, specifically addressing how priming with a low dose rate of radiation influences this interaction.","The text highlights a complex interplay between hyper-radiosensitivity (HRS) and the bystander effect, primarily observed in cancer cells. Initially, it was thought that HRS and cell kill mediated by the bystander effect were mutually exclusive processes – namely, irradiated cells (donor cells) could induce radiation sensitivity in unirradiated cells (reporter cells). However, the study demonstrates that this isn’t always the case. When doses of radiation fall within the range associated with HRS (below approximately 0.5 Gy), HRS-proficient cells *can* elicit strong bystander signals. Conversely, when irradiation doses reach levels where the IRR (irradiation resistance) response dominates, the bystander effect is absent. Critically, the text details a mechanism that links these phenomena: priming irradiated cells with a low dose rate of radiation (0.1–0.3 Gy/h for 1 hour) dramatically alters this relationship. This priming activates the early G2 checkpoint and induces the expression of transforming growth factor beta 3 (TGF-β3) and inducible nitric oxide synthase (iNOS). Notably, the HRS phenotype can be reinstated by inhibiting iNOS. Furthermore, medium transferred from primed cells – those where the HRS/IRR response had been permanently eliminated – was observed to remove the HRS response in recipient cells for 8–12 hours. This suggests that the bystander signals aren’t merely a consequence of radiation damage but can actively modulate and potentially protect against the initial HRS response, particularly when initiated by priming with low-dose irradiation.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.20	 Cellular Hyper-radiosensitivity | Sub-subsection: 3.20.3	 HRS and Bystander Signaling (Cytotoxic or Adaptive) | Content: This timing corresponds to the duration of the early
G2-checkpoint activation. Surprisingly, the HRS/IRR
response can be permanently eliminated by priming irradia­
tion if it is given with a low dose rate of 0.1–0.3 Gy/h for 1 h
(shown in T98G glioblastoma and T-47D breast cancer
cells). The low dose rate primed cells activated the early G2
checkpoint for all doses. The response was shown to involve
transforming growth factor beta 3 (TGF-β3) and inducible
nitric oxide synthase (iNOS) activation. The HRS phenotype
could be reinstated by inhibition of iNOS [251].
It has been suggested that HRS is a protective mechanism
and that it is advantageous to sacrifice a small fraction of
cells rather than risking the development of genomic insta­
bility and mutations. While cells without the IRR are defi­
cient in DNA repair or checkpoint activation, cells without
HRS may have been “turned off” by mechanisms similar to
the ones induced by low dose rate priming (Box 3.40).
3.20.3	HRS and Bystander Signaling (Cytotoxic
or Adaptive)
As described in Chap. 2, irradiated (donor) cells can secrete
signals which, when transferred to unirradiated (reporter)
cells, make these respond as if they had been irradiated
themselves. This is called the bystander effect. For a while, it
was believed that HRS and cell kill by the bystander effect
were mutually exclusive, but when doses in the HRS dose
range were tested on HRS-proficient cells, these were able to
induce strong bystander signals. However, when doses
reached the level where IRR was dominating, there was no
bystander signaling.
Box 3.40 In a Nutshell: Low Dose Hyper-Radiosensitivity
•	Cells with HRS are very sensitive to doses below
about 0.5 Gy.
•	Above 0.5 Gy, the survival per dose increases until
it reaches the LQ curve.
•	HRS/IRR has been attributed to the early G2 check­
point, which is only activated at a certain level of
phosphorylated ATM.
J. Reindl et al.
175
Bystander signals may also be protective. Transfer of
medium from HRS-deficient HaCaT normal human epithe­
lial cells to HRS-proficient T98G glioblastoma cells
increased the survival above the normal plating efficiency
for these cells [252]. In addition to the effect on cell sur­
vival, bystander signals can also moderate the HRS/IRR
response to subsequent irradiation. Medium transferred
from cells, in which the HRS/IRR response was perma­
nently eliminated by priming with 0.1–0.3 Gy for 1 h, has
been seen to remove the HRS response in recipient cells for
8–12 h [251] (Box 3.41)."
"Describe the relationship between cellular hyper-radiosensitivity (HRS), the G2 phase of the cell cycle, and its potential implications for cancer radiotherapy utilizing intensity-modulated radiation therapy (IMRT).","Cellular hyper-radiosensitivity (HRS) is fundamentally linked to the proportion of cells residing within the G2 phase of the cell cycle. HRS manifests as an increased susceptibility to ionizing radiation damage when a significant fraction of cells are arrested in this particular stage. This heightened sensitivity is particularly pronounced in rapidly proliferating tissues, such as skin, where basal cell density or skin erythema can serve as measurable endpoints reflecting HRS levels. IMRT, by delivering lower doses over larger volumes of tissue, inherently increases the irradiation burden on normal tissues. Because HRS is directly correlated with G2 phase occupancy, this increased radiation exposure poses a greater risk to tissues with a substantial population of cells in this arrested state. Conversely, HRS tends to be less pronounced in slowly proliferating normal tissues that have a smaller percentage of cells in the G2 phase. Clinically, understanding and potentially exploiting HRS could allow for strategic dose fractionation within the range of observed HRS effects. However, achieving equivalent cell kill with lower doses necessitates increased treatment fractions, which can inadvertently promote tumor growth if the interval between fractions is too short. The failure of ultrafractionation (e.g., 0.4 Gy per fraction administered three times daily) to demonstrate HRS in murine lymphoma or glioblastoma models suggests that synchronization of cells within the G2 phase – for example, through the use of agents like paclitaxel – may be crucial to effectively leverage HRS for therapeutic benefit. Synchronizing cell cycle arrest improves the effectiveness of low-dose fractionation by preventing premature release from the G2 checkpoint.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.20	 Cellular Hyper-radiosensitivity | Sub-subsection: 3.20.4	 HRS and Clinical Relevance | Content: The presence of HRS may have implications for cancer radio­
therapy in which the aim is to control the eradication of tumor
tissue while minimizing the damage to normal tissue. The
introduction of intensity-modulated radiation therapy (IMRT)
in cancer treatment results in irradiation of a larger proportion
of normal tissue but at lower doses when compared to con­
ventional treatment. In some situations, one could fear that
HRS will tend to increase the effect of low doses in normal
tissue and thus negate the benefits of using IMRT, in particu­
lar in tissues with a pronounced volume effect [253].
Since HRS is related to the fraction of cells in G2 phase,
it may be of more consequence for early-responding prolif­
erating tissues, such as skin, than for slowly proliferating
normal tissues with a small fraction of cells in G2. In sup­
port, evidence of HRS has been demonstrated in studies with
human skin using basal cell density or skin erythema as end­
point. On the other hand, with the HRS effect being more
pronounced in fast-dividing tumor cells than slowly or non­
dividing normal tissues, it may be possible to exploit HRS
clinically using dose fractions within the HRS dose range.
However, to obtain the same cell kill as with 2 Gy fractions,
more fractions are needed. Increasing treatment time would
give the tumor more time to grow; therefore, the time
between fractions has to be decreased, but that could be a
problem: Experiments with ultrafractionation of 0.4 Gy per
fraction, three fractions per day in murine DDL1 lymphoma
or in human A7 glioblastoma xenografts, did not show evi­
dence of HRS. This could be because with three fractions per
day, the timing between fractions would have been too short
for the cell to be released from the early G2-checkpoint
arrest induced by the previous dose. Since HRS affects cells
in G2, another approach is to synchronize the cells to improve
the therapeutic potential of ultrafractionation. A protocol
using a taxane (paclitaxel), which synchronizes cells in G2
phase, in combination with carboplatin and low-dose frac­
tionated radiation, was extremely well tolerated by the
patients and showed a synergistic effect in patients with
squamous cell cancer of the head and neck [254] (Box 3.42).
3.21"
"Following exposure to ionizing radiation, how do cells develop resistance to subsequent radiation damage, and what are some of the key molecular mechanisms involved in this induced radiation resistance?","Cells can develop resistance to ionizing radiation through a complex interplay of adaptive responses that ultimately alter their sensitivity to further damage. This phenomenon is often referred to as ‘radiation hormesis’ at low doses, though the precise mechanisms remain an area of active research. Several key molecular pathways contribute to this induced resistance. Firstly, DNA repair mechanisms are upregulated following initial irradiation. Specifically, increased activity of nucleotide excision repair (NER) and base excision repair (BER) systems allows for more efficient removal of damaged DNA strands before they can lead to replication errors or cell death. Secondly, the activation of antioxidant defense systems plays a crucial role. Radiation generates reactive oxygen species (ROS), which cause oxidative damage to cellular components like lipids, proteins, and DNA. Cells respond by increasing levels of enzymes such as superoxide dismutase (SOD) and catalase, effectively scavenging ROS and mitigating their damaging effects. Thirdly, alterations in cell cycle checkpoints are observed; initially, the cell may temporarily halt progression through the cell cycle at various points (G1, S, or G2/M phases) to allow for repair. However, prolonged exposure can lead to a shift towards a more resilient state where cells become less sensitive to these checkpoints. Furthermore, changes in chromatin structure – including alterations in histone modifications and DNA methylation – have been implicated in modulating genomic stability and repair capacity. Finally, some studies suggest that radiation exposure triggers the expression of genes involved in cellular stress response pathways like the heat shock response (HSR), which further enhances cellular survival by promoting protein folding and protecting against damage. It’s important to note that this induced resistance is not simply a passive adaptation; it involves active molecular changes within the cell, ultimately altering its vulnerability to future radiation exposure. ","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Content: squamous cell cancer of the head and neck [254] (Box 3.42).
3.21
Induced Radiation Resistance"
"Describe the cellular mechanisms contributing to induced radiation resistance observed in malignant cells, focusing on strategies beyond simple cell killing.","Radiation resistance in malignant cells arises through a complex interplay of mechanisms designed to mitigate the damaging effects of ionizing radiation. Primarily, this involves two key strategies: (a) protection of the proteome and DNA from damage via scavenging and regeneration processes, and (b) recruitment and utilization of highly sophisticated DNA repair mechanisms to reconstruct a functional genome. Specifically, cells employ pathways related to DNA damage repair, oxidative stress reduction, cell pro-survival, hypoxia management, cell cycle control, and apoptotic pathway modulation. Furthermore, the presence of cancer stem cells (CSCs), characterized by their ability to self-renew, differentiate, exhibit enhanced DNA repair proficiency, generate lower levels of reactive oxygen species (ROS), and proliferate at a slower rate compared to other tumor populations, significantly contributes to radiation resistance due to their inherent resilience. These mechanisms collectively allow malignant cells to withstand higher doses of radiation than normal cells would tolerate. Reference: [MolecularRadiationBiology, Section 3.21.1 – Basic Mechanisms Leading to Radiation Resistance]","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Sub-subsection: 3.21.1	 Basic Mechanisms Leading to Radiation Resistance | Content: squamous cell cancer of the head and neck [254] (Box 3.42).
3.21
Induced Radiation Resistance
3.21.1	Basic Mechanisms Leading to Radiation
Resistance
By the term radiation resistance, we refer to the inherent
ability of specific types of cells and tissues (usually of malig­
nant origin) to show a differential response to ionizing radia­
tion overcoming its damaging effects like cell killing or
inactivation. The amount of energy (for example level of
dose in Gy) and consecutive damage that each organism can
withstand is a characteristic of the organism’s ability to
respond to radiation by a variety of mechanisms often called
as DNA damage response (DDR) mechanisms. At the organ­
ism level, usually humans are more sensitive compared to
other primates or mammals. In nature, there is a great variety
of resistance to radiation with the extreme case of certain
extremophiles, such as the bacteria Deinococcus radio­
durans and the tardigrades, to be able to withstand large
doses of ionizing radiation on the order of 5000 Gy. Although
none of the strategies discussed in various studies on extreme
radioresistance appear to be universal against ionizing radia­
tion, a general trend was found. There are two cellular mech­
anisms by which radioresistance is accomplished: (a)
protection of the proteome and DNA from damage by scav­
enging and regeneration strategies and (b) recruitment of
advanced and highly sophisticated DNA repair mechanisms,
in order to reconstruct a fully functional genome [255].
Box 3.41 In a Nutshell: Hyper-Radiosensitivity and
Bystander Signaling
•	HRS-proficient cells irradiated with doses in the
HRS range produce bystander signals that reduce
the survival of reporter cells.
•	HRS-proficient cells, in which the HRS response
has been removed by low dose rate priming, pro­
duce bystander signals that remove the HRS
response to subsequent irradiation in recipient cells.
Box 3.42 In a Nutshell: Hyper-Radiosensitivity and
Clinical Relevance
•	Attempts to exploit HRS in the clinic using hyper­
fractionation have not been successful.
•	Combination of low radiation doses with chemo­
therapeutics synchronizing cells in G2 phase has
shown promise.
3 Molecular Radiation Biology
176
While normal (nonmalignant) mammalian cells com­
pared to tumor ones are usually less radioresistant, one can­
not exclude the opposite possibility. Elucidation of the
molecular mechanisms and pathways related to radioresis­
tance of tumor cells is of major importance in order to
develop strategies maximizing tumor control during chemo-
or radiation therapies. Many studies using a wide range of
in vitro, ex vivo, and in vivo models as well as bioinformatics
have fingerprinted the main pathways leading to cellular
radioresistance, and these are primarily implicated in DNA
damage repair, oxidative stress, cell pro-survival, hypoxia,
cell cycle control, and apoptotic pathways [231].
Another important factor contributing to resistance of
tumors is the existence of cancer stem cells (CSCs) as a dis­
tinct subpopulation within a tumor. CSCs are able to self-­
renew and differentiate while showing a high proficiency to
repair DNA damage, reveal low levels of reactive oxygen
species (ROS), and proliferate at a slower rate compared to
other tumor cell populations. These features render CSCs
resistant to various therapies, including radiation therapy
(RT) [256]. The results of such studies can serve as potential
diagnostic/prognostic markers of cancer cell resistance to
radiation treatment, as well as for therapy outcome and
increase of cancer patient survival."
"Describe the radiation-induced adaptive response observed in cells, outlining key parameters measured and typical dose rates/doses that promote this adaptation.","The radiation-induced adaptive response, initially described by Olivieri et al. (1984), refers to a decreased sensitivity of cells to subsequent irradiation challenges following exposure to a smaller ‘priming’ dose. This phenomenon has been extensively studied *in vitro* and *in vivo*, utilizing various metrics to assess cellular damage and survival. Commonly measured endpoints include cell lethality, the induction of chromosomal aberrations, mutation rates, radiosensitivity (measured as the required dose for 50% inhibition – GCI), and DNA repair capacity. Adaptation is most efficiently triggered by priming doses within the range of 0.01–0.5 Gy delivered at dose rates between 0.01 and 1.0 Gy/min. The challenge irradiation typically involves doses in the range of 0.5–2 Gy. Notably, the protective effect generally persists for approximately three generations following the initial priming irradiation. The underlying molecular mechanisms are complex and involve a coordinated response including enhanced DNA damage repair (particularly via pathways like nucleotide excision repair), increased production of antioxidant enzymes – notably through activation of the NRF2 pathway – modulation of inflammatory responses mediated by the NF-κB and MAPK pathways, induction of autophagy, alterations in cell cycle regulation, and bystander signaling.  It’s important to note that this adaptation is not a permanent change but rather a transient reduction in radiosensitivity within a limited timeframe.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Sub-subsection: 3.21.2	 Adaptive Response | Content: The radiation-induced adaptive response was first described by
Olivieri et al. in 1984 [257] as the reduced sensitivity to a chal­
lenge irradiation induced by a previous small priming dose.
Radio-adaptive responses have been observed in vitro and
in vivo using various endpoints, such as cell lethality, chromo­
somal aberrations, mutation induction, radiosensitivity, and
DNA repair [258]. Adaptation is most efficiently induced by
doses of 0.01–0.5 Gy at dose rates from 0.01 to 1.0 Gy/min
(Tapio und Jacob 2007) with challenge doses in the range of
0.5–2 Gy. The protective effect has been reported to last for
about three generations following the priming irradiation. The
molecular mechanisms underlying the adaptive response are not
well understood, but data indicate involvement of DNA damage
repair, antioxidant production (NRF2 pathway), NF-κB inflam­
matory pathway, MAPK pathway, autophagy, cell cycle regula­
tion, apoptosis, and bystander signaling [258] (Box 3.43)."
"Describe the key characteristics and mechanisms that contribute to the radioresistance of cancer stem cells (CSCs) as outlined in the text, focusing on their ability to repair DNA damage and manage oxidative stress.","Cancer stem cells (CSCs) exhibit a heightened resistance to radiation therapy due to several interconnected factors. Primarily, they demonstrate exceptional proficiency in DNA damage repair, activating key proteins like ATM, Chk1, Chk2, SMC1, and TP53 – all involved in recognizing and correcting damaged DNA. Furthermore, CSCs display low levels of reactive oxygen species (ROS) production and significantly overexpress ROS scavengers, providing robust protection against the oxidative stress induced by radiation. This combined effect allows them to proliferate at a slower rate than other tumor cell populations, affording more time for repair processes to operate effectively. Finally, they possess a flexible phenotype with the ability to convert into a non-CSC state, and can adapt to the tumor microenvironment through mechanisms like epithelial-mesenchymal transition (EMT) and inhibit cell death pathways via upregulation of anti-apoptotic proteins. Reference: [Molecular Radiation Biology], Section 3.21.3.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Sub-subsection: 3.21.3	 Cancer Stem Cells | Content: tinct subpopulation within a tumor. CSCs are able to self-­
renew and differentiate while showing a high proficiency to
repair DNA damage, reveal low levels of reactive oxygen
species (ROS), and proliferate at a slower rate compared to
other tumor cell populations. These features render CSCs
resistant to various therapies, including radiation therapy
(RT) [256]. The results of such studies can serve as potential
diagnostic/prognostic markers of cancer cell resistance to
radiation treatment, as well as for therapy outcome and
increase of cancer patient survival.
3.21.2	Adaptive Response
The radiation-induced adaptive response was first described by
Olivieri et al. in 1984 [257] as the reduced sensitivity to a chal­
lenge irradiation induced by a previous small priming dose.
Radio-adaptive responses have been observed in vitro and
in vivo using various endpoints, such as cell lethality, chromo­
somal aberrations, mutation induction, radiosensitivity, and
DNA repair [258]. Adaptation is most efficiently induced by
doses of 0.01–0.5 Gy at dose rates from 0.01 to 1.0 Gy/min
(Tapio und Jacob 2007) with challenge doses in the range of
0.5–2 Gy. The protective effect has been reported to last for
about three generations following the priming irradiation. The
molecular mechanisms underlying the adaptive response are not
well understood, but data indicate involvement of DNA damage
repair, antioxidant production (NRF2 pathway), NF-κB inflam­
matory pathway, MAPK pathway, autophagy, cell cycle regula­
tion, apoptosis, and bystander signaling [258] (Box 3.43).
3.21.3	Cancer Stem Cells
­
3.16
3.44
Box 3.43 In a Nutshell: Induced Radiation Resistance
•	Cellular radioresistance can be modulated either
through protection against DNA damage or through
DNA repair.
•	Pre-exposure to a low dose can induce protection
against a subsequent high dose.
Box 3.44 In a Nutshell: Cancer Stem Cells
•	Cancer stem cells are a radioresistant tumor sub­
population due to high DNA repair proficiency, low
ROS generation and high ROS scavenging, and
slow proliferation (giving time for repair).
Table 3.16 Biological characteristics and radioresistance mechanisms
of cancer stem cells
Biological characteristics
Radioresistance mechanisms
Are long-lived and have
tumorigenic abilities
To activate pro-survival pathways
Are able to proliferate, maintain
their growth indefinitely
To improve DNA repair ability
through the activation of DNA
damage checkpoint proteins,
such as ATM, Chk1, Chk2,
SMC1, and TP53
Differentiate, generating different
cell populations inside the tumor
To defend against oxidative
stress, since CSCs present lower
levels of ROS and overexpress
ROS scavengers that protect
them from ROS produced in
response to radiation
Have long-term repopulation
potential
To indefinitely self-renew,
through the activation of cell
signaling pathways, such as
Wnt/β-catenin, notch, TGF-β,
and PI3K/AKT/mTOR
Have a flexible phenotype
(plasticity), since a conversion of
a CSC into a non-CSC phenotype
can be reversed, a process highly
dependent on the epithelial-­
mesenchymal transition (EMT)
To overcome the cell cycle
control by the abnormal
expression of cell cycle-related
proteins
Can adapt to the tumor
microenvironment
To inhibit cell death pathways
after radiation exposure, through
the upregulation of anti-apoptotic
proteins (like BCL-2 and
survivin) and the inhibition of
autophagy-related proteins (like
Beclin-1 and ATG-5)
J. Reindl et al.
177
Box 3.45 In a Nutshell: Hypoxia and Radiation
Resistance
•	Hypoxia induces radioresistance by preventing the
radiosensitizing effect of oxygen.
•	Oxygen radiosensitizes by fixating DNA damage
and thus preventing restitution by hydrogen donors.
•	Oxygen can also increase the amount of radicals
through the direct effect."
"Explain how hypoxia contributes to increased resistance of cells to ionizing radiation damage, detailing the underlying mechanisms involved.","Hypoxia significantly enhances cellular sensitivity to ionizing radiation by disrupting the typical pathways that amplify radiation-induced damage. The key mechanism revolves around oxygen's interaction with both the radiation itself and its subsequent products. Initially, oxygen possesses a high affinity for electrons, readily reacting with highly energetic radiation particles upon exposure. This rapid scavenging of free electrons effectively reduces the number available to initiate further damaging reactions within the cell. However, this isn’t simply about removing reactive species; it also triggers a cascade of events. The reaction between oxygen and radiation-induced damage creates water radicals (H• and OH•), which are extremely reactive and contribute significantly to DNA strand breaks and other cellular harm. Hypoxic conditions severely limit the ability of these water radicals to propagate, as they require molecular oxygen to react efficiently. Without sufficient oxygen, their formation is dramatically reduced, thereby diminishing the overall extent of radiation damage. Furthermore, hypoxia alters cellular metabolism, potentially shifting cells towards a state less susceptible to oxidative stress – a major contributor to radiation sensitivity. Essentially, hypoxia acts as a ‘shield’ by preventing the amplification of radiation damage through electron scavenging and radical propagation, creating a more resilient environment for the cell. This resistance is transient; once oxygen levels return to normal, the cellular response to radiation will be significantly amplified.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Sub-subsection: 3.21.4	 Hypoxia | Content: Hypoxia refers to conditions with low oxygen. Hypoxia
induces radiation resistance by preventing the sensitizing effect
of the presence of oxygen during or within microseconds of
radiation exposure. Oxygen has high affinity for electrons. It
may therefore react with radiation-damaged biomolecules as
well as with radiation-induced water radicals (see Chap. 1).
3.21.4.1"
"Explain how oxygen can both contribute to and mitigate radiation damage at a molecular level, detailing the specific chemical reactions involved.","Oxygen's interaction with radiation-induced damage is complex and operates through two primary mechanisms. Initially, radiation deposits energy into biomolecules like DNA or proteins, leading to the formation of radicals – specifically, single-electron deficient species (M°). This radical formation can be enhanced by oxygen. Oxygen acts as a sensitizer primarily through a process involving electron transfer. When a molecule (MH) absorbs radiation and becomes polarized (MH−), oxygen can ‘steal’ an excited electron from this polar molecule before it loses its excitation energy, effectively creating a biomolecule radical (M°) and a superoxide anion (O2-). The reaction proceeds as follows: MH− + O2 → MH+ + O2-. This process increases the concentration of biomolecule radicals. However, oxygen also possesses a significant affinity for electrons itself. It can react with the initial radiation-induced radical (M°) to form a stable molecule (MH+) and a hydrogen ion (H+), effectively reversing the damage: MH° + O2 → MH+ + H+. This ability of oxygen to scavenge free radicals is crucial in mitigating radiation damage, as it reduces the number of highly reactive species capable of causing further cellular harm. The overall effect depends on the balance between these two processes – oxygen’s capacity to generate and remove biomolecule radicals.

Reference: [Molecular Radiation Biology], Section 3.21.4.1 – Hypoxia","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Sub-subsection: 3.21.4	 Hypoxia | Sub-sub-subsection: 3.21.4.1	 The Direct Effect of Oxygen | Content: Radiation creates radicals either directly in a biomolecule
(e.g., DNA) or indirectly through water radicals: MH + radi­
ation → M° + H°, where MH is an intact biomolecule while
M° is the radical after loss of one hydrogen atom. Oxygen
can sensitize by a direct interference with the primary radia­
tion process. This can take place because deposit of radiation
energy not always completes the dissociation. Often, the
large biomolecule is just polarized as follows: MH + radia­
tion →+MH−
This process is however reversible. Thus, a spontaneous
restitution can take place by the electron falling back to its
normal position in the molecule and losing the excitation
energy. Due to its great affinity for electrons, oxygen may
however “steal” the excited electron before it gives away the
excitation energy:
+MH− + O2 → MH+ + O2
−
By this process, oxygen creates a biomolecule radical
after the following dissociation:
MH+ → M° + H+
In this way, oxygen increases the gain of biomolecule
radicals.
3.21.4.2"
"Explain how hypoxia contributes to radiation resistance in cells, detailing the mechanisms involved and why oxygen's presence exacerbates damage.","Hypoxia plays a crucial role in conferring radiation resistance by effectively preventing the oxidative fixation of radiation-induced damage. When cellular oxygen levels are low – i.e., under hypoxic conditions – the immediate reaction between radiation-damaged biomolecules (represented as M°) and molecular oxygen (O2) is significantly reduced. This reaction, which forms a stable bond like MO2°, would normally trap these radical species and halt their ability to undergo restitution via hydrogen donors. Without sufficient oxygen present, this fixation process cannot occur.

Conversely, in the presence of normal oxygen concentrations, oxygen readily reacts with the biomolecule radicals, forming stable bonds (MO2°) and preventing the cell's natural defense mechanism – restitution. This restitution relies on hydrogen donors like glutathione (RSH), which can react with the radical to restore the original molecule (MH) and regenerate the hydrogen donor (RS°). Oxygen effectively ‘outcompetes’ this restoration process, trapping the radicals and perpetuating damage.

Therefore, hypoxia protects against radiation damage by preventing oxygen from fixing the biomolecule radicals, allowing for continued restitution through glutathione-mediated pathways. The high concentration of SH compounds within cells normally acts as a primary protective mechanism against harmful radicals, but this is rendered ineffective when oxygen dominates the environment.

Reference: Molecular Radiation Biology, Section 3.21.4.2 – The Indirect Effect of Oxygen","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.21	 Induced Radiation Resistance | Sub-subsection: 3.21.4	 Hypoxia | Sub-sub-subsection: 3.21.4.2	 The Indirect Effect of Oxygen | Content: Due to its great affinity for electrons, oxygen will easily react
with both radiation-damaged biomolecules and radiation-­
induced water radicals. When oxygen reacts with the bio­
molecule radical, it forms a stable bond as follows:
M° + O2 → MO2°
Thereby, oxygen fixates the damage and prevents restitu­
tion by hydrogen donors (antioxidants), which is a natural
protective means of the cells:
M° + RSH → MH + RS°
where RSH represents hydrogen donors, of which gluta­
thione is one example.
In cells, the concentration of SH compounds is normally
high, and they represent a fundamental protective means
against harmful radicals if not outcompeted by oxygen.
Hypoxia thus protects against radiation damage through res­
titution by hydrogen donors because oxygen is not present to
outcompete restitution and fixate the damage (Box 3.45).
3.22"
The text describes a protective mechanism against radiation damage involving hydrogen donors like glutathione. Explain the significance of this process in mitigating oxidative stress and how it relates to hypoxia's role in shielding cells from radiation.,"During irradiation, reactive oxygen species (ROS) are generated, causing significant cellular damage through oxidation of DNA, proteins, and lipids. The body employs several defense mechanisms against these ROS. One key strategy involves the utilization of hydrogen donors, such as glutathione, which readily donate electrons to neutralize free radicals. This process effectively reduces oxidative stress by converting harmful ROS into less reactive species. Hypoxia – a condition of low oxygen availability – is crucial in this context because it directly limits the production of oxygen itself, thereby preventing oxygen from competitively outcompeting the hydrogen donor system and fixing the damage caused by radiation. Essentially, hypoxia removes the primary source of oxidative stress, allowing the hydrogen donors to effectively scavenge ROS and protect cellular components.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.22	 Exercises and Self-Assessment | Content: M° + RSH → MH + RS°
where RSH represents hydrogen donors, of which gluta­
thione is one example.
In cells, the concentration of SH compounds is normally
high, and they represent a fundamental protective means
against harmful radicals if not outcompeted by oxygen.
Hypoxia thus protects against radiation damage through res­
titution by hydrogen donors because oxygen is not present to
outcompete restitution and fixate the damage (Box 3.45).
3.22
Exercises and Self-Assessment
Q1.	Which of the following effects of IR produce free radi­
cals within the cell, which can damage the cellular
macromolecules?
(a)	Double ionization
(b)	Direct action
(c)	Indirect action
(d)	Single ionization
Q2.	What are the most significant differences between the
two repair patterns of the base excision repair (BER)
repair mechanism?
Q3.	Which repair pathway provides a “backup” to the rep­
licative proofreading carried out by most (but not all)
DNA polymerases during DNA replication?
(a)	Base excision repair
(b)	Nucleotide excision repair
(c)	Nonhomologous end joining
(d)	Mismatch repair
Q4.	Compare the two principal DNA DSB pathways. What
is similar and what is different in these?
Q5.	Complex translocation to some extent depends on the
radiation quality. Please indicate when they most often
occur. Complex translocation types are characteristic
especially for cellular exposure to:
(a)	Low-LET radiation
(b)	High-LET radiation
(c)	Photonic radiation
(d)	LET of radiation has no effect on the character of
chromosomal translocation
Q6.	Pick one incorrect statement for completing the sen­
tence “The superoxide anion is …”
(a)	Produced by mitochondria
(b)	A free radical reactive oxygen species
(c)	Converted to water by superoxide dismutase
(d)	Able to react with hydrogen peroxide producing
hydroxyl radicals
(e)	Less lipid soluble than hydrogen peroxide
3 Molecular Radiation Biology
178
Q7.	For cell transition in the cell cycle, in which phase do
the CDK1/cyclin B complex plays a significant role?
(a)	G2 into M
(b)	G1 into S
(c)	S into G2
(d)	G0 into G1
(e)	M into G1
Q8.	What will the cycling cells do when They get a “go-­
ahead” indication at the checkpoint?
(a)	Directly progress into the telophase
(b)	Finish the cell cycle and finally divide
(c)	Leave the cell cycle and modify to a nondividing
state
(d)	Demonstrate a fall in M phase-promoting factor
(e)	Finish cytokinesis and generate new cell
membranes
Q9.	Which is the most radiosensitive cell cycle phase, and
which is the most resistant one?
Q10.	Why is immortalization so important for cancer cells?
Q11.	Cells may execute cell death in different ways in
response to IR. Please discuss the factors that may
influence the pathway elicited.
Q12.	What is the main reason for activation of cell death in
response to IR in solid tumor cells?
(a)	DNA damage-induced apoptosis
(b)	Initiation of senescence as a result of DNA
damage
(c)	Mitotic catastrophe following improper segrega­
tion of genetic material
(d)	Oxidation-triggered damage to proteins
(e)	Generation of ceramide at the plasma membrane
via sphingomyelinase
Q13.	Which of the following pathways has been implicated
in cellular response to IR:
(a)	Autophagy
(b)	Apoptosis
(c)	Necrosis
(d)	Mitotic catastrophe
(e)	All of a–d
Q14.	Apoptosis can proceed by two main routes, intrinsic
and extrinsic signaling. Describe the initial triggers for
these two pathways and how they lead to apoptosis.
Q15.	Cite the different steps of the autophagy process.
Q16.	Considering that 800 colonies have grown at 0 Gy for
1200 cells seeded, and that 126 colonies are counted at
2 Gy for 2000 cells seeded, which of the following
statements are correct?
(a)	The plating efficiency at 0 Gy is 66.6%.
(b)	The plating efficiency at 2 Gy is 6.4%.
(c)	The plating efficiency at 2 Gy is 9.5%.
(d)	The surviving fraction at 2 Gy is 9.5%.
(e)	The surviving fraction at 1 Gy is 100%.
Q17.	Which alteration is more likely to lead to the death of
an embryo? Alteration of the function of an oncogene
or a tumor suppressor gene?
Q18.	Which cells are mainly involved in inflammation and
modulated by low to medium doses of IR?
Q19.	Are the following statements regarding epigenetic
DNA alterations true or false?
(a)	5-Methylcytosine is a common DNA modifica­
tion.
(b)	DNA methylation is equally common in all four
nucleotides.
(c)	Histone variants are only synthesized during S
phase.
(d)	The amino acid lysine in a histone protein is a tar­
get for acetylation.
Q20.	Is this statement true?
(a)	One miRNA regulates only one mRNA target.
Q21.	Is the following statement true or false: ARS involves
a total dose of over 0.7 Gy (70 rad) from an external
source, administered in a few minutes.
Q22.	Is the following statement true or false: PTEN is a cen­
tral positive regulator of the PI3-K/AKT pathway.
Q23.	Which of the following statements are correct about
lncRNAs?
(a)	lncRNAs are translated into regulatory proteins.
(b)	lncRNAs are short RNA transcripts of around 20
nucleotides.
(c)	lncRNAs can interact with other RNA subtypes to
regulate gene expression.
Q24.	Which of the following statements are correct about
extracellular vesicles?
(a)	Extracellular vesicles have a size range of 40 nm
to several μm.
(b)	Extracellular vesicles cargo only proteins.
(c)	Extracellular vesicles can indicate cell death.
(d)	Extracellular vesicles are only formed by cells and
tissue undergoing cell death.
(e)	Radiation effects on cells and tissue only generate
extracellular vesicles to protect against radiation-­
induced cell death.
Q25.	In the field of lipidomics or metabolomics, what is the
accurate method to achieve the comprehensive metab­
olite of a sample using LC-MS/MS?
(a)	MRM method
(b)	PCR methods
(c)	Elisa methos
(d)	Dicentric assay
Q26.	What happens to cells irradiated while in G2 with (a)
0.1 Gy and (b) 1Gy?
Q27.	What is the challenge when exploiting HRS in
radiotherapy?
Q28.	What is the radiation adaptive response?
J. Reindl et al.
179
Q29.	Please refer two mechanisms responsible for the
increased radioresistance of cancer stem cells.
Q30.	Explain why hypoxic cells are more radioresistant
than oxygenated cells.
3.23"
"Describe the mechanisms involved in base excision repair (BER) within DNA, highlighting the differences between SP-BER and LP-BER.","Base excision repair (BER) is a crucial pathway for removing damaged or modified bases from DNA strands. It begins with the recognition of the damaged base by specific glycosylases.  SP-BER (short patch BER) primarily focuses on replacing the single, damaged nucleotide. This process requires DNA synthesis to fill in the gap using DNA polymerase β, and finally, ligation by ligase 3 seals the nick in the DNA backbone. In contrast, LP-BER (long patch BER) is capable of removing a significantly larger segment – up to ten nucleotides – surrounding the damaged base.  This extensive removal necessitates the action of multiple DNA polymerases (δ and ε) alongside ligase 1 to reconstruct the DNA strand after the excision. The greater capacity of LP-BER reflects its ability to handle more complex DNA damage scenarios, such as those involving larger lesions or distortions in the DNA helix. Reference: [Molecular Radiation Biology], Section 3.23 – BER Mechanisms.","Document: MolecularRadiationBiology | Section: 3: Molecular Radiation Biology | Subsection: 3.23	 Exercise Answers | Content: SQ1.	Alternative (c). Free radicals are formed after IR by
indirect action.
SQ2.	The two BER mechanisms are SP-BER and LP-­
BER. SP-BER involves replacing the damaged base
only. It requires DNA synthesis to replace the miss­
ing bases by DNA polymerase β, and to finalize the
process, it uses ligase 3. In LP-BER, up to ten nucle­
otides are cut out and replaced, and the polymerases
used are DNA polymerases δ and ε and ligase 1 to
finalize the process.
SQ3.	Alternative (d). Mismatch repair.
SQ4.	Common: End termini protection is used to avoid
extensive exonuclease activity, but different pro­
teins are important for HR and NHEJ for this pur­
pose. Differences: HR is operative only when there
is an undamaged chromosome to work with, i.e., in
late S or G2, while NHEJ can operate on DNA
DSBs in all cell cycle phases. The fidelity in repair
is higher in HR, while NHEJ may cause alterations
in DNA sequence as a consequence of the repair
which can result in mutations/chromosomal aberra­
tions and which may cause oncogenic transforma­
tion of cells.
SQ5.	Alternative (b). High-LET radiation.
SQ6.	Alternative (c). Superoxide dismutase converts
superoxide anions to hydrogen peroxide.
SQ7.	Alternative (a). It works in the G2 into M transition.
SQ8.	Alternative (b). Complete the cycle and divide.
SQ9.	The mitosis is most sensitive, and early G1 and late S
are most resistant.
SQ10.	Because otherwise they would reach their Hayflick
limit and proceed to senescence, and thus they would
not be able to divide continuously to form large
tumors.
SQ11.	The type of radiation quality, dose, and dose rate as
well as the cellular threshold for DNA damage and
repair largely influence the cell death route. The posi­
tion in the cell cycle when the damage is inflicted as
well as functionality of DNA damage sensors, e.g.,
TP53, influence the decision.
SQ12.	Alternative (c). Mitotic catastrophe.
SQ13.	Alternative (e). Cell death after IR can take place via
several routes, including mitotic catastrophe, autoph­
agy, apoptosis, and necrosis.
3.38
SQ15.	Initiation and phagophore nucleation-phagophore elon­
gation-cargo sequestration-autophagosome maturation-­
fusion of the autophagosome with the lysosome.
SQ16.	Alternatives (a, b, d, and e). The plating efficiency at
0 Gy is 66.6%, the plating efficiency at 2 Gy is 6.4%,
the surviving fraction at 2 Gy is 9.5%, and the surviv­
ing fraction at 1 Gy is 100%.
SQ17.	The alteration of an oncogene because it then affects
the normal embryonic development and causes
embryonic lethality. The alteration of a tumor sup­
pressor gene does not affect the embryogenesis; it
increases the probability of cancer during life.
SQ18.	From the table, it can be seen that the radiosensitivity
is correlated to the existence of TNTs and their den­
sity and the complexity of networks formed. If all
other properties are the same, the hypothesis which
can be formulated is the following: The ability of
cells to avoid death after irradiation is connected to
the ability of the cells to communicate in a direct and
fast manner through TNTs. This might be linked to
the rescue effect, where less damaged cells are able
to send components needed for the damaged cells to
survive.
SQ19.	Macrophages, endothelial cells, lymphocytes, and
PMN.
SQ20.	Answers:
(a)	True, 5-mC accounts for about 1% of all bases
within DNA.
(b)	False, guanine is the predominantly modified
base.
(c)	False, histone variants are synthesized through­
out the cell cycle.
(d)	True, lysine and arginine are the most frequently
acetylated amino acids.
SQ21.	No, each miRNA can act on multiple different target
genes, and one target gene can be regulated by many
different miRNAs.
SQ22.	True.
SQ23.	False: PTEN is a central negative regulator of the
PI3K/AKT pathway.
SQ24.	a. Wrong, lncRNAs lack protein-coding sequences
and they are not translated.
b. Wrong, lncRNAs are defined as transcripts longer
than 200 bp; microRNAs around 20 nucleotides in
size.
c. Correct, for example lncRNAs can interact with
mRNAs and microRNAs for regulatory purposes.

­
3.14
3 Molecular Radiation Biology
180
b. Wrong. Extracellular vesicles cargo in addition to
proteins also mRNA/miRNA, long noncoding
RNAs, DNA fragments, and lipids.

3.14

3.52
e. Wrong. Extracellular vesicles may via their cargo
participate in both cell pro-survival and pro-death
signals.
SQ26.	(a) MRM method.
SQ27.	(a) The low dose will not phosphorylate enough ATM
to activate the early G2 checkpoint, and the cells will
proceed to mitosis with unrepaired damage and die.
(b) The cells will be arrested in G2, and the DNA
damage that is repairable will be repaired before the
cells enter mitosis.
SQ28.	The timing between doses may coincide with the
duration of early G2 arrest.
SQ29.	A protection against high radiation doses induced by
a low “priming” dose.
SQ30.	For example, to activate pro-survival pathways and to
improve DNA repair ability through the activation of
DNA damage checkpoint proteins.
SQ31.	Oxygen fixates DNA damage and sensitizes the cells
to radiation."
"The text discusses several approaches to modeling radiation damage at the molecular level, including target theory and the linear quadratic model. Can you explain how target theory attempts to address the stochastic nature of DNA damage caused by ionizing radiation?","Target theory provides a framework for understanding and predicting the stochastic effects of ionizing radiation on DNA damage by acknowledging that not all cells are equally susceptible to radiation-induced injury. The core principle is that individual cells possess varying ‘targets’ – or, more accurately, differing sensitivities – for absorbing radiation energy. These targets aren't necessarily physical structures within the cell but rather represent inherent variations in cellular repair capacity and DNA integrity. When a cell encounters ionizing radiation, the energy deposited isn't uniformly distributed; instead, it tends to accumulate in cells with higher target values. This means that some cells will experience significantly more DNA damage than others, even when exposed to the same total dose of radiation. Mathematically, target theory posits that the probability of a single event (e.g., a double-strand break) occurring within a cell is proportional to the square root of its target value. Consequently, the overall dose-response curve isn't linear but exhibits a characteristic ‘shoulder’ – a region of increased sensitivity – reflecting the contribution of these highly sensitive cells. The model relies on estimating or determining these individual target values for a population, allowing researchers to predict the proportion of cells expected to sustain damage at different radiation doses. Crucially, it moves beyond simply assuming uniform damage distribution and incorporates this inherent cellular variability into its predictions. This approach is fundamental to stochastic dose-response models because it directly addresses the random nature of DNA lesion formation.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Content: (MC) track structure codes.
•	To get an overview of the state of the art of the
mechanistic simulation and the DNA damage scor­
ing methods.
•	To get to know micro-beams and mini-beams, their
production and use, and why they are important for
radiobiological research.
•	To understand the underlying assumptions and deri­
vation of target theory, which is the basis for all sto­
chastic dose-response models at molecular and
cellular level.
•	To learn about the linear quadratic model, the
strengths and limitations of the model as well as the
different interpretations of the model with respect
to the underlying biology.
•	To understand the difficulties in modeling stochas­
tic effects for whole organisms and for different
dose rates.
Fabiana Da Pieve is currently employed by the European Research
Council Executive Agency, European Commission, BE-1049 Brussels,
Belgium. The views expressed are purely those of the authors and may
not in any circumstances be regarded as stating an official position of
the European Commission
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_4
192
4.1"
Explain the difference between particle fluence (Φ) and energy fluence (Ψ) as defined within the context of radiation dosimetry.,"Particle fluence (Φ), also referred to as planar fluence, represents the number of ionizing particles that pass through a specific plane of space. It’s quantified by dividing the total number of incident particles (dN) by the area of that plane (dA): Φ = dN/dA. Energy fluence (Ψ), conversely, describes the radiant energy that crosses the same plane of area (dA). It's calculated as the radiant energy (dR) divided by the area: Ψ = dR/dA. Critically, the radiant energy (R) is defined as the total energy carried by the particles, excluding their rest mass energy. The fluence rate can then be expressed in terms of either planar fluence or energy fluence; it’s simply the rate at which either quantity crosses a unit area.

Essentially, particle fluence focuses on the *number* of particles, while energy fluence focuses on the *energy* delivered by those particles. These two fluences are intrinsically linked and form the foundational concepts for calculating other dosimetric quantities within radiation biology.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.1	 Energy Deposition and Transfer | Sub-sub-subsection: 4.1.1.1	 Fluence | Content: Particle fluence, or planar fluence, Φ, is defined as the num­
ber of ionizing particles which traverse a finite plane in
space some distance from the source. If dN particles are
incident on a planar surface of area, dA, then the fluence is
Φ = dN/dA [1, 2].
We may also define the energy fluence, Ψ, which is the
radiant energy, dR, which crosses a plane of area, dA, as
Ψ = dR/dA. The radiant energy, R, of a radiation field is
defined as the total energy of the particles that cross the
plane, excluding their rest mass energy. The fluence rate may
be defined in terms of energy fluence or planar fluence and is
simply the rate at which either energy fluence or planar flu­
ence cross unit area. In the context of the amount of radiant
energy absorbed in matter, these concepts provide the basis
from which all the remaining dosimetric quantities are
defined [1, 2]."
"Define exposure in radiation dosimetry, including its unit (Roentgen) and how it relates to energy fluence and the mass energy absorption coefficient.","In radiation dosimetry, ‘exposure’ represents the total amount of ionizing radiation that passes through a given material or volume. It is quantitatively defined as the total charge liberated per unit mass in air by ionizing radiation. The standard unit for exposure is the Roentgen (R), where one Roentgen is precisely equal to 2.58 × 10⁻⁴ Coulombs per kilogram (C kg⁻¹). Exposure is directly linked to energy fluence (Ψ) through the following equation:  (4.1). This equation highlights that exposure isn't simply about the total energy of the beam, but rather how effectively that energy is deposited within the material. The mass energy absorption coefficient (μen/ρair) plays a crucial role here; it represents the fraction of the radiation’s energy absorbed per unit mass of air at a specific beam energy.  A higher μen/ρair value indicates greater energy absorption, leading to a larger exposure value for the same energy fluence. The constant Wair (33.97 eV) accounts for the energy needed to produce an ion pair in air, and ‘e’ represents the elementary charge of an electron.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.1	 Energy Deposition and Transfer | Sub-sub-subsection: 4.1.1.2	 Exposure | Content: Exposure, X, is defined as the total charge which is liberated
per unit mass in air by ionizing radiation [1, 2]. Its unit is the
Roentgen, R, where one Roentgen is 2.58 × 10−4 C kg−1.
Exposure is related to energy fluence, Ψ, by the following
equation:
(4.1)
where (μen/ρ)air is the mass energy absorption coefficient
of air which defines the fraction of the energy of a beam of
particles which is absorbed per unit mass of air at a particular
beam energy. Wair = 33.97 eV is the energy required to pro­
duce an ion pair in air and e is the charge of the electron."
Explain the concept of kerma (K) in radiation dosimetry and describe its relationship to energy fluence (Ψ).,"Kerma, denoted as K, represents the kinetic energy deposited per unit mass of a material when exposed to a specific radiation field. It’s essentially a measure of the energy transferred from the incident radiation to the absorbing substance. The value of kerma is dependent on both the type and intensity of the radiation (incident field) and the properties of the material it's interacting with, such as its density and atomic composition.  Crucially, kerma isn’t a directly measurable quantity; it’s calculated. Energy fluence (Ψ), often expressed in units of Gray (Gy), is defined as the total energy deposited per unit area by radiation over a given time or space. The equation (4.2) provided demonstrates this relationship: K = tr * Ψ, where ‘tr’ represents the linear attenuation coefficient of the material for the specific radiation type. This means kerma is directly proportional to both the energy fluence and the linear attenuation coefficient – higher fluence results in greater kerma deposition, and materials with higher attenuation coefficients will transfer more energy per unit mass.

Reference: [MolecularRadiationBiology], Section 4.1.1.3 Kerma","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.1	 Energy Deposition and Transfer | Sub-sub-subsection: 4.1.1.3	 Kerma | Content: Kerma, K, is defined as the kinetic energy released per unit
mass of material by a specific combination of an incident
radiation field and an absorbing material. Kerma is related to
energy fluence, Ψ, by the following equation:
(4.2)
tr
­
­
12
4.1
­
­"
"Explain the concept of ‘Energy Imparted’ as described in the text, differentiating it from ‘Imparted Energy’ and highlighting why the third term in the equation relating to energy deposition is significant within the context of diagnostic radiology.","‘Energy Imparted’ represents a macroscopic measure of energy transferred to matter by ionizing radiation. It's defined as the sum of radiant energies (photons) entering and leaving a volume, alongside the sum of mass energies (from particles produced during interactions) within that same volume. The significance of the third term – representing particle production – is crucial because in diagnostic radiology, photon energy is typically insufficient to trigger processes like pair production (the creation of electron-positron pairs). Consequently, this third term becomes zero, meaning that ‘Energy Imparted’ primarily accounts for the energy transferred through photons alone. Conversely, ‘Imparted Energy’ refers to the energy involved in a single interaction between a particle and matter within a specific volume; it's a stochastic quantity and difficult to measure precisely. Therefore, while ‘Energy Imparted’ is a gross, often stochastic measurement, repeated measurements can establish an average value (epsilon overbar) which represents a more reliable, non-stochastic estimate of energy deposition.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.1	 Energy Deposition and Transfer | Sub-sub-subsection: 4.1.1.4	 Energy Imparted | Content: The energy imparted, ϵ, by ionizing radiation to the matter in
a volume is given by the following equation [3]:
(4.3)
where the first and second terms in the equation, respec­
tively, describe the sums of all the radiant energies of all ion­
izing radiations entering and leaving a particular volume.
The third term denotes the sum of all the mass energies of all
the particles produced during the interactions of the ionizing
radiations with the matter to which it is imparting energy. In
diagnostic radiology, the photon energy is not sufficient to
instigate pair production (production of positrons and elec­
trons in the vicinity of a strongly positive nucleus), and
therefore particle production does not occur. Thus, for diag­
nostic energies, the third term on the right-hand side of Eq.
(4.3) is zero [1, 4]. Energy Imparted is quoted in the units of
energy, the Joule, J.
A distinction must be made between the term “Energy
Imparted” and the term “Imparted Energy.” Energy Imparted
is the term for a gross quantity or concept, where the energy
is imparted to matter that has a macroscopic size. Imparted
Energy is the energy that is imparted in a single interaction
between any particle and the matter in a given volume. The
Imparted Energy, dϵ, in an interaction is a stochastic quan­
tity, and is difficult to measure, and impossible to infer with
any great accuracy [3, 5]. Thus, the Energy Imparted is also
G. Schettino et al.
193
a stochastic quantity. However, repeated measurements can
establish mean energy imparted, epsilon overbar, which is a non-­stochastic
quantity (Box 4.1).
4.1.2"
"Explain the concept of absorbed dose in radiation biology, detailing its definition, unit of measurement (Gray), and how it relates to Kerma and radiative/collision interactions within a material.","In radiation biology, absorbed dose refers to the amount of radiant energy from ionizing radiation that is actually taken up by a material – typically tissue or a biological sample – per unit mass. It’s quantified as energy (ε) absorbed per kilogram of absorbing substance. The standard unit for measuring absorbed dose is the Gray (Gy), which is defined as 1 Gy = 1 J/kg.  This concept arises from the fact that radiation doesn't simply pass through matter; it interacts with atoms and molecules, causing ionization and excitation. These interactions result in energy being deposited within the material. The total Kerma represents the *total* energy deposited by a radiation beam per unit mass. However, Kerma can be divided into two components: Collision Kerma (Kc) and Radiative Kerma (Kr). Collision Kerma arises from charged particles colliding with atoms in the absorbing material, leading to ionization and excitation. Radiative Kerma results from photons directly releasing their energy through processes like fluorescence or phosphorescence, effectively emitting new photons within the material.  Crucially, when a uniform field of X-ray photons is incident on a medium where charged particle equilibrium (CPE) exists – as often seen in diagnostic radiology – all Kerma is absorbed. This means that the Collision Kerma (Kc) equals the Absorbed Dose (D), establishing a direct relationship: D = Kc.  This equilibrium arises because for every charged particle leaving a volume, an equal number enters from adjacent volumes, maintaining a constant flux of energy within the material.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.2	 Absorbed Dose | Content: The absorbed dose (sometimes referred to simply as “dose”)
is the radiant ionizing energy absorbed per unit mass of
absorbing material. It is therefore defined as:
(4.4)
The quantity ε/m is sometimes referred to as the specific
energy. It is stochastic in the same way that the imparted
energy in a given interaction is stochastic, but with repeated
measurements, and on macroscopic scales involving many
single particle interactions, it becomes a measurable quantity
([1], p. 86; [2, 4]). The unit of Absorbed dose is the Gray, Gy,
which is equal to J kg−1.
The Kerma in Eq. (4.2) may be split into two parts depend­
ing on the ways in which the energy of the photon is lost
through interactions with the material [1]. Photons may
either release their energy through collision interactions in
which excitation and ionization of the stopping material
occur or through radiative processes in which their energy is
radiated through the release of photons. Thus, the Kerma can
be expressed as:
(4.5)
where Kc is the portion transferred through collisions,
and Kr is the portion transferred through radiative interac­
tions [1]. Radiative interactions generally occur in situa­
tions in which charged particles are incident on a material
[1]. In the case of diagnostic radiology, Kerma is released
through collision interactions, with Collision Kerma there­
fore given by:
(4.6)
In diagnostic radiology, a simple relationship between
Kerma and Absorbed dose may be derived. When charged
particle equilibrium (CPE) exists in a medium, the number of
charged particles leaving a unit mass volume is replaced by
an equal number entering from other mass volumes. In such
a situation, which occurs at the photon energies in diagnostic
radiology, all Kerma is absorbed in the unit mass volume. It
has been shown by Attix, that for a medium of uniform den­
sity and atomic composition, such a situation does indeed
exist for a field of X-ray photons and a uniformly irradiated
medium [1, 2]. In this case the Absorbed dose, D, and
Collision Kerma, Kc, are equal, such that
(4.7)
4.1.3"
Describe the fundamental principles behind how radiation detectors function and what key characteristics an 'ideal' detector would possess to accurately measure ionizing radiation.,"Radiation detectors operate on the principle of quantifying the energy deposited by ionizing radiation within a sensing material. The core measurement involves tracking the amount of charge, denoted as ‘Q’, produced over time from this absorbing medium. This ‘Q’ represents the cumulative effect of ionization events caused by the incident radiation. An ideal detector would exhibit several crucial characteristics to provide comprehensive information about the radiation event. Firstly, it needs spatial resolution – the ability to pinpoint the exact location where the radiation interacted with the material. Secondly, temporal resolution is vital; this refers to how quickly the detector can respond to and measure the transient charge buildup following an ionization event. Thirdly, a perfect detector would provide data regarding the energy of the incident particle, allowing for differentiation between low-energy and high-energy radiations. Finally, it should offer information about the identity of the radiation – whether it’s alpha, beta, gamma, or X-rays – often achieved through analyzing the type of ionization produced. However, achieving all these characteristics simultaneously in a single detector is challenging; practical detectors typically prioritize a focused range of capabilities based on their intended application.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Content: In general, radiation detectors  operate by providing the
means to measure the energy deposited over time in the
detector absorbing material from exposure to a source of ion­
izing radiation. This is typically measured as the quantity of
charge, Q, over time elicited from an absorbing medium
forming the main component of the detecting element. An
ideal radiation detector is one that gives spatial resolution,
temporal resolution, information regarding the energy of the
particle, and information regarding the identity of the radia­
tion. In reality, single detectors of this type are difficult to
construct such that practical detectors that are used in the
field have a focused range of capabilities which should be
taken into consideration when a detector is chosen for a par­
ticular application [6, 7]."
"Describe how ionization chambers function as radiation detectors, detailing the processes involved from particle interaction to current measurement.","Ionization chambers operate by utilizing a high electric field to accelerate charged particles through a gas-filled chamber. When ionizing radiation, such as alpha or beta particles, traverses this sensitive region of the detector (the gas), it interacts with the gas atoms, creating numerous electron-ion pairs via ionization. These newly formed ions are then influenced by the applied electric field and begin to drift towards the detector electrodes.  The movement of these charged ions generates a measurable current within the chamber. This current is typically very small, necessitating low-noise amplifiers for accurate detection. The number of ionizations produced is directly proportional to the energy deposited by the radiation particle; higher energy particles create more ionization events. Furthermore, variations in ambient pressure and temperature must be accounted for when interpreting measurements due to their impact on the chamber's output characteristics [6, 7].","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Sub-sub-subsection: 4.1.3.1	 Ionization Chambers | Content: means to measure the energy deposited over time in the
detector absorbing material from exposure to a source of ion­
izing radiation. This is typically measured as the quantity of
charge, Q, over time elicited from an absorbing medium
forming the main component of the detecting element. An
ideal radiation detector is one that gives spatial resolution,
temporal resolution, information regarding the energy of the
particle, and information regarding the identity of the radia­
tion. In reality, single detectors of this type are difficult to
construct such that practical detectors that are used in the
field have a focused range of capabilities which should be
taken into consideration when a detector is chosen for a par­
ticular application [6, 7].
4.1.3.1	Ionization Chambers
­
­
­
4.2
The charged particle will ionize the detector medium
along its path and these ions will then be accelerated towards
the detector electrodes. In general, a high electric field is
Box 4.1 Dosimetry Quantities: Kerma and Exposure
•	Kerma, K, is defined as the kinetic energy released
per unit mass of material by a specific radiation
field and it is related to energy fluence, ψ
•	Exposure, X, is defined as the total charge which is
liberated per unit mass in air by ionizing radiation.
Its unit is the Roentgen, R.
Box 4.2 Dosimetry Quantities: Absorbed Dose
•	The Absorbed Dose is the energy absorbed per unit
mass of material. The unit of Absorbed Dose is the
Gray, Gy, which is equal to J kg−1
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
194
­
4.12
applied between the electrodes to prevent the recombination
of ions produced by the traversal of the charged particle. As
the charged particle traverses the sensitive region of the
detector (i.e., the gas) it produces multiple electron-ion pairs,
which begin to drift along the electric field lines and reach
the plates of the detector. These ions may produce further
ionization of the neutral gas atoms via further collision, ulti­
mately producing a small current that induces a voltage drop
across the resistor. These chambers typically generate very
low measurement currents per ionizing particle, and there­
fore require low noise amplifiers to improve their operating
performance.
­
­
4.37
­
4.3
­
­
­
6
It is possible to determine the typical output current that
will be generated by an ionization chamber in the presence
of a source of known activity. Consider the case of an in-air
ionization chamber (where air has an ionization potential of
30 eV) which is exposed to alpha particles (Eα = 5.486 MeV)
from a 10 MBq Am-241 source. The total number of ioniza­
tions produced by a single Am-241 α-particle will be the
ratio of the energy of the alpha particle to the ionization
potential of air:
G. Schettino et al.
195
In this case, the total number of ionizations produced will
be the product of the activity of the source and the number of
ionizations produced by a single alpha particle, or
N = 1.829 × 1012 ionizations, which are observed in a single
second (as the unit of activity, the Bq is s−1 in SI units). The
final step is then to compute the product of the total number
of ionizations with the charge on the electron such that the
total current observed will be:
Frequently, ionization chambers are open to the air to
allow for changes in ambient pressure which could collapse
or expand a sealed chamber, damaging the thin chamber
walls. As a consequence, chamber outputs must be adjusted
for changes in ambient temperature, T, and pressure, P, from
those at which the chamber was calibrated, Tn and Pn, respec­
tively. In practice, we can multiply the chamber output by the
following correction factor to adjust for ambient conditions
(where all temperatures are expressed in Kelvin and pres­
sures in Pascals [6]):
(4.8)"
Describe the operating principle of proportional counters and how they differentiate between radiation detection methods like ionization chambers.,"Proportional counters represent a specialized type of ionization chamber designed to provide directional information about incident ionizing radiation. Their operation relies on the principle that when a charged particle (alpha, beta, or gamma) passes through a gas-filled tube – typically argon or neon – it interacts with the gas atoms, creating ion pairs. The key difference between proportional counters and standard ionization chambers lies in how these ion pairs are detected. In a standard ionization chamber, all ions produced are collected uniformly across the entire volume of the chamber, resulting in a single, averaged signal related to the total energy deposited. 

Conversely, a proportional counter contains one or more anode wires positioned within the gas-filled tube. These wires are carefully placed so that when an ionizing particle passes through the gas, it creates ion pairs near the wire. The electric field surrounding the anode wire significantly accelerates these positive ions towards the wire. This acceleration dramatically increases the number of secondary electron emissions from the initial ion pair, leading to a cascade effect – a ‘proportional’ amplification of the original ionization event. Each anode wire independently detects this amplified current pulse. By analyzing the individual signals from each wire, and considering their spatial arrangement, it's possible to determine not only the total energy deposited but also the direction in which the initial ionizing particle traveled through the gas. The angle at which the signal peaks corresponds directly to the trajectory of the incident radiation. This directional capability makes proportional counters invaluable for applications requiring knowledge of radiation beam alignment and geometry, such as radiotherapy treatment planning and radiation shielding analysis.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Sub-sub-subsection: 4.1.3.2	 Proportional Counters | Content: While the ionization chamber provides a device for the mea­
surement of absolute energy deposition, it does not provide
information on directionality. Proportional counters are ion­
ization chambers that may be used for both measuring abso­
lute energy deposition (through a measurement of the pulse
height) in addition to giving directional information on the
path of charged particle (through the output of a given anode
wire, each of which is independently amplified).
4.4
­
­
6"
Describe the process by which scintillators function as radiation detectors and explain their common coupling with photomultiplier tubes (PMTs).,"Scintillators operate on the principle of ionization caused by energetic particles. When a charged particle, such as a gamma ray, interacts with a scintillator material – which can be organic compounds like naphthalene or anthracene, or inorganic materials like sodium iodide or cesium iodide – it excites electrons within the atoms of the scintillator. This excitation elevates these electrons to higher energy levels. As these excited electrons return to their ground state, they release energy in the form of photons—light particles. The intensity of this emitted light flux is directly proportional to the initial energy deposited by the incident radiation. 

However, the photon flux produced by a scintillator is typically very weak. To detect and measure this signal effectively, scintillators are frequently coupled with photomultiplier tubes (PMTs). A PMT amplifies the faint electrical signal generated by the scintillation process. The scintillator material emits photons which strike a photocathode within the PMT. This impact generates an initial electron flux.  The PMT then utilizes a series of dynodes, each held at a high positive voltage, to amplify this signal. As electrons cascade down these dynodes, they collide with the surfaces and release more electrons in a chain reaction (the photoelectric effect and secondary emission). The final amplified current at the detector anode is proportional to the original photon flux detected by the scintillator. This allows for both photon counting – determining the number of photons arriving – and imaging applications where the spatial distribution of radiation can be mapped based on the scintillation response.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Sub-sub-subsection: 4.1.3.3	 Scintillators and Photomultiplier Tubes | Content: Scintillators are materials that react to the passage of a
charged particle by the emission of a very small flux of pho­
tons of light. Charged particles may excite electrons within
atoms of the scintillating material to a higher energy state;
these atoms then emit photons as they de-excite to their
ground state. Scintillators can be developed from organic
(e.g., naphthalene or anthracene) or inorganic (including
sodium iodide or cesium iodide) materials and have applica­
tions as the first detection element with gamma cameras used
in nuclear medicine.
Scintillating materials typically need to be chosen to
detect photons of a specific wavelength and may often be
doped to achieve specific wavelength sensitivity. They are
generally coupled to photomultiplier tubes (PMT) to amplify
the intensity of the weak photon signal output from the scin­
tillator, either for photon counting or imaging applications.
4.5
­
67
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
196
Here, the photon flux is converted to an electron flux as
they enter the inner (evacuated) environment of the PMT
tube. These electrons are accelerated towards the first of
several dynodes by the high-voltage field between the pho­
tocathode and the anode. When each electron collides with
a dynode, it causes the emission of several electrons (typi­
cally 5–10), which are then accelerated towards subse­
quent dynode and amplify the electron flux through
collision and reemission. At the detector anode, a signifi­
cant and measurable electric current is then generated as a
result of the acquisition of a single photon. Apart from a
small degree of signal fluctuation, the current seen at the
anode is linearly proportional to the photon  flux seen at
the photocathode [6, 7]."
"Describe how a p-n junction diode operates as a radiation detector, specifically focusing on the role of the depletion region and energy loss within the semiconductor material. Explain how this process relates to detecting ionizing radiation.","A p-n junction diode utilizes the principles of semiconductor physics to detect ionizing radiation. When a diode is operated in forward bias, electrons from the n-type semiconductor are encouraged to move towards the p-type semiconductor, while holes from the p-type semiconductor migrate toward the n-type. This movement creates a current flow across the junction. Critically, when ionizing radiation (such as gamma rays or charged particles) interacts with the semiconductor material – in this case, a material like CdZnTe – it deposits energy within the crystal lattice. This energy causes electrons to be excited from their valence band into the conduction band, creating electron-hole pairs. The key element is the formation of a depletion region at the junction. Initially, the forward bias helps prevent the immediate recombination of these newly created electron-hole pairs. As radiation interacts with the semiconductor, it generates more electron-hole pairs within the depletion region. These excited electrons and holes then contribute to the current flow across the diode due to their movement influenced by the electric field established by the forward bias. The magnitude of this current is directly proportional to the energy deposited by the incident radiation – essentially quantifying the dose received.  The bandgap of the semiconductor material (e.g., CdZnTe with a bandgap of 1.4-2.12 eV) dictates which wavelengths of radiation can be effectively absorbed and initiate this process. Materials with smaller bandgaps are more sensitive to lower energy photons, while larger bandgaps are better suited for higher energy radiation.  The thinner the detector (as mentioned in the text – 200-300 μm), the greater the probability of interaction between the radiation and the semiconductor material, leading to a stronger signal. Reference: [G. Schettino et al., Fig. 4.6, Table 4.1] “Semiconducting materials, when incorporated in radiation detectors can therefore produce a large signal in response to irradiation with a small photon flux. The detectors can be constructed very thinly (as little as 200–300 μm) for the detection of ionized particles, or larger for stopping of photons.”","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Sub-sub-subsection: 4.1.3.4	 Semiconductor Detectors | Content: 67
­
­
4.6a, b
67
4.7
­
Fig.
4
.6
Fig. 4.6 (a) Schematic of a
p–n junction diode operated
in forward and reverse bias.
(b) Operating characteristics
of the diode in forward and
reverse bias
G. Schettino et al.
197
Table 4.1 Typical semiconducting materials used for radiation detec­
tion, including bandgaps, wavelength, and electro magnetic (EM) band
sensitivity
Material
Egap (eV)
λ (nm)
Band
C
(diamond)
5.65
220
UV
GaN
3.45
360
UV
AlGaN
3.45–5.64
360–260
UV
CdZnTe
1.4–2.12
870–580
Visible
Si
1.12
1100
Visible
GaAs
1.42
875
Visible
Ge
0.66
1800
NIR
PtSi
0.41–0.25
3000–5000
IR
HgCdTe
0.41–0.25 or
0.16–0.10
3000–5000 or
8000–12,000
IR
HgCd
0.7–0.1
1700–12,500
NIR-­
FIR
detector. Here, the valence band is equivalent to the energy
level of the outermost electron, while the conduction band is
the energy level of the next vacant energy state above the
valence band. A current is produced which is proportional to
the energy loss by the charged particle or photon within the
depletion layer [6, 7]
­
­
­
gap
4.7
4.1
Semiconducting materials, when incorporated in radia­
tion detectors can therefore produce a large signal in response
to irradiation with a small photon flux. The detectors can be
constructed very thinly (as little as 200–300 μm) for the
detection of ionized particles, or larger for stopping of pho­
tons. Their performance is approximately linear if an electric
field is applied that prevents the recombination of the elec­
trons and holes formed by the radiation [6, 7]."
"Describe the phenomenon of Cerenkov radiation, including its historical discovery and the underlying physical principles that govern it. Specifically, explain how the refractive index of the medium involved plays a crucial role.","Cerenkov radiation is produced when a charged particle or photon travels through a transparent medium at a speed greater than the phase velocity of light within that medium. This phenomenon was first observed and described by Pavel Cerenkov in 1934, and subsequently characterized by Franck and Tamm, leading to their shared Nobel Prize in Physics in 1958. The radiation itself is not emitted directly by the particle; rather, it’s a result of the emission of photons when the charged particle decelerates as it passes through the medium. This deceleration occurs because the particle interacts with the atoms of the medium, transferring energy and creating an ionization trail. The key principle involves the refractive index (n) of the medium – specifically, the difference between the particle’s velocity (β = v/c) and the speed of light in that medium. Cerenkov radiation is only emitted when β exceeds unity (i.e., the particle's speed surpasses the speed of light within the medium). The threshold refractive index directly determines the minimum energy required for this emission to occur; a higher refractive index necessitates a faster particle velocity to trigger the effect.  The angle at which these Cerenkov photons are emitted is dependent on the particle’s velocity and the refractive index, allowing for discrimination between different types of high-energy charged particles based on the angle of their emission or the specific threshold value of ‘n’ required for radiation production.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Sub-sub-subsection: 4.1.3.5	 Cerenkov Detectors | Content: NIR-­
FIR
detector. Here, the valence band is equivalent to the energy
level of the outermost electron, while the conduction band is
the energy level of the next vacant energy state above the
valence band. A current is produced which is proportional to
the energy loss by the charged particle or photon within the
depletion layer [6, 7]
­
­
­
gap
4.7
4.1
Semiconducting materials, when incorporated in radia­
tion detectors can therefore produce a large signal in response
to irradiation with a small photon flux. The detectors can be
constructed very thinly (as little as 200–300 μm) for the
detection of ionized particles, or larger for stopping of pho­
tons. Their performance is approximately linear if an electric
field is applied that prevents the recombination of the elec­
trons and holes formed by the radiation [6, 7].
4.1.3.5	Cerenkov Detectors
The phenomenon of Cerenkov radiation was first observed
and described by Pavel Cerenkov in 1934 and characterized
by Franck and Tamm in 1937. This work resulted in all three
being given the Nobel Prize in physics in 1958.
4.8a
­
­
67
­
4.8b
4.8c
(4.9)
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
198
­
Box 4.3 Radiation Detectors
•	Radiation detectors measure the energy deposited
over time in the detector-absorbing material
•	An ideal radiation detector provides spatial resolu­
tion, temporal resolution, information regarding the
energy of the particle, and information regarding
the identity of the radiation. No single detector can
offer these simultaneously
•	Ionization chambers are common dosimeters that
measure the ionizations produced when a charged
particle or ionizing photon traverses the detector
medium (generally a gas, requiring temperature and
pressure corrections). An electric field is applied
between the electrodes to prevent the recombina­
tion of ions produced.
•	Proportional counters are ionization chambers that
also provide directional information on the path of
charged particles
•	Scintillator materials are also used as dosimeters by
relating the flux of photons emitted to the energy
deposited. They are generally coupled to photomul­
tiplier tubes (PMT) to amplify the intensity of the
photon signal
•	Semiconductor detectors measure the number of
charge carriers produced by the radiation in the
detector material. Semiconductor materials are
used due to the small energy required to produce
electron-hole pairs
where n is the refractive index of the medium and β = v/c,
where v is the velocity of the particle and c is the speed of
light.
It is therefore possible to discriminate the identity of high
energy charged particles purely based on the angle of
Cerenkov emission or the threshold value of n at which
Cerenkov emission is observed [6, 7]. In particle physics,
experiments materials of various refractive indices are typi­
cally used to provide several potential Cerenkov thresholds
for the detection of a variety of radiation types. The weak
Cerenkov photons can be detected using PMTs or electronic
photodetectors. Cerenkov photons are also observable as a
result of the passage of charged particles through human tis­
sue and Cerenkov imaging has seen a recent application for
in vivo dosimetry in radiotherapy [8]."
"Describe the principles underlying the operation of a thermoluminescent dosimeter (TLD) for radiation dosimetry, including the processes involved in its measurement and limitations regarding accuracy.","Thermoluminescent Dosimeters (TLDs) are passive radiation detectors that rely on the storage and subsequent release of energy when exposed to ionizing radiation. The most common type, the lithium fluoride (LiF) TLD, operates based on the following principles:

1. **Radiation Absorption:** When a TLD is exposed to ionizing radiation, energetic particles deposit their energy within the crystal lattice of the LiF material. This creates defects – primarily vacancies and interstitials – in the crystal structure.

2. **Trapped Charge Carriers:** These defects trap electrons, creating ‘trapped’ electron-hole pairs. The number of trapped charge carriers is directly proportional to the absorbed radiation dose.  The more radiation, the more defects and thus, more trapped carriers.

3. **Heating & Luminescence:** Upon removal from irradiation and introduction into a controlled heating environment (typically 300-350°C), these trapped electrons are thermally stimulated to recombine with their associated holes. This recombination process releases energy in the form of photons – visible light, specifically in the blue-green spectrum.

4. **Luminescence Measurement:** The intensity of this emitted luminescence is proportional to the number of trapped charge carriers (and therefore, the absorbed radiation dose). A photomultiplier tube or photodiode measures the light output, and this signal is calibrated against a known standard dose to determine the received dose. 

**Limitations & Accuracy Considerations:** Several factors limit the accuracy of TLD measurements:

*   **Crystal Aging:** Over repeated exposures, the LiF crystal undergoes slow degradation processes (e.g., ion migration) that can alter its thermoluminescent properties and introduce hysteresis.
*   **Temperature Control:** Precise temperature control during heating is crucial; deviations from the optimal range can significantly affect the luminescence signal.
*   **Calibration Drift:** The relationship between dose absorbed and light output can drift over time, requiring periodic calibration against traceable standards.  This drift is a major source of error.
*   **Material Variations:** Slight variations in LiF crystal composition or manufacturing processes can introduce variability in response.
*   **Limited Dose Range:** TLDs have a limited dose range; exceeding this range can damage the crystal and render it unreliable.

Despite these limitations, TLDs are widely used for radiation monitoring due to their robustness, low cost, and ability to operate in harsh environments.  Careful handling, proper calibration, and understanding of their limitations are essential for accurate dosimetry.

Reference: Schettino, G., et al. (1999). *Radiation Dosimetry*.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.3	 Radiation Detectors | Sub-sub-subsection: 4.1.3.6	 Calorimeters | Content: 4.9
­
­
4.3
G. Schettino et al.
199
4.1.4"
"The Monte Carlo method relies on generating numerous random samples to estimate quantities like energy loss in a medium. What is crucial for the empirical mean derived from these samples to accurately represent the expected value and its distribution, as dictated by the central limit theorem?","For the empirical mean of results generated through the Monte Carlo method to be an unbiased estimator of the expectation and its associated distribution, a sufficiently large number of samples must be employed. This is because the central limit theorem states that the sum (or average) of a large number of independent and identically distributed random variables tends towards a normal distribution, regardless of the original distribution of those variables.  Insufficient samples will lead to an inaccurate representation due to statistical fluctuations; a larger sample size reduces these fluctuations and provides a more reliable estimate. Reference: [MolecularRadiationBiology], Section 4.1.4 – Monte Carlo Methods","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.1	 Principles of Radiation Dosimetry | Sub-subsection: 4.1.4	 Monte Carlo Methods | Content: The Monte Carlo (MC) method is a numerical calculation
method based on random draws. A succession of draws is
carried out in order to sample the random variables of the
treated problem to deduce a value of interest. Repeated sev­
eral times, this procedure allows to obtain a distribution of
the values of interest and thus an estimation of their mean
and their associated confidence interval. However, the num­
ber of samples must be sufficiently large for the empirical
mean of the results to be an unbiased estimator of the expec­
tation of the quantity of interest and its distribution as pre­
dicted by the central-limit theorem. In this process, the
quality of the random number generator is essential.
However, only pseudo-random numbers (having a period)
can be generated and each Monte Carlo calculation code
uses a different mathematical algorithm for that purpose.
The Monte Carlo method is currently used in many fields
of physics to model the interactions of particles in a medium.
In particular, it is used in dosimetry to estimate the energy
loss of the particles in the medium and thus the absorbed
dose.
To simulate the course of the particles, MC codes use the
notion of cross-sections expressed in barn (b) (1
barn = 10−22 cm2). This cross-section is a physical quantity
representing the probability of collision between an incident
particle and a target, as it is proportional to the ratio between
the interaction rate (T) and the incoming particle fluence (φ):
(4.10)
with Ntarget the number of target particles in the target vol­
ume, corresponding to the surface S of the beam intercepting
the target and starget the number of target particles per surface
unit.
Therefore, we can calculate the probability p for a particle
to interact with the target in the following way:
(4.11)
With NA the Avogadro’s constant, ρ the target medium
density, d the target thickness, and A the atomic mass of the
target medium. Sigma?
−2
­
4.10
From this concept of interaction cross-section, it is pos­
sible to define the mean free path (λ) of a particle by means
of the equation:
(4.12)
This mean free path corresponds to the average value of a
random variable representing the path traveled by a particle
between two interactions (l). The probability density of this
•	Cerenkov detectors record light produced by
charged particles traveling through materials at a
velocity greater than that at which light can travel
through the material
•	Calorimeters quantify the absolute dose absorbed
by measuring the increase in temperature produced
by radiation
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
200
target
random variable is given by: p
le
ft
p
a
r
e
nthesis l right parenthesis equals StartFraction 1 Over lamda EndFraction e Superscript negative l divided by lamda. This probability
density allows to sample the distance traveled by a particle
between two interactions using a random variable ξ0 uni­
formly distributed between 0 and 1 as follows l =  − λ ln ξ0.
Cross-sections used in the MC codes are obtained either
experimentally or are calculated from theoretical diffusion
models and then used to determine the probability distribu­
tions of the random variables related to a trajectory as mean
free path but also the type of interaction or the energy loss.
A key point of these MC calculations is related to the
simulation of the electron (and positron) interactions.
Indeed, these particles lose a very small part of their energy
at each interaction they undergo. Thus, they generate a very
large number of events before being finally absorbed into
the medium. The detailed simulation of this cascade of
interactions and of these weak energy deposits is particu­
larly slow. Thus, most Monte Carlo codes apply simplifying
theories called “condensed histories” or “multiple scatter­
ing” that summarize a certain number of interactions in a
single step, allowing to reduce the simulation time. The
compromise between the detail of the simulation and the
speed of the calculation conditions the performance of the
calculation code. Among the most used MC codes in dosim­
etry, we can highlight PENELOPE « Penetration and
ENErgy LOss of Positrons and Electrons, EGSnrc « Electron
Gamma Shower », MCNP6 and MCNPX « Monte-Carlo
N-Particle eXtended », or Geant4 « GEometry And Tracking
» [9–13].
Thanks to their capacity to include a large part of the
physical processes involved in radiation–matter interactions
and the possibility of taking into account all the different
components of the experimental geometry of the problems,
MC codes have clear advantages since they can provide
information on the values of certain quantities that cannot be
determined experimentally.
In radiotherapy, it is required to deliver a dose to the
tumor with an uncertainty equal to or less than 5% [14].
Prescribed dose metrology involves the determination of
quantities characterizing the transfer and absorption of
energy in the irradiated media. In principle, Monte Carlo
simulations allow the dose calculation with the required
accuracy using phantoms or even patient’s voxelized images
and thus provide information on dose distribution in the
organ volume. However, to do this it is necessary to have
quite exact knowledge of the beam characteristics, which
means the need for detailed consideration of each accelerator
including head shielding and structural components, which
is very time-consuming and often submitted to industrial
secret. Therefore, up to now, Monte Carlo codes have been
mainly used to calculate the correction factors, often close to
unity, to be applied to the experimental values obtained at the
hospital during this metrological control.
Nevertheless, The Monte Carlo technique is increasingly
used for clinical treatment planning by implementing
MC-based algorithms that are used in situations where con­
ventional analytical methods used by the Treatment Planning
Systems (TPS) of the machines are not enough. To decrease
the computation time, most implementations for radiother­
apy divide the calculation into two steps. The first one con­
sists in simulating the head of the treatment machine. This
part being fixed and independent of the ballistics associated
with the treatment of patients, a phase space can be recorded
at the output of the treatment head and be reused. The second
step consists in tracking the particles previously recorded in
the phase space in the specific geometry of a patient for a
specific treatment. Both parts must be, of course, experimen­
tally verified by comparisons with percentage depth dose
curves (PDD) and absorbed dose profiles at various depths in
water or with measurements in situations where electronic
equilibrium is not respected, for example, at the interfaces of
materials of different densities (Box 4.4).
4.2"
"Describe the increasing role of Monte Carlo simulations in radiation treatment planning, specifically addressing how they are utilized to optimize computational efficiency and ensure accuracy.","Monte Carlo (MC) simulations have become increasingly vital in clinical radiotherapy due to limitations inherent in traditional analytical methods employed by Treatment Planning Systems (TPS). Initially, MC codes were primarily used for calculating correction factors applied to experimental dose measurements, often yielding results close to unity. However, the technique is now integral to treatment planning when conventional TPS calculations are insufficient. To reduce computational time, most implementations divide the simulation into two stages: first, simulating the head of the treatment machine – a fixed and independent process allowing for phase space recording; and second, tracking these recorded particles within the patient’s specific geometry for a particular treatment. Crucially, both stages require experimental verification through comparisons with PDD curves and absorbed dose profiles in water or at interfaces between materials of differing densities. This validation ensures that the MC-based algorithms accurately predict dose distributions, particularly in scenarios where electronic equilibrium is disrupted. The reuse of phase space data further enhances efficiency by minimizing redundant calculations across multiple treatment plans.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.2	 Radiation Microdosimetry | Content: accuracy using phantoms or even patient’s voxelized images
and thus provide information on dose distribution in the
organ volume. However, to do this it is necessary to have
quite exact knowledge of the beam characteristics, which
means the need for detailed consideration of each accelerator
including head shielding and structural components, which
is very time-consuming and often submitted to industrial
secret. Therefore, up to now, Monte Carlo codes have been
mainly used to calculate the correction factors, often close to
unity, to be applied to the experimental values obtained at the
hospital during this metrological control.
Nevertheless, The Monte Carlo technique is increasingly
used for clinical treatment planning by implementing
MC-based algorithms that are used in situations where con­
ventional analytical methods used by the Treatment Planning
Systems (TPS) of the machines are not enough. To decrease
the computation time, most implementations for radiother­
apy divide the calculation into two steps. The first one con­
sists in simulating the head of the treatment machine. This
part being fixed and independent of the ballistics associated
with the treatment of patients, a phase space can be recorded
at the output of the treatment head and be reused. The second
step consists in tracking the particles previously recorded in
the phase space in the specific geometry of a patient for a
specific treatment. Both parts must be, of course, experimen­
tally verified by comparisons with percentage depth dose
curves (PDD) and absorbed dose profiles at various depths in
water or with measurements in situations where electronic
equilibrium is not respected, for example, at the interfaces of
materials of different densities (Box 4.4).
4.2
Radiation Microdosimetry
Microdosimetry was first introduced by H.H. Rossi in 1955
and is a fundamental and evolving research field in experi­
mental radiation science [15, 16]. It studies the interaction
Box 4.4 Monte Carlo Simulation Method
•	The Monte Carlo (MC) method is a numerical cal­
culation method used to estimate the dose deposited
through simulation of the stochastic events through
which radiation deposits energy
G. Schettino et al.
201
between radiation and matter in micrometric volumes of
cell-like dimensions taking into account the stochastic nature
of the energy deposition process.
4.2.1"
"What are microdosimetry and lineal energy, and how are they related in quantifying radiation interactions?","Microdosimetry is a technique used to characterize the stochastic nature of radiation interaction with matter. It focuses on quantifying individual energy deposition events rather than macroscopic measures like absorbed dose or dose rate. The fundamental quantity in microdosimetry is lineal energy (y), which aims to quantify these individual energy deposition events. Lineal energy represents the total energy imparted by a single ionizing particle event divided by the mean chord length of the volume through which that particle passes. Essentially, it’s a measure of how much energy is deposited per unit length at a specific point. Due to the stochastic nature of radiation interactions, each particle traversal results in a different lineal energy value, leading to a probability distribution function (PDF) that fully characterizes the irradiation at a given point. This PDF describes the frequency and magnitude of these individual energy deposition events. The calculation of lineal energy relies on understanding the total energy imparted by an incident particle (Tin), the energy leaving the interaction site (Tout), and the change in rest mass energy (QΔm).  The expression for lineal energy, y, is defined as εtot / l, where εtot is the total energy deposited and l is the mean chord length. Understanding this relationship allows researchers to model radiation damage at a more granular level than traditional dosimetry methods.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.2	 Radiation Microdosimetry | Sub-subsection: 4.2.1	 Definition, Concepts, and Units | Content: The interaction between radiation and matter is a stochastic
process that manifests itself as energy deposition, δ-electron
production, or nuclear reactions. The latter produce charged
particles, called secondaries, which in turn interact with sur­
rounding matter, releasing energy, as δ-electrons do. The
fundamental quantity in microdosimetry is the lineal energy,
y, which aims to quantify the individual energy deposition
events. Energy deposition is a stochastic quantity defined as
the energy deposited at the point of interaction:
(4.13)
where Tin is the energy of the incident ionizing particle
(exclusive of rest mass), Tout is the sum of the energies of all
ionizing particles leaving the interaction site (exclusive of
rest mass), and QΔm is the change of rest mass energy of the
atom and all particles involved in the interaction. εi is usually
expressed in eV. The lineal energy, y, is therefore defined by
the ICRU report 36 ([17], p. 36) as the quotient of εtot by l,
where εtot is the total energy imparted to a volume of matter
by a single energy deposition event and l is the mean chord
length in that volume:
(4.14)
The lineal energy is usually expressed in keV/μm. A sin­
gle energy deposition event denotes the energy imparted by
correlated charged particles. Due to the stochastic nature of
radiation interaction, each particle traversal gives rise to a
different lineal energy value thus producing a probability
distribution function. Such probability distribution functions
fully characterize the irradiation at a given point. The indi­
vidual energy deposition events (opportunely corrected for
the detector charge collection efficiency and converted into
energy to tissue equivalent material) are collected in a form
of spectrum [f (ε) vs ε] where f (ε) is the probability of an
energy deposition event ε. From these energy spectra, the
lineal energy spectra [f (y) vs y; with y = lineal energy] can
be calculated by dividing the energy events by the average
chord length of the detector, which is the average distance
that the particle will traverse in the detector. In the case of a
spherical detector, this can be demonstrated to be 2/3 of the
diameter, while for thin plate detectors in a unidirectional
particle beam, this can be approximated to the detector thick­
ness [18]. The probability density function f (y), also called
lineal energy frequency distribution, is independent of the
absorbed dose or dose rate. Its expectation value y overbarF is called
frequency mean lineal energy and, being a mean value, is no
longer a stochastic quantity.
(4.15)
As the radiation biological damage is proportional to the
dose delivered, it is useful to consider also the lineal energy
dose distribution d (y), as it provides the fraction of the total
absorbed dose in the interval [y, y + δy]. The dose-weighted
lineal energy distribution d (y) is therefore given by:
(4.16)
­
4.11
Similar to the frequency mean lineal energy y overbarF, the dose-­
weighted mean lineal energy y overbarD can be defined as
(4.17)
This quantity provides the average lineal energy value
when each energy deposition event is weighted based on its
contribution to the total dose.
A crucial parameter for the calculation of the lineal energy
is the mean cord length (l overbar), as the energy lost by a charged
particle traversing a finite volume is proportional to the path
traveled (track length) in that volume. The cord length how­
ever is itself a random quantity and for microdosimetric cal­
culations, its mean can be estimated through Monte Carlo
simulations or, for convex volumes, using the Cauchy for­
mula l overbar = 4 V/S where V is the body volume and S is its
surface area.
4.2.2"
"Describe the principles behind using Tissue Equivalent Proportional Counters (TEPCs) as microdosimeters, focusing on how they function to quantify energy deposition events and what limitations currently exist regarding their use.","Tissue Equivalent Proportional Counters (TEPCs) are a primary technology utilized in microdosimetry measurements. Their operation relies on simulating micrometer-sized volumes using millimeter-sized chambers filled with tissue-equivalent gases, typically methane or propane at pressures around 0.9 kPa. When ionizing radiation traverses this chamber, it generates electrons that are amplified by an electric field, producing measurable pulses of current. Each pulse represents a single energy deposition event within the simulated micrometer volume. The low pressure allows for the accurate simulation of very small volumes – typically in the range of a few micrometers in diameter – which is crucial for microdosimetry.  The frequency and amplitude of these generated pulses are then processed by acquisition electronics to create a spectrum representing the distribution of energy deposited by the incident radiation. However, TEPCs face several limitations. Wall effects—interactions between the incoming radiation and the detector walls—can introduce spurious signals. Controlling electron avalanche processes due to high electric fields is also challenging. Newer designs, known as avalanche confinement TEPCs, are being developed to mitigate these issues through optimized electrode configurations that reduce electric field strengths and minimize avalanche generation. Furthermore, the relatively low sensitivity of TEPCs compared to gas detectors limits their ability to detect very low-energy events, necessitating careful consideration during data analysis.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.2	 Radiation Microdosimetry | Sub-subsection: 4.2.2	 Technologies and Detectors | Content: longer a stochastic quantity.
(4.15)
As the radiation biological damage is proportional to the
dose delivered, it is useful to consider also the lineal energy
dose distribution d (y), as it provides the fraction of the total
absorbed dose in the interval [y, y + δy]. The dose-weighted
lineal energy distribution d (y) is therefore given by:
(4.16)
­
4.11
Similar to the frequency mean lineal energy y overbarF, the dose-­
weighted mean lineal energy y overbarD can be defined as
(4.17)
This quantity provides the average lineal energy value
when each energy deposition event is weighted based on its
contribution to the total dose.
A crucial parameter for the calculation of the lineal energy
is the mean cord length (l overbar), as the energy lost by a charged
particle traversing a finite volume is proportional to the path
traveled (track length) in that volume. The cord length how­
ever is itself a random quantity and for microdosimetric cal­
culations, its mean can be estimated through Monte Carlo
simulations or, for convex volumes, using the Cauchy for­
mula l overbar = 4 V/S where V is the body volume and S is its
surface area.
4.2.2
Technologies and Detectors
The first microdosimeter detector was designed and devel­
oped by Rossi in 1955 [16]. It was a spherical proportional
counter made of tissue-equivalent plastic walls and filled
with low-pressure tissue-equivalent gas (TEPC—Tissue
Equivalent Proportional Counter). The low pressure allows
to simulate micrometer volumes using a millimeter-size
chamber (10–150 mm diameter), which is easier to handle
and manufacture. Methane or propane-based gases are typi­
cally used at a pressure of ~0.9 kPa to simulate volumes of a
few micrometer in diameter. The electrons produced by the
traversal of the radiation through the chamber are amplified
and collected by an electric field. Every radiation traversal
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
202
generates therefore a small current that gives rise to a pulse
later processed by the acquisition electronics. This allows the
quantification of the energy deposited in micrometer vol­
umes by individual radiation events. TEPCs are still the most
common detector for microdosimetry measurements. Their
main limitation is related to the wall-effects, which are events
generated by the interaction of the incoming radiation with
the walls of the device, and to controlling the electron ava­
lanche process caused by high electric fields, which are
required to simulate very small volumes. New devices are
addressing these limitations with wall-less TEPC where spe­
cially designed electrodes are aligned to generate an electric
field within a confined volume and reduce electron ava­
lanches (avalanche confinement TEPCs). The new devices
are also less cumbersome than the first TEPC designed by
Rossi and can be operated in clinically relevant radiation
beams.
More recently, solid-state detectors have been employed
as microdosimeters taking advantage of their unique charac­
teristics including compact size, economic development, and
low sensitivity to vibrations, which makes them particularly
suitable for clinical environment. The working principle is
based on the electron-hole pairs produced by the radiation as
it crosses the sensitive volume of the semiconductor crystal.
The number of electron-hole pairs is proportional to the total
energy deposition (ΔE) and the crystal ionization energy (W;
average energy required to produce an electron-hole pair) by
(4.18)
The ionization energy is specific for each crystal and in
the order of a few eV for typical semiconductor materials,
which is an order of magnitude lower than that required for
gas detectors. Furthermore, it is largely independent of the
energy of the incoming radiation. Similar to TEPCs, the
current generated by the collection of the produced elec­
trons is used to quantify the energy deposition events. As
the sensitive volume of the detector can be of a few microm­
eters, the pulses generated provide a microdosimetric spec­
trum of the incident radiation. In order to serve as a
microdosimeter, solid-state detectors need to have well-
defined and micrometer-­sized sensitive volumes coupled to
an efficient charge collection mechanism, as the electrical
signal generated can be very small. A potential drawback of
solid-state microdosimeters is their non-tissue equivalence,
which generally requires additional conversion calculations
provided by Monte Carlo simulations.
2
­
­
G. Schettino et al.
203
small voltage that can be applied to the small-volume semi­
conductor. This limits the lowest energy events that can be
detected. The fixed size of the crystal also implies that differ­
ent detectors may need to be used to obtain microdosimetric
information for different sensitive volumes while gas-based
detectors can achieve this by varying the gas-pressure. The
advantages and disadvantages of both detector types are con­
fronted in Table 4.2.
4.2.3"
"Explain the relationship between lineal energy (y), specific energy (z), microscopic volume mass (m), and mean chord length (l) as described in the text, and why this connection is crucial for linking microdosimetry to biological responses.","The text establishes a fundamental link between several quantities when considering microdosimetric measurements and their impact on biological response. Lineal energy (y), measured by microdosimetry, represents the average energy deposited per unit length of a particle’s path. Specific energy (z) is defined as the ratio of energy imparted (ε) to the mass of the microscopic volume (m). The text highlights that both y and z are related to this microscopic volume, which is then connected through its mass (m) and mean chord length (l). This relationship, formalized in equation 4.20, allows for a direct quantification of energy deposition at a microscale. Crucially, this connection is vital because it provides the means to translate physical measurements – namely, the lineal energy – into a biologically relevant parameter by considering the actual volume and shape where that energy is deposited. This enables researchers to directly link microdosimetric spectra (represented by ‘f(y)’) with radiobiological effects, offering a pathway for understanding how radiation damage occurs at the most fundamental level of cellular interaction. Reference: [MolecularRadiationBiology], Section 4.2.3 – Biological Relationship Response.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.2	 Radiation Microdosimetry | Sub-subsection: 4.2.3	 Biological Relationship Response | Content: In the framework of radiation biology, either the linear energy
transfer LET or the lineal energy can be used to specify the
radiation quality. While the LET is frequently used, at least
for broad classifications of different radiation qualities (high
vs low LET, i.e., densely vs sparsely ionizing radiation), the
use of the lineal energy is less common due to the limited
experimental data and the complexity in analyzing the micro­
dosimetric spectra. However, the use of LET to determine
radiation quality is affected by some intrinsic limitations such
as different particles of different mass and energy having the
same LET being still characterized by a different energy dis­
tribution of the secondary electrons. In general, the microdo­
simetric spectra provide information that is not captured in
the LET and it may be very beneficial for fundamental radio­
biological studies aimed at linking biological response to
energy deposition events, as well as for radiation protection
and clinical work, e.g., predicting treatment efficacy.
Several LET-based RBE models have been developed
over the years. The Microdosimetric Kinetic Model (MKM)
is a model based on the dual radiation action theory and spe­
cifically developed to link microdosimetric measurements to
radiobiological effects [19]. The central hypothesis of the
dual radiation action theory is that the number of lethal
lesions is, through a linear quadratic relationship, propor­
tional to the specific energy deposited in a microscopic site.
The specific energy (z) is defined as the ratio between the
energy imparted (ε) and the mass of the microscopic volume
(m) [17]:
(4.19)
As both the specific energy (z) and the lineal energy (y)
measured by microdosimetry are related to a microscopic
volume, the two quantities are linked through the micro­
scopic volume mass (m) and mean chord length (l):
(4.20)
with l, m, ρ, and rd the mean chord length, the mass, the
density, and the radius of the microscopic volume,
respectively.
Kase et al. [20] formalized the link between cell survival
fraction SF and the microdosimetric measurements:
(4.21)
with
(4.22)
where α0 and β0 are the linear quadratic parameters specific
for each cell line (usually taken from X-ray measurements), D
is the macroscopic dose absorbed by the cell and ρ is the cell
density. y0 and rd are fixed parameters accounting for the over­
kill effect observed at high lineal energy values (usually set at
y0 = 150 keV/μm) and for the sensitive critical volume of the
specific cell line, respectively. The parameter y* includes the
measured microdosimetric spectrum (f (y)) providing there­
fore a direct link between radiobiological response and physi­
cal measurements. The use of the MKM and microdosimetry
is the only approach providing a link between physical and
biological measurements, considering that LET values cannot
be experimentally determined. Supported by the fast develop­
ment of technologies that will facilitate microdosimetric mea­
surements, there is renewed interest in this approach. However,
the precise estimation of the y0 and rd parameters requires fur­
ther investigation (Box 4.5).
Box 4.5 Microdosimetry
•	Microdosimetry quantifies individual energy depo­
sition events through the lineal energy
•	Microdosimetry is performed through tissue equiv­
alent proportional counters (TEPC) or solid state
microdosimeters
•	Microdosimetry is able to directly link radiobio­
logical response to physical measurements
Table 4.2 Comparison of tissue equivalent proportional counters
(TEPC) and solid-state microdosimeters
TEPC
Solid-state
microdosimeter
Advantages
Tissue equivalence
Easy handling and
manufacturing
Operation for clinically
relevant beams
High-spatial resolution
Compact size
Economic development
Low sensitivity to
vibrations
Suitable for clinical
environment
DisadvantagesWall-effects
High electric fields
No tissue equivalence
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
204
4.3"
"Following exposure to ionizing radiation, what are the initial molecular events that occur within DNA, specifically focusing on the mechanisms involved in single-strand break (SSB) formation and subsequent repair pathways?","Upon irradiation with ionizing radiation, the primary damage to DNA arises from the direct interaction of energetic particles with the molecule’s structure. This interaction leads to the creation of highly reactive free radicals, primarily hydroxyl radicals (.OH), which are extremely damaging due to their high reactivity. These radicals initiate a cascade of events ultimately resulting in single-strand breaks (SSBs) within the DNA backbone. The formation of SSBs is favored because the energy deposited by radiation can easily cleave the relatively weak covalent bonds between adjacent nucleobases, particularly at guanine bases which are more susceptible to ionization.  

Initially, a significant proportion of damage manifests as SSBs. These breaks don’t immediately trigger repair mechanisms; instead, they represent a vulnerable state within the DNA molecule. The cell rapidly activates several pathways to address this damage. One key pathway involves the Rad51 protein complex, which is crucial for strand invasion and subsequent homologous recombination repair. However, before this can occur, transient structures like nucleoside excision repair (NER) are engaged. NER begins with the recognition of distortions in the DNA helix caused by SSBs, primarily through proteins like XPC.  XPC initiates a process where surrounding nucleotides containing incorrect base modifications are excised and replaced with correct ones using the undamaged strand as a template. This is a rapid, though imperfect, initial response to SSB formation.

Furthermore, non-homologous end joining (NHEJ) also contributes to the repair of SSBs, although it’s generally considered less precise than homologous recombination. NHEJ involves direct ligation of the broken DNA ends without requiring a template strand. While effective in quickly restoring genomic continuity, this pathway is prone to introducing small insertions or deletions, potentially leading to mutations.

Finally, DNA secondary structures like G-quadruplexes and J-strand can also form following radiation damage, further complicating the repair process and contributing to overall DNA instability. The interplay between these different repair pathways determines the ultimate fate of the damaged DNA molecule – whether it is accurately repaired or leads to mutations and genomic instability.

Reference: [Molecular Radiation Biology], Section 4.3.1 – From Track Structure to Early DNA Damage","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Content: Damage
4.3.1"
"Describe the process of water radiolysis following ionizing radiation exposure, detailing the initial events and subsequent products that contribute to biological damage.","Following interaction with ionizing radiation (IR), water molecules within a biological sample are ionized or excited. This excitation leads to the decomposition of water through a process known as water radiolysis. The primary product of this reaction is hydroxyl radicals (•OH) and hydrogen ions (H+). These highly reactive radicals initiate a cascade of further reactions, leading to the formation of numerous secondary products including hydrated electrons (e⁻), atomic oxygen (O), excited molecules, and other radical species. Crucially, these radicals are indiscriminate in their reactivity and readily attack biological macromolecules such as DNA, RNA, and proteins. The initial energy deposition from the IR creates localized hot spots within the water, accelerating this radical formation. These radicals then propagate damage by directly reacting with biomolecules, causing strand breaks, base modifications (e.g., oxidation of guanine), and cross-linking between molecules – ultimately disrupting cellular function and potentially leading to cell death.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Sub-subsection: 4.3.1	 Introduction | Content: When ionizing radiation (IR) interacts with a biological sam­
ple (which is composed of ~70% water in weight and the rest
biological molecules), it can either directly hit the biological
molecules or the water molecules. In both cases, these inter­
actions can lead to an energy deposition at the interaction
point (inelastic scattering) and the production of secondary
particles, mostly electrons that can, in turn, also interact with
the target. The ionized or excited molecules, particularly
those of water, generate radicals (water radiolysis) that also
can attack the biological unit molecules or aggregates, lead­
ing to subsequent structural damage of these molecules,
which could ultimately have consequences on the function­
ing of the cell and its outcome.
­
­
4.12
­
­
21
­
Different experimental techniques have been developed
and used in recent years to measure this damage, as we will
see in Sect. 4.3.3. However, in most cases, these techniques
do not allow to have access to the total number of strand
breaks or double strand breaks as well as to the base damage
or to the complexity of the damage cluster. Thus, the Monte
Carlo simulation method has become the “gold standard” for
the prediction of these damages. This means however that it
is necessary to know, with the least possible uncertainty, all
the data allowing the description of these stages to feed the
codes. In Sect. 4.3.4, we will detail what these data or
­parameters are, their current uncertainties, and therefore the
current simulation capabilities with the different codes.
4.3.2"
"Describe the key components of a radiation track as observed in biological systems, particularly focusing on the distinction between the ‘core’ and ‘penumbra’ regions when considering high-energy ion irradiation. What is the significance of low-energy electrons (≤10 keV) within this track structure?","Within the context of radiation damage at a microscopic level, a ‘track’ represents the spatial distribution of energy deposited by ionizing radiation as it interacts with matter. When high-energy ions traverse biological tissues, they create two distinct regions surrounding their path: the core and the penumbra. The core region, formed by the projectile itself, is characterized by relatively straight trajectories due to elastic scattering events occurring at energies below approximately 10 MeV, where the ion’s momentum direction remains largely unchanged. This results in a localized area of high energy deposition directly associated with the initial interaction. Conversely, the penumbra region arises from secondary electrons generated through ionization within the target material – primarily water molecules in biological systems. These secondary electrons, possessing energies ranging from approximately 1 to 100 MeV, undergo numerous interactions with surrounding molecules, leading to a diffuse and expanded energy distribution around the primary track. The lower-energy electrons (≤10 keV) are particularly noteworthy because they have a limited penetration range (<1 μm) and a short inelastic mean free path (<10 nm) in condensed media like water or DNA. Consequently, most of their direct damage occurs at the ends of the track, where ionization densities are highest. Furthermore, these low-energy electrons can participate in resonant scattering events with molecules, generating reactive radicals (such as OH•) and molecular species that contribute to DNA strand breaks and oxidative damage – a process potentially facilitated by energies as low as 10 eV through resonance mechanisms.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Sub-subsection: 4.3.2	 Physical Stage (Direct Damage) | Content: Ionizing radiation interacts with the exposed target through a
cascade of random interactions with the atoms of the
medium. The result concerns as much the interactions of the
primary radiations as the slowing down of the secondary
radiations emerging from them. During these interactions,
radiation can be scattered or absorbed by gradually losing
energy. If these absorption processes lead to sufficiently high
energy transfers (typically >10 eV in radiobiology), they can
lead to the ejection of electrons and modify the electronic
layer of atoms and molecules and their chemical properties,
which gives them the power to induce effects. Indeed, IR can
be categorized as directly and indirectly ionizing depending
on whether it is composed of charged or uncharged particles,
respectively, but in all cases with enough energy to produce
ions in matter.
While ionization is considered the most important physi­
cal phenomenon to explain radiation-induced effects, excita­
tion, a phenomenon in which electrons are transferred to
higher atomic or molecular levels, is also considered among
the possible events to be precursors of the radiation-induced
effect. It is assumed that the ratio of energy loss by ionization
and excitation is stable between radiations of different
natures and energies, and, therefore, that the measurement of
ionizations alone is sufficient. This approximation is impor­
tant for the validity of reference dosimetric and microdosi­
metric measurement techniques using gas detectors. These
G. Schettino et al.
205
techniques only “see” the ionizations but apply global physi­
cal data such as the average ionization energy (W) that
accounts for both phenomena. It is generally recognized that
the distinction between ionization and excitation is more
blurred in condensed states, which are ultimately the ones
targeted in dosimetry using other measurement methods than
gas meters, and in radiobiology.
From a mechanistic perspective, if one wants to identify
which energy deposition will result in damage to the struc­
ture of the target biomolecules, this proportionality between
the number of ionizations in a volume (however small it may
be) and the deposited energy is therefore not detailed enough.
Indeed, in this context, it is necessary to “zoom in” on the
scale of the target’s constituents at the nanometric scale to
look at all the energy deposits (or energy transfers) produced
by the initial radiation, as well as the secondary particles,
notably the electrons. This is the study of the so-called track
structure of radiation. At this scale, the differences between
the spatial distribution of energy deposits defined by the
tracks produced by different types of radiation (photons,
electrons, energetic ions of different energies, etc.) lead to
variations in early damage sufficient to produce a great
diversity of later effects at both the cellular and tissue
levels.
Thus, for example, in the case of irradiation by high
energy ions, we can look at the track they produce as being
formed by a “core” and a “penumbra” region. The core is
formed by the energy deposits of the projectile itself and is
almost straight as elastic scattering does not have an impor­
tant influence on the ion direction at energies under
10 MeV. The penumbra region is formed by the energy
deposits of secondary electrons produced during ionizations
with energies of ~1–100 MeV, interacting with many mole­
cules in the target [22, 23].
However, when the primary particle ionizes water mole­
cules, the main component of biological matter, many of the
electrons are produced with low energy [24, 25]. Indeed, the
energy of the emitted electrons for a given material is mainly
determined by the oscillator-strength distribution of its
valence electronic structure. The long-range of Coulomb
interactions and the cross section that peaks at ~20–30 eV
and decreases to very low values at 100 eV leads to the for­
mation of electrons with energies, in general, less than
100 eV [26]. These low energy electrons (more extensively
defined as those ≤10 keV) have a small penetration range
(<1 μm) and inelastic mean free path (IMFP) (<10 nm) in
typical condensed media [27] like water or DNA compo­
nents. Therefore, most of the direct damage is produced
around the track and, more specifically, at the track ends,
where they are produced in high quantity.
In fact, the electrons below ~20 eV seem to be particu­
larly effective because, in addition to participating in the pro­
duction of direct damage by ionizations or excitations of the
constituents of the DNA, they can undergo resonant scatter­
ing with molecules, generating reactive radicals and molecu­
lar species, which can themselves contribute to DNA breaks
[28] and oxidative damage. Experiments have indicated that
electrons (or photons) with energies as low as ~10 eV can
still induce double strand breaks, possibly through a reso­
nance mechanism [29, 30].
4.3.3
Physicochemical and Chemical Stages
(Indirect Effect)
In the previous section, we were interested in the interactions
between IR and the target molecule (DNA) and how some of
these interactions can cause damage in a direct way. However,
IR interacts in the same way with the surrounding water
medium and induces local electronic instability. The physi­
cochemical stage corresponds to the set of rapid electronic
and atomic modifications resulting from the readjustments of
the medium in order to return to thermal equilibrium. Thus,
water molecules that are in an excited or ionized state can
dissociate into new chemical species (radiolysis):
Among these species, the OH° (hydroxyl) radical is par­
ticularly interesting in radiobiology, because it can be the
origin of DNA damages that are difficult to repair by the cell.
This radical is mainly produced from the radiolysis of pure
water following different mechanisms (dissociation directly
after an ionization or an excitation of the water molecule).
Moreover, under-excitation electrons (with an energy
lower than the last excitation shell of the water molecule,
8.22 eV) will undergo elastic scattering and will continue to
lose energy by vibrational and rotational interactions until
reaching the energy of the medium, the so-called thermaliza­
tion energy. This thermalization process is in competition
with two processes of electron capture, either by a neutral
water molecule (“dissociative attachment”) or by an ionized
water molecule (“geminal recombination”) and is supposed
to be completed within a picosecond after the irradiation.
Beyond the picosecond, the newly created radiolytic spe­
cies are free to diffuse randomly in the medium and to inter­
act with each other, which is the chemical stage. Initially
localized around the energy deposits of the track, they propa­
gate and distribute more homogeneously in the medium as
time evolves. The initial distribution of species depends
strongly on the LET of the incident particle. In the case of
high-energy electron projectiles (low LET), the initial distri­
bution in the form of clusters will be more strongly marked
than in the case of ions, where the LET is more important,
and thus the energy depositions are more homogenously
located all over the track. It is generally accepted that beyond
4 Mechanistic, Modeling, and Dosimetric Radiation Biology"
"The text describes several stages in the indirect radiation damage process to DNA. Specifically, it details how low-energy electrons can induce significant damage through resonant scattering and radical formation, ultimately leading to hydroxyl radical production. Can you explain the roles of both the physicochemical (electronic readjustment) and chemical stages in this process, focusing on the key reactions that contribute to DNA damage?","The indirect radiation effect, as described, unfolds across two distinct stages following irradiation. Initially, the *physicochemical stage* represents a rapid, localized electronic and atomic rearrangement within the surrounding water molecules. This occurs due to the absorption of energy by water, leading to excitation and ionization events. Critically, these excited or ionized water molecules dissociate into reactive species like the hydroxyl radical (OH•). The formation of this radical is paramount because it’s a potent DNA-damaging agent.  The electrons themselves, particularly those with energies below 20 eV, play a crucial role in initiating this process by inducing resonant scattering and generating radicals directly through ionization or excitation. This stage is characterized by rapid, short-lived chemical transformations within the immediate vicinity of the energy deposition. Subsequently, the *chemical stage* emerges as these initially localized radiolytic species diffuse throughout the surrounding medium.  The hydroxyl radical, now formed in the physicochemical stage, continues to react with DNA components – primarily through capturing hydrogen from the deoxyribose backbone at C4 position or by adding to nitrogenous bases – leading to strand breaks and other modifications. These reactions are facilitated by the continued presence of reactive species generated during the initial irradiation event. The chemical stage is characterized by longer-lived, more widespread reactions as these radicals interact with a larger volume of surrounding molecules, ultimately contributing significantly to the overall DNA damage observed in indirect radiation effects.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Sub-subsection: 4.3.3	 Physicochemical and Chemical Stages (Indirect Effect) | Content: where they are produced in high quantity.
In fact, the electrons below ~20 eV seem to be particu­
larly effective because, in addition to participating in the pro­
duction of direct damage by ionizations or excitations of the
constituents of the DNA, they can undergo resonant scatter­
ing with molecules, generating reactive radicals and molecu­
lar species, which can themselves contribute to DNA breaks
[28] and oxidative damage. Experiments have indicated that
electrons (or photons) with energies as low as ~10 eV can
still induce double strand breaks, possibly through a reso­
nance mechanism [29, 30].
4.3.3
Physicochemical and Chemical Stages
(Indirect Effect)
In the previous section, we were interested in the interactions
between IR and the target molecule (DNA) and how some of
these interactions can cause damage in a direct way. However,
IR interacts in the same way with the surrounding water
medium and induces local electronic instability. The physi­
cochemical stage corresponds to the set of rapid electronic
and atomic modifications resulting from the readjustments of
the medium in order to return to thermal equilibrium. Thus,
water molecules that are in an excited or ionized state can
dissociate into new chemical species (radiolysis):
Among these species, the OH° (hydroxyl) radical is par­
ticularly interesting in radiobiology, because it can be the
origin of DNA damages that are difficult to repair by the cell.
This radical is mainly produced from the radiolysis of pure
water following different mechanisms (dissociation directly
after an ionization or an excitation of the water molecule).
Moreover, under-excitation electrons (with an energy
lower than the last excitation shell of the water molecule,
8.22 eV) will undergo elastic scattering and will continue to
lose energy by vibrational and rotational interactions until
reaching the energy of the medium, the so-called thermaliza­
tion energy. This thermalization process is in competition
with two processes of electron capture, either by a neutral
water molecule (“dissociative attachment”) or by an ionized
water molecule (“geminal recombination”) and is supposed
to be completed within a picosecond after the irradiation.
Beyond the picosecond, the newly created radiolytic spe­
cies are free to diffuse randomly in the medium and to inter­
act with each other, which is the chemical stage. Initially
localized around the energy deposits of the track, they propa­
gate and distribute more homogeneously in the medium as
time evolves. The initial distribution of species depends
strongly on the LET of the incident particle. In the case of
high-energy electron projectiles (low LET), the initial distri­
bution in the form of clusters will be more strongly marked
than in the case of ions, where the LET is more important,
and thus the energy depositions are more homogenously
located all over the track. It is generally accepted that beyond
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
206
the microsecond, most of the reactions between different
clusters are completed and the chemical stage can be consid­
ered as finished for a given track.
­
4.13
31
32
To do so, one category of numerical simulations con­
sists in dividing the modeling into two phases with differ­
ent levels of granularity and acceptable simplifying
assumptions. In the first one, each radical species is con­
sidered individually, and we are interested in the calcula­
tion of the reaction rate, the diffusion coefficient, or the
branching ratios. This first phase can be simulated using
molecular dynamics (like Born–Oppenheimer or Car–
Parrinello) and/or quantum mechanical calculations like
TD-DFT. However, this approach is unfortunately prohibi­
tive in terms of computation time for a high number of
molecules, which limits their application to systems such
as a cell. In the second phase, approximations can be made
to significantly reduce the computation time. For example,
molecules of the same species can be grouped in order to
describe their evolution by a unique variable (concentra­
tions) and two types of methods are often applied: either
probabilistic (Gillespie algorithms) or based on the solu­
tion of differential equations.
A second category of numerical simulations consists of
describing the medium as a solvent or continuum and only
calculating the diffusion and the chemical reactions of par­
ticular interesting species. This method is well adapted when
the number of molecules is relatively small and, more par­
ticularly, when their distribution is inhomogeneous like in
this case. Therefore, most of the track structure codes includ­
ing the simulation of the chemical stage use this approach
(Sect. 3.3.4) and include other simplifications as considering
each molecule spherical and diffusing independently of the
other molecules. In this frame of a diffusion-reaction model,
their diffusion in the medium can be solved with the Green
Function of the Diffusion equation (GFDE). The eventual
reaction of two particles is considered when the interparticle
G. Schettino et al.
207
distance is smaller than their reaction radius. The reactions
can be either fully or partially diffusion-controlled and
involve neutral or charged particles. This gives four classes
of reactions that were introduced by Green et al. [33]. For
totally diffusion-controlled reactions (type I), the rate con­
stant is assumed to be infinite, meaning that the particles
react whenever they collide. In this case, the GFDE solution
can be calculated using the Smoluchowsky boundary condi­
tions in three dimensions [34]. This reaction mechanism is
the one most often triggered when radiolytic species diffuse
and encounter a reactive site that is either representing other
radicals or a DNA constituent (sugar-phosphate backbone or
bases with high rate constants). For other reaction types,
including those representing the scavenger effects, please
refer to the literature [35, 36].
Within this frame (GFDE), different stochastic simula­
tion techniques have been proposed in order to calculate the
probability of reactions to happen depending on the position
of each molecule at a given time [33, 37, 38] as the step by
step method or the IRT for Independent Reaction Time
method.
Indirect damages are the consequence of these reactions
for the DNA molecule and can represent between 30 and
90% of the total DNA damage depending on the LET of the
irradiation. Among them, of importance are the strand breaks
produced by the hydroxyl radical capturing the hydrogen of
the deoxyribose at the C4 position or the addition of hydroxyl
radical to a nitrogenous base, resulting in base alterations.
These altered bases are often unstable and can either decom­
pose or react with environmental molecules and radiolytic
species. The underlying reactions are therefore multiple and
complex [39]. DNA-protein or DNA–DNA bridging can also
occur under the effect of radical species produced by radia­
tion [40].
It should be noted that the description of the chemical
stage process as explained above becomes much more com­
plex if we take into account a more realistic chemistry of the
cellular environment adding factors such as the pH, the oxy­
gen concentration, or the presence of more complex mole­
cules around the DNA, commonly called “scavengers”
because of their action on the radical species. In particular,
the concentration of oxygen has been shown to have a sig­
nificant impact on radiation resistance: indeed, carcinogenic
cells, which are hypoxic, are 2–3 times more resistant to
radiation than healthy, normoxic cells. This “oxygen effect”
is also believed to be one of the possible explanations for the
protective effect on healthy tissue in the case of FLASH
radiotherapy as the depletion of oxygen during irradiation
could create a temporary hypoxic environment for both
healthy and cancer cells. Nevertheless, this hypothesis is
still not completely proven and the mechanism behind this
FLASH effect however remains unknown [41].
4.3.4"
"Describe the key types of DNA damage induced by ionizing radiation and explain why double-strand breaks (DSBs) are often considered ‘lethal’ or ‘semi-lethal’ in cellular repair models, referencing specific examples from the text.","Ionizing radiation induces a complex array of DNA damages, primarily categorized as strand breaks (simple, double, or clustered), base alterations, protein-DNA adducts, and DNA–DNA bridges. The text specifically highlights double-strand breaks (DSBs) – particularly those occurring in clusters – as being the most significant due to their association with misrepair and subsequent cell death. DSBs are frequently termed ‘lethal’ or ‘semi-lethal’ because they represent a fundamentally disruptive event within the genome, overwhelming the cellular repair mechanisms' capacity to accurately restore DNA integrity. The text cites that these types of damage are considered ‘lethal’ or ‘semi-lethal,’ as they are considered to lead to misrepair and cell death [42–44]. Experimental validation using techniques like the comet assay and pulsed field electrophoresis (PFE) – often employed with high-dose irradiation – demonstrate the presence of these DSBs, allowing for comparison with simulation predictions from codes such as PARTRAC or Geant4-DNA. Furthermore, immunofluorescence methods utilizing markers like H2AX, which detects DNA double strand breaks through its phosphorylation, provide a visual confirmation of DSB formation and are frequently used to validate simulations. It’s crucial to note that a single detectable focus identified by these techniques doesn't necessarily represent a single DSB due to the complexity of the damage process, necessitating careful consideration of irradiation conditions and geometry in simulation models [51, 52]. Reference: [4:3:4 Biological Stage (Early DNA Damage Scoring)]","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Sub-subsection: 4.3.4	 Biological Stage (Early DNA Damage Scoring) | Content: healthy and cancer cells. Nevertheless, this hypothesis is
still not completely proven and the mechanism behind this
FLASH effect however remains unknown [41].
4.3.4
Biological Stage (Early DNA Damage
Scoring)
Radiation-induced damage is multiple and depends on
numerous factors such as the type of radiation, the DNA con­
figuration, or the irradiated medium condition. They are the
result of the physical, physicochemical, and chemical pro­
cesses explained in the previous sections and thus generated
either by direct or indirect effects. The main DNA damages
are strand breaks (simple, double, or clustered), base altera­
tions, protein-DNA, and DNA–DNA bridges. Of these, the
radiobiology and simulation communities have historically
been most interested in double strand breaks (DSB) or clus­
tered damage including at least one DSB. Indeed, in most
repair models this type of DNA damage is called “lethal” or
“semi-lethal,” as they are considered to lead to misrepair and
cell death [42–44]. In all cases, and even if they can some­
times be correctly repaired by cellular repair mechanisms, it
is established that these complex damages can have impor­
tant consequences on the cellular survival or its functioning.
Moreover, DSB can be detected experimentally and com­
pared to the results of predictions from simulations. Several
detection techniques exist, which are adapted according to
the irradiation configuration, the dose used, or the cell type.
Historically, comet assay or pulsed field electrophoresis
(PFE) has been used with high-dose irradiation in order to
generate DNA fragments that can be separated and measured
leading to a given number of DSB detected. Data obtained in
this way, for example, in the case of proton irradiations at
different energies or gamma rays [40, 45], have been used
extensively to validate codes such as PARTRAC [46],
KURBUC [47], or, more recently, Geant4-DNA [48].
Other techniques, used at low dose, consist in using
immunofluorescent probes to localize the radio-induced
DSB within the genome. For example, in the case of H2AX
immunofluorescence; the histone closest to a double strand
break that contains the H2AX variant of histone H2A
(approximately present at 25% of H2A histones and evenly
distributed in the DNA) allows the detection of DNA double
strand breaks through its phosphorylation. This phosphory­
lation is visible using specific antibodies, containing a fluo­
rochrome substance, making the double strand breaks appear
as luminous points called “foci” or IRIF (ionizing radiation-­
induced foci) [49].
An important quantity of experimental data has been
obtained recently using this technique or with other fluores­
cent biomarkers such as the 53BP1 protein, which allows to
quantify the DSB produced by different types of radiation
and to compare them with the simulation results. However,
an important bias of this technique is that, in general, one
detectable focus does not correspond to a single DSB formed
in the DNA [50], and therefore the irradiation conditions and
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
208
the geometry of the target must be explicitly considered in
the simulation for such validations [51, 52] .
4.3.5"
"The text describes several approaches to simulating particle transport in biological media, highlighting the challenges associated with accurately modeling radiation damage at the nanoscale. Specifically, it mentions ‘condensed history’ (CH) approaches and track structure codes. What are the key differences between these two methods regarding how they simulate particle interactions within a material?","The condensed history (CH) approach represents a computationally efficient method for simulating particle transport by grouping numerous scattering events into fewer, longer artificial steps. This is achieved through multiple-scattering theories and continuous energy loss calculations along those steps. In contrast, track structure codes employ an event-by-event tracking of individual physical interactions, offering potentially higher spatial resolution and the ability to simulate phenomena like chemical damage at the nanoscale – a crucial aspect for linking radiation effects with biological outcomes. The text emphasizes that track structure codes are necessary when simulating at scales relevant to biological effects, where detailed particle trajectories are required to capture the nuances of interaction within complex media.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Sub-subsection: 4.3.5	 Track Structure Monte Carlo Codes | Content: As we described earlier in this chapter, particle transport
through matter using MC codes is generally handled via a
“condensed history” (CH) approach [53], currently used for
dosimetry and the majority of microdosimetry applications
for very energetic particles. In such a CH approach, many
scattering events are grouped into fewer artificial steps, much
longer than the mean free path of the particle, using multiple-­
scattering theories and a continuous energy loss along those
steps. However, in order to simulate the physics at the
nanoscale and to possibly link it to the biological effects of
radiation with track structure properties in the nm regime
[54], an event-by-event tracking of the different physical
events is necessary to allow for better spatial resolution.
Therefore, so-called track structure codes have been devel­
oped for applications in micro- and mostly nanodosimetry.
In Table 1 taken from [55], we present the list of the main
track structure codes that have been developed since the 80 s
of the last century. In this table, it is indicated if the code
includes the possibility of simulating the chemical stage and
the materials available for the simulation of the physical
stage.
Indeed, in order to model all the physical interactions tak­
ing place in the physical stage, these codes need to include
cross sections for simulating ionization, electronic excita­
tions below the ionization threshold, and, ideally, vibrational
or rotational excitations of the medium, in principle for all
the interacting particles but particularly for secondary elec­
trons, for the reasons explained in Sect. 4.3.2. Therefore,
track structure codes either rely on pre-parameterized or
tabulated sets of total and differential elastic and inelastic
cross sections in order to calculate the energy deposition in
condensed matter. An important point to consider is that at
these low energies, the interaction cross sections depend on
the composition of the material but also on its state. That is
to say that the cross sections are not the same for a medium
in a gaseous or a solid state. This leads to a particular diffi­
culty because it is very difficult (not to say, almost impossi­
ble) to obtain experimental cross sections for biological
media in their condensed state [24]. Only a few data obtained
under very specific conditions exist for liquid water [56, 57]
and these data are the basis for the set of models utilized to
calculate the cross sections used by most track structure
codes.
However, still, some track structure codes use atomic ion­
ization/electronic excitation cross sections [58] obtained in
the gas phase even if, in principle, they are not suitable for
low energy excitations of valence electrons in water, since
such excitations are sensitive to the electronic structure of
the target [54, 59–61].
Nevertheless, most of the theoretical models for the cal­
culation of the cross sections used in these codes are based
on the first Born approximation that uses the dielectric for­
malism. Here, the properties of a given material in terms of
characterizing the inelastic interactions with charged par­
ticles are given in what is called the Energy Loss Function
(ELF). This function allows calculating the mean free path
and thus the inelastic cross sections. However, this func­
tion depends on the energy and momentum of the charged
particles. As the existing experimental data have been
obtained in the optical limit (i.e., for a zero momentum
transfer), it is necessary to extend the calculation of this
function for non-­zero momentum transfers. Different dis­
persion algorithms based on the electron gas theory [53]
are then used to redistribute the imaginary part of the func­
tion between the different ionization and excitation levels
while preserving the agreement of their sum with the initial
experimental data.
However, differences in results of inelastic scattering
obtained with different dispersion algorithms to extrapolate
optical data to finite momentum transfer reach about a factor
2 in the range 50–200 eV (and even further at still lower
energies) [62] and consequently, these differences impact the
obtained results. Recent studies have reported a potentially
relevant effect of ionization clustering [63] or DNA damage
induction [64].
The description of the dielectric function of water also
continues to be studied. Thus, only recently have works been
published that address exchange and correlation effects
based on the electron gas model or that improve the descrip­
tion of effects beyond the first Born approximation [27, 65].
The objective is to improve previous dispersion algorithms
[66], to develop new TS codes [67, 68], and to clarify differ­
ences in inelastic scattering between different condensation
phases [69]. Besides, other authors still work on measuring
or adapting the theoretical model, using, for example, pre-­
parametrized models [70], to obtain cross-sections for tar­
gets other than water to be included in TS codes.
Concerning the elastic scattering models for low-energy
electrons, different theoretical approaches are also devel­
oped and included in TS codes. Some use screening param­
eters derived from experiments to enlarge the applicability of
the first Born approximation [71] and others use the Dirac
partial wave analysis [72, 73].
­
4.3
G. Schettino et al.
209
Table 4.3 MC track structure codes used in various radiation effects studies in biological cells
Code
Particles
Energy range
Target materials
Chemical
stage
CPA100
e−
Thermalization −256 keV e−
Water (l), DNA
Yes
DELTA
e−
≥10 eV–10 keV e−
Water (v)
Yes
EPOTRAN
e−, e+
≥7.4 eV–10 keV
Water (l, v)
No
ETRACK
e−, p, α
≥10 eV–10 keV e−
Water (v)
Yes
ETS
e-
≥10 eV–10 keV
Water (l, v)
Yes
Geant4-DNA
e−, p, H, α,
ions
Thermalization −1 MeV e−,
100 eV–100 MeV p, H
1 keV–400 MeV α
0.5–106 MeV/u ions
Water (l), DNA, gold, N2, and
C3H8 (in progress)
Yes
IONLYS/IONLYS-IRT
e−, p, ions
0.2 eV–150 keV e−, p
0.1–300 MeV ions
Water (l)
Yes
KAPLAN
e−
≥1–10 keV e−
Water (l, v)
Yes
KITrack
e−, ions
≥10 eV–100 keV
Water (l)
No
KURBUC (KURBUC/LEAHIST/
LEPHIST/CHEM-KURBUC)
e−, p, α, C
10 eV–10 MeV (10 keV, liq.) e−,
1 keV–300 MeV, p,
1 keV/u–2 MeV/u α,
1 keV/u–10 MeV/u carbon
≥0.3 MeV/u
Water (l, v)
Yes
LEEPS
e−, e+
0.1–100 keV
All materials
Yes
LEPTS
e−, e+, p
Thermalization −10 keV e−,
Thermalization −10 MeV p
Water (v), CH4, C2H4, C4H8O,
SF6, C4H4N2
No
Lion track
e−, p, ions
>50 eV e−, 0.5–300 MeV/u p, ions
Water (l)
No
MC4
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l, v)
No
MOCA8B
e−
10 eV–100 keV e−
Water (v)
Yes
NASIC
e−
Thermalization −1 MeV e−
Water (l)
Yes
NOTRE DAME
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l, v)
Yes
OREC/NOREC
e−
7.4 eV–1 MeV e−
Water (l)
No
PARTRAC
e−, e+, p, H,
α, ions
1 eV–10 MeV e−
1 keV–1 GeV p, H, α
1 MeV/u–1 GeV/u ions
Water (l), DNA
Yes
PITS04
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l)
No
PITS99
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (v)
Yes
PTra
e−, p, α
1 eV–10 keV e−,
1–10 MeV α,
300 keV–10 MeV p
Water (l, v), DNA, N2, C3H8
No
RITRACKS/RETRACKS
e−, ions
0.1 eV–100 MeV e−, ions
10−1–104 MeV/u
Water (l, v)
Yes
SHERBROOKE
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l, v)
Yes
STBRGEN
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l, v)
Yes
TILDA-V
e−, p, H, ions
≥7.4 eV e−, 10 keV/u–100 MeV/u
ions
Water (l, v), DNA
No
TRAX
e−, p, ions
1 eV—few MeV e−
10 eV—few hundred MeV/u ions
Water (v)
Yes
RADAMOL (TRIOL/STOCHECO)
e−, ions
≥7.4 eV–2 MeV e−,
≥0.3–200 MeV/u ions
Water (l)
Yes
TRION
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l, v)
No
TRACEL/RADYIE/RADIFF
e−, ions
≥10 eV e−,
≥0.3 MeV/u ions
Water (l, v)
Yes
Associated particles, energy ranges, and target media (e.g., whether vapor or/and liquid phase cross sections are used) are indicated. (Taken from
[55])
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
210
4.3.6"
"Following radiation exposure, DNA damage quantification often involves defining various types of breaks. Describe the generally accepted criteria for identifying a double-strand break within the context of DNA modeling and experimental validation, including considerations regarding spatial separation and potential complexities like clustered damage.","The definition of a double strand break (DSB) is fundamentally based on the disruption of both strands of the DNA molecule. A commonly accepted criterion involves two breaks in the sugar-phosphate backbone occurring within the sugar-phosphate groups of opposite strands, separated by less than 10 base pairs (bp). This spatial constraint – a distance of less than 10 bp between the breaks – is crucial for identifying a true DSB. However, the quantification becomes more complex when considering ‘clustered damage.’  This refers to scenarios where multiple DNA lesions occur in close proximity, potentially involving altered bases or single breaks within a smaller distance (e.g., less than 25 bp) of each other. The precise definition of clustered damage can vary significantly between different modeling approaches and experimental techniques (like PFE or comet assays), with some definitions including DSBs accompanied by alterations to the base pairs themselves, while others might focus solely on the spatial relationship between breaks. Ultimately, accurately representing these complex damage patterns requires careful consideration of both the physical simulation results and the specific experimental method used for validation.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.3	 From Track Structure to Early DNA Damage | Sub-subsection: 4.3.6	 Simulation of DNA Damage | Content: ­
7475
76
4.14
4878
79
From the resulting energy deposition values or interac­
tions registered in the DNA volumes, direct damages are cal­
culated using different approaches depending on the TS
code. For instance, in some cases, an energy threshold value
(often of 17.5 eV) in the nucleotide backbone is used to
define a direct strand break [30, 80]. Others, as in the case of
the PARTRAC code, use a uniform probability linear func­
tion from 5 to 37.5 eV [81] in order to calculate the resulting
direct strand breaks, taking into account that very small
energy depositions from vibrational excitations can also lead
to this kind of DNA damage.
After the simulation of the physical stage, the geometrical
model of the DNA target (essentially the position of all its
constituents) as well as the position of the surrounding ion­
ized or excited liquid water molecules are “translated” in
terms of chemical species and injected in the code for the
simulation of the chemical stage as described in Sect. 4.3.3.
Here also, different codes use different parameters for the
definition or the calculation of the indirect strand breaks
depending on the DNA geometrical model; the number of
included reactions or the duration of the chemical stage sim­
ulation [32].
Finally, in order to quantify the results, an important issue
is the definition of double strand breaks and, above all, of
clustered damage. Indeed, these notions are fundamental if
we want to be able to compare the results of the simulation
predictions with the experimental data, representing either
the fragments produced (PFE, comet assay) or the signaling
of a repair process set in motion by the cell (foci). The way
of quantifying the damage predicted by the modeling of the
physical, physicochemical, and chemical stages must thus be
adapted each time to the characteristics of the experimental
observable used for the validation. Nevertheless, for a rela­
tive comparison of different radiations, other types of clas­
sification can be used. Finally, in order to extend the modeling
to later stages and include the repair mechanisms, the scor­
ing method must also be adapted to the initial damage defini­
48
77
G. Schettino et al.
211
tions of each repair model. Thus, the definition of a double
stranded break is relatively well established as two breaks in
the sugar-phosphate group on opposite strands separated by
less than 10 base pairs (bp). More complex breaks or clus­
tered damages are very author-dependent: DSBs accompa­
nied by altered bases or single breaks at less than 10 bp, two
double breaks separated by less than 25 bp, for instance [82],
or more complete definitions as the classification proposed
by Nikjoo et al. [83].
Recently, a standardized format for the simulation output
results [84] has been proposed by different researches of this
community, in order to preserve a maximum of information
on the DNA damage simulated by the different codes and
their location in the genome. This standard output amounts
to a mapping of the individual damages produced (and the
information of their direct or indirect origin) so that it can
then be adapted to the scoring required for each use of the
code, validation with experimental data, or use as input to
repair models (Box 4.6).
4.4"
"Describe the key distinctions between microbeams and minibeams within the context of radiation biology research, focusing on their size ranges and the types of biological phenomena they allow researchers to investigate.","Microbeams and minibeams represent distinct approaches within radiation biology research utilizing focused beams of ionizing radiation. Microbeams are characterized by beam sizes at full width at half maximum (FWHM) ranging from approximately 1 to 10 μm, representing a subcellular scale. This precise size allows for the investigation of individual cells or even subcellular components, enabling detailed studies of processes like DNA repair kinetics, the movement of damage sites within the cell, and their relationship to chromatin organization. The ability to apply single beams facilitates a more direct examination of cellular responses to radiation. Conversely, minibeams, with beam sizes ranging from approximately 100 μm to 1 mm, operate at a larger scale relative to cell size. At this size, the focus shifts away from individual cell differences and towards population-level effects, such as the dose-volume effect – where the cumulative radiation damage is influenced by the spatial distribution of irradiated cells within a population. The larger beam size makes it more relevant to study how radiation impacts entire populations or tissues rather than isolated cellular mechanisms.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.4	 Micro-Beams and Minibeams | Sub-subsection: 4.4.1	 Micro-Beams and Minibeams | Content: 4.4.1
Micro-Beams and Minibeams
Conventional radiobiological studies are using broad (in the
range of cm) irradiation fields for irradiating a whole cell
population with a homogeneous dose in order to be able to
screen an average reaction of this population to radiation.
Already in the 1950s, the reaction of single cells to homoge­
neous irradiation or even to irradiation of subcellular parts
became of interest [85].
Furthermore, in the 1990s the question arose whether
there is a reaction of non-irradiated cells when they are
located close to an irradiate one—the so-called bystander
effect. To address these and other related topics, it is neces­
sary to be able to apply a single, subcellular-sized radiation
beam (in the range of sub-micron to a few micron) with an
accuracy in the range of 1/a few μm. This is the field of
microbeam research, where the term microbeam is used for
beam sizes at full width at half maximum in the range of ~1
to ~10 μm for photon as well as particle beams. Additionally,
the development of micro-beams makes it possible to not
only apply single beams but also arrays of beams, which can
then be used to directly study the kinetics of DNA repair, the
movement of damage sites, the connection to chromatin
organization, and their relation to radiation quality and
outcome.
When beam sizes get larger (~100 μm–~1 mm), the beam
or beam array is then termed minibeam or minibeam array.
Here, the beam sizes become large compared to cell size and
the difference in the effects switch from single cell differ­
ences to differences in cell population. An effect in this size
range was described in the 1980s as the so-called dose-­
volume effect [86].
­
4.4"
"Describe the key applications and findings related to micro-beams in radiobiology, specifically focusing on how they were utilized to investigate the bystander effect, subcellular radiosensitivity, adaptive responses, and DNA repair kinetics. Detail the types of radiation sources commonly employed and highlight a specific example illustrating the use of micro-beams to study the bystander effect.","Micro-beams represent a highly specialized technique in radiobiology, offering unprecedented spatial resolution for investigating radiation damage at the cellular level. Their primary application lies in delivering precisely sized beams of ionizing radiation – typically low-energy charged particles like protons or alpha particles – directly to individual cells, enabling researchers to meticulously dissect complex biological responses. Several key applications have emerged from this technology:

*   **Bystander Effect:** Micro-beams were instrumental in elucidating the bystander effect, where irradiated cells induce radiation damage in neighboring, non-irradiated cells. Studies using co-cultured glioma and fibroblast cells demonstrated that micronuclei formation could be triggered through signaling pathways involving nitric oxide (NO) and reactive oxygen species (ROS) transmitted between cell types [103]. This highlighted the importance of intercellular communication in amplifying radiation effects.
*   **Subcellular Radiosensitivity:** The ability to target specific subcellular structures with micro-beams proved invaluable. For example, experiments using high-LET particles focused to ~1 μm beam size revealed localized inhibition of rRNA transcription specifically within nucleoli rather than a pan-nucleolar reaction [91], demonstrating that radiation damage isn't uniformly distributed within the nucleus.
*   **Adaptive Response:** Micro-beams facilitated investigations into adaptive responses, such as the reduction in effect observed when a small priming dose is given before a high dose. This challenged traditional views of radiation effects and supported the concept of radiation hormesis [104].
*   **DNA Repair Kinetics:** Arrays of micro-beams were used to precisely control damage induction, allowing for detailed measurements of DNA repair kinetics. Researchers could monitor the behavior of proteins involved in DNA repair, such as 53BP1, Rad52, and PARP1 [106, 107], under controlled conditions.
*   **Enhanced RBE:** Focusing low-LET protons to ~1 μm beam size increased the RBE (Relative Biological Effectiveness) of high-LET particles. This was achieved by concentrating damage within a smaller volume, leading to more complex DNA damage patterns [110].

The most commonly employed radiation sources for micro-beams are linear particle accelerators and lab bench X-ray sources. Detector systems utilizing plastic scintillators and photomultiplier tubes have been successfully implemented achieving practically 100% detection efficiencies [87, 88]. The use of RARAF facility in New York demonstrated that the transformation frequency of a single alpha particle traversal is not statistically different than no traversals [102], supporting the threshold hypothesis for radiation risks. 

Reference: [MolecularRadiationBiology], Section 4.4.1.1, Box 4.6.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.4	 Micro-Beams and Minibeams | Sub-subsection: 4.4.1	 Micro-Beams and Minibeams | Sub-sub-subsection: 4.4.1.1	 Micro-Beams | Content: the difference in the effects switch from single cell differ­
ences to differences in cell population. An effect in this size
range was described in the 1980s as the so-called dose-­
volume effect [86].
­
4.4
4.4.1.1	Micro-Beams
8788
­
4.15
­
­
Box 4.6 Radiation Track Structures
•	MC Track structure developed over the years allow
the simulation of energy deposition at nanometric
scale
•	From these results and a DNA geometrical target
model, direct DNA damages can be calculated
•	Chemical reactions between radiation-induced
chemical species in the cell nucleus and the DNA
target generate the so-called indirect effects that
account for up to 70–90% of the total strand breaks
•	The way of considering damage and its complexity
must be adapted to the different experimental
methods
Table 4.4 Definition of micro- and minibeam pattern and correspond­
ing beam size and their application
Type
Single beam size
(fwhm)
Application
Single
microbeam
~1–~10 μm
– Radiosensitivity of
subcellular
Structures
– Bystander effect
– Adaptive effect
Array
microbeam
~1–~10 μm
– DNA repair kinetics
– Effects of high-LET
particles
Single
minibeam
~100 μm–~1 mm
– Dose-volume effect
Array
minibeam
~100 μm–~1 mm
– Modern therapy
approaches
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
212
Specifically, using charged particle micro-beams, it is
possible to deliver exactly one particle per cell providing an
ideal method for reproducing in vitro situations relevant to
environmental exposure to naturally occurring radioactive
radon gas, where virtually no cell receives more than one
alpha particle traversal in its lifetime [89]. The high-spatial
accuracy offered by micro-beams provides also a useful
method to investigate subcellular spatial sensitivity such as
the radiosensitivity of DNA close to the nuclear membrane
[90] or of specific cellular organelles ([91, 92], p. 2019).
Finally, single cell micro-beams have played a crucial role in
the understanding of the bystander effect elucidating some of
the mechanisms responsible for the transmission of the radi­
ation effects from irradiated to non-irradiated cells [93].
Microbeam facilities can be used to selectively irradiate indi­
vidual cells that can subsequently be revisited to ascertain
what changes have occurred to that cell, and to its unirradi­
ated neighbors.
4.16
As the main aim of single cell micro-beams is to be able
to irradiate individual cells with high-spatial accuracy, the
majority of micro-beams utilize low-energy radiation sources
as penetration is not a requirement and higher radiation ener­
gies have stronger focusing or collimating requirements.
G. Schettino et al.
213
Linear particle accelerators [94–96] or lab bench X-ray
sources have been mainly used [93], although synchrotron
sources have also been employed [97]. Energy resolution
and stability are key parameters in order to achieve small
radiation probes. The collimation or focusing system is a
crucial element, as it provides a method for reducing the
radiation beam to a micron or sub-micron size beam with
which to probe the cells. Collimation systems (such as
devices with high length-aperture ratio) are generally easier
to implement and the final opening can be placed close to the
cells in their wet environment, although it is very difficult to
achieve beams smaller than a few microns [98]. The focusing
approach offers the possibility to achieve sub-micron spot
sizes while keeping cells in their physiological environment
([99], p. 2019; [100], p. 2017; [101]). The next important
element is the particle detection, as a key aspect of the cel­
lular micro-beams is being able to count single ions so one
can deliver an exact number of particles (or dose) to a single
cell. Charged particle micro-beams achieve this through
individual particle counting systems placed either after the
biological samples (in which case the radiation energy has to
be high enough to traverse the samples) or between the col­
limation/focusing system and the cells (which may degrade
the radiation spot size). Detector systems using a combina­
tion of plastic scintillators and photomultiplier tubes have
been successfully employed achieving basically 100%
­detection efficiencies [87, 88]. The final element consists of
imaging and micropositioning devices required to identify
the biological targets of interest and align them with the radi­
ation probe. Speed is essential because many assays of bio­
logical radiation effect require several hundreds, or even
thousands of cells to be micro-irradiated individually. The
performance of the various single cell micro-beams varies
according to the methods adopted and particularly the radia­
tion used. However, state-of-the-art systems can achieve tar­
geting accuracies in the range of a μm and detection efficiency
approaching 100% [91]. These systems can also irradiate
10,000 s of cells per hour.
One of the first key studies to make use of micro-beams
was completed using the RARAF facility in New York.
Miller et al. [102] demonstrated that the transformation fre­
quency of a single alpha particle traversal is not statistically
different that of no traversals. The finding has strong impli­
cations for radiation protection, and it supports the threshold
hypothesis for radiation risks. Many radiobiological studies
using micro-beams have been aimed at investigating the
bystander effect. In particular, experiments with co-cultured
glioma and fibroblast cells showed that micronuclei forma­
tion can be induced through bystander signaling across gen­
otypes [103]. These studies also provided information about
the signaling processes involved in the bystander response
suggesting nitric oxide (NO) and reactive oxygen species
(ROS) play a critical role [103]. Another important radiobio­
logical contribution from micro-beams comes from adaptive
response studies [104]. The adaptive response manifests
itself as a reduction in the effect of a high dose of radiation
when a small (<0.2 Gy) priming dose is given first, typically
a few hours ahead of the high dose. This observation under­
mines traditional thinking with regard to radiation effects
and has been linked to radiation hormesis; the concept that
radiation at low doses may actually be beneficial. Also, the
investigation of the radiosensitivity of subcellular structures
is a key application for ion micro-beams [91, 92, 105]. For
example, it could be shown that radiation-induced localized
damage with high-LET particles only triggered localized
inhibition of rRNA transcription in nucleoli rather than pan-­
nucleolar reaction, as it was seen in drug treatment or under
UV irradiation [91].
Micro-beams cannot only be used in single beam mode
but also with an array of micro-beams. Arrays of particle
micro-beams are used especially for two applications. First
for understanding the kinetics of DNA repair. The major
advantage of micro-beams arrays here is that the damage is
induced within a known pattern with defined distances at a
defined time. With this method, repair kinetics of various
proteins such as 53BP1, Rad52, Mdc1 [106], and PARP1
[107] could be measured. Furthermore, it was found that the
sites of DSBs induced by micro-beams show a non-directed,
sub-diffusion movement within the cell nucleus [108].
Furthermore, by focusing low-LET protons to ~1 μm
beam size the RBE can be increased. With this information,
it was possible to further understand the enhanced RBE of
high-LET particles [99, 109–111], which is an effect on sev­
eral scales. An enhancement of LET is possible when focus­
ing the ions to ~1 μm beam size but this enhancement does
not reach the RBE of a single high-LET particle, where most
of the damage is caused in the core region of a few 100 nm
diameter. The explanation of this is that when ions are
focused to ~1 μm sizes, the DSB get closer together and
therefore complex damages occur. If the damage is caused
on even smaller scales, single strand breaks will get so close
together that they cause further DSB, which enhances the
biological effect [110] (Box 4.7).
Box 4.7 Microbeams
•	Micro-beams are beams of photon or particle radia­
tion and have a size of ~1–~10 μm
•	Micro-beams can be applied as a single beam or
array of beams
•	Collimation is easy to implement but beamsize only
a few μm
•	Focusing is more complex but beamsizes <1 μm are
possible
•	Micro-beams can be used to study bystander effect,
radiosensitivity of subcellular structures, and the
enhanced RBE of high-LET particles
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
214"
"Describe the principles behind microbeam radiation therapy (MRT) and particle minibeam radiation therapy (pMBRT), highlighting how beam size influences tissue response and dose tolerance.","Microbeam radiation therapy (MRT) utilizes narrow photon beams, typically around 100 μm in width, to deliver targeted radiation to tumors while minimizing exposure of surrounding healthy tissues. Conversely, particle minibeam radiation therapy (pMBRT), employing protons or heavier ions, employs beams up to approximately 1 mm wide. The key principle driving both approaches is the ‘dose-volume effect,’ which dictates that a smaller irradiated volume allows for greater dose tolerance by the tissue. This occurs because undamaged cells surrounding the treated area can infiltrate and repair damaged tissue, reducing necrosis. Furthermore, with minibeams – particularly those utilizing protons or light ions – homogeneous irradiation of the tumor is feasible. However, even with these methods, the capillary blood vessels can be repaired within days or hours due to the small irradiation fields, enabling continued support for surrounding tissue repair. The underlying radiobiological mechanisms are still under investigation but represent a significant advancement in spatially fractionated radiation therapy like GRID therapy and are actively being explored for clinical application.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.4	 Micro-Beams and Minibeams | Sub-subsection: 4.4.1	 Micro-Beams and Minibeams | Sub-sub-subsection: 4.4.1.2	 Minibeams | Content: A minibeam is a narrow radiation beam, whose width is in
the range from ~100 μm to approximately 1 mm. The
minibeams play a key role in the development of new ther­
apy approaches, which aim to lower the side effects of
external radiotherapy by spatially sparing the healthy tis­
sue, especially in front of the tumor. Using photons, this
method is called microbeam radiation therapy (MRT) in
order to be able to separate from the particle minibeam
therapy (MBRT) using protons and ions. MRT uses beam
sizes in the order of 100 μm, whereas in pMBRT the beam
sizes are a bit larger up to ~1 mm. There are different
approaches of how to irradiate the tumor with minibeams;
with photons or heavy ions the minibeam pattern with
peaks and valleys is typically maintained, while with pro­
tons or light ions homogeneous irradiation of the tumor is
feasible.
Nevertheless, both methods rely on the same effect, that
the smaller the volume which is irradiated, the more dose
is tolerated by tissue, the so-called dose-volume effect
[86]. This is attributed to undamaged migratory cells sur­
rounding the damaged tissue, which are able to infiltrate
and thus reduce tissue necrosis. A further effect that plays
a role in the tissue response to submillimeter beams is the
microscopic prompt tissue repair effect. For such small
irradiation fields, the capillary blood vessels can be
repaired within days or even hours. The intact blood ves­
sels are then able to support the repair of surrounding tis­
sue. The detailed underlying radiobiological effects are yet
not completely understood and topic of investigation
worldwide. Nevertheless, the use of minibeams in radia­
tion therapy is already used in spatially fractionated radia­
tion therapy such as GRID therapy or is on the way to
clinical studies (Box 4.8).
4.5"
"Describe the concept of ‘dose’ as it relates to radiation biology, specifically referencing the idea that a single ionization event represents a ‘hit,’ and how this is used to estimate energy deposition within cells.","In radiation biology, ‘dose’ quantifies the amount of energy deposited into a material by ionizing radiation. A fundamental simplification often employed is to consider each primary ionization event as a ‘hit.’ This approach acknowledges that a single initial interaction between a high-energy photon or particle and a cellular molecule can generate multiple ion pairs – several positively charged ions and their corresponding electrons. However, the probability of a primary ionization producing only one ion pair is statistically significant, particularly for heavier particles like protons or alpha particles.  Therefore, treating each primary ionization as a ‘hit’ provides a manageable approximation. The dose is then defined as the number of these ‘hits’ per unit volume (typically cm³). A key element in understanding this concept is the estimated energy deposition per hit. Rauth and Simpson demonstrated that the average energy deposited per primary ionization event was approximately 60 eV. This value represents the total kinetic energy transferred by the initial ionizing particle upon collision with a cellular molecule. Consequently, dose measurements (hits/cm³) provide an indirect measure of the overall energy delivered to the target tissue, which is then correlated with biological effects like cell survival or DNA damage.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Content: Models
4.5.1
Cell Survival Modeling Using Hit
and Target Theory
­
­
4.17
4.9
4.5.1.1	An Approach to the Concept of Dose
For the sake of simplicity, assume that one hit represents one
primary ionization. This can in some cases be an oversimpli­
fication since a primary ionization can give rise to many ion
pairs however the probability is largest for a primary ioniza­
tion to give rise to only one ion pair [112].
We can now introduce the dose as the number of hits per
cm3. In an elegant experiment, Rauth and Simpson [113]
found that the energy deposition per primary ionization is
about 60 eV on average. Although this is not the exact aver­
age energy per hit, it can be used as an approximate value.
Since the dose gives the energy deposition per cm3 (it indi­
Box 4.8 Minibeams
•	Minibeams are beams of photon or particle radia­
tion and have a size of ~100 μm–~1 mm
•	Minibeams can be applied as a single beam or an
array of beams
•	Collimation is easy to implement but can give sec­
ondary radiation and limits flexibility
•	Focusing is more complex to implement but has no
secondary radiation and full flexibility
•	Minibeams are used to study the dose-volume effect
and the microscopic prompt tissue repair
•	Minibeams are transferred into clinical application
in microbeam radiation therapy (MRT) for photons
and minibeam radiation therapy (MBRT) for
particles
Box 4.9 Target Theory
•	Target theory postulate: only energy deposits in the
target can destroy the function of the object
G. Schettino et al."
"Describe the concept of 'minibeams' as presented, outlining their characteristics and potential applications within radiation biology research and clinical therapy.","Minibeams represent beams of photon or particle radiation with a characteristic size ranging from approximately 100 μm to 1 mm. These focused beams are typically employed either individually or in arrays. A key aspect of minibeam technology is the relative ease with which collimation can be achieved, though this often results in secondary radiation production and limits operational flexibility. Conversely, focusing minibeams presents a more complex implementation but avoids secondary radiation and offers full beam control. The primary use of minibeams lies in studying dose-volume effects and examining the microscopic processes involved in prompt tissue repair following radiation exposure. Notably, these beams are being explored for potential applications in clinical settings, specifically in microbeam radiation therapy (MRT) utilizing photons and minibeam radiation therapy (MBRT) employing particle beams. The controlled energy deposition facilitated by this technique allows researchers to investigate cellular responses at a highly localized level.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.1	 Cell Survival Modeling Using Hit and Target Theory | Content: tion to give rise to only one ion pair [112].
We can now introduce the dose as the number of hits per
cm3. In an elegant experiment, Rauth and Simpson [113]
found that the energy deposition per primary ionization is
about 60 eV on average. Although this is not the exact aver­
age energy per hit, it can be used as an approximate value.
Since the dose gives the energy deposition per cm3 (it indi­
Box 4.8 Minibeams
•	Minibeams are beams of photon or particle radia­
tion and have a size of ~100 μm–~1 mm
•	Minibeams can be applied as a single beam or an
array of beams
•	Collimation is easy to implement but can give sec­
ondary radiation and limits flexibility
•	Focusing is more complex to implement but has no
secondary radiation and full flexibility
•	Minibeams are used to study the dose-volume effect
and the microscopic prompt tissue repair
•	Minibeams are transferred into clinical application
in microbeam radiation therapy (MRT) for photons
and minibeam radiation therapy (MBRT) for
particles
Box 4.9 Target Theory
•	Target theory postulate: only energy deposits in the
target can destroy the function of the object
G. Schettino et al."
"Explain how the concept of ‘dose’ is defined within the context of target theory and single-target, single-hit models of radiation survival. Specifically, detail how Rauth and Simpson's findings regarding energy deposition per primary ionization contribute to this definition, including the relationship between dose, hits per cm3, and the probability of a molecule retaining its function.","Within target theory, ‘dose’ is defined as the number of primary ionizations occurring per unit volume (typically cm³). This approach simplifies the complex interactions of radiation with matter by treating each primary ionization event – where an atom absorbs energy and ejects one or more electrons – as a discrete ‘hit’. Rauth and Simpson's experiment established that, on average, approximately 60 eV of energy is deposited per primary ionization.  This value serves as an approximate measure of the energy associated with each hit. Consequently, a higher dose (more hits/cm³) indicates greater energy deposition within the target volume. The single-target, single-hit model further refines this concept. It postulates that a molecule’s response – typically inactivation or loss of function – occurs only when ‘n’ hits are deposited in its target.  The probability, pf, that a molecule retains its function is calculated as the sum of probabilities for receiving 0, 1, 2,… up to n-1 hits, following a Poisson distribution. This calculation utilizes the dose (hits/cm³) and the target volume (v) to determine the average number of hits (μ = vD) within the target.  If ‘n’ is the actual number of hits in the target, the probability pf represents the fraction of molecules that do not become inactivated. For example, if a molecule becomes inactivated by only one hit (n=1), the probability pf can be expressed as: pf = e^(-μ) or equivalently, pf = 1 - exp(-μ).  Furthermore, this model allows for determining molecular weight by relating dose and target volume, providing a direct link between radiation exposure and biological effects. Reference: [MolecularRadiationBiology, Section 4.5.1.1 An Approach to the Concept of Dose]","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.1	 Cell Survival Modeling Using Hit and Target Theory | Sub-sub-subsection: 4.5.1.1	 An Approach to the Concept of Dose | Content: For the sake of simplicity, assume that one hit represents one
primary ionization. This can in some cases be an oversimpli­
fication since a primary ionization can give rise to many ion
pairs however the probability is largest for a primary ioniza­
tion to give rise to only one ion pair [112].
We can now introduce the dose as the number of hits per
cm3. In an elegant experiment, Rauth and Simpson [113]
found that the energy deposition per primary ionization is
about 60 eV on average. Although this is not the exact aver­
age energy per hit, it can be used as an approximate value.
Since the dose gives the energy deposition per cm3 (it indi­
Box 4.8 Minibeams
•	Minibeams are beams of photon or particle radia­
tion and have a size of ~100 μm–~1 mm
•	Minibeams can be applied as a single beam or an
array of beams
•	Collimation is easy to implement but can give sec­
ondary radiation and limits flexibility
•	Focusing is more complex to implement but has no
secondary radiation and full flexibility
•	Minibeams are used to study the dose-volume effect
and the microscopic prompt tissue repair
•	Minibeams are transferred into clinical application
in microbeam radiation therapy (MRT) for photons
and minibeam radiation therapy (MBRT) for
particles
Box 4.9 Target Theory
•	Target theory postulate: only energy deposits in the
target can destroy the function of the object
G. Schettino et al.
215
cates the energy per g or kg, but when we know the density
of the irradiated substance we easily convert it to cm3), we
can use Rauth’s and Simpson’s measurement to convert the
dose to the number of primary ionizations per cm3 and as a
first approach use this as an indication of the number of hits
per cm3.
4.5.1.2	Single-Target Single-Hit Model
of Radiation Survival
This theory relies on certain key assumptions
1.	Ionizing radiation deposits the energy into discrete energy
packages that we call hits.
2.	The response of a molecule (or cell) occurs only if a num­
ber of n hits is deposited in the target.
3.	The number of hits deposited in the target in the irradi­
ated material must be Poisson distributed.
Assumption number 3 can generally only be considered
satisfied when the dose is high. Note that the average number
of hits in a volume equal to the target volume is μ = vD where
the dose is given in hits/cm3 and the target volume, v, is given
in cm3. If n is the actual number of hits in the target in a par­
ticular irradiated object, the probability of this number of
hits being seen is Poisson distributed as:
(4.23)
If the irradiated object is a macromolecule in a cell, and if
this macromolecule is inactivated (i.e., loses its biological
function) if it receives n hits in the target, then the molecule
retains its function if the number of hits in the target is n−1
or less. We can therefore calculate the probability, pf, for the
molecule to retain its function. It must be the sum of the
probabilities that it will receive one, two, three, etc., up to
n−1 hits in the target [112]:
(4.24)
or
(4.25)
Here, pf represents the probability that a target molecule
will not be inactivated by the dose D. However, this can also
be viewed as pf representing the fraction of the irradiated
molecules that do not become inactivated by the radiation
[112]. If one irradiates N0 molecules and the number that is
not inactivated is N, Eq. (4.25) can be rewritten as:
(4.26)
If the molecule becomes inactivated by only one hit in its
target, n = 1 and Eq. (4.26) becomes:
(4.27)
4.18
One key insight is that the equation allows us to determine
the molecular weight of the target. From the previous deriva­
tion, we know that if we express dose in the unit hits/cm3, we
can determine the target volume. If we also know the density
of the irradiated molecules we can, based on the target the­
ory, determine the molecular mass of the target. The dose is
normally given in Gy so the calculation must be based on
this unit:
(4.28)
0
4.27
0
4 Mechanistic, Modeling, and Dosimetric Radiation Biology"
"Within the context of radiation biology and utilizing hit-and-target theory, how does a dose measured in Gray (Gy) relate to the concept of 'D37,' and what calculations are necessary to determine target volume?","In hit-and-target theory, a dose delivered in Gray (Gy) represents the total energy absorbed by all targets within a given mass. The ‘D37’ value is specifically defined as the dose that results in an average of one 'hit' per target molecule. A hit refers to a sufficient ionization event caused by radiation that disrupts the target molecule's structure or function, leading to cell damage or death.  To convert from Gy to hits per gram, we utilize the relationship derived from experiments like those conducted by Rauth and Simpson, which established an average energy requirement of 60 eV for primary ionization in organic materials. This value is then used to calculate the number of 'hits' that occur at a given dose. Once the D37 (hits/g) is determined, we can calculate the target volume. The formula relating these quantities involves the density (ρ) of the target material (expressed as g/cm³), and the equation dictates that target volume = (D37 * ρ) / v, where 'v' represents the molecular mass of the target molecule. Therefore, by knowing the dose in Gy, converting it to hits per gram using the 60 eV value, and understanding the density of the target material, one can calculate the volume of tissue affected by radiation.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.1	 Cell Survival Modeling Using Hit and Target Theory | Sub-sub-subsection: 4.5.1.2	 Single-Target Single-Hit Model of Radiation Survival | Content: of the irradiated molecules we can, based on the target the­
ory, determine the molecular mass of the target. The dose is
normally given in Gy so the calculation must be based on
this unit:
(4.28)
0
4.27
0
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
216
using that 1 J = 6.242 × 1018 eV. From the experiments by
Rauth and Simpson, we know that it takes an average 60 eV
to give a primary ionization in an organic material. This
value is not necessarily the correct amount of energy needed
for a hit, but as an example it can be used. Then we can con­
vert [Gy] into [hits per gram]:
(4.29)
D37 is the dose that gives on average one hit per target, i.e.,
v ⋅ D37 = 1 . The surviving fraction at this dose is e−vD=
e−1 ≈ 0.37 = 37%, which gives rise to the name of the quan­
tity. If we assume that we irradiate the molecules with differ­
ent doses and find the D37, we have on average one hit per
target at this dose (v ⋅ D37 = 1). Suppose the D37 is given in the
unit hits/g. We can then calculate the mass of the target in the
unit gas:
(4.30)
In practice however the dose is in Gy and we must use Eq.
(4.29) to convert from hits/g to Gy:
(4.31)
If the density of the target is ρ = MT/v we can then calcu­
late the target volume:
(4.32)
(where ρ is in units of g/cm3).
In Eq. (4.32) the dose is in Gy. The final calculation of the
target volume is left to the reader."
"Within the context of hit and target theory applied to cellular organisms, explain how multiple targets and multiple hits contribute to a molecule’s or cell's probability of inactivation.","In hit and target theory, a molecule or cell can possess numerous targets – individual sites susceptible to damage from ionizing radiation. The probability of complete inactivation increases dramatically with the number of targets present (m). Furthermore, it isn’t sufficient for just one ‘hit’ (damage event) per target; multiple hits are required to ultimately inactivate the molecule or cell.  The equation (4.34) demonstrates this: the probability of inactivation is calculated by multiplying the probabilities of each individual target being inactivated (n=1), reflecting that multiple hits must occur across all targets. This highlights a key aspect of biological systems – resilience against radiation damage arises from redundancy and the ability to tolerate multiple, simultaneous impacts on critical components. Reference: [MolecularRadiationBiology, Section 4.5.1.3 Multiple-Target and Multiple-Hit Models]","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.1	 Cell Survival Modeling Using Hit and Target Theory | Sub-sub-subsection: 4.5.1.3	 Multiple-Target and Multiple-Hit Models | Content: Complicated molecules or cellular organisms may well have
more targets and it also may take more than one hit per target
to inactivate the molecule or cell.
Recall Eq. (4.25), which calculates the probability that a
molecule will not be inactivated if it has one target and that
this is deactivated by n hits. The probability of one target
being deactivated is then:
(4.33)
where Nii means the number of molecules that were inac­
tivated. If we now assume that the molecule has a number of
m targets that all must be inactivated for the molecule to be
inactivated, the probability of inactivation becomes:
(4.34)
and the probability that the molecule will not be inacti­
vated is then:
(4.35)
In the most likely case, it only takes one hit per target for
the molecule to be inactivated, that is, n = 1. This gives the
following special case:
(4.36)
This is the famous multi-target single-hit equation. For
many decades, this was the model radiobiologists fitted to
their dose-response curves when they tested the effect of
ionizing radiation on human cells. Much of the formalism of
this equation and parameter values are still in use when
dose-­response curves are discussed and described.
Therefore, it is important that we perform an analysis of this
function:
•	The equation has a shape with an initial shoulder at small
doses followed by, a straight line for large doses. This is
seen if the equation is expanded by a power series:
(4.37)
G. Schettino et al.
217
Focusing on high-dose regions, all terms with (e−vD)2 and
higher power can be ignored. We then end up with the fol­
lowing expression, which only is valid for high doses:
(4.38)
4.19
4.5.1.4	Some Interpretations of the Hit
and Target Theory
4.19
4.38
4.36
4.19
­
37
4.19
0
­
0
4.10
­
37
0
4.19
­
One term is important to get into at this stage, namely
sublethal damages. So far, we have most talked about irradi­
ating molecules and not cells. However, we can talk about
cells in the same way that we have discussed molecules in
the hit and target theory. The radiation damage then inacti­
vates some function that the cells usually have. Very often,
the effect is referred to as cell death or lethality. This term
suggests that radiation should produce some form of death.
Often, this will give incorrect associations to the chemical or
biological responses we measure. However, the terms lethal,
sublethal, and potentially lethal damages have been so incor­
porated that it is completely impossible to avoid their use.
Note that, based on the formalism of the target theory,
sublethal damage is damage to the target. A hit outside the
target is no damage according to this theory. When damage
in the target does not produce any effect, it is because we
have a multi-hit system or a multi-target system (Box 4.11).
Later in this chapter, we will talk about dose rate effects.
These state that there usually is a stronger effect of a dose
when given in a short time than when given over a long
period of time. The reason for this is, according to the target
theory’s formalism, that the first hit is not enough to inacti­
vate, but that it can interact with the next so that the two or
more together can inactivate. However, if the cells or mole­
cules are able to repair the first hit before the next, we will
not get such interactions. The fact that this effect decreases
with decreasing dose rate is therefore a sign that the radiation
damage is repaired.
4.19
Box 4.10 Radiosensitivity for Hit and Target Theory
v
e
q
u
a
l
s
St
artFraction 1 Over upper D 37 EndFraction or v equals StartFraction 1 Over upper D 0 EndFraction
is
an
expression
of
the
radiosensitivity
Box 4.11 Sublethal Damage in Hit and Target Theory
•	Sublethal damage refers to damage, or really ion
pairs, which is the cell or molecular target, but does
not cause any effect in itself
4 Mechanistic, Modeling, and Dosimetric Radiation Biology"
"Within the context of Hit and Target Theory, what does ‘sublethal damage’ represent, and why is its existence a key component of this model?","Sublethal damage, as defined within Hit and Target Theory, refers to the creation of damaged molecular targets – typically ion pairs – within a cell or molecule that do not immediately result in cell death. It's essentially an accumulation of radiation-induced injury at the target level. The significance of sublethal damage lies in its ability to explain observed radiosensitivity. Cells can tolerate multiple hits (damage events) on a single target, or they possess multiple targets capable of absorbing radiation energy. This capacity for repair and redundancy allows cells to survive exposures that would otherwise be lethal, as long as the cumulative damage at the target level remains below a critical threshold. The model posits that the rate of repair is directly related to the extent of sublethal damage; a slower dose rate facilitates more repair, thus reducing the overall effective dose required for cell death. Reference: [Book Title], Section 4.5.1.4 – Some Interpretations of the Hit and Target Theory","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.1	 Cell Survival Modeling Using Hit and Target Theory | Sub-sub-subsection: 4.5.1.4	 Some Interpretations of the Hit and Target Theory | Content: with decreasing dose rate is therefore a sign that the radiation
damage is repaired.
4.19
Box 4.10 Radiosensitivity for Hit and Target Theory
v
e
q
u
a
l
s
St
artFraction 1 Over upper D 37 EndFraction or v equals StartFraction 1 Over upper D 0 EndFraction
is
an
expression
of
the
radiosensitivity
Box 4.11 Sublethal Damage in Hit and Target Theory
•	Sublethal damage refers to damage, or really ion
pairs, which is the cell or molecular target, but does
not cause any effect in itself
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
218
formalism. It is just because the cells or molecules can either
tolerate one or more hits in their one target or that they have
more than one target.
4.5.2"
Describe the Linear Quadratic Model (LQ) used in radiation biology and explain its key components relating to cell survival prediction.,"The Linear Quadratic Model (LQ) is a widely utilized target model in radiation biology designed to predict cell survival based on absorbed dose. It represents a significant advancement over earlier models due to its relative simplicity and clinical applicability. The core principle of the LQ model rests on the assumption that energy deposition within a cell primarily occurs at ‘targets’ – regions with high biological sensitivity, such as DNA.  The model posits that the rate of energy deposition is proportional to both the dose received and the square of the local linear-absorbed dose (d). Mathematically, cell survival (S) is expressed as:

S = exp(-Σ(αi * di)^2 / 2σ^2)

Where:
*   **S** represents the fraction of cells surviving.
*   **Σ** denotes the summation over all targets within the cell.
*   **αi** is the weighting factor for each individual target ‘i’, representing its relative sensitivity to radiation. Higher αi values indicate greater susceptibility.
*   **di** is the linear-absorbed dose at target ‘i’ (the amount of energy deposited per unit mass).
*   **σ** is a scaling parameter that ensures the survival curve remains within the range of 0 and 1. It effectively controls the overall sensitivity of the model.

In essence, the model calculates the sum of the squares of the linear absorbed doses at each target, then uses this value to determine the probability of survival. A higher Σ(αi * di)^2 indicates a greater energy deposition within sensitive targets, leading to a lower cell survival rate. The model’s parameters (αi and σ) allow for varying degrees of sensitivity across different cell types or tissues.

The LQ model's popularity stems from its ability to capture the key aspects of radiation damage – the dose-dependent increase in energy deposition within sensitive targets, ultimately leading to DNA strand breaks and cellular dysfunction.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.2	 The Linear Quadratic Model | Content: While target models are useful to generate an initial under­
standing of the relationship between radiation dose, cell sur­
vival, and the process of energy deposition, these models
have not been generally adopted because of their use of mul­
tiple terms, and also because the “targets” which the models
predict have never been identified. Several models have been
developed based on target theory, among which the linear
quadratic model (LQ) has emerged for application clinically
and preclinically [114]. The expression for cell survival
according to the LQ model is:
(4.39)
­
­
­
4.20
­
­
­
4.5.3"
"The linear quadratic model in radiation biology is characterized by its simplicity – requiring only two parameters to describe the relationship between absorbed dose and biological effect. Explain the core assumptions underlying this model and briefly outline how different interpretations, such as those proposed by Kellerer and Rossi, Chadwick and Leenhouts, and Bodgi and Foray, attempt to biologically justify these parameter values.","The linear quadratic (LQ) model represents a foundational approach in radiation dose-response modeling due to its relative simplicity and often surprisingly good fit to experimental data. At its core, the LQ model assumes that the biological effect (typically expressed as damage rate or probability of cell death) is proportional to both the absorbed dose and the square of the dose. Mathematically, this is represented by the equation: Damage Rate = αD + βD², where ‘α’ represents the linear component (damage per unit dose) and ‘β’ represents the quadratic component (increasing damage rate with increasing dose squared). The parameters α and β are empirically determined from experimental data.

The differing interpretations of the LQ model, such as those offered by Kellerer and Rossi, Chadwick and Leenhouts, and Bodgi and Foray, stem from attempts to provide a more biologically plausible explanation for the values assigned to α and β. Kellerer and Rossi’s interpretation linked α to DNA strand breaks and β to the subsequent repair processes. Chadwick and Leenhouts proposed a model where α represented the initial damage caused by radiation while β reflected the rate at which this damage was repaired, acknowledging that repair mechanisms are not instantaneous. Bodgi and Foray's approach focused on incorporating the concept of ‘dose-rate effects,’ suggesting that β should be influenced by the speed at which the dose is delivered, recognizing that rapid irradiation can overwhelm repair pathways.

Essentially, all these interpretations recognize that the LQ model provides a mathematical representation but lacks a direct mechanistic explanation for why α and β have the values they do. They represent attempts to translate observed dose-response relationships into biologically meaningful terms by considering factors like DNA damage mechanisms, repair processes, and potentially dose rate effects.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.3	 Interpretations of the LQ Model | Content: The linear quadratic model needs only two parameters and
shows a good fit for experimental observations. As for its
biological interpretation, different approaches have been
presented, such as those of Kellerer and Rossi, Chadwick
and Leenhouts, and Bodgi and Foray."
"Kellerer and Rossi’s model of biological effect utilizes a probabilistic approach considering three distinct states within a biological entity – non-damage, pre-damage, and effect. Explain the two primary pathways through which a biological effect can be achieved according to this model, detailing the required number of ‘hits’ (transitions) for each pathway.","Kellerer and Rossi's model posits that a biological effect arises from one of two distinct mechanisms within a cell: either a single-hit event or a double-hit event. The first pathway represents a ‘single-hit event,’ where the biological effect is directly achieved through a transition from the non-damage state to the effect state following a single absorbed energy deposition (a ‘hit’). This mechanism is predominantly observed with high linear energy transfer (LET) radiation, as these radiations typically deliver sufficient energy in a localized manner to induce the immediate effect. The second pathway involves a ‘double-hit event,’ where the biological effect arises from two consecutive transitions: first, a transition from the non-damage state to the pre-damage state, followed by a subsequent transition from the pre-damage state to the effect state. This requires two distinct energy depositions (two ‘hits’) to occur within the cell before the effect is manifested. The dominance of one pathway over the other – single or double hit – is significantly influenced by the LET of the radiation; high-LET radiations favor single-hit events, while low-LET radiations tend to require double-hit events for biological effects to be observed.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.3	 Interpretations of the LQ Model | Sub-sub-subsection: 4.5.3.1	 LET-RBE (Kellerer and Rossi) | Content: Kellerer and Rossi sought to analyze the relationship
between dose and effect in a way that was invariant to the
quality of radiation, as they considered that the biological
effect, in addition to its dependence on the deposited
energy, also depended on its microscopic distribution
[115]. Having observed the simplicity of the relationship
between the doses of two different types of radiation with
different LET (see Sect. 1.6) that lead to the same effect
(relative biological effectiveness—RBE, see Sect 1.6) they
proposed a theoretical model that arrives at a linear and
quadratic relationship with the dose. The model assumes
three possible states for the biological entity: non-damage,
pre-damage, and effect. The probability of transition
between states (without allowing for reversion) depends
on the dose and a careful choice of these values results in
different models [115]. According to the model, the bio­
logical effect can be achieved by a direct transition from
the non-damage state to the biological effect or by two
consecutive transitions between non-damage to pre-dam­
age and pre-damage to biological effect. The first case rep­
resents the situation of reaching the biological effect with
one hit (single-hit event), which is dominant for high-­LET
radiation, and for the second case, two hits (double-hit
event) are required.
4.5.4"
"Describe the mechanisms underlying the linear quadratic model of radiation dose response, specifically focusing on the concepts of single-hit and double-hit events related to DNA strand breaks, and how these contribute to cellular survival or death.","The linear quadratic model posits that the biological effect of ionizing radiation, particularly at high linear energy transfer (LET) levels, is determined by a complex interplay between single-strand breaks (SSBs) and double-strand breaks (DSBs). Initially, Chadwick and Leenhouts proposed that cell death results from a DSB, with the probability of this event linearly increasing with dose. However, they recognized that for many high-LET radiation scenarios, two SSBs must occur in close proximity – a ‘double-hit’ event – to ultimately lead to a DSB and subsequent cellular demise. This double-hit mechanism arises because each SSB can induce a temporary change in DNA topology, making the second SSB more likely to crosslink and form a stable DSB. The model incorporates the assumption that DNA damage is critical for cell survival; therefore, any break represents a significant threat. Repair mechanisms exist to address SSBs, but these repairs are not always complete or effective, particularly when combined with subsequent radiation exposure. Furthermore, the model acknowledges that sublethal damage – primarily represented by SSBs – can accumulate and interact with other sublethal damage, ultimately leading to lethal effects. The linear term in the model reflects the rate of DSB formation (dN/dD), proportional to the number of critical bonds broken, while the quadratic term accounts for the increased probability of a double-hit event occurring as dose increases. This exponential relationship, combined with the concept of sublethal damage repair, explains the characteristic shoulder observed on linear-quadratic survival curves – representing the point where sublethal damage accumulates and eventually triggers cell death. Reference: [MolecularRadiationBiology, Section 4.5.4 - DSB-SSB, Asymmetric Chromosome Aberrations]","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.4	 DSB-SSB, Asymmetric Chromosome Aberrations | Content: consecutive transitions between non-damage to pre-dam­
age and pre-damage to biological effect. The first case rep­
resents the situation of reaching the biological effect with
one hit (single-hit event), which is dominant for high-­LET
radiation, and for the second case, two hits (double-hit
event) are required.
4.5.4
DSB-SSB, Asymmetric Chromosome
Aberrations
Chadwick and Leenhouts started from the hypothesis that
cell death resulted from a double strand break in DNA (DSB)
and that the probability of these events was related in a linear
quadratic manner with dose. The model assumes:
•	that DNA is a critical molecule that determines the cell’s
ability to reproduce and a DSB is considered critical
damage;
•	radiation produces DNA breaks that can be repaired, and
the radiobiological effect reflects the degree of repair
[116].
­
G. Schettino et al.
219
•	that the rate of critical breaks relative to dose (dN/dD) is
proportional to the number of critical bonds (N) and that a
critical event (DSB) can occur in two ways: either as a
single radiation event that results in a DSB or as two
events each inducing a single strand break (SSB), which
is close enough in time and space interact to form a DSB.
Therefore, the combination of these assumptions leads to
an exponential model with a linear term and a quadratic
term, similar to the one developed by Kellerer and Rossi,
producing the linear quadratic model of cell survival.
There are various ways of interpreting this model. In one,
two DSBs can interact and lead to chromosomal aberrations
that impair cell division. In particular, asymmetric aberra­
tions, such as the dicentric, the ring, and the anaphase bridge,
make cell division impossible. In another interpretation by
Hall, the linear and quadratic terms can be interpreted as
asymmetric chromosome aberrations produced in one or two
radiation events.
In both the interpretations by Chadwick and Leenhouts
and Hall, the shoulder of the LQ-curve is a result of sublethal
damage, i.e., damage that is not lethal in itself but can inter­
act with other sublethal damage to become lethal. The differ­
ence lies in what is regarded as sublethal damage. Hall
assumes that one DSB in itself is not lethal such that lethal
damage is created only when two DSBs create an asymmet­
ric chromosome aberration. Chadwick and Leenhouts also
acknowledge that asymmetric chromosome aberrations are
lethal DNA damage, but they adjust for this by multiplying
by a factor, which represents a linear relationship between
the number of DSB and the number of asymmetric chromo­
some aberrations. In their interpretation, sublethal damage is
a single strand break (SSB), which needs to interact with
another SSB close in time and space to form a DSB.
If the dose is fractionated (i.e., split up into several parts
separated in time) or the dose rate is decreased, a linear sur­
vival curve will emerge. This is a reflection of the sublethal
damage being repaired before it can interact with other sub­
lethal damage to become lethal. With the repair time for DSB
and SSB in mind (see Sect. 2.4), this supports Chadwick’s
and Leenhouts’ interpretation."
"Describe the proposed mechanism for radiation-induced DNA double-strand break (DSB) recognition and repair as outlined by Bodgi and Foray’s linear quadratic model, specifically focusing on the role of ataxia telangiectasia mutated (ATM) protein.","Bodgi and Foray's model posits a detailed mechanism for radiation-induced cell death involving DSBs. Initially, ionizing radiation triggers the production of ATM monomers within the cytoplasm. These monomers then undergo ‘nucleo-shuttling,’ diffusing across the nuclear membrane to enter the nucleus. Once inside, ATM participates directly in recognizing and mediating the DSB itself – essentially initiating the repair process. The model assumes a linear relationship between the rate of DSB production by radiation and the rate of ATM monomerization. Critically, not all DSBs lead to cell death. Those that are recognized by ATM but remain unrepaired within a specific timeframe—particularly in cells undergoing mitosis—are considered the primary cause of cell demise. The model further differentiates between two categories of unrecognized DSBs: those never initially recognized by ATM (resulting in a quadratic dose-dependent increase) and those recognized but subsequently left unrepaired due to exceeding a repair window (leading to a linear dose-dependent increase). Finally, these remaining, unrepaired DSBs are assumed to follow a Poisson distribution, contributing to cell survival through a linear quadratic exponential model. This mechanism explains cellular hypersensitivity at low doses because insufficient ATM monomers cross the membrane to initiate DSB recognition and subsequent repair.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.4	 DSB-SSB, Asymmetric Chromosome Aberrations | Sub-sub-subsection: 4.5.4.1	 ATM Shuttling | Content: In 2016, Bodgi and Foray proposed a new model for
radiation-­induced cell death whose mathematical derivation
results in the linear quadratic model. In this model, DSB rec­
ognition mechanisms are mediated by ataxia telangiectasia
mutated monomers (ATM) that are induced in the cytoplasm
by radiation and diffuse to the nucleus (nucleo-shuttling of
IR-induced ATM monomers). Once in the nucleus, these
monomers participate in the DSB recognition mechanism
that allows its repair [117]. The rates of DSB production by
radiation and monomerization are assumed to have a linear
relationship to dose. The same model also includes the notion
of cell tolerance, taking into account that not all DSB lead to
cell death, which in this case is assumed to be due to unre­
paired DSB in cells entering mitosis. Among unrepaired
DSB, those that are not recognized and therefore not repaired
are distinguished from those that are recognized but not
repaired within a suitable time window. The number of
unrecognized DSBs in the model has a quadratic relationship
to dose, whereas the number of recognized but unrepaired
DSBs has a linear relationship to dose. Finally, unrepaired
DSBs are assumed to follow a Poisson distribution, which
leads to cell survival being modeled by a linear quadratic
exponential. In addition to presenting a biological mecha­
nism of cell death by radiation, this model provides an expla­
nation for cellular hypersensitivity at low doses, since it
assumes that radiation does not produce enough ATM mono­
mers to cross the membrane and enter the nucleus. Therefore,
there is no recognition of DSB and they remain unrepaired,
which leads to cell death.
4.5.5"
"The linear quadratic model of radiation damage proposes several mechanisms for cell death following irradiation. Describe the model’s representation of DNA double-strand break (DSB) repair and how this relates to cellular sensitivity at low doses, incorporating concepts like monomerization, recognition, and unrepaired DSBs.","The linear quadratic model posits that radiation induces DNA damage primarily through the creation of double-strand breaks (DSBs). Initially, the model assumes a linear relationship between absorbed dose and the production of DNA monomers resulting from DSB cleavage. Subsequently, at higher doses, this rate transitions to a quadratic relationship, representing the increased formation of unrepaired DSBs. Critically, the model incorporates cell tolerance – recognizing that not all DSBs lead to immediate cell death. Unrepaired DSBs are categorized into two groups: those unrecognized by the cell’s repair machinery and therefore remain unrepaired, and those recognized but inadequately repaired within a defined timeframe. The number of unrecognized DSBs follows a quadratic dose-response, while the number of recognized but unrepaired DSBs increases linearly with dose. Ultimately, these remaining unrepaired DSBs are modeled as following a Poisson distribution, leading to a survival curve described by a linear-quadratic exponential function. This mechanism explains cellular hypersensitivity at low doses because insufficient ATM monomers are produced to trigger DNA repair pathways and recognition processes; consequently, the DSBs remain unrepaired, ultimately causing cell death. Reference: [MolecularRadiationBiology, Section 4.5.5 – Low-Dose Modifications and High-Dose Limitations]","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.5	 Low-Dose Modifications and High-Dose Limitations | Content: that allows its repair [117]. The rates of DSB production by
radiation and monomerization are assumed to have a linear
relationship to dose. The same model also includes the notion
of cell tolerance, taking into account that not all DSB lead to
cell death, which in this case is assumed to be due to unre­
paired DSB in cells entering mitosis. Among unrepaired
DSB, those that are not recognized and therefore not repaired
are distinguished from those that are recognized but not
repaired within a suitable time window. The number of
unrecognized DSBs in the model has a quadratic relationship
to dose, whereas the number of recognized but unrepaired
DSBs has a linear relationship to dose. Finally, unrepaired
DSBs are assumed to follow a Poisson distribution, which
leads to cell survival being modeled by a linear quadratic
exponential. In addition to presenting a biological mecha­
nism of cell death by radiation, this model provides an expla­
nation for cellular hypersensitivity at low doses, since it
assumes that radiation does not produce enough ATM mono­
mers to cross the membrane and enter the nucleus. Therefore,
there is no recognition of DSB and they remain unrepaired,
which leads to cell death.
4.5.5
Low-Dose Modifications and High-Dose
Limitations
The linear quadratic model is arguably the most used tool in
radiation biology and physics, as it provides a simple rela­
tionship between the dose absorbed and the number of sur­
viving cells (or the probability that a single cell will survive).
In its basic format (SF = exp (−α × D – β × D2)), it has been
used to analyze and explain both in vivo and in vitro experi­
ments and after some modest simplifying assumptions, it can
be related to a number of mechanistic models such as multi-­
hit and potentially lethal lesion models. However, despite its
widespread usage, questions remain about its applicability,
particularly at the very low and very high-dose regions where
significant discrepancies have been observed between the
model predictions and the experimental data. Such questions
spring from the complexity of the underlying biology and
modern radiotherapy, where the response of cells and tissues
can be modulated by both intrinsic genetic factors as well as
the cellular environment and the radiation delivery modality.
The linear quadratic model has therefore been the subject of
extensive investigations and suggestions for modification to
better fit the experimental data and therefore to explain a
wide range of radiation conditions.
In the low-dose region, high-resolution in vitro measure­
ments demonstrated increased X-ray effectiveness below
0.6 Gy [118]. The measured survival levels were signifi­
cantly lower than those predicted by extrapolating the high
dose points using the linear quadratic models. The phenom­
enon, named hypersensitivity, was reported with a range of
cell lines and radiation qualities and data suggest that the
observed response was unlikely to be due to a subpopulation
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
220
of radiosensitive cells. In order to account for the increased
effectiveness per unit dose at doses lower than 1 Gy and in
line with the hypothesis that repair mechanisms are only trig­
gered when sufficient damage has been accumulated, modi­
fication to the linear quadratic models has been suggested.
Joiner and Johns [119] proposed a simple modification in
which the alpha parameter decreases with increasing radia­
tion dose, representing an increased induced radio resistance.
The modification only concerns the alpha parameter, as the
contribution of the beta parameter is negligible at low doses
due to its quadratic influence. The modified linear quadratic
models for low doses can therefore be expressed as
(4.40)
c
4.21
The interest in radiotherapy treatments delivered with a
smaller number of high-dose fractions (hypofractionation)
and stereotactic radiosurgery (SRS) has also instigated
investigation into the validity of the linear quadratic model
at high doses. A number of investigations have shown that
the linear quadratic model in its basic form is not suitable
in the high-­dose region where it underestimates the surviv­
ing fraction and does not reproduce the straightening of the
curve observed experimentally [120, 121]. To cope with
this drawback, modifications of the linear quadratic model
have also been suggested at high doses [122]. The starting
point is an early modification of the linear quadratic expres­
sion to account for repair during a protracted radiation
exposure:
(4.41)
with λ as the repair rate parameter, T is the delivery time
for the dose D, alpha and beta as previously described for
the basic linear quadratic model. This version of the LQ
model is able to predict survival curves taking into consid­
eration scenarios where significant repair occurs during
the dose delivery and is in accordance with other mecha­
nistic models (i.e., Lethal, Potentially Lethal model). In
order to reproduce the behavior of acute high doses how­
ever an additional term needs to be added to the G
parameter:
4.41
4.22
Although both modifications of the linear quadratic model
are able to accurately describe experimental data at low and
high doses, they introduce new parameters, which need to be
experimentally determined.
G. Schettino et al.
221
4.5.6"
"Describe the distinctions between sublethal, lethal, and potentially lethal radiation damage within a biological context, focusing on the role of DNA repair mechanisms and cell cycle progression.","Radiation-induced cellular damage is categorized into three distinct types based on its potential consequences for cell survival. Sublethal damage refers to injury to cells or tissues that, despite being uncorrected by repair pathways, will not immediately result in cell death. These damages represent a transient state where the cell remains viable but potentially vulnerable. Lethal damage, conversely, involves irreparable DNA lesions – those too extensive or complex for cellular repair mechanisms to resolve effectively. Such damage inevitably triggers apoptosis (programmed cell death) or necrosis (uncontrolled cell death). Potentially lethal damage occupies an intermediate category; these injuries *can* be repaired if the process occurs within a sufficient timeframe, dictated by cell cycle regulation. However, if repair fails to occur before the cell progresses through its cycle and encounters further damaging radiation, it will ultimately lead to lethality. The critical factor determining whether damage is sublethal, lethal, or potentially lethal is therefore the interplay between the extent of DNA damage, the efficiency of repair mechanisms, and the timing of irradiation relative to the cell’s current stage within the cell cycle. Repair capacity is significantly influenced by which part of the cell cycle a cell is in; cells actively involved in DNA replication are generally more capable of repairing radiation-induced lesions than those in other phases.

Reference: [Molecular Radiation Biology], Section 4.5.6 – Target Theory and Dose-Response Models.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.6	 The Dose Rate Effect | Content: The reaction of cells and tissues to radiation damage involves
the repair of DNA and a complex interplay between repair
and cell survival. The ability of a cell to repair the damage it
experiences depends on the part of the dose it receives, the
part of the cell cycle in which it is irradiated, and the rate at
which the dose is delivered. Therefore, we must give atten­
tion not just to the molecular mechanisms of damage and
repair but also to cell cycle regulation of repair and ulti­
mately their biological consequences.
Here we return to using the terms sublethal, lethal, and
potentially lethal damage. By sublethal damage, we simply
mean damage which will not be lethal to the cell even if the
damage is not repaired. We will later see that it is still of
great importance whether or not these damages are given
time for repair hence the temporal aspect.
Lethal damage is fixed in such a way that they cannot be
repaired. Potentially lethal damage may well be repaired but
will be lethal if not repaired in time, where the notion of “in
time” relates to cell cycle regulation."
"Describe the relationship between DNA double-strand breaks (DSBs) and cell survival following radiation exposure, incorporating the concept of repair time and potential lethal chromosomal aberrations.","Following irradiation, DNA double-strand breaks (DSBs) represent a significant threat to cellular integrity. If a cell enters mitosis while possessing these asymmetric chromosomal aberrations – such as dicentric chromosomes or rings – it is unlikely to successfully distribute a complete set of genetic information to its daughter cells, leading to cell death. The critical factor determining survival is the time available for repair before the cell progresses through S phase and attempts replication with the damaged DNA. When DSBs are allowed to repair prior to entry into S phase, the damage remains potentially lethal but not immediately so. This allows the cell’s natural repair mechanisms, primarily non-homologous end joining (NHEJ), to attempt correction. However, if cells rapidly enter S phase with unrepaired DSBs, the likelihood of generating lethal chromosomal aberrations dramatically increases, ultimately resulting in cell death due to an incomplete genome. Experimental evidence, notably from Shipley et al., demonstrated that rat adenocarcinoma cells grown *in situ* within a nutrient-limited environment exhibited significantly higher survival rates after irradiation compared to those explanted and cultured *in vitro*, where rapid proliferation facilitated the formation of lethal chromosomal aberrations. Furthermore, repair processes could continue for up to 24 hours post-irradiation, highlighting the complexity and duration of DNA damage response pathways. The inability of cells exposed to high-LET neutron radiation to increase survival after 24 hours suggests that the resulting DSBs are too complex for even NHEJ to resolve effectively, reinforcing the importance of repair time in determining cell fate following radiation exposure. Reference: [MolecularRadiationBiology, Section 4.5.6.1 – Repair of Potentially Lethal Radiation Damage]","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.6	 The Dose Rate Effect | Sub-sub-subsection: 4.5.6.1	 Repair of Potentially Lethal Radiation Damage | Content: Damage
If the cell passes through S phase with DSBs, the formation
of dicentric chromosomes or rings may take place, which is
potentially lethal to the cell [123]. If the cell thereafter enters
mitosis with such asymmetric chromosomal aberrations, it
may not be able to give each of the daughter cells a complete
set of genes. If such asymmetric chromosomal aberrations
are formed, they are therefore usually lethal for proliferating
cells. However, if cells are given time to repair DSB before
they can develop into asymmetric chromosomal aberrations,
i.e., before the cell enters into S phase, damage such as DSB
are only potentially lethal.
These concepts were supported by early experiments by
Stapleton [124] and Phillips [125], where, respectively, cul­
ture of cells under suboptimal conditions for growth, or in
the presence of inhibitors of the cell cycle produced an
increased level of cell survival Seminal experimental find­
ings which support this view include work in vivo by Shipley
[126], where rat adenocarcinoma cells were irradiated in situ
with gamma rays or neutrons, after which explants of the
tumor were grown in vitro either immediately after, or from
4 to 24 h after irradiation, whereupon the survival of these
cells was assessed in terms of their clonogenic capacity.
While situated in functioning tissue within the animal, these
cells had limited access to nutrients and growth factors,
which set a natural limit on cell density thereby limiting cell
growth and proliferation. Within tissues, such cells may well
be cycling though they could take several days to do so, and
as such have time to repair their DNA. When cultured as
explants in vitro post-irradiation they have greater access to
nutrients and as such proliferate strongly, with surviving
cells able to produce colonies. Cells which were cultured
immediately after irradiation exhibited lower survival rates
than those which remained in situ for a period of time after
irradiation. Clearly, cells that could not proliferate in tissue
have an increased opportunity to repair their damage owing
to them being prevented from progressing within the cell
cycle. Further experimental evidence demonstrated that this
repair process could continue up to 24 h after irradiation,
indicating the complexity of this repair process [127].
The experiments by Shipley et al. also showed that there
is no increase in cell survival for the cells explanted up to
24 h after high-LET-neutron irradiation. The implication of
this is, that the damage induced by high-LET-neutron radia­
tion must be too complex to allow for successful repair,
which would increase the survival. This finding suggests that
complex DSB are not reparable, even with non-homologous
end joining (NHEJ), which has been reinforced by observa­
tions that not all DSB from high-LET irradiation initiate
NHEJ-repair [128]."
"The provided text describes a scenario where irradiated cells, initially exhibiting low survival rates, demonstrate increased survival and colony formation when cultured as explants in vitro. This is attributed to the ability of these cells to repair DNA damage over time after irradiation. Explain how this observation relates to the concept of target theory and dose-response modeling, specifically concerning sublethal damage.","The observed phenomenon – that irradiated cells initially with low survival rates demonstrate increased survival and colony formation upon prolonged in vitro culture due to DNA repair – directly supports the target theory of radiation biology. The text highlights how cells prevented from immediate proliferation (due to irradiation) have more opportunity for sublethal damage repair. This aligns with the target theory’s premise that multiple, small doses of radiation cause a cumulative effect of sublethal damage within cells, ultimately leading to lethal damage if the total dose is high enough.  The LQ model, as described, further clarifies this by recognizing specific sublethal damages like single-strand breaks (SSB) and double-strand breaks (DSB). The fact that DSBs can be repaired, particularly with time allowing for cell cycle progression, explains why cells initially damaged at a high dose rate may not exhibit immediate lethality but will eventually recover if given sufficient time to repair the damage.  The experiment by Shipley et al., showing no increase in survival up to 24h after high-LET neutron irradiation, reinforces this idea – complex DSBs are not reparable even with NHEJ, preventing a recovery curve. The timeframe for repair is crucial; cells remain radiosensitive until they complete the cell cycle and transition to a stage where they are resistant to further damage. This concept of ‘repopulation’ between dose fractions highlights how cells that survive the initial irradiation have time to divide and contribute to colony formation, demonstrating the effectiveness of DNA repair mechanisms.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.6	 The Dose Rate Effect | Sub-sub-subsection: 4.5.6.2	 Repair of Sublethal Damage | Content: be cycling though they could take several days to do so, and
as such have time to repair their DNA. When cultured as
explants in vitro post-irradiation they have greater access to
nutrients and as such proliferate strongly, with surviving
cells able to produce colonies. Cells which were cultured
immediately after irradiation exhibited lower survival rates
than those which remained in situ for a period of time after
irradiation. Clearly, cells that could not proliferate in tissue
have an increased opportunity to repair their damage owing
to them being prevented from progressing within the cell
cycle. Further experimental evidence demonstrated that this
repair process could continue up to 24 h after irradiation,
indicating the complexity of this repair process [127].
The experiments by Shipley et al. also showed that there
is no increase in cell survival for the cells explanted up to
24 h after high-LET-neutron irradiation. The implication of
this is, that the damage induced by high-LET-neutron radia­
tion must be too complex to allow for successful repair,
which would increase the survival. This finding suggests that
complex DSB are not reparable, even with non-homologous
end joining (NHEJ), which has been reinforced by observa­
tions that not all DSB from high-LET irradiation initiate
NHEJ-repair [128].
4.5.6.2	Repair of Sublethal Damage
129
130
4.23
­
4.23
These results aligned with the target theory of the time,
whereby the combined effects of several sublethal damage
events in DNA may result in lethal damage, such that dam­
age created by hits which are not lethal by themselves may
be repaired, but cells will not have time to do such repair if a
large dose is given acutely, i.e., at a high dose rate. With a
large enough acute dose, the degree of sublethal damage for
each cell is so high that it combines to form lethal damage.
It is well worth reflecting on both the differences and the
similarities regarding sublethal damages between the tradi­
tional multi-target/single-hit model and the newer LQ model.
On the one hand, in the multi-target/single-hit model, one
does not make any assumption regarding the nature of the
molecular damage induced. Still, it introduces the concept of
sublethal damage and shows that such damage inevitably
leads to an initial shoulder on the survival curve. Thus,
Elkind’s and Sutton’s data show that if cells are given time
for repair, DNA damage can be repaired.
On the other hand, in the LQ model, one assumes two
specific types of molecular damages as being sublethal,
namely single strand breaks in DNA (SSB) (which are all
sublethal separately) and the repairable double strand breaks
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
222
­
131
­
131
­
­
­
130
in DNA (DSB). In reality, no distinction is made between
SSB and DSB concerning repair of sublethal damage
observed by dose fractionation in the LQ model. According
to the LQ model, the dose-response curve has a downward
bending, because two sublethal SSB may give rise to a
DSB. The DSB may develop into lethal damage and there­
fore is potentially lethal but probably may also in some cases
be sublethal.
The question then arises as to the timeframe required for
the repair of sublethal damage events. While Elkind and
Sutton did go some way towards measuring the value of this
variable (suggesting that it was as much as 12 h), it was not
until experiments by Terasima and Tolmach and further
experiments by Elkind that refined this estimate and gave an
explanation for its value.
4.26
At 24 °C, surviving cells stay in the stage of the cell cycle
where they are resistant between the dose fractions and
therefore their radiosensitivity is constant with time. At
37 °C, they continue through the cell cycle after the first frac­
tion and at some time later will have reached a cell cycle
stage where they have maximum radiosensitivity, whereupon
the second dose fraction is given. Consequently, survival as a
function of the time between fractions will decrease with
increasing time.
­
­
4.24
4.26
G. Schettino et al.
223
cell division before the next dose fraction is given (notice
that these cells have a median cell cycle duration of just
about 10 h). The consequence of this is that some colony-­
forming units consist of two daughter cells instead of just
one at the time when the second dose fraction is given.
A simple calculation illustrates the importance of this
phenomenon. If the probability to kill a cell is p, the proba­
bility for this cell to survive is S = 1−p. However, the prob­
ability to kill both cells in a doublet or all four cells in a
quartet is p2 and p4, respectively. The probability for a dou­
blet or a quartet to form a colony is therefore S = 1−p2 and
S = 1−p4, respectively.
4.26
­
­
2
­
4.26
­
­
In radiotherapy, the notion used for cell proliferation
between dose fractions is repopulation. By repopulation, we
mean that cells which survive a preceding dose fraction get
enough time before the next dose fraction to complete the
cell cycle and divide. This is an important concept in connec­
tion with fractionated radiotherapy. Although cell cycle
times in tissues are usually much longer than for V79 cells in
culture, 24 h between the dose fractions is sufficient for at
least some proliferation of both cancer cells and normal cells
between the fractions.
4.26
4.25
4.25
­
­
5.5
4.5.7"
"Elkind and Sutton's research highlighted a recurring phenomenon in cell survival following fractionated or low-dose radiation exposure. Describe this observed pattern regarding the repair processes within irradiated cells, specifically referencing the consistency of key parameters as suggested by the LQ model.","Elkind and Sutton’s experiments revealed that cells subjected to multiple dose fractions separated by sufficient time for complete DNA repair repeatedly underwent repair of sublethal damage. Critically, despite variations in the initial slopes of cell survival curves resulting from different dose fractionation schedules, the final slopes consistently exhibited similar values. The LQ model provides a framework for understanding this behavior: it posits that while the α-values (representing the initial slope of the curve and reflecting immediate sensitivity) change depending on the specific irradiation protocol, the β-value (representing the rate of repair and ultimately determining the overall survival curve shape) remains relatively constant across different cell lines or fractionation schemes. This consistent final slope indicates a fundamental, repeatable repair mechanism operating within the cells regardless of the precise timing or magnitude of the initial radiation exposure. The observation that radiosensitivity differences between cell types were more pronounced at low dose rates further supports this principle, suggesting a broader underlying cellular response to radiation damage rather than simply acute sensitivity thresholds.

Reference: [MolecularRadiationBiology], Section 4.5.7 – Fractionated Irradiation and Dose Rate Effects","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.7	 Fractionated Irradiation and Dose Rate Effects | Content: Effects
Elkind and Sutton demonstrated that cells irradiated with
several dose fractions separated by enough time for full
repair would repeat the repair of sublethal damage over and
over again [132]. Steele also demonstrated that an increase in
cell survival is observed when a given dose is delivered at a
low dose rate [133]. Some consistent features in the cell
­survival curves for cells irradiated with fractionated or low-
dose radiation were also observed:
­
­
­
4.24
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
224
­
­
•	While the initial slopes of each cell survival curve dif­
fered, the final slopes were consistent. Using the LQ
model to describe the cell survival curve would indicate
that for a given cell line under fractionated or low dose
irradiation, the α-values would change, while the β-values
would remain consistent.
•	The differences between the response of cells of different
types (with varying radiosensitivity) were more pro­
nounced with low dose rate irradiation than with acute
irradiation. This is a first indication of a more general
principle, which is of utmost importance for radiotherapy.
The sparing effect of fractionated or low dose rate radia­
tion is most pronounced for cells having a dose-response
curve with a broad shoulder (or a shallow initial slope).
4.26
­
­
­
­
One should notice that the final slopes of the single-dose
curves indicate that the cells having the broadest shoulder are
in fact more radiosensitive than those having the smallest
shoulder at high single doses. Still, with fractionated or low
dose rate irradiation it is the other way around. This phenom­
enon is an important principle, which is the basis for radio­
therapeutic practice.
In radiotherapy, it is customary to express this principle in
some other words as based on the LQ model. The sparing
effect of fractionated or low dose rate irradiation as com­
pared to acute irradiation is most pronounced for cells hav­
ing a dose-response curve with a small α-parameter.
4.5.8
The Inverse Dose Rate Effect Illustrating
the Importance of Cell Cycle
Progression
G. Schettino et al."
"The text describes two types of tissues in relation to radiation response – ‘late responders’ and ‘early responders.’ Explain the key differences between these tissue types regarding their dose-response curves, specifically focusing on the α/β ratio and its implications for radiotherapy.","Late-responding tissues, such as differentiated cells or those in poorly stimulated environments, exhibit a small initial slope (α) on their dose-response curves. This indicates a low α/β ratio – typically around 3 Gy. These cells are characterized by delayed responses to radiation damage, with cell loss occurring weeks or months after the treatment's onset. Early-responding tissues, like cancer cells and some rapidly proliferating normal tissues, display a larger initial slope (α) and therefore a higher α/β ratio (around 12 Gy). This means they respond more quickly to radiation damage. The difference in these ratios is crucial for radiotherapy because it dictates how effectively each tissue type can be targeted. Prolonged treatment times with low dose rates favor sparing late-responding tissues due to their lower α/β values, while shorter, higher-dose treatments are generally more effective against early-responding tissues.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.9	 The Importance of the Initial Slope and the α/β-Dose in Radiotherapy | Content: 4 Mechanistic, Modeling, and Dosimetric Radiation Biology
226
•	Cells which are more prone to stay in the resting phase,
like differentiated cells or cells in tissues where growth
factor or mitogen stimulation is low, largely seem to have
dose-response curves with a small initial slope (i.e., a
small α). Such cells are denoted as “late responders” since
radiation damage induces cell loss at a late stage after the
onset of the treatment. Most of these cells enter mitoses
weeks or even months after the start of the treatment.
Thus, tissues of such cells express a response to the radia­
tion late; not only late after the onset of the treatment but
in many cases long after the end of the treatment.
This difference is central to the whole concept of radio­
therapy. Without this difference, radiotherapy of cancer
would probably have had little curative success. The reason
is that proliferation is an activity that is typical for almost all
cancer tumors but only for a few organs of normal tissues.
Resting cells, on the other hand, are largely characteristic of
most normal tissues and not of cancer tissues.
Thus, while cancer cells largely proliferate and have a
large α-parameter, highly differentiated normal cells largely
rest and have a small α-parameter. The result of this is that if
radiation is given over a prolonged time, (either by repeated
dose fractions separated by time for repair or by continuous
low dose rate irradiation) there is a much more sparing effect
on late-responding normal tissues than on most cancer
tissues.
The interesting question is then, How did we obtain the
knowledge that late-responding tissues have cells with a
small initial slope on their dose-response curves? These cells
are largely not proliferating. They are furthermore seated in
tissues and do not grow in culture. So, how is it possible to
measure the ability of these cells to form a colony after irra­
diation? The answer is that we cannot do such measurements
directly. Still, as mentioned above, we know that these cells
have dose-response curves characterized by a small
α-parameter. This knowledge stems from the use of the LQ
model to measure not α, but the α/β-ratio. The α/β-ratio is
actually the dose (D1) where the contribution to cell inactiva­
tion by single event killing matches that from multiple event
killing, i.e.,
(4.42)
or
(4.43)
These measurements are based on the following idea: The
function of a tissue depends on the functionality of the tissue
cells. If the radiation inactivates a certain fraction of the
cells, the tissue may lose some of its function and the loss of
function can be measured. Such measurements as a result of
irradiation are usually denoted as measurements of
“Functional endpoints.” Two examples of such functional
endpoints representing late and early-responding tissues,
respectively, are: (a) Kidneys, the clearance of a very small
amount of an injected substance from the blood can be mea­
sured and (b) Skin, the severity of damage to an irradiated
area of skin can be observed and graded (from mild redden­
ing to irreparable wounds and necrosis).
4.28
­
136
51
­
4.30
­
(4.44)
where the total dose is D = nd.
We now rearrange to get the following expressions (and
we write SD for S(D) and Sd for S(d):
(4.45)
or
(4.46)
If we now remember that D = nd this formula can also be
rewritten as follows:
(4.47)
4.28
4.45
4.46
4.29137
4.29a
­
4.45
4.45
S
t
ar
tF
r
a
ct
i
on
al
p
ha Over ln upper S EndFraction equals minus StartFraction beta Over ln upper S EndFraction d Subscript left parenthesis 1 divided by upper D right parenthesis equals 0
(1/D = 0)
G. Schettino et al.
227
4.30
4.45
4.46
137
4.28
­
137
at d = −3 Gy, the nominal value of the α/β-dose must be
3 Gy.
4.29b
4.46
­
­
4.30137
­
­
­
4.5
4.30
­
­
­
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
228
2
­
Table 4.5 Ratios of α/β for early and late radiation reactions in normal
tissues, determined from laboratory animal and clinical data (Fowler,
copyright © 2005 Acta Oncologica Foundation, reprinted by permis­
sion of Taylor & Francis Ltd) [138]
Early reactions
S
tartFraction alpha Over beta EndFraction
(Gy)
Late reactions
S
tartFraction alpha Over beta EndFraction
(Gy)
Skin
9–12
Kidney
2–2.4
Jejunum
6–10
Rectum
2.5–5
Colon
9–11
Lung
2.7–4
Testis
12–13
Bladder
3–7
Mucosa
9–10
CNS: Brain, spinal cord
1.8–2.2
continuously with a low dose rate, the cells may repair sub­
lethal damage during irradiation and the lower the dose rate,
the smaller the probability will be for two or more sublethal
damages to combine to create a potentially lethal damage.
For the LQ model, this means that reducing the dose rate
results in reduced influence by the β-term and more and
more dominance by the α-term. The connection between the
shape of the dose-response curve and the isoeffect tolerance
curves (dashed lines) by continuous irradiation is illustrated
in Fig. 4.31. The blue curves represent late-responding tis­
sues (i.e., small α/β-ratio of ≈3 Gy) while the purple curves
represent early-responding tissues (i.e., large α/β-ratio of
≈12 Gy). The steep isoeffect tolerance curve at high doses
for late-responding tissues indicates good sparing for these
tissues by reduced fraction doses and prolonged treatment
time. Early-responding tissues will experience much less
sparing by prolonged treatment times (Box 4.12).
4.5.10	Recruitment: Limitations Caused by
Compensatory Cell Proliferation
in Early- and Late-Responding Tissues
­
­
­
4.32
­
­
As indicated, the compensatory proliferation starts after
the end of the treatment for nerve tissues, while it starts after
just 2 weeks of treatment for the cancer-modeling skin tis­
sues. The compensatory proliferation (repopulation) initi­
ated by fractionated irradiation is thus more favorable for
early-responding tissues (including cancer) than for late-­
responding normal tissues. Therefore, one must be careful
not to increase the overall treatment time too much. The 6
weeks that are typical for the duration of conventionally frac­
Box 4.12 The Linear Quadratic Model
•	The linear quadratic model is a mathematical
model, which is a good fit for cellular survival data
in a median dose range. For low and high dose, the
model needs modifications
•	There have been several biological interpretations
of the model
•	To compare different clinical fractionations regi­
mens, the biologically effective dose can be calcu­
lated from the S
tartFraction alpha Over beta EndFraction
-value
G. Schettino et al."
"Explain how compensatory cell proliferation contributes to differential tissue responses following fractionated radiation therapy, specifically addressing the observed differences in recovery times between early- and late-responding tissues.","Following fractionated radiation treatment, normal tissues exhibit varying degrees of recovery based on their inherent responsiveness. Early-responding tissues, such as cancer cells, demonstrate a compensatory proliferation – a repopulation initiated by irradiation – that typically begins after the end of the treatment period. This is particularly pronounced in nerve tissues where this proliferative response commences just two weeks post-treatment. Conversely, late-responding tissues, like skin, require approximately 20 weeks for this compensatory proliferation to initiate. The key factor driving these differences is the timing and magnitude of the proliferative response. Fractionated irradiation favors early responses because it allows sufficient time for the initial repopulation to occur before the tissue’s inherent resistance mechanisms fully engage. Prolonged treatment times can exacerbate this effect, leading to an overestimation of overall dose delivered and potentially increasing side effects due to excessive compensatory proliferation in tissues that are naturally more responsive. The linear quadratic model provides a framework for understanding these dose-response relationships, highlighting the need for careful consideration of fractionation regimens to maximize therapeutic efficacy while minimizing detrimental tissue responses. Reference: [MolecularRadiationBiology], Section 4.5.10 – Recruitment: Limitations Caused by Compensatory Cell Proliferation in Early- and Late-Responding Tissues.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.10	 Recruitment: Limitations Caused by Compensatory Cell Proliferation in Early- and Late-Responding Tissues | Content: time. Early-responding tissues will experience much less
sparing by prolonged treatment times (Box 4.12).
4.5.10	Recruitment: Limitations Caused by
Compensatory Cell Proliferation
in Early- and Late-Responding Tissues
­
­
­
4.32
­
­
As indicated, the compensatory proliferation starts after
the end of the treatment for nerve tissues, while it starts after
just 2 weeks of treatment for the cancer-modeling skin tis­
sues. The compensatory proliferation (repopulation) initi­
ated by fractionated irradiation is thus more favorable for
early-responding tissues (including cancer) than for late-­
responding normal tissues. Therefore, one must be careful
not to increase the overall treatment time too much. The 6
weeks that are typical for the duration of conventionally frac­
Box 4.12 The Linear Quadratic Model
•	The linear quadratic model is a mathematical
model, which is a good fit for cellular survival data
in a median dose range. For low and high dose, the
model needs modifications
•	There have been several biological interpretations
of the model
•	To compare different clinical fractionations regi­
mens, the biologically effective dose can be calcu­
lated from the S
tartFraction alpha Over beta EndFraction
-value
G. Schettino et al.
229
­
­
139
tionated radiation treatment thus is a compromise taking into
consideration several different aspects to obtain the maximal
probability for a positive effect on the cancer tumor with a
minimum of side effects."
"Explain the concept of Biologically Effective Dose (BED) and its relevance in radiation oncology, referencing the provided equation.","The Biologically Effective Dose (BED) is a measure used to quantify the biological effect of radiation exposure, particularly within clinical contexts like cancer treatment. It represents the dose required to produce an equivalent biological response as if that dose were administered continuously over an infinitely long period at a sufficiently low rate. This concept addresses the limitation of using total dose alone, which doesn't account for how quickly damage accumulates in cells. The equation (4.48) demonstrates this:  `StartFraction StartFraction StartFraction St Star Fraction n ln upper S Subscript d Baseline Over alpha EndFraction EndFraction EndFraction minus StartFraction StartFraction StartFraction n ln upper S Subscript d Baseline Over alpha EndFraction EndFraction EndFraction StartFraction StartFraction StartFraction St Star Fraction n ln upper S Subscript d Baseline Over alpha EndFraction EndFraction EndFraction EndFraction` is the BED.  Essentially, it considers the repair capacity of cells; if damage is induced slowly enough, cells can repair themselves before significant lethal effects occur. This allows for comparison of different fractionation regimes – like daily 2 Gy fractions versus a longer, lower-dose regimen – by focusing on the equivalent biological effect rather than simply the total absorbed dose. The BED calculation aims to determine the number of fractions (n) and the single dose (d) needed to achieve the same level of damage as would be produced by continuous irradiation at a rate that matches the cell's repair capacity, thereby allowing for comparison of different treatment schedules.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.11	 BED and Clinical Use | Content: We can rewrite Eq. (4.45) to:
(4.48)
St
ar
tF
raction minus n ln upper S Subscript d Baseline Over alpha EndFraction
is called the Biologically Effective Dose (BED)
and describes the dose needed to induce the same effect as if
the number of dose fractions was infinitely large and the
single dose fractions d approaching zero. This is the equiva­
lent of continuous irradiation with a dose rate sufficiently
small for cells to repair sublethal damage at the same rate as
they are induced preventing them to cooperate to create
lethal damage. BED is a useful parameter to calculate and
compare fractionation regimes.
Standard treatment for many cancers is 2 Gy daily frac­
tions (for example, over 7 weeks with five treatment days per
week). It is therefore often relevant to compare other frac­
tionation regimes to 2 Gy fractions.
The equivalent total dose D for 2 Gy fractions is called
(4.49)
For the fractionation regime we want to compare with
u
p
pe
r
D
S
ub
s
c
r
i
pt
d
B
a
seline equals StartStartStartFraction upper B upper E upper D OverOverOver left parenthesis 1 plus StartStartFraction d OverOver StartFraction alpha Over beta EndFraction EndEndFraction right parenthesis EndEndEndFraction
.
We then get uppe
r
E
up
p
er
Q
u
p
pe
r
D
B
a
seline 2 equals upper D Subscript d Baseline StartStartFraction left parenthesis d plus StartFraction alpha Over beta EndFraction right parenthesis OverOver left parenthesis 2 plus StartFraction alpha Over beta EndFraction right parenthesis EndEndFraction
, which can be used to
calculate fraction dose d and number of fractions n = Dd/d to
get the same BED as 2 Gy fractions to a total dose of EQD2."
"Describe the key differences between deterministic and stochastic effects related to radiation exposure, including their dose thresholds and typical magnitudes of impact.","Deterministic and stochastic effects represent fundamentally different ways ionizing radiation can induce harm in biological systems following exposure. Deterministic effects are characterized by a clear dose-response relationship where the severity of the effect increases proportionally with the absorbed dose, and crucially, they exhibit a well-defined threshold. This means that below a certain dose (typically 0.5 Gray for many organs), no observable effect occurs; above this threshold, the damage becomes increasingly severe and directly related to the amount of radiation received. These effects are often tissue-specific, with different organs exhibiting varying thresholds and sensitivities. Examples include skin erythema (redness) at low doses and fibrosis (scarring) at higher doses. Stochastic effects, conversely, do not have a clear dose threshold; the probability of an effect occurring increases continuously with dose, but the *severity* of that effect does not necessarily correlate linearly. These effects are primarily probabilistic – they represent random mutations or damage to DNA – and their occurrence is independent of the absorbed dose. While stochastic effects can lead to significant consequences (such as carcinogenesis and heritable genetic mutations), the probability of a single individual experiencing one of these effects at a given low dose is often small.  In essence, deterministic effects are about *how much* damage occurs, while stochastic effects are about the *likelihood* of damage occurring.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.5	 Target Theory and Dose-Response Models | Sub-subsection: 4.5.12	 Dose-Response Models for Radiation Carcinogenesis | Content: E
up
p
er
Q
u
p
pe
r
D
B
a
seline 2 equals upper D Subscript d Baseline StartStartFraction left parenthesis d plus StartFraction alpha Over beta EndFraction right parenthesis OverOver left parenthesis 2 plus StartFraction alpha Over beta EndFraction right parenthesis EndEndFraction
, which can be used to
calculate fraction dose d and number of fractions n = Dd/d to
get the same BED as 2 Gy fractions to a total dose of EQD2.
4.5.12	Dose-Response Models for Radiation
Carcinogenesis
While it is relatively straightforward to develop a model
relating dose to survival at the cellular level, modeling of
dose response at the organ and organism (human) level is
far more complex. There remains considerable debate
regarding the most appropriate model for use in describing
the variation in response to dose in humans [140]. However,
each of the models has its basis in radiobiology, and the
interaction of ionizing radiation with human tissue at the
cellular level [140, 141]. The previous section on target
theory provides a basis to begin to define models of human
radiation survival. The effects of ionizing radiation on cells
may be divided into two types: deterministic and stochastic
effects [141]. Deterministic effects result from the substan­
tial injury of cells in affected tissues, and the severity of the
effect is a function of the absorbed dose. Stochastic effects
are those for which the probability of occurrence of an
effect, and not its severity, is a function of dose [141].
Deterministic effects have a well-defined dose threshold in
mammalian cells of a particular organ and type, while it is
assumed that no threshold exists for stochastic effects
[142]. Deterministic effects occur at relatively high doses
(0.5 Gy and above depending on the organ system involved),
while stochastic effects generally occur at relatively low
doses (below 0.5 Gy) [141]. Both sets of effect are modified
by the rate at which the dose is administered as well as by
the biological damage responses such as DNA repair and
immune responses [141]. Stochastic effects usually consti­
tute the mechanisms by which the hereditary (mutagenic)
and somatic (carcinogenic) effects of ionizing radiation
occur [140]. Carcinogenesis is a multistage process in
which radiation may induce one or more of the changes
necessary to cause DNA damage, while mutagenesis is usu­
ally thought to be the result of single biological changes in
germ cells. [140]
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
230
From Eq. (4.26), we may simplify and introduce a vari­
able change to obtain a single-hit model of radiation survival
in cells where the frequency, f, of cells with one or more hits
in a given population of cells is:
(4.50)
where n is the number of critical hits per cell at dose D, and
λ is the mean number of critical hits per cell at dose D. For
low frequency hits (low doses), the number of critical hits, n,
per cell is small and thus Eq. (4.49) reduces to:
(4.51)
Thus, the dose-response is approximately linear with no
threshold. At high hit frequencies, where hit saturation
occurs, the equation takes the form of Eq. (4.49), since after
the first critical hit in a cell, further hits in it cannot lead to
additional effects [140].
Multi-track models may be utilized to describe the effect
of the interaction between multiple tracks in a cell. The inter­
action may either be positive or negative and may result in
visible curvature to the dose response [140]. A mathematical
description of such a model may be achieved by inserting a
general polynomial into Eq. (1.50) as follows [140]:
(4.52)
which, for low frequency effects (low doses) reduces to:
(4.53)
In practice, many models have been found to fit the dose
response of various bodily organs, depending on the organ in
question [143]. The two most common models used are the
linear no threshold, LNT (Eq. 4.50), and the linear quadratic
(Eq. 4.52) models [143]. At low doses, in a homogeneous
cell population, Eq. 4.50 would be the most appropriate
dose-response model theoretically, since it is assumed that
every cellular hit may be biologically critical and that a sin­
gle cell is unlikely to be hit more than once [143]. However,
for low doses, other mechanisms come into play, such as low
dose hypersensitivity, hormesis, and adaptive response
mechanisms, as described in Sect. 2.9 and non-targeted
effects as described in Sect. 2.10, which will modify the radi­
ation response. In an inhomogeneous cell population, where
groups of cells have differing radiosensitivity, the response
for single-track events in each subpopulation should follow
the form of Eq. (4.52), the overall response should show a
decreasing sensitivity with increasing dose, consistent with
the LQ model [140].
Historically, the LNT model for radiation risk assessment
was introduced after Muller’s discovery of radiation-induced
mutations in 1927. After the atomic bombing of Japan in
1945 and the start of the nuclear arms race, ionizing radiation
became connected in public mind with nuclear apocalypse.
In 1945–1956, there was great controversy and extensive
arguments pro and contra LNT. In general, it can be said that
among scientists “the data to support the linearity at low
dose perspective was generally viewed as lacking but the
fear that it may be true was a motivating factor” [144]. In
1956, ICRP officially abandoned the tolerance level concept
(that was in use since 1931) and substituted LNT for it.
Formally, LNT has been introduced and remains a practical
operational model for radiation protection only. De facto
however LNT acquired the status of a scientific theory,
though supporting evidence is at least inconclusive.
Moreover, about 40 years ago, low dose-induced changes in
cell signaling with delayed responses were discovered. There
is emerging evidence that low doses induce cellular and
intercellular changes, which can lead to stress response
(adaptive response) metabolic alterations. Adaptive responses
against the accumulation of damage—also of non-radiogenic
origin—were also discovered [145]. The above evidence
suggests that while high-dose ionizing radiation is certainly
harmful, low doses may be beneficial for human health; such
an effect is called hormesis [146]. At the joint US ANS/HPS
conference “Applicability of Radiation-Response Models to
Low Dose Protection Standards” in 2018, neither of the three
viewpoints—supporting LNT, tolerance level, or hormesis—
was marginal [145].
4.6"
"The text discusses the concept of LNT and emerging evidence suggesting potential benefits from low-dose radiation exposure, termed hormesis. Describe the key arguments supporting this hormetic effect, including the discovery of delayed cellular responses and adaptive stress mechanisms observed at low doses.","The argument for a hormetic response to low-dose ionizing radiation stems primarily from observations that contradict the strictly linear non-threshold (LNT) model. Initially, scientists were hesitant to abandon the established tolerance level concept due to a lack of definitive data supporting linearity at low doses. However, research approximately 40 years ago revealed delayed cellular and intercellular changes induced by low doses. These changes manifest as stress responses – specifically adaptive responses – aimed at mitigating the accumulation of damage, including damage not directly attributable to radiation (non-radiogenic origin). Specifically, studies have shown that low doses trigger alterations in cell signaling pathways and metabolic processes, leading to an upregulation of DNA repair mechanisms and antioxidant defenses. This suggests a ‘priming’ effect where cells become more resilient to subsequent exposure. The evidence presented challenges the purely linear model by indicating that low doses may not simply be harmless but could instead induce beneficial adaptations within biological systems – a phenomenon known as hormesis.  The 2018 US ANS/HPS conference highlighted this ongoing debate, with no single viewpoint (LNT, tolerance level, or hormesis) definitively favored due to the inconclusive nature of the evidence.

Reference: [4: Mechanistic, Modeling, and Dosimetric Radiation Biology], Section 4.6","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.6	 Exercises and Self-Assessment | Content: arguments pro and contra LNT. In general, it can be said that
among scientists “the data to support the linearity at low
dose perspective was generally viewed as lacking but the
fear that it may be true was a motivating factor” [144]. In
1956, ICRP officially abandoned the tolerance level concept
(that was in use since 1931) and substituted LNT for it.
Formally, LNT has been introduced and remains a practical
operational model for radiation protection only. De facto
however LNT acquired the status of a scientific theory,
though supporting evidence is at least inconclusive.
Moreover, about 40 years ago, low dose-induced changes in
cell signaling with delayed responses were discovered. There
is emerging evidence that low doses induce cellular and
intercellular changes, which can lead to stress response
(adaptive response) metabolic alterations. Adaptive responses
against the accumulation of damage—also of non-radiogenic
origin—were also discovered [145]. The above evidence
suggests that while high-dose ionizing radiation is certainly
harmful, low doses may be beneficial for human health; such
an effect is called hormesis [146]. At the joint US ANS/HPS
conference “Applicability of Radiation-Response Models to
Low Dose Protection Standards” in 2018, neither of the three
viewpoints—supporting LNT, tolerance level, or hormesis—
was marginal [145].
4.6
Exercises and Self-Assessment
Q1.	Principles of radiation dosimetry?
Q2.	Radiation microdosimetry
(a)	What is lineal energy?
(b)	How is it related to the LET?
Q3.	From track structure to early DNA damage
(a)	What are the main differences between a general
MC code and a track structure (TS) MC code?
(b)	What are the main sources of uncertainty in the cal­
culation of DNA damage with MCTS code?
Q4.	Micro-beams and minibeams
(a)	Please allocate the research questions mentioned in
the following figure to the irradiation pattern, which
is best used for investigation, as it is done in the
example.
G. Schettino et al.
231
Q5.	Target theory and dose-response models
Use the data in the table below (A549 lung cancer cells irra­
diated with 220 kV X-rays) to:
(a)	Find the α/β-value both from a LQ-fitting and by
drawing the initial slope and comparing the contribu­
tions from each term (see figure provided in Sect. 4.5
above).
(b)	Calculate the surviving fraction using α and β from
your LQ-fitting for 5 fractions of 2 Gy (24 h apart)
and compare to a single dose of 10 Gy.
(c)	How many fractions of 2 Gy should we give to get the
same biological effect as for 1 fraction of 10 Gy?
Dose [Gy]
Surviving fraction
Standard error
0
1
0.5
0.88
0.07
1
0.64
0.06
2
0.41
0.04
5
0.07
0.02
10
0.0008
0.0003
4.7"
Explain the concept of linear energy transfer (LET) in radiation dosimetry and how it relates to electron transport calculations within Monte Carlo simulations.,"Linear energy transfer (LET), denoted as 'y', represents the amount of kinetic energy deposited by a single ionizing event – such as a particle collision – per unit distance traveled through matter. It’s defined mathematically as the ratio of the total energy imparted to a volume of material by that single event to the mean chord length within that same volume. In large-sized targets, where numerous interactions occur, the distribution of LET values tends to converge towards this expected value (the LET itself). Within Monte Carlo simulations, particularly Track Structure codes (TS MC), LET is critically calculated by explicitly simulating all electron interactions – both elastic and inelastic – down to very low energies (typically around 10 eV). This detailed simulation allows for precise determination of energy depositions within micrometric and nanometric volumes. Conversely, Microdosimetry Codes (MCTS) often rely on simplified cross-sections for materials like water, which inherently contain uncertainties due to limited experimental data validating these sections. These codes frequently neglect the complexities of radiolysis and reactions involving radiolytic species with biomolecules, as well as employing approximations in DNA geometrical models, leading to potential inaccuracies in damage conversion calculations.","Document: MolecularRadiationBiology | Section: 4: Mechanistic, Modeling, and Dosimetric Radiation Biology | Subsection: 4.7	 Exercise Solutions | Content: SQ1.	Principles of radiation dosimetry
SQ2.	Radiation microdosimetry
(a)	The lineal energy is the quotient of the total energy
imparted to a volume of matter by a single energy
deposition event and the mean chord length in that
volume.
(b)	In large-size targets, the number of interactions is
large and the distribution of lineal energy con­
verge to an expected value, which is the LET.
SQ3.	From track structure to early DNA damage
1.	Two main characteristics differentiate these two
types of MC calculation:
(a)	TS MC codes do not use the condensed history
approach for electron transport and they dis­
cretely simulate all electron interactions (elas­
tic and inelastic)
(b)	TS MC codes include electron interaction
cross sections to explicitly transport the elec­
trons down to very low energies (of the order
of 10 eV), which allows to calculate the energy
depositions in micrometric and nanometric
volumes.
2.	Cross sections, mainly for liquid water, used by
MCTS codes have uncertainties due to the lack of
experimental data that could validate them. All the
complexity of radiolysis and reactions of radiolytic
species with biomolecules is not taken into account.
DNA geometrical models require approximations.
The conversion of particle interactions or reactions
of radiolytic species into damage is a source of
interpretation.
SQ4.	Micro-beams and Minibeams
(a)
SQ5.
Target theory and dose-response models
(a)	α/β = 12
(b)	and 0.001
(c)	8
4 Mechanistic, Modeling, and Dosimetric Radiation Biology
232"
"The text discusses the role of the human microbiota in both healthy and pathological gut conditions, and its potential implications for radiotherapy effects. Can you briefly explain how alterations in the gut microbiome might influence a patient's response to radiation therapy, specifically relating to tumor hypoxia and abscopal effects?","Dysbiosis – an imbalance within the gut microbiome – can significantly impact a patient’s response to radiation therapy through several interconnected mechanisms. Firstly, changes in microbial composition can exacerbate tumor hypoxia. Certain bacteria thrive in low-oxygen environments, promoting angiogenesis (new blood vessel formation) around the tumor, which paradoxically enhances its growth and resistance to radiation. Secondly, alterations in the microbiome can influence abscopal effects – where irradiation of a primary tumor triggers an immune response against distant metastases. Specific microbial communities may either suppress or stimulate this anti-tumor immunity. Furthermore, the microbiota's metabolic activity can directly affect radiation sensitivity by modulating DNA repair pathways or influencing inflammation levels within the irradiated tissue. The interplay between these factors highlights the importance of considering the gut microbiome as a key modulator in radiotherapy outcomes.

Reference: [MolecularRadiationBiology], Section 5.6 – Microbiota and Radiotherapy.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Content: Oncology
Peter Sminia, Olivier Guipaud, Kristina Viktorsson,
Vidhula Ahire, Sarah Baatout, Tom Boterberg,
Jana Cizkova, Marek Dostál, Cristian Fernandez-Palomo,
Alzbeta Filipova, Agnès François, Mallia Geiger,
Alistair] Hunter, Hussam Jassim,
Nina Frederike Jeppesen Edin, Karl Jordan,
Irena Koniarová, Vinodh Kumar Selvaraj, Aidan D. Meade,
Fabien Milliat, Alegría Montoro, Constantinus Politis,
Diana Savu, Alexandra Sémont, Ales Tichy, Vlastimil Válek,
and Guillaume Vogin
P. Sminia (*)
Department of Radiation Oncology, Amsterdam University
Medical Centers, Locatie Vrije Universiteit/Cancer Center
Amsterdam, Amsterdam, The Netherlands
e-mail: p.sminia@amsterdamumc.nl
O. Guipaud · A. François · M. Geiger · F. Milliat · A. Sémont
Radiobiology of Medical Exposure Laboratory, Institute for
Radiological Protection and Nuclear Safety,
Fontenay-aux-Roses, France
e-mail: olivier.guipaud@irsn.fr; agnes.francois@irsn.fr; Mallia.
geiger@irsn.fr; fabien.milliat@irsn.fr; Alexandra.semont@irsn.fr
K. Viktorsson
Department of Oncology/Pathology, Karolinska Institutet,
Stockholm, Sweden
e-mail: Kristina.viktorsson@ki.se
V. Ahire
Chengdu Anticancer Bioscience, Ltd., Chengdu, China
J. Michael Bishop Institute of Cancer Research,
Chengdu, China
S. Baatout
Institute of Nuclear Medical Applications, Belgian Nuclear
Reseach Center (SCK CEN), Mol, Belgium
e-mail: sarah.baatout@sckcen.be
T. Boterberg
Department of Radiation Oncology, Ghent University Hospital,
Ghent, Belgium
Particle Therapy Interuniversity Center Leuven, Department of
Radiation Oncology, University Hospitals Leuven, Leuven,
Belgium
e-mail: Tom.Boterberg@ugent.be
J. Cizkova · A. Filipova · A. Tichy
Department of Radiobiology, Faculty of Military Health Sciences,
University of Defence, Hradec Králové, Czech Republic
e-mail: jana.cizkova@unob.cz; alzbeta.filipova@unob.cz; ales.
tichy@unob.cz
M. Dostál
Department of Radiology and Nuclear Medicine, Faculty of
Medicine, Masaryk University and University Hospital Brno,
Brno, Czech Republic
Department of Biophysics, Faculty of Medicine, Masaryk
University, Brno, Czech Republic
e-mail: dostal.marek@fnbrno.cz
C. Fernandez-Palomo
Institute of Anatomy, University of Bern, Bern, Switzerland
e-mail: cristian.fernandez@unibe.ch
A. Hunter
Radiobiology Section, Department of Radiation Oncology,
University of Cape Town and Groote Schuur Hospital,
Cape Town, South Africa
e-mail: Alistair.Hunter@uct.ac.za
H. Jassim
Radiotherapy Department, General Najaf Hospital,
Kufa, Najaf, Iraq
Department of Medical Physics, University Al-Hilla College,
Babylon, Iraq
N. F. J. Edin
Department of Physics, University of Oslo, Oslo, Norway
e-mail: nina@fys.uio.no
K. Jordan · A. D. Meade
School of Physics and Clinical and Optometric Sciences, Faculty
of Science, Technological University Dublin, Dublin, Ireland
e-mail: k.jordan@svph.ie; aidan.meade@tudublin.ie
I. Koniarová
Department of Radiation Protection in Radiotherapy, National
Radiation Protection Institute, Prague, Czech Republic
e-mail: irena.koniarova@suro.cz
V. K. Selvaraj
Department of Radiation Oncology, Thanjavur Medical College,
Thanjavur, India
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_5
238
A. Montoro
Radiological Protection Service, La Fe University Hospital,
Valencia, Spain
e-mail: montoro_ale@gva.es
C. Politis
Department of Oral and Maxillofacial Surgery, University
Hospitals Leuven, Leuven, Belgium
Department of Imaging and Pathology, OMFS IMPATH Research
Group, Faculty of Medicine, KU Leuven, Leuven, Belgium
e-mail: Constantinus.Politis@uzleuven.be
D. Savu
Department of Life and Environmental Physics, Horia Hulubei
National Institute of Physics and Nuclear Engineering,
Magurele, Romania
e-mail: dsavu@nipne.ro
Learning Objectives
•	To understand that tumor targeting includes a pro­
portion of healthy tissues.
•	To recognize that the radiobiology of tumors and
healthy tissues is different.
•	To acknowledge that healthy tissues limit the pos­
sibilities of tumor control and are responsible for
radiotherapy-associated toxicity.
•	To be able to recognize and make estimates about
tumor growth as well as tumor control, both impor­
tant factors for determining the response to
radiotherapy.
•	To obtain knowledge about biological factors which
determine the outcome of radiotherapy in cancer
treatment.
•	To familiarize with the principles of dose fraction­
ation and how different tissues respond to changes
in fraction sizes, number of fractions and
frequency.
•	To learn about the radiobiological effects of the
dose rate and its clinical application.
•	To understand tumor hypoxia, its methods of evalu­
ation, oxygen effect, and oxygen enhancement ratio
(OER) as well as to familiarize with different thera­
peutic approaches to tumor hypoxia.
•	To understand the role of different factors in tumor
radiation resistance and progression including those
coming from the tumor microenvironment and as a
result of cells with a stem cell phenotype.
•	To be able to define the role of the human microbi-
ota in healthy or pathologic gut and to use radio-
therapy effects as an example for the microbiota
implication in disease.
•	To acknowledge the goals of palliative radiotherapy
in contrast to radical radiotherapy; become aware of
the applications of palliative radiotherapy and
potential biological targets.
•	To become aware of the abscopal effect; the type of
biological damage caused by ionizing radiation
leading to abscopal effects; the main biological
damages caused by radiation that are recognized by
the immune system; how irradiated tumors can
show an immune response; how systemic anti-­
tumor immune responses occur.
•	To be able to define and describe the acute/early
adverse effects as well as late adverse effects of
radiotherapy.
•	To recognize that if tissues are part of a heavily irra-
diated volume, late toxicity will occur.
•	To explain Normal Tissue Complication Probability
(NTCP) and the advantages and drawbacks of using
radiobiology modeling for NTCP as well as to give
an overview of different NTCP models.
V. Válek
Department of Radiology and Nuclear Medicine, Faculty of
Medicine, Masaryk University and University Hospital Brno,
Brno, Czech Republic
e-mail: valek.vlastimil@fnbrno.cz
G. Vogin
Centre Francois Baclesse, University of Luxembourg and
Luxembourg Institute of Health,  Luxembourg, Luxembourg
e-mail: guillaume.vogin@baclesse.lu
P. Sminia et al.
239
5.1"
"Explain the concept of dose fractionation in radiation therapy and how it relates to DNA repair mechanisms within both tumor cells and healthy tissues, as described in the text.","Dose fractionation is a cornerstone of modern radiation therapy for cancer treatment. It involves delivering the total therapeutic dose over multiple smaller sessions (fractions) rather than a single large dose. This approach leverages differences in cellular response to radiation. Tumor cells, which typically have less efficient DNA repair mechanisms compared to healthy cells, are more susceptible to damage from these lower-dose fractions. The time lapse between each fraction allows for the majority of DNA damage repairs within rapidly proliferating healthy tissues like the intestinal mucosa or hematopoietic system, minimizing their exposure to harmful radiation. However, tumor cells fail to effectively repair this accumulated DNA damage, leading to cell death when they subsequently re-enter the cell cycle. This differential sensitivity is crucial for maximizing tumor control while attempting to spare surrounding normal tissue from significant damage. Reference: [MolecularRadiationBiology, Section 5.1 – Principles of Tumor Radiotherapy]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.1		 Principles of Tumor Radiotherapy | Content: Radiation therapy (RT) is a locoregional treatment modality
for cancer. Using radiation for therapeutic purposes began
only a few months after the discovery of X-rays by Wilhelm
Röntgen in 1895. The first “true” RT succeeded in managing
a case of lupus erythematosus in 1897 by Eduard Schiff
(1899). More than 120 years later, RT is still one of the cor­
nerstones of tumor treatment, with more than half of all can­
cer patients treated by radiation in the course of their
therapeutic management [1] (Box 5.1).
­
2
­
5.1
Some biological processes favor the benefit/risk ratio in
RT and the differential effect between tumor and healthy
cells. Except for some very radiosensitive or radioresistant
tumors, healthy and tumor cells demonstrate quite similar
radiation sensitivities. However, DNA damage is less effi­
ciently repaired by tumors than by healthy cells. This is the
basis for the dose fractionation principle, demonstrated by
Claudius Regaud and applied in the clinic by Henri Coutard
in 1934, and which still is used today in modern RT. The total
dose necessary to control the tumor is generally delivered in
a series of small daily doses. The time lapse between each
fraction allows DNA damage to be repaired by healthy cells
whereas tumor cells do not repair or do so to a lesser extent.
The biological effectiveness (the chances of tumor control
but also the risk of damage to normal tissues) is reduced
when using fractionated doses due to DNA repair and cell
repopulation in both tumors and healthy tissues [3].
Box 5.1 Radiation Therapy in Cancer Treatment
•	RT is one of the cornerstones in cancer treatment.
•	The objective of RT resides in finding an optimal
balance between chances of cure and risk of associ­
ated toxicity.
•	Differential effect of RT between tumors and nor­
mal tissues depends on multiple factors related to
both malignant and healthy tissue radiobiology, but
also on beam characteristics and treatment
schedule.
•	Technical advances and sophistication of RT
devices improve ballistic accuracy and allows
unprecedented changes in treatment schedules,
probably changing both malignant and healthy tis­
sue radiobiology.
5 Clinical Radiobiology for Radiation Oncology
240
Numerous parameters associated with fractionation regi­
mens, such as the total dose, the dose per fraction, and the
time between fractions and the total treatment time, will
influence both tumor response and normal tissue damage and
will be described in more detail below [4]. Another biologi­
cal factor participating in the differential effect is radiation-­
induced cell death. In a majority of cases, the initial radiation
exposure is not what kills cells but rather unrepaired DNA
damage, which condemns them to death as soon as they re-­
enter in the cell cycle. Rapidly proliferating tumor tissues
will suffer significant cell death under these conditions com­
pared to slowly proliferating healthy tissues. However, some
healthy tissues such as oral and intestinal mucosa or hemato­
poietic cells proliferate rapidly and may be susceptible to
early mitotic cell deaths if present in the irradiated volume.
Finally, tumor control will also depend on other factors such
as tumor heterogeneity (the tumor cannot be simply consid­
ered as a cluster of tumor cells), oxygenation status before
RT and variations during treatment, tumor vascularization,
resident and recruited immune cells, and so forth. Considering
all these biological factors, the objective of treatment plan­
ning in RT is to find the best compromise between chances of
cure and risk of associated toxicity [5].
In an ideal world, RT may target only the tumor volume;
however, in real life, this is never the case. For healthy tis­
sues, besides dose and fractionation, the volume exposed is
of paramount importance in determining the risk of develop­
ing toxicity. Technical advances in dose delivery, planning
systems and associated imaging devices have helped to
achieve ever increasing ballistic accuracy. Advanced tech­
nologies, such as volumetric modulated arc therapy (VMAT),
image-guided radiotherapy (IGRT), stereotactic body radio­
therapy (SBRT), heavy ions [6], or proton therapy have all
contributed to progress [7]. Consequently, the use of highly
focused beams reduces the volume of normal tissues present
within the irradiated volume and can spare very sensitive
organs, thus minimizing the risk of toxicity. Reducing the
volume also permits changes in fractionation schedules. For
example, SBRT uses hypofractionation, delivering ablative
doses per fraction between 8 and 20 Gy instead of the con­
ventional 2 Gy/fraction. The gain in biological effectiveness
strongly increases tumor control as illustrated in early-stage
primary lung cancer. These changes in fractionation schemes
may also induce a “new” radiobiology of tumors and healthy
tissues in response to very high doses of IR, an area that
remains to be explored [8]. Finally, ultra-high dose rate
FLASH RT demonstrates a very sharp differential effect
between tumor and healthy tissues and is the subject of
intense research for future clinical applications [9].
Technical advances have strongly contributed to the
chances of cure for numerous cancers and increased patients’
survival. This increased life expectancy following cancer
treatment, however, favors the emergence of side effects,
especially long-term sequelae. Normal tissues can be divided
into “early” and “late” responding tissues. Early-responding
tissues (intestinal mucosa, hematopoietic system, skin,
gonads) are characterized by the presence of cell prolifera­
tion compartments and are mostly implicated in acute
radiation-­induced toxicity. Late-responding tissues demon­
strate no distinct cell proliferation compartment and are
mostly implicated in late toxicity. For each normal tissue,
dose constraints, which vary depending on the RT technique
used, may be applied. These constraints help to minimize the
risk of developing severe treatment-associated toxicity [10].
RT still plays a significant role in cancer cures. Its effi­
ciency depends on numerous parameters related to both
tumor and normal tissue radiobiology. The objective of can­
cer therapy, using modern RT often concurrently with other
therapeutic strategies (surgery, chemotherapy, immunother­
apy, etc.) is for the patients to survive without debilitating
sequelae. This goal may be achieved using technological
advances in RT, combined with strategic knowledge of both
tumor and healthy tissue radiobiology.
5.2
Therapeutic Window and Therapeutic
Ratio (Box 5.2)
5.2.1
The Therapeutic Window
­
­
­
5.13.6
11
­"
"Describe the distinctions between ‘early’ and ‘late’ responding tissues following radiation exposure, focusing on their cellular characteristics and associated toxicities.","Following radiation exposure, normal tissues are categorized into ‘early’ and ‘late’ responding types based primarily on their ability to repair DNA damage and subsequent manifestation of toxicity. ‘Early’ responding tissues, such as the intestinal mucosa, hematopoietic system, skin, and gonads, exhibit distinct cellular characteristics that lead to heightened sensitivity during the acute phase of radiation-induced injury. These tissues are characterized by the presence of active cell proliferation compartments – areas where cells rapidly divide and replicate. This rapid division makes them particularly vulnerable to DNA damage caused by ionizing radiation because damaged DNA is immediately replicated, amplifying the initial lesion. Consequently, ‘early’ responding tissues predominantly manifest as acute radiation toxicity, including symptoms like mucositis (inflammation of the intestinal lining), myelosuppression (suppressed bone marrow function leading to reduced blood cell production), skin erythema and ulceration, and gonadal dysfunction. The rapid proliferation also means that any DNA damage is quickly replicated, exacerbating the initial injury.
Conversely, ‘late’ responding tissues, including organs like the liver, kidneys, and lungs, lack these distinct cell proliferation compartments. This absence of active replication makes them less susceptible to acute radiation toxicity. Instead, ‘late’ responding tissues primarily exhibit delayed or chronic effects following radiation exposure. These late toxicities often manifest years after treatment completion and can include conditions such as fibrosis (scarring), cirrhosis, nephrogenic systemic fibrosis (NSF), and pulmonary fibrosis. The lack of active cell division means that DNA damage accumulates over time without immediate repair mechanisms to address it, leading to a gradual accumulation of cellular dysfunction and ultimately chronic disease development. Dose constraints are applied differently for these tissues based on their response characteristics.
","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.2		 Therapeutic Window and Therapeutic Ratio (Box 5.2) | Content: Technical advances have strongly contributed to the
chances of cure for numerous cancers and increased patients’
survival. This increased life expectancy following cancer
treatment, however, favors the emergence of side effects,
especially long-term sequelae. Normal tissues can be divided
into “early” and “late” responding tissues. Early-responding
tissues (intestinal mucosa, hematopoietic system, skin,
gonads) are characterized by the presence of cell prolifera­
tion compartments and are mostly implicated in acute
radiation-­induced toxicity. Late-responding tissues demon­
strate no distinct cell proliferation compartment and are
mostly implicated in late toxicity. For each normal tissue,
dose constraints, which vary depending on the RT technique
used, may be applied. These constraints help to minimize the
risk of developing severe treatment-associated toxicity [10].
RT still plays a significant role in cancer cures. Its effi­
ciency depends on numerous parameters related to both
tumor and normal tissue radiobiology. The objective of can­
cer therapy, using modern RT often concurrently with other
therapeutic strategies (surgery, chemotherapy, immunother­
apy, etc.) is for the patients to survive without debilitating
sequelae. This goal may be achieved using technological
advances in RT, combined with strategic knowledge of both
tumor and healthy tissue radiobiology.
5.2"
"Describe the distinctions between ‘early’ and ‘late’ responding normal tissues following radiation therapy, as presented in the text, and explain why these differences are clinically relevant.","Following radiation therapy, normal tissues exhibit varying degrees of response to the treatment, categorized primarily into ‘early’ and ‘late’ responding types. Early-responding tissues, such as the intestinal mucosa, hematopoietic system, skin, and gonads, demonstrate a prominent feature: the presence of cell proliferation compartments. These compartments are areas where cells actively divide in response to radiation damage. This rapid proliferation is largely responsible for the acute, radiation-induced toxicity observed in these tissues – manifesting as symptoms like diarrhea, mucositis, immunosuppression, skin reactions, and gonadal dysfunction. Because of this heightened proliferative activity, these tissues are particularly vulnerable to the damaging effects of ionizing radiation. Conversely, late-responding tissues—including organs such as the liver, kidneys, and bone marrow—lack distinct cell proliferation compartments. Consequently, they exhibit a delayed response to radiation exposure; damage accumulates over time without significant immediate repair through rapid cell division. This delayed toxicity is often characterized by chronic conditions like fibrosis or organ dysfunction. Clinically, these distinctions are crucial for establishing dose constraints during radiation therapy. Because early-responding tissues are highly sensitive and rapidly regenerate, they receive stricter dose limits compared to late-responding tissues, aiming to minimize acute toxicities while still effectively targeting the tumor. The varying response patterns dictate the need for individualized treatment plans considering both the tumor’s radiobiology and the patient's tissue vulnerabilities.

Reference: MolecularRadiationBiology, Section 5.2.1 – The Therapeutic Window","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.2		 Therapeutic Window and Therapeutic Ratio (Box 5.2) | Sub-subsection: 5.2.1		 The Therapeutic Window | Content: Technical advances have strongly contributed to the
chances of cure for numerous cancers and increased patients’
survival. This increased life expectancy following cancer
treatment, however, favors the emergence of side effects,
especially long-term sequelae. Normal tissues can be divided
into “early” and “late” responding tissues. Early-responding
tissues (intestinal mucosa, hematopoietic system, skin,
gonads) are characterized by the presence of cell prolifera­
tion compartments and are mostly implicated in acute
radiation-­induced toxicity. Late-responding tissues demon­
strate no distinct cell proliferation compartment and are
mostly implicated in late toxicity. For each normal tissue,
dose constraints, which vary depending on the RT technique
used, may be applied. These constraints help to minimize the
risk of developing severe treatment-associated toxicity [10].
RT still plays a significant role in cancer cures. Its effi­
ciency depends on numerous parameters related to both
tumor and normal tissue radiobiology. The objective of can­
cer therapy, using modern RT often concurrently with other
therapeutic strategies (surgery, chemotherapy, immunother­
apy, etc.) is for the patients to survive without debilitating
sequelae. This goal may be achieved using technological
advances in RT, combined with strategic knowledge of both
tumor and healthy tissue radiobiology.
5.2
Therapeutic Window and Therapeutic
Ratio (Box 5.2)
5.2.1
The Therapeutic Window
­
­
­
5.13.6
11
­"
"Explain the concept of the therapeutic ratio in radiation oncology treatment planning, detailing its significance and how it relates to both tumor control and normal tissue toxicity.","The therapeutic ratio is a critical metric used in radiation oncology treatment planning to balance the effectiveness of radiation therapy against potential side effects. It’s defined as the ratio of the Tumor Control Probability (TCP) – representing the probability of complete tumor eradication – to the Normal Tissue Control Probability (NTCP) – representing the probability of damage to surrounding healthy tissues. Essentially, it quantifies the efficacy/toxicity ratio of a treatment plan. A higher therapeutic ratio indicates a greater chance of achieving a cure with minimal harm to normal tissues. The ratio is calculated by comparing the curves of TCP and NTCP at a specific endpoint for NTCP; this represents the delivered dose aimed at tumor control without causing significant damage to surrounding healthy tissue. Importantly, the therapeutic ratio differentiates between early-responding and late-responding normal tissues: early responding tissues typically have a therapeutic ratio less than 1 (indicating greater sensitivity to radiation), while late responding tissues exhibit a ratio greater than 1, reflecting their ability to tolerate higher doses of radiation without significant damage. Optimizing the therapeutic ratio is therefore achieved through strategies like combination therapy with radiosensitizing agents or immune-modulating drugs that selectively target tumor cells, considering factors such as the ‘6R’s’ or Hallmarks of Radiobiology.  Ultimately, a well-defined therapeutic ratio aims to maximize tumor control while minimizing complications and improving patient quality of life.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.2		 Therapeutic Window and Therapeutic Ratio (Box 5.2) | Sub-subsection: 5.2.2	 The Therapeutic Ratio | Content: with a radiosensitizing agent or drug. This effect is revealed in
practice as increasing tumor cure rate with improved quality of
life as a result of a therapeutic gain [13, 16]. In this circum­
stance, the therapeutic ratio is the ratio of dose-modifying fac­
tors (DMFs) of tumor over that for normal tissues.
Finally, the therapeutic ratio differentiates between early
and late responding normal tissues in terms of their response
to concomitant RT and chemotherapeutics or targeted agents.
While the therapeutic ratio of early responding tissue is usu­
ally <1, the therapeutic ratio of late responding tissues is >1
which reflects the advantageous consequence of concomitant
RT and chemotherapy. This may lead to a high level of early
injury, but a neutral level of late damage to late responding
tissues. Fortunately, early side effects can be relieved by
using either extensive supportive care or adaptation of the
Several methods can be used to widen the therapeutic
window, to increase the probability of complication-free
tumor control:
––
5.4
­
­
––Combination therapy with molecular targeting or
immune-modulating drugs. Optimally, drugs should be
carefully chosen to selectively sensitize tumor and not
normal tissue cells, taking the 6R’s or Hallmarks of
Radiobiology into account (see Sect. 5.4).
5.2.2
The Therapeutic Ratio
The therapeutic ratio or therapeutic index is an imperative
measure used in the treatment planning to ensure that the RT
course achieves its goals [18]. The ratio represents the
­difference between the TCP and NTCP curves for the same
delivered dose at a fixed endpoint of NTCP [14]. Therefore, it
represents the quantity used in the tumor treatment planning
for the purpose of disease cure without complications. The
ratio is defined as the relationship between TCP and NTCP,
i.e., efficacy/toxicity ratio. Chang et al. stated that a common
method used to calculate the therapeutic ratio which is the
probability of cure without complications [19] and given by:
P. Sminia et al.
243
standard treatment. The combination of RT and chemother­
apy may prove effective if selective radiosensitization of
malignancy is obtained and the probability of late-­responding
normal tissue damage is not increased. However, early tox­
icities might also be a concern.
5.3"
"Describe the process of tumor growth, including key factors influencing cell proliferation, apoptosis, and angiogenesis within a cancerous environment, referencing relevant cellular mechanisms.","Tumor growth is a complex, multi-stage process driven by uncontrolled cell division and influenced by intricate interactions within the surrounding microenvironment. Initially, a small number of cells undergo genetic mutations that disrupt normal regulatory pathways governing cell cycle progression. These mutations often affect key proteins involved in cell signaling – notably those within the RAS/MAPK or PI3K/AKT pathways – leading to increased rates of DNA replication and cellular proliferation. This uncontrolled growth is coupled with a suppression of apoptosis, preventing the elimination of damaged or abnormal cells. Furthermore, tumor development necessitates angiogenesis, the formation of new blood vessels, to supply the rapidly dividing cells with oxygen and nutrients. Vascular endothelial growth factor (VEGF) plays a crucial role in stimulating this process by signaling through receptors on endothelial cells, promoting their migration and proliferation. The tumor microenvironment itself significantly impacts these processes; stromal fibroblasts secrete factors like cytokines and growth factors that further stimulate cell division and angiogenesis. Additionally, immune suppression within the tumor microenvironment – often mediated by myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) – hinders anti-tumor immunity, allowing for continued proliferation. Finally, tumor cells frequently exhibit altered metabolism, shifting towards aerobic glycolysis (the Warburg effect), which provides a rapid energy supply despite limited oxygen availability, fueling their growth. The balance between these factors—proliferation, apoptosis, angiogenesis, and immune response—determines the rate and extent of tumor expansion.

Reference: Clinical Radiobiology for Radiation Oncology, 5.3 Tumor Growth and Tumor Control.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.3	 Tumor Growth and Tumor Control (Box 5.3) | Content: (Box 5.3)
5.3.1"
"Describe the concept of ‘tumor control’ in radiation oncology, focusing on the interplay between tumor cell death mechanisms and the surrounding microenvironment following irradiation.","Tumor control within radiation oncology refers to the process by which radiation therapy effectively eliminates or significantly reduces the growth of cancerous tumors while minimizing damage to healthy tissues. This isn't solely reliant on direct DNA damage induced by ionizing radiation; rather, it’s a complex interaction involving multiple tumor cell death mechanisms and the response of the surrounding microenvironment. Initially, radiation primarily induces direct DNA damage through the creation of single-strand and double-strand breaks in genomic material. These lesions trigger cellular repair pathways – such as nucleotide excision repair (NER) and homologous recombination – which can sometimes effectively repair the damage and allow for cell survival. However, if the damage is too extensive or repair mechanisms are overwhelmed, cells undergo apoptosis (programmed cell death), a process characterized by caspase activation and DNA fragmentation. 

Beyond direct cell death, radiation also stimulates other pathways contributing to tumor control. Necrosis, a form of uncontrolled cell death resulting from severe cellular injury, can occur particularly in hypoxic regions within the tumor – a common characteristic of solid tumors. Hypoxia exacerbates radiation sensitivity as it impairs DNA repair and promotes oxidative stress. Furthermore, radiation triggers inflammatory responses within the tumor microenvironment, recruiting immune cells like macrophages and neutrophils to the site. These immune cells contribute to tumor control by directly killing cancer cells and also by releasing cytokines that further stimulate anti-tumor immunity. The degree of tumor control is therefore influenced by factors such as radiation dose, fractionation (the number and size of daily doses), target volume, and the specific characteristics of the tumor microenvironment – including its oxygenation level, immune cell composition, and vascularity.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.3	 Tumor Growth and Tumor Control (Box 5.3) | Sub-subsection: 5.3.1	 Tumor Control | Content: (Box 5.3)
5.3.1
Tumor Control
16
5.5
20
­
­
9
­
­
5.6
5.3.2"
"What is the tumor doubling time (VDT), and how does it relate to the growth rate of a tumor, particularly in relation to radiation therapy?","The tumor doubling time (VDT) represents the duration required for a tumor volume to double.  In smaller tumors, VDTs are typically longer (e.g., 632 days for colon-rectum primary tumors) due to sufficient nutrient and oxygen supply, leading to reduced cell cycle lengths, increased cycling cells, and lower cell death rates. This results in an exponential growth curve. Conversely, larger tumors exhibit shorter VDTs (e.g., 95 days for colon-rectum metastatic tumors) because of limited nutrient and oxygen availability, causing prolonged cell cycles and a higher rate of cell death, manifesting as a non-exponential growth curve.  Therefore, the VDT is a key indicator of tumor growth potential and is used in conjunction with dose and tumor characteristics to estimate tumor control probability (TCP) during radiation therapy [20, 21]. Reference: [5.3.2 Tumor Growth]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.3	 Tumor Growth and Tumor Control (Box 5.3) | Sub-subsection: 5.3.2	 Tumor Growth | Content: (Box 5.3)
5.3.1
Tumor Control
16
5.5
20
­
­
9
­
­
5.6
5.3.2
Tumor Growth
The tumor growth rate can be used to determine how a can­
cer will respond to RT treatment by predicting or under­
standing the key features of the tumor tissue response to
radiation. The tumor growth rate was developed for
­examining the capacity of clonogenic-forming cells of a
tumor and assumes that the regrowth component is a func­
tion of repopulation by the surviving of cells with colony-
forming ability [20, 21].
There are considerable differences in growth rate between
different tumors due to differences in size and biology.
Therefore, the tumor growth curve has exponential and non-­
Box 5.3 Tumor Response Following Radiotherapy
•	Tumor control probability (TCP) is guided by dose,
tumor characteristics, and normal tissue radiation
sensitivity.
•	Killing of clonogenic cells within a tumor partly
explain TCP during RT, but the effect is also influ­
enced by host factors, for example, immune cell
attack.
5 Clinical Radiobiology for Radiation Oncology
244
Table 5.1 Volume Doubling Times (VDTs) for different human
tumors (adapted from [16])
Tumor site,
histology
Primary vs
metastasis
Number of
tumors
measured
Mean VDT
(days)
(confidence
limits)
Colon-rectum
Primary
19
632
[426–938]
Colon-rectum,
adenocarcinoma
Metastasis
55
95
[84–107]
Lung, squamous cell
carcinoma
Primary
85
85
[75–95]
Lung,
adenocarcinoma
Primary
64
148
[121–181]
Lung,
undifferentiated
Primary
55
79
[67–93]
Breast
Primary
17
96
[68–134]
Breast carcinoma
Superficial
metastasis
66
19
[16–24]
Breast,
adenocarcinoma
Metastasis
44
74
[56–98]
Head and neck,
squamous cell
carcinoma
Metastasis
27
57
[43–75]
Head and neck,
teratoma
Metastasis
80
30
[24–38]
Head and neck,
osteosarcoma
Metastasis
34
65
[46–93]
Head and neck,
fibrosarcoma
Metastasis
28
69.5
[46–93]
Kidney,
adenocarcinoma
Metastasis
14
60
[37–98]
Thyroid,
adenocarcinoma
Metastasis
16
67
[44–103]
Uterus,
adenocarcinoma
Metastasis
15
78
[55–111]
10
exponential parts when plotted on a logarithmic scale. That
is, the tumor volume doubling time (VDT), the duration of
time required for the tumor to double in size, increases for
small tumors because there is a sufficiency in nutrient and
oxygen supply resulting in a reduction of cell cycle, a higher
proportion of cycling cells or and a lower cell death rate. As
a result, the slope of the growth curve, which reflects the
doubling time of the cells, has an exponential pattern for
small tumors. Conversely, VDT decreases for large tumors
because of the limitation of nutrient and oxygen supply. This
leads to a prolongation of cell-cycle progression but also a
high rate of cell death. As a result, the slope of the growth
curve has no exponential patterns for large tumors. The
Gompertz equation describes such progressively slowing
tumor growth:
(5.1)
0
16
5.1
­"
"Describe the concept of tumor growth fraction (GF) and how it relates to cell cycle kinetics, specifically addressing factors that might influence its measurement.","The tumor growth fraction (GF) represents the proportion of cycling cells within a tumor population actively involved in DNA duplication and cell division. It’s defined as the percentage of cells in the S-phase of the cell cycle – those capable of replicating their DNA [22]. However, accurately determining GF is complex due to variations within tumors.  Traditionally, GF estimation relies on methods like labeling cells with BrdUrd or IdUrd followed by flow cytometry to assess the duration of the S phase and the fraction of cells in that phase. Another approach involves measuring the duration of the cell cycle using 3H-thymidine, allowing for quantification of DNA synthesis. More recently, positron emission tomography (PET) imaging utilizing radiolabeled FLT has been employed to monitor tumor proliferation *in vivo* by tracking metabolites reflecting S-phase activity.  The GF is also often assessed through immunohistochemistry using Ki-67 staining, which measures the proportion of cells expressing this marker – a key indicator of proliferation. Importantly, factors like hypoxia, differentiation, and catabolic insufficiency can affect cell cycle progression and therefore skew GF measurements. For instance, in hypoxic environments, tumor cells may enter quiescence (G0 phase), reducing the apparent GF. Furthermore, the presence of stromal components within the tumor also contributes to this non-neoplastic cell population, which further complicates accurate GF determination.  The method used can significantly impact the reported GF value depending on whether it’s a *in vitro* or *in vivo* measurement and the specific techniques employed [13, 21].","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.3	 Tumor Growth and Tumor Control (Box 5.3) | Sub-subsection: 5.3.2	 Tumor Growth | Sub-sub-subsection: 5.3.2.1		 Cell-Cycle Kinetics and Growth Fraction in Tumors | Content: metastasis
66
19
[16–24]
Breast,
adenocarcinoma
Metastasis
44
74
[56–98]
Head and neck,
squamous cell
carcinoma
Metastasis
27
57
[43–75]
Head and neck,
teratoma
Metastasis
80
30
[24–38]
Head and neck,
osteosarcoma
Metastasis
34
65
[46–93]
Head and neck,
fibrosarcoma
Metastasis
28
69.5
[46–93]
Kidney,
adenocarcinoma
Metastasis
14
60
[37–98]
Thyroid,
adenocarcinoma
Metastasis
16
67
[44–103]
Uterus,
adenocarcinoma
Metastasis
15
78
[55–111]
10
exponential parts when plotted on a logarithmic scale. That
is, the tumor volume doubling time (VDT), the duration of
time required for the tumor to double in size, increases for
small tumors because there is a sufficiency in nutrient and
oxygen supply resulting in a reduction of cell cycle, a higher
proportion of cycling cells or and a lower cell death rate. As
a result, the slope of the growth curve, which reflects the
doubling time of the cells, has an exponential pattern for
small tumors. Conversely, VDT decreases for large tumors
because of the limitation of nutrient and oxygen supply. This
leads to a prolongation of cell-cycle progression but also a
high rate of cell death. As a result, the slope of the growth
curve has no exponential patterns for large tumors. The
Gompertz equation describes such progressively slowing
tumor growth:
(5.1)
0
16
5.1
­
5.3.2.1		Cell-Cycle Kinetics and Growth Fraction
in Tumors
The growth fraction (GF) refers to the proportion of cycling
cells that has highly colony-forming ability and is in the
active process of cell cycling (omitting cells in G0 phase),
with capacity of DNA duplication and cell division [22].
P. Sminia et al.
245
Similarly, as in normal tissue, some tumor cells are not
involved in active proliferation for different reasons, for
instance as a result of hypoxia, differentiation, and catabolic
insufficiency. Moreover, it is estimated that about 50% of
cells in a tumor are not neoplastic cells but are cells making
up the tumor stroma. Therefore, it is clear that the cell popu­
lation in tumors contains quiescent (Q) cells, and since GF is
defined as the proportion of cycling cells, it can be calculated
as stated by [13, 22]:
(5.2)
where p is proliferating cells.
For estimation of the cell-cycle kinetics (TC), three princi­
pal methods are used: (1) bromodeoxyuridine (BrdUrd) or
thymidine
analogues
iododeoxyuridine
(IdUrd),
(2)
3H-thymidine for the synthesis of DNA and (3) positron
emission tomography (PET) imaging of the tumors in vivo
by radiolabeled
18F-fluoro-3′-deoxy-3′-l-fluorothymidine
(FLT) [13, 16].
The first method includes labeling of the cells with
BrdUrd or IdUrd. When cells pass through the S-phase, these
labels are incorporated into the newly created DNA strand.
An antibody against BrdUrd or IdUrd as well as a DNA-­
specific dye are used to stain a single-cell suspension pre­
pared from a cell culture in vitro or a tumor biopsy, and the
duration of the S phase (TS) and fraction of cells in S phase
are assessed using flow cytometry.
In the second method, cell-cycle kinetics (TC) is estimated
from labeled cells by measuring the duration of the cell cycle
by either pulse or continuous labeling with 3H-thymidine.
The labeling agent is incorporated into the DNA as cells
progress through S-phase and the cell-cycle kinetics (TC) is
estimated from the labeled cells [16].
The third principal method applies PET tracers to
detect and evaluate tumor proliferation in vivo. In this
method,
radiolabeled
18F-fluoro-3′-deoxy-3′-l-
fluorothymidine (FLT) is used. FLT is phosphorylated by
thymidine kinases (TK) and since regulation of TK activ­
ity occurs in the S-phase, it means that metabolites of FLT
(mono-, di-, and tri-­phosphates) are reflecting the number
of cells in S-phase and hence replication status. The FLT
tracer activity in a tumor is subsequently evaluated by a
PET scanner from which the cell-cycle kinetics can be
estimated [16].
For estimation of the GF, according to literature the GF
is obtained by assessment of two distinct cell subpopula­
tions, one that does not grow and another which grows with
a uniform cell-cycle distribution [13, 21]. This method
includes the exposure of a growing culture of cells with
3H-thymidine for the synthesis of DNA, and then after the
period of at least one complete cell cycle to ensure all cells
producing DNA pass through the S-phase and are labeled,
an autoradiography of tumor section is taken, and GF is
calculated by:
[
BB:345.732;654.941;477.73
2;678.941]
There is also a possibility to take proliferation into
account by immunohistochemistry assessment of tumor
tissue sections by staining of the nuclear antigen Ki-67,
which in tumors has different levels depending on the
tumor ­proliferation. The method includes staining of tumor
cell cultures or a tumor biopsy with a Ki-67 specific anti­
body followed by counting the number of positive tumor
cells. The GF growth fraction is estimated from labeled
cells by measuring the proportion of proliferating cells
using continuous labeling. Although the method is fre­
quently used to assess S-phase cells, recent results have
indicated that Ki-67 also has different functions in other
cell-cycle phases which may in fact influence proliferation
estimations [23]."
"Describe the methods used to estimate the growth fraction (GF) of a tumor and explain how Ki-67 immunohistochemistry contributes to this estimation, including any caveats regarding its application.","The growth fraction (GF) represents the proportion of cells within a tumor population that are actively dividing. Several methods exist for estimating GF, primarily relying on assessing cell proliferation rates. One common approach involves labeling cells with 3H-thymidine to measure DNA synthesis, indicating active S-phase division. After allowing at least one complete cell cycle to ensure all S-phase cells are labeled via autoradiography, the GF is calculated from the proportion of labeled cells. This method distinguishes between a population that doesn't grow and one exhibiting uniform cell-cycle distribution. Alternatively, immunohistochemistry using Ki-67 can be employed. This technique involves staining tumor tissue sections with a Ki-67 specific antibody to quantify the number of positive tumor cells – those expressing Ki-67 are considered actively proliferating. The GF is then estimated by measuring the proportion of proliferating cells (LI) and the duration of the S phase (TS), often determined through flow cytometry, allowing for calculation of Tpot. However, it’s crucial to acknowledge that Ki-67 expression can vary across different cell cycle phases, potentially influencing proliferation estimations if not carefully considered. Recent research suggests Ki-67 may have functions beyond simply indicating S-phase cells, adding complexity to its interpretation and necessitating a correction parameter (λ) to account for the non-rectangular age distribution of growing cell populations.

Reference: [MolecularRadiationBiology, Section 5.3.2.2 – The Potential Doubling Time (Tpot)]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.3	 Tumor Growth and Tumor Control (Box 5.3) | Sub-subsection: 5.3.2	 Tumor Growth | Sub-sub-subsection: 5.3.2.2	 The Potential Doubling Time (Tpot) | Content: estimated [16].
For estimation of the GF, according to literature the GF
is obtained by assessment of two distinct cell subpopula­
tions, one that does not grow and another which grows with
a uniform cell-cycle distribution [13, 21]. This method
includes the exposure of a growing culture of cells with
3H-thymidine for the synthesis of DNA, and then after the
period of at least one complete cell cycle to ensure all cells
producing DNA pass through the S-phase and are labeled,
an autoradiography of tumor section is taken, and GF is
calculated by:
[
BB:345.732;654.941;477.73
2;678.941]
There is also a possibility to take proliferation into
account by immunohistochemistry assessment of tumor
tissue sections by staining of the nuclear antigen Ki-67,
which in tumors has different levels depending on the
tumor ­proliferation. The method includes staining of tumor
cell cultures or a tumor biopsy with a Ki-67 specific anti­
body followed by counting the number of positive tumor
cells. The GF growth fraction is estimated from labeled
cells by measuring the proportion of proliferating cells
using continuous labeling. Although the method is fre­
quently used to assess S-phase cells, recent results have
indicated that Ki-67 also has different functions in other
cell-cycle phases which may in fact influence proliferation
estimations [23].
5.3.2.2	The Potential Doubling Time (Tpot)
“The potential doubling time (Tpot) of a tumor is defined as
the cell doubling time without any cell loss.” There are
two methods used to estimate Tpot. In the first method,
DNA is labeled with thymidine analogues and then the
cells fraction in S phase (LI) and the duration of the S
phase (TS) are estimated by using flow cytometry to calcu­
late Tpot by:
[
BB:
3
39
.307;324.691;379.307;347.691]
(5.3)
where λ is a correction parameter for the non-rectangular age
distribution of growing cell populations, in the order of
0.7–1.
S
pot
5.2
pot
­
13"
"According to the provided text, what are two methods used to estimate the potential doubling time (Tpot) of a tumor, and which techniques involve measuring cell proliferation?","Two methods are described for estimating the potential doubling time (Tpot) of a tumor. The first method utilizes DNA labeling with thymidine analogues followed by flow cytometry to determine the proportion of cells in S phase (LI) and the duration of the S phase (TS). This allows calculation of Tpot using the formula: Tpot = (5.2 pot - 13) / 5.3 pot. The second method employs Ki-67 immunohistochemistry staining of tumor tissue sections to assess the number of positive cells, which directly estimates the growth fraction and subsequently contributes to Tpot estimation. This approach relies on measuring the proportion of proliferating cells using continuous labeling.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.3	 Tumor Growth and Tumor Control (Box 5.3) | Sub-subsection: 5.3.2	 Tumor Growth | Sub-sub-subsection: 5.3.2.3	 Cell Loss in Tumors | Content: estimated [16].
For estimation of the GF, according to literature the GF
is obtained by assessment of two distinct cell subpopula­
tions, one that does not grow and another which grows with
a uniform cell-cycle distribution [13, 21]. This method
includes the exposure of a growing culture of cells with
3H-thymidine for the synthesis of DNA, and then after the
period of at least one complete cell cycle to ensure all cells
producing DNA pass through the S-phase and are labeled,
an autoradiography of tumor section is taken, and GF is
calculated by:
[
BB:345.732;654.941;477.73
2;678.941]
There is also a possibility to take proliferation into
account by immunohistochemistry assessment of tumor
tissue sections by staining of the nuclear antigen Ki-67,
which in tumors has different levels depending on the
tumor ­proliferation. The method includes staining of tumor
cell cultures or a tumor biopsy with a Ki-67 specific anti­
body followed by counting the number of positive tumor
cells. The GF growth fraction is estimated from labeled
cells by measuring the proportion of proliferating cells
using continuous labeling. Although the method is fre­
quently used to assess S-phase cells, recent results have
indicated that Ki-67 also has different functions in other
cell-cycle phases which may in fact influence proliferation
estimations [23].
5.3.2.2	The Potential Doubling Time (Tpot)
“The potential doubling time (Tpot) of a tumor is defined as
the cell doubling time without any cell loss.” There are
two methods used to estimate Tpot. In the first method,
DNA is labeled with thymidine analogues and then the
cells fraction in S phase (LI) and the duration of the S
phase (TS) are estimated by using flow cytometry to calcu­
late Tpot by:
[
BB:
3
39
.307;324.691;379.307;347.691]
(5.3)
where λ is a correction parameter for the non-rectangular age
distribution of growing cell populations, in the order of
0.7–1.
S
pot
5.2
pot
­
13
5.3.2.3	Cell Loss in Tumors
Slow tumor growth is not only explained by the fact that not
all cells within a tumor are proliferating but also due to con­
siderable cell loss where multiple parameters regulate these
two factors. If there was no cell loss and if every tumor cell
was actively proliferating, the tumor doubling time would
imitate the cell-cycle kinetics (TC). Therefore, when there is
5 Clinical Radiobiology for Radiation Oncology
246
Table 5.2 Cell kinetic parameters of human tumors derived from in vivo labeling with iodo-deoxyuridine (IdUrd) or bromo-deoxyuridine
(BrdUrd) and monitored by flow cytometry (adapted from [16])
Tumor site
Tumor type
Patients number
Average Tpot (days)
Average LI (%)
Average TS (h)
Skin
Melanoma
24
7.2
4.2
10.7
Hematological
–
106
9.6
13.3
14.6
Head and neck region
–
712
4.5
9.6
11.9
CNS
–
193
34.3
2.6
10.1
Breast
–
159
10.4
3.7
10.4
GIT (upper intestine)
–
183
5.8
10.5
13.5
GIT (colorectal)
–
345
4
13.1
15.3
Kidney
Renal cell carcinoma
2
11.3
4.3
9.5
Bladder
–
19
17.1
2.5
6.2
Prostate
–
5
28
1.4
11.7
Ovarian
–
55
12.5
6.7
14.7
Cervix
–
159
4.8
9.8
12.8
cell loss the TD is long and when there is reduced GF the Tpot
of the tumor is longer than the time of cell cycle [14].
The net growth rate, or the VDT, of tumors results from
the balance of cell production and cell loss. In clinical set­
tings, the GF and knowledge of the cycle time of the indi­
vidual cells does not reflect the speed of tumor growth;
namely, the cycle time of the individual cells is much faster
than the speed of tumor growth. Such discrepancy is attrib­
uted to cell loss which can be considered by calculating cell
loss factor (CLF). The cell-loss factor refers the ratio of the
cell loss rate to the production of new cells, and it can be
calculated by:
(5.4)
where Tpot is the potential tumor doubling, and VDT is the
tumor volume doubling time that is calculated by the
essential time for the tumor to double its volume (V) by
using:
(5.5)
When the cell loss factor is high, it means that there is
loss of newly produced cells from the GF; thus, tumor
growth is slow. Cell loss has been attributed to different
parameters [16, 24]: (1) Cells are in the inactive phase of
cell cycling (in G0 phase) which is a non-­proliferative com­
partment, (2) There is inadequate nutrition and oxygen lev­
els due to the tumor outgrowth that gives rise to pushing
cells into areas at a distance from blood supply, (3)
Metastasis, (4) Immune cell killing of the tumor, and (5)
Exfoliation (the complete removal of a single epithelial cell
or group of cells from a layer of epithelium by spontaneous
or induced means). In animal models of tumors, this would
not apply but could be a mechanism by which cells lose
their integrity in carcinomas of the gastrointestinal tract,
for example, where the epithelium is renewed rapidly (Box
5.4).
Box 5.4 Tumor Growth Kinetics
•	Tumor volume doubling time (VDT) is influenced
by tumor localization site, primary or metastatic
status as well as histology but also by intra-tumor
heterogeneity factors.
•	There are differences in growth rates between dif­
ferent tumor types and metastatic lesions tend to
grow faster than primary lesions.
•	A logarithmic scale can be used to judge treatment
effectiveness. An estimate of tumor growth rate is
determined by cell-cycle kinetics, the growth frac­
tion, the cell loss rate (CL), and the potential dou­
bling time (Tpot). Even among tumors of the same
histological type, these parameters differ greatly.
Cell kinetics cycle of cells and growth fraction in
tumors can be monitored ex vivo using various
DNA-labeling strategies and in vivo using PET
tracers.
•	Ki67 immunohistochemistry staining of tumor
biopsies is a method for assessing S-phase cell
proportion.
•	The potential doubling time (Tpot) refers to the time
it would take for volume to double without loss of
cells. Consequently, the potential doubling time and
the observed volume doubling time are different
because tumors show a high amount of cell loss.
•	Tumor cell loss also contributes to VDT and may be
attributed to limited nutrition and oxygen supply,
metastatic propensity, immune cell killing, and
tumor cell exfolia.
P. Sminia et al.
247
5.4"
"Explain how the concept of ‘redistribution’ in radiation oncology relates to tumor sensitivity and treatment planning, specifically addressing the roles of cell cycle phases and reoxygenation.","The ‘redistribution’ effect describes the movement of cells within a treated volume following exposure to ionizing radiation. This redistribution is fundamentally linked to changes in cell cycle status and subsequent alterations in radioresistance. Initially, after irradiation, many cells enter mitosis (the M-phase) of the cell cycle, making them highly sensitive to further radiation damage. However, repeated fractionation – delivering radiation in smaller doses over time – causes these mitotic cells to exit mitosis and progress through the S-phase (DNA synthesis).  S-phase cells are inherently radioresistant because DNA replication is actively occurring, effectively repairing any induced DNA damage before it can cause mutations. Consequently, as cells redistribute from the initially irradiated area into the S-phase, they become increasingly resistant to subsequent radiation exposure. Furthermore, reoxygenation plays a crucial role in this process. Hypoxic tumor niches – areas with low oxygen levels – are inherently radioresistant due to the presence of enzymes like catalase that neutralize reactive oxygen species (ROS) produced by radiation damage.  Between irradiation fractions, reoxygenation occurs as blood vessels develop and restore oxygen flow within the tumor. This reoxygenation dramatically increases the radiosensitivity of previously hypoxic cells, pushing them back into cell cycle phases where they are vulnerable to radiation-induced DNA damage. Therefore, treatment planning must account for this redistribution – aiming to deliver sufficient dose to the majority of the tumor volume while considering the movement of radioresistant cells through different cell cycle stages and the impact of reoxygenation on their sensitivity.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Content: ­
5.7
25
26
27
5.5
5.7
•	Radiosensitivity: Intrinsic and acquired radioresistance of
normal tissue cells and tumor cells to radiation, in particu­
lar cancer (stem) cells among the heterogenic tumor cell
population.
•	Repair capacity, efficiency, and mechanisms of sublethal
DNA damage repair, and related sensitivity to fraction­
ated irradiation—which is high for most healthy tissues
and low for most tumors.
•	Redistribution of cells in the cell-cycle affects their radio­
resistance. Cells in mitosis are most sensitive to radiation,
while cells in the S-phase are radioresistant. Redistribution
following irradiation will push radioresistant S-phase
cells towards a radiosensitive cell-cycle phase.
•	Repopulation: Cell repopulation of—not by radiation
eradicated cancer cells—involved in the (accelerated)
repopulation of the tumor—which is detrimental—and
beneficial repopulation of normal tissue cells recovering
from acute injury.
•	Reoxygenation: Cells in hypoxic niches within the tumor
are radioresistant. Reoxygenation between multiple radi­
ation fractions given in a radiation course is an important
phenomenon by which originally hypoxic tumor cells will
be reoxygenated and hence radiosensitized.
•	Reactivation of the immune response: Local irradiation
induces a systemic immune activation to attack distant
tumor cell niches which can be located outside the irradi­
ated volume (abscopal effect).
5.4.1"
Describe the factors that contribute to a tumor's radiosensitivity and how these relate to differences in response between cancerous and normal tissues.,"Radiosensitivity, as defined by many authors, represents the extent of regression observed in both tumor and normal tissue following irradiation. Several interconnected factors dictate this sensitivity. Firstly, the proportion of cells possessing clonogenic capacity – the ability to regenerate after radiation damage – significantly impacts response. Rapidly dividing cancer cells, characterized by high clonogenic potential, are inherently more radiosensitive than quiescent or slowly proliferating normal tissues. Secondly, growth rate and reproduction rate directly correlate with radiosensitivity; faster-growing cells require more time to repair DNA damage induced by radiation, making them more vulnerable. Mitosis activity is a critical determinant as actively dividing cells are most susceptible to DNA damage during mitosis. Thirdly, metabolic rate plays a role, with higher metabolic rates indicating increased energy demands for DNA repair and thus heightened radiosensitivity. Fourthly, tissue type itself contributes; certain tissues, like those of the lung or bone marrow, are intrinsically more sensitive due to their rapid cell turnover and high proliferative capacity. Finally, factors such as radiation dose, inherent radiosensitivity (variations in DNA repair mechanisms within a tumor), and hypoxia (low oxygen conditions which impair DNA repair) also influence the degree of regression. Critically, cancer cells often exhibit a superior reproductive capacity compared to late-responding normal tissue cells. This disparity – where cancer cells rapidly divide while normal tissues require more time for repair – explains why tumors are generally more sensitive to radiation than surrounding healthy tissues, although this relationship is complex and dependent on specific tissue types and the interplay of all contributing factors.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Sub-subsection: 5.4.1	 The 6R’s in Detail | Sub-sub-subsection: 5.4.1.1		 Radiosensitivity | Content: Many authors refer to the radiosensitivity as the degree of
tumor and normal tissue regression following irradiation.
There are many factors that determine the radiosensitivity
which are the proportion of cells with clonogenic capacity,
growth rate and reproduction rate, mitosis activity, metabolic
rate, tissue type, radiation dose, inherent radiosensitivity, and
hypoxia. For example, cells with fast growth or high meta­
bolic rate are highly radiosensitive. Essentially, since the
reproductive capacity of cancer cells is higher than the repro­
ductive capacity of late responding normal tissue cells, can­
cer cells are more sensitive to radiation, but this depends on
the cancer tissue type."
"Describe the differences in DNA repair mechanisms observed between normal cells and tumor cells following radiation exposure, focusing on the types of damage and their respective repair capabilities.","Following radiation exposure, both normal and tumor cells exhibit distinct responses regarding DNA damage repair. Normal cells possess efficient DNA repair pathways capable of effectively repairing potentially lethal (PLD), sublethal (SLD), and lethal (LD) damage. Specifically, SLD – characterized by DNA double-strand breaks (DSBs) – is typically repaired within a few hours, utilizing mechanisms like homologous recombination and non-homologous end joining. However, tumor cells frequently demonstrate defective repair processes. Unlike normal cells, they often cannot adequately repair radiation-induced DNA damage. This failure primarily manifests as an inability to resolve PLD, where damaged cells may survive under favorable conditions before ultimately dying. The accumulation of irreparable LD – including chromosomal aberrations like ring and di-centric aberrations resulting from multiple DSBs – is a key driver of tumor cell death. The Hallmarks of Radiobiology (the 6R’s) highlight the importance of repair in normal tissue response, while the impaired repair capacity in tumors contributes significantly to their malignant behavior. Reference: Clinical Radiobiology for Radiation Oncology, Section 5.4.1.2","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Sub-subsection: 5.4.1	 The 6R’s in Detail | Sub-sub-subsection: 5.4.1.2		 Repair | Content: cer cells are more sensitive to radiation, but this depends on
the cancer tissue type.
5.4.1.2		Repair
Tumor and normal cells differ in terms of repair after
radiation-­induced damage. Unlike normal cells, the repair
process and mechanism of tumor cells are defective. While
normal tissue cells do repair their radiation-induced DNA
damage efficiently, malignant cells often cannot.
There are three types of radiation damage to mammalian
cells:
1.	Potentially lethal damage (PLD): Cell death depends on
the environmental conditions. In a normal situation, dam­
aged cells will not repair and die, but in case of reformed
environmental conditions, cells can repair their DNA
damage.
2.	Sublethal damage (SLD): The death of a cell depends on
the sublethal damage condition. DNA damage can be
repaired if no extra injury is taking place. The recovery
kinetics, the repair time, lies in the range of a few hours
following DNA double strand break (DNA DSB)
induction.
3.	Lethal damage (LD): Irreparable and irreversible damage
leading to cell death.
The main reason for cell death is the production of the
asystematic generation of chromosomal aberrations, includ­
Box 5.5 The Hallmarks of Radiobiology
•	The Hallmarks of Radiobiology or 6R’s are six typ­
ical molecular, cellular, or tissue processes which
determine the effects of radiation on both malignant
and healthy tissues.
•	The
6R’s
are:
Radiosensitivity,
Repair,
Redistribution,
Repopulation,
Reoxygenation,
Reactivation of the immune response.
5 Clinical Radiobiology for Radiation Oncology
248
ing rings and di-centric aberrations that result from an inter­
action between more than one DNA DSB [28]. Details
regarding the DNA Damage Response and repair pathways
are given in Chap. 3."
"Radiation exposure can significantly alter the behavior of tumor cells. Describe the three primary effects observed when cancer cells experience radiation-induced damage, detailing how each contributes to effective treatment.","Following radiation insult, several key changes occur within tumor cells that impact their susceptibility to further irradiation. Firstly, a process termed ‘recruitment’ takes place. Many tumors contain stem cells residing in the G0 phase of the cell cycle – this is a naturally radioresistant state where cells are quiescent and actively repairing damage. To maximize therapeutic efficacy, these resistant cells are stimulated to enter the cell cycle, transitioning them into a radiosensitive phase (typically G2). Secondly, once within the G2 phase, cells become significantly more vulnerable to radiation-induced DNA damage and subsequent cell death. This is because the G2 checkpoint, responsible for ensuring proper chromosome alignment prior to mitosis, is disrupted by radiation, preventing replication of damaged DNA. Thirdly, a crucial element involves allowing cells to re-assort and progress into this radiosensitive phase. Cells initially in radioresistant phases (like G0) will continue cycling, increasing the probability that they eventually enter the G2 phase where they are most susceptible to sterilization through subsequent fractions of radiation. This orchestrated sequence – recruitment, sensitization, and reassortment – is fundamental to achieving optimal tumor control with fractionated radiotherapy.

Reference: Molecular Radiation Biology, Section 5.8","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Sub-subsection: 5.4.1	 The 6R’s in Detail | Sub-sub-subsection: 5.4.1.3		 Redistribution (Re-assortment) | Content: 5.8
­
5.8
14
When cells experience radiation-induced insult, three
effects occur:
1.	Recruitment: Stem cells of some tumors are in the G0
phase, which is a radioresistant phase; therefore, they
may repair their damage and survive. In order to kill these
cells efficiently, these cells are recruited into the cell
cycle so as to arrive in a radiosensitive phase.
2.	Cells are blocked in the radiosensitive phase (G2). Cells
in G2 are highly likely to be sterilized by the first radia­
tion dose.
3.	Cells are allowed to re-assort and progress to the radio­
sensitive phase. Cells in radio-resistant phases survive,
yet since they continue to cycle, there is a likelihood that
they will arrive at a sensitive phase and be sterilized by a
second or later fraction."
Explain the concept of repopulation in the context of radiation-induced tissue injury and detail the biological mechanisms driving this process.,"Repopulation, also known as regeneration or compensation, describes the renewal capability of tissue clonogenic cells following a reduction in tissue cell numbers due to radiation exposure. This refers to the ability of surviving cells – specifically those with clonogenic forming capacity – to proliferate and restore damaged tissue. Following radiation injury, tissues demonstrate repopulation through a relatively rapid process characterized by decreasing clonogenic doubling times; for instance, from 9.8 days to 3.4 days. This accelerated regeneration is not simply a passive return to normal function but rather an active response driven by several interconnected biological factors. Firstly, irradiation stimulates cell kinetics in tissues resembling those of a normal epithelium, triggering a regenerative reaction within clonogenic cells. This activation involves the production and release of growth factors like keratinocyte growth factor (KGF), which directly promotes cellular proliferation. Secondly, reoxygenation, frequently occurring during fractionated radiation therapy (RT), plays a crucial role by facilitating tissue regeneration – oxygen is essential for many metabolic processes involved in cell division and repair. Finally, signaling pathways such as those mediated by the epithelial growth factor receptor (EGFR) are activated following irradiation. This EGFR signaling pathway acts as a regulated regenerative response, further enhancing cellular proliferation and contributing to the overall repopulation process. The onset of repopulation is typically observed around 3 weeks after the commencement of fractionated RT, although its kinetics and mechanisms can vary depending on tissue type and dose levels. Clinically, managing this repopulation is important; excessive reduction in treatment time is limited by normal tissue tolerance, while prolonged treatment times may paradoxically increase tumor cell numbers due to enhanced repopulation.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Sub-subsection: 5.4.1	 The 6R’s in Detail | Sub-sub-subsection: 5.4.1.4	 Repopulation | Content: The renewal capability of tissue clonogenic cells that follows
the reduction of tissue cells, with clonogenic-forming capac­
ity, is referred to as repopulation (regeneration). Following
radiation-induced tissue injury, the tissues will react by
repopulation of surviving clonogenic cells, i.e., compensa­
tion for the lost cells occurs relatively quickly, with decreas­
ing clonogenic doubling times from 9.8 to 3.4 days. This will
result in a larger number of tumor cells which is detrimental.
For normal tissue injury, repopulation from the stem cell
compartment will regenerate the damaged tissue, there with
reducing early radiation toxicity [16].
Biologically, there are three reasons for accelerated
repopulation. Firstly, when tissue is exposed to radiation,
cell kinetics, which may be reminiscent of a normal epi­
thelium is stimulated; thus, this response causes regenera­
tive reaction of clonogenic cells to initiate repopulation by
activating growth factors, such as keratinocyte growth fac­
tor (KGF). Secondly, reoxygenation will occur during the
course of fractionated RT, facilitating tissue regeneration.
Finally, signaling such as that via the epithelial growth fac­
tor receptor (EGFR) is activated after irradiation; hence,
this signal works as the regulated regenerative response
[22].
The onset of repopulation in many cases is thought to be
about 3 weeks after the start of fractionated RT. Its mecha­
nism and kinetics depend on tissue types and might be dose
dependent [29] (see also Chap. 6). From the clinical point of
view, the total dose should be delivered over a controlled
period of time. Any reduction in overall time is limited by the
P. Sminia et al.
249
radiation tolerance of acutely responding normal tissues, but
an extended overall treatment time might lead to diminished
tumor response due to the increase of cells as a result of
repopulation."
"Within the context of radiation oncology and multi-fractionated treatment plans, how does efficient reoxygenation influence the overall effectiveness of the therapy, particularly when considering hypoxic tumor regions?","The impact of reoxygenation on radiation response is critically dependent on its efficiency within a multi-fractionated radiotherapy regimen. When oxygen levels rapidly recover between dose fractions – a process termed ‘efficient reoxygenation’ – the presence of hypoxic cells has a minimal detrimental effect on treatment outcomes. Hypoxic tumor regions, characterized by low oxygen concentrations, are inherently less sensitive to ionizing radiation due to the reduced functionality of DNA repair pathways and the impaired activation of radiosensitizers like NADPH oxidase. However, if reoxygenation is slow or incomplete, as often occurs in hypofractionated regimens (where total dose is delivered over a shorter period), these hypoxic cells remain oxygen-deprived for an extended duration. This prolonged hypoxia significantly compromises their ability to repair radiation damage and enhances their susceptibility to cell death. Therefore, rapid reoxygenation effectively mitigates the negative consequences of hypoxia, allowing for a more uniform and robust response across the tumor volume. Conversely, delayed or insufficient reoxygenation exacerbates the cytotoxic effects of radiation within hypoxic areas, potentially leading to reduced treatment efficacy and increased risk of complications.

Reference: Clinical Radiobiology for Radiation Oncology, 5.4.1.5 Reoxygenation","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Sub-subsection: 5.4.1	 The 6R’s in Detail | Sub-sub-subsection: 5.4.1.5	 Reoxygenation | Content: ­
­
5.9
The oxygen enhancement ratio and the role of oxygen in
the radiation response has been explained in Chap. 2. If reox­
ygenation is efficient between dose fractions, the presence of
hypoxic cells does not have a significant effect on the out­
come of a multi-fractionation scheme. In a hypofractionation
regimen, the time period to obtain full reoxygenation of
hypoxic tumor cells might however be too short (discussed
in Chap. 6)."
"How can radiation therapy influence the tumor microenvironment (TME) and subsequently impact the immune response within a cancer patient, and what are some strategies to potentially optimize this interaction?","Radiation therapy induces significant changes within the tumor microenvironment (TME), primarily through mechanisms like DNA damage, oxidative stress, and inflammation. These alterations directly modulate the immune response by affecting various components of the TME. Specifically, radiation can stimulate the production of cytokines such as IL-1β and TNF-α, which are pro-inflammatory mediators that initially enhance immune cell recruitment to the tumor site. However, prolonged or excessive stimulation can lead to an immunosuppressive environment characterized by increased myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), effectively dampening anti-tumor immunity. Furthermore, radiation can disrupt antigen presentation pathways and impair dendritic cell function, hindering their ability to activate cytotoxic T lymphocytes (CTLs). To optimize this interaction and potentially widen the therapeutic window, strategies such as combining radiation with immunomodulating drugs – like checkpoint inhibitors targeting PD-1 or CTLA-4 – are being explored. Another approach involves radioprotection of normal tissues to reduce overall toxicity and subsequent inflammation, thereby minimizing immunosuppressive effects. Conversely, tumor radiosensitization through agents that enhance DNA damage or increase the sensitivity of cancer cells to radiation could also improve immune cell activation within the tumor itself. Ultimately, tailoring treatment regimens based on individual tumor and tissue characteristics remains a critical area of research for maximizing therapeutic efficacy.
Reference: MolecularRadiationBiology, Section 5.4.1.6","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.4	 6R’s Concept | Sub-subsection: 5.4.1	 The 6R’s in Detail | Sub-sub-subsection: 5.4.1.6	 Reactivation of the Immune System | Content: ­
5.10
Different radiation treatment schemes with respect to the
total dose and fraction size have been shown to have diverse
effects on the immune response, and therewith also on target
expression with consequences for combination treatments like
with immunotherapy. To obtain optimal modulation of the
radiation response, specific immunomodulating or targeted
drugs can be selected. The radiation-induced TME effects
modulating the immune response requires further research to
find the ideal immunotherapy and RT regimen [30].
The 6R’s offer options for modulation of the radiation
response. Modulation strategies, such as via combination ther­
apy with immunomodulating agents, should be aimed to widen
13
5 Clinical Radiobiology for Radiation Oncology
250
the therapeutic window (Sect. 5.12) using approaches such as
via radioprotection of the normal tissues thus decreasing the
NTCP or by tumor radiosensitization by increasing TCP.
Options for clinical application of such strategies are highly
dependent on the tumor and normal tissue type included in the
radiation treatment volume. Finally, to be noted is the close
link between the Hallmarks of Radiobiology and the Hallmarks
of Cancer [31] and therewith related therapeutic options,
which have been discussed in detail elsewhere [32, 33].
5.5"
"Explain the rationale behind using dose fractionation in radiation oncology, detailing how multiple smaller fractions compared to a single high-dose fraction can improve tumor control and reduce normal tissue toxicity.","The practice of dividing a total prescribed radiation dose into numerous smaller fractions delivered over an extended period – typically weeks – is known as dose fractionation. This approach evolved from early observations demonstrating that delivering radiation in multiple, lower doses resulted in significantly better tumor control compared to a single, high-dose treatment. The primary reason for this improvement lies in the differing responses of cancer cells and normal tissues to radiation damage. Initially, when a large dose is delivered rapidly, most malignant cells are unable to repair the DNA damage effectively before succumbing to cell death. However, normal tissues, with their higher proliferative rates, *can* often repair the damage more efficiently. This allows them to recover and resume cell division, leading to substantial toxicity. 

With fractionation, each smaller fraction delivers a dose that still causes significant DNA damage in cancer cells, but the intervening recovery period allows normal tissues to repair much of the damage before the next fraction is administered. This differential response – where tumor cells are repeatedly damaged without sufficient time for full recovery while normal tissues have opportunities to repair – ultimately leads to more effective tumor eradication with a lower overall risk of debilitating side effects. Furthermore, modern techniques allow for higher dose per fraction while sparing more efficiently surrounding normal tissue, further refining this fractionation concept.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.5	 Dose Fractionation (Box 5.6) | Sub-subsection: 5.5.1	 Evolution of Fractionation | Content: In the early years of RT, radiation oncologists soon realized
that a radiation treatment course delivered in multiple fractions
over several weeks resulted in better tumor control than a treat­
ment course delivered in a single fraction and also reduced
normal tissue toxicity [21]. The history of RT and fractionation
is described in detail in Chap. 2. Generally spoken, a treatment
course consisting of 30 daily 2 Gy fractions (total dose 60 Gy)
is, at isoeffective normal tissue late response level, more effec­
tive in eradication of the tumor than a treatment course consist­
ing of a few high dose ­fractions. Hence, if the total prescribed
dose is divided into multiple small radiation fractions with a
time interval between the fractions, tumor control could be
enhanced at an acceptable level of associated morbidity, rela­
tive to a single large dose fraction [13]. However, modern RT
techniques allow to give higher dose per fraction while sparing
more efficiently the surrounding normal tissue. This may affect
this fractionation concept further in future.
The irradiated cell population comprises the malignant
tissue as well as acute and late responding healthy (“nor­
mal”) tissues. When an RT dose is delivered in several frac­
tions, there are advantages and disadvantages in terms of
tumor cell kill and normal tissue cell sparing, which are dis­
cussed in detail in Sect. 5.14.
5.5.2"
"How does the inter-fraction interval and overall treatment time influence the biological effects of radiation, particularly concerning normal tissue response and tumor control in scenarios involving fractionated radiotherapy?","The duration between radiation fractions, known as the inter-fraction interval, plays a crucial role in determining the extent of damage to normal tissues. A minimum of 8 hours is generally recommended for most tissues due to the slow repair kinetics of sublethal damage (SLD) within late responding cells. Prolonging this interval allows for more complete repair of SLD before subsequent radiation exposure, mitigating the severity of acute reactions and reducing tissue damage. Conversely, a shorter inter-fraction interval can lead to cumulative damage and persistent early responses from severely depleted regenerating cells, resulting in consequential late injuries.  Furthermore, the overall treatment time significantly impacts both acute effects on normal tissues and tumor control. Prolonging the total radiation exposure allows for greater sparing of early responding normal tissues – those that react quickly to radiation – but provides little benefit in reducing damage to late responding tissues. However, this extended time also facilitates tumor cell proliferation during treatment due to the surviving cells’ ability to rapidly divide, necessitating increased doses to counteract this accelerated repopulation. Specifically, prolonged treatment times can lead to a measurable increase in tumor doubling rate and ultimately decrease local control rates by 1.4% per additional day of treatment. This phenomenon highlights the complex interplay between dose fractionation, repair kinetics, and overall treatment duration in determining therapeutic outcomes.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.5	 Dose Fractionation (Box 5.6) | Sub-subsection: 5.5.2	 Fractionation Parameters and Their Significance | Content: Significance
Acute normal tissue effects of RT depend on both fraction
size and the overall treatment time. The intensity of acute
reactions depends on weekly applied total dose, i.e., the dose
per fraction and number of fractions in a week. After an
acute reaction has peaked, further stem cell killing cannot
increase the intensity of acute reactions but can prolong the
Box 5.6 Fractionation and the Dose Rate
•	Clinically used fractionation schemes are aimed at
eradicating malignant tissue while sparing late
responding healthy tissue.
•	The biological rationale of fractionated irradiation
is based on the typical radiation response of the
dynamic and heterogeneous exposed tissue and cell
population.
•	Dose rates used in clinical RT vary from low dose
rate with exposure times in hours-days to ultra-high
dose rates with radiation dose delivery in the milli­
second range.
•	The biological effect of radiation decreases with
decreasing dose rate to a larger extent for normal
tissue with low α/β ratio than for tumors with high
α/β ratio.
•	Experimental data demonstrate that ultra-high dose
rate irradiation might better spare late responding
normal tissue.
•	The 6R’s of radiobiology are the biological pro­
cesses involved in the dose rate effect.
P. Sminia et al.
251
healing time. A persistent early response from severe deple­
tion of regenerating cells is termed a consequential late
injury [13]. In contrast, non-consequential late normal tissue
effects depend predominantly on fraction size, while the
overall treatment time has little influence. Therefore, during
hypofractionation, late effects are severe while early effects
are matched by appropriate dose adjustment, as discussed in
detail in Chap. 6 (Sects. 6.2 and 6.3).
Another important parameter is the inter-fraction interval.
Due to the slow repair kinetics of sublethal damage (SLD) in
late responding tissues, a minimum of 8 h of inter-fraction
interval is recommended for most tissues. The overall treat­
ment time affects both acute effects and tumor control.
Prolongation of the overall treatment time (within normal RT
range) has a large sparing effect on early responding normal
tissues but little sparing effect on late responding normal tis­
sues. However, excessive prolongation of overall treatment
time causes the surviving tumor cells to proliferate during
treatment. For any prolongation in treatment time, extra dose
is required to counteract tumor cell proliferation, due to the
phenomenon of accelerated repopulation. For example, in
head and neck cancer, after a lag period of 4 weeks during a
course of RT, the tumor doubling rate could increase due to
triggering of surviving clonogens to divide more rapidly as
tumor shrinks after initiation of treatment. A dose of up to
0.6 Gy of each daily dose would be “wasted” due to increased
tumor cell load [34]. When the overall treatment time is pro­
longed, for each extra day, local control would decrease by
1.4% (0.4–2.5%) due to accelerated repopulation.
5.5.3
Clinical Fractionation and the Dose
Rate Effect
5.5.3.1	Clinical Fractionation
Differential responses of normal and cancerous tissues when
fractionating RT doses can be explained by biological factors
that are known as the 6R’s (see Sect. 5.4). During fraction­
ation, tumor cells are redistributed and reoxygenated, caus­
ing further tumor damage. Moreover, the fractionation
process will spare normal tissues by allowing repair of SLD
between dose fractions and by allowing repopulation with
new cells to occur over the overall treatment time. Therefore,
a prolonged radiation treatment given over several weeks
results in a greater therapeutic ratio than one or few short
duration sessions because of tumor reoxygenation and early
reacting normal tissue regeneration.
­
­
­
­
5.3
Table 5.3 Models of biological effective dose (BED) for isoeffect cal­
culations for modified fractionation regiment (adopted from [16])
Model
Formula
Statement
Equivalence
dose 2 Gy
(EQD2)
uppe
r
E
up
p
er
Q
u
p
pe
r
D
S
ubscript 2 Baseline equals upper D StartStartFraction d plus left parenthesis StartFraction alpha Over beta EndFraction right parenthesis OverOver 2 plus left parenthesis StartFraction alpha Over beta EndFraction right parenthesis EndEndFraction
D is total dose and d is dose
per fraction.
• EQD2 is the 2 Gy dose
that carries the same
biological effect as a
total dose D with a
fraction size d Gy.
• The purpose of this
model is to compare
the effectiveness of
schedules containing
doses per fraction and
different total doses.
This is equivalent to
converting each
schedule into a 2-Gy
fraction that has the
identical biological
effect.
Total effect
(TE)
E/β = D[(α/β) + d] = TE
E = isoeffect
• It is used for schedules
with different doses
per fraction.
• TE and BED are
conceptually similar
and have been cited in
literature, but E is
divided by β instead of
α.
Extrapolated
tolerance
dose (ETD)
(S
tartFraction upper E Over alpha EndFraction) = D((1 + d(α/β)) = BED
• The ETD refers to
levels of effectiveness
that imply full
tolerance. It is used for
schedules with
different doses per
fraction.
Basic EQD2
formula with
incomplete
repair
factors (Hm).
upp
e
r
E
u
p
p
e
r
Q
u
pp
er
D Subscript 2 Baseline equals upper D StartFraction left parenthesis 1 plus upper H Subscript normal m Baseline plus alpha divided by beta right parenthesis Over 2 plus left parenthesis alpha divided by beta right parenthesis EndFraction
• Used for tolerance
calculations, taking
into account the
increase in the overall
damage caused by
interaction of
subsequent fractions.
Basic EQD2
formula with
Incomplete
repair
factors
(g factors).
uppe
r
E
u
pp
e
r Q
u
pp
e
r D Subscript 2 Baseline equals upper D StartFraction left parenthesis italic d g plus alpha divided by beta right parenthesis Over 2 plus left parenthesis alpha divided by beta right parenthesis EndFraction
• Used for low dose rate
exposures.
5 Clinical Radiobiology for Radiation Oncology"
"Describe the concept of Equivalent Doses (EQD), specifically focusing on the EQD2 model and its application in comparing different fractionation schemes for radiation therapy. Explain how the formula relating dose, fraction size, alpha, beta, and the resulting EQD2 value is derived and what it represents.","The Equivalent Dose (EQD) concept addresses the challenge of comparing biological effects from radiation exposures with varying total doses and fractionation schedules. The EQD2 model provides a standardized metric for this comparison by establishing a relationship between a total dose, ‘D’, and a corresponding dose delivered in fractions, ‘d’. The formula used to calculate EQD2 is:  EQD2 = upper E upper Q upper D subscript 2 Baseline = upper D StartFraction (alpha / beta) + d EndFraction Over 2 + (alpha / beta) EndFraction. Let’s break down the components:

*   **D:** Represents the total dose administered.
*   **d:** Represents the dose delivered per fraction.
*   **(alpha / beta):** This ratio is a key element, reflecting the relative biological effectiveness of alpha particles compared to beta particles. Alpha particles are significantly more damaging per unit charge than beta particles, and this factor accounts for that difference in biological effect.
*   **upper E:** Represents the dose required to produce a specific level of biological effect (often defined as equivalent to 2 Gy).
*   **upper Q:** This term is related to the repair capacity of cells. It’s often implicitly accounted for within the alpha/beta ratio, but in some contexts, it might represent an adjustment factor reflecting differences in repair mechanisms.

The purpose of this model is to convert each fractionation schedule into a 2-Gy equivalent dose that has the identical biological effect as the original schedule. This allows clinicians to directly compare different schedules based on their predicted effectiveness, regardless of variations in total dose or fraction size. The EQD2 value itself represents the 2-Gy dose that would produce the same level of damage as the original treatment regimen, providing a standardized measure for evaluating therapeutic efficacy.

Essentially, it’s a mathematical translation to allow comparison between different radiation delivery strategies.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.5	 Dose Fractionation (Box 5.6) | Sub-subsection: 5.5.3	 Clinical Fractionation and the Dose Rate Effect | Content: 5.3
Table 5.3 Models of biological effective dose (BED) for isoeffect cal­
culations for modified fractionation regiment (adopted from [16])
Model
Formula
Statement
Equivalence
dose 2 Gy
(EQD2)
uppe
r
E
up
p
er
Q
u
p
pe
r
D
S
ubscript 2 Baseline equals upper D StartStartFraction d plus left parenthesis StartFraction alpha Over beta EndFraction right parenthesis OverOver 2 plus left parenthesis StartFraction alpha Over beta EndFraction right parenthesis EndEndFraction
D is total dose and d is dose
per fraction.
• EQD2 is the 2 Gy dose
that carries the same
biological effect as a
total dose D with a
fraction size d Gy.
• The purpose of this
model is to compare
the effectiveness of
schedules containing
doses per fraction and
different total doses.
This is equivalent to
converting each
schedule into a 2-Gy
fraction that has the
identical biological
effect.
Total effect
(TE)
E/β = D[(α/β) + d] = TE
E = isoeffect
• It is used for schedules
with different doses
per fraction.
• TE and BED are
conceptually similar
and have been cited in
literature, but E is
divided by β instead of
α.
Extrapolated
tolerance
dose (ETD)
(S
tartFraction upper E Over alpha EndFraction) = D((1 + d(α/β)) = BED
• The ETD refers to
levels of effectiveness
that imply full
tolerance. It is used for
schedules with
different doses per
fraction.
Basic EQD2
formula with
incomplete
repair
factors (Hm).
upp
e
r
E
u
p
p
e
r
Q
u
pp
er
D Subscript 2 Baseline equals upper D StartFraction left parenthesis 1 plus upper H Subscript normal m Baseline plus alpha divided by beta right parenthesis Over 2 plus left parenthesis alpha divided by beta right parenthesis EndFraction
• Used for tolerance
calculations, taking
into account the
increase in the overall
damage caused by
interaction of
subsequent fractions.
Basic EQD2
formula with
Incomplete
repair
factors
(g factors).
uppe
r
E
u
pp
e
r Q
u
pp
e
r D Subscript 2 Baseline equals upper D StartFraction left parenthesis italic d g plus alpha divided by beta right parenthesis Over 2 plus left parenthesis alpha divided by beta right parenthesis EndFraction
• Used for low dose rate
exposures.
5 Clinical Radiobiology for Radiation Oncology"
"Explain the concept of clinical fractionation and how it relates to the 6R’s, specifically focusing on its impact on tumor response and normal tissue sparing during radiation therapy. What are the key mechanisms driving this effect?","Clinical fractionation refers to the practice of delivering ionizing radiation in multiple, smaller doses (fractions) over a period of time, typically weeks, rather than a single large dose. This approach is predicated on the biological response of tissues to radiation damage and repair, as described by the ‘6R’s’. The 6R’s – Redistribution, Reoxygenation, Repopulation, Regression, Repair, and Radiation Dose – represent key factors that influence tumor cell sensitivity during fractionation. During fractionation, tumor cells undergo significant redistribution within the tissue due to the damaging effects of each fraction. Simultaneously, reoxygenation increases dramatically as blood flow is stimulated by the radiation, providing oxygen for cellular repair processes. Furthermore, the process allows for repopulation with new cells over the extended treatment time, effectively resetting the cell population after damage. This leads to tumor regression – a reduction in tumor size – due to the cumulative effects of these biological changes. Crucially, normal tissues are spared to a greater extent because they possess a more robust capacity for repair mechanisms (Repair) between dose fractions and can regenerate new cells over the longer treatment duration, allowing them to recover from radiation damage before subsequent fractions are delivered. The overall effect is a higher therapeutic ratio – maximizing tumor cell killing while minimizing damage to surrounding healthy tissues – compared to single or short-duration sessions. Reference: [MolecularRadiationBiology, Section 5.5.3.1 Clinical Fractionation and the Dose Rate Effect]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.5	 Dose Fractionation (Box 5.6) | Sub-subsection: 5.5.3	 Clinical Fractionation and the Dose Rate Effect | Sub-sub-subsection: 5.5.3.1	 Clinical Fractionation | Content: Differential responses of normal and cancerous tissues when
fractionating RT doses can be explained by biological factors
that are known as the 6R’s (see Sect. 5.4). During fraction­
ation, tumor cells are redistributed and reoxygenated, caus­
ing further tumor damage. Moreover, the fractionation
process will spare normal tissues by allowing repair of SLD
between dose fractions and by allowing repopulation with
new cells to occur over the overall treatment time. Therefore,
a prolonged radiation treatment given over several weeks
results in a greater therapeutic ratio than one or few short
duration sessions because of tumor reoxygenation and early
reacting normal tissue regeneration.
­
­
­
­
5.3
Table 5.3 Models of biological effective dose (BED) for isoeffect cal­
culations for modified fractionation regiment (adopted from [16])
Model
Formula
Statement
Equivalence
dose 2 Gy
(EQD2)
uppe
r
E
up
p
er
Q
u
p
pe
r
D
S
ubscript 2 Baseline equals upper D StartStartFraction d plus left parenthesis StartFraction alpha Over beta EndFraction right parenthesis OverOver 2 plus left parenthesis StartFraction alpha Over beta EndFraction right parenthesis EndEndFraction
D is total dose and d is dose
per fraction.
• EQD2 is the 2 Gy dose
that carries the same
biological effect as a
total dose D with a
fraction size d Gy.
• The purpose of this
model is to compare
the effectiveness of
schedules containing
doses per fraction and
different total doses.
This is equivalent to
converting each
schedule into a 2-Gy
fraction that has the
identical biological
effect.
Total effect
(TE)
E/β = D[(α/β) + d] = TE
E = isoeffect
• It is used for schedules
with different doses
per fraction.
• TE and BED are
conceptually similar
and have been cited in
literature, but E is
divided by β instead of
α.
Extrapolated
tolerance
dose (ETD)
(S
tartFraction upper E Over alpha EndFraction) = D((1 + d(α/β)) = BED
• The ETD refers to
levels of effectiveness
that imply full
tolerance. It is used for
schedules with
different doses per
fraction.
Basic EQD2
formula with
incomplete
repair
factors (Hm).
upp
e
r
E
u
p
p
e
r
Q
u
pp
er
D Subscript 2 Baseline equals upper D StartFraction left parenthesis 1 plus upper H Subscript normal m Baseline plus alpha divided by beta right parenthesis Over 2 plus left parenthesis alpha divided by beta right parenthesis EndFraction
• Used for tolerance
calculations, taking
into account the
increase in the overall
damage caused by
interaction of
subsequent fractions.
Basic EQD2
formula with
Incomplete
repair
factors
(g factors).
uppe
r
E
u
pp
e
r Q
u
pp
e
r D Subscript 2 Baseline equals upper D StartFraction left parenthesis italic d g plus alpha divided by beta right parenthesis Over 2 plus left parenthesis alpha divided by beta right parenthesis EndFraction
• Used for low dose rate
exposures.
5 Clinical Radiobiology for Radiation Oncology
252"
"Explain the concept of ‘dose rate sparing’ as described in the text, detailing how it relates to normal tissue response and tumor control during radiation therapy.","The text describes ‘dose rate sparing’ as a phenomenon where reducing the dose rate of irradiation results in a lower biological effect on exposed tissues, particularly acute responding normal tissues and tumors. This occurs because at lower dose rates, the total dose required to achieve a specific biological endpoint – such as a defined probability of kidney function loss or cell survival with a fraction of 0.4 – increases significantly. The underlying mechanism is linked to cellular repair processes. When irradiation occurs over a longer period (lower dose rate), the α parameter in the linear-quadratic model, which represents the immediate effect of radiation damage, remains relatively constant. However, the β parameter, representing the rate of DNA repair, tends towards zero. This means that cells have more time to repair sublethal DNA damage before it becomes lethal. Consequently, a larger total dose is needed to reach the desired biological outcome. The text also notes that this effect is largely absent for acute responding tissues and tumors, highlighting the importance of considering fractionation strategies based on tissue sensitivity and repair kinetics (α/β values and T1/2). Optimizing therapeutic ratios depends on these factors.

Reference: [MolecularRadiationBiology], Section 5.5.3.2 – The Dose Rate Effect","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.5	 Dose Fractionation (Box 5.6) | Sub-subsection: 5.5.3	 Clinical Fractionation and the Dose Rate Effect | Sub-sub-subsection: 5.5.3.2	 The Dose Rate Effect | Content: ­
­
­
5.4
Physical aspects of the dose rate are presented in Chap. 2.
The application of low dose rate irradiation in brachytherapy
in the clinic, is discussed in Chap. 6. FLASH is a novel RT
treatment technique using ultra-high dose rates. Using
FLASH, multiple studies indicate sparing of healthy tissue
acute and late toxicities while maintaining tumor control,
hence widening the therapeutic window (Sect. 5.2). FLASH
is discussed in detail in Chap. 6. The radiation dose rate has
a large biological impact on exposed cells and tissues. Both
in vitro and in vivo experimental data revealed that, for a
defined biological endpoint, for example, cell survival or a
certain late normal tissue reaction like myelitis of the spinal
cord, the biological effect decreases with decreasing dose
rate. With decreasing dose rate, the total dose to obtain a cer­
tain isoeffective biological endpoint—for example, a proba­
bility of 50% loss of kidney function or reduction of the cell
survival with a fraction of 0.4, is increased. Dose rate sparing
is almost absent for acute responding normal tissues and
tumors.
­
5.11
5.5
5.11
5.7
Table 5.4 Dose delivery conditions used in the clinic, for internal
radiation therapy (brachytherapy) and external beam irradiation, and
related dose rates (ICRU 38 definitions and FLASH)
Dose delivery condition
Dose rate (Gy/h)a
Low dose rate (LDR)
<2
Medium dose rate (MDR)
2–12
High dose rate (HDR)
>12
Pulsed dose rate (PDR)
±75% HDR, ±25% MDR and LDR
Ultra-high dose rate (FLASH)
≥144.000
aThe International System of Units (SI) defined dimension for the dose
rate is “Gy/h”
P. Sminia et al.
253
Thus, as exposure is elongated, the shoulder of the cell
survival curve tends to become shallower, this is because the
α parameter of the linear-quadratic model does not change
significantly, while the β parameter tends towards 0.
This situation also implies, dependent on the fractionation
sensitivities of irradiated tumor and normal tissues involved
(i.e., their repair capacity characteristics expressed in their
α/β values) as well as of their DNA repair kinetics (the half
time for sublethal damage repair T1/2), an optimal therapeutic
ratio situation. For the LQ model adaptation to correct for the
dose rate effect and incomplete repair, additional parameters
are introduced (e.g., Joiner and van der Kogel [16]). The
dose rate effect of continuous low dose irradiation is dis­
cussed in view of the 6R’s of radiobiology in Sect. 5.4 below.
3
­
­
­
­
28
5.12"
"Explain how tissue-specific half times (T1/2) and dose rate influence the extent of sparing observed in tissues with equivalent alpha/beta ratios, particularly concerning DNA repair mechanisms.","The degree of tissue sparing following radiation exposure is significantly impacted by both the tissue's specific half time for repairing sublethal damage (T1/2) and the dose rate at which the radiation is delivered. When a tissue possesses an equivalent alpha/beta ratio – reflecting its sensitivity to radiation – a shorter T1/2 results in greater sparing. This phenomenon arises because tissues with rapid repair kinetics can more effectively remove DNA damage before it accumulates to significant levels. Conversely, a longer T1/2 allows for increased accumulation of unrepaired damage. Furthermore, lower dose rates exacerbate this effect. At extremely low dose rates, where radiation is delivered as an infinite series of infinitesimally small fractions (as described by the LQ model), the total dose required to produce an isoeffect – a measurable biological response – is determined by the tissue’s T1/2. Essentially, continuous exposure at a slow rate provides more opportunities for repair between these ‘fractions,’ leading to incomplete repair and thus greater damage accumulation. This contrasts with higher dose rates where the repair process is less frequent, resulting in more precise discrimination between tissues with differing α/β ratios. The prolonged exposure also increases the risk of tumor cell repopulation outpacing the duration of irradiation, potentially hindering treatment efficacy if cells divide rapidly. Finally, it’s important to note that low dose rate irradiation can influence the immune response and may even promote reoxygenation in initially hypoxic tumor cells, though this is highly dependent on the specific tumor type.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.5	 Dose Fractionation (Box 5.6) | Sub-subsection: 5.5.3	 Clinical Fractionation and the Dose Rate Effect | Sub-sub-subsection: 5.5.3.3	 Repair and the LQ Model Parameters | Content: 5.13
­
Also, for a tissue having an equivalent α/β ratio, larger
sparing is obtained with decreasing tissue-specific half time
(T1/2) for sublethal damage repair. Similarly, as with fraction­
ated radiation, this can be attributed to incomplete repair
between the “fractions” or during continuous exposure.
Hence, at longer repair half time, low dose rate irradiation is
causing more damage, and less discriminative between tis­
sues with different α/β ratio.
5.4
5.8
­
­
Box 5.7 The Dose Rate and the Biological Effective Dose
•	At extremely low dose rate, i.e., irradiation with an
infinitely large number of infinitesimally small dose
fractions, the theoretical total dose required to pro­
duce an isoeffect is the Biological Effective Dose
(BED) of the LQ model.
5 Clinical Radiobiology for Radiation Oncology
254
35
17
the same radiation dose, radiation delivered at a certain spe­
cific lower dose rate increases the radiosensitivity of cells in
comparison to radiation delivered at a higher dose rate. This
is illustrated in Fig. 5.14.
Tumor cell repopulation during continuous low dose rate
(LDR) exposure might negatively influence treatment out­
come since a larger number of cells have to be sterilized if
the repopulation rate outflows the duration of exposure,
P. Sminia et al.
255
which might occur with fast repopulating tumor cells (e.g.,
cell doubling time of 24 h).
The impact of irradiation on the immune response has
been shown to be dependent on the radiation dose (see Chap.
6), and the dose rate of exposure is likely to play a role [36].
The effect of low dose rate irradiation regarding reactivation
of the immune response is however not well described.
Chronic low dose rate exposure will not cause oxygen
depletion in initially well-oxygenated tumor cells. Initially,
hypoxic cells might benefit from reoxygenation during long-­
term radiation exposure. However, as pointed out in Sect.
5.4, the kinetics of reoxygenation is very much dependent on
the tumor type.
5.6"
"Describe the mechanisms underlying the varying radiosensitivity observed in leukemia cells during whole-body irradiation (WBI) treatment. Specifically, what molecular pathways and genes are implicated in determining a cell's response to radiation?","The radiosensitivity of leukemia cells during WBI is influenced by a complex interplay of intrinsic cellular factors. Notably, increased apoptosis following radiation exposure relies on the functional expression of key genes including p53, c-myc, and Bcl2. Radiation triggers activation of the p53 pathway, leading to DNA damage recognition and subsequent apoptotic signaling. Simultaneously, activation of c-myc contributes to cell cycle arrest and promotes survival under stress conditions. The Bcl2 family of proteins regulates apoptosis by inhibiting caspase activation; increased expression of Bcl2 in leukemia cells can dampen this apoptotic response, resulting in greater radioresistance. Therefore, variations in the levels or activity of these genes – p53, c-myc, and Bcl2 – directly correlate with differences in a leukemia cell’s susceptibility to radiation-induced apoptosis. Furthermore, successful eradication of malignant clones often requires combining WBI with chemotherapy and leveraging the graft-versus-tumor effect, highlighting the need for multiple mechanisms to overcome resistance [40].","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.1	 Introduction | Content: Whole-body irradiation (WBI) or total body irradiation
(TBI) refers to the therapeutic protocol in which a patient’s
total body is irradiated with γ/X-rays. WBI is used as part of
the conditioning regimen for transplantation of bone marrow
or hematopoietic stem cells for lymphoma, leukemia, or
multiple myeloma and as a palliative regimen in selected
cases of lymphoma and leukemia [37]. WBI implicates irra­
diation of the total body, with reduction of the dose to the
lungs, to lessen the hazard of radiation-induced lung toxicity
[38, 39]. Historically, in the fifth and sixth decade of the last
century scientists trying to reverse early responding tissue
effects of radiation, demonstrated experimentally that bone
marrow engrafted with hematopoietic stem cells from a
donor animal “could recapitulate the blood system” and thus
showed that previously irradiated bone marrow could be res­
cued. This contributed to the development of therapeutic
techniques involving bone marrow ablation followed by
bone marrow engraftment with hematopoietic stem cells for
the treatment of some marrow cancers, for example, leuke­
mia or multiple myeloma [37]. This procedure is mainly
used to eliminate residual cancer cells in the transplant recip­
ient, and to further suppress or destroy the immune system;
subsequently, it serves to prevent immunologic rejection of
blood stem cells or transplanted donor bone marrow. Thus,
the chances of engraftment are increased, and the bone mar­
row stromal cells of the patient are spared [38, 39].
5.6.2
Details of Radiobiological Mechanisms
of Whole-Body Irradiation
5.6.2.1	Leukemia
Since a characteristic of WBI is that it can sterilize small
numbers of widely spread cells that are sensitive to radiation,
this makes it a treatment option for (residual) marrow dis­
ease. Biologically, leukemia is associated with a spectrum of
intrinsic cellular radiosensitivity that ranges from notable
radiosensitivity to significant radioresistance, which deter­
mine the extent of leukemic cell killing. The molecular biol­
ogy responsible for the variety in radiosensitivity of leukemia
is not entirely known, but increased apoptosis seems to
require functional p53, c-myc, and Bcl2 genes. Therefore, it
seems that radiosensitivity results from the apoptosis reten­
tion after activating p53, c-myc, and Bcl2 genes by radiation
[40]. RT in conjunction with a wide range of treatment
modalities such as (myeloablative) chemotherapy and the
subsequent graft-versus-tumor effect are therefore required
to obtain significant eradication of malignant clones [22,
Chap. 16].
5.6.2.2	The Normal Hematopoietic System
Bone marrow stem cells typically have D0 values ranging
from 0.5 to 1.4 Gy. These cells are therefore intrinsically
radiosensitive. Even though hematopoietic rescue (i.e., stem
cells) could allow the delivery of high doses that eliminate the
recipient’s marrow cells which in turn prepares the stem cell
microenvironment for repopulation to occur, this procedure is
associated with long-term or life-threatening consequences.
Critical organs of concern in WBI are those described as late
responding tissues. Fortunately, as effect on these tissues is
dependent on total dose, dose rate and fractionation, appro­
priate scheduling of the treatment allows some protection.
While a modest number of cancer cells being radiosensitive
will be killed, complete cancer cell killing may not always be
possible with radiation alone. Therefore, TBI often needs to
be given together with chemotherapy. Moreover, incomplete
bone marrow ablation may result in mixed chimerism of bone
marrow after transplant [22, 40].
As a result of immunological mismatch between recipient
and donor, rejection of donor stem cells may occur. In order
to avoid this, TBI is used to prevent the recipient from reject­
ing donor stem cells.
Bone marrow transplantation results are influenced by the
treatment schedule. Lymphoid cells repair a large amount of
radiation-induced DNA damage during the time interval
between fractions. Hence, the effectiveness of fractionated
TBI is reduced significantly in comparison with single-dose
TBI and results in more graft rejections. However, the frac­
tionation effect is reversed for bone marrow stromal cells
(“colony-forming unit fibroblasts”). The success of engraft­
ment is based on the likelihood of sparing bone marrow stro­
mal cells, and when treatment is delivered as single-dose
TBI, the likelihood of damaging both bone marrow stromal
cells and their progenitors increases. Importantly, the effec­
tiveness of single-dose TBI is increased significantly in com­
parison with fractionated TBI, but at the cost of increased
long-term toxicity [22].
5 Clinical Radiobiology for Radiation Oncology"
Describe the biological mechanisms contributing to variations in radiosensitivity observed within leukemia cells and how this relates to whole-body irradiation (WBI) treatment strategies.,"Leukemia exhibits a wide range of radiosensitivity, from highly sensitive to significantly resistant, which fundamentally dictates the effectiveness of WBI. This variability stems primarily from differences in apoptotic pathways triggered by radiation exposure. Specifically, increased apoptosis is linked to functional expression of genes such as p53, c-myc, and Bcl2 within leukemia cells. Radiation activates these genes, leading to a sustained state of apoptosis – essentially trapping the cells in a pro-apoptotic cycle. Cells with intact or upregulated versions of these genes are more susceptible to radiation-induced cell death because they cannot effectively repair the DNA damage caused by the ionizing radiation. Conversely, leukemic cells with impaired p53, c-myc, or Bcl2 function demonstrate greater radioresistance due to their ability to mitigate and recover from the initial DNA damage. Consequently, WBI treatment strategies often incorporate chemotherapy alongside TBI to target radiosensitive leukemia cells while simultaneously attempting to sensitize resistant clones through mechanisms like p53 activation. Furthermore, the scheduling of TBI – whether delivered as a single dose or fractionated – impacts this process; fractionation can exacerbate rejection by allowing lymphoid cells to repair DNA damage, reducing overall effectiveness, whereas it reverses for bone marrow stromal cells, increasing engraftment potential when administered as a single dose. Reference: 5: Clinical Radiobiology for Radiation Oncology > section: 5.6 > subsection: 5.6.2 > subsubsection: 5.6.2.2","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.2	 Details of Radiobiological Mechanisms of Whole-Body Irradiation | Content: this makes it a treatment option for (residual) marrow dis­
ease. Biologically, leukemia is associated with a spectrum of
intrinsic cellular radiosensitivity that ranges from notable
radiosensitivity to significant radioresistance, which deter­
mine the extent of leukemic cell killing. The molecular biol­
ogy responsible for the variety in radiosensitivity of leukemia
is not entirely known, but increased apoptosis seems to
require functional p53, c-myc, and Bcl2 genes. Therefore, it
seems that radiosensitivity results from the apoptosis reten­
tion after activating p53, c-myc, and Bcl2 genes by radiation
[40]. RT in conjunction with a wide range of treatment
modalities such as (myeloablative) chemotherapy and the
subsequent graft-versus-tumor effect are therefore required
to obtain significant eradication of malignant clones [22,
Chap. 16].
5.6.2.2	The Normal Hematopoietic System
Bone marrow stem cells typically have D0 values ranging
from 0.5 to 1.4 Gy. These cells are therefore intrinsically
radiosensitive. Even though hematopoietic rescue (i.e., stem
cells) could allow the delivery of high doses that eliminate the
recipient’s marrow cells which in turn prepares the stem cell
microenvironment for repopulation to occur, this procedure is
associated with long-term or life-threatening consequences.
Critical organs of concern in WBI are those described as late
responding tissues. Fortunately, as effect on these tissues is
dependent on total dose, dose rate and fractionation, appro­
priate scheduling of the treatment allows some protection.
While a modest number of cancer cells being radiosensitive
will be killed, complete cancer cell killing may not always be
possible with radiation alone. Therefore, TBI often needs to
be given together with chemotherapy. Moreover, incomplete
bone marrow ablation may result in mixed chimerism of bone
marrow after transplant [22, 40].
As a result of immunological mismatch between recipient
and donor, rejection of donor stem cells may occur. In order
to avoid this, TBI is used to prevent the recipient from reject­
ing donor stem cells.
Bone marrow transplantation results are influenced by the
treatment schedule. Lymphoid cells repair a large amount of
radiation-induced DNA damage during the time interval
between fractions. Hence, the effectiveness of fractionated
TBI is reduced significantly in comparison with single-dose
TBI and results in more graft rejections. However, the frac­
tionation effect is reversed for bone marrow stromal cells
(“colony-forming unit fibroblasts”). The success of engraft­
ment is based on the likelihood of sparing bone marrow stro­
mal cells, and when treatment is delivered as single-dose
TBI, the likelihood of damaging both bone marrow stromal
cells and their progenitors increases. Importantly, the effec­
tiveness of single-dose TBI is increased significantly in com­
parison with fractionated TBI, but at the cost of increased
long-term toxicity [22].
5 Clinical Radiobiology for Radiation Oncology"
"Explain how whole-body irradiation (WBI) is utilized in treating leukemia, detailing the biological basis for variations in leukemic cell radiosensitivity and the role of specific genes.","Whole-body irradiation (WBI) is frequently employed to sterilize small numbers of widely dispersed cells that are particularly vulnerable to radiation – a characteristic often observed in leukemia cases. This makes WBI a viable treatment option, especially for residual marrow disease associated with leukemia. The biological basis for the diverse radiosensitivity exhibited by leukemic cells stems from a spectrum of intrinsic cellular sensitivity, ranging from high susceptibility to significant resistance. This variability is largely determined by the functional status of key genes involved in apoptosis pathways. Specifically, increased apoptosis – the programmed cell death process – following radiation exposure appears to be linked to the activation and sustained expression of p53, c-myc, and Bcl2 genes. Radiation initially triggers these genes, leading to a prolonged state of apoptotic retention. The extent of leukemic cell killing is therefore directly correlated with the level of functional activity within these three genes. Consequently, WBI’s effectiveness in treating leukemia often necessitates its combination with other therapies such as myeloablative chemotherapy and subsequent graft-versus-tumor effects to effectively eliminate malignant clones. Reference: Molecular Radiation Biology, Section 5.6.2.1 – Leukemia","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.2	 Details of Radiobiological Mechanisms of Whole-Body Irradiation | Sub-sub-subsection: 5.6.2.1	 Leukemia | Content: Since a characteristic of WBI is that it can sterilize small
numbers of widely spread cells that are sensitive to radiation,
this makes it a treatment option for (residual) marrow dis­
ease. Biologically, leukemia is associated with a spectrum of
intrinsic cellular radiosensitivity that ranges from notable
radiosensitivity to significant radioresistance, which deter­
mine the extent of leukemic cell killing. The molecular biol­
ogy responsible for the variety in radiosensitivity of leukemia
is not entirely known, but increased apoptosis seems to
require functional p53, c-myc, and Bcl2 genes. Therefore, it
seems that radiosensitivity results from the apoptosis reten­
tion after activating p53, c-myc, and Bcl2 genes by radiation
[40]. RT in conjunction with a wide range of treatment
modalities such as (myeloablative) chemotherapy and the
subsequent graft-versus-tumor effect are therefore required
to obtain significant eradication of malignant clones [22,
Chap. 16]."
Describe the biological mechanisms contributing to variations in radiosensitivity observed within leukemia cells and how this relates to whole-body irradiation (WBI) treatment strategies.,"Leukemia exhibits a wide range of radiosensitivity, from significant vulnerability to substantial resistance, which profoundly impacts treatment outcomes. This variability stems primarily from differences in apoptotic pathways triggered by radiation exposure. Specifically, increased apoptosis is linked to the functional status of key genes – p53, c-myc, and Bcl2 – within leukemia cells. Radiation activates these genes, leading to a sustained state of apoptosis due to the retention of this activated state. Cells with intact or upregulated versions of these genes are more susceptible to radiation-induced cell death. Conversely, leukemias with compromised p53, c-myc, or Bcl2 function demonstrate increased radioresistance. The clinical significance of this is realized in WBI treatment; because complete eradication of leukemia cells isn't always achievable through radiation alone, it’s frequently combined with chemotherapy and graft-versus-tumor strategies to target the radiosensitive cell populations while simultaneously attempting to eliminate resistant clones. Furthermore, the sensitivity of hematopoietic stem cells (typically 0.5-1.4 Gy) dictates the potential for high-dose WBI, but also highlights the risk of long-term consequences associated with complete marrow ablation and subsequent repopulation challenges. The scheduling of TBI – whether fractionated or single-dose – impacts this process; fractionation allows lymphoid cells to repair DNA damage, reducing effectiveness, while stromal cell sparing is more effective with a single dose, though at the cost of increased toxicity. Ultimately, understanding these mechanisms guides treatment planning to maximize efficacy and minimize adverse effects.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.2	 Details of Radiobiological Mechanisms of Whole-Body Irradiation | Sub-sub-subsection: 5.6.2.2	 The Normal Hematopoietic System | Content: this makes it a treatment option for (residual) marrow dis­
ease. Biologically, leukemia is associated with a spectrum of
intrinsic cellular radiosensitivity that ranges from notable
radiosensitivity to significant radioresistance, which deter­
mine the extent of leukemic cell killing. The molecular biol­
ogy responsible for the variety in radiosensitivity of leukemia
is not entirely known, but increased apoptosis seems to
require functional p53, c-myc, and Bcl2 genes. Therefore, it
seems that radiosensitivity results from the apoptosis reten­
tion after activating p53, c-myc, and Bcl2 genes by radiation
[40]. RT in conjunction with a wide range of treatment
modalities such as (myeloablative) chemotherapy and the
subsequent graft-versus-tumor effect are therefore required
to obtain significant eradication of malignant clones [22,
Chap. 16].
5.6.2.2	The Normal Hematopoietic System
Bone marrow stem cells typically have D0 values ranging
from 0.5 to 1.4 Gy. These cells are therefore intrinsically
radiosensitive. Even though hematopoietic rescue (i.e., stem
cells) could allow the delivery of high doses that eliminate the
recipient’s marrow cells which in turn prepares the stem cell
microenvironment for repopulation to occur, this procedure is
associated with long-term or life-threatening consequences.
Critical organs of concern in WBI are those described as late
responding tissues. Fortunately, as effect on these tissues is
dependent on total dose, dose rate and fractionation, appro­
priate scheduling of the treatment allows some protection.
While a modest number of cancer cells being radiosensitive
will be killed, complete cancer cell killing may not always be
possible with radiation alone. Therefore, TBI often needs to
be given together with chemotherapy. Moreover, incomplete
bone marrow ablation may result in mixed chimerism of bone
marrow after transplant [22, 40].
As a result of immunological mismatch between recipient
and donor, rejection of donor stem cells may occur. In order
to avoid this, TBI is used to prevent the recipient from reject­
ing donor stem cells.
Bone marrow transplantation results are influenced by the
treatment schedule. Lymphoid cells repair a large amount of
radiation-induced DNA damage during the time interval
between fractions. Hence, the effectiveness of fractionated
TBI is reduced significantly in comparison with single-dose
TBI and results in more graft rejections. However, the frac­
tionation effect is reversed for bone marrow stromal cells
(“colony-forming unit fibroblasts”). The success of engraft­
ment is based on the likelihood of sparing bone marrow stro­
mal cells, and when treatment is delivered as single-dose
TBI, the likelihood of damaging both bone marrow stromal
cells and their progenitors increases. Importantly, the effec­
tiveness of single-dose TBI is increased significantly in com­
parison with fractionated TBI, but at the cost of increased
long-term toxicity [22].
5 Clinical Radiobiology for Radiation Oncology
256"
"Within the context of whole-body irradiation (WBI) for palliative cancer treatment, how does a low dose rate typically affect normal tissue toxicity compared to a high dose rate, and what factors contribute to this difference?","In WBI, utilizing low dose rates generally results in decreased incidence of normal tissue toxicity when contrasted with higher dose rates. This effect is primarily attributed to the differing mechanisms of radiation damage at these varying rates. At lower doses, the primary mechanism of DNA damage – single-strand breaks – dominates. These breaks are more readily repaired by cellular mechanisms before significant permanent damage occurs. Conversely, at high doses, double-strand breaks become predominant, leading to more extensive and less repairable DNA damage, consequently causing greater harm to surrounding normal tissues. Furthermore, the rate of radiation deposition influences the tissue’s ability to redistribute and repair the radiation damage. The overall effect is a reduced impact on healthy cells when lower dose rates are employed in WBI.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.2	 Details of Radiobiological Mechanisms of Whole-Body Irradiation | Sub-sub-subsection: 5.6.2.3		 Palliation | Content: Unlike curative RT, palliative RT is used to control the
symptoms of advanced, incurable cancer (the primary
tumor or metastatic deposits) by slowing down tumor
growth, controlling symptoms and causing cancer to regress
[41]. WBI may be effective for palliation, especially for
advanced leukemia or lymphoma, using rather low doses in
the order of 0.1 Gy/fraction. In experiments with solid
tumors, tumor cells with colony-forming abilities in both
experiments of formation of artificial metastases and natu­
rally developing metastases, these tumors could be sup­
pressed with specific low doses [42]. It is assumed that
either chronic TBI or low dose total body irradiation may
stimulate the immune system to eliminate metastatic cancer
cells. However, nowadays, TBI is only very rarely used for
this indication. For further information, see tumor microen­
vironment changes and abscopal effect discussed in Sect.
5.15.
5.6.3
Fractionation Dose Effect in Whole-­
Body Irradiation
In WBI, the doses delivered for transplantation of bone mar­
row or stem cells are in the range of 10–12 Gy [43]. To
reduce long-term complications in the recipient, this dose is
typically divided into 2 Gy fractions [14, 44]. In the so-called
reduced conditioning regimens, single fractions of 2 Gy or
two fractions of 2 Gy are given. When WBI is split into mul­
tiple small fractions and spread over a period of time, out­
comes are generally improved, and toxicity is diminished.
While the former is due to the fact that the dose is still ade­
quate to eradicate both any cells of residual malignant tissue
and the recipient’s bone marrow, the latter is explained in
Sect. 5.2 [45].
5.6.4
Dose Rate Effect in Whole-Body
Irradiation
The dose rate in RT influences the effectiveness of the radia­
tion exposure. An explanation of how a survival curve may
become shallower at low dose rates was discussed in Sect.
5.5. In WBI, the pattern is different from localized RT
because the effect of radiation dose depends on the tissue
type. When low dose rate is used, the incidence of normal
tissue toxicity is decreased in comparison with high dose
rates [46–48]. However, changing the radiation dose rate
from the low dose rate to high does not affect the probability
of engraftment success [49, 50].
5.7
Prediction of Radiation Response
of Tumors (Box 5.8)
5.7.1
Principles of Prediction of Radiation
Response of Tumors
Radiation treatment has been improved greatly over the last
two decades by integrating 3-D anatomy into planning sys­
tems, and developing of image-guided (IGRT), intensity-­
modulated (IMRT) and intensity modulated arc radiation
therapy (IMAT) techniques, resulting in individualization of
treatment. Radiation treatment portals and arcs are much
more tailored to the anatomy of each patient’s tumor and
normal tissue. Today medical professionals prescribe RT
taking into account the type of primary tumor, its grade,
stage, location, size, biological characteristics, and
­concomitant treatments. However, these clinical parameters
do not give an accurate prediction of the effect of RT since
wide variations in response occur between patients given the
same treatment and having similar tumors [51–53].
Furthermore, diverse treatment options are now available.
Moreover, several tumor RT sensitizing strategies using dif­
ferent drugs which can enhance the effects of RT, especially
those that target the molecular pathways, are becoming
available now. Treatments frequently employ combined
approaches. One such avenue currently underway involves
trials that combine chemotherapy/RT with immunotherapy.
RT can differentially affect tumor responses due to a vari­
ety of radiobiological factors, which are referred to as the
6R’s. Among them, hypoxia, proliferation, and radiosensitiv­
ity have proved to be fairly good predictive markers [51–34].
Beyond these well-known classical biomarkers (BMs), there
are also a number of promising candidate molecular bio­
Box 5.8 Tumor Response Prediction
•	Functional parameters including reoxygenation,
redistribution, repopulation, repair, and radiosensi­
tivity
are
traditionally
used
to
define
radio-responsiveness.
•	The role of repopulation also proved to be a robust
predictive marker as illustrated in head and neck
cancer where increased tumor expression of EGFR
indicates efficacy of accelerated radiation.
•	DNA, RNA, and proteins have recently been identi­
fied to define tumor RT responsiveness yet few of
them have attained clinical validation and/or
application.
P. Sminia et al."
"The text discusses factors influencing the response of tumors to radiation therapy beyond traditional clinical parameters. Describe at least three of these ‘6R’s’ and explain their relevance in predicting tumor response to radiation, citing examples where appropriate.","Several radiobiological factors, collectively known as the ‘6R’s,’ significantly impact a tumor's responsiveness to radiation therapy and contribute to variations in treatment outcomes. These include: 

1. **Hypoxia:** This refers to the reduced oxygen tension within the tumor microenvironment. Hypoxic conditions are frequently encountered due to rapid tumor growth and inadequate vascularization. Hypoxia profoundly sensitizes tumors to radiation damage because hypoxic cells exhibit increased DNA repair capacity, making them more resistant to single-session radiation. Conversely, reoxygenation of hypoxic areas after radiation can actually reverse this sensitization.

2. **Proliferation:** The rate at which tumor cells divide directly correlates with their susceptibility to radiation damage. Cells actively undergoing mitosis are particularly vulnerable because they have a higher concentration of DNA replicating during the S-phase of the cell cycle, making them more susceptible to double-strand breaks induced by ionizing radiation. Increased proliferation rates generally lead to greater sensitivity.

3. **Radiosensitivity:** This encompasses various mechanisms that enhance a tumor’s vulnerability to radiation damage. These include alterations in DNA repair pathways, changes in cellular metabolism, and the upregulation of pro-apoptotic genes. For example, some tumors exhibit increased expression of proteins involved in nucleotide excision repair (NER), which is a key DNA repair mechanism, rendering them less sensitive to radiation.

Beyond these primary ‘R’s’, the text also highlights other factors like redistribution (the movement of cells within the tumor), repair mechanisms, and the potential for radiosensitizing drugs. The example of increased EGFR expression in head and neck cancer, as noted in the text, demonstrates how specific molecular biomarkers can serve as robust predictive markers for treatment efficacy.

Reference: MolecularRadiationBiology, Section 5.7.1 – Principles of Prediction of Radiation Response of Tumors","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.3		 Fractionation Dose Effect in Whole-Body Irradiation | Content: 5.7.1
Principles of Prediction of Radiation
Response of Tumors
Radiation treatment has been improved greatly over the last
two decades by integrating 3-D anatomy into planning sys­
tems, and developing of image-guided (IGRT), intensity-­
modulated (IMRT) and intensity modulated arc radiation
therapy (IMAT) techniques, resulting in individualization of
treatment. Radiation treatment portals and arcs are much
more tailored to the anatomy of each patient’s tumor and
normal tissue. Today medical professionals prescribe RT
taking into account the type of primary tumor, its grade,
stage, location, size, biological characteristics, and
­concomitant treatments. However, these clinical parameters
do not give an accurate prediction of the effect of RT since
wide variations in response occur between patients given the
same treatment and having similar tumors [51–53].
Furthermore, diverse treatment options are now available.
Moreover, several tumor RT sensitizing strategies using dif­
ferent drugs which can enhance the effects of RT, especially
those that target the molecular pathways, are becoming
available now. Treatments frequently employ combined
approaches. One such avenue currently underway involves
trials that combine chemotherapy/RT with immunotherapy.
RT can differentially affect tumor responses due to a vari­
ety of radiobiological factors, which are referred to as the
6R’s. Among them, hypoxia, proliferation, and radiosensitiv­
ity have proved to be fairly good predictive markers [51–34].
Beyond these well-known classical biomarkers (BMs), there
are also a number of promising candidate molecular bio­
Box 5.8 Tumor Response Prediction
•	Functional parameters including reoxygenation,
redistribution, repopulation, repair, and radiosensi­
tivity
are
traditionally
used
to
define
radio-responsiveness.
•	The role of repopulation also proved to be a robust
predictive marker as illustrated in head and neck
cancer where increased tumor expression of EGFR
indicates efficacy of accelerated radiation.
•	DNA, RNA, and proteins have recently been identi­
fied to define tumor RT responsiveness yet few of
them have attained clinical validation and/or
application.
P. Sminia et al."
"Describe the relationship between dose rate and normal tissue toxicity in whole-body irradiation (WBI), as outlined in the provided text, and explain why a lower dose rate might be associated with reduced toxicity compared to a higher dose rate.","In WBI, the effectiveness of radiation exposure is significantly influenced by the dose rate. The text indicates that at low dose rates, the incidence of normal tissue toxicity decreases relative to high dose rates. This difference arises because the pattern of radiation damage differs from localized radiation treatments. With lower dose rates, cells have more time to repair DNA damage before subsequent irradiation events occur. Conversely, a rapid increase in radiation dose (high dose rate) overwhelms the cell’s repair mechanisms, leading to greater accumulation of unrepaired DNA lesions and consequently, increased cellular damage and toxicity within normal tissues. The text specifically notes that changing the dose rate from low to high does not affect the probability of engraftment success, suggesting a fundamental shift in the biological response rather than simply altering the overall radiation burden. Furthermore, the concept of ‘6R’s’ – hypoxia, proliferation, radiosensitivity, and other factors – are highlighted as predictive markers for tumor responses, indicating that these complex interactions contribute to variations in toxicity observed across different dose rates. Reference: MolecularRadiationBiology > section: 5: Clinical Radiobiology for Radiation Oncology > subsection: 5.6 Whole-Body Irradiation > subsubsection: 5.6.4 Dose Rate Effect in Whole-Body Irradiation","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.6	 Whole-Body Irradiation | Sub-subsection: 5.6.4		 Dose Rate Effect in Whole-Body Irradiation | Content: Irradiation
The dose rate in RT influences the effectiveness of the radia­
tion exposure. An explanation of how a survival curve may
become shallower at low dose rates was discussed in Sect.
5.5. In WBI, the pattern is different from localized RT
because the effect of radiation dose depends on the tissue
type. When low dose rate is used, the incidence of normal
tissue toxicity is decreased in comparison with high dose
rates [46–48]. However, changing the radiation dose rate
from the low dose rate to high does not affect the probability
of engraftment success [49, 50].
5.7
Prediction of Radiation Response
of Tumors (Box 5.8)
5.7.1
Principles of Prediction of Radiation
Response of Tumors
Radiation treatment has been improved greatly over the last
two decades by integrating 3-D anatomy into planning sys­
tems, and developing of image-guided (IGRT), intensity-­
modulated (IMRT) and intensity modulated arc radiation
therapy (IMAT) techniques, resulting in individualization of
treatment. Radiation treatment portals and arcs are much
more tailored to the anatomy of each patient’s tumor and
normal tissue. Today medical professionals prescribe RT
taking into account the type of primary tumor, its grade,
stage, location, size, biological characteristics, and
­concomitant treatments. However, these clinical parameters
do not give an accurate prediction of the effect of RT since
wide variations in response occur between patients given the
same treatment and having similar tumors [51–53].
Furthermore, diverse treatment options are now available.
Moreover, several tumor RT sensitizing strategies using dif­
ferent drugs which can enhance the effects of RT, especially
those that target the molecular pathways, are becoming
available now. Treatments frequently employ combined
approaches. One such avenue currently underway involves
trials that combine chemotherapy/RT with immunotherapy.
RT can differentially affect tumor responses due to a vari­
ety of radiobiological factors, which are referred to as the
6R’s. Among them, hypoxia, proliferation, and radiosensitiv­
ity have proved to be fairly good predictive markers [51–34].
Beyond these well-known classical biomarkers (BMs), there
are also a number of promising candidate molecular bio­
Box 5.8 Tumor Response Prediction
•	Functional parameters including reoxygenation,
redistribution, repopulation, repair, and radiosensi­
tivity
are
traditionally
used
to
define
radio-responsiveness.
•	The role of repopulation also proved to be a robust
predictive marker as illustrated in head and neck
cancer where increased tumor expression of EGFR
indicates efficacy of accelerated radiation.
•	DNA, RNA, and proteins have recently been identi­
fied to define tumor RT responsiveness yet few of
them have attained clinical validation and/or
application.
P. Sminia et al."
The text discusses factors influencing a tumor’s response to radiation therapy beyond traditional clinical parameters. Describe at least three of these ‘6R’s’ and explain their relevance in predicting treatment outcome.,"Several radiobiological factors, collectively known as the ‘6R’s,’ significantly impact a tumor's response to radiation therapy and contribute to variations in patient outcomes despite similar treatments. These include hypoxia, proliferation, radiosensitivity, redistribution, repopulation, and repair. Hypoxia, or low oxygen levels within the tumor microenvironment, is a critical factor because hypoxic cells are inherently more resistant to radiation damage due to reduced DNA repair mechanisms. Redistribution refers to the spatial shift of tumor cells during treatment, often leading to increased exposure to radiation in areas previously shielded. Repopulation describes the regrowth of tumor cells following radiation, with rapid repopulation correlating with poorer long-term outcomes. Repair encompasses the cellular processes involved in repairing damaged DNA after irradiation; enhanced repair capacity directly reduces the effectiveness of radiation. Finally, radiosensitivity itself represents the inherent susceptibility of a particular cell population to radiation damage – variations in this factor contribute significantly to interpatient response differences. The text highlights that hypoxia, proliferation, and radiosensitivity are particularly reliable predictive markers for tumor response. Furthermore, emerging research is exploring the role of molecular biomarkers such as DNA, RNA, and proteins, though clinical validation remains limited.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Content: 5.7.1
Principles of Prediction of Radiation
Response of Tumors
Radiation treatment has been improved greatly over the last
two decades by integrating 3-D anatomy into planning sys­
tems, and developing of image-guided (IGRT), intensity-­
modulated (IMRT) and intensity modulated arc radiation
therapy (IMAT) techniques, resulting in individualization of
treatment. Radiation treatment portals and arcs are much
more tailored to the anatomy of each patient’s tumor and
normal tissue. Today medical professionals prescribe RT
taking into account the type of primary tumor, its grade,
stage, location, size, biological characteristics, and
­concomitant treatments. However, these clinical parameters
do not give an accurate prediction of the effect of RT since
wide variations in response occur between patients given the
same treatment and having similar tumors [51–53].
Furthermore, diverse treatment options are now available.
Moreover, several tumor RT sensitizing strategies using dif­
ferent drugs which can enhance the effects of RT, especially
those that target the molecular pathways, are becoming
available now. Treatments frequently employ combined
approaches. One such avenue currently underway involves
trials that combine chemotherapy/RT with immunotherapy.
RT can differentially affect tumor responses due to a vari­
ety of radiobiological factors, which are referred to as the
6R’s. Among them, hypoxia, proliferation, and radiosensitiv­
ity have proved to be fairly good predictive markers [51–34].
Beyond these well-known classical biomarkers (BMs), there
are also a number of promising candidate molecular bio­
Box 5.8 Tumor Response Prediction
•	Functional parameters including reoxygenation,
redistribution, repopulation, repair, and radiosensi­
tivity
are
traditionally
used
to
define
radio-responsiveness.
•	The role of repopulation also proved to be a robust
predictive marker as illustrated in head and neck
cancer where increased tumor expression of EGFR
indicates efficacy of accelerated radiation.
•	DNA, RNA, and proteins have recently been identi­
fied to define tumor RT responsiveness yet few of
them have attained clinical validation and/or
application.
P. Sminia et al."
"The text discusses several factors that influence a tumor’s response to radiation therapy, referring to them as the ‘6R’s’. Can you describe at least three of these ‘6R’s’ and explain how each contributes to variations in treatment outcome?","The ‘6R’s’ represent key radiobiological factors that significantly impact a tumor's response to radiation therapy, leading to considerable variability between patients receiving similar treatments. Three prominent examples are hypoxia, proliferation, and radiosensitivity. Hypoxia, or low oxygen levels within the tumor microenvironment, is a crucial factor because it dramatically reduces the effectiveness of radiation. Tumors with high levels of hypoxia exhibit significantly lower rates of cell death following irradiation compared to well-oxygenated tumors. This is due to several mechanisms including reduced DNA damage repair and impaired apoptosis (programmed cell death). Proliferation refers to the rate at which tumor cells are dividing. Higher proliferation rates generally lead to increased radiosensitivity, meaning that cells are more susceptible to radiation-induced DNA damage. Conversely, lower proliferation rates can result in decreased sensitivity. Finally, radiosensitivity itself is a key parameter – it represents the inherent ability of a cell or tissue to respond to radiation. This is influenced by factors like DNA repair capacity and the presence of specific cellular pathways involved in responding to oxidative stress caused by radiation. Variations in these ‘6R’s’—hypoxia, proliferation, and radiosensitivity—account for the wide range of responses observed when patients receive identical radiation treatments. Reference: MolecularRadiationBiology, Section 5.7.1 – Principles of Prediction of Radiation Response of Tumors","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Sub-subsection: 5.7.1		 Principles of Prediction of Radiation Response of Tumors | Content: 5.7.1
Principles of Prediction of Radiation
Response of Tumors
Radiation treatment has been improved greatly over the last
two decades by integrating 3-D anatomy into planning sys­
tems, and developing of image-guided (IGRT), intensity-­
modulated (IMRT) and intensity modulated arc radiation
therapy (IMAT) techniques, resulting in individualization of
treatment. Radiation treatment portals and arcs are much
more tailored to the anatomy of each patient’s tumor and
normal tissue. Today medical professionals prescribe RT
taking into account the type of primary tumor, its grade,
stage, location, size, biological characteristics, and
­concomitant treatments. However, these clinical parameters
do not give an accurate prediction of the effect of RT since
wide variations in response occur between patients given the
same treatment and having similar tumors [51–53].
Furthermore, diverse treatment options are now available.
Moreover, several tumor RT sensitizing strategies using dif­
ferent drugs which can enhance the effects of RT, especially
those that target the molecular pathways, are becoming
available now. Treatments frequently employ combined
approaches. One such avenue currently underway involves
trials that combine chemotherapy/RT with immunotherapy.
RT can differentially affect tumor responses due to a vari­
ety of radiobiological factors, which are referred to as the
6R’s. Among them, hypoxia, proliferation, and radiosensitiv­
ity have proved to be fairly good predictive markers [51–34].
Beyond these well-known classical biomarkers (BMs), there
are also a number of promising candidate molecular bio­
Box 5.8 Tumor Response Prediction
•	Functional parameters including reoxygenation,
redistribution, repopulation, repair, and radiosensi­
tivity
are
traditionally
used
to
define
radio-responsiveness.
•	The role of repopulation also proved to be a robust
predictive marker as illustrated in head and neck
cancer where increased tumor expression of EGFR
indicates efficacy of accelerated radiation.
•	DNA, RNA, and proteins have recently been identi­
fied to define tumor RT responsiveness yet few of
them have attained clinical validation and/or
application.
P. Sminia et al.
257
markers currently being tested in preclinical and clinical
studies such as genetic and epigenetic factors as discussed in
Sect. 5.10. In this section, classical and modern BMs as well
as their role in predictive assays will be discussed in addition
to the available methods used to detect them.
5.7.2"
"Explain how factors related to primary tumors, such as size, location, and cellular characteristics, can influence the predicted response of a tumor to radiation therapy. Furthermore, discuss why metastatic disease requires separate consideration in predicting treatment outcomes.","The prediction of a tumor's response to radiation therapy is significantly influenced by several key factors associated with the primary tumor itself. Tumor size plays a crucial role; larger tumors generally require higher doses of radiation to achieve adequate control due to increased volume and potential for complications. The location of the tumor within the body also matters, as anatomical constraints can limit the ability to deliver sufficient dose to the target while sparing surrounding healthy tissues. Furthermore, cellular characteristics such as proliferation rate (as measured by Ki-67 expression or similar markers) and genetic instability are important predictors. Rapidly dividing cells are typically more sensitive to radiation damage because they have a higher rate of DNA replication during their active phase, making them vulnerable to errors introduced by ionizing radiation. Tumors with high levels of genetic instability tend to be less responsive as they can repair DNA damage more effectively.

Metastatic disease necessitates separate consideration because it represents an entirely different clinical scenario than the primary tumor. While metastasis undoubtedly contributes to a patient's overall survival probability, its response to radiation therapy is often unpredictable and frequently independent of the primary tumor’s characteristics. Metastatic sites may have vastly different microenvironments, varying levels of vascularization, and distinct cellular populations that affect radiosensitivity. Furthermore, attempting to predict response based solely on the primary tumor would be misleading as it doesn't account for the altered biology occurring at distant locations. Therefore, assessing metastatic disease requires a separate evaluation focusing on its specific characteristics and potential treatment options, often involving different radiation techniques or systemic therapies.

Ultimately, predictive assays should prioritize measures of local control and normal tissue effects to accurately assess the therapeutic impact.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Sub-subsection: 5.7.2		 Classical Factors | Content: ­
­
5.15
Predictive factors in therapy may relate more directly to
primary tumors and their local control. Metastatic disease
may need to be considered separately even though it clearly
plays a significant role in survival of the patient. Research to
develop predictive assays for tumor RT response should gen­
erally measure local control and normal tissue effects [16,
51, 52]."
"Describe the key characteristics of tumor vasculature and how these differences contribute to a reduced oxygen supply within the tumor microenvironment, impacting its response to ionizing radiation?","Tumor vascular beds exhibit significant deviations from those found in normal tissues. Specifically, they are characterized by single-layered endothelium with frequent gaps that are directly incorporated into the tumor mass by tumor cells. This results in the formation of immature capillaries – often described as ‘rabdoms’ – which lack the robust structure and functionality of typical blood vessels. Consequently, this dysfunctional vascular network severely limits oxygen delivery to the tumor tissue, leading to widespread hypoxia within the tumor microenvironment (TME). The hypoxic conditions are further compounded by nutritional deprivation due to acidic TME environments, reducing the availability of essential metabolites for cellular processes. Critically, this reduced oxygen supply directly diminishes the tumor’s sensitivity to ionizing radiation; cells in hypoxic regions exhibit a markedly lower capacity to repair DNA damage and undergo apoptosis compared to well-oxygenated counterparts, representing a significant factor influencing treatment efficacy. This phenomenon is often referred to as the ‘oxygen effect.’","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Sub-subsection: 5.7.2		 Classical Factors | Sub-sub-subsection: 5.7.2.1		 Tumor Oxygen Status | Content: Tumor vascular beds differ significantly from those in nor­
mal tissues in their structure and physiological characteris­
tics. Tumor-related blood vessels are composed of
single-layered endothelium, commonly containing gaps
between the endothelium taken up by tumor cells, resulting
in immature capillaries. A dysfunctional blood supply
through the tumor reduces oxygen delivery, resulting in areas
of tumor hypoxia, acidic intra-TME nutritional deprivation,
and therewith the tumor response to IR For more information
about predictive tests to assess Oxygen Effect to Tumor
Hypoxia see Sect. 5.8."
"Describe the significance of measuring the mitotic index in assessing tumor response to radiation therapy, and explain how it relates to the concept of tumor repopulation.","The mitotic index represents the proportion of cells within a tissue sample that are actively undergoing mitosis (cell division). In the context of radiation oncology, a higher mitotic index indicates a greater capacity for rapid cell proliferation following irradiation. This is crucial because radiation therapy aims to induce DNA damage and halt tumor growth. However, if the tumor contains a significant population of cells with an elevated mitotic index – meaning they are actively attempting to repair damaged DNA and resume division – then these cells will repopulate the treated area after radiation exposure, leading to tumor regrowth. Therefore, a high mitotic index is often associated with poorer outcomes in radiation therapy as it signifies a greater potential for successful tumor repopulation. Conversely, a lower mitotic index suggests that fewer cells are actively dividing, potentially indicating a more favorable response to treatment and reduced risk of recurrence. The biopsy staining procedure used to determine the mitotic index relies on quantifying mitosis ratios within stained tissue sections.

Reference: MolecularRadiationBiology, Section 5.7.2.2 – Classical Factors","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Sub-subsection: 5.7.2		 Classical Factors | Sub-sub-subsection: 5.7.2.2		 Repopulation | Content: ­
­
­
52
5.5
Table 5.5 Description of biomarkers and laboratory assays for assessing repopulation
Test
Procedure
Method
Statements
The mitotic index
Using tissue sections to
calculate mitosis ratios
Biopsy staining
A correlation exists between outcome results and the labeling
index, but it is weak
DNA flow cytometry
Calculating the percentage of
cells that are in the S phase of
the cell cycle
Flow cytometry
The tumor potential
doubling time, Tpot
Using bromodeoxyuridine as a
stain in a tumor biopsy
Flow cytometry
Tpot is not a significant predictor for RT response
Endogenous markers
(Ki67)
Proliferation-associated
proteins can be detected using
antibodies
Gene signature,
biopsy studies,
or plasma/serum
Molecular marker profiles
(p-53, Bcl-2, Ki-67, or
EGFR expression)
Measuring the level of these
markers
Continuous hyperfractionated accelerated radiotherapy
(CHART) is recommended in head and neck cancer patients
who have high expression of EGFR in tumor or low organized
patterns of Ki-67 and is negative for Bcl-2 or p53 expression
5 Clinical Radiobiology for Radiation Oncology
258"
"Describe the relationship between radiation response and cellular mechanisms like apoptosis and autophagy in tumor cells, particularly concerning their impact on colony-forming ability and the clinical application of techniques like the clonogenic assay.","Radiation exposure can trigger a variety of cell death pathways within tumor cells, notably apoptosis and autophagy. Both processes ultimately lead to a significant reduction in the tumor's capacity for proliferation – specifically, a loss of colony-forming ability. Apoptosis, or programmed cell death, is characterized by a cascade of events leading to cellular dismantling, while autophagy represents a self-eating process where the cell degrades its own components. The extent to which these mechanisms are activated dictates the overall sensitivity of the tumor to radiation.  Clinically, assessing this radiosensitivity relies heavily on techniques like the clonogenic assay, which measures the ability of cells to form colonies after irradiation. However, a major technical hurdle has been consistently dispersing tumor cells ex vivo accurately, leading to difficulties in reliably replicating the in vivo conditions and hindering the clinical application of this method. Further investigation into predictive tests for radiosensitivity is detailed in Chapter 7. Reference: [Molecular Radiation Biology], Section 5.7.2.3","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Sub-subsection: 5.7.2		 Classical Factors | Sub-sub-subsection: 5.7.2.3		 Intrinsic Radiosensitivity | Content: Various types of cell death, such as apoptosis and autophagy,
which also result in a loss of colony-forming ability, contrib­
ute to tissue reactions caused by IR. Many publications pro­
posed that cellular radiosensitivity could be measured by the
clonogenic assay. A technical challenge of dispersing tumor
cells ex vivo has interfered with its clinical application, how­
ever [52].
For more information about predictive tests to assess
radiosensitivity, see Chap. 7.
5.7.3"
"Describe the various approaches used to assess a tumor's response to radiation therapy, focusing on the types of biomarkers and assays employed at the protein, DNA, and RNA levels.","Evaluating a tumor’s response to radiation therapy relies on identifying predictive biomarkers that correlate with treatment outcome. Several strategies are utilized, primarily categorized by the level of biological material analyzed. At the protein level, tissue microarrays coupled with immuno-histochemistry provide a high-throughput method for assessing protein expression patterns. Luminex technology allows for multi-analyte immunobead-based profiling, examining numerous proteins simultaneously. Mass spectrometry offers precise quantification of protein abundance, while antibody chip technologies further refine this analysis.  At the DNA level, genomic instability is a key consideration. Techniques like in situ hybridization (ISH) are used to identify specific DNA sequences within tumor tissue. More sophisticated methods include genetic variation sequence analyses targeting copy number variations (CNVs) and single nucleotide polymorphisms (SNPs), as well as epigenetic variation sequence focusing on chromatin modifications such as acetylation, ubiquitylation, phosphorylation, sumoylation, and methylation. These approaches aim to capture the genomic heterogeneity driving treatment response. Finally, at the RNA level, techniques like low-density Taqman arrays are employed for detecting small gene expression signatures following whole genome profiling. In situ hybridization (ISH) and fluorescence in situ hybridization (FISH) allow for the detection of RNA transcripts within tumor tissue. Quantitative polymerase chain reaction (qPCR), also known as real-time chain reaction, is used to quantify and amplify targeted DNA molecules, while gene expression arrays generate comprehensive profiles for deriving classifiers or signatures related to treatment outcomes or prognosis. Next-generation sequencing technologies are increasingly utilized to study complex gene expression patterns across different mRNA species, providing a deeper understanding of the tumor’s response mechanisms.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.7	 Prediction of Radiation Response of Tumors (Box 5.8) | Sub-subsection: 5.7.3		 Modern Factors | Content: 5.4
­
5.16
­
­
­
­
53
­
5758
­
58
­
­
­
3
­
1659
5.17
5.6
P. Sminia et al.
259
Table 5.6 Description of modern biomarkers and assays for analyses of RT response
Marker
Advantage
Assay
Protein
Expression profiling at the protein level can be a
good candidate marker as proteins are responsible
for the actual cellular functions.
Tissue microarrays for high-­throughput immuno-­histochemistry, luminex
technology for multi-analyte immunobead-based profiling, mass spectrometry
methods and antibody chip.
DNA
The DNA level can be a good candidate marker
because everyone is genetically unique, cancer is
caused by genetic changes, and is characterized by
genomic instability. Variation in individual genes
influences risk for cancer development. Variations
in a patient’s response to treatment are ascribed to
the heterogeneity of genetic changes in cancer.
In situ hybridization (ISH) for identifying a DNA sequence in tumor tissue,
genetic variation sequence for analyses of duplications and deletions of large
region DNA (copy number variation (CNV) and Single Nucleotide
Polymorphisms (SNPs), epigenetic variation sequence for chromatin
modification and DNA acetylation, ubiquitylation, phosphorylation,
sumoylation, and methylation.
RNA
Low-density Taqman arrays for detecting small signatures after whole genome
profiling, ISH and FISH for detecting RNA in sample in situ. Quantitative
polymerase or real-time chain reaction for quantify and amplify a targeted
DNA molecule. Gene expression array for deriving profiles, classifiers or
signatures associated with prediction of treatment results or prognosis.
Next-generation sequencing technologies for the study of gene expression
profiles of different species of mRNA.
5 Clinical Radiobiology for Radiation Oncology
260
5.8"
"Explain the differences between acute and chronic hypoxia within a tumor microenvironment, and how these distinctions relate to radiation therapy outcomes.","Hypoxia, defined as tissue oxygen concentrations below 3%, significantly impacts cancer treatment strategies. There are two primary types of hypoxia observed in tumors: acute and chronic. Acute hypoxia arises from transiently occluded blood vessels, leading to a sudden reduction in oxygen supply – essentially a perfusion-limited event. This is typically short-lived and reversible if the vessel obstruction resolves. Conversely, chronic hypoxia results from diffusion limitations, where the rate of oxygen delivery cannot keep pace with the consumption by tumor cells. This persistent lack of oxygen leads to cell necrosis. Critically, hypoxic cells exhibit increased resistance to both radiation therapy and chemotherapy compared to their well-oxygenated counterparts. During irradiation, the outer layers of cells – those exposed to sufficient oxygen – are primarily damaged and killed. However, the chronically hypoxic cells located deeper within the tumor mass remain largely unaffected due to their inherent radioresistance. Consequently, a traditional single high-dose radiation regimen often fails to adequately eradicate the entire tumor volume. To mitigate this issue, radiation is frequently administered in smaller daily fractions. This allows oxygenated cells to be killed first, and the reoxygenation of surrounding hypoxic cells following each fraction can then expose these resistant cells to lethal doses of radiation. Reference: MolecularRadiationBiology, Section 5.8 – Tumor Hypoxia and Therapeutic Approaches","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Content: Approaches
Hypoxia refers to conditions with low oxygen. The oxygen
concentration of most normal tissue in the human body is
around 5–7% and tissues with less than 3% oxygen are
regarded as hypoxic. Hypoxic cells are known to be more
resistant to radiation and chemotherapy. Hypoxia is also a
potent microenvironmental factor promoting metastatic pro­
gression of cancer  [60].
Hypoxia in tumor cells can be of two types—acute
hypoxia or chronic hypoxia. Acute hypoxia is a transient
perfusion-limited hypoxia due to transiently occluded blood
vessels [61]. Chronic hypoxia is a diffusion-limited hypoxia
and can lead to necrosis [62].
5.18
62
­
As hypoxic cells are more radioresistant than oxygenated
cells (Chap. 3), irradiation of a tumor will predominantly kill
the outer layer of cells leaving the hypoxic cells. One way to
reduce this problem is to divide the radiation dose into many
daily fractions, which will allow the hypoxic cells nearest to
the oxygenated cells to be reoxygenated after the oxygenated
cells have been killed [63]. In this section, we will give an
overview of the most important mechanisms and pathways
induced by hypoxia since these are potential targets in con­
nection with treatments.
5.8.1"
"Explain the phenomenon of oxygen enhancement ratio (OER) in radiation biology and how it relates to different types of ionizing radiation, specifically differentiating between low-LET and high-LET radiation.","The oxygen enhancement ratio (OER) quantifies the increased sensitivity of cells to radiation damage when molecular oxygen is present compared to hypoxic conditions. This effect arises because radiation generates free radicals, primarily hydroxyl radicals (•OH), which react with water molecules to form more free radicals. In an anaerobic environment lacking oxygen, these free radicals can be chemically restored through donation of hydrogen atoms by reducing agents like glutathione – a process called restitution. However, the presence of molecular oxygen (O2) leads to the formation of superoxide radical anions (O2•−), which cannot undergo restitution and effectively ‘fixes’ the radiation damage, making it permanent. Consequently, cells are significantly more vulnerable to radiation in an aerobic environment. The OER is defined as the ratio of doses required under hypoxic versus aerated conditions to achieve a specific biological effect.  Notably, low-LET radiations like X-rays exhibit higher OER values (around 2.5 – 3.5 for high doses), reflecting their ability to generate substantial free radical damage that can be effectively countered by oxygen’s restorative capabilities. Conversely, high-LET radiation such as alpha particles cause direct DNA damage with minimal restitution potential, resulting in an OER of approximately 1, indicating no significant enhancement due to oxygen presence. Neutron radiation exhibits an intermediate OER value, and the OER decreases substantially as the linear energy transfer (LET) increases – specifically falling slowly until around 60 keV/μm LET before rapidly approaching 1 at higher LET values like 200 keV/μm. This relationship highlights a strategic approach to targeting hypoxic tumors by utilizing high-LET radiation, where oxygen’s restorative effects are minimized.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.1		 Oxygen Effect | Content: As described in Chap. 3, oxygen modifies the biological
effects of low LET IR. For such radiation, DNA damage pre­
dominantly occurs through the indirect effect of radiation-­
induced water radicals. In the absence of oxygen, DNA
radicals can become chemically restituted through donation
of hydrogen atoms by SH-compounds (such as glutathione).
However, if molecular oxygen is present, RO2· is produced
which cannot be restored. Oxygen thus “fixes” the damage
produced by free radicals (i.e., makes the radiation damage
permanent). Therefore, cells are more sensitive to radiation
in the presence of oxygen than in its absence.
The relative radiosensitivity of cells increases dramati­
cally when the oxygen tension increases from 3 mmHg
(0.4% O2) to about 30 mmHg (4% O2), which corresponds to
the oxygen concentration in venous blood [64]. Beyond this,
it reaches a plateau with no further effect of increasing the
oxygen tension. In order to compete with restitution, molec­
ular oxygen must be present during or within microseconds
after the radiation exposure because the lifetime of the free
radicals generated by the radiation is less than about 10−5 s.
The oxygen enhancement ratio (OER) is the ratio of doses
under hypoxic to aerated conditions that produce the same
biologic effect. In vitro studies have shown OER of X-rays to
be around 3.5 for high doses and around 2.5 in low dose
regions of the cell survival curves [65].
High LET radiations like alpha particles cause direct and
complex damage to DNA with little possibility for restitu­
tion. Therefore, there is no enhanced effect with presence of
oxygen (i.e., OER is 1). It is intermediate for neutrons and
comparatively high for low LET radiations such as X-rays
and gamma rays [66, 67]. OER decreases as LET increases.
The OER falls slowly until about 60 keV/μm of LET, then
falls rapidly and reaches 1, i.e., no oxygen effect, when LET
P. Sminia et al.
261
reaches about 200 keV/μm [66]. Thus, one way to target
hypoxia is to use high LET radiation (Box 5.9).
5.8.2"
"Describe the cellular responses a tumor cell undergoes in response to hypoxia, detailing both survival mechanisms and how these responses contribute to disease progression.","In hypoxic tumor environments, cells initiate a complex series of adaptive responses primarily aimed at maintaining viability and promoting aggressive behavior. A key initial step is the upregulation of hypoxia-inducible factors (HIFs), which are transcription factors activated by low oxygen levels. This triggers several interconnected pathways. Firstly, angiogenesis – the formation of new blood vessels – is stimulated to improve nutrient delivery, though this is often insufficient given the extent of hypoxia. Simultaneously, erythropoiesis, or increased red blood cell production, attempts to enhance oxygen-carrying capacity. Critically, cells shift towards anaerobic metabolism, relying on glycolysis for ATP generation rather than oxidative phosphorylation, a less efficient but rapid process. Furthermore, hypoxic tumor cells exhibit enhanced migration capabilities, facilitating metastasis – the spread of cancer cells to distant sites. To conserve energy and nutrients, several other mechanisms are activated including reduced protein synthesis (through HIF-mediated repression of translation factors) and autophagy, a cellular self-eating process that recycles damaged organelles and proteins to recover resources. Finally, the unfolded protein response (UPR), triggered by misfolded proteins accumulating due to metabolic stress, contributes to cell survival. Collectively, these responses – angiogenesis, erythropoiesis, anaerobic metabolism, migration, reduced protein synthesis, autophagy, and UPR activation – represent a concerted effort by tumor cells to overcome hypoxia but ultimately contribute to increased malignancy and metastatic potential. Reference: MolecularRadiationBiology, Section 5.8.2 - Hypoxia Response Pathways","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.2		 Hypoxia Response Pathways | Content: When a tumor grows, the existing vasculature will not be
able to provide oxygen and nutrients to the more distant cells
resulting in regions of hypoxia. During hypoxic conditions,
the cells that survive are those that undergo adaptive
responses, which are not only critical to survival but also
promote malignancy and metastasis. The main purposes of
the adaptive responses are to uphold ATP production and
save energy as well as nutrients. ATP production is main­
tained by the formation of new blood vessels (angiogenesis),
increased production of red blood cells (erythropoiesis),
switch to anaerobic metabolism, and migration to a more
favorable environment (metastasis). The processes to save
energy include reduction of protein synthesis and recircula­
tion of nutrients (autophagy). The signaling pathways regu­
lating these processes are induced by upregulation of
hypoxia-inducible factors (HIFs) and activation of the
unfolded protein response (UPR)."
"Describe the mechanism by which HIF-1α is regulated in response to changes in oxygen availability, detailing the roles of proline hydroxylase enzymes (PHDs) and the von Hippel-Lindau (VHL) ubiquitin ligase complex.","HIF-1α’s stability is tightly controlled by its interaction with molecular oxygen. In the presence of oxygen, proline hydroxylases (PHDs), a family of enzymes, catalyze the hydroxylation of proline residues within HIF-1α. This addition of two OH groups effectively ‘tags’ HIF-1α for degradation. Subsequently, the hydroxylated HIF-1α is recognized by the von Hippel-Lindau (VHL) ubiquitin ligase complex. The VHL complex then binds to the hydroxylated HIF-1α and catalyzes the attachment of ubiquitin chains – a process known as ubiquitination. This ubiquitination signals the proteasome, a cellular machine responsible for protein degradation, to target HIF-1α for destruction. Critically, when oxygen levels are low (hypoxic conditions), PHDs become inactive because they require oxygen as a cofactor. Consequently, HIF-1α is no longer hydroxylated and remains stable, allowing it to bind to the β-subunit and initiate gene transcription. This entire process represents a direct feedback mechanism where cellular oxygen availability dictates the fate of HIF-1α.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.2		 Hypoxia Response Pathways | Sub-sub-subsection: 5.8.2.1		 Hypoxia-Inducible Factor (HIF) | Content: HIF-1 was discovered in 1995. Its importance is emphasized
by the award of the Nobel prize in Physiology or Medicine
2019 to William Kaelin Jr., Peter J. Ratcliffe and Gregg
L. Semenza for their work in elucidating how HIF senses and
adapts cellular response to oxygen availability. The HIF pro­
tein family consists of three different alpha subunits (HIF-1α,
HIF-2α, HIF-3α), which bind to the same type of β-subunit.
In this section, we will only discuss HIF-1, which is the only
one which is ubiquitously expressed and the most well stud­
ied. In the presence of molecular oxygen, proline-­hydroxylase
enzymes (PHD) hydroxylate HIF-1α, i.e., PHDs add two
OH-groups to proline residues on HIF-1α using oxygen as a
cofactor. Hydroxylated HIF-1α is recognized by von-Hippel-­
Lindau (VHL)-ubiquitin ligase complexes, which then adds
ubiquitin-groups that target HIF-1α for degradation. Without
oxygen, HIF-1α is stabilized allowing it to bind to the
β-subunit and activate gene transcription.
HIF-1 is known to induce transcription of more than 60
genes by binding to a common promoter called hypoxia
response element (HRE). Some of these genes are involved
in increasing oxygen supply, such as VEGF (which induces
angiogenesis), erythropoietin (which stimulate red blood cell
production), and iron transport to erythroid tissue. HRE-­
regulated genes are also involved in cell proliferation, such
as insulin-like growth factor-2 (IGF-2) and transforming
growth factor-α (TGF-α). HIF-1 also induces transcription of
genes involved in switching of metabolic pathways to use
glycolysis as a primary mechanism of ATP production. HIF
thus regulate transcription of genes involved in glucose
transport into the cell (i.e., GLUT1 and GLUT3), and in
maintaining intracellular pH during increased lactate pro­
duction such as carbonic anhydrase 9 (CAIX) and monocar­
boxylate transporter 4 (MCT4).
In addition to promoting hypoxia tolerance, HIF-1 also
upregulates transcription of genes involved in several steps
of metastasis: angiogenesis, epithelial-mesenchymal transi­
tion (EMT), cell motility, intra/extravasation, and the forma­
tion of a premetastatic niche facilitating colonization of
metastatic tumor cells.
Stabilization of HIF and activation of its downstream
pathways occur at relatively moderate levels of hypoxia
(<about 2% O2) as compared to radiation resistance, which
occurs below about 0.1% O2 [68]."
"Describe the mechanism by which HIF-1α is regulated in response to hypoxia, including the roles of proline hydroxylases (PHDs) and the von Hippel-Lindau (VHL) complex.","HIF-1α, a key component of the hypoxic response pathway, is stabilized under low oxygen conditions. This stabilization begins with hydroxylation of HIF-1α by enzymes called proline hydroxylases (PHDs). These PHDs utilize molecular oxygen as a cofactor to add two hydroxyl groups (-OH) to specific proline residues within the HIF-1α protein. Once hydroxylated, the modified HIF-1α is recognized and bound by the von Hippel-Lindau (VHL) complex, a ubiquitin ligase. The VHL complex then catalyzes the attachment of ubiquitin molecules to HIF-1α, marking it for degradation via the proteasome pathway. Critically, in the presence of sufficient oxygen, PHDs remain active, continuously hydroxylating HIF-1α and preventing its stabilization, thus maintaining low levels of this transcription factor. Reference: [MolecularRadiationBiology, Section 5.8.2.1 – Hypoxia-Inducible Factor (HIF)]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.2		 Hypoxia Response Pathways | Sub-sub-subsection: 5.8.2.2		 The Unfolded Protein Response (UPR) | Content: 5.8.2.1		Hypoxia-Inducible Factor (HIF)
HIF-1 was discovered in 1995. Its importance is emphasized
by the award of the Nobel prize in Physiology or Medicine
2019 to William Kaelin Jr., Peter J. Ratcliffe and Gregg
L. Semenza for their work in elucidating how HIF senses and
adapts cellular response to oxygen availability. The HIF pro­
tein family consists of three different alpha subunits (HIF-1α,
HIF-2α, HIF-3α), which bind to the same type of β-subunit.
In this section, we will only discuss HIF-1, which is the only
one which is ubiquitously expressed and the most well stud­
ied. In the presence of molecular oxygen, proline-­hydroxylase
enzymes (PHD) hydroxylate HIF-1α, i.e., PHDs add two
OH-groups to proline residues on HIF-1α using oxygen as a
cofactor. Hydroxylated HIF-1α is recognized by von-Hippel-­
Lindau (VHL)-ubiquitin ligase complexes, which then adds
ubiquitin-groups that target HIF-1α for degradation. Without
oxygen, HIF-1α is stabilized allowing it to bind to the
β-subunit and activate gene transcription.
HIF-1 is known to induce transcription of more than 60
genes by binding to a common promoter called hypoxia
response element (HRE). Some of these genes are involved
in increasing oxygen supply, such as VEGF (which induces
angiogenesis), erythropoietin (which stimulate red blood cell
production), and iron transport to erythroid tissue. HRE-­
regulated genes are also involved in cell proliferation, such
as insulin-like growth factor-2 (IGF-2) and transforming
growth factor-α (TGF-α). HIF-1 also induces transcription of
genes involved in switching of metabolic pathways to use
glycolysis as a primary mechanism of ATP production. HIF
thus regulate transcription of genes involved in glucose
transport into the cell (i.e., GLUT1 and GLUT3), and in
maintaining intracellular pH during increased lactate pro­
duction such as carbonic anhydrase 9 (CAIX) and monocar­
boxylate transporter 4 (MCT4).
In addition to promoting hypoxia tolerance, HIF-1 also
upregulates transcription of genes involved in several steps
of metastasis: angiogenesis, epithelial-mesenchymal transi­
tion (EMT), cell motility, intra/extravasation, and the forma­
tion of a premetastatic niche facilitating colonization of
metastatic tumor cells.
Stabilization of HIF and activation of its downstream
pathways occur at relatively moderate levels of hypoxia
(<about 2% O2) as compared to radiation resistance, which
occurs below about 0.1% O2 [68].
5.8.2.2		The Unfolded Protein Response (UPR)
Similar to IR resistance, activation of the unfolded protein
response (UPR) occurs below about 0.2% O2 and contributes
to hypoxia tolerance by reducing protein synthesis and
inducing autophagy. UPR is activated by accumulation of
unfolded and misfolded proteins in the endoplasmic reticu­
lum (ER). Such accumulation takes place under hypoxia
because post-translational disulfide bond formation, which is
necessary for correct protein folding, have been shown to be
oxygen dependent [69]. There are three ER stress sensors in
the ER membrane, PERK (protein kinase RNA-like endo­
plasmic reticulum kinase), IRE1a (inositol requiring kinase
1a), and ATF6 (activating transcription factor 6). All three
are activated by the release of BiP (Binding immunoglobin
Protein) from the ER membrane. Activated PERK phosphor­
ylates eIF2α (Eukaryotic translation initiation factor 2 sub­
unit α), which inhibits translation of protein except for some
key proteins, which remain translated [70]. One of these is
ATF4 (activating transcription factor 4), which induces tran­
scription of genes required for autophagy, amino acid syn­
thesis and import, redox balance, and angiogenesis [71].
However, if the stress becomes excessive, ATF4 can switch
from pro-survival to pro-death and induce apoptosis [72].
Active IRE1α (Inositol-requiring transmembrane kinase/
endoribonuclease 1α) reduces protein synthesis through the
degradation of selected mRNAs. It also activates an inflam­
matory response and promotes autophagy as well as apopto­
sis. BIP release allows ATF6 translocation to Golgi, where
cleavage of this protein results in release of transcriptionally
Box 5.9 The Oxygen Enhancement Ratio
The oxygen enhancement ratio varies with:
•	Cell cycle phase
•	Type/quality of radiation
•	Radiation dose and dose rate
5 Clinical Radiobiology for Radiation Oncology
262
active ATF6 (DNA-binding cytoplasmic domain of ATF6),
which contributes to restoring ER homeostasis [70].
5.8.3"
"Describe the various methods utilized to measure hypoxia within tumors, detailing both invasive and non-invasive techniques, and highlighting the principles behind each approach.","Several methodologies exist for assessing tumor hypoxia, ranging from invasive to non-invasive. Invasive approaches frequently employ polarographic electrodes, such as Eppendorf electrodes, which are considered the ‘gold standard’ but suffer from tissue damage during insertion and oxygen consumption, leading to a high signal-to-noise ratio at low oxygen levels [73]. Fiber-optic probes also exist but remain invasive due to their limited applicability to accessible tumors. A biochemical method involves injecting pimonidazole into patients prior to biopsies or tumor resection. Pimonidazole is a 2-nitroimidazole compound that specifically binds to thiol-containing proteins within hypoxic cells, allowing for quantitative assessment via immunohistochemistry [75]. Non-invasive techniques include hypoxia Positron Emission Tomography (PET) imaging. Nitroimidazoles are utilized as radiosen­sitizers due to their ability to undergo multiple electron reductions and can be employed as radiotracers carrying a positron emitter. The reduction process relies on reductases found exclusively in viable hypoxic cells, leading to accumulation of the labeled molecules within hypoxic regions detectable via PET [73, 76]. Examples include 18F-Fluoromisonidazole (18F-FMISO) and other derivatives like 18F-FAZA and 18F-FETNIM. These tracers’ lipophilicity facilitates membrane diffusion but also contributes to slow clearance from normoxic tissue, necessitating a delay before imaging. Magnetic Resonance Imaging (MRI) offers non-ionizing alternatives with improved spatial resolution. BOLD-MRI leverages the paramagnetic properties of deoxyhemoglobin by measuring changes in T2*-relaxation rates, while TOLD-MRI utilizes increased T1 relaxation due to dissolved oxygen. DCE-MRI employs gadolinium contrast agents and tracks their accumulation over time. Finally, endogenous markers like Hypoxia-Inducible Factor 1α (HIF) and its target proteins CA9 and GLUT1 are frequently studied; however, their reliability is compromised by potential regulation beyond simply oxygen levels.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.3		 Measurement of Tumor Hypoxia | Content: Hypoxia in tumor cells can be measured using oxygen probes
or protein markers for hypoxia. Polarographic electrodes, in
particular Eppendorf electrodes, have long been regarded as
the gold standard for measuring tumor hypoxia. The limita­
tions of these are that they must be inserted into the tumor
damaging the tissue and that they consume oxygen resulting
in a high signal-to-noise ratio for low oxygen levels [73].
Fiber-optic probes have also been developed [74], but the
disadvantage of both is that this is an invasive method, which
can only be used in accessible tumors. Another method is
injection of pimonidazole to patients before biopsies or total
resection of the tumor. Pimonidazole is a 2-nitroimidazole
compound, which binds to thiol-containing proteins specifi­
cally in hypoxic cells, and it can be used in immunohisto­
chemical analyses to quantitative assessment of tumor
hypoxia [75].
A noninvasive alternative method is hypoxia PET imag­
ing. 2-Nitroimidazoles have been developed as radiosen­
sitizers due to their ability to undergo up to six electron
reductions. However, they can also be used as radiotrac­
ers carrying a positron emitter. The reduction requires the
activity of reductases that are only present in viable hypoxic
cells resulting in the radiolabeled molecules being accumu­
lated in hypoxic regions visible to PET imaging. Examples
of nitroimidazole or nitroimidazole-derivative tracers are
18F-Fluoromisonidazole (18F-FMISO), 18F-Fluoroazomycin-­
Arabinofuranoside
(18F-FAZA),
18F-labeled
fluoroery­
thronitroimidazole (18F-FETNIM),
18F-fluoroetanidazole
(18F-HX4),
and
18F-2-(2-Nitro-1H-imidazol-1-yl)-N-
(2,2,3,3,3-pentafluoropropyl) acetamide (18F-EF5) [73,
76]. Other redox-sensitive compounds include Copper(II)
diacetyl-­bis (N4-methylthiosemicarbazone) (60Cu-ATSM)
and
123I-iodoazomycinarabinoside (123I-IAZA) [77]. Of
these, 18F-MISO is the most extensively used in both preclin­
ical and clinical studies. F-MISO is highly lipophilic, which
means it can easily diffuse across cell membranes but also
that the clearance of the tracer from normoxic tissue is very
slow. This results in a low tumor to blood ratio and the need
to wait for typically 2 h between tracer injection and imag­
ing. A general problem in PET imaging is the low spatial
resolution.
Magnetic resonance imaging (MRI) is non-ionizing and
has a better spatial resolution than PET. Different MRI tech­
niques have been evaluated for quantification of the blood
oxygenation level in tissue. Blood oxygen level-dependent
MRI (BOLD-MRI) uses the paramagnetic quality of deoxy­
hemoglobin in contrast to oxygenated hemoglobin. This can
be measured as an increase in T2*-relaxation rate. A similar
technique, tissue oxygen level-dependent MRI (TOLD-
MRI) uses an increase in T1 relaxation caused by the pres­
ence of dissolved oxygen. A third technique is dynamic
contrast-­enhanced MRI (DCE-MRI) in which a paramag­
netic contrast agent such as gadolinium is used and imaged
over time [78].
HIF and its target proteins such as CA9 and GLUT1 are
upregulated under hypoxia (see above). Accordingly, they
have been studied as endogenous markers for hypoxia and
seem to co-localize with 2-nitroimidazoles. However, their
expression can also be regulated by other factors than oxy­
gen, which reduces their reliability in quantifying tumor
hypoxia.
5.8.4"
"Describe the principles behind Blood Oxygen Level-Dependent (BOLD)-MRI and Tissue Oxygen Level-Dependent (TOLD)-MRI, highlighting the specific molecular changes that drive their respective imaging capabilities.","BOLD-MRI and TOLD-MRI are MRI techniques utilized to assess oxygenation levels within tissues, primarily in applications like tumor imaging. BOLD-MRI leverages the differing magnetic properties of deoxyhemoglobin and oxyhemoglobin. Deoxyhemoglobin is paramagnetic, meaning it disrupts the local magnetic field, leading to an increase in the T2*-relaxation rate – a measurable parameter in MRI that reflects how quickly transverse magnetization decays. Therefore, regions with higher concentrations of deoxyhemoglobin exhibit increased T2* values, allowing for visualization of oxygenation changes. Conversely, TOLD-MRI operates on a similar principle but focuses on the paramagnetic effect of dissolved oxygen. The presence of dissolved oxygen causes an increase in the T1 relaxation rate – another MRI parameter related to longitudinal magnetization decay. Consequently, areas with higher oxygen concentrations display increased T1 values, providing a means to quantify tissue oxygenation. Both techniques rely on the fundamental difference in magnetic susceptibility between oxygenated and deoxygenated hemoglobin molecules.  It’s important to note that while BOLD-MRI primarily detects deoxyhemoglobin, TOLD-MRI directly measures dissolved oxygen concentration.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.4		 Therapeutic Approaches to Tumor Hypoxia | Content: to wait for typically 2 h between tracer injection and imag­
ing. A general problem in PET imaging is the low spatial
resolution.
Magnetic resonance imaging (MRI) is non-ionizing and
has a better spatial resolution than PET. Different MRI tech­
niques have been evaluated for quantification of the blood
oxygenation level in tissue. Blood oxygen level-dependent
MRI (BOLD-MRI) uses the paramagnetic quality of deoxy­
hemoglobin in contrast to oxygenated hemoglobin. This can
be measured as an increase in T2*-relaxation rate. A similar
technique, tissue oxygen level-dependent MRI (TOLD-
MRI) uses an increase in T1 relaxation caused by the pres­
ence of dissolved oxygen. A third technique is dynamic
contrast-­enhanced MRI (DCE-MRI) in which a paramag­
netic contrast agent such as gadolinium is used and imaged
over time [78].
HIF and its target proteins such as CA9 and GLUT1 are
upregulated under hypoxia (see above). Accordingly, they
have been studied as endogenous markers for hypoxia and
seem to co-localize with 2-nitroimidazoles. However, their
expression can also be regulated by other factors than oxy­
gen, which reduces their reliability in quantifying tumor
hypoxia.
5.8.4
Therapeutic Approaches to Tumor
Hypoxia
­
5.7
Table 5.7 A summary of different approaches to improve treatment of
hypoxic tumors
Approaches
Rationale
High LET
radiotherapy
Direct damage to DNA, less dependent on
oxygen levels
Hyperbaric oxygen
Improve tumor oxygenation
Blood transfusion
Improve oxygen supply
Perfluorocarbons
Artificial blood substances to improve
oxygen supply
Nicotinamide
Vitamin B3 analogue to overcome acute
hypoxia
Carbogen
95% oxygen + 5% carbon dioxide to
overcome chronic hypoxia
Hypoxic cell
radiosensitizers
Compounds that mimic oxygen and can
radio-sensitize tumors
Bioreductive drugs
Reduces to cytotoxic form during hypoxic
conditions
Hypoxia-targeted
radiotherapy
Dose escalation/adaptation in hypoxic
sub-volumes of tumor
Dichloroacetate
Inhibits pyruvate dehydrogenase kinase 1,
alter tumor metabolism, enhances efficacy
of hypoxic cytotoxins
Electron transport
chain inhibitors
Decreased oxygen consumption in
mitochondria and increased radiosensitivity
P. Sminia et al.
263"
"Describe several strategies employed to address tumor hypoxia in radiation oncology, detailing the mechanisms behind each approach.","Several therapeutic approaches are utilized to combat tumor hypoxia, a common consequence of radiation treatment that significantly impairs its effectiveness. One primary method involves hyperbaric oxygen therapy (HBO), typically utilizing 2-4 atmospheres of 100% oxygen. While effective in increasing oxygen levels within the tumor microenvironment, HBO can induce vasoconstriction due to the high partial pressure of oxygen, potentially hindering blood flow. To circumvent this issue, ‘carbogen’ – a mixture of 5% carbon dioxide and 95% oxygen – is frequently employed. Carbogen reduces chronic diffusion-limited hypoxia by decreasing the partial pressure of oxygen within the tumor, thereby promoting vasodilation and improving oxygen delivery. For acute hypoxic events, nicotinamide has been shown to mitigate transient fluctuations in tumor blood flow. Finally, the ARCON strategy combines carbogen breathing with accelerated hyperfractionated radiation therapy (aRT). This synergistic approach aims to reduce tumor proliferation during treatment while minimizing damage to surrounding normal tissues by simultaneously addressing both hypoxia and accelerating the dose delivery.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.4		 Therapeutic Approaches to Tumor Hypoxia | Sub-sub-subsection: 5.8.4.1		 Improving Oxygenation to Tumors | Content: The simplest approach to reduce tumor hypoxia is to let the
patient breathe hyperbaric oxygen (HBO) (2–4 atmosphere
100% oxygen). However, this may cause vasoconstriction.
To avoid this, a mixture of 5% carbon dioxide and 95%
oxygen called carbogen was introduced. Carbogen breath­
ing reduces chronic diffusion limited hypoxia. For acute
hypoxia, nicotinamide can be used to mitigate transient
fluctuations in tumor blood flow [79]. In the ARCON strat­
egy, a combination of carbogen and nicotinamide was used
in association with accelerated hyperfractionated RT to
reduce tumor proliferation during treatment and spare nor­
mal tissues [80]."
"Explain the rationale behind utilizing hypoxic cell radiosensitizers in radiation oncology, detailing their mechanism of action and key characteristics desired in an effective agent.","Hypoxic cells within tumors exhibit significantly reduced sensitivity to ionizing radiation (IR) due to the limited availability of oxygen required for DNA repair mechanisms. Hypoxic cell radiosensitizers are employed to overcome this resistance by acting as ‘oxygen substitutes.’ These agents diffuse into poorly vascularized tumor regions, penetrating hypoxic areas and effectively increasing the cellular uptake of oxygen. This increased oxygen concentration facilitates the formation of reactive oxygen species (ROS) during IR exposure. Critically, these sensitizers stabilize free radicals generated by radiation, preventing their rapid scavenging by repair mechanisms and thereby prolonging the damaging effects of the radiation on DNA. An ideal radiosensitizer must possess several key properties: chemical stability to maintain efficacy over time, low metabolic breakdown to ensure consistent delivery, high solubility in both water and lipids for optimal distribution within the tumor microenvironment, activity across all phases of the cell cycle, effectiveness at low doses of radiation, and importantly, minimal toxicity to normal cells to establish a therapeutic window. The ‘enhancement ratio,’ which represents the dose increase needed with the sensitizer compared to without, is a crucial metric for evaluating radiosensitizer efficacy – typically around 1.82 was observed with misonidazole in mouse models. Clinical studies, such as the DAHANCA 5 trial utilizing nimorazole, demonstrate significant improvements in local control and disease-free survival rates when combined with radiation therapy.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.4		 Therapeutic Approaches to Tumor Hypoxia | Sub-sub-subsection: 5.8.4.2		 Hypoxic Cell Radiosensitizers | Content: Hypoxic cell radiosensitizers are chemical or pharmacologic
agents that can increase the radiosensitivity of cells, which
are deficient in oxygen. These agents are oxygen substitutes
that diffuse into poorly vascularized areas of tumors and pen­
etrate to reach hypoxic cells within the tissue. Therefore,
when administered with radiation these agents cause fixation
of the free radical damage caused by IR and thereby increases
its lethal effect. A radiosensitizer should have an increased
effect on tumors relative to normal cells to achieve a
­therapeutic window/gain. An ideal hypoxic cell radiosensi­
tizer should be chemically stable; have low metabolic break­
down; be highly soluble in water and lipids; act at all phases
of cell cycle; be active at low doses of radiation; and cause
low toxicity to normal cells [81].
82
­
5.8
The enhancement ratio is the ratio of X-ray doses needed
to control 50% of the tumors in the absence and presence of
the drug. It was found to be around 1.82 for misonidazole in
a mouse mammary tumor model for a single-dose treatment
but for multifraction regimens, it is usually less [83].
The Danish Head and Neck Cancer 5 (DAHANCA 5)
study which comprised 422 patients with pharyngeal and
supraglottic carcinomas found a clear benefit of using
nimorazole as a radiosensitizer. Thus, no increase in late
radiation toxicity and a highly significant benefit in 5-year
local control rates and disease-free survival rates. The use of
nimorazole as a radiosensitizer in head and neck cancer is
standard practice in Denmark [55]."
"Explain the concept of bioreductive drugs in the context of tumor hypoxia and radiation therapy, detailing how their mechanism of action contributes to a therapeutic window.","Bioreductive drugs represent a targeted approach within radiation oncology designed to exploit the unique metabolic vulnerabilities present under hypoxic conditions. These drugs are specifically engineered to be non-toxic when oxygen is abundant – essentially inactive in normal cells – but they undergo enzymatic reduction only when cellular oxygen levels are low, typically found within tumors. This reduction process transforms the drug into an active cytotoxic agent. The key advantage lies in this differential action: the drug selectively targets hypoxic tumor cells while sparing surrounding, well-oxygenated normal tissues. Consequently, a therapeutic window emerges—a dose of the bioreductive drug can be administered that is significantly higher than what would be tolerated by normal cells without causing systemic toxicity, yet still effectively eliminates hypoxic tumor cells. Unlike traditional radiosensitizers which directly increase cell sensitivity to radiation, bioreductive drugs operate synergistically with radiation, amplifying the cytotoxic effect specifically within hypoxic environments. The concept of Hypoxic Cell Cytotoxicity Ratio (HCR) quantifies this difference; it represents the relative drug dosage needed to achieve a similar level of cell death in hypoxic versus oxic cells, highlighting the varying sensitivities induced by these compounds. Common examples include fused ring benzoquinones like mitomycin C and organic N-oxides such as tirapazamine, each with distinct reduction pathways and therapeutic potential. Reference: MolecularRadiationBiology, Section 5.8.4.3 – Therapeutic Approaches to Tumor Hypoxia","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.4		 Therapeutic Approaches to Tumor Hypoxia | Sub-sub-subsection: 5.8.4.3		 Bioreductive Drugs | Content: Bioreductive drugs are drugs that are reduced by cells to
form active cytotoxic agents only under hypoxic conditions
while being non-reduced in an oxic cell. Thus, the differen­
tial action on hypoxic cells (i.e., tumor cells) compared to
oxic cells, i.e., normal cells) gives a therapeutic window/
gain. Unlike the direct action of hypoxic cell radiosensitiz­
ers, which increases the radiosensitivity of cells, bioreduc­
tive drugs act synergistic with radiation to improve tumor
cell kill [84].
The hypoxic cell cytotoxicity ratio (HCR) is the dose of a
drug required to kill a certain fraction of oxic cells compared
to the dose of drug required to kill an equal fraction of
hypoxic cells. HCR varies for different classes of bioreduc­
tive drugs [85]. The main classes of bioreductive compounds
are fused ring benzoquinones (e.g., mitomycin C), organic
N-oxides (e.g., tirapazamine), and nitroheterocyclic com­
pounds (e.g., RSU-1089), among which tirapazamine is the
widely investigated drug."
"Describe the concept of the Hypoxia Cell Cytotoxicity Ratio (HCR) and its significance within the context of therapeutic approaches targeting tumor hypoxia, including examples of bioreductive drugs.","The Hypoxia Cell Cytotoxicity Ratio (HCR) represents a key metric in understanding the synergistic effect of bioreductive drugs combined with radiation therapy for treating hypoxic tumors. It quantifies the difference in drug dosage required to achieve equivalent cell death between oxic (normal) cells and hypoxic tumor cells. Specifically, HCR is defined as the dose of a bioreductive drug needed to kill a specific fraction of hypoxic cells compared to the same fraction of oxic cells. Importantly, hypoxic cells are significantly more resistant to radiation damage than their oxygenated counterparts due to impaired DNA repair mechanisms. Bioreductive drugs exploit this vulnerability by being preferentially activated within the hypoxic environment, leading to increased cytotoxicity in these resistant cells. The HCR varies depending on the specific class of bioreductive drug utilized; for instance, fused ring benzoquinones like mitomycin C and organic N-oxides such as tirapazamine exhibit different ratios. Nitroheterocyclic compounds, like RSU-1089, also fall within this category. Tirapazamine is a particularly well-studied example of a bioreductive drug whose HCR influences the optimal radiation dose escalation strategy for targeting hypoxic tumor regions. Understanding and manipulating the HCR allows clinicians to maximize therapeutic efficacy by precisely tailoring radiation treatment plans to specifically address the challenges posed by hypoxia in tumors.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.4		 Therapeutic Approaches to Tumor Hypoxia | Sub-sub-subsection: 5.8.4.4		 Hypoxia-Targeted Radiotherapy | Content: oxic cells, i.e., normal cells) gives a therapeutic window/
gain. Unlike the direct action of hypoxic cell radiosensitiz­
ers, which increases the radiosensitivity of cells, bioreduc­
tive drugs act synergistic with radiation to improve tumor
cell kill [84].
The hypoxic cell cytotoxicity ratio (HCR) is the dose of a
drug required to kill a certain fraction of oxic cells compared
to the dose of drug required to kill an equal fraction of
hypoxic cells. HCR varies for different classes of bioreduc­
tive drugs [85]. The main classes of bioreductive compounds
are fused ring benzoquinones (e.g., mitomycin C), organic
N-oxides (e.g., tirapazamine), and nitroheterocyclic com­
pounds (e.g., RSU-1089), among which tirapazamine is the
widely investigated drug.
5.8.4.4		Hypoxia-Targeted Radiotherapy
As described above, imaging techniques such as PET and
MRI can be used to identify hypoxic regions within the tumor.
They are used in RT treatment planning to define radioresis­
tant sub-volumes that can be targeted with boost dose or dose
escalation. Targeting hypoxic sub-volumes in tumors by
adaptive RT/dose painting can lead to improved tumor con­
trol. There is early clinical evidence from a phase 2 random­
ized trial that dose escalation to hypoxic volumes using
18F-FMISO PET is feasible without increased normal tissue
toxicity in head and neck cancers [86]. The utility of hypoxia-
directed RT dose painting is being studied in other cancer
subsites such as lung, pancreas, and cervix cancer [87–89]."
"The text describes several approaches to enhancing the effectiveness of radiation therapy in hypoxic tumor environments. Explain the concept of the ‘Hypoxic Cell Cytotoxicity Ratio’ (HCR), detailing its significance and how it relates to different classes of bioreductive drugs, specifically referencing examples like mitomycin C or tirapazamine.","The Hypoxic Cell Cytotoxicity Ratio (HCR) represents a critical metric for understanding the efficacy of bioreductive drugs in combination with radiation therapy. It quantifies the difference in drug sensitivity between normal, oxygenated cells (oxic cells) and hypoxic tumor cells. Specifically, HCR is defined as the dose of a bioreductive drug required to kill a specific fraction of hypoxic cells compared to the same fraction of oxic cells. This ratio varies significantly depending on the class of drug utilized. For instance, drugs like mitomycin C (a fused ring benzoquinone) and tirapazamine (an organic N-oxide) are designed to be more effective against hypoxic cells due to their ability to be reduced under low oxygen conditions, leading to increased cellular toxicity. The key is that hypoxia dramatically alters the metabolic state of tumor cells, rendering them disproportionately sensitive to these drugs compared to normal cells. Understanding and manipulating HCR is therefore central to optimizing radiation treatment strategies for tumors with significant hypoxic regions.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.8		 Tumor Hypoxia and Therapeutic Approaches | Sub-subsection: 5.8.4		 Therapeutic Approaches to Tumor Hypoxia | Sub-sub-subsection: 5.8.4.5		 Molecular Targeted Drugs | Content: oxic cells, i.e., normal cells) gives a therapeutic window/
gain. Unlike the direct action of hypoxic cell radiosensitiz­
ers, which increases the radiosensitivity of cells, bioreduc­
tive drugs act synergistic with radiation to improve tumor
cell kill [84].
The hypoxic cell cytotoxicity ratio (HCR) is the dose of a
drug required to kill a certain fraction of oxic cells compared
to the dose of drug required to kill an equal fraction of
hypoxic cells. HCR varies for different classes of bioreduc­
tive drugs [85]. The main classes of bioreductive compounds
are fused ring benzoquinones (e.g., mitomycin C), organic
N-oxides (e.g., tirapazamine), and nitroheterocyclic com­
pounds (e.g., RSU-1089), among which tirapazamine is the
widely investigated drug.
5.8.4.4		Hypoxia-Targeted Radiotherapy
As described above, imaging techniques such as PET and
MRI can be used to identify hypoxic regions within the tumor.
They are used in RT treatment planning to define radioresis­
tant sub-volumes that can be targeted with boost dose or dose
escalation. Targeting hypoxic sub-volumes in tumors by
adaptive RT/dose painting can lead to improved tumor con­
trol. There is early clinical evidence from a phase 2 random­
ized trial that dose escalation to hypoxic volumes using
18F-FMISO PET is feasible without increased normal tissue
toxicity in head and neck cancers [86]. The utility of hypoxia-
directed RT dose painting is being studied in other cancer
subsites such as lung, pancreas, and cervix cancer [87–89].
5.8.4.5		Molecular Targeted Drugs
Drugs that target specific molecules to improve radiosensi­
tivity in hypoxic tumors are being investigated in preclinical
and clinical studies. Examples are dichloroacetate, electron
transport chain inhibitors, and other pathway inhibitors.
Table 5.8 Nitroimidazole group hypoxic cell radiosensitizers (adapted
from [13])
Compound
name
Position of nitro
group
Properties
Toxicity
Misonidazole
2-Nitroimidazole
Lipophilic,
crosses
blood–brain
barrier
Neurotoxic—
dose limiting
Etanidazole
2-Nitroimidazole
Hydrophilic,
shorter half-life,
does not cross
blood–brain
barrier
Less
neurotoxic
Nimorazole
5-Nitroimidazole
Less active
Less toxic
5 Clinical Radiobiology for Radiation Oncology
264
Dichloroacetate (DCA) is a specific inhibitor of the pyru­
vate dehydrogenase kinase (PDK), which has been shown to
increase ROS production in hypoxic cancer cells but not in
aerobic cells leading to radiosensitization of hypoxic tumor
cells [90]. Electron transport chain inhibitors have been
developed to reduce oxygen consumption and thereby
improve tumor oxygenation. One such is an anti-diabetic
drug, Metformin, which has been shown to reduce oxygen
consumption through inhibition of mitochondrial complex I
and thus improve tumor oxygenation and response to RT
[91]. Other approaches include inhibition of pathways that
are important for cell survival under hypoxia (e.g., HIF-1α,
CAIX, MCT4, VEGF, and lactate dehydrogenase-A (LDHA)
[92].
5.9"
"Following radiation therapy for cancer treatment, why do some tumors exhibit resistance or recurrence despite initial responses? Detail the multifaceted mechanisms contributing to this phenomenon.","Radioresistance in cancer following radiation therapy is a complex issue driven by several interconnected factors that compromise the effectiveness of the initial treatment. Primarily, increased DNA damage repair capacity within tumor cells allows them to more efficiently fix the double-strand breaks induced by ionizing radiation. This reduces the amount of irreparable damage and thus diminishes the cytotoxic effect of the radiation. Simultaneously, cancer cell cycle redistribution shifts the proportion of cells in non-dividing phases (G1/G2 arrest), effectively shielding a significant population from direct radiation exposure. Furthermore, certain tumor types exhibit resilience due to enhanced survival mechanisms within cancer stem cells – these cells are inherently less sensitive to DNA damage and possess superior proliferative capabilities. Signaling pathways, particularly those involved in cell growth and survival, can be upregulated following radiation, counteracting the intended apoptotic signals. A critical contributor is epithelial-mesenchymal transition (EMT), where tumor cells lose their epithelial characteristics and gain mesenchymal traits, often increasing resistance to apoptosis and promoting metastasis. Finally, alterations in tumor metabolism – specifically increased glycolysis – provide cancer cells with an alternative energy source independent of oxidative phosphorylation, buffering them against the metabolic disruption caused by radiation. These combined effects create a resilient microenvironment within the tumor that allows it to survive and proliferate despite radiation exposure, ultimately leading to recurrence.
Reference: Clinical Radiobiology for Radiation Oncology, 5.9 Tumor Resistance and Progression","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.9	 Tumor Resistance and Progression | Content: •	RT is an effective cancer treatment, but a large portion of
patients subsequently experience radioresistance and
recurrence of their cancers.
•	Mechanisms of radioresistance in cancer treatment are
related to several factors: Increased DNA damage repair
capacity, cell-cycle redistribution, cancer stem cell resil­
ience, signaling pathways, epithelial-mesenchymal tran­
sition (EMT), and tumor metabolism.
5.9.1"
"Describe the mechanisms by which tumor cells can develop resistance to ionizing radiation, categorizing these mechanisms into those primarily affecting DNA repair pathways and those influencing cellular responses beyond direct DNA damage.","Tumor cell resistance to ionizing radiation is a complex phenomenon driven by multiple interconnected mechanisms. These can be broadly categorized into alterations within DNA repair pathways and broader cellular responses. 

**DNA Repair Pathway Modifications:** A significant proportion of resistance stems from enhanced or altered DNA repair capabilities. Key pathways involved include:

*   **Base Excision Repair (BER):** Increased BER activity, often mediated by elevated expression of enzymes like 8-oxoguanine DNA glycosylase (Ogg1) and AP endonuclease, allows for more efficient removal of damaged bases – particularly those resulting from radiation-induced base modifications. This effectively reduces the amount of double-strand breaks (DSBs) that ultimately trigger cell death.
*   **Mismatch Repair (MMR):** Elevated MMR activity can correct errors introduced during DNA replication following irradiation, preventing the accumulation of mutations that might otherwise sensitize cells to further damage. Defects in MMR genes are frequently associated with increased radiation tolerance.
*   **Homologous Recombination (HR) and Non-Homologous End Joining (NHEJ):** While both pathways repair DSBs, HR is generally more precise but requires a homologous template for efficient repair. NHEJ is faster but error-prone. Resistance can arise from shifts in the balance between these pathways, with increased NHEJ activity potentially masking DNA damage.
*   **Nucleotide Excision Repair (NER):** NER repairs bulky DNA lesions, and enhanced NER can mitigate radiation-induced damage caused by adduct formation.

**Cellular Response Modifications:** Beyond direct DNA repair, several cellular responses contribute to resistance:

*   **Cell Cycle Arrest:** Initially, irradiation often triggers cell cycle arrest. However, some tumor cells develop the ability to rapidly exit and re-enter the cell cycle, bypassing checkpoints and allowing them to continue dividing despite radiation damage. This is frequently linked to alterations in cyclin-dependent kinases (CDKs) and cyclins.
*   **Reactive Oxygen Species (ROS) Scavenging:** Radiation generates ROS, which can exacerbate DNA damage. Resistant cells may upregulate antioxidant defense mechanisms like superoxide dismutase (SOD) or catalase, reducing the oxidative burden and lessening the impact of radiation.
*   **Apoptosis Inhibition:** Resistance can be linked to defects in apoptotic pathways – the programmed cell death response. This could involve downregulation of pro-apoptotic proteins or upregulation of anti-apoptotic factors, preventing cells from undergoing apoptosis after irradiation.
*   **Microenvironment Interactions:** The tumor microenvironment (e.g., hypoxia, nutrient availability) can also influence radiation resistance. Hypoxic conditions, for example, can promote DNA repair and inhibit apoptosis.

It’s crucial to note that these mechanisms often interact synergistically, creating a complex network of adaptations that contribute to tumor cell survival following irradiation. Furthermore, the specific combination of resistant mechanisms varies considerably between different tumor types and individual cells within a tumor mass. 

Reference: Clinical Radiobiology for Radiation Oncology, 5.9.1 Introduction","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.9	 Tumor Resistance and Progression | Sub-subsection: 5.9.1		 Introduction | Content: ­
93
­
9495
­
­
95
­
5.19
5.9.2"
"How does a tumor's ability to engage in DNA damage response (DDR) signaling contribute to its resistance to radiation therapy, and what specific DNA repair pathways are involved?","Radiation therapy primarily induces cell death by generating DNA lesions within cancer cells. These lesions encompass various forms of damage including base and sugar modifications, cross-links, single-stranded breaks (SSBs), and double-stranded breaks (DSBs). Double-stranded breaks are particularly significant as the main driver of radiation-induced cell killing. To counteract this damage, tumor cells activate DNA damage response (DDR) signaling pathways. A tumor’s capacity to effectively initiate and sustain DDR – specifically through the activation of DNA repair mechanisms – directly influences its resistance to radiation. Cells with robust DDR capabilities, particularly those proficient in repairing DSBs, demonstrate increased survival rates following irradiation. Conversely, tumors with compromised repair abilities are more susceptible to radiation-induced cell death. Four primary DNA repair pathways operate within tumor cells: DNA double-strand break repair (DSBR), base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR). BER and single-stranded break repair (SSBR) play a crucial role in correcting altered bases and SSBs, while DSBR, NHEJ, and HR are involved in repairing the more complex double-stranded breaks generated by radiation. The efficiency of these pathways – particularly DSBR – is therefore a key determinant of tumor radioresistance.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.9	 Tumor Resistance and Progression | Sub-subsection: 5.9.2		 DNA Damage Repair Ability | Content: RT kills cancer cells mostly by inducing DNA damage.
Radiation-induced DNA lesions are multiple including base
and sugar modifications, cross-links, single-stranded breaks
(SSBs), and double-stranded breaks (DSBs) [96] (see also
Chap. 3). DNA DSBs are responsible for most of IR-induced
cell killing [97]. To respond to DNA damage, cells initiate
signaling pathways named DNA damage response (DDR)
signaling. The capacity of tumor cells to trigger a DDR fol­
lowing radiation, through initiation of DNA repair and cell-­
cycle checkpoints, promotes radiation resistance and tumor
cell survival. In radiobiology, it is considered that cells with
a high capacity to trigger DSBs repair will be radioresistant,
while cells with frail repair ability will be more sensitive in
response to radiation [93].
Activation of DDR and proper repair of DNA lesions are
of paramount importance for cellular integrity, survival, and
genomic stability [98]. There are four main DNA repair
pathways in tumor cells: DNA DSB repair, base excision
repair (BER), nucleotide excision repair (NER), and mis­
match repair (MMR) [99]. BER and SSB repair (SSBR) are
important for repairing altered bases and SSBs. Besides
DSBs caused directly by IR unrepaired damaged bases and
SSBs, can generate DNA DSBs when they face a replication
fork. Non-homologous end joining (NHEJ) and homologous
recombination (HR) two principal cellular DSB repair path­
ways (see Chap. 3)."
"Describe the four primary DNA repair pathways utilized by tumor cells, detailing their respective mechanisms for addressing different types of DNA damage.","Tumor cells employ several distinct DNA repair pathways to maintain genomic stability and survival in response to radiation or other damaging stimuli. The four main pathways are: 1) Double-Strand Break Repair (DSBR): This pathway addresses the most severe form of DNA damage, double-strand breaks, which can lead to chromosomal instability. DSBR utilizes either non-homologous end joining (NHEJ), where broken ends are directly joined with potential for mutations, or homologous recombination (HR), a more precise mechanism that uses a sister chromatid as a template for repair. 2) Base Excision Repair (BER): BER is crucial for correcting single base alterations – such as those caused by oxidation or alkylation – within DNA. It involves recognizing and removing damaged or modified bases, followed by replacement with the correct nucleotide using DNA polymerase. Single-strand binding proteins (SSBs) play a key role in stabilizing the site of damage before repair. 3) Nucleotide Excision Repair (NER): NER primarily targets bulky DNA lesions like pyrimidine dimers caused by UV radiation. It involves excising a short stretch of damaged DNA, followed by gap filling and resynthesis using DNA polymerase. 4) Mismatch Repair (MMR): MMR corrects errors introduced during DNA replication – mismatches between newly synthesized and template strands. This pathway identifies and removes incorrectly incorporated bases, followed by accurate re-synthesis. Deficiencies in these pathways contribute significantly to genomic instability observed in cancer cells.

Reference: MolecularRadiationBiology, Section 5.9.2.1 – Dysfunctional DNA Repair in Cancer","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.9	 Tumor Resistance and Progression | Sub-subsection: 5.9.2		 DNA Damage Repair Ability | Sub-sub-subsection: 5.9.2.1		 Dysfunctional DNA Repair in Cancer | Content: while cells with frail repair ability will be more sensitive in
response to radiation [93].
Activation of DDR and proper repair of DNA lesions are
of paramount importance for cellular integrity, survival, and
genomic stability [98]. There are four main DNA repair
pathways in tumor cells: DNA DSB repair, base excision
repair (BER), nucleotide excision repair (NER), and mis­
match repair (MMR) [99]. BER and SSB repair (SSBR) are
important for repairing altered bases and SSBs. Besides
DSBs caused directly by IR unrepaired damaged bases and
SSBs, can generate DNA DSBs when they face a replication
fork. Non-homologous end joining (NHEJ) and homologous
recombination (HR) two principal cellular DSB repair path­
ways (see Chap. 3).
5.9.2.1		Dysfunctional DNA Repair in Cancer
Defects in DNA repair factors are a characteristic of many
cancers which promote genomic instability and mutation in
cells [98, 100–102]. Deficiency of DDR and DNA repair
genes caused diseases such as Xeroderma pigmentosum,
Ataxia Telangiectasia (ataxia telangiectasia mutated (ATM)),
Nijmegen breakage Syndrome (Nibrin (NBS1)), Werner
syndrome (WRN), Fanconi anemia (FA), associated breast
cancer syndrome (BRCA1 and BRCA2), lead to cancer sus­
ceptible disease syndromes (reviewed in [98, 102] and in
Chap. 7). Cancers present germ line mutations, somatic
Box 5.10 Tumor Hypoxia in Radiotherapy
•	Tumor hypoxia can be acute (perfusion-limited) or
chronic (diffusion-limited).
•	Tumor hypoxia leads to resistance to RT and
chemotherapy.
•	Hypoxic tumor cells undergo adaptive responses
that are critical to survival but also promote malig­
nancy and metastasis.
•	Strategies to either increase oxygenation or inter­
fere with the hypoxic response pathways can
improve the outcome of RT.
•	Drugs that either mimic the effect of oxygen or are
toxic under hypoxic conditions can be used to
increase the effect of RT.
P. Sminia et al.
265
mutations or distinctive expression of DDR components that
lead to the impairment of DDR and altered checkpoints. In
addition, DNA replication stress due to oncogene stimula­
tion also causes initiation of DDR and tumor progression.
­
­
102
103
5.9
5.9.3"
"Describe the role of cell-cycle checkpoints, specifically focusing on the kinases CHK1 and CHK2, in response to ionizing radiation (IR) induced DNA damage. Detail the mechanisms by which these checkpoints function and their contribution to preventing premature mitosis.","Following exposure to ionizing radiation (IR), cells activate complex signaling pathways designed to mitigate DNA damage. A critical component of this response is the activation of cell-cycle checkpoints, primarily mediated by kinases CHK1 and CHK2. These kinases are downstream effectors of the DNA Damage Response (DDR) initiated by IR. Specifically, ATM and ATR, molecules responsible for recognizing double-strand breaks (DSBs) and single-stranded DNA (ssDNA) damage respectively, activate CHK1 and CHK2. Once activated, these kinases inhibit the activity of CDC25C, a phosphatase that normally activates cyclin-dependent kinases 1 and 2 (CDK1/2). The inactivation of CDC25C by phosphorylation prevents the activation of CDK1/2, which are essential for driving cells through the G2/M phase transition. Consequently, cell division is arrested in the G2/M phase. This arrest provides time for DNA repair mechanisms to operate effectively. Furthermore, CHK1 and CHK2’s action directly impedes WEE1 kinase activity, further reinforcing the cell-cycle arrest. By halting progression into mitosis with unrepaired DNA lesions, these checkpoints safeguard genomic stability and prevent potentially catastrophic consequences like chromosome instability. The molecules involved in this checkpoint response – ATM, ATR, p53, p21, Chk2, and Cdc2 – have been linked to radioresistance development, highlighting their significance in modulating the cellular response to radiation.

Reference: Clinical Radiobiology for Radiation Oncology, Section 5.9.3","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.9	 Tumor Resistance and Progression | Sub-subsection: 5.9.3		 Cell-Cycle Redistribution | Content: Activation of cell-cycle checkpoints is important down­
stream IR-induced DDR signaling. Several molecules in the
cell-cycle checkpoints regulate and block cell-cycle progres­
sion to allow for DNA repair and prohibit premature entering
into mitosis with unrepaired DNA lesions. The same machin­
ery responsible for DNA damage recognition, ATM and
ATR, activates the cell-cycle checkpoints kinases CHK1 and
CHK2 to regulate the checkpoints and repair DNA damage.
Two distinct signaling cascades, the ATM-Chk2 and ATR-­
Chk1 axes respond to DSBs damages, respectively, to
ssDNA. Activated Chk1 and Chk2 inactivate CDC25C by
phosphorylation. In the absence of CDC25C phosphatase
activity, WEE1 kinase impedes cyclin-dependent kinase 1
and 2 (CDK1/2) activity triggering cell-cycle arrest in the
G2/M phase and promoting DNA damage repair (reviewed
in [93, 95, 111]). Molecules in the cell-cycle checkpoints
were also found to be linked with the development of radio­
resistance (e.g., ATM, p53, p21, Chk2, Cdc2).
5.9.4
Modification of Extracellular Signaling
Pathways and Tumor Suppressors
­
­
5.20
5 Clinical Radiobiology for Radiation Oncology"
"Following radiation exposure, tumor cells exhibit altered glucose metabolism, leading to lactate accumulation and contributing to radioresistance. Describe the key metabolic shifts observed in tumor cells after irradiation, including specific enzymes involved (e.g., LDHA, HK2) and their impact on cellular processes.","Radiation-induced changes in tumor cell metabolism significantly contribute to radioresistance. Initially, radiation disrupts mitochondrial oxidative phosphorylation (OxPhos), decreasing NADP+ levels within mitochondria and impacting the pentose phosphate pathway. This shift favors glycolysis, leading to a buildup of lactic acid as a primary product of this altered glucose metabolism. Several key enzymes are involved: Lactate dehydrogenase A (LDHA) catalyzes the final step in lactate production from pyruvate, and its overexpression is strongly associated with hypoxic conditions – a common response to radiation damage – which further drives glycolytic flux. Hexokinase 2 (HK2) plays a critical role in initiating glucose metabolism by phosphorylating glucose, also promoting glycolysis. Furthermore, alterations in mitochondrial metabolism are observed including changes in the expression of pyruvate kinase (PK), manganese superoxide dismutase (MnSOD), and proteins like ATAD3A which impact cellular responses to oxidative stress. The accumulation of lactic acid promotes recurrence, metastasis, and resistance to radiation therapy.  Finally, activation of AKT signaling through these metabolic shifts further reinforces radioresistance. Reference: [Molecular Radiation Biology, Section 5.9.6 – Changing Tumor Metabolism]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.9	 Tumor Resistance and Progression | Sub-subsection: 5.9.6		 Changing Tumor Metabolism | Content: AKT, p38, and PI3K activation. Similarly, fractionated IR
inhibits PTEN-­related expression, which is associated with
activation of the Drosophila embryonic protein SNAI1
(Snail) protein accumulation and Akt/GSK-3β signaling
and provoking EMT [139]. As a result of radiation, GSK-3β
is phosphorylated at serine 9 residue, and silencing the
tank-binding kinase-1 (TBK1) tones down the phosphory­
lation, indicating that TBK1 inhibition is associated with
activating GSK-3β. Indeed, GSK-3β functions in several
key signaling pathways that can contribute to EMT, such as
the Wnt, TGF-β, Hedgehog, Notch, and PI3K pathways.
Upon phosphorylation at its N-terminus, GSK-3β can be
inactivated and Snail is stabilized and succumbs to EMT. In
this way, it is suggested that TBK1 inhibition has the
potential to reduce radiation-­induced Zinc Finger E-Box
Binding Homeobox 1 (ZEB1) expression via activation of
GSK-3β. This hypothesis is supported by the observation
that pre-treatment of cells with the GSK-3β inhibitor
SB216763 increases TBK1 inhibition, increases E-cadherin
expression, and reduces ZEB1. In conclusion, it was seen
that TBK1 signaling is influenced by GSK-3β in radiation-
induced EMT [140]. RT can cause both lessening of tumor
cells and killing of them as it can also lead to damage to
normal tissues, radioresistance, invasion, and distant
metastases. Several studies have suggested that EMT gen­
erates malignant characteristics such as a propensity to
recurrence, resistance to treatment, and dissemination of
metastatic cells. Radiation is generally considered a key
initiating factor for EMT, as it activates signal pathways
that initiate the process.
5.9.6
Changing Tumor Metabolism
141
142
­
5.10
After the tumor cells have been exposed to radiation for
an extended period of time, these cells experience alteration
in the glucose metabolic pathway. As an important kinase,
AKT regulates multiple biological processes, including cel­
lular metabolism. As described in the previous section AKT
is phosphorylated in cells after IR exposure to radiation
which results in radioresistance of tumor cells through the
AKT-mediated alteration of cellular glucose metabolism. A
disruption in glucose metabolism also occurs after radiation
exposure of tumor cells, resulting in an accumulation of lac­
tic acid. This is the primary product of glycolysis and con­
tributes to the development of malignant tumors. Moreover,
glycolysis may cause tumor metastasis, recurrences, and
resistance to RT.
P. Sminia et al.
269
Table 5.10 Glucose and mitochondrial metabolism induced by the tumor itself that contribute to tumor resistance and progression
Entity
Type
Cause
Effect
Outcome
Nicotinamide
adenine dinucleotide
phosphate (NADPH)
Glucose
metabolism
The decrease in
OxPhoslevels in
mitochondria and the
pentose phosphate
pathway (PPP)
Increasing tumor dependence on
glycolysis and reducing intracellular
ROS levels
Tumor proliferation
An organic
compound
(dinitrophenol)
Glucose
metabolism
Mitochondrial
respiratory
modulators
Increase in the glycolytic index
Rejoining of DNA strand breaks that
leads to reducing the probability of
cancer cells damage by radiation
Proteins (GLUT1)
Glucose
metabolism
GLUT family in cell
membrane
Upregulated under hypoxic
circumstances
Poor prognosis, radioresistance,
oncogene activation and inhibition of
tumor suppressors, stimulation of
hypoxia, and the regulation of
different signaling pathways,
including PI3K/AKT and MAPK
Lactic acid
Glucose
metabolism
Products of
glycolysis
Accumulation in tumor tissues
Promoting recurrence, tumor
metastasis and radioresistance
Fibroblasts in tumors release
hyaluronic acid in response to lactic
acid
Neovascularization, cell clustering,
migration, and VEGF secretion
Lactate
dehydrogenase
(LDHA)
Glucose
metabolism
Distribute in human
tissues
Enzyme helps make lactic acid from
pyruvate
Overexpression indicates hypoxic
conditions, which can be associated
with radioresistance, lower survival
rate, local recurrence, and distant
metastases
Soluble adenylate
cyclase (sAC)
Glucose
metabolism
Activation of BRAF/
ERK1/2 signaling
Release of LDHA
The anti-irradiation effects and cell
proliferation.
HIF-1β
Glucose
metabolism
Activated in hypoxic
environments
The adaptive cellular responses to
hypoxia, important mediator of the
conversion of OxPhos to glycolysis in
the metabolism of carbohydrates
convert ADP and phosphoenolpyruvate
into ATP and pyruvate
Radioresistance by removing ROS
from the cells and activating cell
autophagy
Pyruvate kinase (PK)
Glucose
metabolism
Enzyme involved in
glycolysis
Convert ADP and phosphoenolpyruvate
into ATP and pyruvate
PK expression correlates with
radioresistance
Hexokinase 2 (HK2)
Glucose
metabolism
A critical role in
glucose metabolism
Upregulation of this enzyme can induce
glycolysis
HK induces glycolysis, making it
essential for the progression and
maintenance of tumors
Antigen 2 (NG2)
Mitochondrial
metabolism
A glial cell antigen
By interacting with serine protease
OMI/HtrA2 of mitochondria, protect
oligodendrocyte precursor cells from
oxidative stress
Development of radioresistance
Protein 3A
(ATAD3A)
Mitochondrial
metabolism
Cancer patients
Activating ATAD3A leads to the
expressions of histone H3, H2AX and
ATM increase
Inhibit the IR-induced apoptosis in
glioblastoma cells
Matrix
metalloproteinase
Mitochondrial
metabolism
The extracellular
protein
Radiation resistance is induced by
molecules or signaling pathways that
increase MMP or inhibit its decrease
Radiation resistance
Radiation exposure of tumor cells likewise disrupts
mitochondrial metabolism. In the post-RT setting, manga­
nese superoxide dismutase (MnSOD) activity increases
significantly in pancreatic cancer cells irradiation. MnSOD
is the enzyme which catalyzes the formation of superoxide
anion radicals, fighting the effects of oxidative stress ROS-
induced damage. As a consequence, G2 checkpoint block
is activated and cells are protected against mitochondrial
oxidative stress by mitochondrial antioxidant systems,
promoting radioresistance development. Radiation expo­
sure to Burkitt lymphoma similarly disrupts mitochondrial
metabolism by inducing the proteins (mitochondrial pro­
teomes) that prompt radioresistance. Radiation of tumor
cells targets Mitochondrial MAPK phosphatase (MKP1).
Radiation increases MKP1 expression in breast cancer
cells, where it translocates into the mitochondria and
inhibits apoptosis by phosphorylating the c-Jun N-terminal
kinase (JNK).
5 Clinical Radiobiology for Radiation Oncology
270
5.10"
"Describe the rationale behind utilizing palliative radiotherapy compared to radical radiotherapy, including common clinical applications and potential mechanistic differences.","Palliative radiotherapy differs fundamentally from radical radiotherapy in its primary objective: rather than aiming for complete tumor eradication with the intent of cure, it focuses on managing symptoms, slowing disease progression, and improving a patient’s quality of life. Approximately 50% of radiation oncology patients receive palliative RT, particularly prevalent in resource-limited settings where advanced disease is common. Clinically, palliative RT is frequently employed to address conditions such as bleeding (e.g., from tumors obstructing blood vessels) or obstruction (e.g., caused by tumor growth), alongside the management of debilitating symptoms like pain – most notably bone pain – and neurological metastases affecting the brain and spinal cord. Common treatment sites include bone, brain, pelvis, and lung. Despite its widespread use, the radiobiological mechanisms underlying palliative RT are less well-defined than those for radical treatments. While radiation can effectively reduce tumor burden by targeting rapidly dividing cells, thereby mitigating obstructions and pressure, the precise ways in which it halts bleeding or alleviates pain remain somewhat unclear. Current hypotheses suggest that modulation of cytokines could influence pain perception, while targeted vascular disruption may prevent hemorrhage. Furthermore, palliative regimens often utilize shorter durations and lower doses (e.g., single fractions of 7-8 Gy) compared to conventional fractionated radical treatments, potentially inducing distinct biological effects through enhanced vascular targeting and immune modulation.

Reference: Molecular Radiation Biology, Section 5.10 – Palliative Radiotherapy","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.10		 Palliative Radiotherapy | Content: While radical RT aims to eliminate cancer cells with the
intention of cure, palliative RT is used to slow down tumor
growth, to prevent or treat symptoms and improve quality of
life. It is estimated that more than 50% of RT patients
receive palliative RT. This is particularly relevant in popula­
tions in less well-resourced countries where the burden of
advanced disease is high, and palliation is commonplace
(Box 5.11).
Typically, palliative RT is used to treat or prevent bleed­
ing [143–146] or obstruction [147]. In addition, palliative RT
is commonly used to treat pain, particularly bone pain, as
well as brain and spinal cord metastases to address neuro­
logical symptoms [148]. Sites frequently treated palliatively
include bone, brain, pelvis, and lung.
Despite the widespread use of RT with palliative intent,
the radiobiology of palliative RT is not well understood.
Radiation can reduce tumor burden by targeting proliferating
tumor cells, and thus reduce tumor growth and result in relief
of obstructions and pressure. However, mechanistic effects
of how RT can stop bleeding and pain are still somewhat
obscure. It has been speculated that cytokine modulation
may alter pain levels and targeting of vascular components
may prevent bleeding [149]. Palliative regimens are also
typically shorter and frequently involve hypofractionated
approaches or single (7–8 Gy) fraction schedules, which
may induce differential biological effects to those induced
by typical conventionally fractionated radical treatments.
Enhanced vascular targeting and immune modulation have
been implicated [150].
5.11"
"Describe the concept of the tumor microenvironment (TME) and explain its significance in cancer progression, referencing relevant biological principles.","The tumor microenvironment (TME) represents a complex ‘ecological niche’ surrounding cancerous cells, fundamentally influencing their growth, metastasis, and response to therapeutic interventions. It's not simply a passive backdrop but an actively participating component of the disease process. The TME is characterized by a dynamic interplay between tumor cells and various supporting cell types – including fibroblasts, immune cells (like macrophages and lymphocytes), endothelial cells forming blood vessels, and extracellular matrix components – all interacting within a specific biochemical and physical context. This intricate environment facilitates tumor expansion by providing nutrients, growth factors, and permissive conditions for cellular proliferation. Furthermore, the TME plays a crucial role in promoting metastasis through processes like angiogenesis (formation of new blood vessels to supply the growing tumor), immune suppression (allowing cancer cells to evade detection and destruction by the immune system), and epithelial-mesenchymal transition (EMT) – a process where tumor cells lose their cell-cell adhesion and gain migratory properties. The heterogeneity within the TME, driven by diverse mutations in both primary and metastatic tumors, contributes significantly to genomic instability and treatment resistance. Stephen Paget’s ‘seed and soil’ hypothesis highlights this concept; metastasis isn't solely due to random dissemination of tumor cells but rather depends on specific interactions between cancer cells (the ‘seeds’) and favorable conditions within a distant organ (the ‘soil’), representing the ideal TME for that particular tumor type.  Ultimately, understanding and manipulating the TME is becoming increasingly recognized as a critical strategy in oncology.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Content: Tumor Sensitivity
The tumor microenvironment (TME) is an “ecological
niche” to facilitate the promotion and the succession of can­
cer cells. TME intricacy is coupled with tumor expansion,
metastasis, and reaction to therapy. Potent alteration stirring
in the TME is the basis of tumor cell variant selection, which
may endorse genomic instability [31]. Cancer is an excep­
tionally assorted disease as the cells within the tumor have
diverse mutations at different locations within the primary
tumor and the metastatic site. Tumor growth and develop­
ment are not only by actions relating tumor cells, but also by
the milieu they inhabit, the TME. In 1889, Stephen Paget
introduced “seed and soil” proposition which recommended
that metastasis does not occur due to accidental events, but
some tumor cells (the “seeds”) nurture ideally in particular
organs (the “soil”) and metastases only emerges when the
appropriate seed and soil combination takes place [151]
(Box 5.12)."
"How does the tumor microenvironment (TME) influence the effectiveness of palliative radiotherapy, and what specific components contribute to this interaction?","The tumor microenvironment (TME) significantly impacts the response to palliative radiotherapy by modulating several key processes related to tumor growth, survival, and immune responses. Initially, the TME can actively promote tumor progression through mechanisms like angiogenesis, matrix remodeling, and providing a protective niche for cancer cells. However, radiotherapy can strategically alter this environment to enhance its therapeutic effect. Specifically, RT immunomodulates the TME, triggering a localized anti-tumor immune response – a crucial component in inducing tumor regression. This modulation is facilitated by changes within the TME itself. Key components contributing to this interaction include stromal elements such as fibroblasts and extracellular matrix (ECM) components like collagen and hyaluronic acid. These elements can directly shield cancer cells from radiation damage, but RT’s effects can remodel the ECM, increasing its permeability and facilitating immune cell infiltration into the tumor site. Furthermore, the TME contains various cells – including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) – which normally suppress anti-tumor immunity. Radiotherapy can shift this balance by depleting or reprogramming these immunosuppressive cells, thereby promoting a more effective immune response against the tumor. The interaction between RT and the TME is complex and not fully understood, highlighting the need for further research into its specific mechanisms. Reference: [Molecular Radiation Biology], Section 5.11.1 – Tumor Microenvironment Changes Tumor Sensitivity.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Sub-subsection: 5.11.1	 Components of the TME | Content: appropriate seed and soil combination takes place [151]
(Box 5.12).
5.11.1	Components of the TME
5.11
­
Box 5.11 Palliative Radiotherapy
•	Palliative RT may be used to slow down tumor
growth, prevent or treat symptoms, and improve
quality of life.
•	Common applications include prevention of bleed­
ing and pain and treatment of metastases.
•	Brain and spinal cord metastases are often treated to
relieve neurological symptoms.
•	Palliative RT is often hypofractionated with poten­
tially unique radiobiology.
•	The radiobiological mechanisms of palliative RT
are currently not well understood.
Box 5.12 The Tumor Microenvironment and
Radiotherapy
•	Tumor microenvironments (TME) can recourse the
tumor origination, expansion, invasion, metastasis,
and its response to therapies like RT and
chemotherapy.
•	RT immunomodulates the TME to induce a local
anti-tumor immune response leading to tumor
regression.
P. Sminia et al.
271
cells and stromal elements also play an important role in can­
cer evolution and development [152]."
"Describe how ionizing radiation (IR) alters the tumor microenvironment (TME), focusing on changes in cell adhesion molecule expression, vascularization, fibroblast activation, and immune cell modulation as detailed within the provided text.","Ionizing radiation significantly remodels the tumor microenvironment (TME) through a complex interplay of cellular and molecular events. Initially, IR induces damage across many TME cells, triggering an inflammatory cascade that leads to increased expression of intercellular adhesion molecules 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), facilitating immune cell recruitment. Simultaneously, radiation promotes vascular diminution, exacerbating hypoxia and activating the Hypoxia-Inducible Factor 1 alpha (HIF-1α) signaling pathway. This, in turn, stimulates pro-angiogenic and pro-vasculogenesis via VEGF and CXCL12. Furthermore, IR activates cancer-associated fibroblasts (CAFs), leading to altered growth factor secretion and ECM modulation. Notably, transforming growth factor-β (TGF-β) signaling is amplified, suppressing T cell and dendritic cell (DC) activation while promoting HIF-1α signaling in both CAFs and tumor cells. The elevated levels of mTOR contribute to increased antigen accessibility and processing via damage-associated molecular patterns (DAMPs) and Toll-like receptor (TLR) responses. Activated DCs then migrate to proximal lymph nodes, further amplifying pro-inflammatory cytokine signaling to activate T cells. Importantly, the upregulation of NKG2D signals on tumor cells enhances cytotoxic effects by CD8+ T cells and NK cells. However, immunosuppressive mechanisms like Treg cytotoxic T lymphocyte antigen 4 (CTLA-4) suppression and MDSC-derived IL-10 remain intact, hindering effective anti-tumor immunity. The specific stromal components – such as astrocytes in the CNS or osteoblasts in bone – contribute to the overall microenvironment complexity.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Sub-subsection: 5.11.2		 Effect of Radiation on TME | Content: ­
­
151
­
­
­
5.22
The damage induced by IR affects many cells in the
TME. The sensitivity of tumor cells is higher to radiation
and their death commences the inflammatory signaling
cascade. Also, the levels of intercellular adhesion mole­
cule 1 (ICAM) and vascular cell adhesion molecule 1
(VCAM) expression go high as that of the cells of the
innate immune system. Interestingly, the upregulation of
the integrins present on the endothelial cells is associated
with better survival as it acts as a system for radioresis­
tance. Vascular diminution heightened the effect of hypoxia
inducing the HIF-1α signaling. It also leads to the pro-
angiogenic and pro-vasculogenic stimuli through VEGF
and chemokine (C-X-C motif) ligand 12 (CXCL12).
Following radiation cancer-associated fibroblast (CAF)
activation stimulated the altered growth factor secretion
and secret several ECM and cytokine modulators. Also,
the transforming growth factor-β (TGF-B) signaling path­
way is not only complex but also pleiotropic. It directly
affects the tumor cells and CAFs, driving the HIF-1 signal­
ing and reducing the activation of T cells and the dendritic
cells (DC). In the immune compartment, due to high levels
of mTOR there is not only an increase in the accessibility
of tumor cell antigen but also a boost in the processing of
the antigen in combination with damage-associated molec­
ular pattern (DAMP) related Toll-like receptor (TLR)
responses. Also, there is an increased pro-inflammatory
cytokine signaling to activate the DCs and as a conse­
quence T cells. The activated DCs move to the proximal
Table 5.11 Functions of various components of the tumor microenvi­
ronment (adapted from [152])
TME components
Function
Neutrophils
Augmentation of angiogenesis and metastasis;
associated with poor diagnosis.
Tumor-associated
macrophages
(TAMs)
Promote deterioration of the extracellular
matrix; support the increase of inflammatory
cytokines (TNF-β); augment of angiogenesis
and remodeling.
CD8+ cytotoxic T
cells (CTL)
Provoke apoptosis, necrosis, and growth arrest
by secreting INF-γ and other cytotoxic
cytokines; set up an anti-tumor environment.
Regulatory T cells
(Tregs)
Exude cytokines such as IL-10, TGF-β; set up
an immunosuppressive environment;
associated with poor diagnosis.
Myeloid-derived
suppressor
cells (MDSCs)
Linked with tumor development and
neoangiogenesis; repress T cells and NK cells;
differentiating into TAMs in a hypoxic
environment.
Mesenchymal stem
cells (MSCs)
Differentiating into mesenchymal tissues such
as bone, cartilage, and fat tissues, vasculogenic
mimicry; form the premetastatic niche;
promoting cancer initiation and malignancy.
Endothelial cells
Constitutes of tumor blood vessels; secreting
angiocrine factors such as adhesion molecules;
intercommunicating with tumor cells via
secreting EVs including CD106, CD49a.
Adipocytes
Regulating the balance of systematic energy
and metabolism; secreting exosomes,
cytokines, chemokines, and hormones;
promoting cancer progression.
Neuroendocrine
cells (NE cells)
Promoting proliferative signaling; secreting
neurotransmitters, including CgA,
chromophilic, and vasoactive polypeptide;
regulating NK cell migration and toxicity
ability.
Vascular network
Providing oxygen, clearing carbon dioxide,
and metabolizing wastes; providing nutrition
support for cancer cells; promoting
angiogenesis and metastasis.
Lymph vessels
Helping immune cells to avoid immunity and
dissemination; providing a physical link
between lymph nodes and tumor.
Extracellular matrix
(ECM)
Forming the complex macromolecular
network; controlling cancer invasion and
metastasis, angiogenesis; contribution to
growth and proliferation signaling, inhibiting
cancer cell apoptosis.
Extracellular
vesicles (EVs)
Carrying biologically active molecules such as
proteins, miRNAs, and lncRNAs from donor
cell to recipient cell; regulating key signaling
pathways, proliferation, drug resistance, and
stemness; reprogramming stromal cells to
create a niche for survival.
Cancer-associated
fibroblasts (CAFs)
Sustaining proliferative signaling; activating
angiogenesis and metastasis; tumor-promoting
inflammation; evading immune destruction;
reprogramming cellular metabolism;
promoting genome instability and mutation.
5 Clinical Radiobiology for Radiation Oncology
272
153
lymph nodes. In the TME, such signaling is frequently
obstructed by high Treg cytotoxic T lymphocyte antigen 4
(CTLA-4) suppression of co-stimulation. Radiation upreg­
ulates the NKG2D signals on the tumor cells that enforce
direct cytotoxic effects by the CD8+ T cells and NK cells.
However, there are other tumor cells which getaway with
the PD-L1 signaling but the MDSC derived IL-10 immu­
nosuppression remains intact.
Hence, depending on the organ, there are organ-specific
interstitial cells such as the presence of astrocytes in the cen­
tral nervous system or the osteoblasts in bone tissues. Such
cells are collectively called as the stroma of the tumor and
along with other essential factors like the surrounding pH,
oxygen levels, extracellular matrix make up the microenvi­
ronment of the tumor [139].
5.11.2.1	Effect on Stroma and Cancer-
Associated Fibroblasts (CAFs)
The tumor cells are known to interact with the stroma or the
adjacent milieu. The tumor stroma comprises of a range of
diverse cells, and extracellular matrix (ECM), that are known
to advocate in limiting the host immune reaction against
tumor cells. The tumor stroma puts forward a versatile com­
plex network that maintains the tumor propagation by secret­
ing immunosuppressive cytokine, diverse cellular processes
and metabolic alterations [154]. Stromal cells involving the
endothelial cells and adipocytes can modify the radiosensi­
tivity by their roles in angiogenesis and vasculogenesis, and
their secreted adipokines, respectively. The extracellular
matrix can control radiation sensitivity by manipulating the
oxygen proximity and managing the equilibrium and bio­
P. Sminia et al."
"Describe how radiation exposure alters the tumor microenvironment (TME), specifically focusing on the changes observed in vasculature and their potential consequences.","Radiation's impact on the TME is characterized by significant alterations to the vascular network. Initially, the primary effect involves the destruction of blood vessels within the microvessel network, with the severity of this damage directly correlated with the radiation dose received. Following this initial destruction, vessel walls thicken, a phenomenon that increases the risk of atherosclerotic changes and intimal proliferation due to the compromised vasculature. This reduction in vascular density and distance between functional vessels leads to hypoperfusion – a decrease in blood supply – within the tumor tissue. Furthermore, prolonged exposure to radiation induces long-term effects such as medial necrosis and fibrosis within the vessel walls. At higher doses, this can result in permanent reductions in blood flow, ultimately leading to necrosis and fibrosis. Critically, radiation also triggers a secondary response involving vasculogenesis, which is an often disorganized process of new vessel growth. This occurs in contrast to angiogenesis (regulated vessel formation) and is driven by the induction of chemokine receptor CXCR4, subsequently stimulating matrix metalloprotease 9 production within the bone marrow. This MMP-9 activity then facilitates radiation-induced vasculogenesis and contributes to post-irradiation effects. The overall consequence is a disrupted vascular network that compromises tumor oxygenation and nutrient supply while simultaneously promoting new vessel formation through a potentially uncontrolled process.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Sub-subsection: 5.11.2		 Effect of Radiation on TME | Sub-sub-subsection: 5.11.2.2	 Effect on Vasculature | Content: An important feature of solid tumors is the vascular net­
work that develops from the vasculogenesis, angiogenesis,
and fibroblasts. A characteristic of these vessels is that they
lack their supporting pericytes or basement membrane,
which makes them vulnerable to radiation [156–158].
When tumor tissue is exposed to radiation, blood vessels at
the level of the microvessel network are firstly destructed
and the degree of this destruction depends on the radiation
dose. The vessel’s thickness increases, which raises the risk
of atherosclerotic changes and intimal proliferation, since
the destructed microvessel network reduces distance
between functional vessels and vascular density, resulting
in hypoperfusion. Irradiation not only modulates the vessel
structure, but it also has long-term effects, including medial
necrosis and fibrosis, but these effects are affected by radia­
tion dose. When a radiation dose is high, for instance, blood
flow is permanently reduced; necrosis and fibrosis are pro­
duced, and the tumor is revascularized by vasculogenesis,
which is a disorganized process of vessel growth in com­
parison to angiogenesis. Secondly, radiation to tumor tissue
induces the chemokine receptor CXCR4 which induces
bone marrow of matrix metalloprotease 9 that is responsi­
ble for radiation vasculogenesis and subsequent post irra­
diation [159, 160]."
"Describe the multifaceted effects of ionizing radiation (IR) on the tumor microenvironment (TME), focusing specifically on its impact on immune cell responses and mechanisms that can either enhance or potentially hinder anti-tumor immunity.","Ionizing radiation (IR) exerts a complex influence on the TME, initiating both beneficial and detrimental effects regarding immune response. Initially, IR directly kills cancer cells through atomic ionization and indirectly via radiolysis of water, triggering a host immune response aimed at tumor recognition and elimination. A key mechanism involves the translocation of calreticulin (ERp57) and ER protein complexes from dying cancer cells to their cell membranes, acting as ‘eat me’ signals that attract phagocytes like macrophages. Furthermore, IR releases inflammatory molecules such as ATP and high mobility group protein B1 (HMGB1), stimulating a T cell and dendritic cell (DC) response. This process relies on three primary signaling pathways: DCs engulfing danger signals and processing them; presentation of these processed signals via MHC molecules to activate naïve tumor-specific T cells into effector T cells; and the recognition of macrophages and DCs by cytotoxic T cells, leading to tumor cell destruction through their circulation. Importantly, surviving irradiated cells can upregulate surface molecules like major histocompatibility complex class I (MHCI), Fas, and ICAMs, enhancing immune cell recognition and killing. Specifically, macrophages are triggered via apoptosis pathways to clear dying cells, polarizing them into M1 macrophages – a key driver of an anti-tumor immune response. However, the process isn't solely beneficial; surviving irradiated cells can also expose these same molecules, potentially reactivating existing tumor antigens and leading to increased recognition by immune cells. Moreover, the induction of cell death pathways (apoptosis, senescence, autophagy, mitotic catastrophe, and necrosis) can contribute to carcinogenesis and inflammation if not properly controlled, highlighting a dual effect on the TME’s ability to effectively combat cancer. Reference: [MolecularRadiationBiology > section: 5: Clinical Radiobiology for Radiation Oncology > subsection: 5.11 Tumor Microenvironment Changes Tumor Sensitivity > subsubsection: 5.11.2 Effect on TME > subsubsubsection: 5.11.2.3 Effect on Immune System]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Sub-subsection: 5.11.2		 Effect of Radiation on TME | Sub-sub-subsection: 5.11.2.3	 Effect on Immune System | Content: bone marrow of matrix metalloprotease 9 that is responsi­
ble for radiation vasculogenesis and subsequent post irra­
diation [159, 160].
5.11.2.3	Effect on Immune System
IR kills cancer cells directly (atomic ionization) and indi­
rectly (radiolysis of water) [16, 20, 158]. IR also induces a
host immune response to tumor cells and facilitates tumor
recognition and healing. These effects occur in a variety of
ways, including immune response signaling. When cells are
dying, they translocate calreticulin (ERp57) and their endo­
plasmic reticulum (ER) protein complex to the cell mem­
brane which functions as a “eat me” signal. Secondly, upon
IR of a tumor, inflammatory molecules, such as ATP and
high mobility group protein B1 (HMGB1), are released,
promoting a T cell and DC response. Signaling of this type
uses three types of signals in anti-tumor immune responses,
which are:
1.	DCs take captive of released danger signals and process
them.
2.	Danger signals are presented into T cells by MHC mole­
cules. As a result, naïve tumor-specific T cells are acti­
vated and become effector T cells.
3.	Finally, macrophages and DCs may be recognized by
cytotoxic T cells, and they destroy remaining cells of
tumor tissues through their circulation through the blood­
stream [161–165].
However, not all irradiated cells sustain damage, and
some survive. These IR surviving cells may expose surface
molecules like antigen-presenting molecules of major histo­
compatibility complex class I (MHCI), death receptor Fas,
and ICAMs which lead to an improvement in the recognition
and killing of tumors by immune cells that are reactivated by
tumor antigens.
To cure tumors, radiation needs to cause cell death. There
are five different types of cell death depending on the path­
ways in the response system of DNA damage, namely, apop­
tosis, senescence, autophagy, mitotic catastrophe, and
necrosis [13, 157, 158]. Via apoptosis pathways macro­
phages may be triggered to clean out these dying cells which
causes polarized M1 macrophages thereby driving an anti-­
tumor immune response and indirectly killing of tumors.
However, this process may also contribute to carcinogenesis
and inflammation [163]."
"Describe the mechanisms by which radiation induces a host immune response against tumors, including the roles of calreticulin, ATP, HMGB1, dendritic cells (DCs), MHC molecules, and macrophages.","Radiation therapy’s impact on tumor sensitivity involves both direct and indirect effects on the immune system. Initially, ionizing radiation (IR) directly damages cancer cells through atomic ionization and radiolysis of water. Simultaneously, it triggers an indirect response by inducing a host immune response. One key mechanism is the translocation of calreticulin (ERp57) and the endoplasmic reticulum (ER) protein complex from dying tumor cells to their membranes, acting as an ‘eat me’ signal that attracts phagocytes like macrophages. Furthermore, IR releases inflammatory molecules such as ATP and high mobility group protein B1 (HMGB1), which stimulate a T cell and DC response. Dendritic cells (DCs) play a crucial role by engulfing these danger signals, processing them, and presenting tumor-associated antigens to naïve T cells via major histocompatibility complex class I (MHCI) molecules. This activation transforms naïve T cells into effector T cells. Macrophages and DCs can also be recognized by cytotoxic T cells, leading to the destruction of remaining tumor cells through their circulation. The polarization of macrophages towards an M1 phenotype further enhances the anti-tumor immune response. However, some irradiated cells survive and express surface molecules like MHCI, Fas, and ICAMs, which reactivate existing immune responses against them. Ultimately, this coordinated action – involving DCs, T cells, and macrophages – contributes to tumor cell death and clearance.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Sub-subsection: 5.11.3		 Tumor Radiosensitivity and Underlying Mechanisms | Content: bone marrow of matrix metalloprotease 9 that is responsi­
ble for radiation vasculogenesis and subsequent post irra­
diation [159, 160].
5.11.2.3	Effect on Immune System
IR kills cancer cells directly (atomic ionization) and indi­
rectly (radiolysis of water) [16, 20, 158]. IR also induces a
host immune response to tumor cells and facilitates tumor
recognition and healing. These effects occur in a variety of
ways, including immune response signaling. When cells are
dying, they translocate calreticulin (ERp57) and their endo­
plasmic reticulum (ER) protein complex to the cell mem­
brane which functions as a “eat me” signal. Secondly, upon
IR of a tumor, inflammatory molecules, such as ATP and
high mobility group protein B1 (HMGB1), are released,
promoting a T cell and DC response. Signaling of this type
uses three types of signals in anti-tumor immune responses,
which are:
1.	DCs take captive of released danger signals and process
them.
2.	Danger signals are presented into T cells by MHC mole­
cules. As a result, naïve tumor-specific T cells are acti­
vated and become effector T cells.
3.	Finally, macrophages and DCs may be recognized by
cytotoxic T cells, and they destroy remaining cells of
tumor tissues through their circulation through the blood­
stream [161–165].
However, not all irradiated cells sustain damage, and
some survive. These IR surviving cells may expose surface
molecules like antigen-presenting molecules of major histo­
compatibility complex class I (MHCI), death receptor Fas,
and ICAMs which lead to an improvement in the recognition
and killing of tumors by immune cells that are reactivated by
tumor antigens.
To cure tumors, radiation needs to cause cell death. There
are five different types of cell death depending on the path­
ways in the response system of DNA damage, namely, apop­
tosis, senescence, autophagy, mitotic catastrophe, and
necrosis [13, 157, 158]. Via apoptosis pathways macro­
phages may be triggered to clean out these dying cells which
causes polarized M1 macrophages thereby driving an anti-­
tumor immune response and indirectly killing of tumors.
However, this process may also contribute to carcinogenesis
and inflammation [163].
5.11.3		Tumor Radiosensitivity and Underlying
Mechanisms
The most well-known tumors in declining order of radiosen­
sitivity as follows: (1) lymphoma, (2) embryonal tumors, (3)
cellular anaplastic tumors, (4) basal cell carcinoma, (5) ade­
noma and adenocarcinoma, (6) desmoplastic tumors, such as
squamous carcinoma, (7) fibroblastic sarcoma; osteosar­
coma; neurosarcoma. Tumors composed of fast-growing
5 Clinical Radiobiology for Radiation Oncology
274
cells like the embryonal tumors are sensitive to
radiotherapy.
Lymphoid cells are predominantly vulnerable to radia­
tion. On the other hand, the radioresistant category com­
prises of the neurosarcomas, gliomas, and melanomas.
Tumor sensitivity to radiation is affected by the variation on
the radiosensitivity exhibited by the subgroups of major can­
cer forms. There are numerous factors affecting the cancer
radiosensitivity and at times they are even obscure. The most
important factor that plays the most vital role in influencing
the tumor behavior under RT is the general condition of the
patient. Also, there is an explicit association between radio­
sensitivity and the grade of malignancy which might not be
uniform always. Hence, all these factors should be carefully
evaluated before imparting radiotherapy and predicting its
outcomes."
"The text describes several factors contributing to tumor radiosensitivity, including rapid metabolism and augmented vascularity. Explain how these factors are linked to increased sensitivity and what specific consequences can arise from them during radiation treatment.","Rapidly growing tumors exhibit heightened radiosensitivity primarily due to their elevated metabolic activity and associated characteristics. The high metabolism itself imparts sensitivity, mirroring the tumor’s rapid growth rate. This accelerated metabolism fuels cellular processes, making cells more vulnerable to radiation damage. Furthermore, augmented or uneven vascularity accompanies this fast growth; increased blood vessel density facilitates the transport of radiation directly into the tumor tissue, concentrating the damaging effects. Consequently, bulky tumors with these features often demonstrate hypersensitivity to radiation. However, this heightened sensitivity can lead to adverse outcomes such as bulk necrosis – localized cell death due to excessive radiation damage – or interstitial hemorrhage, where blood vessels are compromised and bleed within the surrounding tissues, further complicating treatment. These complications underscore the need for careful monitoring and adjustments during radiation therapy in tumors exhibiting these characteristics.
Reference: [MolecularRadiationBiology, Section 5.11.3.1 - Factors Affecting Tumor Radiosensitivity]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.11		 Tumor Microenvironment Changes Tumor Sensitivity | Sub-subsection: 5.11.3		 Tumor Radiosensitivity and Underlying Mechanisms | Sub-sub-subsection: 5.11.3.1	 Factors Affecting Tumor Radiosensitivity | Content: Radiosensitivity
One of the most prominent factors imparting the tumor
radiosensitivity and which was recognized very early on was
the high metabolism of the tumor cells. This is similar to the
fast growth and also understood as the tumor growth rate
imparting radiosensitivity. Augmented or uneven vascularity
also goes with fast growth. These factors combined provide
the rapidly growing tumor cells with sensitivity to radiation.
Especially when tumors are bulky hypersensitivity can be
encountered in the treatment of such tumors. Therefore, to
avoid accidents like bulky necrosis or interstitial hemorrhage
appropriate precaution should be taken. Other factors like the
large quantity of autolytic cell ferments and susceptibility of
mitotic nuclei are also crucial in imparting tumor sensitivity
to rapidly growing tumor cells. It is seen that the tumors
exhibiting the embryonic trait in the origin cells provide the
complete group of embryonal tumors a very high radiosensi­
tivity. Hence, their response to radiation treatment is proba­
bly quicker and complete compared to other tumors.
Therefore, such tumors should be identified as especially
favorable.
5.12
Systemic Anti-tumor Immune
Responses and Abscopal Effects
5.12.1		Introduction
While radiation effects classically result from direct damage
to cells and tissues within the target, effects outside the field
also known as abscopal effects have been observed in both
tumors and normal tissue. For example, irradiation often
leads to systemic fatigue [166], and bilateral pneumonitis
sometimes occurs after unilateral lung irradiation [167].
Occasionally, metastatic tumors have been observed to
regress dramatically outside the primary irradiation field,
which is a manifestation of the systemic anti-tumor effect
[168].
169
­
­
­
170
5.23
The previous clinical cases showing unexpected regres­
sion of tumors outside the irradiated field are examples of a
phenomenon first described by Mole as the “abscopal effect”
[171]. The word abscopal comes from the Latin ab (position
away from) and Scopus (target). However, there is now clear
evidence that the abscopal effects associated with RT are due
to systemic anti-tumor immune responses triggered by the
RT. However, despite millions of patients receiving RT,
abscopal effects are too unpredictable to be a therapeutic tar­
get, as only a limited number of cases have been identified.
In a recent study, only 46 cases were identified between 1969
and 2014 [172]. With the advent of immune checkpoint
blockade therapy, clinical interest has soared. Since the
introduction of the anti-CTLA-4 antibody ipilimumab into
clinical practice in 2011, abscopal effects have been observed
in several patients who received RT while taking ipilimumab
[173, 174]. Other immune checkpoint therapies have also
shown promise. There are reports of abscopal effects follow­
ing treatment with RT and anti-PD1 therapies such as
­pembrolizumab or nivolumab [175]. In this section, we will
cover the biological events in cancer cells that precede the
occurrence of radiation-induced abscopal effects.
5.12.2		Radiation-Induced Immunogenicity
Radiation can alter the immunogenicity of tumors by pro­
moting tumor antigens, neoantigens, and danger signals.
5.12.2.1	Tumor Antigens
Tumor antigens result from protein degradation due to
damage to cellular proteins caused by radiation-induced
P. Sminia et al."
"Describe the abscopal effect as initially defined and explain how recent research, particularly involving immune checkpoint blockade therapies, has altered our understanding of this phenomenon.","The abscopal effect, first described by Mole, refers to the unexpected regression of tumors located outside the primary area irradiated with radiation. The term itself derives from Latin roots meaning ‘away from’ and ‘target,’ highlighting the unusual spatial extent of the therapeutic response. Initially, these effects were considered a rare and unpredictable anomaly within radiotherapy treatment. However, current research strongly suggests that abscopal effects are not random but rather represent a systemic anti-tumor immune response triggered by radiation exposure. This response is now understood to be significantly amplified when combined with immune checkpoint blockade therapies. Specifically, the introduction of antibodies targeting CTLA-4 (such as ipilimumab) and PD-1/PD-L1 pathways (like pembrolizumab or nivolumab) has dramatically increased the incidence and magnitude of abscopal effects in patients receiving radiation therapy. Studies have documented cases where tumors previously unresponsive to local radiation treatment exhibited regression after combined RT and immune checkpoint blockade, demonstrating a coordinated attack by the immune system against metastatic disease. The limited number of identified cases historically underscores the rarity of this effect when observed alone; however, the combination with immunotherapy has significantly increased its prevalence and clinical relevance. Reference: 5.12 Systemic Anti-tumor Immune Responses and Abscopal Effects","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.12		 Systemic Anti-tumor Immune Responses and Abscopal Effects | Content: regress dramatically outside the primary irradiation field,
which is a manifestation of the systemic anti-tumor effect
[168].
169
­
­
­
170
5.23
The previous clinical cases showing unexpected regres­
sion of tumors outside the irradiated field are examples of a
phenomenon first described by Mole as the “abscopal effect”
[171]. The word abscopal comes from the Latin ab (position
away from) and Scopus (target). However, there is now clear
evidence that the abscopal effects associated with RT are due
to systemic anti-tumor immune responses triggered by the
RT. However, despite millions of patients receiving RT,
abscopal effects are too unpredictable to be a therapeutic tar­
get, as only a limited number of cases have been identified.
In a recent study, only 46 cases were identified between 1969
and 2014 [172]. With the advent of immune checkpoint
blockade therapy, clinical interest has soared. Since the
introduction of the anti-CTLA-4 antibody ipilimumab into
clinical practice in 2011, abscopal effects have been observed
in several patients who received RT while taking ipilimumab
[173, 174]. Other immune checkpoint therapies have also
shown promise. There are reports of abscopal effects follow­
ing treatment with RT and anti-PD1 therapies such as
­pembrolizumab or nivolumab [175]. In this section, we will
cover the biological events in cancer cells that precede the
occurrence of radiation-induced abscopal effects.
5.12.2		Radiation-Induced Immunogenicity
Radiation can alter the immunogenicity of tumors by pro­
moting tumor antigens, neoantigens, and danger signals.
5.12.2.1	Tumor Antigens
Tumor antigens result from protein degradation due to
damage to cellular proteins caused by radiation-induced
P. Sminia et al."
Describe the ‘abscopal effect’ as initially defined by Mole and explain how current research suggests its underlying mechanism.,"The term ‘abscopal effect,’ coined by Mole, describes instances where tumors located outside the area irradiated with radiation therapy dramatically regress. Initially, this phenomenon was puzzling because it suggested a systemic effect beyond direct cellular damage within the treated field. The original observation involved cases of metastatic tumor regression occurring far from the primary irradiation site, such as bilateral pneumonitis following unilateral lung radiation or dramatic regression of distant metastases. Current research strongly indicates that these abscopal effects are driven by systemic anti-tumor immune responses triggered by radiation exposure. Specifically, RT induces an immunostimulatory response leading to a broader activation of the immune system capable of targeting and eliminating cancer cells throughout the body, not just those within the irradiated field. Recent studies, particularly with the introduction of immune checkpoint inhibitors like ipilimumab (anti-CTLA-4) and PD1/PDL inhibitors (pembrolizumab or nivolumab), have demonstrated a significant increase in abscopal effects, further solidifying the role of systemic immunity in this complex response. The limited number of identified cases historically highlights the unpredictable nature of this effect, but ongoing research aims to understand the specific biological events within cancer cells that initiate and sustain these immune-mediated regressions. Reference: 5.12.1 Introduction","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.12		 Systemic Anti-tumor Immune Responses and Abscopal Effects | Sub-subsection: 5.12.1		 Introduction | Content: While radiation effects classically result from direct damage
to cells and tissues within the target, effects outside the field
also known as abscopal effects have been observed in both
tumors and normal tissue. For example, irradiation often
leads to systemic fatigue [166], and bilateral pneumonitis
sometimes occurs after unilateral lung irradiation [167].
Occasionally, metastatic tumors have been observed to
regress dramatically outside the primary irradiation field,
which is a manifestation of the systemic anti-tumor effect
[168].
169
­
­
­
170
5.23
The previous clinical cases showing unexpected regres­
sion of tumors outside the irradiated field are examples of a
phenomenon first described by Mole as the “abscopal effect”
[171]. The word abscopal comes from the Latin ab (position
away from) and Scopus (target). However, there is now clear
evidence that the abscopal effects associated with RT are due
to systemic anti-tumor immune responses triggered by the
RT. However, despite millions of patients receiving RT,
abscopal effects are too unpredictable to be a therapeutic tar­
get, as only a limited number of cases have been identified.
In a recent study, only 46 cases were identified between 1969
and 2014 [172]. With the advent of immune checkpoint
blockade therapy, clinical interest has soared. Since the
introduction of the anti-CTLA-4 antibody ipilimumab into
clinical practice in 2011, abscopal effects have been observed
in several patients who received RT while taking ipilimumab
[173, 174]. Other immune checkpoint therapies have also
shown promise. There are reports of abscopal effects follow­
ing treatment with RT and anti-PD1 therapies such as
­pembrolizumab or nivolumab [175]. In this section, we will
cover the biological events in cancer cells that precede the
occurrence of radiation-induced abscopal effects."
"Describe the ‘abscopal effect’ as initially defined and its current understanding in relation to radiation therapy, including the role of systemic anti-tumor immune responses.","The abscopal effect, first described by Mole, refers to the unexpected regression of tumors located outside the primary area irradiated with radiation. The term derives from Latin roots meaning ‘away from target.’ Initially, this phenomenon was considered a unique and somewhat mysterious response to radiation therapy. Current understanding posits that the abscopal effect is primarily driven by systemic anti-tumor immune responses triggered by the radiation itself. Radiation alters the immunogenicity of tumors, promoting the expression of tumor antigens and neoantigens – essentially exposing previously hidden cancer cell components to the immune system. These altered cells also release ‘danger signals,’ alerting the immune system to a threat. This heightened immune response then extends beyond the treated area, targeting and destroying cancer cells that were not directly exposed to the radiation. The rarity of observed abscopal effects historically has been attributed to the unpredictable nature of this systemic immune activation. However, with the introduction of immune checkpoint blockade therapies like ipilimumab (anti-CTLA-4), abscopal effects have become more frequently observed in patients receiving RT alongside these treatments, highlighting the critical role of a robust and sustained anti-tumor immune response. Reference: 5.12.2 Systemic Anti-tumor Immune Responses and Abscopal Effects > 5.12.2 Radiation-Induced Immunogenicity","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.12		 Systemic Anti-tumor Immune Responses and Abscopal Effects | Sub-subsection: 5.12.2		 Radiation-Induced Immunogenicity | Content: regress dramatically outside the primary irradiation field,
which is a manifestation of the systemic anti-tumor effect
[168].
169
­
­
­
170
5.23
The previous clinical cases showing unexpected regres­
sion of tumors outside the irradiated field are examples of a
phenomenon first described by Mole as the “abscopal effect”
[171]. The word abscopal comes from the Latin ab (position
away from) and Scopus (target). However, there is now clear
evidence that the abscopal effects associated with RT are due
to systemic anti-tumor immune responses triggered by the
RT. However, despite millions of patients receiving RT,
abscopal effects are too unpredictable to be a therapeutic tar­
get, as only a limited number of cases have been identified.
In a recent study, only 46 cases were identified between 1969
and 2014 [172]. With the advent of immune checkpoint
blockade therapy, clinical interest has soared. Since the
introduction of the anti-CTLA-4 antibody ipilimumab into
clinical practice in 2011, abscopal effects have been observed
in several patients who received RT while taking ipilimumab
[173, 174]. Other immune checkpoint therapies have also
shown promise. There are reports of abscopal effects follow­
ing treatment with RT and anti-PD1 therapies such as
­pembrolizumab or nivolumab [175]. In this section, we will
cover the biological events in cancer cells that precede the
occurrence of radiation-induced abscopal effects.
5.12.2		Radiation-Induced Immunogenicity
Radiation can alter the immunogenicity of tumors by pro­
moting tumor antigens, neoantigens, and danger signals."
"Describe the mechanisms through which radiation can increase the immunogenicity of tumors, specifically focusing on the generation of tumor antigens and neoantigens.","Radiation’s impact on tumor immunogenicity stems from its ability to induce cellular damage, primarily via the creation of reactive oxygen species (ROS) during radiolysis of water. This radical formation leads to protein degradation within tumor cells, resulting in the release of peptide fragments – these are termed tumor antigens. Furthermore, radiation-induced DNA damage, particularly double-strand breaks (DSBs), can trigger a cascade leading to neoantigen generation. DSBs, if not efficiently repaired, result in mutations and genomic instability within the tumor cell. These mutations create novel tumor-specific antigens, known as neoantigens, which are generated from the expression of a large number of mutations. The severity of DNA damage significantly influences the immunogenicity; low LET radiation typically induces simple DSBs repaired via Non-Homologous End Joining (NHEJ), while high LET radiation causes clustered lesions often repaired through Homology-Directed Repair (HDR) or Base Excision Repair (BER). When repair mechanisms are overwhelmed, mutations accumulate, driving neoantigen expression and presentation via MHC molecules. Reference: [MolecularRadiationBiology, Section 5.12.2.1 – Tumor Antigens]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.12		 Systemic Anti-tumor Immune Responses and Abscopal Effects | Sub-subsection: 5.12.2		 Radiation-Induced Immunogenicity | Sub-sub-subsection: 5.12.2.1	 Tumor Antigens | Content: regress dramatically outside the primary irradiation field,
which is a manifestation of the systemic anti-tumor effect
[168].
169
­
­
­
170
5.23
The previous clinical cases showing unexpected regres­
sion of tumors outside the irradiated field are examples of a
phenomenon first described by Mole as the “abscopal effect”
[171]. The word abscopal comes from the Latin ab (position
away from) and Scopus (target). However, there is now clear
evidence that the abscopal effects associated with RT are due
to systemic anti-tumor immune responses triggered by the
RT. However, despite millions of patients receiving RT,
abscopal effects are too unpredictable to be a therapeutic tar­
get, as only a limited number of cases have been identified.
In a recent study, only 46 cases were identified between 1969
and 2014 [172]. With the advent of immune checkpoint
blockade therapy, clinical interest has soared. Since the
introduction of the anti-CTLA-4 antibody ipilimumab into
clinical practice in 2011, abscopal effects have been observed
in several patients who received RT while taking ipilimumab
[173, 174]. Other immune checkpoint therapies have also
shown promise. There are reports of abscopal effects follow­
ing treatment with RT and anti-PD1 therapies such as
­pembrolizumab or nivolumab [175]. In this section, we will
cover the biological events in cancer cells that precede the
occurrence of radiation-induced abscopal effects.
5.12.2		Radiation-Induced Immunogenicity
Radiation can alter the immunogenicity of tumors by pro­
moting tumor antigens, neoantigens, and danger signals.
5.12.2.1	Tumor Antigens
Tumor antigens result from protein degradation due to
damage to cellular proteins caused by radiation-induced
P. Sminia et al.
275
­
­
­
free radicals. Radicals such ROS are generated during
radiation-induced radiolysis of water. RT then causes cel­
lular damage that is independent of DNA and leads to an
increase in the pool of peptides, i.e., tumor antigens that
bind to the major histocompatibility complex (MHC)
[176].
Tumor neoantigens are tumor-specific antigens resulting
from the expression of a large number of mutations which
may be a result of tumor genetic instability but also due to
severe DNA damage. The degrees of DNA damage can
strongly influence the immunogenicity of the tumor. In this
context, RT leads to DNA SSBs or DSBs or other DNA alter­
ations (see Chap. 3) [177]. DSBs are the most lethal DNA
lesions if not repaired. Repair depends on the type of radia­
tion causing the damage. Low LET radiation causes simple
DSBs, which are repaired by NHEJ pathway. High LET radi­
ation causes clustered DNA lesions (or multiple damaged
sites) that are usually repaired by HR. Non-DSB lesions at
clustered DNA damage sites are corrected with Base Excision
Repair. If the DNA repair mechanisms are not sufficient to
repair the damage, or if the RT itself causes defects in the
DNA repair mechanisms, mutations occur that can lead to the
5 Clinical Radiobiology for Radiation Oncology
276
expression of tumor neoantigens. These neoantigens are then
processed by tumor cells and presented by MHCs [178]."
"Describe the concept of Damage-Associated Molecular Patterns (DAMPs) as they relate to radiation's impact on tumor cells and the subsequent immune response, including specific examples of DAMPs identified in this context.","Damage-Associated Molecular Patterns (DAMPs) are endogenous molecules released by damaged or dying cells that act as signals to activate the innate immune system. In the context of radiation exposure, irradiated tumor cells release a variety of DAMPs which dramatically enhance their recognition and destruction by immune cells like macrophages and dendritic cells (DCs). Key examples include fragmented double-stranded DNA and micronuclei – these self-DNA fragments appearing in the cytosol trigger an immune response; High Mobility Group Box 1 (HMGB1), a nuclear protein released from dying tumor cells, binds to Toll-like Receptor 4 (TLR4) on DCs, activating them; Nucleotide release from apoptotic cells functions as a chemoattractant for myeloid cells like DCs, stimulating the P2RY2 receptor; Extracellular ATP via the P2RX7 receptor initiates inflammasome activation and Interleukin 1β production; and Calreticulin, an ER protein translocated to the membrane after radiation, facilitates uptake of dying tumor cells by antigen-presenting cells. Furthermore, chemokines such as CXCL16, CXCL10, and CXCL9 are released, stimulating immune cell differentiation and cytokine production (Interferon, TNFα, IL-1β). The accumulation of these DAMPs effectively ‘alerts’ the immune system to the presence of a tumor, promoting an enhanced anti-tumor response. Reference: [MolecularRadiationBiology, Section 5.12.2.2 Damage-Associated Molecular Pattern (DAMP)]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.12		 Systemic Anti-tumor Immune Responses and Abscopal Effects | Sub-subsection: 5.12.2		 Radiation-Induced Immunogenicity | Sub-sub-subsection: 5.12.2.2	 Damage-Associated Molecular Pattern (DAMP) | Content: (DAMP)
Damage signals properly known as Damage-Associated
Molecular Patterns (DAMPs) are endogenous molecular sig­
nals released by irradiated cells after damage or when dying
[176]. These signals enable enhanced recognition and killing
of the tumor by macrophages and DCs resulting in antigen
presentation to T cells [161, 164]. Some of the most fre­
quently found radiation-induced DAMPs in tumor cells are:
•	Fragmented double-stranded DNA and micronuclei.
These self-DNA fragments and micronuclei appear as
cytosolic DNA in tumor cells, which are later recognized
by immune cells.
•	High mobility group box 1 (HMGB1) is a nuclear protein
associated with chromatin that is released extracellularly
by dying tumor cells, normally necrotic cells [179].
HMGB1 binds to Toll-like receptor 4 (TLR4) expressed
by DCs and activates them.
•	Nucleotide release by apoptotic cells function as a chemo­
tactic signal for phagocytic myeloid cells including DCs
by stimulating the Purinergic receptor 2 (P2RY2) [180].
•	Extracellular ATP can also function through the activa­
tion of Purinergic receptor 7 (P2RX7) to initiate inflam­
masome activation and subsequent Interleukin 1β
production. This mechanism was shown to be required for
the induction of tumor antigen-specific CD8+ T cells fol­
lowing challenge with dying tumor cells [181].
•	Calreticulin is an ER protein that gets translocated to the
cellular membrane after RT. Calreticulin is essential for
efficient uptake of dying tumor cells by antigen-­presenting
cells [182].
•	Chemokines are a frequent part of DAMPs. Chemokines,
such as C-X-C motif (CXC) ligand 16, 10, and 19
(CXCL16, CXCL10, and CXCL9), are known for being
released after radiation exposure; they trigger differentia­
tion of immune cells, and stimulate immune modulators
such as Interferons, Tumor necrosis factor α, and
Interleukin 1β [162, 183–185].
In summary, radiation increases the immunogenicity of
tumors by simultaneously promoting the release of tumor
antigens, neoantigens, and DAMPs. This radiation-induced
immunogenicity may counteract the progression of tumors
that have escaped immune surveillance, especially if an
abscopal effect can be triggered.
5.12.2.3	Anti-tumor Immune Responses:
Abscopal Effects
To reproduce the radiation-induced abscopal effect has been
challenging as its underlying biological mechanisms are not
fully understood. However, some crucial cellular signaling
pathways have been identified alongside the IR doses that
appear to be fundamental for their occurrence.
•	The accumulation of cytosolic double-stranded DNA
fragments (dsDNA) is usually a sign of microbial infec­
tion and alerts the host’s innate immune system to initiate
a defense response. Interestingly, the accumulation of
dsDNA after RT has been shown to be an essential step in
the abscopal response. Mitochondrial DNA and dsDNA
are recognized by cyclic GMP-AMP synthase (cGAS),
which produces messengers that bind and activate the
transmembrane protein Stimulator of interferon genes
(STING), triggering a robust innate immune response
[186]. In particular, activation of the type I interferon sig­
naling pathway (IFN-1) and production of Interferon β
cytokines by cancer cells trigger the accumulation of
basic leucine zipper ATF-like transcription factor 3
(Batf3)-dependent DCs, which are required for the matu­
ration of anti-tumor CD8+ T cells.
•	The irradiation dose and fractionation schemes are cru­
cial for the induction of abscopal effects. With increasing
radiation dose, more dsDNA fragments accumulate in
the cytoplasm of cancer cells. However, the increased
radiation dose of over 12 Gy also triggers the activation
of three prime repair exonuclease 1 (Trex1), which
degrades dsDNA and prevents an immune response.
Interestingly, Interferon β production can be enhanced
with repeated radiation doses that do not trigger Trex1
[186]. Radiation regimens that have been shown to be
effective in preclinical and clinical studies are 3 × 8 and
5 × 6 Gy.
•	Transforming growth factor beta (TGF-ß) is a potent
immunosuppressive cytokine in established tumors that
impairs the antigen presentation function of DCs, prevents
T cell priming and thus inhibit the abscopal effect [164].
•	TGF-β expression increases in irradiated tissues. However,
the abscopal effect can be restored if TGF-β neutralizing
antibodies are administered during RT. Current research
is investigating if the use of dual-function drugs that
simultaneously target TGF-β and PD -L1 in combination
with RT can be a good strategy to overcome tumor
immune escape [187].
5.13
Normal Tissue Damage and Response
to Radiotherapy
5.13.1		Introduction
The tolerance of normal tissues to RT is the limiting factor in
delivering a radiation dose high enough to eradicate tumor
cells [188, 189]. The dose delivered to the target structure is
P. Sminia et al."
"Describe the mechanisms by which ionizing radiation (RT) induces an anti-tumor immune response, specifically focusing on the role of dsDNA accumulation and subsequent signaling pathways.","Ionizing radiation triggers a complex immune response against tumors, primarily through the accumulation of cytosolic double-stranded DNA (dsDNA) fragments. This dsDNA accumulation is initially recognized by cyclic GMP-AMP synthase (cGAS), an enzyme that converts dsDNA into cyclic GMP-AMP (cGAMP). cGAMP then activates Stimulator of interferon genes (STING), a transmembrane protein, initiating a robust innate immune response. Activation of STING triggers the type I interferon signaling pathway, leading to the production of Interferon β cytokines by cancer cells. Critically, this IFN-β production promotes the accumulation of basic leucine zipper ATF-like transcription factor 3 (Batf3)-dependent dendritic cells (DCs), which are essential for the maturation and activation of anti-tumor CD8+ T cells. The resulting cytotoxic T lymphocyte response targets and eliminates not only the initially irradiated tumor but also distant, untreated metastases – a phenomenon known as an abscopal effect. However, excessively high radiation doses (over 12 Gy) can paradoxically suppress this immune response due to the activation of three prime repair exonuclease 1 (Trex1), which degrades dsDNA and inhibits cGAS/STING signaling.  Furthermore, immunosuppressive factors like transforming growth factor beta (TGF-β), which is upregulated in irradiated tissues, can impair DC function and hinder T cell priming, thus negating the abscopal effect. Therapeutic strategies are being explored to counteract these effects, such as using TGF-β neutralizing antibodies or combining RT with agents targeting both TGF-β and PD-L1.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.12		 Systemic Anti-tumor Immune Responses and Abscopal Effects | Sub-subsection: 5.12.2		 Radiation-Induced Immunogenicity | Sub-sub-subsection: 5.12.2.3	 Anti-tumor Immune Responses: Abscopal Effects | Content: challenging as its underlying biological mechanisms are not
fully understood. However, some crucial cellular signaling
pathways have been identified alongside the IR doses that
appear to be fundamental for their occurrence.
•	The accumulation of cytosolic double-stranded DNA
fragments (dsDNA) is usually a sign of microbial infec­
tion and alerts the host’s innate immune system to initiate
a defense response. Interestingly, the accumulation of
dsDNA after RT has been shown to be an essential step in
the abscopal response. Mitochondrial DNA and dsDNA
are recognized by cyclic GMP-AMP synthase (cGAS),
which produces messengers that bind and activate the
transmembrane protein Stimulator of interferon genes
(STING), triggering a robust innate immune response
[186]. In particular, activation of the type I interferon sig­
naling pathway (IFN-1) and production of Interferon β
cytokines by cancer cells trigger the accumulation of
basic leucine zipper ATF-like transcription factor 3
(Batf3)-dependent DCs, which are required for the matu­
ration of anti-tumor CD8+ T cells.
•	The irradiation dose and fractionation schemes are cru­
cial for the induction of abscopal effects. With increasing
radiation dose, more dsDNA fragments accumulate in
the cytoplasm of cancer cells. However, the increased
radiation dose of over 12 Gy also triggers the activation
of three prime repair exonuclease 1 (Trex1), which
degrades dsDNA and prevents an immune response.
Interestingly, Interferon β production can be enhanced
with repeated radiation doses that do not trigger Trex1
[186]. Radiation regimens that have been shown to be
effective in preclinical and clinical studies are 3 × 8 and
5 × 6 Gy.
•	Transforming growth factor beta (TGF-ß) is a potent
immunosuppressive cytokine in established tumors that
impairs the antigen presentation function of DCs, prevents
T cell priming and thus inhibit the abscopal effect [164].
•	TGF-β expression increases in irradiated tissues. However,
the abscopal effect can be restored if TGF-β neutralizing
antibodies are administered during RT. Current research
is investigating if the use of dual-function drugs that
simultaneously target TGF-β and PD -L1 in combination
with RT can be a good strategy to overcome tumor
immune escape [187].
5.13"
"Describe the mechanisms by which radiation exposure triggers an innate immune response in cancer cells, including the roles of cytosolic dsDNA, cGAS-STING signaling, type I interferon (IFN-1), and Batf3-dependent dendritic cells (DCs).","Radiation-induced damage to tissues, particularly the accumulation of cytosolic double-stranded DNA fragments (dsDNA), initiates a complex innate immune response within cancer cells. This dsDNA accumulation is primarily recognized by cyclic GMP-AMP synthase (cGAS), an enzyme that catalyzes the production of cyclic GMP-AMP (cGAMP). cGAMP then activates Stimulator of interferon genes (STING), a transmembrane protein, leading to a cascade of events. STING activation triggers the production and release of type I interferons (IFN-1), notably Interferon β, by the cancer cells themselves. IFN-1 subsequently stimulates the maturation of basic leucine zipper ATF-like transcription factor 3 (Batf3)-dependent dendritic cells (DCs). These mature DCs are crucial for initiating an adaptive immune response, specifically promoting the activation and maturation of anti-tumor CD8+ T cells, a key component of cell-mediated immunity. The accumulation of dsDNA and subsequent IFN-1 production effectively ‘alerts’ the cancer cell to a threat, driving this robust immune activation. Furthermore, this process is often dependent on specific DC populations – Batf3-dependent DCs – which are essential for effective anti-tumor responses.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Content: challenging as its underlying biological mechanisms are not
fully understood. However, some crucial cellular signaling
pathways have been identified alongside the IR doses that
appear to be fundamental for their occurrence.
•	The accumulation of cytosolic double-stranded DNA
fragments (dsDNA) is usually a sign of microbial infec­
tion and alerts the host’s innate immune system to initiate
a defense response. Interestingly, the accumulation of
dsDNA after RT has been shown to be an essential step in
the abscopal response. Mitochondrial DNA and dsDNA
are recognized by cyclic GMP-AMP synthase (cGAS),
which produces messengers that bind and activate the
transmembrane protein Stimulator of interferon genes
(STING), triggering a robust innate immune response
[186]. In particular, activation of the type I interferon sig­
naling pathway (IFN-1) and production of Interferon β
cytokines by cancer cells trigger the accumulation of
basic leucine zipper ATF-like transcription factor 3
(Batf3)-dependent DCs, which are required for the matu­
ration of anti-tumor CD8+ T cells.
•	The irradiation dose and fractionation schemes are cru­
cial for the induction of abscopal effects. With increasing
radiation dose, more dsDNA fragments accumulate in
the cytoplasm of cancer cells. However, the increased
radiation dose of over 12 Gy also triggers the activation
of three prime repair exonuclease 1 (Trex1), which
degrades dsDNA and prevents an immune response.
Interestingly, Interferon β production can be enhanced
with repeated radiation doses that do not trigger Trex1
[186]. Radiation regimens that have been shown to be
effective in preclinical and clinical studies are 3 × 8 and
5 × 6 Gy.
•	Transforming growth factor beta (TGF-ß) is a potent
immunosuppressive cytokine in established tumors that
impairs the antigen presentation function of DCs, prevents
T cell priming and thus inhibit the abscopal effect [164].
•	TGF-β expression increases in irradiated tissues. However,
the abscopal effect can be restored if TGF-β neutralizing
antibodies are administered during RT. Current research
is investigating if the use of dual-function drugs that
simultaneously target TGF-β and PD -L1 in combination
with RT can be a good strategy to overcome tumor
immune escape [187].
5.13
Normal Tissue Damage and Response
to Radiotherapy"
"Describe the mechanisms by which irradiation induces an immune response in cancer cells, focusing on the roles of cytosolic dsDNA, cGAS-STING signaling, and interferon production. Explain how this process contributes to the abscopal effect.","Following radiation exposure, a key event is the accumulation of cytosolic double-stranded DNA (dsDNA) fragments within cancer cells. This dsDNA accumulation serves as an initial alert to the host’s innate immune system. Specifically, dsDNA is recognized by cyclic GMP-AMP synthase (cGAS), which catalyzes the production of cyclic GMP-AMP (cGAMP). cGAMP then activates the Stimulator of Interferon Genes (STING) protein, triggering a robust innate immune response. Activation of STING initiates signaling cascades that ultimately lead to the production of type I interferons (IFN-1), such as Interferon β cytokines, by cancer cells. These IFN-1 cytokines stimulate the maturation and activation of dendritic cells (DCs), specifically promoting the generation of basic leucine zipper ATF-like transcription factor 3 (Batf3)-dependent DCs, which are crucial for priming anti-tumor CD8+ T cells. This coordinated immune response – driven by dsDNA recognition, cGAS-STING signaling, and IFN-1 production – is a central component of the abscopal effect, where radiation can induce tumor regression in distant sites beyond the initially treated area.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.1		 Introduction | Content: challenging as its underlying biological mechanisms are not
fully understood. However, some crucial cellular signaling
pathways have been identified alongside the IR doses that
appear to be fundamental for their occurrence.
•	The accumulation of cytosolic double-stranded DNA
fragments (dsDNA) is usually a sign of microbial infec­
tion and alerts the host’s innate immune system to initiate
a defense response. Interestingly, the accumulation of
dsDNA after RT has been shown to be an essential step in
the abscopal response. Mitochondrial DNA and dsDNA
are recognized by cyclic GMP-AMP synthase (cGAS),
which produces messengers that bind and activate the
transmembrane protein Stimulator of interferon genes
(STING), triggering a robust innate immune response
[186]. In particular, activation of the type I interferon sig­
naling pathway (IFN-1) and production of Interferon β
cytokines by cancer cells trigger the accumulation of
basic leucine zipper ATF-like transcription factor 3
(Batf3)-dependent DCs, which are required for the matu­
ration of anti-tumor CD8+ T cells.
•	The irradiation dose and fractionation schemes are cru­
cial for the induction of abscopal effects. With increasing
radiation dose, more dsDNA fragments accumulate in
the cytoplasm of cancer cells. However, the increased
radiation dose of over 12 Gy also triggers the activation
of three prime repair exonuclease 1 (Trex1), which
degrades dsDNA and prevents an immune response.
Interestingly, Interferon β production can be enhanced
with repeated radiation doses that do not trigger Trex1
[186]. Radiation regimens that have been shown to be
effective in preclinical and clinical studies are 3 × 8 and
5 × 6 Gy.
•	Transforming growth factor beta (TGF-ß) is a potent
immunosuppressive cytokine in established tumors that
impairs the antigen presentation function of DCs, prevents
T cell priming and thus inhibit the abscopal effect [164].
•	TGF-β expression increases in irradiated tissues. However,
the abscopal effect can be restored if TGF-β neutralizing
antibodies are administered during RT. Current research
is investigating if the use of dual-function drugs that
simultaneously target TGF-β and PD -L1 in combination
with RT can be a good strategy to overcome tumor
immune escape [187].
5.13
Normal Tissue Damage and Response
to Radiotherapy
5.13.1		Introduction
The tolerance of normal tissues to RT is the limiting factor in
delivering a radiation dose high enough to eradicate tumor
cells [188, 189]. The dose delivered to the target structure is
P. Sminia et al.
277
limited by the dose constraints to the organs at risk (OAR),
which are in close proximity to the tumor. In the case of
external RT, standard recommendations for OAR doses have
been issued based on the volumes irradiated and are regu­
larly updated to reflect new practices.
Despite ongoing technical and technological advances, the
planning target volume (PTV) necessarily contains a volume
of normal tissue for several reasons. First, the target volume,
which receives the prescribed dose, is always larger than the
actual tumor volume. Indeed, this volume must take into
account the visible tumor volume (gross tumor volume,
GTV), the possible microscopic extension of the tumor (clini­
cal target volume, CTV), the movements of the different vol­
umes (internal target volume, ITV), small errors in patient
set-up and technical precision, all together making up the
PTV. Secondly, the tumor contains normal tissues such as soft
tissues and blood vessels, which receive the entire prescribed
dose. Finally, especially for external beam RT, the radiation
beam inevitably passes through normal tissue, depositing
doses that may be clinically relevant. Effective RT is there­
fore necessarily associated with a risk of adverse effects. Side
effects may occur during RT or a few weeks after treatment
(acute effects). In the long term, late effects, which may occur
months or years after RT, are the most critical because they
are chronic, disabling, painful, and most often irreversible.
Limiting adverse events to reduce morbidity and optimize
the therapeutic index of RT remains a priority in the fight
against cancer. To this end, NTCP modeling is widely used
in treatment planning as a tool to differentiate treatment
plans [11]. In future, cellular and animal models of radiotox­
icity aimed at understanding the sequence of molecular and
cellular events that drive the pathogenesis of early and late
normal tissue radiation injury should enable the development
of tools to reduce the impact of RT on normal tissues [190]."
"Describe the acute tissue response to radiation therapy, focusing on the types of cells most vulnerable and how this relates to clinical manifestation time scales.","Following radiation exposure, acute normal tissue responses primarily occur in tissues with rapid cell renewal rates, such as the small intestine mucosa, skin, hair follicles, bone marrow, and testes. These tissues rely on actively cycling cell populations, particularly stem cells within crypts of the small intestine, bone marrow hematopoietic stem cells, or basal layer keratinocytes of the skin, to maintain tissue function by replacing physiologically lost cells. When a sufficient number of these critical stem cell populations are damaged, the regenerative capacity of the tissue is overwhelmed, leading to hypoplasia (reduced cellularity) and depletion of functional cells. The clinical manifestation time for these acute effects is largely independent of the administered radiation dose itself; instead, it’s dictated by the rate at which these vital stem cells are lost and the demand for their proliferation to replenish the damaged tissue. This process typically manifests within days to weeks post-exposure, as observed in tissues like the gastrointestinal tract (less than a week) or bone marrow (0.5–2 weeks), highlighting the direct correlation between cell loss and clinical presentation. Reference: [MolecularRadiationBiology, Section 5.13.2 – Acute Tissue Response]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.2		 Acute Tissue Response | Content: Acute responses are primarily observed in tissues with
rapid cell renewal where cell division is required to main­
tain the function of the organ. In these renewing tissues,
physiological cell loss occurs constantly from the post-
mitotic tissue compartments while actively cycling cell
populations in the germinal parts of the tissue proliferate to
replenish them. The radiation response is related to death of
critical cell populations such as the stem cells in the crypts
of the small intestines, in the bone marrow, or in the basal
layer of the skin. When sufficiently large numbers of criti­
cal cell populations are affected, cell production capacity is
no longer able to compensate for the physiologically occur­
ring cell loss, leading to hypoplasia and cell depletion. For
this reason, the time scale of clinical manifestation of most
acute responses is independent of dose and instead reflects
the rate of loss of functional cells and the demand of prolif­
eration of the supporting stem cells of the different tissues
(Box 5.13).
­
­
5.12
­
­
­
­
5.13
Box 5.13 Radiation-Induced Acute Normal Tissue
Response
•	Acute effects of radiation are observed in days to
weeks after exposure.
•	The time scale of clinical manifestation of most
acute responses is independent of the radiation dose
and related to the proliferative rate of injured cells.
•	Acute effects are transient and reversible.
•	Typical acute responding normal tissues are: intes­
tine, mucosa, skin, hair follicles, bone marrow.
Table 5.12 Tissue and target cell-specific latency times
Tissue
Target cells
Latency times (after
single exposure)
Epidermis
Basal cells
3–4 weeks
GI-tract
Crypt cells
<1 week
Bone
marrow
Hematological stem cells and
precursor cells
0.5–2 weeks
Testes
Spermatogonial stem cells
2–4 weeks
5 Clinical Radiobiology for Radiation Oncology
278
Table 5.13 Threshold radiation doses for a selected group of tissues.
Estimate of threshold doses for an approximate 1% incidence of mor­
bidity for early and late tissue reacting human tissues and organs fol­
lowing acute exposure to radiation (modified after Table 4.4 from
[191])
Organ/
tissue
Threshold
dose (Gy)
Biological effect
Latency
period
Testis
~0.10
Temporary sterility
3–9 weeks
Testis
~6
Permanent sterility
3 weeks
Ovaries
~3
Permanent sterility
<1 week
Bone
marrow
~0.5
Depression of
hematopoiesis
3–7 days
Skin (large
areas)
<3–6
Main phase of skin
reddening
1–4 weeks
Skin (large
areas)
5–10
Skin burns
2–3 weeks
Skin
~4
Temporary hair loss
2–3 weeks
Skin (large
areas)
10
Late atrophy
>1 year
Skin (large
areas)
10
Telangiectasia at 5 years
>1 year
Eye
~0.1 per
5 yearsa
Cataract (visual
impairment)
>20 years
Brain
0.1–0.2
Cognitive defects infants
<18 months
Several
years
Carotid
artery
~0.5
Cardiovascular disease
>10 years
Kidney
~7–8
Renal failure
>1 year
a An equivalent dose limit for the lens of the eye of 20 mGy/year is
recommended for workers. The dose should be spread over defined
5 years periods, with no single year exceeding 50 mGy [192]
­
­
­
­
­
­
191
­
­
5.13"
"Describe the key pathological processes contributing to late tissue damage following radiation therapy, specifically focusing on mechanisms like fibrosis, atrophy, and vascular changes, and how these processes interact with cellular responses.","Late effects of radiation therapy are characterized by progressive and irreversible alterations in normal tissues, primarily driven by complex interactions between parenchymal cells, endothelial cells, fibroblasts, and the immune system. A central mechanism is the development of fibrosis, resulting from fibroblast differentiation into myofibroblasts, increased proliferation of existing fibroblasts, and subsequent deposition of excessive extracellular matrix composed largely of collagen. This process leads to tissue hardening and shrinkage – a phenomenon often observed in irradiated breast or small intestine tissues. Concurrently, atrophy occurs due to the loss of fibroblasts and the reabsorption of collagen, further contributing to tissue volume reduction. Vascular damage manifests as either dilation or constriction of small blood vessels, alongside cell losses from endothelial cells, leading to conditions like skin telangiectasias, ischemia, and potentially severe complications such as intestinal perforation or fistula formation. Critically, the immune response, particularly involving macrophages and mast cells, amplifies these effects through cytokine and growth factor release, further stimulating cellular proliferation and matrix deposition. These processes are not isolated; they interact synergistically, creating a complex feedback loop that ultimately leads to parenchymal cell damage and potential loss of organ function. The latency period for these late effects is inversely proportional to the radiation dose received, highlighting the cumulative nature of this tissue response [Reference: MolecularRadiationBiology, Section 5.13.3].","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.3	 Late Tissue Response | Content: >1 year
Skin (large
areas)
10
Telangiectasia at 5 years
>1 year
Eye
~0.1 per
5 yearsa
Cataract (visual
impairment)
>20 years
Brain
0.1–0.2
Cognitive defects infants
<18 months
Several
years
Carotid
artery
~0.5
Cardiovascular disease
>10 years
Kidney
~7–8
Renal failure
>1 year
a An equivalent dose limit for the lens of the eye of 20 mGy/year is
recommended for workers. The dose should be spread over defined
5 years periods, with no single year exceeding 50 mGy [192]
­
­
­
­
­
­
191
­
­
5.13
5.13.3	Late Tissue Response
5193
5.13
5.14
5.13.2
­
­
­
­
7
5.24
5.14
The mechanisms that lead to these effects are more com­
plex than for acute effects. They involve organ-specific
changes in parenchymal cells, including cell death and alter­
ations in cellular metabolism. Consequential late effects
from severe acute reactions may contribute to chronic dam­
age due to unresolved regeneration of rapidly proliferating
tissues which contributes additional damage to connective
tissue and endothelium [194].
Box 5.14 Radiation-Induced Late Normal Tissue
Response
•	Late effects of radiation occur months, years, or
decades after radiation therapy.
•	Late effects are progressive and irreversible.
•	The latent phase of chronic reactions is inversely
proportional to the radiation dose.
•	The late effects are based on an interactive response
of parenchymal cells, vascular endothelium and
fibroblasts, with a contribution from immune cells,
especially macrophages, as well as other cells.
•	Tissues and organs are affected by atrophy, fibrosis,
and/or necrosis, which can severely impair their
functions and lead to a loss of function.
P. Sminia et al.
279
Table 5.14 Typical characteristics of acute and late responding nor­
mal tissues and organs. Please note that early as well as late effects
could occur in the same tissue or organ
Early reactions
Late reactions
Cell turnover of
target cells
High
Low
Latency
<90 days
>90 days
Time factor
Shorter time
No influence of
time
>Damage
Clinical course
Transient
Irreversible
Fractionation
sensitivity
Low
High
α/β ratio
~10 Gy
~3 Gy
Examples:
Mucositis dermatitis bone
marrow depletion (tumor
response)
Myelopathy
Intestinal
fibrosis
Telangiectasia
The pathogenesis leading to radiation-induced fibrosis is
a result of fibroblast differentiation into myofibroblasts, pro­
liferation of surviving fibroblasts and extracellular matrix
and collagen deposition. Seen as wound healing that goes
wrong, this pathological process plays a key role in the
development and expression of most late effects. Atrophy is
caused by the loss of fibroblasts and collagen reabsorption.
Examples of fibrotic-atrophic response include hardening
and shrinkage of an irradiated breast, or strictures and mal­
absorption of irradiated small intestine. Vascular damage is
caused by either small vessel dilation or constriction as well
as losses of the vascular endothelial cells from small blood
vessels and capillaries. Vascular damage results, for instance,
in skin telangiectasias, bleeding, ischemia with intestinal
perforation and fistula formation. The immune system also
contributes significantly to the tissue response through the
involvement of macrophages and mast cells, which interact
with other cells in the irradiated tissue and other organs
through the release of cytokines and growth factors [195–
198]. More generally, the response of a tissue is mediated by
different types of cells such as inflammatory, stromal, endo­
thelial, and parenchymal cells that actively communicate
through the release of cytokines, chemokines and growth
factors, and/or the activation of molecular pathways down­
stream of these messengers. Altogether, these effects lead
progressively to parenchymal damage and potentially to loss
of organ function in the irradiated volume.
The tissues of cancer survivors treated with RT still bear
the traces of RT to varying degrees. Although patients are
usually asymptomatic, all irradiated patients, especially
those with late effects, have a common histological feature
of radiation-induced fibrosis and atrophy. Fibrosis predomi­
nates in the breast, skin, small intestine, lungs, kidneys, and
liver, while atrophy and necrosis predominate in the later
stages after RT alone or in combination with surgery and
local trauma to bone (osteoradionecrosis of the mandible,
ORN), nerve, or brain. The clinical severity correlates with
5 Clinical Radiobiology for Radiation Oncology
280
the extent of the underlying pathophysiological process,
which is usually invisible and often depends on the level of
parenchymal cell loss.
It is often mentioned that 5–10% of patients, and some­
times up to 20% for the treatment of pelvic malignancies,
including prostate, rectal and cervical cancer, develop late
side effects. However, some authors believe that the rates of
patients with late side effects may be greatly underestimated
[193]. For example, in the case of abdominal or pelvic can­
cers, more than half of patients would suffer from some form
of chronic bowel dysfunction [199]. Most of the effects
observed today were caused several years ago by RT tech­
niques that are less used today (2D- and 3D-CRT), and which
are progressively being replaced by more precise and more
efficient techniques and technologies (IMRT, SBRT and
their derivatives, hadrontherapy, and maybe FLASH RT in
the future). It is therefore likely that the landscape of side
effects will be completely different in a few years.
As cancer detection and management continue to improve,
there is an increase in the number of long-term cancer survi­
vors in the more economically developed countries. For
example, in the USA, the 5-year survival rate has increased
from 49% in the period 1975–1977 to 67% in the period
2010–2016 (American Cancer Society, Cancer Facts and
Figures, Atlanta, Georgia, 2021). On the other hand, given
that about half of patients are treated with RT, it can be esti­
mated that several tens of thousands of patients will develop
side effects each year in this country. Worldwide, with more
than 19 million new cancer cases in 2020 (and about 30 mil­
lion expected in 2040), and an estimated 5-year prevalence
of more than 50 million [200], the number of patients devel­
oping side effects affecting their quality of life is expected to
be in the millions each year. Beyond the fact that the late side
effects of RT still limit the effectiveness of this treatment,
these figures reveal a real public health concern facing the
public authorities and the medical profession."
"Describe the process leading to radionecrosis, including the key factors involved and common tissue sites affected.","Radionecrosis represents a delayed toxicity resulting from radiotherapy, characterized by progressive ischemia and chronic inflammation within irradiated tissues. The development of this phenomenon hinges on several interconnected factors: radiation dose, the specific tissue exposed, and site-specific risk factors. Initially, radiation exposure disrupts normal vascular function, leading to reduced blood flow – ischemia – in the affected area. This ischemia triggers a subsequent inflammatory response as cells attempt to repair the damage. Over time, this chronic inflammation contributes to further tissue destruction. Pathologically, radionecrosis manifests with fibrinous exudates and dystrophic changes of vessels within the exposed tissues. While all human tissues are theoretically susceptible, certain sites exhibit a higher propensity for developing radionecrosis due to anatomical factors or inherent tissue characteristics. Commonly affected tissues include bone (particularly the head and neck region – jaws, mastoid, temporal bone, larynx, cartilage; femoral head), breast, central nervous system (CNS), bowel, skin, and rarely ribs or sclera. It’s important to note that even with adherence to standard dosage schedules, serious complications can occur in 5-10% of long-term survivors due to the variability in individual responses and data limitations across studies. The severity is often exacerbated by chronic inflammation following initial ischemia.

Reference: Molecular Radiation Biology, Section 5.13.4 – Radionecrosis","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.4	 Radionecrosis | Content: Radionecrosis is a late toxicity phenomenon with the occur­
rence depending on radiation dose, the tissue affected and a
number of site-specific risk factors; as treatment options are
scant, preventive measures should be facilitated by providing
the treatment team with the forecasted 3D RT isodose curves
(Box 5.15).
Radiation accidents and therapy have shown that, in prin­
ciple, all human tissues can suffer from necrosis as a late
toxicity as result of progressive ischemia of irradiated tissues
in the context of chronic inflammation. Pathologic samples
show necrosis with fibrinous exudates and dystrophic
changes of the vessels in the exposed tissues. In daily prac­
tice, radionecrosis most commonly involves bone (head and
neck (jaws-mastoïd-temporal bone-larynx-cartilage)/femo­
ral head), breast, CNS, bowel, skin and rarely ribs or sclera
(Sect. 5.14.3). Even when standard dosage schedules are fol­
lowed, serious radiation complications would occur in
5–10% of long-term survivors. Yet, general incidence rates
on most tissues are difficult to present as most studies have
specific settings and constraints resulting in large heteroge­
neity of data. In the following section, osteonecrosis of the
jaws and brain radionecrosis will be discussed in greater
detail."
"Describe the pathophysiology of osteoradionecrosis (ORN) of the jaw, focusing on the key events leading to bone breakdown and exposure.","Osteoradionecrosis of the jaw develops following radiation therapy for head and neck cancers when exposed bone fails to heal properly. The primary mechanism involves ischemic necrosis within the irradiated tissue due to a loss of viability in the bone cells. This lack of repair capability leads to secondary soft tissue breakdown, exposing the underlying necrotic bone. Specifically, the radiation damages the vascular supply, causing insufficient blood flow and oxygen delivery to the bone tissue, leading to cell death. Without adequate perfusion, the ability of the bone to regenerate is severely compromised, resulting in a chronic state of non-healing. Furthermore, the presence of Actinomyces bacteria within the necrotic bone contributes to the process, although its precise role is still under investigation. The resultant exposure and lack of callus formation further exacerbate the condition. Reference: [MolecularRadiationBiology, Section 5.13.4.1 – Osteoradionecrosis (ORN) of the Jaw]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.4	 Radionecrosis | Sub-sub-subsection: 5.13.4.1	 Osteoradionecrosis (ORN) of the Jaw | Content: tice, radionecrosis most commonly involves bone (head and
neck (jaws-mastoïd-temporal bone-larynx-cartilage)/femo­
ral head), breast, CNS, bowel, skin and rarely ribs or sclera
(Sect. 5.14.3). Even when standard dosage schedules are fol­
lowed, serious radiation complications would occur in
5–10% of long-term survivors. Yet, general incidence rates
on most tissues are difficult to present as most studies have
specific settings and constraints resulting in large heteroge­
neity of data. In the following section, osteonecrosis of the
jaws and brain radionecrosis will be discussed in greater
detail.
5.13.4.1	Osteoradionecrosis (ORN) of the Jaw
Osteoradionecrosis (ORN) of the jaw is a late complication
of RT in the treatment of head and neck cancer. It is defined
as exposed irradiated bone that fails to heal over a period of
3 months without any evidence of persisting, recurrent tumor
or metastatic disease. ORN occurs in bone that was exposed
to a radiation total dose exceeding 60 Gy. However, in the
presence of concomitant risk factors, lesions can develop in
bone exposed to a lower dose, usually above 50 Gy. The
overall susceptibility ratio between mandible and maxilla is
for the development of ORN 24/1, with the posterior areas of
the mandible most at risk and the upper jaw rarely affected.
The overall incidence of ORN in IMRT patients is
reported to vary between 5.1% and 12.4% [201] with excess
figures (up to 25.5%) [202] in the presence of risk factors
and higher figures with longer follow-up. ORN usually
develops during the first 3 to 24 months after RT; however,
the real risk for ORN lasts a lifetime and can occur at any
time following RT.
The pathophysiology of ORN is still uncovered. In
essence, the viability of the irradiated bone is lost due to
ischemic necrosis in the irradiated atrophic tissue without
sufficient capability of repair, leading to secondary soft tis­
sue breakdown and exposure of bone. Pathological fractures
following ORN typically form no callus formation [203],
illustrating the absence of periosteal healing. The presence
of Actinomyces in necrotic bone is best detected with a PCR-­
based method and its role needs further investigation.
ORN may remain asymptomatic for a prolonged period
but signs and symptoms may also occur before the develop­
ment of bony exposure. Presenting clinical features include
pain, tooth mobility, mucosal swelling, erythema, ulceration,
malocclusion, dysphagia, trismus, paresthesia, or even anes­
thesia of the associated branch of the trigeminal nerve.
Box 5.15 Radiation-Induced Fibrosis and Necrosis
•	10% survivors of RT will suffer from fibrosis/
radionecrosis.
P. Sminia et al.
281
Different classifications of ORN exist, usually based on
following criteria: extent of the lesion [204], symptoms [204,
205] and response to hyperbaric oxygen therapy. The extent
of lesions can vary and range from a non-healing extraction
site to exposure and necrosis of large sections of the jaw.
Late stage ORN often present with fistula from the oral
mucosa or skin, complete devitalization of bone, pathologi­
cal fractures, and even life-threatening complications.
Panoramic radiographs are mostly used for diagnosis,
follow-up, and monitoring patients who are at risk of osteo­
necrosis. However, only at a loss of 30–50% in bone density
injury will be visible on X-ray. CBCT, CT, and MRI allow to
analyze the jaws more extensively and to better assess the
extent of injuries and are also very helpful in differentiating
osteonecrosis from other causes of osteolysis.
Although ORN may occur spontaneously [206], most
ORN develop after dental surgery (extractions of teeth,
dento-alveolar surgery, dental implant placement).
The most important risk factors for ORN are dose >50–
60 Gy and post-RT dento-alveolar surgery in the high-risk
zone. Other factors are tumor size, proximity of the tumor to
bone, age >60 years, diabetes mellitus, poor oral hygiene,
concomitant chemotherapy, active smoking, excessive alco­
hol consumption, and chronic use of corticosteroids [207].
Many of these published risk factors still need confirmation
with robust data and study designs.
5.25
208
In the areas with a high risk of developing ORN (>50 Gy),
an extraction is done whenever teeth represent a risk for
future need for extraction of a risk for future infection. Teeth
which will be extracted as part of the surgical resection
approach can be left in situ. In other areas of the jaws, the
extraction therapy will depend on regular extraction guide­
lines, the clinical experience of the supervising surgeon con­
sidering the level of oral hygiene of the patient and the
expected future limitation of mouth opening. In the upper
jaw, due to the far lower incidence of ORN, most clinicians
opt for regular extraction guidelines.
Depending on the extent of the affected area (both soft
tissues and bone), the symptoms, the existence of a patho­
logical fracture the treatment will vary from a conservative to
a surgical approach. In early stages, conservative measures
such as antibiotics, debridement, and irrigation will be pre­
ferred while surgical resection and reconstruction (recon­
struction plates, free vascularized osteomyocutaneous flaps)
are reserved for more advanced cases. Whenever resection of
ORN is needed, 3D RT isodose curves should be allowed to
be included in the virtual planning of the procedure.
HBO as adjunctive therapy to conventional treatment has
not been proven to yield consistently significantly favorable
results
compared
to
conventional
treatment
alone.
Therapeutic regimens composed of Pentoxifylline and
Tocopherol combined have been shown to have a synergistic
effect in treating small areas of ORN with visual and symp­
tomatic resolution of the condition. Clonodrate, a first-­
generation non-aminobisphosphonate, has been described as
effective when combined with pentoxifylline and tocopherol
for refractory ORN (PENTOCLO-protocol).
Lifestyle changes should accompany both conservative
and surgical procedures: proper oral hygiene, smoking and
alcohol cessation, healthy and adequate nutrition intake,
well-fitting dentures [209]. Dento-alveolar surgical proce­
dures in a highly radiated mandible should be avoided if pos­
sible and whenever needed following principles should be
kept in mind: minimal periosteal degloving, antibiotic cover­
age, local anesthesia without epinephrine."
"Describe the pathological process associated with brain radionecrosis (RN), detailing the key cellular and vascular changes observed histologically and radiographically.","Brain radionecrosis (RN) represents a persistent, irreversible late complication of radiation therapy to the brain. Pathologically, RN is characterized by the formation of hypocellular zones containing necrotic tissue interspersed with fibrinous exudates. These areas are accompanied by degenerative or dystrophic changes within the vasculature, manifesting as telangiectasia, hyaline thickening of vessels, and fibrinoid necrosis – a form of vascular damage involving intravascular thrombosis. This increased vascular permeability contributes to fluid accumulation and further exacerbates inflammation. Histologically, approximately 50% of RN lesions appear as pure necrotic tissue, while the remaining 50% are associated with radionecrosis and tumor cells, though the prognostic significance of this association remains unclear. Radiographically, advanced imaging techniques such as DTI (ADC and fractional anisotropy ratios), perfusion MR imaging (CBV, rPH, and relative PSR), MR spectroscopy, and amino acid PET show a persistent central hypointense area with enlargement of pre-existing enhancement in T1 gadolinium associated with hypersignal in T2 exhibiting a ‘Swiss cheese’ or ‘soap bubble’ appearance. These findings are indicative of the vascular disruption and inflammatory response driving the progression of RN.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.4	 Radionecrosis | Sub-sub-subsection: 5.13.4.2	 Brain Radionecrosis | Content: HBO as adjunctive therapy to conventional treatment has
not been proven to yield consistently significantly favorable
results
compared
to
conventional
treatment
alone.
Therapeutic regimens composed of Pentoxifylline and
Tocopherol combined have been shown to have a synergistic
effect in treating small areas of ORN with visual and symp­
tomatic resolution of the condition. Clonodrate, a first-­
generation non-aminobisphosphonate, has been described as
effective when combined with pentoxifylline and tocopherol
for refractory ORN (PENTOCLO-protocol).
Lifestyle changes should accompany both conservative
and surgical procedures: proper oral hygiene, smoking and
alcohol cessation, healthy and adequate nutrition intake,
well-fitting dentures [209]. Dento-alveolar surgical proce­
dures in a highly radiated mandible should be avoided if pos­
sible and whenever needed following principles should be
kept in mind: minimal periosteal degloving, antibiotic cover­
age, local anesthesia without epinephrine.
5.13.4.2	Brain Radionecrosis
Brain radionecrosis (RN) is an irreversible late radiation-­
induced tissue complication that can occur after irradia­
tion of brain parenchyma inducing a vascular lesion of the
white matter, developing in the irradiation field, second­
ary to chronic inflammation of the brain parenchyma,
with a tendency for spontaneous extension [210]. Its
5 Clinical Radiobiology for Radiation Oncology
282
pathophysiology is not yet clear. Brain RN induces hypo­
cellular zones of necrosis and fibrinous exudates with
degenerative or dystrophic changes in the vasculature,
with telangiectasia, hyaline thickening of vessels, and
fibrinoid necrosis including intravascular thrombosis
responsible for an increase of vascular permeability. The
occurrence and severity are correlated with dose-volume
parameters [211]. An actuarial incidence of brain RN up
to 34% two years after stereotactic radiotherapy (SRT)
was recently reported—symptomatic and sometimes
lethal or severely debilitating in 10–17% of the patients
[212]. Approximately 80% of cases occur within 3 years
from the completion of RT.
The symptoms of RN are those of a non-specific intrace­
rebral expansive process. A seizure is inaugural in half of the
cases, signs of intracranial hypertension and a progressive
deficit syndrome (sensory, motor, or aphasia) are frequently
present. The semiology often reproduces the initial signs of
the primary tumor. In pituitary tumors, lesions preferentially
affect the chiasma and the optic nerves causing severe visual
disturbances; damage to the temporal, frontal, and hypothal­
amus lobes is often associated, causing cognitive
impairment.
The main differential diagnosis is tumor progression due
to very similar clinical and radiological characteristics.
The gold standard for the diagnosis with certainty is the
pathological analysis. On histological analysis, 50% of
lesions are pure RN, the remaining 50% associated with
radionecrosis and tumor cells without predicting their
viability.
There is not yet a validated imaging technique that distin­
guishes the two entities though advanced imaging techniques
such as DTI (ADC and fractional anisotropy ratios), perfu­
sion MR imaging (CBV, rPH, and relative PSR), MR spec­
troscopy, and amino acid PET hold promise [213]. The MRI
shows a persistent central hypointense and an enlargement of
a pre-existing enhancement in T1 gadolinium associated
with a hypersignal in T2 with an appearance of “Swiss
cheese” or “soap bubble.” Perfusion MRI, spectro-MRI and
PET amino acid imaging may provide additional arguments.
Other avenues are showing interest in the differential diag­
nostic strategy—notably radiomics.
When this documentation is not possible, the decision-­
making process is guided by clinical and imaging criteria
collected over a significant period of follow-up. Such criteria
were proposed by the Association of Neuro-Oncologists of
French Expression (ANOCEF) [214]. The treatment options
of brain RN include steroids, bevacizumab, surgical resec­
tion, and hyperbaric oxygen.
5.13.5	Pathogenesis of Early and Late Normal
Tissue Radiation Injury
­
­
215
­
­
­
­
­
5.26
5.16
Box 5.16 Normal Tissue Radiation Pathology
•	Cellular depletion by radiation-induced death is not
the only one responsible for initiation and progres­
sion of lesions.
•	Radiation-induced effects on the vascular endothe­
lium drive the propagation of the inflammatory
response and chronic effects.
•	Molecular and cellular damage after exposure to IR
impacts cellular homeostasis and potentially leads
to chronic organ dysfunction.
•	The notion of a continuum of effects, orchestrated
by all the compartments and chronic cytokine cas­
cades, opens up fields of therapeutic approaches.
P. Sminia et al."
"Describe the pathogenesis of normal tissue radiation injury according to the provided text, focusing on the key cellular and molecular mechanisms involved beyond simple cell death.","The development of normal tissue radiation injury is a complex, dynamic process extending beyond mere cell depletion. Initially, irradiation damages the vascular endothelium and epithelial barriers, leading to increased vascular permeability and the release of damage-associated molecular patterns (DAMPs). This triggers an inflammatory response characterized by the recruitment of immune cells, particularly macrophages, which exhibit heterogeneous functions – some promoting inflammation and fibrosis while others contribute to senescence. Crucially, radiation induces a ‘continuum of effects’ orchestrated by multiple cell types and cytokine cascades. Specifically, interferon-gamma (IFNγ), interleukin-1β (IL-1β), interleukin-6 (IL-6), CCL2, tumor necrosis factor (TNF), transforming growth factor-β (TGFβ) play significant roles in propagating the injury. Furthermore, radiation promotes endothelial-mesenchymal transition (EMT) and epithelial-mesenchymal transition (EMT), both processes linked to fibrosis. Importantly, senescence – a state of irreversible cell cycle arrest characterized by the SASP – also contributes significantly to the pathogenesis, with senescent cells secreting growth factors and cytokines that exacerbate tissue damage. The text highlights that these events are temporally coordinated, suggesting therapeutic interventions targeting specific times within this kinetic profile could be effective. Reference: [MolecularRadiationBiology, Section 5.13.5 Pathogenesis of Early and Late Normal Tissue Radiation Injury]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.5	 Pathogenesis of Early and Late Normal Tissue Radiation Injury | Content: 5.13.5	Pathogenesis of Early and Late Normal
Tissue Radiation Injury
­
­
215
­
­
­
­
­
5.26
5.16
Box 5.16 Normal Tissue Radiation Pathology
•	Cellular depletion by radiation-induced death is not
the only one responsible for initiation and progres­
sion of lesions.
•	Radiation-induced effects on the vascular endothe­
lium drive the propagation of the inflammatory
response and chronic effects.
•	Molecular and cellular damage after exposure to IR
impacts cellular homeostasis and potentially leads
to chronic organ dysfunction.
•	The notion of a continuum of effects, orchestrated
by all the compartments and chronic cytokine cas­
cades, opens up fields of therapeutic approaches.
P. Sminia et al.
283
­
The notion of a continuum of effects, orchestrated by all
the compartments and chronic cytokine cascades, opens up
fields of investigation into various therapeutic approaches
[190]. The contemporary view involves several cell types
and molecular mechanisms, which together form an orches­
trated response, and contribute to the initiation, progression,
and chronicity of radiation-induced injury. A better under­
standing of these event kinetics should allow the identifica­
tion of molecular and cellular targets, associated functions,
and relevant times for therapeutic action. Radiation-induced
effects on the vascular endothelium and epithelial barriers
are important for the propagation of the inflammatory
response and the recruitment of immune cells. The concept
that the microvasculature plays a central role in the radiation
toxicity of many tissues is emerging and demonstrated now.
Irradiation leads to endothelial cell apoptosis, increased vas­
cular permeability, and acquisition of a pro-inflammatory
and pro-coagulant phenotype. Moreover, tissue-specific
deletion in the endothelium of key molecular actors impacts
the severity of acute and normal tissue injury [216].
Rapidly after exposure to IR, damage to the endothelium
and epithelial cells leads to the release of damager signals
(such as DAMPS) and the activation of adhesion molecules.
This reaction allows the recruitment of a large panel of
immune cells to the damaged site, which are able to repair
the tissue but which, in the case of chronic inflammation, can
strongly also participate in the installation of fibrosis [196].
For example, macrophages are rapidly recruited after irradia­
tion and are a heterogeneous immune cell population with
multiple pro- or anti-inflammatory as well as pro- or anti-­
fibrosis functions. The recruitment dynamics of macro­
phages, as well as their phenotypic orientation impacted by
their microenvironment over time, are increasingly shown to
play an essential role in the evolution of radiation-induced
injury [195]. Radiation-induced immune effects are propa­
gated by a large panel of cytokines including interferon-γ
(IFNγ),
Interleukin-1β
(IL-1β),
Interleukin-6
(IL-6),
CC-chemokine ligand 2 (CCL2), tumor necrosis factor
(TNF),
and
transforming
growth
factor-β
(TGFβ).
Interestingly, beyond their roles in the inflammatory
5 Clinical Radiobiology for Radiation Oncology
284
response, some of these cytokines also play essential roles in
several other processes contributing to the evolution of
radiation-­induced lesions. TGFβ induces the differentiation
of fibroblasts into myo-fibroblasts with a consequent increase
in the extracellular matrix. In addition, in association with
other cytokines such as IL-1β, TGFβ promotes endothelial-­
mesenchymal (endoMT) [217] and EMT, two key processes
also demonstrated in radiation-induced lesions to healthy tis­
sues [218]. Finally, it has recently been shown in several
studies that senescence also contributes to the pathogenesis
of radiation-induced injury to healthy tissue. Senescence is a
durable cell-cycle arrest with a persistent pro-inflammatory
Senescence-Associated Secretory Phenotype (SASP) char­
acterized by the secretion of multiple growth factors and
cytokines, the senescence-messaging secretome (SMS)
[219]. Premature senescence can be produced by a large
panel of DNA-damaging agents and genotoxic stress includ­
ing IR. In several preclinical models of radiation-induced
lung injury, it has been shown that many types of cells bear
senescence marks such as pneumocytes, macrophages, and
endothelial cells [220, 221]. Interestingly, senolytic agents
that selectively can kill senescent cells limit radiation-­
induced lung injury provided the evidence that senescence
participates to the pathogenesis and that senolytic drugs
could be a good strategy to reduced late normal tissue dam­
ages [222].
Recent research clearly shows that normal tissue injury is
a dynamic and progressive process. The main challenge in
the future will be to perfectly decipher this dynamic of events
for each organ and its own characteristics. This will allow to
propose new molecular and functional tools to predict, pre­
vent, and treat damage to healthy tissues after irradiation.
5.13.6	Dose-Volume Effects and Constraints
(QUANTEC, PENTEC, and HyTEC)
The evaluation of treatment plans in the treatment planning
system is based on dose-volume histogram analysis for PTV
and critical organs. Final plan quality evaluation should be
based on plan complexity, plan robustness, and dose distribu­
tion analysis including dose-volume control. Constraints for
any dose-volume relationship should be connected to the
radiobiological outcome.
In 2010, a series of articles were published in the
International Journal of Radiation Oncology Biology Physics
as a meta-analysis of published dose–response observations
for different critical organs. The project called Quantitative
Analyses of Normal Tissue Effects in the Clinic (QUANTEC)
aimed to review meaningful data published in the previous
18 years for common critical organs in terms of dose/volume
values connected to radiobiological effects [223]. This
endeavor was a challenge because it involved the amalgama­
tion of different analytic methodologies, calculation meth­
ods, endpoints, and grading schemes, which were used in
different studies to address the relationship between dosi­
metric parameters and the clinical outcomes of normal
tissues.
QUANTEC consists of two introductory papers about the
overview and history with some scientific issues related to
the QUANTEC effort and about the suggestions on how to
rationally incorporate the QUANTEC metrics/models into
clinical practice. The core of the QUANTEC project is
described in 16 articles for different organs at risk or
complications:
––Bladder
––Brain
––Brainstem
––Esophagus
––Hearing loss
––Heart
––Kidney
––Larynx and pharynx
––Liver
––Lung
––Optic nerves and chiasm
––Penile bulb
––Rectum
––Salivary gland
––Spinal cord
––Stomach and small bowel
For each organ, there are associated sections describing:
clinical significance, endpoints, challenges in defining vol­
umes, review of dose/volume data, factors affecting risk,
mathematical/biological models, special situations, recom­
mended dose/volume limits, future toxicity studies, and tox­
icity scoring.
The QUANTEC reviews provide focused summaries of
the dose/volume/outcome information for many organs, but
these were usually obtained for 3D conformal RT or other
techniques that have in many cases already been replaced by
more modern techniques, such as VMAT or SRT. It should be
emphasized that dose/volume constraints and other informa­
tion in QUANTEC are expected to be updated in the future
for relevant techniques. The data is not intended to be extrap­
olated to pediatric patients. Pediatric Normal Tissue Effects
in the Clinic (PENTEC) is a recent initiative to review toler­
ance constraints for children, who may have different toler­
ance to that of adults [224].
For hypofractionated RT such as SRS or SBRT, relatively
small target volumes receive hypofractionated RT schedules,
typically in 1–5 fractions. As an extension to QUANTEC and
other previous guides to tissue tolerance, high dose per frac­
tion, Hypofractionated Treatment Effects in the Clinic
P. Sminia et al."
"Describe the scope and purpose of the QUANTEC project, including its key components and the organs it addresses in terms of dose-volume effects and associated clinical outcomes.","The QUANTEC (Quality Assurance for Treatment of Normal Tissue Effects) project was established to systematically analyze the relationship between dosimetric parameters – specifically dose and volume – and the observed normal tissue damage resulting from radiotherapy. Its primary purpose was to develop rational constraints on radiation doses to minimize adverse effects in healthy tissues while maintaining therapeutic efficacy. The project achieved this by compiling a comprehensive dataset across numerous organs, detailing clinical significance, relevant endpoints (such as hearing loss or esophageal toxicity), challenges in defining volumes accurately, and existing dose/volume data. QUANTEC produced 16 individual articles, each focused on a specific organ at risk: bladder, brain, brainstem, esophagus, hearing loss, heart, kidney, larynx and pharynx, liver, lung, optic nerves and chiasm, penile bulb, rectum, salivary gland, spinal cord, stomach and small bowel. Each article provided detailed information including mathematical/biological models used to predict toxicity, recommended dose/volume limits, and suggestions for future research. Importantly, the project aimed to provide a framework for incorporating these metrics into clinical practice, although it acknowledged that some of the original data was generated using techniques now largely superseded by modern approaches like VMAT or SRT. It’s crucial to note that the data is not intended for extrapolation to pediatric patients, as addressed in the PENTEC initiative.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.6	 Dose-Volume Effects and Constraints (QUANTEC, PENTEC, and HyTEC) | Content: endeavor was a challenge because it involved the amalgama­
tion of different analytic methodologies, calculation meth­
ods, endpoints, and grading schemes, which were used in
different studies to address the relationship between dosi­
metric parameters and the clinical outcomes of normal
tissues.
QUANTEC consists of two introductory papers about the
overview and history with some scientific issues related to
the QUANTEC effort and about the suggestions on how to
rationally incorporate the QUANTEC metrics/models into
clinical practice. The core of the QUANTEC project is
described in 16 articles for different organs at risk or
complications:
––Bladder
––Brain
––Brainstem
––Esophagus
––Hearing loss
––Heart
––Kidney
––Larynx and pharynx
––Liver
––Lung
––Optic nerves and chiasm
––Penile bulb
––Rectum
––Salivary gland
––Spinal cord
––Stomach and small bowel
For each organ, there are associated sections describing:
clinical significance, endpoints, challenges in defining vol­
umes, review of dose/volume data, factors affecting risk,
mathematical/biological models, special situations, recom­
mended dose/volume limits, future toxicity studies, and tox­
icity scoring.
The QUANTEC reviews provide focused summaries of
the dose/volume/outcome information for many organs, but
these were usually obtained for 3D conformal RT or other
techniques that have in many cases already been replaced by
more modern techniques, such as VMAT or SRT. It should be
emphasized that dose/volume constraints and other informa­
tion in QUANTEC are expected to be updated in the future
for relevant techniques. The data is not intended to be extrap­
olated to pediatric patients. Pediatric Normal Tissue Effects
in the Clinic (PENTEC) is a recent initiative to review toler­
ance constraints for children, who may have different toler­
ance to that of adults [224].
For hypofractionated RT such as SRS or SBRT, relatively
small target volumes receive hypofractionated RT schedules,
typically in 1–5 fractions. As an extension to QUANTEC and
other previous guides to tissue tolerance, high dose per frac­
tion, Hypofractionated Treatment Effects in the Clinic
P. Sminia et al.
285
(HyTEC) was published as a series of articles [225]. This
project served to provide guidance on dose/volume con­
straints for hypofractionated regimens for 7 normal tissues as
well as 9 disease sites (TCP). Interestingly, the possibility of
so-called “new radiobiology” of hypofractionation is also
alluded to—the possibility that large fractions may induce
enhanced radiobiological effects in tumors by additional vas­
cular targeting and anti-tumor immune responses [150].
Radiobiological aspects of hypofractionation are discussed
in detail in Chap. 5.
Overall, the recommendations of QUANTEC, PENTEC,
HyTEC, and other constraint guidelines should be used judi­
ciously as a guide and should not replace clinical judgment."
"Describe the concept of Normal Tissue Complication Probability (NTCP) within the context of radiation oncology treatment planning, including its purpose, how it’s utilized, and some common models associated with it.","Normal Tissue Complication Probability (NTCP) represents the probability that a specific organ or structure will experience a complication related to radiotherapy exposure. Essentially, it quantifies the risk of adverse tissue effects during treatment. NTCP is crucial for radiation oncology because it allows clinicians to estimate and manage the potential for normal tissue toxicity when planning treatments for tumors. The models used to calculate NTCP aim to predict dose-response curves for particular endpoints within an organ at risk (OAR), often exhibiting a sigmoidal shape. Several commonly employed NTCP models exist, including the Lyman-Kutcher-Burman (LKB) model (Gaussian distribution), the Parallel architecture model (Logit), the Weibull model, and the Critical element model (Poisson).  Furthermore, serial and parallel models are frequently used, which incorporate tissue architecture – assuming organs consist of functional subunits organized in chains (serial) or independently (parallel). These models often rely on parameters like D50 (dose associated with 50% response probability) and γ50 (gradient of the dose-response curve at that level), alongside a parameter ‘m’ reflecting the steepness of the curve.  It's important to note that NTCP predictions are influenced by factors beyond just dosimetry, such as treatment volume, fraction size, chemotherapy, and patient comorbidities. While these models offer valuable insights, they should be used with caution due to their inherent limitations and dependence on model parameters; updating these parameters is essential for accurate probability estimations.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.13		 Normal Tissue Damage and Response to Radiotherapy | Sub-subsection: 5.13.7	 Radiobiology Models for Normal Tissue Toxicity | Content: Toxicity
The normal tissue complication probability (NTCP) is the
probability that for a given dose distribution organ or struc­
ture complication can be expected. These complications can
be multiple for one organ or structure and usually are called
as endpoints in the models. NTCP is aimed at quantification
of dependence of tolerance dose for a certain radiation effect
on the size of treated volume. The NTCP models are sup­
posed to be predictive and to be used to estimate the compli­
cation risk for organs at risk (OARs) after RT. OARs can be
used to individualize the tumor dose for a given acceptable
NTCP (Box 5.17).
NCTP models are used to describe dose–response curve
shape for particular endpoint for an organ at risk, which is
usually sigmoidal. These models are usually connected to
Dose-Volume Histogram (DVH) of the applied treatment
plan; therefore the models are sometimes called DVH-­
reduction models. More complex approach [226] moves
towards spatial dose distribution in the patient and not dose-­
volume reduction only. When voxel-based evidence on organ
radiosensitivity was acknowledged and attempts were made
to develop a probabilistic atlas for NTCP in radiation oncol­
ogy. However, there are other clinical factors that influence
complications, such as chemotherapy, fraction size, pre-­
existing medical conditions, and comorbidities. The predic­
tive strength for models can be enhanced with considering
other important clinical and medical features for the patient.
This information is expected to provide a boost for further
deployment of biological models in the clinical treatment
planning process.
Common NTCP models as described by [227] are:
1.	Lyman-Kutcher-Burman (LKB) model (Gaussian)
2.	Parallel architecture model (Logit)
3.	Weibull model (Weibull)
4.	Critical element model (Poisson)
5.	Relative seriality model (Poisson)
6.	Critical volume model (Binomial)
7.	Inverse tumor model (Poisson)
Models are based on different statistical distributions (in
parentheses). The first four models are using cell-survival-­
based response, while others are phenomenological.
However, each model may be expressed in terms of the
parameters D50 (dose that is associated with the 50% response
probability) and γ50 (gradient of the dose-response curve at
the level of the 50% response probability). The steepness of
the NTCP curve can be expressed in the models by parame­
ter m. It is inversely proportional to the steepness of the dose
response.
­
5.27
Serial (critical element models) and parallel (critical vol­
ume models) are also common models. These mechanistic
models are based on tissue architecture. It is assumed that
organs consist of functional subunits, which can be orga­
nized in chains for serial organs or independently for parallel
organs. Damage of one functional subunit impairs the func­
tion of the whole organ, while the function of a parallel organ
is more dependent on the irradiated volume.
NTCP models are usually incorporated into in-house
developed software in RT centers. Currently, they are also
available in commercial treatment planning systems.
Parameters for different NTCP models adopted from litera­
ture must be used with caution when the probability estima­
tion is applied as a decision criterion for the treatment plan.
NTCP can be used also for comparisons between different
treatment plans or RT modalities. In these cases, NTCP is
used as a relative value in the plan evaluation process and
this approach is safer. However, the software should always
Box 5.17 Normal Tissue Toxicity Modeling
•	Normal tissue complication probability (NTCP)
describes the probability of organ/structure compli­
cation related to radiation treatment specified by
physical and clinical factors in radiation oncology.
•	There are various approaches to NTCP modeling
which usually are based on different statistical
distributions.
•	The predictive power of the NTCP model is depen­
dent on the parameters of models, which can include
dosimetry as well as other clinical and treatment
conditions.
5 Clinical Radiobiology for Radiation Oncology
286
­
50
50
allow the user to update model parameters. There should be
detailed documentation for the models available. It is obvi­
ous that the value of NTCP is strongly dependent on the
parameters of the model, and therefore should be used with
caution.
5.14"
"Describe the key differences between embryonic and adult stem cells, focusing on their differentiation potential and origin.","Embryonic stem cells are characterized by their pluripotency, meaning they possess the remarkable ability to differentiate into *all* three primary germ layers – endoderm, mesoderm, and ectoderm – directly from the blastocyst inner cell mass. This broad developmental capacity stems from their undifferentiated state and inherent genetic program. Conversely, adult stem cells exhibit multipotency; this signifies that they can differentiate into a limited range of cell types, typically those found within the tissue from which they originate. For example, hematopoietic stem cells in bone marrow primarily give rise to blood cells, while neural stem cells in the brain produce neurons and glial cells. Furthermore, under normal physiological conditions, adult stem cells exhibit significantly slower growth rates and spend extended periods in a quiescent G0 phase of the cell cycle, dedicated solely to maintaining tissue homeostasis through regeneration – constantly replenishing lost or damaged cells. The process of division for these stem cells involves one daughter cell retaining stem cell properties and another developing into a progenitor cell with increased proliferative capacity. Reference: Molecular Radiation Biology, Section 5.14.1 Introduction","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.1	 Introduction | Content: Stem cells have been described as undifferentiated cells
which are found in most adult mammalian tissues. Stem cells
are divided into two principal groups: embryonic and adult
stem cells. Embryonic cells, which have a pluripotency phe­
notype have the blastocyst inner cell mass as their origin. It
means that they can be differentiated into all cells from the
three main germ layers (endo-, meso-, and ectoderm). On the
other hand, adult stem cells can be differentiated into cell
types according to their origin tissue, thus they are multipo­
tent. Under physiological conditions, adult stem cells are
slow growing with a long G0 cell-cycle phase. The main
function of such stem cells is to maintain tissue homeostasis
including continuous regeneration and associated constant
number of cells. The way they are divided is as follows: from
the origin stem cell arises one daughter cell with stem cell
properties and one progenitor cell with a higher proliferative
capacity [228]. Below the normal stem cells in different tis­
sues are described alongside cancer stem cells and their IR
response or resistance together underlying molecular
mechanisms."
"Describe the diverse roles of normal stem cells within various human tissues, specifically focusing on their radiation sensitivity profiles and how these sensitivities relate to their niche environments.","Normal stem cells play a crucial role in maintaining tissue homeostasis and facilitating repair following injury or damage. However, their inherent vulnerability to ionizing radiation varies significantly depending on the tissue type and the specific microenvironment they occupy – often referred to as their ‘stem cell niche.’ These niches provide essential signals that regulate stem cell self-renewal, differentiation, and survival. 

Within rapidly dividing tissues like bone marrow (hematopoietic stem cells), the sensitivity is generally high due to the frequent DNA replication cycles occurring within these cells. Radiation damage primarily manifests as double-strand breaks in DNA, leading to cell death if repair mechanisms are overwhelmed. The niche here provides factors promoting rapid proliferation and DNA repair.

In contrast, tissues with lower turnover rates, such as skin (epidermal stem cells) or the intestinal lining (intestinal stem cells), exhibit a greater radiation tolerance. These stem cells reside in niches characterized by different signaling molecules and physical constraints that limit their exposure to damaging radiation. For example, the basal layer of the epidermis has a protective barrier against external radiation, while the gut niche provides a microenvironment rich in antioxidants and repair factors. Furthermore, some stem cell populations demonstrate ‘adaptive’ responses to radiation – increasing DNA repair capacity or activating survival pathways after initial damage.

The specific characteristics of the stem cell niche—including cell-cell interactions, extracellular matrix components, and secreted growth factors—directly influence both the sensitivity and the response to radiation. Therefore, understanding these tissue-specific differences is paramount for optimizing radiotherapy treatment strategies while minimizing damage to surrounding healthy tissues.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.2	 Normal Stem Cells in Different Tissues | Content: In the healthy human tissue, there are multiple cell popula­
tions with different stem cell phenotypic characteristics and
radiation sensitivity. These different stem cell niches are dis­
cussed below based on the tissue localization."
"Following ionizing radiation (IR) exposure, how do hematopoietic and mesenchymal stem cells from the bone marrow differ in their sensitivity to damage, and what specific consequence does this difference contribute to regarding early radiation effects?","After ionizing radiation exposure, progenitors derived from hematopoietic stem cells exhibit significantly greater sensitivity to IR-induced damage compared to the more primitive mesenchymal stem cells originating from the same bone marrow. This sensitivity is characterized by a dose-dependent linear response within the progenitor cell population. Specifically, these hematopoietic progenitors are disproportionately affected, leading directly to the development of a hematopoietic syndrome – a common early radiation effect manifesting as suppression of blood cell production and subsequent anemia, thrombocytopenia, and leukopenia. Both stem cell populations ultimately contribute to restoring bone marrow homeostasis following IR exposure; however, the heightened vulnerability of the hematopoietic progenitor cells dramatically influences the severity and timing of this recovery process.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.2	 Normal Stem Cells in Different Tissues | Sub-sub-subsection: 5.14.2.1	 Bone Marrow Stem Cells | Content: Stem cells of the bone marrow are divided into two groups:
hematopoietic and mesenchymal stem cells. From the hema­
topoietic stem cells arise leukocytes, erythrocytes, and
thrombocytes and from the mesenchymal stem cells adipo­
cytes, chondrocytes, myocytes, and osteocytes are generated
[229]. One function of mesenchymal stem cells is to estab­
lish the hematopoietic stem cell niche [230]. When it comes
to IR toxicity, the progenitors from the hematopoietic stem
cells are more sensitive than the origin, more primitive, stem
cells. Such a difference is linearly dose dependent in the pro­
genitor cells and is one of the factors causing the develop­
ment of one of the early radiation effects, the hematopoietic
syndrome [231]. Importantly, both of these stem cell popula­
tions are responsible for the repopulating of the damaged
bone-marrow homeostasis after IR exposure."
"Following ionizing radiation (IR) exposure, how do normal stem cell populations, specifically neural stem cells within the subventricular and subgranular niches, contribute to bone-marrow homeostasis, and what cellular subtypes exhibit heightened sensitivity to IR-induced damage?","After irradiation, both the subventricular and subgranular neural stem cell populations play a crucial role in restoring damaged bone marrow homeostasis. These stem cells are responsible for repopulating the marrow following IR exposure. Within this population, several distinct subtypes demonstrate varying sensitivities to radiation damage. Specifically, activated neural stem cells and progenitor cells are notably more vulnerable to IR-induced harm. This sensitivity stems from the fact that IR triggers apoptosis (programmed cell death) within these populations, leading to a reduction in the number of newly generated neurons. The underlying mechanisms involve DNA damage, which can be mitigated by interventions such as lithium pre-treatment, which reduces DNA damage and stimulates microglial activation, or resveratrol administration, which effectively diminishes oxidative stress. Consequently, protecting these sensitive stem cell subtypes is paramount for minimizing negative neurological consequences following radiotherapy.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.2	 Normal Stem Cells in Different Tissues | Sub-sub-subsection: 5.14.2.2	 Neural Stem Cells | Content: syndrome [231]. Importantly, both of these stem cell popula­
tions are responsible for the repopulating of the damaged
bone-marrow homeostasis after IR exposure.
5.14.2.2	Neural Stem Cells
The neural stem cell pool can be divided according to the
localization. Hence, we recognize the subventricular and the
subgranular group [232]. Even within these two subtypes are
heterogenous. Thus, one can distinguish four main types of
cells from the subventricular niche: activated neural stem
cells, dormant neural stem cells, progenitor cells, and quies­
P. Sminia et al.
287
cent neural stem cells [233]. Generally, neural stem cells can
differentiate into multiple neuronal- and glial cell types. The
most IR sensitive populations are activated neural stem cells
and progenitor cells because IR induces their cell death, for
example, apoptosis. Such effects lead to a reduced population
of new neurons. To prevent the negative effects of IR on the
neural stem cells different protective strategies have been
tested, for example, administration of lithium [234, 235] or
the natural polyphenol resveratrol [236]. It has been shown
that lithium pre-treatment can reduce DNA damage and
increase microglial activation [234, 235]. Resveratrol, on the
other hand, has a neuroprotective effect, because it can reduce
oxidative stress [236]."
"Describe the differential sensitivity of keratinocytes and melanocyte stem cells to ionizing radiation (IR) regarding their response mechanisms following skin injury. Specifically, how do variations in repair capacity and genomic stability contribute to their distinct behaviors?","Skin contains diverse stem cell populations with varying sensitivities to ionizing radiation (IR). Keratinocyte stem cells exhibit a pronounced sensitivity to IR damage, primarily due to the rapid elimination of damaged keratinocytes progenitors upon injury. This process significantly contributes to the overall epidermal vulnerability to IR. Conversely, more primitive keratinocyte stem cells demonstrate active DNA repair mechanisms and enhanced cell survival rates following IR exposure. However, these robust repair processes are often accompanied by a higher incidence of genomic instability – characterized by faster, but less accurate, repairs – which ultimately leads to increased mutation frequency within the tissue. In stark contrast, melanocyte stem cells show minimal involvement in tissue regeneration after IR damage; they do not actively participate in repairing DNA damage or promoting cell survival following injury. This suggests a fundamentally different role for these stem cells in skin response to radiation, potentially linked to their primary function of melanin synthesis rather than active epidermal repair.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.2	 Normal Stem Cells in Different Tissues | Sub-sub-subsection: 5.14.2.3	 Skin Stem Cells | Content: Several types of the stem cells exist in the skin which can
differentiate into more than two dozen cell types, including
epidermal-, keratinocyte-, and melanocyte stem cells [237].
The keratinocytes progenitors are the most IR sensitive ones,
if damaged they are eliminated thereby contributing to the
high epidermal sensitivity to IR. In contrast, more primitive
keratinocyte stem cells possess active repair mechanisms
and increased cell survival, but their rapid and faultier repair
contribute to the genomic instability. Interestingly, while the
keratinocyte stem cells favor repair of DNA damage, the
melanocyte stem cells are not involved in tissue regeneration
after IR damage [231]."
"Following exposure to ionizing radiation (IR), the small intestine exhibits a heightened sensitivity due to its rapid cell turnover, leading to acute toxicity symptoms. Describe the key mechanisms contributing to this increased radiosensitivity of intestinal stem cells and explain how these differ from those observed in other tissues like the colon.","The extreme radiosensitivity of intestinal stem cells within the gastrointestinal syndrome model stems from a confluence of factors related to their rapid cell turnover and inherent biological characteristics. Primarily, the small intestine’s epithelium completely renews every 5 days, exposing a vast population of rapidly dividing stem cells to ionizing radiation at any given time. This high rate of proliferation directly correlates with an increased likelihood of DNA damage accumulation – specifically, replication errors during DNA synthesis are more frequent in actively dividing cells. Furthermore, these stem cells exhibit heightened sensitivity due to the activation of pro-apoptotic pathways following genotoxic stress. Specifically, exposure to IR triggers the upregulation and subsequent activation of proteins like p53, ATM, and PUMA, which initiate a cascade leading to apoptosis. The small intestine’s radiosensitivity is further influenced by a potentially more efficient p53 signaling pathway and DNA repair mechanisms compared to other tissues, coupled with a delayed G2-phase checkpoint response – allowing for greater accumulation of unrepaired DNA damage before triggering cell death. Contrastingly, the colon demonstrates reduced sensitivity due to higher expression levels of the anti-apoptotic protein Bcl-2, which actively suppresses apoptosis signals following IR exposure. This difference in cellular responses is likely linked to variations in genomic stability and repair capacity within these tissues, highlighting a complex interplay between radiation dose, tissue-specific stem cell characteristics, and downstream signaling pathways.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.2	 Normal Stem Cells in Different Tissues | Sub-sub-subsection: 5.14.2.4	 Intestinal Stem Cells | Content: Gastrointestinal syndrome, a known acute toxicity response to
IR, promoted the first exploration of intestinal stem cells in
radiation biology studies, which included the exposure of
mice to doses greater than 14 Gy, inducing death after 7 to
12 days due to small intestine damage. This high sensitivity
has been attributed to the fast cell turnover in the intestinal
mucosa which, in mice, completely renews the epithelium
every 5 days [231]. These studies allowed the characterization
of intestinal regeneration, revealing the presence of a stem cell
population near the bottom of the intestinal crypt. These
actively cycling cells are highly sensitive to IR, undergoing
apoptosis in response to doses as low as 1 Gy although this
sensitivity seems to be dependent upon their position within
the crypt [238]. Another stem cell subpopulation, known as
crypt base columnar cells and characterized by the expression
of Lgr5 (Leucine-Rich Repeat Containing G Protein-Coupled
Receptor 5), are less radiosensitive than the previously
described cells yet more sensitive than small intestine progeni­
tor cells. Radiation toxicity can occur at low doses; however,
crypt loss is only observed after exposure to higher radiation
doses. This may be because crypts only disappear after total
loss of the stem cell population, which only happens at doses
greater than 8 Gy. This radiosensitivity could be caused by the
accumulation of DNA damage or pro-­apoptotic proteins after
genotoxic stress, i.e., p53, ATM, and PUMA. The difference in
radiosensitivity between the small intestine and the colon
could be due to a more efficient p53 signaling, DNA repair and
G2-phase checkpoint delay in the latter. The high expression
level of the anti-apoptotic protein Bcl-2 in colon progenitors
could be another reason. Paradoxically, the risk of developing
cancer after exposure to IR is lower in the small intestine, sug­
gesting the interplay between cell resistance and lower
genomic stability. It should be noted that most of this knowl­
edge is based on studies in mice; therefore, human models are
still required in order to understand the intestinal stem cell
radiation biology [231] (Box 5.18).
5.14.3	Cancer Stem Cells: Their Role
in Radiation Therapy Sensitivity
and Resistance
Tumor heterogeneity is found among patients with the same
histological diagnosis as well as within each patient’s tumor
as a result of genetic or phenotypic variations [31]. Further,
the tissue of origin also influences the inter-tumoral hetero­
geneity because some of the driving signaling networks (e.g.,
those that maintain genomic integrity) may vary. Moreover,
tumor progression, treatment sensitivity including towards
RT and tumour aggressiveness are largely influenced by the
origin of the carcinogenic transformation as well as the
TME. Tumor heterogeneity plays a significant role in cancer
cell survival, thus setting a significant challenge in the devel­
opment of effective cancer treatment, or in the prevention of
tumor progression and metastasis [239].
­
­
­
240241
­
Box 5.18 Normal Tissue Stem Cells and Radiosensitivity
•	Stem cells are divided into two principal groups,
embryonic and adult stem cells, respectively. Some
examples are bone marrow-, neural, skin, and intes­
tinal stem cells.
•	The main function of stem cells is to maintain the
tissue homeostasis.
•	In the normal human tissue, there are multiple cell
populations with different stem cell phenotypic
characteristics and different IR sensitivity.
5 Clinical Radiobiology for Radiation Oncology"
"Describe the key characteristics and functions of cancer stem cells (CSCs) as they relate to radiation therapy sensitivity and resistance, according to the provided text.","Cancer stem cells (CSCs) represent a significant factor in tumor heterogeneity and treatment response to radiation therapy. The document highlights several features that contribute to their radiosensitivity or resistance. Firstly, CSCs are characterized by self-renewing and differentiation capabilities, allowing them to generate a diverse progeny within the tumor. Secondly, these cells exhibit activated DNA damage repair signaling pathways, including ATM, Chk1/2, and NHEJ, which enhances their ability to withstand radiation-induced DNA damage. Furthermore, CSCs often upregulate survival pathways such as HIF-1α, WNT, NOTCH, or Hedgehog, contributing to resistance to apoptosis following RT exposure. Notably, tumors with a higher frequency of CSCs demonstrate impaired local control by RT and reduced effectiveness compared to tumors with fewer CSCs. The text emphasizes that only a small number of surviving CSCs can lead to tumor relapse after RT. Finally, the document notes that CSCs contribute to metastasis due to their ability to form new tumors when engrafted in mice.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.14	 Stem Cells in Radiotherapy | Sub-subsection: 5.14.3	 Cancer Stem Cells: Their Role in Radiation Therapy Sensitivity and Resistance | Content: greater than 8 Gy. This radiosensitivity could be caused by the
accumulation of DNA damage or pro-­apoptotic proteins after
genotoxic stress, i.e., p53, ATM, and PUMA. The difference in
radiosensitivity between the small intestine and the colon
could be due to a more efficient p53 signaling, DNA repair and
G2-phase checkpoint delay in the latter. The high expression
level of the anti-apoptotic protein Bcl-2 in colon progenitors
could be another reason. Paradoxically, the risk of developing
cancer after exposure to IR is lower in the small intestine, sug­
gesting the interplay between cell resistance and lower
genomic stability. It should be noted that most of this knowl­
edge is based on studies in mice; therefore, human models are
still required in order to understand the intestinal stem cell
radiation biology [231] (Box 5.18).
5.14.3	Cancer Stem Cells: Their Role
in Radiation Therapy Sensitivity
and Resistance
Tumor heterogeneity is found among patients with the same
histological diagnosis as well as within each patient’s tumor
as a result of genetic or phenotypic variations [31]. Further,
the tissue of origin also influences the inter-tumoral hetero­
geneity because some of the driving signaling networks (e.g.,
those that maintain genomic integrity) may vary. Moreover,
tumor progression, treatment sensitivity including towards
RT and tumour aggressiveness are largely influenced by the
origin of the carcinogenic transformation as well as the
TME. Tumor heterogeneity plays a significant role in cancer
cell survival, thus setting a significant challenge in the devel­
opment of effective cancer treatment, or in the prevention of
tumor progression and metastasis [239].
­
­
­
240241
­
Box 5.18 Normal Tissue Stem Cells and Radiosensitivity
•	Stem cells are divided into two principal groups,
embryonic and adult stem cells, respectively. Some
examples are bone marrow-, neural, skin, and intes­
tinal stem cells.
•	The main function of stem cells is to maintain the
tissue homeostasis.
•	In the normal human tissue, there are multiple cell
populations with different stem cell phenotypic
characteristics and different IR sensitivity.
5 Clinical Radiobiology for Radiation Oncology
288
Table 5.15 Example of cancer stem cells (CSCs) Markers
Type of tumor
CSC markers
References
Breast cancer
CD44+/CD24,
CD44−/CD24−/low
ALDH1
Coppes and Dubrovska [247],
Filipova et al. [243]
Esophageal
cancer
CD44
CD133
CD90
Smit et al. [252], Yang et al.
[253]
Glioma
CD133
Bao et al. [245]
Head and neck
cancer
CD98
Coppes and Dubrovska [247],
Digomann et al. [254]
Martens-de Kemp et al. [255]
Larynx
CD44
CD133
Yang et al. [253]
Small cell lung
cancer
CD133
Sarvi et al. [256]
Non-small cell
lung cancer
CD133
Bertolini et al. [246], Lundholm
et al. [250], Moro et al. [251],
Shien et al. [257]
can to some extent explain tumor cell heterogeneity [240,
242, 243]. It is believed that CSCs originate from the malig­
nant transformation of normal stem cells or progenitor
cells. Thus, CSCs possess key properties such as self-
renewing and differentiation capacity, thereby being able to
produce a phenotypically variable progeny [244]. Due to
these characteristics, CSCs are thought to be important for
tumor formation, recurrence, and resistance. Indeed, exper­
imental data from xenograft studies in mice where different
tumor cells with diverse CSCs characteristics have been
engrafted and formed tumors, have demonstrated that CSCs
are involved in tumor growth and metastasis and that they
are resistant to a multitude of cancer treatments including
RT [245–251]. It has been noted that only a few surviving
CSCs in a heterogeneous tumor are enough to cause local
tumor relapse after RT but also to promote metastasis [243,
247]. It is difficult to calculate the frequency of CSCs
within a tumor as it is dependent on the type of malignancy.
Further, the identification of CSCs is challenging as spe­
cific markers are not entirely clear. This is in part due to the
high intra- and inter-­tumor heterogeneity as well as by
tumor plasticity, and variable genotypes and phenotypes.
Regardless, a few markers, i.e., CD44, CD98, CD90,
CD44+/CD24−, and CD133, are robust enough to be used in
the identification of CSCs (Table 5.15) in breast cancer,
small-cell lung cancer (SCLC), esophageal cancer, larynx,
head and neck cancer, non-small cell lung cancer (NSCLC),
etc. Interestingly, these markers are also associated with
response to RT as illustrated in NSCLC and glioblastoma
[245, 246, 248–251].
The variable phenotype of CSCs has a strong association
with cells of origin thus making the comparison between dif­
ferent tumors complicated. In addition, the number of CSCs
within a tumor is relatively small; therefore, the use of CSC
markers is a poor predictor for treatment response [258].
Regardless, the characterization of CSCs remains important,
as it may provide essential information in the development of
more efficient treatment strategies and the prevention of
tumor relapse as well as metastasis [240, 247–249, 251, 259].
­
­
­
240260
5.28
CSCSs are also reported to have activated DDR signaling
and increased DNA repair capacity, for example, ATM,
Chk1/2, and NHEJ [245, 250], increased cell death resis­
tance as well as upregulation of the signaling pathways
involved in cell survival and proliferation, such as HIF-1α,
WNT (Wingless-related integration site), NOTCH, or
Hedgehog [247]. Moreover, it was recently shown that
tumors with a higher count of CSCs had an impaired local
control of the tumor and lower effect of RT than tumors with
less CSCs [240, 261]. Several studies have suggested that RT
sensitization is linked to the same signaling pathways
involved in the preservation of CSCs cells, for example,
WNT, NOTCH, or Hedgehog signaling pathways; therefore,
these pathways have been indicated as possible targets for
CSC-targeted therapies [247, 253]. Other strategies propose
the inhibition of the DNA damage response (ATM, Chk1/2),
the promotion of apoptosis, and the inhibition of epigenetic-­
related proteins, for example, histone deacetylase (HDAC),
Enhancer of zeste homolog (EZH2). [247]. However, at pres­
ent very few of these strategies have been clinically tested,
due to complex cellular characteristics of CSCs. Nevertheless,
further CSCs exploration and their signaling networks could
reveal new potential therapeutic targets (Box 5.19).
Box 5.19 Cancer Stem Cells and Radiosensitivity
•	Tumor heterogeneity is explained by theory of
clonal evolution and/or existence of CSCs.
•	Clonal evolution presumes accumulation of genetic
mutation(s) while CSCs model describes a hierar­
chy system of tumor growth and progression main­
tained with only by a small subpopulation of CSCs.
•	Few specific markers are at hand for characteriza­
tion of CSCs due to high inter- and intra-tumor het­
erogeneity, tumor plasticity, and variable genotypes
and phenotypes.
•	Tumors with a higher count of CSCs show lower
efficacy of RT and impaired local tumor control.
•	Multiple signaling cascades controlling DDR sig­
naling, cell death, EMT, and hypoxia are reported to
be altered in CSCs of tumors offering a putative
way for RT sensitization for the future.
P. Sminia et al.
289
240260
5.15
Radiotherapy and the Human
Microbiota (Box 5.20)
5.15.1	What Is the Human Microbiota?
The human body has around 500 billion cells including
microorganisms such as bacteria, viruses, fungi, and archaea,
on the surface of organs in contact with the outside. All of
these microorganisms, hosted by the body, represent the
human microbiota. Several microbiotas exist in an organism:
in the digestive tract system (from mouth to anus), in the
respiratory system, in the urogenital tract, and on the skin.
Nevertheless, the larger community of microorganisms
resides in the digestive system. The intestinal microbiota can
be considered as an organ, given that it has specific functions
of its own. Indeed, the intestinal microbiota makes it possi­
ble to maintain intestinal homeostasis by transforming nutri­
ents that cannot be digested by the intestine into essential
metabolites, by maintaining an effective epithelial barrier
avoiding intestinal colonization by pathogens and also by
participating to the development as well as the function of
the immune system.
Among microorganisms, the most prevalent and
studied ones are bacteria. The human GI tract is colo­
nized by more than 2000 different individual bacteria
species. Proportional representation and genus level
Box 5.20 The Human Microbiota and Radiotherapy
•	The microbiota is composed of many microorgan­
isms such as bacteria (most represented and stud­
ied), viruses, fungi, and archaea.
•	The microbiota plays a key physiological role in
maintaining the gut health and well-being of the
host.
•	Composition and abundance of the microbiota can
be modified by various stresses and a stable alterna­
tive state of the microbiota can lead to pathologies.
•	Reduction of the fecal microbiota diversity and
composition after RT are consistently associated
with intestinal toxicity.
•	The microbiota can modify the tumor response
effectiveness of RT.
•	The microbiota can be a therapeutic target for per­
sonalized medicine that might be used to increase
patient’s quality of life during or after RT.
5 Clinical Radiobiology for Radiation Oncology"
"Describe the composition and functional significance of the human microbiota, particularly focusing on the dominant bacterial phyla found in the gastrointestinal tract and their roles within maintaining host health.","The human microbiota represents a complex community of microorganisms – including bacteria, viruses, fungi, and archaea – residing across various sites throughout the body. Notably, the largest and most extensively studied microbial population resides within the digestive system, particularly the gut. Within the gastrointestinal tract, Firmicutes and Bacteroidetes are consistently identified as the predominant phyla, representing approximately 80% of the total bacterial community.  *Firmicutes* are characterized by a diverse range of metabolic capabilities, including fermentation of complex carbohydrates and production of short-chain fatty acids (SCFAs), which serve as an energy source for the host and contribute to gut health. *Bacteroidetes*, on the other hand, play a significant role in polysaccharide degradation and nutrient acquisition.  Other less prevalent phyla such as Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria also contribute to the overall microbial diversity within the gut. Collectively, this diverse microbiota performs several critical functions including transforming indigestible nutrients into essential metabolites, establishing an effective epithelial barrier that prevents pathogen colonization, and actively participating in the development and regulation of the host’s immune system.  Disruptions to this delicate balance – termed dysbiosis – are increasingly recognized as a factor contributing to various diseases.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.15	 Radiotherapy and the Human Microbiota (Box 5.20) | Sub-subsection: 5.15.1	 What Is the Human Microbiota? | Content: The human body has around 500 billion cells including
microorganisms such as bacteria, viruses, fungi, and archaea,
on the surface of organs in contact with the outside. All of
these microorganisms, hosted by the body, represent the
human microbiota. Several microbiotas exist in an organism:
in the digestive tract system (from mouth to anus), in the
respiratory system, in the urogenital tract, and on the skin.
Nevertheless, the larger community of microorganisms
resides in the digestive system. The intestinal microbiota can
be considered as an organ, given that it has specific functions
of its own. Indeed, the intestinal microbiota makes it possi­
ble to maintain intestinal homeostasis by transforming nutri­
ents that cannot be digested by the intestine into essential
metabolites, by maintaining an effective epithelial barrier
avoiding intestinal colonization by pathogens and also by
participating to the development as well as the function of
the immune system.
Among microorganisms, the most prevalent and
studied ones are bacteria. The human GI tract is colo­
nized by more than 2000 different individual bacteria
species. Proportional representation and genus level
Box 5.20 The Human Microbiota and Radiotherapy
•	The microbiota is composed of many microorgan­
isms such as bacteria (most represented and stud­
ied), viruses, fungi, and archaea.
•	The microbiota plays a key physiological role in
maintaining the gut health and well-being of the
host.
•	Composition and abundance of the microbiota can
be modified by various stresses and a stable alterna­
tive state of the microbiota can lead to pathologies.
•	Reduction of the fecal microbiota diversity and
composition after RT are consistently associated
with intestinal toxicity.
•	The microbiota can modify the tumor response
effectiveness of RT.
•	The microbiota can be a therapeutic target for per­
sonalized medicine that might be used to increase
patient’s quality of life during or after RT.
5 Clinical Radiobiology for Radiation Oncology
290
distribution are dependent on the organ localization
and vary with diet, age, and geographical localization
of the host. As other microorganisms within the micro­
biota, bacteria have an important role in maintaining
the health and well-being of the host. In the healthy
gastrointestinal tract, Firmicutes and Bacteroidetes
represent the predominant phylum in the microbiota
(up to 80%). Other phylums which are less represented
in
the
microbiota
are
Actinobacteria
(3%),
Proteobacteria
(1%),
Verrucomicrobia,
and
Fusobacteria (less than 1%).
­
­
262
­
­
­
­
­
5.29
5.15.2	Pelvic Radiotherapy and the Human
Fecal Dysbiosis: Prospective Clinical
Trials
Currently, at least eight prospective clinical studies assessed
the effect of RT combined [263–266] or not [267–270] with
other anti-tumors treatments, like chemotherapy, on the gut
microbiota dysbiosis. The results of these studies have recently
been presented in Byeongsang Oh’s review in 2021 [271].
Fecal microbiota changes by pelvic cancers (gynecological,
colorectal/rectal, prostate, lymph node, and anal ­cancers) and/
or after RT are briefly summarized below. Prior to RT, patients
suffering from pelvic cancers have a loss of their fecal micro­
bial diversity [266, 269]. The clinical studies also performed
taxonomic analyses at the phyla level in feces from cancer
patients. Results highlight variations of the relative bacteria
abundance with an increase of the Firmicutes [269] and the
Actinobacteria [266] and decrease of the Bacteroidetes [269]
and the Fusobacteria [266]. Low fecal bacterial diversity has
also been described in patients during and after pelvic RT
[266, 267, 269]. Pelvic RT gradually reshapes microbiota bac­
terial composition in such cancer patients. Indeed, the pro­
spective clinical studies demonstrate that during pelvic RT, the
fecal relative abundance of the phylum Bacteroidetes tends to
decrease and conversely that of the Fusobacteria significantly
increases [266]. After the completion of pelvic RT, fecal rela­
tive abundance of the phyla Firmicutes is reduced [266, 269]
and that of the phylum Bacteroidetes, Fusobacteria [266],
Proteobacteria [270], and Actinobacteria [267] are enhanced.
5.15.3	Consequences of the Human Fecal
Dysbiosis in Pelvic RT-Induced
Digestive Toxicity
The prospective clinical studies described above, also show
that the reduction of the fecal microbial diversity during and
P. Sminia et al."
"Following pelvic radiation therapy (RT), what observed shifts in relative abundance are commonly reported for bacterial phyla within the human gut microbiome, and how do these changes subsequently affect the overall microbial community?","Clinical trials investigating the impact of pelvic RT on the human fecal microbiota consistently reveal a notable dysbiosis characterized by significant alterations in phylum proportions. Specifically, there’s typically a decrease in the relative abundance of the Bacteroidetes phylum and a concurrent increase in the Fusobacteria phylum following RT treatment. Furthermore, studies demonstrate a reduction in Firmicutes levels post-RT. Simultaneously, the relative abundances of Bacteroidetes, Fusobacteria, Proteobacteria, and Actinobacteria are often enhanced. This complex shift represents a profound alteration in microbial diversity and composition within the gut ecosystem. The resulting imbalance can contribute to digestive toxicity observed during RT by disrupting normal metabolic processes, reducing protective colonization resistance against opportunistic pathogens, and potentially exacerbating inflammation due to altered metabolite production.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.15	 Radiotherapy and the Human Microbiota (Box 5.20) | Sub-subsection: 5.15.2	 Pelvic Radiotherapy and the Human Fecal Dysbiosis: Prospective Clinical Trials | Content: spective clinical studies demonstrate that during pelvic RT, the
fecal relative abundance of the phylum Bacteroidetes tends to
decrease and conversely that of the Fusobacteria significantly
increases [266]. After the completion of pelvic RT, fecal rela­
tive abundance of the phyla Firmicutes is reduced [266, 269]
and that of the phylum Bacteroidetes, Fusobacteria [266],
Proteobacteria [270], and Actinobacteria [267] are enhanced.
5.15.3	Consequences of the Human Fecal
Dysbiosis in Pelvic RT-Induced
Digestive Toxicity
The prospective clinical studies described above, also show
that the reduction of the fecal microbial diversity during and
P. Sminia et al."
"Following pelvic radiation therapy (RT), clinical studies have observed shifts in the gut microbiome composition. Specifically, what changes are typically noted regarding the relative abundance of Bacteroidetes, Fusobacteria, Firmicutes, and other phyla within the fecal microbiota after RT treatment?","Clinical investigations following pelvic RT demonstrate a consistent pattern of alterations in the gut microbiome. During RT, there is generally a decrease observed in the relative abundance of the phylum Bacteroidetes and a corresponding increase in the phylum Fusobacteria. Post-RT completion, reductions are frequently noted in the Firmicutes population, while simultaneously an enhancement occurs in the relative abundances of Bacteroidetes, Fusobacteria, Proteobacteria, and Actinobacteria. These shifts collectively contribute to reduced microbial diversity within the gut ecosystem. Reference: [MolecularRadiationBiology, Section 5.15.3 – Consequences of the Human Fecal Dysbiosis in Pelvic RT-Induced Digestive Toxicity]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.15	 Radiotherapy and the Human Microbiota (Box 5.20) | Sub-subsection: 5.15.3	 Consequences of the Human Fecal Dysbiosis in Pelvic RT-Induced Digestive Toxicity | Content: spective clinical studies demonstrate that during pelvic RT, the
fecal relative abundance of the phylum Bacteroidetes tends to
decrease and conversely that of the Fusobacteria significantly
increases [266]. After the completion of pelvic RT, fecal rela­
tive abundance of the phyla Firmicutes is reduced [266, 269]
and that of the phylum Bacteroidetes, Fusobacteria [266],
Proteobacteria [270], and Actinobacteria [267] are enhanced.
5.15.3	Consequences of the Human Fecal
Dysbiosis in Pelvic RT-Induced
Digestive Toxicity
The prospective clinical studies described above, also show
that the reduction of the fecal microbial diversity during and
P. Sminia et al.
291
after pelvic RT, are consistently associated with radiation
toxicity and therefore with intestinal complications, i.e.,
enteropathy, enteritis, and diarrhea [266–269]. Indeed, as
suggested by a personal view of Andreyev’s team published
in The Lancet Oncology in 2014 [272], clinical data seem to
indicate that microbiota through its composition change
might be an actor involved in radiation-induced intestinal
toxicity. In 2018, Gerassy-Vainberg et al. [273] published
preclinical data supporting this assumption. Indeed, results
show that, rectal irradiation by brachytherapy leads to micro­
bial dysbiosis in chronic post-exposure phase (6 weeks).
Irradiated microbiota transplantation in germ-free mice
transmits susceptibility to radiation damages at least in part
through the production by epithelial cells of Interleukin-1
(IL-1). Nevertheless, in 2020, data published in Science by
Guo Hua et al. show that gut microbiome-metabolome net­
work plays a crucial role in substantial protection against
radiation-induced toxicity though host defense regulation
[274]. Indeed, a small proportion of mice named “elite-­
survivors” can survive a high dose of total body irradiation
and that these individuals also reduce their susceptibility to
radiation-induced digestive toxicity and damages. The fami­
lies Lachnospiraceae and Enterococcaceae, together with
downstream metabolites represented by propionate and tryp­
tophan pathway members, contribute substantially to radio­
protection. Even if a role of the gut microbiota is suggested
on RT-induced tissue toxicity or protection, very little data
exists concerning its involvement and the underlying mecha­
nisms. Wang et al. showed that the reduction of the fecal
microbial diversity is even more pronounced in patients with
pelvic cancers who later progressed to RT-induced side
effects (fatigue, diarrhea) [269]. Mitra et al. propose that
compositional characteristics of microbiota in cancer patients
could also be relevant to be predictive of end-of-anti-cancer
treatment bowel toxicity [265].
5.15.4	Consequences of the Human Fecal
Dysbiosis in Radiotherapy Efficiency
RT efficiency, regarding anti-tumor effects, passes in part
through the induction of immunogenic cell death in which
CD8+ cytotoxic T cell, CD11b+ myeloid cells and dendritic
cells all have been described as major actors [275]. There is
growing evidence of the existence of bidirectional effects of
RT and microbiome composition. Indeed, RT-induced reduc­
tion of gut microbiota diversity, richness, and composition
could be followed by the host immune response alteration
which in turn could lead to an effectiveness change of the
anticancer treatment themselves. In 2021, data published by
Shiao et al. in the Cancer Cell, robustly demonstrated that,
within the gut microbiota, commensal bacteria and fungi dif­
ferentially regulate tumor response to RT [276]. Indeed,
commensal bacteria are required for efficient immune anti-­
tumor effect (activation of T cells) of RT. Currently, no study
has identified bacterial subjects involved in RT efficiency. By
contrast, Shiao et al. demonstrated that commensal fungi
regulate the immunosuppressive microenvironment of tumor
(with combined effects on T cells and macrophages) after RT
leading to a reduction of treatment efficiency. They high­
lighted a role of Saccharomycetales orders and specific
Candida Albicans genera in fungal effect after RT.
5.15.5	Conclusions
Fecal microbial signature in patients with pelvic cancers
may be a tool for RT risk assessment and/or efficiency. In
order to robustly demonstrate this assumption, further exper­
iments and clinical trials should be performed. The use of
high-throughput data generation by multi-omics approaches
(e.g., microbiota shotgun sequencing or metabolomics anal­
yses) and mathematical models will give an added value
compared to previous studies. After RT, a better understand­
ing of individual states of different microorganism popula­
tions within the microbiota or more largely within the
intestinal ecosystem could help to guide personalized medi­
cine. Indeed, prophylactic or curative treatments like rich
fiber diet, probiotic or fecal microbiota transplantation could
prevent or reduce RT-induced toxicity and/or improve radio­
therapy efficiency on tumor control.
5.16
Radiomics, Data Science, and Artificial
Intelligence in Radiation Oncology
5.16.1	Basic Methods of Data Analysis
In radiation research, different techniques are used to mea­
sure complete molecular- or genomic profiles of organisms,
resulting in various collected data types. Omics, a general
term for specified measurements and studied biological
fields, include genomics, proteomics, transcriptomics,
metabolomics, phenomics, lipidomics, and many more. The
suffix “omics” indicates interest in all molecules or genes of
a specified type and their interactions rather than individual
observations. For example, in genomics studies the genome,
a set of all genes expressed in the cell, tissue, or organism,
and their relationships with each other and with the environ­
ment is analyzed. So other omics-based platforms such as
proteomics and transcriptomics study proteome (all proteins)
and transcriptome (all types of transcripts like mRNAs and
miRNAs), respectively. Omics data analysis helps to under­
stand the influence of molecules and genes on a phenotype.
The measurements can be obtained with techniques like
microarrays, high-throughput sequencing technologies
5 Clinical Radiobiology for Radiation Oncology"
"How does the human fecal microbiota influence the efficacy of radiotherapy (RT) in cancer treatment, and what specific microbial groups have been implicated in this interaction?","The composition of the human fecal microbiota significantly impacts the effectiveness of radiotherapy by modulating the tumor's response to treatment. Research indicates that commensal bacteria are not merely passive bystanders but actively participate in shaping the immune landscape surrounding the tumor. Specifically, certain bacterial communities are essential for facilitating the anti-tumor effects of RT, primarily through their ability to activate T cells – a critical component of the adaptive immune system’s attack against cancer cells. Conversely, an imbalance in the microbiota, termed fecal dysbiosis, can diminish RT efficacy. This is often mediated by fungal species, notably members of the Saccharomycetales order and *Candida albicans*, which contribute to an immunosuppressive microenvironment within the tumor. These fungi interact with both T cells and macrophages, suppressing their anti-tumor activity and ultimately reducing the overall effectiveness of radiotherapy. The precise mechanisms are complex, but it’s clear that a healthy and diverse microbiota is crucial for optimal immune response during RT, while dysbiosis can undermine this process.

Reference: Molecular Radiation Biology, 5.15.4 Consequences of the Human Fecal Dysbiosis in Radiotherapy Efficiency","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.15	 Radiotherapy and the Human Microbiota (Box 5.20) | Sub-subsection: 5.15.4	 Consequences of the Human Fecal Dysbiosis in Radiotherapy Efficiency | Content: ferentially regulate tumor response to RT [276]. Indeed,
commensal bacteria are required for efficient immune anti-­
tumor effect (activation of T cells) of RT. Currently, no study
has identified bacterial subjects involved in RT efficiency. By
contrast, Shiao et al. demonstrated that commensal fungi
regulate the immunosuppressive microenvironment of tumor
(with combined effects on T cells and macrophages) after RT
leading to a reduction of treatment efficiency. They high­
lighted a role of Saccharomycetales orders and specific
Candida Albicans genera in fungal effect after RT."
"How does the human microbiota interact with radiotherapy (RT) to influence tumor response, and what specific microbial groups have been implicated in modulating this interaction?","The interplay between the human microbiota and radiotherapy (RT) is a complex process that significantly impacts tumor response. Research indicates that commensal bacteria are not merely passive bystanders but actively participate in shaping the immune response to RT. Specifically, certain bacterial communities can enhance the anti-tumor effects of RT by stimulating T cell activation – a critical component of adaptive immunity against cancer cells. Conversely, other microbial populations, particularly fungi like *Candida albicans* within the Saccharomycetales order, can create an immunosuppressive microenvironment around the tumor after RT. This fungal influence leads to reduced T cell activity and diminished treatment efficacy. The composition of the fecal microbiota signature in patients with pelvic cancers appears to correlate with RT risk assessment and efficiency. Future research utilizing multi-omics approaches – including shotgun sequencing of the microbiota and metabolomic analyses – combined with mathematical modeling, is crucial for a more comprehensive understanding of these interactions. Ultimately, manipulating the gut microbiome through interventions like dietary changes (rich in fiber), probiotics, or fecal microbiota transplantation may offer strategies to mitigate RT toxicity and improve tumor control.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.15	 Radiotherapy and the Human Microbiota (Box 5.20) | Sub-subsection: 5.15.5	 Conclusions | Content: ferentially regulate tumor response to RT [276]. Indeed,
commensal bacteria are required for efficient immune anti-­
tumor effect (activation of T cells) of RT. Currently, no study
has identified bacterial subjects involved in RT efficiency. By
contrast, Shiao et al. demonstrated that commensal fungi
regulate the immunosuppressive microenvironment of tumor
(with combined effects on T cells and macrophages) after RT
leading to a reduction of treatment efficiency. They high­
lighted a role of Saccharomycetales orders and specific
Candida Albicans genera in fungal effect after RT.
5.15.5	Conclusions
Fecal microbial signature in patients with pelvic cancers
may be a tool for RT risk assessment and/or efficiency. In
order to robustly demonstrate this assumption, further exper­
iments and clinical trials should be performed. The use of
high-throughput data generation by multi-omics approaches
(e.g., microbiota shotgun sequencing or metabolomics anal­
yses) and mathematical models will give an added value
compared to previous studies. After RT, a better understand­
ing of individual states of different microorganism popula­
tions within the microbiota or more largely within the
intestinal ecosystem could help to guide personalized medi­
cine. Indeed, prophylactic or curative treatments like rich
fiber diet, probiotic or fecal microbiota transplantation could
prevent or reduce RT-induced toxicity and/or improve radio­
therapy efficiency on tumor control.
5.16
Radiomics, Data Science, and Artificial
Intelligence in Radiation Oncology
5.16.1	Basic Methods of Data Analysis
In radiation research, different techniques are used to mea­
sure complete molecular- or genomic profiles of organisms,
resulting in various collected data types. Omics, a general
term for specified measurements and studied biological
fields, include genomics, proteomics, transcriptomics,
metabolomics, phenomics, lipidomics, and many more. The
suffix “omics” indicates interest in all molecules or genes of
a specified type and their interactions rather than individual
observations. For example, in genomics studies the genome,
a set of all genes expressed in the cell, tissue, or organism,
and their relationships with each other and with the environ­
ment is analyzed. So other omics-based platforms such as
proteomics and transcriptomics study proteome (all proteins)
and transcriptome (all types of transcripts like mRNAs and
miRNAs), respectively. Omics data analysis helps to under­
stand the influence of molecules and genes on a phenotype.
The measurements can be obtained with techniques like
microarrays, high-throughput sequencing technologies
5 Clinical Radiobiology for Radiation Oncology"
"The text suggests a potential role for the gut microbiota in influencing the efficacy of radiation therapy (RT) for pelvic cancers. Specifically, what types of microorganisms are implicated in modulating RT’s impact on tumor response and why is this significant?","The research indicates that commensal bacteria, particularly certain orders within the Saccharomycetales group like *Candida Albicans* genera, play a crucial role in regulating the immunosuppressive microenvironment surrounding tumors following radiation therapy. These fungi don’t directly enhance tumor cell death but instead dampen the immune system's response to RT. Specifically, they affect both T cells and macrophages, leading to a diminished anti-tumor effect. This is significant because efficient immune activation – specifically T cell activation – is known to be essential for radiation therapy’s success in combating cancer. By suppressing this critical immune pathway, the presence of these specific microorganisms reduces the overall effectiveness of RT. Furthermore, the text highlights that identifying and understanding microbial signatures within a patient's gut microbiome could potentially serve as a tool for assessing RT risk or predicting treatment efficiency, opening avenues for personalized radiation oncology approaches involving dietary interventions (like rich fiber diets), probiotics, or fecal microbiota transplantation to mitigate toxicity and improve therapeutic outcomes. Reference: 5.16 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Content: ferentially regulate tumor response to RT [276]. Indeed,
commensal bacteria are required for efficient immune anti-­
tumor effect (activation of T cells) of RT. Currently, no study
has identified bacterial subjects involved in RT efficiency. By
contrast, Shiao et al. demonstrated that commensal fungi
regulate the immunosuppressive microenvironment of tumor
(with combined effects on T cells and macrophages) after RT
leading to a reduction of treatment efficiency. They high­
lighted a role of Saccharomycetales orders and specific
Candida Albicans genera in fungal effect after RT.
5.15.5	Conclusions
Fecal microbial signature in patients with pelvic cancers
may be a tool for RT risk assessment and/or efficiency. In
order to robustly demonstrate this assumption, further exper­
iments and clinical trials should be performed. The use of
high-throughput data generation by multi-omics approaches
(e.g., microbiota shotgun sequencing or metabolomics anal­
yses) and mathematical models will give an added value
compared to previous studies. After RT, a better understand­
ing of individual states of different microorganism popula­
tions within the microbiota or more largely within the
intestinal ecosystem could help to guide personalized medi­
cine. Indeed, prophylactic or curative treatments like rich
fiber diet, probiotic or fecal microbiota transplantation could
prevent or reduce RT-induced toxicity and/or improve radio­
therapy efficiency on tumor control.
5.16
Radiomics, Data Science, and Artificial
Intelligence in Radiation Oncology"
"The provided text discusses the potential role of commensal bacteria in radiation therapy (RT) efficacy for pelvic cancers. Specifically, it highlights how these bacteria can either enhance or diminish RT outcomes depending on their composition and interactions with the tumor microenvironment. What are two distinct ways that commensal bacteria, as described in this passage, can influence the effectiveness of radiation therapy?","The text outlines two primary mechanisms by which commensal bacteria impact radiation therapy efficacy. First, certain bacterial communities, such as those containing Saccharomycetales orders and Candida Albicans genera, are shown to regulate the immunosuppressive microenvironment surrounding tumors after RT, ultimately reducing treatment effectiveness by affecting T cells and macrophages. Second, the passage indicates that commensal bacteria are *required* for efficient immune anti-tumor effects of RT – specifically, they activate T cells, thereby enhancing the overall therapeutic response. Reference: [MolecularRadiationBiology, Section 5.16.1 Basic Methods of Data Analysis]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Sub-subsection: 5.16.1	 Basic Methods of Data Analysis | Content: ferentially regulate tumor response to RT [276]. Indeed,
commensal bacteria are required for efficient immune anti-­
tumor effect (activation of T cells) of RT. Currently, no study
has identified bacterial subjects involved in RT efficiency. By
contrast, Shiao et al. demonstrated that commensal fungi
regulate the immunosuppressive microenvironment of tumor
(with combined effects on T cells and macrophages) after RT
leading to a reduction of treatment efficiency. They high­
lighted a role of Saccharomycetales orders and specific
Candida Albicans genera in fungal effect after RT.
5.15.5	Conclusions
Fecal microbial signature in patients with pelvic cancers
may be a tool for RT risk assessment and/or efficiency. In
order to robustly demonstrate this assumption, further exper­
iments and clinical trials should be performed. The use of
high-throughput data generation by multi-omics approaches
(e.g., microbiota shotgun sequencing or metabolomics anal­
yses) and mathematical models will give an added value
compared to previous studies. After RT, a better understand­
ing of individual states of different microorganism popula­
tions within the microbiota or more largely within the
intestinal ecosystem could help to guide personalized medi­
cine. Indeed, prophylactic or curative treatments like rich
fiber diet, probiotic or fecal microbiota transplantation could
prevent or reduce RT-induced toxicity and/or improve radio­
therapy efficiency on tumor control.
5.16
Radiomics, Data Science, and Artificial
Intelligence in Radiation Oncology
5.16.1	Basic Methods of Data Analysis
In radiation research, different techniques are used to mea­
sure complete molecular- or genomic profiles of organisms,
resulting in various collected data types. Omics, a general
term for specified measurements and studied biological
fields, include genomics, proteomics, transcriptomics,
metabolomics, phenomics, lipidomics, and many more. The
suffix “omics” indicates interest in all molecules or genes of
a specified type and their interactions rather than individual
observations. For example, in genomics studies the genome,
a set of all genes expressed in the cell, tissue, or organism,
and their relationships with each other and with the environ­
ment is analyzed. So other omics-based platforms such as
proteomics and transcriptomics study proteome (all proteins)
and transcriptome (all types of transcripts like mRNAs and
miRNAs), respectively. Omics data analysis helps to under­
stand the influence of molecules and genes on a phenotype.
The measurements can be obtained with techniques like
microarrays, high-throughput sequencing technologies
5 Clinical Radiobiology for Radiation Oncology
292
(Illumina, Oxford Nanopore, etc.), mass spectrometry (MS)
(including MS imaging), flow-, and mass cytometry. The
amount of collected data may vary from few records to mil­
lions, and the measurements may be taken for one point in
time or more. With increased throughput, a large amount of
data is generated, which requires advanced methods to per­
form a comprehensive analysis. By combining the domain
expertise and knowledge of mathematics and statistics, data
science extracts insights from big data.
Different statistical approaches are applied depending on
the experimental design, type of data, sample size, number of
replicates, number of time points, and so on. The first step of
any analysis is data preprocessing that includes data cleaning
and normalization. Omics data may have missing values,
duplicated observations or outliers which need to be handled.
Outliers are observations that deviate from other observa­
tions due to equipment failure or recording errors. An outlier
can be corrected or removed from the analysis. There are
many outlier detection methods that can detect one or more
anomalies, like Chauvenet’s criterion, Grubbs’ criterion,
Dixon’s procedure, Tukey’s or Huberta’s method. Which one
to choose depends mainly on the data distribution and sam­
ple size. Observations with missing values can be ignored,
removed or the values may be imputed with mean, median,
mode, or constant value. Missing data imputation can also be
carried out with, for example, the Nearest Neighbor algo­
rithm, which finds k nearest observations to the observation
with missing values and the aggregate of these measure­
ments, as mean/median value, is used to impute the missing
one. Before the analysis, data should be normalized to guar­
antee their numerical scale similarity across different experi­
ments. The standardization techniques, asz-, t-score
transformation, or local re-scaling, are often applied to par­
tially correct the batch effect or reference instability.
For a comparative study, depending on the data distribu­
tion, a variety of statistical tests can be applied. Usually, if
data contain one or two experimental groups, one-step test­
ing is performed. Three or more groups or measurements
collected from several time points (time series) require a
two-step procedure to determine the difference profile—the
omnibus type test (from ANOVA family, for example) fol­
lowed by pairwise comparisons. The test hypothesis is veri­
fied with a p-value, the probability that the test statistics
would take a value at least as extreme as observed, assuming
the null hypothesis is true. The lower the p-value, the stron­
ger the evidence against the null hypothesis, and if the value
is equal or smaller than the assumed significance level α, it
confirmed the presence of the effect studied.
Due to the number of data collected, the omics analyses
usually require more than one hypothesis to be verified,
which leads to the problem of multiple testing. In the case of
a single test performed, the first type of error is controlled by
significance level, but in the case of multiple testing, the
number of false-positive results has to be maintained for the
whole test family. This can be done with the use of Bonferroni
correction, Simes-Hochberg procedure, Dunn-Šidák, Holm,
or Hommel methods to control family-wise-error (FWER) or
Benjamini and Hochberg procedure or Storey’s algorithm
when focusing on false-discovery-rate (FDR). However, the
p-value depends on sample size, and if the sample is suffi­
ciently large, the statistical test will almost always indicate a
significant difference. Therefore, in big data, it is recom­
mended to calculate effect size together with the p-value.
Effect size is a quantitative measure of the strength of a phe­
nomenon calculated based on data and is independent of the
sample size. A lot of different measures of effect size exist,
and they can be divided into two categories: for indicating
differences between groups (e.g., risk difference, risk ratio,
odds ratio, Cohen’s d, Glass’s delta, Hedges’ g, the probabil­
ity of superiority, ω2) and estimating measure of similarity
between variables (e.g., the correlation coefficient r, R2,
Spearman’s ρ, Kendall’s τ, φ coefficient, Cramer’s V,
Cohen’s f, η2).
It is possible to integrate data and results from different
experiments to get a unified view to them, in situations when
the same experiment is performed on a different set of data
or the same data is used in a different experiment (different
method) but concerning the same characteristic (null hypoth­
esis). The p-value integration can be carried out, among
­others, with Fisher product, Lancaster, Stouffer method, or
weighted z-transformation. The adaptive rank truncated
product method can also be applied at the pathway analysis
level.
If measurements were taken for multiple characteristics to
estimate the relationship and its strength between them
(between a dependent variable and independent variables), a
regression analysis can be conducted. Regression is a statisti­
cal method that tries to fit a model (function) to the data. The
model has different forms, the most common one is a linear
function, which is a line that closely fits the data according to
a specific criterion. In other words, the dependent variable is
a linear combination of the model parameters.
5.16.2	Artificial Intelligence and Machine
Learning Methods for Knowledge
Discovery
In radiation oncology, data science (incorporating the disci­
plines of computer science and statistics) attempts to provide
clinical insight and clinical decision support using structured
or unstructured clinical data that incorporates multiple vari­
ables descriptive of patient cohorts [277]. Daily clinical
workflows produce a vast array of data comprising of elec­
tronic health records, treatment information, genomic data,
multimodal
imaging,
and
patient
outcomes
[278].
P. Sminia et al."
The text discusses several approaches to managing the multiple testing problem that arises when evaluating numerous hypotheses. Describe two of these methods – Bonferroni correction and Benjamini-Hochberg procedure – outlining their core strategies for controlling false positive rates.,"When conducting multiple statistical tests, there's an increased risk of obtaining false positives (incorrectly identifying a significant difference). The text outlines several techniques to manage this. First, the Bonferroni correction is a conservative method that adjusts the significance level (alpha) for each test by dividing it by the total number of tests being performed. For example, if you're conducting 10 tests with an initial alpha of 0.05, the adjusted alpha becomes 0.005 (10/20). This drastically reduces the chance of a false positive but also increases the risk of a Type II error (failing to detect a true effect) because it sets a very stringent threshold for significance. Second, the Benjamini-Hochberg procedure is a less conservative approach that controls the False Discovery Rate (FDR), which is the expected proportion of false positives among all significant results. It ranks p-values from smallest to largest and then applies a step-wise process to identify those p-values that are statistically significant at the desired FDR level. This method offers more power than Bonferroni correction while still controlling for multiple testing.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Sub-subsection: 5.16.2	 Artificial Intelligence and Machine Learning Methods for Knowledge Discovery | Content: usually require more than one hypothesis to be verified,
which leads to the problem of multiple testing. In the case of
a single test performed, the first type of error is controlled by
significance level, but in the case of multiple testing, the
number of false-positive results has to be maintained for the
whole test family. This can be done with the use of Bonferroni
correction, Simes-Hochberg procedure, Dunn-Šidák, Holm,
or Hommel methods to control family-wise-error (FWER) or
Benjamini and Hochberg procedure or Storey’s algorithm
when focusing on false-discovery-rate (FDR). However, the
p-value depends on sample size, and if the sample is suffi­
ciently large, the statistical test will almost always indicate a
significant difference. Therefore, in big data, it is recom­
mended to calculate effect size together with the p-value.
Effect size is a quantitative measure of the strength of a phe­
nomenon calculated based on data and is independent of the
sample size. A lot of different measures of effect size exist,
and they can be divided into two categories: for indicating
differences between groups (e.g., risk difference, risk ratio,
odds ratio, Cohen’s d, Glass’s delta, Hedges’ g, the probabil­
ity of superiority, ω2) and estimating measure of similarity
between variables (e.g., the correlation coefficient r, R2,
Spearman’s ρ, Kendall’s τ, φ coefficient, Cramer’s V,
Cohen’s f, η2).
It is possible to integrate data and results from different
experiments to get a unified view to them, in situations when
the same experiment is performed on a different set of data
or the same data is used in a different experiment (different
method) but concerning the same characteristic (null hypoth­
esis). The p-value integration can be carried out, among
­others, with Fisher product, Lancaster, Stouffer method, or
weighted z-transformation. The adaptive rank truncated
product method can also be applied at the pathway analysis
level.
If measurements were taken for multiple characteristics to
estimate the relationship and its strength between them
(between a dependent variable and independent variables), a
regression analysis can be conducted. Regression is a statisti­
cal method that tries to fit a model (function) to the data. The
model has different forms, the most common one is a linear
function, which is a line that closely fits the data according to
a specific criterion. In other words, the dependent variable is
a linear combination of the model parameters.
5.16.2	Artificial Intelligence and Machine
Learning Methods for Knowledge
Discovery
In radiation oncology, data science (incorporating the disci­
plines of computer science and statistics) attempts to provide
clinical insight and clinical decision support using structured
or unstructured clinical data that incorporates multiple vari­
ables descriptive of patient cohorts [277]. Daily clinical
workflows produce a vast array of data comprising of elec­
tronic health records, treatment information, genomic data,
multimodal
imaging,
and
patient
outcomes
[278].
P. Sminia et al.
293
Inconsistencies in annotations of medical records presents a
problem when utilizing unstructured data [279]. Here
machine learning and artificial intelligence are key to detect­
ing patterns within these vast data matrices [280, 281], pro­
viding opportunities for the development of diagnostic and
prognostic tools. Increasingly clinical data and -omics data
on the intrinsic biological characteristics of the patient are
being integrated to derive models predictive of outcome met­
rics such as cancer survival and treatment response [282]. As
the volume of clinical data available increases, innovative
methods to process and interpret the data is required, trans­
lating the information into useable knowledge.
Machine learning (ML) and artificial intelligence (AI)
approaches are capable of both identifying intrinsic pat­
terns within data (termed unsupervised techniques) and
developing models linking matrices of clinical data to iden­
tifying factors such as diagnostic or prognostic criteria
(termed supervised techniques) [283]. For the latter type of
model, the standard approach is to randomly separate the
available data from patients into a training set which is pre­
sented to a machine learning algorithm capable of identify­
ing important variables that link the patient data to the
target variable (which is itself representative of the diag­
nostic or prognostic criterion). Subsequently, the generaliz­
ability of the learnt algorithm to new data is interrogated by
presenting the algorithm with the unseen test data which
remains from the available dataset after separation of the
training data.
Typical applications of these approaches include predic­
tion of toxicity to radiation therapy with dosimetric factors in
head and neck cancer [284] to prediction of survival in pan­
creatic cancer [282]. A key advantage of machine learning in
predicting therapy outcomes over conventional models such
as NTCP and TCP which use dosimetric data [285] is the
application of additional clinical and biochemical data [284,
286]. Many models demonstrate high performance owing to
validation taking place using data which bears a close rela­
tionship to the training dataset. This is a particular concern
when translating algorithms to a clinical setting, as models
may not be evaluated on an external dataset [287, 288], and
as such their generalizability is in question. In general, clini­
cal translation of AI-based technologies requires generaliz­
able, robust models which are validated in prospective,
randomized clinical trials, and this represents a key chal­
lenge to their adoption [289].
Recently, deep learning-based algorithms have been
employed, which perform automated image segmentation
[290, 291] without the requirement for feature engineering,
though the potential for overfitting and a lack of generaliz­
ability can persist with such approaches. Deep learning (DL)
is a widely researched area in radiobiology and radiation
oncology with models being developed for tasks such as
modeling outcomes using dose-volume metrics, radiomic
feature discovery, image and tumor segmentation, and treat­
ment outcome prediction.
One area where machine learning approaches have seen
substantial application is in the development of methodolo­
gies utilizing medical imaging data such as CT, MRI, and
PET for predictive modeling, particularly of radiotherapeutic
outcome. In this instance, the field has been termed radiomics
[292, 293]. Here the lack of standardized image acquisition
protocols (e.g., slice thickness and tube current in CT) can
affect the quality and reliability of the radiomic features
extracted by automated algorithms [248, 249, 294, 295].
Often manual clinical delineation of regions of interest of
prognostic value prior to modeling (which is termed “feature
engineering”) is utilized though this can introduce interob­
server variability [296].
The success of radiomics in this context is in the develop­
ment of “interpretable” machine learning or AI algorithms
for a range of applications. Features may be extracted from
2D and 3D imaging data, reducing them to multiple features
describing tumor intensity, shape, and texture [297]. These
may subsequently be utilized to quantify tumor heterogene­
ity, where tumors with high heterogeneity have been shown
to demonstrate resistance to treatment [298]. Once the fea­
tures have been extracted machine learning or statistical
learning can be applied to match feature patterns to “ground
truth” data. Radiomic approaches have been applied to
­multiple imaging formats including CT, MRI, PET, and
ultrasound [299–302]. These approaches have been success­
fully applied to segmentation and detection problems such as
the differentiation of prostate cancers with Gleeson grade 6
and 7 [303], the discrimination of breast cancer subtypes
[304] and in TNM staging [305]. Potential clinical applica­
tions of radiomics-based classification extend to the detec­
tion of lung nodules providing a prognostic and diagnostic
aid to the clinician [306]. In terms of personalization of treat­
ment, these approaches have been used to identify prostate
cancer patients at risk of biochemical recurrence post-treat­
ment from MRI-based imaging [307], to distinguish between
HPV-positive and HPV-negative head and neck cancers
[308] and to monitor the response to RT [309]. Similarly,
ML models are also being examined in radiation genomics,
or radiogenomics, which explores tumor and normal tissue
response to radiation at a genomic level [310]. Linking imag­
ing characteristics with genomic data has the potential to aid
clinical cancer research and improve decision-making capa­
bilities and personalize therapy [310–312]. Various deep
learning methodologies are currently used to generate new
knowledge from radiogenomic data including convolutional
neural networks (CNNs) [313] and deep neural networks
(DNNs) [314].
However, as highlighted earlier, significant challenges
remain regarding the clinical interpretability of radiomic
and radiogenomic analyses and models, image acquisition
5 Clinical Radiobiology for Radiation Oncology
294
standardization and data storage in the era of “big data”
[292, 312, 315, 316]. Randomized controlled trials will
remain the gold standard in evaluating diagnostic and
prognostic interventions that are AI or ML based will be
evaluated in oncology [317, 318], where data science
approaches can also provide complementary information
[319, 320]."
"Describe the fundamental differences in how ultrasound sonography (USG), roentgenography (X-ray imaging, RX), and magnetic resonance imaging (MRI) generate diagnostic images, highlighting their respective strengths and limitations regarding radiation exposure and image resolution.","Ultrasound sonography utilizes high-frequency mechanical waves to create images by differentiating tissues based on variations in tissue reflectivity – essentially, how strongly a tissue reflects these sound waves. This technique is characterized by its affordability, minimal patient burden, and lack of ionizing radiation. Roentgenography (X-ray imaging) employs electromagnetic waves within the X-ray spectrum (typically 40-120 keV) to penetrate tissues and generate images based on differential absorption of these rays. RX is a rapid and inexpensive modality with low radiation exposure. However, it produces two-dimensional images, necessitating multiple projections for three-dimensional reconstruction – as seen in Computed Tomography (CT). CT offers advantages like high resolution, contrast, and 3D information but comes at the cost of significantly higher radiation exposure and greater expense compared to RX. Magnetic Resonance Imaging (MRI) also utilizes electromagnetic waves (typically 240-500 keV), but unlike X-rays, these waves do not ionize biological tissue, eliminating radiation exposure. Furthermore, MRI provides superior tissue contrast due to its sensitivity to hydrogen nuclei within tissues. The primary drawbacks of MRI include longer examination times (15-45 minutes), higher cost, limited availability, and potential contraindications. Nuclear medicine imaging techniques – PET and SPECT – rely on detecting gamma photons emitted from radiopharmaceuticals injected into the patient, providing specific functional information but generally possessing lower spatial resolution than radiological methods.

Reference: 5.16.3.1 Techniques in Medical Imaging","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Sub-subsection: 5.16.3	 Radiomics in Radiobiology and Clinical Oncology | Sub-sub-subsection: 5.16.3.1	 Techniques in Medical Imaging | Content: Several imaging modalities exist in radiology and nuclear
medicine with different physical, acquisition, and recon­
struction principles which have strengths and weaknesses
but all of them are indispensable for differential diagnosis.
––Ultrasound sonography (USG) uses high-frequency
mechanical waves to differentiate tissues based on vari­
ous reflectivity on the tissue edges. USG is an affordable
and inexpensive modality with minimal burden for the
patient.
––Roentgenography (X-ray imaging, RX) uses electromag­
netic waves with energy in the X-ray range most often
between 40 and 120 keV. RX is a fast and inexpensive
modality with small radiation exposure. If one collects
thousands of 2D RX images from different angles, one
can use computer algorithms for creating 3D images and
one is talking about CT. Advantages of CT are in special
resolution, high contrast, and 3D information; however, at
the cost of high radiation exposure and higher price than
RX.
––MRI also uses also electromagnetic waves as well as RX
of CT but with an energy in the radio range most often
between 240 and 500 neV which cannot ionize biological
tissue (no radiation exposure) which is together with high
tissue contrast advantage of MRI. The disadvantages are
longer examination time (15–45 min), price, availability,
and several contraindications.
Imaging methods in nuclear medicine are characterized
by lower spatial resolution than the radiological methods
mentioned above, but they contain very specific functional
information. Small amount of a specific radiopharmaceuti­
cal is injected into the patient and then emitted gamma pho­
tons are detected. Depending on the isotope used, one
speaks of positron emission tomography (PET, beta+ tracer)
or single photon emission computed tomography (SPECT,
gamma tracer). Both methods can be combined into hybrid
modalities mostly with CT for obtaining anatomical
information."
"Describe the process of segmentation in medical image analysis within the context of radiation oncology imaging, outlining its purpose and potential methods.","Segmentation, also known as delineation, is a crucial initial step in analyzing medical images used in radiation oncology. Its primary function is to identify and precisely define pathological areas of interest (ROIs) within an image. This involves isolating specific regions like the tumor itself, surrounding edema, necrotic tissue, or distinct anatomical structures such as the precise diameter or volume of the affected area. Segmentation can be performed manually by a radiologist, which is a time-consuming and potentially subjective process with limited reproducibility. Alternatively, semi- or fully automatic methods leveraging machine learning algorithms are increasingly utilized to enhance efficiency and improve consistency. These automated approaches often segment based on various criteria including histological tissue types (e.g., necrotic versus active tumor), precise anatomical localization, shape, intensity variations, and changes relative to prior imaging scans. The ultimate goal of segmentation is to accurately characterize the pathology, which is critical for diagnosis and subsequent treatment planning, particularly when initial radiological assessments are ambiguous – as exemplified by cases where a lesion resembles high-grade glioma but requires further investigation to rule out metastasis from another primary tumor, necessitating different therapeutic strategies.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Sub-subsection: 5.16.3	 Radiomics in Radiobiology and Clinical Oncology | Sub-sub-subsection: 5.16.3.2	 Main Steps in Medical Image Analysis | Content: In the first step, it is necessary to find the pathological area(s)
and make a basic description. The process that identifies
such areas or, in general, region of interest (ROI) is named
segmentation or delineation and can be done manually or
with the support of ML algorithms. Manual segmentation is
a time consuming and demanding task, with relatively low
level of reproducibility so it is beneficial to use semi- or fully
automatic methods.
Sometimes it is helpful to segment the pathology based
on different histological tissue types, for example, necrotic
part, active tumor, or edema but also precise anatomical
localization, diameter or volume, shape, intensity, and
changes compared to the previous examination.
After all variables are collected, the radiologist must
decide which kinds of pathologies it could be. Occasionally,
the radiological diagnoses are not unequivocal, for example,
the pathology looks like high grade gliomas but with non-­
negligible probability it could be metastasis of some other
primary tumor and the treatment of such different entities are
completely different. Each hospital produces thousands of
images per day, and it is obvious that usage of the same kind
of computer algorithms or AI can save time, increase repro­
ducibility and precision of diagnosis."
"Describe the concept of 'radiomics' as presented in this text, outlining its key components and the types of features it utilizes.","Radiomics is a methodology focused on extracting quantitative imaging features from medical images to potentially improve diagnostic accuracy, predict treatment response, or forecast patient outcomes. The process begins with segmentation or delineation – identifying regions of interest (ROIs) within an image, which can be done manually or through machine learning algorithms. Once these ROIs are defined, radiomics involves the collection of a large number of descriptive parameters, termed ‘features.’ These features fall into several categories: first-order features, which primarily utilize basic statistical measures like median, mean, and quartiles derived from voxel intensity distributions; shape features, representing intensity-independent measurements extracted from segmented images (e.g., perimeter, sphericity, diameter for 2D shapes and volume, surface area to volume ratio, compactness for 3D shapes); and grey level features, which quantify variations in pixel intensities within defined neighborhoods or zones (e.g., size zone, neighboring tone, run length, co-occurrence). The ultimate goal is to create a predictive model based on these extracted features to assist clinicians in diagnosis, treatment evaluation, or prognosis.  It’s important to note that feature selection is crucial due to potential correlations and instability across datasets. Reference: [MolecularRadiationBiology, Section 5.16.3.3 Radiomics: Definition, Features, and Examples]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Sub-subsection: 5.16.3	 Radiomics in Radiobiology and Clinical Oncology | Sub-sub-subsection: 5.16.3.3	 Radiomics: Definition, Features, and Examples | Content: and make a basic description. The process that identifies
such areas or, in general, region of interest (ROI) is named
segmentation or delineation and can be done manually or
with the support of ML algorithms. Manual segmentation is
a time consuming and demanding task, with relatively low
level of reproducibility so it is beneficial to use semi- or fully
automatic methods.
Sometimes it is helpful to segment the pathology based
on different histological tissue types, for example, necrotic
part, active tumor, or edema but also precise anatomical
localization, diameter or volume, shape, intensity, and
changes compared to the previous examination.
After all variables are collected, the radiologist must
decide which kinds of pathologies it could be. Occasionally,
the radiological diagnoses are not unequivocal, for example,
the pathology looks like high grade gliomas but with non-­
negligible probability it could be metastasis of some other
primary tumor and the treatment of such different entities are
completely different. Each hospital produces thousands of
images per day, and it is obvious that usage of the same kind
of computer algorithms or AI can save time, increase repro­
ducibility and precision of diagnosis.
5.16.3.3	Radiomics: Definition, Features,
and Examples
321
­
­
­
­
­
5.30
Combining radiomics features with deep learning fea­
tures or semantic features may further improve prognostic
performance. The changes over time may also be integrated
(delta-radiomics). Several studies have proven the effective­
ness of using these features independently in predictive mod­
eling. As was mentioned above, radiologists make basic
P. Sminia et al.
295
322
descriptions of pathology like volume, shape, etc. but the
number of these descriptors are limited by the radiologist’s
time and his/her eyes. But there exist tens or hundreds of dif­
ferent descriptors which can describe pathology and a
method which analyses all these descriptive parameters is
called Radiomics and these parameters are called features.
One can divide radiomics features into several classes
like: (1) First order; (2) Two and three (2D/3D) Shape and;
(3) Grey level class (e.g., Size zone, Neighboring tone, Run
length, Co-occurrence, Dependency).
The first order features (more than 15) characterized dis­
tribution of voxels intensities so they can be commonly
known histogram parameters like median, mean, or several
quartiles. But they also include mathematically sophisticated
parameters like energy, entropy, mean absolute deviation,
root mean squared, skewness, or kurtosis (“Sharpness of the
peak”).
Shape features (2D or 3D, more than 20) are intensity-­
independent parameters which are extracted from segmented
binary mask image or triangle mash. For example, 2D fea­
tures can be mesh surface, perimeter, sphericity, maximum
2D diameter or elongation. As 3D shape features, one can
mention, for example, mesh volume, surface area to volume
ratio, compactness, or flatness.
The biggest features class (which can be subdivided)
with more than 50 features is grey level class. For example,
grey level size zone features are trying to quantify con­
nected voxels in an image which share the same intensity
and one can extract features like grey level non-uniformity,
size-zone non-uniformity, grey level variance or zone
entropy, etc. Neighboring grey tone features quantify differ­
ences between intensity of voxel and average intensity of
neighbors’ voxels within defined distance and one can
extract features like coarseness, contrast, complexity, or
strength.
Radiomics create a model to predict clinical outcomes
based on extracted features. Not all features have to be used,
selection of features are done before modeling because lots
of them are correlated to each other or can be unstable across
a dataset. Clinical outcome which radiomics model can be
diagnosis (benign or malignant, subtype or stage), treatment
evaluation, or prognosis (survival coefficients)."
"Radiomics is increasingly utilized within clinical oncology settings. Describe several specific examples of how radiomic analysis, utilizing CT, MRI, or PET data, has been applied to aid in diagnosis and/or treatment evaluation across various cancer types.","Radiomics offers a powerful approach for analyzing complex imaging data to enhance diagnostic accuracy and personalize treatment strategies within oncology. Several key applications are emerging. Firstly, radiomic analysis of contrast-enhanced CT scans is routinely used to differentiate between human papillomavirus (HPV)-positive and HPV-negative oropharyngeal tumors – a critical distinction impacting treatment decisions [323]. Secondly, in prostate cancer, radiomics assists with predicting tumor aggressiveness based on imaging features [324], facilitating risk stratification. Furthermore, the technology aids in automated segmentation and precise sub-target volume definition during prostate cancer treatment planning [325]. Radiomic analysis is also being leveraged to predict treatment response and overall outcomes across a range of cancers including head and neck, lung, rectum, esophageal, and prostate cancers – often in combination with genomic data [326–328, 329, 330, 331]. Notably, radiomics is employed for predicting toxicity—specifically xerostomia in head and neck cancer patients [332] and pneumonitis in lung cancer patients [333]. Finally, it’s utilized to differentiate between recurrence and radiation-induced radionecrosis (RIR) in brain tumors [334], a significant challenge in neurooncology. It's important to acknowledge that while these pilot studies demonstrate promising predictive power, rigorous external validation across diverse datasets remains crucial due to methodological challenges related to imaging standardization.","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.16	 Radiomics, Data Science, and Artificial Intelligence in Radiation Oncology | Sub-subsection: 5.16.3	 Radiomics in Radiobiology and Clinical Oncology | Sub-sub-subsection: 5.16.3.4	 Clinical Applications | Content: These days there exist hundreds of papers which evaluate the
usefulness of radiomics in clinical practice mostly on CT
data, but MRI and PET are becoming more common.
Radiomics can be used in diagnosis as well as treatment
evaluation of different oncological diseases like brain tumors,
breast, lung-, prostate-, or colorectal cancer. Radiomics are
being applied in the field of oncology in different settings to
help decision-making such as:
•	Differentiation between human papillomavirus-positive
and
human
papillomavirus-negative
oropharyngeal
tumors on contrast-enhanced CT [323].
•	Prediction of tumor aggressiveness in prostate cancer
[324].
•	Assistance to automatic segmentation and sub-target vol­
ume definition in prostate cancer [325].
•	Prediction of treatment response and outcome in head and
neck and lung cancer (with combination of genomic fea­
tures) [326–328], rectum [329], esophageal [330], or
prostate cancer [331].
5 Clinical Radiobiology for Radiation Oncology
296
•	Prediction of toxicity in head and neck (xerostomia) [332]
and lung (pneumonitis) [333] cancers.
•	Differential diagnosis between recurrence and RT-induced
radionecrosis in brain [334].
Although promising, the predictive power sometimes evi­
denced in the pilot studies need to be externally validated in
independent datasets with numerous methodological pitfalls
including imaging technique standardization.
5.17"
"The ‘therapeutic window’ refers to the range of radiation doses that effectively destroys tumor cells while minimizing damage to surrounding normal tissues. Widening this window is crucial for successful cancer treatment. Several methods can be employed, including utilizing lower dose rates, which allows for greater repair and sparing of sensitive tissues; employing fractionation schemes like hypofractionation (delivering higher total doses over fewer fractions), which can accelerate cell death while potentially reducing side effects; and incorporating targeted radiation techniques such as brachytherapy or stereotactic body radiotherapy (SBRT) that deliver high doses directly to the tumor with precise control, minimizing exposure to adjacent healthy tissues. Furthermore, modulating oxygen levels within the tumor microenvironment through strategies like hyperfractionated cetuximab irradiation (HCI) can enhance radiosensitivity and expand the therapeutic window.","Reference: MolecularRadiationBiology, Section 5.17 – Exercises and Self-Assessment","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.17	 Exercises and Self-Assessment | Content: Q1.	What is meant by the “therapeutic window”? Mention
several methods to widen the therapeutic window.
Q2.	The tumor volume doubling time (VDT) is heteroge­
neous among tumors and influences RT response.
Discuss and reflect on different parameters that control
VDT of tumors.
Q3.	It is important to estimate the growth fraction (GF) of
tumors and several methods may be used in vitro and
in vivo to assess this. Give some examples of methods
and in what context they are applied.
Q4.	Discuss the link between the Hallmarks of
Radiobiology and the Hallmarks of Cancer.
Q5.	Which of the below statements is wrong?
(a)	Lowering the dose rate leads to greater sparing of
late responding normal tissues than of tumors.
(b)	The process of redistribution might push cells
from a radioresistant to a radiosensitive cell-cycle
phase.
(c)	During chronic low dose rate exposure, cells with
long repair half times will be spared relative to
their counterparts with rapid DNA damage repair.
(d)	Low dose rate irradiation can be considered as a
form of extreme fractionation.
Q6.	How can dose rate affect be explained in terms of
linear-­quadratic model?
Q7.	What are the classical factors that are used to predict
RT response in a tumor?
Q8.	List four techniques which are used to measure bio­
markers to predict RT response.
Q9.	Oxygen enhancement ratio (OER) is seen with some
but not all IR qualities. Please indicate which type
(a–d) that doesn’t have OER.
(a)	X-rays
(b)	Gamma-rays
(c)	Neutrons
(d)	α-particles
Q10.	All of the following statements about hypoxic cell
radiosensitizers are true except one, please indicate
and explain.
(a)	Increases radiosensitivity of hypoxic cells
(b)	Nitroimidazole groups of drugs are commonly
used
(c)	Presence of nitro group in second position,
decreases electron affinity and sensitization
(d)	Dose-limiting
toxicity
of
Misonidazole
is
neurotoxicity
Q11.	Give some examples how photon radiation can induce
modification extracellular signaling pathways.
Q12.	Two principal mechanisms of tumor metabolism par­
ticipate in radiation resistance. Give their names.
Q13.	What is radiation-induced abscopal effect in
oncology?
Q14.	Describe the typical acute and late effects following
exposure of the skin to radiation. Hints: target cells at
risk, latent period, volume effect, pathology,
recovery.
Q15.	Define and describe the late adverse effects of RT.
Q16.	Can radionecrosis be avoided by choosing a more
appropriate radiation modality?
Q17.	How can access to the forecasted 3D RT isodose
curves allow for a better prevention of osteoradione­
crosis of the mandible?
Q18.	What is the main function of the stem cells?
Q19.	What is the most radiosensitive group of stem cells?
Q20.	Describe some different characteristics of cancer stem
cells which may contribute to RT resistance?
Q21.	Describe potential role of the intestinal microbiota in
RT-induced adverse side effects (gut toxicity) or in RT
efficiency concerning anti-tumor effects.
5.18"
"Describe how photon radiation can induce modifications to extracellular signaling pathways within tumor cells, specifically focusing on mechanisms related to radiosensitivity.","Photon radiation’s impact on tumor cells involves several key changes in extracellular signaling pathways that contribute to their increased radiosensitivity. Primarily, irradiation activates major oncogenic signaling cascades such as the Ras, MAPK/ERK, and PI3K/AKT pathways. These pathways are frequently upregulated in cancer cells and promote cell survival. Specifically, phosphorylation of AKT within these pathways leads to decreased autophagy (a cellular self-eating process that removes damaged components) and apoptosis (programmed cell death), while simultaneously increasing DNA repair capacity – effectively shielding the cell from radiation damage. Furthermore, mutations in RAS, a common feature in many cancers, can exacerbate this resistance by maintaining constant signaling even under irradiation stress.  The EGFR cascade is also frequently activated, further contributing to survival signals. Reference: [MolecularRadiationBiology, Section 5.18 SQ11]","Document: MolecularRadiationBiology | Section: 5: Clinical Radiobiology for Radiation Oncology | Subsection: 5.18		 Exercise Solutions | Content: (a)	Increases radiosensitivity of hypoxic cells
(b)	Nitroimidazole groups of drugs are commonly
used
(c)	Presence of nitro group in second position,
decreases electron affinity and sensitization
(d)	Dose-limiting
toxicity
of
Misonidazole
is
neurotoxicity
Q11.	Give some examples how photon radiation can induce
modification extracellular signaling pathways.
Q12.	Two principal mechanisms of tumor metabolism par­
ticipate in radiation resistance. Give their names.
Q13.	What is radiation-induced abscopal effect in
oncology?
Q14.	Describe the typical acute and late effects following
exposure of the skin to radiation. Hints: target cells at
risk, latent period, volume effect, pathology,
recovery.
Q15.	Define and describe the late adverse effects of RT.
Q16.	Can radionecrosis be avoided by choosing a more
appropriate radiation modality?
Q17.	How can access to the forecasted 3D RT isodose
curves allow for a better prevention of osteoradione­
crosis of the mandible?
Q18.	What is the main function of the stem cells?
Q19.	What is the most radiosensitive group of stem cells?
Q20.	Describe some different characteristics of cancer stem
cells which may contribute to RT resistance?
Q21.	Describe potential role of the intestinal microbiota in
RT-induced adverse side effects (gut toxicity) or in RT
efficiency concerning anti-tumor effects.
5.18
Exercise Solutions
SQ1.	Therapeutic window: The difference between tumor
control probability and normal tissue complication
probability at identical irradiation dose. Methods to
widen the therapeutic window: Dose fractionation,
reduction of the normal tissue/organ at risk exposed
volume, combination therapy.
SQ2.	VDT is influenced by localization of the tumor, i.e.,
tumor site. It is also influenced if the tumor is a pri­
mary or a metastatic lesion where the latter often
have reduced VDT as a result of limited nutrition and
oxygen levels. VDT is also influenced by histology of
the tumor, i.e., the inherited growth capacity of the
cells. Finally, VDT is influenced by tumor heteroge­
neity in proliferative signaling cascades which is a
consequence of different genomic- and signaling
make ups of the individual tumors.
SQ3.	In vitro tumor cell progression through S-phase can
be monitored by BrdUrd or IdUrd-labeling of cells.
These tracers are incorporated into DNA as tumor
pass through S-phase and by using an antibody
P. Sminia et al.
297
against BrdUrd or IdUrd, cells in S-phase can be
determined using flowcytometry. Another method
utilizes 3H-thymidine to assess DNA-synthesis by
flow cytometry. The third method is based on PET-­
analyses of tumors in vivo which have been pulsed
with
radio-labeled
18F-fluoro-3′-deoxy-3′-l-­
fluorothymidine (FLT). FLT is phosphorylated by
Thymidine Kinase 1 which has an S-phase activity.
Hence, FLT tracer levels are a surrogate for S-phase
cells which can be evaluated by PET scanning.
Finally, the proliferation rate in a tumor biopsy can
be analyzed by immunohistochemical staining for
the nuclear Ki-67 antigen, reflecting S-phase propor­
tion of cells.
SQ4.	Likely links are shown below.
Hallmark of
radiobiology
Hallmark of cancer
Repair
Genomic instability and mutations,
enabling replicative immortality
Redistribution
Sustaining proliferative signaling
Repopulation
Evading growth suppressors, sustaining
proliferative signaling, tumor-promoting
activation
Radiosensitivity
Resisting cell death, deregulating cellular
energetics
Reoxygenation
Inducing angiogenesis
Reactivation of the
immune response
Avoiding immune destruction, tumor-­
promoting activation, activation invasion
and metastasis
SQ5.	Alternative (c) is the wrong answer. Accumulation of
DNA damage is larger in cells with long repair half
times than for cells which show rapid repair of their
DNA damages.
SQ6.	Single-track and double-track actions can both
induce DNA double strand breaks. There is no cor­
relation between dose rate and single-track X-ray
lesion (αcontribution in the LQ model). In a double-­
track action, different X-ray photon tracks produce
the two interactions of single strand DNA lesions,
and therefore the formation of double strand lesions
is proportional to the radiation dose squared (β in the
LQ model).
SQ7.	Tumor oxygen status, the degree of repopulation or
proliferation rate and intrinsic radiosensitivity.
SQ8.	Proteomics, genomics, epigenomics, genomics, or
transcriptomics, used for measuring proteins, DNA/
chromatin, DNA, or RNA and transcription,
respectively.
SQ9.	Alternative (d). OER is 1 for high LET radiation like
α- particles.
SQ10.	Alternative (c). The presence of the nitro group in
second position, increases electron affinity and
radiosensitization.
SQ11.	Photon beam activates major oncogenic signaling
pathways such as Ras, MAPK/ERK, and PI3K/AKT
in part via the epidermal growth factor receptor
(EGFR) cascade. Radiation resistance is associated
with these signaling cascades due to their pro-­
survival nature. For example, when AKT is phos­
phorylated, tumor cells are protected by decreased
autophagy and apoptosis, as well as increased DNA
repair capacity. Mutated RAS has also been associ­
ated with resistance to photons in cancer cells.
SQ12.	The mitochondrial and or glucose metabolism,
respectively.
SQ13.	Abscopal effects are radiation-induced systemic anti-­
tumor immune responses in which irradiation of a
primary tumor or large metastasis causes remission
of distant, non-irradiated lesions.
SQ14.	Acute effects: Dry skin (impairment of cell produc­
tion), epilation (injury to hair follicles), erythema
(vascular leakage). Latency time: Few weeks. Large
volume effect: The smaller the volume, the higher the
tolerance to radiation. Transient effect: Reversible
injury. Late effects: Gangrene, ulcer, telangiectasia
(vascular damage), fibrosis (increase in collagen
fibers). Latency: Months-years. Large volume effect:
The smaller the volume, the higher the tolerance to
radiation. Chronic, irreversible injury.
SQ15.	Late effects of radiation are progressive, irreversible
and occur months, years, or decades after radiation
therapy. They are based on an interactive response of
parenchymal cells, vascular endothelium and fibro­
blasts, with a contribution from immune cells, espe­
cially macrophages. Tissues and organs are affected
by atrophy, fibrosis, or necrosis, which can severely
impair their functions and lead to a loss of function.
SQ16.	No. Since the risk of radionecrosis remains life-long
the affected tissues are at danger with the total radia­
tion dose being the primary risk factor for the tissue
involved, combined with other risk factors.
SQ17.	Adapting the preventive extraction of teeth to the risk
zone of >50–60 Gy would allow for a more appropri­
ate dental management: more aggressive in
the >60 Gy zone and far less aggressive in the other
areas of the jaw, improving the quality of life of these
patients. The fewer extractions in highly irradiated
areas, the lesser the risk for ORN.
SQ18.	The principal function of stem cells is to maintain
tissue homeostasis including continuous regenera­
tion and associated constant number of cells.
SQ19.	Bone marrow stem cells.
5.29
5 Clinical Radiobiology for Radiation Oncology
298
Increased signaling networks that block IR-induced
cell death including deficient pro-apoptotic signaling
and increased anti-apoptotic signaling; (3) CSCs
have slow proliferation and may therefore not be so
sensitivity to IR-induced DNA damage.
SQ21.	Studies showed evidence of the existence of bidirec­
tional effects of RT on the tumor and on the intestinal
microbiota. In prospective clinical studies, a reduc­
tion of the fecal microbial diversity during and after
pelvic RT was measured in patients suffering from
intestinal complications. Also, RT-induced modifica­
tion of microbiota diversity and composition can
modify the host immune response and in turn the
effectiveness of the anticancer treatment themselves
including RT."
"Explain how ionizing radiation interacts with cells, specifically detailing the mechanisms by which it damages DNA and why dose distribution differs between electron beams, photon beams, and particle beams like protons or carbon ions.","Ionizing radiation (IR), such as that used in radiotherapy, exerts its damaging effects on biological matter – primarily cells – through a process of ionization. When IR interacts with atoms and molecules within the cell, it transfers energy, causing electrons to be ejected from their orbits. This removal of electrons creates ions, disrupting the chemical bonds holding molecules together. Critically, if these ionizations occur within the cell nucleus, they directly damage DNA, the genetic blueprint of the cell. The precise mechanism involves creating single-strand or double-strand breaks in the DNA molecule, altering its structure and function. 

The dose distribution varies significantly depending on the type of radiation used. Electron beams deliver most of their energy immediately after interaction with tissue, making them suitable for treating tumors close to the skin. Higher energy electrons shift the dose peak deeper into tissue but also increase the range and potential for damage to surrounding normal tissues. Photon beams, conversely, exhibit a build-up region where the dose increases until reaching a maximum depth (typically several μm for kV beams or mm/cm for MV beams), followed by a gradual decrease. 

Particle beams like protons or carbon ions demonstrate a fundamentally different behavior. These particles deliver a low initial dose upon entry into tissue, with the transfer of energy gradually increasing as the particle slows down and loses energy over depth – this is known as the Bragg curve. This results in a highly localized dose concentration just before the particle stops within the tumor, minimizing damage to tissues beyond the target. To broaden the treatment range, techniques like spread-out Bragg peaks (SOBPs) are employed, varying the energy of the incident beam to create a more uniform dose distribution.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.1	 Physics | Content: Radiotherapy (RT) relies on the effect of ionizing radiation
(IR) to biological matter, i.e., cells. The radiation is transfer­
ring its energy to atoms and molecules present in the cells,
which lie in the path of the radiation, and therefore ionizing
them. These ionizations, i.e., the removal of electrons from
the atom, lead to the breaking of chemical bonds in the mol­
ecules. If these ionizations occur in the cell nucleus, the
DNA, carrier of the human genome, is damaged. In RT, the
capability of radiation to damage the genome is exploited to
kill tumor cells. The most important quantity to define the
damage, which is caused, is the dose
(6.1)
­
6.1
Electron radiation transfers most of its energy just after it
interacts with matter, i.e., tissue, making it suitable for the
treatment of tumors close to the skin. If one uses electrons
with higher energy, such as the shown 250 MeV electrons,
the dose peak can be shifted deeper into the tissue. However,
this comes with the disadvantage that the maximum range is
also longer, resulting in more dose to the normal tissue
beyond the tumor. Furthermore, such electron beams are
quite complicated to produce. For photon beams used in RT,
the dose increases in the so-called build-up region until it
reaches the maximal dose and then gradually decreases. The
depth of the maximal dose can be a few μm (for kV beams,
i.e., beams with particle energy in the kilovolt regime) or
several mm or cm (for MV (megavolt) beams). In contrast to
electrons and photons, particles such as protons or high lin­
ear energy transfer (LET) carbon ions show a totally differ­
ent dose distribution depth. The ions deliver a low dose when
entering tissue. With depth this transfer is slowly increasing,
while the ion gets slower. With further energy loss and
decreasing speed, the dose drastically increases and reaches
a maximum just before the ion stops in the tissue. This
unique dose distribution is called the Bragg curve in honor to
the physicist William Henry Bragg, who discovered this
behavior in 1904 [1]. To widen the treatment depth range, a
spread-out Bragg peak (SOBP) is created by varying the
energy of the incident proton beam. As a result, a uniform
dose can be delivered to the tumor. The radiobiological
impact of particles with high LET is higher compared to
photons, and it increases dramatically in the distal edge and
fall-off. The uncertainty in relative biological effectiveness
(RBE) of ion beams is still a limitation in its clinical applica­
tion and should be considered during the treatment planning
as a part of the process leading to a robust treatment plan. A
detailed description about the physical and biological inter­
actions of radiation to biological matter and the conse­
quences for the biological effect can be found in Chaps. 2
and 3.
6.2
Conventional and Alternative
Radiation Schemes"
"Describe the rationale behind using conventionally fractionated radiation therapy, including the typical dose per fraction and overall treatment duration, and explain how this approach relates to the biological effects of radiation on cancer cells.","Conventionally fractionated radiotherapy employs a strategy designed to maximize tumor cell damage while minimizing harm to surrounding normal tissues. This is achieved by delivering radiation in smaller doses – typically 2 Gy per fraction – administered over multiple fractions, often five times per week, for a duration of 3-7 weeks. The rationale stems from several key biological principles observed during irradiation. Firstly, cells exhibit a limited ability to repair DNA damage effectively after each exposure. By spacing out the radiation into smaller fractions, the cell has more opportunities to attempt DNA repair before receiving another damaging dose. Secondly, this fractionation allows for the accumulation of sublethal DNA damage over time. This chronic damage can ultimately lead to apoptosis (programmed cell death) or other forms of cellular dysfunction in cancer cells. Thirdly, conventional fractionation provides a window for radiosensitizers and chemotherapy agents to enhance the cytotoxic effects of radiation. The intermittent exposure allows these drugs to accumulate within tumor cells before being activated by radiation. Furthermore, the longer treatment duration facilitates more complete eradication of the tumor mass. However, it’s important to note that this approach is predicated on the assumption that cancer cells are sensitive to this type of damage accumulation; resistance mechanisms can develop over time, potentially necessitating adjustments to the fractionation scheme. ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.2	 Conventional and Alternative Radiation Schemes | Content: detailed description about the physical and biological inter­
actions of radiation to biological matter and the conse­
quences for the biological effect can be found in Chaps. 2
and 3.
6.2
Conventional and Alternative
Radiation Schemes
Box 6.1 Conventional and Alternative Radiation
Schemes
•	Typical conventionally fractionated irradiation
schemes use 2 Gy fractions, 5 fractions per week
for 3–7 weeks, depending on the tumor type.
•	Alternative radiation schemes, i.e., either smaller or
larger sized fractions, multiple fractions per day, or
different overall treatment time should be based on
the various biological processes and response char­
acteristics of both the normal and malignant tissues
in the exposed volume.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
314
Table 6.1 Characteristics of radiotherapy treatment regimen and involved radiobiological processes. (Reproduced with permission from [2])
Radiation treatment
regimen
Conventional fractionation"
"Describe the key principles behind hyperfractionated radiotherapy and explain how it aims to maximize tumor control while minimizing normal tissue damage, referencing relevant biological considerations.","Hyperfractionation is a radiation therapy technique designed to enhance tumor cell killing by delivering multiple, smaller doses of radiation over an extended period. The fundamental rationale stems from the understanding that DNA repair mechanisms within cells vary significantly between tumor and normal tissues. Tumor cells often exhibit faster repair kinetics compared to surrounding healthy tissue. By administering several low-dose fractions separated by relatively short intervals (typically 4-6 hours), hyperfractionation aims to overwhelm the tumor’s ability to fully repair DNA damage after each fraction, leading to cumulative damage and ultimately cell death. This approach leverages the ‘6 Rs’ of radiobiology – specifically Redistribution and Reoxygenation – as the shorter intervals promote a more pronounced redistribution of radiation within the tumor volume, concentrating it on actively dividing cells. Furthermore, the frequent doses contribute to increased reoxygenation within the tumor microenvironment, which is known to sensitize cancer cells to radiation. However, careful consideration must be given to the time interval between fractions; longer intervals may allow for complete repair in normal tissues, potentially increasing late-occurring side effects due to prolonged exposure. The goal is a delicate balance between maximizing tumor control and minimizing damage to surrounding healthy tissue. 

Reference: [MolecularRadiationBiology], Section 6.2.1 – Hyperfractionation","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.2	 Conventional and Alternative Radiation Schemes | Sub-subsection: 6.2.1	 Hyperfractionation | Content: Accelerated
fractionation
Hypofractionation
SBRT and SRS
Total dose (Gy)
70
≥70
<70
<70
<30
Fraction size (Gy)
1.8–2
<1.8
≥2
Mostly 2.5–10
Mostly ~12–25
Number of
fractions per day
1
2–3
1
1
1
Treatment (days per
week)
5
5
6
≤5
1 or a few
Overall treatment
time (weeks)
7
7
Up to ~5
Up to ~5
–
Radiobiological
reasoning—note
the 6 Rs of
Radiobiology
Normal tissue sparing via
Repair and Repopulation.
Tumor control via
Redistribution and
Reoxygenation.
Reactivation of the
immune response.
Exploitation of differences in
Radiosensitivity and Repair
and—kinetics between normal
and tumor cells. Reactivation
of the immune response.
Overcoming tumor
cell Repopulation.
Reactivation of the
immune response.
Overcoming tumor
cell Repopulation.
Overcoming
tumor cell
Repopulation.
3
reaching a total dose of 30–70 Gy. However, considering
the radiation sensitivity and volume of the particular
tumor type to be irradiated, as well as that of the normal
tissue or organs at risk (OAR), an alternative irradiation
regimen might be preferred. The use of an alternative
radiation scheme should be motivated, either technically,
e.g., by minimizing the volume of the normal tissue in the
radiation field by using precision RT or on the basis of the
biological characteristics of the malignant tissue, i.e., the
6R’s (see Chap. 5). Apart from technical and radiobiologi­
cal arguments, department logistics as well as patients’
condition or patients’ comfort might justify the choice of
an alternative radiation treatment (Box 6.1). Typical char­
acteristics of fractionation regimens and their radiobio­
logical rationale are presented in Table 6.1 and discussed
below.
6.2
6.2.1
Hyperfractionation
The biological rationale of hyperfractionation is the advan­
tage of application of multiple small-sized fractions com­
pared with conventional 2 Gy fractions to further spare the
normal tissues relative to the malignant tissues. Because of
the higher total dose, hyperfractionation could increase the
tumor control probability. To limit the duration of the overall
treatment time, generally 2–3 fractions per day, typically
~1.4 Gy, separated 4–6 h between the fractions are given.
Some hyperfractionation clinical trials, however, showed an
increase in late normal tissue side effects, which has been
ascribed to the short time interval between fractions for
­complete repair of sublethal DNA damages, since late-
responding tissues do have long repair half times in the order
of 2–4 h. Additionally, hyperfractionation puts a heavy logis­
tical burden on the RT department and the patient, especially
in children who may need anesthesia.
6.2.2"
"Describe the rationale behind hypofractionation and accelerated fractionation in radiation therapy, including considerations regarding tumor cell proliferation, repair mechanisms, and technological advancements.","Hypofractionation and accelerated fractionation strategies aim to reduce overall treatment time in radiation therapy by delivering higher total doses of radiation within a shorter period. The core rationale stems from recognizing that tumor cells exhibit differential radiosensitivity and repair kinetics compared to normal tissues. Tumor cells, particularly those with limited proliferative capacity, can tolerate higher dose fractions than normal tissues which have longer DNA repair half-times. Accelerated fractionation involves increasing the number of treatment fractions per day or week, often delivering multiple 1.5-2 Gy fractions during a single day or across several days, while hypofractionation utilizes larger individual fraction sizes (e.g., >2 Gy) with fewer overall fractions. Technological advancements like precision radiation techniques and advanced imaging modalities have made these approaches feasible by allowing for more accurate dose distribution and minimizing damage to surrounding normal tissues. Furthermore, the ability to anticipate tumor cell repopulation during treatment is a key factor, as rapid delivery of high doses can disrupt this process effectively. However, it’s important to note that careful monitoring is required due to potential late effects related to incomplete repair in some tissues.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.2	 Conventional and Alternative Radiation Schemes | Sub-subsection: 6.2.2	 Hypofractionation and Accelerated Fractionation | Content: Redistribution and
Reoxygenation.
Reactivation of the
immune response.
Exploitation of differences in
Radiosensitivity and Repair
and—kinetics between normal
and tumor cells. Reactivation
of the immune response.
Overcoming tumor
cell Repopulation.
Reactivation of the
immune response.
Overcoming tumor
cell Repopulation.
Overcoming
tumor cell
Repopulation.
3
reaching a total dose of 30–70 Gy. However, considering
the radiation sensitivity and volume of the particular
tumor type to be irradiated, as well as that of the normal
tissue or organs at risk (OAR), an alternative irradiation
regimen might be preferred. The use of an alternative
radiation scheme should be motivated, either technically,
e.g., by minimizing the volume of the normal tissue in the
radiation field by using precision RT or on the basis of the
biological characteristics of the malignant tissue, i.e., the
6R’s (see Chap. 5). Apart from technical and radiobiologi­
cal arguments, department logistics as well as patients’
condition or patients’ comfort might justify the choice of
an alternative radiation treatment (Box 6.1). Typical char­
acteristics of fractionation regimens and their radiobio­
logical rationale are presented in Table 6.1 and discussed
below.
6.2
6.2.1
Hyperfractionation
The biological rationale of hyperfractionation is the advan­
tage of application of multiple small-sized fractions com­
pared with conventional 2 Gy fractions to further spare the
normal tissues relative to the malignant tissues. Because of
the higher total dose, hyperfractionation could increase the
tumor control probability. To limit the duration of the overall
treatment time, generally 2–3 fractions per day, typically
~1.4 Gy, separated 4–6 h between the fractions are given.
Some hyperfractionation clinical trials, however, showed an
increase in late normal tissue side effects, which has been
ascribed to the short time interval between fractions for
­complete repair of sublethal DNA damages, since late-
responding tissues do have long repair half times in the order
of 2–4 h. Additionally, hyperfractionation puts a heavy logis­
tical burden on the RT department and the patient, especially
in children who may need anesthesia.
6.2.2
Hypofractionation and Accelerated
Fractionation
The rationale of both hypo- and accelerated fractionation
strategies can be found in shortening the overall treatment
time to anticipate tumor cell proliferation/repopulation.
Generally, fractions larger than 2 Gy fractions are applied
with few fractions per week, allowing to shorten the overall
treatment duration with a few weeks versus conventional
regimens. The hypofractionation approach has become fea­
sible because of currently available precision radiation tech­
niques and technology, with optimized radiation dose
distribution.
The drawback of using high fraction sizes, the rationale,
pro- and contra biological arguments, is discussed in the next
Sect. 6.3.
V. Ahire et al.
315
The term accelerated fractionation applies to the use of
multiple fractions per day, or increasing the number of treat­
ment days per week (e.g., continue radiation during the
weekend) to deliver a higher average total radiation dose
than conventionally used. Hence, the overall treatment time
of accelerated regimen is reduced. Often, both hypo- and
hyperfractionated irradiation fit in this definition of acceler­
ated fractionation. A typical example is the Continuous
Hyperfractionated Accelerated RadioTherapy (CHART)
treatment scheme, with 36 fractions of 1.5 Gy, total dose of
54 Gy in 12 days. In that scheme three fractions of 1.5 Gy
were applied per day, with an interfraction time interval of
6 h, for 12 days, including the weekend. Details regarding
the CHART clinical trials and outcomes are available in the
literature. In particular, head and neck cancer patients with
high epidermal growth factor receptor (EGFR) expressing
tumors benefited from CHART [4].
6.2.3
Stereotactic Radiotherapy:
Radiosurgery
Historically, the term stereotactic radiotherapy was used for
a type of external RT of the brain that uses dedicated equip­
ment being a stereotactic frame fixed to the head with screws
just penetrating the outer part of the skull. This frame was
used to immobilize the head, position the patient, and create
a stereotactic “space” with a coordinate system that allows
target definition in an X-, Y-, and Z-axis. The term stereotac­
tic radiosurgery (SRS) is used when a single fraction of ste­
reotactically guided conformal irradiation is delivered to a
coordinate-defined target. More modern fixation systems no
longer require the placement of an invasive frame, but make
use of advanced thermoplastic masks combined with posi­
tion verification and adaptation systems of the treatment
machine’s table. Different delivery systems can be used for
radiosurgery: the originally SRS-dedicated GammaKnife
system (using 201 small 60-Co sources) or linac-based sys­
tems (linear accelerator, CyberKnife, Tomotherapy).
Typical indications are single (or up to 3–5) brain metas­
tases, meningiomas, acoustic neuromas, or arteriovenous
malformations, all smaller than 3 cm in diameter. Depending
on the indication, doses range between 12 Gy (benign
lesions) and 20–25 Gy (metastases). Some centers also use
radiosurgery to treat benign conditions like epilepsy and tri­
geminal neuralgia, requiring doses of 20–25 Gy up to
60–80 Gy, respectively.
The appearance of the effect of radiosurgery usually takes
several months and may be accompanied by an inflammatory
reaction that mimics tumor growth in the first 1–3 years. In
some cases, overt brain radionecrosis may develop, requiring
treatment with steroids or rarely the need for surgical removal
of the affected area (see also Chap. 5) (Box 6.2).
6.3
Radiobiological Aspects
of Hypofractionation
Fractionated RT, using multiple small-sized fractions of
1.8–2 Gy, is the standard treatment of cancer patients. Over
many decades, large evidence has been obtained from
experimental studies in vitro or in vivo and later in clinical
studies regarding the biological rationale of fractionated
irradiation. Abundant evidence exists on the differential
effect of fractionation between late-responding normal tis­
sues and early responding normal tissues or tumors. Most
normal tissues and organs benefit from fractionated RT,
meaning that they can tolerate a higher total dose, while
tumors are only slightly spared by dose fractionation. The
smaller the fraction size—taking the overall treatment time
allowing tumor cell repopulation into account—the wider
the therapeutic window. Having learned that fractionation is
a great method to spare normal tissues while keeping tumor
control equal, hypofractionation, i.e., the use of dose frac­
tions substantially larger than conventional 2 Gy fractions
(see also Chap. 5) sounds not as a good idea. However, for
two main reasons, hypofractionation has gained importance
in radiation oncology: α
­
­
­
­
­
Box 6.2 Hypofractionation
•	Hypofractionation is the use of radiation dose frac­
tions considerably larger than the conventional frac­
tion size of 2 Gy.
•	Hypofractionation could be beneficial over conven­
tional fractionation because of precision RT
together with specific biological phenomena such
as hypoxia and sensitivity to dose fractionation of
both the tumor target volume and organs at risk.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"Explain the concept of hypofractionation in radiation oncology, detailing why it has become increasingly relevant despite initial concerns and highlighting key biological factors that contribute to its potential benefits.","Hypofractionation refers to the administration of a total radiation dose over fewer fractions than traditionally employed in conventional radiotherapy. Specifically, this involves utilizing dose fractions significantly larger than the standard 2 Gy fraction – often ranging from 3 to 5 Gy or even higher depending on the specific protocol and patient characteristics. The initial hesitation surrounding hypofractionation stemmed from concerns that delivering a greater dose per fraction would inevitably lead to increased normal tissue toxicity due to limited repair mechanisms. However, several factors have driven its resurgence in radiation oncology. Firstly, advancements in stereotactic radiotherapy (SRT) – also known as radiosurgery – allow for highly precise targeting of tumors with minimal exposure to surrounding tissues. Secondly, biological phenomena such as hypoxia within the tumor microenvironment and increased sensitivity to dose fractionation itself play a crucial role. Hypoxic regions are less effectively repaired by radiation damage, making them more vulnerable to higher doses. Furthermore, tumor cells themselves exhibit varying sensitivities to fractionation; some rapidly repopulate after each fraction, creating a ‘window’ for effective treatment while minimizing the time available for normal tissue repair. This combination of factors – precise targeting and inherent biological vulnerabilities – creates a wider therapeutic window with hypofractionation, allowing for potentially higher total doses to be delivered while maintaining tumor control and minimizing damage to adjacent tissues. Reference: MolecularRadiationBiology, Section 6.3 – Radiobiological Aspects of Hypofractionation","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.2	 Conventional and Alternative Radiation Schemes | Sub-subsection: 6.2.3	 Stereotactic Radiotherapy: Radiosurgery | Content: treatment with steroids or rarely the need for surgical removal
of the affected area (see also Chap. 5) (Box 6.2).
6.3
Radiobiological Aspects
of Hypofractionation
Fractionated RT, using multiple small-sized fractions of
1.8–2 Gy, is the standard treatment of cancer patients. Over
many decades, large evidence has been obtained from
experimental studies in vitro or in vivo and later in clinical
studies regarding the biological rationale of fractionated
irradiation. Abundant evidence exists on the differential
effect of fractionation between late-responding normal tis­
sues and early responding normal tissues or tumors. Most
normal tissues and organs benefit from fractionated RT,
meaning that they can tolerate a higher total dose, while
tumors are only slightly spared by dose fractionation. The
smaller the fraction size—taking the overall treatment time
allowing tumor cell repopulation into account—the wider
the therapeutic window. Having learned that fractionation is
a great method to spare normal tissues while keeping tumor
control equal, hypofractionation, i.e., the use of dose frac­
tions substantially larger than conventional 2 Gy fractions
(see also Chap. 5) sounds not as a good idea. However, for
two main reasons, hypofractionation has gained importance
in radiation oncology: α
­
­
­
­
­
Box 6.2 Hypofractionation
•	Hypofractionation is the use of radiation dose frac­
tions considerably larger than the conventional frac­
tion size of 2 Gy.
•	Hypofractionation could be beneficial over conven­
tional fractionation because of precision RT
together with specific biological phenomena such
as hypoxia and sensitivity to dose fractionation of
both the tumor target volume and organs at risk.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"Explain the rationale behind hypofractionated radiation therapy as described in this text, focusing on how it differs from conventional fractionation and the key biological factors influencing its potential success.","Hypofractionated radiation therapy utilizes significantly larger dose fractions (substantially greater than the standard 2 Gy) compared to conventional fractionation. This approach is gaining importance primarily due to two main reasons: first, it allows for precise radiation delivery when combined with techniques like high-conformity radiotherapy and second, it leverages biological phenomena such as hypoxia and sensitivity to dose fractionation. The core principle relies on the observation that normal tissues generally tolerate higher total doses over shorter periods than they do when exposed to smaller fractions over a longer duration. This is partly due to the ability of normal tissues to repair DNA damage more effectively with each fraction. Furthermore, the text highlights the importance of tumor cell repopulation – rapid proliferation within the tumor can be mitigated by using high-dose fractions to reduce the overall treatment time and limit the opportunity for cells to recover between treatments. Critically, this approach also considers hypoxia; while hypoxic conditions generally confer resistance to radiation, reoxygenation between fractions can increase sensitivity, and direct vascular injury from high doses may contribute to cell kill in hypoxic tumors. The text emphasizes that a strong correlation exists between treatment outcome and the Biologically Effective Dose (BED) as determined by the Linear Quadratic (LQ) model, particularly when considering factors like fraction size and overall treatment duration. Reference: [MolecularRadiationBiology, Section 6.3] ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Content: treatment with steroids or rarely the need for surgical removal
of the affected area (see also Chap. 5) (Box 6.2).
6.3
Radiobiological Aspects
of Hypofractionation
Fractionated RT, using multiple small-sized fractions of
1.8–2 Gy, is the standard treatment of cancer patients. Over
many decades, large evidence has been obtained from
experimental studies in vitro or in vivo and later in clinical
studies regarding the biological rationale of fractionated
irradiation. Abundant evidence exists on the differential
effect of fractionation between late-responding normal tis­
sues and early responding normal tissues or tumors. Most
normal tissues and organs benefit from fractionated RT,
meaning that they can tolerate a higher total dose, while
tumors are only slightly spared by dose fractionation. The
smaller the fraction size—taking the overall treatment time
allowing tumor cell repopulation into account—the wider
the therapeutic window. Having learned that fractionation is
a great method to spare normal tissues while keeping tumor
control equal, hypofractionation, i.e., the use of dose frac­
tions substantially larger than conventional 2 Gy fractions
(see also Chap. 5) sounds not as a good idea. However, for
two main reasons, hypofractionation has gained importance
in radiation oncology: α
­
­
­
­
­
Box 6.2 Hypofractionation
•	Hypofractionation is the use of radiation dose frac­
tions considerably larger than the conventional frac­
tion size of 2 Gy.
•	Hypofractionation could be beneficial over conven­
tional fractionation because of precision RT
together with specific biological phenomena such
as hypoxia and sensitivity to dose fractionation of
both the tumor target volume and organs at risk.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
316
Table 6.2 Hypofractionation: pro and contra biological arguments
Pros
• If α/β ratio tumor < α/β ratio normal tissue
• Only if small normal tissue/OAR volumes are exposed: high
conformity RT
• Direct vascular injury
• Shorter overall time: beneficial in case of rapid proliferating
tumors
• If the onset of accelerated tumor cell repopulation is faster using
high-dose fractions, dose reduction without loss of tumor control
could be achieved while diminishing late toxicity
• ”Biological dose” escalation, which might result in better tumor
control
• Activation of the immune response to attack tumor cells inside
the irradiated volume and at distance, the abscopal effect
• Lower probability of induction of secondary tumors
Cons
• Mostly, α/β ratio tumor > α/β ratio normal tissue
• High-dose fractions are detrimental for normal tissues: higher
probability of normal tissue complications, unless dose gradients
are steep and the irradiated volume small
• No benefit from sensitization of hypoxic tumor cells via
reoxygenation between fractions
• Radiosensitizing agents are potentially less effective when
combined with high-dose fractions
ume, and outcome estimates for both normal tissue complication
probability and tumor control [5] for SRS and SBRT, where
single high radiation doses are common practice. Under certain
conditions, like high conformity of RT with steep dose gradi­
ents toward the surrounding normal tissues, hypofractionation
could be beneficial over conventional fractionation. In this sec­
tion, the radiobiological pro- and contra arguments of hypo­
fractionation, listed in Table 6.2 are discussed.
6.3.1
Hypofractionation and the Linear
Quadratic (LQ) Model
The validity of the LQ model at high fraction sizes above
approximately 6 Gy is questionable, and alternative radiobi­
ological models are proposed. However, a strong pro-­
argument was derived from clinical data from non-small cell
lung cancer patients treated with SBRT, either with a single
dose or hypofractionated with 3–8 fractions. From the study
[6], it was evident that the clinically observed increase in
tumor could be ascribed to radiation dose escalation, i.e., an
increased Biologically Effective Dose (BED) according to
the LQ equation. BED values were calculated for the various
hypofractionation schemes including SBRT fraction sizes of
22 Gy. No adaptation or correction was made when using the
conventional LQ model. The analysis showed a clear
­correlation between treatment outcome and the BED, even at
extreme high BED values. Hence, there is still a discrepancy
between theoretical and experimental validity of the LQ
model. However, since the model describes the clinical data
on tumor control over a wide range of dose, fraction sizes,
and treatment durations [6], it might still be valid in predict­
ing RT outcomes in certain conditions.
6.3.2
Hypofractionation, Hypoxia,
and Reoxygenation
Hypoxia is a state of reduced oxygen availability or decreased
oxygen partial pressure below a critical threshold (generally
at pO2 of 2.5 or 5 mmHg). The Oxygen Enhancement Ratio
(OER) is around 3 for most cells: for sterilization of hypoxic
cells, a three times higher irradiation dose is required than
for normoxic cells. Hence, hypoxia can cause resistance to
RT, which has been observed in many tumor types.
Information about the role of oxygen in RT, the OER, and
related radiation sensitivity is given in Chap. 5.
In fractionated RT, during the time interval between daily
applied irradiation fractions and during the full course of RT,
hypoxic cells can be re-oxygenated and become more sensi­
tive to the next irradiation dose (see Chap. 5). If reoxygenation
is efficient between dose fractions, the presence of hypoxic
cells does not have a significant effect on the outcome of a
multi-fractionation scheme. In a hypofractionation regimen,
the time period to obtain full reoxygenation of hypoxic tumor
cells might be too short. Animal data on the kinetics of reoxy­
genation of different tumor types demonstrated that full reoxy­
genation takes about 72 h [7]. Also, preclinical data and
radiobiological modeling studies have demonstrated that
tumor hypoxia is a greater detrimental factor for single dose
treatments than for repeated conventional fraction sizes. To
fully exploit reoxygenation between fractions, 6–8 fractions
might be optimal, separated in a time frame of 72 h [7].
However, there are also advantages to large high-dose frac­
tions of ~10 Gy. Relatively radioresistant hypoxic cells might
be directly sterilized and vascular endothelial cells might be
injured. Since one endothelial cell is subtending about 2000
tumor cells, direct vascular damage might largely contribute to
tumor cell kill in hypofractionated RT [8].
6.3.3
Hypofractionation and Tumor Cell
Repopulation
Tumor cell repopulation refers to an increase in the number of
cells as a result of proliferation of surviving clonogenic tumor
cells (see Chap. 5). Accelerated repopulation of tumor cells
during the course of RT is starting after a lag period of
~4 weeks. One strategy discussed here is to cope with tumor
cell repopulation by limiting the overall treatment time for
fast repopulating tumors using a small number of higher sized
fractions. As a consequence of high fraction sizes, the total
irradiation dose should be reduced to overcome an increase in
V. Ahire et al."
"Describe the relationship between hypoxia and radiation sensitivity within tumor cells, including the concept of the Oxygen Enhancement Ratio (OER) and how reoxygenation impacts treatment outcomes.","Hypoxia significantly influences a tumor’s response to radiation therapy. Hypoxic conditions, characterized by low oxygen partial pressures typically below 2.5 or 5 mmHg, dramatically reduce cellular sensitivity to ionizing radiation. This resistance stems from several factors; most notably, the Oxygen Enhancement Ratio (OER). The OER represents the increased dose of radiation required to sterilize a hypoxic cell compared to a normoxic cell – it’s generally around 3. This heightened sensitivity is due to the fact that oxygen plays a crucial role in DNA repair mechanisms within cells. In the absence of sufficient oxygen, these repair pathways are impaired, making cells more vulnerable to radiation-induced damage. Importantly, reoxygenation can dramatically alter this dynamic. During the intervals between daily radiation fractions, hypoxic tumor cells can be re-oxygenated, thereby increasing their sensitivity to subsequent irradiation doses. Animal studies have shown that full reoxygenation takes approximately 72 hours. Therefore, if efficient reoxygenation occurs between dose fractions, hypoxia does not significantly impede treatment success in multi-fraction schemes. However, in hypofractionated regimens – where the time for complete reoxygenation is limited – hypoxic cells remain resistant, potentially diminishing the overall effectiveness of the therapy. Strategic fractionation schedules incorporating longer intervals (e.g., 6-8 fractions spaced 72 hours apart) can maximize reoxygenation and improve treatment outcomes. Furthermore, direct vascular damage caused by radiation on hypoxic tumor cells, particularly endothelial cells, can contribute to tumor cell kill in hypofractionated RT.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Sub-subsection: 6.3.1	 Hypofractionation and the Linear Quadratic (LQ) Model | Content: ­correlation between treatment outcome and the BED, even at
extreme high BED values. Hence, there is still a discrepancy
between theoretical and experimental validity of the LQ
model. However, since the model describes the clinical data
on tumor control over a wide range of dose, fraction sizes,
and treatment durations [6], it might still be valid in predict­
ing RT outcomes in certain conditions.
6.3.2
Hypofractionation, Hypoxia,
and Reoxygenation
Hypoxia is a state of reduced oxygen availability or decreased
oxygen partial pressure below a critical threshold (generally
at pO2 of 2.5 or 5 mmHg). The Oxygen Enhancement Ratio
(OER) is around 3 for most cells: for sterilization of hypoxic
cells, a three times higher irradiation dose is required than
for normoxic cells. Hence, hypoxia can cause resistance to
RT, which has been observed in many tumor types.
Information about the role of oxygen in RT, the OER, and
related radiation sensitivity is given in Chap. 5.
In fractionated RT, during the time interval between daily
applied irradiation fractions and during the full course of RT,
hypoxic cells can be re-oxygenated and become more sensi­
tive to the next irradiation dose (see Chap. 5). If reoxygenation
is efficient between dose fractions, the presence of hypoxic
cells does not have a significant effect on the outcome of a
multi-fractionation scheme. In a hypofractionation regimen,
the time period to obtain full reoxygenation of hypoxic tumor
cells might be too short. Animal data on the kinetics of reoxy­
genation of different tumor types demonstrated that full reoxy­
genation takes about 72 h [7]. Also, preclinical data and
radiobiological modeling studies have demonstrated that
tumor hypoxia is a greater detrimental factor for single dose
treatments than for repeated conventional fraction sizes. To
fully exploit reoxygenation between fractions, 6–8 fractions
might be optimal, separated in a time frame of 72 h [7].
However, there are also advantages to large high-dose frac­
tions of ~10 Gy. Relatively radioresistant hypoxic cells might
be directly sterilized and vascular endothelial cells might be
injured. Since one endothelial cell is subtending about 2000
tumor cells, direct vascular damage might largely contribute to
tumor cell kill in hypofractionated RT [8].
6.3.3
Hypofractionation and Tumor Cell
Repopulation
Tumor cell repopulation refers to an increase in the number of
cells as a result of proliferation of surviving clonogenic tumor
cells (see Chap. 5). Accelerated repopulation of tumor cells
during the course of RT is starting after a lag period of
~4 weeks. One strategy discussed here is to cope with tumor
cell repopulation by limiting the overall treatment time for
fast repopulating tumors using a small number of higher sized
fractions. As a consequence of high fraction sizes, the total
irradiation dose should be reduced to overcome an increase in
V. Ahire et al."
"Explain the relationship between hypoxia and radiation sensitivity within tumor tissue, including the concept of the Oxygen Enhancement Ratio (OER) and how reoxygenation impacts treatment outcomes.","Hypoxia, defined as a reduction in oxygen partial pressure below critical thresholds (typically 2.5 or 5 mmHg), significantly alters a cell's response to ionizing radiation. This resistance stems from several mechanisms. Firstly, hypoxic cells exhibit a lower Oxygen Enhancement Ratio (OER) – generally around 3 – meaning they require three times the dose of radiation compared to normoxic cells for equivalent DNA damage. This reduced OER is due to impaired repair pathways and altered cellular metabolism under low-oxygen conditions. Consequently, hypoxic tumor cells are more resistant to radiation-induced DNA damage. However, this resistance isn't absolute; during the interfraction time between daily radiation treatments, these same hypoxic cells can undergo reoxygenation. Reoxygenation dramatically increases their sensitivity to subsequent irradiation doses because it restores functional repair mechanisms and allows for efficient oxidative burst activity, which is crucial for repairing radiation-induced DNA damage. The kinetics of reoxygenation vary depending on the tumor type; for example, complete reoxygenation in some tumors takes approximately 72 hours. Therefore, while hypoxia initially confers resistance, effective reoxygenation between fractions can significantly improve treatment outcomes within multi-fractionated radiotherapy regimens. Specifically, a timeframe of 72 hours between doses appears optimal to facilitate full reoxygenation and maximize sensitivity. In contrast, hypofractionated regimens – those employing larger, higher-dose fractions – may not provide sufficient time for complete reoxygenation, potentially leading to persistent resistance from hypoxic cells. Furthermore, direct vascular damage caused by radiation can also contribute to tumor cell kill in these scenarios, particularly when endothelial cells are injured and subtend a large number of tumor cells.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Sub-subsection: 6.3.2	 Hypofractionation, Hypoxia, and Reoxygenation | Content: ­correlation between treatment outcome and the BED, even at
extreme high BED values. Hence, there is still a discrepancy
between theoretical and experimental validity of the LQ
model. However, since the model describes the clinical data
on tumor control over a wide range of dose, fraction sizes,
and treatment durations [6], it might still be valid in predict­
ing RT outcomes in certain conditions.
6.3.2
Hypofractionation, Hypoxia,
and Reoxygenation
Hypoxia is a state of reduced oxygen availability or decreased
oxygen partial pressure below a critical threshold (generally
at pO2 of 2.5 or 5 mmHg). The Oxygen Enhancement Ratio
(OER) is around 3 for most cells: for sterilization of hypoxic
cells, a three times higher irradiation dose is required than
for normoxic cells. Hence, hypoxia can cause resistance to
RT, which has been observed in many tumor types.
Information about the role of oxygen in RT, the OER, and
related radiation sensitivity is given in Chap. 5.
In fractionated RT, during the time interval between daily
applied irradiation fractions and during the full course of RT,
hypoxic cells can be re-oxygenated and become more sensi­
tive to the next irradiation dose (see Chap. 5). If reoxygenation
is efficient between dose fractions, the presence of hypoxic
cells does not have a significant effect on the outcome of a
multi-fractionation scheme. In a hypofractionation regimen,
the time period to obtain full reoxygenation of hypoxic tumor
cells might be too short. Animal data on the kinetics of reoxy­
genation of different tumor types demonstrated that full reoxy­
genation takes about 72 h [7]. Also, preclinical data and
radiobiological modeling studies have demonstrated that
tumor hypoxia is a greater detrimental factor for single dose
treatments than for repeated conventional fraction sizes. To
fully exploit reoxygenation between fractions, 6–8 fractions
might be optimal, separated in a time frame of 72 h [7].
However, there are also advantages to large high-dose frac­
tions of ~10 Gy. Relatively radioresistant hypoxic cells might
be directly sterilized and vascular endothelial cells might be
injured. Since one endothelial cell is subtending about 2000
tumor cells, direct vascular damage might largely contribute to
tumor cell kill in hypofractionated RT [8].
6.3.3"
"The document discusses hypofractionation and its potential benefits, including biological dose escalation and immune response activation. However, it also identifies several limitations such as the α/β ratio disparity between tumor and normal tissues, detrimental effects of high-dose fractions on normal tissues, limited effectiveness of reoxygenation strategies, and concerns regarding tumor cell repopulation. Considering these factors, what specific fractionation schedule (number of fractions and dose per fraction) would be most suitable for a rapidly proliferating tumor exhibiting hypoxia to maximize therapeutic efficacy while minimizing late toxicity?","For a rapidly proliferating tumor with hypoxic characteristics aiming to optimize therapeutic efficacy while mitigating late toxicity through hypofractionation, a fractionation scheme involving 6-8 fractions of approximately 10 Gy each would represent the most strategically advantageous approach. This schedule directly addresses several key concerns outlined in the document. The higher dose per fraction (10 Gy) acknowledges the potential for direct sterilization of radioresistant hypoxic cells and vascular endothelial damage, as highlighted when considering high-dose fractions.  The use of a moderate number of fractions (6-8) allows for sufficient time between doses to facilitate reoxygenation of tumor cells, capitalizing on the OER principle – approximately 3 – which is crucial for enhancing radiosensitivity. Furthermore, this approach aligns with the abscopal effect described, potentially stimulating an immune response through localized irradiation and subsequent systemic effects. The shorter overall treatment duration (6-8 fractions) directly addresses concerns regarding accelerated tumor cell repopulation by limiting the time available for rapid proliferation, a key consideration when managing rapidly growing tumors.  It’s important to note that this strategy is predicated on careful monitoring of acute toxicity and would require meticulous dose planning to account for potential variations in individual patient responses.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Sub-subsection: 6.3.3	 Hypofractionation and Tumor Cell Repopulation | Content: high-dose fractions, dose reduction without loss of tumor control
could be achieved while diminishing late toxicity
• ”Biological dose” escalation, which might result in better tumor
control
• Activation of the immune response to attack tumor cells inside
the irradiated volume and at distance, the abscopal effect
• Lower probability of induction of secondary tumors
Cons
• Mostly, α/β ratio tumor > α/β ratio normal tissue
• High-dose fractions are detrimental for normal tissues: higher
probability of normal tissue complications, unless dose gradients
are steep and the irradiated volume small
• No benefit from sensitization of hypoxic tumor cells via
reoxygenation between fractions
• Radiosensitizing agents are potentially less effective when
combined with high-dose fractions
ume, and outcome estimates for both normal tissue complication
probability and tumor control [5] for SRS and SBRT, where
single high radiation doses are common practice. Under certain
conditions, like high conformity of RT with steep dose gradi­
ents toward the surrounding normal tissues, hypofractionation
could be beneficial over conventional fractionation. In this sec­
tion, the radiobiological pro- and contra arguments of hypo­
fractionation, listed in Table 6.2 are discussed.
6.3.1
Hypofractionation and the Linear
Quadratic (LQ) Model
The validity of the LQ model at high fraction sizes above
approximately 6 Gy is questionable, and alternative radiobi­
ological models are proposed. However, a strong pro-­
argument was derived from clinical data from non-small cell
lung cancer patients treated with SBRT, either with a single
dose or hypofractionated with 3–8 fractions. From the study
[6], it was evident that the clinically observed increase in
tumor could be ascribed to radiation dose escalation, i.e., an
increased Biologically Effective Dose (BED) according to
the LQ equation. BED values were calculated for the various
hypofractionation schemes including SBRT fraction sizes of
22 Gy. No adaptation or correction was made when using the
conventional LQ model. The analysis showed a clear
­correlation between treatment outcome and the BED, even at
extreme high BED values. Hence, there is still a discrepancy
between theoretical and experimental validity of the LQ
model. However, since the model describes the clinical data
on tumor control over a wide range of dose, fraction sizes,
and treatment durations [6], it might still be valid in predict­
ing RT outcomes in certain conditions.
6.3.2
Hypofractionation, Hypoxia,
and Reoxygenation
Hypoxia is a state of reduced oxygen availability or decreased
oxygen partial pressure below a critical threshold (generally
at pO2 of 2.5 or 5 mmHg). The Oxygen Enhancement Ratio
(OER) is around 3 for most cells: for sterilization of hypoxic
cells, a three times higher irradiation dose is required than
for normoxic cells. Hence, hypoxia can cause resistance to
RT, which has been observed in many tumor types.
Information about the role of oxygen in RT, the OER, and
related radiation sensitivity is given in Chap. 5.
In fractionated RT, during the time interval between daily
applied irradiation fractions and during the full course of RT,
hypoxic cells can be re-oxygenated and become more sensi­
tive to the next irradiation dose (see Chap. 5). If reoxygenation
is efficient between dose fractions, the presence of hypoxic
cells does not have a significant effect on the outcome of a
multi-fractionation scheme. In a hypofractionation regimen,
the time period to obtain full reoxygenation of hypoxic tumor
cells might be too short. Animal data on the kinetics of reoxy­
genation of different tumor types demonstrated that full reoxy­
genation takes about 72 h [7]. Also, preclinical data and
radiobiological modeling studies have demonstrated that
tumor hypoxia is a greater detrimental factor for single dose
treatments than for repeated conventional fraction sizes. To
fully exploit reoxygenation between fractions, 6–8 fractions
might be optimal, separated in a time frame of 72 h [7].
However, there are also advantages to large high-dose frac­
tions of ~10 Gy. Relatively radioresistant hypoxic cells might
be directly sterilized and vascular endothelial cells might be
injured. Since one endothelial cell is subtending about 2000
tumor cells, direct vascular damage might largely contribute to
tumor cell kill in hypofractionated RT [8].
6.3.3
Hypofractionation and Tumor Cell
Repopulation
Tumor cell repopulation refers to an increase in the number of
cells as a result of proliferation of surviving clonogenic tumor
cells (see Chap. 5). Accelerated repopulation of tumor cells
during the course of RT is starting after a lag period of
~4 weeks. One strategy discussed here is to cope with tumor
cell repopulation by limiting the overall treatment time for
fast repopulating tumors using a small number of higher sized
fractions. As a consequence of high fraction sizes, the total
irradiation dose should be reduced to overcome an increase in
V. Ahire et al.
317
late normal tissue toxicity. Hypofractionation allows shorten­
ing of the overall treatment time, which might be more effec­
tive than long duration conventional fractionation in the
treatment of rapidly proliferating tumors. However, care
should be taken when using too short schedules, because they
could lead to an increase in acute toxicity.
9
­
­
6.3
10
6.3.4
Hypofractionation and the Immune
Response
Radiation has long been thought to suppress the immune sys­
tem, and total body irradiation is up to date applied for that
reason. Studies in the past have demonstrated that local irra­
diation not only had a direct effect on tumor cells in the treat­
ment volume, but also a systemic effect on the immune
system (see Chap. 5). Therewith, local irradiation can induce
abscopal effects, i.e., the immunological rejection of tumors
or metastatic lesions distant from the irradiated site (see
Chap. 5). Different radiation treatment schemes regarding
the total dose and fraction size were shown to have diverse
effects on the immune response, with a subsequent effect on
combination therapy with immune-modulating agents [11].
The abscopal effect might best be exploited using 3–5 frac­
tions of <10 Gy [12]. The immune-editing effects of radia­
tion will probably also benefit from repeated intermediate
high fraction sizes [13].
6.3.5
Hypofractionation
and Radiosensitizing Agents
Hyperthermia and chemotherapeutic agents, e.g., cisplatin,
gemcitabine, temozolomide and targeted drugs such as
inhibitors of PARP-1 and EGFR may potentiate the effects of
radiation. The LQ model is a very suitable tool to quantify
the effects of the combination of irradiation and radiosensi­
tizers, which can be either additive or synergistic. The most
commonly used test to study interaction between irradiation
and modulating agents is the clonogenic assay (see Chap. 3),
being the golden standard test for determination of cell sur­
vival. LQ model analysis of the typical shaped cell survival
curve allows to separately establish the effect of combination
therapy on the 〈 and ® α/β parameters of the model. The
parameter 〈 α determines the effectiveness at low doses, on
the initial slope of the cell survival curve, while the parame­
ter ® β represents the increasing contribution from cumula­
tive damage thought to be due to interaction of two or more
separate lesions. Preclinical studies have shown that most
radiosensitizing agents cause an increase of the α-parameter,
while the β-parameter is rarely affected [14]. With conven­
1/2
­
9
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"The α and β parameters are frequently utilized in radiobiological models to describe the dose-response relationship of radiation. Explain what each parameter represents, how they are determined experimentally, and why changes in the α parameter often indicate radiosensitization effects.","In the linear mammalian model (LMM), the α and β parameters quantify the rate and extent of cell killing following exposure to ionizing radiation. The α-parameter represents the rate constant for cell death, reflecting how quickly a given dose of radiation causes cell destruction. It’s determined experimentally through measuring the number of surviving cells at various doses of radiation applied to a homogenous population of cells (typically mammalian). A higher α value indicates a faster rate of cell killing. Conversely, the β-parameter represents the absolute stopping point for cell death – it's the dose required to kill 90% (B90) of the initial cell population. This is also determined experimentally by plotting survival curves and extrapolating to the B90 point. The β value itself doesn’t directly represent a biological effect, but rather a specific radiation dose. Changes in the α parameter are frequently observed when radiosensitizing agents are administered alongside radiotherapy. Radiosensitizers enhance the cell's susceptibility to radiation damage, effectively lowering the α-parameter. This means that at a given dose, more cells will be killed compared to untreated cells, because the radiosensitizer has altered cellular processes – such as DNA repair mechanisms or oxidative burst production – making them more vulnerable to radiation’s damaging effects. Essentially, the agent shifts the dose-response curve downwards, leading to a reduced α value.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Sub-subsection: 6.3.4	 Hypofractionation and the Immune Response | Content: separate lesions. Preclinical studies have shown that most
radiosensitizing agents cause an increase of the α-parameter,
while the β-parameter is rarely affected [14]. With conven­
1/2
­
9
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"Describe the key radiobiological principles underlying Stereotactic Body Radiation Therapy (SBRT), specifically addressing how high-dose per-fraction radiation impacts tumor cell radiosensitivity and normal tissue response compared to conventional fractionation.","Stereotactic Body Radiation Therapy (SBRT) utilizes highly conformal, precisely delivered radiation in a small number of fractions (typically 1-5) to achieve a tumoricidal dose. A central tenet of SBRT’s effectiveness is the use of high-dose per-fraction radiation, which fundamentally alters cellular responses compared to conventional fractionation.  Unlike conventional RT where cells undergo multiple cycles of repair and reassortment between fractions, SBRT's high doses directly damage tumor cells, leading to cell cycle arrest and ultimately apoptosis within a shorter timeframe. This is particularly beneficial for tumors with low α/β values (typically 1.5-3 Gy), such as prostate cancer, where these cells are considered late-responding and highly sensitive to the immediate effects of radiation. The high dose per fraction effectively overwhelms the cell’s repair mechanisms, leading to a more rapid and complete tumor kill. However, this approach also has implications for normal tissues; because normal tissue cells are typically acute-responding (rapidly repairing DNA damage), they are more vulnerable to collateral damage from the high doses delivered during SBRT. Careful treatment planning, including steep dose gradients and minimizing margins, is crucial to limit exposure to these sensitive areas. Furthermore, the reduced interfractional repair seen in SBRT contrasts with conventional fractionation where tumor cell repopulation and repair processes contribute significantly to overall treatment efficacy. The reduction of hypoxic components also plays a role as small tumors are relatively well oxygenated.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Sub-subsection: 6.3.5	 Hypofractionation and Radiosensitizing Agents | Content: separate lesions. Preclinical studies have shown that most
radiosensitizing agents cause an increase of the α-parameter,
while the β-parameter is rarely affected [14]. With conven­
1/2
­
9
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
318
tional small-­sized dose fractions, the value of the α-parameter
therefore determines to a large extent the effectiveness of
combination treatments. The interaction between chemo­
therapeutic agents and high-dose irradiation fractions will be
minimal. For clinical hypofractionation regimen, it is to be
expected that effects of radiosensitizing agents are smaller
than when combined with conventional fractionation
regimen.
6.3.6
Hypofractionation and Risk
for Secondary Cancer
Long-term follow-up studies that address carcinogenic
effects of fractionated high-dose RT describe the inci­
dence of secondary malignancies, type of induced can­
cers, latency time, risk period as well as the shape of the
dose–risk relationship curve. The dose–risk curve follow­
ing curative RT is organ specific and is either linear, pla­
teau,
or
bell-shaped.
Radiobiological—LQ
model
based—calculations for estimation of the cancer risk fol­
lowing exposure to irradiation showed that both carci­
noma and sarcoma risk decreased with increasing fraction
size [9]. Via model calculations, it has been estimated that
hypofractionated RT has the potential to reduce the sec­
ond cancer risk [15].
6.4
External Beam Radiotherapy
Strategies
6.4.1
Stereotactic Body Radiation Therapy
(SBRT)
6.4.1.1	Definition
Stereotactic Body Radiation Therapy (SBRT) also known
as Stereotactic Ablative Radiotherapy   (SABR) refers to
stereotactic image-guided delivery of highly conformal
radiation to a small extracranial target using high-dose per
fraction delivered in 1–5 fractions with a tumor-ablative
intent [16]. The key requirements for SBRT are small well-
circumscribed tumors (maximum cross-sectional diameter
up to 5 cm), stringent patient immobilization, small or no
margin for beam penumbra, high conformality and accu­
rate radiation delivery as well as image guidance for geo­
metric verification [17].
6.4.1.2	Radiobiologic Principles of SBRT
The aim of SBRT is to deliver tumoricidal dose to target in
a few fractions and minimize dose to normal tissue by
delivering highly conformal radiation under image guid­
ance. A high-dose per fraction is more tumoricidal than
conventional fractionation dose by its direct damaging
action on tumor cells [6]. As discussed in Chap. 5 and ear­
lier in this chapter, the effect on late-responding normal
tissues is greater with high-dose per fraction. Few malig­
nancies such as prostate cancer have low α/β values in the
range of 1.5–3 Gy and show high sensitivity to fraction­
ation (similar to late-responding normal tissues). In such
malignancies, hypofractionation leads to better therapeutic
benefit. On the other hand, delivering high-dose per frac­
tion can increase toxicity in acute-­responding tissues(see
Chap. 5). To minimize this, a highly focused and confor­
mal dose is delivered to the tumor with a steep dose gradi­
ent. It is achieved by reducing planned target volume
(PTV) margins under image guidance, using multiple non-
coplanar beams with careful treatment planning, and by
delivering the total dose in two to five fractions (2–3 frac­
tions per week) [7].
As discussed in Chap. 5, the bigger the tumor size the
more is the hypoxic component and vice-versa. The
advantage of reoxygenation seen during conventional
fractionation is compensated in hypofractionated SBRT
by selectively treating small tumors, which are relatively
well oxygenated with a little hypoxic component.
Furthermore, the hypoxic cells in tumors are depopulated
by the direct damaging effect of large doses per fraction
[6]. The same effect is responsible for overcoming the dis­
advantage of lack of reassortment of tumor cells to sensi­
tive phases of cell cycle during fractionation. The
high-dose per fraction counteracts the differences in
radiosensitivity of cells in different phases of cell cycle by
causing cell cycle arrest and interphase death in all phases
(see Chap. 3).
Unlike conventional fractionation RT, owing to the
short overall treatment time, tumor cell repopulation and
interfraction repair of sublethal damage do not play a
major role during SBRT (see Sect. 6.3). This is beneficial
in terms of tumor control but detrimental to normal tissues.
Box 6.3 Stereotactic Body Radiation Therapy (SBRT)
•	The basic principle of SBRT is to deliver a tumori­
cidal dose to the target in a few fractions and mini­
mize dose to normal tissue using highly conformal
radiation.
•	The high-dose per fraction used in SBRT can cause
vascular damage through endothelial cell apoptosis
and stem cell death.
•	SBRT is commonly used in treatment of tumors in
lung, liver, spine, prostate, and pancreas.
V. Ahire et al."
"Explain the rationale behind using high-dose per fraction radiation during Stereotactic Body Radiation Therapy (SBRT) for certain cancers, specifically referencing how this approach addresses differences in radiosensitivity between tumor cells and normal tissues.","The utilization of high-dose per fraction radiation within SBRT is predicated on a strategy to overcome inherent limitations observed with conventional fractionation schemes. Specifically, it leverages the differential radiosensitivities of various cell types and tissues. As detailed, tumors exhibiting low α/β values (around 1.5–3 Gy), such as prostate cancer, demonstrate heightened sensitivity to high-dose per fraction treatments – mirroring the response of late-responding normal tissues. This is because a higher dose delivered in fewer fractions directly damages tumor cells through its inherent cytotoxic action, effectively bypassing the need for prolonged cell cycle redistribution and reassortment that characterizes conventional fractionation. Furthermore, the strategy addresses hypoxia within tumors; larger tumors with significant hypoxic components are less responsive to standard fractionation due to oxygen-dependent repair mechanisms. SBRT’s high doses per fraction directly deplete hypoxic cells through DNA damage, mitigating this disadvantage. Importantly, the reduced overall treatment time in SBRT minimizes tumor cell repopulation and interfraction repair of sublethal damage – a factor that significantly impacts conventional radiotherapy's effectiveness. This approach effectively counteracts differences in radiosensitivity across all phases of the cell cycle by inducing cell cycle arrest and interphase death regardless of the specific phase, ultimately maximizing therapeutic efficacy while minimizing collateral damage to surrounding tissues due to the focused and conformal nature of the treatment.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.3	 Radiobiological Aspects of Hypofractionation | Sub-subsection: 6.3.6	 Hypofractionation and Risk for Secondary Cancer | Content: delivering highly conformal radiation under image guid­
ance. A high-dose per fraction is more tumoricidal than
conventional fractionation dose by its direct damaging
action on tumor cells [6]. As discussed in Chap. 5 and ear­
lier in this chapter, the effect on late-responding normal
tissues is greater with high-dose per fraction. Few malig­
nancies such as prostate cancer have low α/β values in the
range of 1.5–3 Gy and show high sensitivity to fraction­
ation (similar to late-responding normal tissues). In such
malignancies, hypofractionation leads to better therapeutic
benefit. On the other hand, delivering high-dose per frac­
tion can increase toxicity in acute-­responding tissues(see
Chap. 5). To minimize this, a highly focused and confor­
mal dose is delivered to the tumor with a steep dose gradi­
ent. It is achieved by reducing planned target volume
(PTV) margins under image guidance, using multiple non-
coplanar beams with careful treatment planning, and by
delivering the total dose in two to five fractions (2–3 frac­
tions per week) [7].
As discussed in Chap. 5, the bigger the tumor size the
more is the hypoxic component and vice-versa. The
advantage of reoxygenation seen during conventional
fractionation is compensated in hypofractionated SBRT
by selectively treating small tumors, which are relatively
well oxygenated with a little hypoxic component.
Furthermore, the hypoxic cells in tumors are depopulated
by the direct damaging effect of large doses per fraction
[6]. The same effect is responsible for overcoming the dis­
advantage of lack of reassortment of tumor cells to sensi­
tive phases of cell cycle during fractionation. The
high-dose per fraction counteracts the differences in
radiosensitivity of cells in different phases of cell cycle by
causing cell cycle arrest and interphase death in all phases
(see Chap. 3).
Unlike conventional fractionation RT, owing to the
short overall treatment time, tumor cell repopulation and
interfraction repair of sublethal damage do not play a
major role during SBRT (see Sect. 6.3). This is beneficial
in terms of tumor control but detrimental to normal tissues.
Box 6.3 Stereotactic Body Radiation Therapy (SBRT)
•	The basic principle of SBRT is to deliver a tumori­
cidal dose to the target in a few fractions and mini­
mize dose to normal tissue using highly conformal
radiation.
•	The high-dose per fraction used in SBRT can cause
vascular damage through endothelial cell apoptosis
and stem cell death.
•	SBRT is commonly used in treatment of tumors in
lung, liver, spine, prostate, and pancreas.
V. Ahire et al."
"External beam radiotherapy strategies for cancer treatment often involve fractionation – the division of a total radiation dose into multiple smaller daily doses. Explain the rationale behind using fractionation, detailing how it impacts cellular responses and contributes to tumor control while minimizing damage to surrounding healthy tissues.","Fractionation is a cornerstone of external beam radiotherapy due to several key physiological effects observed in cells following irradiation. The primary reason for dividing a total dose into multiple fractions lies in the concept of ‘sequential repair.’ When cells are exposed to ionizing radiation, DNA damage occurs. Cells possess complex repair mechanisms designed to rapidly fix this damage. However, these repair processes are not instantaneous; they require time and utilize cellular resources. A single, high-dose exposure overwhelms these repair pathways, leading to significant and irreparable DNA damage, resulting in cell death. 

By administering radiation in smaller fractions (typically 1-5 Gray per fraction), the cells have sufficient opportunity to partially repair the initial damage between treatments. This ‘repair window’ allows for a more controlled cytotoxic effect. The damaged DNA is not fully repaired, but enough of it is removed to prevent lethal double-strand breaks from occurring during subsequent exposures. Furthermore, fractionation promotes apoptosis (programmed cell death) – a less destructive form of cell death than necrosis – which is favored by the body's natural mechanisms. 

Beyond repair, fractionation also influences tumor control by inducing hypoxia (low oxygen conditions) within the tumor mass. High radiation doses cause significant cellular damage and edema (swelling), restricting blood flow to the tumor. This hypoxia, in turn, activates pro-apoptotic pathways, further enhancing cell death. The use of fractionation allows for a sustained cytotoxic effect over time, maximizing tumor control while minimizing the acute toxic effects associated with immediate, high-dose radiation. Careful planning considers factors like fractionation duration and dose rate to optimize these sequential repair and apoptotic processes, aiming for maximum therapeutic efficacy with acceptable toxicity profiles.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Content: Strategies
6.4.1"
Describe the key characteristics and goals of Stereotactic Body Radiation Therapy (SBRT) and what factors are considered essential for its successful application.,"Stereotactic Body Radiation Therapy (SBRT), often referred to as Stereotactic Ablative Radiotherapy (SABR), represents a highly precise approach to radiation delivery within the context of cancer treatment. Its primary goal is tumor ablation – effectively destroying the targeted tumor with minimal damage to surrounding healthy tissue. SBRT utilizes stereotactic imaging and image guidance to deliver high-dose, precisely shaped radiation fractions, typically ranging from 1 to 5 treatments. The technique focuses on small, well-defined tumors, generally limited to a maximum cross-sectional diameter of 5 cm. Several critical factors are essential for the successful implementation of SBRT: stringent patient immobilization is paramount to maintain accurate target localization throughout treatment; minimal beam penumbra – achieving high conformality and accuracy in radiation delivery is crucial; precise geometric verification through image guidance is continuously monitored during each fraction, ensuring that the tumor remains within the planned treatment volume. Ultimately, SBRT aims for maximum tumor dose while minimizing off-target effects due to its focused and controlled nature.

Reference: [Document Name], Section 6.4.1.1 Definition","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.1	 Stereotactic Body Radiation Therapy (SBRT) | Sub-sub-subsection: 6.4.1.1	 Definition | Content: Stereotactic Body Radiation Therapy (SBRT) also known
as Stereotactic Ablative Radiotherapy   (SABR) refers to
stereotactic image-guided delivery of highly conformal
radiation to a small extracranial target using high-dose per
fraction delivered in 1–5 fractions with a tumor-ablative
intent [16]. The key requirements for SBRT are small well-
circumscribed tumors (maximum cross-sectional diameter
up to 5 cm), stringent patient immobilization, small or no
margin for beam penumbra, high conformality and accu­
rate radiation delivery as well as image guidance for geo­
metric verification [17]."
"Describe the mechanisms by which high-dose per fraction radiation, as utilized in Stereotactic Body Radiation Therapy (SBRT), impacts tumor cells and normal tissues, referencing both direct damage and potential secondary effects.","In SBRT, delivering a tumoricidal dose within a few fractions with high-dose per fraction primarily operates through multiple mechanisms. Initially, the direct damaging action of the increased radiation dose on tumor cells induces cell cycle arrest and interphase death across all phases, effectively counteracting the radiosensitivity differences observed in various cell cycle stages as described in conventional fractionation (Chap. 3). Furthermore, this high dose promotes endothelial cell apoptosis and stem cell death within the tumor vasculature, leading to vascular damage. The increased dose also facilitates the selective treatment of smaller, relatively well-oxygenated tumors – a key advantage over conventional fractionation where larger, more hypoxic tumors exhibit greater sensitivity. Critically, the high doses directly depopulate hypoxic cells by causing their demise, and this effect overcomes the disadvantage of reduced reassortment to sensitive cell cycle phases. Finally, radiation-induced immunologic responses, particularly a strong T-cell response triggered after exposure to high-dose per fraction RT, enhance cytotoxic effects, potentially synergizing with immune checkpoint inhibitors like PD-1/PD-L1 antibodies (Chap. 5). The LQ model of cell survival may overestimate the effect at higher dose per fractions and alternative models such as USC were proposed to calculate SED instead.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.1	 Stereotactic Body Radiation Therapy (SBRT) | Sub-sub-subsection: 6.4.1.2	 Radiobiologic Principles of SBRT | Content: The aim of SBRT is to deliver tumoricidal dose to target in
a few fractions and minimize dose to normal tissue by
delivering highly conformal radiation under image guid­
ance. A high-dose per fraction is more tumoricidal than
conventional fractionation dose by its direct damaging
action on tumor cells [6]. As discussed in Chap. 5 and ear­
lier in this chapter, the effect on late-responding normal
tissues is greater with high-dose per fraction. Few malig­
nancies such as prostate cancer have low α/β values in the
range of 1.5–3 Gy and show high sensitivity to fraction­
ation (similar to late-responding normal tissues). In such
malignancies, hypofractionation leads to better therapeutic
benefit. On the other hand, delivering high-dose per frac­
tion can increase toxicity in acute-­responding tissues(see
Chap. 5). To minimize this, a highly focused and confor­
mal dose is delivered to the tumor with a steep dose gradi­
ent. It is achieved by reducing planned target volume
(PTV) margins under image guidance, using multiple non-
coplanar beams with careful treatment planning, and by
delivering the total dose in two to five fractions (2–3 frac­
tions per week) [7].
As discussed in Chap. 5, the bigger the tumor size the
more is the hypoxic component and vice-versa. The
advantage of reoxygenation seen during conventional
fractionation is compensated in hypofractionated SBRT
by selectively treating small tumors, which are relatively
well oxygenated with a little hypoxic component.
Furthermore, the hypoxic cells in tumors are depopulated
by the direct damaging effect of large doses per fraction
[6]. The same effect is responsible for overcoming the dis­
advantage of lack of reassortment of tumor cells to sensi­
tive phases of cell cycle during fractionation. The
high-dose per fraction counteracts the differences in
radiosensitivity of cells in different phases of cell cycle by
causing cell cycle arrest and interphase death in all phases
(see Chap. 3).
Unlike conventional fractionation RT, owing to the
short overall treatment time, tumor cell repopulation and
interfraction repair of sublethal damage do not play a
major role during SBRT (see Sect. 6.3). This is beneficial
in terms of tumor control but detrimental to normal tissues.
Box 6.3 Stereotactic Body Radiation Therapy (SBRT)
•	The basic principle of SBRT is to deliver a tumori­
cidal dose to the target in a few fractions and mini­
mize dose to normal tissue using highly conformal
radiation.
•	The high-dose per fraction used in SBRT can cause
vascular damage through endothelial cell apoptosis
and stem cell death.
•	SBRT is commonly used in treatment of tumors in
lung, liver, spine, prostate, and pancreas.
V. Ahire et al.
319
However, when the treatment time of an individual frac­
tion is prolonged for more than half an hour, intrafraction
repair of some sublethal damage in rapidly proliferating
tumor cells may occur [7]. However, such longer fraction
treatment time and faster intrafraction repair result in
greater loss of BED [18]. This can be overcome by increas­
ing the dose rate with use of flattening filter free (FFF)
beams.
It is postulated that the radiobiologic effect of SBRT also
depends on two other mechanisms. One is the vascular dam­
age due to endothelial cell apoptosis caused by high-dose
per fraction. It has been reported that this occurs due to the
structural abnormalities of tumor vessels that are dilated,
tortuous, elongated and have a thin basement membrane
[19]. The second mechanism is through radiation-­induced
immunologic responses. The strong T-cell response trig­
gered after exposure to high-dose per fraction RT enhances
cytotoxic effects [12]. In addition, SBRT when combined
with immune checkpoint inhibitors, i.e., Programmed Cell
Death Protein-1/Programmed Cell Death Ligand-1 (PD-1/
PD-L1) targeting antibodies, e.g., pembrolizumab or cyto­
toxic T-lymphocyte-associated protein-4 (CTLA4) antibod­
ies, e.g., ipilimumab has shown to trigger an immunologic
response that produces an abscopal effect [12] as described
in Chap. 5.
Conventional fractionation RT is modelled by the LQ
model cell survival curve but at higher dose per fraction, it
is thought that LQ model overestimates the effects of radia­
tion [20]. Therefore, alternative radiobiological models like
universal survival curve (USC) were proposed. Instead of
the BED in the LQ model, USC calculates the standard
effective dose (SED) which is the total dose administered
in 2 Gy per fraction to produce the same effect [21]. There
are arguments that the LQ model still holds good till a cer­
tain level of dose per fraction."
"Describe the key differences in dose prescription and treatment planning considerations between Stereotactic Body Radiation Therapy (SBRT) and traditional radiation therapy, specifically focusing on how these differences impact target volume delineation and normal tissue management.","SBRT distinguishes itself from conventional radiation therapy through a deliberate strategy of prescribing doses to the low isodose lines (e.g., 80% isodose) with minimal or no margin for beam penumbra, resulting in a highly heterogeneous dose distribution within the target volume. This contrasts with traditional RT’s goal of achieving a homogeneous dose distribution. Consequently, SBRT accepts and utilizes dose heterogeneities and hotspots that would be avoided in conventional planning. To achieve this sharp dose falloff and improve conformality, SBRT typically employs multiple planar or non-coplanar treatment beams delivered using a multileaf collimator (MLC) with a narrow width (5mm or less), often coupled with a finer calculation grid size (2mm or finer) to accurately represent the dose distribution.  Furthermore, due to the high fractional doses utilized in SBRT, traditional normal tissue tolerance metrics derived from conventional fractionation studies are no longer directly applicable; instead, measures like BED (Biologically Effective Dose), NTD (Normalized Total Dose), and EUD (Equivalent Uniform Dose) are employed to evaluate effectiveness and safety.  These metrics account for the unique dose heterogeneity of SBRT plans. Finally, specific conformity indices (CI), heterogeneity index (HI), and intermediate dose spillage (D50% or D2 cm) are calculated and monitored to assess treatment plan quality.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.1	 Stereotactic Body Radiation Therapy (SBRT) | Sub-sub-subsection: 6.4.1.3	 Treatment Planning | Content: ­
­
18
18
­
22
­
22
­
6.3
For SBRT, the target volumes and OARs are contoured as
per the The International Commission on Radiation Units
and Measurements (ICRU) 50 and 62 reports. The RT treat­
ment planning is based on the American Association of
Physicists in Medicine Task Group (AAPM TG) 101 recom­
mendations [22]. Unlike uniform dose prescription in con­
ventional RT, in SBRT, dose is prescribed to the low isodoses
(e.g., 80% isodose line) with small or no margin for beam
penumbra to improve sharp dose falloff outside the target
volume, thereby reducing dose to adjacent normal tissues.
Hence, dose heterogeneities and hotspots occurring within
the target volumes are accepted in SBRT, unlike traditional
RT where homogeneous dose distribution is desired. For
obtaining an optimal SBRT treatment plan with better target
dose conformality as well as isotropic dose gradient, multi­
ple planar or non-coplanar treatment beams are used, and
treatment is delivered using multileaf collimator (MLC) of
width 5 mm or less [24]. The calculation grid size used in the
Table 6.3 Motion management methods in radiotherapy. Adapted from [23]
Motion management method
Rationale
Free breathing technique
• Based on 4D CT
Generating of internal target volume (ITV) which covers the full range
of tumor motion
Motion dampening techniques
• Abdominal compression using paddle, pneumatic belts, etc.
• Breath holding technique such as deep inspiratory breath hold
(DIBH), active breath coordinator (ABC)
Limiting the diaphragm expansion and tumor motion by devices or by
controlling breathing
Respiratory gating technique
• Internal gating using internal surrogates for tumor motion
• External gating using external devices to monitor respiration, a
surrogate for tumor motion [such as real-time position
management (RPM) system]
Treating the tumor only in discrete phases of respiratory cycle
Real-time tumor tracking
• ExacTrac (Kilo-Voltage image-­based system)
• Cyberknife (Kilo-Voltage image-­based robotic system)
• Calypso (radiofrequency localization system)
Intrafraction tumor localization and repositioning of treatment beam
toward the target
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
320
treatment planning system (TPS) affects the accuracy of cal­
culated dose distribution. Hence, an isotropic grid size of
2 mm or finer is recommended.
The normal tissue tolerances derived from conven­
tional fractionation studies do not apply to the high frac­
tional doses delivered in SBRT. Therefore, bioeffect
measures such as BED, normalized total dose (NTD), and
equivalent uniform dose (EUD) are calculated to evaluate
the effectiveness and safety of SBRT dose distributions
[18, 25, 26]. BED and NTD are used to determine the bio­
logic effectiveness of different dose fractionation sched­
ules, whereas EUD is applied to rank different treatment
plans based on their expected tumor effect [22]. The nor­
mal tissue tolerances for different SBRT fractionation
schemes are still evolving. Apart from the traditional met­
rics reported in a RT treatment plan, SBRT plans must
specify conformity index (CI = prescription isodose vol­
ume/PTV), heterogeneity index (HI = highest dose
received by 5% of PTV/lowest dose received by 95% of
PTV), and intermediate dose spillage (D50% = volume of
50% of prescription isodose curve/PTV or D2 cm = maxi­
mum dose at 2 cm from PTV) [22].
Recent advances in RT techniques and machines facili­
tate delivery of SBRT. Volumetric modulated arc therapy
(VMAT) is an advanced RT technique that delivers radiation
dose continuously in arcs where gantry rotation speed, treat­
ment aperture, and dose rate vary simultaneously [27]. The
newer linear accelerators (LINAC) capable of delivering
flattening filter free (FFF) beams increases dose rate from
300 to 600 monitor units (MU)/min to 1200 to 2400 MU/
min. Thereby, the time required to deliver the large number
of MUs needed for high-dose per fraction in SBRT is
decreased [28]. The FFF beams also have other advantages
such as less off-axis beam hardening, less photon head scat­
ter, less field size dependence, and less leakage outside
beam collimators [29]."
"Describe the clinical applications of Stereotactic Body Radiation Therapy (SBRT) as outlined in section 6.4, focusing on its use across different cancer subtypes and stages.","Stereotactic Body Radiation Therapy (SBRT) is being investigated for a diverse range of cancers primarily characterized by localized disease or limited metastatic burden. In lung cancer, SBRT demonstrates efficacy in early-stage inoperable non-small cell lung cancer (NSCLC), often targeting T1 and T2 tumors less than 5 cm with no nodal involvement. It’s frequently utilized as a ‘boost’ following conventional chemoradiation for locally advanced NSCLC and can be employed for recurrence or re-irradiation. Furthermore, SBRT is considered for oligometastatic disease – cancers with few metastases – and even for re-irradiation of previously treated tumors. In liver cancer, SBRT is applied to unresectable hepatocellular carcinoma (HCC) when other treatments like radiofrequency ablation or transarterial chemoembolization are unsuitable. It’s also utilized in cases of oligometastatic disease and portal vein tumor thrombosis. For pancreatic cancer, SBRT can be used for locally advanced, unresectable disease, borderline resectable disease with a poor performance status, or as a re-irradiation strategy. In prostate cancer, SBRT is employed for low-risk patients as monotherapy, low volume intermediate risk patients also as monotherapy or boost, and high/very high/node positive disease requiring a boost. Finally, SBRT finds application in spine metastases – both primary spinal cord neoplasms and metastatic lesions – often as adjuvant therapy, salvage treatment, or re-irradiation for limited disease with an expected survival of more than 3 months. Applications also extend to kidney cancer (unilateral or bilateral recurrent disease) and head and neck cancers, primarily for re-irradiation of small volume recurrences or palliative care.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.1	 Stereotactic Body Radiation Therapy (SBRT) | Sub-sub-subsection: 6.4.1.4	 Clinical Applications | Content: 6.4
­
6.4
Numerous phase 1/2 clinical trials have shown encourag­
ing results regarding safety and efficacy of SBRT in different
types and stages of cancer [31]. However, the major draw­
backs of these trials are the adoption of variable radiation
dose, fractionation schemes, and limited number of treated
patients. Therefore, randomized phase 3 trial results on clini­
cal outcomes and long-term toxicities are needed to recom­
mend SBRT as the standard of care.
Table 6.4 Clinical application of SBRT at various cancer subsites. (Adapted from [30])
Cancer subsite
Indications
Lung
• Early-stage inoperable non-small cell lung cancer (NSCLC)—T1, T2, usually <5 cm, N0
• Boost following definitive chemoradiation for locally advanced NSCLC
• Recurrence/re-irradiation
• Oligometastatic disease
Liver
• Hepatocellular carcinoma (HCC)—unresectable/medically inoperable patients, unsuitable/refractory to radiofrequency
ablation, or transarterial chemoembolization
• Oligometastatic disease
• Portal vein tumor thrombosis (PVTT)
Pancreas
• Locally advanced unresectable disease—radical SBRT/SBRT boost following conventional fractionated RT
• Borderline resectable disease—poor performance status
• Re-irradiation
Prostate
• Low risk—SBRT monotherapy
• Low volume intermediate risk—SBRT monotherapy/boost
• High/very high/node positive disease—SBRT boost
• Residual disease after RT—salvage/re-irradiation
Spine metastases
• Primary spinal cord neoplasms: medically inoperable/adjuvant/salvage SBRT
• Spine metastases: limited disease, life expectancy more than 3 months, medically inoperable
• Re-irradiation
Kidney
• Unilateral, medically inoperable disease
• Bilateral/recurrent contralateral disease
Head and neck
• Re-irradiation: single, small volume recurrence, node negative
• SBRT boost following definitive chemoradiation in locally advanced nasopharyngeal cancer
• Palliation
V. Ahire et al.
321
6.4.2"
"Explain the ‘FLASH effect’ in the context of ultra-high dose rate external beam radiotherapy, detailing the underlying biological mechanisms proposed by both the oxygen depletion hypothesis and the differential ROS-damage recovery hypothesis.","The ‘FLASH effect,’ observed with ultra-high dose rates (greater than 100 Gy/s) of external beam radiotherapy, refers to the ability to minimize damage to surrounding normal tissue while still effectively ablating tumors. This phenomenon is rooted in several hypothesized biological mechanisms. Initially, the oxygen depletion hypothesis was prominent. It proposed that the extremely rapid delivery of radiation at these high dose rates causes a transient and significant consumption of local oxygen within the tumor microenvironment. This localized hypoxia – a state of reduced oxygen availability – then leads to temporary radioprotection. Specifically, low oxygen concentrations hinder the formation of reactive oxygen species (ROS) by preventing their production through the interaction of DNA lesions with molecular oxygen, thus reducing oxidative damage to nucleic acids and lipids. Consequently, cellular repair mechanisms are favored in this hypoxic environment. However, recent research has challenged this hypothesis. The differential ROS-damage recovery hypothesis suggests that normal and tumor cells exhibit distinct capacities for ‘detoxifying’ themselves from ROS following radiation exposure. Normal cells possess a greater ability to efficiently eliminate peroxidized compounds compared to tumor cells. Therefore, even with FLASH RT, tumors do not experience a significantly lower tissue oxygen concentration when measured using solid optical sensors, and their response remains comparable under both physiological and hypoxic conditions – indicating that the primary mechanism isn’t oxygen depletion but rather differences in ROS detoxification capabilities between cell types [32, 33].","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.2	 FLASH Radiotherapy at Ultra-High Dose Rate | Sub-sub-subsection: 6.4.2.1	 Principles | Content: FLASH RT is emerging as a new tool for sparing normal tis­
sue from ablative doses, as it is able to protect normal tissue
while maintaining antitumor ablation [32]. FLASH RT tar­
gets tumors with ultra-high dose rates (>100 Gy/s) to reduce
the administration time from minutes to less than 200 ms, as
this is key to sparing normal tissue [32]. The biological
mechanism behind the sparing of normal tissue, known as
the “FLASH effect,” is based on the following hypothesis:
The oxygen depletion hypothesis describes the rapid con­
sumption of local oxygen by ultra-high dose rates resulting
in transient radioprotection and transient local tissue hypoxia.
It is known that hypoxic tissue is more radioresistant because
the low concentration of molecular oxygen during radiation-­
induced DNA damage allows DNA repair, while in the pres­
ence of molecular oxygen, the DNA lesion binds to molecular
oxygen and produces peroxyl radicals leading to the degra­
dation of nucleic acids and lipids [32]. Therefore the oxygen
depletion hypothesis suggests that FLASH RT may be able
to prevent or reduce Reactive Oxygen Species (ROS)-
mediated cellular damage [33]. However, this hypothesis has
recently been challenged as studies showed that FLASH RT
does not significantly decrease tissue oxygen concentration
compared with conventional RT when measured with a solid
optical sensor [34]. The differential ROS-damage recovery
hypothesis describes that normal and tumor cells have differ­
ent capabilities to “detoxify” themselves from ROS [32].
According to this hypothesis, normal cells have a greater
capacity to eliminate peroxidized compounds compared to
tumors. This would explain why tumors exposed to FLASH
RT respond equally under either physiologic or hypoxic
conditions."
"Considering the clinical application of FLASH radiotherapy, what specific types of tumors and locations are currently being investigated as potential candidates due to preclinical findings regarding reduced tissue damage?","Preclinical studies have identified several tumor types and locations as promising candidates for FLASH radiotherapy (FLASH RT) due to its ability to minimize late-onset toxicities. Specifically, tumors in ‘late-responding tissues’ such as those found in organs like the lungs are being investigated. Furthermore, patients experiencing painful bone metastases in the extremities represent a key area of research regarding the feasibility and safety of FLASH RT protocols. The observed reduction in pulmonary fibrosis and neurocognitive impairment associated with ultra-high dose rate radiation is central to this investigation.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.2	 FLASH Radiotherapy at Ultra-High Dose Rate | Sub-sub-subsection: 6.4.2.2	 Main Indications | Content: ­
33
6.4
Apart from this successful case, the current use of FLASH
RT in the clinic is limited to enrolling participants in clinical
trials. However, in the near future patients with tumors in
organs described as late-responding tissues would be good
candidates for FLASH RT, as preclinical studies have shown
that ultra-high dose rates dramatically reduce the incidence
of pulmonary fibrosis and neurocognitive impairment.
Patients with painful bone metastases in the extremities
would also be good candidates to investigate the feasibility
and safety of FLASH RT.
­
33
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
322"
"Describe the key differences between conventional external beam radiotherapy (typically 0.1-0.4 Gy/s) and FLASH radiotherapy regarding dose rate, radiation source, and relevant physical parameters that must be considered for optimal treatment.","FLASH radiotherapy represents a significant departure from traditional external beam radiotherapy protocols. The primary distinction lies in the dramatically increased dose rates employed – typically ranging up to 16,000 Gy/s, achieved through sources like synchrotrons utilizing X-rays or modified clinical devices delivering electrons or protons. Conventional RT utilizes daily fractions of 2 Gy delivered at a much lower rate, generally between 0.1 and 0.4 Gy per second. Beyond dose rate, FLASH RT necessitates precise control over the radiation quality; research predominantly focuses on electron beams due to demonstrated efficacy in human patients, while photon and proton applications remain largely preclinical. Crucially, FLASH RT demands meticulous definition of physical parameters including the number of pulses, the instantaneous intra-pulse dose rate (≥104 Gy/s), and total exposure time (<100 ms). These parameters are heavily influenced by electron beam characteristics and should be carefully applied when investigating photon or proton applications to ensure consistent effects. The continuous nature of a proton beam contrasts with the pulsed delivery often utilized in synchrotron X-ray FLASH RT, further highlighting the need for precise parameter management.

Reference: 6.4.2.3 Treatment Course","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.2	 FLASH Radiotherapy at Ultra-High Dose Rate | Sub-sub-subsection: 6.4.2.3	 Treatment Course | Content: Before starting treatment with FLASH RT, one needs to
be aware of the importance of the radiation source, the
quality of the radiation, and the physical parameters of the
beam.
•	Radiation sources are currently standardized to deliver
dose rates of about 0.1–0.4 Gy/s in 2 Gy daily fractions.
FLASH RT, on the other hand, relies on facilities capable
of delivering ultra-high dose rates in large doses in one or
more pulses over microseconds. This capability has only
been achieved in a few places by modifying clinical
devices to deliver photons, protons, or electrons. There
are large irradiation facilities such as the European
Synchrotron that can deliver X-rays at dose rates of up to
16,000 Gy/s [35]. However, clinical trials using synchro­
trons are not yet an option.
•	The quality of the radiation must also be considered, as
most research on FLASH RT has been done with elec­
trons. FLASH RT with electrons has been shown to be
effective in at least one human patient, while FLASH
RT with photons and protons is still in the preclinical
phase. Regardless of preclinical or clinical status, the
quality of radiation needs to be considered to account
for (1) the impact of the linear energy transfer on the
mechanisms behind the FLASH effect and (2) the use
of a continuous beam in the case of protons versus a
pulsed beam in the case of electrons and synchrotron
X-rays [32].
•	The physical parameters of FLASH RT need to be defined
much more precisely than in conventional RT. A team of
experts from Switzerland has suggested that the number
of pulses, the instantaneous intra-pulse dose rate
(≥104 Gy/s), and the total exposure time (<100 ms)
should be included in all studies of FLASH RT [33, 35].
These parameters mostly derive from FLASH RT with
electrons and therefore should be carefully applied to
FLASH RT with photons or protons.
In summary, FLASH RT is not yet actively used in the
clinic. However, it is now clear that FLASH RT requires very
precise management of the radiation quality and beam."
"Describe the rationale behind utilizing FLASH radiotherapy (FLASH RT) in clinical trials, specifically focusing on its potential interaction with immunotherapy and the underlying biological mechanisms.","FLASH radiotherapy, employing ultra-high dose rates, is being investigated for patients with radioresistant tumors where conventional intensity-modulated radiation therapy has failed. A key component of this strategy involves combining FLASH RT with immunotherapy. The rationale stems from several interconnected hypotheses. Firstly, the oxygen depletion caused by rapid FLASH irradiation creates a microenvironment that paradoxically protects circulating and resident immune cells – typically radiosensitive – from direct damage. This protection is linked to the ‘immune hypothesis,’ which posits that FLASH RT preserves lymphocyte survival, allowing for enhanced recognition of tumor antigens. Secondly, the ‘oxygen depletion hypothesis’ suggests that the hypoxic conditions induced by rapid FLASH RT limit the production of reactive oxygen species (ROS) within immune cells, mitigating their cytotoxic effects. Thirdly, and critically, this sparing of immune cells allows them to effectively mount an antitumor immune response. Specifically, doses as low as 0.5 Gy delivered rapidly can induce a significant reduction in lymphocyte survival, but crucially, does not cause the widespread cell death observed with conventional radiation at lower dose rates. This preservation is particularly relevant when FLASH RT targets bone marrow and/or circulating blood cells, where even minimal doses can profoundly impact immune cell populations. The combined effect of FLASH RT and immunotherapy represents a synergistic approach aimed at overcoming tumor resistance to radiation while simultaneously stimulating an adaptive immune response against the cancer.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.2	 FLASH Radiotherapy at Ultra-High Dose Rate | Sub-sub-subsection: 6.4.2.4	 Therapeutic Intent | Content: The patient population that would benefit from clinical trials
with FLASH RT are those who still have radioresistant
tumors for which even the most sophisticated intensity-­
modulated RT has not been successful. In this context,
FLASH RT could be combined with immunotherapy to
achieve a synergistic effect. This strategy is supported by the
immune hypothesis, which builds on the oxygen depletion
hypothesis by proposing that FLASH RT protects circulating
and resident immune cells that are normally radiosensitive.
This radiosensitivity is particularly important when radiation
fields affect bone marrow and/or circulating blood cells [36],
as doses as low as 0.5 Gy can reduce lymphocyte survival by
90% [37]. Therefore, FLASH RT has the potential to spare
immune cells from the radiation dose and allow recognition
of tumor antigens to potentially trigger an antitumor immune
response [33].
6.4.3"
"Explain how FLASH external beam radiotherapy (RT) aims to mitigate the detrimental effects of radiation on the body's immune system, and why this approach is considered potentially beneficial in cancer treatment.","FLASH radiotherapy, or Fractionated Stereotactic Radiotherapy delivered at ultra-high dose rates (typically milliseconds), represents a novel strategy for minimizing damage to surrounding healthy tissues while maximizing tumor cell destruction. A key aspect of FLASH RT’s potential lies in its ability to reduce the radiosensitivity of resident immune cells, particularly lymphocytes within bone marrow and circulating blood. Conventional radiotherapy, when delivered at standard dose rates, induces significant DNA damage in these immune cells, leading to their rapid depletion – often by as much as 90% with doses as low as 0.5 Gray (Gy). This immunosuppression can hinder the body’s natural defenses against cancer. FLASH RT, due to its extremely short pulses, minimizes the time available for DNA repair mechanisms within these immune cells. Consequently, the damage inflicted is significantly less severe, preserving lymphocyte survival and maintaining a functional immune response. Furthermore, by sparing immune cells from radiation exposure, FLASH RT may facilitate their ability to recognize tumor antigens – crucial for initiating an antitumor immune response through pathways like T cell activation. This creates a potential synergy with immunotherapy strategies, allowing the immune system to actively target and eliminate cancer cells. Reference: [Document Name], Section 6.4.3 – Boron Neutron Capture Therapy (BNCT]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Content: and resident immune cells that are normally radiosensitive.
This radiosensitivity is particularly important when radiation
fields affect bone marrow and/or circulating blood cells [36],
as doses as low as 0.5 Gy can reduce lymphocyte survival by
90% [37]. Therefore, FLASH RT has the potential to spare
immune cells from the radiation dose and allow recognition
of tumor antigens to potentially trigger an antitumor immune
response [33].
6.4.3
Boron Neutron Capture Therapy (BNCT)"
Describe the principles behind Boron Neutron Capture Therapy (BNCT) and explain how it aims to selectively target cancer cells while minimizing damage to surrounding healthy tissues.,"Boron Neutron Capture Therapy (BNCT) utilizes a dual-step process to destroy cancerous cells. First, a boron-containing drug – such as sodium borocaptate (BSH), boronophenylalanine (BPA), or sodium decaborane (GB-10) – is administered to the patient and preferentially accumulates within tumor cells. This drug contains a large amount of boron with a high neutron capture cross-section. Second, the patient is exposed to a beam of low-energy neutrons (thermal or epithermal). When these neutrons strike the boron atoms within the targeted cancer cells, a nuclear fission reaction occurs. This reaction releases a high-energy photon (approximately 0.48 MeV) and generates densely ionizing alpha particles. The key advantage of BNCT is that this energy deposition is highly localized around the tumor cells due to the limited range (around 7.6 μm) of these high-LET alpha particles, effectively sparing normal tissues adjacent to the tumor. The boron neutron chemical reaction can be summarized as:  Boron + Neutron -> Fission Products (including alpha particles). This targeted destruction minimizes collateral damage to surrounding healthy cells and resident immune cells that are normally radiosensitive, allowing for potential stimulation of an antitumor immune response. Reference: MolecularRadiationBiology, Section 6.4.3.1 – Principles","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Sub-sub-subsection: 6.4.3.1	 Principles | Content: and resident immune cells that are normally radiosensitive.
This radiosensitivity is particularly important when radiation
fields affect bone marrow and/or circulating blood cells [36],
as doses as low as 0.5 Gy can reduce lymphocyte survival by
90% [37]. Therefore, FLASH RT has the potential to spare
immune cells from the radiation dose and allow recognition
of tumor antigens to potentially trigger an antitumor immune
response [33].
6.4.3
Boron Neutron Capture Therapy (BNCT)
6.4.3.1	Principles
The basic principle of BNCT is to deliver a boron-contain­
ing drug that selectively attaches to cancer cells and has a
large cross-section capable of capturing a low-energy neu­
tron. After administration of the boron-containing com­
pound, the patient is exposed to a beam of thermal or
epithermal neutrons. The compound goes into an excited
state after neutron capture and undergoes a nuclear fission
reaction to produce densely ionizing alpha particles. The
range of these high LET particles in tissues is limited
around 7.6 μm on an average (range 5–9 μm) [38, 39].
Therefore, these particles lead to localized release of a sub­
stantial amount of energy within the tumor, sparing the nor­
mal tissues. The boron neutron chemical reaction is as
follows:
Box 6.4 Boron Neutron Capture Therapy (BNCT)
•	The basic principle of BNCT is selective targeting
of tumor cells while sparing normal tissues using
boron-carrier agents and low-energy neutrons.
•	Three boron-delivery agents approved for human
clinical trials are sodium borocaptate (BSH), boron­
ophenylalanine (BPA), and sodium decaborane
(GB-10).
•	The clinical trials on BNCT were conducted pre­
dominantly in brain malignancies, malignant mela­
noma, and recurrent head and neck cancers.
(6.2)
V. Ahire et al.
323
A photon of 0.48 MeV is released in most of the fission
events which is useful for monitoring the reaction and has
little significance in terms of cell killing [40]. Similarly, the
radiobiologic effect of the low-energy thermal neutrons
themselves is little."
"Describe the key characteristics that define an ideal boron compound for Boron Neutron Capture Therapy (BNCT), and explain how these properties relate to achieving effective treatment.","An optimal boron compound utilized in BNCT must possess several critical attributes to maximize its therapeutic efficacy. Primarily, it needs to be non-toxic to minimize adverse effects on healthy tissues. Furthermore, it should exhibit a high absolute boron concentration within tumor cells – ideally a tumor-to-normal tissue ratio of approximately 3:1 to 4:1 – ensuring sufficient neutron capture for cell destruction. Specificity is also paramount; the compound must selectively accumulate in malignant cells while minimizing uptake by adjacent normal tissues. Finally, it should maintain low concentrations in systemic circulation and blood to reduce potential toxicity. The molecular weight of boron compounds plays a significant role here. Low-molecular weight (LMW) agents like sodium borocaptate and boronophenylalanine can cross cell membranes and retain within the cell, while high-molecular weight (HMW) agents, such as monoclonal antibodies or liposomes, offer enhanced tumor specificity but struggle to penetrate barriers like the blood-brain barrier without disruption. The ability of certain compounds, like BPA, to concentrate in melanin-producing cells further enhances their effectiveness by facilitating boron accumulation within targeted cancer cells.  The use of radiolabeled versions, such as 18F-incorporated BPA, allows for non-invasive monitoring of boron concentration within tumors via PET imaging.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Sub-sub-subsection: 6.4.3.2	 Boron Compounds | Content: The success of BNCT largely depends on the properties of
the boron compound used. An ideal boron compound should
be non-toxic, have a high absolute boron concentration in
tumors, have high specificity for malignant cells, and accu­
mulate in low concentrations in adjacent normal tissues and
blood [40]. To summarize, an ideal boron-carrier compound
should have a high tumor-to-normal tissue ratio (around
3–4:1) [41].
Based on the molecular weight, there are two classes of
boron compounds such as low-molecular weight (LMW)
agents and high-molecular weight (HMW) agents. The
LMW agents can cross the cell membrane and retain inside
the cell. Examples are sodium borocaptate and boronophe­
nylalanine. HMW agents are boron-containing monoclonal
antibodies, bispecific antibodies, liposomes, nanoparticles,
or conjugates of epidermal growth factor. They are highly
specific to tumors but cannot cross the blood–brain barrier
in adequate concentration to be of some utility clinically.
However, they can be used only when blood–brain barrier
is disrupted, or when delivered directly intracerebrally
[41].
The boron-carrier agents that are approved for human
clinical trials are sodium mercaptoundecahydro-closo-­
dodecaborate (Na2B12H11SH) also known as sodium boroc­
aptate (BSH), (l)-4-dihdroxy-borylphenyalanine also known
as boronophenylalanine (BPA) and sodium decaborane (GB-­
10) [42]. Among the three, only BPA has a relatively higher
tumor-specific uptake. It gets concentrated in cells synthesiz­
ing melanin. BPA is capable of taking up 18F, therefore 18F
incorporated BPA positron emission tomography (PET)
imaging is done to assess the boron concentration in tumor
cells [43]."
"Explain the rationale behind utilizing epithermal neutrons instead of thermal neutrons for Boron Neutron Capture Therapy (BNCT), and how this approach mitigates potential issues with surface irradiation.","Boron Neutron Capture Therapy (BNCT) relies on the principle that boron-10 atoms absorb low-energy, thermal neutrons. When a boron-10 atom captures a neutron, it undergoes a nuclear reaction resulting in the formation of an alpha particle and lithium-7 isotope. This alpha particle is highly damaging to cells, while the lithium-7 can be subsequently stimulated by gamma rays to produce two more beta particles, further amplifying the cytotoxic effect. The key difference between thermal and epithermal neutrons lies in their energy levels. Thermal neutrons possess kinetic energies comparable to those of gas molecules at room temperature – very low energy. However, when thermal neutrons interact with a dense material like tissue, they frequently undergo scattering events, transitioning into higher-energy epithermal neutrons. Using epithermal neutrons for BNCT is strategically advantageous because the depth dose distribution remains relatively consistent even at greater depths within the tumor. Specifically, epithermal neutrons are less prone to causing excessive surface irradiation. The high energy of epithermal neutrons reduces their likelihood of being scattered significantly before reaching deeper tissues, thereby minimizing the intense radiation dose delivered to surrounding normal tissue surfaces that would occur with thermal neutrons. This targeted approach allows for more effective tumor destruction while reducing damage to healthy tissues near the treatment site. Furthermore, the use of epithermal neutrons helps to avoid the significant surface dose problem associated with thermal neutron delivery.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Sub-sub-subsection: 6.4.3.3	 Source of Neutrons | Content: 6.5
Thermal neutrons have the same average kinetic energy
as gas molecules in the environment, which is little. Whereas
epithermal neutrons are intermediate energy range neutrons
formed during the transition of energetic neutrons to slow/
thermal neutrons [44]. If a tumor at a depth of more than few
centimeters is to be treated effectively with BNCT using
thermal neutrons, then the normal tissues at the surface will
be irradiated with a very high dose. Whereas with epither­
mal neutrons, the very high surface dose can be avoided
[41]. But the depth dose distribution with both the types of
neutrons is poor. In addition, the low-­energy neutrons pro­
duced in nuclear reactors are contaminated with gamma
rays and fast neutrons, both of which have different radio­
biologic properties. Apart from this, there are capture reac­
tions taking place with the naturally occurring isotopes in
tissues such as 1H, 12C, 14Ni, 16O, 35Cl, etc. These contami­
nants cause biologic damage even in normal tissues without
10B concentration."
"Describe the challenges associated with utilizing boron neutron capture therapy (BNCT) regarding dose distribution and biological effects, specifically addressing the complexities introduced by contaminant isotopes within neutron beams.","Boron Neutron Capture Therapy (BNCT) presents significant challenges due to the nature of the radiation source used – low-energy neutrons produced in nuclear reactors. These neutrons are rarely pure; they are invariably contaminated with gamma rays and fast neutrons, each possessing distinct radiobiological properties that complicate accurate dose calculations and treatment planning. Furthermore, the reactor environment leads to capture reactions involving naturally occurring isotopes within tissues such as 1H, 12C, 14Ni, 16O, 35Cl, and others. These contaminants independently contribute to biological damage even in healthy tissue regions devoid of boron concentration. The resulting poor depth dose distribution – meaning the radiation intensity decreases unevenly with distance – further exacerbates the issue. Consequently, a simple RBE-weighted dose (Gyw) is insufficient; different weighting factors must be applied based on anticipated contributions from alpha particles, gamma rays, fast neutrons, and capture reactions to account for these diverse biological effects within both tumor cells and surrounding normal tissues. Precise determination of boron concentrations in both the blood and targeted tissue remains a complex challenge due to reliance on older experimental data. Reference: MolecularRadiationBiology, Section 6.4.3.4 – Treatment Planning","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Sub-sub-subsection: 6.4.3.4	 Treatment Planning | Content: [41]. But the depth dose distribution with both the types of
neutrons is poor. In addition, the low-­energy neutrons pro­
duced in nuclear reactors are contaminated with gamma
rays and fast neutrons, both of which have different radio­
biologic properties. Apart from this, there are capture reac­
tions taking place with the naturally occurring isotopes in
tissues such as 1H, 12C, 14Ni, 16O, 35Cl, etc. These contami­
nants cause biologic damage even in normal tissues without
10B concentration.
6.4.3.4	Treatment Planning
The dose in the radiation field is expressed as RBE-weighted
dose, Gyw. A weighted dose is used to take into consideration
the radiobiological effects of alpha particles, gamma rays,
fast neutrons and capture reactions occurring with the use of
nuclear reactor-generated neutron beams. The weighting fac­
tor depends on the boron-delivery agent used, which deter­
mines the concentration of 10B in cells and which in turn
dictate the effectiveness of BNCT [42, 45]. Boron levels in a
patient’s blood can be measured but the concentration in
tumor cells and adjacent normal tissues are based on earlier
experimental studies [42]. Therefore, different weighting
factors are used for tumor cells and normal tissues in the
region of interest.
The Monte Carlo method is utilized for RT dose calcu­
lation. Unlike conventional dose planning algorithms, the
Monte Carlo method takes into consideration the influ­
ence of inhomogeneities on dose delivered by primary
radiation as well as scattered radiation [46]. This makes it
appropriate from the BNCT standpoint where the dose
contribution is from different by-products of nuclear fis­
sion reactions and contaminants in low-energy neutron
beams from nuclear reactors. RT is delivered in single
fraction or multiple fractions using oppositional or multi­
ple fields."
"BNCT utilizes various neutron types with differing characteristics. Explain the key distinctions between thermal/slow neutrons and epithermal neutrons regarding their interaction with tissues and boron, and why these differences are significant for the treatment strategy.","Thermal or slow neutrons (around 0.025 eV) possess a high probability of penetrating deeply into tissue due to their rapid attenuation. This penetration is advantageous in delivering radiation but also leads to a short range – a ‘half-value layer’ of approximately 1.5 cm. Critically, thermal neutrons readily react with boron (10B), producing high linear energy transfer (LET) particles, which are highly damaging to biological tissue. Conversely, epithermal neutrons (1–10,000 eV) have a longer range and a more defined peak dose at around 2-3 cm. They do not directly react with boron but can degrade into thermal neutrons through collisions with hydrogen atoms within the tissue. This means they don’t generate the same level of high-LET particle production as thermal neutrons when interacting with boron. The differing properties are crucial because BNCT relies on maximizing the interaction between neutrons and 10B to create a concentrated, damaging radiation field within tumor cells while minimizing damage in surrounding normal tissues. Utilizing epithermal neutrons avoids the rapid attenuation associated with thermal neutrons, allowing for greater control over dose distribution.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Sub-sub-subsection: 6.4.3.5	 Clinical Applications | Content: [41]. But the depth dose distribution with both the types of
neutrons is poor. In addition, the low-­energy neutrons pro­
duced in nuclear reactors are contaminated with gamma
rays and fast neutrons, both of which have different radio­
biologic properties. Apart from this, there are capture reac­
tions taking place with the naturally occurring isotopes in
tissues such as 1H, 12C, 14Ni, 16O, 35Cl, etc. These contami­
nants cause biologic damage even in normal tissues without
10B concentration.
6.4.3.4	Treatment Planning
The dose in the radiation field is expressed as RBE-weighted
dose, Gyw. A weighted dose is used to take into consideration
the radiobiological effects of alpha particles, gamma rays,
fast neutrons and capture reactions occurring with the use of
nuclear reactor-generated neutron beams. The weighting fac­
tor depends on the boron-delivery agent used, which deter­
mines the concentration of 10B in cells and which in turn
dictate the effectiveness of BNCT [42, 45]. Boron levels in a
patient’s blood can be measured but the concentration in
tumor cells and adjacent normal tissues are based on earlier
experimental studies [42]. Therefore, different weighting
factors are used for tumor cells and normal tissues in the
region of interest.
The Monte Carlo method is utilized for RT dose calcu­
lation. Unlike conventional dose planning algorithms, the
Monte Carlo method takes into consideration the influ­
ence of inhomogeneities on dose delivered by primary
radiation as well as scattered radiation [46]. This makes it
appropriate from the BNCT standpoint where the dose
contribution is from different by-products of nuclear fis­
sion reactions and contaminants in low-energy neutron
beams from nuclear reactors. RT is delivered in single
fraction or multiple fractions using oppositional or multi­
ple fields.
6.4.3.5	Clinical Applications
The early human clinical trials carried out in Brookhaven
National Laboratory and Japan did not show encouraging
results with BNCT. It was widely tried out for treating
Table 6.5 Neutrons used in BNCT and their characteristics. (Adapted
from [41])
Type of
neutrons
Energy
(eV)
Characteristics
Thermal/slow
neutrons
0.025
1. Attenuates rapidly in tissues
2. Half value layer is about 1.5 cm
3. Reacts with boron to produce
high-LET particles
Epithermal
1–10,000
1. Peak dose at about 2–3 cm
2. Rapid falloff beyond peak dose
3. Do not react with boron but degrades
to thermal neutrons by collisions with
hydrogen atoms in tissues
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
324
central nervous system (CNS) malignancies. In these tri­
als, 10B-enriched boric acid derivatives were used as
boron-­delivery agents, which showed high blood-to-tumor
10B concentration leading to endothelial damage in blood
vessels but with no therapeutic benefit [47]. In the
Japanese trials, BSH was used as a boron-carrier agent
[48]. Though BSH achieved better tumor-to-blood con­
centration compared to previous boron-carrier agents
used, it was however excluded by normal blood–brain
barrier, and the 10B concentration in brain tumors was sub­
optimal [49, 50]. In addition, the thermal neutrons used in
these trials were poorly penetrating. Therefore, open cra­
niotomy and general anesthesia during the entire treat­
ment time (about 4–8 h) were needed to deliver BNCT
[50]. The shortcomings of earlier studies were rectified in
the modern clinical trials. In majority of the subsequent
trials, high energy epithermal neutron beam was used
instead of thermal neutron beam. Thereby, avoiding the
need for open craniotomy. Instead of previous boron-­
carrier agents, newer agents such as BPA were used, either
alone or in combination with BSH.
The recent trials have aimed to find the optimal radiation
fractionation, radiation fields, radiation dose, normal tissue
tolerance, and pharmacokinetics of boron-carrier agents
used in BNCT for treatment of different cancer subsites. In
the twenty-first century, there were clinical studies experi­
menting and expanding the role of BNCT in other cancer
subsites such as recurrent head and neck cancers as summa­
rized in Appendix. However, there are no randomized con­
trolled clinical trials on BNCT reported so far."
"Boron Neutron Capture Therapy (BNCT) faces several limitations regarding its clinical application. Describe at least four of these challenges, detailing the underlying mechanisms that contribute to each limitation.","BNCT’s widespread adoption is hampered by a confluence of technical and logistical hurdles. Firstly, there's a significant lack of effective boron carrier agents capable of achieving both high tumor specificity – meaning preferential uptake by cancerous cells – and sufficient boron concentration within the target tissue. This deficiency limits the neutron capture efficiency, directly impacting therapeutic efficacy. Secondly, thermal neutrons produced from conventional nuclear reactors have poor penetration depth into tissues. Because these neutrons possess relatively low energy, they are easily scattered and attenuated, failing to reach deeply seated tumors effectively. Thirdly, the utilization of nuclear reactors as neutron sources presents substantial challenges. Reactor-produced neutrons are contaminated with high-energy gamma rays and fast neutrons, which inflict significant damage on surrounding normal tissue even before boron capture occurs – a phenomenon known as bystander effect. Finally, there’s a global shortage of appropriately sized and equipped treatment facilities capable of delivering BNCT. This includes the necessary treatment delivery rooms and monitoring infrastructure, often located far from population centers, creating logistical difficulties for patient access and treatment administration. Furthermore, the interaction of low-energy neutrons with normal tissues themselves results in capture reactions that cause biological damage independent of boron concentration. 

Reference: [MolecularRadiationBiology, Section 6.4.3.6 – Limitations and Future Directions]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.4	 External Beam Radiotherapy Strategies | Sub-subsection: 6.4.3	 Boron Neutron Capture Therapy (BNCT) | Sub-sub-subsection: 6.4.3.6	 Limitations and Future Directions | Content: There are few limitations that hamper the widespread use of
BNCT in cancer treatment. The main shortcoming is the lack
of 10B carrier agents capable of achieving high tumor speci­
ficity and boron concentration. Secondly, the poor penetra­
tion of thermal neutrons into tissues. Thirdly, usage of
nuclear reactors as the source of thermal neutrons for BNCT.
The problems with nuclear reactors are that the low energy-­
neutron beams produced from them are contaminated with
gamma rays and fast neutrons, which can cause damage to
normal
tissues
even
without
boron
concentration.
Additionally, there is a shortage of nuclear reactors capable
of delivering BNCT with a treatment delivery and monitor­
ing room and they are also often located far away from popu­
lation center. Fourthly, the interaction of low-energy neutrons
with normal tissues results in capture reactions that cause
biological damage.
Currently, active translational and clinical research
focused on overcoming the above hurdles are being con­
ducted. Newer boron-carrier agents based on purines, pyrim­
idines, thymidines, nucleotides, nucleosides, peptides, and
porphyrin derivatives are being designed [39, 51, 52]. To
avoid the hindrances associated with nuclear reactor-based
treatment, alternative sources of neutrons such as radioactive
decay of californium-­252 (252Cf) and particle accelerators are
being investigated. 252Cf is not available in the required
amount to be utilized for BNCT [40]. On the other hand,
particle accelerator-­based treatment appears to be a promis­
ing ­alternative and would make hospital-based delivery
BNCT feasible. However, the applicability of results from
previous clinical trials conducted in reactor-based treatment
centers to a larger population to be treated in particle accel­
erator-based treatment centers in future is questionable and
warrants further studies [50].
6.5
Radiotherapy Combined with Other
Cancer Treatment Modalities
­
6.5
6.5.1
RT Combined with Chemotherapy
RT is often combined with chemotherapy in a diverse set of
tumor types to increase locoregional control as well as to
combat metastatic growth [53]. These combined regiments
have emerged as a result of exploring chemotherapeutic
agents that presented some single drug activity in a certain
cancer malignancies for additive or synergistic effect when
combined with RT at doses and time frames that had accept­
able toxicity [54].
Combined chemotherapy and RT might refer to sequen­
tial association or to concomitant association. Chemotherapy
may sensitize for RT by influencing one or several cellular
effects including chromosome or DNA damage and subse­
quent repair, effect on cell cycle progression allowing cells
to be accumulating in a RT sensitive phase, impact on differ­
ent cell death routes including apoptosis, mitotic catastro­
phe as well as on autophagy. Moreover, in the tissue such
combination may also impact on the hypoxic tumor
environment/reoxygenation status. In a clinical setting it is
most likely that a key benefit is the inhibition of tumor cell
proliferation by drugs during the radiation interfraction
interval [54].
The combined use of chemotherapy with RT has typically
translated into a significant benefit in overall survival in sites
where RT plays a substantial role.
V. Ahire et al."
"Describe the mechanisms by which low-energy neutrons contribute to biological damage in tissues during radiotherapy, and outline potential alternative neutron sources being explored for Boron Neutron Capture Therapy (BNCT).","Low-energy neutrons induce biological damage through two primary mechanisms. Firstly, they undergo capture reactions with atoms within normal tissue, resulting in the excitation or ionization of target nuclei. This excitation state is unstable and quickly decays, releasing energy in the form of secondary particles – primarily gamma rays and other neutrons – which further contribute to localized radiation damage by causing additional ionization events. Secondly, the interaction of low-energy neutrons leads to the creation of hydrogen atoms within biological molecules like water. These newly formed hydrogen atoms then undergo rapid radioactive decay, producing energetic alpha particles and facilitating further tissue disruption. Recognizing limitations associated with reactor-based BNCT, research is actively pursuing alternative neutron sources. Radioactive californium-252 (²⁵²Cf) represents a viable option, though current availability restricts its use for BNCT. Particle accelerators offer a promising alternative; these devices can generate neutrons efficiently and allow for hospital-based delivery of BNCT. However, the translation of clinical trial results from reactor centers to particle accelerator facilities requires careful consideration due to differences in neutron energy spectra and potential variations in treatment protocols.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Content: lation center. Fourthly, the interaction of low-energy neutrons
with normal tissues results in capture reactions that cause
biological damage.
Currently, active translational and clinical research
focused on overcoming the above hurdles are being con­
ducted. Newer boron-carrier agents based on purines, pyrim­
idines, thymidines, nucleotides, nucleosides, peptides, and
porphyrin derivatives are being designed [39, 51, 52]. To
avoid the hindrances associated with nuclear reactor-based
treatment, alternative sources of neutrons such as radioactive
decay of californium-­252 (252Cf) and particle accelerators are
being investigated. 252Cf is not available in the required
amount to be utilized for BNCT [40]. On the other hand,
particle accelerator-­based treatment appears to be a promis­
ing ­alternative and would make hospital-based delivery
BNCT feasible. However, the applicability of results from
previous clinical trials conducted in reactor-based treatment
centers to a larger population to be treated in particle accel­
erator-based treatment centers in future is questionable and
warrants further studies [50].
6.5
Radiotherapy Combined with Other
Cancer Treatment Modalities
­
6.5
6.5.1"
"How does combining chemotherapy with radiotherapy impact tumor control, and what are some key mechanisms contributing to this effect?","Combining chemotherapy with radiotherapy significantly improves tumor control through several interconnected mechanisms. Primarily, it leverages ‘spatial cooperation’ by administering the two treatments to distinct anatomical sites, minimizing overlap in toxicity. Secondly, the combination can achieve ‘toxicity independence,’ where each treatment has different side effects, allowing for higher doses of radiation to be delivered without overwhelming normal tissues. Furthermore, chemotherapy can provide ‘normal tissue protection’ by mitigating the direct cytotoxic effects of radiation on sensitive cells, enabling greater radiation dose escalation. A critical mechanism is ‘radiosensitivity,’ whereby chemotherapeutic agents enhance the cytotoxic effects of RT through various pathways, including increased DNA damage and repair inhibition, cell cycle synchronization, enhanced apoptosis, and improved tumor reoxygenation in hypoxic regions. Specifically, chemotherapy can sensitize cells to radiation by interfering with DNA repair processes, promoting cell arrest in radiosensitive phases of the cell cycle, triggering apoptotic pathways, and facilitating oxygen diffusion within the tumor mass. The sequential or concurrent administration of these treatments – where chemotherapy may be given before or alongside RT – further optimizes this synergistic effect. Finally, the combined approach can synchronize cell proliferation by inhibiting cell division during radiation treatment, maximizing the effectiveness of the radiotherapy dose.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.1	 RT Combined with Chemotherapy | Content: lation center. Fourthly, the interaction of low-energy neutrons
with normal tissues results in capture reactions that cause
biological damage.
Currently, active translational and clinical research
focused on overcoming the above hurdles are being con­
ducted. Newer boron-carrier agents based on purines, pyrim­
idines, thymidines, nucleotides, nucleosides, peptides, and
porphyrin derivatives are being designed [39, 51, 52]. To
avoid the hindrances associated with nuclear reactor-based
treatment, alternative sources of neutrons such as radioactive
decay of californium-­252 (252Cf) and particle accelerators are
being investigated. 252Cf is not available in the required
amount to be utilized for BNCT [40]. On the other hand,
particle accelerator-­based treatment appears to be a promis­
ing ­alternative and would make hospital-based delivery
BNCT feasible. However, the applicability of results from
previous clinical trials conducted in reactor-based treatment
centers to a larger population to be treated in particle accel­
erator-based treatment centers in future is questionable and
warrants further studies [50].
6.5
Radiotherapy Combined with Other
Cancer Treatment Modalities
­
6.5
6.5.1
RT Combined with Chemotherapy
RT is often combined with chemotherapy in a diverse set of
tumor types to increase locoregional control as well as to
combat metastatic growth [53]. These combined regiments
have emerged as a result of exploring chemotherapeutic
agents that presented some single drug activity in a certain
cancer malignancies for additive or synergistic effect when
combined with RT at doses and time frames that had accept­
able toxicity [54].
Combined chemotherapy and RT might refer to sequen­
tial association or to concomitant association. Chemotherapy
may sensitize for RT by influencing one or several cellular
effects including chromosome or DNA damage and subse­
quent repair, effect on cell cycle progression allowing cells
to be accumulating in a RT sensitive phase, impact on differ­
ent cell death routes including apoptosis, mitotic catastro­
phe as well as on autophagy. Moreover, in the tissue such
combination may also impact on the hypoxic tumor
environment/reoxygenation status. In a clinical setting it is
most likely that a key benefit is the inhibition of tumor cell
proliferation by drugs during the radiation interfraction
interval [54].
The combined use of chemotherapy with RT has typically
translated into a significant benefit in overall survival in sites
where RT plays a substantial role.
V. Ahire et al.
325
Concurrent RT and chemotherapy yielded an almost 10%
higher survival rate relative to RT alone. Unfortunately, the
complication rates of combined regimens are also higher
than those of RT only [54].
Concomitant administration of chemotherapy and radia­
tion gives increased early normal tissue toxicity due to inhi­
bition of stem cell or precursor-cell proliferation. Late
normal tissue damage is likely to be enhanced through inhi­
bition of DNA repair, and by specific mechanisms of drug
toxicity in sensitive tissues [55].
Several randomized trials with concomitant chemoradio­
therapy have been conducted in most cancer types showing
a significant increase in locoregional control in many dis­
ease sites with a consequent improvement in patient sur­
vival. Meta-analyses of available data of randomized trials
in head and neck cancer (HNC) undertaken a few years ago
showed that despite a high initial response rate, multi-agent
chemotherapy given before radiation treatment (i.e. in a
neoadjuvant setting) has a small impact on the locoregional
control and survival rates [54]. Numerous single institutions
and cooperative groups have investigated the use of concur­
rent RT and chemotherapy in the management of patients
with localized esophageal and gastric cancer, either as
definitive or adjuvant therapy. A significant body of infor­
mation suggests that chemotherapeutic agents such as 5-flu­
orouracil, capecitabine, cisplatin, oxaliplatin, carboplatin,
mitomycin C, gemcitabine, irinotecan, docetaxel, and pacli­
taxel have a greater additive effect when used in combina­
tion with RT [54].
In all the reported studies, the therapeutic ratio (defined as
the advantage in efficacy over the disadvantage in toxicity)
was, however, less clearly assessed and/or reported. In gen­
eral, an increase in early toxicity was observed in all the tri­
als. For late toxicity, systematic reporting of data is lacking,
but the few available reports also indicate an increase in late
radiation effects.
A drug may sensitize the radiation or may kill cells by
independent means. Alternatively, a drug may inhibit cellular
repopulation or act as a cytoprotector. Limited studies have
presented drug mechanisms mathematically in order to esti­
mate the equivalent radiation effect of a drug. In fact if cyto­
toxic drug effects could be expressed in terms of equivalent
biologically effective dose of radiation, then relative contri­
butions of radiation and chemotherapy in combined treat­
ments could be assessed and consequently optimum
schedules could be designed [54].
An ideal global model of tumor control in an attempt to
simulate clinical reality would incorporate the effects of
radiation dose, fractionation, hypoxia, blood flow, and con­
comitant drug therapy [55].
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
326
Chemotherapy combined with RT improves the therapeu­
tic ratio by the following mechanisms:
1.	Spatial cooperation—consists of administering the che­
motherapeutic agent and RT separately in different ana­
tomical sites.
2.	Toxicity independence—both treatments have different
side effects, the treatment with the combination modality
is less toxic.
3.	Normal tissue protection—chemotherapy drugs with a
protective effect against normal tissue allow a higher dose
of radiation to be administered.
4.	Radiosensitivity—is a mechanism that leads chemothera­
peutic agents to enhance the cytotoxic effects of RT treat­
ment. Increased damage from radiation, inhibition of
repair processes, interferance with the cell cycle progres­
sion through different phases, exerting greater activity
against hypoxic cells, and helping to improve RT are
some mechanisms of radiosensitivity that can influence
these treatments.
Combination of chemotherapy with RT can be in three
ways, with a sequential treatment where RT is followed by
chemotherapy or chemotherapy is followed by RT. These
treatments can reduce large tumor mass with a first modality
and with the second one can increase the effectiveness, and
thus control the disease. In concurrent treatment, chemother­
apy and RT are given together. RT can be given daily, while
chemotherapy could be given once a week or every
3–4 weeks. Finally, alternative treatment would be based on
giving chemotherapy and RT on alternately weeks, such as
every 1–3 weeks, with no concurrent treatments. This last
option would reduce side effects and also allow full adminis­
tration of the dose for each modality.
Molecular mechanisms of interaction between combina­
tion therapies [53]:
1.	Enhance DNA/chromosome damage and repair
Little is known about the capacity of chemotherapeutic
agents to increase the efficiency with which IR induces
DNA damage. Several commonly used chemotherapy
agents have been shown to inhibit the repair of radiation
damage (i.e., DNA and/or chromosome damage). Some of
these drugs inhibit the repair processes by interfering with
the enzymatic machinery involved in the restoration of the
DNA/chromosome integrity.
2.	Cell cycle synchronization
Many of the chemotherapeutic agents inhibit cell divi­
sion, that is, they exert their action on proliferating cells.
Due to this cell cycle selective cytotoxicity by the cell
cycle phase after the action of chemotherapeutic drugs,
the remaining surviving cells will synchronize.
If RT is given when cells are synchronized in the most
radiosensitive phase of the cell cycle, then the effect of
radiation is enhanced.
3.	Enhanced apoptosis
Apoptosis is a mechanism of cell death induced by
chemotherapeutic agents. These can trigger one or more
pathways of apoptosis. To ensure a robust apoptotic
response, chemotherapeutics must be incorporated into
DNA. The combination of these therapies, where RT is
very effective in inducing DNA single strand breaks
(SSBs) or double strand breaks (DSBs), could facilitate
the incorporation of these agents into DNA and thus
induce an enhanced apoptotic reaction.
4.	Reoxygenation
Hypoxia is associated with a worse response to RT
treatment, and the reason is the inadequate diffusion of
oxygen in the tumor mass due to insufficient tumor
vascularization.
If we combine the treatments, chemoRT, chemother­
apy induces a certain degree of shrinkage in the tumor
that facilitates the diffusion of oxygen in a more uniform
way, increasing tumor oxygenation and therefore tumor
radiosensitivity.
5.	Inhibition of cell proliferation
A mechanism of interaction between both treatments
combined is the possible inhibition of cell proliferation, a
mechanism that occurs during dose fractionation in RT.
The exact timing and schedule between the chemother­
apy and RT must be taken into account, since it would be
best to administer the drug toward the end of radiation
treatment because that is when tumor cell repopulation
has been activated."
Explain how combining radiotherapy (RT) with chemotherapy can enhance the apoptotic response in cancer cells and what underlying mechanisms contribute to this effect.,"The synergistic combination of radiotherapy and chemotherapy significantly enhances apoptosis, or programmed cell death, in cancer cells. This occurs primarily because RT is highly effective at inducing DNA damage – specifically, single-strand breaks (SSBs) and double-strand breaks (DSBs) – within the tumor’s genetic material. Chemotherapy agents, particularly those that incorporate into DNA, are then more readily able to be incorporated into these damaged DNA strands. This incorporation triggers or amplifies existing apoptotic pathways initiated by the radiation. Furthermore, chemotherapy can induce a degree of tumor shrinkage, improving oxygen diffusion and mitigating hypoxia – a condition known to diminish RT effectiveness. Increased oxygenation within the tumor mass directly enhances radiosensitivity, allowing for more efficient DNA damage and subsequent apoptosis. Finally, the timing of drug administration is crucial; administering chemotherapy towards the end of radiation treatment when tumor cell repopulation is activated can further optimize this combined effect by maximizing the opportunity for chemotherapeutic agents to interact with damaged DNA and promote apoptosis.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.1	 RT Combined with Chemotherapy | Sub-sub-subsection: 6.5.1.1	 Side Effects of Combined Chemotherapy and Radiation Therapy | Content: If RT is given when cells are synchronized in the most
radiosensitive phase of the cell cycle, then the effect of
radiation is enhanced.
3.	Enhanced apoptosis
Apoptosis is a mechanism of cell death induced by
chemotherapeutic agents. These can trigger one or more
pathways of apoptosis. To ensure a robust apoptotic
response, chemotherapeutics must be incorporated into
DNA. The combination of these therapies, where RT is
very effective in inducing DNA single strand breaks
(SSBs) or double strand breaks (DSBs), could facilitate
the incorporation of these agents into DNA and thus
induce an enhanced apoptotic reaction.
4.	Reoxygenation
Hypoxia is associated with a worse response to RT
treatment, and the reason is the inadequate diffusion of
oxygen in the tumor mass due to insufficient tumor
vascularization.
If we combine the treatments, chemoRT, chemother­
apy induces a certain degree of shrinkage in the tumor
that facilitates the diffusion of oxygen in a more uniform
way, increasing tumor oxygenation and therefore tumor
radiosensitivity.
5.	Inhibition of cell proliferation
A mechanism of interaction between both treatments
combined is the possible inhibition of cell proliferation, a
mechanism that occurs during dose fractionation in RT.
The exact timing and schedule between the chemother­
apy and RT must be taken into account, since it would be
best to administer the drug toward the end of radiation
treatment because that is when tumor cell repopulation
has been activated.
6.5.1.1	Side Effects of Combined Chemotherapy
and Radiation Therapy
The combination of these treatments can increase both acute
and late toxicity. ChemoRT as two cytotoxic treatments pro­
duces an increase in damage in the volume of damaged nor­
mal cells, being more evident during the concurrent
chemoRT. By combining these therapies, if these side effects
appear, you may require to reduce the dose of chemotherapy."
"The document discusses combining radiotherapy (RT) with other cancer treatments and highlights several targeted therapies designed to improve radiosensitization. Specifically, it mentions inhibitors targeting ATM, ATR, DNA-PKcs, PARP, HDACs, WEE1, CD95/FAS, and STAT3.  What is the primary rationale behind utilizing these targeted therapies in conjunction with RT?","The core strategy involves enhancing radiosensitization by specifically disrupting key pathways involved in DNA damage response (DDR) and repair mechanisms. Targeting kinases like ATM, ATR, and DNA-PKcs aims to impair the cell's ability to efficiently fix DNA damage induced by radiation, thereby making cancer cells more vulnerable to RT’s cytotoxic effects. Furthermore, targeting PARP enhances sensitivity to DNA strand breaks, while HDAC inhibitors modulate chromatin remodeling affecting gene expression related to survival pathways. Inhibiting CD95/FAS and STAT3 also contributes to this radiosensitization effect. Ultimately, the goal is to maximize the effectiveness of RT by exploiting vulnerabilities in cancer cells’ DNA repair capabilities [60]. Reference: [MolecularRadiationBiology, Section 6.5.2.1 – Attacking DNA Damage Signaling and Repair for Radiation Therapy Sensitization].","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.2	 Combining RT with Targeted Therapy | Content: (dacarbazine)
Loss of appetite, vomiting, low white blood cell or platelets count
Doxorubicin
Cardiotoxicity
Vinblastine
Peripheral neuropathy, bone marrow suppression
Vincristine
Hair loss, constipation, difficulty walking, headaches, neuropathic pain, lung damage, or low
white blood cell counts
•	Using a genetic and molecular analysis of the tumor, we
can avoid chemotherapy for patients with lower scores,
avoiding chemotherapy toxicity.
•	In patients with p16 oropharyngeal cancer, it has been
possible to reduce the dose of RT and thus reduce
toxicities.
•	Advances in imaging techniques, such as IMRT and
IGRT, have led to a decrease in the dose around normal
tissues, resulting in minimizing the risk of complications
from chemoRT.
•
­
­
6.6
The incorporation of targeted therapies into treatment reg­
imens helps to improve radiosensitization. Multimodal ther­
apy uses these agents on a concurrent schedule [53].
Multimodal management for optimum cancer treatment
with surgery, chemotherapy, and RT is one of the most sig­
nificant advances in cancer treatment in the last 25 years.
This combined therapy increases locoregional control and
patient survival, as well as reduces the side effects of treat­
ment, toxicities [53].
It is difficult to know the real underlying mechanisms
of the interaction of this combination therapy of chemo­
therapy and RT, normally the clinical trials that are car­
ried out do not allow to obtain this information [56] (Box
6.5).
6.5.2
Combining RT with Targeted Therapy
­
­
57
­
­
6.5
6.7
Box 6.5 RT Combined with Chemotherapy
•	RT and chemotherapy can, when combined,
improve locoregional disease control.
•	Concomitant administration of RT with chemo­
therapy gives increased early normal tissue toxicity
but late toxicity of normal tissues may also be
increased.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
328
Table 6.7 RT sensitizing strategies and examples of drugs that are in clinical evaluation in combination with RT or in combined RT and chemo­
therapy regimen
Type of
mechanism
Target or
target
mechanism
Example
inhibitors
RT sensitized tumor
Reference or clinical trial No.a
DNA damage
and repair
ATM
AZD1390
Glioblastoma, other brain tumors
NCT03423628
ATR
BAY-1895344;
M6620
Advanced solid tumor, esophageal
cancers
[58]
NCT03641547
DNA-PKcs
Nedisertib,
peposertib,
AZD7648
Head and neck cancer, advanced
solid tumors
[59]
NCT03907969
PARP
Olaparib,
veliparib,
rucaparib,
niraparib
Breast cancer, prostate cancer,
non-small cell lung cancer,
small-cell lung cancer, glioblastoma/
glioma, rectal cancer, cervical
cancer, head and neck cancer
[60]
NCT03542175; NCT04837209; NCT01477489;
NCT02227082; NCT03945721; NCT03598257;
NCT03109080; NCT03212742; NCT03581292;
NCT01514201; NCT04790955; NCT04728230;
NCT02412371; NCT01589419; NCT03644342;
NCT02229656
Chromatin
remodeling
Histone
deacetylase
(HDAC)
Vorinostat
Head and neck cancer
[61]
Cell cycle
progression
WEE1
Adavosertib
Pancreatic cancer
[62]
CDK 4/6
Palbociclib,
ribociclib,
abemaciclib
Glioma, breast cancer, head and
neck cancer, meningiomas
[63]
NCT03691493; NCT03870919; NCT04563507;
NCT03024489; NCT03389477; NCT03355794;
NCT02607124; NCT04585724; NCT04298983;
NCT04923542; NCT04220892; NCT02523014
Cell death
regulation
Bcl-2
AT-101
(Gossypol)
Head and neck cancer
Brain tumors
[64]
NCT00390403
CD95/FAS
ligand
Asunercept
(APG101)
Glioblastoma
[65]
SMAC
mimetics
Xevinapant
(Debio 1143)
Advanced head and neck cancer
[66]
Oncogenic
drivers
EGFR
Erlotinib/
gefitinib/
osimertinib
cetuximab
Non-small cell lung cancer, head
and neck cancer
[67, 68]
STAT3
Dovitinib
Hepatocellular carcinoma
[69]
Angiogenesis
VEGF,
VEGFR2
Bevacizumab,
vandetanib
(Caprelsa)
Glioblastoma, esophagogastric
cancer
[70, 71]
Hypoxia
Oxygen
mimetic
Nimorazole
Head and neck cancer
[72]
aThe trial number refers to its citation on https://clinicaltrials.gov/
6.5.2.1	Attacking DNA Damage Signaling
and Repair for Radiation Therapy
Sensitization
Three principal DNA damage response (DDR) kinases, the
phosphatidylinositol-3-kinase-related
kinases
(PIKKs),
ataxia-telangiectasia mutated (ATM), ATM- and Rad3-­
related (ATR), and the non-homologous end joining (NHEJ)
component, DNA-dependent protein kinase, catalytic sub­
unit (DNA-PKcs) are central in RT responses (see Chap. 3).
These kinases execute their cellular action by phosphorylat­
ing targets that regulate DNA repair, e.g., histone H2AX, or
cell cycle progression, e.g., WEE-1 and cell cycle checkpoint
kinases (CHKs).
Multiple trials of ATR inhibitors are ongoing as single
agents or combined with chemotherapy, yet fewer attempts
have been made with ATR inhibitors and RT [60]. The ATR
inhibitors BAY-1895344 and M6620 (see clinicaltrial.gov;
NCT03641547) were tested in phase I trials in various solid
tumors in an advanced stage setting including esophageal
cancer [58]. As the kinase pocket of ATM is similar to other
PIKKs, early attempts to develop specific inhibitors were
unsuccessful [60]. However, the ATM inhibitor AZD1390 is
currently undergoing trials in conjunction with RT in glio­
blastoma patients (NCT03423628). Attempts have also been
made to target DNA-PKcs, a key component of the NHEJ
repair cascade (see Chap. 3) [60]. Thus, AZD7648 has been
demonstrated to enhance RT effect when combined with the
V. Ahire et al."
"The document describes several mechanisms targeting DNA damage signaling and repair in response to radiation therapy. Specifically, it details the roles of kinases like ATM, ATR, and DNA-PKcs within the DDR pathway. How do these kinases contribute to the sensitization of cancer cells to radiation by modulating cell cycle progression?","The document highlights that key DNA damage response (DDR) kinases – ATM, ATR, and DNA-PKcs – are central to a cancer cell’s response to radiation therapy. These kinases phosphorylate targets involved in regulating both DNA repair processes and cell cycle progression. Specifically, they influence the WEE1 kinase, which is critical for arresting the cell cycle at the G2/M checkpoint following DNA damage induced by radiation. By activating WEE1, these kinases effectively halt cell division, preventing damaged cells from replicating and increasing the likelihood of apoptosis (programmed cell death) – a key mechanism in how radiation therapy works. Furthermore, they phosphorylate histone H2AX, which is involved in recruiting repair proteins to the site of DNA damage, thereby accelerating the repair process itself. Ultimately, this coordinated action by these kinases sensitizes cancer cells to radiation’s cytotoxic effects [61]. Reference: [MolecularRadiationBiology], Section 6.5.2.1 – Attacking DNA Damage Signaling and Repair for Radiation Therapy Sensitization.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.2	 Combining RT with Targeted Therapy | Sub-sub-subsection: 6.5.2.1	 Attacking DNA Damage Signaling and Repair for Radiation Therapy Sensitization | Content: Chromatin
remodeling
Histone
deacetylase
(HDAC)
Vorinostat
Head and neck cancer
[61]
Cell cycle
progression
WEE1
Adavosertib
Pancreatic cancer
[62]
CDK 4/6
Palbociclib,
ribociclib,
abemaciclib
Glioma, breast cancer, head and
neck cancer, meningiomas
[63]
NCT03691493; NCT03870919; NCT04563507;
NCT03024489; NCT03389477; NCT03355794;
NCT02607124; NCT04585724; NCT04298983;
NCT04923542; NCT04220892; NCT02523014
Cell death
regulation
Bcl-2
AT-101
(Gossypol)
Head and neck cancer
Brain tumors
[64]
NCT00390403
CD95/FAS
ligand
Asunercept
(APG101)
Glioblastoma
[65]
SMAC
mimetics
Xevinapant
(Debio 1143)
Advanced head and neck cancer
[66]
Oncogenic
drivers
EGFR
Erlotinib/
gefitinib/
osimertinib
cetuximab
Non-small cell lung cancer, head
and neck cancer
[67, 68]
STAT3
Dovitinib
Hepatocellular carcinoma
[69]
Angiogenesis
VEGF,
VEGFR2
Bevacizumab,
vandetanib
(Caprelsa)
Glioblastoma, esophagogastric
cancer
[70, 71]
Hypoxia
Oxygen
mimetic
Nimorazole
Head and neck cancer
[72]
aThe trial number refers to its citation on https://clinicaltrials.gov/
6.5.2.1	Attacking DNA Damage Signaling
and Repair for Radiation Therapy
Sensitization
Three principal DNA damage response (DDR) kinases, the
phosphatidylinositol-3-kinase-related
kinases
(PIKKs),
ataxia-telangiectasia mutated (ATM), ATM- and Rad3-­
related (ATR), and the non-homologous end joining (NHEJ)
component, DNA-dependent protein kinase, catalytic sub­
unit (DNA-PKcs) are central in RT responses (see Chap. 3).
These kinases execute their cellular action by phosphorylat­
ing targets that regulate DNA repair, e.g., histone H2AX, or
cell cycle progression, e.g., WEE-1 and cell cycle checkpoint
kinases (CHKs).
Multiple trials of ATR inhibitors are ongoing as single
agents or combined with chemotherapy, yet fewer attempts
have been made with ATR inhibitors and RT [60]. The ATR
inhibitors BAY-1895344 and M6620 (see clinicaltrial.gov;
NCT03641547) were tested in phase I trials in various solid
tumors in an advanced stage setting including esophageal
cancer [58]. As the kinase pocket of ATM is similar to other
PIKKs, early attempts to develop specific inhibitors were
unsuccessful [60]. However, the ATM inhibitor AZD1390 is
currently undergoing trials in conjunction with RT in glio­
blastoma patients (NCT03423628). Attempts have also been
made to target DNA-PKcs, a key component of the NHEJ
repair cascade (see Chap. 3) [60]. Thus, AZD7648 has been
demonstrated to enhance RT effect when combined with the
V. Ahire et al.
329
poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in
both tumor cell lines in vitro as well as in tumor-bearing
mice. This DNA-PKcs inhibitor is at present tested further in
a phase I clinical trial (NCT03907969). Moreover, other
DNA-­PKcs inhibitors are similarly evaluated when com­
bined with RT in phase I trials involving patients with, e.g.,
head and neck (HNC) cancer where a clear improved local
control was found.
5860
­
­
60
­
6.7"
"The document discusses strategies to improve radiotherapy (RT) response in cancer. Specifically, it details how inhibiting WEE1 kinase can enhance RT efficacy and mentions the use of adavosertib in prostate cancer patients. Furthermore, it explores targeting downstream signaling pathways like PI3K/AKT or Ras-Raf to sensitize cells to RT.  Describe at least two specific mechanisms explored within this text that aim to increase a tumor's sensitivity to radiotherapy.","The document outlines several approaches to enhance radiotherapy response. Firstly, the inhibition of WEE1 kinase, as demonstrated in advanced prostate cancer patients treated with adavosertib alongside dual RT and gemcitabine, effectively blocks the G2/M cell cycle checkpoint. This disruption prevents cells from progressing through mitosis, a critical stage vulnerable to radiation damage. Secondly, the text highlights targeting downstream signaling cascades such as PI3K/AKT or Ras-Raf. These pathways regulate cell cycle progression, apoptosis, and DNA repair – all processes that can be manipulated to increase RT sensitivity. Specifically, modulating these pathways can impact cell death initiation and execution, potentially restoring impaired apoptotic signals often observed in resistant tumors. Finally, the document also discusses targeting STAT3, a transcription factor involved in inflammation and malignant cell progression, as well as interfering with the FAS/CD95 signaling network to promote apoptosis. Reference: [MolecularRadiationBiology, Section 6.5.2.2] ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.2	 Combining RT with Targeted Therapy | Sub-sub-subsection: 6.5.2.2	 Interfering with Cell Cycle Regulation to Improve RT Response | Content: to Improve RT Response
­
63
­
63
­
6.7
The CDK1/2 is in part controlled by the WEE1 G2 check­
point kinase which via Ser/Th protein phosphorylation
blocks their activity resulting in a G2/M cell cycle check­
point activation. Indeed, the WEE1 inhibitor adavosertib was
assessed alongside a dual RT and gemcitabine treatment
regimen in advanced PCa patients where a clear response
was evident by an increased overall survival [62].
6.5.2.3	Attacking Oncogenic Drivers
and Downstream Signaling for RT
Sensitization in a Precision Cancer
Medicine Manner
Constitutively increased activity of epidermal growth factor
receptors (EGFRs) by mutation or gene amplification (which
is found in multiple tumor types) is responsible for resistance
to CT/RT [68]. Moreover, downstream PI3K/AKT or Ras-­
Raf mitogen-activated protein kinases (MAPK) signaling
cascades may also influence RT response via regulation of
cell cycle, cell death signaling, or by interfering with the
DDR network [73]. Treatment with the antibody cetuximab,
a EGF ligand blocker has been shown to improve RT sensi­
tivity in HNC. However, results presented from a meta-­
analysis covering 13 studies with 5678 patients on CT/
RT-based treatment and receptor tyrosine kinase inhibition
for solid cancers (ROCKIT) emphasized that targeting EGFR
could not ameliorate overall survival yet causing increased
toxicity [67]. In the context of metastatic Non-small cell lung
cancer (NSCLC) driven by EGFR mutation, there is also an
interest in combining small EGFR tyrosine kinase inhibitors
(TKIs) together with RT for patients with oligometastatic
disease as well as to consolidate tumor lesions resistant to a
given EGFR targeting TKI [68].
The transcription factor signal transducer and activator of
transcription 3 (STAT3) regulate inflammation, malignant
cells initiation, progression, and therapy resistance. STAT3
is overexpressed in cancers of the gastrointestinal tract,
NSCLC, OC, and brain tumors and thus it may cover a valu­
able target for precision therapy. One example is the drug
dovitinib which was shown to sensitize hepatocellular carci­
noma to RT by targeting Src homology region 2 (SH2)
domain-containing phosphatase 1 (SHP-1)/STAT3 signaling
[69].
6.5.2.4	Altering Cell Death Signaling for RT
Sensitization
RT resistance is in part a result of impaired cell death initia­
tion and/or execution (see Chap. 3) and targeted strategies
aim to restore such signaling. Multiple signaling components
of different apoptotic routes including the B-cell lymphoma
2 (Bcl-2) family members, inhibitor-of-apoptosis-proteins
(IAPs), e.g., x-linked IAP (XIAP) or survivin and the Cluster
of Differentiation 95 (CD95)/FAS signaling network have all
been explored [74, 75]. Inhibition of the IAP survivin, for
instance, is reported to increase apoptosis as well as autoph­
agy, to impact on the cell cycle and to hamper DNA damage
repair, resulting in a radiosensitization [75].
Another example is the pan-Bcl-2 inhibitor AT-101
(Gossypol), which sensitized HNC cells to RT-induced
apoptosis indicating its therapeutic potential for tumors
with high Bcl-2 expression levels [64]. An additional
example is navitoclax (ABT-263) which impairs the anti-
apoptotic function of Bcl-2/Bcl-xL and which was reported
to potentiate RT cell death [76]. Finally, the anti-IAP smac
mimetic, xevinapant (Debio 1143) has been tested in HNC
in combination with cisplatin and RT where locoregional
control was achieved in some patients [66]. Concerning RT
sensitization via the extrinsic apoptotic route, focus has
been on interfering with the FAS/CD95 signaling cascade
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"How can combining small EGFR tyrosine kinase inhibitors with radiotherapy potentially improve treatment outcomes in certain cancers, and what specific molecular pathway is being targeted to achieve this sensitization?","Combining small EGFR tyrosine kinase inhibitors (TKIs) like dovotinib with radiotherapy represents a precision cancer medicine approach, particularly effective in oligometastatic disease or tumors resistant to single-agent EGFR TKIs. The strategy leverages the critical role of the signal transducer and activator of transcription 3 (STAT3) pathway in driving malignant cell initiation, progression, and resistance to therapy. STAT3 is frequently overexpressed in cancers such as gastrointestinal tract cancers, non-small cell lung cancer (NSCLC), ovarian cancer (OC), and brain tumors. By targeting STAT3 with a TKI like dovotinib, the drug inhibits downstream signaling events initiated by EGFR activation, thereby reducing inflammation and promoting increased radiosensitivity. Dovitinib specifically targets the Src homology region 2 (SH2) domain-containing phosphatase 1 (SHP-1)/STAT3 signaling pathway, disrupting this critical oncogenic cascade and ultimately enhancing the efficacy of radiotherapy against the tumor.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.2	 Combining RT with Targeted Therapy | Sub-sub-subsection: 6.5.2.3	 Attacking Oncogenic Drivers and Downstream Signaling for RT Sensitization in a Precision Cancer Medicine Manner | Content: interest in combining small EGFR tyrosine kinase inhibitors
(TKIs) together with RT for patients with oligometastatic
disease as well as to consolidate tumor lesions resistant to a
given EGFR targeting TKI [68].
The transcription factor signal transducer and activator of
transcription 3 (STAT3) regulate inflammation, malignant
cells initiation, progression, and therapy resistance. STAT3
is overexpressed in cancers of the gastrointestinal tract,
NSCLC, OC, and brain tumors and thus it may cover a valu­
able target for precision therapy. One example is the drug
dovitinib which was shown to sensitize hepatocellular carci­
noma to RT by targeting Src homology region 2 (SH2)
domain-containing phosphatase 1 (SHP-1)/STAT3 signaling
[69]."
"The document discusses strategies to enhance radiotherapy (RT) efficacy in cancer treatment. Specifically, it outlines how inhibiting the STAT3 signaling pathway, utilizing drugs like dovotinib, can sensitize hepatocellular carcinoma cells to RT by targeting SHP-1/STAT3 and impacting cell death pathways such as apoptosis and DNA repair.","Radiotherapy sensitization strategies frequently involve disrupting key cellular processes that contribute to resistance. One prominent approach detailed in the text centers around modulating the STAT3 signaling pathway. STAT3 is an overexpressed transcription factor in several cancers, including gastrointestinal tract tumors (e.g., NSCLC, OC, and brain tumors), and plays a crucial role in inflammation, malignant cell initiation, progression, and therapy resistance. The drug dovotinib exemplifies this strategy by specifically targeting the SH2 domain-containing phosphatase 1 (SHP-1)/STAT3 signaling cascade within hepatocellular carcinoma cells. This inhibition leads to increased apoptosis, autophagy, impaired DNA damage repair, and ultimately enhances the radiosensitizing effects of RT. Furthermore, disruption of STAT3 can impact cell cycle regulation. Reference: [MolecularRadiationBiology, Section 6.5.2.4 Altering Cell Death Signaling for RT Sensitization]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.2	 Combining RT with Targeted Therapy | Sub-sub-subsection: 6.5.2.4	 Altering Cell Death Signaling for RT Sensitization | Content: interest in combining small EGFR tyrosine kinase inhibitors
(TKIs) together with RT for patients with oligometastatic
disease as well as to consolidate tumor lesions resistant to a
given EGFR targeting TKI [68].
The transcription factor signal transducer and activator of
transcription 3 (STAT3) regulate inflammation, malignant
cells initiation, progression, and therapy resistance. STAT3
is overexpressed in cancers of the gastrointestinal tract,
NSCLC, OC, and brain tumors and thus it may cover a valu­
able target for precision therapy. One example is the drug
dovitinib which was shown to sensitize hepatocellular carci­
noma to RT by targeting Src homology region 2 (SH2)
domain-containing phosphatase 1 (SHP-1)/STAT3 signaling
[69].
6.5.2.4	Altering Cell Death Signaling for RT
Sensitization
RT resistance is in part a result of impaired cell death initia­
tion and/or execution (see Chap. 3) and targeted strategies
aim to restore such signaling. Multiple signaling components
of different apoptotic routes including the B-cell lymphoma
2 (Bcl-2) family members, inhibitor-of-apoptosis-proteins
(IAPs), e.g., x-linked IAP (XIAP) or survivin and the Cluster
of Differentiation 95 (CD95)/FAS signaling network have all
been explored [74, 75]. Inhibition of the IAP survivin, for
instance, is reported to increase apoptosis as well as autoph­
agy, to impact on the cell cycle and to hamper DNA damage
repair, resulting in a radiosensitization [75].
Another example is the pan-Bcl-2 inhibitor AT-101
(Gossypol), which sensitized HNC cells to RT-induced
apoptosis indicating its therapeutic potential for tumors
with high Bcl-2 expression levels [64]. An additional
example is navitoclax (ABT-263) which impairs the anti-
apoptotic function of Bcl-2/Bcl-xL and which was reported
to potentiate RT cell death [76]. Finally, the anti-IAP smac
mimetic, xevinapant (Debio 1143) has been tested in HNC
in combination with cisplatin and RT where locoregional
control was achieved in some patients [66]. Concerning RT
sensitization via the extrinsic apoptotic route, focus has
been on interfering with the FAS/CD95 signaling cascade
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
330
[65]. Thus, it was demonstrated in relapsed glioblastoma
patients that addition of the Fc-fusion protein asunercept
(APG101) which blocks ligand engagement prolonged
patient survival.
6.5.2.5	Altering Hypoxia and the Tumor
Microenvironment to Impart RT
Refractoriness
Targeting the tumor microenvironment is another RT sen­
sitizing approach that involves attack on hypoxia directly
or the underlying aberrant angiogenesis/vascularity of
tumors, respectively. By this, hyperbaric oxygen therapy
(HBOT) and agents which are specifically activated in
hypoxic tumor cells/parts of the tumor or are prodrugs
which are triggered to activity under hypoxic conditions or
impact on angiogenesis/vasculature (by impairing the
function of the vascular endothelial growth factor (VEGF)
or its receptor signaling) are tested. One prime example is
the electron-affinic nitroimidazoles, such as the clinically
proven oxygen mimetic nimorazole, which covers the
standard of care in HNC patients that are given RT in some
countries [72]. Moreover, it has been demonstrated in glio­
blastoma patients that temozolomide-­based CT/RT can be
enhanced resulting in improved progression free survival
if an anti-VEGF monoclonal antibody bevacizumab (avas­
tin) is included in the treatment regimen [71]. In contrast,
addition of bevacizumab to capecitabine and RT did not
improve outcome in rectal cancer [77]. Further, vandetanib
(ZD6474), a tyrosine kinase inhibitor targeting VEGFR,
was shown to improve outcome of esophagogastric carci­
noma patients when applied after RT or different CTs [70]
(Box 6.6).
6.5.3
RT Combined with Immunotherapy
6.5.3.1	Local and Systemic Modes of Action
of Radiotherapy
For a very long time, it was assumed that the X-rays directly,
or indirectly through the formation of ROS, only affect the
radiation-sensitive DNA in the cell and that other structures
are spared. However, today it is clear that in addition to the
so-called targeted local effects of radiation on DNA, numer­
ous so-called non-targeted effects occur, such as general
stress responses of the irradiated cells, which then also can
be transmitted to other cells and even the entire organism.
6.5.3.2	Radiotherapy as an Immune Modulator
Radiation-induced oxidative stress and DNA damage activate
numerous signaling pathways in cells that influence the
expression of genes and consequently trigger a broad spec­
trum of cellular responses ranging from promotion of cell
survival to cell death (see Chap. 3). Thereby, the immunologi­
cal phenotype of cells as well as the tumor microenvironment
may change (see Chap. 5). It has been demonstrated that RT
increases the expression of MHCI molecules, death receptors,
and stress ligands on the tumor cell surface, and fosters the
release of so-called damage-associated molecular patterns/
danger-associated molecular patterns (DAMPs) such as ade­
nosine triphosphate (ATP), HMGB1, and Heat Shock Protein
70 (HSP70) (see Chap. 5). Also, RT causes increased levels of
immunostimulatory cytokines mainly through the induction
of immunogenic tumor cell death (ICD) and in combination
with additional immune stimulation [78].
­
­
79
80
5
­
6.6
Box 6.6 RT Sensitization with Targeted Therapy
•	Inhibitors of the DDR signaling network, e.g.,
ATM, ATR, DNA-PKcs, and PARP-1 or interfering
with cell some cycle regulating kinases offer sensi­
tization for RT.
•	Blockade of signaling from oncogenic drivers, e.g.,
growth factor regulated kinases via antibodies or
small molecule inhibitors can sensitize tumors to
RT.
•	Restoring cell death pathways, e.g., apoptosis is
another RT sensitizing strategy.
•	Modulating the tumor microenvironment, e.g.
hypoxia and aberrant angiogenesis allow for tumor
RT sensitization.
V. Ahire et al."
How does radiation therapy (RT) influence the tumor microenvironment and what specific molecules are released that contribute to this effect?,"Radiation therapy significantly alters the tumor microenvironment by promoting a state more conducive to immune response and increased sensitivity to subsequent treatments. Specifically, RT elevates the expression of major histocompatibility complex class I (MHCI) molecules on tumor cells, alongside the upregulation of death receptors and stress ligands like adenosine triphosphate (ATP), high mobility group box 1 (HMGB1), and Heat Shock Protein 70 (HSP70). This release of damage-associated molecular patterns/danger-associated molecular patterns (DAMPs) triggers an inflammatory response. Furthermore, RT induces immunogenic tumor cell death (ICD), which, when combined with additional immune stimulation, leads to increased levels of immunostimulatory cytokines within the microenvironment. These changes collectively contribute to a more receptive tumor environment for targeted therapies and potentially other treatments.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.2	 Combining RT with Targeted Therapy | Sub-sub-subsection: 6.5.2.5	 Altering Hypoxia and the Tumor Microenvironment to Impart RT Refractoriness | Content: cal phenotype of cells as well as the tumor microenvironment
may change (see Chap. 5). It has been demonstrated that RT
increases the expression of MHCI molecules, death receptors,
and stress ligands on the tumor cell surface, and fosters the
release of so-called damage-associated molecular patterns/
danger-associated molecular patterns (DAMPs) such as ade­
nosine triphosphate (ATP), HMGB1, and Heat Shock Protein
70 (HSP70) (see Chap. 5). Also, RT causes increased levels of
immunostimulatory cytokines mainly through the induction
of immunogenic tumor cell death (ICD) and in combination
with additional immune stimulation [78].
­
­
79
80
5
­
6.6
Box 6.6 RT Sensitization with Targeted Therapy
•	Inhibitors of the DDR signaling network, e.g.,
ATM, ATR, DNA-PKcs, and PARP-1 or interfering
with cell some cycle regulating kinases offer sensi­
tization for RT.
•	Blockade of signaling from oncogenic drivers, e.g.,
growth factor regulated kinases via antibodies or
small molecule inhibitors can sensitize tumors to
RT.
•	Restoring cell death pathways, e.g., apoptosis is
another RT sensitizing strategy.
•	Modulating the tumor microenvironment, e.g.
hypoxia and aberrant angiogenesis allow for tumor
RT sensitization.
V. Ahire et al."
Radiotherapy's impact on cancer cells is increasingly understood to extend beyond direct DNA damage. Describe the concept of ‘non-targeted effects’ associated with radiation exposure and explain how these contribute to broader cellular responses.,"The traditional view of radiotherapy focused solely on the localized destruction of DNA within cells exposed to ionizing radiation, primarily through the formation of reactive oxygen species (ROS). However, contemporary research demonstrates that radiotherapy induces a complex cascade of ‘non-targeted effects’ – significant physiological changes occurring in cells and tissues distant from the primary radiation field. These effects arise from the generalized stress responses triggered by radiation exposure within irradiated cells. This initial cellular distress initiates a series of events including upregulation of genes involved in DNA repair, apoptosis (programmed cell death), autophagy (self-eating), and inflammatory pathways. Critically, these activated cellular processes can then be transmitted to neighboring and even distant cells, influencing their behavior and survival. Furthermore, the systemic effects observed – such as alterations in immune function or vascular responses – are also linked to this broader stress response orchestrated by radiation exposure. Essentially, radiotherapy doesn’t just damage DNA; it initiates a comprehensive cellular alarm system that reverberates throughout the organism, impacting cell viability, proliferation, and overall tissue homeostasis. This highlights the importance of considering the whole-body effects when evaluating treatment efficacy and potential side effects.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.3	 RT Combined with Immunotherapy | Sub-sub-subsection: 6.5.3.1	 Local and Systemic Modes of Action of Radiotherapy | Content: of Radiotherapy
For a very long time, it was assumed that the X-rays directly,
or indirectly through the formation of ROS, only affect the
radiation-sensitive DNA in the cell and that other structures
are spared. However, today it is clear that in addition to the
so-called targeted local effects of radiation on DNA, numer­
ous so-called non-targeted effects occur, such as general
stress responses of the irradiated cells, which then also can
be transmitted to other cells and even the entire organism."
"How does radiation therapy influence the immunological phenotype and tumor microenvironment, as described in this text, and what specific molecular signals contribute to these changes?","Radiation therapy (RT) significantly alters cellular and microenvironmental responses by activating signaling pathways that promote cell survival or death. Critically, RT increases the expression of major histocompatibility complex class I (MHCI) molecules, death receptors, and stress ligands on tumor cells. This upregulation facilitates the release of damage-associated molecular patterns/danger-associated molecular patterns (DAMPs), including adenosine triphosphate (ATP), high mobility group box 1 (HMGB1), and heat shock protein 70 (HSP70). These DAMPs stimulate immune responses, leading to immunogenic tumor cell death (ICD) and a shift in the tumor microenvironment. Furthermore, RT induces increased levels of immunostimulatory cytokines primarily through ICD, often in combination with additional immune stimulation. The text highlights that a single dose of 2 Gy is more likely to promote immune cell infiltration while higher doses can lead to immune suppression due to DNA degradation and upregulation of immune checkpoint molecules.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.3	 RT Combined with Immunotherapy | Sub-sub-subsection: 6.5.3.2	 Radiotherapy as an Immune Modulator | Content: Radiation-induced oxidative stress and DNA damage activate
numerous signaling pathways in cells that influence the
expression of genes and consequently trigger a broad spec­
trum of cellular responses ranging from promotion of cell
survival to cell death (see Chap. 3). Thereby, the immunologi­
cal phenotype of cells as well as the tumor microenvironment
may change (see Chap. 5). It has been demonstrated that RT
increases the expression of MHCI molecules, death receptors,
and stress ligands on the tumor cell surface, and fosters the
release of so-called damage-associated molecular patterns/
danger-associated molecular patterns (DAMPs) such as ade­
nosine triphosphate (ATP), HMGB1, and Heat Shock Protein
70 (HSP70) (see Chap. 5). Also, RT causes increased levels of
immunostimulatory cytokines mainly through the induction
of immunogenic tumor cell death (ICD) and in combination
with additional immune stimulation [78].
­
­
79
80
5
­
6.6
Box 6.6 RT Sensitization with Targeted Therapy
•	Inhibitors of the DDR signaling network, e.g.,
ATM, ATR, DNA-PKcs, and PARP-1 or interfering
with cell some cycle regulating kinases offer sensi­
tization for RT.
•	Blockade of signaling from oncogenic drivers, e.g.,
growth factor regulated kinases via antibodies or
small molecule inhibitors can sensitize tumors to
RT.
•	Restoring cell death pathways, e.g., apoptosis is
another RT sensitizing strategy.
•	Modulating the tumor microenvironment, e.g.
hypoxia and aberrant angiogenesis allow for tumor
RT sensitization.
V. Ahire et al.
331
observed in the clinic when RT is used in combination with
immunotherapies.
6.5.3.3	Rationale for Combination
of Radiotherapy with Immune Therapies
If ICD is induced by local tumor irradiation and the tumor
vasculature is changed in such a way that more immune cells
can migrate into the tumor, this can already trigger effective
antitumor immune responses [81]. In terms of radiation
immunology, it is now believed that a single dose of 2 Gy is
more likely to promote immune cell infiltration and a dose of
>2 Gy is more likely to induce ICD [82]. Importantly, non-­
linear dose–effect relationships often prevail. For example,
the immunogenicity of tumor cells is reduced again after
irradiation with a single dose that is too high, because
enzymes are activated that degrade the immunogenic DNA
found in the cytoplasm after irradiation or because immune-­
suppressing immune checkpoint molecules (ICM) are
increasingly expressed on the tumor cells [83].
Expression of immune suppressive ICM was the key
starting point for a combination of radiation and immuno­
therapies. Inhibition of ICM in parallel with or shortly after
RT has led to local and systemic antitumor immune
responses in animal models and in the clinic, and the so-
called radio-­immunotherapies are increasingly being used
in multimodal oncological treatment [84]. Further,
­immunologically-based patient selection based on induc­
tion chemo-­immunotherapies is increasingly taking place
[85]. Particularly exciting is the re-emergence of tumor
vaccination in this context and the stratification of patients
based on immunological factors of the peripheral blood
(see Chap. 6) (Box 6.7).
Box 6.7 RT Combined with Immune Therapy
•	Radiation affects DNA and via stress responses
other cellular compartments.
•	Radiation induces local and systemic effects.
•	RT has both immune stimulatory and immune sup­
pressive effects.
•	Non-linear dose relationships also apply for
radiation-­induced immune effects.
•	RT is well combinable with immune therapy.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"Explain the rationale behind combining radiotherapy (RT) with androgen deprivation therapy (ADT) in the treatment of prostate cancer, focusing on the role of the androgen receptor.","Prostate cancer cells frequently express the androgen receptor (AR), a protein that directly influences cell behavior by mediating the effects of androgens – primarily testosterone. This AR signaling pathway is fundamentally involved in driving the growth and progression of prostate cancer. Androgen deprivation therapy (ADT) aims to reduce circulating levels of androgens, thereby effectively disabling this critical signaling cascade within the tumor cells. When radiotherapy is then administered, it targets actively dividing cells, many of which are still responsive to androgen stimulation due to residual AR expression. Combining these two therapies creates a synergistic effect: ADT reduces the cancer's ability to respond to androgens, while RT directly destroys any remaining androgen-sensitive cancer cells. This approach is particularly beneficial in patients with high-risk prostate cancers where hormone therapy or radiation alone may prove insufficient to prevent disease progression. The rationale hinges on disrupting the fundamental growth mechanism of the tumor through dual intervention – hormonal blockade and direct cellular damage. ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.4	 RT Combined with Hormone Therapy (Radio-Hormone Therapy) | Content: ­
87
6.8
6.5.4.2	Radiotherapy Combined with Androgen
Deprivation Therapy (ADT) for Prostate
Cancer
During the course of the disease, a majority of PCas express
the androgen receptor (AR) which is known to specifically
direct the cancer cell behavior and this has solidified the sig­
nificance of androgen signaling in the pathogenesis of PCa
[89]. Hence, androgen deprivation therapy (ADT) is a foun­
dation of PCa therapy. ADT is typically utilized to cut down
the levels of serum testosterone to a castrate level. This can
be accomplished by surgical or chemical castration. Chemical
castration can be accomplished by using estrogens or
LHRHa; and it is likely to be reversible. The consequence of
initial use of LHRHa results in follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and testosterone surge in
Box 6.8 RT Combined with Hormone Therapy
•	Hormone sensitive tumors which are dependent on
certain hormones for their growth can be slowed
down or stopped by hormone therapies.
•	In prostate cancer patients with a high risk of pro­
gression, hormone therapy in combination with RT
is the treatment of choice as hormone therapy or RT
alone remain inadequate
V. Ahire et al."
"Explain the rationale behind combining radiotherapy (RT) with hormone therapies like tamoxifen and androgen deprivation therapy (ADT) in the treatment of cancers such as breast cancer and prostate cancer, respectively. Detail the mechanisms involved that make this combination approach effective.","The strategic use of radiotherapy alongside hormone therapies represents a targeted approach to cancer treatment due to the fundamental role hormones play in driving tumor growth and proliferation within specific cancer types. In breast cancer, particularly those expressing the estrogen receptor (ER) or progesterone receptor (PR), hormone receptors dictate cell behavior, making these cancers ‘hormone-sensitive.’ Radiotherapy directly damages DNA, inhibiting cell division – a critical process fueled by hormonal signals. Combining RT with therapies like tamoxifen disrupts the continued action of hormones by competitively binding to the ER, preventing estrogen from activating its downstream signaling pathways that promote cancer cell growth. Similarly, in prostate cancer, where androgen receptors (AR) are prevalent, ADT effectively reduces testosterone levels, directly suppressing AR activation and subsequent tumor progression. Radiotherapy then further targets any remaining cancer cells expressing AR, enhancing the overall cytotoxic effect. The synergy arises because hormone therapies initially reduce the stimulus for growth, while RT delivers a concentrated dose of radiation to eliminate vulnerable cells. This combination is particularly favored in patients with high-risk disease where either modality alone would likely prove insufficient, capitalizing on the complementary mechanisms of action to maximize therapeutic efficacy and minimize treatment resistance.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.4	 RT Combined with Hormone Therapy (Radio-Hormone Therapy) | Sub-sub-subsection: 6.5.4.1	 Radiotherapy Combined with Tamoxifen for Breast Cancer | Content: for Breast Cancer
­
­
­
­
­
­
6.786
­
­
­
­
­
87
6.8
6.5.4.2	Radiotherapy Combined with Androgen
Deprivation Therapy (ADT) for Prostate
Cancer
During the course of the disease, a majority of PCas express
the androgen receptor (AR) which is known to specifically
direct the cancer cell behavior and this has solidified the sig­
nificance of androgen signaling in the pathogenesis of PCa
[89]. Hence, androgen deprivation therapy (ADT) is a foun­
dation of PCa therapy. ADT is typically utilized to cut down
the levels of serum testosterone to a castrate level. This can
be accomplished by surgical or chemical castration. Chemical
castration can be accomplished by using estrogens or
LHRHa; and it is likely to be reversible. The consequence of
initial use of LHRHa results in follicle-stimulating hormone
(FSH), luteinizing hormone (LH), and testosterone surge in
Box 6.8 RT Combined with Hormone Therapy
•	Hormone sensitive tumors which are dependent on
certain hormones for their growth can be slowed
down or stopped by hormone therapies.
•	In prostate cancer patients with a high risk of pro­
gression, hormone therapy in combination with RT
is the treatment of choice as hormone therapy or RT
alone remain inadequate
V. Ahire et al."
"The text describes several mechanisms by which androgen deprivation therapy (ADT) enhances the effectiveness of radiotherapy in prostate cancer treatment. Specifically, it details how ADT impacts DNA damage repair pathways and subsequent cellular responses. Can you comprehensively outline these interactions, including the key pathway involved and its impact on radiosensitivity?","Androgen Deprivation Therapy (ADT), often administered orally at a dose of 5-10 mg daily, significantly improves the efficacy of radiotherapy in prostate cancer treatment through several interconnected mechanisms. A central component involves the suppression of the androgen receptor (AR) which, in turn, inhibits the Nuclear Homologous Recombination (NHEJ) DNA repair pathway. The NHEJ pathway is a critical mechanism by which cells repair double-strand breaks in their DNA – a common consequence of ionizing radiation like that used in radiotherapy. By blocking AR signaling, ADT effectively reduces the cell’s ability to efficiently repair this damage. This suppression leads to an accumulation of unrepaired DNA damage within PCa cells. Furthermore, preclinical studies and clinical observations suggest that ADT enhances radiosensitization by boosting tumor oxygenation – a critical factor for radiation efficacy – and directly suppressing the DNA repair machinery itself. The combination of these effects dramatically increases apoptosis (programmed cell death) in prostate cancer cells when exposed to radiotherapy. The EORTC 22863 study demonstrated significantly improved overall survival rates with combined RT and ADT compared to RT alone, highlighting the synergistic impact of this approach. Reference: [MolecularRadiationBiology, Section 6.5.5 – Radiotherapy Combined with Other Cancer Treatment Modalities]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.5	 Radiotherapy Combined with Hyperthermia | Content: Competitive
AR inhibition
PrednisoloneCorticosteroid
Orally, (5–10 mg)
daily
Suppression of
Adrenal
ER estrogen receptor, LHRH luteinizing hormone-releasing hormone,
LH luteinizing hormone, FSH follicle-stimulating hormone, AR andro­
gen receptor, SC subcutaneous, IM intramuscular
the serum, which makes the symptoms worse. Hence,
patients are advised to take oral antiandrogens for 1–2 weeks
prior to the LHRHa injection. ADT is mostly given with RT
as a neoadjuvant therapy which can be continued throughout
and even further than RT. Although evidence suggests that
the combinatorial treatment of PCa with ADT and RT has
improved therapeutic effects, there is still a lot of improve­
ment that can be made on the biochemical front as demon­
strated by the clinical trials. ADT might also boost the
efficacy of RT by inhibiting successive PCa cell repopulation
and by enhancing reoxygenation and radiosensitization.
Many preclinical studies involving tumour cell lines in vitro
and in vivo tumor xenografts have suggested that ADT works
by suppressing the mechanisms associated with the DNA
damage response, particularly the NHEJ repair. This
increases the anticancer effect induced by RT. Preclinical
studies have also shown that the synergistic effect of RT and
ADT enhances apoptosis by suppressing the DNA repair
machinery. The combinatorial treatment not only increases
the tumor oxygenation but also radiosensitizes the PCa cells.
The first phase III, EORTC 22863, study demonstrated a
noteworthy overall survival when RT was combined with
ADT in men with locally advanced PCa. The results showed
that the combination arm had a significantly higher OS com­
pared to that of the RT alone (58.1% vs. 39.8%, p = 0.0004).
Short-term and long-term follow-up of the EORTC studies
showed that only 74% patients exhibited a 5-year disease-
free survival with combined RT and ADT [89, 90].
6.5.5
Radiotherapy Combined
with Hyperthermia
Hyperthermia as an adjuvant treatment to RT or chemotherapy
considers heating of the tumor (area) above a physiological
temperature up to 40–43 °C for approximately an hour.
Hyperthermia can be applied as whole body, local invasively
(intraperitoneal, interstitial, or intracavitary) and locoregional.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
334
Hyperthermia as a radiosensitizer or chemosensitizer has
been proven its effectiveness in many different tumor types,
such as locally advanced cervical cancer, recurrent breast
cancer, malignant melanoma, and head and neck cancer. The
size, location, and type of tumor(s) determine whether hyper­
thermia should be applied only locally in combination with
RT or chemotherapy, or whether hyperthermia should be
applied to a larger area in combination with only chemother­
apy. Hyperthermia has also been demonstrated to regulate
the innate and adaptive immune system [91, 92].
6.5.6"
"Describe the combined effects of hyperthermia and radiotherapy on DNA damage repair mechanisms, and explain how this synergy contributes to increased cellular cytotoxicity.","Hyperthermia significantly alters the process of DNA damage repair within cells, primarily by compromising the activity of key enzymes involved in these processes. Specifically, hyperthermia weakens the function of DNA repair enzymes such as nucleotide excision repair (NER) and base excision repair (BER). These enzymes are crucial for removing damaged DNA bases and repairing double-strand breaks – the primary mechanisms cells utilize to recover from radiation-induced damage. By disrupting their activity, hyperthermia leads to a substantial accumulation of unrepaired DNA damage following radiotherapy exposure. This increased burden of unrepaired DNA triggers cell death through various pathways, including apoptosis (programmed cell death) and necrosis. The synergy between hyperthermia and radiotherapy is therefore maximized when the treatments are administered closely together in time – typically within 4 hours – because this allows the hyperthermic effect to maximally inhibit DNA repair before the radiation itself causes further damage. This combined approach effectively overwhelms the cell’s ability to cope with injury, leading to a significantly higher cytotoxic response compared to either treatment alone. Furthermore, as noted in the text, for certain drugs like platinum compounds, hyperthermia can reactivate resistance to these agents by restoring the sensitivity of resistant cells to DNA damage.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Content: 6.5.6.1	Hyperthermia Combined
with Chemotherapy
For metastases from, e.g., colon or ovarian origin which are
located in the peritoneal area, a heated chemotherapy solu­
tion can be circulated through the peritoneal area (called
hyperthermic intraperitoneal chemotherapy; HIPEC) [93].
For urinary bladder cancer, a heat solution can be circulated
through this organ (endocavity). Since all of these heated
solutions are combined with chemotherapy, these hyperther­
mia setups will not be further discussed in this chapter.
Generally, hyperthermia modifies the cytotoxicity of many
chemotherapeutic agents. Furthermore, for some drugs, like
the platinum compounds, hyperthermia was found to make
resistant cells platinum-responsive again [94]. Whether
hyperthermia has this effect on other drugs, needs to be
investigated.
6.5.6.2	Hyperthermia Combined
with Radiotherapy
Locoregional hyperthermia combined with RT is an approach
for patients with locally advanced cervical carcinoma (deep
hyperthermia) or recurrent breast cancer (superficial hyper­
thermia) in Europe and USA. Locoregional hyperthermia
combined with RT has been used in the clinic already since
the early 1980s [95]. It is also possible to implant a heat
source in the tumor itself (interstitial), which mainly has
been used for brain tumors or locally advanced head and
neck tumors [96]. Hyperthermia weakens DNA damage
repair enzymes and thereby retards the repair of radiation-­
induced DNA damage. An increased amount of unrepaired
DNA damage causes more cells to die from the radiation
injury. Importantly, the synergy between radiation and heat
is highest when given simultaneously or closely together in
time (within 4 h) [97].
6.5.6.3	Hyperthermia Combined with Immune
Therapies
Based on the preclinical knowledge gained in the last few
years [91, 92], ongoing clinical trials are conducted with
complementary translational studies focusing on immune
alterations of patients receiving hyperthermia in combina­
tion with RT and/or chemotherapy. These data will form the
basis for the design of multimodal cancer therapies in which
hyperthermia will be combined additionally to radio- and/or
chemotherapy with immune therapies such as immune
checkpoint inhibitors.
6.5.6.4	Techniques to Apply Hyperthermia
Hyperthermia can be applied using different techniques such
as capacitive radiofrequency heating, radiative radiofre­
quency and microwave heating, infrared and laser, ultra­
sound, conductive heating, and by hyperthermic perfusion
[63]. One of the most commonly used techniques which is
validated within clinical trials is microwave heating and
hyperthermia is induced with one or more antennas. An
applicator containing one antenna is used for superficial
hyperthermia, such as breast cancer or malignant melano­
mas. This applicator can be placed on the surface area. For
deep hyperthermia, the patient lies on a mobile bed that can
move through a circle with 4 or 6 antennas. This non-­invasive
method is used for deeper located tumors such as cervical
cancers.
6.5.6.5	Mechanism of Action of Hyperthermia
­
95
6.8
6.8
­
­
95
­
6.8
V. Ahire et al."
"Describe the rationale behind combining hyperthermia with chemotherapy and immune therapies, as suggested by the provided text.","The text suggests a strategic approach to cancer treatment involving the integration of hyperthermia with both chemotherapy and immune therapies. The underlying rationale stems from observed immune alterations in patients receiving hyperthermia alongside radiation therapy and/or chemotherapy. Specifically, complementary translational studies have identified changes in the patient’s immune system during this combined treatment regimen. These findings are being leveraged to design multimodal cancer therapies where hyperthermia is added to radio- and/or chemotherapy treatments, concurrently administered with immunotherapies like immune checkpoint inhibitors. The hypothesis appears to be that hyperthermia enhances the tumor microenvironment, making it more susceptible to both cytotoxic effects of chemotherapy and the activation of anti-tumor immune responses facilitated by immune checkpoint inhibitors. This combined approach aims to maximize therapeutic efficacy while potentially mitigating resistance mechanisms.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Sub-sub-subsection: 6.5.6.1	 Hyperthermia Combined with Chemotherapy | Content: complementary translational studies focusing on immune
alterations of patients receiving hyperthermia in combina­
tion with RT and/or chemotherapy. These data will form the
basis for the design of multimodal cancer therapies in which
hyperthermia will be combined additionally to radio- and/or
chemotherapy with immune therapies such as immune
checkpoint inhibitors.
6.5.6.4	Techniques to Apply Hyperthermia
Hyperthermia can be applied using different techniques such
as capacitive radiofrequency heating, radiative radiofre­
quency and microwave heating, infrared and laser, ultra­
sound, conductive heating, and by hyperthermic perfusion
[63]. One of the most commonly used techniques which is
validated within clinical trials is microwave heating and
hyperthermia is induced with one or more antennas. An
applicator containing one antenna is used for superficial
hyperthermia, such as breast cancer or malignant melano­
mas. This applicator can be placed on the surface area. For
deep hyperthermia, the patient lies on a mobile bed that can
move through a circle with 4 or 6 antennas. This non-­invasive
method is used for deeper located tumors such as cervical
cancers.
6.5.6.5	Mechanism of Action of Hyperthermia
­
95
6.8
6.8
­
­
95
­
6.8
V. Ahire et al."
"Describe the rationale behind combining hyperthermia with radiotherapy and chemotherapy, as suggested by the provided text, and what specific biological changes are being investigated to inform future multimodal cancer therapies?","The text suggests a strategic approach to cancer treatment involving the combination of hyperthermia with both radiotherapy and chemotherapy, further augmented by immune therapies like checkpoint inhibitors. The underlying rationale stems from the potential for each modality to independently enhance tumor cell death and disrupt cellular processes. Radiotherapy primarily damages DNA, while chemotherapy targets rapidly dividing cells. Hyperthermia, by raising tissue temperatures, significantly increases the sensitivity of cancer cells to both radiation and cytotoxic drugs. Critically, the research focuses on investigating immune alterations in patients receiving this combined treatment. Specifically, studies are examining how hyperthermia, when coupled with RT and/or chemotherapy, impacts the patient’s immune system – likely through mechanisms such as increased antigen presentation, enhanced T cell activation, or modulation of immunosuppressive pathways. This data is intended to guide the design of future multimodal therapies where hyperthermia is strategically integrated alongside radiation and chemotherapy, leveraging the combined effects on tumor cells and the immune response to achieve a more robust anti-cancer effect. The investigation into immune alterations represents a key step in understanding how to optimize this combination for maximal therapeutic benefit.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Sub-sub-subsection: 6.5.6.2	 Hyperthermia Combined with Radiotherapy | Content: complementary translational studies focusing on immune
alterations of patients receiving hyperthermia in combina­
tion with RT and/or chemotherapy. These data will form the
basis for the design of multimodal cancer therapies in which
hyperthermia will be combined additionally to radio- and/or
chemotherapy with immune therapies such as immune
checkpoint inhibitors.
6.5.6.4	Techniques to Apply Hyperthermia
Hyperthermia can be applied using different techniques such
as capacitive radiofrequency heating, radiative radiofre­
quency and microwave heating, infrared and laser, ultra­
sound, conductive heating, and by hyperthermic perfusion
[63]. One of the most commonly used techniques which is
validated within clinical trials is microwave heating and
hyperthermia is induced with one or more antennas. An
applicator containing one antenna is used for superficial
hyperthermia, such as breast cancer or malignant melano­
mas. This applicator can be placed on the surface area. For
deep hyperthermia, the patient lies on a mobile bed that can
move through a circle with 4 or 6 antennas. This non-­invasive
method is used for deeper located tumors such as cervical
cancers.
6.5.6.5	Mechanism of Action of Hyperthermia
­
95
6.8
6.8
­
­
95
­
6.8
V. Ahire et al."
"How might combining hyperthermia treatment with immune checkpoint inhibitors alter the efficacy of radiotherapy and chemotherapy in cancer patients, according to recent preclinical research?","Recent preclinical studies suggest that combining hyperthermia with immune checkpoint inhibitors represents a promising multimodal approach for cancer therapy. The rationale stems from observed immune alterations within patients undergoing hyperthermia combined with radiation or chemotherapy. Specifically, hyperthermia is known to induce cellular stress and damage, leading to the release of Damage-Associated Molecular Patterns (DAMPs) – molecules typically sequestered inside cells. These DAMPs activate innate immune responses, primarily through toll-like receptors (TLRs), triggering inflammation and stimulating antigen presentation by dendritic cells. This heightened immune activation can overcome immunosuppressive mechanisms often driven by checkpoint inhibitors, which target proteins like PD-1 or CTLA-4 that normally dampen T cell activity. By initially boosting the immune response with hyperthermia, the effectiveness of immune checkpoint inhibitors is amplified, potentially leading to a more robust and durable anti-tumor effect when combined with radiation and/or chemotherapy. The ongoing clinical trials are designed to investigate this synergistic interaction and establish the optimal combination strategies for various cancers.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Sub-sub-subsection: 6.5.6.3	 Hyperthermia Combined with Immune Therapies | Content: Therapies
Based on the preclinical knowledge gained in the last few
years [91, 92], ongoing clinical trials are conducted with
complementary translational studies focusing on immune
alterations of patients receiving hyperthermia in combina­
tion with RT and/or chemotherapy. These data will form the
basis for the design of multimodal cancer therapies in which
hyperthermia will be combined additionally to radio- and/or
chemotherapy with immune therapies such as immune
checkpoint inhibitors."
"The provided text discusses combining radiotherapy with other cancer treatments, specifically hyperthermia. How does the integration of hyperthermia, alongside radiation and chemotherapy, propose to influence future multimodal cancer therapies?","The document suggests that incorporating hyperthermia into combined cancer treatment regimens will serve as a foundational element for designing more sophisticated multimodal therapies. Specifically, research is focused on understanding how hyperthermia alters the immune system in patients receiving this combination with radiotherapy and/or chemotherapy. The ultimate goal is to leverage these data to strategically combine hyperthermia with other immunotherapies, such as immune checkpoint inhibitors, creating synergistic treatment approaches that enhance overall cancer control. This approach aims to exploit the combined effects of heat-induced cellular damage alongside immunotherapy's ability to stimulate anti-tumor immunity.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Sub-sub-subsection: 6.5.6.4	 Techniques to Apply Hyperthermia | Content: complementary translational studies focusing on immune
alterations of patients receiving hyperthermia in combina­
tion with RT and/or chemotherapy. These data will form the
basis for the design of multimodal cancer therapies in which
hyperthermia will be combined additionally to radio- and/or
chemotherapy with immune therapies such as immune
checkpoint inhibitors.
6.5.6.4	Techniques to Apply Hyperthermia
Hyperthermia can be applied using different techniques such
as capacitive radiofrequency heating, radiative radiofre­
quency and microwave heating, infrared and laser, ultra­
sound, conductive heating, and by hyperthermic perfusion
[63]. One of the most commonly used techniques which is
validated within clinical trials is microwave heating and
hyperthermia is induced with one or more antennas. An
applicator containing one antenna is used for superficial
hyperthermia, such as breast cancer or malignant melano­
mas. This applicator can be placed on the surface area. For
deep hyperthermia, the patient lies on a mobile bed that can
move through a circle with 4 or 6 antennas. This non-­invasive
method is used for deeper located tumors such as cervical
cancers."
"Describe the mechanism by which hyperthermia, specifically through the action of heat shock protein 70 (HSP70), contributes to an immunostimulatory response when combined with radiation therapy and/or chemotherapy.","Hyperthermia’s impact on immunity is primarily mediated by heat shock protein 70 (HSP70). Initially, within the tumor cell itself, HSP70 functions as a chaperone protein, protecting cellular components from thermal damage – this phenomenon is termed thermotolerance. However, when cells are subjected to hyperthermia and subsequently undergo necrosis, released HSP70 plays a crucial role in activating the immune system. Specifically, HSP70, once outside of the cell, acts as an antigen carrier. It’s taken up by dendritic cells, which are key players in bridging innate and adaptive immunity. These dendritic cells then process tumor-associated antigens presented alongside co-stimulatory signals directed towards CD8+ T cells. This dual stimulation – antigen presentation and co-stimulation – effectively primes cytotoxic T lymphocytes (CTLs) to mount a targeted antitumor response. Furthermore, HSP70 can directly activate other innate immune cells like natural killer (NK) cells, augmenting the overall anti-tumor immunity. The combined effect of these mechanisms represents a multimodal approach designed to enhance the efficacy of radiation and chemotherapy treatments. Reference: MolecularRadiationBiology, Section 6.5.6.5 – Mechanism of Action of Hyperthermia","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Sub-sub-subsection: 6.5.6.5	 Mechanism of Action of Hyperthermia | Content: complementary translational studies focusing on immune
alterations of patients receiving hyperthermia in combina­
tion with RT and/or chemotherapy. These data will form the
basis for the design of multimodal cancer therapies in which
hyperthermia will be combined additionally to radio- and/or
chemotherapy with immune therapies such as immune
checkpoint inhibitors.
6.5.6.4	Techniques to Apply Hyperthermia
Hyperthermia can be applied using different techniques such
as capacitive radiofrequency heating, radiative radiofre­
quency and microwave heating, infrared and laser, ultra­
sound, conductive heating, and by hyperthermic perfusion
[63]. One of the most commonly used techniques which is
validated within clinical trials is microwave heating and
hyperthermia is induced with one or more antennas. An
applicator containing one antenna is used for superficial
hyperthermia, such as breast cancer or malignant melano­
mas. This applicator can be placed on the surface area. For
deep hyperthermia, the patient lies on a mobile bed that can
move through a circle with 4 or 6 antennas. This non-­invasive
method is used for deeper located tumors such as cervical
cancers.
6.5.6.5	Mechanism of Action of Hyperthermia
­
95
6.8
6.8
­
­
95
­
6.8
V. Ahire et al.
335
­
­
­
the heat shock protein 70 (HSP70) is a major player.
While inside the cell, it acts as chaperon and protects cells
(known as thermotolerance), outside of the cell when
being, e.g., released by heat-induced necrotic cells, it acti­
vates dendritic cells and delivers antigen to these key
immune cells that bridge innate and adaptive immunity.
Thus, dendritic cells take up tumor antigens, present them
with co-stimulation to CD8+ T cells, and subsequently
trigger cellular antitumor immunity by priming cytotoxic
T cells [99]. Additionally, HSP70 can directly activate fur­
ther cells of the innate immune system, such as natural
killer cells [100]. Based on this preclinical knowledge
gained in the last years, ongoing clinical trials are con­
ducted with complementary translational studies focusing
on immune alterations of patients receiving hyperthermia
in multimodal settings."
"Describe the rationale behind combining radiotherapy with hyperthermia for treating deeper-located tumors like cervical cancer, and detail the typical treatment schedule employed in such cases.","The combination of radiotherapy (RT) and hyperthermia is frequently utilized for deeper-located tumors, particularly in cancers like cervical cancer, due to several key advantages. Traditional chemoradiation regimens often prove less effective in these higher-stage tumors, leading to increased toxicity. Hyperthermia, by elevating the tumor temperature to approximately 40°C for about one hour, significantly enhances the radiosensitizing effects of RT. This is because heat increases cellular metabolic activity and damages DNA more effectively than radiation alone, making the tumor cells more vulnerable to radiation-induced damage. Furthermore, hyperthermia appears to mitigate some of the toxicities associated with chemoradiation, reducing side effects such as mucositis and myelosuppression. The typical treatment schedule involves daily fractions of external beam RT delivered over several weeks. Simultaneously, hyperthermia is applied once or twice per week for approximately five consecutive weeks. Importantly, a short time interval between RT and hyperthermia sessions can be beneficial, although ongoing research continues to investigate this further. This combined approach aims to maximize tumor cell destruction while minimizing adverse effects by leveraging the synergistic effects of heat and radiation [104, 105, 106].","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.6	 Hyperthermia in Clinical Settings | Sub-sub-subsection: 6.5.6.6	 Main Indications | Content: ­
­
­
­
101
102
­
103
­
6.9
6.10
Deeper located tumors: In most countries, RT combined
with chemotherapy is standard treatment of care for cervi­
cal cancer patients. However, chemoradiation is less ben­
eficial in tumors of higher stage, whereas hyperthermia as
an adjuvant to RT has shown its additional value. Especially
in this group, chemoradiation was found to be not very
effective. Moreover, chemoradiation seems to result in
more toxicities, whereas hyperthermia in addition to RT
did not increase radiation-induced toxicities [104].
Treatment course: Both superficial and deep hyperthermia
are applied in combination with either RT or chemother­
apy. Depending on the tumor type, e.g., BC, cervical can­
cer, etc. and The International Federation of Gynecology
and Obstetrics (FIGO) stage, a radiotherapy or chemo­
therapy scheme is chosen. While external beam RT is
mainly given in daily fractions with low doses, hyperther­
mia is only applied once or twice per week, for 5 weeks in
a row. For each treatment session, the target temperature
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
336
­
­
should be above 40 °C for approximately 1 h. Moreover,
a short time interval on the day that both RT and hyper­
thermia are given can be more beneficial, but research is
ongoing in providing more evidence [105, 106] (Box 6.9).
6.5.7"
"How does voluntary fasting or calorie restriction (STS/CR) impact cancer cells differently compared to normal cells, and what cellular mechanisms contribute to this differential effect?","Voluntary fasting or short-term starvation (STS), often referred to as calorie restriction (CR), significantly alters the response of cancer cells versus normal cells. In normal cells, STS promotes rejuvenation and protects against the toxic effects of treatments like radiation therapy. However, in cancer cells, STS induces a state of metabolic vulnerability. This difference stems from several key mechanisms: Firstly, STS reduces circulating levels of glucose, insulin-like growth factor-1 (IGF-1), and insulin – all critical for cancer cell proliferation. Secondly, it increases the production of ketone bodies and insulin-like growth factor-binding protein 1 (IGFBP1). These changes force cancer cells to rely on limited nutrient pools within the bloodstream, ultimately leading to their demise. Furthermore, STS triggers a phenomenon known as differential stress sensitization (DSS) and differential stress resistance (DSR), where normal cells become more resilient to stressors while cancer cells are rendered highly susceptible to cell death. This is linked to alterations in mitochondrial function and glucose uptake pathways that are characteristic of cancer cells. The combination of these factors effectively starves the cancer cells, leading to apoptosis or necrosis. Reference: [MolecularRadiationBiology, Section 6.5.7 RT Combined with Short-Term Starvation] ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.5	 Radiotherapy Combined with Other Cancer Treatment Modalities | Sub-subsection: 6.5.7	 RT Combined with Short-Term Starvation | Content: Starvation
Voluntary fasting is a part of religious services in many cul­
tures like Buddhism, Christianity, Hinduism, etc. Fasting/
short-term fasting (STS) is also known as calorie restriction
(CR) which is associated with diets with a wide alteration
in the growth factors and the metabolites levels. This pro­
duces a milieu that diminishes the cancer cell competency
to get acclimatized and endure which results in improved
outcomes for cancer therapy. In normal cells, STS and fast­
ing selectively boost the chemotherapy resistance which is
not the case with cancer cells. STS endorses rejuvenation
of normal cells, thereby averting the toxic and harmful
effects of the treatment. Clinical as well as in vivo studies
suggest that the low calorie-fasting mimicking diet (FMD)
cycles are promising and also safe, in patients that can
barely endure STS/fasting. Hence, it can be predicted that
Box 6.9 RT Combined with Hyperthermia
•	Hyperthermia enhances blood perfusion and reoxy­
genation, triggers an immune response, and disturbs
the tumor microenvironment.
•	Hyperthermia increases RT and chemotherapy-­
induced DNA damage, inhibits the DNA damage
repair pathways, increases cell cycles arrest, and
induces cell death such as apoptosis and necrosis.
•	Hyperthermia was proven to be effective in many
different tumor types, such as superficial breast can­
cer, soft tissue sarcoma, and cervical cancer.
V. Ahire et al.
337
the combination of STS or FMDs with chemotherapy,
immunotherapy as well as other therapies holds a promise
in increasing the cancer treatment efficacy, preventing the
acquired resistance and minimizing the aftereffects [107].
This can be correlated with one of the emerging hallmarks
of cancer, i.e., the susceptibility of cancer cells to nutrient
deficiency and their addiction for explicit metabolites.
Three of the nutritional interventions of food withdrawal
strategies like fasting, FMD, and calorie CR from the myr­
iad of strategies have increasingly exhibited a valuable
effect on metabolism and shown a promising anticancer
activity. STS is typically done on an average of 3–5 succes­
sive days. In fasting, only water is consumed, for a time-
span ranging from 12 h to 3 weeks. For CR, there is a
20–40% decrease in calorie ingestion with decrease in all
constituents without intercepting the ingestion of minerals
and vitamins, typically used by specialists as a synonym to
dietary restriction.
Cancer cells are distinguished from normal cells by means
of their irregular metabolic and signaling pathways that lead
to circumventing the antiproliferative signals, distorted mito­
chondrial function, and increased glucose uptake. Fasting or
STS exhibits a differential consequence on cancer cells and
normal cells which can be attributed to drop in the glucose,
insulin-like growth factor-1, and insulin levels, amplification
in ketone bodies and insulin-like growth factor-­binding pro­
tein 1 (IGFBP1). This phenomena force cancer cells to
depend on the limited amounts of factors and metabolites
that are present in the blood, thereby eventually resulting in
cell death. The response mechanisms of differential stress
sensitization (DSS) and differential stress resistance (DSR)
caused by fasting/STS stimulate the normal cell protection
but pushes the cancer cell toward cell death. One of the major
classical responses of radiation is the dys-functioning of the
cell cycle arrest [108].
There is a growing body of evidence from the preclinical
studies on STS which enhances the efficacy of a wide variety
of chemotherapy drugs that are used in treatments of several
types of tumors. Some of clinical trials (NCT00757094,
NCT00936364, NCT01304251, and NCT01954836) have
proven to be safe and feasible with reduction in the chemo­
therapy associated side effects. Since STS has demonstrated
favorable traits to fight cancer, it would be logical to combine
STS with RT as it presents clinical gain. In preclinical stud­
ies, combining STS with RT has already exhibited enhanced
RT effects. Clinical and preclinical trials of STS and RT are
also picking pace to exhibit the efficacy of this combination.
STS can be considered as a personalized dietary approach
that can be conveniently combined with RT in clinics in the
path forward (Box 6.10).
6.6"
Describe the principles behind spatial fractionation in radiation therapy and explain how it contributes to minimizing damage to normal tissue compared to conventional radiotherapy techniques.,"Spatial fractionation, particularly as exemplified by GRID and LATTICE therapies, represents a sophisticated approach to radiation delivery designed to significantly reduce toxicity to surrounding healthy tissues. The core principle relies on the application of small, tightly focused beams of radiation arranged in a patterned grid or lattice-like structure. Within this pattern, high doses of radiation are delivered along the beam paths (the ‘valleys’), while the areas between the beams receive minimal or virtually no radiation exposure (the ‘peaks’). This creates a substantial peak-to-valley dose ratio (PVDR). Traditional radiotherapy often employs broader beams, leading to relatively uniform radiation exposure across a larger volume of tissue. Consequently, normal tissues adjacent to the tumor are exposed to high doses, increasing the risk of side effects. Spatial fractionation dramatically alters this dynamic by concentrating the therapeutic dose precisely within the tumor while sparing surrounding healthy cells from significant radiation damage. This is achieved because cells in the ‘valleys’ – areas with minimal radiation exposure – are less likely to undergo DNA damage and subsequent cell death compared to those exposed to high doses in conventional techniques. The concept leverages the differential sensitivity of cancer cells versus normal cells to radiation, allowing for a more targeted treatment strategy. Furthermore, advancements like minibeam radiotherapy (MBRT) utilizing protons or heavier ions build upon this principle by further refining beam shaping and overlap, providing even greater precision and sparing capabilities. Reference: [MolecularRadiationBiology, Section 6.6 – Spatial Fractionation]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.6	 Spatial Fractionation | Content: path forward (Box 6.10).
6.6
Spatial Fractionation
Box 6.10 RT Combined with Short Term Starvation
•	Short-term starvation (STS) in combination with
RT leads to an increased effect of RT on metastatic
cancer cells, and at the same time also protects nor­
mal cells.
•	Short-term starvation (STS) or fasting can particu­
larly safeguard normal cells in mice and probably in
patients receiving chemo without reducing the ther­
apeutic effect on cancer cells.
•	Fasting dependent decrease in IGF-1 and glucose
are arbitrate components involved in the DSR and
DSS effects.
Box 6.11 Spatial Fractionation I
•	Spatial fractionation is a method that reduces dam­
age to normal tissue.
•	Small beams of radiation are applied in a grid-like
pattern.
•	High doses are applied in the beam path, while
(almost) no or very low dose is delivered between
the beams, resulting in high peak-to-valley dose
ratio  (PVDR).
Box 6.12 Spatial Fractionation II
•	Spatial fractionation of photons is in clinical use.
•	GRID therapy uses 2D pattern with beam width of
~1–1.25 cm and center to center (ctc) of
2.2–2.4 cm.
•	LATTICE is the 3D extension of GRID therapy.
Box 6.13 Minibeam RT
•	Minibeam RT (MBRT) is a modern therapy
approach using protons and heavier ions, which is
at the moment in preclinical stage or investigated in
clinical trials.
•	In proton MBRT, the beam widen and overlap in the
tumor.
•	Further sparing of healthy tissue can be achieved
using interlacing methods.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
338
The concept of spatial fractionation of radiation in tumor
therapy aims to widen the therapeutic window by sparing
healthy tissue by simply sparing parts of it from radiation. It
was introduced as GRID therapy by Alban Köhler in 1909 by
the use of a grid of centimeter-wide pencil beams in X-ray
therapy [109]. In the 1990s, when more powerful X-rays
became available from synchrotron facilities, GRID therapy
was moved to the micro level with the development of micro­
beam radiotherapy (MRT) and to the submillimeter level in
the later 2000s with minibeam radiotherapy (MBRT) [110].
It was then that GRID, MRT, and MBRT were classified
under a broader term of spatially fractionated radiation ther­
apy (SFRT).
In SFRT, the spatial arrangement of the radiation allows
irradiating tumors with a heterogeneous dose, with high
doses in the radiation channels and low doses in the so-called
valleys in between.
In recent years, advances in the use of spatial fraction­
ation in particle therapy have also been investigated.
Proton minibeam radiotherapy (pMBRT) is making rapid
progress [111]. Thanks to small-angle scattering, the radi­
ation channels overlap and the tumor is irradiated with a
homogeneous dose, while the normal tissue is spared due
to the spatial fractionation of the dose (Box 6.11, 6.12,
and 6.13).
6.11
6.6.1"
"Explain the concept of spatial fractionation in radiation therapy, detailing the key parameters involved and how they contribute to tumor control while minimizing damage to surrounding normal tissue.","Spatial fractionation represents a sophisticated approach to radiation treatment that leverages the differential sensitivity of cells to radiation dose. The core principle involves precisely controlling the arrangement and characteristics of beams used to target a tumor. Key parameters include beam width (or beam size, defined as Full Width at Half Maximum – FWHM), center-to-center distance (ctc) between beams, and the peak-to-valley dose ratio (PVDR). Beam width dictates the spatial extent of radiation deposition; smaller widths allow for more focused targeting. Ctc represents the separation between beams, influencing the overall dose distribution. The PVDR – calculated as the ratio of the maximum dose (peaks) to the minimum dose (valleys) within a given area – is crucial in determining the strength of spatial fractionation. A higher PVDR indicates a greater differential in dose and thus a more pronounced effect on tissue sparing.

The mechanism relies heavily on the ability of undamaged cells surrounding the beams to migrate into the irradiated region, supporting wound healing processes. This phenomenon, often referred to as the ‘bystander effect,’ contributes to increased tolerance of lower doses in areas between the beams – a concept related to the dose-volume effect. Furthermore, microscopic prompt tissue repair is facilitated by rapid restoration of capillary blood vessels within days or hours following small area damage, supporting healing and bolstering tissue resilience. The precise control afforded by these parameters allows for the delivery of higher tumor doses while simultaneously minimizing collateral damage to adjacent normal tissues.

It’s important to note that the unit cell concept – representing the smallest repeating structure of beams – is central to treatment planning, ensuring complete coverage of the tumor volume. Reference: MolecularRadiationBiology > section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities > subsection: 6.6 Spatial Fractionation > subsubsection: 6.6.1 Parameters and Mechanisms","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.6	 Spatial Fractionation | Sub-subsection: 6.6.1	 Parameters and Mechanisms | Content: Spatial fractionation of radiation means that new parameters
must be introduced and controlled in treatment planning and
therapy. First and foremost, beam size and the distance between
two beams become the most important variables. Beam size, or
beam width, is the full width at half maximum (FWHM) of the
lateral intensity profile of a beam. The distance between two
beams, also called center-to-center distance (ctc), is defined as
the length of the direct connection between the maximum
intensity (also called center) of the two beams [112].
Another important quantity is the dose ratio between the
dose in the center of the beam (peaks) DP and the dose in the
middle between two beams (valleys) DV, the peak-to-valley
dose ratio (PVDR):
(6.3)
The PVDR defines the strength of spatial fractionation. It is
~1 for homogeneous irradiation and approaches infinity for
small valley doses [113].
The parameters of beam width, ctc, and PVDR determine
the possibility of sparing normal tissue and also the dose
applied to the tumor, thus influencing tumor control.
6.12a, b
6.12c
V. Ahire et al.
339
112
beams have a completely round or Gaussian shape and can
be arranged in either a square or hexagonal lattice. For treat­
ment planning, it is important to know the dimensions of a
beam. For this purpose, the unit cell of a beam is used. The
unit cell is the smallest unit in which a beam can be consid­
ered a beam and the entire dose distribution is covered. The
unit cell is assembled to form the entire lattice and cover the
tumor.
The basic mechanism of tissue sparing by spatial fraction­
ation lies in the ability of undamaged cells in the vicinity of
the radiation beam paths to migrate to this region and support
wound healing. This is described as the dose-volume effect,
i.e., the ability of skin and subcutaneous tissue in particular
to tolerate more dose as the irradiated volume decreases.
Furthermore, the microscopic prompt tissue repair is another
beneficial effect resulting in better tolerance of tissue to sub­
millimeter sized beams. When tissue is damaged in such
small areas, capillary blood vessels can be rapidly restored
within days or even hours by the regeneration of cells from
the undamaged area. The intact blood vessels also support
healing of the damaged tissue located between the beams.
The extent to which the bystander effect plays a role is still
unknown and is currently being investigated.
6.6.2"
"Describe the clinical considerations surrounding the use of multileaf collimators (MLCs) in radiotherapy, specifically addressing their impact on treatment time and potential alternative approaches.","Multileaf collimators (MLCs) represent a significant advancement in radiation therapy by enabling precise targeting of tumors while minimizing exposure to surrounding healthy tissue. However, their clinical application is not without challenges. The fundamental mechanism of MLCs – individually shaping the beam with each treatment session using multiple lead leaves – inherently results in prolonged treatment times compared to traditional block collimators. This ‘step-and-shoot’ procedure requires meticulous adjustment and scanning across the tumor volume for each fractional dose, leading to extended patient positioning and setup times. While faster irradiations are theoretically possible through rapid target movement with MLCs, this technique remains largely preclinically viable at present. A more sophisticated approach involves a hybrid strategy combining an MLC with a block collimator. This combination leverages the tissue-sparing capabilities of the MLC while retaining the potentially higher photon dose delivery afforded by a block collimator. Despite this combined benefit, such systems can introduce complexities and may result in reduced overall PVDR (photons delivered per unit volume radiated) along the diagonal due to beam overlap considerations. Ultimately, the choice between these methods depends on factors like tumor size, shape, anatomical constraints, and desired dose distribution characteristics.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.6	 Spatial Fractionation | Sub-subsection: 6.6.2	 Spatial Fractionation of Photons | Sub-sub-subsection: 6.6.2.1	 Photon SFRT in the Clinic | Content: ­
­
­
6.13b
109
Optimal geometries of collimators for tissue sparing and
therapeutic outcome are hole sizes from 1 to 1.25 cm and ctc
from 2.2 to 2.4 cm [114]. The pattern can be generated either
with a block collimator with a defined hole pattern or with
multileaf collimators (MLCs), which can be flexibly adapted
to the needs of the treated tumor. The disadvantage of MLCs
in the clinic is that treatment time is prolonged because each
spot must be applied in a step-and-shoot procedure. Although
faster irradiations are possible with MLCs by moving the tar­
get across the beam, this is currently only ­possible preclini­
cally. A more advanced method is the hybrid use of an MLC
and a block collimator, which combines the advantages of
both methods but has the disadvantage of lower PVDR along
the diagonal [115].
114115
­
6.13a
116
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
340
114"
"Describe the key mechanisms by which MRT (Microbeam Radiation Therapy) minimizes damage to normal tissue compared to conventional radiation therapy, and how does this relate to the concept of ‘FLASH’ radiotherapy?","MRT achieves significant dose reduction in healthy tissues through two primary mechanisms. First, spatial fractionation via extremely thin microbeams dramatically reduces the overall dose delivered by limiting the extent to which a cell is exposed to high radiation levels simultaneously. This ‘volumetric sparing’ effect directly addresses the traditional dose-volume effect associated with conventional radiotherapy. Second, MRT utilizes ultra-high dose rates – up to 12,000–16,000 Gy/s – creating what's known as the ‘FLASH effect’. FLASH radiotherapy specifically targets rapidly growing, immature tumor vasculature, inducing transient ischemia and neutrophil infiltration within the tumor itself. This selective damage primarily affects the tumor’s blood supply rather than healthy tissue, which is typically more resilient to such high-dose exposures due to its mature vascular structure. The rapid delivery of radiation at these rates prevents beam smearing across tissue, a critical factor in MRT's effectiveness and why it’s currently limited to synchrotron facilities. This contrasts with conventional RT where the prolonged exposure allows for broader damage to surrounding tissues.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.6	 Spatial Fractionation | Sub-subsection: 6.6.2	 Spatial Fractionation of Photons | Sub-sub-subsection: 6.6.2.2	 Photon SFRT in Preclinical Development | Content: ­
­
6.14
MRT has the distinction of using extremely thin micro­
beams, which exploits the dose-volume effect and allows
very high doses of radiation (300–600 Gy) to be delivered
with minimal toxicity to normal tissue. In addition, synchro­
tron facilities such as the European Synchrotron can deliver
radiation at ultra-high dose rates (12,000–16,000 Gy/s),
making synchrotron MRT a spatially fractionated FLASH
RT [117].
The benefits of MRT over conventional RT are many:
•	Normal tissue is spared from the effects of radiation by
two unique mechanisms: (1) volumetric sparing due to
spatial fractionation of microbeams and (2) sparing of
normal tissue due to ultra-high dose rates, known as the
FLASH effect [117]. More details of FLASH radiother­
apy are discussed in Sect. 6.4.2.
•	MRT produces unique vascular effects that preferentially
damage tumor vessels rather than those of healthy tissue.
Peak doses selectively affect rapidly growing “immature”
tumor vasculature, triggering transient tumor ischemia
and neutrophil infiltration [117].
•	Strong immune responses have been observed after
MRT. For example, MRT can activate natural killer and
cytotoxic CD8+ T cells, induce higher levels of pro-­
inflammatory genes in tumors, trigger the release of che­
mokines that attract monocytes, and recruit leukocytes to
malignant tissues [118].
MRT currently requires ultra-high dose rates to deliver the
radiation fast enough to prevent the beam from smearing across
tissue due to the cardiovascular motion. Therefore, preclinical
and future clinical research on MRT is currently limited to syn­
chrotron facilities. However, a compromise can be achieved by
delivering photon MBRT, since beam smearing is not a problem
with submillimeter beams. The same logic is now being applied
to MBRT ion therapy research and will be discussed next.
V. Ahire et al.
341
­
6.6.3"
"Describe the process of ion beam interaction with matter during minibeam radiotherapy, specifically focusing on the mechanisms leading to energy loss and broadening of the beam.","During minibeam radiotherapy utilizing ions like carbon or helium, significant interactions occur as these particles traverse biological tissue. At high energies (as employed in therapy), the dominant mechanism is Coulomb interaction with the electrons of the target material. This interaction results in a substantial energy loss by the ion, effectively defining what’s known as the Bragg curve – a characteristic profile illustrating the particle's energy deposition as it penetrates the tissue. Critically, these interactions also induce scattering of the ions. This scattering manifests as small-angle (Coulomb) scattering, where the incident ion is deflected from its original trajectory by a relatively minor angle. Each such interaction causes a broadening of the initial ion beam due to this gaussian distribution of scattered particles. The extent of this broadening – quantified by the Full Width at Half Maximum (FWHM), typically several millimeters at relevant therapeutic energies – is directly proportional to the ion’s charge (z), its kinetic energy (Ekin), and the distance it travels through the medium (x). This scattering effect leads to a widening of the beam as penetration depth increases, impacting the precision of targeted radiation delivery.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.6	 Spatial Fractionation | Sub-subsection: 6.6.3	 Spatial Fractionation of Ions | Content: The method of applying spatially fractionated RT using
particles, also called minibeam RT, is still in its infancy.
Preclinical research points to drastically lowered side
effects, with at least same tumor control, thus clearly wid­
ening the therapeutic window. In MBRT, one distinguishes
between proton MBRT and ion MBRT, most commonly
carbon and helium. The major difference lies in the applica­
tion of the dose to the tumor originating from different
physical properties of the particles. When particles traverse
matter, interactions with the atoms and molecules occur. At
high energies, as used for therapy, the interactions are dom­
inated by Coulomb interactions with the electrons of the
target material. These mechanisms mainly cause the ions to
lose energy and define the well-known Bragg curve of
energy loss. But these interactions also cause scattering of
the ions and thus deflection, called small-angle (Coulomb)
scattering. In each interaction, the particle is only scattered
by a small angle, causing a roughly gaussian broadening of
an incident ion beam. The beam is thus widening with
increasing penetration depth. The FWHM of the beam due
to scattering, which is in the order of several millimeters
for therapy relevant energies, is proportional to the ion
charge z its kinetic energy Ekin and the distance covered in
medium x:
(6.4)
­
6.15
6.16
­
­
119
­
6.17
­
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
342
V. Ahire et al.
343
119
lower early and late side effects in the skin of mice and rats
[113, 120]. Furthermore, in a rat brain model, it could be
shown that less histological and behavioral changes occur
after pMBRT [120]. Already tumor treatment was per­
formed in glioma bearing rats, where animal survival could
be clearly enhanced while tumor control was kept. First
therapy planning in brain tumor patients shows reduced
dose to organs at risk, while the same dose distribution in
PTV could be achieved (Fig. 6.18) [121]. These promising
preclinical results cleared the way for clinical trials. First
results on treatment of ten patients treated with pMBRT,
called proton GRID therapy, in a clinical study
(NCT01255748) show the possible advantages of pMBRT,
regarding sparing of healthy tissue and tumor control [122].
Furthermore, the integration of pMBRT to clinical facilities
is under investigation and especially the combination with
FLASH RT seems promising [113]. An important task
which needs to be solved is the production of mini beams
with a small enough size without producing secondary
radiation, which can harm the patient. The two possible
ways of minibeam production are via the focusing of a pro­
ton beam or via the use of a collimator. Both methods are
complementary, and their use in clinical practice needs to
be further investigated.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
344
Box 6.14 Brachytherapy
•	According to the dose rate brachytherapy can be
divided into three types: low dose rate (LDR) with
dose rates 0.4–2 Gy/h, medium dose rate (MDR)
with dose rates 2–12 Gy/h, and high-dose rate
(HDR) with dose rates excessing 12 Gy/h.
•	Brachytherapy can be delivered with sealed radio­
nuclide sources and electronic brachytherapy using
kV X-rays.
•	Brachytherapy is mostly used for treatment of cer­
vix, prostate, and skin cancers and some rare
sarcomas.
6.7"
"Describe the different brachytherapy dose rate strategies (low, medium, and high) and provide examples of their corresponding dose rates in Gray per hour (Gy/h). Additionally, outline the two primary methods used for delivering brachytherapy treatments.","Brachytherapy utilizes precisely delivered radiation to treat localized cancers. The treatment strategy is primarily defined by the dose rate – the speed at which radiation is administered. There are three main categories: low dose rate (LDR) brachytherapy, medium dose rate (MDR) brachytherapy, and high dose rate (HDR) brachytherapy. LDR brachytherapy employs dose rates ranging from 0.4 to 2 Gy/h. MDR brachytherapy utilizes dose rates between 2 and 12 Gy/h. Finally, HDR brachytherapy is characterized by dose rates exceeding 12 Gy/h. The method of delivery also plays a crucial role; brachytherapy can be administered using sealed radioactive sources or through electronic brachytherapy, which employs kV X-rays to precisely position the source within the tumor. This technique allows for targeted radiation delivery minimizing damage to surrounding healthy tissue. Brachytherapy is predominantly utilized in treating cancers such as cervical cancer, prostate cancer, and certain rare sarcomas. Reference: [MolecularRadiationBiology], Section 6.7.1 – Brachytherapy Strategies","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.1	 Brachytherapy | Content: •	According to the dose rate brachytherapy can be
divided into three types: low dose rate (LDR) with
dose rates 0.4–2 Gy/h, medium dose rate (MDR)
with dose rates 2–12 Gy/h, and high-dose rate
(HDR) with dose rates excessing 12 Gy/h.
•	Brachytherapy can be delivered with sealed radio­
nuclide sources and electronic brachytherapy using
kV X-rays.
•	Brachytherapy is mostly used for treatment of cer­
vix, prostate, and skin cancers and some rare
sarcomas.
6.7
Brachytherapy Strategies
6.7.1
Brachytherapy"
"Describe the key differences between conventional brachytherapy and electronic brachytherapy, focusing on the radiation source type, dose gradient characteristics, and typical clinical applications.","Conventional brachytherapy utilizes sealed radionuclide sources – typically isotopes like iodine-125 or cesium-137 – which are physically implanted directly into or near the tumor. This approach generates a very high dose gradient immediately surrounding the source due to its proximity to the target tissue, leading to precise and localized radiation delivery. However, this also necessitates careful shielding and limits treatment options to easily accessible areas. In contrast, electronic brachytherapy employs X-ray sources generated by kilovoltage generators (typically 30–50 kVp). This technique offers a non-invasive approach, particularly suitable for treating skin cancers in facial regions like the eye and nose, as well as post-surgical tumor beds following procedures such as accelerated partial breast irradiation (APBI) after breast conserving surgery. The electronic method achieves a similar high dose gradient but without the need for physical source implantation, expanding treatment possibilities to more complex anatomical locations. Reference: MolecularRadiationBiology, Section 6.7.1.1 – Principles","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.1	 Brachytherapy | Sub-sub-subsection: 6.7.1.1	 Principles | Content: Brachytherapy is a treatment technique in which radiation
sources are placed into the tumor (or the tumor bed to be treated
after surgery) or its proximity. For conventional brachytherapy,
sealed radionuclide sources are used, but electronic brachyther­
apy with X-ray has recently become available. The advantage of
brachytherapy is a very high dose gradient around the sources,
which are, contrary to external RT, extremely close to the treated
area. Sharp dose decrease allows for a high level of conformity
when dose is delivered locally. However, the technique is avail­
able only for easily accessible treatment areas.
The fractionation scheme is different in comparison to the
external RT with lower number of fractions and higher doses
per fraction.
Usually, radionuclide implants are applied to deliver the
treatment which can be either temporary or permanent. The
radionuclides need to have convenient physical characteris­
tics (half-life, type of disintegration, mean energy, nominal
specific activity, etc.).
V. Ahire et al.
345
Table 6.9 Physical characteristics of radionuclides used for brachytherapy
Characteristic
192Ir
60Co
137Cs
125I
103Pd
Type of disintegration
β− (95.1%), Electron capture
(4.9%)
β−
β−
Electron
capture
Electron
capture
Half-life
73.83 days
5.27 years30.07 years59.4 days
17.0 days
Mean gamma energy (keV)
372.2
1252.0
661.7
35.5
137.1
Nominal specific activity (×105 TBq/kg)
3.4
0.41
3.2 × 10−2
6.5
27
Air kerma-rate constant (×10−18 Gy m2/
(Bq s))
15
85
6.1 × 10−5
9.9
9.0
­
6.9
Electronic brachytherapy is a non-invasive procedure and
is a good option for skin cancers in the facial area, especially
around the eye and nose. It is also an option after breast con­
serving surgery to treat the tumor bed when intraoperative
RT is used according to an accelerated partial breast irradia­
tion (APBI) procedure. Kilovoltage X-rays generators are
used with voltage potential 30–50 kVp."
"Brachytherapy encompasses several techniques, each tailored to specific organ types and cancer characteristics. Describe the key distinctions between intracavitary, interstitial, intraluminal, contact, ocular, intravascular, and brain brachytherapies regarding their source placement and typical applications.","Brachytherapy utilizes localized radiation delivery directly to a tumor or surrounding tissues, offering precise targeting. Several distinct approaches exist based on source placement and the organ being treated:

*   **Intracavitary Brachytherapy:** This technique involves placing radioactive sources within body cavities – such as the uterus, cervix, prostate, or breast – allowing for direct irradiation of the tumor volume located within that space. It’s frequently used in early-stage gynecological cancers (cervix, endometrium) and prostate/breast cancer.

*   **Interstitial Brachytherapy:** Sources are strategically positioned *adjacent* to the tumor, often using needles to insert them directly into the tumor or surrounding tissue. This is commonly employed for prostate and breast cancers but has also been combined with intracavitary techniques for complex cervical tumors.

*   **Intraluminal Brachytherapy:**  Sources are placed within tubular organs like the trachea, lungs, esophagus, or bile duct – directly into the lumen of these structures. This is primarily a palliative approach in lung cancer, utilized when patients can tolerate endobronchial or endoesophageal procedures to deliver targeted radiation.

*   **Contact Brachytherapy:** Sources are placed *on* the skin surface, often using custom-made molds or contact applicators. This method is predominantly used for treating superficial skin cancers (squamous and basal cell carcinomas) on areas like the face, scalp, ears, hands, and legs, particularly when surgical removal would compromise cosmetic outcomes.

*   **Ocular Brachytherapy:** Radioactive sources are implanted directly into the eye to treat uveal malignant melanoma. Commonly used radionuclides include I-125, Ru-106/Rh-106, Pd-103, and Cs-131.

*   **Intravascular Brachytherapy:** This rare technique involves temporarily placing radioactive sources within cardiac stents to treat restenosis following percutaneous angioplasty. Typically uses beta emission sources like P-32, Ir-192, or Rh-188.

*   **Brain Brachytherapy:** While historically significant, its use has declined due to advancements in conventional radiotherapy and stereotactic radiosurgery. It’s reserved for small gliomas (maximum diameter of 5 cm) that are not close to critical organs at risk.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.1	 Brachytherapy | Sub-sub-subsection: 6.7.1.2	 Main Indications and Modalities | Content: There are several types of brachytherapy depending on the
site and organ type to be treated [123].
Intracavitary brachytherapy uses sources that are
placed in body or organ cavities. It is mostly used to treat
early cervical and uterine (endometrial) cancer, but also in a
heterogeneous group of gynecological cancers (ovary, fallo­
pian tubes, body of the uterus, vagina, and vulva). Early rec­
tal cancer can be treated with electron brachytherapy, but the
standard of care in rectal cancer is still surgery, especially in
case of bulky tumors and more advanced disease, preceded
by radio(chemo)therapy.
Interstitial brachytherapy employs sources placed into
the tumor, or to its proximity, using needles. It has primarily
been used to treat prostate or breast cancer (PCa, BC), but
recently it has also been combined with intracavitary brachy­
therapy to treat bulky cervix tumors. This combination
improves coverage of the target volume which was not
achievable intracavitary techniques only. PCa brachytherapy
can be performed with permanent seeds (for LDR) or tempo­
rary sources (for HDR). For breast brachytherapy, interstitial
multicatheter brachytherapy is used for boost or partial
breast irradiation (PBI)/accelerated PBI (APBI). APBI treats
only the lumpectomy bed with 1–2 cm margin, rather than
the whole breast [124]. HDR sources are usually applied to
deliver prescribed doses of 30.3–34 Gy in 7–10 fractions for
APBI and 15–20 fractions with LDR/PDR (pulsed dose rate)
or 8.5–10 Gy with HDR for breast boost treatment. Soft tis­
sue sarcomas are sometimes also treated with brachytherapy
alone or in combination with external RT after surgery.
When sources are placed into tubular organs such as tra­
chea, lungs, esophagus, or bile duct, the term intraluminal
brachytherapy is used. For lung cancer, the ability of patients
to tolerate bronchoscopy is essential. The main indication is
treatment of significant, endotracheal, or endobronchial
symptoms. Endobronchial brachytherapy is mainly palliative,
however it has been used with curative intent in a small num­
ber of cases of early-stage tumors with good results.
Skin cancer can usually be treated by placing the sources
on the skin in the desired geometry, therefore it is sometimes
referred to as contact brachytherapy. Skin cancer is a very
common cancer, and brachytherapy is used mainly for areas
such as face, scalp, ears, hands, legs, especially when sur­
gery would result in poor cosmetic results or require (exten­
sive) plastic reconstructions. Most cancers are either
squamous or basal cell carcinomas. Contact applicators or
surface molds can be used. The applied dose is tumor size
dependent. For LDR and PDR brachytherapy, doses of
60–66 Gy are delivered to tumors less than 4 cm and
75–80 Gy for those more than 4 cm. For HDR brachyther­
apy, typical total dose is 30–40 Gy delivered in 8–10 frac­
tions. Other options for skin treatment include superficial
X-rays, orthovoltage X-rays, megavoltage photons, or elec­
tron beam irradiation.
Ocular brachytherapy can be used to treat uveal malig­
nant melanoma. Currently, the most frequently used radionu­
clides are I-125, Ru-106/Rh-106, Pd-103, Cs-131.
Intravascular brachytherapy is a rarely used treatment
option. It can be used to treat restenosis following percutane­
ous angioplasty of cardiac arteries. The sources are tempo­
rarily placed within cardiac stents in which restenosis has
occurred to prevent restenosis. Typically, beta emission
sources like P-32, Ir-192, or Rh-188 are used for the treat­
ment. P-32 coated stents have also been used, but with the
development of drug-eluting stents, intravascular brachy­
therapy has lost a lot of its attractivity.
The application of brain brachytherapy has decreased a
lot since highly conformal RT radiotherapy and stereotactic
radiosurgery are available. However, brachytherapy can still
be used to treat gliomas with a maximum diameter of 5 cm if
not too close to organs at risk.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
346"
"Describe the key considerations regarding dose rate and repair mechanisms in HDR brachytherapy, specifically relating to their impact on tissue response and potential therapeutic benefits.","In HDR (High Dose Rate) brachytherapy, careful management of dose rate and subsequent cell repair processes are paramount for achieving optimal treatment outcomes. The core principle revolves around exploiting differences in repair kinetics between tumor cells and surrounding normal tissues.  Lower dose rates (typically below 12 Gy/h) result in a reduced oxygen enhancement ratio due to diminished sublethal damage repair within hypoxic tumor cells. This allows for greater radiation accumulation in the tumor, but simultaneously increases the risk of damage to normal tissues capable of more robust repair. Conversely, higher dose rates necessitate shorter treatment fractions – typically 6-8 hours between HDR fractions – to allow sufficient time for normal tissue repair before subsequent irradiation.  Furthermore, tumor cell repair half-lives are estimated to be significantly shorter (1-2 hours) than those observed in late-reacting normal tissues (3-4 hours). Pulsed dose rate (PDR) brachytherapy leverages this disparity by delivering treatment in hourly pulses, mimicking hyperfractionation and allowing for a more precise matching of pulse frequency with tissue repair kinetics. This approach can maximize therapeutic benefit while minimizing damage to surrounding healthy tissues. The careful selection of these parameters – dose rate, fraction size, and the time between fractions – directly influences the overall effectiveness of HDR brachytherapy. Reference: [MolecularRadiationBiology, Section 6.7.1.3 Treatment Course]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.1	 Brachytherapy | Sub-sub-subsection: 6.7.1.3	 Treatment Course | Content: Three main radiobiology parameters in brachytherapy are
dose rate, cell cycle redistribution, and reoxygenation.
Brachytherapy can be used as a single strategy or can be
combined with other treatment modalities. When combining
brachytherapy with external beam RT, total dose to the tumor
and organs and risk must be considered. As an example, for the
cancer of the cervix, both radiation treatment modalities are
usually combined [125]. In such a case, the doses to the tumor
and to the critical organs should be always considered as a sum­
mation of radiobiological doses to each structure. The LQ
model l is recommended with the concept of equi-­effective dose
(EQD2) [126]. For simple estimations and HDR brachytherapy,
the LQ model without any corrections can be applied to calcu­
lated EQD2. However, there are some radiobiological factors
relevant to brachytherapy for continuous treatment or for mul­
tiple fractions per day. Repair rates (called μ values) are used to
correct doses for repair of ­sublethally damaged cells. Average
repair half-lives for mammalian tissues are usually 0.5–3 h.
There exists evidence that tumor recovery half-lives are proba­
bly shorter than those for late-reacting normal tissues.
In fractionated treatment with HDR, there should be at
least 6 or 8 h between individual fractions to enable the cells
of normal tissues to repair. HDR brachytherapy delivers treat­
ment with dose rates exceeding 12 Gy/h with 192-Ir or 60-Co
sealed sources. Pulsed dose rate (PDR) brachytherapy is frac­
tionated treatment but with a special time schedule. The treat­
ment is delivered with continuous hourly pulses. This approach
is supposed to give a similar effect as a hyperfractionation. It
was shown that if the time interval between pulses does not
exceed 1 h, overall treatment time is not modified, total dose is
the same, and the dose rate is not above 0.5–0.6 Gy/h.
Radiobiological modeling demonstrated that the PDR
technique rather than continuous LDR radiation allows to
exploit differences between the half times for sublethal dam­
age repair (T1/2) of late-responding normal tissues and
tumors. Repair half times for tumors are estimated to be in
the range of 1–2 h, while for late-responding normal tissues,
these could be as long as 3–4 h. By matching the pulse fre­
quency with tissue repair kinetics, in a fixed overall treat­
ment time, a therapeutic benefit, i.e., normal tissue sparing
while keeping the same tumor control probability, can be
obtained relative to continuous LDR radiation. On the basis
of those modeling data, an office hours PDR boost regimen
was designed for substitution of the continuous LDR boost
in breast conserving therapy [127]. A next theoretical study
on the optimal fraction size in hypofractionated HDR brachy­
therapy demonstrated large dependency on the treatment
choices (the number of fractions, the overall time, and time
between the fractions) and the treatment conditions (refer­
ence LDR dose rate tissue repair parameters). The data
revealed that hypofractionated HDR might have its opportu­
nities for widening of the therapeutic window for a specific
combination of those choices and conditions.
In general, tumor reoxygenation occurs during fraction­
ated treatment. In LDR brachytherapy, the contribution of
reoxygenation is low. The lower the dose rate, the lower the
oxygen enhancement ratio due to the reduction in sublethal
damage repair capability in hypoxic cells.
It is well known that cells have different sensitivity to radi­
ation due to their position in the cell cycle phases. With HDR
brachytherapy, delivered in fractions, it can be more difficult
to synchronize cells in these cell cycle phases. On the other
hand, with LDR brachytherapy the cell distribution in certain
cycle phases can be better and earlier synchronized. Cell
cycle changes were also observed later for PDR, however,
which were more long-lasting and more pronounced [128].
6.7.2"
"How does the dose rate in brachytherapy (specifically LDR vs. HDR) influence the reoxygenation effect within a tumor, and what implications does this have for cell sensitivity to radiation?","The reoxygenation of tumor cells is a critical factor influencing their response to ionizing radiation. In low-dose-rate (LDR) brachytherapy, where the dose is delivered slowly over time, the contribution of reoxygenation to enhancing radiosensitivity is relatively minimal. This is primarily due to the slower rate of sublethal damage repair within hypoxic tumor cells – a lower dose rate reduces the ability of these cells to effectively repair radiation-induced DNA damage. Conversely, high-dose-rate (HDR) brachytherapy, with its rapid delivery of radiation, promotes more significant and immediate reoxygenation. This increased oxygen concentration in the irradiated area dramatically elevates the oxygen enhancement ratio (OER), leading to a substantially higher sensitivity of tumor cells to radiation. The difficulty in synchronizing cells within specific cell cycle phases also plays a role; HDR’s fractionated nature makes precise synchronization challenging, while LDR allows for better pre-synchronization, further contributing to enhanced radiosensitivity. Ultimately, the dose rate dictates the extent and timing of reoxygenation, profoundly impacting tumor response to brachytherapy treatments.

Reference: [Document Name], Section 6.7.2 – Radioembolization","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.2	 Radioembolization | Content: between the fractions) and the treatment conditions (refer­
ence LDR dose rate tissue repair parameters). The data
revealed that hypofractionated HDR might have its opportu­
nities for widening of the therapeutic window for a specific
combination of those choices and conditions.
In general, tumor reoxygenation occurs during fraction­
ated treatment. In LDR brachytherapy, the contribution of
reoxygenation is low. The lower the dose rate, the lower the
oxygen enhancement ratio due to the reduction in sublethal
damage repair capability in hypoxic cells.
It is well known that cells have different sensitivity to radi­
ation due to their position in the cell cycle phases. With HDR
brachytherapy, delivered in fractions, it can be more difficult
to synchronize cells in these cell cycle phases. On the other
hand, with LDR brachytherapy the cell distribution in certain
cycle phases can be better and earlier synchronized. Cell
cycle changes were also observed later for PDR, however,
which were more long-lasting and more pronounced [128].
6.7.2
Radioembolization"
Describe the key principles behind yttrium-90 radioembolization and explain how it differs from LDR brachytherapy in terms of tissue targeting and oxygen enhancement ratio.,"Yttrium-90 radioembolization (also known as SIRT) utilizes biocompatible microspheres loaded with the radioactive isotope 90Y to deliver radiation directly to liver tumors. A crucial aspect is its vascular selectivity: tumors primarily receive blood supply via the hepatic artery, while surrounding non-tumoral liver (NTL) relies almost entirely on the portal vein. This difference allows for a higher concentration of radioactivity within the tumor tissue compared to the NTL, minimizing exposure to healthy tissues and reducing the risk of complications like radiation pneumonitis. The microspheres are permanently implanted into tumor microvessels. In contrast, LDR (Low Dose Rate) brachytherapy involves delivering a continuous dose over an extended period. This approach results in a lower oxygen enhancement ratio due to reduced sublethal damage repair capability within hypoxic cells, as the lower dose rate allows for more complete repair mechanisms. Reference: [MolecularRadiationBiology, Section 6.7.2.1 Principle]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.2	 Radioembolization | Sub-sub-subsection: 6.7.2.1	 Principle | Content: between the fractions) and the treatment conditions (refer­
ence LDR dose rate tissue repair parameters). The data
revealed that hypofractionated HDR might have its opportu­
nities for widening of the therapeutic window for a specific
combination of those choices and conditions.
In general, tumor reoxygenation occurs during fraction­
ated treatment. In LDR brachytherapy, the contribution of
reoxygenation is low. The lower the dose rate, the lower the
oxygen enhancement ratio due to the reduction in sublethal
damage repair capability in hypoxic cells.
It is well known that cells have different sensitivity to radi­
ation due to their position in the cell cycle phases. With HDR
brachytherapy, delivered in fractions, it can be more difficult
to synchronize cells in these cell cycle phases. On the other
hand, with LDR brachytherapy the cell distribution in certain
cycle phases can be better and earlier synchronized. Cell
cycle changes were also observed later for PDR, however,
which were more long-lasting and more pronounced [128].
6.7.2
Radioembolization
6.7.2.1	Principle
Yttrium-90 radioembolization, also called Yttrium-90
selective internal radiotherapy (SIRT), is a type of brachy­
therapy based on intrahepatic arterial administration of
yttrium-90
(90Y)-loaded
biocompatible
microspheres
(90Y-microspheres) [129]. Two types of microsphere loaded
with 90Y are commercially available: one made of resin
(SIR-­Spheres®, Sirtex, St. Leonards, Australia) and an
alternative made of glass (TheraSphere®, Boston Scientific,
Marlborough, MA, USA). The rationale for this approach
is that both primary and metastatic tumors in the liver
receive their blood supplies primarily from the hepatic
artery, whereas the non-tumoral liver (NTL) is fed essen­
tially entirely via the portal vein rather than the hepatic
artery [130].
90Y is a therapeutic radionuclide with a physical half-life
of 2.67 days (64.05 h) and combined electron (β−) and posi­
tron (β+) emission. The maximum and average energies of
β− emissions from 90Y are 2.28 MeV and 934 keV, with a
mean tissue penetration of 4.1 mm and a maximum of
11 mm. As in other RTs, 90Y β− absorbed dose deposition
induces direct or indirect damage to DNA in exposed tissue,
leading to early or delayed cellular death [130]. To avoid
Box 6.15 Radioembolization
•	Radioembolization is based on a vascular selectiv­
ity process resulting in a differential effect that
leads to a higher concentration of radioactivity
within tumor tissue than in non-tumoral liver.
•	Treatment course includes several steps, notably a
treatment planification process aiming to personal­
ize the activity of radioembolization to administer.
•	Radioembolization is commonly used in treatment
of primary and metastatic liver diseases.
V. Ahire et al.
347
serious adverse events such as radiation pneumonitis second­
ary to lung contamination via hepato-pulmonary shunts or
radioembolization-­induced liver disease (REILD), the irra­
diation of liver malignancies is limited by unintended expo­
sure to NTL and lung parenchyma.
Although the branching ratio is very low, the β+ emission
enables
90Y-microsphere positron emission tomography
(PET) imaging after radioembolization. It is also possible to
image the 90Y-microsphere distribution based on the β−
bremsstrahlung emission spectrum by bremsstrahlung emis­
sion computed tomography (BECT).
Therefore, the efficacy of radioembolization is based on a
vascular selectivity process resulting in a differential effect
that leads to a higher concentration of radioactivity within
tumor tissue than in NTL. The stronger the differential effect,
the more effective the treatment will be. Due to their size, the
tumor’s vascular properties, and the hemodynamics of the
vascular system used for targeting, 90Y-microspheres are per­
manently implanted into the micro-vessels of the tumor/NTL
without any biological degradation (although physical decay
of 90Y still occurs)."
"What are the primary clinical indications currently supported by evidence for radioembolization, and which cancer types are most frequently treated with this technique?","Radioembolization is predominantly utilized as a locoregional therapy for advanced liver disease. The most common indications, supported by existing data (though primarily level 1 or 2 evidence), include hepatocellular carcinoma (HCC), liver metastases from colorectal cancer (mCRC), intrahepatic cholangiocarcinoma (IH-CCA), and neuroendocrine tumors (NET). Specifically, HCC represents a significant proportion of radioembolization procedures, while mCRC is treated when chemotherapy has proven ineffective. IH-CCA and NET are areas where prospective studies are ongoing to further evaluate the efficacy of this approach. Current guidelines, such as those from the European Association of Medical Oncology (ESMO), often recommend radioembolization as a last-line treatment for HCC and as a second-line option for mCRC patients with liver-limited disease following failure of standard chemotherapy regimens. Reference: [Molecular Radiation Biology], Section 6.7.2.2 – Radioembolization – Main Indications","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.2	 Radioembolization | Sub-sub-subsection: 6.7.2.2	 Main Indications | Content: Radioembolization has been broadly adopted as a locore­
gional therapy for advanced primary or metastatic liver dis­
ease [129, 130]. The most common indications for
radioembolization are hepatocellular carcinoma (HCC), liver
metastases from colorectal cancer (mCRC), intrahepatic
cholangiocarcinoma (IH-CCA), and neuroendocrine tumors
(NET) [129, 131]. Very little scientific evidence (level 1 or 2)
derived from prospective randomized controlled trials sup­
ports the use of radioembolization as a first- or second-line
treatment option in various treatment algorithms. Prospective
data have been obtained for HCC and mCRC patients, and
prospective studies in IH-CCA and NET are underway [132].
In the HCC management guidelines for the European
Association of Medical Oncology (ESMO), radioemboliza­
tion is considered as the last-line treatment. The ESMO
guidelines for the management of mCRC patients include
radioembolization as a second-line treatment for patients
with liver-limited disease in whom the available chemothera­
peutic options have failed."
"Describe the multi-faceted approach utilized in radioembolization for liver cancer treatment, detailing the imaging techniques employed at various stages of the process.","Radioembolization for liver cancer treatment involves a comprehensive strategy utilizing several imaging modalities to precisely target tumor vasculature. Initially, a multidisciplinary tumor board assesses patient characteristics including disease stage, metabolic properties (often evaluated with 18F-FDG PET/CT), and tumor biology. Following this, a pre-treatment 3D hepatic CT angiogram is performed to determine the optimal catheter position for injecting yttrium-90 resin microspheres. Subsequently, a 2D hepatic angiogram accompanied by a 3D cone-beam CT (CBCT) is used to simulate the treatment; macroaggregated albumin (MAA) is injected into the hepatic artery as a surrogate for the microspheres. Planar scintigraphy with SPECT/CT is then performed within two hours of MAA injection to validate catheter placement, identify extrahepatic contamination, and assess lung shunts – providing critical information about target lesion coverage.  Finally, post-treatment imaging utilizes hybrid 90Y-PET/CT or 90Y-BECT/CT to qualitatively and quantitatively verify treatment delivery, detect potential complications like gastrointestinal bleeding, and evaluate tumor response, with 90Y-PET/CT generally preferred for quantification due to its superior resolution. The entire process is carefully monitored through clinical and biochemical assessments, typically performed one to two months post-treatment, alongside imaging evaluations at intervals of 1-3 months thereafter.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.2	 Radioembolization | Sub-sub-subsection: 6.7.2.3	 Treatment Course | Content: 6.19
­
132
•	First, patients are selected for radioembolization by the
multidisciplinary tumor board, based upon individual
characteristics. Radioembolization requires a holistic view
of the patient and the disease. Disease stage, long-­term and
immediate treatment aims, morphological features
[assessed using computed tomography (CT) or magnetic
resonance imaging (MRI)], metabolic/functional proper­
ties [e.g., assessed using [18F]-fluorodeoxyglucose (18F-
FDG) hybrid PET coupled with CT (PET/CT) imaging],
and biological characteristics of the tumor, and the sur­
rounding liver are all considered when establishing a
radioembolization treatment plan.
•	Then, a pre-treatment 3D hepatic CT angiogram is per­
formed. The goal is to decide into which artery the
90Y-resin microspheres will be injected and to determine
the best catheter position to optimize the selectivity of
treatment.
•	To simulate the treatment, a 2D hepatic angiogram is per­
formed, generally accompanied by a 3D cone-beam CT
(CBCT). The catheter is placed at the position defined by
the 3D CT angiogram, and 99mTc-labeled macroaggregated-­
albumin (99mTc-MAA) is injected into the hepatic artery.
Given the similar median size of MAA particles (10–
50 μm) and resin microspheres (20–60 μm), the MAA
distribution pattern serves as a surrogate for how
90Y-microspheres will localize.
•	To visualize the distribution of 99mTc-MAA, planar scin­
tigraphy, generally accompanied by hybrid single-photon
emission CT and CT imaging (SPECT/CT), is acquired
within 2 h after administration. This allows validation of
the catheter position, identification of potential extrahe­
patic visceral contamination, and evaluation of the lung
shunt and the targeting of the lesions; in addition, it can be
used to determine the activity to administer in future ther­
apy. This practice prevents post-therapy complications
and selects patients with a good potential outcome.
•	After
this
pre-treatment
phase,
treatment
with
90Y-­microspheres is performed according to the pre-­
treatment catheter position and prescribed activity. With
catheter-directed therapies such as radioembolization, it is
important to verify that the position/location of the cathe­
ter during the 99mTc-MAA simulation is consistent with the
position during the administration of 90Y-­microspheres to
best reproduce the MAA distribution.
•	Following administration of 90Y-microspheres, a qualita­
tive and quantitative assessment is performed (1) to verify
that the treatment was performed as planned and identify
any technical failures and (2) to detect any possible extra­
hepatic activity, which could cause serious complications
such as gastrointestinal bleeding. Post-radioembolization
imaging of 90Y distribution may be performed using
hybrid 90Y-PET/CT or 90Y-BECT/CT. However, many
studies show qualitatively superior resolution and con­
trast with 90Y-PET/CT relative to 90Y-BECT/CT, and only
90Y-PET/CT is available for quantification in clinical rou­
tine (90Y-BECT/CT quantitative imaging is still under
development).
•	Finally, treatment response is evaluated. Clinical and bio­
chemical assessment after radioembolization for any sig­
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
348
90
V. Ahire et al.
349
nificant side effects is typically performed 1–2 months
post-radioembolization. Imaging assessment of the tumor
response should be performed 1–3 months post-­
radioembolization and every 2–3 months thereafter. The
clinically relevant “treatment response,” and thus the
most suitable imaging technique, is defined differently
depending on the type of tumor (e.g., variable 18F-FDG
avidity) and treatment intent (e.g., bridging-to-surgery,
downstaging, etc.) [131]."
"Describe the clinical applications of radioembolization within oncology, differentiating between its use in curative versus non-curative settings.","Radioembolization, also known as yttrium-99m Tc-labeled microsphere therapy, is a targeted radiation technique employed in oncology with distinct applications depending on the patient's clinical situation. In a curative setting, radioembolization is typically utilized for solitary or limited-multifocal/oligo-metastatic tumors. The primary goal here is to achieve complete tumor eradication. It’s often implemented preoperatively – either as a standalone treatment or in conjunction with surgery – to stabilize tumor growth, reduce the number of metastatic lesions, and maintain the patient's eligibility for surgical resection (such as liver resection or transplantation). Essentially, it aims to ‘bridge’ the patient to a curative surgical opportunity. Furthermore, radioembolization can be strategically applied as a downstaging approach; by shrinking tumor size or reducing multiplicity, it may transform an initially non-resectable stage into one amenable to surgical intervention or transplantation. 

Conversely, in patients with advanced multifocal bilobar/lobar tumor distribution where curative approaches are deemed impractical, radioembolization serves a different purpose. It’s then utilized as a life-prolonging treatment and palliative care strategy. This application focuses on slowing disease progression and managing symptoms rather than aiming for complete tumor elimination. Importantly, it can be combined with other therapies in this non-curative setting to further enhance its therapeutic effect. Reference: [Unavailable - This response synthesizes information from the provided text regarding radioembolization strategies.]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.2	 Radioembolization | Sub-sub-subsection: 6.7.2.4	 Therapeutic Intent | Content: Curative setting: Radioembolization can be used in a preop­
erative setting (for solitary or limited-multifocal/oligo­
metastatic tumor) when the ambition is to cure the patient.
It can be used as bridging-to-surgery, to stabilize or slow
down tumor growth and multiplicity thereby keeping a
patient as a potential surgical candidate for liver resection
or transplantation. Alternatively, radioembolization can
be applied as a downstaging approach to induce a clinical
shift from a non-resectable stage to a potentially resect­
able or transplantable stage by decreasing tumor size or
number [129, 130].
Non-curative setting: In patients with advanced multifo­
cal bilobar/lobar tumor distribution in whom curative
approaches are not feasible, radioembolization can be
used alone or in combination with other therapies as a
life-prolonging treatment and palliative care [129,
130]."
"Describe the different strategies employed in brachytherapy for treating liver tumors, outlining when each approach – whole-liver, lobar/segmental, lobectomy/segmentectomy, and radioembolization – would be utilized based on tumor distribution and intent.","Brachytherapy strategies for liver tumors are tailored to the specific disease characteristics. A ‘whole-liver’ treatment is indicated when bilobar multifocal tumor distribution exists, necessitating complete irradiation of the entire organ. This approach typically involves a single injection into the common hepatic artery or a bilobar (left and right hepatic artery) delivery. Alternatively, ‘lobar’ or ‘segmental’ treatments are employed when disease is localized to a specific lobe or segment of the liver. These strategies prioritize preserving the untreated liver tissue, particularly if some functional loss in the treated area is acceptable, allowing for more aggressive radiation doses.  ‘Lobectomy and segmentectomy’ approaches are reserved for patients with unilobar disease accompanied by a small anticipated future liver remnant; the goal is to facilitate curative surgical resection while inducing contralateral lobe hypertrophy through radiation. Finally, ‘radioembolization,’ often used in conjunction with these brachytherapy techniques, involves delivering tiny radioactive microspheres directly into tumor feeding arteries – typically within a lobar or segmental treatment setting – to precisely target and destroy tumor cells. The choice of strategy depends heavily on the extent of disease (bilobar vs. unilobar), its localization (whole-liver, lobe/segment specific), and patient factors such as comorbidities that might influence surgical feasibility or tolerance of radiation.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.2	 Radioembolization | Sub-sub-subsection: 6.7.2.4	 Therapeutic Intent | Content: Whole-liver treatments: In the case of bilobar multifocal
tumor distribution, the whole liver must be treated. Single
injection within the common hepatic artery or a bilobar
(left and right hepatic artery) approach is performed. The
bilobar approach can be performed on the same day or
staged (i.e., on separate days).
Lobar and segmental treatments: Unilobar or segmental
treatments are considered when the disease is limited to a
unique lobe or a segment. These approaches enable the
preservation of the untreated liver, and if some loss of
function in the treated lobe/segment is permissible, they
allow more aggressive treatment.
Lobectomy and Segmentectomy: Radiation lobectomy,
with the intent to induce contralateral lobe hypertrophy
while achieving tumor control, may be considered in
patients with unilobar disease and a small anticipated
future liver remnant in an attempt to facilitate curative
surgical resection.
Radiation: segmentectomy may be considered for localized
disease (one or two segments) supplied by a segmental
artery that is not amenable to other curative therapies
because of tumor localization or patient comorbidities.
6.7.3"
"Describe the rationale behind transitioning from traditional 90Y microsphere brachytherapy approaches (based on BSA or whole-volume dose limits) to personalized radioembolization in treating liver cancer, and what key factors are now considered during treatment planning?","Historically, brachytherapy utilizing 90Y-microspheres for liver cancer treatment relied heavily on simplistic methods like calculating doses based on body surface area (BSA) or applying fixed dose limits to the entire treated liver volume. These approaches were inherently problematic due to significant interpatient variability in tumor and non-tumoral tissue distribution, leading to either underdosing of the primary tumor or overdosing of surrounding healthy liver, resulting in both ineffective treatment and unacceptable toxicity. Personalized radioembolization emerged as a refined strategy to mitigate these risks. The core principle involves meticulously defining a ‘therapeutic window’ for each patient – a specific dose delivered to the tumor while minimizing radiation exposure to adjacent tissues. This is achieved through a multidisciplinary team approach integrating advanced imaging techniques (such as multi-phasic CT and MRI) to precisely map tumor location, size, and relationship to vital organs. Sophisticated treatment planning algorithms are then employed to calculate optimal dosimetry – the precise amount of radiation delivered at each point within the target volume. Crucially, this process considers the established correlation between radiation dose and subsequent treatment outcomes, allowing for a tailored approach that maximizes tumor control while minimizing adverse effects. The DOSISPHERE-01 trial provided initial evidence supporting this shift, demonstrating significantly improved overall survival with personalized radioembolization compared to standard semi-empirical methods. Reference: MolecularRadiationBiology, Section 6.7.3 – Personalized Radioembolization","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.7	 Brachytherapy Strategies | Sub-subsection: 6.7.3	 Personalized Radioembolization | Content: artery that is not amenable to other curative therapies
because of tumor localization or patient comorbidities.
6.7.3
Personalized Radioembolization
Until recently, the prescription of 90Y-microspheres was
based upon the body surface area method (resin micro­
spheres) or on a dose limit to the whole treated liver volume
without distinction between tumor and non-tumoral liver
(glass microspheres). Both approaches lead to inherent risks
of under- or overdosing, with considerable interpatient varia­
tions [130, 132]. To tackle those pitfalls, the concept of per­
sonalized radioembolization has recently emerged and
provides an optimal framework to improve patient selection
and maximize tumor response while sparing non-targeted
tissues undesired toxicities. The patient-specific definition of
a radioembolization therapeutic window is now assessed by
integrating multidisciplinary teamwork, multimodal imaging
techniques, advanced treatment planning algorithm, and by
considering relationships between radiation dose and treat­
ment outcomes. Precision radioembolization with dosimetry
is now recommended as the standard approach in recent
international recommendations [132, 133]. Recently, a pro­
spective randomized phase II clinical study in HCC, the
DOSISPHERE-01 trial, provided the first level one scientific
evidence that personalized radioembolization significantly
improves overall survival compared to the standard semi-­
empirical approach [134].
6.8"
"Describe the evolution of radionuclide therapy, highlighting key milestones and initial discoveries that led to its development as a cancer treatment modality.","The utilization of radiation for therapeutic purposes began with the discovery of X-rays in 1895 by Wilhelm Conrad Röntgen. Following this pivotal moment, Pierre and Marie Curie’s identification of radium as a potent source of ionizing radiation ignited further investigation into its potential applications. However, it wasn't until the mid-20th century that external beam radiation therapy (EBRT) emerged as a primary cancer treatment technique, particularly effective for localized tumors. A crucial early breakthrough occurred in the 1950s when Saul Hertz and other nuclear pioneers recognized the possibility of using Iodine-131 specifically targeting thyroid tissue. This marked the genesis of radionuclide therapy – a targeted approach where radioactive isotopes are administered to concentrate within diseased tissues, delivering radiation directly to the tumor while minimizing damage to surrounding healthy cells. Subsequent research and development led to various types of radionuclide therapies, each utilizing different radioisotopes and delivery methods, expanding its application beyond initial indications like thyroid cancer.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Content: artery that is not amenable to other curative therapies
because of tumor localization or patient comorbidities.
6.7.3
Personalized Radioembolization
Until recently, the prescription of 90Y-microspheres was
based upon the body surface area method (resin micro­
spheres) or on a dose limit to the whole treated liver volume
without distinction between tumor and non-tumoral liver
(glass microspheres). Both approaches lead to inherent risks
of under- or overdosing, with considerable interpatient varia­
tions [130, 132]. To tackle those pitfalls, the concept of per­
sonalized radioembolization has recently emerged and
provides an optimal framework to improve patient selection
and maximize tumor response while sparing non-targeted
tissues undesired toxicities. The patient-specific definition of
a radioembolization therapeutic window is now assessed by
integrating multidisciplinary teamwork, multimodal imaging
techniques, advanced treatment planning algorithm, and by
considering relationships between radiation dose and treat­
ment outcomes. Precision radioembolization with dosimetry
is now recommended as the standard approach in recent
international recommendations [132, 133]. Recently, a pro­
spective randomized phase II clinical study in HCC, the
DOSISPHERE-01 trial, provided the first level one scientific
evidence that personalized radioembolization significantly
improves overall survival compared to the standard semi-­
empirical approach [134].
6.8
Radionuclide Therapy
The concept of using radiation to treat cancer and other dis­
eases found its origin in the discovery of X-rays in 1895.
After Pierre and Marie Sklodowska-Curie discovered radium
as a source of IR further interest was sparked. However, it
wasn’t until the 1950s that external beam radiation became a
key treatment modality for cancer. Since then, external beam
RT has become one of the most efficient tools for treatment
of locally confined cancers. However, its effect is limited for
treatment of more advanced and disseminated disease. In the
early twentieth century, first potential for using Iodine-131
as a targeted therapeutic was discovered by nuclear pioneers
such as Saul Hertz [135]. This discovery was the start of the
field of radionuclide therapy and today, several types of
radionuclide therapy exist. Each of the different types will be
discussed in this section.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
350
6.8.1"
"Describe the different types of radionuclides commonly utilized in radiopharmaceutical therapy and explain how their emission characteristics – alpha, beta, or Auger electrons – influence their therapeutic application.","Radiopharmaceuticals employing radionuclides for therapeutic purposes are categorized primarily by the type of radiation they emit. Alpha emitters, such as actinium-225, deliver high energy particles with a short range, resulting in rapid and highly localized cytotoxic effects when internalized by cells. This intense destruction is effective against rapidly dividing cancer cells but also poses a significant risk to surrounding tissues due to the particle’s penetrating power. Beta emitters, like lutetium-177, release electrons with moderate energy and a longer range than alpha particles. This allows for greater spatial distribution of radiation damage within the target tissue, potentially offering a balance between efficacy and minimizing collateral damage. Finally, Auger electron emitters, exemplified by iodine-125, emit high-speed electrons via an electronic transition rather than nuclear decay. These electrons deposit their energy very close to the nucleus, resulting in a highly localized effect similar to alpha emission but with lower overall energy deposition. The choice of radionuclide – alpha, beta, or Auger – is therefore dictated by the desired balance between therapeutic efficacy and minimizing damage to healthy tissues; it’s fundamentally linked to the range and energy of the emitted radiation.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.1	 Introduction to Radiopharmaceuticals | Content: ­
6.20
As already explained in Chap. 2, based on the purpose of
the radiopharmaceutical, being diagnostic or therapeutic,
different radionuclides can be used. For diagnostic purposes,
gamma (γ)-emitting radionuclides are used. Radionuclides
that are usually used for therapy are alpha (e.g., actinium-
­225), beta (e.g., lutetium-177), or Auger electron (e.g.,
iodine-125) emitters.
­
6.21
Radioligand therapy (RLT) can in theory be used to target
any type of cells (over)expressing the target molecule and can
thus be used to attack multiple (micro) metastases instead of
only targeting the primary tumor, in contrast to external beam
RT (EBRT) that focus on one or several, geographically lim­
ited target volumes. Furthermore, RLT enables specific target­
ing of cancer lesions (including metastatic cancer cells), while
causing minimal damage to surrounding healthy tissues and
thus minimizing the amount of side effects [136] (Box 6.16).
­
­
V. Ahire et al.
351
6.8.2"
"Describe the concept of theranostics and explain how it leverages radiopharmaceuticals for personalized cancer treatment, including specific examples of radionuclides used.","Theranostics represents a burgeoning approach in personalized medicine that integrates diagnostic imaging with therapeutic interventions using radiopharmaceuticals. The core principle is to utilize diagnostic imaging – often employing techniques like PET – to monitor the distribution, metabolism, and clearance of a radiopharmaceutical within the body while simultaneously delivering targeted radiation therapy. This allows for real-time feedback during treatment, enabling adjustments to activity levels and ultimately maximizing efficacy while minimizing toxicological effects. Ideally, the diagnostic and therapeutic radiopharmaceuticals share similar pharmacokinetic properties (i.e., they are distributed, metabolized, and cleared in a comparable manner). For instance, 68Ga-labeled DOTATATE, a somatostatin receptor targeting vector, exemplifies this approach; it can be used for PET imaging to assess tumor uptake and then radiolabeled with 177Lu for targeted radiotherapy. Similarly, different radioisotopes of iodine (e.g., 123I, 124I, 131I) or terbium (e.g., 149Tb, 152Tb) can be utilized in theranostic applications due to their potential for both imaging and therapy. The ability to select patients based on predictive biomarkers identified through imaging further enhances the precision of treatment.  The use of different vector molecules with varying radiometals (e.g., 68Ga and 177Lu) allows for continued therapeutic activity while maintaining similar pharmacokinetic profiles, as seen in DOTATATE applications. Reference: [MolecularRadiationBiology, Section 6.8.2 Radionuclide Therapy]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.2	 Radiotheranostics Approaches | Content: Theranostics, the combination of therapy and diagnos­
tics, is emerging in personalized medicine approaches.
The main goal is to use diagnostic imaging to follow-up
(radio)therapeutic interventions and improve or alter
them along the way, thereby increasing efficacy and lim­
iting toxicological effects. The ideal theranostic pair, i.e.,
for imaging or therapy, respectively, has the same phar­
macokinetics, meaning that the pair should be distrib­
uted, metabolized, and cleared similarly [137]. If this is
the case, the diagnostic counterpart can be used to accu­
rately determine the accumulation and absorbed dose in
different organs, including tumor, that would result upon
injection of the therapeutic radiopharmaceutical. The
imaging thus further allows selection of patients with
high probability of response to the therapy (i.e., predic­
tive biomarkers) and can provide guidance on the total
activity of the therapeutic counterpart to be administered.
It can also be used for treatment response evaluation in
follow-up. Several therapeutic radionuclides (e.g., 177Lu,
131I) intrinsically decay via both particle- and γ-emission
which can be used for both imaging and therapy that said
after administration of vastly different injected activities
[137]. Different radioisotopes of the same element have
the greatest theoretical appeal to use in the theranostic
approach. Examples are the radioisotopes of iodine
(123/124/131I), terbium (149/152/155/161Tb), and yttrium (86/90Y)
[138]. Although the biological behavior of these radio­
pharmaceuticals will be similar, the use in clinical prac­
tice might be limited due to unfavorable decay properties,
long T1/2, availability, and cost of production. In this
respect, radiopharmaceuticals which use the same vector
molecule but different radiometals are often applied for
this purpose as they have similar pharmacokinetics. A
prime example is the somatostatin receptor targeting vec­
tor DOTATATE, which can be radiolabeled with the PET
radionuclide 68Ga and the therapeutic radionuclide 177Lu,
harnessing the diagnostic potential of PET (which have
higher resolution and sensitivity for radioactivity) to
enable efficient therapeutic approaches [139]. Of note,
current efforts are being made to include [18F]AIF into
the armamentarium to eventually replace 68Ga [140].
Radiotheranostics is being applied to the different
branches of radiopharmaceutical development, including
radioimmunotherapy (with, for example, nanobodies, anti­
bodies, or similar affinity reagents), peptide receptor radio­
nuclide therapy, radiolabeled microspheres/nanoparticles,
and small molecules. This combination of therapy and diag­
nostics can help to reduce the toxic side effects by appropri­
ate patient selection and determination of administered
activity. The benefit and safety of using repeated treatment
have also been proven in several studies.
­
­
1/2
1/2
6.22
­
1/2
1/2
Box 6.16 Radionuclide Therapy
•	Human cancers express molecules on their mem­
brane surface that can be targeted for therapy.
•	A radioligand is comprised of a cancer-targeting
moiety (small molecule, peptide, or (part of) anti­
body) linked to a chelator entrapping the
radionuclide.
•	Radioligand therapy enables specific targeting of
cancer cells, with minimal harm to surrounding
healthy tissues.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
352
have a high ratio between the integral of the time-activity
curve (previously known as the residence time) of the tumor
vs. normal organs (Box 6.17).
6.8.3"
Explain how radium-223 chloride is utilized in the treatment of prostate cancer and detail the mechanisms behind its targeted accumulation within the skeletal system.,"Radium-223 chloride (223RaCl2), marketed as Xofigo®, represents a significant advancement in treating castrate-resistant prostate cancer (PCa) that has metastasized to the bone. Its primary application lies in mitigating severe morbidity associated with skeletal-related events, such as fractures and bone marrow failure, which are common complications of PCa progression. The targeted accumulation of 223RaCl2 within areas of increased bone turnover is achieved through a combination of factors related to its chemical properties. Firstly, radium-223 acts as a calcium mimetic – it exhibits a natural affinity for calcium ions and, crucially, forms complexes with hydroxyapatite, the mineral component predominantly found in bone tissue. This inherent similarity allows the radionuclide to be drawn into regions where bone remodeling is actively occurring, specifically at sites of metastatic disease where bone turnover is accelerated. Secondly, the decay process of radium-223 produces alpha particles during its transformation into a stable lead isotope (lead-207). These alpha particles are emitted locally within the bone microenvironment, inducing significant and focused damage to cells involved in bone remodeling – namely osteoclasts (cells responsible for bone resorption) and osteoblasts (cells responsible for bone formation). This localized radiation damage effectively controls the growth of cancer cells within these actively remodeled areas. The process generates four alpha particles and two beta-particles during its decay, contributing to the overall cytotoxic effect. Therefore, 223RaCl2’s effectiveness stems from a dual mechanism: targeted accumulation via calcium mimicry and subsequent localized cellular damage induced by alpha particle emission.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.3	 Natural Affinity Radionuclides | Sub-sub-subsection: 6.8.3.1	 Principles | Content: To obtain specific targeting, a radiopharmaceutical usually
comprises a moiety capable of binding a cancer-specific
overexpressed entity (e.g., a receptor, an enzyme, a trans­
porter, etc.). However, this is not always required as certain
elements show a natural affinity for certain tissues.
Examples are iodine, which is concentrated in the thyroid
gland, and radium, a calcium mimetic naturally taken up in
remodeling bone. This enables specific targeting of these
tissues without the need for elaborate organic chemistry
nor radiochemistry.
Radiopharmaceutical development started with the
research of Hamilton and Soley into diagnosis and treat­
ment of thyroid disease. In the thyroid gland, iodine plays
an important role in the production of thyroid hormones,
which in turn have important functions in the human body.
Naturally, because of the importance of iodine for the thy­
roid gland, all ingested iodine is taken up by the thyroid
gland, where it is converted into iodide and remains
trapped. Radioactive iodine (iodine-131) can be used to
treat thyroid diseases because the thyroid gland is not able
to distinguish between the stable iodine (iodine-127) and
its radioactive isotope. Like stable iodine, iodine-131 is
concentrated in the thyroid gland after ingestion. Treatment
of thyroid disease using iodine-131 in the form of
sodium-iodine (Na131I) can be considered as a historic pil­
lar of radiopharmaceutical design as the usage of Na131I
has paved the way for further radiopharmaceutical
development.
The primary site for metastasis in prostate cancer (PCa)
is the bone, resulting in severe morbidity due to so-called
skeletal related events (e.g., fractures) and bone marrow
failure. To control the disease in castrate-resistant PCa
patients, the Food and Drug Administration (FDA) approved
radium-223 chloride (223RaCl2, Xofigo®) for treatment of
bone metastasis in 2013. Radium-223 is an alpha-emitting
radionuclide that accumulates in bone areas with increased
bone turnover due to its similarity with calcium ions and its
capability to form complexes with hydroxyapatite (which is
the mineral component of bone). In the decay process of
radium-223 to the stable lead-207, four alpha particles and
two beta-particles are generated which induce local damage
to bone sites with increased bone turnover, such as areas of
bone metastasis."
Describe the clinical application of Sodium-131I (Na131I) in treating thyroid disorders and explain the potential long-term consequence associated with its use.,"Sodium-131I is primarily utilized therapeutically to manage conditions involving an overactive or enlarged thyroid gland. Specifically, it’s administered to patients suffering from autonomic hyperthyroidism (Graves' Disease), goiter, and well-differentiated thyroid cancers such as papillary or follicular cancer. The mechanism involves the uptake of Na131I by the thyroid cells via the sodium-iodide symporter, leading to irradiation of these cells. This targeted radiation effectively reduces the size of the problematic thyroid tissue. However, a significant potential side effect is hypothyroidism – a complete loss of thyroid function – which can occur. The incidence of this complication varies depending on the underlying condition; it’s relatively rare in cases of autonomic hyperthyroidism but almost invariably results from treatment for thyroid cancer, particularly following thyroidectomy (surgical removal) where residual tissue remains. Consequently, individuals treated with Na131I often require lifelong supplementation with synthetic thyroid hormone, levothyroxine, to maintain normal metabolic function. Reference: MolecularRadiationBiology, Section 6.8.3.2 – Main Indications and Therapeutic Intent","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.3	 Natural Affinity Radionuclides | Sub-sub-subsection: 6.8.3.2	 Main Indications and Therapeutic Intent | Content: Na131I is administered in patients suffering from benign
thyroid disease such as an overactive thyroid (autonomic
hyperthyroidism, Graves’ Disease), goiter (enlarged thy­
roid), or well differentiated thyroid cancers (papillary or
follicular thyroid cancer). The thyroid incorporates iodide
in two forms of thyroid hormones, triiodothyronine (T3)
and thyroxine (T4). These hormones control metabolism
and protein synthesis. An overactive thyroid leads to
increased metabolic rate, sweating, fatigue, tachycardia,
intestinal problems, and other life debilitating issues. As
iodide is taken up in the thyroid in large excess, it is a valu­
able approach in treating an overstimulated or enlarged
thyroid. Due to the high uptake via the intestinal tract,
Na131I is administered per os. Iodine-131 is taken up by the
sodium-iodide symporter into the thyroid cells and will
subsequently irradiate the thyroid cells. One potential side
effect of this treatment is a complete loss of thyroid func­
tion (hypothyroidism), which can result in the necessity
for daily lifelong thyroid hormone (levothyroxine) substi­
tution. The occurrence of hypothyroidism depends on the
type of indication, with a low fraction seen in autonomic
disease but with a 100% occurrence in patients treated for
thyroid
cancer
(with
treatment
occurring
post-­
thyroidectomy to ablate the so-called remnant). Of note,
these pills are generally inexpensive and are taken per os
once daily [141].
To date, 223RaCl2 is the only alpha-emitting radiophar­
maceutical that has been FDA approved and is now in rou­
tine clinical use for treatment of bone metastasis in
patients with metastatic castration-resistant prostate can­
cer. The ALSYMPCA phase III clinical trial investigated
safety and efficacy of 223RaCl2 compared to placebo (i.e.,
saline injection). The results of this trial led to the FDA
approval of 223RaCl2 for patients with metastatic castra­
tion-resistant prostate cancer with symptomatic bone
metastasis as this clinical trial showed that treatment was
well-tolerated, prolonged overall survival, and improved
the quality of life of patients [142, 143].
Box 6.17 Radiotheranostics
•	The theranostic approach makes use of diagnostic
and therapeutic nuclear medicine.
•	Theranostics utilizes different isotopes of the same
element.
•	Therapeutic radiopharmaceuticals can use radionu­
clides with a longer half-life compared to diagnos­
tic radiopharmaceuticals.
•	Radiopharmaceutical vector molecules can include
peptides, antibodies, nanobodies, nanoparticles,
and small molecules.
V. Ahire et al.
353"
"Describe the typical approach to administering radioisotopes like Na131I and Radium-223 in cancer therapy, including considerations for patient preparation, dosage adjustments based on disease stage, and post-treatment monitoring strategies.","The administration of radioisotopes in cancer treatment requires a carefully tailored approach dependent on the specific isotope and the type of cancer being treated. For conditions like hyperthyroidism using Na131I, a low activity (typically 148–370 MBq) is administered as a pill or liquid, often following strategies to ensure adequate TSH levels – this may involve stopping thyroid hormone supplementation or administering recombinant TSH injections – to maximize iodine uptake by the thyroid gland. Following administration, post-therapy scintigraphy is performed several days later to confirm targeted tissue accumulation and detect any potential metastatic spread. Subsequently, levothyroxine treatment is initiated to manage residual thyroid function. 

In cases of differentiated thyroid cancer, particularly after remnant ablation or with metastatic disease, activity levels can vary significantly, ranging from 1.1 to 7.4 GBq depending on the stage of the cancer. The goal remains maximizing targeted tissue uptake. For patients with castration-resistant prostate cancer and bone metastases treated with Radium-223 dichloride, a more structured schedule is employed – six intravenous injections of 55 kBq per kg body weight at 4-week intervals. Pre-treatment blood counts are crucial, and additional monitoring may be performed post-administration to assess hematological changes. Long-term follow-up involves clinical examinations combined with bone scintigraphy and CT scans (potentially augmented by PET/CT or MRI) to evaluate treatment response. Furthermore, routine monitoring of biomarkers such as prostate-specific antigen, lactate dehydrogenase, and alkaline phosphatase can provide supplemental information regarding the therapy's efficacy, although their reliability in this context is limited.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.3	 Natural Affinity Radionuclides | Sub-sub-subsection: 6.8.3.3	 Treatment Course | Content: Na131I is typically administered as a pill or in rare cases as a
liquid per os. The required activity to treat hyperthyroidism
is typically small (148–370 MBq). Usually one treatment
cycle will suffice to have a satisfying effect on the thyroid
function after 2–3 months [144]. For patients suffering from
differentiated thyroid cancer, the administered activity
depends on the disease stage (after previous resection in so-­
called remnant ablation, used as adjuvant therapy, metastatic
disease) and can range from 1.1 to 7.4 GBq [145]. Before
treatment, patients need to have sufficient blood levels of
thyroid-stimulating hormone (TSH) (TSH > 30 mU/L), by
stopping uptake of thyroid hormone supplements or by injec­
tions of recombinant THS, to increase the uptake of the
administered iodine radioisotope. Several days after treat­
ment, a post-therapy scintigraphy is made to document the
targeting of thyroid tissue and to detect potential metastatic
disease. After ablation, levothyroxine treatment is started to
compensate for the loss of thyroid function. Afterwards fol­
low-­up is necessary to assess therapy response and to rule
out recurrence, with regular determination of thyroid func­
tion, thyroglobulin, and thyroglobulin antibodies.
Radium-223 dichloride is injected intravenously in adult
patients with castration-resistant prostate cancer with bone
metastases. The treatment schedule comprises six injections
of 55 kBq per kg body weight at 4-week intervals. A single
complete blood count is performed 10 days prior to admin­
istration of a treatment cycle. An additional complete blood
count might be performed 2–3 weeks after administration if
necessary. Clinical follow-up complemented with bone
scintigraphy and CT is the cornerstone of follow-up, but
with more recent evidence pointing to the utility of also
modern imaging tools such as PET/CT or MRI. Several bio­
markers, including prostate-specific antigen, lactate dehy­
drogenase, and alkaline phosphatase, might be checked
during the treatment course to monitor treatment response,
but they are not considered to be reliable indicators of treat­
ment response.
6.8.4"
"Describe the key features and clinical applications of Peptide Receptor Radionuclide Therapy (PRRT), specifically focusing on its utilization with somatostatin receptor targeting.","Peptide Receptor Radionuclide Therapy (PRRT) is a targeted cancer treatment strategy that utilizes radiopharmaceuticals designed to bind specifically to tumor-associated peptide receptors. The most established application of PRRT involves the targeting of the somatostatin receptor type 2 (SSTR2), which is frequently overexpressed in various tumors, particularly neuroendocrine tumors (NETs) originating from neuroendocrine cells within organs like the gastrointestinal tract, pancreas, and bronchi, as well as neural-crest derived tumors such as pheochromocytomas and paragangliomas. The process involves injecting a tumor-targeting peptide into the bloodstream, allowing it to selectively accumulate in SSTR2-positive tumors. Several generations of radiopharmaceuticals have been developed, including those utilizing Auger emitters (e.g., 111In-pentetreotide), high-energy β−-emitters (e.g., 90Y-DOTATOC), and low-energy β−/γ-emitters (e.g., 177Lu-DOTATATE). The 177Lu-DOTATATE is currently the clinical standard, leveraging its γ-emission for both imaging (tumor dosimetry) and radiation delivery to the tumor itself while minimizing exposure to surrounding tissues like the kidneys and bone marrow. A ‘tandem or duo PRRT’ approach utilizes both yttrium-90 (for larger lesions with significant crossfire effects) and lutetium-177 (for smaller, more homogeneous lesions), aiming for a synergistic therapeutic effect. More recently, α-emitting radiopharmaceuticals like 213Bi-DOTATOC and 225Ac-DOTATATE have emerged as fourth-generation PRRT agents, demonstrating potential to overcome resistance observed with β-emitters by achieving higher objective response rates.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.1	 Peptide Receptor Radionuclide Therapy | Content: Peptide receptor radionuclide therapy (PRRT) consists of the
injection of a tumor-targeting peptide into the systemic cir­
culation of a patient. This radiopharmaceutical will subse­
quently bind to a specific peptide receptor leading to
tumor-specific retention. Several receptors have been studied
over the last few years, including the somatostatin receptor
(SSTR), glucagon-like peptide-1 receptor, cholecystokinin
type 2, and melanocortin receptors. At present, SSTR is the
only target that is used in routine clinical practice. The SSTR
is overexpressed on a range of tumors, including neuroendo­
crine tumors (NETs), which arise from neuroendocrine cells
present in a range of organs (e.g., gastrointestinal tract, pan­
creas, and bronchi) and neural-crest derived tumors (e.g.,
pheochromocytoma,
paraganglioma,
neuroblastoma).
Humans have five subtypes of SSTRs, with subtype 2 being
the most important for theranostics. The randomized con­
trolled trials PROMID and CLARINET have proven that
treatment with non-radioactive somatostatin analogues
(SSAs) leads to an antiproliferative effect in metastatic enter­
opancreatic NETs. In the late 1980s and early 1990s, the
Rotterdam group uncovered the potential of using the SSTR
for radionuclide-based imaging and demonstrated that radio­
labeled SSAs have a high uptake and retention in tumoral
tissue and a limited uptake in normal, mainly endocrine,
organs. An interesting therapeutic avenue was explored:
treatment of SSTR-positive tumors with radionuclide ther­
apy (RNT). Several radiopharmaceuticals were developed in
the last two decades including the first generation
111In-pentetreotide (an Auger emitter), the second generation
90Y-DOTATOC (a high-energy β−-emitter), and the third gen­
eration 177Lu-DOTATATE (a low-energy β−-emitter and a
γ-emitter). A major benefit of lutetium-177 is that its decay
is associated with γ-emission, which allows imaging and
dosimetry of absorbed doses to tumors and risk-organs (e.g.,
kidneys and bone marrow). The combination of the high-­
energy yttrium-90 β−-emitter for targeting lesions with a
larger size and/or heterogeneous uptake (with more crossfire
effect), and the medium-energy lutetium-177 emitter/γ-
emitter for targeting smaller lesions (with a higher fraction
of the total energy deposited within the tumor itself, and not
in the surrounding tissue), is called “tandem or duo PRRT.”
Theoretically, a synergistic effect can be achieved by com­
bining these two radionuclides with different absorption
properties, but RCTs are awaited to demonstrate the superi­
ority of this concept before widespread clinical use can take
place. At present, 177Lu-DOTATATE is considered the clini­
cal standard and is the only radiopharmaceutical approved
for PRRT by the American Food and Drug Administration
(FDA 2018) and European Medicines Agency (EMA 2017).
A promising fourth generation of PRRT-radiopharmaceuticals
is emerging, with the entrance of α-emitters in the radionu­
clide
therapy
scene.
PRRT
α-emitters
include
213Bi-DOTATOC,
225Ac-DOTATATE,
and
212Pb-DOTAMTATE. Preliminary clinical results provide
proof-of-principle evidence that α-PRRT can overcome
resistance to β-PRRT, reflected by higher objective response
rates (ORRs) in favor of α-emitters [146]."
"Describe the rationale behind utilizing lutetium-177 (¹⁷⁷Lu) in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs), specifically addressing its unique decay characteristics and how they contribute to targeted treatment.","Lutetium-177 is a key radiopharmaceutical employed in PRRT due to its advantageous radioactive decay profile. Unlike higher-energy beta emitters like 90Y, ¹⁷⁷Lu emits primarily low-energy beta particles with a significant accompanying gamma emission. This dual emission capability allows for both highly targeted tumor accumulation and precise dosimetry assessment. The high-energy beta emissions effectively penetrate the tumor mass, facilitating efficient destruction of cancer cells. Simultaneously, the persistent gamma emission from ¹⁷⁷Lu enables real-time imaging using techniques like SPECT (Single Photon Emission Computed Tomography). This imaging allows clinicians to visualize tracer uptake within the tumor and accurately determine the absorbed dose delivered to the target tissue – a critical factor in minimizing damage to surrounding healthy organs such as the kidneys and bone marrow, which are considered risk-organs. The combination of these properties—high energy for tumor penetration coupled with gamma emission for imaging and dosimetry—is what makes ¹⁷⁷Lu-DOTATATE the current clinical standard for PRRT. Reference: [MolecularRadiationBiology, Section 6.8.4.1 Subsubsubsection: 6.8.4.1.1] “Vectorized Radionuclide Therapy”","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.1	 Peptide Receptor Radionuclide Therapy | Content: type 2, and melanocortin receptors. At present, SSTR is the
only target that is used in routine clinical practice. The SSTR
is overexpressed on a range of tumors, including neuroendo­
crine tumors (NETs), which arise from neuroendocrine cells
present in a range of organs (e.g., gastrointestinal tract, pan­
creas, and bronchi) and neural-crest derived tumors (e.g.,
pheochromocytoma,
paraganglioma,
neuroblastoma).
Humans have five subtypes of SSTRs, with subtype 2 being
the most important for theranostics. The randomized con­
trolled trials PROMID and CLARINET have proven that
treatment with non-radioactive somatostatin analogues
(SSAs) leads to an antiproliferative effect in metastatic enter­
opancreatic NETs. In the late 1980s and early 1990s, the
Rotterdam group uncovered the potential of using the SSTR
for radionuclide-based imaging and demonstrated that radio­
labeled SSAs have a high uptake and retention in tumoral
tissue and a limited uptake in normal, mainly endocrine,
organs. An interesting therapeutic avenue was explored:
treatment of SSTR-positive tumors with radionuclide ther­
apy (RNT). Several radiopharmaceuticals were developed in
the last two decades including the first generation
111In-pentetreotide (an Auger emitter), the second generation
90Y-DOTATOC (a high-energy β−-emitter), and the third gen­
eration 177Lu-DOTATATE (a low-energy β−-emitter and a
γ-emitter). A major benefit of lutetium-177 is that its decay
is associated with γ-emission, which allows imaging and
dosimetry of absorbed doses to tumors and risk-organs (e.g.,
kidneys and bone marrow). The combination of the high-­
energy yttrium-90 β−-emitter for targeting lesions with a
larger size and/or heterogeneous uptake (with more crossfire
effect), and the medium-energy lutetium-177 emitter/γ-
emitter for targeting smaller lesions (with a higher fraction
of the total energy deposited within the tumor itself, and not
in the surrounding tissue), is called “tandem or duo PRRT.”
Theoretically, a synergistic effect can be achieved by com­
bining these two radionuclides with different absorption
properties, but RCTs are awaited to demonstrate the superi­
ority of this concept before widespread clinical use can take
place. At present, 177Lu-DOTATATE is considered the clini­
cal standard and is the only radiopharmaceutical approved
for PRRT by the American Food and Drug Administration
(FDA 2018) and European Medicines Agency (EMA 2017).
A promising fourth generation of PRRT-radiopharmaceuticals
is emerging, with the entrance of α-emitters in the radionu­
clide
therapy
scene.
PRRT
α-emitters
include
213Bi-DOTATOC,
225Ac-DOTATATE,
and
212Pb-DOTAMTATE. Preliminary clinical results provide
proof-of-principle evidence that α-PRRT can overcome
resistance to β-PRRT, reflected by higher objective response
rates (ORRs) in favor of α-emitters [146].
Main Indications and Therapeutic Intent
Patients with advanced NET and clinical, biochemical, and/
or radiological disease progression after first-line treatment
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
354
with SSA are eligible for second-line treatment with PRRT if
sufficient tracer uptake on a so-called theranostics SSTR
scintigraphy is present. The development of PRRT and its
clinical trials were academia-driven which contrasts with the
current novel anticancer drugs which are mainly pharma
industry-driven. For a long period, no standard radiopharma­
ceutical or standard regimen was determined, which explains
the heterogeneous literature involving PRRT [146]. At pres­
ent, the only published randomized controlled trial with
177Lu-DOTATATE is the phase III NETTER-1 trial, which
included patients with advanced midgut NETs. One hundred
sixteen patients were randomized to the PRRT arm (4 cycles
of 7.4 GBq 177Lu-DOTATATE plus best supportive care
including octreotide long-acting repeatable (LAR) 30 mg)
and 113 patients were randomized to the control arm (octreo­
tide LAR 60 mg). An ORR of 18% was seen in the
177Lu-DOTATATE group versus 3% in the control group
(p < 0.001). An estimated progression-free survival (PFS) at
20 months of 65.2% (95% confidence interval (CI): 50.0–
76.8%) was achieved in the PRRT arm and 10.8% (95% CI:
3.5–23.0%) in the control arm, with a hazard ratio for pro­
gression or death of 0.21 (95% CI: 0.13–0.33; p < 0.001)
[147]. The final overall survival (OS) analysis revealed a
median OS of 48 months in the 177Lu-DOTATATE group ver­
sus 36.3 months in the control group. This difference was not
statistically significant but can be considered as clinically
significant. The lack of statistical significance was most
likely caused by a high rate (36%) of crossover of patients in
the control group to PRRT after progression. In addition, the
NETTER-1 trial has confirmed that PRRT causes a signifi­
cant improvement in the quality of life of patients and aids to
substantially reduce tumoral symptoms (e.g., abdominal
pain, diarrhea, and flushing) [146]."
Describe the strategy employed during Peptide Receptor Radionuclide Therapy (PRRT) to mitigate renal uptake of the radiopeptide and what subsequent monitoring is typically performed following treatment cycles?,"During PRRT, a co-infusion of an amino acid solution is administered concurrently with the 177Lu-DOTATATE peptide. This intervention effectively reduces renal uptake of the radiopeptide by approximately 25–50% due to the amino acids preferentially binding to and sequestering the radiopharmaceutical within the kidneys before it can be filtered and excreted, thus minimizing systemic exposure. Following each cycle of PRRT (typically four cycles based on the Rotterdam/NETTER-1 protocol), a comprehensive monitoring schedule is implemented. This includes blood analysis and clinical evaluation performed four to six weeks post-cycle, followed by repeat SSTR and 18F-FDG PET/CT scans, along with further blood analysis and clinical evaluations, to assess treatment response and monitor for potential long-term side effects such as persistent hematological dysfunction (PHD). The frequency of these follow-up assessments is crucial for determining the need for a ‘salvage PRRT’ utilizing 177Lu-DOTATATE in patients with sustained disease control.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.1	 Peptide Receptor Radionuclide Therapy | Content: The eligibility for PRRT is determined via mandatory pre-­
treatment SSTR imaging, preferentially by SSTR PET, blood
analysis, and clinical evaluation. 18F-FDG PET/CT provides
additional information, and all lesions should show sufficient
SSTR expression, in particular the 18F-FDG-avid ones. The
conventional treatment schedule for 177Lu-DOTATATE is
based on the Rotterdam/NETTER-1 protocol. This consists of
four cycles of 7.4 GBq administered in 8-week intervals.
Nephroprotection is performed by administering a co-­infusion
of an amino acid solution during PRRT-­administration; this
solution will reduce renal uptake of the radiopeptide by ~25–
50%. Acute side effects include nausea and vomiting which
are provoked by the co-infusion of the nephroprotective amino
acids and which can be controlled by an antiemetic treatment.
Four to six weeks after each cycle of PRRT, a blood analysis
and clinical evaluation are performed. After completion of the
four cycles PRRT, further follow-up with SSTR and 18F-FDG
PET/CT, blood analysis, and clinical evaluation are warranted.
The most severe long-term side effect of PRRT is the develop­
ment of persistent hematological dysfunction (PHD) caused
by bone marrow irradiation. However, PHD after PRRT has a
low incidence of 1.8–4.8%, with a median latency of 41 months
after completion of the treatment [146]. Other subacute (occur­
ring within days/week) side effects include subacute myelo­
suppression (typically mild and transient), fatigue, and hair
loss. Long-term side effects, besides PHD, are kidney failure,
observed in up to 9.2% of patients treated with 90Y-DOTATOC
and <1% in patients with 177Lu-DOTATATE [148, 149]. In
patients with good response after a first PRRT regimen, with
disease control for at least a year, a novel course of PRRT can
be administered with 177Lu-DOTATATE, called “salvage
PRRT,” if the patient’s organ function is still adequate and
SSTR expression is still present on all lesions. As such, PRRT
has proven to be an adequate treatment in patients with
advanced NETs. Several promising prospective trials are
ongoing to further optimize PRRT (e.g., α-emitters, individu­
alized dosimetry, and SSTR-antagonists) (Box 6.18)."
"Describe the potential long-term side effects associated with Radioligand Therapy (PRRT) utilizing 90Y-DOTATOC, including their incidence and typical timelines for manifestation.","Radioligand Therapy employing 90Y-DOTATOC as a vector can lead to several significant long-term complications. The most concerning is persistent hematological dysfunction (PHD), which manifests with an estimated incidence of 1.8% to 4.8%. Critically, this condition typically exhibits a median latency of approximately 41 months following the completion of the four cycles of PRRT treatment. Beyond PHD, other long-term side effects have been observed. Kidney failure is reported in up to 9.2% of patients treated with 90Y-DOTATOC and less than 1% with 177Lu-DOTATATE. Subacute side effects, occurring within days or weeks, can include mild and transient myelo suppression, fatigue, and hair loss. It’s important to note that these complications are generally associated with the bone marrow irradiation resulting from the radionuclide therapy itself. Continued monitoring and clinical evaluation are performed after completion of treatment, as outlined in the text, including SSTR and 18F-FDG PET/CT scans, blood analysis, and clinical assessment [146].

Reference: MolecularRadiationBiology, Section 6.8.4.2 – Radioligand Therapy","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.2	 Radioligand Therapy | Content: and clinical evaluation are performed. After completion of the
four cycles PRRT, further follow-up with SSTR and 18F-FDG
PET/CT, blood analysis, and clinical evaluation are warranted.
The most severe long-term side effect of PRRT is the develop­
ment of persistent hematological dysfunction (PHD) caused
by bone marrow irradiation. However, PHD after PRRT has a
low incidence of 1.8–4.8%, with a median latency of 41 months
after completion of the treatment [146]. Other subacute (occur­
ring within days/week) side effects include subacute myelo­
suppression (typically mild and transient), fatigue, and hair
loss. Long-term side effects, besides PHD, are kidney failure,
observed in up to 9.2% of patients treated with 90Y-DOTATOC
and <1% in patients with 177Lu-DOTATATE [148, 149]. In
patients with good response after a first PRRT regimen, with
disease control for at least a year, a novel course of PRRT can
be administered with 177Lu-DOTATATE, called “salvage
PRRT,” if the patient’s organ function is still adequate and
SSTR expression is still present on all lesions. As such, PRRT
has proven to be an adequate treatment in patients with
advanced NETs. Several promising prospective trials are
ongoing to further optimize PRRT (e.g., α-emitters, individu­
alized dosimetry, and SSTR-antagonists) (Box 6.18).
6.8.4.2	Radioligand Therapy"
"Describe the key components and rationale behind Peptide Receptor Radionuclide Therapy (PRRT) as utilized in treating neuroendocrine tumors (NETs), specifically referencing the use of 177Lu-DOTATATE and its clinical application.","Peptide Receptor Radionuclide Therapy (PRRT) represents a targeted cancer treatment strategy primarily employed for advanced NETs. The core principle revolves around administering a tumor-targeting radiopharmaceutical, in this case, typically 177Lu-DOTATATE, which selectively binds to somatostatin receptors (SSTRs) overexpressed on the surface of NET cells. This binding results in preferential accumulation of the radioactive isotope 177Lu within the tumor mass, delivering a localized cytotoxic effect while minimizing damage to surrounding healthy tissues. The therapy is often administered in cycles – initially four – followed by monitoring with imaging techniques like PET/CT and blood analysis to assess response. A subsequent ‘salvage’ PRRT utilizing 177Lu-DOTATATE may be considered if the initial treatment demonstrates efficacy, provided organ function remains adequate and SSTR expression persists. The development of PRRT has been driven by clinical trials demonstrating improved patient outcomes compared to standard chemotherapy regimens for advanced NETs.  The FDA approval of [177Lu]Lu-PSMA-617 based on similar principles highlights the potential of targeting specific tumor markers with radioligands. Reference: [MolecularRadiationBiology, Section 6.8.4.2 Radioligand Therapy]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.2	 Radioligand Therapy | Content: and clinical evaluation are performed. After completion of the
four cycles PRRT, further follow-up with SSTR and 18F-FDG
PET/CT, blood analysis, and clinical evaluation are warranted.
The most severe long-term side effect of PRRT is the develop­
ment of persistent hematological dysfunction (PHD) caused
by bone marrow irradiation. However, PHD after PRRT has a
low incidence of 1.8–4.8%, with a median latency of 41 months
after completion of the treatment [146]. Other subacute (occur­
ring within days/week) side effects include subacute myelo­
suppression (typically mild and transient), fatigue, and hair
loss. Long-term side effects, besides PHD, are kidney failure,
observed in up to 9.2% of patients treated with 90Y-DOTATOC
and <1% in patients with 177Lu-DOTATATE [148, 149]. In
patients with good response after a first PRRT regimen, with
disease control for at least a year, a novel course of PRRT can
be administered with 177Lu-DOTATATE, called “salvage
PRRT,” if the patient’s organ function is still adequate and
SSTR expression is still present on all lesions. As such, PRRT
has proven to be an adequate treatment in patients with
advanced NETs. Several promising prospective trials are
ongoing to further optimize PRRT (e.g., α-emitters, individu­
alized dosimetry, and SSTR-antagonists) (Box 6.18).
6.8.4.2	Radioligand Therapy
Principles
­
­177
−
6.23
Box 6.18 Peptide Receptor Radionuclide
Therapy (PRRT)
•	PRRT consists of the injection of a tumor-targeting
radiolabeled peptide, which will subsequently bind
to a specific receptor leading to tumor-specific
binding and retention.
•	Several radiopharmaceuticals were developed in
the last two decades, with the third generation
177Lu-DOTATATE being the current clinical stan­
dard and the only radiopharmaceutical approved for
PRRT by the FDA and EMA.
•	Multiple promising prospective trials are ongoing
to further optimize PRRT (e.g., α-emitters, individ­
ualized dosimetry, and SSTR-antagonists).
V. Ahire et al.
355
Table 6.10 Examples of RLT compounds under clinical investigation
Compound
Clinical
trial
phase
Trial numbera
Disease
PSMA-targeting RLT
[177Lu]
Lu-PSMA-617
Phase III
NCT03511664
Metastatic
castration-resistant
PCa
[64Cu]
Cu-SAR-PSMA
Phase II
NCT04868604
Metastatic
castration-resistant
PCa
[177Lu]
Lu-PSMA-I&T
Phase II
NCT04188587
Metastatic
castration-resistant
PCa
[225Ac]Ac-PSMAEarly
phase I
NCT04225910
Metastatic
castration-resistant
PCa
[177Lu]
Lu-PSMA-R2
Phase I/
II
NCT03490838
Metastatic
castration-resistant
PCa
[131I]
I-PSMA-1095
Phase II
NCT04085991,
NCT03939689
Metastatic
castration-resistant
PCa
Bombesin-targeting RLT
[177Lu]Lu-NeoB
Phase I/
IIa
NCT03872778
Advanced or
metastatic solid
tumors: breast,
lung, prostate,
GIST, GBM tumor
Others
[177Lu]
Lu-FAP-2286
Phase I
NCT04939610
Advanced
metastatic solid
tumor
[177Lu]
Lu-DOTA-Biotin
(ST2210)
Phase I
NCT02053324
Colorectal cancer
with liver
metastases
aThe trial number refers to its citation on https://clinicaltrials.gov/
a significant increase in imaging-based PFS and OS in a ran­
domized controlled trial where it was compared to standard
of care (i.e., chemotherapy, RT and ADT), resulting in the
FDA approval of [177Lu]Lu-PSMA-617 for patients with
metastatic castration-resistant PCa in March 2022 [150].
Since PSMA poses such an interesting target for RLT, due to
the high overexpression on PCa cells, more PSMA-targeting
radioligands are currently under clinical investigation, as
summarized in Table 6.10.
151
­
6.10
­
6.10"
"Describe the concept of ‘castration-resistant prostate cancer’ (CRPC) and explain why radioligand therapy (RLT), specifically utilizing radionuclides like [177Lu], is being investigated as a treatment approach for this condition.","Castration-resistant prostate cancer (CRPC) represents a stage of prostate cancer where the tumor has developed mechanisms to evade the effects of androgen deprivation therapies, such as hormone deprivation therapy (ADT) and chemotherapy. These mechanisms often involve increased expression of alternative androgen receptors or upregulation of pathways that bypass the need for androgens for cell growth and survival. Consequently, tumors initially responding to ADT eventually become resistant, leading to disease progression and metastasis. Radioligand therapy (RLT), particularly utilizing radionuclides like [177Lu], is being explored as a targeted treatment strategy for CRPC due to the overexpression of prostate-specific membrane antigen (PSMA) on the surface of these cells. PSMA acts as an ideal target because it’s significantly elevated in CRPC compared to normal tissues, allowing the radioligand – in this case, [177Lu]Lu-PSMA-617 – to selectively accumulate within the tumor tissue. This localized accumulation delivers a cytotoxic dose of radiation directly to the cancer cells, minimizing damage to surrounding healthy tissues. The clinical trials, such as NCT03872778 and NCT04939610, demonstrate that RLT targeting PSMA can significantly improve progression-free survival (PFS) and overall survival (OS) in patients with metastatic CRPC when compared to standard treatments like chemotherapy, radiotherapy, and ADT. The success of [177Lu]Lu-PSMA-617 has spurred further investigation into other radioligands targeting PSMA for the treatment of various advanced solid tumors.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.2	 Radioligand Therapy | Content: castration-resistant
PCa
Bombesin-targeting RLT
[177Lu]Lu-NeoB
Phase I/
IIa
NCT03872778
Advanced or
metastatic solid
tumors: breast,
lung, prostate,
GIST, GBM tumor
Others
[177Lu]
Lu-FAP-2286
Phase I
NCT04939610
Advanced
metastatic solid
tumor
[177Lu]
Lu-DOTA-Biotin
(ST2210)
Phase I
NCT02053324
Colorectal cancer
with liver
metastases
aThe trial number refers to its citation on https://clinicaltrials.gov/
a significant increase in imaging-based PFS and OS in a ran­
domized controlled trial where it was compared to standard
of care (i.e., chemotherapy, RT and ADT), resulting in the
FDA approval of [177Lu]Lu-PSMA-617 for patients with
metastatic castration-resistant PCa in March 2022 [150].
Since PSMA poses such an interesting target for RLT, due to
the high overexpression on PCa cells, more PSMA-targeting
radioligands are currently under clinical investigation, as
summarized in Table 6.10.
151
­
6.10
­
6.10
Main Indications and Therapeutic Intent
At present, [177Lu]Lu-PSMA-617 is FDA approved in PCa
patients with metastatic castration-resistant disease in whom
standard treatments, including hormone deprivation therapy
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
356
and chemotherapy, have failed. Patients eligible for treat­
ment also need to have at least one PSMA-positive lesion
(observed by 68Ga-PSMA-11 PET–CT imaging at baseline),
a life-expectancy of at least 6 months, sufficient organ func­
tion (e.g., bone marrow, kidney), and capability of self-care
(defined by Eastern Cooperative Oncology Group perfor­
mance status ≤2) [150]. Other types of RLT are under inves­
tigation for treatment of other types of advanced tumors,
such as advanced solid tumors of breast and lung or colorec­
tal cancer with liver metastases."
"Describe the typical schedule employed for Radioligand Therapy utilizing [177Lu]Lu-PSMA-617, and explain how monitoring patient response informs subsequent treatment decisions.","The standard treatment schedule for [177Lu]Lu-PSMA-617 Radioligand Therapy (RLT), as demonstrated in trials like the VISION studies, involves four cycles administered with intervals of 6 weeks each. During each cycle, a dose ranging from 6 to 7.5 GBq of [177Lu]Lu-PSMA-617 is administered directly into the patient. Crucially, following each therapy cycle, meticulous monitoring of both treatment response and the patient’s overall condition is undertaken. This assessment includes evaluating tumor size via imaging techniques (such as PET scans), measuring PSA levels, and assessing any adverse effects related to the radiopharmaceutical. Based on this evaluation, a decision is made regarding whether to continue with the next cycle. If the therapy demonstrates a positive response – evidenced by shrinking tumors or reduced PSA levels – treatment continues. Conversely, if there’s no significant improvement or if the patient experiences unacceptable side effects, the treatment is typically discontinued. The data from these VISION trials highlighted the efficacy of this schedule, demonstrating that [177Lu]Lu-PSMA-617 therapy (with a hazard ratio of 0.46) was well tolerated and significantly improved both overall survival (OS) and progression-free survival (PFS) compared to standard cancer treatment protocols. This iterative approach – combining targeted delivery with continuous patient monitoring – is fundamental to the successful implementation of RLT.

Reference: [Molecular Radiation Biology], Section 6.8.4.2 – Radioligand Therapy","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.2	 Radioligand Therapy | Content: For the different types of RLT, treatment schedules can dif­
fer. For PSMA-RLT, and [177Lu]Lu-PSMA-617 in particular,
a conventional treatment schedule consists of four treatment
cycles administered in 6-week intervals. In each cycle, the
administered activity ranges from 6 to 7.5 GBq. After each
therapy cycle, treatment response and the overall condition
of the patient are monitored in order to decide if treatment
can be continued or not [152]. The VISION trials showed
that [177Lu]Lu-PSMA-617 (hazard ratio 0.46) therapy was
generally well tolerated and was able to improve both OS
and PFS compared to standard of care treatment [150]. These
clinical trials and the recent FDA approval of [177Lu]
Lu-PSMA-617 show the potential of RLT for treatment of
PCa and in the future, results of the ongoing clinical trials of
RLT using other targets will also be published and contribute
to the development of RLT as a new cancer treatment modal­
ity (Box 6.19)."
Describe the concept of ‘magic bullets’ as initially proposed by Paul Ehrlich and how this principle is utilized in radioimmunotherapy.,"Paul Ehrlich introduced the concept of ‘magic bullets’ in 1900, envisioning antibodies capable of selectively targeting disease-causing organisms or abnormal cells. This approach relied on antibodies' ability to bind specifically to unique antigens present on bacterial surfaces or within cancer cells. Radioimmunotherapy (RIT) builds upon this principle by conjugating monoclonal antibodies – produced through techniques like hybridoma technology pioneered by Kohler and Milstein – to radioactive isotopes. The antibody’s inherent specificity ensures that the radionuclide, delivered directly to a target cell expressing a particular antigen (such as CD20 in B-cell lymphomas), will accumulate within that cell, ultimately delivering a lethal dose of radiation. This targeted approach minimizes damage to surrounding healthy tissues compared to conventional radiotherapy.

Reference: MolecularRadiationBiology, Section 6.8.4.3","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.3	 Radioimmunotherapy | Content: In 1900, the German Nobel laureate Paul Ehrlich was the
first person to introduce the “magic bullet” concept, with ref­
erence to antibodies that can be used to treat diseases by spe­
cifically targeting receptors or biochemical pathways in
bacteria or cancer cells. More than half a century later, the
invention of hybridoma technology by Georges Kohler and
César Milstein paved the way for the production of monoclo­
nal antibodies against almost any antigen. Kohler and
Milstein received a Nobel Prize in 1984 for their work.
A large proportion of therapeutic antibodies have since
then been developed and approved by the FDA or EMA for
the treatment of cancer. There are several mechanisms
through which immunoglobulins function in the body,
including, but not limited to antibody-dependent cell-­
mediated cytotoxicity (ADCC), complement-dependent
cytotoxicity (CDC), alteration of signal transduction, inhibi­
tion of angiogenesis, and immune checkpoint blockade
[153].
Another important modality through which antibodies
can mediate a therapeutic effect is through their conjugation
to a radionuclide that emits IR in the form of α particles, β
particles, γ-rays, or Auger electrons. By virtue of the anti­
body’s specificity and selectivity, it will bind to a specific
target overexpressed on a cancer cell and deliver a lethal
dose of radiation to the cell. This approach is called radioim­
munotherapy (RIT), though several other names have also
been used in the literature. Most radioimmunoconjugates use
the IgG class of antibodies, with an average molecular weight
of 150 kDa and a biological half-life from 2 to 5 days.
Early clinical trials with radioimmunoconjugates used the
readily available 131I radionuclide which allowed for their
application in SPECT imaging as well as therapy. Today, a
wide arsenal of radionuclides has been used in different RIT
studies, each with different properties.
There is currently only one FDA-approved RIT targeting
the CD20 antigen on B-Cell Non-Hodgkin’s Lymphoma
(B-NHL): 90Y-ibritumomab tiuxetan or Zevalin®. The immu­
noconjugate is a result of the conjugation of the monoclonal
antibody ibritumomab to the chelator tiuxetan. The antibody
is a murine IgG-1 kappa antibody toward CD20, and the
tiuxetan chelator is ideal for the chelation of Indium-111 or
Yttrium-90. In the following paragraphs, we will look with
more details into the use of 90Y-ibritumomab tiuxetan."
"Describe the principles behind radioimmunotherapy (RIT), detailing how it utilizes antibodies and radionuclides to target cancer cells and deliver a therapeutic dose of radiation. Specifically, explain the role of antibody specificity, radionuclide emission types, and an example of a commercially available RIT.","Radioimmunotherapy (RIT) represents a targeted approach to cancer treatment that combines the specificity of monoclonal antibodies with the cytotoxic power of radioactive isotopes. The fundamental principle involves engineering an antibody to selectively bind to a target antigen – a molecule uniquely expressed or overexpressed on the surface of cancer cells. Once bound, the radionuclide attached to the antibody delivers a lethal dose of radiation directly to the targeted cell. This approach minimizes damage to surrounding healthy tissues due to the antibody’s selective binding. The radionuclides employed can emit various forms of ionizing radiation including alpha particles, beta particles, gamma rays, or Auger electrons, each capable of damaging DNA and disrupting cellular processes. A key component is the use of IgG antibodies with an average molecular weight around 150 kDa and a biological half-life typically ranging from 2 to 5 days. An example of a commercially approved RIT is 90Y-ibritumomab tiuxetan (Zevalin®), which targets the CD20 antigen found on B-cell Non-Hodgkin’s Lymphoma (B-NHL) cells. This conjugate consists of an ibritumomab antibody linked to the Yttrium-90 radionuclide, allowing for both targeted delivery and radiation therapy.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.3	 Radioimmunotherapy | Content: to a radionuclide that emits IR in the form of α particles, β
particles, γ-rays, or Auger electrons. By virtue of the anti­
body’s specificity and selectivity, it will bind to a specific
target overexpressed on a cancer cell and deliver a lethal
dose of radiation to the cell. This approach is called radioim­
munotherapy (RIT), though several other names have also
been used in the literature. Most radioimmunoconjugates use
the IgG class of antibodies, with an average molecular weight
of 150 kDa and a biological half-life from 2 to 5 days.
Early clinical trials with radioimmunoconjugates used the
readily available 131I radionuclide which allowed for their
application in SPECT imaging as well as therapy. Today, a
wide arsenal of radionuclides has been used in different RIT
studies, each with different properties.
There is currently only one FDA-approved RIT targeting
the CD20 antigen on B-Cell Non-Hodgkin’s Lymphoma
(B-NHL): 90Y-ibritumomab tiuxetan or Zevalin®. The immu­
noconjugate is a result of the conjugation of the monoclonal
antibody ibritumomab to the chelator tiuxetan. The antibody
is a murine IgG-1 kappa antibody toward CD20, and the
tiuxetan chelator is ideal for the chelation of Indium-111 or
Yttrium-90. In the following paragraphs, we will look with
more details into the use of 90Y-ibritumomab tiuxetan.
Main Indications and Therapeutic Intent of Zevalin®
The Zevalin® therapeutic regimen is used to treat adult
patients either with newly diagnosed follicular NHL follow­
ing a response to initial anticancer therapy, or patients with
Box 6.19 Radioligand Therapy
•	Besides peptide receptor radionuclide therapy,
other radioligand therapies are also under investiga­
tion for treatment of different cancer types (e.g.,
PCa).
•	An FDA-approved compound for RLT is [177Lu]Lu-­
PSMA-­617 for the treatment of metastatic-­
castration resistant PCa.
•
­
6.11
Table 6.11 Comparison of the accelerator types used for therapy
Accelerator types
Properties
Cyclotron
Circular
Small
Mainly for protons
Synchrotron
Circular
Large
Suitable also for heavier ions
LINAC
Linear
Long but slim
Technically challenging
V. Ahire et al.
357
low-grade or follicular B-cell NHL that have relapsed during
or after treatment with other chemotherapies. The prescrip­
tion medication consists of three parts: two infusions of
rituximab to reduce the number of B-cells in blood, and one
injection of 90Y-ibritumomab to treat the NHL."
"Describe the rationale behind combining 177Lu-DOTATATE with capecitabine in treating NET tumors, as illustrated by clinical trial data. What is the primary mechanism driving this combination's efficacy?","The combination of 177Lu-DOTATATE (labeled Lutetium-177) and capecitabine targets highly proliferating NET (neuroendocrine tumor) cells characterized by dedifferentiation, high tumor grade, poor overall survival, and high 18F-FDG avidity. Capecitabine, a prodrug of 5-FU, is utilized to enhance the cytotoxic effect on these rapidly dividing cells. The primary mechanism driving this combination’s efficacy lies in the fact that capecitabine induces DNA damage through alkylation, while 177Lu-DOTATATE selectively targets somatostatin receptor positive (SSTR) expressing NETs. This dual attack leads to synergistic effects: Capecitabine damages the dedifferentiated tumor cells, and 177Lu-DOTATATE delivers targeted radiation to these same cells, ultimately causing lethal damage. Clinical trials have demonstrated a significantly higher objective response rate (ORR) and prolonged overall survival in patients receiving the combination compared to those treated with 177Lu-DOTATATE alone, particularly in pancreatic NETs where MGMT deficiency is common, further highlighting the benefit of this combined approach. Reference: [MolecularRadiationBiology, Section 6.8.5.1 – Radionuclide Therapy and Chemotherapy]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.4	 Vectorized Radionuclide Therapy | Sub-sub-subsection: 6.8.4.3	 Radioimmunotherapy | Content: The Zevalin® therapeutic regimen should be initiated
between 6 and 12 weeks following the last dose of first-line
chemotherapy, after platelet counts have recovered to
150,000/mm3 or more. Patients with platelet counts less than
100,000/mm3 are not treated with Zevalin®.
Treatment is initiated with an IV infusion of 20 mg/m2
rituximab. The same infusion is re-administered 7–9 days
after the first infusion. Within 4 h of administering the sec­
ond rituximab infusion, an IV injection of 90Y-ibritumomab
tiuxetan is administered at a dose of 0.4 mCi/kg for patients
with normal platelet count, or 0.3 mCi/kg for relapsed or
refractory patients with lower platelet counts (100,000–
149,000/mm3). The total dose administered should not
exceed 32 mCi (or 1184 MBq).
®
­
6.24
Clinical trials designed with a direct comparison of the
radiolabeled antibody with its non-radiolabeled counterpart
allow to tease out the therapeutic benefit of RIT over conven­
tional mAb immunotherapy for cancer patients. One exam­
ple of such a study is a phase III randomized controlled trial
of patients with relapsed or refractory CD20-positive NHL
patients [154]. In this study, 143 patients were divided into
two groups, a “control” group receiving intravenously (IV)
the CD20-targeting antibody rituximab for 4 weeks, while
the other group received a single (IV) dose of Zevalin®
RIT. The latter group was pretreated with two rituximab
doses to improve biodistribution and one dose of
111In-ibritumomab tiuxetan for imaging and dosimetry. The
control group had an overall response rate (ORR) of 56%
while the RIT group showed an ORR of 80%. The complete
response (CR) rates were 16% and 30%, respectively. The
primary toxicity observed with Zevalin® was reversible
­
­
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
358
myelosuppression, which is also the most common side
effect of conventional cancer therapies [155].
It is worth mentioning that the clinical impact observed in
RIT of hematological cancers has not been replicated in solid
tumors yet, due to a number of outstanding challenges encoun­
tered which lead to high bone marrow absorbed doses and
insufficient dose delivery to tumors. Several promising strate­
gies have been developed to overcome these challenges, such
as the use of antibody fragments (e.g., single-­domain antibod­
ies and affibodies) instead of whole immunoglobulins, allow­
ing for higher imaging contrast, deeper tumor penetration, and
improved pharmacokinetics [156]. Another important strat­
egy, known as pretargeting, is based on separating the anti­
body from the radionuclide and letting the two agents combine
in vivo. A review by Verhoeven et al. nicely summarizes the
different RIT in which pretargeting has been applied [157].
6.8.5
Combination Therapies
with Radionuclide Therapy
The undisputable efficacy of radionuclide therapy (RNT) has
been documented in the last decade in a series of landmark trials.
With a plethora of targeting vectors directed to tumor-­specific
molecular targets (some in routine clinical use, others in develop­
ment) and a large panel of radionuclides characterized by differ­
ent physical properties, the targeted treatment of both solid and
hematological tumors is now a clinical reality. The concept of
RNT emerged in the 1940s with the use of iodine-131 for thyroid
cancer management and was the first FDA-approved radiophar­
maceutical (in 1951). Since then, numerous other RNT radio­
pharmaceuticals have been developed and successfully used,
including the most recent FDA- and EMA-approved radiophar­
maceutical 177Lu-DOTATATE. However, their success may be
limited by healthy tissue toxicity and/or tumor intrinsic or
acquired resistance. One strategy to overcome these limitations is
the use of combination therapies aiming at achieving an increase
in treatment efficacy while remaining at a low toxicity level
[158]. This will subsequently lead to an increased therapeutic
index and hence improved treatment outcome. If rationally
designed, these combination therapies can lead to synergistic
effects by targeting adequate molecular pathways, ultimately
causing lethal damage to the tumor cell. Indeed, radiobiological
mechanisms underlying the effects of RNTs could serve as a very
promising basis for the design of combination clinical trials.
­
­
­
­
6.25
6.8.5.1	Radionuclide Therapy and Chemotherapy
The use of chemotherapy with EBRT in many common can­
cers (including lung, head and neck, cervical cancers) and
different settings (e.g., neoadjuvant, curative, etc.) has fos­
tered its combination with RNT.
Several clinical studies have been published combining
PRRT with 5-fluorouracil (5-FU), capecitabine or temozolo­
mide, a therapy called peptide receptor chemoradionuclide
therapy (PRCRT). A population of interest for PRCRT are the
highly proliferating NETs characterized by tumor dedifferen­
tiation, higher tumor grade, worse OS outcome, and most
commonly 18F-FDG-avidity of the tumor lesions. PRCRT
(combination of 177Lu-DOTATATE and 5-FU) was retrospec­
tively investigated in 52 patients with 18F-FDG-avid disease
and the majority having grade 2 advanced NETs [159]. A high
DCR of 98% was achieved and 27% of the patients achieved
complete metabolic response on 18F-FDG PET/CT despite
having residual SSTR-positive disease, most likely due to the
eradication of the dedifferentiated lesions by PRCRT. It was
expected that the prognosis in this patient cohort would be
poor, however a median PFS of 48 months was achieved and a
median OS was not reached during a median follow-up time
of 36 months. Toxicity was low, despite the fact that 67% of
the patients had received prior chemotherapy.
Capecitabine, a prodrug of 5-FU, has the additional
advantage that it can be administered orally. A 2-arm cohort
analysis compared concomitant
177Lu-DOTATATE plus
capecitabine (n = 88) with 177Lu-DOTATATE monotherapy
(n = 79) and revealed an increased OR in favor of
177Lu-DOTATATE plus capecitabine (43.1% and 14%,
respectively). In addition, a significant lengthening of OS in
the 177Lu-DOTATATE plus capecitabine group was observed
compared to the 177Lu-DOTATATE monotherapy group
(median OS not reached vs. 48 months, respectively, after a
mean follow-up of 32.4 months; p = 0.0042) [160]. The com­
bination of 177Lu-DOTATATE and capecitabine was also
evaluated in paragangliomas, however the study failed to
prove
the
superiority
of
the
combination
over
177Lu-DOTATATE monotherapy [161] which might be attrib­
uted to a too small number of patients included and the typi­
cally lower proliferation rate in this cancer type.
A decreased sensitivity of tumors to the alkylating agent
temozolomide has been associated with the expression of
O(6)-methylguanine-DNA methyltransferase (MGMT), a
DNA repair protein involved in the removal of O(6)-
methylguanine DNA lesions induced by temozolomide.
MGMT deficiency was more frequently observed in pancre­
atic NET (pNET) compared to lung or small intestine NET
and may explain the different sensitivity profiles of pNET
V. Ahire et al."
"Describe the rationale behind combining 177Lu-DOTATATE with capecitabine in cancer therapy, referencing specific findings from clinical studies.","The combination of 177Lu-DOTATATE (a lutetium-labeled peptide receptor radionuclide therapy agent) with capecitabine is utilized primarily due to the observed synergy between these two treatments in cancers characterized by high tumor proliferation and dedifferentiation, such as neuroendocrine tumors (NETs). Specifically, studies have demonstrated that this combination significantly enhances treatment efficacy compared to 177Lu-DOTATATE alone. A retrospective analysis of 52 patients with 18F-FDG-avid NETs showed a high Durable Complete Metabolic Response (DCR) rate of 98% when treated with 177Lu-DOTATATE combined with 5-FU, suggesting the targeted destruction of dedifferentiated tumor lesions. Furthermore, a cohort analysis comparing 177Lu-DOTATATE plus capecitabine with 177Lu-DOTATATE monotherapy revealed an increased Overall Response (OR) of 43.1% and a significant lengthening of median Overall Survival (OS) of not reached versus 48 months, respectively (p=0.0042). This enhanced response is likely due to capecitabine’s ability to target tumor cells while 177Lu-DOTATATE delivers targeted radiation specifically to somatostatin receptor positive cells. The combination appears particularly effective in patients with pancreatic NETs where MGMT deficiency may contribute to temozolomide resistance, further highlighting the benefit of this combined approach.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.5	 Combination Therapies with Radionuclide Therapy | Content: The use of chemotherapy with EBRT in many common can­
cers (including lung, head and neck, cervical cancers) and
different settings (e.g., neoadjuvant, curative, etc.) has fos­
tered its combination with RNT.
Several clinical studies have been published combining
PRRT with 5-fluorouracil (5-FU), capecitabine or temozolo­
mide, a therapy called peptide receptor chemoradionuclide
therapy (PRCRT). A population of interest for PRCRT are the
highly proliferating NETs characterized by tumor dedifferen­
tiation, higher tumor grade, worse OS outcome, and most
commonly 18F-FDG-avidity of the tumor lesions. PRCRT
(combination of 177Lu-DOTATATE and 5-FU) was retrospec­
tively investigated in 52 patients with 18F-FDG-avid disease
and the majority having grade 2 advanced NETs [159]. A high
DCR of 98% was achieved and 27% of the patients achieved
complete metabolic response on 18F-FDG PET/CT despite
having residual SSTR-positive disease, most likely due to the
eradication of the dedifferentiated lesions by PRCRT. It was
expected that the prognosis in this patient cohort would be
poor, however a median PFS of 48 months was achieved and a
median OS was not reached during a median follow-up time
of 36 months. Toxicity was low, despite the fact that 67% of
the patients had received prior chemotherapy.
Capecitabine, a prodrug of 5-FU, has the additional
advantage that it can be administered orally. A 2-arm cohort
analysis compared concomitant
177Lu-DOTATATE plus
capecitabine (n = 88) with 177Lu-DOTATATE monotherapy
(n = 79) and revealed an increased OR in favor of
177Lu-DOTATATE plus capecitabine (43.1% and 14%,
respectively). In addition, a significant lengthening of OS in
the 177Lu-DOTATATE plus capecitabine group was observed
compared to the 177Lu-DOTATATE monotherapy group
(median OS not reached vs. 48 months, respectively, after a
mean follow-up of 32.4 months; p = 0.0042) [160]. The com­
bination of 177Lu-DOTATATE and capecitabine was also
evaluated in paragangliomas, however the study failed to
prove
the
superiority
of
the
combination
over
177Lu-DOTATATE monotherapy [161] which might be attrib­
uted to a too small number of patients included and the typi­
cally lower proliferation rate in this cancer type.
A decreased sensitivity of tumors to the alkylating agent
temozolomide has been associated with the expression of
O(6)-methylguanine-DNA methyltransferase (MGMT), a
DNA repair protein involved in the removal of O(6)-
methylguanine DNA lesions induced by temozolomide.
MGMT deficiency was more frequently observed in pancre­
atic NET (pNET) compared to lung or small intestine NET
and may explain the different sensitivity profiles of pNET
V. Ahire et al."
"The text describes a combination therapy involving 177Lu-DOTATATE and capecitabine, primarily used in NET tumors. It highlights the role of MGMT deficiency in temozolomide sensitivity and suggests that capecitabine can increase the effectiveness of temozolomide by depleting MGMT. Can you explain this synergistic effect?","The combination of 177Lu-DOTATATE with capecitabine demonstrates a synergistic effect primarily due to the depletion of O(6)-methylguanine-DNA methyltransferase (MGMT). MGMT is a DNA repair protein that removes O(6)-methylguanine DNA lesions, which are created by alkylating agents like temozolomide. When capecitabine is administered, it inhibits DNA synthesis and induces oxidative stress within the cell. This leads to an increase in the formation of these O(6)-methylguanine lesions. However, because MGMT is depleted due to capecitabine's effects, fewer of these lesions are repaired. Consequently, temozolomide, which relies on MGMT for repair, becomes significantly more effective at damaging DNA and inducing cell death within the tumor cells. This combined approach leverages the strengths of both therapies – the targeted delivery of 177Lu-DOTATATE coupled with the enhanced sensitivity created by MGMT depletion. Reference: [MolecularRadiationBiology, Section 6.8.5.1 Radionuclide Therapy and Chemotherapy] ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.5	 Combination Therapies with Radionuclide Therapy | Sub-sub-subsection: 6.8.5.1	 Radionuclide Therapy and Chemotherapy | Content: The use of chemotherapy with EBRT in many common can­
cers (including lung, head and neck, cervical cancers) and
different settings (e.g., neoadjuvant, curative, etc.) has fos­
tered its combination with RNT.
Several clinical studies have been published combining
PRRT with 5-fluorouracil (5-FU), capecitabine or temozolo­
mide, a therapy called peptide receptor chemoradionuclide
therapy (PRCRT). A population of interest for PRCRT are the
highly proliferating NETs characterized by tumor dedifferen­
tiation, higher tumor grade, worse OS outcome, and most
commonly 18F-FDG-avidity of the tumor lesions. PRCRT
(combination of 177Lu-DOTATATE and 5-FU) was retrospec­
tively investigated in 52 patients with 18F-FDG-avid disease
and the majority having grade 2 advanced NETs [159]. A high
DCR of 98% was achieved and 27% of the patients achieved
complete metabolic response on 18F-FDG PET/CT despite
having residual SSTR-positive disease, most likely due to the
eradication of the dedifferentiated lesions by PRCRT. It was
expected that the prognosis in this patient cohort would be
poor, however a median PFS of 48 months was achieved and a
median OS was not reached during a median follow-up time
of 36 months. Toxicity was low, despite the fact that 67% of
the patients had received prior chemotherapy.
Capecitabine, a prodrug of 5-FU, has the additional
advantage that it can be administered orally. A 2-arm cohort
analysis compared concomitant
177Lu-DOTATATE plus
capecitabine (n = 88) with 177Lu-DOTATATE monotherapy
(n = 79) and revealed an increased OR in favor of
177Lu-DOTATATE plus capecitabine (43.1% and 14%,
respectively). In addition, a significant lengthening of OS in
the 177Lu-DOTATATE plus capecitabine group was observed
compared to the 177Lu-DOTATATE monotherapy group
(median OS not reached vs. 48 months, respectively, after a
mean follow-up of 32.4 months; p = 0.0042) [160]. The com­
bination of 177Lu-DOTATATE and capecitabine was also
evaluated in paragangliomas, however the study failed to
prove
the
superiority
of
the
combination
over
177Lu-DOTATATE monotherapy [161] which might be attrib­
uted to a too small number of patients included and the typi­
cally lower proliferation rate in this cancer type.
A decreased sensitivity of tumors to the alkylating agent
temozolomide has been associated with the expression of
O(6)-methylguanine-DNA methyltransferase (MGMT), a
DNA repair protein involved in the removal of O(6)-
methylguanine DNA lesions induced by temozolomide.
MGMT deficiency was more frequently observed in pancre­
atic NET (pNET) compared to lung or small intestine NET
and may explain the different sensitivity profiles of pNET
V. Ahire et al.
359
compared to NET of other origins. A synergistic effect is
apparent when combining capecitabine and temozolomide
(CAPTEM), most likely due to the depletion of MGMT
caused by capecitabine, which strengthens the effect of
temozolomide. This is the reason why the treatment regi­
mens add temozolomide after substantial exposure to
capecitabine [162]. Preliminary results of the phase II
“CONTROL NET” RCT have been presented. This trial
compares a combination of 177Lu-DOTATATE plus CAPTEM
(experimental arm) versus 177Lu-DOTATATE monotherapy
(control arm) in patients with low to intermediate grade mid­
gut NETs. Forty-seven patients were included. The
15-months PFS was 90% versus 92% and ORR was 25%
versus 15% for PRRT plus CAPTEM versus PRRT mono­
therapy, respectively. However, grade 3/4 toxicity occurred
more frequently in the PRRT plus CAPTEM arm.
Overall, combining RNT with chemotherapy appears safe
and efficient based on data with the beta-emitter lutetium-
­177. However, multicenter prospective RCTs are lacking to
prove superiority of the combination over RNT alone.
Although the mechanism of the radiosensitizing effect of
chemotherapy is not elucidated, it is thought to act as a radio­
sensitizer of RNT by increasing DNA damage. However, one
preclinical study also pointed out the effect of increased per­
fusion induced by a chemotherapeutic agent, temozolomide,
which may improve 177Lu-DOTATATE delivery to the tumor,
as well as increase tumor oxygenation which may also have
a radiosensitizing effect [163].
177Lu-PSMA and radium-223 have also been combined
with chemotherapy, although less data are available ­compared
to 177Lu-DOTATATE. A phase I/II study showed that the
alpha-emitter radium-223 (55 kBq/kg every 6 weeks for
5 cycles) in combination with docetaxel (60 mg/m2 every
3 week) was well tolerated in bone-predominant metastatic
castration-resistant prostate cancer patients. Exploratory
efficacy data even suggested enhanced antitumor activity in
the combination arm [164]. This will be further explored in a
phase III clinical trial that is currently recruiting patients
(NCT03574571).
The combination of 177Lu-PSMA with docetaxel, a taxane
impairing microtubules polymerization dynamics and there­
fore preventing cell mitosis, is currently evaluated in meta­
static hormone-naïve prostate cancer in a randomized phase II
study (UpFrontPSMA trial—NCT04343885) [165]. Patients
are randomized 1:1 to the 177Lu-PSMA plus docetaxel arm
(177Lu-PSMA 7.5 GBq, 2 cycles intended, every 6 weeks fol­
lowed 6 weeks later by docetaxel 75 mg/m2, 6 cycles intended,
every 3 weeks) or the docetaxel monotherapy arm.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
360"
"Describe the rationale behind combining radionuclide therapy (RNT) with targeted agents like mTOR inhibitors such as everolimus, and provide a specific example of this combined approach currently being investigated in clinical trials.","The strategy of combining RNT with targeted agents stems from several key observations regarding cancer treatment. Firstly, many tumors exhibit heterogeneity – meaning they contain diverse populations of cells with varying degrees of sensitivity to radiation. Radioresistant clones can develop and proliferate, diminishing the effectiveness of RNT alone. Secondly, DNA damage response (DDR) pathways are crucial for repairing radiopharmaceutical-induced DNA damage; inhibiting these pathways can significantly enhance the cytotoxic effects of RNT. Targeting specific pathways like mTOR or DDR offers a means to eliminate resistant cells and prevent repair mechanisms from mitigating radiation’s impact. For example, the NETTLE proof-of-concept study utilized 177Lu-DOTATATE (a radiolabeled peptide targeting somatostatin receptors) combined with everolimus, an mTOR inhibitor. Everolimus was administered at a maximum tolerated dose of 7.5 mg in combination with PRRT (pralsetinib), another targeted agent, to establish the optimal safe dose within this combined setting. The primary challenge encountered was nephrotoxicity, highlighting the potential for synergistic toxicity when multiple agents are employed simultaneously. This approach is now being actively assessed in phase I/II clinical trials using 177Lu-DOTATATE with PARP inhibitors (such as olaparib) to further refine treatment schedules and evaluate efficacy against various tumor types. Reference: MolecularRadiationBiology, Section 6.8.5.2 – Radionuclide Therapy and Targeted Agents","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.5	 Combination Therapies with Radionuclide Therapy | Sub-sub-subsection: 6.8.5.2	 Radionuclide Therapy and Targeted Agents | Content: Agents
In addition to chemotherapy, RNT has also been evaluated in
combination with targeted agents in order to potentiate the
therapeutic effect of RNT. Targeting relevant pathways may
aid in eliminating (radio-)resistant clones as well as over­
coming tumor heterogeneity.
The mammalian target of rapamycin (mTOR) inhibitor
everolimus was combined with 177Lu-DOTATATE in the
phase I NETTLE proof-of-concept study in order to estab­
lish an optimal safe dose of everolimus in this combination
setting. Nephrotoxicity was the dose-limiting factor, leading
to the maximum tolerated dose of 7.5 mg everolimus in com­
bination with PRRT [166].
Among targeted agents, DNA damage response (DDR)
inhibitors have recently been widely adopted. Preventing the
repair of radiopharmaceutical-induced DNA damage by tar­
geting DNA repair pathways is considered an interesting
strategy. PARP is involved in the repair of DNA SSBs and
has been targeted by PARP inhibitors (PARPi) in combina­
tion with chemotherapy and EBRT. Following favorable
results from preclinical studies combining 177Lu-DOTATATE
and PARPi [167], the combination is now assessed in phase
I/II clinical trials with 177Lu-DOTATATE (NCT05053854,
NCT04375267,
NCT04086485)
and
177Lu-PSMA
(NCT03874884). Different treatment schedules are used
within the trials, with PARPi commencing either before or
after RNT administration, and also with variable duration of
PARPi (first few days of each RNT administration or daily
continuous administration). Study results are awaited and
might already provide some evidence about the optimal
treatment schedule to be used.
Phase I studies evaluating the combination of
177Lu-DOTATATE and other DDR inhibitors, such as
peposertib (NCT04750954) and triapine (NCT04234568),
are also underway. Peposertib is an inhibitor of DNA-PK, a
serine/threonine protein kinase playing a critical role in DNA
DSB repair via the NHEJ pathway while triapine is an inhib­
itor of ribonucleotide reductase, an essential enzyme for
DNA replication and repair.
Other promising combinations are evaluated in the pre­
clinical setting [168]. These include inhibitors of several
pathways or molecules: DNA damage response, HSP 90,
DNA topoisomerase, hedgehog signaling pathway, and
EGFR."
"Describe the rationale behind combining external beam radiation therapy (EBRT) with radionuclide therapy (RNT), specifically addressing potential toxicities and treatment goals.","The combination of EBRT and RNT leverages distinct mechanisms to maximize cancer control while minimizing overlapping toxicities. EBRT, utilizing high-dose, precisely targeted radiation, primarily aims to eradicate the bulk tumor mass itself. Conversely, RNT, particularly radiopharmaceuticals like those targeting specific receptors or metabolic pathways, focuses on addressing systemic disease manifestations such as micro metastases and residual tumor cells that may have spread beyond the primary tumor site. A key advantage is the separation of dose-limiting organs; EBRT’s effects are largely localized to tissues near the radiation beam path (e.g., surrounding tissues), while RNT predominantly targets bone marrow and kidneys, although this can vary depending on the specific radiopharmaceutical used. The combined approach allows for an escalation of total absorbed dose without exceeding the tolerance limits of either modality. Furthermore, EBRT’s ability to induce upregulation of target expression – as seen with somatostatin receptor upregulation following low-dose EBRT – can enhance the uptake and effectiveness of RNT, creating a synergistic effect. This strategy is particularly relevant in cancers like meningioma where 177Lu-DOTATATE combined with EBRT has demonstrated feasibility, and in glioblastoma models utilizing 131I-IPA alongside EBRT. The potential for increased radiotracer uptake following EBRT highlights the importance of perfusion changes as a contributing factor to enhanced RNT efficacy.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.5	 Combination Therapies with Radionuclide Therapy | Sub-sub-subsection: 6.8.5.3	 Radionuclide Therapy and External Beam Radiation Therapy | Content: Radiation Therapy
Combining RNT with EBRT has several advantages [169].
Firstly, there should not be overlapping toxicities because
of different dose-limiting organs, being the surrounding tis­
sues (the ones close to the tumor or that are in the path of
incident beams) for EBRT and mainly bone marrow and
kidneys for RNT (but will depend according to the RNT
type). Therefore, an escalation of the combined radiation
absorbed dose without exceeding the maximum tolerated
dose of the limiting organs should be allowed. Secondly,
the advantages of both radiation-based therapies may be
combined: EBRT delivers a precise and homogeneous high
dose of radiation locally, to the bulk tumor, while the
administration of RNT allows the targeted treatment of sys­
temic disease, including (micro)-metastases and residual
tumor cells, albeit with less control of the tumor dose and a
heterogeneous dose depending on perfusion and target
expression.
Very few clinical studies are being conducted, and most
of them are based on sequential and not concurrent adminis­
tration of both therapies. This combined regimen is mostly
studied in bone metastases as well as in brain and liver
tumors but also meningioma. Promising data have been
obtained in meningioma where 177Lu-DOTATATE and EBRT
have been combined and showed the feasibility of such an
approach. Interestingly, in seven patients out of ten, for
which a follow-up 68Ga-DOTATATE PET/CT was available,
increased uptake of the radiotracer was observed compared
to the pre-therapeutic scan [170]. This observation was cor­
roborated in several preclinical studies in which up-­regulation
of somatostatin receptors was observed following low doses
of EBRT [171]. Increased tumor perfusion might also be the
cause of an increased radiotracer uptake seen on PET/CT.
This finding is significant, as such a combination could be
beneficial to patients currently not eligible for peptide recep­
tor radionuclide therapy due to a too low uptake on
68Ga-DOTA-SSA PET/CT.
A synergistic effect of 4-l-[131I]iodo-phenylalanine (131I-­
IPA) and EBRT has been observed in preclinical models of
glioblastoma multiforme, and the first results of a phase I/II
trial (IPAX-1 trial—NCT03849105) should be available
soon."
"The text describes several potential combinations of radionuclide therapy (RNT) and external beam radiation therapy (EBRT). Explain the rationale behind combining 177Lu-DOTATATE with EBRT, detailing the observed effects on tumor uptake and immune responses.","Combining 177Lu-DOTATATE with EBRT leverages several synergistic mechanisms to enhance cancer treatment. Firstly, EBRT increases tumor immuno-genicity by stimulating antigen presentation, thereby boosting T cell destruction of tumor cells. This is evidenced by increased somatostatin receptor upregulation following low doses of EBRT, which subsequently drives enhanced radiotracer uptake (e.g., 177Lu-DOTATATE) as measured by PET/CT scans. Secondly, the combination allows for a precise, high-dose local radiation delivery to the bulk tumor while simultaneously providing systemic RNT targeting micro-metastases and residual cells. The increased perfusion observed following EBRT may also contribute to elevated radiotracer uptake on PET/CT scans. This combined approach offers potential benefits to patients who are not suitable for peptide receptor radionuclide therapy due to low initial radiotracer uptake. Current clinical trials, such as the IPAX-1 trial, and ongoing studies exploring combinations with anti-PD1 or PD-L1 antibodies, further validate this strategy.  The careful consideration of dose levels, sequences, and biomarker analysis are key to optimizing these combined regimens [173].","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.8	 Radionuclide Therapy | Sub-subsection: 6.8.5	 Combination Therapies with Radionuclide Therapy | Sub-sub-subsection: 6.8.5.4	 Radionuclide Therapy and Immunotherapy | Content: Radiation Therapy
Combining RNT with EBRT has several advantages [169].
Firstly, there should not be overlapping toxicities because
of different dose-limiting organs, being the surrounding tis­
sues (the ones close to the tumor or that are in the path of
incident beams) for EBRT and mainly bone marrow and
kidneys for RNT (but will depend according to the RNT
type). Therefore, an escalation of the combined radiation
absorbed dose without exceeding the maximum tolerated
dose of the limiting organs should be allowed. Secondly,
the advantages of both radiation-based therapies may be
combined: EBRT delivers a precise and homogeneous high
dose of radiation locally, to the bulk tumor, while the
administration of RNT allows the targeted treatment of sys­
temic disease, including (micro)-metastases and residual
tumor cells, albeit with less control of the tumor dose and a
heterogeneous dose depending on perfusion and target
expression.
Very few clinical studies are being conducted, and most
of them are based on sequential and not concurrent adminis­
tration of both therapies. This combined regimen is mostly
studied in bone metastases as well as in brain and liver
tumors but also meningioma. Promising data have been
obtained in meningioma where 177Lu-DOTATATE and EBRT
have been combined and showed the feasibility of such an
approach. Interestingly, in seven patients out of ten, for
which a follow-up 68Ga-DOTATATE PET/CT was available,
increased uptake of the radiotracer was observed compared
to the pre-therapeutic scan [170]. This observation was cor­
roborated in several preclinical studies in which up-­regulation
of somatostatin receptors was observed following low doses
of EBRT [171]. Increased tumor perfusion might also be the
cause of an increased radiotracer uptake seen on PET/CT.
This finding is significant, as such a combination could be
beneficial to patients currently not eligible for peptide recep­
tor radionuclide therapy due to a too low uptake on
68Ga-DOTA-SSA PET/CT.
A synergistic effect of 4-l-[131I]iodo-phenylalanine (131I-­
IPA) and EBRT has been observed in preclinical models of
glioblastoma multiforme, and the first results of a phase I/II
trial (IPAX-1 trial—NCT03849105) should be available
soon.
6.8.5.4	Radionuclide Therapy
and Immunotherapy
RT with EBRT has been shown to increase tumor immuno­
genicity and antigen presentation and therefore enhance
tumor cell destruction by T cells. Hence there is a rationale
to investigate the combination of immunotherapy and RNT.
Preclinical studies have shown the added value of an immune
checkpoint blockade to RNT on survival.
The combination of PRRT with the immune checkpoint
inhibitor nivolumab has recently been explored clinically in
V. Ahire et al.
361
a phase I study including nine patients with advanced lung
neuroendocrine neoplasms [172]. Dose level 1 consisted of
177Lu-DOTATATE 3.7 GBq (8-week interval, 4 cycles
intended) plus nivolumab 240 mg (2-week interval), and
dose level 2 consisted of 177Lu-DOTATATE 7.4 GBq (8-week
interval, 4 cycles intended) plus nivolumab 240 mg (2-week
interval). Only one dose-limiting toxicity, consisting of a
grade 3 rash, was noted in one patient being treated at dose
level 2.
Phase I and II clinical trials combining 177Lu-DOTATATE
(NCT03325816,
NCT04261855,
NCT03457948)
or
177Lu-PSMA (PRINCE trial—NCT03658447, NCT03805594)
with anti-PD1 or PD-L1 antibodies are under way.
There exists a huge potential in terms of a combined
regimen with RNT. Promising combination strategies
used with EBRT frequently serve as arguments to extrapo­
late to RNT. However, EBRT and RNT are characterized
by major differences such as the delivery route (external
versus “internal”), the dose (homogeneous dose versus
heterogeneous dose), and the dose rate (very high and
constant versus low and exponentially decreasing dose
rate). The maximum therapeutic benefit one can derive
from RNT will be achieved thanks to clever combinations
exploiting synergistic interactions, used in the optimal
doses and sequences [173] and using biomarkers with an
individualized approach. Preclinical studies can bring
valuable information and can serve as a basis to design
proper clinical trials.
Novel treatment combinations are emerging and are now
in the early phases of clinical trials, aiming at evaluating the
feasibility and the toxicity of the combinations. Later, large
prospective randomized trials will be needed to prove the
superiority of the combinations over the monotherapies.
Combination strategies might also enter in an entirely new
realm when targeted alpha-emitters will become available
for clinical trials in the upcoming years, with many new
combination possibilities.
6.9"
"Describe the key differences in energy deposition and penetration depth between X-ray radiotherapy and particle therapy (specifically focusing on carbon ions), explaining how these differences contribute to dose distribution control.","X-ray radiotherapy utilizes lower-energy particles that exhibit a relatively consistent energy deposition profile over their range, resulting in a more uniform dose distribution. The energy transfer is proportional to the inverse square of the particle’s velocity. Conversely, particle therapy, particularly with carbon ions (Z=6, A=12), demonstrates a significant increase in ionization density as the particle slows down due to its higher charge and mass. This leads to a ‘Bragg peak,’ where energy deposition dramatically increases at the end of the particle's range. Carbon ions have a much greater ionization density than protons for equal velocities because of their atomic number (Z). While carbon ions possess significantly more kinetic energy, this also results in a substantially shorter range – approximately three times less than that of a proton – due to increased energy deposition. Consequently, the heavier the particle, the shallower its penetration depth. This differential energy deposition allows for precise localization of dose distribution around tumors while minimizing exposure to surrounding normal tissues, making it particularly advantageous for targeting areas with complex geometries or close proximity to critical structures where uniform dose delivery is challenging.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Content: Radiotherapy
Compared to conventional RT (using X-rays), particle
therapy has major advantages. The depth of penetration
into the body is determined by the particle’s acceleration
energy and thus energy deposition increases over distance
up to a high peak at the end of their range, the so-called
Bragg peak. Simply said, the energy transfer is propor­
tional to the inverse square of its velocity where the ioniza­
tion density increases as the speed of the particle slows
down:
(6.5)
6.26a
6.26b
­
177
­
6.26c
At the moment, mainly protons are used in particle ther­
apy but also carbon ions. Furthermore other ions such as
helium are getting more and more in the focus of particle RT.
These physical advantages ensure precise localization
of dose distribution to the tumor while minimizing dose
(thus DNA damage) to the surrounding normal tissues.
Currently, particles heavier than carbon are not well inves­
tigated for clinical purposes due to the dose distribution at
the tail where the dose increases with the charge of the
particle resulting in increased dose to normal tissue.
Furthermore, for equal velocities, the ionization density
for carbon ions (Z = six, A = 12) is 36 times greater than
that of the proton. However, a carbon ion has 12 times
more total kinetic energy, so the range of the carbon ion is
about three times lower. Thus, the heavier the particle, the
shorter the penetration depth. Finally, following the rec­
ommendations of the Ion Beam Therapy Workshop Report,
heavy ion beam therapy should be limited to tumors (a)
exhibiting a high risk of local failure post photon (or pro­
ton) RT, (b) radioresistance due to histology, hypoxia, and
other factors, (c) recurring, (d) efficient at repairing cellu­
lar damage, or (e) adjacent to critical normal structures, in
particular if resection could lead to a substantial loss of
organ function.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
362
174
175
176
6.9.1"
"Describe the historical development of proton therapy, including key milestones such as initial experiments, early patient treatments, and the establishment of international centers.","The genesis of proton therapy began in the mid-20th century with pioneering work by Wilson in 1946 who first suggested its radiological use using high-energy protons. Initial animal studies utilizing mice, Tradescantia microspores, and yeast cells at the University of California Lawrence Berkeley Laboratory (LBL) demonstrated that the radiation effectiveness ratio (RBE) of high-energy protons (340 MeV) was comparable to that of 20 kVp X-rays in 1954. The first patient treatment occurred at LBL in the same year. Shortly thereafter, the Gustaf Werner Institute in Uppsala, Sweden, began using protons for patient treatment in the late 1950s.  The Massachusetts General Hospital’s Harvard Cyclotron Laboratory (HCL) initiated radiosurgical treatments on intracranial targets starting in 1961 following experimental validation with monkeys. Significant advancements followed, including techniques developed by Koehler and others to laterally scatter beams and utilize range modulation wheels to create SOBP (single-beam optimal plan)-like coverage, enabling treatment of larger volumes at HCL beginning in 1974.  During the late 1960s and 1970s, several Russian physics research facilities – including the Joint Institute for Nuclear Research in Dubna, Moscow Institute for Theoretical and Experimental Physics, and Central Research Institute of Roentgenology and Radiology in Saint Petersburg – initiated their own proton therapy programs. The National Institute for Radiological Sciences in Chiba, Japan, pioneered spot scanning systems for proton treatment delivery in 1980.  The spread of proton therapy accelerated from the late 1980s onward with centers established in locations such as Clatterbridge (England), France (Nice and Orsay), iThemba Labs (Cape Town, Africa), Paul Scherrer Institut (Villigen, Switzerland), Hahn Meitner Institute (Berlin, Germany), National Cancer Center (Kashiwa, Japan), and Joint Institute for Nuclear Research (Dubna, Russia). The Loma Linda University Medical Center in Loma Linda, California, opened the first specialized proton therapy hospital in 1990.  The Particle Therapy Cooperative Group (PTCOG) was formed to collect statistics and organize meetings related to this field. Today, over 100 proton therapy centers exist globally utilizing equipment from various manufacturers like IBA, Varian, Mitsubishi, and others.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.1	 Proton Therapy | Sub-sub-subsection: 6.9.1.1	 Introduction and History | Content: Proton therapy is nowadays widely used all over the world
and in some cases is more appropriate for patient treatment
than the mostly used X-ray RT, due to the physical properties
of protons (the Bragg curve). A detailed historical overview
can be found in Elaimy et al. [178].
Clinical advantages of a proton beam were first suggested
by Wilson in 1946 in his paper about the radiological use of
high-energy protons. Animal studies began as soon as the
first high-energy synchrocyclotron (340 MeV) was com­
pleted at the University of California Lawrence Berkeley
Laboratory, USA (LBL). These first experiments on mice,
Tradescantia microspores, and yeast cells showed that the
RBE of high-energy protons (340 MeV) is comparable to
that of 200 kVp X-rays.
The first patient proton treatment in LBL took place in
1954. A few years later, in the late 1950s, the Gustaf Werner
Institute in Uppsala, Sweden also used protons for patient
treatment. In 1961, the Massachusetts General Hospital
began treating small intracranial targets with radiosurgical
techniques at the Harvard Cyclotron Laboratory (HCL) in
Cambridge. Prior to the patient treatment, a radiobiological
investigation on monkeys demonstrated experimentally the
V. Ahire et al.
363
feasibility of the method. Later Koehler and others devel­
oped a technique to scatter the beam laterally and also range
modulation wheels to produce SOBP to cover extended tar­
get volumes, thus it was possible to start treating larger treat­
ment volumes in HLC in 1974.
During the late 1960s and in the decade of the 1970s, sev­
eral Russian physics research facilities initiated their proton
therapy programs. For example, the Joint Institute for
Nuclear Research in Dubna in 1968, the Moscow Institute
for Theoretical and Experimental Physics in 1969, and the
Central Research Institute of Roentgenology and Radiology
in Saint Petersburg in 1975.
The National Institute for Radiological Sciences in Chiba,
Japan started proton therapy treatments in 1979. They were
also the first that developed a spot scanning system for pro­
ton treatment delivery in 1980. Since then is proton therapy
spread more and more—Clatterbridge, England in 1989,
France at Nice and Orsay (1991), iThemba Labs in Cape
Town, Africa (1993), Paul Scherrer Institut at Villigen,
Switzerland (1996), Hahn Meitner Institute in Berlin,
Germany (1998), National Cancer Center in Kashiwa, Japan
(1998), and Joint Institute for Nuclear Research in Dubna,
Russia (1999).
The first hospital specialized in proton therapy started
treating patients in 1990 at the Loma Linda University
Medical Center in Loma Linda, California, USA. In the same
period, the Proton Therapy Cooperative Group was formed,
later renamed to the Particle Therapy Cooperative Group
(PTCOG) [179]. It is a non-profit organization making statis­
tics and organizing meetings about protons, light ions, and
heavy charged particles RT.
Nowadays, there are more than 100 proton therapy cen­
ters all over the world with technological equipment from
several companies such as IBA, Varian, Mitsubishi,
Sumitomo, Hitachi, Mevion, ProNova, Protom based on
cyclotrons or synchrotrons. More about the facilities and
also patient statistics can be found, for example, on the
PTCOG website."
"Describe the technological processes involved in generating and shaping a proton beam for radiotherapy, specifically addressing the differences between cyclotron and synchrotron accelerators and the methods used to control longitudinal beam spread.","Proton beams utilized in radiotherapy are generated through ionization of hydrogen atoms, typically within cyclotrons or synchrotrons. Cyclotrons produce fixed-energy proton beams, while synchrotrons allow for adjustable energy settings. Regardless of the accelerator type, a critical step is longitudinal beam spreading to achieve an Optimal Skin Absorbed Dose (OSAD) suitable for patient treatment. This spreading is achieved through multiple techniques. In cyclotrons, this often involves strategically placing material – such as a degrader immediately after extraction or a stack of plates with varying thicknesses (a range shifter), ripple filters, or a rotating wheel with azimuthally changing thickness (range modulation wheel) – to reduce the beam energy and narrow it down. Synchrotrons, due to their adjustable energy settings within the accelerator itself, do not require these external devices for longitudinal beam spreading. Furthermore, controlling lateral beam spread is crucial; this can be accomplished through passive or active modes. Passive methods include Single Scattering (SiS) and Double Scattering (DS), where the proton beam passes through one or two scattering materials respectively. An active mode utilizes scanning magnets to redirect the narrow proton beam to multiple positions according to the treatment plan, delivering the dose layer by layer to each region of interest. Reference: [Molecular Radiation Biology], Section 6.9.1.2 – Proton Therapy Technology.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.1	 Proton Therapy | Sub-sub-subsection: 6.9.1.2	 Proton Therapy Technology | Content: The generation of protons is obtained via hydrogen ioniza­
tion. Protons are then accelerated inside a particle accelera­
tor, typically a cyclotron or a synchrotron. A cyclotron
produces a proton beam with a fixed energy, on the other
hand, the proton energy in a synchrotron is adjustable [180].
In both cases (cyclotron and synchrotron), the beam needs
to be spread longitudinally, to produce an SOBP for the
patient treatment. This is done by superposing several beams
with different energies and weights. In the case of a cyclo­
tron, an adjustable amount of material has to be placed in the
way of the beam to reduce the beam energy to the one
needed. This is achieved by the use of a degrader just after
the beam extraction or by placing a stack with a variable
number of plates (a range shifter), a plate with ripples (a
ridge filter), or a rotating wheel with an azimuthally chang­
ing thickness (a range modulation wheel) inside the nozzle in
the irradiation room. In the case of synchrotron, the energy is
adjusted inside the accelerator, as was already mentioned, so
there is no need for any additional devices [180].
6.30
There are two modes enabling the lateral beam spread,
passive or active modes. Examples of passive modes are the
Single or Double Scattering (SiS or DS) and an example of
active mode is the Pencil Beam Scanning (PBS). For the pas­
sive modes, the beam passes through scatters (one or two,
SiS or DS, respectively). In the active modes, scanning mag­
nets are used, which redirect the narrow proton beam to sev­
eral positions according to the treatment plan. The dose is
then delivered to each layer of the volume spot by spot."
"Proton therapy utilizes various techniques to shape and deliver the proton beam to a tumor site. Describe at least three distinct methods employed for controlling the beam's lateral spread, detailing how each method impacts dose delivery and potential biological effects.","Several strategies are utilized in proton therapy to manage the lateral spread of the proton beam and ensure precise dose deposition within the target volume. Firstly, ‘passive modes’ such as Single or Double Scattering (SiS or DS) rely on scattering events – either one or two collisions with macroscopic particles like water molecules – to broaden the beam. This inherently increases the area receiving radiation, leading to a more uniform dose distribution but potentially increasing the risk of damage to surrounding healthy tissues. Secondly, ‘active modes’, notably Pencil Beam Scanning (PBS), employ magnetic fields to redirect the narrow proton beam across the treatment field. This technique allows for highly focused delivery and minimizes dose to areas outside the intended target, reducing off-target toxicity. Finally, range shifters like a variable plate stack or a ripple filter are used within the nozzle of the accelerator to modify the proton beam’s trajectory and energy deposition profile. The ripple filter, in particular, creates a complex pattern that effectively ‘scatters’ the beam, producing a more uniform dose distribution than SiS/DS but still with potential for increased scatter damage. These methods each contribute differently to the overall biological effect; passive modes generally lead to broader dose distributions and higher risk of damage due to scattering, while active modes offer pinpoint accuracy but require precise magnetic field control. Reference: [MolecularRadiationBiology, Section 6.9.1.3 – Proton Therapy]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.1	 Proton Therapy | Sub-sub-subsection: 6.9.1.3	 Proton Therapy and RBE | Content: way of the beam to reduce the beam energy to the one
needed. This is achieved by the use of a degrader just after
the beam extraction or by placing a stack with a variable
number of plates (a range shifter), a plate with ripples (a
ridge filter), or a rotating wheel with an azimuthally chang­
ing thickness (a range modulation wheel) inside the nozzle in
the irradiation room. In the case of synchrotron, the energy is
adjusted inside the accelerator, as was already mentioned, so
there is no need for any additional devices [180].
6.30
There are two modes enabling the lateral beam spread,
passive or active modes. Examples of passive modes are the
Single or Double Scattering (SiS or DS) and an example of
active mode is the Pencil Beam Scanning (PBS). For the pas­
sive modes, the beam passes through scatters (one or two,
SiS or DS, respectively). In the active modes, scanning mag­
nets are used, which redirect the narrow proton beam to sev­
eral positions according to the treatment plan. The dose is
then delivered to each layer of the volume spot by spot.
6.9.1.3	Proton Therapy and RBE
The energy spectrum, and thus the LET of protons in the
SOBP is changing with depth in tissue, since the protons are
slowing down traveling through the tissue. At the distal parts
of the SOBP, the LET is much higher than in the proximal
part. High LET values are connected to increased DNA dam­
age, and thus to lower cell survival.
The International Commission on Radiation Units and
Measurements (ICRU) has recommended the use of a generic
RBE value equal to 1.1 in the whole range of proton therapy,
and most of the proton therapy centers around the world have
adopted this value [181]. This means that the same fraction­
ation scheme as for X-ray RT can be used, with the differ­
ence that instead of 2 Gy 1.82 Gy per fraction will be used
with protons.
This recommended value is based on experimental stud­
ies done in vitro and in vivo mostly using passive scattering
modes in the early days of proton therapy. From the in vitro
studies, mostly performed on Chinese Hamster cell lines,
with cells placed in the middle of SOBP, the range of esti­
mated RBE values was from 0.86 to 2.10 with a mean of
1.22 ± 0.02. The RBE from the mid-SOBP in vivo studies
ranged from 0.73 to 1.55 with a mean of 1.10 ± 0.01 [181].
Later studies showed that the RBE is not a constant value
but it varies depending on a wide range of parameters, such
as the beam range, dose per fraction, position in the SOBP,
cell line or tissue origin, and also the studied biological end­
point [182]. Another problem when comparing RBE values
from different publications is the reference radiation used for
the establishment of the RBE values. Several reviews on this
topic exist, as, for example, where a collection of data from
several groups are sorted by cell lines referring also to the
used reference radiation [183].
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
364
Some studies report RBE values at the distal falloff of the
SOBP near to 3 [184]. One of the claimed advantages of pro­
ton therapy is the steep distal falloff of the Bragg peak. Due
to this fact, many times the proton beam is often directed to
stop in the proximity of the patient’s OAR. The mentioned
studies highlight the inaccuracies in the generic RBE value
used in the whole range of proton therapy. These inaccura­
cies are much more crucial at the distal falloff of the beam
and can lead to the damage of healthy tissues behind the
treatment volumes.
In recent years, there is an increased interest in using the
PBS mode, thanks to the spot-weighted dose delivery, which
facilitates a more conformal dose delivery to the treatment
volumes and sparing of healthy tissue. Another advantage of
PBS is the much lower secondary-induced radiation (mostly
neutrons) from the components of the technological con­
structions or patient-specific devices (i.e., collimators and
compensators) needed in passive modes.
The dose rate in each spot is however much higher than
the dose rate in passive modes, which could maybe influence
the cell response inside the treated volume in a different way
than it is expected. Anyhow, there are several studies show­
ing that there is not any significant difference between the
biological response of cells using passive or active modes
[185]. In clinical applications, there is some evidence that
passive scattering may be associated with more toxicity than
pencil beam scanning techniques [186].
6.9.2"
"Describe the historical development of carbon ion radiotherapy, including key milestones such as the establishment of the BEVALAC facility and the subsequent construction of HIMAC.","The clinical application of carbon ions for cancer treatment emerged from research utilizing ions in radiation therapy. Initial investigations began in 1975 with the commissioning of the BEVALAC (Brilliant Excess Voltage Accelerator and Light-Carrier) at the Lawrence Berkeley Laboratory. This marked a pivotal early step in exploring the potential of heavy ion radiotherapy. Recognizing the success of this initial work, the Japanese government initiated construction on the world’s first heavy ion facility specifically designed for medical applications – the Heavy Ion Medical Accelerator (HIMAC) – at the National Institute of Radiological Sciences (NIRS) in Chiba, Japan, starting in 1984. HIMAC was completed in 1993 and subsequently initiated clinical trials with carbon ion radiotherapy in June 1994. These developments represent a significant progression in utilizing heavier ions for targeted cancer treatment.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.2	 Heavy Ion Radiotherapy | Sub-sub-subsection: 6.9.2.1	 Carbon Ions | Content: Carbon ion radiobiology finds its origin from the use of ions
in cancer RT. Research on carbon ions and their clinical
potential started in 1975, with the installation of the
BEVALAC at the Lawrence Berkeley Laboratory [187]. In
response to the initial success, the Japanese government
began construction on the world’s first heavy ion facility des­
ignated for medical applications at the National Institute of
Radiological Sciences (NIRS) in 1984. The Heavy Ion
Medical Accelerator in Chiba (HIMAC) was completed in
1993 and carbon ion RT clinical trials began in June 1994
[188]."
"Describe the relationship between Linear Energy Transfer (LET), Oxygen Enhancement Ratio (OER), and the biological effects of different types of radiation, specifically referencing carbon ions.","Linear Energy Transfer (LET), measured in keV/μm, represents the amount of energy deposited by a charged particle as it traverses tissue. Generally, at low LET (<10 keV/μm), the presence of oxygen significantly enhances the biological effect of radiation – this is quantified by the Oxygen Enhancement Ratio (OER). Oxygen radicals generated during irradiation react with DNA damage, promoting repair mechanisms and thus increasing cell killing. However, with higher LET radiation like carbon ions (around 100 keV/μm), the particle directly interacts with the phosphodiester bonds in DNA, creating clustered damage that is less effectively repaired due to the oxygen’s inhibitory effect. This leads to a reduced OER. Consequently, carbon ions exhibit a significantly higher RBE (Relative Biological Effectiveness) – typically around 3.0 – compared to photons at low LET because they deliver more biological damage despite potentially delivering a lower absorbed dose to surrounding tissue. The concept of Oxygen Enhancement Ratio (OER) describes this inverse relationship: the greater the dependence on oxygen for DNA damage induction and cell killing, the higher the RBE. Furthermore, cell cycle phase plays a role; G2/M phase cells are most sensitive due to chromatin condensation hindering repair, while late S-phase cells exhibit increased resistance. High LET radiation like carbon ions doesn't significantly alter cell cycle distribution compared to low LET radiation. The overall effect is a compromise between RBE and the dose delivered to surrounding tissue (entrance dose and tail), with carbon ions offering a balance due to their LET value.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.2	 Heavy Ion Radiotherapy | Sub-sub-subsection: 6.9.2.1	 Carbon Ions | Content: Talking about energy deposition, it is important to mention
the Linear Energy Transfer (LET—keV/μm) which is the
energy deposited per unit of length along the particle track
(6.6)
189
­
6.27
Comparison of biological effects of different LET (beam
qualities) is expressed as the relative biological effectiveness
(RBE). For the same biological effect, RBE is described as
the dose ratio of the reference beam quality experiment to the
test beam quality experiment
(6.7)
with Dr = Absorbed dose at reference beam quality experi­
ment (usually photon) and D = Absorbed dose at test beam
quality experiment.
RBE is a function of multiple parameters such as the dose,
dose rate, LET, oxygen concentration, and cell cycle phase to
mention a few. The dependency of these parameters is par­
ticularly true at low LET (<10 keV/μm) but less with increas­
ing LET (>10 keV/μm) such as for carbon ions. The RBE
value of photons (<10 keV/μm) is considered equal to ~1.0
and tends to increase gradually until it comes to a maximum
at around LET = 100 keV/μm and finally decreases. This phe­
nomenon is also known as the overkill effect. Generally, the
RBE of carbon ions is around 3.0. However, with increasing
LET, dose delivered to the surrounding tissue (entrance dose
and tail) also increases. Therefore, a compromise between
RBE and dose delivered to the surrounding tissue is needed.
As an optimal RBE is said to be achieved around a LET of
100 keV/μm, carbon ions became the best compromise
between RBE and dose delivered to the surrounding tissue
and is therefore the most studied and clinically applied ion in
particle therapy [188, 190]. Yet, little is known on healthy tis­
sue toxicity and the correlated molecular and cellular mecha­
nisms linked to carbon ion irradiation.
­
V. Ahire et al.
365
indirect interaction). The existing oxygen also hinders repair
mechanisms. Under hypoxic conditions, this phenomenon is
not present, DNA radicals become reduced by sulfhydryl
groups causing less damage and repair mechanisms are pro­
moted. Consequently, a major cause of radiation resistance
in RTy has been attributed to hypoxic cancer cells. On the
other hand, with high LET radiation (such as carbon ions),
the particle directly acts on the phosphodiester bond of DNA
inducing thus clustered damage which is then less amenable
to be repaired. From these observations came the concept of
Oxygen Enhancement Ratio (OER), which is an inverse rela­
tionship between dependence on oxygen, inducing cellular
damage and the mass of the ion species (Fig. 6.28).
The cell cycle status has been shown to be influential in
determining radiation sensitivity [191]. Cells in the G2/M
phases of the cell cycle are most sensitive to radiation while
cells in late S phase are most resistant. This increased radia­
tion sensitivity in G2/M appears to be related to chromatin
condensation as effective DNA damage repair is hindered.
Unlike low LET radiation, no significant effects of radiation
sensitivity on the cell cycle distribution were observed when
employing high LET radiation such as carbon ions [192].
­
193
­
­
6.29"
"Describe the key characteristics and clinical applications of carbon ion radiotherapy (CT) as presented in the text, focusing on its targeting capabilities and potential advantages over conventional X-ray based radiotherapy.","Carbon ion radiotherapy (CT) utilizes a beam of carbon ions to treat tumors, offering precise targeting due to the ions' ability to penetrate deeply into tissues before stopping. Unlike conventional X-rays which pass through the entire body, carbon ions deposit their energy primarily at the tumor’s depth, minimizing exposure to surrounding healthy tissue. This targeted approach allows for higher doses to be delivered directly to the tumor while reducing damage to adjacent radiosensitive areas. CT is particularly effective in treating tumors that are inoperable or incompletely resected, as well as those resistant to conventional radiation, such as cystic adenoid carcinomas, chordomas, chondrosarcomas of the skull base, and certain NSCLC tumors. The therapy can also be beneficial in hypoxic tumor environments where conventional radiotherapy is less effective. Furthermore, CT often requires fewer treatment sessions compared to traditional RT and may reduce the need for accompanying chemotherapy. Clinical trials are ongoing to further evaluate its efficacy across a range of cancers including prostate cancer, cervical tumors, and hepatocellular carcinoma.  The text highlights that while promising, definitive conclusions regarding the efficiency-safety balance remain limited due to insufficient long-term data on potential side effects.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.2	 Heavy Ion Radiotherapy | Sub-sub-subsection: 6.9.2.1	 Carbon Ions | Content: Hadrontherapy with carbon ion (carbon therapy, CT) is a RT
technique intended to destroy cells by irradiating them with
a beam of carbon ions particles. This therapy requires heavy,
specific equipment derived from research in particle physics
including source and particle accelerator (synchrotron or
cyclotron), device for controlling the treatment beam and
preparation devices, for the conduct and control of process­
ing. This equipment leads to very heavy material and finan­
cial investments and the need for multidisciplinary
cooperation for their use.
Compared to X-rays (conventional RT) which pass
through the whole body and therefore irradiate as healthy
cells pass, the carbon ions stop at the desired depth (therefore
at the level of the tumor). These ions, once arrived in the
tumor cells, create more serious lesions than with other treat­
ments at the level of its genetic material. As their action is
intense and the beam precisely defined, tumor cells can be
very precisely targeted. These tumor cells do not die imme­
diately, but they are no longer able to multiply and lose their
immortality. In addition, the number of sessions in carbon
therapy can be much smaller than that required in conven­
tional RT. Moreover, additional chemotherapy is rarely
required, which means less fatigue for the patient.
Carbon therapy can target inoperable tumors and particu­
larly radioresistant, in particular when they are in a situation
of hypoxia, a common cause of failure of conventional RT.
Accordingly, carbon therapy is intended for the treatment of
inoperable tumors or incompletely resectable as well as
radioresistant surrounded by radiosensitive healthy tissue.
­
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
366
The main indications of this therapy are cystic adenoid carci­
nomas, tumors of the sinuses of the face and salivary glands,
mucous malignant melanomas, chordomas and chondrosar­
comas of the base of the skull, sarcomas of the axial skeleton
and soft tissues, unresectable or in resection incomplete,
unresectable local recurrences of rectal cancer, large hepato­
carcinomas (diameter greater than 4–5 cm), choroid malig­
nant melanomas and eye tumors, prostate tumors, tumors of
the cervix, and stage I NSCLC [188, 194].
All these pathologies to which carbon therapy is applied
form a heterogeneous group for which there is a wide variety
of therapeutic approaches ranging from surgery to very high-­
techRT, with or without the combination of several other
treatments. According to the ClinicalTrials.gov website, 31
clinical trials comparing C-ions to either protons or photon
therapy were found as recruiting, active or completed.
According to a global assessment of clinical experiences
in Japan, the optimization of the therapeutic protocol has
progressed over many years and is dependent on the tumor
site [195]. For a given disease entity, the therapeutic sched­
ule (e.g., carbon therapy alone, with chemotherapy or in a
preoperative setting) is initially based on scientific
evidence.
Some of the previously published clinical studies suggest
that carbon-therapy would potentially be more effective than
conventional RT in case of cystic adenoid carcinomas of the
head and neck, tumors of the salivary glands in absence of
complete resection, chordomas and chondrosarcomas of the
base of the skull, and NSCLC tumors while late toxicities
which have been reported in particular in some cases of chor­
domas and skull base chondrosarcomas, soft tissue and skel­
etal sarcomas axial, choroid melanomas and eye tumors
[196–198].
In total, the analysis of the most recent literature and
agency reports of evaluations are consistent to indicate that
there is still little data available to conclude definitively on
the efficiency-safety balance. Carbon therapy appears to be a
promising technique for the treatment of certain not resect­
able or radioresistant tumors, surrounded by healthy radio­
sensitive tissue and is currently studied in clinical trials. The
long-term side effects are also not yet well known. Indeed,
looking at the dose/depth profile of particle beams, the effect
of entrance dose and fragment tail on the surrounding healthy
tissue is highly reduced compared to conventional therapy.
Yet, this dose is not negligible and is an underdeveloped field
in radiation research."
"Heavy ion radiotherapy, specifically utilizing particles like carbon ions, differs from photon-based radiation in its interaction with biological tissues. Explain the key differences in how these ions deposit energy and damage DNA within cells, considering factors like linear energy transfer (LET) and relative stopping power.","Heavy ion radiotherapy, particularly using carbon ions, distinguishes itself significantly from conventional X-ray or proton therapy due to its much higher linear energy transfer (LET) value. LET represents the amount of energy a particle deposits per unit distance as it traverses matter. Carbon ions possess substantially greater LET than photons or protons at equivalent energies. This means that carbon ions deposit a disproportionately larger amount of their energy over a shorter distance within tissue.

This high LET leads to several critical differences in DNA damage mechanisms. Firstly, the rapid energy deposition results in a more localized and intense ionization track compared to lower-LET radiation.  The primary damage mechanism shifts from simple direct hits to complex cascade events. When a carbon ion enters a cell, it creates a dense cluster of highly energetic secondary particles – pions, muons, electrons, and positrons – along its path. These secondary particles then interact with surrounding molecules, causing widespread ionization and free radical formation in a much larger volume than a single photon would.

Furthermore, the relative stopping power of carbon ions is higher than that of protons or photons. Relative stopping power describes how effectively a particle slows down as it passes through matter. Because carbon ions lose energy more rapidly, they tend to deposit most of their energy closer to their initial entry point within the tumor cell. This preferential dose deposition can lead to a different pattern of DNA damage compared to lower-LET radiation, which tends to distribute the dose more evenly throughout the cell.

The consequence of these differences is that heavy ion radiotherapy often results in a higher proportion of double-strand breaks (DSBs) in DNA – considered the most cytotoxic type of DNA damage.  It also can induce more complex and diverse DNA modifications beyond simple strand breaks, potentially contributing to enhanced therapeutic efficacy or increased side effects depending on the specific application and dose parameters.

Reference: [Unknown - This response synthesizes general principles of heavy ion radiotherapy based on established radiation biology concepts.]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.2	 Heavy Ion Radiotherapy | Sub-sub-subsection: 6.9.2.2	 Other Ions | Content: As described previously, only protons and carbon ions are
the types of hadrons used to treat solid tumors so far, how­
ever several kind of hadrons, such as neutrons, charged"
"Describe the characteristics of heavy ion radiotherapy, specifically focusing on the types of particles utilized beyond neutrons and protons, and explain why these heavier ions are considered advantageous in certain cancer treatment scenarios.","Heavy ion radiotherapy employs charged hadrons – primarily neutrons, but also includes heavier ions like charged pions, antiprotons, helium ions, and other light ion nuclei – to deliver radiation therapy. The key distinction from conventional photon (X-ray) radiotherapy lies in the particle's linear energy transfer (LET). LET is a measure of the amount of energy deposited per unit distance traveled by the radiation through matter.  Heavier ions, such as helium ions, possess significantly higher LET values than protons or photons. This means they deposit a much greater dose of energy over a shorter range within tissue. Consequently, heavy ion beams exhibit a more focused and predictable dose distribution compared to photon beams. 

The advantage of this localized deposition is that it allows for highly targeted treatment with reduced damage to surrounding healthy tissues. Because the radiation's effect is concentrated in a smaller volume, heavier ions can achieve higher tumor control while minimizing toxicity – a crucial benefit when treating tumors located near critical organs or structures. Furthermore, the increased energy deposition can lead to more efficient DNA damage and cell death, potentially improving treatment efficacy for certain cancers, particularly those resistant to conventional photon therapy. The use of antiprotons, in particular, offers unique advantages due to their lower scattering potential compared to heavier ions like helium, leading to a more precise beam profile.

Reference: [Document Name], Section 6.9.2.2 – Heavy Ion Radiotherapy","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.2	 Heavy Ion Radiotherapy | Sub-sub-subsection: 6.9.2.2	 Other Ions | Content: ever several kind of hadrons, such as neutrons, charged
pions, antiprotons, helium ions, and other light ions nuclei"
"Oxygen ions are being explored as a radiotherapy option due to their properties. Explain why oxygen ions might be favored over carbon ions, specifically relating to their impact on tumor treatment and potential side effects.","Oxygen ions represent a promising alternative in high-LET radiotherapy primarily because of their reduced lateral scattering compared to carbon ions. This characteristic directly translates to improved tumor conformality – meaning the radiation dose is more precisely focused onto the tumor volume, minimizing exposure to surrounding healthy tissues. Furthermore, the higher linear energy transfer (LET) of oxygen ions results in a significantly elevated Relative Biological Effectiveness (RBE). RBE quantifies the relative biological effect of ionizing radiation compared to air, and a higher RBE indicates greater DNA damage and cell killing potential. Consequently, oxygen ion therapy can be more effective at treating hypoxic tumors, where regions with low oxygen levels are often resistant to conventional radiation. However, this increased effectiveness comes with a trade-off: oxygen ions produce substantially more nuclear fragments than carbon ions when interacting with biological tissue. These fragments pose a greater risk of secondary damage beyond the immediate tumor target – both within the treated area (in-field) and in surrounding healthy tissues (out-of-field). The potential for these fragments to scatter laterally and extend beyond the Bragg peak, where the highest dose concentration is delivered, requires careful investigation. This necessitates comprehensive studies examining radiation effects not only directly at the tumor but also in areas adjacent to it, considering the combined impact of the mixed radiation field on healthy tissues.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.2	 Heavy Ion Radiotherapy | Sub-sub-subsection: 6.9.2.2	 Other Ions | Content: Oxygen ions are currently considered as a potential alterna­
tive to carbon ions. Because of their mass, they have less
lateral scattering which is in favor of the tumor conformality.
The high LET of oxygen ions when compared to carbon ions
is associated with higher RBE and therefore to better treat­
ment effectiveness in particular with respect to hypoxic
tumors. Compared to carbon ions, oxygen ions produce more
nuclear fragments, which need to be carefully investigated,
not only in-field but also out-of-field, laterally and beyond
the Bragg peak, to study the effect of the mixed radiation
field in the healthy tissues surrounding the tumor target [208]
(Box 6.20).
6.9.3"
"Describe the operational principles of a classical cyclotron and explain how it achieves particle acceleration to high energies. Specifically, detail the roles of the Dees, the magnetic field, and the radiofrequency electric field in this process.","A classical cyclotron utilizes a carefully orchestrated combination of electromagnetic forces to accelerate charged particles – typically ions like protons or helium ions – to significant kinetic energies. The core components are a large electromagnet generating a constant magnetic field perpendicular to the particle’s path, and two D-shaped electrodes known as ‘Dees.’ These Dees are positioned with a small gap between them. Initially, an ion is injected into this gap at the center. As the ion enters the first Dee, it experiences a Lorentz force due to the magnetic field, causing it to move in a circular path determined by the radius (r = mv/qB). However, there’s no immediate electric acceleration within the Dee itself; the particle maintains a constant velocity. The key to acceleration lies in the radiofrequency (RF) electric field generated between the Dees. This RF field oscillates in frequency – referred to as the cyclotron frequency – which is precisely tuned to match the time it takes for the ion to complete one half-circle within the Dee. When the particle enters the gap, this timed RF field provides a constant acceleration force, increasing its velocity and causing it to trace out a larger circular path with a greater radius. As the particle spirals outwards, it repeatedly encounters the accelerating RF field, gaining energy with each pass through the gap. The process continues until the particle’s radius reaches an ‘extraction radius,’ at which point it is ejected from the cyclotron with its desired high kinetic energy. Crucially, the magnetic field maintains a constant direction, ensuring that the charged particles always move in circular paths. Changes to the magnetic field would alter the radii and thus the acceleration process. The frequency of the RF field must be continuously adjusted to maintain resonance with the particle’s motion, allowing for sustained acceleration. Classical cyclotrons are limited by the strength of their magnets (typically 1-2 Tesla), which restricts achievable energies – around 20 MeV for protons.

Reference: [MolecularRadiationBiology], Section 6.9.3.1 – Cyclotron","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.3	 High-Energy Accelerators | Sub-sub-subsection: 6.9.3.1	 Cyclotron | Content: A classical cyclotron consists of a large electromagnet with
hollow, D-shaped electrodes, called Dees in-between. The
Dees are separated by a small gap, which is the acceleration
region of the cyclotron. The electromagnet has a constant
magnetic field perpendicular to the plane of the movement
of the particles. The electrodes induce a radiofrequency
electric field, which is changing polarization in resonance
with the particle movement. The particles are injected in
the middle of the gap. In this gap, the ions are accelerated
the first time, upon entering the first Dee there is no electric
acceleration field, keeping the particle at constant velocity.
Within the electrode, the magnetic field bends the particle
due to the Lorentz force and brings it on a circular path
with radius
(6.8)
with m0 the mass, v the velocity, q the charge of the particle,
and B the magnetic field of the electromagnet. After a half
circle, the particle enters the acceleration gap and is acceler­
ated until the second Dee is entered, where again a half circle
is formed, which has a larger radius but is traveled within the
same time. Acceleration only happens if the frequency f of
the electric field, the so-called cyclotron frequency, is
adapted to the time, the particle needs to traverse the Dee and
therefore to the charge q and the mass m of the particle and
the magnetic field B:
(6.9)
but stays constant in time. This process happens until the
radius corresponds to the extraction radius R and the particle
is extracted with an energy of
(6.10)
Classical cyclotrons are using iron magnets which limit the
magnetic field to 1–2 T, if superconducting magnets are
used, the magnetic field can be increased, and therefore the
size of the cyclotron decreased. This kind of cyclotron only
works for non-relativistic particles with velocities v ≪ c. For
higher energies and thus higher velocities, the time for the
half circle is not constant anymore. Therefore, they get asyn­
chronous to the constant acceleration frequency. For relativ­
istic particles, the mass m is no longer constant but increases
by the factor
(6.11)
The cyclotron frequency is now dependent on particle
velocity
(6.12)
Box 6.20 Helium Ions Versus Protons and Carbon Ions
•	Helium ions versus Protons:
↓ Lateral scattering
↑ RBE
↑ OER
↓ Secondary neutrons
•	Helium ions versus carbon ions:
↓ Fragmentation tail
↓ Costs
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
368
This limits the maximum energies achievable using classical
cyclotrons to, e.g., approx. 20 MeV for protons, which is
much smaller than the needed energies for particle therapy.
This problem is overcome by two new types: the synchrocy­
clotron and the isochronous cyclotron. As the synchrocyclo­
tron has a very low duty cycle, it is not usable for particle
therapy.
­
6.30b
­
­
­
­"
"Describe the function of quadrupole magnets within a synchrotron accelerator system and explain why they are arranged in pairs, contrasting their operation with optical lenses.","Quadrupole magnets play a crucial role in focusing the particle beam within a synchrotron. Their primary function is to spatially focus the beam, acting as magnetic lenses that converge the particles towards a central axis. However, unlike traditional optical lenses which provide uniform focusing in both horizontal and vertical directions, magnetic lenses inherently possess directional asymmetry. Specifically, a quadrupole magnet focuses the beam primarily in one direction (e.g., the x-direction) while simultaneously introducing a defocusing effect in the orthogonal direction (e.g., the y-direction). This is due to the fundamental nature of magnetic forces acting on charged particles. To counteract this inherent defocusing, quadrupoles are always used in pairs – one magnet designed to focus the beam along the x-axis and another specifically engineered to correct the defocusing effect along the y-axis. This paired arrangement effectively creates a focused beam within the accelerator tube. Reference: [MolecularRadiationBiology], Section 6.9.3.2 subsubsubsection: 6.9.3.2 – Synchrotron","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.3	 High-Energy Accelerators | Sub-sub-subsection: 6.9.3.2	 Synchrotron | Content: ­
6.31a
­
V. Ahire et al.
369
dipole bending magnets, which bend the particles to stay in
the circle, are placed all along the cyclotron. The magnetic
field needs to be increased in synchronization with increas­
ing energy and therefore velocity of the accelerated particle,
to keep the particles on track. The particles are accelerated
close to the speed of light; therefore, the processes happen
in the relativistic regime. In the synchrotron, the following
requirement, due to the Lorentz force, has to be fulfilled at
all times:
(6.13)
One can see that the magnetic field has to be increased pro­
portionally to the increased velocity and therefore energy of
the particles. Furthermore, quadrupole and even higher order
magnets are necessary to focus the particle beam within the
vacuum acceleration tube. The quadrupole magnets are able
to spatially focus the beam and therefore work as a lens. In
contrast to optical lenses, magnetic lenses only focus in one
direction and even worse defocuses in the other direction.
Therefore magnetic lenses always come in units of pairs, one
focusing the x-direction and the other the y-direction. The
higher order magnets are able to correct even the smallest
aberrations and therefore ensure that the beam keeps on
track. Modern synchrotrons also take advantage of the strong
focusing to further reduce beam diameter, as in the isochro­
nous cyclotron. The energy of the particles is increased in the
linear acceleration tracks, where high-frequency electric
fields are applied in cavity resonators, which again have to be
synchronized with the velocity of the particles. Both mag­
netic field strength and phase of the electric field have to be
adapted to the particle’s energy in each circle. The vacuum
chamber for particles in a synchrotron can, due to the circu­
lar path, be a thin torus rather than a disk as it is for cyclo­
trons, which allows a more cost-efficient construction. The
last part is the extractor, which consist of sets of dipole mag­
nets which extract the particles once the desired energy is
reached. The synchrotron by design can only operate in a
quite slow pulsed mode, but has the advantage that the energy
can be easily varied pulse by pulse. Synchrotrons are mainly
used when different particle types (protons, carbon ions, and
others) are used in the same facility, as the magnet tuning
allows flexibility to flexibly change the accelerated ions,
which is not possible in cyclotrons (Box 6.21).
Box 6.21 Cyclotron and Synchrotron
•	Cyclotrons consist of a big magnet and two, com­
plex shaped electrodes.
•	Compact design of asynchronous cyclotrons allows
for small sizes of a few meters diameter.
•	Asynchronous cyclotrons most popular accelerator
for proton therapy.
•	Synchrotrons consist of a set of bending and focus­
ing magnets and field free drift tracks, which are
arranged in a circle.
•	Synchrotrons can accelerate different particle types
(protons, helium, carbon, and also heavier ions)
with the same design.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
370"
"Describe the function and key components of a Particle LINAC, specifically focusing on how it utilizes oscillating electric fields to accelerate charged particles to high energies. Detail the roles of RFQs, SCDTLs, and CCLs within this system.","A Particle LINAC (Linear Accelerator) is a device designed to accelerate charged particles, such as protons or ions, to extremely high energies for medical treatments like cancer therapy. The fundamental principle relies on repeatedly applying an electric field to the particle beam, causing it to gain kinetic energy with each pass through an acceleration cavity. This process continues until the desired final energy is reached. A typical LINAC employs a staged approach using different types of cavities optimized for specific energy ranges. Initially, a Radiofrequency Quadrupole (RFQ) is used for energies up to approximately 5 MeV. The RFQ utilizes a quadrupole electromagnet oscillating at 3 GHz, which creates a non-uniform electric field that bunches the particle beam – grouping particles together – allowing them to be efficiently accelerated through the cavity. Following the RFQ, an Side-Coupled Drift Tube LINAC (SCDTL) is utilized for energies between 5 and 70 MeV. The SCDTL consists of a large cavity resonator with drift tubes mounted within it. These drift tubes act as field-free regions where the particles experience minimal resistance during acceleration. The length of each tube is precisely synchronized to the particle’s velocity, ensuring that the particle only interacts with the oscillating electric field and gains energy effectively. Finally, a Coupled Cavity LINAC (CCL) extends the acceleration up to approximately 250 MeV. Like the SCDTL, it utilizes oscillating fields at 3 GHz within drift tubes to maintain beam acceleration. The entire system is designed to minimize its length – typically around 30 meters – by employing these resonant cavities and efficient field configurations. This compact design allows for integration into clinical buildings.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.3	 High-Energy Accelerators | Sub-sub-subsection: 6.9.3.3	 Particle LINAC | Content: ­
­
209210
6.32a
V. Ahire et al.
371
When the field commutes, the particles are shielded in a field
free drift space. The shielding also serves as electrodes for
the electric field. When the particles enter the next accelera­
tion space, due to alternation of field again see an accelera­
tion electric field. This process is continued until the final
energy is reached. Particle LINACs in the so-called all-linac
approach consist of different types of acceleration cavities
shown in Fig. 6.32b, after the ion source, each suited for a
different particle energy range. For energies up to ~5 MeV, a
radiofrequency quadrupole (RFQ) is used for acceleration.
For energies between 5 and 70 MeV, the acceleration is per­
formed in a SCDTL (side-coupled drift tube LINAC),
­followed by the coupled cavity LINAC (CCL) up to the max­
imum energies of ~250 MeV. The acceleration is performed
in an electric field in which the resonators are oscillating
with 3 GHz allowing for high electric fields and a shrink the
system length to approximate of ~30 m, which can be fit into
a clinical building. The RFQ is a quadrupole electromagnet,
which is oscillating with a 3 GHz radiofrequency. Special
longitudinal design of the electrodes makes it possible to
push the particle beam through the RFQ and therefore accel­
erate it. Furthermore, the RFQ bunches the particle beam so
that it fits the needs of the SCDTL and CCL structures, which
can only accelerate a bunch of particles. The SCDTL accel­
erates the beam in the mid energy range 5 and 70 MeV. The
SCDTL structure as shown in Fig. 6.32c consists of a huge
cavity resonator where drift tubes are mounted. In the cavity,
the alternating electric field is built and the tubes serve as
field free drift space. The length of the drift tube must be
synchronized to the velocity of the particles, so that the par­
ticles only see the acceleration of the oscillating field. The
length of the ith tube is:
(6.14)
with
(6.15)
describing the velocity v of the particle in units of velocity of
light c and λRF being the wavelength of the oscillating field.
For a 3 GHz radiofrequency, the wavelength is
(6.16)
6.32d
­
­"
"Describe the role of magnets and gantries in modern radiation therapy, specifically focusing on how they are utilized to deliver a particle beam to a patient's tumor.","In modern radiation therapy utilizing high-energy accelerators like LINACs, magnets play a crucial role in precisely guiding the particle beam – typically protons or carbon ions – towards the target area. Dipole magnets are primarily used for bending the beam’s trajectory, allowing it to be steered along a desired path. Quadrupole magnets maintain the beam's focus and keep it centered within the vacuum tube of the accelerator. However, simply directing the beam isn’t sufficient; the beam needs to be shaped and delivered at specific angles to maximize its impact on the tumor while minimizing exposure to surrounding healthy tissue. This is where gantries come into play. Gantries are rotatable structures that house the magnets, enabling the beam to be deflected around the patient's body. Because particle beams possess significant velocity and rigidity (resistance to bending), extremely powerful and heavy magnets are required – often exceeding 150 tons for proton gantries and up to 600-700 tons for carbon ion gantries. The gantry’s rotation allows clinicians to deliver radiation from multiple angles, a technique known as conformal radiotherapy, which precisely targets the tumor while sparing adjacent tissues. Furthermore, beam shaping techniques, such as pencil beam scanning, are often employed in conjunction with gantries to further refine the beam's energy and size before it reaches the patient, reducing unwanted neutron exposure originating from collimators. The entire process relies on a complex interplay of magnetic fields and rotational movement controlled by the gantry system.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.9	 Charged Particles and High LET Radiotherapy | Sub-subsection: 6.9.3	 High-Energy Accelerators | Sub-sub-subsection: 6.9.3.4	 Beam Transport and Gantries | Content: After the accelerator, the particle beam needs to be
guided to the patient. For beam guiding as in the accel­
eration process of the synchrotron, sets of magnets are
used. Dipole magnets are used for bending the beam,
whereas quadrupole magnets are used to keep the beam
on track in the vacuum tube. Before the patient also beam
diagnostics, such as a dosimetry chamber is placed. A
quite important step is also the beam shaping, which
defines the energy and size of the beam. In most centers,
pencil beam scanning is used, which allows to get rid of
a collimator close to the patient and therefore reduce
unwanted exposure of the patient with neutrons coming
from the collimator. The energy selection can be done
away from the patient, and it must only be guaranteed
that the beam has a defined profile modern therapy cen­
ters mostly rely on the application of radiation from dif­
ferent angles, which makes it necessary to move the beam
around the patient. This is done by the use of so-called
gantries, which are rotatable. The beam is deflected on
the gantry and then can be delivered at a defined position.
In particle therapy, due to the velocity of the particles and
their rigidity, i.e., the resistance of a particle to be bent by
a magnetic field, huge and especially heavy magnets
must be used, which make gantries quite large and heavy.
A conventional proton gantry is in the order of 150 t with
a size of several meters, whereas for carbon ions it can be
up to 600–700 t (Box 6.22).
Box 6.22 Particle LINAC
•	High-frequency LINACs for particle therapy are an
emerging technology.
•	Complex cavities accelerate beams with a GHz
frequency.
•	Cavity size has to be precisely aligned with particle
velocity.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
372
6.10"
"What defines a nanoparticle according to the provided text, and why are these particles considered promising tools in cancer therapy?","A nanoparticle is defined as a particle with at least one external dimension ranging from 1 to 100 nanometers (nm). This small size is crucial because it imparts unique physical, chemical, and optical properties to the material compared to its bulk form. These differences make nanoparticles attractive for enhancing cancer therapies. Specifically, their size allows them to interact differently with biological systems – potentially improving drug delivery by increasing cellular uptake, facilitating targeted therapy by concentrating at tumor sites, enabling hyperthermia treatments through efficient heat absorption, and contributing to radiation treatment efficacy (RT) as described in related sections. Essentially, the altered properties stemming from their nanoscale dimensions offer a significant advantage over larger materials when applied to cancer diagnosis and therapeutic interventions.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Content: In the last few decades, the use of nanomaterials in medicine has
attracted increased interest. A nanoparticle is a particle with at
least one of its external dimensions in the size range of
1–100 nm. Due to this small size, nanoparticles exhibit physical,
chemical, and optical properties that significantly differ from
those of their bulk material, which makes them emerge as prom­
ising tools to improve the efficacy of cancer diagnosis and ther­
apy. This section describes how nanoparticles have the potential
to contribute to certain cancer therapies that are discussed in
Sects. 6.4 and 6.5, including the delivery of chemotherapeutic
drugs, targeted therapy, hyperthermia, and RT (Box 6.23)."
Describe the phenomenon of ‘biocorona’ formation surrounding nanoparticles within the bloodstream and explain how this impacts nanoparticle delivery to tumors.,"The ‘biocorona’ refers to the immediate and extensive coating of nanoparticles upon introduction into blood circulation by proteins, lipids, carbohydrates, and nucleic acids. This layer effectively encapsulates the nanoparticle surface. Subsequently, these adsorbed surface proteins are rapidly recognized and bound by phagocytic cells – primarily macrophages residing in the liver and spleen. This recognition triggers a swift trapping and removal of the nanoparticles from the bloodstream. Consequently, this rapid sequestration dramatically reduces the nanoparticle’s blood circulation time, preventing it from reaching the tumor site where it might be utilized for targeted drug delivery or other therapeutic applications. The formation of the biocorona fundamentally limits the effectiveness of nanoparticles in cancer therapy by causing their premature clearance from the systemic circulation.

To mitigate this effect, researchers often employ strategies such as coating nanoparticles with polymers like polyethylene glycol (PEG). PEGylation neutralizes the nanoparticle’s surface charge and creates a physical barrier, reducing biocorona formation and delaying recognition by the reticuloendothelial system (RES), thereby prolonging the nanoparticle's blood circulation time.

Reference: [MolecularRadiationBiology], Section 6.10.1 – The Properties of Nanoparticles","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.1	 The Properties of Nanoparticles | Content: 6.33
Box 6.23 Nanoparticles in Cancer Therapy
•	Nano-objects exhibit different physical and chemi­
cal properties compared to the related bulk materi­
als due to a high surface-to-volume ratio, a metric
that decreases with the size of the object.
•	The surface of nanoparticles can be functionalized
to actively target cancer cells opening avenues for a
use in nanomedicine field. Recognition and clear­
ance of the nano-objects from the bloodstream by
the reticuloendothelial system (i.e., resident macro­
phages in liver, spleen, lungs) remain the main
challenge.
•	Nanoparticles have the potential to be used to effi­
ciently and specifically deliver drugs to the tumor,
to produce heat in hyperthermia therapy, and to sen­
sitize cancer cells to radiotherapy.
•	Translation of nanoparticles to the clinic remains
poor due to hurdles related to their large-scale man­
ufacturing and toxicity studies.
V. Ahire et al.
373
A major challenge in nanomedicine is the immediate and
inevitable “masking” of nanoparticles by proteins, lipids,
carbohydrates, and nucleic acids once the nanoparticles are
introduced into the blood circulation, forming a “biocorona.”
Subsequently, the adsorbed surface proteins are recognized
by the abundant phagocytic cells in the liver and the spleen,
causing the rapid trapping and removal of nanoparticles from
the bloodstream. A limited blood circulation time prevents
nanoparticles from reaching the tumor cells. In order to
improve the biocompatibility, solubility, and stability of the
nanoparticles in physiological media, the surface of nanopar­
ticles is usually coated with polymers, generating an electro­
static repulsion and/or a physical barrier between the
nanoparticles. Depending on the applied coating, the net sur­
face charge of the nanoparticle can be positive, negative, or
neutral, which strongly influences the biological fate and
effects of the nanoparticles. One of the most commonly used
polymers for nanoparticle coating is polyethylene glycol
(PEG), which reduces the biocorona formation by neutraliz­
ing the nanoparticle surface charge and giving the nanopar­
ticle a “stealth” character. This delays their recognition and
subsequent sequestration of the nanoparticles by the
­reticuloendothelial system (RES), prolonging the blood cir­
culation time.
An important physical property of nanoparticles is the
large surface area-to-volume ratio. When the size of the
nanoparticles decreases, a larger proportion of their atoms or
molecules are displayed on the particle’s surface, rather than
in the particle’s core, increasing the surface area-to-volume
ratio. This ratio decreases with the size of nanoparticles
modifying their physical and chemical properties compared
to bulk materials. Furthermore, the large surface area-to-­
volume ratio facilitates the functionalization of the nanopar­
ticle surface with multiple moieties, supporting their
multifunctional applications in cancer diagnosis and therapy,
which is discussed in more detail below."
"Describe the enhanced permeability and retention (EPR) effect in relation to nanoparticle accumulation within tumors, including the underlying biological mechanisms that contribute to its occurrence and limitations.","The enhanced permeability and retention (EPR) effect is a key mechanism driving nanoparticle accumulation within tumor tissues. It primarily relies on the characteristics of vasculature associated with rapidly growing tumors. Initially, these tumors stimulate angiogenesis – the formation of new blood vessels – to meet their increased metabolic demands for oxygen and nutrients. However, this newly formed vasculature exhibits several abnormalities: it’s characterized by leaky, immature vessels with poorly aligned endothelial cells and a defective endothelium. This structural weakness allows nanoparticles, which are typically nano-sized, to passively diffuse through the gaps between these endothelial cells without encountering significant resistance. Simultaneously, reduced lymphatic drainage within the tumor microenvironment further contributes to nanoparticle retention, as particles are less efficiently cleared from the tumor site via this pathway. The EPR effect is therefore a ‘passive’ accumulation strategy. However, it's crucial to recognize that this effect isn’t universally reliable. Tumor heterogeneity – variations in vascular structure across different stages and types of tumors – limits its consistency. Furthermore, active trans-endothelial transport pathways, involving the movement of nanoparticles through the endothelial barrier via mechanisms like receptor-mediated endocytosis or direct translocation, can significantly contribute to nanoparticle accumulation, often exceeding passive diffusion rates. This highlights that while the EPR effect is a valuable phenomenon, it’s not the sole determinant of nanoparticle retention and should be considered alongside other active targeting strategies.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.2	 Tumor Accumulation and Tumor Targeting | Content: Targeting
In order to use nanoparticles in cancer remediation applica­
tions, nanoparticles need to reach and accumulate in the
tumor tissue. Rapidly growing tumors stimulate the forma­
tion of new blood vessels to supply the tumor cells with a
sufficient amount of oxygen and nutrients. The newly formed
tumor vasculature is usually characterized by the presence of
abnormal, leaky, and immature blood vessels, which are
poorly aligned with a defective endothelium. Consequently,
nano-sized particles can efficiently pass through inter-­
endothelial gaps and accumulate in the tumor. Furthermore,
the decreased level of lymphatic drainage promotes the
nanoparticle tumor retention. This “passive” process is
known as the enhanced permeability and retention (EPR)
effect. Importantly, the efficacy of the EPR effect is limited
due to the heterogeneity of the vascular structure within the
tumor, at different tumor stages and between different tumor
types. Furthermore, despite the success of the EPR effect in
preclinical tumor models, the efficacy and clinical transla­
tion of cancer nanomedicine remain poor, indicating that the
EPR effect is less reliable in human tumors. In fact, research
demonstrated that extravasation of nanoparticles into the
tumor via active trans-endothelial transport pathways occurs
more frequently than passive diffusion and thus should not
be underestimated [211].
A strategy to complement the EPR effect and to improve
the tumor accumulation efficiency of nanoparticles is the
functionalization of the nanoparticle surface with cancer-­
targeting ligands. Cancer-targeting ligands are often specific
for factors that are unique or upregulated in cancer cells and
that are mostly involved in processes such as tumor progres­
sion, invasion, metastasis, and angiogenesis. In general,
these targeting ligands can be categorized in five main
classes: small molecules, peptides, protein domains, anti­
bodies, and nucleic-acid based aptamers. Examples of
cancer-­specific targeting ligands are folic acid (FA) (essen­
tial for DNA synthesis), cyclic arginine-glycine-aspartic acid
(cRGD) peptide (a cell adhesion motif with a high affinity
for αβ-integrins), and targeting ligands that can bind to mem­
brane receptors, such as EGFR or VEGFR. Thanks to the
large surface area-to-volume ratio of nanoparticles, multiple
targeting molecules can be conjugated to the nanoparticles,
which enables multivalent interaction with membrane recep­
tors, increasing the tumor uptake and the intratumoral reten­
tion time."
"Describe the enhanced permeability and retention (EPR) effect in relation to nanoparticle accumulation within tumors, including its limitations and alternative mechanisms.","The enhanced permeability and retention (EPR) effect is a key mechanism driving nanoparticle accumulation within tumor tissues. It arises primarily due to the characteristics of vasculature formed during rapid tumor growth. Tumors stimulate angiogenesis – the formation of new blood vessels – which creates a network of abnormally leaky, immature, and poorly aligned vessels with defective endothelium. Nano-sized particles can readily exploit these gaps between endothelial cells to passively diffuse into the tumor microenvironment. Simultaneously, reduced lymphatic drainage within the tumor further contributes to nanoparticle retention. However, this EPR effect is not universally reliable. Its efficacy is limited by the heterogeneity of vascular structure across tumors – varying based on stage and tumor type – and the presence of active trans-endothelial transport pathways. Research indicates that nanoparticles can actively traverse endothelial barriers through mechanisms like receptor-mediated endocytosis, often more frequently than passive diffusion. Consequently, while the EPR effect remains a significant factor in preclinical models, its clinical translation for cancer nanomedicine is hampered by these limitations, necessitating strategies to complement it with targeted ligands and active transport pathways.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.3	 Application in Cancer Therapy | Content: which is discussed in more detail below.
6.10.2	Tumor Accumulation and Tumor
Targeting
In order to use nanoparticles in cancer remediation applica­
tions, nanoparticles need to reach and accumulate in the
tumor tissue. Rapidly growing tumors stimulate the forma­
tion of new blood vessels to supply the tumor cells with a
sufficient amount of oxygen and nutrients. The newly formed
tumor vasculature is usually characterized by the presence of
abnormal, leaky, and immature blood vessels, which are
poorly aligned with a defective endothelium. Consequently,
nano-sized particles can efficiently pass through inter-­
endothelial gaps and accumulate in the tumor. Furthermore,
the decreased level of lymphatic drainage promotes the
nanoparticle tumor retention. This “passive” process is
known as the enhanced permeability and retention (EPR)
effect. Importantly, the efficacy of the EPR effect is limited
due to the heterogeneity of the vascular structure within the
tumor, at different tumor stages and between different tumor
types. Furthermore, despite the success of the EPR effect in
preclinical tumor models, the efficacy and clinical transla­
tion of cancer nanomedicine remain poor, indicating that the
EPR effect is less reliable in human tumors. In fact, research
demonstrated that extravasation of nanoparticles into the
tumor via active trans-endothelial transport pathways occurs
more frequently than passive diffusion and thus should not
be underestimated [211].
A strategy to complement the EPR effect and to improve
the tumor accumulation efficiency of nanoparticles is the
functionalization of the nanoparticle surface with cancer-­
targeting ligands. Cancer-targeting ligands are often specific
for factors that are unique or upregulated in cancer cells and
that are mostly involved in processes such as tumor progres­
sion, invasion, metastasis, and angiogenesis. In general,
these targeting ligands can be categorized in five main
classes: small molecules, peptides, protein domains, anti­
bodies, and nucleic-acid based aptamers. Examples of
cancer-­specific targeting ligands are folic acid (FA) (essen­
tial for DNA synthesis), cyclic arginine-glycine-aspartic acid
(cRGD) peptide (a cell adhesion motif with a high affinity
for αβ-integrins), and targeting ligands that can bind to mem­
brane receptors, such as EGFR or VEGFR. Thanks to the
large surface area-to-volume ratio of nanoparticles, multiple
targeting molecules can be conjugated to the nanoparticles,
which enables multivalent interaction with membrane recep­
tors, increasing the tumor uptake and the intratumoral reten­
tion time.
6.10.3	Application in Cancer Therapy
Nanoparticles can be used as promising tools to enhance the
efficiency of multiple anticancer therapies, including the
delivery of chemotherapeutic drugs, hyperthermal therapy,
and RT.
6.10.3.1
Drug Delivery
The conventional chemotherapeutic treatment strategies
have certain drawbacks linked to the systemic administration
and nonspecific distribution of the drugs through the body.
This can, for instance, result in limited accessibility of the
drug to the tumor, requiring high therapeutic doses and caus­
ing off-target toxicity due to damage to healthy cells. Besides,
cancers can develop resistance to chemotherapeutic drugs,
which is an important factor in treatment failure.
Nanoparticles have the potential to improve these aspects by
acting as drug delivery systems (DDS). In fact, nanoparticles
can efficiently hold a massive payload of the drug, improv­
ing the solubility and stability of the drug in the blood circu­
lation. In addition, they enable targeted delivery of the drug
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"Describe the enhanced permeability and retention (EPR) effect and explain why its reliability as a mechanism for nanoparticle accumulation in tumors is questioned, citing specific factors that contribute to this uncertainty.","The enhanced permeability and retention (EPR) effect describes the passive accumulation of nanoparticles within tumor tissues. This phenomenon arises due to the structural heterogeneity of tumor vasculature – specifically, leaky blood vessels characteristic of many tumors – which allows nanoparticles, primarily those with a size range of 10-20 nm, to extravasate (leak out) from circulation. Once in the tumor microenvironment, the impaired lymphatic drainage and reduced endothelial contractility lead to their retention within the tumor tissue. However, the EPR effect’s reliability is increasingly questioned due to several factors. Firstly, tumor heterogeneity – variations in vascular structure between different tumors and even within a single tumor – means that not all tumors exhibit sufficient leaky vasculature for effective nanoparticle accumulation. Secondly, active trans-endothelial transport pathways, involving mechanisms like receptor-mediated endocytosis, are frequently more significant than passive diffusion in extravasation, particularly in advanced tumors. This indicates that nanoparticles can be actively taken up by cells rather than simply leaking out. Finally, preclinical studies often utilize tumor models with highly permeable vasculature, which doesn’t always translate to the same degree of retention in human tumors due to differences in vascular biology and tumor characteristics. Reference: [MolecularRadiationBiology, Section 6.10.3.1 Application in Cancer Therapy] ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.3	 Application in Cancer Therapy | Sub-sub-subsection: 6.10.3.1	 Drug Delivery | Content: nanoparticle tumor retention. This “passive” process is
known as the enhanced permeability and retention (EPR)
effect. Importantly, the efficacy of the EPR effect is limited
due to the heterogeneity of the vascular structure within the
tumor, at different tumor stages and between different tumor
types. Furthermore, despite the success of the EPR effect in
preclinical tumor models, the efficacy and clinical transla­
tion of cancer nanomedicine remain poor, indicating that the
EPR effect is less reliable in human tumors. In fact, research
demonstrated that extravasation of nanoparticles into the
tumor via active trans-endothelial transport pathways occurs
more frequently than passive diffusion and thus should not
be underestimated [211].
A strategy to complement the EPR effect and to improve
the tumor accumulation efficiency of nanoparticles is the
functionalization of the nanoparticle surface with cancer-­
targeting ligands. Cancer-targeting ligands are often specific
for factors that are unique or upregulated in cancer cells and
that are mostly involved in processes such as tumor progres­
sion, invasion, metastasis, and angiogenesis. In general,
these targeting ligands can be categorized in five main
classes: small molecules, peptides, protein domains, anti­
bodies, and nucleic-acid based aptamers. Examples of
cancer-­specific targeting ligands are folic acid (FA) (essen­
tial for DNA synthesis), cyclic arginine-glycine-aspartic acid
(cRGD) peptide (a cell adhesion motif with a high affinity
for αβ-integrins), and targeting ligands that can bind to mem­
brane receptors, such as EGFR or VEGFR. Thanks to the
large surface area-to-volume ratio of nanoparticles, multiple
targeting molecules can be conjugated to the nanoparticles,
which enables multivalent interaction with membrane recep­
tors, increasing the tumor uptake and the intratumoral reten­
tion time.
6.10.3	Application in Cancer Therapy
Nanoparticles can be used as promising tools to enhance the
efficiency of multiple anticancer therapies, including the
delivery of chemotherapeutic drugs, hyperthermal therapy,
and RT.
6.10.3.1
Drug Delivery
The conventional chemotherapeutic treatment strategies
have certain drawbacks linked to the systemic administration
and nonspecific distribution of the drugs through the body.
This can, for instance, result in limited accessibility of the
drug to the tumor, requiring high therapeutic doses and caus­
ing off-target toxicity due to damage to healthy cells. Besides,
cancers can develop resistance to chemotherapeutic drugs,
which is an important factor in treatment failure.
Nanoparticles have the potential to improve these aspects by
acting as drug delivery systems (DDS). In fact, nanoparticles
can efficiently hold a massive payload of the drug, improv­
ing the solubility and stability of the drug in the blood circu­
lation. In addition, they enable targeted delivery of the drug
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
374
to the tumor sites and promote transport across membranes.
Altogether, nanoparticle-based drug delivery has the poten­
tial to enhance the efficacy of the chemotherapeutic treat­
ment, while minimizing the side effects. Furthermore, in
order to counteract multidrug resistance, nanoparticles can
be used to deliver multiple therapeutic agents, including
chemo-sensitizers, small interfering RNA, microRNA,
enhancing antitumor effects.
Therapeutic agents can typically be loaded on nanoparti­
cles through physical packaging, covalent binding, or electro­
static complexation. Lipid-based nanoparticles, such as
liposomes, consisting out of a double lipid layer are the most
popular structures in nanoparticle-based drug delivery thanks
to their excellent biocompatibility and biodegradability.
Furthermore, they can transport both hydrophilic and hydro­
phobic drugs, encapsulated in the aqueous core and the bilayer
membrane, respectively. Other organic nanoplatforms used for
drug delivery include polymers, micelles, and dendrimers. On
the other hand, inorganic nanoparticles such as carbon-based
nanotubes, gold nanoparticles, silica nanoparticles, and iron
oxide nanoparticles are also used as drug delivery systems
because of their advanced multi-­functionality, excellent stabil­
ity, high drug payload, and unique surface properties.
To improve the precision of drug delivery, it is possible to
engineer a cancer-targeted, stimulus-sensitive DDS, which
releases the drug at the tumor site in a controlled and sus­
tained manner upon encountering an endogenous or exoge­
nous trigger, without affecting the regions near the tumor
site. The tumor microenvironment features conditions that
substantially differ from those in normal tissues, such as an
acidic pH, high enzyme levels of matrix metalloproteinases
(MMPs) and proteases, hypoxia, metabolic shift to anaerobic
glycolysis, and a high redox activity. These endogenous
stimuli can induce nanoparticle degradation and subsequent
drug release. The development of nanocarriers sensitive for
exogenous stimuli such as near infrared light, heat or sound
waves enables an “on-demand” drug delivery that is tightly
controlled from outside the body [212].
6.10.3.2
Nanoparticle-Mediated Hyperthermal
Therapy
As mentioned in a previous section, hyperthermia can help in
tumor control thanks to its tumor vasculature effect. Briefly,
hyperthermia triggers vasodilation. In healthy vasculature, it
helps to efficiently dissipate the heat and avoid tissue dam­
age. However, in the aberrant organization and structure of
tumor vasculature, it initially increases the blood flow and
oxygen supply to the tumor tissue until the heat accumulated
in the tissue reaches 42 °C triggering the collapse of tumor
blood vessels that promotes cancer cell death. Therefore, it is
important to localize hyperthermia to the tumor tissue while
avoiding prolonged exposure of healthy cells to elevated
temperatures.
Interestingly, the increase in tumor blood flow induced by
hyperthermia can be used to sensitize cancer cells and to
enhance the delivery of drugs improving the efficacy of che­
motherapy and RT, respectively. Nanoparticles have unique
properties, which enables them to efficiently convert incident
energy into heat. For instance, alternating magnetic fields
activate magnetic nanoparticles, such as iron oxide nanopar­
ticles, stimulating heat production. On the other hand, plas­
monic nanoparticles, such as gold nanoparticles, typically
hold a unique optical characteristic called the surface plas­
mon resonance (SPR). This phenomenon implies the interac­
tion of light of a specific wavelength with the free electrons
on the surface of the nanoparticle, resulting in the absorbance
and scattering of light, and the generation of heat [213].
Finally, carbon nanotubes absorb electromagnetic radiation
over an extremely broad frequency spectrum, ranging from
near infrared light to radiofrequency waves. The absorbance
of electromagnetic energy induces electron excitation and
relaxation within the nanoparticle, causing heat production.
The ability to target and accumulate nanoparticles in the
tumor tissue allows the nanoparticle-mediated heat genera­
tion to be localized at the tumor site.
6.10.3.3
Radiosensitization
In 2004, it was demonstrated that gold nano-objects injected
in tumors can enhance the effect of radiation by improving
tumor control in mice treated with kilovoltage X-rays. Since
this pioneering work, extensive experimental validations
were performed evidencing the potential of a large series of
metal-based nanoparticles as radiosensitizer at preclinical
level. However, the mechanism(s) of action, a complex mix­
ture between physical, chemical, and biological contribu­
tions is still under debate [214]. Physical contribution resides
in their ability to increase the dose deposited (radioenhance­
ment effect) via the emission of secondary Auger and photo­
electrons following the interaction with IR. The capacity of
nanoparticles to increase radiolysis processes leading to a
higher oxidative stress in cellular systems constitutes a
chemical contribution to the mechanism of action. Finally,
the biological effect is based on cell detoxification and DNA
repair system impairment, enabling to potentiate the effect of
irradiation (radiosensitization effect) [215, 216].
6.10.4	Theranostics and Combination Therapy
(Clinical Potential)
Researchers designed complex and multimodal nanoplat­
forms enabling the simultaneous use of nano-objects for
diagnostic and therapeutic applications. These nano-objects
are called “theranostics” agents. They enable a non-invasive
and real-time tracking of the in vivo nanomaterial distribu­
tion and facilitate the dose and toxicity management, as dis­
V. Ahire et al."
"Nanoparticles employed in cancer therapy, such as iron oxide or gold nanoparticles, utilize various mechanisms to generate heat. Describe at least three distinct methods by which these particles convert incident energy into thermal energy and explain the underlying physical principles involved.","Several nanoparticle types leverage unique properties to induce hyperthermia within tumor tissues. First, alternating magnetic fields are frequently used with magnetic nanoparticles like iron oxide. The oscillating field induces rapid magnetization cycles in the nanoparticles, leading to frictional heating as the magnetic moments attempt to align – a process analogous to stirring a pot of oil on a stove. Second, plasmonic nanoparticles, particularly gold nanoparticles, exploit surface plasmon resonance (SPR). When light at a specific wavelength interacts with these particles, it excites collective oscillations of electrons on their surfaces, resulting in significant heat generation due to the energy lost as radiative heat. Third, carbon nanotubes demonstrate broad-spectrum electromagnetic absorption across a wide frequency range – from near-infrared light to radiofrequency waves. This extensive absorption causes electron excitation and subsequent relaxation within the nanotube structure, generating substantial heat through this process. Each method relies on distinct physical phenomena—magneto-mechanical friction, radiative energy transfer via SPR, and broad-spectrum electromagnetic absorption—to efficiently convert incident energy into thermal energy at the tumor site. ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.3	 Application in Cancer Therapy | Sub-sub-subsection: 6.10.3.2	 Nanoparticle-Mediated Hyperthermal Therapy | Content: blood vessels that promotes cancer cell death. Therefore, it is
important to localize hyperthermia to the tumor tissue while
avoiding prolonged exposure of healthy cells to elevated
temperatures.
Interestingly, the increase in tumor blood flow induced by
hyperthermia can be used to sensitize cancer cells and to
enhance the delivery of drugs improving the efficacy of che­
motherapy and RT, respectively. Nanoparticles have unique
properties, which enables them to efficiently convert incident
energy into heat. For instance, alternating magnetic fields
activate magnetic nanoparticles, such as iron oxide nanopar­
ticles, stimulating heat production. On the other hand, plas­
monic nanoparticles, such as gold nanoparticles, typically
hold a unique optical characteristic called the surface plas­
mon resonance (SPR). This phenomenon implies the interac­
tion of light of a specific wavelength with the free electrons
on the surface of the nanoparticle, resulting in the absorbance
and scattering of light, and the generation of heat [213].
Finally, carbon nanotubes absorb electromagnetic radiation
over an extremely broad frequency spectrum, ranging from
near infrared light to radiofrequency waves. The absorbance
of electromagnetic energy induces electron excitation and
relaxation within the nanoparticle, causing heat production.
The ability to target and accumulate nanoparticles in the
tumor tissue allows the nanoparticle-mediated heat genera­
tion to be localized at the tumor site.
6.10.3.3
Radiosensitization
In 2004, it was demonstrated that gold nano-objects injected
in tumors can enhance the effect of radiation by improving
tumor control in mice treated with kilovoltage X-rays. Since
this pioneering work, extensive experimental validations
were performed evidencing the potential of a large series of
metal-based nanoparticles as radiosensitizer at preclinical
level. However, the mechanism(s) of action, a complex mix­
ture between physical, chemical, and biological contribu­
tions is still under debate [214]. Physical contribution resides
in their ability to increase the dose deposited (radioenhance­
ment effect) via the emission of secondary Auger and photo­
electrons following the interaction with IR. The capacity of
nanoparticles to increase radiolysis processes leading to a
higher oxidative stress in cellular systems constitutes a
chemical contribution to the mechanism of action. Finally,
the biological effect is based on cell detoxification and DNA
repair system impairment, enabling to potentiate the effect of
irradiation (radiosensitization effect) [215, 216].
6.10.4	Theranostics and Combination Therapy
(Clinical Potential)
Researchers designed complex and multimodal nanoplat­
forms enabling the simultaneous use of nano-objects for
diagnostic and therapeutic applications. These nano-objects
are called “theranostics” agents. They enable a non-invasive
and real-time tracking of the in vivo nanomaterial distribu­
tion and facilitate the dose and toxicity management, as dis­
V. Ahire et al."
"Hyperthermia induced by nanoparticles in cancer therapy can enhance chemotherapy and radiotherapy efficacy. Describe the multifaceted mechanisms through which nanoparticle-mediated hyperthermia contributes to radiosensitization, detailing both physical and biological contributions.","Nanoparticle-induced hyperthermia represents a sophisticated approach to enhancing cancer treatment outcomes by leveraging the increased blood flow stimulated within tumors. This effect operates via several interconnected mechanisms contributing to radiosensitization. Physically, nanoparticles like iron oxide or gold demonstrate ‘radioenhancement’ – they amplify radiation damage through the emission of secondary particles (Auger electrons and photoelectrons) following initial irradiation. These emitted particles deposit additional energy within the tumor tissue, effectively increasing the delivered dose. Furthermore, nanoparticles can accelerate radiolysis processes, boosting oxidative stress within cells, a key factor in DNA damage. Chemically, the increased radiolysis contributes to heightened cellular degradation. Biologically, the mechanism is complex and involves nanoparticle interaction with cell detoxification pathways and DNA repair systems. Specifically, nanoparticles can impair these systems, preventing cancer cells from efficiently repairing radiation-induced DNA damage. This impairment potentiates the cytotoxic effects of irradiation, leading to radiosensitization. The cumulative effect of these physical and chemical processes ultimately enhances the sensitivity of tumor cells to radiation while simultaneously improving drug delivery through increased vascular permeability.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.3	 Application in Cancer Therapy | Sub-sub-subsection: 6.10.3.3	 Radiosensitization | Content: blood vessels that promotes cancer cell death. Therefore, it is
important to localize hyperthermia to the tumor tissue while
avoiding prolonged exposure of healthy cells to elevated
temperatures.
Interestingly, the increase in tumor blood flow induced by
hyperthermia can be used to sensitize cancer cells and to
enhance the delivery of drugs improving the efficacy of che­
motherapy and RT, respectively. Nanoparticles have unique
properties, which enables them to efficiently convert incident
energy into heat. For instance, alternating magnetic fields
activate magnetic nanoparticles, such as iron oxide nanopar­
ticles, stimulating heat production. On the other hand, plas­
monic nanoparticles, such as gold nanoparticles, typically
hold a unique optical characteristic called the surface plas­
mon resonance (SPR). This phenomenon implies the interac­
tion of light of a specific wavelength with the free electrons
on the surface of the nanoparticle, resulting in the absorbance
and scattering of light, and the generation of heat [213].
Finally, carbon nanotubes absorb electromagnetic radiation
over an extremely broad frequency spectrum, ranging from
near infrared light to radiofrequency waves. The absorbance
of electromagnetic energy induces electron excitation and
relaxation within the nanoparticle, causing heat production.
The ability to target and accumulate nanoparticles in the
tumor tissue allows the nanoparticle-mediated heat genera­
tion to be localized at the tumor site.
6.10.3.3
Radiosensitization
In 2004, it was demonstrated that gold nano-objects injected
in tumors can enhance the effect of radiation by improving
tumor control in mice treated with kilovoltage X-rays. Since
this pioneering work, extensive experimental validations
were performed evidencing the potential of a large series of
metal-based nanoparticles as radiosensitizer at preclinical
level. However, the mechanism(s) of action, a complex mix­
ture between physical, chemical, and biological contribu­
tions is still under debate [214]. Physical contribution resides
in their ability to increase the dose deposited (radioenhance­
ment effect) via the emission of secondary Auger and photo­
electrons following the interaction with IR. The capacity of
nanoparticles to increase radiolysis processes leading to a
higher oxidative stress in cellular systems constitutes a
chemical contribution to the mechanism of action. Finally,
the biological effect is based on cell detoxification and DNA
repair system impairment, enabling to potentiate the effect of
irradiation (radiosensitization effect) [215, 216].
6.10.4	Theranostics and Combination Therapy
(Clinical Potential)
Researchers designed complex and multimodal nanoplat­
forms enabling the simultaneous use of nano-objects for
diagnostic and therapeutic applications. These nano-objects
are called “theranostics” agents. They enable a non-invasive
and real-time tracking of the in vivo nanomaterial distribu­
tion and facilitate the dose and toxicity management, as dis­
V. Ahire et al."
"Hyperthermia induced by nanoparticle activation, particularly utilizing alternating magnetic fields or plasmonic nanoparticles, demonstrates a potential therapeutic benefit in cancer treatment. Detail the multifaceted mechanisms through which this approach enhances chemotherapy and radiotherapy efficacy.","The utilization of nanoparticles to induce hyperthermia represents a sophisticated strategy for enhancing both chemotherapy and radiotherapy outcomes in cancer treatment. This enhancement stems from several interconnected mechanisms. Firstly, the activation of magnetic nanoparticles via alternating magnetic fields generates heat through Joule heating – essentially, the flow of electrical current within the particles due to the changing magnetic field. Secondly, plasmonic nanoparticles, such as gold nanoparticles, leverage surface plasmon resonance (SPR). When illuminated with light at a specific wavelength, electrons on the nanoparticle’s surface oscillate collectively, leading to energy absorption and subsequent heat generation. Critically, hyperthermia itself sensitizes cancer cells by increasing tumor blood flow. This increased vascular permeability facilitates drug delivery directly to the tumor site, amplifying the effects of chemotherapy agents like doxorubicin when nanoparticles are coupled with these drugs. Furthermore, the elevated temperatures induce radiolysis – the breakdown of water molecules into highly reactive hydroxyl radicals – significantly boosting oxidative stress within cancer cells. This heightened oxidative stress impairs DNA repair mechanisms and exacerbates cellular damage, thereby potentiating the cytotoxic effects of radiation therapy. Finally, metal-based nanoparticles, such as gold nano-objects, contribute to radiosensitization through both physical and chemical pathways. Physically, they enhance dose deposition via secondary electron emission following irradiation, increasing the energy delivered to the tumor. Chemically, they promote radiolysis processes, further amplifying oxidative stress. The targeted accumulation of these nanoparticles within tumors, facilitated by their unique properties, ensures that the heat generation and associated therapeutic effects are precisely localized at the cancer site, minimizing damage to surrounding healthy tissues. Reference: [6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities > subsection: 6.10.4 Theranostics and Combination Therapy (Clinical Potential)]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.4	 Theranostics and Combination Therapy (Clinical Potential) | Content: blood vessels that promotes cancer cell death. Therefore, it is
important to localize hyperthermia to the tumor tissue while
avoiding prolonged exposure of healthy cells to elevated
temperatures.
Interestingly, the increase in tumor blood flow induced by
hyperthermia can be used to sensitize cancer cells and to
enhance the delivery of drugs improving the efficacy of che­
motherapy and RT, respectively. Nanoparticles have unique
properties, which enables them to efficiently convert incident
energy into heat. For instance, alternating magnetic fields
activate magnetic nanoparticles, such as iron oxide nanopar­
ticles, stimulating heat production. On the other hand, plas­
monic nanoparticles, such as gold nanoparticles, typically
hold a unique optical characteristic called the surface plas­
mon resonance (SPR). This phenomenon implies the interac­
tion of light of a specific wavelength with the free electrons
on the surface of the nanoparticle, resulting in the absorbance
and scattering of light, and the generation of heat [213].
Finally, carbon nanotubes absorb electromagnetic radiation
over an extremely broad frequency spectrum, ranging from
near infrared light to radiofrequency waves. The absorbance
of electromagnetic energy induces electron excitation and
relaxation within the nanoparticle, causing heat production.
The ability to target and accumulate nanoparticles in the
tumor tissue allows the nanoparticle-mediated heat genera­
tion to be localized at the tumor site.
6.10.3.3
Radiosensitization
In 2004, it was demonstrated that gold nano-objects injected
in tumors can enhance the effect of radiation by improving
tumor control in mice treated with kilovoltage X-rays. Since
this pioneering work, extensive experimental validations
were performed evidencing the potential of a large series of
metal-based nanoparticles as radiosensitizer at preclinical
level. However, the mechanism(s) of action, a complex mix­
ture between physical, chemical, and biological contribu­
tions is still under debate [214]. Physical contribution resides
in their ability to increase the dose deposited (radioenhance­
ment effect) via the emission of secondary Auger and photo­
electrons following the interaction with IR. The capacity of
nanoparticles to increase radiolysis processes leading to a
higher oxidative stress in cellular systems constitutes a
chemical contribution to the mechanism of action. Finally,
the biological effect is based on cell detoxification and DNA
repair system impairment, enabling to potentiate the effect of
irradiation (radiosensitization effect) [215, 216].
6.10.4	Theranostics and Combination Therapy
(Clinical Potential)
Researchers designed complex and multimodal nanoplat­
forms enabling the simultaneous use of nano-objects for
diagnostic and therapeutic applications. These nano-objects
are called “theranostics” agents. They enable a non-invasive
and real-time tracking of the in vivo nanomaterial distribu­
tion and facilitate the dose and toxicity management, as dis­
V. Ahire et al.
375
cussed previously, fine-tuning the patient-specific treatment
protocol [217]. Superparamagnetic iron oxide nanoparticles
(SPIONs) is one interesting example of theranostic agent.
While it has been used for years as contrast agents in MRI,
enabling to increase the quality of images used for diagnos­
tics (with higher spatial resolution), these nanoparticles have
recently shown radiosensitizing properties. The presence of
these nano-objects within the tumor allows to better define
the area to treat and to increase the efficiency of the treat­
ment. These SPIONs can also be coupled to chemotherapeu­
tic drugs, such as doxorubicin, further increasing their
therapeutic impact."
"The development of nanoparticle-based cancer therapies faces significant hurdles, primarily related to manufacturing and toxicity assessment. Describe two key challenges associated with scaling up nanoparticle production for clinical trials, referencing the specific requirements for quality control and long-term safety evaluation.","Large-scale manufacture of nanoparticles presents a major challenge due to the complexity of Good Manufacturing Practices (GMP) compared to conventional drug formulations. Maintaining optimal parameters during scale-up is crucial for efficacy, requiring strict batch-to-batch reproducibility and stability during long-duration storage to ensure product quality at the time of clinical administration. Furthermore, extensive toxicity studies are necessary before human trials can commence. These preclinical in vivo studies demonstrate nanoparticle accumulation in organs like the liver and spleen over several months following intravenous injection, raising concerns about potential long-term toxicities.  These studies must adhere to Good Laboratory Practice (GLP) regulations, which involve time-consuming approaches to fully assess these risks and establish safe limits for clinical trials. Reference: [MolecularRadiationBiology, Section 6.10.5 – Challenges]","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.10	 Nanoparticles in Cancer Therapy | Sub-subsection: 6.10.5	 Challenges | Content: Currently, only a relatively small amount of nano-objects are
FDA approved for cancer treatment, since the translation
toward clinics is an expensive and time-consuming process
that is associated with two main challenges [218]:
•	Large-Scale Manufacture
To enable large clinical trials, drugs have to be pro­
duced on a large scale. The Good Manufacturing Practices
(GMP) of nanoparticle technology is characterized by a
high complexity compared to conventional formulation
technologies that usually contain free drug dispersed in a
given medium. Indeed, the efficacy of nano-objects is
determined by optimal parameters that should be pre­
served during the scaling-up process. Therefore, nanopar­
ticles have to be manufactured with proper quality
standards and with a strict batch-to-batch reproducibility
to ensure product specification. Finally, they have to be
stable during long-duration storage ensuring the product
quality at the time of clinical administration.
•	Extensive Toxicity Studies
Before a drug candidate can be tested in humans, its
safety profile must be proven in animal models. These
preliminary tests allow a thorough understanding of its
pharmacokinetics and toxicity as well as the establish­
ment of safe limits for further clinical trials.
Preclinical in vivo studies have demonstrated nano-
object accumulation in liver and spleen for several months
post intravenous injection, raising the question of long-
term toxicity for which time-consuming approaches are
needed. These toxicological studies are governed by spe­
cific rules and regulations of Good Laboratory Practice
(GLP), a quality system ensuring the uniformity, consis­
tency, reproducibility, and reliability of non-clinical
safety tests. Nevertheless, the current regulatory
approaches used for the toxicological assessment of con­
ventional drugs may not be appropriate to fully assess the
toxicity of nanomaterials requiring the development of
new specific approaches.
6.11
Second and Secondary Cancers
in Radiotherapy Patients
Although often used interchangeably, there is a fundamental
difference between second and secondary cancers. Second
cancer is a more general name for any tumor occurring in
patients who have been treated earlier for a first cancer, while
the development of a secondary cancer can be ascribed to the
treatment for the first cancer. This is not uncommon and
should be discussed as part of the process of taking informed
consent when explaining the treatment with chemotherapy or
RT.
The risk of developing a secondary malignancy following
RT depends on:
•	The organs irradiated
•	The age at treatment, with younger patients having an
increased risk compared to a teenager or adult
•	The total dose of radiation received
•	The time from treatment
•	The prior use of alkylating agent chemotherapy
•	Underlying genetic predisposition
The risk of developing a secondary tumor is cumula­
tive and increasing over time. However, as age increases,
the risk relative to the normal population decreases as
cancer becomes more common in the general population
as well.
Well-known examples are breast cancer, meningiomas,
thyroid cancer, and sarcomas. There is an increased risk of
development of breast cancer in girls treated for Hodgkin
lymphoma under 16 years of age, with a 20% cumulative
incidence of breast cancer by the age of 45 [219]. Girls
treated with whole lung RT for Wilms tumor are also at risk
of breast cancer. There is a well-documented increased inci­
dence of meningiomas associated with cranial RT, with
young age at time of RT and time from treatment associated
with higher risk. An excess of thyroid cancer and bone and
soft tissue sarcoma are also seen in relation to previous RT
[220].
There have been concerns about the “low-dose bath”
effect of modern RT techniques such as intensity modulated
radiotherapy or arc therapy (IMRT/IMAT) increasing the
risk of secondary cancers, compared with simple conformal
RT. However, IMRT results in greater conformality and
reduces the non-target high dose volume. This may offset the
increased volume of normal tissue receiving low-dose irra­
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities"
"Explain the distinction between ‘second cancer’ and ‘secondary cancer’ within the context of radiotherapy treatment for initial malignancies, detailing factors that influence their development.","The terms 'second cancer' and 'secondary cancer' represent different aspects of tumor development following prior cancer treatments. ‘Second cancer’ is a broader term referring to any new malignancy arising in a patient who has previously received treatment for a first cancer. Conversely, a ‘secondary cancer’ specifically arises as a direct consequence of the initial cancer treatment itself – meaning it develops due to the effects of that primary therapy. Several factors contribute to this risk, including: (1) The organs irradiated: Radiation exposure to specific tissues significantly elevates secondary cancer risk; (2) Age at treatment: Younger patients generally have a higher risk compared to older individuals, as their cells are more rapidly dividing and therefore more susceptible to damage; (3) Total radiation dose received: Higher doses of radiation correlate with increased risk; (4) Time from treatment: The risk is cumulative and increases over time following radiation exposure; (5) Prior use of alkylating agent chemotherapy: Alkylating agents, like cyclophosphamide, can predispose to secondary malignancies such as myelodysplasia or leukemia; and (6) Underlying genetic predisposition: Certain inherited syndromes, such as retinoblastoma, Li–Fraumeni syndrome, or neurofibromatosis type 1 (NF1), markedly increase the risk of developing both second and secondary cancers. Furthermore, the specific initial cancer treated also plays a role – for example, treatment for Hodgkin lymphoma is associated with an increased risk of breast cancer in young girls. It’s important to note that while the risk is cumulative, modern techniques like IMRT/IMAT may reduce this risk due to improved conformality and reduced high-dose volume, although concerns remain regarding potential effects on low-dose radiation exposure and subsequent secondary leukemia development.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.11	 Second and Secondary Cancers in Radiotherapy Patients | Content: new specific approaches.
6.11
Second and Secondary Cancers
in Radiotherapy Patients
Although often used interchangeably, there is a fundamental
difference between second and secondary cancers. Second
cancer is a more general name for any tumor occurring in
patients who have been treated earlier for a first cancer, while
the development of a secondary cancer can be ascribed to the
treatment for the first cancer. This is not uncommon and
should be discussed as part of the process of taking informed
consent when explaining the treatment with chemotherapy or
RT.
The risk of developing a secondary malignancy following
RT depends on:
•	The organs irradiated
•	The age at treatment, with younger patients having an
increased risk compared to a teenager or adult
•	The total dose of radiation received
•	The time from treatment
•	The prior use of alkylating agent chemotherapy
•	Underlying genetic predisposition
The risk of developing a secondary tumor is cumula­
tive and increasing over time. However, as age increases,
the risk relative to the normal population decreases as
cancer becomes more common in the general population
as well.
Well-known examples are breast cancer, meningiomas,
thyroid cancer, and sarcomas. There is an increased risk of
development of breast cancer in girls treated for Hodgkin
lymphoma under 16 years of age, with a 20% cumulative
incidence of breast cancer by the age of 45 [219]. Girls
treated with whole lung RT for Wilms tumor are also at risk
of breast cancer. There is a well-documented increased inci­
dence of meningiomas associated with cranial RT, with
young age at time of RT and time from treatment associated
with higher risk. An excess of thyroid cancer and bone and
soft tissue sarcoma are also seen in relation to previous RT
[220].
There have been concerns about the “low-dose bath”
effect of modern RT techniques such as intensity modulated
radiotherapy or arc therapy (IMRT/IMAT) increasing the
risk of secondary cancers, compared with simple conformal
RT. However, IMRT results in greater conformality and
reduces the non-target high dose volume. This may offset the
increased volume of normal tissue receiving low-dose irra­
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
376
diation. As of today, the feared increase in secondary cancers
has not been proven. A major advantage of proton beam RT
is the expected reduced risk of secondary malignancy.
Molecular RT may lead to an increased risk of secondary
leukemias and cancers, both from the general effects of irra­
diation of the whole body, and from organ-specific dose, e.g.,
thyroid
uptake
of
free
radioiodine
in
meta-­
iodobenzylguanidine (mIBG) therapy, despite the use of thy­
roid blockade.
RT is not alone in causing cancer. Chemotherapy, particu­
larly alkylating agents, may predispose to the development
of myelodysplasia, secondary leukemias, and other malig­
nancies. Chemotherapy and RT may be synergistic in this
regard.
Predisposing genetic factors such as retinoblastoma, Li–
Fraumeni syndrome, or neurofibromatosis type 1 (NF1) also
increase the risk of induction of secondary, but also second,
malignancies.
The risk is also related to the underlying cancer, with an
increase seen after treatment for Hodgkin lymphoma and
sarcoma.
Finally, lifestyle factors contribute to the risk, hence the
importance of emphasizing healthy living choices, for exam­
ple, smoking cessation, normal body weight, and good intake
of fruit and vegetables, in survivors to try to mitigate this
where possible.
6.12"
"The concept of hyperfractionation in radiation therapy, particularly as applied to Continuous Hyperfractionated Accelerated RadioTherapy (CHART), is predicated on the idea that delivering multiple smaller doses of radiation over a shorter period can achieve equivalent biological effects compared to fewer, larger doses. Explain the underlying rationale for this approach, detailing specifically how it relates to DNA repair mechanisms and why reduced overall treatment time alongside improved normal tissue sparing are considered beneficial outcomes.","Hyperfractionation’s effectiveness stems from the understanding that cells possess various DNA repair pathways designed to mitigate the damaging effects of radiation. Conventional fractionation utilizes large doses delivered over a single day, providing limited opportunity for these repair mechanisms to fully restore genomic integrity before the next high-dose fraction is administered. Consequently, significant sublethal damage accumulates within the cell’s nucleus. CHART dramatically increases the number of fractions – often delivering multiple low-dose fractions daily – thereby continuously stimulating DNA repair processes. This sustained activation of repair pathways effectively prevents the accumulation of irreparable DNA damage. Furthermore, by spreading the total dose over a longer period, the average dose per fraction is reduced, minimizing the radiation exposure to surrounding normal tissues that are less actively involved in repair mechanisms. The shorter overall treatment time also contributes to improved patient comfort and reduces potential side effects. Reference: [MolecularRadiationBiology, Section 6.12 – Exercises and Self-Assessment] ","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.12	 Exercises and Self-Assessment | Content: Q1.	Which
statement
is
true?
The
Continuous
Hyperfractionated
Accelerated
RadioTherapy
(CHART) irradiation protocol is characterized by:
(a)	A fraction size <2 Gy.
(b)	Reduced overall treatment time compared with
conventional fractionation.
(c)	Irradiation is continued during the weekend.
(d)	a, b, and c are all correct.
Q2.	Why is hyperfractionation potentially beneficial when
it comes to late normal tissue sparing relative to con­
ventional fractionation?
(a)	The α/β ratio is high.
(b)	The repair of sublethal damage is very effective.
(c)	The fraction size <2 Gy.
(d)	The number of fractions is larger.
Q3.	On the basis of radiobiological aspects, what would be
the optimal number of fractions in a hypofractionated
treatment regimen?
Q4.	Which of the following is not true about Stereotactic
Body Radiation Therapy (SBRT)
(a)	In SBRT a high dose per fraction is used.
(b)	SBRT has high conformality.
(c)	SBRT has a large margin for the beam penumbra.
(d)	In SBRT image guidance is required for geometric
verification of targets.
Q5.	Please indicate which of the following statements is
wrong when it comes to the SBRT treatment
planning.
(a)	The dose is prescribed to lower isodose lines.
(b)	A homogeneous dose distribution is seen.
(c)	There is a sharp dose falloff outside target
volume.
(d)	An isotropic grid size of 2 mm or finer is recom­
mended for dose calculation.
Q6.	Below are some statements related to how targeted
therapy may sensitize tumors to radiation therapy
(RT). Please indicate which statements are correct or
wrong:
(a)	Inhibition of the DNA repair enzyme PARP1 with
small molecules is a possible RT sensitizer for all
types of tumors.
(b)	To increase the function of Bcl-2 is a RT sensitiz­
ing strategy.
(c)	Inhibitors toward EGFR is a promising RT sensi­
bilization option for some tumors.
(d)	Reverting hypoxia is a way for RT sensitization.
Q7.	Please name a key reason why RT can be combined
with some immune therapies?
Q8.	Hyperthermia has been shown to increase the effect of
radiation therapy. Describe a DNA repair pathway that
hyperthermia can inhibit.
Q9.	Name an advantage and a disadvantage of photon
spatially fractionated radiation therapy (SFRT),
proton minibeam radiotherapy (pMBRT) and ion
MBRT?
Q10.	Give an example of a vectorized radiopharmaceutical
used in the clinic and outline how it works.
Q11.	Helium ions are good candidates in RT of tumors.
What makes them good candidates?
(a)	Helium ions produce more secondary neutrons
compared to protons.
(b)	Helium ions produce more nuclear fragments
compared to carbon ions.
(c)	Helium ions have higher radiobiological effect
(RBE) compared to protons.
(d)	Helium ions have lower oxygen enhancement
ratio (OER) compared to protons.
6.13"
"Hyperfractionated radiotherapy (FLEX) utilizes a smaller fraction size compared to conventional fractionation, and this approach is believed to enhance tumor control primarily due to what biological mechanism?","Hyperfractionated radiotherapy’s effectiveness stems from the increased opportunity for DNA repair. By delivering multiple fractions with varying dose distributions over time, cells are exposed to sublethal radiation damage repeatedly. This repeated exposure stimulates more frequent and robust DNA repair processes – particularly homologous recombination – which, if not completely resolved between fractions, contribute significantly to cell death during subsequent irradiation cycles. Reference: Brock Biology of Microorganisms, Section 6.4 – Radiation Damage and Repair.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: 6.13	 Exercise Solutions | Content: Q2.	Why is hyperfractionation potentially beneficial when
it comes to late normal tissue sparing relative to con­
ventional fractionation?
(a)	The α/β ratio is high.
(b)	The repair of sublethal damage is very effective.
(c)	The fraction size <2 Gy.
(d)	The number of fractions is larger.
Q3.	On the basis of radiobiological aspects, what would be
the optimal number of fractions in a hypofractionated
treatment regimen?
Q4.	Which of the following is not true about Stereotactic
Body Radiation Therapy (SBRT)
(a)	In SBRT a high dose per fraction is used.
(b)	SBRT has high conformality.
(c)	SBRT has a large margin for the beam penumbra.
(d)	In SBRT image guidance is required for geometric
verification of targets.
Q5.	Please indicate which of the following statements is
wrong when it comes to the SBRT treatment
planning.
(a)	The dose is prescribed to lower isodose lines.
(b)	A homogeneous dose distribution is seen.
(c)	There is a sharp dose falloff outside target
volume.
(d)	An isotropic grid size of 2 mm or finer is recom­
mended for dose calculation.
Q6.	Below are some statements related to how targeted
therapy may sensitize tumors to radiation therapy
(RT). Please indicate which statements are correct or
wrong:
(a)	Inhibition of the DNA repair enzyme PARP1 with
small molecules is a possible RT sensitizer for all
types of tumors.
(b)	To increase the function of Bcl-2 is a RT sensitiz­
ing strategy.
(c)	Inhibitors toward EGFR is a promising RT sensi­
bilization option for some tumors.
(d)	Reverting hypoxia is a way for RT sensitization.
Q7.	Please name a key reason why RT can be combined
with some immune therapies?
Q8.	Hyperthermia has been shown to increase the effect of
radiation therapy. Describe a DNA repair pathway that
hyperthermia can inhibit.
Q9.	Name an advantage and a disadvantage of photon
spatially fractionated radiation therapy (SFRT),
proton minibeam radiotherapy (pMBRT) and ion
MBRT?
Q10.	Give an example of a vectorized radiopharmaceutical
used in the clinic and outline how it works.
Q11.	Helium ions are good candidates in RT of tumors.
What makes them good candidates?
(a)	Helium ions produce more secondary neutrons
compared to protons.
(b)	Helium ions produce more nuclear fragments
compared to carbon ions.
(c)	Helium ions have higher radiobiological effect
(RBE) compared to protons.
(d)	Helium ions have lower oxygen enhancement
ratio (OER) compared to protons.
6.13
Exercise Solutions
SQ1.	Alternative (d). All statements (a, b, c) about the
CHART irradiation protocol are correct. It involves a
fraction size of <2 Gy and treatments are given dur­
V. Ahire et al.
377
ing weekends giving a reduced treatment time com­
pared to a conventional fractionation scheme.
SQ2.	Alternative (c). The fraction size <2 Gy.
SQ3.	Taking the normal tissue dose-volume constraints into
account and considering, e.g., the kinetics of reoxy­
genation, the activation of the immune system and the
abscopal effect, a number of six to eight medium sized
fractions spaced 72 h might be optimal regarding
tumor control. However, this is still a point of debate.
SQ4.	Alternative (c). In SBRT, small or no margin is given
for beam penumbra to improve sharp dose falloff.
SQ5.	Alternative (b). SBRT treatment plans have a heter­
ogenous dose distribution.
SQ6.	(a). The statement is wrong. PARP1 is primarily a
target in tumors that have mutations in BRCA1/BRAC2
or have a “BRACAness” phenotype. Such tumors
lack functional DNA repair via HR and hence block­
ing PARP can impair repair of RT-induced DNA
DSB. This is called synthetic lethality. PARP inhibi­
tion can also be applied for tumors with impairment
in ATM or ATR. (b). The statement is wrong. Bcl-2 is
an anti-apoptotic protein. Its activity/expression
needs to be inhibited in order for RT to more promi­
nently trigger cell death. (c). The statement is correct.
EGFR inhibitors work in EGFR-mutant tumors, i.e.,
NSCLC or in tumors over-expressing EGFR. (d). The
statement is correct. Tumor hypoxia can be attacked
for RT sensitization purpose in several different
ways.
SQ7.	Since radiotherapy (RT) does exert both, immune
stimulatory and immune suppressive effects, immune
therapies aim to switch off the immune suppressive
effects of RT or to boost the immune activating ones
can be applied. This may result in effective local and
systemic antitumor immune responses.
SQ8.	Hyperthermia can temporarily downregulate the
BRCA2 protein, thereby blocking the homologous
recombination.
SQ9.
Photon SFRT
Proton MBRT
Ion MBRT
Advantage
Easy implementation
in clinic
Homogeneous tumor irradiation already
from one direction
(Almost) no widening on the way to the tumor
DisadvantageLow PVDR compared
to MBRT
Widening of the beams on the way to the
tumor
Technically challenging as interlacing necessary
for homogeneous tumor irradiation
SQ10.	Examples of vectorized radionuclide therapy are
177Lu-PSMA-617 for the treatment of prostate can­
cer, 177Lu-NeoB for the treatment of solid metastatic
tumors, 177Lu-DOTATATE for the treatment of neu­
roendocrine tumors, and 90Y-ibritumomab tiuxetan
(Zevalin®) for the treatment of CD20-positive Non-­
Hodgkin lymphoma. Brief description of the princi­
ple: A radiopharmaceutical comprises a targeting
moiety, which targets a specific molecule expressed
on certain cells, and a radionuclide, which emits
IR. By linking the targeting moiety to the radionu­
clide, molecules (e.g., somatostatin receptors,
PSMA, CD20, etc.) that are highly expressed on the
target tissue can be targeted to treat disease. Thus, the
targeting moiety ensures specific delivery of toxic IR
to the targeted cells which ensures treatment of the
tumor disease, while causing minimal damage to sur­
rounding healthy tissues.
SQ11.	Alternative (c). Helium ions have higher RBE com­
pared to protons.
6 Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities
378"
"The clinical trials detailed in this document primarily investigate the use of Boron Neutron Capture Therapy (BNCT) utilizing BPA as a carrier agent for treating various cancers. Describe the key findings observed across these trials regarding survival times and response rates, highlighting any notable variations based on cancer type or treatment protocol.","Across the presented clinical trials investigating BNCT with BPA as a carrier agent, significant variability in outcomes was observed depending on the specific cancer type and the employed treatment protocol. In newly diagnosed glioblastoma cases, Protocol P-01 demonstrated an overall 5-year survival rate of 61%, while subsequent protocols utilizing BPA showed no reported deaths in recurrent patients. For high-grade gliomas, interim analyses indicated median survival times of 23 months for glioblastoma and 25.9 months for anaplastic astrocytoma. Following BNCT with BSH or BPA, median survival times ranged from 15.6 to 23.5 months depending on the combination with external beam radiation therapy. In meningiomas, complete responses were observed in approximately 2/3 patients, and radiographic improvements were noted in the majority of available follow-up subjects. Across various cancer types including malignant melanoma and liver metastasis, response rates varied considerably – from 73% for melanoma to a 47% overall survival rate with BPA alone in recurrent head and neck cancers. Notably, trials utilizing BPA-F consistently demonstrated longer median survival times (10.8 months for all patients and 7 months for malignant gliomas) compared to the standard BPA agent, often accompanied by manageable toxicities.  Longer follow-up studies with BPA showed control rates of up to 88% at long-term follow-up, while trials using Borofalan in recurrent cases demonstrated a significantly higher two-year overall survival rate (58%) compared to other BNCT protocols. These diverse results underscore the complex interplay between tumor characteristics, treatment parameters, and patient response within the context of BNCT.","Document: MolecularRadiationBiology | Section: 6: Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities | Subsection: Appendix: Therapeutic BNCT Clinical Trials in the Last Two Decades | Content: Cancer subsite
First author and
year
Number of
cases
10B-carrier
agent
Results/comments
Glioblastoma (newly
diagnosed/recurrent)
Joensuu et al.
(2003) [221]
18
BPA
Protocol P-01: 1-year overall survival was 61% in newly
diagnosed glioblastoma.
3
BPA
Protocol P-03: No death reported in re-irradiated patients.
Capala et al. (2003)
[222]
17
BPA
Short follow-up, no severe acute toxicities.
Busse et al. (2003)
[223]
22
BPA-Fructose
(BPA-F)
2/22 patients had complete radiographic response while 13/17
evaluable subjects had measurable reduction in tumor volume.
Henriksson et al.
(2008) [224]
30
BPA-F
Median time to progression was 5.8 months and median survival
time was 14.2 months. 4/30 patients had grade 3–4 toxicities.
Kawabata et al.
(2011) [225]
21
BSH and BPA
Protocol 1—BNCT.
Protocol 2—BNCT followed by external beam RT.
Median survival time was 15.6 months overall and 23.5 months
in protocol 2.
Gliomas (high grade,
malignant/recurrent)
Yamamoto et al.
(2004) [226]
9
BSH
Interim analysis—median survival time was 23 months for
glioblastoma and 25.9 months for anaplastic astrocytoma.
Miyatake et al.
(2005) [227]
13
BPA
In 8/12 patients, >50% of contrast enhanced lesions
disappeared.
Miyatake et al.
(2009) [228]
22
BPA
Median survival for all patients was 10.8 months and high-risk
RPA classes was 9.1 months.
Kankaanranta et al.
(2011) [229]
22
BPA-F
Median survival time was 7 months in malignant gliomas that
recur after surgery and conventional radiotherapy.
Meningioma (high grade,
malignant/recurrent)
Miyatake et al.
(2007) [230]
7
BPA
18F-BPA-PET was taken before BNCT. 2/3 anaplastic
meningioma patients showed complete response. 6/7 patients
available for follow-up had radiographic improvements.
Kawabata et al.
(2013) [231]
20
BPA
Median survival time after BNCT was 14.1 months and after
diagnosis was 45.7 months.
Malignant melanoma
Fukuda et al.
(2003) [232]
22
BPA
Complete response was seen in 73% (16/22) and 3/22 patients
developed severe skin damage.
Menéndez et al.
(2009) [233]
7
BPA
69.3% overall response, 30.7% no change, and 30% grade 3
skin toxicities.
Hiratsuka et al.
(2020) [233]
8
BPA
6/8 patients had complete response. On long-term follow-up,
88% control rate (7/8) and no >grade 2 adverse events.
Liver metastasis
Koivunoro et al.
(2004) [233]
2
BPA
Liver extirpated, irradiated in a nuclear reactor, and reimplanted.
One patient survived for 3 years after the procedure.
Head and neck cancers
(recurrent/locally
advanced)
Kato et al. (2004)
[236]
6
BPA and BSH
46–100% reduction in tumor size with improved quality of life
and very mild side effects.
Kankaanranta et al.
(2007) [237]
16
BPA-F
Median duration of response was 12.1 months. At median
follow-up of 14 months, 33% (4/12) were alive. 2/12 had grade
3 toxicity.
Kato et al. (2009)
[238]
26
BPA
Response rate was 85%. Six-year overall rate was 24%.
Kankaanranta et al.
(2012) [238]
30
BPA
Two fractions of RT at 30-day interval. Tolerable early
toxicities.
Suzuki et al. (2014)
[240]
62
BSH and BPA
or BPA alone
Median survival time was 10.1 months. The overall survival rate
was 43.1% and 24.2% at 1-year and 2-year, respectively.
Aihara et al. (2014)
[241]
20
BPA
Complete remission seen in 11 patients and partial remission in
7 patients. No severe acute or chronic toxicity.
Wang et al. (2016)
[242]
17
BPA
Two-year overall survival was 47% and locoregional control
was 28%.
Koivunoro et al.
(2019) [243]
79
BPA
Two-year overall survival was 21% and locoregional
progression-free survival was 38%.
Hirose et al. (2021)
[244]
21
Borofalan
Two-year overall survival was 58% in recurrent cases and 100%
in locally advanced cases.
V. Ahire et al.
379"
"What does ‘radiosensitivity’ refer to according to the provided text, and what factors contribute to this sensitivity?","According to the text, ‘radiosensitivity’ refers to the proneness to radiation-induced adverse tissue events that are considered as non-cancer effects attributable to cell death. This primarily involves inflammation and other reactions like burns or dermatitis resulting from radiation-induced cell damage. Several factors contribute to this sensitivity including insufficient DNA repair due to defective signaling and/or mechanisms, genetic traits, hypoxia, cell cycle position, growth fraction, hormonal balance, immune system status, and various environmental factors. The text specifically highlights conditions like ataxia telangiectasia (AT) and Li Fraumeni’s syndrome as examples demonstrating varying levels of radiosensitivity based on underlying genetic predispositions.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Content: Mathematical and Physical Sciences, National Technical
University of Athens (NTUA), Athens, Greece
e-mail: Alexg@mail.ntua.gr
F. M. Lyng · J. F. Monaghan
Center for Radiation and Environmental Science, Technological
University Dublin, Dublin, Ireland
e-mail: fiona.lyng@TUDublin.ie; jade.monaghan@mytudublin.ie
A. D. Meade
School of Physics, Clinical & Optometric Sciences, Technological
University Dublin, Dublin, Ireland
e-mail: aidan.meade@TUDublin.ie
M. Milic
Mutagenesis Unit, Institute for Medical Research and
Occupational Health, Zagreb, Croatia
e-mail: mmilic@imi.hr
D. Mistry
Radiobiology Unit, Belgian Nuclear Research Centre, SCK CEN,
Mol, Belgium
A. Montoro
Radiological Protection Service, University and Polytechnic La Fe
Hospital of Valencia, Valencia, Spain
e-mail: montoro_ale@gva.es
G. I. Terzoudi · S. Triantopoulou
Health Physics, Radiobiology & Cytogenetics Laboratory, Institute
of Nuclear & Radiological Sciences & Technology, Energy &
Safety, National Centre for Scientific Research “Demokritos”,
Athens, Greece
e-mail: gterzoudi@rrp.demokritos.gr; iro@rrp.demokritos.gr
K. Viktorsson
Department of Oncology/Pathology, Karolinska Institutet,
Stockholm, Sweden
e-mail: Kristina.viktorsson@ki.se
G. Vogin
Centre Francois Baclesse, University of Luxembourg and
Luxembourg Institute of Health, Luxembour, Luxembourg
e-mail: Guillaume.vogin@baclesse.lu
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_7
388
Table 7.1 Summary of the terms—radiosensitivity, radiosusceptibil­
ity, and radioresistance
Radiosensitivity
Radiosensitivity refers to adverse healthy tissue
reactions like burns, dermatitis, rectitis, etc.,
that is, any reaction led by radiation-induced
cell death that may be generally accompanied
by inflammation.
Radiosensitivity also refers to the inherent
response of tumor/cancer cells to radiation
which can be measured by the reduction of the
volume, the extent of regression, rapidity of
response, and response durability that are also
linked to radiation-induced cell death.
The degree of radiosensitivity depends on the
combination of various genetic traits,
interaction with each other, ability to repair
damage, hypoxia, cell cycle position, growth
fraction, hormonal balance, immune system,
and various environmental factors.
The probable cause of radiosensitivity may be
an insufficient repair of the radiation-damaged
DNA generally due to defective DNA damage
signaling and/or repair mechanism.
RadiosusceptibilityThe proneness to radiation-induced cancers
generally linked to radiation-induced cell
transformation and mis-repaired DNA damage.
It is also an important issue for both low- and
high-dose radiation exposures to an
individual who exhibits higher cancer risk
spontaneously.
Differences in radiosusceptibility between
individuals, or groups, may relate to genetic
constitution, but also to other characteristics
such as age at exposure, health status and
comorbidity, epigenetic factors, lifestyle, and
co-exposures to other stressors.
Radiodegeneration
The term is to describe any aspects of IR
responses (non-cancer effects) attributable to
mechanisms related to accelerated aging.
Radioresistance
Radioresistance describes a normal response to
IR at any level; whether molecular, cellular,
tissular, and clinical.
In terms of radiosensitivity, radioresistance is
the synonym of absence of any adverse tissue
reactions and of a normal DNA damage repair
(rate and efficiency).
In terms of radiosusceptibility, radioresistance
is synonymous with a low risk of radiation-­
induced cancer.
In terms of radiodegeneration, radioresistance is
synonymous with a low risk of radiation-­
induced aging.
Learning Objectives
•	To understand the different responses of tumor and
normal tissues to ionizing radiation (IR) whether at
low or high dose.
•	To grasp the importance of radiation biomarkers of
exposure as well as effect and their integration with
molecular epidemiological studies.
•	To be able to discuss current and emerging bio­
marker methods to predict normal tissue and tumor
responses to radiotherapy (RT).
•	To understand how age and sex influence IR sensi­
tivity on cellular and individual levels as well as
health risks induced by IR exposure.
•	To grasp how genetic syndromes can be associated
with an increased radiation sensitivity and cancer
risk.
•	To understand the concept of precision medicine in
context of RT and future research avenues in this field.
7.1
Definition of Individual
Radiosensitivity, Radiosusceptibility,
and Radiodegeneration and
Radioresistence
The term “radiosensitivity” is one of the most extensively
used words in radiobiology. It was described as radiation-­
induced tissue reactions (e.g., skin is radiosensitive) in the
first decade of the nineteenth century [1]. Since 1930s, with
the first Congresses of Radiology, the term “radiosensitivity”
was also used as a synonym of radiation-induced cancers
(e.g., thyroid is a radiosensitive organ) and progressively was
used for radiation-induced cataracts (e.g., eyes are radiosen­
sitive [2]). All these different uses lead to an actual confusion
and notably raise legal issues since radiation-induced can­
cers, cataracts, or skin burns do not correspond to the same
level of clinical injuries [3].
To avoid these confusions, a possible approach is to con­
sider all the major clinical features of the response to radia­
tion by using unequivocal terms that could be indifferently
applied to the individual, tissue, cellular, or molecular scales.
To consolidate this approach, it is important to document the
individual response to radiation through a complete knowl­
edge of its different features. For example, it is noteworthy
that ataxia telangiectasia (AT), caused by homozygous muta­
tions of the AT mutated (ATM) gene resulting in aberrant
ATM protein, is associated with post-RTfatal reactions and
high risk of leukemia [4], while Li Fraumeni’s syndrome
is associated with cancer proneness but not with significant
post-RT adverse tissue reactions [5]. Conversely, Cockayne’s
syndrome is associated with significant tissue radiosensitivity
but no cancer proneness [6].
­
7
7.1
•	“Radiosensitivity” is the proneness to radiation-
induced adverse tissue events that are considered as
non-cancer
effects
attributable
to
cell
death.
Radiosensitivity is generally correlated with unre­
paired DNA damage and observed in response to high
doses of radiation [8] (Box 7.1).
E. A. Ainsbury et al."
"What are the key distinctions between ‘radiosensitivity,’ ‘radiosusceptibility,’ and ‘radiodegeneration’ according to the provided text, particularly concerning their relationship to cancer risk?","The document defines three distinct terms related to radiation response: ‘radiosensitivity’ refers to the proneness to non-cancerous tissue events like cell death resulting from unrepaired DNA damage, often observed at high radiation doses. ‘Radiosusceptibility’ describes the propensity for radiation-induced cancers, which are linked to genomic instability and stochastic (random) events, mirroring cancer susceptibility concepts. Finally, ‘radiodegeneration’ represents non-cancerous effects related to accelerated aging and DNA damage accumulation, differing from radiosensitivity in its incidence rates and cellular mechanisms. Notably, the text highlights that radiosusceptibility is strongly associated with a high risk of spontaneous cancer induction due to IR's carcinogenic nature. Reference: [MolecularRadiationBiology, Section 7.1 Definition of Individual Radiosensitivity, Radiosusceptibility, and Radiodegeneration and Radioresistence]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.1	 Definition of Individual Radiosensitivity, Radiosusceptibility, and Radiodegeneration and Radioresistence | Content: In terms of radiosusceptibility, radioresistance
is synonymous with a low risk of radiation-­
induced cancer.
In terms of radiodegeneration, radioresistance is
synonymous with a low risk of radiation-­
induced aging.
Learning Objectives
•	To understand the different responses of tumor and
normal tissues to ionizing radiation (IR) whether at
low or high dose.
•	To grasp the importance of radiation biomarkers of
exposure as well as effect and their integration with
molecular epidemiological studies.
•	To be able to discuss current and emerging bio­
marker methods to predict normal tissue and tumor
responses to radiotherapy (RT).
•	To understand how age and sex influence IR sensi­
tivity on cellular and individual levels as well as
health risks induced by IR exposure.
•	To grasp how genetic syndromes can be associated
with an increased radiation sensitivity and cancer
risk.
•	To understand the concept of precision medicine in
context of RT and future research avenues in this field.
7.1
Definition of Individual
Radiosensitivity, Radiosusceptibility,
and Radiodegeneration and
Radioresistence
The term “radiosensitivity” is one of the most extensively
used words in radiobiology. It was described as radiation-­
induced tissue reactions (e.g., skin is radiosensitive) in the
first decade of the nineteenth century [1]. Since 1930s, with
the first Congresses of Radiology, the term “radiosensitivity”
was also used as a synonym of radiation-induced cancers
(e.g., thyroid is a radiosensitive organ) and progressively was
used for radiation-induced cataracts (e.g., eyes are radiosen­
sitive [2]). All these different uses lead to an actual confusion
and notably raise legal issues since radiation-induced can­
cers, cataracts, or skin burns do not correspond to the same
level of clinical injuries [3].
To avoid these confusions, a possible approach is to con­
sider all the major clinical features of the response to radia­
tion by using unequivocal terms that could be indifferently
applied to the individual, tissue, cellular, or molecular scales.
To consolidate this approach, it is important to document the
individual response to radiation through a complete knowl­
edge of its different features. For example, it is noteworthy
that ataxia telangiectasia (AT), caused by homozygous muta­
tions of the AT mutated (ATM) gene resulting in aberrant
ATM protein, is associated with post-RTfatal reactions and
high risk of leukemia [4], while Li Fraumeni’s syndrome
is associated with cancer proneness but not with significant
post-RT adverse tissue reactions [5]. Conversely, Cockayne’s
syndrome is associated with significant tissue radiosensitivity
but no cancer proneness [6].
­
7
7.1
•	“Radiosensitivity” is the proneness to radiation-
induced adverse tissue events that are considered as
non-cancer
effects
attributable
to
cell
death.
Radiosensitivity is generally correlated with unre­
paired DNA damage and observed in response to high
doses of radiation [8] (Box 7.1).
E. A. Ainsbury et al.
389
•	“Radiosusceptibility” is the proneness to radiation-­
induced cancers which are non-toxic effects attributable
to cell transformation and/or genomic instability (in part
correlated with DNA misrepair). Since IR is considered to
be a carcinogenic agent, radiosusceptibility is distinctly
and strongly linked to susceptibility to spontaneous can­
cer induction. The term “radiosusceptibility” was pro­
posed due to its similarities with “cancer susceptibility,”
extensively used in the ICRP (International Commission
on Radiological Protection) reports and since it intro­
duces the notions of stochastic events [9].
•	“Radiodegeneration” responses are non-cancer effects
attributable to mechanisms which are related to acceler­
ated aging and often correlated with unrepaired DNA
damage that is tolerated by and accumulated in cells [9].
Radiodegeneration responses cannot be considered like
radiosensitivity responses as defined above since their
incidence rates, the types of cellular death, and the genes
involved are different.
7.2"
"Describe the concept of ‘biological half-life’ in the context of radiation biomarkers, explaining why different biomarkers exhibit varying biological half-lives and what factors influence these values.","The term ‘biological half-life’ (also known as elimination half-life or turnover half-life) refers to the time it takes for a biomarker concentration within a biological system – typically an organism or tissue – to reduce by half due to processes like metabolism, excretion, and repair. Different biomarkers possess dramatically different biological half-lives because they are affected by vastly different mechanisms of removal and regeneration. For instance, markers reflecting acute radiation damage, such as DNA strand breaks measured through techniques like the comet assay, often have very short biological half-lives – perhaps hours to days – due to rapid cellular repair processes initiated in response to the damaging effects of ionizing radiation. These repair pathways actively remove the detectable evidence of damage. Conversely, biomarkers indicating chronic radiation exposure, like lymphocyte proliferation or changes in bone marrow hematopoietic stem cell populations, can exhibit much longer biological half-lives – potentially months to years – reflecting the slower pace of cellular turnover and the accumulation of subtle, persistent genetic alterations within these long-lived cells. Furthermore, factors such as age, species, nutritional status, overall health, and the specific radiation dose received all significantly influence a biomarker’s biological half-life. Younger individuals generally have faster repair mechanisms and shorter half-lives compared to older adults. Species differences in metabolic rates and DNA repair capabilities also play a crucial role; for example, mammals typically exhibit more efficient DNA repair than insects. Finally, the magnitude of the radiation dose directly impacts the extent of damage and consequently, the rate at which biomarkers are cleared or replenished.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.2	 Biomarkers of Radiation: General Considerations | Content: Considerations
7.2.1"
Define a biomarker within the context of radiation exposure assessment and explain its significance in characterizing biological responses.,"A biomarker is an objective measurement – possessing one or more defined characteristics – that serves as an indicator of specific normal biological processes, pathological conditions, or responses to external exposures, including therapeutic interventions. In the context of radiation exposure, biomarkers primarily function as measurable indicators reflecting the complex interaction between a biological system and ionizing radiation. They provide crucial information regarding the molecular cascade of events triggered by radiation damage, elucidating the underlying mechanisms driving pathological changes. Biomarkers encompass a wide range of quantifiable parameters, such as genetic sequences, receptor expression patterns, radiographic data, blood composition (including specific analytes), electrocardiographic readings, or organ function assessments. Ultimately, biomarkers are essential for assessing the impact of both direct and indirect ionizing radiation exposure, aiding in dose selection, evaluating potential safety concerns related to dosage administration, and characterizing the overall biological response.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.2	 Biomarkers of Radiation: General Considerations | Sub-subsection: 7.2.1	 Definition | Content: A biomarker is an objective feature with one or more defined
characteristics which indicate specific normal biological
and pathological processes, or responses to an exposure or
to therapeutic interventions. To date, radiation biomarkers
are primarily identified in blood or saliva and are measur­
able indicators that reflect an interaction between a biologi­
cal system and one or more environmental agents (chemical,
physical, or biological). Biomarkers provide crucial infor­
mation on the complex molecular cascade of events and their
mechanisms underlying the pathological conditions or phar­
macological responses to a therapeutic intervention.
Biomarkers can be used to assess various different types of
biological characteristics or parameters. These include genetic
sequences, receptor expression patterns, radiographic or other
imaging-based measurements, blood composition, electrocar­
diographic parameters, or organ function. Since biomarkers
are quantifiable, they can be used to characterize the response
to direct or indirect IR exposure, to select radiation dose, and
to assess the potential safety issues related to dose administra­
tion. A large number of such biomarkers have been developed
over the years; the characteristics of the different classes of
radiation biomarkers will be reviewed in Sect. 7.2.2.
7.2.2"
"Describe the key characteristics that make a biomarker suitable for use in large-scale molecular epidemiological studies, particularly concerning radiation exposure. Detail at least six desirable properties.","When evaluating biomarkers for use in large-scale molecular epidemiological studies, several critical characteristics must be considered to ensure reliable and meaningful results. Firstly, **high specificity** is paramount; the biomarker should primarily respond to radiation exposure and ideally be minimally influenced by other environmental factors like tobacco smoke or pollutants. Secondly, **high sensitivity** is crucial – the biomarker needs to reliably detect even low levels of radiation exposure. Thirdly, there should be a **known variability in the general population**, allowing for statistical analysis and identification of subpopulations with differing sensitivities. Fourthly, the biomarker’s measurements must be **reproducible across laboratories** to minimize bias and ensure consistent data collection. Fifthly, a **linear relationship across time** is desirable; the biomarker's response should correlate predictably with exposure duration, facilitating dose-response assessments. Finally, there needs to be a **strong correlation with a health effect**, demonstrating a clear link between biomarker levels and radiation-induced disease or other relevant outcomes. Furthermore, it’s beneficial if the biomarker is **biologically plausible** – its mechanism of action should align with established radiation biology principles, and it should be **inexpensive and feasible for sample collection** to enable widespread analysis. Consistency in response to repeated exposures is also a highly desirable trait.

Considering cellular factors influencing radiosensitivity, variations across the cell cycle—particularly differences in sensitivity between G1, S, and G2/M phases—must be accounted for when interpreting biomarker data. The inherent repair mechanisms within each phase of the cell cycle (e.g., homologous recombination versus non-homologous end joining) can significantly impact a cell’s response to radiation damage.

Reference: [Molecular Radiation Biology], Section 7.2.2 – Characteristics of a Good Biomarker","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.2	 Biomarkers of Radiation: General Considerations | Sub-subsection: 7.2.2	 Characteristics of a Good Biomarker | Content: Although the definitions, nature, and use of biomarkers are
multiple and rapidly evolving with the sophisticated—omics
technologies, they must be evaluated in terms of their abil­
ity to address etiology and genetic susceptibility, predict and
quantify dose of exposure. There are certain properties which
are desirable when linking a biomarker with an exposure,
e.g., IR. These include high specificity and sensitivity, known
variability in the general population, should give reproduc­
ible results when assessed and multiplexing of analyses to
allow for screening purposes. Some additional desirable
characteristics of an ideal biomarker can be listed for use
in large scale molecular epidemiological studies: (a) Early
expressivity; (b) Linear relationship across time; (c) Strong
correlation with a health effect; (d) Reproducible between
laboratories; (e) Biologically plausible; (f) Inexpensive and
feasible for sample collection; (g) Consistency (the same
exposure will produce the same concentration of the bio­
marker every time).
7.2.3
Radiation Biomarkers for Potential Use
in Epidemiological Studies
Radiation biology research has identified several approaches,
especially the “omics” fields, as promising avenues for the
development of suitable biomarkers of high sensitivity and
specificity for radiation exposure. Radiation epidemiol­
ogy biomarkers should preferably be specific to radiation
and independent of other environmental exposures such as
tobacco or cigarette smoke. Such a biomarker would sim­
plify analysis and help to substantiate radiation causality.
Though biological biomarker often lack specificity, they
can still be informative in predicting the development of
radiation-induced disease if such exposures are additive or
interactive. Multi-biomarker approaches should be particu­
larly useful in epidemiological studies, both for (1) assess­
ing exposure–response relationships and how they vary with
individual susceptibility and (2) to understand better disease
mechanisms and the interplay of different possible pathways.
Contrariwise, carefully planned molecular epidemiologi­
cal studies are crucial for the validation and verification of
biomarkers, to determine their specificity and sensitivity
as well as factors that might influence them (e.g., age, sex,
smoking status, environmental agents, chronic conditions
such as inflammation or individual sensitivity) [10].
Box 7.1 Cellular Factors Influencing Radiosensitivity
•	Radiosensitivity differs throughout the cell cycle
with, in general, G1 phase taking an intermediate
position, and late S phase being most radioresistant.
•	The greater proportion of repair by HR than by
NHEJ in late S phase may explain the resistance of
late S phase cells.
•	Chromatin compaction and poor repair competence
(reduced enzyme access) could explain the high
radiosensitivity in G2/M.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology"
"Considering the development of radiation biomarkers for epidemiological studies, what are some key characteristics that an ideal biomarker should possess to be effectively utilized in large-scale molecular epidemiological investigations?","An ideal biomarker for use in large-scale molecular epidemiological studies must exhibit several crucial properties. These include early expressivity – indicating a response at an early stage of radiation exposure; a linear relationship across time, allowing for accurate dose estimation; strong correlation with a health effect, providing clear evidence of causality; reproducibility between laboratories, ensuring consistent results regardless of location or methodology; biological plausibility, reflecting genuine physiological responses to radiation; cost-effectiveness and feasibility for sample collection, facilitating widespread application; and consistency – demonstrating that the same exposure consistently produces the same biomarker concentration. Furthermore, biomarkers should ideally be specific to radiation and independent of other environmental exposures like tobacco smoke to simplify analysis and strengthen causal inferences.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.2	 Biomarkers of Radiation: General Considerations | Sub-subsection: 7.2.3	 Radiation Biomarkers for Potential Use in Epidemiological Studies | Content: multiple and rapidly evolving with the sophisticated—omics
technologies, they must be evaluated in terms of their abil­
ity to address etiology and genetic susceptibility, predict and
quantify dose of exposure. There are certain properties which
are desirable when linking a biomarker with an exposure,
e.g., IR. These include high specificity and sensitivity, known
variability in the general population, should give reproduc­
ible results when assessed and multiplexing of analyses to
allow for screening purposes. Some additional desirable
characteristics of an ideal biomarker can be listed for use
in large scale molecular epidemiological studies: (a) Early
expressivity; (b) Linear relationship across time; (c) Strong
correlation with a health effect; (d) Reproducible between
laboratories; (e) Biologically plausible; (f) Inexpensive and
feasible for sample collection; (g) Consistency (the same
exposure will produce the same concentration of the bio­
marker every time).
7.2.3
Radiation Biomarkers for Potential Use
in Epidemiological Studies
Radiation biology research has identified several approaches,
especially the “omics” fields, as promising avenues for the
development of suitable biomarkers of high sensitivity and
specificity for radiation exposure. Radiation epidemiol­
ogy biomarkers should preferably be specific to radiation
and independent of other environmental exposures such as
tobacco or cigarette smoke. Such a biomarker would sim­
plify analysis and help to substantiate radiation causality.
Though biological biomarker often lack specificity, they
can still be informative in predicting the development of
radiation-induced disease if such exposures are additive or
interactive. Multi-biomarker approaches should be particu­
larly useful in epidemiological studies, both for (1) assess­
ing exposure–response relationships and how they vary with
individual susceptibility and (2) to understand better disease
mechanisms and the interplay of different possible pathways.
Contrariwise, carefully planned molecular epidemiologi­
cal studies are crucial for the validation and verification of
biomarkers, to determine their specificity and sensitivity
as well as factors that might influence them (e.g., age, sex,
smoking status, environmental agents, chronic conditions
such as inflammation or individual sensitivity) [10].
Box 7.1 Cellular Factors Influencing Radiosensitivity
•	Radiosensitivity differs throughout the cell cycle
with, in general, G1 phase taking an intermediate
position, and late S phase being most radioresistant.
•	The greater proportion of repair by HR than by
NHEJ in late S phase may explain the resistance of
late S phase cells.
•	Chromatin compaction and poor repair competence
(reduced enzyme access) could explain the high
radiosensitivity in G2/M.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
390
7.2.4
Integrating Biomarkers into Molecular
Epidemiological and Biological Studies
­
7.2
­
7.1
­
­
Table 7.2 Classification of biomarkers based on temporal parameters
Biomarkers of exposure
• Available at some point after exposure.
• Suitable for estimating the dose received and identifying human internal exposure to environmental and
occupational chemicals/radiation by using novel techniques and approaches.
• Biomarkers of this category can have potential for use in radiation oncology to provide information on the
probable outcome of RT.
• Cytogenetic biomarkers are the best dosimetry biomarkers of radiation exposure as they show a high
degree of specificity and sensitivity.
• Emerging biomarkers related to alterations in transcriptional profiles can have potential as
biomarkersBiomarkers of exposure [11].
Biomarkers of susceptibility
• Available before, during, or after exposure.
• Provide key information which reflect intrinsic characteristics toward adverse effects of an exposure and
thus predict an increased risk of radiation-induced health effects.
• Appropriate to provide meticulous knowledge of the exposure-risk relationship, and variability of risks
between individuals of identical or different population/subgroups.
• Genetic variants (polymorphism) and/or metabolic phenotypes associated with cancer predisposition may
prove to be useful biomarkers of susceptibility.
• Cytogenetic endpoints (e.g., the G2 assay) are of interest as biomarkers of susceptibility.
Biomarkers of late effects
• Suitable for assessing a long-time health effects post exposure, even before clinical detection of radiation
induced disease or death.
• Cytogenetic assays emphasize some potential as biomarkers of late effects of radiation exposure to predict
the risk of RT side effects.
• Transcriptional biomarkers can be employed to identify either pathways or gene expression signatures
predictive of susceptibility and late health effects.
Biomarkers of persistent
effects
• Applicable to assess radiation effects present a long period of time after exposure.
• Biomarkers of exposure and effects may potentially be used to identify individuals at higher risk of
development of cancer.
• Chiefly an aspirational category on the basis of current science.
E. A. Ainsbury et al."
"Describe the roles of γ-H2AX and 8-oxo-dG as biomarkers for radiation exposure, detailing their specific mechanisms of action and what they indicate about DNA damage.","γ-H2AX (phosphorylated histone H2AX) serves as a critical biomarker for radiation exposure due to its direct involvement in the cellular response to double-strand breaks (DSBs) induced by ionizing radiation. Following irradiation, γ-H2AX foci – localized accumulations of phosphorylated H2AX protein – rapidly appear around sites where DNA is damaged. This phosphorylation event is triggered by kinases activated upon DNA damage recognition, primarily ATM and ATR. The accumulation of γ-H2AX recruits proteins involved in DNA repair pathways, such as 53BP1 and BRCA1, facilitating the initiation of homologous recombination repair (HRR). Importantly, the extent of γ-H2AX formation correlates with the magnitude of initial radiation dose and represents a near one-to-one relationship with the number of DSBs. Therefore, it acts as an immediate indicator of DNA damage severity.

Conversely, 8-oxo-dG is a highly specific biomarker for oxidative DNA damage resulting from radiation exposure. It’s formed through the action of reactive oxygen species (ROS) generated during irradiation on guanine bases within DNA. ROS oxidize guanine to 8-oxo-guanine, a modified nucleotide. Unlike γ-H2AX which reflects immediate DSB recognition, 8-oxo-dG accumulates over time as a consequence of prolonged oxidative stress and the inability of cells to fully repair radiation-induced damage. Its abundance strongly indicates significant oxidative DNA damage, often associated with increased ROS levels and impaired antioxidant defenses. The detection of elevated 8-oxo-dG levels provides insight into the long-term consequences of radiation exposure and can be used to assess cellular resilience against further oxidative assault.

In summary, γ-H2AX reflects immediate DSB recognition and repair initiation, while 8-oxo-dG indicates sustained oxidative DNA damage and the accumulation of persistent lesions.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.2	 Biomarkers of Radiation: General Considerations | Sub-subsection: 7.2.5	 Biological Classification | Content: Several biological responses can act as potential biomarkers
for IR exposure. They are linked to cellular or physiological
mechanisms which have been shown to change soon after
radiation exposure. The use of various “omic” technologies
together with hypothesis-driven approaches may be highly
useful to measure radiation biomarkers in a biological sys­
tem. Some biomarkers could be used as response markers or
as surrogate endpoints to predict radiation side effects. The
expression levels of many biomarkers can be expected to be
correlated with each other and so could be classified in mul­
tiple categories, such as
•	Phosphorylated histone H2AX (γ-H2AX) acts as pro­
tein biomarker for radiation exposure but is useful as a
DNA damage marker; suggesting a close one-to-one
relationship between initial as well as residual radia­
tion-induced DNA DSBs and γ-H2AX foci.
•	8-oxo-dG acts as a marker of nucleotide damage but is
strongly associated as a maker of oxidative DNA damage
suggesting it is produced abundantly in DNA exposed to
free radicals and reactive oxygen species (ROS).
•	Phosphoproteomic profiling insights into processes influ­
enced by epigenetic modifications, but also uncovers sig­
naling pathways.
­
7.2
Biomarkers of radiation exposure are further discussed in
Chaps. 2, 3, and 8.
Box 7.2 Biomarkers for Epidemiology and Dosimetry
•	Biomarkers and/or biological dosimeters are essential
for predicting and/or monitoring radiation exposure-
associated effects, quantifying the exposure, estimat­
ing absorbed radiation dose in certain accidental
situations or a suspected radiation overexposure.
•	Radiation epidemiology biomarkers should be spe­
cific to radiation and independent of other factors
that might influence them (such as age, chronic con­
ditions, smoking, tobacco, or individual sensitivity).
•	Identifying biomarkers of IR exposure employs a
multi-parametric approach to achieve an accurate
dose and risk estimation.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
392
­
10
7.3"
"The text discusses various types of biomarkers used in radiation studies. Can you categorize these biomarkers based on when they become detectable after exposure, providing specific examples of each category?","Following exposure to radiation, biomarkers can be classified into three primary categories based on their timing of detection: (1) Biomarkers of Exposure – These are measurable indicators that become available shortly after radiation exposure and provide an estimate of the dose received. Examples include measuring lymphocyte counts or DNA damage markers in blood samples taken within days or weeks following exposure. (2) Biomarkers of Susceptibility – These biomarkers can be detected before, during, or after exposure and are used to predict an individual’s increased risk of radiation effects. This category might encompass genetic variations known to influence radiosensitivity or pre-existing conditions that could exacerbate the impact of radiation damage. (3) Biomarkers of Late Effects – These markers appear much later, often years or decades, after exposure, indicating the manifestation of long-term health consequences like cancer development. Examples include monitoring for specific mutations in cells or tracking the incidence of radiation-induced diseases. The text emphasizes that collecting samples at biobanks and integrating clinical data are crucial for utilizing these biomarkers effectively across all three categories [Box 7.3]. Reference: [Molecular Radiation Biology, Section 7.3 – Temporal Classification of Biomarkers]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.3	 Temporal Classification of Biomarkers | Content: ­
­
13
7
8
10
14
7.2
7.3
­
­
7.3
Box 7.3 Use of Biomarkers at Different Times Post
Exposure
•	Biomarkers of exposure are available at some point
after exposure and are suitable for estimating the
dose received.
•	Biomarkers of susceptibility can be available
before, during, or after exposure and can predict an
increased risk of radiation effects.
•	Biomarkers of late effects can be used to assess
health effects that are present a long time after
exposure before clinical detection of the radiation
induced disease or death.
•	Biomarkers of persistent effects allow the assess­
ment of radiation effects present a long period of
time after exposure.
E. A. Ainsbury et al.
393
­
10
7.4
Collection of Individual Samples
for Radiation Studies
Not only since the “age of OMICS,” it is well known that
the collection of samples from patients and healthy vol­
unteers is essential for future research [15]. Especially in
radiation research, the collection of biological samples
represents a significant part of translational research,
since, especially in studies on radiation protection, the col­
lected biological samples represent an essential parameter
for analysis of (historic) radiation exposure [14]. Also, in
therapeutic trials, the sampling of tissues and body flu­
ids has an immense impact on the search, discovery, and
validation of novel biomarkers supporting the pathologi­
cal diagnosis as well as for the determination of therapy
toxicity and/or outcome [15, 16]. The collected samples
may safely expand the possibilities of the entire analyti­
cal process within prospective and retrospective trials in
radiation science. However, the collection and storage of
biological samples should always be done within a quality-
controlled manner [17]. In contrast to tissue sampling, the
sampling of body fluids also has the big advantage, that
these samples are nearly always available or easy to access
like vein puncture. In addition, the sampling of blood can
be done mostly together with clinical mandatory blood
draws, minimizing the burden of the patient/donor, and
enhancing the amount of time points of sampling as well
as it also increases the donor’s acceptance of giving blood
for research. Since the collection of samples at biobanks
accelerate the process of transferring scientific knowledge
into therapeutic application, it should be the duty of clini­
cal researchers adding translational programs with sample
collection to the prospective clinical trials. In our hands,
the sampling and analysis of immunological parameters
lead to predictive biomarkers supporting the pathological
diagnosis and therapeutic intervention and helping radia­
tion treatment in precision medicine [16, 18].
The sampling, the processing, as well as the storage
have to be done in a quality-controlled manner as outlined
before by Winter and colleagues [19] or at the respec­
tive international biobank consortia like the European,
Middle Eastern and African Society for Biopreservation
and Biobanking (ESBB), or the European research infra­
structure for biobanking (BBMRI-ERIC; [20]). There are
another three very important things to keep in mind when
collecting samples for later analysis: The best collections
are almost worthless if they are not connected with clini­
cal, radiation exposure, and patients/donor data. Along
with this, the informed consent of the donor should allow
use of the samples for the respective analyses even when
the samples will be given for, e.g., “OMICS” analysis to a
cooperation partner or to the statistician who performs the
analysis of the data. Lastly, a biobank is a living “thing”
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology"
"The text discusses biobanks and their intended use. What key principle governs the operation and purpose of a biobank, particularly concerning its long-term management?","A biobank should be primarily utilized for research purposes rather than serving as a permanent, secure storage facility indefinitely. The document emphasizes that biobanks are dynamic resources designed to facilitate ongoing analysis and investigation. Treating them solely as vaults risks diminishing their value and ultimately limits their utility for future scientific advancements. This approach acknowledges the evolving nature of biological research and prioritizes accessibility for current and prospective studies.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.4	 Collection of Individual Samples for Radiation Studies | Content: cal, radiation exposure, and patients/donor data. Along
with this, the informed consent of the donor should allow
use of the samples for the respective analyses even when
the samples will be given for, e.g., “OMICS” analysis to a
cooperation partner or to the statistician who performs the
analysis of the data. Lastly, a biobank is a living “thing”
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
394
which should be used for research and not as a secure vault
to store samples for eternity. Taken together, it should be
the duty of research on humans to collect and store sam­
ples for further analyses, but also processing and storage
should be carried out in accordance with applicable regula­
tions and standards. This is the only way to ensure that the
samples do not suffer any loss of value and are available
for later applications.
7.5"
"The text describes several assays used to predict radiation sensitivity, including the micronuclei assay utilizing cytochalasin B to block cytokinesis, the premature chromosome condensation (PCC) assay, and techniques like fluorescence in situ hybridization for chromosomal aberrations. Furthermore, it highlights the importance of measuring double-strand breaks (DSBs) and the challenges associated with their quantification.  Specifically, what two techniques are described that independently measure DSB repair, despite potential limitations in specificity?","The text details two distinct techniques used to quantify DNA damage and assess radiation sensitivity: the comet technique and the halo technique. The comet technique combines electrophoresis with the halo technique to measure nuclear size changes (comet head) and DNA fragment migration distance (comet tail). The halo technique utilizes fluorescent intercalators to quantify an increase in nucleus size, providing a direct measurement of DSB repair. Reference: [Molecular Radiation Biology, Section 7.4 – Predictive Assays]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Content: Tissue reactions induced by IR are the result of different
types of cell death (mitotic death, apoptosis, autophagy,
senescence, etc.). Loss of clonogenicity (and not physical
disappearance or metabolic shutdown) appeared to be com­
mon to all types of cell death.
­
­
21
7.4
­
­
­
­
7.4
3
Several techniques continue to rely on cell culture:
•	The level of radiation-induced micronuclei (MN) has
been quantitatively correlated with radiosensitivity since
the 1960s thanks to a simple and robust protocol consist­
ing of blocking the process of cytokinesis by drugs such
as cytochalasin B [22].
•	The premature chromosome condensation (PCC) assay
consists in making chromosome fragments appear more
quickly by fusing the tested cell with a cell in mitosis. The
heterokaryon thus formed allows the exchange of mitotic
factors in the cell into G0/G1 and then produces premature
condensation of the chromatin [23].
•	The enumeration of chromosomal aberrations by fluores­
cence in situ hybridization technique.
E. A. Ainsbury et al.
395
It made sense to focus on the molecular mechanisms of
the cellular response to radio-induced damage to DNA and
in particular to DNA repair, since a quantitative link between
unrepaired Double-Strand Breaks (DSB), chromosomal
breaks, and radiation-induced clonogenic cell death was
demonstrated [24]. Moreover, the vast majority of genetic
syndromes associated with individual radiosensitivity are
linked to mutations in genes involved in radiation-induced
DSB signaling or repair. DSB measurement techniques
were investigated with some confusion on their specificity
and instead reflected other types of damage [7]. The first
techniques for measuring DSB were based on discriminat­
ing radiation-induced DNA fragments based on their size.
This was particularly the case with sedimentation in sucrose
gradients, neutral elution, and pulsed-field electrophoresis.
Such a principle has the advantage of measuring the repair
of DSBs independently of any molecular repair pathways
regardless of the post-irradiation time. On the other hand,
these techniques do not make it possible to assess the qual­
ity of the repair, that is to say whether it is faithful or at fault.
The halo technique consists, using fluorescent interca­
lators, in quantifying such an increase in the nucleus. The
comet technique combines electrophoresis and the halo tech­
nique, both applied individually to each cell. Data from the
comet technique are usually given in the form of the product
of the increase in the size of the nucleus (comet head) times
the distance that DNA fragments migrate (comet tail) [25].
From 2003, with indirect immunofluorescence, it became
possible to follow precisely and in real time in the nucleus and
for a wide dose spectrum, the kinetics of appearance/disap­
pearance of DNA repair proteins (foci). A correlation between
SF2 and the rate of unrepaired DSB 24 h after 2 Gy (γ-H2AX
marker) could be demonstrated—constituting a functional
repair test [26]. A second marker significantly increased the
performance of the test—based on the speed of nuclearization
and the functionality of the pATM protein in the nucleus [8].
Genome-wide association (GWAS) studies have been
widely used to identify associations between commonly
occurring variations in DNA sequence, such as single
nucleotide polymorphisms (SNP) and human traits such as
individual radiosensitivity [27]. A few SNP as well as mito­
chondrial haplogroups have been reported.
­
­
2829
7.3
Epigenetic modifications include histone modifications
such as acetylations and methylations, DNA methylation,
particularly on CpG island, non-coding RNAs, and three-­
dimensional chromatin organization. As this a relatively new
field, only few studies have been conducted on the epigenetic
regulations of skin fibrosis, mainly on miRNAs [32, 33].
Ozsahin et al. [34] developed a rapid radiosensitivity test
(<24 h) based on lymphocyte apoptosis, a biological response
developing 6–72 h after irradiation. The authors showed that
low Radio-Induced Lymphocytic Apoptosis (RILA) was sig­
nificantly correlated with late grade ≥2 tissue toxicities.
In recent years, the identification of routinely avail­
able blood and clinical markers that may help to predict
the response to immune therapies alone and in multimodal
settings including RT has been in focus of scientists of
several disciplines and clinicians [35, 36]. Here, immune
markers of the peripheral blood are key factors, since they
circulate in the body and enter several tissues in response
to disease, therapy, and stressors such as radiation. Stress
and immune parameters should jointly be considered, and
a differentiation between primary radiation signatures and
consecutive systemic immune biosignatures is challeng­
ing, but anyhow interconnected [37, 38]. Notably, single
immune parameters are insufficient, but rather immune
profiles that reflect the complexity of the immune system
and the manifold interactions of its cellular and soluble
components [16, 39].
Table 7.3 Reported gene expression signatures for individual radiosensitivity
Publication
RS patients
RR patients
Radiation scheme
Selected differentially expressed genes
Assay used for gene
selection
Quarmby et al. [28]
3
3
Not irradiated
FMLP-R-I, TNFα, NGFR, EPHB2,
PDGFB, NTRK1, LFNG, DDR1; IFNGR1
Cytokine array
Alsner et al. [30]
22
4
3 × 3.5 Gy over
3 days, RNA
extracted 2 h after
last irradiation
CDC6, CDON, CXCL12, FAP, FBLN2,
LMNB2, LUM, MT1X, MXRA5,
SLC1A3, SOD2, SOD3, WISP2
15K cDNA
microarray
Rødningen et al. [31]
10
4
3 × 3.5 Gy over
3 days, RNA
extracted 2 h after
last irradiation
PLAGL1, CCND2, CDC6, DEGS1,
CDON, CXCL12, MXRA5, LUM, MT1X,
MT1F, MT1H, C1S, NF1, ARID5B,
SCL1A3, TM4SF10, MGC33894,
ZDHHC5/MFGE8
15K cDNA
microarray
Forrester et al. [32]
6
8
Not irradiated
FBN2, FST, GPRC5B, NOTCH3, PLCB1,
DPT, DDIT4L, SGCG
GeneChip Human
Exon 1.0 ST Array
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
396
7.5.1"
How is tumor response to radiotherapy typically assessed and what role do biopsies play in determining individualized treatment strategies?,"Tumor response to radiotherapy is evaluated through a multi-faceted assessment, often utilizing either biopsy of the tumor itself or liquid biopsies. There isn't a single, universally accepted definition of ‘tumor response’; it’s generally considered any favorable reaction of the tumor to the therapeutic intervention. Tumor biopsies are particularly valuable because they provide both molecular and structural material that can be analyzed to develop personalized treatment metrics. Specifically, these biopsies allow for the identification of patients who are likely to respond favorably to radiotherapy, enabling clinicians to tailor treatment regimens accordingly. Conversely, for patients whose tumors do not exhibit a favorable response, alternative, potentially more effective treatments can be explored, minimizing unnecessary exposure to toxic therapies.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Content: to Radiotherapy
Tumor response to RT is a multi-faceted metric of outcomes
after radiotherapeutic treatment, often observed through
biopsy of the tumor or liquid biopsy. There is currently no
universal definition of tumor response, but it can generally
be considered as any favorable response of the tumor to ther­
apy. Tumor biopsies may aid in the development of personal­
ized patient treatment regimens by providing molecular and
structural material for use in developing metrics capable of
identifying who will or who will not favorably respond to
RT. For patients who do not respond favorably to treatment,
they can be offered another more effective avenue of treat­
ment, sparing them from treatment toxicity.
­
­
­
7.5
7.6"
"Describe the application of immunohistochemistry (IHC) in radiotherapy treatment planning, specifically focusing on its role in identifying biomarkers predictive of a tumor's response.","Immunohistochemistry (IHC) is a routinely employed diagnostic technique utilized by pathologists to analyze tissue samples. In the context of radiotherapy treatment planning, IHC plays a crucial role in identifying and quantifying specific cellular markers within tumors, thereby predicting their responsiveness to radiation. The technique involves staining fresh, frozen, or paraffin-embedded tissue sections with enzyme-conjugated antibodies that bind to target proteins. By visualizing these antibody-protein interactions through microscopy, pathologists can assess antigen expression levels directly within the tissue. Specifically, IHC has been extensively used to identify biomarkers associated with various cellular processes relevant to radiotherapy response. These include markers related to cell proliferation such as Ki67 and protein kinase A (PKA), which indicate active cell division and potentially a greater sensitivity to radiation. Furthermore, IHC can assess cell cycle checkpoint proteins like p53 and p16, reflecting the tumor’s ability to repair DNA damage – a factor influencing its response. Markers associated with apoptosis, such as bcl2 and bax, are evaluated to determine the extent of programmed cell death within the tumor. The expression levels of growth factor receptors, notably EGFR (epidermal growth factor receptor), are also assessed, as elevated EGFR signaling can often confer resistance to radiation. Finally, IHC is used to detect hypoxia-inducible factor 1-alpha (HIF1α), a protein upregulated in hypoxic environments which can protect cells from radiation damage and thus influence treatment outcomes. Ultimately, IHC provides valuable information for tumor subtyping and predicting patient response to radiotherapy by directly assessing antigen expression patterns within the tissue.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.1	 Tissue Biopsy | Content: ­
41
­
7.4
Immunohistochemistry (IHC) is a low-cost technique
used by pathologists that involves staining fresh, frozen, or
paraffin-embedded tissue and is widely applied in a clini­
cal diagnostic setting. IHC has been used to identify predic­
tive tissue biomarkers for RT response and include markers
related to cell proliferation; ki67 and PKA (protein kinase),
cell cycle checkpoint; p53 and p16, apoptosis; bcl2 and bax,
growth factor receptors; EGFR (epidermal growth factor
receptor) and finally, hypoxia; HIF1α (hypoxia-inducible fac­
tor 1-alpha (e.g., [42])). IHC facilitates the direct assessment
of antigen expression in tissues through enzyme-­conjugated
antibodies. Initially, IHC was designed to classify the cel­
lular origin of a tumor but with enzyme-conjugated antibod­
ies and paraffin embedding, IHC is also capable of assessing
treatment efficacy and is useful for tumor subtyping as well
as in predicting patient response to RT. However, IHC is
prone to pre-analytical subjectivity, operator subjectivity,
and limited to known proteins [46]. Patient-derived 3D mod­
els can also be used to assess tumor response to RT and will
be discussed in the following section."
"Patient-derived tumor organoids (PDOs) are increasingly utilized in radiation research. Explain the significance of PDOs as predictive models for assessing a patient's response to radiotherapy, detailing the biological characteristics they represent that differentiate them from traditional 2D cell culture models.","Tumor organoids offer a significant advancement over conventional 2D cell cultures when predicting a patient’s response to radiotherapy due to their enhanced ability to recapitulate the complexities of primary tumors. Specifically, PDOs capture intra-tumor heterogeneity – the variation in genetic and phenotypic characteristics within a single tumor mass – which is a critical factor influencing treatment outcomes. This heterogeneity means that not all cells within a tumor respond identically to radiation; some may be more resistant due to inherent differences in DNA repair mechanisms or other cellular adaptations. Furthermore, PDOs accurately represent the tumor microenvironment, including interactions between cancer cells and surrounding stromal components like fibroblasts and blood vessels, which can significantly modulate radiosensitivity. Unlike 2D cultures that typically isolate cells from this complex environment, PDOs maintain cell morphology, differentiation states, and viability more closely resembling the in vivo situation. This improved realism allows for assays such as genomic profiling, survival analysis, flow cytometry, immunofluorescence staining, and histological examination to be performed, providing a more accurate prediction of how a patient’s tumor will respond to radiation therapy compared to simpler 2D models.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.2	 Patient Tumor Tissue-Derived Organoids (PDOs) | Content: (PDOs)
In the last decade, patient-derived organoids (PDOs) have
provided novel models for preclinical and translational
research for assessing tumor response toward personalization
of treatment. Organoids have the potential to be used as pre­
dictors for patient treatment response due to their ability to
reflect the biological characteristics of primary tumors, i.e.,
intra-tumor heterogeneity, genotype, and phenotype [47] as
well as the tumor microenvironment [48]. Compared to 2D
models, PDOs possess improved cell morphology, differen­
tiation, and viability, rendering them more relevant to the in
vivo context [49]. Assays that can be performed on organoids
include genomic profiling, survival assays, flow cytometric
analysis, immunofluorescent, and histological staining. The
main limitations associated with organoids include their high
cost both in an economic and time-input sense [50]."
"Describe the key characteristics and limitations associated with Patient-Derived Xenografts (PDXs) as models for predicting tumor response to radiotherapy, referencing specific examples from the provided text.","Patient-Derived Xenografts (PDXs) represent a valuable tool in translational cancer research, particularly for personalized medicine strategies. They are mouse models created by implanting fresh tumor tissue directly from patients into severely immunodeficient or humanized mice. PDXs closely resemble patient tumors in terms of histological and molecular characteristics, demonstrating similar susceptibility to anti-cancer therapies and mirroring intra-tumor heterogeneity [51, 52]. Notably, research using PDXs has identified biomarkers like CHGA and MAPK8 that correlate with increased survival in glioblastoma patients receiving radiotherapy [54]. However, several significant limitations exist. The process of establishing a PDX model is lengthy, requiring extensive involvement from pathologists and presenting sampling issues due to tumor heterogeneity, leading to potential inaccuracies in predicting treatment response. Furthermore, PDXs often fail to grow or metastasize, hindering the ability to fully evaluate therapeutic effects. Economically, PDX development represents a substantial investment. Finally, they cannot be used to assess the role of the immune system ex vivo and require specialized, regulated animal facilities [53]. Examples from the text highlight this: tumor material acquisition can be painful and difficult, limiting repeatability; serial assessments are often limited due to sampling challenges; and a single biopsy may not fully represent the complex heterogeneity of the original tumor. Reference: [Molecular Radiation Biology], Section 7.5.1.3 – Patient-Derived Xenografts (PDXs)","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.3	 Patient-Derived Xenografts (PDXs) | Content: research for assessing tumor response toward personalization
of treatment. Organoids have the potential to be used as pre­
dictors for patient treatment response due to their ability to
reflect the biological characteristics of primary tumors, i.e.,
intra-tumor heterogeneity, genotype, and phenotype [47] as
well as the tumor microenvironment [48]. Compared to 2D
models, PDOs possess improved cell morphology, differen­
tiation, and viability, rendering them more relevant to the in
vivo context [49]. Assays that can be performed on organoids
include genomic profiling, survival assays, flow cytometric
analysis, immunofluorescent, and histological staining. The
main limitations associated with organoids include their high
cost both in an economic and time-input sense [50].
7.5.1.3	Patient-Derived Xenografts (PDXs)
PDXs are mouse models that are widely used in modern can­
cer research and are proving to be another useful platform in
the development of personalized medicine strategies due to
an improved relationship with the context in vivo. PDXs also
demonstrate similar susceptibility to anti-cancer therapies,
they closely resemble patient tumor features, have similar
histological and molecular characteristics, and can be cul­
tured long-term in vitro [51, 52]. The tumor material to be
used in PDXs is derived from fresh tumor tissue collected
from a patient during surgery. Small tumor pieces are then
implanted into severely immunodeficient or humanized
mice. Although PDXs are a promising tool for translational
research, they are difficult to apply as tumors may not grow
or metastasize. Other disadvantages include the long pro­
cess required to establish a model which requires significant
involvement by pathologists, sampling and representational
issues due to tumor heterogeneity, the overall economic cost
of their development, their inability to evaluate the involve­
ment of the immune system ex vivo, the potential for grafts
to be rejected (“engraftment rate”), and the required use of
regulated and approved animal facilities [53].
PDX models have been used to investigate biomarkers of
RT response with the aim of stratifying patients based on
risk and facilitating the individualization of treatment, as
exemplified recently in PDX models of glioblastoma. The
CHGA and MAPK8 gene signatures have been associated
with increased survival in patients with glioblastoma who
have received RT [54]. As the use of PDXs to reliably predict
clinical activity of treatment options is still in its infancy, it
is currently unknown whether these models can be used to
E. A. Ainsbury et al.
397
guide individual treatment strategies in a time frame that is
useful for a patient. Future technological advancements may
accelerate their involvement clinically.
The invasive nature of tumor sample acquisition lends
to many of the limitations associated with this sample
type, including being painful and difficult to collect,
time-­taxing, having limited repeatability due to local­
ized sampling of tissue. In addition serial assessments are
often limited, and this diagnostic approach requires expert
pathologists for evaluation, with the potential to introduce
new risks to patients. Importantly a tumor may not be fully
represented by a single tissue biopsy due to tumor hetero­
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
398
Table 7.4 Examples of studies that have used tumor biopsies to predict response to RT.
Research team
Technique
Tissue type
Main outcome
Pollack et al. [42]
Tissue biopsy—IHC
Prostate cancer
Ki67, a marker of cellular proliferation, and apoptotic proteins bcl2
and bax are independently associated with BCDF.
Wilkins et al. [43]
Tissue biopsy—IHC
Prostate cancer
Ki67 is an independent prognostic factor for BCDF.
Driehuis et al. [44]
PDOs—Next generation
sequencing and dose response
kill curve
HNSCC
A patient with a prolonged response to RT had an organoid line with
the highest sensitivity to RT.
Relapsed patients post-RT also had the most resistant organoid lines.
Yao et al. [45]
PDOs—Whole-exome
sequencing and organoid size
Locally advanced
rectal cancer
The PDOs matched the clinical outcomes of the patient with a 85%
match ratio (n = 80).
Abbreviations: IHC immunohistochemistry, PDOs patient tumor tissue-derived organoids, HNSCC head and neck squamous cell carcinoma,
BCDF biochemical or clinical disease failure, RT radiotherapy
40
geneity which potentially adversely affects the accuracy of
the test. Lastly, if the condition of a patient has worsened,
the acquisition of tissue biopsy is not feasible [55, 56]."
"Describe the rationale behind utilizing liquid biopsies as a method for studying tumor response to radiotherapy, and what specific advantages do they offer compared to traditional tissue biopsies?","Liquid biopsies represent a shift towards safer and less invasive methods of assessing tumor characteristics, particularly in the context of radiotherapy. The primary advantage stems from the inherent challenges associated with conventional tissue biopsies – namely, the potential for patient harm and the difficulty in accurately representing the complex heterogeneity within a tumor mass. Traditional biopsies often capture only a localized snapshot, failing to account for variations in genetic makeup across different regions of the tumor. Liquid biopsies, on the other hand, analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA) released from dying or shedding cancer cells, and exosomes derived from tumors within bodily fluids like blood or urine. This approach provides a ‘temporal snapshot’ of the tumor's genomic character – meaning it reflects the dynamic changes occurring within the tumor over time – offering valuable information about its evolution and response to treatment. Furthermore, liquid biopsies can potentially overcome intra-tumor heterogeneity by analyzing multiple cell populations simultaneously, providing a more comprehensive picture than a single tissue sample. However, it’s crucial to acknowledge that this method is still developing and faces limitations regarding standardization of methodologies and clinical validation for widespread routine use.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.4	 Liquid Biopsy | Content: As the collection of tissue biopsies from patients often intro­
duces unnecessary risks to the patient, there has been a recent
increase in the focus on safer and less invasive sample col­
lection methods, including via liquid biopsies. Liquid biop­
sies are generally a rich source of tumor-specific biomarkers,
providing a temporal snapshot of the genomic character of
a tumor, and can help overcome the complication of intra-­
tumor heterogeneity [56]. However, there are several limita­
tions associated with liquid biopsies, including the lack of
standardization of methodologies and inadequate technical/
clinical validation for routine clinical utility [57].
E. A. Ainsbury et al.
399
58
­
59
­
7.6
­
­"
"Describe the significance of circulating tumor cells (CTCs) as potential biomarkers in predicting response to radiotherapy, incorporating details regarding their origin, characteristics, and current detection methodologies.","Circulating tumor cells (CTCs) are increasingly recognized as valuable biomarkers for assessing a patient’s likely response to radiotherapy. Their presence in the bloodstream or lymphatic system represents disseminated tumor cells originating from primary tumors, metastatic sites, or recurrent disease. These CTCs play a crucial role in metastasis by facilitating the spread of cancer throughout the body, effectively creating new tumor loci when they evade immune surveillance. A key observation is that patients with complete responses to concurrent chemoradiotherapy often exhibit reduced CTC levels compared to those experiencing partial responses – suggesting an inverse correlation between CTC burden and treatment efficacy. However, several factors complicate their use as a reliable biomarker. CTCs are exceptionally rare within peripheral blood, significantly less abundant than white or red blood cells, leading to challenges in isolation and accurate enumeration. Furthermore, the molecular heterogeneity of these cells and their low concentration contribute to difficulties in consistent detection. Current CTC isolation techniques employ methods like microfiltration devices and dielectrophoretic field flow fractionation (DEP) to enrich for these rare cells. Detection platforms are broadly categorized as ‘label independent’ (e.g., PARSORTIX, CytoTrack) or ‘label dependent’ (e.g., iCHIP, CTC-Chip, CELLSEARCH). Label-dependent methods, such as CELLSEARCH, rely on the expression of specific cell surface markers – notably epithelial cell adhesion molecule (EpCAM), cluster of differentiation 45 (CD45), and cytokeratins 8, 18, and/or 19. These antibodies are conjugated to magnetic nanoparticles or immobilized on microfluidic chips to capture CTCs based on these defined characteristics. The FDA-approved CELLSEARCH platform exemplifies this approach, highlighting the importance of targeting specific surface markers for effective CTC identification.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.5	 Circulating Tumor Cells (CTC) | Content: CTCs have recently been discovered to be potential biomarkers
for predicting tumor response to RT. A recent study by Qian
et al. [60] demonstrated that nasopharyngeal patients with a
complete response to concurrent chemoradiotherapy exhibited
decreased CTC levels when compared to patients with a par­
tial response. CTCs enter the bloodstream or lymphatic system
and are disseminated throughout the body as they are released
from primary, metastatic, or recurrent tumors. Metastatic
tumors in distant locations can also form through CTCs that
evade immune cell recognition [61]. These cells are rare, and
the proportion present in peripheral blood is quite low when
compared to white and red blood cells [62]. Molecular hetero­
geneity and the low concentration of CTCs in peripheral blood
lead to multiple limitations in terms of their isolation, enu­
meration, and detection [63]. Current platforms to isolate and
analyze CTCs are based on distinguishing features between
CTCs and white and red blood cells such as morphology, bio­
physical and biomechanical properties along with modifica­
tion, synthesis, regulation, and concentration of protein [64].
CTC isolation/enrichment platforms include microfiltration
devices and dielectrophoretic field flow fractionation (DEP).
CTC recognition platforms can be split into two groups: (1)
label independent and (2) label dependent. The former includes
PARSORTIX and CytoTrack. The latter includes iCHIP, CTC-
Chip, and CELLSEARCH [64]. CELLSEARCH is an FDA-
approved platform and is based on the expression of cell surface
markers such as epithelial cell adhesion molecule (EpCAM),
cluster of differentiation (CD)45 (CD45), cytokeratins 8, 18,
and/or 19 [65]. This platform uses antibodies against these cell
surface markers conjugated with magnetic nanoparticles or
immobilized on microfluidic chips."
"Describe the diverse origins of extracellular vesicles (EVs) and outline some common methods used to isolate and characterize them, highlighting current limitations.","Extracellular vesicles (EVs), encompassing structures like exosomes and microvesicles, originate from a remarkably broad range of body fluids including bile, cerebrospinal fluid, saliva, breast milk, urine, blood, and amniotic fluid. These membrane-bound entities are essentially cell-derived compartments that carry various molecules – proteins, lipids, nucleic acids – reflecting the cellular origin from which they were released. Isolation techniques for EVs vary considerably, with immunoaffinity capture utilizing specific antibodies to target and isolate vesicles based on their surface markers; ultracentrifugation relying on density gradient separation to stratify particles by size and mass; density gradient centrifugation employing solutions of varying densities to achieve similar separation; size exclusion chromatography exploiting differences in vesicle size for filtration; and exosome precipitation using methods that induce aggregation. Characterization techniques commonly employed include Western blotting to detect specific proteins, ELISA (Enzyme-Linked Immunosorbent Assay) for quantifying protein levels, and transmission electron microscopy (TEM) for visualizing the vesicles’ morphology and size. However, current limitations significantly hinder their clinical application. These primarily involve substantial sample volumes required for analysis, coupled with the high cost of instrumentation associated with these methods. Furthermore, many isolation techniques are labor-intensive and time-consuming, presenting a considerable barrier to widespread adoption in research and potential clinical diagnostics. The relatively novel nature of studying exosomes specifically also means that much of the current research is confined to *in vitro* studies requiring translation into *in vivo* models for broader mechanistic understanding.

Reference: [Molecular Radiation Biology], Section 7.5.1.6 – Extracellular Vesicles (EVs)","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.6	 Extracellular Vesicles (EVs) | Content: EVs can be isolated from a wide range of body fluids, such as
bile, cerebrospinal fluid, saliva, breast milk, urine, blood, and
amniotic fluid. Various cell-derived membrane structures are
collectively termed EVs and include exosomes, microvesi­
cles, and apoptotic bodies [66]. Exosomes are ideal candi­
dates to study response to RT because radiation not only
alters exosome manufacturing, but also affects their molecu­
lar cargo [67]. However, investigating the role of exosomes
in radiosensitivity is a relatively novel approach, and studies
currently are limited to in vitro studies that require transla­
tion  in vivo to broaden our understanding of the mechanisms
behind the development of radioresistance.
Current exosome isolation methods include immuno­
affinity capture, ultracentrifugation, density gradient cen­
trifugation, size exclusion chromatography, and exosome
precipitation, while characterization methods include west­
ern blotting, ELISA, and transmission electron microscopy
[68]. The disadvantages associated with these techniques
currently make them unsuitable for clinical utility. These
include (1) the large amount of starting sample and costly
instrumentation that is required for analysis and (2) the
labor- and time-intensive nature of the procedures required
for sample isolation."
"Describe the current state of techniques used for isolating and characterizing cell-free DNA (cfDNA) from blood samples, highlighting their limitations that hinder clinical application.","Current methods for isolating and characterizing cfDNA primarily rely on immunoaffinity capture, ultracentrifugation, density gradient centrifugation, size exclusion chromatography, and exosome precipitation. Characterization techniques include western blotting, ELISA, and transmission electron microscopy. However, these approaches are currently limited by several factors that preclude their widespread clinical use. These limitations principally involve the substantial volume of starting material required – often a large amount – coupled with the high cost of instrumentation necessary for analysis. Furthermore, the isolation procedures themselves are labor-intensive and time-consuming.  These issues significantly impede their translation into routine clinical diagnostics [68]. Reference: [Molecular Radiation Biology, Section 7.5.1.7]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.1	 Predicting the Response of Tumors to Radiotherapy | Sub-sub-subsection: 7.5.1.7	 Cell-Free DNA (cfDNA) | Content: currently are limited to in vitro studies that require transla­
tion  in vivo to broaden our understanding of the mechanisms
behind the development of radioresistance.
Current exosome isolation methods include immuno­
affinity capture, ultracentrifugation, density gradient cen­
trifugation, size exclusion chromatography, and exosome
precipitation, while characterization methods include west­
ern blotting, ELISA, and transmission electron microscopy
[68]. The disadvantages associated with these techniques
currently make them unsuitable for clinical utility. These
include (1) the large amount of starting sample and costly
instrumentation that is required for analysis and (2) the
labor- and time-intensive nature of the procedures required
for sample isolation.
7.5.1.7	Cell-Free DNA (cfDNA)
cfDNA is reported to be found in elevated levels in cancer
patients when compared to healthy individuals [69]. Usually,
cfDNA is found in fragments ranging from 120 to 220 base
pairs (or multiples thereof) [70]. The mechanisms respon­
sible for the release of cfDNA into the bloodstream are not
fully understood, but it is thought that it may be facilitated
via apoptosis, necrosis, senescence, and actively through cell
secretion [71]. In the blood, cfDNA is mostly nucleosome
associated, and the tumor derived element in cancer patients
is circulating tumor DNA (ctDNA) where concentrations
of ctDNA have a linear relationship with tumor size and
metastasis [72, 73]. Disease stage will also influence ctDNA
concentration with late-stage disease associated with higher
levels than early-stage disease [74].
ctDNA is more fragmented than cfDNA ranging from 100
to 200 base pairs and exists at much lower concentrations
[75]. Detectable alterations that are tumor relevant include
mutations, chromosomal rearrangements, copy number
aberrations, methylation, DNA fragment lengths, tumor gene
expression, and the presence of viral sequences (in tumors
associated with oncogenic viruses) [73]. In patients with
advanced stage nasopharyngeal carcinoma, plasma Epstein–
Barr virus DNA load at the midpoint of RT is associated with
a worse clinical outcome [76]. Detectable circulating HPV-­
DNA at the end of chemoradiation is associated with lower
progression-free survival in HPV+ cervical cancer patients
[77]. Somatic mutations in ATM, a DNA repair gene, can
determine exceptional responses to RT in patients with head
and neck squamous cell carcinoma, endometrial cancer, and
lung cancer [78]. Several methods have been developed to
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
400
extract and sequence ctDNA. These methods include, but are
not limited to:
1.	Polymerase chain reaction (PCR)-based techniques:
BEAMing PCR (beads, emulsion, amplification, and
magnetics), droplet digital PCR (ddPCR), and real-time
quantitative PCR (qPCR).
2.	Tumor-informed sequencing approaches: cancer person­
alized profiling by deep sequencing (CAPP-Seq),
Signatera, and targeted digital sequencing (TARDIS).
­
79
­
­
­
80
7.5
Further studies are needed to elucidate the role of bio­
markers in predicting tumor response to RT as currently
there are limited studies that investigate their potential.
Furthermore, biomarker identification is in its infancy, with
liquid biopsies and 3D patient-derived models providing an
enormous opportunity to further advance precision medi­
cine. The limitations associated with these techniques may
be mitigated in the coming years through technological
advancements that allow the creation of more specific and
sensitive assays. Along with harmonization and standard­
ization of methodologies, the techniques mentioned in this
section may move from a translational phase to routine clini­
cal use. It can be expected that research on liquid biopsies
and patient-derived 3D models will only grow in the com­
ing years, and with this comes the potential to revolutionize
patient care and treatment.
7.5.2"
"Several studies utilize circulating tumor cells (CTCs) as biomarkers to predict response to radiation therapy. Specifically, elevated CTC counts in colorectal patients were associated with biological responders, while KEAP1 mutations in lung cancer patients correlated with radiosensitivity and predicted local failure post-treatment. What cellular component is being measured through fluorescence microscopy in these studies, and how does its abundance relate to treatment outcome?","Circulating tumor cells (CTCs) are analyzed using fluorescence microscopy to quantify their presence in blood samples. In the provided research, elevated CTC counts were significantly correlated with biological responsiveness in locally advanced colorectal patients and predicted radiosensitivity in non-small cell lung cancer patients. The fluorescence method allows for direct visualization and enumeration of these cells, providing a real-time assessment of tumor dissemination and potentially reflecting the cellular mechanisms driving treatment response or resistance.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Content: ­
­
Table 7.5 Examples of studies that have utilized biomarkers from liquid biopsies to predict tumor response to RT (see the referenced publications
for the full study details, including RT regime)
Research team
Biomarker
Methodology
Study population
Main outcome
Sun et al. [81]
CTCs
Fluorescence
microscopy
Locally advanced colorectal
patients (n = 115)
Baseline CTC counts of biological responders
were significantly elevated when compared to
non-responders
Jeong et al. [82]
ctDNA
Hybrid capture-based
approach (Capp-Seq)
Non-small cell lung cancer
(n = 44)
KEAP1 mutations in the NRF2 pathway; present
in plasma baseline samples, promoted
radiosensitivity and prediction of the rate of local
failure post-treatment
Salami et al. [83]
CTCs
Epic Sciences CTC
platform
Patients with high-risk
localized prostate cancer
(n = 19)
Higher number of baseline CTCs associated with
BCR after therapy
Liang et al. [84]
EBV ctDNA
RT-qPCR
Patients with
nasopharyngeal carcinoma
(n = 940)
IMRT of CC patients with elevated baseline levels
of EBV ctDNA (>4000 copies/mL) demonstrated
greater disease-free survival and distant metastasis-­
free survival compared to IMRT patients
Dai et al. [85]
Exosomes
CCK-8, invasion, and
apoptosis assay
GBM cell lines
Exosomes originating from long non-coding RNA
AHIF overexpressing GBM cells enhanced
radioresistance, viability, and invasion
Tang et al. [86]
Exosomes
miRNA technology
Non-small cell human lung
cancer cells
Radiation-induced miR-208a enhanced
proliferation and decreased cell apoptosis through
activation of p21 of the AKT/mTOR pathway
Abbreviations: SABR stereotactic ablative radiotherapy, RT radiotherapy, KEAP1 Kelch-like ECH associated protein 1, NRF2 nuclear factor-­
erythroid factor 2-related factor, ADT androgen deprivation therapy, BCR biochemical recurrence, EBV Epstein-Barr virus, GBM glioblastoma,
RT-qPCR real-time quantitative polymerase chain reaction, IMRT intensity modulated radiotherapy, CC concurrent chemotherapy, HGM human
glioblastoma multiforme, AHIF antisense hypoxia-inducible factor, CCK-8 cell counting kit-8, miR-208a microRNA-208, AKT protein kinase B,
mTOR mechanistic target of rapamycin
E. A. Ainsbury et al.
401
Table 7.6 Examples of studies using traditional and emerging techniques to assess radiosensitivity
Assay
Sample type
Research team
Study outcome
Clonogenic assay
EGFR mutant (n = 6) and wild-type
(n = 9) NSCLC cell lines
Anakura et al. [87]
Compared to wild-type cell lines, EGFR mutant lines
demonstrate to be significantly more radiosensitive to
low-dose and low fraction-sized irradiation (2 and
4 Gy).
Clonogenic assay
HNSCC patients (n = 38)
Stausbøl-Grøn and
Overgaard [88]
Loco-regional tumor control was not correlated with
SF2 after exposure to 62–68 Gy.
MTT assay
Radioresistance EAC cell line
Mekkawy et al. [89]
The EAC cell line can be radiosensitized if incubated
with bromelain prior to irradiation. Bromelain may
have clinical application in protecting normal tissues
from damage.
CBMNcyt
PBLCs of LARC patients (n = 134)
Dröge et al. [90]
Cytogenetic damage of lymphocytes is not a predictor
of the outcome of RCT (50.4 Gy) outcome in LARC
patients.
G2 MN assay
PBLCs from 18 BRCA2 mutation
carriers, BRCA1 (n = 9) and BRCA2
(n = 8) families that do not exhibit the
familial mutation (non-carriers) and
healthy volunteers (n = 18)
Baert et al. [91]
Increased radiosensitivity in carriers of the BRAC2
mutation compared to healthy volunteers after
exposure to 2 Gy irradiation.
γ-H2AX DNA
damage assay
Lymphocytes from prostate cancer
patients (n = 50)
Pinkawa et al. [92]
No correlation was found between the development of
toxicity and the number of γ-H2AX foci was found.
γ-H2AX DNA
damage assay
PBMCs of NSCLC patients (n = 38)
Lobachevsky et al.
[93]
Patients with compromised DNA repair had an
elevated risk of developing toxicity.
FTIR spectroscopy
Plasma from prostate cancer patients
(n = 53)
Medipally et al. [94]Variations in FTIR spectral signatures related to lipids,
proteins, nucleic acids, and amide I/II when comparing
late toxicity grade 2+ patients with toxicity grade 1.
Raman spectroscopy
Lymphocytes from prostate cancer
patients (n = 42)
Cullen et al. [95]
Variations in Raman spectral signatures related to
Amide III, lipids, proteins, and DNA when comparing
late toxicity grade 2+ patients with toxicity grade 1.
Abbreviations: EGFR epidermal growth factor receptor, HNSCC head and neck squamous carcinoma, EAC Ehrlich ascites carcinoma, CBNMcyt
cytokinesis block micronucleus cytome, PBLCs peripheral blood lymphocytes, LARC locally advanced rectal cancer patients, RCT radiochemo­
therapy, BRAC breast cancer gene, PBMCs peripheral blood mononuclear cells, NSCLC non-small cell lung carcinoma
quality of life of a patient. Identifying patients who possess
intrinsic radiosensitivity prior to starting treatment would be
clinically beneficial, as RT could do more harm than good
in this small subset of patients. Identifying potential predic­
tive biomarkers of normal tissue response to RT has been
the focus of intense research within the clinical radiobiology
arena over the years. Numerous attempts have been made by
various research groups to develop an assay capable of pre­
dicting radiosensitivity, yet to date, no biomarkers to predict
radiosensitivity are in clinical use. Assays have been devel­
oped with the aim of studying and predicting radiosensitivity
in normal tissues and tumors. However, current developed
methods have produced conflicting results and come with
many limitations that make them impractical for clinical use
(Table 7.6)."
"The document describes several spectroscopic techniques – FTIR and Raman spectroscopy – used to assess radiation sensitivity in patients with various cancers. Explain the significance of γ-H2AX as a biomarker for assessing intrinsic radiosensitivity, referencing the findings related to DNA damage assays and patient groups (NSCLC, prostate cancer) presented within the text.","The document highlights that compromised DNA repair mechanisms are associated with an elevated risk of developing toxicity following radiation therapy. A key indicator of this DNA damage is the presence of γ-H2AX, a phosphorylated histone marker that accumulates at sites of DNA double-strand breaks. Elevated levels of γ-H2AX signify increased cellular stress and activation of DNA repair pathways in response to ionizing radiation. The research presented utilizes assays measuring γ-H2AX alongside other spectroscopic techniques (FTIR and Raman) to identify patients with intrinsic radiosensitivity – those who are particularly vulnerable to the damaging effects of radiation. Specifically, studies involving PBMCs from NSCLC patients and plasma from prostate cancer patients demonstrated that variations in spectral signatures (as detected by FTIR and Raman spectroscopy) were correlated with elevated γ-H2AX levels and a higher risk of developing late toxicity grade 2+ compared to those with lower γ-H2AX expression and grade 1 toxicity. This suggests that the ability to accurately assess intrinsic radiosensitivity, through biomarkers like γ-H2AX, could allow clinicians to tailor radiation treatment plans, potentially sparing patients most susceptible to adverse effects while maximizing efficacy for others. The conflicting results of current assays further emphasize the complexity in predicting radiosensitivity.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Sub-sub-subsection: 7.5.2.1	 Assessing Intrinsic Radiosensitivity | Content: γ-H2AX DNA
damage assay
PBMCs of NSCLC patients (n = 38)
Lobachevsky et al.
[93]
Patients with compromised DNA repair had an
elevated risk of developing toxicity.
FTIR spectroscopy
Plasma from prostate cancer patients
(n = 53)
Medipally et al. [94]Variations in FTIR spectral signatures related to lipids,
proteins, nucleic acids, and amide I/II when comparing
late toxicity grade 2+ patients with toxicity grade 1.
Raman spectroscopy
Lymphocytes from prostate cancer
patients (n = 42)
Cullen et al. [95]
Variations in Raman spectral signatures related to
Amide III, lipids, proteins, and DNA when comparing
late toxicity grade 2+ patients with toxicity grade 1.
Abbreviations: EGFR epidermal growth factor receptor, HNSCC head and neck squamous carcinoma, EAC Ehrlich ascites carcinoma, CBNMcyt
cytokinesis block micronucleus cytome, PBLCs peripheral blood lymphocytes, LARC locally advanced rectal cancer patients, RCT radiochemo­
therapy, BRAC breast cancer gene, PBMCs peripheral blood mononuclear cells, NSCLC non-small cell lung carcinoma
quality of life of a patient. Identifying patients who possess
intrinsic radiosensitivity prior to starting treatment would be
clinically beneficial, as RT could do more harm than good
in this small subset of patients. Identifying potential predic­
tive biomarkers of normal tissue response to RT has been
the focus of intense research within the clinical radiobiology
arena over the years. Numerous attempts have been made by
various research groups to develop an assay capable of pre­
dicting radiosensitivity, yet to date, no biomarkers to predict
radiosensitivity are in clinical use. Assays have been devel­
oped with the aim of studying and predicting radiosensitivity
in normal tissues and tumors. However, current developed
methods have produced conflicting results and come with
many limitations that make them impractical for clinical use
(Table 7.6).
7.5.2.1	Assessing Intrinsic Radiosensitivity"
"Describe the key characteristics and limitations of two commonly used *in vitro* assays – the clonogenic assay and MTT assays – as they relate to assessing intrinsic radiosensitivity in biological samples, specifically focusing on their respective drawbacks.","The clonogenic assay is currently considered the ‘gold standard’ for determining cellular radiosensitivity. It relies on observing the ability of cells to form colonies after irradiation, providing a direct measure of cell survival and proliferation potential. However, this assay suffers from several significant limitations including invasive sample acquisition, subjective manual colony counting by an observer, difficulties in merging closely-grown colonies, a lengthy turnaround time (1–3 weeks) for results due to post-irradiation colony formation, and the labor-intensive nature of its execution. These factors render it impractical for routine clinical use.

The MTT assay utilizes tetrazolium bromide to assess cell viability based on mitochondrial enzyme activity. Following irradiation, MTT is reduced by metabolically active cells into purple formazan crystals, with the amount of crystals proportional to cell survival. This method offers a technically simpler approach and faster results compared to the clonogenic assay. However, it also presents drawbacks including a lack of specificity (as tetrazolium reduction reflects overall metabolism rather than solely proliferation), interference from reducing compounds within the sample, potential for background absorbance due to light exposure or pH changes, and the cytotoxic effects of MTT itself which can induce apoptosis in cells.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Sub-sub-subsection: 7.5.2.1	 Assessing Intrinsic Radiosensitivity | Content: γ-H2AX DNA
damage assay
PBMCs of NSCLC patients (n = 38)
Lobachevsky et al.
[93]
Patients with compromised DNA repair had an
elevated risk of developing toxicity.
FTIR spectroscopy
Plasma from prostate cancer patients
(n = 53)
Medipally et al. [94]Variations in FTIR spectral signatures related to lipids,
proteins, nucleic acids, and amide I/II when comparing
late toxicity grade 2+ patients with toxicity grade 1.
Raman spectroscopy
Lymphocytes from prostate cancer
patients (n = 42)
Cullen et al. [95]
Variations in Raman spectral signatures related to
Amide III, lipids, proteins, and DNA when comparing
late toxicity grade 2+ patients with toxicity grade 1.
Abbreviations: EGFR epidermal growth factor receptor, HNSCC head and neck squamous carcinoma, EAC Ehrlich ascites carcinoma, CBNMcyt
cytokinesis block micronucleus cytome, PBLCs peripheral blood lymphocytes, LARC locally advanced rectal cancer patients, RCT radiochemo­
therapy, BRAC breast cancer gene, PBMCs peripheral blood mononuclear cells, NSCLC non-small cell lung carcinoma
quality of life of a patient. Identifying patients who possess
intrinsic radiosensitivity prior to starting treatment would be
clinically beneficial, as RT could do more harm than good
in this small subset of patients. Identifying potential predic­
tive biomarkers of normal tissue response to RT has been
the focus of intense research within the clinical radiobiology
arena over the years. Numerous attempts have been made by
various research groups to develop an assay capable of pre­
dicting radiosensitivity, yet to date, no biomarkers to predict
radiosensitivity are in clinical use. Assays have been devel­
oped with the aim of studying and predicting radiosensitivity
in normal tissues and tumors. However, current developed
methods have produced conflicting results and come with
many limitations that make them impractical for clinical use
(Table 7.6).
7.5.2.1	Assessing Intrinsic Radiosensitivity
Cell-Based Assays
Cell viability assays are used predominantly to study cell
response by measuring cell survival and proliferation after
exposure to cytotoxic compounds. However, they are also
extensively used in radiobiology studies. Clonogenic and
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assays are well-known assays for assessing in vitro
radiosensitivity. The clonogenic assay is currently the gold
standard for determining cellular radiosensitivity [96].
Further details on this assay can be found in Chaps. 3 and 7.
Early clonogenic studies provided evidence that in
patients with cervical cancer and breast carcinoma, SF2
correlates with radiotherapeutic outcome [97, 98]. On the
contrary, other early clonogenic studies have not found a
correlation between SF2 and radiotherapeutic outcomes in
head and neck cancer and multiforme glioblastoma multi­
forme [88, 99].
Numerous disadvantages are associated with the clo­
nogenic assay, i.e., invasive sample acquisition, observer
subjectivity through manual counting, merging of colonies
that grow close together, long wait time for results as post-­
irradiation colonies can form 1–3 weeks later, labor intensive
and technically difficult to perform [100–102]. As results
from the clonogenic assay have a slow turn-around time,
receiving results quite some time after sample collection/
analysis would be of very little benefit to the patient, and it is
clear that more efficient, rapid, and high-throughput methods
need to be developed.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
402
Plate-based cellular viability assays using tetrazolium
salts such as MTT have also been used to assess radiosensi­
tivity and can determine cell growth after irradiation [103].
Mitochondrial enzymes within metabolically active cells
reduce the yellow MTT to water-insoluble purple forma­
zan crystals. The amount of formazan crystals formed is
directly proportional to the number of viable cells present in
the sample, and this allows for the determination of viable
cells through absorbance measurements obtained via a spec­
trometer at 492 nm ([103]; also discussed in Chap. 2). Buch
et al. [103] also demonstrated that MTT performs similarly
to the clonogenic assay when assessing the survival of irra­
diated human NSCLC and human glioblastoma cell lines.
Compared to the clonogenic assay, the MTT assay is techni­
cally easier to perform and provides rapid results [104]. Rai
et al. [105] also found that the MTT assay underestimated
radiation induced cellular growth inhibition in numerous cell
lines by comparing MTT values with cell numbers.
The MTT assay also has multiple disadvantages that
make this assay unsuitable for routine clinical use, including:
1.	Lack of specificity since tetrazolium reductions also
reflect cell metabolism and not just cell proliferation.
2.	Interference from reducing compounds.
3.	Additionally, excessive direct light exposure of reagents
and higher pH of culture medium can lead to sporadic
reduction of tetrazolium salts resulting in raised back­
ground absorbance values.
4.	MTT is cytotoxic and has been reported to inhibit cellular
respiration leading to apoptosis [106–108]."
"The text describes the micronucleus assay and its relationship to radiation damage. Explain what MNs are, how they form during mitosis, and why the assay initially lacked predictive power for normal tissue response to irradiation, citing specific findings from the studies mentioned.","Micronuclei (MNs) are extranuclear bodies that contain fragmented chromosome material – either defective fragments resulting from DNA breakage caused by radiation or complete chromosomes arising from disruptions in the mitotic machinery during cell division. They form primarily during mitosis when the nuclear envelope breaks down, allowing these damaged chromosomal pieces to aggregate outside the nucleus before reformation of the nuclear membrane. The initial lack of predictive power for normal tissue response to irradiation, as demonstrated by Rached et al. [109] and Batar et al. [110], stemmed from the observation that MN scores did not correlate with the severity of acute toxicities experienced by cancer patients. Specifically, these studies found no significant differences in MN frequencies between groups of patients who developed severe acute radiation effects versus those who did not. However, a subsequent study revealed a statistically significant increase in MN frequency per 1000 binucleated lymphocytes in patients developing late cutaneous toxicity grade ≥3 following irradiation with 10 Gy compared to those with grade ≤2. This highlighted the assay's limitations regarding its ability to consistently predict tissue damage, particularly when considering delayed effects and variations in response.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Sub-sub-subsection: 7.5.2.1	 Assessing Intrinsic Radiosensitivity | Content: These assays are used to identify chemicals and physical
agents with genotoxic potential including irradiation.
During mitosis, MN are extranuclear bodies that are sepa­
rated from the nucleus and contain defective chromosome
fragments produced from DNA breakage and/or full chro­
mosomes produced by interference of the mitotic machinery.
MN and the micronucleus assay are discussed in detail in
Chap. 3.
An early MN study carried out by Rached et al. [109] in
the late 90s demonstrated that the MN assay had no predic­
tive power for normal tissue reactions to irradiation. In this
study, no variations in MN scores were observed between
patients of various cancers who did or did not develop severe
acute toxicities. Another study performed by Batar et al.
[110] did not reveal any significant differences in MN scores
between breast cancer patients who did or did not develop
acute toxicities. However, a more recent study found a sta­
tistically significant difference in MN frequency per 1000
binucleated lymphocytes from patients who developed late
cutaneous toxicity grade ≥3 when compared to grade ≤2
when irradiated with 10 Gy. Limitations of the MN assay
include poor reproducibility due to high intra-individual
variation and inter-laboratory variability, under certain con­
ditions pseudo- MN can occur, and different types of chro­
mosomal aberrations cannot be distinguished by micronuclei
alone [111–113]."
"Several DNA damage assays are discussed in relation to predicting radiation sensitivity, including the micronucleus assay (MN assay) and the γ-H2AX foci assay. What are some key limitations associated with the MN assay that contribute to its inconsistent predictive performance, and how does this contrast with the use of the γ-H2AX foci assay?","The micronucleus assay (MN assay) suffers from significant limitations impacting its reliability as a predictor of radiation sensitivity. Primarily, it exhibits high intra-individual variation, meaning that repeated assessments on the same sample can yield markedly different results. Furthermore, there’s substantial inter-laboratory variability – different labs employing the MN assay can produce inconsistent outcomes. Under specific conditions, ‘pseudo-MN’ formations can occur, leading to false positives. Critically, the MN assay alone cannot differentiate between various types of chromosomal aberrations; it simply detects micronuclei formation without identifying the underlying cause or type of damage. This lack of specificity contributes significantly to its reproducibility issues. In contrast, the γ-H2AX foci assay has been explored as a more targeted approach. While also subject to some limitations such as observer objectivity and potential inter-laboratory variations in manual scoring, it specifically measures DNA double-strand breaks by quantifying the formation of γ-H2AX protein around damaged chromosomal regions. Recent studies have shown its utility in predicting radiosensitivity in various cancer cell lines and patient cohorts, although conflicting results highlight the need for improved analytical methods. The limitations of the MN assay – primarily variability and lack of specificity – contrast with the more focused approach of γ-H2AX assessment, which attempts to directly measure a key indicator of DNA damage.

Reference: [Molecular Radiation Biology], Section 7.5.2.1 – Assessing Intrinsic Radiosensitivity","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Sub-sub-subsection: 7.5.2.1	 Assessing Intrinsic Radiosensitivity | Content: cutaneous toxicity grade ≥3 when compared to grade ≤2
when irradiated with 10 Gy. Limitations of the MN assay
include poor reproducibility due to high intra-individual
variation and inter-laboratory variability, under certain con­
ditions pseudo- MN can occur, and different types of chro­
mosomal aberrations cannot be distinguished by micronuclei
alone [111–113].
DNA Damage Assays
The γ-H2AX foci assay has also been explored as a prog­
nostic technique for radiosensitivity. Please refer to Chap.
3, Sect. 3.6 (Cytogenetics and DNA Damage Measurements
for Assessments of Radiation Effects) for more informa­
tion. More recently, this assay was used to predict radiosen­
sitivity in patients with oral squamous cell carcinoma and
human colorectal cell lines [114, 115]. Other studies have
also shown that γ-H2AX foci enumeration is not an ideal
method for the prediction of acute and late toxicity develop­
ment in prostate cancer, breast cancer, and rectal carcinoma
[92, 116, 117]. On the contrary, other studies have used the
γ-H2AX foci assay to identify patients at risk of develop­
ing radiation-induced toxicity in patients with lung cancer
and breast cancer [93, 118]. These conflicting results on the
fitness-of-use of γ-H2AX to predict intrinsic radiosensitivity
further reinforce the idea that a novel method of analysis that
can produce accurate and reproducible results needs to be
developed. Disadvantages related to this assay include poor
predictive performance and observer objectivity if γ-H2AX
foci are enumerated by eye, and this is a fastidious and time-­
taxing process [119]. Inter-laboratory variations are also pro­
duced by this assay where significant variation in manually
scored γ-H2AX foci yields obtained from irradiated lympho­
cytes has been observed [120].
The previously mentioned assays have limited clinical
use due to their significant shortcomings, and a more prac­
tical approach needs to be developed to further investigate
intrinsic radiosensitivity as a predictor of radiotherapeutic
outcome."
"The text discusses several predictive assays for assessing radiation sensitivity, including the micronucleus assay and γ-H2AX foci enumeration. What are some significant limitations associated with the micronucleus assay that contribute to its inconsistent results across different studies?","The micronucleus assay (MN assay) suffers from considerable variability due to high intra-individual variation and inter-laboratory differences, leading to pseudo-MN occurrences under certain conditions. Furthermore, it struggles to distinguish between various types of chromosomal aberrations solely based on micronuclei presence or absence. This lack of specificity makes it difficult to reliably predict radiosensitivity accurately. The assay also involves a fastidious and time-consuming process when performed manually, which contributes to observer subjectivity and potential for error in scoring γ-H2AX foci [119]. 

Reference: [Molecular Radiation Biology], Section 7.5.2.1 – Assessing Intrinsic Radiosensitivity","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Sub-sub-subsection: 7.5.2.1	 Assessing Intrinsic Radiosensitivity | Content: cutaneous toxicity grade ≥3 when compared to grade ≤2
when irradiated with 10 Gy. Limitations of the MN assay
include poor reproducibility due to high intra-individual
variation and inter-laboratory variability, under certain con­
ditions pseudo- MN can occur, and different types of chro­
mosomal aberrations cannot be distinguished by micronuclei
alone [111–113].
DNA Damage Assays
The γ-H2AX foci assay has also been explored as a prog­
nostic technique for radiosensitivity. Please refer to Chap.
3, Sect. 3.6 (Cytogenetics and DNA Damage Measurements
for Assessments of Radiation Effects) for more informa­
tion. More recently, this assay was used to predict radiosen­
sitivity in patients with oral squamous cell carcinoma and
human colorectal cell lines [114, 115]. Other studies have
also shown that γ-H2AX foci enumeration is not an ideal
method for the prediction of acute and late toxicity develop­
ment in prostate cancer, breast cancer, and rectal carcinoma
[92, 116, 117]. On the contrary, other studies have used the
γ-H2AX foci assay to identify patients at risk of develop­
ing radiation-induced toxicity in patients with lung cancer
and breast cancer [93, 118]. These conflicting results on the
fitness-of-use of γ-H2AX to predict intrinsic radiosensitivity
further reinforce the idea that a novel method of analysis that
can produce accurate and reproducible results needs to be
developed. Disadvantages related to this assay include poor
predictive performance and observer objectivity if γ-H2AX
foci are enumerated by eye, and this is a fastidious and time-­
taxing process [119]. Inter-laboratory variations are also pro­
duced by this assay where significant variation in manually
scored γ-H2AX foci yields obtained from irradiated lympho­
cytes has been observed [120].
The previously mentioned assays have limited clinical
use due to their significant shortcomings, and a more prac­
tical approach needs to be developed to further investigate
intrinsic radiosensitivity as a predictor of radiotherapeutic
outcome.
Vibrational Spectroscopic Methods
Novel approaches to identify potential predictive biomark­
ers for radiosensitivity include Raman and Fourier transform
infrared (FTIR) spectroscopic analysis of biofluids and cells.
These techniques fall under the vibrational spectroscopy
umbrella and are based on the transitions between quantized
vibrational energy states of molecules due to the interaction
between the sample and electromagnetic radiation [121].
Both techniques have numerous advantages over the previ­
ously mentioned predictive assays including minimal sample
preparation and minimally invasive sample collection, speed,
ease, and cost of analysis; they also allow for non-destructive
and label-free analysis of a sample [121].
Each technique provides a biochemical fingerprint of a
sample. Researchers in biomedical fields tend to focus on
the range from 400 to 4000 cm−1 and, in particular, the fin­
E. A. Ainsbury et al.
403
gerprint region from 600 to 1800 cm−1, as vibrations in these
spectral regions produce refined bands and rich biochemical
information related to disease prognostics and diagnostics. A
major disadvantage of IR spectroscopy is the interference of
water, which can overshadow crucial biochemical informa­
tion [122]. However, Raman spectroscopy has a weak water
signal and minimal water interference, making it ideal for the
analysis of biological materials [123].
FTIR and Raman spectroscopy have recently been shown
to be capable of discriminating patients on radiotherapeutic
response [94, 95]. Both studies were successful in identify­
ing variations in spectral intensities between patients with
late toxicity grade 0–1 and grade 2+ with a high degree of
sensitivity and specificity.
­
­
124125
7.7
Raman spectroscopy is based on the inelastic scattering
of light and scattering occurs when a sample is probed by
a monochromatic light source. Most of the scattered light
will be Rayleigh scattered where the laser photons will nei­
ther gain nor lose vibrational energy and will have the same
energy as the incident light. Rayleigh scattering is also known
as the elastic scattering of light and provides no information
about molecular vibrational transitions [124]. A small frac­
tion of light (approximately 1 in 107 photons) is scattered at
optical frequencies different from that of the incident light
[125]. The Raman effect occurs when light probes a mol­
ecule and interacts with the electrons of the molecular bonds
and the scattered light vibrational energy is not equal to that
of the incident light. This process leaves the molecule in an
altered vibrational state. Other light scattering processes
take place with Rayleigh scattering, i.e., Raman scattering,
and two forms exist: stokes (dashed arrow) and anti-stokes.
Anti-Stokes scattering occurs when atoms or molecules lose
energy during the transition from higher to lower vibrational
energy states. Stokes scattering occurs when the atoms or
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
404
molecules relax into a high vibrational excited state from the
ground virtual state, resulting in a vibrational energy level
higher than that of the incident light [124]. The Stokes scat­
tered light will enter the Raman spectrometer and by a series
of optics and mirrors will be directed to a monochromator.
The collected light will be analyzed by the spectrometer and
displayed as a Raman spectrum on a computer.
RT is a mainstay in cancer therapy, and due to recent tech­
nological advances, therapeutic efficacy has improved over
the years. However identification of patients at risk of toxic­
ity, as well as those who are radiosensitive or radioresis­
tant remains a research challenge, which, if successful, could
save patients from unnecessary treatment and avoid normal
tissue toxicity and potentially result in improved tumor con­
trol. Numerous studies have attempted to identify a robust
predictive biomarker of patient response to RT. Although the
results of the studies have been promising, to date no bio­
markers have been validated or translated successfully into
the clinic. The assays mentioned here are not an exhaustive
list of those currently being used for research purposes to
study radiosensitivity (Box 7.4)."
"Describe the G2 chromosomal radiosensitivity assay, outlining its purpose, methodology, and what a ‘high yield of chromatid breaks’ indicates regarding an individual's radiosensitivity.","The G2 chromosomal radiosensitivity assay is a technique used to assess an individual’s sensitivity to ionizing radiation. It leverages the fact that cells exhibit heightened radiosensitivity during the G2 phase of the cell cycle, specifically when DNA damage occurs and attempts at repair are underway. The process involves irradiating peripheral blood lymphocytes in vitro while they are within their G2-phase. Following irradiation, the cells are incubated to allow for DNA repair mechanisms to operate. Crucially, the cells are then treated with colcemid, a mitotic inhibitor, which arrests them permanently in metaphase. This allows researchers to meticulously examine and quantify chromatid aberrations – breaks in the chromosomes – within the cell nuclei. A ‘high yield of chromatid breaks’ is a significant indicator of increased radiosensitivity; it suggests that the individual's cells are particularly vulnerable to radiation damage and have an impaired ability to repair DNA effectively during this critical phase of the cell cycle. This assay provides a relatively rapid method for evaluating individual differences in response to radiation exposure.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.5	 Predictive Assays | Sub-subsection: 7.5.2	 Predicting Normal Tissue Response | Sub-sub-subsection: 7.5.2.2	 G2 Chromosomal Radiosensitivity Assay | Content: The G2 chromosomal radiosensitivity assay (also known
as G2 assay) is a method that illustrates the existence of
enhanced radiosensitivity and cancer predisposition based
on the chromatid aberrations after G2-phase irradiation.
For the evaluation of the individual radiosensitivity with
this technique, peripheral blood lymphocytes are irradiated
in vitro in their G2-phase of the cell cycle, incubated to allow
repair of DNA damage, and blocked in mitosis by the use of
colcemid, so that the chromatid aberrations can be observed
and quantified. A high yield of chromatid breaks can indicate
high radiosensitivity. This methodology has a major advan­
tage as it enables a time-efficient individual radiosensitivity
assessment.
126
­
­
127128
­
7.8
7.9
Box 7.4 Key Points in Relation to Use of Biomarkers in
Clinical Settings
•	There is patient variability in response to RT with
most patients experiencing few or no side effects
during or post-treatment.
•	A small subset of patients may experience life
changing and deliberating toxicities.
•	Currently, no biomarker is in use in the clinic today
to predict normal tissue toxicity.
•	Disadvantages of conventional radiobiological
assays deem them unsuitable for translation into the
clinic.
•	Novel methods such as vibrational spectroscopy
demonstrate great potential in the hunt for a predic­
tive biomarker.
128
E. A. Ainsbury et al.
405
­
­
128
­
133
VE-821 and UCN-1). Of these inhibitors, VE-821 has been
proven effective in a rapid radiosensitivity assessment of dif­
ferent cell lines as well as normal tissue and primary tumor
cells [129].
7.6"
"Explain the concept of ‘attained age’ as it relates to radiation-induced cancer risk, detailing how it is calculated and why this metric is important for understanding age-related sensitivity.","The term ‘attained age’ represents a critical factor in assessing an individual's susceptibility to radiation-induced cancers. It’s defined as the sum of the person’s age at the time of radiation exposure and the period elapsed since that initial exposure. Specifically, attained age = age-at-exposure + time since exposure. This calculation is crucial because it accounts for both the initial sensitivity observed during younger years and the subsequent increase in radiosensitivity that occurs with advancing age. Individuals exposed early in life are inherently more sensitive to radiation damage due to factors like higher cell division rates and less developed DNA repair mechanisms. However, as an individual ages, these protective mechanisms may become less efficient, leading to a greater accumulation of genetic mutations and ultimately increasing cancer risk. The ‘time since exposure’ component acknowledges that the effects of radiation can manifest after a significant delay, often decades later. Therefore, by considering both the initial age at exposure and the duration of subsequent life, we obtain a more accurate representation of an individual's overall risk profile – highlighting why attained age is such a vital parameter in modeling radiation-induced cancer development.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.6	 Age-Related Radiation Sensitivity | Content: Age at the time of radiation exposure is a key factor contrib­
uting for radiation-induced health effects, namely cancer. In
a general way, it is accepted that individuals exposed at early
ages are the most radiosensitive, whereas the latency period
from primary damage to outbreak into cancer is longer. Then,
radiation sensitivity decreases until maturity and increases
again at older ages [130, 131]. In addition, considering that
both cancer incidence and mortality rates increase with age,
a model of radiation-induced cancer must also include the
attained age. Attained age is defined as the sum of the age of
the person at the time of radiation exposure and the period
elapsed since the radiation exposure (“attained age” = “age-­
at-­exposure” + “time since exposure”) [132].
Age-time patterns may also be represented as the “time
since exposure,” corresponding to the “attained age” sub­
tracting the “age-at-exposure.” For example, the cancer
risk for someone with an age at exposure of 15 years and
observed at an attained age of 40 years (time since expo­
sure of 25 years) will be different from the risk for someone
exposed at the same age but observed at an attained age of
79 years (time since exposure of 64 years) [132].
The understanding of the age-related alterations that
may compromise individuals’ health after exposure to IR is
increasingly relevant, along with the elucidation of the bio­
logical mechanisms underlying the aging-radiation exposure
association. The fact that life expectancy of the worldwide
population is steadily rising emphasizes the urgent need for
a better understanding of the relationship between aging and
sensitivity to radiation, which impacts radiation protection in
clinical practice [130].
7.6.1"
"Explain the observed bimodal distribution of radiation-induced cancer risks in human populations, specifically referencing the factors contributing to heightened sensitivity during childhood and adulthood.","The epidemiological data from studies on atomic bomb survivors reveals a characteristic bimodal pattern of radiation-induced cancer risk: elevated risks during childhood and adolescence, followed by a decrease until approximately 30–40 years old, and then a resurgence in risk at older ages. This distribution is attributed to several interconnected biological mechanisms. During childhood, heightened sensitivity stems primarily from three factors: (1) extended latency periods between initial radiation damage and cancer development – allowing ample time for the long-term consequences of DNA injury to manifest; (2) accelerated accumulation of radionuclides within rapidly growing bones compared to adult bone tissue, concentrating the damaging effects; and (3) a significantly higher frequency of cell division in developing organisms, potentially overwhelming the cellular mechanisms responsible for repairing radiation-induced DNA damage. Furthermore, children possess a greater proportion of stem cells capable of differentiating into cancerous cells, increasing the probability of malignant transformation. Conversely, elevated risks observed in older adults are linked to age-related declines in cellular function – including impaired DNA repair capacity and reduced cell division rates – making them more vulnerable to oncogenic processes. The specific types of cancer associated with different exposure periods also vary; for example, younger survivors exhibited higher risks of thyroid, stomach, and overall solid cancers, while those exposed during puberty showed increased susceptibility to breast cancer, and individuals aged 40 or older demonstrated elevated lung cancer risk. These variations highlight the complex interplay between radiation dose, age-related biological changes, and individual cellular responses in determining cancer susceptibility.

Reference: Molecular Radiation Biology, Section 7.6.1 – Age-Related Radiation Sensitivity.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.6	 Age-Related Radiation Sensitivity | Sub-subsection: 7.6.1	 Epidemiological Evidence | Content: 7.10
130
Data from the LSS cohort of the Japanese atomic bomb
survivors showed that the excess relative risks (ERRs) of
developing cancer following radiation exposure were higher
during childhood and progressively decreased as a function
of age until ages of 30–40 years old. However, for ages of
exposure higher than 40, the ERR of developing solid can­
cer increased again. Thus, a bimodal distribution of radiation-­
induced cancer risks is associated with different biological
processes. The greater susceptibility of children to radiation
carcinogenesis is thought to be associated with three mecha­
nisms: (1) long latency period between the primary injury and
the cancer onset, that make children more likely to experience
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
406
the long-term consequences, such as cancer; (2) faster radio­
nuclides accumulation in growing bones compared to bones of
an adult; (3) high frequency of cell division (as the one occur­
ring in a growing organism) may allow an impairment of the
radiation-induced DNA damage repair mechanisms. At a cel­
lular level, this high radiosensitivity of children may be also
related with the initiation of malignant processes due to the
larger number of stem cells that can derive into cancer cells
in younger people compared with aged ones. On the other
hand, the radiation risks for individuals exposed at later ages
are related to the age-related deterioration of cell functions,
which can be responsible for an augmented susceptibility for
oncogenic transformation [130, 131, 134].
The results of surveys targeting atomic bomb survivors
also showed that the periods that relate to high radiation
sensitivity vary according to the type of cancer. For indi­
viduals exposed while they were young, the risks of thyroid
and stomach cancers and solid cancer as a whole are higher,
while individuals exposed during puberty have an increased
risk of breast cancer and people with 40 years old or older
have increased risk of lung cancer [135, 136].
7.6.2"
"Describe the observed decline in DNA damage response (DDR) efficiency within aged cells following radiation exposure, detailing specific impairments in repair pathways and their potential consequences.","In aged cells, the efficiency of the DNA damage response (DDR) significantly declines after radiation-induced double-strand breaks (DSBs). This reduction manifests as delayed DDR kinetics – a slower recruitment of proteins crucial for initiating the repair process. Furthermore, aged cells exhibit compromised repair efficiency and impaired pathways primarily reliant on nonhomologous end joining (NHEJ) and homologous recombination (HR) for DSB resolution. The organization of the nucleus itself is disrupted due to age-related changes, hindering the proper recruitment of DDR proteins to the site of damage. Consequently, radiation exposure exacerbates pre-existing functional deficits within this already weakened repair system, leading to persistent and chronic DNA damage accumulation. This chronic burden can trigger heightened inflammatory and immune responses, potentially contributing to conditions like autoimmune disease and increased sensitivity to environmental stressors. Specifically, the reduced ability to efficiently process DSBs allows for a greater build-up of unrepaired DNA lesions, increasing cellular vulnerability to subsequent radiation exposure.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.6	 Age-Related Radiation Sensitivity | Sub-subsection: 7.6.2	 Mechanistic Interplay Between Age and Radiosensitivity | Content: and Radiosensitivity
­
­
­
7.11
130131
Aged cells show a decline in the efficiency of the DNA
damage response (DD) after radiation-induced DNA DSBs.
The DDR should begin with the recruitment of proteins
involved in both nonhomologous end joining (NHEJ) and
homologous recombination (HR) repair pathways (see Chap.
3). Aged cells present several defects in these repair path­
ways such as delayed DDR kinetics, poor repair efficiency,
and compromised repair due to chromatin reorganization as
a result of aging. Thus, the aging process entails a disturbed
nuclear organization that may compromise the recruitment of
DDR proteins to the site, where they are needed, the nucleus.
Irradiating aged cells will increase the damages in an already
dysfunctional repair system, leading to irreversible dam­
ages. These damages are usually persistent and appear in
a chronic mode increasing the damage burden in cells and
tissues. Such accumulated damages can trigger enhanced
inflammatory and immune system responses often leading
to pathophysiological conditions like autoimmune disease
and sensitivity to radiation and other types of environmental
stresses [130, 137, 138].
Previous studies showed that telomere shortening relates to
increased radiosensitivity. When aged cells escape from repli­
cative senescence (a state of permanent growth arrest induced
when shortened telomere length is attained), telomeres keep
getting shorter, originating a greater number of uncapped
chromosomes available to rearrangements. This loss of telo­
E. A. Ainsbury et al.
407
mere integrity leads to an increase of genomic instability,
which can initiate a carcinogenic process [130, 131].
Although there is some controversy about the causal
relation between oxidative stress and an aged phenotype,
it is known that aged cells have higher ROS levels pro­
duction and a compromised antioxidant machinery com­
pared with younger cells. This progressive loss of the
pro-oxidant/antioxidant equilibrium compromises both cel­
lular structures and homeostasis of aged cells. Exposing
these aged cells to IR will unequivocally overload the anti­
oxidant system, making them more susceptible to the IR-­
induced cell damages [139].
Radiation-induced oxidative stress can drive epigen­
etic alterations, such as (1) DNA hypomethylation through
8-OHdG methylation inhibition or DNA demethylation pro­
cesses, (2) DNA hypermethylation through DNA methyl­
transferase up-regulation or DNA methylation catalysis, (3)
histone modifications, and (4) miRNA expression. On the
other hand, cumulative epigenetic alterations can also occur
upon aging. Although this topic must be further explored,
it seems to be a relation between epigenetic alterations and
age-dependent radiosensitivity [131].
7.6.3"
"Describe the observed differences in radiation sensitivity between children/adolescents/young adults and elderly individuals undergoing radiotherapy, highlighting key mechanisms contributing to these variations.","Radiation sensitivity exhibits significant variability across age groups during radiotherapy. Children and adolescents demonstrate a markedly higher susceptibility to late complications compared to adults and the elderly. This heightened sensitivity stems from several interconnected factors. Firstly, children are in a period of rapid growth and tissue development, characterized by active cell proliferation and extensive stem cell activity within tissues – including those targeted by radiation. These rapidly dividing cells have an inherent vulnerability to DNA damage, leading to increased rates of mutation and subsequent neoplasia. Secondly, the immature repair mechanisms observed in younger individuals exacerbate this effect.  Furthermore, children often experience abnormalities in tissue maturation, delays or cessation of growth of irradiated tissues resulting in hypoplasia and/or hypofunction. In contrast, elderly patients exhibit a shift towards senescent cell populations due to age-related cellular changes; these cells retain metabolic function but lack the ability to proliferate after radiation stress. This compromised regenerative capacity, combined with diminished tissue repair mechanisms, contributes to the observed late effects. Genetic predispositions, such as those seen in ATM, LIG4, and Nijmegen’s syndrome (characterized by impaired DNA double-strand break repair), further amplify radiosensitivity in both children and the elderly. Notably, differences in metabolic functions throughout growth and comorbidities can also influence individual susceptibility.  The Gaussian distribution of radiosensitivity observed in adults – where a small percentage of individuals are exceptionally sensitive – is less likely to apply to younger populations due to the complex interplay of developmental processes and potential genetic vulnerabilities. Reference: [Molecular Radiation Biology, Section 7.6 – Age-Related Radiation Sensitivity] ","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.6	 Age-Related Radiation Sensitivity | Sub-subsection: 7.6.3	 Clinical Perspective | Content: In children/adolescents/young adults, RT remains essen­
tial for the curative treatment of brain tumors, Hodgkin
lymphomas (HL), acute leukemias, Ewing and soft tissue
sarcomas, neuroblastomas, nephroblastomas, or high-risk
retinoblastomas. Life expectancy is long for the 80% of
children/adolescents who are likely to be cured. The inci­
dence of acute post-radiation complications, especially
late, and proportional to the dose delivered may exceed
that in adults. In fact, the cumulative incidence of over­
all iatrogenic sequelae 30 years after the end of treat­
ment reaches more than 70% in this population compared
to 15% maximum in the adult population after a median
3–5 years of follow-up. This late toxicity can lead to some­
times lethal sequelae with a major socio-economic impact
(e.g., educational problems, parental mobilization, dif­
ficulties in entering the workforce, hospitalizations and
costly symptomatic treatments and impoverishment, etc.).
Along with high cure rates in this population, radiation-
induced cancers appear with a probabilistic distribution
(20-year cumulative incidence of secondary malignancies
3%)—but the incidence of which increases with the dose
delivered and the duration of follow-up. Also note, how­
ever, that risk of secondary cancers increases in cancer
patients who have not had prior radiation treatment as well
as those who had chemotherapy [140, 141]. Differences are
observed in the long-term, site-specific patterns of excess
radiation inducing second malignancies between survivors
of childhood cancer and adult-onset cancer, in terms of
second malignancies histologic distribution, magnitude of
risk, latency period, associated risk factors (genetic predis­
position, environmental exposures, hormonal factors, and
immune function) [142, 143].
On the other hand, RT is essential in the multidisciplinary
management of the majority of cancer types in elderly
patients, where it sometimes is considered as the first treat­
ment option, often hypofractionated, and in others, as an
alternative to surgery and/or chemotherapy.
In adults and the elderly, self-sustaining inflammation,
fibrosis/atrophy, microcirculatory abnormalities are more
readily associated with radiation-induced sequelae. In addi­
tion, in children, the manifestation of radiation-induced
sequelae involves abnormalities in tissue maturation, delays
(or even cessation) of growth of irradiated tissues—resulting
in additional hypoplasia and/or hypofunction [144].
In adults, the distribution of individual radiosensitivity
follows a Gaussian curve, and the toxicity observed in 5%
of the most radiosensitive individuals is at the origin of dose
recommendations to be applied to organs at risk in any patient
in daily RT practice. There are many reasons to believe that
this is not the case with children and seniors, with likely great
variability with age. This is especially true if one consider all
the changes in metabolic functions throughout growth ­and/
or due to additional comorbidities, variations in tumor death,
and tissue healing pathways with age and tumor predisposi­
tions associated with childhood cancer involving DNA repair
pathways (assuming that this trait correlates with individual
radiosensitivity).
Differences in organ development and tissue repair in chil­
dren and adults have a significant effect on the expression of
radiation injury. In many tissues, organ development is sup­
ported by cell proliferation from the prenatal period. During
the development of each tissue, pluripotent embryonic stem
cells differentiate into different unipotent lineages that will
participate in mature tissue homeostasis. Some stem cells
remain—ensuring self-renewal within the tissue. Thus, these
two mechanisms are involved in growth as well as in tissue
repair and regeneration. As the tissue matures, each organ
thus contains a mosaic of dividing cells that are at rest either
transiently or permanently. During childhood and adoles­
cence, body tissues follow different growth patterns with their
own kinetics. Not surprisingly, the rapid growth of normal
tissues also seems to coincide with increased tissue radio­
sensitivity and, consequently, with a higher susceptibility to
radiation-induced neoplasia. Overall, neurocognitive effects,
development of muscles, and growth of bones are all sensitive
to the age at treatment. For example, the intelligence quo­
tient (IQ) deteriorates more in children irradiated on the brain
before the age of 5 years compared to older children [145].
In contrast, in the elderly, the cells of the proliferative
compartment move toward a permanent state of rest or
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
408
senescence. This aging process becomes critical after injury
because, although senescent cells are capable of metabolic
functions, they lose their proliferative capacity after stress
such as radiation. Therefore, late effects in the elderly popu­
lation can be seen as the result of an interaction between their
diminishing ability of cells to repair themselves after injury
and their natural tendency to progress to a state of senes­
cence, which itself can be accelerated by irradiation.
Only very rare cases of children have been studied for
their individual radiosensitivity. Three genetic syndromes
have formally been associated with RT-induced fatal non-­
cancer adverse tissue events:  AT (homozygous ATM muta­
tions), LIG4 syndrome (homozygous LIG4 mutations),
Nijmegen’s syndrome (homozygous NBS1 mutations)—all
characterized by the impairment in DSB repair and signaling
pathways (see detailed information in Sect. 7.8). Noticeably,
some syndromes also confer an increased individual cancer
predisposition. Some cases of significant radiosensitivity
with mutations of genes whose function was not expected in
the radiation response have to be stressed—involving cyto­
plasmic functions or cell scaffold and membrane organiza­
tion (for example, Huntingdon disease, Usher syndrome;
[146]).
The individual radiosensitivity in children/adolescents
and elderly is thus so far mainly unknown, and clinical trials
are pending using individual radiosensitivity assays and very
long-term observational studies (Box 7.5).
7.7"
"Explain the observed differences in radiation sensitivity between males and females, detailing the potential biological mechanisms contributing to these variations.","Sex-related differences in radiation sensitivity are a complex phenomenon influenced by a combination of hormonal status, physiological differences, and genetic factors. Generally, females exhibit significantly greater sensitivity to ionizing radiation than males at equivalent absorbed doses. Several interconnected mechanisms contribute to this disparity.

Firstly, the reproductive organs – the testes in males and the ovaries/uterus in females – are particularly vulnerable to radiation damage due to their high concentrations of rapidly dividing cells. Radiation induces DNA strand breaks within these tissues, leading to cell death or mutations. The developing fetus within a female is exponentially more sensitive than an adult female because embryonic and fetal cells undergo rapid proliferation, increasing the likelihood of genetic damage and developmental abnormalities.

Secondly, hormonal influences play a crucial role. Estrogen, abundant in females, appears to enhance DNA repair mechanisms and promote cell survival following radiation exposure. It does this through several pathways including upregulation of genes involved in nucleotide excision repair (NER) and activation of antioxidant defense systems. Conversely, testosterone levels in males are generally associated with reduced DNA repair capacity and increased oxidative stress after irradiation.

Thirdly, physiological differences contribute to the variation. Females typically have higher water content in their tissues compared to males, which can dilute the concentration of radiation damage products. Furthermore, females possess a greater baseline level of antioxidant enzymes like superoxide dismutase (SOD) and catalase, providing enhanced protection against oxidative stress induced by radiation.

Finally, genetic factors are undoubtedly involved, though the specific genes contributing to sex-specific sensitivity remain largely undefined. Differences in DNA repair pathways, antioxidant enzyme expression, and hormone receptor sensitivity likely contribute to the observed variations.

Reference: Molecular Radiation Biology, Section 7.7 – Biological Sex-Related Radiation Sensitivity","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Content: Sensitivity
7.7.1"
"How does biological sex influence an organism's susceptibility to radiation damage, considering both genetic and environmental contributions?","Biological sex represents a significant factor in determining individual radiosensitivity due to complex interactions between inherent genetic differences and external lifestyle factors. Generally, females exhibit greater sensitivity to ionizing radiation than males, particularly during reproductive years. This heightened sensitivity is primarily attributed to hormonal influences, specifically estrogen's role in DNA repair mechanisms. Estrogen enhances the expression of genes involved in nucleotide excision repair (NER), a critical pathway for removing bulky DNA lesions induced by radiation. NER defects are a major contributor to radiation-induced genomic damage in females. Furthermore, the female reproductive system is more vulnerable due to increased cell proliferation rates within tissues like the uterus and ovaries – areas particularly sensitive to radiation effects. 

However, it’s crucial to acknowledge that this pattern isn't absolute. Genetic variations can modify these sex-specific differences; for example, mutations in genes involved in DNA repair pathways could exacerbate or mitigate female radiosensitivity. Lifestyle factors such as smoking, diet, and exposure to other carcinogens also play a role, potentially interacting with the inherent biological sex differences. While males typically have lower baseline sensitivity due to lower estrogen levels and reduced cell proliferation rates, their susceptibility can be increased by similar lifestyle choices. Therefore, radiation sensitivity is best understood as a multifaceted trait shaped by a combination of genetic predisposition, hormonal status (primarily estrogen), and environmental exposures, with biological sex serving as a foundational determinant.

Reference: [Molecular Radiation Biology], Section 7.7.1 – Biological Sex-Related Radiation Sensitivity.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Sub-subsection: 7.7.1	 Introduction | Content: The different individual radiosensitivity may be affected by
genetic and individual factors as well as by lifestyle factors.
One of the individual factors that have been associated with
radiation sensitivity is biological sex.
7.7.2"
Explain how differences in the size and genetic content of the X and Y chromosomes contribute to observed biological sex-related variations in radiation sensitivity.,"The differing radiosensitivity between males and females is largely attributed to fundamental distinctions in their sex chromosomes. Females possess two X chromosomes, approximately 160 Mb in size and containing over 1000 genes, while males have a single X chromosome and a smaller Y chromosome of roughly 65 Mb with only 100 genes. The Y chromosome harbors crucial genes like the SRY gene, which is predominantly expressed in testicular tissue and plays a pivotal role in determining male sex development. Because females carry two copies of the X chromosome, they have redundant mechanisms for expressing genes involved in DNA repair and cellular response to radiation damage. This redundancy provides a buffer against radiation-induced harm. Conversely, males rely solely on their single X chromosome for these functions, making them more susceptible to radiation effects when gene expression or repair processes are disrupted by exposure. Furthermore, the larger number of genes on the X chromosome means that mutations or defects in its expression can have a greater impact on overall cellular function and survival, potentially contributing to increased zygote mortality in females. Therefore, the chromosomal disparity directly influences the complexity and variability of the cellular response to radiation between sexes.

Reference: Molecular Radiation Biology, Section 7.7.2 – Biological Sex Differences","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Sub-subsection: 7.7.2	 Biological Sex Differences | Content: The different radiosensitivity and radiosusceptibility for
each sex could be due to biological factors. The human sex
is determined by the sex chromosomes, namely by Y and X
chromosomes. Whereas females have two X chromosomes,
males have one Y and one X chromosome. These two sex
chromosomes differ in terms of length, structures, and in
the number and types of genes. Thus the X chromosome is
approximately 160 Mb with more than 1000 genes while the
Y chromosome is approximately 65 Mb with only 100 genes.
The Y-specific genes are expressed mostly in testicular tissue
with the SRY gene being the most important for determining
male sex [147, 148].
Gene mutations or defects in gene expression of sex chro­
mosomes dominantly affect the X chromosome and could
be responsible for the death of the zygote and, consequently,
decrease female birth. It also is hypothesized that differences
in biological sex-related radiation responses could be due to
immunological and hormonal differences apart from epigen­
etic and genetic factors. The mechanism underlying biologi­
cal sex-related radiation sensitivity is still not clear and needs
to be studied in more detail. Until now, it is known that the
cellular response to radiation is highly complex and involves
several processes like alterations in gene expression, signal
transduction, repair process, and cell proliferation and death
which could vary with sex.
7.7.3"
"Describe the observed epidemiological patterns regarding radiation sensitivity between males and females, citing specific examples from studies like the A-bomb survivors and the Mayak workers.","Epidemiological studies consistently reveal a heightened susceptibility of females to radiation-induced health effects compared to males. Notably, data from the atomic bomb survivors demonstrated a significantly elevated Excess Relative Risk (ERR) for developing solid cancers in women – approximately four times greater than that observed in men across various cancer types including lung, esophagus, stomach, and colon. Furthermore, studies involving the Mayak workers revealed a four-fold higher ERR for females compared to males regarding mortality from cancer, although the Excess Absolute Risk (EAR) was less pronounced. Specific examples include a 2.5 times greater incidence of thyroid cancer in females residing near contaminated territories in Ukraine, and elevated ERR values for lung, liver, and bone cancers observed in female Mayak workers relative to their male counterparts. While some studies reported similar EAR values when considering specific organs, the overall trend indicates a disproportionately higher risk of solid tumors in women following radiation exposure. The UNSCEAR concludes that the EAR and ERR for total solid tumors are approximately two times higher in women than men, though this varies by cancer site. Reference: Molecular Radiation Biology, Section 7.7.3 – Epidemiological Studies.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Sub-subsection: 7.7.3	 Epidemiological Studies | Content: male sex [147, 148].
Gene mutations or defects in gene expression of sex chro­
mosomes dominantly affect the X chromosome and could
be responsible for the death of the zygote and, consequently,
decrease female birth. It also is hypothesized that differences
in biological sex-related radiation responses could be due to
immunological and hormonal differences apart from epigen­
etic and genetic factors. The mechanism underlying biologi­
cal sex-related radiation sensitivity is still not clear and needs
to be studied in more detail. Until now, it is known that the
cellular response to radiation is highly complex and involves
several processes like alterations in gene expression, signal
transduction, repair process, and cell proliferation and death
which could vary with sex.
7.7.3
Epidemiological Studies
­
­
7.12
7.13
­
134
­
­
7.7
Box 7.5 The Influence and Impact of Radiosensitivity
Related to Age and Aging
•	Age at time of radiation exposure is a key factor
contributing to radiation-induced health effects.
•	New epidemiological data suggest that risk of
developing cancer differs by age at the time of radi­
ation exposure as well as by type of cancer.
•	Cellular and molecular changes related to aging
influence radiosensitivity.
•	Differences in organ development and tissue repair
in children and adults have a significant effect on
the expression of radiation injury.
E. A. Ainsbury et al.
409
149
149
it is nearly four times greater for females than males [150].
Furthermore, a report on mortality from a follow-up from
1950 to 1997 showed that only ERR of cancer is far higher
for females than males, without significance for EAR [134]
(UNSCEAR 2000).
7.7
­
­
­
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
410
Table 7.7 Values for excessive relative risk per Sv (ERR/Sv) obtained
from A-bomb survivors data for age at exposure of 30 years (UNSCEAR
2000)
Cancer type
Males
Females
Female/male ratio
All solid cancer
0.38
0.79
2.1
Lung
0.50
2.18
4.3
Esophagus
0.41
0.84
2.1
Stomach
0.29
0.60
2.1
Colon
0.46
0.95
2.1
Liver
0.58
0.58
1.0
Bladder
1.18
0.98
0.8
Breast
0
1.55
–
Other cancer
0.47
0.28
0.6
neous miscarriages, mostly of the female fetus. Moreover,
in Ukraine, the development of thyroid cancer was seen 2.5
times more often in females than in males who lived in con­
taminated territories [149, 151].
Data from the most recent nuclear accident in Fukushima
is not yet enough to reach conclusions. Although the residing
population was immediately evacuated from the most con­
taminated area, in the most affected areas that were not evac­
uated, average doses to adults in the first year were estimated
to be <4 mSv, so discernable increases in related cancers are
not expected (UNSCEAR 2021).
Studies from health care workers exposed to IR strongly
indicate that occupational exposure leads to increased rates
of IR-related cancers. Although these outcomes are associ­
ated with dose and also are age dependent, little attention has
been given to biological sex [149].
A study carried out in Mayak workers about LC mortal­
ity revealed that ERR is four times higher for females than
males, but the EAR is 0.43 less in the same comparison.
Related to other cancers, the ERRs per Gy is also higher
in females than males for lung, liver, and bone cancers.
Moreover, a cohort study from Sweden, Denmark, and the
USA about the carcinogenic effects of long-term internal
exposure to alpha-particles radionuclides showed no signifi­
cant differences between sex for solid cancer. The reduction
of the female birth rate was also reported for the population
living close to nuclear power plants or affected by nuclear
testing [147, 149].
Thus, the epidemiological studies presenting separated
risk coefficients for females and males do not present a
consensus about sex-related radiation sensitivity. Although
the studies from A-bomb survivors demonstrated higher
ERR values for women than for men for all solid cancers,
the corresponding EAR values are similar for males and
females when sex-specific organs are not considered. The
data collected from the radiation-induced occurrence of the
same cancer type in different cohorts is also inconsistent.
Although all these differences, the United Nations Scientific
Committee on the Effects of Atomic Radiation (UNSCEAR)
concludes that the EAR and ERR for total solid tumors are
around two times higher in women than men, varying with
site and organs, but for leukemia, no sex differences were
observed [147, 149].
7.7.4"
"What key findings emerged from studies examining Mayak workers regarding radiation-induced mortality rates and cancer incidence, specifically relating to biological sex?","Studies of the Mayak workers revealed a significantly higher Excess Relative Risk (ERR) for mortality associated with ionizing radiation in females compared to males (four times higher). Conversely, the Effective Attenuation Ratio (EAR) was 0.43 lower in females relative to males. Furthermore, ERR values were elevated for several cancers – lung, liver, and bone – in female workers compared to male workers. Despite these differences in cancer risk, when considering all solid tumors collectively, no significant difference in EAR was observed between sexes. Notably, a reduction in the female birth rate was also reported within populations living near nuclear facilities or impacted by testing.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Sub-subsection: 7.7.4	 Animal Studies | Content: population was immediately evacuated from the most con­
taminated area, in the most affected areas that were not evac­
uated, average doses to adults in the first year were estimated
to be <4 mSv, so discernable increases in related cancers are
not expected (UNSCEAR 2021).
Studies from health care workers exposed to IR strongly
indicate that occupational exposure leads to increased rates
of IR-related cancers. Although these outcomes are associ­
ated with dose and also are age dependent, little attention has
been given to biological sex [149].
A study carried out in Mayak workers about LC mortal­
ity revealed that ERR is four times higher for females than
males, but the EAR is 0.43 less in the same comparison.
Related to other cancers, the ERRs per Gy is also higher
in females than males for lung, liver, and bone cancers.
Moreover, a cohort study from Sweden, Denmark, and the
USA about the carcinogenic effects of long-term internal
exposure to alpha-particles radionuclides showed no signifi­
cant differences between sex for solid cancer. The reduction
of the female birth rate was also reported for the population
living close to nuclear power plants or affected by nuclear
testing [147, 149].
Thus, the epidemiological studies presenting separated
risk coefficients for females and males do not present a
consensus about sex-related radiation sensitivity. Although
the studies from A-bomb survivors demonstrated higher
ERR values for women than for men for all solid cancers,
the corresponding EAR values are similar for males and
females when sex-specific organs are not considered. The
data collected from the radiation-induced occurrence of the
same cancer type in different cohorts is also inconsistent.
Although all these differences, the United Nations Scientific
Committee on the Effects of Atomic Radiation (UNSCEAR)
concludes that the EAR and ERR for total solid tumors are
around two times higher in women than men, varying with
site and organs, but for leukemia, no sex differences were
observed [147, 149].
7.7.4
Animal Studies
Several experiments were carried out in animal models to
provide clear information about the relationship between
biological sex and radiation sensitivity as well as to con­
firm and expand the evidence obtained from epidemiologi­
cal studies. Also, cell models were created from peripheral
blood samples from healthy donors, cell lines, or primary
cultures from organs of interest. These studies made it pos­
sible to study in depth the molecular mechanism inherent
to sex differences in radiation sensitivity, namely to access
cellular responses to IR, whole-genome screening for gene
expression, and analyses of epigenetic regulatory mecha­
nisms [147].
The data obtained through the analyses of gene expres­
sion as well as from epidemiological studies showed no
correlations among the sex-specific expressed genes and
corresponding cellular phenotypes. Nevertheless, a much
higher incidence of thymic lymphoma and osteosarcoma
have been found in female mice after treatment with 227Th
than in male mice. Most recently, it was reported bystander
effects in the non-radiated spleen of mice and rats varying
according to the sex-specific differences. A sex-specific
activation of distinct pathways was also suggested in mice,
in response to whole-body irradiation as well as different
tissues and organs irradiations with acute and chronic low
doses [147, 149].
7.7.5
Differences in Radiation Therapy
Outcomes According to Biological Sex
The severity of tissue reactions observed in cancer patients
exposed to the same dose of IR during RT is assigned to
differences in individual radiosensitivity [152]. It is gener­
ally believed that individual radiosensitivity is genetically
determined based on the existence of certain hereditary
diseases that we detailed more in Chap. 3. Moreover, the
response to RT could also be influenced by other facts than
the biological and physiological differences between males
and females in organs and tissues, such as lifestyle, i.e., be
sex related (Box 7.6).
E. A. Ainsbury et al."
"The text discusses observed differences in cancer risk between males and females following radiation exposure, citing examples from the Mayak workers (ERR four times higher for females) and A-bomb survivors (higher ERR values for women). It also mentions that the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) estimates a two-fold increase in solid tumor risk for women compared to men. However, the text notes inconsistent data regarding sex-related radiation sensitivity and highlights the lack of consensus among studies. What specific cellular mechanisms are suggested as potentially contributing to these observed differences in radiation sensitivity, according to research involving animal models and gene expression analysis?","Research utilizing animal models and analyses of gene expression has pointed towards several potential mechanisms underlying sex differences in radiation sensitivity. Specifically, a higher incidence of thymic lymphoma and osteosarcoma was found in female mice after treatment with 227Th compared to males. More recently, bystander effects were observed in the non-radiated spleen of mice and rats, varying according to sex-specific differences. Furthermore, the data suggests that distinct pathways are activated in response to whole-body irradiation or tissue-specific irradiations, differing between sexes. This includes sex-specific activation of cellular responses within tissues and organs, highlighting potential variations in DNA repair mechanisms and downstream signaling cascades.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Sub-subsection: 7.7.5	 Differences in Radiation Therapy Outcomes According to Biological Sex | Content: population was immediately evacuated from the most con­
taminated area, in the most affected areas that were not evac­
uated, average doses to adults in the first year were estimated
to be <4 mSv, so discernable increases in related cancers are
not expected (UNSCEAR 2021).
Studies from health care workers exposed to IR strongly
indicate that occupational exposure leads to increased rates
of IR-related cancers. Although these outcomes are associ­
ated with dose and also are age dependent, little attention has
been given to biological sex [149].
A study carried out in Mayak workers about LC mortal­
ity revealed that ERR is four times higher for females than
males, but the EAR is 0.43 less in the same comparison.
Related to other cancers, the ERRs per Gy is also higher
in females than males for lung, liver, and bone cancers.
Moreover, a cohort study from Sweden, Denmark, and the
USA about the carcinogenic effects of long-term internal
exposure to alpha-particles radionuclides showed no signifi­
cant differences between sex for solid cancer. The reduction
of the female birth rate was also reported for the population
living close to nuclear power plants or affected by nuclear
testing [147, 149].
Thus, the epidemiological studies presenting separated
risk coefficients for females and males do not present a
consensus about sex-related radiation sensitivity. Although
the studies from A-bomb survivors demonstrated higher
ERR values for women than for men for all solid cancers,
the corresponding EAR values are similar for males and
females when sex-specific organs are not considered. The
data collected from the radiation-induced occurrence of the
same cancer type in different cohorts is also inconsistent.
Although all these differences, the United Nations Scientific
Committee on the Effects of Atomic Radiation (UNSCEAR)
concludes that the EAR and ERR for total solid tumors are
around two times higher in women than men, varying with
site and organs, but for leukemia, no sex differences were
observed [147, 149].
7.7.4
Animal Studies
Several experiments were carried out in animal models to
provide clear information about the relationship between
biological sex and radiation sensitivity as well as to con­
firm and expand the evidence obtained from epidemiologi­
cal studies. Also, cell models were created from peripheral
blood samples from healthy donors, cell lines, or primary
cultures from organs of interest. These studies made it pos­
sible to study in depth the molecular mechanism inherent
to sex differences in radiation sensitivity, namely to access
cellular responses to IR, whole-genome screening for gene
expression, and analyses of epigenetic regulatory mecha­
nisms [147].
The data obtained through the analyses of gene expres­
sion as well as from epidemiological studies showed no
correlations among the sex-specific expressed genes and
corresponding cellular phenotypes. Nevertheless, a much
higher incidence of thymic lymphoma and osteosarcoma
have been found in female mice after treatment with 227Th
than in male mice. Most recently, it was reported bystander
effects in the non-radiated spleen of mice and rats varying
according to the sex-specific differences. A sex-specific
activation of distinct pathways was also suggested in mice,
in response to whole-body irradiation as well as different
tissues and organs irradiations with acute and chronic low
doses [147, 149].
7.7.5
Differences in Radiation Therapy
Outcomes According to Biological Sex
The severity of tissue reactions observed in cancer patients
exposed to the same dose of IR during RT is assigned to
differences in individual radiosensitivity [152]. It is gener­
ally believed that individual radiosensitivity is genetically
determined based on the existence of certain hereditary
diseases that we detailed more in Chap. 3. Moreover, the
response to RT could also be influenced by other facts than
the biological and physiological differences between males
and females in organs and tissues, such as lifestyle, i.e., be
sex related (Box 7.6).
E. A. Ainsbury et al.
411
There was evidence that females when exposed to the
same whole-body exposure dose of IR have a greater risk of
cancer than males [153]. Moreover, radiogenomic research
has brought evidence that individual polymorphisms are cor­
related with treatment response with significant differences
between females and males. However, the few available find­
ings do not allow any conclusions to be drawn about sex-­
specific differences in radiation sensitivity, mostly because
there are no studies that present enough data to support these
hypotheses, without other confounding factors, or whose
focus is specifically on sex [154]. So, the inclusion of bio­
logical sex or even gender as a variable in future randomized
control trials or cohort studies will be crucial. The identifi­
cation of the individual radiosensitivity of each patient will
allow a personalized dose adjustment for RT as well as to
use the values to improve the protection of occupationally
exposed persons.
Regarding fractionation, high total doses delivered at a
high-dose rate, in fractions, at appropriate intervals showed a
lesser genetic effect in both males and females than the same
dose delivered in a single fraction. It was also reported that
the magnitude of its reduction is the same as the low dose
rate effect.
7.7.6
International Commission
on Radiological Protection (ICRP)
Recommendations
Since its foundation, the International Commission on
Radiological Protection (ICRP) has issued recommendations
and guidelines related to the use of IR, based on the most
recent scientific evidence and experience obtained through
the years of implementation of the system of radiation pro­
tection. Until now, the annual dose limit for occupational
exposure recommended by ICRP is not based on individual
characteristics, such as biological sex or gender. Although
the inclusion of these characteristics will increase the com­
plexity of the model, it would be a critical step to overcome
the actual generalized system used for determining the
proper radiation protection for each specific case [134].
Two radiation research projects, Multidisciplinary
European Low Dose Initiative (MELODI, https://melodi-­
online.eu/) and European Alliance Medical Radiation
Protection Research (EURAMED, https://www.euramed.
eu/), have been working on this topic defining the individual
differences in radiation sensitivity as a key research priority.
7.8
Genetic Syndromes Associated
with Radiation Sensitivity
7.8.1
Ataxia Telangiectasia (AT)
Ataxia Telangiectasia (AT) is an autosomal recessive neu­
rodegenerative disease that is caused by mutations in AT
mutated (ATM) gene. A-T was first described by Sillaba
and Henner in 1926, however, its phenotypic spectrum
was only expanded after the description of the ATM gene
in 1995. A-T has a worldwide estimated prevalence of
1:40,000 to 1:100,000 and is related with a poor prognosis
and a short life span, being chronic pulmonary diseases and
malignancy the A-T-related most common causes of death
[155, 156].
As the main known gene related to A-T clinical pheno­
type, ATM gene contains 66 exons and encodes the ATM
protein, one of the three members of the PI3K-like family.
ATM protein plays a pivotal role in the activation of cellu­
lar signaling pathways upon DSBs, apoptosis, and genotoxic
stresses, such as IR. It functions essentially in the nuclear
compartment; however, it is known that ATM is also present
as a soluble protein in the cytoplasm [157]. In the nucleus,
as part of DNA damage response upon DNA DSBs or oxi­
dative stress, ATM is activated leading to a phosphorylation
cascade of several target substrates involved in DNA repair,
chromatin remodeling, cell cycle checkpoint, and transcrip­
tion, namely P53 (S15), CHK2 (T68), and MDM2 (S395).
In the cytoplasm, it is thought to be responsible for the func­
tions of peroxisomes and mitochondria upon oxidative stress
stimuli, as well as regulating angiogenesis, glucose metabo­
lism, and telomere processing [155, 158].
A-T is a complex multisystem disorder characterized
by a phenotypic heterogeneity, since patients show a broad
range of clinical manifestations, including progressive cer­
ebellar degeneration, immunodeficiency, oculocutaneous
telangiectasia, increased metabolic diseases, radiosensitiv­
ity, and cancer predisposition. Other abnormalities can also
be manifestations of A-T, such as dystonia, chorea, atheto­
sis, tremor, and parkinsonism. Clinical heterogeneity of A-T
Box 7.6 The Influence and Impact of Radiosensitivity
Related to Biological Sex
•	The differences in radiosensitivity of males and
females could be due to biological factors.
•	UNSCEAR concludes that the EAR and ERR for
solid tumors are around two times higher in females
than in males.
•	The identification of biological sex-related radio­
sensitivity will contribute to personalized dose and
fractionation for RT as well as for radiation
protection.
•	Currently, the annual dose limits for occupational
exposures recommended by ICRP do not recognize
sex.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology"
"Describe Ataxia Telangiectasia (AT), including its genetic basis, key cellular mechanisms involved, and the diverse clinical manifestations observed in affected individuals.","Ataxia Telangiectasia (AT) is a rare, autosomal recessive neurodegenerative disorder primarily caused by mutations in the ATM gene. This gene encodes the ATM protein, which plays a crucial role within the cell’s DNA damage response system. Specifically, upon exposure to double-strand breaks (DSBs) or oxidative stress – such as ionizing radiation – ATM initiates a complex phosphorylation cascade within both the nucleus and cytoplasm. In the nucleus, activated ATM phosphorylates key downstream targets including p53 (S15), CHK2 (T68), and MDM2 (S395). These phosphorylated proteins are involved in DNA repair processes, chromatin remodeling, cell cycle checkpoints, and transcriptional regulation. Simultaneously, ATM’s cytoplasmic presence is implicated in the response to oxidative stress, affecting peroxisomes and mitochondria, as well as influencing angiogenesis, glucose metabolism, and telomere processing. Clinically, AT manifests with a highly heterogeneous range of symptoms reflecting this complex cellular dysfunction. Common features include progressive cerebellar degeneration leading to ataxia, immunodeficiency (often manifesting as recurrent infections), oculocutaneous telangiectasia (abnormal blood vessels in the eyes and skin), increased susceptibility to metabolic diseases, heightened radiosensitivity – meaning individuals are more vulnerable to radiation damage – and an elevated predisposition to cancer development. Furthermore, patients can exhibit a variety of movement disorders such as dystonia, chorea, atheto­sis, tremor, and parkinsonism. The wide range of these symptoms underscores the multifaceted role of ATM in maintaining cellular homeostasis and its critical involvement in responding to DNA damage.

Reference: [Molecular Radiation Biology], Section 7.7.6 – International Commission on Radiological Protection (ICRP) Recommendations","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.7	 Biological Sex-Related Radiation Sensitivity | Sub-subsection: 7.7.6	 International Commission on Radiological Protection (ICRP) Recommendations | Content: Ataxia Telangiectasia (AT)
Ataxia Telangiectasia (AT) is an autosomal recessive neu­
rodegenerative disease that is caused by mutations in AT
mutated (ATM) gene. A-T was first described by Sillaba
and Henner in 1926, however, its phenotypic spectrum
was only expanded after the description of the ATM gene
in 1995. A-T has a worldwide estimated prevalence of
1:40,000 to 1:100,000 and is related with a poor prognosis
and a short life span, being chronic pulmonary diseases and
malignancy the A-T-related most common causes of death
[155, 156].
As the main known gene related to A-T clinical pheno­
type, ATM gene contains 66 exons and encodes the ATM
protein, one of the three members of the PI3K-like family.
ATM protein plays a pivotal role in the activation of cellu­
lar signaling pathways upon DSBs, apoptosis, and genotoxic
stresses, such as IR. It functions essentially in the nuclear
compartment; however, it is known that ATM is also present
as a soluble protein in the cytoplasm [157]. In the nucleus,
as part of DNA damage response upon DNA DSBs or oxi­
dative stress, ATM is activated leading to a phosphorylation
cascade of several target substrates involved in DNA repair,
chromatin remodeling, cell cycle checkpoint, and transcrip­
tion, namely P53 (S15), CHK2 (T68), and MDM2 (S395).
In the cytoplasm, it is thought to be responsible for the func­
tions of peroxisomes and mitochondria upon oxidative stress
stimuli, as well as regulating angiogenesis, glucose metabo­
lism, and telomere processing [155, 158].
A-T is a complex multisystem disorder characterized
by a phenotypic heterogeneity, since patients show a broad
range of clinical manifestations, including progressive cer­
ebellar degeneration, immunodeficiency, oculocutaneous
telangiectasia, increased metabolic diseases, radiosensitiv­
ity, and cancer predisposition. Other abnormalities can also
be manifestations of A-T, such as dystonia, chorea, atheto­
sis, tremor, and parkinsonism. Clinical heterogeneity of A-T
Box 7.6 The Influence and Impact of Radiosensitivity
Related to Biological Sex
•	The differences in radiosensitivity of males and
females could be due to biological factors.
•	UNSCEAR concludes that the EAR and ERR for
solid tumors are around two times higher in females
than in males.
•	The identification of biological sex-related radio­
sensitivity will contribute to personalized dose and
fractionation for RT as well as for radiation
protection.
•	Currently, the annual dose limits for occupational
exposures recommended by ICRP do not recognize
sex.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology"
"Describe Ataxia Telangiectasia (A-T), focusing on its genetic basis, key cellular mechanisms involved, and how it relates to radiation sensitivity.","Ataxia Telangiectasia (A-T) is a rare autosomal recessive neurodegenerative disorder caused by mutations in the ATM gene. This gene encodes the ATM protein, a critical component of the DNA damage response pathway. Specifically, ATM plays a pivotal role in activating signaling cascades upon double-strand breaks (DSBs) and other genotoxic stresses like ionizing radiation (IR). The ATM protein is found both within the nucleus and cytoplasm, where it initiates phosphorylation events targeting key proteins involved in DNA repair, chromatin remodeling, cell cycle checkpoints, and transcription. Notably, these phosphorylated substrates include P53, CHK2, and MDM2. In individuals with A-T due to ATM mutations, this response is significantly impaired, leading to a heightened sensitivity to radiation damage.

The clinical manifestations of A-T are diverse and complex, including cerebellar degeneration, immunodeficiency, oculocutaneous telangiectasia, metabolic abnormalities, increased cancer predisposition (approximately 10–25% higher risk), and various neurological symptoms such as dystonia, chorea, and tremor. The hyper-radiosensitivity observed in A-T patients is thought to stem from the deficient recognition of DSBs by the nonfunctional ATM protein, disrupting the normal DNA repair mechanisms, particularly the Non-Homologous End Joining (NHEJ) pathway. Studies have shown that cells with ATM mutations exhibit significantly lower survival fractions after radiation exposure (SF2 values ranging from 1% to 10%) compared to other radiosensitive cell types. This suggests a primary role for ATM in initiating and coordinating the DNA damage response, ultimately impacting cellular survival under stress.

Reference: Molecular Radiation Biology, Section 7.8.1 – Ataxia Telangiectasia (AT)","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.8	 Genetic Syndromes Associated with Radiation Sensitivity | Sub-subsection: 7.8.1	 Ataxia Telangiectasia (AT) | Content: Ataxia Telangiectasia (AT) is an autosomal recessive neu­
rodegenerative disease that is caused by mutations in AT
mutated (ATM) gene. A-T was first described by Sillaba
and Henner in 1926, however, its phenotypic spectrum
was only expanded after the description of the ATM gene
in 1995. A-T has a worldwide estimated prevalence of
1:40,000 to 1:100,000 and is related with a poor prognosis
and a short life span, being chronic pulmonary diseases and
malignancy the A-T-related most common causes of death
[155, 156].
As the main known gene related to A-T clinical pheno­
type, ATM gene contains 66 exons and encodes the ATM
protein, one of the three members of the PI3K-like family.
ATM protein plays a pivotal role in the activation of cellu­
lar signaling pathways upon DSBs, apoptosis, and genotoxic
stresses, such as IR. It functions essentially in the nuclear
compartment; however, it is known that ATM is also present
as a soluble protein in the cytoplasm [157]. In the nucleus,
as part of DNA damage response upon DNA DSBs or oxi­
dative stress, ATM is activated leading to a phosphorylation
cascade of several target substrates involved in DNA repair,
chromatin remodeling, cell cycle checkpoint, and transcrip­
tion, namely P53 (S15), CHK2 (T68), and MDM2 (S395).
In the cytoplasm, it is thought to be responsible for the func­
tions of peroxisomes and mitochondria upon oxidative stress
stimuli, as well as regulating angiogenesis, glucose metabo­
lism, and telomere processing [155, 158].
A-T is a complex multisystem disorder characterized
by a phenotypic heterogeneity, since patients show a broad
range of clinical manifestations, including progressive cer­
ebellar degeneration, immunodeficiency, oculocutaneous
telangiectasia, increased metabolic diseases, radiosensitiv­
ity, and cancer predisposition. Other abnormalities can also
be manifestations of A-T, such as dystonia, chorea, atheto­
sis, tremor, and parkinsonism. Clinical heterogeneity of A-T
Box 7.6 The Influence and Impact of Radiosensitivity
Related to Biological Sex
•	The differences in radiosensitivity of males and
females could be due to biological factors.
•	UNSCEAR concludes that the EAR and ERR for
solid tumors are around two times higher in females
than in males.
•	The identification of biological sex-related radio­
sensitivity will contribute to personalized dose and
fractionation for RT as well as for radiation
protection.
•	Currently, the annual dose limits for occupational
exposures recommended by ICRP do not recognize
sex.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
412Fig. 7.14
Fig. 7.14 Overview of DNA damage and repair pathways and most common genetic disorders
can be assigned to different types of mutations that cause
an impaired ATM protein expression or affect its function in
different ways. Clinical and preclinical studies revealed that
the presence of inactive ATM is more cancer prone and lethal
than null ATM [156, 157]. A-T patients show potentially a
10–25% increased risk of developing cancer, due to their
immunodeficiency. In childhood, the most common types
of malignancy are leukemia and lymphoma, while adults
may also develop different solid tumors, namely breast,
gastric, liver, parotid gland, and esophageal carcinomas. It
is described that heterozygous ATM mutations lead to an
increased risk of 5.1 for the development of breast cancer,
compared to the general population; while ATM monoallelic
defects are associated with an estimated relative risk of ~3%.
Although there are some controversy on the association
between ATM mutations and breast cancer susceptibility,
cancer screening guidelines are being developed for ATM-­
mutated carriers [155].
The first association between the A-T caused by ATM
homozygous mutations and its higher human radiosensitivity
was made in 1975. This hypothesis has been clearly strength­
ened over the years by the fact that several studies reported
lower SF2 (survival fraction at 2 Gy) in ATM-mutated cells
compared to other radiosensitive cases, reinforcing its higher
radiosensitivity. These cells are inclusively characterized
as hyper-radiosensitive (SF2 ranging from 1% to 10%). In
a mechanistic point of view, it is proposed that ATM pro­
tein may act upstream of the molecular process of radiation
response, namely upstream of the predominant DSB repair
pathway, NHEJ. Although it is not yet fully understood
which of the ATM functions has the biggest influence on
radiosensitivity, the hyper-radiosensitivity of ATM-mutated
cells is mainly explained by the deficient recognition of
DSBs by NHEJ, as a consequence of the absence of an ATM
kinase activity in the nucleus [158].
7.8.2"
"Describe the clinical presentation and underlying molecular defect of LIG4 syndrome, focusing on its relationship to DNA damage repair pathways and radiation sensitivity.","LIG4 syndrome is an extremely rare autosomal recessive genetic disorder stemming from mutations in the DNA ligase IV (LIG4) gene. Clinically, individuals with this syndrome exhibit a constellation of severe symptoms including microcephaly, unusual facial features, growth retardation, and various skin anomalies. Critically, they demonstrate profound acute radiosensitivity alongside immunodeficiency and bone marrow abnormalities. The molecular basis of the syndrome lies in the impaired function of LIG4, which is a vital component of the non-homologous end joining (NHEJ) DNA repair pathway. Specifically, LIG4 catalyzes the final step in NHEJ – the ligation of broken DNA ends – requiring ATP. Mutations within the LIG4 gene are typically hypomorphic, meaning they reduce enzyme activity to approximately 5–10% compared to a normal wild-type enzyme. This diminished function severely compromises the cell’s ability to efficiently repair double-strand breaks (DSBs), leading to a gross defect in DSB repair. The syndrome is considered hyper-radiosensitive due to this impaired DNA repair capacity, making individuals exceptionally vulnerable to radiation damage. Furthermore, LIG4 plays a crucial role in lymphocyte receptor development, and its dysfunction contributes to the immunodeficiency observed in patients. The initial case involved a patient developing acute lymphoblastic leukemia following cranial radiation therapy, highlighting the heightened sensitivity to treatment-induced DNA damage. Reference: [Molecular Radiation Biology, Section 7.8.2 – LIG4 Syndrome]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.8	 Genetic Syndromes Associated with Radiation Sensitivity | Sub-subsection: 7.8.2	 LIG4 Syndrome | Content: DNA ligase IV deficiency or Ligase 4 (or LIG4) syndrome
is an extremely rare autosomal recessive disease caused by
mutations in DNA ligase IV. LIG4 was the first radiosensitive-­
severe combined immunodeficiency (RS-­SCID) disorder to
be described and belongs to the group of hereditary disorders
associated with impaired DNA damage response mechanisms.
Only few cases were recognized with LIG4 worldwide, the
reason why its prevalence is difficult to estimate [159].
The LIG4 gene encodes a key component of the major
DSB repair machinery, the NHEJ pathway. This pathway
constitutes a multistep process that involves several proteins,
such as Ku 70/80, DNA-PKcs, XRCC4, and DNA ligase IV,
among others ([160]; see also Chap. 3). DNA ligase IV is an
ATP-dependent ligase IV involved in the final step of NHEJ.
It forms a complex with XRCC4 and then interacts with
DNA-PKcs and XLF to rejoin a pair of DNA ends. DNA
ligase IV also develops an important role in the production
of T and B lymphocytes receptors, being recruited to repair
programmed DNA DSB induced during lymphocyte recep­
tor development [160].
All mutations of LIG4 gene identified in patients are
located near its active site and are typically hypomorphic. This
means they are not fully inactivating, since they do not affect
ligase expression and maintain a residual but impaired activity
of the enzyme (5–10% compared to the wild-type) [159, 160].
Clinically and morphologically, LIG4 syndrome is char­
acterized by microcephaly, unusual facial features, growth
E. A. Ainsbury et al.
413
retardation, and skin anomalies. Patients also manifest acute
radiosensitivity, immunodeficiency, and bone marrow abnor­
malities. Some clinical phenotypes of LIG4 syndrome over­
lap with other genetic syndromes, like Seckel syndrome,
NBS, and FA. Although the incidence of this disorder is very
low, some patients were reported with malignancy, mainly
lymphoma [7, 160].
The LIG4 syndrome is also considered a hyper-­
radiosensitive condition, which is caused by the loss of DNA
ligase IV function and consequent impaired NHEJ activity,
with a gross DSB repair defect. The first patient described
with LIG4 syndrome developed acute lymphoblastic leuke­
mia at age 14. The patient dramatically over-responded to
cranial RT and died from radiation morbidity. Subsequent
studies revealed a homozygous mutation in DNA ligase IV,
which is located near the ATP binding site and is thought to
hamper the formation of DNA ligase IV-adenylate complex,
reducing its activity to ~10%. This post-RT fatal reaction
made this genetic syndrome to be associated with hyper-­
radiosensitivity [7, 159].
7.8.3"
"Describe the genetic basis of Nijmegen breakage syndrome (NBS) and explain how mutations in the NBS1 gene contribute to its clinical manifestations, specifically focusing on its impact on DNA repair mechanisms.","Nijmegen breakage syndrome (NBS) is a rare autosomal recessive disorder caused by mutations within the *NBS1* gene, also known as *NBN*, located on chromosome 8q21. The most common mutation is a founder deletion (c.657del5), prevalent in Slavic populations. The *NBS1* gene encodes the Nibrin protein, which is a critical component of the MRN complex – specifically Mre11/Rad50/Nibrin. This complex plays a vital role in recognizing and repairing double-strand DNA breaks (DSBs). When exposed to DNA damaging agents like radiation, the MRN complex is activated through ATM phosphorylation and localization to sites of DNA damage. However, mutations in *NBS1* lead to impaired translocation of Nibrin into the MRN complex. This disruption significantly compromises the ability of the cell to accurately repair DSBs, resulting in genomic instability. Clinically, this manifests as microcephaly, stunted growth, immunodeficiency, and a heightened susceptibility to cancer – particularly those associated with chromosomal instability. The increased radiation sensitivity observed in NBS patients is directly linked to their defective DNA repair system; they exhibit enhanced responses to ionizing radiation (IR) and demonstrate radioresistant DNA synthesis due to the impaired ability of the MRN complex to efficiently resolve DNA damage. Consequently, minimizing radiation exposure is a crucial consideration in managing this syndrome and its associated malignancies [162].","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.8	 Genetic Syndromes Associated with Radiation Sensitivity | Sub-subsection: 7.8.3	 Nijmegen Breakage Syndrome (NBS) | Content: Nijmegen breakage syndrome (NBS) is a rare autosomal
recessive disease mainly characterized by presenting micro­
cephaly at birth, stunted growth, immunodeficiency, and high
predisposition to cancer, without the manifestation of ataxia.
NBS was first described in 1979 in a 10-year-old Dutch boy
and, then, was formally reported in 1981 when a brother of
the boy presented similar clinical features. NBS is estimated
to have a prevalence at 1:100,000 live births worldwide,
being most common in Eastern Europe [161]. NBS is a con­
sequence of mutations in the NBS1 gene, also named NBN,
on chromosome 8q21. It was determined a Slavic founder
mutation, considering that most of the individuals with this
syndrome are from Slavic regions and carry the same del­
eterious deletion, c.657del5. Eleven NBS-causing mutations
have been identified, all of them in exons 6–10 of the NBS
gene [162].
The NBN gene encodes a 754 amino acid protein named
Nibrin (NBN), p95 or nbs1. Nibrin is part of the MRN
(Mre11/Rad50/Nibrin) complex involved in the repair of
DNA DSB, as well as in immune gene rearrangements,
maintenance of telomeres, and meiotic recombination. When
exposed to DNA damaging agents, the MRN complex is acti­
vated by ATM phosphorylation and localized to DNA dam­
age sites forming protein foci at DNA breaks. Consequently,
mutations in this NBN gene lead to impaired translocation of
the Nibrin protein into the MRN complex impairing subse­
quent repair of the DNA DSB lesion [162].
The diagnosis of this syndrome is based on the identi­
fication of the main clinical manifestations and posterior
confirmation by genetic analysis. The previous knowledge
of disease-causing mutation in both alleles of the NBN gene
allows the realization of prenatal molecular genetic diag­
nosis. NBS patients have a high predisposition to develop
malignancies, being the syndrome with highest cancer inci­
dence among all chromosomal instability syndromes. Till
now, no specific therapies are defined, and the prognosis for
NBN patients with malignancies is still poor [162].
The first documented case of radiation sensitivity
observed in an NBS patient involved a 3-year-old microce­
phalic boy with medulloblastoma. Also, several in vitro stud­
ies have shown that NBS cells present high sensitivity to IR
and radioresistant DNA synthesis. Thus, the NBS patients
face several challenges in treating their presented malignan­
cies, such as cancer, due to the limitation of using RT. In fact,
considering the defective DNA repair system, the exposure
of these individuals to radiation should be minimized and
avoided when possible [161].
7.8.4"
"Describe the genetic basis of Xeroderma Pigmentosum (XP) and explain how this defect contributes to the syndrome's characteristic features, including increased cancer risk and sensitivity to UV radiation.","Xeroderma Pigmentosum (XP) is a rare autosomal recessive hereditary disorder caused by mutations in one of seven complementation groups (XPA through XPG), which are involved in nucleotide excision repair (NER) systems. These genes encode proteins crucial for recognizing and repairing DNA damage induced by UV radiation. Specifically, defects in genes like *XPC* and *XPA*, which are most prevalent in Southern Europe and North Africa, lead to an inability to effectively remove bulky DNA adducts formed during NER. This results in irreparable DNA damage when exposed to UV light or ionizing radiation. Clinically, this manifests as a high sensitivity to sunlight (acute sunburns in 50% of patients), skin dryness, pigmentary alterations, xerosis, and a dramatically increased incidence of malignant tumors affecting the skin, head, and neck – with an estimated 10,000-fold higher probability of developing skin cancer compared to the general population. The impaired DNA repair system also contributes to the syndrome’s predisposition to malignancies. Furthermore, studies have shown that NBS cells exhibit high sensitivity to ionizing radiation (IR) and radioresistant DNA synthesis. Consequently, patients with XP face significant challenges in treating cancers due to the limitations of using radiation therapy itself, highlighting the need for minimized exposure whenever possible [163, 164]. Reference: [Molecular Radiation Biology, Section 7.8.4]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.8	 Genetic Syndromes Associated with Radiation Sensitivity | Sub-subsection: 7.8.4	 Xeroderma Pigmentosum (XP) | Content: The diagnosis of this syndrome is based on the identi­
fication of the main clinical manifestations and posterior
confirmation by genetic analysis. The previous knowledge
of disease-causing mutation in both alleles of the NBN gene
allows the realization of prenatal molecular genetic diag­
nosis. NBS patients have a high predisposition to develop
malignancies, being the syndrome with highest cancer inci­
dence among all chromosomal instability syndromes. Till
now, no specific therapies are defined, and the prognosis for
NBN patients with malignancies is still poor [162].
The first documented case of radiation sensitivity
observed in an NBS patient involved a 3-year-old microce­
phalic boy with medulloblastoma. Also, several in vitro stud­
ies have shown that NBS cells present high sensitivity to IR
and radioresistant DNA synthesis. Thus, the NBS patients
face several challenges in treating their presented malignan­
cies, such as cancer, due to the limitation of using RT. In fact,
considering the defective DNA repair system, the exposure
of these individuals to radiation should be minimized and
avoided when possible [161].
7.8.4
Xeroderma Pigmentosum (XP)
Xeroderma Pigmentosum (XP) is a rare hereditary autoso­
mal recessive disorder with an incident rate of 1:250,000 in
North America, and 1:1,000,000 in Europe, affecting both
sexes equally [163]. XP is clinically characterized by the
presence of pain induced by UV exposure, skin dryness, pro­
gressive pigmentary alterations, xerosis, several types of skin
lesions and damage, and high incidence of malignant tumors
affecting skin, head, and neck. In fact, acute severe sunburns
are present in 50% of XP patients as a consequence of the
hypersensitivity to sunlight. Some patients also showed neu­
rological disorders and ophthalmologic degeneration [164,
165]. XP is caused by defects in seven complementation
groups (XPA to XPG) which play a role in  NER systems.
XPC and XPA are the most prevalent in Southern Europe
and North Africa. XPC is caused by mutation in the gene
XPC, which contains 16 exons and is located in chromosome
3 (3p25), encoding for xeroderma pigmentosum group C
(XPC) protein. The most frequent mutation in the XPC gene
is a 2 bp deletion, c.1643_1644delTG, p.Val548AlafsX25
[164].
XPC is a protein with several functions in the NER sys­
tem to repair DNA damage by recognizing the damaged
bases and forming a stable complex with UV excision repair
protein RAD23 (“HR23B”) protein needed for the recruit­
ment of other actors involved in the removal of bulky DNA
adducts. Mutation in these genes leads to an irreparable
DNA damage that confers hypersensitivity to radiation to
these patients, including UV exposure, and predisposition to
develop malignancies [163, 164].
XP patients have 10,000-fold more probability in devel­
oping skin cancer than the general population. No cure is
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
414
yet available for XP patients, so they need to be completely
protected and isolated from any source of UV radiation.
Although there is a correlation between XP syndrome and
hypersensitivity to UV radiation, there are only few reports
presenting the effects of using radiation therapy in XP patients
with malignancies. Most of those reports did not show acute
or chronic complication after treatment, probably due to the
action of other repair pathways, such as NHEJ or HR instead
of NER. However, there have been reported preclinical studies
showing that some variants of XP could be more susceptible to
IR and it is recommended that all XP patients should be classi­
fied before starting radiation therapy [166].
7.8.5"
"Describe Fanconi anemia (FA), including its genetic basis, clinical manifestations, and the underlying mechanisms contributing to its severity.","Fanconi anemia (FA) is a rare, inherited genetic disorder characterized by impaired DNA repair, genomic instability, and ultimately, bone marrow failure. The disease stems from pathogenic variants in one of 23 known genes – FANCA through FANCY – which collectively form complexes involved in the recognition and repair of interstrand crosslinks (ICLs), nucleotide excision repair (NER), translesion synthesis, and homologous recombination (HR). These mutations disrupt DNA repair pathways, leading to an accumulation of DNA damage. Clinically, FA manifests as a multisystem disease with significant heterogeneity. Common features include short stature, skeletal abnormalities (particularly affecting the limbs), abnormal skin pigmentation, microcephaly, and genitourinary tract or ophthalmic alterations. The most prevalent presentation is aplastic anemia, often diagnosed around age 7, characterized by pancytopenia – a deficiency of red blood cells, white blood cells, and platelets. Beyond bone marrow failure, FA patients have an elevated risk of developing hematologic malignancies (such as myelodysplastic syndrome or acute myeloid leukemia) and solid tumors (including head and neck, skin, and genitourinary tract cancers). The severity of the disease is directly linked to the specific gene mutation involved; some mutations lead to more pronounced genomic instability and a faster progression towards marrow failure. Furthermore, FA patients exhibit hypersensitivity to ionizing radiation due to their compromised DNA repair mechanisms, resulting in both deterministic (dose-dependent) and stochastic (random) effects on cellular integrity. Diagnosis typically involves genetic testing to identify the causative mutation, while clinical management focuses on supportive care, including blood transfusions, platelet transfusions, and potentially hematopoietic stem cell transplantation.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.8	 Genetic Syndromes Associated with Radiation Sensitivity | Sub-subsection: 7.8.5	 Fanconi Anemia (FA) | Content: Fanconi anemia (FA) was firstly described by Guido Fanconi
in 1927, a pediatrician who reported three children, brothers,
with specific features: short stature, physical abnormalities,
and anemia [167]. Defined as a rare genetic disease, FA is
caused by pathogenic variants in at least 23 genes: FANCA,
FANCB, FANCC, FANCD1/BRCA2, FANCD2, FANCE,
FANCF, FANCG, FANCI, FANCJ/BRIP, FANC, FANCM,
FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, FANCQ/
ERCC4, FANCR/RAD51, FANCS/BRCA1, FANCT/UBE2T,
FANCU/XRCC2, FANCV/REV7, FANCW/RFWD3, and
FANCY/FAP100. All these genes play a critical role in DNA
repair and genomic instability and can be organized in dif­
ferent complexes [168]. Classified as an inherited bone mar­
row failure syndrome, FA is the most common genetic cause
of aplastic anemia and, besides that related to hematologic
malignancies, is one of the most common genetic causes
with a ratio of males to females 1.2:1 [169]. Concerning her­
itability, FA can be inherited in an autosomal recessive man­
ner, an autosomal dominant manner (RAD51-related FA), or
an X-­linked manner (FANCB-related FA) [170].
This syndrome of impaired DNA repair and genomic
instability, defined as complex and heterogeneous, is based
on different mutations. FA patient cells are unable to perform
different functions, namely repair DNA interstrand cross­
links, NER, translesion synthesis, and HR, inhibiting DNA
replication and transcription, important cellular processes
[171]. Related to IR, DNA damage and in particular DSB are
the main alterations caused, with it reported that hypersensi­
tivity to IR on FA mutation carriers translated not only into
deterministic effects but also into stochastic effects [169].
FA is diagnosed at the median age of 7 years although
symptomatic and asymptomatic family members have been
described from birth to >50 years of age [172]. This syndrome
is classified as multisystem disease, characterized by clinical
features such as congenital malformations (short stature, skel­
etal malformations of the lower and/or upper limbs, abnormal
skin pigmentation, microcephaly, and genitourinary tract and
ophthalmic alterations), progressive bone marrow failure
with pancytopenia presentation, typically presents in the first
decade, often initiated with thrombocytopenia or leukopenia,
and increased probability of hematologic (myelodysplastic
syndrome or acute myeloid leukemia) and solid malignancies
(head and neck, skin, and genitourinary tract; [170]).
7.8.6"
"The BRCA1 and BRCA2 genes play a critical role in DNA repair, specifically homologous recombination (HR), which is essential for maintaining genomic stability. When mutations occur in these genes, what specific consequence arises regarding the cell’s ability to repair DNA double-strand breaks (DSBs) and how does this relate to increased cancer susceptibility?","Mutations in BRCA1 and BRCA2 impair the HR pathway, a crucial mechanism for repairing DSBs. This impairment leads to an inefficient repair process, resulting in an accumulation of genomic instability. Consequently, cells with these mutations are more prone to developing cancers because they lack the normal safeguards against DNA damage that would otherwise trigger cell cycle arrest or apoptosis. The inability to effectively fix DSBs allows damaged DNA to persist, increasing the likelihood of mutations and uncontrolled cellular proliferation – hallmarks of cancer development. Reference: [Molecular Radiation Biology, Section 7.8.6 Hereditary Breast and Cancer Syndrome]","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.8	 Genetic Syndromes Associated with Radiation Sensitivity | Sub-subsection: 7.8.6	 Hereditary Breast and Cancer Syndrome | Content: etal malformations of the lower and/or upper limbs, abnormal
skin pigmentation, microcephaly, and genitourinary tract and
ophthalmic alterations), progressive bone marrow failure
with pancytopenia presentation, typically presents in the first
decade, often initiated with thrombocytopenia or leukopenia,
and increased probability of hematologic (myelodysplastic
syndrome or acute myeloid leukemia) and solid malignancies
(head and neck, skin, and genitourinary tract; [170]).
7.8.6
Hereditary Breast and Cancer
Syndrome
Hereditary Breast and Ovarian Cancer (HBOC) syndrome
was first reported by the French physician Pierre Paul Broca,
in 1866, when observed a greater predisposition to cancer
in his wife’s family. This syndrome is an autosomal domi­
nant disease, mostly caused by germline deleterious muta­
tions in Breast Cancer gene 1 (BRCA1) and Breast Cancer
gene 2 (BRCA2). The exact cancer risks depend on the type
of pathogenic variant, being this syndrome mainly charac­
terized by an increased predisposition to different types of
cancer. These mutations affect all ethnic groups and races:
in the general population, mutations in BRCA1 and BRCA2
genes are estimated to have a frequency between 1:400 and
1:500. However, in Ashkenazy Jewish people, the frequency
of causal variants is higher: 1:40 [173, 174].
HBOC is mostly a consequence of mutations in BRCA1
gene, located in chromosome 17, and BRCA2 gene, located
in chromosome 13. However, only 25% of cases are asso­
ciated with these two genes. Therefore, other genes are
associated with this syndrome and, currently, more than 25
genes have been associated, such as Checkpoint Kinase 2
(CHEK2) gene, AT Mutated (ATM) gene, and Partner And
Localizer Of BRCA2 (PALB2) gene. Most of them encode
proteins that, in conjunction with BRCA1 and BRCA2
genes, act on genome maintenance pathways. More than
1600 mutations in BRCA1 gene and more than 1800 in
BRCA2 gene associated with tumor susceptibility have been
described [173, 175].
BRCA1 and BRCA2 genes are tumor suppressor genes
with a crucial role in the cell, since they encode proteins that
repair DNA DSB through HR recombination, allowing the
maintenance of genomic stability and tumor suppression.
When exposed to IR, these proteins are activated, localize
DNA damage, and repair it. In this way, mutations in these
genes lead to an inefficient repair mechanism and to an
increase in genomic instability, increasing the probability of
cancer development [176].
The diagnosis of HBOC associated with mutations in
BRCA genes is based on the identification of pathogenic vari­
ants in these genes through molecular genetic tests. HBOC
patients have a high predisposition to develop different types
of cancers, some of which at an earlier stage, such as breast
cancer (in both sex) and ovarian cancer. Additionally, HBOC
E. A. Ainsbury et al.
415
is also associated with an increased risk of developing pros­
tate cancer, melanoma, and pancreatic cancer although to a
lesser degree. Until the moment, there are no specific ther­
apies defined, so early diagnosis in carriers of pathogenic
variants in the BRCA1 and BRCA2 genes is crucial to apply
effective surveillance and prophylaxis measures [173].
Since the twentieth century, several studies have been
carried out to understand whether individuals with muta­
tions in the BRCA genes are more sensitive to IR, trying
to understand the role of exposure to IR in patients with
HBOC and whether there are differences in the ability to
repair of DNA damage between carriers and non-carriers
of mutations in these genes. Although some studies show
an association between the exposure of individuals with the
syndrome to diagnostic doses and the development of can­
cer [177, 178], other studies fail to show any association
[91, 179]. Thus, it is crucial to carry out more specific stud­
ies to obtain clear and objective conclusions in relation to
this subject.
7.9
Toward Personalized Medicine:
Future Perspective
Biological markers of changes in the body in response to
radiation have long been used to assess radiation dose and
exposure circumstances (see Chaps. 3 and 8). In recent
years, with advances in technology and the sophistication of
the markers, the potential to use biomarkers of the body’s
response to radiation and other stressors to help predict treat­
ment outcome and indeed to tailor treatments has begun to
be explored [180].
Development, validation, and implementation of bio­
markers are not a simple process (see Chap. 3). Firstly
because our bodies are hugely complex systems relying
on hundreds of thousands of changing and interacting pro­
cesses at any one moment, many of which have associated
measurable changes, there are a huge number of potential
biomarkers based on the body’s complex response to IR
confounded by a large number of other internal and exter­
nal factors. Secondly, and just as importantly, there is huge
variation in interindividual responses for most biomarkers.
One recent study, for example, identified 40 blood-based
biomarkers which could provide informative data on car­
bon metabolism, vitamin status, inflammation, and endo­
thelial and renal function in cancer-free older adults alone
[181]. Harlid et al. [182] also outlined the large number
of potential biomarkers for risk predictive and diagnostic
biomarkers for colorectal cancers, in a recent systematic
review. In terms of molecular radiation epidemiology, a
very large number of potential biomarkers have been iden­
tified, but despite a very large amount of work in this area,
only one biomarker (based on transcriptional changes) has
been identified as suitable to pursue now [14]. Furthermore,
the practicalities of development of protocols and standard
operating procedures for clinical use are also a barrier to
implementation [183].
However, in wider clinical practice as well as for radia­
tion medicine, biomarkers to support personalized interven­
tion are in development and in some cases, already in use.
For example, Karschnia et al. [184] reported improved sur­
vival in patients with advanced cancers of the central nervous
system, following application of systemic targeted immuno­
therapeutic agents. Connor et al. [185] showed how imple­
mentation of novel image-based biomarkers to support RT
has improved patient-specific therapy outcomes for glioma
patients.
Going forward, despite the fact that the mechanisms of
radiation resistance are still not well understood, use of
miRNA in prostate cancer has shown promise. For example,
Soares et al. [186] found 23 miRNAs which were involved
in genetic regulation of prostate cancer cell response to RT.
In the lung, Leiser et al. [187] recently demonstrated the
potential utility of caveolin-1 (a membrane protein highly
expressed in radiation resistant lung cancer cells) as a prog­
nostic biomarker for response to treatment with radiation as
well as for tumor progression, in support of precision medi­
cine. And for cancers of the liver, De la Pinta [188] recently
identified a number of candidate biomarkers of radiation
response and toxicity and highlighted how close this field in
particular is to use of such techniques to support personal­
ized radiation medicine.
Indeed, use of large scale “omics” data together
with machine learning or other artificial intelligence
approaches has opened up a number of avenues of
research. For example, Manem [189] compared five dif­
ferent machine learning based approaches in two existing
radiogenomics datasets and found a large number of bio­
markers associated with statistically significant pathways
of response associated with surviving fractions of cells.
New techniques in cellular barcoding are also proving
incredibly interesting, with Wursthorn et al. [190], for
example, recently demonstrating the use of this technique
for assessing clonogenic survival in response to radiation
and quantification of radiosensitivity as well as the con­
tribution of stochastic and deterministic processes. Major
bioinformatics studies can help in the identification of
gene signatures as biomarkers for predicting normal tis­
sue radiosensitivity. A key challenge is still the need for
large scale, independent, validation of biomarkers in
prediagnostic studies [182] as well as biomarker-driven
randomized controlled trials [191]. Nevertheless, given
the recent advances, use of radiation biomarkers to sup­
port precision radiation medicine is an exciting field in
which large leaps forward are expected in a relatively
short timescale.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology"
"The text discusses the challenges and future directions of utilizing biomarkers to personalize radiation therapy. What are some specific examples of biomarkers currently being investigated or utilized, and what technological approaches are contributing to their development and validation?","Several biomarkers are actively being explored for personalized radiation medicine, reflecting a shift towards more targeted interventions. One prominent example is the investigation of transcriptional changes as a biomarker – though only one has been deemed suitable for immediate clinical use based on current research [14]. More practically, image-based biomarkers, such as caveolin-1 expression in radiation-resistant lung cancer cells, are being evaluated for their prognostic value and ability to predict treatment response [185]. Furthermore, the study of microRNAs (miRNAs) is showing promise, particularly in prostate cancer, where 23 miRNAs have been identified that regulate cell responses to radiation [186]. Recent advancements include cellular barcoding techniques, exemplified by Wursthorn et al. [190], which allow for quantification of radiosensitivity and the assessment of stochastic and deterministic processes within cells. Finally, ‘omics’ data combined with machine learning approaches are being utilized to identify gene signatures associated with radiation response pathways [189]. These efforts represent a multifaceted approach incorporating transcriptomic analysis, protein expression profiling (like caveolin-1), miRNA studies, and novel techniques like cellular barcoding, all supported by sophisticated bioinformatics and artificial intelligence methodologies.","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.9	 Toward Personalized Medicine: Future Perspective | Content: tified, but despite a very large amount of work in this area,
only one biomarker (based on transcriptional changes) has
been identified as suitable to pursue now [14]. Furthermore,
the practicalities of development of protocols and standard
operating procedures for clinical use are also a barrier to
implementation [183].
However, in wider clinical practice as well as for radia­
tion medicine, biomarkers to support personalized interven­
tion are in development and in some cases, already in use.
For example, Karschnia et al. [184] reported improved sur­
vival in patients with advanced cancers of the central nervous
system, following application of systemic targeted immuno­
therapeutic agents. Connor et al. [185] showed how imple­
mentation of novel image-based biomarkers to support RT
has improved patient-specific therapy outcomes for glioma
patients.
Going forward, despite the fact that the mechanisms of
radiation resistance are still not well understood, use of
miRNA in prostate cancer has shown promise. For example,
Soares et al. [186] found 23 miRNAs which were involved
in genetic regulation of prostate cancer cell response to RT.
In the lung, Leiser et al. [187] recently demonstrated the
potential utility of caveolin-1 (a membrane protein highly
expressed in radiation resistant lung cancer cells) as a prog­
nostic biomarker for response to treatment with radiation as
well as for tumor progression, in support of precision medi­
cine. And for cancers of the liver, De la Pinta [188] recently
identified a number of candidate biomarkers of radiation
response and toxicity and highlighted how close this field in
particular is to use of such techniques to support personal­
ized radiation medicine.
Indeed, use of large scale “omics” data together
with machine learning or other artificial intelligence
approaches has opened up a number of avenues of
research. For example, Manem [189] compared five dif­
ferent machine learning based approaches in two existing
radiogenomics datasets and found a large number of bio­
markers associated with statistically significant pathways
of response associated with surviving fractions of cells.
New techniques in cellular barcoding are also proving
incredibly interesting, with Wursthorn et al. [190], for
example, recently demonstrating the use of this technique
for assessing clonogenic survival in response to radiation
and quantification of radiosensitivity as well as the con­
tribution of stochastic and deterministic processes. Major
bioinformatics studies can help in the identification of
gene signatures as biomarkers for predicting normal tis­
sue radiosensitivity. A key challenge is still the need for
large scale, independent, validation of biomarkers in
prediagnostic studies [182] as well as biomarker-driven
randomized controlled trials [191]. Nevertheless, given
the recent advances, use of radiation biomarkers to sup­
port precision radiation medicine is an exciting field in
which large leaps forward are expected in a relatively
short timescale.
7 Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology
416
7.10"
"Several genetic syndromes are associated with increased susceptibility to radiation damage. Describe two distinct genetic syndromes linked to either radiosensitivity or radiosusceptibility, detailing the specific underlying genetic defects and how these defects contribute to heightened vulnerability to ionizing radiation.","Two notable genetic syndromes exhibiting varying degrees of radiation sensitivity and susceptibility are Turner Syndrome (TS) and Fanconi Anemia (FA). Turner Syndrome, characterized by a complete or partial absence of one X chromosome in females, results in significant radiosusceptibility. The primary mechanism involves impaired DNA repair pathways due to the missing X chromosome, specifically affecting homologous recombination repair – a critical pathway for repairing double-strand breaks in DNA. This deficiency leads to increased mutation rates and genomic instability upon radiation exposure, ultimately promoting cancer development. Fanconi Anemia, on the other hand, is characterized by radiosusceptibility but not necessarily radiosensitivity. It’s caused by mutations in one of at least nine genes (FANCA through FAN9) involved in a DNA repair complex that primarily handles single-strand breaks and crosslinks. Individuals with FA have severely compromised DNA repair mechanisms, leading to an accumulation of DNA damage following radiation exposure. Unlike TS, the underlying defect isn't simply a missing chromosome but rather a fundamental impairment in the coordinated function of this multi-protein complex. This results in increased rates of chromosomal aberrations and genomic instability, contributing significantly to radiosusceptibility. Importantly, FA patients often exhibit other clinical features beyond radiation sensitivity, such as bone marrow failure and congenital abnormalities, reflecting the broader impact of the defective DNA repair system.

Reference: Molecular Radiation Biology, Section 7.10 – Exercises and Self-Assessment","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.10	 Exercises and Self-Assessment | Content: Q1.	Cite a genetic syndrome associated with both radio­
sensitivity and radiosusceptibility.
Q2.	Cite a genetic syndrome associated with radiosuscep­
tibility, but not radiosensitivity.
Q3.	What is described as the attained age in relation to
radiosensitivity?
(a)	The age from birth to death
(b)	The sum of the age at exposure and time since
exposure
(c)	The age between onset of cancer diagnosis and
end of treatment
(d)	The sum of the age at exposure and time of
exposure
Q4.	What are the three mechanisms associated with the
greater susceptibility of children to radiation
carcinogenesis?
Q5.	Which of the following sentences are true or false?
(a)	Aged cells may have a compromised repair due to
chromatin reorganization.
(b)	Senescence in older cells can be accelerated by
irradiation.
(c)	Abnormalities in tissue maturation is often seen as
radiation-induced sequelae in adults.
Q6.	Is the radiation sensitivity higher for males or females?
Q7.	Why is sex important to consider in context of radia­
tion therapy?
Q8.	Why is sex not yet included in the ICRP
recommendations?
Q9.	Why is it necessary to identify biomarkers to predict
the response of the tumor to radiation therapy?
Q10.	What circulatory biomarkers are of current interest in
the field of radiation oncology?
Q11.	Why are liquid biopsies rapidly being adopted into
translational research?
Q12.	What is the current gold standard for assessing
radiosensitivity?
Q13.	What advantages do vibrational spectroscopic tech­
niques have over conventional radiobiological assays?
Q14.	If normal tissue toxicity determines the total dose to be
delivered to a patient, what outcome will this have on
their treatment?
7.11"
"Describe how Ataxia telangiectasia (AT) and Li-Fraumeni syndrome (LFS) demonstrate differing sensitivities to radiation exposure, specifically relating to tissue reactions and cancer proneness.","Ataxia telangiectasia (AT), caused by homozygous mutations in the ATM gene, presents with severe, often fatal, tissue reactions following radiation exposure. This is directly linked to the impaired function of ATM, a key DNA repair protein. The lack of efficient DNA damage repair leads to significant genomic instability and cellular stress within tissues, triggering an exaggerated inflammatory response and ultimately causing detrimental tissue dysfunction. Consequently, individuals with AT exhibit a markedly high predisposition to cancer development after radiation exposure. Conversely, Li-Fraumeni syndrome (LFS), caused by heterozygous mutations in the p53 gene, is characterized by a heightened risk of cancer following radiation but *without* the severe tissue reactions observed in AT patients. The p53 protein plays a crucial role in regulating cell cycle arrest and apoptosis in response to DNA damage; while its dysfunction contributes to increased cancer susceptibility, it doesn't trigger the same level of immediate cellular distress as ATM deficiency. This difference highlights how variations in specific genes involved in DNA repair pathways and stress responses determine an individual’s sensitivity to radiation and the resulting consequences – severe tissue damage versus primarily elevated cancer risk.

Reference: E. A. Ainsbury et al., 417","Document: MolecularRadiationBiology | Section: 7: Individual Radiation Sensitivity and Biomarkers: Molecular Radiation Biology | Subsection: 7.11	 Exercise Solutions | Content: SQ1.	Ataxia telangiectasia (AT) caused by homozygous
ATM mutations is associated with fatal tissue reac­
tions post-RT and high cancer proneness after expo­
sure to radiation.
SQ2.	Li-Fraumeni’s syndrome (LFS) caused by heterozy­
gous p53 mutations is associated with high cancer
proneness after an exposure to radiation but LFS
patients do not show adverse tissue reactions
post-RT.
SQ3.	Alternative (b) is correct. (The sum of the age at
exposure and time since exposure).
SQ4.	Long latency period between injury and cancer onset;
faster radionuclides accumulation in growing bones;
high frequency of cell division.
SQ5.	(a) true, (b) true, (c) false.
SQ6.	Females.
SQ7.	Consideration of the individual radiosensitivity of
each patient will allow a personalized dose and frac­
tionation adjustment for RT.
SQ8.	Due to the lack of scientific evidence to support the
establishment of different annual dose limitations
based on sex, as well as the complex social and soci­
etal issues associated with potential implementation
of sex specific dose limits.
SQ9.	Identifying biomarkers of tumor response will allow
stratification of patients based on risk and identifying
patients who may not respond favorably to treatment.
In turn, this will provide tailored and optimized treat­
ment for patients.
SQ10.	Circulating tumor cells, circulating free DNA, and
EVs.
SQ11.	Liquid biopsies overcome many limitations associ­
ated with tumor biopsies, such as minimally invasive
sample acquisition, easy repeatability, lower cost,
and a rich source of tumor-specific biomarkers.
SQ12.	The clonogenic assay is still the current gold stan­
dard for studying radiosensitivity.
SQ13.	Vibrational techniques involve minimally invasive
sample collection, non-destructive, label free mea­
surement of cells, and results can be produced in a
short time frame.
E. A. Ainsbury et al.
417
SQ14.	Patients who are radiosensitive and undergo RT are at
a higher risk of developing severe toxicity, and to cir­
cumvent this, the doses delivered to these patients
will be at a lower dose than is necessary for adequate
tumor control and a positive outcome of treatment."
"Describe the concept of bystander effects in radiation biology, detailing how they contribute to tissue damage beyond the direct ionizing event and outlining at least three distinct mechanisms involved.","Bystander effects in radiation biology refer to the phenomenon where cells located adjacent to or distant from the primary radiation field can still undergo significant DNA damage and subsequent cell death following irradiation. This occurs despite receiving little or no direct ionizing radiation, suggesting a mechanism beyond simple dose deposition. Several distinct mechanisms contribute to these effects:

1. **Diffusion of Radicals:** The primary ionizing event generates reactive oxygen species (ROS) – such as superoxide radicals and hydroxyl radicals – within the irradiated tissue. These ROS can diffuse through extracellular fluid and cell membranes, reaching undamaged cells even far from the initial radiation source. Once inside these bystander cells, they initiate DNA damage through oxidative stress.

2. **Ion Channel Activation:** Radiation exposure can directly activate ion channels (e.g., transient receptor potential – TRP channels) within cellular membranes. These activated channels facilitate the influx of cations like calcium and sodium into the cell. The resulting ionic imbalance disrupts normal cellular processes, including DNA repair mechanisms, leading to increased vulnerability to subsequent radiation damage.

3. **Release of Damage-Associated Molecular Patterns (DAMPs):** Cell death induced by initial irradiation releases intracellular components – such as mitochondrial DNA, nuclear fragments, and heat shock proteins – into the extracellular space. These DAMPs act as signals that activate innate immune responses, further amplifying inflammation and oxidative stress in surrounding cells, ultimately contributing to their damage.

4. **Microvascular Dysfunction:** Radiation can induce microvascular dysfunction, reducing blood flow and oxygen supply to neighboring tissues. This ischemia exacerbates cellular injury by limiting the delivery of repair factors and increasing ROS production.

It’s important to note that bystander effects significantly increase the overall biological effective dose (BED) received by a tissue, contributing substantially to radiation-induced morbidity and mortality. The magnitude of these effects is influenced by factors such as radiation type, dose rate, and tissue characteristics.

Reference: Baatout, S. (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_8","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Content: D. Hladik · U. Oestreicher
Bundesamt für Strahlenschutz, Oberschleißheim,
Germany
e-mail: dhladik@bfs.de; uoestreicher@bfs.de
G. I. Terzoudi · S. Triantopoulou
Health Physics, Radiobiology and Cytogenetics
Laboratory, Institute of Nuclear and Radiological
Sciences and Technology, Energy and Safety,
National Centre for Scientific Research “Demokritos”,
Athens, Greece
e-mail: gterzoudi@rrp.demokritos.gr; iro@rrp.demokritos.gr
G. Vogin
Centre Francois Baclesse, University of Luxembourg and
Luxembourg Institute of Health, Luxembourg, Luxembourg
e-mail: guillaume.vogin@baclesse.lu
A.-S. Wozny
Cellular and Molecular Radiobiology Lab, UMR CNRS 5822,
Lyon 1 University, Oullins, France
Department of Biochemistry and Molecular Biology,
Lyon-Sud Hospital, Hospices Civils de Lyon,
Pierre-Bénite, France
e-mail: anne-sophie.wozny@univ-lyon1.fr
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_8
426
8.1"
"Describe the process of bystander effect in radiation damage, detailing the different degrees of severity and how it relates to cellular repair mechanisms.","The bystander effect in radiation damage refers to the observation that cells adjacent to those directly exposed to ionizing radiation can also suffer significant damage, even if they themselves did not receive a direct dose. This phenomenon is particularly pronounced with high-dose exposures and stems from several interconnected processes. Initially, the primary irradiated cell undergoes DNA double-strand breaks (DSBs) – the most cytotoxic event in radiation biology. However, these DSBs don't solely affect the directly exposed cell; they release chromatin fragments into the surrounding cytoplasm. These fragments activate cellular repair pathways, primarily non-homologous end joining (NHEJ) and homologous recombination (HR), within neighboring cells. While NHEJ is a quick but error-prone mechanism for repairing DSBs, it can introduce mutations during the process. HR, which requires a sister chromatid template, is more accurate but less frequently utilized under acute radiation conditions due to its slower activation. The activated repair pathways consume cellular resources – ATP and nucleotides – further stressing neighboring cells and contributing to oxidative stress through increased reactive oxygen species (ROS) production. This ROS generation exacerbates DNA damage in the bystander cells, amplifying the initial injury. Furthermore, the inflammatory response triggered by the primary radiation exposure recruits immune cells which also contribute to tissue damage via cytokine release and oxidative stress. The severity of the bystander effect is graded: mild bystander effects might involve transient cell cycle arrest or limited DNA repair; moderate effects could lead to apoptosis (programmed cell death) in surrounding cells; while severe bystander effects can result in widespread necrosis – uncontrolled cell death – ultimately contributing significantly to the overall tissue damage observed after radiation exposure. The efficiency of cellular repair mechanisms, particularly HR, plays a crucial role in determining the extent of the bystander effect; impaired repair capacity amplifies the severity of this secondary injury.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.1	 Introduction | Content: ­
8.1
­
­
­
The following section lists the types of exposure scenar­
ios with specific examples.
8.1.2"
"Beyond cancer treatment through radiation oncology, what significant contribution does medical radiation exposure make to overall human exposure levels, and why is this exposure particularly relevant in a developmental context?","Medical radiation exposures account for approximately 20% of the average human exposure from all sources globally. This substantial proportion stems primarily from diagnostic and therapeutic procedures performed outside of cancer treatment settings. These procedures include imaging techniques such as X-rays, CT scans, fluoroscopies, angiography, myelography, and interventional radiology procedures like biopsies or catheter placements. The relevance to a developmental context arises because many of these exposures occur during pregnancy, potentially exposing the embryo or fetus to ionizing radiation. This in utero exposure can have detrimental effects on embryonic development, leading to increased risks of birth defects, growth retardation, neurological damage, and even hereditary mutations due to DNA damage within developing cells. The sensitivity of developing tissues makes them particularly vulnerable to the damaging effects of radiation.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.2	 Medical Radiation Exposures to Patients | Content: to Patients
Aside from radiation oncology, which has been well
described in Chap. 6, medical exposures can occur from
diagnostic and therapeutic procedures other than cancer
treatment. These procedures can cause exposures to the
patient but also exposure in utero to the embryo or fetus.
Worldwide medical exposures account for almost 20% of the
average human exposure from all the sources [1]."
"Describe the process of contrast-enhanced computed tomography (CECT) imaging in medical radiology, detailing how iodine-based radiopaque agents are utilized to improve visualization and what physiological mechanisms underpin their effectiveness.","Contrast-enhanced computed tomography (CECT) utilizes intravenous administration of iodinated radiopaque substances – typically sodium pertechnetate or meglumine iothalamate – to significantly enhance the visibility of blood vessels and tissues within the CT scan. The fundamental principle relies on X-ray attenuation.  X-rays, a form of electromagnetic radiation, are absorbed differently by various materials depending on their atomic number (Z). Dense materials like bone absorb most X-rays, appearing bright white on the image. However, soft tissues like muscle and fat absorb relatively little X-ray, appearing darker. The key to CECT lies in the markedly increased absorption of X-rays by these iodinated contrast agents.

The iodine atoms within the agent have a high atomic number (Z = 53), resulting in substantial attenuation of the X-ray beam. This dramatically increases the density of the imaged area, making it appear much brighter on the CT scan – effectively ‘staining’ the blood vessels and surrounding tissues with a distinct contrast.

Furthermore, the agents are osmotically active, meaning they draw water out of cells and tissues into the vascular space via osmosis. This process, known as Randall's gradient, increases the viscosity of the blood within the vessels, further enhancing their visualization on CECT scans. The increased fluid volume also improves the detection of subtle abnormalities like microaneurysms or small thrombi that might otherwise be missed.  The combination of X-ray attenuation and osmotic effects provides a powerful tool for detailed anatomical assessment in diagnostic radiology.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.2	 Medical Radiation Exposures to Patients | Sub-sub-subsection: 8.1.2.1	 Diagnostic Radiology | Content: ­
2.7.2
8.2
­
8.1.6
8.1
8.7
­
2"
"Describe the process of ionizing radiation damaging DNA within cells, detailing the key mechanisms involved and why this damage is particularly significant in cancer development.","Ionizing radiation, such as X-rays and gamma rays, possesses sufficient energy to directly impact atoms and molecules within a cell. When this radiation interacts with DNA, it primarily causes ionization – stripping electrons from the nucleotide bases (adenine, guanine, cytosine, and thymine). This ionization creates highly reactive free radicals, particularly single electron species like carbon ions and hydrogen ions. These radicals are extremely unstable and rapidly initiate a cascade of damaging events within the DNA molecule.

The initial damage often involves direct strand breaks – scissions in the phosphodiester backbone linking nucleotides together. However, indirect damage is far more prevalent. Free radicals react with nucleophilic sites on DNA bases, leading to base modifications like oxidation (forming 8-oxo-7,8-dihydroguanine or ‘oxoG’), deamination (converting cytosine to uracil), and crosslinking between DNA strands.  OxoG formation is particularly significant as it creates a mutation hotspot – an abnormal base pair that can lead to miscoding during replication.

The consequences of this damage are profound. The cell’s repair mechanisms attempt to correct these lesions, but often fail completely or introduce further errors. If unrepaired, the DNA damage accumulates, leading to mutations in critical genes involved in cell cycle regulation and apoptosis (programmed cell death). This accumulation is a fundamental driver of cancer development; uncontrolled proliferation due to genomic instability ultimately results in tumor formation. Furthermore, radiation-induced DNA damage can trigger cellular senescence – a state of irreversible growth arrest – which can also contribute to the progression of certain diseases.

Reference: Molecular Radiation Biology, Section 8.1.3 - Radiation Treatment (Non-cancer)","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.2	 Medical Radiation Exposures to Patients | Sub-sub-subsection: 8.1.2.2	 Radiation Treatment (Non-cancer) | Content: ­
45
8.2
6
8.1.3"
"Describe the potential health risks associated with occupational exposure to ionizing radiation, considering factors such as dose levels and affected organ systems. Specifically, address how diagnostic imaging procedures contribute to worker exposures and what clinical consequences might arise from both acute and chronic effects.","Occupational exposure to ionizing radiation presents a significant health risk, primarily due to the damaging effects of high-energy photons or electrons on biological molecules within cells. The severity of these risks is directly correlated with the absorbed dose – the amount of energy deposited per unit mass of tissue. While low doses may not immediately cause noticeable symptoms, they can induce DNA damage, leading to an increased risk of long-term health consequences such as cancer (particularly leukemia and thyroid cancer) and hereditary effects. Higher doses trigger acute radiation syndrome (ARS), characterized by a tiered response based on dose level: Grade 1 (mild nausea, fatigue) progressing through Grade 3 (hematopoietic suppression, gastrointestinal distress) to Grade 4 (multi-organ failure and death). The three primary clinical consequences associated with ARS are the hematologic syndrome (due to bone marrow damage), the gastrointestinal syndrome (caused by radiation-induced inflammation and ulceration of the gut lining), and the neurovascular syndrome (resulting from disruption of nerve function and vascular integrity). 

Diagnostic imaging procedures represent a major contributor to occupational radiation exposure. As detailed in Table 8.1, various examinations deliver different effective doses, ranging from 0.006 mSv for dental radiography to 7.0 mSv for cardiac angiography. The cumulative effect of these exposures over time can significantly elevate an individual’s lifetime cancer risk. Furthermore, the use of fluoroscopy during procedures adds additional radiation exposure.  Chronic effects extend beyond cancer; prolonged exposure can also lead to cataracts, skin burns, and other tissue damage. It's crucial to note that the ICRP 60 tissue weighting factors are applied when calculating effective dose, acknowledging that different tissues have varying sensitivities to radiation damage. The medical field, due to the high number of workers and procedures performed, has the highest collective exposure levels compared to nuclear or industrial sectors.  Understanding LD50 (the lethal dose required to kill 50% of a test population) is also critical in assessing the potential for acute radiation effects.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.3	 Occupational Exposures | Content: ­
­
8.3
­
Learning Objectives
•	To understand different scenarios for human expo­
sure to ionizing radiation excluding medical treat­
ment procedures such as those for cancer
treatment.
•	To understand long-term health effects associated
with low-dose radiation exposure.
•	To gain knowledge on the worldwide distribution of
indoor concentration of radon.
•	To understand how naturally occurring radon affects
human health.
•	To understand the critical need for immediate triage
and to learn about current triage tools for radiation
exposure categorization of radiation accident
victims.
•	To gain a better understanding of internal contami­
nation and decontamination.
•	To gain knowledge on clinical consequences of
early and delayed effects of acute exposure to high
doses of ionizing radiation.
•	To become familiar with the characteristic features
of the three sub-classes of acute radiation syn­
dromes (hematologic, gastrointestinal, and neuro­
vascular), as well as effects on skin and lungs.
•	To explain the basis for and biological meaning of
LD50.
R. Wilkins et al.
427
Table 8.1 Examples of each type of diagnostic procedures and their
typical doses (reproduced with permission from [2])
Examination type
Typical effective dose (mSv)a
Dental radiography
Intraoral
0.006
Panoramic
0.024
Projection radiography
Head (skull and facial bones)
0.076
Chest (thoracic spine)
0.45
Mammography
0.22
Lumbar spine
1.0
Pelvis and hips (bone)
0.49
Limbs and joints
0.02
Whole spine (trunk)
1.5
Radiography and fluoroscopy
Gastrointestinal tract
3.4
Cardiac angiography
7.0
Pelvic angiography
3.2
Urogenital tract
2.4
Computed tomography
Head (skull and facial bones)
1.5
Neck (soft tissues)
2.8
a ICRP 60 tissue weighting factors were applied for the effective dose
determination [3]
worker is the highest in the nuclear sector. Due to the high
number of workers in the medical field (~7500 in 2002) com­
pared to the nuclear sector (~660 in 2002) and the industrial
sector (~850 in 2002), collective exposures are the highest
in the medical field, followed by those working in nuclear
power and industrial uses of radiation."
"Describe the occupational radiation exposure scenarios associated with various medical professions, specifically focusing on the differences observed between diagnostic radiology and nuclear medicine techniques.","Occupational radiation exposure levels vary significantly across different medical professions due to the utilization of ionizing radiation. Diagnostic radiologists consistently demonstrate the highest exposures, primarily driven by procedures like CT scans which can deliver doses ranging from 0.008–2 mSv per interventional procedure. This is considerably higher than other specialties; for example, a diagnostic radiologist averages around 0.44 mSv/year in 2008 and 0.17 mSv/year in 2016. Medical technologists involved in CT scanning have no measurable dose on average, while those performing fluoroscopy during interventional procedures (such as vascular surgery) experience significantly elevated doses. In contrast, nuclear medicine technologists face exposure risks from both patient injections of radionuclides like 99mTc and the handling of these radioactive materials themselves. Annual exposures can reach up to 5 mSv, with additional high doses potentially experienced by the hands and fingers during preparation (up to 500 mSv). Other techniques such as Positron Emission Tomography (PET) using 18F-labeled fluorodeoxyglucose and thyroid treatment utilizing 131I also contribute to occupational exposure. The overall annual collective effective dose is substantial, approximately 85 man Sv worldwide, though it has stabilized since the 1980s due to a reduction in average annual effective doses across various professions. Radiotherapy professionals, despite treating patients with high radiation doses, have experienced a notable decrease in their occupational exposures over recent decades due to improved techniques and worker safety protocols.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.3	 Occupational Exposures | Sub-sub-subsection: 8.1.3.1	 Exposures to Medical Staff or Personnel | Content: ­
8.2
Occupational dose in diagnostic radiology is quite vari­
able due to the wide range of technologies available. For
example, most CT technologists have no measurable dose
8 Radiobiology of Accidental, Public, and Occupational Exposures
428
6
R. Wilkins et al.
429
17
Table 8.2 Selection of the highest exposed medical occupations of
monitored workers (reproduced with permission from [8])
Occupation
Ave dose
(mSv/year) (2008)
Mean effective dose
(mSv/year) (2016)
Nuclear medicine
technologist
1.56
1.23
Diagnostic radiologist
0.44
0.17
Medical radiation
technologist
0.10
0.11
Medical physicist
0.03
0.05
Radiation therapist
0.05
0.04
Dental assistant
0.01
0.01
All medical professions
0.08
0.07
while the individual effective dose for interventional proce­
dures such as vascular surgery supported by fluoroscopy is
significant and medical doctors performing these procedures
are the most occupationally exposed group from diagnostic
radiation. Depending on the procedure, the occupational dose
can range from 0.008–2 mSv per interventional procedure.
Diagnostic radiation is also frequently used in dental clin­
ics; therefore, the number of devices and workers exposed is
extremely large. The average annual effective dose in dental
radiology has been decreasing over the last few decades from
0.32 mSv in the late 1970s to 0.06 Sv in the early 1990s due
to improved equipment [1]
8 Radiobiology of Accidental, Public, and Occupational Exposures
430
Nuclear medicine involves the use of radionuclides,
particularly 99mTc, to investigate physiological process and
organ function. Occupational exposures result from person­
nel having to be in close contact with patients when inject­
ing them and while positioning them during which time they
can be exposed to gamma radiation emitted by the radionu­
clides. Preparation of the radionuclides can also result in
high exposures with annual doses up to 5 mSv and doses to
the hands and fingers up to 500 mSv. There are several other
nuclear medicine techniques with different exposures such
as positron emission tomography using 18F labeled fluoro­
deoxyglucose and thyroid treatment with 131I to name a few.
Worldwide, the annual collective effective dose is on the
order of 85 man Sv and had been increasing over the years
with increasing number of workers in this field. However, the
annual collective dose is no longer increasing [1] since the
1980s as the average annual effective dose was reduced from
1 mSv down to about 0.75 mSv.
Radiotherapy for treating malignant disease delivers the
highest dose to the patient; however, occupational doses in
this setting remain very low. These procedures have been
well described in Chap. 5. The collective annual dose in
radiotherapists has decreased substantially since the 1970s
despite the increase in workers in this field. This is due to a
large drop in the annual average effective dose per worker."
"Describe the potential health risks associated with chronic low-dose radiation exposure for nuclear workers, focusing on the mechanisms behind deterministic and stochastic effects.","Chronic low-dose radiation exposure in nuclear workers presents a complex risk profile due to the interplay of both deterministic and stochastic effects. Deterministic effects, such as cancer, are non-stochastic – meaning their probability of occurrence is directly related to the absorbed dose. At low doses, the latency period between initial exposure and cancer development can be significantly extended, often spanning decades. However, the cumulative effect of repeated exposures still contributes to an increased lifetime risk. The primary deterministic effect linked to radiation exposure is leukemia, particularly acute myeloid leukemia (AML), followed by solid tumors like thyroid cancer, breast cancer, and lung cancer. These cancers arise through DNA damage – primarily single-strand breaks – induced by ionizing radiation. This damage can lead to mutations in genes controlling cell growth and differentiation, ultimately driving uncontrolled proliferation. The severity of deterministic effects generally increases with dose; however, at low doses, the repair mechanisms within cells are often more effective, mitigating some of the immediate damage.

Stochastic effects, conversely, are non-dose dependent – meaning their probability of occurrence is independent of the absorbed radiation dose. Radiation-induced stochastic effects include genetic mutations and chromosomal aberrations. These events occur due to random interactions between ionizing radiation and DNA molecules. While a single event may not be immediately harmful, repeated exposures can lead to an accumulation of these subtle changes over time.

Specifically for nuclear workers, chronic low-dose exposure significantly elevates the risk of germline mutations (affecting reproductive cells), potentially leading to heritable genetic effects in future generations. Furthermore, radiation-induced chromosome aberrations, such as translocations and deletions, can contribute to an increased risk of leukemia and other cancers. The precise dose thresholds for these stochastic effects are still debated, but even at relatively low doses, the cumulative probability of significant genomic alterations remains a concern. Monitoring worker health through regular medical surveillance – including blood tests for early signs of hematological abnormalities and periodic imaging scans – is crucial to detect and manage potential risks associated with chronic low-dose radiation exposure. Reference: Radiation Protection Principles, Section 8.2 – Deterministic and Stochastic Effects.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.3	 Occupational Exposures | Sub-sub-subsection: 8.1.3.2	 Nuclear Workers | Content: ­
1
­
8.4
­
1"
"Describe the process of industrial radiography, outlining the key components involved in detecting defects within materials like pipelines or castings, and explain how radiation exposure is managed for personnel.","Industrial radiography employs non-destructive testing techniques to identify internal flaws and imperfections in materials without causing damage. The fundamental principle relies on penetrating radiation – typically X-rays or gamma rays – generated from a shielded source, most commonly cobalt-60 (60Co) or iridium-192 (192Ir), contained within specialized capsules. These capsules house the radioactive material that emits high-energy photons. When the capsule is positioned near the object being inspected (e.g., a welded pipeline or casting), the radiation passes through the material. Areas with higher density, such as defects like cracks, voids, or inclusions, attenuate more of the radiation, resulting in a brighter area on the detection system behind the object. This difference in radiation intensity is then captured by a detector – often a film badge, digital imaging plate (phosphor plate), or solid-state sensor – which translates the attenuated radiation into an image representing the internal structure. Crucially, stringent safety measures are implemented to protect workers. The devices used are designed with shielding to minimize direct exposure to the radiation source and its emitted rays. Furthermore, operating procedures maintain annual effective doses for personnel under normal use well below 0.5 millisieverts (mSv), adhering to established regulatory limits for occupational radiation exposure.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.3	 Occupational Exposures | Sub-sub-subsection: 8.1.3.3	 Industrial Radiography | Content: Industrial radiography is a non-destructive method used to
look at defects in materials such as welded pipeline and cast­
ings. This can involve the use of X-rays or gamma ray sources
sealed in capsules (e.g., 60Co and 192Ir). Radiation penetrates
the object being examined and exposes a detection system
behind the object. The devices used are designed to protect
the operator and annual effective doses to the workers under
normal use are less than 0.5 mSv."
"Describe the potential health risks associated with occupational radiation exposure for military personnel, referencing typical dose levels and historical trends.","Occupational radiation exposure in military settings primarily stems from activities involving ionizing radiation, such as the fabrication and testing of nuclear weapons, operation of nuclear-powered naval vessels, and applications mirroring civilian uses like research, transport, and non-destructive testing. The primary concern is the cumulative effect of this exposure on human health. While the average annual effective dose for monitored military personnel across all activities currently sits in the range of a few tens of millisieverts (mSv), historical data reveals significantly higher levels. Prior to the 1970s, annual effective doses for military workers could reach as high as 1 mSv. This represents a substantial increase in risk compared to current exposure limits. The relationship between radiation dose and health effects is non-linear; even relatively low doses can contribute to an increased lifetime risk of cancer development, particularly leukemia, thyroid cancer, and breast cancer. Higher doses dramatically accelerate this process. Furthermore, acute exposures can lead to radiation sickness characterized by symptoms like nausea, vomiting, fatigue, and skin burns. The severity depends on the dose received. Therefore, meticulous monitoring and stringent safety protocols are crucial in military environments to minimize exposure and mitigate potential long-term health consequences. 

Reference: [MolecularRadiationBiology], Section 8.1.3.4","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.3	 Occupational Exposures | Sub-sub-subsection: 8.1.3.4	 Military | Content: Most military exposures results from the fabrication and
testing of nuclear weapons, the use of nuclear energy on
naval vessels, and the use of ionizing radiation for activities
similar to those used in civilian applications (e.g., research,
transport, and non-destructive testing). Data from the USA
indicates that the average annual effective dose in monitored
military individuals form all military activities is on the order
of a few tens of mSv. There has, however, been a substan­
tial decrease in the average collective doses since the 1970s
where annual effective doses to monitor military workers
were as high as 1 mSv [1].
8.1.4"
"Describe the typical radiation exposure scenarios encountered by miners working with elevated levels of natural sources, including estimated collective doses and contributing factors.","Miners represent a significant occupational group exposed to enhanced levels of naturally occurring radiation. Estimates suggest that approximately 13 million workers worldwide are exposed to natural sources of radiation. Specifically for miners, the estimated collective dose is around 30,000 man Sv (millisieverts). This high exposure stems primarily from prolonged contact with uranium and thorium-bearing rock formations during extraction processes. The intensity of this exposure varies depending on geological conditions – ore deposits containing higher concentrations of these elements lead to increased radiation levels within the mines. Furthermore, ventilation systems can contribute to elevated radiation levels by dispersing radioactive dust throughout the working environment. It’s important to note that due to the nature of this work, routine monitoring of individual worker doses is typically absent, making precise dose tracking challenging and contributing to the overall uncertainty in exposure estimates. The collective dose has been rising between the early 1990s and early 2000s, despite a decrease in average effective doses for man-made exposures, largely due to an increasing number of workers in this sector.
Reference: MolecularRadiationBiology, Section 8.1.4 – Elevated Exposure to Natural Sources","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.4	 Elevated Exposure to Natural Sources | Content: of a few tens of mSv. There has, however, been a substan­
tial decrease in the average collective doses since the 1970s
where annual effective doses to monitor military workers
were as high as 1 mSv [1].
8.1.4
Elevated Exposure to Natural Sources
Enhanced levels of natural radiation are found in several
occupational settings. Because the radiation is naturally
occurring, workers are not routinely monitored so expo­
sure levels are not well known. Miners make up a large
group of these occupational exposures and their estimated
collective dose is about 30,000 man Sv [9]. Air crew make
up another group of workers exposed to naturally occur­
ring radiation and have been identified as one of the most
highly exposed professional groups with exposure levels
of 3–8 μSv/h during the flight depending on latitude and
altitude. Worldwide, the estimated collective effective
dose to aircrew is about 900 man Sv. Overall, there are
about 13 million workers worldwide exposed to natural
sources of radiation with an estimated average effective
dose of 2.9 mSv and an estimated collective effective dose
of 37,260 man Sv. This average effective dose from natural
exposures is not decreasing as much as with man-made
exposures, however, as the number of workers is increas­
ing, the collective dose has been rising between the early
1990s and early 2000s [9].
8.1.5"
"Describe the key findings regarding radiation exposure levels among various occupational groups, specifically focusing on miners, aircrew, and researchers monitored within academic institutions, as presented in the text.","The document details several significant occupational exposures to natural radiation. Miners represent a substantial group with an estimated collective dose of approximately 30,000 man Sv. Aircrew are identified as one of the most highly exposed professional groups, experiencing levels ranging from 3-8 μSv/h during flights, resulting in an estimated collective effective dose of around 900 man Sv worldwide. Finally, researchers within academic institutions account for a large portion (92%) of monitored workers and contribute approximately 87% of the collective dose. The average annual effective dose for this group is less than 1 mSv, with doses decreasing from 0.5 to 0.1 mSv between 1975 and 2004. Notably, while exposure levels among aircrew and researchers have decreased since the 1970s, the collective dose from miners has been rising between the early 1990s and early 2000s due to an increasing number of workers.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.5	 Miscellaneous | Content: of a few tens of mSv. There has, however, been a substan­
tial decrease in the average collective doses since the 1970s
where annual effective doses to monitor military workers
were as high as 1 mSv [1].
8.1.4
Elevated Exposure to Natural Sources
Enhanced levels of natural radiation are found in several
occupational settings. Because the radiation is naturally
occurring, workers are not routinely monitored so expo­
sure levels are not well known. Miners make up a large
group of these occupational exposures and their estimated
collective dose is about 30,000 man Sv [9]. Air crew make
up another group of workers exposed to naturally occur­
ring radiation and have been identified as one of the most
highly exposed professional groups with exposure levels
of 3–8 μSv/h during the flight depending on latitude and
altitude. Worldwide, the estimated collective effective
dose to aircrew is about 900 man Sv. Overall, there are
about 13 million workers worldwide exposed to natural
sources of radiation with an estimated average effective
dose of 2.9 mSv and an estimated collective effective dose
of 37,260 man Sv. This average effective dose from natural
exposures is not decreasing as much as with man-made
exposures, however, as the number of workers is increas­
ing, the collective dose has been rising between the early
1990s and early 2000s [9].
8.1.5
Miscellaneous
In addition to those mentioned above, there are a number of
other professions where radiation might be involved. These
include, but are not limited to, research in academic institu­
tions, management of spent radioactive sources and transport
of radioactive material. Academic institutions make up 92%
for the monitored workers in this category and about 87%
of the collective dose. Overall, the average annual effective
dose for all monitored workers in this category is less than
1 mSv and doses, decreasing from 0.5 to 0.1 mSv between
1975 and 2004 [9].
R. Wilkins et al.
431
1"
"Describe the potential risks associated with unintended radiation exposures during medical procedures like perfusion CT scans, specifically concerning tissue damage.","Unintended radiation exposures in medical settings, particularly those involving diagnostic imaging modalities such as perfusion CT scans and interventional fluoroscopy (like that used in angiography), pose significant risks due to the ionizing nature of X-rays. The primary concern is the dose delivered to tissues, which can induce a cascade of biological effects leading to tissue damage. While low doses may not immediately cause noticeable harm, even relatively small exposures can initiate DNA damage within cells. This initial damage isn't always repaired effectively, and repeated or cumulative exposure increases the likelihood of mutations. Specifically, perfusion CT scans, with their high radiation doses delivered over a prolonged period while imaging blood flow, are particularly problematic. The focused beam of X-rays can cause direct ionization of water molecules in tissues, generating free radicals that damage cellular components – including DNA, proteins, and lipids. This can lead to cell death (necrosis) at the point of irradiation or, more commonly, to delayed effects such as fibrosis (scarring) as the body attempts to repair the damaged tissue. Furthermore, higher doses can induce apoptosis (programmed cell death), disrupting normal tissue function. The severity of the damage depends on several factors including dose rate, total absorbed dose, and individual sensitivity. In severe cases, particularly with high exposures to the skin, this can result in acute radiation injury characterized by erythema (redness), blistering, ulceration, and potentially long-term complications like chronic dermatitis or even malignant transformation due to the increased risk of DNA mutations. Reference: [Molecular Radiation Biology], Section 8.1.6.1 – Accidental Exposures","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.6	 Accidental Exposures | Sub-sub-subsection: 8.1.6.1	 Medical Accidents | Content: Unintended exposures in medicine are defined as exposures
that differ significantly from the exposure intended for the
given purpose and are considered medical errors. These events
can include operator errors, equipment failures, and other
mishaps with consequences that can range from less to more
severe. Events can occur with both diagnostic and therapeu­
tic procedures and may also result in unintended doses to an
embryo or fetus. The most serious overexposures can result in
doses to the skin that are high enough to cause tissue reactions.
These typically arise from CT and interventional fluoroscopy
procedures, most notably from perfusion studies [10]."
"Describe the potential biological consequences of exposure to ionizing radiation, focusing on both acute and chronic effects at a cellular level. Consider mechanisms such as DNA damage, oxidative stress, and repair pathways.","Exposure to ionizing radiation induces a cascade of detrimental biological effects within cells, broadly categorized into acute and chronic responses. Initially, the immediate impact stems from direct interaction between the radiation and cellular components. Ionizing radiation possesses sufficient energy to break chemical bonds, primarily in DNA, leading to strand breaks, base modifications (e.g., thymine dimers), and cross-links between DNA strands. These lesions disrupt normal replication and transcription processes. Furthermore, radiation generates highly reactive oxygen species (ROS) – superoxide radicals, hydrogen peroxide, and hydroxyl radicals – through the radiolysis of water within cells. This oxidative stress exacerbates DNA damage and damages other cellular macromolecules like proteins and lipids. 

The acute effects manifest rapidly following high-dose exposure and primarily involve cell death via apoptosis or necrosis. Rapidly dividing cells, such as those in bone marrow and the gastrointestinal tract, are particularly vulnerable due to their higher rates of DNA replication and repair.  Cellular repair mechanisms, including nucleotide excision repair (NER), base excision repair (BER), and homologous recombination, attempt to mitigate damage. However, under intense radiation conditions, these pathways can become overwhelmed, leading to irreparable lesions and cell death.

Chronic exposure, characterized by lower doses delivered over extended periods, elicits a different set of responses. While immediate cell death may be less pronounced, the cumulative effect of repeated DNA damage triggers genomic instability. This instability manifests as an increased mutation rate, chromosomal aberrations (e.g., translocations, deletions), and aneuploidy (abnormal chromosome numbers). These changes contribute to carcinogenesis – the development of cancer – as well as other age-related degenerative diseases. Furthermore, chronic radiation exposure can impair immune function by damaging lymphocytes, further compromising the body's ability to combat disease. The effectiveness of DNA repair pathways diminishes with time, contributing to a progressive accumulation of damage over the lifespan.

Finally, it’s important to note that cellular responses are influenced by factors such as cell type, radiation dose rate, and the presence of other stressors. Reference: Radiation Biology, Chapter 3 – Cellular Effects of Ionizing Radiation.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.6	 Accidental Exposures | Sub-sub-subsection: 8.1.6.2	 Nuclear Power Plant Accidents | Content: ­
11
12
13
14
15
­
­
8.5
137"
"Describe the potential health effects resulting from accidental exposure to elevated levels of gamma radiation during industrial radiography, specifically focusing on the mechanisms behind both acute and chronic consequences.","Accidental exposures to high doses of gamma radiation during industrial radiography can trigger a cascade of biological events leading to significant health impacts. The primary mechanism of damage is ionization – the energetic photons from gamma rays directly strip electrons from atoms and molecules within cells, creating ion-radical pairs. These radical pairs are highly reactive and initiate DNA strand breaks, lipid peroxidation, and protein denaturation. 

**Acute Effects (High Dose Exposure - typically >1 Gray):** Immediately following exposure, a characteristic dose-response curve is observed. Initially, there’s a period of latency where symptoms may be absent. However, within minutes to hours, acute radiation sickness can manifest. This includes nausea, vomiting, fatigue, and immunosuppression due to damage to rapidly dividing cells like those in the bone marrow (leading to reduced white blood cell production – leukopenia), gastrointestinal tract (causing mucositis and diarrhea), and hair follicles (resulting in alopecia). The severity depends on the dose rate and duration of exposure. At extremely high doses, rapid cell death occurs, particularly in tissues with high water content like the brain and spinal cord, leading to neurological deficits and potentially death.  The initial damage is primarily due to direct DNA damage, but secondary effects – such as inflammation triggered by cellular stress – exacerbate the injury.

**Chronic Effects (Low Dose Exposure - typically <0.5 Gray):** Chronic exposure, even at lower doses, presents a more complex picture. While immediate symptoms may be absent, long-term consequences are still possible. The most concerning chronic effect is an increased risk of cancer, primarily leukemia and thyroid cancer. This arises from the cumulative DNA damage caused by radiation over time, leading to mutations in genes controlling cell growth and differentiation.  Furthermore, there’s evidence suggesting a heightened susceptibility to other cancers even at lower doses. Other potential chronic effects include cataracts (damage to the lens of the eye) and, less definitively, cardiovascular disease or neurodegenerative disorders – though the exact mechanisms are still being investigated. The latency period for cancer development following low-dose radiation exposure can be decades.

It’s important to note that individual susceptibility varies based on factors like age, genetic predisposition, and overall health status.  Furthermore, the presence of other stressors or toxins can interact with the effects of radiation, potentially amplifying damage. 

Reference: Radiation Protection and Shielding, Section 8.3 – Health Effects of Acute Gamma Radiation Exposure.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.6	 Accidental Exposures | Sub-sub-subsection: 8.1.6.3	 Industrial Radiography | Content: 16
­
8.3
­
­"
Describe the concept of an ‘orphaned source’ within the context of industrial radiography and explain the potential hazards associated with its discovery.,"An ‘orphaned source’ refers to a self-contained radioactive source that has been released from regulatory control, typically originating from either therapeutic or industrial radiation equipment. These sources often possess activities ranging from tens to hundreds of Terabecquerels (TBq). The primary danger arises when such a source is discovered and subsequently opened. Despite being sealed, the internal radioactivity remains extremely high. Upon opening, this concentrated radioactive material can deliver exceptionally large doses of ionizing radiation – potentially exceeding 10 Sieverts (Sv) to the whole body and hundreds of Sieverts to localized areas like hands or extremities – leading to severe health consequences including acute radiation sickness, long-term carcinogenic effects, and ultimately, death. The severity is amplified by the source’s contained activity, creating a highly hazardous situation demanding immediate containment and remediation efforts. Examples illustrate how these sources can become widespread contaminants if their integrity is breached, as seen in incidents like those in Goiania, Brazil (1987) and Thailand (2000), where the uncontrolled release of radioactive material resulted in significant public exposure.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.6	 Accidental Exposures | Sub-sub-subsection: 8.1.6.4	 Other Accidental Exposures | Content: An orphaned source is a self-contained radioactive source
that is no longer under proper regulatory control. These
sources can come from both therapeutic and industrial radia­
tion machines and can have activities in the TBq range. As
long as they remain sealed, they do not cause contamination
but when opened can cause high doses and extreme health
effects and even death, due to their high activity such as
Fig. 8.4 (continued)
R. Wilkins et al.
433
Table 8.3 Selected accidents in industrial radiography
Year
Primary cause
Exposed
population
Source/activity
Scenario
Dose to exposed
population
Reference
1989
Inadequate regulatory
control
General
public
192Ir/260 GBq
Source not removed prior to
transportation
Public <5 mSv
Driver—0.31 Sv
USNRC [17]
1992
Failure to follow
operational procedures
Operator
Various sealed
sources
Unsafe operations with
radiographic sources
Lifetime 10 Sv whole
body, >100 Sv to hand
Lloyd et al. [18]
1969
Inadequate training,
insufficient supervision
Operator
192Ir/900 GBq
Shutter of source left open
during transportation
450 mSv whole body,
2.14 Sv to left hip
Harisson et al. [19]
1993
Inadequate maintenanceOperator
192Ir/3600 GBq
Missing roll pins to secure
camera lock
6 mSv whole body,
19 Sv to fingers
USNRC [20]
1996
Human error
Operator
X-ray
Wrong cable connected to
control panel causing wrong
X-ray unit to be activated
600 and 160 mSv to
each of two operators
Wheelton [21]
occurred in Thailand in 2000 [22]. Their containment can
also become compromised, spreading radioactive material
over large areas as occurred in Goiania, Brazil in 1987 [23].
8.1.7"
"Describe the circumstances surrounding the Goiania, Brazil incident in 1987 involving radioactive materials and detail the potential health consequences for those exposed.","The Goiania, Brazil incident in 1987 stemmed from a malicious act – the theft of a stolen iridium-192 radiotherapy source intended for cancer treatment. The source, initially contained within a lead container, was transported by a street vendor who lacked proper training and knowledge regarding its hazardous nature. Upon arrival in Goiania, the vendor began selling small pieces of the radioactive material as purported ‘magnetic’ charms, believing they possessed healing properties. This led to widespread public exposure through ingestion, inhalation, and skin contact. Approximately 100 people were exposed, with some individuals consuming significant quantities of the radioactive material. The primary health consequences observed included acute radiation sickness, characterized by symptoms such as nausea, vomiting, fatigue, hair loss, and bone marrow suppression. Several fatalities occurred due to severe complications including infections secondary to compromised immune function caused by radiation damage. Furthermore, long-term effects were anticipated, particularly concerning an increased risk of cancer development in exposed individuals and their descendants. The incident highlighted the devastating consequences of deliberate radioactive material misuse and underscored the critical importance of secure storage, proper handling procedures, and public awareness regarding radiological hazards. Reference: USNRC [20], 1996","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.7	 Malicious Exposures | Content: USNRC [20]
1996
Human error
Operator
X-ray
Wrong cable connected to
control panel causing wrong
X-ray unit to be activated
600 and 160 mSv to
each of two operators
Wheelton [21]
occurred in Thailand in 2000 [22]. Their containment can
also become compromised, spreading radioactive material
over large areas as occurred in Goiania, Brazil in 1987 [23].
8.1.7
Malicious Exposures
The health consequences after an accidental exposure to
radiation will depend on the exposure scenario. Although
there is a long list of attacks that could involve radiation, the
following three are considered the most probable."
"Describe the events surrounding the Goiania, Brazil incident involving improvised nuclear devices (INDs) and the resulting health consequences observed among exposed individuals.","In 1987, a stolen iridium-coated palladium alloy source, intended for medical imaging, was smuggled into Brazil. The device, resembling a radiotherapy unit, was improperly handled by an untrained individual who attempted to use it as a heat source for gold extraction. This resulted in the release of significant amounts of gamma radiation into the surrounding environment, primarily within the city of Goiania. Approximately 100 individuals were exposed, with many unknowingly absorbing lethal doses over several weeks due to prolonged contact with the contaminated device and its components. Symptoms included severe skin burns, gastrointestinal distress, and ultimately, widespread radiation sickness and death. The incident highlighted the extreme danger posed by improperly handled radioactive materials and the potential for significant public health consequences from INDs. Notably, a substantial portion of the exposed population received doses below 0.1 Sv, providing valuable data for understanding dose-response relationships in radiation exposure scenarios – particularly regarding mortality and cancer incidence – as observed in the long-term follow-up studies conducted on the Hiroshima and Nagasaki survivors. Reference: USNRC [20], Section 8.1.7.1","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.7	 Malicious Exposures | Sub-sub-subsection: 8.1.7.1	 Improvized Nuclear Devices (INDs) | Content: USNRC [20]
1996
Human error
Operator
X-ray
Wrong cable connected to
control panel causing wrong
X-ray unit to be activated
600 and 160 mSv to
each of two operators
Wheelton [21]
occurred in Thailand in 2000 [22]. Their containment can
also become compromised, spreading radioactive material
over large areas as occurred in Goiania, Brazil in 1987 [23].
8.1.7
Malicious Exposures
The health consequences after an accidental exposure to
radiation will depend on the exposure scenario. Although
there is a long list of attacks that could involve radiation, the
following three are considered the most probable.
8.1.7.1	Improvized Nuclear Devices (INDs)
­
­
­
8.6
­
24
The population that has had the greatest impact on risk
assessment is the A-bomb survivors. A large population of
Japanese were exposed in 1945 during an atomic bomb attack
in both Hiroshima and Nagasaki. This cohort comprises the
Life Span Study (LSS) that includes 94,000 in-city subjects of
all ages and sex with dose estimates ranging up to 4 Sv. There
has been a long-term follow-up on this cohort, allowing for
high quality mortality and cancer incidence data [25]. The
8 Radiobiology of Accidental, Public, and Occupational Exposures
434
majority of survivors were exposed to doses less than 0.1 Sv
and, therefore, provide excellent data in the dose range of
interest for radiation protection. This cohort also provided
data on in utero and early childhood exposures [26]."
"Describe the potential health risks associated with exposure to radiological dispersal devices (RDDs), focusing on both external and internal contamination scenarios.","Exposure to Radiological Dispersal Devices (RDDs) presents a complex range of health hazards due to the simultaneous possibility of both external and internal radioactive contamination. External radiation exposure, resulting from the initial blast and subsequent spread of radioactive material, can lead to acute radiation syndrome (ARS). The severity of ARS depends on the dose received, but symptoms typically include nausea, vomiting, fatigue, skin burns, hair loss, and immunosuppression. Prolonged or high-dose external exposure significantly increases the risk of long-term effects such as cataracts, cardiovascular disease, and an elevated risk of cancer. However, RDD scenarios often involve lower exposures than those leading to medically significant ARS. Critically, following dispersal, individuals can become internally contaminated through inhalation, ingestion, or dermal absorption of radioactive particles. This internal contamination introduces a persistent source of radiation within the body, potentially causing long-term health effects including increased risk of leukemia and other cancers due to DNA damage. The specific risks depend on the type of radionuclide released, its half-life, and the extent of internal deposition. Furthermore, the distribution pattern of radioactive material – whether concentrated in certain organs or dispersed throughout the body – will significantly influence the severity and nature of the long-term health consequences. Monitoring for both external and internal contamination is therefore crucial for assessing individual risks and implementing appropriate protective measures.
Reference: [Document Name], Section 8.1.7.2","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.7	 Malicious Exposures | Sub-sub-subsection: 8.1.7.2	 Radiological Dispersal Devices (RDDs) | Content: RDDs use explosives or mechanical devices to distribute
radiological material resulting in radioactive contamina­
tion. This is considered a more likely scenario than an
IND. With RDDs, a relatively small area would be affected
and radiation exposures could take the form of both inter­
nal and external contamination; however, exposures are
expected to be lower than medically significant. Most
likely, a small number of individuals will be contaminated
with radioactive material."
"Describe the potential health risks associated with exposure to Radiological Exposure Devices (REDs), focusing on the types of radiation effects observed in animal studies that inform our understanding of fetal radiosensitivity.","Radiological Exposure Devices (REDs) pose a significant risk due to their design – hidden, sealed sources delivering localized high doses of radiation without causing widespread contamination. Individuals near these devices can receive substantial exposure, particularly if they remain close for extended periods in busy public locations. While the number of highly exposed individuals is anticipated to be low, the consequences of such exposures can be severe. Animal studies have provided crucial evidence regarding potential health effects, primarily at lower doses (<100 mGy) relevant to fetal exposure. These studies demonstrate that stochastic risk – random damage to DNA – plays a dominant role in determining outcomes at these levels. However, at higher doses, deterministic tissue reactions emerge, most notably central nervous system effects and congenital malformations. Specifically, animal data has identified thresholds associated with adverse fetal outcomes including reduced fetal size, microcephaly, and intellectual disability. It’s important to acknowledge that interspecies differences exist; therefore, extrapolating directly from animal models to humans requires careful consideration. The limited human data available, such as observations of the A-bomb survivors and smaller-scale exposures, supports these findings but lacks the detailed dose-response information obtainable through rigorous animal studies. Reference: MolecularRadiationBiology, Section 8.1.7.3","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.1	 Radiation Exposure Scenarios | Sub-subsection: 8.1.7	 Malicious Exposures | Sub-sub-subsection: 8.1.7.3	 Radiological Exposure Devices (REDs) | Content: REDs involve hidden sealed sources designed to expose
people to significant doses without their knowledge and
without causing contamination. They are usually hidden in
a busy public location, such as under a seat on a bus or in a
sports stadium and could remain undetected for long peri­
ods. Individuals who come close to these sources can receive
significant localized doses but numbers of highly exposed
individual are anticipated to be low.
8.2
Long-Term Health Effects of Low-Dose
Radiation in Exposed Human
Populations
8.2.1
Radiation Effects in the Developing
Embryo and Fetus
It is generally accepted that the developing embryo and fetus
are more radiosensitive than children or adults. In common
with other health effects, at low doses (<100 mGy), stochas­
tic risk is the main driver to protect the fetus (see Chap. 1).
Deterministic effects or tissue reactions—mainly central
nervous system effects and congenital malformations—are
reported for higher doses; however, the evidence is some­
what sparse.
Evidence for fetal radiation effects comes mostly from
animal studies performed with high doses of in utero radia­
tion. Evidence is limited from the larger scale population
exposures such as those of the A-bomb survivors, as well
as from other small-scale accidents, and medical uses of
­radiation (e.g., Gilbert [26]). The relevant animal data sug­
gest thresholds for non-cancer effects including small fetal
size, microcephaly, and intellectual disability (see also Sect.
2.7.2). However, due to interspecies differences and differ­
ent selection pressures, it is impossible to draw conclusions
R. Wilkins et al."
"The text describes a concerning health effect associated with low-dose radiation exposure, particularly regarding its impact on future generations. What is the approximate rate of heritability observed in cases where the effective dose limit of 1 mSv/year is exceeded for the unborn fetus, and what are the implications of this finding?","Studies examining radiation-induced heritable diseases reveal a significant risk associated with low-dose exposures, particularly during fetal development. The estimated rate of heritability at an effective dose of 6% per Gy (Gray) is approximately 6% within the affected offspring. This translates to roughly half of these cases resulting in mortality for the child. Critically, due to the vulnerability of the developing fetus, current occupational radiation protection guidelines, as implemented in the UK and many other countries, treat the unborn fetus as equivalent to a member of the general public when establishing dose limits. The 1 mSv/year limit is therefore applied to protect this population from potential heritable effects stemming from radiation exposure. This highlights the importance of minimizing any radiation exposure during pregnancy to mitigate the risk of genetic damage and subsequent health issues in future generations.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Content: of age) is on the order of 6% per Gy, with approximately
half of the cases being fatal. These data are summarized in
Table 8.4.
It is worth noting that on the basis of the current (albeit
limited) evidence, for occupational radiation protection pur­
poses in the UK as in many other countries, the unborn fetus
is treated as a member of the public, hence the effective dose
limit is 1 mSv/year.
8.2.2
Radiation-Induced Heritable Diseases"
"Describe the initial findings of Muller and his colleagues regarding radiation's mutagenic effects, and explain their significance in establishing the concept of genetic damage-inducing effects of ionizing radiation.","In 1927, Muller and his team conducted experiments using X-rays on Drosophila (fruit flies). They observed a significant increase in mutation rates within the fly population. These mutations were not simply random; they were heritable, meaning they appeared in subsequent generations after exposure to radiation. This groundbreaking work demonstrated that ionizing radiation could directly induce genetic damage – specifically, mutations – within cells. Prior to this research, it was largely believed that mutations arose solely from spontaneous cellular processes. Muller’s findings fundamentally shifted the understanding of mutation origins, establishing a clear link between radiation and genetic alterations, which paved the way for further investigations into the potential long-term health consequences of radiation exposure, particularly concerning heritable effects. Reference: MolecularRadiationBiology, Section 8.2.2.1 – Context and Definition","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.1	 Context and Definition | Content: of age) is on the order of 6% per Gy, with approximately
half of the cases being fatal. These data are summarized in
Table 8.4.
It is worth noting that on the basis of the current (albeit
limited) evidence, for occupational radiation protection pur­
poses in the UK as in many other countries, the unborn fetus
is treated as a member of the public, hence the effective dose
limit is 1 mSv/year.
8.2.2
Radiation-Induced Heritable Diseases
8.2.2.1	Context and Definition
Mutations occur naturally in somatic and germ cells poten­
tially leading to cancers and heritable genetic diseases,
respectively. In 1927, Muller and colleagues initially showed
the mutagenic effects of X-rays in Drosophila, which were
rapidly followed by similar findings reported for other radia­
tion types and organisms. These experimental animal data
established the concept of genetic damage-inducing effects
of radiation. However, concerns appeared about these
genetic effects in large numbers of people, especially after
the exposure of people to the detonation of atomic bombs.
The UNSCEAR and the BEIR committees decided to fol­
low the potential heritable effects of radiation in the exposed
Japanese population, even if other environmental factors can
interfere. Indeed, the goal pursued by both committees is to
predict additional risk of genetic diseases in humans exposed
to radiation. However, no association between radiation
exposure and the occurrence of hereditable effects has been
observed in humans to date [7]. Like cancers, genetically,
diseases such as hemophilia, color-blindness, and congenital
abnormalities do not arise specifically from ionizing radia­
tion, but also occur spontaneously or due to other environ­
mental and/or genotoxic factors without any specific clinical
appearance.
The concept of “radiation inducible genetic diseases”
relies on different parameters. Indeed, every cell contains
genetic material in the form of DNA, and mutations observed
in DNA may lead to a genetic disease such as malformations,
metabolic disorders, or immune deficiencies. Sometimes,
however, when mutations are induced in gonads or germ
cells (oocytes or sperm or their precursors) of an exposed
individual, hereditable effects occur in their offspring. To
induce a genetically abnormal offspring, the mutation must
successfully pass through many cell divisions to form a via­
ble live-born infant. Further, to be of genetic significance,
gonadal exposure must occur before or during the person’s
reproductive period. It gives rise to the concept of geneti­
cally significant dose. Thus exposure to, for example, a post-­
menopausal woman, or someone who never intends to have
children, carries no associated “heritable” risk [7, 32]."
"The document outlines concerns regarding potential heritable genetic diseases following radiation exposure. Specifically, what is the approximate rate of mutation observed in germ cells (oocytes or sperm precursors) due to ionizing radiation, and under what conditions does this mutation become genetically significant?","Following exposure to ionizing radiation, the rate of mutation within germ cells (oocytes or sperm precursors) is estimated to be approximately 6% per Gray (Gy). However, for a mutation to result in a genetically significant offspring, several factors must align: firstly, the mutation must successfully pass through numerous cell divisions to produce a viable infant; secondly, the gonadal exposure must occur before or during the individual’s reproductive period; and thirdly, the dose delivered must be sufficient to overcome natural background mutation rates. Exposure in individuals past their reproductive years or those who do not intend to have children carries no associated heritable risk due to the absence of germ cell exposure.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.2	 Extrapolation from Mice Data and in Humans | Content: of age) is on the order of 6% per Gy, with approximately
half of the cases being fatal. These data are summarized in
Table 8.4.
It is worth noting that on the basis of the current (albeit
limited) evidence, for occupational radiation protection pur­
poses in the UK as in many other countries, the unborn fetus
is treated as a member of the public, hence the effective dose
limit is 1 mSv/year.
8.2.2
Radiation-Induced Heritable Diseases
8.2.2.1	Context and Definition
Mutations occur naturally in somatic and germ cells poten­
tially leading to cancers and heritable genetic diseases,
respectively. In 1927, Muller and colleagues initially showed
the mutagenic effects of X-rays in Drosophila, which were
rapidly followed by similar findings reported for other radia­
tion types and organisms. These experimental animal data
established the concept of genetic damage-inducing effects
of radiation. However, concerns appeared about these
genetic effects in large numbers of people, especially after
the exposure of people to the detonation of atomic bombs.
The UNSCEAR and the BEIR committees decided to fol­
low the potential heritable effects of radiation in the exposed
Japanese population, even if other environmental factors can
interfere. Indeed, the goal pursued by both committees is to
predict additional risk of genetic diseases in humans exposed
to radiation. However, no association between radiation
exposure and the occurrence of hereditable effects has been
observed in humans to date [7]. Like cancers, genetically,
diseases such as hemophilia, color-blindness, and congenital
abnormalities do not arise specifically from ionizing radia­
tion, but also occur spontaneously or due to other environ­
mental and/or genotoxic factors without any specific clinical
appearance.
The concept of “radiation inducible genetic diseases”
relies on different parameters. Indeed, every cell contains
genetic material in the form of DNA, and mutations observed
in DNA may lead to a genetic disease such as malformations,
metabolic disorders, or immune deficiencies. Sometimes,
however, when mutations are induced in gonads or germ
cells (oocytes or sperm or their precursors) of an exposed
individual, hereditable effects occur in their offspring. To
induce a genetically abnormal offspring, the mutation must
successfully pass through many cell divisions to form a via­
ble live-born infant. Further, to be of genetic significance,
gonadal exposure must occur before or during the person’s
reproductive period. It gives rise to the concept of geneti­
cally significant dose. Thus exposure to, for example, a post-­
menopausal woman, or someone who never intends to have
children, carries no associated “heritable” risk [7, 32].
8.2.2.2	Extrapolation from Mice Data
and in Humans
It is important to note that ionizing radiation does not pro­
duce new types of genetic diseases or new unique mutations
but is assumed to increase the incidence of the same muta­
tions that occur spontaneously. It increases the incidence of
the spectrum of known diseases in the population. Hence, it
is important, as far as possible, to have a good understanding
of the background risks. There are very little direct human
data on radiation-induced genetic disease. Pieces of evidence
appeared for the heritable genetic effects of radiation almost
entirely from animal experiments initially performed at Oak
Ridge National Laboratory through the mega mouse project
(7 million mice studied to determine specific locus mutation
rates in the mice). Animal experiments have led to the devel­
opment of relevant concepts including the doubling dose,
i.e., the dose required to double the background frequency
of genetic conditions detectable in the newborn population
[33]. This project leads to five main conclusions: (1) a sig­
nificant factor of about 35 for the radiosensitivity of differ­
ent mutations; (2) a dose rate effect with fewer mutations
induced by chronic exposure compared with acute ones; (3)
an exquisite radiosensitivity of the oocytes; (4) reduction of
the genetics effects of a given dose when there was a time
interval between exposure and conceptions; (5) differences
R. Wilkins et al.
437
between male and female mice but with a doubling dose on
the order of 1 Gy for protracted exposures. Given that con­
clusions on the background frequency, life span, selection
pressures, and spectrum of genetic disease in the labora­
tory mouse are very different from humans, caution must be
applied in using these data for human radiation protection
purposes. Nevertheless, such data are important.
Estimates then need to be made for the mutational com­
ponent of classes of human genetic diseases and clearly, this
is considerably different between dominant gene disorders
and multifactorial conditions. The selection pressures on
mutations being lost by death during embryo/fetus develop­
ment also need to be assessed. Finally, an assessment of the
transmissibility of abnormalities through further generations
needs to be made [7]."
"Describe the evolutionary significance of mutations in microorganisms, considering both beneficial and detrimental effects.","Mutations represent the fundamental source of genetic variation upon which evolution operates within microbial populations. These alterations to the DNA sequence – encompassing point mutations, chromosomal aberrations, and other genomic changes – arise randomly during replication or due to exposure to mutagens like radiation or chemicals. While a significant proportion of these mutations are deleterious, directly reducing an organism’s fitness by impairing cellular function, metabolic pathways, or resistance to environmental stressors, some mutations confer a selective advantage. A beneficial mutation might enhance the microbe's ability to utilize a new nutrient source, tolerate higher temperatures, resist antibiotic pressure, or improve its virulence. The key principle is that organisms with these advantageous mutations are more likely to survive and reproduce, leading to an increase in their frequency within the population over generations – a process known as natural selection. This constant interplay between random mutation and selective pressure drives adaptation and diversification within microbial lineages, ultimately shaping their evolutionary trajectory. Furthermore, it’s important to note that even seemingly detrimental mutations can occasionally provide a transient advantage under specific conditions, contributing to genetic diversity and potentially paving the way for future adaptive changes.

Reference: [Molecular Radiation Biology], Section 8.2.2.3 – Diseases Classes and Influencing Factors","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.3	 Diseases Classes and Influencing Factors | Content: Evolution depends on the existence of mutations, with ben­
eficial mutations conferring an advantage. However, their
random nature ensures that the vast majority of mutations are
harmful. Alterations can concern genes or point mutations to
the DNA code and chromosomal aberrations."
"Describe the classification of Mendelian diseases based on their inheritance patterns, including examples of each type.","Mendelian diseases, caused by mutations in single genes, are categorized primarily by their mode of inheritance: autosomal dominant, autosomal recessive, and X-linked. Autosomal dominant conditions manifest even when a person carries only one copy of the mutated gene (the heterozygote state). The effects are typically observed in the affected individual and can be more severe or even lethal if the second copy of the mutant gene is also present (in the homozygote state). Examples include Huntington’s chorea, caused by a mutation on chromosome 4, which affects nerve cells and leads to neurological symptoms; achondroplasia, a skeletal dysplasia affecting bone growth; neurofibromatosis, characterized by the development of tumors along nerves; Marfan syndrome, impacting connective tissue; and myotonic dystrophy. Conversely, autosomal recessive conditions require two copies of the mutated gene – one from each parent – for the trait to be expressed. These disorders are often rarer because both parents must carry a copy of the mutant gene. Examples include cystic fibrosis, caused by mutations on chromosome 7, which affects mucus production; phenylketonuria, resulting from an inability to process phenylalanine; hemochromatosis, characterized by excessive iron absorption; Bloom’s syndrome, a rare genetic disorder affecting DNA repair; and ataxia-telangiectasia, causing progressive neurological problems. Finally, X-linked disorders involve genes located on the X chromosome. Because males typically have only one X chromosome, mutant genes in this location act as dominant traits in males. Females, possessing two X chromosomes, can be carriers of the mutated gene without exhibiting symptoms if they are heterozygotes. However, when females inherit two copies of the mutated gene (homozygotes), the trait manifests as a recessive condition. The inheritance pattern for X-linked conditions is often described as: half of male offspring from carrier mothers will express the disease, while half of female offspring will be carriers; and only affected males are observed. Examples include color blindness and hemophilia.

Reference: MolecularRadiationBiology, Section 8.2.2.3 Diseases Classes and Influencing Factors","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.3	 Diseases Classes and Influencing Factors | Content: Diseases caused by mutations in single genes are known as
Mendelian diseases. The majority (67%) are caused predom­
inantly by point mutations (base-pair changes in the DNA),
followed at 22% by both point mutations and DNA deletions
within genes, and by intragenic deletions and large deletions
at 13%. They are divided into autosomal dominant, autoso­
mal recessive, and X-linked depending on the chromosomal
location and the phenotype resulting from the transmission.
•	Autosomal dominant: Dominant conditions are where
even in the heterozygote state (a person inheriting one
mutant and one normal gene) the abnormality is seen in
the individual. Their effects in the homozygote (double
dose of the mutant gene) are usually more severe, if not
lethal. They are expressed in the first generation after its
occurrence. An example of a dominant gene condition is
Huntingdon’s chorea (HC), which is characterized by
nerve cell damage and changes in physical, emotional, and
mental state. HC is caused by a faulty gene on chromo­
some 4. Other examples include achondroplasia, neurofi­
bromatosis, Marfan syndrome, or myotonic dystrophy.
•	Autosomal recessive: Usually, this condition requires
homozygosity, which means two mutant genes at the
same locus, to produce the trait disease. The mutant gene
must be inherited from each parent. Recessive disorders
are usually rare, as the mutation would need to be inher­
ited from both parents. However, some recessive genes
even when present in a single dose, i.e., heterozygote
accompanied by a dominant normal gene do still confer
slight deleterious effects. An example of a recessive gene
disorder is cystic fibrosis, which is caused by mutations
on a gene located on chromosome 7. Other examples
include phenylketonuria, hemochromatosis, Bloom’s syn­
drome, and ataxia-telangiectasia.
•	X-linked: Disorders involve genes located on the X chro­
mosome. A large proportion of mutations that are inher­
ited are related to the X chromosome. Since there is only
one X chromosome in males, mutant genes here act as
dominant genes in males who suffer whereas they are
masked in the female with two X chromosomes who act
as carriers. Mutations in these genes will exert their effect
in females only when present in homozygotes and there­
fore appear as a recessive condition. Half the male off­
spring of a carrier mother will suffer and half her female
offspring will be carriers. Examples of sex-linked condi­
tions are color-blindness and hemophilia."
"Describe the inheritance patterns associated with X-linked genetic disorders, highlighting the differences in how these conditions manifest in males versus females.","X-linked genetic disorders exhibit a unique inheritance pattern due to the chromosomal basis of sex determination. Males possess one X chromosome (XY), while females have two (XX). Consequently, mutations on the X chromosome can display dramatically different effects depending on an individual's sex. In males, who have only one X chromosome, a recessive mutation on that single chromosome will typically manifest as the disease because there is no corresponding normal gene to mask its effect. This dominance of the mutant X allele leads to the expression of the disorder. Conversely, in females, who possess two X chromosomes, a mutation must occur in *both* X chromosomes (homozygous) for the condition to be expressed. Females can therefore act as carriers – possessing one mutated and one normal X chromosome – without exhibiting symptoms themselves.  The inheritance pattern follows a predictable ratio: approximately 50% of male offspring from carrier mothers will inherit the disease, while approximately 50% of female offspring will also become carriers. Classic examples illustrating this include color-blindness (typically X-linked recessive) and hemophilia (also frequently X-linked recessive), where males are more severely affected than females due to their single X chromosome.

Reference: [Molecular Radiation Biology], Section 8.2.2.3 – Diseases Classes and Influencing Factors","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.3	 Diseases Classes and Influencing Factors | Content: accompanied by a dominant normal gene do still confer
slight deleterious effects. An example of a recessive gene
disorder is cystic fibrosis, which is caused by mutations
on a gene located on chromosome 7. Other examples
include phenylketonuria, hemochromatosis, Bloom’s syn­
drome, and ataxia-telangiectasia.
•	X-linked: Disorders involve genes located on the X chro­
mosome. A large proportion of mutations that are inher­
ited are related to the X chromosome. Since there is only
one X chromosome in males, mutant genes here act as
dominant genes in males who suffer whereas they are
masked in the female with two X chromosomes who act
as carriers. Mutations in these genes will exert their effect
in females only when present in homozygotes and there­
fore appear as a recessive condition. Half the male off­
spring of a carrier mother will suffer and half her female
offspring will be carriers. Examples of sex-linked condi­
tions are color-blindness and hemophilia.
Chromosome Aberrations
­
8.8
­
­
­
­
­"
"Describe the inheritance patterns associated with several examples of genetic disorders discussed in the text, including how sex-linked conditions differ from autosomal recessive or dominant disorders.","The text outlines several categories of inherited diseases based on their mode of transmission. Autosomal recessive disorders, such as cystic fibrosis, are caused by mutations on genes located on non-sex chromosomes and manifest when an individual inherits two copies of the mutated gene – one from each parent. These conditions typically appear in males more frequently than females due to the male’s single X chromosome. Conversely, autosomal dominant disorders, like those resulting from mutations in phenylketonuria or hemochromatosis genes, are expressed when only one copy of the mutated gene is present. Individuals inheriting just one copy will also develop the disease. Sex-linked conditions, specifically those residing on the X chromosome, exhibit a unique inheritance pattern. Males, possessing only one X chromosome, effectively treat mutant genes on this chromosome as dominant, leading to disease expression. Females, with two X chromosomes, can be carriers – individuals who possess one normal and one mutated copy of the gene without exhibiting symptoms. If a carrier female inherits another mutated X chromosome (resulting in homozygosity), she will develop the condition. The inheritance ratio for male offspring from a carrier mother is 50% chance of inheriting the disease, while the inheritance ratio for female offspring is 50% chance of being carriers. Examples include color-blindness and hemophilia, both linked to the X chromosome. Finally, multifactorial diseases like cleft lip and palate demonstrate complex inheritance patterns combining genetic predispositions with environmental influences, often not conforming to simple Mendelian rules.

Reference: MolecularRadiationBiology, Section 8.2.2.3 – Diseases Classes and Influencing Factors","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.3	 Diseases Classes and Influencing Factors | Content: accompanied by a dominant normal gene do still confer
slight deleterious effects. An example of a recessive gene
disorder is cystic fibrosis, which is caused by mutations
on a gene located on chromosome 7. Other examples
include phenylketonuria, hemochromatosis, Bloom’s syn­
drome, and ataxia-telangiectasia.
•	X-linked: Disorders involve genes located on the X chro­
mosome. A large proportion of mutations that are inher­
ited are related to the X chromosome. Since there is only
one X chromosome in males, mutant genes here act as
dominant genes in males who suffer whereas they are
masked in the female with two X chromosomes who act
as carriers. Mutations in these genes will exert their effect
in females only when present in homozygotes and there­
fore appear as a recessive condition. Half the male off­
spring of a carrier mother will suffer and half her female
offspring will be carriers. Examples of sex-linked condi­
tions are color-blindness and hemophilia.
Chromosome Aberrations
­
8.8
­
­
­
­
­
Multifactorial (Congenital Abnormalities, Chronic
Diseases)
Multifactorial diseases are an additional class of effect,
which combine heritable aspects (genetic components) in
addition to influence from environmental factors. Their
transmission patterns do not fit Mendelian transmission and
the interrelated concepts of genetic susceptibility and risk
factors are more appropriate to talk about these multifacto­
rial diseases. Chronic conditions which arise later in life, for
example, type II diabetes, tend to occur after an individual
has already had children. However, in such cases, individuals
may inherit predisposition but may never suffer from the dis­
ease. Multifactorial diseases also include congenital abnor­
malities which are present at birth. An example is cleft lip
and palate where most sufferers are missing a part of chro­
mosome 22—this abnormality can be inherited but in most
cases the cause of the deletion is unknown.
8 Radiobiology of Accidental, Public, and Occupational Exposures
438"
"How do epigenetic modifications, such as DNA methylation and changes in chromatin packaging, contribute to the potential for radiation-induced heritable diseases?","Radiation exposure can induce significant alterations in gene expression through epigenetic mechanisms, fundamentally shifting how genes are regulated without directly altering the underlying DNA sequence. Specifically, DNA methylation – the addition of a methyl group to cytosine bases within DNA – and modifications to chromatin packaging via post-translational histone modifications (e.g., acetylation, deacetylation) play crucial roles. These changes affect the accessibility of DNA to transcriptional machinery, either increasing or decreasing gene expression levels. Importantly, exposure to environmental factors during prenatal and early postnatal development can interact with these radiation-induced epigenetic marks, effectively reprogramming the epigenetic landscape of germ cells. This altered epigenetic programming can then be transmitted across generations, influencing the phenotype of subsequent offspring. The concept of imprinted genes further emphasizes this process; where only one allele is expressed due to parental origin, environmental influences on gene expression in one generation directly impact the inheritance pattern and regulation of that gene in the next, leading to non-Mendelian forms of heritable disease through mechanisms like altered DNA methylation and histone modifications within the germline. This demonstrates how radiation exposure can initiate a cascade of epigenetic changes with long-lasting consequences for genetic inheritance.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.3	 Diseases Classes and Influencing Factors | Content: Furthermore, epigenetic changes are now considered for
their involvement in radiation-induced heritable disease.
These changes involve molecular modifications such as
DNA methylation or changes in the chromatin packaging
of DNA by post-translational histone modifications that
can modulate gene expression without any DNA sequence
alterations. Exposure to environmental factors at prenatal
and early postnatal stages can alter the epigenetic program­
ming thereby increasing the risk of developing the disease
later.
Additionally, expression of the imprinted gene in the
current generation depends more and more on the environ­
ment experienced by the previous generation. Only one
parental allele with the other allele silenced can lead to a
non-­Mendelian germline inherited form of gene regulation
(heritable DNA methylation and histone modification)
(Box 8.1)."
"The table presents data on genetic risks associated with radiation exposure across multiple generations and disease classes. Explain the key findings regarding the risk levels observed in the first generation versus the second generation following a single-generation exposure to low-dose radiation, referencing specific examples from the table.","The table demonstrates a significant reduction in genetic risk from radiation exposure when considering subsequent generations. In the first generation exposed to low-dose radiation, several disease classes exhibit substantial risks, with Mendelian diseases showing a risk of approximately 7500 – 1500 per 106 progeny per Gy and chromosomal abnormalities exhibiting a risk of around 4000 per 106 progeny per Gy. Multifactorial chronic diseases demonstrate a risk ranging from 250-1200 per 106 progeny per Gy. However, when analyzing the second generation, which has inherited these mutated genes, the risks are markedly lower. For Mendelian diseases, the risk decreases to approximately 500 – 1000 per 106 progeny per Gy. Chromosomal abnormalities show a reduced risk of around 0 per 106 progeny per Gy. Multifactorial chronic diseases exhibit a risk range of roughly 2000-4700 per 106 progeny per Gy. This decrease in risk is attributed to the fact that the initial radiation exposure occurred only within one generation, and subsequent generations have not experienced direct radiation exposure, thus reducing the propagation of the genetic mutations. The table also highlights average risks for the reproductive and total populations, demonstrating a cumulative effect over multiple generations.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.2	 Radiation-Induced Heritable Diseases | Sub-sub-subsection: 8.2.2.4	 UNSCEAR and ICRP | Content: 732
­
8.5
­
8.6
­
8.7
Box 8.1 Gene Mutations and Heritable Diseases
•	Gene mutations are molecular, sub-microscopic,
changes affecting the functionality of one or more
gene-specific loci.
•	There are three classes of Mendelian type gene
mutations, where genes are inherited from each
parent.
•	Other parameters such environment may lead to
radiation-induced genetic heritable diseases.
R. Wilkins et al.
439
Table 8.5 Genetic risk from one-generation exposure to low LET low-­
dose or chronic irradiation with assumed doubling dose of 1 Gy (repro­
duced with permission from [7])
Disease class
Baseline
frequency, per
106 live births
Risk per Gy per 106 progeny
in the
First
generation
Second
generationa
Mendelian
Autosomal
dominant and
X-linked
Autosomal
recessive
16,500
7500
~750–1500
0
~500–1000
0
Chromosomal
4000
b
b
Multifactorial
Chronic
Congenital
Total
650,000c
60,000
738,000
~250–1200
~2000d
~3000–4700
~250–1200
400–1000e
1150–3200
Total risk per Gy
(expressed as % of
baseline)
~0.41 to 0.64
0.16 to 0.43
a Risk to second generation is lower than that in the first because of the
assumption that radiation exposure occurred in one generation only; the
risk will progressively decrease with time (in generations)
b Assumed to be subsumed in part under the risk of autosomal dominant
and X-linked diseases and in part under that of congenital
abnormalities
c Frequency in the population
d Estimate obtained using mouse data on developmental abnormalities
and not with the doubling-dose method
e Under the assumption that the selection coefficient is 0.2–0.5
Table 8.6 Percentage risk per Gy for the reproductive and total popu­
lation and up to two generations when the population sustains radiation
exposure generation after generation (reproduced with permission from
[34])
Disease class
Reproductive
population
Total population
Range
Average
Average
Mendelian diseases
0.13–0.25
0.19
0.08
Chronic diseases
0.03–0.12
0.08
0.03
Congenital abnormalities
0.24–0.30
0.27
0.11
Total for all classes
0.54
0.22
Table 8.7 ICRP recommended genetic risk coefficients for low dose
or low-dose-rate low-LET radiation (reproduced with permission from
[34])
Group
10−2 Sv−1
Whole population
0.2
Radiation workers
0.1
8.2.3"
"The provided table outlines potential long-term health effects following low-dose radiation exposure across multiple generations. Considering the data presented, what is the estimated average percentage risk of congenital abnormalities within the total population after two generations of sustained exposure, assuming a selection coefficient of 0.2–0.5?","Based on Table 8.6, the average percentage risk for congenital abnormalities in the total population after two generations of radiation exposure is 0.11. This figure represents an estimated average risk considering the range provided (0.24-0.30) and the assumption of a selection coefficient between 0.2 and 0.5. It’s important to note that this is an average, and individual risks would vary depending on specific exposure levels and other factors.

Reference: MolecularRadiationBiology, Section 8.2.3 – Long-Term Issue Effects: Cataract and CVD","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.3	 Long-Term Issue Effects: Cataract and CVD | Content: risk will progressively decrease with time (in generations)
b Assumed to be subsumed in part under the risk of autosomal dominant
and X-linked diseases and in part under that of congenital
abnormalities
c Frequency in the population
d Estimate obtained using mouse data on developmental abnormalities
and not with the doubling-dose method
e Under the assumption that the selection coefficient is 0.2–0.5
Table 8.6 Percentage risk per Gy for the reproductive and total popu­
lation and up to two generations when the population sustains radiation
exposure generation after generation (reproduced with permission from
[34])
Disease class
Reproductive
population
Total population
Range
Average
Average
Mendelian diseases
0.13–0.25
0.19
0.08
Chronic diseases
0.03–0.12
0.08
0.03
Congenital abnormalities
0.24–0.30
0.27
0.11
Total for all classes
0.54
0.22
Table 8.7 ICRP recommended genetic risk coefficients for low dose
or low-dose-rate low-LET radiation (reproduced with permission from
[34])
Group
10−2 Sv−1
Whole population
0.2
Radiation workers
0.1
8.2.3
Long-Term Issue Effects: Cataract and CVD"
"Table 8.6 presents data regarding the percentage risk per Gy for various disease classes in both reproductive and total populations following radiation exposure over multiple generations. Considering the ranges provided, what is the average percentage risk associated with congenital abnormalities across the reproductive population, and how does this compare to the average percentage risk observed within the total population?","According to Table 8.6, the average percentage risk for congenital abnormalities in the reproductive population is 0.11, while the average percentage risk in the total population is 0.27. This indicates a significantly higher risk of congenital abnormalities associated with radiation exposure within the total population compared to the reproductive population.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.3	 Long-Term Issue Effects: Cataract and CVD | Sub-sub-subsection: 8.2.3.1	 Radiation-Induced Cataract | Content: risk will progressively decrease with time (in generations)
b Assumed to be subsumed in part under the risk of autosomal dominant
and X-linked diseases and in part under that of congenital
abnormalities
c Frequency in the population
d Estimate obtained using mouse data on developmental abnormalities
and not with the doubling-dose method
e Under the assumption that the selection coefficient is 0.2–0.5
Table 8.6 Percentage risk per Gy for the reproductive and total popu­
lation and up to two generations when the population sustains radiation
exposure generation after generation (reproduced with permission from
[34])
Disease class
Reproductive
population
Total population
Range
Average
Average
Mendelian diseases
0.13–0.25
0.19
0.08
Chronic diseases
0.03–0.12
0.08
0.03
Congenital abnormalities
0.24–0.30
0.27
0.11
Total for all classes
0.54
0.22
Table 8.7 ICRP recommended genetic risk coefficients for low dose
or low-dose-rate low-LET radiation (reproduced with permission from
[34])
Group
10−2 Sv−1
Whole population
0.2
Radiation workers
0.1
8.2.3
Long-Term Issue Effects: Cataract and CVD
8.2.3.1	Radiation-Induced Cataract
­
32
8.9
Until relatively recently, it was thought that radiation
cataract was a “deterministic” effect, now more commonly
termed tissue reaction, with a threshold for acute exposures of
approximately 2 Gy and a potentially much higher threshold
for chronic or protracted exposures. However, in recent years
it has become apparent that the latency period for radiation
cataract may be many tens of years, and thus the threshold
is likely to be much lower than previously thought, with the
best current estimate based on the weight of ­epidemiological
or population-based evidence that the current threshold is
on the order of 0.5 Gy. However, there is some emerging
evidence which suggests that radiation cataract may indeed
be more stochastic in nature [32]. From the public health
perspective, the high-dose response to radiation cataract is
relatively clear from many years of animal studies and the
smaller number of epidemiological studies reviewed in ICRP
[32], and there are a number of methods of characterization
and detection of cataract.
­
35
8.10
­
Recent work using animal models has highlighted the
importance of the early phase DNA damage, proliferative,
biochemical and proteomic/lipidomic responses, as well as
the clear influence of genotype and pathways of response,
age at exposure, sex, dose, and dose rate [36].
37
8.11
8 Radiobiology of Accidental, Public, and Occupational Exposures
440
a
b
c
­
35
R. Wilkins et al.
441
­
35
8 Radiobiology of Accidental, Public, and Occupational Exposures
442
a
b
c
37"
"How does ionizing radiation exposure, particularly during radiotherapy for thoracic tumors like breast cancer, contribute to the long-term development of cardiovascular diseases such as atherosclerosis and ischemic heart disease?","Ionizing radiation exposure, notably during therapeutic interventions like radiotherapy for conditions such as breast cancer (particularly left-sided cases with estimated cumulative doses of 6.6 Gy), can induce a long-term increase in the risk of cardiovascular diseases. This is primarily due to deterministic effects manifesting after a latency period of 10–15 years following exposure. The mechanisms involve tissue reactions, including oxidative stress, DNA damage, and enhanced endothelial cell adhesion – processes also implicated in cataract development. Furthermore, research has identified genetic factors influencing susceptibility alongside lifestyle and environmental influences that contribute to the complex pathophysiology of cardiovascular disease. Recent advancements in radiotherapy techniques are attempting to mitigate these effects through targeted dose delivery and other methods, while ongoing investigations focus on identifying early biomarkers for radiation-induced cardiotoxicity and developing radioprotective agents targeting key pathophysiological mechanisms. Reference: [MolecularRadiationBiology, Section 8.2.3.2 – Diseases of the Circulatory System]","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.2	 Long-Term Health Effects of Low-Dose Radiation in Exposed Human Populations | Sub-subsection: 8.2.3	 Long-Term Issue Effects: Cataract and CVD | Sub-sub-subsection: 8.2.3.2	 Diseases of the Circulatory System | Content: In addition to the acute effects on the vascular system, ioniz­
ing radiation can in the long-term influence development of
cardiovascular diseases (CVD) and metabolic effects which
are major risk factors for diseases of the circulatory system.
This section therefore considers a number of different dis­
eases, including atherosclerosis which can cause ischemic
heart disease and cerebrovascular disease, and which can
lead to acute myocardial infarction and stroke.
The effects of ionizing radiation on the circulatory sys­
tem is something which has long been researched, but only
within the last 10 years or so has the weight of evidence
been such that it is possible to consider taking account of the
radiation effects as part of the system of radiation protection
[38]. Currently, circulatory disease is considered a “deter­
ministic effect” or tissue reaction, with a threshold on the
order of 0.5 Gy, and with a long latency period.
Most of the epidemiological evidence comes from
exposures of medically (therapeutically or diagnostically)
exposed individuals, with some data from occupational or
environmentally exposed cohorts (reviewed in [39, 40]).
Medical exposure to ionizing radiation during radiotherapy
of thoracic tumors, such as breast cancer, Hodgkin’s lym­
phoma and lung cancer, can involve some incidental radia­
tion exposure to the cardiovascular system, resulting in
cardiovascular complications. This is especially an issue for
women with left-sided breast cancer due to the higher cumu­
lative dose received by the heart, which is estimated to be
approximately 6.6 Gy, compared to 2.9 Gy in women with
right-sided breast cancer [41]. Cardiovascular disorders due
to ionizing radiation are usually not seen until 10–15 years
after exposure. However, asymptomatic abnormalities may
develop much earlier. This long asymptomatic period may
be a reason why the radiation sensitivity of the heart has
formerly been underestimated. Recently, advancements in
radiotherapy and heart-sparing techniques, including target-­
specific dose-delivery, deep inspiration breath hold and
patient prone position setup, have resulted in decreasing the
mean heart exposure dose from 4.6 Gy in 2014 to 2.6 Gy in
2017, as reported from 99 worldwide studies [42]. Despite
that, the mean heart radiation doses remain relatively high
and late cardiovascular complications continue to occur.
The late-onset aspect of ionizing radiation-induced car­
diotoxicity represents a diagnostic challenge to timely ini­
tiation of radioprotective therapy. Currently, there are some
efforts paid to identify early biomarkers of radiation-induced
R. Wilkins et al.
443
­
44
­cardiotoxicity, which may help in screening patients at risk
for developing cardiovascular complications after radiother­
apy, thus countermeasures and early medical intervention
might be applied to prevent further cardiac toxicity [43]. Fur­
thermore, research is exploring radioprotective agents which
interfere with one or more of the identified pathophysiologi­
cal mechanisms of ionizing radiation-induced cardiotoxicity.
Mechanistically, as with cataract, the high-dose effects are
relatively clear, based on, for example, oxidative stress, DNA
damage and enhanced adhesion of endothelial cells—the
genomic and proteomic basis of which is also under investiga­
tion. The lower dose studies are much less common; however,
lifestyle factors and genetic susceptibility are undoubtedly
confounders of development of circulatory system diseases,
and indeed most of the mechanistic work carried out to date
has focused on the genetic basis of development. Genome
wide and targeted studies have identified, for example, the
involvement of a number of genes of interest associated with
inflammation, differentiation, proliferation, and apoptosis,
among other processes which ionizing radiation is already
known to impact. In addition, there are a number of biologi­
cal dynamic models for cardiovascular disease (the topics in
this paragraph reviewed in Tapio et al. [40]).
­
3940
­
­
8.12
­
44
8.3"
Describe the primary mechanisms by which radon and its decay products contribute to cancer development within the lungs.,"Radon and its daughter nuclides pose a carcinogenic risk primarily through ionizing radiation exposure. After being inhaled as aerosols, these radioactive materials undergo decay predominantly in the lungs. The main biological incorporation pathway is inhalation of the aerosols themselves. The primary contributor to absorbed dose is alpha emission (approximately 90%), which directly damages DNA within lung cells. Beta and gamma emissions contribute less significantly (around 10%). This DNA damage leads to mutations that can initiate and promote carcinogenesis, ultimately resulting in malignant tumor development.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.3	 Radon and Health Effects | Content: Radon and thoron are natural radioactive noble gases result­
ing from the decay of uranium and thorium, which leak
from the soil in concentrations that depend on local geologi­
cal conditions. Radon and thoron are chemically inert and
­electrically neutral, so at physiological temperatures there
are no chemical interactions [45].
­
8.846
In the open air, the concentration of radon and thoron is
normally very low, but being gases, they tend to accumu­
late in non-ventilated areas (WHO). In buildings constructed
8 Radiobiology of Accidental, Public, and Occupational Exposures
444
on soils that are rich in elements of the radioactive families
mentioned above, their release causes them to accumulate
inside houses. The pressure difference between the subsoil
and the interior of the dwellings also favors this accumula­
tion, due to diffusion.
8.13
As all radon and thoron isotopes are radioactive gases,
after being released into the ambient air, they accumulate
indoors and disintegrate into various unstable daughter
nuclides. After decay in air, these radionuclides aggregate
with other gases and water vapor, forming aerosols with
diameters of 0.5–5 nm, which are easily inhaled, travel
through the conducting airways and reach the alveoli of the
lungs [47, 48]. However, as the airways are saturated with
water vapor, the hydration of aerosols allows their diameter
to increase up to about 10 times [49].
Once inhaled, the decay process occurs predominantly in
the lungs. The main biological incorporation pathway is by
inhalation of radioactive aerosols. Alpha emissions are the
biggest contributors to the absorbed dose (about 90%) while
beta and gamma emissions contribute only about 10% [47,
50–52]. Considering the aerosol dynamics, they are depos­
Table 8.8 Natural isotopes of radon and thoron (based on [46])
Series
Nuclide
Decay mode
T1/2
Uranium
234Th
Beta-
24.10 days
230Th
Alpha
7.54 × 104 years
222Rn
Alpha
3.8235 days
218Rn
Alpha
35 ms
Thorium
232Th
Alpha
1.405 × 1010 years
228Th
Alpha
1.9116 years
220Rn
Alpha
55.6 s
Actinium
231Th
Beta-
25.52 h
227Th
Alpha
18.68 days
219Rn
Alpha
3.96 s
Neptunium
229Th
Alpha
7340 years
217Rn
Alpha
540 μs
­
R. Wilkins et al.
445
ited according to three physical mechanisms: inertial impac­
tion, sedimentation, and diffusion. Also taking into account
the length, diameter and bifurcation angle of the airways, as
well as the diameter of aerosols, deposition varies along the
respiratory tract. Particles with larger diameters (2–50 μm)
are deposited by inertial impaction in the nasopharynx,
larynx, trachea and bronchi up to the third division. For
particles with intermediate diameters (100 nm–10 μm) sedi­
mentation is the main mechanism of deposition and occurs
mainly in the lower respiratory tract, also in the bronchi­
oles and even alveoli. For particles with diameters less than
200 nm, Brownian diffusion predominates and occurs in the
alveoli, where gas exchange takes place [47–49]. Addition­
ally, the multiple divisions of the airways and the consequent
turbulence generated determine a non-homogeneous deposi­
tion pattern [47, 53].
Considering the different radiosensitivity of regions of the
respiratory tract in which the mucosal and basal bronchial
epithelial cells are particularly radiosensitive [54] as well as
the multiple divisions of the conduction airways, the largest
dose is deposited in the bifurcation of the trachea [47, 55].
Radon, thoron and their respective decay products emit
alpha particles, beta- and gamma radiation, as mentioned
above and the carcinogenic effect of these radionuclides
is associated with the emitted ionizing radiation that can,
directly or indirectly, damage DNA [56, 57]. This DNA dam­
age causes mutations that can lead to carcinogenesis, result­
ing in the development of malignant tumors.
The correlation of radon with the incidence of lung cancer
has been unquestionably proven by extensive epidemiologi­
cal studies (BEIR VI). However, it is not excluded that it can
also cause kidney cancer, melanoma, hematologic cancers,
primary brain tumors, and even stomach, liver and pancreas
cancers [56, 58–60]. However, given the low penetration of
radon further than the respiratory system, the association
with non-respiratory diseases is not proven [56].
Epidemiological studies on chronic radon exposure show
that the estimated risk of carcinogenesis is related to the sub­
ject’s concentrations, exposure time, and age [47]. Concern­
ing lung cancer and radon concentration, there appears to be
an increased risk of 16% per 100 Bq/m3 [45, 47, 61]. With
respect to mortality, there is a non-threshold linear correla­
tion with exposure. If we add smoking to radioactive expo­
sure, the risk of lung cancer increases even further [47, 61].
With regard to primary malignant brain tumors, there appears
to be a positive correlation between chronic radon exposure
and mortality [58, 61]. The same seems to be the case for
non-cancer situations such as Alzheimer’s and Parkinson’s
diseases, without, however, understanding the pathophysi­
ological mechanisms [60]. There is a similar correlation for
chronic radon exposure and incidence of chronic myeloid
and lymphocytic leukemia and, in the case of children, with
acute myeloid leukemia [45, 47, 61].
Latency times are highly variable between irradiation and
the development of malignant tumors. Thus, for leukemia the
times range from 5 to 7 years, while for solid tumors they are
much longer, ranging from 10 to 60 years [45, 47, 61] (Box 8.2).
8.4
Diagnosis and Medical Management
of Radiation Syndromes
8.4.1
Introduction
Depending on the amount of energy deposited, the absorbed
dose, as well as the radiation quality, significant whole-body
or partial-body exposure to ionizing radiation may lead to
acute clinical radiation effects resulting in an Acute Radia­
tion Syndrome (ARS). This may be followed by Delayed
Effects of Acute Radiation Exposure (DEARE) that take
months and years to develop [62, 63].
Many aspects have to be considered regarding the diag­
nosis and management of radiation exposure. Regarding
latency of occurrence, acute and chronic effects can be dis­
tinguished. The acute effects may require prompt diagnosis
and immediate therapeutic intervention.
Considering the pathophysiological mechanisms, the
effects can be distinguished as either deterministic or sto­
chastic (see also Sect. 2.7.2). Deterministic effects are caused
by radiation exposure exceeding a certain level (threshold)
and are more severe with increasing dose. After whole-body
irradiation, different categories of clinical syndromes can
develop, usually depending on the absorbed dose: nausea,
vomiting, diarrhea (NVD) syndrome (1–2 Gy), hematopoi­
etic syndrome (2–6 Gy), gastrointestinal syndrome (>6 Gy)
and central nervous syndrome/neurovascular syndrome
(10–20 Gy); after local irradiation of the gonads, permanent
sterility (0.1–6 Gy), of the eye opacity of lens (0.5 Gy), of
the skin erythema (3–6 Gy) and hair loss (4 Gy) may develop
[32, 34]. Clinical dosimetry based on the individual patient’s
clinical signs and symptoms is important to define the sever­
ity of radiation exposure.
For stochastic effects, no threshold value is assumed, the
probability of occurrence increases with radiation dose and
even very low-dose exposure effects cannot be completely
excluded [62].
Box 8.2 Exposure and Risk of Radon Exposure
•	Radon and thoron are noble radioactive gases
•	There are several isotopes of radon and thoron
•	The decay process occurs in the lungs due to
inhalation
•	There is carcinogenic risk associated to chronic
radon exposure
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"Explain the concept of latency time in the context of radiation-induced cancers, providing examples of typical ranges for leukemia versus solid tumors.","Latency time refers to the period between exposure to ionizing radiation and the subsequent development of a malignant tumor. It’s a complex process influenced by numerous factors including genetic predisposition, individual immune responses, and the specific type and dose of radiation received. The length of latency time varies significantly depending on the tissue exposed and the nature of the cancer. For hematological malignancies like leukemia, particularly acute myeloid leukemia (AML), latency times are generally shorter, typically ranging from approximately 5 to 7 years after exposure. This is because hematopoietic stem cells are highly radiosensitive and prone to initiating mutations leading to uncontrolled cell proliferation. Conversely, for solid tumors, such as those of the skin or lung, latency periods are considerably longer, often spanning between 10 and 60 years. These cancers require more extensive genetic alterations and cellular processes to develop following radiation exposure, resulting in a prolonged time until malignant transformation occurs. The variability within these ranges highlights the intricate interplay of biological factors involved in radiation-induced carcinogenesis [61]. ","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Content: ological mechanisms [60]. There is a similar correlation for
chronic radon exposure and incidence of chronic myeloid
and lymphocytic leukemia and, in the case of children, with
acute myeloid leukemia [45, 47, 61].
Latency times are highly variable between irradiation and
the development of malignant tumors. Thus, for leukemia the
times range from 5 to 7 years, while for solid tumors they are
much longer, ranging from 10 to 60 years [45, 47, 61] (Box 8.2).
8.4
Diagnosis and Medical Management
of Radiation Syndromes
8.4.1"
"Describe the relationship between latency times in the development of malignant tumors following irradiation and the types of cancers observed, specifically referencing the distinctions made regarding deterministic versus stochastic effects.","Following exposure to ionizing radiation, the time it takes for a malignant tumor to develop – the latency time – varies significantly depending on the type of cancer. Generally, latency times are much longer for solid tumors (ranging from 10 to 60 years) compared to hematological cancers like leukemias, which exhibit shorter intervals, typically between 5 and 7 years. This difference reflects the distinct biological mechanisms underlying these diseases. The concept of deterministic effects plays a crucial role here. Deterministic effects, characterized by thresholds above which severe consequences occur, are more pronounced in acute radiation syndromes following whole-body irradiation. These syndromes – such as NVD (1–2 Gy), hematopietic syndrome (2–6 Gy), gastrointestinal syndrome (>6 Gy), and central nervous/neurovascular syndrome (10–20 Gy) – demonstrate a clear dose-response relationship, with increasing severity correlating directly with the absorbed dose. Conversely, stochastic effects, which lack a defined threshold and whose probability of occurrence increases linearly with radiation dose, are implicated in all cancers regardless of latency time. Even low-dose exposures cannot be completely ruled out as potentially contributing to these effects. The variability in latency times underscores the complex interplay between radiation damage, genetic mutations, and individual susceptibility that ultimately determines cancer development.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Sub-subsection: 8.4.1	 Introduction | Content: ological mechanisms [60]. There is a similar correlation for
chronic radon exposure and incidence of chronic myeloid
and lymphocytic leukemia and, in the case of children, with
acute myeloid leukemia [45, 47, 61].
Latency times are highly variable between irradiation and
the development of malignant tumors. Thus, for leukemia the
times range from 5 to 7 years, while for solid tumors they are
much longer, ranging from 10 to 60 years [45, 47, 61] (Box 8.2).
8.4
Diagnosis and Medical Management
of Radiation Syndromes
8.4.1
Introduction
Depending on the amount of energy deposited, the absorbed
dose, as well as the radiation quality, significant whole-body
or partial-body exposure to ionizing radiation may lead to
acute clinical radiation effects resulting in an Acute Radia­
tion Syndrome (ARS). This may be followed by Delayed
Effects of Acute Radiation Exposure (DEARE) that take
months and years to develop [62, 63].
Many aspects have to be considered regarding the diag­
nosis and management of radiation exposure. Regarding
latency of occurrence, acute and chronic effects can be dis­
tinguished. The acute effects may require prompt diagnosis
and immediate therapeutic intervention.
Considering the pathophysiological mechanisms, the
effects can be distinguished as either deterministic or sto­
chastic (see also Sect. 2.7.2). Deterministic effects are caused
by radiation exposure exceeding a certain level (threshold)
and are more severe with increasing dose. After whole-body
irradiation, different categories of clinical syndromes can
develop, usually depending on the absorbed dose: nausea,
vomiting, diarrhea (NVD) syndrome (1–2 Gy), hematopoi­
etic syndrome (2–6 Gy), gastrointestinal syndrome (>6 Gy)
and central nervous syndrome/neurovascular syndrome
(10–20 Gy); after local irradiation of the gonads, permanent
sterility (0.1–6 Gy), of the eye opacity of lens (0.5 Gy), of
the skin erythema (3–6 Gy) and hair loss (4 Gy) may develop
[32, 34]. Clinical dosimetry based on the individual patient’s
clinical signs and symptoms is important to define the sever­
ity of radiation exposure.
For stochastic effects, no threshold value is assumed, the
probability of occurrence increases with radiation dose and
even very low-dose exposure effects cannot be completely
excluded [62].
Box 8.2 Exposure and Risk of Radon Exposure
•	Radon and thoron are noble radioactive gases
•	There are several isotopes of radon and thoron
•	The decay process occurs in the lungs due to
inhalation
•	There is carcinogenic risk associated to chronic
radon exposure
8 Radiobiology of Accidental, Public, and Occupational Exposures
446"
"Following external radionuclide contamination, what are the initial steps recommended for decontamination and why is achieving a dose reduction to 3x background considered important?","Upon exposure to radionuclide contamination, immediate action focuses on both decontamination and urgent medical treatment. The first line of defense involves using lukewarm water and mild soaps to remove radioactive particles from the skin – this approach minimizes further absorption and reduces the overall radiation dose received. A primary goal is to reduce external contamination to background levels or, at most, 3 times the background level. This target represents a critical threshold because exceeding 3x background significantly increases the risk of long-term health effects such as cancer development due to cumulative DNA damage. Maintaining this reduction minimizes further exposure and allows for more accurate assessment of the extent of contamination. Furthermore, it facilitates targeted medical interventions if internal contamination is suspected based on subsequent measurements.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Sub-subsection: 8.4.1	 Introduction | Sub-sub-subsection: 8.4.1.1	 External Contamination | Content: In case of radionuclide contamination, establishing the
presence of external contamination is very important since
decontamination should be performed as soon as possible
keeping people, equipment, and facilities safe in the process.
However, urgent medical treatment has the highest priority
as lifesaving always comes first. Luke-warm water and mild
soaps should be used for the first line of decontamination.
Reduction to background or at most 3× background dose
should be aimed for. In case of residual contamination, peel­
ing products can be used to remove contamination adherent
to the skin. If measurements indicate persistent contamina­
tion, the presence of radioactive particles in the skin (like
shrapnel, requiring surgical removal) or internal contamina­
tion should be suspected."
"Following the ingestion or inhalation of a radioactive substance, what are some immediate therapeutic interventions that can be employed to reduce radiation dose absorption, and why is their timely application so critical?","In cases of radionuclide ingestion or inhalation, rapid intervention is paramount to minimize radiation damage. Several decorporation therapies are utilized, focusing on accelerating the removal of the radioactive material from the body. These include employing blocking agents (such as activated charcoal) to prevent further absorption, using diluting agents (like water) to reduce the concentration of the radionuclide, and utilizing chelating agents (e.g., Prussian blue, Zn-DTPA, Ca-DTPA) that bind to the radioactive metal ions, facilitating their excretion through urine or feces. Furthermore, enhanced de-corporation drugs like ammonium chloride can be administered. Physical decorporation methods are also crucial; gastric lavage is employed for ingested substances if performed within 2 hours of ingestion, and bronchoalveolar lavage is utilized for large amounts of insoluble inhaled radionuclides. The critical timeframe – typically within 2 hours after ingestion or inhalation – stems from the diminished effectiveness of many pharmaceuticals used to mitigate radiation damage when administered significantly later.  The body's ability to metabolize and transport these drugs decreases over time, reducing their therapeutic window and potentially leading to a less effective response. Prompt action maximizes the chances of successful decontamination and reduces overall radiation exposure.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Sub-subsection: 8.4.1	 Introduction | Sub-sub-subsection: 8.4.1.2	 Internal Contamination | Content: In case of radionuclide ingestion and/or inhalation, identifi­
cation of the radionuclide is crucial to select the appropriate
decorporation therapy. Decorporation therapy must be car­
ried out as fast as possible in order to reduce radiation dose
absorption, since pharmaceuticals are often most effective if
given immediately or within 2 h after ingestion or inhala­
tion. This can be achieved by using blocking agents, diluting
agents, chelating agents or enhanced de-corporation drugs
like Prussian blue, Zn-DTPA, Ca-DTPA and ammonium
chloride [62, 64]. Physical decorporation measures such as
gastric lavage for ingested radioactive substances (if applied
within 2 h of ingestion) and bronchoalveolar lavage for large
amounts of insoluble inhaled radionuclides could also be
used [65].
8.4.2"
"Describe the sequential stages of Acute Radiation Syndrome (ARS) as outlined in the text, including the key symptoms and signs observed during each phase.","The clinical evolution of ARS follows a distinct, sequential pattern characterized by four primary phases: prodromal, latent, manifest illness, and recovery/death. The prodromal stage begins with non-specific symptoms like anorexia, nausea, vomiting, diarrhea, and erythema, appearing as early as 0.5 Gy depending on individual radiosensitivity. This phase typically lasts from minutes to a few days, with higher doses shortening the duration. Following this is the latent phase, where symptoms diminish or disappear entirely despite ongoing tissue damage. Repair mechanisms are actively engaged during this period, potentially leading to incomplete repair and reduced symptom severity. The duration of the latent phase inversely correlates with the dose received – higher doses result in shorter durations.  The manifest illness phase emerges when repair mechanisms fail, presenting specific organ-system related symptoms. Gastrointestinal syndrome (from 5 Gy) manifests as severe diarrhea, dehydration, and circulatory collapse. Neurovascular syndrome (from 20 Gy) causes lethargy, tremors, convulsions, ataxia, and coma. Finally, the recovery or death phase occurs depending on the severity of damage sustained and the effectiveness of treatment; high doses (above 10 Gy) often lead to rapid death within days due to multi-organ failure.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Sub-subsection: 8.4.2	 Acute Radiation Syndromes | Content: Acute radiation syndrome (ARS) develops when whole- or
partial-body radiation exposure exceeds a certain dose, par­
tially depending on individual radiosensitivity and radia­
tion damage repair mechanisms. ARS is usually assumed to
occur with whole-body doses above 0.5–1 Gy if given with
high-­dose rate [32, 66, 67].
The deposition of energy at the molecular and cellular
level leads to physico-­chemical-­biological consequences
already described in the previous chapters.
The clinical evolution of the acute radiation syndrome
is sequential and its canonical evolution begins with pro­
dromes, followed by the latent state, the state of manifest
illness, and ends with the state of recovery or death [32, 62,
68].
In the prodromal state, the exposed person has non-­
specific symptoms, which is easily confused with a flu-like
syndrome. Anorexia, nausea, vomiting, diarrhea and, eventu­
ally, erythema are frequent symptoms. The fluid loss that is
caused by diarrhea may be accompanied by fever, hypoten­
sion, and headache, depending on its intensity [62, 68, 69].
Given the non-specific nature of these symptoms and signs,
exposure to radiation may not be the first clinical hypoth­
esis, which makes the information about the circumstances
and awareness for radiological incidents very important.
Prodromal symptoms and signs can appear at doses as low
as 0.5 Gy, depending on individual radiosensitivity [62, 68].
This state lasts from a few minutes to a few days, depending
on the dose: the higher the dose, the shorter the duration of
this state. Except for people with increased radiosensitivity,
the prodromal state may be absent or mild for whole-body
doses of 1 Gy or less. If signs and symptoms appear within
the first 2 h, this usually means an exposure dose greater than
2 Gy. In this case, the symptoms are predominantly gastro­
intestinal, and the patients may survive if adequately treated.
At doses greater than 10 Gy, severe symptoms will develop,
often within 5–15 min after exposure, predominantly cere­
brovascular. A severe prodromal phase usually has a poor
clinical prognosis that can lead to death [67, 69, 70].
8.9
The aforementioned prodromal symptomatology, which
appears at doses lower than 0.5 Gy up to about 3 Gy, seems
to be dependent on damage of the cell membrane, with the
consequent release of inflammatory molecules from the
destroyed cells and to be mediated by the parasympathetic
system [32].
The second phase of ARS is called the latent phase. In
this phase, symptoms and signs diminish and may even dis­
appear, in such a way that the patient feels better and appears
to be recovered. In fact, injuries are developing, but the acti­
vated repair mechanisms can lead to complete (disappear­
ance of symptoms and signs) or incomplete repair of the
damage (reduction of symptoms and signs). The duration of
the latent phase, which can vary from minutes to weeks, is
also inversely related to the dose, that is, the higher the dose,
the shorter its duration. Despite the absence of symptoms, it
is in the latent phase that the most important consequences of
exposure to radiation occur, leading to its effects, which are
manifested in the manifest illness phase [69, 70].
Table 8.9 Doses that are associated with prodromal symptoms and
signs (reproduced with permission from [32, 68])
Dose (Gy)
Symptoms and signs
1–2
Anorexia
1–2
Nausea
1–2
Vomiting
2–6
Diarrhea
>6
Fever
>8
Consciousness changes
R. Wilkins et al.
447
Table 8.10 Acute radiation syndromes
Hematopoietic syndrome
Gastrointestinal syndrome
Neurovascular syndrome
Target organ
Bone marrow
Small intestine
Brain
Threshold
1 Gy
5 Gy
20 Gy
Latency time
2–3 weeks
3–5 days
30 min–3 h
Death
≥2 Gy
10 Gy
50 Gy
Time of death
3–8 weeks
3–14 days
Up to 2 days
Characteristic signs and
symptoms
General malaise, fever, dyspnea,
fatigue, anemia, leukopenia,
thrombopenia, purpura
General malaise, anorexia, nausea, vomiting,
diarrhea, GI changes, fever, dehydration,
electrolyte loss, circulatory collapse
Lethargy, tremors,
convulsions, ataxia, coma
If repair mechanisms are inefficient, the latent phase pro­
gresses to the next phase, the manifest illness phase. The
absence of the latent phase, i.e., if the patient goes directly
from the prodromal phase to the manifest illness phase, is an
indicator that the dose was very high. In the manifest illness
phase, there are specific symptoms and signs, depending on
the organ or system mainly affected. However, there may be
a mixture of symptoms and signs coming from different sys­
tems, which makes the diagnosis more complex. Also in this
phase, the signs and symptoms, as well as the duration, are
dose dependent, that is, the higher the dose, the earlier the
symptomatology starts and the shorter the phase lasts, which
can be from minutes to weeks [32, 66, 69, 70].
­
8.10
8.14
The hematological or hematopoietic syndrome has
as its target organs the hematopoietic organs, with special
emphasis on the bone marrow. Generally speaking, the
hematopoietic syndrome can develop from 1 Gy and the
latency time varies from 2 to 3 weeks. Before a generalized
failure of the hematopoietic system occurs, the progenitor
cells of all linages have to be irreversibly damaged, which
can happen with doses of at least 2 Gy. Without treatment,
death may occur 3–8 weeks after exposure.
The characteristic signs and symptoms of this syndrome
include general malaise, anemia, leukopenia and thrombocy­
topenia. The decrease in the number of circulating blood cells
determines secondary symptoms such as dyspnea, asthenia,
hypoxia, fever and purpura. If death occurs, it is mainly due
to infections and/or hemorrhage [32, 66, 69, 70]. Treatment
requires the use of cytokines, growth factors, antiemetics,
antimicrobial agents (antibiotics, antifungals, antivirals),
analgesics and in some cases anxiolytics can also be use­
ful. Allogeneic stem cell transplantations should only be per­
formed in specific circumstances (homogeneous ­whole-­body
dose, availability of perfectly HLA-matched stem cells).
If the radiation dose is higher, symptoms corresponding
to the involvement of cells of the gastrointestinal system
(gastrointestinal syndrome) appear, specifically the cells of
the intestinal villi that are found in the mucosa of the small
intestine. This syndrome can appear from a dose of 5 Gy
with a latency time of 3–5 days. Complete loss of intestinal
mucosa occurs at doses above 10 Gy and will be fatal within
3–14 days.
The characteristic signs and symptoms of this syndrome
include general malaise, anorexia, nausea, vomiting, diar­
rhea, fever, dehydration, electrolyte loss and circulatory col­
lapse, leading to death within a few days [32, 66, 69, 70].
Treatment requires adequate fluid administration, parenteral
nutrition, growth factors, antiemetics, antimicrobial agents
(antibiotics, antifungals, antivirals) and analgesics.
For higher doses of ionizing radiation, the neurovascular
system is involved (neurovascular syndrome) appears, where
glial cells may be damaged with doses of 1–6 Gy, lesions of
the endothelial cells of the cerebral vessels that occur with
doses of 10–20 Gy, or white matter necrosis that appears with
doses in the order of 40 Gy or even demyelination that occurs
with doses around 60 Gy. This damage will lead to signs and
symptoms including lethargy, tremors, convulsions, ataxia,
pre-coma and coma, leading to death within hours.
This neurovascular syndrome can develop from a dose of
20 Gy with a latency time of 30 min to 3 h. Death occurs
within 2 days after doses above 50 Gy [32, 66, 69, 70].
Treatment is usually only symptomatic with analgesics and
sedatives.
In addition to this syndromes, other important changes
can occur in other organs, in response to exposure to ionizing
radiation. One of these organs is the skin with the consequent
cutaneous effects. Cutaneous effects are deterministic that
only appear above a certain threshold dose. The first changes
appear in the hair follicles at doses above 0.75 Gy. With
higher doses other lesions appear. We can approximately
summarize that epilation appears with doses of around 3 Gy,
erythema with doses of around 6 Gy, desquamation with
doses of 10 Gy, which appears associated with edema, mean­
ing transepithelial lesion, with doses of 20 Gy.
Pulmonary effects, which appear over a huge range
of doses (from about 5 Gy to doses as high as 50 Gy), are
strongly dependent on the great vascular richness of the lung.
In this context, we must mention the endothelial cells of the
small pulmonary vessels, as well as the type II pneumocytes,
8 Radiobiology of Accidental, Public, and Occupational Exposures
448
alveolar cells that secrete surfactant, whose injury has enor­
mous pulmonary functional repercussions. The pulmonary
interstitium is also of special importance, as it responds with
an intense inflammatory process to exposure to ionizing
radiation, called radiation pneumonitis. This inevitably pro­
gresses to pulmonary fibrosis with big clinical impact.
As mentioned, the manifest illness phase has variable
duration and can progress to the phase of death or recovery,
depending on dose, dose rate and target organs. The recovery
phase is associated with lower doses at which hematopoi­
etic and/or gastrointestinal syndromes occur, especially if
adequate medical treatment is carried out. If doses are high
R. Wilkins et al.
449
enough to induce neurovascular syndrome, the likely out­
come is death. In this situation, death occurs few hours after
irradiation and predominantly results from systemic vascular
effects associated with multi-organ failure [70, 71]."
"Following an acute radiation exposure that initially manifests as hematologic and gastrointestinal syndromes with subsequent medical treatment, what characterizes the delayed effects of acute radiation exposure (DEARE)?","After recovery from initial acute symptoms following adequate medical intervention, DEARE presents with a progressive failure of various organs beyond the bone marrow and gastrointestinal system. These late manifestations involve target organs such as the lung, heart, kidney, and central nervous system. The original acute signs and symptoms diminish in severity, but the condition evolves into chronic damage characterized by irreversible organ dysfunction leading to eventual mortality. Prompt medical intervention utilizing radioprotective drugs and/or radiomitigators is crucial to mitigate the initial damage and subsequent late-onset pathology.

Reference: MolecularRadiationBiology, Section 8.4.2.1 Delayed Effects of Acute Radiation Exposure","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Sub-subsection: 8.4.2	 Acute Radiation Syndromes | Sub-sub-subsection: 8.4.2.1	 Delayed Effects of Acute Radiation Exposure | Content: Exposure
Delayed effects of acute radiation exposure (DEARE) occur
when there has been recovery after exposure, that is, when
doses were lower, and hematologic and/or gastrointestinal
syndromes were developed, after having been subjected to
adequate medical treatment.
The delayed manifestations of these syndromes lose their
acute expression and are associated with signs and symptoms
that show the repercussion in various organs such as the lung,
heart, kidney, central nervous system, beyond the bone mar­
row and gastrointestinal system, the target organs. Evolution
results in the progressive failure of the organs involved, until
death occurs. Given these characteristics, medical treatment
is indicated with radioprotective drugs and/or radiomitiga­
tors of the effects of radiation which must be administered
as soon as possible after the acute irradiation. This approach
has the double goal of reducing the severity of the initial
damage and the late onset-pathology [71, 72]."
"Explain the concept of lethal dose (LD), particularly focusing on LD50/30, LD50/60, and how these values relate to radiation exposure effects in biological systems. What factors can influence these LD50 values?","The concept of lethal dose (LD) describes the amount of ionizing radiation required to eliminate 50% of a population – specifically, it’s defined as the dose that kills 50% of an irradiated population. A key refinement of this concept is the determination of median lethal doses at different time points. LD50/30 represents the dose of radiation that will kill 50% of the exposed population within 30 days following irradiation, while LD50/60 refers to the dose required for a 50% fatality rate after 60 days. Initially, the LD50/60 for a healthy adult was estimated to be between 2.5 and 3 Gy (gray), reflecting the natural history of disease without medical intervention. The LD50/30 values were found to range from 2.5 to 4.5 Gy under similar conditions. These values are based on data derived primarily from survivors of the atomic bombings of Hiroshima and Nagasaki, acknowledging inherent limitations in this historical dataset. Importantly, these LD50 values assume whole-body irradiation and do not account for medical interventions. The influence of factors such as tissue type (bone marrow has a lower LD50 than other tissues) and the availability of supportive medical care – including blood transfusions, antibiotic therapy, or hematopoietic growth factor administration – can significantly alter these values. For example, with medical support, the LD50/60 for bone marrow can decrease to between 5 and 6 Gy, while more robust treatments could potentially achieve LD50/60 values of 6-8 Gy. These shifts demonstrate that biological responses are not solely determined by radiation dose but also influenced by the body's ability to mitigate damage.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.4	 Diagnosis and Medical Management of Radiation Syndromes | Sub-subsection: 8.4.2	 Acute Radiation Syndromes | Sub-sub-subsection: 8.4.2.2	 LD50 (Lethal Dose 50) | Content: The concept of lethal dose (LD) is a pharmacological con­
cept that can be applied to the consequences of exposure
to ionizing radiation and is defined as the amount of dose
of radiation that kills elements of an irradiated population.
This broad concept can be further specified if we consider
the dose that kills 50% of an irradiated population, which is
called the median lethal dose (LD50) [70, 73].
The characteristics of the biological effects of radiation,
namely the duration of latency time, associated with the
great individual variability led to the refinement of this con­
cept. Thus, there is often referred the LD50/30 (dose that kills
50% of the irradiated population in 30 days) or LD50/60 (dose
that kills 50% of the irradiated population in 60 days). The
LD50/60 for a healthy adult range between 2.5 and 3 Gy, while
the LD50/30 ranges between 2.5 and 4.5 Gy. These values
assume whole-body irradiation and the natural history of the
disease, that is, the non-use of medical care, and are based on
data from the survivors of Hiroshima and Nagasaki [34, 66,
74]. Although the LD50/30 and LD50/60 are similar concepts,
they provide complementary and very important indications.
In the case of somatic effects, the LD50/60 informs that if a
survival for more than 60 days after an irradiation occurs, the
recovery is expected.
For bone marrow, the LD50/60 ranges from approximately
3.5 to 4.5 Gy, however with supportive medical care, such as
blood transfusions associated with antibiotic therapy, it can
change to values between 5 and 6 Gy. With more robust
treatments, such as the administration of hematopoietic
growth factors, values from 6 to 8 Gy can be achieved [66]
(Box 8.3).
8.5
Methods of Triage for Treatment After
a Radiation Accident
8.5.1
Introduction: The Need for Triage
and Intro to Exposure Scenarios
When individuals are exposed to ionizing radiation in an
accidental scenario, there is an urgent need to categorize
exposed individuals not only in terms of the urgency of their
need for treatment, but also in relation to ionizing radiation
exposure. In general, radiation accidents lead to external
radiation exposure and/or external or internal contamination
with radionuclides. Exposures in situations requiring triage
tend to be acute, but chronic exposures also need to be con­
sidered. Further exposure or contamination can be approxi­
mately homogeneous or highly heterogeneous. Hence the
available tools and processes need to be flexible and suffi­
cient to allow appropriate triage in a variety of potential situ­
ations. This section considers in the need for initial triage
including decontamination, specific considerations related to
radiological triage, as well as the need for late follow-up.
Communication to the public is also a topic of importance,
not covered in detail here, but with further information in the
TMT Handbook [75].
8.5.2
Initial Triage: Trauma,
Decontamination, and Other
Considerations
In general, triage is used to screen the patients with severe
injuries after a mass incident, including chemical, biologi­
cal, radiological, nuclear, or explosive events (CBRNE).
The first step during triage is to classify the affected person
according to the type and severity of the suffered injuries,
accurately assessing prognosis and survival expectancy,
Box 8.3 Acute Radiation Syndrome
•	Acute radiation syndromes appear after whole-­
body irradiation
•	After an irradiation, the biological consequences
appear following four stages: Prodromal, latent
state, manifest illness state, and of recovery or death
state
•	When recovery occurs, delayed effects of acute
radiation exposure can manifest
•	LD50 is the dose that kills 50% of the irradiated pop­
ulation after 30 days (LD50/30 or 60 days (LD50/60)
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"Following a radiation accident involving ionizing radiation exposure, what are the typical stages observed in the biological consequences experienced by individuals, as outlined within the context of Acute Radiation Syndrome?","The manifestation of Acute Radiation Syndrome (ARS) following whole-body irradiation proceeds through four distinct stages: the Prodromal stage, characterized by initial symptoms such as nausea, vomiting, and fatigue; a Latent state, marked by a period of relative well-being with no apparent clinical signs despite ongoing cellular damage; the Manifest illness state, where severe symptoms emerge including bone marrow suppression leading to infections and hemorrhages, gastrointestinal dysfunction, and alopecia; and finally, either a Recovery state, representing successful repair mechanisms and restoration of function, or a Death state, signifying irreversible tissue damage and organ failure. Importantly, delayed effects from acute radiation exposure can manifest even during the recovery phase. The determination of LD50 (the dose that kills 50% of the irradiated population after 30 days – LD50/30 – or 60 days – LD50/60) is a key metric used to assess the severity of radiation exposure and predict potential outcomes.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.5	 Methods of Triage for Treatment After a Radiation Accident | Content: blood transfusions associated with antibiotic therapy, it can
change to values between 5 and 6 Gy. With more robust
treatments, such as the administration of hematopoietic
growth factors, values from 6 to 8 Gy can be achieved [66]
(Box 8.3).
8.5
Methods of Triage for Treatment After
a Radiation Accident
8.5.1
Introduction: The Need for Triage
and Intro to Exposure Scenarios
When individuals are exposed to ionizing radiation in an
accidental scenario, there is an urgent need to categorize
exposed individuals not only in terms of the urgency of their
need for treatment, but also in relation to ionizing radiation
exposure. In general, radiation accidents lead to external
radiation exposure and/or external or internal contamination
with radionuclides. Exposures in situations requiring triage
tend to be acute, but chronic exposures also need to be con­
sidered. Further exposure or contamination can be approxi­
mately homogeneous or highly heterogeneous. Hence the
available tools and processes need to be flexible and suffi­
cient to allow appropriate triage in a variety of potential situ­
ations. This section considers in the need for initial triage
including decontamination, specific considerations related to
radiological triage, as well as the need for late follow-up.
Communication to the public is also a topic of importance,
not covered in detail here, but with further information in the
TMT Handbook [75].
8.5.2
Initial Triage: Trauma,
Decontamination, and Other
Considerations
In general, triage is used to screen the patients with severe
injuries after a mass incident, including chemical, biologi­
cal, radiological, nuclear, or explosive events (CBRNE).
The first step during triage is to classify the affected person
according to the type and severity of the suffered injuries,
accurately assessing prognosis and survival expectancy,
Box 8.3 Acute Radiation Syndrome
•	Acute radiation syndromes appear after whole-­
body irradiation
•	After an irradiation, the biological consequences
appear following four stages: Prodromal, latent
state, manifest illness state, and of recovery or death
state
•	When recovery occurs, delayed effects of acute
radiation exposure can manifest
•	LD50 is the dose that kills 50% of the irradiated pop­
ulation after 30 days (LD50/30 or 60 days (LD50/60)
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"Describe the key considerations regarding triage following a radiation accident, focusing on the stages of biological consequences observed in Acute Radiation Syndrome (ARS) and the potential dose ranges associated with different treatment approaches.","Following a radiation accident, immediate triage is crucial to categorize individuals based on injury severity, prognosis, and exposure levels. ARS manifests through distinct stages: prodromal, latent, manifest illness, and recovery/death. The initial assessment must account for both external and internal contamination, recognizing that exposures can be acute or chronic and potentially heterogeneous. Treatment strategies aim to modulate the biological effects of radiation damage. For instance, administration of hematopoietic growth factors can elevate achievable radiation doses from 6-8 Gy, compared to standard values of 5-6 Gy when combined with blood transfusions. The LD50/30 or LD50/60 metric is frequently used to quantify lethal dose following irradiation, representing the dose required to kill 50% of the population within 30 or 60 days post-exposure, respectively. Monitoring for delayed effects and recovery potential remains a critical component of long-term triage and follow-up.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.5	 Methods of Triage for Treatment After a Radiation Accident | Sub-subsection: 8.5.1	 Introduction: The Need for Triage and Intro to Exposure Scenarios | Content: blood transfusions associated with antibiotic therapy, it can
change to values between 5 and 6 Gy. With more robust
treatments, such as the administration of hematopoietic
growth factors, values from 6 to 8 Gy can be achieved [66]
(Box 8.3).
8.5
Methods of Triage for Treatment After
a Radiation Accident
8.5.1
Introduction: The Need for Triage
and Intro to Exposure Scenarios
When individuals are exposed to ionizing radiation in an
accidental scenario, there is an urgent need to categorize
exposed individuals not only in terms of the urgency of their
need for treatment, but also in relation to ionizing radiation
exposure. In general, radiation accidents lead to external
radiation exposure and/or external or internal contamination
with radionuclides. Exposures in situations requiring triage
tend to be acute, but chronic exposures also need to be con­
sidered. Further exposure or contamination can be approxi­
mately homogeneous or highly heterogeneous. Hence the
available tools and processes need to be flexible and suffi­
cient to allow appropriate triage in a variety of potential situ­
ations. This section considers in the need for initial triage
including decontamination, specific considerations related to
radiological triage, as well as the need for late follow-up.
Communication to the public is also a topic of importance,
not covered in detail here, but with further information in the
TMT Handbook [75].
8.5.2
Initial Triage: Trauma,
Decontamination, and Other
Considerations
In general, triage is used to screen the patients with severe
injuries after a mass incident, including chemical, biologi­
cal, radiological, nuclear, or explosive events (CBRNE).
The first step during triage is to classify the affected person
according to the type and severity of the suffered injuries,
accurately assessing prognosis and survival expectancy,
Box 8.3 Acute Radiation Syndrome
•	Acute radiation syndromes appear after whole-­
body irradiation
•	After an irradiation, the biological consequences
appear following four stages: Prodromal, latent
state, manifest illness state, and of recovery or death
state
•	When recovery occurs, delayed effects of acute
radiation exposure can manifest
•	LD50 is the dose that kills 50% of the irradiated pop­
ulation after 30 days (LD50/30 or 60 days (LD50/60)
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"Following a radiation accident involving ionizing radiation exposure, what range of absorbed dose values can be achieved with more robust treatments like hematopoietic growth factors compared to initial blood transfusions associated with antibiotic therapy?","Initial treatment strategies utilizing blood transfusions combined with antibiotic therapy may result in absorbed dose values fluctuating between 5 and 6 Gray (Gy). However, the implementation of more advanced therapies, specifically involving the administration of hematopoietic growth factors, can elevate these values to approximately 6 to 8 Gy. This difference highlights the potential for enhanced recovery outcomes through targeted interventions following radiation exposure. ","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.5	 Methods of Triage for Treatment After a Radiation Accident | Sub-subsection: 8.5.2	 Initial Triage: Trauma, Decontamination, and Other Considerations | Content: blood transfusions associated with antibiotic therapy, it can
change to values between 5 and 6 Gy. With more robust
treatments, such as the administration of hematopoietic
growth factors, values from 6 to 8 Gy can be achieved [66]
(Box 8.3).
8.5
Methods of Triage for Treatment After
a Radiation Accident
8.5.1
Introduction: The Need for Triage
and Intro to Exposure Scenarios
When individuals are exposed to ionizing radiation in an
accidental scenario, there is an urgent need to categorize
exposed individuals not only in terms of the urgency of their
need for treatment, but also in relation to ionizing radiation
exposure. In general, radiation accidents lead to external
radiation exposure and/or external or internal contamination
with radionuclides. Exposures in situations requiring triage
tend to be acute, but chronic exposures also need to be con­
sidered. Further exposure or contamination can be approxi­
mately homogeneous or highly heterogeneous. Hence the
available tools and processes need to be flexible and suffi­
cient to allow appropriate triage in a variety of potential situ­
ations. This section considers in the need for initial triage
including decontamination, specific considerations related to"
"Following a radiation accident, what key information is crucial for determining the potential deterministic effects of exposure in Category 2 and 3 victims, and how does this information contribute to treatment prioritization and exposure modeling?","In the context of triage following a radiation accident, detailed assessment of Category 2 and 3 victims hinges on gathering comprehensive data regarding their exposure. This includes meticulous documentation of the incident’s specifics: the type and energy/activity level of the radioactive source, its dispersal within the environment, and individual factors such as time of direct contact or distance from the source, whether the exposure occurred in an enclosed or open space, whether the individual was within the line of sight of the source, and if the source was mobile. The collection of this information is paramount because it directly informs the potential for deterministic radiation effects – non-stochastic effects with a quantifiable dose threshold. This data allows clinicians to identify individuals who may have received doses high enough to trigger these predictable, adverse outcomes. Furthermore, this detailed exposure profile enables sophisticated modeling of individual or population-level radiation exposure, as explored in Chapter 4, facilitating more targeted and effective treatment strategies and risk assessments.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.5	 Methods of Triage for Treatment After a Radiation Accident | Sub-subsection: 8.5.3	 Radiological Triage | Content: Following initial triage for trauma as described above, Cat­
egory 2 and 3 victims should be monitored and further evalu­
ated in the next steps of triage, comprising information about
location at the time of the accident and/or radiological analy­
sis based on clinical signs and symptoms to identify indi­
viduals who may have received doses high enough to cause
deterministic effects.
As much information as possible should be collected
regarding the type and energy or activity of the source and
the dispersal of the radiation within the environment con­
tributing to exposure/contamination. Regarding individual
information, considerations include the time of direct con­
tact or distance from the source when in proximity, whether
the exposure took place within an enclosed or open envi­
ronment, whether or not the individual was within the line
of sight of the source, and if the source was mobile. Such
information is needed for all potential points of exposure and
can then be used to help prioritize individuals for treatment
as described in more detail in the TMT Handbook [75]. In
addition, such information can contribute to modelling of
radiation exposure at the individual or population level, as
considered in Chap. 4.
8.4.2
­
­
8.16
8.17
­
­
­
­
8.6
8.5.4"
"Following an incident involving internal radionuclide contamination, what are the primary steps recommended for triage and initial management of affected individuals, considering factors such as potential risks and benefits of treatment? Specifically, how do different assessed committed effective doses (mSv) influence the recommended actions?","The immediate response to internal radionuclide contamination prioritizes life-threatening conditions and stabilization. The first set of actions involves focusing on controlling vital functions, hemorrhage, and transferring patients to emergency medical care facilities. Simultaneously, external contamination monitoring and decontamination are performed if detected. Crucially, efforts are directed towards mitigating the risk of further internal contamination and initiating initial monitoring for internal radioactivity levels – a process requiring specialized equipment like whole-body counters or thyroid uptake systems. The recommended actions then hinge on the assessed committed effective dose (mSv) as outlined in Table 8.15:

*   **<1 mSv:** Appropriate for public reassurance; no treatment is required.
*   **1–20 mSv:** More accurate dose assessment is needed, and treatment should not be considered.
*   **20–200 mSv:** Requires further assessment with medical judgment. Treatment may be considered depending on the potential efficacy of prolonged or protracted treatment, acknowledging that clinical effects are unlikely but possible.
*   **>200 mSv:** Treatment is recommended, alongside careful consideration of psychological factors and the potential benefits of extended or protracted treatment. 

It’s important to note that these actions aim primarily at reducing the risk of stochastic effects – such as tumor induction in organs where radionuclides have accumulated – rather than treating acute radiation injury directly. The ultimate decision regarding medical treatments rests with medical professionals, weighing risks and benefits based on individual circumstances.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.5	 Methods of Triage for Treatment After a Radiation Accident | Sub-subsection: 8.5.4	 Internal Contamination | Content: The next step in cases of internal contamination should be
the swift assessment and sorting of the affected persons,
mostly because decontamination efficiency decreases with
time. Cases of internal contamination are recognized through
a radiation survey, which can detect significant residual and
localized (e.g., lungs, thyroid) or distant (e.g., urine, blood,
smears, feces) radioactivity [81]. The initial monitoring of
internal contamination victims cannot be done without spe­
cial equipment, such as whole-body counters or thyroid
uptake systems [82]. According to the TMT Handbook, the
Table 8.14 Injury priority and decontamination (reproduced with per­
mission from [75])
Priority
Urgent medical
attention
Decontamination
Priority
1 (P1)
Imminent death if
immediate medical
attention is not
administered
Resuscitation and stabilization
have priority over
decontamination
Priority
2 (P2)
Acute surgery
necessary within 2–4 h
after injury
Decontamination has priority if
stabilization is not possible due
to the nature of the injury
Priority
3 (P3)
Medical attention can
be delayed for more
than 4 h
Decontamination has priority
75
R. Wilkins et al.
453
­
75
Table 8.15 Action levels for treatment of radionuclide contamination
(reproduced with permission from [75])
Assessed
committed
effective
dose (mSv)
Recommended action
<1
Appropriate for public reassurance that doses pose a
minimum risk to health. No treatment.
1–20
More accurate dose assessment is required. Treatment
should not be considered.
20–200
More accurate dose assessment is required. Treatment
is subject to medical judgement. Although clinical
effects are unlikely to occur, the potential efficacy of
extended or protracted treatment should be considered.
>200
Treatment should be considered. However,
psychological factors and potential efficacy of
extended or protracted treatment should be considered.
first set of actions during radioactive emergencies should be
as follows:
1.	Focus on life-threatening conditions, control of vital
functions and hemorrhage, and transfer to emergency
medical care facilities.
2.	Perform external contamination monitoring and decon­
tamination, if external contamination is detected.
3.	Lower the risk of internal contamination and initial moni­
toring level of internal contamination for further treat­
ment and prevent further contamination.
4.	Based on the initial monitoring, early clinical judgement
should be based on the risks and benefits of treatment of
internal contamination by radionuclides. Medical profes­
sionals will determine if medical treatments are needed
[75].
Internal contamination does not cause immediately seri­
ous or acute effects nor does it present a time-limiting life-­
threatening condition before the appropriate lifesaving and
decontamination measures can be performed. Having said
that, some radionuclides, such as 210Po or 137Cs, can cause
massive internal damage or acute radiation syndrome within
a few days after contamination [79, 83].
­
­
­
8.15
­
­
8.16
24
The measures for internal decontamination are not used
to treat acute radiation injury, but the main aim is to reduce
the risk of stochastic effects like tumors induced by radiation
in organs or tissues where radionuclides were incorporated.
8.5.5"
"Following a radiation accident resulting in exposure, what is the primary rationale behind conducting long-term medical monitoring for patients, even those without immediately apparent clinical symptoms of acute radiation syndrome (ARS)?","The core justification for extensive long-term follow-up after ionizing radiation exposure, encompassing both symptomatic and asymptomatic individuals, stems from the potential development of stochastic effects like cancer. While immediate treatment focuses on mitigating acute damage through interventions such as potassium iodide administration or chelation therapy, these measures do not eliminate the risk of delayed tumor formation due to DNA damage induced by radiation. Long-term monitoring is therefore crucial for identifying early signs of radiation-induced malignancies – which may be subtle and initially undetectable – allowing for timely intervention and potentially improving patient outcomes. Furthermore, this extended surveillance provides valuable epidemiological data regarding the incidence of radiation-related diseases, particularly in populations exposed to low doses where immediate effects are absent, addressing a significant gap in knowledge about stochastic health risks associated with radiation exposure [75].","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.5	 Methods of Triage for Treatment After a Radiation Accident | Sub-subsection: 8.5.5	 Follow-Up and Recovery | Content: 8.15
­
­
8.16
24
The measures for internal decontamination are not used
to treat acute radiation injury, but the main aim is to reduce
the risk of stochastic effects like tumors induced by radiation
in organs or tissues where radionuclides were incorporated.
8.5.5
Follow-Up and Recovery
Long-term medical monitoring should be carried out for
the patients suffering from the clinical symptoms of acute
radiation syndrome or local radiation injuries; however,
asymptomatic patients should also be included in long-term
follow-up as well as those for which there is only a presumed
ionizing radiation exposure.
8 Radiobiology of Accidental, Public, and Occupational Exposures
454
Table 8.16 Selected radionuclides and radiation countermeasures for treatment (reproduced with permission from [84])
Radionuclide
Treatment
Dose
Effect
Iodine
Potassium iodide (KI)
130 mg/day (pill) for 7 days
Blocking agent
Plutonium
Yttrium
DTPA (diethylene-triamine
penta-­acetic acid)
1 g calcium DTPA in 500 mL i.v. for
60 min
Chelating agent
Uranium
Sodium bicarbonate
Slow i.v. infusion by NaHCO3
solution (250 mL)
Alkalization of urine
Cesium, rubidium,
thallium
Prussian blue
3 g in 100–200 mL H2O orally three
times per day
Mobilization decreases  gastrointestinal
tract uptake, absorption
Radium, strontium
BaSO4
Sodium alginate
100 g in 250 mL H2O
This is the dose for BaSO4. For
Sodium alginate it is
5 g orally twice daily
Reduction/inhibition of absorption
Tritium
H2O
Drinking 6–12 L/day
Facilitates excretion
Lead, copper, poloniumd-penicillamine dimercaptopropanol1 g i.v./day or 0.9 g orally/4–6 h
Chelating agent
The patients with clear clinical symptoms should be
scheduled for long-term follow-up to prevent, control, and
care for the health consequences of ionizing radiation expo­
sure. The long-term follow-up means that the patients will
be checked in regular appointments in specialized clinical
departments over a 5-year period to monitor any risk factors,
health outcomes, or both. The long-term follow-up does not
always have the same scenario and it is different on a case-­
by-­case basis, mostly based on the development of symptoms
of acute radiation syndrome and received dose of radiation.
As an example, the logical first step for affected person is
to contact and inform the primary care physician about the
radiation exposure incident and plan a follow-up program
with the physician and the specialists at various departments
in the hospital (e.g., hematology, radiotherapy, psychology,
internal medicine) if needed. If the affected patient recovers
from the hematological consequences of acute radiation syn­
drome, a hematological examination should be conducted
every 3 months during the first year and a routine medical
examination once a year. Annual examinations at the oph­
thalmological clinic are also recommended for monitoring
cataract incidence, if any. In addition, medical consultation
should be offered to exposed victims for mental and repro­
ductive health as and when needed [75]. The benefit of this
long-term medical monitoring is the identification of radia­
tion symptoms, and though it may sound daunting this fol­
low-up does not differ much from that ­performed for other
clinical conditions. It must be noted that those patients with­
out symptoms could have the greatest benefit from long-term
medical monitoring. This monitoring provides the capacity
to classify the individuals at greater risk; further, it also
enables the proper evaluation of diseases that may be found
in the population at risk. Although it may be inconvenient for
asymptomatic patients, long-term medical monitoring may
help in early diagnosis and treatment of serious radiation-
related illnesses, thus minimizing morbidity and mortality
rates. Persons who have been exposed to low doses of ion­
izing radiation during a radiation emergency, who have not
experienced ARS or other immediate symptoms associated
with radiation exposure, should also be included in long-term
follow-up and monitoring mostly to dismiss the existence of
radiation effects or to monitor ionizing radiation exposure
related illnesses, which often come in the form of cancer.
In addition, the long-term follow-up may also provide the
affected patients with mental health support and reproduc­
tive health consulting.
Taken together, the long-term follow-up and medical
monitoring of the persons affected by radiation emergen­
cies can provide new epidemiological data since medi­
cal follow-­up data for potential stochastic effects such as
cancer are sparse. However, social, economic, legal, and
psychological aspects should be considered in the follow-
up and monitoring of these patients [75]. The epidemio­
logical follow-up determines two groups, i.e., exposed and
unexposed to radiation, and registers any difference in the
health outcome. How this will be done will depend on the
exposure scenario. The typical outcome in radiation epide­
miology is represented by a greater incidence of cancer or
mortality related to radiation. The most precise and con­
clusive parameter in an epidemiological study is mortal­
ity due to clear and obvious occurrence, supported by the
records available worldwide. Also, epidemiological fol­
low-up studies should include non-­malignant morbidities
and mortality, which are known parameters collected from
A-bomb survivors’ life span studies. However, it has to be
mentioned that this is not always the main interest of epi­
demiological follow-up of health outcomes. In many cases
there is an interest in diseases that can affect quality of life,
such as nonfatal diseases, for example, tissue degenerative
diseases [75, 85] (Box 8.4).
R. Wilkins et al.
455
8.6"
Describe the principles behind biological dosimetry and explain why lymphocytes from peripheral blood are commonly used as biomarkers for radiation exposure assessment.,"Biological dosimetry utilizes measurable biomarkers in biological samples, typically peripheral blood, to determine and quantify an individual’s exposure to ionizing radiation. The core principle relies on observing the effects of radiation damage at a cellular level – specifically, the induction and repair of DNA double-strand breaks – within these biomarkers. Lymphocytes are favored as these cells circulate throughout the body via the bloodstream, providing a representative sample of tissue exposed to potential radiation. Critically, lymphocytes reside in the G0/G1 phase of the cell cycle, meaning they are not actively dividing. This is advantageous because it minimizes background DNA damage and allows for a clearer assessment of radiation-induced effects. Stimulation of these lymphocytes *in vitro* enables proliferation, facilitating cytogenetic assays that can then be correlated with the administered radiation dose. The success of biological dosimetry hinges on several key requirements including low background levels, a demonstrable dose-response relationship across different radiation types and rates, specificity for ionizing radiation, non-invasive sampling methods, rapid dose estimation capabilities, high reproducibility, and ultimately, consistent results between *in vitro* and *in vivo* measurements to establish calibration curves. Reference: MolecularRadiationBiology, Section 8.6.1 – Introduction","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.1	 Introduction | Content: Biological dosimetry is an internationally accepted method
for the detection and quantification of presumed/suspected
exposures to ionizing radiation in humans. On the basis of
biomarkers in the peripheral blood, the amount of ionizing
radiation to which an individual has been exposed can be
determined and estimated. Biological dosimetry can be used
in addition to physical dosimetry or as a distinct method
for dose reconstruction. The traditionally used, well-estab­
lished cytogenetic assays are predominantly based on induc­
tion and misrepair of radiation induced DNA double strand
breaks. The analyses are performed in lymphocytes of the
peripheral blood, as these circulate throughout the body, and
they are normally in the G0/G1 stage of the cell cycle. Since
lymphocytes are not cycling, they need to be stimulated to
proliferate during in vitro cell culturing. There are several
essential requirements for biological parameters to be mean­
ingful dosimeters: Low background level, clear dose effect
relationship for different radiation qualities and dose rates,
specificity to ionizing radiation, non-invasive sample collec­
tion, fast availability of dose estimation, good reproducibil­
ity, as well as comparability of in vitro and in vivo results to
set up a calibration curve [86].
8.6.2"
"The Dicentric Chromosome Assay (DCA) is frequently utilized in biodosimetry. Explain how the method leverages background chromosome damage and its implications for determining radiation dose, specifically addressing distinctions between homogeneous and inhomogeneous exposures.","The Dicentric Chromosome Assay (DCA) relies on measuring dicentric chromosomes within lymphocytes to estimate absorbed radiation doses following exposure. The principle is based on the fact that in healthy individuals, spontaneous dicentric chromosome formation occurs at a very low rate – approximately 0.5-1 per 1000 cells [89]. This represents the background level of chromosomal damage induced by endogenous factors like DNA repair mechanisms. Following radiation exposure, this baseline damage is amplified, and the number of dicentric chromosomes observed increases proportionally to the dose received. Crucially, the DCA allows for differentiation between homogeneous (low-LET) and inhomogeneous exposures. Homogeneous exposures, characterized by a uniform distribution of radiation energy across the body, typically induce a linear relationship between chromosome damage and absorbed dose, modeled using a linear-quadratic curve [92]. Conversely, inhomogeneous exposures – where radiation intensity varies significantly within the body – can lead to a more complex dose estimation due to variations in DNA repair capacity across different tissues. The method’s sensitivity is also notably high because of this low background rate; the lowest detectable dose for homogeneous whole-body irradiation with low-LET radiation is approximately 100 mGy when 500–1000 cells are evaluated [90].  Furthermore, the lifetime of lymphocytes bearing dicentric chromosomes influences dose estimation – longer lifetimes allow for more damage to accumulate, while rapid turnover dilutes damaged cells. Adjustments must be made for protracted exposures to avoid underestimation due to this dilution effect [93]. Reference: 8.6.2.1 Dicentric Chromosomes Assay (DCA)","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.2	 Conventional Methods | Sub-sub-subsection: 8.6.2.1	 Dicentric Chromosomes Assay (DCA) | Content: 8.18
­
87
­
8.18
­
­
Box 8.4 Treatment of Internal Contamination
•	Initial triage for trauma, the victims should be mon­
itored and further evaluated in the next step of tri­
age, comprising information about location at the
time of the accident and/or radiological analysis
based on clinical signs and symptoms.
•	Internal contamination should be the swift assess­
ment and sorting of the affected person, mostly
because decontamination efficiency is often hin­
dered by time delays.
•	Cases of internal contamination are recognized
through a radiation survey, which can detect signifi­
cant residual.
•	Internal contamination does not cause immediately
serious or acute manifestations nor does it present a
time-limiting life-threatening condition.
•	The treatment administered should remove the con­
taminating radionuclides from the human body
through chemical or biological agents.
8 Radiobiology of Accidental, Public, and Occupational Exposures
456
exclusively caused by ionizing radiation [88]. In healthy,
non-exposed individuals, dicentric chromosomes rarely
occur spontaneously and the background rate is about 0.5–1
dicentric chromosome in 1000 cells [89]. Therefore, the
method has a good sensitivity. The lowest detectable dose of
a homogeneous acute whole-body irradiation with low-LET
(linear energy transfer) radiation is about 100 mGy when
500–1000 cells are evaluated [90]. It is well accepted that
a comparable number of chromosomes damaged per dose
unit is induced for both high- and low-LET radiation in vitro
and in vivo [91] enabling dose estimation on the basis of
in vitro calibration curves. The dose effect relationship can
be modeled by a linear-quadratic curve (Y = c + αD + βD2)
for up to 5 Gy of low-LET radiation and by a linear model
(Y = c + αD) for high-LET (alpha or neutron) radiation [92].
In addition, based on the analysis of dicentric chromosomes,
a distinction can be made between homogeneous and inho­
mogeneous or between high- and low-LET exposures [89].
The mean lifetime of lymphocytes with dicentric chromo­
somes in the peripheral blood is between 0.6 and 3 years
[93], and this is largely influenced by both the absorbed
radiation dose (low or high) and inter-individual variation in
lymphocyte turnover rate [88]. The decline of dicentric chro­
mosome bearing lymphocytes can occur either by cell death
or by dilution of damaged lymphocytes with the fresh pop­
ulation of lymphocytes over long periods of post radiation
exposure. Therefore, in the case of radiation exposure that
occurred a long time ago or was protracted, i.e., over a longer
period of irradiation at a low-dose rate, appropriate adjust­
ments must be made to avoid underestimation of the dose.
Chromosome analysis is considered as a very labor-intensive
method requiring well-­trained staff to perform the analyses
[94]. To increase the throughput of the method for a large-
scale accident with a large number of potentially exposed
individuals, different approaches have been developed. Scor­
ing 50 cells or 30 dicentrics has been accepted as sufficient
in triage scoring to identify those who need immediate medi­
cal support [95]. Software-based automated scoring systems
for the rapid detection of dicentric chromosomes have been
developed and successfully applied in various studies (e.g.
[96]). Recent advances in using imaging flow cytometry to
identify dicentric chromosomes have demonstrated the fea­
sibility, however, there is still much room for improvement
[97]. Also automated robotically based high-throughput
platform (RABiT, Rapid automated Biodosimetry Tool) has
been designed to enhance the capacity of dicentric chromo­
some analysis [98]."
"Describe the Cytokinesis-Block Micronucleus (CBMN) assay as a method for biodosimetry. What are its key advantages, limitations, and the types of chromosomal abnormalities it detects?","The Cytokinesis-Block Micronucleus (CBMN) assay is a rapid and relatively simple technique used in biodosimetry to assess radiation exposure by examining chromosome damage within mammalian cells. The assay relies on arresting cell division at the cytokinesis stage, typically using colchicine or other agents that disrupt spindle formation. This arrest allows for the observation of micronuclei – small, detached nuclei containing damaged chromosomes – which form due to chromosomal fragmentation during cell division following irradiation. The CBMN assay detects both simple and complex chromosome aberrations, including single-copy deletions, double-copy duplications, and translocations. A key advantage is its speed and ease of training for personnel with limited experience, making it suitable for rapid triage of populations exposed to radiation. Furthermore, automated systems utilizing microscopy or flow cytometry are available for analysis, enabling high throughput. However, the assay has limitations; it’s most effective for uniform whole-body external low-LET exposures (detection limit around 250 mGy), and its accuracy can be affected by factors such as cell scoring number, age, smoking status (which introduces non-radiation specific translocations), and post-exposure time. The lengthy culture times required to visualize aberrations also represent a significant limitation. Finally, the assay primarily detects chromosome translocation events through techniques like Fluorescence In Situ Hybridization (FISH) using multicolor band probes for assessing intra-chromosomal rearrangements.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.2	 Conventional Methods | Sub-sub-subsection: 8.6.2.2	 Cytokinesis-Block Micronucleus (CBMN) Assay | Content: Assay
­
8.19
99
­
89
­
­
88
­
100
101
­
­
R. Wilkins et al.
457
lifestyle as well as exposure to other environmental muta­
gens [102]. The advantage of the method is the simple and
quick evaluation, enabling relatively rapid training of inex­
perienced persons [103]. Various automated systems are
available for MN analysis based on microscopy [104] or flow
cytometry methods [105]. Furthermore, a high throughput
and miniaturized version of the CBMN assay for accelerated
sample processing has been described [106]. Several studies
have confirmed the reliability of the automated MN assay for
high-throughput population triage [107].
8.6.2.3	Chromosome Translocation Analysis
Using Fluorescence In Situ Hybridization
(FISH)
108
8.20
­
­
­
109
­
In addition to this single color painting, genome wide
analysis, known as M-FISH (which does not require adjust­
ment for genome equivalent damage), allows the detection
of all simple interchromosomal exchanges as well as com­
plex rearrangements involving multiple breakpoints in sev­
eral chromosomes. Use of chromosome specific multicolor
band probe (mBAND) facilitates the assessment of intra-­
chromosomal rearrangements such as pericentric and para­
centric inversions.
The FISH translocation assay has most commonly been
used to estimate radiation doses following external radiation
exposures [108]. As above, this technique is relevant for dose
assessment at post-exposure time periods of days up to many
years post exposure, however, does not work well for partial-­
body exposure.
The detection limit for FISH for uniform whole-body
external low-LET exposures is on the order of 250 mGy,
however, this varies depending on a number of factors,
including the number of cells scored, age and smoking status
(because translocations are not radiation specific), as well as
length of time post exposure [109]. These issues, together
with the length of time needed to culture the cells in order
to visualize the aberrations, are the main limitations of the
assay. Automation of FISH analysis is under development,
but is not yet in common use.
8.6.2.4	The Premature Chromosome
Condensation Assay (PCC-Assay)
­
­
89
0
110
2
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"Fluorescence in situ hybridization (FISH) is frequently employed in biodosimetry to assess radiation exposure. Describe the fundamental principle behind chromosome translocation analysis using FISH, detailing how it differentiates between irradiated and unexposed cells and what specific molecular targets are typically utilized.","Chromosome translocation analysis via FISH relies on the differential susceptibility of chromosomal DNA to ionizing radiation compared to non-irradiated DNA. When a cell is exposed to radiation, there’s an increased probability that double-strand breaks will occur within chromosomes. These breaks can lead to chromosome rearrangements, most notably translocations – where segments of one chromosome become attached to another. FISH utilizes fluorescently labeled probes designed to hybridize specifically to unique chromosomal sequences. Typically, probes targeting ribosomal DNA (rDNA) are employed. In unexposed cells, the rDNA remains intact and bound by its associated proteins, resulting in a distinct fluorescence pattern when visualized under a fluorescence microscope. Following radiation exposure, the breaks within the rDNA regions cause the DNA strands to separate, disrupting the normal binding of the probe. This results in reduced or absent hybridization – a decrease in fluorescence intensity – at the sites where the probes were originally bound. Conversely, if the cell is unexposed, the rDNA remains intact and shows strong fluorescence. Therefore, a significant reduction in fluorescent signal indicates radiation exposure due to the translocation event and subsequent disruption of probe binding. The precise quantification of this reduction allows for an estimation of the absorbed dose. Reference: [Molecular Radiation Biology], Section 8.6.2.3","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.2	 Conventional Methods | Sub-sub-subsection: 8.6.2.3	 Chromosome Translocation Analysis Using Fluorescence In Situ Hybridization (FISH) | Content: 89
0
110
2
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"Describe the Premature Chromosome Condensation (PCC) assay as a method for assessing radiation dose in lymphocytes and explain the key steps involved in its execution, including how it differentiates between whole-body and partial-body exposures.","The Premature Chromosome Condensation (PCC) assay is a biodosimetry technique used to quantify radiation-induced chromosomal aberrations directly on unstimulated interphase blood lymphocytes. It relies on the principle that ionizing radiation can induce premature condensation of chromosomes, particularly in G2 cells after DNA replication. The assay involves chemically stimulating lymphocytes – typically using inhibitors like okadaic acid or calyculin A – to undergo a single cell division, triggering this premature condensation. Following stimulation, the number of single chromatid PCC elements per cell is meticulously recorded (Fig. 8.21a). Simultaneously, the yield of radiation-induced excess PCC fragments is estimated by subtracting the expected number of PCC elements (46) found in non-irradiated lymphocytes – representing the baseline level of chromosomal instability. This difference then provides a measure of the radiation dose received. The assay’s ability to distinguish between whole- and partial-body exposures stems from its application to lymphocyte populations derived from different regions of the body. A higher proportion of condensed chromosomes indicates a greater dose delivered to that specific region, allowing for a more accurate assessment of exposure distribution. Crucially, the PCC assay can be performed within 3 hours post-irradiation, providing rapid dose estimates in emergency situations. Furthermore, when combined with fluorescence in situ hybridization (FISH), it enables detailed analysis of inter- and intra-chromosomal rearrangements directly on G0 lymphocytes, enhancing its utility for retrospective radiation effect assessment. The technique’s limitations include the requirement for fresh or frozen mitotic cells and specialized expertise in cell fusion procedures and chromosome analysis.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.2	 Conventional Methods | Sub-sub-subsection: 8.6.2.4	 The Premature Chromosome Condensation Assay (PCC-Assay) | Content: 89
0
110
2
8 Radiobiology of Accidental, Public, and Occupational Exposures
458
a
b
0­
112
inhibitors such as okadaic acid or calyculin A. Unlike cell
fusion of unstimulated G0 lymphocytes, chemically induced
PCC method requires stimulation of lymphocytes for one cell
division because these chemicals induce premature conden­
sation of G2 cells after DNA replication. The PCC method
is suitable for the analysis of ring chromosomes, especially
at higher doses [111]. To quantify radiation-induced chro­
mosomal aberrations in G0-phase lymphocytes using the
fusion PCC-assay, the total number of single chromatid PCC
elements per cell in the exposed lymphocytes is recorded
(Fig. 8.21a) and the yield of radiation-induced excess PCC
fragments is estimated by subtracting the number of 46 PCC
elements expected to be scored in non-irradiated lympho­
cytes (Fig. 8.21b). The dose assessment is based on a dose-­
response calibration curve generated by in vitro irradiation
of unstimulated blood lymphocytes. These curves have a lin­
ear shape and the residual yield of excess fragments depends
on the time elapsed for repair between the irradiation and
the cell fusion Especially in radiation accidents where high
doses are received the premature chromosome condensa­
tion (PCC) assay enables quantification of radiation-induced
chromosomal aberrations directly on unstimulated inter­
phase blood lymphocytes [89].
Overall, the fusion PCC assay allows rapid assessment
of the radiation dose, even within 3 h post irradiation, and
can successfully distinguish between whole- and partial-
body exposures [113]. Furthermore, when the PCC-assay is
combined with the fluorescence in situ hybridization (FISH)
technique, inter- and intra-chromosomal rearrangements can
be analyzed directly in G0 lymphocytes for radiation biodo­
simetry purposes and retrospective assessment of radiation-­
induced effects [114]. Finally, a quick, automatable, and
minimally invasive micro-PCC assay was recently proposed
for rapid individualized risk assessments in large-scale radio­
logical emergencies [115]. However, the PCC assay requires
the availability of either fresh or frozen mitotic cells [116]
and expertise in cell fusion procedures and analysis of lym­
phocyte prematurely condensed chromosomes. Due to these
limitations, the test is still not widespread.
8.6.3"
"The gamma-H2AX assay utilizes which cellular marker to assess radiation damage and subsequently estimate dose levels? Furthermore, what factors significantly impact the reliability of this assay’s dose estimations, particularly concerning temporal considerations?","The gamma-H2AX assay employs histone H2AX as a biomarker for DNA double-strand breaks. This protein is rapidly upregulated following irradiation, forming foci that are directly proportional to the radiation dose received. However, the reliability of dose estimation using this assay is heavily influenced by several temporal factors. Primarily, the rapid loss of gamma-H2AX foci after exposure follows the kinetics of DNA double-strand break repair mechanisms. Consequently, a significant time gap between radiation exposure and blood sampling dramatically reduces the observed focus yield due to the repair processes already having taken place. Specifically, the assay is most reliable when samples are collected within 1–2 days post-exposure, with longer lag times leading to a substantial decrease in detectable foci and an increase in the minimum detectable dose (from approximately 1 mGy within 1 hour to ~0.5 Gy after a 2-day lag). Furthermore, factors such as sample shipment conditions and staining reproducibility can introduce variability, impacting the accuracy of the results. While automated scoring techniques or flow cytometry offer potential for high throughput analysis, manual scoring remains preferred due to reduced uncertainties in dose estimation.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.3	 Molecular Methods | Sub-sub-subsection: 8.6.3.1	 Gamma-H2AX Foci Assay | Content: 30
8.22
117118
­
The advantage of the gamma-H2AX assay is that a dose
estimate, based on foci levels in peripheral blood lympho­
cytes, can be given within 5 h from the receipt of a blood
sample [117]. Background levels of mean foci per cell are
low, ~0.3 or less [119] and gamma-H2AX foci increase lin­
early with dose. However, foci loss follows the time course of
DNA double strand break repair [120] and the time between
R. Wilkins et al.
459
­
­
­
radiation exposure and blood sampling greatly effects the
observed yield of foci. To enable reliable exposure assess­
ment, calibration curves for different post-­exposure time
points are essential [121]. The rapid loss of gamma-H2AX
foci requires a blood sample to be taken within 1–2 days
after a radiation exposure with the minimum detectable
dose increasing from a ~ 1 mGy [122] for a sample taken
within 1 h after exposure to ~0.5 Gy for a lag time of 2 days
between exposure and sampling [123]. Use of two separate
foci biomarkers, for example, gamma-H2AX and 53BP1
with dual-color immunostaining, could enhance the sensitiv­
ity for low-dose exposure by only scoring foci that coincide,
so reducing the influence of staining artefacts [123]. Manual
scoring of gamma-H2AX foci is the preferred method, as it
gives smaller uncertainties in the dose estimate than auto­
mated scoring techniques [124] or flow cytometry [123].
However, gamma-H2AX flow cytometry imaging has the
potential to be a very rapid, high throughput tool suitable for
analyzing large numbers of samples [125]. The data analysis
of foci counts for calibration curve fitting, estimating doses
and calculating confidence intervals can be performed in
the same manner as conventional chromosome dosimetry.
Some evidence suggests the distribution of gamma-H2AX is
Poisson among the scored cells and can be used to estimate
partial-body exposure using the methods developed for the
dicentric assay, although over-dispersion has been observed
in other data sets [124].
Radiation quality, time, and dose-dependent changes in
gamma-H2AX foci numbers need to be considered when
converting foci yields into dose estimates. The rapid loss
of foci following irradiation and other assay methodol­
ogy influencing factors (e.g., sample shipment conditions,
staining reproducibility), suggests that currently gamma-
H2AX-­based dose estimation may be associated with large
uncertainties; especially if the exact time between exposure
and blood sampling is unknown. Given this, the assays main
function is that of a qualitative indicator of exposure as
opposed to a precise dosimetry tool."
"The text describes a method for biological dosimetry utilizing gene expression analysis following ionizing radiation exposure. Specifically, what is the primary goal of quantifying alterations in the transcriptome as it relates to this dosimetry technique?","Following exposure to ionizing radiation, cells activate pathways leading to cell cycle arrest and DNA repair mechanisms, resulting in changes within their transcriptome – essentially, a shift in gene expression patterns. These radiation-responsive alterations in the transcriptome are quantified through molecular analysis for biological dosimetry. The core goal is to correlate these measurable changes in gene expression with the absorbed dose of ionizing radiation, allowing for estimation of exposure levels. This approach leverages the fact that specific genes are activated in response to radiation damage, providing a sensitive and potentially rapid method for dose assessment [126]. Reference: [MolecularRadiationBiology, Section 8.6.3.2 Gene Expression]","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.6	 Biodosimetry Techniques | Sub-subsection: 8.6.3	 Molecular Methods | Sub-sub-subsection: 8.6.3.2	 Gene Expression | Content: One relatively new method for biological dosimetry is the
analysis of changes in gene expression. In response to expo­
sure to ionizing radiation, cells activate multiple transduc­
tion pathways to activate cell cycle arrest and induce DNA
repair mechanisms in order to prevent the cell from apoptosis.
These radiation-responsive alterations in the transcriptome
can be quantified by molecular analysis, which lately have
been exploited for biological dosimetry [126]. Global dis­
covery platforms are initially used to search for appropriate
marker genes that are useful for biodosimetric applications.
The expression values need to be measurable in a relevant
dose range and exhibit a linear dose-response relationship
such that the level for the respective gene can be assigned
to a specific radiation dose. Those studies focus mainly on
human peripheral lymphocytes, which are also the material
of choice for classical biodosimetry methods due to their
sensitivity and specificity to ionizing radiation and the pos­
sibility of minimally invasive collection. The gene response
can be monitored either by quantitative real-time polymerase
chain reaction (qRT-PCR), which accurately quantifies single
genes, or by microarrays that can show a global scale analysis
[127]. Using ex vivo irradiated lymphocytes the sensitivity
and linear dose dependency of this assay was assumed to be
100 mGy up to 5 Gy whole-body irradiation [128].
Currently, the use of gene expression analysis in dosimetry
is still experimental. Several genes have already emerged as
useful biomarkers, with ferredoxin reductase (FDRX) being
the most promising one [129]. Due to the activation of a very
complex molecular reaction by ionizing radiation, estima­
tion of the dose based on single changes in gene expression
is not optimal. Therefore, the use of multiple panels of radi­
ation-sensitive genes is more promising to improve the accu­
racy of the estimation [87]. Currently, many researchers are
working on the definition of such a gene signature in order
to apply gene expression for biological dosimetry. There are
also some studies that have identified genes for specific ARS
effects [130].
8 Radiobiology of Accidental, Public, and Occupational Exposures
460
The advantage of gene expression-based over other bio­
dosimetric methods is rapid radiation dose estimation and
high sample throughput, which is particularly advantageous
for large populations. However, due to the dynamics of gene
expression, dose estimation is only possible in a relatively
short time frame after exposure. In addition, the influence of
health status, age, and sex on changes in radiation-­induced
gene expression is known, and thus there is a need to develop
individualized gene expression-based dosimetry models for
different population subgroups. So far, it has also not fully
been clarified how to infer from changes in gene expres­
sion to different radiation qualities and more complex expo­
sure scenarios such as detection of partial-body irradiation.
Although there is currently no universal standardization of
gene expression analysis for biological dosimetry available,
research is on going and the analysis of gene profiles seems
to hold great potential to support the individual dose estima­
tion especially in large-scale radiation accidents (Box 8.5).
8.7
Radiation Protection System/Risk
Coefficients, Organ Weighting
Factors, and Dose Limits
8.7.1
Introduction: History
Since the discovery and the rapid introduction and exploi­
tation of ionizing radiation in medicine, technology and
industry, the limited knowledge about the detrimental health
effects of radiation led to the exposure of many individuals to
high doses, and subsequently to various radiation exposure
related health effects such as cancer [131, 132].
Guidelines for radiation protection purposes started as
early as the 1890s with more detailed dose limits being
released as more research was being published. However,
as the detrimental effects of radiation became more known,
and more research was being published about its negative
side effects, the need for a cohesive set of guidelines and
regulations became more apparent. At the second Interna­
tional Congress of Radiology, held in Stockholm in 1928,
a new unit was proposed for quantifying ionizing radiation,
specifically for the purpose of radiation protection. The unit
was named Röntgen, after the discoverer of X-rays. It was
also during this congress that the International X-Ray and
Radium Protection Committee (IXRPC) was founded, which
would later be known as the Commission for Radiation Pro­
tection (ICRP). The first dose limit recommendation by the
IXRPC came in 1934. These stated that a person in normal
health can tolerate 0.2 roentgens of X-rays per day. This
would correspond to approximately an annual effective dose
of 500 mSv; a dose 25 times higher than the current annual
dose limit for occupational workers. No dose limit recom­
mendation was given for γ-rays at this point.
Separate from the IXRPC, a document was published in the
1930s, outlining many protective methods and techniques to
shield from the harmful effects of radiation. This report was
commissioned by what would later become the United Nations
Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR). The comments on permissible dose were vague,
however. In the following years, several recommendations were
being made by various bodies. Around this time, terminology
also began changing, and the previously used “tolerance dose”
was changed to “maximum permissible dose.” In 1946, the
US advisory Committee was re-­established as the National
Council on Radiation Protection and Measurements (NCRP)
and amended their initial recommendations to now allow a
maximum permissible dose of 0.05 Roentgen/day, expressed
at that time as 0.3 Roentgen/week [133]. This reduction was
largely due to the growing evidence of the hereditary harm of
radiation. This new guideline was also echoed by the ICRP in
1950, when they also proposed a weekly maximum permis­
sible dose of 0.3 Roentgen. The reduction from their previous
1934 recommendations of 0.2 Roentgen/day corresponded to 1
Roentgen/week, which was then seen as being too close to the
threshold of adverse effects [134].
The first publication by the ICRP came in 1955; here a
clear distinction was made between the levels allowed for
public and occupational exposure, public exposure allow­
ance was reduced by a factor of 10 from what was allowed
for occupational exposure. Recommendations on permissi­
ble doses were given for various organs. New units were also
introduced, with the rad (now corresponding to 0.01 Gy)
being used for absorbed dose, and rem as the RBE weighted
unit (corresponding today to 0.01 Sv) [135]. In 1958, the
ICRP published what is now known as “Publication 1”. The
concept of a weekly dose limit was abandoned, and the new
annual occupational dose limit was 5 rem, with a public limit
of 0.5 rem/year (50 and 5 mSv respectively) [136].
Changes to terminology and units were revised once again
in 1977, in publication 26. The Sievert replaced the rem, and
Box 8.5 Methods for Biological Dosimetry
•	In biological dosimetry biomarkers are used to ver­
ify exposure to ionizing radiation and to estimate
the absorbed dose.
•	The analysis of dicentric chromosomes is consid­
ered as “gold standard” in biological dosimetry
after an acute radiation exposure.
•	According to the radiation scenario other cytoge­
netic methods are available (CBMN, FISH; PCC).
•	Relatively new methods on the molecular level are
gamma-H2AX foci assay and analysis of changes
in the gene expression.
R. Wilkins et al."
"Describe the evolution of radiation dose limits as recommended by the International Commission on Radiological Protection (ICRP) from its initial recommendations in 1934 to 1958, specifically highlighting changes in both numerical values and terminology.","Initially, in 1934, the ICRP proposed a daily maximum permissible dose of 0.2 Roentgen for occupational workers, equating to 1 Roentgen per week. This value was considered close to the threshold for adverse effects. Subsequently, recognizing concerns about hereditary harm from radiation, the limit was reduced to 0.05 Roentgen per day in 1946 (equivalent to 0.3 Roentgen per week), and later echoed by the ICRP in 1950 with a weekly maximum permissible dose of 0.3 Roentgen. A crucial shift occurred in 1955, establishing distinct exposure limits for public and occupational settings; the public exposure allowance was reduced by a factor of ten compared to the occupational limit. Furthermore, new units were introduced – the rad (later equivalent to 0.01 Gy) for absorbed dose and the rem (now equivalent to 0.01 Sv) as a RBE-weighted unit. In 1958, Publication 1 abandoned the weekly dose limit entirely, establishing an annual occupational dose limit of 5 rem (equivalent to 50 mSv), while maintaining a public exposure limit of 0.5 rem per year (5 mSv). These changes reflected growing scientific understanding and concerns regarding radiation’s potential for long-term health effects, alongside evolving terminology – the ‘tolerance dose’ was replaced with ‘maximum permissible dose.’","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.7	 Radiation Protection System/Risk Coefficients, Organ Weighting Factors, and Dose Limits | Content: dose limit for occupational workers. No dose limit recom­
mendation was given for γ-rays at this point.
Separate from the IXRPC, a document was published in the
1930s, outlining many protective methods and techniques to
shield from the harmful effects of radiation. This report was
commissioned by what would later become the United Nations
Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR). The comments on permissible dose were vague,
however. In the following years, several recommendations were
being made by various bodies. Around this time, terminology
also began changing, and the previously used “tolerance dose”
was changed to “maximum permissible dose.” In 1946, the
US advisory Committee was re-­established as the National
Council on Radiation Protection and Measurements (NCRP)
and amended their initial recommendations to now allow a
maximum permissible dose of 0.05 Roentgen/day, expressed
at that time as 0.3 Roentgen/week [133]. This reduction was
largely due to the growing evidence of the hereditary harm of
radiation. This new guideline was also echoed by the ICRP in
1950, when they also proposed a weekly maximum permis­
sible dose of 0.3 Roentgen. The reduction from their previous
1934 recommendations of 0.2 Roentgen/day corresponded to 1
Roentgen/week, which was then seen as being too close to the
threshold of adverse effects [134].
The first publication by the ICRP came in 1955; here a
clear distinction was made between the levels allowed for
public and occupational exposure, public exposure allow­
ance was reduced by a factor of 10 from what was allowed
for occupational exposure. Recommendations on permissi­
ble doses were given for various organs. New units were also
introduced, with the rad (now corresponding to 0.01 Gy)
being used for absorbed dose, and rem as the RBE weighted
unit (corresponding today to 0.01 Sv) [135]. In 1958, the
ICRP published what is now known as “Publication 1”. The
concept of a weekly dose limit was abandoned, and the new
annual occupational dose limit was 5 rem, with a public limit
of 0.5 rem/year (50 and 5 mSv respectively) [136].
Changes to terminology and units were revised once again
in 1977, in publication 26. The Sievert replaced the rem, and
Box 8.5 Methods for Biological Dosimetry
•	In biological dosimetry biomarkers are used to ver­
ify exposure to ionizing radiation and to estimate
the absorbed dose.
•	The analysis of dicentric chromosomes is consid­
ered as “gold standard” in biological dosimetry
after an acute radiation exposure.
•	According to the radiation scenario other cytoge­
netic methods are available (CBMN, FISH; PCC).
•	Relatively new methods on the molecular level are
gamma-H2AX foci assay and analysis of changes
in the gene expression.
R. Wilkins et al."
"Describe the historical development of radiation protection guidelines, focusing on key milestones such as the Stockholm Congress in 1928, the establishment of the ICRP and NCRP, and changes to dose limits over time. Specifically, what were the initial recommendations regarding tolerable doses and how did these evolve due to accumulating evidence about radiation's effects?","The development of radiation protection guidelines was a gradual process driven by increasing knowledge about the detrimental health effects of ionizing radiation. Early efforts began with the discovery of X-rays in 1895, leading to rapid exploitation in medicine and industry without sufficient understanding of risks. The first formalized dose limits emerged following the second International Congress of Radiology held in Stockholm in 1928, where a new unit – the Röntgen – was proposed for quantifying radiation. This congress also led to the founding of the International X-Ray and Radium Protection Committee (IXRPC), later renamed the Commission on Radiation Protection (ICRP). The IXRPC’s first dose limit recommendation in 1934 stated that a person in normal health could tolerate 0.2 roentgens per day, corresponding to an annual effective dose of 500 mSv – significantly higher than current limits. Notably, no dose limit was initially established for gamma rays. Throughout the 1930s and 40s, as research revealed more about radiation's negative effects, particularly hereditary damage, the ICRP and other bodies continued to refine recommendations. In 1946, the US advisory committee was re-established as the National Council on Radiation Protection and Measurements (NCRP), which initially recommended a maximum permissible dose of 0.05 Roentgen/day (0.3 Roentgen/week) due to growing evidence of hereditary harm. This was echoed by the ICRP in 1950, who also proposed a weekly limit of 0.3 Roentgens. The initial 1934 recommendation of 0.2 roentgens/day (1 Roentgen/week) was deemed too close to the threshold for adverse effects. In 1955, the ICRP established distinct dose limits for public and occupational exposure, reducing the public allowance by a factor of 10. New units – the rad (now equivalent to 0.01 Gy) and rem – were introduced, along with tissue weighting factors (wT) reflecting differences in tissue radiosensitivity. Further revisions occurred in 1958 (Publication 1), abandoning the weekly dose limit and setting an annual occupational limit of 5 rem, followed by a public limit of 0.5 rem/year (50 mSv).  A major shift occurred in 1977 (Publication 26) with the adoption of the Sievert unit and the introduction of effective dose equivalent, alongside cost-benefit assessment and concepts like radiation health detriment. Subsequent changes in 1991 (Publication 60) reduced the occupational limit to 20 mSv/year, while public exposure was limited to 1 mSv/year averaged over five years. Finally, Publication 103 in 2007 updated guidelines based on the most recent scientific data and shifted towards an exposure situation-based approach. 

Reference: MolecularRadiationBiology, Section 8.7.1 Introduction: History","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.7	 Radiation Protection System/Risk Coefficients, Organ Weighting Factors, and Dose Limits | Sub-subsection: 8.7.1	 Introduction: History | Content: Since the discovery and the rapid introduction and exploi­
tation of ionizing radiation in medicine, technology and
industry, the limited knowledge about the detrimental health
effects of radiation led to the exposure of many individuals to
high doses, and subsequently to various radiation exposure
related health effects such as cancer [131, 132].
Guidelines for radiation protection purposes started as
early as the 1890s with more detailed dose limits being
released as more research was being published. However,
as the detrimental effects of radiation became more known,
and more research was being published about its negative
side effects, the need for a cohesive set of guidelines and
regulations became more apparent. At the second Interna­
tional Congress of Radiology, held in Stockholm in 1928,
a new unit was proposed for quantifying ionizing radiation,
specifically for the purpose of radiation protection. The unit
was named Röntgen, after the discoverer of X-rays. It was
also during this congress that the International X-Ray and
Radium Protection Committee (IXRPC) was founded, which
would later be known as the Commission for Radiation Pro­
tection (ICRP). The first dose limit recommendation by the
IXRPC came in 1934. These stated that a person in normal
health can tolerate 0.2 roentgens of X-rays per day. This
would correspond to approximately an annual effective dose
of 500 mSv; a dose 25 times higher than the current annual
dose limit for occupational workers. No dose limit recom­
mendation was given for γ-rays at this point.
Separate from the IXRPC, a document was published in the
1930s, outlining many protective methods and techniques to
shield from the harmful effects of radiation. This report was
commissioned by what would later become the United Nations
Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR). The comments on permissible dose were vague,
however. In the following years, several recommendations were
being made by various bodies. Around this time, terminology
also began changing, and the previously used “tolerance dose”
was changed to “maximum permissible dose.” In 1946, the
US advisory Committee was re-­established as the National
Council on Radiation Protection and Measurements (NCRP)
and amended their initial recommendations to now allow a
maximum permissible dose of 0.05 Roentgen/day, expressed
at that time as 0.3 Roentgen/week [133]. This reduction was
largely due to the growing evidence of the hereditary harm of
radiation. This new guideline was also echoed by the ICRP in
1950, when they also proposed a weekly maximum permis­
sible dose of 0.3 Roentgen. The reduction from their previous
1934 recommendations of 0.2 Roentgen/day corresponded to 1
Roentgen/week, which was then seen as being too close to the
threshold of adverse effects [134].
The first publication by the ICRP came in 1955; here a
clear distinction was made between the levels allowed for
public and occupational exposure, public exposure allow­
ance was reduced by a factor of 10 from what was allowed
for occupational exposure. Recommendations on permissi­
ble doses were given for various organs. New units were also
introduced, with the rad (now corresponding to 0.01 Gy)
being used for absorbed dose, and rem as the RBE weighted
unit (corresponding today to 0.01 Sv) [135]. In 1958, the
ICRP published what is now known as “Publication 1”. The
concept of a weekly dose limit was abandoned, and the new
annual occupational dose limit was 5 rem, with a public limit
of 0.5 rem/year (50 and 5 mSv respectively) [136].
Changes to terminology and units were revised once again
in 1977, in publication 26. The Sievert replaced the rem, and
Box 8.5 Methods for Biological Dosimetry
•	In biological dosimetry biomarkers are used to ver­
ify exposure to ionizing radiation and to estimate
the absorbed dose.
•	The analysis of dicentric chromosomes is consid­
ered as “gold standard” in biological dosimetry
after an acute radiation exposure.
•	According to the radiation scenario other cytoge­
netic methods are available (CBMN, FISH; PCC).
•	Relatively new methods on the molecular level are
gamma-H2AX foci assay and analysis of changes
in the gene expression.
R. Wilkins et al.
461
effective dose equivalent was introduced. More thought was
also being placed on cost benefit assessment and the concept
of radiation health detriment was introduced. Three general
rules for the use of radiation were also introduced, justifica­
tion, optimization and individual dose limitation. The term
maximum permissible dose was replaced by dose limit; how­
ever, no changes were made to the guidelines, a dose limit
of 50 mSv remained for occupational workers, with a public
dose limit of 5 mSv [137]. In 1991, publication 60 reduced the
occupational dose limit from 50 mSv to 20 mSv/year, aver­
aged over 5 years. Public exposure was now limited to 1 mSv,
with higher exposer levels being permissible as long as the
annual average over a span of 5 years did not exceed 1 mSv. A
radiation weighting factor was introduced, and the measure of
dose equivalent was replaced by quantity equivalent dose. As
there were now also tissue weighting factors for many more
organs, effective dose equivalent was also replaced by the term
effective dose [3]. The latest recommendations were issued in
2007 (publication 103) updating consolidating and developing
additional guidance on the protection from radiation sources.
One of the main characteristics of publication 103, is that it
evolves from the previous process-based protection approach
(practices and interventions) to an approach based on the
exposure situation (planned emergency and existing exposure
situations). The radiation and tissue weighting factors, effec­
tive dose and detriment are updated based on the most recent
scientific data available. Finally, ICRP 103 focuses also on the
radiological protection of the environment [34].
8.7.2
Organ Weighting Factors, Risk
Coefficients, and Dose Limits
Ionizing radiation can have severe damaging effects in the
human body. These harmful effects can be classified into two
general categories: the deterministic effects and the stochastic
effects. The deterministic effects are due to the killing or mal­
function of cells after exposure to high radiation doses. The
stochastic effects refer to either cancer or hereditary effects
due to mutations of somatic cells or germ cells respectively.
The deterministic effects are manifested when the dose
exceeds the dose threshold for a given effect [85]. These
effects appear mostly after high irradiation doses. These
thresholds are essential in preventing risk of morbidity in
specific cell populations and overall mortality [32]. Tissues
generally have different threshold dose baselines for these
deterministic effects which depend on the radiosensitivity of
the cells and the functional reserve of the tissue.
Depending on the absorbed dose and the type and energy
of the radiation source, the equivalent dose (HT, mSv) for
individual organs can be calculated. Equivalent dose (HT) is
the absorbed dose, in tissue or organ T weighted for the type
and quality of radiation R.
It is defined by the following equation:

(8.1)
T,R
R
­
R
­
R
8.17
When the radiation field is composed of types and ener­
gies with different values of wR, the total equivalent dose, HT,
is given by:

(8.2)
The stochastic effects are characterized for not having a
known threshold and include cancer and hereditary disor­
ders. The stochastic effects can represent a serious risk even
at low doses of ionizing radiation, especially if the dose
exceeds 100 mSv. The risk of induction represents the value
of the effective dose absorbed in the whole organism. The
effective dose is related to the health status detriment caused
by stochastic effects. Because the tissues differ in their sen­
sitivity to radiation, a tissue weighting factor (wT) has been
determined. wT is the factor by which the equivalent dose
in a tissue or organ T is weighted to represent the relative
contribution of that tissue or organ to the total health detri­
ment resulting from uniform irradiation of the body [34]. It
is weighted such that
s
i
g
m
a summation Underscript upper T Endscripts w Subscript upper T Baseline equals 1.
The effective dose (E) can be calculated as the sum of the
weighted equivalent doses in all the tissues and organs of the
body from internal and external exposure. It is defined by:

(8.3)
T,R
R
T
8.18
Table 8.17 Radiation weighting factors, as defined in the ICRP 103.
All values relate to the radiation incident on the body or, for internal
sources, emitted from the source (reproduced with permission from
[34])
Radiation type
wR
Photons
Electrons and muons
Protons and charged ions
Alpha particles, fission fragments, heavy ions
Neutrons, En < 1 MeV
Neutrons, 1 MeV ≤ En ≤ 50 MeV
Neutrons En > 50 MeV
1
1
2
20
2.5 p
lu
s
18
.
2
n
o
rm
al
e Superscript minus left bracket ln left parenthesis upper E Super Subscript n Superscript right parenthesis right bracket squared divided by 6
5 p
l
u
s
1
7
no
rm
a
l
e
Superscript minus left bracket ln left parenthesis 2 upper E Super Subscript n Superscript right parenthesis right bracket squared divided by 6
2.
5 p
lus
3
.
2
5
n
o
r
m
a
l
e
S
u
perscript minus left bracket ln left parenthesis 0.04 upper E Super Subscript n Superscript right parenthesis right bracket squared divided by 6
8 Radiobiology of Accidental, Public, and Occupational Exposures"
"The concept of tissue weighting factors (wT) is central to radiation risk assessment. Explain the purpose of wT values and how they are utilized in calculating the effective dose following ionizing radiation exposure, referencing the equation involving summation and weighted doses.","Tissue weighting factors (wT) represent a critical component of radiation protection by acknowledging that different tissues within the body exhibit varying sensitivities to ionizing radiation. The primary purpose of wT values is to account for this differential sensitivity when estimating the overall health detriment resulting from uniform irradiation across the entire body. These factors are used in conjunction with the equivalent dose (D, measured in Sieverts) in a specific tissue or organ to determine its contribution to the total risk.  The equation provided (T,R = R * wT) demonstrates this: the equivalent dose in tissue T is multiplied by its corresponding weighting factor (wT) to reflect its relative importance in determining the overall health effect. The summation of these weighted doses across all tissues and organs ultimately yields the effective dose (E), which represents the total risk from radiation exposure.  The value of wT is determined such that the sum of the weighted equivalent doses equals 1, reflecting the entire organism's response to uniform irradiation.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.7	 Radiation Protection System/Risk Coefficients, Organ Weighting Factors, and Dose Limits | Sub-subsection: 8.7.2	 Organ Weighting Factors, Risk Coefficients, and Dose Limits | Content: the absorbed dose, in tissue or organ T weighted for the type
and quality of radiation R.
It is defined by the following equation:

(8.1)
T,R
R
­
R
­
R
8.17
When the radiation field is composed of types and ener­
gies with different values of wR, the total equivalent dose, HT,
is given by:

(8.2)
The stochastic effects are characterized for not having a
known threshold and include cancer and hereditary disor­
ders. The stochastic effects can represent a serious risk even
at low doses of ionizing radiation, especially if the dose
exceeds 100 mSv. The risk of induction represents the value
of the effective dose absorbed in the whole organism. The
effective dose is related to the health status detriment caused
by stochastic effects. Because the tissues differ in their sen­
sitivity to radiation, a tissue weighting factor (wT) has been
determined. wT is the factor by which the equivalent dose
in a tissue or organ T is weighted to represent the relative
contribution of that tissue or organ to the total health detri­
ment resulting from uniform irradiation of the body [34]. It
is weighted such that
s
i
g
m
a summation Underscript upper T Endscripts w Subscript upper T Baseline equals 1.
The effective dose (E) can be calculated as the sum of the
weighted equivalent doses in all the tissues and organs of the
body from internal and external exposure. It is defined by:

(8.3)
T,R
R
T
8.18
Table 8.17 Radiation weighting factors, as defined in the ICRP 103.
All values relate to the radiation incident on the body or, for internal
sources, emitted from the source (reproduced with permission from
[34])
Radiation type
wR
Photons
Electrons and muons
Protons and charged ions
Alpha particles, fission fragments, heavy ions
Neutrons, En < 1 MeV
Neutrons, 1 MeV ≤ En ≤ 50 MeV
Neutrons En > 50 MeV
1
1
2
20
2.5 p
lu
s
18
.
2
n
o
rm
al
e Superscript minus left bracket ln left parenthesis upper E Super Subscript n Superscript right parenthesis right bracket squared divided by 6
5 p
l
u
s
1
7
no
rm
a
l
e
Superscript minus left bracket ln left parenthesis 2 upper E Super Subscript n Superscript right parenthesis right bracket squared divided by 6
2.
5 p
lus
3
.
2
5
n
o
r
m
a
l
e
S
u
perscript minus left bracket ln left parenthesis 0.04 upper E Super Subscript n Superscript right parenthesis right bracket squared divided by 6
8 Radiobiology of Accidental, Public, and Occupational Exposures
462
Table 8.19 Nominal risk coefficients for cancer and hereditary effects
(10−2 Sv−1) (reproduced with permission from [34])
Exposed population
Cancer
Hereditary effects
Total
General
Workers
5.5
4.1
0.2
0.1
5.7
4.2
Table 8.20 Recommended dose limits in planned exposure situations
(reproduced with permission from [34])
Type of limit
Occupational
Public
Effective dose
20 mSv/yeara,b1 mSv in a yearc
Annual equivalent dose in
Lens of the eye
20 mSv/yeara,d15 mSv
Skin (averaged over 1 cm2 of skin)500 mSv
50 mSv
Hands and feet
500 mSv
–
a 100 mSv in 5 years (averaged over 5 consecutive years), with no single
year exceeding 50 mSv
b After a worker declares a pregnancy, the dose to the embryo/fetus
should not exceed about 1 mSv during the remainder of the pregnancy
c Value applies to the average value over a period of 5 years
d Revised value by ICRP Statement on tissue reactions in ICRP publica­
tion 118 [32]
Table 8.18 Tissue weighting factor (wT) values (reproduced with per­
mission from [34])
Tissue
wT
ΣwT
Bone-marrow (red), colon, lung, stomach, breast,
remainder tissuesa (nominal wT applied to the
average dose to 14 tissues)
0.12
0.72
Gonads
0.08
0.08
Bladder, esophagus, liver, thyroid
0.04
0.16
Bone surface, brain, salivary glands, skin
0.01
0.04
a Remainder tissues (14 in total): adrenals, extrathoracic (ET) region,
gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa,
pancreas, prostate, small intestine, spleen, thymus, uterus/cervix
­
­
­
­
­
8.19
­
8.20
85
8.8"
"The provided text lists several organs potentially affected by radiation exposure, including the bladder, esophagus, liver, and thyroid. Considering the mechanisms of radiation damage – primarily DNA damage leading to cell death – explain why these specific organs, particularly those with high rates of cell division (like the thyroid) or significant iodine uptake (like the thyroid), would be expected to exhibit greater sensitivity to ionizing radiation compared to, for example, bone or skin.","The heightened sensitivity of organs like the bladder, esophagus, liver, and thyroid to ionizing radiation stems from several key factors related to their physiology and cellular characteristics. Firstly, these organs are involved in rapid cell division processes – the bladder lining cells constantly regenerate due to urine flow, esophageal epithelial cells rapidly replace themselves after damage, and hepatocytes (liver cells) undergo frequent mitosis. Secondly, DNA damage is a primary mechanism of radiation injury, and damaged DNA triggers cell cycle arrest or apoptosis (programmed cell death). Because these organs have high rates of cell division, they accumulate more DNA damage per unit time than tissues with slower turnover rates like bone or skin. Thirdly, the thyroid gland possesses a unique vulnerability due to its highly vascularized tissue and significant iodine uptake capacity. Radiation can directly induce the formation of radioactive iodine within the thyroid, leading to localized hyperthyroidism and potentially severe consequences including hypothyroidism and tumor development. The esophagus is particularly vulnerable because radiation passes through it relatively quickly, exposing the rapidly dividing epithelial lining to a high dose. Finally, while the liver has regenerative capabilities, its extensive vascular network allows for rapid distribution of radiolytic products (chemicals formed when radiation interacts with water) which can exacerbate cellular damage. Therefore, the combination of rapid cell division and vulnerability to DNA damage makes these organs disproportionately susceptible to ionizing radiation compared to tissues with lower proliferative rates or less efficient mechanisms for dealing with radiolytic products.","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.8	 Exercises and Self-Assessment | Content: Bladder, esophagus, liver, thyroid
0.04
0.16
Bone surface, brain, salivary glands, skin
0.01
0.04
a Remainder tissues (14 in total): adrenals, extrathoracic (ET) region,
gall bladder, heart, kidneys, lymphatic nodes, muscle, oral mucosa,
pancreas, prostate, small intestine, spleen, thymus, uterus/cervix
­
­
­
­
­
8.19
­
8.20
85
8.8
Exercises and Self-Assessment
Q1.	When radon is inhaled the largest dose is found at the
level of the
(a)	Mouth
(b)	Bronchial wall
(c)	Bifurcation of the trachea
(d)	Alveoli
Q2.	When is the initial triage used?
Q3.	How many categories of priority are used in initial
triage?
Q4.	What methods of treatment are used for internal con­
tamination with radionuclides?
Q5.	In hematopoietic syndrome the death is mainly due to
(a)	Anemia
(b)	Dyspnea
(c)	Hemorrhage and infection
(d)	Thrombopenia
Q6.	In gastrointestinal syndrome the death is mainly due to
(a)	Anemia
(b)	Fever
(c)	Vomiting
(d)	Circulatory collapse
Q7.	The LD50 for humans is about without medial support
measures is
(a)	1 Gy
(b)	4 Gy
(c)	10 Gy
(d)	50 Gy
R. Wilkins et al.
463
Q8.	Discuss the most appropriate biodosimetric assay(s) for
use in a suspected cases of radiation exposure which
occurred approximately?
(a)	12 h ago
(b)	1 month ago
(c)	1 year ago
8.9"
"Following exposure to ionizing radiation, a key cellular response is the phosphorylation of histone H2AX. Explain the significance of this event and its role in subsequent DNA repair processes.","The rapid phosphorylation of histone H2AX (γ-H2AX) represents a crucial initial response to DNA double-strand breaks induced by ionizing radiation. This phenomenon serves as a widespread marker of DNA damage, essentially ‘flagging’ the affected regions for repair. The mechanism begins with the direct interaction between ionizing radiation and the phosphate backbone of histones within chromatin. This interaction triggers a cascade of phosphorylation events, predominantly mediated by kinases such as ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related). γ-H2AX recruits DNA repair proteins to the site of damage, forming a nucleus around the break. Specifically, it facilitates the recruitment of 53BP1, a key protein involved in homologous recombination repair pathways. Furthermore, γ-H2AX promotes chromatin condensation at the damaged site, limiting the spread of breaks and preventing non-homologous end joining (NHEJ), which is prone to errors. The level of γ-H2AX correlates with the extent of DNA damage; higher levels indicate more severe radiation exposure. Ultimately, this phosphorylation event initiates a complex signaling pathway that orchestrates the repair process, contributing significantly to cellular survival after irradiation. Reference: [Molecular Radiation Biology], Section 8.9 – Exercise Solutions","Document: MolecularRadiationBiology | Section: 8: Radiobiology of Accidental, Public, and Occupational Exposures | Subsection: 8.9	 Exercise Solutions | Content: SQ1.	c
SQ2.	Initial triage is used to screen the patients with severe
injuries after a mass biological, chemical, radiological
or nuclear event.
SQ3.	Four categories of priority.
SQ4.	Isotope blocking, dilution, or displacement, and the
use of ion exchange resins, and ion mobilization or
chelation.
SQ5.	c
SQ6.	d
SQ7.	b
SQ8.	The data in Sect. 8.6 should be referred to in order to
formulate a full answer, based on the scenario of expo­
sure. However, the short answers are: (a) ­gamma-­H2AX
and dicentric assays; (b) dicentric or CBMN assays;
(c) FISH translocation assay."
"Describe the process of bacterial conjugation, detailing the roles of the donor cell (F+), recipient cell (F-), and the resulting genetic exchange.","Bacterial conjugation is a specialized form of horizontal gene transfer that allows for direct DNA transfer between two bacterial cells. It’s primarily mediated by plasmids, specifically the F plasmid (fertility factor). The process begins with the formation of a pilus, a protein appendage extending from the donor cell (F+), which physically attaches to the recipient cell (F-). Once connected, a mating bridge – a temporary channel – forms between the two cells. This bridge facilitates the one-way transfer of DNA from the F plasmid within the donor cell to the recipient cell. The F plasmid contains genes necessary for pilus formation and conjugation itself. During transfer, a single strand of circular F plasmid DNA is copied by the donor cell and threaded through the mating bridge into the recipient cell. Once inside the recipient, this single-stranded DNA integrates into the recipient’s chromosome via homologous recombination, converting the F- cell to an Hfr (High Frequency of Recombination) cell. Importantly, not all transferred DNA always integrates; sometimes, a complete copy of the plasmid is taken up. Following conjugation, the mating bridge breaks, and both cells return to their original states – the donor remains F+, and the recipient becomes Hfr. This process significantly contributes to bacterial genetic diversity and adaptation within microbial populations.

Reference: Prescott’s Microbiology, 8th Edition, Section 15.3 – Conjugation.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Content: Joana Lourenço, Carmel Mothersill, Carmen Arena,
Deborah Oughton, Margot Vanheukelom, Ruth Pereira,
Sónia Mendo, and Veronica De Micco
9.1"
"Considering the complexities outlined in Section 9.1 regarding environmental radiobiology, explain why extrapolating results from laboratory studies focusing on single species to broader ecosystem assessments presents significant challenges, specifically referencing the potential for misleading conclusions due to factors like chronic exposure and confounding variables.","Extrapolating findings from controlled laboratory experiments involving single organisms to complex ecological systems is fraught with difficulty due to several critical differences. Primarily, environmental radiobiology studies demonstrate that radiation effects often manifest at population or ecosystem levels, far exceeding the acute impacts observed in isolated organisms. Laboratory studies frequently utilize high doses and short exposure durations, which are rarely representative of natural conditions. In ecosystems, chronic, low-level exposures are common, and these can induce subtle but significant changes over extended periods – a factor largely absent from traditional laboratory investigations. Furthermore, numerous confounding variables complicate the picture; these include genetic diversity within populations, variations in age and life stage impacting radiosensitivity, predation pressures, resource availability, and interactions with other environmental stressors (e.g., pollution or climate change). These factors can dramatically alter an organism’s response to radiation, leading to inaccurate interpretations when extrapolated from a simplified model. The complexities of measuring impacts at the ecosystem level—including assessing functions and services—further exacerbate these challenges, highlighting the need for robust biomarkers and sophisticated monitoring techniques like those employed in ‘Radioecological Observatories.’ Reference: [MolecularRadiationBiology, Section 9.1 – Introduction]","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.1	 Introduction | Content: Environmental radiobiology refers to the study of the effects
of radiation on ecosystems and species that are part of vari­
ous habitats, collectively known as “the environment.” The
discipline is part of Radioecology which is a broad area of
research, covering the transfer, uptake and effects of radio­
nuclides in the environment. Radioecology includes, for
example, the speciation of radionuclides in environmental
media, the transfer of radionuclides through the different
environmental compartments and exposure of wildlife to
ionizing radiation and its consequences. While this chapter
focuses predominantly on the biological and ecological
impacts of radiation on non-human species—since transfer
is a key aspect of wildlife dosimetry—the environmental
behavior of key radionuclides is briefly covered in Sect. 9.2.
It is important to understand that the basic mechanisms
that lead to effects in humans, discussed in earlier chapters,
also occur in non-human biota, but the effects of concern lie
at higher levels of organization, such as the population or
ecosystem. For example, a harmful mutations induced by
radiation exposure may lead to cancer on humans, but in the
environment, where the sustainability of the population is a
critical endpoint, low levels of carcinogenic mutations are
unlikely to impact the overall population. This means that
J. Lourenço (*) · S. Mendo
Department of Biology & CESAM, University of Aveiro,
Aveiro, Portugal
e-mail: joanalourenco@ua.pt; smendo@ua.pt
C. Mothersill
Faculty of Science, McMaster University, Hamilton, ON, Canada
e-mail: mothers@mcmaster.ca
C. Arena
Department of Biology, University of Naples Federico II, Naples, Italy
e-mail: c.arena@unina.it
D. Oughton
Norwegian University of Life Sciences (NMBU), Ås, Norway
e-mail: deborah.oughton@nmbu.no
M. Vanheukelom
Biosphere Impact Studies, Belgian Nuclear Research Centre, SCK
CEN, Mol, Belgium
e-mail: margot.vanheukelom@sckcen.be
R. Pereira
GreenUPorto—Sustainable Agrifood Production Research Centre/
Inov4Agro, Department of Biology, Faculty of Science of the
University of Porto, Campus de Vairão, Vila do Conde, Portugal
e-mail: ruth.pereira@fc.up.pt
V. De Micco
Department of Agricultural Sciences, University of Naples
Federico II, Naples, Italy
e-mail: demicco@unina.it
Learning Objectives
At the end of this chapter, the reader should be able to:
•	Know the basic concepts associated with environ­
mental radioactivity
•	Know the challenges involved in measuring impacts
of radiation in the environment
•	Know the methodologies and tools available to
measure the dose and effect at the level of the indi­
vidual, population, and ecosystem
•	Know the effects of ionizing radiation in living
organisms from microorganisms to vertebrates
•	Know the basic molecular effects associated with
high and low Linear Energy Transfer (LET)
radiation
•	Understand the concept of radiosensitivity and its
relation with organism’s complexity and life stage
•	Understand the mechanisms underlying microbial
tolerance and/or resistance to radionuclides and
metals
•	Understand the complexity of natural environments
and the consequent limitations of laboratory
studies
•	Understand the particularities associated with
NORM contamination
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_9
470
the tools and techniques needed to document and evaluate
radiobiological effects in natural populations, and ultimately
in ecosystems, are much more complex to those used in
human radiobiology.
A key issue is the importance and the difficulty of con­
ducting good experiments in field situations, particularly at
environmentally relevant concentrations and with proper
controls. Single species studies in the laboratory have an
important role in determining high and low dose effects,
understanding mechanisms and testing resistance. But results
can be misleading if they are extrapolated to environmental
conditions, with lower doses, chronic exposures, and a vari­
ety of confounding factors such as genetics, age, life stage,
predation, availability of resources, as well as the interaction
with other stressors and difficulties to make a proper dosim­
etry [1].
Another important issue is how to measure impacts on
ecosystems. Several robust biomarkers are available to deter­
mine impacts at the level of the gene, cell, tissue, organ, and
organism. These are discussed in Sects. 9.3 and 9.4 of this
chapter. Population level markers are also available includ­
ing population numbers, mortality and morbidity, fecundity
and population growth rate, but at the level of the ecosystem,
the complexity makes it very difficult to assess ecosystem
health following radiation exposure, including effects on
functions and services. The importance of legacy sites is dis­
cussed in Sect. 9.4, as natural labs like, for example,
“Radioecological
observatories”
(https://radioecology-­
exchange.org/content/radioecological-­observatories) where
all the mechanisms of effect from populations to ecosystems
can be deeply studied. Other approaches include measure­
ments of biodiversity index and the use of drone technolo­
gies to monitor ecosystem change at the gross level, for
example, forest cover and diversity, lake eutrophication, or
extreme habitat change.
9.2"
"Describe the process of biomagnification within a food chain, detailing how radionuclides can accumulate in organisms at higher trophic levels and the factors that influence this phenomenon.","Biomagnification refers to the increasing concentration of a substance, typically a pollutant or radionuclide, as it moves up through successive trophic levels in a food chain. This process occurs because primary producers (e.g., plants) absorb radionuclides from the environment – soil, water, or air. These radionuclides are then incorporated into the tissues of herbivores that consume these plants. Herbivores, in turn, accumulate even higher concentrations when consumed by carnivores. The process continues up the food chain, with each predator consuming multiple prey containing increasingly concentrated levels of the substance. Several factors contribute to biomagnification's effectiveness: first, the inefficiency of metabolism – organisms don’t typically excrete or rapidly metabolize absorbed radionuclides; second, the longer residence time within an organism’s tissues; and third, the lack of efficient removal mechanisms like excretion. The magnitude of biomagnification is also influenced by factors such as lipid solubility (radionuclides tend to accumulate in fatty tissues), bioavailability (the extent to which a substance is available for uptake), and the specific radionuclide involved – some radionuclides are more readily absorbed and retained than others. Furthermore, food web complexity and the number of trophic levels significantly impact the overall accumulation potential. Finally, the rate of transfer between trophic levels also plays a role; faster transfers lead to greater biomagnification.
Reference: Environmental Radiobiology, Section 9.2 – Behavior and Fate of Radioelements in the Environment","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.2	 Behavior and Fate of Radioelements in the Environment | Content: in the Environment
Transfer of anthropogenic radionuclides through food chains
has been studied since the time of atmospheric weapons test­
ing and has been supported by data from nuclear power gen­
eration and accidents, as well as studies of the behavior of"
The provided text discusses uncertainties in dosimetry related to internal radionuclides. How does understanding the behavior of naturally occurring radionuclides within the environment contribute to addressing these dosimetric uncertainties and supporting exposure assessments?,"The document highlights that significant uncertainties exist in measuring radiation effects on organisms, particularly concerning internal radionuclides. A critical component in mitigating these uncertainties lies in a thorough understanding of how naturally occurring radionuclides behave within environmental compartments – air, soil, water, and biota. Specifically, knowledge of these radionuclides’ behavior is fundamental for calculating background doses to organisms. This calculation allows for contextualizing anthropocentric exposure data against natural background levels, providing a crucial benchmark. Furthermore, characterizing the distribution and transformation pathways of naturally occurring radionuclides (such as <sup>238</sup>U, <sup>232</sup>Th, <sup>235</sup>U, etc.) within ecosystems is essential for accurate dosimetry. By understanding how these elements are absorbed, metabolized, and ultimately eliminated by organisms – a process heavily influenced by their environmental interactions – researchers can refine exposure models and reduce the inherent uncertainties associated with measuring biological effects from internal radiation sources. This approach directly supports more reliable dose assessments in areas with elevated natural radioactivity.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.2	 Behavior and Fate of Radioelements in the Environment | Sub-subsection: 9.2.1	 Naturally Occurring Radionuclides | Content: wealth of data on the transfer of radionuclides through
human food chains, there has been less focus on wildlife and
especially organisms that are not common sources of food
for humans such as insects and invertebrates. While much of
the focus in studying the environmental impacts of radiation
has been on the uncertainties in effects measurement, it is
important to stress that there are also uncertainties in dosim­
etry, and especially from internal radionuclides. Hence,
knowledge of the factors influencing the behavior of radio­
nuclides in the environment will be fundamental to support
dosimetry and exposure assessments. This includes informa­
tion on the behavior of naturally occurring radionuclides,
which is needed both to calculate background doses to
organisms, and thus put anthropocentric exposures into per­
spective, as well as to assess doses in areas with enhanced
levels of natural radioactivity.
9.2.1
Naturally Occurring Radionuclides
­
14
3
40
238
232
235
2
9.1
9.2
­
3
­
9.1
222
220
226
223
228
­
210
216
212
­
9.2.2
Radionuclide Interaction with Water,
Air, Soil, and Biota
­
9.2
­
4
The natural environment is a highly complex system in
which elements flow and circulate through the spheres of the
Earth. To simplify the study of radionuclides, the environ­
ment can be divided compartments such as air, surface and
J. Lourenço et al."
"The text highlights a significant challenge in assessing radiation exposure to biota: underestimation of internal dose rates. Specifically, what is the primary reason for this underestimation, and how does it relate to the types of radionuclides involved?","A major cause of underestimated internal doses in studies examining radiation effects on wildlife stems from a failure to adequately account for the uptake and retention of radionuclides by organisms. This is particularly pronounced with beta-emitting radionuclides (e.g., Sr) and gamma-emitting radionuclides (e.g., Ra), where internal exposure represents the dominant contribution to overall dose. The text emphasizes that many field studies incorrectly rely solely on ambient air dose rates, neglecting the substantial internal burden of these radionuclides accumulated through ingestion from contaminated soil, sediment, or food sources. Furthermore, variations in organism size and trophic level significantly influence radionuclide accumulation – smaller organisms like larval midge Chironomus tetans receive a greater alpha radiation dose due to higher concentrations within their gastrointestinal tracts compared to larger predators.  The tool itself attempts to address this by using concentration ratios (CR) which represent the activity concentration of radionuclides in biota, but these CRs can be subject to uncertainty and require careful consideration. Reference: [MolecularRadiationBiology, Section 9.2.3 Radionuclide Transfer and Exposure]","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.2	 Behavior and Fate of Radioelements in the Environment | Sub-subsection: 9.2.3	 Radionuclide Transfer and Exposure | Content: Information on the uptake of radionuclides to biota is vital
for calculating dose to the organisms, since both external and
internal irradiation contributes to exposure. Soil and sedi­
ment dwelling organisms often have high external dose rates
by virtue of their habitat, but also internal exposure from
ingested radionuclides. Many field studies on radiation
effects in wildlife are flawed due to underestimation of the
internal dose, reporting only ambient air dose rates [28]. This
is particularly important for 〈- (e.g., Ra) and ®-emitting
(e.g., Sr) radionuclides, for which internal exposure is the
greatest contributor to dose, but also internal contributions
from radiocesium or radium, for example, can make a sig­
nificant contribution to the overall dose.
There are a number of programs available for estimating
the dose to biota. These are usually based on rather simplistic
geometry and homogeneous internal distribution, but the
basic principles are similar to those used for human dosime­
try. They can also be adapted to give organ specific doses.
For example, the ERICA Assessment Tool can calculate
doses to a wide range of reference animals and plants, as
well as user constructed organisms (see Box 9.1).
Box 9.1 The ERICA Assessment Tool
The ERICA Assessment Tool is a free to download,
computer software system for assessing the risks of
ionizing radiation to terrestrial, freshwater and marine
biota (https://erica-­tool.com/). The system is based on
the three tier ERICA Integrated Approach that was
originally developed as part of the ERICA EURATOM
project [29] (see also https://wiki.ceh.ac.uk/display/
rpemain/ERICA).
The ERICA Tool includes various components, all
of which are linked to internationally recognized pro­
grams and databases. These include
––Modelling transfer of radionuclides through the
environment: links to IAEA Wildlife Transfer
Database (WTD) and IAEA handbooks [30];
https://www.wildlifetransferdatabase.org/.
––Methodology for estimating dose rates to biota
from internal and external distributions of radionu­
clides: ICRP biota DC software version 1.5.1 for
the calculation of dose conversion coefficients
(DCC) [31].
––Risk characterization in order to evaluate the sig­
nificance of the dose rates received by organisms,
including comparison with background radiation
doses, screening values [32], Environmental Media
Concentration Limits (EMCL) [33], derived con­
sideration reference levels (DCRL) and biological
effects
(FREDERICA
database,
https://www.
frederica-­online.org/mainpage.asp).
The tool contains data on concentration ratios and
DCC for all radionuclides in publication 107 [34], and
in addition to a selection of pre-created reference
9 Environmental Radiobiology
476
Internal and external exposures are determined from spe­
cific dose conversion factors (DCC) combined with using
field measurements of concentration activities or default
concentration ratios (CR). The CR represents the activity
concentration of radionuclides in biota (fresh and dry weight
in animals and plants, respectively) and the activity concen­
tration in soil (dry weight, upper 10 cm), water, or air for a
given radionuclide [38]. The tool also allows the calculated
exposures to be compared to background radiation or screen­
ing values.
The calculation of external dose rates takes account of the
occupancy of the organism (i.e., percentage of time spent in,
on, or above soil, sediment, or water) and is determined by:
DR—dose rate (Gy/unit of time)
DCC—dose conversion coefficient
Cmedia (Bq/kg or Bq/L)
Internal doses
DR—dose rate (Gy/unit of time)
DCC—dose conversion coefficient
Corganism (Bq/kg)
There are several other simplifications to the approach,
including assumptions on habitat ranges and feeding habits
of biota [38]. CR are lacking for many organisms and radio­
nuclides; however, the tool provides default CR based on
available data and assumptions (e.g., similar taxonomy or
chemical behavior to other organisms or radionuclides).
Uncertainties in dose estimates can be reduced if field
measurements are available, but determination of internal
concentrations of radionuclides can also be challenging, as
organisms may be too small for direct radiochemical analy­
ses, or it can be difficult to distinguish between radionuclides
internalized in animal tissues, from those adsorbed to the
body segment or cuticle. Efforts have been made to compare
ERICA default CRs with field measurements at Chernobyl,
showing a relatively good agreement between the CR values
calculated for many organisms [39]. However, it was con­
cluded that such similarity may have resulted from the broad
range of estimated CR values available [40].
In soil, Beaugelin-Seiller [41] concluded that DCC values
are highly dependent on factors such as the porosity and soil
water content, the body size of the organisms within other
factors. For ®-emitters, the difference in DCC values
recorded reached a factor of 3, between dry and saturated
soil conditions. The calculation of doses in organisms under
exposures to NORM is also highly dependent on ­assumptions
of equilibrium that must be made for several radionuclides
from the 238U decay series [42]. Usually a 100% equilibrium
is assumed, although different equilibrium percentages are
also accepted for radon, as it can escape to the atmosphere.
The positioning of organisms in the trophic chains and the
composition of their diets may be determinant for the magni­
tude of exposures. In a coastal sand dune system, under a
long-term contamination through atmospheric deposition
and sea-to-land transfer of radionuclides at Sellafield nuclear
reprocessing site (West Cumbria, England), Wood and col­
laborators [43] recorded high activity concentrations of
137Cs, 238Pu, 239+240Pu, and 241Am in soil detritivorous (e.g.,
Collembola and Isopoda) when compared with predators
(e.g., Coleoptera larvae). Within the same trophic level, these
authors also found significant differences in the whole-body
activity concentrations of different invertebrate groups. Size
also influences the internal doses to organisms. Dose calcu­
lations for two benthic invertebrates, the larval midge
Chironomus tetans and the amphipod Hyalella azteca, based
on estimations from NORM activity concentrations in sedi­
ments impacted by uranium mining demonstrated that the
smaller amphipod, received a greater dose of alpha irradia­
tion. This reflected the high content of ingested radionuclides
within the gastrointestinal tract and that as diameter of the
gastrointestinal tube decreases, the assessment factor (AF)
for ingested alpha-emitters increases, as more alpha-particles
are expected to reach the tissues of the organisms [42].
Therefore, it was suggested that the contribution of sediment
within the gastrointestinal tract for the calculation of internal
doses must be considered, and not only the activity concen­
trations of radionuclides recorded in external sediments.
In the case of accidents, there is also a need to account for
historical dose and radionuclide decay, since observed effects
may be a legacy of high levels of exposure after the accident.
These high exposures can also be a source of confounding
factors, since the initial damage may lead to indirect ecosys­
tem changes (such as the replacement of pine trees by less
sensitive species) [44]. While much of the focus in studying
the environmental impacts of radiation has been on the
uncertainties in effects measurement, it is important to stress
that there are also uncertainties in dosimetry.
organisms, allows users to create their own assessment
organism.
The ERICA tool has been updated since its original
release, and the current version, ERICA Tool 2.0 (beta
version released in November 2021—https://erica-­
tool.com/the-­erica-­assessment-­tool-­has-­been-­updated-­
to-­version-­2-­0/) includes updates on concentration
ratios, as well as new approaches for calculation of
dose contribution from short-lived progeny, noble
gases radon and thoron [35–37].
J. Lourenço et al.
477
9.3
Impacts of Ionizing Radiation on Non-­
human Biota
Following the discovery of X-rays by Wilhelm Roentgen in
1895 and of radioactivity by Henri Becquerel in 1896, stud­
ies on its effects started immediately. The detonation of the
atomic bombs over Hiroshima and Nagasaki in 1945 raised
the concern about the health impacts of radioactive contami­
nation and the behavior of radionuclides in the environment
[45]. Therefore, a great number of studies using a variety of
plants and animals have been performed since then.
­
­
46
­
46
9.3
45
­
­
­
­
47
­
47
­
45
9.3
­
­
4648
9 Environmental Radiobiology"
"Describe the molecular effects observed following exposure to ionizing radiation, differentiating between low and high Linear Energy Transfer (LET) radiation on DNA damage and repair mechanisms.","Ionizing radiation, regardless of its LET, induces a range of DNA damage primarily through the creation of single-strand breaks (SSBs), double-strand breaks (DSBs), abasic sites, apurinic/apyrimidinic (AP) sites, and oxidized base lesions. However, the *type* and *extent* of these damages are significantly influenced by LET. Low LET radiation (such as beta particles, gamma rays, and X-rays) primarily generates SSBs and oxidative clustered DNA lesions like SSBs, oxidized base lesions, and AP sites. These damage types are generally more repairable due to the efficiency of cellular repair mechanisms. Conversely, high LET radiation (including alpha particles and neutrons) tends to produce DSBs and complex DNA damage – specifically, closely spaced DNA lesions forming clusters. These clusters consist of two or more DNA lesions, often DSBs or oxidative clustered lesions like SSBs, oxidized base lesions, and AP sites, located in close proximity on opposite strands of the DNA molecule. Because these clustered lesions are exceptionally difficult for cellular repair systems to process efficiently due to their complexity and spatial arrangement, they are considered highly mutagenic and carcinogenic, frequently being repair-resistant or unrepairable. The inability of individual repair pathways to effectively address these closely spaced lesions leads to a retardation of repair processes and the generation of further damage. High LET radiation is strongly associated with DSB clustering and increased chromosome aberrations, while low LET radiation primarily results in oxidative clustered DNA lesions. Ultimately, high LET exposure often correlates with greater cell killing efficiency due to the accumulation of unrejoined DSBs, which are particularly detrimental to genomic stability.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.1	 Basic Molecular Effects of Low and High Linear Energy Transfer (LET) Radiation | Content: Basic Molecular Effects of Low and High
Linear Energy Transfer (LET) Radiation
­
­
­
­
­
­
51
52
­
5354
55
­
J. Lourenço et al.
479
quence of the attempt of the cell to repair sugar and base resi­
dues, which can be converted to SSBs (Single Strand Breaks)
and DSBs (Double Strand Breaks) [51]. If DNA is correctly
repaired, the cell will continue its cycle normally, if not, the
cell can undergo transformation as mutations and chromo­
some aberrations may occur or if the damage is too severe,
programmed cell death (apoptosis) will occur. The repair­
ability of the damage and the repair accuracy will depend on
damage severity and complexity. Low LET (beta particles,
gamma and X-rays) and high LET (alpha particles and neu­
trons) radiation exposure can cause several types of DNA
damage that are usually repairable, like SSBs, abasic and
apurinic and apyrimidinic sites and DSBs (Fig. 9.5).
However, the fraction of irreparable DNA damage depends
strongly on LET. High and low LET radiation exposure can
cause complex DNA damage, but this type of damage is
more frequently associated with high LET radiation.
Complex DNA damage is composed by closely spaced DNA
lesions that form clusters [51]. Clusters contain two or more
DNA lesions of the same or different origins, close to each
other and on opposite strands (bistranded lesions). These
lesions can be DSBs or non-DSBs oxidative clustered DNA
lesions like SSBs, oxidized base lesions, and oxidized apu­
rinic/apyrimidinic sites (AP sites) [51] (Fig. 9.5). These clus­
tered lesions have a high mutagenic and carcinogenic
potential since they are considered repair-resistant or even
unrepairable due to the relative inefficiency of DNA repair
systems to process such closely spaced and complex lesions.
As there are several DNA repair systems in the cells and each
of them is specialized in the processing of specific lesions,
when several types of lesions are closely spaced in the DNA
molecule, the different repair systems cannot act properly,
retarding the repair and often generating other lesions. High
LET radiation is mostly associated with the generation of
DSB’s clustered DNA lesions and low LET radiation to non-­
DSB’s oxidative clustered DNA lesions [51], but this is not
completely clear and needs further studies. High LET radia­
tion is also associated with increased frequency of chromo­
some aberrations, and also to a high frequency of unrejoined
DSBs and consequently with a higher cell killing efficiency,
as unrejoined DSBs are a cause of cell death.
9.3.2"
"Describe the diverse adaptations that microorganisms, particularly extremophiles, employ to survive exposure to ionizing radiation, citing specific examples of molecules and their protective functions.","Microorganisms have evolved remarkable resilience to ionizing radiation through a variety of adaptive mechanisms. Prokaryotes, including bacteria and Archaea, demonstrate this adaptability across a broad range of extreme conditions – temperature, pressure, salinity, pH, and crucially, radiation. Extremophiles, capable of thriving in multiple harsh environments simultaneously, are particularly noteworthy. These organisms produce several key molecules to combat the damaging effects of radiation. ‘Extremolytes,’ such as ectoine, play a vital role by forming protective water layers around cell structures and macromolecules, shielding them from UV light, heat, and dryness. Carotenoids function as chemical scavengers, mitigating oxidative stress by absorbing harmful UV radiation. Furthermore, microorganisms utilize enzymes and pigments that contribute to their radioresistance. The ability of these biomolecules to maintain cellular integrity and metabolic function under intense radiation pressure is fundamental to the survival of many microbial species in contaminated environments. Recent research utilizing metagenomic approaches continues to illuminate the specific genes and cell functions affected by radiation exposure, furthering our understanding of the molecular mechanisms underlying microbial radioresistance and the role of horizontal gene transfer in shaping these communities [56, 57, 58].","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.2	 Effects on Microorganisms | Content: Microorganisms, including fungi, can be seen as good indi­
cators of the ecosystem’s “health.” They include ubiquitous
and taxonomically diverse microorganisms that play impor­
tant key roles on diverse ecosystems’ function. Specifically,
with regard to radiation, microorganisms play a very impor­
tant role in the health of these systems and in their cleaning
and decontamination.
9 Environmental Radiobiology
480
9.3.2.1	An Overview on Microbial Radiobiology:
Radioresistance and Radiotolerance
Microorganisms play a key role in the biogeochemical cycle
of elements. In soils, they are important for organic matter
turnover and maintenance of soil structure and fertility. As
such, changes in the structure of microbial communities, by
either metals or radionuclides, can have indirect effects on the
above processes. Prokaryotes (bacteria and Archaea) have
dominated a large part of the history of our planet, occupying
virtually every “inhabitable” niche on earth. To be able to do
that they have adapted to withstand large ranges in: (1) tem­
perature, e.g., the hot temperatures found in hot springs and
fumaroles, and the contrasting cold temperatures found on
sea ice and polar regions, (2) pressure, e.g., deep sea, (3)
salinity, e.g., hypersaline lakes, (4) pH, e.g., acid mine drain­
age sites, and (5) radiation, e.g., naturally occurring (deserts
and high mountains, mining sites) and from nuclear contami­
nated sites [56]. Microorganisms that have adapted to such
environments are referred to as extremophiles or polyex­
tremophile (the latter being capable of withstanding different
extreme conditions simultaneously), and these conditions are
a requirement for their normal metabolic and biochemical
operation. Most of these microorganisms belong to the
domains Bacteria and Archaea although some fungal species
have also been described. To survive these harsh conditions,
extremophiles produce various primary and secondary
metabolites, such as extremolytes, enzymes, and pigments
[57]. Extremolytes, for example, are known to protect
extremophiles cell structures and macromolecules from their
harsh environments by forming protective water layers (e.g.,
ectoine), which is a co-solvent that shields proteins and cell
membranes from UV light, heat, and dryness [58] around
them or acting as chemical scavengers (e.g., carotenoids),
protecting cells and their structures from UV radiation and
oxidative stress [58]. Ultimately, the exceptional properties of
these biomolecules find possible applications in various
industrial sectors, in human healthcare, and well-being [59].
With regard to radioactively contaminated sites, microor­
ganisms play an essential role on the mobility, toxicity, and
distribution of radionuclides, through processes that include
reduction, uptake, and accumulation by the cells, biosorption,
and biomineralization with phosphates and carbonates [16].
Culture dependent and culture-independent approaches
have shown the effects of long-term exposure to metals
or radionuclides on individual species and on microbial
communities. In addition, they have allowed those spe­
cific genes and cell functions mostly affected by radiation
and metals to be identified, thus contributing to a better
understanding of the molecular mechanisms behind micro­
bial metal/radioresistance. Furthermore, the acquisition of
genetic determinants by horizontal gene transfer contrib­
utes to shape microorganisms and microbial communities
occupying these sites. More recently, refined metagenomic
approaches focusing on prokaryotic communities have been
employed and are expected to shed more light on the cells’
strategies to overcome radiation stress to remain operational.
J. Lourenço et al."
"Describe the mechanisms employed by microorganisms, particularly Deinococcus radiodurans, to achieve radioresistance and how these strategies have evolved through adaptation processes like experimental evolution.","Microorganisms exhibit remarkable resistance to ionizing radiation (IR) through a combination of DNA repair mechanisms and physiological adaptations. Notably, Deinococcus radiodurans demonstrates exceptional radioresistance, tolerating levels of IR that would be lethal to most organisms. This resistance is largely attributed to highly efficient DNA repair processes, primarily homologous recombination (HR) and non-homologous end joining (NHEJ), which rapidly mend damaged DNA strands following irradiation. Furthermore, Deinococcus actively regulates the expression of genes involved in these repair pathways, along with proteins that protect against oxidative stress and maintain DNA supercoiling – all crucial for preserving genomic integrity under radiation exposure. Experimental evolution studies have shown that populations of *E. coli* can evolve significantly increased radioresistance over multiple generations through smooth genetic alterations affecting DNA repair and metabolic functions.  Interestingly, Deinococcus’s adaptation also includes strategies to cope with desiccation, which appears linked to its overall radioresistance. The organism's ability to rapidly repair DNA damage is not solely due to radiation itself but likely a consequence of selective pressure in environments lacking the extreme radiation levels it typically encounters, making it an invaluable model for understanding these complex mechanisms.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.2	 Effects on Microorganisms | Sub-sub-subsection: 9.3.2.1	 An Overview on Microbial Radiobiology: Radioresistance and Radiotolerance | Content: bial metal/radioresistance. Furthermore, the acquisition of
genetic determinants by horizontal gene transfer contrib­
utes to shape microorganisms and microbial communities
occupying these sites. More recently, refined metagenomic
approaches focusing on prokaryotic communities have been
employed and are expected to shed more light on the cells’
strategies to overcome radiation stress to remain operational.
J. Lourenço et al.
481
The following section addresses in more detail some of
the mechanisms that contribute to the survival and mainte­
nance of microorganisms in these environments. We will end
by referring to the impact of more recent methodologies,
such as metagenomics and other omics technologies, and
their contribution to clarify aspects such as the impact of
these contaminants on the microorganisms and communities
that exist in these sites.
9.3.2.2	Mechanisms Underlying Microbial
Radiation Resistance: Cell Damage
and Repair
It has been reported that when radiosensitive microorgan­
isms are subjected to multiple high IR exposures, their resis­
tance increases [60]. This was recently demonstrated by
experimental evolution, where populations of Escherichia
coli very resistant to IR were generated in the laboratory,
after 100 selection cycles, and to which the dose needed to
kill 99% of the population increased from 750 Gy to about
3000 Gy [61]. Likewise, radioresistant species can become
even more resistant with repeated exposure [62]. This “mem­
ory” adaptation is associated with smooth genetic alterations
that affect DNA repair and metabolic functions. During this
process of adaptation, other physiological characteristics of
the microorganisms are profoundly affected as, for example,
growth which is slowed down, because the microorganism
must direct its energies to other processes, such as effectively
repairing the damaged DNA.
­
­
1
­
1 Homologous recombination (HR) repair: while in eukaryotes the pro­
cess occurs during meiosis and requires homologous DNA sequences,
in bacteria HR is a major DNA repair mechanism that facilitates the
incorporation of exogenous DNA.
2
­
62
Radioresistant microbial extremophiles have developed
strategies to survive and withstand dose rates that to the
majority of organisms, including humans, would result in
acute health effects [63]. It is believed that radioresistant
microorganisms possess highly efficient processes to repair
DNA damage. However, it has recently been demonstrated
that the repair mechanisms and the proteins involved are
common to those found in radiation sensitive microorgan­
isms [64].
The genus Deinococcus is probably the most well studied
and characterized and there is a great deal of information, to
what its radioresistance is concerned. Metabolically active
Deinococci vegetative cells can tolerate chronic radiation
levels of more than 100 Gy/h, whereas other bacteria,
Archaea, and fungi can be resistant to several kGy of acute
IR. D. radiodurans exhibits resistance to acute IR up to
15 kGy, to 60 Gy/h of chronic radiation, and also to high
levels of resistance to UV-C irradiation (100–295 nm), desic­
cation and oxidative stress. Thus, regarding the example of
Deinococcus radiodurans, it can be argued that it efficiently
and rapidly repairs DNA damage caused by IR. A number of
genes have been identified whose expression is activated
after irradiation, namely those encoding proteins associated
with (1) efficient DNA repair, (2) protection against oxida­
tion and (3) DNA supercoiling, which helps to maintain
DNA integrity after irradiation [65]. More recently, it was
demonstrated that in this organism, the adaptation to dryness
and desiccation is at the basis of its radioresistance [64].
Nonetheless, it has been reported that Deinococcus’ abil­
ity to repair DNA damage results from a selective pressure
other than ionizing radiation, because there are no terrestrial
environments subjected to the levels of radiation it tolerates.
Still, the information gathered, albeit with some degree of
uncertainty, has contributed to a better understanding of the
mechanisms of radioresistance in other organisms, making
this an excellent model organism to unravel these mecha­
nisms [66].
­
­
­
2 Non-homologous end joining (NHEJ) repair: in eukaryotic cells, DSB
are repaired predominantly by this pathway. Broken double-stranded
ends are repaired by direct ligation without the need for a homologous
template.
9 Environmental Radiobiology"
"Deinococcus radiodurans exhibits remarkable radioresistance due to its efficient DNA repair mechanisms. Specifically, what are at least three key processes or systems identified that contribute to this resistance, and how do they relate to the organism's ability to cope with ionizing radiation?","Deinococcus radiodurans demonstrates exceptional radioresistance primarily through a multifaceted approach centered around rapid and efficient DNA repair. Three crucial mechanisms involved are (1) Non-Homologous End Joining (NHEJ) repair, which allows for direct ligation of broken double-stranded DNA ends without requiring a homologous template – this is facilitated by proteins like pprI, essential for genome recovery; (2) Extended Synthesis-Dependent Strand Annealing (ESDSA), a process where single-stranded DNA overhangs are synthesized and then used to reconstruct the damaged chromosome through homologous recombination, supported by RecFOR pathway genes; and (3) rapid DNA supercoiling. Maintaining DNA integrity after irradiation is achieved through this mechanism. Furthermore, adaptation to dryness and desiccation plays a significant role in its resistance, likely due to protective mechanisms activated during these stressful conditions. The interplay of these factors – efficient repair, DNA stabilization, and environmental adaptation – collectively contribute to Deinococcus’s ability to withstand extreme levels of ionizing radiation [65, 66].","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.2	 Effects on Microorganisms | Sub-sub-subsection: 9.3.2.2	 Mechanisms Underlying Microbial Radiation Resistance: Cell Damage and Repair | Content: what its radioresistance is concerned. Metabolically active
Deinococci vegetative cells can tolerate chronic radiation
levels of more than 100 Gy/h, whereas other bacteria,
Archaea, and fungi can be resistant to several kGy of acute
IR. D. radiodurans exhibits resistance to acute IR up to
15 kGy, to 60 Gy/h of chronic radiation, and also to high
levels of resistance to UV-C irradiation (100–295 nm), desic­
cation and oxidative stress. Thus, regarding the example of
Deinococcus radiodurans, it can be argued that it efficiently
and rapidly repairs DNA damage caused by IR. A number of
genes have been identified whose expression is activated
after irradiation, namely those encoding proteins associated
with (1) efficient DNA repair, (2) protection against oxida­
tion and (3) DNA supercoiling, which helps to maintain
DNA integrity after irradiation [65]. More recently, it was
demonstrated that in this organism, the adaptation to dryness
and desiccation is at the basis of its radioresistance [64].
Nonetheless, it has been reported that Deinococcus’ abil­
ity to repair DNA damage results from a selective pressure
other than ionizing radiation, because there are no terrestrial
environments subjected to the levels of radiation it tolerates.
Still, the information gathered, albeit with some degree of
uncertainty, has contributed to a better understanding of the
mechanisms of radioresistance in other organisms, making
this an excellent model organism to unravel these mecha­
nisms [66].
­
­
­
2 Non-homologous end joining (NHEJ) repair: in eukaryotic cells, DSB
are repaired predominantly by this pathway. Broken double-stranded
ends are repaired by direct ligation without the need for a homologous
template.
9 Environmental Radiobiology
482
nase recA and pprA, which is a protein involved in DNA
ligation that is essential for the radiation resistance exhib­
ited by D. radiodurans. Strains lacking pprI show impaired
genome recovery [66]. Another important DNA repair system
involves the synthesis of long and single-stranded overhangs,
a process referred to as “Extended Synthesis-Dependent
Strand Annealing” (ESDSA).3 The process allows the recon­
struction of a functional genome from the chromosome frag­
ments produced by the exposure to radiation. Accordingly,
the process is used by the RecFOR pathway to repair DNA
double strand breaks. To support these observations, strains
mutated in the genes involved in the RecFOR pathway are
susceptible to γ-radiation [67].
Laboratory experiments with Escherichia coli, and other
mesophilic bacteria, have shown that these may become
resistant to the chronic exposure to IR just by adding Mn2+
and orthophosphate to its growth medium, which spontane­
ously form potent Mn-antioxidant complexes. Another
important factor associated with radioresistance is cell den­
sity. For example, in D. radiodurans high cell concentrations
seem to exert a protective effect against a radiation dose of
67 Gy/h [60]. Still, further and more complete studies are
required until we know all the phenomena that contribute to
the radioresistance exhibited by microorganisms. One thing
is certain, it results from the interplay of several factors.
9.3.3
Multiomic Approaches Applied
to the Study of Radioresistant
Microorganisms
Undoubtedly, multi-omics approaches (genomics, transcrip­
tomics, proteomics, and metabolomics) will shed light and
will further contribute to our understanding of the mecha­
nisms involved in microbial radioresistance and detoxifica­
tion. In order to contribute to a better understanding of the
mechanisms involved in uranium resistance/tolerance, a
recent high-throughput proteogenomic study was applied to
bacteria of the genus Microbacterium, isolated from
Chernobyl U contaminated soils and from natural U rich
soils. The approach allowed the identification of proteins
involved in membrane transport (e.g., ABC transporters and
efflux pumps), phosphate (e.g., phosphatases involved in
biomineralization) and iron metabolism (e.g., siderophores),
in addition to a large percentage of proteins of unknown
function, which reveals the complexity of this mechanism
[68]. Still, in another study carried out with a member of the
3 Extended Synthesis-Dependent Strand Annealing (ESDSA): a type of
homologous recombination where the sequence around a DNA double-­
strand break (DSB) is replaced by a copy of a homologous DNA tem­
plate, while the original configuration of the flanking regions is
maintained.
genus Geobacter exposed to 100 μM U, proteins involved in
DNA protection, in efflux pumps of the RND family and in
oxidative stress responses (e.g., SOD and superoxide reduc­
tase), were also identified. Exploring these recent approaches
will certainly allow us to gain knowledge that will contribute
to clarify this complex intricate process. Furthermore, they
will allow the selection for the best microorganism(s) with
the potential to clean-up these contaminated sites by more
eco-friendly processes. So far, in addition to the above study,
genomic approaches proved useful in the identification of
key genes and their respective products, encoded in the
genomes of microorganisms resistant/tolerant to radionu­
clides/metals and which are, therefore, involved in the detox­
ification of this contaminants. With this approach, U-resistant
bacteria of the genus Burkholderia and fungi of the genus
Penicillium have been identified. Transcriptomics studies, by
giving access to the analysis of gene expression and regula­
tion, have gained relevance in the area of bioremediation.
The information gathered from this comprehensive analysis,
and also from future studies employing these methodologies,
will surely shed light on the mechanisms of microbial resis­
tance/tolerance to radionuclides/metals, while helping in the
identification and selection of microorganisms that can be
employed for bioremediation purposes of radionuclide/met­
als contaminated sites [69].
9.3.3.1	Contribution of Metagenomics
Approaches to Understanding
Microorganisms’ Radioresistance
Unlike most laboratory studies, environmental exposure to
radionuclides, (e.g., NORM sites and nuclear power plant
accident sites), includes different radiation types (α and β, as
well as γ) combined with many other stressors (e.g., tem­
perature, nutrients, toxic chemicals like metals, etc.) over
long periods. Thus, in polyextremophiles, the response to the
adaptation/resistance should be broader and involve an intri­
cate crosstalk between the different cellular processes [70].
Culture-independent field studies have shown that radio­
nuclide contaminated environments host a wide diversity of
bacteria and that radionuclides strongly impact community
function and structure. Recently, a metagenomics approach
carried out in surface soil samples from Chernobyl and
Fukushima, over a gradient of radionuclide concentrations
(137Cs 1680—0.4 and 90Sr 209.1—1.9 kBq/kg), revealed that
samples clustered according to the level of radiological con­
tamination, irrespective of the collection site [71].
Nonetheless, a lower microbiota diversity was found in
Chernobyl samples, which was expected as Chernobyl soils
are more contaminated. The following were reported to be
the most common phyla: Proteobacteria, Acidobacteria and
Actinobacteria. Furthermore, as expected, the functions
encoded by the genes identified seem to be related with
stress, metal and radiation tolerance. For instance, genes
J. Lourenço et al."
"Describe the multiomic approaches being utilized to study microorganisms exhibiting resistance or tolerance to radionuclides and metals, specifically referencing examples from the provided text.","Researchers are employing a range of multiomic techniques – including genomics, transcriptomics, and metagenomics – to investigate microbial responses to ionizing radiation and associated stressors like metals. Genomic analyses have identified key genes involved in DNA protection, efflux pumps (specifically RND family members), and oxidative stress defense mechanisms (such as superoxide reductase and SOD) within organisms like *Geobacter*. Transcriptomic studies provide insights into gene expression regulation during these adaptive processes. Metagenomics, exemplified by studies conducted on soil samples from Chernobyl and Fukushima, reveals that microbial communities cluster based on radionuclide contamination levels, irrespective of the specific site. These analyses consistently identify genes related to stress, metal, and radiation tolerance within dominant phyla like Proteobacteria, Acidobacteria, and Actinobacteria. The ability to analyze these complex interactions across multiple layers of biological information is crucial for understanding the intricate mechanisms underlying radioresistance and ultimately selecting suitable microorganisms for bioremediation applications.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.3	 Multiomic Approaches Applied to the Study of Radioresistant Microorganisms | Content: maintained.
genus Geobacter exposed to 100 μM U, proteins involved in
DNA protection, in efflux pumps of the RND family and in
oxidative stress responses (e.g., SOD and superoxide reduc­
tase), were also identified. Exploring these recent approaches
will certainly allow us to gain knowledge that will contribute
to clarify this complex intricate process. Furthermore, they
will allow the selection for the best microorganism(s) with
the potential to clean-up these contaminated sites by more
eco-friendly processes. So far, in addition to the above study,
genomic approaches proved useful in the identification of
key genes and their respective products, encoded in the
genomes of microorganisms resistant/tolerant to radionu­
clides/metals and which are, therefore, involved in the detox­
ification of this contaminants. With this approach, U-resistant
bacteria of the genus Burkholderia and fungi of the genus
Penicillium have been identified. Transcriptomics studies, by
giving access to the analysis of gene expression and regula­
tion, have gained relevance in the area of bioremediation.
The information gathered from this comprehensive analysis,
and also from future studies employing these methodologies,
will surely shed light on the mechanisms of microbial resis­
tance/tolerance to radionuclides/metals, while helping in the
identification and selection of microorganisms that can be
employed for bioremediation purposes of radionuclide/met­
als contaminated sites [69].
9.3.3.1	Contribution of Metagenomics
Approaches to Understanding
Microorganisms’ Radioresistance
Unlike most laboratory studies, environmental exposure to
radionuclides, (e.g., NORM sites and nuclear power plant
accident sites), includes different radiation types (α and β, as
well as γ) combined with many other stressors (e.g., tem­
perature, nutrients, toxic chemicals like metals, etc.) over
long periods. Thus, in polyextremophiles, the response to the
adaptation/resistance should be broader and involve an intri­
cate crosstalk between the different cellular processes [70].
Culture-independent field studies have shown that radio­
nuclide contaminated environments host a wide diversity of
bacteria and that radionuclides strongly impact community
function and structure. Recently, a metagenomics approach
carried out in surface soil samples from Chernobyl and
Fukushima, over a gradient of radionuclide concentrations
(137Cs 1680—0.4 and 90Sr 209.1—1.9 kBq/kg), revealed that
samples clustered according to the level of radiological con­
tamination, irrespective of the collection site [71].
Nonetheless, a lower microbiota diversity was found in
Chernobyl samples, which was expected as Chernobyl soils
are more contaminated. The following were reported to be
the most common phyla: Proteobacteria, Acidobacteria and
Actinobacteria. Furthermore, as expected, the functions
encoded by the genes identified seem to be related with
stress, metal and radiation tolerance. For instance, genes
J. Lourenço et al."
"The text describes how metagenomic approaches are used to study microorganisms resistant to radionuclides and metals. Specifically, what types of genes and functions are frequently identified within the genomes of these radioresistant bacteria and fungi, as highlighted in studies conducted at Chernobyl and Fukushima?","Metagenomic analyses of radionuclide-contaminated environments, such as those at Chernobyl and Fukushima, consistently reveal a predominance of genes involved in stress responses, metal tolerance, and radiation resistance. Key functional categories identified include genes related to DNA repair and protection (suggesting mechanisms for mitigating damage from ionizing radiation), efflux pumps within the RND family (involved in transporting toxic metals out of the cell), oxidative stress response pathways utilizing enzymes like superoxide reductase and SOD (to combat reactive oxygen species generated by radiation exposure), and metabolic processes adapted for handling contaminants. Furthermore, genes associated with decontamination, information storage/processing, cellular signaling, and overall metabolism are commonly observed. These findings underscore the complex interplay between various cellular mechanisms that contribute to microbial radioresistance and tolerance to metal contamination.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.3	 Multiomic Approaches Applied to the Study of Radioresistant Microorganisms | Sub-sub-subsection: 9.3.3.1	 Contribution of Metagenomics Approaches to Understanding Microorganisms’ Radioresistance | Content: maintained.
genus Geobacter exposed to 100 μM U, proteins involved in
DNA protection, in efflux pumps of the RND family and in
oxidative stress responses (e.g., SOD and superoxide reduc­
tase), were also identified. Exploring these recent approaches
will certainly allow us to gain knowledge that will contribute
to clarify this complex intricate process. Furthermore, they
will allow the selection for the best microorganism(s) with
the potential to clean-up these contaminated sites by more
eco-friendly processes. So far, in addition to the above study,
genomic approaches proved useful in the identification of
key genes and their respective products, encoded in the
genomes of microorganisms resistant/tolerant to radionu­
clides/metals and which are, therefore, involved in the detox­
ification of this contaminants. With this approach, U-resistant
bacteria of the genus Burkholderia and fungi of the genus
Penicillium have been identified. Transcriptomics studies, by
giving access to the analysis of gene expression and regula­
tion, have gained relevance in the area of bioremediation.
The information gathered from this comprehensive analysis,
and also from future studies employing these methodologies,
will surely shed light on the mechanisms of microbial resis­
tance/tolerance to radionuclides/metals, while helping in the
identification and selection of microorganisms that can be
employed for bioremediation purposes of radionuclide/met­
als contaminated sites [69].
9.3.3.1	Contribution of Metagenomics
Approaches to Understanding
Microorganisms’ Radioresistance
Unlike most laboratory studies, environmental exposure to
radionuclides, (e.g., NORM sites and nuclear power plant
accident sites), includes different radiation types (α and β, as
well as γ) combined with many other stressors (e.g., tem­
perature, nutrients, toxic chemicals like metals, etc.) over
long periods. Thus, in polyextremophiles, the response to the
adaptation/resistance should be broader and involve an intri­
cate crosstalk between the different cellular processes [70].
Culture-independent field studies have shown that radio­
nuclide contaminated environments host a wide diversity of
bacteria and that radionuclides strongly impact community
function and structure. Recently, a metagenomics approach
carried out in surface soil samples from Chernobyl and
Fukushima, over a gradient of radionuclide concentrations
(137Cs 1680—0.4 and 90Sr 209.1—1.9 kBq/kg), revealed that
samples clustered according to the level of radiological con­
tamination, irrespective of the collection site [71].
Nonetheless, a lower microbiota diversity was found in
Chernobyl samples, which was expected as Chernobyl soils
are more contaminated. The following were reported to be
the most common phyla: Proteobacteria, Acidobacteria and
Actinobacteria. Furthermore, as expected, the functions
encoded by the genes identified seem to be related with
stress, metal and radiation tolerance. For instance, genes
J. Lourenço et al.
483
involved in decontamination, DNA repair, information stor­
age and processing, cellular processes and signaling and
metabolism. A comprehensive listing of the function of the
genes responsive to this type of contaminants has been
recently reviewed by Hoyos-Hernandez and co-workers
[71].
A similar approach was employed in a study performed
by Theodorakopoulos and colleagues [72], in Chernobyl,
which demonstrated the high diversity of bacteria in those
contaminated sites. The same authors isolated cultivable bac­
teria of the genus Microbacterium that were employed in
laboratory exposure studies, contributing to a better under­
standing of the mechanisms of tolerance to radionuclides/
metals in those bacteria. The identified mechanisms involve
biosorption, efflux and biomineralization [68].
Although further studies are required to better understand
how radiological contamination exerts a selective pressure
and how it shapes the structure of the microbial community,
the sensitivity of the various organisms to radioactive con­
tamination under environmental conditions generally
exceeds the sensitivity of the same organisms to experimen­
tal laboratory exposures [62]. It is clear though that commu­
nities from soils of these contaminated sites have functional
profiles that allow them to deal with this type of radiological
and chemical contamination. Furthermore, these environ­
ments constitute a genetic pool from which the phylogenetic
affiliation of cultivable and non-cultivable microorganisms
can be determined, thus allowing the identification of new
genes involved in the resistance to these contaminants, in
addition to further contributing to clarify those mechanisms.
9.3.4"
"How do plant responses to ionizing radiation vary depending on their developmental stage and genetic characteristics, as evidenced by studies following the Chernobyl and Fukushima disasters?","Plants exhibit a remarkable plasticity in their response to ionizing radiation, with variations strongly influenced by developmental stage and genetic makeup. Younger tissues, particularly meristems (e.g., branches and trunks), are significantly more vulnerable to damage than older tissues due to their higher metabolic activity and increased DNA replication rates. Genetic factors also play a crucial role; polyploid species demonstrate enhanced radioresistance because gene redundancy provides protection against mutations. Following the Chernobyl disaster, pine trees displayed dramatic alterations in trunk and branch morphology at meristems, indicating radiation-induced damage. Similarly, Japanese red pine and fir species after the Fukushima accident showed developmental anomalies mirroring those observed in Chernobyl. However, it remains uncertain whether these aberrations were solely due to direct radiation effects or compounded by other stressors like biotic factors and abiotic conditions. Furthermore, studies highlight that plant sensitivity is linked to chromosome volume; larger chromosomes correlate with greater radiosensitivity. Recent research suggests that non-lethal doses of ionizing radiation can actually increase plant resistance to environmental stresses through mechanisms such as increased production of reactive oxygen species (ROS)-mediated signaling and a boost in secondary metabolites, contributing to enhanced radioresistance.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.4	 Effects on Plants | Content: Plants are sessile organisms that cannot leave the surround­
ing environment if the ecological factors are not suitable for
their growth. Thus, under unfavorable circumstances, plants
have only the choice to perish or adapt to changing environ­
ments. The extreme physiological plasticity of plants allowed
their diffusion in all ecosystems of the Earth and today we
may have a comprehensive vision of the multitude of adapta­
tions carried out by these organisms in diverse places. Indeed,
plants such as other living organisms can adapt to cyclical
natural disturbances over time, developing the capacity for
endurance (resistance) and self-repair (resilience) in differ­
ent ecosystems.
Laboratory and field studies showed that ionizing radia­
tion may exert different effects on plant metabolism, growth
and reproduction, depending on plant developmental stage at
the time of exposure, plant physiological and morphological
traits, as well as genetic characteristics [73, 74]. Moreover,
depending on the dose or radiation type (low or high-LET),
ionizing radiation induces detrimental outcomes at high
doses, harmful consequences at intermediate levels and stim­
ulatory effects at low doses.
In some cases, ionizing radiation exposure increases
embryo lethality, induces dwarf architecture and modifies
floral elements [74] and literature herein. Other studies indi­
cated that some irradiated crops showed a taller architecture,
increased yields and reproductive success and the ability to
endure water shortage [75, 76]. As for many other ­organisms,
within plant cells, the nucleus is considered the primary site
of injury by ionizing radiation, which is responsible for ran­
dom DNA damage and generates different kinds of muta­
tions, such as deletions, base substitutions and chromosomal
alteration [74, 77]. There is a direct relationship between the
radiosensitivity of a plant and the average volume occupied
by a chromosome in the cell nucleus. If the chromosome vol­
ume is large, the plant will be more sensitive and, therefore,
the dose of ionizing radiation causing severe damages is less.
Hence, polyploid species exhibit a minor sensitivity to radia­
tion damage because gene redundancy protects polyploidy
from the deleterious effect of mutations [78]. Besides plant
cells, it is noteworthy that ionizing radiation may have differ­
ent impacts on organs and tissues. Generally, more complex
tissue architecture is less sensitive to damage; thus, young
tissues are more vulnerable than old [73, 79]. At functional
level, many studies have evidenced that radiation is danger­
ous for the photosynthetic apparatus. Generally, a decline of
photosynthesis often implicates damage to photosystem II
(PSII) and in particular to D1 protein, implicated in the right
functioning of photosynthetic electron transport. Together
with the impairment of PSII, a significant decrease of photo­
synthetic pigments and enzymes of the carbon assimilation
cycle was also detected [73].
The majority of information on the impacts of radioactiv­
ity on plants comes from studies carried out by scientists
after the nuclear disasters of Chernobyl (Ukraine) in 1986
and Fukushima (Japan) in 2011 [80].
Since 1986 the Chernobyl red forest has represented a liv­
ing laboratory for biologists to study for long-lasting plant
behavior in response to acute and chronic radioactive con­
tamination. The name “Red Forest” comes from the ginger-­
brown color of the pine trees as a result of the high radiation
levels immediately after the explosion of the nuclear plant.
Studies continued in the post-accident period and enlarged
the knowledge on the effects of acute and chronic radiation
on plants [81]. Generally different plant species show diverse
sensitivity to radiation, being shrubs more resilient than
conifers. The sensitivity of the pine compared to other tree
species was most apparent in the Chernobyl exclusion zone
and trees showed dramatic alterations in the morphology of
trunks and branches, indicating damage at meristems level
[82]. Following the Fukushima accident, despite the much
lower exposure levels, Japanese red pine (Pinus densiflora
Siebold & Zucc.) and Japanese fir (Abies firma Siebold &
9 Environmental Radiobiology
484
Zucc.) species showed developmental anomalies similar to
those observed in Chernobyl [83, 84]. However, it is uncer­
tain if the aberrations observed in Chernobyl are due to direct
effects of radiation on the trees or multiple stresses due to
biotic and other abiotic factors.
It is noteworthy that the quantity of radionuclides
absorbed by plants depends on their phenological stage and
growth status which, in turn, varies with the pedo-climatic
conditions and cultivation factors. Once deposited on the
vegetation and in particular on the leaf surface, the radioiso­
topes are absorbed through stomata and then transported to
the other organs including fruits, thus possibly entering the
food chain through edible leaves and fruits [85].
Today the Red Forest remains one of the most contami­
nated sites globally, and the surrounding forest area also rep­
resents an area of active research and scientific interest
because of the return of wildlife in the exclusion zone. Here,
the understory vegetation and deciduous (silver birch) trees
have reappeared, but radioactive dust still remains stored in
plant biomass and soil, for the very slow matter cycle.
The occurrence of revegetation has proven to be remark­
ably resilient to the intense radiation around the nuclear
disaster zone. The exclusion zone is now dominated by
grasslands and shrublands, while the most representative
trees are Scots pine and silver birch Betula pendula [74] and
literature herein.
Recent studies suggest that plants subjected to not-lethal
doses of ionizing radiation show an increased resistance to
other environmental stresses. Two strategies have been
hypothesized, namely the production of ROS-mediated cell
signaling and/or a boost of secondary metabolites [86].
The resilience to radiation in plants of the Chernobyl
exclusion zone and from most contaminated sites at
Fukushima is due to different mechanisms to protect the
genetic material, improving the plant radioresistance [80].
Generally, plants are more radioresistant than animals
because they present integrated adaptation mechanisms at
genetic, anatomical, and physiological levels.
At genetic level, mechanisms include the regulation of
expression of some genes encoding for radical scavenging
and DNA-repair enzymes, homologous and non-­homologous
recombination, and the activation of scavengers. The higher
stability induced by polyploidy, typical among plant king­
dom, enhances radioresistance thanks to the presence of
several copies of the same genes, which may serve as addi­
tional wild type copies in the case of radiation-induced inju­
ries [87]. At the structural and metabolism level, plant cells
present some traits such as thickened cell walls, cuticles,
pubescence, increased deposition of phenolic compounds
around membranes [88, 89]. At the anatomical level, com­
plex tissue organization is associated with high resistance to
mutagenic effects and the capability to adopt repair
mechanisms.
Non-lethal doses of ionizing radiation may also induce
hormesis improving plant defense against stressors, through
the stimulation of the production of antioxidant enzymes
(SOD, CAT, APX) or morpho-anatomical and photosynthetic
changes that favor plant growth and metabolism [74, 90, 91].
Radiation-induced hormesis is still an unclear phenome­
non in plants because it strongly depends on species intrinsic
characteristics. At present, further studies are in progress to
understand if it is a sort of compensation to irradiation dam­
age or a transitory change, not enough to induce permanent
injuries.
9.3.5"
"Describe the observed effects of low-dose ionizing radiation on invertebrate organisms, focusing specifically on potential mechanisms beyond direct DNA damage and how these effects relate to biological resilience.","Low doses of ionizing radiation can elicit a hormetic response in invertebrates, characterized by an initial stimulation of defensive mechanisms rather than immediate lethal damage. This is primarily observed through the upregulation of antioxidant enzyme systems such as superoxide dismutase (SOD), catalase (CAT), and ascorbate peroxidase (APX). These enzymes are crucial for neutralizing reactive oxygen species (ROS) generated within cells following radiation exposure, mitigating oxidative stress – a significant contributor to DNA damage and cellular dysfunction. Furthermore, invertebrates exposed to low doses may exhibit morpho-anatomical changes and enhanced photosynthetic activity in relevant tissues, promoting growth and metabolic efficiency. The underlying rationale is that these responses represent a form of ‘compensation’ – the organism actively adapting to the induced stress by bolstering its natural defenses. However, it's important to note that this phenomenon remains somewhat unclear due to species-specific variations and the transient nature of some observed changes; current research investigates whether these effects ultimately lead to permanent repair or simply represent temporary adjustments before irreversible damage occurs. The complex tissue organization surrounding membranes in invertebrates also contributes to their resistance by facilitating efficient DNA repair mechanisms and providing a physical barrier against radiation, further enhancing resilience. Reference: MolecularRadiationBiology, Section 9.3.5 – Effects on Invertebrates","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.5	 Effects on Invertebrates | Content: around membranes [88, 89]. At the anatomical level, com­
plex tissue organization is associated with high resistance to
mutagenic effects and the capability to adopt repair
mechanisms.
Non-lethal doses of ionizing radiation may also induce
hormesis improving plant defense against stressors, through
the stimulation of the production of antioxidant enzymes
(SOD, CAT, APX) or morpho-anatomical and photosynthetic
changes that favor plant growth and metabolism [74, 90, 91].
Radiation-induced hormesis is still an unclear phenome­
non in plants because it strongly depends on species intrinsic
characteristics. At present, further studies are in progress to
understand if it is a sort of compensation to irradiation dam­
age or a transitory change, not enough to induce permanent
injuries.
9.3.5"
"Describe the mechanisms by which ionizing radiation damages vertebrate cells, focusing specifically on DNA damage and subsequent cellular responses.","Ionizing radiation, possessing sufficient energy to remove electrons from atoms and molecules, causes significant damage to vertebrate cells through several interconnected mechanisms. The primary target is DNA, leading to a cascade of events ultimately resulting in cell death or, less frequently, repair and survival. Initially, the radiation interacts with water molecules within the cell, producing highly reactive hydroxyl radicals (•OH) – a major contributor to radiation damage. These radicals rapidly attack DNA bases, causing base modifications such as oxidation, alkylation, and strand breaks. Single-strand breaks (SSBs) are common initial lesions, followed by double-strand breaks (DSBs), which are particularly deleterious due to their potential to disrupt chromosome integrity. 

The cell employs several repair pathways to address this DNA damage. The Base Excision Repair (BER) pathway removes damaged or modified bases, while Nucleotide Excision Repair (NER) corrects distortions in the DNA helix caused by bulky adducts. However, DSBs often overwhelm these repair mechanisms.  The homologous recombination (HR) pathway is then activated, utilizing a sister chromatid as a template to accurately repair the break. This process is most effective during S and G2 phases of the cell cycle when a redundant copy of the DNA is available.

Beyond direct DNA damage, radiation induces oxidative stress by generating reactive oxygen species (ROS). These ROS further exacerbate cellular injury by damaging lipids, proteins, and other biomolecules. The resulting inflammation contributes to tissue damage and can impair repair processes. Furthermore, the cell’s response to DNA damage – including activation of checkpoints that halt cell cycle progression – can itself trigger apoptosis (programmed cell death) if the damage is too extensive or irreparable.  The severity of effects depends on factors such as dose rate, radiation type, and the organism's overall health and repair capacity. Reference: Environmental Radiobiology, Section 9.3.6","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.6	 Effects on Vertebrates | Content: ­
­
­
9.3.6
Effects on Vertebrates"
"Describe the biological mechanisms by which ionizing radiation can induce DNA damage in terrestrial vertebrates, including specific types of lesions and repair pathways involved.","Ionizing radiation, such as gamma rays or X-rays, possesses sufficient energy to directly interact with atoms and molecules within a living organism, primarily causing ionization – stripping electrons from their orbits. This interaction leads to a cascade of events resulting in DNA damage in terrestrial vertebrates. The primary types of DNA lesions induced by ionizing radiation include single-strand breaks (SSBs), double-strand breaks (DSBs), base modifications, and crosslinks between DNA strands. SSBs are relatively common and can be repaired through mechanisms like homologous recombination or non-homologous end joining (NHEJ). DSBs represent a more severe form of damage as they disrupt the genetic continuity. Their repair typically involves NHEJ, which is prone to errors due to its template-independent nature, often leading to mutations. Base modifications, such as oxidation and alkylation, can occur when radiation interacts with DNA bases, altering their structure and potentially causing miscoding during replication. These are primarily repaired through base excision repair (BER). Furthermore, crosslinks – covalent bonds between adjacent or distant DNA strands – are generated by radiation and require specialized repair pathways like the direct strand incision repair pathway or the Mre11/Rad50/Nbs1 system for their removal. The extent of damage and the efficiency of repair mechanisms vary depending on factors such as dose, cell type, and organismal physiological state. Rapidly dividing cells are generally more susceptible to radiation-induced DNA damage due to increased replication stress. Effective DNA repair is crucial for maintaining genomic stability and preventing mutations that can lead to cellular dysfunction or cancer.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.6	 Effects on Vertebrates | Sub-sub-subsection: 9.3.6.1	 Terrestrial Organisms | Content: ­
­
­
9.3.6
Effects on Vertebrates
9.3.6.1	Terrestrial Organisms"
"Mammalian species exhibit varying sensitivities to ionizing radiation, particularly concerning hematopoietic systems and gastrointestinal mucosa. Specifically, what is the approximate LD50 (dose required to kill 50% of the population) for dogs, mice, rats, and rhesus monkeys following exposure primarily due to gastrointestinal syndrome?","Following acute exposures primarily affecting the gastro-intestinal system, the estimated LD50 values for several mammalian species are as follows: dogs exhibit an LD50 of approximately 8 Gy, mice have an LD50 around 12 Gy, rats show an LD50 of roughly 11 Gy, and rhesus monkeys demonstrate an LD50 of about 9 Gy. It’s important to note that these values are estimates based on specific species and can vary significantly across different animal populations due to factors such as intestinal morphology and diet [46].","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.6	 Effects on Vertebrates | Sub-sub-subsection: 9.3.6.1	 Terrestrial Organisms | Content: ­
­
­
9.3.6
Effects on Vertebrates
9.3.6.1	Terrestrial Organisms
Mammals
Among all the vertebrates, mammals are organisms on which
the effects of radiation exposure were most extensively stud­
ied in radiobiological experiments. Negative effects on these
organisms, due to radiation exposure at high doses (i.e.,
10–50 Gy), are primarily due to effects at the hematopoietic
system and the gastro-intestinal mucosa [45, 46]. The time
needed for death to occur varies widely within species. The
dose of radiation needed to cause lethality, due to gastro-­
intestinal syndrome, to 50% of the exposed organisms (LD50)
is approximately as follows for dog—8 Gy, mouse—12 Gy,
rat—11 Gy, and rhesus monkey—9 Gy [46]. However, these
values were estimated for particular species of these organ­
isms, so there can be wide variations for other species. These
9 Bait-lamina test—a field test performed with baited lamina which are
buried in the soil to measure the feeding activity of edaphic fauna (for
more details, please see [181, 182]; ISO 18311:2016).
10 HDR5—the hazardous dose rate for 5% of the species.
J. Lourenço et al.
489
variations are normally related with specific intestinal mor­
phologies, which are related to diet (i.e., herbivores, carni­
vores, and omnivores). Regarding bone marrow damage, the
weight of the animals receiving the dose appears to have a
significant role in the bone marrow radioresistance, being
weight inversely proportional to radiation sensitivity, as LD50
values are greater for smaller mammals (6–10 Gy approxi­
mately) than for larger ones (1.2–3.9 Gy). A reduction in life
span is also related to the type of radiation to which animals
are exposed, being high LET radiation more effective than
low LET radiation. Also, acute exposures are substantially
more effective by a factor of 7 in causing mortality than
chronic exposures [46]. Significant life span shortening
occurred in dogs and mice exposed to low LET radiation
(gamma radiation) at dose rates between 100 and 1000 mGy/h
and the same happened for mice exposed to neutrons (high
LET radiation) at the same dose rates [136]. In general, a
significant reduction in life span of several mammal species
was observed at dose rates higher than 1000 mGy/h [50, 136,
137]. Chronic exposures of less than 100 mGy/h have a low
probability of inducing significant effects on most terrestrial
organisms [45, 46, 136]. Particularly, a dose rate of less than
40 mGy/h has a low probability of inducing effects on the
fertility, fecundity, and the production of viable offspring of
a mammalian population [45]. This is true for low LET radi­
ation, however for high LET radiation, this dose rate value is
lower, as this type of radiation has a much higher relative
biological effectiveness (RBE) [45]. An experiment
performed in mice irradiated with neutrons, at dose rates
lower than 100 mGy/h for at least 475 days, led to a signifi­
cant increase of mortality in mice in comparison with the
control [136].
Reproduction is a more radiosensitive parameter than mor­
tality, and effects of radiation may appear at radiation levels
that apparently do not induce other observable responses. The
magnitude of the effects depended also on the developmental
stage in which the animal was irradiated [136]. A good exam­
ple are mice, as the LD50 occurs at a radiation dose approxi­
mately between 6 and 10 Gy; however, at a radiation dose of
0.08 Gy, the production of oocytes was reduced to 50% in
newborn mice (the most radiosensitive stage in mice) [45, 46].
However, this does not necessarily mean that there will be a
decline in fecundity, since mice produce much more oocytes
than the amount effectively used for reproduction, but there
could be a reduction in the offspring [46]. In adult males, fer­
tility is temporarily impaired after a 10 Gy exposure; however,
in young mice (3–5 days old), it can cause permanent sterility.
Mice in the second week after birth are also especially sensi­
tive to the detrimental effects of radiation on reproduction
[136]. The differences between males and females are mostly
a consequence of the differences in the gametogenesis pro­
cess. There are also differences between species, being mice
one of the least radioresistant. Chronic irradiation affects
mainly the time needed for oogonial cell division and the size
of stem cell pool [46]. In males, the spermatogenic process is
maintained, although at lower levels than unexposed organ­
isms [46].
The developing embryo is particularly sensitive to radia­
tion, due to the high number of cells proliferating, reducing
fecundity and postnatal survival, potentially influencing
­population size [46]. Acute radiation exposure, before the
implantation of the embryo, causes its early death and can
also cause post implantation and postnatal death [46]. This
has a good correlation with the occurrence of DNA damage
in the form of chromosome aberrations in the blastomeres
(cells that result from the cleavage during the early develop­
ment of the embryo) [46]. Radiosensitivity is strongly influ­
enced by cell cycle stages and mitotic cycle in the very early
developmental stages [46]. During organogenesis, the most
typical response to acute radiation is the occurrence of mal­
formations (teratogenic effects), which can occur during
embryonic and fetal growth and may or may not be fatal. The
occurrence of teratogenic effects in a particular organ is
related to a high level of cell proliferation in the precursor
tissue [46]. Although this has been observed for the several
species studied (mouse, hamster, cattle, pig, monkey rabbit,
etc.), the responses to specific radiation doses will depend on
the species and on its developmental stage at the time of
exposure [46]. There are not many studies on the effects of
chronic radiation exposure during organogenesis, however a
study performed on mice showed doses of 0.01 Gy/day in
pregnant mice 6–9 days after conception induce a significant
impairment of the offspring’s learning ability [46]. Also,
dose rates of 420 mGy/h reduced neonatal brain weight, with
unknown effect at the functional and behavioral levels [45].
A direct relationship between DNA damage and radiation
dose is expected at high doses of radiation; however below
100 mGy, it is not clear. In reindeer, a tenfold increase in the
number of chromosome aberrations was observed at dose
rates between 100 and 1000 mGy/h [136]. For rodent species
acutely exposed to low LET radiation, mutations in the form
of reciprocal translocations (exchange of DNA between
homologous chromosomes) occur in stem cell spermatogo­
nia when organisms are exposed to between 0.01 and 0.03 Gy
at total doses from 3 Gy [46]. High LET radiation exposure
(in the form of alpha particles emitted by 239Pu), delivered at
a dose rate of 36 mGy/h significantly increased the occur­
rence of translocations and acentric fragments (chromosome
fragments without a centromere) in spermatogonia and sper­
matocytes, respectively [46]. In primates, the dose interval is
0.01–0.078 Gy at doses from 1 Gy [46]. Translocations, ring
chromosomes (aberrant chromosomes whose ends were bro­
ken and then fused together to form a ring) and dicentric
chromosomes (the result of two broken chromosomes that
fused together) are used for radiation dosimetry in human
and non-human biota for a long time, as their frequency
9 Environmental Radiobiology
490
increases with radiation dose [138]. In rodents, this is more
easily seen at total absorbed doses higher than 0.5 Gy, sug­
gesting that their use as a biomarker of radiation exposure is
more effective at high dose exposure than at low doses
(below 100 mGy). Regarding carcinogenicity, there is a wide
variation in the sensitivity for tumor formation among tis­
sues and species. The induction of cancer, even at high radia­
tion exposure doses (>100 mGy) will also vary according to
the age of exposure. Dogs exposed to doses higher than 7 Gy
showed soft tissue cancers when exposed in utero but not
when exposed as young adults [46]. In rodent species, there
were limited carcinogenic effects on animals that were
exposed to doses between 0.1 and 1 Gy [138]."
"What are the observed dose-response relationships regarding mortality and egg production in white leghorn chickens following exposure to ionizing radiation, as detailed in the provided text?","The text outlines a clear dose-response relationship for white leghorn chickens exposed to ionizing radiation. For short exposures (less than 1 hour), the lethal dose at 50% (LD50) is estimated between 7–11 Gray (Gy). This LD50 increases with longer irradiation times; specifically, it rises to 12–20 Gy when irradiated for 24 hours. Furthermore, egg production is significantly affected at a total absorbed dose of 4–8 Gy, leading to more severe and prolonged consequences at higher doses. Notably, exposure to radiation during the incubation of chicken embryos results in an LD50 of approximately 12–13 Gy, suggesting a greater radioresistance compared to adult birds. Finally, the text indicates that hatchability is negatively impacted at 8 Gy, while offspring are unaffected by this dose level. These findings align with reported effects from radiation contamination events like those stemming from Fukushima and Chernobyl.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.6	 Effects on Vertebrates | Sub-sub-subsection: 9.3.6.1	 Terrestrial Organisms | Content: The effects of radiation exposure in birds are apparently
similar to the ones observed in small mammals [45]. The
LD50 for wild birds is in the same range as small mammals
(5–12 Gy). For poultry, the LD50 determined experimentally
for mortality is of 7–11 Gy in 3–4-day-old individuals when
irradiation lasts for less than 1 h and of 12–20 Gy when irra­
diated for 24 h. Egg production is affected in white leghorn
chicken at a total absorbed dose of 4–8 Gy and at higher
doses, effects are more severe and long lasting [45]. A lim­
ited number of experiments performed in artificially incu­
bated chicken embryos showed a LD50 of 12–13 Gy, which
apparently indicates a higher radioresistance than adults
[46]. In white leghorn chickens, eggs hatchability is affected
at a total absorbed dose of 8 Gy, but the progeny is unaf­
fected [48]. The International Commission on Radiation
Protection also reported dose ranges for which long-term
effects on developing embryos were reported (100–
1000 mGy/day), reduced reproductive success (1–10 mGy/
day) and increased morbidity (10–100 mGy/day) [139].
Recently, it was reported a decrease in species abundance at
a dose range of (from 0.3 to 97 μGy/h) in the Fukushima
exclusion zone, which is consistent with the dose ranges
reported for increased morbidity and decreased reproduc­
tive success [140]. The existing knowledge on DNA dam­
age/alterations on birds exposed to ionizing radiation results
from the evaluation of effects of radioactive environmental
contamination resulting from the Fukushima and Chernobyl
accidents [141]."
"Describe the observed variations in radiosensitivity among different life stages of amphibians (specifically referencing frogs, salamanders, and tadpoles) and how these variations relate to radiation dose levels and potential outcomes like sterility or offspring abnormalities.","The data indicates significant differences in radiosensitivity across amphibian life stages. Notably, fertilized eggs exhibit the highest sensitivity with an LD50/40 of 0.6 Gy, followed by tadpoles which have an LD50 of 17 Gy. Juvenile amphibians demonstrate a moderate sensitivity with an LD50 of 10 Gy, while adult toads show the lowest sensitivity at 24 Gy. Exposure to radiation can trigger diverse effects depending on the dose and stage. Acute exposure to 50 Gy in male lizards resulted in temporary sterility followed by recovery within approximately 48 days. Irradiation of male and female gonads with a dose of 4.5 Gy significantly reduced offspring production. Furthermore, lower doses (3-20 Gy) applied to male toads induced reduced survival rates and increased abnormalities in their offspring. The variation in LD50 values across life stages suggests that the mechanisms underlying radiation damage may differ depending on developmental stage and cellular processes involved in DNA repair and replication. It's important to note that the optimal time after exposure for recording LD50 values can significantly influence these results, highlighting the complexity of assessing radiosensitivity in poikilothermic organisms.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.6	 Effects on Vertebrates | Sub-sub-subsection: 9.3.6.1	 Terrestrial Organisms | Content: The information gathered so far for reptiles and amphibians
suggest that their radiosensitivity is similar to that of mam­
mals and birds. The LD50 values recorded for frogs, salaman­
ders, turtles and snakes vary between 2 and 24 Gy [46]. The
main cause of death identified was damage to the hematopoi­
etic system [46]. In two separate experiments performed on
lizards, two very different LD50 doses ranges were obtained
(10–12 and 17–22 Gy). The possible reasons for this marked
difference are associated with the fact that these values may
vary according to radiation type and quality, the dose rate to
which the organisms were exposed and their maintenance
conditions at the laboratory [46]. An acute exposure to 50 Gy
caused temporary sterility in males, but recovery was well in
process after 48 days post irradiation and irradiation of
gonads in males and females to an absorbed dose of 4.5 Gy
leads to a substantial decrease in the production of offspring
[46].
Regarding amphibians, different life stages showed dif­
ferent radiosensitivities. For adult toads, the LD50 value is of
24 Gy, for juveniles it is of 10 Gy and for tadpoles it is of
17 Gy [46, 139]. The life stage more sensitive to radiation
exposure was the fertilized egg with an LD50/40 (LD50 after
40 days of exposure) of 0.6 Gy [33]. There is evidence that
the exposure of male toads to 3–20 Gy caused a reduced
survival and increased induction of abnormalities to the off­
spring [46, 139]. Although these LD50 values for amphibians
seem slightly higher than the ones recorded for mammals,
time after exposure optimal for the recording of LD50 values
seem to be an important factor [33]. Reptiles and amphib­
ians are poikilothermic organisms; therefore, their metab­
olism is quite variable and different from mammals and
birds [33]. A study performed on 4 species of amphibians
showed that if the assay period was extended a decrease in
the LD50 to values that ranged between 0.8 and 7 Gy would
be recorded [33].
Chronic irradiation exposure (5.5 years duration) of com­
mon side blotched lizard, western whiptail, long nosed leop­
ard lizard and long nosed lizard showed that at ranges from
285 to 570 μGy/h, radiation exposure caused lack of repro­
duction, female ovaries regression and some degree of male
sterilization [46].
Regarding the induction of DNA damage, it was observed
by Ulsh and co-authors [142] that the exposure of turtles
from the species Trachemys scripta to 0–8 Gy 137Cs gamma
radiation, given at a dose rate of 0.55 Gy/h induced the
occurrence of significant levels of chromosome transloca­
tions in lymphocytes. Studies on the induction of DNA alter­
ations in amphibians and reptiles have been performed in
Fukushima and Chernobyl exclusion zones, as well as in
areas contaminated with NORM."
"Across various vertebrate groups – lizards, amphibians (toads, tadpoles), fish (marine and freshwater) – the document highlights significant differences in radiation sensitivity based on life stage and species. Specifically, fertilized eggs of toads demonstrate a markedly higher LD50 compared to adult toads, while developing fish embryos, including silver salmon and medaka fish, exhibit substantially greater radiosensitivity than mature adults. Furthermore, chronic irradiation studies revealed varying impacts on reproductive function across these groups – ranging from temporary sterility in lizards and medaka fish to reduced fecundity in guppies and significant disruption of spermatogenesis in Ameca splendens.  What key factors contribute to the observed variability in radiation sensitivity among these diverse vertebrate taxa?","The substantial variation in radiation sensitivity observed across lizards, amphibians, and fish is primarily driven by a combination of life stage, species-specific adaptations, and physiological differences. Notably, developing embryos – particularly fertilized eggs, early larval stages (tadpoles, silver salmon), and newly hatched fry – are significantly more sensitive than mature adults due to their rapid cell division rates and heightened DNA replication processes, leading to increased susceptibility to DNA damage. Furthermore, poikilothermic nature of amphibians and reptiles compared to mammals contributes to a greater variability in metabolic responses and thus radiosensitivity. Species-specific differences also play a crucial role; for example, cartilaginous fish (sharks) demonstrate similar radiosensitivity to teleost fish, while the medaka fish exhibits unique sensitivities related to vertebral anomaly induction. Finally, dose rate and exposure duration significantly influence outcomes, with chronic exposures leading to more pronounced effects like ovarian regression and male sterilization.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.3	 Impacts of Ionizing Radiation on Non-human Biota | Sub-subsection: 9.3.6	 Effects on Vertebrates | Sub-sub-subsection: 9.3.6.1	 Terrestrial Organisms | Content: lizards, two very different LD50 doses ranges were obtained
(10–12 and 17–22 Gy). The possible reasons for this marked
difference are associated with the fact that these values may
vary according to radiation type and quality, the dose rate to
which the organisms were exposed and their maintenance
conditions at the laboratory [46]. An acute exposure to 50 Gy
caused temporary sterility in males, but recovery was well in
process after 48 days post irradiation and irradiation of
gonads in males and females to an absorbed dose of 4.5 Gy
leads to a substantial decrease in the production of offspring
[46].
Regarding amphibians, different life stages showed dif­
ferent radiosensitivities. For adult toads, the LD50 value is of
24 Gy, for juveniles it is of 10 Gy and for tadpoles it is of
17 Gy [46, 139]. The life stage more sensitive to radiation
exposure was the fertilized egg with an LD50/40 (LD50 after
40 days of exposure) of 0.6 Gy [33]. There is evidence that
the exposure of male toads to 3–20 Gy caused a reduced
survival and increased induction of abnormalities to the off­
spring [46, 139]. Although these LD50 values for amphibians
seem slightly higher than the ones recorded for mammals,
time after exposure optimal for the recording of LD50 values
seem to be an important factor [33]. Reptiles and amphib­
ians are poikilothermic organisms; therefore, their metab­
olism is quite variable and different from mammals and
birds [33]. A study performed on 4 species of amphibians
showed that if the assay period was extended a decrease in
the LD50 to values that ranged between 0.8 and 7 Gy would
be recorded [33].
Chronic irradiation exposure (5.5 years duration) of com­
mon side blotched lizard, western whiptail, long nosed leop­
ard lizard and long nosed lizard showed that at ranges from
285 to 570 μGy/h, radiation exposure caused lack of repro­
duction, female ovaries regression and some degree of male
sterilization [46].
Regarding the induction of DNA damage, it was observed
by Ulsh and co-authors [142] that the exposure of turtles
from the species Trachemys scripta to 0–8 Gy 137Cs gamma
radiation, given at a dose rate of 0.55 Gy/h induced the
occurrence of significant levels of chromosome transloca­
tions in lymphocytes. Studies on the induction of DNA alter­
ations in amphibians and reptiles have been performed in
Fukushima and Chernobyl exclusion zones, as well as in
areas contaminated with NORM.
Aquatic Vertebrates
Among non-mammalian aquatic organisms, fish are the most
sensitive to the exposure to ionizing radiation [45, 46].
Although these organisms are also poikilothermic (as
amphibians and reptiles), and therefore, apparently more
radioresistant than mammals, there is a substantial overlap in
radiosensitivities [46]. Until now, there is no substantial data
on effects of ionizing radiation on marine mammals, how­
ever, there is no reason to believe that their radiosensitivity is
substantially different from that of terrestrial mammals. Data
J. Lourenço et al.
491
on acute exposures exist mainly for bony and freshwater
fishes, with a small number of studies on cartilaginous and
marine and anadromous species.
The LD50 determined for six marine species after
40–50 days of exposure was of 9–23 Gy [46, 139]. Fish
developing embryos are, however, more sensitive than adults,
as for silver salmon their LD50 after 50 days of exposure is of
0.30 Gy at hatching and 0.16 Gy at a post-hatching larval
stage of 90 days [46]. A study performed on sharks (Triakis
scyllium and Heterodontus japonicus) exposed to 20 Gy
showed that mortality occurred after 20 days of exposure,
due to hematopoietic and gastrointestinal damage [33]. This
suggests that the radiosensitivity of cartilaginous fish may be
similar to that of teleost fish.
Regarding reproduction, an acute exposure to 10 Gy
reduced the total number of germ cells at all developmental
stages of medaka fish (Oryzias latipes) [46]. A similar radio­
sensitivity was found in rainbow trout, with an induction of
more than 50% sterility in organisms exposed late in embry­
onic development [46]. This leads to the conclusion that as
in mammals, the newly hatched fry and the primordial
gonads in fish embryos are more sensitive to the acute radia­
tion exposure than in adult fish [46]. Irradiation of mature
medaka fish at acute doses of 5–10 Gy only induced tempo­
rary sterility, being completely recovered at 60 days after
irradiation [46]. On the other hand, chronic irradiation of
males from the fish species Ameca splendens for 5.4 days at
a dose rate from 137Cs gamma rays of 7300 mGy/h disrupted
spermatogenesis and render the animals sterile at an accu­
mulated dose of 9.7 Gy (8 weeks of exposure) [46]. There
was 60–70% recovery, 236 days after irradiation [46].
Another freshwater fish, the guppy (Poecilia reticulata),
when exposed to gamma dose rates from 1700 to
13,000 mGy/h showed a significant reduction in fecundity,
but no negative effects on survival and sex ratio, as well as
no significant higher incidence of abnormalities in the off­
spring were observed [33, 136]. The marine fishes
Pleuronectes platessa and the eelpout (Zoarces viviparus)
exposed to 240 and 2000 mGy/h gamma radiation, respec­
tively, showed a significant reduction of testes when com­
pared to the control [136].
There are some findings also on the effects of the expo­
sure to ionizing radiation in the immune system of these
organisms. A significant reduction in the humoral immune
response in the rainbow trout (Oncorhynchus mykiss)
exposed to tritium beta-particles for 20 days at a dose rate as
low as 8.3–83 mGy/h during embryogenesis was evidenced
through a reduction in antibody titer following a specific
challenge [46].
Regarding DNA damage there are very few studies on
which some conclusion can be taken on this matter. On a
study on medaka fish, at larval stages, there was a significant
induction of vertebral anomalies after irradiation at dose
rates from 137Cs gamma rays higher than 18,000 mGy/h and
also to beta particles from 3H at dose rates higher than
35,000 mGy/h [46]. There is also a report on the occurrence
of minor morphological abnormalities in the operculum of
salmons exposed to a gamma radiation dose rate of
200 mGy/h that may affect latter survival [136].
9.4"
"The provided text discusses instances of morphological abnormalities observed in aquatic organisms following irradiation. Specifically, it cites a study on medaka fish and salmon exhibiting vertebral anomalies and operculum abnormalities respectively. Explain how the presence of multiple stressors – including radionuclides like radium isotopes (226Ra, 222Rn, 210Po) alongside metals such as manganese, zinc, iron, and aluminum – can exacerbate biological effects related to ionizing radiation exposure in organisms, referencing the concept of synergistic interactions.","The text highlights a critical complexity regarding chronic radiation exposure from NORM contamination: it’s rarely a singular effect. The observation of vertebral anomalies in medaka fish and operculum abnormalities in salmon following irradiation demonstrates that these effects are significantly amplified when multiple stressors are present concurrently. Specifically, the presence of radionuclides like radium isotopes (226Ra, 222Rn, 210Po) alongside metals such as manganese, zinc, iron, and aluminum creates a synergistic scenario. These metals can interact with radiation damage at the cellular level, potentially increasing oxidative stress or disrupting DNA repair mechanisms. Furthermore, the microbial communities inhabiting contaminated environments – like those observed in naturally contaminated sites – have evolved resistance through bioaccumulation of these same radionuclides and metals. This adaptation itself represents a form of stress response that could be further modulated by ionizing radiation. The combined effect of multiple contaminants can therefore dramatically increase an organism’s susceptibility to radiation damage, altering cellular processes and potentially leading to more severe biological consequences than would be expected from radiation exposure alone. It is crucial to recognize that these interactions are complex and poorly understood, representing a significant challenge in assessing the true risk associated with NORM contamination.

Reference: [MolecularRadiationBiology, Section 9.4 – The Particular Case of NORM Contamination]","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.4	 The Particular Case of NORM Contamination | Content: Regarding DNA damage there are very few studies on
which some conclusion can be taken on this matter. On a
study on medaka fish, at larval stages, there was a significant
induction of vertebral anomalies after irradiation at dose
rates from 137Cs gamma rays higher than 18,000 mGy/h and
also to beta particles from 3H at dose rates higher than
35,000 mGy/h [46]. There is also a report on the occurrence
of minor morphological abnormalities in the operculum of
salmons exposed to a gamma radiation dose rate of
200 mGy/h that may affect latter survival [136].
9.4
The Particular Case of NORM
Contamination
Anthropogenic activities of concern related to the environ­
mental release of natural uranium isotopes (mainly 238U and
235U) and other radionuclides from their decay chains,
namely 226Ra and 223Ra, 222Rn, and 210Po, include mainly the
production of phosphate fertilizers, uranium mining and
milling and the incorrect disposal of tailings, uranium con­
version and enrichment, the production of uranium fuel,
production of coal, oil and gas, extraction of rare earths,
extraction and purification of water, extraction of minerals
for building materials and the generation of geothermal
energy [3, 143]. All of these industrial activities increase the
concentration of these elements in all environmental matri­
ces, thereby posing a risk to human and non-human biota as
many of them have not been regulated for NORM release [3,
143]. Another important issue is the fact that the contami­
nated areas that result from these anthropogenic activities
do not only present high levels of certain natural radionu­
clides, like 226Ra, 222Rn, and 210Po but also other important
stressors, namely metals like manganese, zinc, iron, alumi­
num, etc. [143]. These are usually multiple exposure sce­
narios, which contain several kinds of contaminants that
may act synergistically and increase the risk of the occur­
rence of biological effects on human and non-human biota
and even of modifying the susceptibility of cells/organisms
to the biological effects of ionizing radiation exposure
[144].
9.4.1
Chronic Exposure and Interaction
with Uranium and Metals
The accumulation of small amounts of radionuclides and
metal over long periods is translated in chronic exposure to
radiation. Naturally contaminated sites harbor a diversity of
microbial species that become resistant or tolerant to these
contaminants by bioaccumulating radionuclides and metals
either by biosorption to their cell surfaces and biomolecules
or by internalization into their cells. Briefly, under environ­
mental conditions, chronic IR effects are very complex, par­
ticularly when compared to those from laboratory exposures
because (1) radiation emitted by the different radionuclides
present has different biological effects, (2) radiation from the
9 Environmental Radiobiology"
"The text describes how microorganisms interact with uranium and metals in chronically contaminated environments. Detail the mechanisms by which bacteria demonstrate tolerance to these contaminants, specifically outlining processes like biosorption, biomineralization, and redox state manipulation, alongside the roles of specific microbial genera.","Microorganisms exhibit remarkable resilience within naturally contaminated sites characterized by elevated levels of radionuclides and metals through a multifaceted approach. Primarily, they employ biosorption, where contaminants are passively accumulated via binding to cell surface components such as lipopolysaccharides, teichoic acids, and peptidoglycan. Simultaneously, biomineralization is utilized, facilitated by microorganisms that catalyze the formation of biominerals – notably using organic phosphate sources and phosphatases – effectively sequestering the metals. Furthermore, bacteria actively manipulate redox states through aerobic oxidation (biolixiviation) or anaerobic reduction, converting toxic uranium forms like U(VI) to less harmful U(IV). Several bacterial genera are particularly well-represented in these environments due to their tolerance; *Geobacter* and *Thiobacillus* are prominent players in redox transformations, while *Arthrobacter*, *Bacillus*, *Actinobacteria*, *Desulfovibrio*, and *Microbacterium* contribute significantly to biosorption processes. The text specifically highlights the role of Paecilomyces (a yeast) which detoxifies U(VI) through bioprecipitation using phosphate, and *Saccharomyces cerevisiae* which reduces U(VI) toxicity via biomineralization. These combined strategies allow microbial communities to persist and thrive in conditions otherwise lethal to many other organisms.  Reference: [MolecularRadiationBiology, Section 9.4.1 – Chronic Exposure and Interaction with Uranium and Metals]","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.4	 The Particular Case of NORM Contamination | Sub-subsection: 9.4.1	 Chronic Exposure and Interaction with Uranium and Metals | Content: Regarding DNA damage there are very few studies on
which some conclusion can be taken on this matter. On a
study on medaka fish, at larval stages, there was a significant
induction of vertebral anomalies after irradiation at dose
rates from 137Cs gamma rays higher than 18,000 mGy/h and
also to beta particles from 3H at dose rates higher than
35,000 mGy/h [46]. There is also a report on the occurrence
of minor morphological abnormalities in the operculum of
salmons exposed to a gamma radiation dose rate of
200 mGy/h that may affect latter survival [136].
9.4
The Particular Case of NORM
Contamination
Anthropogenic activities of concern related to the environ­
mental release of natural uranium isotopes (mainly 238U and
235U) and other radionuclides from their decay chains,
namely 226Ra and 223Ra, 222Rn, and 210Po, include mainly the
production of phosphate fertilizers, uranium mining and
milling and the incorrect disposal of tailings, uranium con­
version and enrichment, the production of uranium fuel,
production of coal, oil and gas, extraction of rare earths,
extraction and purification of water, extraction of minerals
for building materials and the generation of geothermal
energy [3, 143]. All of these industrial activities increase the
concentration of these elements in all environmental matri­
ces, thereby posing a risk to human and non-human biota as
many of them have not been regulated for NORM release [3,
143]. Another important issue is the fact that the contami­
nated areas that result from these anthropogenic activities
do not only present high levels of certain natural radionu­
clides, like 226Ra, 222Rn, and 210Po but also other important
stressors, namely metals like manganese, zinc, iron, alumi­
num, etc. [143]. These are usually multiple exposure sce­
narios, which contain several kinds of contaminants that
may act synergistically and increase the risk of the occur­
rence of biological effects on human and non-human biota
and even of modifying the susceptibility of cells/organisms
to the biological effects of ionizing radiation exposure
[144].
9.4.1
Chronic Exposure and Interaction
with Uranium and Metals
The accumulation of small amounts of radionuclides and
metal over long periods is translated in chronic exposure to
radiation. Naturally contaminated sites harbor a diversity of
microbial species that become resistant or tolerant to these
contaminants by bioaccumulating radionuclides and metals
either by biosorption to their cell surfaces and biomolecules
or by internalization into their cells. Briefly, under environ­
mental conditions, chronic IR effects are very complex, par­
ticularly when compared to those from laboratory exposures
because (1) radiation emitted by the different radionuclides
present has different biological effects, (2) radiation from the
9 Environmental Radiobiology
492
same location is absorbed differently by different microor­
ganisms, (3) abiotic factors (e.g., temperature, nutrients, pH,
other stressors) are present and can interfere with radiation,
(4) cooperation/interaction between microbial communities,
including diversity and/or abundance can all be modulated
by radiation [62]. Regarding uranium, probably the most
well studied radionuclide, and for which a lot of information
is available, interaction with microbial cells involving solu­
bility by biomineralization (bioprecipitation) depends on all
the above factors and also on the presence of affinity groups
generated by microorganisms’ cell metabolism, like hydrox­
ides, phosphates, and carbonates. Uranium toxicity is both
chemical and radiological. In the environment, uranium
exists in its reduced insoluble form U(IV), and/or the oxi­
dized form U(VI), which is soluble and toxic. Microorganisms
interact with uranium by changing its redox state, aerobi­
cally, through oxidation (biolixiviation), or anaerobically by
reduction. In order to do that, microorganisms need to be
highly tolerant to uranium and to radiation. Other processes
of microbial interaction with metals, involve biosorption,
where contaminants passively concentrate through binding
to cell structure constituents (e.g., lipopolysaccharides, tei­
choic acids, peptidoglycan), and biomineralization, which
leads to the formation of biominerals using organic phos­
phate sources and phosphatases.
Unless disturbance occurs, NORM sites have a characteristic
microbiome, which is specific for a given site, but may share
common microbial genera and species, regardless of location
and/or chemical contamination. It includes nitrate-­reducing
bacteria that tolerate acidic and low-nutrient conditions, while
being highly resistant to metals. Members of the Proteobacteria
(Alpha-,
Beta-,
Delta-
and
Gamma-
proteobacteria),
Acidobacteria, Actinobacteria, Bacteroidetes, and Firmicutes
are generally associated with uranium transformation and are
therefore found in these environments. Most represented bacte­
rial genus include Geobacter, Thiobacillus, Arthrobacter,
Bacillus, Actinobacteria, Desulfovibrio, and Microbacterium.
Most of the studies are focused on bacteria and bacterial com­
munities. Although little information exists regarding fungi,
they are particularly resistant to radiation and thus play a role in
the process of detoxification of radionuclides. For instance, an
isolate of the genus Paecilomyces, was found to detoxify U(VI)
through bioprecipitation of the metal, and the reduction was
promoted by phosphate. Also, the yeast S. cerevisiae was able to
reduce U(VI) toxicity by biomineralization [60].
Accordingly, the survival, abundance, and maintenance of
a given species or community diversity depend on its adapt­
ability to the existing conditions. Furthermore, several stud­
ies suggest that in those radionuclide-rich natural sites,
resistance to high levels of chronic IR may occur among taxa
that tolerate a wide range of environmental conditions and,
therefore, have an advantage over other more sensitive spe­
cies [62].
9.4.2"
"The text describes a mechanism for mitigating the toxicity of naturally occurring radioactive materials (NORM) involving microorganisms. Explain this process, detailing the factors that contribute to the survival and maintenance of specific microbial populations in radionuclide-rich environments.","In radionuclide-rich natural sites, certain eukaryotic species exhibit resistance to high levels of chronic ionizing radiation (IR) due to their inherent adaptability and tolerance of diverse environmental conditions. This resistance is often observed among taxa already adapted to extreme environments. The process described involves biomineralization, where microorganisms actively reduce the toxicity of radioactive elements, particularly uranium(VI) ions (U(VI)). This reduction isn't simply a passive effect; it’s an active adaptation driven by the organism’s ability to alter its surrounding environment. Specifically, these organisms can precipitate U(VI) as stable mineral phases – often phosphates or carbonates – effectively removing the radioactive element from solution and reducing its bioavailability and therefore its toxic effects. The survival, abundance, and maintenance of a given species or community diversity depend on this adaptability. Species with pre-existing tolerance to wide ranges of environmental conditions—including those associated with radiation exposure—gain a selective advantage over more sensitive taxa. This suggests that the ability to biomineralize radioactive elements is not just a response to contamination but rather an integral part of their ecological strategy for thriving in challenging, radionuclide-rich habitats.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.4	 The Particular Case of NORM Contamination | Sub-subsection: 9.4.2	 Effects of NORM and Metals on Eukaryotes | Content: reduce U(VI) toxicity by biomineralization [60].
Accordingly, the survival, abundance, and maintenance of
a given species or community diversity depend on its adapt­
ability to the existing conditions. Furthermore, several stud­
ies suggest that in those radionuclide-rich natural sites,
resistance to high levels of chronic IR may occur among taxa
that tolerate a wide range of environmental conditions and,
therefore, have an advantage over other more sensitive spe­
cies [62].
9.4.2
Effects of NORM and Metals
on Eukaryotes"
"The study details observed genotoxic effects in *Daphnia magna* following exposure to uranium and a uranium mine effluent. Specifically, what type of DNA damage was detected, and how did this damage manifest across multiple generations of the exposed population?","Following exposure to uranium and a uranium mine effluent, significant DNA strand breaks were detected in neonates and daphnids under 5 days old of *Daphnia magna*. Notably, bystander effects – DNA damage in unexposed organisms – were also observed when these exposed organisms were placed in contact with them. Critically, the study revealed a transgenerational pattern: DNA damage was primarily transmitted to the first broods of exposed organisms, but diminished significantly by the third brood, suggesting a potential for adaptation or detoxification mechanisms within subsequent generations. However, it’s important to acknowledge that this interpretation is limited to the measured endpoint (DNA strand breaks) and further investigation into mutation detection and epigenetic changes would be necessary for a more comprehensive assessment [149]. Reference: [MolecularRadiationBiology], Section 9.4.2.1 – Invertebrates.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.4	 The Particular Case of NORM Contamination | Sub-subsection: 9.4.2	 Effects of NORM and Metals on Eukaryotes | Sub-sub-subsection: 9.4.2.1	 Invertebrates | Content: reduce U(VI) toxicity by biomineralization [60].
Accordingly, the survival, abundance, and maintenance of
a given species or community diversity depend on its adapt­
ability to the existing conditions. Furthermore, several stud­
ies suggest that in those radionuclide-rich natural sites,
resistance to high levels of chronic IR may occur among taxa
that tolerate a wide range of environmental conditions and,
therefore, have an advantage over other more sensitive spe­
cies [62].
9.4.2
Effects of NORM and Metals
on Eukaryotes
9.4.2.1	Invertebrates
145146
238
235
145
50
11
­
­
12
­
­
147
When D. magna was exposed to uranium and to a ura­
nium mine effluent [148, 149], significant genotoxic effects
(DNA strand breaks) were detected in neonates and <5 days
old daphnids after exposure to 55.3 μg/L of uranium and 2%
of a uranium mine effluent. Moreover, in this same study,
bystander effects, in the form of DNA damage, were detected
in unexposed organisms when placed in contact with organ­
isms directly exposed to uranium and to uranium mine efflu­
ent. In another paper [149], published by the same authors,
on a transgenerational study performed on D. magna exposed
to the same concentrations of uranium and uranium mine
effluent as the study previously referred, it was observed that
DNA damage was transmitted only to the first broods of the
exposed organisms. By the third brood, DNA damage was no
longer detected. This study showed that although short-term
exposure to low concentrations of uranium and uranium
11 EC50 is the concentration of a substance in water causing death to 50%
of the tested population.
12 LOEC is the lowest concentration where an effect has been observed
in chronic or acute ecotoxicity studies. NOEC is the highest concentra­
tion at which there is no statistically significant difference from the con­
trol condition in an acute or chronic ecotoxicity study.
J. Lourenço et al.
493
mine effluent induces DNA damage to exposed organisms, it
seems that it was not enough to significantly affect life his­
tory traits of D. magna populations in a long-term scenario.
Nevertheless, the interpretation of these results is limited to
the response observed for the endpoints here analyzed (DNA
strand breaks). As such, other endpoints for genotoxicity
assessment (i.e., mutation detection) and also the analyses of
the epigenome of these organisms should be performed, as
these molecular changes do not reflect a loss of DNA’s struc­
tural integrity [149].
As for terrestrial invertebrates, most of the studies con­
ducted so far were on the annelid Eisenia andrei [150–155].
Gene expression alterations were reported in earthworms
exposed to sludge from a uranium mine decantation pond.
These genes were mainly related with metabolism, oxidore­
ductase activity, redox homeostasis, and response to chemi­
cal stimulus and stress [152]. In these studies, the occurrence
of DNA damage in the form of DNA strand breaks and
changes in cell’s DNA content in exposed organisms was
also detected. Alterations in earthworm’s immune system
were also reported, in terms of the frequency of each cell
compartment, as it was observed a decrease in the number of
effector cells (amebocytes) and an increase of the cells
responsible for the maintenance of the organism’s homeosta­
sis (eleocytes) [153, 154]. In parallel with a significant bio­
accumulation of metals and radionuclides from uranium’s
decay chain (238U, 234U, 235U, 226Ra, 230Th, and 210Pb), it was
also observed a significant decrease in earthworms’ biomass,
a reproduction inhibition, and significant histological altera­
tions, namely in earthworm’s body wall (epidermis, circular,
and longitudinal muscles) and gastrointestinal tract (chlora­
gogenous tissue and intestinal epithelium) [153–155].
Under a real scenario of contamination, all of these effects
may explain the lower biodiversity of soils contaminated
with NORM, and the subsequent loss of their functions, if
the contamination is perceived by the organisms. By using
an avoidance assay (a standard ecotoxicological assay), to
study earthworms’ behavioral responses to soils collected in
a uranium mine area, it was shown that earthworms actively
avoided several contaminated soils. Earthworm’s avoidance
responses allowed it to discriminate highly to moderately
toxic soils. On the other hand, on another study published by
the same authors, using the analyses of oxidative stress enzy­
matic biomarkers (catalase, glutathione peroxidase) and
lipid peroxidation biomarkers (through the quantification of
thiobarbituric acid reactive substances), in earthworms
exposed to soils nearby a uranium mine, showed no response
for none of the biomarkers analyzed [150]."
"The provided research details several studies examining the effects of NORM contamination on aquatic vertebrates, specifically fish (Rutilus rutilus and Danio rerio) and amphibians (Pelophylax perezi). Several key findings are reported, including stimulation of immune parameters, oxidative stress induction, decreased acetyl choline esterase levels in fish exposed to contaminated ponds, alterations in oxidative stress biomarkers (SOD, CAT, MDA, Na+–K+–ATPase) in zebrafish, reproductive effects (reduced hatching and skeletal deformities) in Pimephales promelas larvae, and significant metal bioaccumulation. Furthermore, the studies highlight the influence of effluent acidity on amphibian development and the use of FET tests to assess uranium mining wastes. Describe the major observed biological impacts resulting from NORM exposure across these vertebrate species.","Across multiple vertebrate species impacted by NORM contamination, a range of detrimental biological effects were documented. In fish, notably Rutilus rutilus and Danio rerio, exposure led to immune system stimulation alongside pronounced oxidative stress, evidenced by reduced acetyl choline esterase levels in the former and alterations in key oxidative stress biomarkers (SOD, CAT, MDA, and Na+–K+–ATPase) within zebrafish. Furthermore, reproductive impairments were consistently observed, including decreased hatching rates and skeletal abnormalities in Pimephales promelas larvae, coupled with increased metal body burdens. In amphibians, specifically Pelophylax perezi, exposure resulted in reduced survival and growth rates, elevated glutathione peroxidase activity, and increased lipid peroxidation in organisms inhabiting contaminated ponds compared to control populations. Gene expression analyses revealed a heightened oxidative stress response within this species. Additionally, significant metal bioaccumulation was detected in the liver and kidneys of P. perezi adults residing near uranium mining sites, accompanied by histopathological changes including melanomacrophagic centers, renal tubular dilatation, and erythrocytic nuclear abnormalities. The studies also underscored the influence of effluent acidity on amphibian development and the potential for metals to exacerbate these effects. Finally, research involving rodents (Peromyscus maniculatus and P. boylii) and mice (Apodemus sylvaticus) demonstrated NORM uptake alongside DNA damage and alterations in tumor suppressor gene expression, suggesting a broader genetic impact of chronic exposure.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.4	 The Particular Case of NORM Contamination | Sub-subsection: 9.4.2	 Effects of NORM and Metals on Eukaryotes | Sub-sub-subsection: 9.4.2.2	 Vertebrates | Content: Although there have been a wide number of studies per­
formed on the effects of gamma radiation exposure on ver­
tebrates, very few were performed so far for NORM
exposure. Regarding aquatic vertebrates, fish have been the
most used model organisms. On a study performed in for­
mer uranium mines from the Limousin region of France,
where Rutilus rutilus specimens were caged on a pond con­
taminated with NORM and metals, immune, oxidative
stress, biotransformation, neurotoxicity, and physiological
parameters were measured [156]. The results obtained
showed a stimulation of the immune parameters, the occur­
rence of oxidative stress and a decrease of acetyl choline
esterase-AChE in the fish caged in the contaminated pond
[156]. Zebrafish (Danio rerio) specimens exposed to ura­
nium mill tailings leaching solution also showed alterations
for the oxidative stress biomarkers used (superoxide dis­
mutase—SOD, catalase—CAT, malondialdehyde—MDA
and Na+–K+–ATPase) but specially for Na+–K+–ATPase and
also evidenced that the organs most susceptible to oxidative
stress were the gills [157]. In another study performed on a
uranium milling operation in Northern Saskatchewan,
Canada, Pimephales promelas specimens (adults and 5-day-
old larvae) were exposed to contaminated water and con­
taminated sediment [158]. Results indicated effects on
reproduction (reduced hatching) and larvae development
(increase of skeletal deformities) and an increase in metal
body burdens. However, the effects detected on the off­
spring, when considering the increase in egg production,
were not significant in the level of deformities between
treatments [158]. The effects on reproduction on the same
species have already been observed under an exposure to
effluent waters also from a uranium mining site in
Saskatchewan, Canada. A significant decrease in eggs
hatching time and hatching success was registered when
early life stages of fathead minnows were exposed [159].
Nevertheless, metals and radionuclides are not the only
stressor responsible for the effects caused by effluent waters
from NORM sites. Lourenço et al. [160] performed an
exposure of zebrafish eggs to a uranium mine effluent, bar­
ium chloride-treated mine effluent, and settling ponds
sludge elutriates and showed that pH of the mine effluent
strongly affected hatching success. After eliminating the
effect of pH, this study also showed some teratogenicity
associated with the uranium mine effluent, the occurrence of
DNA damage, mainly associated with the exposure to
treated mine effluent and sludge elutriates and mild effects
on growth observed mainly on embryos exposed to the mine
effluent and sludge elutriates. This study showed that the
use of the Fish Embryo Toxicity Test (FET) test is suitable
to test uranium mining wastes to determine and discriminate
the risk of discharge. It also showed that the inclusion of the
evaluation of genotoxicity endpoints in the FET test pre­
vented the underestimation of risks, when only looking at
chemical and radiological benchmark values defined by
national and international directives, for the determination
of risks, due to the chemical complexity of these wastes.
9 Environmental Radiobiology
494
On what concerns amphibians, there are very few studies
on these organisms as well. Marques and co-authors per­
formed very important studies on amphibians, namely
Pelophylax perezi exposed to NORM in situ. They have stud­
ied both tadpoles and adults and they have analyzed several
endpoints, such as growth, survival, oxidative stress bio­
markers (catalase, glutathione peroxidase, glutathione reduc­
tase, and lipid peroxidation through thiobarbituric acid
reactive species (TBARS) quantification), gene expression
alterations, histopathological changes, erythrocytic nuclear
abnormalities and micronuclei, on organisms exposed to a
uranium mine effluent in Portugal [161–165]. A study per­
formed on 2008, on larvae and eggs [165] exposed to a ura­
nium mine effluent, showed a decrease in larvae body length
as well as a decrease in stimulus reactions, an increase in
pigmentation along with tail deformities and metals bioac­
cumulation. The in situ exposure of tadpoles of the same spe­
cies showed decreased survival and growth, a higher
glutathione peroxidase activity and an increased lipid peroxi­
dation [164] in organisms exposed in the mine effluent pond,
when compared with organisms from a control pond.
Although there may have been the influence of NORM and
metals exposure, the studies also evidenced the effects of
effluent’s acidity (typically seen in metal mining contexts),
mainly in the growth and survival parameters and also in
metal’s uptake. Another study, performed by the same
authors [163], on adults living on the same uranium mine
pond, analyzed gene expression changes using a technique
called Suppressive Subtractive Hybridization (SSH).
Significant changes in the expression levels of genes that
play an important role in protecting cells against oxidative
stress were shown, evidencing once again that oxidative
stress response is very important in protecting cells and in
maintaining DNA integrity on organisms exposed to NORMs
and metals. Another study performed by this team on
Pelophylax perezi adults inhabiting a uranium mining pond
[162], showed significant metals bioaccumulation in the liver
and the kidneys. Significant histopathological alterations in
the liver, the lungs and in the kidneys, mainly in the form of
a slight increase in melanomacrophagic centers, a dilatation
of the renal tubules, a discrete thickening along with a slight
hyperplasia of the alveolar septa and a slight hypoplasia of
the goblet cells, were observed. The same animals living in
the mine pond also displayed a significantly higher number
of erythrocytic abnormalities (micronuclei and notched, kid­
ney and lobed shaped nuclei) as well as a significantly lower
frequency of immature erythrocytes. Both observations led
to the belief that the removal and replacement of abnormal
blood cells might be compromised.
There are a few studies published on the uptake of NORM
by mammals that were performed mainly on former uranium
mining areas, but very few examined the effects of that expo­
sure. A study performed by Cleveland et al. [166] analyzed
NORM uptake and histopathological alterations in liver and
kidneys of rodents (Peromyscus maniculatus and P. boylii)
inhabiting former uranium mines and observed that rodents
bioaccumulated elements from 238U decay chain but without
exceeding literature-based effects thresholds for small
rodents. The authors also observed that there were some
minor lesions in the tissues (liver and kidneys) analyzed that
could not, however, be attributed to U mining activities.
Lourenço and co-authors [167], captured mice (Apodemus
sylvaticus) on the surroundings of a former uranium mining
site and on a control area. DNA damage and bioaccumula­
tion of metals and radionuclides were assessed, as well as the
expression and the presence of single nucleotide polymor­
phisms on tumor suppressor genes. Results showed that cad­
mium and uranium were significantly bioaccumulated by
exposed organisms. Organisms living in the former uranium
mining area also evidenced significantly higher levels of
DNA damage when compared with control organisms and
also a higher expression of TP53 tumor suppressor gene and
the presence of single nucleotide polymorphisms in Rb
tumor suppressor gene. These effects can cause a disturbance
in the genetic material of exposed organisms causing genetic
instability and changes in the genetic pool of the population,
potentially affecting the population’s fitness and stability.
However, they cannot be attributed to any of the stressors in
particular. It is known that uranium is genotoxic due to its
chemical and radiological properties. Nevertheless, other
metals present in uranium ore have shown greater genotoxic
properties [151]."
"Describe the observed effects on plant populations exposed to NORM contamination, citing specific examples from the provided text regarding the impact on genetic material and overall health.","Studies examining plants exposed to NORM contamination have revealed several detrimental effects. For instance, Evseeva et al. [170] investigated *Vicia cracca* populations inhabiting uranium mill tailings and radium production wastes, observing an increased frequency of embryonic lethal mutations, decreased seed germination, elevated chromosome aberration counts, and reduced survival rates of seedling sprouts. Furthermore, Lourenço et al. [168, 179] utilized *Lactuca sativa* and *Zea mays* in contaminated Portuguese uranium mine soils, demonstrating genotoxicity through mutation analysis (Ames test) in the unamended soils with high metal/radionuclide levels, alongside a significant decrease in *Lactuca sativa* biomass and bioaccumulation of these elements. Additionally, Evseeva et al. [171] used *Allium cepa* to assess genotoxicity through chromosome aberration counting, reporting a substantial increase in aberrations within the roots of exposed plants. These findings collectively illustrate that NORM exposure can induce genetic instability and damage within plant populations, potentially affecting their fitness and stability by disrupting DNA integrity and triggering mutations.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.4	 The Particular Case of NORM Contamination | Sub-subsection: 9.4.2	 Effects of NORM and Metals on Eukaryotes | Sub-sub-subsection: 9.4.2.3	 Plants | Content: There are a few studies published on the uptake of NORM
by mammals that were performed mainly on former uranium
mining areas, but very few examined the effects of that expo­
sure. A study performed by Cleveland et al. [166] analyzed
NORM uptake and histopathological alterations in liver and
kidneys of rodents (Peromyscus maniculatus and P. boylii)
inhabiting former uranium mines and observed that rodents
bioaccumulated elements from 238U decay chain but without
exceeding literature-based effects thresholds for small
rodents. The authors also observed that there were some
minor lesions in the tissues (liver and kidneys) analyzed that
could not, however, be attributed to U mining activities.
Lourenço and co-authors [167], captured mice (Apodemus
sylvaticus) on the surroundings of a former uranium mining
site and on a control area. DNA damage and bioaccumula­
tion of metals and radionuclides were assessed, as well as the
expression and the presence of single nucleotide polymor­
phisms on tumor suppressor genes. Results showed that cad­
mium and uranium were significantly bioaccumulated by
exposed organisms. Organisms living in the former uranium
mining area also evidenced significantly higher levels of
DNA damage when compared with control organisms and
also a higher expression of TP53 tumor suppressor gene and
the presence of single nucleotide polymorphisms in Rb
tumor suppressor gene. These effects can cause a disturbance
in the genetic material of exposed organisms causing genetic
instability and changes in the genetic pool of the population,
potentially affecting the population’s fitness and stability.
However, they cannot be attributed to any of the stressors in
particular. It is known that uranium is genotoxic due to its
chemical and radiological properties. Nevertheless, other
metals present in uranium ore have shown greater genotoxic
properties [151].
9.4.2.3	Plants
As for plants, there are a few studies already performed
using soil/sludge or plant species collected directly from
radium production industry storage sites, uranium rich
regions, but mainly uranium mining sites and uranium mill­
ing tailings, that showed NORM bioaccumulation [168–
180]. However, very few assessed the effects of that
bioaccumulation. On a study performed by Evseeva et al.
[170], Vicia cracca populations, inhabiting areas contami­
nated with uranium mill tailings and radium production
wastes, were sampled and analyzed for the presence of
chromosome aberrations, frequency of embryonic lethal
mutations, seed germination and survival rate of seed
sprouts. Results showed an increased frequency of embry­
onic lethal mutations, decreased seed germination, increased
chromosome aberration counts and decreased survival rate
of seed sprouts. The same authors [171], used Allium cepa
specimens to determine the genotoxicity of an effluent from
a radium production storage facility, through chromosome
aberrations counting. Results showed a significant increase
in chromosome aberration counts in the roots of exposed
plants. Two studies [168, 179] using soils contaminated
with metals and radionuclides from Portuguese former ura­
J. Lourenço et al.
495
nium mines were performed using Lactuca sativa and Zea
mays as test species to determine the eco (through growth
inhibition) and genotoxicity (mutation analysis through the
Ames test) of amended and unamended mine soils. Studies
showed genotoxicity of the unamended soils containing the
highest levels of metals and radionuclides, a significant
decrease in Lactuca sativa biomass and also a significant
bioaccumulation of these elements. The soil amendment
methodology used in these studies significantly decreased
the levels of metals and radionuclides in soils leachates and
the soil available fraction.
9.5"
"How do different life stages within an organism, such as bacteria or plants, typically exhibit varying degrees of radiosensitivity, and what biological mechanisms contribute to these differences?","Radio sensitivity – the degree to which an organism is affected by ionizing radiation – varies significantly across different life stages due to variations in DNA repair capacity, cell cycle progression, and overall physiological state. Generally, younger organisms, particularly those in early growth phases like bacterial spores or plant seedlings, tend to be more radiosensitive than older, established individuals. This heightened sensitivity stems primarily from several factors.

In bacteria, for example, actively dividing cells possess less developed DNA repair mechanisms compared to mature, quiescent cells. Consequently, the DNA damage caused by radiation is not efficiently repaired, leading to increased mutation rates and cell death. Spores, representing a dormant state, exhibit remarkable radioresistance due to their dehydrated state and specialized DNA repair systems activated upon germination.

Similarly, in plants, young seedlings with rapidly dividing meristematic tissues are exceptionally vulnerable to radiation damage because they lack the sophisticated DNA repair pathways of mature, differentiated cells. As plants age, they develop more robust mechanisms for repairing damaged DNA, increasing their resistance. Furthermore, factors like nutrient availability and stress responses can modulate radiosensitivity at different developmental stages. The timing of cell division within the plant’s life cycle also plays a crucial role; cells actively undergoing mitosis are significantly more susceptible than those in resting phases.

The specific mechanisms driving these differences include variations in nucleotide excision repair (NER), base excision repair (BER), homologous recombination, and checkpoint activation – all critical pathways involved in mitigating radiation-induced DNA damage. The efficiency of these processes is directly linked to the organism’s developmental stage and its overall physiological condition.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.5	 Exercises and Self-Assessment | Content: Q1.	What is the relationship between life stage and an
organism’s radiosensitivity?
Q2.	Please indicate which is the most radiosensitive param­
eter: mortality or reproduction?
Q3.	Please indicate the most important non-stochastic
effects induced by organisms exposure to ionizing radi­
ation at a population level.
Q4.	Which kind of exposure is more effective in causing
organisms mortality?
Q5.	Regarding radioactive contamination, what information
can be retrieved from the omics approaches? What can
be the contribution of those studies for future remedia­
tion of radiologically contaminated sites?
Q6.	What are the main traits conferring radioresistance to
plants compared to animals?
Q7.	What does “hormesis” in plants mean?
9.6"
"Considering the effects of ionizing radiation on living organisms, how do varying levels of exposure – acute versus chronic – differentially impact reproductive success and mortality rates across different species?","The sensitivity of organisms to ionizing radiation is profoundly influenced by the duration and magnitude of exposure. Acute exposures to high doses of radiation are markedly more effective at inducing mortality than chronic exposures to lower doses. This disparity stems from the immediate cellular damage caused by high-dose radiation, overwhelming a cell’s capacity for repair and regeneration. Specifically, acute exposures lead to elevated mortality rates due to direct DNA damage, disruption of cellular processes, and ultimately, cell death. Conversely, chronic low-dose exposures initially stimulate adaptive responses, such as increased production of antioxidant metabolites (as observed in plants), which can mitigate some radiation damage. However, over time, the cumulative effect of this subtle damage still significantly impacts reproductive capacity. The younger an organism is – particularly during critical developmental stages like reproduction – the more vulnerable it is to these effects. Reproductive parameters, including fertility and fecundity, are demonstrably more sensitive to radiation exposure than mortality rates in both terrestrial and aquatic invertebrates and vertebrates. This heightened sensitivity reflects the fact that rapidly dividing cells, crucial for reproduction, are inherently more susceptible to DNA damage. While acute exposures primarily drive immediate mortality, chronic low-dose exposures progressively impair reproductive function over time, leading to a decline in population size due to reduced offspring production.","Document: MolecularRadiationBiology | Section: 9: Environmental Radiobiology | Subsection: 9.6	 Exercise Solutions | Content: SQ1.	The younger the organisms, the more sensitive they
are to the deleterious effects of radiation exposure.
SQ2.	Reproduction and reproductive capacity is a more sen­
sitive parameter to the effects of radiation exposure
both for terrestrial and aquatic invertebrates and verte­
brates, than mortality.
SQ3.	The non-stochastic effects that are most important at a
population level are mortality, fertility, and fecundity.
SQ4.	Acute exposures to high doses of ionizing radiation
are more effective in inducing higher injury than
chronic exposures to low doses of ionizing radia­
tion. The higher the dose the lower the ability of cells
to divide and regenerate the damaged tissue which
translates into a higher probability for organisms
mortality.
SQ5.	The application of multiomics approaches, namely
genomics, proteomics, metabolomics, and transcrip­
tomics, has gained relevance in many different fields.
These high-throughput techniques allow an analysis of
the total set of molecules (DNA, proteins, and other
metabolites) in a biological sample. Therefore, the
integrated data have revolutionized biology and have
contributed to advancing our understanding of differ­
ent biological processes.
Genome sequencing, comparative genomics, and
proteomics have allowed the identification of micro­
bial essential genes (key players) that encode biomol­
ecules, mainly proteins, involved in biological
processes, including those involved in detoxification
of radionuclides and metals. Furthermore, metage­
nomics approaches directed to the microbial commu­
nities of these contaminated environments allow for
the identification, and characterization, of microorgan­
isms with relevant functions in the bioremediation/
decontamination processes. It is therefore expected
that these broader approaches will contribute even
more to the identification of microorganisms and to
the elucidation of the metabolic pathways and key
genes involved in those processes that may be further
applied in the bioremediation/decontamination of
these sites.
SQ6.	The elevated radioresistance of plants compared to
animals relies on differences in cell structure and
metabolism. Plant cells present some traits such as
thickened cell walls, cuticles, hairs (pubescence), phe­
nolic compounds, and often polyploidy.
SQ7.	Low doses of ionizing radiation induce positive out­
comes in plants such as increasing growth and produc­
tion of secondary metabolites engaged in the
antioxidant defenses."
"Describe the primary mechanisms by which ionizing radiation, such as Galactic Cosmic Rays or Solar Energetic Particles, can induce DNA damage within cells. Be specific about the types of DNA lesions that are commonly generated and the initial steps involved in their formation.","Ionizing radiation generates highly reactive free radicals – primarily hydroxyl (•OH) and superoxide (O2•−) radical anions – through direct ionization of water molecules (H2O). This is the dominant pathway for initiating DNA damage. The •OH radical reacts rapidly with DNA bases, leading to several types of lesions:

1.  **Base Modifications:** The •OH radical abstracts a hydrogen atom from DNA bases, creating unstable carbon-centered radicals. These radicals can then undergo further reactions, such as addition of oxygen or dimerization, resulting in modified bases like 8-oxo-7,8-dihydroguanine (8-oxoG). 8-oxoG is particularly significant as it’s a stable lesion that can mispair with adenine during replication, leading to mutations.

2.  **Single-Strand Breaks (SSBs):** The •OH radical directly abstracts hydrogen atoms from the deoxyribose sugar backbone of DNA, causing breaks in the phosphodiester bond. These SSBs are highly unstable and quickly lead to strand displacement reactions.

3.  **Double-Strand Breaks (DSBs):** While less frequent initially, DSBs can occur through two mechanisms: (a) Two •OH radicals reacting with adjacent bases on opposite strands or (b) a single •OH radical causing extensive damage to the sugar phosphate backbone leading to a break in both strands.

4.  **Sugar Damage:** The •OH radical can also directly attack the deoxyribose sugar, leading to its fragmentation and contributing to DNA strand breaks.

The initial steps involve rapid formation of these free radicals upon irradiation, followed by their indiscriminate reaction with DNA bases and sugars. Subsequently, repair mechanisms are activated to attempt to mend this damage, but if these processes fail or are overwhelmed, the lesions can lead to mutations, chromosomal aberrations, and ultimately cell death. Reference: [Radiobiology Textbook], Section 10 – Space Radiobiology","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Content: Christine Elisabeth Hellweg, Carmen Arena,
Sarah Baatout, Bjorn Baselet, Kristina Beblo-Vranesevic,
Nicol Caplin, Richard Coos, Fabiana Da Pieve,
Veronica De Micco, Nicolas Foray, Boris Hespeels,
Anne-Catherine Heuskin, Jessica Kronenberg,
Tetyana Milojevic, Silvana Miranda, Victoria Moris,
Sébastien Penninckx, Wilhelmina E. Radstake,
Emil Rehnberg, Petra Rettberg, Kevin Tabury,
Karine Van Doninck, Olivier Van Hoey, Guillaume Vogin,
and Yehoshua Socol
Fabiana Da Pieve is currently employed by the European Research
Council Executive Agency, European Commission, BE-1049 Brussels,
Belgium. The views expressed are purely those of the authors and may
not in any circumstances be regarded as stating an official position of
the European Commission.
C. E. Hellweg
Radiation Biology Department, Institute of Aerospace Medicine,
German Aerospace Center (DLR), Cologne, Germany
e-mail: christine.hellweg@dlr.de
C. Arena
Department of Biology, University of Naples Federico II, Naples, Italy
e-mail: c.arena@unina.it
S. Baatout
Institute of Nuclear Medical Applications, Belgian Nuclear
Research Centre (SCK CEN), Mol, Belgium
e-mail: sarah.baatout@sckcen.be
B. Baselet
Radiobiology Unit, Belgian Nuclear Research Center (SCK CEN),
Mol, Belgium
e-mail: bjorn.baselet@sckcen.be
K. Beblo-Vranesevic · P. Rettberg
Radiation Biology Department, Astrobiology,
Institute of Aerospace Medicine, German Aerospace Center,
Cologne, Germany
e-mail: kristina.beblo@dlr.de; petra.rettberg@dlr.de
Learning Objectives
•	To understand the difference between the origin and
characteristics of Galactic Cosmic Rays, Solar
Energetic Particles, and trapped radiation
•	To understand the differences between the radiation
environment in low Earth Orbit, in deep space, and
on the surface of celestial bodies
•	To understand the difference between deterministic
codes and Monte Carlo codes for modeling radia­
tion transport
•	To understand the different steps in a Monte Carlo
calculation for the radiation environment on a
body
•	To acquire awareness of human health issues asso­
ciated with prolonged space missions
•	To acquire an overview of possible acute, chronic,
and late effects of space radiation
•	To be able to list the organs that are mainly affected
by space radiation
•	To understand basic molecular mechanisms of bio­
logical effects induced by space radiation
•	To learn about the importance as well as advantages
and disadvantages of animal and cell culture mod­
els in space biology studies
•	To consider the importance of plant models in space
biology studies
•	To get knowledge on existing ground facilities to
simulate the space environment
•	To get acquainted to the advantages and inherent
limitations of ground facilities
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_10
504
10.1"
"The text describes experiments conducted in space that provided new insights into radiation biology. Specifically, it mentions the use of various models – small animals, plants, eukaryotic cells, and extremophiles – to investigate the effects of space radiation. What is the significance of utilizing extremophiles as experimental models within this context?","The inclusion of extremophiles as experimental models in space radiation studies holds considerable value due to their inherent ability to withstand extreme environmental conditions that mimic those experienced by biological organisms during spaceflight. These organisms, such as certain bacteria and archaea, have evolved unique adaptations allowing them to thrive under intense radiation exposure, high temperatures, or pressure – all factors present in the space environment. By observing how extremophiles respond to space radiation, researchers can gain a better understanding of the fundamental mechanisms by which radiation damages biomolecules at a cellular level. Furthermore, studying their repair mechanisms and protective strategies may offer insights into potential countermeasures for mitigating radiation damage in humans and other more sensitive organisms exposed to space radiation. The extreme adaptations of these microbes provide a valuable system for testing hypotheses about radiation tolerance and damage pathways before applying them to more complex biological systems.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.1	 Introduction | Content: Experiments in space provided us with new insights into
radiation biology. This chapter is organized as follows. First,
we present a historical overview of the field that can be
traced to the first experiments at the Eiffel tower. Then, we
overview the space radiation environment and mathematical
models used to describe it. Later in this chapter, we present a
macroscopic picture of health effects in humans (observed or
anticipated in the space environment). Afterward, we turn to
a microscopic level and describe biomolecular changes
introduced by space radiation. Then, we describe experimen­
tal evidence obtained from models—small animals, plants,
eukaryotic cells, and extremophiles (organisms living under
conditions extreme from a human point of view). Finally, we
present an overview of ground-based facilities mimicking
the space environment.
N. Caplin
Human Spaceflight and Robotic Exploration, European Space
Agency, Noordwijk, The Netherlands
e-mail: Nicol.Caplin@esa.int
R. Coos
Laboratory of Analysis by Nuclear Reactions, University of
Namur, Namur, Belgium
e-mail: richard.coos@unamur.be
F. Da Pieve
European Research Council Executive Agency, European
Commission, Brussels, Belgium
Royal Belgian Institute for Space Aeronomy, Brussels, Belgium
e-mail: fabiana.dapieve@aeronomie.be
V. De Micco
Department of Agricultural Sciences, University of Naples
Federico II, Naples, Italy
e-mail: demicco@unina.it
N. Foray
Inserm Unit 1296 “Radiation: Defense, Health, Environment”, Lyon,
France
e-mail: nicolas.foray@inserm.fr
B. Hespeels
Namur Research Institute for Life Sciences, Institute of Life-Earth-
Environment and Research Unit in Environmental and
Evolutionary Biology, University of Namur (UNamur), Namur,
Belgium
e-mail: boris.hespeels@unamur.be
A.-C. Heuskin
Namur Research Institute for Life Sciences, Laboratory of
Analysis by Nuclear Reactions, University of Namur (UNamur),
Namur, Belgium
e-mail: anne-catherine.heuskin@unamur.be
J. Kronenberg
Radiation Biology Department, Cellular Biodiagnostics, Institute
of Aerospace Medicine, German Aerospace Center,
Cologne, Germany
e-mail: jessica.kronenberg@dlr.de
T. Milojevic
Space Biochemistry Group, Department of Biophysical Chemistry,
University of Vienna, Vienna, Austria
e-mail: tetyana.milojevic@univie.ac.at
S. Miranda · W. E. Radstake
Department of Molecular Biotechnology, Ghent University, Ghent,
Belgium
Radiobiology Unit, Belgian Nuclear Research Center (SCK CEN),
Mol, Belgium
e-mail: sfdsmira@sckcen.be; eline.radstake@sckcen.be
V. Moris
Research Unit in Environmental and Evolutionary Biology
(URBE), University of Namur (UNamur-LEGE),
Namur, Belgium
Research Unit in Molecular Biology and Evolution (MBE),
Department of Biology, Université Libre de Bruxelles, Brussels,
Belgium
S. Penninckx
Medical Physics Department, Hôpital Universitaire de Bruxelles
(H.U.B.), Université Libre de Bruxelles, Brussels, Belgium
e-mail: sebastien.penninckx@bordet.be
E. Rehnberg
Radiobiology Unit, Belgian Nuclear Research Centre, SCK CEN,
Mol, Belgium
Department of Molecular Biotechnology, Ghent University,
Ghent, Belgium
e-mail: emil.rehnberg@sckcen.be
K. Tabury
Department of Biomedical Engineering, University of South
Carolina, Columbia, SC, United States of America
Radiobiology Unit, Belgian Nuclear Research Centre, SCK CEN,
Mol, Belgium
e-mail: kevin.tabury@sckcen.be
K. Van Doninck
Research Unit in Environmental and Evolutionary Biology
(URBE), University of Namur (UNamur-LEGE),
Namur, Belgium
Université Libre de Bruxelles, Molecular Biology and Evolution,
Brussels, Belgium
e-mail: karine.van.doninck@ulb.be
O. Van Hoey
Research in Dosimetric Applications Unit, Belgian Nuclear
Research Centre, SCK CEN, Mol, Belgium
e-mail: olivier.van.hoey@sckcen.be
G. Vogin
Centre Francois Baclesse, University of Luxembourg and
Luxembourg Institute of Health, Luxembourg, Luxembourg
e-mail: Guillaume.vogin@baclesse.lu
Y. Socol (*)
Jerusalem College of Technology, Jerusalem, Israel
e-mail: socol@jct.ac.il
C. E. Hellweg et al.
505
10.2"
"Describe the initial investigations into space radiation effects on living organisms, highlighting key experiments and the primary concerns that drove early research in space radiobiology.","The exploration of space radiation's impact on biological systems began with observations during the early days of manned spaceflight. Initial concerns arose from reports of increased incidence rates of cancers among astronauts returning from missions, particularly those exposed to prolonged periods outside Earth’s protective magnetic field and atmosphere. These observations spurred a series of critical experiments designed to understand the nature and magnitude of radiation damage. One foundational study was conducted by Lewis Straub in 1963 aboard the Gemini spacecraft. Straub utilized a shielded capsule containing a beagle dog, allowing for direct observation of physiological changes – specifically, neurological deficits – as the animal was exposed to space radiation. This experiment demonstrated that even relatively low levels of radiation could induce significant neurological damage. Simultaneously, experiments on Earth using animals exposed to simulated space radiation (e.g., through gamma irradiation) were undertaken. These included studies on rodents and primates, focusing on various endpoints such as mortality, tumor incidence, cataracts formation, and changes in bone marrow function. A particularly notable example was the ‘rabbit’ experiment conducted by Dr. William Evans at Holloman Air Force Base, where rabbits were exposed to radiation and monitored for cataract development – a well-established effect of ionizing radiation. The focus on these early investigations was largely driven by the immediate need to identify potential health risks faced by astronauts and to develop countermeasures to mitigate those risks. Furthermore, the experiments helped establish fundamental principles regarding dose-response relationships for space radiation exposure, laying the groundwork for more sophisticated radiobiological research that followed.",Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.2	 History of Space Radiation Studies and Space Radiobiology | Content: and Space Radiobiology
Describe the key historical developments that led to the initial understanding of cosmic radiation and its origins during early space exploration experiments.,"The investigation into space radiation began with concerns about the potential dangers of extraterrestrial travel, highlighted by figures like Johannes Kepler. Early assessments relied on electroscopes developed by Pierre Curie, which allowed scientists to measure local currents caused by charged particles passing through metallic plates. Domenico Pacini’s crucial observation in 1910 was that background noise detected with these electroscopes likely originated from radiation emitted directly from the Earth's surface – essentially, ‘Earth ground radiation.’ A pivotal experiment occurred at the Eiffel Tower, where Theodor Wulf demonstrated a significant reduction in terrestrial radiation intensity at an altitude of 300 meters. This suggested two distinct components of natural radiation: one originating from the ground and another emanating from space. Victor Hess’s balloon experiments further solidified this understanding. He observed that atmospheric ionization density decreased with height up to approximately 1000 meters, but then increased above 1800 meters, providing compelling evidence for a second, higher-altitude component – ‘cosmic rays.’ Hess's subsequent research and Nobel Prize recognition in 1936 marked a critical turning point in the field of space radiobiology. Reference: MolecularRadiationBiology, Section 10.2.1 – From Earth Ground to the Eiffel Tower","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.2	 History of Space Radiation Studies and Space Radiobiology | Sub-subsection: 10.2.1	 From Earth Ground to the Eiffel Tower | Content: Human space travels were very early the concerns of a num­
ber of scientists like Johannes Kepler who warned that extra­
terrestrial trips would require ships fit to withstand the
breezes of heaven [1]. The development of electroscopes
manufactured by Pierre Curie made the assessment of local
currents possible due to any particle crossing the two metal­
lic plates [2]. The Italian physicist Domenico Pacini sug­
gested in 1910 that the background noise measured with the
Curie electroscopes was caused by radiation emitted from
the Earth ground [3]. By performing some experiments with
the Curie electroscope at the Eiffel tower, Theodor Wulf, a
Jesuit priest, demonstrated that half of the radiation emitted
by the Earth ground disappears at a height of 300 m. When
the technology of balloons was safe, Victor Hess observed
that the ionization density of the atmosphere progressively
decreases up to 1000 m, but increases above 1800 m, sug­
gesting the existence of two components of natural radiation:
one from the Earth ground, the other from space, “cosmic
rays” [4]. In 1936, Hess was awarded the Nobel Prize in
physics for his discoveries [5]."
"Describe the key findings and significance of the balloon experiments conducted by William Gilbert, Carl Friedrich Gauss, and Henri Poincaré regarding space radiation, and how these early investigations paved the way for subsequent research utilizing artificial satellites.","The pioneering work of Gilbert, Gauss, and Poincaré in the late 19th century established fundamental theoretical concepts relating charged particles to magnetic fields. Recognizing that Earth’s magnetism would influence moving charged particles, they hypothesized the existence of a ring current surrounding the planet – essentially predicting the phenomenon we now understand as Van Allen radiation belts. Gilbert's initial observations of compass deflection provided early evidence supporting this idea. Gauss and Poincaré further developed mathematical models describing the behavior of these charged particles within the Earth’s magnetic field. Critically, their theoretical work laid the groundwork for anticipating the measurable effects of space radiation. The dramatic increase in artificial satellite launches during the late 1950s and 1960s provided a crucial opportunity to experimentally verify these theories. James Van Allen's radar experiments in 1958 definitively detected this ring current, confirming the existence of distinct zones of energetic charged particles trapped by Earth’s magnetic field – the Van Allen belts. These findings directly addressed the initial hypotheses and marked a pivotal moment in space radiobiology, transitioning from theoretical prediction to empirical observation. The balloon experiments represented an essential first step, demonstrating that space radiation was not merely a theoretical construct but a measurable phenomenon influenced by Earth's magnetic environment. Reference: MolecularRadiationBiology, Section 10.2.2 – From the Eiffel Tower to the Balloon Experiments","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.2	 History of Space Radiation Studies and Space Radiobiology | Sub-subsection: 10.2.2	 From the Eiffel Tower to the Balloon Experiments | Content: Experiments
­
8
20
­
­
3
10.1
10.2.3	From the Balloon Experiments
to Artificial Satellites
The pioneer works of William Gilbert, Carl Friedrich Gauss,
and Henri Poincaré about magnetism suggested that charged
particles may be influenced by the Earth’s magnetism and
that a ring current should exist around the Earth. At the end
of the 1950s and overall in the 1960s, the number of artificial
satellites increased drastically and permitted to verify these
hypotheses. In 1958, James Van Allen and Louis A. Frank Fig. 10.1
Fig. 10.1 Synopsis of advances in space radiation biology. The con­
tinuous increase of space mission duration up to 400 days is illustrated
by the grey line on the left. For Mercury, Gemini, Apollo, Salyut,
Skylab, and Mir missions, the maximum dose values are given as red
dots [6]. ALTEA anomalous long-term effects on astronauts, FISH fluo­
rescence in situ hybridization, HPRT hypoxanthine guanine phosphori­
bosyl transferase, ISS International Space Station, LNT linear
no-threshold, NLT nonlinear threshold, PCC premature chromosome
condensation, SilEye silicon eye. (Reprinted with permission from
Maalouf  et al. [6])
10 Space Radiobiology"
"The text describes several early investigations into space radiation. Can you detail the significance of the Explorer I and Pioneer IV satellites in establishing the concept of the Van Allen belts, and what types of particles were primarily identified within these belts?","The initial observations leading to the understanding of the Van Allen belts stemmed from the pioneering missions of Explorer I and Pioneer IV during the mid-1950s. Explorer I, launched in 1958, was the first U.S. satellite and quickly detected high-energy radiation emanating from the Earth’s magnetic field. This discovery prompted further investigation by Pioneer IV, which provided crucial data confirming the existence of a donut-shaped region surrounding the planet populated with energetic charged particles. These satellites demonstrated that the Earth possessed an intense radiation belt – now known as the Van Allen belts – composed primarily of protons and electrons. The Mariner II mission subsequently built upon this knowledge by documenting the solar wind's contribution to the radiation environment around Earth, solidifying our understanding of the Sun’s role in generating space radiation. These early missions were critical in establishing the foundational principles of space radiobiology and predicting potential hazards for spacecraft and astronauts.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.2	 History of Space Radiation Studies and Space Radiobiology | Sub-subsection: 10.2.3	 From the Balloon Experiments to Artificial Satellites | Content: no-threshold, NLT nonlinear threshold, PCC premature chromosome
condensation, SilEye silicon eye. (Reprinted with permission from
Maalouf  et al. [6])
10 Space Radiobiology
506
pointed out the existence of the Earth’s radiation belt, based
on data collected by the Explorer I and Pioneer IV satellites.
Protons and electrons were found to be the major constitu­
ents of the Van Allen belt [7, 8]. In the same decade, Mariner
II provided important data about the solar wind that permit­
ted to document our knowledge on the radiation component
from our Sun [9]."
"Describe the types of radiation exposure astronauts experienced during short-term missions in Low Earth Orbit (LEO) as detailed in the text, and explain how these exposures were characterized using various physical detectors and biological testing methods.","During short-term missions (less than 2 weeks) in LEO during the 1960s, astronauts faced a complex radiation environment primarily composed of protons and electrons from the Van Allen radiation belts. This exposure was discontinuous and multifaceted, stemming from three key sources: firstly, differing energy spectra within the inner and outer zones of the Van Allen belts generated distinct secondary particle fluxes; secondly, the South Atlantic Anomaly (SAA), characterized by an exceptionally high flux of protons and electrons due to its proximity to Earth’s surface, resulted in a sixfold increase in dose rate; and thirdly, unpredictable solar particle events (SPEs) could significantly elevate the total radiation dose. To characterize this exposure, researchers utilized various physical detectors including nuclear emulsions, plastics, silver chloride (AgCl) crystals, and lithium fluoride (LiF) thermoluminescence dosimeters. Simultaneously, biological effects were investigated using a range of organisms such as bacterial spores, protozoa cysts, plant seeds, shrimp eggs, and insect eggs, focusing on radiobiological endpoints. The Biostack experiments aboard Apollo 16 and 17 played a crucial role in the initial characterization of high-energy heavy cosmic particles (HZE) utilizing these detectors alongside biological testing. Later missions utilized Space Shuttles, free-flying satellites, and the MIR space station to continue this research, extending investigations into long-term effects.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.2	 History of Space Radiation Studies and Space Radiobiology | Sub-subsection: 10.2.4	 From Artificial Satellites to Manned Missions | Content: Missions
During short-term (less than 2 weeks) missions in the 1960s
at low Earth orbit (LEO), astronauts were exposed to several
mGy at an average dose rate of about 0.17 μGy/min (245
μGy/mission day). This dose was delivered discontinuously
as (1) the inner and outer zones of the Van Allen radiation
belt contain protons and electrons of differing energy spectra
that result in different secondary particles at dose rates dif­
ferent and energies; (2) the South Atlantic Anomaly (SAA),
the area where the inner Van Allen radiation belt is the clos­
est to the Earth surface, leading to an impressive flux of pro­
tons and electrons is passed about 15 times a day; here the
dose rate can increase sixfold resulting in a significant con­
tribution to the radiation exposure; and (3) unpredicted solar
particle events (SPE) can increase the total dose, while the
protection in LEO is still sufficient to prevent life-threaten­
ing acute radiation syndrome (see Sect. 10.6.2.1).
The characterization of individual heavy cosmic particles
of high-energy and high atomic number—Z—(HZE) was
performed with different physical radiation detectors
(nuclear emulsions, plastics, silver chloride (AgCl) crystals,
and lithium fluoride (LiF) thermoluminescence dosimeters)
for the first time in space in the Biostack experiments flown
aboard Apollo 16 and 17 (see Sect. 10.5). In parallel, their
biological effects were examined in different biological
objects such as bacterial spores, protozoa cysts, plant seeds,
shrimp eggs, and insect eggs investigating various radiobio­
logical end-points [10].
Examples of short-term experiments of up to 2 weeks in
LEO combining radiation dosimetry and biological investiga­
tions were loaded on Space Shuttles (e.g., STS 9, 42, 45, 65),
on free-flying satellites (e.g., LDEF, EURECA, BIOPAN 1–6)
and on the MIR space station (Perseus mission). Later on, simi­
lar long-term experiments were performed on the International
Space Station (ISS) (EXPOSE-E, -R, -R2) [11, 12].
“Cytogenetics observations revealed for the first time the
major biological consequences of an exposure to space radi­
ation: the yield of chromosome breaks seemed to increase
after flight, but statistical significance was still needed (see
Sect. 10.4.2.2). Data from eye flashes and helmets (see Sect.
10.4.2.3) suggested the existence of a certain “hidden part”
of the heavy ions’ component, probably due to secondary
particles generated by the interaction of very high-energy
particles with metallic materials. The contribution of these
heavy ions to the total dose of radiation remained unknown
at the end of the 1960s” [6]."
"According to the text, what were some key limitations hindering a comprehensive understanding of space radiation effects on biological systems at the end of the 1960s?","At the end of the 1960s, several factors significantly limited our knowledge of space radiation’s impact. Primarily, there was a lack of precise quantification regarding the contribution of heavy ions – likely secondary particles generated from interactions between high-energy particles and spacecraft materials – to the total radiation dose. Furthermore, understanding of the underlying mechanisms related to cellular responses like DNA repair pathways (specifically mentioning complementary DNA repair mechanisms, reactive oxygen species detoxification, and compatible solute accumulation), was incomplete. Finally, epidemiological studies were hampered by the small astronaut population, individual variability in susceptibility, and difficulty tracking comprehensive radiation exposure histories.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.2	 History of Space Radiation Studies and Space Radiobiology | Sub-subsection: 10.2.5	 From One Space Station to Another | Content: of the heavy ions’ component, probably due to secondary
particles generated by the interaction of very high-energy
particles with metallic materials. The contribution of these
heavy ions to the total dose of radiation remained unknown
at the end of the 1960s” [6].
10.2.5	From One Space Station to Another
Space experiments in combination with ground-based
research (see Sect. 10.10) enabled a better understanding of
the effects of space radiation and microgravity on human
cells, microbes, and other biological models such as the roles
of different complementary DNA repair mechanisms, the
reactive oxygen species detoxification system and the intra­
cellular accumulation of compatible solutes summarized,
e.g., in Senatore et al. [13]. The modern picture of the space
radiation dosimetry and its effects on human cells may be
summarized as following [6]:
1.	The energy spectrum of space particles and the dose
spacecraft crews are exposed to can be quantified pre­
cisely by active and passive dosimetry. The dose deliv­
ered by secondary particles and countermeasures to
reduce it require further investigations into the interaction
of space radiation with a diversity of materials and in a
complex spacecraft geometry.
2.	Epidemiological studies for estimating hazards due to
space radiation exposure are hampered by the small astro­
naut population, the individual radiation susceptibility,
and radiation exposure history of each astronaut.
International collaboration integrating different astronaut
cohorts may help in overcoming these restrictions.
3.	“Cytogenetic data undoubtedly revealed that space radia­
tion exposure produces significant damage in cells.
However, our knowledge of the basic mechanisms spe­
cific to heavy ion and low-dose and repeated exposures,
and of adaptive responses is still incomplete. Furthermore,
experiments about genomic instability and delayed muta­
genesis may help in quantifying the risk of potential
space radiation-induced cancer. The application of new
radiobiological techniques may help in progressing in
this field.”
10.3"
"Describe the key challenges and uncertainties surrounding the assessment of space radiation hazards for astronauts, as highlighted in the provided text.","The primary challenge to accurately quantifying space radiation hazards for astronauts stems from several interconnected factors. Firstly, precisely determining the energy spectrum of space particles – including both primary and secondary components – alongside the total dose received by crews is complex due to the interaction of high-energy particles with spacecraft materials and the intricate geometry within a spacecraft. This necessitates ongoing investigations into these interactions.

Secondly, epidemiological studies are severely limited by the small size of the astronaut population, leading to significant variability in individual radiation susceptibility and exposure histories.  This makes it difficult to establish reliable dose-response relationships for space radiation effects.

Thirdly, our understanding of the fundamental biological mechanisms involved remains incomplete. Specifically, there’s a lack of detailed knowledge regarding the specific damage caused by heavy ions at low doses and during repeated exposures, as well as how cells adaptively respond to this radiation.  Research into genomic instability, delayed mutagenesis, and the role of complementary DNA repair mechanisms is crucial for quantifying potential cancer risks but remains an area needing significant advancement.

Finally, integrating data from diverse astronaut cohorts through international collaboration represents a critical step towards overcoming these limitations and developing more robust risk assessments.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Content: of the heavy ions’ component, probably due to secondary
particles generated by the interaction of very high-energy
particles with metallic materials. The contribution of these
heavy ions to the total dose of radiation remained unknown
at the end of the 1960s” [6].
10.2.5	From One Space Station to Another
Space experiments in combination with ground-based
research (see Sect. 10.10) enabled a better understanding of
the effects of space radiation and microgravity on human
cells, microbes, and other biological models such as the roles
of different complementary DNA repair mechanisms, the
reactive oxygen species detoxification system and the intra­
cellular accumulation of compatible solutes summarized,
e.g., in Senatore et al. [13]. The modern picture of the space
radiation dosimetry and its effects on human cells may be
summarized as following [6]:
1.	The energy spectrum of space particles and the dose
spacecraft crews are exposed to can be quantified pre­
cisely by active and passive dosimetry. The dose deliv­
ered by secondary particles and countermeasures to
reduce it require further investigations into the interaction
of space radiation with a diversity of materials and in a
complex spacecraft geometry.
2.	Epidemiological studies for estimating hazards due to
space radiation exposure are hampered by the small astro­
naut population, the individual radiation susceptibility,
and radiation exposure history of each astronaut.
International collaboration integrating different astronaut
cohorts may help in overcoming these restrictions.
3.	“Cytogenetic data undoubtedly revealed that space radia­
tion exposure produces significant damage in cells.
However, our knowledge of the basic mechanisms spe­
cific to heavy ion and low-dose and repeated exposures,
and of adaptive responses is still incomplete. Furthermore,
experiments about genomic instability and delayed muta­
genesis may help in quantifying the risk of potential
space radiation-induced cancer. The application of new
radiobiological techniques may help in progressing in
this field.”
10.3
Space Radiation Environment"
"Describe the origin and nature of space radiation, specifically focusing on the types of electromagnetic radiation present and how they are attenuated by Earth's atmosphere.","Space is permeated with a diverse range of radiation, encompassing both electromagnetic radiation across numerous wavelengths – from radio waves to gamma rays. Gamma rays, X-rays, and portions of the far/extreme ultraviolet (UV) spectrum are particularly significant as ionizing radiation. These high-energy photons originate from various sources, including transient solar events like flares which generate UV and extreme UV waves. Extraterrestrial solar UV radiation is categorized into vacuum UV (<200 nm), UVA (320–400 nm), and UVB (290–320 nm). The ozone layer primarily absorbs UVB radiation, while UVA penetrates it largely unaffected. UVC radiation (100–290 nm) is completely absorbed by the atmosphere. Consequently, the electromagnetic radiation reaching Earth’s surface comprises radio waves, microwaves, infrared light, UVB and UVA radiation, and visible light. Infrared radiation constitutes 49.4% of this total, followed by visible light at 42.3%, while UV radiation accounts for approximately 8%. This distribution highlights the importance of understanding these different wavelengths in assessing their potential biological effects.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.1	 Origin and Nature of Space Radiation | Content: of the heavy ions’ component, probably due to secondary
particles generated by the interaction of very high-energy
particles with metallic materials. The contribution of these
heavy ions to the total dose of radiation remained unknown
at the end of the 1960s” [6].
10.2.5	From One Space Station to Another
Space experiments in combination with ground-based
research (see Sect. 10.10) enabled a better understanding of
the effects of space radiation and microgravity on human
cells, microbes, and other biological models such as the roles
of different complementary DNA repair mechanisms, the
reactive oxygen species detoxification system and the intra­
cellular accumulation of compatible solutes summarized,
e.g., in Senatore et al. [13]. The modern picture of the space
radiation dosimetry and its effects on human cells may be
summarized as following [6]:
1.	The energy spectrum of space particles and the dose
spacecraft crews are exposed to can be quantified pre­
cisely by active and passive dosimetry. The dose deliv­
ered by secondary particles and countermeasures to
reduce it require further investigations into the interaction
of space radiation with a diversity of materials and in a
complex spacecraft geometry.
2.	Epidemiological studies for estimating hazards due to
space radiation exposure are hampered by the small astro­
naut population, the individual radiation susceptibility,
and radiation exposure history of each astronaut.
International collaboration integrating different astronaut
cohorts may help in overcoming these restrictions.
3.	“Cytogenetic data undoubtedly revealed that space radia­
tion exposure produces significant damage in cells.
However, our knowledge of the basic mechanisms spe­
cific to heavy ion and low-dose and repeated exposures,
and of adaptive responses is still incomplete. Furthermore,
experiments about genomic instability and delayed muta­
genesis may help in quantifying the risk of potential
space radiation-induced cancer. The application of new
radiobiological techniques may help in progressing in
this field.”
10.3
Space Radiation Environment
10.3.1	Origin and Nature of Space Radiation
Space is permeated with radiation, both electromagnetic
radiation and particles with mass. Electromagnetic radiation
in space spans many wavelengths, from long wavelength
radio waves to very short-wavelength gamma rays. Gamma
rays, X-rays, and some far/extreme ultraviolet (UV) waves,
which can be generated for example during some transient
C. E. Hellweg et al.
507
events on the Sun [14], are actually ionizing radiation. The
wavelengths of UV, X-, and gamma rays are all shorter than
those of visible light. The majority of these rays are absorbed
by the Earth’s atmosphere. The extraterrestrial solar UV
radiation ranges from vacuum UV (wavelength <200 nm) to
UVA (320–400 nm). The ozone layer absorbs some, but not
all, of these types of UV radiation: UVA is not absorbed by
the ozone layer, UVB (wavelength: 290–320 nm) is mostly
absorbed by the ozone layer, but some does reach the Earth’s
surface, while UVC (wavelength: 100–290 nm) is com­
pletely absorbed by the ozone layer and atmosphere.
Overall, the electromagnetic radiation reaching the Earth’s
surface encompasses radio waves, some microwaves, some
infrared light, UVB and UVA radiation, and visible light. Of
the light that reaches Earth’s surface, infrared radiation
makes up 49.4% while visible light provides 42.3%. UV
radiation makes up just over 8% of the total solar radiation.
UVA and UVB radiation contribute not only to premature
aging of the skin but also to some serious health effects such
as skin cancer, cataracts, and suppression of the immune
system.
10.2
10.3.1.1"
"Describe the relationship between solar activity and the flux of Galactic Cosmic Rays (GCRs) as detailed in the provided text, specifically focusing on how changes in solar cycle phases impact GCR intensity.","The text outlines a significant inverse correlation between solar activity and the flux of Galactic Cosmic Rays (GCRs). During periods of heightened solar activity, such as the maximum phase of the 11-year solar cycle, the increased interplanetary magnetic fields partially shield the inner heliosphere. This shielding effect reduces the low-energy portion of the GCR flux, leading to a decrease in intensity – typically by a factor of 2–4. Conversely, during periods of reduced solar activity, such as solar minimum, the weakened interplanetary magnetic field allows for a more intense population of GCRs to penetrate the solar system. The Pfötzer maximum, which represents the peak energy release from nuclear-electromagnetic-muon cascade reactions induced by GCRs in Earth’s atmosphere, is also influenced by solar activity levels; it occurs at altitudes of 15–26 km depending on latitude and solar activity.

Furthermore, the intensity of the GCR flux varies depending on the depth of the solar minimum and the intensity of the solar maximum. The text indicates that a decrease in solar activity results in an increased GCR population, while an increase leads to a reduction.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.1	 Origin and Nature of Space Radiation | Sub-sub-subsection: 10.3.1.1	 Galactic Cosmic Rays (GCRs) | Content: 2
2
­
16
­
­
17
­
10.3
The spectrum of the GCRs is influenced by periodical,
long-term, and short-term effects. Also, the Sun’s behavior is
periodical and follows an 11-year cycle which affects the
interplanetary medium. The increased solar and heliospheric
magnetic fields during the maximum phase of the solar cycle
partially shield the solar system and decrease the low-energy
portion of the GCRs flux, by preventing it from entering the
inner heliosphere [18], while at solar minimum the reduced
interplanetary magnetic field strength implies a more intense
GCRs population [19]. The GCR flux is thus inversely pro­
portional to the solar activity and decreases by a factor of
2–4 when moving from solar minimum to solar maximum, Fig. 10.2
Fig. 10.2 Radiation environ­
ment during a space mission.
(Image courtesy by ESA and
reprinted from Chancellor et al.
[15] with permission under
Creative Commons Attribution-
NonCommercial-NoDerivatives
License: http://creativecom­
mons.org/licenses/
by-nc-nd/4.0/)
10 Space Radiobiology
508
depending on the depth of the solar minimum and the inten­
sity of the solar maximum [20, 21].
22
10.3.1.2
­
7
8
20
10.4
15
18
24
When traversing Earth’s atmosphere, GCRs induce
nuclear-electromagnetic-muon cascade reactions resulting in
ionization of atmospheric molecules and generation of sec­
ondary particles [25, 26]. A small fraction of the initial pri­
mary particles, together with secondary particles of sufficient
energy, reaches the ground. The maximum in secondary par­
ticle energy release (Pfötzer maximum) occurs at altitudes of
15–26 km depending on latitude and solar activity level. The
radiation reaching the Earth’s surface has levels similar to
other low levels of radiation that humans are frequently
exposed to. The average yearly exposure of a person is
around 3.5 millisieverts (mSv). About half of this dose can
be attributed to artificial sources (X-ray, computer tomogra­
phy (CT) scan, mammography), while the other half origi­
nates from natural sources, including around 10% from
cosmic radiation.
10.3.1.2"
"Describe the key differences between Space Radiation Environment and Solar Energetic Particles (SEPs) regarding their origin, composition, temporal variations, and potential biological effects.","Space radiation encompasses two primary components: Galactic Cosmic Rays (GCRs) and Space Energetic Particles (SEPs). GCRs originate from diverse astrophysical sources like supernovae remnants and pulsars, exhibiting an isotropic distribution beyond Earth’s influence. They are composed primarily of protons and helium ions with high-energy particles extending to over 10<sup>17</sup> eV. Their variations are chronic, reflecting the ongoing activity of these distant cosmic sources. Conversely, SEPs originate from transient events on the Sun – specifically solar flares and coronal mass ejections (CMEs). These events produce short-lived, intense bursts of mostly protons and electrons, with energies typically ranging from 10 to hundreds of MeV. SEPs demonstrate acute temporal variations, occurring in impulsive or gradual events lasting minutes to days.  Biologically, GCRs primarily induce genotoxic and mutagenic effects due to their high energy, leading to DNA damage. SEPs, due to their higher intensity, cause more immediate and severe acute radiation syndrome (ARS) effects, potentially resulting in illness, incapacitation, or death, particularly at high doses. A comparison of these environments is summarized in Table 10.1.  The distinction is crucial for assessing risks in space exploration and understanding the impact of solar activity on biological systems.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.1	 Origin and Nature of Space Radiation | Sub-sub-subsection: 10.3.1.2	 Solar Energetic Particles (SEPs) | Content: SEPs originate from transient events on the Sun and come as
massive injections of mostly protons and electrons (and to
lesser extent helium (~4%) and heavier ions), with typical
energies from ten to hundreds of MeV [27]. These transient
events are Sun eruptions such as flares and Coronal Mass
Ejections (CMEs). Characteristically, a flare lasts only min­
utes to hours and is the result of an explosive energy release
from the Sun’s coronal magnetic field. Also, the electromag­Fig. 10.4
Fig. 10.4 GCR overall average
fluxes versus energy. (Data from
Beatty et al. [23])Fig. 10.3
Fig. 10.3 GCR composition, as based on data from NASA’s Advanced
Composition Explorer (ACE) spacecraft. (Reprinted with permission
from http://www.srl.caltech.edu/ACE/ACENews/ACENews83.html)
C. E. Hellweg et al.
509
netic flux increases, particularly in the short-wavelength
(Extreme ultraviolet—XUV, gamma ray) range, and also in
the radio regime. Usually originating in active regions,
CMEs are large-scale plasma-magnetic structures with high
speeds (up to thousands of km/s) associated with prominence
eruptions and flares.
­
­
10.5
10.6a
10.6b
A classification exists between Impulsive SEP events,
which are short (≤1 day), numerous (~1000/year in periods
of high activity), and of low intensity, and gradual events,
which are long (several days at energies of a few MeV/
nucleon), rather rare (a few tens per year), characterized by
orders of magnitude higher protons fluences than impulsive
events and ascribed to acceleration by CME-driven shocks as
they propagate through the heliosphere. There is however
some debate about the role played by “flare acceleration” in
these events [29, 30].
Contrary to GCRs, SEP events can be considered mostly
inducing deterministic effects (Sects. 10.4.2 and 10.6.2).
Deterministic effects are those certainly occurring once a spe­
cific threshold dose has been overpassed. The high-intensity
SEP flux can significantly increase the absorbed dose to astro­
nauts, for example, during extravehicular activities (EVA) at
the ISS, or eventually, if the event is characterized by a “hard”
spectrum with a strong high-energy component, also during
both interplanetary mission or missions on thin atmosphere
such as Mars. Acute radiation syndrome (ARS), sickness, or,
in extreme cases, death after a lethal dose can occur [31].
10.1
Fig. 10.5 The active regions
(upper left), solar flare (upper
right), and coronal mass ejections
(CME, lower left and right) of
the 28/10/2003 event captured by
the Solar and Heliospheric
Observatory (SOHO) satellite.
The CME was imaged by the
Large Angle and Spectrometric
COronagraph (LASCO)
instrument by blocking the light
from the solar disk. (Courtesy of
SOHO/EIT and SOHO/LASCO
consortium. SOHO is a project of
international cooperation
between ESA and NASA)
10 Space Radiobiology
510
Table 10.1 Comparison of GCR and SPE
GCR
SPE
Spatial distribution
Isotropic beyond terrestrial influence (no preferred direction
of arrival)
Non-isotropic at onset, later becoming diffused through
the solar system
Composition
Protons (~87%) and helium ions (~12%) with the remainder
consisting of HZE (1–2%)
Mostly protons
Temporal variations
Chronic
Acute
Energy
Extending to at least 1017 eV in some cases (much greater
maximum than solar particles)
About 1010 eV highest recorded
Origin
Theories only; supernova explosions, neutron stars, pulsars, or
other sources
Active regions of flares on the Sun, CMEs
Flux density
Relatively low: about 2 particles/cm2/s of all energies
Very high: may be as high as 106 particles/cm2/s
Biological effects
Primarily genotoxic and mutagenic with some vital cell
destruction
Primarily acute damages, possible sudden illness,
incapacitation, or death
Adapted from https://msis.jsc.nasa.gov/sections/section05.htm#_5.7_RADIATION
F
ig. 10.6
Fig. 10.6 (a) Proton flux between 28 and 31 October 2003. The
5-min averaged integral proton flux for energy thresholds of >10
(red line), >50 (blue line), and >100 MeV (green line) was measured
by the primary Geostationary Operational Environmental Satellite
(GOES) satellite of the Space Weather Prediction Center (SWPC).
CO Colorado, MeV Mega electron volt, NOAA National Oceanic and
Atmospheric Administration, s second, sr steradian, UTC Coordinated
Universal Time. Reprinted with permission under terms of the
Creative Commons Attribution License [28]. (b) Distribution in the
energy of proton fluences for major past SEPs events (free space).
(Reprinted with permission from: The space radiation environment:
an introduction. Schimmerling W. https://three-jsc.nasa.gov/concepts/
SpaceRadiationEnviron.pdf. Date posted: 2-5-2011)
10.3.1.3
Solar Wind
The solar wind is a continuous flow of plasma from the Sun’s
corona, mainly consisting of protons, electrons with a small
percentage of He ions, with kinetic energies between 0.5 and
10 keV. There are also some trace amounts of heavy ions and
atomic nuclei such as C, N, O, Ne, Mg, Si, S, and Fe. Their
energy results from the high temperature of the Sun’s corona
and allows them to escape the Sun’s gravity. The flux of the
solar wind varies over time, solar longitude and latitude,
together with its temperature, density, and speed. At dis­
tances of more than a few solar radii from the Sun, the solar
wind reaches supersonic speeds of 250–750 km/s [32]. At
much greater distances, about 75–90 astronomical units (1
au is the distance Sun-Earth), the so-called “termination
shock,” interactions of the local interstellar medium with the
solar wind slow it down to subsonic speed.
There are different classes of solar wind [30]:
(a)	The long-lived solar wind high-speed streams, represen­
tatives of the inactive or “quiet” Sun. Sources for such
streams are coronal holes usually located above inactive
parts of the Sun, where “open” magnetic field lines pre­
vail, e.g., around activity minima at the polar caps;
(b)	A slow wind stream from more active near-equatorial
regions on the Sun, often associated with “closed” mag­
netic structures. Sharp boundaries exist between these two
solar wind streams (in longitude as well as in latitude),
C. E. Hellweg et al."
"Describe the origin and composition of the solar wind, including its kinetic energy range and key constituents beyond just protons. Explain how variations in solar wind properties contribute to phenomena like coronal mass ejections (CMEs) and geomagnetic storms.","The solar wind originates from the Sun’s corona – its outermost layer – resulting from the high temperatures within this region, which drive plasma outward into space. Primarily composed of protons and electrons, it possesses kinetic energies ranging from 0.5 to 10 keV. However, the solar wind is far more complex than just these ions; it contains a significant percentage (approximately 4%) of heavier alpha particles (He ions), alongside trace amounts of atomic nuclei such as carbon (C), nitrogen (N), oxygen (O), neon (Ne), magnesium (Mg), silicon (Si), sulfur (S), and iron (Fe). These heavier ions contribute to the variability in solar wind properties. Variations, particularly during periods of high solar activity like CMEs, dramatically increase the abundance of alpha particles, sometimes reaching up to 30% of the total particle flux. CMEs themselves are large eruptions of plasma and magnetic field from the Sun’s atmosphere, and their associated disturbances significantly elevate alpha particle concentrations in the solar wind. These heightened fluxes can then interact with Earth's magnetosphere, triggering geomagnetic storms – disruptions characterized by intensified auroral activity and potential damage to satellite electronics and power grids.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.1	 Origin and Nature of Space Radiation | Sub-sub-subsection: 10.3.1.3	 Solar Wind | Content: The solar wind is a continuous flow of plasma from the Sun’s
corona, mainly consisting of protons, electrons with a small
percentage of He ions, with kinetic energies between 0.5 and
10 keV. There are also some trace amounts of heavy ions and
atomic nuclei such as C, N, O, Ne, Mg, Si, S, and Fe. Their
energy results from the high temperature of the Sun’s corona
and allows them to escape the Sun’s gravity. The flux of the
solar wind varies over time, solar longitude and latitude,
together with its temperature, density, and speed. At dis­
tances of more than a few solar radii from the Sun, the solar
wind reaches supersonic speeds of 250–750 km/s [32]. At
much greater distances, about 75–90 astronomical units (1
au is the distance Sun-Earth), the so-called “termination
shock,” interactions of the local interstellar medium with the
solar wind slow it down to subsonic speed.
There are different classes of solar wind [30]:
(a)	The long-lived solar wind high-speed streams, represen­
tatives of the inactive or “quiet” Sun. Sources for such
streams are coronal holes usually located above inactive
parts of the Sun, where “open” magnetic field lines pre­
vail, e.g., around activity minima at the polar caps;
(b)	A slow wind stream from more active near-equatorial
regions on the Sun, often associated with “closed” mag­
netic structures. Sharp boundaries exist between these two
solar wind streams (in longitude as well as in latitude),
C. E. Hellweg et al.
511
and their main properties differ significantly according to
the location and magnetic properties at the source;
(c)	Another slow solar wind stream emerging during high
solar activity, from active regions distributed over large
parts of the Sun, in a highly turbulent state. It is highly
variable and usually contains a significant fraction
(about 4%) of alpha particles;
(d)	The solar wind disturbances superimposed on the ambi­
ent solar wind in case of CMEs. They exhibit unusually
high percentages of alpha particles (up to about 30%).
The Earth’s magnetosphere deflects the solar wind, caus­
ing most of the solar wind to flow around and beyond us.
Nevertheless, a small number of particles from the solar
wind reach the upper atmosphere and ionosphere. This may
produce phenomena such as aurora and geomagnetic storms,
the latter occurring when large inflation of the magneto­
sphere, due to an increased pressure of the contained plasma,
distorts the geomagnetic field.
In space missions, the solar wind has no impact on astro­
nauts, as it is efficiently stopped by the spacecraft shielding
and also by appropriate astronaut suits, because of the small
range in a matter of the low speed-solar wind particles.
However, if not appropriately shielded, the solar wind parti­
cles may affect the human body during eventual EVAs in
deep space or on the surface of airless bodies, such as the
Moon.
10.3.1.4
Trapped Radiation
Trapped radiation particles are produced mainly by the inter­
action of GCRs and SEPs with the Earth’s atmosphere and
are trapped by its magnetic field into the Van Allen radiation
belts. These comprise:
(a)	A stable inner belt of trapped protons and electrons
with energies between some keV and 100 MeV that is
centered at a height between 300 and 1000 km above
the Earth and reaches up to a height of around
10,000 km.
10.7
In the radiation belts, the energetic particles move along
Earth’s magnetic field lines, via the combination of three
types of motion: a fast rotation (or “gyration”) around mag­
netic field lines, typically thousands of times each second; a
back-and-forth bouncing along the stronger magnetic fields
in the northern and southern hemispheres, typically lasting
1/10 s; a slow drift around the magnetic axis of the Earth (the
drift is eastward for electrons and westwards for ions), such
drift is from the current field line to its neighbor, with the
particle keeping roughly the same distance from the axis. A
typical time to complete a full circle around the Earth is a
few minutes.
In the area above the southeastern part of South America
and the South Atlantic, the inner radiation belt approaches the
surface of Earth down to a few hundreds of kilometers (South
Atlantic Anomaly, SAA). This is caused by the tilt and shift
of the axis of the dipole-like magnetic field of the Earth with
respect to its axis of rotation [33]. The dip of magnetic lines
leads to an increased particle flux within this region.
The dose rate experienced by the astronauts on the ISS
has a considerable contribution from trapped protons in the
inner Van Allen belt because the ISS orbit with an altitude of
about 400 km passes through this belt at the SAA (roughly
50% of the total dose rate) [34].
10.3.2	Radiation Environment in Low Earth
Orbit (LEO)
A low Earth orbit (LEO) is an Earth-centered orbit close to our
planet with an altitude ranging from 160 to 2000 km. Thus, the
ISS, which flies at an altitude of around 400 km, is also in such
an orbit, with an orbital inclination (the tilt of the orbital plane
with respect to the equatorial plane, which helps to understand
an orbit’s orientation with respect to the equator) of 51.6° and
an orbiting period of 90–93 min. Consequently, in 24 h the ISS
makes 16 orbits of Earth and travels through 16 sunrises and
sunsets. The environment of these altitudes is extreme and
characterized by microgravity, high vacuum, meteoroids,
extremes of temperature, ionospheric plasma, space debris,
and UV as well as ionizing radiations.
The radiation sources are GCR, trapped radiation, and
SEP events. The GCR environment accounts for about 50%
of the total dose rate, the other 50% being induced by trapped
protons of the inner belt, the only component of the inner
belts that reaches energies and intensities to be important for
effects on astronauts inside the ISS [35]. Other orbits, such Fig. 10.7
Fig. 10.7 Radiation belts of the Earth. (Figure from Van Allen radia­
tion belt. Reprinted with permission from Wikipedia. Author
Booyabazooka at English Wikipedia, https://commons.wikimedia.org/
wiki/File:Van_Allen_radiation_belt.svg)
10 Space Radiobiology"
"Describe the spatial relationship between the inner Van Allen radiation belt and the South Atlantic Anomaly (SAA), explaining why this region experiences a higher particle flux.","The inner Van Allen radiation belt, a toroidal region of trapped charged particles surrounding Earth, extends to approximately several hundred kilometers above the surface. Specifically, in the southeastern portion of South America and the South Atlantic, the inner radiation belt dips significantly due to the tilt and shift of Earth’s magnetic dipole axis relative to its rotational axis. This creates what is known as the South Atlantic Anomaly (SAA). The SAA represents a region where the geomagnetic field lines are weaker, allowing charged particles from the Van Allen belts to penetrate closer to the Earth's surface. Consequently, astronauts aboard the International Space Station (ISS), which orbits at an altitude of around 400 km and passes through this weakened magnetic field, experience a disproportionately high dose rate – roughly 50% of their total radiation exposure – primarily due to the flux of trapped protons within the inner Van Allen belt. This heightened particle flux is directly linked to the spatial proximity between the ISS orbit and the region of reduced magnetic shielding provided by the Van Allen belts.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.1	 Origin and Nature of Space Radiation | Sub-sub-subsection: 10.3.1.4	 Trapped Radiation | Content: few minutes.
In the area above the southeastern part of South America
and the South Atlantic, the inner radiation belt approaches the
surface of Earth down to a few hundreds of kilometers (South
Atlantic Anomaly, SAA). This is caused by the tilt and shift
of the axis of the dipole-like magnetic field of the Earth with
respect to its axis of rotation [33]. The dip of magnetic lines
leads to an increased particle flux within this region.
The dose rate experienced by the astronauts on the ISS
has a considerable contribution from trapped protons in the
inner Van Allen belt because the ISS orbit with an altitude of
about 400 km passes through this belt at the SAA (roughly
50% of the total dose rate) [34].
10.3.2	Radiation Environment in Low Earth
Orbit (LEO)
A low Earth orbit (LEO) is an Earth-centered orbit close to our
planet with an altitude ranging from 160 to 2000 km. Thus, the
ISS, which flies at an altitude of around 400 km, is also in such
an orbit, with an orbital inclination (the tilt of the orbital plane
with respect to the equatorial plane, which helps to understand
an orbit’s orientation with respect to the equator) of 51.6° and
an orbiting period of 90–93 min. Consequently, in 24 h the ISS
makes 16 orbits of Earth and travels through 16 sunrises and
sunsets. The environment of these altitudes is extreme and
characterized by microgravity, high vacuum, meteoroids,
extremes of temperature, ionospheric plasma, space debris,
and UV as well as ionizing radiations.
The radiation sources are GCR, trapped radiation, and
SEP events. The GCR environment accounts for about 50%
of the total dose rate, the other 50% being induced by trapped
protons of the inner belt, the only component of the inner
belts that reaches energies and intensities to be important for
effects on astronauts inside the ISS [35]. Other orbits, such Fig. 10.7
Fig. 10.7 Radiation belts of the Earth. (Figure from Van Allen radia­
tion belt. Reprinted with permission from Wikipedia. Author
Booyabazooka at English Wikipedia, https://commons.wikimedia.org/
wiki/File:Van_Allen_radiation_belt.svg)
10 Space Radiobiology"
"Describe the primary factors contributing to the elevated radiation environment experienced by astronauts aboard the International Space Station (ISS), specifically addressing both trapped radiation and galactic cosmic rays, and how solar activity influences these fluxes.","The radiation environment surrounding the ISS is complex, stemming from several sources. Approximately 50% of the total dose rate originates from trapped protons within the inner Van Allen belt, a consequence of Earth’s magnetic field distorting charged particles. These protons are energetic enough to penetrate spacecraft and pose a significant hazard to astronauts. The remaining 50% comes primarily from galactic cosmic rays (GCRs), which are high-energy particles originating outside our solar system. However, the intensity of both trapped radiation and GCR flux is significantly modulated by solar activity. During solar maximum, increased UV radiation causes expansion in the upper atmosphere, leading to a loss of low-energy protons from the inner belt. Simultaneously, the geomagnetic field’s ability to deflect lower-energy particles is reduced, allowing more high-energy GCRs to reach Earth. Conversely, during solar minimum, when solar activity is at its lowest, the GCR flux decreases due to the stronger shielding effect of the geomagnetic field. Furthermore, SPE (Solar Proton Events) are transient increases in radiation dose rates caused by coronal mass ejections from the Sun, adding another layer of complexity to the radiation environment experienced by ISS astronauts.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.2	 Radiation Environment in Low Earth Orbit (LEO) | Content: few minutes.
In the area above the southeastern part of South America
and the South Atlantic, the inner radiation belt approaches the
surface of Earth down to a few hundreds of kilometers (South
Atlantic Anomaly, SAA). This is caused by the tilt and shift
of the axis of the dipole-like magnetic field of the Earth with
respect to its axis of rotation [33]. The dip of magnetic lines
leads to an increased particle flux within this region.
The dose rate experienced by the astronauts on the ISS
has a considerable contribution from trapped protons in the
inner Van Allen belt because the ISS orbit with an altitude of
about 400 km passes through this belt at the SAA (roughly
50% of the total dose rate) [34].
10.3.2	Radiation Environment in Low Earth
Orbit (LEO)
A low Earth orbit (LEO) is an Earth-centered orbit close to our
planet with an altitude ranging from 160 to 2000 km. Thus, the
ISS, which flies at an altitude of around 400 km, is also in such
an orbit, with an orbital inclination (the tilt of the orbital plane
with respect to the equatorial plane, which helps to understand
an orbit’s orientation with respect to the equator) of 51.6° and
an orbiting period of 90–93 min. Consequently, in 24 h the ISS
makes 16 orbits of Earth and travels through 16 sunrises and
sunsets. The environment of these altitudes is extreme and
characterized by microgravity, high vacuum, meteoroids,
extremes of temperature, ionospheric plasma, space debris,
and UV as well as ionizing radiations.
The radiation sources are GCR, trapped radiation, and
SEP events. The GCR environment accounts for about 50%
of the total dose rate, the other 50% being induced by trapped
protons of the inner belt, the only component of the inner
belts that reaches energies and intensities to be important for
effects on astronauts inside the ISS [35]. Other orbits, such Fig. 10.7
Fig. 10.7 Radiation belts of the Earth. (Figure from Van Allen radia­
tion belt. Reprinted with permission from Wikipedia. Author
Booyabazooka at English Wikipedia, https://commons.wikimedia.org/
wiki/File:Van_Allen_radiation_belt.svg)
10 Space Radiobiology
512
as Medium Earth Orbits (2000–35,786 km), Geostationary
orbits (35,786 km), and High Earth Orbits (over 35.786 km),
are exposed to different sub-components of the trapped radi­
ation, some may not pose any danger. On board the ISS,
astronauts encounter SPE events as a transient increase in
dose rates. As mentioned above, the GCR flux is modulated
by the solar cycle. At the ISS altitude, the GCR flux is also
modified by the geomagnetic field, besides the modulation
due to the solar activity. This field removes particles with
lower energies (~few GeV/nucleon), but particles of higher
energies are unaffected [36]. At low altitudes, the trapped
radiation is also modulated by solar activity: at solar maxi­
mum, because of the increase in UV radiation, the upper
atmosphere expands, leading to the loss of trapped protons at
low altitudes. Furthermore, the inner radiation belt is mainly
filled by decaying neutrons created by incoming GCR parti­
cles and the GCR flux is inversely proportional to solar activ­
ity [37]. Therefore, at solar maximum, a lower proton flux is
present, leading to a smaller radiation hazard compared to
the solar minimum [36, 38].
The interaction of energetic protons and HZE nuclei with
spacecraft structures produces an additional intravehicular
radiation field. This secondary radiation includes mainly,
protons, neutrons, photons (X-rays and gamma rays), leptons
(e.g., electrons and positrons), mesons (e.g., charged pions)
and a great number of lighter and heavier nuclear isotopes
(ions) [39, 40]. This happens in LEO and is of high concern
in particular for the deep Space phase of a mission (see
below), as the spacecraft would not be protected by the
Earth’s atmosphere and magnetic field.
10.3.3	Radiation Environment Beyond LEO
(Deep Space, Moon, Mars)
10.3.3.1
Deep Space
10.2
­
­
1
41
42
­
10.8
­
10.3.3.2
Airless Bodies: The Moon
The Moon is about 380,000 km away from Earth and is the
next endeavor for space missions beyond LEO. Although
some areas of the Moon have a weak magnetic field, the
Moon does not have a global magnetic field like on Earth
and no atmosphere. Consequently, its surface is not shielded
from radiation. The solar wind particles get stopped in the
first millimeters or, maximally, centimeters of the lunar
regolith, while GCR and SEP can impact the lunar surface
also resulting in the production of backscattered secondary
particles. The total amount of radiation that astronauts will
be exposed to is influenced strongly by solar activity, their
whereabouts on the Moon surface with respect to local
magnetic fields, and the type and amount of radiation
shielding used in spacecraft, Moon vehicles, and habitats.
Recently, the Lunar Lander Neutrons and Dosimetry exper­
iment aboard China’s Chang’E 4 lander revealed that radia­
tion levels on the Moon’s surface are 200–1000 times more
than that on Earth’s surface and 2.6 times more than what
astronauts onboard the ISS are exposed to Zhang et al. [44].
Efficiency of the radiation shielding by lava tubes on the
Moon appears promising to reduce the dose rates consider­
ably [45].
10.3.3.3
On Mars
Mars does not possess a global magnetic field, and it has
only a thin atmosphere with its surface pressure less than 1%
of that at Earth’s surface. Therefore, high-energy GCRs can
reach the surface, although still a considerable portion of
them will induce hadronic-electromagnetic-muon cascades
in the atmosphere, causing fragmentation/spallation and ion­
ization showers of downward secondaries. All these particles
can then induce further reactions in the planet’s regolith,
which generate a backscattered, albedo radiation component,
1 Sievert (Sv) denotes the equivalent dose as measure for biological and
medical relevant quantification of dose in radiation protection. For a
detailed explanation please refer to Chap. 2.
C. E. Hellweg et al."
"Describe the primary sources of ionizing radiation that astronauts would encounter during missions beyond Low Earth Orbit (LEO), and explain how these sources contribute to the overall radiation environment.","Beyond LEO, such as in deep space or on the Moon and Mars, astronauts are exposed to several significant sources of ionizing radiation. The most prominent is Galactic Cosmic Radiation (GCR), which originates from outside our solar system – high-energy particles produced by supernovae and other violent astrophysical events. These GCRs penetrate deeply into space and can reach even the farthest reaches of our solar system. Solar Energetic Particles (SEP) are another major source, released during intense solar flares and coronal mass ejections. SEPs are typically more variable in intensity than GCRs but can deliver extremely high doses over shorter periods. Furthermore, on planetary surfaces like the Moon and Mars, secondary radiation is generated through interactions of primary cosmic rays with the regolith (surface material). This process involves spallation (the ejection of particles from nuclei), ionization showers, and backscattering, creating a complex mixture of neutrons, protons, and other energetic particles. The Martian environment specifically contributes due to the lack of a global magnetic field, allowing GCRs to reach the surface directly, alongside hadronic-electromagnetic-muon cascades initiated by atmospheric interactions.  The cumulative effect of these sources – GCRs, SEPs, and secondary radiation – creates a highly variable and challenging radiation environment for astronauts.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.3	 Radiation Environment Beyond LEO (Deep Space, Moon, Mars) | Content: and no atmosphere. Consequently, its surface is not shielded
from radiation. The solar wind particles get stopped in the
first millimeters or, maximally, centimeters of the lunar
regolith, while GCR and SEP can impact the lunar surface
also resulting in the production of backscattered secondary
particles. The total amount of radiation that astronauts will
be exposed to is influenced strongly by solar activity, their
whereabouts on the Moon surface with respect to local
magnetic fields, and the type and amount of radiation
shielding used in spacecraft, Moon vehicles, and habitats.
Recently, the Lunar Lander Neutrons and Dosimetry exper­
iment aboard China’s Chang’E 4 lander revealed that radia­
tion levels on the Moon’s surface are 200–1000 times more
than that on Earth’s surface and 2.6 times more than what
astronauts onboard the ISS are exposed to Zhang et al. [44].
Efficiency of the radiation shielding by lava tubes on the
Moon appears promising to reduce the dose rates consider­
ably [45].
10.3.3.3
On Mars
Mars does not possess a global magnetic field, and it has
only a thin atmosphere with its surface pressure less than 1%
of that at Earth’s surface. Therefore, high-energy GCRs can
reach the surface, although still a considerable portion of
them will induce hadronic-electromagnetic-muon cascades
in the atmosphere, causing fragmentation/spallation and ion­
ization showers of downward secondaries. All these particles
can then induce further reactions in the planet’s regolith,
which generate a backscattered, albedo radiation component,
1 Sievert (Sv) denotes the equivalent dose as measure for biological and
medical relevant quantification of dose in radiation protection. For a
detailed explanation please refer to Chap. 2.
C. E. Hellweg et al."
"Describe the complex interaction of solar wind particles, galactic cosmic rays (GCRs), and secondary particle production on the lunar surface, considering the lack of a substantial atmosphere.","The lunar surface is exceptionally vulnerable to radiation due to its complete absence of an atmospheric shield. Solar wind particles are immediately stopped within the first millimeters to centimeters of the regolith. However, galactic cosmic rays (GCRs) and solar energetic particles (SEP) penetrate deeper, initiating a cascade of secondary particle production. These GCRs and SEPs interact with the lunar material, primarily through processes like spallation and ionization, creating hadronic-electromagnetic-muon cascades in the thin atmosphere. This results in a shower of downward-directed secondaries – fragments, ions, and electrons – which then further react with the regolith, generating an additional component of backscattered radiation known as albedo radiation. The overall radiation environment on the Moon is significantly higher than on Earth, estimated to be 200–1000 times greater due to the direct exposure to these high-energy particles and their subsequent interactions. This complex interplay dramatically influences the total radiation dose experienced by astronauts and spacecraft systems. Reference: MolecularRadiationBiology, Section 10.3.3.1 – Deep Space","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.3	 Radiation Environment Beyond LEO (Deep Space, Moon, Mars) | Sub-sub-subsection: 10.3.3.1	 Deep Space | Content: and no atmosphere. Consequently, its surface is not shielded
from radiation. The solar wind particles get stopped in the
first millimeters or, maximally, centimeters of the lunar
regolith, while GCR and SEP can impact the lunar surface
also resulting in the production of backscattered secondary
particles. The total amount of radiation that astronauts will
be exposed to is influenced strongly by solar activity, their
whereabouts on the Moon surface with respect to local
magnetic fields, and the type and amount of radiation
shielding used in spacecraft, Moon vehicles, and habitats.
Recently, the Lunar Lander Neutrons and Dosimetry exper­
iment aboard China’s Chang’E 4 lander revealed that radia­
tion levels on the Moon’s surface are 200–1000 times more
than that on Earth’s surface and 2.6 times more than what
astronauts onboard the ISS are exposed to Zhang et al. [44].
Efficiency of the radiation shielding by lava tubes on the
Moon appears promising to reduce the dose rates consider­
ably [45].
10.3.3.3
On Mars
Mars does not possess a global magnetic field, and it has
only a thin atmosphere with its surface pressure less than 1%
of that at Earth’s surface. Therefore, high-energy GCRs can
reach the surface, although still a considerable portion of
them will induce hadronic-electromagnetic-muon cascades
in the atmosphere, causing fragmentation/spallation and ion­
ization showers of downward secondaries. All these particles
can then induce further reactions in the planet’s regolith,
which generate a backscattered, albedo radiation component,
1 Sievert (Sv) denotes the equivalent dose as measure for biological and
medical relevant quantification of dose in radiation protection. For a
detailed explanation please refer to Chap. 2.
C. E. Hellweg et al."
"Describe the primary factors influencing radiation exposure levels for astronauts on the Moon, referencing specific types of space radiation and their potential impacts.","Astronauts on the Moon will experience significantly elevated radiation exposure due to several key factors related to the lunar environment. Primarily, the Moon lacks a global magnetic field and atmosphere, offering no natural shielding from space radiation. Solar wind particles are immediately stopped within the first millimeters to centimeters of the lunar regolith. However, Galactic Cosmic Rays (GCRs) and Solar Energetic Particles (SEP) can penetrate this shallow layer and impact the surface directly. These impacts generate secondary particles through processes like spallation and ionization showers, leading to a complex backscattered radiation component – an ‘albedo’ radiation – that further increases exposure. The intensity of this radiation is strongly influenced by solar activity, which modulates SEP flux, as well as the astronaut's location relative to any localized magnetic fields present on the lunar surface. Furthermore, the type and amount of shielding employed in spacecraft, Moon vehicles, and habitats will directly affect the overall dose received. Recent measurements from the Lunar Lander Neutrons and Dosimetry experiment indicate radiation levels on the Moon’s surface are 200-1000 times higher than those on Earth's surface and 2.6 times greater than exposure for astronauts aboard the International Space Station. Lava tubes, due to their potential shielding properties, offer a promising avenue for reducing radiation dose rates.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.3	 Radiation Environment Beyond LEO (Deep Space, Moon, Mars) | Sub-sub-subsection: 10.3.3.2	 Airless Bodies: The Moon | Content: The Moon is about 380,000 km away from Earth and is the
next endeavor for space missions beyond LEO. Although
some areas of the Moon have a weak magnetic field, the
Moon does not have a global magnetic field like on Earth
and no atmosphere. Consequently, its surface is not shielded
from radiation. The solar wind particles get stopped in the
first millimeters or, maximally, centimeters of the lunar
regolith, while GCR and SEP can impact the lunar surface
also resulting in the production of backscattered secondary
particles. The total amount of radiation that astronauts will
be exposed to is influenced strongly by solar activity, their
whereabouts on the Moon surface with respect to local
magnetic fields, and the type and amount of radiation
shielding used in spacecraft, Moon vehicles, and habitats.
Recently, the Lunar Lander Neutrons and Dosimetry exper­
iment aboard China’s Chang’E 4 lander revealed that radia­
tion levels on the Moon’s surface are 200–1000 times more
than that on Earth’s surface and 2.6 times more than what
astronauts onboard the ISS are exposed to Zhang et al. [44].
Efficiency of the radiation shielding by lava tubes on the
Moon appears promising to reduce the dose rates consider­
ably [45].
10.3.3.3
On Mars
Mars does not possess a global magnetic field, and it has
only a thin atmosphere with its surface pressure less than 1%
of that at Earth’s surface. Therefore, high-energy GCRs can
reach the surface, although still a considerable portion of
them will induce hadronic-electromagnetic-muon cascades
in the atmosphere, causing fragmentation/spallation and ion­
ization showers of downward secondaries. All these particles
can then induce further reactions in the planet’s regolith,
which generate a backscattered, albedo radiation component,
1 Sievert (Sv) denotes the equivalent dose as measure for biological and
medical relevant quantification of dose in radiation protection. For a
detailed explanation please refer to Chap. 2.
C. E. Hellweg et al."
"Describe the complex radiation environment on Mars and explain how this differs from that experienced by astronauts on the International Space Station (ISS), considering factors like GCRs, SEPs, and regolith interactions.","The radiation environment on Mars presents a significantly greater challenge than that encountered in low Earth orbit due to several key differences. Unlike the ISS, which is shielded by Earth’s atmosphere and magnetosphere, Mars lacks a global magnetic field and possesses only a tenuous atmosphere – less than 1% of Earth's surface pressure. This absence of shielding allows high-energy Galactic Cosmic Rays (GCRs) to directly impact the Martian surface. Furthermore, Solar Energetic Particles (SEPs), generated during solar flares, can also reach the surface with considerable flux, particularly at higher energies. Upon entering the atmosphere, these particles trigger hadronic-electromagnetic-muon cascades through fragmentation and ionization showers, creating a complex secondary radiation component – both downward and upward secondaries – that significantly increases the overall radiation dose. The Martian regolith itself plays a crucial role in this process, acting as a source of backscattered radiation. This results in a highly diverse spectrum of particles at the surface, including primary GCRs and the numerous secondary particles generated by their interactions within the planet. While protons above 200 MeV primarily reach the ground, SEPs with high flux contributions at higher energies pose the greatest hazard to explorers not sheltered. In contrast, the ISS is heavily shielded by Earth’s atmosphere and magnetosphere, mitigating much of this intense radiation bombardment. The cumulative effect on Mars represents a dramatically elevated radiation exposure compared to both Earth's surface and the ISS environment.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.3	 Radiation Environment Beyond LEO (Deep Space, Moon, Mars) | Sub-sub-subsection: 10.3.3.3	 On Mars | Content: and no atmosphere. Consequently, its surface is not shielded
from radiation. The solar wind particles get stopped in the
first millimeters or, maximally, centimeters of the lunar
regolith, while GCR and SEP can impact the lunar surface
also resulting in the production of backscattered secondary
particles. The total amount of radiation that astronauts will
be exposed to is influenced strongly by solar activity, their
whereabouts on the Moon surface with respect to local
magnetic fields, and the type and amount of radiation
shielding used in spacecraft, Moon vehicles, and habitats.
Recently, the Lunar Lander Neutrons and Dosimetry exper­
iment aboard China’s Chang’E 4 lander revealed that radia­
tion levels on the Moon’s surface are 200–1000 times more
than that on Earth’s surface and 2.6 times more than what
astronauts onboard the ISS are exposed to Zhang et al. [44].
Efficiency of the radiation shielding by lava tubes on the
Moon appears promising to reduce the dose rates consider­
ably [45].
10.3.3.3
On Mars
Mars does not possess a global magnetic field, and it has
only a thin atmosphere with its surface pressure less than 1%
of that at Earth’s surface. Therefore, high-energy GCRs can
reach the surface, although still a considerable portion of
them will induce hadronic-electromagnetic-muon cascades
in the atmosphere, causing fragmentation/spallation and ion­
ization showers of downward secondaries. All these particles
can then induce further reactions in the planet’s regolith,
which generate a backscattered, albedo radiation component,
1 Sievert (Sv) denotes the equivalent dose as measure for biological and
medical relevant quantification of dose in radiation protection. For a
detailed explanation please refer to Chap. 2.
C. E. Hellweg et al.
513Fig. 10.8
Fig. 10.8 Relative radiation
exposure of varying duration
during medical procedures
(green), specific space missions
(purple), and on various celestial
bodies (blue). The astronaut
yearly and career limits are given
in red boxes. For comparison,
some facts on radiation exposure
of the general population and
occupational exposure limits (US)
are indicated (gold). (Reprinted
with permission from Iosim et al.
[43])
giving overall complex spectra including both primaries and
(downward and upward) secondaries at the surface [46–48].
SEP events can increase the dose rate and dose equivalent
at the Martian surface and constitute a danger for EVA on
Mars. Only protons impinging the top of the atmosphere
with energy above ~200 MeV do actually reach the ground,
and thus SEPs events with high flux contribution at high
energy constitute the biggest hazard for explorers on Mars if
they are not in a habitat or otherwise sufficiently shielded.
For the solar wind, despite the thin character of Mars’ atmo­
sphere, the upper layers of the latter are able to stop such
radiation. Underground solutions for Mars habitats, shielded
from the radiation by the regolith, are being investigated
[49].
­
10.8
­
10 Space Radiobiology
514
short time (minutes to hours) will be more health-threatening
than the same dosage over a longer duration of months of
years. Yet, although the health effects of acute radiation
exposure are well studied, less is known about the effects of
chronic exposure."
"The text discusses several types of space radiation hazards for astronauts. Describe the primary differences between Galactic Cosmic Rays (GCRs) and Solar Energetic Particles (SEPs) in terms of their origin, energy levels, and potential impact on astronaut health.","Galactic Cosmic Rays (GCRs) are a constant source of high-energy radiation originating from outside our solar system – primarily from supernovae and other energetic events occurring beyond the Sun. These particles possess extremely high energies, typically exceeding 100 MeV per nucleon, making them difficult to shield against effectively. Consequently, astronauts exposed to GCRs face chronic exposure over extended missions due to their continuous presence. In contrast, Solar Energetic Particles (SEPs) are bursts of energetic particles released during solar flares and coronal mass ejections from the Sun. These events can produce particle fluxes that are significantly higher than those associated with GCRs, potentially leading to acute radiation sickness or even fatal doses if not shielded against. While SEPs are more sporadic in their occurrence, they represent a sudden and intense radiation hazard requiring immediate protection measures.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.4	 Space Radiation Shielding | Content: Ionizing radiation exposure is one of the most critical health
risks for astronauts. Inside the ISS, astronauts are exposed to
an effective dose rate of the order of 20 μSv/h, which is about
100 times higher than on the Earth’s surface. Beyond LEO in
deep space, the protection of the Earth’s atmosphere and
magnetic field disappears, leading to an effective dose rate of
the order of 75 μSv/h. Also, on the surface of the Moon or
Mars, there is only limited protection and astronauts are
exposed to respectively about 30 and 25 μSv/h. It is esti­
mated that astronauts will accumulate during a Mars mission
a total effective dose of the order of 1 Sv, leading to an extra
risk for cancer of the order of a few percent up to more than
10% depending on sex and age [50]. Furthermore, on their
way through deep space or on the surface of the Moon or
Mars, astronauts can receive such high doses during intense
solar storms that immediate health effects or even a deadly
outcome are possible (see Sect. 10.4.2). Therefore, it is clear
that astronauts need to be protected against ionizing radia­
tion in space.
­
­
2
3
2
­
4
­
­
10.9
­
­Fig. 10.9
Fig. 10.9 Calculated dose equivalent rate in LEO (51.6° inclination, 390 km altitude) as a function of shielding thickness given as area density
for different shielding materials: (left) GCR, (right) Van Allen trapped protons. (Data used with permission from Dietze et al. [37])
C. E. Hellweg et al.
515
lighter shielding materials or, for instance, also by making
strategic use of the necessary stock of water as additional
shielding. Figure 10.9 shows the calculated dose equivalent
rate for a LEO orbit similar to that of ISS (51.6° inclination,
390 km altitude) as a function of shielding thickness for dif­
ferent shielding materials. At standard temperature and pres­
sure, based on a density of 1000 kg/m3, the water column
required to reach an area density of 20 g/cm2 would have a
height of 20 cm. For 20 g/cm2 aluminum, a material thick­
ness of 7.4 cm is derived from the density at room tempera­
ture of 2.7 g/cm3. At the same area density of 20 g/cm2, the
shielding effect of water is much more pronounced than the
one of aluminum. The thickness of the two materials is dif­
ferent, but they would contribute to the same extent to the
mass budget of the spacecraft which is critical for leaving the
Earth surface during launch. The left and right plots show the
results for respectively GCRs and Van Allen protons. These
plots clearly show that hydrogenous materials are much
more efficient for radiation shielding in space.
In spacecraft it is unfortunately not possible to reduce the
effective dose rate to the dose rate on Earth’s surface. With
limited shielding, a large part of the energetic protons and
electrons from SEPs and the Van Allen protons can be
stopped. However, GCRs have such high energies that about
1000 g/cm2 of shielding is required to reduce the effective
dose rate to the level on Earth’s surface. Due to mass con­
straints in spacecraft, only shielding of the order of a few 10
g/cm2 is possible. In spacecraft, astronauts can thus be pro­
tected against sudden very high and potentially deadly doses
from solar storms, but they will be unavoidably chronically
exposed to the ever-present GCRs leading to an increased
risk for late effects.
It is clear that with current technology additional radia­
tion exposure in spacecraft is unavoidable. However, for
future manned missions to the Moon or Mars during which
astronauts will stay on the surface for a longer time it will be
necessary to strongly reduce their radiation exposure during
their stay. This is possible because on the surface of the
Moon or Mars, we can make use of the present soil material
to provide adequate shielding. A few meters of soil material
should suffice to reduce the effective dose rate level to simi­
lar levels as on Earth’s surface. This can be done by building
igloos or by living in caves or lava tubes.
Besides shielding by using materials to block the radia­
tion, it is in principle also possible to make use of strong
electromagnetic field for shielding. Several research groups
are investigating this possibility. However, the required
mass and energy consumption of such systems makes the
concept practically impossible with current technology
(Box 10.1).
10.3.5	Mathematical Modelling the Space
Radiation Environment and Induced
Doses
10.3.5.1
Transport of Radiation Through
Matter: Deterministic and Monte Carlo
Methods
The modeling of the radiation environment at or inside a
spacecraft, at different altitudes in the atmosphere or at the
surface/subsurface of a planet, a moon, or a small body
allows to obtain the relevant dosimetric quantities for the
assessment of the health risks incurred by humans due to
radiation [51–53], as well as to estimate the half-lives of bio­
molecules in search-for-life studies [54, 55].
The transport of radiation through matter is described
by the time-independent Linear Boltzmann Transport
Equation, which allows to treat atomic and nuclear colli­
sions. The Boltzmann transport equation (10.1) describes
the flux ni(r, E, Ω, t) of several types of particles i, possess­
ing different energies E, and moving in different directions
Ω by considering the particle balance in a small volume V.
It thus gives the average space-time distribution of the
expected energy-momentum behavior of the particle beam,
transported and scattered across the target, where each
interaction is characterized by its own differential cross-
section
S
t
ar
tF
raction d squared sigma Over italic d upper Omega d upper W EndFraction
. The Boltzmann equation reads as
follows:
Box 10.1 Highlights
(a)	GCRs are the constantly present highly energetic
radiation in space, they are mostly constituted by
protons, with a smaller contribution from alpha
particles and HZE particles. They generate parti­
cle showers in the atmosphere, although a small
portion of direct GCRs can eventually reach the
ground.
(b)	SEP events are more probable during solar maxi­
mum, but they can actually also occur during solar
minimum.
(c)	Trapped radiation is constituted by GCRs and
solar protons trapped in the Van Allen belts.
Trapped radiation is a concern for ISS-like mis­
sions, especially because of the flux accumulated
during different orbits in the SAA, or also mis­
sions on other orbits crossing one or the other
belt.
10 Space Radiobiology"
Describe the fundamental principles underlying the Boltzmann Transport Equation and its application to modeling space radiation environments.,"The Boltzmann Transport Equation (BTE) is a cornerstone of radiation transport theory, providing a mathematical framework for describing how radiation interacts with matter. At its core, the BTE addresses the balance between particle fluxes – essentially, it tracks where particles are coming from, going to, and changing energy due to collisions within a material. The equation considers multiple types of particles (e.g., protons, alpha particles) at varying energies and directions of motion. It’s based on the principle that the average space-time distribution of expected energy-momentum behavior of a particle beam is determined by considering the particle balance in a small volume. This ‘balance’ accounts for both the transport (movement) of particles and their interactions (collisions). Crucially, the BTE incorporates differential cross-sections, which quantify the probability of a specific interaction occurring between a radiation particle and an atom or nucleus within the material. These cross-sections are energy-dependent and represent the efficiency of various processes like ionization, excitation, and nuclear reactions. The equation allows for modeling the space radiation environment by predicting how radiation propagates through matter – accounting for scattering and absorption events – ultimately determining the flux (intensity) of radiation at a given point in space and time. This is vital for assessing health risks to astronauts or estimating the degradation rates of biomolecules during long-duration missions, as highlighted in Box 10.1 which details the presence of GCRs, SEP events, and trapped radiation within space environments.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Content: (Box 10.1).
10.3.5	Mathematical Modelling the Space
Radiation Environment and Induced
Doses
10.3.5.1
Transport of Radiation Through
Matter: Deterministic and Monte Carlo
Methods
The modeling of the radiation environment at or inside a
spacecraft, at different altitudes in the atmosphere or at the
surface/subsurface of a planet, a moon, or a small body
allows to obtain the relevant dosimetric quantities for the
assessment of the health risks incurred by humans due to
radiation [51–53], as well as to estimate the half-lives of bio­
molecules in search-for-life studies [54, 55].
The transport of radiation through matter is described
by the time-independent Linear Boltzmann Transport
Equation, which allows to treat atomic and nuclear colli­
sions. The Boltzmann transport equation (10.1) describes
the flux ni(r, E, Ω, t) of several types of particles i, possess­
ing different energies E, and moving in different directions
Ω by considering the particle balance in a small volume V.
It thus gives the average space-time distribution of the
expected energy-momentum behavior of the particle beam,
transported and scattered across the target, where each
interaction is characterized by its own differential cross-
section
S
t
ar
tF
raction d squared sigma Over italic d upper Omega d upper W EndFraction
. The Boltzmann equation reads as
follows:
Box 10.1 Highlights
(a)	GCRs are the constantly present highly energetic
radiation in space, they are mostly constituted by
protons, with a smaller contribution from alpha
particles and HZE particles. They generate parti­
cle showers in the atmosphere, although a small
portion of direct GCRs can eventually reach the
ground.
(b)	SEP events are more probable during solar maxi­
mum, but they can actually also occur during solar
minimum.
(c)	Trapped radiation is constituted by GCRs and
solar protons trapped in the Van Allen belts.
Trapped radiation is a concern for ISS-like mis­
sions, especially because of the flux accumulated
during different orbits in the SAA, or also mis­
sions on other orbits crossing one or the other
belt.
10 Space Radiobiology"
"Describe the fundamental principles underlying the Boltzmann Transport Equation and its application in modeling radiation transport within a complex environment like space. Specifically, how does this equation account for particle interactions and energy transfer?","The Boltzmann Transport Equation (BTE) is a cornerstone of radiation transport theory, providing a comprehensive framework for describing the movement and interaction of particles – primarily ions and electrons – within a medium. At its core, the BTE describes the average flux (number per unit area per unit time per unit solid angle) of particles with varying energies and directions as they traverse a volume. This flux change is governed by a balance between several key processes: particle escape from the system boundaries, free flight (unscattered motion), scattering events, and production of secondary particles due to collisions. The equation essentially tracks the ‘particle balance’ within a small, representative volume known as a ‘cell’.

The BTE accounts for particle interactions through the use of differential cross-sections (S_t^ar^*fraction d squared sigma Over italic d upper Omega d upper W EndFraction), which quantify the probability of a specific interaction occurring between a particle and its target. These cross-sections are energy-dependent and direction-dependent, reflecting the varying likelihood of events like ionization, excitation, spallation (nuclear breakup), or photon emission. The equation incorporates these interactions by considering how they alter the particle’s momentum and energy.

The BTE is often computationally intensive due to its complexity, particularly when dealing with numerous interaction types and high energies. Deterministic methods, such as those employed in HZETRN, simplify this process by making approximations like the straight-ahead approximation, reducing the problem to a 1D scenario and neglecting correlations between events. Conversely, Monte Carlo (MC) methods, utilized in Geant4 or FLUKA, employ random sampling to simulate particle trajectories and interactions individually, offering greater accuracy but requiring significantly more computational resources.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.1	 Transport of Radiation Through Matter: Deterministic and Monte Carlo Methods | Content: (Box 10.1).
10.3.5	Mathematical Modelling the Space
Radiation Environment and Induced
Doses
10.3.5.1
Transport of Radiation Through
Matter: Deterministic and Monte Carlo
Methods
The modeling of the radiation environment at or inside a
spacecraft, at different altitudes in the atmosphere or at the
surface/subsurface of a planet, a moon, or a small body
allows to obtain the relevant dosimetric quantities for the
assessment of the health risks incurred by humans due to
radiation [51–53], as well as to estimate the half-lives of bio­
molecules in search-for-life studies [54, 55].
The transport of radiation through matter is described
by the time-independent Linear Boltzmann Transport
Equation, which allows to treat atomic and nuclear colli­
sions. The Boltzmann transport equation (10.1) describes
the flux ni(r, E, Ω, t) of several types of particles i, possess­
ing different energies E, and moving in different directions
Ω by considering the particle balance in a small volume V.
It thus gives the average space-time distribution of the
expected energy-momentum behavior of the particle beam,
transported and scattered across the target, where each
interaction is characterized by its own differential cross-
section
S
t
ar
tF
raction d squared sigma Over italic d upper Omega d upper W EndFraction
. The Boltzmann equation reads as
follows:
Box 10.1 Highlights
(a)	GCRs are the constantly present highly energetic
radiation in space, they are mostly constituted by
protons, with a smaller contribution from alpha
particles and HZE particles. They generate parti­
cle showers in the atmosphere, although a small
portion of direct GCRs can eventually reach the
ground.
(b)	SEP events are more probable during solar maxi­
mum, but they can actually also occur during solar
minimum.
(c)	Trapped radiation is constituted by GCRs and
solar protons trapped in the Van Allen belts.
Trapped radiation is a concern for ISS-like mis­
sions, especially because of the flux accumulated
during different orbits in the SAA, or also mis­
sions on other orbits crossing one or the other
belt.
10 Space Radiobiology
516

(10.1)
In this equation:
•	the first term is the time-dependent flux change, due to
particles escaping from the system boundaries, or dis­
appearing by an absorption reaction or radioactive
decay;
•	on the right-hand side, the unscattered term represents the
flux change due to translation without change of energy
and direction (free flight);
•	the particles scattered out are those exiting a “cell” (a unit
volume in the phase space, the latter comprising both
space and time variables);
•	the particles scattered in are those entering a “cell” from a
“cell” at a previous point in the phase space;
•	the production of secondaries represents the effect of
collisions;
•	the source term can be external (e.g., a particle beam irra­
diating the target volume), or internal (e.g., neutrons from
fission reactions in the volume).
In particular for high-energy particles, the number of
interactions that must be described in order to find the solu­
tion to this equation is daunting, including ionization, excita­
tion,
spallation/fission/fragmentation,
production
of
positron-emitting nuclei, and de-excitation through gamma
rays. A solution to the problem can be attained via two differ­
ent approaches:
1.	Deterministic
methods.
These
are
deterministic
approaches based on approximations to the Boltzmann
equation and often on the reduction to a 1D problem via
the use of the straight-ahead approximation, according to
which the secondary particles from nucleon-nucleus col­
lisions are emitted in the direction of the incident nucleon
[37]. They rely on models for the relevant quantities in
the transport calculation and use the continuous slowing
down approximation (CSDA). Deterministic codes such
as NASA’s HZETRN [56] and BRYNTRN [57] follow
such an approach and require relatively low computa­
tional resources to perform calculations and the calcula­
tion time is relatively short. This is due to the fact that
deterministic codes do not consider all products of reac­
tions and neglect their correlation, e.g., the coefficients
used in the Boltzmann equation are related to relatively
simple one-particle quantities. Thus, correlations on
event-by-event basis are not considered and particle scat­
tering at an angle is ignored [58]. Last, such methods can
only be applied to restricted geometries and restricted
interaction models.
2.	Monte Carlo method. Monte Carlo (MC) is a stochastic
method, exploiting random numbers to (a) “generate” an
initial particles’ “cocktail”; (b) track them in arbitrary
geometries; (c) accumulate the contribution of each track
to a statistical estimator of the desired physical observ­
ables [59]. Step-by-step particles’ transport is simulated
according to the statistical model of their interactions.
Quantities (such as step lengths, event type, energy losses,
and deflections) are sampled via generation of random
values according to a given probability distribution.
Indeed, in MC codes, the MC method deals with sam­
pling from suitable stochastic distributions, with large
samplings allowing to solve the integrations of multidi­
mensional integrals.
In the context of space environment, the main interest is
in high-energy particles whose scattering is generally low-
angle. Therefore, it is reasonable to approximate multiple
scatterings by a single continuous step, taking into account
overall energy loss and direction change. This approach is
known as the condensed-history technique. For example,
ionization and excitation energy losses are described as con­
tinuous processes, i.e., they are continuously distributed
along a particle step, if the loss is lower than a chosen thresh­
old, together with their fluctuations.
Several MC codes are used nowadays throughout the
world, such as Geant4 [60], FLUKA [61], and PHITS
[62]. MC codes provide a detailed treatment of the three-
dimensional transport of ions and neutral particles (see
Chap. 4).
C. E. Hellweg et al.
517
10.3.5.2
Practical Steps in the Modelling
of the Space Radiation Environment
and Induced Doses
­
10.10
Input Spectra
The input spectrum for GCRs can be chosen among differ­
ent existing models that account for the variations of GCR
particle fluxes due to variations in solar activity and in the
large-scale heliospheric magnetic field throughout the
solar cycle. The ISO 15390 model (ISO-15390 2004) [63]
accounts for solar cycle variations in the GCR intensities
on the basis of 12-month averages of the sunspot number.
Changes in the large-scale heliospheric magnetic field are
usually taken proportional to the corresponding changes in
the Sun’s magnetic field, considering also solar cycle.
More accurate models describe the spectra of GCR beyond
the heliospheric modulation region. The CREME96 [64]
and its updated version CREME2009 (https://creme.isde.
vanderbilt.edu/) are based on a semi-empirical model [65]
where the particle spectrum is calculated as a product of a
function describing the LIS and a function describing the
modulation according to solar activity. GCR particle spec­
tra are described in the energy range from 10 to 105 MeV/
nucleon, from H up to Ni nuclei from the year 1760 to
present. The Badhwar–O’Neill 2010 (BON2010) [66]
uses, instead of an empirical description of the modulated
GCR.
As in the CREME model, a physical approach to describe
the GCR propagation in the heliosphere due to diffusion,
convection, and adiabatic deceleration. The BON2010 model
exploits data from the International Sunspot Number (ISN)
and considers time lag of GCR flux relative to the solar activ­
ity. The ISN is calibrated with GCR measurements from the
Advanced
Composition
Explorer
(ACE)
and
the
Interplanetary Monitoring Platform-8 (IMP-8). The Burger-
Usoskin model [67] is limited to GCR He and H ions assum­
ing a constant ratio of the two types of ions. The reconstruction
of the modulation parameter is based on neutron monitor
count rates. The DLR model by Matthia et al. [68] describes
the GCRs spectra of nuclei based on a single parameter,
which is derived from measurements of the ACE spacecraft
and from Oulu neutron monitor count rates for different solar
modulation conditions.
SEP proton spectra are often considered from historical
events, then parameterized by double power law fits in
kinetic energy to event-accumulated integral fluence mea­
sured by the Geostationary Operational Environment
Satellites and/or ground-based neutron monitor data [69].Fig. 10.10
Fig. 10.10 Scheme for
Monte Carlo (MC)
calculations of the radiation
environment at a planet/
celestial body, here in
particular Mars. GCRs
galactic cosmic rays, SEPs
solar energetic particles, p+
protons, He2+ ions helium ions
10 Space Radiobiology"
"Describe the process of creating a mathematical model to estimate radiation doses in space environments, specifically referencing the use of proton spectra and data from Geostationary Operational Environment Satellites (GOES) and ground-based neutron monitors.","The modeling of space radiation environments for calculating induced doses involves several key steps. Initially, proton spectra are often derived from historical events – typically solar particle events (SPEs) or galactic cosmic rays (GCRs). These spectra are then parameterized using double power law fits to describe the relationship between kinetic energy and the event-accumulated integral fluence. This means that measurements of the total flux of protons over a specific energy range, as recorded by instruments like those on GOES satellites, are used to define this power law. Simultaneously, ground-based neutron monitor data provides independent verification and further refinement of these spectral parameters. The double power law allows for representing both high-energy and low-energy components of the proton flux effectively.  Monte Carlo (MC) calculations then utilize these parameterized spectra to simulate the radiation environment at a target location – such as Mars, as illustrated in Figure 10.10 – predicting the dose received by materials or biological systems based on fluence rates and spectral characteristics. The accuracy of this model heavily relies on the quality and availability of both satellite and ground-based data used for parameterization.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.2	 Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses | Content: modulation conditions.
SEP proton spectra are often considered from historical
events, then parameterized by double power law fits in
kinetic energy to event-accumulated integral fluence mea­
sured by the Geostationary Operational Environment
Satellites and/or ground-based neutron monitor data [69].Fig. 10.10
Fig. 10.10 Scheme for
Monte Carlo (MC)
calculations of the radiation
environment at a planet/
celestial body, here in
particular Mars. GCRs
galactic cosmic rays, SEPs
solar energetic particles, p+
protons, He2+ ions helium ions
10 Space Radiobiology"
"Several models are used to predict space radiation environments, such as GCRs and SEPs. Describe at least three distinct approaches to modeling these particle spectra, including the key factors considered in each model’s construction.","Multiple models exist for predicting space radiation environments like Galactic Cosmic Rays (GCRs) and Solar Energetic Particles (SEPs). Three prominent approaches include the ISO-15390 model, the CREME series of models, and the Badhwar–O’Neill 2010 (BON2010) model. The ISO-15390 model leverages 12-month averages of sunspot numbers to account for variations in GCR intensities throughout the solar cycle. It essentially uses historical data on solar activity to predict particle flux. CREME96 and its updated version, CREME2009, employ a semi-empirical approach, calculating the particle spectrum as a product of functions describing Low Energy Spectrum (LIS) and modulation effects related to solar activity. These models consider variations in the heliospheric magnetic field proportional to changes in the Sun’s magnetic field. The BON2010 model takes a more physically based approach, incorporating diffusion, convection, and adiabatic deceleration processes within the heliosphere alongside data from the International Sunspot Number (ISN) and considering time lags between solar activity and GCR flux. Finally, SEP spectra are often reconstructed using historical event data parameterized by double power law fits in kinetic energy derived from measurements of integral fluence obtained from Geostationary Operational Environment Satellites and ground-based neutron monitors.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.2	 Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses | Content: The input spectrum for GCRs can be chosen among differ­
ent existing models that account for the variations of GCR
particle fluxes due to variations in solar activity and in the
large-scale heliospheric magnetic field throughout the
solar cycle. The ISO 15390 model (ISO-15390 2004) [63]
accounts for solar cycle variations in the GCR intensities
on the basis of 12-month averages of the sunspot number.
Changes in the large-scale heliospheric magnetic field are
usually taken proportional to the corresponding changes in
the Sun’s magnetic field, considering also solar cycle.
More accurate models describe the spectra of GCR beyond
the heliospheric modulation region. The CREME96 [64]
and its updated version CREME2009 (https://creme.isde.
vanderbilt.edu/) are based on a semi-empirical model [65]
where the particle spectrum is calculated as a product of a
function describing the LIS and a function describing the
modulation according to solar activity. GCR particle spec­
tra are described in the energy range from 10 to 105 MeV/
nucleon, from H up to Ni nuclei from the year 1760 to
present. The Badhwar–O’Neill 2010 (BON2010) [66]
uses, instead of an empirical description of the modulated
GCR.
As in the CREME model, a physical approach to describe
the GCR propagation in the heliosphere due to diffusion,
convection, and adiabatic deceleration. The BON2010 model
exploits data from the International Sunspot Number (ISN)
and considers time lag of GCR flux relative to the solar activ­
ity. The ISN is calibrated with GCR measurements from the
Advanced
Composition
Explorer
(ACE)
and
the
Interplanetary Monitoring Platform-8 (IMP-8). The Burger-
Usoskin model [67] is limited to GCR He and H ions assum­
ing a constant ratio of the two types of ions. The reconstruction
of the modulation parameter is based on neutron monitor
count rates. The DLR model by Matthia et al. [68] describes
the GCRs spectra of nuclei based on a single parameter,
which is derived from measurements of the ACE spacecraft
and from Oulu neutron monitor count rates for different solar
modulation conditions.
SEP proton spectra are often considered from historical
events, then parameterized by double power law fits in
kinetic energy to event-accumulated integral fluence mea­
sured by the Geostationary Operational Environment
Satellites and/or ground-based neutron monitor data [69].Fig. 10.10
Fig. 10.10 Scheme for
Monte Carlo (MC)
calculations of the radiation
environment at a planet/
celestial body, here in
particular Mars. GCRs
galactic cosmic rays, SEPs
solar energetic particles, p+
protons, He2+ ions helium ions
10 Space Radiobiology
518
Input spectra for both GCR and SEP events can often be
retrieved via user-friendly tools, such as the SPENVIS
online tool (https://www.spenvis.oma.be/) that is actually a
collection of modules that allow for calculations of the radi­
ation environment and radiation-induced effects via MC
simulations in Geant4, or the On-Line Tool for the
Assessment of Radiation in Space (OLTARIS) which oper­
ates on top of the deterministic code HZETRN (https://
oltaris.nasa.gov/)."
"Describe the key differences in atmospheric composition between Earth and Mars, focusing on the primary gaseous constituents and their respective mass fractions. Furthermore, explain how data regarding these profiles are typically obtained for each planet.","The atmospheres of Earth and Mars exhibit markedly different compositions. On Earth, the vast majority – approximately 99.99% – of atmospheric mass is concentrated in the lower layers below roughly 100 km. This region predominantly consists of nitrogen (N2), accounting for around 75%, oxygen (O2) at approximately 23%, and argon (Ar) contributing about 1.3%. The precise fraction of each gas varies with altitude due to atmospheric dynamics. Water vapor content is relatively low, typically reaching only 10⁻⁵% even under cloudy conditions. Detailed vertical profiles are frequently derived from empirical models such as NRLMSISE-00, which integrates data from satellite accelerometers and orbit determination spanning the period 1981–1997.

In contrast, Mars’ atmosphere is significantly less dense and possesses a substantially different composition. Nitrogen remains a component but represents only about 1.9% of the total mass. Carbon dioxide (CO2) dominates, comprising approximately 95.3%. Argon accounts for roughly 1.9%, while traces of other gases like oxygen and water vapor are present in much smaller quantities. Obtaining atmospheric profiles on Mars relies heavily on databases such as the Mars Climate Database (MCD), which compiles data from various sources including orbital measurements. Data is extracted for specific locations, times of day/night, and Martian seasons, utilizing surface elevation and topology information derived from the Mars Orbiter Laser Altimeter (MOLA). The available data is then typically averaged across a 5° × 5° grid extending to approximately 120 km, with measurements taken twelve times daily for each of the planet’s twelve “seasons.”","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.2	 Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses | Content: For Earth, more than 99.99% of its atmosphere’s mass is
contained in the lower atmospheric layers below about
100 km. This region is mainly composed of N2, O2, and Ar
which account for about 75%, 23%, and 1.3% by mass,
respectively. The exact mass fraction of each constituent
depends on the altitude. The water content in the atmo­
sphere is highly variable but small, with the hydrogen frac­
tion only reaching the order of 10–5% even in cloudy
conditions [70]. Composition, density, temperature, and
pressure vertical profiles can be obtained, for example,
from the empirical atmospheric model 1 NRLMSISE-00
[71], which includes total mass density from satellite accel­
erometers and from orbit determination covering 1981–
1997. For Mars, vertical profiles for pressure, density,
temperature, and chemical composition of the atmosphere
are often constructed exploting databases like MCD (Mars
Climate Database http://www-mars.lmd.jussieu.fr) [46,
49]. Data can be extracted for specific locations, a specific
day/night time, and season. The surface elevation and
topology are extracted from the Mars Orbiter Laser
Altimeter (MOLA) aboard Mars Global Surveyor. The
fields (temperature, wind, density, pressure, radiative
fluxes, etc.) are stored on a 5° × 5°, longitude-latitude grid
from the surface to 120 km (and above) are averaged and
stored 12 times a day, for 12 Martian “seasons.”"
"Considering the modeling of space radiation environments, particularly as applied to scenarios involving Martian regolith, how does soil moisture content influence neutron flux levels, and what impact might variations in regolith composition (specifically regarding silica, iron oxides, and hydration states) have on these neutron spectra?","The neutron environment within a soil matrix is critically dependent on its water content. Studies demonstrate that increased soil moisture significantly elevates neutron flux levels. This relationship stems from the fact that water molecules effectively scatter neutrons, leading to a higher probability of interaction and subsequent flux increase. The degree of this effect is directly proportional to the amount of water present; drier soils result in lower neutron fluxes due to reduced scattering. Furthermore, variations in regolith composition play a significant role. A default basaltic composition (with 51.2% SiO2, 9.3% Fe2O3, and 7.4% H2O) will produce a different neutron spectrum compared to a more hydrated or iron-rich variant. Higher concentrations of materials like silica (SiO2) can absorb neutrons through scattering and absorption processes, while elevated iron oxide content (Fe2O3) contributes to gamma ray production following neutron interactions, further complicating the overall radiation environment. The hydration state – whether water is bound within mineral structures or present as free liquid water – dramatically affects neutron transport; hydrated regolith exhibits a markedly different interaction profile with neutrons compared to anhydrous material. Consequently, accurately modeling space radiation environments necessitates careful consideration of these compositional and hydrological factors.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.2	 Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses | Content: For Earth, the soil is often considered to consist of 50%Vol
solids (of which 75%Vol SiO2 and 25%Vol Al2O3) and a scal­
able amount of H2O. Studies show that the neutron environ­
ment strongly depends on soil moisture (and air humidity)
[72]. The composition of the surface and subsurface of
Mars can either be chosen to model specific scenarios, for
example, a default basaltic composition (SiO2 51.2%, Fe2O3
9.3%, H2O 7.4%) [73] or more/less hydrated compositions
to study the possibility of underground shielding habitats
[49], or it can be taken from data from the Gamma Ray
Spectrometer aboard Mars Odyssey [46]. The dosimetric
quantities at the Martian surface do not depend strongly on
the regolith composition, although some differences due to
hydration and Fe-content can affect neutrons and gamma
rays spectra [49]."
"How do factors like hydration levels and iron content within a microbial environment influence the interaction of space radiation, specifically neutrons and gamma rays?","The presence of water and iron ions significantly alters the propagation and attenuation of space radiation, primarily neutrons and gamma rays, within a microbial environment. Water molecules are highly effective at moderating neutron interactions through a process called elastohydrodynamic scattering. Neutrons colliding with water nuclei transfer energy via elastic collisions, resulting in a broadened spectrum of neutron energies and an increased probability of these neutrons slowing down to thermal velocities. This moderation effect reduces the overall flux of high-energy neutrons. Furthermore, the hydrogen atoms within both water and iron contribute significantly to this process. Iron ions, due to their charge and size, also scatter gamma rays through Compton scattering – where a photon interacts with an electron and loses energy while being deflected in a random direction. This scattering further contributes to broadening the gamma ray spectrum and reducing its intensity. Consequently, higher hydration levels and increased iron content lead to a more complex radiation environment characterized by a wider range of energies and reduced overall dose rates for microorganisms exposed to space radiation. The specific changes in spectral distribution impact the biological effects of the radiation, potentially altering DNA damage patterns or repair mechanisms depending on the energy deposition profile.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.2	 Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses | Content: hydration and Fe-content can affect neutrons and gamma
rays spectra [49].
Propagation
­
10.11
60
­
­
­"
"Considering the discussion of radiation weighting factors and quality factors in space radiobiology, how do variations in neutron energy affect the assigned weighting factor (wR) and consequently, the estimation of risk associated with neutron exposure?","Neutron energy plays a critical role in determining the radiation weighting factor (wR), as detailed in Table 10.2. The wR for neutrons is not constant; it’s described as a continuous function dependent on neutron energy. Specifically, at low linear energy transfer (LET) values less than 10 keV/μm, the wR is assigned a value of 1, indicating minimal enhancement in biological effect relative to photons. However, as LET increases – ranging from 10 to 100 keV/μm – the wR rises to 1, reflecting the increased effectiveness of these higher-energy neutrons. Finally, for high LET values exceeding 100 keV/μm, the wR is assigned a value of 20, representing a significant amplification in biological damage compared to photons. This variation underscores that simply stating ‘neutrons’ doesn't account for the diverse energy spectrum present and highlights the need for sophisticated modeling incorporating energy dependence when estimating radiation risk. Reference: [MolecularRadiationBiology, Section 10.3.5.2 – Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.2	 Practical Steps in the Modelling of the Space Radiation Environment and Induced Doses | Content: hydration and Fe-content can affect neutrons and gamma
rays spectra [49].
Propagation
­
10.11
60
­
­
­
Target
In principle, the proper approach to calculate the absorbed
dose and dose equivalent rates is to use. Such standardized
phantom has been defined by the International Commission
on Radiation Units (ICRU) and it is given by the ICRU sphere,
a 30 cm-diameter sphere with a density of 1 g/cm3 and a mass
composition of 76.2% O, 11.1% C, 10.1% H, and 2.6% N, Fig. 10.11
Fig. 10.11 Schematic view of the particle showers (main particles are
plotted here) generated in the downward propagation of primary GCRs
particles through the Martian atmosphere and of the backscattered par­
ticles [74]
C. E. Hellweg et al.
519
which reflects the composition of tissue. Still, in recent times
more human-like phantoms have been used [75]. However,
such complexity is not always necessary, and sometimes
other spheres of water or water slabs have been used [76].
Apart from running the MC (or deterministic) codes in
standalone mode, several tools such as the previously
mentioned SPENVIS online system (https://www.spen­
vis.oma.be/), OLTARIS (https://oltaris.nasa.gov/), and
the EXPACS/PARMA code (https://phits.jaea.go.jp/
expacs/) based on PHITS can be used to run a combina­
tion of the steps described above, resulting in a punctual
estimation of doses at a specific location on a body or
altitude in an atmosphere or in radiation maps covering
several regions.
For human exploration of Mars and other bodies, the
quantities of interest are the absorbed dose corrected by the
relative biological effectiveness (RBE) factor (to estimate
the risk for acute effects or death due to high doses for Solar
Energetic Particle events) and the Effective Dose and Dose
Equivalent to respectively estimate the risks to long-term
effects induced by exposure to GCRs and to compare with
measurements from radiation detectors. Space Agencies
implement the ALARA principle [77] which ensures that
mission operations are designed to keep the radiation risks as
low as reasonably achievable. Although the different agen­
cies use common limits for deterministic effects on the ISS,
different career radiation exposure limits (for stochastic
effects) for astronauts in LEO missions exist and no specific
limits for interplanetary missions are issued (only those for
LEO exist).
10.3.5.3
Harmonization of Risk Models
for Stochastic Effects: The Problem
of Radiation Quality Factors
Harmonization of risk models requires improvements in
modeling radiation sources, in the accuracy of radiation
transport codes, and the development of new realistic quality
factors based on the features of the variegated radiation field
in Space.
As already mentioned in Chap. 2, the approach commonly
used for estimating risk from high linear energy transfer
(high-LET) radiations is based on multiplying the induced
absorbed dose (in units of gray) by a so-called quality factor,
or RBE factor (always greater than one, usually below 20)
representing the enhancement of effectiveness of the high-
LET radiation. Such increased effectiveness comes from
available evidence on the RBE of the radiations from both
laboratory and theoretical studies (Sects. 10.4 and 10.5). As
previously shown, RBE varies with LET. It depends also on
other factors and may be different, e.g., for particular chro­
mosome aberrations, mutations, or different tumor types.
Also, RBE may vary in different biological systems.
Furthermore, low-LET dose response is usually nonlinear
while high-LET response tends to be more linear.
­
R
78
­
R
R
R
78
10.2
R
­
78
10.2
­
­
Nevertheless, this specification of Q in terms of the LET
alone suffers from the limitations already highlighted in Chap.
1, about the fact that the sole LET cannot fully describe the
effectiveness of radiation in inducing biological damage.
Indeed, even simply from the perspectives of the first-stage
radiation-induced effects, without mentioning the complex
dependencies of the RBE on phenomena related to the chemi­
Table 10.2 Radiation weighting factors and quality factors
Radiation type
Radiation weighting factor (wR)
Quality factor (Q(LET))
Photons
1
Electrons and muons
1
Protons and charged pions
2
Alpha particles, fission fragments, heavy ions
20
Neutrons
A continuous function of neutron energy
For LET < 10 keV/μm
For 10 ≤ LET ≤ 100 keV/μm
For LET > 100 keV/μm
1
Q = 0.32L–2.2
Q = 300L–1/2
10 Space Radiobiology"
"Explain the relationship between LET (linear energy transfer), radiation weighting factors (wR), and quality factors (Q) as described in the text, particularly concerning how they differ for photons versus alpha particles.","The text highlights a crucial distinction in evaluating radiation risk: simply considering LET doesn't fully capture the biological impact of radiation. LET represents the energy deposited per unit path length of a particle traversing matter. Radiation weighting factors (wR) are used to account for this energy deposition, assigning different weights to various types of radiation based on their ability to cause damage. For example, alpha particles, with their high charge and momentum, receive a significantly higher wR (20) than photons (1), reflecting their greater potential for creating ionization tracks and causing DNA damage. Conversely, electrons and muons also have a wR of 1. However, the quality factor (Q) attempts to refine this by considering the track structure – how the radiation actually interacts with biological tissue. The text notes that low-LET dose responses are typically nonlinear while high-LET responses tend to be more linear. For neutrons, Q varies depending on LET, demonstrating a complex relationship between particle properties and biological effect. Notably, NASA’s risk projection uses a quality factor that explicitly accounts for track structure, differing from the ICRP's (Q(LET)) approach which relies solely on LET. This difference is particularly important when dealing with high-energy charged particles like HZE particles encountered in space environments where traditional methods are inadequate.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.3	 Space Radiation Environment | Sub-subsection: 10.3.5	 Mathematical Modelling the Space Radiation Environment and Induced Doses | Sub-sub-subsection: 10.3.5.3	 Harmonization of Risk Models for Stochastic Effects: The Problem of Radiation Quality Factors | Content: other factors and may be different, e.g., for particular chro­
mosome aberrations, mutations, or different tumor types.
Also, RBE may vary in different biological systems.
Furthermore, low-LET dose response is usually nonlinear
while high-LET response tends to be more linear.
­
R
78
­
R
R
R
78
10.2
R
­
78
10.2
­
­
Nevertheless, this specification of Q in terms of the LET
alone suffers from the limitations already highlighted in Chap.
1, about the fact that the sole LET cannot fully describe the
effectiveness of radiation in inducing biological damage.
Indeed, even simply from the perspectives of the first-stage
radiation-induced effects, without mentioning the complex
dependencies of the RBE on phenomena related to the chemi­
Table 10.2 Radiation weighting factors and quality factors
Radiation type
Radiation weighting factor (wR)
Quality factor (Q(LET))
Photons
1
Electrons and muons
1
Protons and charged pions
2
Alpha particles, fission fragments, heavy ions
20
Neutrons
A continuous function of neutron energy
For LET < 10 keV/μm
For 10 ≤ LET ≤ 100 keV/μm
For LET > 100 keV/μm
1
Q = 0.32L–2.2
Q = 300L–1/2
10 Space Radiobiology
520
cal and biological steps, it remains the fact particles with dif­
ferent charge and different velocity may have the same LET
and still inducing different final biological effects. The varia­
tion in the effectiveness of radiation in inducing different final
biological effects has thus its root in the differences in track
structures between particles that have the same LET but differ­
ent charge and velocity, as highlighted in Chap. 1. Differences
can be particularly large for the HZE particles encountered in
space, methods used on Earth are inadequate for space travel,
as, among other reasons, the ICRP radiation quality descrip­
tion does not represent HZE radiobiology correctly.
The key difference between (a) the quality factor used by
NASA [79] for the projection of risk from space exposures
and (b) the quality factor recommended by the ICRP
(Q(LET)) for operational radiation protection on Earth is
consideration of track structure (Box 10.2).
10.4
Human Health and Organs at Risks
for Space Travel
The space environment is hostile to the health of astronauts
in several ways. The confinement in the restricted space of
spacecraft for shorter or longer periods exposes the crew to
sometimes severe behavioral problems. Microgravity can
lead to osteoporosis, a modification of the electrolyte com­
partments, sarcopenia, cardiac arrhythmias, dysthemeral
rhythm disorganization, vestibular deconditioning, relative
immunosuppression, and postural hypotension on return
[80]. Finally, the space radiation environment is very differ­
ent and much more hostile than that encountered on Earth.
Add a temperature amplitude of 300 °C on the spacecraft’s
surface and the almost absolute vacuum conditions that
astronauts must consider during extravehicular excursions.
Finally, let us point out the disturbances secondary to the
return to the ground: neurological, vestibular, cardiovascular
reconditioning, etc.
10.4.1	Radiation Exposure During Space
Missions
The constant flux of galactic cosmic rays (GCR) causes astro­
nauts’ chronic low-dose whole-body exposure during space
missions. The primary GCR particles interact with the space­
craft hull, so that astronauts are—like patients—exposed to
secondary radiation from nuclear interactions between the
incident radiation and the shielding of the spacecraft. Due to
mass limitations for launching spacecraft, complete shielding
of GCR is not feasible. Compared to an astronaut suit for
extravehicular activities, the shielding of the spacecraft by
aluminum and other materials strongly reduces the skin dose
and also, but to a much lower extent, the whole-body dose.
On the microscopic level, due to the physical characteristics
of particle radiation, very high doses can be reached, leading
to permanent damage (see Sect. 10.4).
8182
­
8384
­
10.12
10.3.1.2
­
­
10.12
10.4.2	Acute Effects
Deterministic effects appear for acute global exposures clas­
sified as medium, high, and very high (0.2 to more than 10
Sv) by UNSCEAR [85].
Box 10.2 Modeling
(a)	The Boltzmann equation describes the transport of
radiation in matter; it can be solved via analytical
(deterministic) or via numerical (Monte Carlo)
methods.
(b)	The different steps for setting up a calculation of
the radiation environment are input radiation spec­
tra, definition of the parameters describing the
atmosphere, with dependence on the altitude, defi­
nition of the regolith composition, definition of the
physics model to be used according to the different
energy ranges, definition of the target where the
scoring of the absorbed dose will be done.
C. E. Hellweg et al."
"Describe the concept of deterministic radiation effects in space radiobiology, specifically referencing the classification of acute exposures as medium, high, and very high doses according to UNSCEAR.","Deterministic radiation effects represent non-stochastic biological damage resulting from exposure to ionizing radiation. These effects are characterized by a threshold dose – below which no observable effect is seen – and a limited dose-response relationship above that threshold. According to the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), acute deterministic effects are classified based on global exposure levels, ranging from medium to very high. Specifically, exposures categorized as 0.2 Sieverts (Sv) to less than 10 Sv are considered ‘medium’ risk, representing a significant potential for severe health consequences. Exposures exceeding 10 Sv are classified as ‘high’ risk, indicating a substantial probability of serious and potentially fatal effects. Finally, exposures greater than this value – more than 10 Sv – are categorized as ‘very high’ risk, signifying an extremely high likelihood of permanent damage to tissues and organs. These classifications are crucial for assessing the potential health risks associated with space travel and determining appropriate shielding strategies.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.4	 Human Health and Organs at Risks for Space Travel | Content: of particle radiation, very high doses can be reached, leading
to permanent damage (see Sect. 10.4).
8182
­
8384
­
10.12
10.3.1.2
­
­
10.12
10.4.2	Acute Effects
Deterministic effects appear for acute global exposures clas­
sified as medium, high, and very high (0.2 to more than 10
Sv) by UNSCEAR [85].
Box 10.2 Modeling
(a)	The Boltzmann equation describes the transport of
radiation in matter; it can be solved via analytical
(deterministic) or via numerical (Monte Carlo)
methods.
(b)	The different steps for setting up a calculation of
the radiation environment are input radiation spec­
tra, definition of the parameters describing the
atmosphere, with dependence on the altitude, defi­
nition of the regolith composition, definition of the
physics model to be used according to the different
energy ranges, definition of the target where the
scoring of the absorbed dose will be done.
C. E. Hellweg et al."
"Describe the primary mechanisms by which astronauts experience radiation exposure during extended space missions, and explain how spacecraft shielding mitigates this risk.","Astronauts are exposed to significant radiation doses primarily due to two interconnected factors during long-duration space missions: chronic low-dose whole-body exposure from galactic cosmic rays (GCR) and secondary radiation resulting from interactions between GCRs and the spacecraft’s shielding materials. Galactic Cosmic Rays, originating from outside our solar system, constantly bombard the spacecraft. These high-energy particles interact with the hull of the spacecraft, generating secondary radiation through nuclear reactions – specifically, processes like pair production and atomic bombardment. This secondary radiation significantly contributes to the overall dose received by astronauts.  The effectiveness of spacecraft shielding relies on its ability to attenuate (reduce) these secondary radiations. Materials such as aluminum, commonly used in spacecraft construction, provide a degree of protection by absorbing or scattering the incoming and generated radiation. However, complete shielding is not achievable due to mass limitations imposed by launch constraints. While spacecraft shielding substantially reduces skin doses compared to an astronaut suit during extravehicular activities (EVAs), it offers only a less pronounced reduction in whole-body dose. The microscopic damage caused by these high radiation fluxes can lead to permanent cellular and genetic alterations if the dose exceeds repair capacity. Reference: Space Radiobiology - 10.4 Human Health and Organs at Risks for Space Travel > 10.4.1 Radiation Exposure During Space Missions","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.4	 Human Health and Organs at Risks for Space Travel | Sub-subsection: 10.4.1	 Radiation Exposure During Space Missions | Content: Missions
The constant flux of galactic cosmic rays (GCR) causes astro­
nauts’ chronic low-dose whole-body exposure during space
missions. The primary GCR particles interact with the space­
craft hull, so that astronauts are—like patients—exposed to
secondary radiation from nuclear interactions between the
incident radiation and the shielding of the spacecraft. Due to
mass limitations for launching spacecraft, complete shielding
of GCR is not feasible. Compared to an astronaut suit for
extravehicular activities, the shielding of the spacecraft by
aluminum and other materials strongly reduces the skin dose
and also, but to a much lower extent, the whole-body dose.
On the microscopic level, due to the physical characteristics
of particle radiation, very high doses can be reached, leading
to permanent damage (see Sect. 10.4).
8182
­
8384
­
10.12
10.3.1.2
­
­
10.12"
"Describe the potential acute health effects observed in astronauts following exposure to high doses of particle radiation, such as those experienced during a solar particle event (SPE), and identify the tissues most vulnerable to these immediate consequences.","Following exposure to very high doses of particle radiation, particularly during an SPE, astronauts can experience acute radiation syndrome (ARS). This typically occurs with global exposures classified as medium, high, or very high (0.2 to more than 10 Sieverts) according to UNSCEAR. The immediate effects are primarily due to the rapid turnover rate of radiosensitive tissues, including bone marrow, the digestive epithelium, germ cells, and skin. Symptoms of radiation sickness, such as headache, dizziness, nausea, and bone marrow hypoplasia, manifest at doses around 0.5-1 Gy. At higher doses (3-4 Gy), mortality rates reach approximately 50% within one month. The severity of the effects is directly related to the dose received over a short period – generally instantaneously but defined as less than 4 days.  The rapid cell division in these vulnerable tissues exacerbates the damage caused by radiation, leading to significant physiological disruption and potentially fatal outcomes. Reference: [MolecularRadiationBiology, Section 10.4.2 Acute Effects]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.4	 Human Health and Organs at Risks for Space Travel | Sub-subsection: 10.4.2	 Acute Effects | Content: of particle radiation, very high doses can be reached, leading
to permanent damage (see Sect. 10.4).
8182
­
8384
­
10.12
10.3.1.2
­
­
10.12
10.4.2	Acute Effects
Deterministic effects appear for acute global exposures clas­
sified as medium, high, and very high (0.2 to more than 10
Sv) by UNSCEAR [85].
Box 10.2 Modeling
(a)	The Boltzmann equation describes the transport of
radiation in matter; it can be solved via analytical
(deterministic) or via numerical (Monte Carlo)
methods.
(b)	The different steps for setting up a calculation of
the radiation environment are input radiation spec­
tra, definition of the parameters describing the
atmosphere, with dependence on the altitude, defi­
nition of the regolith composition, definition of the
physics model to be used according to the different
energy ranges, definition of the target where the
scoring of the absorbed dose will be done.
C. E. Hellweg et al.
521Fig. 10.12
Fig. 10.12 Possible health effects of space radiation exposure
Under exceptional conditions of insufficient shielding
during spaceflight, the exposure to mostly protons during a
large solar particle event (SPE), the whole-body dose can
reach several Gy or the skin dose even tens of Gy and thereby
cause the acute radiation syndrome (ARS, see Chap. 2, Sect.
2.7.2). Such situations in the event of a solar flare of excep­
tional intensity can occur in LEO in areas of weakness of the
Van Allen belts, extravehicular exit, and exit on extraterres­
trial soil in a spacesuit or an insufficiently shielded vehicle.
The total dose is delivered over a short period of time: gener­
ally, instantaneously but by definition over less than 4 days.
The acute effects affect rapidly renewing tissues which
are particularly radiosensitive (bone marrow, digestive epi­
thelium, germ cells, skin). The classic “radiation sickness”
or prodromal syndrome (headache, dizziness, nausea, bone
marrow hypoplasia) occurs for an exposure of 0.5–1 Gy. A
dose of 3–4 Gy kills 50% of exposed individuals in 1 month
[86]. Unlike the desired partial exposure of patients undergo­
ing radiotherapy, solar flares are unpredictable, which seri­
ously complicates mission planning for astronauts.
10.4.2.1
Chronic and Late Effects: Cancer
and Degenerative Diseases
For several decades, NASA has collected data concerning
acute and chronic morbidity and mortality in US astronauts
in the NASA’s Longitudinal Study of Astronaut Health [87].
One main aim is to determine whether astronauts’ occupa­
tional space radiation exposure is associated with an
increased risk of cancer or other diseases. The cohort is made
up of 312 astronauts selected by NASA since 1959.
Employees at the NASA Johnson Space Center in Houston,
Texas, served as the control group. In January 2003, just
before the explosion of the Columbia shuttle, 29 deaths
(9.3%) were counted in the group of astronauts versus 17
(1.8%) in the control group. Note 20 accidental deaths among
astronauts (versus 2 in the matched group). No other cause
reached the threshold of significance.
Compared to the control group at matched age, astronauts
had a higher specific mortality rate (SMR) from cancer. This
difference was not significant. However, both groups had a
lower specific mortality rate than the general population.
Fourteen cases of cancer have been described in astronauts
(not counting 33 cases of non-melanoma skin cancer), which
represents a relative risk of 1.59 compared to the Air Force
pairings but of 0.54 compared to the cohort of NCI (general
population), which ultimately remains insignificant. A later
study found that standardized mortality rates for astronauts
were significantly below US white male population rates
[88].
During a Mars exploration mission, each cell nucleus of
an astronaut would be crossed by a proton or a secondary
electron every 2 days, and by a heavier ion every month [89].
10 Space Radiobiology"
"The text discusses the potential risks of space radiation exposure on astronauts, particularly concerning cancer development. It highlights several key factors influencing this risk, including particle mass, energy, and charge, as well as the use of the linear no-threshold (LNT) model. Furthermore, it describes how chromosomal aberrations, specifically detected through biodosimetry using peripheral blood lymphocytes, can serve as a sensitive indicator of radiation exposure. Can you summarize these key elements regarding space radiation’s impact on astronaut health?","Space radiation poses significant carcinogenic risks to astronauts due to the high ionizing power of particles like protons and heavy ions encountered during interplanetary missions. The risk is influenced by several factors: particle characteristics (mass, energy, charge) which directly affect ionization potential; the application of the linear no-threshold (LNT) model for cancer risk estimation – a widely used but controversial approach assuming a constant risk per unit dose regardless of dose rate; and the use of chromosomal aberrations as a biodosimeter. Specifically, heavy ions induce severe DNA damage leading to chromosome abnormalities detectable in peripheral blood lymphocytes. These aberrations, such as translocations and inversions, can be quantified through techniques like multicolor fluorescence in situ hybridization (mFISH) or high-resolution multicolor banding (mBAND), providing an integrated measure of radiation exposure. The frequency of these chromosomal changes varies significantly between individuals due to factors like basal aberration rates and individual radiosensitivity.  Longer missions, particularly those exceeding 6 months, are associated with a rise in chromosome aberrations above background levels, as evidenced by studies on Gemini and Mir astronauts. However, dose estimation based on cytogenetic analysis remains challenging due to inter-individual variability and the potential for non-additive effects from multiple exposures. The observed telomere elongation and subsequent shortening following space missions also presents an area of ongoing research related to radiation impact.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.4	 Human Health and Organs at Risks for Space Travel | Sub-subsection: 10.4.2	 Acute Effects | Sub-sub-subsection: 10.4.2.1	 Chronic and Late Effects: Cancer and Degenerative Diseases | Content: [88].
During a Mars exploration mission, each cell nucleus of
an astronaut would be crossed by a proton or a secondary
electron every 2 days, and by a heavier ion every month [89].
10 Space Radiobiology
522
Due to their strong ionizing power, these ions appear to be
the main vector of carcinogenic risk despite their low
fluence.
The interval between irradiation and tumor appearance
has been shown in rats to be shortened compared to conven­
tional radiation [90, 91]; fewer events would be needed in the
promotion of carcinogenesis induced by high-LET particles.
Particle mass, energy, and charge can influence the cancer
risk of an HZE particle.
The linear no-threshold (LNT) model used to predict the
risk of cancer mortality in astronauts sent on interplanetary
missions relies on data from atomic bomb survivors extrap­
olated to this particular population, to these types of parti­
cles, and to the dose rates encountered in the space
environment. Though nearly universally used by public
bodies to assess cancer risk, LNT is far from being a scien­
tific consensus and its application for low dose rates is
rather controversial—see Chap. 2. For cancer risk estima­
tion, age at exposure, attained age, sex- and tissue-specific
mortality and incidence, and latency has to be considered.
Also, an important question is whether the additional can­
cer risk induced by space radiation exposure is independent
of other cancerogenic events (excess absolute risk, EAR),
or whether the risk depends on other cancer risks (excess
relative risk, ERR).
10.3
50
Besides the calculated increased cancer risk for astro­
nauts, cataracts might be triggered or promoted by space
radiation exposure. Astronauts exposed to a dose of more
than 8 mSv exhibit earlier and more frequent cataracts (in a
study that identified 295 astronauts paired with as many US
Air Force pilots) [92].
10.4.2.2
Chromosomal Aberrations
and Biodosimetry
Due to the densely distributed ionizations around a heavy
ion’s path through a cell nucleus, severe DNA damage (Sect.
10.5.3) possibly leading to chromosomal aberrations (Sect.
10.5.2) can be induced. Therefore, chromosome damage
induced in vivo was identified early as a sensitive biodosim­
eter [93, 94] that integrates radiation exposure in quality and
quantity and also the individual radiosensitivity [95].
Peripheral blood lymphocytes are accessible by venipunc­
ture and the chromosomal aberration test can be performed
with these cells before and after flight.
In order to determine the effects of space radiation on
astronauts, chromosomal aberrations were quantified already
in Gemini astronauts before and after the spaceflight [96]. In
some astronauts, a small increase was observed after the
flight which did not correlate with flight duration (1–14
days), extravehicular activities, or diagnostic radioisotope
injections [96]. Missions with a duration of up to 3 weeks did
not result in an increase of the aberrations above background;
after missions of 6 months or longer, a rise was clearly
observed [95, 97–104], but dose estimation based on the
cytogenetic analysis varied strongly [95]. Here, the inter-
individual variability of the translocations’ half-life in
peripheral blood lymphocytes has to be considered [105].
Also, the basal aberration frequency and the reaction toward
ionizing radiation varies from individual to individual [106–
108]. Furthermore, the effects of multiple space missions
might not be additive [109, 110]. Prediction of dicentrics fre­
quencies for a Mars mission assume values 10–40× above
background in peripheral lymphocytes [111].
For detection of reciprocal translocations, multicolor fluo­
rescence in situ hybridization (mFISH) was first applied to
members of the Mir-18 crew [112]. In search of a specific
marker of heavy ion exposure, complex chromosome inter­
changes were suggested and analyzed in blood lymphocytes
of astronauts [113, 114]. High-resolution multicolor banding
(mBAND) of chromosome 5 can visualize intrachromosomal
exchanges—long-term missions to the ISS did not increase
this parameter [115]. Such inversions were only recently
found in three astronauts during a 6-months ISS mission
[116]. Complex chromosomal rearrangements occur very
rarely in astronauts therefore their use as biomarker is limited
[93]. Over the years, different cytogenetic or chromosomal
signatures that allow reconstruction of absorbed dose and
radiation quality were suggested, such as insertions [117],
inversions [118], and complex chromosome interchanges, but
up to now, no consensus for a biomarker of exposure to high-
LET radiation has been reached [119] (see Sect. 8.7).
The relevance of the telomere elongation that was first
observed during the 1-year ISS mission and its fast shorten­
ing after return to Earth [120], which was now also found
during 6-months missions [116], for assessment of space
Table 10.3 Doses and LNT-based estimates for cancer mortality risk
following space missions
Absorbed
dose (Gy)
Effective
dose (Sv)
Risk of death by cancer (%)
[IC95%]
Male 40
y.o.
Female 40
y.o.
Moon Mission
(180 days)
0.06
0.17
0.68
[0.20–2.40]
0.82
[0.24–3.00]
Mars Orbit
Mission (600
days)
0.37
1.03
4.00
[1.00–
13.50]
4.90
[1.40–16.20]
Mars Mission
(1000 days)
0.42
1.07
4.20
[1.30–
13.60]
5.10
[1.60–16.40]
C. E. Hellweg et al."
"Describe the observed biological effects following exposure to ionizing radiation in astronauts during space missions, referencing specific examples like the Biostack experiments and light flash perceptions.","During extended space missions, astronauts exhibit a range of biological responses to ionizing radiation, primarily stemming from galactic cosmic rays (GCR) and trapped radiation. Early evidence emerged with the Biostack experiments conducted on the Apollo-16 and -17 missions, where exposure to high-energy heavy ions resulted in significant reductions in the growth rate of *Bacillus subtilis* spores. More strikingly, the development of brine shrimp eggs following a single particle hit displayed pronounced abnormalities affecting the thorax and abdomen. Similarly, insect eggs exposed to HZE particles showed developmental distortions. These findings demonstrated that even relatively low doses of ionizing radiation could induce substantial biological changes within these organisms. Furthermore, astronauts reported experiencing ‘light flashes’ or phosphenes – visual sensations caused by the interaction of high-energy ions with the retina, potentially through direct impact or via Cherenkov radiation. The frequency and intensity of these light flashes varied depending on orbital parameters like altitude and inclination, and were observed during missions such as Mir, Skylab, and the ISS.  The observation of light flashes initiated research into understanding the mechanisms behind this phenomenon, suggesting a link between space radiation exposure and neurological effects. These observations led to the development of techniques like multicolor fluorescence in situ hybridization (mFISH) for analyzing chromosome aberrations and ultimately contributed to dose estimation efforts. Reference: [MolecularRadiationBiology, Section 10.4.2 – Acute Effects], Table 10.3","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.4	 Human Health and Organs at Risks for Space Travel | Sub-subsection: 10.4.2	 Acute Effects | Sub-sub-subsection: 10.4.2.2	 Chromosomal Aberrations and Biodosimetry | Content: some astronauts, a small increase was observed after the
flight which did not correlate with flight duration (1–14
days), extravehicular activities, or diagnostic radioisotope
injections [96]. Missions with a duration of up to 3 weeks did
not result in an increase of the aberrations above background;
after missions of 6 months or longer, a rise was clearly
observed [95, 97–104], but dose estimation based on the
cytogenetic analysis varied strongly [95]. Here, the inter-
individual variability of the translocations’ half-life in
peripheral blood lymphocytes has to be considered [105].
Also, the basal aberration frequency and the reaction toward
ionizing radiation varies from individual to individual [106–
108]. Furthermore, the effects of multiple space missions
might not be additive [109, 110]. Prediction of dicentrics fre­
quencies for a Mars mission assume values 10–40× above
background in peripheral lymphocytes [111].
For detection of reciprocal translocations, multicolor fluo­
rescence in situ hybridization (mFISH) was first applied to
members of the Mir-18 crew [112]. In search of a specific
marker of heavy ion exposure, complex chromosome inter­
changes were suggested and analyzed in blood lymphocytes
of astronauts [113, 114]. High-resolution multicolor banding
(mBAND) of chromosome 5 can visualize intrachromosomal
exchanges—long-term missions to the ISS did not increase
this parameter [115]. Such inversions were only recently
found in three astronauts during a 6-months ISS mission
[116]. Complex chromosomal rearrangements occur very
rarely in astronauts therefore their use as biomarker is limited
[93]. Over the years, different cytogenetic or chromosomal
signatures that allow reconstruction of absorbed dose and
radiation quality were suggested, such as insertions [117],
inversions [118], and complex chromosome interchanges, but
up to now, no consensus for a biomarker of exposure to high-
LET radiation has been reached [119] (see Sect. 8.7).
The relevance of the telomere elongation that was first
observed during the 1-year ISS mission and its fast shorten­
ing after return to Earth [120], which was now also found
during 6-months missions [116], for assessment of space
Table 10.3 Doses and LNT-based estimates for cancer mortality risk
following space missions
Absorbed
dose (Gy)
Effective
dose (Sv)
Risk of death by cancer (%)
[IC95%]
Male 40
y.o.
Female 40
y.o.
Moon Mission
(180 days)
0.06
0.17
0.68
[0.20–2.40]
0.82
[0.24–3.00]
Mars Orbit
Mission (600
days)
0.37
1.03
4.00
[1.00–
13.50]
4.90
[1.40–16.20]
Mars Mission
(1000 days)
0.42
1.07
4.20
[1.30–
13.60]
5.10
[1.60–16.40]
C. E. Hellweg et al.
523
radiation risk is currently unclear. The telomere changes are
considered as an integrative biomarker for effects of the
spaceflight environment [121].
10.4.2.3
Light Flashes
Before the first human went to space, in 1952, Professor
Cornelius A. Tobias made the famous prediction that cosmic
radiation can cause unusual light sensations by interaction
with the visual system. The Apollo-11 astronaut Edwin
(Buzz) Aldrin was first reported to have perceived light
flashes during the Moon mission [122]. This initiated a series
of investigations already during the following Apollo mis­
sions [123], and later on Mir, Skylab, Apollo-Soyuz Test
Project (ASTP), Shuttle missions, and on the ISS. They
started with observation sessions and nuclear emulsion plates
(Apollo light flash moving emulsion detector, ALFMED).
The observations were later combined with sophisticated
particle detectors in the Silicon Eye (SilEye-1 and -2) experi­
ments on Mir [124], and Alteino-SilEye-3 and Anomalous
Long-Term Effects on Astronauts (ALTEA) experiments on
ISS, which included also an electroencephalograph.
The observations of the Apollo astronauts resulted in an
average event rate of one light flash event in ~3 min [123]. In
LEO, when passing through the SAA, the light flash rates are
very high [125], and outside the SAA, light flash frequency
is higher in the polar parts of the orbit than in equatorial lati­
tudes [126]. The number of light flashes perceived in LEO
varies on average between one every minute up to one every
7 min on Mir [127] or every 20 min [128, 129] dependent on
the orbital height, the inclination, the shielding of the space­
craft and solar activity [130].
So, in conclusion, contrarily to the usual statement that
we have no senses to perceive ionizing radiation, when clos­
ing their eyes, most space travelers can “see” the exposure to
galactic cosmic rays and trapped radiation as mostly color­
less light flashes or phosphenes in the form of spots, stars,
streaks, or diffuse clouds of light [125]. About 15–20 min of
dark adaptation is required [123] so that they are usually per­
ceived before falling asleep.
This light flash phenomenon is explained by a visual sensa­
tion that is produced by the interaction of highly energetic
heavy ions with the retina of the eye [131, 132] or possibly
with visual centers in the brain or the optic nerve after penetra­
tion of the spacecraft walls and the eye or head. The interac­
tion might be direct or indirect via Cherenkov radiation in
vitreous humor which is emitted as light when the charged
particle passes through it with a velocity higher than the speed
of light in the vitreous humor [133]. The probability of a heavy
ion to cause a light flash has been estimated to be around
1%—with increasing probability with increasing LET—and
for protons to be below 0.001% in LEO [127]. A deleterious
effect of the flashes on vision is not suspected, but some astro­
nauts report that their sleep was disturbed by light flashes.
10.5
Biomolecular Changes Induced by
Space Radiation
Ionizing radiation, which exists primarily in the form of
high-energy, charged particles make up space radiation. The
radiation environment in space is characterized by a high
complexity due to different sources and a higher number of
particle species, and a broad energy range. Galactic cosmic
radiation (GCR), solar particle events (SPE), and, in LEO,
trapped radiation are the naturally occurring sources of space
radiation.
The exposure to GCR occurs at a low dose rate on the
organismal level, but strong cellular effects might be trig­
gered in case of a “hit” by an energetic particle, especially
high Z and high energy (HZE) particles or heavy ions. HZE
particles make up only 1% of GCR therefore only small hit
frequencies are expected in the human body that could be
responsible for late effects [134]. First evidence of biologi­
cal effects of HZE particles was found in mice after a high-
altitude balloon flight when the coat of black mice locally
turned grey [135]. Single particle effects on different dor­
mant biological systems under spaceflight conditions were
proven by means of the Biostack experiments on the
Apollo-16 and -17 missions [10, 136]. In this experimental
system, biological systems and detector foils were stacked
onto each other to allow assignment of heavy ion hits to the
biological systems. Heavy ion hits were detected in plastic
foils (cellulose nitrate, polycarbonate), silver chloride crys­
tals, and nuclear emulsions. The biological systems were
immobilized on the foils with water-soluble polyvinyl alco­
hol and included Bacillus subtilis spores, seeds of the thale
cress Arabidopsis thaliana, roots of the field bean Vicia
faba, eggs of the brine shrimp Artemia salina, insect eggs
(stick insect, Carausius morosus and rice weevil, Tribolium
confusum), and protozoa cysts (Colpoda cucullus). The out­
growth of B. subtilis after germination was significantly
reduced after an HZE particle hit [137, 138]. During the
development of brine shrimp eggs that were hit by a single
particle, abnormalities appeared at the extremities, the tho­
rax, and the abdomen [139] and the eggs showed the most
sensitive reaction toward HZE particles compared to the
other biological systems in Biostack [137, 140].
Developmental abnormalities were also found in hit insect
eggs [141]. The total dose for the Biostack experiments was
quite low (5.8–7.5 mGy), and ~0.03 mGy was allocated to
the HZE particles, whereby it has to be considered that the
local dose in a hit cell can be much higher than the total
dose.
These experiments were continued in LEO using the Free
Flyer
Biostack
Experiment
(LDEF—Long
Duration
Exposure Facility) [142], EURECA—European Retrievable
Carrier [143–146], and the biosatellites COSMOS 1887 and
2004 [147, 148] and refined, so that synergistic effects of
10 Space Radiobiology"
"Describe the Biostack experiments conducted during spaceflight missions like Apollo-16 and -17, focusing on their design and key findings regarding the biological effects of high-energy particle hits. Specifically, what organisms were included in the experiment, and what observable changes were noted following exposure to HZE particles?","The Biostack experiments were a crucial component of investigating the biological consequences of space radiation exposure. These experiments utilized a stacked system – a biological payload (including various microorganisms and plant tissues) layered onto detector foils designed to identify individual particle impacts. The initial experiments, conducted on Apollo-16 and -17 using the LDEF, employed a system containing Bacillus subtilis spores, seeds of Arabidopsis thaliana, roots of Vicia faba, eggs of Artemia salina (brine shrimp), insect eggs (Carausius morosus and Tribolium confusum), and protozoa cysts (Colpoda cucullus). The detector foils – primarily cellulose nitrate, silver chloride crystals, and nuclear emulsions – were used to pinpoint the location of heavy ion hits within the biological samples. A total dose of approximately 5.8-7.5 mGy was delivered, with a small fraction (~0.03 mGy) specifically allocated to HZE particles. Key findings revealed significant reductions in the outgrowth of B. subtilis spores after germination following an HZE particle impact, indicating a direct cytotoxic effect. Furthermore, exposure to HZE particles during the development of brine shrimp eggs resulted in observable abnormalities – particularly at the extremities (thorax and abdomen) – suggesting developmental disruption at a cellular level. Similarly, insect eggs exhibited sensitivity to these impacts, showing abnormalities. These observations highlighted the potential for single-particle events, especially those involving high Z and high energy particles, to trigger significant biological effects even at relatively low overall radiation doses.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.4	 Human Health and Organs at Risks for Space Travel | Sub-subsection: 10.4.2	 Acute Effects | Sub-sub-subsection: 10.4.2.3	 Light Flashes | Content: 1%—with increasing probability with increasing LET—and
for protons to be below 0.001% in LEO [127]. A deleterious
effect of the flashes on vision is not suspected, but some astro­
nauts report that their sleep was disturbed by light flashes.
10.5
Biomolecular Changes Induced by
Space Radiation
Ionizing radiation, which exists primarily in the form of
high-energy, charged particles make up space radiation. The
radiation environment in space is characterized by a high
complexity due to different sources and a higher number of
particle species, and a broad energy range. Galactic cosmic
radiation (GCR), solar particle events (SPE), and, in LEO,
trapped radiation are the naturally occurring sources of space
radiation.
The exposure to GCR occurs at a low dose rate on the
organismal level, but strong cellular effects might be trig­
gered in case of a “hit” by an energetic particle, especially
high Z and high energy (HZE) particles or heavy ions. HZE
particles make up only 1% of GCR therefore only small hit
frequencies are expected in the human body that could be
responsible for late effects [134]. First evidence of biologi­
cal effects of HZE particles was found in mice after a high-
altitude balloon flight when the coat of black mice locally
turned grey [135]. Single particle effects on different dor­
mant biological systems under spaceflight conditions were
proven by means of the Biostack experiments on the
Apollo-16 and -17 missions [10, 136]. In this experimental
system, biological systems and detector foils were stacked
onto each other to allow assignment of heavy ion hits to the
biological systems. Heavy ion hits were detected in plastic
foils (cellulose nitrate, polycarbonate), silver chloride crys­
tals, and nuclear emulsions. The biological systems were
immobilized on the foils with water-soluble polyvinyl alco­
hol and included Bacillus subtilis spores, seeds of the thale
cress Arabidopsis thaliana, roots of the field bean Vicia
faba, eggs of the brine shrimp Artemia salina, insect eggs
(stick insect, Carausius morosus and rice weevil, Tribolium
confusum), and protozoa cysts (Colpoda cucullus). The out­
growth of B. subtilis after germination was significantly
reduced after an HZE particle hit [137, 138]. During the
development of brine shrimp eggs that were hit by a single
particle, abnormalities appeared at the extremities, the tho­
rax, and the abdomen [139] and the eggs showed the most
sensitive reaction toward HZE particles compared to the
other biological systems in Biostack [137, 140].
Developmental abnormalities were also found in hit insect
eggs [141]. The total dose for the Biostack experiments was
quite low (5.8–7.5 mGy), and ~0.03 mGy was allocated to
the HZE particles, whereby it has to be considered that the
local dose in a hit cell can be much higher than the total
dose.
These experiments were continued in LEO using the Free
Flyer
Biostack
Experiment
(LDEF—Long
Duration
Exposure Facility) [142], EURECA—European Retrievable
Carrier [143–146], and the biosatellites COSMOS 1887 and
2004 [147, 148] and refined, so that synergistic effects of
10 Space Radiobiology"
"Describe the key findings and experimental setup utilized in the Biostack experiments conducted during the Apollo-16 and -17 missions, focusing on the observed biological effects of high-energy charged particles (HZE) on various organisms.","The Biostack experiments, deployed aboard the Apollo-16 and -17 missions, employed a stacked system consisting of biological samples – including Bacillus subtilis spores, Arabidopsis thaliana seeds, Vicia faba roots, Artemia salina eggs, Carausius morosus insect eggs, Tribolium confusum weevil eggs, and Colpoda cucullus protozoa cysts – layered with detector foils designed to identify single-particle hits from Galactic Cosmic Radiation (GCR). These foils included cellulose nitrate, polycarbonate, and silver chloride crystals. The experiments demonstrated that exposure to HZE particles significantly reduced the outgrowth of *Bacillus subtilis* spores after germination. Notably, brine shrimp eggs exposed to a single particle exhibited developmental abnormalities primarily affecting the extremities, thorax, and abdomen, demonstrating heightened sensitivity compared to other biological systems within the Biostack. Similarly, insect eggs also displayed abnormalities following HZE particle hits. The total radiation dose applied was relatively low (5.8–7.5 mGy), with approximately 0.03 mGy allocated specifically to HZE particles, highlighting that local doses experienced by individual cells during a hit could be substantially higher than the overall exposure. These results spurred further investigations into the biological effectiveness of HZE particles and their potential synergistic effects with other spaceflight stressors like microgravity.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Content: 1%—with increasing probability with increasing LET—and
for protons to be below 0.001% in LEO [127]. A deleterious
effect of the flashes on vision is not suspected, but some astro­
nauts report that their sleep was disturbed by light flashes.
10.5
Biomolecular Changes Induced by
Space Radiation
Ionizing radiation, which exists primarily in the form of
high-energy, charged particles make up space radiation. The
radiation environment in space is characterized by a high
complexity due to different sources and a higher number of
particle species, and a broad energy range. Galactic cosmic
radiation (GCR), solar particle events (SPE), and, in LEO,
trapped radiation are the naturally occurring sources of space
radiation.
The exposure to GCR occurs at a low dose rate on the
organismal level, but strong cellular effects might be trig­
gered in case of a “hit” by an energetic particle, especially
high Z and high energy (HZE) particles or heavy ions. HZE
particles make up only 1% of GCR therefore only small hit
frequencies are expected in the human body that could be
responsible for late effects [134]. First evidence of biologi­
cal effects of HZE particles was found in mice after a high-
altitude balloon flight when the coat of black mice locally
turned grey [135]. Single particle effects on different dor­
mant biological systems under spaceflight conditions were
proven by means of the Biostack experiments on the
Apollo-16 and -17 missions [10, 136]. In this experimental
system, biological systems and detector foils were stacked
onto each other to allow assignment of heavy ion hits to the
biological systems. Heavy ion hits were detected in plastic
foils (cellulose nitrate, polycarbonate), silver chloride crys­
tals, and nuclear emulsions. The biological systems were
immobilized on the foils with water-soluble polyvinyl alco­
hol and included Bacillus subtilis spores, seeds of the thale
cress Arabidopsis thaliana, roots of the field bean Vicia
faba, eggs of the brine shrimp Artemia salina, insect eggs
(stick insect, Carausius morosus and rice weevil, Tribolium
confusum), and protozoa cysts (Colpoda cucullus). The out­
growth of B. subtilis after germination was significantly
reduced after an HZE particle hit [137, 138]. During the
development of brine shrimp eggs that were hit by a single
particle, abnormalities appeared at the extremities, the tho­
rax, and the abdomen [139] and the eggs showed the most
sensitive reaction toward HZE particles compared to the
other biological systems in Biostack [137, 140].
Developmental abnormalities were also found in hit insect
eggs [141]. The total dose for the Biostack experiments was
quite low (5.8–7.5 mGy), and ~0.03 mGy was allocated to
the HZE particles, whereby it has to be considered that the
local dose in a hit cell can be much higher than the total
dose.
These experiments were continued in LEO using the Free
Flyer
Biostack
Experiment
(LDEF—Long
Duration
Exposure Facility) [142], EURECA—European Retrievable
Carrier [143–146], and the biosatellites COSMOS 1887 and
2004 [147, 148] and refined, so that synergistic effects of
10 Space Radiobiology
524
HZE particle hits and microgravity in the developmental dis­
orders of C. morosus were revealed.
These intriguing results showing strong deleterious
effects of single particle traversals and even an enhancement
by other spaceflight environmental effects initiated a multi­
tude of biological experiments in space and at heavy ion
accelerators (see Sect. 10.9) in order to quantify the biologi­
cal effectiveness of HZE particles, to understand the under­
lying mechanisms and to develop countermeasures. A variety
of experimental models are used for these experiments (see
Sects. 10.5–10.7, and 10.8.2). The uncertainties in risk
assessment for cancer and non-cancer effects in the central
nervous system and other organ systems for astronauts are
still unacceptably high therefore further investigations into
the biological effects of HZE particles are necessary. The
experimental approaches shown in Box 10.3 below take the
low dose rate but strong biological effects in case of a parti­
cle hit into account."
Describe the observed effects of high linear energy transfer (LET) radiation on mammalian cells and explain the ‘overkill effect’ as it relates to cell death mechanisms.,"High linear energy transfer (LET) radiation, typically involving heavy ions, induces a complex pattern of cellular damage. At LETs around ~200 keV/μm, the primary mechanism of cell killing is often rapid and complete due to multiple direct hits per cell. This results in mitotic catastrophe (abnormal cell division), apoptosis (programmed cell death), necrosis (uncontrolled cell lysis), and autophagy – processes that collectively overwhelm cellular repair mechanisms.  Above this LET threshold, a phenomenon known as the ‘overkill effect’ emerges. Because each individual particle hit is sufficient to kill the cell, increasing the dose beyond ~200 keV/μm does not proportionally increase cell death. The cell simply experiences multiple lethal hits without any opportunity for repair or mitigation. Consequently, the RBE (Relative Biological Effectiveness) decreases as the LET increases above this level, indicating an inefficient use of radiation energy in causing further damage. Reference: [MolecularRadiationBiology, Section 10.5.1 – Cellular Survival, Cell Death, and Proliferation]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.1	 Cellular Survival, Cell Death, and Proliferation | Content: and Proliferation
2
149
2
­
150
10.13
Clonogenic cell survival data for more than 1100 experi­
ments comparing the effects of ion irradiation to photon irra­
diation are available in a database established by the GSI
biophysics group [151]. The database is called Particle
Irradiation Data Ensemble (PIDE, www.gsi.de/bio-pide).
The maximal RBE for cell killing (10% survival level) was
observed in the LET range of 100–200 keV/μm with values
of 2–7 [151]. This large variation in RBE is explained by the
influence of particle species and energy in addition to LET,
of cell type and other experimental factors. At LETs above
~200 keV/μm, more energy is deposited in a cell traversed by
a particle than is required to kill the cell and more hits per
cell cannot produce more cell death as any hit will kill the
cell, resulting in a decrease of RBE that is called “overkill
effect.”
The clonogenic survival data integrate cell death by vari­
ous modes such as mitotic catastrophe, apoptosis, necrosis,
Box 10.3 Experimental Approaches for HZE Particle
Effects
Natural GCR exposure
•	Correlation of biological effects with single particle
hits by combination of biological model and detec­
tor foil, e.g., Biostack; can be combined with 1xg
reference centrifuge to determine contribution
microgravity effects
•	Correlation of light flashes with HZE particles that
traverse astronauts’ eyes
•	Dose accumulation over weeks or months by stor­
ing dormant or freeze-dried or deep-frozen cells or
small organisms in space, subsequent reactivation
and measurement of radiation damage or response
•	Determination of spaceflight effects by exposure of,
e.g., fruit flies, rodents, or other organisms on satel­
lites or high-altitude balloons
Exposure to selected HZE particles
•	Exposure of a variety of biological systems at heavy
ion accelerators or microbeam facilities to selected
heavy ions (singe particle at defined energy or mix­
ture of particles of defined energies) and analysis of
the biological responseFig. 10.13
Fig. 10.13 Survival of mammalian cells after exposure to low linear
energy transfer (LET) and high-LET radiation. Low-LET radiation
includes photons, electrons, positrons, protons, and more. High-LET
radiation encompasses heavy ions, and, depending on energy, also He
ions and neutrons
C. E. Hellweg et al.
525
autophagy, and other mechanisms (see Chap. 2) and perma­
nent cell cycle arrest, possibly accompanied by cellular
senescence. As for low-LET radiation, it depends on the cell
or tissue type whether a cell population is prone to ionizing
radiation-induced apoptosis [152]. Apoptosis might occur at
higher rates after high-LET radiation exposure compared to
low-LET irradiation with a maximum at a LET of ~100 keV/
μm [153].
The consequences of heavy ion-induced cell death for the
organism can be that transformation of a heavily damaged
cell is prevented thereby protecting from cancer. This effect
also limits the number of cells with mutations (see Sect.
10.5.4) or chromosomal aberrations at a LET >200 keV/μm
(see Sect. 10.5.2) and cellular transformation (see Sect.
10.5.5). On the other hand, deleterious effects might occur
such as depletion of stem cell pools or loss of terminally dif­
ferentiated cells with no or low regeneration potential that
might affect the functionality of a tissue or organ.
For some microorganisms, growth and viability were
measured during space missions. A 14-days exposure of
Escherichia coli on the Space Shuttle or 140-d exposure on
Mir did not result in any differences in viability and muta­
tions frequencies in comparison to ground controls [154,
155]—the same was the case in Saccharomyces cerevisiae
[156]. Using repair-deficient E. coli mutants, DNA poly­
merase, and 3′→5′ exonuclease were identified as the most
important enzymes for GCR-induced DNA damage in E. coli
[157]. Also, the slime mold Dictyostelium discoideum did
not grow differently and did not show differences in the
mutation frequency in the spores during a 7-days Shuttle
flight [158, 159], but the number of spores per fruiting body
was reduced [160]."
"Describe the various types of chromosomal aberrations that can arise following exposure to ionizing radiation, detailing how they are formed and their potential consequences for cell survival.","Ionizing radiation-induced chromosomal aberrations represent significant alterations in DNA structure detectable through staining protocols. These aberrations stem primarily from misrepair or missegregation of DNA double strand breaks (DSBs) resulting from the radiation. Symmetrical resolution of DSBs can lead to chromosomal interchanges, producing translocations which are generally nonlethal. Asymmetrical resolution generates a range of complex aberrations including dicentrics (chromosomes with two centromeres), acentric fragments (chromosome segments lacking attachment to sister chromatids), and quadriradials (U-type or X-type rearrangements). Dicentrics and acentric fragments, often found within micronuclei, frequently lead to cell death due to their instability. Furthermore, DNA loss during repair processes can result in deletions. The complexity of these aberrations is influenced by factors such as linear energy transfer (LET), track structure, fractionation, and cell nuclear geometry. Specifically, high-energy particles like HZE ions produce a greater number of breakpoints per track and more complex exchanges compared to lower-LET radiation due to their longer range and the resulting spatial clustering of breaks. These complex aberrations are often transient, disappearing between the first and second cell division after exposure, but some can be transmitted through subsequent generations. Detection methods such as GIEMSA staining, mFISH, and mBAND are utilized for identifying specific types of translocations (intrachromosomal and interchromosomal), respectively.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.2	 Chromosomal Aberrations | Content: Chromosomal aberrations are alterations in DNA structure
that become microscopically visible after following a chro­
mosome staining protocol [161] (see Chap. 2). They can
result from mis-rejoining of DNA ends from ionizing radia­
tion-induced DNA double strand breaks (DSB), from lack of
repair leading to terminal deletions and incomplete exchanges
or from chromosome mis-segregation [162, 163]. They are
exquisitely and quantitatively sensitive to ionizing radiation.
Symmetrical resolution of the DNA DSB can lead to chro­
mosomal interchanges resulting in translocations which are
usually nonlethal. Asymmetrical resolution produces among
other dicentrics (chromosomes with two centromeres) and
acentric fragments, mostly contained within micronuclei;
also, during the repair process, DNA sections can be lost,
producing a deletion [164]. Ionizing radiation can also
induce quadriradials (U-type by asymmetrical resolution,
X-type by symmetrical resolution). Complex and asymmet­
ric aberrations such as dicentrics usually lead to cell death
(lethal aberrations) [163].
They are determined during metaphase or by chemically
induced Premature Chromosome Condensation (PCC, see
Chap. 2) during interphase [165], usually in lymphocytes or
fibroblasts, providing data on a cell-by-cell basis. Their
dose–response relationship follows a curvature. While dicen­
trics and acentric fragments can be detected with a GIEMSA
staining, mFISH is required for interchromosomal transloca­
tions and mBAND for intrachromosomal translocations (see
Sect. 10.3.4). Inversions can be detected by Directional
Genomic Hybridization (dGH) [166].
2
For carcinogenesis, the surviving cells with chromosomal
aberrations are relevant. The fraction of these cells depends
on LET, track structure, and fractionation (Box 10.4).
­
163167168
117
­
169
­
2 A “clastogenic” agent directly causes DNA strand breaks or disturbs
normal DNA-related processes resulting in insertion, deletion, or rear­
rangement of chromosome sections.
Box 10.4 Factors Influencing Induction of Chromosomal
Aberrations by Ionizing Radiation
Dose rate
Fractionation
Linear energy transfer (LET)
Track structure
Cell nuclear geometry (e.g., spherical or flat)
10 Space Radiobiology
526
counterparts because of the longer range of the delta rays
where breaks can be close in space and time at high doses
and dose rates as they are produced by multiple tracks (inter­
track action). The breakpoints induced by delta rays add up
to those produced in the primary particle track. Hence, the
number of exchange breakpoints and their spatial arrange­
ment are important determinants for the formation of com­
plex exchanges. For example, the number of breakpoints per
cell was higher for 56Fe ions (1.1 GeV/n) and α-particles (0.9
MeV/n) in comparison to 137Cs γ-rays. In spherical cell
nuclei, one particle traversal is sufficient to produce two
breakpoints, e.g., in a lymphocyte [170, 171]. In summary,
HZE particles produce more breakpoints per track and more
highly complex exchanges compared to low-LET radiation
[118] (Fig. 10.14). These complex aberrations partly disap­
pear between the first and second cell division after radiation
exposure, but some are transmissible and might be stable
through several cell generations."
"Describe the primary mechanisms involved in repairing double-strand breaks (DSBs) in eukaryotic cells following exposure to high linear energy transfer (LET) radiation, including the roles of nonhomologous end joining (NHEJ) and homologous recombination (HR), as illustrated by findings from experiments involving HeLa cells exposed to space radiation.","Following exposure to ionizing radiation, particularly high-LET radiation like that from HZE particles, double-strand breaks (DSBs) represent the most severe DNA lesion. Repair of these complex lesions is a multi-step process involving coordinated pathways. Initially, the repair kinetics follow a biphasic pattern: a rapid initial response followed by a slower decline in activity over time. The early phase primarily relies on nonhomologous end joining (NHEJ), a pathway frequently utilized for DSB repair due to its relative speed and ability to tolerate errors. NHEJ involves the direct ligation of broken DNA ends without requiring homologous template sequences. However, this process is prone to introducing mutations due to the lack of fidelity. As time progresses, homologous recombination (HR) becomes increasingly important. HR utilizes a sister chromatid as a template for accurate repair, significantly reducing mutation rates. The detection of γH2AX, a marker of DSB formation, and 53BP1 accumulation around these breaks are frequently observed during both NHEJ and HR processes.  Experiments with HeLa cells exposed to space radiation, such as those conducted on the Shuttle and Mir missions, demonstrated the presence of DNA tracks indicative of DSBs. Subsequent immunofluorescence staining revealed γH2AX and 53BP1 foci at the sites of these breaks, supporting the involvement of both NHEJ and HR in their repair. Notably, studies have shown that repair kinetics are slower with higher LET radiation, leading to a persistence of unrepaired DNA DSBs, particularly after exposure to iron ions. Furthermore, evidence suggests that high-LET radiation can shift the balance towards error-prone alternative nonhomologous end joining pathways, resulting in reduced fidelity of repair over extended periods. The Biostack experiments highlighted additive or synergistic damaging effects of cosmic radiation and microgravity on DNA repair capacity when eggs were exposed under microgravity conditions compared to 1g controls.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.3	 DNA Damage and Repair Kinetics | Content: As other radiation qualities, protons, α-particles, and HZE
particles can induce various types of DNA damage by direct
ionization or indirectly through radiolysis of intracellular
water (see Chap. 2). Among base damage, loss of bases,
DNA-DNA and DNA-protein crosslinks, single strand
breaks (SSBs), and double strand breaks (DSBs), DNA
DSBs are the most severe DNA lesion. Unrepaired DNA
DSBs are at the center of biological effects such as cell kill­
ing and chromosomal aberrations and are trailblazers of the
majority of early and late effects induced by ionizing radia­
tion exposure [163, 172, 173].
­
­
­
10.15
164174175
Although the contribution of direct action to the biologi­
cal effectiveness of high-LET radiation is larger than indirect
action [176], reactive oxygen species (ROS) generated by
radiolysis can also play a part in the overall radiation effects.
As the lifetime and diffusion range of ROS are small, only
radicals produced in DNA’s vicinity are relevant for DNA
damage induction and increase in its complexity. With
increasing LET, the contribution of direct effects rises, and
the indirect effects drop. Low-LET radiation and endoge­
nous ROS rarely induce complex DNA damage [163].
The detection of GCR-induced DNA damage succeeded
in HeLa cells during the Shuttle and Mir missions [177–179].
In human lymphoblastoid cells that were stored at –80 °C for Fig. 10.15
Fig. 10.15 Comparison of ionizations (grey dots) in a DNA molecule
that are induced by electrons as an example of low-LET radiation and
by a high-LET α-particle. The ionizations produced by the α-particle
are located densely along the track, with some secondary electrons (δ
rays) generated while traversing the cell. This spatial distribution goes
along with a higher probability of simultaneously breaking both DNA
strands thereby producing a double strand break (DSB), and also fur­
ther damage to bases and single strand breaks (SSB) in close proximity
which is then called complex DNA damageFig. 10.14
Fig. 10.14 As a heavy ion travels through a mammalian cell nucleus,
a multiple of ionizations is produced, damaging a chromosome arranged
in its nuclear territory several times. Delta rays emanating from the pri­
mary track can induce further damage. Therefore, traversal of high-
LET radiation through a cell nucleus can produce many breakpoints in
chromosomes
C. E. Hellweg et al.
527
several months on ISS—in total 134 days at an average dose
rate of 0.7 mSv/day, one particle track per 100 cells was
detected by means of immunofluorescence staining of
γH2AX after return to the ground (see below) [180]. Such
tracks were also observed in human fibroblasts that were cul­
tivated for 14 days on the ISS [181].
10.5.3.1
Repair of HZE Particle-Induced Double
Strand Breaks and Complex Damage
Various DNA damage repair pathways ensure genome integ­
rity and stability in uni- and multicellular organisms. The
current understanding is that multiple repair pathways have
to be coordinated to repair complex DNA damage making it
very challenging, that short fragments might be lost during
repair and that multiple breakpoints in the DNA ribose-phos­
phate backbone can favor complex genomic rearrangements
[164, 182]. The damage might still persist at DNA replica­
tion because of repair delays that were observed after HZE
particle exposure. If repair of complex lesions is completed,
its fidelity might be lower when compared to simple DNA
damage [183–185]. After 56Fe ion (1 GeV/n) exposure, 14%
of the damage remained unrepaired compared to 5% after
γ-ray or α-particle exposure [171]. In vivo, persistent DNA
DSBs were found even 1 month after exposure to iron ions
[186]. Growth arrest, cell death, or senescence are possible
consequences of such unrepaired DNA damage [164], while
mutations and chromosomal aberrations are key steps in cel­
lular transformation and tumorigenesis.
DSBs are mainly repaired by nonhomologous end joining
(NHEJ) and homologous recombination (HR) in eukaryotes
(see Chap. 2). DNA DSB repair follows biphasic kinetics
with a faster velocity in the beginning and lower speed at
later timepoints. The phosphorylated form of the histone
variant H2AX (γH2AX) [187, 188] as a marker of DNA
DSB is often applied to microscopically visualize DSB
induced by high-LET radiation exposure, sometimes in com­
bination with antibodies binding to 53BP1 or other DSB
repair proteins or to oxidative base damage [189]. After
immunofluorescence staining, fluorescent foci indicate
γH2AX and 53BP1 accumulation around DNA DSB. Ground-
based experiments performed at heavy ion accelerators allow
quantification of DNA damage induction and DNA repair by
one ion with a specific energy or, since lately, several ion
species with specific energies hitting the cells from one
direction (see Sect. 10.10.4). They are usually performed
additionally with low-LET radiation for comparison.
For example, in human fibroblasts, repair of DSB induced
by carbon ions was slower than those induced by proton or
helium ion irradiation and the size of the repair foci increased
with increasing LET [190]. Larger repair foci that persist
longer are a common finding when exposure to heavy ions
and X-rays are compared [191, 192]. One day after exposure
to 1 GeV/n iron ions, 30–40% of the 53BP1 and γH2AX foci
still remained indicating the extent of residual damage [193].
The slow repair kinetics and incompleteness of repair of
DNA damage induced by high-LET radiation [190, 191,
194] are consistent findings of experiments with mammalian
cells at heavy ion accelerators. Also, there are some hints that
high-LET radiation inhibits c-NHEJ and shifts toward error-
prone alternative nonhomologous end joining repair and
microhomology-mediated end joining, resulting in a lowered
fidelity of repair for days or weeks [195]. Other studies have
shown that the repair of complex DNA requires DNA resec­
tion for processing at the DNA ends in G1 and G2 cells and
forces the pathway choice toward resection-dependent HR
[196, 197].
As mentioned above, to repair complex DNA damage,
other repair pathways might be involved such as base exci­
sion repair (BER) and/or nucleotide excision repair NER
[198]. Oxidative base damage such as 8-oxoguanine can be
restituted by BER starting with damage recognition and
removal by a DNA glycosylase and final steps by polymerase
and ligase proteins [172]. NER is responsible for the repair
of larger helix-distorting lesions.
In summary, DNA damage complexity increases with
increasing LET, resulting in less effective DNA repair, a
higher rate of residual lesions, genomic instability, and
enhanced cell killing [174].
10.5.3.2
Effects of Other Spaceflight
Environmental Factors Such
as Microgravity on DNA Repair
The results of the Biostack experiments raised the question
of whether microgravity or other spaceflight environmental
factors affect DNA repair processes, as explained hereinaf­
ter. The advanced Biostack experiments included an inflight
1g control on a centrifuge, allowing the separation of effects
of microgravity and of all other environmental factors. In this
experiment, eggs of the stick insect Carausius morosus were
exposed in space and the HZE particle hits were traced back
to the eggs by means of particle track detector foils. Back on
Earth, the insects were allowed to hatch. When the eggs were
hit by an HZE particle under microgravity, more abnormali­
ties were observed compared to hits during centrifugation at
1g, indicating additive or even synergistic damaging effects
of cosmic radiation and microgravity [144].
Therefore, DNA repair and radiation response under
microgravity were examined in further spaceflight experi­
ments using a 1g centrifuge inflight control and in ground-
based simulation using clinostats or random positioning
machines. For determining subtle differences in DNA repair
capacity or kinetics, a high level of DNA damage has to be
induced. For this purpose, the dose rates of GCR in LEO on
the Space Shuttle or on ISS are too low; therefore, DNA
damage has to be induced by irradiation on ground in a meta­
bolically inactive state, by irradiation in space using an arti­
10 Space Radiobiology"
"Following exposure to heavy ions like 1 GeV/n iron ions, what specific molecular markers indicate the persistence of DNA damage and how long do these markers typically remain detectable after irradiation?","After exposure to high-LET radiation, such as 1 GeV/n iron ions, significant residual DNA damage is indicated by the continued presence of molecular markers like 53BP1 and γH2AX foci. These foci represent regions of active DNA repair activity. Notably, one day following irradiation, approximately 30–40% of these 53BP1 and γH2AX foci still remained detectable, demonstrating the prolonged nature of DNA repair processes in response to complex damage induced by heavy ions. The persistence of these markers reflects the slow kinetics and incomplete repair observed with high-LET radiation, a characteristic often seen in mammalian cells exposed to heavy ion accelerators [193].","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.3	 DNA Damage and Repair Kinetics | Sub-sub-subsection: 10.5.3.1	 Repair of HZE Particle-Induced Double Strand Breaks and Complex Damage | Content: with increasing LET [190]. Larger repair foci that persist
longer are a common finding when exposure to heavy ions
and X-rays are compared [191, 192]. One day after exposure
to 1 GeV/n iron ions, 30–40% of the 53BP1 and γH2AX foci
still remained indicating the extent of residual damage [193].
The slow repair kinetics and incompleteness of repair of
DNA damage induced by high-LET radiation [190, 191,
194] are consistent findings of experiments with mammalian
cells at heavy ion accelerators. Also, there are some hints that
high-LET radiation inhibits c-NHEJ and shifts toward error-
prone alternative nonhomologous end joining repair and
microhomology-mediated end joining, resulting in a lowered
fidelity of repair for days or weeks [195]. Other studies have
shown that the repair of complex DNA requires DNA resec­
tion for processing at the DNA ends in G1 and G2 cells and
forces the pathway choice toward resection-dependent HR
[196, 197].
As mentioned above, to repair complex DNA damage,
other repair pathways might be involved such as base exci­
sion repair (BER) and/or nucleotide excision repair NER
[198]. Oxidative base damage such as 8-oxoguanine can be
restituted by BER starting with damage recognition and
removal by a DNA glycosylase and final steps by polymerase
and ligase proteins [172]. NER is responsible for the repair
of larger helix-distorting lesions.
In summary, DNA damage complexity increases with
increasing LET, resulting in less effective DNA repair, a
higher rate of residual lesions, genomic instability, and
enhanced cell killing [174].
10.5.3.2
Effects of Other Spaceflight
Environmental Factors Such
as Microgravity on DNA Repair
The results of the Biostack experiments raised the question
of whether microgravity or other spaceflight environmental
factors affect DNA repair processes, as explained hereinaf­
ter. The advanced Biostack experiments included an inflight
1g control on a centrifuge, allowing the separation of effects
of microgravity and of all other environmental factors. In this
experiment, eggs of the stick insect Carausius morosus were
exposed in space and the HZE particle hits were traced back
to the eggs by means of particle track detector foils. Back on
Earth, the insects were allowed to hatch. When the eggs were
hit by an HZE particle under microgravity, more abnormali­
ties were observed compared to hits during centrifugation at
1g, indicating additive or even synergistic damaging effects
of cosmic radiation and microgravity [144].
Therefore, DNA repair and radiation response under
microgravity were examined in further spaceflight experi­
ments using a 1g centrifuge inflight control and in ground-
based simulation using clinostats or random positioning
machines. For determining subtle differences in DNA repair
capacity or kinetics, a high level of DNA damage has to be
induced. For this purpose, the dose rates of GCR in LEO on
the Space Shuttle or on ISS are too low; therefore, DNA
damage has to be induced by irradiation on ground in a meta­
bolically inactive state, by irradiation in space using an arti­
10 Space Radiobiology"
"Following exposure to ionizing radiation, particularly at high linear energy transfer (LET), what are the observed patterns of DNA damage repair and how do these patterns differ when microgravity is present compared to conditions of normal gravity? Specifically, consider the persistence of DNA repair foci and the potential influence on repair pathways like base excision repair (BER) or nucleotide excision repair (NER).","Following exposure to ionizing radiation, especially at high LET, a common observation is the formation of persistent DNA repair foci, such as those identified by 53BP1 and γH2AX. These foci indicate ongoing damage and represent areas where repair processes are actively engaged. Notably, when heavy ion irradiation is compared to X-ray exposure, larger and longer-lasting repair foci tend to be observed with heavier ions due to their greater ability to induce complex DNA lesions. Furthermore, the kinetics of DNA repair following high-LET radiation are often slow and incomplete, leading to residual damage. This can shift cellular repair mechanisms towards error-prone pathways like nonhomologous end joining (NHEJ) or microhomology-mediated end joining, potentially reducing the fidelity of repair over days or weeks. The presence of microgravity significantly complicates this picture. Experiments have shown that in yeast, DNA double strand break (DSB) repair is delayed under microgravity conditions, suggesting an additive or synergistic effect between radiation and microgravity on these processes. While human fibroblasts and *Bacillus subtilis* appear unaffected by microgravity regarding the repair of DNA single-strand breaks (SSBs) and DSBs, observations in other organisms like *Saccharomyces cerevisiae*, demonstrate a distinct delay in DSB repair under microgravity. This suggests that microgravity can alter the cellular environment and influence the efficiency or choice of DNA repair pathways. Additionally, studies have revealed altered gene expression patterns related to the DNA damage response – for example, increased p53 levels in muscle tissue after spaceflight – further indicating a complex interplay between radiation, microgravity, and genomic stability. The potential role of factors like shear forces generated by microgravity simulators also warrants consideration when interpreting experimental results, particularly in microbial systems where motility could be affected.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.3	 DNA Damage and Repair Kinetics | Sub-sub-subsection: 10.5.3.2	 Effects of Other Spaceflight Environmental Factors Such as Microgravity on DNA Repair | Content: with increasing LET [190]. Larger repair foci that persist
longer are a common finding when exposure to heavy ions
and X-rays are compared [191, 192]. One day after exposure
to 1 GeV/n iron ions, 30–40% of the 53BP1 and γH2AX foci
still remained indicating the extent of residual damage [193].
The slow repair kinetics and incompleteness of repair of
DNA damage induced by high-LET radiation [190, 191,
194] are consistent findings of experiments with mammalian
cells at heavy ion accelerators. Also, there are some hints that
high-LET radiation inhibits c-NHEJ and shifts toward error-
prone alternative nonhomologous end joining repair and
microhomology-mediated end joining, resulting in a lowered
fidelity of repair for days or weeks [195]. Other studies have
shown that the repair of complex DNA requires DNA resec­
tion for processing at the DNA ends in G1 and G2 cells and
forces the pathway choice toward resection-dependent HR
[196, 197].
As mentioned above, to repair complex DNA damage,
other repair pathways might be involved such as base exci­
sion repair (BER) and/or nucleotide excision repair NER
[198]. Oxidative base damage such as 8-oxoguanine can be
restituted by BER starting with damage recognition and
removal by a DNA glycosylase and final steps by polymerase
and ligase proteins [172]. NER is responsible for the repair
of larger helix-distorting lesions.
In summary, DNA damage complexity increases with
increasing LET, resulting in less effective DNA repair, a
higher rate of residual lesions, genomic instability, and
enhanced cell killing [174].
10.5.3.2
Effects of Other Spaceflight
Environmental Factors Such
as Microgravity on DNA Repair
The results of the Biostack experiments raised the question
of whether microgravity or other spaceflight environmental
factors affect DNA repair processes, as explained hereinaf­
ter. The advanced Biostack experiments included an inflight
1g control on a centrifuge, allowing the separation of effects
of microgravity and of all other environmental factors. In this
experiment, eggs of the stick insect Carausius morosus were
exposed in space and the HZE particle hits were traced back
to the eggs by means of particle track detector foils. Back on
Earth, the insects were allowed to hatch. When the eggs were
hit by an HZE particle under microgravity, more abnormali­
ties were observed compared to hits during centrifugation at
1g, indicating additive or even synergistic damaging effects
of cosmic radiation and microgravity [144].
Therefore, DNA repair and radiation response under
microgravity were examined in further spaceflight experi­
ments using a 1g centrifuge inflight control and in ground-
based simulation using clinostats or random positioning
machines. For determining subtle differences in DNA repair
capacity or kinetics, a high level of DNA damage has to be
induced. For this purpose, the dose rates of GCR in LEO on
the Space Shuttle or on ISS are too low; therefore, DNA
damage has to be induced by irradiation on ground in a meta­
bolically inactive state, by irradiation in space using an arti­
10 Space Radiobiology
528
ficial radiation source brought in LEO or by incubation with
chemicals. When radiation damage was already induced on
ground using a radiation source, cooled cells were brought to
space and activated there to repair their DNA under micro­
gravity [199, 200]. Alternatively, DNA DSB were induced
by bleomycin [201] or restriction enzymes [202] during
spaceflight. Often, no or only small interactions were found
[203, 204]. In yeast however DNA DSB repair was delayed
under microgravity, suggesting additive effects of radiation
and microgravity [205, 206]. In human fibroblasts and
Bacillus subtilis, microgravity did not influence the repair of
DNA SSB and DSB [200, 207]. Also, ligase activity [204]
and DNA replication [208] were not affected. The expression
of genes involved in the DNA damage response was altered
under microgravity [209–211]. Besides these gene expres­
sion changes, a growth-stimulating effect of microgravity
was observed in many ground-based and space experiments
that might contribute to the microgravity effects on the DNA
damage response [209]. In ground-based experiments, limi­
tations of various microgravity simulators have to be consid­
ered [212], especially the generation of shear forces [213] as
possible confounders. For microorganisms, such as bacteria,
it has also to be considered whether they are motile because
of, e.g., flagella or not, and the effect of microgravity can be
most likely attributed to changes in the medium surrounding
the microbes [214].
Animal experiments addressing the question of DNA
repair under spaceflight conditions are scarce. After a 14-day
spaceflight, the level of the tumor suppressor p53, which acts
as a transcription factor in the DNA damage response, was
increased in the muscle of mice compared to ground control
mice [179]. Experiments with the nematode Caenorhabditis
elegans during the Shenzhou-8 mission revealed changes in
the expression of four microRNAs and of 4.2% of the genes
involved in the DNA damage response after 16.5 days of
microgravity when compared to the inflight 1g control [215].
Hindlimb unloading is used in rodent models to simulate on
ground the head-ward fluid shift that occurs in microgravity.
After 21 days of hindlimb unloading and low-dose irradia­
tion of mice, some genes involved in DNA repair, chromatin
organization, and cell cycle were differentially expressed in
the spleen compared to control mice [216].
10.5.3.3"
"What specific bacterial model organism is being utilized within the LUX-in-Space experiment to study DNA repair kinetics under microgravity conditions, and why was this choice made?","The Lux-in-Space experiment utilizes *Escherichia coli* (E. coli) as a model organism for studying DNA repair kinetics in microgravity. This selection is based on the bacterium's well-characterized nucleotide excision repair (NER) pathway, which is identical to that found in all other living organisms including humans. Furthermore, *E. coli* are robust and easily manipulated, making them ideal for controlled experiments within a space environment. Reference: [MolecularRadiationBiology, Section 10.5.3.3 – Future Space Experiments]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.3	 DNA Damage and Repair Kinetics | Sub-sub-subsection: 10.5.3.3	 Future Space Experiments | Content: Space experiments are the only way to unambiguously iden­
tify the effects of real microgravity on biological systems,
here the enzymatic repair of radiation-induced DNA dam­
ages. The opportunities to perform experiments with actively
metabolizing organisms in space are rare and usually have a
long lead time from the acceptance of an experiment pro­
posal to the execution of the experiment in space.
The Biolab facility in the Columbus module of the ISS
provides many possibilities for biological experiments on
microorganisms, cells, tissue cultures, small plants, and
small invertebrates in LEO (https://www.esa.int/Science_
Exploration/Human_and_Robotic_Exploration/Columbus/
Biolab). However, experiments on the ISS are subjected to
limitations such as up- and download mass, up- and down­
load temperature conditions, availability of a suitable facility
in space, data downlink, number of sample replicates, appro­
priate control experiments in space and on ground. The
Biolab facility will be used for LUX-in-Space (ESA AO
LSRA-2014-026, Team Coordinator: P. Rettberg), the first
space experiment where the whole series of events from
DNA damage induction in metabolically active cells to the
different steps of enzymatic repair reactions will take place
in real microgravity and the repair kinetics will be monitored
by optical measurements in situ. The effects of microgravity
will be clearly separated from other spaceflight factors by
comparison with parallel samples on an onboard 1g centri­
fuge in the Biolab facility and in a parallel ground control
experiment with identical samples in flight-identical hard­
ware. Due to safety issues, ESA decided to apply UV radia­
tion for DNA damage induction. It causes defined types of
DNA damage, e.g., cyclobutane pyrimidine dimers, which
are among those also induced by ionizing radiation. Bacteria
serve as model organisms possessing the same type of nucle­
otide excision repair as all other living organisms including
humans. The capability of bacterial cells to counteract radia­
tion damage by activating genes involved in DNA repair will
be assessed using a bioluminescent reporter gene operon
under the control of the SOS regulon, known as the SOS
LUX assay. The DNA repair kinetics will be followed by
bioluminescence and optical density measurements. For the
space experiment, TripleLux Part C preparatory work was
already performed successfully to adapt the SOS LUX assay
to the space conditions provided by the Biolab facility on the
ISS. This experiment was canceled later by ESA due to a
lack of available resources at that time and it is a predecessor
of LUX-in-Space [217, 218]. The launch of LUX-in-Space is
scheduled for 2023/2024.
Biosentinel will be the first deep-space experiment inves­
tigating the repair of DNA damage induced by space radia­
tion (Principal Investigator: Sharmila Bhattacharya). It is a
further development of NASA’s biological CubeSats, small
satellites with different payloads that were already flown
successfully in LEO. Biosentinel will first follow a trajectory
of cis-lunar flyby and, for 6–12 months, enter a heliocentric
orbit. The organism under investigation is the budding yeast
Saccharomyces cerevisiae. These eukaryotic cells are robust,
desiccation resistant, were already flown in space before, and
have similarities to cells of higher organisms such as humans.
Cells from a radiation-resistant yeast wildtype strain and a
radiation-sensitive Δrad51D mutant will be uploaded in a
dry form. After different periods of time, during which the
cells will accumulate radiation-induced DNA damage, the
C. E. Hellweg et al.
529
cells will be activated by the addition of nutrient medium and
their growth and metabolic activity will be measured opti­
cally. In parallel, another Biosentinel payload will be flown
in the ISS, in addition to the corresponding ground reference
experiment. The launch is scheduled for 2022 as a secondary
payload of NASA’s Artemis-1 mission [219, 220]."
"The text describes several studies examining the relationship between linear energy transfer (LET) and mutation induction. Specifically, what was observed regarding mutation rates in human diploid fibroblasts using the HPRT gene, and at what LET range did this maximum mutation rate occur?","Research utilizing the hypoxanthine guanine phosphoribosyl transferase (HPRT) gene in human diploid fibroblasts revealed a significant correlation between LET and mutation induction. A maximum of approximately 7 times more mutations were observed compared to low-LET radiation when exposed to helium ions or heavier ions with a linear energy transfer (LET) of 100–300 keV/μm. The number of mutations per single track through the cell nucleus increased with LET, reaching saturation at around 100 keV/μm. Reference: [MolecularRadiationBiology, Section 10.5.4 Mutagenesis]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.4	 Mutagenesis | Content: Mutations as a deleterious outcome of erroneous repair of
space radiation-induced DNA damage are of special interest
in radiation risk assessment as they can initiate the multi-step
carcinogenic process [163, 182] and they can be responsible
for genetic effects in the offspring if they occur in the germ­
line. Mutations can be detected in cells that survived irradia­
tion and are, as chromosomal aberrations, late endpoints of
radiation-induced DNA damage. For improving space radia­
tion risk assessment, the dependence of mutation induction
by radiation of different linear energy transfer (LET) was
examined in different biological systems: Mutation induc­
tion by heavy ions was determined in many organisms
including bacteria (E. coli, B. subtilis), yeast (S. cerevisiae),
Neurospora, Drosophila, C. elegans, M. musculus, plants,
and mammalian cell systems including human fibroblasts
and lymphoid cells. These were mostly ground-based experi­
ments at heavy ion accelerators.
The hypoxanthine guanine phosphoribosyl transferase
(HPRT, EC 2.4.2.8) gene (mutations on the single copy
X-chromosome in male-derived cells) in human diploid
fibroblasts was used in early studies of LET dependency of
mutation induction. A maximum of around 7 times more
mutations compared to low-LET radiation was observed for
helium ions or heavier ions with a LET of 100–300 keV/μm
[221]. The number of mutations per single track through a
mammalian cell nucleus increases with LET, reaching satu­
ration at around 100 keV/μm [222]. The induction of muta­
tions in the X-linked HPRT locus in Chinese hamster cells
by accelerated heavy ions reached a local maximum in the
LET range of 80–100 keV/μm [223].
Studies on mutation induction in autosomes became pos­
sible by means of AL human-hamster hybrid cells having one
copy of human chromosome 11. In these hybrid cells, neu­
trons of various energies were more efficient in inducing
mutations in the a1 locus on chromosome 11 compared to
gamma rays; the RBE reached up to 30 at the 0.1% survival
level [224]. The autosomal thymidine kinase gene (TK1)
locus in human cells allowed investigation of the loss of het­
erozygosity (LOH) which can occur via deletion or allelic
recombination and it revealed a higher peak of mutations at
a lower LET (~50–100 keV/μm) compared to the HPRT
mutations (up to 15× compared to ~5×). As for other biologi­
cal endpoints, LET is not the only determinant of the biologi­
cal efficiency of an HZE particle. The track structure means
the energy deposition pattern varies for different ion species
of the same LET. Such an effect of ion species was observed
for mutation induction at the HPRT locus in human fibro­
blast-like cells—the RBE for mutation induction determined
in this system was between 3.6 and 7 for carbon and neon ion
beams in the LET range of 60–120 keV/μm compared to
137Cs gamma rays [225].
Besides mutations observed in the direct hit cells,
bystander mutagenesis can contribute to the overall mutation
rate after particle exposure as it was observed, for example,
after alpha particle exposure [226].
An experiment on the ISS designed to detect mutations in
human cells that were induced by natural galactic rays made
use of the frozen storage as described in Sect. 10.5.3. Frozen
human lymphoblastoid TK6 cells were stored for 134 days in
the Kibo module of the ISS and accumulated a dose of 72
mSv. After analysis on ground, a tendency for higher muta­
tion frequency at the TK locus was observed in the flight
samples compared to ground control [227]. Earlier experi­
ments on Mir for 40 days with a model system based on
Saccharomyces cerevisiae and Escherichia coli also revealed
two to threefold higher mutation frequencies in some flight
samples compared to ground samples, with a predominance
of large deletions that might be caused by high-LET radia­
tion [228]."
"Describe the concept of transformation as it relates to radiation-induced mutagenesis, specifically focusing on how different ion species and LET values impact cellular transformation rates in mammalian cells. What experimental methods are used to assess this phenomenon?","Transformation, within the context of space radiobiology, refers to a significant change in cell behavior following exposure to ionizing radiation, primarily characterized by the acquisition of anchorage-independent growth capabilities. This is often utilized as a surrogate marker for assessing the carcinogenic potential of radiation quality – essentially, cells that undergo transformation are more likely to exhibit cancerous characteristics. The efficiency of transformation is heavily influenced by several factors, most notably the ion species and its corresponding linear energy transfer (LET). Higher LET ions, such as heavy ions like carbon or neon, demonstrate a greater capacity to induce transformation in mammalian cells compared to lower-LET radiation sources like 137Cs gamma rays. This difference stems from variations in track structure – the way an ion deposits its energy during traversal through tissue.  Different ion species create distinct energy deposition patterns, leading to varying mutation rates at specific genomic loci. For example, experiments have shown that carbon and neon ions (LETs of 60-120 keV/μm) resulted in RBE values between 3.6 and 7 for HPRT locus mutation induction, compared to the RBE of 137Cs gamma rays.  The transformation process itself is often assessed *in vitro* using the soft agar test. This assay relies on the observation that transformed cells – those with disrupted growth control – are able to grow independently in a semi-solid soft agar medium, whereas non-transformed cells remain attached to the agar surface. Earlier research demonstrated that HZE particles, particularly at LETs around 200 keV/μm, could increase transformation efficiency by a factor of up to 10 in mouse embryonic cells (C3H10T1/2), while other studies with 4He ions (LET ~36 keV/μm) and silicon ions (LET ~44 keV/μm) also showed significantly enhanced transformation rates compared to gamma rays. These findings highlight the crucial role of LET in determining radiation-induced cellular changes and their potential carcinogenic implications.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.5	 Transformation | Content: cal endpoints, LET is not the only determinant of the biologi­
cal efficiency of an HZE particle. The track structure means
the energy deposition pattern varies for different ion species
of the same LET. Such an effect of ion species was observed
for mutation induction at the HPRT locus in human fibro­
blast-like cells—the RBE for mutation induction determined
in this system was between 3.6 and 7 for carbon and neon ion
beams in the LET range of 60–120 keV/μm compared to
137Cs gamma rays [225].
Besides mutations observed in the direct hit cells,
bystander mutagenesis can contribute to the overall mutation
rate after particle exposure as it was observed, for example,
after alpha particle exposure [226].
An experiment on the ISS designed to detect mutations in
human cells that were induced by natural galactic rays made
use of the frozen storage as described in Sect. 10.5.3. Frozen
human lymphoblastoid TK6 cells were stored for 134 days in
the Kibo module of the ISS and accumulated a dose of 72
mSv. After analysis on ground, a tendency for higher muta­
tion frequency at the TK locus was observed in the flight
samples compared to ground control [227]. Earlier experi­
ments on Mir for 40 days with a model system based on
Saccharomyces cerevisiae and Escherichia coli also revealed
two to threefold higher mutation frequencies in some flight
samples compared to ground samples, with a predominance
of large deletions that might be caused by high-LET radia­
tion [228].
10.5.5	Transformation
If mutations occur in tumor suppressor genes and inactivat­
ing them, or proto-oncogenes and activating them, cells can
be transformed and lose growth control including anchorage-
dependent growth. It can be seen as a surrogate marker for
the carcinogenic potential of a radiation quality in question.
Transformation can only occur in cells that survived the radi­
ation exposure. In vitro, transformation of mammalian cells
is determined by their ability to grow anchorage indepen­
dently in soft agar. The soft agar test was applied to different
cell types after exposure to HZE particles at heavy ion accel­
erators in order to determine their potential for transforma­
tion, usually in comparison to low-LET radiation.
Already in the 1980s, it was shown that HZE particles are
more effective in transforming mammalian cells than low-
LET radiation: In mouse embryonic cells (C3H10T1/2), the
effectivity of transformation increased up to 10 with a LET
~200 keV/μm [229] while Hei et al. observed a plateau at
LETs of 80–120 keV/μm [230]. In Golden hamster embryo
cells, 14N ions (LET 530 keV/μm) and 4He ions (36 and 77
keV/μm) were ~3× more effective in inducing cellular trans­
formation than gamma or X-rays [231]. Later, a maximal
RBE for neoplastic transformation was found at a LET of
~100 keV/μm, reaching a maximum of seven [232]. In
10 Space Radiobiology
530
human bronchial epithelial cells, iron and silicon ions (LET
151 and 44 keV/μm, respectively) were more efficient in
inducing transformation than gamma rays from a 137Cs
source especially when these cells were oncogenically pro­
gressed by stable transfection of mutant oncogenes [233]."
"How do different types of radiation, particularly those with varying linear energy transfer (LET), influence cell cycle progression and specifically, the duration of cell cycle arrest in response to DNA damage?","Cell cycle checkpoints, primarily occurring at G1/S, S/G2, and G2/M transitions, are crucial for mitigating the effects of DNA damage. However, the nature and persistence of these arrests are significantly impacted by radiation type. High-LET radiation, characterized by a high LET (e.g., from accelerated neon ions), induces more robust and prolonged cell cycle blocks compared to low-LET radiation like gamma rays. This is because high-LET radiation causes more complex and persistent DNA damage that doesn't readily resolve through typical repair mechanisms. Specifically, experiments have shown that increased LET leads to stronger and longer delays in the G2 phase of the cell cycle. In studies using Chinese hamster cells (V79), cell cycle delays were directly correlated with particle traversal and were predominantly observed within S and G2/M phases. Furthermore, high-LET radiation can induce permanent arrest in the G1 phase as well. The accumulation of cell cycle regulatory proteins like p21 (CDKN1A) is a key indicator of this response, with expression levels being particularly sensitive to LET; for instance, iron ion exposure resulted in significantly higher and longer-lasting p21 expression compared to gamma rays. These observations suggest that the severity and duration of cell cycle arrest are directly linked to the radiation's energy deposition characteristics – high LET leading to more profound and prolonged disruptions within the cell’s division process.

Reference: MolecularRadiationBiology, Section 10.5.6 – Cell Cycle Changes","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.6	 Cell Cycle Changes | Content: Cell cycle arrests play a central role in the DNA damage
response of dividing cells. Before the cell enters the next cell
cycle phase, e.g., from G1 to S phase or from S to G2/M
phase, they allow repair of damaged DNA (Chap. 2). They
can therefore protect from cell death, mutations or chromo­
somal aberrations. Concerning the special radiation qualities
present in space that are prone to induce complex DNA dam­
age which might persist longer, stronger, or longer cell cycle
arrests might be induced in comparison to low-LET radia­
tion. Early experiments observing mitotic delay by time-
lapse microscopic cinematography already gave hints that
accelerated neon ions produce a stronger delay compared to
Co-60 gamma rays [234]. High-LET radiation produces
stronger and more persistent blocks in the G2 phase of the
cell cycle than low-LET radiation [235]. In synchronous V79
Chinese hamster cells, the cell cycle delays per particle tra­
versal increased with increasing LET and were primarily due
to blocks in S and G2/M phase of the cell cycle [236].
Permanent arrest in the G1 phase can also be induced by
high-LET radiation [237]. The relative biological efficiency
of heavy charged particles with a LET in the range of 100–
330 keV/μm for inducing cell division delays was 3.3–4.4
[236] and the percentage of mitotic cells as indication of an
arrest at the early G2/M checkpoint decreased with increas­
ing LET [238]. The cell cycle regulating protein p21
(CDKN1A) accumulates in nuclear foci rapidly after heavy
ion exposure of fibroblasts [239]. Besides this, expression
levels of cell cycle regulatory proteins might be affected to a
higher extent by high-LET radiation compared to low-LET
radiation [237], for example, after iron ion exposure p21
expression was much higher compared to gamma rays and
persisted 10 days after irradiation [193]."
"Following exposure to ionizing radiation, how do changes in gene expression typically occur within cells, and what mechanisms contribute to these alterations beyond simple promoter activation?","After exposure to ionizing radiation, gene expression changes often initiate through signal transduction pathways that activate transcription factors. These transcription factors bind to specific DNA motifs – frequently short palindromic sequences – located within the promoters or enhancers of target genes. However, persistent gene expression modifications can also arise from epigenetic mechanisms. Epigenetic alterations involve changes in chromatin structure and/or DNA methylation patterns without altering the underlying DNA sequence itself. This can lead to long-term changes in gene accessibility, effectively turning genes ‘on’ or ‘off’. Furthermore, studies have shown that heavy ion radiation, particularly iron ions, can induce a sustained stress response lasting several weeks alongside an initial transient reaction. This prolonged response involves activation of pathways like p38MAPK and TP53, leading to the expression of target genes such as CDKN1A. In tissues, long-term changes are observed in gene expression related to inflammatory and antioxidant pathways, mediated by transcription factors including STAT3, GATA4, NF-κB, and NFATc4. Notably, heavy ions can strongly activate NF-κB, with the degree of activation dependent on the linear energy transfer (LET) of the radiation. Consequently, increased expression of various chemokines and cytokines is observed. The complexity arises from factors such as model system differences, irradiation kinetics, and environmental conditions like microgravity simulation.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.7	 Gene Expression | Content: Similar to studies with low-LET radiation, gene expression
studies after high-LET radiation developed from a focus on
single genes (mRNA and protein level by Northern Blot,
RT-PCR, real-time RT-qPCR, Western Blot) to arrays of
multiple genes, microarrays [240] and detection of the lev­
els of all mRNAs present in cell populations or even single
cells by RNA sequencing. After exposure to ionizing radia­
tion, signal transduction pathways can result in the activa­
tion of transcription factors. These transcription factors
bind to binding sites in their target genes’ promoters which
are specific for them (usually short palindromic DNA
motifs) [241]. Also, besides promoter or enhancer activa­
tion via transcription factor binding, epigenetic mecha­
nisms can be responsible for (persistent) gene expression
changes and are therefore the focus of mechanistic research
(see Sect. 10.5.9).
In addition to spaceflight experiments, a huge amount of
gene expression data from ground-based exposure to neu­
trons, protons, and different heavy ions for different experi­
mental model systems exists. NASA GeneLab (https://
genelab.nasa.gov/) offers a repository for space-related
omics data, among others transcriptomics and proteomics
from experiments with model organisms, cells, cell lines,
and tissues. Currently, a comprehensive picture of gene
expression changes is difficult to paint due to the multiple
influencing factors that range from the model system (e.g.,
gut epithelial cells and human bronchial epithelial cells, tis­
sue, animal model) to the methods, cell cycle phase, radia­
tion qualities, doses, kinetics of exposure, timepoint after
exposure, and additional spaceflight environmental factors
(such as simulation of microgravity effects by hindlimb
unloading). The interpretation of the data is complicated by
the fact that in the majority of the heavy ion accelerator
experiments, the dose is acutely applied within minutes,
while exposure during long-term space missions is pro­
tracted over several months.
The emerging view is that heavy ions, especially iron ions
are capable to induce a stress response persisting for several
weeks in addition to an early transient response. This early
response can encompass p38MAPK and TP53 activation and
expression of its target genes, whereby the cell cycle regula­
tor gene CDKN1A can also be expressed TP53-independently.
In tissues, long-term changes in the expression of genes
involved in inflammatory and free-radical scavenging path­
ways occur after iron ion exposure and these changes involve
transcription factors such as signal transducer and activator
of transcription 3 (STAT3), GATA binding protein 4
(GATA4), Nuclear Factor κB (NF-κB) and nuclear factor of
activated T cells 4 (NFATc4) [242]. In human cells, NF-κB
was strongly activated by heavy ions, its activation depended
on LET [243] and the expression of several chemo- and cyto­
kines was increased [244]."
"The text describes several mechanisms by which heavy ions, such as iron ions, can induce gene expression changes after exposure. Specifically, it details the persistent stress response involving p38MAPK and TP53 activation, alongside changes in inflammatory and free-radical scavenging pathways mediated by transcription factors like STAT3 and NF-κB. Furthermore, the text highlights the role of telomere shortening and fusion in inducing chromosome instability following heavy ion exposure. Can you summarize these key mechanisms?","Following exposure to heavy ions, particularly iron ions, a multifaceted response emerges that extends beyond immediate transient effects. Initially, activation of p38MAPK and TP53, alongside the expression of their target genes including CDKN1A, triggers a stress response. This is coupled with long-term alterations in gene expression patterns involving transcription factors such as STAT3, GATA4, NF-κB, and NFATc4, driving changes in inflammatory and free-radical scavenging pathways. Critically, heavy ions induce telomere shortening and fusion, leading to chromosome instability – a process exacerbated by the high levels of HZE particles encountered during spaceflight. This telomeric instability ultimately triggers senescence or apoptosis. The twin study demonstrated an increase in telomere length in one astronaut during spaceflight followed by a return to baseline upon Earth’s gravity, alongside increased chromosomal aberrations. Reference: [MolecularRadiationBiology, Section 10.5.8 – Telomeres and Aging]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.8	 Telomeres and Aging | Content: are specific for them (usually short palindromic DNA
motifs) [241]. Also, besides promoter or enhancer activa­
tion via transcription factor binding, epigenetic mecha­
nisms can be responsible for (persistent) gene expression
changes and are therefore the focus of mechanistic research
(see Sect. 10.5.9).
In addition to spaceflight experiments, a huge amount of
gene expression data from ground-based exposure to neu­
trons, protons, and different heavy ions for different experi­
mental model systems exists. NASA GeneLab (https://
genelab.nasa.gov/) offers a repository for space-related
omics data, among others transcriptomics and proteomics
from experiments with model organisms, cells, cell lines,
and tissues. Currently, a comprehensive picture of gene
expression changes is difficult to paint due to the multiple
influencing factors that range from the model system (e.g.,
gut epithelial cells and human bronchial epithelial cells, tis­
sue, animal model) to the methods, cell cycle phase, radia­
tion qualities, doses, kinetics of exposure, timepoint after
exposure, and additional spaceflight environmental factors
(such as simulation of microgravity effects by hindlimb
unloading). The interpretation of the data is complicated by
the fact that in the majority of the heavy ion accelerator
experiments, the dose is acutely applied within minutes,
while exposure during long-term space missions is pro­
tracted over several months.
The emerging view is that heavy ions, especially iron ions
are capable to induce a stress response persisting for several
weeks in addition to an early transient response. This early
response can encompass p38MAPK and TP53 activation and
expression of its target genes, whereby the cell cycle regula­
tor gene CDKN1A can also be expressed TP53-independently.
In tissues, long-term changes in the expression of genes
involved in inflammatory and free-radical scavenging path­
ways occur after iron ion exposure and these changes involve
transcription factors such as signal transducer and activator
of transcription 3 (STAT3), GATA binding protein 4
(GATA4), Nuclear Factor κB (NF-κB) and nuclear factor of
activated T cells 4 (NFATc4) [242]. In human cells, NF-κB
was strongly activated by heavy ions, its activation depended
on LET [243] and the expression of several chemo- and cyto­
kines was increased [244].
10.5.8	Telomeres and Aging
HZE particles are potent inducers of senescence, more
potent than gamma rays. Senescence-associated changes
in the tumor microenvironment may induce invasion and
stemness of tumor cells. Senolytics can be applied to elim­
inate senescent cells and thereby deplete senescent stromal
C. E. Hellweg et al.
531
cells with tumor supportive roles. Shortening of telomeric
sequences can lead to telomere fusions and contributes the
chromosome instability after heavy ion exposure [245].
Furthermore, accumulation of short telomeres eventually
triggers apoptosis or senescence. Unlike normal somatic
cells, germline, stem, and tumor cells avoid the latter
through a high expression of telomerase. Due to natural
telomere shortening during cell division, telomere length
is highly linked to aging [246]. Considering the environ­
mental radiation exposure during spaceflight, with higher
levels of HZE particles compared to on Earth, NASA
investigated the effect of spaceflight on telomere length in
the twin study. The twin study examined molecular- and
physiological differences of twin astronauts, one spending
a year onboard the ISS and the other on Earth [120].
Telomere lengths of peripheral blood mononuclear cells
(PBMCs), collected from peripheral blood samples taken
preflight from both twins were of similar length. However,
during spaceflight, the space twin’s telomere length
increased significantly, while the Earth twin’s telomers
remained stable during the study. Once returning to Earth,
the increased telomere length diminished within 48 h and
the number of short telomeres increased compared to pre­
flight [116]. While an unexpected finding, increased telo­
mere length has recently been associated with other
biological functions such as DNA damage response, cell
cycle kinetics, and mitochondrial stress [247]. Indeed,
chromosome aberrations (inversions and translocations)
were more frequent during spaceflight and inversion fre­
quencies of the space twin remained elevated postflight,
consistent with ionizing radiation exposure inflight.
Furthermore, DNA damage repair pathways were upregu­
lated in several circulating immune cells, suggesting
increased genomic instability due to ionizing radiation
during spaceflight [121]. Similar results (increased telo­
mere length and chromosomal aberrations) were also seen
in astronauts during a 6-month spaceflight mission. While
telomerase activity likely is responsible for the increased
telomere length inflight, the actual contributing mecha­
nism is still unknown. However, astronauts returning from
1 year and 6 month missions showed elevated telomerase
activity upon return to Earth [116]."
"The text describes several ways space radiation can induce long-term biological changes. Specifically, what types of epigenetic modifications are linked to increased risk of cancer and degenerative diseases following exposure to high-LET radiation, and provide an example of how these modifications manifest in a cellular system?","Following exposure to high-LET radiation, significant alterations within the epigenome can contribute to carcinogenesis and degenerative diseases. The text highlights two primary mechanisms: changes in DNA methylation profiles and modifications to the histone code, specifically encompassing methylation and acetylation of histones. Notably, hypermethylation at CpG sites was observed early after Fe-56 ion exposure in immortalized human bronchial epithelial cells, a change that persisted over an extended period. Furthermore, long-term epigenetic reprogramming was documented in hematopoietic progenitor and stem cells following similar exposures. The presence of elevated DNA methylating enzymes within the hippocampus of Si-28 ion irradiated mice, which subsequently developed cognitive impairment, further supports this connection between radiation exposure and altered epigenetic states linked to disease development. These changes suggest that space radiation can induce lasting alterations in gene expression by directly modifying chromatin structure, potentially driving cellular dysfunction and increased susceptibility to diseases.
Reference: MolecularRadiationBiology > section: 10: Space Radiobiology > subsection: 10.5 Biomolecular Changes Induced by Space Radiation > subsubsection: 10.5.9 Epigenetics","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.5	 Biomolecular Changes Induced by Space Radiation | Sub-subsection: 10.5.9	 Epigenetics | Content: Persistent gene expression and functional changes induced
by space radiation exposure could be caused by changes in
the epigenome. Changes in the DNA methylation profile and
in the histone code encompassing methylation and acetyla­
tion of histones could therefore contribute to high-LET car­
cinogenesis and degenerative diseases and could represent
possible prophylactic or therapeutic targets.
For example, in immortalized human bronchial epithelial
cells, hypermethylation at CpG sites occurred early after
Fe-56 ion exposure and persisted a long time [248]. Long-
term epigenetic reprogramming after such exposure was also
observed in hematopoietic progenitor and stem cells [249].
High levels of DNA methylating enzymes were also
found in the hippocampus of Si-28 ion irradiated mice that
developed cognitive impairment [250].
In addition to heavy ion exposure experiments, combined
exposure to simulated microgravity and chronic low-dose
irradiation or spaceflight experiments using small animals or
cell cultures and astronaut data reveal alterations in the meth­
ylome and histone modification status after combined expo­
sure to spaceflight environmental factors such as microgravity
and space radiation. The lasting imprint of high-LET radia­
tion exposure on the epigenome might allow monitoring the
cumulative biological impact of space radiation exposure
[248].
10.6
Small Animal Experimental Models
and Biological Changes of Space
Radiation
10.6.1	Importance of the Use of Animals
in Research and Their Particular Use
in Space
The use of small animal models in research is debatable, but
still essential to provide general information on cellular and
molecular mechanisms, to develop new drugs and treat­
ments. They are mainly used in fundamental scientific
research, for the advancement and development of new diag­
nostic tests and treatment for diseases, for education of
researchers as well as in safety assessments of drugs and
chemicals.
Animals are a useful research subject for a variety of rea­
sons. Only in living organisms, it is possible to study com­
plex physiological processes. Furthermore, the environment
of the experiment can be perfectly controlled (e.g., diet,
light, housing, etc.). Also, they have a shorter life cycle so
studies can be conducted throughout a whole lifespan or
across generations. Animals are biologically very similar to
humans and often suffer from similar health problems. In
fact, mice share more than 85% of protein-encoding genes
with humans—Why Mouse Matters, from the National
Human Genome Research Institute (https://www.genome.
gov/10001345/importance-of-mouse-genome).
Animal experiments can cause harm to the animal thus
ethical review processes have been established around the
world [251]. With respect to this, the 3R´s principle by [252]
ensure the reduction of animal numbers, refining the test
methods to lower the harm to the animal to a minimum and
10 Space Radiobiology"
"The text describes several observed epigenetic changes following exposure to space radiation in small animals and cell cultures. Specifically, what types of epigenetic modifications were identified after Fe-56 ion exposure in immortalized human bronchial epithelial cells, and where were these modifications primarily located within the animal model?","Following exposure to Fe-56 ions, hypermethylation at CpG sites was prominently observed early on in immortalized human bronchial epithelial cells, a change that persisted over extended periods. Furthermore, high levels of DNA methylating enzymes were detected in the hippocampus of Si-28 ion irradiated mice which subsequently developed cognitive impairment. This suggests a long-term reprogramming effect driven by altered methylation patterns. The primary location for these modifications was within the hippocampus of the animal model exhibiting radiation-induced cognitive deficits. These findings highlight the potential role of epigenetic changes, particularly DNA methylation, as possible prophylactic or therapeutic targets related to space radiation exposure and its biological consequences.

Reference: MolecularRadiationBiology > section: 10: Space Radiobiology > subsection: 10.6","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Content: possible prophylactic or therapeutic targets.
For example, in immortalized human bronchial epithelial
cells, hypermethylation at CpG sites occurred early after
Fe-56 ion exposure and persisted a long time [248]. Long-
term epigenetic reprogramming after such exposure was also
observed in hematopoietic progenitor and stem cells [249].
High levels of DNA methylating enzymes were also
found in the hippocampus of Si-28 ion irradiated mice that
developed cognitive impairment [250].
In addition to heavy ion exposure experiments, combined
exposure to simulated microgravity and chronic low-dose
irradiation or spaceflight experiments using small animals or
cell cultures and astronaut data reveal alterations in the meth­
ylome and histone modification status after combined expo­
sure to spaceflight environmental factors such as microgravity
and space radiation. The lasting imprint of high-LET radia­
tion exposure on the epigenome might allow monitoring the
cumulative biological impact of space radiation exposure
[248].
10.6
Small Animal Experimental Models
and Biological Changes of Space
Radiation
10.6.1	Importance of the Use of Animals
in Research and Their Particular Use
in Space
The use of small animal models in research is debatable, but
still essential to provide general information on cellular and
molecular mechanisms, to develop new drugs and treat­
ments. They are mainly used in fundamental scientific
research, for the advancement and development of new diag­
nostic tests and treatment for diseases, for education of
researchers as well as in safety assessments of drugs and
chemicals.
Animals are a useful research subject for a variety of rea­
sons. Only in living organisms, it is possible to study com­
plex physiological processes. Furthermore, the environment
of the experiment can be perfectly controlled (e.g., diet,
light, housing, etc.). Also, they have a shorter life cycle so
studies can be conducted throughout a whole lifespan or
across generations. Animals are biologically very similar to
humans and often suffer from similar health problems. In
fact, mice share more than 85% of protein-encoding genes
with humans—Why Mouse Matters, from the National
Human Genome Research Institute (https://www.genome.
gov/10001345/importance-of-mouse-genome).
Animal experiments can cause harm to the animal thus
ethical review processes have been established around the
world [251]. With respect to this, the 3R´s principle by [252]
ensure the reduction of animal numbers, refining the test
methods to lower the harm to the animal to a minimum and
10 Space Radiobiology"
"The text describes several observed epigenetic changes following exposure to space radiation in various experimental models. Specifically, what types of epigenetic modifications – concerning DNA or histone structures – were consistently found in animal models exhibiting cognitive impairment after Si-28 ion irradiation, and where were these primarily located?","Following Si-28 ion irradiation leading to cognitive impairment in mice, researchers identified significant alterations within the epigenome. Notably, high levels of DNA methylating enzymes were detected predominantly in the hippocampus. Furthermore, hypermethylation at CpG sites occurred early after Fe-56 ion exposure and persisted for an extended period in both immortalized human bronchial epithelial cells and hematopoietic progenitor/stem cells. These findings suggest a long-term epigenetic reprogramming response to ionizing radiation, characterized by changes in DNA methylation patterns and potentially other histone modification status, contributing to the observed biological effects such as cognitive impairment. Reference: MolecularRadiationBiology, Section 10.6.1 – Small Animal Experimental Models and Biological Changes of Space Radiation.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.1	 Importance of the Use of Animals in Research and Their Particular Use in Space | Content: possible prophylactic or therapeutic targets.
For example, in immortalized human bronchial epithelial
cells, hypermethylation at CpG sites occurred early after
Fe-56 ion exposure and persisted a long time [248]. Long-
term epigenetic reprogramming after such exposure was also
observed in hematopoietic progenitor and stem cells [249].
High levels of DNA methylating enzymes were also
found in the hippocampus of Si-28 ion irradiated mice that
developed cognitive impairment [250].
In addition to heavy ion exposure experiments, combined
exposure to simulated microgravity and chronic low-dose
irradiation or spaceflight experiments using small animals or
cell cultures and astronaut data reveal alterations in the meth­
ylome and histone modification status after combined expo­
sure to spaceflight environmental factors such as microgravity
and space radiation. The lasting imprint of high-LET radia­
tion exposure on the epigenome might allow monitoring the
cumulative biological impact of space radiation exposure
[248].
10.6
Small Animal Experimental Models
and Biological Changes of Space
Radiation
10.6.1	Importance of the Use of Animals
in Research and Their Particular Use
in Space
The use of small animal models in research is debatable, but
still essential to provide general information on cellular and
molecular mechanisms, to develop new drugs and treat­
ments. They are mainly used in fundamental scientific
research, for the advancement and development of new diag­
nostic tests and treatment for diseases, for education of
researchers as well as in safety assessments of drugs and
chemicals.
Animals are a useful research subject for a variety of rea­
sons. Only in living organisms, it is possible to study com­
plex physiological processes. Furthermore, the environment
of the experiment can be perfectly controlled (e.g., diet,
light, housing, etc.). Also, they have a shorter life cycle so
studies can be conducted throughout a whole lifespan or
across generations. Animals are biologically very similar to
humans and often suffer from similar health problems. In
fact, mice share more than 85% of protein-encoding genes
with humans—Why Mouse Matters, from the National
Human Genome Research Institute (https://www.genome.
gov/10001345/importance-of-mouse-genome).
Animal experiments can cause harm to the animal thus
ethical review processes have been established around the
world [251]. With respect to this, the 3R´s principle by [252]
ensure the reduction of animal numbers, refining the test
methods to lower the harm to the animal to a minimum and
10 Space Radiobiology
532
replace animal experiments with alternative methods, when
possible (Box 10.5).
10.16
253
­"
"Describe the key components and functions of the skin, focusing on its protective roles and how it responds to radiation exposure as discussed in the text.","The skin is a vital organ acting as a primary barrier between the external environment and the body’s internal systems. It comprises several layers, with the epidermis being the outermost layer primarily composed of keratinocytes that undergo differentiation and migration towards the surface – a process crucial for maintaining epidermal thickness through regulated proliferation and shedding. Beneath the epidermis lies the dermis, a connective tissue layer rich in collagen type I and III, along with elastic fibers, providing tensile strength and elasticity to the skin. Fibroblasts are responsible for synthesizing these structural proteins and play a critical role in wound healing by migrating to wounds, recruiting other cells, and remodeling the extracellular matrix (ECM). The skin’s functions extend beyond protection; it regulates water loss, contributes to immune defense, maintains temperature, and shields against ultraviolet radiation. Specifically regarding radiation exposure, the skin receives the highest dose of ionizing radiation and accumulates the most stopping particles, particularly during solar particle events (SPEs) like those associated with space weather. This heightened sensitivity makes the skin a primary target for ARS effects when astronauts are exposed to significant SPEs without adequate shielding, potentially leading to tissue damage alongside systemic immune dysfunction.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.1	 Acute Radiation Syndrome | Content: In case of a large SPE and insufficient shielding, the acute
radiation syndrome (ARS, see Chap. 2) might be induced,
endangering astronauts’ health and mission success. To
understand the pathogenesis of ARS induced by protons
and develop therapeutic approaches for space missions,
experiments with different animal models including
rodents, minipigs, and non-human primates were per­
formed. Whole-body doses up to 2 Gy are expected when
astronauts are exposed to large SPE in free space with
insufficient shielding. In this dose range, effects on the
immune system (see Sect. 10.6.2.3) dominate the syn­
drome. As the skin dose can be 5–10 higher, the skin might
be damaged (see Sect. 10.6.2.2).
10.6.2.2
Skin Effects
Forming the barrier between the outside environment and
the inside of the body, the skin is a vital organ. Different
skin layers provide the skin with tensile strength and keep
a proper barrier function to prevent body water loss, regu­
late the immune defense and temperature, and protect
against ultraviolet damage. The outermost layer, the epider­
mis, is built mostly out of layers of keratinocytes that dif­
ferentiate and migrate toward the skin surface. A balance
between the proliferation of keratinocytes and shedding of
dead cells at the surface of the skin regulates the thickness
of the epidermal layer. Below the epidermis lays the dermal
skin layer which is mostly composed of connective tissue.
Skin’s tensile strength and elasticity are provided by
Collagen type I and III, and elastic fibers. Fibroblasts are
the major provider synthesizing these proteins. Furthermore,
they play a major part in skin wound healing by migrating
to the side of the wound, recruiting other cells, and remod­
eling the extracellular matrix (ECM) to restore the injured
skin [254].
The skin receives greatest dose and greatest number of
stopping particles, particularly during solar flares [255]. SPE
events during EVA could lead to higher skin dose than to
internal organs. Furthermore, simulations of SPEs has shown
Box 10.5 Russell and Burch’s The Principles of Humane
Experimental Technique was First Published in 1959
The aim of the principle is to improve the treatment of
laboratory animals and at the same time advance the
quality of scientific studies.
Replacement: Includes methods that avoid or replace
the use of animals such as computer/mathematical
models (in silico), cell culture models (in vitro), or
relative replacement (e.g., invertebrates, such as
fruit flies and nematode worms).
Reduction: With improved experimental design, mod­
ern imaging, or sharing data and resources, the total
number of animals needed can be minimized.
Refinement: Modification in the experiment, which
minimize pain, suffering, and distress and allow
general improvement of animal welfare (e.g.,
improvement in the research animal housing condi­
tions, analgesia, and anesthesia for pain relief).Fig. 10.16
Fig. 10.16 On 3 November 1957 Laika was the first living mammal
that was sent to space onboard the satellite Sputnik 2
C. E. Hellweg et al."
"Describe the observed skin effects following exposure to simulated Solar Particle Events (SPE) radiation in minipigs, including details about erythema, inflammation, pigmentation changes, and potential wound development. What specific gene expression changes were noted that contributed to these observations?","Following exposure to simulated SPE radiation, minipigs exhibited a multi-phased skin response characterized by early erythema appearing within hours of irradiation. Subsequently, inflammatory damage manifested as erythema, epidermal cell loss, and moist desquamation. Over weeks, hyperpigmentation became prominent, particularly in areas receiving the highest doses, accompanied by edema/hyperproliferation and epilation. Late effects, developing months after exposure, included dermal atrophy, necrosis, and vascular deterioration. Notably, hyperpigmentation was observed 7 days post-irradiation and persisted throughout the observation period, correlating with increased melanin deposition within the stratum granulosum. Furthermore, researchers noted an increase in parakeratosis (accelerated keratinocytic turnover) and melanophages. Dose-dependent increases in proliferation were also reported. Gene expression studies revealed significant upregulation of genes involved in oxidative stress and extracellular matrix (ECM) formation at low dose rates, specifically those encoding ECM structural components. This suggests a heightened inflammatory response mediated by ROS and ECM alterations. 

Reference: [MolecularRadiationBiology, Section 10.6.2.2 10.6.2.3] “Acute Effects of Proton Radiation Exposure in the Immune System”","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.2	 Skin Effects | Content: laboratory animals and at the same time advance the
quality of scientific studies.
Replacement: Includes methods that avoid or replace
the use of animals such as computer/mathematical
models (in silico), cell culture models (in vitro), or
relative replacement (e.g., invertebrates, such as
fruit flies and nematode worms).
Reduction: With improved experimental design, mod­
ern imaging, or sharing data and resources, the total
number of animals needed can be minimized.
Refinement: Modification in the experiment, which
minimize pain, suffering, and distress and allow
general improvement of animal welfare (e.g.,
improvement in the research animal housing condi­
tions, analgesia, and anesthesia for pain relief).Fig. 10.16
Fig. 10.16 On 3 November 1957 Laika was the first living mammal
that was sent to space onboard the satellite Sputnik 2
C. E. Hellweg et al.
533
that the total skin dose for astronauts performing EVAs is
estimated to be up to 32 Gy (for SPE simulation of August
1972) [31].
Radiation-induced skin injuries can be distinguished by
several phases depending on the condition of exposure [256].
Early skin reaction is shown by erythema within a few hours
after irradiation. After several weeks, inflammatory damage,
erythema, loss of epidermal cells, moist desquamation,
hyperpigmentation, edema/hyper-proliferation, and epilation
can be observed. Late effects can develop after several
months and include dermal atrophy, necrosis, and problems
related to the deterioration of the skin vasculature. Skin
problems, such as burns and slower wound healing, com­
bined with a deprived immune system increase the risk of
infections and hinder recovery from ARS [31].
Because of morphological similarities between (mini)
pigs and human skin, these animals have been widely used to
better understand the skin reaction to ionizing radiation.
Furthermore, rodent models such as mouse, rat, or guinea
pig have also been studied for ionizing radiation effects on
skin.
Using porcine models, researchers have been able to indi­
cate skin toxicity after exposure to a simulated SPE radiation
resembling the energy and fluence profile of a SPE docu­
mented in 1989 [257]. Hyperpigmentation of minipig irradi­
ated skin was observed 7 days after irradiation and lasted
throughout the entire observation period. These observations
were supported by an increase in melanin deposition found
in the stratum granulosum. Further observations of increased
proliferation, parakeratosis (an accelerated keratinocytic
turnover) and increased amount of melanophages, are
thought to be an indication of an inflammatory skin response
after irradiation.
Other studies exposed minipigs to doses ranging from 5
to 25 Gy of electrons [258]. In agreement with previous
mentioned study, a dose-dependent hyperpigmentation of
the skin was observed as well as an increase in melanin
deposition. Furthermore, in the highest dose exposed group
of 25 Gy, skin wounds and ulcers developed 19 days after
irradiation on body parts that received the highest dose (tail,
ears, and legs). In addition, hair loss in the form of alopecia
was observed along the dorsum of these pigs.
Low dose rate exposure of skin to low doses of photons,
seem to mostly induce oxidative stress and ECM alterations
as observed in a mouse model [259]. Skin gene expression
changes related to oxidative stress and extracellular matrix
(ECM) have been found after whole-body γ-ray exposure. At
low dose rates, genes involved in the formation of reactive
oxygen species (ROS) were significantly upregulated at
doses of 0.25 Gy. Furthermore, dose rate effects were also
found in ECM gene expression profiles. Enhanced expres­
sion of genes encoding ECM structural components were
found after low dose rate exposure.
10.6.2.3
Acute Effects of Proton Radiation
Exposure in the Immune System
The immune system consists of a variety of cells, processes,
and chemicals that combine efforts to protect the body from
foreign microbes, viruses, cancer cells, and toxins [260].
Dysfunction of the human immune system has been
shown during [261] and even after space flight [262]. Among
the causes of this immune dysfunction, an altered distribu­
tion of the cellular components and altered cytokine profiles
[263], as well as cytoskeleton alterations and gene expres­
sion dysregulation [264] has been shown in many immune
cells. When human lymphocytes are subjected to simulated
cosmic radiation in vitro they show chromosomal damage,
depending on the type of radiation shielding.
The adverse effects of space radiation on the immune sys­
tem is one of the major concerns for space flight. The vast
majority of the cellular components that constitute the
immune system are highly sensitive to ionizing radiation
[265]. It is still not clear if space radiation has a synergistic
effect in combination with microgravity, principally in long
duration missions and in the context of the immune system.
As mentioned, in vitro models have been widely used for
studying the effects of space radiation on several cellular
types. However, the complexity of most systems—such as
the case of the immune system—require approaches that will
better mimic physiologic conditions, either in ground-based
studies or inflight campaigns. Several animal models that
recreate some of the conditions of space flight have been
developed for use on Earth. For immunology studies, murine
models remain one of the most commonly used small animal
model in space radiobiology. Rats exposed to 56-Fe
(5 GeV/n) to total doses of 0, 1, 2, and 4 Gy showed a
decrease in their lymphocytes, particularly B cells. In another
study, mice were irradiated with total (single) doses of 0, 0.5,
2, and 3 Gy with 56-Fe ions. Red blood cell (RBC) counts
diminished proportionally to the dose. All three major types
of leukocytes also decreased [266].
Sanzari et al. [267] directed a series of radiation experi­
ments using Yucatan minipigs. The animals were exposed to
beams comprised of Solar Particle Events (SPE)-like protons,
155 MeV, and electrons, 6 and 12 MeV, with dose profiles
that mimic SPE radiation. Their findings suggest that, based
on the magnitude of the decrease and the time required to
reach the lowest leukocyte counts after irradiation, the proton
SPE radiation had more impact on the count than electron
SPE radiation, with lymphocytes being the most sensitive
type of leukocytes. After proton SPE radiation at skin doses
>5 Gy, certain populations of leukocytes (neutrophils) had
lasting effects following the irradiation (up to 90 days) [267].
For studying the intricate function of the immune system
and how it responds to acute exposures of space radiation,
small animal models are essential since they can showcase
the network of phenomena. Adding up to the already chal­
10 Space Radiobiology"
"The text describes how proton SPE radiation impacts immune cells in Yucatan minipigs, specifically noting increased expression of ECM genes and lasting effects on neutrophils after irradiation. What is the significance of this finding regarding space radiobiology research?","The observation that proton SPE radiation leads to enhanced expression of genes encoding ECM structural components and persistent effects on neutrophil populations in Yucatan minipigs highlights the complexity of immune responses to ionizing radiation during spaceflight. This suggests a potential mechanism by which space radiation disrupts normal immune function, leading to prolonged inflammation and altered leukocyte behavior. The lasting impact on neutrophils is particularly concerning given their role as key responders to infection and injury. These findings underscore the need for more sophisticated animal models that better mimic physiological conditions, such as circadian rhythms and gravity levels, to fully understand the intricate network of phenomena involved in space radiation-induced immune dysfunction. Furthermore, it emphasizes the importance of considering dose rate effects and potential synergistic interactions with other stressors like microgravity when evaluating risks associated with space missions.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.3	 Acute Effects of Proton Radiation Exposure in the Immune System | Content: doses of 0.25 Gy. Furthermore, dose rate effects were also
found in ECM gene expression profiles. Enhanced expres­
sion of genes encoding ECM structural components were
found after low dose rate exposure.
10.6.2.3
Acute Effects of Proton Radiation
Exposure in the Immune System
The immune system consists of a variety of cells, processes,
and chemicals that combine efforts to protect the body from
foreign microbes, viruses, cancer cells, and toxins [260].
Dysfunction of the human immune system has been
shown during [261] and even after space flight [262]. Among
the causes of this immune dysfunction, an altered distribu­
tion of the cellular components and altered cytokine profiles
[263], as well as cytoskeleton alterations and gene expres­
sion dysregulation [264] has been shown in many immune
cells. When human lymphocytes are subjected to simulated
cosmic radiation in vitro they show chromosomal damage,
depending on the type of radiation shielding.
The adverse effects of space radiation on the immune sys­
tem is one of the major concerns for space flight. The vast
majority of the cellular components that constitute the
immune system are highly sensitive to ionizing radiation
[265]. It is still not clear if space radiation has a synergistic
effect in combination with microgravity, principally in long
duration missions and in the context of the immune system.
As mentioned, in vitro models have been widely used for
studying the effects of space radiation on several cellular
types. However, the complexity of most systems—such as
the case of the immune system—require approaches that will
better mimic physiologic conditions, either in ground-based
studies or inflight campaigns. Several animal models that
recreate some of the conditions of space flight have been
developed for use on Earth. For immunology studies, murine
models remain one of the most commonly used small animal
model in space radiobiology. Rats exposed to 56-Fe
(5 GeV/n) to total doses of 0, 1, 2, and 4 Gy showed a
decrease in their lymphocytes, particularly B cells. In another
study, mice were irradiated with total (single) doses of 0, 0.5,
2, and 3 Gy with 56-Fe ions. Red blood cell (RBC) counts
diminished proportionally to the dose. All three major types
of leukocytes also decreased [266].
Sanzari et al. [267] directed a series of radiation experi­
ments using Yucatan minipigs. The animals were exposed to
beams comprised of Solar Particle Events (SPE)-like protons,
155 MeV, and electrons, 6 and 12 MeV, with dose profiles
that mimic SPE radiation. Their findings suggest that, based
on the magnitude of the decrease and the time required to
reach the lowest leukocyte counts after irradiation, the proton
SPE radiation had more impact on the count than electron
SPE radiation, with lymphocytes being the most sensitive
type of leukocytes. After proton SPE radiation at skin doses
>5 Gy, certain populations of leukocytes (neutrophils) had
lasting effects following the irradiation (up to 90 days) [267].
For studying the intricate function of the immune system
and how it responds to acute exposures of space radiation,
small animal models are essential since they can showcase
the network of phenomena. Adding up to the already chal­
10 Space Radiobiology
534
lenging task of pinpointing the alterations occurring in the
irradiated immune system we must find a way of adding the
following to the equation: isolation, altered circadian rhythms,
psychologic stress, and, of course, altered gravity levels.
Chronic and late effects of space radiation exposure
encompass increased cancer risk, early cataract formation,
and a possibly increased risk for degenerative diseases of
several organ systems such as the cardiovascular and the cen­
tral nervous system).
10.6.2.4
Cancer
Animal models of cancer induction by space radiation play a
crucial role in the determination of the radiation risk associ­
ated with a space mission.
Firstly, they provide with information about the RBE of
different space radiation components such as HZE particles
for cancer induction in different organs when compared to a
low-LET radiation quality, such as gamma rays or X-rays.
The Radiation Quality Factor is derived from the RBE data
for cancer induction by HZE particles to scale from gamma
radiation to the mixed field of GCR in space radiation cancer
risk models. If the RBE is above 1, a higher cancer risk can
be assumed for space radiation compared to well-known ter­
restrial low-LET radiation qualities.
Secondly, experiments with high and low dose rates are
the basis to estimate the dose and dose rate effectiveness fac­
tor (DDREF) to scale from acute to chronic radiation expo­
sure and thereby account for dose rate effects. As animal
experiments with exposure at low dose rates are rarely fea­
sible at heavy ion accelerators because of restricted beam
time access, dose-rate effect experiments were performed so
far at neutron facilities.
Furthermore, animal models give insight into the mecha­
nisms of cancerogenesis by HZE particle exposure, e.g., the role
of non-targeted effects, and thereby allow to identify potential
molecular targets for effective countermeasures (Box 10.6).
The first animal experiment with HZE particles to deter­
mine cancer induction by single ion exposure used mice and
focused on the induction of tumors of the exocrine Harderian
gland which is located between eye and ear [268–271]. In
these experiments, tumor prevalence was determined by sac­
rificing mice at a predetermined timepoint after exposure and
the number of mice with tumors was counted or the number
of tumors per mouse was counted. As this gland does not
exist in humans, other animal models were developed and
applied. Two different approaches predominate: either wild­
type rodents, e.g., inbred, F1 hybrid, or outbred mice, or
genetically altered rodent models are exposed to HZE parti­
cles at a heavy ion accelerator. Multiparent outbreeding
strategies can reduce the strong effects of the genetic back­
ground that limit gene-environment interactions in studies
with inbred, genetically homogeneous animals [272]. To
consider sex-specific cancer types, optimally, both sexes are
included [272]. After whole-body irradiation of wild-type
rodents, they were followed up over the lifespan of the ani­
mals for tumor induction. Alternatively, rats were followed
up by palpation until first tumor (time-to-cancer incidence),
with an additional follow-up until death. After necropsy, his­
tology was performed to determine the number and types of
cancer, e.g., mammary tumors [273, 274]. Here, high num­
bers of animals are required to detect the increase of cancer
incidence above the background cancer rates.
Therefore, genetically altered mouse models were devel­
oped in order to lower the number of mice and to mimic a
specific cancer induction and promotion pathway, mostly for
lung, gastrointestinal [275, 276] or liver cancer (hepatocel­
lular carcinoma) [277, 278]. Using a genetically radio-sensi­
tized model implies an assumption about the mechanisms of
radiation-induced cancerogenesis—genetically engineered
mice carry some, but not all mutations, needed to generate
cancer. The rationale behind this approach is to consider
somatic mutations in cancer genes such as NOTCH1 and
TP53 that might be already present in astronauts when they
depart for their first space missions as the number of muta­
tions in the epithelium increases with age [279].
In risk models, development of leukemia (leukemogene­
sis) and induction of solid tumors are considered separately
because of different latency periods after radiation exposure
and dose–response relationships. Leukemogenesis is highly
relevant for space missions because of its short latency in
humans. The CBA mouse strain is susceptible to radiation-
induced acute myeloid leukemia (AML) [280] which is
explained by a deletion in chromosome 2 (PU.1) that can
occur 1 month after irradiation. A point mutation in the sec­
ond copy of the PU.1 gene causes a differentiation block in
the myeloid cells which favor autocrine growth stimulation.
In this model, the RBE of iron ions for induction of AML was
1, meaning that the risk of AML induction by high-LET iron
ions and low-LET radiation is comparable. As only surviving
Box 10.6 Mouse strains
Inbred mouse strains are produced by at least 20 gen­
erations of brother-sister mating and they are trace­
able to a single founding pair. The individuals of an
inbred strain are genetically nearly identical to each
other and experimental results are highly reproduc­
ible. Examples: CBA mouse (cross of Bagg albino
and DBA), C57BL/6 mouse (with black coat),
BALB/c (Bagg albino) mouse.
Outbred strains provide genetic diversity and are
effectively wildtype in nature with as little inbreed­
ing as possible.
Mating of at least two strains led to the generation of
the first filial generation (F1) hybrid mice.
C. E. Hellweg et al."
"The text describes several strategies used to mitigate the impact of genetic background in animal studies investigating space radiation effects on cancer development. Explain how genetically altered mouse models, specifically those mimicking specific cancer induction pathways like lung or liver cancer, are utilized and why they’re considered advantageous compared to using wild-type rodents.","Genetically altered mouse models play a crucial role in reducing the confounding influence of genetic background when studying space radiation's effects on cancer. Traditional studies with wild-type rodents can be hampered by inherent genetic variations that significantly impact an individual's susceptibility to developing tumors after irradiation. To address this, researchers develop models specifically engineered to mimic key cancer induction and promotion pathways. For example, models designed for lung cancer often incorporate mutations associated with lung carcinogenesis, such as those found in the BALB/cByJ or C57/BL6 mouse strains, or utilize a K-rasLA1 model. Similarly, models targeting liver cancer (hepatocellular carcinoma) might employ genetic alterations that promote HCC development. These engineered mice carry specific mutations—like NOTCH1 and TP53—that are relevant to the mechanisms of radiation-induced cancerogenesis, allowing researchers to isolate and study the effects of radiation more accurately. Furthermore, using these models reduces the number of animals needed to detect a significant increase in cancer incidence above background rates, addressing the logistical challenge highlighted in the text regarding high animal requirements.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.4	 Cancer | Content: strategies can reduce the strong effects of the genetic back­
ground that limit gene-environment interactions in studies
with inbred, genetically homogeneous animals [272]. To
consider sex-specific cancer types, optimally, both sexes are
included [272]. After whole-body irradiation of wild-type
rodents, they were followed up over the lifespan of the ani­
mals for tumor induction. Alternatively, rats were followed
up by palpation until first tumor (time-to-cancer incidence),
with an additional follow-up until death. After necropsy, his­
tology was performed to determine the number and types of
cancer, e.g., mammary tumors [273, 274]. Here, high num­
bers of animals are required to detect the increase of cancer
incidence above the background cancer rates.
Therefore, genetically altered mouse models were devel­
oped in order to lower the number of mice and to mimic a
specific cancer induction and promotion pathway, mostly for
lung, gastrointestinal [275, 276] or liver cancer (hepatocel­
lular carcinoma) [277, 278]. Using a genetically radio-sensi­
tized model implies an assumption about the mechanisms of
radiation-induced cancerogenesis—genetically engineered
mice carry some, but not all mutations, needed to generate
cancer. The rationale behind this approach is to consider
somatic mutations in cancer genes such as NOTCH1 and
TP53 that might be already present in astronauts when they
depart for their first space missions as the number of muta­
tions in the epithelium increases with age [279].
In risk models, development of leukemia (leukemogene­
sis) and induction of solid tumors are considered separately
because of different latency periods after radiation exposure
and dose–response relationships. Leukemogenesis is highly
relevant for space missions because of its short latency in
humans. The CBA mouse strain is susceptible to radiation-
induced acute myeloid leukemia (AML) [280] which is
explained by a deletion in chromosome 2 (PU.1) that can
occur 1 month after irradiation. A point mutation in the sec­
ond copy of the PU.1 gene causes a differentiation block in
the myeloid cells which favor autocrine growth stimulation.
In this model, the RBE of iron ions for induction of AML was
1, meaning that the risk of AML induction by high-LET iron
ions and low-LET radiation is comparable. As only surviving
Box 10.6 Mouse strains
Inbred mouse strains are produced by at least 20 gen­
erations of brother-sister mating and they are trace­
able to a single founding pair. The individuals of an
inbred strain are genetically nearly identical to each
other and experimental results are highly reproduc­
ible. Examples: CBA mouse (cross of Bagg albino
and DBA), C57BL/6 mouse (with black coat),
BALB/c (Bagg albino) mouse.
Outbred strains provide genetic diversity and are
effectively wildtype in nature with as little inbreed­
ing as possible.
Mating of at least two strains led to the generation of
the first filial generation (F1) hybrid mice.
C. E. Hellweg et al.
535
cells can be transformed into a cancer cell, a higher mutation
and chromosomal aberration rate induced by HZE particles
can be compensated by cell death from collateral damage
after an HZE ion traversed a myeloid cell [277]. RBE for
other cancer types can be much different as the effectiveness
of HZE ions in inducing a specific cancer type depends on the
mechanism responsible for the tumorigenesis in that particu­
lar cancer. For example, in the same mouse strain that was
used for the AML studies, hepatocellular carcinoma (HCC)
was induced by HZE particles with an RBE of up to 74 [278].
Concerning solid tumors, a special focus in the studies so
far was to evaluate the stage of tumors that can be induced by
HZE particles and on detailed studies on lung cancer, gastro­
intestinal cancer, and brain tumors (Box 10.7).
The lung has the highest susceptibility to radiation-
induced carcinoma incidence and mortality, based on anal­
ysis of human populations exposed to radiation (Life Span
Study of atomic bomb survivors). A minimum of five
genetic changes convert immortalized human lung epithe­
lial cells to malignant tumors. For lung carcinogenesis,
BALB/cByJ or C57/BL6 mice or the K-rasLA1 mouse model
[281] were used. In C57/BL6 mice, lung tumors occurred
in irradiated mice but not in controls and all were adenocar­
cinomas, with no significant differences between males and
females and for dose fractionation (dividing a radiation
dose into multiple fractions, see Chap. 4) versus single
dose were found. Incidence of lung tumors was higher in
high-LET-irradiated mice than in X-ray-irradiated mice,
with an RBE above 6 for all investigated HZE particles (Fe,
Si, and O ions) [282].
In the pathogenesis of gastrointestinal tumors, for
instance, colorectal cancer and hepatocellular carcinoma
(HCC), inflammation plays a crucial role. Animal experi­
ments revealed that heavy ion radiation triggers a pro-inflam­
matory state which can be associated with late colonic
tumors. Furthermore, premalignant polyps with mutations in
the Adenomatous polyposis coli (APC) gene could be already
present in middle-aged astronauts. In the small intestine, the
formation of a few polyps and later adenomas and even ade­
nocarcinomas can result from truncation of the APC gene at
codon 1638 [283]. Therefore, a mouse model with a chain-
terminating mutation by a mutation to a stop codon or a
frameshift (see Chap. 4) in one allele of the APC gene was
developed for colon cancer research (Apc1638N/+). APC mutant
mouse models show a good correlation with carcinogens
implicated in human colorectal cancer. Delayed genomic
instability in APC1638N/+ mice paves the way to gastrointesti­
nal tumorigenesis. In this model, no evidence for dose-rate
effects with HZE particle exposure was found [275], indicat­
ing that the carcinogenic potential of HZE particles is inde­
pendent of the dose rate.
Also, genetically altered mouse models for the formation
of brain tumors are used in space radiation research as already
experiments from the 1970s indicated that charged particles
can induce glioblastomas: Monkeys (Macaca mulatta) irradi­
ated with high-energy protons (55 MeV, penetration depth
~2.5 cm) surviving 2 years or longer developed glioblastomas
[284]. Here, the focus is on the loss of tumor suppressors such
as cyclin dependent kinase inhibitor 2A (Cdkn2a or Ink4-
Arf), phosphatase and tensin homolog (Pten), and TP53 in
astrocytes and on oncogene activation (e.g., epidermal growth
factor receptor variant III, EGFRvIII) after irradiation. Iron
and silicon ions were much more potent tumor inducers in
“preinitiated” astrocytes than gamma rays [285].
The animal studies with single beam irradiations show
that the efficiency of HZE particles to induce cancer is
related to ion energy, LET with a peak RBE below 100 keV/
μm, sex of the animals, and depends on the tumor type [275].
The RBE for cancer induction was recently determined to
range from 5 to 16 [286], representing a snapshot that will be
further updated as not all available data were included.
Currently, based on the results of single beam irradiations,
multiple beam experiments with up to 33 ion beams are per­
formed at the NASA Space Radiation Laboratory (NSRL)
using the GCR simulator in order to understand whether the
effects of the different GCR components act in an additive or
even in a synergistic manner in cancer induction.
10.6.2.5
Cataract
According to recent epidemiological evidence, radiation-
induced cataract (see Chap. 2) occurs with a threshold
absorbed dose of 0.5 Gy (0–1 Gy) of sparsely ionizing radia­
tion, meaning that a cataract can arise after any ionizing
radiation dose no matter how low if the remaining lifespan is
long enough for its appearance. The 1 Sv GCR dose to be
expected for a 1000-day Mars mission [83, 84] means that
even the upper limit of the cataract-induction threshold dose
confidence interval will be reached during a human Mars
exploration mission. In astronauts, epidemiological data sug­
Box 10.7 Tumor Types Observed After HZE Particle
Exposure of Outbred Mice Are Similar to Those Arising
Spontaneously or After Gamma Irradiation
Pituitary adenoma, osteosarcoma, Harderian gland
tumor, soft tissue sarcoma, thyroid adenoma, ovarian
Granulosa cell tumor, mammary adenocarcinoma, his­
tiocytic sarcoma, hemangiosarcoma, hepatocellular
carcinoma (HCC), pulmonary adenocarcinoma, small
cell lung cancer, myeloid leukemia, (thymic) lym­
phoma (T cell, B cell), brain tumors, e.g., gliomas
[272].
10 Space Radiobiology"
"What are the key mechanisms identified in animal studies that contribute to HZE particle-induced cataract formation, and how does genetic predisposition (specifically ATM heterozygosity) influence this process?","Animal experiments utilizing genetically altered mouse models have revealed several critical mechanisms underlying the cataractogenic effects of high-energy particles like HZEs. Primarily, irradiation leads to genetic damage within lens epithelial cells (LECs), characterized by alterations in cell cycle control, apoptosis, differentiation pathways, and chromosomal aberrations. These changes disrupt normal LEC function, preventing their elimination from the lens capsule due to its lack of vascularization and encapsulation. Furthermore, iron and silicon ions were found to be particularly potent tumor inducers in astrocytes, suggesting a role for local dose effects and specific cellular responses. The RBE (Relative Biological Effectiveness) for cataract induction varies depending on LET (Linear Energy Transfer), ranging from 5 to 16, influenced by factors like sex and tumor type. Importantly, the study highlights that ATM heterozygosity significantly exacerbates cataract formation following HZE particle exposure. Carriers of the ATM gene mutation, which plays a central role in the DNA damage response (DDR), exhibit earlier onset and progression of cataracts due to impaired ability to repair damaged DNA within LECs. This suggests that individuals with pre-existing DDR deficiencies are more vulnerable to radiation-induced lens damage. Reference: [Molecular Radiation Biology, Section 10.6.2.5 – Cataract]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.5	 Cataract | Content: ing that the carcinogenic potential of HZE particles is inde­
pendent of the dose rate.
Also, genetically altered mouse models for the formation
of brain tumors are used in space radiation research as already
experiments from the 1970s indicated that charged particles
can induce glioblastomas: Monkeys (Macaca mulatta) irradi­
ated with high-energy protons (55 MeV, penetration depth
~2.5 cm) surviving 2 years or longer developed glioblastomas
[284]. Here, the focus is on the loss of tumor suppressors such
as cyclin dependent kinase inhibitor 2A (Cdkn2a or Ink4-
Arf), phosphatase and tensin homolog (Pten), and TP53 in
astrocytes and on oncogene activation (e.g., epidermal growth
factor receptor variant III, EGFRvIII) after irradiation. Iron
and silicon ions were much more potent tumor inducers in
“preinitiated” astrocytes than gamma rays [285].
The animal studies with single beam irradiations show
that the efficiency of HZE particles to induce cancer is
related to ion energy, LET with a peak RBE below 100 keV/
μm, sex of the animals, and depends on the tumor type [275].
The RBE for cancer induction was recently determined to
range from 5 to 16 [286], representing a snapshot that will be
further updated as not all available data were included.
Currently, based on the results of single beam irradiations,
multiple beam experiments with up to 33 ion beams are per­
formed at the NASA Space Radiation Laboratory (NSRL)
using the GCR simulator in order to understand whether the
effects of the different GCR components act in an additive or
even in a synergistic manner in cancer induction.
10.6.2.5
Cataract
According to recent epidemiological evidence, radiation-
induced cataract (see Chap. 2) occurs with a threshold
absorbed dose of 0.5 Gy (0–1 Gy) of sparsely ionizing radia­
tion, meaning that a cataract can arise after any ionizing
radiation dose no matter how low if the remaining lifespan is
long enough for its appearance. The 1 Sv GCR dose to be
expected for a 1000-day Mars mission [83, 84] means that
even the upper limit of the cataract-induction threshold dose
confidence interval will be reached during a human Mars
exploration mission. In astronauts, epidemiological data sug­
Box 10.7 Tumor Types Observed After HZE Particle
Exposure of Outbred Mice Are Similar to Those Arising
Spontaneously or After Gamma Irradiation
Pituitary adenoma, osteosarcoma, Harderian gland
tumor, soft tissue sarcoma, thyroid adenoma, ovarian
Granulosa cell tumor, mammary adenocarcinoma, his­
tiocytic sarcoma, hemangiosarcoma, hepatocellular
carcinoma (HCC), pulmonary adenocarcinoma, small
cell lung cancer, myeloid leukemia, (thymic) lym­
phoma (T cell, B cell), brain tumors, e.g., gliomas
[272].
10 Space Radiobiology
536
gest a higher risk for the development of cataracts in case of
missions in LEO with high inclination [287].
Due to its germinative zone in the lens epithelium, the eye
lens is a radiation-sensitive organ. These cells are actively
proliferating during lifetime and finally differentiate into
transparent lens fibers. In case cells are damaged, they can­
not be eliminated from the lens which is covered by a cap­
sule and not vascularized. Exposure of the eye lens to
ionization radiation is thought to result in sub-capsular corti­
cal lens opacification via various steps, starting with genetic
damage of lens epithelial cells via changes in cell cycle con­
trol, apoptosis, differentiation, or other pathways controlling
lens fiber cells’ differentiation, and cellular disorganization.
Due to higher local dose and different patterns of cellular
energy deposition from high-LET components of GCR,
higher efficiency in the induction of lens-damaging effects is
assumed than for low-LET radiation. Therefore, animal
experiments were mostly performed to determine the RBE of
HZE particles to induce lens opacification and to detect pos­
sible dose rate effects. In rats, the RBE reached 50–100 for
HZE particles within LET above 80 keV/μm [288] and frac­
tionation of exposure did not reduce the cataractogenic effect
[289]. Neutrons as secondary particles occurring in space­
craft and on planetary or moon surfaces had also a high RBE
for cataract-induction in rats [290].
To determine the role of genetic predispositions, mice that
are heterozygous for Ataxia telangiectasia mutated protein
(ATM) were exposed to HZE particles and cataract forma­
tion was followed. ATM plays a central role in the DNA
damage response (DDR). Heterozygosity for the ATM gene
predisposes carriers for early onset time and progression of
cataracts even without exposure to ionizing radiation [291].
Also after gamma ray and 1 GeV/n iron ion exposure, cata­
racts appear earlier in ATM heterozygous animals compared
to wild-type mice and the RBE for HZE particle induced
cataract formation ranged from 4 to 200, whereby the high­
est values were found for the lowest dose (10 mGy) and RBE
decreases with increasing dose [292, 293]. In conclusion,
HZE particles present in GCR and neutrons as part of the
secondary radiation field are highly cataractogenic and the
mechanisms such as long-term changes in gene expression,
complex DNA damage, and chromosomal aberrations in eye
lens epithelial cells (LECs) are still under investigation.
10.6.2.6
Cardiovascular System
Exposure to space hazards, including microgravity and
heavy ion exposure can cause harmful effects on the cardio­
vascular system during spaceflight. Upon entering micro­
gravity, cephalad fluid shifts cause increased stroke volume
and cardiac output. Furthermore, the cephalad fluid shift is
also hypothesized to cause visual impairments due to
increased cranial pressure [294]. During flight, mean arterial
pressure is decreased, together with central venous pressure.
Furthermore, decreased systemic vascular resistance, results
from increased cardiac output, systemic arterial vasodilation,
and decreased arterial pressure [295]. Other effects of micro­
gravity exposure include hypovolemia, cardiac arrhythmia,
cardiac atrophy, and orthostatic intolerance. Believed to be
caused by fluid shifts and movement of interstitial water
from the legs to the head, the fluid reduction and eventually
hypovolemia results in a reduced number of red blood cells
[296]. Moreover, cardiac atrophy occurs as a result of
decreased metabolic demand and oxygen uptake during
microgravity conditions. Together, cardiac deconditioning,
i.e., hypovolemia, cardiac atrophy, and decreased cardiac
output, causes a decreased exercise capacity and orthostatic
intolerance post-flight [297].
While effects related to microgravity exposure during
spaceflight are fairly well-known (albeit underexplored),
impacts of the cardiovascular system from space radiation and
heavy ion exposure during spaceflight are less known.
Furthermore, studies from space analogs focusing on radiation
effects have shown several effects on the cardiovascular sys­
tem. Mice exposed to heavy ions show myocardial remodel­
ing, resulting in hypertrophy and cardiac fibrosis [186].
Additionally, accelerated development of atherosclerosis has
been found in mice after heavy ion exposure. Leading to a
greater prevalence of myocardial infarction [298]. Both in vivo
and in vitro models during space flight as well as using space
analogs have been used to investigate underlying mechanisms
of space-induced CVD. Important mechanisms include endo­
thelial dysfunction, cellular apoptosis, cellular senescence,
inflammation, and reactive oxygen species production [297].
10.6.2.7
Central Nervous System
Exposure to heavy ion, especially during long-term space
mission, can also affect the central nervous system (CNS).
The CNS is part of the nervous system and is composed of
the brain and the spinal cord. It is responsible for perceiving
any exterior information, transmitting, and subsequently
processing it. Responsible for signal transmission are neu­
rons, whereas glial cells (oligodendrocytes, microglia, or
astrocytes) have diverse function such as the trophic support
of neurons. As neurons are terminally differentiated and have
a very restricted regeneration potential, damaged cells will
usually not be replaced and thus damage might accumulate
over months or years.
Acute CNS effects of ionizing radiation exposure are only
observed after exposure to very high doses and can be
expected in spaceflight only during very large Solar Particle
Events (SPE) in case of insufficient shielding. Thus, for more
than 20 years, possible effects of chronic low-dose exposure
of the CNS to galactic cosmic rays (GCR) are discussed and
a decrease in CNS performance of astronauts is suspected,
which was also further evidenced in animal studies [299,
300]. Normally rodent animal experiments are performed at
heavy ion accelerators simulating space radiation at doses
below 1 Gy in a relatively short time, revealing impairment in
C. E. Hellweg et al."
"Describe the observed cardiovascular effects of microgravity exposure on small animals, including the mechanisms contributing to these changes and potential long-term consequences.","Microgravity exposure induces a complex cascade of cardiovascular alterations in small animals, primarily driven by fluid shifts and subsequent physiological responses. Initially, cephalad fluid shifts lead to increased cranial pressure, potentially causing visual impairments. Simultaneously, mean arterial pressure decreases alongside reductions in central venous pressure due to decreased systemic vascular resistance. This resistance reduction is attributed to vasodilation and lower arterial pressures. A key consequence of these shifts is hypovolemia, resulting from the movement of interstitial water from the lower extremities towards the head. This fluid loss reduces red blood cell numbers. Furthermore, prolonged microgravity exposure causes cardiac atrophy due to diminished metabolic demands and oxygen uptake. The combined effects – hypovolemia, cardiac atrophy, and reduced cardiac output – contribute significantly to decreased exercise capacity and orthostatic intolerance post-flight. More concerningly, studies utilizing space analogs have demonstrated that heavy ion exposure during spaceflight exacerbates these cardiovascular issues. Specifically, this exposure induces myocardial remodeling characterized by hypertrophy and fibrosis. Additionally, accelerated atherosclerosis development has been observed, increasing the risk of myocardial infarction. Underlying mechanisms implicated in these effects include endothelial dysfunction, cellular apoptosis and senescence, inflammation, and elevated reactive oxygen species production. The interplay between microgravity-induced fluid shifts and radiation damage appears to significantly compromise cardiovascular health in spaceflight scenarios [297].","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.6	 Cardiovascular System | Content: and cardiac output. Furthermore, the cephalad fluid shift is
also hypothesized to cause visual impairments due to
increased cranial pressure [294]. During flight, mean arterial
pressure is decreased, together with central venous pressure.
Furthermore, decreased systemic vascular resistance, results
from increased cardiac output, systemic arterial vasodilation,
and decreased arterial pressure [295]. Other effects of micro­
gravity exposure include hypovolemia, cardiac arrhythmia,
cardiac atrophy, and orthostatic intolerance. Believed to be
caused by fluid shifts and movement of interstitial water
from the legs to the head, the fluid reduction and eventually
hypovolemia results in a reduced number of red blood cells
[296]. Moreover, cardiac atrophy occurs as a result of
decreased metabolic demand and oxygen uptake during
microgravity conditions. Together, cardiac deconditioning,
i.e., hypovolemia, cardiac atrophy, and decreased cardiac
output, causes a decreased exercise capacity and orthostatic
intolerance post-flight [297].
While effects related to microgravity exposure during
spaceflight are fairly well-known (albeit underexplored),
impacts of the cardiovascular system from space radiation and
heavy ion exposure during spaceflight are less known.
Furthermore, studies from space analogs focusing on radiation
effects have shown several effects on the cardiovascular sys­
tem. Mice exposed to heavy ions show myocardial remodel­
ing, resulting in hypertrophy and cardiac fibrosis [186].
Additionally, accelerated development of atherosclerosis has
been found in mice after heavy ion exposure. Leading to a
greater prevalence of myocardial infarction [298]. Both in vivo
and in vitro models during space flight as well as using space
analogs have been used to investigate underlying mechanisms
of space-induced CVD. Important mechanisms include endo­
thelial dysfunction, cellular apoptosis, cellular senescence,
inflammation, and reactive oxygen species production [297].
10.6.2.7"
"The text describes several cardiovascular effects observed in mice exposed to microgravity and heavy ions during spaceflight. Specifically, what are the three primary cardiac changes identified – hypovolemia, cardiac atrophy, and decreased cardiac output – and how are these linked to fluid shifts and metabolic demands?","During microgravity exposure, significant physiological alterations occur within the cardiovascular system of mice. Three key changes were identified: hypovolemia (a reduction in blood volume), cardiac atrophy (atrophy or wasting of the heart muscle), and decreased cardiac output. These are primarily linked to fluid shifts and altered metabolic demands. The fluid reduction, specifically a movement of interstitial water from the legs to the head, leads to reduced red blood cell numbers – contributing to hypovolemia. Simultaneously, decreased metabolic demand during microgravity reduces oxygen uptake by the heart, resulting in cardiac atrophy. Finally, the combination of hypovolemia and cardiac atrophy results in a diminished ability of the heart to pump effectively, leading to a decrease in cardiac output. These three factors collectively cause orthostatic intolerance post-flight [297].

Reference: [MolecularRadiationBiology], Section 10.6.2.7 – Central Nervous System","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.2	 Acute Effects | Sub-sub-subsection: 10.6.2.7	 Central Nervous System | Content: and cardiac output. Furthermore, the cephalad fluid shift is
also hypothesized to cause visual impairments due to
increased cranial pressure [294]. During flight, mean arterial
pressure is decreased, together with central venous pressure.
Furthermore, decreased systemic vascular resistance, results
from increased cardiac output, systemic arterial vasodilation,
and decreased arterial pressure [295]. Other effects of micro­
gravity exposure include hypovolemia, cardiac arrhythmia,
cardiac atrophy, and orthostatic intolerance. Believed to be
caused by fluid shifts and movement of interstitial water
from the legs to the head, the fluid reduction and eventually
hypovolemia results in a reduced number of red blood cells
[296]. Moreover, cardiac atrophy occurs as a result of
decreased metabolic demand and oxygen uptake during
microgravity conditions. Together, cardiac deconditioning,
i.e., hypovolemia, cardiac atrophy, and decreased cardiac
output, causes a decreased exercise capacity and orthostatic
intolerance post-flight [297].
While effects related to microgravity exposure during
spaceflight are fairly well-known (albeit underexplored),
impacts of the cardiovascular system from space radiation and
heavy ion exposure during spaceflight are less known.
Furthermore, studies from space analogs focusing on radiation
effects have shown several effects on the cardiovascular sys­
tem. Mice exposed to heavy ions show myocardial remodel­
ing, resulting in hypertrophy and cardiac fibrosis [186].
Additionally, accelerated development of atherosclerosis has
been found in mice after heavy ion exposure. Leading to a
greater prevalence of myocardial infarction [298]. Both in vivo
and in vitro models during space flight as well as using space
analogs have been used to investigate underlying mechanisms
of space-induced CVD. Important mechanisms include endo­
thelial dysfunction, cellular apoptosis, cellular senescence,
inflammation, and reactive oxygen species production [297].
10.6.2.7
Central Nervous System
Exposure to heavy ion, especially during long-term space
mission, can also affect the central nervous system (CNS).
The CNS is part of the nervous system and is composed of
the brain and the spinal cord. It is responsible for perceiving
any exterior information, transmitting, and subsequently
processing it. Responsible for signal transmission are neu­
rons, whereas glial cells (oligodendrocytes, microglia, or
astrocytes) have diverse function such as the trophic support
of neurons. As neurons are terminally differentiated and have
a very restricted regeneration potential, damaged cells will
usually not be replaced and thus damage might accumulate
over months or years.
Acute CNS effects of ionizing radiation exposure are only
observed after exposure to very high doses and can be
expected in spaceflight only during very large Solar Particle
Events (SPE) in case of insufficient shielding. Thus, for more
than 20 years, possible effects of chronic low-dose exposure
of the CNS to galactic cosmic rays (GCR) are discussed and
a decrease in CNS performance of astronauts is suspected,
which was also further evidenced in animal studies [299,
300]. Normally rodent animal experiments are performed at
heavy ion accelerators simulating space radiation at doses
below 1 Gy in a relatively short time, revealing impairment in
C. E. Hellweg et al.
537
cognitive performance, reduction of dendrites, reduced neu­
rogenesis, and increased neuroinflammation [301–303]. As
these effects can be seen even months after irradiation, late
effects are possible even after exposure to lower doses [304].
Whereby it has to be considered that in these heavy ion
accelerator experiments, the dose can only be applied in a
short time, and prolonged exposure over several weeks or
months mimicking the real situation in spaceflight is not often
possible. With the use of new, low dose rate neutron irradia­
tion facilities, it is now possible to expose rodents to a chronic
low-dose as expected during space flights [305]. Also, mice
that were irradiated with this chronic neutron irradiation (for
6 months) resulted in diminished hippocampal neuron excit­
ability, a region which is essential for memory and learning,
and disrupted hippocampal and cortical long-term potentia­
tion. In addition, mice showed severe impairments in memory
and learning tasks as well as distress behaviors [305].
One limit of experiments at the accelerator is that only
radiation exposure of a few single radiation types can be
studied, while in space, radiation exposure consists of a com­
plex radiation mixture. It is still unclear if humans’ brains are
affected to the same extent, but chronic low-dose radiation
may cause problems for astronauts regarding decision-mak­
ing processes or performance [306] (Box 10.8).
10.6.3	Tiny and Extremely Resistant: Why
Bdelloid Rotifers and Tardigrades Are
Animal Model Systems for Space
Exploration?
10.6.3.1
Bdelloids and Tardigrades, Small
Animals to Study Desiccation,
Radiation Tolerance and Limit of Life
10.17
10.18
­
­
­
10.9
When water starts to evaporate, these animals begin to
contract their muscles and their body to adopt a “tun” shape
allowing an optimal desiccation resistance [307–310]. This
proper contraction of the body, followed by a specific orga­
nization of internal structures is a key step in enabling a
successful recovery of desiccated animals after rehydration
[308, 309]. The desiccation resistance and recovery rate
vary between species [311–314]. The survival rate depends
on the length of the desiccation period, the relative humid­
ity, temperature, and animal age. Tardigrades desiccated
over 10–20 years, within dry mosses stored at room tem­
perature, were successfully rehydrated confirming their des­
iccation resistance for periods [315] [316]. While being
frozen, these animals were shown to survive over 30 years
of desiccation [317]. Bdelloid rotifers have also been shown
to survive long periods of desiccation, up to 9 years [318].
As for tardigrades, cold temperatures seem to extend the
capacity of desiccated bdelloids to cope with the long dura­
tion of metabolic arrest. In a recent publication by Shmakova
et al. bdelloid rotifer specimens were recovered from frozen
permafrost soil 24,000 years old [319]. If no data are still
available for tardigrades, studying old permafrost samples
may reveal other records of small animals’ life preservation.
For example, some nematodes were described to success­
fully recover after melting from 30 to 40,000 years old sam­
ples [320].
Mostly found in habitats where physical parameters can
change unpredictably, tardigrades and bdelloid rotifers were
described to be able to cope with a wide range of physical
extremes besides desiccation and freezing, such as UV radia­
Box 10.8 Section Highlights
Since their discovery by Antonie van Leeuwenhoek in
1702, bdelloid rotifers and tardigrades have remained
intriguing organisms. Their tolerance to desiccation at
any stage of their life and their ability to survive a vari­
ety of stresses (e.g., low and high temperatures,
absence of oxygen, vacuum, high level of ionizing
radiation, etc.), makes them good candidates to study
extreme resistance mechanisms in the context of space
research. Tardigrades have a long history of space
astrobiology experiments being among the first ani­
mals exposed to space vacuum and radiation. Recent
experiments performed onboard of the ISS used bdel­
loid rotifers and tardigrades to study the adaptation to
microgravity and cosmic radiation during spaceflight.
Box 10.9 Desiccation or Drought Tolerance?
Desiccation tolerance must be differentiated from
drought tolerance. Many organisms are able to tolerate
drought as a reduction in water availability in the envi­
ronment for longer or shorter times. However, a
reduced number is able to survive a loss of 90% or
more of their body water content. Complete desicca­
tion is reached when the water content decreases below
10% of the dried mass, not enough to form a mono­
layer around macromolecules, preventing enzymatic
reactions and therefore metabolism.
10 Space Radiobiology"
"Bdelloid rotifers and tardigrades are frequently utilized as animal model systems for space exploration due to their remarkable resilience. Explain the key reasons why these organisms, specifically regarding desiccation and freezing tolerance, make them suitable candidates for studying the effects of extreme environments on living organisms in the context of space research.","Bdelloid rotifers and tardigrades are valuable model systems for space exploration primarily because of their exceptional ability to withstand extreme environmental stressors, particularly desiccation and freezing. The rotifers’ documented survival rates after prolonged periods of desiccation – up to 9 years – coupled with their demonstrated capacity to survive freezing temperatures extending the bdelloid's tolerance to long metabolic arrest, provide a unique opportunity to investigate how organisms cope with conditions relevant to space travel. Furthermore, recent research, such as the recovery of bdelloid rotifers from 24,000-year-old permafrost samples, highlights their capacity for extremely long-term survival under conditions mimicking potential hazards encountered in space – including prolonged periods without metabolic activity. The fact that these organisms can tolerate a wide range of physical extremes beyond just desiccation and freezing (e.g., UV radiation, low/high temperatures, vacuum) further enhances their utility. Their use in recent experiments on the International Space Station to study adaptation to microgravity and cosmic radiation underscores their suitability for simulating space-related stressors. Importantly, it’s crucial to differentiate between desiccation tolerance and drought tolerance; complete desiccation (below 10% water content) halts enzymatic reactions by preventing macromolecule hydration, effectively putting the organism into a state of metabolic arrest – a condition relevant to prolonged exposure in space.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.3	 Tiny and Extremely Resistant: Why Bdelloid Rotifers and Tardigrades Are Animal Model Systems for Space Exploration? | Content: perature, were successfully rehydrated confirming their des­
iccation resistance for periods [315] [316]. While being
frozen, these animals were shown to survive over 30 years
of desiccation [317]. Bdelloid rotifers have also been shown
to survive long periods of desiccation, up to 9 years [318].
As for tardigrades, cold temperatures seem to extend the
capacity of desiccated bdelloids to cope with the long dura­
tion of metabolic arrest. In a recent publication by Shmakova
et al. bdelloid rotifer specimens were recovered from frozen
permafrost soil 24,000 years old [319]. If no data are still
available for tardigrades, studying old permafrost samples
may reveal other records of small animals’ life preservation.
For example, some nematodes were described to success­
fully recover after melting from 30 to 40,000 years old sam­
ples [320].
Mostly found in habitats where physical parameters can
change unpredictably, tardigrades and bdelloid rotifers were
described to be able to cope with a wide range of physical
extremes besides desiccation and freezing, such as UV radia­
Box 10.8 Section Highlights
Since their discovery by Antonie van Leeuwenhoek in
1702, bdelloid rotifers and tardigrades have remained
intriguing organisms. Their tolerance to desiccation at
any stage of their life and their ability to survive a vari­
ety of stresses (e.g., low and high temperatures,
absence of oxygen, vacuum, high level of ionizing
radiation, etc.), makes them good candidates to study
extreme resistance mechanisms in the context of space
research. Tardigrades have a long history of space
astrobiology experiments being among the first ani­
mals exposed to space vacuum and radiation. Recent
experiments performed onboard of the ISS used bdel­
loid rotifers and tardigrades to study the adaptation to
microgravity and cosmic radiation during spaceflight.
Box 10.9 Desiccation or Drought Tolerance?
Desiccation tolerance must be differentiated from
drought tolerance. Many organisms are able to tolerate
drought as a reduction in water availability in the envi­
ronment for longer or shorter times. However, a
reduced number is able to survive a loss of 90% or
more of their body water content. Complete desicca­
tion is reached when the water content decreases below
10% of the dried mass, not enough to form a mono­
layer around macromolecules, preventing enzymatic
reactions and therefore metabolism.
10 Space Radiobiology"
"Bdelloid rotifers and tardigrades exhibit remarkable tolerance to various environmental stressors, including radiation. Explain the key differences in their observed radioresistance between hydrated and desiccated states, referencing specific dose levels and reproductive outcomes.","Bdelloid rotifers and tardigrades demonstrate significantly different levels of radioresistance depending on whether they are hydrated or desiccated. Hydrated bdelloids, such as *Adineta vaga* and *Philodina roseola*, exhibit a notable sensitivity to ionizing radiation, with a Lethal Dose 50 (LD50) ranging from approximately 2 to 6 Gray (Gy) after X-ray irradiation. Importantly, these hydrated rotifers can survive up to 1200 Gy of gamma radiation while maintaining fecundity and fertility. However, their survival is limited by the damaging effects of radiation on cellular processes. In contrast, desiccated bdelloid rotifers demonstrate substantially higher radioresistance. They have been shown to survive doses exceeding 5000 Gy of X-ray and proton radiation, a level far surpassing the LD50 of mammalian cells. Furthermore, these desiccated organisms retain their ability to reproduce even after exposure to such high doses. Conversely, tardigrades display an even greater tolerance to high-LET radiation. The LD50 for *Richtersius coronifer* was approximately 10,000 Gy, and desiccation further enhances this resistance, with some species surviving up to 6000 Gy of X-ray or gamma radiation. However, unlike bdelloids, desiccated tardigrades typically lose their ability to produce fertile eggs after exposure to even relatively low doses of radiation (e.g., >100 Gy), highlighting a critical difference in their response to ionizing radiation compared to the rotifers.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.3	 Tiny and Extremely Resistant: Why Bdelloid Rotifers and Tardigrades Are Animal Model Systems for Space Exploration? | Sub-sub-subsection: 10.6.3.1	 Bdelloids and Tardigrades, Small Animals to Study Desiccation, Radiation Tolerance and Limit of Life | Content: perature, were successfully rehydrated confirming their des­
iccation resistance for periods [315] [316]. While being
frozen, these animals were shown to survive over 30 years
of desiccation [317]. Bdelloid rotifers have also been shown
to survive long periods of desiccation, up to 9 years [318].
As for tardigrades, cold temperatures seem to extend the
capacity of desiccated bdelloids to cope with the long dura­
tion of metabolic arrest. In a recent publication by Shmakova
et al. bdelloid rotifer specimens were recovered from frozen
permafrost soil 24,000 years old [319]. If no data are still
available for tardigrades, studying old permafrost samples
may reveal other records of small animals’ life preservation.
For example, some nematodes were described to success­
fully recover after melting from 30 to 40,000 years old sam­
ples [320].
Mostly found in habitats where physical parameters can
change unpredictably, tardigrades and bdelloid rotifers were
described to be able to cope with a wide range of physical
extremes besides desiccation and freezing, such as UV radia­
Box 10.8 Section Highlights
Since their discovery by Antonie van Leeuwenhoek in
1702, bdelloid rotifers and tardigrades have remained
intriguing organisms. Their tolerance to desiccation at
any stage of their life and their ability to survive a vari­
ety of stresses (e.g., low and high temperatures,
absence of oxygen, vacuum, high level of ionizing
radiation, etc.), makes them good candidates to study
extreme resistance mechanisms in the context of space
research. Tardigrades have a long history of space
astrobiology experiments being among the first ani­
mals exposed to space vacuum and radiation. Recent
experiments performed onboard of the ISS used bdel­
loid rotifers and tardigrades to study the adaptation to
microgravity and cosmic radiation during spaceflight.
Box 10.9 Desiccation or Drought Tolerance?
Desiccation tolerance must be differentiated from
drought tolerance. Many organisms are able to tolerate
drought as a reduction in water availability in the envi­
ronment for longer or shorter times. However, a
reduced number is able to survive a loss of 90% or
more of their body water content. Complete desicca­
tion is reached when the water content decreases below
10% of the dried mass, not enough to form a mono­
layer around macromolecules, preventing enzymatic
reactions and therefore metabolism.
10 Space Radiobiology
538
F
i
g
.
10.18
Fig. 10.18 Morphology of adult tardigrades and eggs. (a, b) Lateral
and dorsal views of Echiniscus testudo. (c) Dorsal view of
Paramacrobiotus areolatus. (d, e) Global morphology of eggs laid by
Macrobiotus kamilae and P. areolatus. Pictures were captured using
scanning electron microscopy. (Illustration kindly provided by Daniel
Stec and reprinted with his permission)Fig. 10.17
Fig. 10.17 Overview of the bdelloid rotifer Adineta vaga life cycle.
Bdelloid rotifers live in limno-terrestrial habitats like mosses and
lichens. Adapted to these environments, they can be desiccated at any
stage of their life cycles including egg stage. When they are exposed
to desiccation, adults adopt a “tun” shape allowing optimal desiccation
resistance. Adineta vaga is about 200–250 μm long. (Credits
B. Hespeels)
C. E. Hellweg et al.
539
tion, high temperatures (exceeding 100 °C for a few min­
utes), high pressure or deep space vacuum [317, 321–327].
Among others, bdelloid rotifers and tardigrades were
described to be highly resistant to low- and high-LET [328]
radiation. In 2008, it was demonstrated for the first time that
two bdelloid rotifer species, A. vaga and Philodina roseola,
were resistant to ionizing radiation while being hydrated,
surviving up to 1200 Gy of gamma radiation with fecundity
(i.e., the total number of daughters produced by irradiated
animals) and fertility (i.e., the capacity to produce at least
one daughter) showing a dose response [329]. Later, it was
demonstrated that desiccated bdelloid rotifers survive doses
>5000 Gy of X-ray and proton radiation. These levels of
radiation exposure were contrasting the Lethal Dose 50
(LD50) (i.e., dose required to kill 50% of the irradiated pop­
ulation) of mammalian cells which range from 2 to 6 Gy
after X-ray irradiation. Similarly, desiccation-resistant tardi­
grades were described to survive high dose of X-ray and
gamma ray (LD50 ranging between 3000 and 6000 Gy)
(reviewed in [322]). Unexpectedly, radio-resistance of
hydrated and desiccated tardigrades appeared to be more tol­
erant to high-LET radiation. For example [330], LD50 of the
eutardigrade Richtersius coronifer was approx. 10,000 Gy. A
major difference in comparison with bdelloid rotifers was
that, despite a high survival after irradiation, most tardi­
grades were unable to produce fertile eggs for doses >100 Gy
[322]. As an example, the tardigrade Hypsibius dujardini
treated with gamma radiation had an estimated LD50/48 h
for survival of ∼4200 Gy, and doses above 100 Gy dramati­
cally impaired the production and hatching of laid eggs
[331].
10.6.3.2"
"Why are bdelloid rotifers and tardigrades considered potentially valuable animal models for space research, specifically in the context of studying radiation effects?","Bdelloid rotifers and tardigrades are being investigated as animal models for space research due to a combination of factors that simplify complex biological investigations. These include their Metazoan complexity – possessing tissues and organs yet remaining relatively simple organisms with approximately 1000 cells compared to the millions in humans, facilitating easier analysis; miniaturization allowing experiments with numerous individuals within small vessels; ease of cultivation under controlled conditions; short life cycles for reasonable study periods; parthenogenetic reproduction which reduces biological variability; extremotolerance – demonstrated resistance to DNA double-strand breaks and various stressors encountered during spaceflight; storage capabilities due to desiccation and freezing survival; and the correlation between desiccated states with increased stress resistance, including vacuum and extreme temperatures. Their ability to withstand radiation damage is particularly relevant for understanding adaptation to space environments and potentially enhancing radio-resistance.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.3	 Tiny and Extremely Resistant: Why Bdelloid Rotifers and Tardigrades Are Animal Model Systems for Space Exploration? | Sub-sub-subsection: 10.6.3.2	 Small Animals and Space Research | Content: As an alternative to other animal models, the use of rotifers
and tardigrades was proposed for space research. Indeed,
these animals may contribute to better understanding dam­
age and consequences induced by exposure to radiation and/
or microgravity. How these organisms may respond and
adapt to these stresses pave the road to the discovery of new
molecules or candidate genes. Ultimately research outputs
may be used to improve health span and protect astronauts or
individuals subjected to radiation during space flights or
medical treatments.
The use of rotifers and tardigrades as space research mod­
els was proposed because of the following aspects. (1)
Complexity: they are Metazoans (multicellular animals),
containing tissues and organs, having a complete gut and a
complex muscular structure, yet being very simple animals.
Rotifers and tardigrades are however made up of about 1000
cells, while a human is made up of several millions of cells.
This simplification allows to disentangle complex problems
through easier approaches. (2) Miniaturization: rotifers and
tardigrades are small; experiments performed with numerous
individuals require small vessels. (3) Distribution: rotifers
and tardigrades are readily found in nature and are easily cul­
tivated under controlled conditions. (4) Life span: rotifers
and tardigrades have short life cycles that can be studied in a
reasonable time period. (5) Reproductive mode: all bdelloid
rotifers and some tardigrade species reproduce parthenoge­
netically. This reproduction system offers two key advan­
tages: a rapid expansion of the population, and a high degree
of reliability, as the genome is fully transmitted to the off­
spring. Therefore, the use of clonal lines reduces the biologi­
cal variability noise in biological experiments. (6)
Extremotolerance: both bdelloid rotifers and tardigrades
were described to be able to deal with a high number of DNA
DSBs and various stressors encountered by astronauts during
space flight. Small extremotolerant animals can provide new
perspectives in the adaptation of life to the space environ­
ment and ultimately lead to enhancing radio-resistance. For
both clades, radiation resistance and radiation-sensitive spe­
cies can be used in comparative experiments. (7) Storage: as
most tardigrades and bdelloids survive desiccation and freez­
ing, they can be stored easily before and after scientific
experiments with limited impact on their biology and the
scientific output. (8) Desiccation resistance: the desiccated
state of tardigrades and bdelloid rotifers correlates with
increased resistance to stresses, including deep space vac­
uum and extreme temperatures. These multiple properties
and advantages for space experiments make bdelloid rotifers
and tardigrades good candidates to test the limits of life dur­
ing space exposure. An overview of space experiments
involving tardigrades and rotifers is presented in the next two
sub-sections.
10.6.3.3
Tardigrades, Pioneer Animals
of Astrobiology Field
In September 2007, tardigrades were exposed to LEO within
the Biopan-6 experimental platform provided by the
European Space Agency (ESA) (“Tardigrades in Space,”
TARDIS. FOTON-M3 mission). During 10 days at LEO
(258–281 km above sea level) samples of desiccated adult
eutardigrades of the species Richtersius coronifer, Milnesium
tardigradum, Echiniscus testudo, and Ramazzottius ober­
haeuseri were exposed to space vacuum, cosmic radiations,
and two different UV-radiation spectral ranges [323]. It was
demonstrated that tardigrades were able to survive space
vacuum and cosmic radiation with a survival rate ranging
between 70% and 80%. Any impact on the reproductive
capacities of exposed animals was reported. However, sam­
ples exposed to full solar radiation experienced high mortal­
ity. A small fraction of survivors died a few days
post-rehydration without the production of any viable off­
spring. By filtering UV and restricting the exposure of desic­
cated tardigrades only to UVA and UVB, a significant part of
desiccated tardigrades was able to be reactivated and was
10 Space Radiobiology"
"Bdelloid rotifers and tardigrades are frequently utilized as animal model systems for space exploration due to several key characteristics. Describe at least four of these advantages, focusing on factors related to their biology that contribute to their suitability for studying the effects of extreme environments like those encountered during spaceflight.","Bdelloid rotifers and tardigrades are valuable model organisms for investigating the impacts of space radiation and other stressors due to a confluence of biological attributes. Firstly, their diminutive size – typically less than 1mm – allows for experiments utilizing relatively small vessel volumes, simplifying logistical constraints when conducting studies with numerous individuals. Secondly, these animals exhibit a rapid reproductive mode, specifically parthenogenesis in bdelloid rotifers and parthenogenetic reproduction in some tardigrade species. This system generates clonal lines, minimizing biological variability within experimental populations and enhancing the reliability of data analysis. Thirdly, both groups demonstrate remarkable extremotolerance; they have been shown to withstand significant DNA double-strand breaks (DSBs) and other stressors commonly associated with space radiation exposure. Finally, their ability to survive desiccation and freezing provides a practical advantage for storage before and after experiments, reducing potential biological alterations due to handling or environmental conditions. These combined characteristics make them ideal candidates for assessing adaptation mechanisms in extreme environments like those found during space exploration. Reference: [MolecularRadiationBiology, Section 10.6.3.3 – Tardigrades, Pioneer Animals of Astrobiology Field]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.3	 Tiny and Extremely Resistant: Why Bdelloid Rotifers and Tardigrades Are Animal Model Systems for Space Exploration? | Sub-sub-subsection: 10.6.3.3	 Tardigrades, Pioneer Animals of Astrobiology Field | Content: cells, while a human is made up of several millions of cells.
This simplification allows to disentangle complex problems
through easier approaches. (2) Miniaturization: rotifers and
tardigrades are small; experiments performed with numerous
individuals require small vessels. (3) Distribution: rotifers
and tardigrades are readily found in nature and are easily cul­
tivated under controlled conditions. (4) Life span: rotifers
and tardigrades have short life cycles that can be studied in a
reasonable time period. (5) Reproductive mode: all bdelloid
rotifers and some tardigrade species reproduce parthenoge­
netically. This reproduction system offers two key advan­
tages: a rapid expansion of the population, and a high degree
of reliability, as the genome is fully transmitted to the off­
spring. Therefore, the use of clonal lines reduces the biologi­
cal variability noise in biological experiments. (6)
Extremotolerance: both bdelloid rotifers and tardigrades
were described to be able to deal with a high number of DNA
DSBs and various stressors encountered by astronauts during
space flight. Small extremotolerant animals can provide new
perspectives in the adaptation of life to the space environ­
ment and ultimately lead to enhancing radio-resistance. For
both clades, radiation resistance and radiation-sensitive spe­
cies can be used in comparative experiments. (7) Storage: as
most tardigrades and bdelloids survive desiccation and freez­
ing, they can be stored easily before and after scientific
experiments with limited impact on their biology and the
scientific output. (8) Desiccation resistance: the desiccated
state of tardigrades and bdelloid rotifers correlates with
increased resistance to stresses, including deep space vac­
uum and extreme temperatures. These multiple properties
and advantages for space experiments make bdelloid rotifers
and tardigrades good candidates to test the limits of life dur­
ing space exposure. An overview of space experiments
involving tardigrades and rotifers is presented in the next two
sub-sections.
10.6.3.3
Tardigrades, Pioneer Animals
of Astrobiology Field
In September 2007, tardigrades were exposed to LEO within
the Biopan-6 experimental platform provided by the
European Space Agency (ESA) (“Tardigrades in Space,”
TARDIS. FOTON-M3 mission). During 10 days at LEO
(258–281 km above sea level) samples of desiccated adult
eutardigrades of the species Richtersius coronifer, Milnesium
tardigradum, Echiniscus testudo, and Ramazzottius ober­
haeuseri were exposed to space vacuum, cosmic radiations,
and two different UV-radiation spectral ranges [323]. It was
demonstrated that tardigrades were able to survive space
vacuum and cosmic radiation with a survival rate ranging
between 70% and 80%. Any impact on the reproductive
capacities of exposed animals was reported. However, sam­
ples exposed to full solar radiation experienced high mortal­
ity. A small fraction of survivors died a few days
post-rehydration without the production of any viable off­
spring. By filtering UV and restricting the exposure of desic­
cated tardigrades only to UVA and UVB, a significant part of
desiccated tardigrades was able to be reactivated and was
10 Space Radiobiology
540
able to reproduce. Since the fertility of descendant genera­
tions of M. tardigradum was not impacted, it was suggested
that survivors were able to repair a priori the damages
induced by the spaceflight and did not transfer them to future
generations [332].
10.19
­
­
333
­
­
­
­
A few years later, the TARDIKISS experiments
(Tardigrades In Space) were launched with the last Space
Shuttle mission (STS-134 2011) [334]. During this 16-days
mission, the enzyme activity of key antioxidants was investi­
gated in desiccated tardigrades from the two species
Paramacrobiotus richtersi and Ramazzottius oberhaeuseri
[334]. Supporting the idea that desiccated animals were
weakly affected by microgravity and cosmic radiation, com­
parative data analysis between flight and ground samples
showed no significant differences in the enzymatic activity
of antioxidants.
In June 2021, a fifth experiment was launched onboard
of the ISS to investigate the short-term and multigenera­
tional survival of tardigrades. The aim of the Cell Science-04
experiment (CS-04) was to evaluate the transcriptomic
response of hydrated tardigrades cultured on the ISS using
a dedicated cell culture system (Bioculture System, devel­
oped at NASA Ames Research Center). For this experi­
ment, the tardigrade Hypsibius exemplaris was used as
model species. Scientists are currently evaluating the abil­
ity of these animals to survive onboard of ISS for short and
long periods of time (up to four generations). In parallel,
the transcriptomic responses of these animals are being
investigated to follow the evolution of the expression pro­
files of tardigrades in a microgravity environment. A pro­
gressive adaptation of tardigrades onboard of ISS may lead
to a better understanding of the molecular responses
involved in gravity sensing and will help expand research
to secure astronaut’s health for future space missions.
Among others, tardigrades were described to express sev­
eral antioxidant proteins to face desiccation and radiation
stresses [322, 335]. In particular, tardigrades were described
to express specific proteins binding to DNA and protecting
their genome from ROS induced by desiccation and ioniz­
ing radiation [336, 337].
10.6.3.4
Bdelloid Rotifers, a New Model Species
for Space exploration
How microgravity and cosmic radiation may affect desic­
cated bdelloid rotifers was tested for the first time in 1997.
F
ig. 10.19
Fig. 10.19 View of TARDIS experiment. (a) View of the exobiology
Biopan platform containing TARDIS experiment. For 12 days in
September 2007, approximately 3000 water bears were launched in
space during the Foton-M3 mission. Reprinted with permission from
ESA. (b) Details of the sample holder containing the tardigrades
Richtersius coronifer. Tardigrades on the top level were exposed to the
Sun and were optionally protected with filters. (Image kindly provided
by K. Ingemar Jönsson and reprinted with his permission)
C. E. Hellweg et al."
"Bdelloid rotifers were initially investigated as a model organism for studying the effects of spaceflight due to their apparent resilience to microgravity and cosmic radiation. Specifically, research focused on whether these organisms could complete their embryological development under altered gravitational conditions, such as 20 g or simulated microgravity (0.0001 g). What was the primary focus of early experiments involving desiccated bdelloid rotifers in space, and what specific environmental condition was being tested to assess their developmental capacity?","Early experiments with desiccated bdelloid rotifers in space primarily focused on determining if these organisms could complete their embryological development under altered gravitational conditions. Specifically, researchers investigated the rotifer’s ability to continue developing despite changes in g-force, initially testing both 20 g and simulated microgravity (0.0001 g) using a 3D random positioning machine (3DRPM). The goal was to understand how these forces impacted early embryo development. Reference: [MolecularRadiationBiology, Section 10.6.3.4 – Bdelloid Rotifers, a New Model Species for Space exploration]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.6	 Small Animal Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.6.3	 Tiny and Extremely Resistant: Why Bdelloid Rotifers and Tardigrades Are Animal Model Systems for Space Exploration? | Sub-sub-subsection: 10.6.3.4	 Bdelloid Rotifers, a New Model Species for Space exploration | Content: Bdelloid Rotifers, a New Model Species
for Space exploration
How microgravity and cosmic radiation may affect desic­
cated bdelloid rotifers was tested for the first time in 1997.
F
ig. 10.19
Fig. 10.19 View of TARDIS experiment. (a) View of the exobiology
Biopan platform containing TARDIS experiment. For 12 days in
September 2007, approximately 3000 water bears were launched in
space during the Foton-M3 mission. Reprinted with permission from
ESA. (b) Details of the sample holder containing the tardigrades
Richtersius coronifer. Tardigrades on the top level were exposed to the
Sun and were optionally protected with filters. (Image kindly provided
by K. Ingemar Jönsson and reprinted with his permission)
C. E. Hellweg et al.
541
For their first exposure to space, dry samples of Macrotrachela
quadricornifera were transported onboard of the space shut­
tle STS-81 for a total of 10 days. The data revealed a similar
survival rate and reproductive fitness for ground controls and
flight samples [312]. Since desiccated rotifers appeared to be
protected from the impact of microgravity and cosmic radia­
tion, at least in this short-term exposure experiment, research­
ers started to investigate the consequences of space flight on
hydrated bdelloids. In absence of gravity, it has been hypoth­
esized that the distribution of cytoskeletal elements or yolk
granules in the egg cytoplasm is impacted. This abnormal
organization of the cytoskeleton could impact the rotifer
reproduction. Therefore, researchers first investigate the
capacity of bdelloid rotifers to complete their embryological
development under microgravity was initially investigated.
Pre-flight experiments were performed under hyper-gravity
environment (up to 20 g) and under simulated microgravity
(as low as 0.0001 g) using a 3D random positioning machine
(3DRPM). Results showed that the rotifer development
remained constant regardless of the treatment experienced,
except for some minor modifications in early embryos expe­
riencing 20 g with no subsequent impact on the develop­
ment. This first investigation suggests that bdelloid rotifers
continue embryological development despite changes in
g-force. Unfortunately, no data from flight experiment devel­
opment associated with embryological development of bdel­
loid rotifers exposed to space environment was released
post-flight.
­
­
­
10.20
­Fig. 10.20
Fig. 10.20 View of Rob1
hardware used to culture hydrated
A. vaga individuals onboard of
ISS (December 2019). Top left:
Rob1 hardware after its assembly
at the launch site at Kennedy
Space Center. Rob1 hardware is a
passive hardware containing five
culture bags containing hydrated
specimens of A. vaga. Hardware
enables gas exchanges between
rotifer cultures and the outside
through a permeable membrane.
Top right: View of the culture
bags assembled inside Rob1
hardware. Culture bags, loaded
with 10,000 A. vaga individuals
each, are made of Teflon and
ensure an optimal gas exchange
between the culture medium and
the outside. Bags are waterproof
and avoid any leakage of the
medium (composed of mineral
water and sterile lettuce juice) or
rotifers. Reprinted with permis­
sion of Marc Guillaume. Bottom
left: View of ESA astronaut Luca
Parmitano loading two Rob1
hardware on KUBIK. KUBIK is a
small incubator, temperature-
controlled, with removable inserts
designed for self-contained
microgravity experiments.
(Reprinted with permission of
NASA)
10 Space Radiobiology
542Fig. 10.21
Fig. 10.21 View of one Rob2 hardware used onboard of the ISS (left)
and Astronauts checking the correct rehydration of A. vaga individuals.
Sixteen pieces of hardware were sent to ISS, each containing 40,000
dry rotifers. Once onboard, rotifers were automatically rehydrated and
cultivated 11 days before their fixation and download to Earth.
(Reprinted with permission of Boris Hespeels and NASA)
confirmed the successful maintenance of hydrated bdelloid
individuals on ISS, without additional food or oxygen supply
and without astronaut intervention. All the replicates (ten) of
the autonomous A.vaga cultures survived and reproduced on
ISS with no visible impact on the morphology in space-
exposed samples.
­
163
­
207215338
­
209
­
10.21
­
­
In general, the ongoing rotifer space experiments will
contribute to a better understanding of the mechanisms
involved in the protection and repair of damages induced by
radiation. They pave the road to the discovery of new mole­
cules or candidate genes that could ultimately be used to
improve health span and protect astronauts or individuals
subjected to radiation during space flights or medical treat­
ments. This research is also of fundamental importance for
the understanding of extreme biology and the questions
raised on the origin of life and its ability to spread through
outer space. A third experiment, supported by ESA, is under
preparation to evaluate whether rotifers can survive full
space exposure, outside ISS, as was previously reported for
tardigrades.
C. E. Hellweg et al.
543
10.7
Plant Experimental Models
and Biological Changes of Space
Radiation
10.7.1	Plants vs. Animal Models
Long space exploration missions, settlement on orbital sta­
tions, or future planetary settlement (e.g., on Mars) will require
further development of Life Support Systems (LSS). The LSS
are able to regenerate a great amount of essential resources for
survival and represent an ideal solution since it is not techni­
cally and economically feasible in long space missions to
transport a large amount of consumables from the Earth [339–
341]. Bioregenerative Life Support Systems (BLSS) are an
artificial closed ecosystem characterized by the same structure
as a terrestrial ecosystem: producers (plants), consumers
(humans/animals), and decomposers (microorganisms).
Among biological components within BLSS, higher
plants would have the same role on Earth as producers.
Through photosynthesis, plants would utilize carbon dioxide
produced by space crew and provide oxygen and fresh food.
Moreover, they would use nutrients derived from human
wastes and guarantee water purification by transpiration.
Furthermore, plant cultivation in space also would provide
psychological support against isolation [342, 343].
Each organism in Space is subjected to several factors
which are potential constraints for biological life. Among the
environmental factors (e.g., altered gravity, interaction
between microgravity and fluid-dynamics, modified condi­
tions of pressure, temperature, confinement, etc.) limiting
plant growth in space, ionizing radiation influences severely
the development of organisms at molecular, morpho-struc­
tural, and physiological levels [163, 182, 344]. Indeed, ion­
izing radiation is considered one of the main constraints for
the long permanence of humans in Space.
All organisms in extraterrestrial environments are subject
to higher levels of ionizing radiation than on Earth and, not­
withstanding the large number of studies aimed at under­
standing the effect of ionizing radiation on animals, the
knowledge on plant reaction is limited. Available informa­
tion is limited to horticultural model crops which are candi­
date for fresh food production in BLSS. Moreover, most
experiments are based on the irradiation of dry seeds and
data from irradiation tests using other biological models
(e.g., seedlings, adult plants, actively growing tissues) are
scanty.
10.22
­Fig. 10.22
Fig. 10.22 A comparison
among different responses of
Plants (P) and Mammals (M) to
ionizing radiation. (Reprinted
with permission from Arena et al.
[346])
10 Space Radiobiology"
"Describe the potential biological changes observed in plant experimental models exposed to ionizing radiation, and explain why these changes might occur at a cellular level considering the nature of this type of radiation.","Exposure to ionizing radiation can induce a variety of significant biological alterations in plants. Commonly reported effects include morphological changes such as stunted growth, altered leaf development (e.g., chlorosis – yellowing due to chlorophyll loss), and increased sensitivity to environmental stresses like drought or heat. At the cellular level, these changes stem from the direct and indirect damage caused by the high-energy particles produced by ionizing radiation. Ionizing radiation possesses sufficient energy to directly break chemical bonds within DNA, RNA, and proteins, leading to mutations and strand breaks. Furthermore, the radiation generates secondary free radicals – highly reactive molecules like hydroxyl radicals (•OH) – through interactions with water molecules. These free radicals initiate a cascade of oxidative damage, targeting lipids, proteins, and nucleic acids. Specifically, DNA is particularly vulnerable due to its structural features; the double helix structure makes it susceptible to strand scission, while modifications to base pairs can disrupt replication and transcription processes. Protein denaturation occurs as radiation disrupts the weak bonds that maintain their three-dimensional conformation, impairing enzymatic function and cellular stability. Lipid peroxidation, initiated by free radicals, damages cell membranes, compromising membrane integrity and permeability. The cumulative effect of these diverse damage pathways ultimately manifests as the observed physiological symptoms in plants – reduced growth, altered metabolism, and increased vulnerability to stress.

Reference: [Unknown - This response synthesizes general knowledge regarding ionizing radiation effects on biological systems; a specific reference for plant radiobiology would require further contextual information.]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.7	 Plant Experimental Models and Biological Changes of Space Radiation | Content: Plants (P) and Mammals (M) to
ionizing radiation. (Reprinted
with permission from Arena et al.
[346])
10 Space Radiobiology"
"Describe the potential role of plants within a Bioregenerative Life Support System (BLSS), specifically focusing on their contribution to resource regeneration and psychological well-being.","Within a Bioregenerative Life Support System (BLSS), plants are envisioned as producers, mirroring their function on Earth. Through photosynthesis, they would utilize carbon dioxide exhaled by the space crew, converting it into oxygen and generating fresh food. Crucially, plants could also process human waste products – nutrients derived from urine and feces – effectively purifying water through transpiration. Beyond these practical benefits, plant cultivation within a BLSS is considered vital for psychological support, mitigating the negative effects of isolation often experienced during long-duration space missions. The presence of living vegetation provides a familiar and potentially restorative environment, contributing to crew morale and well-being. Furthermore, plants are expected to contribute to a more balanced ecosystem mimicking terrestrial conditions.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.7	 Plant Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.7.1	 Plants vs. Animal Models | Content: Long space exploration missions, settlement on orbital sta­
tions, or future planetary settlement (e.g., on Mars) will require
further development of Life Support Systems (LSS). The LSS
are able to regenerate a great amount of essential resources for
survival and represent an ideal solution since it is not techni­
cally and economically feasible in long space missions to
transport a large amount of consumables from the Earth [339–
341]. Bioregenerative Life Support Systems (BLSS) are an
artificial closed ecosystem characterized by the same structure
as a terrestrial ecosystem: producers (plants), consumers
(humans/animals), and decomposers (microorganisms).
Among biological components within BLSS, higher
plants would have the same role on Earth as producers.
Through photosynthesis, plants would utilize carbon dioxide
produced by space crew and provide oxygen and fresh food.
Moreover, they would use nutrients derived from human
wastes and guarantee water purification by transpiration.
Furthermore, plant cultivation in space also would provide
psychological support against isolation [342, 343].
Each organism in Space is subjected to several factors
which are potential constraints for biological life. Among the
environmental factors (e.g., altered gravity, interaction
between microgravity and fluid-dynamics, modified condi­
tions of pressure, temperature, confinement, etc.) limiting
plant growth in space, ionizing radiation influences severely
the development of organisms at molecular, morpho-struc­
tural, and physiological levels [163, 182, 344]. Indeed, ion­
izing radiation is considered one of the main constraints for
the long permanence of humans in Space.
All organisms in extraterrestrial environments are subject
to higher levels of ionizing radiation than on Earth and, not­
withstanding the large number of studies aimed at under­
standing the effect of ionizing radiation on animals, the
knowledge on plant reaction is limited. Available informa­
tion is limited to horticultural model crops which are candi­
date for fresh food production in BLSS. Moreover, most
experiments are based on the irradiation of dry seeds and
data from irradiation tests using other biological models
(e.g., seedlings, adult plants, actively growing tissues) are
scanty.
10.22
­Fig. 10.22
Fig. 10.22 A comparison
among different responses of
Plants (P) and Mammals (M) to
ionizing radiation. (Reprinted
with permission from Arena et al.
[346])
10 Space Radiobiology
544
ment, and reproduction, ranging from detrimental outcomes
at high doses, harmful consequences at intermediate levels,
and stimulatory effects at very low doses. This phenomenon
is called “hormesis.” Particularly, low doses of ionizing radi­
ation have been reported to stimulate seed germination and
root growth [345, 346].
However, ionizing radiation can also induce dwarf growth
that is a desirable trait under conditions of limited volume
availability in missions on orbital stations or during explora­
tion traveling. The increased radioresistance of plants is still
a debated issue since it can be associated with a genetic
basis, but it can also reflect biochemical and biomolecular
mechanisms of shelter from genotoxic damage.
The severity of the effects of ionizing radiation on plants
is dependent upon several factors including radiation-related
parameters (e.g., dose, LET) and organism-related traits
(e.g., species, cultivar, physiological status, and structural
properties, as well as plant genome organization including
the polyploidy) [345, 347]."
"The text describes several ways plants respond to ionizing radiation affecting photosynthesis. Specifically, what two types of changes were observed in leaf tissues of plants exposed to high doses of X-rays regarding antioxidant defenses?","In plants exposed to very high doses of X-rays (50 and 100 Gy), the text observes a decrease in the total antioxidant pool and alterations in the distribution of phenolic compounds within leaf tissues. Reference: [MolecularRadiationBiology, Section 10.7.2 Biological Changes from Genetics to Organogenesis]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.7	 Plant Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.7.2	 Biological Changes from Genetics to Organogenesis | Content: to Organogenesis
In adult plants, in the case of organs at complete develop­
ment, resistance to stressors can be often ascribed to inte­
grated
mechanisms
of
adaptation
operating
at
morpho-structural and eco-physiological levels since the
limits of major metabolic and physiological processes are
dictated by the plant’s structure [348, 349]. Growth, repro­
duction, and, ultimately, survival of plants in Space depend
on photosynthesis which is strongly responsive to ionizing
radiation acting on the various components of the photosyn­
thetic apparatus, such as pigment–protein complexes respon­
sible for light absorption, electron transport carriers, and
enzymes of carbon reduction cycle [345]. Ionizing radiation
leads to several detrimental effects in photosynthetic appara­
tus, such as loss of functionality of photosystem II (PSII) and
generation of free radicals causing photosynthetic mem­
branes’ oxidation [350–352]. Changes in the total antioxi­
dant pool and in the distribution of phenolic compounds in
leaf tissues were observed in plants exposed to very high
doses of X-rays, namely 50 and 100 Gy [353].
However, chronic exposure to low doses of ionizing radi­
ation seems to enhance the activity of some antioxidant
enzymes, providing plants with a radio-resistance [354,
355]. Moreover, the degree of plasticity of leaf cytological
and anatomical traits in response to environmental changes
can be responsible for enhancing or constraining processes
such as light interception and gas exchanges, definitely
affecting photosynthesis. Similarly, the correct functioning
of the whole water transport system throughout the plant is
responsible for water supply up to the leaves, necessary for
efficient photosynthesis. The ability of xylem to transport
water efficiently depends on the morphological features of
its conduits and on the ultra-structural properties of conduit
cell walls, whose main components can be differently
affected by ionizing radiation.
Apart from a few findings mainly related to specific ultra-
structural modifications occurring on irradiated seeds, the
effect of cosmic radiation on organ/tissue organization, espe­
cially in relationship with eco-physiological traits, is still
poorly explored. Moreover, most of the studies regard exper­
iments with low-LET ionizing radiation [346, 355], and only
a few data are available on the effects of chronic radiation
exposure on plants in general, mainly deriving from nuclear
accidents as Chernobyl in Ukraine (1986) and Fukushima in
Japan (2011).
10.8
Eukaryotic Cell Experimental Models
and Biological Changes of Space
Radiation
10.8.1	Definition of Eukaryotes
Regarding the complexity of their cells, all living organisms
can be classified into two groups-prokaryotes and eukary­
otes. Compared to prokaryotes, eukaryotic cells are highly
organized and contain a cell nucleus. Prokaryotes are bacte­
ria and archaea, while protists, plants (see Sect. 10.5.8), ani­
mals (see Sect. 10.5.7), and fungi (see Sect. 10.5.9) are
eukaryotes.
In the following the effect of space radiation on in vitro
models (conducted in a cell culture dish) and ex vivo models
(experiments outside a living body) will be described.
10.8.2	Definition of In Vitro Models
In vitro models used in science, are very important, as they
provide insight into cells. With this, the function of primary
cells and cell lines of various origin (vertebrates including
human, insects, and mussels) can be studied.
10.8.3	Definition of Ex Vivo Models
Ex vivo models or tissue explants allow studying complex
functions and interactions of different cells within an organ.
For these experiments, the living tissues are directly removed
from a living organism or can be generated by means of plu­
ripotent stem cells and cultivated under controlled
conditions.
C. E. Hellweg et al."
"How might ionizing radiation impact the water transport system within a plant, specifically concerning xylem function and leaf photosynthesis?","Ionizing radiation can significantly disrupt the efficiency of the plant's water transport system, primarily through its effects on the xylem conduits. The xylem is responsible for transporting water from the roots to the leaves – a critical process for photosynthesis. This disruption occurs due to alterations in the ultra-structural properties of conduit cell walls. Specifically, ionizing radiation can modify the primary components composing these cell walls, potentially weakening their integrity and reducing their ability to maintain proper hydraulic conductivity. Reduced xylem efficiency directly impacts water supply to the leaves, limiting the plant's capacity for photosynthesis. Consequently, photosynthetic rates are likely diminished as a result of impaired water transport and subsequent constraints on this vital biochemical process. Furthermore, changes in anatomical traits related to light interception and gas exchange, potentially triggered by radiation-induced stress, would exacerbate the negative effects on photosynthesis. The overall impact highlights the interconnectedness of plant physiological processes and the vulnerability of these systems to ionizing radiation exposure.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Content: and anatomical traits in response to environmental changes
can be responsible for enhancing or constraining processes
such as light interception and gas exchanges, definitely
affecting photosynthesis. Similarly, the correct functioning
of the whole water transport system throughout the plant is
responsible for water supply up to the leaves, necessary for
efficient photosynthesis. The ability of xylem to transport
water efficiently depends on the morphological features of
its conduits and on the ultra-structural properties of conduit
cell walls, whose main components can be differently
affected by ionizing radiation.
Apart from a few findings mainly related to specific ultra-
structural modifications occurring on irradiated seeds, the
effect of cosmic radiation on organ/tissue organization, espe­
cially in relationship with eco-physiological traits, is still
poorly explored. Moreover, most of the studies regard exper­
iments with low-LET ionizing radiation [346, 355], and only
a few data are available on the effects of chronic radiation
exposure on plants in general, mainly deriving from nuclear
accidents as Chernobyl in Ukraine (1986) and Fukushima in
Japan (2011).
10.8
Eukaryotic Cell Experimental Models
and Biological Changes of Space
Radiation"
"The text describes several key differences between prokaryotic and eukaryotic cells, highlighting the presence of a nucleus in eukaryotes. Beyond this fundamental distinction, what specific anatomical or structural features within plant cells are identified as potentially being affected by ionizing radiation, and how might these changes impact photosynthetic processes?","The passage emphasizes that eukaryotic cells, unlike prokaryotes (bacteria and archaea), possess a distinct cell nucleus. Within plants, the text specifically identifies the xylem’s water transport system – including its conduits and the ultra-structural properties of conduit cell walls – as being susceptible to changes due to ionizing radiation. These alterations in the xylem's components could impair its efficiency in transporting water upwards to the leaves. This reduced water supply directly impacts photosynthesis by limiting the plant's ability to effectively carry out this vital process, particularly considering the need for efficient water transport and light interception for optimal photosynthetic rates. The text notes that morphological features and ultra-structural properties of xylem conduits are key factors affected by radiation.
Reference: MolecularRadiationBiology, Section 10.8.1 – Definition of Eukaryotes","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.1	 Definition of Eukaryotes | Content: and anatomical traits in response to environmental changes
can be responsible for enhancing or constraining processes
such as light interception and gas exchanges, definitely
affecting photosynthesis. Similarly, the correct functioning
of the whole water transport system throughout the plant is
responsible for water supply up to the leaves, necessary for
efficient photosynthesis. The ability of xylem to transport
water efficiently depends on the morphological features of
its conduits and on the ultra-structural properties of conduit
cell walls, whose main components can be differently
affected by ionizing radiation.
Apart from a few findings mainly related to specific ultra-
structural modifications occurring on irradiated seeds, the
effect of cosmic radiation on organ/tissue organization, espe­
cially in relationship with eco-physiological traits, is still
poorly explored. Moreover, most of the studies regard exper­
iments with low-LET ionizing radiation [346, 355], and only
a few data are available on the effects of chronic radiation
exposure on plants in general, mainly deriving from nuclear
accidents as Chernobyl in Ukraine (1986) and Fukushima in
Japan (2011).
10.8
Eukaryotic Cell Experimental Models
and Biological Changes of Space
Radiation
10.8.1	Definition of Eukaryotes
Regarding the complexity of their cells, all living organisms
can be classified into two groups-prokaryotes and eukary­
otes. Compared to prokaryotes, eukaryotic cells are highly
organized and contain a cell nucleus. Prokaryotes are bacte­
ria and archaea, while protists, plants (see Sect. 10.5.8), ani­
mals (see Sect. 10.5.7), and fungi (see Sect. 10.5.9) are
eukaryotes.
In the following the effect of space radiation on in vitro
models (conducted in a cell culture dish) and ex vivo models
(experiments outside a living body) will be described."
"The text discusses the impact of ionizing radiation on plant systems, specifically relating to water transport and photosynthesis. Describe the key structural components involved in xylem’s function for efficient water transport, and how these components might be affected by space radiation according to the provided information.","According to the text, the efficiency of xylem's water transport relies heavily on both its morphological features – specifically the conduits within the xylem – and the ultra-structural properties of conduit cell walls. The main components of these cell walls are described as potentially being differentially affected by ionizing radiation. This suggests that changes in the composition or integrity of these cell wall components, likely due to radiation damage, could disrupt the normal functioning of the water transport system. Consequently, this disruption would negatively impact the plant’s ability to efficiently supply water to its leaves, ultimately hindering photosynthesis.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.2	 Definition of In Vitro Models | Content: and anatomical traits in response to environmental changes
can be responsible for enhancing or constraining processes
such as light interception and gas exchanges, definitely
affecting photosynthesis. Similarly, the correct functioning
of the whole water transport system throughout the plant is
responsible for water supply up to the leaves, necessary for
efficient photosynthesis. The ability of xylem to transport
water efficiently depends on the morphological features of
its conduits and on the ultra-structural properties of conduit
cell walls, whose main components can be differently
affected by ionizing radiation.
Apart from a few findings mainly related to specific ultra-
structural modifications occurring on irradiated seeds, the
effect of cosmic radiation on organ/tissue organization, espe­
cially in relationship with eco-physiological traits, is still
poorly explored. Moreover, most of the studies regard exper­
iments with low-LET ionizing radiation [346, 355], and only
a few data are available on the effects of chronic radiation
exposure on plants in general, mainly deriving from nuclear
accidents as Chernobyl in Ukraine (1986) and Fukushima in
Japan (2011).
10.8
Eukaryotic Cell Experimental Models
and Biological Changes of Space
Radiation
10.8.1	Definition of Eukaryotes
Regarding the complexity of their cells, all living organisms
can be classified into two groups-prokaryotes and eukary­
otes. Compared to prokaryotes, eukaryotic cells are highly
organized and contain a cell nucleus. Prokaryotes are bacte­
ria and archaea, while protists, plants (see Sect. 10.5.8), ani­
mals (see Sect. 10.5.7), and fungi (see Sect. 10.5.9) are
eukaryotes.
In the following the effect of space radiation on in vitro
models (conducted in a cell culture dish) and ex vivo models
(experiments outside a living body) will be described.
10.8.2	Definition of In Vitro Models
In vitro models used in science, are very important, as they
provide insight into cells. With this, the function of primary
cells and cell lines of various origin (vertebrates including
human, insects, and mussels) can be studied."
"How does ionizing radiation potentially impact the water transport system within plants, as described in the text, and what specific cellular components are most vulnerable to these effects?","The text highlights that a plant's efficient water transport system – specifically the xylem – is critically dependent on both its morphological features (the size and structure of the conduits) and the ultra-structural properties of conduit cell walls. Ionizing radiation can disrupt the function of this system by affecting the main components of these cell walls, primarily through alterations to their structural integrity. This disruption can impair the xylem's ability to efficiently transport water from the roots to the leaves, which is essential for photosynthesis. The precise mechanisms are not detailed in the text, but it suggests that changes at the cellular level – specifically within the conduit cell walls – directly compromise this vital physiological process. Reference: MolecularRadiationBiology, Section 10.8.3 – Definition of Ex Vivo Models","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.3	 Definition of Ex Vivo Models | Content: and anatomical traits in response to environmental changes
can be responsible for enhancing or constraining processes
such as light interception and gas exchanges, definitely
affecting photosynthesis. Similarly, the correct functioning
of the whole water transport system throughout the plant is
responsible for water supply up to the leaves, necessary for
efficient photosynthesis. The ability of xylem to transport
water efficiently depends on the morphological features of
its conduits and on the ultra-structural properties of conduit
cell walls, whose main components can be differently
affected by ionizing radiation.
Apart from a few findings mainly related to specific ultra-
structural modifications occurring on irradiated seeds, the
effect of cosmic radiation on organ/tissue organization, espe­
cially in relationship with eco-physiological traits, is still
poorly explored. Moreover, most of the studies regard exper­
iments with low-LET ionizing radiation [346, 355], and only
a few data are available on the effects of chronic radiation
exposure on plants in general, mainly deriving from nuclear
accidents as Chernobyl in Ukraine (1986) and Fukushima in
Japan (2011).
10.8
Eukaryotic Cell Experimental Models
and Biological Changes of Space
Radiation
10.8.1	Definition of Eukaryotes
Regarding the complexity of their cells, all living organisms
can be classified into two groups-prokaryotes and eukary­
otes. Compared to prokaryotes, eukaryotic cells are highly
organized and contain a cell nucleus. Prokaryotes are bacte­
ria and archaea, while protists, plants (see Sect. 10.5.8), ani­
mals (see Sect. 10.5.7), and fungi (see Sect. 10.5.9) are
eukaryotes.
In the following the effect of space radiation on in vitro"
"Describe the key differences in cellular behavior observed when comparing monolayer cell cultures to three-dimensional (3D) cell culture models like organoids and spheroids, highlighting why 3D models are considered valuable for studying biological processes.","Monolayer cell cultures, typically grown on flat plastic or glass surfaces, present a significantly simplified representation of in vivo cellular environments. Cells in these cultures exhibit flattened morphologies, limited intercellular contact, and lack the natural extracellular matrix found surrounding cells within tissues. This fundamentally alters cellular metabolism and function, often leading to phenotypic changes such as impaired differentiation. Conversely, 3D cell culture models like organoids, spheroids, and slice cultures more accurately mimic the complex architecture and interactions present in native tissues. Organoids, derived from stem cells, recreate the physiological organization of human organs, facilitating studies of cellular heterogeneity, cell-matrix and cell-cell interactions, and morphological changes. Spheroids represent simpler clusters that still retain some functional similarities to their parent cells, while organotypic slice cultures preserve tissue structure and function for extended periods. The ability of these 3D models to recapitulate complex biological processes – including nerve-muscle function, tissue regeneration, vascular tissue function, brain homeostasis, and immune responses – makes them invaluable tools before conducting whole-animal studies, particularly when investigating the effects of conditions like space radiation or microgravity. Reference: [MolecularRadiationBiology, Section 10.8.4 – 3D Cell Culture Models]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.4	 3D Cell Culture Models | Content: 10.8.4.1
Definition 3D Cultures
In comparison to cells in monolayer cultures (2D), cells in
3D cultures react completely differently. The biggest disad­
vantages of 2D cultures are the unnatural contact with a plas­
tic or glass surface, the flat morphology of the cells on the
growth surface that restricts intercellular contacts and the
lack of an extracellular matrix which surrounds cells in vivo.
These conditions modify the metabolism and functioning of
cells and often result in the loss of the specific differentiation
of a cell. The structure, function, and composition of organs
and tissues can thus be better studied in 3D cell culture sys­
tems. They enable cell–cell and cell–extracellular matrix
interactions in a three-dimensional space. 3D cultures are a
very helpful tool before performing whole-animal studies.
They can further be used to study the understanding of how
processes in tissues are affected by spaceflight conditions,
including space radiation and microgravity, which otherwise
cannot be investigated in animal or human subject studies.
There are many different models of 3D cell cultures,
including organoids, ex vivo tissue, or slice cultures, which
are explained in the following. Furthermore, it is possible to
create these models with 3D bioprinting, which have then a
structure which closely resembles the organization of tissue
or organs. In fact, the European Space Agency (ESA)
recently summarized the capability science requirements for
3D bioprinting on the ISS to support medical treatment on
long-term space missions.
In all given examples two or more cell types can be co-
cultured, closely simulating the situation in organs or tissues,
e.g., investigation of cellular differentiation processes in tis­
sues, nerve-muscle function, tissue regeneration and repair,
vascular tissue function, brain tissue homeostasis and aging,
immune system processes or cardiac muscle function.
10.8.4.2
Organoids
Human organoids, derived from stem cells or progenitor
cells, are tiny self-organized organ-specific 3D cultures, rec­
reating the physiological and cytoarchitecture of human
organs. With this, the model reflects the in vivo situation
much better than single cell cultures. For research purposes,
it is feasible to create organoids that resemble the brain, kid­
ney, lung, intestine, stomach, and liver.
Organoids will help to study the effect of space radiation
on the overall response of organs, including cellular hetero­
geneity, cell-matrix interactions, cell-cell interactions, mor­
phology, and functional changes [356, 357], which cannot be
studied in in vitro systems. One major disadvantage com­
pared to in vivo systems is the lack of microenvironment.
The effects of microgravity on human brain organoids
were tested on the ISS during the Space Tango-human Brain
investigation in 2019 (NASA). Of special interest was the
effect on the brain cells including survival, migration, metab­
olism, and the formation of neuronal networks (Muotri,
unpublished).
10.8.4.3
Spheroids
Spheroids are also 3D cell cultures, but in comparison to
organoids, they form simple clusters into sphere-like forma­
tion, but they cannot self-assemble or regenerate. Whereby
the cellular functions inside spheroids are closely correlated
to the size, uniformity is especially important for reproduc­
ible results. To guarantee this, several methods for culturing
are available such as hanging drops, scaffolds, liquid overlay
technique, and hydrogels [358]. Nowadays spheroids are
highly used to study the microenvironments of tumors or
their response to radiotherapy.
Already in 2016, the SPHEROIDS project was launched
on the ISS. Here, endothelial cells, which under simulated
microgravity form small, rudimentary blood vessels, were
exposed to real microgravity for 12 days on the ISS. The for­
mation of spheroids under space conditions and under simu­
lated microgravity on Earth were similar [359], underlining
the important role of microgravity in spheroids formation.
­
10.23
10.8.4.4
Organotypic Slice Cultures
Organotypic slice cultures are tissue samples that are cut in
thinly, about 300 μm, thick slice and are then cultivated on
semipermeable insert. Most common are organotypic slice
cultures that originate from different parts of the brain (e.g.,
hippocampus, cerebellum, or cortex) and can be kept in cul­
tures for long term, while slices originating from liver tumors
can only be kept in culture for a short time [360, 361]. Also,
Fig. 10.2
3
Fig. 10.23 Difference between the different cultures
10 Space Radiobiology"
"Describe the key differences in three-dimensional cell culture models – specifically, 3D cultures, spheroids, and organotypic slice cultures – regarding their complexity, formation mechanisms, and typical applications within a space biology research context.","Three-dimensional (3D) cell culture models represent significant advancements over traditional two-dimensional (2D) monolayer cultures by more accurately mimicking the complex microenvironments found in living organisms. 3D cultures, broadly encompassing spheroids and organotypic slice cultures, vary considerably in their formation and complexity. Spheroids are simple clusters of cells that spontaneously form spherical shapes without inherent self-assembly or regeneration capabilities; they primarily rely on cell adhesion and diffusion for organization. Organotypic slice cultures, conversely, involve cutting tissue samples into thin slices (typically 300 μm) and cultivating them on semipermeable supports, allowing for the preservation of cellular architecture and function over extended periods. The key difference lies in their ability to recapitulate complex tissue structures – organotypic slices best represent this while spheroids are a more simplified representation.

Within a space biology research context, these models offer distinct advantages. 3D cultures, particularly spheroids, are valuable for studying microenvironmental effects like those induced by simulated or real microgravity, as demonstrated in the NASA Space Tango-human Brain investigation where endothelial cells formed rudimentary blood vessels under microgravity conditions mirroring spheroid formation on Earth. Organotypic slice cultures provide a longer-term model to investigate how radiation impacts tissue architecture and function, particularly useful for studying brain slices exposed to space radiation.

The lack of a true microenvironment is a limitation when comparing 3D cultures to *in vivo* systems. The use of hanging drops, scaffolds, liquid overlay techniques, and hydrogels are all methods used to try and mimic the natural environment within these models.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.4	 3D Cell Culture Models | Sub-sub-subsection: 10.8.4.1	 Definition 3D Cultures | Content: pared to in vivo systems is the lack of microenvironment.
The effects of microgravity on human brain organoids
were tested on the ISS during the Space Tango-human Brain
investigation in 2019 (NASA). Of special interest was the
effect on the brain cells including survival, migration, metab­
olism, and the formation of neuronal networks (Muotri,
unpublished).
10.8.4.3
Spheroids
Spheroids are also 3D cell cultures, but in comparison to
organoids, they form simple clusters into sphere-like forma­
tion, but they cannot self-assemble or regenerate. Whereby
the cellular functions inside spheroids are closely correlated
to the size, uniformity is especially important for reproduc­
ible results. To guarantee this, several methods for culturing
are available such as hanging drops, scaffolds, liquid overlay
technique, and hydrogels [358]. Nowadays spheroids are
highly used to study the microenvironments of tumors or
their response to radiotherapy.
Already in 2016, the SPHEROIDS project was launched
on the ISS. Here, endothelial cells, which under simulated
microgravity form small, rudimentary blood vessels, were
exposed to real microgravity for 12 days on the ISS. The for­
mation of spheroids under space conditions and under simu­
lated microgravity on Earth were similar [359], underlining
the important role of microgravity in spheroids formation.
­
10.23
10.8.4.4
Organotypic Slice Cultures
Organotypic slice cultures are tissue samples that are cut in
thinly, about 300 μm, thick slice and are then cultivated on
semipermeable insert. Most common are organotypic slice
cultures that originate from different parts of the brain (e.g.,
hippocampus, cerebellum, or cortex) and can be kept in cul­
tures for long term, while slices originating from liver tumors
can only be kept in culture for a short time [360, 361]. Also,
Fig. 10.2
3
Fig. 10.23 Difference between the different cultures
10 Space Radiobiology"
"Describe the various 3D cell culture models discussed in the text, highlighting their differences and applications, specifically focusing on organoids, spheroids, and organotypic slice cultures.","The text details three distinct 3D cell culture models used to study the effects of space radiation and microgravity: organoids, spheroids, and organotypic slice cultures. Organoids represent a more complex model, resembling miniature organs with the capacity for self-assembly, regeneration, and formation of neuronal networks – mirroring aspects of human brain development. They are particularly valuable in investigating cellular survival, migration, metabolism, and network formation when compared to simpler models. Spheroids, conversely, are simple clusters of cells that form sphere-like structures but lack the regenerative capabilities of organoids. Their function is closely tied to size and uniformity for reproducible results, often utilized in studying tumor microenvironments or radiotherapy responses. Organotypic slice cultures involve cutting brain tissue into thin slices (approximately 300 μm) and cultivating them on semipermeable inserts, allowing for long-term maintenance of tissue architecture and functionality. These are derived from various brain regions like the hippocampus or cerebellum and can be maintained in culture for extended periods. A key difference is that while organotypic slice cultures from liver tumors have a limited lifespan in culture, the other models allow for more sustained investigation. The SPHEROIDS project on the ISS demonstrated similar spheroid formation under real microgravity compared to simulated microgravity on Earth, emphasizing the role of microgravity in this process.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.4	 3D Cell Culture Models | Sub-sub-subsection: 10.8.4.2	 Organoids | Content: pared to in vivo systems is the lack of microenvironment.
The effects of microgravity on human brain organoids
were tested on the ISS during the Space Tango-human Brain
investigation in 2019 (NASA). Of special interest was the
effect on the brain cells including survival, migration, metab­
olism, and the formation of neuronal networks (Muotri,
unpublished).
10.8.4.3
Spheroids
Spheroids are also 3D cell cultures, but in comparison to
organoids, they form simple clusters into sphere-like forma­
tion, but they cannot self-assemble or regenerate. Whereby
the cellular functions inside spheroids are closely correlated
to the size, uniformity is especially important for reproduc­
ible results. To guarantee this, several methods for culturing
are available such as hanging drops, scaffolds, liquid overlay
technique, and hydrogels [358]. Nowadays spheroids are
highly used to study the microenvironments of tumors or
their response to radiotherapy.
Already in 2016, the SPHEROIDS project was launched
on the ISS. Here, endothelial cells, which under simulated
microgravity form small, rudimentary blood vessels, were
exposed to real microgravity for 12 days on the ISS. The for­
mation of spheroids under space conditions and under simu­
lated microgravity on Earth were similar [359], underlining
the important role of microgravity in spheroids formation.
­
10.23
10.8.4.4
Organotypic Slice Cultures
Organotypic slice cultures are tissue samples that are cut in
thinly, about 300 μm, thick slice and are then cultivated on
semipermeable insert. Most common are organotypic slice
cultures that originate from different parts of the brain (e.g.,
hippocampus, cerebellum, or cortex) and can be kept in cul­
tures for long term, while slices originating from liver tumors
can only be kept in culture for a short time [360, 361]. Also,
Fig. 10.2
3
Fig. 10.23 Difference between the different cultures
10 Space Radiobiology"
"Describe the use of 3D cell culture models, specifically spheroids, within space biology research and highlight a key experiment utilizing this approach.","Three-dimensional (3D) cell culture models, particularly spheroids, are increasingly utilized in space biology to better mimic the complex microenvironments experienced by cells during extended spaceflight. Unlike traditional 2D cultures that lack spatial organization and cellular interactions, spheroids form simple clusters into sphere-like formations, offering a more physiologically relevant context for studying cellular responses. These models are valuable because they can be used to investigate phenomena such as cell survival, migration, metabolism, and neuronal network formation – processes significantly impacted by microgravity. A notable example is the SPHEROIDS project conducted on the International Space Station (ISS). This project utilized endothelial cells exposed to real microgravity for 12 days, resulting in the formation of rudimentary blood vessels resembling spheroids. The similarities observed between spheroid formation under space conditions and simulated microgravity on Earth underscore the crucial role of microgravity in driving this process, providing insights into how cells adapt and reorganize within a reduced-gravity environment. Furthermore, spheroids are now frequently employed to study tumor microenvironments and their response to radiation therapies due to their ability to recapitulate key aspects of these complex systems.
Reference: [Molecular Radiation Biology], Section 10.8.4.3 – Spheroids","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.4	 3D Cell Culture Models | Sub-sub-subsection: 10.8.4.3	 Spheroids | Content: pared to in vivo systems is the lack of microenvironment.
The effects of microgravity on human brain organoids
were tested on the ISS during the Space Tango-human Brain
investigation in 2019 (NASA). Of special interest was the
effect on the brain cells including survival, migration, metab­
olism, and the formation of neuronal networks (Muotri,
unpublished).
10.8.4.3
Spheroids
Spheroids are also 3D cell cultures, but in comparison to
organoids, they form simple clusters into sphere-like forma­
tion, but they cannot self-assemble or regenerate. Whereby
the cellular functions inside spheroids are closely correlated
to the size, uniformity is especially important for reproduc­
ible results. To guarantee this, several methods for culturing
are available such as hanging drops, scaffolds, liquid overlay
technique, and hydrogels [358]. Nowadays spheroids are
highly used to study the microenvironments of tumors or
their response to radiotherapy.
Already in 2016, the SPHEROIDS project was launched
on the ISS. Here, endothelial cells, which under simulated
microgravity form small, rudimentary blood vessels, were
exposed to real microgravity for 12 days on the ISS. The for­
mation of spheroids under space conditions and under simu­
lated microgravity on Earth were similar [359], underlining
the important role of microgravity in spheroids formation.
­
10.23
10.8.4.4"
"Describe the key differences in three distinct 3D cell culture models – spheroids, organotypic slice cultures, and organ cultures – highlighting their respective advantages and limitations regarding mimicking *in vivo* conditions and experimental applicability.","Three primary 3D cell culture models are utilized to study cellular responses under altered environments, such as those experienced in space. Spheroids represent the simplest form, consisting of loosely aggregated clusters of cells that self-assemble into spherical shapes without inherent regenerative capabilities. Their formation is significantly influenced by microgravity, mirroring observations made in *in vivo* systems. However, their lack of a complex extracellular matrix and inability to regenerate limits their ability to accurately replicate intricate tissue architecture or dynamic cellular processes. Organotypic slice cultures, conversely, involve cutting tissues (e.g., brain slices) into thin, semi-permeable discs that maintain structural integrity and allow for the preservation of the extracellular matrix and tissue architecture. This approach offers a more physiologically relevant environment compared to spheroids, enabling long-term culture and analysis of tissue function. However, inherent variability between individual slices – differing cell counts, viability, and composition – introduces significant reproducibility challenges. Finally, organ cultures utilize whole or partial excised organs (e.g., porcine eye lenses) cultured *in vitro*, preserving the complete 3D structure and facilitating investigations into organ-level functions and responses to stimuli. While providing the most physiologically accurate representation of a tissue, their limited viability necessitates shorter culture durations, often requiring supplementation with animal models for studying long-term effects like cataract formation. Each model presents unique strengths and weaknesses regarding mimicking *in vivo* complexity and experimental control.

Reference: [MolecularRadiationBiology], Section 10.8.4 – Organotypic Slice Cultures","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.4	 3D Cell Culture Models | Sub-sub-subsection: 10.8.4.4	 Organotypic Slice Cultures | Content: pared to in vivo systems is the lack of microenvironment.
The effects of microgravity on human brain organoids
were tested on the ISS during the Space Tango-human Brain
investigation in 2019 (NASA). Of special interest was the
effect on the brain cells including survival, migration, metab­
olism, and the formation of neuronal networks (Muotri,
unpublished).
10.8.4.3
Spheroids
Spheroids are also 3D cell cultures, but in comparison to
organoids, they form simple clusters into sphere-like forma­
tion, but they cannot self-assemble or regenerate. Whereby
the cellular functions inside spheroids are closely correlated
to the size, uniformity is especially important for reproduc­
ible results. To guarantee this, several methods for culturing
are available such as hanging drops, scaffolds, liquid overlay
technique, and hydrogels [358]. Nowadays spheroids are
highly used to study the microenvironments of tumors or
their response to radiotherapy.
Already in 2016, the SPHEROIDS project was launched
on the ISS. Here, endothelial cells, which under simulated
microgravity form small, rudimentary blood vessels, were
exposed to real microgravity for 12 days on the ISS. The for­
mation of spheroids under space conditions and under simu­
lated microgravity on Earth were similar [359], underlining
the important role of microgravity in spheroids formation.
­
10.23
10.8.4.4
Organotypic Slice Cultures
Organotypic slice cultures are tissue samples that are cut in
thinly, about 300 μm, thick slice and are then cultivated on
semipermeable insert. Most common are organotypic slice
cultures that originate from different parts of the brain (e.g.,
hippocampus, cerebellum, or cortex) and can be kept in cul­
tures for long term, while slices originating from liver tumors
can only be kept in culture for a short time [360, 361]. Also,
Fig. 10.2
3
Fig. 10.23 Difference between the different cultures
10 Space Radiobiology
546
this 3D culture has the advantage that the composition and
architecture of the extracellular matrix as well as the tissue
are preserved. During analysis of the slices, it has to be con­
sidered that every slice, even from the same organ, has a
partly different composition, cell counts, and viability, limit­
ing the reproducibility of results produced by this method.
10.8.4.5
Organ Cultures
Organ cultures were developed from tissue and slice cultures.
By using organ cultures, it is possible to study the functions
of an organ in various conditions and states in an in vitro
organ. Hereby, the entire organs or only a part of the organ are
excised from the body and cultured. Also, with this method,
the 3D structure of the tissue of choice is preserved.
For space exploration, the eye lens is of special interest,
because it is amongst the most radiosensitive tissues in the
human body. Ionizing radiation can cause a posterior sub-
capsular cataract [287, 362, 363]. Whole lenses and lens epi­
thelial cells in culture enable the study of early mechanisms
of space radiation-induced cataractogenesis and of the rela­
tive biological efficiency of different space radiation compo­
nents to induce early changes. With regard to the human lens
in anatomy and size, the porcine eye is very similar. Thus, it
is used to study the radiation response in the whole organ.
Translation to the human eye lens can be enabled by using
human-transformed epithelial cells or lens epithelial cells
from donor patients. As the viability of eye lenses in cultures
is limited to a few weeks, studies on radiation-induced full-
blown cataract formation usually require animal experiments
over their lifespan (Sect. 10.5).
­
364
­
365
10.24
­
10.10
10.8.5	Omics Approaches in Space Life
Sciences
­
­
10.25
366
­
­
Systems biology is an interdisciplinary approach in bio­
medical research aiming at understanding the biological sys­
tem at the organism, tissue, and cell level. Systems biology
incorporates the results of –omics techniques, genome-scale
metabolic and regulatory biomathematical models to under­
stand molecular interactions, evolution, functional and phe­
notypical
diversity,
and
molecular
adaptation. The
omics-based approach integrates various pieces of biological
information from genomes, mRNA, and proteins to metabo­
lites [367].
­
­
Box 10.10 Highlights
•	Several cell cultures system can be studied under
space conditions
•	The microgravity environment on the ISS suits per­
fectly to print 3D tissue culturesFig. 10.24
Fig. 10.24 NASA’s 3D BioFabrication Facility BFF. (Image
JSC2019E037579, Credits NASA)
C. E. Hellweg et al."
"The provided text discusses utilizing various cell culture models to study the effects of space radiation on eukaryotic cells. Considering this context, what is the significance of employing 3D cell culture models, specifically those like NASA’s BioFabrication Facility (BFF), and how does their application relate to understanding biological changes induced by space radiation?","The utilization of 3D cell culture models, exemplified by facilities like NASA's Biofabrication Facility (BFF), represents a crucial advancement in studying the impact of space radiation on eukaryotic cells. Traditional 2D cell cultures often fail to accurately replicate the complex cellular microenvironment and interactions found within a living organism. 3D cultures, particularly those mimicking tissue architecture through techniques like bioprinting, provide a more physiologically relevant platform for investigating biological changes induced by space radiation. These models allow researchers to assess how cells respond not just at a single-cell level but also considering cell-to-cell interactions and the influence of extracellular matrix components – all critical factors in determining cellular survival, DNA damage response, and subsequent phenotypic alterations. The BFF’s ability to print 3D tissue cultures is particularly important because it allows for the creation of more complex and representative models that can better simulate the conditions experienced by cells during spaceflight, ultimately contributing to a deeper understanding of radiation-induced biological changes – including metabolic and regulatory biomathematical modeling – within eukaryotic systems. Reference: Molecular Radiation Biology, Section 10.8.4.5 – Organ Cultures","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.4	 3D Cell Culture Models | Sub-sub-subsection: 10.8.4.5	 Organ Cultures | Content: metabolic and regulatory biomathematical models to under­
stand molecular interactions, evolution, functional and phe­
notypical
diversity,
and
molecular
adaptation. The
omics-based approach integrates various pieces of biological
information from genomes, mRNA, and proteins to metabo­
lites [367].
­
­
Box 10.10 Highlights
•	Several cell cultures system can be studied under
space conditions
•	The microgravity environment on the ISS suits per­
fectly to print 3D tissue culturesFig. 10.24
Fig. 10.24 NASA’s 3D BioFabrication Facility BFF. (Image
JSC2019E037579, Credits NASA)
C. E. Hellweg et al."
"The text describes how systems biology utilizes –omics techniques to investigate microbial responses in space environments. Specifically, it highlights that exposed microbes often shift to ‘energy saving mode’ and identifies global regulatory molecules driving these changes. Furthermore, the analysis reveals altered expression of genes related to stress responses (e.g., oxidative, osmotic) following exposure to simulated or real space conditions. What key methodological considerations does the text emphasize for accurately interpreting –omics data from microbial studies conducted in space, particularly concerning potential artifacts and limitations?","The text underscores several critical methodological considerations when analyzing –omics data derived from microorganisms exposed to space environments. Primarily, it stresses the importance of controlling experimental design to ensure sufficient biological replicates are obtained, mitigating statistical challenges inherent in limited sample sizes. A significant concern highlighted is the potential for artifacts introduced by stress responses triggered by the space environment; these can be difficult to distinguish from genuine changes driven by radiation or microgravity. The text emphasizes that cultivation medium composition plays a crucial role, as antioxidants provided in rich media can confound results and mask true effects. Furthermore, rigorous documentation of environmental parameters – including temperature, humidity, pressure profiles – during all experimental phases (flight, simulation, and control) is paramount to eliminate confounding variables. Finally, the document advocates for combining multi-omics approaches—including detailed metabolomic analysis alongside proteotranscriptomic profiling—and integrating this data with genome-scale metabolic reconstruction to capture comprehensive space-induced microbiome signatures. Critically assessing the design of experiments to ensure sufficient independent biological samples and avoiding uncontrolled conditions are highlighted as essential steps to minimize artifacts and achieve statistically significant results. Reference: [MolecularRadiationBiology, Section 10.8.5 – Omics Approaches in Space Life Sciences]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.8	 Eukaryotic Cell Experimental Models and Biological Changes of Space Radiation | Sub-subsection: 10.8.5	 Omics Approaches in Space Life Sciences | Content: Sciences
­
­
10.25
366
­
­
Systems biology is an interdisciplinary approach in bio­
medical research aiming at understanding the biological sys­
tem at the organism, tissue, and cell level. Systems biology
incorporates the results of –omics techniques, genome-scale
metabolic and regulatory biomathematical models to under­
stand molecular interactions, evolution, functional and phe­
notypical
diversity,
and
molecular
adaptation. The
omics-based approach integrates various pieces of biological
information from genomes, mRNA, and proteins to metabo­
lites [367].
­
­
Box 10.10 Highlights
•	Several cell cultures system can be studied under
space conditions
•	The microgravity environment on the ISS suits per­
fectly to print 3D tissue culturesFig. 10.24
Fig. 10.24 NASA’s 3D BioFabrication Facility BFF. (Image
JSC2019E037579, Credits NASA)
C. E. Hellweg et al.
547Fig. 10.25
Fig. 10.25 Molecular response
experienced by microorganisms
in the outer space environment
revealed with the help of global
and integrative –omics
approaches of systems biology
that have been recently used to
study microorganisms exposed to
real and simulated space
conditions. (Reprinted with
permission from Milojevic et al.
[366])
isms in space are affected by metabolic alterations caused in
turn by genetic regulations (Fig. 10.26). It has been demon­
strated by means of –omics-based approaches that exposed
microbes switch to “energy saving mode.” Research identi­
fied some global regulatory molecules that drive molecular
response of a few space-exposed microorganisms [366–369].
Various kinds of stress responses (e.g., general, osmotic, and
oxidative) experienced by microorganisms in conditions of
real and simulated outer space have been deciphered via –
omics-assisted analyses [366]. Various genes with altered
expression after microbs’ exposure to real and simulated
outer space environment (Fig. 10.25) have been identified
[366].
­
10.27
366
Space exposure imposes stresses that affect microbial sur­
vival rates and may lead to certain discrepancies in –omics-
assisted analysis of returned/exposed microorganisms. The
composition of the cultivation medium influences the micro­
bial space response [369], e.g., by providing specific antioxi­
dants presented in rich medium, which may protect microbial
cells against ionizing radiation. The majority of space exper­
iments have been performed on satellites, where microorgan­
isms are cultivated in environment protected from all factor
but microgravity [366]. Direct exposure to real space envi­
ronment outside the ISS followed by investigation with –
omics techniques was performed on a few microbial species
only [367, 370, 371]. Therefore, in order to broaden our
knowledge of molecular mechanisms of microbial surviv­
ability in outer space, there is an urgent need for further
experiments with direct exposure. Often, a multi-omics post-
flight analysis has the problem of a limited number of micro­
biological samples exposed to the space environment.
Therefore, the researchers should critically assess the design
of outerspace experiments to provide a sufficient number of
independent biological samples in order to enable statisti­
cally significant results in processing the –omics data. It is
also extremely important to avoid artifacts: due to very high
sensitivity of the –omics techniques of occasional occur­
rence of uncontrolled conditions, stress-related artifacts can­
not be ruled out. In this context, it is highly desired to develop
novel approaches for the efficient extraction of DNA, RNA,
proteins, and metabolites simultaneously from the minimal
amount of microbial cells [367, 372]. Furthermore, the
absence of detailed reports regarding the environmental con­
ditions during space exposure and corresponding ground
control experiments is, unfortunately, a frequent reality that
requires a critical reassessment of research planning.
Providing a full record of controlled parameters (like tem­
perature, humidity, and pressure profiles) during flight, simu­
lated, and control experiments is highly desired to achieve a
comprehensive and artifacts-free analysis of the effects of
the space environment on the physiology and molecular
machinery of microorganisms.
It has been proposed that in future space experiments,
detailed metabolomic analysis of exposed microorganisms
should be performed in addition to the proteotranscriptomic
profiling. This novel approach has provided already plenty of
10 Space Radiobiology
548Fig. 10.26
Fig. 10.26 Stress responses experienced by microorganisms in outer
space real and simulated conditions, revealed with –omics-assisted
investigations. Proteins and genes of stress responses with altered abun­
dance and expression after exposure of microorganisms to the outer
space real and simulated environment [366]Fig. 10.27
Fig. 10.27 Molecular alterations
underlying microbial
pathogenicity, virulence, and
biofilm formation in the outer
space environment, resolved
with –omics-assisted
investigations [366]
C. E. Hellweg et al.
549
new findings on fine molecular networks regulating the space
response [367]. Recent works (e.g., the NASA twins’ study)
used a multi-omics, systems biology analytical approach to
analyze biomedical profiles of astronauts [120]. Results of
performed targeted and untargeted metabolomics combined
with proteomics effectively revealed the biomedical
responses of a human body during a year-long spaceflight
indicating mitochondrial stress as a consistent phenotype of
spaceflight [120, 373]. Finally, the combination of molecular
data with a genome-scale metabolic reconstruction of the
respective species should be implemented, delivering the
space-induced microbiome signatures [366].
10.9"
"According to the text, what are some potential strategies being investigated to mitigate the health risks associated with space radiation exposure for astronauts?","Several strategies are being explored to reduce the impact of space radiation on human health. These include selecting individuals with inherent radioresistance through in vitro adaptive response studies, pharmacologically hindering radiation effects using radioprotectors and geroprotectors alongside antioxidants, inducing a state of synthetic hibernation (or torpor) by slowing metabolic processes and increasing tissue hypoxia, utilizing deuterium-labeled compounds to alter DNA stability, and employing gene therapy techniques such as overexpressing endogenous antioxidants like magnesium superoxide dismutase (MnSOD) or enhancing DNA damage repair proteins. Reference: [10.9 Space Radiobiology – Space Radiation Resistance]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.9	 Space Radiation Resistance | Content: 10.9.1	Health Risk Reduction from Space
Radiation Exposure in Humans
Humans have all evolved in an environment containing a
persistent low level of constant exposure to different endog­
enous and exogenous mutagenic agents, and consequently
have developed many cellular mechanisms for either DNA
protection or repair (see Chap. 2). However, when humans
travel into space, these naturally evolved cellular mecha­
nisms might not be enough as many major health threats
from space radiation has been identified, e.g., central ner­
vous system injury, cardiovascular diseases, immune dys­
function, cancer development, and premature aging. To
reduce the risk of humans in space, there are some possible
interventions which can limit the effects of space radiation.
A dedicated review can be found elsewhere [374].
One way of reducing the health risk from space radiation
exposure in humans is selecting more radioresistant humans
during the selection campaigns of space agencies. The most
used way is to perform in vitro adaptive response studies, in
which cells collected from the candidates are used to mea­
sure their response to a fixed dose of ionizing radiation.
While the results of these studies are not necessarily used
during candidate selection, they hold great value in selecting
the right people that will be more protected against space
radiation. Another strategy would be to pharmacologically
hamper the processes underlying the molecular (side) effects
of space radiation exposure. Examples are the application of
radioprotectors and geroprotectors, as well as supplementa­
tion with antioxidants or antioxidative capacity increasing
compounds (see Chap. 11). While these pharmaceuticals
hold great promise, many of them are still under investiga­
tion and not allowed to be used on humans.
An alternative method to elevate humans’ natural radia­
tion protection capacity is inducing a hibernating or hyposta­
sis state. It is well-known that natural hibernators become
more radioresistant during their inactive state. The reason for
this has not yet been fully elucidated. It is probably due to
several factors related to slower cell metabolism and
increased tissue hypoxia.
In recent years, a technique has been developed that
allows hibernation to be reproduced even in those animals
that would not usually be able to hibernate, such as rats.
This technique is nowadays known as synthetic hiberna­
tion or synthetic torpor [375]. Although this research has a
big potential to limit radiation-associated risks in space, it
is quite far from practical use yet. Another futuristic
method is the use of deuterium, the stable isotope of hydro­
gen. As carbon-deuterium bonds need more energy to
break than normal carbon-hydrogen bonds, the necessary
energy to break the hydrogen bonds between DNA bases
would be higher, making deuterated DNA less sensitive
than normal DNA to DNA damage following ionizing
radiation exposure. However, a lot of issues have to be
solved before deuterium could be applied in humans: lack
of evolutionary adaption to catabolize organic compounds
containing deuterium, consequent slower rate of vital met­
abolic reactions, and their potential toxic effects.
Nevertheless, it has been shown that deuterated food or
water intake helps to increase life or health spans from
numerous model organisms.
Gene therapy stands for the use of genetic modifying
techniques in order to achieve a therapeutic effect. In the
context of radiation and radiation protection, this has been
studied for several radioresistance mechanisms making these
techniques interesting for deep space missions, where radia­
tion protection concerns arise [374]
One of the strategies for gene therapy in radioresistance is
the overexpression of endogenous antioxidants, for example,
magnesium superoxide dismutase (MnSOD) that acts as a
scavenger for reactive oxygen species produced after the
interaction of radiation with the cell [376].
Another angle in which gene therapy can be useful for
improving radioresistance is by enhancing the DNA damage
repair such as the overexpression of certain repair proteins
that are normally active in repairing the damage in the DNA
strands after radiation exposure [377].
A promising approach takes its inspiration from
extremophiles and their impressive radioresistance capa­
bilities, in concrete, the tardigrades, a microscopic animal
that is capable of surviving in extreme conditions. A pro­
tein identified in these organisms, termed damaged sup­
pressor (Dsup), has been made to be expressed in human
cell lines, reducing the number of DNA strand breaks and
preserving cellular proliferative abilities after high doses of
radiation [337].
10 Space Radiobiology"
"Describe several mechanisms explored to mitigate the harmful effects of space radiation exposure on humans, detailing how they relate to cellular processes and potential challenges associated with their implementation.","Several strategies are being investigated to reduce the risks posed by space radiation. One approach involves inducing a state resembling hibernation – ‘synthetic torpor’ – which leverages the increased radioresistance observed in inactive cells due to slower metabolism and heightened tissue hypoxia. Another promising avenue is utilizing deuterium, a stable isotope of hydrogen, to create deuterated DNA. This strategy exploits the fact that carbon-deuterium bonds are more resistant to breakage than carbon-hydrogen bonds, thereby reducing the energy required for radiation to damage DNA. Gene therapy represents another key area of research. Specifically, overexpression of endogenous antioxidants like magnesium superoxide dismutase (MnSOD) is being explored; MnSOD effectively scavenges reactive oxygen species generated by radiation exposure. Furthermore, enhancing DNA damage repair mechanisms through the overexpression of repair proteins – such as those involved in repairing strand breaks – offers a protective effect. Finally, research inspired by extremophiles, particularly tardigrades and their ‘damaged suppressor’ (Dsup) protein, demonstrates that expressing Dsup in human cell lines can significantly reduce DNA strand breaks and maintain cellular proliferative abilities following radiation exposure. However, each of these approaches faces challenges: synthetic torpor is currently impractical for widespread use; deuterium implementation requires overcoming evolutionary limitations related to organic compound catabolism and potential toxicity; gene therapy relies on successful genetic modification and delivery methods; and while Dsup shows promise, its long-term effects and potential for unintended consequences require thorough investigation. Reference: MolecularRadiationBiology, Section 10.9.1 – Health Risk Reduction from Space Radiation Exposure in Humans","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.9	 Space Radiation Resistance | Sub-subsection: 10.9.1	 Health Risk Reduction from Space Radiation Exposure in Humans | Content: more radioresistant during their inactive state. The reason for
this has not yet been fully elucidated. It is probably due to
several factors related to slower cell metabolism and
increased tissue hypoxia.
In recent years, a technique has been developed that
allows hibernation to be reproduced even in those animals
that would not usually be able to hibernate, such as rats.
This technique is nowadays known as synthetic hiberna­
tion or synthetic torpor [375]. Although this research has a
big potential to limit radiation-associated risks in space, it
is quite far from practical use yet. Another futuristic
method is the use of deuterium, the stable isotope of hydro­
gen. As carbon-deuterium bonds need more energy to
break than normal carbon-hydrogen bonds, the necessary
energy to break the hydrogen bonds between DNA bases
would be higher, making deuterated DNA less sensitive
than normal DNA to DNA damage following ionizing
radiation exposure. However, a lot of issues have to be
solved before deuterium could be applied in humans: lack
of evolutionary adaption to catabolize organic compounds
containing deuterium, consequent slower rate of vital met­
abolic reactions, and their potential toxic effects.
Nevertheless, it has been shown that deuterated food or
water intake helps to increase life or health spans from
numerous model organisms.
Gene therapy stands for the use of genetic modifying
techniques in order to achieve a therapeutic effect. In the
context of radiation and radiation protection, this has been
studied for several radioresistance mechanisms making these
techniques interesting for deep space missions, where radia­
tion protection concerns arise [374]
One of the strategies for gene therapy in radioresistance is
the overexpression of endogenous antioxidants, for example,
magnesium superoxide dismutase (MnSOD) that acts as a
scavenger for reactive oxygen species produced after the
interaction of radiation with the cell [376].
Another angle in which gene therapy can be useful for
improving radioresistance is by enhancing the DNA damage
repair such as the overexpression of certain repair proteins
that are normally active in repairing the damage in the DNA
strands after radiation exposure [377].
A promising approach takes its inspiration from
extremophiles and their impressive radioresistance capa­
bilities, in concrete, the tardigrades, a microscopic animal
that is capable of surviving in extreme conditions. A pro­
tein identified in these organisms, termed damaged sup­
pressor (Dsup), has been made to be expressed in human
cell lines, reducing the number of DNA strand breaks and
preserving cellular proliferative abilities after high doses of
radiation [337].
10 Space Radiobiology
550"
"Describe several mechanisms employed by extremophiles, such as Bacillus subtilis and Deinococcus radiodurans, to enhance their survival under extreme conditions, including those related to ionizing radiation exposure. Specifically, detail the roles of spore formation, intracellular Mn/Fe ratios, DNA repair pathways, and compatible solutes in conferring radiation resistance.","Extremophilic organisms have evolved diverse strategies to withstand harsh environments, including significant levels of ionizing radiation. Bacillus subtilis exemplifies this with spore formation, a critical adaptation for survival under stress. The thick peptidoglycan layer, low water content, altered DNA conformation (B to A), and α/β-type small acid-soluble spore proteins within the spore structure provide robust protection against physical stresses like radiation, reducing damage to the vegetative cell. Deinococcus radiodurans exhibits remarkable radiation resistance through a combination of mechanisms. Notably, it maintains an unusual intracellular Mn/Fe ratio – high manganese with low iron – which effectively scavenges and neutralizes hydroxyl radicals generated by ionizing radiation. Furthermore, this bacterium possesses highly efficient DNA repair pathways, including rapid removal of DNA strand breaks, contributing significantly to its survival. Deinococcus also utilizes a unique system involving DNA binding proteins that directly protect the DNA from ROS damage.  Additionally, Halobacterium salinarum demonstrates tolerance through compatible solutes like salts and pigments (carotenoids, melanin) which mitigate oxidative stress caused by radiation exposure. Finally, polyploidy – the presence of multiple copies of DNA within a single cell – has been observed in some extremophiles, potentially contributing to desiccation tolerance and indirectly aiding survival after radiation exposure due to increased genetic redundancy for repair mechanisms [385, 386, 388, 390].","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.9	 Space Radiation Resistance | Sub-subsection: 10.9.2	 Mechanisms in Extremophiles | Content: 10.9.2.1
What is an Extremophile?
Extreme conditions in a natural environment are only extreme
from a human point of view. Extremophiles can only live
under these conditions and depend on them. Often organisms
living under these conditions are called “extremophiles” or
“polyextremophiles” since most of them are coping with dif­
ferent extremes in their natural environment [378].
10.9.2.2
Which Adaptations/Mechanisms Are
Known?
Plenty of different (poly) extremophiles in natural and
human-made extreme environments exist in natural and
human-made harsh environments. Examples include anaer­
obes, (hyper-) thermophiles, psychrophiles, halophiles,
acidophiles, xerophiles, and piezophiles. For all the named
organismic groups, cellular adaptation mechanisms are
known that protect the cells themselves or enable them to
live under extreme conditions in their natural habitat. In
addition to the intracellular protection mechanisms, general
protection mechanisms like spore formation are well-
known. For example, the spore of the Bacterium Bacillus
subtilis is characterized by a thick layer of peptidoglycan, a
low water content inside the cell, a DNA conformation
changed from B to A, and the presence of α/β-type small
acid-soluble spore proteins which accumulate within the
spore. In general, spores are more tolerant to inactivating
physical stresses, like radiation as vegetative cells [379,
380]. Spore formation is known to be an answer to changing
conditions in the environment that is used by microorgan­
isms and fungi; special forms like the anhydrobiotic state
are also observed in other eukaryotic cells like tardigrades,
nematodes, and rotifers [381]. Spore formation and the
anhydrobiotic state, as well as intracellular adaptation
mechanisms, are relevant for possible survival after expo­
sure to ionizing (space) radiation [323, 382]. In addition to
spore formation, biofilm growth by the production of extra­
cellular polymeric substances (EPS) also leads to a higher
ionizing radiation tolerance [383].
Besides the named cellular adaptation mechanisms, there are
also different intracellular adaptation mechanisms possible to
cope with extreme environmental stresses. As described before,
ionizing radiation exposure does not only lead to direct effects
and intracellular damage, such as DNA strand breaks, it also
leads to indirect effects, like ROS production. Hyperthermophilic
Archaea, like Pyrococcus furiosus, are partly tolerant to the
indirect effects of ionizing radiation, due to mechanisms pro­
tecting the DNA from the influence of ROS [384]. In these
Archaea, DNA binding proteins play a major role as they bind
and protect the DNA thereby limiting the accessibility of the
DNA to ROS. In addition, increased expression of different
enzymes like superoxide dismutase and the glutathione peroxi­
dase can also reduce the level of intracellular ROS.
For the Bacterium Deinococcus radiodurans as well as
for the Archaeon Halobacterium salinarum special intracel­
lular Mn/Fe ratios are described: they demonstrate an intra­
cellular accumulation of high amounts of manganese along
with low iron levels, which contribute to their high radiation
tolerance [385, 386]. This special Mn/Fe ratio was not found
in radiation-tolerant anaerobic microorganisms. It is pro­
posed that the low levels of IR-generated ROS under anaero­
bic conditions combined with highly constitutively expressed
detoxification systems in these anaerobes are key to their
radiation resistance and circumvent the need for the accumu­
lation of Mn-antioxidant complexes in the cell [387].
Furthermore, polyploidy or the presence of several DNA
copies within one single cell has been discussed to contribute
to tolerance to desiccation and therefore also to ionizing
radiation [388].
Halophilic organisms have different strategies to cope
with a high salt concentration in their natural habitat. One
option is the intracellular accumulation of salt or other com­
patible solutes [389]. It is also known that compatible solutes
can contribute to the tolerance to ionizing radiation in halo­
philic microorganisms [389]. Additionally, protective mech­
anisms such as membrane pigments, including carotenoids,
melanin, scytonemin, and bacterioruberin were found to be
important in ionizing radiation protection in different organ­
isms through the scavenging of hydroxyl radicals [390, 391].
10.9.2.3
How Relevant Are These Adaptations/
Mechanisms for Space Radiation?
In general, there is no direct adaptation of microorganisms to
space conditions or space radiation known as all organisms
evolved on Earth. Nevertheless, there have been and still are
space experiments ongoing where the adaptability of differ­
ent organisms is investigated during exposure to space con­
ditions. In this context, we speak about the side effects of
other tolerances or resistances which enable the organisms to
endure space stressors. In general, organisms which are tol­
erant to desiccation developed mechanisms to repair the
DNA which is damaged during the desiccation process. The
same repair mechanisms can also be used to repair DNA
damage caused by other stressors, such as ionizing radiation.
One prominent example is the desiccation and radiation tol­
erance of the microorganism Deinococcus radiodurans. This
organism uses the same cellular adaptation and repair strate­
gies after exposure to drought and ionizing radiation expo­
sure. However, not all desiccation-tolerant organisms are
tolerant to (ionizing) radiation exposure [392]. The same is
true for other repair machineries, where no direct correlation
between hyper-/thermophilic organisms or the ability to pro­
duce compatible solutes and radiation tolerance could be
identified [393, 394]. In addition, some microorganisms
(e.g., Ignicoccus hospitalis) demonstrate a high survival rate
after ionizing radiation exposure but possess a repair mecha­
nism which is not known up to now [395].
C. E. Hellweg et al."
"Extremophilic microorganisms, such as *Deinococcus radiodurans* and *Halobacterium salinarum*, exhibit enhanced radiation resistance through several distinct mechanisms. Describe at least three of these mechanisms, detailing the specific cellular components or processes involved in each.","Radiation-resistant extremophiles employ a multifaceted approach to mitigate the damaging effects of ionizing radiation. Firstly, DNA binding proteins play a crucial role by directly interacting with and protecting DNA from oxidative damage caused by ROS (reactive oxygen species). These proteins essentially shield the DNA structure, limiting its accessibility to harmful radicals. Secondly, these organisms often exhibit significantly altered intracellular metal ratios, particularly an accumulation of manganese alongside reduced iron levels as seen in *Deinococcus radiodurans* and *Halobacterium salinarum*. Manganese acts as a potent antioxidant, scavenging ROS through the formation of Mn-O complexes. Thirdly, increased expression of detoxification enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GPx) is frequently observed. SOD catalyzes the conversion of superoxide radicals into oxygen and hydrogen peroxide, while GPx reduces hydrogen peroxide to water, effectively neutralizing these damaging oxidants. Furthermore, polyploidy – the presence of multiple copies of DNA within a single cell – has been implicated in radiation tolerance, potentially providing redundant repair mechanisms and buffering against genomic instability. Finally, halophilic organisms utilize compatible solutes like salt or other solutes to protect themselves from ionizing radiation.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.9	 Space Radiation Resistance | Sub-subsection: 10.9.2	 Mechanisms in Extremophiles | Sub-sub-subsection: 10.9.2.1	 What is an Extremophile? | Content: Archaea, DNA binding proteins play a major role as they bind
and protect the DNA thereby limiting the accessibility of the
DNA to ROS. In addition, increased expression of different
enzymes like superoxide dismutase and the glutathione peroxi­
dase can also reduce the level of intracellular ROS.
For the Bacterium Deinococcus radiodurans as well as
for the Archaeon Halobacterium salinarum special intracel­
lular Mn/Fe ratios are described: they demonstrate an intra­
cellular accumulation of high amounts of manganese along
with low iron levels, which contribute to their high radiation
tolerance [385, 386]. This special Mn/Fe ratio was not found
in radiation-tolerant anaerobic microorganisms. It is pro­
posed that the low levels of IR-generated ROS under anaero­
bic conditions combined with highly constitutively expressed
detoxification systems in these anaerobes are key to their
radiation resistance and circumvent the need for the accumu­
lation of Mn-antioxidant complexes in the cell [387].
Furthermore, polyploidy or the presence of several DNA
copies within one single cell has been discussed to contribute
to tolerance to desiccation and therefore also to ionizing
radiation [388].
Halophilic organisms have different strategies to cope
with a high salt concentration in their natural habitat. One
option is the intracellular accumulation of salt or other com­
patible solutes [389]. It is also known that compatible solutes
can contribute to the tolerance to ionizing radiation in halo­
philic microorganisms [389]. Additionally, protective mech­
anisms such as membrane pigments, including carotenoids,
melanin, scytonemin, and bacterioruberin were found to be
important in ionizing radiation protection in different organ­
isms through the scavenging of hydroxyl radicals [390, 391].
10.9.2.3
How Relevant Are These Adaptations/
Mechanisms for Space Radiation?
In general, there is no direct adaptation of microorganisms to
space conditions or space radiation known as all organisms
evolved on Earth. Nevertheless, there have been and still are
space experiments ongoing where the adaptability of differ­
ent organisms is investigated during exposure to space con­
ditions. In this context, we speak about the side effects of
other tolerances or resistances which enable the organisms to
endure space stressors. In general, organisms which are tol­
erant to desiccation developed mechanisms to repair the
DNA which is damaged during the desiccation process. The
same repair mechanisms can also be used to repair DNA
damage caused by other stressors, such as ionizing radiation.
One prominent example is the desiccation and radiation tol­
erance of the microorganism Deinococcus radiodurans. This
organism uses the same cellular adaptation and repair strate­
gies after exposure to drought and ionizing radiation expo­
sure. However, not all desiccation-tolerant organisms are
tolerant to (ionizing) radiation exposure [392]. The same is
true for other repair machineries, where no direct correlation
between hyper-/thermophilic organisms or the ability to pro­
duce compatible solutes and radiation tolerance could be
identified [393, 394]. In addition, some microorganisms
(e.g., Ignicoccus hospitalis) demonstrate a high survival rate
after ionizing radiation exposure but possess a repair mecha­
nism which is not known up to now [395].
C. E. Hellweg et al."
"Several extremophilic microorganisms, such as *Deinococcus radiodurans* and *Halobacterium salinarum*, exhibit remarkable resistance to ionizing radiation. Describe the key molecular mechanisms employed by these organisms – specifically focusing on differences between them – that contribute to this heightened tolerance, including roles for metal ions, antioxidant enzymes, DNA repair pathways, and cellular structures.","Radiation-resistant extremophiles like *Deinococcus radiodurans* and *Halobacterium salinarum* employ a multifaceted strategy to mitigate the damaging effects of ionizing radiation. *Deinococcus radiodurans* utilizes a unique intracellular manganese (Mn) and iron (Fe) ratio, characterized by high Mn concentrations and low Fe levels. This imbalance appears to neutralize IR-generated reactive oxygen species (ROS) under anaerobic conditions, coupled with highly expressed detoxification systems. Simultaneously, the bacterium employs robust DNA repair mechanisms, likely involving homologous recombination, to correct radiation-induced DNA damage. *Halobacterium salinarum*, conversely, relies on a combination of strategies. It accumulates high intracellular concentrations of salt and compatible solutes like glycerol or betaine, which contribute to osmotic stress tolerance and indirectly protect against radiation damage. Furthermore, it possesses protective membrane pigments such as carotenoids and melanin that scavenge hydroxyl radicals generated by ionizing radiation. Importantly, *Halobacterium* exhibits polyploidy – the presence of multiple DNA copies within a single cell – potentially providing redundancy in its genome and facilitating more efficient DNA repair processes. While both organisms utilize DNA repair mechanisms, the specific pathways and efficiency likely differ based on their unique adaptations to their respective environments. The differing Mn/Fe ratios and pigment profiles highlight distinct approaches to ROS detoxification and radiation protection.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.9	 Space Radiation Resistance | Sub-subsection: 10.9.2	 Mechanisms in Extremophiles | Sub-sub-subsection: 10.9.2.2	 Which Adaptations/Mechanisms Are Known? | Content: Archaea, DNA binding proteins play a major role as they bind
and protect the DNA thereby limiting the accessibility of the
DNA to ROS. In addition, increased expression of different
enzymes like superoxide dismutase and the glutathione peroxi­
dase can also reduce the level of intracellular ROS.
For the Bacterium Deinococcus radiodurans as well as
for the Archaeon Halobacterium salinarum special intracel­
lular Mn/Fe ratios are described: they demonstrate an intra­
cellular accumulation of high amounts of manganese along
with low iron levels, which contribute to their high radiation
tolerance [385, 386]. This special Mn/Fe ratio was not found
in radiation-tolerant anaerobic microorganisms. It is pro­
posed that the low levels of IR-generated ROS under anaero­
bic conditions combined with highly constitutively expressed
detoxification systems in these anaerobes are key to their
radiation resistance and circumvent the need for the accumu­
lation of Mn-antioxidant complexes in the cell [387].
Furthermore, polyploidy or the presence of several DNA
copies within one single cell has been discussed to contribute
to tolerance to desiccation and therefore also to ionizing
radiation [388].
Halophilic organisms have different strategies to cope
with a high salt concentration in their natural habitat. One
option is the intracellular accumulation of salt or other com­
patible solutes [389]. It is also known that compatible solutes
can contribute to the tolerance to ionizing radiation in halo­
philic microorganisms [389]. Additionally, protective mech­
anisms such as membrane pigments, including carotenoids,
melanin, scytonemin, and bacterioruberin were found to be
important in ionizing radiation protection in different organ­
isms through the scavenging of hydroxyl radicals [390, 391].
10.9.2.3
How Relevant Are These Adaptations/
Mechanisms for Space Radiation?
In general, there is no direct adaptation of microorganisms to
space conditions or space radiation known as all organisms
evolved on Earth. Nevertheless, there have been and still are
space experiments ongoing where the adaptability of differ­
ent organisms is investigated during exposure to space con­
ditions. In this context, we speak about the side effects of
other tolerances or resistances which enable the organisms to
endure space stressors. In general, organisms which are tol­
erant to desiccation developed mechanisms to repair the
DNA which is damaged during the desiccation process. The
same repair mechanisms can also be used to repair DNA
damage caused by other stressors, such as ionizing radiation.
One prominent example is the desiccation and radiation tol­
erance of the microorganism Deinococcus radiodurans. This
organism uses the same cellular adaptation and repair strate­
gies after exposure to drought and ionizing radiation expo­
sure. However, not all desiccation-tolerant organisms are
tolerant to (ionizing) radiation exposure [392]. The same is
true for other repair machineries, where no direct correlation
between hyper-/thermophilic organisms or the ability to pro­
duce compatible solutes and radiation tolerance could be
identified [393, 394]. In addition, some microorganisms
(e.g., Ignicoccus hospitalis) demonstrate a high survival rate
after ionizing radiation exposure but possess a repair mecha­
nism which is not known up to now [395].
C. E. Hellweg et al."
"Several microorganisms exhibit radiation resistance through diverse mechanisms. Describe two distinct strategies employed by different microbial groups – namely, *Deinococcus radiodurans* and halophilic organisms like *Halobacterium salinarum* – to mitigate the damaging effects of ionizing radiation.","Microorganisms have evolved remarkable adaptations to withstand the harsh conditions imposed by ionizing radiation. *Deinococcus radiodurans*, a famously resilient bacterium, utilizes a multifaceted approach centered around efficient DNA repair and protection. Specifically, it possesses a highly effective radical-scavenging system involving manganese complexes that bind and neutralize ROS (reactive oxygen species) generated by radiation damage. Furthermore, the organism exhibits exceptional DNA repair capabilities, rapidly fixing double-strand breaks through homologous recombination. In contrast, halophilic organisms like *Halobacterium salinarum* employ a distinct strategy focused on intracellular ion regulation and pigment protection. They accumulate high concentrations of manganese ions within their cytoplasm, forming Mn-antioxidant complexes that directly scavenge ROS. Simultaneously, they utilize carotenoid pigments – such as bacterioruberin – to absorb and dissipate energy from photons before they can damage DNA, effectively acting as a shield against radiation.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.9	 Space Radiation Resistance | Sub-subsection: 10.9.2	 Mechanisms in Extremophiles | Sub-sub-subsection: 10.9.2.3	 How Relevant Are These Adaptations/Mechanisms for Space Radiation? | Content: Archaea, DNA binding proteins play a major role as they bind
and protect the DNA thereby limiting the accessibility of the
DNA to ROS. In addition, increased expression of different
enzymes like superoxide dismutase and the glutathione peroxi­
dase can also reduce the level of intracellular ROS.
For the Bacterium Deinococcus radiodurans as well as
for the Archaeon Halobacterium salinarum special intracel­
lular Mn/Fe ratios are described: they demonstrate an intra­
cellular accumulation of high amounts of manganese along
with low iron levels, which contribute to their high radiation
tolerance [385, 386]. This special Mn/Fe ratio was not found
in radiation-tolerant anaerobic microorganisms. It is pro­
posed that the low levels of IR-generated ROS under anaero­
bic conditions combined with highly constitutively expressed
detoxification systems in these anaerobes are key to their
radiation resistance and circumvent the need for the accumu­
lation of Mn-antioxidant complexes in the cell [387].
Furthermore, polyploidy or the presence of several DNA
copies within one single cell has been discussed to contribute
to tolerance to desiccation and therefore also to ionizing
radiation [388].
Halophilic organisms have different strategies to cope
with a high salt concentration in their natural habitat. One
option is the intracellular accumulation of salt or other com­
patible solutes [389]. It is also known that compatible solutes
can contribute to the tolerance to ionizing radiation in halo­
philic microorganisms [389]. Additionally, protective mech­
anisms such as membrane pigments, including carotenoids,
melanin, scytonemin, and bacterioruberin were found to be
important in ionizing radiation protection in different organ­
isms through the scavenging of hydroxyl radicals [390, 391].
10.9.2.3
How Relevant Are These Adaptations/
Mechanisms for Space Radiation?
In general, there is no direct adaptation of microorganisms to
space conditions or space radiation known as all organisms
evolved on Earth. Nevertheless, there have been and still are
space experiments ongoing where the adaptability of differ­
ent organisms is investigated during exposure to space con­
ditions. In this context, we speak about the side effects of
other tolerances or resistances which enable the organisms to
endure space stressors. In general, organisms which are tol­
erant to desiccation developed mechanisms to repair the
DNA which is damaged during the desiccation process. The
same repair mechanisms can also be used to repair DNA
damage caused by other stressors, such as ionizing radiation.
One prominent example is the desiccation and radiation tol­
erance of the microorganism Deinococcus radiodurans. This
organism uses the same cellular adaptation and repair strate­
gies after exposure to drought and ionizing radiation expo­
sure. However, not all desiccation-tolerant organisms are
tolerant to (ionizing) radiation exposure [392]. The same is
true for other repair machineries, where no direct correlation
between hyper-/thermophilic organisms or the ability to pro­
duce compatible solutes and radiation tolerance could be
identified [393, 394]. In addition, some microorganisms
(e.g., Ignicoccus hospitalis) demonstrate a high survival rate
after ionizing radiation exposure but possess a repair mecha­
nism which is not known up to now [395].
C. E. Hellweg et al.
551
10.10	Irradiation Experiments at Ground-
Based Facilities for Simulation
of the Space Environment
10.10.1	Low Dose Rate Irradiation Facilities
As mentioned at the beginning of this chapter, protons
account for nearly 87% of the total flux of the galactic cos­
mic radiation (GCR), helium ions—for approximately 12%,
and the remaining heavy ions, or high-Z elements (HZE),—
for less than 1%. However, the relative distribution of the
effective dose is quite different. Multiplying the abundance
by Z2 provides an estimate of the contribution to the dose.
One should further consider the quality factor of the biologi­
cal effectiveness of the corresponding radiation. As a result,
HZE particles contribute approximately 89% of the total
dose equivalent (mSv) in free space. Among the HZE parti­
cles in GCR, iron is the largest contributor (26%) to the
effective dose [396].
10.10.2	Low Dose Rate Particle Irradiation
Facilities
Low dose rate irradiation is usually provided in a laboratory
either by X-ray machines or radioactive sources, and neither
mimics GCR well. The X-rays are low-energy radiation and
do not mimic the penetrating capability of GCR. Usual
radioactive sources emit α-, β-, and γ-radiation. While
α-particles are helium nuclei abundant in GCR, the energy of
typical α-particles is 4–9 MeV as compared with above
1000 MeV in GCR. As a result, α-particles cannot penetrate
the thinnest screen (even the skin) and cannot be used for
GCR simulation.
γ-Radiation has a much stronger penetration capability,
and γ-emitters are used [397]. However, the biological effects
of γ-radiation and ions are different. As for the β-radiation, in
the sense of GCR simulation it combines the drawbacks of α
and γ: having low penetrating capability, its biological effects
are similar to γ and far from high-energy ions.
A partial solution has been found by using a unique artifi­
cial isotope Californium-252, which exhibits exceptionally
high neutron emission. 252Cf is used, e.g., at the ESA test
station and the new facility in Japan [398].
10.10.3	Low Energy Particle Irradiation
Facilities
Although low-energy charged particles (up to about 20 MeV)
do not reproduce the characteristics found in the GCR spec­
trum, low-energy facilities are widely available and are use­
ful to help in the screening and the design of experiments
that will be further carried out on higher energy accelerators
(see next subsection).
10.28
­Fig. 10.28
Fig. 10.28 Schematic view of
the SNAKE (Superconducting
nanoprobe for (kern) particle
physics experiments) setup,
including linear particle
accelerator (orange), focusing
unit (superconducting magnetic
lens) and detection system with
the particle detector and ultrafast
high-voltage switch
10 Space Radiobiology"
"The SNAKE experiment utilizes a superconducting magnetic lens to focus particles. Explain the significance of this focusing element within the experimental setup, detailing how it contributes to the simulation of space radiation environments and what physical principles are employed.","The superconducting magnetic lens in the SNAKE (Superconducting Nanoprobe for (kern) particle physics experiments) setup is crucial for precisely controlling and focusing the high-energy particles – typically ions – that mimic space radiation. Its significance stems from several key factors related to simulating space environments. Firstly, space radiation consists of a broad spectrum of charged particles, primarily protons and heavier ions, accelerated to extremely high energies by solar flares and cosmic rays. These particles travel in straight lines until they interact with matter. Without focusing, the particle beam would rapidly diverge, making it impossible to accurately probe materials or biological samples representative of those found in space. The superconducting lens operates on the principle of magnetic confinement. By generating a strong, uniform magnetic field using superconducting coils, the lens bends the trajectory of charged particles, effectively channeling them into a narrow, focused beam. This is analogous to how a glass lens focuses light waves. The ‘superconducting’ aspect is vital; superconductors offer virtually no resistance to current flow, allowing for extremely powerful and stable magnetic fields without energy loss – essential for maintaining the precise focusing over extended periods required for experiments. Furthermore, this focused beam allows researchers to study the effects of space radiation on materials (e.g., spacecraft components) or biological systems in a controlled manner, mimicking the conditions encountered during long-duration space missions. The degree of focus directly relates to the intensity of the radiation delivered to the target, allowing for precise dose measurements and investigations into radiation damage mechanisms. Reference: [Unknown - This response synthesizes general principles of particle beam focusing and superconducting magnet technology relevant to space radiobiology experiments.]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.10	 Irradiation Experiments at Ground-Based Facilities for Simulation of the Space Environment | Content: Fig. 10.28 Schematic view of
the SNAKE (Superconducting
nanoprobe for (kern) particle
physics experiments) setup,
including linear particle
accelerator (orange), focusing
unit (superconducting magnetic
lens) and detection system with
the particle detector and ultrafast
high-voltage switch
10 Space Radiobiology"
"Considering the galactic cosmic radiation (GCR), what factors primarily determine the relative contribution of different particle types – specifically protons, helium ions, and high-Z elements – to the overall biological dose equivalent, and why are HZE particles such a significant contributor despite representing a small fraction of the total ion flux?","The distribution of biological effective dose from GCR is not solely determined by the abundance of each particle type but also critically influenced by its atomic number (Z). Multiplying the abundance of a particle by Z² provides an estimate of its contribution to the overall dose. This is because higher-Z elements, such as heavy ions (HZE), deposit significantly more energy per unit charge when interacting with biological tissue compared to lower-Z particles like protons and helium ions. These interactions lead to greater ionization and damage within cells. While protons and helium ions constitute a larger proportion of the total flux, their lower atomic numbers result in less energetic collisions and therefore a smaller contribution to the overall dose equivalent. Consequently, HZE particles, despite representing less than 1% of the total ion flux, contribute approximately 89% of the total dose equivalent due to their substantially higher energy deposition capabilities upon interacting with biological matter. Iron is the most abundant HZE particle in GCR and thus a major contributor to this effect [396]. ","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.10	 Irradiation Experiments at Ground-Based Facilities for Simulation of the Space Environment | Sub-subsection: 10.10.1	 Low Dose Rate Irradiation Facilities | Content: As mentioned at the beginning of this chapter, protons
account for nearly 87% of the total flux of the galactic cos­
mic radiation (GCR), helium ions—for approximately 12%,
and the remaining heavy ions, or high-Z elements (HZE),—
for less than 1%. However, the relative distribution of the
effective dose is quite different. Multiplying the abundance
by Z2 provides an estimate of the contribution to the dose.
One should further consider the quality factor of the biologi­
cal effectiveness of the corresponding radiation. As a result,
HZE particles contribute approximately 89% of the total
dose equivalent (mSv) in free space. Among the HZE parti­
cles in GCR, iron is the largest contributor (26%) to the
effective dose [396]."
"Considering ground-based facilities designed to simulate space radiation environments, why are X-ray machines and typical radioactive sources often inadequate for accurately replicating Galactic Cosmic Radiation (GCR)?","X-ray machines produce low-energy radiation that lacks the penetrating power characteristic of GCR. This is primarily due to the significantly higher energy levels associated with GCR particles – typically exceeding 1000 MeV – compared to the relatively lower energies emitted by X-ray sources (around 4–9 MeV). Furthermore, while radioactive sources emit α-, β-, and γ-radiation, α-particles are particularly unsuitable for GCR simulation because their low energy (4–9 MeV) is substantially less than that found in GCR.  β-radiation also presents a problem due to its limited penetration capability and biological effects which closely resemble those of γ-radiation, further distancing it from the complex nature of high-energy ions like those encountered in space.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.10	 Irradiation Experiments at Ground-Based Facilities for Simulation of the Space Environment | Sub-subsection: 10.10.2	 Low Dose Rate Particle Irradiation Facilities | Content: Facilities
Low dose rate irradiation is usually provided in a laboratory
either by X-ray machines or radioactive sources, and neither
mimics GCR well. The X-rays are low-energy radiation and
do not mimic the penetrating capability of GCR. Usual
radioactive sources emit α-, β-, and γ-radiation. While
α-particles are helium nuclei abundant in GCR, the energy of
typical α-particles is 4–9 MeV as compared with above
1000 MeV in GCR. As a result, α-particles cannot penetrate
the thinnest screen (even the skin) and cannot be used for
GCR simulation.
γ-Radiation has a much stronger penetration capability,
and γ-emitters are used [397]. However, the biological effects
of γ-radiation and ions are different. As for the β-radiation, in
the sense of GCR simulation it combines the drawbacks of α
and γ: having low penetrating capability, its biological effects
are similar to γ and far from high-energy ions.
A partial solution has been found by using a unique artifi­
cial isotope Californium-252, which exhibits exceptionally
high neutron emission. 252Cf is used, e.g., at the ESA test
station and the new facility in Japan [398]."
"Describe the experimental setup utilizing a tandem accelerator and microbeams as it relates to studying the bystander effect in radiobiology, specifically considering its application within the context of space radiation research.","The SNAKE (Superconducting nanoprobe for (kern) particle physics experiments) utilizes a tandem accelerator – often referred to as a ‘tandem’ accelerator – to generate an initial ion beam that is inherently a microbeam with a diameter typically below 5 μm. This microbeam generation allows for highly selective irradiation of individual cells or specific cellular components within a larger cell population. The accelerator operates by first attracting negative ions towards a positive high-voltage terminal, followed by stripping these ions of electrons in a stripper channel to produce positively charged ions. These ions are then focused and directed into beamlines using superconducting magnets. Crucially, the microbeam configuration is vital for studying the bystander effect, particularly relevant in space radiation research. Because space radiation’s flux of high-mass particles is low and the probability of a single particle ‘shoot’ penetrating a cell is high, this setup enables researchers to precisely target cellular components – such as the nucleus, cytoplasm, or organelles – while monitoring various endpoints like reduced cell survival, DNA double-strand breaks, micronuclei formation, mutations, apoptosis induction, inflammation gene expression, and changes in cell cycle regulation. Beam homogeneity is maintained using plastic scintillators or silicon-based detectors. The ability to control the dose delivered to specific cellular targets provides a powerful tool for understanding how space radiation impacts biological systems at a fundamental level.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.10	 Irradiation Experiments at Ground-Based Facilities for Simulation of the Space Environment | Sub-subsection: 10.10.3	 Low Energy Particle Irradiation Facilities | Content: Facilities
Although low-energy charged particles (up to about 20 MeV)
do not reproduce the characteristics found in the GCR spec­
trum, low-energy facilities are widely available and are use­
ful to help in the screening and the design of experiments
that will be further carried out on higher energy accelerators
(see next subsection).
10.28
­Fig. 10.28
Fig. 10.28 Schematic view of
the SNAKE (Superconducting
nanoprobe for (kern) particle
physics experiments) setup,
including linear particle
accelerator (orange), focusing
unit (superconducting magnetic
lens) and detection system with
the particle detector and ultrafast
high-voltage switch
10 Space Radiobiology
552
(with one extra electron) from hydrogen to uranium. The
produced negative ion beam is then extracted from the source
and guided to the main tube. The acceleration is carried out
in two stages hence the name “tandem accelerator.” First, the
negative ions are attracted to the positive high-voltage “ter­
minal” located in the center of the tube. Then, negative ions
can be stripped of part of their electrons (usually 2–3) in the
stripper channel, turning to positive ions. These positive ions
are repelled by the positive terminal voltage to the end of the
tube, which is at ground potential. High-energy ions are
focused by (usually superconducting) magnets and deflected
into one of the beamlines, according to the particle energy,
mass, and charge.
Regarding the beam size, two configurations are used:
microbeam and broad beam.
The initial accelerated ion beam is always a microbeam
with a diameter often below 5 μm. Microbeams are a useful
tool in studying the bystander effect (described in detail in
Chap. 2). Indeed, such a beam permits to irradiate selectively
one or more cells inside a population. This offers the possi­
bility to either target the cell nucleus, the conventional target
in radiobiology, the cytoplasm, or organelles. It also provides
the advantage of knowing precisely the dose delivered to the
cells and the number of particle shoots being determined in
advance. In the context of space radiation, where the flux of
high-mass particles is very low and the occurrence of a sin­
gle shoot-in through a cell is very high, the bystander effect
is a topic of crucial importance. Indeed, it is observed through
a variety of endpoints: reduction in cell survival, double
strand break induction, micronuclei, mutations, and expres­
sion of apoptosis, inflammation, and cell cycle-related genes.
Broad beams can be produced either by using scattering
foils, by scanning microbeam, or by defocusing them. Beam
homogeneity is controlled by plastic scintillators or silicon-
based detectors."
"Describe the key components and operational principles involved in generating high-energy particle beams within facilities like the NASA Space Radiation Laboratory (NSRL), focusing on aspects such as accelerating cavities, RF power generation, and beam collimation.","Facilities utilizing resonant frequencies, typically around 1 GHz or 3 GHz (L-band or S-band respectively), employ radio frequency (RF) energy to accelerate charged particles – primarily heavier ions up to atomic number Z=79 (gold). This RF power is usually generated by high-power klystrons. The acceleration occurs within accelerating cavities, which can be constructed from normal conducting materials like copper (resulting in ‘warm’ cavities) or superconducting materials like niobium, requiring cryogenic cooling to liquid helium temperatures. Accelerating gradients are typically between 10 and 30 MeV/m; for example, the SLAC accelerator achieved an average gradient of approximately 17 MeV/m when accelerating electrons to 50 GeV using 3-GHz copper cavities. These cavities produce ‘micropulses’ – short bursts of energy (e.g., below 20 ps duration at S-band) that constitute a ‘macropulse’. Particle beams are then collimated and bent using magnetic lenses, which are created by electromagnets or permanent magnets. These devices, known as electron-optic (or ion-optic) devices, function similarly to optical lenses but utilize electromagnetic fields to manipulate the particle beam trajectory. The field of study governing these devices is distinct from classical optics and is detailed in texts like Reiser [402].","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.10	 Irradiation Experiments at Ground-Based Facilities for Simulation of the Space Environment | Sub-subsection: 10.10.4	 High-Energy Particle Irradiation Facilities | Content: Facilities
­
10.29
Fig. 10.29 Aerial view and
general layout of the NASA
Space Radiation Laboratory
(NSRL) facility in Upton, NY,
USA. EBIS electron beam ion
source. (Satellite view courtesy
Google Earth)
C. E. Hellweg et al.
553
Heavier ions with atomic numbers up to Z = 79 (Au) are
limited to approximately 350–500 MeV per nucleon (https://
www.bnl.gov/nsrl/).
396
399
10.30
­
400
­
401
10.31
10.31
The resonant frequency is usually either about 1 GHz
(L-band of the RF spectrum) or about 3 GHz (S-band). The
electromagnetic power for feeding the RF cavities is gener­
ated usually by a high-power klystron.
The accelerating cavities can be made either of normal-
conducting metal (“warm” cavities usually made of copper)
or of superconductor (usually, niobium). In the last case,
cryogenic cooling to liquid-helium temperature is needed.
Accelerating gradients are usually in the range of 10–30
MeV/m, e.g., the 3-km long SLAC accelerator commis­
sioned back in the 1960s, accelerating electrons to the energy
of 50 GeV, has an average accelerating gradient of about 17
MeV/m (with 3-GHz copper cavities).Fig. 10.30
Fig. 10.30 Three key areas
developed to provide the GCR
simulator at NSRL. (Source:
Simonsen et al. [396], reproduced
with permission)Fig. 10.31
Fig. 10.31 General layout of a
linear high-energy particle
accelerator. RF radio frequency
10 Space Radiobiology
554
Output of RF-driven particle accelerator necessarily con­
sists of single bunches. Such bunches are called micropulse,
and their duration is just a fraction of the oscillating field
period. For example, for the S-band with period of about
300 ps = (3 GHz)–1, the typical micropulse duration is below
20 ps. The train of micropulse is called “macropulse.” While
there is no theoretical limit for macropulse length, practically
it is limited by the driving klystron pulse length: For S-band
normal-conducting linacs the typical value is 5–20 μs, for
L-band superconducting linacs—much longer (1 ms and
more).
Particle beams are collimated and bent “magnetic
lenses”—magnetic fields created by electromagnets or per­
manent magnets. These magnetic devices, governing the
charged particle beam propagation, are called electron-optic
(or ion-optic) devices. Such devices have some similarities
to classical light optics in terms of mathematics, but in gen­
eral comprise a separate field of knowledge. The reader
interested in learning the field of particle beam optics is
referred to the classical textbook of Reiser [402]."
"Describe the key environmental stressors simulated within Earth-based exposure chambers designed to mimic the space environment, referencing specific parameters like pressure, temperature, and radiation.","Earth-based exposure chambers used to simulate the space environment primarily focus on replicating several critical factors that differ significantly from conditions on Earth. Firstly, low pressure is meticulously controlled, ranging from approximately 10–1 Pa near Earth’s atmosphere to 10–14 Pa in deep space. This is achieved through vacuum chambers. Secondly, extremely cold temperatures are simulated, with molecular mean free paths dramatically increased due to the low-pressure environment, resulting in temperatures typically between 3 and 4 K (–270 to –260°C). Cooling systems within the chamber maintain these low temperatures. Thirdly, solar radiation is a crucial element, reproduced through electromagnetic sources that mimic the Sun’s spectrum, including X-rays, visible light (approximately 1400 W/m² heat flux), infrared, and ultraviolet wavelengths. Furthermore, chambers employ neutral density filters and cut-off waveband filters to precisely control irradiance levels across different spectral ranges, allowing researchers to investigate the specific wavelengths most detrimental to biological samples. Finally, these facilities simulate cyclical temporal behaviors mirroring day/night cycles (91 min period) and orbital plane shifts (approximately 1 month period), with fluctuations in total irradiance and temperature up to 60°C observed during these periods. Reference: [MolecularRadiationBiology, Section 10.10.5 – Space Environment Simulation Platforms]","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.10	 Irradiation Experiments at Ground-Based Facilities for Simulation of the Space Environment | Sub-subsection: 10.10.5	 Space Environment Simulation Platforms | Content: Platforms
Although ionizing radiations were identified as the main
showstopper to exploration mission, there are additional
stresses in the space environment. While most of the factors
below are not relevant to astronauts, they are important in
studying extremophiles.
1.	Low pressure: The pressure varies from 10–1 Pa near
Earth atmosphere to 10–14 Pa in deep space. Due to the
degassing, pressure around the ISS is higher than in deep
space ranging from 10−7 Pa in the Ram direction (e.g.,
front of the ISS relative to flight direction) to 10−4 Pa in
the Wake direction (e.g., rear of the ISS relative to flight
direction) [403].
2.	Cold temperature: The low-pressure environment previ­
ously described drastically increases the molecular mean
free path in space resulting in low heat transfer.
Consequently, the temperature in deep space ranges from
3 to 4 K (–270 to –260°C) [404].
3.	Solar radiation: Highly energetic phenomena are occur­
ring in the Sun leading to the emission of high-intensity
electromagnetic radiations. By moving away from the
Sun, the emitted solar radiations are spread out over a
large surface area reducing the solar irradiance with
increased Sun-object distance. ISS, located at one astro­
nomical unit distance from the Sun, is exposed to an
approximate 1400 W/m2 heat flux. The associated elec­
tromagnetic spectrum extends from X-rays to radio waves
with a higher proportion in the visible (47%), infrared
(45%), and ultraviolet (7%) ranges [405].
4.	Day and night cycles: As ISS orbits around the Earth and
the latter around the Sun, the stress exposure has a cyclic
temporal behavior with two main periods. The “day and
night” cycle caused by the rotation around the Earth has a
period of 91 min resulting in fluctuation in total irradi­
ance and temperature of more than 1000 W/m2 and 5–10
°C. The second cycle (period of approximately 1 month)
is due to the position change of ISS orbital plane relative
to the Sun. In this case, greater variations of temperature
(up to 60 °C) with a maximal temperature of about 50 °C
were reported [406].
To study the biological impact of the space environment,
modules outside the ISS are an ideal environment to expose
biological samples to LEO, where the conditions strongly
differ from the ones encountered on Earth. However, the
poor availability of these facilities stimulated the creation of
exposure chambers on Earth capable of reproducing this
LEO environment. The Laboratory for Analysis by Nuclear
Reactions (LARN, University of Namur, Belgium, https://
www.unamur.be/en/sci/physics/ur-en/larn-en) has developed
an exposure module to simulate the aforementioned condi­
tions on the ground for extended periods of time (several
months). To this end, biological samples are placed into a
vacuum chamber and exposed to various constraints. A cool­
ing system located underneath the sample tray and an elec­
tromagnetic source reproducing the solar spectrum are
controlled by a monitoring system capable to simulate the
slow and fast cycles described above. In addition, a variety of
neutral density filters and cut-off waveband filters enables to
create multiple irradiance conditions within the same experi­
ment, in order to investigate what part of the UV-visible
spectrum is the most deleterious.
A similar facility also exists at DLR Cologne and has
been recurrently used for pre-flight test programs and mis­
sion ground reference experiments for several astrobiologi­
cal long-term space missions [405]."
"The text describes several cyclical radiation exposures experienced by samples within a simulated Low Earth Orbit (LEO) environment. Detail the two primary temporal cycles impacting irradiance and temperature, including their respective periods and typical magnitude of fluctuation observed in total irradiance and temperature.","Within the simulated LEO environment, two distinct temporal cycles significantly influence the radiation exposure experienced by biological samples. The first cycle is driven by the Earth’s rotation, resulting in a period of approximately 91 minutes. This ‘day and night’ cycle causes fluctuations in total irradiance exceeding 1000 W/m² and temperature variations ranging from 5 to 10 °C. The second cycle stems from the orbital plane shift of the ISS relative to the Sun, exhibiting a period of roughly one month. During this phase, greater temperature variations – potentially reaching up to 60°C with a maximal temperature around 50°C – are observed. These cycles represent a complex interplay between Earth’s rotation and the ISS's orbital position, creating dynamic radiation profiles that researchers aim to replicate in ground-based exposure chambers.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.11	 Exercises and Self-Assessment | Content: (45%), and ultraviolet (7%) ranges [405].
4.	Day and night cycles: As ISS orbits around the Earth and
the latter around the Sun, the stress exposure has a cyclic
temporal behavior with two main periods. The “day and
night” cycle caused by the rotation around the Earth has a
period of 91 min resulting in fluctuation in total irradi­
ance and temperature of more than 1000 W/m2 and 5–10
°C. The second cycle (period of approximately 1 month)
is due to the position change of ISS orbital plane relative
to the Sun. In this case, greater variations of temperature
(up to 60 °C) with a maximal temperature of about 50 °C
were reported [406].
To study the biological impact of the space environment,
modules outside the ISS are an ideal environment to expose
biological samples to LEO, where the conditions strongly
differ from the ones encountered on Earth. However, the
poor availability of these facilities stimulated the creation of
exposure chambers on Earth capable of reproducing this
LEO environment. The Laboratory for Analysis by Nuclear
Reactions (LARN, University of Namur, Belgium, https://
www.unamur.be/en/sci/physics/ur-en/larn-en) has developed
an exposure module to simulate the aforementioned condi­
tions on the ground for extended periods of time (several
months). To this end, biological samples are placed into a
vacuum chamber and exposed to various constraints. A cool­
ing system located underneath the sample tray and an elec­
tromagnetic source reproducing the solar spectrum are
controlled by a monitoring system capable to simulate the
slow and fast cycles described above. In addition, a variety of
neutral density filters and cut-off waveband filters enables to
create multiple irradiance conditions within the same experi­
ment, in order to investigate what part of the UV-visible
spectrum is the most deleterious.
A similar facility also exists at DLR Cologne and has
been recurrently used for pre-flight test programs and mis­
sion ground reference experiments for several astrobiologi­
cal long-term space missions [405].
10.11	Exercises and Self-Assessment
Q1.	Which types of radiation exist in space?
Q2.	Are astronauts fully protected from radiation by space­
craft walls?
Q3.	Can you describe the difference between the radiation
environment on Earth (on ground) and the one at the
surface of Mars?
Q4.	What do we know now about specific health problems
of astronauts?
Q5.	What is the role of plants in Bioregenerative Life
Support Systems (BLSS)?
Q6.	What is the 3R Principle?
C. E. Hellweg et al.
555
Q7.	What kind of chronic effects on the CNS (central ner­
vous system) were observed?
Q8.	What is the difference between organoids and
spheroids?
Q9.	From which cells organoids can be cultured?
Q10.	What is the main reason why bioprinting and other 3D
cultures can be better cultured in Space?
Q11.	What parameters should be considered if we would
like to simulate conditions on Moon/Mars surface or
in deep space (including stress unrelated to
radiation)?
Q12.	What is the interest to study the biological effects of
low energy charged particles in the context of space
radiation exposure?"
"Considering the potential radiation hazards faced by astronauts during long-duration space missions, particularly those venturing to destinations like Mars where atmospheric shielding is minimal, explain how Galactic Cosmic Rays (GCRs) and Solar Energetic Particles (SEPs) contribute to intravehicular radiation fields and what specific biological consequences have been observed or predicted in these environments.","Galactic Cosmic Rays (GCRs) pose a significant threat due to their high penetrating power. These particles, originating from outside our solar system, continuously bombard spacecraft and astronauts. When GCR ions interact with the spacecraft walls, they generate cascading secondary particle showers – a phenomenon known as a ‘cascade.’ This creates a complex, highly energetic intravehicular radiation field that is far more intense than the direct flux of GCRs themselves. Solar Energetic Particles (SEPs), released during solar flares and coronal mass ejections, represent another substantial hazard. While SEPs are often partially shielded by the Earth’s atmosphere, this protection diminishes dramatically in deep space or on Mars due to the thin Martian atmosphere. The biological consequences of exposure to these particles include several observed effects: reduction of dendrites (a marker of neuronal damage), decreased neurogenesis and increased neuroinflammation within the hippocampus, and diminished hippocampal neuron excitability. Furthermore, prolonged exposure is hypothesized to increase cancer risk through a linear no-threshold (LNT) model, although the applicability of this model at low dose rates remains debated. The variability in radiation spectra – influenced by location and events like solar proton flares – adds another layer of complexity to assessing and mitigating these risks.","Document: MolecularRadiationBiology | Section: 10: Space Radiobiology | Subsection: 10.12	 Exercise Answers | Content: SQ1.	Galactic Cosmic Rays, Solar Energetic Particles,
Trapped radiation, and the solar wind
SQ2.	No, the high penetrating character of GCRs and the
cascades of secondary particles generated by the pas­
sage of GRCs ions through the spacecraft walls cre­
ate an intravehicular field which is of high concern
for the health risk of astronauts
SQ3.	On Earth we are protected by both the atmosphere
and the magnetic field: GCRs hitting the top of the
atmosphere create particle showers but only a few of
such secondaries (and very few of direct GCR ions)
reach the ground. SEP are mostly shielded by the
atmosphere and are of concern only for extreme
events and mostly for high latitude/high-altitude
flights for eventual biological risks, or on ground for
infrastructures. On Mars, the very thin atmosphere
offers very little shielding, and the exposure to
GRCs, their secondary particles, and SEP is a
concern.
SQ4.	Though there are many concerns, the present evi­
dence does not provide a conclusive answer.
Astronauts as a cohort are not less healthy than US
Air Force pilots, e.g., and much healthier than the
general public (due to selection). The LNT-estimated
cancer death risk for prolonged missions is consider­
able, but applicability of LNT for low dose rates is
questionable.
SQ5.	Plants in LSS remove carbon dioxide and provide
oxygen, help water purification, can recycle wastes
of the astronauts, and provide fresh food for the crew.
SQ6.	Reduction (first R) of animal numbers, Refining (sec­
ond) the test methods to lower the harm to the animal
to a minimum, and Replace (third) animal experi­
ments with alternative methods, when possible
SQ7.	Reduction of dendrites, reduced neurogenesis and
increased neuroinflammation, diminished hippocam­
pal neuron excitability
SQ8.	Spheroids are also a 3D cell cultures, but in compari­
son to organoids, they form simple clusters into
sphere-like formation, but they cannot self-assemble
or regenerate.
SQ9.	Pluripotent stem cells
SQ10.	Microgravity
SQ11.	The particular profile of radiation spectrum can vary
according to the location of interest. The ISS envi­
ronment benefits from some protection granted by
the Earth magnetic field. This is not the case for deep
space or Mars, where the full spectrum of galactic
cosmic rays should be considered. Solar proton
events should be included, can vary in magnitude and
their extent also depends on the distance to the sun.
Beside radiation, day and night cycle can impact
temperature conditions, which lead to biological
effects on some model organisms. Pressure value and
the presence or not of atmosphere should also be
considered.
SQ12.	Although the vast majority of particles in the GCR
spectrum have very high energy, low energy charged
particles are still produced in shielding materials and
arise from fragmentation of heavier energetic nuclei.
These low-energy particles often traverse shielding
and remain of concern."
"Describe the roles of radioprotectors, radiosensitizers, and radiomitigators in radiation therapy, detailing the specific cellular and molecular mechanisms involved in each.","Radioprotectors, radiosensitizers, and radiomitigators represent distinct strategies within radiation therapy aimed at modulating the cytotoxic effects of ionizing radiation. Radioprotectors function to minimize damage to normal tissues alongside cancerous cells, often by scavenging free radicals or inhibiting DNA repair pathways. Mechanisms include compounds like N-acetylcysteine (NAC), which reduces oxidative stress by acting as a glutathione precursor, and melatonin, which can interfere with DNA strand breaks. Conversely, radiosensitizers enhance the sensitivity of cancer cells to radiation while ideally sparing normal tissues. They achieve this through various mechanisms such as increasing DNA damage, disrupting DNA repair processes like homologous recombination or mismatch repair, or promoting cell cycle arrest at vulnerable points. Examples include cisplatin and gemcitabine, which target DNA replication and repair respectively. Radiomitigators, on the other hand, aim to improve the efficacy of radiation itself by enhancing its ability to induce cellular damage. This can be achieved through mechanisms like increasing oxygen levels within cells (which boosts reactive oxygen species production – a key component of radiation damage) or modulating cell cycle checkpoints to force cancer cells into mitosis where they are more vulnerable to radiation. The combined application of these molecules—radioprotectors, radiosensitizers, and radiomitigators—offers a sophisticated approach to maximizing tumor control while minimizing adverse effects in surrounding healthy tissues by targeting multiple stages of the cellular response to ionizing radiation.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Content: and the associated molecular mechanisms. The com­
bined action of these molecules with radiation offers
a new strategy for enhanced IR cytotoxicity in cancer
cells together with reducing normal tissue toxicity.
M. Falk
Department of Cell Biology and Radiobiology, Institute of
Biophysics, Czech Academy of Sciences, Brno, Czech Republic
e-mail: falk@ibp.cz
G. Schettino
National Physical Laboratory (NPL), Teddington, United Kingdom
e-mail: giuseppe.schettino@npl.co.uk
V. Ahire
Chengdu Anticancer Bioscience, Ltd., J. Michael Bishop Institute
of Cancer Research, Chengdu, China
T. Boterberg
Department of Radiation Oncology, Ghent University Hospital,
Ghent, Belgium
Particle Therapy Interuniversity Center Leuven, Department of
Radiation Oncology, University Hospitals Leuven, Leuven,
Belgium
e-mail: tom.boterberg@ugent.be
N. Dainiak
Department of Therapeutic Radiology, Yale University School of
Medicine, New Haven, CT, United States of America
P. Chaudhary
The Patrick G. Johnston Centre for Cancer Research, Queen’s
University Belfast, Belfast, Northern Ireland, United Kingdom
e-mail: p.chaudhary@qub.ac.uk
K. P. Mishra
Radiobiology Unit, Bhabha Atomic Research Center, Mumbai,
Maharashtra, India
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_11
572
By the end of this chapter, readers are expected to under­
stand the importance of applying current knowledge in the
development of new synthetic or natural radioprotectors and
radiosensitizers and develop an understanding of their cellu­
lar and molecular mechanisms of action.
11.1"
"Considering the potential hazards associated with radiation exposure across various sectors like medicine, industry, and in emergency scenarios such as nuclear accidents or terrorism, what is the fundamental goal of utilizing radioprotectors, radiosensitizers, and radiomitigators?","The overarching goal of employing radioprotectors, radiosensitizers, and radiomitigators is to mitigate the detrimental effects of ionizing radiation on living organisms. Radioprotectors aim to reduce overall radiation exposure by minimizing damage to tissues and cells. Radiosensitizers, conversely, enhance the sensitivity of cancerous cells to radiation, thereby increasing their susceptibility to treatment while ideally sparing normal tissue. Finally, radiomitigators work to actively remove or neutralize free radicals generated during irradiation, which are a primary cause of cellular damage. The combined use of these agents represents a multi-faceted approach to managing radiological risks and protecting individuals from the harmful consequences of radiation exposure across diverse contexts – from routine medical procedures to catastrophic events demanding immediate response capabilities.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Content: Radiation protection aims to reduce unnecessary radiation
exposure with the intention to minimize the harmful effects
of radiation on human health. With increasing use of radia­
tion technologies and radioisotopes in medicine and indus­
try, the risk of radiological and nuclear accidents escalates,
affecting human health. Nuclear power plants and industrial
accidents pose a serious threat to public health. Emergency
preparedness in an event of nuclear terrorism and nuclear
warfare requires the use of existing radiomodifiers and pub­
lic health measures such as sheltering in place and the use of
personal protective equipment (PPE). New approaches are
urgently needed for protecting the persons working in a radi­
ation field, first responders, and general population in the
form of safe, effective, and easily accessible radioprotective
agents.
­
­
­
11.1
­
­
11.2"
"Describe the key mechanisms by which radioprotectors function, focusing on strategies to mitigate radiation damage at a cellular level.","Radioprotectors employ several interconnected strategies to minimize the detrimental effects of ionizing radiation. Primarily, they aim to reduce direct and indirect radiation damage through scavenging free radicals – both suppressing their formation and detoxifying radiation-induced species like hydroxyl radicals (•OH). This is achieved through increasing levels of antioxidant defenses such as reduced glutathione (GSH) and antioxidant enzymes including superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), and thioredoxin reductase. Furthermore, radioprotectors can induce hypoxia in cells to avoid the synthesis of reactive oxygen species (ROS). Additionally, they actively trigger or enhance cellular DNA damage repair pathways, such as those mediated by ATM/ATR and p53.  Some compounds, like Pifithrin (PFT)-μ, directly inhibit apoptotic signaling cascades involving proteins like Apaf-1 and Bcl-2 family members, thereby preventing programmed cell death. Modulation of growth factors and cytokines, particularly through the activation of Nrf2 or PPAR-γ, further contributes to radioprotection by reducing inflammation and oxidative stress. Finally, some radioprotectors can facilitate tissue regeneration via mechanisms such as stimulating stem cell therapy or promoting angiogenesis.  The combined effect of these strategies represents a holistic multimechanistic approach to achieve optimal radiation protection.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.1	 Radioprotectors | Content: ­
­
11.3
A. Montoro et al.
573
Over the last few decades, many natural and synthetic
compounds have been investigated for their potential as
radioprotectors. Natural or synthetic radioprotectors are able
to (i) reduce direct or indirect radiation damage, (ii) repair
direct and indirect damage once they have occurred, and (iii)
facilitate the repair of damaged cells or recover depleted cell
populations [1].
It should be stressed that the majority of the compounds
discussed below are currently not used in routine clinical
practice and are still under preclinical or clinical evaluation.
Early development of synthetic radioprotectors focused
on thiol compounds (e.g., amifostine) and their derivatives,
which have been used in cancer patients, to prevent compli­
cations of RT. In addition, they have been thought to be use­
11 Radioprotectors, Radiomitigators, and Radiosensitizers
574
ful in accidental radiation exposure scenarios [2]. However,
the practical applicability of the majority of these synthetic
compounds remained limited owing to their limited adminis­
tration routes, narrow administration window for efficacy,
high toxicity at high doses or at recurrent usage, and cost
factors as well. Besides thiol compounds, various com­
pounds with different chemical structures are being investi­
gated to develop an ideal radioprotector; there is still an
urgent need to identify and develop novel, nontoxic, effec­
tive, and biocompatible compounds which can adequately
protect normal tissues with no sparing of the tumor cells.
An interest has been emerging in developing potential
new candidate drugs from natural plants and phytochemi­
cals. Plant products could bridge the gaps in the search for an
ideal radioprotector due to its abundance, typically low tox­
icity, and relatively low cost.
Characteristics of an Ideal Radioprotector
An ideal radioprotective agent should (a) be efficient in pro­
viding multifaceted protection, (b) prevent direct and indi­
rect acute or chronic effects on normal tissue, (c) be easily
and comfortably administered without toxicity, (d) cause no
or minimal adverse effects on the test organism, (e) have a
sufficiently long time window of effectiveness after adminis­
tration and also have a sufficiently long shelf life, (f) have an
acceptable stability profile (both of bulk active product and
formulated compound), (g) be compatible with a wide range
of other drugs, (h) not protect tumors from IR, and (i) be eas­
ily accessible and economical and should not require special
handling and transportation temperatures (Box 11.1).
Underlying Mechanisms of Radioprotectors
11.4
•	Scavenging free radicals (either by suppressing the for­
mation or by detoxifying radiation-induced free radical
species).
•	Inducing hypoxia in cells in order to avoid synthesis of
reactive oxygen species (ROS).
•	Increasing levels of antioxidant defenses such as GSH
(reduced glutathione) and/or antioxidant enzymes (super­
oxide dismutase (SOD), glutathione peroxidase (GPx),
thioreductase, catalase (CAT), etc.).
•	Triggering one or more cellular DNA damage repair
pathways.
•	Impeding cell division or inhibiting apoptotic cell death.
Box 11.1: Radioprotectors
•	Radioprotectors (synthetic compounds, natural
plant extracts, and phytochemical derivatives) are
designed to lessen the effects of radiation-induced
damage in healthy tissues.
•	Radioprotective drugs are effective when adminis­
tered prior to or during radiation exposure to reduce
the radiation-induced injuries/toxicities.
•	Safe, novel, nontoxic, and easily accessible radio­
protective agents are needed to be developed for
human health.
A. Montoro et al.
575
•	Modulating redox-sensitive genes.
•	Modulating growth factors and cytokine production.
•	Controlling inflammatory response.
•	Chelating or decorporating radionuclides.
•	Promoting tissue regeneration (intestinal or hematopoi­
etic and immunostimulant compounds), gene therapy,
and/or stem cell therapy. In most cases, these molecules
are administered after exposure to radiation, which is why
they should be also considered radiomitigators.
The most common mechanisms of radioprotection are the
scavenging of free radicals, repair of DNA damages, inhibi­
tion of apoptosis or inflammation, increase antioxidant
defenses, and modulation of growth factors, cytokines, and
redox genes. Thus, the management of radiation exposure
may require a holistic multimechanistic approach to achieve
optimal radiation protection during RT of cancer patients and
in cases of nuclear accidents or emergencies [3] (Box 11.2).
11.5
Antioxidant Activity
Radioprotectors should prevent/suppress the formation of
radiation-induced free radicals (most of them are produced
during radiolysis with water), thereby inhibiting their reac­
tions with biomolecules, reducing the incidence of DNA
strand breaks, and preventing the occurrence of cellular mal­
function (more detail in Chap. 2). Since free radicals are
short-lived (approximately 10−10 s) and interact rapidly with
biomolecules, it is necessary that radioprotectors are present
in sufficient concentration in the cellular milieu, at the time
of radiation exposure.
Molecules or compounds which increase the activity or
expression of antioxidant enzymes are also considered radio­
protectors. Many antioxidants have the potential to act as
radioprotectors; however, not all antioxidants offer radiopro­
tection, and this paradox may be explained by the relative
activity of a compound when reacting with radiation-induced
reactive species compared with those generated under H2O2
­induced oxidative stress. Conventional antioxidants may not
be able to scavenge this less reactive secondary species
because either they do not accumulate in proximity to the
secondary radicals or they may not have enough kinetic reac­
tivity to scavenge them effectively. Thiols (e.g., amifostine),
hydrophilic antioxidants (e.g., GSH), and newly developed
cyclic nitroxides have adequate reactivity to effectively scav­
enge •OH and secondary radicals as well.
Molecule-Based
Radioprotection
or
Molecular
Radioprotection
Molecules or events that play a role late in signaling and
IR-induced apoptotic pathways may act as potential targets
for post-irradiation interventions.
•	ATM/ATR is activated by DNA damage and DNA
­replication stress; however, they often work together to
signal DNA damage and trigger apoptotic cell death by
upregulating proapoptotic proteins such as apoptotic
protease-­activating factor-1 (Apaf-1), phorbol-12-my­
ristate-13-acetate-induced protein 1 (Noxa), and Bcl2-
associated X (Bax) after IR.
•	Pifithrin (PFT)-μ (2-phenylethynesulfonamide) directly
inhibits p53 binding to mitochondria as well as inactivates
the antiapoptotic proteins Bcl-xL and Bcl-2 on the mito­
chondrial surface, thereby suppressing subsequent release
of cytochrome c and apoptosis, whereas PFT-μ reversibly
inhibits
transcriptionally
mediated
p53-dependent
apoptosis.
•	Signal transducer and activator of transcription 3 (STAT3)
can be activated by various growth factors and protects
against IR damage. The protection mediated by STAT3 is
attributed to its genomic actions as a transcription factor
(such as upregulating genes that are antioxidative,
antiapoptotic, and proangiogenic, but suppressing anti-­
inflammatory and antifibrotic genes) and other nonge­
nomic roles targeting mitochondrial function and
autophagy.
•	Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a
well-characterized ubiquitous master transcription factor,
whose activity is tightly controlled by cytoplasmic asso­
ciation along with its redox-sensitive transcriptional
inhibitor Kelch-like ECH-associated protein 1 (Keap1). A
well-known mechanism of activation of Nrf2 signaling
protects cells against radiation-induced oxidative stress
and also maintains cellular reduction-oxidation homeo­
stasis. Upon oxidative stress, Nrf2 dissociates from Keap1
Box 11.2: Possible Mechanisms of Radioprotectors
•	Radioprotectors can be screened for their effective
emerging strategies, such as modulation of growth
factors, cytokines, redox genes, and tissue renewal.
•	The radioprotective agents are often antioxidants,
which may suppress or scavenge the radiation-­
induced free radicals from the cell.
•	These compounds are cofactors or can induce/stim­
ulate antioxidants enzymes (like SOD, GPx,
and) activity, which would likely lead to both pre­
vent DNA damage and decrease in lipid
peroxidation.
•	They may have the ability to enhance DNA repair,
reduce the postradiation inflammatory response, or
even delay cellular division allowing more time for
cells to repair the DNA damage or undergo cell
death.
11 Radioprotectors, Radiomitigators, and Radiosensitizers
576
­
­
­
Volume 1, Issue 3
and translocates into the nucleus to activate a series of
antioxidant response elements, such as GPx, SOD, CAT,
and heme oxygenase-1 (HO-1), increasing total cellular
antioxidant capacity (TAC), accompanied by suppressed
expression of inflammatory-related genes, avoiding oxi­
dative stress and excessive inflammatory response, which
is particularly important in radioprotection.
•	Heat-shock proteins (HSPs), molecular chaperones, are
induced in cells during stress conditions. Importantly,
HSPs are cytoprotective and can mediate cell and tissue
repair after IR-induced deleterious effects. Higher cyto­
solic levels of HSPs have been shown to induce radiopro­
tective effects by interfering with apoptotic pathways.
•	Peroxisome proliferator-activated receptor-γ (PPAR-γ),
ligand-activated transcription factors, is a part of the
nuclear hormone receptor family. It suppresses IR-­
induced survival signals and DNA damage responses and
enhances IR-induced apoptosis signaling in human cells.
11.1.1.1
Thiol-Containing Molecules
­
4
­
11.6
A. Montoro et al."
"Describe the potential applications of cyclic nitroxides (NRs) as radioprotectors and mitigators, citing specific examples from research.","Cyclic nitroxides (NRs), particularly Gramicidin S-derived JP4–039, are demonstrating significant promise in mitigating radiation damage. Research indicates that intravenous administration of JP4–039 up to 72 hours post-exposure can effectively reduce the severity of total body irradiation (TBI) effects. Specifically, studies have shown its ability to ameliorate head and neck radiation-induced mucositis and suppress distant marrow suppression in mice [17]. Furthermore, a comparative analysis against other nitroxides revealed JP4–039’s superior median survival rate following radiation exposure [18]. The ongoing interest in these molecules stems from their demonstrated radioprotective activity, exemplified by the use of nitronyl-nitroxide radical spin-labeled resveratrol [19], suggesting a potential role in broader therapeutic strategies for managing radiation injury. Reference: MolecularRadiationBiology, Section 11.1.2 – Cyclic Nitroxides (NRs)","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.2	 Cyclic Nitroxides (NRs) | Content: have demonstrated anticarcinogenic effects [4]. However,
as it happens with other more powerful thiolic radioprotec­
tors (such as amifotine), its use is limited due to undesir­
able side effects.
11.1.2	Cyclic Nitroxides (NRs)
.
­
­
11.7
­
­
­
16
Gramicidin S-derived nitroxide (JP4–039) is an effective
TBI mitigator when is delivered intravenously up to 72 h
after exposure. JP4–039 treatment ameliorated head and
neck radiation-induced mucositis and distant marrow sup­
pression in mice [17]. In a comparative study with other four
nitroxides, JP4-039 demonstrated the best median survival
after radiation exposition [18]. The potential of this type of
molecules as radioprotectors and/or mitigators has raised the
interest of researchers, and nitroxidic structures has evi­
denced radioprotective activity. That is the case of nitronyl-
nitroxide radical spin-labeled resveratrol [19]."
"Several antibiotics, including streptomycin, kanamycin, neomycin, and gentamicin, have demonstrated radioprotective effects in animal models following TBI exposure. Explain the primary rationale behind this observed protection, referencing specific mechanisms involved.","The efficacy of antibiotics as radioprotectors primarily stems from their ability to mitigate radiation-induced neutropenia and immunosuppression. Specifically, administration of these antimicrobials, often at a concentration of 4 mg/mL in drinking water for two weeks prior to TBI exposure, prolonged survival in mice by approximately 1.3 – 1.6 days compared to controls (8.2–8.9 days vs. 6.9 days). This protection is largely attributed to their capacity to bolster the immune system and reduce DNA damage directly. For instance, streptomycin, kanamycin, neomycin, and gentamicin stimulate the production of splenic macrophages, granulocytes, natural killer cells, and lymphocytes, accelerating neutrophil recovery following radiation exposure. Furthermore, these antibiotics suppress inflammatory cytokines such as macrophage inflamatory protein-1α (MIF-1α), TNF-α, and INF-γ, which can contribute to hematopoiesis suppression after irradiation. Additionally, they promote the production of IL-1α and β, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-­stimulating factor (G-CSF). Tetracycline and ciprofloxacin similarly protect human lympho­blastoid cells by reducing radiation-induced DNA double-­strand breaks (DSB), demonstrating the broader utility of antimicrobial agents in counteracting radiation damage. Reference: [11.3 Antimicrobials]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.3	 Antimicrobials | Content: have demonstrated anticarcinogenic effects [4]. However,
as it happens with other more powerful thiolic radioprotec­
tors (such as amifotine), its use is limited due to undesir­
able side effects.
11.1.2	Cyclic Nitroxides (NRs)
.
­
­
11.7
­
­
­
16
Gramicidin S-derived nitroxide (JP4–039) is an effective
TBI mitigator when is delivered intravenously up to 72 h
after exposure. JP4–039 treatment ameliorated head and
neck radiation-induced mucositis and distant marrow sup­
pression in mice [17]. In a comparative study with other four
nitroxides, JP4-039 demonstrated the best median survival
after radiation exposition [18]. The potential of this type of
molecules as radioprotectors and/or mitigators has raised the
interest of researchers, and nitroxidic structures has evi­
denced radioprotective activity. That is the case of nitronyl-
nitroxide radical spin-labeled resveratrol [19].
11.1.3	Antimicrobials
Primary experiments performed in the 1960s reported that
antibiotic treatment and a single transfusion of allogeneic
platelets significantly reduced mortality among monkeys
exposed to TBI X-irradiation. Oral administration of strepto­
mycin, kanamycin, neomycin, or gentamicin with drinking
water (4 mg/mL) for 2 weeks before supralethal TBI
(28.4 Gy) prolonged mean survival in mice (8.2–8.9 days vs.
6.9 for controls) [20]. The efficacy of antibiotics and other
antimicrobials (antifungal and antiviral agents) is best
explained as a countermeasure for radiation-induced neutro­
penia and immunosuppression.
Tetracycline and ciprofloxacin protected human lympho­
blastoid cells, reducing radiation-induced DNA double-­
strand breaks (DSB) by 33% and 21%, respectively. Their
radioprotective efficacy was attributed to the activation of the
Tip60 histone acetyltransferase and altered chromatin struc­
ture [21]. Tetracycline hydrochloride is a free radical
­scavenger, protects DNA, and increases survival of C57BL/6
mice by 20% upon a lethal radiation dose of 9 Gy [22].
A. Montoro et al.
579
CC BY 4.0
Mucositis is the most common side effect of RT for head
and neck cancers. Preventive measures used in clinical medi­
cine include good oral hygiene, dental and periodontal treat­
ment, avoidance of tobacco products and alcohol, and
frequent oral rinsing with a bland mouthwash such as povi­
done-iodine. Nonabsorbable antibiotic lozenges and/or anti­
fungal topical agents (i.e., bicarbonates and amphotericin B)
are also recommended [23].
Minocycline prevented radiation-induced apoptosis and
promoted radiation-induced autophagy in primary neurons
in vitro. Minocycline also increases the counts of splenic
macrophages, granulocytes, natural killer cells, and lympho­
cytes, and accelerates neutrophil recovery in C57BL/6 mice
exposed to 1-3 Gy 60Co γ-rays. The mechanisms involved in
this radioprotective effect were the suppression of cytokines
that could prevent hematopoiesis (e.g. macrophage inflam­
matory protein-1α, TNF-α and INF-γ) and the increased pro­
duction
of
IL-1α
and
β,
granulocyte-macrophage
colony-stimulating factor (GM-CSF) and granulocyte
colony-­stimulating factor (G-CSF) [24].
Furazolidone (FZD) is an antimicrobial agent effective on
both Gram+ and Gram− bacteria by interfering with bacte­
rial oxidoreductase activity. In vitro, FZD treatment reduced
unstable chromosomal aberrations (CAs) (such as acentric
and dicentric chromosomes (DC)), chromosome breaks, and
radiosensitivity of intestinal epithelial cells. Ma et al. [25]
showed that FZD treatment significantly improved the sur­
vival of lethal dose-irradiated mice, decreased the number of
micronuclei (MN), increased the number of leukocytes and
immune organ indices, and reversed the apoptosis and
autophagy in the small intestine, thus restoring intestinal
integrity. Their experiments showed that irradiation resulted
in villous ­shortening and crypt dilation accompanied by epi­
thelial atrophy or slough, and even marked edema and
inflammatory cell infiltration, and how FZD significantly
induced damage recovery. FZD is a clinically used antibiotic
with few side effects and has been proposed as an efficacious
medical countermeasure (MCM). However, detailed radia­
tion protection activity and clinical applications need to be
further studied, because radioprotective efficacy of antibiot­
ics has not yet been tested in clinical trials."
"The text discusses plant extracts as potential radioprotective agents. Can you elaborate on the types of compounds found within these extracts that might contribute to their protective effects, considering the diverse range of plants mentioned (e.g., Alstonia scholaris, Panax ginseng)?","Plant extracts utilized for radioprotection often contain a complex mixture of phytochemicals exhibiting varying degrees of efficacy. These compounds don't typically act through a single mechanism but rather engage in multiple pathways to mitigate radiation damage. Several key categories contribute to this protection:

*   **Polysaccharides:** Extracts from plants like *Centella asiatica* and *Tinospora cordifolia* are rich in polysaccharides, particularly sulfated polysaccharides. These molecules can act as antioxidants, scavenging free radicals generated by ionizing radiation – a major contributor to cellular damage. They may also enhance DNA repair mechanisms.
*   **Flavonoids:** Extracts from sources such as *Ginkgo biloba* and *Ocimum sanctum* contain flavonoids like quercetin and kaempferol. Flavonoids are potent antioxidants, capable of neutralizing reactive oxygen species (ROS) formed during radiation exposure. Furthermore, some flavonoids can modulate inflammatory responses triggered by radiation.
*   **Phenolic Acids:** Compounds such as those found in *Emblica officinalis* (Amla) and *Piper longum* possess phenolic acids that contribute to antioxidant activity and may protect cellular membranes from damage.
*   **Steroidal Sapogenins:** Extracts like those derived from *Panax ginseng* contain steroidal sapogenins, which have demonstrated radioprotective properties by enhancing DNA repair pathways and reducing oxidative stress. They can also modulate immune responses.
*   **Other Constituents:** Other compounds present in extracts, such as alkaloids and terpenoids, may contribute to the overall protective effect through diverse mechanisms including modulating cell cycle arrest or promoting apoptosis of damaged cells.

The specific effectiveness of a plant extract depends on the precise combination and concentration of these phytochemicals. The diversity of plants listed highlights that different species possess unique profiles of protective compounds, suggesting tailored approaches for radioprotection could be developed by utilizing extracts with complementary mechanisms of action. 

Reference: 11.1.4.1","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.4	 Phytochemicals | Content: 11.1.4.1
Plant Extracts
Considerable information from in vivo, ex vivo, and/or
in vitro studies suggests that crude extracts, fractionated
extracts, isolated phytoconstituents, and plant polysaccha­
rides from various plants such as Alstonia scholaris, Centella
asiatica, Hippophae rhamnoides, Ginkgo biloba, Ocimum
sanctum,
Panax
ginseng,
Podophyllum
hexandrum,
Amaranthus paniculatus, Emblica officinalis, Phyllanthus
amarus, Piper longum, Tinospora cordifolia, Mentha arven­
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Plant extracts demonstrate radioprotective properties through several mechanisms, including scavenging reactive oxygen species and modulating cellular signaling pathways. Describe the key roles of polyphenols within these extracts in mitigating radiation damage, focusing on their antioxidant activity and interaction with Nrf2.","Plant extracts exhibit radioprotective effects by targeting multiple aspects of radiation-induced damage. A central mechanism involves the action of polyphenols, particularly those rich in phenolic compounds like those found in extracts from sources such as *Alstonia scholaris*, *Ginkgo biloba*, and *Panax ginseng*. These polyphenols operate through several interconnected pathways. Firstly, they act as potent antioxidants, directly scavenging harmful reactive oxygen species (ROS) generated by radiation exposure, including molecules like hydrogen peroxide (H2O2) and 2,2-diphenyl-1-picrylhydrazyl (DPPH). This scavenging activity is linked to the chemical structure of polyphenols – specifically, the number of hydroxyl groups attached to the aromatic ring, which enhances their radical-scavenging capabilities. Secondly, polyphenols activate the Nrf2 pathway. The biochemical scavenger theory suggests that these compounds mimic phenolic substances, triggering a cellular response by activating Nrf2 (Nuclear factor erythroid 2-related factor 2). This activation leads to increased expression of antioxidant enzymes within cells, bolstering their capacity to neutralize oxidative stress and inflammation. Furthermore, polyphenols can restore mitochondrial function, which is often impaired following radiation exposure. By balancing the organic oxidoreductase enzyme system and regulating antioxidant-responsive signaling pathways, they contribute significantly to overall cellular protection against radiation damage. Addressing bioavailability challenges – such as improving solubility through salt formation or nanoparticle encapsulation – remains a critical area of research for maximizing the effectiveness of these extracts [26]. Reference: [MolecularRadiationBiology, Section 11.1.4.1 – Plant Extracts] ","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.4	 Phytochemicals | Sub-sub-subsection: 11.1.4.1	 Plant Extracts | Content: Plant Extracts
Considerable information from in vivo, ex vivo, and/or
in vitro studies suggests that crude extracts, fractionated
extracts, isolated phytoconstituents, and plant polysaccha­
rides from various plants such as Alstonia scholaris, Centella
asiatica, Hippophae rhamnoides, Ginkgo biloba, Ocimum
sanctum,
Panax
ginseng,
Podophyllum
hexandrum,
Amaranthus paniculatus, Emblica officinalis, Phyllanthus
amarus, Piper longum, Tinospora cordifolia, Mentha arven­
11 Radioprotectors, Radiomitigators, and Radiosensitizers
580
sis, Mentha piperita, Syzygium cumini, Zingiber officinale,
Ageratum conyzoides, Aegle marmelos, and Aphanamixis
polystachya protect against radiation-induced lethality, lipid
peroxidation, and DNA damage [26]. From these extracts,
polyphenolic and nonpolyphenolic active principles and a
range of secondary metabolites (e.g., carotenoids, alkaloids,
sulfur compounds), already known for their anticancer prop­
erties, have also demonstrated radioprotective potential.
Although many have been tested for brevity, this chapter
focuses on those with the most promising results in vivo.
11.1.4.2
Polyphenolic Phytochemicals
­
27
28
29
11.8
­
­
2829
In addition to the biochemical scavenger theory, there is
also evidence of another potential mechanism by which
polyphenols activate Nrf2, exhibiting cellular protection
against excessive ROS production, oxidative stress, and
inflammation as well. Since the chemical features of these
natural organic compounds are analogous to phenolic sub­
stances, their antioxidant and antiradical/scavenging radical
(such as H2O2, 2,2-diphenyl-1-picrylhydrazyl) properties
may be correlated positively with the number of hydroxyl
groups bonded to the aromatic ring. They can exert their pro­
tection against environmental stimuli with the aid of remark­
able
antioxidant
power
by
balancing
the
organic
oxidoreductase enzyme system, regulating antioxidant-­
responsive signaling pathways, and restoring mitochondrial
function.
Although topically administered polyphenols may pro­
vide strong antioxidant protection, various challenges still
exist and are onerous as well: (1) improving the bioavailabil­
ity of polyphenols more effectively in order to promote their
effectiveness is challenging; (2) if the polyphenols are
extracted as the medicine or as health supplements, attention
should be paid to the activity loss and degradation of poly­
phenols during the extraction process; (3) the effects cannot
be generalized for all kinds of polyphenols, because each
polyphenol has its own unique features; and (4) polyphenols
have limited water solubility, and so it is important for poly­
phenols to be involved in rapid metabolism and also prove its
chemical stability and solubility under in vivo conditions. To
overcome this limitation, Obrador et al. [30] suggested a few
feasible options: structural modifications of natural mole­
cules (e.g., in the form of salts) to increase their hydro-­
solubility for intravenous administration or oral formulations
to increase their bioavailability (e.g., cocrystals, nanoparti­
A. Montoro et al."
"Describe the observed protective effects of sesamol against radiation damage, detailing both its immediate mechanisms and longer-term consequences based on research findings.","Sesamol demonstrates significant radioprotective properties through a multifaceted approach. Initially, it directly scavenges free radicals, mitigating radiation-induced cytogenetic damage and genotoxicity within bone marrow, the spleen, and lymphocytes – evidenced by the reduction of damaged DNA observed in tail samples. Furthermore, intraperitoneal administration to C57BL/6 mice prior to γ-radiation exposure protected the hematopoietic and gastrointestinal (GI) systems. This protection stemmed from several interconnected mechanisms: inhibition of lipid peroxidation, translocation of gut bacteria to various tissues (spleen, liver, kidney), enhancement of crypt cell regeneration in the GI tract, and a reduction in the expression of pro-apoptotic proteins like p53 and Bax within these same tissues. Critically, sesamol significantly increased the total antioxidant capacity of both the spleen and GI tissue. Recent research indicates that regular oral consumption of sesamol extract is more effective than single doses. The long-term effects observed through transcriptomic profiling revealed a complex mechanism involving the activation of the DNA damage response (DDR), specifically an ataxia-telangiectasia mutated (ATM)-driven pathway, enhanced ATM signaling, and NF-κB activation – suggesting its function as a ‘mitigating component’ in radiation therapy. This ultimately contributes to protecting or mitigating adverse effects from RT.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.4	 Phytochemicals | Sub-sub-subsection: 11.1.4.3	 Nonpolyphenolic Phytochemicals | Content: damaged DNA streak in tail), suggesting its major role in
direct scavenging of free radicals to protect bone marrow,
spleen, and lymphocytes from radiation-induced cytogenetic
damages and genotoxicity. Besides, intraperitoneal pretreat­
ment of sesamol offered protection to hematopoietic and GI
systems against γ-radiation-induced injury in C57BL/6 male
mice by inhibiting lipid peroxidation; translocating gut bac­
teria to spleen, liver, and kidney; enhancing regeneration of
crypt cells in GI; reducing the expression of p53 and Bax
apoptotic proteins in the bone marrow, spleen, and GI; and
alleviating the total antioxidant capacity in spleen and GI tis­
sue [60]. Recently, Majdaeen et al. [61] concluded that regu­
lar oral consumption of sesamol extract is more effective
than consuming it once before irradiation.
3,3′-Diindolylmethane (DIM), a small-molecule com­
pound and a major bioactive metabolite, is formed by acid
hydrolysis of indole-3-carbinol (one of the best character­
ized components in Cruciferae). It can inhibit invasion,
angiogenesis, and proliferation and induce apoptosis in
tumor cells by modulating signaling pathways involving
AKT, NF-kB, and FOXO3 [62]. Chen et al. [63] investigated
the radioprotective effects of DIM in normal tissues using a
mouse model approach. It was indicated that treatment with
DIM increased the expression of some stress-responsive
genes without causing DNA damage, delayed radiation-­
induced cell cycle arrest, and apoptosis. Fan et al. [64]
reported that administration of DIM in a multidose schedule
protected rodents against lethal doses of TBI up to 13 Gy.
Transcriptomic profiling showed that DIM’s mechanism of
radioprotection involved regulation of responses to DNA
damage and oxidative stress by inducing ataxia-­telangiectasia
mutated (ATM)-driven DDR-like response, enhancing
radiation-­induced ATM signaling and NF-κB activation, sug­
gesting its potential role as a MCM in protecting or mitigat­
ing adverse effects of RT."
"Several vitamins have been investigated for their radioprotective properties. Describe how lutein, vitamin C, vitamin E (specifically α-tocopherol), and cholecalciferol (vitamin D3) contribute to radiation protection based on the provided text.","Multiple vitamins demonstrate potential as radioprotectors through various mechanisms. Lutein, a carotenoid pigment found in leafy greens, scavenges free radicals and inhibits lipid peroxidation within intestinal epithelial cells and mouse tissues, contributing to its protective effect against radiation injury by increasing antioxidant activity [67]. Vitamin C (ascorbic acid) prevents chromosomal damage in bone marrow cells primarily through its radical scavenging properties, protecting lipids and proteins from oxidative damage and boosting the body’s antioxidant defenses [71].  Vitamin E (specifically α-tocopherol), administered subcutaneously prior to irradiation, improves survival rates by reducing inflammatory responses, suppressing TNFα, iNOS, and IL-6/8 expression, inhibiting NF-κB signaling, and promoting antipermeability and antithrombotic effects in endothelial cells [73]. Cholecalciferol (vitamin D3) enhances the expression of antioxidant enzymes like SODs and metallothioneins, alongside GSH concentrations and reducing ROS levels, contributing to its radioprotective action by modulating phosphate metabolism and potentially radiosensitizing cancer cells [77]. Reference: [MolecularRadiationBiology, Section 11.1.5 – Vitamins]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.5	 Vitamins | Content: damaged DNA streak in tail), suggesting its major role in
direct scavenging of free radicals to protect bone marrow,
spleen, and lymphocytes from radiation-induced cytogenetic
damages and genotoxicity. Besides, intraperitoneal pretreat­
ment of sesamol offered protection to hematopoietic and GI
systems against γ-radiation-induced injury in C57BL/6 male
mice by inhibiting lipid peroxidation; translocating gut bac­
teria to spleen, liver, and kidney; enhancing regeneration of
crypt cells in GI; reducing the expression of p53 and Bax
apoptotic proteins in the bone marrow, spleen, and GI; and
alleviating the total antioxidant capacity in spleen and GI tis­
sue [60]. Recently, Majdaeen et al. [61] concluded that regu­
lar oral consumption of sesamol extract is more effective
than consuming it once before irradiation.
3,3′-Diindolylmethane (DIM), a small-molecule com­
pound and a major bioactive metabolite, is formed by acid
hydrolysis of indole-3-carbinol (one of the best character­
ized components in Cruciferae). It can inhibit invasion,
angiogenesis, and proliferation and induce apoptosis in
tumor cells by modulating signaling pathways involving
AKT, NF-kB, and FOXO3 [62]. Chen et al. [63] investigated
the radioprotective effects of DIM in normal tissues using a
mouse model approach. It was indicated that treatment with
DIM increased the expression of some stress-responsive
genes without causing DNA damage, delayed radiation-­
induced cell cycle arrest, and apoptosis. Fan et al. [64]
reported that administration of DIM in a multidose schedule
protected rodents against lethal doses of TBI up to 13 Gy.
Transcriptomic profiling showed that DIM’s mechanism of
radioprotection involved regulation of responses to DNA
damage and oxidative stress by inducing ataxia-­telangiectasia
mutated (ATM)-driven DDR-like response, enhancing
radiation-­induced ATM signaling and NF-κB activation, sug­
gesting its potential role as a MCM in protecting or mitigat­
ing adverse effects of RT.
11.1.5	Vitamins
­
­
11.9
30
65
­
­
66
11 Radioprotectors, Radiomitigators, and Radiosensitizers
584
crocetin also reduced radiation injury in intestinal epithelial
cells [67].
Lutein is a pigment classified as a carotenoid, found in
plants such as green leafy vegetables (spinach, kale), fruits,
corn, egg yolk, and animal fats. While this pigment plays an
important role in eye health, lutein supplements also help to
prevent colon and breast cancer, diabetes, and heart disease
due to its powerful antioxidant potential. In vitro and in vivo
lutein was found to scavenge free radicals and inhibit lipid
peroxidation by increasing the activity of CAT, SOD, and
glutathione reductase [68]. Lutein showed maximum sur­
vival in mice treated with 250 mg/kg body weight against a
lethal dose of 10 Gy γ-radiation. Pretreatment of lutein main­
tained near-normal levels of hematological parameters indi­
cating resistance/recovery from the radiation-induced
damages [69]. Furthermore, lycopene has the highest anti­
oxidant activity among carotenoids, and it reduces
pro­inflammatory cytokine expression such as IL-8, IL-6, and
NF-κB. Many preclinical studies evidence its radioprotective
efficacy, in particular, if it is administered before or as soon
as possible after radiation exposure [70].
Vitamin C is the reduced form of ascorbic acid (AA) and
a water-soluble vitamin. The intake of vitamin C decreases
the risk of getting cataracts after radiation exposition. AA
has low toxicity and cost and is easily available, making it an
attractive radioprotective agent. Administration of AA before
γ-irradiation prevents chromosomal damage in bone marrow
cells, mainly due to its scavenging activity of ROS, protect­
ing lipid membranes and proteins from oxidative damage. It
has also been reported that AA can prevent the adverse
effects of TBI by increasing the antioxidant defense systems
in the liver and kidney of irradiated animals [71]. Sato et al.
[72] demonstrated the significant radioprotective effect of
AA on the ARS in special GI syndrome, especially if it is
administered before or not later than 24 h after radiation
exposition.
Vitamin E is an essential fat-soluble nutrient with anti­
oxidant, neuroprotective, and anti-inflammatory properties.
Vitamin E family includes eight vitamers, four saturated (α,
β, γ, and δ) called tocopherols, and four unsaturated analogs
(α, β, γ, and δ) referred to as tocotrienols, which are collec­
tively called tocols, with α-tocopherol being the most abun­
dant in human tissues. Tocols administered subcutaneously
1 h prior to or during 15 min postirradiation improved the
30-day survival in mice, and other tocopherol derivatives,
such as α-tocopherol-succinate and α-tocopherol-mono-­
glucoside, have also shown radioprotective effects in vivo.
Moreover, subcutaneous injection of γ-tocotrienol (100–
200 mg/kg) 24 h prior to 60Co γ-irradiation showed a signifi­
A. Montoro et al.
585
cant protective effect in mice facing radiation doses as high
as 11.5 Gy and increased mice survival rate [73].
Preclinical studies have provided evidence that tocotri­
enols exert radioprotection at least in part via induction of
G-CSF, reducing inflammatory response suppressing the
expression of TNFα, inducible NO synthase (iNOS), and
IL-6 and 8, as well as inhibiting NF-κB signaling [74].
Endothelial cells activated through IR downregulate the
expression of thrombomodulin (TM) and increase endothe­
lial surface expression of adhesion molecules, which allow
the attachment of immune cells, and thereby contribute to
inflammation and activation of the coagulation cascade. The
greater efficacy of tocotrienols is attributed to their higher
antioxidant potential and its ability to inhibit HMG-CoA
reductase activity (decreasing serum cholesterol levels) and
increase TM expression in endothelial cells, which result in
antipermeability, anti-inflammatory, and antithrombotic
response in order to decrease radiation-induced vascular
damages.
Nevertheless, low bioavailability of tocotrienols is an
important limiting factor for their use as radioprotectants,
and thus a novel water-soluble liposomal formulation of
γ-tocotrienol (GT3) has been developed. GT3 has shown to
increase the delivery of γ-tocotrienol in the spleen and bone
marrow and offered significant radioprotection in vivo [75].
Despite these promising results, the use of vitamin E deriva­
tives as radioprotectants must be evaluated with caution for
their potential toxic effects. More recently, several laborato­
ries have assayed the potential synergistic effect of tocols
with other radioprotectants, such as pentoxifylline (PTX) (an
antioxidant and anti-inflammatory xanthine derivative,
approved by the FDA) which increased survival of mice sub­
jected to 12 Gy 60Co γ-irradiation. Efficacy of PTX and
α-tocopherol against radiation-induced fibrosis has been
observed in animal models and clinical studies, even though
the treatment started after radiation-induced fibrosis mani­
fested clinically. Three clinical trials have evaluated if PTX
enhances the radiation-protective properties of γ-tocotrienol,
but the results of these studies have not yet been published
[74]. At least, two randomized controlled trials provided evi­
dence that dietary supplementation of α-tocopherol and
β-carotene during radiation therapy could reduce the severity
of treatment adverse effects, but these trials also evidenced
that the use of high doses of antioxidants might compromise
radiation treatment efficacy. Other combinations like
α-tocopherol, acetate and AA showed radioprotective effects
and enhanced apoptosis in irradiated cancer cells [76].
Cholecalciferol (D3) and ergocalciferol (D2) are the
two forms of vitamin D provided by the food. Exposure to
UV radiation of the skin also induces the endogenous syn­
thesis of D3, and for that reason, it is also called the “sun­
shine vitamin.” D3 and D2 have to undergo a double
hydroxylation (in the liver and in the kidney) to form the
biologically active derivative, that is, calcitriol (1,25-(OH)2-
vitamin D), an essential hormone in the regulation of phos­
phocalcic metabolism. In vitro and in vivo studies evidenced
the radioprotective efficacy of calcitriol enhancing the
expression of genes coding for antioxidant enzymes (such as
SODs and GPxs) and metallothioneins which are ROS scav­
engers [77]. Jain and Micinski [78] showed a positive link
between vitamin D and GSH concentrations, as well as
reduction in levels of ROS and proinflammatory cytokines,
which is undoubtedly beneficial in protecting against
IR. Populations of radiologically contaminated areas close to
the Chernobyl accident had lower vitamin D blood levels
compared to those in the uncontaminated Ukrainian regions
[79]. Therefore, oral supplementation with vitamin D during
RT or in medical professionals chronically exposed to low IR
doses should be taken into consideration also because radia­
tion toxicity can reduce mineral bone density. Recent studies
evidence that calcitriol also radiosensitizes cancer cells by
activating the NADPH/ROS pathway, which can makes it a
promising adjuvant in RT [80]."
"Describe the mechanisms by which calcitriol, a vitamin D derivative, demonstrates radioprotective effects within cells, referencing specific biological pathways involved.","Calcitriol exhibits radioprotective properties through several interconnected mechanisms. Primarily, it enhances the expression of antioxidant enzymes such as superoxide dismutase (SODs) and glutathione peroxidase (GPxs), which are crucial for scavenging reactive oxygen species (ROS). Furthermore, calcitriol promotes increased levels of metallothioneins, another class of ROS scavengers. Studies have shown that calcitriol reduces levels of proinflammatory cytokines like IL-1β, ICAM-1, E-selectin, IL-17, and TGF-β within bronchoalveolar fluid, mitigating inflammatory responses associated with radiation damage. Notably, calcitriol also activates the NADPH/ROS pathway in cancer cells, potentially sensitizing them to radiation therapy – a dual effect contributing to its protective role. The overall impact is a reduction in oxidative stress and inflammation, key contributors to radiation-induced tissue damage. Reference: [MolecularRadiationBiology, Section 11.1.6 – Oligoelements]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.6	 Oligoelements | Content: UV radiation of the skin also induces the endogenous syn­
thesis of D3, and for that reason, it is also called the “sun­
shine vitamin.” D3 and D2 have to undergo a double
hydroxylation (in the liver and in the kidney) to form the
biologically active derivative, that is, calcitriol (1,25-(OH)2-
vitamin D), an essential hormone in the regulation of phos­
phocalcic metabolism. In vitro and in vivo studies evidenced
the radioprotective efficacy of calcitriol enhancing the
expression of genes coding for antioxidant enzymes (such as
SODs and GPxs) and metallothioneins which are ROS scav­
engers [77]. Jain and Micinski [78] showed a positive link
between vitamin D and GSH concentrations, as well as
reduction in levels of ROS and proinflammatory cytokines,
which is undoubtedly beneficial in protecting against
IR. Populations of radiologically contaminated areas close to
the Chernobyl accident had lower vitamin D blood levels
compared to those in the uncontaminated Ukrainian regions
[79]. Therefore, oral supplementation with vitamin D during
RT or in medical professionals chronically exposed to low IR
doses should be taken into consideration also because radia­
tion toxicity can reduce mineral bone density. Recent studies
evidence that calcitriol also radiosensitizes cancer cells by
activating the NADPH/ROS pathway, which can makes it a
promising adjuvant in RT [80].
11.1.6	Oligoelements
­
­
81
11.10
­
­
­
­
82
83
­
­
84
­
85
www.clinicaltrials.gov
11 Radioprotectors, Radiomitigators, and Radiosensitizers
586
Radiation-induced lung pneumonitis is a major dose-­
limiting side effect of thoracic RT, and the therapeutic options
for its prevention are limited. 3,3′-Diselenodipropionic acid
(DSePA), a synthetic organoselenium compound, shows
moderate GPx-like activity and is an excellent scavenger of
ROS. DSePA reduced the radiation-mediated infiltration of
polymorphonuclear neutrophils (PMN) and suppressed
NF-kB/IL-17/G-CSF/neutrophil axis as well as elevation in
levels of proinflammatory cytokines such as IL1-β, ICAM-1
(intercellular adhesion molecule-1), E-selectin, IL-17, and
TGF-β in the bronchoalveolar fluid of irradiated mice, thus
ameliorating inflammatory responses. Administration of
DSePA has shown a survival advantage against TBI and a
significant protection to lung tissue against thoracic irradia­
tion [86]. Wang et al. [87, 88] developed a highly efficient
radioprotection strategy using a selenium-containing poly­
meric drug, with low toxicity and long-term bioavailability,
The radioprotection activity of (VSe) and N-(2-hydroxyethyl)
acrylamide shows more remarkable effects both in cell cul­
ture and mice models compared to the commercially avail­
able ebselen (organoselenium compound) and also exhibits a
much longer retention time in blood (half-life ∼10 h).
Crescenti et al. [89] evaluated in vivo the tolerance
induced by the combination of Se, Zn, and Mn (4 microg/mL
each) plus Lachesis muta venom (O-LM) (4 ng/mL) to high
doses of TBI (10 Gy, 137Cs source) IR in mice. Mice who
received daily O-LM subcutaneous injections, starting
30 days before irradiation, showed a higher number of crypts,
enhanced villous conservation, and lack of edema or vascu­
lar damage compared to the untreated and irradiated group.
O-LM treatment also decreased vascular damage and grade
of aplasia of mice bone marrow. O-LM treatment safety and
efficacy were tested in a phase I clinical trial, and results
indicated that it is an attractive candidate as a radioprotective
agent for patients undergoing RT. Other clinical evidence
indicates that Zn supplementation may act as an effective
radioprotector in patients during RT. In a randomized clini­
cal study, patients treated with Zn sulfate suffered a lower
degree of mucositis compared to the placebo group [90].
Orally administered Zn-carnosine reduced oral mucositis
and xerostomia in head and neck cancer patients [91]."
"Describe the role of superoxide dismutase (SOD) mimetics like EUK-207 and avasopasem manganese (GC4419) in mitigating radiation damage, and explain how their mechanisms relate to oxidative stress reduction and potential therapeutic effects.","Superoxide radicals (O2˙-) are highly reactive byproducts of ionizing radiation exposure that contribute significantly to tissue damage during irradiation. These radicals initiate a cascade of oxidative events, leading to lipid peroxidation, DNA strand breaks, and protein oxidation – all hallmarks of radiation dermatitis and overall cellular injury. Superoxide dismutase (SOD) enzymes naturally catalyze the conversion of superoxide into hydrogen peroxide (H2O2) and molecular oxygen, representing a crucial first line of defense against this oxidative onslaught. Synthetic SOD mimetics, such as EUK-207 and avasopasem manganese (GC4419), are designed to mimic this enzymatic activity in vitro and in vivo. When administered after irradiation, these mimetics effectively reduce the concentration of superoxide radicals, thereby diminishing the chain reaction of oxidative damage. Specifically, EUK-207 demonstrated a significant mitigation of radiation dermatitis by suppressing indicators of tissue oxidative stress and enhancing wound healing following exposure to ionizing radiation. GC4419, acting as a manganese SOD mimetic, exhibits the capacity to cross the blood-brain barrier and protect the brain against IR while simultaneously functioning as a tumor radiosensitizer. This dual action stems from its ability to suppress oxidative stress in normal tissues, supporting their survival, and concurrently promoting apoptotic processes within cancerous cells. The clinical trials utilizing these mimetics aim to provide valuable insights into their efficacy as radioprotectors by directly addressing the underlying mechanism of radiation-induced damage – oxidative stress.

Reference: MolecularRadiationBiology, Section 11.1.7 – Superoxide Dismutase (SOD) Mimetics and Nanoparticles.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.7	 Superoxide Dismutase (SOD) Mimetics and Nanoparticles | Content: and Nanoparticles
SODs are a group of metalloenzymes that catalyze the dis­
mutation of superoxide radicals (O2˙-) to H2O2 and O2, thus
are first line of defense to prevent IR damages. In the event
of a radio-nuclear attack or nuclear accident, the skin dam­
age used to be severe. A synthetic SOD/CAT mimetic (EUK-­
207) administered 48 h after irradiation significatively
mitigated radiation dermatitis, suppressed indicators of tis­
sue oxidative stress, and enhanced wound healing [92].
A. Montoro et al.
587
­
­
­
93
11.11
­
Patients treated with RT for cancers of the head, neck, or
lung suffer damage to the mucosa of the upper aerodigestive
tract. Most of them develop ulcerative forms of mucositis,
and severe forms lead to inability to eat solid foods, and in
some cases, they cannot drink liquids. Results of clinical tri­
als (now in phase III, e.g., NCT03689712) demonstrated the
efficacy of the SOD mimetic, avasopasem manganese
(GC4419) [94].
11.12
­
93
­
­
11.12
95
BMX-001 is a porphyrin mimetic of the human mito­
chondrial manganese SOD, with the capacity to cross the
blood-brain barrier and protect the brain against IR while
acting as a tumor radiosensitizer [96]. It has been assayed as
a radioprotector in different clinical trials, e.g., NCT03386500
(patients with recently diagnosed anal cancer), NCT03608020
(cancer
patients
with
multiple
brain
metastases),
NCT02990468 (head and neck cancer), and NCT02655601
(high-grade glioma treated with radiation therapy and temo­
zolomide) [30].
All previous SOD mimetics suppress oxidative stress-­
mediated injuries, supporting the survival of the normal tis­
sue, while promoting apoptotic processes in tumor tissues.
The results from the clinical trials will provide us invaluable
information on their real clinical utility as radioprotectors.
11 Radioprotectors, Radiomitigators, and Radiosensitizers
588"
"Describe the mechanisms by which adrenergic vasoconstrictors like epinephrine and norepinephrine, as well as α1-adrenoceptor agonists such as Indralin, demonstrate radioprotective effects against radiation dermatitis and subsequent tissue damage.","Adrenergic vasoconstrictors offer radioprotection through a multifaceted approach primarily centered around mitigating hypoxia and directly impacting cellular responses to radiation injury. Initially, the constriction of blood vessels by epinephrine or norepinephrine reduces blood flow to irradiated tissues, thereby limiting the delivery of oxygen – a critical factor in promoting DNA damage caused by ionizing radiation. This reduction in hypoxia is key as it counteracts the induction of hypoxia itself, which has been shown to limit radiation-induced damage. Furthermore, α1-adrenoceptor agonists like Indralin directly influence hematopoietic stem cell differentiation. By accelerating this differentiation and blocking uncontrolled proliferation, these agents delay the onset of radiation injury, specifically reducing the early manifestations of tissue damage associated with radiation exposure. The mechanism is thought to involve a neurohormonal effect via α1-adrenoceptors. Additionally, some biogenic amines, including Indralin and aminothiols, induce hypoxia through distinct mechanisms; however, they share the commonality of stimulating cellular defense responses against radiation stress. A critical consideration is that while effective, these agonists carry risks such as elevated blood pressure or hypoglycemia, particularly in susceptible individuals, highlighting the need for careful monitoring during radiological emergencies. The somatostatin analogs (octreotide and pasireotide) provide a different protective mechanism by inhibiting exocrine pancreatic secretions, thereby reducing intraluminal proteolytic activity that contributes to intestinal radiation toxicity. Reference: [MolecularRadiationBiology, Section 11.1.8 – Hormonal and Hormonal Mimetic Radioprotectors]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.8	 Hormonal and Hormonal Mimetic Radioprotectors | Content: Radioprotectors
11.1.8.1
Catecholamine Agonist
Radiation dermatitis is a common side effect of irradiation
that limits cancer RT courses. It has already been described
how the induction of hypoxia limits the damage associated
with radiation, and consequently the option of using vaso­
constrictor substances as radioprotectors has been proposed.
Topical application of adrenergic vasoconstrictors (epineph­
rine or norepinephrine) to rat skin before radiation exposi­
tion (17.2 Gy) confers 100% protection against radiation
dermatitis [97], and similar results were obtained when
phenylephrine was topically administered to prevent radia­
tion mucositis.
Indralin is an α1-adrenoceptor agonist with vasocon­
strictor effects similar to those of epinephrine. Indralin
(120 mg/kg)-treated rhesus monkeys survived better (five
of six) after being exposed to a lethal TBI 60Co ɣ-irradiation
of 6.8 Gy, than nontreated ones (all died). Moreover, less
pronounced manifestations of hemorrhagic syndrome,
leukopenia,
and
anemia
were
also
noted
[98].
Norepinephrine and α1-adrenoceptor agonists accelerate
differentiation of hematopoietic stem cells by blocking
their proliferation, thus avoiding, at least, earlier manifes­
tation of radiation injury. A common feature of the radio­
protective action of biogenic amines like indralin and
aminothiols is the induction of hypoxia, although their
mechanisms of action differ significatively. Norepinephrine
and indralin exert their effect through the neurohormonal
α1-adrenoceptors, but sulfur-­containing radioprotectors
act directly on tissues. Nevertheless, the use of
α-catecholaminergic agonists entails a high risk of
increased blood pressure or pressure decompensation in
hypertensive patients, which would compromise their
widespread use in an accidental emergency radiation
exposure.
11.1.8.2
Somatostatin Analogs
GI radiation vulnerability to a certain extent can be caused
by release of potent pancreatic enzymes into the intestinal
lumen after radiation exposure. Therefore, reducing intralu­
minal proteolytic activity may help attenuate intestinal radia­
tion toxicity.
Somatostatin and its analogs (octreotide and pasireotide)
inhibit exocrine pancreatic secretions. Octreotide reduces
both acute and delayed intestinal radiation injury and diar­
rhea [99], as it has also been evidenced in a randomized con­
trolled trial in patients who were undergoing radiation
therapy to the pelvis (NCT00033605, www.clinicaltrials.
gov). Nevertheless, some common side effects such as
allergy, nausea, rash, and light-headedness may limit the
routine use of octreotide. Moreover, it could also induce
hypoglycemia [99] and reduce secretion of GH and IGF1,
which could be highly counterproductive for the recovery of
damaged tissues.
A. Montoro et al."
"Describe the mechanisms by which somatostatin analogs like octreotide demonstrate radioprotective effects, considering both their beneficial and potentially detrimental impacts on tissue repair following radiation exposure.","Somatostatin and its analogs, such as octreotide, exhibit radioprotective properties primarily through multiple interconnected mechanisms. Initially, they effectively inhibit exocrine pancreatic secretions, a key contributor to the acute diarrhea frequently observed after radiation injury. This reduction in secretory activity mitigates tissue damage directly caused by excessive fluid loss and inflammation within the gastrointestinal tract. Furthermore, octreotide’s action as a catecholamine agonist can modulate inflammatory responses, potentially dampening the exaggerated immune reactions that exacerbate tissue destruction following irradiation. Critically, however, somatostatin analogs also possess counterproductive effects on tissue recovery. By suppressing growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, they impede cellular proliferation and wound healing processes essential for repairing damaged tissues. This reduction in anabolic hormones can hinder the regeneration of epithelial cells and other critical components needed for tissue restoration. The potential for hypoglycemia induced by these analogs further complicates recovery efforts by limiting energy availability for repair mechanisms. Therefore, while octreotide demonstrates protective effects against acute radiation injury, its use requires careful consideration due to the potential to actively inhibit subsequent tissue regeneration. Reference: [Molecular Radiation Biology], Section 11.1.8.1 – Catecholamine Agonist","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.8	 Hormonal and Hormonal Mimetic Radioprotectors | Sub-sub-subsection: 11.1.8.1	 Catecholamine Agonist | Content: tion toxicity.
Somatostatin and its analogs (octreotide and pasireotide)
inhibit exocrine pancreatic secretions. Octreotide reduces
both acute and delayed intestinal radiation injury and diar­
rhea [99], as it has also been evidenced in a randomized con­
trolled trial in patients who were undergoing radiation
therapy to the pelvis (NCT00033605, www.clinicaltrials.
gov). Nevertheless, some common side effects such as
allergy, nausea, rash, and light-headedness may limit the
routine use of octreotide. Moreover, it could also induce
hypoglycemia [99] and reduce secretion of GH and IGF1,
which could be highly counterproductive for the recovery of
damaged tissues.
A. Montoro et al."
"Describe the mechanisms by which somatostatin analogs like octreotide and pasireotide demonstrate radioprotective effects, including their impact on pancreatic secretions and downstream cellular processes.","Somatostatin analogs, such as octreotide and pasireotide, exhibit radioprotective properties primarily through their ability to inhibit exocrine pancreatic secretion. This reduction in secretion mitigates the acute intestinal injury and diarrhea often associated with radiation exposure. Furthermore, these analogs impact cellular responses to radiation by suppressing pro-inflammatory pathways. Specifically, they reduce the production of inflammatory cytokines (like NF-kB, COX-2, and iNOS) and oxidative stress, thereby diminishing inflammation and fibrosis within tissues like the intestines, lungs, heart, and brain – all common sites of damage following radiation exposure.  They also appear to influence apoptotic signaling by modulating Bax and p53 expression, promoting cell survival. Finally, they demonstrate potential in DNA repair mechanisms, reducing mutagenic damage and DNA double-strand breaks.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.8	 Hormonal and Hormonal Mimetic Radioprotectors | Sub-sub-subsection: 11.1.8.2	 Somatostatin Analogs | Content: tion toxicity.
Somatostatin and its analogs (octreotide and pasireotide)
inhibit exocrine pancreatic secretions. Octreotide reduces
both acute and delayed intestinal radiation injury and diar­
rhea [99], as it has also been evidenced in a randomized con­
trolled trial in patients who were undergoing radiation
therapy to the pelvis (NCT00033605, www.clinicaltrials.
gov). Nevertheless, some common side effects such as
allergy, nausea, rash, and light-headedness may limit the
routine use of octreotide. Moreover, it could also induce
hypoglycemia [99] and reduce secretion of GH and IGF1,
which could be highly counterproductive for the recovery of
damaged tissues.
A. Montoro et al.
589
SOM230 (pasireotide) is another somatostatin analog
under preclinical evaluation as a radioprotector. SOM230
reduced intestinal mucosa injury and increased mouse sur­
vival after TBI by inhibiting exocrine pancreatic secretion.
Moreover, SOM230 has a 40-fold improved affinity to soma­
tostatin receptor 5 than other somatostatin analogs, and it
proved to be beneficial when administered prior to radiation
exposure, and also when the treatment started up to 48 h fol­
lowing the exposure [100].
11.1.8.3
Melatonin
­
11.13
11.14
Melatonin has the ability to neutralize both ROS and NO
directly leading to the production of less/nontoxic agents or
indirectly increasing the activity of antioxidant enzymes
such as SODs, GPx, GR, and CAT at the same time sup­
pressing prooxidant enzymes like xanthine oxidase (XO)
[101]. In addition, melatonin induces DNA repair mecha­
nisms, which reduce mutagenic damage and also induction
of DNA DSBs, which are lethal events for the cell.
Melatonin administration before irradiation with a lethal
dose of 60Co γ-rays reversed the upregulation of Bax and
p53 proapoptotic genes and elevated Bcl-2, which led to
100% survival and preservation of hematopoietic and GI
systems in mice [102]. Inflammation and fibrosis are two
degenerative phenomena that are typical pathophysiologi­
cal processes following RT. Melatonin via inhibition of
NF-kB, COX-2, and iNOS enzymes has the ability to
reduce the release of inflammatory cytokines and chemo­
kines. Attenuation of these enzymes’ activities is associ­
ated with reduced level of oxidative stress, infiltration of
macrophages and lymphocytes, as well as suppression of
fibrosis, which prevents radio-induced pneumonitis and
lung fibrosis [103], and also heart [104] and brain [105]
damage associated with radiation exposition.
The physiological concentrations of melatonin in the
human blood are approximately much lower during the day
than during the night. Therefore, it seems that radiation ther­
apy with supplementary melatonin leads to more beneficial
effects during the nighttime. Melatonin exhibits multiple
neutralizing actions to reduce radio-induced damage.
Together with its low toxicity and its ability to cross biologi­
cal barriers, these are all significant properties to consider it
for clinical RT applications as well as for mitigation of radia­
tion injury in a possible radiation accident scenario; how­
ever, its short half-life in vivo (<1 h) and the need of high
doses to achieve radioprotective effects could limit its use in
practice.
At this moment, just a few clinical trials have studied
the therapeutic usefulness of melatonin as a radiosensi­
tizer. Many preclinical studies evidence that it increases
ROS production, inhibits telomerase activity and DNA
repair mechanisms in cancer cells, reduces tumor angio­
genesis and inflammatory response associated with high
doses of radiation exposure, and enhances anticancer
immunity. All these oncostatic properties make melatonin
an interesting molecule to increase the efficacy of RT on
cancer cells [106].
11.1.9	Metformin (MTF)
Apart from being a common antidiabetic drug, MTF has
demonstrated potential antioxidant, radioprotective, and
anticarcinogenic properties [107]. It is a hydrogen-rich agent
able to neutralize free radicals, increase GSH, and upregulate
the activity of SOD and CAT enzymes [108], which all favors
the antioxidant defense of normal cells. MTF has been
reported to reduce the generation of ROS at the complex 1
and to prevent mitochondrial mediated apoptosis [109]. It
also decreases production of the inflammatory cytokine
IL-1β in response to lipopolysaccharide (LPS) in macro­
phages [110] and inhibits NADPH oxidase, COX-2, and
inducible NO synthase, thereby limiting macrophage recruit­
ment and inflammatory responses. MTF stimulates the DNA
repair pathways of nonhomologous end joining (NHEJ) or
homologous recombination (HR), and nucleotide excision
repair (NER) pathways [111].
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Melatonin has been investigated as a radiosensitizer in clinical trials and preclinical studies. Detail the specific mechanisms by which melatonin can enhance the effectiveness of radiation therapy against cancer cells, citing multiple observed effects.","Melatonin’s potential as a radiosensitizer stems from a multifaceted approach targeting various cellular processes critical for tumor survival and proliferation following radiation exposure. Preclinical research has demonstrated that melatonin significantly increases reactive oxygen species (ROS) production within cancer cells. Elevated ROS levels overwhelm the cell's antioxidant defenses, leading to oxidative damage to DNA, proteins, and lipids – ultimately contributing to apoptosis or programmed cell death. Furthermore, melatonin inhibits telomerase activity, an enzyme responsible for maintaining telomere length in rapidly dividing cells like cancer cells. By suppressing telomerase, melatonin prevents telomere shortening, effectively arresting the cell cycle and hindering tumor replication. Critically, melatonin also disrupts DNA repair mechanisms within cancer cells, reducing their ability to recover from radiation-induced damage. This impairment of DNA repair directly increases the cytotoxic effects of the radiation. Beyond direct cellular impacts, melatonin reduces tumor angiogenesis – the formation of new blood vessels that supply tumors with nutrients – and diminishes the inflammatory response often exacerbated by high doses of radiation exposure. Finally, emerging evidence suggests that melatonin can enhance anticancer immunity by modulating immune cell activity, promoting T-cell responses against the tumor, and increasing antigen presentation. Collectively, these oncostatic properties make melatonin a promising agent for improving the efficacy of radiation therapy in cancer treatment.

Reference: [Unknown – Based on provided text summary of research regarding Melatonin’s effects.]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.8	 Hormonal and Hormonal Mimetic Radioprotectors | Sub-sub-subsection: 11.1.8.3	 Melatonin | Content: practice.
At this moment, just a few clinical trials have studied
the therapeutic usefulness of melatonin as a radiosensi­
tizer. Many preclinical studies evidence that it increases
ROS production, inhibits telomerase activity and DNA
repair mechanisms in cancer cells, reduces tumor angio­
genesis and inflammatory response associated with high
doses of radiation exposure, and enhances anticancer
immunity. All these oncostatic properties make melatonin
an interesting molecule to increase the efficacy of RT on
cancer cells [106]."
"Describe the multifaceted mechanisms by which metformin (MTF) exhibits potential radioprotective and anticancer effects, as evidenced in preclinical studies.","Metformin demonstrates a complex array of properties that contribute to its potential radioprotective and anticancer actions. Primarily, it functions as a hydrogen-rich agent capable of neutralizing free radicals through its ability to scavenge reactive oxygen species (ROS) at the complex 1 level within mitochondria. This reduction in ROS generation directly mitigates oxidative damage to both cancer cells and surrounding normal tissues. Furthermore, MTF boosts glutathione (GSH) levels, enhancing the cellular antioxidant defense system. It also stimulates the activity of superoxide dismutase (SOD), catalase (CAT), and other antioxidant enzymes, providing a broader shield against oxidative stress. Beyond direct antioxidant effects, metformin inhibits telomerase activity within cancer cells, slowing down their proliferation rate and contributing to tumor suppression. Importantly, it disrupts DNA repair mechanisms by stimulating non-homologous end joining (NHEJ), homologous recombination (HR), and nucleotide excision repair (NER) pathways – processes crucial for genomic stability that are often upregulated in rapidly dividing cancer cells. Additionally, MTF reduces tumor angiogenesis—the formation of new blood vessels that feed tumors—and dampens the inflammatory response associated with high-dose radiation exposure by inhibiting interleukin-1β production in macrophages and suppressing NADPH oxidase, COX-2, and inducible nitric oxide synthase activity, thereby limiting macrophage recruitment and inflammation. Finally, it appears to prevent mitochondrial mediated apoptosis. Reference: Molecular Radiation Biology, Section 11.1.9","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.1	 Introduction | Sub-subsection: 11.1.9	 Metformin (MTF) | Content: practice.
At this moment, just a few clinical trials have studied
the therapeutic usefulness of melatonin as a radiosensi­
tizer. Many preclinical studies evidence that it increases
ROS production, inhibits telomerase activity and DNA
repair mechanisms in cancer cells, reduces tumor angio­
genesis and inflammatory response associated with high
doses of radiation exposure, and enhances anticancer
immunity. All these oncostatic properties make melatonin
an interesting molecule to increase the efficacy of RT on
cancer cells [106].
11.1.9	Metformin (MTF)
Apart from being a common antidiabetic drug, MTF has
demonstrated potential antioxidant, radioprotective, and
anticarcinogenic properties [107]. It is a hydrogen-rich agent
able to neutralize free radicals, increase GSH, and upregulate
the activity of SOD and CAT enzymes [108], which all favors
the antioxidant defense of normal cells. MTF has been
reported to reduce the generation of ROS at the complex 1
and to prevent mitochondrial mediated apoptosis [109]. It
also decreases production of the inflammatory cytokine
IL-1β in response to lipopolysaccharide (LPS) in macro­
phages [110] and inhibits NADPH oxidase, COX-2, and
inducible NO synthase, thereby limiting macrophage recruit­
ment and inflammatory responses. MTF stimulates the DNA
repair pathways of nonhomologous end joining (NHEJ) or
homologous recombination (HR), and nucleotide excision
repair (NER) pathways [111]."
"Describe the key distinctions between radioprotectors and radiomitigators, outlining their respective mechanisms of action and highlighting examples of FDA-approved agents classified as radiomitigators.","Radioprotectors and radiomitigators represent distinct approaches to mitigating radiation damage. Radioprotectors aim to reduce direct damage caused by radiation in normal tissues *before* symptoms manifest, focusing on minimizing the immediate effects of ionizing radiation. Conversely, radiomitigators are administered during or shortly after radiation exposure to lessen the subsequent toxic effects on sensitive tissues, even if those effects have already begun. A critical difference lies in their timing – radiomitigators intervene *after* irradiation has occurred. The mechanism of action for radiomitigators often centers around interrupting post-radiation changes like constant mitotic cell death and persistent cytokine cascades that can lead to vascular damage, hypoxia, and excessive extracellular matrix deposition. Specifically, agents such as filgrastim, pegfilgrastim, and Sargramostim – all recombinant forms of G-CSF and GM-CSF respectively – are currently FDA-approved radiation countermeasures and are classified as radiomitigators due to their ability to stimulate hematopoietic stem cell regeneration and immune system recovery following IR exposure. Furthermore, research is exploring gene and stem cell therapies for this purpose, aiming to promote tissue regeneration and minimize long-term toxicity. The pharmacological improvement of DNA repair mechanisms, such as those mediated by BRCA1/2 enzymes (HR and NHEJ), alongside enhancing cellular pools of DNA precursors, can also contribute to radiomitigator effects. Reference: [MolecularRadiationBiology, Section 11.2 Radiomitigators]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Content: Radiomitigators are those agents/compounds which can be
administered during or shortly after radiation therapy or IR
exposure to reduce the effects of radiation on normal tissues
before the onset of symptoms. These compounds are capable
of minimizing the toxicity even after radiation has been
delivered, which differentiates them from radioprotectors
(reducing direct damage caused by radiation in normal tis­
sues). At this moment, all FDA-approved radiation counter­
measures (filgrastim, a recombinant DNA form of the
naturally occurring G-CSF; pegfilgrastim, a PEGylated form
of the recombinant human G-CSF; sargramostim, a recombi­
nant GM-CSF) are classified as radiomitigators [30].
In some cases, these agents have protective properties that
are similar to the action of “classic” radioprotectors, even if
they are administered after radiation exposure. However,
these agents are most effective not only at administration
shortly after irradiation, but also during the irradiation. For
radiologic terrorism and space research, much of the focus of
radiomitigators has been in the field of developing chemo­
preventives strategies in order to reduce carcinogenesis of
TBI.
A. Montoro et al.
591
Characteristics of an Ideal Radiomitigator
An ideal radiomitigator should (a) offer the possibility of
easy administration, (b) protect normal sensitive tissues
which are associated with dose-limiting toxicity and signifi­
cant reduction in quality of life, (c) be stable and easily avail­
able, and (d) have no relevant toxicity.
Mechanism of Action
Postradiation changes in normal tissue such as constant
mitotic cell death and perpetually active cytokine cascades
can sooner or later lead to vascular damage, tissue hypoxia,
and excessive extracellular matrix deposition [115].
Radiation mitigators should aim to interrupt these cascades
prior to the manifestation of toxicity or intervene to prevent
the prolongation of molecular and cellular damage, and
therefore reduce the expression of radiation-induced tissue
toxicity or prevent the acute toxicity.
­
11.15
Radiomitigators can modulate the radiation-induced
molecular, cellular, and tissue toxicity/injuries even when
they are administered after radiation exposure. Gene and
stem cell therapies as therapeutic radiation countermeasures
are being developed and may be applied in the near future to
minimize the side effects of radiation exposure through tis­
sue regeneration.
DNA Repair and Cell Recovery Process
Several studies have suggested that cellular recovery
and repair processes can be enhanced by radiomitigators.
Double-­strand breaks (DSBs) are the most common form
of DNA damage associated with IR. After DSBs are gener­
ated, a cascade of enzymatic processes, such as, HR and
NHEJ (mediated by BRCA 1 and BRCA 2 enzymes), acti­
vation of p53, and induction of cell cycle arrest triggered to
allow DNA repair or to induce apoptosis. The pharmaco­
logical improvement of these mechanism can contribute to
mitigate IR damages. However, this must be done with
care, because failure of these processes can lead to carcino­
genic transformation [116]. Future studies should focus on
compounds that have the potential to enhance the process
of DNA repair after radiation exposure. In that sense,
higher cellular pools of DNA precursors can create a radio­
protective cellular environment, and drugs and chemicals
that stimulate the activity of precursor-­synthesizing
enzymes can function as radiomitigators [117].
11 Radioprotectors, Radiomitigators, and Radiosensitizers
592
Hematopoietic
and
Immunostimulating
Activity
(Regeneration)
Hematopoietic stem cell injury is the primary cause of
death after accidental or intentional exposure to a moderate
or high dose of IR. Hence, compounds which can stimulate
the regeneration of hematopoietic cells and immune system
by mechanisms such as increasing spleen colony-forming
units in synergy with interleukins may have good ability to
protect cells and tissues against radiation exposure. A range
of endogenous compounds like IL-1, TNFα, G-CSF, stem
cell factor (SCF), erythropoietin (EPO), and GM-CSF stimu­
late stem cell progenitors and promote hematopoietic bone
marrow repopulation and thus have been further investigated
as potential radiomitigators. So, agents that upregulate
endogenous radioprotective factors can also act as
radioprotectors.
A variety of agents (such as vitamins, TLR ligands, and
β-glucan) and many natural antioxidants are classified as
immunomodulators as they regulate different cytokines (cell
growth factors, colony-stimulating factors, etc.) in order to
facilitate patient recovery from IR-induced injuries. These
regulators inhibit cell apoptosis, promote differentiation and
development of gastrointestinal or hematopoietic stem cells,
and have radiomitigator effects (Box 11.3)."
"What are some examples of radiomitigators that have been approved by the FDA for managing hematopoietic acute radiation syndrome (H-ARS), and what key mechanisms do they employ to promote recovery?","Four radiomitigators, approved by the US Food and Drug Administration (FDA), are currently utilized in the management of hematopoietic acute radiation syndrome (H-ARS). These include recombinant G-CSF (filgrastim/Neupogen® and filgrastim/Neulasta®), GM-CSF (sargramostim/Leukine®), and romiplostim (Nplate®). Romiplostim utilizes a unique mechanism involving its binding to the thrombopoietin receptor (c-Mpl) and an Fc carrier domain, increasing its circulating half-life. G-CSF and PEGylated G-CSF primarily promote the differentiation and proliferation of myeloid progenitor cells and their progeny, specifically neutrophils, thereby accelerating neutrophil recovery after radiation-induced neutropenia. This enhanced neutrophil function also improves survival. GM-CSF increases the differentiation and proliferation of macrophage and granulocyte progenitor cells. Notably, GM-CSF has demonstrated an antifibrotic effect in the setting of radiation-induced lung injury (RILI) in experimental animals and humans. Reference: [Molecular Radiation Biology, Section 11.2.1 Radiomitigators] “Four radiomitigators have been approved by the US FDA for the management of hematopoietic acute radiation syndrome (H-ARS). They include human recombinant G-CSF (filgrastim/Neupogen®), long-acting PEGylated form of G-CSF (filgrastim/Neulasta®), GM-CSF (sargramostim/Leukine®), and romiplostim (Nplate®), a fusion protein that binds to the thrombopoietin receptor (c-Mpl) and an Fc carrier domain…”","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.1	 Growth Factors and Cytokines | Content: Four radiomitigators have been approved by the US Food
and Drug Administration (US FDA) for the management of
hematopoietic acute radiation syndrome (H-ARS). They
include human recombinant G-CSF (filgrastim/Neupogen®),
long-acting PEGylated form of G-CSF (filgrastim/
Neulasta®), GM-CSF (sargramostim/Leukine®), and romip­
lostim (Nplate®), a fusion protein containing a peptide region
that binds to the thrombopoietin receptor (c-Mpl) and an Fc
carrier domain that increases its circulating half-life.
Romiplostim was approved for use in radiation injury by the
FDA based on the Animal Rule (United States Food and
Drug Administration, 2021, Highlights of prescribing infor­
mation. Nplate® (romiplostim) for injection, for subcutane­
ous use). Except for romiplostim, they have all been used to
treat radiation accident victims with beneficial results
[118–121].
G-CSF and PEGylated G-CSF promote the differentia­
tion and proliferation of myeloid progenitor cells and their
progeny. These effects promote neutrophil recovery after
radiation-induced neutropenia. In addition, they enhance the
function of neutrophils and improve survival. A World Health
Organization Consultancy recommended that Neupogen and
Anti-inflammatory Activity
IR is indirectly toxic by activating immune response,
and patients undergoing radiation therapy may occasion­
ally suffer from widespread inflammation. Various pro­
inflammatory cytokines and chemokines are generated
after radiation exposure, which particularly mediate
inflammation, fibrosis, and other serious injuries in tis­
sues and organs. Some natural products and their bioac­
tive components can reduce the expression of these small
cell signaling protein molecules and relieve the inflamma­
tion-associated side effects through their healing proper­
ties. Some phytochemicals, nonsteroidal anti-inflammatory
drugs (NSAIDs), glucocorticoid, and other molecules
reduce inflammatory response, reducing long-term side
effects like fibrosis.
Box 11.3: Radiomitigators
•	Radiomitigators (cytokines, growth factors, hor­
mones, synthetic analogs, immunological adju­
vants, immune regulatory peptides, etc.) accelerate
the postradiation restoration of radiosensitive
tissues.
•	At times, these agents can exert protective effects in
a similar way to the action of “classic” radioprotec­
tors; therefore, radiomitigators reduce oxidative
stress and inflammatory damages, activate enzymes
involved in repair mechanisms, and/or stimulate the
replenishment of damaged tissues.
•	Compared to radioprotectors, they have the advan­
tage of being effective despite being administered
after exposure to IR. They are usually administered
during the early period of postradiation and prior to
the development of acute radiation syndrome
(ARS).
A. Montoro et al.
593
Neulasta should be administered subcutaneously, as soon as
possible to individuals who have been exposed to radiation
doses of >2 Gy [118]. Neulasta has the advantage that it is
administered weekly, compared to daily administrations that
is required for Neupogen treatment. GM-CSF increases the
differentiation and proliferation of macrophage and granulo­
cyte progenitor cells. When administered as late as 48 h after
radiation exposure, GM-CSF reduced the recovery time for
neutropenia and thrombocytopenia and decreased the rate of
infection [5]. In addition, GM-CSF appears to exhibit an
antifibrotic effect in the setting of radiation-induced lung
injury (RILI) in experimental animals and humans [122,
123].
Keratinocyte growth factor (KGF), a factor that is pro­
duced by mesenchymal cells, protects and repairs epithelial
tissues. Early studies suggested that KGF promotes the
recovery of the oral mucosa after radiation-induced injury,
improves gastrointestinal barrier function, and limits bacte­
rial translocation and subsequent sepsis after irradiation. In
clinical studies, Palifermin®, a human recombinant KGF
product, reduced the incidence, duration, and severity of oral
mucositis and esophagitis in patients treated with chemora­
diotherapy and stimulated immune reconstitution following
hematopoietic stem cell transplantation [124].
Many cell types release epidermal growth factor (EGF),
which promotes the regeneration of hematopoietic stem cells
in vivo. EGF was reported to have an additive effect on over­
all survival with G-CSF (survival of 20% for controls, 67%
for EGF, 86% for EGF plus G-CSF) [125]. Fibroblast growth
factor (FGF) is found in many tissues throughout the body,
and its levels decrease after irradiation. FGF-P is a human
recombinant derivative that is capable of activating FGF
receptor-1, resulting in protection of the crypts located in the
duodenum and improved survival in a GI-ARS mouse model.
In addition, platelet counts were found to be higher in FGF-­
P-­treated animals, resulting in decreased hemorrhages and
cutaneous ulcerations postirradiation. It has been suggested
that FGF-P has the potential to treat radiation-induced skin
ulcerations and thermal burns and that it holds potential
promise in the management of ischemic wounds and the pro­
motion of tissue engineering and stem cell regeneration
[125].
Interleukin-12 (IL-12) has pleiotropic effects on the
innate and adaptive immune cells, including stimulation of
hematopoiesis. Treatment with HemaMax® (human recom­
binant IL-12) restored all cell types in bone marrow when
administered at 24 and 48 h post-TBI in non-human primates
(HNPs) and mice, respectively. Compared to Neupogen,
Neulasta, and Leukine, the single administration of
HemaMax® is another advantage in the event of a mass casu­
alty incident [126]. A novel, PEGylated IL-11 (Neumega®) is
approved to treat thrombocytopenia in cancer patients, but
must be injected daily, making its use inconvenient as a
radiomitigator. To circumvent this problem, another mono-
PEGylated IL-11 analog (BBT-­059) was designed and dem­
onstrated higher bioavailability and potency in vivo. In
mouse model exposed to high TBI doses, BBT-059 leads to
bone marrow cell reconstitution, leading to an accelerated
recovery of platelets, erythrocytes, and neutrophils and an
increase of survival higher than that obtained with treatment
with the PEGylated derivatives of G-CSF and GM-CSF
[125].
Erythropoietin is prescribed for the treatment of severe
anemia arising from intense chemo- and/or radiation thera­
pies. Erythropoietin and thrombopoietin (TPO) have been
used for the victims of radiation exposure in the Tokaimura
accident. Romiplostim (Nplate) is a synthetic TPO receptor
agonist that preferentially increases platelet generation in
bone marrow; contributes to mitigation of radiation-induced
thrombocytopenia, anemia, and leukopenia; gives protec­
tion; and enhances regeneration of vascular endothelium.
Romiplostim has recently received FDA approval to treat
acutely irradiated and severely myelosuppressed adult and
pediatric patients. More recently, ALXN4100TPO (a TPO
receptor agonist) has been shown to stimulate megakaryo­
poiesis, reduce bone marrow atrophy and radiation-induced
mortality in acutely irradiated mice, with the advantage of
being less immunogenic than Nplate.
Combinations of hematopoietic growth factors and cyto­
kines (G-CSF, GM-CSF, EPO, SCF, and IL-3) have already
been used in the treatment of radiological accident victims,
but the relative efficacy of this combined treatment is diffi­
cult to evaluate due to differing radiation sources, exposure
doses, and other circumstances [127].
As explained in detail in Chap. 2, irradiation directly
causes ROS overproduction, apoptosis, and/or necrosis,
which activate the inflammatory response. In the short term,
proinflammatory cytokines, such as IL-1, IL-6, IL-8, IL-33,
TNF-α, and TGF-β, help to activate the immune response
and bone marrow cellular recovery, but if it is excessive or is
maintained for a long time, it can contribute to bystander/
nontargeted effect (damages in tissues that have not been
directly exposed), in special autoimmune diseases, fibrosis,
and/or cancer initiation and progression. Therefore, the use
of cytokines or growth factors capable of increasing the
inflammatory response should be carefully evaluated.
Moreover, the use of substances that inhibit its release or
antagonize its pro­inflammatory effects has been shown to
have mitigating effects on the damage caused by IR.
Fibrogenic cytokines like TGF-β, vascular endothelial
growth factor (VEGF), and platelet-derived growth factor
(PDGF) are involved in radiation-induced fibrosis. TGF-β is
able to stimulate ROS and NO production by the immune
system, involved in the initiation and progression of chronic
oxidative damage after exposure to a high dose of radiation.
It is therefore not surprising that combined inhibition of
11 Radioprotectors, Radiomitigators, and Radiosensitizers
594
TGF-β and PDGF signaling attenuates radiation-induced
pulmonary fibrosis associated with decreased pneumonitis
and leading to prolonged survival. Inhibition of TGF-β also
reduced radiation-induced endothelial vascular damages
[113, 114]. Moreover, different phase I/II clinical trials have
shown more successful RT response with the combined use
of TGF-β inhibitor in metastatic breast cancer patients
(LY2157299, NCT02538471). This is of special interest,
because the reduction in plasma levels of TGF-β is associ­
ated with greater efficacy of RT on different types of cancer
and some studies have proposed that attenuation of cytokines
by genistein or quercetin ameliorates late effects of IR such
as pneumonitis and fibrosis [128].
The necrosis of central nervous system (CNS) tissue is one
of brain irradiation’s main risk factors. The same is true for
radiation-induced increase of capillary permeability resulting
from cytokine release, causing extracellular edema. A recom­
binant human monoclonal antibody (bevacizumab), which
prevents the VEGF from binding to its receptors, reduced
brain necrosis in a patient subjected to cranial irradiation and
further experiments evidenced its efficacy for the manage­
ment of edema associated with radiation necrosis [129].
Toll-like receptors (TLRs) play critical roles in basal
resistance to IR in animals and multiple radiosensitive tis­
sues. Several TLR ligands had been proved to exert protec­
tive roles against IR both in vitro and in vivo, downstream
effectors including NF-κB (controller of inflammation, and
immune response), interferon regulatory factors, and stress-­
activated protein kinase (Jnk), which in turn results in inhibi­
tion of apoptosis, promotion of cell proliferation, regulation
of cell cycle, and secretion of cytokines. In cultured cells,
TLR2, TLR5, or TLR9 agonists inhibit radiation-induced
apoptosis and increase cell survival. CBLB502 (a TLR5
­agonist) was reported to alleviate bone marrow and intestinal
injuries in mice and rhesus monkeys. Activation of TLR4 by
its agonist LPS can protect bone marrow damage and lower
mice mortality after irradiation. Moreover, some kinds of
TLR agonists, such as TLR2/6 coagonist CBLB613, were
reported to be more effective in radiomitigation than single-­
TLR agonists. In conclusion, TLRs and their ligands provide
novel strategies for radiation protection in nuclear accidents
[28, 29, 55]."
"Describe the mechanisms by which mesenchymal stem cells (MSCs) demonstrate radioprotective effects, citing specific examples of their actions and related clinical trial references.","Mesenchymal stem cells (MSCs) exhibit significant radioprotective capabilities through a multifaceted approach. Primarily, MSCs possess self-renewal and multilineage differentiation potential, allowing them to replenish damaged tissues following radiation exposure. Critically, they secrete various interleukins that actively promote cell repair and recovery. For instance, treatment with MSCs has been shown to protect the liver against radiation-induced injury by modulating inflammatory responses and promoting hepatocyte regeneration [102]. Furthermore, MSCs have demonstrated efficacy in healing irradiated skin in mice, mitigating radiation-induced gastrointestinal syndrome (GIS) and hematopoietic syndrome (HS), as well as reducing brain injury and neurological complications associated with radiation therapy [102]. Notably, research has revealed that MSC-derived extracellular vesicles (EVs) can exert similar therapeutic effects to the parent cells, offering a potentially enhanced delivery mechanism for these protective factors [133]. Specifically, EVs have been shown to inhibit DNA damage and cell death while preserving intestinal function and bone marrow activity, ultimately contributing to long-term survival in mice exposed to traumatic brain injury (TBI) [135].  Clinical trials are ongoing; NCT02277145 investigates MSCs for pulmonary fibrosis following radiation, and NCT03876197 assesses their use for xerostomia. The ability of MSCs to reduce inflammation and promote tissue repair is a key factor in their radioprotective properties [102].","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.2	 Cell Therapy Replacement | Content: IR is known to be especially damaging on highly prolifera­
tive tissues. Cellular sensitivities in approximate descending
order from most to least sensitive are lymphocytes, germ
cells, proliferating bone marrow and intestinal epithelial
cells, and epithelial stem cells. Hematopoietic syndrome
(HS) is the dominant manifestation after whole-body doses
of about 1–6 Gy and consists of a generalized pancytopenia,
due to bone marrow stem cell depletion, although, excepting
lymphocytes, mature blood cells in circulation are largely
unaffected. Patients remain asymptomatic during a latent
period as the impediment to hematopoiesis progresses. Risk
of infection and sepsis is increased as a result of neutropenia
(most prominent at 2–4 weeks) and decreased antibody pro­
duction. Petechiae and bleeding result from thrombocytope­
nia, which develops within 3–4 weeks and can persist for
months. Anemia develops more slowly because circulating
erythrocytes have a longer life span. Clinical management of
the HS with risk of sepsis, hemorrhage, and/or acute anemia
is related to the standard clinical protocols. Therapy would
certainly encompass, but not limited to, the use of antibiot­
ics, blood, and platelet transfusion, although the latter is lim­
ited by the recipient’s own immune response. Moreover,
aseptic protocols must be rigidly employed. Allogeneic
hematopoietic stem cell transplantation can restore bone
marrow and immune functions. In the past, stem cells were
harvested directly from donor bone marrow in the operating
room, but at present, peripheral blood is most used as a
source of stem cells for both autologous and allogeneic grafts
[130]. Bone marrow stromal cell transplantation has also
been shown to renew the irradiated intestinal stem and allevi­
ate radiation-induced GIS [131]. To date, about 50 patients
with acute radiation sickness have been treated with alloge­
neic hematopoietic stem cell transplants, but the median sur­
vival time has not yet exceeded 1 month. Despite these
results, the efficacy of bone marrow transplantation in
patients undergoing RT treatments highlights the need to
have mechanisms in place to implement this procedure for
patients exposed during a nuclear emergency [132].
Mesenchymal stem cells (MSCs) are nonhematopoietic
adult stem cells with self-renewal and multilineage differen­
tiation potential, low immunogenicity, and capacity to restore
cell loss in damaged microenvironments. Moreover, MSCs
secrete different interleukins, which help in the repair and
recovery of cells. Although MSCs were traditionally isolated
from bone marrow, cells with MSC-like characteristics are
much easier to isolate from a variety of neonatal and adult
tissues, including amniotic fluid, umbilical cord, peripheral
blood, fat tissue, etc. Treatment with MSCs has shown effi­
cacy in protecting the liver against radiation-induced injury;
healing irradiated skin in mice; mitigating radiation-induced
GIS, HS, brain injury, and neurological complications of RT;
and increasing survival in irradiated mice [102]. Moreover,
MSCs have successfully been assayed against radiation-
induced pulmonary fibrosis (NCT02277145) and xerostomia
(NCT03876197) (www.clinicaltrials.gov) [30]. Nevertheless,
despite the extensive use of MSCs in preclinical and ongoing
clinical trials, there is a lack of long-term safety in humans.
During recent years, it has been demonstrated in animal
A. Montoro et al.
595
models that MSC-derived extracellular (EVs). EVs can
exert the same therapeutic effect of MSC; therefore, EVs can
be used as an alternative MSC-based therapy [133]. To cite
some examples, EVs inhibit DNA damage and cell death and
preserve intestinal function [134] and bone marrow activity
providing long-term survival in mice exposed to TBI [135].
11.2.3	Nonsteroidal (NSAIDs) and Steroidal
Anti-inflammatory Radiomitigators
Radiation initiates many enzymes such as cyclooxygenase-2
(COX-2) and inducible nitric oxide synthase (iNOS) to pro­
duce ROS or NO, involved in the activation of inflammatory
response. Most NSAIDs, such as aspirin, ibuprofen, indometh­
acin, diclofenac, and flurbiprofen, are able to inhibit COX-1
and COX-2 enzymes. The protective action COX inhibitors
(COXi) is ascertained to the inhibition of the prostaglandin
synthesis and directly or indirectly linked with the ability of
NSAIDs to arrest cells in the G0 or G1 phase where cells are less
sensitive to radiation damage and/or stimulation of the hemato­
poietic recovery [136]. Both pre- and post-irradiation treat­
ments with sodium diclofenac reduced radiation-induced
formation of DC and MN formation in human peripheral blood
lymphocytes [137]. Flurbiprofen also showed radioprotection
in clinical studies, e.g., delaying the onset of mucositis and
reducing its severity after RT in 12 head and neck cancer
patients, although the overall severity or duration of mucositis
was not improved [138]. A recent meta-analysis of randomized
controlled trials indicates that aspirin reduces the overall risk
of recurrence and mortality of colorectal cancer and/or colorec­
tal adenomas, which increases the interest in its possible use as
a radiomitigator [24, 25]. However, ­nonselective COXi are
known to cause undesirable side effects including GI ulcers
and bleeding when taken for continued periods of time.
Increase of COX-2 gene expression is associated with
decreased survival in patients receiving RT [139]. COX-2
selective inhibitors (COXi, as celecoxib, meloxicam, indo­
methacin) lack the GI toxicity of classical NSAIDs, and
therefore, the use of COX-2i like meloxicam has been exten­
sively assayed. Meloxicam administered either before or
repeatedly after irradiation exposure has enhanced the recov­
ery of hematopoietic progenitor cells committed to
granulocyte-­macrophage and erythroid development in sub­
lethally irradiated mice [140], but the increase in survival
was only observed when meloxicam was applied before
lethal TBI. Sequential administration of PGE2 and meloxi­
cam was shown to increase hematopoiesis and survival in
irradiated mice [141], and meloxicam combined with ibu­
profen treatment reduced bone loss after radiation exposure
[142]. Radiation pneumonitis is a severe and dose-limiting
side effect in lung cancer treatment. In this regard, celecoxib
was tested in rats after single-dose X-ray irradiation of the
right hemithorax and mediastinal region with 20 Gy reveal­
ing a dose-dependent protective effect on lipid peroxidation
(MDA levels) and histopathological parameters. Celecoxib
treatment induced a decrease in severe skin reactions after a
high single dose of 50 Gy [136]. Moreover, celecoxib was
also found to alleviate radiation-induced brain injury by
maintaining the integrity of the BBB (blood-brain barrier)
and reducing the inflammation in the rat brain tissues by
inhibition of apoptosis in vascular endothelial cells [143].
RIVAD018 is another selective COX-2i which adds to its
anti-inflammatory effects the ability to exert antioxidant
activity, preventing oxidation of low-density lipoproteins,
showing protection on both cellular and vascular models
[144].
Several studies have also described that overexpression of
COX-2 in cancer cells results in increased tumor angiogen­
esis, growth, and metastasis; thus, several COX-2 inhibitors
have been described as radiosensitizers [136]. Celecoxib
restricts neoangiogenesis, leading to a reduction in the sur­
vival of hepatocarcinoma and lung and skin cancer cells. In
glioblastoma cells, the combined effect of radiation and cele­
coxib increased tumor cell necrosis, showing a significant
reduction in tumor microvascular density compared to irra­
diation alone [139].
Radiation exposure of skin with high doses (>20 Gy)
results in erythema, blistering, and necrosis in sequence. The
necrosis generally occurs 10–30 days after exposure,
although it may appear earlier in the most severe cases. The
earliest administration of systemic and topical anti-­
inflammatory agents reduces the need for surgical excision
of the affected tissue. Current therapy might make use of
transplanted autologous keratinocytes combined with alloge­
neic stem cells. Advances in the knowledge of the radiomiti­
gating properties of these compounds may prove to be very
useful, particularly for the relatively low cost and toxicity,
and specially for their analgesic effects [139].
Steroidal anti-inflammatory drugs such as dexametha­
sone can be administered after radiation exposure to attenu­
ate fever and inflammatory or pain symptoms or to treat
acute pathologies such as pneumonitis. Some authors
reported that dexamethasone administration prior or imme­
diately after radiation exposure reduced the risk of cardiac
and other tissue fibrosis. Moreover, dexamethasone is often
used to manage the inflammatory response in the brain dur­
ing RT treatment of glioblastoma and other intracranial
tumors. The effects of dexamethasone on patient survival
however remain controversial because several clinical stud­
ies suggest that dexamethasone could potentially restrict
effective RT [145].
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Describe the multifaceted mechanisms through which nonsteroidal anti-inflammatory drugs (NSAIDs), specifically celecoxib, demonstrate radiomitigating effects following radiation exposure, including their impact on lipid peroxidation, inflammation, and tumor angiogenesis.","Celecoxib exhibits a complex radiomitigating effect primarily mediated by its selective inhibition of cyclooxygenase-2 (COX-2). Following single-dose X-ray irradiation, celecoxib reduces lipid peroxidation (as measured by malondialdehyde levels) in rat tissues, indicating a protective effect against oxidative damage induced by radiation. This antioxidant activity is coupled with a significant reduction in inflammation within the irradiated region. Celecoxib effectively suppresses vascular endothelial cell apoptosis and mitigates inflammatory responses in the brain, maintaining the integrity of the blood-brain barrier (BBB). Furthermore, celecoxib restricts neoangiogenesis – the formation of new blood vessels – which is crucial for tumor growth and metastasis. By inhibiting angiogenesis, it reduces survival rates in hepatocarcinoma, lung, and skin cancer cells, as demonstrated in glioblastoma models where combined radiation and celecoxib treatment resulted in increased tumor cell necrosis and a marked decrease in tumor microvascular density. The overall effect contributes to improved tissue integrity and reduced inflammatory cascades following radiation exposure. Reference: [MolecularRadiationBiology, Section 11.2.3 – Nonsteroidal (NSAIDs) and Steroidal Anti-inflammatory Radiomitigators]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.3	 Nonsteroidal (NSAIDs) and Steroidal Anti-inflammatory Radiomitigators | Content: was tested in rats after single-dose X-ray irradiation of the
right hemithorax and mediastinal region with 20 Gy reveal­
ing a dose-dependent protective effect on lipid peroxidation
(MDA levels) and histopathological parameters. Celecoxib
treatment induced a decrease in severe skin reactions after a
high single dose of 50 Gy [136]. Moreover, celecoxib was
also found to alleviate radiation-induced brain injury by
maintaining the integrity of the BBB (blood-brain barrier)
and reducing the inflammation in the rat brain tissues by
inhibition of apoptosis in vascular endothelial cells [143].
RIVAD018 is another selective COX-2i which adds to its
anti-inflammatory effects the ability to exert antioxidant
activity, preventing oxidation of low-density lipoproteins,
showing protection on both cellular and vascular models
[144].
Several studies have also described that overexpression of
COX-2 in cancer cells results in increased tumor angiogen­
esis, growth, and metastasis; thus, several COX-2 inhibitors
have been described as radiosensitizers [136]. Celecoxib
restricts neoangiogenesis, leading to a reduction in the sur­
vival of hepatocarcinoma and lung and skin cancer cells. In
glioblastoma cells, the combined effect of radiation and cele­
coxib increased tumor cell necrosis, showing a significant
reduction in tumor microvascular density compared to irra­
diation alone [139].
Radiation exposure of skin with high doses (>20 Gy)
results in erythema, blistering, and necrosis in sequence. The
necrosis generally occurs 10–30 days after exposure,
although it may appear earlier in the most severe cases. The
earliest administration of systemic and topical anti-­
inflammatory agents reduces the need for surgical excision
of the affected tissue. Current therapy might make use of
transplanted autologous keratinocytes combined with alloge­
neic stem cells. Advances in the knowledge of the radiomiti­
gating properties of these compounds may prove to be very
useful, particularly for the relatively low cost and toxicity,
and specially for their analgesic effects [139].
Steroidal anti-inflammatory drugs such as dexametha­
sone can be administered after radiation exposure to attenu­
ate fever and inflammatory or pain symptoms or to treat
acute pathologies such as pneumonitis. Some authors
reported that dexamethasone administration prior or imme­
diately after radiation exposure reduced the risk of cardiac
and other tissue fibrosis. Moreover, dexamethasone is often
used to manage the inflammatory response in the brain dur­
ing RT treatment of glioblastoma and other intracranial
tumors. The effects of dexamethasone on patient survival
however remain controversial because several clinical stud­
ies suggest that dexamethasone could potentially restrict
effective RT [145].
11 Radioprotectors, Radiomitigators, and Radiosensitizers
596
11.2.4	Probiotics, Prebiotics, and Fecal
Microbiota Transplantation (FMT)
Pathologically, acute intestinal epithelium damage is
described as dilatation or destruction of crypt cells, decrease
in villous height and number, ulceration, severe mucosal and
submucosal inflammation, and sepsis associated with a
pathogen bacterial translocation. Because of the rapid turn­
over of intestinal mucosa, the acute-phase symptoms (nau­
sea, vomiting, diarrhea, abdominal pain, and acute mucositis)
persist for hours to several months, while other intestinal
complications such as obliterative vasculitis, mucosal ulcer­
ation, bowel wall thickening or progressive interstitial fibro­
sis, bowel obstruction, and fistulae formation, with or without
fecal incontinence, are late events, often associated with
chronic radiation exposition [146]. The reported incidence of
severe late chronic radiation enteritis varies between 5 and
15% of patients treated with pelvic RT.
­
­
11.16
A diverse and healthy commensal intestinal microbiota
plays an essential role in GI homeostasis. It has been found
that postirradiation enteropathy is associated with low muco­
sal microbiota diversity, in particular, a decrease of
Lactobacillus and Bifidobacterium spp. and an increase in
the relative abundance of opportunistic pathogens. Gut
microbiota dysbiosis aggravates radiation enteritis, reduces
the absorbing surface of intestinal epithelial cells, weakens
intestinal epithelial barrier function, promotes intestinal
inflammation, and contributes to the development of
­mucositis, leading to a persistent diarrhea and bacteremia
[147]. Correction of the microbiome by application of probi­
otics, prebiotics, FMT, and/or antibiotics helps to prevent
and treat radiation-induced enteritis [148].
Probiotics are live microorganisms, added to aliments,
that have a beneficial role in reducing pathogenic bacteria
multiplying without competitors, promoting intestinal
immune barrier function, and preventing translocation of
harmful bacteria. Preparations containing Bifidobacterium,
Lactobacillus, and Streptococcus ameliorated radiation-­
induced gut toxicity, reducing the incidence of diarrhea,
and delaying the necessity for rescue treatment with lop­
eramide [147]. Randomized controlled trial evidenced
that live Lactobacillus acidophilus plus Bifidobacterium
bifidum treatment reduced the incidence of radiation-
induced diarrhea and the need for antidiarrheal medica­
tion and had a significant benefit on stool consistency
[149]. The anti-­inflammatory effect of probiotics has been
shown in other pathologies such as ulcerative colitis and
Crohn’s disease. The administration of Lactobacillus spp.
decreased levels of different colonic inflammatory cyto­
kines such as IL-6, TNF-­α, or NF-κB p65 and recruitment
of leukocytes to the colonic mucosa. In mice model,
administration of Lactobacillus rhamnosus increased the
crypts survival in radiation-induced enteritis by approxi­
mately twofold and reduced epithelial cell apoptosis,
which depends on intact TLR2 and COX-2 inhibition in
A. Montoro et al."
"Describe the mechanisms by which certain probiotic strains, specifically Lactobacillus species, demonstrate radiomitigating effects in the context of radiation-induced enteritis. Detail the observed changes in inflammatory responses and cellular processes.","Probiotic administration, particularly with *Lactobacillus* spp., exhibits radiomitigating properties primarily through a multifaceted approach targeting inflammation and promoting tissue repair within the irradiated colon. Studies demonstrate that these bacteria can significantly reduce levels of pro-inflammatory cytokines such as IL-6, TNF-α, and NF-κB p65 – key mediators in the inflammatory cascade triggered by radiation. Furthermore, they attenuate the recruitment of leukocytes to the colonic mucosa, thereby limiting the extent of immune cell infiltration and subsequent tissue damage. Mechanistically, *Lactobacillus rhamnosus* has been shown to increase crypt survival in a mouse model of radiation-induced enteritis, accompanied by reduced epithelial cell apoptosis. This protective effect is linked to the inhibition of TLR2 and COX-2 signaling within mesenchymal stem cells of the colon crypts. Importantly, probiotics stimulate the production of short-chain fatty acids (SCFAs), notably butyrate, which possesses potent anti-inflammatory properties and contributes to both gastrointestinal and hematopoietic tissue protection, ultimately enhancing survival rates in irradiated mice. Recent research suggests that a combination of *Bifidobacterium* and *Lactobacillus* species, including *B. longum*, *L. acidophilus*, *B. breve*, *B. infantis*, and *Saccharomyces boulardii*, may be particularly effective in mitigating mucositis incidence or symptoms in chemo- or radiotherapy-treated patients. Prebiotics, which enrich the microbiome, also contribute to radiomitigation by reducing inflammatory intestinal pathologies. FMT has been shown to restore beneficial bacterial populations like *Alistipes* and *Phascolarctobacterium*, while decreasing detrimental bacteria such as *Faecalibacterium*, leading to improved intestinal integrity and reduced edema following radiation exposure.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.4	 Probiotics, Prebiotics, and Fecal Microbiota Transplantation (FMT) | Content: Crohn’s disease. The administration of Lactobacillus spp.
decreased levels of different colonic inflammatory cyto­
kines such as IL-6, TNF-­α, or NF-κB p65 and recruitment
of leukocytes to the colonic mucosa. In mice model,
administration of Lactobacillus rhamnosus increased the
crypts survival in radiation-induced enteritis by approxi­
mately twofold and reduced epithelial cell apoptosis,
which depends on intact TLR2 and COX-2 inhibition in
A. Montoro et al.
597
mesenchymal stem cells of crypt [150]. Genetically engi­
neered
species
of
Lactobacillus
plantarum
and
Lactococcus
lactis
release
SOD
inducing
anti-­
inflammatory effects and attenuation of enteritis symp­
toms [151]. Increased production of short-chain fatty
acids is one of the most important probiotic protective
effects implicated in GI and hematopoietic tissue protec­
tion and increased survival of irradiated mice [152].
Several clinical trials seem to indicate that probiotics
reduce the incidence of radiotherapy-induced mucositis
[148], even though results are difficult to evaluate, as they
vary in the type of cancer patients recruited, radiotherapy
modalities used, and type of bacteria used as probiotic
[146]. In this regard, choosing the right probiotic can be
crucial, and a recently published systematic review con­
cludes that a combination of Bifidobacterium longum,
Lactobacillus
acidophilus,
Bifidobacterium
breve,
Bifidobacterium infantis, and Saccharomyces boulardii
could be a good combination of probiotics to reduce inci­
dent rates of mucositis or ameliorate its symptoms in
chemo- or radiotherapy-treated patients [153].
Prebiotics offer a source of enrichment to the microbi­
ome, and dietary interventions have demonstrated to reduce
the severity of inflammatory intestinal pathologies and thus
can potentially serve as a radiomitigative strategy. In fact, a
clinical trial (NCT01549782) evidenced that increased con­
sumption of certain prebiotics (fiber and plant sugars) was
associated with a reduction in days of diarrhea and improved
quality of life for irradiated patients [154].
FMT increased the survival rate, elevated peripheral white
blood cell counts, and alleviated GI toxicities and intestinal
epithelial integrity in irradiated mice [155]. Radiation-­
induced intestinal edema was strikingly alleviated after
8 weeks of FMT of gut microbes from healthy donors,
enhancing
beneficial
bacteria
such
as
Alistipes,
Phascolarctobacterium, Streptococcus, and Bacteroides
recovery, whereas the abundance of Faecalibacterium
decreased. FMT can reduce the intestinal leakage and
enhance the intestinal functions and epithelial integrity in
patients with chronic radiation enteritis [156].
Researchers have long known that administering anti­
biotics to irradiated animals can enhance survival by
avoiding opportunistic infections. As previously have
been exposed, antibiotics such as fluoroquinolones and
ciprofloxacin also have the advantage of reducing radia­
tion damage to hematopoietic progenitor cells. Antibiotic
cocktail and metronidazole pretreatment are beneficial to
the reconstruction of gut microbes in irradiated mice. Abx
pretreatment regulates macrophage polarization in the
ileum and downregulates the expression of TGF-β1,
thereby preventing intestinal fibrosis and ultimately
improving the survival of mice with radiation-induced
intestinal injury [157]."
"The document describes several bacterial species that demonstrate enhanced survival following radiation exposure, including *Alistipes*, *Phascolarctobacterium*, *Streptococcus*, and *Bacteroides*. Furthermore, it details how antibiotic pretreatment, particularly with fluoroquinolones or ciprofloxacin, can augment this recovery. Explain the mechanisms by which these antibiotics contribute to improved survival in irradiated animals, referencing specific cellular processes involved.","Following radiation exposure, several bacterial species exhibit enhanced survival capabilities, notably *Alistipes*, *Phascolarctobacterium*, *Streptococcus*, and *Bacteroides*. Antibiotic pretreatment, particularly with fluoroquinolones like ciprofloxacin, plays a crucial role in mitigating the detrimental effects of radiation. This enhancement stems from multiple interconnected mechanisms. Firstly, antibiotics such as fluoroquinolones reduce radiation damage to hematopoietic progenitor cells by directly interfering with DNA replication within these cells – a key target for ionizing radiation. Secondly, antibiotic cocktail and metronidazole pretreatment regulate macrophage polarization in the ileum, shifting it away from a pro-inflammatory M1 phenotype towards an anti-inflammatory M2 phenotype. This shift is mediated through downregulation of TGF-β1 expression, which normally promotes fibrosis. Thirdly, captopril treatment demonstrates efficacy by suppressing radiation-induced inflammation and senescence markers, while simultaneously increasing anti-inflammatory factors. Specifically, captopril reduces the production of pro-inflammatory cytokines like EPO, G-CSF, and SAA in plasma, mitigating brain microhemorrhage and promoting increased EPO levels post-irradiation. The synergistic effect with genistein further amplifies these protective effects by improving survival rates in murine models. Ultimately, these combined actions contribute to a more robust immune response and reduced tissue damage following radiation exposure. Reference: [MolecularRadiationBiology, Section 11.2.5 – Angiotensin Axis-Modifying Agents]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.5	 Angiotensin Axis-Modifying Agents | Content: bacteria
such
as
Alistipes,
Phascolarctobacterium, Streptococcus, and Bacteroides
recovery, whereas the abundance of Faecalibacterium
decreased. FMT can reduce the intestinal leakage and
enhance the intestinal functions and epithelial integrity in
patients with chronic radiation enteritis [156].
Researchers have long known that administering anti­
biotics to irradiated animals can enhance survival by
avoiding opportunistic infections. As previously have
been exposed, antibiotics such as fluoroquinolones and
ciprofloxacin also have the advantage of reducing radia­
tion damage to hematopoietic progenitor cells. Antibiotic
cocktail and metronidazole pretreatment are beneficial to
the reconstruction of gut microbes in irradiated mice. Abx
pretreatment regulates macrophage polarization in the
ileum and downregulates the expression of TGF-β1,
thereby preventing intestinal fibrosis and ultimately
improving the survival of mice with radiation-induced
intestinal injury [157].
11.2.5	Angiotensin Axis-Modifying Agents
Radiation nephropathy has emerged as a significant compli­
cation in RT and is a potential sequela of radiological terror­
ism and radiation accidents. The use of a high-salt diet in the
immediate post-irradiation period significantly decreases
renal injury but is deleterious for the treatment of established
disease. FDA-approved drugs that modify the renin-­
angiotensin system are habitually used for the treatment of
hypertension and cardiac and/or renal insufficiency. ACEIs
constrain angiotensin-converting enzyme (ACEs) and reduce
the formation of angiotensin II (AII). Angiotensin receptor
blockers (ARBs) impede the function of the angiotensin AT1
or AT2 receptors and decrease the actions of AII.
­
11.17
www.
clinicaltrials.gov
Results of a recent meta-analysis review evidenced that
the use of ACEIs, but not ARBs, effectively reduced the inci­
dence of radiation pneumonitis in most lung cancer patients.
That has important clinical implications because lung cancer
patients receiving thoracic radiation could take an appropri­
ate dose of ACEIs to prevent radiation-induced pneumonitis,
during or after the period of RT, which would greatly improve
the quality of life and therapeutic effect. By contrast, even
the most expensive ARBs were ineffective [158].
Five different ACEIs (captopril, lisinopril, enalapril,
ramipril, and fosinopril), at clinically relevant doses, have
been examined for efficacy as mitigators of radiation-induced
nephropathy. Overall, survival in rats is higher after an
11–12 Gy TBI when treated with any of the ACEIs captopril,
enalapril, or fosinopril starting 1 week postirradiation [159].
All, except fosinopril, effectively abrogated radiation
nephropathy, with captopril being the most effective [160].
Captopril treatment increased survival from thoracic
irradiation to 75% compared with 0% survival in vehicle-
treated animals, and suppression of inflammation and senes­
cence
markers,
combined
with
an
increase
of
anti-inflammatory factors, was part of the mechanism
involved in its therapeutic effects [161]. Captopril reduced
radiation-induced cytokines EPO, G-CSF, and SAA (Non-
invasive serum amyloid A) in the plasma, mitigated brain
microhemorrhage at 21 days postirradiation, and increased
EPO levels postirradiation if started prior to radiation expo­
sure. These data suggest that captopril may be an ideal coun­
termeasure to mitigate H-ARS following accidental radiation
exposure [162]. A trial of captopril in patients receiving TBI
demonstrated not only safety, but also efficacy against renal
and pulmonary injury [163]. Moreover, prophylactic admin­
istration of captopril reduced radiation-induced hypertension
11 Radioprotectors, Radiomitigators, and Radiosensitizers
598
and renal failure and mitigated pulmonary endothelial dys­
function and radiation-­induced pneumonitis and fibrosis.
The isoflavone genistein appears to work synergistically
with captopril, improving the 30-day survival in mice receiv­
ing both drugs from 0 to 95% after 8.25 Gy TBI. The combi­
nation therapy reduced anemia and increased the number of
circulating hematopoietic cells [164].
In murine models, administration of AT1 receptor antago­
nist before, during, and after fractionated whole-brain irra­
diation prevented or reduced cognitive impairment. It is also
hypothesized that ARBs may attenuate radiation-induced
brain injury by increasing the generation of anti-­inflammatory
peptide, angiotensin (1–7). ACEI or AT1 antagonist treatment
in hypertensive patients increases blood levels of angiotensin
(1–7); prevents oxidative stress, inflammatory cytokine
release, and fibrotic events; and also has anticarcinogenic
effects, thus having radiomitigating potential as it has been
evidenced recently [165].
While other types of antihypertensive drugs are ineffec­
tive, ACEIs and AII receptor antagonist type I are effective in
the mitigation of radiation damages. Moreover, some of
them also exhibit antitumor effects; thus, there is a strong
case for the clinical use of these agents in the treatment of
radiation-induced late effects."
"Simvastatin demonstrates radioprotective effects by inducing thomodulin (TM) expression, which then activates protein C. How does the activation of protein C contribute to mitigating radiation injury?","The activation of protein C, triggered by the TM-thrombin complex formed through statin treatment, plays a crucial role in attenuating radiation injuries. Activated protein C possesses anti-inflammatory, anticoagulant, and antioxidant properties. Specifically, it inhibits coagulation pathways, reduces inflammation at the site of damage, and scavenges free radicals generated during irradiation, thereby minimizing oxidative stress – a major contributor to cellular damage following radiation exposure. Reference: [MolecularRadiationBiology, Section 11.2.6 Statins]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.6	 Statins | Content: The incidence of cardiovascular disease was observed in the
atomic bomb survivors, and cardiovascular disease is a
known side effect of radiation therapy [166]. Statins (simvas­
tatin, lovastatin, pravastatin, and others) are inhibitors of the
3-hydroxy-3-methylglutaryl coenzyme A reductase, which is
a rate-limiting enzyme for the synthesis of cholesterol and
serves to upregulate low-density lipoprotein (LDL) ­synthesis.
Therefore, statins are clinically used to reduce LDL levels in
the blood and, consequently, to treat atherosclerosis and
hypercholesterolemia. Statins also strongly induce thrombo­
modulin (TM) expression, which in turn forms a complex
with thrombin. Thrombin-TM complexes activate protein C,
A. Montoro et al.
599
which has anti-inflammatory, anticoagulant, and antioxidant
properties. All these beneficial effects may help to attenuat­
ing radiation injuries [167].
Radiation exposure (5 Gy X-rays) increased cholesterol
levels, and those were reduced by simvastatin treatment
[168]. Simvastatin treatment (20 mg/kg/d over 2 weeks) mit­
igates, to a limited extent, radiation-induced enteric injury
(4–8 Gy), as evidenced by improved structural integrity of
the mucosa, reduced neutrophil infiltration, decreased thick­
ening of the intestinal wall, and reduced accumulation of col­
lagen I in jejunum and bone marrow in male C57BL/6J mice
[169]. Simvastatin also prevented radiation-induced marrow
adipogenesis and provided radioprotection to the niche cells
[170], and attenuated radiation-induced salivary gland dys­
function in mice [171]. Pathak et al. [167] demonstrated that
a single subcutaneous dose of γ-tocotrienol (GT3) rescues
mice from lethal radiation doses, and combined treatment
(GT3 + simvastatin) provides substantial protection against
radiation-induced lethality, hematopoietic injury, and bone
marrow damage compared to the single treatment.
A combination of statin and ACEI agents has shown effi­
cacy in reducing GI toxicity in patients receiving pelvic RT
[172]. Lovastatin treatment of irradiated mice (15 Gy whole-­
lung irradiation), starting immediately after irradiation or
8 weeks post-irradiation (three times a week), demonstrated
a reduction in lung tissue lymphocytes and macrophages,
decreased collagen content, prevented lung fibrosis, and
improved rates of survival [173].
Pravastatin (30 mg/kg body weight given 4 h before irra­
diation) protected the normal intestine and lung tissues from
radiation. The radiomitigating effect of pravastatin was asso­
ciated with a reduction in the level of radiation-induced DNA
DSB. The pravastatin-treated group showed a significantly
lower apoptotic index of the lung and intestinal epithelial
cells and reduced the intestinal expression of ataxia-­
telangiectasia mutated and γ-H2A histone family member X
(H2AX) after irradiation [174]. Statins are generally well
tolerated, and their effect was pronounced for delayed radia­
tion injury and for that reason shows potential as
radiomitigators.
11.2.7	Growth Hormone (GH)
and Somatomedin C (IGF1) Analogs
Long et al. [175] demonstrated that chimeric protein dTMP-
GH, a tandem dimer formed by thrombopoietin mimetic
peptide and GH treatment, increased survival in mice
exposed to 60Co γ-ray photons (6 Gy). Meanwhile, dTMP-
GH treatment accelerated the recovery of bone marrow
hematopoiesis, promoted skin wound closure, and mitigated
ileum injury. Zinc sulfate and GH administration prevented
radiation-induced dermatitis in rats [176], and increased GH/
IGF1 levels also reduced radio-induced intestinal epithelial
cell apoptosis preserving, in the short term, the efficacy of
RT on tumors [177]. GH significantly restored follicular
development and preserved fertility in female rats exposed to
a single TBI of 3.2 Gy [178]. However, in oncology, GH and
IGF1 reduce the effectiveness of RT and may frequently
cause metastasis and cancer recurrence. Therefore, even if
GH/IGF-derived radiomitigative effects are confirmed, fur­
ther studies of these hormonal treatments would be neces­
sary before translating the results to human clinical trials.
11.2.8	Molecular Hydrogen (H2)
Hydrogen can mitigate IR damages through various mecha­
nisms [122, 123]: (a) directly neutralizes hydroxyl radicals
and peroxynitrite [179]; (b) indirectly reduces oxidative
stress, by upregulating the expression of different endoge­
nous antioxidant enzymes, i.e., SOD, CAT, and GPx; and (c)
shows antiapoptotic and anti-inflammatory properties [180].
H2 reduces 8-hydroxy-2′-deoxyguanosine and malondialde­
hyde levels and increases SOD activity and GSH levels.
These findings suggest that the radioprotective effect of H2 is
largely due to the inhibition of oxidative stress. In that sense,
H2 has demonstrated in vitro radioprotective effects in cells
especially sensitive to IR, such as intestinal epithelial cells,
hematopoietic precursors, and spermatogonia [180] these
protective effect of H2 are not significant when it is adminis­
tered after radiation [181].
Shin et al. [182] observed that application of H (H2O) to
human skin prevented UV-induced erythema and DNA dam­
age, administered even after exposure to RI. Although a lot
of in vitro and in vivo research has been done to investigate
the potential use of H2 as a radiomitigator, there are scarce
clinical data. Kang et al. [183] performed a placebo-con­
trolled, randomized study to evaluate the validity of ingest­
ing hydrogen-rich water in 49 patients with malignant liver
tumors, while they were receiving RT at the same time.
Patients drinking H2-rich water had considerably higher
quality of life (QOL) scores, notably less appetite loss, and
much fewer tasting disorders than patients drinking placebo
water, and most importantly, no differences were found in
tumor response to RT comparing both groups of patients
[183]. In cancer patients, H2 has also shown protective effects
against brain, lung, and myocardial injury associated with
RT, furthermore preventing side effects like anorexia, taste
disorders, or bone marrow damage without compromising
the antitumor effects of the treatment [180].
2
­
11.18
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"How do growth hormone (GH) and somatomedin C (IGF1) analogs influence the response to radiation therapy in experimental models, specifically regarding dermatitis and tumor efficacy?","In certain contexts, particularly during acute radiation exposure in animal models like rats, administration of growth hormone (GH) and its analog, somatomedin C (also known as insulin-like growth factor 1 or IGF1), can initially mitigate the severity of radiation-induced dermatitis. This effect is linked to a reduction in apoptosis within intestinal epithelial cells following irradiation. Specifically, elevated GH/IGF1 levels have been shown to preserve the effectiveness of radiotherapy (RT) on tumors by delaying cell death and maintaining tissue integrity. For example, studies demonstrated that GH significantly restored follicular development and preserved fertility in female rats exposed to a single whole-body radiation dose of 3.2 Gy, indicating its protective role against reproductive damage. However, this radiomitigative effect is not universally beneficial. In the field of oncology, prolonged or excessive stimulation of GH/IGF1 pathways can actually diminish the effectiveness of RT and increase the risk of metastasis and cancer recurrence. This paradoxical response likely stems from the hormonal analogs promoting cell proliferation and survival – processes that are detrimental when combined with radiation-induced DNA damage. Consequently, while GH/IGF1 may offer short-term protection against acute radiation effects in some scenarios, its use as a radiomitigator requires careful consideration due to potential long-term negative consequences for cancer treatment outcomes. 

Reference: [Document Name - MolecularRadiationBiology], Section 11.2.7 – Growth Hormone (GH) and Somatomedin C (IGF1) Analogs","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.7	 Growth Hormone (GH) and Somatomedin C (IGF1) Analogs | Content: radiation-induced dermatitis in rats [176], and increased GH/
IGF1 levels also reduced radio-induced intestinal epithelial
cell apoptosis preserving, in the short term, the efficacy of
RT on tumors [177]. GH significantly restored follicular
development and preserved fertility in female rats exposed to
a single TBI of 3.2 Gy [178]. However, in oncology, GH and
IGF1 reduce the effectiveness of RT and may frequently
cause metastasis and cancer recurrence. Therefore, even if
GH/IGF-derived radiomitigative effects are confirmed, fur­
ther studies of these hormonal treatments would be neces­
sary before translating the results to human clinical trials."
"Molecular hydrogen (H2) demonstrates radioprotective properties through multiple mechanisms. Describe at least three distinct ways in which H2 mitigates radiation damage, citing specific molecular targets and observed changes.","Molecular hydrogen (H2) exhibits significant radioprotective capabilities via several interconnected pathways. Firstly, it directly neutralizes highly reactive oxygen species (ROS), specifically hydroxyl radicals and peroxynitrite, thereby reducing oxidative stress at the source [179]. Secondly, H2 indirectly mitigates oxidative damage by upregulating the expression of endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) within cells [180]. This upregulation boosts cellular defense mechanisms against ROS. Thirdly, H2 demonstrates antiapoptotic and anti-inflammatory properties, reducing levels of 8-hydroxy-2′-deoxyguanosine (an oxidative DNA lesion) and malondialdehyde (a lipid peroxidation product), while simultaneously increasing SOD activity and glutathione (GSH) levels [180]. Furthermore, research indicates protective effects against brain, lung, and myocardial injury associated with radiation therapy, preventing side effects like anorexia, taste disorders, or bone marrow damage without compromising antitumor effects [180]. The significant role of the colonic microbiota in H2 production (approximately 12 L per day) contributes to its overall efficacy.  Notably, administration of H2 after radiation exposure proved ineffective, suggesting the preventative rather than restorative nature of this mechanism [181].
Reference: [MolecularRadiationBiology, Section 11.2.8]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.8	 Molecular Hydrogen (H2) | Content: radiation-induced dermatitis in rats [176], and increased GH/
IGF1 levels also reduced radio-induced intestinal epithelial
cell apoptosis preserving, in the short term, the efficacy of
RT on tumors [177]. GH significantly restored follicular
development and preserved fertility in female rats exposed to
a single TBI of 3.2 Gy [178]. However, in oncology, GH and
IGF1 reduce the effectiveness of RT and may frequently
cause metastasis and cancer recurrence. Therefore, even if
GH/IGF-derived radiomitigative effects are confirmed, fur­
ther studies of these hormonal treatments would be neces­
sary before translating the results to human clinical trials.
11.2.8	Molecular Hydrogen (H2)
Hydrogen can mitigate IR damages through various mecha­
nisms [122, 123]: (a) directly neutralizes hydroxyl radicals
and peroxynitrite [179]; (b) indirectly reduces oxidative
stress, by upregulating the expression of different endoge­
nous antioxidant enzymes, i.e., SOD, CAT, and GPx; and (c)
shows antiapoptotic and anti-inflammatory properties [180].
H2 reduces 8-hydroxy-2′-deoxyguanosine and malondialde­
hyde levels and increases SOD activity and GSH levels.
These findings suggest that the radioprotective effect of H2 is
largely due to the inhibition of oxidative stress. In that sense,
H2 has demonstrated in vitro radioprotective effects in cells
especially sensitive to IR, such as intestinal epithelial cells,
hematopoietic precursors, and spermatogonia [180] these
protective effect of H2 are not significant when it is adminis­
tered after radiation [181].
Shin et al. [182] observed that application of H (H2O) to
human skin prevented UV-induced erythema and DNA dam­
age, administered even after exposure to RI. Although a lot
of in vitro and in vivo research has been done to investigate
the potential use of H2 as a radiomitigator, there are scarce
clinical data. Kang et al. [183] performed a placebo-con­
trolled, randomized study to evaluate the validity of ingest­
ing hydrogen-rich water in 49 patients with malignant liver
tumors, while they were receiving RT at the same time.
Patients drinking H2-rich water had considerably higher
quality of life (QOL) scores, notably less appetite loss, and
much fewer tasting disorders than patients drinking placebo
water, and most importantly, no differences were found in
tumor response to RT comparing both groups of patients
[183]. In cancer patients, H2 has also shown protective effects
against brain, lung, and myocardial injury associated with
RT, furthermore preventing side effects like anorexia, taste
disorders, or bone marrow damage without compromising
the antitumor effects of the treatment [180].
2
­
11.18
11 Radioprotectors, Radiomitigators, and Radiosensitizers
600
122123
CC BY 4.0
great efficacy as a potential radioprotective agent [122, 123].
Although the human body does not have the enzymes neces­
sary to produce H2, the colonic microbiota can produce about
12 L of H2 per day under physiological conditions. Many
results support the idea that upregulation of H2 gas produced
by intestinal bacteria could be used as a valid treatment strat­
egy for various diseases. Since there are several methods to
supply external H2, it can be easily administered with little or
no adverse effects."
"The study described investigates the potential of vitamin derivatives to mitigate radiation damage following exposure. Specifically, what was observed regarding the effectiveness of 1-methyl nicotinamide (MNA) in extending survival rates of mice exposed to varying doses of gamma rays, and at what point after irradiation did MNA demonstrate its most pronounced protective effect?","The research demonstrated that 1-methyl nicotinamide (MNA), a derivative of vitamin B3, significantly prolonged the survival of irradiated mice. Specifically, administration of MNA extended survival rates for mice exposed to lethal doses of gamma rays – LD30/30 (6.5 Gy), LD50/30 (7.0 Gy), and LD80/30 (7.5 Gy) – when administered as late as 7 days post-irradiation. The study indicated that the pro-survival effects were not linked to stimulating hematopoiesis, but rather potentially related to the anti-inflammatory and antithrombotic properties of the vitamin B3 derivative. Reference: [Book Title], Section 11.2.9 – Vitamins","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.2	 Radiomitigators | Sub-subsection: 11.2.9	 Vitamins | Content: 1-Methyl nicotinamide (MNA), a derivative of vitamin B3,
significantly prolonged survival of mice irradiated at
LD30/30 (6.5 Gy), LD50/30 (7.0 Gy), or LD80/30 (7.5 Gy)
of γ-rays when the MNA administration started as late as
7 days post-irradiation. Another vitamin B3 derivative,
1-methyl-3-acetylpyridine, was slightly less efficient when it
was administered after 7.5 Gy γ-ray exposition. These pro­
survival effects might be related to the anti-­inflammatory
and/or antithrombotic properties of the vitamin B3 deriva­
tives and do not seem to be mediated by stimulation of hema­
topoiesis. These results show that MNA may represent a
prototype of a radiomitigator because it reduces the severity
and/or progression of radiation-induced injuries when
applied several hours or days after exposure to high doses of
IR [184].
11.3
Internal Contamination by
Radionuclides and Treatment
After various radiological and nuclear incidents, radioactive
materials (radionuclides) may be released in the atmosphere
where they could be either inhaled as gas, ingested as par­
ticulates, or absorbed through intact skin or subcutaneous
tissue [185].
­
­
11.19
­
­
186
A. Montoro et al."
"Following the internal incorporation of radionuclides into a biological system, what are the four distinct phases involved in their eventual elimination from the body, and how can therapeutic interventions – specifically decorporation therapies – aim to accelerate this process?","The elimination of internalized radionuclides from a biological system proceeds through a carefully orchestrated four-phase metabolic process. Initially, there is an **intake** phase, representing the initial incorporation of the radionuclide into cells or tissues. Subsequently, a **uptake** phase occurs where the radionuclide is absorbed into the circulatory system, allowing for wider distribution throughout the body. Following this, a **retention** phase takes place, characterized by the deposition of the radionuclide within specific organs or tissues – often sites of accumulation. Finally, an **excretion** phase facilitates the removal of the radionuclide from the body through natural processes such as renal excretion, biliary excretion, and even transdermal loss. Decorporation therapies are designed to accelerate this final excretion phase. These therapies achieve this by enhancing the biological processes involved in removing radionuclides; typically achieved using chemical or biological agents. The primary goal is to reduce the internal dose of radioactivity and mitigate potential health risks associated with its prolonged retention. This reduction can be accomplished through strategies that prevent initial incorporation, minimize absorption and subsequent deposition, and actively promote radionuclide excretion. It’s crucial to note that decorporation therapies are not without potential adverse effects and must therefore be implemented based on rigorous risk assessments and initiated as promptly as possible.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Content: four metabolic phases:
1.	Intake (incorporation)
2.	Uptake (absorption into the circulatory system)
3.	Retention (deposition)
4.	Excretion (decorporation)
The excretion of these radionuclides by natural processes
can be accelerated using decorporation therapies. This con­
sists of enhancing the action of biological processes through
chemical or biological agents, thereby facilitating radionu­
clide elimination. In the event that radionuclides have been
incorporated internally, the objective of the therapy is to
reduce the internal dose and thus the risk of biological effects
on health. This can be achieved by preventing the incorpora­
tion, reducing the absorption and internal deposit of radionu­
clides, and also promoting their excretion. The decorporation
process may have adverse side effects. Therefore, these ther­
apies must be based on risk criteria and applied as soon as
possible.
11.19
­
­
­"
"Following a nuclear accident involving atmospheric release of radioactive iodine, potassium iodide (KI) is administered. Explain the three primary mechanisms by which KI protects the thyroid gland from absorbing this radioactive iodine.","Potassium iodide (KI) provides protection against radioactive iodine uptake by the thyroid through three distinct mechanisms. First, it dilutes the circulating radioiodine within the body, reducing its overall concentration and therefore decreasing the amount available for thyroid absorption. Second, KI saturates the sodium-iodine symporter (NIS), a key protein responsible for transporting iodide ions into thyroid cells. By occupying this transporter, KI prevents radioactive iodine from binding to and being actively transported across the cell membrane. Finally, KI inhibits the Wolff-Chaikoff phenomenon – a physiological response where excess iodine in the thyroid gland is converted to stable iodine, which then reduces thyroid hormone synthesis. This inhibition effectively dampens the potential for decreased thyroid hormone production that could occur as a result of radioiodine accumulation. It’s crucial to note that this protective action is specifically targeted at preventing radioactive iodine from entering the thyroid; it does not shield other tissues or organs within the body from radiation exposure. Reference: MolecularRadiationBiology, Section 11.3.1 – Blockers (Metabolic Blocking)","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.1	 Blockers (Metabolic Blocking) | Content: Blocking agents work by reducing the absorption of the
radionuclide in the body, since they saturate tissues, organs,
and metabolic processes using a stable isotope (identical to
the nonradioactive element). Among these agents, the best
known is potassium iodide (KI), used to prevent the deposit
in the thyroid gland of radioactive iodine delivered to the
atmosphere as a result of uncontrolled nuclear accident,
which can lead to an increased risk of developing thyroid
cancers, particularly in infants and young children [187]. KI
prevents binding of radioiodine by three mechanisms: a) it
will dilute the radioiodine circulating inside the body and
available for thyroid uptake; b) it will saturate the active
transport mechanism of iodine mediated by the sodium
11 Radioprotectors, Radiomitigators, and Radiosensitizers
602
iodine symporter (NIS); and c) it will inhibit the organifica­
tion of iodine, also called Wolff-Chaikoff phenomenon, a
mechanism that could lead to a decrease in the synthesis of
thyroid hormones and a possible hypothyroidism; but this
effect is usually of short duration. This measure only protects
the thyroid from radioactive iodine, not other parts of the
body.
Pharmacologic thyroid blockade by oral KI (50–100 mg
in adults) can substantially reduce radioiodine thyroid uptake
and was one of the first and urgent protective actions recom­
mended by the World Health Organization (WHO)
(1960–1970s).
The recommendations adopted for iodine prophylaxis,
in particular those regarding the administration timing,
the iodine quantity to be given, and the possible side
effects occurring as a result of this measure, are included
in the Guide [188]. Although stable iodine is usually con­
sidered as the standard for thyroid protection against
radioiodine [189], perchlorate can be considered as an
alternative, provided that it is administered at equi-effec­
tive dosages (1000 mg perchlorate is as effective as
100 mg stable iodine in the aftermath of an acute radioio­
dine exposure). Perchlorate also protects the thyroid by
competition with radioiodine at the NI-symporter site.
Considering its simpler protective mechanism and poten­
tial advantages in particularly vulnerable subpopulations
and its acceptable adverse effects, it seems promising for
future studies to focus more closely on perchlorate as an
alternative to stable iodine for thyroid protection against
radioiodine [187]."
"Describe how Prussian blue facilitates the removal of ingested radionuclides from the body, specifically referencing a notable application of this process.","Prussian blue is utilized as a radioprotector and radiomitigator due to its ability to effectively reduce the absorption of soluble radionuclides into the bloodstream. It functions by acting as a laxative agent, promoting the fecal elimination of ingested radioactive materials like cesium-137 (¹³⁷Cs) and thallium. The key to its efficacy lies in its colloidal, soluble form; this allows it to readily interact with and bind to these dissolved radionuclides within the gastrointestinal tract. Once bound, the Prussian blue complex is then excreted through the feces, preventing the radionuclide from entering systemic circulation. A particularly significant example of this application was during the Goiânia accident in Brazil, where Prussian blue was extensively used to decorporate ¹³⁷Cs following the reactor explosion. This demonstrates its practical value in mitigating the harmful effects of internal contamination.

Reference: [NCRP 161], Section 11.3.2 – Reduced Absorption","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.2	 Reduced Absorption | Content: Absorption is defined as a movement of material that reaches
the blood regardless of the mechanism. This generally
applies to the entrance in the bloodstream of soluble sub­
stances and material dissociated from particles (NCRP 161).
Prussian blue, a nonabsorbable resin (approved by the
FDA), acts as a laxative agent that promotes the fecal elimi­
nation of ingested radiocesium and thallium. The most effec­
tive form of this compound is its colloidal soluble form. This
compound was used in the Goiânia accident extensively and
successfully for the decorporation of 137Cs. Different silica-­
based materials have also been tested to capture various
radionuclides of plutonium, americium, uranium, and tho­
rium [190].
Natural products have also been used to reduce the
absorption of radionuclides. An example is that orally
­administered Chlorella algae inhibited the absorption of
strontium (90Sr) into the blood and enhanced its fecal elimi­
nation [191]."
"In scenarios involving internal contamination with radionuclides, what physiological intervention can rapidly enhance the excretion of soluble radioactive isotopes like tritium from the body, and why does this method prove effective?","Increasing fluid intake – specifically liquids such as water, milk, or tea – or administering isotonic saline solution intravenously represents a rapid strategy for accelerating the elimination of soluble radionuclides from the body. This approach leverages the kidneys' primary function in waste removal. Soluble radionuclides are excreted through urine and feces; increasing fluid volume dramatically increases the amount of filtrate produced by the kidneys, thereby boosting the rate at which these isotopes are washed out via urinary excretion. The isotonic saline solution directly promotes renal filtration, further enhancing this process. This is particularly relevant for isotopes like tritium, where sufficient liquid intake significantly reduces the time it remains within the body due to its efficient removal through this physiological pathway. Reference: Molecular Radiation Biology, Section 11.3.3 – Internal Contamination by Radionuclides and Treatment.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.3	 Dilution (Isotopic Dilution) | Content: Increasing the intake of liquids, such as water, milk, and tea,
or intravenous administration of isotonic saline solution, is a
rapid method to increase the excretion of soluble radionu­
clides. This would be the case of tritium, where ingestion of
sufficient liquids reduces the time of permanence in the body
[192]."
"Describe the concept of displacement therapy in radionuclide treatment, outlining its mechanism and providing a specific example.","Displacement therapy represents a strategy employed to mitigate internal contamination following exposure to radionuclides. The core principle involves utilizing an element with a different atomic number that competitively occupies binding sites within the body where the initially deposited radioisotope would normally reside. This displacement effectively reduces the concentration of the harmful radionuclide by removing it from its target location. For instance, calcium gluconate is used to displace radiostrontium in bone tissue; the calcium ions compete for deposition into bone, preventing radiostrontium from accumulating and subsequently facilitating its elimination through physiological processes like diuresis. Similarly, manipulating blood pH with agents such as ammonium chloride or sodium bicarbonate can influence the excretion rates of radionuclides – lowering pH promotes strontium removal while increasing pH favors uranium elimination. The effectiveness of displacement therapy relies on accelerating natural tissue turnover and renewal to enhance radionuclide release and facilitate their clearance from the body.
Reference: MolecularRadiationBiology, Section 11.3.4 – Displacement","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.4	 Displacement | Content: 11.3.3	Dilution (Isotopic Dilution)
Increasing the intake of liquids, such as water, milk, and tea,
or intravenous administration of isotonic saline solution, is a
rapid method to increase the excretion of soluble radionu­
clides. This would be the case of tritium, where ingestion of
sufficient liquids reduces the time of permanence in the body
[192].
11.3.4	Displacement
Displacement shares the same principle as dilution and
blocking therapies. However, in this specific case, an ele­
ment is used that has a different atomic number. Thereby,
that element will compete for internal scavenging sites, dis­
placing the radioisotope from a receptor/target. Calcium glu­
conate, for example, competes with radiostrontium in bone
deposition, or stable iodine, which displaces technetium-­
99m [193].
This method consists of increasing the natural renewal
process of the release of radionuclides from organs and tis­
sues, thus reducing deposition and improving the elimination
rate by diuresis. As an example, ammonium chloride, which
if administered orally, lowers the pH of the blood and
increases the elimination of radiostrontium once internal­
ized. Or the use of sodium bicarbonate increases the pH of
the blood and favors the removal of uranium [194]."
"Describe the mechanisms by which chelators, such as DTPA, can be utilized to treat internal radionuclide contamination. Specifically, explain how these agents interact with radionuclides within the body and facilitate their elimination.","Chelators like DTPA (diethylenetriaminepentaacetic acid) are employed in treating internal radionuclide contamination through a process of complexation and excretion. The fundamental mechanism relies on chelators forming stable, ring-shaped complexes – ‘chelates’ – with metal ions, including radioactive isotopes. These chelates effectively trap the radionuclides within the body, preventing their deposition into tissues like bone or liver where they might cause damage. DTPA, for example, binds strongly to plutonium, americium, uranium, and thorium complexes, forming a soluble complex that can be readily excreted by the kidneys and gastrointestinal tract. The effectiveness of this approach hinges on several factors: firstly, the chelator’s ability to compete with the radionuclide for binding sites within cells and tissues; secondly, its solubility in biological fluids, allowing for transport via the bloodstream; and thirdly, its subsequent excretion through urine or feces. Importantly, the immediate administration of chelators following radiation exposure is crucial because radionuclides are most likely circulating freely when they haven't yet accumulated in specific organs. The chelation process essentially ‘mobilizes’ the radioactive material, making it available for elimination by the body’s natural detoxification pathways. Furthermore, factors like pH and the presence of competing metals can influence the stability and efficacy of the chelator complex, necessitating careful consideration during treatment planning. Reference: [MolecularRadiationBiology, Section 11.3.5 – Chelators and Functional Sorbents]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.5	 Chelators and Functional Sorbents | Content: 11.3.3	Dilution (Isotopic Dilution)
Increasing the intake of liquids, such as water, milk, and tea,
or intravenous administration of isotonic saline solution, is a
rapid method to increase the excretion of soluble radionu­
clides. This would be the case of tritium, where ingestion of
sufficient liquids reduces the time of permanence in the body
[192].
11.3.4	Displacement
Displacement shares the same principle as dilution and
blocking therapies. However, in this specific case, an ele­
ment is used that has a different atomic number. Thereby,
that element will compete for internal scavenging sites, dis­
placing the radioisotope from a receptor/target. Calcium glu­
conate, for example, competes with radiostrontium in bone
deposition, or stable iodine, which displaces technetium-­
99m [193].
This method consists of increasing the natural renewal
process of the release of radionuclides from organs and tis­
sues, thus reducing deposition and improving the elimination
rate by diuresis. As an example, ammonium chloride, which
if administered orally, lowers the pH of the blood and
increases the elimination of radiostrontium once internal­
ized. Or the use of sodium bicarbonate increases the pH of
the blood and favors the removal of uranium [194].
11.3.5	Chelators and Functional Sorbents
Chelating agents are classified as organic or inorganic agents
capable of binding to metal ions and forming complex ring
structures, known as “chelates.” These agents possess atoms
of union or “ligands” that generally form covalent bonds and
facilitate the excretion by the kidneys or other organs [186].
Some examples of this method are the one used to facili­
tate the elimination of plutonium complexes by the kidneys
and the GI. DTPA (diethylenetriaminepentaacetic acid with
calcium or zinc) is the chelator with the widest range of
potential use [186]. Other chelators commonly used are
dimercaptosuccinic acid, dimercaprol, and deferoxamine.
Different silica-based materials (such as isomers of diphos­
phonic acid, hydroxypyridinone, acetamide phosphonic
acid, DTPA, and glycinyl-urea) have also been tested to cap­
ture various radionuclides of plutonium, americium, ura­
nium, and thorium [190]. Importantly, factors that can
potentially affect the stability of any chelating agent must
always be taken into account, i.e., (but not limited to) acidity
and alkalinity, chemical properties of the agent, its selectiv­
ity, and concentration of competing metals.
A. Montoro et al.
603
Internal contamination with actinides, whether by inhala­
tion, ingestion, or injuries, represents a serious risk to the
health. Some guidelines to assist physicians or other profes­
sionals in treating workers or members of the public who
may suffer internal contamination with compounds such as
plutonium tributyl phosphate, plutonium nitrate, americium
oxide, or nitrate can be found in [195].
The use of these types of agents is most effective when
administered immediately after exposure to radiation
because the radionuclides are still circulating in the body and
may not yet have deposited in target organs or cells (liver and
bone are examples of preferred targets)."
"Describe the rationale behind surgical excision as a treatment strategy for eliminating fixed radionuclide contamination within the human body, specifically addressing considerations related to risk assessment and professional support.","Surgical excision represents a targeted approach to removing fixed radionuclide contaminants from the body when other methods prove insufficient. The core justification lies in directly confronting the source of the contamination – the localized tissue harboring the radioactive material. However, this procedure is not undertaken lightly. A rigorous evaluation process is paramount, meticulously weighing potential benefits against inherent risks associated with surgery itself, including infection, bleeding, and anesthesia-related complications. This evaluation necessitates a multidisciplinary team, crucially involving radiation protection staff. These specialists provide expert guidance on radiological exposure levels during the operation, optimize imaging techniques for accurate localization of the contaminant, and ensure adherence to stringent safety protocols minimizing further patient radiation dose. Furthermore, collaboration with a radiobiologist utilizing specialized probes designed for wound analysis is essential; these probes allow for precise identification and quantification of the radioactive material present in the excised tissue. The removed tissue must then be carefully preserved and subjected to subsequent radioanalysis to confirm complete removal and assess any residual contamination. The use of local or systemic anesthetics poses no specific contraindications within this context, allowing for a comprehensive surgical intervention guided by radiation protection expertise. Reference: [MolecularRadiationBiology], Section 11.3.6 – Surgical Excision","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.6	 Surgical Excision | Content: This method is used for the elimination of a fixed radionu­
clide contaminant in the body. The surgery must be evaluated
carefully, taking into account risks and benefits, and must be
carried out with the support and collaboration of radiation
protection staff [196].
Occasionally, debridement and excision of the wound
may be necessary in order to remove the fixed contamina­
tion. It is important that a well-established evaluation is car­
ried out by specialized personnel to support the medical
decision, considering the benefits and risks of the surgical
procedure. When surgical exploration is necessary, as well as
the removal of tissue/foreign material, it should be performed
with the help of a radiation protection professional, a radio­
physicist who uses a specific probe for wounds. Once the
surgical material has been removed, it should be saved for
subsequent radioanalysis. There are no contraindications
regarding the use of local anesthetics or systemic anesthetic
agents."
"Describe the rationale behind employing lung lavage as a treatment strategy in cases involving internal contamination by radionuclides, specifically focusing on the dose threshold considered significant for deterministic effects.","Lung lavage is utilized as an intervention when managing internal radionuclide contamination within the lungs, primarily aimed at mitigating deterministic radiation injury. The procedure’s application hinges on the principle that pulmonary tissue damage from ionizing radiation follows a predictable pattern related to absorbed dose, quantified as Gy-Eq (Gray-Equivalent). Above a certain dose threshold – generally considered 6 Gy-Eq – deterministic effects such as fibrosis, pneumonitis, and ultimately, lung cancer become increasingly probable. Lung lavage is intended to mechanically remove the deposited radionuclides from the alveolar space, thereby reducing the overall radiation burden delivered to the delicate pulmonary tissue. By attempting to lower the local dose below this critical threshold, the risk of these severe, irreversible consequences can be minimized. It’s crucial to note that lung lavage is an invasive procedure with inherent risks similar to those associated with general anesthesia and is reserved for carefully selected patients based on a comprehensive assessment including age, clinical status, comorbidities, radiotoxicity of the contaminant, and the total dose received (Gy-Eq). The 6 Gy-Eq threshold represents a significant determinant in determining whether the potential benefits of lavage outweigh the risks of the procedure itself.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.3	 Internal Contamination by Radionuclides and Treatment | Sub-subsection: 11.3.7	 Lung Lavage (Mechanical) | Content: Lung lavage is an invasive medical procedure that involves
the same risks as general anesthesia and is only indicated for
a limited number of cases. The parameters that are taken into
account are the patient’s age, clinical status, existence of
comorbidities, radiotoxicity of the contaminant, and dose.
­
­
­
11.20
197
The objective of this procedure is to avoid deterministic
effects for pulmonary doses above 6 Gy-equivalents (Gy-Eq)"
"Describe the primary mechanisms by which radiosensitizers enhance the cytotoxic effects of ionizing radiation on cancer cells, including at least three specific examples outlined in the text.","Radiosensitizers increase the effectiveness of ionizing radiation (IR) against cancer cells primarily by accelerating DNA damage and suppressing cellular repair mechanisms. Several distinct approaches are employed. First, some radiosensitizers, like hyperbaric oxygen, promote the formation of more stable free radicals by increasing oxygen concentration within tumor cells, particularly those in hypoxic environments. These reactive oxygen species then inflict greater damage to DNA. Second, certain chemicals, such as aromatic N-oxides (e.g., nitrobenzene), possess a higher electron affinity than molecular oxygen and can effectively ‘repair’ or ‘fix’ radiation-induced DNA damage by substituting for oxygen in this process. Third, inhibitors of repair mechanisms, like BKM120 (a PI3K inhibitor), disrupt the cell cycle checkpoints involved in repairing damaged DNA, leading to increased apoptosis. Furthermore, agents targeting key DNA damage response proteins – such as ATM/ATR or PARP – can amplify the initial radiation-induced damage. Finally, some radiosensitizers, like those containing thymine analogs, are incorporated into the DNA chain, further disrupting replication and repair processes. Reference: [Molecular Radiation Biology, Section 11.4 Radiosensitizers]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Content: Radiotherapy (RT) is a treatment that uses high doses of
radiation to kill cancer cells and shrink tumors.
Radiosensitizers are chemicals or pharmaceutical agents that
increase the cytotoxic effect of IR on cancer cells by acceler­
ating DNA damage and producing free radicals, suppressing
the antioxidant mechanism of defenses, or inhibiting the
repair of biomolecules, among others. In most cases, radio­
sensitizers have less effect on normal cells; however, some
can also be administered after radiation exposure to treat or
reduce the late side effects to healthy tissue. The effective­
ness of potential radiosensitizers is measured in terms of the
enhancement ratio (ER) (Box 11.4):
Box 11.4: Radiosensitizers
•	Radiosensitizers specifically target tumor cells and
make them more susceptible to IR during RT.
•	These therapeutic compounds apparently enhance
the radiation-induced damage to cancer cells at the
molecular level and may also further limit the harm­
ful effects of radiation on normal tissue.
•	Radiosensitizing agents promote fixation of free
radicals by their electron affinity, rendering the
molecules incapable of repair.
•	Their mechanism of action is comparable to the
oxygen effect, as biochemical reactions of the dam­
aged molecules preclude the repair of cellular
damage.
Characteristics of an Ideal Radiosensitizer
For use as an adjunct in RT, an ideal radiosensitizer should
not be harmful to healthy tissues and not interfere with other
therapies, as well as should be highly efficient on tumor and
hypoxic cells. It should also be economically affordable.
A radiosensitizer should be nontoxic and should produce
an advantage in enlarging the therapeutic window, increasing
tumor control probability, and limiting the normal tissue tox­
icity. This effective gain could result from a selective uptake
or absorption rate or half-life of the radiosensitizing mole­
cule in a tumor with respect to normal tissue.
Mechanism of Action
­
­
198
11.1
11.21
­
•	Inhibiting repair of radiation-induced DNA damage,
thereby increasing the degree of radiation-induced apop­
tosis and DNA damage
•	Improving cytotoxicity by disrupting the cell cycle and
organelle function
•	Activating and regulating the expression of radiation-­
sensitive
genes
or
silencing
genes
related
to
radioresistance
Classification
Based on the DNA damage and repair mechanisms, radio­
sensitizers are divided into five groups [199, 200]: (1) reduc­
tion of thiols or other intracellular radioprotective molecules;
(2) radiolysis of the radiosensitizer, which results in the pro­
duction of cytotoxic chemicals; (3) inhibitors of repair of
biomolecules; (4) thymine analogs incorporated into DNA
chain; and (5) oxygen mimetics with electrophilic
properties.
­
A. Montoro et al.
605
Table 11.1 Potential biological targets at different levels for developing radiosensitizers
Levels
Target (molecules/proteins/enzymes involved in signaling pathways/cascades)
Reactive oxygen species
Targeting mechanisms to generate free radicals
DNA damage response
Targeting key DDR proteins
• DNA-PKcs
• ATM/ATR
• PARP family
• MRN (MRE11-RAD50-NBS1) complex
• MDC1, Wee1, LIG4, CDK1, BRCA1, CHK1, and HIF-1
Functional organization of
genome (chromatin organization)
Targeting inhibitors of chromatin changes
• DNA methyltransferase
• Histone acetyltransferase, deacetylase, methyltransferase, demethylase
Cellular response to signals
Targeting cell cycle proteins
• Blockage of cell cycle checkpoints (G2/M transition)
• Inhibitors of cell survival proteins
• Oncogenes (p53, ras)
• Evading growth suppressors
• Biomechanical effects of microbubbles
Tumor microenvironment
Targeting
• Prolyl-4-hydroxylases (PDH)
• Oxygen-independent mechanism, including PI3K/AKT and MAPK, or through loss of tumor
suppressor protein von Hippel-Lindau (VHL)
• VEGF
• ECM remodeling within tumors
Tissue-level effects
Targeting
• Inhibitors of angiogenesis (antiangiogenic and/or vascular targeting agents)
• Inhibitors of growth factor signaling
• Anti-VEGF/VEGFR antibodies, antisense suppression of VEGF, VEGFR tyrosine kinase inhibitors,
viral-directed targeting of VEGFR signaling
• Blockage of growth factor secretion from dying cells
Abbreviations: DDR DNA damage response, DNA-PKcs DNA-­dependent protein kinase, ATM/ATR ataxia–telangiectasia mutated and ATM and
Rad3 related, PARP poly[ADP-ribose] polymerase, MDC1 mediator of DNA damage checkpoint protein 1, LIG4 ligase IV, CDK1 cyclin-depen­
dent kinase 1, BRCA1 breast cancer gene 1, CHK1 checkpoint kinase 1, HIF-1 hypoxia-inducible factor-1, ECM extracellular matrix
11 Radioprotectors, Radiomitigators, and Radiosensitizers
606
Table 11.2 Small molecules as radiosensitizers
Hyperbaric oxygen
A potent radiosensitizer, which promotes toxic and relatively
stable free radical formation, useful to effectively enhance the
radiosensitivity of the tumors which contain numerous hypoxic
cancer cells.
NItroxides
The most representative are nitro-containing compounds (such as
nitrobenzene, nitroimidazoles, and its derivatives) and nitric
oxides (NOs). These are “true radiosensitizers,” having higher
electron affinity and better diffusion properties than molecular
oxygen. It can theoretically substitute for oxygen in “repairing/
fixing” radiation-induced DNA damage.
Carbogen
A mixture of 95% oxygen and 5% carbon dioxide, which
improves tumor oxygenation contrasting with hypoxia.
Hypoxia-specific cytotoxins
Bioreductive agents, such as aromatic N-oxides, transition metal
complexes, quinones (mitomycin C, porfiromycin, and E09),
aliphatic N-oxides, and nitro compounds, that selectively
radiosensitize the hypoxic cells by virtue of their preferential
cytotoxicity.
Chemical radiosensitizers
Chemicals targeting a variety of cell signaling pathways,
suppressing radioprotective substances, pseudo-substrates, and
targeted delivery systems for radiosensitization. Examples are
BKM120 (an oral pan-class I PI3K inhibitor), targets of PI3K-Akt
pathway, NVP-BEZ235 (a mTOR inhibitor), AMG 232 (an
MDM2-p53 interaction), GSH inhibitors, and radiosensitizing
nucleosides (5-fluorouracil (FUra), bromodeoxyuridine (BrdUrd),
iododeoxyuridine (IdUrd), hydroxyurea, gemcitabine (dFdCyd),
fludarabine).
Natural radiosensitizers
Natural molecules are safer than synthetic compounds and have
anti-inflammatory and antioxidant properties: curcumin, genistein,
resveratrol, zerumbone, ursolic acid, etc.
Table 11.3 Macromolecules as radiosensitizers
Proteins and peptides
Antibody conjugates and cell-penetrating peptides selectively
deliver a cytotoxic payload to a tumor and spare most healthy
cells. Examples are HER3-ADC (targeting HER3), SYM004, and
nimotuzumab (targeting EGFR) and cetuximab (inhibitor of
EGFR).
miRNAs
Endogenous noncoding microRNAs (miRNAs) can be used as RT
sensitization targets. These can be regulatory miRNAs of DNA
damage response (DDR) and HR repair factors.
siRNAs
Exogenous short interfering RNAs or silencing RNAs (siRNAs),
which are noncoding RNA molecules, that can selectively target
key mRNAs belonging to pathways involved in the response to
radiation, such as DDR, cell cycle regulation, and survival/
apoptosis balance.
Oligonucleotides
Small DNA or RNA sequences are able to disturb key mRNA
translation. Studies have concerned oligonucleotides targeting the
telomerase RNA subunit or telomerase reverse transcriptase
(hTERT) or cyclic AMP response element (CRE) decoy
oligonucleotide.
structures of small molecules (Table 11.2); (2) macromole­
cules with their mechanism of radiosensitivity (Table 11.3);
and (3) nanomaterials (Table 11.4) with low cytotoxicity, good
biocompatibility, usability, and functionality (Box 11.5)."
"Curcumin has been investigated as a radiosensitizer in several cancer cell lines. Describe two specific mechanisms by which curcumin can enhance the effects of radiation on tumor cells, citing examples from the provided text regarding its impact on MCF-7 and MDA-MB-231 breast cancer cells.","Curcumin demonstrates radiosensitizing properties through multiple pathways. Firstly, it inhibits survival and proliferation in cell lines like MCF-7 (a hormone receptor positive breast cancer) by disrupting apoptotic signals and blocking the G2/M cell cycle phase mediated by Bcl-2. Specifically, the text details a dose-modifying factor (DMF) of 1.78 for MCF-7 cells when treated with vehicolated curcumin alongside X-ray radiation. Secondly, curcumin exhibits an enhanced effect on MDA-MB-231 cells (a triple-negative breast cancer), where free curcumin resulted in a DMF of 1.38. Furthermore, the transcriptomic and metabolomics analysis revealed that curcumin acts as both an autophagy enhancer for tumor cells and an antioxidant agent. This dual action contributes to its radiosensitizing potential by increasing cellular vulnerability to radiation damage. Reference: [MolecularRadiationBiology, Section 11.4.1.1 Curcumin]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.1	 Curcumin | Content: which are noncoding RNA molecules, that can selectively target
key mRNAs belonging to pathways involved in the response to
radiation, such as DDR, cell cycle regulation, and survival/
apoptosis balance.
Oligonucleotides
Small DNA or RNA sequences are able to disturb key mRNA
translation. Studies have concerned oligonucleotides targeting the
telomerase RNA subunit or telomerase reverse transcriptase
(hTERT) or cyclic AMP response element (CRE) decoy
oligonucleotide.
structures of small molecules (Table 11.2); (2) macromole­
cules with their mechanism of radiosensitivity (Table 11.3);
and (3) nanomaterials (Table 11.4) with low cytotoxicity, good
biocompatibility, usability, and functionality (Box 11.5).
11.4.1	Nutraceutical Compounds
Several nutraceutical chemicals have attracted significant
interest in recent decades due to their possible involvement
in the prevention and treatment of various illnesses, as well
as their favorable effects in boosting human and animal
health. In particular, literature data often report their positive
effect in combination with chemotherapy in cancer care.
Even while intriguing results have been published on this
issue at multiple cellular levels, less is known about their role
as radiosensitizers. Presence of these compounds during
radiation augments their effect by several mechanisms
including the lethal reactions of free radicals.
Among compounds of various origins that showed radio­
sensitizer potential, numerous studies have revealed the
important role of molecules of natural origin, when adminis­
tered in combination to IR.
­
11.22
­
11.5
203
11.4.1.1
Curcumin
Curcumin, the main component in the Indian culinary spice
turmeric (Curcuma longa), has been shown to have antican­
cer potential in several studies. The biological mechanism
can be ascribed to cell signaling pathway effects, resulting in
the inhibition of cell proliferation and induction of
apoptosis.
Regarding its radiosensitizing properties evaluated by an
in vitro approach, the inhibition of survival and proliferation
has been observed on the MCF-7 breast cancer cell line. In
addition, the effect of vehicolated curcumin, using solid
nanoparticles, combined with X-ray radiation was tested by
Minafra and coworkers [204] on the human non­tumorigenic
breast epithelial MCF10A cell line and the breast adenocar­
A. Montoro et al.
607
cinoma MCF7 and MDA-MB-231 cell lines. The vehico­
lated curcumin has been shown to be more effective than the
free curcumin on MCF7 and MCF10A, whereas the free
molecule resulted to be slightly more effective on
MDA-MB-231. The dose-modifying factors (DMFs) were
calculated to quantify the radiosensitizing effect, which
resulted in 1.78 for MCF7 using vehicolated curcumin and
1.38 with free curcumin on MDA-MB-231 cells.
Transcriptomic and metabolomics approach supported this
study, revealing the double-positive effect of curcumin as an
autophagy enhancer for tumor cells and antioxidant agents
[204].
Antiapoptotic signals and block in G2/M cell cycle phase
mediated by Bcl-2 were demonstrated in human immortal­
ized prostate adenocarcinoma cells (PC-3) after 5 Gy irradia­
tion combined with 2μM curcumin. Instead, an increased
radiosensitivity was observed in HCT116 and HT29 human
colorectal cancer cell lines treated with 25μM of curcumin
and a single dose of X-ray radiation (10 Gy). Curcumin was
also able to decrease COX-2 expression by the inhibition of
EGFR phosphorylation both in vitro on the human head and
neck squamous cell carcinoma (HNSCC) cell line and in two
in vivo models of head and neck tumor.
On the human glioblastoma U87MG cell line, the viabil­
ity was reduced in a dose-dependent manner by 3 Gy of
X-ray combined with curcumin at a concentration range of
5–10μM, sustained by the arrest of cell cycle in phase G2/M
(which is the most sensitive step to radiation) and the
­inhibition of two master regulators of tumor progression, the
MAP kinases ERK and JNK [203].
However, curcumin is an unstable, nonbioavailable com­
pound due to its poor absorption in the GI system. Hence, its
therapeutic application is delimited by its pharmacokinetics.
Despite promising preclinical studies, no double-blinded
placebo-controlled clinical trial, using curcumin as a radio­
sensitizer, has been successful. The interaction of curcumin
with RT on different cancer types has been reviewed by
Verma [205]; however, there is still a lack of solid clinical
evidence of radiosensitization. For instance, in vitro and
in vivo studies together with clinical bioavailability data do
not give evidence for a radiosensitizing effect of curcumin in
the treatment of high-grade brain tumors (glioblastoma mul­
tiforme). On the other hand, there is limited data on curcum­
in’s radioprotective function, despite the fact that some
clinical trials suggest that curcumin is beneficial for the man­
agement of radiation toxicities [205].
11.4.1.2
Resveratrol (RV) and Pterostilbene
(PT)
The antineoplastic ability of RV encouraged its application
also as a radiosensitizer to overcome radioresistance of many
cancers.
A dose-dependent reduction in the surviving fraction of a
non-small cell lung cancer (NSCLC) cell line after ­irradiation
with 0–8 Gy of γ-rays in combination with 20μM of RV was
Table 11.4 Nanomaterials as radiosensitizers
Noble metal nanomaterials
Nanoparticles, such as gold (Au, Z = 79), silver (Ag, Z = 47), and
platinum (Pt, Z = 78), can effectively interact with radiation,
emitting secondary electrons which amplify the radiation effects.
Heavy metal nanomaterials
Physical dose enhancement methods are comparable for
gadolinium (Gd, Z = 64), hafnium (Hf, Z = 72), tantalum (Ta,
Z = 73), tungsten (W, Z = 74), and bismuth (Bi, Z = 83) or their
stable forms such as oxides, sulfides, and selenides. Examples are
gadolinium-based nanoparticles (AGuIX), hafnium oxide (HfO2)
nanoparticle (NBTXR3), tantalum pentoxide (Ta2O5) and tantalum
oxide (TaOx), bismuth oxide (BiO) nanoparticles, and tungsten
oxide nanopowder or nanoparticles (WO3).
Ferrite nanomaterials
They can catalyze the reaction of H2O2, generating highly toxic
hydroxyl free radicals in the tumor microenvironment with the
aim of boosting the radiation therapeutic efficacy. Explored
examples are superparamagnetic magnesium ferrite spinel
(MgFe2O4) nanoparticles (SPMNPs) and zinc ferrite (ZnFe2O4)
nanoparticles
Semiconductor nanomaterials
Semiconductor nanosensitizer materials, such as silicon (Si),
germanium (Ge), gallium arsenide (GaAs), and semiconductor
quantum dots, have unique properties making them great
candidates as photosensitizers and radiosensitizers for tumor
treatment ([201]; [202]). Explored examples are WO2.9-WSe2-­
PEG semiconductor heterojunction nanoparticles (WSP NPs),
titanium peroxide (PAA-TiOx) nanomaterial, copper bismuth
sulfide (Cu3BiS3,CBS) nanoparticles, and TiO2 nanotubes.
Nonmetallic nanomaterials
Similarly to the metallic nanoparticles’ mechanism of action,
nonmetallic nanomaterials can increase oxidative damage.
Explored examples are ultrasmall uncapped and amino-silanized
oxidized silicon nanoparticles; nanocrystals of underivatized
fullerene, C60, (nano-C60); nanodiamonds and carbon nanotubes;
and selenium (Se) nanoparticles.
Nanostructured substances and drug delivery systems
Chemicals, oxygen carriers, siRNAs, and other radiosensitizing
agents are transported via relatively new nano-based delivery
systems. Explored examples are the poly(D,L-lactide-co-­
glycolide) (PLGA) nanoparticles containing paclitaxel (a cell
cycle-specific radiosensitizer) and etanidazole (a hypoxic
radiosensitizer).
Box 11.5: Radiation Sensitizers
•	Small molecules are classified based on radiation-­
induced free radicals, pseudo-substrates, and other
mechanisms.
•	Macromolecules such as miRNAs, proteins, pep­
tides, and oligonucleotides have been explored to
develop radiosensitizers as they are capable of regu­
lating radiosensitivity.
•	Promising nanotechnology methods used as radio­
sensitizers include well-developed nanomaterials
with low toxicity, good biocompatibility, and func­
tionalization ease.
•	Other technologies, such as molecular cloning tech­
nology, analysis of molecular structure, and bioin­
formatics, can speed up the development of new
effective radiosensitizing drugs.
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Describe the mechanisms by which resveratrol (RV) and pterostilbene (PT) demonstrate radiosensitizing effects in cancer cells, referencing specific cellular processes observed in studies involving non-small cell lung cancer (NSCLC) and prostate cancer models.","Resveratrol (RV) and pterostilbene (PT) exhibit radiosensitizing properties through multiple interconnected mechanisms. In NSCLC cell lines like SU-2 glioblastoma multiforme, RV has been shown to suppress cell proliferation by inhibiting STAT3 phosphorylation, a key transcription factor driving inflammation and cancer progression. Critically, RV also diminishes hypoxia-inducible factor 1α (HIF-1α) expression, a major driver of radioresistance in many cancers. This reduction in HIF-1α limits the tumor’s ability to repair DNA damage after irradiation. Furthermore, combined treatment with RV has been linked to increased autophagy – specifically, elevated LC3-II levels – which facilitates cellular degradation and apoptosis following enhanced DNA double-strand breaks (DSBs) induced by reactive oxygen species (ROS). In prostate cancer models, RV's effects extend beyond simple cell death; it’s observed to reduce AKT phosphorylation, another proproliferative marker.  Moreover, studies demonstrate that PT can inhibit the generation of adrenocorticotropic hormone in the brain, thereby impairing Nrf2-dependent antioxidant defenses within melanoma and pancreatic tumors, ultimately leading to tumor growth restraint and sensitization to oxidative stress. PT also induces lysosomal membrane permeabilization, releasing cytotoxic enzymes and further promoting cell death.  The combined effect often involves increased ROS generation and DNA damage repair impairment. Notably, both compounds can interact with other agents like iododeoxyuridine (IUdR), further reducing the formation of cancer colonies. Reference: [Molecular Radiation Biology], Section 11.4.1.2 – Nutraceutical Compounds.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.2	 Resveratrol (RV) and Pterostilbene (PT) | Content: The antineoplastic ability of RV encouraged its application
also as a radiosensitizer to overcome radioresistance of many
cancers.
A dose-dependent reduction in the surviving fraction of a
non-small cell lung cancer (NSCLC) cell line after ­irradiation
with 0–8 Gy of γ-rays in combination with 20μM of RV was
Table 11.4 Nanomaterials as radiosensitizers
Noble metal nanomaterials
Nanoparticles, such as gold (Au, Z = 79), silver (Ag, Z = 47), and
platinum (Pt, Z = 78), can effectively interact with radiation,
emitting secondary electrons which amplify the radiation effects.
Heavy metal nanomaterials
Physical dose enhancement methods are comparable for
gadolinium (Gd, Z = 64), hafnium (Hf, Z = 72), tantalum (Ta,
Z = 73), tungsten (W, Z = 74), and bismuth (Bi, Z = 83) or their
stable forms such as oxides, sulfides, and selenides. Examples are
gadolinium-based nanoparticles (AGuIX), hafnium oxide (HfO2)
nanoparticle (NBTXR3), tantalum pentoxide (Ta2O5) and tantalum
oxide (TaOx), bismuth oxide (BiO) nanoparticles, and tungsten
oxide nanopowder or nanoparticles (WO3).
Ferrite nanomaterials
They can catalyze the reaction of H2O2, generating highly toxic
hydroxyl free radicals in the tumor microenvironment with the
aim of boosting the radiation therapeutic efficacy. Explored
examples are superparamagnetic magnesium ferrite spinel
(MgFe2O4) nanoparticles (SPMNPs) and zinc ferrite (ZnFe2O4)
nanoparticles
Semiconductor nanomaterials
Semiconductor nanosensitizer materials, such as silicon (Si),
germanium (Ge), gallium arsenide (GaAs), and semiconductor
quantum dots, have unique properties making them great
candidates as photosensitizers and radiosensitizers for tumor
treatment ([201]; [202]). Explored examples are WO2.9-WSe2-­
PEG semiconductor heterojunction nanoparticles (WSP NPs),
titanium peroxide (PAA-TiOx) nanomaterial, copper bismuth
sulfide (Cu3BiS3,CBS) nanoparticles, and TiO2 nanotubes.
Nonmetallic nanomaterials
Similarly to the metallic nanoparticles’ mechanism of action,
nonmetallic nanomaterials can increase oxidative damage.
Explored examples are ultrasmall uncapped and amino-silanized
oxidized silicon nanoparticles; nanocrystals of underivatized
fullerene, C60, (nano-C60); nanodiamonds and carbon nanotubes;
and selenium (Se) nanoparticles.
Nanostructured substances and drug delivery systems
Chemicals, oxygen carriers, siRNAs, and other radiosensitizing
agents are transported via relatively new nano-based delivery
systems. Explored examples are the poly(D,L-lactide-co-­
glycolide) (PLGA) nanoparticles containing paclitaxel (a cell
cycle-specific radiosensitizer) and etanidazole (a hypoxic
radiosensitizer).
Box 11.5: Radiation Sensitizers
•	Small molecules are classified based on radiation-­
induced free radicals, pseudo-substrates, and other
mechanisms.
•	Macromolecules such as miRNAs, proteins, pep­
tides, and oligonucleotides have been explored to
develop radiosensitizers as they are capable of regu­
lating radiosensitivity.
•	Promising nanotechnology methods used as radio­
sensitizers include well-developed nanomaterials
with low toxicity, good biocompatibility, and func­
tionalization ease.
•	Other technologies, such as molecular cloning tech­
nology, analysis of molecular structure, and bioin­
formatics, can speed up the development of new
effective radiosensitizing drugs.
11 Radioprotectors, Radiomitigators, and Radiosensitizers
608
Table 11.5 Natural compounds related to cancer radiation treatments
Natural
compounds
Tumor target
Type of treatment
Curcumin
Colorectal cancer, glioblastoma, head and neck squamous cancer, prostate cancer
X-rays
Resveratrol
Breast cancer, glioblastoma, head and neck squamous cancer, melanoma, nasopharyngeal carcinoma,
non-small cell lung cancer, prostate cancer
γ-rays, X-rays
Withaferin A
Breast cancer, cervical cancer, Ehrlich ascites carcinoma, fibrosarcoma, histiocytic human lymphoma,
liver cancer, melanoma, renal carcinoma
γ-rays, X-rays
Celastrol
Lung cancer, prostate cancer
γ-rays, X-rays
Ursolic acid
Colon carcinoma, gastric adenocarcinoma, non-small cell lung cancer, melanoma, prostate cancer
γ-rays, X-rays
Zerumbone
Colorectal cancer, glioblastoma, lung adenocarcinoma, non-small cell lung cancer, prostate cancer
γ-rays, X-rays
Caffeic acid
phenethyl ester
Adenocarcinoma, breast cancer, lung cancer, medulloblastoma
γ-rays, X-rays
Emodin
Cervical cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, sarcoma
γ-rays, X-rays
Flavopiridol
Cervix cancer, esophageal adenocarcinoma, esophageal squamous carcinoma, glioma, lung carcinoma,
ovarian carcinoma, prostate cancer, zebrafish model
γ-rays, X-rays
Berberine
Breast cancer, esophageal carcinoma, nasopharyngeal carcinoma, osteosarcoma, prostate cancer
γ-rays, X-rays
Genistein
Breast cancer, cervical cancer, non-small cell lung cancer
γ-rays, X-rays
Selenium
Melanoma, glioma, breast cancer
γ-rays, X-rays
­
203
CC BY 4.0
A. Montoro et al.
609
observed along with accelerated senescence and cell death
following enhanced DNA DSB induced by ROS [203].
However, an increased expression of LC3-II for autoph­
agy response after X-ray and RV treatment (75μM) was
demonstrated in SU-2 glioblastoma multiforme cell lines
[206]. Also, in GBM, RV showed inhibition of the hypoxia-­
inducible factor HIF-1α, which is responsible for a well-­
known mechanism of radioresistance. Moreover, the
interaction of RV with other agents as iododeoxyuridine
(IUdR) was also tested and demonstrated the ability to
decrease the formation of cancer colonies [203].
In the HNSCC cancer model, suppression of cell prolif­
eration was obtained on a cell line, treated with 100μM of
RV combined with 10 Gy of X-ray, also observing the inhibi­
tion of STAT3 phosphorylation, a well-known transcription
factor driving inflammation and cancer progression. Even
the peanut stem extract (PSE), which contains a high amount
of RV, has been tested in combination with X-rays, which
showed similar radiosensitization effects on radioresistant
human prostate cancer cell lines. In this regard, the tumor
growth of a prostate cancer xenograft mouse model was
reduced with RV and/or PSE (total dose 12 Gy, 5 or 250 mg/
kg, respectively) [203]. RV was also used as a pretreatment
(25–150μM) to treat the human NPC CNE-1 cell line with
X-ray irradiation (0–6 Gy), revealing the inhibition of the
AKT phosphorylated form, a known proproliferative marker.
These effects were also confirmed in NPC xenograft models,
combining the RV treatment with 4 Gy for 3 days, resulting
in a tumor volume reduction.
Nevertheless, a key problem is the short RV half-life and
low bioavailability under in vivo conditions. In vivo, pteros­
tilbene was proven to be beneficial in the treatment of mela­
noma and pancreatic cancer. This study demonstrated that
PT can be helpful against melanoma by inhibiting the gen­
eration of adrenocorticotropic hormone in the brain of a
mouse, which impairs the Nrf2-dependent antioxidant
defenses of melanoma and pancreatic tumors. This produces
tumor growth restraining and tumor sensitization to oxida­
tive stress. In addition, PT has been shown to increase cancer
cell death by the induction of lysosomal membrane permea­
bilization [53].
11.4.1.3
Withaferin A
Withaferin A (WA) was the first withanolide to be isolated
and extracted from the plant Withania somnifera. WA-induced
radiosensitization has been observed in human histiocytic
lymphoma, renal carcinoma, and liver, breast, and several
other types of cancer. Overall, these studies highlight the
effect of combined treatment, mediated by the increase of
apoptosis and production of ROS.
WA has been shown to suppress cancer cell growth by
targeting the intermediate filament protein vimentin, a struc­
tural protein of the cell cytoskeleton. In light of its anticancer
capability, WA was also tested in order to investigate its
effect in inducing the radiosensitization of cancer cells.
WA’s effects were initially investigated in vitro and in
combination with γ-irradiation on a lung fibroblast cell line,
and WA was found to be well tolerated by cells and to medi­
ate a synergistic impact with γ-rays in terms of cell death.
Based on these encouraging results, WA was further tested
in vivo to assess its effect as a radiosensitizing agent in sev­
eral cancer models such as the spontaneous murine mam­
mary adenocarcinoma (Ehrlich ascites carcinoma—EAC), a
mouse model of fibrosarcoma, and a mouse model of mela­
noma. Overall, each of the studies demonstrated that the WA
and γ-ray combined treatment inhibits tumor growth, increas­
ing tumor-free survival and median survival time of animals
[203].
11.4.1.4
Celastrol
Celastrol, also known as tripterine, is a triterpenoid derived
from the root of the “thunder god wine” plant often found in
China and utilized in traditional Chinese medicine for its
anti-inflammatory qualities in a variety of conditions, includ­
ing autoimmune diseases. Moreover, anticancer properties
have been revealed, due to its proteasome inhibitory activity
and antimetastatic ability.
A study has evaluated its radiosensitizer effect on PC-3
cells, both in vitro and in vivo. The in vitro pretreatment with
celastrol before irradiation with X-rays resulted in a signifi­
cant dose-dependent enhancement of IR-induced clonogenic
cell killing. This effect was explained by (1) a longer gH2AX
activation for a longer time in combined treated cells with
respect to the only irradiated ones, thus revealing a DNA
repair impairment action by celastrol, and (2) a major expres­
sion of apoptosis markers (cleaved PARP and caspase-3).
Thus, the same group tested the celastrol radiosensitizer
effect on a PC-3 xenograft model. 1 mg/kg of celastrol
(5 days/week for 3 weeks) was given to the mice 1 h before
irradiation with a single dose of 2 Gy (5 days/week for
2 weeks). The histological analysis showed a significantly
increased apoptosis and angiogenesis reduction in the com­
bined treated tumors [203].
Similar effects have been found on the NCI-H460 human
lung cancer cell line, combining celastrol with 0–4 Gy of
X-rays. Indeed, the EGFR, ErbB2, and survivin irradiation
markers were found to be reduced, whereas the celastrol-­
dependent inhibition of HSP90 was observed. Furthermore,
celastrol induces a more pronounced ROS generation after
irradiation, thanks to its quinone methide moiety [203].
Finally, the effect of celastrol as a radiosensitizer was
evaluated on lung cancer with different approaches. Indeed,
one research group has identified it as one of the most prom­
ising sensitizer candidates among 30 drugs, by an in silico
study. Thus, they tested its effect in vitro on A549 and H460
cells, subjected to pretreatment with celastrol and 2–10 Gy
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
Celastrol's radiosensitizing effect on PC-3 cells involves both DNA repair impairment and increased apoptosis. Detail the specific molecular mechanisms observed that contribute to this enhanced sensitivity to radiation.,"In studies evaluating Celastrol’s (WA) impact on PC-3 cells in combination with γ-irradiation, several key mechanisms were identified contributing to radiosensitization. Firstly, celastrol induced a prolonged activation of the gH2AX protein, indicating an extended period of DNA damage recognition and repair attempts. This impairment of DNA repair directly increased the cell’s vulnerability to radiation-induced DNA damage. Secondly, celastrol significantly upregulated the expression of apoptosis markers, specifically cleaved PARP (poly(ADP-ribose) polymerase) and caspase-3, proteins crucial in executing programmed cell death. The combined effect of these two mechanisms – prolonged DNA repair impairment and heightened apoptotic signaling – resulted in a dose-dependent enhancement of γ-irradiation’s ability to induce clonogenic cell killing within the PC-3 cell line. Furthermore, celastrol was shown to promote increased Reactive Oxygen Species (ROS) generation following irradiation, which contributes to oxidative stress and further exacerbates DNA damage. Reference: [MolecularRadiationBiology, Section 11.4.1.3 – Nutraceutical Compounds], Subsubsection: 11.4.1.4","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.3	 Withaferin A | Content: apoptosis and production of ROS.
WA has been shown to suppress cancer cell growth by
targeting the intermediate filament protein vimentin, a struc­
tural protein of the cell cytoskeleton. In light of its anticancer
capability, WA was also tested in order to investigate its
effect in inducing the radiosensitization of cancer cells.
WA’s effects were initially investigated in vitro and in
combination with γ-irradiation on a lung fibroblast cell line,
and WA was found to be well tolerated by cells and to medi­
ate a synergistic impact with γ-rays in terms of cell death.
Based on these encouraging results, WA was further tested
in vivo to assess its effect as a radiosensitizing agent in sev­
eral cancer models such as the spontaneous murine mam­
mary adenocarcinoma (Ehrlich ascites carcinoma—EAC), a
mouse model of fibrosarcoma, and a mouse model of mela­
noma. Overall, each of the studies demonstrated that the WA
and γ-ray combined treatment inhibits tumor growth, increas­
ing tumor-free survival and median survival time of animals
[203].
11.4.1.4
Celastrol
Celastrol, also known as tripterine, is a triterpenoid derived
from the root of the “thunder god wine” plant often found in
China and utilized in traditional Chinese medicine for its
anti-inflammatory qualities in a variety of conditions, includ­
ing autoimmune diseases. Moreover, anticancer properties
have been revealed, due to its proteasome inhibitory activity
and antimetastatic ability.
A study has evaluated its radiosensitizer effect on PC-3
cells, both in vitro and in vivo. The in vitro pretreatment with
celastrol before irradiation with X-rays resulted in a signifi­
cant dose-dependent enhancement of IR-induced clonogenic
cell killing. This effect was explained by (1) a longer gH2AX
activation for a longer time in combined treated cells with
respect to the only irradiated ones, thus revealing a DNA
repair impairment action by celastrol, and (2) a major expres­
sion of apoptosis markers (cleaved PARP and caspase-3).
Thus, the same group tested the celastrol radiosensitizer
effect on a PC-3 xenograft model. 1 mg/kg of celastrol
(5 days/week for 3 weeks) was given to the mice 1 h before
irradiation with a single dose of 2 Gy (5 days/week for
2 weeks). The histological analysis showed a significantly
increased apoptosis and angiogenesis reduction in the com­
bined treated tumors [203].
Similar effects have been found on the NCI-H460 human
lung cancer cell line, combining celastrol with 0–4 Gy of
X-rays. Indeed, the EGFR, ErbB2, and survivin irradiation
markers were found to be reduced, whereas the celastrol-­
dependent inhibition of HSP90 was observed. Furthermore,
celastrol induces a more pronounced ROS generation after
irradiation, thanks to its quinone methide moiety [203].
Finally, the effect of celastrol as a radiosensitizer was
evaluated on lung cancer with different approaches. Indeed,
one research group has identified it as one of the most prom­
ising sensitizer candidates among 30 drugs, by an in silico
study. Thus, they tested its effect in vitro on A549 and H460
cells, subjected to pretreatment with celastrol and 2–10 Gy
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Celastrol has been investigated as a radiosensitizer, primarily through mechanisms involving DNA repair impairment and increased apoptosis. Describe the two key findings observed in vitro when Celastrol is combined with X-ray irradiation on PC-3 cells, detailing the molecular events that contribute to this effect.","When celastrol was combined with X-ray irradiation on PC-3 cells *in vitro*, researchers identified two primary mechanisms contributing to radiosensitization. First, celastrol prolonged the activation of γH2AX, a marker of DNA double-strand breaks (DSBs), for a longer duration compared to irradiated cells alone. This indicates that celastrol impairs the cell’s ability to rapidly repair DSBs following irradiation. Second, celastrol significantly increased the expression of apoptosis markers, specifically cleaved PARP and caspase-3. Cleaved PARP reflects impaired DNA repair processes, while activated caspase-3 is a key effector enzyme in the apoptotic cascade. These findings collectively demonstrate that celastrol enhances radiation sensitivity by delaying DNA damage repair and promoting cell death through apoptosis [203].

Reference: [MolecularRadiationBiology, Section 11.4.1.4 – Celastrol]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.4	 Celastrol | Content: apoptosis and production of ROS.
WA has been shown to suppress cancer cell growth by
targeting the intermediate filament protein vimentin, a struc­
tural protein of the cell cytoskeleton. In light of its anticancer
capability, WA was also tested in order to investigate its
effect in inducing the radiosensitization of cancer cells.
WA’s effects were initially investigated in vitro and in
combination with γ-irradiation on a lung fibroblast cell line,
and WA was found to be well tolerated by cells and to medi­
ate a synergistic impact with γ-rays in terms of cell death.
Based on these encouraging results, WA was further tested
in vivo to assess its effect as a radiosensitizing agent in sev­
eral cancer models such as the spontaneous murine mam­
mary adenocarcinoma (Ehrlich ascites carcinoma—EAC), a
mouse model of fibrosarcoma, and a mouse model of mela­
noma. Overall, each of the studies demonstrated that the WA
and γ-ray combined treatment inhibits tumor growth, increas­
ing tumor-free survival and median survival time of animals
[203].
11.4.1.4
Celastrol
Celastrol, also known as tripterine, is a triterpenoid derived
from the root of the “thunder god wine” plant often found in
China and utilized in traditional Chinese medicine for its
anti-inflammatory qualities in a variety of conditions, includ­
ing autoimmune diseases. Moreover, anticancer properties
have been revealed, due to its proteasome inhibitory activity
and antimetastatic ability.
A study has evaluated its radiosensitizer effect on PC-3
cells, both in vitro and in vivo. The in vitro pretreatment with
celastrol before irradiation with X-rays resulted in a signifi­
cant dose-dependent enhancement of IR-induced clonogenic
cell killing. This effect was explained by (1) a longer gH2AX
activation for a longer time in combined treated cells with
respect to the only irradiated ones, thus revealing a DNA
repair impairment action by celastrol, and (2) a major expres­
sion of apoptosis markers (cleaved PARP and caspase-3).
Thus, the same group tested the celastrol radiosensitizer
effect on a PC-3 xenograft model. 1 mg/kg of celastrol
(5 days/week for 3 weeks) was given to the mice 1 h before
irradiation with a single dose of 2 Gy (5 days/week for
2 weeks). The histological analysis showed a significantly
increased apoptosis and angiogenesis reduction in the com­
bined treated tumors [203].
Similar effects have been found on the NCI-H460 human
lung cancer cell line, combining celastrol with 0–4 Gy of
X-rays. Indeed, the EGFR, ErbB2, and survivin irradiation
markers were found to be reduced, whereas the celastrol-­
dependent inhibition of HSP90 was observed. Furthermore,
celastrol induces a more pronounced ROS generation after
irradiation, thanks to its quinone methide moiety [203].
Finally, the effect of celastrol as a radiosensitizer was
evaluated on lung cancer with different approaches. Indeed,
one research group has identified it as one of the most prom­
ising sensitizer candidates among 30 drugs, by an in silico
study. Thus, they tested its effect in vitro on A549 and H460
cells, subjected to pretreatment with celastrol and 2–10 Gy
11 Radioprotectors, Radiomitigators, and Radiosensitizers
610
of dose range. The encouraging results from this in vitro
study were the premises for a preclinical study on a A549
xenograft mouse model. The combined treatment using
2 mg/kg/5 each day and 10 Gy of IR for 12 days produced
larger intratumoral necrotic areas [203].
11.4.1.5
Ursolic Acid
Ursolic acid (UA) belongs to the family of the pentacyclic
triterpenoids. It is generally obtainable from the peel of
many fruits, e.g., apples, blueberries, and prunes, and also in
many herbs, such as rosemary and thyme. Recently, the fol­
lowing therapeutic properties of UA have been described:
anticancer, anti-inflammatory, and antimicrobial, and also its
radiosensitization activity in models in in vitro and in vivo
studies. For example, in human prostate and colon cancer
cells, and in mouse melanoma cells, the UA is able to radio­
sensitize cells with a significant reduction in cell viability
associated with an increase of typical signs of apoptosis cas­
cade, such as cell volume reduction, nuclei fragmentation or
condensation, caspase-3 activation (one of the key enzymes
involved in the apoptotic pathway), increased levels of
cleaved PARP (enzyme involved in DNA repair processes),
DNA fragmentation, and also increased ROS generation. In
melanoma mouse models, the treatment with UA and IR is
able to inhibit tumor growth owing to a downregulation of
Bcl-2 and survivin, two known key protein regulators of cell
survival [203].
Moreover, UA can also exert a differential effect after
exposure of normal or cancer cells to UV, acting as a photo­
sensitizer for the latter and as a photoprotector for normal
ones. This action was observed in human melanoma cells
and in human retinal pigment epithelium control cells, where
induced oxidative stress by ROS production, cell cycle arrest,
and cell death induction were evaluated following UA and
UV treatments. Furthermore, the UA has a significant radio­
sensitizing effect in human gastric adenocarcinoma cells, as
evidenced by (i) a decrease in the cell survival fraction and
otherwise an increase in the number of apoptotic cells (posi­
tive to the propidium iodide and annexin V apoptotic mark­
ers); (ii) the arrest of the cell cycle (in the G1 and G2/M
phases); and (iii) the increase in ROS amount and a decrease
of Ki-67-positive proliferating cells [207].
11.4.1.6
Zerumbone
Zerumbone (ZER) is a cyclic ketone and a sesquiterpene
compound, a cytotoxic component obtained by steam distil­
lation of the Zingiber zerumbet Smith. ZER is used in food
and herbal medicine, and it also has anti-inflammatory, anti­
proliferative, and antitumor properties, as observed in many
tumor types (including breast, pancreas, colon, lung, and
skin). In addition, the radiosensitizing effects of ZER on
tumors, by means of its regulatory activities on DNA DSB
repair, cell cycle, and apoptotic pathways, have been high­
lighted too [203].
ZER was able to significantly increase radiation-induced
cell death in human lung adenocarcinoma cells by inhibiting
heat-shock proteins (HSP), increasing caspase 3 and PARP
cleavage, and inhibiting HSP27 binding to apoptotic mole­
cules such as PKCδ and cytochrome C [203].
In addition, the radiosensitizing effect was also observed
in human glioblastoma cells. The same authors showed an
IR-induced decrease of cell survival on human prostate can­
cer cells, associated with a reduced expression of proteins
involved in the DNA damage repair pathway, such as γH2AX
and ATM [203].
Moreover, in human colon-rectal cancer cells, ZER pre­
treatment is able to induce apoptosis and enhance radiation-­
induced G2/M arrest and reduction of activation of the DSB
DNA repair machinery.
11.4.1.7
Caffeic Acid Phenethyl Esther
CAPE is an active component of honeybee propolis, a phe­
nolic compound, and a structural derivative of flavonoids. It
was described for its antiviral, bactericidal, anti-­
inflammatory, and antioxidant properties. CAPE compound
is also able to change the redox state by perturbing the acti­
vation of GSH and to induce apoptosis. Furthermore, it has
been shown to be more toxic to cancer cells than normal
cells, as well as to amplify the action of RT in a variety of
cancers.
CAPE has been shown to improve radiation-induced cell
cycle arrest and death in human medulloblastoma DAOY
cells. In particular, the combined treatment with CAPE and
2 Gy of IR caused an ROS enhancement production, a sig­
nificant inhibition of NF-kB activity, apoptosis activation,
and downregulation of cyclin B1 protein expression. In line
with these data, a strong reduction of cell survival, in a
concentration-­dependent manner, was described in the same
cell line pretreated with CAPE (0.1–10 M) for 24 h before
exposure to γ-ray irradiation at various doses (0–8 Gy), asso­
ciated with cell cycle progression inhibition, by arresting
cells in the S phase [203].
The CAPE pretreatment radiosensitizing effect was
also shown in mouse CT26 adenocarcinoma cells, using
both in vitro and in vivo approaches showing decreased
cell survival rate and reduced NF-kB activation. CAPE-
induced decrease of survival rate was also described in
breast and lung cancer cell lines. In particular, in
MDA-MB-231 and T47D breast cancer cell lines, CAPE
and X-ray combined treatments decreased cell growth and
delayed the DNA repair process for up to 60 min after
exposure [203].
A. Montoro et al."
"Describe the mechanisms by which ursolic acid, as investigated in research concerning tumor cells, contributes to radiosensitization and how this effect manifests across different cancer types.","Ursolic acid demonstrates significant radiosensitizing properties within various human tumor cell lines, primarily through multifaceted interventions targeting DNA damage response pathways. Specifically, ursolic acid inhibits heat-shock proteins (HSPs), notably HSP27, which normally facilitates the binding of apoptotic molecules like PKCδ and cytochrome C to cancer cells. By disrupting this interaction, ursolic acid reduces the cellular capacity to withstand radiation-induced apoptosis. Furthermore, it promotes caspase 3 and PARP cleavage, key events in the execution phase of programmed cell death triggered by ionizing radiation. Importantly, ursolic acid’s effects are observed across diverse tumor types including lung adenocarcinoma, glioblastoma, colon-rectal cancer, breast (MDA-MB-231 and T47D), and prostate cancer. In colon-rectal cells, pre-treatment with ursolic acid induces apoptosis alongside a G2/M arrest and reduces the activation of DNA double-strand break (DSB) repair machinery – namely γH2AX and ATM – thereby amplifying the cytotoxic impact of radiation. The radiosensitizing effect is also notable in breast cancer cell lines, delaying DNA repair processes and contributing to reduced cell survival following combined CAPE and X-ray treatments. These mechanisms collectively enhance the efficacy of radiation therapy by increasing the vulnerability of tumor cells to ionizing radiation damage [203].","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.5	 Ursolic Acid | Content: tumor types (including breast, pancreas, colon, lung, and
skin). In addition, the radiosensitizing effects of ZER on
tumors, by means of its regulatory activities on DNA DSB
repair, cell cycle, and apoptotic pathways, have been high­
lighted too [203].
ZER was able to significantly increase radiation-induced
cell death in human lung adenocarcinoma cells by inhibiting
heat-shock proteins (HSP), increasing caspase 3 and PARP
cleavage, and inhibiting HSP27 binding to apoptotic mole­
cules such as PKCδ and cytochrome C [203].
In addition, the radiosensitizing effect was also observed
in human glioblastoma cells. The same authors showed an
IR-induced decrease of cell survival on human prostate can­
cer cells, associated with a reduced expression of proteins
involved in the DNA damage repair pathway, such as γH2AX
and ATM [203].
Moreover, in human colon-rectal cancer cells, ZER pre­
treatment is able to induce apoptosis and enhance radiation-­
induced G2/M arrest and reduction of activation of the DSB
DNA repair machinery.
11.4.1.7
Caffeic Acid Phenethyl Esther
CAPE is an active component of honeybee propolis, a phe­
nolic compound, and a structural derivative of flavonoids. It
was described for its antiviral, bactericidal, anti-­
inflammatory, and antioxidant properties. CAPE compound
is also able to change the redox state by perturbing the acti­
vation of GSH and to induce apoptosis. Furthermore, it has
been shown to be more toxic to cancer cells than normal
cells, as well as to amplify the action of RT in a variety of
cancers.
CAPE has been shown to improve radiation-induced cell
cycle arrest and death in human medulloblastoma DAOY
cells. In particular, the combined treatment with CAPE and
2 Gy of IR caused an ROS enhancement production, a sig­
nificant inhibition of NF-kB activity, apoptosis activation,
and downregulation of cyclin B1 protein expression. In line
with these data, a strong reduction of cell survival, in a
concentration-­dependent manner, was described in the same
cell line pretreated with CAPE (0.1–10 M) for 24 h before
exposure to γ-ray irradiation at various doses (0–8 Gy), asso­
ciated with cell cycle progression inhibition, by arresting
cells in the S phase [203].
The CAPE pretreatment radiosensitizing effect was
also shown in mouse CT26 adenocarcinoma cells, using
both in vitro and in vivo approaches showing decreased
cell survival rate and reduced NF-kB activation. CAPE-
induced decrease of survival rate was also described in
breast and lung cancer cell lines. In particular, in
MDA-MB-231 and T47D breast cancer cell lines, CAPE
and X-ray combined treatments decreased cell growth and
delayed the DNA repair process for up to 60 min after
exposure [203].
A. Montoro et al."
"ZER has been shown to exhibit radiosensitizing effects in various tumor types. Describe the mechanisms by which ZER achieves this, citing specific cellular processes it impacts.","ZER demonstrates its radiosensitizing properties through a multifaceted approach targeting key cellular responses involved in DNA damage repair and cell death pathways. Primarily, ZER significantly increases radiation-induced cell death in human lung adenocarcinoma cells by inhibiting heat-shock proteins (HSPs). This inhibition leads to increased caspase 3 and PARP cleavage, both critical steps in the apoptotic cascade. Furthermore, ZER inhibits HSP27 binding to apoptotic molecules such as PKCδ and cytochrome C, disrupting downstream signaling events that would otherwise mitigate radiation damage. In human glioblastoma cells, a similar effect is observed with IR-induced decreases in cell survival linked to reduced expression of DNA damage repair proteins like γH2AX and ATM. Finally, in human colon-rectal cancer cells, ZER pretreatment induces apoptosis while simultaneously enhancing radiation-induced G2/M arrest and reducing the activation of DNA double-strand break (DSB) DNA repair machinery. These combined effects amplify the cytotoxic impact of ionizing radiation.

Reference: [Document Name], Section 11.4.1.6 – Nutraceutical Compounds – 11.4.1.7 – Zerumbone","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.6	 Zerumbone | Content: tumor types (including breast, pancreas, colon, lung, and
skin). In addition, the radiosensitizing effects of ZER on
tumors, by means of its regulatory activities on DNA DSB
repair, cell cycle, and apoptotic pathways, have been high­
lighted too [203].
ZER was able to significantly increase radiation-induced
cell death in human lung adenocarcinoma cells by inhibiting
heat-shock proteins (HSP), increasing caspase 3 and PARP
cleavage, and inhibiting HSP27 binding to apoptotic mole­
cules such as PKCδ and cytochrome C [203].
In addition, the radiosensitizing effect was also observed
in human glioblastoma cells. The same authors showed an
IR-induced decrease of cell survival on human prostate can­
cer cells, associated with a reduced expression of proteins
involved in the DNA damage repair pathway, such as γH2AX
and ATM [203].
Moreover, in human colon-rectal cancer cells, ZER pre­
treatment is able to induce apoptosis and enhance radiation-­
induced G2/M arrest and reduction of activation of the DSB
DNA repair machinery.
11.4.1.7"
"ZER has been shown to increase radiation-induced cell death in human lung adenocarcinoma cells by inhibiting heat-shock proteins (HSP), increasing caspase 3 and PARP cleavage, and inhibiting HSP27 binding to apoptotic molecules such as PKCδ and cytochrome C.  Describe the specific molecular mechanisms through which ZER achieves this radiosensitizing effect.","ZER’s radiosensitizing action stems from a multifaceted approach targeting key cellular processes involved in DNA damage repair and apoptosis following radiation exposure. Specifically, ZER inhibits heat-shock protein 27 (HSP27), a protein that normally protects cells from stress by binding to apoptotic molecules like PKCδ and cytochrome C. By disrupting this interaction, ZER releases these molecules, leading to increased caspase 3 activation and PARP cleavage – both hallmarks of apoptosis. Furthermore, the inhibition of HSPs contributes to a greater accumulation of DNA damage within the cell, as the usual protective mechanisms are compromised. This ultimately results in heightened sensitivity to radiation-induced cell death. Reference: [MolecularRadiationBiology, Section 11.4.1.7 – Nutraceutical Compounds], ","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.7	 Caffeic Acid Phenethyl Esther | Content: tumor types (including breast, pancreas, colon, lung, and
skin). In addition, the radiosensitizing effects of ZER on
tumors, by means of its regulatory activities on DNA DSB
repair, cell cycle, and apoptotic pathways, have been high­
lighted too [203].
ZER was able to significantly increase radiation-induced
cell death in human lung adenocarcinoma cells by inhibiting
heat-shock proteins (HSP), increasing caspase 3 and PARP
cleavage, and inhibiting HSP27 binding to apoptotic mole­
cules such as PKCδ and cytochrome C [203].
In addition, the radiosensitizing effect was also observed
in human glioblastoma cells. The same authors showed an
IR-induced decrease of cell survival on human prostate can­
cer cells, associated with a reduced expression of proteins
involved in the DNA damage repair pathway, such as γH2AX
and ATM [203].
Moreover, in human colon-rectal cancer cells, ZER pre­
treatment is able to induce apoptosis and enhance radiation-­
induced G2/M arrest and reduction of activation of the DSB
DNA repair machinery.
11.4.1.7
Caffeic Acid Phenethyl Esther
CAPE is an active component of honeybee propolis, a phe­
nolic compound, and a structural derivative of flavonoids. It
was described for its antiviral, bactericidal, anti-­
inflammatory, and antioxidant properties. CAPE compound
is also able to change the redox state by perturbing the acti­
vation of GSH and to induce apoptosis. Furthermore, it has
been shown to be more toxic to cancer cells than normal
cells, as well as to amplify the action of RT in a variety of
cancers.
CAPE has been shown to improve radiation-induced cell
cycle arrest and death in human medulloblastoma DAOY
cells. In particular, the combined treatment with CAPE and
2 Gy of IR caused an ROS enhancement production, a sig­
nificant inhibition of NF-kB activity, apoptosis activation,
and downregulation of cyclin B1 protein expression. In line
with these data, a strong reduction of cell survival, in a
concentration-­dependent manner, was described in the same
cell line pretreated with CAPE (0.1–10 M) for 24 h before
exposure to γ-ray irradiation at various doses (0–8 Gy), asso­
ciated with cell cycle progression inhibition, by arresting
cells in the S phase [203].
The CAPE pretreatment radiosensitizing effect was
also shown in mouse CT26 adenocarcinoma cells, using
both in vitro and in vivo approaches showing decreased
cell survival rate and reduced NF-kB activation. CAPE-
induced decrease of survival rate was also described in
breast and lung cancer cell lines. In particular, in
MDA-MB-231 and T47D breast cancer cell lines, CAPE
and X-ray combined treatments decreased cell growth and
delayed the DNA repair process for up to 60 min after
exposure [203].
A. Montoro et al.
611
11.4.1.8
Emodin
Traditional Chinese medicine uses emodin (6-methyl-1,3,8-­
trihydroxyanthraquinone), a natural phenolic derived from
the roots and rhizomes of numerous plants (e.g., Polygonum
cuspidatum and Cascara buckthorn).
Emodin is chemically similar to the mitochondrial ubi­
quinone
named
DMNQ
(2,3-dimethoxy-1,4-­
naphthoquinone), an endogenous ROS inductor, as it is able
to transfer electrons. It is also known to have antibacterial,
antiviral, anti-inflammatory, and anticancer effects. The
emodin’s antitumor effect has been observed in several types
of cancer (leukemia, breast, colon, and lung cancer), also in
combination with RT schedules, although its mechanism of
action still remains unclear.
Under hypoxic conditions, emodin treatment enhanced
the radiosensitivity of CNE-1 NPC human nasopharyngeal
carcinoma cell line. In particular, treatment with 3.9 and
7.8 g/mL emodin 24 h before 2 Gy IR induced an increase in
the apoptosis ratio and cell cycle arrest in the G2/M phase.
Moreover, an increase of ROS production in tandem with a
downregulation of HIF-1 levels (both mRNA and protein)
was also described. These data were also confirmed by using
CNE-1 xenograft models where a tumor growth delay was
observed after emodin and IR combined treatments [203].
The radiosensitizing effect of emodin has also been
observed in the HeLa cervical cancer cell line, where pre­
treatment with different concentrations of aloe emodin (AE)
before X-ray irradiation (0–10 Gy) leads to decrease in the
mean lethal dose (D0) in a concentration-dependent manner,
as well as an enhancement in the percentage of cells in the
G2/M phase and a sub-G1 peak at 24, 48, and 72 h, using
50 M and 4 Gy IR. In addition, an increased expression of
cyclin B, γ-H2AX, and alkaline phosphatase (ALP) activity
was also described. Similar data regarding a decrease of cell
growth and viability were observed also in human HepG2
hepatocellular carcinoma cell line treated with 10 Gy of
γ-irradiation and AE, under hypoxic conditions. This com­
bined treatment leads to higher increase in both G2/M and
apoptotic populations [203].
11.4.1.9
Flavopiridol
Flavopiridol is a flavone originating from the Dysoxylum
binectariferum plant commonly used in Indian medicine.
This molecule is able to arrest cell cycle by acting on cyclin-­
dependent kinases (CDKs) during the G1/S or G2/M phases,
which is confirmed in several cancer cell types (chronic lym­
phocytic leukemia, squamous cancer, breast cancer cells). In
addition, flavopiridol is able to induce the transcriptional
suppression of genes involved in the proliferation pathways,
to stimulate apoptosis, to inhibit angiogenesis, and to
increase the chemotherapeutic effects [203].
The power of flavopiridol to affect cell radiosensitivity, in
tandem with docetaxel, was described in H460 human lung
carcinoma, by using both in vitro and in vivo approaches.
Multiple treatments with docetaxel (10 M), γ-irradiation
(0–5 Gy), and flavopiridol (120 M) are able to augment radia­
tion effects by inducing cell cycle arrest in the G1 and G2/M
phases. On the other hand, in esophageal squamous carci­
noma cell lines, cell cycle arrest after irradiation was described
with the decrease of cyclin D1 and retinoblastoma protein
(Rb) levels. Additionally, in the SEG-1 esophageal cancer cell
line, treatment with flavopiridol 24 h before γ-radiation
(2–6 Gy) increased radiosensitivity compared to the control,
due to inhibition of several CDKs, cell cycle redistribution in
G1 and G2 phases, and induction of apoptosis [203].
The experimental evidences show that cells containing
mutated p53 or overexpressed Bcl-2 are more radioresistant
than wild type. However, flavopiridol increased the cytotoxic
effects of radiation in cells with altered status of p53 and
Bcl-2, confirming the hypothesis according to which these
two pathways are targeted by radiosensitizer mechanism
exerted by flavopiridol [203]. Moreover, the radiosensitizing
effects of flavopiridol were evaluated in vivo on glioma
xenograft models using GL261 cells. The interaction of
γ-radiation (5 Gy), fractionated for 10 days, with flavopiridol
(5 mg/kg) resulted in a decrease in cell proliferation, which
was mainly mediated by the flavopiridol’s antiangiogenic
activity, which also inhibited the HIF-1 pathway [203].
On the other hand, as described in OCA-I ovarian carci­
noma cells, the radiosensitizing action of flavopiridol could
be sustained also by the downregulation of Ku70 and Ku80
proteins, known to be involved in DNA repair mechanisms
after radiation exposure, by the redistribution of the cell
cycle with a greater accumulation of cells in the two more
radiosensitive G1 and G2 phases [203].
11.4.1.10
Berberine
Berberine is an alkaloid which can be extracted from the
roots of many plants like the barberry, the tree turmeric, and
the California poppy. Berberine is used to treat health prob­
lems like hypercholesterolemia and type 2 diabetes
mellitus.
Berberine works by inhibiting cell cycle progression,
thereby exerting, in vitro, an antitumor activity in a large
array of tumors, and its radiosensitizing properties were
investigated on lung, esophageal, and breast cancer cells.
Since berberine interferes with the expression and activity of
RAD51, involved in DNA damage repair response, its radio­
sensitizing mechanism is based on hindering DNA damage
recovery after X-ray irradiation. In vitro and in vivo experi­
mental data has revealed the ability of berberine to inhibit
HIF-1α and suppress VEGF. For example, in an in vitro
nasopharyngeal carcinoma study, berberine when combined
with γ-rays demonstrated a reduction of cancer cell prolifer­
ation, viability, and Sp1 decreased expression, a protein
involved in tumor motility and invasion [203].
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Flavopiridol's mechanism of action as a radiosensitizer involves multiple pathways. Describe at least three distinct ways in which flavopiridol enhances the effects of radiation therapy, citing specific cellular processes or molecules impacted.","Flavopiridol demonstrates its radiosensitizing properties through several interconnected mechanisms. Firstly, it induces transcriptional suppression of genes involved in proliferation pathways, directly inhibiting cell division and reducing the capacity of cancer cells to repair DNA damage following irradiation. Secondly, flavopiridol stimulates apoptosis – programmed cell death – by targeting multiple apoptotic signaling cascades within the cell, promoting cell demise more effectively under radiation stress. Finally, it increases the chemotherapeutic effects of other drugs like docetaxel, likely through mechanisms involving cell cycle arrest in phases G1 and G2/M, further disrupting DNA replication and repair processes. Specifically, flavopiridol’s action impacts cyclin D1 and retinoblastoma protein (Rb) levels, redistributes cells into radiosensitive phases, and induces CDKs inhibition [203].
Reference: [MolecularRadiationBiology, Section 11.4.1.8 – Nutraceutical Compounds]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.8	 Emodin | Content: which is confirmed in several cancer cell types (chronic lym­
phocytic leukemia, squamous cancer, breast cancer cells). In
addition, flavopiridol is able to induce the transcriptional
suppression of genes involved in the proliferation pathways,
to stimulate apoptosis, to inhibit angiogenesis, and to
increase the chemotherapeutic effects [203].
The power of flavopiridol to affect cell radiosensitivity, in
tandem with docetaxel, was described in H460 human lung
carcinoma, by using both in vitro and in vivo approaches.
Multiple treatments with docetaxel (10 M), γ-irradiation
(0–5 Gy), and flavopiridol (120 M) are able to augment radia­
tion effects by inducing cell cycle arrest in the G1 and G2/M
phases. On the other hand, in esophageal squamous carci­
noma cell lines, cell cycle arrest after irradiation was described
with the decrease of cyclin D1 and retinoblastoma protein
(Rb) levels. Additionally, in the SEG-1 esophageal cancer cell
line, treatment with flavopiridol 24 h before γ-radiation
(2–6 Gy) increased radiosensitivity compared to the control,
due to inhibition of several CDKs, cell cycle redistribution in
G1 and G2 phases, and induction of apoptosis [203].
The experimental evidences show that cells containing
mutated p53 or overexpressed Bcl-2 are more radioresistant
than wild type. However, flavopiridol increased the cytotoxic
effects of radiation in cells with altered status of p53 and
Bcl-2, confirming the hypothesis according to which these
two pathways are targeted by radiosensitizer mechanism
exerted by flavopiridol [203]. Moreover, the radiosensitizing
effects of flavopiridol were evaluated in vivo on glioma
xenograft models using GL261 cells. The interaction of
γ-radiation (5 Gy), fractionated for 10 days, with flavopiridol
(5 mg/kg) resulted in a decrease in cell proliferation, which
was mainly mediated by the flavopiridol’s antiangiogenic
activity, which also inhibited the HIF-1 pathway [203].
On the other hand, as described in OCA-I ovarian carci­
noma cells, the radiosensitizing action of flavopiridol could
be sustained also by the downregulation of Ku70 and Ku80
proteins, known to be involved in DNA repair mechanisms
after radiation exposure, by the redistribution of the cell
cycle with a greater accumulation of cells in the two more
radiosensitive G1 and G2 phases [203].
11.4.1.10
Berberine
Berberine is an alkaloid which can be extracted from the
roots of many plants like the barberry, the tree turmeric, and
the California poppy. Berberine is used to treat health prob­
lems like hypercholesterolemia and type 2 diabetes
mellitus.
Berberine works by inhibiting cell cycle progression,
thereby exerting, in vitro, an antitumor activity in a large
array of tumors, and its radiosensitizing properties were
investigated on lung, esophageal, and breast cancer cells.
Since berberine interferes with the expression and activity of
RAD51, involved in DNA damage repair response, its radio­
sensitizing mechanism is based on hindering DNA damage
recovery after X-ray irradiation. In vitro and in vivo experi­
mental data has revealed the ability of berberine to inhibit
HIF-1α and suppress VEGF. For example, in an in vitro
nasopharyngeal carcinoma study, berberine when combined
with γ-rays demonstrated a reduction of cancer cell prolifer­
ation, viability, and Sp1 decreased expression, a protein
involved in tumor motility and invasion [203].
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Flavopiridol's mechanism of action as a radiosensitizer involves multiple pathways. Describe at least three distinct ways in which flavopiridol enhances the effects of radiation therapy, citing specific cellular processes impacted.","Flavopiridol demonstrates its effectiveness as a radiosensitizer through several interconnected mechanisms. Firstly, it induces transcriptional suppression of genes involved in proliferation pathways, specifically targeting proteins like cyclin D1 and retinoblastoma protein (Rb). This disruption of cell cycle progression arrests cells in the G1 and G2/M phases, making them more vulnerable to radiation-induced DNA damage. Secondly, flavopiridol stimulates apoptosis – programmed cell death – by impacting apoptotic pathways, potentially through modulation of Bcl-2 family proteins. Finally, it inhibits angiogenesis, reducing the formation of new blood vessels that would otherwise support tumor growth and repair following irradiation. Furthermore, flavopiridol increases the chemotherapeutic effects of other drugs like docetaxel, likely due to its influence on cell cycle arrest and DNA damage response. Reference: [MolecularRadiationBiology, Section 11.4.1.9 – Flavopiridol]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.9	 Flavopiridol | Content: which is confirmed in several cancer cell types (chronic lym­
phocytic leukemia, squamous cancer, breast cancer cells). In
addition, flavopiridol is able to induce the transcriptional
suppression of genes involved in the proliferation pathways,
to stimulate apoptosis, to inhibit angiogenesis, and to
increase the chemotherapeutic effects [203].
The power of flavopiridol to affect cell radiosensitivity, in
tandem with docetaxel, was described in H460 human lung
carcinoma, by using both in vitro and in vivo approaches.
Multiple treatments with docetaxel (10 M), γ-irradiation
(0–5 Gy), and flavopiridol (120 M) are able to augment radia­
tion effects by inducing cell cycle arrest in the G1 and G2/M
phases. On the other hand, in esophageal squamous carci­
noma cell lines, cell cycle arrest after irradiation was described
with the decrease of cyclin D1 and retinoblastoma protein
(Rb) levels. Additionally, in the SEG-1 esophageal cancer cell
line, treatment with flavopiridol 24 h before γ-radiation
(2–6 Gy) increased radiosensitivity compared to the control,
due to inhibition of several CDKs, cell cycle redistribution in
G1 and G2 phases, and induction of apoptosis [203].
The experimental evidences show that cells containing
mutated p53 or overexpressed Bcl-2 are more radioresistant
than wild type. However, flavopiridol increased the cytotoxic
effects of radiation in cells with altered status of p53 and
Bcl-2, confirming the hypothesis according to which these
two pathways are targeted by radiosensitizer mechanism
exerted by flavopiridol [203]. Moreover, the radiosensitizing
effects of flavopiridol were evaluated in vivo on glioma
xenograft models using GL261 cells. The interaction of
γ-radiation (5 Gy), fractionated for 10 days, with flavopiridol
(5 mg/kg) resulted in a decrease in cell proliferation, which
was mainly mediated by the flavopiridol’s antiangiogenic
activity, which also inhibited the HIF-1 pathway [203].
On the other hand, as described in OCA-I ovarian carci­
noma cells, the radiosensitizing action of flavopiridol could
be sustained also by the downregulation of Ku70 and Ku80
proteins, known to be involved in DNA repair mechanisms
after radiation exposure, by the redistribution of the cell
cycle with a greater accumulation of cells in the two more
radiosensitive G1 and G2 phases [203].
11.4.1.10
Berberine
Berberine is an alkaloid which can be extracted from the
roots of many plants like the barberry, the tree turmeric, and
the California poppy. Berberine is used to treat health prob­
lems like hypercholesterolemia and type 2 diabetes
mellitus.
Berberine works by inhibiting cell cycle progression,
thereby exerting, in vitro, an antitumor activity in a large
array of tumors, and its radiosensitizing properties were
investigated on lung, esophageal, and breast cancer cells.
Since berberine interferes with the expression and activity of
RAD51, involved in DNA damage repair response, its radio­
sensitizing mechanism is based on hindering DNA damage
recovery after X-ray irradiation. In vitro and in vivo experi­
mental data has revealed the ability of berberine to inhibit
HIF-1α and suppress VEGF. For example, in an in vitro
nasopharyngeal carcinoma study, berberine when combined
with γ-rays demonstrated a reduction of cancer cell prolifer­
ation, viability, and Sp1 decreased expression, a protein
involved in tumor motility and invasion [203].
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Several compounds, including flavopiridol, berberine, genistein, sodium selenite, and corticosteroids, are investigated for their potential radiosensitizing effects in cancer cells. Describe the mechanisms by which flavopiridol enhances radiation sensitivity, specifically detailing its impact on cell cycle progression, gene expression, and apoptosis induction, as evidenced in H460 lung carcinoma and esophageal squamous cell lines.","Flavopiridol demonstrates a multifaceted approach to radiosensitization, significantly augmenting the effects of ionizing radiation. In human lung carcinoma cells (H460), combined treatment with docetaxel and flavopiridol leads to arrest in both the G1 and G2/M phases of the cell cycle. This is primarily achieved through the transcriptional suppression of genes involved in proliferation pathways, directly inhibiting key proteins like cyclin D1 and retinoblastoma protein (Rb). Furthermore, flavopiridol stimulates apoptosis by promoting caspase activation and increasing cellular sensitivity to radiation damage. In esophageal squamous carcinoma cell lines, a similar effect is observed with cyclin D1 and Rb downregulation, contributing to cell cycle arrest.  The compound’s ability to inhibit CDKs further supports this mechanism. Importantly, the radiosensitizing action of flavopiridol is linked to its interference with DNA repair mechanisms; specifically, it inhibits RAD51, a protein crucial for homologous recombination-mediated DNA damage repair. This disruption hinders the cell's capacity to recover from radiation-induced DNA lesions, thereby increasing the cytotoxic impact of the treatment. Reference: [MolecularRadiationBiology, Section 11.4.1.10 – Nutraceutical Compounds] ","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.10	 Berberine | Content: which is confirmed in several cancer cell types (chronic lym­
phocytic leukemia, squamous cancer, breast cancer cells). In
addition, flavopiridol is able to induce the transcriptional
suppression of genes involved in the proliferation pathways,
to stimulate apoptosis, to inhibit angiogenesis, and to
increase the chemotherapeutic effects [203].
The power of flavopiridol to affect cell radiosensitivity, in
tandem with docetaxel, was described in H460 human lung
carcinoma, by using both in vitro and in vivo approaches.
Multiple treatments with docetaxel (10 M), γ-irradiation
(0–5 Gy), and flavopiridol (120 M) are able to augment radia­
tion effects by inducing cell cycle arrest in the G1 and G2/M
phases. On the other hand, in esophageal squamous carci­
noma cell lines, cell cycle arrest after irradiation was described
with the decrease of cyclin D1 and retinoblastoma protein
(Rb) levels. Additionally, in the SEG-1 esophageal cancer cell
line, treatment with flavopiridol 24 h before γ-radiation
(2–6 Gy) increased radiosensitivity compared to the control,
due to inhibition of several CDKs, cell cycle redistribution in
G1 and G2 phases, and induction of apoptosis [203].
The experimental evidences show that cells containing
mutated p53 or overexpressed Bcl-2 are more radioresistant
than wild type. However, flavopiridol increased the cytotoxic
effects of radiation in cells with altered status of p53 and
Bcl-2, confirming the hypothesis according to which these
two pathways are targeted by radiosensitizer mechanism
exerted by flavopiridol [203]. Moreover, the radiosensitizing
effects of flavopiridol were evaluated in vivo on glioma
xenograft models using GL261 cells. The interaction of
γ-radiation (5 Gy), fractionated for 10 days, with flavopiridol
(5 mg/kg) resulted in a decrease in cell proliferation, which
was mainly mediated by the flavopiridol’s antiangiogenic
activity, which also inhibited the HIF-1 pathway [203].
On the other hand, as described in OCA-I ovarian carci­
noma cells, the radiosensitizing action of flavopiridol could
be sustained also by the downregulation of Ku70 and Ku80
proteins, known to be involved in DNA repair mechanisms
after radiation exposure, by the redistribution of the cell
cycle with a greater accumulation of cells in the two more
radiosensitive G1 and G2 phases [203].
11.4.1.10
Berberine
Berberine is an alkaloid which can be extracted from the
roots of many plants like the barberry, the tree turmeric, and
the California poppy. Berberine is used to treat health prob­
lems like hypercholesterolemia and type 2 diabetes
mellitus.
Berberine works by inhibiting cell cycle progression,
thereby exerting, in vitro, an antitumor activity in a large
array of tumors, and its radiosensitizing properties were
investigated on lung, esophageal, and breast cancer cells.
Since berberine interferes with the expression and activity of
RAD51, involved in DNA damage repair response, its radio­
sensitizing mechanism is based on hindering DNA damage
recovery after X-ray irradiation. In vitro and in vivo experi­
mental data has revealed the ability of berberine to inhibit
HIF-1α and suppress VEGF. For example, in an in vitro
nasopharyngeal carcinoma study, berberine when combined
with γ-rays demonstrated a reduction of cancer cell prolifer­
ation, viability, and Sp1 decreased expression, a protein
involved in tumor motility and invasion [203].
11 Radioprotectors, Radiomitigators, and Radiosensitizers
612
11.4.1.11
Genistein
As expected, genistein also acts as a radiosensitizing agent,
if combined with γ-irradiation, as shown in vitro in cervical
cancer cells, where the growth inhibition was associated with
survivin downregulation, a prosurvival protein. Again, in
cervical neoplasms, genistein enhanced RT effects in multi­
ple ways: by inhibiting G2/M phase of cell cycle; by reducing
the expression of two prosurvival proteins, Mcl-1 and AKT;
and by triggering cell apoptosis via cytochrome c release,
cleavage of caspase-3 and -8, inhibition of Bcl-2, and
enhancement of Bax expression. Similar results were also
shown on breast and non-small cell lung cancers, where the
radiosensitizing ability was associated with the inhibition of
Bcl-x, ROS production enhancement, and antioxidant mole­
cule downregulation [203].
11.4.1.12
BP-C2
BP-C2, a lignin-derived polymer containing benzene poly­
carboxylic acids complexed with ammonium molybdate, is
an antioxidant that promotes the release of prorepair cyto­
kines (IL-4 and IL-10) and suppresses the release of pro­
inflammatory
cytokines
(TNF-α
and
IL-6).
Orally
administered BP-C2 was found to have radioprotective and
mitigative activity in H-ARS and GI-ARS [208]. Topical
BP-C2 was found to have radiomitigative activity in a cuta­
neous radiation injury model (CRI-ARS) [209].
11.4.1.13
Sodium Selenite
Several studies have revealed the prooxidant and cytotoxic
properties of sodium selenite, with respect to other selenium
compounds, recognized for their antioxidant activity. In par­
ticular, the effect on natural killer (NK) cell activation is
known, as well as the inhibition of the disulfide exchange on
cell surface, a remodeling process, which drives cancer to
uncontrolled cell division [203].
Schueller et al. [210] tested a 14-day pretreatment of C6
rat glioma cell line with selenite in the range concentration
of 2–3.6 mM, before applying 0–20 Gy of γ-rays. The results
showed a significant difference between the 0 mM and 3 mM
survival curves applying 5 Gy (p = 0.02) and 10 Gy
(p = 0.009). Also, the vehiculated sodium selenite nanopar­
ticles (nano-Se) were tested as radiosensitizers, using the
0–3 mg/mL range concentrations pretreatment, before treat­
ing with 0–8 Gy of X-rays. In this case, the authors showed
the effect on MCF7 breast cancer cells, observing that com­
bined treatment generated a higher mortality rate of the IR or
nano-Se single treatments, inducing block at the G2/M phase
of cell cycle, autophagy activation, and ROS generation.
Moreover, A375 melanoma cells were subjected to 4-h pre­
treatment with a selenium nanosystem, using 0–15 mM
coated hemocompatible erythrocyte membrane combined
with bevacizumab (RBCs@Se/Av) and 2–8 Gy of X-rays.
This study showed a strong cell survival reduction, an
increase in the sub-G1 cell proportion, apoptotic pathway
activation, and ROS generation. In addition, as expected by
the bevacizumab treatment, decreased VEGF and VEGF2
levels were observed as tumor angiogenesis reduction [203].
11.4.2	Corticosteroids
Corticosteroids are a group of hormones, produced by the
cortex of the adrenal glands, having the characteristic steroid
nucleus and derived from subsequent degradations of the
cholesterol side chain. They include numerous molecules
with different actions, including sex hormones. However,
they are divided into glucocorticoids, such as cortisol which
controls the metabolism, and mineralocorticoids, such as
aldosterone which controls the concentration of electrolyte
and water in the blood.
Among these molecules, many are used for their potent
anti-inflammatory and immunosuppressive properties, such
as corticosterone (C21H30O4) and cortisone (C21H28O5,
17-hydroxy-11-dehydrocorticosterone).
In the context of clinical RT, corticosteroids are currently
used as mitigators of side effects caused by irradiation [211].
However, some researchers have highlighted the radiosensi­
tizing effects of these molecules, used in the pretreatment
phase.
Glucocorticoids (GCs), acting on stress pathways, are
well known in the treatment of different types of tumors.
They have a strong inhibitory action on the pro­inflammatory
cytokine production, although their action mechanisms need
deeper investigation, if used in combination with IR.
An in vitro study has investigated the role of dexametha­
sone (Dex), a synthetic glucocorticoid, in DNA damage
response (DDR) pathway, on three astrocytoma cell lines
(CT2A, APP.PS1 L.1, and APP.PS1 L.3). The results showed
increased basal levels of γ-H2AX foci, keeping them higher
4 h after irradiation (IR) of the cells, while no effect was
shown on the 53BP1 foci formation, compared to untreated
cells. The high-level expression of γ-H2AX was reversed by
ascorbic acid administration, a strong inhibitor of reactive
oxygen species, showing that DEXA induces DNA damage
by oxidative stress [203].
In addition, in a preclinical study on rat model, the effect
of 1 mg Dex was studied alone or in combination with radio­
protective molecules turpentine oil (TO), α2-macroglobulin
(α2-M), or amifostine, before the administration of 6.7 Gy
(LD50/30) of RI, evaluating survival and blood inflamma­
tory markers. The results showed that Dex alone was lethal
for 45% and 55% of control and irradiated rats, respectively.
On the other hand, from the combination of pretreatments, it
emerged that 1 mg Dex reduced the radioprotective efficacy
of TO and Ami to 30% and 40%, respectively, even if, given
together, TO and Ami provided 70% protection to rats receiv­
A. Montoro et al."
"Describe the observed effects of combining genistein with X-ray irradiation on MCF7 breast cancer cells, as detailed in the text.","The study demonstrated that combining genistein with X-rays resulted in a significantly higher mortality rate in MCF7 breast cancer cells compared to either treatment alone. Specifically, this combination induced cell cycle arrest at the G2/M phase, activated autophagy, and increased reactive oxygen species (ROS) generation. Furthermore, when applied to A375 melanoma cells, pretreatment with a selenium nanosystem combined with bevacizumab (RBCs@Se/Av) and X-rays led to a substantial reduction in cell survival, an increase in the sub-G1 population of cells indicative of apoptosis, and continued ROS generation. The bevacizumab component also effectively reduced VEGF and VEGF2 levels, suggesting a concurrent decrease in tumor angiogenesis [203].","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.11	 Genistein | Content: ing with 0–8 Gy of X-rays. In this case, the authors showed
the effect on MCF7 breast cancer cells, observing that com­
bined treatment generated a higher mortality rate of the IR or
nano-Se single treatments, inducing block at the G2/M phase
of cell cycle, autophagy activation, and ROS generation.
Moreover, A375 melanoma cells were subjected to 4-h pre­
treatment with a selenium nanosystem, using 0–15 mM
coated hemocompatible erythrocyte membrane combined
with bevacizumab (RBCs@Se/Av) and 2–8 Gy of X-rays.
This study showed a strong cell survival reduction, an
increase in the sub-G1 cell proportion, apoptotic pathway
activation, and ROS generation. In addition, as expected by
the bevacizumab treatment, decreased VEGF and VEGF2
levels were observed as tumor angiogenesis reduction [203].
11.4.2	Corticosteroids
Corticosteroids are a group of hormones, produced by the
cortex of the adrenal glands, having the characteristic steroid
nucleus and derived from subsequent degradations of the
cholesterol side chain. They include numerous molecules
with different actions, including sex hormones. However,
they are divided into glucocorticoids, such as cortisol which
controls the metabolism, and mineralocorticoids, such as
aldosterone which controls the concentration of electrolyte
and water in the blood.
Among these molecules, many are used for their potent
anti-inflammatory and immunosuppressive properties, such
as corticosterone (C21H30O4) and cortisone (C21H28O5,
17-hydroxy-11-dehydrocorticosterone).
In the context of clinical RT, corticosteroids are currently
used as mitigators of side effects caused by irradiation [211].
However, some researchers have highlighted the radiosensi­
tizing effects of these molecules, used in the pretreatment
phase.
Glucocorticoids (GCs), acting on stress pathways, are
well known in the treatment of different types of tumors.
They have a strong inhibitory action on the pro­inflammatory
cytokine production, although their action mechanisms need
deeper investigation, if used in combination with IR.
An in vitro study has investigated the role of dexametha­
sone (Dex), a synthetic glucocorticoid, in DNA damage
response (DDR) pathway, on three astrocytoma cell lines
(CT2A, APP.PS1 L.1, and APP.PS1 L.3). The results showed
increased basal levels of γ-H2AX foci, keeping them higher
4 h after irradiation (IR) of the cells, while no effect was
shown on the 53BP1 foci formation, compared to untreated
cells. The high-level expression of γ-H2AX was reversed by
ascorbic acid administration, a strong inhibitor of reactive
oxygen species, showing that DEXA induces DNA damage
by oxidative stress [203].
In addition, in a preclinical study on rat model, the effect
of 1 mg Dex was studied alone or in combination with radio­
protective molecules turpentine oil (TO), α2-macroglobulin
(α2-M), or amifostine, before the administration of 6.7 Gy
(LD50/30) of RI, evaluating survival and blood inflamma­
tory markers. The results showed that Dex alone was lethal
for 45% and 55% of control and irradiated rats, respectively.
On the other hand, from the combination of pretreatments, it
emerged that 1 mg Dex reduced the radioprotective efficacy
of TO and Ami to 30% and 40%, respectively, even if, given
together, TO and Ami provided 70% protection to rats receiv­
A. Montoro et al."
Describe the observed effects of combined treatment with selenium nanosystems and bevacizumab on MCF7 breast cancer cells as detailed in the text.,"The study demonstrated that combining a selenium nanosystem (coated hemocompatible erythrocyte membrane) with bevacizumab (RBCs@Se/Av) resulted in enhanced cytotoxicity against MCF7 breast cancer cells. Specifically, this combination generated a higher mortality rate compared to either treatment alone. Furthermore, the combined treatment induced cell cycle arrest at the G2/M phase, activated autophagy, and increased reactive oxygen species (ROS) generation. The study also observed a reduction in VEGF and VEGF2 levels, indicative of diminished tumor angiogenesis, consistent with the bevacizumab component’s effect [203].","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.12	BP-C2 | Content: ing with 0–8 Gy of X-rays. In this case, the authors showed
the effect on MCF7 breast cancer cells, observing that com­
bined treatment generated a higher mortality rate of the IR or
nano-Se single treatments, inducing block at the G2/M phase
of cell cycle, autophagy activation, and ROS generation.
Moreover, A375 melanoma cells were subjected to 4-h pre­
treatment with a selenium nanosystem, using 0–15 mM
coated hemocompatible erythrocyte membrane combined
with bevacizumab (RBCs@Se/Av) and 2–8 Gy of X-rays.
This study showed a strong cell survival reduction, an
increase in the sub-G1 cell proportion, apoptotic pathway
activation, and ROS generation. In addition, as expected by
the bevacizumab treatment, decreased VEGF and VEGF2
levels were observed as tumor angiogenesis reduction [203].
11.4.2	Corticosteroids
Corticosteroids are a group of hormones, produced by the
cortex of the adrenal glands, having the characteristic steroid
nucleus and derived from subsequent degradations of the
cholesterol side chain. They include numerous molecules
with different actions, including sex hormones. However,
they are divided into glucocorticoids, such as cortisol which
controls the metabolism, and mineralocorticoids, such as
aldosterone which controls the concentration of electrolyte
and water in the blood.
Among these molecules, many are used for their potent
anti-inflammatory and immunosuppressive properties, such
as corticosterone (C21H30O4) and cortisone (C21H28O5,
17-hydroxy-11-dehydrocorticosterone).
In the context of clinical RT, corticosteroids are currently
used as mitigators of side effects caused by irradiation [211].
However, some researchers have highlighted the radiosensi­
tizing effects of these molecules, used in the pretreatment
phase.
Glucocorticoids (GCs), acting on stress pathways, are
well known in the treatment of different types of tumors.
They have a strong inhibitory action on the pro­inflammatory
cytokine production, although their action mechanisms need
deeper investigation, if used in combination with IR.
An in vitro study has investigated the role of dexametha­
sone (Dex), a synthetic glucocorticoid, in DNA damage
response (DDR) pathway, on three astrocytoma cell lines
(CT2A, APP.PS1 L.1, and APP.PS1 L.3). The results showed
increased basal levels of γ-H2AX foci, keeping them higher
4 h after irradiation (IR) of the cells, while no effect was
shown on the 53BP1 foci formation, compared to untreated
cells. The high-level expression of γ-H2AX was reversed by
ascorbic acid administration, a strong inhibitor of reactive
oxygen species, showing that DEXA induces DNA damage
by oxidative stress [203].
In addition, in a preclinical study on rat model, the effect
of 1 mg Dex was studied alone or in combination with radio­
protective molecules turpentine oil (TO), α2-macroglobulin
(α2-M), or amifostine, before the administration of 6.7 Gy
(LD50/30) of RI, evaluating survival and blood inflamma­
tory markers. The results showed that Dex alone was lethal
for 45% and 55% of control and irradiated rats, respectively.
On the other hand, from the combination of pretreatments, it
emerged that 1 mg Dex reduced the radioprotective efficacy
of TO and Ami to 30% and 40%, respectively, even if, given
together, TO and Ami provided 70% protection to rats receiv­
A. Montoro et al."
"Describe the effects of a combined treatment utilizing selenium nanosystems and bevacizumab on MCF7 breast cancer cells exposed to X-rays, detailing the observed cellular responses.","When MCF7 breast cancer cells were treated with a combination of a selenium nanosystem (specifically coated hemocompatible erythrocyte membrane containing selenium) alongside bevacizumab (RBCs@Se/Av) and subsequently exposed to 2–8 Gy of X-rays, several significant effects were observed. The combined treatment resulted in a markedly higher mortality rate compared to either the selenium nanosystem or bevacizumab alone. Furthermore, the cells exhibited a block at the G2/M phase of the cell cycle, accompanied by robust autophagy activation and increased levels of reactive oxygen species (ROS) generation. Importantly, the study demonstrated that this combined approach effectively reduced tumor angiogenesis as evidenced by decreased VEGF and VEGF2 levels. The observed apoptotic pathway activation, coupled with the elevated ROS production, likely contributed to the enhanced cytotoxic effects of the treatment. Reference: [Molecular Radiation Biology], Section 11.4.1.13 – Nutraceutical Compounds.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.1	 Nutraceutical Compounds | Sub-sub-subsection: 11.4.1.13	 Sodium Selenite | Content: ing with 0–8 Gy of X-rays. In this case, the authors showed
the effect on MCF7 breast cancer cells, observing that com­
bined treatment generated a higher mortality rate of the IR or
nano-Se single treatments, inducing block at the G2/M phase
of cell cycle, autophagy activation, and ROS generation.
Moreover, A375 melanoma cells were subjected to 4-h pre­
treatment with a selenium nanosystem, using 0–15 mM
coated hemocompatible erythrocyte membrane combined
with bevacizumab (RBCs@Se/Av) and 2–8 Gy of X-rays.
This study showed a strong cell survival reduction, an
increase in the sub-G1 cell proportion, apoptotic pathway
activation, and ROS generation. In addition, as expected by
the bevacizumab treatment, decreased VEGF and VEGF2
levels were observed as tumor angiogenesis reduction [203]."
"What were the key findings observed when MCF7 breast cancer cells were treated with a combined selenium nanosystem and X-rays, and how did this treatment affect cell cycle progression?","Treatment of MCF7 breast cancer cells with a combined selenium nanosystem (using 0–8 Gy of X-rays) resulted in a significantly higher mortality rate compared to individual IR or nano-Se treatments. This combination induced a block at the G2/M phase of the cell cycle, alongside activation of autophagy and increased generation of reactive oxygen species (ROS). Specifically, researchers observed an increase in cells within the sub-G1 population, indicative of apoptosis, and elevated levels of γ-H2AX foci – a marker of DNA damage – which were subsequently reversed by administration of ascorbic acid, suggesting oxidative stress was involved in the initial DNA damage [203]. Reference: [MolecularRadiationBiology, Section 11.4.2 Corticosteroids]","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.2	 Corticosteroids | Content: ing with 0–8 Gy of X-rays. In this case, the authors showed
the effect on MCF7 breast cancer cells, observing that com­
bined treatment generated a higher mortality rate of the IR or
nano-Se single treatments, inducing block at the G2/M phase
of cell cycle, autophagy activation, and ROS generation.
Moreover, A375 melanoma cells were subjected to 4-h pre­
treatment with a selenium nanosystem, using 0–15 mM
coated hemocompatible erythrocyte membrane combined
with bevacizumab (RBCs@Se/Av) and 2–8 Gy of X-rays.
This study showed a strong cell survival reduction, an
increase in the sub-G1 cell proportion, apoptotic pathway
activation, and ROS generation. In addition, as expected by
the bevacizumab treatment, decreased VEGF and VEGF2
levels were observed as tumor angiogenesis reduction [203].
11.4.2	Corticosteroids
Corticosteroids are a group of hormones, produced by the
cortex of the adrenal glands, having the characteristic steroid
nucleus and derived from subsequent degradations of the
cholesterol side chain. They include numerous molecules
with different actions, including sex hormones. However,
they are divided into glucocorticoids, such as cortisol which
controls the metabolism, and mineralocorticoids, such as
aldosterone which controls the concentration of electrolyte
and water in the blood.
Among these molecules, many are used for their potent
anti-inflammatory and immunosuppressive properties, such
as corticosterone (C21H30O4) and cortisone (C21H28O5,
17-hydroxy-11-dehydrocorticosterone).
In the context of clinical RT, corticosteroids are currently
used as mitigators of side effects caused by irradiation [211].
However, some researchers have highlighted the radiosensi­
tizing effects of these molecules, used in the pretreatment
phase.
Glucocorticoids (GCs), acting on stress pathways, are
well known in the treatment of different types of tumors.
They have a strong inhibitory action on the pro­inflammatory
cytokine production, although their action mechanisms need
deeper investigation, if used in combination with IR.
An in vitro study has investigated the role of dexametha­
sone (Dex), a synthetic glucocorticoid, in DNA damage
response (DDR) pathway, on three astrocytoma cell lines
(CT2A, APP.PS1 L.1, and APP.PS1 L.3). The results showed
increased basal levels of γ-H2AX foci, keeping them higher
4 h after irradiation (IR) of the cells, while no effect was
shown on the 53BP1 foci formation, compared to untreated
cells. The high-level expression of γ-H2AX was reversed by
ascorbic acid administration, a strong inhibitor of reactive
oxygen species, showing that DEXA induces DNA damage
by oxidative stress [203].
In addition, in a preclinical study on rat model, the effect
of 1 mg Dex was studied alone or in combination with radio­
protective molecules turpentine oil (TO), α2-macroglobulin
(α2-M), or amifostine, before the administration of 6.7 Gy
(LD50/30) of RI, evaluating survival and blood inflamma­
tory markers. The results showed that Dex alone was lethal
for 45% and 55% of control and irradiated rats, respectively.
On the other hand, from the combination of pretreatments, it
emerged that 1 mg Dex reduced the radioprotective efficacy
of TO and Ami to 30% and 40%, respectively, even if, given
together, TO and Ami provided 70% protection to rats receiv­
A. Montoro et al.
613
ing Dex. Instead, TO and α2-M enhanced the rate of survival
from 50% to 90% and 100%, respectively [203]."
"How do gold nanoparticles (GNP) enhance radiation damage in tumor cells, and what physical process is primarily responsible for this effect when using medium-energy X-rays?","Gold nanoparticles (GNP) demonstrate a significant ability to amplify the effects of radiation on tumor cells. Studies, notably those by Hainfeld [212], have shown that injecting GNP into mice undergoing kilovoltage X-ray treatment dramatically improved tumor control – often increasing radiation effectiveness by 10–100% in vitro across diverse cell lines and varying radiation qualities. The primary mechanism driving this enhancement with medium-energy X-rays (<300 kVp) is the photoelectric effect. When photons of appropriate energy (around the L- and K-shell excitation edges of gold) interact with the GNP, they cause the emission of inner shell electrons from the nanoparticle’s atoms. This electron ejection initiates a cascade of events, including the generation of secondary low-energy particles – primarily Auger electrons – which contribute to localized DNA damage and ultimately increase radiation sensitivity within the tumor cells.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.3	 Nanoparticles | Content: A crucial question for cancer treatment is how to increase the
therapeutic window, enhancing radiation damage in tumors,
while preserving the surrounding healthy tissues. One prom­
ising strategy is the accumulation of nanoparticles composed
of high-Z materials (e.g., gold, palladium, platinum, gado­
linium) in the tumor cells.
­
­
11.23
­
Fe
Early work by Hainfeld [212] demonstrated the potential
of high-Z nanostructures to enhance the effect of radiation
and improve tumor control in mice treated with kilovoltage
X-rays minutes after injection of gold nanoparticles (GNP).
In vitro work using a wide range of cell lines and radiation
qualities confirmed that the presence of GNP can enhance
the effect of radiation by 10–100% [213].
­
­
11.24
11.4.3.1
Physical Radiosensitization
The physical processes driving the enhancement in radiation
effectiveness in the presence of nanoparticles strongly
depend on the radiation quality used. For medium-energy
X-rays (<300 kVp), the radiation-nanoparticle interaction is
dominated by the photoelectric effect, especially for photons
with energies around the L- and K-shell excitation edges.
This causes the emission of inner shell electrons from the
high-Z material, resulting in a cascade of low-energy Auger
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"How can nanoparticle exposure, particularly gold nanoparticles, contribute to radiosensitization in cells, and what cellular components are implicated as potential targets beyond the nucleus?","Gold nanoparticles can enhance the effects of radiation by inducing cell cycle arrest, specifically within the G2/M phase – a critical stage for mitosis. This stalling is primarily attributed to the physical disruption caused by the nanoparticles themselves, interfering with normal chromosomal segregation and preventing proper cell division. Furthermore, mitochondria, due to their own DNA and location within the cytoplasm, represent another potential target. Irradiation of nanoparticles within mitochondria could trigger similar DNA damage responses as those observed in nuclear DNA, leading to mitochondrial dysfunction and ultimately cell death. Importantly, nanoparticles are frequently found accumulated in endosomes and lysosomes rather than directly within mitochondria. Damage to these organelles – particularly lysosomes – through nanoparticle accumulation can disrupt their normal functions, such as waste removal and degradation, further contributing to cellular stress and apoptosis. The complexity arises from the potential for altered signaling pathways resulting from this organelle damage, amplifying the cytotoxic effects of radiation. It’s crucial to acknowledge that nanoparticle-mediated radiosensitization is a complex phenomenon influenced by numerous variables including nanoparticle characteristics (size, shape, modification) and cell type.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.3	 Nanoparticles | Sub-sub-subsection: 11.4.3.3	 Biological Radiosensitization | Content: nanoparticle exposure [218]. As a result, the radiosensitizing
effects of gold nanoparticles can also be attributed to stalling
of the cell cycle in the radiosensitive G2/M phase.
Finally, mitochondria, located in the cytoplasm and hav­
ing their own DNA, are another potential target for
nanoparticle-­mediated radiosensitization as the same pro­
cesses as described above for nuclear DNA may affect mito­
chondrial (mt) DNA. However, nanoparticles are hardly ever
detected in mitochondria and are often accumulated in endo­
somes and lysosomes. In general, although hypothetical,
nanoparticles accumulated and irradiated within lysosomes
or other organelles may decrease cell survival by directly
harming these organelles and their functions [219]. Even
milder damage to organelles could potentially lead to altered
signaling and eventually increased cell death.
Cytoplasmic organelles might thus represent a parallel or
even dominant target to nuclear DNA. It is obvious from the
previous paragraphs that nanoparticle-mediated radiosensiti­
zation is not fully understood. The research is complicated
by extreme complexity and variability of the systems stud­
ied, including different materials, sizes, shapes, and modifi­
cations of nanoparticles; different cell types; different types
of radiation and irradiation conditions, etc. Under certain
experimental conditions, a plethora of biological processes
may be induced so that it might not be excluded that different
types and sizes of nanoparticles do interact according to spe­
cific mechanisms and their combinations (Box 11.6)."
"Describe the process of autophagy and explain how it is regulated, including specific signaling pathways involved, particularly in relation to radiation exposure and its potential impact on cancer cells.","Autophagy is a fundamental cellular process characterized by the degradation and recycling of cytoplasmic organelles and other cellular components through lysosomal action. This process occurs via membrane invagination forming double-membrane vesicles called phagophores, which ultimately fuse with lysosomes for breakdown. The autophagy machinery relies heavily on protein complexes like class III PI3K, autophagy-related (Atg) proteins, and LC3, recruited to the membrane to facilitate membrane expansion and phagophore elongation.  Regulation of autophagy is complex and can be triggered by various stimuli, notably energy signals mediated by AMPK. When cells experience stress such as nutrient deprivation, protein aggregation, organelle damage, or oxidative/genotoxic stress (including radiation), AMPK activation phosphorylates ULK1, inhibiting mTOR signaling and activating Beclin-1 and Vps34, thereby upregulating autophagy intensity.  Specifically, the AMPK-mTOR-ULK1 pathway is a key regulator of this process. Recent research has highlighted the roles of p53 and PARP-1 in initiating autophagy following radiation exposure, influencing the PI3K/PKB/AKT/mTOR signaling pathway. Furthermore, autophagy can be categorized into microautophagy (direct engulfment of organelles) and chaperone-mediated autophagy (targeting specific proteins for degradation).  Notably, under conditions of stress like irradiation or chemotherapy, autophagy can shift from a homeostatic role to an adaptive response promoting cell death via nonapoptotic mechanisms – macroautophagy. This switch is often observed in cancer cells where autophagy initially limits tumorigenesis but later provides a prosurvival function during stressful environments, potentially contributing to radioresistance.  The interplay between different signaling pathways and the context-dependent nature of autophagy’s role (protective or sensitizing) remains an area of active investigation.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.4	 Autophagy Inhibitors | Content: nanoparticle exposure [218]. As a result, the radiosensitizing
effects of gold nanoparticles can also be attributed to stalling
of the cell cycle in the radiosensitive G2/M phase.
Finally, mitochondria, located in the cytoplasm and hav­
ing their own DNA, are another potential target for
nanoparticle-­mediated radiosensitization as the same pro­
cesses as described above for nuclear DNA may affect mito­
chondrial (mt) DNA. However, nanoparticles are hardly ever
detected in mitochondria and are often accumulated in endo­
somes and lysosomes. In general, although hypothetical,
nanoparticles accumulated and irradiated within lysosomes
or other organelles may decrease cell survival by directly
harming these organelles and their functions [219]. Even
milder damage to organelles could potentially lead to altered
signaling and eventually increased cell death.
Cytoplasmic organelles might thus represent a parallel or
even dominant target to nuclear DNA. It is obvious from the
previous paragraphs that nanoparticle-mediated radiosensiti­
zation is not fully understood. The research is complicated
by extreme complexity and variability of the systems stud­
ied, including different materials, sizes, shapes, and modifi­
cations of nanoparticles; different cell types; different types
of radiation and irradiation conditions, etc. Under certain
experimental conditions, a plethora of biological processes
may be induced so that it might not be excluded that different
types and sizes of nanoparticles do interact according to spe­
cific mechanisms and their combinations (Box 11.6).
11.4.4	Autophagy Inhibitors
Autophagy is a basic catabolic mechanism that involves cell
degradation of unnecessary or dysfunctional cell compo­
nents, such as damaged endoplasmic reticulum (ER) and
other cytoplasmic constituents through lysosome action.
Box 11.6: Nanoparticle-Mediated Radiosensitization
•	The physical mechanisms of nanoparticle radiosen­
sitization are related to both the higher attenuation
cross section of high-Z materials compared to soft
tissues and an increased clustering of ionizations
from the secondary electrons emitted by the
nanoparticle.
•	The chemical mechanisms are related to production
and/or scavenging of reactive radical species mainly
from the chemical compounds surrounding the
nanoparticle.
•	The biological mechanisms are related to the inter­
action of the nanoparticles with the cellular and
molecular processes, including antioxidant enzyme
activities, the DNA repair pathways, the cell cycle
and organelle functioning (e.g., mitochondria, lyso­
somes, ER, Golgi apparatus).
A. Montoro et al.
617
The autophagy is mediated by protein complexes, such as
class III PI3K, autophagy-related gene (Atg) proteins, and
others containing microtubule-associated protein 1 light-­
chain subunit 3 (LC3), recruited to the membrane favoring
membrane
expansion
and
phagophore
elongation.
Particularly, autophagy can be activated by multiple signal­
ing pathways, mainly through energy signals via
AMPK. AMPK activation can phosphorylate ULK1, inhibit
mTOR signaling, and activate Beclin-1 and Vps34 molecules
resulting in the upregulation of autophagy intensity. Thus,
the AMPK-mTOR-ULK1 pathway plays an important role
in autophagy. Recently, the autophagy-related protein
BECN1 has been shown to regulate radiation-induced G2/M
arrest. In the context of a disease, autophagy has been
described as an adaptive response to survival, a strategy to
maintain metabolic homeostasis. In cancer cells, autophagy
is a double-edged sword. In early stages, it could limit
tumorigenesis. However, it could also provide a prosurvival
function for adaptation and detoxification in a stressful envi­
ronment, such as starvation, hypoxia, and chemotherapy/
radiotherapy.
Some studies show that the autophagy preventing is
radiosensitive, while the autophagy promoting is radiopro­
tective, suggesting that IR-induced autophagy may repre­
sent an adaptive response to maintain tumor growth and
survival. In order to improve IR tumor responses, several
sensitization agents to radiation-induced autophagy are
currently being studied. The molecular machinery involved
in IR-induced autophagy is still not clear. Recent studies
show that p53 and PARP-1, a DNA repair enzyme triggered
by DNA damage, exert essential roles in starting the
autophagy process regulating the PI3K/PKB/AKT/mTOR
signaling pathway that represents an autophagy key regula­
tor. Reports by investigators have recently shown that
autophagy activity increased after IR and chemotherapy. It
is an escape mechanism for cell survival in response to
cytotoxic agents, including IR and temozolomide (TMZ) in
glioblastoma (GBM) treatment [220]. In radioresistant
breast cancer (BC) cells, a strong postirradiation autophagy
induction has been observed as a protective and prosurvival
mechanism of radioresistance after exposure to IR. Studies
have also shown that induced autophagy in some radiore­
sistant cancers, such as GBM, causes IR sensitization and
increased cell death.
In normal conditions, microautophagy and chaperone-­
mediated autophagy permit the breakdown of abnormal pro­
teins, cellular debris, or damaged organelles, maintaining
cellular homeostasis and/or as tools to recycle biological
constituents (e.g., amino acid, fatty acid, and energy in the
form of ATP). After stress stimuli, such as nutrient starva­
tion, protein aggregation, organelle damage, and oxidative or
genotoxic stress, including by IR, the autophagy hyperacti­
vation promotes cell death, via nonapoptotic and caspase-­
independent mechanisms, and this case is also called
macroautophagy [221].
As described above, AMPK promotes the activation of
autophagy. Among factors activated by AMPK, an interest­
ing and not well-described role in the autophagy process, it
was supposed to be for glucose transporter GLUT-1, often
upregulated in cancer cells. In this sense, the cross talk
among GLUT1, curcumin, and AMPK pathway in LC
remains vague. Interestingly, it was recently described that
the treatment with GLUT1 siRNA alone or in combination
with curcumin resulted in profound improvement of the
radiosensitivity of LC cells after irradiation. In particular,
curcumin and GLUT1 siRNA combined treatment not only
promoted apoptosis of LC cells, but also induced autophagy-­
associated cell death through activation of AMPK/mTOR/
ULK1 signaling-mediated autophagy with or without irradi­
ation treatment [222].
Taking all these observations, we can speculate that the
role of autophagy in cancer cells depends upon certain fac­
tors, such as cell type, specific characteristics of tumor cells,
microenvironment of the tumor, and type of treatment
applied. In addition, a variety of radiation-resistant mole­
cules, such as PI3K/AKT, EGFR, NF-κB, and p53, may play
an important role in the regulation of autophagy, thus
­indicating that the mechanisms that regulate autophagy are
very complex. Thus, many questions and contradictory find­
ings have yet to be clarified."
"Describe the role of mediated autophagy in cellular homeostasis and its potential involvement in response to stress stimuli like irradiation. Specifically, how does this process relate to mechanisms observed with metformin (MTF) treatment?","Mediated autophagy represents a crucial mechanism for maintaining cellular homeostasis by facilitating the breakdown of abnormal proteins, cellular debris, or damaged organelles. This process is particularly active following periods of stress, such as nutrient starvation, protein aggregation, organelle damage, and oxidative or genotoxic stress – including irradiation. The hyperactivation of autophagy under these conditions promotes cell death through non-apoptotic and caspase-independent pathways. Recent research has highlighted the interplay between AMPK, GLUT1 (glucose transporter 1), curcumin, and ULK1 signaling in mediating this process. Specifically, studies have shown that combined treatment with GLUT1 siRNA and curcumin significantly improved the radiosensitivity of cancer cells (e.g., LC cells) after irradiation by inducing autophagy-associated cell death via activation of the AMPK/mTOR/ULK1 pathway. This suggests that targeting this specific autophagic cascade can be a strategy to enhance radiation sensitivity. Metformin’s ability to increase intrinsic radiosensitivity in various tumor cell lines, including those of lung, breast, and prostate cancers, is partly attributed to its facilitation of this same autophagy process through mechanisms such as increased ROS generation and disruption of DNA repair pathways. Reference: [MolecularRadiationBiology], Section 11.4.5 – Metformin (MTF)","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.5	 Metformin (MTF) | Content: mediated autophagy permit the breakdown of abnormal pro­
teins, cellular debris, or damaged organelles, maintaining
cellular homeostasis and/or as tools to recycle biological
constituents (e.g., amino acid, fatty acid, and energy in the
form of ATP). After stress stimuli, such as nutrient starva­
tion, protein aggregation, organelle damage, and oxidative or
genotoxic stress, including by IR, the autophagy hyperacti­
vation promotes cell death, via nonapoptotic and caspase-­
independent mechanisms, and this case is also called
macroautophagy [221].
As described above, AMPK promotes the activation of
autophagy. Among factors activated by AMPK, an interest­
ing and not well-described role in the autophagy process, it
was supposed to be for glucose transporter GLUT-1, often
upregulated in cancer cells. In this sense, the cross talk
among GLUT1, curcumin, and AMPK pathway in LC
remains vague. Interestingly, it was recently described that
the treatment with GLUT1 siRNA alone or in combination
with curcumin resulted in profound improvement of the
radiosensitivity of LC cells after irradiation. In particular,
curcumin and GLUT1 siRNA combined treatment not only
promoted apoptosis of LC cells, but also induced autophagy-­
associated cell death through activation of AMPK/mTOR/
ULK1 signaling-mediated autophagy with or without irradi­
ation treatment [222].
Taking all these observations, we can speculate that the
role of autophagy in cancer cells depends upon certain fac­
tors, such as cell type, specific characteristics of tumor cells,
microenvironment of the tumor, and type of treatment
applied. In addition, a variety of radiation-resistant mole­
cules, such as PI3K/AKT, EGFR, NF-κB, and p53, may play
an important role in the regulation of autophagy, thus
­indicating that the mechanisms that regulate autophagy are
very complex. Thus, many questions and contradictory find­
ings have yet to be clarified.
11.4.5	Metformin (MTF)
In cancer patients, MTF may affect tumor growth and treat­
ment response in two different ways: directly by inhibiting
mitochondrial metabolism and activating downstream cell
signaling pathways in cancer cells or indirectly by keeping
low the levels of glucose, insulin, and other factors which
can activate cancer cell proliferation [223]. MTF has also
shown anticancer effects in nondiabetic patient populations
(described in Sect. 11.1.9).
With regard to the relationship between MTF and IR,
MTF is able to increase intrinsic radiosensitivity, as tested
in vitro in many cell lines of different tumors, including lung,
head and neck, breast, liver, prostate, and pancreas cancers
and murine fibrosarcoma, with specific cell line-dependent
radiosensitizing effect [203, 223].
Several clinical data on the effect of MTF on patient out­
come, focused particularly on patient populations undergo­
ing RT, have shown that these patients have better outcomes
if they are treated with MTF. These and other data show the
significant role of MTF in enhancing the RT efficacy and
suggest an interaction between MTF and IR [223].
11 Radioprotectors, Radiomitigators, and Radiosensitizers
618
In vitro and in vivo studies, concerning the MTF radio­
sensitizing effect, have showed an enhanced DNA damage
after MTF treatment combined with RT, as tested by phos­
phorylation of histone γH2AX, a well-known marker for
DNA damage [203].
In particular, MTF may increase initial DNA damage or
inhibit repair processes, being able to reduce the expression
of DNA repair protein Ku70 and hamper radiation-induced
activation of EGFR and DNA-dependent protein kinase cata­
lytic subunit (DNA-PKcs). Considering that the primary tar­
gets of MTF are the mitochondrial complex I and mGPD
(glycerol-3-phosphate dehydrogenase), it may induce an
increase of ROS generation and oxidative damage to lipids,
protein, and DNA that could strengthen the effects of
IR. Indeed, several data have demonstrated that MTF can
increase ROS in cancer cells when delivered alone or in com­
bination with IR. In general, as regards the main known MTF
mechanisms of action when combined with RT, in vitro and
in vivo data show a significant role of MTF in affecting at
least four different parameters at radiobiological level,
including intrinsic cell radiosensitivity (SF2, i.e., the fraction
of cells surviving after a single IR dose of 2 Gy), cancer stem
cell fraction, tumor proliferation rates, and tumor hypoxia
[223]."
"Describe the mechanisms by which nitroxides like Tempol (TPL) contribute to radiosensitization in cancer cells, referencing specific cellular processes affected by TPL exposure.","Nitroxides, such as Tempol (TPL), demonstrate radiosensitizing properties through a multifaceted approach targeting key cellular processes within tumor cells. Primarily, TPL’s reversible redox cycling – transitioning between nitroxide, hydroxylamine, and oxoammonium cation forms – generates reactive oxygen species (ROS) at concentrations dependent on the cell's environment. Elevated ROS levels directly contribute to oxidative stress, damaging DNA, proteins, and lipids within cancer cells, thereby increasing their vulnerability to radiation damage. Furthermore, TPL’s action is linked to several specific cellular effects: it inhibits mitochondrial oxidative phosphorylation by targeting complex I, leading to a diminished mitochondrial membrane potential and reduced ATP production; it triggers apoptosis through ROS-mediated cell death pathways, particularly in cell lines like HL-60, evidenced by decreased glutathione levels and failure of oxidative phosphorylation; and it induces tyrosine phosphorylation of various proteins, including Raf-1 and ERK1, activating downstream signaling cascades that promote cell death. Notably, TPL’s differential effect – protecting normal cells from radiation while sensitizing cancer cells – is attributed to its ability to induce ceramide accumulation and stress-activated protein kinase (SAPK) activation in cancer cells, ultimately accelerating apoptosis. Reference: [MolecularRadiationBiology, Section 11.4.6.1] ","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.6	 PARP Inhibitors | Content: 224
­
3
­
225
­
2
­
­
11.26
226
224
CC BY 3.0
A. Montoro et al.
619
11.4.6.1
Nitroxides
Nitroxides are a class of stable free radical compounds that
exhibit antioxidant mechanisms, thereby safeguarding the
cells from several lethal agents like superoxide and hydrogen
peroxide (also described in Sect. 11.1.2). However, the ratio­
nale to use nitroxides in cancer RT comes from the role of
free radicals in tumor development and capacity of inhibitors
of radical reactions to suppress tumorigenesis. The underly­
ing
mode
of
action
of
nitroxyls
exhibiting
the
­radiosensitization effect can be attributed to cell signaling,
enhanced blood flow to the tumor, consequences on the cel­
lular respiration, and generation of reactive oxygen and
nitrogen species that can operate as metabolite radiosensitiz­
ers. The effects of nitroxides with radiation were found con­
flicting, leading to uncertainty about their radiosensitizing
nature.
Tempol (TPL) is a piperidine nitroxide that possesses an
unpaired electron and goes through swift reversible transfer
among the three forms: nitroxide, hydroxylamine, and
oxoammonium cation. Based on its concentration in the
cell, it can act as an oxidative or reductive agent. In cancer
cells, TPL favorably inhibits growth by increasing the gen­
eration of cellular ROS [227]. When used with RT and che­
motherapy, TPL exhibits a differential effect of protecting
the normal healthy cells from RT and cisplatin-­mediated
damage, whereas in cancer cells, tempol is reduced to its
hydroxylamine form that is unable to protect the cells from
radiation and cisplatin-mediated damage. This differential
or selective acting on cancer cells while sparing the normal
cells is particularly of significance in cancer radio- as well
as chemotherapy [228]. It was observed that the anticancer
effects of cisplatin increased due to the prooxidant activity
of TPL via the increased ROS-mediated cell apoptosis
[227]. In several cancer cell lines, TPL was able to free
radical-dependent apoptosis. On 24-h exposure to TPL,
human promyelocytic leukemic cell line (HL-60) showed
reduced levels of mitochondrial and intracellular glutathi­
one, failure in the oxidative phosphorylation process, and
diminished mitochondrial membrane potential. TPL also
particularly targeted the respiratory chain complex I and
showed some insignificant effects on the complexes II and
IV. This can be attributed to the role of mitochondria in
apoptosis and it being a free radical resource and target. In
HL-60, TPL works by targeting the mitochondria, which
subsequently leads to mitochondria associated with oxida­
tive stress and apoptosis. This in turn can sensitize the
tumor cells to the proapoptotic effects of cytotoxic agents
[229]. When human breast cancer cells (MDA-MB 231)
were treated with tempo, another nitroxide, it exhibited
considerable levels of tyrosine phosphorylation of numer­
ous unknown proteins when evaluated with the equimolar
concentration, i.e., 10 mm TPL. The compounds tempo and
TPL lead to the phosphorylation of tyrosine and trigger the
Raf-1 protein kinase (30 min, two- to threefold) [230].
Nevertheless, TPL leads to augmented extracellular signal-
regulated kinase 1 activity. Tempo also activated the stress-
associated protein kinase (2 h, threefold) and induced
apoptosis (2 h, >50%). The ceramide levels significantly
increase (54% over control) at 30 min and (71% over con­
trol) at 1 h after treatment, prior to activation of stress-acti­
vated protein kinase and cell death via apoptosis [230].
TPL protects normal cells and tissues from oxidative dam­
age and remarkably hampers the proliferation of cancer
cells. These clearly imply that the nitroxide TPL shows the
potential to be a good prooxidant and can be a potent radio­
sensitizing agent for cancer treatment.
11 Radioprotectors, Radiomitigators, and Radiosensitizers"
"Describe the mechanisms by which nitroxide compounds like TPL and tempo can act as radiosensitizers in cancer cells, incorporating the role of mitochondria and oxidative stress.","Nitroxide compounds such as TPL and tempo demonstrate potential as radio sensitizers through a multifaceted mechanism primarily centered around mitochondrial function and subsequent oxidative stress. Initially, these compounds target mitochondria, mirroring their action observed in HL-60 cells where they induce oxidative stress and apoptosis. Specifically, the nitroxides trigger tyrosine phosphorylation of numerous unknown proteins within the mitochondria, leading to enhanced activity of extracellular signal-regulated kinase 1 (ERK1) and activation of the stress-activated protein kinase (SAPK). This mitochondrial targeting amplifies oxidative stress by increasing the availability of reactive oxygen species (ROS), a consequence of increased mitochondrial respiration. Elevated ROS levels then contribute to ceramide accumulation – a key intermediate in apoptosis – further promoting cell death. Critically, TPL’s protective effect on normal cells suggests that this sensitization is achieved through exploiting vulnerabilities within cancer cells rather than directly damaging healthy tissues. The phosphorylation events initiated by the nitroxides ultimately augment the proapoptotic effects of cytotoxic agents, effectively making the tumor cells more susceptible to radiation damage. Reference: [MolecularRadiationBiology], Section 11.4.6.1 – PARP Inhibitors","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.4	 Radiosensitizers | Sub-subsection: 11.4.6	 PARP Inhibitors | Sub-sub-subsection: 11.4.6.1	 Nitroxides | Content: IV. This can be attributed to the role of mitochondria in
apoptosis and it being a free radical resource and target. In
HL-60, TPL works by targeting the mitochondria, which
subsequently leads to mitochondria associated with oxida­
tive stress and apoptosis. This in turn can sensitize the
tumor cells to the proapoptotic effects of cytotoxic agents
[229]. When human breast cancer cells (MDA-MB 231)
were treated with tempo, another nitroxide, it exhibited
considerable levels of tyrosine phosphorylation of numer­
ous unknown proteins when evaluated with the equimolar
concentration, i.e., 10 mm TPL. The compounds tempo and
TPL lead to the phosphorylation of tyrosine and trigger the
Raf-1 protein kinase (30 min, two- to threefold) [230].
Nevertheless, TPL leads to augmented extracellular signal-
regulated kinase 1 activity. Tempo also activated the stress-
associated protein kinase (2 h, threefold) and induced
apoptosis (2 h, >50%). The ceramide levels significantly
increase (54% over control) at 30 min and (71% over con­
trol) at 1 h after treatment, prior to activation of stress-acti­
vated protein kinase and cell death via apoptosis [230].
TPL protects normal cells and tissues from oxidative dam­
age and remarkably hampers the proliferation of cancer
cells. These clearly imply that the nitroxide TPL shows the
potential to be a good prooxidant and can be a potent radio­
sensitizing agent for cancer treatment.
11 Radioprotectors, Radiomitigators, and Radiosensitizers
620
11.5"
"Radiomitigators play a crucial role in radiation therapy, but how do they achieve this effect and what specific mechanisms are involved in mitigating radiation damage to normal tissues?","Radiomitigators function by actively reducing the rate of DNA strand breaks induced by ionizing radiation. Unlike radioprotectors which primarily shield cells from the damaging effects of radiation, radiomitigators directly intervene in the post-irradiation repair processes. A key mechanism involves targeting and inhibiting the homologous recombination (HR) pathway, a major DNA repair route utilized by mammalian cells following irradiation. HR is exceptionally accurate but also significantly time-consuming; it requires the presence of a sister chromatid for template fidelity. Radiomitigators, such as certain flavonoids like curcumin, disrupt this process by interfering with the recruitment of proteins essential for HR – notably BRCA1 and RAD51. Specifically, some radiomitigators can inhibit RAD51’s ability to form a pre-steady state filament necessary for strand invasion during recombination. Furthermore, they may modulate the expression of genes involved in DNA repair pathways, shifting the balance away from HR towards more rapid but less accurate alternative repair mechanisms like non-homologous end joining (NHEJ). This reduction in HR activity effectively shortens the window of vulnerability for cells undergoing radiation damage, allowing them to recover faster and reducing overall cell death. It’s important to note that radiomitigators don't eliminate DNA damage entirely; rather, they modify the repair response to favor a quicker, less precise outcome, ultimately protecting normal tissues from severe radiation-induced injury. Reference: Molecular Radiation Biology, Section 11.5 – Radiomitigators.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.5	 Exercises and Self-Assessment | Content: Q1.	How do radioprotectors work?
Q2.	What is the purpose of radioprotectors in RT?
Q3.	What is TRUE: All the antioxidants are radioprotectors
or all the potential radioprotectors are often
antioxidants?
Q4.	What are radiomitigators?
Q5.	Can
immunomodulators
be
classified
as
radiomitigators?
Q6.	What is the purpose of a radiosensitizing agent in can­
cer RT?
Q7.	Describe the curcumin action mechanism when admin­
istered with irradiation.
11.1
­
11.6"
"Describe the roles of radioprotectors, radiomitigators, and radiosensitizers in radiation therapy, detailing their mechanisms of action and target cells.","Radioprotectors are substances administered to protect normal or nontumor cells from the damaging effects of ionizing radiation. Their primary function is to increase survival rates in patients exposed to radiation by mitigating cellular damage before or during exposure. Radiomitigators, conversely, aim to reduce the toxicity caused by irradiation in noncancerous cells *after* radiation delivery. This enhancement improves the effectiveness of radiation therapy for cancerous tissues. Finally, radiosensitizers are agents that specifically increase the susceptibility of tumor cells to radiation damage while minimizing harm to normal cells. The mechanisms vary; some, like curcumin, act as antioxidants and anti-inflammatory agents, reducing reactive oxygen species (ROS) generation and associated side effects. Others, such as curcumin itself, directly interfere with cellular processes like cell cycle progression, proliferation, apoptosis, and autophagy within tumor cells.  Essentially, radioprotectors focus on prevention, radiomitigators on post-treatment reduction of toxicity, and radiosensitizers on increasing the effectiveness of radiation against cancerous tissue.","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.6	 Exercise Solutions | Content: SQ1.	The detailed mechanisms are described in Sect. 11.1.1.
The possible mechanisms are listed in Box 11.2 as
well.
SQ2.	Radioprotectors, which should be safe and nontoxic
for human health, are used to protect the normal cells
or nontumor cells from the harmful insults of ionizing
irradiation and to increase survival rate in patients
when administered before the exposure to radiation or
at the time of RT for their effectiveness.
SQ3.	The potential radioprotectors are often antioxidants,
but not all the antioxidants are radioprotectors.
SQ4.	Radiomitigators are used to minimize the toxicity or
damage caused by ionizing irradiation in noncancer­
ous cells even after radiation has been delivered and
thus able to improve the effectiveness of radiation
therapy.
SQ5.	Yes. Radioprotective agents with potency to stimulate
the proliferation and modify the function of hemato­
poietic and immunopoietic stem cells, often referred to
as immunomodulators, can be considered as radiomit­
igators. The mode of action (MOA) of radiomitigators
is depicted in the figure (figure number will be
written).
SQ6.	Radiosensitizer is a chemical or pharmaceutical agent
which enhances the killing effect on tumor cells by
making them more susceptible/sensitive to radiation
therapy and at the same time having less effect on nor­
mal tissues/cells.
SQ7.	Curcumin has been shown to have a double-face
mechanism. Indeed, on the one hand, it is an antioxi­
dant and anti-inflammatory molecule, useful in limit­
ing the IR-induced ROS generation and IR side effects.
On the other, it acts as an anticancer molecule, inter­
acting with cellular processes, such as cell cycle, pro­
liferation, apoptosis, and autophagy.
SQ8.	Gd/water mass attenuation coefficient ratio @
100 keV = 72.6.
A. Montoro et al.
621
11.7"
"Following internal radionuclide contamination, what are the key considerations regarding the selection and administration of radiomitigators, and how do their mechanisms of action contribute to mitigating radiation damage?","Radiomitigators represent a critical component of medical countermeasures designed to reduce the severity of injury following internal radionuclide exposure. Their primary goal is to enhance cellular repair processes and bolster antioxidant defenses within tissues exposed to ionizing radiation. The selection of an appropriate radiomitigator depends heavily on several factors, including the specific radionuclides involved, the dose received, the route of exposure (e.g., intravenous, oral), and the target tissue(s) affected. Generally, radiomitigators fall into a few broad categories with distinct mechanisms:

*   **Antioxidants:** Many radiomitigators function as potent antioxidants to combat oxidative stress – a major contributor to radiation damage. Elevated levels of reactive oxygen species (ROS) generated by ionizing radiation overwhelm cellular antioxidant defenses, leading to DNA strand breaks, lipid peroxidation, and protein oxidation. Examples include ascorbic acid (vitamin C), glutathione precursors, and selenium. These compounds directly scavenge ROS or enhance the production of endogenous antioxidants.
*   **DNA Repair Enhancers:** Some radiomitigators stimulate the cell’s own DNA repair mechanisms. This can involve increasing the expression of DNA repair enzymes or promoting more efficient repair processes. For instance, certain nucleotide analogs may be incorporated into damaged DNA, triggering repair pathways.
*   **Cellular Protective Agents:** Certain compounds can directly protect cells from radiation damage by modulating cellular signaling pathways involved in stress response and apoptosis (programmed cell death). This might involve activating survival factors or inhibiting apoptotic signals.

The effectiveness of a radiomitigator hinges on its ability to rapidly neutralize ROS, support DNA repair, and maintain cellular viability. The timing of administration is also crucial; early intervention after exposure is generally more effective than delayed treatment. It’s important to note that the precise mechanism of action can vary depending on the specific compound and the radiation environment.

Reference: [Document Name], Section 11.7 Annex 1","Document: MolecularRadiationBiology | Section: 11: Radioprotectors, Radiomitigators, and Radiosensitizers | Subsection: 11.7	 Annex 1 | Content: Contamination by radionuclides and medical countermeasures (MCMs)
Radiation
type
Element
Radioactive
half-life
Major exposure pathwaysFocal accumulation
Medical countermeasure for internal contamination
Mechanism of action"
"Radiological protection is presented as a multifaceted concept extending beyond simply quantifying radiation dose. Elaborate on the key factors that contribute to determining the acceptability of radiation risks, drawing upon the principles outlined within this framework.","The acceptability of radiation risks isn't solely determined by the numerical value of the received dose; it’s fundamentally rooted in a complex interplay of scientific understanding, ethical considerations, and societal values. The core concept of justification within radiological protection highlights that risk assessment must be guided by principles like justice, dignity, and autonomy. This means acknowledging uncertainties inherent in radiation effects – both biological and social – and considering the potential impacts on different populations unequally affected by exposure. Furthermore, acceptability requires a holistic evaluation encompassing not just dose but also factors such as: the type of radiation (alpha, beta, gamma, etc.), the duration and frequency of exposure, the individual’s vulnerability (age, health status), and the potential for cumulative effects. Risk perception itself plays a crucial role; individuals may react differently to the same risk based on their beliefs, values, and prior experiences. Effective communication strategies are therefore essential to translate scientific data into understandable and acceptable risks for the public, acknowledging value pluralism and incorporating theory-based, evidence-driven approaches.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Content: e-mail: socol@jct.ac.il
Learning Objectives
•	To recognize that radiological protection is a matter
of science and values.
•	To appreciate that the acceptability of radiation
risks needs to take into account more than the radia­
tion dose alone.
•	To identify risk perception and risk perception
characteristics.
•	To understand justification, being the first pillar of
the system of radiological protection, as a principle
instructed by the ethical values of justice, dignity,
and autonomy.
•	To understand the relevant underlying principles of
nuclear law.
•	To be aware of the general frameworks relating to
nuclear law.
•	To understand the difference between nuclear lia­
bility and general tortious liability.
•	To realize that radiation risk communication should
be theory-based, evidence-driven, and strategic.
•	To get insight into how to communicate with gen­
eral public and mass media about radiobiology.
•	To get insight into the functioning of science and its
impact on policy taking into account uncertainties
and value pluralisms.
© The Author(s) 2023
S. Baatout (ed.), Radiobiology Textbook, https://doi.org/10.1007/978-3-031-18810-7_12"
The text discusses human exposure to ionizing radiation. What are the primary sources contributing to this natural background radiation?,"Human exposure to ionizing radiation primarily stems from two sources: cosmic rays and radioactivity within the Earth’s continental crust. Cosmic rays originate from outside our planet, penetrating the atmosphere and reaching the surface. Simultaneously, rocks composing the continental crust contain naturally occurring radioactive elements such as uranium, thorium, and potassium-40. The decay of these isotopes continuously emits ionizing radiation, contributing significantly to the overall background radiation levels experienced by humans.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.1	 Introduction | Content: Ionizing radiation and radioactive substances can be natural
or human-made. Humans have always been exposed to natu­
ral ionizing radiation (background radiation), because of the
exposure of the Earth’s surface to cosmic rays and the radio­
activity contained in rocks that form the continental crust.
The use of radiation and radioactive substances in medicine,
research, industry, agriculture, and teaching, as well as the
generation of nuclear power, have brought important benefits
to society. Acceptance by society of the risks associated with
radiation depends on the perceived relationship between
these risks and the benefits to be gained from the use of
radioactive sources. Logically, risks must be limited, and
adequate protection provided. This does not mean that indi­
viduals or the environment must be protected from any and
A. Dobney (*)
Queen Mary University of London, London, United Kingdom
A. J. González
Argentine Nuclear Regulatory Authority, Buenos Aires, Argentina
D. Oughton
Norwegian University of Life Sciences (NMBU), Ås, Norway
e-mail: deborah.oughton@nmbu.no
F. Romain
University of Manchester, Manchester, United Kingdom
G. Meskens
Science and Technology Studies Unit, Belgian Nuclear Research
Centre, SCK CEN, Mol, Belgium
Centre for Ethics and Value Inquiry, Ghent University, Ghent,
Belgium
e-mail: gaston.meskens@sckcen.be
M. Bourguignon
University of Paris Saclay (UVSQ), Paris, France
T. Wils
Catholic University of Leuven (KU Leuven), Leuven, Belgium
T. Perko
Belgian Nuclear Research Centre, SCK CEN, Mol, Belgium
University of Antwerp, Antwerp, Belgium
e-mail: tanja.perko@sckcen.be
Y. Socol
Jerusalem College of Technology, Jerusalem, Israel
e-mail: socol@jct.ac.il
Learning Objectives
•	To recognize that radiological protection is a matter
of science and values.
•	To appreciate that the acceptability of radiation
risks needs to take into account more than the radia­
tion dose alone.
•	To identify risk perception and risk perception
characteristics.
•	To understand justification, being the first pillar of"
"The text describes the development of the radiological protection system, highlighting key organizations like ICRU and ICRP. Explain how the concepts of absorbed dose (Gray), equivalent dose (Sievert), and effective dose (Sievert) were established within this system to quantify radiation risk and its biological effects.","Following early observations of radiation-induced health issues, particularly the leukemia epidemic among radiologists, the International Society of Radiology initiated efforts to quantify radiation exposure. This led to the creation of the ICRU in 1925, which focused on dose quantification. To address the varying biological impacts of different types of ionizing radiation, two key units were introduced: the Gray (Gy) for absorbed dose – representing energy deposited per unit mass – and the Sievert (Sv) for equivalent dose. The Sievert incorporates a radiation weighting factor (WR), reflecting the relative biological effectiveness of different radiations, allowing conversion from absorbed dose to equivalent dose. Furthermore, a tissue weighting factor (WT) was developed to account for varying sensitivities of different tissues to radiation damage, ultimately calculating the effective dose (E) – representing the overall risk to an individual by summing the weighted contributions from all organs.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.2	 The Radiological Protection System | Content: After the initial and isolated observations of the first health
effects of ionizing radiation (i.e., skin burns and cancers) by
the pioneers at the turn of the nineteenth and twentieth cen­
turies, two decades passed before a clear need for radiation
protection was identified. One of the first signs was the leu­
kemia epidemic that developed among radiologists after
World War I, reflecting the use of X-ray radioscopy by mili­
tary surgeons, without any kind of protection, to localize
shrapnel in wounded soldiers. This epidemic lasted until the
1950s and affected approximately 500 radiologists [1].
To face the situation, the International Society of
Radiology created the International Committee on Radiation
Units (ICRU) in 1925 to develop the first concepts regarding
dose quantification which were obviously needed. This was
followed by the creation in 1928 of the International X-ray
and Radium Protection Committee which was restructured
in 1950 to take account of new uses of radiation outside the
medical area and then renamed the International Commission
on Radiological Protection (ICRP). Both ICRU and ICRP
are still major actors of radiological protection.
Although the radiological protection (RP) system was
established by ICRP, it is worth noticing the critical contribu­
tion of the United Nations Scientific Committee on the
Effects of Atomic Radiations (UNSCEAR) created in 1955.
The ICRP RP system is developed on the basis of the scien­
tific knowledge gathered and synthetised by UNSCEAR.
The ICRP publishes a wide range of recommendations
dealing with various aspects of radiological protection, but
the current RP system with the three principles of justifica­
tion, optimization, and dose limitation was first established
with recommendation 26 [2]. It has been updated since then
by recommendations ICRP 60 [3] and ICRP 103 [4].
12.2.1	Dosimetric Factors and Effects
of Ionizing Radiation
ICRP has designed dosimetric factors to properly quantify
the exposures to IR and then to establish links between dose
and effects. The absorbed dose D is the energy deposited in
the tissue: the unit of 1 J/kg is the Gray (Gy) in memory of
James Gray. To take into account that different types of radi­
ation do not produce the same biological effects for the same
absorbed dose, a radiation weighting factor WR is used to
convert the absorbed dose into the so-called equivalent dose
HR = WR⋅D. This unit is the Sievert (Sv) in memory of Rolf
Sievert. But the biological response also depends on the tis­
sue and a tissue weighting factor WT is used to convert the
equivalent dose for each organ to the so-called effective dose
E by adding the contributions of all organs E = ΣR,TWTHR,T.
The effective dose unit is still the Sv and when a dose is
given in Sv it is mandatory to indicate if it relates to an equiv­
alent dose or to an effective dose. Thus, only the absorbed
dose is a physical parameter. Equivalent and effective doses
are calculated parameters reflecting the likelihood of detri­
ments in humans.
The effects of IR have been classified for years into two
categories named deterministic and stochastic effects.
Deterministic effects, e.g., skin burns, are due to high doses
of ionizing radiation and the responsibility of radiation in
their occurrence is clear. Deterministic effects always occur
after a dose threshold is exceeded even though some indi­
vidual variation exists, and the severity of the effect increases
with dose. Stochastic effects, such as cancers, may occur
after exposure to ionizing radiation but it is only possible to
statistically express the occurrence. In other words, it is
impossible to say who will develop cancer and when it will
appear. One can only say that a percentage of cancers will
appear in a population of persons exposed to a given dose,
and the probability of developing cancer will increase with
dose. Partly because of relatively high background rates of
cancers in human populations, the establishment of a causal
relationship between exposure to ionizing radiation exposure
and the occurrence of cancer can be quite difficult (see
Chap. 4).
More recently the separation between deterministic and
stochastic effects does not appear to be so clear since some
effects may combine both approaches, such as radio-induced
cataracts. Therefore, ICRP now uses the classification tissue
effect instead of deterministic effects.
Risk evaluation has resulted from epidemiologic studies
that have established solid correlations (but not causality)
between the frequency of cancers and the dose of IR in the
dose range above 100 mGy. But ICRP recommendations are
not so clear since the same numerical value is given some­
times in Sv. The calculated risk of cancer is roughly 5% per
Sv of effective dose, while the risk to the developing fetus is
50% per Sv. The risk of hereditary disease has been esti­
mated as 0.5% per Sv based on animal models, although it
has not been documented so far in humans.
12.2.2	Practical Implementation of ICRP
Recommendations
Epidemiologic studies have paved the way for effective man­
agement of radiation protection with the three ICRP princi­
A. Dobney et al."
"Explain the concepts of absorbed dose, equivalent dose, and effective dose within the context of radiation exposure assessment, referencing the provided text’s explanation of these units.","Within the framework described, ‘absorbed dose’ represents a fundamental physical measurement of the energy deposited by ionizing radiation per unit mass of material. It is quantified in Grays (Gy), where 1 Gy equals one joule of energy absorbed per kilogram of tissue. However, simply knowing the absorbed dose doesn't fully capture the biological impact of radiation exposure. To account for this, a ‘radiation weighting factor’ (WR) is introduced. This factor adjusts the absorbed dose to reflect the specific type of radiation encountered – alpha particles, beta particles, gamma rays, etc. – and their relative damaging potential. The resulting unit, the ‘equivalent dose,’ is calculated as HR = WR ⋅ D, where HR stands for equivalent dose and is measured in Sieverts (Sv). One Sv represents one joule of energy deposited per kilogram of tissue, taking into account the radiation weighting factor. Finally, recognizing that different tissues exhibit varying sensitivities to radiation damage, a ‘tissue weighting factor’ (WT) is employed. This WT accounts for the fact that organs like the thyroid or bone marrow are more susceptible to radiation effects than others, such as skin. The ‘effective dose’ (E) is then calculated by summing the equivalent doses for each organ in the body: E = Σ(R ⋅ TW ⋅ H), where R represents the equivalent dose to a specific tissue, TW is the tissue weighting factor for that tissue, and H represents the equivalent dose itself. The effective dose unit is also measured in Sieverts (Sv) and provides a comprehensive measure of the overall risk associated with radiation exposure by considering both the type of radiation and its impact on different tissues within an organism.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.2	 The Radiological Protection System | Sub-subsection: 12.2.1	 Dosimetric Factors and Effects of Ionizing Radiation | Content: absorbed dose, a radiation weighting factor WR is used to
convert the absorbed dose into the so-called equivalent dose
HR = WR⋅D. This unit is the Sievert (Sv) in memory of Rolf
Sievert. But the biological response also depends on the tis­
sue and a tissue weighting factor WT is used to convert the
equivalent dose for each organ to the so-called effective dose
E by adding the contributions of all organs E = ΣR,TWTHR,T.
The effective dose unit is still the Sv and when a dose is
given in Sv it is mandatory to indicate if it relates to an equiv­
alent dose or to an effective dose. Thus, only the absorbed
dose is a physical parameter. Equivalent and effective doses
are calculated parameters reflecting the likelihood of detri­
ments in humans.
The effects of IR have been classified for years into two
categories named deterministic and stochastic effects.
Deterministic effects, e.g., skin burns, are due to high doses
of ionizing radiation and the responsibility of radiation in
their occurrence is clear. Deterministic effects always occur
after a dose threshold is exceeded even though some indi­
vidual variation exists, and the severity of the effect increases
with dose. Stochastic effects, such as cancers, may occur
after exposure to ionizing radiation but it is only possible to
statistically express the occurrence. In other words, it is
impossible to say who will develop cancer and when it will
appear. One can only say that a percentage of cancers will
appear in a population of persons exposed to a given dose,
and the probability of developing cancer will increase with
dose. Partly because of relatively high background rates of
cancers in human populations, the establishment of a causal
relationship between exposure to ionizing radiation exposure
and the occurrence of cancer can be quite difficult (see
Chap. 4).
More recently the separation between deterministic and
stochastic effects does not appear to be so clear since some
effects may combine both approaches, such as radio-induced
cataracts. Therefore, ICRP now uses the classification tissue
effect instead of deterministic effects.
Risk evaluation has resulted from epidemiologic studies
that have established solid correlations (but not causality)
between the frequency of cancers and the dose of IR in the
dose range above 100 mGy. But ICRP recommendations are
not so clear since the same numerical value is given some­
times in Sv. The calculated risk of cancer is roughly 5% per
Sv of effective dose, while the risk to the developing fetus is
50% per Sv. The risk of hereditary disease has been esti­
mated as 0.5% per Sv based on animal models, although it
has not been documented so far in humans."
"According to the ICRP's recommendations, what are the three primary principles governing radiological protection, and how do they relate to minimizing radiation risks?","The International Commission on Radiological Protection (ICRP) establishes radiological protection based on three core principles: justification of all exposures, optimization of justified exposures (following the ALARA principle – As Low As Reasonably Achievable), and limitation of doses for workers and the population. These principles aim to suppress deterministic effects and substantially minimize the probability of stochastic effects associated with radiation exposure. The ALARA principle specifically focuses on reducing exposure levels to the lowest possible level, considering both technical feasibility and societal factors.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.2	 The Radiological Protection System | Sub-subsection: 12.2.2	 Practical Implementation of ICRP Recommendations | Content: absorbed dose, a radiation weighting factor WR is used to
convert the absorbed dose into the so-called equivalent dose
HR = WR⋅D. This unit is the Sievert (Sv) in memory of Rolf
Sievert. But the biological response also depends on the tis­
sue and a tissue weighting factor WT is used to convert the
equivalent dose for each organ to the so-called effective dose
E by adding the contributions of all organs E = ΣR,TWTHR,T.
The effective dose unit is still the Sv and when a dose is
given in Sv it is mandatory to indicate if it relates to an equiv­
alent dose or to an effective dose. Thus, only the absorbed
dose is a physical parameter. Equivalent and effective doses
are calculated parameters reflecting the likelihood of detri­
ments in humans.
The effects of IR have been classified for years into two
categories named deterministic and stochastic effects.
Deterministic effects, e.g., skin burns, are due to high doses
of ionizing radiation and the responsibility of radiation in
their occurrence is clear. Deterministic effects always occur
after a dose threshold is exceeded even though some indi­
vidual variation exists, and the severity of the effect increases
with dose. Stochastic effects, such as cancers, may occur
after exposure to ionizing radiation but it is only possible to
statistically express the occurrence. In other words, it is
impossible to say who will develop cancer and when it will
appear. One can only say that a percentage of cancers will
appear in a population of persons exposed to a given dose,
and the probability of developing cancer will increase with
dose. Partly because of relatively high background rates of
cancers in human populations, the establishment of a causal
relationship between exposure to ionizing radiation exposure
and the occurrence of cancer can be quite difficult (see
Chap. 4).
More recently the separation between deterministic and
stochastic effects does not appear to be so clear since some
effects may combine both approaches, such as radio-induced
cataracts. Therefore, ICRP now uses the classification tissue
effect instead of deterministic effects.
Risk evaluation has resulted from epidemiologic studies
that have established solid correlations (but not causality)
between the frequency of cancers and the dose of IR in the
dose range above 100 mGy. But ICRP recommendations are
not so clear since the same numerical value is given some­
times in Sv. The calculated risk of cancer is roughly 5% per
Sv of effective dose, while the risk to the developing fetus is
50% per Sv. The risk of hereditary disease has been esti­
mated as 0.5% per Sv based on animal models, although it
has not been documented so far in humans.
12.2.2	Practical Implementation of ICRP
Recommendations
Epidemiologic studies have paved the way for effective man­
agement of radiation protection with the three ICRP princi­
A. Dobney et al.
631
ples of radiological protection, i.e., justification of all
exposures, optimization of the justified exposures (ALARA
principle), and limitation of doses for the workers and the
population. Dose limitation does not apply for patients
because doses need to be adapted for both diagnosis and
treatment. The overarching goal was to suppress the deter­
ministic effects and to substantially minimize the probability
of the occurrence of stochastic effects.
On the basis of scientific evidence, ICRP has progres­
sively recommended the mandatory decrease in the exposure
to the level of low doses. The actual exposure of workers to
ionizing radiation has clearly decreased over the years and is
now in the order of or below 1 mSv/year of effective dose in
most countries, although the legal limit is still 20 mSv/year
for the effective dose. The dose limit of 1 mSv effective dose
for the public is below the variations of natural background.
At present, the dose limits of the system of radiological pro­
tection are quite low and are therefore not foreseen to be
changed in the near future. However, doses from medical
exposures are still steadily rising.
The ethical foundations of the system of radiological pro­
tection were reviewed by ICRP in its publication 138 [5].
This underlined that radiological protection is not only a mat­
ter of science but has been developed on ethical values either
intentionally or indirectly. Four core ethical values (benefi­
cence/non-maleficence, prudence, justice, and dignity) under­
pin the present system and relate to the three principles of
radiological protection. This publication also addresses key
procedural values (accountability, transparency, and inclu­
siveness) required for the practical implementation of the sys­
tem (see the following section for more details).
Although the system of radiological protection developed
and updated by ICRP for more than eight decades has proved
robust and operational, there remain a number of ethical,
legal, and social challenges
•	Risk evaluation is a major concern since this drives the
allocation of resources for radiation protection. The
majority of doses in humans are in the low-dose range
with a very low risk of cancer. The effective dose should
not be used for risk evaluation for a specific individual
[4]. Regarding medical exposures, there is a need to
develop individual risk evaluation based on doses to the
organs exposed [6].
•	The human individual response to ionizing radiation
should be included in the system in order to optimize
radiological protection. This will be part of personalized
and predictive medicine, for example, in persons with a
high familial risk of cancer or in patients who are likely to
be repeatedly exposed to ionizing radiation for medical
reasons (especially children, women, prior to radiother­
apy or to repeated screening).
•	There should be an increased focus on communication
with the public and media. There is a need to understand
the psychological aspects of risk perception, especially
when these show diversion from the real exposures and
risks.
12.2.3	The Ethical Motivation for the Linear
Non-Threshold Hypothesis
Discussion about the meaning and appropriateness of the
acronym LNT has been central in the debate on radiation
protection against low-level exposure situations. As an acro­
nym, LNT is non-translatable; a fact that does not facilitate
communication. LNT is aimed to denote an imprecise
expression: “linear-non-threshold,” a short reference to the
relationship between the probability of suffering a radiation
health effect and the incurred radiation dose, following low
doses, low dose rate, radiation exposures.
It is to be noted that this imprecise acronym has been
widely used with different connotations by relevant profes­
sional communities, a conundrum that can be simplistically
summarized as follows:
•	For radiation biologists, LNT usually refers to a biologi­
cal hypothesis postulating that at low radiation doses a
given increment in dose will produce a directly propor­
tionate increment in the probability of incurring malig­
nancies or heritable effects attributable to radiation.
•	For radiation epidemiologists, LNT is an epidemiological
conjecture by which the incidence of effects per unit dose
measured at radiation exposure situations involving rela­
tively high doses delivered at relatively high dose rates,
where an epidemic of increases in malignancies have
been recorded, is presumed to occur also at radiation
exposure situations involving low doses and low dose
rates in spite that epidemiological evidence is not achiev­
able in such situations.
•	For radiation-protectionists, LNT represents a practical
operational model for managing radiation protection and
controlling that protection against additional doses
regardless of the level of accumulated dose, and, there­
fore, preventing discrimination—particularly age-related
labor discrimination in cases of occupational radiation
protection.
The wide and imprecise use of the acronym LNT without
clarification of its precise meaning has been a cause of
­serious confusion on the health effects attributable follow­
ing low dose, low dose rate, and radiation exposure
situations.
It could be succintly said that LNT is intended to mean a
practical model rather than a sophisticated scientific theory
and that it is based on the globally accepted principles of
ethical prudence and on labor rights for non-­discrimination—
long established by international undertakings.
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"The text discusses several interpretations of the ‘Linear Non-Threshold’ (LNT) hypothesis within radiation protection. Can you detail the distinct understandings of LNT held by radiation biologists, epidemiologists, and radiation-protectionists, highlighting the key differences in their application of this concept?","The Linear Non-Threshold (LNT) hypothesis has been subject to varied interpretations depending on the discipline applying it. Radiation biologists generally view LNT as a biological hypothesis asserting that even at extremely low doses, each additional unit of radiation dose directly increases the probability of inducing cancer or heritable genetic effects. This interpretation emphasizes a fundamental causal relationship between dose and risk, regardless of the magnitude of the dose. In contrast, radiation epidemiologists utilize LNT primarily as an epidemiological conjecture. They apply this framework when analyzing high-dose, high-rate exposures where statistically significant correlations between radiation exposure and increased incidence rates of malignancies have been observed. This approach assumes that similar relationships will hold at lower doses and rates, even if direct evidence is lacking due to the difficulty in accurately measuring such effects. Finally, radiation-protectionists interpret LNT as a practical operational model for managing risk regardless of dose level. This perspective prioritizes preventative measures and aims to eliminate any potential discrimination based on age or occupation related to radiation exposure, aligning with principles of ethical prudence and labor rights—a justification often rooted in international agreements. The differing interpretations stem from the contexts in which each group applies the hypothesis: biologists focus on fundamental biological mechanisms, epidemiologists analyze observed correlations, and protectionists utilize it for practical risk management. This ambiguity surrounding LNT’s precise meaning has contributed to confusion regarding health effects following low-dose exposures.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.2	 The Radiological Protection System | Sub-subsection: 12.2.3	 The Ethical Motivation for the Linear Non-Threshold Hypothesis | Content: reasons (especially children, women, prior to radiother­
apy or to repeated screening).
•	There should be an increased focus on communication
with the public and media. There is a need to understand
the psychological aspects of risk perception, especially
when these show diversion from the real exposures and
risks.
12.2.3	The Ethical Motivation for the Linear
Non-Threshold Hypothesis
Discussion about the meaning and appropriateness of the
acronym LNT has been central in the debate on radiation
protection against low-level exposure situations. As an acro­
nym, LNT is non-translatable; a fact that does not facilitate
communication. LNT is aimed to denote an imprecise
expression: “linear-non-threshold,” a short reference to the
relationship between the probability of suffering a radiation
health effect and the incurred radiation dose, following low
doses, low dose rate, radiation exposures.
It is to be noted that this imprecise acronym has been
widely used with different connotations by relevant profes­
sional communities, a conundrum that can be simplistically
summarized as follows:
•	For radiation biologists, LNT usually refers to a biologi­
cal hypothesis postulating that at low radiation doses a
given increment in dose will produce a directly propor­
tionate increment in the probability of incurring malig­
nancies or heritable effects attributable to radiation.
•	For radiation epidemiologists, LNT is an epidemiological
conjecture by which the incidence of effects per unit dose
measured at radiation exposure situations involving rela­
tively high doses delivered at relatively high dose rates,
where an epidemic of increases in malignancies have
been recorded, is presumed to occur also at radiation
exposure situations involving low doses and low dose
rates in spite that epidemiological evidence is not achiev­
able in such situations.
•	For radiation-protectionists, LNT represents a practical
operational model for managing radiation protection and
controlling that protection against additional doses
regardless of the level of accumulated dose, and, there­
fore, preventing discrimination—particularly age-related
labor discrimination in cases of occupational radiation
protection.
The wide and imprecise use of the acronym LNT without
clarification of its precise meaning has been a cause of
­serious confusion on the health effects attributable follow­
ing low dose, low dose rate, and radiation exposure
situations.
It could be succintly said that LNT is intended to mean a
practical model rather than a sophisticated scientific theory
and that it is based on the globally accepted principles of
ethical prudence and on labor rights for non-­discrimination—
long established by international undertakings."
"Describe the four distinct contexts of concern outlined in the text regarding radiological risk, detailing the specific types of radiation and associated justifications considered within each context.","The text identifies four key ‘contexts of concern’ when evaluating radiological risks, each demanding a unique approach to ethical assessment. First, there's the ‘naturally enhanced’ natural radiation context – characterized by elevated levels of naturally occurring elements like Radon. Justification here focuses on evaluating exposure and potential mitigation strategies due to the inherent presence of the radiation. Second is the context of ‘technically enhanced natural radiation,’ often seen in industries such as oil refining or aviation, where radiation emerges as a byproduct. Evaluation centers around contesting practices but primarily assesses exposure risks and potential protective measures. Third is the ‘peaceful applications’ context involving nuclear technology – encompassing fission/fusion for energy production, medical treatments (radiotherapy), and industrial uses of decay radiation. Justification here requires balancing projected benefits (energy generation, healthcare) with assessed risks, acknowledging differing opinions on those benefits. Finally, there's the ‘use of nuclear technology as a weapon’ context, representing a fundamentally contested scenario where justification is impossible due to the inherently neutral nature of the application itself – whether viewed through a pacifist or power-oriented lens.  Each context necessitates a distinct evaluation framework based on its specific circumstances and potential impacts. Reference: [12.3 Ethical Aspects of Radiation Exposure]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Content: 12.3.1	Radioactivity and Justification: Raising
Awareness for the Contexts of Concern
What are we speaking about when we speak about ethical,
legal, social, and psychological aspects in relation to the
radiological risk? Dealing with radioactivity in society is a
complex challenge in any respect, but one can distinguish
four fundamental “contexts of concern” that require different
visions on complexity, and what it would mean to responsi­
bly deal with it. When considering ethical, legal, social, and
psychological aspects of radiation exposure, it is important
to always do this with the context of application or “the con­
text of concern,” in mind.
The first context is the context of “naturally enhanced”
natural radiation. The second context concerns industrial
practices that involve technically enhanced natural radiation.
The third context is the context of peaceful applications of
nuclear technology. These include applications of nuclear
physics processes, such as the fission or fusion of nuclei for
energy production or the use of decay radiation in medical
treatment and diagnosis or for industrial purposes. The fourth
context is the use of nuclear technology or material as a
weapon, either as a means for political deterrence, in orga­
nized military operation or in terrorist actions.
The reason to distinguish these different contexts is moti­
vated by a specific understanding of the ethics of radiologi­
cal risk governance and its relation to the social and political
aspects of governance, and this as well in theory as in prac­
tice. To put it simply, if we consider average natural back­
ground radiation as an element of our natural habitat, then
any significantly enhanced level of radioactivity in the vicin­
ity of living species represents a risk—in the sense of a
potential harm—to the health of those living species. In these
cases, pragmatic reasoning thus requires us to consider the
possibility of protection, mitigation, or avoidance, but essen­
tially to first evaluate why the additional radioactivity occurs
in the first place, and whether we can possibly justify it. But
whether that justification exercise can be done meaningfully
or not depends on how we perceive the context of the occur­
rence of radiation.
From what the first context is concerned, whether we
want it or not, natural radiation is there and any naturally
enhanced occurrence (e.g., in the case of high concentrations
of Radon) has a potential impact on health. Thinking in terms
of justification of the presence of that radiation is meaning­
less, which leaves us with evaluating the justification of
exposure, and thus of the possibility of protection, mitiga­
tion, or avoidance of its impact.
In the second context of technically enhanced natural
radiation (for example, in the oil refinery industry or in avia­
tion), radiation exposure manifests as a “side effect.”
Practices as such may be contested (as is the case with the oil
or phosphate industry), but very rarely the issue of radiation
exposure will become a decisive factor in the evaluation of
the justification of these practices. Similar to the case of nat­
urally enhanced natural radiation, the radiation justification
exercise thus restricts itself to the evaluation of exposure,
and thus to the evaluation of the possibility of protection,
mitigation, or avoidance of its impact.
In the third context, evaluation of the justification of the
use of nuclear technology obviously takes the reason for that
proposed use (the projected “benefits”) as a first criterion,
with the aim to “balance” it with the projected risks. Despite
the fact that opinions on these projected benefits and risks
differ among people, in this context, an evaluation of the jus­
tification of the use of a risk-inherent technology, or thus of
the presence or “creation” of radiation, remains meaningful,
and this is because the application context is “neutral”; while
opinions may differ on how to produce energy or perform a
medical treatment, nobody is “against energy” or “against
medical care” as such. The neutral context thus makes a
meaningful joint evaluation of the justification of the nuclear
technology application possible, and it will not affect possi­
ble outcomes (rejection or acceptance of the technology) as
such.
Finally, in the fourth context, a meaningful joint evalua­
tion of the justification of (the risk of) the nuclear technology
application is not possible, and this is for the reason that the
context of application itself is not neutral. A pacifist perspec­
tive does not support a principal justification of nuclear
deterrence and armed conflict strategies, while, in a perspec­
tive that sees politics always as a politics of power and con­
flict, these strategies may be perceived as justified.
12.3.2	The Justice of Justification as a Central
Ethical Concern
Any evaluation of the acceptability of a radiological risk is
characterized by a “double” complexity. Firstly, it needs to
take into account the uncertainties with regard to whether
and how the risk will manifest. Science has an authoritative
voice in this evaluation, but it needs to recognize that there
will always be uncertainties that cannot be cleared out (sto­
chasticity of biological effects at low radiation dose, possible
delayed harm of medical diagnosis or therapy, the possibility
of a nuclear accident, the fate of a radioactive waste disposal
site in the far future, …). In addition, we have to accept that
important factors remain to a large degree beyond control:
human behavior, nature, time, and potential misuse of tech­
nology… Secondly, an evaluation of the acceptability of a
radiological risk also needs to consider diverse value judg­
A. Dobney et al."
"The text describes several contexts in which evaluating radiation exposure justification occurs. Can you detail the key distinctions between these contexts regarding the evaluation process and the factors considered, specifically highlighting how differing perspectives influence the assessment of risk?","The text outlines four distinct contexts for justifying radiation exposure, each presenting unique challenges to the evaluation process. Initially, in technically enhanced environments like oil refineries or aviation, radiation exposure is treated as a ‘side effect,’ primarily assessed through the possibility of protection, mitigation, or avoidance. This approach focuses on minimizing exposure without necessarily considering the underlying justification for utilizing potentially hazardous technologies. Secondly, when evaluating nuclear technology use – such as energy production or medical treatments – the evaluation balances projected benefits with projected risks, acknowledging differing opinions regarding these projections. Crucially, this context operates within a ‘neutral’ framework where objections to the technology itself (e.g., ‘against energy’ or ‘against medical care’) are absent, allowing for a comparative assessment of risk and benefit. However, this neutrality is challenged in the fourth context: when radiation exposure is linked to nuclear deterrence or armed conflict strategies. Here, the evaluation becomes deeply politicized, influenced by fundamentally opposed value systems – specifically, pacifist perspectives versus those prioritizing power dynamics and conflict. This context demonstrates that a meaningful justification cannot be achieved due to the inherently non-neutral nature of the application itself. The double complexity inherent in any radiological risk assessment is highlighted: firstly, acknowledging inherent scientific uncertainties (like stochastic biological effects or long-term consequences) alongside uncontrollable factors like human behavior and time; secondly, recognizing the diverse value judgments that shape perceptions of risk and influence the acceptability of the technology based on differing ethical and political viewpoints. Reference: A. Dobney et al., 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure > 12.3 Ethical Aspects of Radiation Exposure > 12.3.1 Radioactivity and Justification","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.1	 Radioactivity and Justification: Raising Awareness for the Contexts of Concern | Content: In the second context of technically enhanced natural
radiation (for example, in the oil refinery industry or in avia­
tion), radiation exposure manifests as a “side effect.”
Practices as such may be contested (as is the case with the oil
or phosphate industry), but very rarely the issue of radiation
exposure will become a decisive factor in the evaluation of
the justification of these practices. Similar to the case of nat­
urally enhanced natural radiation, the radiation justification
exercise thus restricts itself to the evaluation of exposure,
and thus to the evaluation of the possibility of protection,
mitigation, or avoidance of its impact.
In the third context, evaluation of the justification of the
use of nuclear technology obviously takes the reason for that
proposed use (the projected “benefits”) as a first criterion,
with the aim to “balance” it with the projected risks. Despite
the fact that opinions on these projected benefits and risks
differ among people, in this context, an evaluation of the jus­
tification of the use of a risk-inherent technology, or thus of
the presence or “creation” of radiation, remains meaningful,
and this is because the application context is “neutral”; while
opinions may differ on how to produce energy or perform a
medical treatment, nobody is “against energy” or “against
medical care” as such. The neutral context thus makes a
meaningful joint evaluation of the justification of the nuclear
technology application possible, and it will not affect possi­
ble outcomes (rejection or acceptance of the technology) as
such.
Finally, in the fourth context, a meaningful joint evalua­
tion of the justification of (the risk of) the nuclear technology
application is not possible, and this is for the reason that the
context of application itself is not neutral. A pacifist perspec­
tive does not support a principal justification of nuclear
deterrence and armed conflict strategies, while, in a perspec­
tive that sees politics always as a politics of power and con­
flict, these strategies may be perceived as justified.
12.3.2	The Justice of Justification as a Central
Ethical Concern
Any evaluation of the acceptability of a radiological risk is
characterized by a “double” complexity. Firstly, it needs to
take into account the uncertainties with regard to whether
and how the risk will manifest. Science has an authoritative
voice in this evaluation, but it needs to recognize that there
will always be uncertainties that cannot be cleared out (sto­
chasticity of biological effects at low radiation dose, possible
delayed harm of medical diagnosis or therapy, the possibility
of a nuclear accident, the fate of a radioactive waste disposal
site in the far future, …). In addition, we have to accept that
important factors remain to a large degree beyond control:
human behavior, nature, time, and potential misuse of tech­
nology… Secondly, an evaluation of the acceptability of a
radiological risk also needs to consider diverse value judg­
A. Dobney et al."
"Within the context of justifying radiation exposure, particularly in technically enhanced environments like oil refineries or aviation, what are the two primary complexities identified regarding risk evaluation beyond purely scientific uncertainty?","The core challenges in ethically justifying radiological risks extend beyond simply acknowledging scientific uncertainties. Firstly, evaluations require consideration of diverse value judgments concerning acceptability – a phenomenon known as moral pluralism. Even if all parties agree on the scientific data, differing values such as freedom, security, or environmental protection can lead to conflicting assessments of risk. Secondly, the evaluation process necessitates deliberation among all potentially affected individuals and groups, recognizing that science alone cannot dictate choices. The authority rests with the ‘authority of conversation,’ emphasizing participatory decision-making rather than a top-down approach driven solely by expert opinion. Reference: [A. Dobney et al., Section 12.3.2 – The Justice of Justification as a Central Ethical Concern]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.2	 The Justice of Justification as a Central Ethical Concern | Content: In the second context of technically enhanced natural
radiation (for example, in the oil refinery industry or in avia­
tion), radiation exposure manifests as a “side effect.”
Practices as such may be contested (as is the case with the oil
or phosphate industry), but very rarely the issue of radiation
exposure will become a decisive factor in the evaluation of
the justification of these practices. Similar to the case of nat­
urally enhanced natural radiation, the radiation justification
exercise thus restricts itself to the evaluation of exposure,
and thus to the evaluation of the possibility of protection,
mitigation, or avoidance of its impact.
In the third context, evaluation of the justification of the
use of nuclear technology obviously takes the reason for that
proposed use (the projected “benefits”) as a first criterion,
with the aim to “balance” it with the projected risks. Despite
the fact that opinions on these projected benefits and risks
differ among people, in this context, an evaluation of the jus­
tification of the use of a risk-inherent technology, or thus of
the presence or “creation” of radiation, remains meaningful,
and this is because the application context is “neutral”; while
opinions may differ on how to produce energy or perform a
medical treatment, nobody is “against energy” or “against
medical care” as such. The neutral context thus makes a
meaningful joint evaluation of the justification of the nuclear
technology application possible, and it will not affect possi­
ble outcomes (rejection or acceptance of the technology) as
such.
Finally, in the fourth context, a meaningful joint evalua­
tion of the justification of (the risk of) the nuclear technology
application is not possible, and this is for the reason that the
context of application itself is not neutral. A pacifist perspec­
tive does not support a principal justification of nuclear
deterrence and armed conflict strategies, while, in a perspec­
tive that sees politics always as a politics of power and con­
flict, these strategies may be perceived as justified.
12.3.2	The Justice of Justification as a Central
Ethical Concern
Any evaluation of the acceptability of a radiological risk is
characterized by a “double” complexity. Firstly, it needs to
take into account the uncertainties with regard to whether
and how the risk will manifest. Science has an authoritative
voice in this evaluation, but it needs to recognize that there
will always be uncertainties that cannot be cleared out (sto­
chasticity of biological effects at low radiation dose, possible
delayed harm of medical diagnosis or therapy, the possibility
of a nuclear accident, the fate of a radioactive waste disposal
site in the far future, …). In addition, we have to accept that
important factors remain to a large degree beyond control:
human behavior, nature, time, and potential misuse of tech­
nology… Secondly, an evaluation of the acceptability of a
radiological risk also needs to consider diverse value judg­
A. Dobney et al.
633
ments with regard to the acceptability of the risk. In philo­
sophical terms, one can say that the evaluation is troubled by
moral pluralism: even if we would all agree on the scientific
knowledge base for the assessment of the risk, then opinions
on its acceptability could still differ. The reason is that evalu­
ations of acceptability do not only rely on “knowledge” but
are also influenced by references to things people value as
important, such as freedom, security, the value of nature, the
rights of the next generations, and their safety and that of
their loved ones. In that case, science may thus inform the
technical and societal aspects of options, it cannot instruct or
clarify the choice to make.
Taking this complexity into account, one may understand
that risk cannot be justified through a one-directional “con­
vincing explanation” by scientific experts or political
decision-­makers. Ethics supports the idea that the evaluation
of a possible justification of a radiological risk needs to be
done in deliberation among all concerned, including those
potentially affected by the risk. In that deliberation, visions
from science, policy, civil society, and citizens have an equal
place, bearing in mind that (quoting the philosopher Philip
Kitcher) “There are no ethical experts. The only authority is
the authority of conversation” [7]. Obviously, the outcome of
that conversation can either be to reject or to accept the
radiological risk. In other words, from an ethical perspective,
the argument is that the justice of justification, ensured by
the possibility of self-determination of the potentially
affected, should be the central concern of risk governance. In
practice, that means formal methods for decision-making
and formal procedures within the organization should care
for the possibility of participation of those potentially
affected by the radiological risk.
12.3.3	Recognizing the Limits
of the Radiological Protection System
for Risk Justification
Seen from a different perspective, ethics in relation to radio­
logical protection is also about considering and recognizing
the limits of the radiological protection system when it
comes to providing a rationale for justification of radiation
risk. In other words, we cannot question the ethical dimen­
sions of the radiological protection system without also
questioning the ethical dimensions of the “bigger” systems
in which the radiological protection system operates and on
which it depends. Given that the radiological protection sys­
tem, in its concern for providing guidance for decision-­
making, relies on science but also and essentially wants to
take into account human and societal values, the bigger sys­
tems that need to be questioned in terms of their ethics, are
those of knowledge production (research and policy advice)
and decision-making. For risks that manifest in medical
diagnostic or therapeutic practices, that “system” is the pos­
sibility of deliberative dialog between the patient, the doctor,
the nurse, the radiation control and protection service of the
hospital, other hospital agencies, as well as regulatory and
professional bodies. For risks that manifest in an occupa­
tional context, the system of decision-making is the radiation
control and protection service, the management system of
the organization, other relevant agencies, trade unions, and
professional bodies. For risks that manifest on a societal
level, that system of decision-making is the system of democ­
racy, including input from citizens, civil society, trade unions,
professional bodies, advocacy groups, and of scientific and
ethical advisory committees.
12.3.4	The Ethical Foundations of the System
of Radiological Protection
The evolving ethics of the developing international system of
protection against ionizing radiation could be viewed as the
branch of some kind of embryonic radiological protection
philosophy, which from the beginning of the profession was
dealing with main protection principles and their values. It
challenged questions about the morality of the protection
principles—that is, concepts such as good and bad, right and
wrong, virtue and vice in radiological protection. It tried to
tackle issues such as the meaning and reference of moral
propositions on radiological protection; the practical means
of determining a moral protective action, how moral protec­
tive outcomes can be achieved in specific situations, how a
moral capacity for recommending a protection paradigm
develops and what its nature should be and what moral val­
ues on radiological protection people in general and stake­
holders in particular should actually abide by.
Ethics was the primordial earliest concept for judging
human actions such as those involved in radiological protec­
tion and provides its fundamental basis. Radioprotectionists
had been (and continue to be) very keen on exploring and
reassessing the rules and standards governing their profes­
sional conduct. They have had an unusual curiosity to self-­
inspect whether they hold the right behavior and what is the
set of principles for self-ensuring that such behavior is right.
This interest in self-appraisal of conduct correlates with the
notion of ethics.
The ethical basis of radiological protection was early rec­
ognized by the profession’s forefathers [1]. The primordial
radiation protection principle related to individuals (in fact
these individuals were at the beginning just radiologists; it
would take a number of years to incorporate individual mem­
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Describe the multifaceted system of decision-making surrounding radiation exposure risks across different contexts – medical, occupational, and societal – as outlined in the text. What key stakeholders are involved in each context, and what overarching ethical considerations drive this system?","The text details a tiered system for justifying radiation risk decisions, recognizing that the approach varies significantly depending on the scale of the exposure. In medical diagnostic or therapeutic practices, a deliberative dialog is established involving the patient, physician, nurse, and the hospital’s radiation control and protection service alongside regulatory and professional bodies. This emphasizes individualized assessment and informed consent. For occupational exposures, responsibility rests primarily with the radiation control and protection service and the organization's management system, supplemented by relevant agencies, trade unions, and professional bodies – reflecting a focus on worker safety and compliance. Finally, at a societal level, decision-making is governed by democratic processes, incorporating input from citizens, civil society organizations, trade unions, professional bodies, advocacy groups, and scientific/ethical advisory committees. This represents the broadest scope of risk assessment, considering potential impacts on public health and well-being.

The ethical foundation of this system centers around continually questioning the morality of protection principles – concepts like ‘good’ versus ‘bad,’ ‘right’ versus ‘wrong.’ Radioprotectionists have historically demonstrated a strong interest in self-assessment of their professional conduct, driven by an inherent ethical framework. This involves determining appropriate protective actions, achieving desired outcomes, and establishing moral values that stakeholders should adhere to. The system is designed to ensure accountability and promote responsible practices across all levels of radiation exposure management.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.3	 Recognizing the Limits of the Radiological Protection System for Risk Justification | Content: and decision-making. For risks that manifest in medical
diagnostic or therapeutic practices, that “system” is the pos­
sibility of deliberative dialog between the patient, the doctor,
the nurse, the radiation control and protection service of the
hospital, other hospital agencies, as well as regulatory and
professional bodies. For risks that manifest in an occupa­
tional context, the system of decision-making is the radiation
control and protection service, the management system of
the organization, other relevant agencies, trade unions, and
professional bodies. For risks that manifest on a societal
level, that system of decision-making is the system of democ­
racy, including input from citizens, civil society, trade unions,
professional bodies, advocacy groups, and of scientific and
ethical advisory committees.
12.3.4	The Ethical Foundations of the System
of Radiological Protection
The evolving ethics of the developing international system of
protection against ionizing radiation could be viewed as the
branch of some kind of embryonic radiological protection
philosophy, which from the beginning of the profession was
dealing with main protection principles and their values. It
challenged questions about the morality of the protection
principles—that is, concepts such as good and bad, right and
wrong, virtue and vice in radiological protection. It tried to
tackle issues such as the meaning and reference of moral
propositions on radiological protection; the practical means
of determining a moral protective action, how moral protec­
tive outcomes can be achieved in specific situations, how a
moral capacity for recommending a protection paradigm
develops and what its nature should be and what moral val­
ues on radiological protection people in general and stake­
holders in particular should actually abide by.
Ethics was the primordial earliest concept for judging
human actions such as those involved in radiological protec­
tion and provides its fundamental basis. Radioprotectionists
had been (and continue to be) very keen on exploring and
reassessing the rules and standards governing their profes­
sional conduct. They have had an unusual curiosity to self-­
inspect whether they hold the right behavior and what is the
set of principles for self-ensuring that such behavior is right.
This interest in self-appraisal of conduct correlates with the
notion of ethics.
The ethical basis of radiological protection was early rec­
ognized by the profession’s forefathers [1]. The primordial
radiation protection principle related to individuals (in fact
these individuals were at the beginning just radiologists; it
would take a number of years to incorporate individual mem­
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Describe the ethical principles initially established within radiological protection, outlining their underlying philosophical frameworks – specifically referencing deontological ethics, teleological ethics, utilitarian ethics, and arête ethics – and how these principles relate to protecting individuals versus broader societal or environmental concerns.","The foundational ethical framework for radiological protection emerged from a consideration of duty, consequence, optimization, and ultimately, intergenerational prudence. Initially, the principle of individual dose restrictions was rooted in deontological ethics, often summarized as ‘one should do unto others as they would have done unto them.’ This emphasized a responsibility to minimize harm to individuals exposed to radiation. Simultaneously, the principle of justification – utilizing teleological (consequence-based) ethics and expressed through the adage ‘the ends justify the means’ – demanded that any intervention involving radiation exposure must demonstrably produce more benefit than detriment. The principle of optimization, grounded in utilitarian ethics and the phrase ‘provide the greatest good for the greatest number,’ focused on minimizing overall doses while maximizing beneficial outcomes. Finally, the principle of intergenerational prudence, or protection of present and future generations, represented an ethical stance based on arête (virtue) ethics – striving for a standard of protection that transcends human nature and extends to all humanity and its environment, regardless of time or place. This highlights a shift from purely anthropocentric views towards broader considerations of sustainability and the well-being of both current and future populations, alongside their ecosystems. The differing ethical frameworks reflect distinct priorities: teleological and utilitarian ethics prioritize societal benefit, while deontological and arête ethics emphasize individual protection and inherent moral values.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.4	 The Ethical Foundations of the System of Radiological Protection | Content: and decision-making. For risks that manifest in medical
diagnostic or therapeutic practices, that “system” is the pos­
sibility of deliberative dialog between the patient, the doctor,
the nurse, the radiation control and protection service of the
hospital, other hospital agencies, as well as regulatory and
professional bodies. For risks that manifest in an occupa­
tional context, the system of decision-making is the radiation
control and protection service, the management system of
the organization, other relevant agencies, trade unions, and
professional bodies. For risks that manifest on a societal
level, that system of decision-making is the system of democ­
racy, including input from citizens, civil society, trade unions,
professional bodies, advocacy groups, and of scientific and
ethical advisory committees.
12.3.4	The Ethical Foundations of the System
of Radiological Protection
The evolving ethics of the developing international system of
protection against ionizing radiation could be viewed as the
branch of some kind of embryonic radiological protection
philosophy, which from the beginning of the profession was
dealing with main protection principles and their values. It
challenged questions about the morality of the protection
principles—that is, concepts such as good and bad, right and
wrong, virtue and vice in radiological protection. It tried to
tackle issues such as the meaning and reference of moral
propositions on radiological protection; the practical means
of determining a moral protective action, how moral protec­
tive outcomes can be achieved in specific situations, how a
moral capacity for recommending a protection paradigm
develops and what its nature should be and what moral val­
ues on radiological protection people in general and stake­
holders in particular should actually abide by.
Ethics was the primordial earliest concept for judging
human actions such as those involved in radiological protec­
tion and provides its fundamental basis. Radioprotectionists
had been (and continue to be) very keen on exploring and
reassessing the rules and standards governing their profes­
sional conduct. They have had an unusual curiosity to self-­
inspect whether they hold the right behavior and what is the
set of principles for self-ensuring that such behavior is right.
This interest in self-appraisal of conduct correlates with the
notion of ethics.
The ethical basis of radiological protection was early rec­
ognized by the profession’s forefathers [1]. The primordial
radiation protection principle related to individuals (in fact
these individuals were at the beginning just radiologists; it
would take a number of years to incorporate individual mem­
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
634
bers of the public, and some more to incorporate individual
patients undergoing radiodiagnostic or radiotherapy), as
follows:
•	The principle of individual dose restrictions, which was
aimed at ensuring that the total dose incurred by any indi­
vidual should be restricted to protect the individual
exposed. Although not explicitly, it was implicitly based
on an ethics of duty, the so-called deontological ethics,
which is usually expressed with the aphorism “One should
do unto others as they would have done unto them.”
Over time it became clear that the protection of individual
was a necessary but not necessarily a sufficient condition,
and the system of collective ethical requirements evolved.
Two basic principles would fill this gap, as follows:
•	The principle of justification, which was aimed at ensur­
ing that any decision that alters the radiation exposure
situation should do more good than harm—meaning that
by introducing new radiation sources or by intervening
for reducing existing doses, sufficient individual or soci­
etal benefit should be achieved to offset the detriment
such actions may cause. This principle was based on the
ethics of consequence or teleological ethics, which is usu­
ally expressed with the aphorism “The ends justify the
means.”
•	The principle of optimization, which aimed at ensuring
that the level of protection would be the best under the
prevailing circumstances, maximizing the margin of ben­
efit over harm, and thus the number of people exposed
and of their individual doses be kept as low as reasonably
achievable, taking into account economic and societal
factors. This was based on the ethics of efficacy or utili­
tarian ethics, which is usually expressed with the apho­
rism “Provide the greatest good for the greatest number of
people.”
These two principles and their ethics are the basis of the
radiation protection paradigm recommended by the ICRP.
In addition, there was an intrinsic value of these princi­
ples, or de facto principle in its own right, which unfortu­
nately was not specifically declared as such by ICRP, but
which is implicitly referred to in many statements and under­
lines most of the ICRP recommendations and it was recog­
nized in subsequent international standards. It could be
formulated as follows:
•	The principle of intergenerational prudence, also termed
principle of protection of present and future generations
in international standards, is aimed at ensuring that pro­
tection extends to all humanity and its environment,
regardless of where and when people live, and which
implies that all humans, present and future, and their envi­
ronment shall be afforded with a level of protection that is
not weaker than the level provided to those populations
causing the protection needs. It can be construed that this
important principle is mainly based on the ethics of virtue
or ethics of arête, which is usually expressed with the
aphorism “No return should be expected from good
actions, as goodness is an ideal that transcends human
nature.”.
Teleological and utilitarian ethics belong to a family of
“social-oriented” ethics; deontological and arête ethics
belong to a family of “individual-oriented” ethics. In relation
to radiation protection, teleological and utilitarian ethics aim
at protecting society as a whole, while deontological and vir­
tue ethics are more focused on individual protection and
individual rights. Teleological, utilitarian, and deontological
ethics have evolved in a mainly anthropocentric framework.
Conversely, arête ethics is able to deal with more general
ethical issues such as intergenerational and environmental
protection.
The start of the twenty-first century saw a growing criti­
cism of the anthropocentric focus of the system of radiologi­
cal protection, exemplified by the statement that “… the
standard of environmental control needed to protect man to
the degree though desirable will ensure that other species
are not put at risk” [3]. Critics noted that there were cases
where human doses could be low and doses to wildlife high
(e.g., waste disposal), that the approach was not in line with
management of other environmental stressors, and that there
was a need to demonstrate explicitly that non-human species
were being protected [8–10]. The IAEA published a report
on “Ethical Considerations in protection of the environment
from the effects of ionising radiation,” exploring ethical prin­
ciples that might underlie a system of protection and stress­
ing the need to be compatible with international legal
instruments such as those related to sustainability and pro­
tection of biodiversity [11]. The requirement to address the
impacts of ionizing radiation on the environment is now
included in international radiation protection recommenda­
tions and standards [4, 12, 13]."
"The ICRP’s ethical framework for radiological protection emphasizes several core values. Briefly describe how beneficence/non-maleficence, justice, dignity, and prudence contribute to the overall system, specifically addressing the complexities involved in measuring consequences and considering diverse stakeholders like animals and future generations.","The International Commission on Radiological Protection (ICRP) operates under a set of core ethical values designed to guide radiological protection practices. Beneficence/non-maleficence is fundamentally about minimizing harm from radiation exposure while actively promoting well-being, a task complicated by the need to evaluate both tangible and intangible costs – including economic impacts and societal benefits alongside direct health effects. Justice plays a crucial role in ensuring equitable distribution of risks and benefits related to radiation protection, acknowledging that vulnerable populations or future generations may disproportionately bear burdens. Dignity emphasizes respect for autonomy and self-determination, requiring engagement with affected communities and upholding individual rights throughout the process. Finally, prudence acknowledges the inherent uncertainty surrounding radiation risk assessments; it encourages discerning choices based on available information without complete knowledge of potential consequences, particularly when dealing with complex environmental interactions or long-term effects – a principle closely aligned with the precautionary approach. The complexities highlighted include grappling with how to measure outcomes that affect non-human species and future generations, recognizing differing values across cultures, and balancing immediate needs with long-term sustainability.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.5	 ICRP Core Ethical Values | Content: ronment shall be afforded with a level of protection that is
not weaker than the level provided to those populations
causing the protection needs. It can be construed that this
important principle is mainly based on the ethics of virtue
or ethics of arête, which is usually expressed with the
aphorism “No return should be expected from good
actions, as goodness is an ideal that transcends human
nature.”.
Teleological and utilitarian ethics belong to a family of
“social-oriented” ethics; deontological and arête ethics
belong to a family of “individual-oriented” ethics. In relation
to radiation protection, teleological and utilitarian ethics aim
at protecting society as a whole, while deontological and vir­
tue ethics are more focused on individual protection and
individual rights. Teleological, utilitarian, and deontological
ethics have evolved in a mainly anthropocentric framework.
Conversely, arête ethics is able to deal with more general
ethical issues such as intergenerational and environmental
protection.
The start of the twenty-first century saw a growing criti­
cism of the anthropocentric focus of the system of radiologi­
cal protection, exemplified by the statement that “… the
standard of environmental control needed to protect man to
the degree though desirable will ensure that other species
are not put at risk” [3]. Critics noted that there were cases
where human doses could be low and doses to wildlife high
(e.g., waste disposal), that the approach was not in line with
management of other environmental stressors, and that there
was a need to demonstrate explicitly that non-human species
were being protected [8–10]. The IAEA published a report
on “Ethical Considerations in protection of the environment
from the effects of ionising radiation,” exploring ethical prin­
ciples that might underlie a system of protection and stress­
ing the need to be compatible with international legal
instruments such as those related to sustainability and pro­
tection of biodiversity [11]. The requirement to address the
impacts of ionizing radiation on the environment is now
included in international radiation protection recommenda­
tions and standards [4, 12, 13].
12.3.5	ICRP Core Ethical Values
Previous writers have compared the ICRP principles with
ethical theories, highlighting the similarities between the
principle of justification with teleological or contractarian
ethics, the principle of optimization with utilitarian
approaches, and the principle of dose limitation with deon­
tological ethics [14, 15]. In its recent work on the ethical
foundations of radiological protection, ICRP has focused
on commonly recognized ethical values, rather than over­
A. Dobney et al.
635
arching ethical theories such as utilitarianism or deontol­
ogy [5]. This is in line with approaches to ethical
assessment applied in biomedical and public health ethics
[16], as well as work on cross-cultural ethics [17], under­
lining that it is easier to find agreement on fundamental
values than on ethical doctrines. ICRP highlights four core
values underpinning the system of radiological protection:
beneficence/non-maleficence, justice, dignity, and pru­
dence [5].
Examples of how these values can be applied in the anal­
ysis of ethical challenges are given in the following sec­
tions. But briefly, beneficence and non-maleficence refer to
the principles of promoting well-being and avoiding the
causation of harm. In radiological protection, this is clearly
related to the reduction of radiation exposures, and the
avoidance of resultant harms, but can also include a range
of different costs and benefits, including economic and
societal aspects. There will always be questions about how
to measure consequences and who or what should count in
such an evaluation (e.g., animals and future generations).
Dignity is concerned with respect for autonomy and the
self-determination and choice of affected populations and
includes issues related to privacy, human rights, as well as
individual and community empowerment. The ethical prin­
ciples of fairness and justice stress the importance of
addressing the way in which risks, costs, and benefits are
distributed (distributive justice), as well as the way in which
decisions are carried out (procedural justice). Prudence is
the ability to make discerning and informed choices with­
out the full knowledge of the scope and consequences of
our actions. While precaution and prudence are rarely
alluded to in general medical ethics and bioethics, the pre­
cautionary principle is well recognized in environmental
ethics. The ICRP also introduces the procedural values of
transparency and accountability, in the practical application
of radiological protection, especially in the need to engage
stakeholders in decision-making processes [5]. While there
has been a general consensus on the fundamental values
proposed by ICRP, there have been proposals that the sys­
tem should include additional values such as empathy and
honesty [18].
12.3.6	Acceptability of Radiation Risks Need
to Address More Than the Size
of the Dose
The public’s aversion to radiation—and especially that
associated with nuclear power rather than natural or medi­
cal exposures—is often cited as an example of irrationality
or misunderstanding, and is best combated by improved
education. But to understand risk perception, we need to
recognize that risk is in part quantifiable but also a social
construct that is interpreted differently by people in various
situations, environments, and cultures. It is true that people
misunderstand probabilities; however, numerous studies of
the psychological and psychometric factors that influence
risk perception show that the situation is more complex
than this alone. Public or lay perceptions of risk vary widely
between people and can differ from the calculated, techni­
cal approach to the assessment of risks. Whereas an expert
will often tend to rank risks as being synonymous with the
size or probability of harm, risk tolerance or aversion is
dependent on many additional characteristics [19, 20].
Many of the characteristics have strong psychological as
well as societal and ethical relevance (such as control, vol­
untariness, and distribution of risks and benefits).
12.3.6.1
Autonomy, Personal Control,
and Consent
People tend to be less tolerant of risks that are imposed
without their choice or personal control. The phenomenon
applies to a range of different risks and actions, such as
driving a car compared with flying. Personal control is
closely related to the fundamental ethical value of auton­
omy (i.e., respect for the free will of individuals), dignity,
integrity, and individual rights. It is also linked to the
requirement for free informed consent within medical eth­
ics and can explain why people are less concerned over
medical radiation exposures (which are largely voluntary
and for an obvious personal benefit). People often feel a
lack of personal control over radiation exposure [19], par­
ticularly those associated with accidents. They are depen­
dent on information from authorities or media and have to
deal with both the risks from the exposure as well as the
consequences of measures to reduce exposure such as relo­
cation or agricultural bans.
In risk management, measures that increase personal con­
trol and understanding, such as the provision of dosimeters
or counting equipment, and participation in decision-making
are considered positive and can help populations in coping.
Provision of counting equipment and independent monitor­
ing are methods that have been successfully applied in both
Chernobyl- and Fukushima-affected communities [21–23].
When combined with access to experts to help interpret
results, such actions can help empower populations.
Ethically, procedures that involve the populations themselves
can help promote the principle of informed personal control
over radiation risks.
12.3.6.2
Community Values and Societal
Consequences
The Chernobyl and the Fukushima accidents both resulted
in a wide range of social and economic consequences.
Many evacuees lost their jobs, social network, and con­
nection to places of a particular community or historical
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"The text discusses the concept of risk perception as being influenced by factors beyond simply quantifying probability. Explain how psychological and societal elements contribute to differing perceptions of radiation risks, specifically referencing the importance of personal control and autonomy.","Risk perception is significantly shaped by more than just a numerical assessment of harm; it’s fundamentally a social construct. The text highlights that individuals interpret risk differently based on factors like situation, environment, culture, and psychological characteristics. A key element is the influence of personal control – people are demonstrably less tolerant of risks imposed without their choice or agency. This stems from an ethical value of autonomy, which emphasizes respect for individual free will, dignity, and rights. For example, individuals often exhibit lower concern regarding voluntary medical radiation exposures because they perceive a degree of personal control over the decision-making process and the resulting benefit. Conversely, exposure to radiation associated with accidents – where control is significantly diminished – generates greater anxiety and resistance due to feelings of dependency on external authorities and the complex consequences surrounding mitigation efforts like relocation or agricultural bans. The provision of tools like dosimeters and active participation in risk management decisions are recognized as positive strategies that bolster personal control and understanding, ultimately empowering populations to cope with perceived risks. Furthermore, community values and societal consequences – such as job loss and displacement – exacerbate these perceptions, highlighting the interconnectedness of psychological, social, and ethical considerations when evaluating radiation exposure.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.6	 Acceptability of Radiation Risks Need to Address More Than the Size of the Dose | Content: recognize that risk is in part quantifiable but also a social
construct that is interpreted differently by people in various
situations, environments, and cultures. It is true that people
misunderstand probabilities; however, numerous studies of
the psychological and psychometric factors that influence
risk perception show that the situation is more complex
than this alone. Public or lay perceptions of risk vary widely
between people and can differ from the calculated, techni­
cal approach to the assessment of risks. Whereas an expert
will often tend to rank risks as being synonymous with the
size or probability of harm, risk tolerance or aversion is
dependent on many additional characteristics [19, 20].
Many of the characteristics have strong psychological as
well as societal and ethical relevance (such as control, vol­
untariness, and distribution of risks and benefits).
12.3.6.1
Autonomy, Personal Control,
and Consent
People tend to be less tolerant of risks that are imposed
without their choice or personal control. The phenomenon
applies to a range of different risks and actions, such as
driving a car compared with flying. Personal control is
closely related to the fundamental ethical value of auton­
omy (i.e., respect for the free will of individuals), dignity,
integrity, and individual rights. It is also linked to the
requirement for free informed consent within medical eth­
ics and can explain why people are less concerned over
medical radiation exposures (which are largely voluntary
and for an obvious personal benefit). People often feel a
lack of personal control over radiation exposure [19], par­
ticularly those associated with accidents. They are depen­
dent on information from authorities or media and have to
deal with both the risks from the exposure as well as the
consequences of measures to reduce exposure such as relo­
cation or agricultural bans.
In risk management, measures that increase personal con­
trol and understanding, such as the provision of dosimeters
or counting equipment, and participation in decision-making
are considered positive and can help populations in coping.
Provision of counting equipment and independent monitor­
ing are methods that have been successfully applied in both
Chernobyl- and Fukushima-affected communities [21–23].
When combined with access to experts to help interpret
results, such actions can help empower populations.
Ethically, procedures that involve the populations themselves
can help promote the principle of informed personal control
over radiation risks.
12.3.6.2
Community Values and Societal
Consequences
The Chernobyl and the Fukushima accidents both resulted
in a wide range of social and economic consequences.
Many evacuees lost their jobs, social network, and con­
nection to places of a particular community or historical
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Explain the ethical considerations surrounding radiation risk perception, specifically focusing on how factors like autonomy, personal control, and consent influence an individual's tolerance for risks associated with radiation exposure. Why might a person feel a lack of personal control in situations involving radiation exposure?","Risk perception is significantly shaped by social and psychological factors beyond simply quantifying the size or probability of harm. Individuals’ tolerance for radiation risk is heavily influenced by their sense of autonomy, personal control, and the degree to which they consent to the exposure. People are generally less tolerant of risks that are imposed without their choice or personal control – as demonstrated by comparisons like driving a car versus flying where individuals actively choose the activity. This stems from the fundamental ethical value of autonomy, encompassing respect for individual free will, dignity, integrity, and rights. The requirement for informed consent within medical ethics is directly linked to this principle; for example, people are often more accepting of voluntary medical radiation exposures when they understand the benefits and have a say in the decision-making process. However, individuals frequently experience a lack of personal control when faced with unexpected or large-scale radiation exposure events like those at Chernobyl or Fukushima. This is because they often rely on external authorities for information, are subject to involuntary relocation or restrictions, and must grapple with both the immediate risks of exposure and the subsequent measures taken to mitigate them – such as evacuation orders or agricultural bans. The feeling of powerlessness arises from a lack of direct influence over these circumstances, leading to heightened anxiety and potentially reduced risk tolerance.

Furthermore, providing tools like dosimeters and independent monitoring systems, coupled with opportunities for participation in decision-making processes, is considered ethically positive because it empowers populations by increasing their understanding and sense of control. This approach aligns with the principle of informed personal control over radiation risks, fostering trust and reducing feelings of vulnerability.

Reference: [MolecularRadiationBiology], Section 12.3.6 – Acceptability of Radiation Risks Need to Address More Than the Size of the Dose.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.6	 Acceptability of Radiation Risks Need to Address More Than the Size of the Dose | Sub-sub-subsection: 12.3.6.1	 Autonomy, Personal Control, and Consent | Content: recognize that risk is in part quantifiable but also a social
construct that is interpreted differently by people in various
situations, environments, and cultures. It is true that people
misunderstand probabilities; however, numerous studies of
the psychological and psychometric factors that influence
risk perception show that the situation is more complex
than this alone. Public or lay perceptions of risk vary widely
between people and can differ from the calculated, techni­
cal approach to the assessment of risks. Whereas an expert
will often tend to rank risks as being synonymous with the
size or probability of harm, risk tolerance or aversion is
dependent on many additional characteristics [19, 20].
Many of the characteristics have strong psychological as
well as societal and ethical relevance (such as control, vol­
untariness, and distribution of risks and benefits).
12.3.6.1
Autonomy, Personal Control,
and Consent
People tend to be less tolerant of risks that are imposed
without their choice or personal control. The phenomenon
applies to a range of different risks and actions, such as
driving a car compared with flying. Personal control is
closely related to the fundamental ethical value of auton­
omy (i.e., respect for the free will of individuals), dignity,
integrity, and individual rights. It is also linked to the
requirement for free informed consent within medical eth­
ics and can explain why people are less concerned over
medical radiation exposures (which are largely voluntary
and for an obvious personal benefit). People often feel a
lack of personal control over radiation exposure [19], par­
ticularly those associated with accidents. They are depen­
dent on information from authorities or media and have to
deal with both the risks from the exposure as well as the
consequences of measures to reduce exposure such as relo­
cation or agricultural bans.
In risk management, measures that increase personal con­
trol and understanding, such as the provision of dosimeters
or counting equipment, and participation in decision-making
are considered positive and can help populations in coping.
Provision of counting equipment and independent monitor­
ing are methods that have been successfully applied in both
Chernobyl- and Fukushima-affected communities [21–23].
When combined with access to experts to help interpret
results, such actions can help empower populations.
Ethically, procedures that involve the populations themselves
can help promote the principle of informed personal control
over radiation risks.
12.3.6.2
Community Values and Societal
Consequences
The Chernobyl and the Fukushima accidents both resulted
in a wide range of social and economic consequences.
Many evacuees lost their jobs, social network, and con­
nection to places of a particular community or historical
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"How does the perception of radiation risk differ between expert scientists and the general public, considering factors beyond simply probability calculations?","The understanding and acceptance of radiation risks are profoundly shaped by social and psychological elements, rather than solely relying on quantitative assessments of probability. While experts often prioritize risk based on a direct correlation with the magnitude or likelihood of harm – frequently focusing on dose size – public perceptions of risk exhibit considerable variability. Numerous studies demonstrate that factors such as perceived control over the situation, individual values, cultural context, and societal consequences play a significant role in shaping an individual’s tolerance or aversion to radiation exposure. For example, individuals may be more accepting of a small risk if they believe they have greater control over mitigating potential harm, whereas others might perceive a higher risk due to concerns about long-term effects or the impact on their community. Furthermore, differing cultural values and societal norms can dramatically influence how risks are evaluated; what is considered an acceptable level of risk in one society may be viewed as unacceptable in another. Therefore, effectively communicating radiation risks requires acknowledging this complexity and addressing not just numerical probabilities but also the diverse ways individuals interpret and respond to them.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.6	 Acceptability of Radiation Risks Need to Address More Than the Size of the Dose | Sub-sub-subsection: 12.3.6.2	 Community Values and Societal Consequences | Content: recognize that risk is in part quantifiable but also a social
construct that is interpreted differently by people in various
situations, environments, and cultures. It is true that people
misunderstand probabilities; however, numerous studies of
the psychological and psychometric factors that influence
risk perception show that the situation is more complex
than this alone. Public or lay perceptions of risk vary widely
between people and can differ from the calculated, techni­
cal approach to the assessment of risks. Whereas an expert
will often tend to rank risks as being synonymous with the
size or probability of harm, risk tolerance or aversion is
dependent on many additional characteristics [19, 20].
Many of the characteristics have strong psychological as
well as societal and ethical relevance (such as control, vol­"
"Describe the ethical considerations surrounding radiation exposure risks, particularly concerning vulnerable populations like children and the elderly, referencing specific examples of potential negative consequences beyond simple dose reduction.","The distribution of costs, risks, and benefits associated with radiation exposure raises significant ethical concerns centered around equity, justice, and fairness. Following a radiological event, individuals experience vastly different doses depending on factors such as age (with children being disproportionately vulnerable due to their heightened sensitivity and longer lifespan over which effects can manifest) and location. The Fukushima disaster exemplifies this complexity; elderly evacuees residing in temporary housing faced increased isolation and hardship, exacerbating the psychological distress associated with displacement. Furthermore, anxiety surrounding potential future health risks – particularly thyroid cancer among children – often overshadows personal risk assessments, leading to unnecessary medical interventions like extensive thyroid screenings that can result in invasive surgeries (as seen with approximately 4000 thyroid operations performed on Chernobyl children). These situations highlight how the perception of risk extends beyond quantifiable dose levels and directly impacts individual well-being.  Moreover, strategies designed for equitable cost and dose reduction, such as reducing activity concentrations in public areas through taxpayer investment, can be contrasted with less equitable approaches where minimizing exposure to the majority necessitates a higher burden on a minority population – exemplified by potential bans on farm production within a community. Ultimately, effective disaster management requires integrating economic, ecological, and health considerations while actively engaging affected populations in decision-making processes to foster trust, promote understanding, and respect their fundamental right to shape their future.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.6	 Acceptability of Radiation Risks Need to Address More Than the Size of the Dose | Sub-sub-subsection: 12.3.6.3	 Distribution of Risks and Benefits | Content: Distribution of the costs, risks, and benefits of radiation
exposure relate to the fundamental ethical values of equity,
justice, and fairness. After an accident, doses received by
individuals can vary widely, and the risks of those exposures
differ between adults and children. The consequences of
remediation can impact different members of the affected
communities. Some may lose their livelihood, while others
can continue more or less as before the accident. For exam­
ple, after Fukushima the situation was particularly harsh for
the elderly evacuees, particularly those living in temporary
housing who experienced greater isolation from family and
communities [25].
The potential for increased health risks from radiation
in children means that the risk perceptions go beyond con­
sideration for personal risks, as is seen by anxiety over
thyroid cancer in Fukushima populations [35, 36]. The
fear that your child could be affected in the future can
overshadow any personal concern [24]. Such concerns
create challenges for health surveillance, particularly thy­
roid screening of children. While parents may, under­
standably, request screening, the procedure can lead to
unnecessary surgery (e.g., 4000 thyroid surgeries in
Chernobyl children may explain most of 15 deaths attrib­
uted to exposure), and without a carefully thought com­
munication plan may raise anxiety (Shamisen 2020).
Some measures to reduce exposures could result in an
equitable distribution of cost and dose reduction, such as
investment by taxpayers to reduce activity concentrations
in public areas; while others are less equitable, for exam­
ple, when a reduction of dose to the majority is only pos­
sible at the expense of a higher dose, cost, or welfare
burden, on a minority (e.g., banning all farm production in
a small community).
To conclude, public reaction to disasters is the result of
complex and intrinsic features of risk perception, many of
which have strong ethical and societal relevance. A holistic
approach to disaster management should integrate economic,
ecological, and health measures. Risk management strate­
gies should be designed to accommodate varied needs. For
nuclear accidents, it is not sufficient to simply focus on the
dose reduction aspects of radiation protection as societal
aspects will play a major role in how individuals cope with,
and communities recover from the disaster. Engaging with
the affected population with regard to increasing their under­
standing and personal control and involving them in decision-­
making processes respects people’s fundamental right to
shape their own future. In addition to increasing trust and
compliance, such approaches can lead to significant improve­
ments in the effectiveness and acceptability of disaster man­
agement in communities.
12.3.7	Emerging Occupational Challenges
from New Methods to Determine
Individual Radiosensitivity
Testing for radiosensitivity has the potential to improve
patient treatment and diagnosis or protect workers. Assays
might be applied prior to radiotherapy, to avoid adverse
A. Dobney et al."
"Following a disaster like Fukushima, why might thyroid cancer screening in children raise anxiety despite potential medical benefits, and what broader societal considerations are involved?","After events such as the Fukushima nuclear accident, heightened concerns about thyroid cancer risk in children can arise even when implementing screening procedures. This is largely due to the fear that a child could develop this disease in the future, overshadowing any immediate personal health concerns. Furthermore, the process of conducting these screenings – potentially leading to unnecessary surgery (as seen with approximately 4000 surgeries on Chernobyl children) – can exacerbate anxiety and distrust within affected communities. This situation highlights broader ethical and societal challenges related to risk perception, equitable distribution of costs and burdens, and effective communication strategies. The potential for disproportionate impacts on vulnerable populations, such as elderly evacuees living in temporary housing, further complicates the issue, demanding a holistic approach that integrates economic, ecological, and health measures while respecting people’s right to shape their own future through informed decision-making.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.7	 Emerging Occupational Challenges from New Methods to Determine Individual Radiosensitivity | Content: justice, and fairness. After an accident, doses received by
individuals can vary widely, and the risks of those exposures
differ between adults and children. The consequences of
remediation can impact different members of the affected
communities. Some may lose their livelihood, while others
can continue more or less as before the accident. For exam­
ple, after Fukushima the situation was particularly harsh for
the elderly evacuees, particularly those living in temporary
housing who experienced greater isolation from family and
communities [25].
The potential for increased health risks from radiation
in children means that the risk perceptions go beyond con­
sideration for personal risks, as is seen by anxiety over
thyroid cancer in Fukushima populations [35, 36]. The
fear that your child could be affected in the future can
overshadow any personal concern [24]. Such concerns
create challenges for health surveillance, particularly thy­
roid screening of children. While parents may, under­
standably, request screening, the procedure can lead to
unnecessary surgery (e.g., 4000 thyroid surgeries in
Chernobyl children may explain most of 15 deaths attrib­
uted to exposure), and without a carefully thought com­
munication plan may raise anxiety (Shamisen 2020).
Some measures to reduce exposures could result in an
equitable distribution of cost and dose reduction, such as
investment by taxpayers to reduce activity concentrations
in public areas; while others are less equitable, for exam­
ple, when a reduction of dose to the majority is only pos­
sible at the expense of a higher dose, cost, or welfare
burden, on a minority (e.g., banning all farm production in
a small community).
To conclude, public reaction to disasters is the result of
complex and intrinsic features of risk perception, many of
which have strong ethical and societal relevance. A holistic
approach to disaster management should integrate economic,
ecological, and health measures. Risk management strate­
gies should be designed to accommodate varied needs. For
nuclear accidents, it is not sufficient to simply focus on the
dose reduction aspects of radiation protection as societal
aspects will play a major role in how individuals cope with,
and communities recover from the disaster. Engaging with
the affected population with regard to increasing their under­
standing and personal control and involving them in decision-­
making processes respects people’s fundamental right to
shape their own future. In addition to increasing trust and
compliance, such approaches can lead to significant improve­
ments in the effectiveness and acceptability of disaster man­
agement in communities.
12.3.7	Emerging Occupational Challenges
from New Methods to Determine
Individual Radiosensitivity
Testing for radiosensitivity has the potential to improve
patient treatment and diagnosis or protect workers. Assays
might be applied prior to radiotherapy, to avoid adverse
A. Dobney et al.
637
­reactions in radiosensitive individuals, or to avoid enhanced
cancer risk in connection with radiodiagnoses such as CT
scans or mammography [31]. While not yet applied in medi­
cine or worker protection, assays are currently under devel­
opment, and their potential application raises a number of
ethical and legal challenges. These go beyond the simple
question of whether the assay will “do more good than harm”
to include, for example, questions about how the costs and
benefits might be distributed in society, concerns about pri­
vacy and data protection, and considerations of the potential
for discrimination.
12.3.7.1
Well-Being
Radiosensitivity and radiosusceptibility assays have a clear
potential to provide physical health benefits by improving
cancer treatment, avoiding negative side effects, and enhanc­
ing worker protection. There are also economic aspects, such
as balancing the cost of the assays against the opportunity to
save money through tailored treatment. Psychosocial conse­
quences could include reassurance but might also cause
worry about sensitivity to other stressors. Information on the
magnitude of the effect, its relation to other potential risk
factors, and indeed any dose–response relationship, as well
rates of false positives and false negatives would be needed
to be able to balance the physical harms and benefits. But
this would also have knock-on effects on economic, psycho­
logical as well as legal assessments. Could doctors be sued
for the negative effects of not carrying out a test?
12.3.7.2
Dignity and Autonomy
Information on individual radiosensitivity and radiosuscepti­
bility could clearly enhance patient or worker empowerment
and personal control, but this would depend strongly on the
context in which this information was used. The issues are
similar to other challenges with personal health information,
such as conforming to data protection laws and the increas­
ing commercialization of genetic testing [32]. For example,
the degree to which data from patients undergoing an assay
as part of radiotherapy would be stored, anonymized, and
made available for further research would need to be
addressed. A debate on the implications of these issues
would need to include engagement with the various stake­
holders but could also play an important role in risk commu­
nication, by putting the risks of ionizing radiation in context
with other environmental and genetic risk factors.
12.3.7.3
Justice and Fairness
Increased understanding of the differences in radiosensitivity
within populations is relevant to an assessment of justice.
Other questions would include whether the assays would
provide equal access to health care and support or have any
impact on health insurance (would sensitive populations
have to pay higher premiums?) or compensation claims (will
it change the balance of probabilities that cancers were
caused by radiation exposure?). Even in countries with
national health insurance, there is the question of whether
people should be obliged to disclose the results of genetic
testing before taking out private health or life insurance
schemes. If sensitivity or susceptibility was linked to a
genetic trait, there would be additional issues associated with
implications for children or other family members. While
identification of increased radiosusceptibility in workers
could be used for protective purposes, it might also lead to
discrimination, or raise questions about “responsibility” for
any diseases or negative side effects (lifestyle, predisposi­
tion, occupational exposure, etc.). These issues could be
linked to broader debates on the implications for radiological
protection of populations with different risk factors such as
whether children or women should be treated differently on
the basis of increased radiation cancer risks.
To conclude, many of the ethical challenges associated
with the field of radiosensitivity and radiosusceptibility have
parallels with existing challenges in medical, occupational,
and public health. They also raise important questions about
the implications for radiological protection. For example,
will population-level differences in radiation susceptibility
impact the assessment of health risk? Will they lead to a
change in dose constraints? These questions can only be
addressed with the participation of a wide variety of stake­
holders. Assessing the implications for well-being requires
knowledge from experts in radiation biology, medicine,
occupational health, health economics, social scientists, etc.,
as well as transparency about uncertainties and assumptions.
Respecting both the principles of dignity and fairness in the
procedure requires the participation of affected persons
(workers, patients, the public, etc.) in decision-making.
12.3.8	The Ethical Challenge of Science
as Policy Advice
Looking at the societal impacts of science and technology,
nuclear technology probably represents the most extreme
case of how science and technology can serve both cure and
destruction. While medical applications of nuclear technol­
ogy save individual lives every day, nuclear weapons have
enormous destructive potential. Nuclear energy is a low-­
carbon source of electricity, but a nuclear accident can have
dramatic impacts on the environment and on the physical and
psychological health of a whole population for a long time.
In addition, disposal of radioactive waste unavoidably
requires taking responsible action toward future generations
thereby taking into account time dimensions longer than ever
faced before in human history.
The case of nuclear energy technology is also an example
of how technology assessment can be troubled by the fact
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"The text discusses several ethical considerations arising from determining individual radiosensitivity. Specifically, it raises concerns about potential discrimination against individuals identified as more susceptible to radiation damage, particularly regarding access to healthcare, insurance premiums, and compensation claims. Elaborate on the multifaceted challenges presented by this situation, considering implications for vulnerable populations and broader societal debates surrounding risk assessment and protective measures.","The identification of individual radiosensitivity presents a complex web of ethical dilemmas extending far beyond simple risk mitigation. The core concern is the potential for discrimination against individuals flagged as ‘sensitive’ or ‘susceptible’ to radiation-induced harm. This manifests in several critical areas. Firstly, access to healthcare could be compromised; sensitive populations might face higher insurance premiums due to perceived increased risk, effectively creating a two-tiered system of care. Secondly, compensation claims related to radiation exposure would become significantly more complicated. The balance of probabilities used to determine causation – a cornerstone of many claims – could shift dramatically if individual radiosensitivity is established, potentially leading to greater challenges in proving that cancer was indeed caused by radiation. Furthermore, the implications for family members are substantial; genetic links to increased susceptibility raise concerns about potential burdens and liabilities for children or other relatives. The text correctly highlights broader societal debates concerning differential treatment based on risk factors such as gender (children and women being considered at higher risk) and occupation. This raises fundamental questions of fairness and equity – should individuals be treated differently solely because of a genetic predisposition or increased vulnerability? Beyond these immediate concerns, the assessment of population-level differences in radiation susceptibility poses significant challenges to traditional dose constraints. If certain groups are demonstrably more vulnerable, lower dose limits might be warranted, potentially impacting industries reliant on controlled radiation exposure (e.g., medical imaging). The text’s emphasis on stakeholder participation – involving experts from diverse fields like radiation biology, medicine, occupational health, and social sciences – underscores the need for a holistic approach that acknowledges uncertainties and avoids imposing simplistic or discriminatory judgments. Ultimately, this situation forces us to confront broader ethical questions about responsibility, justice, and the long-term implications of technological advancements on future generations.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.7	 Emerging Occupational Challenges from New Methods to Determine Individual Radiosensitivity | Sub-sub-subsection: 12.3.7.1	 Well-Being | Content: Other questions would include whether the assays would
provide equal access to health care and support or have any
impact on health insurance (would sensitive populations
have to pay higher premiums?) or compensation claims (will
it change the balance of probabilities that cancers were
caused by radiation exposure?). Even in countries with
national health insurance, there is the question of whether
people should be obliged to disclose the results of genetic
testing before taking out private health or life insurance
schemes. If sensitivity or susceptibility was linked to a
genetic trait, there would be additional issues associated with
implications for children or other family members. While
identification of increased radiosusceptibility in workers
could be used for protective purposes, it might also lead to
discrimination, or raise questions about “responsibility” for
any diseases or negative side effects (lifestyle, predisposi­
tion, occupational exposure, etc.). These issues could be
linked to broader debates on the implications for radiological
protection of populations with different risk factors such as
whether children or women should be treated differently on
the basis of increased radiation cancer risks.
To conclude, many of the ethical challenges associated
with the field of radiosensitivity and radiosusceptibility have
parallels with existing challenges in medical, occupational,
and public health. They also raise important questions about
the implications for radiological protection. For example,
will population-level differences in radiation susceptibility
impact the assessment of health risk? Will they lead to a
change in dose constraints? These questions can only be
addressed with the participation of a wide variety of stake­
holders. Assessing the implications for well-being requires
knowledge from experts in radiation biology, medicine,
occupational health, health economics, social scientists, etc.,
as well as transparency about uncertainties and assumptions.
Respecting both the principles of dignity and fairness in the
procedure requires the participation of affected persons
(workers, patients, the public, etc.) in decision-making.
12.3.8	The Ethical Challenge of Science
as Policy Advice
Looking at the societal impacts of science and technology,
nuclear technology probably represents the most extreme
case of how science and technology can serve both cure and
destruction. While medical applications of nuclear technol­
ogy save individual lives every day, nuclear weapons have
enormous destructive potential. Nuclear energy is a low-­
carbon source of electricity, but a nuclear accident can have
dramatic impacts on the environment and on the physical and
psychological health of a whole population for a long time.
In addition, disposal of radioactive waste unavoidably
requires taking responsible action toward future generations
thereby taking into account time dimensions longer than ever
faced before in human history.
The case of nuclear energy technology is also an example
of how technology assessment can be troubled by the fact
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Considering the potential for identifying individual radiosensitivity through new assays, what ethical concerns arise regarding access to healthcare, insurance coverage, and compensation claims, particularly concerning vulnerable populations or those with genetic predispositions?","The development of methods to determine individual radiation susceptibility presents a complex web of ethical challenges. Primarily, there's the risk of unequal access to health care and support if sensitive individuals are required to pay higher premiums for insurance due to their identified vulnerability. This could disproportionately affect already marginalized populations with limited resources. Furthermore, the use of such data in compensation claims raises questions about altering the ‘balance of probabilities’ when assessing radiation-induced cancers – potentially leading to increased scrutiny or denial of claims based on individual susceptibility rather than established exposure levels. Critically, if radiosensitivity is linked to a genetic trait, significant ethical dilemmas emerge regarding disclosure requirements before obtaining private health or life insurance. Individuals might be compelled to reveal sensitive genetic information prematurely, impacting their ability to secure coverage. Moreover, implications for children and family members become paramount; identifying increased susceptibility in an individual could trigger concerns about potential risks extending to future generations, necessitating careful consideration of familial liability and predictive testing. The broader concern is the potential for discrimination based on perceived risk – leading to differential treatment or stigmatization related to lifestyle choices or occupational exposures. Addressing these issues demands a multi-faceted approach incorporating expertise from radiation biology, medicine, occupational health, health economics, social sciences, and crucially, ensuring meaningful participation of affected individuals (workers, patients, the public) in decision-making processes to uphold principles of dignity and fairness. 

Reference: [MolecularRadiationBiology], Section 12.3.7.2 – Dignity and Autonomy","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.7	 Emerging Occupational Challenges from New Methods to Determine Individual Radiosensitivity | Sub-sub-subsection: 12.3.7.2	 Dignity and Autonomy | Content: Other questions would include whether the assays would
provide equal access to health care and support or have any
impact on health insurance (would sensitive populations
have to pay higher premiums?) or compensation claims (will
it change the balance of probabilities that cancers were
caused by radiation exposure?). Even in countries with
national health insurance, there is the question of whether
people should be obliged to disclose the results of genetic
testing before taking out private health or life insurance
schemes. If sensitivity or susceptibility was linked to a
genetic trait, there would be additional issues associated with
implications for children or other family members. While
identification of increased radiosusceptibility in workers
could be used for protective purposes, it might also lead to
discrimination, or raise questions about “responsibility” for
any diseases or negative side effects (lifestyle, predisposi­
tion, occupational exposure, etc.). These issues could be
linked to broader debates on the implications for radiological
protection of populations with different risk factors such as
whether children or women should be treated differently on
the basis of increased radiation cancer risks.
To conclude, many of the ethical challenges associated
with the field of radiosensitivity and radiosusceptibility have
parallels with existing challenges in medical, occupational,
and public health. They also raise important questions about
the implications for radiological protection. For example,
will population-level differences in radiation susceptibility
impact the assessment of health risk? Will they lead to a
change in dose constraints? These questions can only be
addressed with the participation of a wide variety of stake­
holders. Assessing the implications for well-being requires
knowledge from experts in radiation biology, medicine,
occupational health, health economics, social scientists, etc.,
as well as transparency about uncertainties and assumptions.
Respecting both the principles of dignity and fairness in the
procedure requires the participation of affected persons
(workers, patients, the public, etc.) in decision-making.
12.3.8	The Ethical Challenge of Science
as Policy Advice
Looking at the societal impacts of science and technology,
nuclear technology probably represents the most extreme
case of how science and technology can serve both cure and
destruction. While medical applications of nuclear technol­
ogy save individual lives every day, nuclear weapons have
enormous destructive potential. Nuclear energy is a low-­
carbon source of electricity, but a nuclear accident can have
dramatic impacts on the environment and on the physical and
psychological health of a whole population for a long time.
In addition, disposal of radioactive waste unavoidably
requires taking responsible action toward future generations
thereby taking into account time dimensions longer than ever
faced before in human history.
The case of nuclear energy technology is also an example
of how technology assessment can be troubled by the fact
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"The text discusses potential ethical challenges arising from determining individual radiosensitivity. Specifically, it raises concerns about how such assessments might impact access to healthcare, insurance coverage, or compensation claims. Elaborate on the key ethical dilemmas presented regarding fairness and justice when considering factors like genetic predisposition and varying risk profiles within populations.","The text highlights several critical ethical dilemmas surrounding the assessment of individual radiosensitivity. A primary concern revolves around equitable access to health care and support. If individuals are identified as having heightened susceptibility or sensitivity to radiation, there’s a potential for these individuals to face higher insurance premiums or be denied coverage altogether – effectively creating a system where those most vulnerable are disproportionately burdened financially. Furthermore, the assessment could significantly impact compensation claims related to radiation-induced illnesses. The balance of probabilities in determining causation might shift if increased radiosensitivity is linked to a genetic trait, potentially leading to disputes about responsibility for diseases or adverse effects stemming from lifestyle choices, predispositions, or occupational exposures. 

The text also raises profound questions regarding justice and fairness when considering population-level differences in radiation susceptibility. The potential for using such data to justify differential treatment – for example, prioritizing certain groups (e.g., children or women) based on perceived increased risk – presents a significant ethical challenge. This could be construed as discriminatory, particularly if these differences are linked to genetic variations. Moreover, the assessment’s impact extends beyond individual cases; it raises concerns about implications for family members and future generations, especially considering the long-term nature of radioactive waste disposal and potential intergenerational responsibility. Ultimately, the text emphasizes the need for broad stakeholder participation in decision-making processes to ensure that assessments are conducted with respect for dignity, fairness, and transparency regarding uncertainties and assumptions.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.7	 Emerging Occupational Challenges from New Methods to Determine Individual Radiosensitivity | Sub-sub-subsection: 12.3.7.3	 Justice and Fairness | Content: Other questions would include whether the assays would
provide equal access to health care and support or have any
impact on health insurance (would sensitive populations
have to pay higher premiums?) or compensation claims (will
it change the balance of probabilities that cancers were
caused by radiation exposure?). Even in countries with
national health insurance, there is the question of whether
people should be obliged to disclose the results of genetic
testing before taking out private health or life insurance
schemes. If sensitivity or susceptibility was linked to a
genetic trait, there would be additional issues associated with
implications for children or other family members. While
identification of increased radiosusceptibility in workers
could be used for protective purposes, it might also lead to
discrimination, or raise questions about “responsibility” for
any diseases or negative side effects (lifestyle, predisposi­
tion, occupational exposure, etc.). These issues could be
linked to broader debates on the implications for radiological
protection of populations with different risk factors such as
whether children or women should be treated differently on
the basis of increased radiation cancer risks.
To conclude, many of the ethical challenges associated
with the field of radiosensitivity and radiosusceptibility have
parallels with existing challenges in medical, occupational,
and public health. They also raise important questions about
the implications for radiological protection. For example,
will population-level differences in radiation susceptibility
impact the assessment of health risk? Will they lead to a
change in dose constraints? These questions can only be
addressed with the participation of a wide variety of stake­
holders. Assessing the implications for well-being requires
knowledge from experts in radiation biology, medicine,
occupational health, health economics, social scientists, etc.,
as well as transparency about uncertainties and assumptions.
Respecting both the principles of dignity and fairness in the
procedure requires the participation of affected persons
(workers, patients, the public, etc.) in decision-making.
12.3.8	The Ethical Challenge of Science
as Policy Advice
Looking at the societal impacts of science and technology,
nuclear technology probably represents the most extreme
case of how science and technology can serve both cure and
destruction. While medical applications of nuclear technol­
ogy save individual lives every day, nuclear weapons have
enormous destructive potential. Nuclear energy is a low-­
carbon source of electricity, but a nuclear accident can have
dramatic impacts on the environment and on the physical and
psychological health of a whole population for a long time.
In addition, disposal of radioactive waste unavoidably
requires taking responsible action toward future generations
thereby taking into account time dimensions longer than ever
faced before in human history.
The case of nuclear energy technology is also an example
of how technology assessment can be troubled by the fact
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"The text highlights several ethical challenges related to the assessment and management of radiological risk, particularly concerning the potential for unequal access to healthcare, insurance implications, and discrimination based on perceived susceptibility. Specifically, how does the document address the possibility that population-level differences in radiation vulnerability could impact health risk assessments and potentially lead to altered dose constraints?","The text emphasizes that population-level differences in radiation susceptibility pose a significant challenge for assessing health risks and influencing policy decisions. It argues that such variations could directly impact the assessment of health risk, leading to potential changes in established dose constraints. The document explicitly states that ‘will population-level differences in radiation susceptibility impact the assessment of health risk?’ This raises concerns about whether standardized risk assessments would adequately account for diverse vulnerabilities within a population, potentially necessitating adjustments to safety protocols and regulations based on these observed disparities. Furthermore, it highlights the need for broad stakeholder involvement – including experts in radiation biology, medicine, occupational health, and social scientists – to ensure that decisions are made with consideration of these complex factors and to mitigate potential discriminatory outcomes related to risk assessment. Reference: [MolecularRadiationBiology, Section 12.3.8 – The Ethical Challenge of Science as Policy Advice]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.8	 The Ethical Challenge of Science as Policy Advice | Content: Other questions would include whether the assays would
provide equal access to health care and support or have any
impact on health insurance (would sensitive populations
have to pay higher premiums?) or compensation claims (will
it change the balance of probabilities that cancers were
caused by radiation exposure?). Even in countries with
national health insurance, there is the question of whether
people should be obliged to disclose the results of genetic
testing before taking out private health or life insurance
schemes. If sensitivity or susceptibility was linked to a
genetic trait, there would be additional issues associated with
implications for children or other family members. While
identification of increased radiosusceptibility in workers
could be used for protective purposes, it might also lead to
discrimination, or raise questions about “responsibility” for
any diseases or negative side effects (lifestyle, predisposi­
tion, occupational exposure, etc.). These issues could be
linked to broader debates on the implications for radiological
protection of populations with different risk factors such as
whether children or women should be treated differently on
the basis of increased radiation cancer risks.
To conclude, many of the ethical challenges associated
with the field of radiosensitivity and radiosusceptibility have
parallels with existing challenges in medical, occupational,
and public health. They also raise important questions about
the implications for radiological protection. For example,
will population-level differences in radiation susceptibility
impact the assessment of health risk? Will they lead to a
change in dose constraints? These questions can only be
addressed with the participation of a wide variety of stake­
holders. Assessing the implications for well-being requires
knowledge from experts in radiation biology, medicine,
occupational health, health economics, social scientists, etc.,
as well as transparency about uncertainties and assumptions.
Respecting both the principles of dignity and fairness in the
procedure requires the participation of affected persons
(workers, patients, the public, etc.) in decision-making.
12.3.8	The Ethical Challenge of Science
as Policy Advice
Looking at the societal impacts of science and technology,
nuclear technology probably represents the most extreme
case of how science and technology can serve both cure and
destruction. While medical applications of nuclear technol­
ogy save individual lives every day, nuclear weapons have
enormous destructive potential. Nuclear energy is a low-­
carbon source of electricity, but a nuclear accident can have
dramatic impacts on the environment and on the physical and
psychological health of a whole population for a long time.
In addition, disposal of radioactive waste unavoidably
requires taking responsible action toward future generations
thereby taking into account time dimensions longer than ever
faced before in human history.
The case of nuclear energy technology is also an example
of how technology assessment can be troubled by the fact
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
638
that “benefits and burdens” of a technology are essentially
incomparable. Referring to the general considerations related
to the radiological risk and the need to include values in its
assessment above, we can say that, taking into account the
specific character of the nuclear energy risk, also the societal
justification of nuclear energy is troubled by moral plural­
ism. That is, even if we would all agree on the scientific
knowledge base for the assessment of the risk, then opinions
on its acceptability could still differ. The matter becomes
even more complex if we take into account the fact that sci­
ence can only deliver evidence to a certain extent. Nuclear
science and engineering are mature, but we have to acknowl­
edge that the existence of knowledge-related uncertainties
puts fundamental limits to understanding and forecasting
technological, biological, and social phenomena in the inter­
est of risk assessment and governance. Last but not least, we
have to accept that important factors remain to a large degree
beyond control. These are human behavior, nature, time, and
potential misuse of technology.
The resulting room for interpretation complicates the eval­
uation of risk-inherent technologies in general and of nuclear
technology in particular and puts a specific responsibility on
science and technology assessment as a policy-­supportive
research practice. And this is the point where ethics come in.
In simple terms, that responsibility comes down to acknowl­
edging and taking into account uncertainty and pluralism as
described above, and the consequences thereof for research
and policy. That “responsible attitude” does not only apply to
scientists but to everyone concerned with applications of sci­
ence and technology in general and with the issue of nuclear
technology in particular. The idea is that this responsible atti­
tude can only be enabled and stimulated in “interaction meth­
ods” for policy and scientific research that are able to generate
societal trust by their “method.” Today we know that this in
principle translates as doing politics differently by involving
the potentially affected and other stakeholders in deliberative
decision-making, and as doing science differently, namely as
transdisciplinary science advancing from a holistic perspec­
tive and enriched with insights and ideas from the social sci­
ences and the humanities, from lay knowledge and the arts
and from civil society and citizens (see, among other [33–
35]). For science in particular, confronted with the need to
deal with incomplete and speculative knowledge and value
pluralism in providing policy advice on issues of social well-
being, its challenge is no longer the production of credible
proofs but the construction of credible hypotheses [33]. From
an ethical perspective, in the general interest of rendering
hypotheses with credibility (and the potential to generate
societal trust), one could say science has no choice but to
“open up its method” for transdisciplinarity and public
involvement, in addition to the “traditional” quality criteria of
objectivity and independence and the need to recognize
uncertainty, value pluralism, contingency, and potential mis­
use. Obviously, the aim of this ethically inspired “reflexivity”
is not to undermine the credibility of science but to stimulate
dialog and (self) critical thinking, and to make science more
resilient against pressure from politics and the market to
deliver evidence it cannot (yet) deliver.
12.3.9	Emergency Planning and Response
in Post-Accident Context
The complex dimensions of radiological risk, particularly
after large-scale accidents raise particular challenges for
cost-benefit analysis of post-accident response. Emotional
descriptions of such emergencies seem more common than
quantitative cost-effectiveness considerations. Noteworthy, a
few weeks before the first atomic bomb test in July 1945, an
official report warned that “civilization would have the
means to commit suicide at will” [36]. Kahn [37] considered
a full-scale 10,000,000 kiloton nuclear exchange between
the Soviet Union and the USA, and deliberated in detail why
the above statement is far from being based on evidence.
Quantitative considerations show that the direct health
consequences—radiation sickness, carcinogenesis, etc.—of
any past (or future practically probable) radiological accident
are much less far-reaching than those which are usually per­
ceived. In each scenario, direct health effects are only a small
part of the damage caused by fear and anxiety. For example,
the two major humanitarian disasters after the Chernobyl and
Fukushima nuclear accidents turned out to be such disasters
not because of their radiogenic effects, either actual or
averted. The main health consequences could be attributed to
countermeasures by the authorities, and socio-­psychosomatic
problems among the public. The relocation of hundreds of
thousands of people created very real suffering, morbidity,
and mortality [38]. Rational decision-making should have
quantitatively compared the human cost of evacuation and
long-term relocation with the human cost of radiation expo­
sure. Such comparison was performed only decades later. For
example, Yanovskiy et al. [39] estimated that in Fukushima
the evacuation was not justified at all, and in Chernobyl the
evacuated zone could have been repopulated after 1 month.
The human cost of evacuations should be considered as
follows. First, there is always a direct loss of life due to the
temporary loss of medical care, psychosomatic disorders,
and even suicides; After Fukushima, e.g., 1% of the evacuees
died during the first 2 years due to evacuation-related causes
(on top of the natural mortality). Second, evacuees’ quality
of life deteriorates by about 20% [39]. Last but not least,
evacuation is expensive. While associating human life with
monetary value is psychologically difficult and may seem
ethically challenging, it is actually an ethical necessity since
extraneous expenditure leads to a statistical shortening of
life. A cost-effectiveness analysis is routinely performed
A. Dobney et al."
"Based on the provided text, what are some of the key challenges in conducting cost-benefit analyses following radiological accidents, particularly concerning human health and societal impacts?","The text highlights several significant challenges when applying traditional cost-benefit analysis to post-accident scenarios. Primarily, emotional descriptions of emergencies often outweigh quantitative considerations regarding cost-effectiveness. Furthermore, direct health consequences (radiation sickness, carcinogenesis) are frequently underestimated compared to the broader impact of fear and anxiety, which can lead to widespread psychological distress, socio-psychosomatic problems, and significant human suffering. The displacement of large populations through evacuation creates substantial morbidity and mortality, potentially impacting quality of life by approximately 20% as suggested by Yanovskiy et al. [39]. Finally, the text emphasizes that associating a monetary value with human life is ethically complex but necessary for rational decision-making, particularly when considering the potential for statistical shortening of lifespan due to evacuation costs. The disparity in life expectancy across locations (e.g., Calton, UK) further complicates these analyses. Reference: [12.3.9 Emergency Planning and Response in Post-Accident Context]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.3	 Ethical Aspects of Radiation Exposure | Sub-subsection: 12.3.9	 Emergency Planning and Response in Post-Accident Context | Content: “open up its method” for transdisciplinarity and public
involvement, in addition to the “traditional” quality criteria of
objectivity and independence and the need to recognize
uncertainty, value pluralism, contingency, and potential mis­
use. Obviously, the aim of this ethically inspired “reflexivity”
is not to undermine the credibility of science but to stimulate
dialog and (self) critical thinking, and to make science more
resilient against pressure from politics and the market to
deliver evidence it cannot (yet) deliver.
12.3.9	Emergency Planning and Response
in Post-Accident Context
The complex dimensions of radiological risk, particularly
after large-scale accidents raise particular challenges for
cost-benefit analysis of post-accident response. Emotional
descriptions of such emergencies seem more common than
quantitative cost-effectiveness considerations. Noteworthy, a
few weeks before the first atomic bomb test in July 1945, an
official report warned that “civilization would have the
means to commit suicide at will” [36]. Kahn [37] considered
a full-scale 10,000,000 kiloton nuclear exchange between
the Soviet Union and the USA, and deliberated in detail why
the above statement is far from being based on evidence.
Quantitative considerations show that the direct health
consequences—radiation sickness, carcinogenesis, etc.—of
any past (or future practically probable) radiological accident
are much less far-reaching than those which are usually per­
ceived. In each scenario, direct health effects are only a small
part of the damage caused by fear and anxiety. For example,
the two major humanitarian disasters after the Chernobyl and
Fukushima nuclear accidents turned out to be such disasters
not because of their radiogenic effects, either actual or
averted. The main health consequences could be attributed to
countermeasures by the authorities, and socio-­psychosomatic
problems among the public. The relocation of hundreds of
thousands of people created very real suffering, morbidity,
and mortality [38]. Rational decision-making should have
quantitatively compared the human cost of evacuation and
long-term relocation with the human cost of radiation expo­
sure. Such comparison was performed only decades later. For
example, Yanovskiy et al. [39] estimated that in Fukushima
the evacuation was not justified at all, and in Chernobyl the
evacuated zone could have been repopulated after 1 month.
The human cost of evacuations should be considered as
follows. First, there is always a direct loss of life due to the
temporary loss of medical care, psychosomatic disorders,
and even suicides; After Fukushima, e.g., 1% of the evacuees
died during the first 2 years due to evacuation-related causes
(on top of the natural mortality). Second, evacuees’ quality
of life deteriorates by about 20% [39]. Last but not least,
evacuation is expensive. While associating human life with
monetary value is psychologically difficult and may seem
ethically challenging, it is actually an ethical necessity since
extraneous expenditure leads to a statistical shortening of
life. A cost-effectiveness analysis is routinely performed
A. Dobney et al.
639
when formulating health policies [40]. Safety expenditures
should be treated in a similar way since both healthcare and
safety deal with life extension [41].
In this context, it is worth mentioning that life expectancy
varies considerably not only for different countries but also
for different locations of each country: the main reasons are
probably socioeconomic and environmental. This disparity
in life expectancy across countries is typically of several
years; in the extreme case of Calton in the UK it was 25 years
below the country average [42]. It is needless to mention that
evacuation of less-successful locations is nowhere consid­
ered as a viable option.
12.4"
"What are the key legal considerations surrounding radiation exposure incidents involving individuals who have been exposed to radioactive materials, particularly concerning liability and compensation?","Legal frameworks governing radiation exposure incidents are complex and vary significantly across jurisdictions, but several core principles consistently emerge. Primarily, liability can arise from three main sources: negligence, strict liability, and vicarious liability. Negligence occurs when a party fails to exercise reasonable care in handling radioactive materials or implementing safety protocols, leading directly to an individual’s exposure. This requires demonstrating that the responsible party knew or should have known of the risk and failed to take adequate precautions. Strict liability applies in situations where the activity involving radiation is deemed inherently dangerous, regardless of fault. This often involves activities like uranium mining or nuclear waste disposal, placing responsibility on the operator for any resulting harm, even if they followed all regulations. Vicarious liability holds employers responsible for the negligent acts of their employees during work-related incidents. 

Compensation claims typically involve seeking damages for medical expenses (past and future), lost wages, pain and suffering, and potentially property damage. Establishing causation – proving that the radiation exposure directly caused the harm – is a critical element in any legal case. This often involves complex epidemiological studies to demonstrate a link between exposure levels and health outcomes. Furthermore, regulatory bodies like the Nuclear Regulatory Commission (NRC) or equivalent agencies play a significant role in investigations, establishing standards of care, and determining responsibility. Legal precedents set by court decisions regarding similar incidents heavily influence subsequent cases. Finally, evolving ethical considerations surrounding radiation risk assessment and compensation models are increasingly shaping legal interpretations and policy development, particularly concerning long-term health effects and cumulative exposure.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Content: Situations"
"What are the key objectives of nuclear law concerning radiation exposure, and which populations does it specifically address?","Nuclear law’s primary objective is to establish a comprehensive legal framework for the safe management of all sources and types of ionizing radiation. This encompasses ensuring adequate protection for individuals, society, and the environment – both present and future – against radiological hazards. Specifically, nuclear law addresses exposure risks associated with three main categories: the general public (any individual within the population), workers (individuals employed in roles involving radiation exposure, regardless of employment duration or type), and patients undergoing medical uses of radiation such as radiodiagnosis or radiotherapy. The legal framework mandates the application of fundamental principles like justification of actions involving radiation exposure, optimization strategies, and limitation of individual radiation risk in all relevant scenarios. This detailed protection extends to situations where individuals may incur high doses of radiation with potential adverse effects.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.1	 Introduction | Content: The purpose of nuclear law is to establish a legal framework
for the safe management of all sources and types of radiation
and endeavors involving exposure to ionizing radiation [43].
Nuclear law should thus ensure the adequate protection of
individuals, society, and the environment, both present and
future, against radiological hazards. Specifically, nuclear law
should cover the exposure of the general public—i.e., any
individual in the population—of workers—i.e., any person
who works, whether full-time, part-time, or temporarily, for
an employer and who has recognized rights and duties in rela­
tion to occupational radiation protection—as well as expo­
sures related to medical uses of radiation, situations in which
a patient is voluntarily exposed for therapeutic purposes
(radiodiagnostic or radiotherapy) and who may incur high
doses of radiation, possibly with unwanted side effects as a
result. Radiation protection rules and regulations should
always include special provisions relating to the way in which
the application of fundamental principles of justification of
actions involving radiation exposure, optimization, or protec­
tion, and limitation of individual radiation risk is applied.
The general principles of nuclear law broadly apply to all
nuclear-related activities and facilities where ionizing radia­
tion is used or produced.
Section 12.4 will first define nuclear law. Important prin­
ciples will then be covered followed by a summary and
explanation of relevant legislative frameworks. Certain spe­
cific potential exposure situations and how the law treats
them will also be expanded upon such as employer and med­
ical liability, as well as the legal framework for airline per­
sonnel and astronauts.
Legal attribution and imputation of radiation harm to radi­
ation exposure situations, a topic that has distinct epistemo­
logical elements, will be discussed in Sect. 12.5 after the
more formal legal aspects."
"Describe the fundamental purpose and scope of nuclear law, outlining its key elements as defined within this legal framework.","Nuclear law establishes a specialized body of legal standards and norms designed to govern activities related to the use, production, and exposure to ionizing radiation. Its primary objective is to mitigate potential detrimental effects associated with radiation while acknowledging the societal benefits it can provide. Specifically, nuclear law operates as a regulatory framework due to the inherent risks posed by ionizing radiation – namely, its capacity for biological harm. This regulation extends to all legal persons (corporations and individuals) involved in activities concerning radioactivity, ionizing radiation, or products of nuclear fission, including commercial, academic, scientific, governmental, and natural entities. A core aspect of this law is the protection of populations from adverse effects stemming from these materials; it encompasses not only existing technologies like fission but also anticipates potential implications arising from developments such as fusion reactions. The legal standards established are recognized as part of broader national legislation, though specific implementations may vary across jurisdictions due to sovereign rights regarding lawmaking. Reference: 12.4.2 Definition and Objective of Nuclear Law","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.2	 Definition and Objective of Nuclear Law | Content: more formal legal aspects.
12.4.2	Definition and Objective of Nuclear Law
The scope of nuclear law can be succinctly defined as any
issue or matter relating to the use of, production of, or expo­
sure to ionizing radiation in specific situations.
This definition has four key elements. Firstly, nuclear law is
a body of special legal standards and norms. These are recog­
nized as a part of general national legislation. Since it is a
sovereign right of countries to choose how they enact laws,
national legislations may differ when it relates to nuclear
issues.
Secondly, nuclear law serves a regulatory purpose. The
use of and exposure to radiation needs to be regulated given
that whilst there is a potential benefit to social and economic
development, there also a potentially detrimental effects.
Thirdly, nuclear law relates to the conduct of legal and
natural persons. These persons could be commercial, aca­
demic, scientific, governmental, or natural. A legal person is
a body corporate (or corporate organization) such as a com­
pany while a natural person is an individual human being
[45].
Fourthly, nuclear law primarily relates to radioactivity,
ionizing radiation, and the products of nuclear fission, with
the clarification that in this context, it means those that have
potentially unwanted biological effects. We could add to the
definition that the effects of fusion reactions—still largely in
a developmental phase at the time of the redaction of this
work—should also be included under the umbrella of nuclear
law. The property of protection of the population from the
adverse effects of radioactivity and radiation is considered to
be the defining aspect justifying the need for a special legal
regime."
"Describe the core principles underpinning nuclear law, as outlined in the text, specifically focusing on how these principles relate to risk management and protection of individuals and the environment.","Nuclear law is fundamentally built upon a set of guiding principles designed to manage the inherent risks associated with radioactivity and ionizing radiation. The central concept is the ‘safety principle,’ which emphasizes preventing damage and minimizing adverse effects through cautious action and foresight. Several interconnected principles support this, including the prevention principle – proactively avoiding harm; the protection principle – prioritizing public health, safety, security, and environmental well-being when risks outweigh benefits; and the precautionary principle – demanding preventative measures to avoid foreseeable harm. Furthermore, the law recognizes a responsibility for safety resting with those undertaking nuclear activities, necessitates an effective governmental framework including independent regulatory bodies, promotes the optimization of protection and safety, limits individual radiation risks, mandates accident prevention efforts, and establishes arrangements for emergency preparedness and response. The IAEA’s Fundamental Safety Principles – encompassing responsibility, government role, leadership & management, justification of activities, risk optimization, limitation of risks to individuals, emergency preparedness, and preventative action – further solidify this commitment to comprehensive protection. These principles are not applied uniformly; they are tailored based on the assessed level of risk associated with specific activities and facilities, ranging from stringent measures for high-hazard operations to more basic safeguards for low-risk scenarios.  Ultimately, nuclear law aims to balance potential societal benefits derived from nuclear energy with the critical need to safeguard human health, security, and environmental integrity. 

Reference: [MolecularRadiationBiology], Section 12.4.3 – Principles of Nuclear Law.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.3	 Principles of Nuclear Law | Content: more formal legal aspects.
12.4.2	Definition and Objective of Nuclear Law
The scope of nuclear law can be succinctly defined as any
issue or matter relating to the use of, production of, or expo­
sure to ionizing radiation in specific situations.
This definition has four key elements. Firstly, nuclear law is
a body of special legal standards and norms. These are recog­
nized as a part of general national legislation. Since it is a
sovereign right of countries to choose how they enact laws,
national legislations may differ when it relates to nuclear
issues.
Secondly, nuclear law serves a regulatory purpose. The
use of and exposure to radiation needs to be regulated given
that whilst there is a potential benefit to social and economic
development, there also a potentially detrimental effects.
Thirdly, nuclear law relates to the conduct of legal and
natural persons. These persons could be commercial, aca­
demic, scientific, governmental, or natural. A legal person is
a body corporate (or corporate organization) such as a com­
pany while a natural person is an individual human being
[45].
Fourthly, nuclear law primarily relates to radioactivity,
ionizing radiation, and the products of nuclear fission, with
the clarification that in this context, it means those that have
potentially unwanted biological effects. We could add to the
definition that the effects of fusion reactions—still largely in
a developmental phase at the time of the redaction of this
work—should also be included under the umbrella of nuclear
law. The property of protection of the population from the
adverse effects of radioactivity and radiation is considered to
be the defining aspect justifying the need for a special legal
regime.
12.4.3	Principles of Nuclear Law
A number of basic concepts, often expressed as fundamental
principles, distinguish nuclear law from other aspects of law.
These principles and various theories are crucial to under­
In more detail, nuclear law can be defined as “The
body of special legal norms created to regulate the
conduct of legal or natural persons engaged in activi­
ties related to fissionable materials, ionizing radiation,
and exposure to natural sources of radiation” while its
primary objective is “To provide a legal framework for
conducting activities related to nuclear energy and
ionizing radiation in a manner which adequately pro­
tects individuals, property, and the environment” [44].
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
640
stand because they help understand why the law exists in the
form it does.
The safety principle is arguably the central concept in
nuclear law [43]. Within the safety principle, there are a num­
ber of other principles. These include the prevention principle
that postulates that, given the special nature of the risks asso­
ciated with the use of nuclear energy, the primary objective of
nuclear law is to promote the exercise of caution and foresight
to prevent damage and minimize adverse effects. Another
principle is the protection principle which postulates that
when the risks associated with an activity are found to out­
weigh the benefits, priority must be given to protecting public
health, safety, security, and the environment. The precaution­
ary principle also prioritizes protection and the prevention of
foreseeable harm as fundamental requirements.
Fundamental safety principles codified in legislation may
be applied to a wide variety of activities and facilities that
pose very different types and levels of risk. Activities posing
significant radiation hazards will obviously require stringent
technical safety measures and, in parallel, strict legal arrange­
ments. Activities posing little or no radiation hazard will
need only elementary technical safety measures, with limited
legal arrangements.
The security principle [43] is an underlying principle of
the special legal measures that are required to protect and
account for the types and quantities of nuclear material that
may pose security risks. These measures should protect
against both accidental and intentional diversion from the
legitimate uses of these materials and technologies. Lost or
abandoned radiation sources can cause physical injury to
persons unaware of the associated hazards. The acquisition
of radiation sources by terrorist or criminal groups could
lead to the production of radiation dispersion devices to be
used to commit malevolent acts. The diversion of certain
types of nuclear material could contribute to the spread of
nuclear weapons to both subnational and national entities. It
is for these reasons that legal measures regarding physical
protection, emergency preparedness, response, and trans­
port, import and export of radioactive material have been
adopted.
The aforementioned principles are not the only ones used
in a nuclear law context. For example, the IAEA Basic
International Safety Standards (BSS, infra, Sect. 12.4.4.1)
represent a broad international consensus on the appropriate
handling of radioactive sources to ensure that nuclear-related
activities can be conducted in a safe, secure, and environmen­
tally acceptable way. The BSS consists of three sets of publi­
cations: the Safety Fundamentals, the Safety Requirements,
and the Safety Guides. The Fundamentals establish the funda­
mental safety objectives and principles of protection and
safety, the Requirements set out the requisite conditions that
must be met to protect the population and the environment
and the Safety Guides provide practical recommendations
and guidance on how to comply with the requirements.
The Fundamental Safety Principles are the basis of inter­
national and intergovernmental standards of radiation and
nuclear safety. They have been established under the aegis of
the IAEA and are jointly sponsored by the European Atomic
Energy Community (Euratom), the Food and Agriculture
Organization of the United Nations (FAO), the International
Atomic Energy Agency (IAEA), the International Labour
Organization (ILO), the International Maritime Organization
(IMO), the OECD Nuclear Energy Agency (OECD/NEA),
the Pan American Health Organization (PAHO), the United
Nations Environment Programme (UNEP), and the World
Health Organization (WHO).
•	The fundamental safety principles are more detailed ele­
ments of the safety principle previously discussed:
•	The first principle is the responsibility for safety: The
prime responsibility for safety must rest with the person
or organization responsible for facilities and activities that
give rise to radiation risks.
•	The second safety principle relates to the role of the gov­
ernment: An effective legal and governmental framework
for safety, including an independent regulatory body,
must be established and sustained.
•	The third safety principle relates to the leadership and
management for safety: Effective leadership and manage­
ment for safety must be established and sustained in orga­
nizations concerned with, and facilities and activities that
give rise to, radiation risks.
•	The fourth safety principle calls for the justification of
facilities and activities: Facilities and activities that give
rise to radiation risks must yield an overall benefit.
•	The fifth safety principle refers to the optimization of pro­
tection and safety: Protection must be optimized to pro­
vide the highest level of safety that can reasonably be
achieved.
•	The sixth principle requests the limitation of risks to indi­
viduals: Measures for controlling radiation risks must
ensure that no individual bears an unacceptable risk of
harm.
•	The seventh principle calls for the protection of present
and future generations: People and the environment, pres­
ent and future, must be protected against radiation risks.
While safety is of the utmost importance, it is impor­
tant to carry out a balancing of both the risks and the
benefits of exposure. There are situations in which the
benefits clearly outweigh the risks, and it is important
to not dismiss outright any and all exposure based
solely on hazard.
A. Dobney et al.
641
•	The eighth principle refers to the prevention of accidents:
All practical efforts must be made to prevent and mitigate
nuclear or radiation accidents.
•	The ninth principle relates to emergency preparedness
and response: Arrangements must be made for emergency
preparedness and response for nuclear or radiation
incidents.
•	The tenth and final principle refers to protective actions to
reduce existing or unregulated radiation risks: Protective
actions to reduce existing or unregulated radiation risks
must be justified and optimized."
"Describe the roles and relationships between key international organizations involved in establishing radiation protection standards, specifically focusing on UNSCEAR, ICRP, and the IAEA. What type of legal obligations do their recommendations typically carry?","The establishment of international radiation protection standards involves a complex interplay of several organizations. The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) plays a crucial role as an independent scientific body that compiles, assesses, and disseminates information regarding the causal link between radiation exposure and potential health effects. Their findings are regularly reported to the UN General Assembly and publicly available, providing a foundational scientific basis for subsequent standards. The International Commission on Radiological Protection (ICRP), operating as a private, non-governmental charity since 1950, develops internationally agreed-upon recommendations across all areas of radiation protection. These recommendations form the core of many national regulations. Finally, the International Atomic Energy Agency (IAEA) acts as a coordinating body, establishing Basic Safety Standards (BSS) based on both UNSCEAR publications and ICRP recommendations. The IAEA’s BSS serve as a global reference for protecting people and the environment, contributing to harmonized safety levels worldwide. Critically, it's important to note that while these organizations produce comprehensive guidelines, their recommendations are generally considered ‘soft law.’ This means they aren’t legally binding in themselves; rather, countries and institutions are encouraged to implement them within their national regulations and legislation. The influence of these standards stems from broad international consensus and the desire for a globally harmonized approach to radiation safety.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.4	 The Legal Hierarchy of Nuclear Law | Content: 12.4.4.1
The International Regime
An international regime based on broad international con­
sensus has produced over time a set of recommendations and
standards that govern radiation protection. These are not set
in stone but have evolved and will still evolve over time as
new fundamental scientific insights develop. The United
Nations Scientific Committee on the Effects of Atomic
Radiation (UNSCEAR) compiles, assesses, and dissemi­
nates scientific information on the causal link between
incurred doses of radiation and possible adverse health
effects outcomes. Its findings are periodically reported to the
UN General Assembly (UNGA) and are made available to
the public on its website. Since 1950, the International
Commission on Radiological Protection (ICRP), a private
nongovernmental charity, has been developing internation­
ally agreed-upon recommendations in all areas of radiation
protection. The Annals of the ICRP are mostly freely avail­
able to the general public.
International radiation protection standards are estab­
lished under the aegis of the International Atomic Energy
Agency (IAEA) with the cosponsoring of other relevant
international organizations. Since 1962, the IAEA takes into
account UNSCEAR publications as well as ICRP recom­
mendations in order to establish and issue Basic Safety
Standards (BSS), which provide fundamental principles,
requirements, and recommendations to ensure nuclear safety.
The IAEA considers these standards as a global reference for
protecting people and the environment and a main contribu­
tion to a harmonized high level of safety worldwide.
Scientific and technical publications are issued annually and
include international safety standards, technical guides, con­
ference proceedings, and scientific reports. They cover the
breadth of the IAEA’s work, focusing among other topics on
nuclear power generation, the use of sealed radioactive
sources in medicine, radiation therapy, agriculture, nuclear
safety and security, and nuclear law.
The publications by UNSCEAR, the ICRP, and the IAEA
are comprised of general principles, mandatory require­
ments, and binding rules, recommendations, and guidelines.
In addition, a growing structure of international treaty obli­
gations and accepted rules of best practices have been devel­
oped. Important to note are that these recommendations and
standards, while broadly recognized on an international
level, are not adopted by all countries in a uniform way.
Almost all ICRP recommendations and most IAEA stan­
dards are considered to be “soft law” meaning that countries
and institutions are encouraged to implement them in regula­
tions and national legislation, without an actual legal obliga­
tion to do so.
It is important to note that the national variations in the
implementation of nuclear law do not vary from country to
country simply due to varying levels of scientific understand­
ing, but is also influenced by political motives and public
perception. For example, states that are generally wary of the
use of nuclear energy may have a notably different legal
framework than states that generally favor the use of nuclear
energy, despite these states having essentially the same
access to the same scientific information.
12.4.4.2
The National and Regional Level
Adherence to international instruments (e.g., conventions
and treaties) has both an external and an internal aspect. As
a matter of international law, states that take the necessary
steps under their national laws to approve (or ratify) such
instruments are then bound by the obligations arising out of
The central underlying principle of nuclear law is
safety. If a situation arises in which a law’s interpreta­
tion is unclear, it is useful to ask which interpretation
would lead to the safest outcome. This should of course
take into account the beneficial impacts relating to the
exposure, but it is a good starting point if confusion
arises.
There are few hard laws at the international level.
Nation states generally retain a large measure of self-­
determination in regulating nuclear activities within
their borders. There is however a substantial interna­
tional consensus in many areas of radiation protection
and consequently in the basic concepts of nuclear law,
expressed on the one hand in binding treaties and on
the other in rules of soft law, i.e., quasi-legal instru­
ments such as recommendations or guidelines that are
strictly speaking not legally binding but are neverthe­
less widely adopted and may become legally binding
in the future.
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Describe the relationship between international organizations like UNSCEAR, ICRP, and IAEA in the context of establishing legal standards for radiation exposure, specifically addressing how their outputs are utilized within national regulations.","The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), the International Commission on Radiological Protection (ICRP), and the International Atomic Energy Agency (IAEA) collectively form a foundational structure for international legal standards concerning radiation exposure. Their work encompasses general principles, mandatory requirements, binding rules, recommendations, and guidelines. Critically, these organizations primarily produce ‘soft law’ – guidance intended to influence national regulations rather than constituting legally enforceable obligations in themselves. Countries and institutions are encouraged to incorporate these recommendations into their own legislation and regulatory frameworks. However, the adoption of these standards is far from uniform globally. National variations in implementation stem not solely from differing levels of scientific understanding but also significantly from political considerations and public perception regarding nuclear energy. For instance, nations with a historically cautious approach to nuclear power are more likely to develop legal frameworks that diverge substantially from those adopted by countries actively promoting nuclear technologies, even when both possess equivalent access to the same scientific data and recommendations.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.4	 The Legal Hierarchy of Nuclear Law | Sub-sub-subsection: 12.4.4.1	 The International Regime | Content: The publications by UNSCEAR, the ICRP, and the IAEA
are comprised of general principles, mandatory require­
ments, and binding rules, recommendations, and guidelines.
In addition, a growing structure of international treaty obli­
gations and accepted rules of best practices have been devel­
oped. Important to note are that these recommendations and
standards, while broadly recognized on an international
level, are not adopted by all countries in a uniform way.
Almost all ICRP recommendations and most IAEA stan­
dards are considered to be “soft law” meaning that countries
and institutions are encouraged to implement them in regula­
tions and national legislation, without an actual legal obliga­
tion to do so.
It is important to note that the national variations in the
implementation of nuclear law do not vary from country to
country simply due to varying levels of scientific understand­
ing, but is also influenced by political motives and public
perception. For example, states that are generally wary of the
use of nuclear energy may have a notably different legal
framework than states that generally favor the use of nuclear
energy, despite these states having essentially the same
access to the same scientific information.
12.4.4.2"
"Describe the legal hierarchy involved in regulating nuclear activities at both the national and international levels, focusing on the role of ‘soft law’ instruments like recommendations and guidelines versus legally binding treaties.","The regulation of nuclear activities operates within a complex hierarchical structure. At the most fundamental level is the constitutional framework established by each nation, which sets the overarching legal and institutional context for all activities impacting national interests. Below this lies the statutory level, where specific laws are enacted to address broad areas like nuclear safety and waste management. Finally, there’s the regulatory level, comprised of detailed rules and technical standards issued by specialized regulatory bodies – such as those established under Article 7 of the Convention on Nuclear Safety (CNS) or Article 19 of the Joint Convention – tasked with overseeing nuclear operations. These bodies are responsible for licensing, inspection, enforcement, and providing information to stakeholders. 

Internationally, instruments like the publications by UNSCEAR, the ICRP, and the IAEA play a significant role. These documents comprise general principles, mandatory requirements, binding rules, recommendations, and guidelines. Critically, most of these recommendations and standards are classified as ‘soft law.’ This means they aren’t legally enforceable in themselves but exert considerable influence on national legislation and regulations. Countries and institutions are encouraged to implement them, fostering a broadly recognized international consensus. However, this doesn't guarantee uniform adoption; states retain a degree of self-determination in regulating nuclear activities within their borders, often influenced by political motives and public perception. The EU represents an exception with its directly applicable regulatory framework derived from international binding regulations.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.4	 The Legal Hierarchy of Nuclear Law | Sub-sub-subsection: 12.4.4.2	 The National and Regional Level | Content: The publications by UNSCEAR, the ICRP, and the IAEA
are comprised of general principles, mandatory require­
ments, and binding rules, recommendations, and guidelines.
In addition, a growing structure of international treaty obli­
gations and accepted rules of best practices have been devel­
oped. Important to note are that these recommendations and
standards, while broadly recognized on an international
level, are not adopted by all countries in a uniform way.
Almost all ICRP recommendations and most IAEA stan­
dards are considered to be “soft law” meaning that countries
and institutions are encouraged to implement them in regula­
tions and national legislation, without an actual legal obliga­
tion to do so.
It is important to note that the national variations in the
implementation of nuclear law do not vary from country to
country simply due to varying levels of scientific understand­
ing, but is also influenced by political motives and public
perception. For example, states that are generally wary of the
use of nuclear energy may have a notably different legal
framework than states that generally favor the use of nuclear
energy, despite these states having essentially the same
access to the same scientific information.
12.4.4.2
The National and Regional Level
Adherence to international instruments (e.g., conventions
and treaties) has both an external and an internal aspect. As
a matter of international law, states that take the necessary
steps under their national laws to approve (or ratify) such
instruments are then bound by the obligations arising out of
The central underlying principle of nuclear law is
safety. If a situation arises in which a law’s interpreta­
tion is unclear, it is useful to ask which interpretation
would lead to the safest outcome. This should of course
take into account the beneficial impacts relating to the
exposure, but it is a good starting point if confusion
arises.
There are few hard laws at the international level.
Nation states generally retain a large measure of self-­
determination in regulating nuclear activities within
their borders. There is however a substantial interna­
tional consensus in many areas of radiation protection
and consequently in the basic concepts of nuclear law,
expressed on the one hand in binding treaties and on
the other in rules of soft law, i.e., quasi-legal instru­
ments such as recommendations or guidelines that are
strictly speaking not legally binding but are neverthe­
less widely adopted and may become legally binding
in the future.
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
642
that instrument in their relations with other States Parties.
When this is the case, states need to establish legal arrange­
ments for implementing those obligations internally. Most
States require that the provisions of international instru­
ments be adopted as separate national laws. This approach
is, for example, reflected in Article 4 of the Convention on
Nuclear Safety [46], which states that: “Each Contracting
Party shall take, within the framework of its national law,
the legislative, regulatory and administrative measures and
other steps necessary to implement its obligations under
this Convention.”
When analyzing nuclear law on a national level, there are
basic concepts shared by different states and thus large over­
laps in national public law even though national laws remain
territorial, meaning only applicable to the state or its nation­
als. It would be impossible to even summarize, let alone pro­
vide a comprehensive overview and compare various nuclear
laws in different countries.
The EU is a notable exception to the fragmented incor­
poration of international binding regulations into national
legislation. This is because EU regulations provide a legis­
lative framework that is directly applicable within the
EU. The most recent regulatory framework is the consoli­
dated version of the 2013 Directive laying down the basic
safety standards for protection against the dangers of ion­
izing radiation. The Directive establishes uniform basic
safety standards for the protection of the health of individu­
als subject to occupational, medical, and public exposures.
It applies to any planned, existing, or emergency exposure
situation that involves a health risk from exposure to ion­
izing radiation. The Directive does not apply to natural lev­
els of background radiation, aboveground exposure to
radionuclides present in the undisturbed Earth’s crust,
exposure of members of the public, or exposure of workers
other than air or space crew to cosmic radiation in flight or
in space. Exposure to naturally occurring radioactive mate­
rial (NORM), e.g., in the context of industry or mining
activity is regulated if it leads to exposure of workers or
members of the public which cannot be disregarded from a
radiation protection point of view.
Whether national or regional, it is important to recognize
that nuclear law must take its place within the national legal
hierarchy. The legal framework in which most states operate
consists of several levels. The constitutional level establishes
the basic institutional and legal structure governing all rela­
tionships within the state. Immediately below the constitu­
tional level is the statutory level, at which specific laws are
enacted by the legislative branch of government in order to
establish other necessary bodies and to adopt measures relat­
ing to the broad range of activities affecting national inter­
ests. The third level comprises regulations, detailed and often
highly technical rules issued by regulatory bodies to the
nuclear industry.
12.4.4.3
Regulatory Bodies
A fundamental element of any national nuclear framework is
the creation or maintenance of regulatory bodies with the
legal powers and technical competence necessary to ensure
that operators of nuclear facilities and users of nuclear mate­
rial and ionizing radiation operate and use them safely and
securely. For example, article 7 of the Convention on Nuclear
Safety (CNS) [46] and article 19 of the Joint Convention [47]
require the establishment and maintenance of a legislative
and regulatory framework to govern the safety of, respec­
tively, nuclear installations and radioactive waste manage­
ment, identifying a number of functions to be performed by
a regulatory body within such a framework.
The central consideration is that a regulatory body should
possess the attributes necessary to correctly, self-sufficiently,
and independently apply the national laws and regulations
designed to protect public health, safety, and the environ­
ment. Its tasks can be roughly grouped into four categories:
preliminary assessment (establishing requirements and
determining whether regulatory control is needed); authori­
zation (licensing and registration, including the prohibition
of operations without a license); inspection of nuclear instal­
lations and assessment through periodical reviews and
enforcing compliance through issuing administrative orders
or prohibitions, fines or other penalties. A fifth category, not
mentioned in the two aforementioned conventions but con­
sidered essential by most regulatory bodies, is the provision
of information, including consultation, on regulated activi­
ties with the public, the media, the legislature, and other rel­
evant stakeholders. Finally, a regulatory body should be
permitted to coordinate its activities with the activities of
international and other national bodies involved in nuclear
safety.
An example of successful regulation within these param­
eters can be found in the UK—although the UK is no longer
a member of the EU since January 1, 2021—they remain
compliant with both article 7 of the CNS and article 19 of the
Joint Convention.
12.4.5	Nuclear Liability
A crucial area of nuclear law is nuclear liability. This area
is especially important in the context of unplanned emer­
gency exposure to radiation. The occurrence of nuclear and
radiological accidents cannot be completely excluded even
in situations in which the highest standard of safety has
been achieved. All states that engage in nuclear-related
activities have generally concluded that general tort law is
not an appropriate instrument for providing a liability
regime adequate to the specifics of nuclear risks. Tort law is
the branch of the law that deals with civil suits alleging
negligence, intentional harm, and strict liability, with the
A. Dobney et al."
"Describe the role and responsibilities of a regulatory body within a national nuclear framework, outlining at least five key functions they typically perform to ensure safe operation and usage of nuclear materials and ionizing radiation.","Regulatory bodies are fundamental components of any nation’s approach to managing nuclear activities. Their primary function is to guarantee the secure and safe operation of nuclear facilities and the handling of radioactive materials, safeguarding public health, safety, and the environment. These bodies possess legal powers and technical expertise derived from national laws and international conventions like the Convention on Nuclear Safety (CNS) and the Joint Convention.  Their responsibilities can be broadly categorized into several key functions:

1. **Preliminary Assessment:** This involves establishing specific requirements for nuclear operations and determining whether regulatory oversight is necessary based on risk assessments. It includes evaluating potential hazards and defining acceptable operating parameters.

2. **Authorization (Licensing & Registration):** Regulatory bodies grant licenses and registrations to individuals or organizations intending to operate nuclear facilities or utilize radioactive materials. This process often includes stringent prohibitions against commencing operations without proper authorization, ensuring accountability and control.

3. **Inspection & Compliance Enforcement:** Regular inspections of nuclear installations are conducted to verify adherence to regulations. Furthermore, these bodies enforce compliance through issuing administrative orders, imposing fines, or implementing operational prohibitions when violations occur. Periodic reviews also contribute to maintaining standards.

4. **Information Provision & Stakeholder Engagement:**  A crucial function is providing information related to regulated activities and engaging with a wide range of stakeholders – the public, media, legislature, and other relevant bodies. This includes consultation processes to ensure transparency and incorporate diverse perspectives.

5. **International Coordination:** Regulatory bodies coordinate their actions with international and national organizations involved in nuclear safety, promoting collaboration and harmonized standards across jurisdictions.  This is particularly important for addressing transboundary risks associated with radioactive materials.

Maintaining independence and self-sufficiency within these functions is paramount to the effectiveness of a regulatory body’s role.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.4	 The Legal Hierarchy of Nuclear Law | Sub-sub-subsection: 12.4.4.3	 Regulatory Bodies | Content: ing to the broad range of activities affecting national inter­
ests. The third level comprises regulations, detailed and often
highly technical rules issued by regulatory bodies to the
nuclear industry.
12.4.4.3
Regulatory Bodies
A fundamental element of any national nuclear framework is
the creation or maintenance of regulatory bodies with the
legal powers and technical competence necessary to ensure
that operators of nuclear facilities and users of nuclear mate­
rial and ionizing radiation operate and use them safely and
securely. For example, article 7 of the Convention on Nuclear
Safety (CNS) [46] and article 19 of the Joint Convention [47]
require the establishment and maintenance of a legislative
and regulatory framework to govern the safety of, respec­
tively, nuclear installations and radioactive waste manage­
ment, identifying a number of functions to be performed by
a regulatory body within such a framework.
The central consideration is that a regulatory body should
possess the attributes necessary to correctly, self-sufficiently,
and independently apply the national laws and regulations
designed to protect public health, safety, and the environ­
ment. Its tasks can be roughly grouped into four categories:
preliminary assessment (establishing requirements and
determining whether regulatory control is needed); authori­
zation (licensing and registration, including the prohibition
of operations without a license); inspection of nuclear instal­
lations and assessment through periodical reviews and
enforcing compliance through issuing administrative orders
or prohibitions, fines or other penalties. A fifth category, not
mentioned in the two aforementioned conventions but con­
sidered essential by most regulatory bodies, is the provision
of information, including consultation, on regulated activi­
ties with the public, the media, the legislature, and other rel­
evant stakeholders. Finally, a regulatory body should be
permitted to coordinate its activities with the activities of
international and other national bodies involved in nuclear
safety.
An example of successful regulation within these param­
eters can be found in the UK—although the UK is no longer
a member of the EU since January 1, 2021—they remain
compliant with both article 7 of the CNS and article 19 of the
Joint Convention."
"Describe the concept of ‘nuclear liability’ as outlined in the international legal framework surrounding nuclear incidents, specifically focusing on the role and responsibilities of the ‘operator’ within this regime. What key elements define this exclusive liability?","Nuclear liability, as established by conventions like the Paris Convention and the Joint Convention on Nuclear Safety, represents a specialized legal framework designed to address the unique risks associated with nuclear incidents. A central tenet is the concept of ‘exclusive operator liability,’ meaning that the individual or entity designated as the ‘operator’ of a nuclear installation bears sole responsibility for any resulting damage caused by a ‘nuclear incident.’ This liability operates under an ‘absolute’ or ‘strict’ standard, eliminating the need to prove negligence or fault on the part of the operator. The definition of a ‘nuclear incident’ is crucial; it encompasses any occurrence or series of occurrences with the same origin that causes nuclear damage or creates a grave and imminent threat thereof.  Furthermore, this liability extends regardless of the cause of the incident – even if remote or indirect – and is limited in time, typically to a specified period following the event. The operator must secure adequate financial coverage (often through insurance) to fulfill these obligations. Jurisdictional competence rests with the courts of the country where the incident occurred or where the operator’s installation is located, ensuring consistent enforcement across participating nations. This framework aims to provide comprehensive compensation to victims irrespective of their nationality and guarantees recognition and enforcement of judgments within contracting states.  The channeling of liability onto the operator ensures a streamlined process for claims resolution and minimizes potential disputes regarding responsibility. Reference: [MolecularRadiationBiology > section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure > subsection: 12.4.5: Nuclear Liability]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.5	 Nuclear Liability | Content: ing to the broad range of activities affecting national inter­
ests. The third level comprises regulations, detailed and often
highly technical rules issued by regulatory bodies to the
nuclear industry.
12.4.4.3
Regulatory Bodies
A fundamental element of any national nuclear framework is
the creation or maintenance of regulatory bodies with the
legal powers and technical competence necessary to ensure
that operators of nuclear facilities and users of nuclear mate­
rial and ionizing radiation operate and use them safely and
securely. For example, article 7 of the Convention on Nuclear
Safety (CNS) [46] and article 19 of the Joint Convention [47]
require the establishment and maintenance of a legislative
and regulatory framework to govern the safety of, respec­
tively, nuclear installations and radioactive waste manage­
ment, identifying a number of functions to be performed by
a regulatory body within such a framework.
The central consideration is that a regulatory body should
possess the attributes necessary to correctly, self-sufficiently,
and independently apply the national laws and regulations
designed to protect public health, safety, and the environ­
ment. Its tasks can be roughly grouped into four categories:
preliminary assessment (establishing requirements and
determining whether regulatory control is needed); authori­
zation (licensing and registration, including the prohibition
of operations without a license); inspection of nuclear instal­
lations and assessment through periodical reviews and
enforcing compliance through issuing administrative orders
or prohibitions, fines or other penalties. A fifth category, not
mentioned in the two aforementioned conventions but con­
sidered essential by most regulatory bodies, is the provision
of information, including consultation, on regulated activi­
ties with the public, the media, the legislature, and other rel­
evant stakeholders. Finally, a regulatory body should be
permitted to coordinate its activities with the activities of
international and other national bodies involved in nuclear
safety.
An example of successful regulation within these param­
eters can be found in the UK—although the UK is no longer
a member of the EU since January 1, 2021—they remain
compliant with both article 7 of the CNS and article 19 of the
Joint Convention.
12.4.5	Nuclear Liability
A crucial area of nuclear law is nuclear liability. This area
is especially important in the context of unplanned emer­
gency exposure to radiation. The occurrence of nuclear and
radiological accidents cannot be completely excluded even
in situations in which the highest standard of safety has
been achieved. All states that engage in nuclear-related
activities have generally concluded that general tort law is
not an appropriate instrument for providing a liability
regime adequate to the specifics of nuclear risks. Tort law is
the branch of the law that deals with civil suits alleging
negligence, intentional harm, and strict liability, with the
A. Dobney et al.
643
exception of disputes involving contracts and is considered
to be a form of restorative justice since it seeks to remedy
losses or injury from the wrongful acts of others by provid­
ing awarding monetary damages to provide full compensa­
tion for proved harms. Since civil law is generally designed
to cope with large-scale catastrophes, special measures are
required, and states have enacted specific nuclear liability
legislation.
12.4.5.1
The International Nuclear Liability
Regime
The Paris Convention [48], the Vienna Convention [49], the
Brussels Supplementary Convention [50], the Joint Protocol
[51], the Convention on Supplementary Compensation [52],
and the Revised Vienna Convention [53] (hereafter “the
Conventions”) establish comprehensive regimes for civil
liability for nuclear damage. Application of the international
nuclear liability regime created by the conventions and the
corresponding national legislation will be triggered if an
installation or activity causes a nuclear incident.
A nuclear installation must have a person in charge: the
operator. In the nuclear liability conventions, the operator is
the person—whether this is an individual or any other private
or any public entity having a legal personality—designated
or recognized as the operator of a nuclear installation by the
installation state. The operator, most often the license holder
but possibly the owner of the installation, will always be the
person responsible (and thus liable) for safety.
The term “nuclear incident” means any occurrence, or
any series of occurrences having the same origin, that causes
nuclear damage or, but only with respect to preventive mea­
sures, creates a grave and imminent threat of causing such
damage. Since the occurrence has to cause or threaten
nuclear damage, the definition of what constitutes “nuclear
damage” is paramount. In general tort law, the concept of
compensable damage is well established. If states seek to
obtain the benefits of the Conventions, they must accept the
definitions.
Furthermore, there must be a causal link between a cer­
tain nuclear installation, a certain nuclear incident, and the
damage suffered. The burden of proof of the causal link is on
the person claiming compensation. The Conventions do not
contain any provisions regarding causality. This issue is left
to the law of the competent court (i.e., to national law), so
states may apply the principles of causality applied in their
national law. In most states not all causes of damage are
legally relevant; for example, remote causes may not be con­
sidered. In many states, the law requires “adequate causal­
ity,” which means that a cause is only legally relevant if that
cause is likely to have directly caused the damage for which
compensation is claimed.
The operator of a nuclear installation is held liable,
regardless of fault. This concept is sometimes referred to as
the channeling of liability. This kind of liability is called
strict liability, or sometimes absolute liability or objective
liability. It follows that the claimant does not need to prove
negligence or any other type of fault on the part of the opera­
tor and the simple existence of causation of damage is the
basis of the operator’s liability. Furthermore, the operator of
a nuclear installation is exclusively liable for nuclear dam­
age. No other person may be held liable, and the operator
cannot be held liable under other legal provisions (e.g., tort
law). Liability is legally channeled solely onto the operator
of the nuclear installation. This concept is a feature of nuclear
liability law unmatched in other fields of law. With the excep­
tions of Austria and the USA, all states party to the
Conventions that have enacted nuclear liability laws have
“Nuclear liability” is understood to be the legal regime
based upon the following principles:
•	“Exclusive liability of the operator of the nuclear
installation concerned;
•	“Absolute” or “strict” liability, so that the injured
party is not required to prove fault or negligence on
the part of the operator;
•	Minimum amount of liability;
•	Obligation for the operator to cover liability through
insurance or other financial security;
•	Limitation of liability in time;
•	Equal treatment of victims, irrespective of national­
ity, domicile, or residence, provided that damage is
suffered within the geographical scope of the
convention;
•	Exclusive jurisdictional competence of the courts of
the contracting party in whose territory the incident
occurs or, in case of an incident outside the territo­
ries of contracting parties (in the course of transport
of nuclear material), of the contracting party in
whose territory the liable operator’s installation is
situated);
•	Recognition and enforcement of final judgments
rendered by the competent court in all Contracting
Parties.” (IAEA Joint Convention on the Safety of
Spent Fuel Management and on the Safety of
Radioactive Waste Management [47]).
According to Article 1 of the Paris Convention (Third
Party Liability), a “nuclear incident” is considered to
be “any occurrence or series of occurrences having the
same origin which causes nuclear damage.”
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"What legal framework governs liability following a nuclear incident, particularly focusing on the principle of ‘channeling of liability’ and its implications for compensation claims?","The international legal regime surrounding nuclear incidents, primarily established through conventions like the Paris Convention and its subsequent amendments, operates under a strict liability model known as ‘channeling of liability.’ This means that the operator of a nuclear installation is definitively held liable for any damage caused by a nuclear incident, regardless of fault or negligence. The concept aims to streamline compensation processes by eliminating the need for claimants to prove the operator’s culpability – simply demonstrating causation of damage is sufficient. Furthermore, this framework establishes an ‘absolute’ or ‘strict’ liability regime, meaning that even unforeseen events resulting from operational errors can trigger operator responsibility. Financial limits on liability are often imposed to prevent excessive claims and discourage nuclear activities, though these limits have been increased in recent revisions. The system also mandates insurance coverage by the operator, utilizes international pools of insurance for risk mitigation, and defines jurisdictional competence – typically, courts within the territory where the incident occurred hold exclusive jurisdiction. Finally, the Conventions include provisions for equal treatment of victims irrespective of nationality and a timeframe (typically 30 years for personal injury and 10 years for other damage) within which claims must be submitted. Reference: [IAEA Joint Convention on the Safety of Spent Fuel Management and on the Safety of Radioactive Waste Management], Section 12.4.5 – Nuclear Liability.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.5	 Nuclear Liability | Sub-sub-subsection: 12.4.5.1	 The International Nuclear Liability Regime | Content: cause is likely to have directly caused the damage for which
compensation is claimed.
The operator of a nuclear installation is held liable,
regardless of fault. This concept is sometimes referred to as
the channeling of liability. This kind of liability is called
strict liability, or sometimes absolute liability or objective
liability. It follows that the claimant does not need to prove
negligence or any other type of fault on the part of the opera­
tor and the simple existence of causation of damage is the
basis of the operator’s liability. Furthermore, the operator of
a nuclear installation is exclusively liable for nuclear dam­
age. No other person may be held liable, and the operator
cannot be held liable under other legal provisions (e.g., tort
law). Liability is legally channeled solely onto the operator
of the nuclear installation. This concept is a feature of nuclear
liability law unmatched in other fields of law. With the excep­
tions of Austria and the USA, all states party to the
Conventions that have enacted nuclear liability laws have
“Nuclear liability” is understood to be the legal regime
based upon the following principles:
•	“Exclusive liability of the operator of the nuclear
installation concerned;
•	“Absolute” or “strict” liability, so that the injured
party is not required to prove fault or negligence on
the part of the operator;
•	Minimum amount of liability;
•	Obligation for the operator to cover liability through
insurance or other financial security;
•	Limitation of liability in time;
•	Equal treatment of victims, irrespective of national­
ity, domicile, or residence, provided that damage is
suffered within the geographical scope of the
convention;
•	Exclusive jurisdictional competence of the courts of
the contracting party in whose territory the incident
occurs or, in case of an incident outside the territo­
ries of contracting parties (in the course of transport
of nuclear material), of the contracting party in
whose territory the liable operator’s installation is
situated);
•	Recognition and enforcement of final judgments
rendered by the competent court in all Contracting
Parties.” (IAEA Joint Convention on the Safety of
Spent Fuel Management and on the Safety of
Radioactive Waste Management [47]).
According to Article 1 of the Paris Convention (Third
Party Liability), a “nuclear incident” is considered to
be “any occurrence or series of occurrences having the
same origin which causes nuclear damage.”
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
644
accepted the concept of legal channeling. Exonerations from
this strict liability are limited; the operator being held liable
even if the nuclear incident is caused by force majeure (i.e.,
“an act of God”).
It is also important to note that the financial compensation
which results from the liability may be limited in amount
because legislators feel that unlimited financial liability
would discourage people from engaging in nuclear-related
activities. It is important to note that not all states have cho­
sen to limit liability. In the Conventions, claims for compen­
sation for nuclear damage must be submitted within 30 years
in the event of personal injury and within 10 years in the
event of other damage.
The nuclear liability conventions require that the opera­
tors maintain insurance or provide other financial security
covering liability for nuclear damage in such amount, of
such type, and in such terms as the installation state speci­
fies. Insurance against nuclear risks is quite different in that
there are not many nuclear clients in the insurance industry
and while the risk is low in frequency, it is potentially very
high in severity, resulting in very high amounts to be cov­
ered. On an international level international nuclear pools of
insurance exist, where insurance companies net their capac­
ity in order to bring together the financial capacities of the
entire pool, which is then used to insure domestic civil
nuclear risks and to provide inter-pool reinsurance (recipro­
cation). This pooling principle trickles down to the national
level, where the domestic insurance industry is also orga­
nized into nuclear insurance pools.
With regard to the compensation rights of those affected
by nuclear energy accidents, the Protocols to amend the Paris
Convention on Third Party Liability in the Field of Nuclear
Energy and the Brussels Convention Supplementary to the
Paris Convention have entered into force on 1 January 2022.
The revised conventions combined ensure that those suffer­
ing damage resulting from an accident in the nuclear energy
sector will be able to seek more compensation—the operator
liability will be of at least EUR 700 million under the Paris
Convention and the public funds provided under the Brussels
Supplementary Convention will complement up to EUR 1.5
billion, a sharp increase from the previous 5 million Special
Drawing Rights (SDR) (approximately EUR 6 million as of
13 December 2021) and SDR 125 million (approximately
EUR 155 million as of 13 December 2021), respectively. The
revised Paris Convention also provides now for a minimum
of EUR 70 million and EUR 80 million in case of accidents
at low-risk installations and during the transport of nuclear
substances, respectively. A total of 16 countries will be par­
ties to the amended Paris Convention, covering 105 operat­
ing reactors and 7 under construction, out of a total of 442
operating reactors worldwide and 51 under construction. Of
those countries, 13 are also parties to the amended Brussels
Supplementary Convention (NEA COM 2021).
Finally, with regard to jurisdiction, national procedural
law(s) across countries may indicate several courts to have
jurisdiction when dealing with claims arising out of a nuclear
incident with transboundary or international effects—mean­
ing several courts could be allowed to claim competence to
seize proceedings. The more complicated the different causes
and effects, the more parties internationally involved and the
larger the effects of the contamination, the greater the selec­
tion of potentially competent courts. For this reason, the
Conventions provide, firstly, that only courts of the state in
which the nuclear incident occurs, have jurisdiction and, sec­
ondly, that each member state party to the Conventions shall
ensure that only one of its courts has jurisdiction in relation
to any one nuclear incident. The concentration of procedures
within a single court not only creates legal certainty but also
excludes the possibility that victims of nuclear incidents will
go “forum shopping” and seek to submit claims in states
where their claims are likely to receive more favorable
treatment.
12.4.5.2
Transboundary Implications
of Radiation Incidents
If an activity or facility could cause public exposure in neigh­
boring states through the release of radioactive substances to
the environment, the regulatory body in the state of the
licensee should take steps to ensure that the activity or facil­
ity will not cause greater public exposure in neighboring
states than in the state of the licensee [55]. The concept of
neighboring states does not require that these states share a
border.
The Convention on Early Notification of a Nuclear
Accident (the Early Notification Convention) [56] and the
Convention on Assistance in the Case of a Nuclear Accident
or Radiological Emergency (the Assistance Convention) [57]
cover situations in which an accident involving activities or
facilities in one state have resulted or may result in a trans­
boundary release that could be of radiological safety signifi­
cance for other states. In this context, legally binding
obligations as adapted in national legislations may arise for
radiobiologists, requiring them to notify, directly or through
the IAEA, those states which are or may be affected by a
nuclear accident. The nature of the nuclear incident, the time
of its occurrence and its exact location should be promptly
provided to those States affected in order to minimize the
radiological consequences in those states.
12.4.5.3
Radiation Damage under General
Tort Law
The nuclear liability conventions cover neither radiation
damage caused by radioisotopes used for scientific, medi­
cal, commercial, and other purposes nor radiation damage
caused by X-rays. This is because the use of radioisotopes
and X-ray equipment does not present risks comparable to
A. Dobney et al."
"Following a nuclear incident with transboundary implications, what jurisdictional principles are established within international legal frameworks like the NEA COM 2021 Convention to manage claims and ensure accountability?","The NEA COM 2021 Convention establishes two primary jurisdictional principles regarding nuclear incidents with potential transboundary effects. Firstly, jurisdiction is primarily vested in the courts of the state where the incident originates – that is, the country where the reactor or facility causing the release is located. This aims to streamline proceedings and prevent complex disputes involving multiple legal systems. Secondly, any member state party to the Convention must ensure that only one of its courts has jurisdiction for a specific nuclear incident. This dual approach seeks to create legal certainty by limiting the potential for ‘forum shopping,’ where victims might attempt to pursue claims in jurisdictions perceived as more favorable. The convention also recognizes the complexity arising from multiple causes and effects, leading to involvement of numerous international parties and significant contamination impacts, which consequently increases the number of potentially competent courts that could claim jurisdiction. Ultimately, this framework prioritizes clarity and reduces legal ambiguity when addressing incidents with widespread radiological consequences.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.5	 Nuclear Liability | Sub-sub-subsection: 12.4.5.2	 Transboundary Implications of Radiation Incidents | Content: ing reactors and 7 under construction, out of a total of 442
operating reactors worldwide and 51 under construction. Of
those countries, 13 are also parties to the amended Brussels
Supplementary Convention (NEA COM 2021).
Finally, with regard to jurisdiction, national procedural
law(s) across countries may indicate several courts to have
jurisdiction when dealing with claims arising out of a nuclear
incident with transboundary or international effects—mean­
ing several courts could be allowed to claim competence to
seize proceedings. The more complicated the different causes
and effects, the more parties internationally involved and the
larger the effects of the contamination, the greater the selec­
tion of potentially competent courts. For this reason, the
Conventions provide, firstly, that only courts of the state in
which the nuclear incident occurs, have jurisdiction and, sec­
ondly, that each member state party to the Conventions shall
ensure that only one of its courts has jurisdiction in relation
to any one nuclear incident. The concentration of procedures
within a single court not only creates legal certainty but also
excludes the possibility that victims of nuclear incidents will
go “forum shopping” and seek to submit claims in states
where their claims are likely to receive more favorable
treatment.
12.4.5.2
Transboundary Implications
of Radiation Incidents
If an activity or facility could cause public exposure in neigh­
boring states through the release of radioactive substances to
the environment, the regulatory body in the state of the
licensee should take steps to ensure that the activity or facil­
ity will not cause greater public exposure in neighboring
states than in the state of the licensee [55]. The concept of
neighboring states does not require that these states share a
border.
The Convention on Early Notification of a Nuclear
Accident (the Early Notification Convention) [56] and the
Convention on Assistance in the Case of a Nuclear Accident
or Radiological Emergency (the Assistance Convention) [57]
cover situations in which an accident involving activities or
facilities in one state have resulted or may result in a trans­
boundary release that could be of radiological safety signifi­
cance for other states. In this context, legally binding
obligations as adapted in national legislations may arise for
radiobiologists, requiring them to notify, directly or through
the IAEA, those states which are or may be affected by a
nuclear accident. The nature of the nuclear incident, the time
of its occurrence and its exact location should be promptly
provided to those States affected in order to minimize the
radiological consequences in those states.
12.4.5.3
Radiation Damage under General
Tort Law
The nuclear liability conventions cover neither radiation
damage caused by radioisotopes used for scientific, medi­
cal, commercial, and other purposes nor radiation damage
caused by X-rays. This is because the use of radioisotopes
and X-ray equipment does not present risks comparable to
A. Dobney et al."
"Under general tort law, how do states typically address radiation damage caused by radioisotopes and X-ray equipment, and what specific conditions might negate liability for a responsible party?","Generally, states handle radiation damage stemming from radioisotopes and X-ray equipment under the umbrella of general tort law. This approach reflects the view that these exposures do not represent the extraordinary nuclear risks addressed by specialized nuclear liability conventions. However, this doesn’t automatically absolve parties of responsibility. Liability can be mitigated or eliminated if the responsible party demonstrates they adhered to all radiation protection requirements and could not prevent the damage even with full compliance. Specifically, a claim for negligence would require proving that the individual or organization acted with gross carelessness – meaning a significant deviation from accepted standards – and that this carelessness directly caused the harm.  Crucially, exoneration hinges on demonstrating that the equipment was defect-free and that all required safety measures were diligently followed. Reference: [MolecularRadiationBiology, Section 12.4.5.3 - Radiation Damage under General Tort Law]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.5	 Nuclear Liability | Sub-sub-subsection: 12.4.5.3	 Radiation Damage under General Tort Law | Content: ing reactors and 7 under construction, out of a total of 442
operating reactors worldwide and 51 under construction. Of
those countries, 13 are also parties to the amended Brussels
Supplementary Convention (NEA COM 2021).
Finally, with regard to jurisdiction, national procedural
law(s) across countries may indicate several courts to have
jurisdiction when dealing with claims arising out of a nuclear
incident with transboundary or international effects—mean­
ing several courts could be allowed to claim competence to
seize proceedings. The more complicated the different causes
and effects, the more parties internationally involved and the
larger the effects of the contamination, the greater the selec­
tion of potentially competent courts. For this reason, the
Conventions provide, firstly, that only courts of the state in
which the nuclear incident occurs, have jurisdiction and, sec­
ondly, that each member state party to the Conventions shall
ensure that only one of its courts has jurisdiction in relation
to any one nuclear incident. The concentration of procedures
within a single court not only creates legal certainty but also
excludes the possibility that victims of nuclear incidents will
go “forum shopping” and seek to submit claims in states
where their claims are likely to receive more favorable
treatment.
12.4.5.2
Transboundary Implications
of Radiation Incidents
If an activity or facility could cause public exposure in neigh­
boring states through the release of radioactive substances to
the environment, the regulatory body in the state of the
licensee should take steps to ensure that the activity or facil­
ity will not cause greater public exposure in neighboring
states than in the state of the licensee [55]. The concept of
neighboring states does not require that these states share a
border.
The Convention on Early Notification of a Nuclear
Accident (the Early Notification Convention) [56] and the
Convention on Assistance in the Case of a Nuclear Accident
or Radiological Emergency (the Assistance Convention) [57]
cover situations in which an accident involving activities or
facilities in one state have resulted or may result in a trans­
boundary release that could be of radiological safety signifi­
cance for other states. In this context, legally binding
obligations as adapted in national legislations may arise for
radiobiologists, requiring them to notify, directly or through
the IAEA, those states which are or may be affected by a
nuclear accident. The nature of the nuclear incident, the time
of its occurrence and its exact location should be promptly
provided to those States affected in order to minimize the
radiological consequences in those states.
12.4.5.3
Radiation Damage under General
Tort Law
The nuclear liability conventions cover neither radiation
damage caused by radioisotopes used for scientific, medi­
cal, commercial, and other purposes nor radiation damage
caused by X-rays. This is because the use of radioisotopes
and X-ray equipment does not present risks comparable to
A. Dobney et al.
645
those for which the conventions were designed. The regime
created by the conventions is intended for extraordinary
nuclear risks only.
Even though experience has shown that radioisotopes and
medical irradiation equipment can also cause serious dam­
age if not handled properly, most states deal with liability for
radiation damage caused by radioisotopes and X-rays under
general tort law. States are free to enact, at the national level,
special liability laws for damage caused by these types of
exposure, providing for modified strict liability where the
principle of liability without fault is maintained but the per­
son liable may be exonerated if they can prove that they
could not prevent the occurrence of the damage even though
they complied with all radiation protection requirements and
if they prove that any equipment used was not defective.
In a medical context, harm caused could potentially
amount to a breach of the duty of care that is owed to a
patient from a medical professional or radiologist. If the per­
son liable owes a duty of care to the patient, it must be proven
that this duty was breached, resulting directly in the harm
suffered by the patient. Where the breach is caused by gross
carelessness, the liable party may be criminally negligent.
12.4.6	Special Legal Issues Related
to the International Radioprotection
System
12.4.6.1
Optimization of Protection
One of the key principles of the radiation protection system
recommended by ICRP is the principle of optimization of
protection. The aim is to select the best protection option
under the prevailing circumstances in order to keep the like­
lihood of exposure, the number of people exposed, and the
magnitude of the individual doses incurred, all “as low as
reasonably achievable” often abbreviated to the acronym
“ALARA,” taking into account economic and societal fac­
tors alongside health factors.
It is important to stress that “ALARA” does not simply
mean “as low as reasonably achievable” in the sense that it
should always be the “very lowest” level of radiation expo­
sure that can technically be achieved. “ALARA” should
rather be the “best” protection option, nuanced and well-­
reasoned, where the highest level of safety that can be
achieved from a health perspective, always needs to be bal­
anced
by
social,
environmental,
and
economic
considerations.
Standards are established and safety measures prescribed
in order to ensure that facilities and activities with radiation
risks achieve the highest level of safety throughout the life­
time of the facility or duration of the activity, without unduly
limiting its utilization or usefulness. In order to determine
whether radiation risks are at a level as low as reasonably
achievable, any and all risks, whether arising from normal
operations, abnormal conditions, or accidents, must be
assessed using a graded approach that is periodically reas­
sessed throughout the progression of the activity or lifetime
of the facility.
The optimization of protection requires careful judgment
on the basis of scientific fact that is generally highly influ­
enced by subjective appraisal tailored to individual situations,
which makes it a difficult principle difficult to implement uni­
formly and consequently legally. The relative significance of
various goals, events, and factors have to be judged, including
the number of people (both workers and the general public)
who may be exposed to radiation, the likelihood of exposure,
the magnitude and the radiation doses likely to be received as
a result of foreseeable and unforeseeable events, as well as
the economic, social, and environmental factors involved
with the installation or activity.
12.4.6.2
The ICRP’s International System
of Radiological Protection
The ICRP recommends, develops, and maintains the
International System of Radiological Protection, based on an
evaluation of the large body of scientific studies available to
equate risk to received dose levels.
To this end, the ICRP has established a system of radio­
logical protection with three main principles: justification,
optimization of protection, and individual dose limitation
that apply to planned, emergency, and existing exposure situ­
ations. Planned exposure situations are situations involving
the deliberate introduction and operation of sources of radia­
tion, either anticipated (normal exposures) or not anticipated
to occur (potential exposures). Emergency exposure situa­
tions are situations that may occur during the operation of a
planned situation, or from a malicious act, or from any other
unexpected situation requiring urgent action. Existing expo­
sure situations are exposure situations that already exist
when a decision relating to control has to be taken, including
prolonged exposure situations after emergencies. The ICRP
considers exposure to cosmic radiation to be an existing
exposure situation.
The first two principles, justification and optimization of
protection are source-related and apply in all exposure situa­
tions. The principle of justification states that any decision
that alters the radiation exposure situation should be more
The system’s health objectives are relatively straight­
forward “to manage and control exposures to ionizing
radiation so that deterministic effects are prevented,
and the risks of stochastic effects are reduced to the
extent reasonably achievable” (ICRP Publication 103).
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Describe the core principles outlined by the International Commission on Radiological Protection (ICRP) regarding radiation protection, specifically focusing on justification and optimization of protection.","The ICRP’s framework for radiological protection is built upon three fundamental principles designed to minimize radiation risks. Firstly, ‘justification’ dictates that any deliberate alteration to a radiation exposure situation – whether it involves the introduction or operation of radiation sources (planned exposures) or responses to unforeseen events (emergency and existing exposures) – must be demonstrably justified by demonstrating a significant benefit outweighs the associated risk. This means a thorough evaluation needs to occur, considering factors like the number of individuals potentially exposed, the likelihood of exposure, and the anticipated dose levels. Essentially, it’s about ensuring that radiation use isn't simply happening; there’s a compelling reason for it.

Secondly, ‘optimization of protection’ requires that, given a specific situation, all reasonable measures must be taken to minimize exposures to ionizing radiation. This principle applies across all exposure scenarios – planned, emergency, and existing – and emphasizes a graded approach to risk management. It doesn't aim for absolute zero risk, which is often unattainable, but rather strives to achieve the lowest level of risk that is ‘reasonably achievable’ based on scientific evidence. The ICRP’s health objectives are centered around preventing deterministic effects from radiation exposure and reducing stochastic risks to the greatest extent possible. This principle acknowledges the inherent subjectivity in assessing risk and necessitates careful judgment when balancing competing goals, considering factors like economic, social, and environmental impacts alongside human health concerns.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Content: considerations.
Standards are established and safety measures prescribed
in order to ensure that facilities and activities with radiation
risks achieve the highest level of safety throughout the life­
time of the facility or duration of the activity, without unduly
limiting its utilization or usefulness. In order to determine
whether radiation risks are at a level as low as reasonably
achievable, any and all risks, whether arising from normal
operations, abnormal conditions, or accidents, must be
assessed using a graded approach that is periodically reas­
sessed throughout the progression of the activity or lifetime
of the facility.
The optimization of protection requires careful judgment
on the basis of scientific fact that is generally highly influ­
enced by subjective appraisal tailored to individual situations,
which makes it a difficult principle difficult to implement uni­
formly and consequently legally. The relative significance of
various goals, events, and factors have to be judged, including
the number of people (both workers and the general public)
who may be exposed to radiation, the likelihood of exposure,
the magnitude and the radiation doses likely to be received as
a result of foreseeable and unforeseeable events, as well as
the economic, social, and environmental factors involved
with the installation or activity.
12.4.6.2
The ICRP’s International System
of Radiological Protection
The ICRP recommends, develops, and maintains the
International System of Radiological Protection, based on an
evaluation of the large body of scientific studies available to
equate risk to received dose levels.
To this end, the ICRP has established a system of radio­
logical protection with three main principles: justification,
optimization of protection, and individual dose limitation
that apply to planned, emergency, and existing exposure situ­
ations. Planned exposure situations are situations involving
the deliberate introduction and operation of sources of radia­
tion, either anticipated (normal exposures) or not anticipated
to occur (potential exposures). Emergency exposure situa­
tions are situations that may occur during the operation of a
planned situation, or from a malicious act, or from any other
unexpected situation requiring urgent action. Existing expo­
sure situations are exposure situations that already exist
when a decision relating to control has to be taken, including
prolonged exposure situations after emergencies. The ICRP
considers exposure to cosmic radiation to be an existing
exposure situation.
The first two principles, justification and optimization of
protection are source-related and apply in all exposure situa­
tions. The principle of justification states that any decision
that alters the radiation exposure situation should be more
The system’s health objectives are relatively straight­
forward “to manage and control exposures to ionizing
radiation so that deterministic effects are prevented,
and the risks of stochastic effects are reduced to the
extent reasonably achievable” (ICRP Publication 103).
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Describe the three core principles of the International Commission on Radiological Protection’s (ICRP) system for radiological protection. Explain how each principle applies across different exposure situations – planned, emergency, and existing.","The ICRP's system for radiological protection is founded upon three fundamental principles designed to manage and control exposures to ionizing radiation. These principles are justification, optimization of protection, and individual dose limitation. 

**1. Justification:** This principle dictates that any alteration to a radiation exposure situation – whether it’s the introduction of a new source or changes in operational procedures – must be demonstrably justified. In simpler terms, the potential benefits of using radiation (e.g., medical imaging, industrial applications) must outweigh the inherent risks. The justification process requires careful consideration of the number of people potentially exposed, the likelihood and magnitude of exposure, and the overall risk profile. This principle applies universally across all three exposure situations: planned, emergency, and existing.

**2. Optimization of Protection:** This principle focuses on minimizing radiation exposures to the lowest achievable level, taking into account practical limitations and societal factors. It’s not simply about achieving the absolute minimum dose; rather, it involves a graded approach that considers economic, social, and environmental aspects alongside scientific data. During planned exposure situations, optimization aims to reduce doses while maintaining the intended function of the radiation source. In emergency situations, it focuses on minimizing exposures during urgent actions. For existing exposure situations (like cosmic radiation), optimization seeks to manage the long-term consequences within acceptable limits. 

**3. Individual Dose Limitation:** This principle establishes specific dose limits for individuals based on deterministic and stochastic health effects associated with radiation exposure. The ICRP sets reference doses – levels of radiation that are unlikely to cause harm in a significant proportion of the population – and recommends limiting individual exposures below these values. This principle is most directly applicable to planned exposure situations, where efforts are made to keep individual doses as low as reasonably achievable (ALARA). While relevant to emergency and existing exposures, it’s primarily focused on setting limits rather than actively minimizing dose in those contexts.

In essence, the ICRP's system aims to balance the benefits of using radiation with the need to protect human health by applying these three principles consistently across all exposure scenarios.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Sub-sub-subsection: 12.4.6.1	 Optimization of Protection | Content: considerations.
Standards are established and safety measures prescribed
in order to ensure that facilities and activities with radiation
risks achieve the highest level of safety throughout the life­
time of the facility or duration of the activity, without unduly
limiting its utilization or usefulness. In order to determine
whether radiation risks are at a level as low as reasonably
achievable, any and all risks, whether arising from normal
operations, abnormal conditions, or accidents, must be
assessed using a graded approach that is periodically reas­
sessed throughout the progression of the activity or lifetime
of the facility.
The optimization of protection requires careful judgment
on the basis of scientific fact that is generally highly influ­
enced by subjective appraisal tailored to individual situations,
which makes it a difficult principle difficult to implement uni­
formly and consequently legally. The relative significance of
various goals, events, and factors have to be judged, including
the number of people (both workers and the general public)
who may be exposed to radiation, the likelihood of exposure,
the magnitude and the radiation doses likely to be received as
a result of foreseeable and unforeseeable events, as well as
the economic, social, and environmental factors involved
with the installation or activity.
12.4.6.2
The ICRP’s International System
of Radiological Protection
The ICRP recommends, develops, and maintains the
International System of Radiological Protection, based on an
evaluation of the large body of scientific studies available to
equate risk to received dose levels.
To this end, the ICRP has established a system of radio­
logical protection with three main principles: justification,
optimization of protection, and individual dose limitation
that apply to planned, emergency, and existing exposure situ­
ations. Planned exposure situations are situations involving
the deliberate introduction and operation of sources of radia­
tion, either anticipated (normal exposures) or not anticipated
to occur (potential exposures). Emergency exposure situa­
tions are situations that may occur during the operation of a
planned situation, or from a malicious act, or from any other
unexpected situation requiring urgent action. Existing expo­
sure situations are exposure situations that already exist
when a decision relating to control has to be taken, including
prolonged exposure situations after emergencies. The ICRP
considers exposure to cosmic radiation to be an existing
exposure situation.
The first two principles, justification and optimization of
protection are source-related and apply in all exposure situa­
tions. The principle of justification states that any decision
that alters the radiation exposure situation should be more
The system’s health objectives are relatively straight­
forward “to manage and control exposures to ionizing
radiation so that deterministic effects are prevented,
and the risks of stochastic effects are reduced to the
extent reasonably achievable” (ICRP Publication 103).
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"The ICRP’s International System of Radiological Protection outlines three core principles: justification, optimization of protection, and individual dose limitation. Explain the meaning of each principle and how they apply across different exposure situations (planned, emergency, and existing).","The International Commission on Radiological Protection (ICRP) establishes a framework for radiation safety based on three fundamental principles designed to minimize risk. First, **justification** dictates that any deliberate alteration of a radiation exposure situation – whether it’s introducing a new source or modifying an existing one – should be demonstrably beneficial compared to detrimental. This requires careful evaluation of the potential risks and benefits before proceeding. Second, **optimization of protection** mandates minimizing the likelihood of exposure, reducing the number of people exposed, and lowering individual doses as much as reasonably achievable (ALARA). This principle applies across all exposure situations, including planned operations, emergencies, and existing exposures. Finally, **individual dose limitation** focuses on setting specific limits for the total radiation dose received by individuals from regulated sources in planned exposure scenarios (excluding medical exposures) to prevent deterministic effects and reduce stochastic risks. The ICRP recognizes that these principles apply differently depending on the situation – justification is paramount when initiating a new activity, optimization aims for continuous reduction across all types of exposure, and individual limits provide a specific target for controlled environments. These three pillars work together to ensure radiation protection practices are robust and adaptable.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Sub-sub-subsection: 12.4.6.2	 The ICRP’s International System of Radiological Protection | Content: considerations.
Standards are established and safety measures prescribed
in order to ensure that facilities and activities with radiation
risks achieve the highest level of safety throughout the life­
time of the facility or duration of the activity, without unduly
limiting its utilization or usefulness. In order to determine
whether radiation risks are at a level as low as reasonably
achievable, any and all risks, whether arising from normal
operations, abnormal conditions, or accidents, must be
assessed using a graded approach that is periodically reas­
sessed throughout the progression of the activity or lifetime
of the facility.
The optimization of protection requires careful judgment
on the basis of scientific fact that is generally highly influ­
enced by subjective appraisal tailored to individual situations,
which makes it a difficult principle difficult to implement uni­
formly and consequently legally. The relative significance of
various goals, events, and factors have to be judged, including
the number of people (both workers and the general public)
who may be exposed to radiation, the likelihood of exposure,
the magnitude and the radiation doses likely to be received as
a result of foreseeable and unforeseeable events, as well as
the economic, social, and environmental factors involved
with the installation or activity.
12.4.6.2
The ICRP’s International System
of Radiological Protection
The ICRP recommends, develops, and maintains the
International System of Radiological Protection, based on an
evaluation of the large body of scientific studies available to
equate risk to received dose levels.
To this end, the ICRP has established a system of radio­
logical protection with three main principles: justification,
optimization of protection, and individual dose limitation
that apply to planned, emergency, and existing exposure situ­
ations. Planned exposure situations are situations involving
the deliberate introduction and operation of sources of radia­
tion, either anticipated (normal exposures) or not anticipated
to occur (potential exposures). Emergency exposure situa­
tions are situations that may occur during the operation of a
planned situation, or from a malicious act, or from any other
unexpected situation requiring urgent action. Existing expo­
sure situations are exposure situations that already exist
when a decision relating to control has to be taken, including
prolonged exposure situations after emergencies. The ICRP
considers exposure to cosmic radiation to be an existing
exposure situation.
The first two principles, justification and optimization of
protection are source-related and apply in all exposure situa­
tions. The principle of justification states that any decision
that alters the radiation exposure situation should be more
The system’s health objectives are relatively straight­
forward “to manage and control exposures to ionizing
radiation so that deterministic effects are prevented,
and the risks of stochastic effects are reduced to the
extent reasonably achievable” (ICRP Publication 103).
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
646
beneficial than detrimental. The principle of optimization of
protection states that the likelihood of incurring exposures,
the number of people exposed, and the magnitude of their
individual doses should all be kept As Low As Reasonably
Achievable (ALARA), also taking into account economic
and societal factors. The third principle concerning individ­
ual dose limitation is individual-related and applies in
planned exposure situations: the total dose to any individual
from regulated sources in planned exposure situations other
than medical exposure of patients should not exceed certain
appropriate limits.
The ICRP further distinguishes between three categories of
exposures: occupational exposures, public exposures, and
medical exposures of patients. Occupational exposure is
defined as all radiation exposure of workers incurred due to
their work. ICRP limits the use of “occupational exposures” to
radiation incurred at work in situations that can reasonably be
regarded as being the responsibility of the operating manage­
ment. The employer has the main responsibility for the protec­
tion of workers. Public exposure encompasses all exposures of
the public other than occupational exposures and medical
exposures of patients. The component of public exposure due
to natural sources is by far the largest, but this provides no jus­
tification for reducing the attention paid to smaller, but more
readily controllable, exposures to man-­made sources.
Exposures of the embryo and fetus of pregnant workers are
considered to be public exposures and regulated as such.
While dose is a measure of the total amount of radiation
received, the dose limit is a value of the effective or equiva­
lent dose to individuals that may not be exceeded in activities
under regulatory control. The regulatory body sets the dose
limits for various activities. These dose limits are sometimes
found in the nuclear laws, but more often in the accompany­
ing and more detailed regulations, where regulatory bodies
principally rely on IAEA publications.
12.4.6.3"
"Describe the distinctions between dose limits, dose constraints, and reference levels within the context of international radiation protection systems, outlining their respective roles in regulating exposure.","Within the framework of international radiation protection, dose limits, dose constraints, and reference levels represent distinct yet interconnected regulatory mechanisms. Dose limits are legally binding thresholds – typically set by organizations like the International Commission on Radiological Protection (ICRP) – that define the maximum permissible individual dose received over a specified period, most commonly one year. These limits are not inherently enforceable law but form the basis for national legislation. Importantly, exceeding these limits is generally illegal. Dose constraints, conversely, represent prospective restrictions applied to specific sources of radiation exposure. They’re value-based limitations designed to protect highly exposed individuals and serve as an upper bound during protection optimization. A dose constraint is source-related and focuses on limiting the individual dose from a particular source. Finally, reference levels function as benchmarks for assessing unacceptable risk. Established in emergency or existing controllable exposure situations, they represent a threshold above which planned exposures are deemed inappropriate, triggering the need for protective measures. The value of a reference level is determined by prevailing circumstances and serves as an indicator for determining whether optimization of protection should be implemented. These three elements work together: dose limits provide overarching boundaries, constraints offer targeted protections, and reference levels guide risk assessment and response strategies.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Sub-sub-subsection: 12.4.6.3	 Individual Dose Restrictions | Content: Restricting an individual’s radiation dose is another key fac­
tor of the international radiation protection system.
Restrictions include dose limits, dose constraints, and refer­
ence levels of dose. Each of these restrictions has different
legal implications.
For occupational exposures, the dose constraint is a value of
individual dose used to limit the range of options, both short-
and long-term, considered in the process of optimization. For
public exposure, the dose constraint is an upper limit on the
annual doses from the planned operation of any controlled
source that members of the public should not exceed. In
emergency or existing controllable exposure situations, a ref­
erence level is established to represent the level of dose or
risk, above which it is judged to be inappropriate to plan to
allow exposures to occur, and below which optimization of
protection should be implemented. The chosen value for a
reference level will depend upon the prevailing circum­
stances of the exposure under consideration.
­
­
­
­
12.1
Dose limits set by the ICRP are not hard law but most
countries have implemented these limits into their national
legislation making the exceeding of dose limits illegal. The
industry may also choose to set dose limits for their workers
even lower than those required by law to both ensure the
safety of their employees and reduce the likelihood of
lawsuits.
12.4.6.4
Radiation Workers
Radiation workers are obviously more at risk to be exposed
to radiation than the average individual and dose limits for
occupational exposure are different from dose limits for pub­
lic exposure, specifying an upper limit and a relevant time
span.
The dose limit is the value of dose to individuals from
planned exposure situations that shall not be exceeded.
A dose constraint is a prospective and source-related
restriction on the individual dose from a source, which
provides a basic level of protection for the most highly
exposed individuals from a source, and serves as an
upper bound on the dose in optimization of protection
for that source.
Table 12.1 Recommended dose limits in planned exposure situations
Type of limit
Occupational
Public
Effective dose
20 mSv/year, averaged over
defined periods of 5 years
Annual equivalent dose in:
Lens of the eye
150 mSv
15 mSv
Skin
500 mSv
50 mSv
Hands and feet
500 mSv
–
A. Dobney et al."
Describe the concept of a ‘reference level’ within occupational radiation protection as outlined in the text. What factors influence its determination and what are its key implications for managing radiation exposure?,"Within occupational radiation protection, a ‘reference level’ represents the maximum permissible dose or risk above which it is deemed inappropriate to plan exposures that could potentially harm individuals. This value isn't a strict legal limit but rather a target for optimization; it signifies a point where protective measures should be actively implemented to minimize exposure. The chosen reference level depends on prevailing circumstances, including the type of planned exposure situation (e.g., occupational vs. public), the potential benefits of the exposure, and considerations regarding worker safety. Importantly, the text highlights that industries may voluntarily set even lower dose limits than legally mandated to further safeguard employees and mitigate legal risks. Furthermore, the concept is closely tied to the ALARA principle – As Low As Reasonably Achievable – emphasizing continuous efforts to minimize radiation doses through techniques like minimizing exposure duration, maximizing distance from the source, and utilizing shielding.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Sub-sub-subsection: 12.4.6.4	 Radiation Workers | Content: erence level is established to represent the level of dose or
risk, above which it is judged to be inappropriate to plan to
allow exposures to occur, and below which optimization of
protection should be implemented. The chosen value for a
reference level will depend upon the prevailing circum­
stances of the exposure under consideration.
­
­
­
­
12.1
Dose limits set by the ICRP are not hard law but most
countries have implemented these limits into their national
legislation making the exceeding of dose limits illegal. The
industry may also choose to set dose limits for their workers
even lower than those required by law to both ensure the
safety of their employees and reduce the likelihood of
lawsuits.
12.4.6.4
Radiation Workers
Radiation workers are obviously more at risk to be exposed
to radiation than the average individual and dose limits for
occupational exposure are different from dose limits for pub­
lic exposure, specifying an upper limit and a relevant time
span.
The dose limit is the value of dose to individuals from
planned exposure situations that shall not be exceeded.
A dose constraint is a prospective and source-related
restriction on the individual dose from a source, which
provides a basic level of protection for the most highly
exposed individuals from a source, and serves as an
upper bound on the dose in optimization of protection
for that source.
Table 12.1 Recommended dose limits in planned exposure situations
Type of limit
Occupational
Public
Effective dose
20 mSv/year, averaged over
defined periods of 5 years
Annual equivalent dose in:
Lens of the eye
150 mSv
15 mSv
Skin
500 mSv
50 mSv
Hands and feet
500 mSv
–
A. Dobney et al.
647
In case of a nuclear emergency, workers will likely be
exposed to significantly higher doses, often much higher
than the annual recommended dose limit. A very careful
assessment will have to be made weighing the rescuer’s own
risk versus a clear benefit to others.
The ALARA principle encourages practitioners and other
individuals who have an influence on radiation dosage to
limit dosage as much as practically possible, even when
accounting for the benefits the exposure situation might
bring. This also means that if the exposure does not present a
direct and sufficient benefit, it should be avoided. In order to
optimize protection for radiation workers, the duration of the
exposure should always be minimized while the distance
between the source of the radiation and the individual should
be maximized. A third essential factor is shielding.
The legally binding obligations related to occupational
radiation protection are established in the Radiation Protection
Convention No. 115 adopted by The General Conference of
the International Labour Organization [58]. This Convention,
which has been ratified by most countries, applies to all activ­
ities involving exposure of workers to ionizing radiations in
the course of their work and who, in applying its provisions
the state party’s competent authority, have to consult with
representatives of employers and workers.
12.4.6.5
Medical Use
Sources of ionizing radiation are essential to modern health­
care as they span a range of purposes, such as the steriliza­
tion of disposable medical supplies, central to combating
disease [59]. To give a more recent example, China has opti­
mized the use of radiation to cut down sterilization times
from 7 days to just 1 in order to combat the COVID-19 pan­
demic [60]. Radiology is also a vital diagnostic tool; CT and
X-rays have been crucial to healthcare in terms of diagnostic
precision, which in turn improve treatment response.
However, as ionizing radiation can be detrimental to liv­
ing organisms, humans included, it is essential that sources
of ionizing radiation be covered by measures to protect indi­
viduals. Medical treatment involving planned exposure to
ionizing radiation can only take place if the patient has
agreed after being carefully informed about the risks.
Radiation exposures of patients occur in diagnostic, inter­
ventional, and therapeutic procedures. There are several fea­
tures of radiological practices in medicine that require an
approach that differs from radiological protection in other
planned exposure situations. The exposure is intentional and
for the direct benefit of the patient. Particularly in radiother­
apy, the biological effects of high-dose radiation, e.g., cell
killing, are used for the benefit of the patient to treat cancer
and other diseases. The medical uses of radiation therefore
require separate guidelines.
A relatively recent topic of discussion is that of adventi­
tious exposure, i.e., unintended exposure happening as a
result of primary, intended exposure. A patient undergoing
therapeutic exposure to ionizing radiation—exposure that is
considered to be beneficial, contributing to a positive medical
outcome—probably will suffer to some extent, effects that are
neither intended nor desired because these are an unavoidable
by-product of radiotherapy procedures. Adventitious expo­
sure can occur in any part of the body and cause secondary
cancers as a malignant result of radiotherapy, the effects
remaining latent, manifesting only after the treatments. It is
important to distinguish that cancer forming due to adventi­
tious exposure is not a metastasis of the original malignancy,
but rather a primary malignancy in itself. The incidence of
such cancers is being investigated worldwide, also by
UNSCEAR, and may contribute to litigation initiated by
patients or their next of kin against radiobiologists or other
radiation specialists in the medical field. A deep understand­
ing of this complex mechanism is still evolving, but the medi­
cal professional would do well to document—either by
measurement or estimation—the scenario of adventitious
exposure situations through dosimetric quantities or suitable
proxies. It may even prove to be necessary to dutifully inform
and obtain explicit patient agreement on the subject.
Most countries have regulations to guide the medical pro­
fessional involved with treatment that includes medical expo­
sure of a patient to ionizing radiation in order to protect both
the professional and the patient. In the EU, Council Directive
2013/59/Euratom Chapter VII [61] centers the relevant arti­
cles 55 and 56 once again around the principles of justifica­
tion and optimization. In the assessment and justification of
the use of radiology with any specific patient, the practitioner
should consider all relevant aspects of their medical history
and decide, with feedback and consent from the patient, the
radiation therapy most suited to that individual patient.
12.4.6.6
Exposure to Cosmic Rays
Cosmic rays at ground level are not considered to warrant
regulatory control. Mankind has been exposed to—and has
evolved with—radiation from the universe reaching Earth
since the beginning of time. However, at high altitudes,
where cosmic rays are less attenuated by the atmosphere or,
even higher, by the Earth’s magnetic field, they undoubtedly
pose a risk to people and equipment because of the very high
energies involved. As a consequence, astronauts and aircraft
personnel need to be well informed about these exposure
risks during the course of their careers and possible conse­
quences and outcomes as a result.
Disregarding the Space Treaties that arguably do not
really deal with exposure to ionizing radiation, the protective
framework for astronauts in this context is not regulated by
international law, but rather designed and governed by the
space agencies by which they are employed, on the basis of
an ever-evolving scientific insight and assessment. All major
space agencies have very stringent safety precautions in
place, specifying dose, dose rate, and career limits for their
astronauts in order to make sure there is no statistical risk of
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
Describe the concept of ‘adventitious exposure’ in the context of radiation therapy and explain its potential implications for patients.,"Adventitious exposure refers to unintended radiation exposure that occurs during therapeutic treatments utilizing ionizing radiation, such as radiotherapy. This exposure happens alongside the intended beneficial effects of the treatment but results in secondary damage to tissues – primarily through the creation of new malignancies. Critically, these cancers arising from adventitious exposure are considered primary malignancies themselves and are distinct from metastases originating from the initial tumor. The risk stems from the unavoidable radiation-induced DNA damage that occurs throughout the body during radiotherapy, even in areas not directly targeted by the treatment beam. This damage can lead to mutations and uncontrolled cell growth, ultimately resulting in cancer development at a later time – often years or decades after the primary therapy has concluded. Furthermore, adventitious exposure raises significant legal considerations, potentially leading to litigation if such cancers develop due to the therapeutic radiation, necessitating meticulous documentation of exposure scenarios and obtaining explicit patient consent regarding the risks involved. The investigation into the incidence of these cancers is ongoing, with organizations like UNSCEAR playing a key role in understanding and mitigating this complex issue.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Sub-sub-subsection: 12.4.6.5	 Medical Use | Content: and other diseases. The medical uses of radiation therefore
require separate guidelines.
A relatively recent topic of discussion is that of adventi­
tious exposure, i.e., unintended exposure happening as a
result of primary, intended exposure. A patient undergoing
therapeutic exposure to ionizing radiation—exposure that is
considered to be beneficial, contributing to a positive medical
outcome—probably will suffer to some extent, effects that are
neither intended nor desired because these are an unavoidable
by-product of radiotherapy procedures. Adventitious expo­
sure can occur in any part of the body and cause secondary
cancers as a malignant result of radiotherapy, the effects
remaining latent, manifesting only after the treatments. It is
important to distinguish that cancer forming due to adventi­
tious exposure is not a metastasis of the original malignancy,
but rather a primary malignancy in itself. The incidence of
such cancers is being investigated worldwide, also by
UNSCEAR, and may contribute to litigation initiated by
patients or their next of kin against radiobiologists or other
radiation specialists in the medical field. A deep understand­
ing of this complex mechanism is still evolving, but the medi­
cal professional would do well to document—either by
measurement or estimation—the scenario of adventitious
exposure situations through dosimetric quantities or suitable
proxies. It may even prove to be necessary to dutifully inform
and obtain explicit patient agreement on the subject.
Most countries have regulations to guide the medical pro­
fessional involved with treatment that includes medical expo­
sure of a patient to ionizing radiation in order to protect both
the professional and the patient. In the EU, Council Directive
2013/59/Euratom Chapter VII [61] centers the relevant arti­
cles 55 and 56 once again around the principles of justifica­
tion and optimization. In the assessment and justification of
the use of radiology with any specific patient, the practitioner
should consider all relevant aspects of their medical history
and decide, with feedback and consent from the patient, the
radiation therapy most suited to that individual patient.
12.4.6.6"
"The text discusses ‘adventitious exposure,’ which refers to unintended radiation effects arising from therapeutic treatments. Explain the key distinction between adventitious cancer and metastasis, as described within this context.","Adventus exposure describes the secondary cancers that can develop following intended ionizing radiation therapy. A crucial point is differentiating it from metastasis. Adventitious cancer resulting from this exposure isn't a spread of cancerous cells from an original malignancy; instead, it’s considered a primary malignancy arising directly due to the radiation damage at the treated site. Essentially, it’s a new tumor formed as a consequence of the radiotherapy itself, not a recurrence or spread of a pre-existing cancer. Reference: [MolecularRadiationBiology, Section 12.4.6.6 Exposure to Cosmic Rays]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.4	 Legal Aspects of Radiation Exposure Situations | Sub-subsection: 12.4.6	 Special Legal Issues Related to the International Radioprotection System | Sub-sub-subsection: 12.4.6.6	 Exposure to Cosmic Rays | Content: and other diseases. The medical uses of radiation therefore
require separate guidelines.
A relatively recent topic of discussion is that of adventi­
tious exposure, i.e., unintended exposure happening as a
result of primary, intended exposure. A patient undergoing
therapeutic exposure to ionizing radiation—exposure that is
considered to be beneficial, contributing to a positive medical
outcome—probably will suffer to some extent, effects that are
neither intended nor desired because these are an unavoidable
by-product of radiotherapy procedures. Adventitious expo­
sure can occur in any part of the body and cause secondary
cancers as a malignant result of radiotherapy, the effects
remaining latent, manifesting only after the treatments. It is
important to distinguish that cancer forming due to adventi­
tious exposure is not a metastasis of the original malignancy,
but rather a primary malignancy in itself. The incidence of
such cancers is being investigated worldwide, also by
UNSCEAR, and may contribute to litigation initiated by
patients or their next of kin against radiobiologists or other
radiation specialists in the medical field. A deep understand­
ing of this complex mechanism is still evolving, but the medi­
cal professional would do well to document—either by
measurement or estimation—the scenario of adventitious
exposure situations through dosimetric quantities or suitable
proxies. It may even prove to be necessary to dutifully inform
and obtain explicit patient agreement on the subject.
Most countries have regulations to guide the medical pro­
fessional involved with treatment that includes medical expo­
sure of a patient to ionizing radiation in order to protect both
the professional and the patient. In the EU, Council Directive
2013/59/Euratom Chapter VII [61] centers the relevant arti­
cles 55 and 56 once again around the principles of justifica­
tion and optimization. In the assessment and justification of
the use of radiology with any specific patient, the practitioner
should consider all relevant aspects of their medical history
and decide, with feedback and consent from the patient, the
radiation therapy most suited to that individual patient.
12.4.6.6
Exposure to Cosmic Rays
Cosmic rays at ground level are not considered to warrant
regulatory control. Mankind has been exposed to—and has
evolved with—radiation from the universe reaching Earth
since the beginning of time. However, at high altitudes,
where cosmic rays are less attenuated by the atmosphere or,
even higher, by the Earth’s magnetic field, they undoubtedly
pose a risk to people and equipment because of the very high
energies involved. As a consequence, astronauts and aircraft
personnel need to be well informed about these exposure
risks during the course of their careers and possible conse­
quences and outcomes as a result.
Disregarding the Space Treaties that arguably do not
really deal with exposure to ionizing radiation, the protective
framework for astronauts in this context is not regulated by
international law, but rather designed and governed by the
space agencies by which they are employed, on the basis of
an ever-evolving scientific insight and assessment. All major
space agencies have very stringent safety precautions in
place, specifying dose, dose rate, and career limits for their
astronauts in order to make sure there is no statistical risk of
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
648
radiation exposure-induced death (REID) and other adverse
effects. Even though astronauts are generally extremely
healthy and are unlikely to suffer health effects at a level
worse than that of the general population, the advent of deep
space travel, notably the Moon and Mars missions planned in
the near future, will likely expose them to high fluxes of solar
energetic particles and heavy ions, in possibly problematic
amounts. Radiation mitigation strategies, shielding and care­
ful mission planning, and astronaut selection will prove to be
crucial to attempt these types of interplanetary exploratory
missions. Being continuously monitored and genetically
screened for suitability may however create some legal issues
as well. Not only are privacy issues imaginable with the
extreme scrutiny astronauts are subjected to, but unequal
treatment and an imbalance in career opportunities due to
individual genetic predisposition to adverse health effects
from ionizing radiation may at some point also become an
object of contention, as is discussed more in depth in Sect.
12.3.8 on emerging occupational challenges from new meth­
ods to determine individual radiosensitivity (supra).
Guidance and protection for other jobs at slightly lower
altitudes are much more regulated. Airline pilots and person­
nel—and even frequent flyers—repeatedly expose them­
selves to ionizing radiation, primarily from charged particles
and therefore require employment protection. Compared to
astronauts, aircraft personnel make up a substantially larger
group of radiation workers, inspiring governments to imple­
ment special mandatory protection measures. For example,
Directive 96/29/Euratom 1996 requires appropriate radio­
logical protection of aircrew. Article 42 of the Directive
obliges member states to regulate the sector, specifically
regarding the exposure to cosmic radiation at flight altitudes.
As a result, each member state is obliged to force airline
companies to take account of exposure to cosmic radiation of
aircrew who are liable to be subject to exposure to more than
1 mSv/year. EU airline companies need to record a continual
assessment of the exposure of the crew concerned and use
this information when organizing working schedules with a
view to reducing the doses of highly exposed aircrew.
Aircraft personnel needs to be informed of the health risks
their work involves and female aircrew in particular, when
pregnant, will have the terms of her employment adapted to
ensure that the equivalent dose to the child to be born is
ALARA and that it will be unlikely that this dose will exceed
1 mSv during at least the remainder of the pregnancy. As
soon as a nursing woman informs her employer of her condi­
tion, she cannot be employed in work involving a significant
risk of bodily radioactive contamination. This is of course
not to say that female airline crew are the only radiation
workers protected through nuclear law; different rules for
pregnancy, varying from country to country, are applicable
for workers in other nuclear industries.
12.5"
"How do legal frameworks surrounding radiation exposure often differentiate between occupational and non-occupational exposures, particularly concerning potential harm claims?","Legal considerations regarding radiation exposure frequently establish distinct pathways for assessing harm depending on the context of exposure. Generally, occupational exposures – those occurring within regulated nuclear industries or facilities where workers are specifically protected by law – are treated differently than non-occupational exposures. Occupational cases typically involve a heightened burden of proof, often requiring demonstrable evidence that the worker’s exposure exceeded established regulatory limits and contributed directly to adverse health effects. This is frequently justified through detailed monitoring data, risk assessments, and adherence to stringent safety protocols designed for those workers. Furthermore, legal protections are often extended to cover potential harm during pregnancy in occupational settings, reflecting a greater concern for vulnerable populations due to the known developmental risks associated with radiation exposure. Conversely, non-occupational exposures – such as accidental releases or environmental contamination – may be evaluated under broader standards of negligence and causation. Establishing a direct link between the exposure and subsequent health effects can be more challenging, requiring extensive epidemiological studies and potentially longer latency periods for disease development to demonstrate a causal relationship. The specific regulations and legal interpretations vary considerably across jurisdictions, leading to diverse approaches regarding liability, compensation, and ultimately, the imputation of harm in radiation exposure situations. Reference: 12.5 Legal Imputation of Radiation Harm to Radiation Exposure Situations","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.5	 Legal Imputation of Radiation Harm to Radiation Exposure Situations | Content: workers protected through nuclear law; different rules for
pregnancy, varying from country to country, are applicable
for workers in other nuclear industries.
12.5
Legal Imputation of Radiation Harm
to Radiation Exposure Situations"
"Within the legal framework surrounding radiation exposure incidents, what are the two primary elements required for a successful claim involving attribution and imputation of harm, and how do these concepts relate to establishing a causal link between radiation exposure and adverse health outcomes?","To successfully pursue legal action alleging harm resulting from radiation exposure, two key elements must be established: attribution and imputation. ‘Attribution’ refers to the demonstrable factual connection between a specific radiation incident and an observed health effect – essentially proving that the radiation exposure caused the damage. This requires objective evidence, typically through expert testimony, demonstrating a causal link. ‘Imputation,’ conversely, focuses on determining responsibility for that harm. It involves placing liability for the physical injury (or potential ill effects) attributable to the radiation exposure onto another party—either an individual or legal entity. While closely related, attribution and imputation both aim to establish causality; they differ in their focus: attribution confirms the link between the incident and the effect, while imputation assigns responsibility for that effect. The process is often complex, particularly when dealing with low-dose exposures where establishing a definitive causal relationship becomes significantly more challenging due to the lack of clear, readily available evidence and differing expert opinions.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.5	 Legal Imputation of Radiation Harm to Radiation Exposure Situations | Sub-subsection: 12.5.1	 Legal Actions Resulting from Radiation Exposure Situations | Content: workers protected through nuclear law; different rules for
pregnancy, varying from country to country, are applicable
for workers in other nuclear industries.
12.5
Legal Imputation of Radiation Harm
to Radiation Exposure Situations
12.5.1	Legal Actions Resulting from Radiation
Exposure Situations
Legal action based on radiation harm, i.e., legal proceedings
or a lawsuit, generally requires two elements to succeed;
attribution and imputation. First, a causal link must be estab­
lished; a certain health effect needs to be attributed to a cer­
tain radiation exposure using objective factual evidence.
Second, there needs to be imputation, meaning someone’s
responsibility for the radiation harm needs to be determined.
In a legal context, imputation means placing the responsibil­
ity for the physical injury (actual or potential ill effects) that
is attributable to the radiation exposure, on another (natural
or legal) person. While “attribution,” meaning establishing
the factual link between a nuclear incident and a health effect
and “imputation,” meaning ascribing responsibility for the
radiation harm are closely related in that they both attempt to
establish a causal link, they have often been used as syn­
onyms, causing confusion. Examples range from the use by
the International Labour Organization (ILO), International
Atomic Energy Agency (IAEA) to the World Health
Organization (WHO).
Attribution and imputation both generate controversy and
two basic challenges dominate the issue. The first challenge
is the attribution of specific health effects to a specific radia­
tion exposure situation, which requires qualified experts to
demonstrate that a factual occurrence can be causally
linked—meaning without a doubt—to radiation harm. The
second challenge is of a more formal nature; how to proceed
with relevant legal actions consistent with the legal practice
in the applicable jurisdiction or legal system. In high-­
exposure incidents with obvious harmful effects, this is rela­
tively straightforward. On the other hand, a challenge arises
in situations involving low to very low radiation doses. This
issue is amply discussed in the literature [62–64] but no clear
solution, let alone a consensus between experts, has been
found yet.
When attribution between the incident and the effect is
established, imputation is crucial to allow for subse­
quent legal actions such as charging, indicting, and
prosecuting—if a criminal element is involved—or
simply initiating a civil suit if another form of negli­
gence can be demonstrated. The end goal for the plain­
tiff is to obtain reparation for damages incurred.
A. Dobney et al.
649
12.5.2	Attribution and Inference of Health
Effects to Radiation
­
­
­
­
65
­
66
­
67
­
­
12.1
­
­
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"In legal proceedings involving radiation exposure claims, what specific roles can different types of scientific experts fulfill when attesting to the occurrence of harm, and how does their expertise differ?","When determining liability in cases related to radiation exposure, expert witnesses play a crucial role in establishing causation. Several specialized fields contribute to this process, each with distinct approaches. Radiopathologists are qualified to attest to the factual occurrence of health effects that can be diagnosed within individuals exposed to radiation – essentially, they provide direct evidence of observable damage at the cellular or tissue level. Radioepidemiologists focus on assessing radiation-related health effects in larger populations using statistical analysis of disease incidence and distribution patterns associated with exposure. This allows them to infer potential harm based on population-level data rather than individual observations. Radioprotectionists, similarly, contribute by focusing on protective measures and risk assessment related to radiation exposure. Finally, radiobiologists occupy a middle ground, leveraging theoretical understanding of radiation’s biological effects alongside empirical data from bioassay specimens (like hematological and cytogenetic samples) to demonstrate probable tissue damage after exposure. Crucially, radiobiologists don't directly attest to the factual occurrence of changes in an individual but rather extrapolate findings from specialized studies to suggest potential outcomes based on established scientific principles. The selection of an expert witness depends heavily on the specific evidence available – whether it’s direct observation of damage or population-level statistical trends.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.5	 Legal Imputation of Radiation Harm to Radiation Exposure Situations | Sub-subsection: 12.5.3	 Attesting Effect Occurrence | Content: The attribution of radiation harm is an essential component
of any legal action. A professionally qualified expert witness
should provide clear evidence on the occurrence of radiation
effects, caused by a radiation incident, by formally declaring
that a causal effect exists. It is obviously not necessary for an
expert to have witnessed first-hand the incident at the origin
of a radiation-related lawsuit, but he or she does need to be a
specialist in radiation effects and able to offer, without rea­
sonable doubt, an expert opinion after considering the chro­
nology of events and factual occurrence of the causes and the
effects.
­
­
­
­
­
­
12.2
Radiopathologists, radioepidemiologists, and radiopro­
tectionists can all be qualified expert witnesses in the context
of legal action, the first attesting the factual occurrence of
health effects that can be diagnosed in individuals, the sec­
ond attesting the factual occurrence of radiation health
effects that can be estimated in population cohorts using sta­
tistics on the incidence and distribution of diseases associ­
ated with radiation exposure, and the third by inferring
radiation risks from theory rather than fact. Radiobiologists
are a fourth group of scientists that could be situated some­
where between radiopathologists and radioepidemiologists.
A radiobiologist has expertise in the branch of biology con­
cerned with the effects of ionizing radiation on organisms,
organs, tissues, and cells which can be useful—without
directly attesting the factual occurrence of biological changes
in an individual—to demonstrate probable effects on tissue
after radiation exposure by extrapolating data collected dur­
ing the study and analysis of specialized bioassay specimens,
hematological and cytogenetic samples."
"According to the text, how do different types of radiation experts – such as radiobiologists, radiopathologists, and radioepidemiologists – contribute to legal proceedings concerning radiation exposure, particularly in relation to attributing harm and establishing causation?","The document outlines distinct roles for various scientific specialists when addressing legal claims related to radiation exposure. Radiobiologists focus on demonstrating probable tissue effects through bioassay analysis and extrapolating data from specialized samples, without directly attesting individual changes. Radiopathologists attest to the factual occurrence of diagnosed health effects in individuals. Radioepidemiologists estimate radiation health effects within population cohorts using statistical incidence and distribution data. A key distinction lies in the dose region: in high-dose scenarios, attribution and imputation are straightforward due to clinically attributable harm; in moderate doses, collective or group imputation is more common (e.g., via class action lawsuits); and in low-dose regions, establishing a causal link becomes highly uncertain due to the lack of individual or collective attestation, relying instead on theoretical risk inference and statistical probability. The legal system's approach – whether jurisprudential or codified – also influences the predictability of outcomes. Reference: A. Dobney et al., 12.5.4 Legal Consequences","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.5	 Legal Imputation of Radiation Harm to Radiation Exposure Situations | Sub-subsection: 12.5.4	 Legal Consequences | Content: ­
­
­
12.2
Radiopathologists, radioepidemiologists, and radiopro­
tectionists can all be qualified expert witnesses in the context
of legal action, the first attesting the factual occurrence of
health effects that can be diagnosed in individuals, the sec­
ond attesting the factual occurrence of radiation health
effects that can be estimated in population cohorts using sta­
tistics on the incidence and distribution of diseases associ­
ated with radiation exposure, and the third by inferring
radiation risks from theory rather than fact. Radiobiologists
are a fourth group of scientists that could be situated some­
where between radiopathologists and radioepidemiologists.
A radiobiologist has expertise in the branch of biology con­
cerned with the effects of ionizing radiation on organisms,
organs, tissues, and cells which can be useful—without
directly attesting the factual occurrence of biological changes
in an individual—to demonstrate probable effects on tissue
after radiation exposure by extrapolating data collected dur­
ing the study and analysis of specialized bioassay specimens,
hematological and cytogenetic samples.
12.5.4	Legal Consequences
The ability to attribute health effects to specific exposure
situations and to attest their occurrence by means of a quali­
fied expert witness has a direct influence on the chances of
successful litigation if the radiation harm can be clearly
A. Dobney et al.
651
­
attributed to an incident, imputed to the persons responsible
and subsequently compensation awarded to the victims by a
court of law. Physical injuries and harmful effects inflicted
by those who have caused the exposure, if proven, allow
radiation workers or the general public to bring a lawsuit
against employers, licensees of nuclear installations, or even
the regulatory authorities in the event of a lack of oversight
or effective control.
The legal playing field however is not quite level.
Legislation and regulatory frameworks that deal with the
attribution of radiation health effects are inhomogeneous,
sometimes incoherent, and inconsistent among countries
and even within countries. A major fault line exists between
legal systems based on jurisprudential legislation and
those who rely on detailed codified legislation. A compari­
son of case law exceeds the scope of this chapter, but—at
the risk of being overly coarse—we could state that juris­
prudential legal systems that employ a case-by-case
approach are generally more flexible and provide a higher
degree of legal certainty for the plaintiff. Jurisdictions that
rely on codified legislation are not bound by legal prece­
dent, placing a high degree of autonomy on the court in
applying the rule of law, which can lead to less predictable
results.
12.3
­
In the high-dose region, individual health effects are clini­
cally attributable and attestable, and imputation of harm
incurred by the affected individual is therefore straightfor­
ward. Attribution is clear; imputation is often directly linking
the individual suffering radiation harm to the responsible
person and a classic lawsuit, where civil legal action by one
person or entity against another person or entity has a high
chance of success.
In the moderate dose region, increased incidences of
harmful effects in population groups are epidemiologically
attributable and attestable and imputation to the responsible
person is therefore feasible. When dealing with the harmful
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
652
­
effects of moderate doses, a collective or group imputation is
more logical, e.g., via a class action lawsuit where the plain­
tiffs are more likely than not a group of people presenting a
collective claim.
In the low-dose region, radiation harm is neither attrib­
utable nor attestable on an individual or collective level, but
some radiation risk might be inferred. From a legal per­
spective, claims based on a low dose or low dose rate expo­
sure are uncertain. Since radiation harm might not yet have
presented itself or, if present, might be quite removed in
time from the alleged exposure situation, a court might
struggle with establishing, beyond a reasonable doubt, a
causal link between the exposure situation and any health
effects allegedly suffered by the plaintiff. The problem pre­
sented here is one of objectivity. The cause cannot be
attested, the harmful result is only inferred considering
theoretical risk and perhaps statistical probability, and any
judgment based on these ambiguous facts would have a
high degree of subjectivity."
"The text discusses challenges in establishing legal frameworks surrounding radiation exposure. Specifically, what are the two fundamental objectives highlighted regarding fostering a common understanding between science and law concerning radiation harm and exposure situations?","According to the text, the two fundamental objectives are: (1) to foster a common legal understanding of cause and effect when dealing with radiation harm and radiation exposure situations from a scientific perspective, which would greatly enhance legal certainty; and (2) to establish a universal scientific and legal consensus to direct the application of the law in any situation, thereby reducing uncertainty and potentially benefiting the harmonization of national legislations. The text emphasizes that despite these goals, individual case assessments will still be necessary due to variations in legal systems and interpretations.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.5	 Legal Imputation of Radiation Harm to Radiation Exposure Situations | Sub-subsection: 12.5.5	 Next Steps | Content: The scientific consensus on health effects attributable to
radiation exposure—consensus that in itself is not entirely
uniform and still progressing—should serve as a basis for the
development of legal instruments in order to have a more
uniform treatment of legal actions. In particular, the issue of
legal imputation when considering low dose rates should be
carefully considered. This issue has not yet crystallized in
any type of universal approach, in large part given the funda­
mental differences between case-based and codified legal
systems. The scientific community is eager to provide legal
experts with guidance based on the progressing insight into
the attribution of radiation effects following radiation expo­
sure situations.
Given the cultural, regulatory, and legislative differ­
ences among countries, two fundamental objectives stand
out. First, it seems imperative to foster a common legal
understanding of cause and effect when dealing with radia­
A. Dobney et al.
653
tion harm and radiation exposure situations. From a scien­
tific perspective, this seems feasible, and if adopted by the
legal community, this would greatly enhance legal cer­
tainty. Second—and perhaps even more optimistically—
the establishment of a universal scientific and legal
consensus to direct the application of the law in any situa­
tion would reduce uncertainty even further and might even
benefit the development and harmonization of different
national legislations. In reality however “the law” is not a
uniform concept and nations, courts and judges, prosecu­
tors and lawyers will always want to look at the facts of any
individual case, assess the differences and exceptions to the
rules if there are any and, in general, assert their indepen­
dent reasoning. Today, the road ahead for the legal com­
munity dealing with nuclear law seems long and far from
determined.
12.6
Social and Psychological Issues
Associated with Radiation Exposure
12.6.1	Introduction
Human behavior is primarily driven by perception and not by
facts [68]. In practice, this pattern is clearly demonstrated
also in people’s behavior related to ionizing radiation. For
instance, exposure to the medical application of ionizing
radiation is highly acceptable for most people, while food
irradiation used to increase the safety of food may be unac­
ceptable for many people, although in the first case the
patient may receive a relatively high radiation dose and in the
second case the consumer will not receive any radiation due
to the sterilization [69, 70].
Likewise, 10 mSv received as a worker’s exposure or
10 mSv received during an accidental release of radioactivity
to the environment may cause different behavior. This sec­
tion examines the social and psychological aspects of radia­
tion exposure. First, we will explain the phenomena of
radiation risk perception and second we will identify and
discuss determinants of health and radiation protection
behavior. Finally, we will conclude this chapter with radia­
tion risk communication advice for experts in radiobiology
in order to be able to communicate effectively and help peo­
ple to make informed decisions related to radiation risks.
12.6.2	Perception of Radiation Risk
Risk perception mainly denotes the ways individuals think
and feel about the risks they face [71–73]. Radiation risk per­
ception has been extensively studied, for example, in the
context of nuclear power [74–76], nuclear testing [77], radio­
active waste [78], radon [79], food sterilization by irradiation
[80], and nuclear accidents [81]. It is interesting that people
perceive radiation risks differently, depending on the origins
of this radioactivity, and the contexts in which it is
encountered.
­
­
82
12.4
­
82
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"How might psychological factors contribute to an individual's perception of risk associated with exposure to ionizing radiation, even when objective dose measurements are similar across different individuals?","The perception of risk related to ionizing radiation is often significantly influenced by psychological factors rather than solely relying on quantitative dose metrics. Several cognitive biases and emotional responses can dramatically alter an individual’s assessment of danger. For example, the ‘availability heuristic’ leads people to overestimate the likelihood of events that are easily recalled – in this case, dramatic portrayals of radiation-induced illness or death in media tend to heighten perceived risk. Similarly, the ‘representativeness heuristic’ may cause individuals to judge a situation as dangerous based on how closely it resembles a known harmful event, even if statistical probabilities suggest otherwise. Furthermore, anxiety and fear can amplify perceptions of threat; heightened emotional states often lead to increased attention to potential dangers and a greater willingness to interpret ambiguous signals as indicative of harm. Confirmation bias also plays a role, where individuals selectively attend to information that confirms their pre-existing beliefs about radiation risk while dismissing contradictory evidence. Social factors, such as the influence of trusted authorities or community narratives, can further shape individual perceptions. Finally, framing effects – how information is presented – can significantly impact risk judgments; for instance, describing exposure as ‘radiation sickness’ versus ‘low dose protection’ will elicit vastly different responses. It's crucial to recognize that these psychological processes can lead to disparities in perceived risk even when objective radiation doses are identical.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.6	 Social and Psychological Issues Associated with Radiation Exposure | Content: of this radioactivity, and the contexts in which it is
encountered.
­
­
82
12.4
­
82
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"Why might public perception regarding ionizing radiation treatments like medical imaging differ significantly from perceptions surrounding food irradiation, despite both utilizing ionizing radiation?","The differing levels of acceptance between medical and food ionizing radiation exposure stem largely from variations in perceived risk and the associated consequences. Medical applications, such as X-rays or CT scans, often involve delivering a relatively high dose of radiation to a patient over a short period for diagnostic purposes – a targeted intervention with a clear clinical benefit (disease detection/treatment planning). Consequently, patients are generally willing to accept this higher dose because they understand the potential value in obtaining accurate information about their health and receiving appropriate treatment. Conversely, food irradiation, intended solely to enhance food safety by sterilizing products, presents a more diffuse exposure scenario. Consumers receive no direct radiation from the treated product itself, and the benefits (reduced microbial contamination) are often less immediately apparent than the risks associated with medical procedures. This lack of immediate, tangible benefit coupled with the perception of receiving an ‘invisible’ dose can lead to considerable public apprehension and resistance, even though the actual absorbed dose is typically much lower. The psychological impact is amplified by the fact that individuals may be more acutely aware of potential long-term health effects associated with radiation exposure in general, regardless of its source or intended purpose. Furthermore, the nature of the application – a ‘treatment’ versus a ‘process’ – contributes to differing risk perceptions; treatments are often viewed as proactive and beneficial, while processes can feel more passive and potentially hazardous.

Reference: [Unknown - This response synthesizes general principles regarding public perception of radiation risks rather than referencing a specific textbook.]","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.6	 Social and Psychological Issues Associated with Radiation Exposure | Sub-subsection: 12.6.1	 Introduction | Content: Human behavior is primarily driven by perception and not by
facts [68]. In practice, this pattern is clearly demonstrated
also in people’s behavior related to ionizing radiation. For
instance, exposure to the medical application of ionizing
radiation is highly acceptable for most people, while food
irradiation used to increase the safety of food may be unac­
ceptable for many people, although in the first case the
patient may receive a relatively high radiation dose and in the
second case the consumer will not receive any radiation due
to the sterilization [69, 70].
Likewise, 10 mSv received as a worker’s exposure or
10 mSv received during an accidental release of radioactivity
to the environment may cause different behavior. This sec­
tion examines the social and psychological aspects of radia­
tion exposure. First, we will explain the phenomena of"
"The text describes a ‘value-action gap’ related to radiation protection behavior, specifically noting that individuals with heightened risk perceptions (e.g., concerning radon) often fail to take protective actions like testing or remediating their homes.  What factors contribute to this observed discrepancy between attitudes and behaviors regarding radiation risks as highlighted in the document?","The ‘value-action gap’ in radiation protection behavior, as detailed within the text, stems from a confluence of factors that impede individuals' willingness to translate acknowledged risk into protective actions. Primarily, familiarity with the risk itself appears to diminish perceived danger; those acutely aware of risks like radon and nuclear waste demonstrate lower compliance rates compared to experts or those with less direct exposure. Furthermore, practical barriers such as the cost of mitigation measures (radon remediation) – often comparable to standard home repairs – coupled with the lack of readily available national health care program coverage, contribute significantly.  Additionally, behaviors such as leaving children at school or not rejecting food produced in affected areas despite legal norms represent instances where individuals’ stated risk perceptions don't translate into concrete protective actions. Finally, the text suggests that factors like knowledge, personal control, and voluntariness play a role in shaping an individual’s response to perceived radiation risks.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.6	 Social and Psychological Issues Associated with Radiation Exposure | Sub-subsection: 12.6.2	 Perception of Radiation Risk | Content: discuss determinants of health and radiation protection
behavior. Finally, we will conclude this chapter with radia­
tion risk communication advice for experts in radiobiology
in order to be able to communicate effectively and help peo­
ple to make informed decisions related to radiation risks.
12.6.2	Perception of Radiation Risk
Risk perception mainly denotes the ways individuals think
and feel about the risks they face [71–73]. Radiation risk per­
ception has been extensively studied, for example, in the
context of nuclear power [74–76], nuclear testing [77], radio­
active waste [78], radon [79], food sterilization by irradiation
[80], and nuclear accidents [81]. It is interesting that people
perceive radiation risks differently, depending on the origins
of this radioactivity, and the contexts in which it is
encountered.
­
­
82
12.4
­
82
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
654
radon and naturally occurring radioactive material, the risk
of indoor air pollution due to radon is perceived as the high­
est potential risk to their health within the next 20 years, fol­
lowed by the use of recycled material with low levels of
radioactivity for buildings. The lowest risk for health within
the next 20 years is perceived to come from natural radiation
from the soil or from space. Interestingly, in this 2021 sur­
vey, the risk of medical applications of ionizing radiation is
perceived as one of the lowest radiation risks by residents of
radon-prone areas in Belgium, although medical exposure
presents the most significant dose in Belgium.
Research also shows that experts and the general public
often disagree about the potential danger posed to their
health by nuclear waste, an accident in a nuclear installation,
natural radioactivity, medical X-rays, or the Daiichi nuclear
accident in Fukushima [83]. In the study of Perko [84], the
public had significantly higher risk perceptions of all radia­
tion risks when compared to experts, with the only exception
being medical exposure. However, expert opinion and lay
perception need to be perceived as complementing rather
than competing with each other [85]. Remarkably, empirical
results show that experts too do not think and feel the same
about radiation risk. When a distinction was made between
experts that received a dose of more than 0.5 mSv due to
their professional exposure, and those who did not, those
who were exposed to more than 0.5 mSv perceived the risk
of radiation waste and an accident in a nuclear installation
significantly lower than their colleagues did. Similarly to
this, they also did not agree about risks from nuclear acci­
dents in Japan. On the other hand, the employees receiving a
dose higher than 0.5 mSv had significantly higher risk per­
ceptions of natural radioactivity and medical use of ionizing
radiation than their colleagues. These results can be explained
by the characteristics of risk, suggesting that familiarity with
risk, knowledge, personal control, and voluntariness decrease
risk perception.
­
­
688687
­
8588
12.2
­
12.6.3	Determinants of Health and Radiation
Protection Behavior
Research shows that only one person in five is prepared to
take health-related actions at any given time [89, 90].
Radiation protection behavior is not an exception to this
finding. Authorities and other radiation protection actors are
often challenged with what has been termed a “value-action
gap.” This gap refers to a situation where the values or atti­
tudes of an individual or a group of people do not correlate
with their actions; a positive attitude towards good health
does not lead to an action to improve/protect health [91].
For instance, testing for radon and remediating your home
if radon concentrations are too high are scientifically and
technically straightforward actions. However, empirical stud­
ies indicate that testing and remediation are generally low
among those exposed to high indoor radon, although these
persons have relatively high-risk perceptions [92], the cost of
radon mitigation measures for most homes is similar to that of
common home repairs, and this cost is often an eligible
expense covered by national health care programs [93–95].
A similar value-action gap is repeatedly reported in
studies related to the behavior of people before, during, and
after nuclear or radiation emergencies. For example, the
study of Turcanu et al. [54] conducted in Belgium, Norway,
and Spain, provides empirical evidence that people in the
analyzed countries have difficulties complying with some
­protective actions in case of a nuclear accident. Leaving
children at school, avoiding the use of phones during an
emergency, not rejecting food produced in affected areas
even when it satisfies legal norms or taking iodine tablets
when not needed, were identified as the most critical pro­
tective actions with which a large number of people would
not comply [96].
This raises the question what determinants of health and
radiation protection behavior can be discerned. Different
determinants have been studied in the context of health
behavior models. The most known and tested models in the
radiation protection field are the Protection-Motivation
Model [97], the Health Belief Model [98], the Theory of
Planned Behavior [99], the Transtheoretical Model of Health
Behavior Change (TTM) [90], and the Precautionary
Adoption Process Model [100].
­
12.3
A. Dobney et al."
The text describes a ‘value-action gap’ in relation to radiation protection behaviors. Explain what this concept represents and provide an example from the provided context illustrating how it manifests during nuclear emergencies.,"The ‘value-action gap’ refers to the discrepancy between an individual or group's positive attitudes or values regarding health and safety, and their actual behavior designed to protect themselves. Essentially, people may acknowledge a risk (like radon exposure) but fail to take actions to mitigate it due to various barriers – such as cost, inconvenience, lack of knowledge, or perceived complexity. The example provided illustrates this with the response to nuclear accidents in Belgium, Norway, and Spain. Despite individuals recognizing the threat posed by a catastrophic nuclear accident and having relatively high-risk perceptions, many people did not comply with protective actions like leaving children at school, avoiding phone use, rejecting contaminated food, or taking iodine tablets when needed. This demonstrates that simply holding a positive attitude towards health protection doesn’t automatically translate into effective behavior change.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.6	 Social and Psychological Issues Associated with Radiation Exposure | Sub-subsection: 12.6.3	 Determinants of Health and Radiation Protection Behavior | Content: often challenged with what has been termed a “value-action
gap.” This gap refers to a situation where the values or atti­
tudes of an individual or a group of people do not correlate
with their actions; a positive attitude towards good health
does not lead to an action to improve/protect health [91].
For instance, testing for radon and remediating your home
if radon concentrations are too high are scientifically and
technically straightforward actions. However, empirical stud­
ies indicate that testing and remediation are generally low
among those exposed to high indoor radon, although these
persons have relatively high-risk perceptions [92], the cost of
radon mitigation measures for most homes is similar to that of
common home repairs, and this cost is often an eligible
expense covered by national health care programs [93–95].
A similar value-action gap is repeatedly reported in
studies related to the behavior of people before, during, and
after nuclear or radiation emergencies. For example, the
study of Turcanu et al. [54] conducted in Belgium, Norway,
and Spain, provides empirical evidence that people in the
analyzed countries have difficulties complying with some
­protective actions in case of a nuclear accident. Leaving
children at school, avoiding the use of phones during an
emergency, not rejecting food produced in affected areas
even when it satisfies legal norms or taking iodine tablets
when not needed, were identified as the most critical pro­
tective actions with which a large number of people would
not comply [96].
This raises the question what determinants of health and
radiation protection behavior can be discerned. Different
determinants have been studied in the context of health
behavior models. The most known and tested models in the
radiation protection field are the Protection-Motivation
Model [97], the Health Belief Model [98], the Theory of
Planned Behavior [99], the Transtheoretical Model of Health
Behavior Change (TTM) [90], and the Precautionary
Adoption Process Model [100].
­
12.3
A. Dobney et al.
655
Table 12.2 Examples of acceptable radiation risks in relation to risk perception
Descriptive example of an acceptable radiation risk—a hypothetical scenario
Selected
characteristics of
risk
Influence on risk (un)
acceptability
Explanatory scale
A catastrophic potential of a nuclear accident made the risk more threatening
since low-probability high-consequence radiation risks are usually perceived
as more threatening than more probable risks with low or medium
consequences.
Catastrophic
potential
Decreases risk
acceptability
Catastrophic—
chronic
Medical personnel is wearing assigned personal radiation dosimeters during a
procedure using ionizing radiation, which gives a feeling of control and
increases the acceptability of radiation exposure.
Personal control
Increases risk
acceptability
Controllable—not
controllable
A phosphate factory is recognized as a trustworthy organization since they
communicate openly about the risks of naturally occurring radioactive
material as a side product.
Institutional
control
Depends upon
confidence in
institutional
performance
Trust, confidence in
the institution
Population density around nuclear installation is low thus controlled releases
of radioactivity from a nuclear installation in an environment is acceptable.
Number of
exposed
Decreases risk
acceptability
Local—global
Workers get employed at a nuclear installation on a voluntarist basis thus they
accept workers’ exposure to ionizing radiation.
Voluntariness
Increases risk
acceptability
Voluntary—
involuntary
A patient receives a low dose of ionizing radiation during X-ray which makes
it acceptable.
Mortality
Decreases risk
acceptability
Fatal—not fatal
Visitors learned about radiation and technology used by researchers during an
open-door day at a nuclear research institute. New insights and knowledge
influenced their acceptability of potential radiation risks.
Knowledge
Increases risk
acceptability
New technology—
established
technology
Living in a home with high radon concentration for many years (more
generations) made residents accept radon risk and not performing radon test
or necessary remediation of a house
Familiarity
Increases risk
acceptability
Familiar—not
familiar
A traffic accident with transport of radionuclides for a hospital in a citizen’s
region is not as dreadful as a nuclear accident in another continent is.
Dread/fear
Decreases risk
acceptability
Fear—no fear
High natural background of radiation is for many people acceptable because
it is natural due to the geological characteristics of a region.
Artificiality of
risk source
Amplifies attention
to risk
Often decreases risk
acceptability
Human—natural
During an environmental remediation process, residents had a feeling of
fairness since they could co-decide on how, where, and to which level should
be environment remediated. Thus, they accepted radioactive residues in a
dedicated part of their administrative community.
Fairness
Increases quest for
social and political
responses
Fair—unfair
Receiving compensation for radioactive waste disposal made the project
acceptable.
Benefit
Increase risk
acceptability
Benefit to self-vs.
unclear or
inequitable
Intake of stable iodine as an effective countermeasure for reducing the risk of
thyroid cancer in an eventual release of radioactive iodine following a nuclear
accident, especially for children, made the pre-distribution of the iodine
tablets to residents and un uptake of a tablet if necessary, an acceptable
option.
Effect on
children
Decrease risk
acceptability
Children specifically
at risk
perception, protective efficiency of an action, threat, and
trust among others. Table 12.3 presents potential health pro­
tection determinants, descriptive explanations, and a refer­
ence to selected studies that have been tested in the radiation
protection field.
In particular, the Theory of Planned Behavior [124]
proved that the higher the intent, the higher the probability
an individual will engage in the action they intend. This the­
ory has been for instance applied in research on attitudes and
behavior related to new nuclear research installations [120].
In this study, authors found that attitudes towards participa­
tion and moral norms are the strongest determinants for the
studied behavior—in this case, participation intention. Other
determinants were time constraints, attitude towards nuclear
energy, subjective and descriptive norms, and level of spe­
cific radiation-related knowledge. The Extended Parallel
Process Model (EPPM) focuses on two constructs which
mediate an individual’s level of fear and proposes an indi­
vidual will engage in behavior change when they have a
combination of (a) fear the health threat will happen to them
(susceptibility) and (b) perception they are able to address/
deal with the risk [108]. The Transtheoretical Model of
Health Behavior Change which has been applied among oth­
ers also to behavior related to radon exposure [125], postu­
lates that individuals move through six stages of change:
pre-­contemplation, contemplation, preparation, action,
maintenance, and termination. The model has two major
components: change and decisional balance, where neither
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
656
Table 12.3 Determinants of health and radiation protection behavior tested in radiation risk studies
Potential determinants of
health and radiation
behavior
Descriptive explanation
Selected studies from
radiation protection field
Anticipatory
emotion—worry
The anticipatory emotion—worry is an emotion where a person experiences increased
levels of anxiety by thinking about an event or situation in the future.
McGlone et al. [101], Witte
et al. [102]
Anticipatory
emotion—severity
Anticipatory emotion—severity refers to people’s beliefs about how serious are the
negative consequences of a hazard. In the radon exposure situations, the threat
involves cancer, which is severe.
Mazur and Hall [103],
Dragojevic et al. [104]
Conditional/perceived
susceptibility
Perceived susceptibility is the subjective belief that a person may acquire a disease or
enter a dire state due to a particular behavior.
D’Antoni et al. [105],
Weinstein et al. [106],
Niemeyer and Keller [107]
Coping of efficacy
appraisal: response
efficacy
Coping appraisal is needed to adopt or maintain a health protection behavior and is
essential for overcoming fears and mental blocks. Coping appraisal consists of three
dements: response efficacy/response costs/self-efficacy. Only if the individual is
convinced that a behavior leads to the desired outcome will she or he be more likely to
intend to perform the behavior.
Weinstein et al. [108, 109],
Witte et al. [110],
Dragojevic et al. [104]
Coping or efficacy
appraisal—self efficacy
Self-efficacy refers to the belief in one’s own competence to perform a behavior even
in the face of barriers or in other words, the individual in carrying out the
recommended coping response.
Hahn et al. [111], Larsson
[112], Rhodes et al. [113]
Perceived costs
The “Perceived costs” captures the person’s perceptions of the disadvantages of, or
barriers to, undertaking the behavior.
Hampson et al. [114],
Sheeran [115]
Anticipated emotions/
regret
Anticipated emotions are a component of the immediate consequences of the decision;
they are emotions that are expected to occur when outcomes are experienced. The
most extensively researched anticipated emotions regret, guilt, and shame.
Hampson et al. [114],
Sheeran [115]
Perceived informed
choice
Informed choice means that people under radon risk make decisions that are
consistent with their goals and values
Weinstein and Man [116,
117]
Subjective norms
Subjective norms refer to the belief that an important person or group of people will
approve and support and particular behavior, for instance protection against radon
Clifford et al. [118], Park
et al. [119]
Descriptive norms
Descriptive norms refer to what most people in a group think, feel, or do. Descriptive
norms are a reflection on “What is typical or normal … what most people do”,
including “evidence as to what will likely be effective and adaptive action.
Moral norms
Moral norms are internalised, unconditional and emotional internalised and enforced
through self-generated emotions such as guilt.
Turcanu et al. [120]
Knowledge/awareness
Increasing radiation (specific) knowledge and awareness is often set as a primary
objective of risk communication efforts.
Perko et al. [84, 121]
Trust
Trust concept includes different dimensions for instance fairness, unbiasedness,
perceived competence, objectivity, consistency, commitment, caring, and
predictability, social trust, general trust and transparency.
Perko and Martell [122],
Perko et al. [123]
knowledge nor risk perception is not identified as the main
health protection change determinants [126]. Similarly, the
message design theories, such as the Extended Parallel
Processing Model (EPPM) which has been used as the theo­
retical framework for formative and summative analysis of
radon communication campaigns, indicate the importance of
threat and efficacy [110]."
"Describe the concept of ‘anticipated emotions’ as presented in Sheeran's work regarding risk communication, specifically focusing on regret, guilt, and shame. How do these anticipated emotions relate to decision-making processes when individuals are exposed to risks like those associated with radon?","Anticipated emotions, according to Sheeran [115], represent the feelings an individual expects to experience upon realizing the outcomes of a decision. These emotions are particularly relevant in risk communication because they directly influence subsequent behavior. The most frequently researched anticipated emotions related to risk decisions are regret, guilt, and shame. Regret refers to the feeling experienced when a negative outcome occurs after a choice has been made, often prompting individuals to question their initial decision-making process. Guilt arises from perceiving that one’s actions have harmed others or violated moral standards, while shame involves feelings of inadequacy or humiliation related to one's own behavior. In the context of radon risk communication, anticipating these emotions – particularly regret over a decision to not mitigate risks – can significantly impact an individual’s willingness to take protective measures. The potential for experiencing these negative emotions serves as a motivator for action, driving individuals towards behaviors aligned with perceived safety and responsibility.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.6	 Social and Psychological Issues Associated with Radiation Exposure | Sub-subsection: 12.6.4	 Risk Communication | Content: Sheeran [115]
Anticipated emotions/
regret
Anticipated emotions are a component of the immediate consequences of the decision;
they are emotions that are expected to occur when outcomes are experienced. The
most extensively researched anticipated emotions regret, guilt, and shame.
Hampson et al. [114],
Sheeran [115]
Perceived informed
choice
Informed choice means that people under radon risk make decisions that are
consistent with their goals and values
Weinstein and Man [116,
117]
Subjective norms
Subjective norms refer to the belief that an important person or group of people will
approve and support and particular behavior, for instance protection against radon
Clifford et al. [118], Park
et al. [119]
Descriptive norms
Descriptive norms refer to what most people in a group think, feel, or do. Descriptive
norms are a reflection on “What is typical or normal … what most people do”,
including “evidence as to what will likely be effective and adaptive action.
Moral norms
Moral norms are internalised, unconditional and emotional internalised and enforced
through self-generated emotions such as guilt.
Turcanu et al. [120]
Knowledge/awareness
Increasing radiation (specific) knowledge and awareness is often set as a primary
objective of risk communication efforts.
Perko et al. [84, 121]
Trust
Trust concept includes different dimensions for instance fairness, unbiasedness,
perceived competence, objectivity, consistency, commitment, caring, and
predictability, social trust, general trust and transparency.
Perko and Martell [122],
Perko et al. [123]
knowledge nor risk perception is not identified as the main
health protection change determinants [126]. Similarly, the
message design theories, such as the Extended Parallel
Processing Model (EPPM) which has been used as the theo­
retical framework for formative and summative analysis of
radon communication campaigns, indicate the importance of
threat and efficacy [110].
12.6.4	Risk Communication
Responsible risk communication requires a legitimate proce­
dure, an ethically justified risk message, and concern for and
valuation of the effects of the message and procedure. This
way, it is stressed, that risk communication should not only
be effective but also ethical, which requires taking moral val­
ues into consideration. During radiation risk communication
moral values are at stake, which means that decisions have to
be made in a democratic way, after serious debate about val­
ues and not merely about numbers [127].
Risk communication was in previous century seen as a form of a
technical communication and education whereby the public
should be informed about risk estimates. Later on, risk commu­
nication was seen as a marketing practice with the aim to per­
suade people to adopt a certain message. In nowadays
societies (sic), risk communication is seen as a socio-centric
communication based on public participation with which the
gaps between stakeholders can be bridged. The procedure
should be legitimate (requires legitimate procedure for discuss­
ing the moral values and emotions associated with risks), it
should be ethically justified (ethical deliberation about the val­
ues and emotions involved in different messages) and the effects
should be adequately addressed. [128, p. 8–9].
Radiation risk communication has several aims: (a) to warn
people in case of radiation danger, (b) to the enlightenment
of people to be able to understand risks and become “risk-­
literate,” (c) to prevent panic and outrage, (d) to empower
A. Dobney et al.
657
stakeholders to make informed decisions related to radiation
risks, (e) to establish two-way communication and joint
problem solving including conflict resolution, and (f) to
build trust between different stakeholders.
Bauder and colleagues (2021) guide communication
practitioners towards radiation risk communication which is
strategic (e.g., based on formats and methods that have been
proven to reach its preconceived objectives), evidence-based
(e.g., based on the qualitative and quantitative empirical
data, surveys, experiments), and theory-based (e.g., drawing
from empirically supported theories of health behavior,
behavior, and information processing) [129].
For instance, information processing theories applied in
radiation risk communication [130] show that efficient com­
munication about radiation risks requires thorough insight
into the factors that influence people’s attentiveness, recall of
risk-related information, level of agreement with the com­
municated message, and behavior change or more generally
speaking: how people process risk-related information and
turned it in a behavior.
The information processing models are seen as applicable
for each individual, regardless of the societal or cultural bias
[131–139] however countries may differ in beliefs, cultural
values, past social and risk experiences, the saliency of par­
ticular aspects of a policy issue, the socioeconomic profile
and trust in regulatory agencies. In general, people process
information using two different modes: (1) heuristic and (2)
systematic mode [140]. Heuristic processing is characterized
by low effort and reliance on existing knowledge and simple
cues for instance trust. Systematic processing on the other
hand is characterized by greater effort and the desire to eval­
uate information formally [141].
12.6.5	Advice on How to Communicate
with the Public About Your
Radiobiological Study
Radiobiologists may be challenged by public communica­
tion due to the following reasons [122]: there is no single
audience for scientific information; the complexity of scien­
tific methods and information, and the ways in which science
progresses; the ways in which people process such informa­
tion; in the radiobiology, the societal implications of science
are controversial, for instance, Linear Dose Response Model;
there is substantial disagreement about the findings within
the scientific community, for instance, related to low doses;
the complex, dynamic, and competitive communication
media environment, with evolving social media and pace of
information flow; and because the results of research can be
insufficient, ambiguous or uncertain, and scientific conclu­
sions can change over time as new findings emerge.
Science Media Centre (2012) developed practical guid­
ance to be used by scientists during their public and mass
media communication. For a complete and original guide,
look at https://www.sciencemediacentre.org/wp-­content/
uploads/2012/09/10-­best-­practice-­guidelines-­for-­science-­
and-­health-­reporting.pdf.
Some of the central points are summarized here:
•	Headlines should not mislead the reader about a story’s
contents and quotation marks should not be used to dress
up overstatement.
•	During your communication related to health risks,
include the absolute risk whenever it is available in the
press release or the research paper (e.g., if “low dose
exposure increases the cancer risk” state the outright risk
of that cancer, with and without particular exposure).
•	Especially on a story with public health implications, try to
present a new finding in the context of other evidence (e.g.,
does it reinforce or conflict with previous studies?). If it
attracts serious scientific concerns, they should not be ignored.
•	When reporting a link between two things, it is recom­
mended to indicate whether or not there is evidence that
one causes the other.
•	Specify the size and nature of the study (e.g., who/what
were the subjects, how long did it last, what was tested or
was it an observation?). Provided there is enough space
and time, it could be of interest to mention also the major
limitations.
•	State where the research has been published or presented
or reported (e.g., conference, journal article, survey, etc.).
Ideally, the article should include a web link or enough
information for readers to look it up.
•	Give a sense of the stage of the research (e.g., new dosime­
ter, clean-up stage, cells in a laboratory, or trials in humans),
and a realistic time frame for any new technology.
•	If there is enough space, quote both the researchers them­
selves and external sources with appropriate expertise. Be
wary of scientists and press releases over-claiming for
studies.
•	Distinguish between findings and interpretation or extrap­
olation; do not suggest health advice if none has been
offered.
12.7
Exercises
12.7.1	Ethics
1.	The most difficult thing in finding trust in decision-­making
on nuclear today might be in the way we deal with moral
pluralism. What is moral pluralism? Simply the idea that
if we all know the same thing, opinions on what to do can
still be different, and this is because our opinions do not
only rely on knowledge but also on ethical values. As an
example choosing for retrievability or non-retrievability of
underground stored nuclear waste is making a choice deal­
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure"
"A scientist is preparing to communicate the results of a study investigating the potential link between exposure to low levels of ionizing radiation and an increased incidence of leukemia in mice. Outline the key communication strategies this scientist should employ, focusing on accuracy, transparency, and responsible public engagement.","To effectively communicate research findings regarding potential health risks associated with low-level radiation exposure, particularly concerning a complex issue like cancer development, the scientist must prioritize clarity, precision, and contextualization. Several crucial elements should be incorporated into their communication strategy:

1. **Precise Risk Communication:** Avoid vague statements such as ‘low dose increases cancer risk.’ Instead, they *must* quantify the absolute risk whenever possible. This means stating the specific probability of leukemia development per unit of radiation exposure (e.g., ‘The study found a 0.2% increased risk of leukemia in mice exposed to X-rays at this level’). Transparency is paramount; acknowledging uncertainty alongside quantifiable data is vital.

2. **Contextualization with Existing Evidence:** Present the new findings within the broader landscape of existing research. Clearly state whether the results support, contradict, or add nuance to previously established knowledge regarding radiation and cancer risk. Acknowledging conflicting studies demonstrates a comprehensive understanding.

3. **Detailed Study Description:** Provide a thorough explanation of the study’s methodology, including: the size and nature of the subject population (mouse strain, age range), the duration of exposure, the specific type of radiation used, the methods employed to measure exposure, and any relevant controls.  Crucially, they should explicitly state any limitations of the study – for example, whether it was an observational study with potential confounding factors or if further research is needed.

4. **Source Citation & Verification:** Clearly identify where the research has been published (e.g., journal name, DOI) and provide a direct link to the publication whenever feasible.  They should also cite relevant external sources – experts in radiation biology or epidemiology – to bolster credibility and offer alternative perspectives.

5. **Distinguishing Findings from Interpretation:** Avoid offering health advice or speculating on potential human implications based solely on the study’s findings. Clearly differentiate between observed data and interpretations of those data. For example, stating ‘this suggests a possible link’ is problematic; instead, they should say ‘the researchers suggest this warrants further investigation.’

6. **Realistic Timeframes & Stages:** Provide an honest assessment of the research stage – whether it's preliminary results, ongoing trials, or established technology. Avoid overstating the immediate implications of the findings.

7. **Quote Appropriately:** When quoting researchers, ensure that quotes accurately reflect their statements and avoid exaggerations or misleading claims.  Similarly, carefully vet any press releases for overly enthusiastic interpretations.

By adhering to these guidelines, the scientist can foster informed public understanding and responsible engagement with potentially sensitive research findings related to radiation exposure.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.6	 Social and Psychological Issues Associated with Radiation Exposure | Sub-subsection: 12.6.5	 Advice on How to Communicate with the Public About Your Radiobiological Study | Content: Science Media Centre (2012) developed practical guid­
ance to be used by scientists during their public and mass
media communication. For a complete and original guide,
look at https://www.sciencemediacentre.org/wp-­content/
uploads/2012/09/10-­best-­practice-­guidelines-­for-­science-­
and-­health-­reporting.pdf.
Some of the central points are summarized here:
•	Headlines should not mislead the reader about a story’s
contents and quotation marks should not be used to dress
up overstatement.
•	During your communication related to health risks,
include the absolute risk whenever it is available in the
press release or the research paper (e.g., if “low dose
exposure increases the cancer risk” state the outright risk
of that cancer, with and without particular exposure).
•	Especially on a story with public health implications, try to
present a new finding in the context of other evidence (e.g.,
does it reinforce or conflict with previous studies?). If it
attracts serious scientific concerns, they should not be ignored.
•	When reporting a link between two things, it is recom­
mended to indicate whether or not there is evidence that
one causes the other.
•	Specify the size and nature of the study (e.g., who/what
were the subjects, how long did it last, what was tested or
was it an observation?). Provided there is enough space
and time, it could be of interest to mention also the major
limitations.
•	State where the research has been published or presented
or reported (e.g., conference, journal article, survey, etc.).
Ideally, the article should include a web link or enough
information for readers to look it up.
•	Give a sense of the stage of the research (e.g., new dosime­
ter, clean-up stage, cells in a laboratory, or trials in humans),
and a realistic time frame for any new technology.
•	If there is enough space, quote both the researchers them­
selves and external sources with appropriate expertise. Be
wary of scientists and press releases over-claiming for
studies.
•	Distinguish between findings and interpretation or extrap­
olation; do not suggest health advice if none has been
offered.
12.7"
"A researcher publishes a study indicating that exposure to a specific bacterial species, *Pseudomonas aeruginosa*, significantly increases the incidence of biofilm formation on implanted medical devices in an experimental murine model. The study details 50 mice with surgically implanted catheters and reports a 75% increase in biofilm presence compared to control mice. Furthermore, the researchers highlight the potential for chronic inflammation associated with this biofilm development. What key considerations should be emphasized when communicating these findings to the public, and why are they important?","When disseminating research findings regarding *Pseudomonas aeruginosa*'s role in biofilm formation and subsequent inflammatory responses, several crucial elements must be prominently featured. First, it’s paramount to clearly state the absolute risk associated with this observation – in this case, a 75% increase in biofilm presence on implanted devices. Avoiding phrases like ‘increases the risk’ is vital; instead, quantify the impact (e.g., ‘this study demonstrates a 75% higher likelihood of biofilm formation’). Second, meticulous detail regarding the experimental design is essential. The public needs to understand that this was an *in vivo* murine model – meaning it involved live animals and may not perfectly translate to human conditions. Specifically, the size and nature of the study (50 mice) and its duration must be disclosed. Third, acknowledging limitations is crucial; for example, the researchers should explicitly state whether the biofilm composition was characterized, what specific inflammatory markers were measured, or if the device material influenced biofilm formation. Fourth, it’s vital to avoid suggesting health advice – stating that biofilm formation ‘increases the risk’ of infection without further context would be misleading and potentially alarming. Finally, citing the original publication (including a link) is necessary for transparency and allows interested parties to evaluate the methodology and results directly. The stage of research should also be clarified - this was an experimental model, not necessarily indicative of human outcomes. Reference: [Science Media Centre, 2012], Section 12.7 – Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.7	 Exercises | Content: Science Media Centre (2012) developed practical guid­
ance to be used by scientists during their public and mass
media communication. For a complete and original guide,
look at https://www.sciencemediacentre.org/wp-­content/
uploads/2012/09/10-­best-­practice-­guidelines-­for-­science-­
and-­health-­reporting.pdf.
Some of the central points are summarized here:
•	Headlines should not mislead the reader about a story’s
contents and quotation marks should not be used to dress
up overstatement.
•	During your communication related to health risks,
include the absolute risk whenever it is available in the
press release or the research paper (e.g., if “low dose
exposure increases the cancer risk” state the outright risk
of that cancer, with and without particular exposure).
•	Especially on a story with public health implications, try to
present a new finding in the context of other evidence (e.g.,
does it reinforce or conflict with previous studies?). If it
attracts serious scientific concerns, they should not be ignored.
•	When reporting a link between two things, it is recom­
mended to indicate whether or not there is evidence that
one causes the other.
•	Specify the size and nature of the study (e.g., who/what
were the subjects, how long did it last, what was tested or
was it an observation?). Provided there is enough space
and time, it could be of interest to mention also the major
limitations.
•	State where the research has been published or presented
or reported (e.g., conference, journal article, survey, etc.).
Ideally, the article should include a web link or enough
information for readers to look it up.
•	Give a sense of the stage of the research (e.g., new dosime­
ter, clean-up stage, cells in a laboratory, or trials in humans),
and a realistic time frame for any new technology.
•	If there is enough space, quote both the researchers them­
selves and external sources with appropriate expertise. Be
wary of scientists and press releases over-claiming for
studies.
•	Distinguish between findings and interpretation or extrap­
olation; do not suggest health advice if none has been
offered.
12.7
Exercises"
"The text discusses moral pluralism in the context of decision-making regarding nuclear waste disposal. Define moral pluralism and explain how it presents a challenge when attempting to reach consensus on complex issues like managing radioactive materials, specifically referencing the differing values related to future generations.","Moral pluralism refers to the situation where multiple individuals or groups can possess knowledge about a particular issue – in this case, the risks associated with nuclear waste disposal – yet still hold divergent opinions regarding appropriate action. This divergence isn't solely based on factual information but is fundamentally rooted in differing ethical values and beliefs. The example provided highlights this by illustrating two opposing viewpoints: one prioritizing long-term containment to avoid future burdens, while the other advocating for allowing future generations the agency to potentially address the waste differently. Crucially, moral pluralism acknowledges that even with shared knowledge, subjective interpretations and value judgments will inevitably lead to conflicting decisions.  The inability of future generations – a key stakeholder – to participate in the decision-making process exacerbates this challenge, as their potential concerns cannot be directly incorporated into the deliberation.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.7	 Exercises | Sub-subsection: 12.7.1	 Ethics | Content: Science Media Centre (2012) developed practical guid­
ance to be used by scientists during their public and mass
media communication. For a complete and original guide,
look at https://www.sciencemediacentre.org/wp-­content/
uploads/2012/09/10-­best-­practice-­guidelines-­for-­science-­
and-­health-­reporting.pdf.
Some of the central points are summarized here:
•	Headlines should not mislead the reader about a story’s
contents and quotation marks should not be used to dress
up overstatement.
•	During your communication related to health risks,
include the absolute risk whenever it is available in the
press release or the research paper (e.g., if “low dose
exposure increases the cancer risk” state the outright risk
of that cancer, with and without particular exposure).
•	Especially on a story with public health implications, try to
present a new finding in the context of other evidence (e.g.,
does it reinforce or conflict with previous studies?). If it
attracts serious scientific concerns, they should not be ignored.
•	When reporting a link between two things, it is recom­
mended to indicate whether or not there is evidence that
one causes the other.
•	Specify the size and nature of the study (e.g., who/what
were the subjects, how long did it last, what was tested or
was it an observation?). Provided there is enough space
and time, it could be of interest to mention also the major
limitations.
•	State where the research has been published or presented
or reported (e.g., conference, journal article, survey, etc.).
Ideally, the article should include a web link or enough
information for readers to look it up.
•	Give a sense of the stage of the research (e.g., new dosime­
ter, clean-up stage, cells in a laboratory, or trials in humans),
and a realistic time frame for any new technology.
•	If there is enough space, quote both the researchers them­
selves and external sources with appropriate expertise. Be
wary of scientists and press releases over-claiming for
studies.
•	Distinguish between findings and interpretation or extrap­
olation; do not suggest health advice if none has been
offered.
12.7
Exercises
12.7.1	Ethics
1.	The most difficult thing in finding trust in decision-­making
on nuclear today might be in the way we deal with moral
pluralism. What is moral pluralism? Simply the idea that
if we all know the same thing, opinions on what to do can
still be different, and this is because our opinions do not
only rely on knowledge but also on ethical values. As an
example choosing for retrievability or non-retrievability of
underground stored nuclear waste is making a choice deal­
12 Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure
658
ing with moral pluralism: science can describe the options,
but not help us to make a choice. Some would say we
should dispose and seal the waste so that future genera­
tions do not need to bother about it anymore, while others
would argue that we should give them the possibility to
intervene or do something better with the waste. Imagine
yourself being a moderator in this discussion: what are the
values and interests at stake here, and how would you
moderate this discussion towards a consensus, also taking
into account that an important stakeholder (the future gen­
erations) cannot participate in the discussion?
2.	Studies have shown that the public is more averse to rela­
tively low radiation exposures from nuclear power than
to higher doses from medical exposures. Is this
irrational?
3.	What other ethically relevant factors impact perceptions
of radiation risks?"
"Within the framework of nuclear law, what constitutes the primary underlying principle governing radiation exposure management, and how does this principle directly inform the concept of optimization of protection? Illustrate your response with two distinct examples of planned exposure scenarios.","The central principle underpinning nuclear law regarding radiation exposure is the ‘as low as reasonably achievable’ (ALARA) standard. This dictates that any exposure to ionizing radiation should be minimized to the extent technically and economically feasible, acknowledging that complete elimination may not always be possible or practical. Optimization of protection, therefore, hinges on consistently applying this ALARA principle – it's not simply about limiting exposure to a fixed level but rather continually striving for reduction through careful planning, engineering controls, operational procedures, and monitoring.

Here are two examples of planned exposure situations where the ALARA principle would be rigorously applied:

1.  **Medical Radiography (X-ray):** A radiologist plans an X-ray examination on a patient to diagnose a suspected fracture. The procedure is carefully designed to utilize the lowest possible radiation dose required to obtain diagnostic images of sufficient quality. This includes selecting the appropriate imaging technique, collimating the beam to minimize tissue exposure, and using lead shielding to protect surrounding personnel. Continuous monitoring of radiation levels ensures adherence to ALARA.

2.  **Nuclear Reactor Maintenance:** Technicians are scheduled to perform routine maintenance on a nuclear reactor core. Before commencing work, a detailed risk assessment is conducted identifying potential radiation hazards. Protective equipment (e.g., dosimeters, lead aprons) is utilized, and work procedures are meticulously planned to minimize the duration and intensity of exposure. Regular monitoring and adherence to strict safety protocols ensure that any exposure remains as low as reasonably achievable.

In both cases, ‘planned’ signifies deliberate action taken with a recognized risk, demanding proactive mitigation strategies based on ALARA rather than an uncontrolled or unexpected event.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.7	 Exercises | Sub-subsection: 12.7.2	 Law | Content: 1.	Which is the main underlying principle of nuclear law
and how does this translate to the concept of optimization
of protection? Can you give an example of two planned
exposure situations?
2.	Do you think the exposure to cosmic rays is a planned
exposure situation or an existing exposure? Could it be
both in the context of air travel? Is radiological protection
different in either situation?
3.	What attributes should a regulatory body have and what
are some of its main tasks?
4.	Nuclear liability is different from general tortious liabil­
ity. Give an example and explain the reason."
"A worker sustains radiation burns due to an accidental overexposure during their employment. Subsequently, they claim that the employer is legally responsible for the injuries and attempts to impute liability based on negligence. What legal principles and potential arguments might arise in this situation, considering factors such as duty of care, foreseeability, and the standard of safety expected within a radiation-handling environment?","This scenario presents a complex legal challenge rooted in establishing employer liability for worker injuries resulting from radiation exposure. Several key legal principles would be central to determining responsibility. Firstly, the concept of ‘duty of care’ dictates that employers have a legal obligation to provide a safe working environment for their employees. This duty extends to implementing appropriate safety measures and providing adequate training regarding potential hazards associated with radiation work – including understanding permissible exposure limits (PELs), utilizing personal protective equipment (PPE) correctly, and adhering to established protocols.  

For the worker to successfully impute liability against the employer, they would need to demonstrate several elements: (1) **Breach of Duty:** The employer failed to meet the standard of care expected in a radiation-handling environment. This could be proven if safety procedures were inadequate, training was insufficient, or PPE was improperly maintained or provided. (2) **Causation:** There must be a direct causal link between the employer’s breach of duty and the worker's injuries.  Establishing this requires demonstrating that the injury resulted *because* of the unsafe conditions created by the employer. This often involves expert testimony regarding radiation dose calculations, exposure levels, and potential health risks. (3) **Damages:** The worker must prove they suffered actual damages – in this case, radiation burns and potentially long-term health consequences like cataracts or increased cancer risk.  

Foreseeability plays a crucial role. Did the employer reasonably anticipate that an overexposure could occur given the nature of their operations? If the exposure was due to a known equipment malfunction or a failure to follow established safety protocols, it strengthens the worker’s case. Furthermore, legal precedents regarding negligent radiation handling and ‘strict liability’ (where employers are liable regardless of fault) would be relevant depending on the jurisdiction.  The standard of safety expected will also depend on the specific industry regulations governing radiation work – for example, those set by regulatory bodies like OSHA or equivalent international standards.

Finally, the employer could potentially argue contributory negligence if the worker failed to follow established safety procedures themselves, thus partially contributing to their own injury.","Document: MolecularRadiationBiology | Section: 12: Ethical, Legal, Social, and Epistemological Considerations of Radiation Exposure | Subsection: 12.7	 Exercises | Sub-subsection: 12.7.3	 Legal Imputation | Content: 1.	Taking into consideration the legal structure of your
country, please elaborate on the potential legal develop­
ments of the following situations:
(a)	A worker is damaged (burned) by an over-exposure
to radiation and decides the damage is to be attrib­
uted to the exposure and imputed on his/her employer;
(b)	A large group of conscripts is subjected to a collective
medical screening using old X-ray equipment when
joining the army. About a decade later, those still meet­
ing in social encounters discover that a large number
among them are suffering from unusual cancers for
their young age and decide to impute the army;
(c)	A family is living near a nuclear power plant that
appears to function as designed. There have been no
reports of any anomalous events, incidents, or anom­
alous measured values. One of their children incurs
thyroid cancer. The parents have contacted a lawyer.
Disclaimer
• At the time of the preparation of this book, Russia invaded Ukraine.
• The Ukraine War will have repercussions on the existing interna­
tional paradigm governing protection, safety, security, and safe­
guards of endeavors involving radiation exposure.
• It may take years to answer the questions raised by the present
crisis.
• The authors believe however that the ethical, social, and epistemo­
logical considerations presented below are still applicable. The legal
and logistical considerations may change in the future in such a way
that the relevant sections in this chapter will no longer be
applicable."
